

0001613103-24-00016510-Q Medtronic plc 2024-112620241126161606161606161606 0 0001613103-24-000165 10-Q 113 20241025 20241126 20241126 Medtronic plc 0001613103 3845
000000000 0425 10-Q 34 001-36820 241504013 BUILDING TWO PARKMORE BUSINESS PARK WEST GALWAY L2 1 01135314381700 BUILDING TWO PARKMORE BUSINESS PARK WEST
GALWAY L2 1 Medtronic Ltd 20150112 Medtronic Holdings Ltd 20140711 Kalani I Ltd 20140709 10-Q 1 mdt-20241025.htm 10-Q mdt-2024102500016131034/25falseQ22025H91
VY19P6GY6PY3YP3YP5YP5YP8YP8YP5YP6YP6YP8YP8YP5YP5YP12YP12YP12YP9YP9YP12YP12YP10YP12YP12YP20YP20YP12YP12YP30YP30YP20YP20YP30YP30YP20YP20YP30YP30
2024-10-250001613103mdt:A0.2505SeniorNotesDue2025Member2024-04-272024-10-250001613103mdt:A0.000SeniorNotesDue2025Member2024-04-272024-10-
250001613103mdt:A2.6255SeniorNotesDue2025Member2024-04-272024-10-250001613103mdt:A1.125SeniorNotesDue2027Member2024-04-272024-10-
250001613103mdt:A0.3755SeniorNotesDue2028Member2024-04-272024-10-250001613103mdt:A3.000SeniorNotesDue2028Member2024-04-272024-10-
250001613103mdt:A3.650SeniorNotesDue2029Member2024-04-272024-10-250001613103mdt:A1.625SeniorNotesDue2031Member2024-04-272024-10-
250001613103mdt:A1.000SeniorNotesDue2031Member2024-04-272024-10-250001613103mdt:A3.125SeniorNotesDue2031Member2024-04-272024-10-
250001613103mdt:A0.750SeniorNotesDue2032Member2024-04-272024-10-250001613103mdt:A3.375SeniorNotesDue2034Member2024-04-272024-10-
250001613103mdt:A3.875SeniorNotesDue2036Member2024-04-272024-10-250001613103mdt:A2.250SeniorNotesDue2039Member2024-04-272024-10-
250001613103mdt:A1.5005SeniorNotesDue2039Member2024-04-272024-10-250001613103mdt:A1.375SeniorNotesDue2040Member2024-04-272024-10-
250001613103mdt:A4.1505SeniorNotesDue2043Member2024-04-272024-10-250001613103mdt:A1.750SeniorNotesDue2049Member2024-04-272024-10-
250001613103mdt:A1.6255SeniorNotesDue2050Member2024-04-272024-10-250001613103mdt:A4.150SeniorNotesDue2053Member2024-04-272024-10-2500016131032024-11-
2000016131032024-07-272024-10-2500016131032023-07-292023-10-2700016131032023-04-292023-10-2700016131032024-10-2500016131032024-04-260001613103us-
gaap:CommonStockMember2024-04-260001613103us-gaap:AdditionalPaidInCapitalMember2024-04-260001613103us-gaap:RetainedEarningsMember2024-04-260001613103us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-260001613103us-gaap:ParentMember2024-04-260001613103us-gaap:NoncontrollingInterestMember2024-04-260001613103us-
gaap:RetainedEarningsMember2024-04-272024-07-260001613103us-gaap:ParentMember2024-04-272024-07-260001613103us-gaap:NoncontrollingInterestMember2024-04-272024-07-
2600016131032024-04-272024-07-260001613103us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-272024-07-260001613103us-gaap:CommonStockMember2024-04-272024-
07-260001613103us-gaap:AdditionalPaidInCapitalMember2024-04-272024-07-260001613103us-gaap:CommonStockMember2024-07-260001613103us-
gaap:AdditionalPaidInCapitalMember2024-07-260001613103us-gaap:RetainedEarningsMember2024-07-260001613103us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-
260001613103us-gaap:ParentMember2024-07-260001613103us-gaap:NoncontrollingInterestMember2024-07-2600016131032024-07-260001613103us-gaap:RetainedEarningsMember2024-07-
272024-10-250001613103us-gaap:ParentMember2024-07-272024-10-250001613103us-gaap:NoncontrollingInterestMember2024-07-272024-10-250001613103us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-272024-10-250001613103us-gaap:CommonStockMember2024-07-272024-10-250001613103us-
gaap:AdditionalPaidInCapitalMember2024-07-272024-10-250001613103us-gaap:CommonStockMember2024-10-250001613103us-gaap:AdditionalPaidInCapitalMember2024-10-
250001613103us-gaap:RetainedEarningsMember2024-10-250001613103us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-10-250001613103us-gaap:ParentMember2024-10-
250001613103us-gaap:NoncontrollingInterestMember2024-10-250001613103us-gaap:CommonStockMember2023-04-280001613103us-gaap:AdditionalPaidInCapitalMember2023-04-
280001613103us-gaap:RetainedEarningsMember2023-04-280001613103us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-280001613103us-gaap:ParentMember2023-04-
280001613103us-gaap:NoncontrollingInterestMember2023-04-2800016131032023-04-280001613103us-gaap:RetainedEarningsMember2023-04-292023-07-280001613103us-
gaap:ParentMember2023-04-292023-07-280001613103us-gaap:NoncontrollingInterestMember2023-04-292023-07-2800016131032023-04-292023-07-280001613103us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-292023-07-280001613103us-gaap:CommonStockMember2023-04-292023-07-280001613103us-
gaap:AdditionalPaidInCapitalMember2023-04-292023-07-280001613103us-gaap:CommonStockMember2023-07-280001613103us-gaap:AdditionalPaidInCapitalMember2023-07-
280001613103us-gaap:RetainedEarningsMember2023-07-280001613103us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-280001613103us-gaap:ParentMember2023-07-
280001613103us-gaap:NoncontrollingInterestMember2023-07-2800016131032023-07-280001613103us-gaap:RetainedEarningsMember2023-07-292023-10-270001613103us-
gaap:ParentMember2023-07-292023-10-270001613103us-gaap:NoncontrollingInterestMember2023-07-292023-10-270001613103us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-292023-10-270001613103us-gaap:CommonStockMember2023-07-292023-10-270001613103us-
gaap:AdditionalPaidInCapitalMember2023-07-292023-10-270001613103us-gaap:CommonStockMember2023-10-270001613103us-gaap:AdditionalPaidInCapitalMember2023-10-
270001613103us-gaap:RetainedEarningsMember2023-10-270001613103us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-270001613103us-gaap:ParentMember2023-10-
270001613103us-gaap:NoncontrollingInterestMember2023-10-2700016131032023-10-270001613103us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember2024-07-272024-10-250001613103us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember2023-07-292023-10-270001613103us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember2024-04-272024-10-250001613103us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember2023-04-292023-10-270001613103us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:StructuralHeartAndAorticDivisionMember2024-07-272024-10-250001613103us-

[illegible]

[illegible]

[illegible]

notes included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. The Company's fiscal years 2025, 2024, and 2023 will end or ended on April 25, 2025, April 26, 2024, and April 28, 2023, respectively. 2. New Accounting Pronouncements Recently Adopted Accounting Standards As of October 25, 2024, there have been no newly adopted accounting pronouncements that materially impact our consolidated financial statements. Refer to the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024 for pronouncements recently adopted. Not Yet Adopted Accounting Standards Segment Reporting In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. Income Taxes In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures. 3. Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Certain prior period net sales have been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. Refer to Note 17 to the consolidated financial statements for additional information regarding the Company's reporting structure. In addition, starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales have been recast to conform to the new presentation. 6 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) The table below illustrates net sales by segment and division and by market geography for the three and six months ended October 25, 2024 and October 27, 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries. World-wide Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Cardiac Rhythm & Heart Failure \$1,578A \$1,492A \$3,114A \$2,938A Structural Heart & Aortic 881A 819A 1,736A 1,633A Coronary & Peripheral Vascular 643A 613A 1,259A 1,202A Cardiovascular 3,102A 2,923A 6,108A 5,773A Cranial & Spinal Technologies 1,234A 1,157A 2,382A 2,260A Specialty Therapies 737A 705A 1,450A 1,400A Neuromodulation 480A 426A 937A 846A Neuroscience 2,451A 2,288A 4,768A 4,506A Surgical & Endoscopy 1,649A 1,641A 3,193A 3,187A Acute Care & Monitoring 748A 622A 930A 921A Medical Surgical 2,128A 2,103A 4,123A 4,107A Diabetes 686A 610A 1,333A 1,189A Reportable segment net sales 8,366A 7,923A 16,333A 15,575A Other operating segment (1) 37A 61A 75A 111A Other adjustments (2) (A) (A) (90) (A) Total net sales \$8,403A \$7,984A \$16,318A \$15,686A A U.S. International U.S. International Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Cardiovascular 1,434A 1,427A \$1,668A 1,496A \$2,836A \$2,776A \$2,966A Neuroscience 1,677A 1,560A 774A 728A 3,242A 3,057A 1,526A 1,449A Medical Surgical 944A 948A 1,183A 1,155A 1,825A 1,815A 2,298A 2,292A Diabetes 232A 217A 455A 394A 447A 405A 886A 784A Reportable segment net sales 4,286A 4,151A 4,080A 3,772A 8,350A 8,054A 7,983A 7,521A Other operating segment (1) 118A 23A 19A 37A 37A 45A 38A 66A Other adjustments (2) (A) (A) (A) (A) (A) (A) (A) (A) (90) (A) Total net sales \$4,304A \$4,175A \$4,099A \$3,809A \$8,387A \$8,099A \$7,931A \$7,587A (1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested. (2) Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At October 25, 2024, \$1.0 billion of rebates were classified as other accrued expenses, and \$639 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 26, 2024, \$1.0 billion of rebates were classified as other accrued expenses, and \$574 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. 7 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) Deferred Revenue and Remaining Performance Obligations Deferred revenue at October 25, 2024 and April 26, 2024 was \$467 million and \$453 million, respectively. At October 25, 2024 and April 26, 2024, \$369 million and \$352 million was included in other accrued expenses, respectively, and \$98 million and \$101 million was included in other liabilities, respectively. During the six months ended October 25, 2024, the Company recognized \$196A million of revenue that was included in deferred revenue as of April 26, 2024. During the six months ended October 27, 2023, the Company recognized \$216A million of revenue that was included in deferred revenue as of April 28, 2023. Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At October 25, 2024, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately \$0.4 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years. 4. Acquisitions and Dispositions Acquisition Activity During the three and six months ended October 25, 2024, the Company had no acquisitions that were accounted for as business combinations. During the fiscal year ended April 26, 2024, the Company had acquisitions that were accounted for as business combinations. For the three and six months ended October 25, 2024 and the fiscal year ended April 26, 2024, purchase price allocation adjustments were not significant. Fiscal year 2024 The acquisition date fair value of net assets acquired during the fiscal year ended April 26, 2024 was \$335A million. Based on preliminary valuations, assets acquired were primarily comprised of \$131A million of goodwill, \$150A million of IPR&D, and \$29A million of technology-based intangible assets with estimated useful lives of 10 years. For tax purposes, \$51A million of goodwill is deductible while \$80A million is not deductible. The IPR&D was placed into service as a definite-lived intangible asset during the second quarter of fiscal year 2025. The Company recognized \$30A million of non-cash contingent consideration liabilities in connection with these business combinations during the fiscal year ended April 26, 2024, which are comprised of revenue and product development milestone-based payments. Contingent Consideration Certain of the Company's business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within other operating income, net in the consolidated statements of income. The fair value of contingent consideration liabilities at October 25, 2024 and April 26, 2024 was \$124 million and \$149A million, respectively. At October 25, 2024, \$77 million was recorded in other accrued expenses, and \$47 million was recorded in other liabilities in the consolidated balance sheet. At April 26, 2024, \$96 million was recorded in other accrued expenses, and \$53 million was recorded in other liabilities in the consolidated balance sheet. The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities: Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Beginning balance \$128A \$206A \$149A \$206A Purchase price contingent consideration (A) 25A (A) 25A Payments (8) (A) (14) (3) Change in fair value 4A (10) (11) (7) Ending balance \$124A \$220A \$151A \$220A 8 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs: Fair Value at (in millions) October 25, 2024 Unobservable Input Range Weighted Average (1) Revenue and other performance-based payments \$58 Discount rate 16.5% - 28.2% 22.1% Projected fiscal year of payment 2025 - 2029 2027 Product development and other milestone-based payments \$66 Discount rate 5.5% 5.5% Projected fiscal year of payment 2025 - 2027 2025 (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average. On April 1, 2023, the Company and DaVita Inc. (a DaVita Inc.) completed the transaction for the Company to sell half of its Renal Care Solutions (RCS) business. In connection with the sale, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2026 through 2029. The fair value of the contingent consideration receivable at October 25, 2024 and April 26, 2024 was \$61 million and \$58A million, and was recorded in other assets in the consolidated balance sheet. The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable: Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Beginning balance \$58A \$152A \$58A \$195A Change in fair value 3A (A) 3A (43) Ending balance \$61A \$152A \$61A \$152A 5. Restructuring and Other Costs Restructuring and associated costs for the three and six months ended October 25, 2024 were \$46 million and \$108 million, respectively, as compared to \$91 million and \$182 million for the three and six months ended October 27, 2023, respectively. Restructuring and associated costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives. Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated. Associated and other costs primarily include salaries and wages of employees that are fully-dedicated to restructuring activities, consulting expenses, and asset write-offs. The following table presents the classification of restructuring and associated costs in the consolidated statements of income: Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Cost of products sold \$11A \$15A \$20A \$30A Selling, general, and administrative expenses \$46A 36A 11A 57A Restructuring charges, net \$30A 40A 77A 94A Total restructuring and associated costs \$46A \$91A \$108A \$182A 9 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) The following table summarizes the activity for the six months ended October 25, 2024: (in millions) Employee Termination Benefits Associated and Other Costs Total April 26, 2024 \$136A \$11A \$147A Charges 87A 31A 118A Cash payments (156) (25) (181) Settled non-cash (A) (4) (4) Accrual adjustments (1) (10) (A) (10) October 25, 2024 \$58A \$13A \$70A (1) Accrual adjustments primarily relate to certain employees identified for termination, finding other positions within the Company. 10 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) 6. Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at October 25, 2024 and April 26, 2024: A A A October 25, 2024 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities \$538A (A) (A) \$11 \$527A \$527A (A) Level 2: Corporate debt securities \$429A 13A (59) 3,384A 3,384A (A) U.S. government and agency securities 874A (A) (28) 845A 845A (A) Mortgage-backed securities 772A 3A (33) 742A 742A (A) Non-U.S. government and agency securities 9A (A) (A) 9A 9A (A) Other asset-backed securities 1,051A 5A (31) 1,053A 1,053A (A) Total Level 26,134A 22A (124) 6,032A 6,032A (A) Level 3: Auction rate securities 36A (A) (3) 33A (A) Total available-for-sale debt securities \$6,708A \$22A (138) \$6,592A \$6,592A \$33A April 26, 2024 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities \$494A (A) (A) (22) \$472A \$472A (A) Level 2: Corporate debt securities \$3,953A 4A (125) 3,832A 3,832A (A) U.S. government and agency securities 847A (A) (A) (80) 804A (A) Mortgage-backed securities 692A 1A (50) 643A 643A (A) Non-U.S. government and agency securities 5A (A) (A) 5A 5A (A) Other asset-backed securities 941A 2A (9) 934A (A) Total Level 26,438A 7A (227) 6,218A 6,218A (A) Level 3: Auction rate securities 36A (A) (3) 33A (A) Total available-for-sale debt securities \$6,968A \$7A (252) \$6,723A \$6,690A \$33A The amortized cost of debt securities excludes accrued interest, which is reported in other current assets in the consolidated balance sheets. 11 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) The following tables present the gross unrealized losses and fair values of the Company's available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 25, 2024 and April 26, 2024: A October 25, 2024 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities \$565A (7) \$1,645A (51) U.S. government and agency securities 216A (2) 713A (37) Mortgage-backed securities (A) (A) 535A (33) Other asset-backed securities (A) (A) 212A (3) Auction rate securities (A) (A) 33A (3) Total \$782A (10) \$3,137A (128) April 26, 2024 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities \$661A (10) \$2,448A (116) U.S. government and agency securities 177A (4) 730A (61) Mortgage-backed securities (A) (A) 582A (50) Other asset-backed securities (A) (A) 502A (9) Auction rate securities (A) (A) 33A (3) Total \$838A (14) \$4,296A (238) The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three and six months ended October 25, 2024 and October 27, 2023. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. Activity related to the Company's available-for-sale debt securities portfolio is as follows: A Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Proceeds from sales \$2,087A 1,573A \$4,244A 3,320A Gross realized gains 7A 6A 14A 11A Gross realized losses (6) (3) (13) (15) The contractual maturities of available-for-sale debt securities at October 25, 2024 is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) Amortized Cost Fair Value Due in one year or less \$1,488A \$1,478A Due after one year through five years 3,322A 3,248A Due after five years through ten years 750A 749A Due after ten years 1,148A 1,117A Total \$6,708A \$6,592A Interest income is recognized in other non-operating income, net, in the consolidated statements of income. During the three and six months ended October 25, 2024, there were \$137A million and \$249A million of interest income, respectively. During the three and six months ended October 27, 2023, there was \$148A million and \$259A million of interest income, respectively. 12 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) Equity Securities, Equity Method Investments, and Other Investments The Company holds investments in equity securities with readily determinable fair values, equity method investments for which the Company has elected the fair value option, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments for which the Company has elected the fair value option are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses a discounted cash flow methodology, taking into consideration various assumptions including discount rate, and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values, and that are not accounted for via the fair value option, are included within Level 3 of the fair value hierarchy, as they are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer. The following table summarizes the Company's equity and other investments at October 25, 2024 and April 26, 2024, which are classified as primarily other assets in the consolidated balance sheets: (in millions) October 25, 2024 April 26, 2024 Investments with readily determinable fair value (marketable equity securities) \$34A \$28A Investments for which the fair value option has been elected \$311A Investments without readily determinable fair values \$826A \$59A Equity method and other investments \$92A \$84A Total equity and other investments \$1,265A \$1,282A Gains and losses on the Company's portfolio of equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. During the three and six months ended October 25, 2024, there were \$10A million of net unrealized losses and \$7A million of net unrealized gains, respectively, on equity securities and other investments still held at October 25, 2024. During the three and six months ended October 27, 2023, there were \$7A million and \$70A million, respectively, of net unrealized losses on equity securities and other investments still held at October 27, 2023. Mozarc Medical Investments further described in Note 4, on April 1, 2023, the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50 percent equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction. Under the fair value option, changes in the fair value of the

investment are recognized through earnings each reporting period in other non-operating income, net in the consolidated statements of income. During the three and six months ended OctoberÂ 25, 2024 and OctoberÂ 27, 2023, the change in fair value was not significant.7. Financing Arrangements Commercial PaperThe Company maintains commercial paper programs that allow the Company to issue U.S. dollar or Euro-denominated unsecured commercial paper notes. The aggregate amount outstanding at any time under the commercial paper programs may not exceed the equivalent of \$3.5 billion. Commercial paper outstanding at OctoberÂ 25, 2024 was \$899 million. During the three and six months ended OctoberÂ 25, 2024, the commercial paper outstanding had a weighted average original maturity of 13 days and 14 days, respectively and a weighted average interest rate of 5.23 percent and 5.34 percent, respectively. Commercial paper outstanding at AprilÂ 26, 2024 was \$1.1 billion. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. The issuance of commercial paper reduces the amount of credit available under the Companyâ€™s existing Credit Facility, as defined below. Line of CreditThe Company has a \$3.5 billion five-year unsecured revolving credit facility (Credit Facility), which provides back-up funding for the commercial paper programs described above. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At OctoberÂ 25, 2024 and AprilÂ 26, 2024, no amounts were outstanding under the Credit Facility. 13Medtronic plcNotes to Consolidated Financial Statements(Unaudited)Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Companyâ€™s long-term debt ratings, assigned by Standard & Poorâ€™s Ratings Services and Moodyâ€™s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with the covenants under the Credit Facility. Debt ObligationsThe Company's debt obligations consisted of the following:(in millions)Maturity by Fiscal YearOctober 25, 2024April 26, 2024Current debt obligations2025 - 2026\$3,719Â \$1,092Â Long-term debt0.250 percent six-year 2019 senior notes2026â€”Â 1,070Â 2.625 percent three-year 2022 senior notes2026â€”Â 535Â 0.000 percent five-year 2020 senior notes2026â€”Â 1,070Â 1.125 percent eight-year 2019 senior notes 20271,620Â 1,606Â 4.250 percent five-year 2023 senior notes20281,000Â 1,000Â 3.000 percent six-year 2022 senior notes20291,080Â 1,070Â 0.375 percent eight-year 2020 senior notes20291,080Â 1,070Â 3.650 percent five-year 2024 senior notes2030918Â â€”Â 1.625 percent twelve-year 2019 senior notes20311,080Â 1,070Â 1.000 percent twelve-year 2019 senior notes20321,080Â 1,070Â 3.125 percent nine-year 2022 senior notes20321,080Â 1,070Â 0.750 percent twelve-year 2020 senior notes20331,080Â 1,070Â 4.500 percent ten-year 2023 senior notes20331,000Â 1,000Â 3.375 percent twelve-year 2022 senior notes20351,080Â 1,070Â 4.375 percent twenty-year 2015 senior notes20351,932Â 1,932Â 3.875 percent twelve-year 2024 senior notes2037918Â â€”Â 6.550 percent thirty-year 2007 CIFSA senior notes2038253Â 253Â 2.250 percent twenty-year 2019 senior notes20391,080Â 1,070Â 6.500 percent thirty-year 2009 senior notes2039158Â 158Â 1.500 percent twenty-year 2019 senior notes20401,080Â 1,070Â 5.550 percent thirty-year 2010 senior notes2040224Â 224Â 1.375 percent twenty-year 2020 senior notes 20411,080Â 1,070Â 4.500 percent thirty-year 2012 senior notes2042105Â 105Â 4.000 percent thirty-year 2013 senior notes2043305Â 305Â 4.150 percent nineteen-year 2024 senior notes2044648Â â€”Â 4.625 percent thirty-year 2014 senior notes2044127Â 127Â 4.625 percent thirty-year 2015 senior notes20451,813Â 1,813Â 1.750 percent thirty-year 2019 senior notes20501,080Â 1,070Â 1.625 percent thirty-year 2020 senior notes 20511,080Â 1,070Â 4.150 percent twenty-nine-year 2024 senior notes2054756Â â€”Â A Finance lease obligations2026 - 203650Â 55Â Deferred financing costs2027 - 2054(125)(110)Debt discount, net2027 - 2054(56)(55)Total long-term debt\$24,607Â \$23,932Â Interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums is recognized in interest expense, net in the consolidated statements of income. During the three and six months ended OctoberÂ 25, 2024, there was \$252.14Medtronic plcNotes to Consolidated Financial Statements(Unaudited)million and \$469Â million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums. During the three and six months ended OctoberÂ 27, 2023, there was \$230 million and \$427 million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums. Senior NotesThe Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.On June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of â‚¬3.0Â billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately \$3.2Â billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.Financial Instruments Not Measured at Fair ValueAt OctoberÂ 25, 2024, the estimated fair value of the Companyâ€™s Senior Notes was \$25.3 billion compared to a principal value of \$27.4 billion. At AprilÂ 26, 2024, the estimated fair value was \$21.2 billion compared to a principal value of \$24.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.8. Derivatives and Currency Exchange Risk Management The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.Fair Value HedgesBeginning in the first quarter of fiscal year 2025, the Company began using foreign currency forward contracts designated as fair value hedges to manage its exposure to changes in the fair value of its fixed-rate debt obligation.At inception, foreign currency forward contracts are designated as fair value hedges. Changes in the fair value of these derivatives are reported as a component of other operating income, net. Amounts excluded from the assessment of effectiveness are recognized in interest expense, net on a straight-line basis over the term of the hedge. During the three and six months ended OctoberÂ 25, 2024, after-tax unrealized losses related to included components in other operating income, net were not significant. During the three and six months ended OctoberÂ 25, 2024, amounts related to excluded components that are amortized in interest expense, net over the life of the hedging instrument were not significant. Cash flows related to the Company's derivative instruments designated as fair value hedges are reported as financing activities in the consolidated statements of cash flows. Cash flows attributed to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows. Cash Flow Hedges The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.At inception, foreign currency forward and option contracts are designated as cash flow hedges. Changes in the fair value of these derivatives are reported as a component of accumulated other comprehensive loss until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.The Company's cash flow hedges will mature within the subsequent three-year period. At OctoberÂ 25, 2024 and AprilÂ 26, 2024, the Company had \$139 million and \$229 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in accumulated other comprehensive loss. The Company expects that \$108 million of after-tax net unrealized gains at OctoberÂ 25, 2024 will be recognized in the consolidated statements of income over the next 12 months.Net Investment HedgesThe Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts.15Medtronic plcNotes to Consolidated Financial Statements(Unaudited)For instruments that are designated as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss. The gains or losses are reclassified to earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in interest expense, net on a straight-line basis over the term of the hedge. During the three and six months ended OctoberÂ 25, 2024, the Company recognized \$47 million and \$98 million, respectively, in after-tax unrealized gains representing excluded components in interest expense, net. During the three and six months ended OctoberÂ 27, 2023, the Company recognized \$50 million and \$99 million, respectively, in after-tax unrealized gains representing excluded components in interest expense, net. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows. Unesignated DerivativesThe Company uses foreign currency forward exchange contracts to offset the Companyâ€™s exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows. These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Companyâ€™s unesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.Outstanding InstrumentsThe following table presents the contractual amounts of the Company's outstanding instruments:As of (in billions)DesignationOctober 25, 2024April 26, 2024Currency exchange rate contracts(1)Fair value hedge\$1.1Â \$â€”Â A Currency exchange rate contractsCash flow hedge1.1Â 1.3Â A Currency exchange rate contracts(2)Net investment hedge7.5Â 7.4Â A Foreign currency-denominated debt(3)Net investment hedge19.4Â 17.1Â A Currency exchange rate contractsUnesignated4.7Â 5.9Â A (1)At OctoberÂ 25, 2024, includes derivative contracts with a notional value of â‚¬,â‚¬1.0 billion, or \$1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.(2)At OctoberÂ 25, 2024, includes derivative contracts with a notional value of â‚¬,â‚¬5.0 billion, or \$5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of Â¥322.2 billion, or \$2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033. (3)At OctoberÂ 25, 2024, includes â‚¬,â‚¬18.0 billion, or \$19.4 billion, of outstanding Euro-denominated debt designated as hedges of a portion of our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.16Medtronic plcNotes to Consolidated Financial Statements(Unaudited)Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging InstrumentsThe amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three and six months ended OctoberÂ 25, 2024 and OctoberÂ 27, 2023 were as follows: (Gain)Â LossÂ Recognized in Accumulated Other Comprehensive Loss(Gain) Loss Reclassified into IncomeThree months endedSix months endedThree months endedSix months endedLocation of (Gain) Loss in Income Statement(in millions)October 25, 2024October 27, 2023October 25, 2024October 27, 2023October 25, 2024October 27, 2023October 25, 2024October 27, 2023Cash flow hedgesCurrency exchange rate contracts\$â€”Â A \$(394)\$42Â A \$(398)\$(3)\$(75)\$(39)\$(125)Other operating income, netCurrency exchange rate contracts20Â A (75)â€”Â A (109)(21)(15)(39) (19)Cost of products soldNet investment hedgesForeign currency-denominated debt(91)(725)160Â A (612)â€”Â A â€”Â A â€”Â A N/A Currency exchange rate contracts52Â A (190)12Â A (160)â€”Â A â€”Â A â€”Â A â€”Â A N/A Total \$(19,384)\$214Â A \$(1,278)\$(24)\$(89)\$(78)\$(145)The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements during the three and six months ended OctoberÂ 25, 2024 and OctoberÂ 27, 2023 were as follows:(Gain) Loss Recognized in IncomeThree months endedSix months endedLocation of (Gain) Loss in Income Statement(in millions)October 25, 2024October 27, 2023October 25, 2024October 27, 2023Currency exchange rate contracts\$(35)\$94Â A \$(45)\$92Â A Other operating income, netBalance Sheet PresentationThe following table summarizes the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at OctoberÂ 25, 2024 and AprilÂ 26, 2024. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.Â Fair Value - AssetsÂ Fair Value - Liabilities(in millions)October 25, 2024April 26, 2024Balance Sheet ClassificationOctober 25, 2024April 26, 2024Balance Sheet ClassificationDerivatives designated as hedging instrumentsÂ A Â A Currency exchange rate contracts \$328Â A \$368Â A Other current assets\$56Â A \$37Â A Other accrued expensesCurrency exchange rate contracts227Â A 276Â A Other assets22Â A 17Â A Other liabilitiesTotal derivatives designated as hedging instruments\$56Â A 644Â A 78Â A 54Â A Derivatives not designated as hedging instrumentsCurrency exchange rate contracts19Â A 15Â A Other current assets32Â A 12Â A Other accrued expensesTotal return swaps15Â A â€”Â A Other current assetsâ€”Â A â€”Â A Other accrued expensesTotal derivatives not designated as hedging instruments34Â A 15Â A 32Â A 12Â A Total derivatives\$589Â A \$659Â A \$110Â A \$66Â A 17Medtronic plcNotes to Consolidated Financial Statements(Unaudited)The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. October 25, 2024April 26, 2024(in millions)Derivative AssetsDerivative LiabilitiesDerivative AssetsDerivative LiabilitiesLevel 1\$574Â A \$110Â A \$659Â A \$66Â A Level 215Â A â€”Â A â€”Â A â€”Â A Totals\$589Â A \$110Â A \$659Â A \$66Â A The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows. The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 25, 2024Gross Amount Not Offset on the Balance Sheet(in millions)Gross Amount of Recognized Assets (Liabilities)Financial InstrumentsCash Collateral (Received) PostedNet AmountDerivative assets:Currency exchange rate contracts\$574Â A \$(107)\$(52)\$417Â A Total return swaps15Â A â€”Â A â€”Â A 15Â A 589Â A (107)\$(52)\$432Â A Derivative liabilities:Currency exchange rate contracts(110)107Â A â€”Â A (4)Totals\$479Â A â€”Â A \$(52)\$428Â A April 26, 2024Gross Amount Not Offset on the Balance Sheet(in millions)Gross Amount of Recognized Assets (Liabilities)Financial InstrumentsCash Collateral (Received) PostedNet AmountDerivative assets:Currency exchange rate contracts\$659Â A \$(66)\$(101)\$492Â A Derivative liabilities:Currency exchange rate contracts(66)66Â A â€”Â A â€”Â A Totals\$593Â A â€”Â A \$(101)\$492Â A 9. Inventories Inventory balances were as follows:(in millions)October 25, 2024April 26, 2024Finished goods\$3,729Â A \$3,668Â A Work-in-process728Â A 642Â A Raw materials1,022Â A 907Â A Totals\$5,479Â A \$5,217Â A 18Medtronic plcNotes to Consolidated Financial Statements(Unaudited)10. Goodwill and Other Intangible Assets GoodwillThe following table presents the changes in the carrying amount of goodwill by segment: (in millions)CardiovascularNeuroscienceMedical SurgicalDiabetesTotalApril 26, 2024\$7,966Â A \$11,644Â A \$19,121Â A \$2,255Â A \$40,986Â A Currency translation and other4Â A 24Â A 147Â A â€”Â A 176Â A October 25, 2024\$7,970Â A \$11,668Â A \$19,268Â A \$2,255Â A \$41,161Â A As further described in Note 17, the Company had changes to the operating segments and goodwill reporting units during the fourth quarter of fiscal year 2024. For further information on the reporting unit changes, refer to Note 9 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. No goodwill impairment was recognized during the three and six months ended OctoberÂ 25, 2024 and OctoberÂ 27, 2023. The following table presents the gross carrying amount and accumulated amortization of intangible assets: October 25, 2024April 26, 2024(in millions)Gross Carrying AmountAccumulated AmortizationGross Carrying AmountAccumulated AmortizationDefinite-lived:Customer-related\$16,523Â A \$(9,164)\$16,518Â A \$(8,689)Purchased technology and patents11,727Â A (7,206)11,557Â A (6,868)Trademarks and tradenames425Â A (280)424Â A (274)Other254Â A (90)256Â A (84)Totals\$28,929Â A \$(16,741)\$28,755Â A \$(15,915)Indefinite-lived:IPR&D\$235Â A \$â€”Â A \$385Â A \$â€”Â A The Company did not recognize any definite-lived intangible asset impairment charges during the three and six months ended OctoberÂ 25, 2024 and OctoberÂ 27, 2023. The Company did not recognize any indefinite-lived intangible asset impairment charges during the three and six months ended OctoberÂ 25, 2024. Indefinite-lived intangible asset impairment charges were not significant for the three and six months ended OctoberÂ 27, 2023. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future. Amortization ExpenseIntangible asset amortization expense for the three months ended OctoberÂ 25, 2024 and OctoberÂ 27, 2023 was \$413Â million and \$425Â million, respectively. Intangible asset amortization expense for the six months ended OctoberÂ 25, 2024 and OctoberÂ 27, 2023 was \$827 million and \$855 million, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at OctoberÂ 25, 2024, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:(in millions)Amortization ExpenseRemaining 2025\$824Â A 20261,639Â A 20271,616Â A 20281,565Â A 20291,488Â A 20301,356Â A 19Medtronic plcNotes to Consolidated Financial Statements(Unaudited)11. Income Taxes The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which are effective for

Company in fiscal year 2025. We will continue to monitor the impact of further legislation, regulatory guidance, and regulations issued in the countries in which we do business. The Israeli Central-Lod District Court issued its decision in the Medtronic Ventrator Technologies Ltd (Ventrator) v. Kfar Saba Assessing Office on June 1, 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a \$187A million income tax charge during the first quarter of fiscal year 2024 and has filed an appeal with the Supreme Court of Israel. The Company's effective tax rate for the three and six months ended October 25, 2024 was 18.0% and 17.7%, respectively, as compared to 30.6% and 32.0% for the three and six months ended October 27, 2023, respectively. The decrease in the effective tax rate for the three months ended October 25, 2024, primarily relates to the establishment of a valuation allowance on certain net operating losses recorded during the three months ended October 27, 2023, which was partially offset by the implementation of the Pillar Two global minimum tax. In addition to the items discussed in the current quarter, the decrease in the effective tax rate for the six months ended October 25, 2024 was also attributable to an income tax reserve adjustment made during the six months ended October 27, 2023 associated with the Ventrator court decision noted above. At October 25, 2024 and April 26, 2024, the Company's gross unrecognized tax benefits were \$2.9A billion and \$2.8A billion, respectively. In addition, the Company had accrued gross interest and penalties of \$45A million at October 25, 2024. If all of the Company's unrecognized tax benefits were recognized, approximately \$2.7A billion would impact the Company's effective tax rate. At October 25, 2024 and April 26, 2024, the amount of the Company's gross unrecognized tax benefits, net of cash advance, recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets was \$1.9A billion and \$1.8A billion, respectively. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets. Refer to Note 16 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

12. Earnings Per Share Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share.

	Three months ended October 25, 2024	Six months ended October 25, 2024	Three months ended October 27, 2023	Six months ended October 27, 2023
Basic earnings per share	\$0.99A	\$0.99A	\$0.99A	\$0.99A
Diluted earnings per share	\$0.99A	\$0.99A	\$0.99A	\$0.99A

13. Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, performance share units, and employee stock purchase plan shares recognized for the three and six months ended October 25, 2024 and October 27, 2023.

	Three months ended October 25, 2024	Six months ended October 25, 2024	Three months ended October 27, 2023	Six months ended October 27, 2023
Stock options	\$30A	\$35A	\$42A	\$46A
Restricted stock	\$68A	\$55A	\$11A	\$9A
Performance share units	\$54A	\$48A	\$69A	\$60A
Employee stock purchase plan	\$8A	\$8A	\$19A	\$19A
Total stock-based compensation expense	\$159A	\$146A	\$229A	\$219A

Cost of products sold: \$17A \$13A \$26A \$20A Research and development expense: \$19A \$18A \$29A \$27A Selling, general, and administrative expense: \$123A \$115A \$187A \$172A Total stock-based compensation expense: \$159A \$146A \$229A \$219A Income tax benefits: (25) (25) (38) (36) Total stock-based compensation expense, net of tax: \$134A \$121A \$204A \$183A

14. Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 25, 2024 and October 27, 2023:

	Three months ended October 25, 2024	Six months ended October 25, 2024	Three months ended October 27, 2023	Six months ended October 27, 2023
Service cost	\$13A	\$15A	\$11A	\$10A
Interest cost	\$26A	\$30A	\$22A	\$20A
Expected return on plan assets	(66) (65)	(17) (17)	(132) (130)	(134)
Amortization of prior service cost	(1) (1)	(2) (2)	(1) (1)	(2) (2)
Net periodic benefit cost	\$7A	\$8A	\$10A	\$9A

15. Accumulated Other Comprehensive Loss The following table provides changes in accumulated other comprehensive loss (AOCL), net of tax, and by component: (in millions)

	Unrealized (Loss) Gain on Investment Securities	Cumulative Translation Adjustments	Net Investment Hedges	Net Change in Retirement Obligations	Unrealized Gain (Loss) on Cash Flow Hedges	Total Accumulated Other Comprehensive (Loss) Income
April 26, 2024	\$(212)	\$(3,686)	\$878A	\$(529)	\$229A	\$(3,318)
October 25, 2024	\$(101)	\$(3,468)	\$708A	\$(529)	\$139A	\$(3,250)
Change	\$(111)	\$(218)	\$(170)	\$(0)	\$(90)	\$(468)
October 27, 2023	\$(111)	\$(3,430)	\$711A	\$(529)	\$139A	\$(3,250)
Change	\$(111)	\$(218)	\$(170)	\$(0)	\$(90)	\$(468)

16. Commitments and Contingencies Legal Matters The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as certain litigation charges, net in the consolidated statements of income. The Company recognized no certain litigation charges and \$81A million of certain litigation charges during the three and six months ended October 25, 2024, respectively, whereas the Company recognized \$65A million and \$105A million of certain litigation charges during the three and six months ended October 27, 2023, respectively. At October 25, 2024 and April 26, 2024, accrued litigation was approximately \$0.2A billion. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.

Intellectual Property Matters At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages and/or royalty payments, and negatively impact the Company's ability to sell current or future products, which could have a material adverse impact on the Company's business, results of operations, financial condition, and cash flows.

Colibri The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company's Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately \$106A million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.

Product Liability Matters Hernia Mesh Litigation Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of October 30, 2024, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 8,800 individual plaintiffs, and certain plaintiffs' law firms have advised the Company that they may file additional cases in the future. Approximately 6,850 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,450 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus fewer than ten one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

23 Medtronic plc Notes to Consolidated Financial Statements (Unaudited) Diabetes Pump Retainer Ring Litigation Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of November 4, 2024, after a number of recent dismissals of individual plaintiffs, there are 23 lawsuits filed on behalf of 76 individuals. Plaintiffs' law firms previously notified the Company that they may file additional lawsuits in the future on behalf of thousands of additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Environmental Proceedings The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of

it is possible that the amount of the Company's liability could differ from the amount currently accrued. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS's position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the IRS's position. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023. The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006. Medtronic, Inc.'s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS. Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2020. Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. Refer to Note 11 for additional discussion of income taxes. Guarantees In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates' products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company's maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees. The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company's consolidated earnings, financial position, and/or cash flows. 17. Segment and Geographic Information Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. The Company's management evaluates performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest income or expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment. There have been no changes to reportable segments during the quarter ended October 25, 2024. We continue to have four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. Prior period amounts have been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. For further information on the operating segment structure changes, refer to Note 19 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. 25. Medtronic plc Notes to Consolidated Financial Statements (Unaudited) The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements: Segment Operating Profit Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Cardiovascular \$1,164 \$1,117 \$2,289 \$2,208 Neuroscience 1,024 929 1,985 1,858 Medical Surgical 774 795 1,464 1,521 Diabetes 116 101 218 186 Reportable segment operating profit 3,079 2,942 5,956 5,773 Other operating segment 1,124 1,426 2,550 2,848 Corporate (443) (903) (879) Interest expense, net (209) (180) (376) (329) Other non-operating income, net 173 154 330 230 Amortization of intangible assets (413) (425) (827) (855) Stock-based compensation (159) (166) (242) (219) Centralized distribution costs (405) (391) (800) (786) Currency (21) (39) 32 (44) Restructuring and associated costs (46) (91) (108) (182) Acquisition and divestiture-related items 25 58 13 13 Certain litigation charges, net 65 (81) (105) Medical device regulations (12) (30) (27) (62) Other adjustments (3) 3 2 2 Income before income taxes \$1,559 \$1,313 \$2,827 \$2,510 (1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested. (2) Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating income, net. (3) Incremental Italian payroll accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. Geographic Information Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three and six months ended October 25, 2024 and October 27, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries: Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 October 25, 2024 October 27, 2023 Ireland \$29 29 \$59 58 United States 4,304 4,175 8,387 8,099 Rest of world 4,070 3,780 7,872 7,528 Total other countries, excluding Ireland 8,374 7,955 16,259 15,627 Total \$8,403 \$7,984 \$16,318 \$15,686 26. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations UNDERSTANDING OUR FINANCIAL INFORMATION The following discussion and analysis provides information management believes to be relevant to understanding the financial condition and results of operations of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company, or we, us, or our). For a full understanding of financial condition and results of operations, you should read this discussion along with Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the fiscal year ended April 26, 2024. In addition, you should read this discussion along with our consolidated financial statements and related notes thereto and for the three and six months ended October 25, 2024. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding. Financial Trends Throughout this Management's Discussion and Analysis, we present certain financial measures that facilitate management's review of the operational performance of the Company and as a basis for strategic planning; however, such financial measures are not presented in our financial statements prepared in accordance with accounting principles generally accepted in the United States (U.S.) (U.S. GAAP). These financial measures are considered "non-GAAP financial measures" and are intended to supplement, and should not be considered as superior to, financial measures presented in accordance with U.S. GAAP. We believe that non-GAAP financial measures provide information useful to investors in understanding the Company's underlying operational performance and trends and may facilitate comparisons with the performance of other companies in the medical technologies industry. As presented in the GAAP to Non-GAAP Reconciliations section on the following pages, our non-GAAP financial measures exclude the impact of amortization of intangible assets and certain charges or benefits that contribute to or reduce earnings and that may affect financial trends and include certain charges or benefits that result from transactions or events that we believe may or may not recur with similar materiality or impact to our operations in future periods (Non-GAAP Adjustments). In the event there is a Non-GAAP Adjustment recognized in our operating results, the tax cost or benefit attributable to that item is separately calculated and reported. Because the effective rate can be significantly impacted by the Non-GAAP Adjustments that take place during the period, we often refer to our tax rate using both the effective rate and the non-GAAP nominal tax rate (Non-GAAP Nominal Tax Rate). The Non-GAAP Nominal Tax Rate is calculated as the income tax provision, adjusted for the impact of Non-GAAP Adjustments, as a percentage of income before income taxes, excluding Non-GAAP Adjustments. Free cash flow is a non-GAAP financial measure calculated by subtracting property, plant, and equipment additions from operating cash flows. Refer to the "GAAP to Non-GAAP Reconciliations," "Income Taxes," and "Free Cash Flow" sections for reconciliations of the non-GAAP financial measures to their most directly comparable financial measures prepared in accordance with U.S. GAAP. 27. EXECUTIVE LEVEL OVERVIEW Medtronic is the leading global healthcare technology company alleviating pain, restoring health, and extending life for millions of people around the world. Our primary products include those for cardiac rhythm disorders, cardiovascular disease, advanced and general surgical care, respiratory and monitoring solutions, neurological disorders, spinal conditions and musculoskeletal trauma, urological and digestive disorders, and ear, nose, and throat, and diabetes conditions. The following is a summary of revenue and diluted earnings per share for the three months ended October 25, 2024 and October 27, 2023, and operating cash flow for the six months ended October 25, 2024 and October 27, 2023: 28. GAAP to Non-GAAP Reconciliations The tables below present our GAAP to Non-GAAP reconciliations for the three months ended October 25, 2024 and October 27, 2023: Three months ended October 25, 2024 (in millions, except per share data) Income Before Income Taxes Income Tax Provision (Benefit) Net Income Attributable to Medtronic Diluted EPS Effective Tax Rate GAAP \$1,559 \$281 \$1,270 0.99 18.0 % Non-GAAP Adjustments: Amortization of intangible assets 413 75 338 0.26 18.2 % Restructuring and associated costs (146) 9 37 0.03 19.6 % Acquisition and divestiture-related items (2) (25) 5 (30) (0.02) (20.0) (Gain)/loss on minority investments (3) (10) 7 (1) (0.02) (100.0) Medical device regulations (4) 12 2 10 0.01 16.7 % Certain tax adjustments, net 6 16 0.01 6.0 % Non-GAAP \$1,995 \$366 \$1,620 1.26 18.3 % Three months ended October 27, 2023 (in millions, except per share data) Income Before Income Taxes Income Tax Provision (Benefit) Net Income Attributable to Medtronic Diluted EPS Effective Tax Rate GAAP \$1,313 \$402 \$909 0.68 30.6 % Non-GAAP Adjustments: Amortization of intangible assets 425 65 360 0.27 15.3 % Restructuring and associated costs (191) 16 76 0.06 17.6 % Acquisition and divestiture-related items (2) 58 7 51 0.04 12.1 % Certain litigation charges, net 65 15 50 0.04 23.1 % (Gain)/loss on minority investments (3) 25 5 21 0.02 20.0 % Medical device regulations (4) 30 6 24 0.02 20.0 % Certain tax adjustments, net 6 16 0.01 6.0 % Non-GAAP \$1,761 \$504 \$1,257 0.76 22.9 % Three months ended October 25, 2024 (in millions, except per share data) Income Before Income Taxes Income Tax Provision (Benefit) Net Income Attributable to Medtronic Diluted EPS Effective Tax Rate GAAP \$2,827 \$500 \$2,312 1.79 17.7 % Non-GAAP Adjustments: Amortization of intangible assets 827 149 678 0.52 18.0 % Restructuring and associated costs (110) 21 89 0.07 19.4 % Acquisition and divestiture-related items (2) (13) 6 19 (0.01) (46.2) Certain litigation charges, net 81 13 68 0.05 16.0 % (Gain)/loss on minority investments (3) (27) 10 38 (0.03) (37.0) Medical device regulations (4) 27 5 22 0.02 18.5 % Other (5) 90 20 70 0.05 22.2 % Certain tax adjustments, net 6 33 0.03 6.0 % Non-GAAP \$3,921 \$693 \$3,216 1.97 17.7 % Six months ended October 27, 2023 (in millions, except per share data) Income Before Income Taxes Income Tax Provision (Benefit) Net Income Attributable to Medtronic Diluted EPS Effective Tax Rate GAAP \$2,510 \$802 \$1,700 1.28 32.0 % Non-GAAP Adjustments: Amortization of intangible assets 855 130 724 0.54 15.2 % Restructuring and associated costs (118) 30 152 0.11 16.5 % Acquisition and divestiture-related items (2) 107 10 97 0.07 9.3 % Certain litigation charges, net 105 24 81 0.06 22.9 % (Gain)/loss on minority investments (3) 89 5 84 0.06 5.6 % Medical device regulations (4) 62 13 49 0.04 21.0 % Certain tax adjustments, net 6 37 0.03 6.0 % Non-GAAP \$3,910 \$640 \$3,262 1.45 16.4 % (1) Associated costs primarily include salaries and wages for employees supporting the restructuring activities, consulting expenses, and asset write-offs. (2) The charges primarily include business combination costs, changes in fair value of contingent consideration, and exit of business-related charges. The six months ended October 25, 2024 also includes gains related to certain business or asset sales. (3) We exclude unrealized and realized gains and losses on our minority investments as we do not believe that these components of income or expense have a direct correlation to our ongoing or future business operations. (4) The charges represent incremental costs of complying with the new European Union (E.U.) medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses. We consider these costs to be duplicative of previously incurred costs and/or one-time costs, which are limited to a specific time period. (5) Reflects the recognition of incremental Italian payroll accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. (6) The charge relates to an income tax reserve adjustment associated with the June 2023, Israeli Central-Lod District Court decision, the establishment of a valuation allowance against certain net operating losses and amortization of previously established deferred tax assets from intercompany intellectual property transactions. 30. Free Cash Flow Free cash flow, a non-GAAP financial measure, is calculated by subtracting additions to property, plant, and equipment from net cash provided by operating activities. Management uses this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to evaluate our operating results. Free cash flow should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with U.S. GAAP. Reconciliations between net cash provided by operating activities (the most comparable U.S. GAAP measure) and free cash flow are as follows: Six months ended (in millions) October 25, 2024 October 27, 2023 Net cash provided by operating activities \$1,944 \$1,536 Additions to property, plant, and equipment (924) (815) Free cash flow \$1,020 \$721 Refer to the Summary of Cash Flows section for drivers of the change in cash provided by operating activities. NET SALES Segment and Division Certain prior period net sales has been recast to reflect the new reporting structure in the fourth quarter of fiscal year 2024. Refer to Note 17 to the consolidated financial statements for additional information regarding the Company's reporting structure. In addition, starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales has been recast to conform to the new presentation. The charts below illustrate the percent of net sales by segment for the three months ended October 25, 2024 and October 27, 2023: 31. The table below illustrates net sales by segment and division for the three and six months ended October 25, 2024 and October 27, 2023: Three months ended Six months ended (in millions) October 25, 2024 October 27, 2023 Change October 25, 2024 October 27, 2023 Change Cardiac Rhythm & Heart Failure \$1,578 \$1,492 6 % \$3,114 \$2,938 6 % Structural Heart & Aortic \$881 \$819 8 % 1,736 1,633 6 % Coronary & Peripheral Vascular 643 613 5 % 1,259 1,202 5 % Cardiovascular 3,102 2,923 6 % 6,108 5,773 6 % Cranial & Spinal Technologies 1,234 1,157 7 % 2,382 2,260 5 % Specialty Therapies 737 705 5 % 1,450 1,400 4 % Neuromodulation 480 426 13 % 937 846 11 % Neuroscience 2,451 2,288 7 % 4,768 4,506 6 % Surgical & Endoscopy 1,649 1,641 1 % 3,193 3,187 0 % Acute Care & Monitoring 478 462 4 % 930 921 1 % Medical Surgical 2,128 2,103 1 % 4,123 4,107 0 % Diabetes 686 610 12 % 1,333 1,189 12 % Reportable segment net sales 8,366 7,923 6 % 16,333 15,575 5 % Other operating segment (1) 37 61 39 75 111 32 Other adjustments (2) 6 3 2 6 10 4 Total net sales \$8,403 \$7,984 5 % \$16,318 \$15,686 4 % (1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested. (2) Incremental Italian payroll accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. Segment and Market Geography The charts below illustrate the percent of net sales by market geography for the three months ended October 25, 2024 and October 27, 2023: 32. The table below includes net sales by market geography for each of our segments for the three and six months ended October 25, 2024 and October 27, 2023: A U.S. (1) International (2) Three months ended Three months ended (in millions) October 25, 2024 October 27, 2023 Change October 25, 2024 October 27, 2023 Change Cardiovascular \$1,434 \$1,427 1 % \$1,668 \$1,496 12 % Neuroscience 1,677 1,560 8 % 774 728 6 % Medical Surgical 944 948 0 % 1,183 1,155 3 % Diabetes 232 217 7 % 455 394 16 % Reportable segment net sales 4,286 4,151 3 % 4,080 3,772 8 % Other operating segment (3) 18 23 22 19 37 49 Total net sales \$4,304 \$4,175 3 % \$4,099 \$3,809 8 % A U.S. (1) International (2) Six months ended Six months ended (in millions) October 25, 2024 October 27, 2023 Change October 25, 2024 October 27, 2023 Change Cardiovascular \$2,836 \$2,766 2 % \$3,272 \$2,996 9 % Neuroscience 3,242 3,057 6 % 1,526 1,449 5 % Medical

Surgical,1,825\$ 1,815\$ 1.4, 2,298\$ 2,292\$ æ” Å Diabetes447\$ 405\$ 10\$ 886\$ 784\$ 13\$ Reportable segment net sales\$8,350\$ 4\$ 8,054\$ 4\$ 7,983\$ 7,521\$ 6\$ Other operating segment(3)37\$ 45\$ (19)38\$ 66\$ (42)Other adjustments(4)\$ æ” Å æ” Å (90)\$ Å 100\$ Total net sales\$8,387\$ 4\$ \$7,931\$ \$7,587\$ 5\$ % (1)U.S. includes the United States and U.S. territories.(2)Includes all other non-U.S. countries and U.S. territories.(3)Includes historical operations and ongoing transition agreements from businesses the Company has exited or divested.(4)Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.The increase in net sales for the three and six months ended October\$ 25, 2024, as compared to the corresponding periods in the prior fiscal year, was driven primarily by growth in most businesses, including strong growth in Diabetes, Cranial & Spinal Technologies, Neuromodulation, TAVR, Cardiac Rhythm Management, and Cardiac Surgery. The increase in net sales for the six months ended October 25, 2024, was partially offset by the \$90 million incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.Looking ahead, a number of macro-economic and geopolitical factors could negatively impact our business, including without limitation: æ” Å Competitive product launches and pricing pressure, geographic macro-economic developments including changes in global trade policies and fluctuations in currency exchange rates, general price inflation, changes in interest rates, reimbursement challenges, impacts from changes in the mix of our product offerings, delays in product registration approvals, replacement cycle challenges, and supply chain challenges from time to time;æ” Å National and provincial tender pricing for certain products, particularly in China;æ” Å The sanctions and other measures being imposed in response to the Russia-Ukraine conflict are having, and could continue to have impacts on revenue and supply chain. The financial impact of the conflict in the second quarter of fiscal year 2025, including on accounts receivable and inventory reserves, was not material, and for the three and six months ended October\$ 25, 2024, the business of the Company in these countries represented less than 1% of the Company’s consolidated revenues and assets. Although the implications of this conflict are difficult to predict at this time, the ongoing conflict may increase pressure on the global economy and supply chains, resulting in increased future volatility risk for our business operations and performance.33æ” Å Although the long-term implications of Israel’s recent conflicts are difficult to predict at this time, the financial impact of the conflicts in the second quarter of fiscal year 2025, including on accounts receivable and inventory reserves, was not material. As of October\$ 25, 2024, the Company had 6 facilities and approximately 1,500 employees in Israel. For the three and six months ended October\$ 25, 2024, the business of the Company in Israel represented less than 1% of the Company’s consolidated revenues and assets.CardiovascularCardiovascular products include pacemakers, insertable cardiac monitors, cardiac resynchronization therapy devices, implantable cardioverter defibrillators, leads and delivery systems, products for the treatment of atrial fibrillation, information systems for the management of patients with Cardiac Rhythm & Heart Failure devices, products designed to reduce surgical site infections, coronary and peripheral stents and related delivery systems, balloons and related delivery systems, endovascular stent graft systems, heart valve replacement technologies, cardiac tissue ablation systems, and open heart and coronary bypass grafting surgical products. Cardiovascular also includes Care Management Services and Cath Lab Managed Services (CLMS) within the Cardiac Rhythm & Heart Failure division. Cardiovascular’s net sales for the three and six months ended October\$ 25, 2024 were \$3.1 billion and \$6.1 billion, an increase of 6 percent for both periods as compared to the corresponding periods in the prior fiscal year. The net sales increase was primarily due to strong performance of TAVR, Cardiac Rhythm Management, and Cardiac Surgery. The graphs below illustrate the percent of Cardiovascular net sales by division for the three months ended October\$ 25, 2024 and October\$ 27, 2023:Cardiac Rhythm & Heart Failure (CRHF) net sales for the three and six months ended October\$ 25, 2024 increased 6 percent for both periods as compared to the corresponding periods in the prior fiscal year. The net sales increase was driven by Cardiac Pacing Therapies and Defibrillation Solutions with growth in Micra transcatheter pacing systems, Aurora extracardiac implantable cardioverter defibrillator (EV-ICD) system, and TRYX. Cardiac Ablation Solutions experienced strong growth in PulseSelect Pulsed Field Ablation with offsetting declines in cryoablation.Structural Heart & Aortic (SHA) net sales for the three and six months ended October\$ 25, 2024 increased 8 percent and 6 percent, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales increase was driven by U.S. and international growth in Structural Heart from adoption of Evolut FX+ TAVR system and in Cardiac Surgery driven by growth in Perfusion and Surgical Valves.Coronary & Peripheral Vascular (CPV) net sales for the three and six months ended October\$ 25, 2024 increased 5 percent for both periods as compared to the corresponding periods in the prior fiscal year. The increase in net sales was driven by growth in Coronary led by guide catheters and balloons, in addition to growth in Peripheral Vascular and Vascular Embolization.34In addition to the macro-economic and geopolitical factors described in the Executive Level Overview, looking ahead, we expect Cardiovascular could be affected by the following:æ” Å Continued global penetration of our Micra transcatheter pacing portfolio.æ” Å Continued acceptance and growth from the Azure XT and Azure S SureScan pacing systems and the 3830 lead.æ” Å Global adoption of Aurora Extravascular ICD.æ” Å Growth of the Cobalt and Crome portfolio of ICDs and CRT-Ds.æ” Å Growth of the CRT-P quadripolar pacing system.æ” Å Continued growth, adoption, and utilization of the TYRX Envelope for implantable devices. æ” Å Continued use and acceptance of Reveal LINQ and expansion of the LINQ II cardiac monitor.æ” Å Continued acceptance, adoption, and growth of our innovative portfolio of products in the electrophysiology (EP) segment, including the Arctic Front cryoablation system, PulseSelect PFA, and Affera mapping and ablation system. The Affera mapping and ablation system and Sphere-9 catheter received U.S. FDA approval in late October 2024. æ” Å Continued acceptance and growth of the self-expanding CoreValve Evolut transcatheter aortic valve replacement platform. This includes Evolut PRO which provides enhanced hemodynamics, reliable delivery, enhanced durability, advanced sealing, and Evolut FX, a system designed to improve the overall procedural experience through enhancements in deliverability, implant visibility, and deployment stability. The Evolut FX+ TAVR system maintains the valve performance benefits of the legacy Evolut TAVR platform and is designed to facilitate coronary access. The system was approved by the U.S. FDA in March 2024 and received CE Mark in late October 2024.æ” Å Market acceptance and reimbursement for the Symplixity Spinal renal denervation system, also known as the Symplixity blood pressure procedure, for the treatment of hypertension.æ” Å Continued acceptance and growth of the Onyx Frontier DES platform. Onyx Frontier is a DES that introduces an enhanced delivery system and is used for complex percutaneous coronary intervention (PCI).æ” Å Acceptance and growth of IN.PACT 018 drug-coated balloons (DCB). IN.PACT 018 adds to the existing IN.PACT Admiral DCB portfolio and is used to treat femoropopliteal disease.æ” Å Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline.NeuroscienceNeuroscience’s products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems, robotic guidance systems used in the robot-assisted spine procedures, and systems that incorporate advanced energy surgical instruments. Neuroscience’s products also focus on therapies to treat the diseases of the vasculature in and around the brain, including coils, neurovascular stents, and flow diversion products, as well as products to treat ear, nose, and throat (ENT), and the treatment of overactive bladder and urinary retention. Neuroscience also manufactures products related to implantable neurostimulation therapies and drug delivery systems for the treatment of chronic pain, movement disorders, and epilepsy. Neuroscienceæ” Å ’s net sales for the three and six months ended October\$ 25, 2024 were\$ 2.5 billion and \$4.8 billion, respectively, an increase of 7 percent and 6 percent, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales increase for both periods was primarily due to growth in Neuromodulation, Spine and Biologics, Neurosurgery, and Hemorrhagic Stroke.35The graphs below illustrate the percent of Neuroscience net sales by division for the three months ended October\$ 25, 2024 and October\$ 27, 2023:Cranial & Spinal Technologies (CST) net sales for the three and six months ended October\$ 25, 2024 increased 7 percent and 5 percent, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales increase was driven by the continued adoption of the AIBLE ecosystem of spine implants and enabling technology with growth in Core Spine, Biologics, and Neurosurgery.Specialty Therapies (Specialty) net sales for the three and six months ended October\$ 25, 2024 increased 5 percent and 4 percent, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales increase was driven by hemorrhagic stroke products, growth on continued adoption of the Interstim X system, and ENT.Neuromodulation (NM) net sales for the three and six months ended October\$ 25, 2024 increased 13 percent and 11 percent, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales increase was driven by the continued launch of both the Inceptiv spinal cord stimulator in the U.S. and the Percept RC deep brain neurostimulator.In addition to the macro-economic and geopolitical factors described in the Executive Level Overview, looking ahead we expect Neuroscience could be affected by the following:æ” Å Continued adoption and growth of our integrated solutions through the AIBLE offering, which integrates spinal implants with enabling technologies (StealthStation, O-arm Imaging Systems, and Midas), Mazor robotics, and UNiD Adaptive Spine Intelligence AI-driven technology for surgical planning and personalized spinal implants.æ” Å Market acceptance and continued global adoption of innovative new spine products and procedural solutions within our CST operating unit, such as Catalyft PL, ModuleX, CD Horizon Voyager System, and our Infinity OCT System, as well as continued growth from Titan spine titanium interbody implants with Nanolock technology.æ” Å Continued growth of Pipeline Embolization Devices, endovascular treatments for large or giant wide-necked brain aneurysms.æ” Å Continued acceptance and growth of the Solitaire X revascularization device for treatment of acute ischemic stroke and our React Catheter and Riptide aspiration system.æ” Å Continued acceptance and growth of our Pelvic Health therapies, including our InterStim therapy with InterStim X and InterStim II recharge-free neurostimulators and InterStim Micro rechargeable neurostimulator for patients suffering from overactive bladder, (non-obtrusive) urinary retention, and chronic fecal incontinence. 36æ” Å Continued acceptance and growth of our ENT therapies, including capital equipment sales of the StealthStation ENT surgical navigation system and intraoperative NIM nerve monitoring system, and the Propel sinus implants used in the treatment of chronic rhinosinusitis.æ” Å Continued acceptance and growth from spinal cord stimulation (SCS) therapy for treating chronic pain and Diabetic Peripheral Neuropathy (DPN) on the Inceptiv closed-loop rechargeable neurostimulator, Intellis rechargeable neurostimulator and Vanta recharge-free neurostimulator. The Inceptiv closed-loop rechargeable SCS received U.S. FDA approval in April 2024.æ” Å Continued acceptance and growth of our Percept family of deep brain stimulation (DBS) devices with proprietary BrainSense technology for objectifying and personalizing the treatment of Parkinson’s Disease, epilepsy, and other movement disorders. In August 2024, the U.S. FDA approved Asleep DBS surgery for people with Parkinson’s and people with essential tremor. æ” Å Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include hemorrhagic stroke intravascular device and our next-generation spine enabling technologies.Medical Surgical Medical Surgicalæ” Å ’s products span the entire continuum of patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, obesity, and preventable complications. The products include those for advanced and general surgical products, surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, hernia mechanical devices, mesh implants, advanced ablation, interventional lung, airway products, and sensors and monitors for pulse oximetry, capnography, level of consciousness and cerebral oximetry. Medical Surgical’s net sales for the three and six months ended October\$ 25, 2024 were \$2.1 billion and \$4.1 billion, an increase of 1 percent and flat, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales were primarily impacted by growth in Advanced Energy and Blood Oxygen Management with partially offsetting declines in Stapling.The graphs below illustrate the percent of Medical Surgical net sales by division for the three months ended October\$ 25, 2024 and October\$ 27, 2023:37Surgical & Endoscopy (SE) net sales for the three and six months ended October\$ 25, 2024 increased 1 percent and flat, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales for both periods were impacted by growth in Advanced Energy, driven by continued adoption of the LigaSure Maryland XP vessel sealer, and strength in Hernia and Wound Management products. The net sales results were partially offset by declines in Advanced Stapling and Endoscopy. Acute Care & Monitoring (ACM) net sales for the three and six months ended October\$ 25, 2024 increased 4 percent and 1 percent, respectively, as compared to the corresponding periods in the prior fiscal year. The net sales increase for both periods was largely due to growth in Nellcor pulse oximetry driven by strong sensor sales and continued adoption of the RespArray patient monitor in addition to strength in Bispectral Index monitoring system (BIS).In addition to the macro-economic and geopolitical factors described in the Executive Level Overview, looking ahead we expect Medical Surgical could be affected by the following:æ” Å Acceptance and continued growth of Open-to-MIS (minimally invasive surgery) techniques and tools through our efforts to transition open surgery to MIS. Open-to-MIS initiative focuses on capturing the market opportunity that exists in transitioning open procedures to MIS, whether through traditional MIS, advanced instrumentation, or robotics. Through our approach, in parallel, we also expand our presence and optimize open surgery in current open surgery markets.æ” Å Continued global acceptance and future growth of powered stapling and energy platform.æ” Å Our ability to execute ongoing strategies addressing the near-term pressures to bariatric surgery procedure volumes in the U.S. from pharmaceuticals, and growth of surgical soft tissue robotics procedures in the U.S.æ” Å Our ability to create markets and drive products and procedures into emerging markets with our high quality and cost-effective surgical products designed for customers in emerging markets. æ” Å Continued acceptance and growth in patient monitoring and airway management. Key products in this area include Microstream Capnography, Nellcor pulse oximetry system with OxiMax technology, Shiley tracheostomy and endotracheal tubes, and McGRATH MAC video laryngoscopes.æ” Å Acceptance of less invasive standards of care in chronic and colorectal, as well as hepatology products, including products that span the care continuum from diagnostics to therapeutics. Recently launched products include GI Genius.æ” Å Expanding the use of less invasive treatments and furthering our commitment to improving options for women with abnormal uterine bleeding. Our expanded and strengthened surgical offerings complement our global gynecology business.æ” Å Global adoption of robotic-assisted surgery and installations of Hugo robotic assisted surgery (RAS) system for urologic, bariatric, gynecologic, hernia, and general surgery procedures. This includes continued integration and adoption of Touch Surgery Enterprise with the first artificial intelligence powered surgical videos and analytics platform to make it easier to train and discover new techniques within the robotics platform. The Hugo RAS system, which received CE Mark in October 2021, as well as secured additional regulatory approvals outside the U.S., is designed to help reduce unwanted variability, improve patient outcomes, and, by extension, lower per procedure cost.æ” Å Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, which include our Hugo RAS system in the U.S., the adoption of AI in Endoscopy, Signia powered stapling devices, and our next-gen Ligasure and Sonication vessel sealing devices.DiabetesDiabetes’ products include insulin pumps, continuous glucose monitoring (CGM) systems, and consumables. Diabetes’ net sales for the three and six months ended October\$ 25, 2024 were \$686 million and \$1.3 billion, respectively, an increase of 12 percent for both periods as compared to the corresponding periods in the prior fiscal year. The increase in net sales for both periods was primarily driven by strong U.S growth as a result of the continued adoption of the MiniMed 780G automated insulated delivery (AID) system, and strong international growth in CGM systems from increased attachment rates and adoption of Simplera Sync.In addition to the macro-economic and geopolitical factors described in the Executive Level Overview, looking ahead we expect Diabetes could be affected by the following:æ” Å Continued acceptance and growth for the MiniMed 780G insulin pump system, which is powered by SmartGuard technology and features the added benefits of meal detection technology that automatically adjusts and corrects sugar levels every five minutes. The global adoption of our AID systems has resulted in strong sensor attachment rates. The MiniMed 780G insulin pump system with the Guardian 4 Sensor is available in the U.S., and the MiniMed 780G insulin pump system with Simplera Sync received CE Mark in early January 2024.38æ” Å Continued acceptance and growth of the Guardian Connect CGM system, which displays glucose information directly to a smartphone to provide patients access to their glucose levels seamlessly and discretely. The Guardian Connect CGM system is available on both Apple iOS and Android devices.æ” Å Market acceptance and growth of our sensor Simplera, which received U.S FDA approval in August 2024 and CE Mark in September 2023. æ” Å Market acceptance and growth of our InPen smart pen system, which allows users to have their Medtronic CGM readings in real-time alongside insulin dose information, all in one view. æ” Å Continued pump, CGM, and consumable competition in an expanding global market. æ” Å Changes in medical reimbursement policies and programs, along with additional payor coverage on insulin pumps.æ” Å Our ability to meet growing demand for our existing products and to successfully develop, obtain regulatory approval of and commercialize the products within our pipeline, including our Minimed 780G insulin pump system with Simplera Sync in the U.S., and the products resulting from our partnership with Abbott to expand CGM options for people living with diabetes.COSTS AND EXPENSESThe following is a summary of cost of products sold, research and development, and selling, general, and administrative expenses as a percent of net sales for the three and six months ended October\$ 25, 2024 and October\$ 27, 2023:Cost of Products Sold Cost of products sold for the three and six months ended October\$ 25, 2024 was \$2.9 billion and \$5.7 billion, respectively, as compared to \$2.8 billion and \$5.4 billion, respectively, for the corresponding periods in the prior fiscal year. The increase in cost products sold as a percentage of net sales for the three and six months ended October\$ 25, 2024 was primarily due to unfavorable currency impact.Research and Development Expense We remain committed to deliver the best possible experiences for patients, physicians, and caregivers we serve; to create technologies that expand whatæ” Å ’s possible across the human body to transform lives; to turn data and insights into real action to serve patient needs, improving care; and to expand healthcare access and deliver positive outcomes. Research and development expense for the three and six months ended October\$ 25, 2024 was \$697 million and \$1.4 billion, respectively, as compared to \$698 million and \$1.4 billion, respectively, for the corresponding periods in the prior fiscal year.Selling, General, and Administrative Expense Our goal is to

continue to leverage selling, general, and administrative expense management initiatives. Selling, general, and administrative expense primarily consists of salaries and wages, other administrative costs, such as professional fees and marketing expenses, certain acquisition and divestiture-related costs, and restructuring associated expenses. Selling, general, and administrative expense for the three and six months ended October 25, 2024 was \$2.8 billion and \$5.4 billion, respectively, as compared to \$2.7 billion and \$5.3 billion, respectively, for the corresponding periods in the prior fiscal year. The increase in selling, general, and administrative expense for both periods is primarily due to new product launches and commercialization activities.39The following is a summary of other costs and expenses (income):Three months endedSix months ended(in millions)October 25, 2024October 27, 2023October 25, 2024October 27, 2023Amortization of intangible assets\$413A \$425A \$827A \$855A Restructuring charges, net30A 40A 77A 94A Certain litigation charges, netA 65A 81A 105A Other operating income, net(34) (31)(33)(30)Other non-operating income, net(173)(154)(330)(230)Interest expense, net209A 180A 376A 329A Amortization of Intangible Assets Amortization of intangible assets includes the amortization expense of our definite-lived intangible assets, consisting of purchased patents, trademarks, tradenames, customer relationships, purchased technology, and other intangible assets. Restructuring Charges, Net For the three and six months ended October 25, 2024 and October 27, 2023, restructuring costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives.For additional information about our restructuring activities, refer to Note 5 to the current period's consolidated financial statements.Certain Litigation Charges, Net We classify specified certain litigation charges and gains related to significant legal matters as certain litigation charges, net in the consolidated statements of income. For additional information, refer to Note 16 in the current period's consolidated financial statements. Other Operating Income, Net Other operating income, net primarily includes expenses associated with royalties paid for the in-license of intellectual property from third parties, currency remeasurement and derivative gains and losses, changes in the fair value of contingent consideration, certain acquisition and divestiture-related items, and income from funded research and development arrangements.For the three and six months ended October 25, 2024, the increase in other operating income, net was largely driven by insignificant gains from certain business or asset sales in the Cardiovascular and Neuroscience Portfolio. The increase in other operating, income net was partially offset by the net impact of currency remeasurement and our hedging programs, which resulted in net expense of \$39A million and \$44A million for the three and six months ended October 25, 2024, respectively, as compared to a net gain of \$32A million and \$29A million, respectively, in the corresponding periods in the prior fiscal year. Other Non-Operating Income, Net Other non-operating income, net includes the non-service component of net periodic pension and postretirement benefit cost, investment gains and losses, and interest income.For the three months and six months ended October 25, 2024, the increase in other non-operating income, net is primarily attributable to an increase in net gains on our minority investment portfolio. Net gains on minority investments were \$10A million and \$27A million for the three and six months ended October 25, 2024, respectively, compared to net losses of \$25A million and \$89A million for the three and six months ended October 27, 2023, respectively. Interest Expense, Net Interest expense, net includes interest incurred on our outstanding borrowings, amortization of debt issuance costs and debt premiums or discounts, and amortization of amounts excluded from the effectiveness assessment of certain net investment and fair value hedges.For the three and six months ended October 25, 2024, the increase in interest expense, net was primarily driven by the A~3.0A billion debt issuance on June 3, 2024. 40INCOME TAXESThree months endedSix months ended(in millions)October 25, 2024October 25, 2023October 25, 2024October 27, 2023Income tax provisions281A 402A \$500A \$802A Income before income taxes1,559A 1,313A 2,827A 2,510A Effective tax rate18.0A %30.6A %17.7A %32.0A %Non-GAAP income tax provisions366A \$339A \$693A \$640A Non-GAAP income before income taxes1,995A 2,008A 3,921A 3,910A Non-GAAP Nominal Tax Rate18.3A %16.9A %17.7A %16.4A %Difference between the effective tax rate and Non-GAAP Nominal Tax Rate0.3A % (13.7)%A A % (15.6)%The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which are effective for Medtronic in fiscal year 2025. We will continue to monitor the impacts of further legislation, regulatory guidance, and regulations issued in the countries in which we do business.The Israeli Central-Lod District Court issued its decision in Medtronic Vantor Technologies Ltd (Vantor) v. Kfar Saba Assessing Office on June 1, 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a \$187A million income tax charge during the first quarter of fiscal year 2024 and has filed an appeal with the Supreme Court of Israel.Our effective tax rate for the three and six months ended October 25, 2024 was 18.0% and 17.7%, respectively, as compared to 30.6% and 32.0% for the three and six months ended October 27, 2023, respectively. The decrease in our effective tax rate for the three months ended October 25, 2024 primarily relates to the establishment of a valuation allowance on certain net operating losses recorded during the three months ended October 27, 2023, which was partially offset by the implementation of the Pillar Two global minimum tax. In addition to the items discussed in the current quarter, the decrease in the effective tax rate for the six months ended October 25, 2024 was also attributable to an income tax reserve adjustment made during the six months ended October 27, 2023 associated with the Vantor court decision noted above.Our Non-GAAP Nominal Tax Rate for the three and six months ended October 25, 2024 was 18.3% and 17.7%, respectively, as compared to 16.9% and 16.4% for the three and six months ended October 27, 2023, respectively. The change in our Non-GAAP Nominal Tax Rate was primarily due to the implementation of the Pillar Two global minimum tax and year-over-year changes in operational results by jurisdiction. An increase in our Non-GAAP Nominal Tax Rate of 1 percent would result in an additional income tax provision for the three and six months ended October 25, 2024 of approximately \$20A million and \$39A million, respectively.LIQUIDITY AND CAPITAL RESOURCESWe are currently in a strong financial position, and we believe our balance sheet and liquidity as of October 25, 2024 provide us with flexibility, and our cash, cash equivalents, and current investments, along with our credit facility and related commercial paper programs will satisfy our foreseeable operating needs.Our liquidity and capital structure are evaluated regularly within the context of our annual operating and strategic planning processes. We consider the liquidity necessary to fund our operations, which includes working capital needs, investments in research and development, property, plant, and equipment, and other operating costs. We also consider capital allocation alternatives that balance returning value to shareholders through dividends and share repurchases, satisfying maturing debt, and acquiring businesses and technology.41Summary of Cash FlowsThe following is a summary of cash provided by (used in) operating, investing, and financing activities, the effect of exchange rate changes on cash and cash equivalents, and the net change in cash and cash equivalents:A Six months ended(in millions)October 25, 2024October 27, 2023Cash provided by (used in):A Operating activities\$1,944A \$1,536A Investing activities(604)(963)Financing activities(1,265)(591)Effect of exchange rate changes on cash and cash equivalents35A (214)Net change in cash and cash equivalents\$110A \$(232)Operating Activities The \$408 million increase in net cash provided was primarily driven by an increase in cash collected from customers due to an increase in sales and a decrease in cash paid to vendors, which was partially offset by an increase in cash paid for taxes and increased annual incentive payouts. Investing Activities The \$359 million decrease in cash used was primarily attributable to an increase in net sales and maturities of investments of \$386 million partially offset by an increase in net additions to property, plant, and equipment of \$109 million. Financing Activities There was a \$674 million increase in net cash used during the six months ended October 25, 2024, as compared to the corresponding period in the prior fiscal year. In the current period, there was a decrease in total short-term borrowings of \$67 million, as compared to an increase of \$1.3 billion in the prior year. Additionally, on June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of A~3.0A billion, or \$3.2 billion, which was partially offset by a \$2.3 billion increase in net share repurchases during the six months ended October 25, 2024, as compared to the corresponding period in the prior fiscal year. For more information on commercial paper and Senior Notes issued, refer to the Debt and Capital section below.Debt and Capital Our capital structure consists of equity and interest-bearing debt. We primarily utilize unsecured senior debt obligations to meet our financing needs and, to a lesser extent, bank borrowings. From time to time, we may repurchase our outstanding debt obligations in the open market or through privately negotiated transactions.Total debt at October 25, 2024 was \$28.3 billion as compared to \$25.0 billion at April 26, 2024. The increase in total debt was primarily driven by issuance of Euro-denominated Senior Notes and fluctuations in exchange rates.On June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of A~3.0A billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately \$3.2A billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.We repurchase our ordinary shares on occasion as part of our focus on returning value to our shareholders. In March 2024, the Company's Board of Directors authorized the repurchase of \$5.0A billion of the Company's ordinary shares. There is no specific time period associated with these repurchase authorizations. During the six months ended October 25, 2024, the Company repurchased a total of 33A million shares under this program at an average price of \$82.61. At October 25, 2024, we had approximately \$2.6 billion remaining under the share repurchase program authorized by our Board of Directors. For more information on credit arrangements, refer to Note 7 to the current period's consolidated financial statements and Note 6 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 26, 2024.LiquidityOur liquidity sources at October 25, 2024 included \$1.4 billion of cash and cash equivalents and \$6.6A billion of current investments. Additionally, we maintain commercial paper programs and a Credit Facility. Our investments primarily include available-for-sale debt securities, including U.S. and non-U.S. government and agency securities, corporate debt securities, mortgage-backed securities, and other asset-backed securities. Refer to Note 6 to the current period's consolidated financial statements for additional information regarding fair value measurements.42We maintain multicurrency commercial paper programs for short-term financing, which allow us to issue unsecured commercial paper notes on a private placement basis up to a maximum aggregate amount outstanding at any time of \$3.5 billion. At October 25, 2024 and April 26, 2024, we had \$899A million and \$1.1 billion commercial paper outstanding, respectively. The issuance of commercial paper reduces the amount of credit available under our existing line of credit, as explained below.We also have a \$3.5 billion five-year syndicated credit facility (Credit Facility), which expires in December 2028. At each anniversary date of the Credit Facility we can request a one-year extension of the maturity date. The Credit Facility provides backup funding for the commercial paper programs and may also be used for general corporate purposes. The Credit Facility provides us with the ability to increase our borrowing capacity by an additional \$1.0 billion at any time during the term of the agreement. At October 25, 2024 and April 26, 2024, no amounts were outstanding under the Credit Facility.Interest rates on advances of our Credit Facility are determined by a pricing matrix based on our long-term debt ratings assigned by Standard & Poor's Ratings Services (S&P) and Moody's Investors Service (MoodyA ́s). Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. We are in compliance with all covenants related to the Credit Facility.The following table is a summary of our S&P and Moody's long-term debt ratings and short-term debt ratings:Agency Rating(1)October 25, 2024April 26, 2024Standard & Poor's Ratings ServicesA A Long-term debtAAA A A Short-term debtA-1A-1Moody's Investors ServiceA A A Long-term debtA3A3A A A Short-term debtP-2P-2(1) Agency ratings are subject to change, and there may be no assurance that an agency will continue to provide ratings and/or maintain its current ratings. A security rating is not a recommendation to buy, sell or hold securities, and may be subject to revision or withdrawal at any time by the rating agency, and each rating should be evaluated independently of any other rating.S&P and Moody's long-term debt ratings and short-term debt ratings at October 25, 2024 were unchanged as compared to the ratings at April 26, 2024. We do not expect the S&P and Moody's ratings to have a significant impact on our liquidity or future flexibility to access additional liquidity given our balance sheet, Credit Facility, and related commercial paper programs.We have future contractual obligations and other minimum commercial commitments that are entered into in the normal course of business. We believe our off-balance sheet arrangements do not have a material current or anticipated future effect on our consolidated earnings, financial position, and/or cash flows. Refer to the Debt and Capital section above for changes in debt obligations during the first quarter of fiscal year 2025; there have been no other material changes to our long-term contractual obligations as reported in our most recent Annual Report filed on Form 10-K for the fiscal year ended April 26, 2024.ACQUISITIONS AND DISPOSITIONSInformation regarding acquisitions and dispositions activity is included in Note 4 to the current period's consolidated financial statements.GOODWILLWe assess goodwill and indefinite-lived intangible assets for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate the carrying amount may be impaired.The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis and revenue and earnings multiples using comparable public company information. The test for impairment of goodwill requires the Company to make several estimates related to projected future cash flows and appropriate multiples to determine the fair value of the goodwill reporting units. Significant assumptions used in the reporting unit fair value measurements include forecasted cash flows, including revenue and expense growth rates, discount rates, and revenue and earnings multiples. An impairment loss is recognized when the carrying amount of the reporting unitA ́s net assets exceeds the estimated fair value of the reporting unit.Definite-lived intangible assets are tested for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. There were no impairments of intangible assets in the current period. Further adverse changes to macroeconomic conditions or significant changes to our current and future expected financial performance could lead to goodwill or intangible asset impairment charges in future periods, and such charges could be material to our results of operations.43CRITICAL ACCOUNTING ESTIMATESWe have used various accounting policies to prepare the consolidated financial statements in accordance with U.S. GAAP. Our significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended April 26, 2024.The preparation of the consolidated financial statements, in conformity with U.S. GAAP, requires us to use judgment in making estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses. These estimates reflect our best judgment about economic and market conditions and the potential effects on the valuation and/or carrying value of assets and liabilities based upon relevant information available. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. As of October 25, 2024, there were no material changes to our critical accounting estimates. NEW ACCOUNTING PRONOUNCEMENTSInformation regarding new accounting pronouncements is included in Note 2 to the current period's consolidated financial statements.SUPPLEMENTAL GUARANTOR FINANCIAL INFORMATIONMedtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Medtronic plc and Medtronic, Inc. each have provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Senior Notes (Medtronic Luxco Senior Notes). The following is a summary of these guarantees:Guarantees of Medtronic Senior NotesA A Parent Company Guarantor A A Medtronic plcA A Subsidiary Issuer A A Medtronic, Inc.A A Subsidiary Guarantor A A Medtronic LuxcoGuarantees of Medtronic Luxco Senior NotesA A Parent Company Guarantor A A Medtronic plcA A Subsidiary Issuer A A Medtronic LuxcoA A Subsidiary Guarantor A A Medtronic, Inc.Guarantees of CIFSA Senior NotesA A Parent Company Guarantor A A Medtronic plcA A Subsidiary Issuer A A CIFSA A A Subsidiary Guarantors A A Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors)The following tables present summarized financial information for the six months ended October 25, 2024 and summarized balance sheet information at October 25, 2024 and April 26, 2024 for the obligor groups of Medtronic and Medtronic Luxco Senior Notes, and CIFSA Senior Notes. The obligor group consists of the parent company guarantor, subsidiary issuer, and subsidiary guarantors for the applicable senior notes. The summarized financial information is presented after elimination of (i) intercompany transactions and balances among the guarantors and issuers and (ii) equity in earnings from and investments in any subsidiary that is a non-guarantor or issuer. 44The summarized results of operations information for the six months ended October 25, 2024 was as follows:(in millions)Medtronic & Medtronic Luxco Senior Notes (1)CIFSA Senior Notes (2)Net sales\$1,373A \$4A Operating profit173A 98A (Loss) income before income taxes(181)113A Net (loss) income attributable to Medtronic(151)118A The summarized balance sheet information at October 25, 2024 was as follows:(in millions)Medtronic & Medtronic Luxco Senior Notes (1)CIFSA Senior Notes (2)Total current assets(315)0,037A \$4,146A Total noncurrent assets(4)11,462A 5,338A Total current liabilities(5)22,215A 5,858A Total noncurrent liabilities(6)37,793A 24,463A Noncontrolling interests222A 222A (1)The Medtronic Senior Notes and Medtronic Luxco Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, and Medtronic, Inc. Refer to the guarantee summary above for further details.

The Cifsa Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, Cifsa, and Cifsa Subsidiary Guarantors. Refer to the guarantee summary above for further details. (3) Includes receivables due from non-guarantor subsidiaries of \$12.0A billion and \$1.7A billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. (4) Includes loans receivable due from non-guarantor subsidiaries of \$5.2A billion and \$5.2A billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. (5) Includes payables due to non-guarantor subsidiaries of \$16.7A billion and \$2.1A billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. (6) Includes loans payable due to non-guarantor subsidiaries of \$11.3A billion and \$7.7A billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. The summarized balance sheet information at April 26, 2024 was as follows: (in millions) Medtronic & Medtronic Luxco Senior Notes (1) Cifsa Senior Notes (2) Total current assets (3) \$17,389A \$4,179A Total noncurrent assets (4) \$11,548A 19,246A Total current liabilities (5) \$25,228A 43,416A Total noncurrent liabilities (6) \$33,508A 26,995A Noncontrolling interests 206A 206A (1) The Medtronic Senior Notes and Medtronic Luxco Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, and Medtronic, Inc. Refer to the guarantee summary above for further details. (2) The Cifsa Senior Notes obligor group consists of the following entities: Medtronic plc, Medtronic Luxco, Cifsa, and Cifsa Subsidiary Guarantors. Refer to the guarantee summary above for further details. (3) Includes receivables due from non-guarantor subsidiaries of \$14.3A billion and \$1.7A billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. (4) Includes loans receivable due from non-guarantor subsidiaries of \$5.2A billion and \$19.1 billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. (5) Includes payables due to non-guarantor subsidiaries of \$21.8A billion and \$42.1A billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. (6) Includes loans payable due to non-guarantor subsidiaries of \$7.7A billion and \$7.7A billion for Medtronic & Medtronic Luxco Senior Notes, and Cifsa Senior Notes, respectively. 45CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, and other written reports of Medtronic plc, organized under the laws of Ireland (together with its consolidated subsidiaries, Medtronic, the Company, or we, us, or our), and oral statements made by or with the approval of one of the Company's executive officers from time to time, may include forward-looking statements. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financial position, business strategy and plans, objectives of management for future operations and current expectations or forecasts of future results, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Our forward-looking statements may include statements related to our growth and growth strategies, developments in the markets for our products, therapies and services, financial results, product development launches and effectiveness, research and development strategy, regulatory approvals, competitive strengths, the potential or anticipated direct or indirect impact of public health crises and geopolitical conflicts on our business, results of operations and/or financial condition, restructuring and cost-saving initiatives, intellectual property rights, litigation and tax matters, governmental proceedings and investigations, mergers and acquisitions, divestitures, market acceptance of our products, therapies and services, accounting estimates, financing activities, ongoing contractual obligations, working capital adequacy, value of our investments, our effective tax rate, our expected returns to shareholders, and sales efforts. In some cases, such statements may be identified by the use of terminology such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "look ahead," "may," "plan," "possible," "potential," "project," "should," "will," and similar words or expressions. Forward-looking statements in this Quarterly Report include, but are not limited to, statements regarding: our ability to drive long-term shareholder value; development and future launches of products and continued or future acceptance of products, therapies and services in our segments; expected timing for completion of research studies relating to our products; integration of new technologies, including artificial intelligence (AI) and data analytics, into our products, therapies and services; market positioning and performance of our products, including stabilization of certain product markets; divestitures and the potential benefits thereof; the costs and benefits of integrating previous acquisitions; anticipated timing for United States (U.S.) Food and Drug Administration (U.S. FDA) and non-U.S. regulatory approval of new products; increased presence in new markets, including markets outside the U.S.; changes in the market and our market share; our ability to meet growing demand for our existing products; acquisitions and investment initiatives, including the timing of regulatory approvals as well as integration of acquired companies into our operations; the resolution of tax matters; the effectiveness of our development activities in reducing patient care costs and hospital stay lengths; our approach towards cost containment; our expectations regarding healthcare costs, including potential changes to reimbursement policies and pricing pressures; our expectations regarding changes to patient standards of care; our ability to identify and maintain successful business partnerships; the elimination of certain positions or costs related to restructuring initiatives; outcomes in our litigation matters and governmental proceedings and investigations; general economic conditions; the adequacy of available working capital and our working capital needs; our payment of dividends and redemption of shares; the continued strength of our balance sheet and liquidity; our accounts receivable exposure; our human capital management with respect to our global workforce; and the potential impact of our compliance with governmental regulations and accounting guidance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, results of operations, financial condition, and/or cash flows. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of risks, uncertainties and assumptions described in the "Risk Factors" section and elsewhere in our Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. One must carefully consider forward-looking statements and understand that such forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and involve a variety of risks and uncertainties, known and unknown, including, among others, those discussed in the sections entitled "Government Regulation" within Item 1. Business and Item 1A. Risk Factors in our Annual Report on Form 10-K, as well as those related to: competition in the medical device industry; delays in regulatory approvals; public health crises; reduction or interruption in our supply; failure to complete or achieve the intended benefits of acquisitions or divestitures; adverse regulatory action; laws and governmental regulations; litigation results; quality problems; healthcare policy changes; cybersecurity and privacy incidents; international operations, including the impact of armed conflicts; self-insurance; commercial insurance; changes in applicable tax rates; positions taken by taxing authorities; decreasing selling prices and pricing pressure; liquidity shortfalls; fluctuations in currency exchange rates; inflation; or disruption of our current plans and operations. Consequently, no forward-looking statement may be guaranteed, and actual results may vary materially from those projected in the forward-looking statements. We intend to take advantage of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 regarding our forward-looking statements and are including this sentence for the express purpose of enabling us to use the protections of the safe harbor with respect to all forward-looking statements. While we may elect to update these forward-looking statements at some point in the future, whether as a result of any new information, future events, or otherwise, we have no current intention of doing so except to the extent required by applicable law. Item 3. Quantitative and Qualitative Disclosures About Market Risk CURRENCY EXCHANGE RATE RISK Due to the global nature of our operations, we are exposed to currency exchange rate changes, which may cause fluctuations in earnings and cash flows. Fluctuations in the currency exchange rates of currency exposures that are unhedged, such as in certain emerging markets, may result in future earnings and cash flow volatility. The gross notional amount of all currency exchange rate derivative instruments outstanding at October 25, 2024 and April 26, 2024 was \$24.6 billion and \$23.7 billion, respectively. At October 25, 2024, these contracts were in a net unrealized gain position of \$464A million. Additional information regarding our currency exchange rate derivative instruments is included in Note 8 to the current period's consolidated financial statements. A sensitivity analysis of changes in the fair value of all currency exchange rate derivative contracts at October 25, 2024 and April 26, 2024 indicates that, if the U.S. dollar uniformly strengthened/weakened by 10 percent against all currencies, the fair value of these contracts would increase/decrease by approximately \$1.7A billion. Any gains and losses on the fair value of derivative contracts would generally be offset by gains and losses on the underlying transactions. These offsetting gains and losses are not reflected in the above analysis. INTEREST RATE RISK We are subject to interest rate risk on our short-term investments and our borrowings. We manage interest rate risk in the aggregate, while focusing on our immediate and intermediate liquidity needs. Our debt portfolio at October 25, 2024 was comprised of debt predominantly denominated in U.S. dollars and Euros, which is primarily fixed rate debt. We are also exposed to interest rate changes affecting our investments in interest rate sensitive instruments, which include our marketable debt securities. A sensitivity analysis of the impact on our interest rate-sensitive financial instruments of a hypothetical 50 basis point change in interest rates, as compared to interest rates at October 25, 2024 and April 26, 2024, indicates that the fair value of these instruments would correspondingly change by \$65A million and \$64A million, respectively. For a discussion of current market conditions and the impact on our financial condition and results of operations, please see the "Liquidity" section of the current period's Management's Discussion and Analysis. For additional discussion of market risk, refer to Notes 6 and 8 to the current period's consolidated financial statements. 47 Item 4. Controls and Procedures EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) and changes in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this quarterly report, our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) are effective. CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) under the Exchange Act) during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting. PART II & OTHER INFORMATION Item 1. Legal Proceedings In accordance with Item 103 of Regulation S-K, we have adopted a \$1 million disclosure threshold for proceedings under environmental laws to which a governmental authority is a party, as we believe matters under this threshold are not material to the Company. A discussion of the Company's legal proceedings and other loss contingencies are described in Note 16 to the current period's consolidated financial statements. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds Issuer Purchases of Equity Securities The following table provides information about the shares repurchased by the Company during the second quarter of fiscal year 2025. Fiscal Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as a Part of Publicly Announced Program Maximum Approximate Dollar Value of Shares that may yet be Purchased Under the Program 7/27/2024-8/23/2024 1,380,200A \$82.71A 1,380,200A \$2,690,475,982A 8/24/2024-9/27/2024 807,700A \$89.42A 807,700A 2,618,252,054A 9/28/2024-10/25/2024 691,854A 691,854A 2,556,222,068A Total 2,879,754A \$86.26A 2,879,754A 2,556,222,068A In March 2024, the Company's Board of Directors authorized the repurchase of \$5.0A billion of the Company's ordinary shares. There is no specific time period associated with these repurchase authorizations. Item 5. Other Information Rule 10b5-1 Director and Officer Trading Arrangements During the three months ended October 25, 2024, certain of our officers and directors adopted Rule 10b5-1 trading arrangements, and intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act as follows. On October 10, 2024, Brett Wall, Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan. Mr. Wall's trading plan provides for the sale of up to 22,287 shares of the Company's common stock prior to the plan's August 1, 2025 termination date. 48 Item 6. Exhibits (a) Exhibits A 31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A 31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. A 32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A 32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. A 101. SCHInline XBRL Schema Document. A 101. CALInline XBRL Calculation Linkbase Document. A 101. DEFInline XBRL Definition Linkbase Document. A 101. LABInline XBRL Label Linkbase Document. A 101. PREInline XBRL Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) 49 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned authorized officer. A A Medtronic plc A (Registrant) A A Date: November 26, 2024/s/ Jennifer M. Kirk Jennifer M. Kirk Senior Vice President, Global Controller and Chief Accounting Officer (Principal Accounting Officer) 50 EX-31.1 2 md-2025q210qex311.htm EX-31.1 Document Exhibit 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, Geoffrey S. Martha, certify that: 1. I have reviewed this Quarterly Report on Form 10-Q of Medtronic plc; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities,

change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

November 26, 2024/s/ Gary Corona

Gary Corona

Senior Vice President and Interim Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 mdt-2025q210qxex321.htm EX-32.1 Document

Exhibit 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with this quarterly report on Form 10-Q of Medtronic plc for the quarter ended October 25, 2024, the undersigned hereby certifies, in his capacity as Chief Executive Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc.

November 26, 2024/s/ Geoffrey S. Martha

Geoffrey S. Martha

Chief Executive Officer (Principal Executive Officer)

EX-32.2 5 mdt-2025q210qxex322.htm EX-32.2 Document

Exhibit 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

In connection with this quarterly report on Form 10-Q of Medtronic plc for the quarter ended October 25, 2024, the undersigned hereby certifies, in his capacity as Interim Chief Financial Officer of Medtronic plc, for purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: (1) The report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) The information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Medtronic plc.

November 26, 2024/s/ Gary Corona

Gary Corona

Senior Vice President and Interim Chief Financial Officer (Principal Financial Officer)

EX-101.SCH 6 mdt-20241025_xd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover

link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Consolidated Statements of Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Consolidated Statements of Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Consolidated Statements of Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Consolidated Statements of Equity (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Acquisitions and Dispositions link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Restructuring and Other Costs link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Derivatives and Currency Exchange Risk Management link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - Retirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - Segment and Geographic Information link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - Acquisitions and Dispositions (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - Restructuring and Other Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - Financing Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - Goodwill and Other Intangible Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - Retirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - Segment and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - Revenue - Schedule of Disaggregation of Net Sales by Segment and Division (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - Revenue - Schedule of Disaggregation of Net Sales by Market Geography (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - Acquisitions and Dispositions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - Acquisitions and Dispositions - Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - Restructuring and Other Costs - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - Restructuring and Other Costs - Schedule of Restructuring and Related Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - Restructuring and Other Costs - Schedule of Activity of Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - Financial Instruments - Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - Financial Instruments - Schedule of Gross Unrealized Losses and Fair Values of Available-for-Sale Securities, Aggregated by Investment Category (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - Financial Instruments - Schedule of Activity Related to Available-for-Sale Securities Portfolio (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - Financial Instruments - Schedule of Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - Financial Instruments - Schedule of Equity and Other Investments (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - Financing Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - Financing Arrangements - Schedule of Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Outstanding Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Gains and Losses on Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Offsetting Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Offsetting Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Changes in the Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Gross Carrying Amount and Accumulated Amortization of Definite and Indefinite Lived Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Future Aggregate Amortization Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - Earnings Per Share - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - Earnings Per Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 9955559 - Disclosure - Retirement Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 9955560 - Disclosure - Accumulated Other Comprehensive Loss - Schedule of Changes in Accumulated Other Comprehensive Loss (AOCL), Net of Tax, by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9955561 - Disclosure - Accumulated Other Comprehensive Loss - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955562 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9955563 - Disclosure - Segment and Geographic Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955564 - Disclosure - Segment and Geographic Information - Schedule of Segment Operating Profit and Income Before Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9955565 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers by Geography (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mdt-20241025_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mdt-20241025_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mdt-20241025_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Purchased technology and patents

Purchased Technology And Patents [Member] Purchased technology and patents. Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] (Gain) Loss Reclassified into Income Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before Tax 4.150 percent nineteen-year 2024 senior notes Senior Notes 2024 Due 2044, 4.150 Percent [Member] Senior Notes 2024 Due 2044, 4.150 Percent Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Cover page. Cover [Abstract] Net change in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect IPR&D In Process Research and Development [Member] 0.750% Senior Notes due 2032 0.750% Senior Notes due 2032 [Member] 0.750% Senior Notes due 2032 Discount rate Measurement Input, Discount Rate [Member] Non-U.S. Foreign Plan [Member] Schedule of Indefinite-Lived Intangible Assets [Table] Intangible Asset, Indefinite-Lived [Table] Other accrued expenses Other Liabilities, Current Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Accrued compensation Deferred Compensation Liability, Current Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair value hedge Fair Value Hedging [Member] Change in fair value of instrument Equity Securities, FV-NI, Realized Gain (Loss) Comprehensive income including noncontrolling interests Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Long-term debt Total long-term debt Long-Term Debt and Lease Obligation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Derivative assets, fair value Gross Amount of Recognized Assets (Liabilities) Derivative Asset, Subject to Master Netting Arrangement, before Offset 2.625 percent three-year 2022 senior notes Senior Notes 2022 Due 2026, 2.625 Percent [Member] Senior Notes 2022 Due 2026, 2.625 Percent Non-NEOs Non-NEOs [Member] Schedule of Computation of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Income tax benefits Share-Based Payment Arrangement, Expense, Tax Benefit Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Dividends to shareholders (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income taxes Income Taxes Paid, Net Allowances for accounts receivable Accounts Receivable, Allowance for Credit Loss, Current Schedule of Components and Classification of Stock-Based Compensation Expense Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Revenue and other performance-based payments Revenue Milestone [Member] A milestone in achieving certain revenue target. Equity method and other investments Equity Method Investments Pay vs Performance Disclosure [Line Items] Medtronic Luxco Senior Notes Medtronic Luxco Senior Notes [Member] Medtronic Luxco Senior Notes Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Unrealized gain (loss) on investment securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] Net investment hedge Net Investment Hedging [Member] Total stock-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax Other operating assets and liabilities Increase (Decrease) in Other Operating Assets and Liabilities, Net 4.625 percent thirty-year 2014 senior notes Senior Notes 2014 Due 2044, 4.625 Percent [Member] Senior Notes 2014 Due 2044, 4.625 Percent Other Performance Measure, Amount Other Performance Measure, Amount 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three 1.000 percent twelve-year 2019 senior notes Senior Notes 2019 Due 2032, 1.000 Percent [Member] Senior Notes 2019 Due 2032, 1.000 Percent Goodwill [Line Items] Goodwill [Line Items] Ordinary shares outstanding (shares) Beginning balance (shares) Ending balance (shares) Common Stock, Shares, Outstanding Interest income Interest Income (Expense), Operating Number of claimants (in claimants) Loss Contingency, Pending Claims, Number Fair Value Inputs, Liabilities, Quantitative Information [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Payments Business Acquisition, Contingent Consideration, Milestone Payment Contingent milestone payments in business acquisition transactions. Cash flow hedge Cash Flow Hedging [Member] Gross realized losses Debt Securities, Available-for-Sale, Realized Loss Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] U.S. United States UNITED STATES Rest of world Total Other Countries, Excluding United States And Ireland [Member] Total Other Countries, Excluding United States And Ireland [Member] Service cost Defined Benefit Plan, Service Cost Issuance of ordinary shares Proceeds from Issuance or Sale of Equity Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Medical device regulations Medical Device Regulations Medical Device Regulations Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] Accounting Standards Update and Change in Accounting Principle [Abstract] 3.000% Senior Notes due 2028 3.000% Senior Notes due 2028 [Member] 3.000% Senior Notes due 2028 Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Retirement Plan Type [Axis] Retirement Plan Type [Axis] Operating Segments Operating Segments [Member] Denominator: Earnings Per Share

Reconciliation, Denominator [Abstract] -- None. No documentation exists for this element. -- Selling, general, and administrative expense Selling, General and Administrative Expenses [Member] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Operating Activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Schedule of Changes in Accumulated Other Comprehensive Loss (AOCL), Net of Tax, by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] 0.000% Senior Notes due 2025 0.000% Senior Notes due 2025 [Member] 0.000% Senior Notes due 2025 4.150% Senior Notes due 2053 4.150% Senior Notes due 2053 [Member] 4.150% Senior Notes due 2053 Equity Components [Axis] Equity Components [Axis] Accrual adjustment Loss Contingency Accrual, Period Increase (Decrease) Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Net periodic (credit) benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Derivative, excluded component, gain (loss), recognized in earnings Derivative, Excluded Component, Gain (Loss), Recognized in Earnings Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Restructuring Type [Axis] Restructuring Type [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Ordinary Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Charges Restructuring Charges, Including Accrual Adjustments Restructuring Charges, Including Accrual Adjustments 4.000 percent thirty-year 2013 senior notes Senior Notes 2013 Due 2043, 4.000 Percent [Member] Senior Notes 2013 Due 2043, 4.000 Percent Compensation Amount Outstanding Recovery Compensation Amount Accounts receivable, net Increase (Decrease) in Accounts and Notes Receivable Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Rebate obligations Contract with Customer, Refund Liability, Current Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Schedule of Restructuring and Related Costs and Activity of Restructuring Costs Restructuring and Related Costs [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Level 3 Fair Value, Inputs, Level 3 [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accrual adjustments Restructuring Reserve, Accrual Adjustment Weighted Average Weighted Average [Member] Unrealized gain (Loss) Unrealized Gain (Loss) on Derivatives Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Other liabilities Other Liabilities [Member] 4.150% Senior Notes due 2043 4.150% Senior Notes due 2043 [Member] 4.150% Senior Notes due 2043 Hernia Mesh Litigation Hernia Mesh Litigation [Member] Hernia Mesh Litigation Accrued litigation charges Loss Contingency Accrual Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Accrued income taxes Accrued Income Taxes, Noncurrent Antidilutive securities excluded from computation of earnings per share (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Cash payments Payments for Restructuring Credit Facility [Domain] Credit Facility [Domain] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total return swaps Total Return Swap [Member] Investments with readily determinable fair value (marketable equity securities) Equity Securities, FV-NI, Current 1.750% Senior Notes due 2049 1.750% Senior Notes due 2049 [Member] 1.750% Senior Notes due 2049 4.500 percent thirty-year 2012 senior notes Senior Notes 2012 Due 2042, 4.500 Percent [Member] Senior Notes 2012 Due 2042, 4.500 Percent Current assets: Assets, Current [Abstract] Goodwill Beginning balance Ending balance Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Inventories Inventory Disclosure [Text Block] Diabetes Diabetes Group [Member] Diabetes Group [Member] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Entity Information [Line Items] Entity Information [Line Items] Employee stock options Stock options Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Weighted average interest rate Short-Term Debt, Weighted Average Interest Rate, over Time Goodwill [Roll Forward] Goodwill [Roll Forward] Other financing activities, net Proceeds from (Payments for) Other Financing Activities Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Comprehensive income attributable to Medtronic Comprehensive Income (Loss), Net of Tax, Attributable to Parent Pension Plan Pension Plan [Member] Accrued income taxes Accrued Income Taxes, Current International International [Member] International 1.375% Senior Notes due 2040 1.375% Senior Notes due 2040 [Member] 1.375% Senior Notes due 2040 Security Exchange Name Security Exchange Name Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Schedule of Available-for-Sale Debt Securities by Contractual Maturity Investments Classified by Contractual Maturity Date [Table Text Block] Award Type [Axis] Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Schedule of Net Sales to External Customers by Geography Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block] Currency translation and other Goodwill, Foreign Currency Translation Gain (Loss) Net Amount Derivative, Fair Value, Amount Offset Against Collateral, Net Gain (Loss) on Securities [Line Items] Gain (Loss) on Securities [Line Items] Work-in-process Inventory, Work in Process, Net of Reserves Property, plant, and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Noncontrolling interests Equity, Attributable to Noncontrolling Interest Unrealized Losses Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract] Amortized Cost Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract] Ordinary shares, par value (usd per share) Common Stock, par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification Debt Securities, Available-for-Sale [Table Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Expiration Date Trading Arrangement Expiration Date Investing Activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Fair Value Inputs Fair Value Measurement Inputs and Valuation Techniques [Abstract] Subsegments [Axis] Subsegments [Axis] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Ordinary shares issued (shares) Common Stock, Shares, Issued Other Assets Other Assets [Member] Due after ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Line of credit, maximum capacity Line of Credit Facility, Maximum Borrowing Capacity Cash paid for: Income Taxes and Interest Paid [Abstract] Income Taxes and Interest Paid [Abstract] Gross realized gains Debt Securities, Available-for-Sale, Realized Gain Derivative Liabilities Derivative Liability Interest expense on outstanding borrowings Interest Expense, Borrowings Schedule of Debt [Table] Schedule of Debt [Table] A table or schedule providing information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Structural Heart & Aortic Structural Heart And Aortic Division [Member] Coronary and Structural Heart Division [Member] Recognized in AOCL, cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development expense Research and Development Expense [Member] Europe Europe [Member] Ordinary shares authorized (shares) Common Stock, Shares Authorized Other Adjustments Consolidation, Eliminations [Member] Acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted weighted average shares outstanding (shares) Diluted - weighted average shares outstanding (shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Remaining 2025 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total shareholdersâ€™ equity Equity, Attributable to Parent 4.500 percent ten-year 2023 senior notes Senior Notes 2023 Due 2033, 4.500 Percent [Member] Senior Notes 2023 Due 2033, 4.500 Percent Due in one year or less Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Financial Instruments Financial Instruments Disclosure [Text Block] Amortization of net actuarial loss Defined Benefit Plan, Amortization of Gain (Loss) Litigation Case [Axis] Litigation Case [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense, net Interest Expense, Nonoperating 3.875% Senior Notes due 2036 3.875% Senior Notes due 2036 [Member] 3.875% Senior Notes due 2036 Recognized in income, cash flow hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of Changes in the Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Selling, general, and administrative expense Selling, General and Administrative Expense Entity Address, Country Entity Address, Country Current debt obligations Debt, Current Recurring Fair Value, Recurring [Member] Accounts receivable, less allowances and credit losses of \$195 and \$173, respectively Accounts Receivable, after Allowance for Credit Loss, Current Cost of products sold Cost of Sales [Member] Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] More than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus Acquisition and divestiture-related items Business Combination, Acquisition Related Costs All Executive Categories All Executive Categories [Member] Effect of dilutive securities (shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Total Derivative Asset (Liability) [Abstract] Derivative Asset (Liability) [Abstract] Unrealized (Loss) Gain on Investment Securities AOCL, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Period over which remaining performance obligations are expected to be recognized as revenue Revenue, Performance Obligation, Description of Timing Other comprehensive income Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Proceeds from (repayments of) debt Proceeds from (Repayments of) Debt Offsetting Assets and Liabilities [Line Items] Offsetting Assets and Liabilities [Line Items] [Line Items] for Offsetting Assets and Liabilities [Table] 1.125 percent eight-year 2019 senior notes Senior Notes 2019 Due 2027, 1.125 Percent [Member] Senior Notes 2019 Due 2027, 1.125 Percent Commercial paper, maximum borrowing amount Commercial Paper, Maximum Borrowing Capacity Commercial Paper, Maximum Borrowing Capacity Restructuring charges, net Restructuring Charges [Member] 4.150 percent twenty-nine-year 2024 senior notes Senior Notes 2024 Due 2054, 4.150 Percent [Member] Senior Notes 2024 Due 2054, 4.150 Percent Employee stock purchase plan Employees Stock Purchase Plan [Member] -- None. No documentation exists for this element. -- Basis of Presentation Basis of Accounting [Text Block] Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan [Table] Schedule of Estimated Future Aggregate Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Total Shareholdersâ€™ Equity Parent [Member] Gross Carrying Amount Indefinite-Lived Intangible Assets (Excluding Goodwill) Maximum Maximum [Member] Amortization of intangible assets Amortization expense Amortization of intangible assets Amortization of Intangible Assets Deferred revenue Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] 2.625% Senior Notes due 2025 2.625% Senior Notes due 2025 [Member] 2.625% Senior Notes due 2025 Income tax charge Effective Income Tax Rate Reconciliation, Tax Contingency, Amount 3.650 percent five-year 2024 senior notes Senior Notes 2024 Due 2030, 3.650 Percent [Member] Senior Notes 2024 Due 2030, 3.650 Percent Schedule of Reconciliation of Contingent Consideration Liabilities and Receivables Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Number of tranches Debt Instrument, Number of Tranches Debt Instrument, Number of Tranches Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Acquisitions and Dispositions Business Combination Disclosure [Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Investments Short-Term Investments Effect of dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 3.375% Senior Notes due 2034 3.375% Senior Notes due 2034 [Member] 3.375% Senior Notes due 2034 Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] 0.250% Senior Notes due 2025 0.250% Senior Notes due 2025 [Member] 0.250% Senior Notes due 2025 Name Outstanding Recovery, Individual Name Other comprehensive income (loss) before reclassifications, tax expense (benefit) Other Comprehensive Income (Loss) before Reclassifications, Tax Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Issuance of shares under stock purchase and award plans (shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Country Region Country Region Goodwill impairment Goodwill, Impairment Loss Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Accrued compensation and retirement benefits Liability, Defined Benefit Plan, Noncurrent Tax assets Deferred Income Tax Assets, Net Non-PEO NEO Non-PEO NEO [Member] Estimated useful life (in years) Finite-Lived Intangible Asset, Useful Life Foreign currency-denominated debt Foreign Currency Denominated Debt [Member] Foreign Currency Denominated Debt 0.25 percent six-year 2019 senior notes Senior Notes 2019 Due 2026, 0.250 Percent [Member] Senior Notes 2019 Due 2026, 0.250 Percent Additional Paid-in Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Finance lease obligations Finance Lease, Liability, Noncurrent Award Timing Predetermined Award Timing Predetermined [Flag] Unrecognized tax benefits, net Unrecognized Tax Benefits, Net Unrecognized Tax Benefits, Net Subsequent Event Type [Domain] Subsequent Event Type [Domain] Dividends to shareholders Payments of Ordinary Dividends, Common Stock Retirement Benefit Plans Retirement Benefits [Text Block] Employee restricted stock units (shares) Incremental Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends Commitments and Contingencies Contingencies Disclosure [Text Block] Recently Adopted Accounting Standards and Not Yet Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Acute Care & Monitoring Acute Care & Monitoring [Member] Acute Care & Monitoring Diluted earnings per share (usd per share) Earnings Per Share, Diluted After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCL Unrealized Gain (Loss) On Interest Rate Cash Flow Hedges, Accumulated Other Comprehensive Income (Loss), Net Of Tax Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective. 6.550 percent thirty-year 2007 CIFS senior notes CIFS Senior Notes 2007 Due 2038, 6.550 Percent [Member] CIFS Senior Notes 2007 Due 2038, 6.550 Percent Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current 1.125% Senior Notes due 2027 1.125% Senior Notes due 2027 [Member] 1.125% Senior Notes due 2027 Type of Restructuring [Domain] Type of Restructuring [Domain] Business Combinations Series of Individually Immaterial Business Acquisitions [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Other adjustments Other Nonrecurring (Income) Expense Proceeds from sales Proceeds from Sale of Debt Securities, Available-for-Sale 0.375 percent eight-year 2020 senior notes Senior Notes 2020 Due 2029, 0.375 Percent [Member] Senior Notes 2020 Due 2029, 0.375 Percent Goodwill, Impairment Loss, Net of Tax Goodwill, Impairment Loss, Net of Tax Ownership [Axis] Ownership [Axis] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Pending Litigation Pending Litigation [Member] Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Employee Termination Benefits Employee Severance [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Other asset-backed securities Asset-Backed Securities

[Member] Restructuring and Other Costs Restructuring and Related Activities Disclosure [Text Block] Contingent consideration, significant unobservable inputs Business Combination, Contingent Consideration, Liability, Measurement Input Stock-based compensation Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Cardiovascular Cardiovascular [Member] Cardiovascular Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Net income Net income Net income Net income (Loss), Including Portion Attributable to Noncontrolling Interest Net Change in Retirement Obligations Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Contingent consideration receivable Beginning balance Ending balance Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable Disposal Group, Including Discontinued Operation, Contingent Consideration Receivable (Gain) Loss Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Income tax provision Income Tax Expense (Benefit) Interest cost Defined Benefit Plan, Interest Cost Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Gross notional amount Derivative, Notional Amount Coronary & Peripheral Vascular Coronary And Peripheral Vascular Division [Member] Aortic, Peripheral and Venous Division [Member] Net Periodic Benefit Cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract] Derivative Assets Derivative Asset Schedule of Investments [Line Items] Schedule of Investments [Line Items] Supplemental Cash Flow Information Supplemental Cash Flow Information [Abstract] Total equity and other investments Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, And Equity Method Investments Net sales Total net sales Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Outstanding Instruments and Gains and Losses on Hedging Instruments and Derivatives Not Designated as Hedging Instruments Derivative Instruments, Gain (Loss) [Table Text Block] Neuroscience Neuroscience Group [Member] Neuroscience Group Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Effective tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating profit Reportable segment operating profit Operating Income (Loss) Corporate Corporate Overhead Corporate overhead expenses AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Business Acquisition [Line Items] Business Acquisition [Line Items] Research and development expense Research and Development Expense (Excluding Acquired in Process Cost) Number of reportable segments Number of Reportable Segments Total liabilities and equity Liabilities and Equity Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Additional paid-in capital Additional Paid in Capital Short-term Debt, Type [Domain] Short-Term Debt, Type [Domain] Hedging Designation [Axis] Hedging Designation [Axis] Derivatives and Currency Exchange Risk Management Derivative Instruments and Hedging Activities Disclosure [Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Restructuring charges Restructuring and associated costs Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest expense, net Interest Income (Expense), Nonoperating Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Legal Entity [Axis] Legal Entity [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] 1.375 Percent Underlying Security Market Price Change Underlying Security Market Price Change, Percent Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Measurement Input Type [Axis] Measurement Input Type [Axis] Individual: Individual [Axis] 5.550 percent thirty-year 2010 senior notes Senior Notes 2010 Due 2040, 5.550 Percent [Member] Senior Notes 2010 Due 2040, 5.550 Percent Accumulated Other Comprehensive Loss Total Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Unrealized Gain (Loss) on Cash Flow Hedges Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories Total Inventory, Net U.S. government and agency securities US Government Agencies Debt Securities [Member] Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Statement [Line Items] Statement [Line Items] Measurement Input Type [Domain] Measurement Input Type [Domain] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Schedule of Segment Operating Profit and Income Before Income Taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] 1.625 percent twelve-year 2019 senior notes Senior Notes 2019 Due 2031, 1.625 Percent [Member] Senior Notes 2019 Due 2031, 1.625 Percent Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Total consideration for the transaction, net of cash acquired Business Combination, Consideration Transferred LIABILITIES AND EQUITY Liabilities and Equity [Abstract] Offsetting Assets and Liabilities [Table] Offsetting Assets and Liabilities [Table] Offsetting Assets and Liabilities [Table] Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Number of plaintiffs (in plaintiffs) Loss Contingency, Number of Plaintiffs Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Currency Foreign Currency Costs Foreign Currency Costs 0.750 percent twelve-year 2020 senior notes Senior Notes 2020 Due 2033, 0.750 Percent [Member] Senior Notes 2020 Due 2033, 0.750 Percent (Gain)A LossA Recognized in Accumulated Other Comprehensive Loss Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax Reportable segment net sales Total Reportable Segments [Member] Total Reportable Segments Due after five years through ten years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Net investment hedge Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Derivative Instruments, (Gain) Loss [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Other operating income, net Other operating income, net Other Operating Income (Expense) [Member] Provision for credit losses Accounts Receivable, Credit Loss Expense (Reversal) Short-term Debt, Type [Axis] Short-Term Debt, Type [Axis] Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Associated and Other Costs Associated and Other Costs [Member] Associated and Other Costs California CALIFORNIA 0.375% Senior Notes due 2028 0.375% Senior Notes due 2028 [Member] 0.375% Senior Notes due 2028 4.250 percent five-year 2023 senior notes Senior Notes 2023 Due 2028, 4.250 Percent [Member] Senior Notes 2023 Due 2028, 4.250 Percent Earnings Per Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Costs and expenses: Costs and Expenses [Abstract] Goodwill and Other Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] (Gain)A LossA Recognized in Accumulated Other Comprehensive Loss (Gain)A LossA Recognized In Accumulated Other Comprehensive Loss [Abstract] (Gain)A LossA Recognized In Accumulated Other Comprehensive Loss Shareholdersâ€™ equity: Equity, Attributable to Parent [Abstract] Less than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months Subsegments [Domain] Subsegments [Domain] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Segments [Domain] Segments [Domain] Medical Surgical Medical Surgical [Member] Medical Surgical [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Term of debt instrument Debt Instrument, Term Financial Instruments Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Trademarks and tradenames Trademarks and Trade Names [Member] PEO PEO [Member] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entities [Table] Entities [Table] Name Trading Arrangement, Individual Name Other non-operating income, net Other non-operating income, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Recognized in AOCI, net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Cash Collateral (Received) Posted Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash Derivative Assets and Liabilities, Net, Collateral, Obligation to Return Cash Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Settled non-cash Restructuring Reserve, Settled without Cash 1.500 percent twenty-year 2019 senior notes Senior Notes 2019 Due 2040, 1.500 Percent [Member] Senior Notes 2019 Due 2040, 1.500 Percent Business Combination and Asset Acquisition [Abstract] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] All other operating segments Other Other Operating Segment [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] 1.000% Senior Notes due 2031 1.000% Senior Notes due 2031 [Member] 1.000% Senior Notes due 2031 Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Centralized distribution costs Centralized Distribution Costs Centralized Distribution Costs 2.250% Senior Notes due 2039 2.250% Senior Notes due 2039 [Member] 2.250% Senior Notes due 2039 Local Phone Number Local Phone Number Other current assets Prepaid Expenses and Other Current Assets [Member] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Medtronic Luxco Medtronic Luxco [Member] Medtronic Luxco [Member] Deferred tax liabilities Deferred Income Tax Liabilities, Net Diabetes Pump Retainer Ring Litigation Diabetes Pump Retainer Ring Litigation [Member] Diabetes Pump Retainer Ring Litigation Schedule of Equity Method Investments [Table] Equity Method Investment [Table] Net unrealized gains (losses) on equity and other investments Unrealized Gain (Loss) on Investments Net Amount Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction Mozarc Mozarc [Member] Mozarc Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Maximum remaining maturity of foreign currency derivatives Maximum Remaining Maturity of Foreign Currency Derivatives Change in operating assets and liabilities, net of acquisitions and divestitures: Increase (Decrease) in Operating Capital [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Intangible assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Derivative liabilities, fair value Gross Amount of Recognized Assets (Liabilities) Derivative Liability, Subject to Master Netting Arrangement, before Offset Net change in retirement obligations Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 6.500 percent thirty-year 2009 senior notes Senior Notes 2009 Due 2039, 6.500 Percent [Member] Senior Notes 2009 Due 2039, 6.500 Percent 2.250 percent twenty-year 2019 senior notes Senior Notes 2019 Due 2039, 2.250 Percent [Member] Senior Notes 2019 Due 2031, 1.625 Percent [Member] Fair Value Total Debt Securities, Available-for-Sale, Excluding Accrued Interest 3.125 percent nine-year 2022 senior notes Senior Notes 2022 Due 2032, 3.125 Percent [Member] Senior Notes 2022 Due 2032, 3.125 Percent Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Definite-lived intangible asset charges Impairment of Intangible Assets, Finite-Lived Product development and other milestone-based payments Product Development Milestone [Member] A milestone in achieving certain product development target. Debt Disclosure [Abstract] Debt Disclosure [Abstract] Ordinary Shares Common Stock [Member] Measure: Measure [Axis] Issuance of shares under stock purchase and award plans Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Cash Collateral (Received) Posted Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset Investments [Abstract] Investments [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Reclassified into Income, net investment hedges Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Commercial Paper Program 2015 Commercial Paper Program [Member] 2015 Commercial Paper Program [Member] Line of Credit Line of Credit [Member] Colibri Colibri Heart Valve LLC (Colibri) [Member] Colibri Heart Valve LLC (Colibri) 3.375 percent twelve-year 2022 senior notes Senior Notes 2022 Due 2035, 3.375 Percent [Member] Senior Notes 2022 Due 2035, 3.375 Percent Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] 3.875 percent twelve-year 2024 senior notes Senior Notes 2024 Due 2037, 3.875 Percent [Member] Senior Notes 2024 Due 2037, 3.875 Percent Brett Wall [Member] Brett Wall Segment Reporting [Abstract] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key Credit Facility Amended And Restated Revolving Credit Agreement [Member] Amended and Restated Revolving Credit Agreement [Member] Schedule of Inventory Balances Schedule of Inventory, Current [Table Text Block] Accrued gross interest and penalties Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Cumulative Translation Adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Restructuring charges, net Restructuring Charges, Net Of Restructuring Reversals Including Cost Of Product Sold Impact Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retiremte obligation. 3.650% Senior Notes due 2029 3.650% Senior Notes due 2029 [Member] 3.650% Senior Notes due 2029 2024 accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Segment and Geographic Information Segment Reporting Disclosure [Text Block] JAPAN JAPAN Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Reclassifications Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Change in fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability New Accounting Pronouncements Accounting Standards Update and Change in Accounting Principle [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Numerator: Earnings Per Share Reconciliation, Numerator [Abstract] -- None. No documentation exists for this element. -- Title Trading Arrangement, Individual Title Amortized excluded component Derivative, Excluded Component, Amortized Cost Derivative, Excluded Component, Amortized Cost Goodwill, Not Allocated, Amount Goodwill, Not Allocated, Amount Statement [Table] Statement [Table] 1.625% Senior Notes due 2050 1.625% Senior Notes due 2050 [Member] 1.625% Senior Notes due 2050 Ireland IRELAND Measurement Frequency [Domain] Measurement Frequency [Domain] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Gross unrecognized tax benefits Unrecognized Tax Benefits Comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Consolidation Items [Domain] Consolidation Items [Domain] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] 1.625 percent thirty-year 2020 senior notes Senior Notes 2020 Due 2051, 1.625 Percent [Member] Senior Notes 2020 Due 2051, 1.625 Percent Investments Investments [Member] Change in current debt obligations, net Proceeds from (Repayments of) Short-Term Debt, Maturing in Three Months or Less Contingent consideration, fair value Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] 1.500% Senior Notes due 2039 1.500% Senior Notes due 2039 [Member] 1.500% Senior Notes due 2039 Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Other Other Segment [Member] Other Segment Repurchase of ordinary shares Payments for Repurchase of Common Stock Financial Instruments Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, gross Long-Term Debt, Excluding Current Maturities Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Due after five years through ten years Debt Securities, Available-for-

[illegible]

[illegible]

[illegible]

[illegible]

!!1110 4444 %%%% !M1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% M% % !!1110 4444
%% %% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 444 M4 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110
4444 %%%% !!1110 M 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% ! M1110 4444 %%%%
!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%% M% % !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444
%% %% !!1110 444 M4 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 M 4444 %%%% !!1110
4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 M 4444 %%%% !!1110
4444 %%%% !!1110 4444 %%%% !!1110 4444 %%% M% % !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%%
!1110 444 M4 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 M 4444 %9VB^+_"?B34-
2TGP[XHTZ_NM&NQ::Q;65['+]8SE%D\$4RJ28GV.C M6P=KJ<8(J3Q'X>TOQ9H5WX;UM)FL[V\$Q7*6]W)
[(>H#Q,KKD<'!(IU^VAO'%&"Q)(5%5022 M>.30!^@_Q,+_P
)O@MH"^*_C'\4/#OA/2WF\$*.EXFUN"PMVD.2\$D[JIX/M<<5H>\$/&?@_X@^&[3QEX]\5Z;KFD7)?F6.JZ/?1W-
M<)DC='+'&2KC((R">E M?FY^V=^U+I7_3W_P""WGAC][I#N+0+@?!/QS*"H"/7PX^)4UH9]/\ VO_M &R2:[AFP#]E-
T@C+W &YD2,9,<,IC]H_P""7/@?QAJW[0'[1O[77A?0KGP[M\OC%XJT34OA-X=N+8VOVX6VFB#4/\$26I ^SQZE+Y?\
P3_-/\ V-TM_!W];/\ P4@_-:TJ/^/WQP=9?#6K:[H=V#_(LKDE[M3PYI%) ;"R9(MAN%\$PG>
M0/'&+P!5U8<,I!!!!KX.^.;7=G_P '!PZU#X[26]?#3_AE'Q(O@B772@L
M%#1#5H&U;;9/D\$O)DB,OWD/GY0U<=_P1L^/OC]'FW _@B3X(9>,?#6J;W=: MCXFU;2?@AX3F/YQ*PV0V<9F.(HB0 ?
HO9>+/"NI M<(L_':=XFT^XU?2H(Q)[3TJ"]1[FSBG(SR7EB;W1K)Y4NPL &M\9VG&A7F M'[*][\ J'P&^'MT_CKQ##K_
(\6:F^N_\$;Q3%\$475-7E1%;RE);CM8(TBM MKS<(DF.WMXE)+!F;T^@ HHHH **** "BBB@ HHHH
***Q^_.W]:7D)/[.43M^ MT!\T?X-)3(F6&LZ_!%=R#&?DM]WFR?\!4UU8/XW,:ZH82E*I-[1C%R;]\$ MDV3*48*G9'IU'?
G);\^ #H?._@FA,Y)K'X=S->?B#<)E8I?#WAW[+,P_O2 M7SP.%_VEC;V!~?*7Q7_ .#O#XD7KRV_P_.8ST/354D07GBOQ1-
>EQV+OV\4 M&WZ"1OK7ZIDW@\XL9VE^EEDZ<7UJN_*W_:LW&7W19PU,TP-+=_37[C]R**_MFN^(?
_!SE_P56:F3_A'/&_[PB'SM'A[P;!)]L^GVXW/ZYKQGQ?_,_j]/^"J M7C?? ;7];WC6#\$O/V/(VV?BW?!NJ)?Q'U.1<<8 M?:
)XZD^^_B'\9_%FO6'_ ANL2?8M:\1W5U# MO\$28;9*[+D>N*KB;Z+N;\,<,XO-Z^94Y+#TY5'^-.7O?'V?)C)9[%6-5>\D[6?
57/9YS^S:B0Y%/!7_=O_@KMx!E6;0O MV[\&12@_C7M_PS_P"#K'_ @K5X\$DC;Q5XJ]">-%7[R^)/!4
M<._Z_P!GO;8_"LZG"&91^&47VOT#G1_3Y17X,![_ @P\=VABM/C]^P_I-^ NDW@37_Q;+;;/=;YAFW?0RCZU]=_ K_
(.LO^"50Q7,%G0\8];_#BZD(60 M^#/##7#6N'/I+I[7!VY_B94]P!7FU^"WH:NMDWZ?Y:CYHGZ5T5YC_\VT_V1
MOVI;5+G[G7]I/P5XR=H][6F@^(\(>+YB&,_O(WFGQ'.4&O3J\B<)TY3SS0!\K?%C10#?[=W_!7?QQ^P9^V+X6M
M]5^%7@OX(6.N^#_A]J9;/Q1>:A<26]YK3J]"#.JF +:(Y/V>21I4VRE77_X M(R_!KXL?L*?MC?M\$?\\$T])%^()6J^,O@EV;?
OM? \ AK=ZU<&:X\+MJB7\$LFBO M+WPJ+*\$&%VR[5-P0?N/XP_LT_?X^WFDZK\7/AIFL:CH\$DCZ!K,D;17^EM
M(NV3[-=1%9H Z@!Q&ZAP &SBM7X8?![X6_!;PW+X2^%/@/3-IT^XNY+N[@T^ MU"&ZN9,>9<3-JZ:9\#=*Y9VP,DT ?
\$/_6X3PU_P4F_X(??&#J#]B;XBZ-\1 M4BM[>[AF&:I%J\$5V^DZI:WEY;*8&8/*L5O(1&,LS!, [AGFO^"F>I_/JJG
M_\VLU+Q9H4-GJFB:Y)!][UX\$AM4\$LHU=?);86L"KEAA>"O#K:C/?MH_A^Q6W@-S,P:24JO5C@#V55 M48"@# '_L+?
L?[_#@QFGCWPT?SMX7TW48=9DUBS*MIP6V[L2DW>9?6]M/J; M>Y; >^Z>)%D>v6.XY *[/GP3BF_8?\ A;+?
VP/("FB^)=9.\?#K0HO%R>+* M"*[A&JVVG0I6KZ3H/>?BC\?!QH^'FL?"GXE; ,MVH^']?
L7LM9TX7'OB(LNJW#)K.F7^LZO83Z\$UH[F->+"WM#+R8M@%N]OYB!2SEOVUKQ[0/V_M_P!D+PQ\78/CCH?P7M(=?
L]=O:-M-D97=\$&"VZL.O\[1J>Q)XK);VWO^#G']M+][H8WGA#[FNQM_A)X M9E+1K/_ (45XC);6-Y=>9?
72CO#:1IYNG5\$('"?F3^UA_P=H_#SO7N/#O[%_I M/-WK\ZY6+Q-X\F-I:
[AT9+.!C*A_P!J6%O]FOQ#\4^+/%/CGQ!=>+?&WB74 M-8U6^E,MIJ]>JWCW%Q<.>K/)
(2SGW))K/K^N^\$ /HL<#Y*HUGD2OY M1B^9_P#;TVG_"G@8C/,34TIKE7WO^OD?5W[3'_!;7_@IA^U/+<6OC3]IO6=
M"TF?(_LPow]CVJH>L; &WVRs+[2R/7RK=W=W?W4E]?7,DTTSEY9IG+,\$Y+\$ MGDDGN:CHK^B,GR#(^'-
l7RS#4Z\$.Y.\$8KY[j5WYO4[FI5JU97G)M^84445Z MYF%>%% 1?ZY%\&PW_5+2?] L2=9_P#125^>E?H7_P &PW_5+2?
^Q)UG_T4 ME?G?BY_R;#./^P>K_P"DLZ! OM/U1[_P#!P?\ IC?CA_V';#_-=G7QI M7V7_,!'_P#RF-^-'_8=L\ TUV=?
&E?Y[9;_P BZC_@C^2/M7N%>%>=H!11 M10!-8:A?Z5?0ZGI=[;-7-O)(+BWE*/&X.0RL.00>XKZ]_9;P""[/\ P5/_M
&3I+>S'_M2ZQXET>WP/[^(!_MJV9!TC#W!;)\2CTBE3TKX\HK&OAL/B8\M M6"DO-7!-H_?]?D/_ (/#@9XC>V\.?MO?
LW7_ANX;"R^)_\$_P!ML[QZL]G.MRS0H/[B6=O\ 9K]3OV5_V/V/OVV?#O_DG[+G[0?ASQ>BQ"2YL+]"JV7UHI
M[SVDH6>#_MHB Y[5_%U6CX2\8>+?'_B.S\8^!/%.HZ)J^GS"6PU72+Z2VN;:0 M='CEC(9&'J"#7S>,X2P%?
6@W!\>ON>OXEj;6Y_#_VG[V.^?A6';&]QJDHM-CNQP/-7K7[;?L"_!9'
4US_@HS90Z=#/B#U'8">VBWW^@+Q2JV6KQX&6V1%BERH') :Y% ^\O>*^~S#(MLQRZ\IQO'NM5\^J^9:DF?
M@%>%>.:4%>%% !!1110 4444 %%%% !!1110 4444 M %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%%
!1110 M4444 %%%% !!1110 4444 %%%% !!1110 4444 %%%% !!117YE_P#157_@XR^" MO[]#ZG\$\?V2AIWQ
^(\!>WO=4\SS-%T&49!\\$CH1[KF4>5&0JG(=PRF_,3\)M\&\1;YK'+\FH.K4>[VC]?S3D]
(Q\WOLKNR,:^(HX:GSU'9'W+^U;^V5^S9^ MQ+^\I/BG^TK\4]/\Z;RV4,S&2ZU"4#E6T"9DG?D9"@A0-WFJ2MB"/X829
1_KL': M/SW_&B/VE_CO^UA\2[SXO\ I0_Q.U3Q3X@O#AKS49LK#"DD10QJ D\$0).(X MU51DX')KAJ_OKPT^C;PKPC&&-
SI+&8M:^\OW,'=@_C: FGY-1BSY7&9Q7Q% MXT=C^+_ *B?5-4U/7-2N-
9UK49[RYFFNKZF:26:1CEG=F)+,2222.%>%%, HHHH **** "BBB@ KJ]"_#8;_E*'EI\ V).L_P#H
MI*_ /2OT+P_P"#8;_E*'EI_8DZS_Z*2OSOQ<_Y-A#_ 8/5_P#26=>_P!]I^J/ MG?\ X.#_ /E;,\$O\$NG-
H^IZ3<,"Z9!;*5#E)HFP-T4BLC#@J:^9S3 MAG!XU.=W)^6S]5T]5]S+4VC^VJBOR: X)(/'P:_E?3/@\ MT-I?P^
M,(Q2WT_Q2C>5H6NR' 9G)^PSM_=PM%<@PHHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH *Q/B1\2O 'P>\"ZI\3?
BEXPT_0/#

EV+Q6L(Z=WHOZ)#\%O#/A7Q/XUUN#PS MX-\.7^K:E=/MM=/TRS>XGF;T6- 68^P%?7OP_XC"\ \!4][H%(-0L_V;GP
MCIL^#:/CV^CTKR\ P!ZWD)NORA-?TG_ ' &6OV4J>0Y?'G1*!LW.7KRQ M<5% ^LIH[FCD%-:U9W]-#-[_ P:
(_J_CBN_C ^V/H>EN,&:P\ ^&IK\Z@ M3W,EOM^OE'Z5](_ #K_@U_-X)V>%DCG\<_ \$XF>%)P!YR7.N6MI;L?9(+99%
M][^&OTWHK\;S7Q\6C3RK 4]H7]=3XG\+?&[MW_!('PQ\$H? 96;4Y5ZW&J^,M7E+?51=!/\ QVO8?V>?
^"9"!O[*CZ/XI? ML]?LUZ'X8\0Q6Z<7*S7E:QTPPN&IN8)?'S-! = ^".7 !, _IKXF:M\9/CG M^R9H6O\
BC7;A)M7UJ>_08IKITC6)2WDSH.\$15P !\HKR/QI_P &SO\ P1M\ M7*[V?][+U][H*('F^&?
Q@^*/A6Z(_=J^J6= ;#ZQR6RR'_OZ*^8/C1_P9K?' M+1[::[_ 9_] />+>()!EH;'Q?X;N-)X_NF6WDN@Q]]B@^U?O[17?
1XBSBCM5O MZI/] +BY8G\EO[0G_ ;\?%:/V)M%N].U"TD,=W8W\LT,T+CJ KHX#*?8BO[E:
M\T_:'_8U_92 :TT4Z%^TG^SUX2;1>48X9]=T2*:XMU/_/&?'FPGKS&RGGK7
MMX7C*JG;4T_..GX_ YHET^Q_%517]#'_[97_ :\$?LU_\$'[7XH_8H^-&K?#[_ M47W/#X:_3AM5TICVC2;
(N8#)6=K@=*_ 'S]N/_@D7^WO_P_P][KZ>X_ :\$?^!M\ M^/TB3K\$Y_NU]3@<[R],_*<[2[/1_'\Y7(<6C MYJHHHKU1!1110
4444 %%%/%% 17T1_P \$UO\ @;(\ T)_P3&^/<'QB^<'VIF[TN M\,<[B'P?>3LMEKUFK9\N0#ERKEC', 6C8G[RLZ/\
[T5G6HT]]TZBO[H#^ MS[[AC]N3X"?%?"V?_* :)_9][1 :M.O1YJ:7<%1>:./>JH,EG' P!HSX!>*TU?PUXBM!+;
M2X"RV\@XDMYTR?+FC<%'0]".003^6YYDM3*JW-'6G+9]O)^?YFT971Z%111 M7@E!1110 4444 %%%/%% !1110 4444
%%/%% !1110 4444 %%%/%% !1110 444 M4 %%%/%% !1110 4444 %%%/%% !1110 4444 %%%/%% !4.HZCI^CZ?/JVK7T-K:6
ML+37-S<2A(X8U!9G9FP%4 \$DG@ 5-7XU?^+_ P#P5DF\+Z=?\$Y/V?_ !(4 MOI^V1_BGJ]E-AH+=U#1Z2K#D-(I5YO\
IF4CY\$DBC[3P_P"!U\0N)Z.3X%6 MYM9SM=4Z:MS3?ILEUDU'J" MDW0:OK4?!#3D_-90-Z8\YQG B!60_)8\;-_M)K!\60
M&L063R]5M-NAV,G7\$5FQ/V@@Y&^'=+BV6.D:/+#+%ZL0.6=CRSL2S\$DL223735_ 'B1](WB_C*&)E
MWMXEC@(@C')&BC"JJC@ #@5+117/[MMN]/'7"BBBD 4444 %%%/%% !1110 M4444 %%%/%% !4.H:?
8:M8S:7JEE#.#5&&5E/# @D\$@^@U-10! M^8G 4= _P"7S]C7]K07_Q%_9@:#X/>.)MTIATFRWZ?>RGG\$MFI^V8DX&^W
M*JN2QBD-?@?^W3_P3= :_X)T?+\$ _A_OVG?A=<;#); FXTG5U'.ZV MN0 K')C8+*H(W(N: LKKF/C#\%_A-
^T%V/-1^\$WQN^>D>*?#>K1>7J&C:W M9)!*S;6'RLIY5QAE(4@&&OI,LXFQN":A5]^'GNO1_H_P(<\$S^(:BOV&_X
M*^?!\&O?Q!'!^*ZG^T'_P3ML-2\6^#8P]QJGP[D=KC5]'3J3;J,VFAM% M%=%@&HHHH **** "ON[_ ((6?%\@_%7_3#_;
7PWX^U*[O?@_XSO8XO&>D M+ND LV4X1-5MT'(DC&![JC][\\$-N"R1%?A&BL,5AJ_,H2HU5>+!.S/[D?"_BC MPYXW_-?
XS\ZY::IL.K645YIFI6,ZRP75O*@>.6-U)#HRL&##&@&@U?K%O^ M#6S_ (+ 2>=&:M/^"9G[1/B0(D4:@EF9CPH !))X %-
)MV0'S) M_P_P#REYKJXE_"IDT?P!;,2\$:T1_WEX5/1[B M0>820&""# _JQ7R/7^H/_@-X90\>\$8U<5^-V-
Q*4ZM]XJWN40^W\$[R_ON6Z2/ MBLTQKQ>(M^X8]YA1117[D>8%/%/% !1110 51^#/_!GBWXZ^+^!^ O#5]K.
MM:O>1VFEZ5IMLTUQ=3NP5(XT4\$LQ)P *=X%\^",?B=XSTOX>?#WPU>_SKFM7 MT=GL.E:? 9)[>1@J1HHY))
(K^D;_@BS_P \$40 O_!. P7;_ !A^,5A8ZY\9 M-8L_]U 8E@.\PNOS6=H>A?Q+..6Y52\$SO_ "WQ3\5,D_,E^L8C]YB:EU2
MI)V>?%\?^?#?;P-^R7;:5^TG^V'H] MCXB^*&\$NM(\.5GT_P +U4]UN+Q>IDY2-O]7Dj)3^H%/%?YC<8<9<0\=9S/
M,\WK.=1[+;.(J(PCJF^)[MMMM_9X?#TL+3Y*:LOS"BBBOEC<**** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@
HHHH *_+_O_@M? P;K_#;JNF#5/VD MOV3;/3O"7Q?V-<:EI^!!IOBQ@,D38^6WNSVN!\KGB7KYJ?J)175@;B;!756
MC*S_ #\GY":3/X>_B7_,B!\&O^'K_"OXJ^#[_0/\$>@WSV>L:-JEN8I[6=#A MD93^8/0@@@D\$&L.OZJ_ ^"U?_ 1!^%/_
4_ ^"TOQ""QV/AKXRZ'8%= \2F M/9#J]; E; M^3C+1D)+@O3D;EW(W\NOQ8^%Q&^!Q)UKX0?%WP?>Z!XE\
MZA)9:SH^H1;);9#RI[!'@A@2K0RD@_@G]3RC-Z&T;QTFMU^J'C*46F<[11 M17KDA1110 4444
6=%UK5_#>L6GB'P_JEQ8W]AVDS1RV\R,&21'4@J MRL 01R" : K%_P""&/_ P5
T[_@II^QU9^(_%NHVZ_\$KP7Y6D_\$*QCPIEGVG MR=05!TCN45FX "RI,@&\$!/_)C7U'_P1^_X*)>(O^":?
[:WAWXX_ ;F3PEJ# M#2?B!I4&6^UZ3,Z^8X0?>EA8+/'T):/D!VXS?>96LRP3Y5[=8_JOG^=BHN MS/Z_ :^H^&?
\$OA_QIX;T_QCX3UFWU'2M6L8KS3-OLY0\5U;RH'CE1APRLK!@1 MU!%7J_]VFG9FP4444 %%%/%% !1110 4444 %%%/%%
!1110 4444 %%%/%% !1110 M 4444 %%%/%% !1110 4444 %%%/%% !1110 4444 %?F?\ \,7 !05OV9_V4(? MV6?A[K1A\8?
%B&6WOV@DQ)9:"AVW+G'0SDBW&*&0W&#E: 2C5]7TOP_I-UKV MN:A#:65E;O<7EU<2!(X8D4L[LQX"A022>@%?
R7_!%/_ JM36/V^OVU?&/[0M MQ/,&-N+S^S_ "%G-D?9=(MR4MEVG[K_-TSC_GI-7]"1PX CQCRL=BH7PV"
MM4E?>52 _J/WIS?1J%GN>3G&^*KX;ECO+3Y=3Y_HHHK_ \$P/C0HHHH **** M"GVUM<7EQ':6D#RRRN\$BBC4LSL3@
JBRMY>1L5?5&4%\ (7!2'/656?CRD+?&\>Y3X?<,ULXQ M[NHZ0C>SJ3?PPCYO=07EBG)Z(Z,+AJF+K^G'_AD?
4W_!!_@C)I_[\$O@*V_ :M@ :*_12_%OQ'8[K&QNHPQ*6,B_ZA0>EW(I_>OU0'REP/,GZ4T45_E'Q?Q M;G7&^?ULWS2?
-4J;/[8KX8172,5LO5N[;]^ZP]"GAJ2IP6B"BBBOF38**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ KX_ ^ M" ^O_ 1/_ \%OA1!YH&?(E/
M1CY;\$ (VY/T)%_36511PP.\$N,=04E(&)G/X4U^N9;F%,'L*JU/YKL^W]=#% MJS"BBBN04444 %%%/%% ']'_<_<
:A_P#1!F3X[LWZG^PI2=; \WQ-^+H!=>% M7GDS)>>Y9,>6,\G[+,XCST\$<'@?:(_7&OX\$ _ @G^V9XI_8#_&SO W[4
M/AMYGMI]U94\06\$+?>?E3?NKRWQT):G*YX614;JHK^<Q_P?XN\^/\ PEI? MCOP;K\$.HZ/K>G07^E:A;-
NCN;:-9(I5/=61E8'T-?F/%&7?4=[6]"VIK\^ MO^?S-8.Z-&BBBOF2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@S']K/PK\(_B_P#!O6_V:OBY M\4Y_"MG\1='N='^UZ?
JL5G>2Q.JI^d\$DJLFXJX0@J=PVM. MI0JPO3DW/O^TXOELM&M=V?RSG/TA.')Q?BLLQV\$E+ #TIN\$:U.5Y>[I]N#L
MI+GYK-2^&UDV?@Y\3/A3\3O@OXON?A_70A[K7A?7+,XNM(U_3);2XC]"8Y5
M5L"!Q@JJP*_ITU][J;J]B;J]M/P>GPP;K_9YT>[@*D1W6H:=]NMX6(,D,B@ M7%HY.0#^D@=7KY+_<_<
&H_ ^#6[X\$_ _1Y_B;_P3E_:+@T))RS6_AOQ+>G4-,90 M^>><5]"&FA Z8D6=L]6%?
T3D'TB,4XX;BK"3P%1Z<^M2A)^4XJ];JG%I>+1^ MG9#GG#G%M#VN1XR%>RNXWY:D?
(\4)6D06UGT/P_HKW]IKC_@FI^VK^PYJ]3V_ I M1_P%UG1]/\$OEVB.VB%WI5P2?EV7<):(>H1F5QGE0>*.K]^RW-
,MSC!QQ6 M K0JTI;2A)2B_1IM'I3A.G+EDK/S"BBE56=@B*22< M_B;_ (*_M=Z-
&XH[FW*];C5/'FL0#^V33(W&Y%;H)IF(BCZD^R^"J-C^J MSP3X*)_#?P=I7P^"\!:;5HFB:~#8Z3IEG'LBM;:) D<2#LJJH
^E?(? !" M_P#X)X6_I [/ %FF0>+M\$%O\ '\$QXD.M^>Y)8\2VSLF;>P/<"WC8@CG[I],0< M\$5]H5_F%X_>)
<^/N,)8?"SO@*W"G;: MEJ_@HHHK/(4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH
**** "BBB@GX@V/Z^XLT&^*^)]'MM0TS4[.6TU&PO(5DAN M8)%*21.C
AD925^G@<D5_)E_P6^_X)F:C_P3+;/_U'P)X:L+EOAYXL636/AW M?S\$OBT9\2V3.?026TA\LY)8QF%SS)7];-?(G_!;+_@G-
I'_!2/\ 8 MZ=#9R8\ (O\$MU+]/J22>IKQ>(<,\$L;EDTE[?>7R_5SRHNS/ZL****)38**** M* "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ K
^*GCNR^&/PVUSX@W^TQZ/I37L(%PMPAC//AEK^&(/AJXNO M](O!C=+8W+)Y@!R%<#AUS_"P/(<5BT5-
6E3K4W"i%2B]TU=U1IA\3B,)7C6 MH3<)Q=U*+::?=-:I^A]8?##_ (*?ZZ^F-X0_.*^'UGXETRXA,%Y>64\$:2RQD
M\$);= W,V[H5'EKC!/KS3XX?\\$6?^"1?_!16&X\1?LZ:NGPO\97"-(-8_":+! M\$7QDF72IL(R+GDVWE
G^,UXU3H9IK>9+BWE::2-@R.C8*D<@CH: ^=PW#;]) M,8;P[B]F/K/?
V;J]R^_F_ =DO+;R/W/A;Z07&.31CA\U4<+17_/S2HEY5\$KW MYJ;SXU_:-_X-VO^"AW[*VOQ'X0\$1?
%PO!N8:OX%1YKN,=#+8,//4X! M)H2HH^+U_-P;Y_L#7/[6W]?UGK_,00#DA*_ "9H]=2VUY;D+?) (5LK-U
M8<6^IT,C(PPR6LJGK7ZM+XJTM" UIKK%YE7.3LN!^ M\I#?O [+7WW&KO0?&'A&T^-,K).K3P_JGBW3K:[U0)#']HF
0^4)9556EV MJQVEN0&Z#)%>MQ7XY^(F4<(XG*UHTYU:\73IXFE+D:OI)RIM?%R'G'?7B'6?JG<*\M-*4ZZ_T?W?D
M8S5F%/%/%>^2%/%/% !5C1]7U/P_JUKKVB7\MK>V5REQ:74#E7AE1@R.I^0A@" M#ZBj]%'&X']H_["[2MA^V^QO\<
OVF;)HO,8>\$;2^&U&.'[D-JLV7<(_W+A) MD_X!7K-?DO\ &AG[24OQ'_88\8?LXZM]/FWGPU\9F:PA+?ZG3=20S1J!_U\
MPWS9_P!O\ UHK\9S/"_4?4H]\$\]/3=?@;IW04445PC"BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ K\^O^"IW MCS_A/(CMI_@BFWF0^'M%02)G[L\Y\QOSC\$-?H+7Y/_M6>+?^\$W_:_\9^ (5EW

MHV03P00G[T<)\E#]-L:U^H>%&"6(X@GB&M*<;UDTORYC^SJMNOSS,/ <1JY_"OUNMK">"SMX[2UA6.*) D<+:A54#
'8 5\(? \ MI*/X>IK/Q.\0? \$B[MJR:]IB6MJS# @37#'+ #W"1./I)[U]Y5_. BKF;Q6?0PD M7[M&/_DTM7^'?'WK]&;AR.6)%5\$? \
R?G_"BBBOR_\H\M****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@
HHHH ;+%<1-!/\\$KHZE71UR&!Z@CN*_CE_P""JOI)1_8@ M_P""@GQ/_9RL\,PZ3I'B-[KPVN./[*NE6ZLP#_\$5AF2-
B/XD8<8Q?][CE?@_ MP>?;LS_\(_&[X5_M;Z/I^("?\$N@7/AK6Y8UPHN;.3S[=G]6>*ZE4'^[;8]" MOJ>\$L4Z.8NDWI-?
BM5^%R)K0_%ZBBBOTLR"BBB@ HHHH_4K_@TE^/;?#;_@ MI+JOP:OK[;9_? \$
P%>VL%ONP)+ZS9+R)O#_@9K^E:OXX_P#@D[9C^S_M^ \!2KX(_%-[KR+>S^ (VFNH39QLLJ]46EP?
PAGDX[U_8Y7YOQ?0]GF;.B^ MU^\5I^5C6&P4445\F6% % % % !1110 4444 % % % % !1110 4444 % % % % !1110 M 4444
% % % % !1110 4444 % % % % '%/Q/K47AOPUJ/B?*&RPL9KE\],(A8_P J M'_&
[NKB^NY;Z[E+RS2,][KG]S\$Y)_.OU;_.:OU[_A&_P!FOQOJ8?:3X;N8\$;T: M5#\$/U<5^4%?NWA!AU"!8JO\ S2C'_P !3? \
[;Y9@K_!3J3M_C ME&/_ +8% % % % ?L1_)X4444 % % % % 'Z+_\$QO!4?AO]FI/\$;0XE0:Q'DCVM% XO&?
^"BWPNQJ_8&^_ PK2VVV;6_AAKE MO9MSBY^PRF!L=R)0A_"NS+ZSP^_15.TE^>HFKH_C%HHHK[H, HHHH ****
M)]*U_.T34[;6+=N6AN;2=)K:9#RDB,&5A[@&@&O[>/_A% X]M/BK*/# 'Q0L%40 M>)/#UEJD(OY 2X@288]L.* B
K^P![_COXZD^ (W_2S^ ?B6: S'3X7:382 M29R6:T@6U)/OF\$Y]Z^*XSIWH4:G9M?>E_D73W/I*BBBO@ #4**** "BBB@
HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /% _^ M"A&H?8/V10%>UL--]BB7;R#/_Z
U^8]?I!_P4PN'A_99OHT.!+K%FC>XWEOY M@5^;]?T5X3P4>&IR[U9?^DP7Z'\#_2>K.IXA48?RX>"^^=5_] % % % % ?
IQ_.84 M444 %3?:9RZC?P:?"?GGF6-/JQ '\ZAKH/A+8KJ?Q5\,Z: 2X\0641S_+4Z M#^M95ZGLJ,I]DW]R.G!T/K6,IT?YI)?
>TCl]>M.L;?3-/@TVU7\$50"L48]4 M#]!4U% % ?Q:VY.[/]>HQC""C%:(****OPHHHH **** "BBB@ HHHH **** "B MBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IEU;6]I; M26=W/LD4J%)8W&0RD8(I"?10!_#U2_"K^!/_B-
X@)\$2*0VC:W=W+!NH, S M1_ LM8E>P_!%#=\$M_#7[?OQR\,6B;8M/_;/_B/VB7T6/5;E0/R%>/5^X4I<I
M*,NZ1SA1116@!1110 5_5U_P;^)\?2? \$8_@TTI>6Q77+.3)Z"/6[(\A MOV4K^46OZBO^#674#>_\\$A/"UL6S]D\7:
[\$!GIF\9_ \V>OE>+XWRN+[37Y, MN&Y^BU% % % % ?FI] % % % >9_M>_M?_+/_PI!M7_:4_;<#P_X2T66WBO+U;22
MXE>6>98HHXX8E:25RSCY5!(9CA5)'F?/[_5Q_8C_."G&K>)=(_8[V\, %M]H9UA3S+B)%9WJ]0A02<1L>U 'TQ17@'Q-
X*4 MLT_#+Q7XP-2?)3X@M AL\$/Q/U_PCX4NM2T[P@#&)2+V>%2-Z1\$2R10B62& M,AY412"?..125= M&1E96!
(((H OT4DD<4;2RN%502S,< =S7D7PA_ ;8^#O[1/BF;1OV=K'7O M'.C66HRV.I>.=!TO'A^";,E9%CO[AHHK]:P*;;(W
5LJV"" >O45[? \$'_ @ MJ) ^R=/_>M^>_M^\$6NZR^D>%&AX3_.K/1GDT^PYKE[Y0MM/O+L'"2\$SVZ
MNZJ]4#3QK[,18"O?? \$'B'00">@7WBKQ1K%MIVF:99RW>HZA>SK%#;01H7DED M=B B^H+B< DT 7**YOX/?
%#1/C7\, -#^+7AG2-5L=, \0Z>E]ID&MV!M;IK M:3F*1X6.Z+>FV0^*""N RJV5'24 % % % % !1110 4444 % % % % !1110 4444
M% % % % !1110!]\? \!3@X_9>G'KKMG_-J_.2OTF_X*367VK]E+5I9^S:E92? M3,ZI_P"SU^;-?T;X4R3X8DETJ2_*)_
7TFH2CXB;P;ZX>F_ \R:HOT"BBBOTL M_G@**** "NI^!@!^_G@X,>/^\$IT_? \ KYCKEJW/AG>_V;/_2/#^HEL?
9]\$5ZU^WWK^^(V[?C5XA60.+ _+?B2X#@YW;]4N&S^M>2U^VX9-8;"E M^1SO<****W **** "OZ@/_#52-D_X)'Z(Q!
?QQK9'O^^4?TK^7^OZFO^#7[M1GTS_@CEX O6CVC4=>U^X4 W@-4N(L_G\$1^%?+<7.V5K \$OR9<-S]!J*** -
M#4^O^"K'P#_ ".J_P 2?BG+OC= P \$ZO\$'PDFB^%;ZAJ\$>\$/B6;L_VS]L M#VJNGE)Y:M':R7\$<;-+\$0;R4EEPIIG[?
_17+7?VK?@9[?XX? 6[?&OQR^ _M =E./B= \KZ4R1Q2K;336J;U;2=9+<0OMY;CAG1HY9/2?CU_P %5_V6OV8/
MVHK;]E3X]Z?XZV;:GJ6A1:EHGB8^ [ZT75]"NOV6"YM\$E9KA=A+R*HR &+ M\$+7_LP?LY6WQ9_Z^G[>]BSX<:EX?
T/XJ>\$-%'\>']#U_39+4-3TNQC? M/U^M9 LML;AKE88H9@DRPVBLZ(9 B@'CW_!L7H".="? \$;_/_3/B\$RZQJ
MOQ8\7^+=? \;7=ZH=M5NY]7NK2>2;^ ^72V4/4<53_P"#5[XE>)?&'!+N;X; M>(-5GO;?X8?
%3Q!X1T6XN7+OJAADBNDWD^A?M;(OHJJHP, O\ X)C? \$0_ \ M\$? \]C7QG^P#^T1H^M3^+_A3XLUT_"C2;'1+FYN/B-I-
Y)?;=)I:PQM]JFD MFGDAEBCRUNZGS=B_-70?L\$>\$3_P0_X(H6GCWJ]?P)XI0^(K6^?Q-!1="! MZ7'J-^NIZK>Q1B"-
/_2-O(1[>_1S(\$S#(RL05! ,;_@X= :&^*NJZI"/^"7 MOP2A\027_P"T=XSEM?
&Z^&KB&'4Y?"UCY+W]G;R3RQ1Q/<)*1O>1\$V02H! M8UZU%?^"BO@ [JGO]JKP'_P2^_.? [&VH?
QO\$7APQ_!XMM;L]1T+6+;SC"M M81RVVW[+<1HH'DL&!^7YR1>9P_ 5/^\$GC>? \;_.9_X*Y?#X>Z_KFD? M!O7;L?
\$'P]9Z+ +_JMMX;UJT2"6_ %FJF5WLP00)"BM(I(QVXC;\$G]6_@?PE_P M4X_];_91\3_LW:S#XC+!+_Q;? \
CGQKX_TD&33K%!\% +32TN0-DMW<7\$2>9 M;HQ>&.%GE5,QAP#Y^_G.[#/[4]I^Q)^U[_P32T;X+^)=<18?O\ :@G\5_#_
M_5PZ-/)H2;?3OVN?CSXH^\$OA32O 7P>T^TU+XG>/_J0;1OA[I5XI:".YV%Y]1NE4@ MBR LX0UQ,006")"IR>(-
F%B/V00&GP^_X(A^ _@-^SS8ZYXHN[?TS6?' M4D,1FU;Q5_-8M[W6KR81C,LX\$]Q*J@ J'C5=NU*/_MOX.?M#?
G]H/3KW4_M@=_6_#_B]#39(H)0.AZG^<&U,L8EB\Q5.4\$D;+(A(=&# +E2#795^?/[.GC# M2/V@?^" ^/BW]H/\
9= \56/B'X36[*.D: !XO>2^'+E9]*N_ \$;ZW+>6-N)8R8 MY+B+3Y&8@\$M",JL%WBOT&H **** "BBB@ HHHH **** "BBB@
HHHH **** M "BBB@ #R#]O;2I-8_9*86T2Y:.VMIQ[".[AD/Z: ^+ZOUN_?T3_A)/@XT MT14W//X7OA\$,?QB!RO\
X\!7Y(U^ P#A?7YLFQ%^6I? P "BE[_;?PW]*; \ MN"%F!Q7]#E_ \ J2_ MX4445^LG0A1110
4Z*62"59X7^NC!E8=B.AIM%&X M)M.Z/V4V: M'KV@6.NPXV7MG%.F/1T#^=7* \X_9'\5?)E^S+X*UHR;V70H
MK61L\EK? ,# \$^ ^8S7H]?QEC\,'CJN'^\>)2C]S:/<E76M:E, ([>SMWGN)#_ M HBEF/Y U8KP;_@J+\7O^%#_ P#!.?XV?
%2.Z\FYTWX::LFGRYQMNYK9X+? _M_C2QUI1INM6C!=6E]X'\=7C/Q->^?&&K>,M2)^T:OJ<| [<9.?GED9V_5C6
M;117[>DDK(YPHHHI@% % % % !7];/_ ;]>\$9/_A P1V^!VC2Q;#X>O+ &_H MN]2N[H'\1, #^?R35_9Y_P \$! ?AV_P)?
V!O@K\9H=DVB_"O0+6[4C']]=/_ MA\T_C)N/XU=QE.V#IP[RO\ _Y/_/HH MH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@".\M+?4+26PNX@4 M;1RH>C*1@C\C7XY^+ - N/"GBG40"]WGS=-U":UER.=T;E#^HK]D*_+C]N+P
M9)X)_D6V7E;8KZ_&HPMCAQ@ (LK\$? \ V. /?>^!FI^"IYMTN@ZVYC3/W8)U#K_P"1!-7T[7YYP_X+^+SXD M?(\I>[GP-
=7&VW\3Z6>2(3@&X&S&?^ ^/_U85^AE?R]XAY<[OXJK+^W:EI MK_M]?_R92/\ 2'P&SZ.>>&F\$3=YT.:C+RY?>* \
!;@% % % % ? \$' [&% % % % !11 M10 4444 % % % % !1110 4444 % % % % !1110 4444 % % % % !1110 4444 % % % % M !1110 4444
%?F=_P_'7'Q^C^\$ _!+>?X6VEV%O?B7XTTW1_5L/JEMW.H2 MN\ 9#VD*'_KJ!T)K];_G>_X/_VG+?
QI^UM/VOV6=%OO,M_A[X5EU/5E1^ M%O\ 4G0B-AZK;VUNX/I<"4U]?#V&^LYO372/O/Y:K; \$R=HGY 4445^LF(4
M444 % % % % '5? OX:WGQG^_O@ [X: <&-QXK]5: ?HT 0?-ONKF.!<>^7%?VX6% MA9Z780:9I]NL-O;OK%!\\$@P\$10 JCV %?
R;_/_!O5\ \$6^?_ 5V^\$.ESV1E MLO#FK7'B6^?;D0BPMI;B%S_V\K;K]6%?UG5^>95N;%4J79- _>_ ^ :4UH% % % M%?
&F@4444 % % % % !1110 4444 % % % % !1110 4444 % % % % !1110 4444 % % % % !1110 4444 % % % % ?#/\ P5F#?
8O"A;XC00_+J&FRV%PZC@/'^>^<Y\$S\$Z] M[5]S5X9_P42^& \ PL#]F75+^V@WW?AV>5+? YV)E?>?01.[? \ 17UO V8
MK+,*/_4D=D^1_ \ ;WNK]FT_D?EWC-D,N(?#?'T(*X1]K'UIM3=O-Q4H_ _M_*BBBOZK\ S HHHH **** _GX=^_
=4^&_CO1_'NBG_2M(U&*[B7. ^Q@2I]F M *GV)K]>?# 'B+20%_AO3_%FAS^;9:G9175I)_>CD0.I (BOQMK]!O^"8?QH'
MC?X0W/PMU:ZW:AX5FQ;!CR]E*2R?7: ^]?8; \WK\F\5F>)RVGF%-TG:7^&6 MS^4K?^!,_J'Z,7%D3XO\
% =S=:7'1JWQ(O[KQ?J 9>3';;7I];749_CC=2K#035NBG&4H24HNS1?2\$*L":NFK-=TS>
MOB3X&U3X9^/_J9^ ^!L@ :='U&6UD?;@2!&(#CV888>Q%8E?5/_!5#X2GP[\4- M+^+6G6N+;Q#9_9[YU7@74 !)] ;HB@'_
%R:OE:OZ^X>S6.=9+0QBWE%7_Q+ M22^],_RLX\X;J<(<7XS*9+W:R?(A1110 5Z-^RI M;[GX ?&K2O'+R/_ &[_9-
;B49WVDA MYB)"[K]Z&OJ&OY&SO*,1D>=5,%6WB]J'W71KU7^1_J=P=Q3@., ^/,F^%?NU
M(ZKK&2TE%^<7=>:_LUHT% % % % >2?3!1110 4444 % % % % !1110 4444 % % % % ! M1110 4444 % % % % !1110 4444
% % % % !1110 4\$@#)-%?G7_,'(O_!2V\ M88_8IN^A+ \.? \$0M_B\ %>&?2-%^SS8FTW32NV]O^_4(1A#&W!\$DP=<^4U=.
M\$PM7&XF-&GO)_P!Y";LC\5/^#&@;_@H% % ^WS_P "%=?U+P9KPO/ O@!6-># M&ADW0W\$<+G[3>+CAO.N"Y5Q]Z)(?
2OAZBBOV3#8>GA,/ &C#:_L8/4****W * M**** "N_ &5?@#XF_:I_:4'_LX>\$ XO_&OBFRTF.9\$W?9TFE59)R/[L<9>1
MOJE#7 5^O7_!HI^QF_Q_-N\6?MF^))WZ5\='F^YI\$X;6+1&1G0]S%:" M96';[7&:XD;!15 MOINE6B=
(+:")8HD'L\$51^%:M% % % C3;;NS<****0!1110 4444 % % % % !1110 M 4444 % % % % !1110 4444 % % % % !1110 4444

%%%%%%%% !1110 4444 >: M;? M!E/CI\="&6UL)-2BB^VZ,<-S'(I5E.&4C!!K M]GZ_-? \ X*?\$ =O@|;Y_\$.D6931?
%1>_LBJ_+%/G]_%^#L' Z!9%':OV;PG MSU4ZU3*JK^+WX>J^)?-6?R9_) 'TGN"Y5\+A^)L-'6G^ZJv_E;O3D_23<6_[T
M5T/I/Z***_%_J!6R<8(MX(K\A)JJO_8C_&JKO]G7Q[_9/B*YD?PIK4]IJL(RWV63HMT@]1T8#[R^I5:_ M//\A-Y_@%B<-
_I_26G]Z.[CZ]8^=UU/WGP+3UP1G;R_)VP6:(NWM3GLJG MDG_*TOLV?
Z8T5%97MG]5G#].G7<<[O<1+)]/"X9)\$895E(X(((CJ6OYK: M:=F?Z%1E&233NF%%%%%%%%(84444 %%%%%%%%% !1110 4444
%%%%%%%% !1110 4444 %%%%%%%%% M% !1110 4444 %%%%%%%%% !112,RHI=V &22> * .3^_ .QP^&?[-?P<\1_'GXQ^
M)8M(\,^%=*EU#5[^8_/*F4,#B2U@)9(L?*[IY? MF'E'?RSK]*X9R=X*C]8JkWY;>2_S?7_AS*.O%^BFX\#_"4P
M>)]\$+2QYBN;Q9#_9]F>QWSH92I&&CM95/45_4W7P7%^/YIQPD'MK+UZ+[M?F MC2"ZA1117Q!H%%%%%%%%% !1110
4444 %%%%%%%%% !1110 4444 %%%%%%%%% !1110 4444 M%%%%%%%% !1110 4444 %%%%%%%%% !1110 4444 %>6_MA? >\ :
^">H>%K&W5M8LO M]-T)SP?M'_N\^CJ63TRP/:O4]*Z\#C<1EV,IXJ@]3@TU\OT>S[H\\$.LHP.?
MY37R[1&Y]5+>C>35KKLUNG?3/QBNQ][6=[6ZA>.6-RLDD3\$\'^ GGY3E?O \$\$\$9!R#T-?
B_7U^_PU^WG^X:AM/|S;]7/V!=L. MAZ_6\X+KWE%= YEUW6M M|_UOX&^-5/ P|\.
<05+4U[M&K)_#VIS;^STA) _#|\^VUON&BD1TD021N&5AE M6!R"/6EK\/_-W"BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH *** M* "BBB@ HHHH *_\$_@Y*_X+IVWAK3M9_P""=?["C99-4N4DL_BIXOTNXR+
M*,Y632+>13_K6Y%PZGY%S%DLT@CWO^""^_P#P:C> M1:?!I]K)/<3R+!|!#&6>1V.%55')) '6HZ_5G_@UQ_X)@3?M/?
M*M^VQ6/ M#GF>!/A9J""08IF+,>J^(@%>\$#/WEM599V)]&MQR"P)CL92P&%E7J;+7T7 MS&E=G[#?
\\$/O^"=EK_P3A_81\ \ PX\1:5'XZ\3A=>^(\,^ 76_F1=MIN_NV M\02')4NLKC_%AK[!HHK\IBJ]JM1ZR=V;K0****Q ****
"BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/XE^;WX?^ M5\9:7X,U
M7Q'=V%FTEEH&APA[O49^D=O'N(12[E5WNRQH"7=D168? WQ/_P""DO\ P5&_ M8L_:9^\$FD_MX_LL_"0"?XU?
\$*R\%Z]/JOPK4:E?ZIX7U:_8BTAOFNX8H[LG M:Q8P1*\$415LJJ/^BM?EO_P6L^/?;]'I&WQ^%7I='QB^!OPY?LQ?"_P
< M0W&HZ/IUU>-KFAZA=9LK?7Y1(\$A>:!)Y(X%4.BR73AAO,,\0!|A_MY_MRG]D M^\\^"P?^7A&U\3_!3^,WB]?#GPY_
WUZUO:[U427FI7*D8P_? \ L30:4MR#C^'RF?/MN]Z /TZKXS_9_P#VWOVKOVW_-G?Q#^V
MA^RG%,\,.'^VNJ;W;^?"^_ BW3;Zyu+Q%!IES/:O-.9H]?U'PS*T"CVKW";7PL^S\$<,-Y\$?HUXN_X+ :+XJ_8_9V^ M/?
P""!)_PDO[3OC#2/#/@C2/%!>45:>&U\$,WRQLAG;RPK1A MRZ^C?L0?MI^-/CG\=_CI^R#;:] (T:X@_?Q-
IEIK&I>&K:WT_6=,U2Q%I MM['!/+;-).T0D22\$RRA6CR)"" 7S_4?V;_V;/^"BW[%?].?QG_80\1:7X;T7
MX7^ (M''):_9VTUOL,*6 :!](NX58/'&T?FVTNUC)*@;YRA5;2_@M\4?V1? MBQ\40B7X>|4Z-
K\2OI70BVS33+73K9Y=)*:5I-BMI%=OYFU[FVTZU=I9)G M6(7-Q<6]N\$B,R&@#Z2\
(?'SQ5\5/VH=>^%OPSTG3YO!7@"Q-IXX37".[S^(
M)EBEATNS*N\$W6]NWG73L"FYMXE^<3>7ZU7PY%^WM\!OV\$?"OQ&^!_P?^\$'B M?QAX/_9HTVPN_C?
XRAU!*KJ"YU\$O>7-RJR8;5+[#RW]XV8>:VTR2DQ#[3*_M>*?
#OCGPMIOC;PAJ\,H:3K&GPWVEW]LV8[FWE021RJ>ZLC*P]C0!H4444 87
MQ,^7AGXL^!-3^'GB^T\ZPU.V,4N,;HVZK(I/1E8!@?4"ORE^,_PD\4?_XC M:C\./%L/^D6,O[FX52\$NH3RDR?
[+#{C'D&OUWK P#;A_98M_VA_A]_:WAR MU1?%6AQ/)I4G -
W'U:V8_P"UU4GHW&:OT/P^XK609A]6Q\$OW%5Z_P!V6REZ M=)>5GT/P?QT\,GQOD2S# 0OC<.FXI;U;(RI^;7QO\
[Q^U=?F?14EU:W5C=26 M;?];20SOR%)H94*LC X^D!\$'P^@/U'7!II]Z/|&G%V>X4444""BBB@ HHHH M^F/V/?
V_=;#^RVOPX^+\$L^I>%U(CM+T9>XTM>P'>2(?W/O*/NY ""[Z-^)= M \8:;)>)O"VL6^H:?
>1"2UN[64/'(I|@C\L=CP: &_VO2OV=_VJ/BC^SAK?VG MPEJ/VK2II
VH:%>.3;S^K#_GF^.CKSP,A@,5^6\8>'6'S>4L9EUH5GJX[1F_M_:9/OLWO;5G])^%/CYCN%H4JS[FK81649[U*2[?
WX+M\45_-TE\$ _5:BO+ _V M> _VM_A'^T78+%X8U7!%K*1[KK0+J]PMPF.I3M*G^TO08W!T2?Z\$+?!=ZO'RKP:> M#A|>
C(YQ+(&A1&N6D^-?) @J9_P7&:_W_X*>:S/X6\0:D?!OPSNB1)IGP\ MT.[8PR[6RDM[-A6O)00"-P6-2 4C4Y8_%M?
H&3<,OPS5;?QZRZ1+U/O\4RE M.^B DDY)HHHK[@**** "BBB@ HHJ6QL;W4[V'3=-LY;BXN)5BM[>_N\KL< M*JJ.6))
)H J_-80_&1OBQ^W/\TKX6_9B^#_G;K'B6_3\$=(HPSGN:.10 M)KV_P#X)"V_.!3]G=OBO\&+0(U^,' MQ_LHY?
%/FJ>?#;(>+2T;LP.))R.&D"K\PA1C#A]?F'\$F;_VAB/8TG^[A^+| M_HOOZFL(V04445\T6%%%%%%%%% !1110 4444 %%%%%%%%%
!1110 4444 %%%%%%%%% !1110 M4444 %%%%%%%%% !1110!P_[25W^T58?_P 17O]FD^\$K_XB16:OX7LO'4]Q%I4\
MPD3>D[VW[U08_,"ED7\$T M:2/ ES_%F6.0QNBG8RLPK&*_L;_%?X_P#_4\,?%\%/VK/#6C^'5^%_A M"]JT/X3^
M,UHZG+;7=_NH:O>7 BCC65X<6<=\$8=50&1I-S!\$^M** /&/@I+ M^W;/^U#|6+;|H&Q\ 1_"%6TX?!^7P])(M_L)_LM?
MY_88^'OPN)?\$3PCX=U75F^%_BG4?%S:?._2Z^O)[MQ;768#;2.LD4MS*AEMA.)DVG9&V17VK10!XA_P
\$Y/V,=#_X)Z_L5>!_V1_# M^OC6%*65RUYJ,5MY"75Y=7?<2B-"Q*H\$!8D\$F3]ESX.\$?!/ M%_B7]JC]H?
1TL_B#XTVVEIH?VJ.X7PEX?@DD1R1LT;2\$LUS=21LRR7,S* MK/?!!M]KHH_-;|H;_@G7^UOX9NOVROA7\ /A|9>*-%_:
[O M)-\$2W60VUI! MX0NYI)M/U\ M)7\$D*QM\Y!M(YV8DQLD> Y^<^/V=OA!8?L] _L_>!?@'I>K M27]KX'\:9X?MKZ9-
KW\$=G:16RR,,G!81@D9/6NQHH **** "BBB@#XZ_P"" MB?[';ZM'=?M"?#?2\W,:>9XGTZ!.94 YNT_B ^^.X&
[J&)^*_9]E5U*.H(M(P01UKX'_;T_8GE^&U|<_&7X4:23X=N)"^KZ;I_R#)">9\$ _P"6+'M_3C[
MI&/W#PZXV4XPRG'RU6E.3Z]H-]_Y>_P]K_QMX^>#Z52IQ1DE.\7>5>G%;/K M5BNSWJ);/W]G*WRQ1117[0?
R(%%%%%%%%% !1110 4444 3:=J.H:1?PZII-_-W- MOO)(+FWE*21N#D,K+@@CU%?4G|/O_!3OQSX\CPY\<-?<
Q#IRX4:M;!5OHAZ ML.\$FQ[[6[EFKY5HKR,WR+*L]H>RQM)2[/:2]&M5^3ZW/J>%>->)N"\;|9RC\$
M2IM_'>O*4'[K];771IGZY?"GX[??"XV:7 _G&\-?&MGJ.U T]JK[+B#_?B M;#KSQDC!\$UUU?
C3HVMZUX6];H+NSG:6-0564@_20H7X0 M_P#;13/X^<O^T[Q[!:_+!+, F\<78'M,@PUW=6)]:_;Z)\=0;J99452/\
MLM)?)"_GRG]9<'_G[!/[7MWA[Q1X9\6V U7PKXBL=3 MM6^|+IU MEVC).2]8_%YI%ZBBBO-/H HHHH **** "BBB@
HK!^(WQ4^&'P>\-R>,?BW M\1]!\+;1#_KM5\1ZQ!8VR<9YEF95'YU*?M6?'-O_!+3]FZWN-/&?\$W4?B
MEKD0*IIG@#3S;ANQ;|G,=N4)ZF)Y"!_">,.|.'P>+QD=4M[;|--<-_LQHQ'4X'- M?
@#^V9_P=B_MV'_>UN_"G|,WA+1/A!HL^Y!;V;#5-99#P1]IG18HLCO' KJ> MDG&:_OXC?\$[XD?&'Q?=_\$_XL^/M:|3Z[?
ONO=9U_4Y;RZG/J\LK,S?B:^HP M/"&J]-2Q4N5=EJ_OV7XDN:Z['?%"%O^#MGXE^/|;4/AC_P3N\ 2^\$--E#0M
M\00%\$\$\$7PY;\$+=WU?JS-MO<***** M[A!1110 4444 %%%%%%%%% !7[E?&RO_1-FGN-'_X*6?M5^%"L4>+GX2>&=0@Y
M=OX=:E1AT'+L#U/[X=(6/@_!O;_P \$*-2_?7\6'[8]'5?A26#X0)>];] \$ MT:]C^QGA>1M]W!ZV4;C\$C])64Q+D"0K_
\$E6=G:;?;16A%:QP001K!!!"@5(MT48"J!P |TKXGB7/5"+P>=>NTGV[EY]VWII"5DE%?%? F@4444 %%%%%%%%% M !1110
4444 %%%%%%%%% !1110 4444 %%%%%%%%% !1110 4444 %%%%%%%%% !1110 4444 M%%%%%%%% !1110 4444 %%%%%%%%% !1110 4444
%1W5K:WUK)8WUM'-#-&4FAEO,KJ1 M@J0>""."#4E%--IW0FE)6>Q^?O[;W["U\)]FY^*OPDTV2X\+R,9-0T^,%GT
MHGJ1W:#WZIT/S#7/[30PW\$+V]Q\$LD;J5='7(8'@@@|17Q#^V;_P \$];G1 M&NOB\ =
(>:R.Z74_#5NN7M^YDMP.63UC'*_PY""_NG_B%"O&.7YK.T]HU'
ML^RD^:77KKJ_P"+O&7P(JX*=3/>]&J5Z3O*I1BM8=Y4TMX]7!:QWC[ND?C^B M@@@X(P1U%?%L9_)H4444 %%%%%%%%%
!1110 4444 %7=!\2>(O"U^N^J^&->O=.ND M^ [WBNMWU>12_Y,*]V_\!5[XV66U/\$?@+PU?J.K6<\#M]3Y
MCC\EKY:HKY(%<)-<8UWJX2^>MCRO[XV/N,Z9G'G_531;?'^I[H^_ .TZ_*N-N%,CDCY)]2^?^?7!QW1 M-->?|H?X?
A717"AG]5_P N|_ \ ;TO\S^D.>1^MOQC_X\|OV]=>R#X8_L^ M? "WP["^=LE_:W^H3H.V&^&TQ)GQZG5R_&S_
(.%O^"N_P *M5<-\$J?B369[XZ(Z\3.S?K7/T45Z*2BK(04444P"B MBB@ HHHH **** "BBB@ K]/^/"#_ /P0-
_5_M^(\(']IO]]+1;[1_@QIUUOL MK-]T%SXPFI1N883PR6@8\$23C!8@QQG=O>+T?_ (G;\&WWB]/H>71OVM_V^?# M-
Wl'@#,,=YX8\ W2M#>>)%X9)[H<-!9G@A.))AS\D95I/Z\$]#T/1/#&BV?AOP MUH]KI^G:?:QVUA86-NI4-
M"BA4CC10%1%4 !0 *^,S[B.-%/#X1^]UEV\ MEY^?3UVN,;ZLB+^%_#?@CPUI_@WP;H-
GI6DZ59QVFF:9I]NL,%I;QJ\$CBC1 M0%1%4 !0 !5^BBOSYMMW9J%%%%%%%%% !1110 4444 %%%%%%%%% !1110 4444 %%%%%%%%% M

!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M%% !1110 4444 %%% 'S3^UQ_P3[-?&W/Q ^%"6^D>)VS)(KPGGXTT^YTW4;1]MQ:74>UE/8^A!ZA
MAD\$<@D5^QM<%= _V;OA;^T/H^JD>/M\$^VJ%_=#5[7^75H3_=?!RN>J-E3Z9P M1^G)>(V+R=1PN87J45HGJ]/_P
E%=GJNCZ^X^*7@%EG%G)RIR&^XKQVOWS 9C@8RP.9T M)4JL=XR7XI[23Z23?:1A1117:>0%% !1110 4444
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
'CVH^5^QK^*-(W?Z_XFR38_W-.N%_J]5^4>G;YL[RR/9U' Z1 M D?V+J%._%L/F[^H+[O;?YG\\5%%<1_6X4444 %%%
!1110 4444 %%% M!117UW_P3_X(K_MD_\\!3;Q#!J/PX^+GPSX!CN-FJ_\$;Q%;.EA& <.ELO#7 MLPP1LC^4'
D>,\$&L:^(HX6DZE62C%=6%KGS#-/_AE/0_C+X[TOX7_?"P5J?B M+Q%K5TMMI6BZ/9O/<74IZ^B("3QDD) 2< \$U_0;_P
\$8_\\ @V=#_LRSZ5^ MTQ^WSIVF^*?B!#LNM\$##;D^LDYY2\\NEXQUAC8\$KYC!)^U^\\ @FO_M_\$C/V1?^"8?@?\\
LOX*^%3J?BR^MA^XA^(&N1))J>H="R*P&+:#(&(8+\\J MER[#>?J*OS[.>)]N+3HX7W8=7U?^2_\\C6,+;A1117R184444
%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
\\\$U/AU\\16G\\3?""YB\\;N^7:QV\$V%PW^ MZ.8#[IE?]CO7TY17JY3G69YB/8;*JX/KV?DUL_G\\CYKB?A#ASC' ?5,WP\\:
ML>C>DHOO&2M*+J^KL[H_\\WXM? GXK?_6/[^']7@^YL-[D6]WMWV\\Q[QRKE6 MXYPQG([@5R-?
LIX@\\;Z!XKTB;0/\$^B6FHV-PNV>SO;=98Y!Z%6!!KYB^-O_!+ MGX=>+&FUKX-
:__AR];+#3;O=#9.WH#S)S[N!T"BOVC(?%7 8I^EF4YGDN+>Q]"=HMXSBOXO[FEIY[,****Z3SPHHH **** -_P"" M-O\\
:_BCX:M<9\\W7[-,?6=#7/_\\!Y?J/E? 7X:(1N_U_B_5IL?[EK^O_M2N MN^=O]K^_O@JUQGS?%NFICZW48KS+_@]
U^RO"G[/&D;O?J^BB;^Y^I: _^MU*_)./_S<3Y?^M&H_P / ^?VE]%^>G;]LSGWJ4U]T9?YGX/T445S']5!1110 M4444 %%%
!117T%^QO_\\,\$L_PIO+JO.^A^I-[G.VMZJ,DNR7Q5J\$0LM(AP M<,3>3[8W*]2D9=_12<"LZM:E0ASU)**[MV ^?:]4_9/_
&)/VJ/VX?^Z_#;] MEOX+;SXLU167[9-90!+2P5CPI\$N#(RYQ@9/%?MS^P= P:++?!#X=2V
M7CG]OGXJR^/-3CVR/X_*22V6D(W=);D;[FY7_<%OZ^<.OZV?^#X+?^+J]G_P M):?#^X'_ TT/PGX>L!BUT?P_IL=K;H<#+;
(P 6.,ECEF/)-?^9AQ;A:-XX M5<[[O2/^;_#U+4^U/RH_X)I?^&H_P+^"3Z=\\5OV_\$_%K\\1O\$T16;+P3IA=-!
MLG'(\$[_%DOR"!P1'\$>59)!S7ZYZ#H&A>%=M/M/#7AC1;33=.L+=(+3["V6&" MVB086.-\$ 5% 4
5;HKX;&YAB[PJ<]>5_R7HC1)+8****XQA1110 4444 M %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
%% !1110 M4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%%
",JN1GJ!&""."*\\C^*W[?#[-_Q:;2]U/P+^I-)_G.HZ P
MM9,1U2!&C<^[(3[UZ]179@LQO^6U?:X6K\$#N6U]JM_F>3G&0Y+Q!A?J^98> M%:':
<5*WFKK1^:LSX6^)^7_]*#QSIADO?A3\\O!^58ADI9:O\$;:8#^Z'76UO]I@]3+^"60?B17ZQ45^@9;XJ<0X1 M*.)C&LO-
13P\$ _P#?*R8KZ.AXA<(UUIB;/SC)?^VV M_\$^ QO@3XIX)N^7N:[PG3E^"GS?@>?%LP6_VK]H_P]^C./%VGO\\]W"-_2O
M!_\\ @!]U'S?\$O[.^D;O]18^*9L?[[Z4O_M.OOSX^?\\\$ZOCQ\\,?C7X:\\<>(+_ M_/7&GZ3K\$5S=-8ZA(S;\$.(_V
M6?^NB:G9>\$M%U^VU5=4U^&R=9;B:%EVB7 8;8N2#Z5\\#Q9GF4X_B?"5J%>,H M1A*[3T3=]&?T]I'?
A;/N&.^\\=2S7#2HSG532DK-I06J][JS^;^BOT;LO^#5W M_@KM=;O/^'?@RVVXQY_CBV.[Z;-WZXZUT6A?
\\&DW_!5#5V1=0USX5:6&."U_MXNN6"<=3Y-G)]._UD\\YRI?^+Z/WG]^\\K/S^HK]A?^!G_9P?MBWTB#XA_M8
M_#32T./;1K74+\\KZX\$-LOG\\Q7MGFV_X,S/AI\\L7JEAX8MS?<=,W3JTS8]W->;7XPP,X/4)2?R2_5_@/D9_**^SI_P2
MQ_X^M^M^M^CJC_P^;ZO97R\\(UFYTA^R^3GSZ7EY4^O)^OT*_9<_X,^?VH MO&LMOK7[6O[OGAGP-8-
AY=\\,0/K&H\$=XV=O^@B;_:5I@/0U_0Q17AXKBW;:
MVE)*^_CI^!2@CX<_9" _P^#=K_@EQ^R*]MK=M\\#O^%@^^(+./,U]O6-C9:790Z;IMG%;V]O&L<%O!&\$2-_,!54< <
M#I4M%?.8C%8G%3YJTW)^;*22"BBBL!A1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%%
%% !1110 4444 %%% !1110 4444 M %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
M4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 M
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% !1110 4444 %%% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
M7*JRK1G^4^YN_I7Y:_\\1E/L_\\ T9GXZ_\\!_9?X5WX3*^?CH.=^",EIT_5 MB;2W/V6HK):^?(RG]F?_*,S\\=?
^#^R_PKZR_P""3O\\ P7^%7_!6^XA>+?A M[V?@9XA)3>\$]&@U&XN-9U&";A9)?***
(N00>>:UKY+F>&HNK5IM16[NO\\ MPYDS[DHHKSCXY?M=_LR_LUZAIFA_"XV:IX>U36MQT30J]\\#ZCJ(7.XV]G^N MGG
PCT5Y9X!_:=_9'^)^NZ?X3\\#?M">@[6]3U^\\ L^TV?VD ML>I?:OL\\USY+V)C!;S2_.BY6-B.*=\\=?VUOV5/V:/\$=AX,^-_P
<=#T+ M7-3M^N[\\#07E:~_FME;:UP+;:7E\$;(Y3*5V_\\%LT >HT5YQ)\\?VP/V5OCWIFK M:W\\\$OVB/!OBRRT'28-3UR\\V>
(;>[AT^UF-P(Y)WC8K%OVER^(*2^0,5YV MO_!7K_@E:UHUO^O\\ P48^"A@5]C3#XE;L#>A/G8S[4 ?1=*>,?
#^_HS^P)M:M:OB/I_P=^\$[/:^PP3>+6S^R_#6A>^[_ZOKORXGFD/N".ON^V_.1S@^"HQ MZ U/I0 4444 %%%
!17@7[0_P"WSX0_9Y^)\$OPWUGP!J6HSQ6D5P;FUN8T0 MB0\$@8;GC%<-_P]K^?^\\ T2/6O_Z&OJ,+P7Q/CU_#O_HD>M?
^!T-? M5>@:O^X@T&RUZ&%HTO;2.X2-CDJ^4_?SK@S7A].UVG>V^S?< M]KAGCKA/C&=6&38I5G32.!]5U[4\$MXFFD.
(X4+\$&25SPL:Y=CPH)KA_AG_P4+_8C^/_B:T\\ M_#O]IOPG?^<(KZ^6SM?"[ZD(-5>9HWE4?8I@EP 4BD8,8PI",
<\\&O&/K3V2BB MB@ HHHH ***X_9E_\\X_9U_;/\\(G: SX]_9I^)^MMXJTCP_XIO?#FKWMM9W\$^V^ MIVA3S]?
\$\\;VT2(0Z@HRNK*S @T >CT45Y3XA_A_9-\\+?M0^'OV+-7^_6C?
M\\+&4\\PW\$NC^";5I+B\\;."UDNY&F\$2LMJ]/(B=P9FCW@+_N+*" >K4444 %%% M !1110 4444 %%% ?E!\\0?^#KS]GSX?
>|=<[\\7G)WC^XFT35[G3Y;B+6K0+*T M,K1E@^;,@\$KG;R/^\\(NK)G\\ Z-#;?\\ @\\L_*_:?@/XMU::G#*YM-77OTM
MG_V^<#S3)VY_P_\\CJ]=J*_P#9& X.7O@;^UQ^TIX_.9L_\\.LS>+-(OO&& MKKI]M]=
[J]M);L59MS^HR1\\O:OTNFFBMH7N)Y J1J6=CT R37Q/!/O\$W! M6,AA<[PSHU)QYHIN+O&
[5_:=6Z:_.FAB*).BY4W=#J^U^%O[9?]7QN^)&I_M!SX/_M*^!_ \$WB[1;9KC5_\\^B>)[XU&RB5E5I);='D:AG0\$LH
+J#U%=>)6 M?C/\\)O@/X/G^<(7QJ^<^C>%=!M03=;SK^H):VL_))>60A4)R2!7S!L=-17 MDGBC[OC]B;P^\\-J-
^,GC3]JWP!I^A^6"!I/BC4_%-M!I]YD^1Y5P[B.3(92- MK'.1BO2?!_C#PG\\00">F>/? ?B6PUG0]:T^&^T?
5]+NTGMKVUE0/%-%(A^R1 MNC^RLI(((H T]^XSXZ?M&_#]F#P=%\\0_VC_C5X6"):/?I8P:QXNUV#3[:
M2Y=7=85DG95,A6.1@H.2\$8XP#6YX%?>"OB=X7M?&WP\\466M:/?1A[+4].N M!+!AZ,CKPP/8C@T_:]%% !1110
4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
T;%7\\AM?UY?\\%RO^42/QX_[\$67_T;%7\\AM?HO!O^XU^\\7Z(RJ;A7[+^\\ M&:W_ "MQ#_R]JWHOS1, M?B/W6_/_^,VD_LY?
L>\\//VA-?LFN;^P)X,U3Q#>VR-M_L5E:2W+H^V)6(C/O M7P=_P;5>#-8^-'D)6K?
\\%2OCY=IXA^+O[0^BK5K[6\$]XFZ:RTJSOI;^VTNV MSG[/:1M:R.L2X&^0'(1,?>O[0OP=T^\\:(^ 7CC]G_Q/=IIOCKP?J?
A[4]X MURT<%[R6TC =R%D)_OS8_X-^_VFO#O[#/P?O?^"-W[=GB+3?AS\\5_A-XDU M-?#-
KXEO%L[3Q;HMY>RW<5[IMQ,52Z!EGG&Q26"!#C(<)^2&Y][?M#?L9_ "[MX^_&3X5_M\$;CI%G: ^-_A+XJ.I^?

\$(M0;@VDUO-;7=@SC#&&6*=FVYP)(XVQ MP<_FUXL;TOO^"+7_!8SXX^,O^"AOPGUUOA?
^T/JFCW7@/XXZ7ICWD.EVJG9 M^2NESA 7J+Y+YBCS^A3S!%(LP=?T^N_VH?AIJOQ+T X.?"O6K'QCXEGG236;
M#0M2CF30;#DO>7TD>X6X\F6-&-OGGD(5!L6;6+Q7P)\V1^QM^VU\2?C3_,\$^ M?VD7#\#AKO@KQC/HVI?#_P
5QPLNM:6T,;JO>1P7)(N /-;,(F3')%DA-R\$@ M&G\ _P1G3D3XU^+?C#^UU^X[V\ZGX5_0V"-I/B'5_ EU"Z7EW9#5XIK
M_P Q0R"Y:4HHV#+N5[7YUW%L]? !UOX%'?#_ ((>+1M"TZQ MAX=LM(TG3K=8H+2WCD94C1%X50H
K%_X)!_LN^#OV0?^"V?{0'P=_8'\9WF MI_LUQ_#JRO/\$NFP:L]I!>@>,I;F'RM-
@N"S"2:.U%P[#CZ;_P1O]U#5+>&YU'XB:)'86\LP5[AU>61@BGE\$5F..@!- 'Z+_\$;X M%?#;XJ>,?!7Q#\7:#%+K?
P_UZ35_"^I%Y]I)9W%G*H=E+ ".2&YD5E4C=\ MI_A%=C570]:T?Q)HMIAX\ZG!>V%];)
<65Y:RB2*>)U#*Z,O#*0001P0:M4 M%%!!1110!^* P!H+|E;|HKJFO\ X*7>&O@7J/Q1^%?P1U;7I/B-X2TM M-
\VFF^M(|>'6%CP06@3SBLKC;\$P4%HQ,77UCX'_3_@G'_P6@4?';|KO|F' MXFZ%JWC'X.>)VUE;:|MA;^(-
)MKBQN;XL;F!OWJON;A6W#="D'E';&|/_ M E/|^"AWP8_93_;&^&[-7Q]|9Z+X8T;XI^%ML=F\S ML(XQ-%=S;2^
SQ^@YU50SU_X8_L+ LV? ? @I5^S^#T= P2R3Z/"WQW\7? M&Q@/5>"OA =HMIJWAAE>74]5NK2 [+>W2-!'-
(JHDJW3\$AG4-7X8?V/O WCCX26MQK.K7|D|:J4 M1M'DOYY_+0M&H;;SF=67[K-VW[1WQU\?
\\$Q_P#@L#^SM^VI=O@^OPN^!WC M|F1?A=);66G+_9WP^U(:@VII92):H(X%4"VA^10H59BN4A8@ ^U/V:/^"EA
M^-_QV^,|(WC?)G370#OQ;^#-O9WFM>\$M+U:WU"UUJRNX5EM9].OYOLL3[PR M@K.(-I<9/#
[.8_8_P""KOI.GQ6_83^*_P"W7=?!#5?AEX,^&7BSQ#!XET6: MUMI-0FEL\$CFN9VBM3Y?VB624J5#OEQDR\$'(I
<_9O;_N_9]; ^ (6L:~?^RMXJ ML/"A?P_I8/B3X@:'*7TR* =T-OIT-QM\NZE\$1GEE\MCY\D-S.,?F=_P3>_ M;?"IE/\ X(?
+7O[4'PR&:7X]O_ "7QX\W=MX?F/VBULG6XGLHTEN\$0Y>V6 M.;SY "-\4;X9<[|@ ?:-I_P %:O\$/A/7_-G_ %X^?
LKW^A7P;^TKJ-GIOP| M\1Z;XQB_UYL+Z|@>6PMM4M/L0MGG1AS!+3J|@SQ[=6HN&_,C17>B,+8M'(%=#(0556
8L"N,C& &MKX4_ ;P ;E\7_ /!-?V" VE7A) P %LO@IX%U#73X.E'@+XU>&|]3_ \$C7?"^I3!;5_.C26|\\ M>P'|(TDT)"H:
/L3X\$ _M1^*_C7^T1\5O@N/@Y_9VB_ "S6K?1[CQG'X@2XM]5 MOYK.VOEMX8A\$K^*=M=0F;<<1R2!%,GS,OL=>?/L(?
[Q5!\V9="_ \$R2*; MQQKLUXE^ (MW"OZ((?_@KY^Q/^TK\6?| M@J|J|[8?_! /CQ&=%^_ .7P1^!OAGQ/X>TRVMT\$?
BV*35]?@O-.N,8,SR6\<:| MCM=5,)P'5X_H/P3_ ,%(O@_P5)_X(M?&?XV>"+;_7KMG\(?\$^E_\$+P/>MFZ
MV:/LFD7(FMI58 M&W+1R\$#>AY"NKHOJ'|@QMX/N/^"T?Q \%V_BBPDU>|/FK MPH\FFI=H9T":|K|-E C#/PG_
,%T_P!A;XZ?L,Z[2?^"JG_ M 3IT3S-(^('C5/#W[37PTMD;[+JMA=VLL)UZ.).DT+2^;*ZC*L#,04>ZW? MR<>Z?6/_
4J^&OA#XI_\\$6;X3^-,-,SVB:[9?#W3+^VB.P_9Y==T6)@I'W" M%8X(X'!%>7?&[OQ7<_!"U^+7_!&? \ :
UM[|CQK^S5XJEA,75UKZOX3) M#-97* \E5_ @/HD=U')QBO7?^"AWC'PIX'_X)'>M98^([+2[3|_-P+B_NE
MB0D: HSD1JEA]"JS'T56/0\$U\^ \ !;KP+|=^V+?VX?@; _P %COV+?APWBKQ% M<72?#X@>%+1RJ>
(K74R8]*,A3L+IPF\|9I9C.%H ^??^#J35=3_ &GOA5XF M\<6M_W@3X#^/M#(\(:;%')?
(U3Q5J(%UJDK8XD%G9BQMEZ@2WMXIPT=?NNJJ MJA54 8 Z5^,G_!Q1\&-#_8_P#^""@WX(>*/&=MJ'B23XI:1?
^)=:FD"S> M(-=N9;N_U6_"G#;9;F6XFQSM5E7HHK|E=+U33-&_ %NFM8ZQ%8W1@F:\$L&
(20./V7|\$)0VM_XFTV*QU1M9UY[Q6ACD\Q0H M8#:=W>OJ.BKJYGF%>FX5*LFGNFV%D@KDOBU\ O@3|?
+=@/T/XZ_!7PEXULK9R M|M9^+?#EKJ443^&2J7\$;A2<#D#M76T5PC,#X;?"GX7?!KPQ'X)^\$'PVT#PIH ML+EXM(\-
Z/18V|,<9[B@54!;!SCM691V=V/B|H|>&/BS"!OBC3&NY+ MIM.1>&+2|@,(AS)*8YHV7>QY+8R3U-=E10!B_#_
&_PI^\$WA:W#?"OP%HM OAG1+//V31_#^EPV5K!DY.R*%51M)TRUT32K71K%6\$%I;#&");(H49/?@58HKDQ^<9KF
MBBL96E44=N9MVOO:YZ>2<*-<-RG+*L)3H.=E+DBHWM>U|;VN[>IE>(O W@G MQA'-
#XM'\:5JB7%DJG.NHZ?'.)+9V5GA8.IS&S(A*^@E5)' KG?A)^S-^S?\ M ;F|O?
@3^S[X(\%3:E_R\$9?"7A2STUKKG/[PV\:%^>?FS7;T5YI] ?G/X@_9 M4^*?Q2_X+U>(VC_ (P_L/ZAXC^">M?
L[P_#U]51P+:?6,VIIK<-^)Y+*6Z M:4VP1& O@%JWQ/@^~VJ? [P?<^+50MMXON/#-J^]0 M@#: MT8_-4
#ANG%?'CSX>^ ?BGX6NO WQ.\#Z/XCT2] %YH^O:9%>6LX!R M \4JLCX(!Y!Y%;%%_ '/Z#)OA7X6\
+)|_#PTVZ=X62V;W7PU8:~!#IXA; M.Z,6Z(\PAR6@WH<_=(KJ:* ..TS|GCX_+X0M/A|H_P-
'\6F@6&IKJ5AE=MX9M([.VO5 M.5N8X5C"),#R) P/>G^?V?O@-XT0S>+?&P2|(ZMJMP4-QJ>I^&K6>XE*
M*\$4M(99L*JJ,G@*_E.=10!D:KVO 6N^*M.\=:WX(TB\US1TD32=9NM-BD MN|)7&\$,%S*7C##@A2,|Z^//#R_\
!1_JMSX\)\OVM?V.- ^%'P=\ _Q-=3 M78?B!|J]UX^ATZX,^D6|=K"@^S0BYCM;V:29@6\A(1&-TA7|:HH **** "BB MB@
HHHH ^!/%_P#P;7?|\P_&_BS5/&FN^%?&37VKZC/>WC1>+Y54RRR-(Y V M\#/V?]-\2)XQT[X&>#H-
7CN_M4>JP^&;1;E9J[V\$1*(|P?=SN MSG/.:ZR^L;+4[*;3=2LXKBWN(FBN+>>.,DJ,,K*>&!!((/|J6BO#-3F/%G
MP4^#7CV*QM_ /PD\;U'ID'DZ:FK:#;W(M(N!LB\$B'RU^5>%P.!Z5IZ+X(\% M^&_#UMX1\.^\$-+L-
)LY%DL]+LM/CBMX'63S59(U4*I\$GS@#@##?-UYK4HH Y? MQI#_@K|2-637OB)\(^OWT<
@CO=:VUU^L0)8('E1B%|9B!G&6/K6KX1 M\%>#?A_HJ]>^?A+3-\$TZ-V=+#2+"VA5F.68)&H4\$GDG'-:=% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444
%% %% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!1110!_9 end GRAPHIC 13 mdt-20241025_g11.jpg IMAGE 11 begin 644 mdt-20241025_g11.jpg M_JC_X 02D9)1@ !
@\$ 8 !@ #_[@ .06108F4 90 !_JL 0P " 0\$! M 0\$ " 0\$! @< " @(\$ P(" @(%! 0#! 8%! @8&!08&!@<)" 8""0<&!@+@" D*
M"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"
M"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"@H"
@,\$!08"" D* M"_ \$ +40 (! P,"! ,%!00\$!?0\$" P \$ \$042(3%!!A-180'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ]?+S|/7V M|_CY^O_\$!\! ,! 0\$! 0\$! 0\$! @,\$!08"" D*"_ \$ +41 (! M @0\$ P0!00\$
\$="P ! @,1! 4A,08205\$'87\$3(C*!"1"D:QP0DC,U+P M%6)RT0H6)#3A)?
\$7&!D:)BH^#A(6&AXB)BI^3E)66EYB9FJ*CI^6FIZBIJK*SM+6V MM|BYN+L+#Q,7&Q\C)RM+3U-
76U|C9VN+CY.7FY^CIZO+S|/7V|_CY^O : P# M 0 "\$0,1 #_?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH
*_ /C_@X? X+'ZC_,\$F?V7=+C^\$=I97?Q5^ M(UQ5YL*QQM\K22J6#*CJ?
T^K^H06!N'D:R)CGMI8W0_*A1@|2B.OUJ_P""1&JZ/K/_ M 2J_9NO-#D1H%~!GA6\$[.8\$D>DVT*;TL--T32_%UK+
J!4L&%MA'7."CYHO]Q00X_!|_@IQ?OCY^RQ M_P &RG|'_P'RE;ZG?ZOWQ:TVZO/\$TL;M')<:-\$YO;>R8]1'(M_..5[K %/RE
M@?T,;_L X(6_##_@J%SC^R^)_1 @C?Y?A7_ ,*H\$:0^AZGH.A+=->:3+V M,|0A=9HC#-&T
DBERP#3.2I.#0!O_P#!P9_P76^O_! ,OX'ZE%?@EXSL; X M|>*-/_ ,@Z;M'.WA>"5>=4NT(9495.8(G[IQRK%6C5_=_P2_;;
&;?VEJ' MOO\$7|./|0G@?X@?:I=P(-300!|BR\$U6&TE*[A*]|K(ZQL5Y"L0< Y/BOX|L|">N77A#2(=,;|'+:7
MEU<9,"J"9(|(VY)Y,P|]OZ/_ ,%/_P#@G1X@^)B?![0_VW_A?=>^)=0. MGP:;|XTLV,UX, VJ.)-CSY('DJQ?/&W->|_'\^*FPVW_
1R^+7Q&TRYNK#Q M!X6M]+O/#NMZ;>26UW|SZO90R-+%\$RLN^)W1AG#*Q!!KX'^_P6^'FD_P#! MDWH-
XOABR%SIVE:)XCL|G|.N]-1N_%<,'M3UKQ|KL>FS^/_ !@@ MO+V-)D&8Q/(97C3."P!50MTDBFB9DD4_WE)?
B1_P05_8K_9A^_W_ ;G_\$Z|^ (GP3\Z MCK/B>W\6VJ|XBOM^BEOD^SP;1HYW40'Y#XDC'D'|RX&YF)\9_X-?OV|_C\ M!_\

@F;^VB+^*FU#30@UX*C/P1:7>98;+4IK#4V>!/SB.22QMW*#C(E;&68 MD _=+XO _/!03]AWX >.S\,/C9^UGV/_
MX@C\$+76DZUXIMH)K-92!\$]P&? M_1E":Z_XL_M\$?L_ /P1; \$SXZ?/P=X+^-W<^<-KX@/6^)K33;
M&:212T;)/<)&S,JLR@-D@C\$I7X#_P#!"J7X[_M2?@\$B_P]JKX=>@OV,_%Q MA\9 _OQ/K^F^)?B+)XNT& ?;YJ]&M_L?
VK^TKZ&Y_VX/V8 _^#57XV_LV? _!07P;-,\2>/#^#?6?ABVGUZU1CH@>UN+0^; M;2Rj!-)/\$B%MR) @ "A* /TXU+_
(*%_L&Z7%+K]I&;JLWX73> ++53IES MXRL?5A>*=/ MUS0=;L(K[1]9TJ][2>VO;;5
 \VTG7I; ^'+C[!ILMWJ%N]JYB>>XW6[3-,D MH"6BJJKN;=^]G[_/P!^"[*WP^)?
LX_"&PN+;PSX*T&WTG18KNY,TWD0H%# M2.?ONV"S' !+' XH ^?!/X8OI;!&H<"8+^%/PN\"_MO _\ !O1_
MP77^ _]W@_X[ZCXMT'QIXIT*.>RM7EAL_%NBZK>_9"T]DTCK'=*XF56RY22 M(K%6(/1^N^Z[HGA?1+SQ-
XEU>VT_3M.M)+K4+^]G6*&V@C4N\LCL0\$15!8L M2 "37Y2_L2_LES?%000^K6O? \ !=?XUZ!/IWPK\)PQZ\/
LW:5K\$]BEUFU MLT>,>04D ,=L9)+F>W# ,S3*_RB%3(>V?\'#G[15M]-_V-]'_9HTK]HS1?
MA3KWQS/70>+&;Q[KNIM:0!IT2M>:A>O(A**OE0+;?*02UZ@&\"?)>\$8M1@&MWO@#QKJ&H,L!<&2-7BN71)2@8 M
/C#:=1P:_3G_ (*V_P#!"SX\$;%C/\$?A+QM?V_VAO^GAW_A#]&N+3P[I_AF6 MR?3P;B19];EDF@=WD<) I*R*I6%,#_2?
Q1_ ;A_X)? _!07_ (-J/BQX;_V M_94 _%;Q-X,MM MBZ;X;T2S_-Z; ^39V%K';6D1%/B MU;Z9)91^*/#5AJ\=G*RM7EAL_%NB
MZK>_9"T]DTCK'=*XF56RY22(K%6(\ 4?KNNZ)X7T2\3>)=7MM/T[3K22Z MU" _O9UBAMH(U+O+([!\$506+\$@
DU^40[\$O])M?T>Y:&]M^A:.)8(I%(: M+[1+*P+H0VRV=,XD->4 _%K'/VB _&^'[97]_'QX_82T-_"?AOQ!INI; \4/
M!NESNMEXNL= /FT_->1\$])KUHKR7%VP,N\ (Q8XP?\$\ @\CTO5# _,%+O@7X MM9R^C7WPSLX+&=3F-
Y8M9NWE*D<'Y)X#]"*]_X/EY%.L_LR1=Q;>,2?Q;1? M* /TY_X*6?LJ_M= _P#12_P_X>^ 7!/'[4USV'?
A%JF@#6/&/C_P]#]IU3Q(MTQQ:Z5;(D)+P6XC#33R,P\$@F@C4./."_A\+O OI; _P;T?^%U_A _LG># M_COJ/BW0?
&BGB0HY[*U>6&S6Z+JM][D+3V32.L=TKB95;+E)(@RL58@_P!(M?)3^X9?L/?#)_B7J<_FGP\]*=%/B"]JU&
<11VOD:9#YDKN0\$5=CEF))!K M\?V?V2YO\ @J%_P5;U! _@NO! GT[X5^\$X8] _9NTK6%#%+K-K9H\8\02 MI(
8[8R27,JN& 9FF5_E\$F0_5?Q)XC\ \ @ [P]?^+O%FM6NFZ5I5E+>:GJ M-].L4%K;Q(7DED=B B*JEBQ. 2: G;_
&H/^"CGQO\ VY?^#CGJ'F'PYK>B: MGX<^%WA_QYH6H?"_P] "M%+?V-Y*KIK=Q\$>4DNXPDD:. T=NT0*JS2;ON+ _@
MM'_P5C_8W^% '[6?@ []@C]L+QQJVA?"W_ (1^U; :? \$0:1HDU^WC%#<.-/T+]P M#LLFD@:XNF;_
%R1Q0#*2S8_)S]L3_@J9^QQ\7 _^#BGX=_ \!17X?>*=4D^% M7A06?# \$^HZA)H\$T5Q%#8Q(L^VV(WG:0<
#GM0!_5E16/\?/A[XG^=#^)? MA&XDETQGQ%H]M] >F2RQ%&>WGB66-BIY4E'4D'D5L4 %%% % !1110 4444 %%% M%
!1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444
%%% % !1110 4444 %?-O_!5' _@F M3\ _^"K/] *U _S?;V;N72KR&Y74?"/BNSMUEN-#U)94G521YD;S*)\$2 Z,
M<%6".OTE10!^97_!+GPE_P_%6? _@D] ^S]' ^Q#? \?V+M0^-_A#PC>7(^'OQ M^\$7C/11*;5YA9W5GK-
Y8RILD=RLBE@JN(\ \$1JS>8 _&C_@C! ^V+_P_%G\ M@H?HO[7?_!3KPCIOPK^#_@BSAL/"GP;L/\$LJZQJ-M*TSK>7-
F6MH//D8F5 MXI?'RU6%<%1/7!T4 ?#'_!=C_@D#9? \?4_V*+X,?"\$4M*^-/_>H)J?P[MGNHS%8@K'89-/D\M28H)
(JH#^IV/#\$<%0P/S;_P24^'W_!R= \!O@GHW[_QB M^!7PZ! ^#O" \7]FZ\)8 _\$OB:TU74-(TH'B*ULK*ZE% [+ \$AQ; ^>L4:
(LN\ (4 MK)>:*/R1_X.= _\ @BM^UA_P4UTOX7_%7]D7^S=? \!> K2_TS5_#>KZI!8S7
M]JOLW5MJW@O2O#FJ/]JOX7U"UC B:YN_+C^TM*[7"R>4@6.&YV(973S7^Y MJ* /Q6;: ?L'?%;?B;_P1.V_P#!\$B[_&X-
_U^SUBTTO6/B]=_\$+1F+MH MEKJW]H074:1W+>D9.TK;8HQB9PI9F6*-4&]@,_H_10!^1' M["'O\ P51_X)K?
 \P_B) P3*_L_Q<0?KQ+XABU=/_P_3?""CO2;_>0+7 M;18YODU*XMKV-K:1I7 BMY1, J@H>:]P_X(?\$+O
_P"P%_P3M;_+)_MQRUFS\2>) ?C-IUU!\5M0T+VRTWQ M_P#&+XK64EO?
6NC:E#I^A>'S.8(P6SWCK)]DMX80@8AYIYG:5DC\$K"/[;HH M_3_(-K_P!AG]KS_@FU^R+XG_9:_T^\$ \$6CW]UX]O/\$FF:
[I7B.ROK.>&>T ML;?].PBE(U)@UL[:&27\$LPDBCW M(L4C/YB?>=% 'X^? *_P@_X+^"&=7\?M1_\\$_ -
H'4?/P;^\$WP/N=3/4 M:5X\;:#138WEF(TSSS0!T%_');BW@B@Q* T;KL E);]2OV8/&'Q ^(?[-/P\ M?)\ Q9TH6'BK7/
VD:AXFL1#Y8M]0FLXI+B/9 _#ME9QM[8Q5#X\ _LO\ @/\ M:60=&T_XPZOJN!%-)O8;ZX\!>=\$FDZO=PRK-
;RWRB/S;I(I\$1UMVD)%NS*&D MBD^IM](H_#_@X/^W_5N;_&^\$UC^R-_P3W^>^>C0>"]A6Y^ (OB?40%EI
M9SZFJR;I!4<4K9%O\H>8D?005C^X)! \'_P3' _#L+XC#3?
@KIOEIC'H_@KJVFZ+ \4/AG>37G@:74&[UO8)4C%QI\ C]#Y0?R8' MC?!"O"H.%=F7Q _\ ;#_X)I_M:_ \!;];K_X!^-
OVQ/V8YO@U\,/ @YI]JUXST MW70%&E:G>^*-1N);;2XL;)-N;A5LV-G\$GGSM%(8Y'(BW_K)10!^;_ /P< M'?
7_@K;^V9)+#]D3_@GK.M&@\%:U"MQ\1/\$^I>*>[2SGU)5<^7I4<4K9%O MH>8D8E!6/[@D\$GP?H7_3'_P"#L+XC#3?
@KIOEIC(80%WQH_ M9,^&?B_5H+*.SAU3Q1X#T_4+F.WCSLA\$ \+,(UW-ARLK.!8H;>%% "I&B* J]@*_M !5FBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHKE_'7QL^\$7PS5O^\$)^&C:7(HR;>ZOT
M\$Q^D8.]OP!K6C0KXFHH4HN4GT2;?W(YL7C<'E]!UL54C3@MY2:BEVTCJ]**^ M<_&?
_!3]JF[PXSP^'^\$UO7Y!D([CI_E1\$^ [3LC >X4UY9X]_X^V^*)V9!/P= ML+91]R75=2>(?
^"E_[4^M.S;KVD:0#T73]&C8#Z>?YE< M=K'[90[4FN,6O?C9K2?]?L\$W\$-17JU:+) :7Q%(/&FK7]O\
V/=MY9YJ;LJ;@HP=K_1FGF?A?B\K MRRKC)XF+]G^RLHO6RO:]_P!">?I(95Q'Q^AR6MNU
MS]"** EA_P""[73'1_@+ _@K? \&KPKX% :!;Z+I=KKME]FTW2?%=Y;6/6 M=,LR=L<@<@5GQELU!_U=O\ \$[550]>J
M_ ;J>HKYNAPE7Q&A5C570).UGU5S^D><_LUHK^1;P7_P_W _\ @KQX!*MH M?=[GC&?9C']M+:ZE^?VN&7/XU[C\->
 _@ZV_X^S>]FC_.\$J]0> ?&83& \ MX2/P8D)?Z_8)+;X5%3A#_H_#*+^;7Z!SH_IXHK\OA!_P 'F/BRW:&S^/O[
M#FG78.//U'P?XPDM]GJ5M[F"3=]#;/K7U]"^?#J;_@E)\6W@LO'?BCQC\; MJ7"LOB[PL[L(<]A+8-<@+G^)P@QR<5YE?
(,WH:RI-^EG^5V/FBS](Z^Z^!/ M[7G[+ '[3U@-1_9W_&B?IGC1#^O>+PYXCMJ:] (?]-D^%U[6-
/T:ZN=)T..X6)M1N8XF:*V#MPAD<*FX M[#=D]*_FBORG_X*\$ _L_P#18O\ 8Y_9R\2? \?%) P5?U7Q%XS\!67_"0 M^+?
A?<^# [2#P=Z?&P>YL;2WYD1(HBP661FFE6/_.1MR_77BCQQ^UE^VQ^R M+ \ (]=_9?5CX27OQ9\ (Z;XC\6>-
IM,BU&Z*?<6S-R]I9P3822^DDN(X4DD M!2.-)Y.%UC5@>BZ>HKNOAYXI_P""A? \P3'_X^O? \C]C_P",7[8FO'_ _.\$'
M[15EKD<C77;3X%UOPU]>F6@N97\$T(FQ\$-#P2\$V22816B#2?J+O 45^:/[< M? [60BO)
_J;_YO/V"/V7/^"QGA7]F36_AY9V< &IV]UX9L-7O_&6M7Z^;_*!+ MRXA11:0+; \1LTDDMY*A0>1FNM;_B^)G[9'_!+
[_@DT8]:_SU#XH_%O5_&6F M>\$^+6K>%;2Q^Q'5=42_7*6\$9DAC^SVS%8P[2!IOKMD,8Z /T!HKXF_9L^,W
MQ2^#O_!8#Q[_,\$X]4^)7B/QAX)G^!.E? \$7PY>>+ =2_-?+=C46TR[MOM3CS M)(YSY=P\$ \T[X:?"**^FM?\$^H6\$N
MP>*O\$S1%#IBN/O6EA')OGVG\$EW)%%D?9+B-@#WFB@ HHHH **** "BBB@ MHKS+XY?M<_!'X
PR6WB_Q.MSJKE-#TS\$UT3VW+D"(>[E<]LU\RZEJ M]-T4E^1^#YIG6<9YB;YCB)UI]YRE)_ M[=O1!1117>8% %%%

!7T%_P3+_Y.DM/^P+>?^@BOGVOH+_@F7_R=):?@6\ _M]!%?.\7?DQC/^O-+)\$5KE=%U%
M7N+3=T\$]NV)K=C_ =D13[5_ %56W\ .OB9\1OA#XOM/B!*/\NL^&=T]]]CK.@
M:G+9W5NWJDL3*R!@=:^:QO"6!K>]AVX/[U^ .OX_(M3:W/[A:*_G#_&"O^#L3 M]KKX%O9^"?VSO"EO?6?#
<96,ZY;^78:];]TSO11!:=X':1\$=CRTU?MK^PM_P5 M/_8B_P""BGA]=1_9J^,EI=ZQ'YNH>#M7Q9ZS8COOM7.74<
RQ&2+/_ M>\$?!/QO"N_>K:EITMM8>)M/LX;B?3)'7 GB MCG5HV=7G_!/_3P=>2#P>]]9R?'SQ+;2\$+9Z8
MK1W*^H"6^O@ (A(M/_V/?#W[&O&7QC_P""
MM/[0GQ)VZ!KUKJMUX&\3ZS;+INKR6T@FABNEAC5I81*D;F,G:VP!@170^G_ M+*OCNR_;MO_ -L27]JOQU/X=O?
">'8_@_+>9T"WN5N%E.I)'G'GE5V[MN_MYV_>%2\$!PW];_ \P1T_XY?
M]>"M1()6#D.4E+QN1\ZL*^A_X)9_ "+Q#^VS_P1Y!'W_!02:QW!IOB'7
M_!5UXAGNI8Y]9M=&UJ>UL]0CG#>8)8GM4\N<,+7W6RN6+9))\#?%\$[/VH_!_ MC?Q=#=_\%8?
C%]7@Q5KEUJ""^\$[/VPT;4=,CGD9VL[76]H9+FW@/_EJ[@CQHMY!Y31O^KZ8^&?PT!_!OX?/^*OA?
X7M=%/V>_]/JCLM(TNS4B.V@C7'J,DEC MW+>2S\$DDDDF@#Y3^ (WP3L/V=?BM?:5_'6O>*OVC_CU80:._P_1?&+6MU=^
M'/'6G*JSZD8:;""VAMK03@QQK\$OVJ^NK992X9G3D)OCW\4OAG^T7XM_X)G?L M%Q^&_#_E_
+X&0^*M3UCQ=I,_JS:UK%T\CVMG*1<0G9%*DN+JZ+--+<9!1@ M[_5?P7_9[F^OQ+!7""R1Q^4?
M""\\$/[_CC]HWQ3^U1^S?!=;3X?>+?'_PO?P)X MXDU3PFVL6]W9J[-;7")=VQ@OH!)
(BR.TL3(5#1':#0!WW_!/_3]KW2/V]OV* MOAS^U[HWAUM(3QQX>2\NM),WF"RND=X;F%7P-
Z)/%*JL0"R@\$@9Q7LM>=?LC M_LP_#7]B_P#9I%_LL_&".Y'AWP1H<6FZ?+?2!Y[C;EI)Y2H ,DDC/(VT ;G M. !@#T6@
HHHH ***^9/VI?^"BW@_P""KW/[CX0"WU[Q!&3'?%MUE8MW&0? MWSC^ZIV@]6R"M>IE&39EGF*6'P=-
REU]=V]DOZ6I\WQ3P=P_P_ Y8\=FU=4 MX=%O*3_EA'>3]-MVTM3W+XL_&GX: '!PXWB?XD^*(-
/_@((MX2)=TURP_@BC'S M.>G08&XN)6DDD8L[NV2Q]R22>IIM%?H^Q^ -MN["BBB@04444 %%% M% !1110 5]!?
\\$R_ ^3I+3_L"WG_H(KY)KZ" _X)E_ \G26G_8%O\ T\$5[Q=_ MR3&,_ P"O M.-
,1\$UVQ3H&G3Y8][]O,K%Y3@5^[_P"S3^U3^SU^V\+[3XQ_LU?%?2? M%OAZ[P/MFF3Y>WDP"89XF
DMY0",QR*KC(XY%?Q/UZG^R_ ^VE^TO^PO\5K?X MQ_LP_%34/_#6KQE5O(H'WVFHP@Y\BZ@; ,=Q&>?E<'!^92K
,/EZQI7B"7I_H,TARDK' _EVD_ .D!'FPV/TAK\^Q>#Q_."K.E6C9_P!;=S1-.* M*YAA1110 4444 %%% % !1110 4444 %%% %
!1110 4444 %%% % !1110 444 M4 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 M
51\2^O#_@ [0KKQ/XJUBWL/(LHC)=7=U(3-1W)/Y =22 .:S?B=\3_ 3\ M' !UUXZ?ZTEEI]J.6/+RN?NQQKU=SC@#W/!
(-O]JC]KGQK@TMXA,4S2; MX;M)2=(T1)./02S\$D>K7>_MC&FT?W(>\$O%OA;Q[X8T_QMX\1
MV.L:/JUG'=:9JNF723V]W ZADECD0E71@00P)!!K0K^5O_@C'_P77^-/_!,G
MQ;:_#X@2W_B[X,ZC>9U7PNTN^XT5G;+W>G%R C9)9X"1'+S]QSY@_IU^ _Q MZ^\$ '[3GPGT;XX_CQY8^)/"VOVHN-
,U73Y,JXZ,C*^-'(K J;_@.C*58 @BO MR[-LGQ&55;2U@]I?H^S-8R3.OHHHKKR"@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH ****
"N=^*GQ3&?!KP1>>/_ '>J"VL;- ,&2>0_ =BC7^)V M/_U)P_2+WC3QGX: ^'GA:^\>,-6CL=-TZ RW5S*>%4=@.I8G
"CDD@#DU^8 MW[5? [4'BG]I;QTVJ732VFA6+LFAZ26XB3_GH^ .#*W!)[<*.!D_9<'<(XCB?& M^)]>-"QR_P#;8^;_
6KZ)_DOBQXI8#PYRBT+3QE5/V4.W3GGU4\$^F\GHOM. M-7]I?JIGQ@TIXT.N^()&M+=M69='T:.0F.UC/<_WY#QN?
OT& !YM117]X.M]X7+!+/#X>"C""LDOZ^!][MZL_SFS;-LRSW;FQ]5U^U1WE)[M_HELMD\$K)M)!11172><%% %
!1110 4444 %>H? !7]CWX\?'4Q7GA/P@]I'LC;A7J]TU]F'O2^?1?-H_3N\$?"#CSC:;N#PKA1?_+RK[D+=
MU=.4EYPC)'P7I&C:QK]_I6A:5]!L_M1^/_D MP^'IT>W?_EXUZY6VV_6/F4?][5^C_@KX<^ OAQIPTGP%X.TW2+? #1Z?
9I%O M]V^C+'W.36U7YGF7BYC:C<<#AXQ7>;_X M)8?L;6BMK>N^)=3D_C\$E]%\$A^@2(\$?)]&OI:BOCL5Q[Q9BW[V]
<5VBE\DG M^)^L9;X(^% ^5Q7)ET9O04E.=_E*3C]R1XMIQ_!;/]DC35&?A8;EQ_P M+K6;
MQL@)00Z5U_P^_9G^!/PK\0+XJ^'_P_- [+3-02%HENX7D9@C?>'S,>N*[JBO M\$Q&>YWBH.%;%5))Z-.
(/\$^O.CZOK4]S<37+&)(L3L MQBF49"(JY ""BO(O%W_!M'_P1I\51G[-^RI(LXHO2K?U2?Z7%RQ/Y+OVBO\ @WV_X*S?
MLW)<:AKO'J]>*,@!(U3P!-(&4AFUS1XY;BV!_YXW&+!>O;J>>M>WA>,JJ=L133XZ?@[_FB7 M3['\55%?T+_MF_\
!H5^S9\08[OQ1^Q)\9=5^VIL&>#PSXH+ZII+-VC2;/V
M]JW7U=FN#Q]VOQI_ ;A_X)%_M_ P#!/>ZEN_VA_@7?)X>279!XUT_ ;]FR<*3
M<1C]P6/1)UB<_P]VOJ;#G>79A94YVEV>C_X/RN0XM'S51117K""BBB@ HHHH M ****
"OLK_@CU_P6^*_P#P2N^,'F6_VOQ#/,/\$%VA!>"3/PW1?MMIN.V* MZ10/1954(_1'C^-*QQ&'HXJBZ557BP3L?VU_LI_
+0_P? \VK/@UH7Q]^_ MC2UU_P +^(I,7&FZA;'\&BD4_-'C H\;_C*5(!%=K7/H/_1-_P""R'Q% M_P""7'QL71O\$]S>ZS\
(O%#Z@ \9^&48NUFYF@U^T4G"W""N48\$R+L;YEC=/Z MHOAK\2? 7QC^'^C_
!4^%WBNRUSP[X@T^*T;5]/F#PW5O(H9'4^X/OX(.00 M""*_LYRBKE6(MO![\ 1^:_\$VC+F1N4445XQ04444 %%% %
!1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 4444 %%% % !1110 44 M44 %%% % !1110
4V::&WA>XN)5CCC4L[NV H''))Z"G5@_%_VJ_["T^3] MGGP#J6+R\B#>)
[J%^886&5M@1_\$XP7_V"!SO_./9R#),7Q!F<,'0ZZM](Q6[? MIT[NRZGR7&_&&6<#<.ULVQKNHZ1C>SG_-#!>O5]
(IRV1X]^W;^UO)I)&"HB+DL2< #J:^O/V5O^":_J_K=MX_:&AFLK-L2 M6WAA&*3S#J#
<,.8A_L#Y_4KC!\;_ ^RSA_""^WQD[+HEK*3]=?R75H^MX/X(MXCXYS-8+*:/;U;FD]
(07>]/S[CD9&WI7N>@>'M"";/_ ^'O#.CVVGV%K&\$MK.SA6...?0*HP*N M5^
<1^(>EOVE9='<_N3@#P&X3X/C#\$XV*Q6*6O-->Y% M_P!R#NM.DI7EU7+L(JJBA\$4 8 X I:**_ /S]S"BBB@ HHHH ****
"BBB@ M HHHH **** "H=1T[3]7L)]*U:QANK6YB;YMKBL(/+&PPR,K9#*02"#P0:F MHH_+_@HU_P;?<
L9_M70W_Q" _9;\$/P>\ XS#Q_7BOR_X*ME^*E0J;K15T9LFF@HHHKC M&%%% % !1110 4444 %%% % !1110 4444
%% % !1110 4444 %%% % !1110 M4444 %%% % !1110 4444 %%% % !112.Z1H9)"JHRS,< #UH#8\Y_:E^/^D_
MLZ?">\:7!CEU*;-MH=DY_U]RP.TD?W%&7;V7&-U_3O_/#*R#*%4JQ_?5;.7+=I^Y;OS;[(_SE?;U:/U)Z-L****^[/Q4****
"BBB@ K0*>\$ _\$GCG MQQ:>\$ _".C3ZAJ5]*(I6TMDW/(Q_D ,DDX)) %/\&>#?\$WQ"\467@SP=I\$M
M_J6H3""UM81RS>I/O #)+@_ \$D@"OTK_&2/V1?"OI-7AG[5<^3J'BB^A U7
M5MG#*KY\$>5C!ZG@N1DXPJKCQ;Q;@^%)=^]6E\,U/?*_ '9=6OU+PO\+?%>@;P>- '_20:MXN= RRE=
MT&FY*P@]7[&O]EP,[OH.BBOYFS3-L^G;,EB<7/FF_N2]= \$NWZG^B?#7#& M2<(Y3#+LKI*G2C][GUE)[RD^K?
HK))!117G/OA1110 4444 %%% % !1110 M4444 %%% % !1110 4444 %%% % !7Y?]?6]J_ ^#<CX7_ MT66J?M&?
LG:=IOA#X MP!7N+^R4"#3?%C8R5G ^6"[^P!AR<2YR)(_P!O:*ZL^C<1@*ZJT96: ^Y^3 M[H329_#Y3?AC\0O@O\
#\$5_A5\5_!VH>' _\$>@WKVFL;-JEL8I[69>JLI_@ M]""""00:PJ_JQ_X+4? \!KX4? \!4/X;2>-?!L=AX;^>,@V17PWXI:+;#J<
M:@D6%^5&7A)^Y)@O"QR-RET;^7/XQ?![X_F_L_P#Q/UOX,?&3P9>^'_ \$ _AR_> MSUG2-
0CVRVJ_3AE((974E75E925()_4HBSAFM&ZTFMU^J^C*46F3_@G[^VC: ^?2B-XB- MM\,OB=+!IBK[1+B'3;O<19ZD<*
(WQ:0^A?':OOO#O M(%G6>J]55Z5&TGV;^ROF]?-)H_ \$/'KC>7""!4L/AY6Q&+O3AW4;?O)+TB^5/
M=2FGT/,Z***_IH_SJ"BBB@ HHHH *GTW3=0UG48-(TFREN;JZF6*VMX\$+/(MQ_55 Y)) (%05]P_ \ \$W?
V3H]M^TZ]H;X@Z9F]NXS_P (Q:3I_J(2,Z/&3C M(3T7+<[ACP>), _PO#F5RQ=;5[1CUE+HOU;Z(^V^/^!\RX_XCIY9A?
=C\52 M M(06\O71%=9+17;_,_8J_9%TS]G7PD/\$'B:VAN/%V]P#^T+@88649Y%M&?;@
MNP^P[A5KW.BBOY4S/,L9F^_.GB\5+FG)_=V2]);)^F?#O#V5<+9/2RS+J?) M2IJR75OK*3ZRD]6^K"BBBN]I****
"BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ K\^"/_!%3PU_P4G^\$K_&#X,Z19V'QI)Z
M>W]C77RQ+XCM\$RQTVX?@;NIAD;A')4D(Y9?T/HKHPF*KX*O&M2=FOZL_(32:
M/X:_\$A[7?"6OWWA7Q3HUUIVIZ9>26FHZ?20%-:SQL4DBD1@"CJP*E2,@@@ MU3K][\ @Z'_ _".,/BOOK_
(*7_LV>%575-,@!^+6BV\$/_ !^6J@*NKHJ_ M\M(P_L^L.864X\N1F_!.OUS+,PHYGA56A\UV?;_+R,6K,****] 04444 %%% %

M% 'J2 \ P;? _ /!1G AN?|A.R^'WCW7OM/Q ^\$ZP:%XA,TF9KVQV\$6%Z<L7 MB1HF8DEI+;1C)\5^A-?R1? \#!'JOR3_ (O
[P#!0;PK\0_\$>L&V%\^*7'AS MQVKOB-+"Y=0MTW8?9YA%,3@G8DBC|YK^MQ65U#HP((R"#UKJXCR[ZAF#<5[
ML]5^J^3_ -H.Z%HHHKP@|HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
**** "BBB@ #Q#_ /H#(93V)/V>|0L M].NO+U3Q(QTNQVMAE1U/G2#OQ&&S.M?F=7T;_P4S^+/_="_'I? |A<[|'P
MI9BVPiRINI,23,|H/+0^9KYRK^GO#O)UE/#=.P?L2?LVR?M#_%>--: MMF/AS1-
EUK_@YIW@L1(=3F476N7"8/FW;@;AGNJ !|JESU)KTBOY:XX MXDEQ%G\$I4W^YIWC#S[R]>?X61_I1X-
^'U/@+A.\$*T?|JJKVG5?5.WNT_2"=O M\3D|F%?%?%?&GZV%?%?% !1110 4444 %?%?% !1110 4444 %?%?% !1110 444 M4
%?%?% !1110 4444 %?%?% \$&J;7IFN:9<+:K6GP7=G>0!=VES\$(YHG4JR M.K AE(!)X(*_E\$_P""\ P2ZO/^:/[85S8^"-
)F'PQ|=&;5? %TW=U R23%)")Q)8MC^L*OE[_@K_ \ \$ \ _# \ P4H_8D2? LVMNGB MNP0ZOX
U*;"FUU>%&I'Q^['I>|ST"REL\$H/N;R'-EN-3D_>-BCQNIY5E8\$'\$D\$& MJE?K.YB%?%?% !1110 5_6!_P;W?MQO\ MO?
\\$V?>H^N)M6-SXM^X^Y_X1+Q4T MCDYEDM8T^S7#9Y8RVK0,SG|T@E|J#7|G|J9_P->_MD2_O\ ;XU#|F7Q#J9C
MT^XOZ(UM;QN^<\$36+>9+BV?G@;H3=Q8ZLTD8[5\ Q+@EB/L^&WH>\O3K^&O MR*@[_I4HHHK/K-@HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "LSQIXJTSP+X/U3QIK+
[;32=FN[@Y MP2D:%R!|G&|UIU\ ? \ !20XA? \ "&?LU7.@6\^VY2:C!8H%/S>4"9I#],1 MA3_UTKT|ER|YKFU#" +
[K*I4=Y2;;;W;>K844451F%?%?% !7TK_P \$SO@:/B#79?B?K=GOTSP MFJR0;U^62^?/E#WV ,_LP3UKYJ|K|3OV-?
@|GP5_9^T3PWLD?N|/@IP='BGC|&K MQO1PB5679SO:G'_P+WO-0:/4J*** F8_T3"BBB@ HHHH **** "BBB@ HHHH M
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /YKO\ M@ZK_."?/?[W|9EG^UGX#T40>%?C#')
<:D(\1VNOP!1= XX'GHT,|J_D2K|2X9Q|QF7*\$G[T-'Z=|PT^1C-684445|\$2%?%?% !74 M_ _XN^+?
@!|90"QGR\7|DZUX\ \$5\$K.EN6('GVTR3|&QU4E ".X.)>N6HI M2BI1:>S _M\^#?Q2|+ _"X1^%OC1X)N/-
T;Q=X=LM9TJ3|Q:WN8\$FCSCOM<9 M|ZZ2OSQ_ .#73|I:7X| \ \$K|J\$#:OJ'G:I,?5\$|X9G|QLR&VRMW:L1_=\$5T
M(5|K+3XP _H\77JR M|H|_ ^6PB&>%\B-8F _X&KGZDU^D^%F"6)XF|L|J4)/YNT?R;Y\^DKG#R_P\ M6\$B|
<15A!_X8WJ/\81^\\EHHHK^CS_/X**** "BBB@ #TK|D3X7+\7OVAO#?A M*[M?-LDO1>:DK#*FW@'F,K>S;0G_ _5^JU?
%7_!)?X>B2|]5_ %6Z@_ U<<6E M64F.|'S9A_X|!^=? :M?S?XH9F\;Q'|73|VC%+YOWF_Q2^1_H%|&[AV.4< ?7
MYJT\7.4_/D@^2"]+J4E_B"BBBOS<_H(**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH * D#_ ."T M|/*0_8V_X*7_ !5^#^FZ9|ET6?Q"^M^&41,1C3|\[BCC|5B,K0?6\$U_7Y7X M2_\
|Y)!S;:6VL_!|]KK2_-Q+=P7OA+7KD+P+;/VRQ7|K|U| >E?3^8KV M&9^R>TU;YK5?JOF1-71^-_-WQ%?%?%?%?
!1110!^RG_9R_ ^7P|^TE\5_ MV9KZ^Q;>?*"%MK|C|_@W'VBPN!"X3_::^R?40C^|7|E?R4?&_ WQHE^!_\
MP5T^#6MM>>5:Z|K|OAR\0M@3#4;>6TC4_P#;>6%AJ|*_K7K|RXLH>RS3G7VT MG|UI^B-8/0****^8+"BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!ES|?Q:5| MCPK@98B-
6K&K.FU9)PDXOK?;Y'FYGE>5YM15+4(5H=IPC=?)-'|3'A2;_@ MB;^T(|K#\&OVZ_!UK>W_ /QXZ5!|1K*.YD/7;|EO?
WY/M@&NPUO_().QZA; M#40AW|=+>ZAD&8%OM+RK#L?-BD/(X+7F|=^/,C/90@EJSZ|)&/BYXG\ (W MT@
>| \;_<6\$K8Z9>!U)_ONJ6(XHPG#\,)/RG&, _P 7J?G>9>#/AAFEW5RV
M\$7WIN5.WRA** "Q_3#XG_P""8G|3FA;FT>WT+6@/NC3|5|MC^\$ZQ@'\;Y\4 M?LG_ +2?@_/\ P4?|(O:6GQ)^&'PN
M\76D6|>32Z+=V-Y<@#VD@NO)0^_DD>U>A2XJXRPW\2%&JO^WHR_ WX'Y_F7T8 M^!L5=X/\$5Z+|8SC|SBI?
^3|UC|.EZGH|TUC|JVG3VLR_>AN861A|0P|]'L?X= M?|BGP+|9| V3^T|^P|K%E8A1F?P|XGM=8+GO\ N+J"U"CI_P
M&KUCP;_P M7=_X-|?CM8&|^ (WA_4O \$C8:VUSX?W4,I.<9WZ-|H7WSN^M>C2\0L53_P| MR^:_P24_PT_ ^
S+Z*^:PN\OS.G|RJOE#8NI^7R/O+ _()X^"U'|?LL:%, \ M>V?69KC49QCKOD*(?^_4<=>W5F^#=# ^/^%?"^F>&?"EH8-
_L+ "&WT^\$EB4A1 M J E_F)P|DMSZ|UI5^!YMC GF6:5\6 _EY.4M>S=TODM#^N.%\F7#W#>#RQ6_M_T\$VH>|;W3_
!3IP^Z; ><17#>V+2XN3^G>OO6O-?VR_A7_ ,+S M_9\$^*7P86VU_%?P|UG284 R?,N+*);"/<,P(|P^ZL#6>'QE.K_+)|
\$35T M?Q4T445^U& 4444 %?%?% '4? _XCWOP=^-/A#XNZ;(Z7/A7Q1I^L6[1_>#VU
MS',I'OE|7|NEI=VU_:17UG.LL.T:R12(DFNZ>A'Y-BOY.J_1N#HVR^ MI+^|>B,I|A1117UQ 4444 %=M^S5X)7XF?M&>
/AP|E'B#QM16FF(C.3WD M46/QWUQ->|?>K|&C0?%\;?V?+=F&4;XS^&7D&.J|J=NYXA<5EB)N%)Q\$N/NJ=4N"!^
/_PKP|JOV^A+GH1EW2 (YV%?%?%:@%?%?% !7|)=O\ P0H\ M3/XM_P""1?P(U624N8O!2V62>@MKB:W_ 18_"OY\$J|_Y_X-
L=2;4O\ @BU\ M&C(Y9X|X@A8D| OB#40H_P" ^<5EQC^&70E_?7Y,N&Y|ST445^<&H4444 %?% M%?% !1110 4444
%?%?% !1110 4444 %?%?% !1110 4444 %?%?% !1110 444 M4 ?#'_IRA"\W_!%7XSA"/2'5K*8_HE?R75^D</_
(39K^^_RB93W"BBBOK" HHHH *^C\ M@D++^#_P5_9|>09|^+FA*J;V, #|37SG7M|/_WQ&GA#_@H=|^/%\$TVR.P^
M,?AF>9B>|&NJVQ;/MMS7/BUS86HO|K_ (%N?V;T445^G0%?%?% !1110 4444 M %?%?% !1110 4444 %?%?% !1110
4444 %?%?% !1110 4444 %?%?% !1110 M4444 %?%?% !1110!_#_ ,%8P!_P4_\ VA,?|F2? \ IRGKY|KUS|O|Q\A
M|)M^W=|; &F;QJWQ:1W@;U\$FIW#C^>=1U^VX5..&GV7Y'|.P|HHHK< HHH MH *_JJ_X-
EHV3 @C%|*F|SWWB\$CV_XGEVZ5_*K7|8'_|N|HQT3 @B_|%|=[MQAIK?7+AB>_F:|J#C_QTBOE,_'PF07|]?
E(N&Y|P4445^&H4444 %?%?% ! M1110 4444 %?%?% !1110 4444 %?%?% !1110 4444 %?%?% !1110 4444 ?- MW_!8?
P@WCC_@EE|?|#2,LT7PJUB^51U)M;9|G_VC7|>%?VX?M"?#T?%SX|>. M/A08|_\ PD_@_4|)V?WOM-
K)#C_Q^OXD&5D8HZD\$!!(-?H'!E2^|JP|-| MU_P#.IN)1117VAF%?%?% !6S|.O%|S|OB#H7CVR4F;1-
9M=0B"G!+0RK|(U6 ML:BDTFK, #^YG2|3L=:TRVUC3+@2VUW DUO*O1T90RL|J"#4|>?"\$M?C GQY
M_P""Y_C125|W7XA6INC5E3>Z;7W'0 M%?%?%9@%?%?% !1110 4444 %?%?% !1110 4444 %?%?% !1110 4444 %?%?% !
M1110 4444 %?%?% !1110 4444 %4?\$_B'3|/"AK4?%FM3>79Z78S7=W)=BC M0NQ_*:O5\Z_\ "WDA^&NIV-E-
G&R|O(39VY^OG7\$ M>#UH4W6K1IK|T008?|GC3Q/ ^-O&K>.,|24"YU?4Y|VX_.0'ED:10U8UF44 M5^W)"*R.
<****8!1110 5_7W_P \$2?"1%?|F_@|)HQBv=|V+2_QC_GZ+76 M?Q\|XU_07|K?|'_P|^?%2?LE?|X5>1Y1\, #O1-
,>;3;V\$,/_ !RO MC.,YVPU=M_S1|&'L17|H|?RS?'\7P0_X4|_P5R\8Z|;V MGDV?CS0=*|26B|< [|<6DS#UW7%G,Q|V-?
7\5N3'5*7|T;_/_ (+ (FM#_ M^****_13(**** "BBB@ #^F+ _ (-?C_%4?^"9,_P@N|S=>_#3QO?
ZLMQ|_(P_HYK|GXPWU;-JG:70+Y|_ (W-HN\0HHHKPR@H MHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ K|L/^#N#X|CX<_P#!+_1/@Q8WNV|^ (OCZT@N(-V/, ML);)'NY#
[XN\$|L_P#OJOU/K^;G_@|B_@B^*_|?|AW|G+1M2|ZP^%?A%?%OH0^1 M%|JFHE;F8?^ RV'OG->
|PYAGB+O'ND;|>,Y6YO8H6S[8_.T'X^?M6; M8X^S7=_X4UFYV?|,47EFN>V|+OC_,"K|Q^*- _@OK^S*?VI? \ @E\5/"N
MG:=|HU?PSI*^*M\$VIN=9M,|1\$'4L|LMS3_.3YO>=IDN^|J9I2|;|GZ|3| M125T?R3T445^P& 4444 %?%?%
'H_|([17B|]DC|J+P%^TMX55WN_!7BFSU0 MV\;|3=0QR#SK+M:|Q1|';T6,"2R
M9DGT2X+R6;|]1&PGM|A4AAS|X5|;Q?@G4P\,3%:QT?H|ON?YEP>MC|OZ*** M_/34**** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH Q/B5\00"?PC^'6O?%7QYJBV.A^&=&NM5UB|?
MI!:V\32RN?HB;?PK^+G|J|G|H#Q3^U7^TEXY_:0\9Y74?&OB>|U:: ON%NLTK M-' I_NQILC7_&4%?T(?'\7|7XE^+|JY-
|D+X>#0|5 MTEN6..5\VR(0#PZ-/X2* FPK|\$X0P3I8:6)DM9Z+T7^; (RF);!1117V! M4444 %?%?% '|@?|
!FO^SZUQXJ^,W|5.HV!'VFGV'A31|DK|RN;N\0'MCR; M\$_Z_>"OAK_@W-_9FD_9G_
_"3OP|BU333;MX|_C#5@4P7^W, #.L> _ MQY1VG6ON6OR/^<3|:S6K-;|V7R7X)M%604445Y)04444 %?%?% !1110
444 M4 %?%?% !1110 4444 %?%?% !1110 4444 %?%?% !1110 4444 %0ZAI|CJUA M/I6J6<=Q;7,+17%O, @9|8V|!#P|!!!
(|ZFH_H_C#_X*%?LNZC^Q=^VQ\2_V M9+ZVEC@|*>*KF#2&FSNFTZ0B:RE.>|VTD+ _|KQNOVO_ .#PC|C230?B+V|
MV|?"VD8M->LSX4\6S1)A5O(|JE^WJTD)N(|A:.)?BA7|'E6,6.R^G6ZM: M^JT?XF\$E9A1117HB"BBB@ KZL_X(Q?
M_77_!;|)O7P|;|6OI\$|(ZHYT+Q| MF2'TFY= |NT?>:"18K@_A3Q-&5*HKJ2LP6A_Q7-KC&E|6459&#U"BBBM0"BBB@
K|TW|C'|F_Q|^U|^U=|VOV9 M_#22?;|&?BFTTZ: (9-M;X-Q& M+F? %M|JUN1/9ON_@4RHJ.1_RSD<=S7RU#3|J2VOK
M.YC*2031L5>-U/*LK @|]"*_N6K^9G_@Z0_X)^3?LM_MQ'|IGP3HWE>#OC)Y MNI.T,>(|378|HOHCCIYNY+D\$>::8

80U]IPACU3K2PDGI+5>JW7S7Y&TF ZQ2QL\;#KAL@@@?V _L6?M??"++[NS]FSPS^TW%=4[1_-\$-D&
MFLY\!GTV[7Y9[.<#[LL3Y4]F&7*LI/6=?/?!!3_@_K_K'_3+__\$:/WXG M:GJPH,G<@PLJKS)%V9HXP/F^(\G_+1P_M:2
M_>1_%=O\ONZE1E9G[4]4%4 #0B+0/%_A_Q6>%-:M=2TO4[.."BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "ASP3X:U#QEXPVUTO2= M)LI;S4]2OYUB@M;>-
"DLCL0\$1518L3@ \$T)-NR \R ;C_.*^\$G[_LOB;] MIWXS7^W3-M!M/]TZ.0+J/MZ^1;V4(621#/#15#%V%1B/X_OVL?
VG_BI^V9^ MT1XJ_:7^,^K_ &OQ!XKU1[JX5"?*M8L!8;:(\$DK%%&J1H.NU!DDY)^J_^[_M /P5YUS_ (*=?M%?
V!\.]1NK7X1>"+F6#P7IT@:/^TYONR:K.AYWR#B-6&8X ML#"L\F?A"OU#AW)_LP_M:J_>2W\EV_S_P"
8RE=A1117TA(4444 %%% \$E MG9W>HW<6GZ?:R3SSR+!'!"A9Y'8X"J!R220 !UK^P7_@D+^Q'#_P3]_8 \!?
ML^7]E"XA73_ .U?&DB 9DU>[Q+<*2.&\$64MU;NENE?@A_P;-? \!/M_VQOV M^;/XP^,]&, @GX.F#7]3:6/, =UJF\ _V=;'L?
WJ-<\$<@K:E3]\5_4-7P/%^/Y MZD<!)[:R]>B^ [7YHT@NH4445\2:1110 4444 %%% %!1110 4444 %%% %! M1110 4444
%%%% %!1110 4444 %%% %!1110 4444 %%% %!7S5_P5J_8\$T'_M_@I!^Q!XK_9XGC@C\OK\$-5\#:/C/@ "SUFW5C
2Q^ZD@9X'!(.YW(Y KZ5HK6C M6J8>M&K!V<7=]3^&WQ1X90^~O\$NH^#?%NCW&G:K!%]-9:GI]W&4EM;B)RD
MD3J>5975E(!\$&J_-?L= _P=:_\OS\)?BQ:_ \!17X/^'2OASQO=I9?\$_WM8OD
ML=9VXBO"!J]U+E%VL<8\Z,DDM.!7XXU^Q9?C:>882->'7==GU1@U9V"BBBNT0 M4444 %%% %'Z']_
!NI_P7=C_9@U33OV%?VPO%^SX<:C=>7X(\6:A-\OABYD M;/V6=STLI')(<0.Q)_=LQC_*(XI8IXEG@D5T=0R.C9#
]'#W%?PPU^QO\ MP0-_X.(OV?8]&_8J_ ;O\6R3>!'%"6?@KQ]?_7D\.#HEG=MR7LN@24Y_""G_6 M##\5Q%P^ZS>*PJJ
[[4>_FO/NNOKOI&71G]"= %0Z;J6G:SIUOK&CW%\W:7<"3 M6MU;2B2.-@&5T920RD\$\$\$<\$-35\ :!1110 4444 %%% %
!1110 4444 %%% %M% %!1110 4444 %%% %!1110 4444 %%% %!1110 445!JFJ:9H>F7&M:UJ,%G9V<#SW=W=3+ '%! M\$BEF=V8@*H)))P
"31N!+!/:P/T!>:K)RDGB4="M+5N"EEU# MR<XZ#6B?_ 'FOO^>'W1:Q6*7O?9CV\WYJET]=LY2Z(****^U,PHHHH ***
M" K&E:5J>NZI;:)HNGSW=Y>7"06EI;1%Y)I78*](HY9B2_2.35>OUQ_P"# M5W_@F
_ [0'Q]G_ ;V^+OALR>#OAM?" +P=#=1?N]3\0;0PF&?O):(RR9_Y[20D M\$^6XKCQ^,I8#"2KSZ?B^B&E=G[_\8_>FF_
!-S]A;PU\&=2L81XQU=1 MK?Q!O(\,9-5G1=T(8?>2!%2!2.#Y1? +FOJZBBOQVO7J8FM*K4=W)W9NM HH MHK\$
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M" "BBB@ HHHH **** "BBB@ HHHH X]]H/X#?
#+[J#X)^OV??C)X>35/#/B MS29=/U:T; ;8XXD1L'9(C!9\$<^]3E(3[7D S:9YX& M^BX=S? \L[\$^SJ]/W/?R?
1_Y^7H3?-T?R?T5>\3>&?\$/@OQ]J'@ _Q=HEUIF\ MZ5>RV>IZ=?0-%:W\$;E)(I\$8 HZLI4J>0015&OU)--71B% %% %!1110
4444 M_?I/_P_7W\@_X3^+G_!?'ZT_P' 7[0G]H^-/ @TTH2'U5_ 'U'PP^+V1<@20 M9)+6S\$#^*,H=PD_I&_9_:'^"G[4_P
M+^~O! /OQ'TWQ3X7UB+>9:KIDVY< MC&Z.13AHI5)PT;A70, > _B2KWJ@7_ (*4 M9?!\\$W?B?' 7]'_!1FTL/
&LZK#_OBA,JQR>?"\$-^OEZA+W_L M^Y(5;K:(A)AS\A4;S]XU^=XG"XC!U73K1<6N_\
6IHFF% %%% %*_FX_P""T7_!PA/7/^"AJY? _\$ _9]_M'P7\&DE*36C/Y>H^)]IX MDO2A(C@R 5ME)7^*0N=HC^5OV_?
^"EO[67_!27XG'XA_M)>/WN+UE!5^BY-PW1P+5:O[U3%Z=WY_ =W,Y3N M% %%% %?4\$!1110 4444
%% %6=%T76/\$FLVGAWPII5Q?:A?W,=M8V5G"TDMQ,! M4C1%!,S\$ _*!DD@ "C8#U?]A#]BWXL_
!0#]J#PU^S#\ 'K_ ;]\$M*2 MRL4;'F3,,M)/*0!NEED9Y7; R[!>,U\C_P#!!'_@D;IO_!,S]FP^)OB7IEO+ M\6_'EM#
<^,KH;7.E0 ;H=*B<9&V/.Z5E.'E)Y98XR/O6OR_B/-_!Q/LJ;_ =MPV\WW_R_X)K&-D% %%% %?-EA1110 4444 %%% %!1110
4444 %%% %!1110 4 M444 4 M444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %'XQ M?' ,'_!\$Q_BWHNJ?
 \&/V5]"9?Q3I=IYWQ_-? !EM6LXDQ_ :<*+UN(D4>:H M_P!9&N!8>-O_ G\K^Z @,"K#"(4&OYZ?
^#BW_@@YI7^,'@.V"Q1VOB"~*:SI0X @OR&:10\ EG.L MG "JT8K\UJ^YL5@ \+C:?)7@I+^MGNOD--H_KT_81_P""T?\
P3[_."A%I: M9\&OC1:5XKN% ?P'XN*:?JROCE(XV8I=8];=Y_ .E?5E?PPQ2RP2K/!(R. MC!D=#@J1T(8U)O?L9?'#'_
4Z_8S2UT#3OC2?'_AJV"JOAOXD(^I(B#@+ M'<[UNH@!PJK+L'R'&^*,QW!\DW+"3^4O_\U\RU/N?
U@45^1/!^*G_!WO^QW M1(K71/VL/@QXG^&HOA9]6T?&M:6#W=M@2Y0'J%6&7'3<>I_0]G;_@HK^P MK^UC""/V>?
VK?!"B:ZG ,>DVNN1Q:@ >FZSF*7?"\05\MBLKS#!O]]3:7?= M?>M"TTSVBBBBN 84444 %%% %!1110 45X[^T\A
 \!%OV(?V3H)G_:(_G\$ M^%KB \$MI=_KT37[8Z];2,M_ _4-?GG^U5_P=X?L5_#6.ZT7]E7X1^*?B9J2 M K!JFHK_
&+I3'HJ]RV.I4P1Y&X9X[\&EF88Q_N;:;[VLOO>@FTC];J^
M6_VZ_P#@LC^P!_P3ULKJ^Q^./QKM+WQ1;H3'X\$)+%;_6)&QD*%_%MLJFN'B4 MXX)/%?
SU_MF_\'%'_!3K]L:Z\,M\85^'7AJYW^WA[X;H^G>9&>-LMWO:ZDR MO#+YH1LGY
#BOAJXN+B[N'N[N=Y997+RRR,69V)R22>22>]24X'@^3:EBYV\ MH_J_ \E'R'/L?I=_P4<_X.>/VTOVP([IX<_LZ"3X/>!;@-
%(FB7QDUO4(CQ^ ^ MO@%, (YV6X0C)5I)!7YH3337\$SW%Q*TTDC%G=VR6Y)))/4TVBOLL)@L+@:?) M0@HK_5[OYD-
MA11174(**** "BBB@ HHHH * >[_@V;_P""3^";'2O^"D7 M[5_A KK%W"+CX4>&=2@P;&!AQ]R\A
6NI_<*1B'S>6>,IX7_P;M_\'\$+S M]IC7M* ;G_ ;\$&E/AOITXN?!/A74HI)X/#O\ Q\ JM7Z =W-(1ZL6BBBO@S0**** M
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
**** "H=0L+&5;?"2]4LH;FUN86B MN;XC#QROL^1E/#*02"#P0:FHH_GO_X+Z_ \&^6K_LJWVL?MF?L5>%IKWX8
MSRO=^* "%E&7F)L3EIX5&2]AG)/>#OF/YD_(ZO[G;JUMKZVDLKVWCFAFC*2 MQ2H&5U(P5(!/!!K\O^"Y? !M;?
>'Y]7:_[X]O^!WN-.NRD^OD_/SZ]=\Y1ZH_\$.BG M2Q202-#-&R.C%71A@J1U!':FU]L9A1110 4444 %%% %!1110 4
D'(.AH MHH]N^"O_!2C_@H!^SM%#9_!C]LCXC:%9V^)TN#Q7+T3 5?\$W@FR!QZ%K-+=C]22?>OSRHKCK9?@*
M[O4I1?JE?IQW:/UV)?'BO[=-A\$D?C?]FCX4:FRC#OIL.I69]IS\W, <9] ML]ATKM;#_@U^,,;D:I^PEX:F; VFW;W\$0!
[];9L_T]Z_%2BN*7#^32WHK[MVOU'S2/VLO_ _@U^+ \D0&E_L(^&X7YRUQXXN)! [<"U7^=<7XL_X/_VY+Y'
M7P1^S\'*=~)&%;4X]20"OO\)=0YK\AZ*(V/9-'BOO;-AS2/T0^)? _=' M_P'7!7OQ]#)!X?^+?A?P@LF0?^\$:\\$Y\$2
]@UZMP1]0<@?]>?&X?&%'_)V MAUFMOC^V=1M8M+@&3:6?%-Q!9-GK_HT+)_P".5X917;1R_4/X=**^2_
M3;8K,SL7=B23DDGK2445V""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
Z3^V'^V;X;N=/^%=O,MSX9+7*-' /XN93 ME9"!CL,CKPT_1<)\Y]O_P""&W_!M9J\BNXTC]KK_@H]X>UTA?+O/"?PJU*
M(K+?'ADN=3C/*1="MJ?F?_EJ%4&.3]YK.SM-/M(K"PM8X(((UCAAA0*D*;! M5 X Z5\3GW\$B@GA(] >LET^EY^?
3IKMI&/5C-^TK3-#TRVT31-.@L]'S M@2"TM+6%8XH(D4*B(B@!54 # %3T45\#N:1110 4444 %%% %!1110 M4444
%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %
!1110!^7O_67_P"#<;X3?MTR:I^T M5^RE_9W@CXM2AKC4;-D\K2?%\$G))G"C_ \$>Z8_ \+PH(<_ZQ26\Q?YS_(Y_M
7XR?LS_! /U3X,?'OX=:IX6\3Z--Y= I&K6^R1/1U/R1L5D0LCJ058@U M ;E7@'_10#_@F=^R_9_P4F^&9^' [2^@%)
[VTB<^'_%NF;8=5T9V_B@GVG^D) MMX\$;B 64D CZK(N):V"2HXCWH=U7^:ON[5A2&^C>HK\F_P""HW_!#]L
M/_@FQ=WOCQ-?Q]\+TD)@ \>>]O]"CSP-OMP6:T;H-^6A)(DW':/AFOT/# M8G#XNDJE&2E%]JOZT,FF@HHHK<
HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBON\ X)<_ \%?VP_ ^"E-[9^5TM_7PP:
M0&Y>^>(+)L7B9Y73]"L(((FX;3AB,30PE)U^TE&*[@DV?)/P.^! M'QB_:5^)VE_!KX?#K5%/B?6)O+T_2-(MC)
(J]'[L<:CEI*HB@LQ I-?T M7? \!&C_ (-POA/^PX^E?M%_M9KIWC;XLQ!+G3;5\W2?"\O53"&^ ^DW2G_E
MNPVHV/+4%1*WV)_P3]_X)E_LF? \I-?X9_ \ " ?LX> EBO[N]!X@/7:IMFU; M677^>?;,
(#RL2!8UR2!)) ^@:_/YXEK8U.CA_ =AU?5_P"2\OO[&L86W"BB MBOE2PHHKYB_Z^#/_!1O]H7Q7X6^W[5\$7]6]G\ "-
^TVVGO\ QAX[F'6GB"Z MU.9R([;3]:SN2%54"S2RR,Z'+VX3?^" @T]17YH?L^ ^ ^ \ @JK!?" @JJ\
M.OV9_C1_P5QU+XT^?QV=8V;\$?0/\&M&V!;V*.EAIT9F@(:1FGO)9'4QD M+82#_ /@KG!"O"NI:W*!/ _PUTKX;3XB
M;3=-CQ%"]W<2QL9YE03R1@R+&S(KD** /O>BOBK_@B#XH_:^^ (7P,^ (7C[M]JW]K6^,5J?
BQK.A_#SQ7<>\$;#1H[[1]+G-BUY;V:X59KN&[(#)\D49!& MXBOH7]M+JJKX?_L1_LL>-_VI_B;
<1+I7@[OY+P6]MPL7VRY)\$=M;J]<*TT[Q M0J3P#("> : /4**_ \&8^#_P#P4A^/CGPM^TW=? \! ? *?%KX;1ZPMY
MXF%_#CX8;&X.;2UU".226)%8JA+*)C&#]QCN&?^T-^UE^T_9/C3^W)
MI_PS^_VM_#^U_9^&^E7OP_LM%M[7RM3UF71K06][O45GAD-S"WD16RPDB,1 M&1]OF,KJ ?I917SK*_V^~

'UW_@F[VOV]?' A2=+_QKX" T/5+3PCHZ[KG4M M9U&"\$6^EV2N?
GDFNIEABW\$##!F*J&8>E_LS^#_C%X1^%%JW[07C8:WXTU>ZF MU3Q\$;5\V6G3W#
[_[L@0#]EME*P1LPWR+>S7^>1J_ _HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BB MB@ HHHH **** "BBB@ HHHH CNK6UOK62RO;...&:,I-#*974C!4@(\$\$<\$& MORV_X*8?
&N7[* _J5DE _4OV0;VS^\$?CF?+=+I=O:0%O#VIRGGYI[=/FLF)Q\ M #DF%B\$QV*P-3GH2<7^#]5U\$TF?QH_ML?
!#]LC_@GQXR_P"\$ M2_:A^#H:~+!,8J,]16R_:=*U+&2#!=QYC8XY\LE9%!!&Y%Z5X;7JQ7CGP%X'
M^)_A2]!_GP;I7B#0]2A_.HZ/K>GQW5K=1GJLD4JLCCV(-?E;^WG_P;?LE M_'.>]=?L9^-;GX4>)MTG_"/W*/?
Z#/)UPJ,WGVF2>2CR(HP%B XK[?+^+J M%6T,7'E?=:K[MU^)FX/H?SCT5]3?MJ_\\$8?^"BG[!LUYJ/QI_9^U&^-\VA8G
MQKX25M3TDQC_):/+&NZV4]A<)\$WM7RS7UM&O1Q\$.>E)27=.Y#5@HHHK4 HH MHH **** "BBB@ HHHH ****
"BBB@ HHHH ***^H_P!BO_@C/_P43_?TDM-3 M^"[/FI6OAN[(\>*@=,TD1G_EHDTW7*CN+=)6]JRK5Z.'ASU9**
[MV"US MYI>OT^SZ5IN<\$FXNY,1H0 M#N\LX=,=J,>*<:]@[_(-,OV3_((R6/CG)M#QQ=?%7Q!"5D/AZS5[#0H'
M'.UE4^?=X(ZL;.,AHB* 53P)X _" "[PE8^ OAIX,TKPIH>F0B3M&T33X[
M6UM8Q_#'%\$JJ@]@!7R>8<78>E>&\$CS/N]%)V[_ M0?4_;;@FA_P:W LM?LK M36'Q3_;"OI/XM^X-
LL6DS6A7P]ILHY^6W?YKY@</_AX/DJ0#7ZF6EI:V% MK%8V-M'#!#&L<,2!4C0# 50.!.!4E%?#XO'8K'5.>O)R?
X+T6R-\$D@HHH MKD&%%!!116)3/#_BOQ9\./\$A;P)XR7P[KFIZ)=VFC>(&L?M0TR[DA=(;
MHP[X_ \MRK^7O3=MQN7.0 ?+G_!Q/A>_QH_:" P""@5Y^&M?_P 1&(^ M KC[R-X9\&33HY8F/(2?43JL_!'\$B'L
/1_ ^F7[1'B+JEW]AKXA?%7P%&T MOBY](71O =K\$W[RX\0:C*FGZ8BC^[_:[F\$D#^%6/&UVO]O[OA/]D?]F;P
M^)_S)X(N6N--#>%K/1X;UX?+>]>)&5DN77)P\LF^5N3\TC'KJ1'N="5:);ZA9RNIRK-#<(Z,0 M>02,CM5?
X\ _#SQ17/@GXM^%O@GXHZI(UCQ%X=O-TOQAHB\KS19YH6C2[A MI(R\;,"*G*,IPP+^&O["W[4B;]C/X=_L_#_
/X*62\$'PO/_&P%<6-Q M<_&"/2;>]NO\$'OC)3HOAW\6 A7I\$[_V1JD\$S97EUJ\$5L21 M_9;2>4A,(I1"JH#-YGV%^T%_P
\$QO@5\? QM\0/_C?QGXI1D^+GA.T\~? M%JRV':C\V'C#3;82)##=F>VFDC<033VWG6[PRF&9D+_ "H4WO@Q^R-
XOT+Q MWH_QI_:@_!U#XK>~_#ME/:^&[^X/VND:9H@G0)<3VEC;9"W\$L8\MY9)76
M,O'&8DDE5^M_:=^#OBGX_P#PJF^#V@_ \$"7PWINO7L-MXNOK*- _MD^C%LW=G;
M2JZFWEN\$'D>>,M&DLC)B0(R@_ROJ?Q4^%O@_X3^)/^"AUUX.4? ?]FCP1J,/_ MP&\
(Z=B.+5Y+&S>VGUJ(*A'1IU@YRH@:XN 62[C*S?+_@HU^T58?'KJF? MX3_M3Z1X.GM_VJOAGJ7B/PF_A'2KFTD_
:I96-OJ"?\$?@^X\,W.EZ4BVZVNGRV MYMPD VQ&-"F!A'JX'?OP!_X)=^-/_QP^""Q>:_%&^/FG^X_V;?AY>^% M/A-
9Z3X6?3I&-W;164^IZ@[W,PEN&LK>&'9&L<6;S)/XU1_#1%HHHH **** M"BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (# JP!!(-?['7G !
M'3_@F)^V:]WK/Q!_9OT_P]X@NRS/XI\!L-(O3(>LCB\$>1.Y_O312&OK^BMJ& M(KX?:/2DXOR=@:3/P(_D_X,Z?
BUH1N=;_8Y_:ET?Q#_SP!:X]L'L+E5'! M=6XECE<^K10KGJ1UK\?VC?^"-7_4Z_96\^Z^+?['C_?:Y,NL^';(Q9
M(@_C>>Q:5(U/_30J>Q_/%?V" T5]%)A>+,RHZ5+37GH_O7^1#@C^&&>":VF>VN M86CDC8K)&ZD,K
X((/0TVO[5/CC^QC^R/^TO#)^'T#^S/X&\8O(NW[5X@ \+V MMS<)QC*3.ADC..ZL#[U\B_&+_@V\$ _P""0_Q6,MQH?
P6U[P1Y0XQP4_XM.4?2S7Z?D2X, EEHK^@3XF?&:?[.VJ\$S\ M/VU/&FA G]V/\$WANTU;'U;#VF?TKP_QO_P
&:_J3E@SCX;_MD^ _J649\LYH M5[IY;TSY7VG^ZUZ=(B3)JG+_VWJG_E87)(_&NBOU*1?&B?_!4#1F;^RO'W
MP@U=1DJ;+Q3?H2.W\$U@F#^>N;N_P#@U*_XTV\QBA\^_9UQ_K(O&J ?\ MCT8/25U+LIE_P OH_>+ED?
FS17Z36W_ :F?%:IYUBE\^ 85.' _/@T3_X*:@O*JZX_P#@_I2\$ NUYXIOW*YZC\$-@^2/R)^#S MK*8[UH_>'+
(+_6BOV4\%?&:_P"TY?S(OQ&_);!Z5&0/;1-#O=0^*N!+JG MS^8KW#X;:&:&?
[.VERHWQB_;5::Z@QYB^&O#5II)/K@SO=X_(URU.),FI\ MO;^B?^5A\LC^?NGP03W4Z6UM"\DDCA8XXU)9F)P .I)
[5_4O\O^&#87_@D/_M*98[06O@MKWC:YAP8Y_&/BZZ<9'MDOU_(:@S^4 M7]G#_@C;_P_-
_VJV@N/A%&QSXP.GSD&/60\$5D-'L67NZSWQB20#_IF6/8 G MBOT-_99_X,ZOB[KYM]<_(:BT?P];G#2^'
%8OJ%TRGJC75P(XX7JL)? M\$%K@KXI?D:O>[QTD195\B!Q_>ABC-28"JJ*\$10 !@ _#@ "EHKYVOB^")GSU9
M.3\W"]&4;K2[&98YKE595V(S _@_W]J\$)J\$5=O1?_#TRBOQI_P"(RG)F M?_HS/QU_X/[+_C_(C*?
V9_&C_,'7_@_LO^*C_ %>SG GR_O7^9/_\$ _9:B MOAO_(). P#I^KZ<+;^(\$N-4!@T:9L8BO;A08;)\$';.Z\$ @XP:
[2P_:@_9UU3X777QOT MOXV>&GP;97-Q;W7BNWU>)].C>!F2;-PI,>\$9&#-G:"IYXK 9W=*>#;3_P % M2O\ @FUK]B-
3T+J]N_P"\$U[;_2!<6GCVQD0D=1N64CBO1?>9^T? \L _[3OA M6[<_LY?&KPOXZT:PU-J-OM5)ZY!>V]O>(DQ_48J2/KB
MO6RK(LVSN4XX&DYN-KV;5K];M=CY?B;C3AC@Z%*>UU MN?5=%?)/_#VOX=_J\$CUK_P #H:Z+X2_%)_!'Q:~)&C_
WT[X:ZK:3ZQ=BW MCN9KN)DC)!2R>E>K6X'XJP]&56IA6HQ3;=XZ):O[1\UA/&3PTQV*IX:AF,
M93G)1BN6IK*3LEK"VK9]*4445\H?IH45A?#WXF_#[XL:]<^(_AMXPL-;L+/6 M+[2KJZTZXB17MEI^ M"
[C]IKPS=7VAW#0_ P#V3V5XK1E'++,Z%>^*Z:T_;\$_92U_M MP?K'Q\$TS]HOP9=^'O#\<\$FM^(+/Q%);S6-DDT/G1-)
<(QC4-%^!\W8VD-T(- M'I%K%<=#OVAO^&^TUX+;XC_LZ_&7PQXZ/I>R6;ZUX2UR#4+5;A K/"98&90
MZAT)7.0&4]Q6[XV\;^#OAKX/U3XA?\$/Q5I^AZ#HEA+?:SK.K7B6[K8VT2%Y) MI97(6-%4%BS\$ _F@#4HKB?@?
^TI^S[^TSX=D]8?L[_&CPSXXTB-]CZKX5UF M&^M@V64KYL+,A(*L_ ">#7;4 %%%!!1110 4444 %%%!!1110 4444
%%M% !1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 M %%%!!1110 4444 %%%!!1110
4444 %%%!!1110 5H_ \%RO^42/QX[_ M\$67_ -&Q5]75H_ \%RO^42/QX[_ \$67_T;?77@/\ ?J7^*YH3V/Y#;***_3 M
9;@S6_P"3F/C- P!B+8?^EIK]_P#7[34[_0KVQT74A9WDU]:'7AC#^1* M5(63:>NTD'"%?@! P&:W_)S'QF_P"Q%L/_
\$M-?O[XDU&?2/#M_JUJF6U MLI9HPXR"RH6&?;(K\LXH_P"1S/TC^2-8?"?C7_P1X_XF!_@G)X5;_ ((I M?%8/
LOPA^(@N:YJA;QKXH@+Z)XV%)>SSM?3WCC&Z?S67]1*3#*D:DRJW[L M?IG^R3^RO+>V2VO=9^\$7P<33?^\$-
O]=U]70#UGI:@VEM9ZG=37JV\6"5,2 M>>53;[NP*Q7]1Q@^WXD? \$L/^"7 3XT^QE^T2>OP_ \$5I-X:BNO%-CJ&IQ
M6FH^"M3,"_:@LK.L]@R2!L2;@LD85LO&W/F'_IN3I/C7X*_ \\$_OB_H'BSXGW MNM?!CPK\6/\$UM\#_
!EXDF\M;_PG;@M]\$85;-Y\$ED5AA=[3\$87?/%GEO_M_#;#_M_+_&7[/'_2*_.>!?C?^TIX3\;S9>*=N;K3-
7U18IXXFN=7* MG!7D>M?I/^P_XN^!QM^%&H_M<_L^Z1]FT?XP:[+X@ENE7:-3:;%TR&^V%5* M--;6%LY#&#<.
>+==;UW1R2!AE65AD<@@U]T_L?_M!?'LU>/_ %WB_P#9^_9#O-*UKPG\ M.)4.L>(/#^J)OQ M]\4?
L\LR:YXG^&=K%=>.M=GMO#7PWT^896Z\1:E,MG8!A@YC2:59I?[L_,K M' 4FO8Z^/(BM)X)_X*.'%&^
/@P#;:U/1M)9ET2'7=8G\#ZU:I?Q=JZ M7%M;)^]CF7%GIR7@?Y.'U5!N1L'_9_K ?O_!%+3?7_!3_@H[_/_@C
M\4_ 'NHZ[L.M6TQ_&'B'6Y/W^K07")J2DGI\TGF*!_:%7+V[B[O_ (6 M/VL?B[])?V>?AC^QW\ O&-WX;4_M(?\$J]T&2>
(K&0I/8:6[QI=^4RD%<=KB MWB)/ER2@8)!CG_7;_9XUO_@G7= !_; @L/X)_%<^,%?7P8^([C9:M9> M-.*
[L]7X&^&O^"@?[/P?_ M^"@ _[#0_ '\$6O@WXPL/B#X5T_1'\]M!.4R6G5H;3ROOXAE0*9"JD M_0][GSX ?"3]EKX,^?<
@#\"_!EIH'A;POIL=EL.G6<04*B#ID<@#S)7.7>1 MLL[LS,2237#_ 4_8I^\$W[.'Q:~+_P 3?A;H5CUFF?%R>QU3Q!X?
M+-8X]JL M4\$%U=15PH%Q&;&O\$WQ# \ M,74\ Z+;\$V?CV:[5-/U;8DC7,ULY 62TB C N@QCD8RA"1%N8_+_@@@!KN
MK_ \ ,/J?X7?LO^+>-3G3X8?MC? ?PYX[^]U=RDQ6GBZ'2H3J-H&; #3?O6 M([&L4&2:~^T_ ^]6LZO\ _#]G_P 3?
L/>#]2G@MY/A3XC^&(OQ.NK20]JUMH.CV M?VA_V5]<_I_X-L?V*ZTS3X/M]HI7)+;(7;RQRT]I\$I%>Q^>=6\7_\$;_ ((\
M_M(_\%)_VF-\$M?^"WB_X^?136-672KFY^300M^T.A;BZ:CO@D.LDMYMZF;5) M%Y.!0ZA_P&Z,,4'_!%3X I#J
^%KIB%&3.J5V2?J22?QK[6KXA_X-PM;T M?6_ _""GP?1]4M[H60A\MKGR)O_E3]J5T^C;'W6!Z@\\BOMZ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
**** "BBB@ HHHH **** "BBB@ H MHHH **** "N)_/_&?OAU^U3#? \$W[/Q:MKN;PWXMTUK'6(K&Z,\$S0E@Q"
M2#E3E1S7;45492A)2B[-_?F[_P 0J/\ P21_Z\$_QU_X6TO\ _11_Q"H_ \$D? M^A\=?\ A;2_ \$5^D5%>A_&:_\
/Z7WL7*CY<_8" _X(^_L8_P#1-3Q?X@< M?LOZ)XAM;_Q-IL5CJC:SKSWBM#')YBA0P&T[N]?4,T-
Q"]O<1+)'(I5T=" "#U%.HKBK5ZV(J.=63D^[':QYUX^_9!_9_&*U]I^I_ '%]E[X=>)+G288X M=+N-?\\$V%X]G'& L:1--\$QC50

[illegible]

MEGJ:K(2FE1Q2MD6 P H>8D?0O05C^X)\:\':% P3' X.POB.--"QQQ:4OH M?AKJ\UMI/BVQL/B181HFBNZ17,2L;A7V?
9JZ^6F-R +C|Q7|"%% 'Y|_ \ W M_|&J_P#~"K7[-'AZ/X*ZMINB_%#X9WDUYX&EU!O*M;V"5(Q<:(Z@^4\F!X
MWP0KPJ#A79E[? ;#_P""?:[6O !;;|K_ . ?C;|L3|F.;X-?#X.:?/=,>,- MU[Q1I6IWOBCL4;B6VDN+&R33;FX5;-C9Q)Y\
[12&.1R(MP /ZR44 ?F_ ,!' MWP%_X*V_MF?"2P_9\$ _X)Z_ #K1H!/6M0KOEIC'_!1#Q)_P %_?@C^V|X7^*O M_!/?
X5^\$OBG\!K;0+>UUOX5/J&EZ9=-D)2W?@?4?95EK6L^)=6(B\$ M-J[V!>UMK!/+W2,)9)9]VSRX@-]?H%10 4444 %%%
!1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% %% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444
%% %% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444
4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444
%% %% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444
%% %% !1110 4444 %%% !1110 4444 %%% T>=[?@#6M&A7Q%10I1\$W\$-17JU:5Y95QD|3%^SBY647K97M>_Z\$|.2
M0RK B/B+"Y51R^<77G&"DYQTYG:JE'6WJ7H117L/ !>+|JC|H_P%_P %; C5 MX5|"_M ^-
J)TNUUVR^S:;|BN\MK>+.F69.V..0*N22>!U-&@_ |%) ^"B? MAOVN&7XU|?|-O|_M@ZS_."M/@8Q_P#"4^)_ ?
C((10/B/P7%YGU^P;|8_ #%14X0S^PRB_FU^@ MZ*_IKX0_P#!YCXWM3%:'OJAW2KX' GU#PAXOEM-
KL5M[F&;|=]/#K7 MUY|'_P#@ZP_X)5?%=H;/X@:YXU^-U(OK | "5>%VN(Y)| ">:X^7/\ \$RIZ MD"O,KY|F|#65)OTL_P
GJ?-\$.2FBO_@+^V=^R5^U);+=_ L|?M(^"O&1:/>U MKH'B.WN^F(8S^|@5 -
C..SJ#7IE>3.\$ZF2>,_ %5IIHN7&X1?;) \$|S;D9VYQD9Q77>#?&G@[XB^%K'QQ M/V/OFF:
[HFJ6ZSZ9K&C7|=U:W<1Z212QEDD4|F4D5XIXO_X)H?L>?&XK^+_ M(U_M_ SPI|4?\$/BH16D-
WX|_.6^HKHNE10K%"IUBEP)!;1:A+.[1|6DFN) M')^XJ?('_|";|FSQ3|,?AK^UI|!O@G|OM7T+X31_'7Q'H'P2U,3-6UD))8N2
?<;?MR_L6)|:O^&;F:X^&@^(VK|+ PA M|!<6'|J_ ;X|C|+YOF^;_P|,|N|OBO4Z +|_ (+2?)\$F?^";_P +/^"2?Q%M
MOP%^S|X4|*)? ^@1WW@CQCH6CI^K|FM">.+5)+Y1|IO);F=TB;S7D:1IMWW MPK#|_/V2|^*+A.?

LJ_#/1/CYJ\$MWXZL_AJHT'C2ZF?<|VK)8PK;Q[DSB0J MR:_J|>\$#P|+/"-_ |#\$XG>-M(|.:IO:E%9V=I'D#?+-*RI&N2
M|EB|R'S_(3?&SX.'?KPNWC:X(?%7P|XOT=+|I;34_#6LP7T"3IC?\$SPLP5U MR,H<\$9&17P/I?Q|? \$>_
&@O^#@?|FS|A#Q ?M7@?P%X"U/XJZWHLG-OJ.KC M|79Z:R'AS:20B>/L ESR0,6/CU|2M1_94_X.-?
@MI7A"8VFA_M+_"K5=\$|< MZ:#|L-WJ6C)/=6.HNH^|<+&1:A^OE-MZ_8/MU/VG_V;|B|_P_)|?|Q|_M<|S'_P
(@/\$EM_:7F"(3&/|O|SS|\$1*4QN\$9#XVG-=K?7UEI=E-J>IWD5O; M6|32W%Q/((\$2)%&69F/"@ \$DG@
5^%.D6/Q&C_P"";_@'IF2:|;3|J|6T_;Y-Y M?ZZL@.L)K:ZY >#O% AC MX@^\$|,|=^"==MM4T;6;"&^TG4|.3?
#=VTJ|XYHV'#(R,&5AP001UK2IEO;P6 MD"6MK D442!(XXU"JB@8_0 =J?0 4444 %%% !1110 45YM|_P|K'X)? M
&X?&OBI)=3"9CT330)KM^,C*@@1@|BY4'L37QS|:_ ^"E_QH^(+3:3|(H_M">F/E0|JWFWLB^|Q&\$|?
D52|IQKZW(N"L S^TZ-/EIO|/'!_-2Q?>VE=?|NJ=I33_+VJC#_MYIVV3/N7XF?'#X3?!VQ^W?#\$GGYI^
MEY3=;S3;IY1ZI\$N7?| 137S|5/^"L&@V32Z?| IOX=RWKC(34M>DJ+/J| M8R68)?

5T/M7Q1J>J:GK5_+JNLZC/=W4|EY|FZF:22105F8DD^YJ"OUW)_ "S(| M\$E/&2=:7_@,?N3N_F/L?ROQ5|)3C/. *EE,
(X2GW5IU/G*2Y5_V|!-?S|? MQ)_;1_3^*#21:W|3;VRM),C|HQ^QQ|3_"?+PSC_?9JNEEDFD:::1G=V)9 MF.22>D)IM'?

H>#P&|R^G|/#4HPCVBDOR/P?<[SC,1|?,<1.M/O.4I/Y7;L MO):!11176>6%% !7T%_P \$R_|DZ2T_P"P+>?
^@BOGV0H+ @F7_P G26G_M &;S_T\$5|Q=_R3&, ZJR (^||+O^3C93_U_I ^E(C_\$@X/_Y3&'#_L_V_M'_IKLZ^-
*^R_#@_E;,:|N";_1^_G|(?_IX7|(O%\$UKX:._: 9QU'PK,8DB\$ES9Z;?!;VT4 MXP9|20+|U_Y:(M?Q;5J)>"_&_C3X<>)
|/QM|/%^J;C.GRB6PU?1=ODM;JV M<=&CEB970^X(-2-8WA+ 5[N@W!_>ON>OX_(M3:W/[C**_FK_&#?^#JW]MS]
MG66S|&_M6Z7;?&P'MP:C|JO9LJ|=MH^F5ND4I<8&21.C.QP-7K7|;L\$?| M|7_JA'|@HUIL50|_XN0V_B;R?;N_
GB4+9:S|@9;)\$8K<*HY+P-(@R,L#Q M7QV89'F&77E.-X_S+5?/JOF6D)GT|1117CE|1110 4444 %%% !1110 444 M4
%% %% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110|_!
+=W_|3G|F7X<_\$_P|AZ|\;2|_#+Q?>Z>L_C3 MQ=XAL7V-C)X1TR48S;+<.!+JDRD^1AE@!^TS J(8;GNOV,?VK?^"
<%WX'F_M9_| V)/C7X,UGPCI*"O"<-SK%YX5UJ.|TK0;(E|C7=^&+SI?*N969Y&D;RII M)""=S=?XM_X)[L#^/O\$^H>-
O'7|\$P@UK6M6NY+O5=7U;X::5TGP/I] MM8ZLJY"BZ@CA\$=P|DX#JV,F@#XR/_!4#_@F#^V)|7]+^)_QC;R^\$&C_V^
M'7B WW@/PAK7Q T^"Z|OZU;LR)KE|;O*'C@@;=JBMG 8O_I4BAA;"/ZKUC_@ MHE^QEX6_9PT#|KCQS|>-V?
#GQ5JR:=X;|4Z|SVMOJ4LDTL4+1;URT5 M'QM,(W(3)\$7_#LK_@FY_P|(!?@?_P"??.1J|CQM^S3^SK|2OAKI/P9^
M(P(|'ZXW0T&6SDT/PMJGANUGT|3FM !;_W"#=#?Y2@*FU1M7Y1@<4 ?#G|8 M7PXU#X ?|'OJ_|'<?O1&#P7|1/AIJ?
PIU36^X@T|6(C@D93XZ?#74/VK?^#C|X-ZSX03|9H'|-'PFU/6?&^HP?-"9ZIK"W%K9=(MP^|<-'MNA&>?3=T(S^@7Q
^'7P^+^/@^^^OQ3|#:XET#4XQ'J.B: ID5Y M:72!@P62&561P" <\$'D JJI_KX,?"X%>&#X

[illegible]

BBK6B: +JGB/6:3 MP/H:DI5>WUREO:6:0RTLKL%51HDD*F*48QB2W:2?1MGI! MGLZ 'OXH?'
VYXGL2 AGP|R3ZBKK|MW-G,=O|@X+-LKCC<#7Z4JHH1% & M. *X:IG'X':1?A)I?PITY8WN(H_U6Z0??:VX!D?
Z9-5<1%51VKNJ_E; MC3B.?\$><2J1?J'NP7EUEZR>O19=#_2_PBX I<-<)TZ%2*^LU:3K/^\UI"-
M"-NU^:2^/****^1/U,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH ****
*BOPKX:|<^%11|>,=#M=3TC6+!RU33 M;V\$20W5O*A22*13PR,K%2#P037/E/!?:_@F=K7-
3%_)U+X8Z3?P9R&M7?^*:W?|VW=E|N0>>8!7|G?%)O MV(-8|'^=+B?
X@>\$1)KGP|NRH#M>1H?LMW|RYC|BQD 2>2YSY8KWN?|>78 MU*3IR6C|NS^7Y7)DKH_DFHH|U:W-
E<@&MBD18|LIM*:E>K|+2^#67|L>7IG+ @HY\$!\$=>U;R/!OOATEM%G MGD?\$.ZI
&GL)#ZL2)K=1ZW=>#Q)@OKF62:700|Y?+?|J#LS^G.BBBORDV" MBBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH *YWXM^/3X7?#7OB">|2ND:7-!23ZGJ%PTUQ< MS-
+/*YR7=B2S'W)|-0T45_7R22LC_*B4I2DY2=VPHHHHB"BBB@ KZI_X)>?MT>+?
B>>_&G7+/-=8^!Y&F:UX>|D7EAZ^7&<^QD0CI7RNB/*XCC0LS"JHR2? M2OU?_9>^\$-/P/^!VA> FA"WD=J+C56 Y:
|E^>3)|I2=@/U!7YWXE9V|JR|X M>F|3K^|_N:~?W6C V|?O7T>>#H2|K'5XWHX_*H^SJ-VIKY..?AZ!11
M17UG^A04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%%
!1110|_+ _O_!|A 8|_SG^@:1A;^" MOC&HUC?|5;KCEO.M6G 0?>D6+@X?R@U^|X| MXW+4|WH>Z_T?W?
BF8S5F% %%%>^2% %%%% !6U|_ BCGX3_\$0?BEX^U%K/6O M#6LVNJZ1=IUANK>598G'T=/%X5BT4FE)68!M?
|_QN|_M*?L_ ^"OV@O|K# M^S/&GA>QUFS0/N,2W\$2^6W^TA8HPZ@J17:U^9'_B_M+^XS?|SC|_5O
M_U+X6>+;S2DC=LO|@N3|MMW)|-US&H|"#0"OTWK|7Q^&>#QM2C_*VOET_M W3N@HHHKD&% %%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 % M %%% !1110 4444 %%%% !7Y?
|%3?#Z_P#^N0|&Q39@T#1(U/^W9YEC| M4|G|_0>OR=_F|8_X|_*|9>|2.WDKT|_#YZO0GR8S_P|AK7ZAX48)5^(
M)XAK2G|V|9-?AS^W_2C&OU#K MX|X).?Y;|PYX|^5S;/_W<6F6+DK5,5.51|^5/D@O2T7)?X@HHHK|
M/W@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ %%%/\$T\$|_NCJ5='7(8|'_XK^.# (E?LG2 M L2?M_?%#|G&'P.WT010STL AQ2_#I5R|_#_B"6_ "1_\$C#MBO|(-G_|
M^#^QK|F|>^ CE|*/VKM)T_\$|B7P|=>&|8FC7_%Q92^?S^K|'=RJ#Z6^_PKZG MA+%.CF+|_:_%K|+D36A^+1% %%%?
I9D% %%% !1110|^NW_!GU?Y|/|:7Q! M_9WOKS99^_RZA;1EN)+|39P44#U|B|NFS_+?%T55_(7_P0|^_OP&_P"
ML/P|_B|F&|_0Z%=_6PIBU_!T|O8?_0W/0J#VK^O2OS3BVA|+U47VHK| MUI^5C6&P4445|L6% %%% !1110 4444
% %%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% %Q1KD^ACPU|B6ZQY6GV,US)D|_8T+G|7X
MXW=U?71SU9B% %%% !113|_WFN|B.TMXR|DKA(U^4L3@^"AM)#2;=D2|I^PO
MX_|G|EGPG9R0|9K?R;49FORWVAVE0G_+9L@_"O6ZS_EH_A7PKIGABVQ MY>FZ?
#:QXZ;8T"?|!6A7|YGBWC|RK8E_!E*7WML_P|N'+MX;_37GPH4:3X@MBJY=5_V&7'L(HUV(Z83/85^BM>_1%"_A3;_
|Q_80^_M2PFGM?_272AIK5M:K)C)P_*4PL/=90C#W KLR^M|7QU*IVDOSU\$U=^8_% %%% M2M|@% %%% !1110|K>?
&_J_#OQUHOQ T&0I?%JUMJ%DX_!L|IR(<|RBO| M??#7B#3?%GAS3_%6C3>99ZG8Q7=I)>BD0.I_\$5\$ #97|EG-
3"|>^XF_|M|_X%>-Y)_FO?A+H^VM|YS.EA#+_Y\$1Z^XSIWIT:G9M??_(TIGNE% %%% M!&@4444 %%%% !1110
4444 %%%% !1110 4444 %?GC_P%_OVROCU|OV_M_BG|OV_/&-
SH^BGPX&7Q|A00^6F7#QS^%M.FG6&UM; >6.AH|O7W^600T-MO|<395S;
|_N3XZ>+ _OP^ ^GB_OY|_*AY+XN|3Z+X9O|PI|X5AN%A?6+Z*W= MX+2-PAED58|OZ;LU^*W|>?|2G|8WA/_(|?
&CX0_%S_@E%|6M|U3QMI+ZK M|3_B|XBUS2#|7|2GC_X@W_P_6OBMI&DMI&L_\$5/\$ MUEXP|+31ROJU|T%|<3):?
9(E%PUS;|I#Y#J(W&U_*JD?^"C7C;X2_!\$2=^/_MQ;_8GOM%UF?3|'^_A#P|X0+FVN+|Q0|_V5|:7MOY! =1|AN)&>_
L_R02P_M74U|Z7_!\$WQ: P"#:|H+P3+U^U^SWXDB|??WO|K6E>?C/X8U32H40?#_Q?
M72J+ 2^4%X+;W.FX6H8|F_0REDFE/VGK|_OAW^T|I/|57_5X^/G|%/|3 M^OE|8>%)?AYIFAM|_A_X|>ZEX:76M-
GL|<7^K>=IMQ:S;A;)9%0HTC1P1J MNV/>)7K|!_*|M3|C#X<_|?+|K+XP?#&TU0?#F_|V9(K7PSX4^(^CV*M
MJ|^I^G_VW^USI=,<%M*MT(B%L,/))/O\$^RN 7+_/X*&_M8?|K_ (Z_M7_M+2?A#Q7?>+(_AA|1-?|? ?
XBZQ&MU<_QH2WEK9P:DA|A79?BUFN+E5NF#"< M689|YWL_H?P6|2|
Q0_9C_X*K_#|E+1/C%XT|9>#OBQ^SI=7_@D3|9/BC^UQ^S)|4_ ^"?_M
42^#OAO_&7P8U9OAW|0+2#|C310\$>ERV8-M<1PQJD<:S6Q.4147:L=5CW M^6G8?S'X|?#|C+Q+HT?
|+^FZCKWQY|<^XOA_+ #5/_NM7&KOX<|VA\$TL MS>^|B;4_-!2";
M5;_4/B3K>D7LD#;UKP19|PI|DL9|_!%>7H!PV^TMSN26Y0?0=?^3^?&OP ME_C^?_1P_9=|?7?@ZSL_@HOQ_|M?
|SFVUO%G|?|?A?3XCZ|8;_XLM=8U3P_XMMM M)5Q9OJ.GWDMK)|_ARS+%(UE"DDIYA3\$1%'
MAJ(OC3X1T^URMYXGL(7|_NM<(#^A-"H":=6G^|Y|ZL4445_&I_K2% %%% !11 M10 4444 %%%% !1110 4444
% %%% !1110 4444 %%%% !1110 4444 %%%% M|1110 4444 %%%% !4=U_V|H:R65W^LD4T926-QD|&#"|5)10!_#_
/0C MP8?AS|4_\$OP|+%CH/B"|TXLW4^1.17/_S7|U|_P_%O#R^\$O^"@_QU|+H MH"Z?80\$UN@3:FW*CI
*|9K|PHSH2C+NDSC)BBB"BBB@ K^M7_@WP|4 M^O= P1Q^!^JERWDZ?V63_T|I>6VA R^7E5?U1_|
|L9J+|5?S*?0ZS>?SD-?>81OEL^VFORD7#<^_*_*_*S4**** "BBB@ HHH MH **** "BBB@ HHHH **** "O_VQ_V5?
A|^-V|_*XP_91^<^LZSL AWQMI8 ML_5O2?#UO^>?Q1B1).O/_%&K90^LHH IE^+|S_P\$^?|H_8G^+6
MA7>M^"E|_V.D|Y|V8KR.6:Q?9KDH@ACN8WACE61 N^4^/EKG)_V\$SX|B|_MZ)^TA^TAXT^)^V@^!_L|7TG0?
\$EH=O#?ZA9OOL|O4&LK2%|R2&0)*JY2%I\$ M5WB=E4K|H10:X\$XX_8TTSQO^VIX)_7X>U;_MGS,W^U:|?
WDJ^;D^<_F&_|+ (9S=8_81|/_^T?XG_!J^7Q=|2?#GQ5X|L M+2V|?
V^BV|E=Z;XB>UG=-K=SVUW)|LHHHSY:S0M^N3B19_#^O% %'G7|_GL MGP^_9ITC7XO"=|J>K:UXO|0S:|XS|5Z|_
|J.O:E(B1FXG;*_)=L4442111 MQQ1QQ*|H^X|_9L_"_QW|8?M%>*O\$|NO>(O\$D^OIFD236HBCT#1(C#)IUL
MNYN^N#+<32Y#32_@('00HGHM%_'@W|OG|\$4?Q0_+|+8OP@^*SG@7XH>&
M^"NH% %TUJM^CU^UU#1:QUE>UN;9WCWF^%=GA=9%V2_MZRHO2NC_8H_8_ ^%G|_M^"|?AW|F/X/S:AK44
% %%% %'SQ_P4|+|H^O< <7|3|_ (ZYS5^

MU%#IKKPYX_9AT7IH32?MYJVH^+3#E">#H%2IUS5=0B5K+3T)X1F+YD MD(VPQ1RS/A(G(F^G!
 (-X&-%BX^*NG77Q1\1>& /OLUO3M<^/ @K3&MHI M;6+JRH0)&'&BIX0^\$VC:)5&AD9W+.W75IK?;#IM_P".G?
 MM:9^P7^U;X8;P>?%PBB?>=&=;'Q7 M\$-GA+G\?;1+<22NTT#E'2X5E6>,L3%"Rf6^J: "BBB@ HHHH ****
 "BBB M@ HHHH **** "BBB@ HHHH |< :|TO| M;|DGO=\$JY:&*UG4^FRIA8 ^.@U^ M85?K1^TOH\3_L|>=
 =%1=SR>&:QHEf72G4?|I**>OZ\|ZREDM>EVJ7^ ^M.5 |;?PSI* ".GO?@L5;2=#E_P#*DW
 .WH**** 6#^80HHHH ^V_AGXJ># MOB1X?|3.VU= .UNTNB<|'|C _*Q*BK3C5I2A+9IK|S;#5YX7\$0K0WBTUZI
 MW1^T%>=|f(/%8|=?"GPURK&FXZIH53X) X)% _C1C\|P4M_C_K|N)KK/X^=G|_D2K^U#|B+X>GX2?L8 _"3
 MX6O;4 ^ASX9Z%ILD9&""@T^"-L ^5;?>OC>|JEL+2AWDWIR X)<_SU"BBBOS MTU/G'H7IG_-
 (*>*_VC|%^G|O|>>A^" "T'A|;KWPU|9 _#'/7=-NIO+ M(V^6&ZM+E)=KJA02A?W;|X)%= ^SY^S7;?K6?
 \$7Q;|8^-|KOC|0?&:6O _M EGC&^LH|8S06RNMK96UO'E;6S@|V8QP@NVZ:6222621Y&|/HH ^2O^"@/_ M 3J^O|:?
 QI^" QD|(_M0^&O|EE|_ '\$47B00|&OOAE|JTFHWPBJBF.XG75K8 M>40KC"1JPW>..?9/VJ_A|' XT?LL>(_A|_#_VB|!-
 _B%JVDPP:9|O|T(M3+HRLD:RRIVTDC%5D59(P|9HQ+N#R@GU&B@#X^;E_8 _A_Y^! P|'^ MW@# _(#26G@-
 /#5E8R>_M6N?@U;W)XUU*V2/\$US#>/OVR6SRH96LS%)&S_MQ95"UC?|3 _@GO_P5*T?XT^%&7f5O_!;#5?B?
 X(|:PFI:EX"TKX%:1X7 M> M6)6:W26L^@RB))Q%"T15EE\$91AAB1|M44 >6?M6?|QA^TAX2TOX_6_B2VT
 MSP5&JJ/B;JR2+>:KHR(S|9^WC^O5|_P|O M^|B|QO|L6>|Z31=\$7Z"96|
 HULFS02Q3VDR19566*>""+RH9)MRN<
 MCV:B@#Y2^!O|"WOFO/VX-;U:Q|=>&K_Q/X6^\$D7@+PKHO@^&X^R:7N/M% MJT5W
 5O;X5%MUI2&,\$\$29CO^U;110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%%
 \$&IZ?ZMIMO15VN8KF|X|I7JRD|1#7XXZ|HHWX>UR|T"-7
 M\$|C=R6|PQT=&G|O_-96ORP_-2|'OX)_A|8Z5Y_Q+G5FOHN."MPHGXI|LR\$?MA7I#X0XM0QV*PK^U&O_
 %M/_T|'H_2IRIUTW399M|^>7|Q|ITDYP& MU/P"2JH_P|VO>:^%O|_@D_1A|OCCGQ|^+;RXPfJ6"7|DC'CS86VN!
 |LD@/T MBKH|<5>.LN>6|4XB%M|G7I/5 _<|KY^F7@OGT>(|#; 56|RIQJE+R+=W5? MUBHR^84445|B?J04444
 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 5^_>W^%G_
 2RNOAE M#?|+WXD>_TA(|#M_VIG4)7_W0UI\$|P"NH">OTOK^=W_@|%;.5C|=?M=? M#W|E_1|2\$MKX|
 (R:GJD4;|W^I2 ^6X_O+;VMNXST%OOU>U|A|GBW;5 _%_C M?2M%\$;CK|JNXH3^CU_*B)&@CC0*JC"J|!>E?
 RD_P#|M|)\$?C;_P %>/AD MTUIYMAX0%_XEU\$|<^6+6UD\$#?^!4EL/QK^K>OSSC*MS8NG2_EC?|W_P#66L%
 M9%%%?%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 5|_
 /!6'P=,^)WASXA00XC|2'MDF4<6WDW9/N4F4 M?1/OO"O_A @I|_O|_A_OV;KO7;#?=>&
 |^4(RH^8Q\$^5*|MDWG _YU M|AP'F^RWBG#SD_=_F^1|O;+ _FLS|I;A?|\$AKCJ4%>=*JQ_|AOFE|%) M?_-
 ZBBBOZHAT0HHHH ****_P^_Q_E^#OOFL_ \$=81;J2"|=-6MGRDR MCW;..|HU^MMKX(K|8J_2?_OW?&A/BH
 3;P|H|UOU7PHH5TZ|5F^9H_V| 38-GN8FK|=16LF=7"IT>(_\$&HQ6=AHK)%M8^S^OC%U?
 R|5^@<X)PH3Q4OM;+T6_WO|C;Z|1117VAF%%%% !1110!^W_/P9 ML?L|O<>*C)^U?
 J5D0MH|CX3T>X*|.97^V7BY|1#8G_@=?O#7P|_P;J_LQ_M^|F+ @E|_K;4=.^SZOX|CF|8ZQE-I=KXJUL2.N?
 L4=H#GN#7W%7Y#GF)^M9 MK5FMD|+Y;?|_HJR"BBBO)*"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@
 HHHH **** "BBB@ HHHH **** "BBB@ JAXK|Z7XR|;CX1UN^S+/5+&6 MTND|8Y\$*_R|J_150G*G-2B|_
 ;HS|T|>=E*G45XR333V;>C1^?C?PEJG@+Q MEJO@G6DQ=Z3J\$UI<8|!-RI|CC|C677TY_P5"^\$/A_PA_OBL_B?
 IMKML _M-I-I+*%NX0J|_T9C|N0Y|_&Z_K_(N?+|1110 5|_P|>1"OCE97>K7?E_MZ)K8&GZSN;"QJS#RYCZ;P2?
 |?|UQORBN+;TT_GU|5NO;|? M_G|QW#F=8?;|&5*E)>=MT_2NFN|1^T (R#17S|_,\$|VC\$^?PG3P1 MXBU#?
 XA|1);S^8WSW-|TBFY|&QCSRH|^ ^ ^@J_D7-LQ_39C4P==>|V| M5T;FM4?ZG<+|19?
 Q9D&S;|_!K%_W6+VE%^<97B_-|1117G^OA1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
 4444 %%%% !1110 M 4\$A068X_ZDT5^_/_PT58P>H4445N 4444 %>|_L0?LTZY^V+^UU|_V8|_27S/&7
 MBJUL+N;\$9_VLR^>ZG^D5NLLA|D>65^SO_!H|^QA_XO^?CKINGQ|H6|30"&
 MGGPUX5FE3Y7U*Z59+J1#V;*VVIGVOJX_TOBP_J5NJ6G|H%^(TKL_?CP_H.C M>%=!L?" AW3HK/3|_
 LXX6PM(%PD\$;_A\$11V"J|I"K=%%?C3;_PHHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
 "BBB@ HHHH **** "BBB@ #R?|_3^>T"*_P^U;O/_M?U731_+C|1EFGB|S&4NA=/_5/M^M^U?
 E07|05^9|/P;X) _6|HTRTQ1?1?4="K44+|^A|L<|LKI7I5X_M3YZHJRJY55>_OP_|
 ;E^32_Q_D'Z3W|;G3P_\$V&C|_J56W;|Z* MT445^W|C_@|13=-^)_A|B|VDFV|/M2^%NK=N)(F MIB_AYPP5NH%?JO|
 #KX@>&|BGX)T|Q_X_OO<=J=N)8' B7LR;_5*P*D=B"*_M_'FOH7|@S|K9_@3XN_X0/QO|'A/6K@>_)
 (W&G7|P|_1#@^QZ_- "0?S7Q\$ MX2>=X/Z|A8WKTULMYIWMZK=|5U1_0O@+XHOX.S9Y1F4|8/\$2T;VIU'9*7E&
 M6BGYM&6B3O|_HW|138I8KB)9X)5=^4.CHV0P/0@|Q3J_G'8_O|-704444 %%% M%% !1110 4444 %%%% !1110 4444
 %%%% !1110 4444 %%%% !1110 444 MV>>>&VA>YN9ECCC4M(|_*|@9)/0^#@B_P|H_P#;%^%G|*7P_|3?
 M#&KQ\$F ME^&?"FEO?G|_N17V3_-,%G_!9 ML_M|?%H_L0?L|C(RWPA|S;HS?VLR>*4CW^O(^!1Y=
 (1T;+2G.Y GYCU M^F<9_|#1057|R7X+MZOK|W|YJ=MH MNC6\$UU>7DZ06EK_QEY)I8*J^HY9B2_I-I-V(?
 \$IOY%#_O_?L>?V;_M6MXAK5C|8OOX%QO|>?K?R?NCN^WUIV&E_YYP|ZX;?&O_3Z;|K^JNE/MVA_&A?
 P9|&Q#JS&_5WK;D_8(>>OELCW)OT-O&_*_IPKX#B_%.K""0 M>D=7Z|!EK|S2"ZA1117Q1H%%%% !1110 4444
 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>0_MK_L_P#"_P#X
 M+7>F;3A|_TE>O45V9?C1EF.IXN@|3@TUAN_MC|GL_@G;E6BXR^?5=FG9H&DS|8^1XG_9Y;|^>LX+KWE?<
 ^E+YKJ?U|X^_M/#TZ7# MG\$-6T5;_&K)Z);*G_O9=(2>WPO2S_M>BD5E=0Z_""@@|_4M?B|_8X4444 %M%%%
 !1110 4444 %%%% !1110 4444 %%%

%%%%%%%%111104444%%%%%%%%111104444M%%%%%%%%111104444%%%%%%%%111104444%%%%%%%%111104444%%%%%%%%'QC_P%
M\$OV.F-Y^T+L.RV#XITV.LOK=H!Y\$W_P'^^+9IT25#'(96&5A MD\$>E?
/I=[L\$OPJO.CXO.O3&PSU.P',O'OP>EAZE3B?)*=X.JI.*^M.JL5.*JYKH>VHHHKJFY('BBB@ HHHH *****
P3SVLZ7.M,17FN399G6JCC.2FNEJUZ.KY.CX.XNXCXQWUK*.3*E+JEK&7E*+O M&2J4I=#17_@S^U\$OCQ;H/
7C*\$WQZ.FCWVGN/U=L2GJLA9?>00.&&M.VF2XMYFGDC8.CHQ!4CH01T>V_3_@H+^T+BTZZI2)XCT^/
%IX@4S.MJ.LP(D'3+LZ5^OYUX35X.U.KJR.EGH.E)/YI>I.57"/TH<'5C&AQ'A7M'7./REK'U=-OF7GRREY11^F.
%?./PT_X*F?17Q*L=I10#VI^&KEL>9.B?+M8>^Z.'3V+/UKW?P+LOA'13\$4^
OB1HVJNPSJGM;I#./K'G>OX@5^9YEPIC MF4M_6I/**76UX_|@2NOO/Z)X?XIX.XHBGEF.IU&L|UI_|
@K\$37_@YI%%M%>*27!11104444%%%%%%%%117F2QX.;_9*_92LL:WHH;H+P5X.,4>_I+KWB
M.WMIF08SB.IGV4X.A123Z5^7/I47_IVO.P3X^\$8N=(9W)&^+?BMJ<8807-
MM.'1I+=AV.ITOGCGNMQSIGMPV78I/&IS3;I:??L)M(5*OGHM;_(*C M?L-?
I\$='DNOYF/COI>F:KY/F6GA33V^V:Q=CY=EI%EU5N/DDV1^KBOYZ.VMRA@YF_X*?M42?_#_@:QI9_?PY/N5=-
^L0WK(>GF.A(6N_X00F\$^I M7Y.WKFM>)M8N?\$/B36+K4+^I\$.:OKZX.6:>1CEG=V)9F)Y)))?48:@^K)
MJ6*G9=HZOHE^)#GV/U:_P'''C?_P=7_+4'I0POOAM^Q'HEQ!*/'4VZ)O\$4
MTB2^(KV,19\$BYCL,CM%OD4C(F'2ORFUI7I=15:W=^)?%&M7>I:C?W#3WVH7I
MRTTIO*QRTDCN2SL22222J45H@|A.I3Y*\$SOS2JHV0VY%%%%%%%%=8@HHHH_*M***"BBB@K^A?XJ_^(GPV:2-
.%I?VK?!"C|OFT/HW5>AXP.^9*_9Z:&&YA>MWN(5DCD4K)&Z@IRD8((451?MF?
I\$|+G17NOBG^S_HI361W2ZGX9MURIOW.MENO5DI8QRO|_#D?
*OHP/XAPO^CE^:SM/-I12I*3IH=>NNK_BIQD|ZN^G M4SSAJE>DIRJ4(K6'>5+>5P6L?
LWGLX^HI2"Y1""#R#25^QGFA11104M444%%%%%%%%111104444AT8JRG(G.#244IL=OX0_6^/_@:GA:XOZ;Q)I
MRWDUY81_P|LY^R?I7HWAUW@L^U/H@U'7I)U?'_01T>-<_I^/+KP&BO^Q7M#^18YMU|_3D^|BK_'VN?
599QUQGDR4<%F:G%=%4GR_^WY?P/T.^\$W|GB
MO7OV/OB1^U^10#FDPGCP#I>J7S6^G"6**>.RT_16X8NIEB7!VG)M/B'_.#SG@_9/V_P_IJ^V_&%Y!X+_X(A_I06MW!"^+
MJ7P_16I@GNTVG.^+^N17MI2B\$|CRBK6G_@J2Y(5.6*3.2LM=GW/I'_#C'9E MF'F78O'5'4K5*492DIWS:IOY_'LW_
>=.\$1F.F?L:+"-ORB?XBS2\$-MZG%BN1I?K7&^/_@|@:_#048>_2V3?AHC\$?(=8N|0O@#|B.:#/Z5^/5%=,M>^(9-
/M90>S06GE1L/8K MBOG>BNVCEN7T:=-**2O|XKL?7#W=Y661RS.Q.223R2?6F44 M5VB"BBB@ HHHH *****
"BBB@ HHJ6PL+I5;Z2I+LLFYN95BM|>WC+R2R.O M%15'+20_!R2:(J_9/_(('P_!O+?_
IONM&:_9_P|%26_@E.QWO@CP|J_M<I5_>X:|O(VY6SZ.D1YN.&8>5@3>H2I\$-^#:/PQ+H_17O_!1P:DFHH8
M|SPG|^OB#):D8:YU1#PTG0K:'A>/_RV8E_.Q55%"(H_P!P!7PV?<2))X_M;/_RWM+=+6U@2**)D<<:A510_#@
#M3Z**^\$-MHHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"B MBB@ HHHH *****"BBB@
HHHH *****"BBB@ HHHH *****"BBB@ HHHH ^?2 MYMO^"?OACXS/<^/OA=IFT.O.V9+F KMM=2;J2^/I7(IX&"?
O#GZ/@|>JD%3W!P*_3N\$O\$7%Y.HX7'WJ45HGJH" M|OYEY/5='I8_G3Q1|KXLE/LDY:&+>LH4ZC|TO@F_YDK-
_\$KMR7Y+T5I5_M^TG^PY15_P|G^:27+V?7O#2DLFLV.)S O|TWC&3%-ODENNZ>TD^DHMH&%%
M%=%=QXP4444%%%%%%%%111104444>O_|.12O5HX>?I&U_C_4/<1W&H6%G:N
M3_%=>);>Q^+FOYH*_H_|X+Y>H|AW_P^&FA>?99I&WBO5/#=E\$|C9I&MU"Y6Q/X5_.7X/ET.XG&5?
YH1_*Y_JOP7AOI?I?N6T/Y/17W4XH****|O_M^E"BBB@ HHHH *****"BBB@ HHHH ***1_ (08?&Z?6OI?TVG?
%_XM6M MW|/A;_LF&OZO8D:CK\$)YQ86KX)5AC%Q)MBPVY/P5KGO6+PV"1.I6DHK^MN
MXTFSXN_9E_99^/W|8OO:T_X(2LW?#+40%/B/46REI81?);Q9:>>5L)!"N1N MDD*J.CG)A_2_P1S_X-
I/@9_P3HM|XW_&R6P|>?&(Q|TU9H"VG>_&(^9+M|^+291CSKNX(W2MR<+PB:B\$5%XKV2OSK.)^/^O2H>
I3_%^O9>7WFD8VW"BBBO MF"PHHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****M
"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ HHHH *****"BBB@ HHHH M*****"BBB@!1)\$X MOP#P>;X>-6'2_P
47WC)6E%=:f0)CX\$?LX_%^XZD+XB^\$HH+=GVV^J6_M_P|M)_I4<9H6PWJ?7#5^S.IZ7IFMZ?
+I.LZ=!=VMPA2>VNH5DCD4I0RL" M"/8U|X?&|_@F5|('I2ZSLV3PGJ+Y8V49FLI#_P!%S+SHU%TGQ?
JKIKS5TPHH MHKK/+"BBB@ HHJ2TMLVZBLXIEY9%1!ZDG_H;25V-)R=D7?^#K&Y@|.1\$G_M((
6(67_A8.D.B=|MOH5_&?R.R_G7|U?N|_P>8^)+G1O OI.WPULV LIF M|1WDJYY#6T6F11.N,YK#\$8G#X6
M'/6DHS8)GQ_7TM^P5_P21_>F_X*.:S&OI/PAN%|B?R|IOSX@+6>C6N#A
MOWI*3.RIXX%DD&IE0.;=3I@W_@UL_8_9_EE_&OIOTEQ|90%=OM?XBM;Z M)|C.2DTI683=P?
M#RJ>#L4U^EFBZ)HWA02+P_X=TBUL+"R@6&SLK*W6*&"-M1A41%55_&_17R.8<74H7AA(W?SV^2W?
SL.'<_S_@FE_P&UGI^I#| MFG_\$SXT01?KXBI6:/5-?L5&E.9..0:2Q8LK.IZ2S&1J&01'BOT=&_*M^*)Q6.Q.-
J^TKR+?X^GYGE.5YUA7AL?0A6IOI.XJ2^YIZ^9I7_\$G_@DRAMEWA(OBCZ^7M8>G?;_VO^A_VG^>\$>?V?<
VG_A17EU#X67NH6Z9Q6YA3J+M4C*F_)?:+OD2EI7 M1?"+3/I_+^AC1MN?M?
B*RAQZ|YT7^M?OB/_@E+I#=#0+2^&_&GB337/1))H M9XU^@.:M_P"/5G_#I_@E|_#KXH:10;#XQFIAT76+>^:QN-
"V-)Y4(<*)!_M0.5^>U5I2>?J^#J*_5QDXNR<);VT5TFOO/D?3?% M_U|^L5I>W+2;H+>4;2+L=|H?6OA>
I_P"#/K_@P?&>V^-?P/G_."*OB75_MU9AG&<2L#CD_|G7YKDN:97ALLI4U4FEJO5MG^@DDVSI**_5Z'_@SU_P'''
ME32P)_CI#50L-DXCUEB|Z@'2AG|Q71^'^#_+|L^YE0>*OVJ_AA9(?OMI M.HW1'7H'@BSVIBO3>?9.O^7R_'(7+
(_ZBOW+I\$?I&8=XTBS_\$?_@H#\$B#&M^UT3XX?#A_X_O^"?AITNOB9I4^BOQ@LWX"OZP|@_&IW_!
(3X>5<1^QOHVN74>HUXPU* MU;S2.I17.KP_@P:QJOX?I?OXO_I CIAX<^#WPJ|^\$!_%AX:T.WL<^#H M-
D"*O'TKS*_&6C_32IOTRN-024_E5_9R_P'#?+@K+^TE+!<1^RKJ2A M'39LM6^<I.2WUO|_0_+PN+TC|G|
M_#;3Q"F1R1INO?9F4I"|H<=&|/I445X>*XIS2OI|J|EK|HO^%BE!SG^MR+ P27_X)Z?L.K;WOI/7L?A^OUFW
*^*_6A.HZKN|LMUDR?=NY>P4445F 4444 %%%%%%%%%111104444 %%%%%%%%%11110 M 4444 %%%%%%%%%11110 4444 %%%%%%%%%
11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%1 M1110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444
%% M9%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 444 M4 %%%%%%%%%11110 4444 %%%%%%%%%
11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 M 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444
%%%%%%%%1 M1110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %M%%11110 4444 %%%%%%%%%
11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 444 M4 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444
%%%%%%%%11110 M 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%1 M1110 4444 %%%%%%%%%
11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %M%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444
%%%%%%%%11110 444 M4 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 M 4444 %%%%%%%%%
11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%1 M1110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444
%%%%%%%%11110 4444 %M%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 444 M4 %%%%%%%%%
11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 M 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444
%%%%%%%%11110 4444 %%%%%%%%%1 M1110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %M%%
11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 4444 %%%%%%%%%11110 444 M4 %%%%%%%%%11110 4444 %%%%%%%%%11110
45^07Q'_P"#O|G'X<\$+7OA|>_L@>-MKE:0=9NM.FN(M=LPLK03-\$7(R_2N1GUK&XC*?V9|HS/QU_X/I+_"O97#
M^<-75)>O|R>:.)^RU?>EK^QM_P_2/P\$;(:@1%?LO^&OV6?%<C7_C365TZ MUU2^UFUDAMF96;>ZH-
Q'RIO6OU*K@Q>"Q6!FH5X|K>O3!HH|17D"_|%OV M'7^*O_"B4_:T^Q|_<9Y?_"#Q5:VINVHOV7?YN=OS?=Z<I*
IGXL_&2X3?M?P2A0OC51I|&Y?Z#:@FZUG7I02UM8_22|LA"H_|D@5RC.FHKG?A9|7IA M?Q@O M^SAX%D^)?
QY^*&B>\$M|CN(I?^T|=U!+>.2>0XC@CW'.DKD86-78|*:.MH MKQ\$X8?|_I0C|B;XR^*+P%|

~~PHKPGJ/B/4+X6=IX7.I"#57F.DX!L90MP.MH.4.KAFC"E8V(/%>QT %%% % !1110 445X%^T/ M!^\$/V>?B1+!-I9~~
~~:EJ M.15I%<&YM:F \$(D!(&&YXQ7H99E689QB?88.GSSM>RLM%UU:IGA<0!39PI@ M%CU #O!MZ)'K7_@=#7O~~
~~.H7W_0* OC P#)'P _!&[PL Z&VS?V2OV6YI6V_:4_:3!\$^ 600 M^/' (3#Q):.<+@X)PAG=0YP"<#)XKY&47"3B!T?~~
~~J5.<*L%.+NFKKT9Z9169 MX!+:>\$ _B'X;M?&'@:Q#::KI5ZF^SU"QF\$D4R_P!Y6'##W"%:=(L**** "BBB M@ HHHH~~
~~***H^) \$NA>#/#>H>,%&I1V6F:38RWFHWDN=D\$\$2%Y)&QSA54D_2 M@"H7#?~~
~~LU M*?!+IK_X(Z#^T=^SEXZB!2^" \$T.LNB:W#9SVXN5BGD@D=7" M1RH5EBD0JZ*04/%=S0 4444~~
~~%%%>4 M1_MP_LF_L6:3I6L?M0?'+1O"*ZIJ\$ M5CHMK>_) +=7\|C!%2&V@5YI?F(194(7N0*/5J)*** "BBB@ HHHH~~
~~**** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH ****~~
~~"BBB@ HHHH **** /XF?VH?^3F/B) V/6K P#L+7" MUW7I4A RM7_P#2V6N%KIQI?PH^B.<^KO!@AK _L.O@/_-CU~~
~~M%_Z^EK^O*OY#?^" &O_*6IX#_ /8!1! ?HJ6OZV_ />.O!^I_X?U9K#8_+O3K M"Q'_ =RWIQIDC\ S_AD42H@SOI~~
~~I3C3=GUV?+CTXKID_P""A<\$ _S^P!<?> MXB5XY/@_XF5T<9#_Z5<@=@CN^%?VM==TWJB7_@Y(^%W!8_QUOH?~~
~~#_P+OBI M#;CP!%XYU1Q%ING:!'=RW26US.WR0&1\$MPC.0&.C=HW(^HO^"E_!4OP>MOV0 M?&_P!?!? \$'1?~~
~~\$GQ\$^*?@W4O" _P_?I6AZI%=:AK>IZA:2VTEPQ.S^0C2B2: MWL_V9 AW:6L*QQI>!= (2._%PJ+*(#H_*^ ^~~
~~M"\C3X _+)'I4!_O_ P4VT7X%:E\4/A_-!&+O7E^(?A?24R?1WO!:_." +6\$ M0@KNBCIW;*X"QLH4O'YV!29WQI:_~~
~~<_9F_P""!_!7AGQ7^U9!7I/PKX8TS^R M_#,&MW=E<3)->-%Y<2!(Y^&X1.O;M559F*JI(YSIHG_@H?%OV7OVS?~~
~~AU^ MRH?OQ>B>&=(^) A#5KK0M=UV<06IZI:7_G&MD\SL(X _BN9"F_9X@=_YU5_M@#S3X&?&O_@G-~~
~~_P64:?" +JLWIEWXC:#K'B_X.>(YI4:&XMA:Z_I=I=::>64 MIA=Y?D9W?*W7F>9 MM!::MYH_I.HHHH ****~~
~~"OSA_P""FG_)TEW_@6S_!037Z/5^7_7N7YO/YZ^DS_R:F'_ %_I_P#I-O^?::*** HT_M@_8:X:_/)_I_!MK_~~
~~.B5KI_UO^#LRSM;W_@GS!_HKRV25?^&C?#RR*": M;?4%/7U!(^A_?I3!_!DG>@?I@6U_!1*U^9?I~~
~~P=M^*O#?7AH@/X96VN:~M:6DLWI0_AV:**XN%5GBBMHH7_)R50\$%FZ#(SU%?Q=B?IYGZO\ S_%XRI_D7 MT?!_#^!D?~~
~~5W_4@_P""G^AW_@F\ P_+COS^SIXP!2Z5!1OB!H?A.V!Z*! MJ!+3KN\D?"2H'O))1#%-*L<5LZR>7LWJQ~~
~~KG?"O_!5KQ)9_MV^"OV+VBOV M*/&OPMB ^*^GZGPB\$|Q#/_6DLC:?(2""2.SY=%949L#Q MS_@XX!8^\$;X6?~~
~~LEZC<>)H2WG_?2!"WT,I7B:M8XHGG#9P8U#H2_W0'7) MY%2_!%9_\$OAW2_!@L?_,\$I??~~
~~4M!+QQ%|&D+=:G;Q!+&8WES""59_ D1"0F)97D214^5_AH;OA MD\|^#E+X^P?&CX@:9X;F!8_!PC%X0MM4N!'~~
~~KLPE2'R+*/H!W_9.JL409V M*L IVG^A'I' QW_X)H?L@?M\$?M"2L1_!% =OA5!_?#GQ#TWXS^(/%A?QK!3O_M!%I<1>*_~~
~~U*Y:YMYH[V>!M!S,%9AE955+=8ATBY:"XL+/_A'-O: XML 26_R2.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Income (Unaudited) - USD (\$) shares in Millions, \$ in Millions	3 Months Ended	6 Months Ended
	Oct. 25, 2024	Oct. 27, 2023

Income Statement [Abstract]				
Net sales	\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686
Costs and expenses:				
Cost of products sold, excluding amortization of intangible assets	2,946	2,761	5,707	5,390
Research and development expense	697	698	1,373	1,365
Selling, general, and administrative expense	2,757	2,686	5,412	5,299
Amortization of intangible assets	413	425	827	855
Restructuring charges, net	30	40	77	94
Certain litigation charges, net	0	65	81	105
Other operating income, net	(34)	(31)	(33)	(30)
Operating profit	1,595	1,340	2,873	2,608
Other non-operating income, net	(173)	(154)	(330)	(230)
Interest expense, net	209	180	376	329
Income before income taxes	1,559	1,313	2,827	2,510
Income tax provision	281	402	500	802
Net income	1,278	911	2,327	1,708
Net income attributable to noncontrolling interests	(9)	(2)	(15)	(8)
Net income attributable to Medtronic	\$ 1,270	\$ 909	\$ 2,312	\$ 1,700
Basic earnings per share (usd per share)	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28
Diluted earnings per share (usd per share)	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28
Basic weighted average shares outstanding (shares)	1,282.4	1,330.2	1,288.6	1,330.3
Diluted weighted average shares outstanding (shares)	1,286.9	1,331.9	1,292.5	1,332.8

~~XML 27_R3.htm IDEA: XBRL DOCUMENT~~

Consolidated Statements of Comprehensive Income (Unaudited) - USD (\$) \$ in Millions	3 Months Ended	6 Months Ended
	Oct. 25, 2024	Oct. 27, 2023

Statement of Comprehensive Income [Abstract]				
Net income	\$ 1,278	\$ 911	\$ 2,327	\$ 1,708
Other comprehensive income (loss), net of tax:				
Unrealized gain (loss) on investment securities	35	(19)	111	(38)
Translation adjustment	116	(926)	218	(911)
Net investment hedge	35	915	(170)	771
Net change in retirement obligations	0	1	1	4
Unrealized (loss) gain on cash flow hedges	(27)	324	(93)	294
Other comprehensive income	161	295	69	120
Comprehensive income including noncontrolling interests	1,439	1,206	2,396	1,828
Comprehensive income attributable to noncontrolling interests	(9)	0	(15)	(6)
Comprehensive income attributable to Medtronic	\$ 1,431	\$ 1,206	\$ 2,381	\$ 1,822

~~XML 28_R4.htm IDEA: XBRL DOCUMENT~~

Consolidated Balance Sheets (Unaudited) - USD (\$) \$ in Millions	Oct. 25, 2024	Apr. 26, 2024

Current assets:		
Cash and cash equivalents	\$ 1,394	\$ 1,284
Investments	6,595	6,721
Accounts receivable, less allowances and credit losses of \$195 and \$173, respectively	6,260	6,128
Inventories	5,479	5,217
Other current assets	2,710	2,584
Total current assets	22,438	21,935
Property, plant, and equipment, net	6,438	6,131
Goodwill	41,161	40,986
Other intangible assets, net	12,423	13,225
Tax assets	3,572	3,657
Other assets	4,009	4,047
Total assets	90,042	89,981
Current liabilities:		
Current debt obligations	3,719	1,092

Accounts payable	2,376	2,410
Accrued compensation	1,893	2,375
Accrued income taxes	947	1,330
Other accrued expenses	3,260	3,582
Total current liabilities	12,195	10,789
Long-term debt	24,607	23,932
Accrued compensation and retirement benefits	1,084	1,101
Accrued income taxes	1,432	1,859
Deferred tax liabilities	473	515
Other liabilities	1,534	1,365
Total liabilities	41,326	39,561
Commitments and contingencies (Note 16)		
Shareholders' equity:		
Ordinary shares— par value \$0.0001, 2.6 billion shares authorized, 1,282,553,150 and 1,311,337,531 shares issued and outstanding, respectively	0	0
Additional paid-in capital	20,824	23,129
Retained earnings	30,919	30,403
Accumulated other comprehensive loss	(3,250)	(3,318)
Total shareholders' equity	48,494	50,214
Noncontrolling interests	222	206
Total equity	48,716	50,420
Total liabilities and equity	\$ 90,042	\$ 89,981

~~***XML 29 R5.htm IDEA: XBRL DOCUMENT***~~

Consolidated Balance
Sheets (Unaudited)
(Parenthetical) - USD
Oct. 25, 2024 Apr. 26, 2024
(\$)
\$ in Millions

Statement of Financial Position [Abstract]

Allowances for accounts receivable	\$ 195	\$ 173
Ordinary shares, par value (usd per share)	\$ 0.0001	\$ 0.0001
Ordinary shares authorized (shares)	2,600,000,000	2,600,000,000
Ordinary shares issued (shares)	1,282,553,150	1,311,337,531
Ordinary shares outstanding (shares)	1,282,553,150	1,311,337,531

~~***XML 30 R6.htm IDEA: XBRL DOCUMENT***~~

Consolidated Statements of Equity (Unaudited) - USD (\$) \$ in Millions	Total	Total Shareholders' Equity	Ordinary Shares	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss	Noncontrolling Interests
Beginning balance (shares) at Apr. 28, 2023			1,331,000,000				
Beginning balance at Apr. 28, 2023	\$ 51,665	\$ 51,483	\$ 0	\$ 24,590	\$ 30,392	\$ (3,499)	\$ 182
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Net income	797	791			791		6
Other comprehensive income (loss)	(175)	(175)			(175)		
Dividends to shareholders	(918)	(918)			(918)		
Issuance of shares under stock purchase and award plans (shares)			1,000,000				
Issuance of shares under stock purchase and award plans	73	73		73			
Repurchase of ordinary shares (shares)			(2,000,000)				
Repurchase of ordinary shares	(148)	(148)		(148)			
Stock-based compensation	73	73		73			
Ending balance (shares) at Jul. 28, 2023			1,330,000,000				
Ending balance at Jul. 28, 2023	51,366	51,178	\$ 0	24,587	30,265	(3,674)	188
Beginning balance (shares) at Apr. 28, 2023			1,331,000,000				
Beginning balance at Apr. 28, 2023	51,665	51,483	\$ 0	24,590	30,392	(3,499)	182
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Net income	1,708						
Other comprehensive income (loss)	120				122		
Ending balance (shares) at Oct. 27, 2023			1,330,000,000				
Ending balance at Oct. 27, 2023	51,647	51,460	\$ 0	24,580	30,256	(3,377)	187
Beginning balance (shares) at Jul. 28, 2023			1,330,000,000				
Beginning balance at Jul. 28, 2023	51,366	51,178	\$ 0	24,587	30,265	(3,674)	188
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Net income	911	909			909		2
Other comprehensive income (loss)	295	297			297		(2)
Dividends to shareholders	(918)	(918)			(918)		
Issuance of shares under stock purchase and award plans (shares)			2,000,000				
Issuance of shares under stock purchase and award plans	35	35		35			
Repurchase of ordinary shares (shares)			(2,000,000)				
Repurchase of ordinary shares	(189)	(189)		(189)			
Stock-based compensation	146	146		146			
Ending balance (shares) at Oct. 27, 2023			1,330,000,000				
Ending balance at Oct. 27, 2023	\$ 51,647	51,460	\$ 0	24,580	30,256	(3,377)	187
Beginning balance (shares) at Apr. 26, 2024	1,311,337,531		1,311,000,000				
Beginning balance at Apr. 26, 2024	\$ 50,420	50,214	\$ 0	23,129	30,403	(3,318)	206
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Net income	1,049	1,042			1,042		6
Other comprehensive income (loss)	(92)	(92)			(92)		
Dividends to shareholders	(898)	(898)			(898)		
Issuance of shares under stock purchase and award plans (shares)			1,000,000				
Issuance of shares under stock purchase and award plans	87	87		87			
Repurchase of ordinary shares (shares)			(30,000,000)				
Repurchase of ordinary shares	(2,489)	(2,489)		(2,489)			
Stock-based compensation	83	83		83			
Ending balance (shares) at Jul. 26, 2024			1,282,000,000				
Ending balance at Jul. 26, 2024	\$ 48,160	47,947	\$ 0	20,810	30,547	(3,410)	213
Beginning balance (shares) at Apr. 26, 2024	1,311,337,531		1,311,000,000				
Beginning balance at Apr. 26, 2024	\$ 50,420	50,214	\$ 0	23,129	30,403	(3,318)	206
Increase (Decrease) in Stockholders' Equity [Roll Forward]							
Net income	2,327						
Other comprehensive income (loss)	\$ 69				69		

Ending balance (shares) at Oct. 25, 2024	1,282,553,150		1,283,000,000				
Ending balance at Oct. 25, 2024	\$ 48,716	48,494	\$ 0	20,824	30,919	(3,250)	222
Beginning balance (shares) at Jul. 26, 2024			1,282,000,000				
Beginning balance at Jul. 26, 2024	48,160	47,947	\$ 0	20,810	30,547	(3,410)	213
Increase (Decrease) in Stockholders' Equity							
Roll Forward							
Net income	1,278	1,270			1,270		9
Other comprehensive income (loss)	161	161				161	
Dividends to shareholders	(897)	(897)			(897)		
Issuance of shares under stock purchase and award plans (shares)			3,000,000				
Issuance of shares under stock purchase and award plans	103	103		103			
Repurchase of ordinary shares (shares)			(3,000,000)				
Repurchase of ordinary shares	(248)	(248)		(248)			
Stock-based compensation	\$ 159	159		159			
Ending balance (shares) at Oct. 25, 2024	1,282,553,150		1,283,000,000				
Ending balance at Oct. 25, 2024	\$ 48,716	\$ 48,494	\$ 0	\$ 20,824	\$ 30,919	\$ (3,250)	\$ 222

~~***XML 31 R7.htm IDEA: XBRL DOCUMENT***~~

Consolidated	3 Months Ended			
Statements of Equity				
(Unaudited)				
(Parenthetical) - \$ / shares	Oct. 25, 2024	Jul. 26, 2024	Oct. 27, 2023	Jul. 28, 2023
Statement of Stockholders' Equity [Abstract]				
Dividends to shareholders (in dollars per share)	\$ 0.70	\$ 0.70	\$ 0.69	\$ 0.69

~~***XML 32 R8.htm IDEA: XBRL DOCUMENT***~~

Consolidated	6 Months Ended	
Statements of Cash		
Flows (Unaudited) - USD (\$)	Oct. 25, 2024	Oct. 27, 2023
\$ in Millions		
Operating Activities:		
Net income	\$ 2,327	\$ 1,708
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	1,337	1,344
Provision for credit losses	45	37
Deferred income taxes	57	(36)
Stock-based compensation	242	219
Other, net	(98)	182
Change in operating assets and liabilities, net of acquisitions and divestitures:		
Accounts receivable, net	(181)	(117)
Inventories	(278)	(616)
Accounts payable and accrued liabilities	(707)	(699)
Other operating assets and liabilities	(800)	(486)
Net cash provided by operating activities	1,944	1,536
Investing Activities:		
Acquisitions, net of cash acquired	0	(22)
Additions to property, plant, and equipment	(924)	(815)
Purchases of investments	(4,019)	(3,403)
Sales and maturities of investments	4,338	3,336
Other investing activities, net	1	(59)
Net cash used in investing activities	(604)	(963)
Financing Activities:		
Change in current debt obligations, net	(67)	1,321
Issuance of long-term debt	3,209	0
Dividends to shareholders	(1,795)	(1,836)
Issuance of ordinary shares	232	149
Repurchase of ordinary shares	(2,780)	(378)
Other financing activities, net	(64)	153
Net cash used in financing activities	(1,265)	(591)
Effect of exchange rate changes on cash and cash equivalents	35	(214)
Net change in cash and cash equivalents	110	(232)
Cash and cash equivalents at beginning of period	1,284	1,543
Cash and cash equivalents at end of period	1,394	1,311
Cash paid for:		
Income taxes	1,335	1,110
Interest	\$ 513	\$ 476

~~***XML 33 R9.htm IDEA: XBRL DOCUMENT***~~

Basis of Presentation	6 Months Ended
	Oct. 25, 2024
Organization	
Consolidation and Presentation of Financial Statements	
[Abstract]	
Basis of Presentation	

The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. The Company's fiscal years 2025, 2024, and 2023 will end or ended on April 25, 2025, April 26, 2024, and April 28, 2023, respectively.

~~***XML 34 R10.htm IDEA: XBRL DOCUMENT***~~

New Accounting Pronouncements	6 Months Ended
	Oct. 25, 2024
Accounting Standards Update and Change in Accounting Principle	
[Abstract]	
New Accounting Pronouncements	
Recently Adopted Accounting Standards	
As of October 25, 2024, there have been no newly adopted accounting pronouncements that materially impact our consolidated financial statements. Refer to the Company's Annual Report on	

Not Yet Adopted Accounting Standards

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

~~XML 35 R11.htm~~ **IDEA: XBRL DOCUMENT**

Revenue

6 Months Ended
Oct. 25, 2024

[Revenue from
Contract with
Customer \[Abstract\]](#)
[Revenue](#)

Revenue

The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Certain prior period net sales has been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. Refer to Note 17 to the consolidated financial statements for additional information regarding the Company's reporting structure. In addition, starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales has been recast to conform to the new presentation.

The table below illustrates net sales by segment and division and by market geography for the three and six months ended October 25, 2024 and October 27, 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.

(In millions)	World wide			
	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cardiac Rhythm & Heart Failure	\$ 1,578	\$ 1,492	\$ 3,114	\$ 2,938
Structural Heart & Aortic	881	819	1,736	1,633
Coronary & Peripheral Vascular	643	613	1,259	1,202
Cardiovascular	3,102	2,923	6,108	5,773
Cranial & Spinal Technologies	1,234	1,157	2,382	2,260
Specialty Therapies	737	705	1,450	1,400
Neuromodulation	480	426	937	846
Neuroscience	2,451	2,288	4,768	4,506
Surgical & Endoscopy	1,649	1,641	3,193	3,187
Acute Care & Monitoring	478	462	930	921
Medical Surgical	2,128	2,103	4,123	4,107
Diabetes	686	610	1,333	1,189
Reportable segment net sales	8,366	7,923	16,333	15,575
Other operating segment ⁽¹⁾	37	61	75	111
Other adjustments ⁽²⁾	—	—	(90)	—
Total net sales	\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686

(In millions)	U.S.		International		U.S.		International	
	Three months ended		Six months ended		October 25, 2024		October 27, 2023	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cardiovascular	\$ 1,434	\$ 1,427	\$ 1,668	\$ 1,496	\$ 2,836	\$ 2,776	\$ 3,272	\$ 2,996
Neuroscience	1,677	1,560	774	728	3,242	3,057	1,526	1,449
Medical Surgical	944	948	1,183	1,155	1,825	1,815	2,298	2,292
Diabetes	232	217	455	394	447	405	886	784
Reportable segment net sales	4,286	4,151	4,080	3,772	8,350	8,054	7,983	7,521
Other operating segment ⁽¹⁾	18	23	19	37	37	45	38	66
Other adjustments ⁽²⁾	—	—	—	—	—	—	(90)	—
Total net sales	\$ 4,304	\$ 4,175	\$ 4,099	\$ 3,809	\$ 8,387	\$ 8,099	\$ 7,931	\$ 7,587

- (1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.
(2) Incremental Italian payroll accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.

The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At October 25, 2024, \$1.0 billion of rebates were classified as *other accrued expenses*, and \$639 million of rebates were classified as a reduction of *accounts receivable* in the consolidated balance sheet. At April 26, 2024, \$1.0 billion of rebates were classified as *other accrued expenses*, and \$574 million of rebates were classified as a reduction of *accounts receivable* in the consolidated balance sheet.

Deferred Revenue and Remaining Performance Obligations

Deferred revenue at October 25, 2024 and April 26, 2024 was \$467 million and \$453 million, respectively. At October 25, 2024 and April 26, 2024, \$369 million and \$352 million was included in *other accrued expenses*, respectively, and \$98 million and \$101 million was included in *other liabilities*, respectively. During the six months ended October 25, 2024, the Company recognized \$196 million of revenue that was included in deferred revenue as of April 26, 2024. During the six months ended October 27, 2023, the Company recognized \$216 million of revenue that was included in deferred revenue as of April 28, 2023.

Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At October 25, 2024, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately \$0.4 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years.

~~XML 36 R12.htm~~ **IDEA: XBRL DOCUMENT**

Acquisitions and
Dispositions

6 Months Ended
Oct. 25, 2024

[Business
Combination, Asset
Acquisition, and Joint
Venture Formation
\[Abstract\]](#)
[Acquisitions and
Dispositions](#)

Acquisitions and Dispositions

Acquisition Activity

During the three and six months ended October 25, 2024, the Company had no acquisitions that were accounted for as business combinations. During the fiscal year ended April 26, 2024, the Company had acquisitions that were accounted for as business combinations. For the three and six months ended October 25, 2024 and the fiscal year ended April 26, 2024, purchase price allocation adjustments were not significant.

Fiscal year 2024

The acquisition date fair value of net assets acquired during the fiscal year ended April 26, 2024 was \$335 million. Based on preliminary valuations, assets acquired were primarily comprised of \$131 million of goodwill, \$150 million of IPR&D, and \$29 million of technology-based intangible assets with estimated useful lives of 10 years. For tax purposes, \$51 million of goodwill is deductible while \$80 million is not deductible. The IPR&D was placed into service as a definite-lived intangible asset during the second quarter of fiscal year 2025. The Company recognized \$30 million of non-cash contingent consideration liabilities in connection with these business combinations during the fiscal year ended April 26, 2024, which are comprised of revenue and product development milestone-based payments.

Contingent Consideration

Certain of the Company's business combinations involve potential payment of future consideration that is contingent upon the achievement of certain product development milestones and/or contingent on the acquired business reaching certain performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the change in fair value is recognized within *other operating income, net* in the consolidated statements of income.

The fair value of contingent consideration liabilities at October 25, 2024 and April 26, 2024 was \$124 million and \$149 million, respectively. At October 25, 2024, \$77 million was recorded in *other accrued expenses*, and \$47 million was recorded in *other liabilities* in the consolidated balance sheet. At April 26, 2024, \$96 million was recorded in *other accrued expenses*, and \$53 million was recorded in *other liabilities* in the consolidated balance sheet.

The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:

(In millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
	\$	\$	\$	\$
Beginning balance	128	206	149	206
Purchase price contingent consideration	—	25	—	25
Payments	(8)	—	(14)	(3)
Change in fair value	4	(10)	(11)	(7)
Ending balance	\$ 124	\$ 220	\$ 124	\$ 220

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:

(In millions)	Fair Value at October 25, 2024	Unobservable Input	Range	Weighted Average ⁽¹⁾
Revenue and other performance-based payments	\$58	Discount rate	16.5% - 28.2%	22.1%
		Projected fiscal year of payment	2025 - 2029	2027
Product development and other milestone-based payments	\$66	Discount rate	5.5%	5.5%
		Projected fiscal year of payment	2025 - 2027	2025

(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.

On April 1, 2023, the Company and DaVita Inc. ("DaVita") completed the transaction for the Company to sell half of its Renal Care Solutions (RCS) business. In connection with the sale, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2026 through 2029. The fair value of the contingent consideration receivable at October 25, 2024 and April 26, 2024 was \$61 million and \$58 million, and was recorded in *other assets* in the consolidated balance sheet.

The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
	\$	\$	\$	\$
Beginning balance	58	152	58	195
Change in fair value	3	—	3	(43)
Ending balance	61	152	61	152

~~[XML 37 R13.htm](#) IDEA: XBRL DOCUMENT~~

Restructuring and Other Costs

[Restructuring and Related Activities](#)
[\[Abstract\]](#)
[Restructuring and Other Costs](#)

6 Months Ended
Oct. 25, 2024

Restructuring and Other Costs

Restructuring and associated costs for the three and six months ended October 25, 2024 were \$46 million and \$108 million, respectively, as compared to \$91 million and \$182 million for the three and six months ended October 27, 2023, respectively. Restructuring and associated costs primarily related to employee termination benefits and facility consolidations to support cost reduction initiatives.

Employee-related costs primarily consist of termination benefits provided to employees who have been involuntarily terminated. Associated and other costs primarily include salaries and wages of employees that are fully-dedicated to restructuring activities, consulting expenses, and asset write-offs.

The following table presents the classification of restructuring and associated costs in the consolidated statements of income:

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
	\$	\$	\$	\$
Cost of products sold	11	15	20	30
Selling, general, and administrative expenses	6	36	11	57
Restructuring charges, net	30	40	77	94
Total restructuring and associated costs	46	91	108	182

The following table summarizes the activity for the six months ended October 25, 2024:

(in millions)	Employee Termination Benefits		Associated and Other Costs		Total
April 26, 2024		\$ 136	\$ 11		\$ 147
Charges		87	31		118
Cash payments		(156)	(25)		(181)
Settled non-cash		—	(4)		(4)
Accrual adjustments ⁽¹⁾		(10)	—		(10)
October 25, 2024		\$ 58	\$ 13		\$ 70

⁽¹⁾Accrual adjustments primarily relate to certain employees identified for termination, finding other positions within the Company.

~~[XML 38 R14.htm](#) IDEA: XBRL DOCUMENT~~

Financial Instruments

[Investments](#)
[\[Abstract\]](#)
[Financial Instruments](#)

6 Months Ended
Oct. 25, 2024

Financial Instruments

Debt Securities

The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at October 25, 2024 and April 26, 2024:

(in millions)	October 25, 2024				Balance Sheet Classification	
	Cost	Unrealized Gains	Unrealized Losses	Fair Value	Investments	Other Assets
	\$	\$	\$	\$	\$	\$
Level 1:						
U.S. government and agency securities	538	—	(11)	527	527	—
Level 2:						
Corporate debt securities	3,429	13	(59)	3,384	3,384	—
U.S. government and agency securities	874	—	(28)	845	845	—
Mortgage-backed securities	772	3	(33)	742	742	—
Non-U.S. government and agency securities	9	—	—	9	9	—
Other asset-backed securities	1,051	5	(3)	1,053	1,053	—
Total Level 2	6,134	22	(124)	6,032	6,032	—
Level 3:						
Auction rate securities	36	—	(3)	33	—	33
Total available-for-sale debt securities	\$ 6,708	\$ 22	\$ (138)	\$ 6,592	\$ 6,559	\$ 33

(in millions)	April 26, 2024				Balance Sheet Classification	
	Cost	Unrealized Gains	Unrealized Losses	Fair Value	Investments	Other Assets
	\$	\$	\$	\$	\$	\$
Level 1:						
U.S. government and agency securities	494	—	(22)	472	472	—
Level 2:						
Corporate debt securities	3,953	4	(125)	3,832	3,832	—
U.S. government and agency securities	847	—	(43)	804	804	—
Mortgage-backed securities	692	1	(50)	643	643	—
Non-U.S. government and agency securities	5	—	—	5	5	—
Other asset-backed securities	941	2	(9)	934	934	—
Total Level 2	6,438	7	(227)	6,218	6,218	—
Level 3:						
Auction rate securities	36	—	(3)	33	—	33
Total available-for-sale debt securities	\$ 6,968	\$ 7	\$ (252)	\$ 6,723	\$ 6,690	\$ 33

The amortized cost of debt securities excludes accrued interest, which is reported in *other current assets* in the consolidated balance sheets.

The following tables present the gross unrealized losses and fair values of the Company's available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 25, 2024 and April 26, 2024:

(in millions)	October 25, 2024				October 25, 2024	
	Less than 12 months		More than 12 months		Unrealized Losses	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses		
Corporate debt securities	\$ 565	\$ (7)	\$ 1,645	\$ (51)		
U.S. government and agency securities	216	(2)	713	(37)		
Mortgage-backed securities	—	—	535	(33)		
Other asset-backed securities	—	—	212	(3)		
Auction rate securities	—	—	33	(3)		
Total	\$ 782	\$ (10)	\$ 3,137	\$ (128)		

(in millions)	April 26, 2024				April 26, 2024	
	Less than 12 months		More than 12 months		Unrealized Losses	
	Fair Value	Unrealized Losses	Fair Value	Unrealized Losses		
Corporate debt securities	\$ 661	\$ (10)	\$ 2,448	\$ (116)		
U.S. government and agency securities	177	(4)	730	(61)		
Mortgage-backed securities	—	—	582	(50)		
Other asset-backed securities	—	—	502	(9)		
Auction rate securities	—	—	33	(3)		
Total	\$ 838	\$ (14)	\$ 4,296	\$ (238)		

The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the three and six months ended October 25, 2024 and October 27, 2023. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement.

Activity related to the Company's available-for-sale debt securities portfolio is as follows:

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
	\$	\$	\$	\$
Proceeds from sales	2,087	1,573	4,244	3,320
Gross realized gains	7	6	14	11
Gross realized losses	(6)	(3)	(13)	(15)

The contractual maturities of available-for-sale debt securities at October 25, 2024 is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

(in millions)	Amortized Cost	Fair Value
Due in one year or less	\$ 1,488	\$ 1,478
Due after one year through five years	3,322	3,248
Due after five years through ten years	750	749
Due after ten years	1,148	1,117
Total	\$ 6,708	\$ 6,592

Interest income is recognized in *other non-operating income, net*, in the consolidated statements of income. During the three and six months ended October 25, 2024, there were \$137 million and \$249 million of interest income, respectively. During the three and six months ended October 27, 2023, there was \$148 million and \$259 million of interest income, respectively.

Equity Securities, Equity Method Investments, and Other Investments

The Company holds investments in equity securities with readily determinable fair values, equity method investments for which the Company has elected the fair value option, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments for which the Company has elected the fair value option are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses a discounted cash flow methodology, taking into consideration various assumptions including discount rate, and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values, and that are not accounted for via the fair value option, are included within Level 3 of the fair value hierarchy, as they are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.

The following table summarizes the Company's equity and other investments at October 25, 2024 and April 26, 2024, which are classified as primarily *other assets* in the consolidated balance sheets:

(in millions)	October 25, 2024	April 26, 2024
Investments with readily determinable fair value (marketable equity securities)	\$ 34	\$ 28
Investments for which the fair value option has been elected	311	311
Investments without readily determinable fair values	826	859
Equity method and other investments	92	84
Total equity and other investments	\$ 1,265	\$ 1,282

Gains and losses on the Company's portfolio of equity and other investments are recognized in *other non-operating income, net* in the consolidated statements of income. During the three and six months ended October 25, 2024, there were \$10 million of net unrealized losses and \$7 million of net unrealized gains, respectively, on equity securities and other investments still held at October 25, 2024. During the three and six months ended October 27, 2023, there were \$7 million and \$70 million, respectively, of net unrealized losses on equity securities and other investments still held at October 27, 2023.

Mozarc Medical Investment

As further described in Note 4, on April 1, 2023, the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50 percent equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.

Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in *other non-operating income, net* in the consolidated statements of income. During the three and six months ended October 25, 2024 and October 27, 2023, the change in fair value was not significant.

~~XML 39 R15.htm IDEA: XBRL DOCUMENT~~

Financing
Arrangements
[Debt Disclosure \[Abstract\]](#)
[Financing Arrangements](#)

6 Months Ended
Oct. 25, 2024

Financing Arrangements

Commercial Paper

The Company maintains commercial paper programs that allow the Company to issue U.S. dollar or Euro-denominated unsecured commercial paper notes. The aggregate amount outstanding at any time under the commercial paper programs may not exceed the equivalent of \$3.5 billion. Commercial paper outstanding at October 25, 2024 was \$899 million. During the three and six months ended October 25, 2024, the commercial paper outstanding had a weighted average original maturity of 13 days and 14 days, respectively and a weighted average interest rate of 5.23 percent and 5.34 percent, respectively. Commercial paper outstanding at April 26, 2024 was \$1.1 billion. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing Credit Facility, as defined below.

Line of Credit

The Company has a \$3.5 billion five-year unsecured revolving credit facility (Credit Facility), which provides back-up funding for the commercial paper programs described above. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At October 25, 2024 and April 26, 2024, no amounts were outstanding under the Credit Facility.

Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company's long-term debt ratings, assigned by Standard & Poor's Ratings Services and Moody's Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with the covenants under the Credit Facility.

Debt Obligations

The Company's debt obligations consisted of the following:

(in millions)	Maturity by Fiscal Year	October 25, 2024	April 26, 2024
Current debt obligations	2025 - 2026	\$ 3,719	\$ 1,092
Long-term debt			
0.250 percent six-year 2019 senior notes	2026	—	1,070
2.625 percent three-year 2022 senior notes	2026	—	535
0.000 percent five-year 2020 senior notes	2026	—	1,070
1.125 percent eight-year 2019 senior notes	2027	1,620	1,606
4.250 percent five-year 2023 senior notes	2028	1,000	1,000
3.000 percent six-year 2022 senior notes	2029	1,080	1,070
0.375 percent eight-year 2020 senior notes	2029	1,080	1,070
3.650 percent five-year 2024 senior notes	2030	918	—
1.625 percent twelve-year 2019 senior notes	2031	1,080	1,070
1.000 percent twelve-year 2019 senior notes	2032	1,080	1,070
3.125 percent nine-year 2022 senior notes	2032	1,080	1,070
0.750 percent twelve-year 2020 senior notes	2033	1,080	1,070
4.500 percent ten-year 2023 senior notes	2033	1,000	1,000
3.375 percent twelve-year 2022 senior notes	2035	1,080	1,070
4.375 percent twenty-year 2015 senior notes	2035	1,932	1,932
3.875 percent twelve-year 2024 senior notes	2037	918	—
6.550 percent thirty-year 2007 CIFSA senior notes	2038	253	253
2.250 percent twenty-year 2019 senior notes	2039	1,080	1,070
6.500 percent thirty-year 2009 senior notes	2039	158	158
1.500 percent twenty-year 2019 senior notes	2040	1,080	1,070
5.550 percent thirty-year 2010 senior notes	2040	224	224
1.375 percent twenty-year 2020 senior notes	2041	1,080	1,070
4.500 percent thirty-year 2012 senior notes	2042	105	105
4.000 percent thirty-year 2013 senior notes	2043	305	305
4.150 percent nineteen-year 2024 senior notes	2044	648	—
4.625 percent thirty-year 2014 senior notes	2044	127	127
4.625 percent thirty-year 2015 senior notes	2045	1,813	1,813
1.750 percent thirty-year 2019 senior notes	2050	1,080	1,070
1.625 percent thirty-year 2020 senior notes	2051	1,080	1,070
4.150 percent twenty-nine-year 2024 senior notes	2054	756	—
Finance lease obligations	2026 - 2036	50	55
Deferred financing costs	2027 - 2054	(125)	(110)
Debt discount, net	2027 - 2054	(56)	(55)
Total long-term debt		\$ 24,607	\$ 23,932

Interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums is recognized in *interest expense, net* in the consolidated statements of income. During the three and six months ended October 25, 2024, there was \$252

million and \$469 million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums. During the three and six months ended October 27, 2023, there was \$230 million and \$427 million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums.

Senior Notes

The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.

On June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of €3.0 billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately \$3.2 billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.

Financial Instruments Not Measured at Fair Value

At October 25, 2024, the estimated fair value of the Company's Senior Notes was \$25.3 billion compared to a principal value of \$27.4 billion. At April 26, 2024, the estimated fair value was \$21.2 billion compared to a principal value of \$24.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

~~XML 40 R16.htm IDEA: XBRL DOCUMENT~~

Derivatives and
Currency Exchange
Risk Management
[Derivative Instruments and Hedging Activities Disclosure \[Abstract\]](#)

6 Months Ended
Oct. 25, 2024

Derivatives and Currency Exchange Risk Management

The Company uses derivative instruments and foreign currency denominated debt to manage the impact that currency exchange rate and interest rate changes have on reported financial statements. The Company does not enter into derivative contracts for speculative purposes.

Fair Value Hedges

Beginning in the first quarter of fiscal year 2025, the Company began using foreign currency forward contracts designated as fair value hedges to manage its exposure to changes in the fair value of its fixed-rate debt obligation.

At inception, foreign currency forward contracts are designated as fair value hedges. Changes in the fair value of these derivatives are reported as a component of *other operating income, net*. Amounts excluded from the assessment of effectiveness are recognized in *interest expense, net* on a straight-line basis over the term of the hedge. During the three and six months ended October 25, 2024, after-tax unrealized losses related to included components in *other operating income, net* were not significant. During the three and six months ended October 25, 2024, amounts related to excluded components that are amortized in *interest expense, net* over the life of the hedging instrument were not significant. Cash flows related to the Company's derivative instruments designated as fair value hedges are reported as financing activities in the consolidated statements of cash flows. Cash flows attributed to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.

Cash Flow Hedges

The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.

At inception, foreign currency forward and option contracts are designated as cash flow hedges. Changes in the fair value of these derivatives are reported as a component of *accumulated other comprehensive loss* until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.

The Company's cash flow hedges will mature within the subsequent three-year period. At October 25, 2024 and April 26, 2024, the Company had \$139 million and \$229 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in *accumulated other comprehensive loss*. The Company expects that \$108 million of after-tax net unrealized gains at October 25, 2024 will be recognized in the consolidated statements of income over the next 12 months.

Net Investment Hedges

The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts.

For instruments that are designated as net investment hedges, the gains or losses are reported as a component of *accumulated other comprehensive loss*. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in *interest expense, net* on a straight-line basis over the term of the hedge. During the three and six months ended October 25, 2024, the Company recognized \$47 million and \$98 million, respectively, in after-tax unrealized gains representing excluded components in *interest expense, net*. During the three and six months ended October 27, 2023, the Company recognized \$50 million and \$99 million, respectively, in after-tax unrealized gains representing excluded components in *interest expense, net*. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.

Undesignated Derivatives

The Company uses foreign currency forward exchange contracts to offset the Company's exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows.

These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company's undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.

Outstanding Instruments

The following table presents the contractual amounts of the Company's outstanding instruments:

(in billions)	Designation	As of	
		October 25, 2024	April 26, 2024
Currency exchange rate contracts ⁽¹⁾	Fair value hedge	\$ 1.1	\$ —
Currency exchange rate contracts	Cash flow hedge	11.3	10.4
Currency exchange rate contracts ⁽²⁾	Net investment hedge	7.5	7.4
Foreign currency-denominated debt ⁽³⁾	Net investment hedge	19.4	17.1
Currency exchange rate contracts	Undesignated	4.7	5.9

- (1) At October 25, 2024, includes derivative contracts with a notional value of €1.0 billion, or \$1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.
(2) At October 25, 2024, includes derivative contracts with a notional value of €5.0 billion, or \$5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of ¥322.2 billion, or \$2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033.
(3) At October 25, 2024, includes €18.0 billion, or \$19.4 billion, of outstanding Euro-denominated debt designated as hedges of a portion of our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.

Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments

The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three and six months ended October 25, 2024 and October 27, 2023 were as follows:

	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				(Gain) Loss Reclassified into Income				
	Three months ended		Six months ended		Three months ended		Six months ended		
(in millions)	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	Location of (Gain) Loss in Income Statement
Cash flow hedges									
Currency exchange rate contracts	\$ —	\$ (394)	\$ 42	\$ (398)	\$ (3)	\$ (75)	\$ (39)	\$ (125)	Other operating income, net
Currency exchange rate contracts	20	(75)	—	(109)	(21)	(15)	(39)	(19)	Cost of products sold
Net investment hedges									
Foreign currency-denominated debt	(91)	(725)	160	(612)	—	—	—	—	N/A
Currency exchange rate contracts	52	(190)	12	(160)	—	—	—	—	N/A
Total	\$ (19)	\$ (1,384)	\$ 214	\$ (1,278)	\$ (24)	\$ (89)	\$ (78)	\$ (145)	

The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements during the three and six months ended October 25, 2024 and October 27, 2023 were as follows:

(in millions)	(Gain) Loss Recognized in Income				Location of (Gain) Loss in Income Statement
	Three months ended		Six months ended		
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	
Currency exchange rate contracts	\$ (35)	\$ 94	\$ (45)	\$ 92	Other operating income, net

Balance Sheet Presentation

The following table summarizes the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at October 25, 2024 and April 26, 2024. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.

(in millions)	Fair Value - Assets			Fair Value - Liabilities		
	October 25, 2024	April 26, 2024	Balance Sheet Classification	October 25, 2024	April 26, 2024	Balance Sheet Classification
Derivatives designated as hedging instruments						
Currency exchange rate contracts	\$ 328	\$ 368	Other current assets	\$ 56	\$ 37	Other accrued expenses
Currency exchange rate contracts	227	276	Other assets	22	17	Other liabilities
Total derivatives designated as hedging instruments	556	644		78	54	
Derivatives not designated as hedging instruments						
Currency exchange rate contracts	19	15	Other current assets	32	12	Other accrued expenses
Total return swaps	15	—	Other current assets	—	—	Other accrued expenses
Total derivatives not designated as hedging instruments	34	15		32	12	
Total derivatives	\$ 589	\$ 659		\$ 110	\$ 66	

The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis.

(in millions)	October 25, 2024		April 26, 2024	
	Derivative Assets	Derivative Liabilities	Derivative Assets	Derivative Liabilities
Level 1	\$ 574	\$ 110	\$ 659	\$ 66
Level 2	15	—	—	—
Total	\$ 589	\$ 110	\$ 659	\$ 66

The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.

(in millions)	October 25, 2024			
	Gross Amount Not Offset on the Balance Sheet			
	Gross Amount of Recognized Assets (Liabilities)	Financial Instruments	Cash Collateral (Received) Posted	Net Amount
Derivative assets:				
Currency exchange rate contracts	\$ 574	\$ (107)	\$ (52)	\$ 417
Total return swaps	15	—	—	15
	589	(107)	(52)	432
Derivative liabilities:				
Currency exchange rate contracts	(110)	107	—	(4)
Total	\$ 479	\$ —	\$ (52)	\$ 428

(In millions)	Gross Amount of Recognized Assets (Liabilities)	April 26, 2024		
		Gross Amount Not Offset on the Balance Sheet		
		Financial Instruments	Cash Collateral (Received) Posted	Net Amount
Derivative assets:				
Currency exchange rate contracts	\$ 659	\$ (66)	\$ (101)	\$ 492
Derivative liabilities:				
Currency exchange rate contracts	(66)	66	—	—
Total	<u>\$ 593</u>	<u>\$ —</u>	<u>\$ (101)</u>	<u>\$ 492</u>

~~XML 41 R17.htm IDEA: XBRL DOCUMENT~~

Inventories

[Inventory Disclosure \[Abstract\]](#)

[Inventories](#)

6 Months Ended			
Oct. 25, 2024			
Inventories			
Inventory balances were as follows:			
(In millions)	October 25, 2024	April 26, 2024	
Finished goods	\$3,729	\$3,668	
Work-in-process	728	642	
Raw materials	1,022	907	
Total	<u>\$5,479</u>	<u>\$5,217</u>	

~~XML 42 R18.htm IDEA: XBRL DOCUMENT~~

Goodwill and Other Intangible Assets

[Goodwill and Intangible Assets Disclosure \[Abstract\]](#)

[Goodwill and Other Intangible Assets](#)

Goodwill and Other Intangible Assets

Goodwill

The following table presents the changes in the carrying amount of goodwill by segment:

(In millions)	Cardiovascular	Neuroscience	Medical Surgical	Diabetes	Total
April 26, 2024	\$ 7,966	\$ 11,644	\$ 19,121	\$ 2,255	\$ 40,986
Currency translation and other	4	24	147	—	176
October 25, 2024	<u>\$ 7,970</u>	<u>\$ 11,668</u>	<u>\$ 19,268</u>	<u>\$ 2,255</u>	<u>\$ 41,161</u>

As further described in Note 17, the Company had changes to the operating segments and goodwill reporting units during the fourth quarter of fiscal year 2024. For further information on the reporting unit changes, refer to Note 9 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. No goodwill impairment was recognized during the three and six months ended October 25, 2024 and October 27, 2023.

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

(In millions)	October 25, 2024		April 26, 2024	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Definite-lived:				
Customer-related	\$ 16,523	\$ (9,164)	\$ 16,518	\$ (8,689)
Purchased technology and patents	11,727	(7,206)	11,557	(6,868)
Trademarks and tradenames	425	(280)	424	(274)
Other	254	(90)	256	(84)
Total	<u>\$ 28,929</u>	<u>\$ (16,741)</u>	<u>\$ 28,755</u>	<u>\$ (15,915)</u>
Indefinite-lived:				
IPR&D	\$ 235	\$ —	\$ 385	\$ —

The Company did not recognize any definite-lived intangible asset impairment charges during the three and six months ended October 25, 2024 and October 27, 2023.

The Company did not recognize any indefinite-lived intangible asset impairment charges during the three and six months ended October 25, 2024. Indefinite-lived intangible asset impairment charges were not significant for the three and six months ended October 27, 2023. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.

Amortization Expense

Intangible asset amortization expense for the three months ended October 25, 2024 and October 27, 2023 was \$413 million and \$425 million, respectively. Intangible asset amortization expense for the six months ended October 25, 2024 and October 27, 2023 was \$827 million and \$855 million, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 25, 2024, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:

(In millions)	Amortization Expense
Remaining 2025	\$ 824
2026	1,639
2027	1,616
2028	1,565
2029	1,488
2030	1,356

~~XML 43 R19.htm IDEA: XBRL DOCUMENT~~

Income Taxes

[Income Tax Disclosure \[Abstract\]](#)

[Income Taxes](#)

Income Taxes

The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which are effective for the Company in fiscal year 2025. We will continue to monitor the impacts of further legislation, regulatory guidance, and regulations issued in the countries in which we do business.

The Israeli Central-Lod District Court issued its decision in the Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office on June 1, 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a \$187 million income tax charge during the first quarter of fiscal year 2024 and has filed an appeal with the Supreme Court of Israel.

The Company's effective tax rate for the three and six months ended October 25, 2024 was 18.0% and 17.7%, respectively, as compared to 30.6% and 32.0% for the three and six months ended October 27, 2023, respectively. The decrease in the effective tax rate for the three months ended October 25, 2024, primarily relates to the establishment of a valuation allowance on certain net operating losses recorded during the three months ended October 27, 2023, which was partially offset by the implementation of the Pillar Two global minimum tax. In addition to the items discussed in the current quarter, the decrease in the effective tax rate for the six months ended October 25, 2024 was also attributable to an income tax reserve adjustment made during the six months ended October 27, 2023 associated with the Ventor court decision noted above.

At October 25, 2024 and April 26, 2024, the Company's gross unrecognized tax benefits were \$2.9 billion and \$2.8 billion, respectively. In addition, the Company had accrued gross interest and penalties of \$45 million at October 25, 2024. If all of the Company's unrecognized tax benefits were recognized, approximately \$2.7 billion would impact the Company's effective tax rate. At October 25, 2024 and April 26, 2024, the amount of the Company's gross unrecognized tax benefits, net of cash advance, recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets was \$1.9 billion and \$1.8 billion, respectively. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets.

Refer to Note 16 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

~~XML 44 R20.htm IDEA: XBRL DOCUMENT~~

Earnings Per Share

[Earnings Per Share \[Abstract\]](#)

[Earnings Per Share](#)

Earnings Per Share

Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

The table below sets forth the computation of basic and diluted earnings per share:

6 Months Ended

Oct. 25, 2024

6 Months Ended

Oct. 25, 2024

6 Months Ended

Oct. 25, 2024

(in millions, except per share data)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Numerator:				
Net income attributable to ordinary shareholders	\$ 1,270	\$ 909	\$ 2,312	\$ 1,700
Denominator:				
Basic – weighted average shares outstanding	1,282.4	1,330.2	1,288.6	1,330.3
Effect of dilutive securities:				
Employee stock options	0.6	0.5	0.6	0.9
Employee restricted stock units	2.1	0.9	2.0	1.3
Employee performance share units	1.8	0.2	1.3	0.3
Diluted – weighted average shares outstanding	1,286.9	1,331.9	1,292.5	1,332.8
Basic earnings per share	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28
Diluted earnings per share	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28

The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 28 million and 27 million ordinary shares for the three and six months ended October 25, 2024, respectively, and 31 million and 27 million ordinary shares for the three and six months ended October 27, 2023, respectively, because their effect would have been anti-dilutive on the Company's earnings per share.

XML 45 R21.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation
[Share-Based Payment Arrangement \[Abstract\]](#)
[Stock-Based Compensation](#)

**6 Months Ended
Oct. 25, 2024**

Stock-Based Compensation

The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, performance share units, and employee stock purchase plan shares recognized for the three and six months ended October 25, 2024 and October 27, 2023:

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Stock options	\$ 30	\$ 35	\$ 42	\$ 46
Restricted stock	68	55	111	93
Performance share units	54	48	69	60
Employee stock purchase plan	8	8	19	19
Total stock-based compensation expense	\$ 159	\$ 146	\$ 242	\$ 219
Cost of products sold	\$ 17	\$ 13	\$ 26	\$ 20
Research and development expense	19	18	29	27
Selling, general, and administrative expense	123	115	187	172
Total stock-based compensation expense	159	146	242	219
Income tax benefits	(25)	(25)	(38)	(36)
Total stock-based compensation expense, net of tax	\$ 134	\$ 121	\$ 204	\$ 183

XML 46 R22.htm IDEA: XBRL DOCUMENT

Retirement Benefit Plans
[Retirement Benefits \[Abstract\]](#)
[Retirement Benefit Plans](#)

**6 Months Ended
Oct. 25, 2024**

Retirement Benefit Plans

The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 25, 2024 and October 27, 2023:

(in millions)	U.S.		Non-U.S.		U.S.		Non-U.S.	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Service cost	\$ 13	\$ 15	\$ 11	\$ 10	\$ 26	\$ 30	\$ 22	\$ 20
Interest cost	43	40	13	12	86	80	26	24
Expected return on plan assets	(66)	(65)	(17)	(17)	(132)	(130)	(34)	(34)
Amortization of prior service cost	(1)	(1)	—	—	(2)	(2)	—	—
Amortization of net actuarial loss	4	5	—	—	8	10	1	—
Net periodic (credit) benefit cost	\$ (7)	\$ (6)	\$ 7	\$ 5	\$ (14)	\$ (12)	\$ 14	\$ 10

Components of net periodic benefit (credit) cost other than the service component are recognized in *other non-operating income, net* in the consolidated statements of income.

XML 47 R23.htm IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss
[Equity \[Abstract\]](#)
[Accumulated Other Comprehensive Loss](#)

**6 Months Ended
Oct. 25, 2024**

Accumulated Other Comprehensive Loss

The following table provides changes in accumulated other comprehensive loss (AOCI), net of tax, and by component:

(in millions)	Unrealized (Loss) Gain on Investment Securities	Cumulative Translation Adjustments	Net Investment Hedges	Net Change in Retirement Obligations	Unrealized Gain (Loss) on Cash Flow Hedges	Total Accumulated Other Comprehensive (Loss) Income
April 26, 2024	\$ (212)	\$ (3,686)	\$ 878	\$ (529)	\$ 229	\$ (3,318)
Other comprehensive income (loss) before reclassifications	102	218	(170)	(1)	(37)	111
Reclassifications	9	—	—	3	(55)	(43)
Other comprehensive income (loss)	111	218	(170)	1	(93)	69
October 25, 2024	\$ (101)	\$ (3,468)	\$ 708	\$ (529)	\$ 139	\$ (3,250)
April 28, 2023	\$ (258)	\$ (2,839)	\$ 245	\$ (741)	\$ 93	\$ (3,499)
Other comprehensive income (loss) before reclassifications	(49)	(909)	771	—	404	217
Reclassifications	11	—	—	4	(110)	(95)
Other comprehensive income (loss)	(38)	(909)	771	4	294	122
October 27, 2023	\$ (296)	\$ (3,748)	\$ 1,016	\$ (737)	\$ 387	\$ (3,377)

The income tax on gains and losses on investment securities in other comprehensive income before reclassifications during the six months ended October 25, 2024 and October 27, 2023, was an expense of \$19 million and a benefit of \$8 million, respectively. During the six months ended October 25, 2024 and October 27, 2023, realized gains and losses on investment securities reclassified from AOCI were reduced by income taxes of \$2 million and \$3 million, respectively. When realized, gains and losses on investment securities reclassified from AOCI are recognized within *other non-operating income, net*. Refer to Note 6 to the consolidated financial statements for additional information.

For the six months ended October 25, 2024 and October 27, 2023, there was no income tax on cumulative translation adjustments.

The income tax on net investment hedges in other comprehensive income before reclassifications during the six months ended October 25, 2024 was a benefit of \$1 million. During the six months ended October 27, 2023, there were no tax impacts on net investment hedges.

The net change in retirement obligations in other comprehensive income includes amortization of net actuarial losses included in net periodic benefit cost. During the six months ended October 25, 2024 and October 27, 2023, there were no tax impacts on retirement obligations. During the six months ended October 25, 2024 and October 27, 2023, the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of \$1 million and \$2 million, respectively. When realized, net gains and losses on defined benefit and pension items reclassified from AOCI are recognized within *other non-operating income, net*. Refer to Note 14 to the consolidated financial statements for additional information.

The income tax on unrealized gains and losses on cash flow hedges in other comprehensive income before reclassifications during the six months ended October 25, 2024 and October 27, 2023, was a benefit of \$5 million and expense of \$103 million, respectively. During the six months ended October 25, 2024 and October 27, 2023, gains and losses on cash flow hedges reclassified from AOCI were reduced by income taxes of \$22 million and \$34 million, respectively. When realized, gains and losses on currency exchange rate contracts reclassified from AOCI are recognized within *other operating income, net* or *cost of products sold*. Refer to Note 8 to the consolidated financial statements for additional information.

XML 48 R24.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies
[Commitments and Contingencies Disclosure \[Abstract\]](#)
[Commitments and Contingencies](#)

**6 Months Ended
Oct. 25, 2024**

Commitments and Contingencies

Legal Matters

The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United

States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.

The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly

when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters as *certain litigation charges, net* in the consolidated statements of income. The Company recognized no certain litigation charges and \$81 million of certain litigation charges during the three and six months ended October 25, 2024, respectively, whereas the Company recognized \$65 million and \$105 million of certain litigation charges during the three and six months ended October 27, 2023, respectively. At October 25, 2024 and April 26, 2024, accrued litigation was approximately \$0.2 billion. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in *other accrued expenses and other liabilities* on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.

Intellectual Property Matters

At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages and/or royalty payments, and negatively impact the Company's ability to sell current or future products, which could have a material adverse impact on the Company's business, results of operations, financial condition, and cash flows.

Colibri

The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company's Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately \$106 million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.

Product Liability Matters

Hernia Mesh Litigation

Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of October 30, 2024, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 8,800 individual plaintiffs, and certain plaintiffs' law firms have advised the Company that they may file additional cases in the future. Approximately 6,850 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,450 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus fewer than ten one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Diabetes Pump Retainer Ring Litigation

Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of November 4, 2024, after a number of recent dismissals of individual plaintiffs, there are 23 lawsuits filed on behalf of 76 individuals. Plaintiffs' firms previously notified the Company that they may file additional lawsuits in the future on behalf of thousands of additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Environmental Proceedings

The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.

The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter.

The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above.

Anti-Corruption Matters

The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in China regarding certain activities, including in China. The Company is committed to regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Other Matters

Italian Payback

In 2015, "payback" legislation was enacted in Italy requiring companies selling medical devices to make payments to the Italian state if Italy's medical device expenditures exceed annual regional maximum ceilings. The payment amounts are calculated based upon the amount by which the regional ceilings were exceeded for any given year. There has been significant scrutiny on the legality and enforceability of the payback law since its inception, and litigation challenging the law has been proceeding through the Italian Courts. Since the law was enacted, the Company has recognized an estimate for the amount of variable consideration but has not made any payments under the payback law. In July 2024, two rulings by the Constitutional Court of Italy found that the medical device payback law is constitutional. Therefore, the Company increased its liability pertaining primarily to certain prior years since 2015 by \$90 million during the three months ended July 26, 2024, as a reduction to *net sales* in the consolidated statements of income. As litigation before Italian Courts is still pending, final resolution is unknown at this time, and it is possible that the amount of the Company's liability could differ from the amount currently accrued.

Income Taxes

In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS's position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals

for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023.

The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.

Medtronic, Inc.'s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.

Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2020.

Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.

Refer to Note 11 for additional discussion of income taxes.

Guarantees

In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates' products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company's maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.

The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company's consolidated earnings, financial position, and/or cash flows.

~~XML 49 R25.htm~~ IDEA: XBRL DOCUMENT

**Segment and
Geographic
Information**

6 Months Ended

Oct. 25, 2024

**Segment Reporting
[Abstract]**

**Segment and
Geographic Information**

Segment and Geographic Information

Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. The Company's management evaluates performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest income or expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments.

The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.

There have been no changes to reportable segments during the quarter ended October 25, 2024. We continue to have four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. Prior period amounts have been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. For further information on the operating segment structure changes, refer to Note 19 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024.

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Segment Operating Profit

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cardiovascular	\$ 1,164	\$ 1,117	\$ 2,289	\$ 2,208
Neuroscience	1,024	929	1,985	1,858
Medical Surgical	774	795	1,464	1,521
Diabetes	116	101	218	186
Reportable segment operating profit	3,079	2,942	5,956	5,773
Other operating segment ⁽¹⁾	12	4	26	1
Corporate	(448)	(431)	(903)	(879)
Interest expense, net	(209)	(180)	(376)	(329)
Other non-operating income, net	173	154	330	230
Amortization of intangible assets	(413)	(425)	(827)	(855)
Stock-based compensation	(159)	(146)	(242)	(219)
Centralized distribution costs	(405)	(391)	(800)	(786)
Currency ⁽²⁾	(39)	32	(44)	29
Restructuring and associated costs	(46)	(91)	(108)	(182)
Acquisition and divestiture-related items	25	(58)	13	(107)
Certain litigation charges, net	—	(65)	(81)	(105)
Medical device regulations	(12)	(30)	(27)	(62)
Other adjustments ⁽³⁾	—	—	(90)	—
Income before income taxes	\$ 1,559	\$ 1,313	\$ 2,827	\$ 2,510

(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.

(2) Includes the net impact of remeasurement and the Company's hedging programs recorded in *other operating income, net*.

(3) Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.

Geographic Information

Net sales are attributed to the country based on the location of the customer taking possession of the products or in which the services are rendered. The following table presents net sales for the three and six months ended October 25, 2024 and October 27, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries:

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Ireland	\$ 29	\$ 29	\$ 59	\$ 58
United States	4,304	4,175	8,387	8,099
Rest of world	4,070	3,780	7,872	7,528
Total other countries, excluding Ireland	8,374	7,955	16,259	15,627
Total	\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686

~~XML 50 R26.htm IDEA: XBRL DOCUMENT~~

Pay vs Performance Disclosure - USD (\$) \$ in Millions	3 Months Ended		6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023

Pay vs Performance Disclosure

<u>Net Income (Loss)</u>	\$ 1,270	\$ 909	\$ 2,312	\$ 1,700

~~XML 51 R27.htm IDEA: XBRL DOCUMENT~~

Insider Trading Arrangements	3 Months Ended	
	Oct. 25, 2024	Shares
<u>Trading Arrangements, by Individual</u>		
<u>Non-Rule 10b5-1 Arrangement Adopted</u>	false	
<u>Rule 10b5-1 Arrangement Terminated</u>	false	
<u>Non-Rule 10b5-1 Arrangement Terminated</u>	false	
<u>Brett Wall (Member)</u>		
<u>Trading Arrangements, by Individual</u>		
<u>Material Terms of Trading Arrangement</u>	On October 10, 2024, Brett Wall, Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan. Mr. Wall's trading plan provides for the sale of up to 22,287 shares of the Company's common stock prior to the plan's August 1, 2025 termination date.	
<u>Name</u>	Brett Wall	
<u>Title</u>	Executive Vice President and President	
<u>Rule 10b5-1 Arrangement Adopted</u>	true	
<u>Adoption Date</u>	October 10, 2024	
<u>Expiration Date</u>	August 1, 2025	
<u>Arrangement Duration</u>	295 days	
<u>Aggregate Available</u>	22,287	

~~XML 52 R28.htm IDEA: XBRL DOCUMENT~~

Basis of Presentation (Policies)	6 Months Ended
	Oct. 25, 2024

Organization, Consolidation and Presentation of Financial Statements (Abstract)

Basis of Presentation

The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.

Consolidation

The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding.

Fiscal Period

The Company's fiscal years 2025, 2024, and 2023 will end or ended on April 25, 2025, April 26, 2024, and April 28, 2023, respectively.

Recently Adopted Accounting Standards and Not Yet Adopted Accounting Standards

Recently Adopted Accounting Standards

As of October 25, 2024, there have been no newly adopted accounting pronouncements that materially impact our consolidated financial statements. Refer to the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024 for pronouncements recently adopted.

Not Yet Adopted Accounting Standards

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

~~XML 53 R29.htm IDEA: XBRL DOCUMENT~~

Revenue (Tables)	6 Months Ended
	Oct. 25, 2024

Revenue from Contract with Customer (Abstract)

Schedule of Disaggregation of Net Sales by Segment and Division and by Market Geography

The table below illustrates net sales by segment and division and by market geography for the three and six months ended October 25, 2024 and October 27, 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.

(in millions)	World wide							
	Three months ended				Six months ended			
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cardiac Rhythm & Heart Failure	\$ 1,578	\$ 1,492	\$ 3,114	\$ 2,938				
Structural Heart & Aortic	881	819	1,736	1,633				
Coronary & Peripheral Vascular	643	613	1,259	1,202				
Cardiovascular	3,102	2,923	6,108	5,773				
Cranial & Spinal Technologies	1,234	1,157	2,382	2,260				
Specialty Therapies	737	705	1,450	1,400				
Neuromodulation	480	426	937	846				
Neuroscience	2,451	2,288	4,768	4,506				
Surgical & Endoscopy	1,649	1,641	3,193	3,187				
Acute Care & Monitoring	478	462	930	921				
Medical Surgical	2,128	2,103	4,123	4,107				
Diabetes	686	610	1,333	1,189				
Reportable segment net sales	8,366	7,923	16,333	15,575				
Other operating segment ⁽¹⁾	37	61	75	111				
Other adjustments ⁽²⁾	—	—	(90)	—				
Total net sales	\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686				

(in millions)	U.S.				International			
	Three months ended				Six months ended			
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cardiovascular	\$ 1,434	\$ 1,427	\$ 1,668	\$ 1,496	\$ 2,836	\$ 2,776	\$ 3,272	\$ 2,996
Neuroscience	1,677	1,560	774	728	3,242	3,057	1,526	1,449
Medical Surgical	944	948	1,183	1,155	1,825	1,815	2,298	2,292
Diabetes	232	217	455	394	447	405	886	784
Reportable segment net sales	4,286	4,151	4,080	3,772	8,350	8,054	7,983	7,521
Other operating segment ⁽¹⁾	18	23	19	37	37	45	38	66
Other adjustments ⁽²⁾	—	—	—	—	—	—	(90)	—
Total net sales	\$ 4,304	\$ 4,175	\$ 4,099	\$ 3,809	\$ 8,387	\$ 8,099	\$ 7,931	\$ 7,587

- (1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.
(2) Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.

XML 54 R30.htm IDEA: XBRL DOCUMENT

Acquisitions and Dispositions (Tables)

[Business Combination, Asset Acquisition, and Joint Venture Formation \[Abstract\]](#)

[Schedule of Reconciliation of Contingent Consideration Liabilities and Receivables](#)

6 Months Ended Oct. 25, 2024

The following table provides a reconciliation of the beginning and ending balances of contingent consideration liabilities:

(in millions)	Three months ended				Six months ended			
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Beginning balance	\$ 128	\$ 206	\$ 149	\$ 206				
Purchase price contingent consideration	—	25	—	25				
Payments	(8)	—	(14)	(3)				
Change in fair value	4	(10)	(11)	(7)				
Ending balance	\$ 124	\$ 220	\$ 124	\$ 220				

The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:

(in millions)	Three months ended				Six months ended			
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Beginning balance	\$ 58	\$ 152	\$ 58	\$ 195				
Change in fair value	3	—	3	(43)				
Ending balance	\$ 61	\$ 152	\$ 61	\$ 152				

[Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability](#)

The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:

(in millions)	Fair Value at October 25, 2024	Unobservable Input	Range	Weighted Average ⁽¹⁾
Revenue and other performance-based payments	\$58	Discount rate	16.5% - 28.2%	22.1%
		Projected fiscal year of payment	2025 - 2029	2027
Product development and other milestone-based payments	\$66	Discount rate	5.5%	5.5%
		Projected fiscal year of payment	2025 - 2027	2025

- (1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.

XML 55 R31.htm IDEA: XBRL DOCUMENT

Restructuring and Other Costs (Tables)

[Restructuring and Related Activities \[Abstract\]](#)

[Schedule of Restructuring and Related Costs and Activity of Restructuring Costs](#)

6 Months Ended Oct. 25, 2024

The following table presents the classification of restructuring and associated costs in the consolidated statements of income:

(in millions)	Three months ended				Six months ended			
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cost of products sold	\$ 11	\$ 15	\$ 20	\$ 30				
Selling, general, and administrative expenses	6	36	11	57				
Restructuring charges, net	30	40	77	94				
Total restructuring and associated costs	\$ 46	\$ 91	\$ 108	\$ 182				

The following table summarizes the activity for the six months ended October 25, 2024:

(in millions)	Employee Termination Benefits	Associated and Other Costs	Total
April 26, 2024	\$ 136	\$ 11	\$ 147
Charges	87	31	118
Cash payments	(156)	(25)	(181)
Settled non-cash	—	(4)	(4)
Accrual adjustments ⁽¹⁾	(10)	—	(10)
October 25, 2024	\$ 58	\$ 13	\$ 70

- (1) Accrual adjustments primarily relate to certain employees identified for termination, finding other positions within the Company.

XML 56 R32.htm IDEA: XBRL DOCUMENT

Financial Instruments (Tables)

[Investments \[Abstract\]](#)

[Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification](#)

6 Months Ended Oct. 25, 2024

The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at October 25, 2024 and April 26, 2024:

(in millions)	October 25, 2024					Balance Sheet Classification	
	Valuation				Fair Value	Investments	Other Assets
	Cost	Unrealized Gains	Unrealized Losses				
Level 1:							
U.S. government and agency securities	\$ 538	\$ —	\$ (11)	\$ 527	\$ 527	\$ —	\$ —
Level 2:							
Corporate debt securities	3,429	13	(59)	3,384	3,384	—	—
U.S. government and agency securities	874	—	(28)	845	845	—	—
Mortgage-backed securities	772	3	(33)	742	742	—	—
Non-U.S. government and agency securities	9	—	—	9	9	—	—
Other asset-backed securities	1,051	5	(3)	1,053	1,053	—	—
Total Level 2	6,134	22	(124)	6,032	6,032	—	—
Level 3:							
Auction rate securities	36	—	(3)	33	—	—	33
Total available-for-sale debt securities	\$ 6,708	\$ 22	\$ (138)	\$ 6,592	\$ 6,559	\$ —	\$ 33

	April 26, 2024				Balance Sheet Classification	
	Cost	Unrealized Gains	Unrealized Losses	Fair Value	Investments	Other Assets
(in millions)						
Level 1:						
U.S. government and agency securities	\$ 494	\$ —	\$ (22)	\$ 472	\$ 472	\$ —
Level 2:						
Corporate debt securities	3,953	4	(125)	3,832	3,832	—
U.S. government and agency securities	847	—	(43)	804	804	—
Mortgage-backed securities	692	1	(50)	643	643	—
Non-U.S. government and agency securities	5	—	—	5	5	—
Other asset-backed securities	941	2	(9)	934	934	—
Total Level 2	6,438	7	(227)	6,218	6,218	—
Level 3:						
Auction rate securities	36	—	(3)	33	—	33
Total available-for-sale debt securities	\$ 6,968	\$ 7	\$ (252)	\$ 6,723	\$ 6,690	\$ 33

[Schedule of Gross Unrealized Losses and Fair Values of Available-for-Sale Securities, Aggregated by Investment Category](#)

The following tables present the gross unrealized losses and fair values of the Company's available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 25, 2024 and April 26, 2024:

	October 25, 2024			
	Less than 12 months	Unrealized Losses	More than 12 months	Unrealized Losses
(in millions)	Fair Value		Fair Value	
Corporate debt securities	\$ 565	\$ (7)	\$ 1,645	\$ (51)
U.S. government and agency securities	216	(2)	713	(37)
Mortgage-backed securities	—	—	535	(33)
Other asset-backed securities	—	—	212	(3)
Auction rate securities	—	—	33	(3)
Total	\$ 782	\$ (10)	\$ 3,137	\$ (128)

	April 26, 2024			
	Less than 12 months	Unrealized Losses	More than 12 months	Unrealized Losses
(in millions)	Fair Value		Fair Value	
Corporate debt securities	\$ 661	\$ (10)	\$ 2,448	\$ (116)
U.S. government and agency securities	177	(4)	730	(61)
Mortgage-backed securities	—	—	582	(50)
Other asset-backed securities	—	—	502	(9)
Auction rate securities	—	—	33	(3)
Total	\$ 838	\$ (14)	\$ 4,296	\$ (238)

[Schedule of Activity Related to Available-for-Sale Securities Portfolio](#)

Activity related to the Company's available-for-sale debt securities portfolio is as follows:

	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
(in millions)				
Proceeds from sales	\$ 2,087	\$ 1,573	\$ 4,244	\$ 3,320
Gross realized gains	7	6	14	11
Gross realized losses	(6)	(3)	(13)	(15)

The contractual maturities of available-for-sale debt securities at October 25, 2024 is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

	Amortized Cost		Fair Value	
(in millions)				
Due in one year or less	\$ 1,488	\$ 1,478		
Due after one year through five years	3,322	3,248		
Due after five years through ten years	750	749		
Due after ten years	1,148	1,117		
Total	\$ 6,708	\$ 6,592		

[Schedule of Equity and Other Investments](#)

The following table summarizes the Company's equity and other investments at October 25, 2024 and April 26, 2024, which are classified as primarily *other assets* in the consolidated balance sheets:

	October 25, 2024		April 26, 2024	
(in millions)				
Investments with readily determinable fair value (marketable equity securities)	\$ 34	\$ 28		
Investments for which the fair value option has been elected	311	311		
Investments without readily determinable fair values	826	859		
Equity method and other investments	92	84		
Total equity and other investments	\$ 1,265	\$ 1,282		

~~XML 57 R33.htm IDEA: XBRL DOCUMENT~~

Financing Arrangements (Tables)

6 Months Ended

Oct. 25, 2024

[Debt Disclosure \[Abstract\]](#)

[Schedule of Debt Obligations](#)

The Company's debt obligations consisted of the following:

(in millions)	Maturity by Fiscal Year	October 25, 2024	April 26, 2024
Current debt obligations	2025 - 2026	\$ 3,719	\$ 1,092
Long-term debt			
0.250 percent six-year 2019 senior notes	2026	—	1,070
2.625 percent three-year 2022 senior notes	2026	—	535
0.000 percent five-year 2020 senior notes	2026	—	1,070
1.125 percent eight-year 2019 senior notes	2027	1,620	1,606
4.250 percent five-year 2023 senior notes	2028	1,000	1,000
3.000 percent six-year 2022 senior notes	2029	1,080	1,070
0.375 percent eight-year 2020 senior notes	2029	1,080	1,070
3.650 percent five-year 2024 senior notes	2030	918	—
1.625 percent twelve-year 2019 senior notes	2031	1,080	1,070
1.000 percent twelve-year 2019 senior notes	2032	1,080	1,070
3.125 percent nine-year 2022 senior notes	2032	1,080	1,070
0.750 percent twelve-year 2020 senior notes	2033	1,080	1,070
4.500 percent ten-year 2023 senior notes	2033	1,000	1,000
3.375 percent twelve-year 2022 senior notes	2035	1,080	1,070
4.375 percent twenty-year 2015 senior notes	2035	1,932	1,932
3.875 percent twelve-year 2024 senior notes	2037	918	—
6.550 percent thirty-year 2007 CIFSA senior notes	2038	253	253
2.250 percent twenty-year 2019 senior notes	2039	1,080	1,070
6.500 percent thirty-year 2009 senior notes	2039	158	158
1.500 percent twenty-year 2019 senior notes	2040	1,080	1,070
5.550 percent thirty-year 2010 senior notes	2040	224	224
1.375 percent twenty-year 2020 senior notes	2041	1,080	1,070
4.500 percent thirty-year 2012 senior notes	2042	105	105
4.000 percent thirty-year 2013 senior notes	2043	305	305
4.150 percent nineteen-year 2024 senior notes	2044	648	—
4.625 percent thirty-year 2014 senior notes	2044	127	127
4.625 percent thirty-year 2015 senior notes	2045	1,813	1,813
1.750 percent thirty-year 2019 senior notes	2050	1,080	1,070
1.625 percent thirty-year 2020 senior notes	2051	1,080	1,070
4.150 percent twenty-nine-year 2024 senior notes	2054	756	—
Finance lease obligations	2026 - 2036	50	55
Deferred financing costs	2027 - 2054	(125)	(110)
Debt discount, net	2027 - 2054	(56)	(55)
Total long-term debt		\$ 24,607	\$ 23,932

~~XML 58 R34.htm IDEA: XBRL DOCUMENT~~

Derivatives and Currency Exchange Risk Management (Tables)

6 Months Ended

Oct. 25, 2024

[Derivative Instruments and Hedging Activities Disclosure \[Abstract\]](#)

[Schedule of Outstanding Instruments and Gains and Losses on Hedging Instruments and Derivatives Not Designated as Hedging Instruments](#)

The following table presents the contractual amounts of the Company's outstanding instruments:

(In billions)	Designation	As of	
		October 25, 2024	April 26, 2024
Currency exchange rate contracts ⁽¹⁾	Fair value hedge	\$ 1.1	\$ —
Currency exchange rate contracts	Cash flow hedge	11.3	10.4
Currency exchange rate contracts ⁽²⁾	Net investment hedge	7.5	7.4
Foreign currency-denominated debt ⁽³⁾	Net investment hedge	19.4	17.1
Currency exchange rate contracts	Undesignated	4.7	5.9

- (1) At October 25, 2024, includes derivative contracts with a notional value of €1.0 billion, or \$1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.
- (2) At October 25, 2024, includes derivative contracts with a notional value of €5.0 billion, or \$5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of ¥322.2 billion, or \$2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033.
- (3) At October 25, 2024, includes €18.0 billion, or \$19.4 billion, of outstanding Euro-denominated debt designated as hedges of a portion of our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.

The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three and six months ended October 25, 2024 and October 27, 2023 were as follows:

(In millions)	(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				(Gain) Loss Reclassified into Income				Location of (Gain) Loss in Income Statement
	Three months ended		Six months ended		Three months ended		Six months ended		
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	
Cash flow hedges									
Currency exchange rate contracts	\$ —	\$ (394)	\$ 42	\$ (398)	\$ (3)	\$ (75)	\$ (39)	\$ (125)	Other operating income, net
Currency exchange rate contracts	20	(75)	—	(109)	(21)	(15)	(39)	(19)	Cost of products sold
Net investment hedges									
Foreign currency-denominated debt	(91)	(725)	160	(612)	—	—	—	—	N/A
Currency exchange rate contracts	52	(190)	12	(160)	—	—	—	—	N/A
Total	\$ (19)	\$ (1,384)	\$ 214	\$ (1,278)	\$ (24)	\$ (89)	\$ (78)	\$ (145)	

The amount of the gains and losses on our derivative instruments not designated as hedging instruments and the classification of those gains and losses within our consolidated financial statements during the three and six months ended October 25, 2024 and October 27, 2023 were as follows:

(Gain) Loss Recognized in Income					
(In millions)	Three months ended		Six months ended		Location of (Gain) Loss in Income Statement
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	
Currency exchange rate contracts	\$ (35)	\$ 94	\$ (45)	\$ 92	Other operating income, net

Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets

The following table summarizes the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at October 25, 2024 and April 26, 2024. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.

	Fair Value - Assets			Fair Value - Liabilities		
(in millions)	October 25, 2024	April 26, 2024	Balance Sheet Classification	October 25, 2024	April 26, 2024	Balance Sheet Classification
Derivatives designated as hedging instruments						
Currency exchange rate contracts	\$ 328	\$ 368	Other current assets	\$ 56	\$ 37	Other accrued expenses
Currency exchange rate contracts	227	276	Other assets	22	17	Other liabilities
Total derivatives designated as hedging instruments	556	644		78	54	
Derivatives not designated as hedging instruments						
Currency exchange rate contracts	19	15	Other current assets	32	12	Other accrued expenses
Total return swaps	15	—	Other current assets	—	—	Other accrued expenses
Total derivatives not designated as hedging instruments	34	15		32	12	
Total derivatives	\$ 589	\$ 659		\$ 110	\$ 66	

Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis.

(In millions)	October 25, 2024		April 26, 2024	
	Derivative Assets	Derivative Liabilities	Derivative Assets	Derivative Liabilities
Level 1	\$ 574	\$ 110	\$ 659	\$ 66
Level 2	15	—	—	—
Total	\$ 589	\$ 110	\$ 659	\$ 66

Schedule of Offsetting Assets

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.

(In millions)	October 25, 2024			
	Gross Amount Not Offset on the Balance Sheet			
	Gross Amount of Recognized Assets (Liabilities)	Financial Instruments	Cash Collateral (Received) Posted	Net Amount
Derivative assets:				
Currency exchange rate contracts	\$ 574	\$ (107)	\$ (52)	\$ 417
Total return swaps	15	—	—	15
	589	(107)	(52)	432
Derivative liabilities:				
Currency exchange rate contracts	(110)	107	—	(4)
Total	\$ 479	\$ —	\$ (52)	\$ 428

(In millions)	April 26, 2024			
	Gross Amount Not Offset on the Balance Sheet			
	Gross Amount of Recognized Assets (Liabilities)	Financial Instruments	Cash Collateral (Received) Posted	Net Amount
Derivative assets:				
Currency exchange rate contracts	\$ 659	\$ (66)	\$ (101)	\$ 492
Derivative liabilities:				
Currency exchange rate contracts	(66)	66	—	—
Total	\$ 593	\$ —	\$ (101)	\$ 492

Schedule of Offsetting Liabilities

The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.

(In millions)	October 25, 2024			
	Gross Amount Not Offset on the Balance Sheet			
	Gross Amount of Recognized Assets (Liabilities)	Financial Instruments	Cash Collateral (Received) Posted	Net Amount
Derivative assets:				
Currency exchange rate contracts	\$ 574	\$ (107)	\$ (52)	\$ 417
Total return swaps	15	—	—	15
	589	(107)	(52)	432
Derivative liabilities:				
Currency exchange rate contracts	(110)	107	—	(4)
Total	\$ 479	\$ —	\$ (52)	\$ 428

(In millions)	April 26, 2024			
	Gross Amount Not Offset on the Balance Sheet			
	Gross Amount of Recognized Assets (Liabilities)	Financial Instruments	Cash Collateral (Received) Posted	Net Amount
Derivative assets:				
Currency exchange rate contracts	\$ 659	\$ (66)	\$ (101)	\$ 492
Derivative liabilities:				
Currency exchange rate contracts	(66)	66	—	—
Total	\$ 593	\$ —	\$ (101)	\$ 492

~~XML 59 R35.htm~~ IDEA: XBRL DOCUMENT

Inventories (Tables)

6 Months Ended
Oct. 25, 2024

Inventory Disclosure [Abstract]

Schedule of Inventory Balances

Inventory balances were as follows:

(In millions)	October 25, 2024	April 26, 2024
Finished goods	\$3,729	\$3,668
Work-in-process	728	642
Raw materials	1,022	907
Total	\$5,479	\$5,217

XML 60 R36.htm IDEA: XBRL DOCUMENT

**Goodwill and Other
Intangible Assets
(Tables)**

[Goodwill and Intangible Assets Disclosure
\[Abstract\]](#)

[Schedule of Changes in the Carrying Amount of
Goodwill](#)

**6 Months Ended
Oct. 25, 2024**

The following table presents the changes in the carrying amount of goodwill by segment:

(in millions)	Cardiovascular	Neuroscience	Medical Surgical	Diabetes	Total
April 26, 2024	\$ 7,966	\$ 11,644	\$ 19,121	\$ 2,255	\$ 40,986
Currency translation and other	4	24	147	—	176
October 25, 2024	\$ 7,970	\$ 11,668	\$ 19,268	\$ 2,255	\$ 41,161

[Schedule of Gross Carrying Amount and
Accumulated Amortization of Definite-Lived
Intangible Assets](#)

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

(in millions)	October 25, 2024		April 26, 2024	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Definite-lived:				
Customer-related	\$ 16,523	\$ (9,164)	\$ 16,518	\$ (8,689)
Purchased technology and patents	11,727	(7,206)	11,557	(6,868)
Trademarks and tradenames	425	(280)	424	(274)
Other	254	(90)	256	(84)
Total	\$ 28,929	\$ (16,741)	\$ 28,755	\$ (15,915)
Indefinite-lived:				
IPR&D	\$ 235	\$ —	\$ 385	\$ —

[Schedule of Gross Carrying Amount of Indefinite-
Lived Intangible Assets](#)

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

(in millions)	October 25, 2024		April 26, 2024	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Definite-lived:				
Customer-related	\$ 16,523	\$ (9,164)	\$ 16,518	\$ (8,689)
Purchased technology and patents	11,727	(7,206)	11,557	(6,868)
Trademarks and tradenames	425	(280)	424	(274)
Other	254	(90)	256	(84)
Total	\$ 28,929	\$ (16,741)	\$ 28,755	\$ (15,915)
Indefinite-lived:				
IPR&D	\$ 235	\$ —	\$ 385	\$ —

[Schedule of Estimated Future Aggregate
Amortization Expense](#)

Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 25, 2024, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:

(in millions)	Amortization Expense
Remaining 2025	\$ 824
2026	1,639
2027	1,616
2028	1,565
2029	1,488
2030	1,356

XML 61 R37.htm IDEA: XBRL DOCUMENT

**Earnings Per Share
(Tables)**

[Earnings Per Share \[Abstract\]](#)

[Schedule of Computation of Basic and Diluted Earnings Per Share](#)

**6 Months Ended
Oct. 25, 2024**

The table below sets forth the computation of basic and diluted earnings per share:

(in millions, except per share data)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Numerator:				
Net income attributable to ordinary shareholders	\$ 1,270	\$ 909	\$ 2,312	\$ 1,700
Denominator:				
Basic - weighted average shares outstanding	1,282.4	1,330.2	1,288.6	1,330.3
Effect of dilutive securities:				
Employee stock options	0.6	0.5	0.6	0.9
Employee restricted stock units	2.1	0.9	2.0	1.3
Employee performance share units	1.8	0.2	1.3	0.3
Diluted - weighted average shares outstanding	1,286.9	1,331.9	1,292.5	1,332.8
Basic earnings per share	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28
Diluted earnings per share	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28

XML 62 R38.htm IDEA: XBRL DOCUMENT

**Stock-Based
Compensation
(Tables)**

[Share-Based Payment Arrangement
\[Abstract\]](#)

[Schedule of Components and Classification of
Stock-Based Compensation Expense](#)

**6 Months Ended
Oct. 25, 2024**

The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, performance share units, and employee stock purchase plan shares recognized for the three and six months ended October 25, 2024 and October 27, 2023:

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Stock options	\$ 30	\$ 35	\$ 42	\$ 46
Restricted stock	68	55	111	93
Performance share units	54	48	69	60
Employee stock purchase plan	8	8	19	19
Total stock-based compensation expense	\$ 159	\$ 146	\$ 242	\$ 219
Cost of products sold	\$ 17	\$ 13	\$ 26	\$ 20
Research and development expense	19	18	29	27
Selling, general, and administrative expense	123	115	187	172
Total stock-based compensation expense	159	146	242	219
Income tax benefits	(25)	(25)	(38)	(36)
Total stock-based compensation expense, net of tax	\$ 134	\$ 121	\$ 204	\$ 183

XML 63 R39.htm IDEA: XBRL DOCUMENT

**Retirement Benefit
Plans (Tables)**

[Retirement Benefits \[Abstract\]](#)

[Schedule of Components of Net Periodic
Benefit Cost](#)

**6 Months Ended
Oct. 25, 2024**

The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 25, 2024 and October 27, 2023:

(in millions)	U.S.				Non-U.S.			
	Three months ended				Six months ended			
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Service cost	\$ 13	\$ 15	\$ 11	\$ 10	\$ 26	\$ 30	\$ 22	\$ 20
Interest cost	43	40	13	12	86	80	26	24
Expected return on plan assets	(66)	(65)	(17)	(17)	(132)	(130)	(34)	(34)
Amortization of prior service cost	(1)	(1)	—	—	(2)	(2)	—	—
Amortization of net actuarial loss	4	5	—	—	8	10	1	—
Net periodic (credit) benefit cost	\$ (7)	\$ (6)	\$ 7	\$ 5	\$ (14)	\$ (12)	\$ 14	\$ 10

XML 64 R40.htm IDEA: XBRL DOCUMENT

**Accumulated Other
Comprehensive Loss
(Tables)**

[Equity \[Abstract\]](#)

**6 Months Ended
Oct. 25, 2024**

[Schedule of Changes in Accumulated Other Comprehensive Loss \(AOCL\), Net of Tax, by Component](#)

The following table provides changes in accumulated other comprehensive loss (AOCL), net of tax, and by component:

	Unrealized (Loss) Gain on Investment Securities	Cumulative Translation Adjustments	Net Investment Hedges	Net Change in Retirement Obligations	Unrealized Gain (Loss) on Cash Flow Hedges	Total Accumulated Other Comprehensive (Loss) Income
(in millions)						
April 26, 2024	\$ (212)	\$ (3,686)	\$ 878	\$ (529)	\$ 229	\$ (3,318)
Other comprehensive income (loss) before reclassifications	102	218	(170)	(1)	(37)	111
Reclassifications	9	—	—	3	(55)	(43)
Other comprehensive income (loss)	111	218	(170)	1	(93)	69
October 25, 2024	\$ (101)	\$ (3,468)	\$ 708	\$ (529)	\$ 139	\$ (3,250)

	Unrealized (Loss) Gain on Investment Securities	Cumulative Translation Adjustments	Net Investment Hedges	Net Change in Retirement Obligations	Unrealized Gain (Loss) on Cash Flow Hedges	Total Accumulated Other Comprehensive (Loss) Income
(in millions)						
April 28, 2023	\$ (258)	\$ (2,839)	\$ 245	\$ (741)	\$ 93	\$ (3,499)
Other comprehensive income (loss) before reclassifications	(49)	(909)	771	—	404	217
Reclassifications	11	—	—	4	(110)	(95)
Other comprehensive income (loss)	(38)	(909)	771	4	294	122
October 27, 2023	\$ (296)	\$ (3,748)	\$ 1,016	\$ (737)	\$ 387	\$ (3,377)

~~XML 65 R41.htm IDEA: XBRL DOCUMENT~~

Segment and Geographic Information (Tables)

[Segment Reporting \[Abstract\]](#)
[Schedule of Segment Operating Profit and Income Before Income Taxes](#)

6 Months Ended

Oct. 25, 2024

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Segment Operating Profit

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cardiovascular	\$ 1,164	\$ 1,117	\$ 2,289	\$ 2,208
Neuroscience	1,024	929	1,985	1,858
Medical Surgical	774	795	1,464	1,521
Diabetes	116	101	218	186
Reportable segment operating profit	3,079	2,942	5,956	5,773
Other operating segment ⁽¹⁾	12	4	26	1
Corporate	(448)	(431)	(903)	(879)
Interest expense, net	(209)	(180)	(376)	(329)
Other non-operating income, net	173	154	330	230
Amortization of intangible assets	(413)	(425)	(827)	(855)
Stock-based compensation	(159)	(146)	(242)	(219)
Centralized distribution costs	(405)	(391)	(800)	(786)
Currency ⁽²⁾	(39)	32	(44)	29
Restructuring and associated costs	(46)	(91)	(108)	(182)
Acquisition and divestiture-related items	25	(58)	13	(107)
Certain litigation charges, net	—	(65)	(81)	(105)
Medical device regulations	(12)	(30)	(27)	(62)
Other adjustments ⁽³⁾	—	—	(90)	—
Income before income taxes	\$ 1,559	\$ 1,313	\$ 2,827	\$ 2,510

(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.

(2) Includes the net impact of remeasurement and the Company's hedging programs recorded in *other operating income, net*.

(3) Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.

[Schedule of Net Sales to External Customers by Geography](#)

The following table presents net sales for the three and six months ended October 25, 2024 and October 27, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries:

(in millions)	Three months ended		Six months ended	
	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Ireland	\$ 29	\$ 29	\$ 59	\$ 58
United States	4,304	4,175	8,387	8,099
Rest of world	4,070	3,780	7,872	7,528
Total other countries, excluding Ireland	8,374	7,955	16,259	15,627
Total	\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686

~~XML 66 R42.htm IDEA: XBRL DOCUMENT~~

Revenue - Schedule of Disaggregation of Net Sales by Segment and Division (Details) -

USD (\$)
\$ in Millions

3 Months Ended

6 Months Ended

Oct. 25, 2024 Oct. 27, 2023 Oct. 25, 2024 Oct. 27, 2023

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Other Adjustments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Reportable segment net sales | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Cardiovascular | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Cardiovascular | Cardiac Rhythm & Heart Failure | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Cardiovascular | Structural Heart & Aortic | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Cardiovascular | Coronary & Peripheral Vascular | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Neuroscience | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Neuroscience | Cranial & Spinal Technologies | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Neuroscience | Specialty Therapies | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Neuroscience | Neuromodulation | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Medical Surgical | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Medical Surgical | Surgical & Endoscopy | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

[Medical Surgical | Acute Care & Monitoring | Operating Segments](#)

[Disaggregation of Revenue \[Line Items\]](#)

Total net sales

\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686
0	0	(90)	0
8,366	7,923	16,333	15,575
3,102	2,923	6,108	5,773
1,578	1,492	3,114	2,938
881	819	1,736	1,633
643	613	1,259	1,202
2,451	2,288	4,768	4,506
1,234	1,157	2,382	2,260
737	705	1,450	1,400
480	426	937	846
2,128	2,103	4,123	4,107
1,649	1,641	3,193	3,187
478	462	930	921

Diabetes Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	686	610	1,333	1,189
All other operating segments Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	\$ 37	\$ 61	\$ 75	\$ 111

~~XML 67 R43.htm IDEA: XBRL DOCUMENT~~

Revenue - Schedule of	3 Months Ended		6 Months Ended	
Disaggregation of Net				
Sales by Market				
Geography (Details) -	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023
USD (\$)				
\$ in Millions				

Disaggregation of Revenue [Line Items]				
Total net sales	\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686
Other Adjustments				
Disaggregation of Revenue [Line Items]				
Total net sales	0	0	(90)	0
U.S.				
Disaggregation of Revenue [Line Items]				
Total net sales	4,304	4,175	8,387	8,099
U.S. Other Adjustments				
Disaggregation of Revenue [Line Items]				
Total net sales	0	0	0	0
International				
Disaggregation of Revenue [Line Items]				
Total net sales	4,099	3,809	7,931	7,587
International Other Adjustments				
Disaggregation of Revenue [Line Items]				
Total net sales	0	0	(90)	0
Reportable segment net sales Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	8,366	7,923	16,333	15,575
Reportable segment net sales U.S. Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	4,286	4,151	8,350	8,054
Reportable segment net sales International Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	4,080	3,772	7,983	7,521
Cardiovascular Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	3,102	2,923	6,108	5,773
Cardiovascular U.S. Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	1,434	1,427	2,836	2,776
Cardiovascular International Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	1,668	1,496	3,272	2,996
Neuroscience Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	2,451	2,288	4,768	4,506
Neuroscience U.S. Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	1,677	1,560	3,242	3,057
Neuroscience International Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	774	728	1,526	1,449
Medical Surgical Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	2,128	2,103	4,123	4,107
Medical Surgical U.S. Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	944	948	1,825	1,815
Medical Surgical International Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	1,183	1,155	2,298	2,292
Diabetes Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	686	610	1,333	1,189
Diabetes U.S. Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	232	217	447	405
Diabetes International Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	455	394	886	784
Other Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	37	61	75	111
Other U.S. Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	18	23	37	45
Other International Operating Segments				
Disaggregation of Revenue [Line Items]				
Total net sales	\$ 19	\$ 37	\$ 38	\$ 66

~~XML 68 R44.htm IDEA: XBRL DOCUMENT~~

Revenue - Narrative	6 Months Ended		
(Details) - USD (\$)	Oct. 25, 2024	Oct. 27, 2023	Apr. 26, 2024
\$ in Millions			
Disaggregation of Revenue [Line Items]			
Deferred revenue		\$ 467	\$ 453
Revenue recognized that was previously included in deferred revenue		196	\$ 216
Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations		\$ 400	
Period over which remaining performance obligations are expected to be recognized as revenue		three years	
Other accrued expenses			
Disaggregation of Revenue [Line Items]			
Rebate obligations		\$ 1,000	1,000
Deferred revenue		369	352
Accounts Receivable			

Disaggregation of Revenue [Line Items]								
Rebate obligations					639		574	
Other liabilities								
Disaggregation of Revenue [Line Items]								
Deferred revenue					\$ 98		\$ 101	

~~***XML 69 R45.htm IDEA: XBRL DOCUMENT***~~

Acquisitions and Dispositions - Narrative (Details) - USD (\$) \$ in Millions	3 Months Ended		6 Months Ended		12 Months Ended			
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023	Apr. 26, 2024	Jul. 26, 2024	Jul. 28, 2023	Apr. 28, 2023
Business Acquisition [Line Items]								
Goodwill	\$ 41,161		\$ 41,161		\$ 40,986			
Purchase price contingent consideration	0	\$ 25	0	\$ 25	30			
Contingent consideration, fair value	124	\$ 220	124	\$ 220	149	\$ 128	\$ 206	\$ 206
Contingent consideration receivable					58			
Business Combinations								
Business Acquisition [Line Items]								
Total consideration for the transaction, net of cash acquired					335			
Goodwill					131			
Goodwill, Impairment Loss, Net of Tax					51			
Goodwill, Not Allocated, Amount					80			
Business Combinations IPR&D								
Business Acquisition [Line Items]								
Indefinite-lived intangible assets					150			
Business Combinations Technology-Based Intangible Assets								
Business Acquisition [Line Items]								
Intangible assets acquired					\$ 29			
Estimated useful life (in years)					10 years			
Other accrued expenses								
Business Acquisition [Line Items]								
Contingent consideration, fair value	77		77		\$ 96			
Other liabilities								
Business Acquisition [Line Items]								
Contingent consideration, fair value	\$ 47		\$ 47		\$ 53			

~~***XML 70 R46.htm IDEA: XBRL DOCUMENT***~~

Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Liabilities (Details) - USD (\$) \$ in Millions	3 Months Ended		6 Months Ended		12 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023	Apr. 26, 2024	
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments [Roll Forward]						
Beginning balance	\$ 128	\$ 206	\$ 149	\$ 206	\$ 206	
Purchase price contingent consideration	0	25	0	25	30	
Payments	(8)	0	(14)	(3)		
Change in fair value	4	(10)	(11)	(7)		
Ending balance	\$ 124	\$ 220	\$ 124	\$ 220	\$ 149	

~~***XML 71 R47.htm IDEA: XBRL DOCUMENT***~~

Acquisitions and Dispositions - Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability (Details) \$ in Millions	3 Months Ended		6 Months Ended		12 Months Ended	
	Oct. 25, 2024	Jul. 26, 2024	Apr. 26, 2024	Oct. 27, 2023	Jul. 28, 2023	Apr. 28, 2023
	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)	USD (\$)
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]						
Contingent consideration, fair value	\$ 124	\$ 128	\$ 149	\$ 220	\$ 206	\$ 206
Revenue and other performance-based payments Recurring Level 3						
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]						
Contingent consideration, fair value	\$ 58					
Revenue and other performance-based payments Minimum Recurring Level 3 Discount rate						
Fair Value Inputs						
Contingent consideration, significant unobservable inputs	0.165					
Revenue and other performance-based payments Maximum Recurring Level 3 Discount rate						
Fair Value Inputs						
Contingent consideration, significant unobservable inputs	0.282					
Revenue and other performance-based payments Weighted Average Recurring Level 3 Discount rate						
Fair Value Inputs						
Contingent consideration, significant unobservable inputs	0.221					
Product development and other milestone-based payments Recurring Level 3						
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]						
Contingent consideration, fair value	\$ 66					
Product development and other milestone-based payments Recurring Level 3 Discount rate						
Fair Value Inputs						
Contingent consideration, significant unobservable inputs	0.055					
Product development and other milestone-based payments Weighted Average Recurring Level 3 Discount rate						
Fair Value Inputs						
Contingent consideration, significant unobservable inputs	0.055					

~~***XML 72 R48.htm IDEA: XBRL DOCUMENT***~~

Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Receivables (Details) - USD (\$) \$ in Millions	3 Months Ended		6 Months Ended			
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023		
Beginning and Ending Balances of Contingent Payments [Roll Forward]						
Beginning balance			\$ 58			
Level 3 Recurring						
Beginning and Ending Balances of Contingent Payments [Roll Forward]						

Beginning balance	\$ 58	\$ 152	58	\$ 195
Change in fair value	3	0	3	(43)
Ending balance	\$ 61	\$ 152	\$ 61	\$ 152

~~XML 73 R49.htm IDEA: XBRL DOCUMENT~~

Restructuring and Other Costs - Narrative (Details) - USD (\$) \$ in Millions	3 Months Ended Oct. 25, 2024	6 Months Ended Oct. 27, 2023	3 Months Ended Oct. 25, 2024	6 Months Ended Oct. 27, 2023

[Restructuring and Related Activities \[Abstract\]](#)

Restructuring charges	\$ 46	\$ 91	\$ 108	\$ 182

~~XML 74 R50.htm IDEA: XBRL DOCUMENT~~

Restructuring and Other Costs - Schedule of Restructuring and Related Costs (Details) - USD (\$) \$ in Millions	3 Months Ended Oct. 25, 2024	6 Months Ended Oct. 27, 2023	3 Months Ended Oct. 25, 2024	6 Months Ended Oct. 27, 2023

[Restructuring Cost and Reserve \[Line Items\]](#)

Restructuring charges	\$ 46	\$ 91	\$ 108	\$ 182

[Cost of products sold](#)

[Restructuring Cost and Reserve \[Line Items\]](#)

Restructuring charges	11	15	20	30

[Selling, general, and administrative expense](#)

[Restructuring Cost and Reserve \[Line Items\]](#)

Restructuring charges	6	36	11	57

[Restructuring charges, net](#)

[Restructuring Cost and Reserve \[Line Items\]](#)

Restructuring charges	\$ 30	\$ 40	\$ 77	\$ 94

~~XML 75 R51.htm IDEA: XBRL DOCUMENT~~

Restructuring and Other Costs - Schedule of Activity of Restructuring Costs (Details) \$ in Millions	6 Months Ended Oct. 25, 2024

[Restructuring Reserve \[Roll Forward\]](#)

Beginning balance	\$ 147
Charges	118
Cash payments	(181)
Settled non-cash	(4)
Accrual adjustments	(10)
Ending balance	70

[Employee Termination Benefits](#)

[Restructuring Reserve \[Roll Forward\]](#)

Beginning balance	136
Charges	87
Cash payments	(156)
Settled non-cash	0
Accrual adjustments	(10)
Ending balance	58

[Associated and Other Costs](#)

[Restructuring Reserve \[Roll Forward\]](#)

Beginning balance	11
Charges	31
Cash payments	(25)
Settled non-cash	(4)
Accrual adjustments	0
Ending balance	\$ 13

~~XML 76 R52.htm IDEA: XBRL DOCUMENT~~

Financial Instruments - Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification (Details) - USD (\$) \$ in Millions	Oct. 25, 2024	Apr. 26, 2024

[Schedule of Investments \[Line Items\]](#)

Cost	\$ 6,708	\$ 6,968
Unrealized Gains	22	7
Unrealized Losses	(138)	(252)
Fair Value	6,592	6,723

[Investments](#)

[Schedule of Investments \[Line Items\]](#)

Fair Value	6,559	6,690

[Other Assets](#)

[Schedule of Investments \[Line Items\]](#)

Fair Value	33	33

[Level 2](#)

[Schedule of Investments \[Line Items\]](#)

Cost	6,134	6,438
Unrealized Gains	22	7
Unrealized Losses	(124)	(227)
Fair Value	6,032	6,218

[Level 2 | Investments](#)

[Schedule of Investments \[Line Items\]](#)

Fair Value	6,032	6,218

[Level 2 | Other Assets](#)

[Schedule of Investments \[Line Items\]](#)

Fair Value	0	0

[U.S. government and agency securities | Level 1](#)

[Schedule of Investments \[Line Items\]](#)

Cost	538	494
Unrealized Gains	0	0

Unrealized Losses	(11)	(22)
Fair Value	527	472
U.S. government and agency securities Level 1 Investments		
Schedule of Investments [Line Items]		
Fair Value	527	472
U.S. government and agency securities Level 1 Other Assets		
Schedule of Investments [Line Items]		
Fair Value	0	0
U.S. government and agency securities Level 2		
Schedule of Investments [Line Items]		
Cost	874	847
Unrealized Gains	0	0
Unrealized Losses	(28)	(43)
Fair Value	845	804
U.S. government and agency securities Level 2 Investments		
Schedule of Investments [Line Items]		
Fair Value	845	804
U.S. government and agency securities Level 2 Other Assets		
Schedule of Investments [Line Items]		
Fair Value	0	0
Corporate debt securities Level 2		
Schedule of Investments [Line Items]		
Cost	3,429	3,953
Unrealized Gains	13	4
Unrealized Losses	(59)	(125)
Fair Value	3,384	3,832
Corporate debt securities Level 2 Investments		
Schedule of Investments [Line Items]		
Fair Value	3,384	3,832
Corporate debt securities Level 2 Other Assets		
Schedule of Investments [Line Items]		
Fair Value	0	0
Mortgage-backed securities Level 2		
Schedule of Investments [Line Items]		
Cost	772	692
Unrealized Gains	3	1
Unrealized Losses	(33)	(50)
Fair Value	742	643
Mortgage-backed securities Level 2 Investments		
Schedule of Investments [Line Items]		
Fair Value	742	643
Mortgage-backed securities Level 2 Other Assets		
Schedule of Investments [Line Items]		
Fair Value	0	0
Non-U.S. government and agency securities Level 2		
Schedule of Investments [Line Items]		
Cost	9	5
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	9	5
Non-U.S. government and agency securities Level 2 Investments		
Schedule of Investments [Line Items]		
Fair Value	9	5
Non-U.S. government and agency securities Level 2 Other Assets		
Schedule of Investments [Line Items]		
Fair Value	0	0
Other asset-backed securities Level 2		
Schedule of Investments [Line Items]		
Cost	1,051	941
Unrealized Gains	5	2
Unrealized Losses	(3)	(9)
Fair Value	1,053	934
Other asset-backed securities Level 2 Investments		
Schedule of Investments [Line Items]		
Fair Value	1,053	934
Other asset-backed securities Level 2 Other Assets		
Schedule of Investments [Line Items]		
Fair Value	0	0
Auction rate securities Level 3		
Schedule of Investments [Line Items]		
Cost	36	36
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	33	33
Auction rate securities Level 3 Investments		
Schedule of Investments [Line Items]		
Fair Value	0	0
Auction rate securities Level 3 Other Assets		
Schedule of Investments [Line Items]		
Fair Value	\$ 33	\$ 33

~~***XML 77 R53.htm IDEA: XBRL DOCUMENT***~~

Financial Instruments

- Schedule of Gross

Unrealized Losses

and Fair Values of

Available-for-Sale

Securities,

Oct. 25, 2024 Apr. 26, 2024

Aggregated by

Investment Category

(Details) - USD (\$)

\$ in Millions

Fair Value

Less than 12 months \$ 782 \$ 838

More than 12 months 3,137 4,296

Unrealized Losses

Less than 12 months (10) (14)

More than 12 months (128) (238)

U.S. government and agency securities

Fair Value		
Less than 12 months	216	177
More than 12 months	713	730
Unrealized Losses		
Less than 12 months	(2)	(4)
More than 12 months	(37)	(61)
Corporate debt securities		
Fair Value		
Less than 12 months	565	661
More than 12 months	1,645	2,448
Unrealized Losses		
Less than 12 months	(7)	(10)
More than 12 months	(51)	(116)
Mortgage-backed securities		
Fair Value		
Less than 12 months	0	0
More than 12 months	535	582
Unrealized Losses		
Less than 12 months	0	0
More than 12 months	(33)	(50)
Other asset-backed securities		
Fair Value		
Less than 12 months	0	0
More than 12 months	212	502
Unrealized Losses		
Less than 12 months	0	0
More than 12 months	(3)	(9)
Auction rate securities		
Fair Value		
Less than 12 months	0	0
More than 12 months	33	33
Unrealized Losses		
Less than 12 months	0	0
More than 12 months	\$ (3)	\$ (3)

XML 78 R54.htm IDEA: XBRL DOCUMENT

Financial Instruments	3 Months Ended	6 Months Ended
- Schedule of Activity		
Related to Available-		
for-Sale Securities	Oct. 25, 2024	Oct. 27, 2023
Portfolio (Details) -	Oct. 25, 2024	Oct. 27, 2023
USD (\$)		
\$ in Millions		

Activities Related to Debt Securities Portfolio				
Proceeds from sales	\$ 2,087	\$ 1,573	\$ 4,244	\$ 3,320
Gross realized gains	7	6	14	11
Gross realized losses	\$ (6)	\$ (3)	\$ (13)	\$ (15)

XML 79 R55.htm IDEA: XBRL DOCUMENT

Financial Instruments	
- Schedule of	
Available-for-Sale	
Debt Securities by	Oct. 25, 2024
Contractual Maturity	Apr. 26, 2024
(Details) - USD (\$)	
\$ in Millions	

Amortized Cost	
Due in one year or less	\$ 1,488
Due after one year through five years	3,322
Due after five years through ten years	750
Due after ten years	1,148
Total	6,708
Fair Value	
Due in one year or less	1,478
Due after one year through five years	3,248
Due after five years through ten years	749
Due after ten years	1,117
Total	\$ 6,592
	\$ 6,723

XML 80 R56.htm IDEA: XBRL DOCUMENT

Financial Instruments	3 Months Ended	6 Months Ended
- Narrative (Details) -		
USD (\$)	Oct. 25, 2024	Oct. 27, 2023
	Oct. 25, 2024	Oct. 27, 2023
	Apr. 01, 2023	
Gain (Loss) on Securities [Line Items]		
Interest income	\$ 137,000,000	\$ 148,000,000
Change in fair value of instrument	0	0
Mozarc		
Gain (Loss) on Securities [Line Items]		
Non-controlling equity interest (percentage)		50.00%
Equity Securities and Other Investments		
Gain (Loss) on Securities [Line Items]		
Net unrealized gains (losses) on equity and other investments	\$ 10,000,000	\$ (7,000,000)
	\$ 7,000,000	\$ (70,000,000)

XML 81 R57.htm IDEA: XBRL DOCUMENT

Financial Instruments	
- Schedule of Equity	
and Other	
Investments (Details)	Oct. 25, 2024
- Other Assets - USD	Apr. 26, 2024
(\$)	
\$ in Millions	

Schedule of Equity Method Investments [Line Items]		
Investments with readily determinable fair value (marketable equity securities)	\$ 34	\$ 28
Investments for which the fair value option has been elected	311	311
Investments without readily determinable fair values	826	859
Equity method and other investments	92	84
Total equity and other investments	\$ 1,265	\$ 1,282

XML 82 R58.htm IDEA: XBRL DOCUMENT

Financing	3 Months Ended	6 Months Ended	12 Months Ended
Arrangements -			
Narrative (Details)	Jun. 03, 2024	Oct. 25, 2024	Oct. 25, 2024
€ in Billions	USD (\$)	USD (\$)	USD (\$)
		Oct. 27, 2023	Oct. 27, 2023
		USD (\$)	USD (\$)
			Apr. 26, 2024
			USD (\$)
			Jun. 03, 2024
			EUR (€)
			tranche

Schedule of Debt [Line Items]				
Current debt obligations	\$ 3,719,000,000		\$ 3,719,000,000	\$ 1,092,000,000
Interest expense on outstanding borrowings	252,000,000	\$ 230,000,000	469,000,000	\$ 427,000,000
Senior Notes				
Schedule of Debt [Line Items]				
Principal value	27,400,000,000		27,400,000,000	24,000,000,000.0
Estimated fair value	25,300,000,000		25,300,000,000	21,200,000,000
Commercial Paper				
Schedule of Debt [Line Items]				
Current debt obligations	\$ 899,000,000		\$ 899,000,000	\$ 1,100,000,000
Term of debt instrument	13 days		14 days	20 days
Weighted average interest rate	5.23%		5.34%	5.45%
Commercial Paper Program Commercial Paper				
Schedule of Debt [Line Items]				
Commercial paper, maximum borrowing amount	\$ 3,500,000,000		\$ 3,500,000,000	
Credit Facility Line of Credit				
Schedule of Debt [Line Items]				
Term of debt instrument			5 years	
Line of credit, maximum capacity	3,500,000,000		\$ 3,500,000,000	
Line of credit, amount outstanding	\$ 0		\$ 0	\$ 0
Medtronic Luxco Senior Notes Senior Notes				
Schedule of Debt [Line Items]				
Principal value €				€ 3.0
Proceeds from (repayments of) debt	\$ 3,200,000,000			
Medtronic Luxco Senior Notes Senior Notes Medtronic Luxco				
Schedule of Debt [Line Items]				
Number of tranches tranche				4

~~***XML 83 R59.htm IDEA: XBRL DOCUMENT***~~

Financing Arrangements - Schedule of Debt Obligations (Details) - USD (\$) - \$ in Millions	6 Months Ended 12 Months Ended	
	Oct. 25, 2024	Apr. 26, 2024
Debt Instrument [Line Items]		
Current debt obligations	\$ 3,719	\$ 1,092
Long-term debt		
Finance lease obligations	50	55
Deferred financing costs	(125)	(110)
Debt discount, net	(56)	(55)
Total long-term debt	\$ 24,607	\$ 23,932
0.25 percent six-year 2019 senior notes		
Long-term debt		
Stated interest rate	25.00%	25.00%
Term of debt instrument	6 years	6 years
2.625 percent three-year 2022 senior notes		
Long-term debt		
Stated interest rate	2.625%	2.625%
Term of debt instrument	3 years	3 years
0.000 percent five-year 2020 senior notes		
Long-term debt		
Stated interest rate	0.00%	0.00%
Term of debt instrument	5 years	5 years
1.125 percent eight-year 2019 senior notes		
Long-term debt		
Stated interest rate	1.125%	1.125%
Term of debt instrument	8 years	8 years
4.250 percent five-year 2023 senior notes		
Long-term debt		
Stated interest rate	4.25%	4.25%
Term of debt instrument	5 years	5 years
3.000 percent six-year 2022 senior notes		
Long-term debt		
Stated interest rate	3.00%	3.00%
Term of debt instrument	6 years	6 years
0.375 percent eight-year 2020 senior notes		
Long-term debt		
Stated interest rate	0.375%	0.375%
Term of debt instrument	8 years	8 years
3.650 percent five-year 2024 senior notes		
Long-term debt		
Stated interest rate	3.65%	3.65%
Term of debt instrument	5 years	5 years
1.625 percent twelve-year 2019 senior notes		
Long-term debt		
Stated interest rate	1.625%	1.625%
Term of debt instrument	12 years	12 years
1.000 percent twelve-year 2019 senior notes		
Long-term debt		
Stated interest rate	1.00%	1.00%
Term of debt instrument	12 years	12 years
3.125 percent nine-year 2022 senior notes		
Long-term debt		
Stated interest rate	3.125%	3.125%
Term of debt instrument	9 years	9 years
0.750 percent twelve-year 2020 senior notes		
Long-term debt		
Stated interest rate	0.75%	0.75%
Term of debt instrument	12 years	12 years
4.500 percent ten-year 2023 senior notes		
Long-term debt		
Stated interest rate	4.50%	4.50%
Term of debt instrument	10 years	10 years
3.375 percent twelve-year 2022 senior notes		
Long-term debt		
Stated interest rate	3.375%	3.375%
Term of debt instrument	12 years	12 years
4.375 percent twenty-year 2015 senior notes		

Long-term debt		
Stated interest rate	4.375%	4.375%
Term of debt instrument	20 years	20 years
3.875 percent twelve-year 2024 senior notes		
Long-term debt		
Stated interest rate	3.875%	3.875%
Term of debt instrument	12 years	12 years
6.550 percent thirty-year 2007 CIFSA senior notes		
Long-term debt		
Stated interest rate	6.55%	6.55%
Term of debt instrument	30 years	30 years
2.250 percent twenty-year 2019 senior notes		
Long-term debt		
Stated interest rate	2.25%	2.25%
Term of debt instrument	20 years	20 years
6.500 percent thirty-year 2009 senior notes		
Long-term debt		
Stated interest rate	6.50%	6.50%
Term of debt instrument	30 years	30 years
1.500 percent twenty-year 2019 senior notes		
Long-term debt		
Stated interest rate	1.50%	1.50%
Term of debt instrument	20 years	20 years
5.550 percent thirty-year 2010 senior notes		
Long-term debt		
Stated interest rate	5.55%	5.55%
Term of debt instrument	30 years	30 years
1.375 percent twenty-year 2020 senior notes		
Long-term debt		
Stated interest rate	1.375%	1.375%
Term of debt instrument	20 years	20 years
4.500 percent thirty-year 2012 senior notes		
Long-term debt		
Stated interest rate	4.50%	4.50%
Term of debt instrument	30 years	30 years
4.000 percent thirty-year 2013 senior notes		
Long-term debt		
Stated interest rate	4.00%	4.00%
Term of debt instrument	30 years	30 years
4.150 percent nineteen-year 2024 senior notes		
Long-term debt		
Stated interest rate	4.15%	4.15%
Term of debt instrument	19 years	19 years
4.625 percent thirty-year 2014 senior notes		
Long-term debt		
Stated interest rate	4.625%	4.625%
Term of debt instrument	30 years	30 years
4.625 percent thirty-year 2015 senior notes		
Long-term debt		
Stated interest rate	4.625%	4.625%
Term of debt instrument	30 years	30 years
1.750 percent thirty-year 2019 senior notes		
Long-term debt		
Stated interest rate	1.75%	1.75%
Term of debt instrument	30 years	30 years
1.625 percent thirty-year 2020 senior notes		
Long-term debt		
Stated interest rate	1.625%	1.625%
Term of debt instrument	30 years	30 years
4.150 percent twenty-nine-year 2024 senior notes		
Long-term debt		
Stated interest rate	4.15%	4.15%
Term of debt instrument	29 years	29 years
Senior Notes 0.25 percent six-year 2019 senior notes		
Long-term debt		
Long-term debt, gross	\$ 0	\$ 1,070
Senior Notes 2.625 percent three-year 2022 senior notes		
Long-term debt		
Long-term debt, gross	0	535
Senior Notes 0.000 percent five-year 2020 senior notes		
Long-term debt		
Long-term debt, gross	0	1,070
Senior Notes 1.125 percent eight-year 2019 senior notes		
Long-term debt		
Long-term debt, gross	1,620	1,606
Senior Notes 4.250 percent five-year 2023 senior notes		
Long-term debt		
Long-term debt, gross	1,000	1,000
Senior Notes 3.000 percent six-year 2022 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 0.375 percent eight-year 2020 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 3.650 percent five-year 2024 senior notes		
Long-term debt		
Long-term debt, gross	918	0
Senior Notes 1.625 percent twelve-year 2019 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 1.000 percent twelve-year 2019 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 3.125 percent nine-year 2022 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 0.750 percent twelve-year 2020 senior notes		

Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 4.500 percent ten-year 2023 senior notes		
Long-term debt		
Long-term debt, gross	1,000	1,000
Senior Notes 3.375 percent twelve-year 2022 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 4.375 percent twenty-year 2015 senior notes		
Long-term debt		
Long-term debt, gross	1,932	1,932
Senior Notes 3.875 percent twelve-year 2024 senior notes		
Long-term debt		
Long-term debt, gross	918	0
Senior Notes 6.550 percent thirty-year 2007 CIFSA senior notes		
Long-term debt		
Long-term debt, gross	253	253
Senior Notes 2.250 percent twenty-year 2019 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 6.500 percent thirty-year 2009 senior notes		
Long-term debt		
Long-term debt, gross	158	158
Senior Notes 1.500 percent twenty-year 2019 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 5.550 percent thirty-year 2010 senior notes		
Long-term debt		
Long-term debt, gross	224	224
Senior Notes 1.375 percent twenty-year 2020 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 4.500 percent thirty-year 2012 senior notes		
Long-term debt		
Long-term debt, gross	105	105
Senior Notes 4.000 percent thirty-year 2013 senior notes		
Long-term debt		
Long-term debt, gross	305	305
Senior Notes 4.150 percent nineteen-year 2024 senior notes		
Long-term debt		
Long-term debt, gross	648	0
Senior Notes 4.625 percent thirty-year 2014 senior notes		
Long-term debt		
Long-term debt, gross	127	127
Senior Notes 4.625 percent thirty-year 2015 senior notes		
Long-term debt		
Long-term debt, gross	1,813	1,813
Senior Notes 1.750 percent thirty-year 2019 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 1.625 percent thirty-year 2020 senior notes		
Long-term debt		
Long-term debt, gross	1,080	1,070
Senior Notes 4.150 percent twenty-nine-year 2024 senior notes		
Long-term debt		
Long-term debt, gross	\$ 756	\$ 0

~~***XML 84 R60.htm IDEA: XBRL DOCUMENT***~~

Derivatives and Currency Exchange Risk Management - Narrative (Details) - USD (\$)	3 Months Ended		6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023 Apr. 26, 2024
Derivative Instruments and Hedging Activities Disclosures [Line Items]				
Derivative, excluded component, gain (loss), recognized in earnings	\$ 47,000,000	\$ 50,000,000	\$ 98,000,000	\$ 99,000,000
Fair value hedge				
Derivative Instruments and Hedging Activities Disclosures [Line Items]				
Unrealized gain (loss)	0		0	
Amortized excluded component	0		\$ 0	
Currency exchange rate contracts Derivatives designated as hedging instruments Cash flow hedge				
Derivative Instruments and Hedging Activities Disclosures [Line Items]				
Maximum remaining maturity of foreign currency derivatives			3 years	
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	\$ 139,000,000		\$ 139,000,000	\$ 229,000,000
Cash flow hedge unrealized gains to be reclassified over the next 12 months			\$ 108,000,000	

~~***XML 85 R61.htm IDEA: XBRL DOCUMENT***~~

Derivatives and Currency Exchange Risk Management - Schedule of Outstanding Instruments (Details) € in Billions, ¥ in Billions, \$ in Billions	Oct. 25, 2024		Oct. 25, 2024		Oct. 25, 2024		Apr. 26, 2024	
	USD (\$)		EUR (€)		JPY (¥)		USD (\$)	
Derivatives designated as hedging instruments Currency exchange rate contracts Europe								
Derivative Instruments and Hedging Activities Disclosures [Line Items]								
Gross notional amount	\$ 5.4		€ 5.0					
Derivatives designated as hedging instruments Currency exchange rate contracts JAPAN								
Derivative Instruments and Hedging Activities Disclosures [Line Items]								
Gross notional amount	2.1				¥ 322.2			
Derivatives designated as hedging instruments Fair value hedge Currency exchange rate contracts								
Derivative Instruments and Hedging Activities Disclosures [Line Items]								
Gross notional amount	1.1		1.0				\$ 0.0	
Derivatives designated as hedging instruments Cash flow hedge Currency exchange rate contracts								
Derivative Instruments and Hedging Activities Disclosures [Line Items]								
Gross notional amount	11.3						10.4	
Derivatives designated as hedging instruments Net investment hedge Currency exchange rate contracts								
Derivative Instruments and Hedging Activities Disclosures [Line Items]								
Gross notional amount	7.5						7.4	
Derivatives designated as hedging instruments Net investment hedge Foreign currency-denominated debt								

Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Gross notional amount	19.4	€ 18.0	17.1
Derivatives not designated as hedging instruments Currency exchange rate contracts			
Derivative Instruments and Hedging Activities Disclosures [Line Items]			
Gross notional amount	\$ 4.7		\$ 5.9

~~***XML R62.htm IDEA: XBRL DOCUMENT***~~

Derivatives and Currency Exchange Risk Management - Schedule of Gains and Losses on Hedging Instruments (Details) - USD (\$) \$ in Millions	3 Months Ended	6 Months Ended
	Oct. 25, 2024	Oct. 27, 2023
	Oct. 25, 2024	Oct. 27, 2023

(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	\$ (19)	\$ (1,384)	\$ 214	\$ (1,278)
(Gain) Loss Reclassified into Income				
(Gain) Loss Reclassified into Income	(24)	(89)	(78)	(145)
Currency exchange rate contracts				
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				
Recognized in AOCL, net investment hedges	52	(190)	12	(160)
(Gain) Loss Reclassified into Income				
Reclassified into Income, net investment hedges	0	0	0	0
Currency exchange rate contracts Other operating income, net				
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				
Recognized in AOCL, cash flow hedges	0	(394)	42	(398)
(Gain) Loss Reclassified into Income				
Recognized in income, cash flow hedges	(3)	(75)	(39)	(125)
Currency exchange rate contracts Cost of products sold				
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				
Recognized in AOCL, cash flow hedges	20	(75)	0	(109)
(Gain) Loss Reclassified into Income				
Recognized in income, cash flow hedges	(21)	(15)	(39)	(19)
Foreign currency-denominated debt				
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss				
Recognized in AOCL, net investment hedges	(91)	(725)	160	(612)
(Gain) Loss Reclassified into Income				
Reclassified into Income, net investment hedges	\$ 0	\$ 0	\$ 0	\$ 0

~~***XML R63.htm IDEA: XBRL DOCUMENT***~~

Derivatives and Currency Exchange Risk Management - Schedule of Gains and Losses on Derivatives Not Designated as Hedging Instruments (Details) - USD (\$) \$ in Millions	3 Months Ended	6 Months Ended
	Oct. 25, 2024	Oct. 27, 2023
	Oct. 25, 2024	Oct. 27, 2023

Other operating income, net Currency exchange rate contracts				
Derivative Instruments, (Gain) Loss [Line Items]				
(Gain) Loss Recognized in Income	\$ (35)	\$ 94	\$ (45)	\$ 92

~~***XML R64.htm IDEA: XBRL DOCUMENT***~~

Derivatives and Currency Exchange Risk Management - Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets (Details) - USD (\$) \$ in Millions	
	Oct. 25, 2024
	Apr. 26, 2024

Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	\$ 589	\$ 659
Derivative liabilities, fair value	110	66
Currency exchange rate contracts		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	574	659
Derivative liabilities, fair value	110	66
Total return swaps		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	15	
Derivatives designated as hedging instruments		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	556	644
Derivative liabilities, fair value	78	54
Derivatives designated as hedging instruments Currency exchange rate contracts Other current assets		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	328	368
Derivatives designated as hedging instruments Currency exchange rate contracts Other Assets		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	227	276
Derivatives designated as hedging instruments Currency exchange rate contracts Other accrued expenses		
Derivatives, Fair Value [Line Items]		
Derivative liabilities, fair value	56	37
Derivatives designated as hedging instruments Currency exchange rate contracts Other liabilities		
Derivatives, Fair Value [Line Items]		
Derivative liabilities, fair value	22	17
Derivatives not designated as hedging instruments		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	34	15
Derivative liabilities, fair value	32	12
Derivatives not designated as hedging instruments Currency exchange rate contracts Other current assets		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	19	15
Derivatives not designated as hedging instruments Currency exchange rate contracts Other accrued expenses		
Derivatives, Fair Value [Line Items]		

Derivative liabilities, fair value	32	12
Derivatives not designated as hedging instruments Total return swaps Other current assets		
Derivatives, Fair Value [Line Items]		
Derivative assets, fair value	15	0
Derivatives not designated as hedging instruments Total return swaps Other accrued expenses		
Derivatives, Fair Value [Line Items]		
Derivative liabilities, fair value	\$ 0	\$ 0

~~***XML 89 R65.htm IDEA: XBRL DOCUMENT***~~

Derivatives and Currency Exchange Risk Management - Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD (\$) \$ in Millions	Oct. 25, 2024	Apr. 26, 2024

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Derivative Assets	\$ 589	\$ 659
Derivative Liabilities	110	66
Level 1		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Derivative Assets	574	659
Derivative Liabilities	110	66
Level 2		
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]		
Derivative Assets	15	0
Derivative Liabilities	\$ 0	\$ 0

~~***XML 90 R66.htm IDEA: XBRL DOCUMENT***~~

Derivatives and Currency Exchange Risk Management - Schedule of Offsetting Assets and Liabilities (Details) - USD (\$) \$ in Millions	Oct. 25, 2024	Apr. 26, 2024

Derivative assets:		
Gross Amount of Recognized Assets (Liabilities)	\$ 589	\$ 659
Financial Instruments	(107)	
Cash Collateral (Received) Posted	(52)	
Net Amount	432	
Derivative liabilities:		
Gross Amount of Recognized Assets (Liabilities)	(110)	(66)
Total		
Gross Amount of Recognized Assets (Liabilities)	479	593
Financial Instruments	0	0
Cash Collateral (Received) Posted	(52)	(101)
Net Amount	428	492
Currency exchange rate contracts		
Derivative assets:		
Gross Amount of Recognized Assets (Liabilities)	574	659
Financial Instruments	(107)	(66)
Cash Collateral (Received) Posted	(52)	(101)
Net Amount	417	492
Derivative liabilities:		
Gross Amount of Recognized Assets (Liabilities)	(110)	(66)
Financial Instruments	107	66
Cash Collateral (Received) Posted	0	0
Net Amount	(4)	\$ 0
Total return swaps		
Derivative assets:		
Gross Amount of Recognized Assets (Liabilities)	15	
Financial Instruments	0	
Cash Collateral (Received) Posted	0	
Net Amount	\$ 15	

~~***XML 91 R67.htm IDEA: XBRL DOCUMENT***~~

Inventories (Details) - USD (\$) \$ in Millions	Oct. 25, 2024	Apr. 26, 2024

Inventory Disclosure [Abstract]		
Finished goods	\$ 3,729	\$ 3,668
Work-in-process	728	642
Raw materials	1,022	907
Total	\$ 5,479	\$ 5,217

~~***XML 92 R68.htm IDEA: XBRL DOCUMENT***~~

Goodwill and Other Intangible Assets - Schedule of Changes in the Carrying Amount of Goodwill (Details) \$ in Millions	6 Months Ended
	Oct. 25, 2024
	USD (\$)

Goodwill [Roll Forward]	
Beginning balance	\$ 40,986
Currency translation and other	176
Ending balance	41,161
Cardiovascular	
Goodwill [Roll Forward]	
Beginning balance	7,966
Currency translation and other	4
Ending balance	7,970
Neuroscience	
Goodwill [Roll Forward]	
Beginning balance	11,644
Currency translation and other	24
Ending balance	11,668
Medical Surgical	
Goodwill [Roll Forward]	

Beginning balance	19,121
Currency translation and other	147
Ending balance	19,268
Diabetes	
Goodwill [Roll Forward]	
Beginning balance	2,255
Currency translation and other	0
Ending balance	\$ 2,255

XML 93 R69.htm IDEA: XBRL DOCUMENT

Goodwill and Other Intangible Assets - Narrative (Details) - USD (\$)	3 Months Ended		6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023
Goodwill [Line Items]				
Goodwill impairment	\$ 0	\$ 0	\$ 0	\$ 0
Definite-lived intangible asset charges	0	0	0	0
Indefinite-lived intangible asset charges	0	0	0	0
Amortization expense	\$ 413,000,000	\$ 425,000,000	\$ 827,000,000	\$ 855,000,000

XML 94 R70.htm IDEA: XBRL DOCUMENT

Goodwill and Other Intangible Assets - Schedule of Gross Carrying Amount and Accumulated Amortization of Definite and Indefinite Lived Intangible Assets (Details) - USD (\$) \$ in Millions	Oct. 25, 2024	Apr. 26, 2024

Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	\$ 28,929	\$ 28,755
Accumulated Amortization	(16,741)	(15,915)
IPR&D		
Indefinite-lived Intangible Assets [Line Items]		
Gross Carrying Amount	235	385
Customer-related		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	16,523	16,518
Accumulated Amortization	(9,164)	(8,689)
Purchased technology and patents		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	11,727	11,557
Accumulated Amortization	(7,206)	(6,868)
Trademarks and tradenames		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	425	424
Accumulated Amortization	(280)	(274)
Other		
Finite-Lived Intangible Assets [Line Items]		
Gross Carrying Amount	254	256
Accumulated Amortization	\$ (90)	\$ (84)

XML 95 R71.htm IDEA: XBRL DOCUMENT

Goodwill and Other Intangible Assets - Schedule of Estimated Future Aggregate Amortization Expense (Details) \$ in Millions	Oct. 25, 2024
USD (\$)	

Goodwill and Intangible Assets Disclosure [Abstract]

Remaining 2025	\$ 824
2026	1,639
2027	1,616
2028	1,565
2029	1,488
2030	\$ 1,356

XML 96 R72.htm IDEA: XBRL DOCUMENT

Income Taxes (Details) - USD (\$) \$ in Millions	3 Months Ended		6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Jul. 28, 2023	Oct. 25, 2024
			Oct. 27, 2023	Apr. 26, 2024

Income Tax Disclosure [Abstract]

Income tax charge			\$ 187		
Effective tax rate	18.00%	30.60%		17.70%	32.00%
Gross unrecognized tax benefits	\$ 2,900			\$ 2,900	\$ 2,800
Accrued gross interest and penalties	45			45	
Unrecognized tax benefits that would impact effective tax rate	2,700			2,700	
Unrecognized tax benefits, net	\$ 1,900			\$ 1,900	\$ 1,800

XML 97 R73.htm IDEA: XBRL DOCUMENT

Earnings Per Share - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD (\$) \$ / shares in Units, shares in Millions, \$ in Millions	3 Months Ended		6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023

Numerator:

Net income attributable to ordinary shareholders	\$ 1,270	\$ 909	\$ 2,312	\$ 1,700

Denominator:

Basic - weighted average shares outstanding (shares)	1,282.4	1,330.2	1,288.6	1,330.3

Effect of dilutive securities:

Diluted - weighted average shares outstanding (shares)	1,286.9	1,331.9	1,292.5	1,332.8

Basic earnings per share (usd per share)	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28

Diluted earnings per share (usd per share)	\$ 0.99	\$ 0.68	\$ 1.79	\$ 1.28

Employee stock options

Effect of dilutive securities:

Effect of dilutive securities (shares)	0.6	0.5	0.6	0.9

Employee restricted stock units				
Effect of dilutive securities:				
Employee restricted stock units (shares)	2.1	0.9	2.0	1.3
Employee performance share units				
Effect of dilutive securities:				
Effect of dilutive securities (shares)	1.8	0.2	1.3	0.3
~~XML 98 R74.htm IDEA: XBRL DOCUMENT~~				
Earnings Per Share -			3 Months Ended	6 Months Ended
Narrative (Details) -				
shares			Oct. 25, 2024	Oct. 27, 2023
shares in Millions				

Stock options				
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]				
Antidilutive securities excluded from computation of earnings per share (shares)	28	31	27	27

~~XML 99 R75.htm IDEA: XBRL DOCUMENT~~				
Stock-Based			3 Months Ended	6 Months Ended
Compensation				
(Details) - USD (\$)			Oct. 25, 2024	Oct. 27, 2023
\$ in Millions				

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	\$ 159	\$ 146	\$ 242	\$ 219
Income tax benefits	(25)	(25)	(38)	(36)
Total stock-based compensation expense, net of tax	134	121	204	183
Cost of products sold				

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	17	13	26	20
Research and development expense				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	19	18	29	27
Selling, general, and administrative expense				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	123	115	187	172
Stock options				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	30	35	42	46
Restricted stock				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	68	55	111	93
Performance share units				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	54	48	69	60
Employee stock purchase plan				
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]				
Total stock-based compensation expense	\$ 8	\$ 8	\$ 19	\$ 19

~~XML 100 R76.htm IDEA: XBRL DOCUMENT~~				
Retirement Benefit		3 Months Ended	6 Months Ended	
Plans (Details) -				
Pension Plan - USD		Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024
(\$)				Oct. 27, 2023
\$ in Millions				

U.S.				
Net Periodic Benefit Cost				
Service cost	\$ 13	\$ 15	\$ 26	\$ 30
Interest cost	43	40	86	80
Expected return on plan assets	(66)	(65)	(132)	(130)
Amortization of prior service cost	(1)	(1)	(2)	(2)
Amortization of net actuarial loss	4	5	8	10
Net periodic (credit) benefit cost	(7)	(6)	(14)	(12)
Non-U.S.				
Net Periodic Benefit Cost				
Service cost	11	10	22	20
Interest cost	13	12	26	24
Expected return on plan assets	(17)	(17)	(34)	(34)
Amortization of prior service cost	0	0	0	0
Amortization of net actuarial loss	0	0	1	0
Net periodic (credit) benefit cost	\$ 7	\$ 5	\$ 14	\$ 10

~~XML 101 R77.htm IDEA: XBRL DOCUMENT~~						
Accumulated Other Comprehensive Loss - Schedule of Changes in Accumulated Other Comprehensive Loss (AOCL), Net of Tax, by Component (Details) - USD (\$) \$ in Millions	3 Months Ended				6 Months Ended	
		Oct. 25, 2024	Jul. 26, 2024	Oct. 27, 2023	Jul. 28, 2023	Oct. 25, 2024
						Oct. 27, 2023
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]						
Beginning balance	\$ 48,160	\$ 50,420	\$ 51,366	\$ 51,665	\$ 50,420	\$ 51,665
Other comprehensive income	161	(92)	295	(175)	69	120
Ending balance	48,716	48,160	51,647	51,366	48,716	51,647
Total Accumulated Other Comprehensive (Loss) Income						
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]						
Beginning balance	(3,410)	(3,318)	(3,674)	(3,499)	(3,318)	(3,499)
Other comprehensive income (loss) before reclassifications					111	217
Reclassifications					(43)	(95)
Other comprehensive income	161	(92)	297	(175)	69	122
Ending balance	(3,250)	(3,410)	(3,377)	(3,674)	(3,250)	(3,377)
Unrealized (Loss) Gain on Investment Securities						
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]						
Beginning balance		(212)		(258)	(212)	(258)
Other comprehensive income (loss) before reclassifications					102	(49)
Reclassifications					9	11
Other comprehensive income					111	(38)
Ending balance	(101)		(296)		(101)	(296)
Cumulative Translation Adjustments						
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll						

Forward					
Beginning balance	(3,686)		(2,839)	(3,686)	(2,839)
Other comprehensive income (loss) before reclassifications				218	(909)
Reclassifications				0	0
Other comprehensive income				218	(909)
Ending balance	(3,468)	(3,748)		(3,468)	(3,748)
Net Investment Hedges					
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]					
Beginning balance	878		245	878	245
Other comprehensive income (loss) before reclassifications				(170)	771
Reclassifications				0	0
Other comprehensive income				(170)	771
Ending balance	708	1,016		708	1,016
Net Change in Retirement Obligations					
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]					
Beginning balance	(529)		(741)	(529)	(741)
Other comprehensive income (loss) before reclassifications				(1)	0
Reclassifications				3	4
Other comprehensive income				1	4
Ending balance	(529)	(737)		(529)	(737)
Unrealized Gain (Loss) on Cash Flow Hedges					
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]					
Beginning balance	\$ 229		\$ 93	229	93
Other comprehensive income (loss) before reclassifications				(37)	404
Reclassifications				(55)	(110)
Other comprehensive income				(93)	294
Ending balance	\$ 139	\$ 387		\$ 139	\$ 387

XML 102-R78.htm
IDEA: XBRL DOCUMENT

Accumulated Other Comprehensive Loss - Narrative (Details) - USD (\$)	6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023
Unrealized (Loss) Gain on Investment Securities		
Accumulated Other Comprehensive Income (Loss) [Line Items]		
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	\$ 19,000,000	\$ (8,000,000)
Reclassifications, tax expense (benefit)	(2,000,000)	3,000,000
Cumulative Translation Adjustments		
Accumulated Other Comprehensive Income (Loss) [Line Items]		
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	0	0
Net Investment Hedges		
Accumulated Other Comprehensive Income (Loss) [Line Items]		
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	(1,000,000)	0
Net Change in Retirement Obligations		
Accumulated Other Comprehensive Income (Loss) [Line Items]		
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	0	0
Reclassifications, tax expense (benefit)	1,000,000	2,000,000
Unrealized Gain (Loss) on Cash Flow Hedges		
Accumulated Other Comprehensive Income (Loss) [Line Items]		
Other comprehensive income (loss) before reclassifications, tax expense (benefit)	(5,000,000)	103,000,000
Reclassifications, tax expense (benefit)	\$ (22,000,000)	\$ (34,000,000)

XML 103-R79.htm
IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details) \$ in Millions	3 Months Ended					6 Months Ended			
	Nov. 04, 2024 plaintiff lawsuit	Oct. 30, 2024 plaintiff claim lawsuit	Feb. 08, 2023 USD (\$)	Oct. 25, 2024 USD (\$)	Jul. 26, 2024 USD (\$)	Oct. 27, 2023 USD (\$)	Oct. 25, 2024 USD (\$)	Oct. 27, 2023 USD (\$)	Apr. 26, 2024 USD (\$)
Loss Contingencies [Line Items]									
Certain litigation charges, net \$			\$ 0			\$ 65	\$ 81	\$ 105	
Accrued litigation charges \$			\$ 200				\$ 200		\$ 200
Accrual adjustment \$					\$ 90				
Colibri									
Loss Contingencies [Line Items]									
Amount of settlement paid \$									\$ 106
Hernia Mesh Litigation Pending Litigation Subsequent Event									
Loss Contingencies [Line Items]									
Number of plaintiffs (in plaintiffs) plaintiff		8,800							
Number of claimants (in claimants) claim		1,450							
Number of lawsuits (in lawsuits) lawsuit		10							
Hernia Mesh Litigation Pending Litigation Massachusetts Subsequent Event									
Loss Contingencies [Line Items]									
Number of plaintiffs (in plaintiffs) plaintiff		6,850							
Hernia Mesh Litigation Pending Litigation Minnesota Subsequent Event									
Loss Contingencies [Line Items]									
Number of plaintiffs (in plaintiffs) plaintiff		500							
Diabetes Pump Retainer Ring Litigation California Subsequent Event									
Loss Contingencies [Line Items]									
Number of plaintiffs (in plaintiffs) plaintiff		76							
Number of lawsuits (in lawsuits) lawsuit		23							

XML 104-R80.htm
IDEA: XBRL DOCUMENT

Segment and Geographic Information - Narrative (Details)	6 Months Ended	
	Oct. 25, 2024	segment
Segment Reporting [Abstract]		
Number of reportable segments	4	

XML 105-R81.htm
IDEA: XBRL DOCUMENT

Segment and Geographic Information - Schedule of Segment Operating Profit and Income Before Income Taxes	3 Months Ended		6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023

(Details) - USD (\$)
\$ in Millions

[Segment Reporting Information \[Line Items\]](#)

Reportable segment operating profit	\$ 1,595	\$ 1,340	\$ 2,873	\$ 2,608
Other non-operating income, net	173	154	330	230
Amortization of intangible assets	(413)	(425)	(827)	(855)
Stock-based compensation			(242)	(219)
Restructuring and associated costs	(46)	(91)	(108)	(182)
Certain litigation charges, net	0	(65)	(81)	(105)
Income before income taxes	1,559	1,313	2,827	2,510

[Operating Segments](#)

[Segment Reporting Information \[Line Items\]](#)

Reportable segment operating profit	3,079	2,942	5,956	5,773

[Operating Segments | Cardiovascular](#)

[Segment Reporting Information \[Line Items\]](#)

Reportable segment operating profit	1,164	1,117	2,289	2,208

[Operating Segments | Neuroscience](#)

[Segment Reporting Information \[Line Items\]](#)

Reportable segment operating profit	1,024	929	1,985	1,858

[Operating Segments | Medical Surgical](#)

[Segment Reporting Information \[Line Items\]](#)

Reportable segment operating profit	774	795	1,464	1,521

[Operating Segments | Diabetes](#)

[Segment Reporting Information \[Line Items\]](#)

Reportable segment operating profit	116	101	218	186

[Operating Segments | Other](#)

[Segment Reporting Information \[Line Items\]](#)

Reportable segment operating profit	12	4	26	1

[Segment Reconciling Items](#)

[Segment Reporting Information \[Line Items\]](#)

Corporate	(448)	(431)	(903)	(879)
Interest expense, net	(209)	(180)	(376)	(329)
Other non-operating income, net	173	154	330	230
Amortization of intangible assets	(413)	(425)	(827)	(855)
Stock-based compensation	(159)	(146)	(242)	(219)
Centralized distribution costs	(405)	(391)	(800)	(786)
Currency	(39)	32	(44)	29
Restructuring and associated costs	(46)	(91)	(108)	(182)
Acquisition and divestiture-related items	25	(58)	13	(107)
Certain litigation charges, net	0	(65)	(81)	(105)
Medical device regulations	(12)	(30)	(27)	(62)
Other adjustments	\$ 0	\$ 0	\$ (90)	\$ 0

[XML 106 R82.htm IDEA: XBRL DOCUMENT](#)

Segment and Geographic Information - Schedule of Net Sales to External Customers by Geography (Details) - USD (\$) \$ in Millions	3 Months Ended		6 Months Ended	
	Oct. 25, 2024	Oct. 27, 2023	Oct. 25, 2024	Oct. 27, 2023

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net sales	\$ 8,403	\$ 7,984	\$ 16,318	\$ 15,686

[Ireland](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net sales	29	29	59	58

[Total other countries, excluding Ireland](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net sales	8,374	7,955	16,259	15,627

[United States](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net sales	4,304	4,175	8,387	8,099

[Rest of world](#)

[Revenues from External Customers and Long-Lived Assets \[Line Items\]](#)

Net sales	\$ 4,070	\$ 3,780	\$ 7,872	\$ 7,528

[EXCEL 107 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4\\$L#!0 \(](#)
[/R!>ED'04UB@0 +\\$ 0 9&|C4'\)O<';087!P+GAM M;\\$V-/0L",1!\\$ _|IQO;=|P4\)B0-!2L+](#)
[\(/>QLOD&1#LD\)^OCG!CVX>;QA&WPIG M^N^I#BV&5\(C\(H\(/!47BK9.7;=N'\)=HI6-Y](#)
[#OGDK7A.YNJQ<&4GPZ4A!0W J=0U!R;UEA 6!#MI7E!+ P04 M " #\|@7I9272<-;X K @ \\$0 &108U!R;W!S+V-](#)
[O&ULS9+! M3L P#\(9?!>7>NLG&#E&7"X@32\\$A, G&+ \\$F^+;-HH,6KWJ1AZX3@ 3C&-O/Y](#)
[ML^36!&F&B,IQ"!C\)8;J9? NPI +Y, #5/ M#*>I:~\\$*F&&\\$T:~?O MJ%6*I 8DL'V#DY\);>DQG&LQU7\)Y1TXO#T!OI1U*1](#)
[6W;9 +JZN!H,"4:L;XXK1F\)ICDMW\(MWF?7" WY783I8MW? MV/@BJ%KX=12! "U!+ P04 " #\|@7I9F5R<\(Q & "<\)P \\$P](#)
[!AL+W1H M96UE+W1H96UE,2YX;6SM6EMSV C@4?N^OT^AGIFT+QC;!MK03621A'^ 1S80RY8-!9\)-](#)
[N!H!/"SI^|Y%1^?H.'GS|BYBZ\(: \(E\)X M8-DOV!;IMR >X%#BVR\]*+ M41B1%G\|@M MNN01.+5\)#3\(PB=AIAJ4!P"!I](#)
[DOEJ&&^+3&K!@\\$WVWO@C\(WXV\(IZMOFCU7 MH5A\)VH3X\\$8;XIQSYG/1;/L!4;1HE6\W*.76!4!EQC? *HU+,76>\)>7](#)
[+V< M/!T3\\$LV4"TP;IAI@S M&L%&KQMUAYC2/K^!2F<-0HACA*FNVB<5@\\$ 9Y>PTG!Z\(+ +90VX?](#)
[H;5,VPLCO='U!='Y \FIS _LC0' MHYI9"V\\$5FJ?JH,@H%!,D>/N5Z> HWEL;4*Z">P' T=HWPJOX@L Y M?RYISZ7ON?](#)
[0IH='W-R-J9!3BUO>1FY;Q/NN;=K7-"XH8U=RSTS0LS0! =R2^JVE+ZU\)CA* MI+!;](#)
[<\\$X>RPP!9SR2';9WH!TU^ _9==N0CI3!3ET.X&D*^ VVZG=PZ.\)Z8D;D* MTU*0;VYZ<5X&N\(YV02Y?9A7;?>](#)
[8T='|Y|%1L*O\)8=QXCRHB'NH8;8S\ # MAWE!7YAGE<90 -!M;*PD+\\$;W8+C7!2P4X&1@+;:'@Z!1-O\)256](#)
[Q6!8#*Y"B M?S\\$R,1>APYY=<7^/1DN;/IF6U;JI=OEM\(ECPFF8\\$V>KRMVEL<%5'<156 *P](#)
[MOFHJ!M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%B%D2XDU=\[=7GFYRN>B\)V^I=W MP6#R_7#\)1P_E.^=?!%U#KG|VW>/Z;L](#)
[!2\\$R<>><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U!F M\\$RQ#I!H?](#)
[8!*&|S&K8KZZKT Y\)9P!M'OQ@2"-;:;L;=X Q U*M;I60K\\$3!+ M!WP2D@9CC%OT-%^/%&*MIK&MQMHQ#F](#)
[6/..H68XWX=%FAHSU8NL.8T*;T'5 M0.4 V!0-;/8 -!R1!5XQF;8VH^1."CS< N!_L+\\$CN'MBI\!4\\$L#!!0 \(M](#)
[/R!>EDPHM\\$5EPP /M! 8 > &PO=V!R;W H965T!UL MM9UK<|NZ\\$8;_"D>|3#L36P1OHE+;;Q;3G.-I+D!LGC-](#)
[H!8";8TH4B5!SX MWQ>D+J!R@%T!6GO\)=_O72-%B\\$H+2^>B \)I->>|=GXLL|RZ';SK>O5Z.*RF M<|Y,J_-](#)
[BQ7/QSD-1+M;-/'T?A!6JY.FL#5IF0\JUH^\\$R7>2#JXOVM=ORZ\)8](#)
[MUIDBY!>E4ZV7R!1F? "L>+X5XMBMPI^JJAIO'PKBN -DY09Y+JZ1XXJ5SYE3SM.35Q; 6FLT!P^DV?](#)
[K*\)!S3QD?AR.MY MY;S-9WQV&#|4V!+?\(&^W0!;/%/PTK<|+=WSE>*X7*+8G@<_-_%D\BW%6%'VR. MOQ!Q!7S-](#)
[7!O\W!1OS@W^6;*-\)GWC _2B;Y-S9?5?U4#MA\\$,U\(+ -O^Q=K=\(I MOQR\(B5?Q\)HD/KO!Z\)Q;Y_U"Y\)1\(!!](#)

HL00>0^M6;8KH64I9VIEI67.44#F?N MV6>5)3#*T%*XMQ0>9^GS.BUK7F80SA>^*LI:90^6JLNU:E
2..K07K2W%QUG M[Y:7BV+63\$!E 7ESH.5IM-0.P-!>\$.?H[W/T9&96;;BD-).2_U^A+4>TJ02 M[D@PS-!@O#
<8@QNU+300%AEW/JZ7WWBL@9KN'X|Z/8+QRFHQYVB=))BG=?EB_A IO2.J+_W5(IA(€/+'9A@QUB^3W\X-S.Q
M/Q=W7JDJ70)KEPZ'9'4E+ MXL@?AB-IGHE4OR^><^50P* I-ES^J+T.0.+F.0B|H-'WQNIK+2(JQTIU9I
MSP8B.'U.=04E%Q9>2E.V M-(A)\$&(PO;POHGEFW;Z+'(%)1"3P19\$=N4I0@\$-- 4D.8C#\$W"JJ@4#%@+I
MOWW\NW/I^M2I\$>E25CI4RG*:BK2>G.J^I9I:7SE&9KIOS9/7<%+3DK<2K<
MOJL<^!O(Q'0S,1AV!..FVAX6|E^6W(E/Z1VCIS;W2E@U^B0D>3#&|':H_'M=)
IFCUS+@HC0QZIWREH*AYGZDT3D'45\$R;HLF_.5S4E*NQ!%:ZZ5"RZ(XE?E M,DT"1YGZE"3D'45"-
IDXJ=XLS34GNGC.N-(GK*CS:0-Q/(DXWE&(TYR8"807 M*/I8J_ \B.HM:2Y?CV=|C:)^XMOJ.?B M&+I&&XTR-
2NSQ8&K9&KU;IEFVYVE/UA'F|H&_WB2?SP87W;^ MYESX@W8?
+*.W9X.\$/E\$""@PQ^V^I/77M)=SZMZZI.|^:~J7I)Q=5;|ONUL%5K MKIT73\$O|KPXC&*!C4J9Y*!O*,6@Q)11TL!>S?
YG/IP_LG5.P|.\$W)9Q'SF M*=@\$=#C;=@(Q)OAO=@?)=XNJ|@J07.M(*)R)V=N<&9%RJ-VH>7T*/#I/*
MJ9+GLW;|IEV6*K.3\$=#.03C.U)BD'1|FD_VZ|'87;I>AWXF7E944D?NL7.."
M@TP|2M+Q82|YV6..|GJ'L)CGJA.4#C/UV+GHU6|AY|80I31S_KU8:<^=\$<5? MQ|SY|2L*!W: !Q?
HX|XAH|H7N7|2I9;XH2N=C48N#QTR<%6KVS026ZWV! MSP;T^!)Z_)#|^B81QFSIVX B7T*1#I-
_C_4%1*EG&B6PG*EQB4L^C\$OX>@ (B M|'_ _5#CS.:2D2|QOR8<9Y_@E|41(MZ0 AYGZDYCDPUS3+E;UJ5=\$L+;U;P.=
M HE..@4M=KP(B)MI^>|S&8062L (8B7K4*T2I9QHEL)RI<8E= 4Q*>+U"!#;U MZEHS09M!9*V IB-
CB|8B)"N8.%AIOXZ7R." J91 LN9&I> %9P*6(C IF|E-9L\$%8@"2N@ M(BQ\$2%NP;!!6(DK@ F+G3-
=IHV4+DD)BTKM'2DK|'..93 D?:(5E=KA M+ S0D7T7D?|61|A65VJ%_R5<1&5|A2CW3*
(E3(U+OHL Y2M\$82%.OE"M8<*2I M-0E8\$15@ (4*Z@<6^F2J3@|7I@.6?1HK.ZHKEA-8K0>\$M0%8D02LB|RP(E+
MHE(|I_ Y31T98""%*/=.H@>5.C4O BDX%+\$2@+5AJ9S8 *Y*%5\$!%B*DK5|I: *R1!*P1.6"-2 &+2NW0OP2L\$1E@ (4H|
MTRB|Y4R-2|:G0I8B\$!3KS3.;/#52/+5B(JO\$"%=08+#3/U)OAK|?6T)*^N M5|I
<|_EJ@Z|&DJH&Y'PU(N4K*K5#_ Y*O1F1A2CU3*,\$EC,UWFEB<"I?(*;_M>J4|(80C3;U)PH1 18BI"U8-@!K)
%KA*U@Z2|I M: H6*6!1J1VVI|' %9;# M5DP*6%1JA_XE8,5D@ (4H14RC|D8S-2X!*SX5L!"I3<%2?J4|CG2U@)DKIB(I
M1\$A7L_P4W^2L&+L\$N%(L_3@JWYD,8'E>DI8&X052|**R0DK)B4L*K5#_Y*P
M8C+^0I1ZIE\$ "RYD:EX05GTI8B\$|;L-3.K+2'ZO2'H@ (L1\$A:KVP 5BP!*|8
M2WN5E0Z>KG90E#|I|8|00Q=Q.FTZ7+^MYDF1C8*6EHJOIZ>F2 MH1;J>K
MIXM|4TNW0!&HVK%.\$+W^|@*B76;1#-Z\$J|I0Q1TA8Q.IW0N^W0D2|F MP3G3X^@ZC,X0?3Z3V K)-9MF,
|H28RJ&_IN#*R06+>|L M(=05<1@Z5ZYE." MZ|F;|Y 8TD'IF""&DUC@:XJ8%1+K-F%>|J?
W*6*&)&:GO7JWOSK2'YUI+VT' MZM-)JL|HNP&P0F*=3NS.HR|BADCUS*<\$T3,V MWR\$QI/Z\$44,46B+F;.=%1#K-
&YG2.?U'C4,4+=+6."N=VEFG53M#6JOK?|I 1 MJL|EJ5JNP; "HAU6K@SCQ|S|J-JR|; "HAUVKPSI\$%
|KQJ&+8GURJ<\$T3,V MWP\$QI O|34.|S&=-.RLD|SSI-X|G2MET/_|H2DT0 MO?
|SUPJ'=9K#_Y^>PZCZO F_P\$H;=>=I(|^0SNH:A@BU3.?\$D3A'R'PY"F M|\$?4.\$2AK6\$=-W9N\$=B|1R
9AR%*VAI&VU|V+FI=C,3G;:FX4S;>Z2MGI1 MJOI5_9W-KJO>0 EQS>W1?^0-O?0J9R/XC0YLO4 Z?L7 MVY*__*
I.QX_2G="7GX5&18D>MGFA;@2;:3KW0.5MOI+XQF=|MZ)H|_EEZ45Y/62YIM62\$R7J"2K>Y#_ AV03QM M4""^R-
A1G/Q&FLJ2|Z_ZXD-Z/W+TC% C.\$JE=4/5U8#.6YHJ3FL<_C=-1.Z8V M/WIZOW7BKPBLZ2"S7C^9Y;*\$S?
TH&J&4K>@^EY_Y|3?6\$/*UOX3GHOI\$QP;K MC%"R%Y)O&V.U@VU6U_-TI0G\$B8'R
QN0QH"8IEZ|/@=L8N&|=P6L,O+>_X#<&M%?
5)S:T*W)Q*.KTK^1&5&JVZ|H5I"MK%;^L|C7R+@OU;Z;LY'3&^|S+*62 MI>A9JBI5!5(@OD(?
BH1O&:KZ4M|IFJG_WZ;_1.5YC|H>O4=B0TLF4%:@IRS/ M5GDWD6IZ>I|TDSEL9X*Z9F*BYXX(3<"+8J4I8#I?->
@^&+"?J+^T ML2&OL7DD@PX_)G*;B'^B\$.|8#ZSMYB'E+D+T?FOT1?/?I9.-RV4-S*G|OC MKZF&MD307PI+
(4NUT^&4ETHV|GNOO=BAU-V/U(M3?|R@;37_<^0?_+U"<M+^EL?
DEGBPLYA(NUV;\$&(^_5UM(X+F#%QJM6EOF>K-XC"/.\$25P>\$TKC8H MC"/O'#2W03AP<72.6@
H/XB"%G7&T&|9^H.U-^"M2):I(B|J)U1.'\$+T.O1G3+ M2YGI|ZO=7P&S0M)BG2USAJ@030%6H_IGQ0-B;W_%0(%
:8%*(Y(=.:0H M_)C|R|I1 U..|B8SRK4M\$PV596F|*4UZYJCTW%0K1#;QY!;QU|F&_3>W M;=@-
C36^@\$'|#Y..6M+1(EGI>M4TJ_1FA6LI/EUQ9ZF2HD>D_0VFH !&0 M4M^_Z:2AU"R0|V%BA
D3B&0Q"W(8@'0_#P?4>6Q|Q|F3_0SQ#=#8V M|B)FL0.8OR?MV.G\$HO.M:I>E6Q_|4J_Y1&G_-5"KV 2E'N.-0?
7.>@&_ MS%.;-(%+170_=\$&^/AKL=*JOBK)6:7|^0D2:Q(WKF%@V MU@DN>"S|B|I=M2Q.=|9B|)-0FA7+;M+ "
4Z4UTIR?QH\$A2AQC)E#AJ=^=^ MQKX=>RA|S9! A^&HJ@DVAD6*+LWRO'|=^9QC(F(|H>PP MV" @H#!"J-
PR=:B|JYVNA6|U'D|)%@QZ4FEFSUR?3?"^%_.D5#R>NZGMP..I MHK.5\$9&QJ6\$AG-
(M8LWP;ZBL;GE|_ES>|+2Z3LRK.|>J^'|^!1(*Q52D MSG6QB9N#_F(R-OLF(|^S7J9G+STV#)U*_-
OFP1*^+Z0I6|M|FH1NNA>HIC MW'_ \$MS..W)_CVT7|OJIS7|I^>U)GP*P0*&R:Q?=-|R%WF1*LIWVUU<(@FTAB-
OZO8#1 M|2=|N|MJT7C/^>182S:2Y%3,7\$R*3>WKBN2#|= (W+ -INJ?%>,%DNJ1KUVQ
MX1BEVJ|C7>AYD5L@0IW16(|JNT8:65.*ID0&R+ O&_|G_|IA'=UX'ODU M|LL|=SK>H#5^PO)Y||C5D|NPI*3 5!!&
<>KB7/GWR|H|L#30B%|(WHNC>U!* M63+VO7SXE\$X;IEU_%F3.LV'Q_2O|1RU>B5DB M@6D>(6VN?
S*|C_6M"@Y\$M8+00OV=8SP')5DA6U,9J|06A MU16|U(XX.E|= @-8&T#3C.PP^|J#X-
P9PMH@/>^&06V|/I;N5=NVX.9)H.N9L M#W(B)5FSEC?^ME;^<(K1,E")U;|SV 4+|^IES?7LO=J5:6\$G0
M|O4B|HM%PQY%!. "I49D|L_13BWV|HJ.?>50YIO_?O7/>|PE_|/(&P.\$ M_#T86M8S.|=|J T#FYS_ _OBA|^XHR@29%
|P4=?\$U6=.%;W=+ (EZYW^W MQ;YB#^WL92&|%1N4X(FCB 7F.^Q.? S|CIR?;(Z-)G|DF2+"Y&=A"AL0A3V
ML4|_JOV%Z%C8 E#91MJVW#AV4Q|.1V-W=^S8-BCV_5/O(V|_1R>@A:6V8;> M8;83?8-&WZ
W|_ (#'.0G.0>J0M2SH2X^@ HUODIT#2R;A)I41L\$?>7MB(CMQQ(G742|V=47";J&8X75M+S^CM@+8A
ML6|@YFW_M2HJ|ALXV:#CLD|DW.N.W9289HNNRW*B^6|>|X3+G*QUI*UY+>6 M8BQVUD:8Q?9-Q**_.UR?
>_0#7KGOL/UZZM?9970"1(96*GOBBK8|B|/A?) MW|IF%E 0T.|C2D.#/T6\$(R|7'#4\$|N|+NC>:ZR2_7:8(M^4W
!V.QQ|R*B M3<66V:#7H1@>%.>Q3;OJHNN6KTZ1H0ID:HY\$RU|_J14(G5YB'M&Q#;"PR# MV2'!04JL1994#"
(I,E%)X1^CD_J|G|7O|/M/D)2<+|<2+7;)/MWG@DL M&6WZ|8WQ3#=8;QRN;"H@Z/'%|O|_|LC#SA5|J DL;K
TAJ0>MEL:6K M|>2P|:(CLT+;N80&JYPCSZ?"S7^MQ"J!*PL+Z3&I&FL.1.WTB8(S?^J;FFZ&*&;_-
JH'R3;ZXWW)I&2%OLTP M2C\$O >K_%6/R|&ED/FM&ZQ08 +H< 8 M->&PO=VIR:W-
H965T&ULK5EM;|LX\$OXKA#=8M(|BZ1> MVA1
F^+V%KC=+9KMW6?;8FOB)=%+TGFY7W^DY%BV.&127#^TD:R9X3.CSCS# MT=6#5'_I+><&/9-IZ|G6V-
V|Q<+O=|RENE+N>.=27(G5 MJ6T6)\$GR1|H4-Z/@7A?2^;9EZ^L0;^7 IP|G|Z*\$S=;X
M'Q;+JQW;1%MNONV^*NW.%H1>W_ "F<98LCK|1F?'-9WBZ?6S|7_TSEMG M5DSS&|G|1|HF>STK9ZCF=VS?
F*_RX9|X%#F|UEH_Q_T<+!FAI5X;V1Z M+8)6=.;?|G@ (Q|D'3@;_*Y!_7JM_#PJT=W1 UKOUF1FVO#R
2DG;_VYBSXV MO;_UIG3N=X:92|YV>6-|+3LA\$U;|O&GUC#NC5'MZ<1F^<^6Q?"_OD+7J'
MOMU^1FINWJ(+)#KTFV@: ^Q:TU<)8\$.|48GU8|_P(C DL^_?;7"*2S1%)2 JH MW|35/^Z45<|AI85U->@_?<
I/>GLTY|I>*=X9Q+2V+K^'|_D.I+ !EV;O|8ZM M^?7.YI'FZH/EC_ A/D ^3=#S)VYBL|^DICUI M5=D\$%R|4\$
SCRHZXLBNC^NUW%M0MGBMN8W,JCKB***X_S)8K6PO/Q4"6'AKDP)/P< (M9:\$M6QX|EE&?TK#FE<
+|VU24K+^4) "E.7|*|L96=U.B5T'A<0HX0\$WCP> M*0Y'667Y)WN.;J#|NFI-
"O(Q^L@E6>|Q.8C(^\$X)0V1C("CP|M,ID4'E\$|I# MX\$8BPG\$F&M(Z

LZGF2D4B1TOEA9564H048^PMFK6I=&L)5HA+%E^<Q?<)37 MOK>!^5'6SIT>*0K!>K9Z9J0#)*K1FR8"3:B/AG1
GN:OY?"244",V?D+!PG MK6:IL&-/KE< 0)D1(M"A"02DIX1S@R%DX3EH6H-K:IG\M6WLFU'T809 ^
M^&R\FH7P%JT"6ND:5PG+>08K.PN3(L\$>X-!\$^!U4G!>" T1?"E 8"24:B M(G&B.M2P U+^Z*
(H)RO^U&M8.DLC*P(M?LMN,URU?9Z# 'T^<(FF>3%Y)58K&@KFR%LDSEM0I00M
ME>)&*YZ*3B^A3*40G!P%P4DZ5Y 43+@+049>(W%>>VU2\$9^X<\$JG1 9)
ME5EH"XSL1N+^K< |CMNM6CMX+^Y6 S24%M,*!0AE.%"@R,A')Y'0 * A ^@ MF(QZ;QN0LCU6-%
(1"1.1\$>OX30YYC4IY3*+@\$)7EH1TY!DYO!W=,|I2'DBC9RMUNF M^%8V-5?ZYY!>U!^T!-S!|CXI2YGI
7R5+7HF!^V@5A M<)|HL\$Y300>LV7-TD5PF28+GB%SF:#6,0 "B.W-5BKQ7U!/\$9Z3DLRSC,YQ MEO2,"IMOJH,
<|H?E816KQ2YY!+O=^V!&??W!P!E*\$^*4IY.RIR'IZ1M&F< MM# 6M7#<8G-
XQT3I3G1HS7,"9C0(TJ=CDI3\$F!H!8A230,FF(V03.&M Y8:9 MGV/P/Q%1GHPK!%8 %)Y73DHEB8T@!%D!|HB<>_?<
=,^N^4P5I(4,M!!9FX MY_W4H3M4 \$I2C)O#T!B% <Q%V= &|AC>2AF00@!LTD%BK\$!#|/Z2E!L-^WQU
M^RY _H02P.\$%> ^C%Z61(AZ:7A @ ' @!@!X:"!W;W)K%, MP#P17>8Y54I7P.5VXOC.!!=6V?
&#KCON*!K6("Y+^8*>V!KDK(PU3MM8C-92OE@.1 2B>-9C."0&.M!&!&7!NC1#C=^/I
MM#|IA:OM9_Z8RY)JF\$G^@Z4FFSCG#DEA14MNIN3V*S3Y1-8OD5O7WV3; MQ'H.24IM9-Z(D2!GHG!2OZ8..P)_<\$
0-(+@K8*P\$815HC59E=8U-30>*|DE MRD:CFVU4M:G4F T3!BTNC,)9ACH3SZ30DK.4&DC)%>54)\$
6UDZ3WKV@9B=1.NP.A+!+6:M(7-4 P0& MV!2J5. M20&JGNIW0=?>%SM WIGG>2X+!E?
#IM"C%CUZ#SJAIDX ;+R0K M@@!<QJH!#S\$ RY^%R0.0?#@2KJ!+!>?JD51U.&?Z!6FNNHMZOKVQWZ_FBV*
M=5Z!^6^+C?K+YW*|SFOUX :F7!UNBWR^;|1>|=E@D/37^7+3N|!< ^|H|OJR MO*M7RTWQ?
AM4=^MUOOWKEV)5WE _UPMZ7WQ8WBSJWR_ZUY>W^4WQL:A_OWV_
M53 UCY3YS<X&|AGN&NPC_KTLJN3FX=H7PJRR^!|H MKWJ#78^*53K&=XA!B:E MZC_+>;VXZHUZP:SGG-
^MZ@ _EO2P.!Q30>+R5>W #^X?8H>#7C"J^IR?6BL M>K!>;AZ^YGL>3L1)|Y W-&"!|LOJP(8-#?BA,&@SM+L4-
#4:'|J|Z#X.QWXLTI\$S.KR^WY7VPW44KVNZ; MO2#VK=40+C<|H7ZLM^J02!6NOIZ4FZI<+>=Y7L M_PI>_!D
!<9+!>?P47P^V/7I^Z#|8+D)?EVN5DJ U66_5EW9 ?NS0H? M'M*RAK3 *NM|132;M&@6?
%SDVY)1KN:%MOKANO\$+AS|=DL04S_QW7:~W*B+ M|@%*%M@4H5K+;833=?B^"2945H9_Z6!F9E9M26ZKQ
MWMP\$;S=UH4Y6;9^Z2GM' *C-D>'36@?RENEIO=P:HL;)5O9D7PJM/H/Q>L@ MKX.?|<O-C;Z>|
&C%R|)W\$ _/U6T^*ZZYZA04Q?9KT;O^X:LP&?Q\$B0!) M2Q|@1ZVNX-!O0XY#P?|Y?|KZ<*0^_D#"!A\$D0S)
9AJ=;Y19&W4!|.3 M,8S#|(G_X9M04=&(FU&I&V7+P(U@43RVHC(WB@_XF)E1PHVZX^X\$;9)-RH<
M:9)QH|/GB8IVC7C#B7Z!F:DU5*4NX|1X^_JUIE;QL2YG7PYS|M^~W5K^~T%-M*(%:@ISGV_G_I&
(D)C@>6IG\$1#NT)O\$U0ZNUKO;=48ZGR!#YA-(F 3!#%F\$ ^V@#;S'^% LZW;3*F4%S"BA-HFBF%K1K&OIMTIV?
9YO^X6_EM33^ZWT' M24L/-LW!|W'F3F#\$H34)I\$T4RQ:4W!%ISMMA::2QROC\$.>9+8|PX5%@Z=
MNTITUCTG2"R*1T-I2G'#^(&9GKX@PBYX.HPL(X0'TF=+V!D+0U=6H!Q6PR:8/2!)0F4313;H8#?
W.ZN.VQT+7*JIVQ!@P=WOL M\$;IPET2M4%&A%\$|9\$08M45&A#7ND87:PPR'+|A+|B+=O0F4ED)H4R@M@I(\$
ME"91-%.@VF4-3:K?|LL')S)XKU;ID MZ"D)|HJ4%K*7%>U>D6FCF#T@24)E\$T4VS:5V5^7!5|NCVO,=>_5&O?
R^X9 M(<BQ|K!H!#F6_L2LW3K;WV)+<4TVL/74+(NR"VZ524F\$A24IY7F:N#TGY M5V28ZU^Q!H6?!
(GRKX@PRK|BPBC_B@AKJ*8M@Q92!_FV!1*260FE3*V# MT@24)E\$T4Z#8&5*09EKD"!F4LH?6@T)H69L#-\$
"4DDC9X*0Q M!5VR9Z@*9823.+2S)H:(PM"P42LN@-F=\$@BZ*)IB+59RH 5GZQ5R6>K MJ-3?
K|Z#" 4N6QV!@.:4*)JL^U)LIS'59Z0HL;-H,2A-0 MFD313_5J.Y.16 THD_AYWCJ!9|R@&064)E\$T5S6&VK;DSU4*
MZ@=WG8>@M)2W+@6%YLV@- &E213-%)JV+FX%)13!90 M;GIT->C9O0P_NO.M!UH-RCM4@T(S9U":@-
(DBE.*3=NIO&LUZ'F.N?6;U^X9 MIZ!H?TR@N:(@X&==Y.@P&=?+B#JJOXP@!POXJLY\$^O!DWV!SXB3SU5
M<1FJIV@8<|O4!>D||5+9Z8O7JBW":4)*\$VB;*.M%_*UWKZ1.16YT9#R*G M)
(<3M9X#%D;V!7N^UL@.1XR9UE(U7I& VY?OU2M)!?=>DDE'32!P'7!B5 _MR5I#JWUA-)2*^T*I650FH#2)
(H"E3HJOPIM9Z<>@UZY#PYDE,OO^A-9Q0 M6M;J" 0TR1R-DTWVJ!DSU!PR5W?|*NF)^T"4KJO>L!Q- Z2BA-
M#D=\$I72 M2?"N:4A&?D.RT!991/AH!&I=8J*O7WJZL;H+2LU1\$(\$Z)HIDZT'YAY/<+
MGV/KS)^RZTH\$2DLCHG*1?Z ILV@- &E213-5*!V*2_2PG<.HMX!YVW/F\$\$S"BA-HFBF/K2#&?D=S,=OG?
G!G>=|XBPUCD;-YUBXL!>N!ZS3*FD&32J@-(FBF7+0 M!FKDMU>|)H%KJ-
IOY:YTB(F!7>HLP;9|R@&064)E\$T4P#;8W!CNC9=U+Q M^*)^=,=|Y#*61L0KUIF(+MR 9LZ@- &E213-%)LV@R-
+6O3.ZGX-#9TW@H M%J8U!+!0B-AF-|BRTE:(X87!G:C\$)|XPC(XX/83BB(L L>V31))0TY:89% MVMJ!-F\$ 2.(L3:-
H!>D||5+9Z8O7J@/"J4)*\$VB;*.M+4:~W5Q^V= M':#G|X|BUTZD|LX(FJ'ET3MG1%AU-X9\$4;MG5%)F_~8NU?
QH,7W#N+H466 M4M*H*I4VAM Q*\$U":1.%@6IC:78;JV<^5H!XU39GS@<+0*U/*&T*61650FH#2 M)
(H"DGH!7WWM4MMV!>7HS2&Q:PI^!W!H|@GBF4ED%|G;17/O<2E1&4S;M.XV?749-
Z!8J*R4CT=OFIA&IM+\$W!W.DN(S,S)H2TTUU+4%SQ\$#4= Y&S")E!|@?C\$/H!+""4ED)H4R@M@I(\$E"91-%.@VAJ-
GU+U&1/^(!?UFA"1DOU !W MI+- H&YGCJR,0T)R2R#ENF&ZT-1D_0!5G3+P39&+|VFV"4G_O.@\QM.H32A-M
M3H=\$I30_)U&H@FPZC,AJR%MCZI55.KO5U<90&E9JR,0T)P213-UH,W)Y.6K M/OTINZY\$H+0TH=|HDGKN*~;
H#0!H4D4S52@=C63%ZOZ3(B7B-N:59.V0:F MSYUGJ18LVA*:5%)Y4B#8QD<^HKDS*Y!90F4313"!!37!%GP?
4J6!5 MOO8N6T*XGG90ZN!49Q&T2)E!4PHH3;)HI@9./D!^T76?9 <^\$KJVDMP!W>C M!XV%S-
QP:1%<S^SV<^A59THFBDE;78F7:LZSRN(JNIT=|C'7WC ASQ."M4+MG1!BU>T:\$4;MG5%)GIZO?
+7JB3Q,ZO!ZS6^*7 MS5(HAJZ*\$SZK5X,U0 MB7V!O!D>K#Y5-9UN=Y NRAR!5BQ"U!_UR6!HFU2-534!<T#R8Y
MB%73FTVG^LQ.RJ\$+!H(CYVW?W!>|B^<^6ZGN=09@R&A1YF3"FE>_K M)
(.AH#EIN1U_5V@ENVSH5P5^/PH&M8@+DKY@I/?L2LAR\$9E(0!;N1=|V|
MFD76WAG!9+5>WMB(UE*6V/W!1U!\$7 @Z)L0P4EPU,@-+A=XJ#F!QJ4% M!N!W!|!
<|!C+DFJ82/Z+I28;>9<>26%2VYNY78KU/T+|BN7;_9%O9#GH> M24IM9%Z#108Y\$15*^L|H &ZQP!!#0B>
Z(C@+ &A*<"HAH0G0KHU0 7NE %M!A(WI8;&0R6W1!EK9+;EWV'QGPO8;^3A5&H98@S!40*+3E+J8&4+
PN^!\$8 M3>2*S!Y*9H(CV9V@9A|T FBEOM,7H9 _M+SG"^T?ATU!#QP!C/30%^V08-2\$;85#9T?.\$1OJ:8MI8+
(Y|/3(4E'Z_MJ^SOZZ4V"!JG!;5>Q1.MM7YU>ZH F.;Q/M0&O/C=VZV_!DM:)-GU-
MLMDKD1V4*&J^%+W\$D_9AJ4@4DV,K%Y172)RQ@1!>>4!P6H2GG>5J;P!Y ML\$A\$W M2)LI=V:|S/Y&*3-
4S^T52C!8J-1:~<%(A)0:*#5-XZ(Z&%FX2KB4|KNK M!V8X84%9_12O!#2!@W70S:SX+U!+P04 " #|@7I9)IV#K^<
&">'@ M& 'AL+W=OH"Q^O)O1QDU#?14 MEIS_U#>WV?4@THAH3E.I71#U-2M)Y0HOVE!/_-7_!8VT8#D.Y+R;?
U8(5@ MRXKJESS5"|J\$H/SX!Z!Z.H.B'L&X'H-A.MD)EI?222S*\$?P1"6RMO^L*L
MC1FM9L *!<8*=-1 F1HGYPM>E#QG&9\$T P!2_@8R1+P%5B0<@_!JSB7XV/M@NPSIFS^ \$/PX^\$C>/_N#_!I
H87FNXE%>C.2"HYV.TOK5M!6K4<^KQ^+M+^2F!)^*C&XT=J&LUJ *M:3B0 ?SWW^#
MX^A/WQ\$Y.OHQG\$SXSCD??Y5T0XK4KZEOFE68!>FK&:7PQQA+D:=KP72,X MB:~T1&LI(&5!-
QD_VK"JG*:A5^:2!2%E.0=@U<_U7:IS?B?X@:F4!MG MP)L@DG_0DW;&4S.CE9KWS*6!C\$CU0Y31FI6+;(-
ER(=E YH%OY16H!TR.MC+MQ!1G:L3<NDP.D!(CT7L)Z(F2,Y *JA@*Y+PL!9>_)@ZS.F@=\$U:\$SG"
M.&TP3E!9S145"EF39^3)CV!JO#KIKJ%K.L1C/IQ9_V!6A/<@>?ISJ'4P_PJ? M:@!WCC/G->C&'4@>FS@S_11E:BHB#
(.W)#Q86N3Z_(1.ZRS*8=7!XC.\$4! MP%K:"8/\$LMB08DVU"K9H0J6?XAE=.#DC2Y8;RC#HM:B2!>=Y.Q>X|HH4UU;
M*9GUXQ9!=.10.Y4V:KWF844QE!W(CJ!@45N8.\$4=B/K MLX(I50NM=L.@4,
IOBH/2"RZ8OUKKT4=O1L.GZSQ68!A3LM"J+ S+;+.C_*L M5!BZ305>WJ4=|@L0MI\$G69QFTH+ "H-*^
MF63.Y.UXUE9R85AS;UH!49)*F(E&(8U^";+M:CU03:A*958!OD"!F)2R

M3?%2AWNG^U8Q;U=SA##D)YK&:PL2/5E11F%I MOM^+=*,Z/I-A9";3) M XH0AU'K?:@WJ1YS' H
MS?I>F%HX!35TVT;NTSOL<*XKWZ1E4L4ELN*,%E3Q99J>E43N7K8E4R/R3#I M(7=D%1.%%:-
AR7UIVETO;|JBGTI&W03V6|*Z#1V/'W?I:8P0Q
M@CW/!LD*,PD)5Y9F!2YJRS;GQ7HHJ=@:Z%ZDKJ9B%#ETXUI%/3BM|*+PQO0C MTVU"D1E&+S=\$T
W/RKIZ>|N.H=P.NMN3;UFTUZ*L6*)PE+97E.N.E4.XKG" MI\$?K2B#"W5Y@QPG&201C=1*%=2(IW=5J?
THK45%=.076M|+VH&S|E^~9"MU('U0GTJ#UVI1\$| M4 'OX(IWDPZVQO"?H>?E-I%UMA+"|YAZC8;MTCV%
<7AS>BB#R@=@\$BSI MFA6%3B(5(=77,NYMO;&|W81HZB2^QRJ)^S+?.B%^10M#\$U_D_@ITG|+.'@^
M*|B7_58A3C|_O?*)U3L2B3\$ M;OEZK-K5<@S.ZBA^14<+U8RH?M<+.;J<:B00=W&Y1O&D*^~^CUDG?EHJU.0 M
M@?D>5!V4-4^~0I8;<|38>7X+ +Q?54:EU4YW?RY4: H#F2GOV4\$!#!!0 (/R! M>EG7L82/B 4 *!-8 >&PO=VJR:W-
H965T&ULI5=M M;|LV\$XKA L4+>#8CLF09L8<+)|U*X:B6;)N X9IH*6SQ98B%:|57|HGB-E
M66G=M%N_V)YHQSCKZ3.UM9I!51\$|J.K;?SYH JAJ>3\$>~Z*B6OJ1;W6KL&T>R3\$JU'D|GDY-Q+949S;
I2V16;G=D8M_N|TY82/=2W=YH*T79|/M#<?;A6NUJ@(|OC&=GC5S1#85WS97#V|A#55-
QBMKA*/E^6|^~. +BF.63P.^* MUK|W+ -B3A;4?~.5U>3Z8,"25-1&D/B|HTO2FH% XL%?"0F6;' O\$5-E7R'
M+POIZ=+J/U09JO/!Z4"4M)11AVN| IE:~YXQ7F&U3|HBWN6%78HK1YY.D|RKLW\$-N.BQ;F(L-OP|S(MY8\$RHO?
C0EE?~?UQZ#4 M9IN>5U,'P16X21F#X;BNED>OP WE'GYU"' H2GEMH_Y)|@W%I37>:E7* M7|FFO;
<^A^~.5.M(42FIQ@T5"&08Q_IHO? HI+ W12@3-Y|@|OKA6ID0>># MAFVY.QK' C|Z|F|2."|X|Z|XX?20OSV_P-
&_%81NJ>P=2/-1IF5B\$;&4@4J M1=\$%\$B_++F9~%S. O:\$R.&M4(1I=I&@K:/BX)*I4TBGRXLDIF>%.92BL\$P\$
M+K/YIZ*2=R061\$8@CHUT.*Q,XN=F"S2|V39.@56C869%AIS4>L/I MU(2LR_#O3/(G)3N1GM?
D5~%DW>CFI'3 _="FL^OG@J.OJ|@%|~|GY7|(W); M48D&0RN#HHEI"D1K.I|@XG|HFL;D+JM"\$;9Z3:NH|+
P9IC|3|SLXTR.M:6'6TFE8OK&8#W.I9(H=9)OY;O.5?RGJ&"O.D8G|Q*X.ST.GD%T*JD2FOK(L2&9|K|4\$3&.;CK.R
MXY-; >5C).9%B%#9|AVMJDO|SCF5NK-4|:5XFS-"|G->C|OM&V&4(+ \$O?- MJ&\$;4)Q-E.'3:UD)K'8|AY
M22M<*60|!HO^H8@9<\$&/&78_4S+ MF.:|@T2)3,"O\$K6"+2ZTH2C:&89I5*\$S;2.'LW7G(V=E99EZ?(7Y702;#.;! M
FSY*K7#@AM';G/S|HC>V.E?IT/!+=Z';+5-T(|:5?/SH='KX_*47~8HX:U6)ZDJHP.4J? O>T/(NUHU<\$G@Z@KLXM0#(
MUX", "M=);&|WU36;M=.TUK1SSK|\$ISC'N|&>V|<8UIEB<.:OTJ9!FDPGY
M/MVM=E|C|WP)WXGG3YDWTJUPZ@M-2ZA.1L~?#83+GP?Y)=@F7EE I6C1&P0 \$H* 9 M>&PO=VJR:W-
H965T)DYG#ES M>)FLM?EB:T0'CXU4=IK4SK7G:6IYC0VS0|VBHIE2FX8YZIHJM_U!5@2G1J9Y
MEHW3A@F5S"9A|;."KIS4BB|6"|HF'EZQ*E7D<3HY0S<"NJVOF!=#91684+ M=|MC.%>ND4I1(*"JW 8#E-YD?
G#R-O'PQ<\$;BV.VWPF2RU N(|U4TR7Q M*)\$|C(|HM|)+E.(#41@/6:R7=(|HK8WZ.1#
|I3+DEFU/*S%PI3OT|^WQ_||7TH8OK*/M22@|WEFGFIZ9(FB\$BG_VV|PXW"6O>&0|PYMB#LN%*|8H|
)D:OP7AK0O.-D&KPIN"\$D59.\$S@OS<|/Q-N<=|H)5<&- MT8K:'(EW9R>IHR6|8/+_%=Y QSPCM_
V|EUX9@JF"DLW+<%L M".5%*Q%^FR^M.R2EW_=O\$Y<>|5_::ZISVS*TX3VCT6SPE3V15=X^R' XF-MMHF-
#|'|T|^~"SBX14Y_~03S0K<."|A+ZIR"+H\$JD=HMD4<@*O1(-1LA;|!\$ M5*T*%P3&NO1V#-:~W)A5S-
|G=H|/D(|HBU('N#"MK);."5|* 4BA&)6.2 MK*.:Z#RDN\$N*Q&D? EQJHNM-@2FP&|X_.K>_01T| 7C4EA.
M0D_ (#*#7-LQ;(R3DXA5;'P5K-FPU.9:<#N&XHD-6&;T'|LW0H_5GVW0#6 MM>U!?
QD"9(E29<X\$O1%2UU+;SX^\$0|@H21Q|1DPH*0%>>"TG2UT5U6 M\$S^TB3A|IPESNPP.209<-PAW|)X)\$U^)
|O",V|Z4H|05-Z4C!_7 MB?|TACOE|_6^5|5T&Z<|W:~KPBK\$0SHYXU6|MP^E>7P?QO5|9H@F
M"Q)+B=3^K1"0 ^A@ |D|X:"|W;W)K&ULQ5G;;MLX&GX5PA-T6|U=);W-Z MJO-2-%PO9"=?:
%E+U7"~#5|4YU9T2O+! 37T:>%YRVO"JG9V?V;W/ZOO;J:N M6O%9,=TW#5?HJZ*6NW%M|)2U\$UHM65
M;)D2ZW>S" _^XC.VP_5V*K#WXSDF0EY3=Z^5"FWG\$D*A%:@#@QI(5EZ*N M'T'8^&O
9M(\$N#A|Q|+U9VR++B6ES*~H^J.6|639CA5CSOC97K&2) M"5|N:VV?;.?.1NF.Y;TVLAF P4%3M6|E-X,>#@ R|Q&
8 (+~.D.7R9V|X M~9F2.Z;H-+ #1#RNJA09S54M&N38*7RO F?;KL15M+|Y.#9#1UFD^+YW@;\$C M@
G|*%M3;O;WMA#%?.PIE)|@X"49.W@=/(OR4FP4+XCD+O"|Z E|X219:?.?3 MDK&UD@V|!*"|@#MFD)=6KT*Q?
YYL=|V-UI/*<#ACQI&3|R1G<|~%|F" VR>XCR;NHZ>P/V67IPD7TH|J9N.M_N_:82/W=6,*|5\$Z5;5Y MU?
&ZWL.1%:*B<%H|Q+~*Q6OR|H(UHJAR7C-3"L6|BF#;|@I<~.5.8:VYPS\$B6 MU,"2Z6E
EX|=U_DENN|K|FB+P*XYZP5O9*UW%@"TWE+8#@#8-U5 M+3|GLBT|BF#WO>D)F=3?-\$-
B&V%.;SA(E4JY5JG;#M*\$| ZI"~B)T B|&Y&5K=X5>W#\$P;\$D) M=4@9I\$S8N.X+P4K!;U-.3O1>&I&07> U58X?
HJQ4|KCRNP#X+E;>6T!(49 M5;UZ|GP|LDC@|X*-2/|CA@)|I%:H5JD;3+.;MI6INT2W8I5 &=B2H&(<=?
%223@S3O(8I_160E|5R+DVU@=E2Q6*?H(| MG-TQ%"|HVB|7;(@A|DE@B|I< #<=6|M>
(1|U4_|D\$5NY;K2I|(|G_.FH@6| M\$FM M|I';3T<2H BC586-@C5<%3%QC+8(|H;V|7|PSD-OE2MJZ&NG&TH M-
";N1.GG52.YV?7|2003FCEA|=~&6H%#3PN 3Q_) \$N&Y6R|B?P|TY|L7W|= M7"~H|%&.>.X|ZKX)HX>(\$
RBP)=!;0Q0M9"?M|3"SGR0S7U%) "1NW* 8) _M&|/9A H(|NS.TPU?U0*0:)85=
<H6V*REOJ_UD9Q>WV|V#O2";WHA|(|5QNJVXH)"FH"2IJ#"5)KJ#5L2K94|F:C=#QY|5XY|EQ1#3I"OB&WBN
MC>65H.TY;\$|9P|=Z/FGZ6*W4"%;#Y\$W62V7/|J:309_2%47U#10XB=YCN2X MOBO82SA/ S52M+VZ+^9=\$;_CQ.50
ZY<#7C|F^XM^Q4^;~@OQ*HYDZ8/X_3 MS\$|L.L_SGT_PAK.EV\$&+3F/A_0.T^YH(|(69;Y+|7@ \$W#|;D|%&)|G\$|9
MSYW|&?&K2IN!Q|+3A*%+|/%#_0Q 8-9Q^MM50(7V 0/\$"/|XS%|S0%=H64 M|P.^~6K1E|K%)|OLT=|S
MV&^4Y1M4AHEA2CS6|0D;(FS692X|SJO)"H.4\$>Q3P2RC\$7S_*%G|'7L>BPV
MCD^T8P"1W9YT%"WMTR<9ER\$JLY1=Y#T2V24E90?R;8.1;|/E 3@P&+P&~OA_8IY>RG|NMM+Y?>|>872?
7IEHL3|!|A|B|.G%)YZZWOG(2R(22A*\$@?V/K_ M1_VB^#J+|1&D9N#5\$DLD808F-VBOT.YHF-I|H-
_#1O+SCNP!_4PI_!\$>: M1BR%#^%X%.#IQ?9+0\$=\$P6'ON=PRBO"765^R'A53%&6|??HOA<0RL|_@U@V# M\$&
(8AWA<+B.6|3A-|(|O@R53V=)|EXP09 DY-@(|NFGN(RA R|N2JB-T,+\$?6 M34(|X|_TE'A0N382_+8D/AA2'5P^_SV>?
69WPZFH=>9% MTOHF*5V=7L0*O3M&F.?VAPUA|J425Z0>0).LH@|B5RW8C;3>#G*DK-VIO M\$ E#
(T3@Q;FIR>T'G"-#0DU|+&EDE)\$\(|6C;HH%EB8;(|\$T\$|P*-W|'Q_M_8KGWS#YZKG;5.&A.X\$;=D:\$G?2?;/'M-\$
S>KGITO|O!|#CBM|TK<%|2 M&TB|S\$Q'9N|&2H/FY*~3L:9*HT^P^=CS8U?|>4.%F.#|JHWF1F|0ST*HBCA\$
M_R|L<~(|H|J;@B40.FCGO?BP|5 ^(\$S;|@SW11~!2E\$VY|766G)JM#;Y8 M-)8CH#2W+A3AQE.B\$ICV3+1;6U
3ETMD<_HHK7<~|A|F 25"/DA|F MRR|C|STOQ3E9YHO@(|B-DSMQ<27H0HU\$Y-1L(XM.JKC9#U\$U@H|_Q^P.Y
MJ|H|Q'9@ "1TDE&*W04A<~&U.%O2VKP|ZS@-XH?P61XC#>.@VMCO:2(M M2"N/F>"0IF 0|G YB^L1|@3OR
M\$6<"4|((=UDJ|AE*\$|RO^KZ3L:%6AY8X|HOK)QNKUO>| %>6!~XXW#1LI MBSNW1)9PR;\$PS-&.*&T\$-
=W&7?|0RU_*G2J*WA53TK|LA1O> =M(MT":|0Y:NK&HT"=>(MH3'5%T&#+\$|F^~28!)4N&37|3Q&<~)B>
=TX#D3-MTZ7_~W?F&%DML5P|=!Y^G|233=|A;=^WF57U.%_L7|CH|K|G|K|! M3MUE&9|(0+30SO.M_P-02P,\$%
@_(\$Z66;D<L|P NQ8 |D|X:"|W;W)K&ULS5AK;|LX%OTKA.FX Z|9C&PH\$|H9N*?|_A|P-7I7H|
MN5MS>XKETLE;@VS55%PL|X6N5Y==*+.9N).+C)'\$X+|Y(OQ+UP7|L;@Z=| M(R65A5|6:L6.F%|TKJ(|UV-;
|Q=|E6)E6V&FLRT-IT>|J<7G2|\$KE(|\$G@ M^+<4 R+/21!@?~ME=IHC:6|O)^~R>L.76;Y>Y.MK_XL|GTF)"_1N?
6_~%60'7984EFGWBHS\$12A2_|H;#2S;\$18;8XPX?>90? MN>.7YT.OF*5D\$8#KZK?
#7|2D5/NG<%B7WN|BKY5DDKR4*6<96RC|*6NIXX
M'S@<00L'22WN.HB+~XB;L|^TZ("Z|IBQEI|VHXN95)ST|+\$K:Q'+5OTO"W^L5R|*M0
MKC*~A2B@4/KU;F=04#|9Y^% H#Q?@~"49|HLR1-QT4\$666&6HG/Y|H=H.CQ| M1KUQH|
|X>FO=^>SXO:#??;MA\$Q1LD MV8?R/5@KE.X|X;=9^<~"\$V" MHH7|UWHF3/|NGM|1Y5ED3F+|X>_Y-
G(X|>P*_ZF5@R|HD&?B)83Z| M^#S720A7G0X&(@&3.AL*~UP|\$+)|N4RX0H)|D.GWQ_X|\$VUM6V+~#2

%/ZM&HV@CFIX76J]>6%-79 MOY#TW?A1^ZT32:9TKA?K=S./#Y3 U4+.D\$Q:E).T00{0.:M,XK=[NH6-
J^3\$J9J^=UFC MBK=NF2-S/6#-*=J6,15+6DDZ(XO/-6JHT8ISPRC?
FXVINO2:P>F3.)&2J2MFW9J03SE.69A.1-4F-Z%D%:/T/*PM@8VX.O<:I&@%
M<02,WX@6QC>+ "N&V%=EG5XV#UP26(L6D-6F2Z&T&{1(-O3L8,VU8+X*0?D* M.1Y0{BM2#F8D{3"5*D-
:2"EISYI#1#:#.B&PK1U2*U5'24M.1H+5?BE/AD M2)(*WA8ISYI2:5!9GHZ+THC*+*WL.SCX@B#3:YZ(HS&
M#1/VH)@MA6^A1S51^50NR.SDI!% \$AL/-U9 I305)LO#^A4@0%93IOAI&Q11 MPQ.CS7CNXITWPAI>XZ30OI_ ^C^
FHI6G'>E1GE>>76 A1"=B854BC80)O :#60!HJ7A1 %G4^NQTW+\$+1HNC,F'<%1E?-GYD4B4C=IR
M:RIHOB@)L1^=4\$ZP(^@+Q*12AN3=RT^C=6*3VC N1#2:JR*>M.IX_@3 B_ WD%B),PIFM>6K(I)FN-
K.;K:WST-5R(M#7U*4F M)\$+W6'X'8:BS\^H) REC:2FV4*DDC>\$4@.EBI7-)^"YL9?2:SJHDT"JF1 M>R?
RES_ ^53J.\$GZI(AR+AZ>A3G_ \$)T=^RXK%R37WWX,5Y8G3?^W!?!&%>UO MQO.YKWY>"
<4I+RA=NU>YU7HD8{N:NZ/FQZDC^/WM8O,IESLOB{X&E\$J+^R M.2'2E&B"O,+3U#<0.&W7!/-O>29?
JHJNE.+BJX69MU1-)^SF&.J^W 5-O MH-QC1Y1/72U(W^XUYI2E="72TRGP.OIG&"HCY,7!,73*!=M@#YW'0%-'&@
MEH:IT=16#VGI1A1=;9/PL%V1_1/4*2=4**.)W S73_7LE%3IT:L:~S:4!S@
MRHVH9KCOJL.@14&Q&\$;A/YO2_0*T\$KXM-K-/E|FK|\$%RNSQ|UOV)&ZAD62IF
MV#KLGTPZS(1/I>^Z=)_ G|QIYW3AAYG@| DMP/NY1HK4#W1 |WZ|@I02P,\$ M% @ _(%Z613NVN=;! M H !D
IX:"IW:W)K&ULI5;,,,N,V\$/V5@=98)\$!B2D)2=8VX*1;M ^+9*7T2CZ0\$LCBUIV*M5\$DJCOOU'5*7.YL-HL^F:IF3-
GKN)BI_074R!>:"R%_-N@L+:Z'(U.6F#) MS%15*.E-
KG3)+&WU=F0JC2SS2J48Q6\$X'96,RV""U&K50M15C2^AB=FW6JAU0ZTDR8T|^!=I=\$ MCDN7E#NKZ2TG/:NZ16-
UG=I:(<D)C/X/O4<*V_8N1)1-.)2V<Q%<-7/P- MN^E4M(6!C|^#+/G^B.BUO.+WY7!N GU;
IAAR!G\$8)Z_@C7M QQYQ_&9 M:U\$PBQQL77UPR|^G^L-25!/_52!!H#RA%#^#LJD!=#4
ME\$&U(Q/R.K9*VLF"8TJV|P M\$1VISN/^X\$<(S3RA|7-SP|>X76E.(XR+:/DVU4.L*R\$VI-5BYHZE?FILT&)
M.2<5AY.SE MN|X0BC1(1|S+&*9NZJ12V^H L|H96EQ213+^S SA8VO@O#-Z M3,;|>:/>|H5R M3(+5-
09@F&"#K#Q>T?CW3A63T9MP2Q01B&OA=B?S RF>=H^4SQ/0|^69=Y#& MK30&1_HN&7789H@^8#O-
+9ZK/*=@W5,1Y\$K01)=16|81"+XAI36^0E)I2CQW M9EV0B)W^2N*Y;3|_\$.8^FOI+@\$0@%0)5Z225>
SPK0|K@23PBN+5QS^G6C M!?!J&R1NNR("G^N)\$.)O!10+WRC+QEI.@\$;! "X| M0QH"M%(_OY2^YN+
14F@6UA|N> ^|HN3R*~>=0<^_0+5==MQS5^&^%D;Q; M4JD+B*=M,HCX>-K'.IG!=1;F.I@^-
'Q'*Z9;1B^Z9:3J1+)^LZ@DMT3PZ MI9Q0\$B<5/(1=+QW^WC/X)H|ZW35=DF65_T16@0WJX>F3L-M152H#
MF/C8CFF9A4|KI<1.X.F42Q= Y4K;,,/1177U^U!+M P04_#|@7I9IVM?+^+I)@&0
'AL+W=QQ2J|*|NPI%HO8IK/\$W13ZLYU?@N29&'.|HYD|X|&Q%#*E-) M210DOK,JMY8=LBRD4Z1-1KM.R_7+LIF92-
52 M5EGYB|G|NZKE&1.IQ&2.K^+.SPVC.Y%4KCIYO1@%) (M,S\$ MF*5MH*^2_?BL@HFG"9U&1>>3+A
V0FX|TIRK43WQ6I2O?77X*EEJ^PX>M5-M^"C|GY-R*,+Q0(2C,'Z\$7M3*&3&1Z %Z;XJM8^"YDZ%#|
I#4JEQ)5UE.IO#\$/&CY_1L|IT?V|/M%8"VC32G@PF.A:O%3.UF M8W4FPHD?
NCJ<D).*D_B54W_ENF_WJ= 3O;168;?I@)J<*5X7P"5.V@FI?H
M7FK+1)7HOL#/\$N*^&<4;GY46Y6)X\$J^IX.OWP"CS:C;0W\$AHD\$G,3!OUS3?
H275|DDE11A(|B.QH\$8@X4+_AW5UY:UKZ9\$(-2_M%)1\$.4B**Y,+I I2@*Z^N^XJ.K<5/Y|BZ|Z|HLM.6-
HUV>^&GW^Z\$*J& M;:T?>JCCP|S1YW\$!SY'L_APO1YR.5CH.R45#XE#P^#67W1"SQV|B\$|G|('C\$|OX_,P
MXN_)?.0=G/*5S%0Z|L>\$7-4L#|BI3TE6I?B!7&DK3-3(ER@ERH&X6^MD+;1# MOH\$E?Q.&8FI4:VAW=DC%-
>>C@?/90^N6@!5JHLL8Y4>U"";1,0;,+RF: MMA1-CH3HY%I6X?
2;HZG|)FPEELE%DH5G)>)YU(7E:D.MA8;XS0;.E6H#9IZ M#=:)4N443_9^ \$|<6;7RTMX?SIA?
FG= 5(IY+400BMP7LP@CU1_@Z_.Z|R' MHL|HP|B G#D9DV1-R."P23FNS&2ZFGQ&83."92%R71""0>
8"#R(W&N| M^K;I9;AP4#T4>_WY4<33?>=0AE&8^6XQ(X@C9C&K;H\$S=RQ_ K6\$FDV#9SB(MXYDO=R:GFB:8
L^0HJ?12Q)/@J>9!DIBI?Z;:<8CCZ|2?)I9Y&6;=,=POF\$ M88_R>K=ELI+1+3)#PPXMQ%HKQ&JRON17Q%SC?
ZPD<,UFIIV_OI&7?D6T-1" M9J|H@W""^ZNF*RGH(M!>S+)6WNT9I0\$?T-MI*3)*#8Z:D394F)B1P%W
MNES7&Q|CG*\$3G9'E(|(I|Q%6RI+7I)C5IB*H;U.O"*MN&TA>N7;*M_B_VI M<4U0%3?Q7&H'ISP8#
<7O:T52I0IZ0L-?BTYBIXKT4@M+S8GW"&(HTXWF:MEJ MU@;U \$M.L=(1;4Q7@FI_@CIHT;HJO &X;OUCQVIT?
D|C++NKJK.SF*@Z&X MH9,6XJ5IF^IU7Y! *TBAYE#7\$M7YS-W!0N1GO?T>|M7^#XB*B_K_H39KRS M)E\$*G?
+2FEP0QXYA832;G"TY&/F3AF6(O"D2B!LVP+-BOX(MH,1%1+(*@ M_|A.P>? %XDE--T&?
00H11)YQ85XC279;.D6.P\$51I+C%"J6YNIH@F_7KD
M9I|Q#"H,>OOF#X/9+NW#5TQ2ER@|OI,YI0;.R.ZI^VU=&NQ).39U<1_?&7 M,\$:T-
4I="35EDXHD@H9I0)+E<I#;JDI&1&?;<I28M+G' MZ62J;RN6W11"W"MI.=PDY+Q;:9_YI.>)Y<0BFHJ4
C4ZV@4|WU(XZ=DK|. M.ZNZ\$QHUI2PG|^9CD=HB.>=Z;MGP2 (5R#;9M FH;0|X|O&COI(C&YAN5M M8H X?
W0+W+_AID 6\$JRN|I\$ 7@;7"TVG4EOGR+!POY^4.P^"5(S"C9/XS MJD5JN_#R9R%D;P9XKSV!|I2_-HI/E|I)
I-00TO+ D#N&:ETGX/Q4SCX|F-% MZ+L|ZALT0V15#^+M|L<#GX78!-VV^;.'@|I3|&55 K)4(IVW*8?21Z>9Q^+
M<|H*ERIE;I"E=W=H1\$^Q%=1V;.#<592D)+JPFIS_/37;5_?%G14L;WW/9
M|OQ!6=QJ>GJH0/0V%)Z@HYC.I3B@9YCI4H TJ>>'C/B|MSU.J1ZWVL#(G@ MCVI!/CH1_!|^C*964'9I?
S@48GJ+Z"03AFHH(CMMDI:6TH*!;9M-&G; M;
H5ZD10>-7&FA0|@.AD521K6K76K1P"&RXV|H7TS448.V_!LS!M9EA>2H M.IFY=:2N!W&?GQJ>-WN?S|L_-
%Z 1!UNWWE;+AZ+!^IWN79"A19T.%E8" MWU000Q;PR&MI4";SB3EN?R+RI68X>_>Q>G+C>FY;:
MW(Z"VHGG*Y7VH/(1\$ DVN>1ODC%#BTZ?/WBFY2|!|W%#H=*; MQ74)H|A|J5P_@;@WI-0_-
"X^Z*=PYR*X)HVK146_AUWJG%7?"5W?_ MX|INU*VC:/_COY_/H_XQ9NO^@:D-8.2Z+C6D*_@R2P5EEZ++S^=
7)@O9* MV&DK|P"?ZGASPO4FF-7| @E%|HHQCNU@0-PBIRC+!5+G\$ZH5WFFYI0P:"/ M)B9|G <=
(=O!#8D)\$7+9DMT\$C/SR^E8L"-YS-#4&I>)U %9\$9;U9C9@=LI MNE;1B1\$F\$#K|I-B>VRFR+|YH^&LZ;
(GJU|A:+'8A&3MWJ=|X/4CUSKS4 M)^REG>HF%\$X"?2AH9@LI-3(IK58#13K!;H8A;1#1H=I9?I"91H|>"\$KZ:X MX-
Y;+6E;/P>17YA<)|VYWALHC9UYI^JA>-16UD?2>I)_GA0T^45V!;IG5%
M9U|@4T@HDW7|H68@^6U;_GG_&CTM&S/V_3W6E^1W1J^ZE(ZDC%|^C_32XI
M_P3*E5WQ_YU0DI#A_9^"VM^V+U4W H\$N^G^_UA0I5U19LC4ZDM^P^GXS|IV M-#>EV?#_BA:F+\$W-/I?
(;K2!#Q?&@1Q?4;M^TN_XW4\$!#!!0 (-/R! M>EG L/WG2PD/H9_9>&PO=VIR:W-
H965T=K^|8>Q"UWME/YFUD)8=E_D|D>K:W=O#@_ ^E;%-P\$ M:B-*O%DJ77"+6|TZ-QLM>.:8BOP^L/9>
<%E;JYGR:AY\$6NUI8>G-J<:2A*W GI=2-9X^Z1*WRO|O.KJH%R.6B26QV"L_%^A#5#-\$3F|OR&GYAEM^I+%;?
L5FM>K@0<LW5N04V49RG-YX'O"9N(^%9!+Q;)D;<1%X2!9"=QD+""S'-4BI#O@|IT|NQ
MJ19XW(0GVW"#3BXN+Y&A<2;2A,Q2;)K+6!%F3\$C|UGATT10FCP^A^WHR|^MS3/&V#%#%_|+
I:C98YBV9|YTV?2?_ MVGE<9"LP|@^!U'GGYTS_H1I)*M@0NXE^;@74=AYZB@H5<((-FF2>,%|:4 M
L@ZYH0"A\$52I,0V^B&F1X+;5+9U2 M>YYW/4Y+IXS*|I"4@8PO:0/V 3<\$7Y/VLWQ M|B|K|>BC/GZ2X|M=B|
M?5OB:A67M3CV_#\$^Z9CMUC)=49M9083%SS|=E9MV++RID;A|CY8+1 MO5!;X=UY(=+D.85X7-68-
^59I!4BS+=LX72J+_.E* X\$YD*C25,T;A*9<2 MX'B*=2U9S2BIWMP>26F*@F&@CE%"ZF45" Y(Z,=3;I&&.@?L?
3IN#*~>)M2 MD+CK(RR.SP3X^K|BNQ)""5=,4>T:GD_=KU(U@|H(=XS|HP7FY?LLU*ZY?
_B&=@=|C9)BI(|HJ5=2+>EU08I^1+%"3Z M+P6QP|@-WIN0?LQ_*CI#6Z6G-!REO>IE"=:RGS&#|*MWB2:BI2%&!
R_&1#U7N=X@N92/IWI6:I.#^\$ MRUZPYU"DW@;.*?08U"0X_\$&_13"URXD|4-Q>)NP_I9L1.6C^>32_Q.QN%E

MQ#X.5SH.HB1L*S5M.(+K5KTDGCF(8N"6=36K7I &I E<0*D..R0J#X<@T+=
M/D&YBDED<[R>H:#B.YRQZ4"1I\N]"(.*P.HX'XFK%+^GE15C+"H.X?D36D"@.M9@|EQ2&
|G%QTJ@-MWXG<4TT&2).1AU5=""O|X"2BNX#FC"8)|>0X@'5-\$CZ
MAD39D02@|#BZ.8LT|KIH%25_UM=0>ZP)1/O/M8\$|<-EF0V-.W% E5SXSX"BP9F&
XSDN#Z@BU|H)DE"2V^%6I7IE.YFG0^G|^G6(\$%72A1|J.@%:N8Q.WW M.(P;JB0)"-
NC6.FA_9.'JW961VR9?..D2W0_1PB6"^PXAW5IYNI2/&- 2Q(4 MTJ70U#LLV^\$C5<8:7Q/./AS9.PI0B?
AJ: ^\&1HIVE:OPPH)\$UFH\$Q _INR MZ:D.IK43AFUY%LH(G91W>ZUXGXC2N-VGOXVW;8)V Q|.^&:TD)I* _JP9E%)
M=^|M*^ ^.^|.'IOXUEZV3?N=|RF(7 3=|_DEGHO MX_MHGO%CD)Y@-|W|3CU#=#5_-2_.'5"U8J;ZAH.JM5*5.4
M@C3P1Q+4I5=H_6|/NA9.H|=?OPP.J09V>R7*WAD\$&C54LPTJ\$A1&./9|"4Z.MEF9&GN6>@ "5WG4K-
XQH51P.L@A3F\$+ES44EC3\$@)#=PXR8H.J-P2@|G4|QK M42>0:@G%WR#\$AH%(DP<>6TF:-P%++GQP)#.
(XO>6\$>X*.\$EA=(8GC8T;13 ME|A/UW2TY\$=B%#5W|&;(0#30-#2|LY;|C3|TP^_A1X%5=H7/A87I0|@)RPAK M9?
5>G/(E'X?%+DX#4 M|>=>5^+8+.;@=E+A5@+|1-1;1SV;I78V&D:3K1|W I.;%|<^YFO=AJ.4^B M>3#MSD-
N#|L.GM#(2YMFH?)(STJ9=*(O/| #L)%6&@O5H>BFX/H;PIF4|C9-MC/B;"D4J1<B=VA(T@=?
IU9P5T."7YC21NL\$<8CX(U"86N>6M2UA/D;44FNMT MO3|4L2FO V|J;T9^:AG:\$M14U^NW3 M:'8|=N!
|WCN/+X1>N7|=2'" ^*/Y|FG|Q:MA_OR/V_(A^Y7M%Q;"Z68*5! M8L2T_Z?|WUBU<:?
I"V6M*MSE6G"8301XOU3P>7U# M|_>V|^#5|+ P04 M" #|@7I9USW21|@, "=-,@ &0 'AL+W=OW^Z"TO-
TG^8I1"6W.VRW+PX65J|2GIY M.9*E6"34VN1PYVYTBMNX-
>7)JU%CRE3:OL.N|WQY)HG%4O<&+XQJ;|AW4&7&3?B1F6_R|0N7YQBT<7+.;I'PSWT|I4-!D1O<-&|&UNK"Y0
M3V>.GT2ZD/I"76/P2'O|2J^E23)E"BW8WZYGL|P_Z|J=5G%AJU,=F>FC5|MQ(L3R"8C|*TX>?G|=|&X_VR/2L-
4\$>^ZH_CUKT|NA5X.%V>2G8C5JM>7H/M"/@|TMH;1N4-P"#(LASRPE-1.X@.;@5*826685)?
29A;H2B".P.4EM_4> M44JB81N1E;D5H(%U5IQ=PY8<)"#D62N-#.;*\$|DSYBQ|)\$#ZC7D3Q7LRY5E M_BDB716|DT
:8+085(29M4B*S-U9%WJM0/D>>|.E9K_OK!_4>T#OE8 (\$#\$ (M94Y:S.4&6;47",3-8<+)|@&|H/77F!*0P:B86/?
3(H4M |%#=#=H(%HJ M#*P@BW(0%,6Y)7&63IS:PA)6B|NU2P6X7|JN%+|/>"C+BXXKF|\$D3.C(Y2|TR MN>
(SCUV;6%?(M;XZ>(8.;D6AV3ML9M|L\$5(P+_)J5NX\$B|WZKM|8PAV&"5>8*YB.5(&J9N02:D_KM67BVG?X^|
M+C3*27>76KAH-*.K1P@ "P1D|G"J9D"D1-0+QN=|(GE=ZS(H=)G)|H@J:G M%AD9|P.^CM-*RN1I?
>9:0.J48:@X^1<)|CRWWR/G-WD@4V7|0";*?S0TK~V M@)U+L(^#8)W|#\$@RWJL5.L_0
M4@0G.&|MXG08VU#F6ZXE|E.VGM"W<+BS5K<=M2'HUW65|L0U|; MD|=&|XDOQ:IP
+W2&V|KL<3N"(L0&PPLJL4A^Q.USPWWW3;\$"1N4|QE(C M^#ML/G:U|V@+CNBB3?E-H?
9A\$F79!"BD(|>#2INN|Y)3AZN8QIDN8@2)>\$ MOPZ7P1|_ *3YW("K2#?R"R#.*?@W4B|L1-3/B2X%6(
Q^0NT\$2"-52N": MAE^\$S>NU|_ 'XQ*1P|9CR5-V&@VF,+9D&7D5-IS&<7T|> SFOG MA>S^J%0?>%NJ|8+
<6!\$R1H"3J|^&8Z&UV+D%J^6P;|LL>9#>"5NU^ MC9|+2T3%ZS_U5G+7:M&|XS_+ZF|2J|C#N":F"
|8F&@.HXMP:|TJVT-L3 M|9-.VV#>_H+VOH|30F|CP3;SA=E.TI6&F@KUB3?+Y)<"0Q>-(VZ)IP9M
MZICV&4.ER'L(@4.FDN0|_ZF>.0S70+C3X:2)2|_2MH MQ<-T=4&|JZ MW)UF>+!.\$D|L%NG4.^ET_3/UPF#-
GFL=KLSY;|RRZUX|);SS+Q7|5T_YH' MQ@D/=(YOOCM %S14|
|D1#6#_KNK)|HUV^ZU_78O>-6XYBL_BIR:A)YUEVY MT%#H6|#+SS;I\$|.0P.25(YIBBT81PLC8?
8K.H4CYL_*X\$7HY.XS|D9D/22"Z)0|+1OTW'6:'F0|L|'WA>6ZBG&;7@\$ M^YGI1@94"|H53QDF%(@\$K>:"@3R+J(4
%U_>JN:?\$9*#=#S|&7.(>="M61#SZ-R=Z 6C|/ME42^" ^2+^EA*C?-IY%46_HG|O M&
'BOW3G;|8CIVCMZD)GYF*KQ#=#2 M?;NB"KWGL|+@ |WZ;Q|HU|9H|9^N.C;_7#N%OL\$4W9.3-(ZP4|AT:3P.-!X->^Q'
M_YN"LI^Y#A^XED^WVD^|PJ*Y>YU0_ZN70C4#G|+^%U4_+*7|>@|NLD*T>- M|!@:<.C;HN|/+
|J>.Q*U0AJQOD:|R.R3XV M:O5U_6|HZGKIC%UT9;6|JM:<|J=9-|J)ZH.TG|KB'|FG;JM&C(&83VG3Z7)
M|J|N|JFJX99PMP_PY*V|:IU@'2TY=7T|AVZ?#QY@'.0;|QW-DOM9U_229S\$4N|.(KA.GLPC^W2A#V;+6*BUP*1|RVEEJ
MS3?E>HH<)|BA_-89QE%<"|KJ9?+Z|;C6*4MW^_1T|G0|LX|L^5A50|=;KB
MR|7@B|P01T|W.9XXA|T+>S*K2;7HRS_H_4_%X+2KSI0^&84 M>@ "\$_&?
AX8A_/AM0DDXI<(<N?;PW35_Q#P|@M.7FSZXD<\$|V353N|D@>G<M5#SNIW7HEIA0>>FC?%M1_15CT>
|AJ<&B^XSX^WS=7?J\$3_O1OZ+|#IX+*^| MJ|(|D5V_1K|MA_T2^:7/8?|W&KB.R9Q|?X?
_QE<|85T.L/RB|6Z.QW|_X MVSQ)="2|KSM"19Q|(%T|?I'=DXAMG07PJ.8GQ=2|^DY @D' ^;'+%1L.M M|O01C|1-
633|J-L|@QKJWPS1.&2V@ "1^9V?"U03IE&>RDUZZ5>RFG#U9U;\$0) MG-#;-
_#75U/X|Q|A_RCJX_OOCF.6=2M3FBW<5S|Q-B\$#.W\$K|JJO#J#|ZT=E M.O|W|OG^_6N*6|?B)X*5%F@E9\$Z
U3N80\$HS MF@QK4Y9P&#N=APZN_U;|C_..X*W|X4G|J\$CQ)7U)UAW4>QCM."0_.;GBKSO))>MP\$?..0.FF5?
2"18|B7-D|HG3|4_H|?R:3;=#MB@<^7FEBRIS9L\$OC*)*>B>N#L|?R:\$-?|Z77C.|6PSJ=Z8V0+*WXD=
|OGA^P7(/#>=&-.?C"ZELK.H<*Z.Q+^"BRY/=45*MI9:5-R1Z99 MOI8RR|
F7.DF08EURH)T&WZU)IWKCI%|X:|NRI*;EP5*7<^B;K1SW(EU
MX;PC3J<57^_JN|_5K2\$K;EER4.*R0BLPN)I%|^YDT??Q(>"7P-KNK<%GLM3Z
MTI07^2Q*Q""4F#G/P&EZPG.4TA.1C+L;S|@T@WUSOVRY |Y;+D%L^U?|Y M*V;1.
((<5WPCW9VNKW";|S|#S95K.;\$+=Q/98|_G&.EUNP:2@%*J9^?V'08 MX^0_-L'6-#='147G#"TZG1-1@?36Q^\$5(-!
(GE^4>V=H5Q0_.I=?J"973_M1J'=O|HX(O3O.MN1P_V9O@=(PHY4K+^Q3.;_XV.2TJIA.S4+=I3P>^9.@0TZ
MP|+6A+7;|K;|>_J|FJP(6PF=1V8Q|^SY?6&2J|XJ|H#JIC*#;+(S8&(9|G|IA)V: 27%KJ=A#\$X2T;P0SLN"3WH
M|S=G86;=#1RZUWBOX\$LTZ|6%C*|4:ZL=;_ASSIF>PYMOYX;M5-6)*X(
MFIR.|A&8H4;P^DJM_|2.VK&L"SH|T/C VA_L;7;&?Z |C|_P%02P.\$% M @_ (%Z6?A\$A9IT|@ =Q ID
|X;"|W;W)K&ULO5A1;|LV\$XKA|=T.;#;EFS);(FVN4JD2E)Q MWW^_CZ0LVW&:IL6PA|8D=;S|G|CW'9G3E52?|)
(Q0^|+0NBSSM*8ZJ3?U|F2_ME53W9.4\$OLRE*JG|5"WZNE*,YFY36?2CP2#IEY2+SOFI6|M6YZ>R-@47|H1
M79L+5LC562?L;|9N^&)H|\$+_+2B"_:1F=^K:X59O|62|Y|O\$;4@BLW/M.M/PY&)|DY9W_YRM|;Z86\$|F4GZRD|?
Y66=@: &"9<9JH|BY8Y>L**PBP/C<M.Z.RT)NW&W?%&^R_=_@RHYI=RN)/GIOE62?MD)\$S:5V8&
|GZE37^Q%92)|@OM M_BS9(J|8*!9|5C\$RU M9D:?)@TL6?E^UEB|)%JCKVA-R#LIS%3UR)G^?|/^A"V.;-
S(OH284?M.C M41R0:" GM W;-T>_GW#Y|A|X#"YXCHK|X5(W|H-9|HH).?CX7|6QD|L46
MU(FN;..J@85=0=ZXR_@ "E_|J^>|&^4^C|Z2OL|IV36A_ ' |Q3|6Z73(R MEP7JG8L%=>3*%T"4MA.LB6V.DVX|%.JU-
J*TE+6PA Y)XN-KMF;.+8 "Y@3 M<@SY\$HNH9MTEEU3E7-Y1G=4%5>0JY74&6*Z<|9SI3?..9R&|?WTC_H#UP
+V594;\$F2YJWL372?0)| M*X|!\$<)|LP:H>VC;|BE53N>RTX/N:UYKWV++)MC R Z-R8;L|D.5A8|IP9.SKF@ (N.PIPT6
M/8N|J+|.20AV/|9DZD0-61OG\$5KWY(V"0N/L7FL3KW9_MZ8D)Z:D|Q2_8CA>;MC+ CTY/T%9V4|'U\$O%O#0J(@GB:
(C|_4HQ&76;I= 6 MR7\$;).FD2ZYKA9S2D#6FP22:6'3_1Z%7;AV=N5|;.;)(R|X.W|@>|OKV|>T+)Z=67EAU9X0QY'
M9)CNSF|W:|CWG.1'2;|.2N-4|W0=9L|O4")RR1|&?9_/3"+GXWS#V#H+|+&.K MAK9O@6L.V'/T#WS<<_ASS+?
1N*K9AMH\$-28V@EY#^XG.H\$B_IK|_|MT+9O9?|;.&#+3*ID/P5M-|P|GT&G^9U|L_0 MY%T;-A"GNM#N
Y^|@_4Y|KKN" M+1MF58-P=6U7T+W-U\$LR5G=X@7H|0H M;TOGQ9K<|8;FI(47D";V.2@9>4@|V-
94PYL|MO.>)|#00*)QLT|>("H>7#!_WCX-O4.1H% XW_.NDCBS7 M-NV.^J*N9=*L>Y|DZX?UJ|*@5+|H%*XZ^B>|T-
+WW762R0>Q@^#@R7M|V> M.W.;+1|<^I'LM2N_Y0JSMPC>|3 EKT1N.Z(XJEPYFY+4S9|L*!&(@.M|!7'
MS89F32Y02W*UY-D2|RCM"&-B)?XUS875R=S1F&#%|RL |*US4;?P/7*#^JC MN7;#|%O9_H8#EMU3' R&"<%=
<#BQPI\$=AHD=IAG&26R'\$PQ:8KA<(#A\$|WG ML5=\$?^|<=PA MRC|S_<3(RCTM9|*@?OAD|&)*BN
|W.)^UTSL0:OS6<_PM02P.\$% @ M_ (%Z64|NST*|T|@ EQ !D |X;"|W;W)K&UL MG5C;|F=DE*9&67|0='T_?

1K0V<:Yw1*:=):6PX'ZUC:%Y-IZ%8QX6BMM1Q=G:>V#0SAS:33:\@=/H:UKY:>O MV:C-
^6@^Za<^ZM4ZRL+TXJ01*-[s]=-IX^OZ:"EU#7:H)TES|7VZ+^ZO6A MG\$!^M:!"7N-22)9.O>?:
%R7Yz.9..2&BR@:%/I<A4:(XK@QN^=SM%#@4@3W M? ?-Y9B1RQ+?%C*F5|T&=?GHJ,1E5RIUL2:/O-
W|N(Y\$Gv%,R^I2YM|N|@- M1\$4:HJL|87A0:YO_JKLN^WL"J|,O""PZ@47R.QM*7KY145V<>:A37ZD M4),TG-
-6B0d>NQJR.6+I:UNXFNE&W7\$XFT9HE/5|TF4E SM*++T@?TSMGXS60
M6UMR>5|^-D|&=Q:I.ZI73RI^7|0)+8|&M)@M#I_0=S"\$=Y#T^3P:'KW1H3-N MM)H/V?+&#T
+=/A9PU'GY>HS3)J|H@L|Z(+_I9%|I^,S^>?B\$OX># MOX=:/7^V"|:-55!*4KIAH=I&U:A(+^<9EQP*I2&I0
MB446J?G12|^66\$'WKZW7H=2YQ:&8+29_O&L:RD%RF.1\("Y:JT!|VX))A|B M.E6!*4&\$, 2M6ETJv6Z|N|5EBL|KT-
"0JZ JAAJ_1\$@^94+!&#:\$KJX:PY+& M(4I9WW0Z+!*G=1BH_ M5Q@XD /\$K(K:(I+=+L44<.77&O@U=L-
%TA7J_#S^Y4IH>DD5\$3^FT|L% MNX4.'6C\$R#LNHT<01SP|7:.N-68OBG6-)W>>-(NIW0/RLDY)-*KH_ M
1Y(B=Y7E09JH/('K66:Q)(R+X5R7S)D3WJSH(4E:J\$ FR 1X4|!%*LW:\$T MG!%794|H&S&U4*06I0 H
>EX!69\$#I2\$|AG?JYMG&+X48_-+>D)D3V.6CC31 M TQ0L4Z=5Z|N|O:MM ^I2F^5CJGJ@J(2IB)|
|U3:B&ZT0M.PDH\$5<+=L:L&(M-7>YAH|H|0=N6^OFW&+Z3F ELX5EMA F@Y,&Z8=#2MO| M=#)
|F<|/3R8G+P5=H0XGSY8B-S76#W)U;QO(4<&
M).\$Z%+A'TK/Q/IG7&!76N|H(X4TPEWB>U(PF|0VE&_5>D_X^!2IG@:'C &LVYF9T M O>|HND&/_S^%5>T5(Y:E??
ZZ5DH_9W!%5H)CP|MU"%/3Q<=15DGA|32W3+: M/CYV6|I|="P86ASW,(KWF@I3,
1JK11_A2M|HAI:LL4.!QUNA(E>+"9_I67'
M%J(3"Z?|PD/HIY7M/OVL%7PM"B|F|T^@4\$X)IUX3BC,>TXCXL7AT4|ZG%@ ML%
(LGLD=2:~>9T,3_Y=EX=IMC(200|MI9X_*M|^8R1+IQK2FIP?59,X|A MJ75E4+5,L =!/%^4<>Y?W A4P*PN;_PW-
&|# #K:~|61BN\$|,YX4G;H0H| MY\$K6^Z%J@S:8P (M|&2BCO2.""D+7LP?8F'^92S=>)-.IQV+-N 7(DSCD2U9^-
PZKPZO|C|V=|2S MD_T=+A\$:US7#%41GDY:C\$?G|\$,X?T37IZ:ET\$0_9|/'(\$HO|!|?>2I^Q_# MP_|%7/P?4\$|L#!|0(
/R|>EF3&(#U(0_%,*9>&PO=V|R:W-H M965T2V:|V&VOZ-M>2CZ0\$MCBPA%JB05QW_?
(2G+&N(8:5|<3ASy@R'^1|J_2CJ1 M/-="FD54
M6=O.DL04%=:O^I|22MKI6MF::HwB6DTLM:(U2+)TW2;RCI|LIPW:(/:|O|C7-DAZEY#5*PY4\$ MC>M%=)-7-
KD=-.WRO|P7%KCO|!1:|2ZM%-?BD74>H(H<#".@1&PQ/>H|..B&C|
MTV%&O4MG>/R_1_B8Z=85LS@C1)|M)6BV@208Eku@K|76U_QBZ>"X=7*&^M%
I9|=YA&4+3&JKHS)6UEV%DS|T^!E,WC+&(X/<|PZ:/M;9MERKM46M_F M-/?
C0_761(Y+EX0|JVF5DYU=WC\$MN=P8N<-#Q73.\$|LX;K5L.@PK@&-@;& M&+XJ:2L#=
|+|\$J5|0GQZ4OF>U^5^%O#7PL:07PP@3_/1&:QA'^30XPW?'23|M=:4R5M.9^/M40
%N=:K.UV(5K9G@!N%|H:,'X!6Z@4'736BS|H2^!|*LA6"%M_S&G.GE!3U8)L MZQ69J34H77))A1T@#%
+.)9)\$FYBN_7"@_TO7^_R.0 N^~I+&F"UAP^:U:6
MW^4!)O:6MF*6.D8K2J@H%E@ARE.XD|8>I%\$6I>5.B|V4+@KJ(HX>&MN3(OE M B ^E79%J>8|X1:BA)G<4?
<|!8|JHO):+FM @.M"l32P%JKVGMALD_ MJB: X"6&^>0IWT3;4E&5A6//X44L"W3Y&CF709:*FRI0L%ES+JS)*
(.0D&3Q M|Q=4G8T|QWGOX8^)|J\$ Z:~?CXSkuPWCBA&?30V03|ZU MOG-FIZZ2Y.BBH.S|<|95VVM|..
|Z7IB^DJ|!0.ZN&Y|971#:>+|""Q03:|I? M7D2@PQ.F3*QJ+|A|2P|0Q01+|U\$Z|UM>*>DLW<0|Z=^3R7+P04 M'
#|@7I96C^+HH@# 'R" &0 'AL+W=O_8 BD@)2D=^H.16%:_NAZH?%O JZUuw=PFD MO|XS:~!Q.4)3@<:
|L|S+SOK|61K|^K\$#WL:J7=-*J:V|BV|45UL)=F08U
M|:R.K86GJ5W'KK\$HR@J59PER3"NA=31:|+6YG8V,1NOL:Y|!>I:V&?|U"9 M|31*H|/"@UQ7GA?
BV:01:UR@_ZV96YK%4LL:H.&@T65|H-HKVYRUD_*/PN M<>N.QL"1+(UYX.FGS_07W|0R8KS#*!0G;5C?01U!LG#?
U'DP> MU%*W3|Y^\$C|I> 61|0|:~@T%+W|67LPFUF\$|LC:Q|2"\$&M#DG-1*MO
M:5<2SL6WA2/|^HKA+N34UG|02G:Q|H8F>=N-
@SW:5,Y2M,0_ ALM^+IYW5^9_G0J^Y=YYGHG_U^~)=;IM)@OT<.7"F%E%U=CD\$6GB|AIP<-VO#ZT06"
MXU:\$C9>5-DHUHTRSXA|FF9GBXKL0:;\$K4=419FK>4_1.D&V75?6<(P@9,| MJ-O212Y=H,(S2|I=
|06M:O\$Z+|90*#O.|UR|9+JG=1T:Y7BR"Z_)WY)^@:- MQ7&RX+Z"8L|B3QC,82%'F#X0@&
TC3%,9|F_)0QRR\$,"EGOFD6?M0(@ MX8A0D_A(\$HE:2A"ML,'^C",4YI@06|X*M<>K%&C%:JM\$E'2RU/R_>8N
M|:5(&4U32L|HFNQF;PV) ^)P.|@.Y9,F:~H|L8,E65UQ0MJE@N|NZ|8#"? M2-|#C2\$SS,>IR%EF:4A&&
(Z<JUS\$A_U@1KM.G0|IS8VVK^ MJK?+=+P.TD%IG!%T.3|>A^!3M<_&F"5UE:3SUJ#"LZ*,+200_LH8?YBP
M@>XS8_804\$|L#!|0 (/R|>EE H2&PO=V|R:W-H M965T|C1MI#=#QKQ,?/-@|^FNZT^69+,<>*JGL
M+~B=JZ_8T.8E5-P=0T*=|:5-SAU&Q'6QO@A3>J9)A\$T3BLN%#|?K7|LO|
MJALGA8(IPVQ35=SL#R#U:A:\$P6'A7FQ1POA?%KS#2S|?GO#,"|J40%2@K MM&(&UK|@)KY>9*30%?
X0L+G8T:9K+3^1L/Q2R(***0D#M"X/C:PBU(24_8 MQM)=9M"D|/3|0^15Y|YK+B\$FZU_ "H*5|Z"2<*6/-
&NGN|^PVZ?%\$EVM| MO62|5C=%CWECC:XZ8YQ70K5Q_M#5X<1@\$OW(.D,\$AIWZ|A^0MW?#XU>L<,
M:2:~#7RJWAJ#\$XH.9>D,|@JT<-|<,(5MFQ|2A8"!N)%=V&C|S)YTP|Y 6 M+5+R Z0Q^ZB5*RU|KPHH'MN'&%4?
6G((9&.E|VKG9GS:|U/(M(MN#&E<%X:"21DNAPRJ6NH|@50%:5Z7,*|ME!4%,(>%-
I4\$064"!8|@^TSRS\$5IM=>|VS6775PFU376N)7C|++LMWOK|X|EGC_X(M=^G4S4
H_9(B=^B^=.GSK|GS26V\$DBA|FKUF+D7?|>\$%SR M^?TD|/\$0/TP-|B/Vc-36LHR-GIE-
J^Q|_UTRMV|K#EW:5C&K|F |P+Y9CD M%3Y4W\$&<^<4XH5>|!#*P-5%(7/S5:)|@_M@MVD:|@DCR^|T-
3RZ|^LS&7^L6033*M?=?O|K_ M=RT%910?WM^&C-1F#?2EBC:32|&@7.M%=Y.W&Z|M?G2CN|C|VPO+|?,*2
M^VNMW6%"#OK_I?D_4\$|L#!|0 (/R|>EFH)R#?J@4_*3_9>&PO M=V|R:W-H965T M.<1SGEK2P|OP|
<|STD1NO&|TMFH39+@=GNM_+V+6.9,~/*O|J,CL_ R0_ MR/B4+7|/4.W>|2J>'NE+56|E%J#0YH|<-
f)>WUFX&:SF.LIR4-4=7X|M6&R36 M%\$5%:~M8#*#R9V;K227|A2;J*X0>8YY:EKP16)YR<4/U-LDCUKP.U87P|R^
ME#?<6*P)%C|Q=^F%>C+N^2#:'|63|HJX^11|L^RG&S@_YK?SGL_PJ"WHY= M0|3|VZ?%YF|:I^+F=-
BMKUQ:E0NH8\$Q.W-XBSBM|7U6EN7P7R|7"BXE L|A MM-BAZ!24AM.H|GX08N>8;N?|*F5Q_GU>|&
>D\$P*\$=#/VE5|G:~%Z7F9N|L M3#B6;HX%-V9.6(JTBHPWPL@|^H^K'7PG_ |A7\$+?~|*Y/L#+%PEZ|H|^
MANA1<W6B|"%>D:~.1^~ Q3K#P 36TUO=IW%&|KO^14_43^A5NQM_""%0!| MC_S^WU;G<|)S&E&*+|<@?QW|
MB,B+<@WC>SQ_9 H\$<^Z^|H^<@|Y#?&F&R:9)_2(P^"#8B+1|& 8I<<0 M|=N>WW= \$,~
/(\$SB^H=BI%|JZQA?:+EF>%J&5>GR#HN#|X3&PZ8#8&(7(>= M/XA@AO)47-
&R\$;=0E+LEH|WRY90@/^Z^V885(P^!W^+YS' JKB?^8)T^3H:A M?DV0|UD9_S(*
|XU|^UX'73>E|OG#@=M@F)3K0J@G0)6W.&5+5/N M-HG-N|R#"/8"?
\$D/|355UR^VJ_VTQUCY3JH72|KH2=UVLOE?P-C|D:%Q>| M+|TNMIP:)L49U@%Y3ET*<6(9TB"U0N,I?J4R&93_46
&/Q15EWD#G_LDP0_M87|S|R/(\$CKT.X('T2>M%7G/>(*GN43_5\$2|51^9IB)V|B0.Q:H%Y|PL:K|B M.5P:
|!#=#7U/B@=2^CPK|2P4F2CP@&?P0A+&*&HK?<O=D+U-9>#(KE3&7H|:|RSL"7B M+JBY3.A0G*JB(=D>
<95S3|R?2*HRUZI"!E)N^~|102P.\$%@- (%Z M66 USPI:~%O EC|D |X:"|W;W)K&UL|5M; M:5T>E1NO#1+):+|IR|?
KE6"WVMP|_65PZ_30|C5GI MSAO:54|/7QU=G^TWYBD|SP |W>B+ ZNZ"0S:V_HQ|OFU=&4"-*MK@.MH/#? MK;
|4;4L+@8Q_Q#6|L:T8OEW6OU'/CO..E>7|KV-|.\$Y:NC|ZJT75M^&C MW?
RDXWF>T7JU:3W_6VWVDV6=G1U7=^V!7|650L#*=*_N(A^%0|ZGHQP%E|X
M8HE(Z:R|Q74ZY?..B|3V.U^H|RF^#-..14^Z#PUV#|+K2|M:F0 N|U^I MKJDN;1=MI!:=;1_>1*P|3UX4L?
EWLAR9_3ZFQZ|O2|I9|D|S|A|I9|D?~6/QA?M|:W3E?_C'S MP4|L_OT0%V23IX5N";Z6YM>ZMQ M#R97=?

UJIEUEYU7+"RFV15_-G5U5=9=!2Q_RWO8N%HV_1UJ+H#N^I.32_MJW5KMT3C!
!&V#".NL=Z>.:M71J:IQ\$N!K@>FAN@=)D\HO0=72M@W(<+H% MG0WLAX^#=:M;XVQ^"MBM=8-
.: "MH.Z*56CYA;W5!L"SPHG5OM@%HK/IU36 M;4^WJ!"T7@,H?.W.#)O/" B/JH,6((@O)B E?
M\IK;G1EPQ)GJED<)"HP MW/8_ S6 #0#NA4):Q@-W9L_ 'S?1=(%RHU!:@T; >|;#7;5AW_15JP+8!3_=8;X>AU\$#9CB2-
_003.~.5'NN+Q9FGHYHNY)H%4!<=Q M=8'+Q";
K(C>B0H!)L&_>XC^"IW"@GO!<:^4_ G9ZIH3_@V3H)+NJ3T;2VVX?W(GHZK
M=UWE04:5!1!=WBKUL2Q@5^CKFE@!>M,BM%4."UOJD:M<)3I/^ ^VL#JZ/^H
M=N;6M/0FM\IN">=S6+6AY;X9=-JTO_==//=.2?VH"NO6DY41E,'IYD*P_Z@\$_
M;W77TPW0W8+L4'+;XA&.\$9TH6,0FO4>>.FSHOUNL56,1_TNR1HF&GVKJ&_M5#>#6%H "WO;FH.!:
I.=0Q8;&|"PA2K=%6/8W@6!\$<:HU+AFB<-8'MJXIVB?9^_A1S2L M!%-VP0)"!)E_W+1X(+
(^8TDT!#"1T@&L4GEIB,%WWOEFPP?_YV!"P!MNX MA(-&?")I82L@79CIPNEC [E8>V..819K.KAQSP
KC1&+W3<8&+43,0Y8Q_MJ=;*,J!"YA;629Q6!"EJ@TW^4=FIZ)*0!S!(.)0D+/90=,HJMJKDBS!"K
M8_UG0P_UVTF*/F_!!"^6"8HY;18F1X;CHOQ0QR;OMH!16VVP!P0X\$2!;71!_M3D#_JM^'W9'SS&^R40DF)<115;T4-
>P&\$S\$D.9XP6H 5;."=;KA',O.J^*R@_M*TTD)BSH%M&_+O#4R/1+Y1"V9#X/R^XO-JDZ^0YB4XE(. [ZPJ%!/P\$8GD?
K@1('FAJAGS#XAHU1^65LKN4?)HZ(P+V%#8>Y>DE.FGX50&2ACI+Y6!;4\$#05Z)5R_-B! MMNNMHPI.NHX
N^8ZQ-Q/Q^XXI?SFW=6C*KW+^1,0GA2&C!>>64I+GB,JU@*H M(D2-N MD"\$T9/?
TUD2"3D^<%X53U<+9#1!-F\$SHX2C!";I>=LAI%MO^O&U)4F.*RUY8
MMB<_S=8'8FW\$H=9,U!"YCCGB9R)\8&RPM+.Q+R@T@6GDPVP,N4 !VF,>(3)
MO88EOI^!)8MR^32U3PE^J+.OC=N2JX49T4&Z;PHMD)LYN\$8HLZ?F5*#!'T9KV
MQ^2I/+>G,93!HJ328.3.&:TH&CV^EA!H-ABP26#9!VT%!2P!3\$3!">4/U=413W_OUE
M!4V!2@7+8ZOCZGB!7"@2YMC!<)>/E<6!BT7P;A!E4K<^!SJB!3K\$ZOV-U
M.'BG\$Y4@Z1!,O@5.P9+G"D^EA41T;ZO%9ZEK\$=9"IVK6R;?Z76K8M;Z>Z%O_M2_1G<8O2"A-
E2P0!)%R2%_S;53_J&PPM.H!Q2.*E@*BJ_%'5Y6%23,KDAQ_M=#G2);,3M!Q.GV>0B8N_-S06_1TB\$DB;Z:)
PEZW11*(H\$J&+;!)&UZCTIY;9J_M62C;19L!);\$PIDSJF#P2EP7>YI0^N;.:2-&E&14%#F=V\BGD=*?B4@8X;F2
MMH5B\$INFR#B_HI33S&\$_L&-Z!6'6!7Q/7,L2B+G!B!)3';D@*MS_M("+L4^F*6C=K>XE!BF1"Y!"@::F89#
!2*Q.^8^>R2V;*&!)9NUZJ=L!F_MAI%&GD_.H!"!13!G8SH&*Y>Z1-L+Y;17J=H8^K!41Z#?
J@<ZS&I=\$>HGYLVDI<I^Z^*U;ES"5YM!;VY+Q&)QNO< VK6>S1^6SZ1ZB,=5FBT;#TO_UJ3%TL_M,='V3N!
(G3R%*Q)A;MR6=XG*?2CFN;A,GO1T^HR"!A(O#I)=M#^72&^UB_M8@.N<?V_DBC5"6)=K!F1;\$8)W&2.1\$^R,
W@*5)R6F.2@>;%6,8NEN*N!_MLE />(!DfL&AC5.;6(E2+Z)1SJ7H;7>@_6+IF#)5%G)?BC8/H6:8"3H
M!5PTR6@Y1M-1A7&O?L;@>I&MJ-WO6O12861>[!7?BF!KI*9.=5\$*5DJ;\$F_M(RVG\ARD*FJF*4^IZE?KZJ,F< !;/Y)
/P_\$3H_Q\$4+XXXQ_)\$S5\$WZ_@S M;G_H!R7VO&TN<.?S@N81R_%*MH,3>@%!(RB4(!T I>.+C6QSS;D(D6
M.C@WNJ7\$'1*55!70S#F;GGI+U!(KDC_XQ=XJ;OLIS46.;<O;\$4!5#5_M,1YFX!<%_0M7-"M;#9#1B<1DOT^0BSWY
P!2-KH5R36R=W01?MGI@/21N+ MOG'S>\$V_EH@12^/;#H;^J^QY_1*3?4@4NB^8L*W\$;YB!"L=R2T^RB<1D0I
M>!A!1T_*4E?;KEN-JR^0R7^5LBQ*T4>?1EJ,2KNG43FT0)7NK,S7P,+H(! MCA=^HR3DM^LXZ4&5BZ3U6)+
(Z!5_2M?#IV=DDUBF!7_!/>>FV9786_-Z M89_ZJP<*W;JL)*L9G#9@&M;U^!NOF?Q^1S!(4C9B(2CL6Y72&2V
18Y+G_M/1X>OV!%;8JH"3)D4[VYX?&/L7K=OXX!5MIX^!@?Z!(Y_5H*!;B!YPH;B-
BEC!C!/KXL>I5\$Z6Z17*!;Y@Z^6!@68;".PVI MDQHGL>OM750M^M?B-R81,S1H>RH_0S*0*,P;F*ZH%7<3\$*)Z
0JD#0E!4?_MJA;IA3VTJWEP++JYJ!#DM^%:>K%UT,"C(T;16M-D\$;*&!<!)C6^.>\$CIZD^I MN.4K4(3W%DZMA
=)7ZCPT!6!^<A)AO;NX>JD^F7=@4.C!LG\$OM1PWEACE2)' M?R&XYK^_M^2=,YZJ6ZG&1XS(18%J_ P9_K_HK"
!(A6J0"/;I^JH.RSTRD MD0<+!)GR6,W!42ON;Q^_M/K/X/#_3B3X*!_I0=H!F#WD5EVII4S5-X0OR&:>
M32K*%\$XK;6/4P?;41_*HXDY7Q@#"Z+2_M_SJ7!I/#2#1)E(^S!=\$Y9KR#0^6P\$WX0_H,972!P)F^T4G<!(%-
K3DISW7@K_M!+;MS^G4^V_!L1Q(C;K^VHR3Q;%K-I>8.TL*2-0@5--E&Y.+?J*%OFG?\$(
MZ;*.4,8J>AX=W@M5L4U^!&YXFSG7&H;54<4UC85%N5+GSANQ/PKA! MCS2X6Z2P@=I+M!0EMK#D7L)(I>QX^/
^Z2W^S48^!)XR%\$A.JEP"NF&QCF!_M-"M!&LN*8T^9+.=43^2S2_I")NI7;9,"K"4Q5V_S/I13JY"!&DM!'5Y5K
M!Z+";K;Z=Y4F-O%F.T@R&!&\$8I9);4ZF!L(2S/OM_L8D;7_MSYB_N1CU96-!:=PH/&T;0&*J#DYB^
A#I;X/5RQ)B#)MONRF&(CC&(F.#K<8 MQ^<6NRVE@;GB=F1>(T-A>GM_ZV\$!CL!6_57=@17O*QSL^/D%=&*;
HO\$Z1_M.#ML1;D3_-6<2?P@VX"0E%33VBE8U;RHDH;5GL4PT?7Z!SPWH,E04F^MB(5H9RN3K);H
=#SMZ12+4%ILN-I>W@OJ.F!1U+@.<#Z#B?H#0NGN\$9^IHZ
MIPJB\$#2FN"\$ (V3U4BG(W2PM/IQB^YA)/^QLBP(@=,^JAH;I%&U36U8GF+6_M;
I);G#9>FNIR\$XT7ZN;A1.2*\$&*E?Y/?\$33KT9ON-(EPX@TVCY)PHH_M!QU;&
(PEI5PXY!H2T%!.2_T25Z4.=@G6,P!^U@U%_H) E5OIH"!%_T" 3^1 M?Y#>JA&\$QE^08N*(3O2.FS(IGDH2I(NT?
^&X2HJT_!XL;G7U+X_2\$*W/_+MV89-KN'5I;@@(R&)4/*OIT";_UOL_M>Y&#!K*@?
7Q+90G9CQOZNX!^3A0K8R)F^H)!-9#>B_!8/R;FFJ0S\HK!#_M.I^
_H5N(1OYSCNG/\$%Y>CZ)KY^*_NE!DGD@+A@WSI_ _TE^#CYJB_M(W&&*6KT!-4!QJ.X6E!0J1CJN_I D;-
2+A%M^7TC*^5"J2_ U\$!TO!\$ MQ\G3ID>Q,Y/4S6);DJVG!1DEJ8);@X,2^1N-T^X9P/^0*G1^X#+-GY62LRW
M!DN5<^!QT_C=%5SG@:B^0B^_V0#^/RL>THGTC(!*0TE6!UOK.E#=#L!5^W_M1UEJS_U#;Q;O6@-
U0L/Q#_2>QT^VW<0XQ=4=SJ\$S67F.K/0UB3H-M9TX_M\$J!TU0_>8XK*AOZ6(JO@;
!^D3+8\$>I4=\$O^OX&+>7ER_>E>I.GOR<^ED9!00=0@_#15_9_M>&PO=VIR;W-H965TD%1\$(2&@I0-
"RI^G!_0!)2;^L='K37@>B@?^I M!B!WVGRQ;R\$<>|K4REX-ULYM+R836Z!%AMNQW@J%DZ4V&^!P;E83NS6"5QYI
M4T^2*)I-ERJP?6EW!LWUY>Z<;54XMXPVVPVW#Q_\$+7>70WB0;?Q2;16CC8F
MUY=;OA(POVZO3=XF_14*KD1RDJMF!^!H%-?/\$A)7@A^_MRM/O*/U);+5Q4JW8
M/VX6UAF\$R#1/J1NH!>I4=16&%>12#ZQ!_B&?1^S=D37M9TH>H_M_Y<.>I/F;8F_SXAU06T9;UM
US&C6"476PKC(=4I_!D9;5&KEK'6^L!%LS_MJ9PPBM>(7X6\$!ZL_YX(Q^QDER/(.-/62N;5@MWJSY>KY#
I;%XHM;.!MDL*!6_MUDTEF%#5>4@480#X*W#0\$DNC_YX(422^6Z.KI@2>W^P4_7BMMW9\$(C5+^)!T
M&GD;0\$EGY*)OPH!9Y!TX/_Y0)"^WAYJ(1YYW7!_EFA5;.7F^CRNM;EAP0C_MW9@23U15^C^BZBU
H)V0*."&^CB%#DN)5^AXY83L1/YLS0_+L(6_*)J<_R) MU!/_9#K"RX1UG4_VN_0!=\$&#%GODINZZ);KE20G<&N%
Z\$2K_ROY>_B_MP%\$X\$7FKKSQMCA"J?F83I2D=4#"\$S&*73Z8%N+;@591DQI=;Y7Z85\$3#JQ!4P1
M^DX&\$0%;G*-3"OWE9_MZD8%!)^LEG(?F?BD1(A!_R&#
(1G#9DK84M8!3P@L3!_W8!H6;E2*W^@D0;3R^1J=)/Y*^Q/_%)J#0_M3BMO8X.0@I?K(RYPXYH_4N8(9*2FX%
(+A+JE_NKQI#3B/+7AAND4VLI-"V!MP%07M;L-^H^+@1L_US6;(&G*)P6ZYJ;1^Y+9L;CCD^A!+.%^/4"@;HRU"
MA(K.P?Y^44ERX\$-C5O!AX(SB_RRU^O^M%A7#APIU^K;"O5#_ENV;XZ!O+/D#NOV/YO#9"L\$T8_MZX*2#_+I>&
(CAM9UZ3%V8OPWV_D?FZ^TADP+O6#R^9VGXCWA)Z.DF(?_MJ#C.BWA\$).?)\$S(L-
;9,7+%;GSE.5S.DYI.1YE2;S!DSB>P=4Q2^*Q<6L_MC8+^#W9@J>C*)J#H^F;L!PTSV98!QS;^M!^&QMF/W?
9JFAF\$2X6P8*Q^6;3ZC<%.X^J!0;!)&)+%_M6B%4YD5+2;@D36B-L7/IYNP_M#A%QF_Y)_R(BO?")&ZID6*8^..S-
DW(6<.<KOXDNK)_BOIYRUI/<)+%>B2_M^Y!^7>9B!T4WYMD)7AHNB^OT>0DE1?
SHVH/7Y(JR1CPPQX!90(Y&=13ZR!_MO0HJ!_(F=C/B/E!-IOYBP7&>.Q"\$3.H+^EOKA#DH00.8Z;Z>P-/SLZ3_+J
M7QAU0_8/X8>.>_JD^NTWUX=7T*9=G<_T^A^J40G.G_LSCR47D7BF*8F.?P_MD#9>X#;22%_5;F5!F7-
<-59<(5J\$83T16016-0EQ(A!+\$GH_"@=3Y)LBUC;_M3"ZJL??L\$7.RXUL3Y'&=;^=)2DA<8C9V/Y/2_J;-

#Q(AK&W*!@'RM#T#HOD MBFWYX*77VA(,^@&2G;'K9 P^Z+L=IKJM:F?69*TYW03S2*7JH M&T1?Q^1Y-
H=#E0>J+M).?XE*/D-GL T5^D-5JFNLP0(6V9"B2 WM#/<&0 M-TT/H?
408W/LBZ;M/H /WGVPT:SHF\$0U(NFT1\$Z;'Q'<9H9J0:S=0V'ATT: ML_W=I'
6IW/WJBY;AE%W;VMCIT>^H/HUQ3N*%8CTCBI>N_A41G^C>8ZDS01V>C;+,\$V6B&@H"AL9JZ
M3G(Y^*B%@%SY3W>M;|WK7ZW SIX\$SZ*I<#H6/*<2Y:H62ZL&XSP;L^ MUX47H?^\$IE" T2 ?UP+C@ F)PO-
2;.*IH48I-L_K-14\$L#!0 (/R/ M>EF/ZW @0(+D' 9>&PO=VIR:W-H965T0.WQ(0Y26QI.9 P&%3!D&K'KF *EAD@?
XV_#Z;22!KBIWK)_LIGK7.ZPA"FG?TBN MBK'SQ4\$Y+/'*JFN^ ^0Y/GW#EW\$JH1=MZMA^Y*L)140&| ^04E8_<2-
'M)9H#L*^_.98!2HG,*)@SNKU)T>G)&3H! MA*\$K0JF^71F12DL; C=K9';U3/'*3(BN.%.%1#.60!Z!3P_C!P?
PKDZYS308 MYCT)#A+^RE0!/?U/*'''J;LTV/@0PL/N!+Y/ 79F17WBA&VCR" T2.%:'D'7
M9==T43>=:6TC6>\$,QH/N71+&\$ISDXP= X'WMJO1!DJ70239D)!*XG;XD. ML2<-18RX9!D0
9W^X%>==U#33&P%&8BK!;_&JONJZM!N<^H/R9J&1.\$ M?K ?-.M0&WI/G6!DX0*D\$LL1!0*_.KINH7V7K;7-
AV^LS-1023?T?ZKG M4CU&GNCKH7?Q9(PB2+L)M037&^I6*>H41N5!83WG&E^ZI=%GJV@C!>G_!
MN=H:1J"=ULD 4\$L#!0 (/R/!>EE*^8#RNP;4_9>&PO=VIR M:W-H965T7-LCL>D;0%VFL7F MX#9(T_PV
_MC64B%*DE*3OY!SN4!%DI*8(T(LM4C,OG^7C*8H1-!M'"
M4RFDFO4;:ZNK.#39!DMFAJ!"26_62I?4E,7H:DTLKQO*D681-\$X+!F703IM
M^NYT.E6U%5SBG093ER73SPL4:C<+XN"EXYX7&^LZPG1:L0* H/U:W6EJA9U* MSDN4ABL)&M>S8!Y?
+>*Q*W\$=Y!S2R8!)#CFM7"WJO=WI@/M_:3T.B5;PNIUO;L,H'L.E:5>V!>E6Y405M-
3GXVO:7YS5'#>V8YEP7,M6:R0)IW M:Z;A11&<79CMU1:M6G)"10R62MJ@1N98 !/R2R#BIYP5LD7L'/F1U",AI
M:6B7G8#9,H_!GG51G6SR6R=DCT4I@-4SW,J<@;WE>_W\$L^%;T+BL.S17IF(9 MS@Z(-U%H/TH_B?E/QP7PN\$,%J-
H1H=)CGJK(SG>+MH==,V'0\$JX\$9>G5-@%ZAIS(3;_I-MJC&=OXW1/GY /KOL5WT2?=>46 M&JV%
|TP(^&>)Y0KUO)=@O'+OW'N3#G'R*XI+Y!<@7W;(E1Y97=*B:LY\$!0& MU/K8#7<_VB_160)=28H6B;93>RL-X+""
IAYPJQVB0;^10SACB*C^Y6V&I-Y MK_4):ZU,OE\$Z(Z7M6@FN!L#:DPP,^EO6!M\$KP>00EGK8#/->?4"*JUH+=
MY6JP&P3#2((BKRNP"D)DD\$PNIG>HZW8FUZJLF'PFJ4R5)65)2CC9(TEQIZ\$; M&R=;O.ZH'0\$<1/U".S^Z+C4FM-
D#SV+!%D>_!3Y#RLK16C;:L=5L!T=Q8?<&GOS8-H@N&U!1%QH'F";9;Q@5;G3@)K5!<&_4!8,EUP:4#@FERCX06-
K=N:NVU8-M535U!DI9HJ;QPUHIZ!V!O1^K91!;@!NB^?I!102P,\$% @_(%Z6>(F M,Z&^!@ NA\$!D
!X;_!JW;W)K&ULO5AM;HLV M\$XKA MT">#8CLX69L\$<)E*X9V65!6#<_T+9XDJ1*DG%R7!HGB-E6TE=M-!
V!<LMB;SGWIZ/HW0M^ZC+XB"N^U2>=(H3J5_OLX)*Z7NV(HL5J76E
M#>AULIZO;D"16Z/QP_10U2*MY8I/+MWILV#5H8NG?IU64KW<\$;SDIZ
MNYW%@RLU*P(Z)>5W)&UQ1NJTN'N_X2)5YB>= 1M\$FK+!)_ =W1.6C,0S/C48'6*EFP2;U OXB^
MPY>)I'1N!0>5A^*D<101.4UEK<.5G?I C3^C)=9!>.OF#=#QV1U3!8LA&& M!;4RZ5_>-
W%XCL"P\$1A&NY.B:4;&>3H;_SX7@WT@BNAJE89PRG)3KX+"J M(=,SZ177MBIN'3DR0098!5U;7*%/GMXWZ
%ML\$QK\$X0X_+B2+RS)A1> M?&=RRA+IV'=TL3APL2SX4; G!+0\$!.#KA@.AOL;V:6+NI%O+TOX;F9_-JO
MZ&E7G%OCX6R>)=BG6Y.^J M*! 4WHZS.ZSLC_#<%H60R6U;2
M/"@S\$!61=:X"Y2);A@PWTV5T_"HZT/Z;N"149FH=:CJk#>@ZXE7N9(W!); MC_9T5R)=89T(-J=16A;PC;2\$R
A&KH(-B9;)H=Z0M6\$(M!7)K"UE5.P MJM)0.R-#3FKJP.M4A23+!+E^14)L76:>^ZMYW^Q?C!>6V0/^#
M6;!ZV?9F=07%IR)9C"T,J!"3N/%\ \$*B%B=[#S<|PV=D%EFO" M5!1K-8) MXWKGUYYXFZRSE3(-
14MIT"\$YMMVX!4,P'M=YTBAUE%"YG^BF:0U0QEYCQ8<
MG9)B*!5;R7)P@.1^J?0%K&H2?.R07T>C3D3\$00U13Q2EZNFC":N CT1^E4P.L M:B(U%VN;*J05HHLBC)KIZ6'-
HJ MT"\$S\$FU&S\$S_ M7-C\$)-E@1E%;>ICE4R"PBA;=9!J#.<4SDHJM!R)B:OE_" M6.0(*E-
E!1MPE6#76YK7L1H<=N3(!/S*P14L<5/JBJRI*(SRNFPB!3JO;3L MK#2S74!1-U3\$;D1HXV4OE ^@Q^7:'
V7U<1F!505@1Y^>)HN'OX&O1)D%RS MGH=W;)3M^U!P_1G@AW(!KQ<8&S_-S=:J'C0A^VP!;9SVPE%-13#YN"
<f@.SN%&Z!f0,4T O<:YC0-D0)HFI!XFERY/B7N/#V&L_2FC>NB M^V_H^XTS(B)%HOD
MOXU/C'6+*#5^19Z5#7%-LSCWDCFA@!WMY1&<8"<4F78ROS!#12,U UF=Q M96=PV!502QARMYHGP-
NW6"89V)X-CN-AW5H8,H)3'@8NR<#>'UIKZF!_ MEQX&B.W9)TRTJM1W%=P;!1K K\$!FZK^5-
QKV8FSE/8TL@+NL?KG"?ZV* M3748HY;ZZ:Q6Z5@UH9DRAEUH!O\$4J<>H&FXS+=VIKA68V:8(#E>=&14ISM
M,U05&XUGOJ080<\$3J%?/*#4RM/XA!T)W4MHT <0C;PM((03:>H^\$187JFK MQ\$S?Y#GY&(N SU3UVB-).X(S-
#X2=S(>+03G'@#?CV+\$H^SHD5EGC3RE)# MC_/IKQ"CB>63!*L\$&MG
G.NX.@XN;/58.&>5NDXU7VT6U12Y:F!6FX/CQW MCZ@Q6D^-_S?+ZZ9#Q_4^C3>"6?QJX\$7L>G5>OET^6%BG-
f!5J035XUWTB%, M7FB:0G30.13!TJ40!>DFV"J^G4LP+M^O"P(YV?&f ^M7" ^N6\$%R!UIW# M4\$L#!0 (-
f!>EE"). U104_X-9>&PO=VJR:W-H965TCSNWR6@5 MPN:9=J.E5XK/I\$;W>+^E75K%?
#JEE_<5HMHM.ZG8HD*9K9;K1Z7\$GTA2?K!)?*5 HUMZ!;Z:GOQNUU#=#WF!N'-ZFAR@+ ML!;=-18CIZ!1F?
ILO>2!/:!!Z-O_)UGXDSFUG|BE!>+DU'"@2KF! 1%+IK M2;fE@;!OM^f*/#E.OX!WD?_67;G,E=?
GMOUH%F%U,J!&M-17JF_#L:UY MI7?YY!ROL:V/+ =WL);1;T/=KUS!H^UZ89>?=ZMPX\XB)V#B+B'B2+*GU50
MH2.W!C.T3CAYAJ!8XT_&FS(+ #5P_<JHKW77:SIZI^_MID^/IP%1^=NT MV45X.400_O*AH#>Y"RM/QW0+O?C2?
PHT!TAB#^F%>##@VR9.2.1C\$HF0#13+ M#BEE.5!VG12OG%W3;_Z4_+'%9TA=8_ KC;[C^)_W+<07IX?
GV7SS&14 MHT!&T(77IEJ3H!2HOD^0/HY0&1?)CZZ0PR7/2M)GCM%/QNOEDNGERHR&B_-
M0!8SA8VC^99F>@FY!+=J;7)@J'7"MC7*78NKMdNG-JOM?6D^#3=2E@_MDM'LX#).X3V>QC^#HS%5S#6
XSE@;A6*!D5=-ZVCES6=-;#XS2 MS'"@'"<J2G1+0Z#19Q.)L0XWL_F4UP5 SL;JF!1+!XS 7%F(6)EIV@Z
MM'F6>T!|=10F\$Z#'=Q?57L;2C5MF1AYZBSW4!Q3&-14 I!)O31NG;! M9 MP_E!D4ZOM"!
M7BK3!D!38TK">5G%7M8"?39.4XE>C.NLPBJYO@F!0_#XQ#DS+I@&HJE*JT MAF^9%6B+#+)-
A!5RVYWEA79F@Q5"@ WVK!4RHR+X"IR=@:8_NJWIL M!0;! 6D4>*XH'Y<)MDD!#4X&"Y\$-
LD50E(45;_VDL7PW3=& M=XU&.)FG/\$%5D1R7!;=Y4M"L=TO3"#B+(2+W6QYC60=VY1SK#_NJY+_FCYH M7@2I
<1\$!&MG8+4EB?V0A@'"A6J3T1B!B!_D8IR*BMLDP_RIB&U2005JKIGD M155@P3G#+_E3ZN;+O4&FQ@50)?
HK6ZK<5845;E3XO!*P=130BS+V1.%7 M;Q%56V5#7Y9%5+;HQ;#F^BONPK4L6?X01UE**L\$AF\$N!-
LGC%1&BEB#L_Y2K MJ<2OBER*C,I9196(-9JS).HJMN*6AB*#&-2)(RS6!4>(-!NQDB?U!D)(2 M(BN8V!"
<"=0988(9;FDY<[S!D)!JTA?E@AXRB 7/O>XU!W?Q3JWZXWJMK12D,7G M>#WB0L.MK3V>)W\$U+_F+
(3#A:S1&=:11VIEJ!H;ERO6H^TJ.YLGC-/%*
MO!T6HN28@=VUV/HF(9BX1A!LX'\$ J=;JMC^L&10U/LD7\$=MC*8*G18 GT
MNG\$&+XESSJA"@>YD^N;_FMZIB5'A+6/E!X?>BB/#Z;_7Q=G0TUI:SL M.T'MM#18XE9?
P369E/F(W%#M#R_!F%&/_&ULS5=9CH(\$/XK)9*)0)IPF&_!D;\$FU6&2V;*P^K M26CL O?&IG.ZVS#1^ZUI&+&#+IL-
_*^F)U5?57IXOA6IOO-9DTV)@FRHYJ
ML7/99:MEPQA389LZ0T4G"VU2X>C5+%LV,R@BKY0FK;#='K12(55M/2VF1D/
M=>X2J7IF.9!LQFBHE>CVJ=VI9Q(Y>Q8T9K;S\$S_F_1W6>)N!HW+!WQ \$.= M6/^\$=2G;KD&86Z?34ID0I%
(50^*QC_K%02(?^XBXL!RH_"B?0Z#48EB9K M3'A7O3;IDXJ3-+?
\$L1:N=#J72K#*IS"QEAlA+RBC/BB_!ZDQ082T*\$SDPH1;^?B449>*^BQ)N/X;0%6GYVBJ MPMLQSCRC^PJ:06^1
QOH1.= \$ _M'/4NE; MH2^S77%;N51R(4-!%G.EYSRE?#U+E>6.9L9>5(3!5?W<fUOXPA;@QJ?FH!
M'_5D18B)4>_NR_% =NE?M \$RT"&QN!9E!OWO&M\$D&V^_BU5\$GY:0YT34GC_ MH3-
HJD_@/03GS>"\$^K+9.8&9T7_3OD.*"Y(5"6Q0&_Y<:8=AJEFG'5SPXXPU MHCQTM.E0!7FA7: R%>D'431#&SL:B6?K-

U((/+&^5=QJ^9T4.H.O-BEFLMOKB ,!0(9>&PO=VIR.W-H965T#D.D(!>U7XXW6JA!8>J'TPR M\$/<<.I7-L=M?
W!\$=V#V60-L!)Y!///B)=, #DI-16BA<=:2#.-*FN:<1R.MHL*.F305H*006Z5K9FFK=[%I-+2+14BSDD\$>,RV@V!.)
I/9NH015(32LEKE(8K"1JWTVB>MCA>YT<?W|F!OX"+9/75;7XKIU"B"* PCH\$1HJON\$0A!#1^+?%C\$XN
MG>+!RZ+SYVBF7#?"Z5^).7MH&HPA*W+*!L J!NV!20=7J&\$!2L<6MTD M@F)OK!8V)0!+!PUL,LM8@!R#
(L R9V;9:*+5;33)C3W3D/UUD2. M2U>4E=7TE9.=G3V@L7I2V+WF<@=,EO#%5JAAJ8PUTY%FSC4#3G<26?
#F+N&AQ M%P\$W^P'N #XK:2L#GV2)Y?V,7\$!\$?I22D#P4%^V8\$!36/3L *G\$1T7@ H; M1K(WH)A0\$*?
Q\$/I^&EO1Z2SW D%MX<>AA"HZ2104TVM|KW,IO.L\$UA7" M5@DZU!\$NCX!Z*I?I5DFC!" J M%V/I47M<
N&R4#6.85UI1*A#DZ%K,ECQO^!%*3*KN1#DWW2!DAMJ+6/3?0L M&H!
IPT+EF.1-529\$8(HEW\$;NJ5/2Y;0TDM@18.&PKR%4K43-R&@SLZ MPISUE!M&@!T7 TUV@!Z P?
2YY5IZB8WJ&Y!4D#FF#S!(9#^)#6EDFWI+2 M&@M'SP#).16T<97"!I&S\PP%9,>6H='O!>8!O^?
Y&HJ_0%/'=5/595JC MIKA#(RPH'UM.O./3. G3@ANWF@N(NTQ2#BO<\$IU_D0EB\$W,!I"+R7Q");; M5-"PH
MG;0_Z\$(GZL2CM(NU<1:0>ZDDC!5307JNU&69A^ADW?I;UX4>D^> M6?D/C=XCBG;
/NL *O.J56Z@IW/HV68.*M+ISO^,EK);N/C)4J.VT86B? MI*C:INT4 MZ/M6*70<.>G/P*S_P%02P,\$% @
-(%Z6?://3+L!P DAD !D !X M;"IW;W)K&ULU5E;<INV\$OXX&+738H%@E>Y=B> M49RF)S)-ZXF3IN",>8!(2,\$)%0
E*/SZIL+4"0E2ZR(LMY/* M8D(I+YZ43%2CNQO;H#N;F1M"E'Q!T5T799,;=_P0C!COS1KN&36*X,-DSN
M;M9LR1^Y^)^49%,"M%1R42)*"UD1Q1>WHYE_2;%I7;IX(Z=XW04GF4GF% MROO!N0A0IS@F4\$*#%X;?L^+
@D!&WAV-\$?MDCBQ !VC LI*#K+,F>;WLOA# MY&9U.TI).<+5A?FDWSZ-
V_DB9!>)@MM2+4C/5&)*NUD64S&3@H1>7>[!NC MAW.FT&8"M7R!A2R7;YEA=S=*/A&%HX\$?:
EA!H6Q@3E1HE\$>CH?>"/AW3E2L MR@OKR/M*U6*OHTF%Y_9O.#ZIF9B8 T<.FHHWSV"!^5U MP8E!4FO4?H
MHT!D06EQV54HX&LXK%YHP\$7%+,#1#1F""I2SKEJ06FS=9%*(3&KNGZ^.#2 M65\$!\$D.)A<@8RF*
KIU):A!&*E@FA;@&;R_N<D!H0ERO<|AN(I: F+/L*NNG-31)*@(\$@N"1)2.VSF_6KK%Z=O"TG;-I3WMM M3N4,57Z\$
7_L13Z)@(+>+QTTY6!V9VD@^#;)/8#T)"*6B>AI=0!0+;E/N* M#Z!K')S>J^K_XTO8L&G1KP;=I@PO^A&633R\$
W""#2 C22IL83:E!IU-X M !EIZ/I_#VJ% M!CD#Z#&8Q0=AP-U86"?EP,I>@;TJ-0F-1L(8GB)SJJV8X!Y7TM'MP/?
F!0<&WYK8A/2>DVON'C +!M!CU(MKQ M.=K/IUT(""\$0(W0=CZXSBTM0@RIGG.30T84 !Y\$3-T
%0&HLNSL!!\$+JD. MOX3#;5!8CSWEV(?C@|=RX?JZ5.2AQ &D2NNX/FX)#I+0/VN8./8!NDX M#%.WEXK/-8V?
0'R\$_)!\$KF(9>9!H1DT!#+3!-Y+GA_IVG2P,D8VC0ZIM/8 MOE38-Q\$S!B-GO9T7.&QWAAMNWI?Q!\$R2!J
=A#0ACT7#X87;Q52WV'= &MM?6."R)@O&Z"K+XFGU>*QT>_9Z;X?#V;;JA'Z/PE#;D-B&X(P1#TIFG.?
MAY(OE8ZUQ;J7)C;1\$C@#I&UM<(ZC6)J_6 !L5;+D)3/R0^YA=X;7+@#T M"!380&(1#>\$A:2&0G(^LX!#
<2U! T:P/J1>>PYFAP'USUIFLUZY\$M'7K@<M> 8RCF4?P(A>R2>;D46B%>.)
I4=4\$F203!:=|AV/L(#B!ILM.&C'N!:#"JXU0 MT@:!*W3> Q65;\$MRL5B !:.)S0YYQFKM;L;\$;
!5^T.HR<9\$K/2V;JWL>A MPX*UUM AYX58VK-)D^@/5E!LL&XC606(%4K@Z!8;J;\$(^"-7+!FIK*!N!M.-
ERHA4L"!@_X3HED)ZD=QQ:@E&ZH62E9+T&G8N-.M/4Q/#;0L#^C-V W MOX#E7\$!2>7"BG?&=WW^V
="4/D&Z1W)SIWB!MPQ+1UQ/1L1_SYSQHC)28T MEWEZH5CKC9(^>R+H^!>2!|<!/&.'VGYZ=IDG;?
C&Y.GE<+)ZR2(IWA3RP!V.OTC+Z(6XVN.Z^8<I V.;)70;;S) MI?#UE30=-"KH/3NFS@TW2/!2F1E0;;#J8DL_ (2A
=&=IV !XT*+H;_1NB.&="D2WT=/7G*U MM"!BKKHRL!FL_UO;W?W@UW?ZRL^,K7\$!J?P!4SUKA(X5BGW!H5C%\$;
M6>Y-\$:6!G,%BN\$*!T#_0DJSJ^ "I6^8N! 4\$!#!!0 (/R!>EGIR6Z? M" 0 '\$* 9>&PO=VIR.W-
H965TU#>2RQ2!0H\$&3!CXLIJD&6QK902022=)W!_0YUL^0H?A E MBF?.G"%G2,
IV4OW4&T0#+X4H!=\$S9&+.HCR=;K!(M'NW6-(2JHB,=15:T!O M%299950(+V
LJHHD+YW%K/KWJ!8SN3,B+_1!@=X51!>;U' (=SOG?;IWR! M;?MYAMDS4^H?FQ?
534!SJ6+"^PU+DL0>%JMSXU!>1Q5>OW+9V!3,HT+I=PHU12KI\$FW&@X>TZ6
07YS#DQ\$*!M&K0F#PAC=)"EV6CX MOUP;N;JU*J3> M*81;L;.*J.?!>"K;FB<2Y;==ZFZ0X=Z@D.*I?
Z"P<??:C!OF\$TJA3&IUB M7SQ1!68I@2!74*G^MA3Y.K'9K>TGF0;U !0;B3Q38I7W_3E,WD1!Z<0\$I-
MK@UF5H(A!\$H**F.*EVLXRTM*2"\$L!P>\$K-3N7F%Y200BLDEJFI!X&;K<@%I MW'30=DHEKUUIZ,
<+NTKAH!07DS!WK!%^PJ@*^R7%I;5\$5MOMR,IBB2BV3 MSEJHT?IH\$??+8V\$P;!&Q-A"SCA3B\$!9 3\$V,IA7M\$6-
4ONOWJ*I;M!) M#<JHDE;T)V.8+5J401Q=)C#Z*^C<6B;2;@N%GO<0=L6F?MBVPS1J49P=I>TH\$S^,WW^S M;I=-
JO(QOQ0Z/51B""03OGC?2FNH4P!F+CG+;C%=(FEE'AM>=G*K7!H9YP M69.24<6<4^NS!WK_SNC4D;027 !-
X1#*8TDR@C!+DP@0PIWN(P0!I3_3^Q%6 M63UYO^B!T"!EU=NPFE3B!K&T'WM!M/W=37B
!OHPD)J=4^0"5V!JZIH! M55!PZHZ1V^!L2L92&KBC5YX;NA*!L@.974JIV8QUTM!S%_U!+ P04 " #! M@7I9TD3^?
_.(G) &0 'AL+W=OZP%W_1!+HLC!AO#XSP^ABH_07LQ+!LOLTR?J@L8^ZJL+E=M\$9N*C M9B9/4ZX?KD6B-
I<=KU_.?)++E<6!M7%FB_KK" KCHJ>I75&*9BLOEY3M M%I>=F7=^/<Y_.\$W\$3.F=I!0DKE27 #AE BR.T" &1"
(BBQ0X7.!\$C4@2) 1L M_%0!%L;XL+Z?4G!#2EAGKUX)+>|X:L8PGL7L)M=:9-\$#>WT?K7BV%.R3 M-%.8.YZ!B<
8EG4 !WDBS.E%W!+^2*4?%7M=N!W!)_8:L7QB)OK M^!|WQ;Q?G_MMQ+!\$-D>|L.SY@_!H(7>L%+&D.@-
#RJ#_9(9JW,4V.GE9Q\$O M9;9D,_0B:26HZY4T4);K@7IQVP.T!#_KE^*V!38/^F&'7G9LTC<=F!L#)"
MWXG.U8!>*/RO:1@DJDH(WZU2U\$<9PG@JD%^Y!;8T\$8E&-70H@?MW=6V4, M2<14!J.I?N,^5A6";90"4
&DK+H<8RT@SQ8 M>I!J)Z""^Q69K+1FCXK*DI&24.Q*^8.JSKG;(W7&IVQY<,+ !S#EA
M7L^#WQ! F/B>_(PE1MN5FP!2B@(>)%YOR+Q!IO@&_%/V'C!>9F E2X'K;(OI M(P?P%#%-'"L#C'&47L0B4P
P9,98S"0AT^0*;PWAN#+ ?9^!4B07*.H#=#F M86!RIG91TH^@YVB)(<%L!5B%M;#VE7C+;H8G !ZU8\$?0YW
4O/IZ@!*<M9TOI=H+!K@;BAL2.(0\$C*V5)H#@!HU6!A!\$;@_4@-!H!O;F%Z9%;P.L MAINLAZ#AYL!>-T%
!AT);2&RV>M<0QIG,'MM!&0OFYW!JC_70JWM^DUW_ M+VGZ;7; SB&("=IKI/888((1^SF&I(PP#"L7,K
!H/@VJ!H0H \$K?+E"AZ& MPQXY=;L!2V^!/*G;=TH),67E#!CT/H*U2Q*.*SJ0%I&\$GL-DG!;@F<1B0 MV@J\$+
%R66%!4F!JD!MN8/UA+4) T8N9,1+ENU*F3UTT'&(Q0C;&-4(F.2 M?0\$ZR2()7(*^K'#404"B#MP*052,O&>HJQ
\$5@B/8!AG58-C&ARRC0#3 M"%@%:2U2J0"M(M<;FIWV3HFSENUU6H8V"VV.FV5!GEJH3*5X^4T@QWV;&
M3I(RAY"/@.>0#Q.@U.X!KY!F)S2E7!H7N8TL7SX=\$9K8@)!>I09
NNM#_NIZ,\$X!>3WXN5&HF6M59SC40#E>&R;@.COP.@BS>CP7%D/RL+H7CB1,7+V7!"10"JP#W! M8V<'GX;
!\$S>O&/0"\$OX5\$DJ V\$V5P@N^R!QV!+07&NJ;S!OBCT# CY!+& M\$9<'5*03LEQ G?OMX5I2T!35CU->1/<1T#&0-
U=V_E37+&S5T=Z;J)_2 MH\$%LGO?V**ULI&<IC4N!L #K;I-EWFQKSMTB1X+L @V#B# \$_%3U"OD4\$5#
MM/7VQA80'X!+'MJHV=6X4J+V>=E7<5TU7T;F61+C5XXYT;R.*%Y)A>M ML_S L;5%XZ>(DFQ?
8;Q>KOIOI5R_&Q1AP%RX)A^ M3-L/9G"IRC\$7H;X/V(M2#^J\$+!T=&(7P/T(NCHU*KF!;.\$QU.Y&'&OG@P0 MN"
3@!90KFL\$KWYHW!K*!;@/M>.=C*E'2@3OGFZ8*#BR!IZ?!Z9B2!)WUW\$%U MHG+;(BTM+;
(CK%R773*F!FQ1!8ZK0Y94V!@F6BB;%QK1#Z\$D13!&A53HZP MCA!ZS;6ES+F+L2;? PLD13G;Z);I7R1R*3\$;
(BPIRN*\$U+E'M?_B8J5F>M6 M;.#F1LC!HEKYL MF8#26@C2U0KIP_VI-ZT_9FZK!J!>;U"+?@!^C6!ZP(9 M
=+!T^PC=)K"M9;+JJV>^!F#3LH@PZVC^U;.*%I33?DR/8D4EYA"/K;25 M:AC94;
(AW!3Q?""9K2P7C;T.G649T;XVSP_*J&2V&\$! P27_4SKCD;N MN!YX!HOIUV@2.0%(HFFHTV%3 !5-6X!U4@'KY*
!TW;^!UE>9W=V.KM_1 M!3NZ_B^B;I V!48H)(^43\$NJMUW'-5H!17.S'WL9WN/T%YQ_42ST,3L8"E
M@!XXI#M/DMQ#U:MZ5.0N;.)6I72!\$AP@#2?^X52MGS #;IO@Z!^!%I+ P04 M " #!@7I94,\$GC8\$"!K!0 &0
'AL+W=OZ9+5+2R MTJ;@CD*SCFUID.JMDT+AK0&I+0IN7ACO#44Q2U++@I45F@%E>S;-Z=+H^/R3!%C9
MO3'X2I9;G@H%BI>\$C/G&3AUSWB!4GHBDO&GX8S;+3UP?IQCOPJU4RU+
M;O%"RT>1N!TL&D>0XXIOI;O3U3=LZAEXODQ+&UJHZMP>BR#;6J>+!DP*"J!J MGK!TYI '&'?Q

%@#8\$%WO5%0>X=E"#=:N8V%KRK'_%I3(I: M66PG:|&.\$GI/W!FP00=8POI'^IMF:W
U M/F:JP*6PFM=T:A%_SI76&WL7O M0Q77A/W#A_XK\$UOR#&<1F<&B><8H_?2A.TR^):,^7VCI&G1^2I?"L1I K>
MI^XY1I#>TCM4I,1#:M^<(EPTQ5\$C'PBVL M2WV@F<"603DHRD/T,="MZB::I
M&B71DA@PR:| \$DK04QAK75NX2/T:B-V'OKA< R/Y,13H4Y+HYDS"R,VAF&? MP1VOZ\$DI-(O+)"IU.PAB<)>R-
XT(Y+0@I_Z_="YZ%EW!(>:-JXS0(%F'6QN(=-: MY6HOM+M3S*O#?267GI#-JRLA:
(@<470Y&PTB,#4UIX#IM@IZ5V9.XPW-!O MB,8GT/I*!<+ ,M_YK^!5!+ P04 " #|@7I9\$UI3GI\$ "J#@&0 M
'AL+W=OQ,3OSJN5GMLXG!/,H+:NGD1*LE:*>-WIS@4_76"(Y+MREW5N,J1SL|^:14ON1")4Y M?+\$ETW
E+94%GPD&4V.8-="HS@RO9.^Q9#.L)^MW9IULEWW,=PK:0M#5S* MG.7:IGV\$VN(E&IQG9*_ #+YDI!:(%0
9DM,??L,U_Z/T-WY+ _Z!PON,F\$,K5F M.=T9JQ&%OVUJPO-E-'N**ZSCLR"9NRT@ZUCF'Y@G_)8=3E-KG M?
7*"G9K7"%K-X;S\$#)@!+@ \$W\$|ZIUBLN"YA6JL6:6PRWI7%WCB|LIC*",E ML+E=&N(GY58OD-D) M.(YC?
(9A\$'<1#@.0A*B0 (21?@<#8)Q&L-YK36&6 'NNS2"-N1)(KRC3(" M=!:>.\$CAXEY*0\$.8Q(\$53-4<#AGV9976\$E+
|FMK'ZEI|B|YF2I|=POV@^IM<84K|A\$RS+WA MF?Z@6:-Y(B#B Q1Z"(KXU%O/14ZOG33(\$!/:BI-
::507W+LE(JH8J5+|T" MG:@("M42DD W" <@<@KEA%.\$P#M(XI<&HCE^V &HXVL&TL:8<,>2 1=D@YZ
M*%&E2(+OFZ| "B7 |Q@42Q8@#YYON0A*GP9B,'3K\$F8S"7C.7>&9WPR@8AU\$/ M>92_R/WJYO:
5HOC"Z<_ =J:/GH/P_3Y>\$!?Q&U?Q/^Q+W#A<&8?(/>P#_) M_YA_QOYDY;R9O)?
VDLKWRU/I:6G6NF1.%9@3/FW7YB.=^PW81?F^PW81_MBDK;<%OL94TX=P28XYD+;|MBM#EPX^?VQ='A@8K:)
I=U=2!VI?>4" L3)1 MY|ZOY H6R&%O.F JL04+W:B>^!+;DOLOF|UU^|T.I?LN19"4A(D,HB:@L5
M_EH^A)G&\$.P06WJP_XPC+K|C.<"8@.-&BOQ\$08|40S' M3DR<&.9.3%&.XLB)8Q1'.8KB<(#B\$-
F|BTH9<_<I.?WY+P|>:N;E*M+M M16S:W#<^>U)M;W#7%0Y@T(-@<30>"1X=;'S:@96+?QM9*8L-K|72IQ,,NT4
M<VNE-T.7(#V>CKYIU+| P04 " #|@7I9&Y9.S6H# #:|P &0 'AL M+W=OX^:Z#;#.Q4%GR27+3_?
NC9,=ML2S8OE@F13Y|*%D|J#-@ZT0
M'3S54ME55#G7+)+\$%A76W:,Z044I.VUJHD@T^|OV|GD9G&J9L#2=)#47*EHO M@^|K)>Z=5(HO#-
@V|KFYML&I3ZLHBPZ*KZ(>6)(EDO&|I'+,JOS9TA*1EO M2E&CLD(K,+A;15?98CAV|L'@+X\$'^^<??":YU@|>^*
<1:DGA!(!+YQ\$X+8IX MC5)Z(*+Q7X|9#2&IX|O (-IO(7?>)><6K|7|6Y2N6D6S"\$K<15:Z+ KP_ ;Y M7|J0DL;OG#H;"?
C"(K6.EWWSL2@%JL^5_#B|<9ND"/%COP+O+E|@><= M7R^-/H#QUH3F?T*JP9O(">409>L
|0KR<^M;I10>PMW&|;<8/P_HG\$NV M9>(H@#=#BAYLT&X&Q'X|X) 6KK)PJTHL7_LG1&Q@QX|L-
NPLX)<%BX%=7@!+ MY?@|WFC(=A3P1C@?|3I7N76&BN/4_EV<_I3_UN_>
M9)/TXQFRXX'L^!SZ>DL/L&P&E@M|!M;Z;UO%PEQ"1NN!4%<%7"C9"MPQ*^S^Q4 M.F<#GD|GOD)POB
@|R|8+H+U Q**IW*0G87@^%=BX9PPHJ=@_6'SDEW+)%GQ30H1C|A
M|;FMT7"GS0(^4Q,4BE)"X,X9D;==YDZ#-J50U+6Z)66)1H+;R&I8-4UGDZ MIR^|&&4L:*="I"C>H-
#W9#KN|LG=O9BS+/L(A= M*DS|2|U|V|L:H:5|QT5@F.W|I
M|70>%C8:B/RBVZF7G+QHN%0|^S|6+V&5KFNIPL:87)=0W|V;P;>Y^XV0NZ M%XDI|T\$HWKAT-@_!T?
1%XPUIH?Z>U.PH^P#%/U_!#4\$|L# M:|O (-/R!>ED+<_N#G@,)<(-9>&PO=VJR:W-H965T65K%|Y1"5JB=-|HL+L?
1:7HS|;A M\$A#XL8=S8\$|61CSQ(LQQ3A*F| JS#TC" HXQTJQ4|\$X|A=9G0PR8K|SWZ MY^|<:
(0#N^_&E.60AQ@P@*?7|U|@|F|QON_-DR7FZ4R-L&MD^">=KYTVU M4R8&E=3-
4VOW<3A2&"30*0|A2SP;@P%EK|*+R8C:S9@69K0>!)<#=-I\$3FI.MRMQ:I6DYR=S; *G3U/R|X
|4U&NG0CANGP4"X7N:A1|L|/"<Z#G#:0V3N0 M/?AJM"|W.L"B|?Z,=\$|<,SV"*96<#?
TEOYQAWCDPIYQ#G|S|3A9KA6"6(5M&\$U|'0E/RE'!.+F7>I(|\$WDWM_M_9;G>JYL^9/_=8(BR-
HMLM|0H|5PV\$4V:FZ3!_333_@: @+1!>!:Y;%|NB M|&|;3 U|!@600H|3+WI!):6E"C#>|HG2,XSC"LM?
0DRD:QJ|5Y0=S|U&N; MEV0/B5T(^T|C|EJ*|6>7?T(-!T Q+SXV#!|:03'KHT=#(>O#P)G|O M&T"W"VF:PK-
L|QA&X':@/H#&?7P/VYD |HEP|Y_VB|4/^?X@M(NT>B=L M9(%F1NIWQGFND=J:8IT3|6=4P7)|'MHL%102|@%
<0B)*"/9^DT=KO>|/;9 M0#>D,;T|SSTKXQ(WP*.(3*QZ'H)BE(1AA/FC# MJ5=,?0L*K2KT|=(V5AKW_2-
P<ZAZIXVS>:|>-.ROP|DE1@|I">DFESWNQ8 MI@TV"V_JF'H6QE,C"1.2OAS0L@="=+XWQ^P4;|.R+3/X#4\$|L#!|O (-
/R! M>EGNVJ|L4_-.8'9>&PO=VJR:W-H965T/E51V\$97.U=Q;|2*VY'ND9%.SMM M*NZ(-?
08U@9Y\$8PJ&:,DF<85%RL:SH-L;99SW3@I%*X-V*;JN/E|A5(?%E\$:
M'07W8E|Z+XB7|YKQ<8/N<|TVQ,4I2B\$J5%9H|09WB^@FO5YE7C|H_""P8\$ _6 MX#/9:OW-
_Q^+193X@%|B|GP"THWQ\$4I|T"%|5>'&?
4NO>^I^HC^6B=7|1R<TBDI6*"G7"PEEQ9&#SPK40|G>|.W'CE..|@5RTD^P'D%#YIY4H+
M|U6|Q5|F+|K8V|&%?L(N#ON1!F_P"+&9|:QOG_XX(W=|X6OMQLK3-4 M(U_)=SB9>?Q?-
I"!1%/|HCSZYV8^_57>YF(|1UF)04 M0IV^=(K|DPD1-B4R#BOF20(TE4.ZQNZFLC%D MB;=,&C%F@="=%Q
MUI&2ALG_N%ASE)=U%00-/A/(Q^DP_")>35C*7O;_P<>CKV4/X?T=4C=V7_C MN
2IK84.)B_9OY\$TIZ|ZW>06ZP\$&|XM(Q?PX#R(CKU|H^?|B#- O'E/E? MFK5'?Z;XY/96Z'9AQ?&\$G:C7#N&>VG_B-
VTL_L_!28%_3-7E#32-R1:3*Z MFD1@VE>E99RNPR3?:D?O0EB6|!"C|0JTO|:'1GOH'_E_!4\$|L#!|O (-M
/R!>EG:_.2OW0_@)9>&PO=VJR:W-H965TDXF2_M?I>4|A=F@78XQXD|>?>
<||H0*0XW2GIS=2.6;AKA#2SH+9V>QJ&HJ090|V)
MVC#|.VNE&VJOJS>AV6I&^_4B#".HDG84"Z#^=2/7>KY5+56<_DN-9BV::B^ M/V-"|68!?"
8#5WQ36S<0SJ=:NF'7S|^|=7FKLA0>4BC=,&JXD+>:|0MR>I8Z M>V_PV<|<|0&E|E*J6^N_3W/G?;944-
6RK0&ZIL/00R |JVHV5VKWD?7YCU>?J83Q|J CUME\$ 96NL M:GIG9!PV7WI7;_#2QSBWB'VO+M GN4OU-
+Y5*L=:&>:.*|A4_7>2(Y+MRC7 M5N,L1S|7Y1EV|2"6E|A:V9AJ5|<'EKI LM@T_*&|C%':\$XC'(XBC.'T&+SGD
MGWB|Y"=X|ZWW-|X|XN5L1|+Y(^GW MS%@|+RQ01RS|3I2ZAA@24T-|U&G/=Z-LE3|Z|+U_<2!6"PV&HN(OYT
MU0Z081"3>_B^R6B23UPKSW+7|>%Z|5QT1> MN<27SMCK-8A">=(52SIV_2SUBA9)+VM1_*?&:3H/R@B?&
<9.51\$&J6XQMD3 MU4/(AHGQ74F;OV*|4NX#)+|. "0&*E(@>SU|O M.&H@V|I=HY-
L'(#N|A%=QZJM_W>OE.6;@&_6>/5BVAG@_%HIN^X (?+W/QO M4\$|L#!|O (-/R!>ED1#?#*3P8 P.9>&PO=VJR:W-
H965TRVD/G1X@ M\$J+0D(0^+|:57|W "7+B>/FUH_ L2^_7|H2QW??:?)KJ1T|+ZI6WLR6#FW
M|A|;_&2C;"">BUO%EF|TPB|U_-|=H47JAIA\$*)&Z:P>FQW|LRI>Z M<|5JY95AMFL:83;GLM9W)X-XL-
VX5M?7T<X|@M^CF7|N|ZRN|H0\$;I52_ MJW3+C%R>#|BH_4SOL#?RAY9_?N&7FRT|H3|5R6)X.
(#)*U+!PA"%QNY86L M:P*"&9HS,%.J0GNWV_1?_&^PY>%L)"UW^JTJU.!OF E7(INMI=Z|O?9.^/M-|#0M?
4KNPMGISA<=-;HA>&|8UJPU7<|W'8\$|BC|PCP7H|INX,B;^4;X<3I ML=%WS-|H-&-
=|5+PSC54E+FSN"M@IPIGK*B/5%*>RR#?FF MP UOQ**6|N|X|*"0Q,9%#WX>P/EWP*?
LG6|=RK*W;2G+Q_)C&+JSEF^M/>?/M
GXHW""CZ8CQB"?X\$UVWD|WN0_O+^6:VV<:BOVUIG".@.N_/V4NP\$M>1J- MZN?(KD4A3P8H\$"O-
K1R5T4L5TGC9%KJ1H%PBA7+|=="/N|7W|>>5WJPD6^H:|4M*G"<"|Y|NY&% M;@M5*|132X8M52NP)6JF|ABT-
+IA#E VV&V9T_Y9K>U>*@B5D6:FG&PLI|W+M"|V|L|OYV3*HLH6I7"RW%_A'38|WM'W(W*S,E'R)O!0\$@_97-
T_WAA"8Z/I MFKPX8""97DBSX|G#1N8W)C|PXD*84NE;88NN%H:|8/\$HGB:A&F>X|A'/9^\$: MY>R|
I(RVA9)M(7&\$(&=|AKM9GF+-TYR|DR4B5;-Y9RI_DV4)RV:T.@%R/\$IY MS-XHL9_*8KC*8NCF/\$X9W\$^|0GN
|WG@.E=I8A4I-1E,U@T"SA+!W-TBG6 M+(-W2C:9.|X%&8'+.8L81RZD" T#%4@(&R9)?H|U@O?#633:FF>S
S#123#'_M_7F/D6+EB+48.D>X=TPSB.LDVQ**|=T-KJ|H6#9N6Y.1B6|G"9M,(L;Q
M.VNH@K|\$PH&)|JG6BK11Y+*R5X-PPBPFF-61;RW_CBU)N6D%\$|X;3&V+F

```

H:Z@L$2H5VH1:=%RBT17HBTCT9D?IY1YE.2.N.M.F.OX.U0.-L-#-N$4K.&5%|C.*8K7&?(42IC6*U!
<^>M^KADAT>-HJS'#$!G MQ>=.615&7$!&W0)* 4B^.,K+V|J&L>.,J&*>3B"0%DY K7D*Z"R!5*F$K:
M$.*/7/4YJ_9<.,HC%A3C=DO%4MXJ-7("B0/+6_8>|.(9Q_@*=-f4I3_8)j% MZA|B#UOPG9)9|+9-
ZU%:;&$A|>@^&^A.)TYJ3N$(EA&3Z:Q!G|40K|L2 MAZF-K) A:;S|/9/(4J5:BOMVYH|H3:."%I%-(WK45GT9?_?O?
DMA^H^7< M^XJM-GW(97GH_-M<8510:9PQ$D#:&$!(W*X=|^10(H#,CRJQ*)$R|9B|Q#0%WSI%*83-2%:?
^0)*XINSO?N J M#>.,V>F0S+N%ML>@-;SRB*?> O=&>.,Z1DPSS)?!@U*W|K&U0"7#92&.,L0
M0)"1W%-Z^P43=3,WA^?@>P9T+FDA0_?8>W<6;YS^>H^F;S|H-D^OFT#:"UPX<2;^>.,=#KUS1S9
NW/P/@-9T/^E|H M&+ @0-A4T|RGW K^JE8M0?EPC$;THU>=>|Z/06N|ZH.-A A|271|^8|(*.M8+ XZL;
(^|CZ^|O3F+.%S|X6?G_(7TRP|?Z;G?W5^!O5_-B|)@T=P/NEUFH0 IV M?P|/ P502P,$% @_-(%Z62 PI>|!" ;T<|D
|X;"|W:W)K&ULM9Q=;^,V&H7_"N$MBA:8CL4/R7*.;B$+%|J@Z0SB M:~>BZ(4B,|V|N1*B7O|,CDGI^K6L_JR7
M4G;H|U5>U#>C9=,LK;C.EW*55)_*>R4)|E|4J:=3:;C&NUY5.YEVC53XF M01".5TE6C&ZONVV?|HOKK%9)?
91YN7KS0B|WC<|9HMETVX8 MWUZODX6;7|>=*Q100*/L)8LZ*PM4R>;>T1V^$FS:-N@40V7RM=Y|C=JN
M/7EG^V;G^8WHZ-|G+M&D1B?KS(N|EGK):O/AJ^0V^+2|N|OY%K|TV&.*%T4S?E
M|J^LCF^5>=N_R=-|B=AKH^CN|J|O0.P&|&#|VC>@Q^Z|H0W8L7L(^P9=U|?; MOG9:M2;-|CZ8?O|92=%/C5S5?
|BJON4R|>U MQJ|MZG:3R9J2KY;5BQS=2OT/' 7?NXY|)(Q#P@00S"@.VQ6^>BW7|HFR5&A
MOK5U^ZUU56$+B+I ^_>RVW_C4P7O:/E TF<.;%&A"$<4QZ9*%1A%$<| ME=/'<-?/T-
O/3|U25NAN_FIEE.TG.7OJ19PZWB|A'|(F&|&'&)'=:'(+F4$ $ M61Q(&
|>$"2"849S)KCB3<|U@"PCWOIR|Y03_4|&'BN^FED;X*$;?XEW?8F_?
M^N6ZK)KD25VXU/UER:ZCZ#_HTUI6:D@6B_>+.%F?OO;LX=0Q"PC@D3_#|C#|L-M=W6:7L@.@H#%@81Q2)@
@AG%P8&.<&Y%M$3|K^L8TBRR8WB?5/"M?DCK=Y$EUM$WXJ<.;15_+Z4*)I9 M^Z+K0RYD%CT8JD20_Y*$U
TLT0Z_*&O?#G*.,C@VTMQ0&S&#*J(P$&|J@' M=L1P|.)A|ZP"YVEL#L#>RBVY"DZ"YUBQ7Z.MDM?
X>2B3JD$_)%F^J>3Q MGN+=|2Q"DGCH#0|13|KIV;GCB|E)Z|I$Y3&06D"BF:62"=|L,U;
M1|G)=|A|8FRIB4.|H:9#$5X0B/3|RJB|ZX0"$ZO1%>AM>H)1562356VB MGV65K9>R|9;?
3@T|_EV?EQ!;1R4)J|H9A%U*"7X0HY"0_!^V#T@04S2R1 MSJ7$&Z|. <92>8
059L^JN$38CCP.$2:AY30"J=H+669/=;PC_GCWBJQ499UF MLDB/SS)^YLGC$1F#Y0FH&AF=70@)>Q25@$:-
T?I^0FH&AFB73<|)Z)R6.L M(APF"Q:;5Q|N%8ECVRR&*C:)|^17*HP.# %2W1N(|<9IG%?944F>K|H|MC
MMLX*>.;+3)=%F9>+|(|Y&2|^3QZMH+.#H#0|13.KJ_..HE5S*4$ #)RB-@|($ M%_TLD0Z8RAQ(YK
62"SB:"T@04S:S7WE+2BZTEA5U_"KN:.%8YZ24R M)|69DYZ|HK0G&/$BMM>1N40DLLUC*)K;-B0S
M3;7H7AQM|J#3A* T^DH34#2S0CINTDNM:6@>1*4QD%I HIFEDCG27KVBE,Z M7
I*+.%GY4Z=Z@8MM>0"EH^?H#0C.2A-0+X.FG22RU+L:#|I3&06D"BF;>R**#)3M|;2IS+2=E MUE3)O5ME_=
|*2J|H:7.%7Q_2|A.J$Q?TDS>.,E=NFEDN^).|FIR4|994U+M MA10K) ZIGCI606D9+^_>^4^GDGCT#0J4%0
MFH"BF971"9=-B4J_XV8H#0.2A-0+$.F*RLU>BLN&ZT/V|6?M3|!A^|XY MAP@/|X5QJ7_V6_3.JDQ?U*|RW-4=C?
1ECN7Z&^D.|$Z0"-WSZ*YB%12:>H42Z?U:Z"#Q-E<-7VZ2|_TVY|AY?|E0V3;GJ7BYE,I=5
M*U"/?Y=F|_ZFW<^N&3NW_P502P,$% @_-(%Z68&@+4<6"@ @^|D M_|X;"|W:W)K&ULM9U=;^,X&87_BN
NBEY@Q:% M#|G3)."R:8#^+N#2:>|*JAV(SCCFUE)279_2KC*W_$.^E.L>*CF02AX|S MO=1K?&5=/%ZWKZ/?
E8E5=#N|K^N|^|<%A-|O4RK|X5#WK5?_7E.N|M;MZ6LV^U4.INFFT7_R3.;#93Y?#;XN-
H|+J|NBL=Z;5_ISV54/2Z?>?G| MHUX4SY<#;GCYX,M|=E^O/QA>73SD,WVCZZV/G|OFW7|/FE7-BU54ZKO+ MP0?
R7J5TW6"C^.=KY%>Z$F1N3-OR<|U|H0% MFM2LQV|Z&" S'7#PHO|H@FNJ|_1?1RF> M_Z9W^>)|KWJ|85)N_T?
-;P^BR6-5|M=XV8-E0|5|G ^>VY#.#1H.X&R;Y| MXC9@10K070-ZZA+8K@|S|=0E|UV#3|>&V|Y|-
_)_ZO|HHB^>H7*L.VOK%9NMO M6C2:;|Y:#Y2;NFR^G3?MZ|HLO^DFO^G7T?KC8Q^_&G
MZ(=HOHJNYXM%0Z@NAG6SLNM%#B>|?%NX7;"DR(K|Z+I8U?>5I%93/?6TE^>V
M(M|^V&RD_99*7K;4QR0C_520XL2_JA^V_-CQIAM0?(RT#Z|H:;?2IULQ|H|ZH;|G;SUVGQ?>50S|IEX;FIU6Z M?
*#|S_@8CXSIY-CH1)|$R|8%9PV#XX+$2_>D=1YXMHU>RAU7J|45A"Q;
MP/JWY.DJ8W$).X.MVY.E(XR9HMD6T0$)9FM4AX5%YG8JZQ^|GT_>."?O|W
MNH9^3/;L.GFMZOV|C2(Z#K>D#")A"D0S(J_V4;=|D)0.!(X2)A$PA0(9@4G MW0.G4SPJD*V%3^/'(T*4:R^9?
N^9<&^?7UW|H7H6"KKL_*M"9_(F+|K$T_VF_Z4_|_@9"1.(F$*|+."0V)S5!^?N|?O"(>|Z.O)_>
M|JE(RIV|WZ*)8Z^|H%8|&_AQ_#AP_>34+1/^+3CH:"*ZCCXH34)I"D6S M@Y*8H"0IY8<=&4B)$U":0I%LT-
D+|P)F|3<@|H=#@=8E|7:*"$KM_Q@61 ML_WZM^IUN=J.OWSA|5VP?>>1A|1)*$VA:'8DC$|CO^|D
+504)J$TA2*9H?( M6#>2-"$G)0/1A0X_/G>;>.VBC:|FY*.*02$25N5O"H^,%AA=U7XXA(V|)9 MB>'D(X<@L_-(1-
(DE^90-#LZQM.1K*|D_?5|4)J$TA2*9H?(>#12="|G)8Q1 MZT<_KTJD1H^<K1#DY*?ZC7|*PO|HBWXHRCJ_7>BHFK-
U4C#>76>.,|UTVPW.U MBVZVWWJW07@97<21|09RQ_ MRR+0&3.H34)I"D6S@V_|8L+ZRB)0(PFE22A-
H6AVB(R13).(S?J=D$=YV*4G6 MRB(>%)$S2)M54;Y>_SA4|6<'8Y9Y&Y1L;CHFF.N.FDK4I'
M6>N(Q*B/3F23(QC2|*.;9R7TWGOE^>3QT5>GIXNH)-U4)J$TA2*9E=3&|) MXY|2|86:3"A-0FD*1;-#9$PF#4|SGI
N=>@0K$9#8201CCR|H.OB/2I#8K;OR MJB:4G^ZH.MT.;Z6+3HXE#.|)|*$S>%"0M'L;T48?96A8DMP|3686(+ M;?
LPE=282GIV+>.;8)V$8-0MQ/"IDM3+FU5DE^A9@V/*DV/5&-2X|YHV)VU
MLL:;|IX*9W")G3.#T|3*)H=+^P.5|UFQ1J(Z$T":4I%;T.D;&1|.S|3=HN MJR1"9&
|Z|*C82+CHZVBB>MDE$>5C$;TH?Q8S3LQW|1CV513>9Z-=&G)POH
MG|^4)J$TA+9T3$;DO95|($FA)A)*DU":0M'L|JSZ.B6|G%WVR=@EPPMSSGF.? M*LF%1=N08='11/F^F#X5#$_M4O?
%#BZ+>"W|Q)V>|S9V$E|I%Y9$+G^J TA+9T3)NDO55_-J@!A)*DU":0M'L M$|D#R$|4/?
A$R6MPXVVB#$/;7A4S%VY|H39GP8" NP:SV=3YJ^ MWCR6L|V+D|_%=#8/2|0FD+1| @9|CZ*AME4
L|4DH3;H&=HB.A61GEXVR M=BUG0MQ4;|JW,O7I4?2B#O|HKRJ^,BQ:C=>C(>|F"=A=/(
```


fta#(x+MYN.D89543&E960^ZVAL0/I/1MI.1S-KB1514\$;MGO/9)700/70_N1/H(Y=#Z+Q.5NCGX09|K@3|?
(JET6\$5+;.%UE5P7^.;L;U7G^U8+?;MHL2VTKJCI6M/W%_NO/'3"MDY"(B=1+7@|W\$Y'(5GHG!?
|OOFK.'CG!'Y(30?H3OAGCXNUB\$RVVA=;5_M;_J=X\$=0%8,VZ_6Y5;38%EI7U'W|Y|Y|E?
EP=0%)VAI?P?@U>=QZ/O^4B|U==f|_UW_LV|OJ|H8K8C|Y,EA_M*2&JY&,%9?2-8-0=2ZBFYIA:."%?LP_#4/E^2:G8-
92#JEIX|B|02P.\$M%<_(_%Z68/S""HH|P_148|D_IX;_JW;W)K&ULM9Q;_JY&G;_N\$0PNMD242?
DR4&DNC\$8>V""MMLNAETP.AT3T|\$5_MZ:0%|N_")9LLS8W=N;1*+U/9|S0I9(OC(OGI+L'I|GB7)\$O<93(JY*J?5%
MOR_#%8^9?)NN>:(6:99S)3>S1|ZL.CI.FJ9_6>"SZ(AY7*"KRSR5|X|^Y^G|UE^F|_L.R.M\$#%/I\$@3DO'E5>_N|J#V)
|HCOA#1">YLTWR2|E/TW_R;JXZ@WR_^(1#U6.M8/K?(I_E4923|'E|KJ'|;X5%Z|OYIY)?IM&?XJ%6EWU9CVRX\$NY
MB=2'1"G@U06-3'@DW4J5Q%:S/(I9)^9HJ2IB)T|SN@/L_M*L|N|XP_|RK@.&Q&495P.C8#_.J8-P..31DRI@>-MD"
(7GB0L61!'R'7Z7|'O&=9QG(I|D<.5TQ\$K4N_?VC0U|H^)|K|2\$1"WHDH
MRH<|^'|M|0CFV|U);|KD|H'D0_(N3=1*\$C=9|5\$O^..G|P4|YGC+=L_Z.N:MW%:G_5R=-|:1^%NHWA)|I?
;LH@3WJ.*;8*G1?BPJSI^7W;W_V7WS.'7ZTR'M3PYFAWOYBPB8WAP3|GLX.G38TZ^_|PAA.V>S4L>.,#O)N-
U""52DIT0&/GK_M5UU&J_*Q+OKVU(B|HW(+%W(=F>AS/TT73_HFWR79.G)21.8=J|2YR+(FUF7_
M<5>+1OZI6CPJH8M.Z76D')S|LV4/C)E@(|1\$*RAGO%6/6.C>NXV6;C2W5&R_MSD3(2:@?N")YX(G*_
Z58|+Q_D29=XBK|XYU|'I2\$=YK&'O*^#/'V_M(<.6Q3?6PJFMCX11\$*S1^I-MZT^_K7|H|H+G/R)*C#RR;.
|FGZR5^%6WBMH_M-/YDO|WL5JLX1W#<(SA>|V=TWE+|L>R9|UC@HY<@|9|A)|J|33#=-L.TV|J
M|CU>#;EX9/=19RL8H;=V2)P|PESD3|ONJ>4<4L\$/C)?@(|1\$*RAT=E6HS.C
M1K==YMLTOA=)H<_.0:41=4W(TYWZE2A|(<*,V%TKR*UAA|/#%OC\$Q^.;H#2_M*(K6%/+!+?US;_7YM"3-
8FD.5";Z5Y%;TQ^H;4TB4P90&D71FJT.TW:M1VGR<|XK>7=-3Z/E7D.HK2D"F^."7<|;I)5*=2H68&E.9_:2Z4
MYE6T?7.YE-T(P|E\$91M*92;D0'.GL5G9.(Y%|I|SHQ+|USTZG5I&3L;=0_MF@.EN5";Z7Y4%
I5\$4K.GJVD*QOQBI|0MI(MQ".0Z4YD)|I3F0VD|E\$91_MM*;J.VO(GM#-%GPI4B\$XFB|
<@71'2*)Q_B/N*\$2VW&6;/OT.6_6G-0F@.EN5";Z7Y_M4%
H_I5\$4K.GJ|VJ*SC*)G+9|&&+NK.06D.E.9";5Y%:
IS|TGX9|HQ@-(H_MBM9|A;RVWFRS|>9*)>)|?HUL)%|N(A*)|2>O1\$*^>FVWVW'Y3*YH6VN8;_2*^9;02?K%NK
06DNE.9|3Z4%D|H%\$5K2KFVZFP.WP^VH38=E.9_2Z4YD%I
M/I060&D416N|NC.T;+A|ZV09=O|H|M1TVG|HMYVSZ9+F^G.&%900JVF|O|S|M4P|H|Q@!|*HRA:4UJU
V>;:CRV1)=B|B?;<|B'.FY0F@.EN5";Z7Y4%
H_MI5\$4K.GBVG&SOX/C9D;=-RC(=)<*,V*TGPH+8#2*(K65'7MN-
G?YI=8JOY|MDD9|C|V|H|D|W9\$1A>T>O@|ZV'_M0>PQ*HRA*;W^SI(2,<|>BO5(I%;_)-E'E
MK<"WI=LU3Z2+E3Y;Y3?6Q.W54>Y8%VZYHDF+Q=8><>R|Y%(\$O&E3C5X.17?MF:QFZ6-#B/E4J|C8O-
%6=:R_D|^O-EFJKGG3S!=N68^7|02P.\$%M@_(_%Z6:H9L)NK_P_V@T!D
|X;|W;W)K&ULK5=MC|HX\$/XK5EI5K=3=O_'|HX"TS"-==*NB7?7NPZD?3&*(5<=.;0/M
MOHQ\$K*0>+HW2_@_|_|V(XG1R&_J900C7YDC*NIDVJ=CUU7Q2G)L+H5_M.>'P9BMDAC4RIVK%
|H9IMR938JYM9Q-Q%XSRL&.(K7/BQ_MS@D3QZGC.Z>)|H+M9EP9Y.<|@CT5_RM80GMV9);\$.XHH(C2;93YX?
KT&MO&C*XA|Y*C.ALCD|E&B&FX|DZG@F(C)|K_T#AK|61#&#&|\$.WB=&J7|G@^
M/K&OBMPAEP|U69""80S31Z=09.2@A6|QG^2\$<_R15|@/#%PNFBE|TK&P|H5|MI456@2&"C|+R'_^H=#@#
I)=%\$2_HGH/P/H58#>M1|Z%;_L_K8=|I1@T>\$S_M@+"A(7V|5B%TA'6>#;1XHBDL08V.RC*5;|H8.I-
8SUJ'6|X/3L+OZ^|XJ.M*BN\$>8(BJG)QFKA|C|)#R9X1)+;H<2"QY117#0%S"P\$UY30"=FJ&A"9/GN
M;XHW8*@I4>A|1#2F3'TNB^/\$7K_|@ZBRA|Y|OQXV;B;LC\$Q./&5=3S.NK@
MF;A|Z|X|PHM>4(2"SHJQH#_H('A'4=@E;=YD\$GX^=8WZ)|V|\$%M7M"W|+2X|CXLX#V;K_G??E|WE?=|+M<
CRT>;_0LE?W=*@ZSW#U^|3.=E1MSJ%3BQ:FIGA'#|8VC0RT&KB2P|A|P3ME"MT|/C\$\$.|D1R^2KK5W+
M@/KV@.SA.%8YCLG4@=U?S7D@SNS=&S_TME*9IDT6N2+5^3;/5*9|&E363AZ2|Q;..|@F?5
M;7.APZ#68="IPWHOX00.9I1+&A;4RV#^'P_MZE3\$@.HO\$VK0M@D%#FA=)MEB^3K-
HF<|N2UC+&G;+4JU|6JYAR|M-LRG;|HVL@N)WV|D;K^I+3+OS.(7_ME|PUFC8J=\$BQ=IYAS?8BK1;_|=14-
6VDT\$EVT+6|H|FV&|AE5FV|'L_M.Z52%&O4'S;J%*PZ=CHVG)%EPVF*U;8)|J985_LK^1967C.-JY2|/2LV5.C_M41?
WGKNL81=7"%&MMN#*NOU"Z65YDR@?M.B+|I^T/=70Q3N'P1.0S@_58(?7HP#NKKW.Q_4\$|_M|!0-(
/R|>EGIGZ?3T@4_4X_9>&PO=V|JR-W-H965TQV'4MI^&A7C3;J.W%:B|F>&R/M"@R%P4FE_?S|@PD8EU
f>:O>Q'S,>68&7LX)+S'f%=F7?Y8)'=QE.2GQEK*
M|U@D(=K%MAI*0L47N6(HNI5*09;I"GC;+BB_|K9L.H.8|L28S|IME|E|M)|H9|81=9B0OXIAFW|ZR2-
R>&I9QO^&*K|92;QC.9RE=L6LF/Z.7F5H;U)0%MCUF2**_DMNJK6F0L.BEB*M@-8*8)|M?>E<=B)T_VWX@P*X"
I\$;#MAE7|_|414P.CI@7_6;#PUPJ@#GT(I)3I3|VZ);GQJ62SF>9N"69;JUH
M>J\$|OY6T.B|I5*EIG:RU6I^)^PRMRK;2_*)&MO)|H8L6D2'Q*
<_OQH5C%PPFA<94|H4N6YR+A+)DY5;U8LY7|'.ED3%PWYMP.DC|C|1|Z|3%(>Y2_-(|3CS>AUNXWW?1O;-
MMM_(XVIM-N\$2W:1V^47WX1KV'_M|TJE^\$1=D;H2'+EF&4E95EY2Z2Z9J|('GIMLWW_Y\$K%A99IHZW6JZJ0I?|
M|>WSV"L2"7.1_|Y&P_1K26I<2VK|_|+|&*D|J.Q%PCPDS\$?"A"LI2JG_M5I7S4_*|UW.'^E|V/>CH^5A+F(6\$^\$A:
8"TI3&H|3)_UZ(XG/'|B|N|JE_MEM0-4'@*I2LEJ\$X)|8IFV+R#A+E(F(>\$^4A8(*UQ#;MQ38|KHU*62*5_@2
MYB|A'A+F(V\$|"-92R.M;C|269ERODKXDH?J_QU2).&|TQO(D;X@TK;=F69_M_7*/+&<|5DZAW1L|H|PCPDS\$?"
A"LI1+&PW\$UJTZ-W3BE;_<(|-25":M"Z5Y4)H|04H6EMT.UZ0|?3B53%02D'27"C-@|)|""U_T=I*;Q9J|>DPQ:Q
MJJ^I^F9|T|TJUC^FHH4=5NA-I|""U"ME8:Q|7JMUR+&6?RZ>#;MO91HEJ_MQ9Y0TWK'=72F0M)
<*.V#TGPH+4#1VNIK#&MK|*A|4<:2G.A-I^ZT\$5\$K_M*Z7QH;U>0Q)7+3"R*4)*%
MKD8BU;5KIH%/%&*Y%GCGXCU=W|T0H);UE";Z7Y4%J_HK5%UOC6UN37/|FS_MH|8UE.9";1Z4YD-I
8K65E=C5%N|+N>CGY;5V-U'9(ZS7|6@IC24YD%I|06_MH&AM233.M-5O32.KVD\$W;\$C#|AQ*3.PKYIC'W5&NN;?
9EXY|A?MN_6T/_=4_M;E1#;2Z4YD%I|06H&AMI31&M=UK;X*KV^C_Z@:U|J\$T#TKSH;0_1=MJ9;#S_M?
9;^P.^"9BN>Y"1B2X4W3R9C@V3;^V*U*DY2;=T)*\$9>+T:58G0#M7|I_MA+Q?T5^!U5|NSO'4\$|_H|0-(
/R|>EEKWNZE<@.(L_9>&PO_M=V|JR-W-H965T-Q_|M3T|'.#6<|I|A31>99|174&7.XG7M<|'-RS|<;8_W|ZWM(U/(#Y
MN+U3N/;KE|E|E#23@BA83;R;|O5B9.V=P2<&=VVT)E);4LK|=O.AG7@=&Q|P
M2(QEH/BU@SEP;HDPCC|EHU>YM;#C|H8;=..6I94PESROUAJ-A-OZ)\$45C3G_MYE|NWT.D)|B>3;?
9)|=OQ2)|K(L2C|D3|3?|+PQ\$>>H|00D\$&|M|P|A'0A?ZJ%7_GHOH"5_?"=+
I2|Q.74T.E8R3U1UAK9L)EWZ\$Q7TS8/GDP_M"ARQ)GI3?(E9YK9HFE"14IBIK?R1V#H8SK-TCW|2\$FKU^|K|(
(\$^26<6f=C^V#_M2FP|?E)&2NB#IZ.(B2WZ'FCR4*DD;_@XV9|OP'O8P;K-;'.Z"1L(\$W-%M@N@W\$G2"7DT|Y?
|PX>ULGY.>^+^S)|EAU5.AXPN?X)O|F@F|?>\$;'E-I_MES/*J4BP'4|YHY^Q5O';+WO>2RD)'Z|F
M65R0|HV9_8/<3;AV_-I9I4&5>4&W|##9Z|M|^7)MTH+6)"YNHZ3JHH|E%EL|Z@;_*X*A18/ES:ZC?
Z"*K>Z9MDN3R_H|3|H_MIBGD^4=OUQFHM1MK-\$ED+DSQ4E2=5|3C1L8SLYGW>MYM^8|QDFK&(R^TQ=C
MVBU5V.Z;<%BAH|5_NABM&GV|BY=>_V2VEP4G#+4Z+H*P|/E|);0X;ZZ";M/Z?_E|+P04_"#|@7I906^@#YX"
#@|P&0'_AL+W=O-3"0+SA_YDL^&5|B+0;OULIS-I.M@+OK+2LG&
|N.98\$E3#G|3G)5C|PK|^6PQ\$55<|HY#&T|X8OXU3;+|HTNI<#_M|V6U5+Q|P=J#DK#FCQ_/_P-\$|(&@|P5-I|@:
'AL1:B%A=^&B|=C0_MW29VF|@4*YS\$@F^0_J:S2QL|BU:YXLP|I|V|6A"V0ICE_MZ\$85(-"42R71>_05"X%-
+=%I"|@H3*L^T|XN1;|ZB;Y4(=,Y9#WX/#^\$;|O*L3T64CV&9C\$APDO.G4.0HN_MWJ'"Z(>?
Z;P"M|P+Y^LS_I9^EXRPN|JA)8O/HJS(CB|3D;F|=-%&)M?HP76DL_|YHY6|1T&3
LTDW;C;&R|YQ|I_1YXJL=7_M.VW^TC>S|UJGB#")*RU">_4G=4TED_9);JR@.&@4_9>&PO=V|JR_M;W-

H965T*RD K2L AQ.^ND7+E@+=+OZN9SMG\M2(@D J% MP/+G\$=9 B"+)=?Q=0YUF3F5X?
OU_ U4I+YUYP!S6E/R19V*~<*8.RF"+CT3< MT\O4#LT4KR4\$JL HE.M1R4KF@16TL5U#D926+G^I G!E(CMD@J
V"KD'T M X.P.@A?T.4&T2OG6%4&VC7WU>JHE7!R053 (-)J*:Q2,KE#@:/9%A/>O7F\$^T M>6ARY__
GOSGV5O1"OB"340?%7QJ"=HJX(#>P3TYQ>I1Y1%/%PO4^HK>&2& MJPYPPXA84C6Z F.LN??_+WB^FN-
N\$Q39AB258*T-1DZ8*HB\J4+K-;?& MUL"#C#5& 7-Y7\$;CN2MX'N^&9-.W)7%?XG03MB8Q:*9!HVEY.6J\ UZJ2M/
M-J@#HYETEB-.B:E9K 8QEU:<35AL\$Y98@K5R.6YR.7I+GC"VF2&;L-@F+!+\$
M:V5HTF1H8J>'7!LFHTQ/ZDL#KM(2^)/3.'6':^#@=!'\$C=Y\2 MNRNT@Q(8)E>Z'"\$F=U"Y\ZKW2F")\G=YF!R?
9!^:1G:A.4V88DE6"M%LR9% ML\=L%#;.&;OBVW"\$DNP5H9\|^7CP+/3*FK.^2O7KX#_<&F OZ1-C;_8=>MU'T-
9'7:1H5632;1H52SJ- KWF.2D M
+EJ=63%44J\B^@YO1YECLDS.ZHRO_)NU;QB/U3&;JEYP5=G<+I&T(\^MWF@0M!"7^X!9!"40#I?
4BJ>:I0\$S>'B!E10 M2P.\$% @_(-%Z6<@0*4+\$ P C@!\D !X;"IW;W)K&ULM9==;JLV%(\;"J\$50PLLD4A_)K.%Q.F&
I2)HD\$S;Q=+1CJV MV%#D2E)Q\^I2HIDUQ)M9.V+4H\WL.33\666RE^JPS (-^YESH99.94UR&
MH4XRR*D^EP4(\^V0M54Z-;J-JL%~*Y"/=I\$+B/@D!@G0>W7\$UP#YTD)YO&E
M\$0U:3Q>X>_VB_GM5O"WFD6JXEOP?EHL&M%%E8DK%Q 91D:+W)@.%KJ4V&IVA\IL-
MTI(#DFMTY5:0F6=WO1I7SWY\ X8RKM^A X@)=LXMPNO%Z&QB3JL&F26M5) MD8&DINA6"I-
H)M((=V/#VV\;97DIKNH-XJ0N:P#*P)ZW2 M#.*2?
I+3Z%=/SN.VYI%//5\A\GA\GVDG(H\$^A*L)::5A#O83S\$>SQ:A4X_O MI/6=>'VO.ZHVT+L;ZL#)KAN>HM-
6I>IWXWJ#!7TV0+\$\I.L\$SSA\SWFY: MTYG7U#+,<\$B1D.(LLGT^YUO4H255*./K)\F*PX'E/P5&_ M\T7K?.%UML?
SR#ZZ.#=#76BJ"-6Y"?-RZ"?=I?H"P1:47W%0A8L_I*_7JO M&YXA\#XAT"BD?W.:9,N;?
+.=%H\I\W=F73@^ZHBKT J^BB=PUG ^"7=\$ MQ\XD'H5%\$H_>"9#=79\$Q\XDLG^?C'H\4L1\IX7@B.7 ?
(X?.T9B/R2/M0P.2.G(R\>_TCB(Y346B;.&KONXBB\^#*#O'YEVJ0C M_&3^21D-IK_JORH&\$N\01HXG<I1L-
^75P)'XX'B4&.03C&9D.V'9@M)'XPG@(\,\$\$Z2\)(-)(SHA'8>UL=?6;.\K1(M.=B\XAH'C1)9"E-
W2^W=MMFJENL;GK=J=I:K<:\$1AS6-C0ZGUE\53=_J<#(MHFJX\J6Q\5MUF=F&&92;8)^OI30O-V?0MN#Q?U!+
P04 " #!@719:8\IC M.TI*:6P&0^AL+W=OT=?I<%65SOKIOVX\K#FM M'FC)?KFMZEW6LJ_UW;IYJ&FV\0?
MBC5QW6BIR_)R=7'6_ ^US?7%6/:9%7M+/ MM=.\G99_?
TM+:KG\Y6W>OG#E_SNONW^L+XX>|CNZ#5MOSY\KMF\J5'+M_1 MLLEKTJGH?GJTGMSY;E)-
Z(7^2.GS\W@L\=RTU5?>N^?B>KJS.#K03=OI MR_A_3_2*%D6GBAGROX/6U?&@W<#AYQ?
M\ NS9V=SDS?TJBK^G6_>_5LG*V M\#9I+-HOU?OI\&8:=O4Q5_-Z S?)U5\H6FKW6\$PLV"7E_O_LSVGA@, M
+%(80*8+|\#_Y\$Y;UI_4N:I+LHZ=NI.FFGK/O2^Z4>SLIG+;AZO MVYK\FK-Q\<7IO.S*39X55H>R:>M'-
D5MXYPXURO@MH\%=:I;JL3;=K\+WGI M7#YE>9'=%/2\$A=)=<.\$WM&;UKFFF\O\KLOO\TU6M@.%SE76
MTKNJ_NYDY=:Y0@OV=>M<5653%?FY_(\^YAYU+GNP_BJR)FUI/\^D_O.N.MWOS.3/QZ_<IYZ8>?
G1ZHS\I<\$SF&K-UR\IS2G=MZ<_# VITB.(#OV_4X>\$ M_W2(2P+)|"M\^_5#S89'LN%K-
A?"2"2&I/E^A3^7X_WOD@LZ'ENZ;_H M<_@^_I^-<54U MK>P\$Z.B?E1W=WJZB&(W.5L_#0V7"*41'"\$&!4>#
M2@KR6\01Y7RPV?V4W M1FF(I36@^_2.C)^(GE=H5^N*I=GVLFH9*#0N%HYXX_MAK\$B\$2\$KEUT=&Z
M'+7N29:7SAI914AE9D7\$;P'7M.(A037YV62*#0K1LT.7%(RN\#I2YT+=5*#2F_O M;=U(*)
(4LO)\$"A#02B*C8"L/_'#06\$2 M71UT\A%!.DI A160@9WD/SI^ZVDHA3YQ\YR12Q--+.1>#T^AUN+I>C
MX2U\Z&J-OQ&*YH\HS8>)PFD.>);R'<'<8/4F&M/^ M !X@D9U(13%CMA.,+>=.!!\$2PD1XTX T"\$X.DS"-
B\$ R)YXWMDXB1!1%!.^8P>?I0\SF\$P-Z<#.#S4 M-\$6A(%89:GG:Q_/TS'N'N7PX\VI"\$UIXIT#J.#J<+I1L'E#;>"8-
"/%X@_MT.2N/R5V12%UI\$(RIS45^=FOJP_>_('SY\W&L\X/6.&^=H+7*\$N8TL8\5C" M7D)_6*P3A;H2*149#;?
4U185;@2DMS^!%F3Y*_'H4/8_>Z5+X1ML4K3Q_M3@("\$\7&\$438\12)XG%M2284*\$I+
5!+@%/+D:GB'7C2P@5X4T#;@DTW#(% M^*Q@!'!QJPL\$PH45?4 R"%84NP/Q\$)^H1CPR1"K@+B\CF 9I-9IYH,"'
M'V_N16A^&^=08_?3L@_H.IK3Q3@P"/IZA"9VQ2;)'8E0LK8A60>;H% MLV-7\WSX
62\FXV200!8\$<1V@M\LM\$5"@G03ELD-H6;#6=-P)@2XACBPKR0A%"
M_("WT212:6A@E5"8)409Y4IF!>*.~7T^0R"AN^2@2JC!E4EOMXGEA1/A M-1Z9D\$="A8%
#.&2CD(HM@M\OG3NTPJ17UD7#P8J"NV;^I\Z^CO#C_&I/O/M1C4@!((I7060J.88\$H;IP3
A!"O/F@B5FP=R")6(J6.6\$C>.(9Z\IT6L#NKP M@IR>+1ME@1#0(4SMA*Q1=C"EC7^&_@A6M(^B?0E"%2\$-
PIR>83G\DI5W=ZQ MQX^3FVSSC>6GJ52\YTLZ;T\4X=HCL=\$@BHQT24HX)P"D1*LJQ")R!"
MPNOMHE"4JMZZ\RR)EJH6B"38.39.%/4I@&61_86+22Q0C"^I RH5!U70\6 M+"Q_LB\YR3
0YE2R9D\$54XP@<4=XXIYRP\#\$"7Z0V5>>C:?"(ALM.YB(PB M@BEMO!;\$ (E:QPBL34@"5C)
(@=5P:0ME\4.6\W/X4>9O1S\I@4@I\FJ M\2R#B(U2@REMO!_&N(EW9%8K",>0X5X8V"+HC6?Q?
57EBH#+'V7V1-GH MA\2 \$;&=2DALM\JB2AOO! "6^'6+)F(1A9%)XF(HN(4 Y \$RY=+O/H7&U 1
MWK3\JDH\JR5BL78@V(C)\+8!*L1+&@.Q6/47YE(44N1\$01NPDD\01/XJ^+ M71WLX0>=/6V"@_)
(\$5B9\U%8I0A3&GCG0_D2SID"3Z-1>H"&\4Y\0\$S^G\ M,,RZ;)Q;O\USYX<&QV1!& BL=,128QV1\$QIXYT V)*J;JU%
(F*(YX:C%0.2 M\J3105.F2P<8-
RQ=);!B1'(P3112UQ02@)3&PV"*1K*.8U^ID.JGLL4C%%H\$L:\$4I=!'!DIQ\#T\:'5DAQHHH39J FDP ^IG<45
MJ5%X_#6=-P+0HJD4Y+J:Q"H"&\4)/43^:7C.N="?07""2AZDMM=H4;:6-
MJP@0VJG^9(;8J8TL8I8;#OT^N64Z0B<_C1."Q1F=&&3;=GY8OIWC1@5TU MN,S(O,\$>3:Z)1402E"NTPB-
+"0#Q?MH.1.V40%QJ9_MASR<43N;N.V\$3 M%P0\I2LK>?DCO8<FUTSQXT6O.\$390@08P!%+>E2IC,8O>4QF9-
A@XR47_M3^!3HE: 49W14H Q=2.G#9H\6@WV+NUVC/V7U4N/3D%OV2#WM&NBU?MJE/=?
VNJAW\KXIFK;M=O*?9 MEM:=/O\MIJ K.ER_=\LC'I_O_@I02P.\$% @_(-%Z6;J_L8=X\0 I"(M !D
!X;"IW;W)K&ULM9IA;HX&_>_BL5-ITF: M);;3 #U_ZJBZF\I\JU5\WKPT8B\IBSC&PWJ<_)Z0QCA.WJ.Z;EL#C?_Z_CY
M\$9\ID?&G=\$.I+^W<9*_.OLA=M>I7KK8T"U)K\B.O*3%>;(N0A7_?2;=D
MF0_>QCWD>6%Q2Z*D.QGE\SWPR8CM1PE\H&#>+==\$O\A<;L..I_SLL;/Z/U
M1F1OJ":C'5G3&16/NPYHC&="SR"2+>B4QG&F\W\6XAVRG-F\?OZC?Y<8#345V1C"5\ZT9?
P82;ZF0\$NDGZ>%Q=@L^M?O@\$H H?>1'OKGHYZ0J;=F2\ MBA2_G%)\$#2G^6(@K@(+/'G(KQD^M0^_
MV7\$Y/P.WI.37GK=\$<6=-R1BS:E_! MDS_@*W5UUBCL2T_&9)K;I3Y363-B0Q(\$=BR1&QJ+IU),Q%LI9SF/0'
M:0IG*=AQ@SPH(S1W/FE.I JIYQVL+=220X.S.&N% ^Q9P;Y;!C6^PM*?X&U
M2(S%5NA5\ID8=3%^_7HE^I\Z+FJE7W-F.*C8 MJPE"3;4*/T-
K/X>KV978.T.E"=Y+W;LB1PLG@&=E\ZQQ.92^M'T=BY@P.MRQD8OJ&E#EYFZ4A.2Q-
Z"M:>BX52JDR7&8)A\I1K@F" 7U^*!.SK!2Q6 J5 M\Y/W;XZK G"7H-#A5HHYV^KU@J=;
IQN5W5'F'!>OM#6\UL6U\QY@AHK. M_?Q:X56KE^6CG?ME8C\I^J&9H86.9*M\#.^G;+I2!V=E#
MW\H1B"?_@N A6*H9W\=JK4R:I4M_OYQ24D1H(Y.WW6KWJHN\#<1#BLG(M"9.1B=MN *L;X(@;+C;06?
WQ#8\$9A;%6GYH<D\XDF6CKW#VL4NODM^#SHC M16>=SW\T28\$7IQ;DZ4M-
35;!=M"W72DFPZNV>=80W9V"/+)#ONTR"G8(R=P\B;G.U6.VM=S+#!GT(QMF19
MW^Q^O/T/FFP+VEFI7NKAJW@/(6 \$9H_24JTOSA51VIZJHKNV\$W\WM@O\$!+>Q
M0&PANGM%=FPG>JL%_C1_PC(6B#5&_WU-L=>W\I=50_6=(MB5FIZQ0K#O!;' ^MZPBVANCN%
(IDP@N5\$);0I7'G/SUSAY)R\X'N2=V'24IB.E*#O*N^C(Y?GK\$
MXG0@V"Y_2F.A&#;_6&DB7E68#\2.68>#G(C'GPH'W29_102P.\$% @_M_(-%Z622P.R\3 P_X0D^D !X;"IW;W)K&UL

MK59=-JHP%/TK5E9-K:0VGZ15Y'XZM:'JBHVI-)+F#5B9EMH-VOWW629A!<MU&U!@=@^YUR?
ZYOX=K="JHE@'9/214SUEJQ:IV794N(:2J0JR@P)6YD#G5 M.10+5ZTDT*PDY=P-
/'IV<H*)^F6<_K^J3@V^!+PG<%6I3P3 MXV0FQ*,9W&8JQS,:@ZI@H4_S8P!Z-\$&{C9ZWI-"\$-9E3! M4/?+-
/+GG/ED-SF=,WUO=A^A=I/Q^BE@JOREVQKK>0=*VTR&LRIB!G1?5/MG^H
!H0QTX<D+0)2DQ\$,XU0E03HK=&Z-2\$TKL:>2!3-Z*:JETIMD0:M-*J9AS+D)1OSQ0I3)U,M<94A3REO*,-
TON\$<: 5!2A\$YA70MF6:@R\$1/(1><"7(Z HU(M=8::#L1.3TY(R>\$%>2.<5PO5-25:-
LODWK+0^J+0>O:#DD=Z+02T7&10:9 MA3\ZSH^A/U,7Y/#X"6"@^"HX+=47Y"@\XD\$7A!9IC-
!"_VRI(2\$38%99ZX2MZ=,&8*M@IEQ',M+5,=7!8CL TTSCM"7Z M10JE!\$:CG/W"6ES@U6FU6JET=F*W?
1XBXL)0X3?MFB!^:~#<6,P AN#\$?V MPXP/LGO>,C"TO-H:8'X+!^6CTOLP4:~!A=O Q.@Z>J2WU!+ P04 "
#|@7I9F=JKR4D#~!L M#0 &0 'AL+W=O5*O*VEV;< "K3LOL!H^_8Z3-'R%#*V!F+!^OSV") M27&.>XC:IK:ZOP
ML=A1\$2%M^K*W(:*?D;XB7NL;1RO62'OU!MOYA+E?I7;+!+6SG3MDM7.22-8JR5!DJU!2C8-
MR6&TUAY-T)VRR&KG/L,1G(AEJ,?PI#!@<R&P+LU-B=CXJT77V M'I9FL+MEM,:=R,
(ZZS>||SFIKO#=RG7>WDFJG U4NHWZQ?VD=%<8;<6I9F>7 MKG;V4^G6Q85;^TC-N45+MLYSPUV63ZC>'#7U8-
&7SX<3'ON?K7@MSJHJ2J M48'7*\$?E4=D;L;#Y#GF@=W@C+G*L UDGEIGS>TF&?5\4AHK+6SRQE^ M#H\$T_#^1
CIWC %= _F!?:X#4\$L#!0 (-/R!>EG&'Z-H@, .H4 9 M>&PO=VJR:W-
H965T@:8,&W2Z&73#2L4U4(EV2LMO^<I&4K-H9HR0MFXM8HLH4#PO M=21RMF?HJ@ 2/2Y+*B8>QLIMU/?
%ID&2BSZ; M475DQ7F*I3OG:%UL..#>B MLO"C(CD2;46\Q.VRU?S%@E"'+AEB-
1E27F7ZZ<8/NY%WJ!AO=DO9&ZP5, MMG@=R_&^Y.O;2DY*H((PBCBLYMYE.\$U#(S 1?Q'8BZ-CI(=RSJA'?7*=
MSHU WQ\$4D\$F-P.IG!TLH"DU2J_&I@7IMGUIX?R@IV:P:C#W6,"2?7^37&JF MWKF'B@8/B(8-(+!CWJ^O9KY476N
GS7=7-7=1(1T.T WC,J-0-G:2HXVJ MN\$QJR&WXXX,XI?Z,H'O ME'T>AW% 7IT('R^2OT8^L WGWWT/?
JSWM%M^ MN>5!%(0V^4DN!^T<&AC>X!>:U7 4,~!VJ.J&)Q!UG%B20@T#105"BZEE"* M?VV3IN8.
f5Q=5*=BBS.8>ZIJ"N I!:_1*.@SILCKF\$Q2YAB4M8Z@AVXO2P M=7K815|<4PF**A&A&2O!9FD-&IN?<
JWM%N%@\$IB_F\HLL2.3RW1<: CXR& M%I:(Q!(YLD:FG0!ISC2.VG2..M.XW&'ZIH5\$M,*\$HQTN'D!LI1H.)=B6V9HY
M.AK:PXP^&1\$ &9\$!&9%VCNTLS=N,S?NS-P.^XIY9LM.I^ZEI<0E+8)2US" M4D>P\$R69=,L262&M@TH%|^#G;
MG9>7YMT_VHHI@:~H&E:~NHK%?4;6NL7=IMJ.>M%~%TV5H:8_#;5)ONWW# MUIN-
YBOM6D%K%1707^B/M1YO:6GTBV-1M!JTQ*5IK##>,R<.) MIJ#=WES!U!+ P04 " #|@7I9I7&%F/L" !F" &0
'AL+W=OW.2VL7#BS8:~>|=D(VI Q:2^~!ZY/N?8ONZD%?)0":*8!4U,G
MT3H_ =5T5)9I2=2QRR!'F*61* 7,ERE6Y!;L4,I=KJ<+W)2RS DG=NO6AA-1 M;XRN)5\$%6E*Y=,Y<%%.G;
IS/'#5HDV VXXR>D*YJ#O\UN)/:?)\$K,4L5\$ M1B0LHY9_W0V,O\$VX#N#4K7:Q"A9"/%@.E?QU.D90L
ATB8#Q<:9L"Y280T M?M0J%!:I#48&:0LJHITL?A!>@/7P%X-??!= -A&8QN=\$)2 Q=@)5Z.\$%:,JX.D)0-7NF%-
@<L, +3:2X)5!#<5R#4XX?MW_#WJ(N\$=5J?EM\$O!^E M8G_A@R_D>'T_9@(?_#G5>47^'VM@+MNAWQ/@GW?
2#AGZPEWYIP=+J@ID*M)&R-82^RNM@&.TQ.O"VRNR'C83?74<-UM)?K-Z&QC,)+L7P3U='R>UI@:I%
MMBMH!&W1=5NO@'F!KZEEDS^!UX:P< (9& 9 M>&PO=VJR:W-H965T!2="I ?/TI6+N6: MXEP^))>L!AQ:?
D.HH)M6F62SI>IL M5<3%49:OJ@?LS#I32+^?7=>B>IFN9!0F_&Z0;17'3+S>!"AJONJ90;<=W!+
MIHQWJ*>72I!@HUQ^7JX)M=724&9AS);L3,B^/RJ=VU>^/0#7RB.#&IDSIG6 M;Y)E(2EQIHF!,"J*W^1Y?>R(JDBP
MRF0:E!&J!7&8K/^RE)\$; 70M@!;!M!C ZPRP#HV8% &#(X&8!PV,#1F7 MZ-B <1DPW@FPC);
21DP*7IWW1U%7HLNFE2^)^R(16M/Q%(8@B6G5AF.3:
MO9="O1NJ.#EUPX0E09@LR+40+%EPI4N9D5_5Z:V,,F.SQKB'7WAZ%="I
MIX\WJ0:05Z=O.BZ>>& Z ITY.CXVB0P)LY\$P!PESD3 /"?~!L)KT!AOI#73TZ>U*M"#6 JIE;R2YIB,(%DRW#I
(V6U%5U:IBH@.7UTM/4&IOG10%SV7:UA0RKW+M7A>9UIO:QKGM"FO#I;T-!PHX>A5@^?&LD551+^HJK=3
U)"5\$5;"99,LLG M_8=4**)ZU:@+;NK0M:PX=89H/&V\$8/I\XMM8RF(YUIYF#4W/GIS \$=-OWI M(3^T#X+5^GZTZ?
N1MN_O>1*F@GQ)6_L76UTUJY%PEPDS""7"3,0)!\$*RF MM/%&6-LP3-&2@)LY\$P!PESD3 /"?~
L)KTAOI3,2#W)T(U=?7)8O(XM6 MOSLEL6D:7L4WV9!OP&B9V&M(O.FI6^J \$M>4<+Y1PKE6"4XF MPYA)/B-
S%HIV.6@I7>5PWE#46"UR0'9V.B1VD8FIAL0F:9\$%#*%#J91.5N& M_KM0&L=@17=4
I=E0F@.EN5":!Z7Y*%I==EN&JHDMADH> M2H-(F@VE.5"."Z5Y4)J/HM4U2"L4I@-
I\$=UEA_ =^Z(1.6_V@:)G>:3N!#\$ M7D-BTVR9\$%&9ZI?H?&E3ZSU_ ^ BSH>E0A9ADDFORI=I&E4!;0/M,NTR(RI
M-JG3AK;#.=2.05LI7&@IO /MH\$9.WQ4.^H*INQE4^Q_RC6@E6-S9ZX8 NN M5%0:C\$*5WHU"@MK;)E'0QWQY7-
MPV,V*Y/9U+O,NY4VN1/I0K"8_&N.*L*A/C.49D-I#I3F0FD>E.:C.'5%5M:W M.O(7X5-W'JSH30'2G.A-
!&U&TN@8K4!S4&I_!H^R'_H^Y?MA\$JKE;= M"(O354L!!O7(2UIMG738XE-!,SL=,KO0S!Z4YJ-H=3%5-K>H
!EO:9^%DK@L M""00J9M1C0U"/V?J=10E#G&TJSH30'2G.A-!&U&TN@PKCIT!^!K4+L= M2K.A-
=E.:C.'6E558^U=JTFWED0T&O\$H30' M2G.A-!&U&TNB(K*Y).L*4A3KY4)H-I3E0F@NE>5":CZ+5-5@M%#IPL!
MU7MJ("OOQVG4'W29 \$JSH30'2G.A-!&TN::6V7F9N9NZZJRORG^@O?IT0: M<#
I+R%RD,3D1?,E>U!HA\$S,6B>*)1H+<+UO?>[9NWEH MRC7QJ)"=,;?
FA6TV?,"W?I2)0*OWY"RQ6'IA6'ER JYKX!Y40Q3_TJ/+ETWWV_A:QODH?5>OONJ*OGIY> M7&QO'MK'Q?
9H!2NAI<:,K'13 IV-U2:)^Z=G&I: 2XNI!I6EX+L,KLZO+ MW>I^ZJXN-!LKEN?^J2I?CXZ+
IXJMVW7EY=R:7G_Q|^+^H!|<?%U^<2X M;S^U_!J/W7?3Q='E-OE8IO>+C?KI&OOWIV!%V^OI6C&%KN0?
RI:ERVX=S+F MGFS^6WAX/MNI-T%*!F_Z6.Q_!+>JVN5B4.)#_E#/CIV.#>= 7!& MVV4_9/YL6VO-
ZM_+6 IAW=G1SERVIXMGE2ISYN7O!>C(H1IV:SVNI^FIP< M8M.SY.9YVVI>#XV\$3PNU_O+W X 7 G08.IQ-
Y""IM)L4\$XTR X-LEVB^Y'M MTOJPZ!>7E!WF)>G&Z %M_?NVNQ:#IDLU^,?NJHX: +H5U_I=URO5C?+?W MR?
NN6ZSOVV&.^FWR)ODT5,SMZI-G?)A_9SG_SX>:6!7XS7?IM_!:'M%IO5 MIB!#X^?/B1??
_67Y*MDN4Y^6*Y68!3E13!;NSBXN8PD&_W Y\$3 RF3'S;K M_F&:_&UIVIXZVE_C!85\$ "Z&JW*!-
/+UTGPK4<02_ KS1!;?)#*5N6M > //W M3!W00'0UUX:3'6+M16MRTHZ&I;IMNR MV=6? R3*!^<N5)G
M.3S8^(YAGYU=QU8!W MXP78J"IT);U*G=(XRWLRU56B>;RX@M.Q@X2:2./0=H@B^,@ "W1VOM^LH_T M;?
>X&Z9K;7G?#"!::F6QU1+=#IVMXPV6;7#I9:D#U4:YUD1K3X0@IW)-1 M'4=8H2AT-ZU0W<)G?^NJO-
9MLHUA90;1LC^Z H2J7N0!7&0-3(H9Q0 MEJN:S?Z_R99MzJH>Y>B!H(8G2MFX@HVQ!&UFZ!^V?2+5;
(BBHJOE!+,RI0R M!NB(RIHL8L6)5&U=*3K(I?P6R5+!W8QWA^WRIS= M(MNN-V*)MFVZ^6F2L;
MOG7O12BRIVKD0M.O IC"1>"IYP# E2X3FIZN5.E*=H_18M^6-O+!9!RN^V3 M;OCIF?0>1@A0=V)&5)ANG#5-
NU0#?%JU_&"1G(TV!6A!W;>=(<:0R&00; M5@N76/W1M^IK@I*07' KN78%:/JE4'NI"-WI!>MN
MSX6FIZOV>X%Q^+ 7W!Y&Y-!2F5IKID9D?I@U=8O!+W29IGA2!FR!\$YHJ>>C M6(+;
<)P6=+TN.SNAL^QU67TJL.Q?8N0R8T_4HH2B*~T%6'DAKO=)G0! ^? MBMU(G-W,774^&'W,M8;J/4-\$B>IS/BN-
0"JF5JHI+25!%*^0.*!0YP)L M<#OJQX-1XN"^M<>?IE!^Q5TDKC702TVRR@M<:JZBMI(G-K,7FJY<JL2I!@?&
M.9Z8!7YD.ANH7L<0:678GM-3S4>Q"XNPB!CVQ?7T:L.Q?8N0R8T_4HH
MZB*KT?6"!@IO=JG0!05LY\$XLYFIZO8P0NIK*,<7!VH#U51*TG(1YK#D?" MMKH36NI^LN(6&GI*HJ3
M!4@GF5.323-CP9%A^C#!20>:=\$(@=(+)*2WU?I2_R!^D9YGU02SG/\$A#@?W MKL 8TDFFFV\$L6*IUDK-
(%)YJ>KB(W&8!TDKD%D72H&W/ S8C4!ZOX18FG1!(M"+,I:6>CR(8&4XPLO-RBEGF!ICE4ZXT/0KH?
A+%BJ=9*S2"1>:~EZLZ\$W. M(YT<8\$S"F)7FHL1J_15\$9"<340AD!IF>4I+!1_%)*1-."5!E5HU,U04 M'-
VW#+G0I&NA:\$P>JH+DK^H*%YJ>+GA,@T=%R2>Ts?N88\$ZD/EC%0W(V%85
M\$A)9>*CR(:26G5,743C=#3!100LOAIY2@,=,@Y!Y7WP-(>4BB24_#H M*0<8!P-

;;LDL P+UH2H.4K"1*002MMN=U%3/2-&.J<9^7D!&6:HCBHPZ&I MJS"&G%
(H(E.\$RBD%JYS"A.8 JU83LDCIY1NE20WUQP=IP14D9"234PAD\$0Z
MO>1.:JIG1A&B?.,3#LY,+8ZFF+BZ+YER(6F7PM%8\I0.:5DE5.XT/1T%

:GSVCIXU^."MHCL:ISJ&'-=+G=KV-MW7SCDV

>24TBV29/1P9Q(?;"*A11L<@J1A&UV)S75.P)?2S%6WKK_XRBC%/3* M8Y53N-
#T:Z&H3!DJHY2L<@H7FIZNXCDECYQR@/#74^Y8>3,BI<\$J+E*RB2H\$
MDL3VQ%.:ZM =4G2CHD25>GK/HP_N<374N1"TZ^%8C15J*Q2LD:*>E
M57+I\;M/I^GUORJO<*I5T3QFBI47IE8Y14N-#U=17HJ'GFE#BZ=R'&4%@IQ6H4(6E M8E58N-
#T:X(KRE/S*"RU6SF1UFG"C\$!J(J1U&P:"X&\$!CUOV.JEN(7&CZM5": MGBXP/N'15VKWJWF\$M>K(.V@BH74;-
H*^83N=<.:2J.(1H,3C0+YA"?HHW,< MW;<N=#T:Z&83!JK32LV@H7FIZNHCD-CI9R@/#74V%JML1J
I5L9"&35DA MD+ #=J2F>D.*.#0XT1#C:<*1U9P=-J"C*&I-(K+-*&2LJJ7"AZ>DJHM/P M:"J^XLJPCY-
F!;I#U8QD89-52&OLIWOI*9Z1HIL-%X/K>@['GV"CJ-IEV(-M5:4HFZAJDK#JHPIH1G^<-@CD=7>
<4A'UV9\$6@,%KBXI6S*"@6%:7NGM36R MDB KC':D^M<2I/5'/S=&P/LI<705T0*7.'24(7E%8\$MY1@:BTB!
<5S*HJ*! MXIA?/,BM14C%&4,%QXFIFY"0>%K,%AI\$2GP;TNI9UD\$^-0W?DVA;+3F_29 M.M&!?
TG&T%M\$ "DSBTE%#Y16I+>48FHM(@81%.R>)*WCM
M<IG@C)0:22(<=/64OTGNN\UV8K+W0/"M5^9K&5PO(JTFWLP@,OCN(5PL,8HV M-TI>&?^DOB%Y@
I7G\$PN0VI6UY)XKKK@ "VNP(WN06IVSU0@=:M'5-DDV_ M L2'LLUHI4AHI!^_*?PB@\$"+CSBBR8.'FNOXI1R%
P,I7\$ Z^E5KOP31 MKEHI!KO; N*#^JF:9IOV(AFB_ DC"+N #><7#'#:A;W_7.V4N."E0(PC M1HWY=7L
TFIRE%:LL/2AD+T9?-\$9I@(-KP@V!6I M#KYL<\$:*! "6/N +D4:FYXVZ:VI5+A!DC!8R&_IU*C?DE29\$5_ZS&5D"U@!
MBX_!DCAIK*C*(_CC^"MOCUZ=PL:8QR^@4I@D4>?J%_ SZIOR%(\$384&X",\OW0.05;K.L,G2!2_-K?5 MM>^Y
2_8/(KRGL8HCL "6 *+@T5OR%N!>0D2?YR1,B!(A*NO1^5F5DDVHK8* MUXZ:K*K:0B_8.OC6= K*HC>_"2IZY_(*
(I<^06!Z??D-KE)4A1K(<%\IX6 MN-NO3^TVIVK7%399N_V6%"^P29;"A9 M&7IS1RPID7IU"LOCL##<:IDY M"D\$J
4\$JN<I_#D!4Y3K#IBL7!KLP5=*LP8*2 VA(FP11>"K.^)WOPG,HI* M!%R1115\;C,9K? "RH(P4YY?0;5I M3B:+S*Q>
(LH8)V WA(FQI8QND/TWT9OW_+!&9<4*HZ^#B-UWJ9#@Y@R;O.L"V9;N#<;M1MHYDSTYCV14>R<
M!?!S%L&&SH+7T9D-SD@9D"3"U^E^I3;V69F4EK,>\$66,\$S ;PDS9NNL&V2\$3 MO?E/8Q2Q"+A#BR:X0(W7 IH-
SD@94'3<=MFG"=RA9IHZHB9Q?VG?E-G@C)0%2)GIL T5"-9D9E4N
M%66,4X)Q>IZG!1K8\$OWY3V0,J4@ "&VD9;"M>6VDV>"E_0.M.)VBL0K,HR M-Q4&5I0\$6Y#
05H2ULU6Y089OA*!^4IB#)E(BMJF8:>IDE>KVDV_"/E"J3,M=)KV"J3Q %E9=8M'&>.LP3BISM,"#5*)WORG,89,)
(\$AM4Q3I(DIB7MGW+4M@<3U,(-2R#1CI#7X+-MKX09"E*!8ID5\$IR7PG)8B M!Q-XH5_BE'(4C
M5H2=M\$>M30K+,T=-J402.1\$+0DG:OSK;XVG\$10 A,9 M0RB2PA:A:AM32UYC:C8X(V5 D@AC:H_-G?7U-?
8=T";D-80..?TTXSKB2Z M!)_&J1/I64H0>J4E>"VLV_"EP)5POVB? MX#00>JBBM^K6CS.*IV#ZT
M;?IAT2^N+A_!KZ!;E>K;7*S>5X/;48F=S\Z%=W+;=&#M_6XS%/?AAI&#ETWWVYX5_+4\$!#!!0 (
/R!>EDX(JKQS@0 IL: 9 M>&PO=VJR;W-H965TW-UTD2@_8
MT_\$2+!@C44 +>P%W=HT2TXPP23E#@LPGUK5I%:HIK5!(-)\$)6NY<(IV49\Z_MZIO;>&
(Y>D8D)9'2\$!A^5F1&TE0CP3S^J4"MVJ96W+W>HH?%XF\$QSUB2&4 MI+%*)M;
(0C&9XSQ5#WSJF50+&FBI8*>R^(-6E:OCH2B7BF>5,LP@HZZS\Q90* M\$3L*@(NX%4*WKY" PV%7J70^ZB%?
J70_ZB%0:4P^C*L%&8%KXOG55XVL<*M3!>"KY0TH" F+PJZ" FUP,&4ZLAZ5@*<4I-34)X*NL&97(LQB,N%
(^QZ0<\$F M2C;\$/1 Y5=TAQG&4240I 0IUB(0@6=<\$1AFLI3&'UZI-)SZ=C6I&T+@= M55.X*?
@O3&% 'KKC3"42!2PF<8N^WZT_I-"WP1VU3IRM3VZ\3L OD3I'WN ,M>8I7.YG/I"/J% X5ZKVTYVW<I^#IK8;?Z15*
^K#->L.703J^>@5>H WX0K=, M*IK&'I#(3.)%Y0MT+5.+E11B\$"?RBCE,A=P_==O (5N%1T."WXF\$
M,T0V49K#RXHGBBTY@Y X0PLH@^@\$V)>G9U"S(KY@I%10@5&"!8-(D6UA4!H=-M%D9U&5U-
^Q=-13>V5IL4'PH.G#9!_U#P.%(FP!\$8YIE4R"^2;+I@H2&PIJ?#FM A#TJH0Y.18!+, M-PD6F
0+ #8\$U(N&BCH2+SK?IB4\$ID19UYW5^4/VL#IL*!J-HOE&T MP A.;JM&1 IFR!N9^*XPON:Y1FT'7HS3O.?
894+JEX0GZ,Y%P02!8JVZ25^ M32*M0=:H.@;@,GFO^,CGJ9JMM58'1>82FT)J\$>Z^\$>I TU>ZZ(^*3P!C&B M4-
IBI+EQ02HU 7)(H42+65^4H;I2# 7*ANU8IESWKI929;6MP>?UV.VU
MMHVSI\CHW"KD>RHKMPU:RC&XR&47S*[0>[[1H51PZ\$IM)R>V?O.B-B M49PR2/AFRYDIMOGKT?
HDX\K80I;OW&O9F\+N.I!>4YQ2M!>6QRA15"QTA* MYF#*.;^;W)1GD24-XH0BYWS9ZX4SXX+A#(EH
GLIY5IL;.. ^#YK^!U!+ M P04 " #I@7I9 N)/-Q(% !M)@ &0 'AL+W=OYZVMU%K;HFO;"!2>Q
M"CBS3=*3IL?A1PRK&>@J2I;0Q\W% ^ON8;N/IGO\$GL2%\$HN;3I-R2SZX>8I;D O#^B= M&M#/
JG!@SR@&SHJF'L6>(I+I%RMD><=U:T?2+/M9M,H73?1\$N9=*;
M.L!T;DWU<.I+>#N=I_ M(-)I6\$DI&G=&C60'>0.WB&WZ_1PIV'+MZ\K<\$L
MYF#IASMTD8^@H@7U;_J% A>N1U+>+9=;7EBC5L&I^MQ"IF@%O_#?CID^8 M
2\$1=)U@24\$!5(JK16NM*+K/4,(2)SA*L %+!\$<;\$#9ESQ)H?C)E8XZ7;IO@ 8Y
M)&_K<5^ (5&=4.YDME_ZOT4%6YPM0F@=*Z% HIL;EVH\$S.)?I@;X5@-(4)H/ M13,E+<
<+G,;*MH71#5_9Q* @S./8YT.(>E.;7#N!-E>6I\$YSS0YD,\$Q6+ M@MSNWH/0Y-4K@KR5\8I &1\7HJ!5?
%W"1I7ZY'R+69;G;G-Y M7G4PE1Z0EP"UKS AJ_(*%T#I?E0-%/0.O8D&H*1I&(NKUD+*MY:5E"6H
(U=3RGS.G.Z1.5/Y8/7)U9.<4/ M(AJ+@.6CIE5ZQI?J2Q\$Y*(OP*Z\$3Q'2?EF;\$727+K7I7^HYH2#VI\$;IZ M6_-I#4-
40?Q3P9MY6WJO-WC+?UKTGG5F6=7T"D+_PYN;AJ#5O(IS-W0?IFLV\$#L)BF_-(%D"J29T
MIR1TLH3.L2UTLX3NL2WTLH2DZU;JV3@;%>ZDS*G&1UM*+I@V3TDVPU7D&L MA?(DN?HV4'ER8E,>K%U=+
(B):TFI2I)EVD+7?+>NH15(L78I>M11+4+ZFK4G:O'DHD+; M\$N8 P4KEZ^E;ZS-1W!5I;I2.5"PFQ(F,\$
M*Y6FGY>F2X1R3R!-2NWMZHI4M#0UO PKRK4_3MI2??'C/I;D!WF !XW! MSE=NNEVYN?
IE(D^M<5PICAE_B8W\$4^4("A80X0K%2685Z6X8>M@T/(D" M;\$B8 P0KE6^4EV_4^*NJ%.I^>OL%Q#K\$/ASB-
(>7^DZ+_Y\$V+^OHOFU#9DJHOM"L-B@\$R M#D=C@R=+%Y)F@I(<%JY=(4_Q!IG\$#&H0P2EV;
TXI6+F+A\$G&S330MCYXK M#F@6*E3#I_L/G40XIHZH#_1IUVNCF:3'>+"N+W\8 8U 2"TFQ0F@-% M*Q>H,
(*XV0F6Q:F=IX^2A&@=;KZ-!F7E6>)M"HJD^3'21H" N_!"^FR%4 M.^4."G?XBXYU?ZDF"AZ4WJ37-
3)VL6U"J" TAPH6KEHA5O\$V<7.;A?!"79 MH#0'BE8N8N\$9!>FF:AH^I B2&U9-
#B!^K13#ZHIC9L<8WMDGG1(X1C)&SA& M NH806DV^V!HI4+5#A&=GB>;
I3F\$5!G\$RF/GTV>L!FYLGBI/6\$H#0'BE:N3N\$R<=Y M0@+J'4%I-BC-@:*5BUAX0G*Z)SSZ;10Q>+51;9(Q!
U<9;H1^V^\$LW&RH#I M\I@Q=+8I!X0W)^WA# NH-06DV^V!HI4+5'A#B64UUO%.MVS D5-
MW==)YN:*M=O.44&Z(-^)) M-V15^00V9W+YWH/4\$AGJIGVQ4 5EJ?;LI(3R9;) J-G)B6+DL,%=7W*=8#Z M?
L:8W)H\O)-"7SAN- K;f">W\$Y9S=G2=JK68,PQIA8!D9_ MG5*BUP=;UD_ ^!)UJNF<:1S+_RQ&1I
IXT"418+ #=71#/(M)%%I28+"BI*?W9?Q6\$%0\$S_@*"!\$!X3_3@7H MO%1#6 "'EYKH5@#GNE_ZI@ (Z,
<.&247H*PTL=F%BIY#4IRXL'5R;11Y80S M@P@5GS.;+ U.)#;"84B?H#Q?9POD2)<<7T"%TQ0U5!H&#B
:RK69)8CR E MI%(LD>=2:R*AY*IR?I*HJG@AE, @&DXQ23E(H4SH8V:64H-NO\$QG.I1^PW MUQ\LINS!#G
!%SSJ9YTSS?DK#79CROAJ5CP3..=>!"I-I&L\$DP9MIE_MM_O4Y#K2 ?+2 ^#G82?8W,(07@GIV;\$I3>
I&G_Q\YM?"T:G M+KN.CXPNTXS,9*J!NIZA;J!BXB&6!^R"H_ YZ+)\$<%B&)(<24\$6=L;\$:-NJS MW?9\$3UE,?

8:J48U1V_P^E7HJ/6N*17:)(NV23;>ME:TL(Z:.%C[-RU5ZQ>MWGW8M4U@SS4^9.
(#@S6.CO36D*MYFE:9)%VR0;XEL+4W=.DW=C7=K-1U7 M&,M4) 4>JF;GKE;UI26DO(-=K18CXXZ?1[-GPUVG_*O
W71:(&FO)S;B! M)JA*2H?JE?>L0)6Z04+3_9)4_.8^K2>5=Z(-K)^!;FHWG\$N(-_902P.\$% @_ (%Z6;3&1#ZN!0
XBH ID IX; "JW;W)K&ULM9IM;JLV\$;> "N\$50PMD45*MI/9!M)DQ0(L;)"L MW8MA+QB9MH7(DD?
2=>KLPX^4%5&T^B(%IS>)91 _NCO>231GIX2_B56C*GF
MLHEB,1NLI=Q>.HX(UFO#Q7FR9;Z99GP#97JD*16,+M)!FIC:P^-(V= P M LRGZ7?W?#Y=C(*8W;/D=AM-
I3_ ^,RBY# :N(/7+QI"U5KJ+YSY=\$M7I)) M;IM|KHZ<7&41:E@LPB1&G"UG@ROW|MHC>D;J13UD!U'XC'0H3TGRK
JN%|/! M4'O\$(A9(+4'5OSV|9E&DE90?_Y:B@_R<>F#Q|ZOZES1X%PZB?X*%W(I
M&TP&;&6=-?)A^3P.L"K5>D\$0B_8L.F>UP@(*=D.DF&ZP|V(3Q13HR1)1 M&:IZ0-P-@ "W'4"R 6GFG*-G:5@W5-
+YE"<'4+6U4M.?TMRDHU4T8:RG|5%R MJ6NHQOLGY#>/AGN14'D3C|;K><<|BX?
Z|258TWC?T\$,HGM\$=C=6DJNF3Z!T MJ&HL8L82I;H.J)"A.LPH;=941)?;C1=QKM4@-S G0;"EW6D2@.\$:?.43C
M@*%|;Q_V^8I&\$D|JDS?N01|_?\$(M-U=&\$5*6TP=J0+6;GM;%MSG8W"X M|KBO@3Q'V#1#>(B|BN'7S<.OMEP-
'U4=U2;USC/MJ004FOIP&8#U|J?7 MULH|S|A%J00>GL4=.O.*ZPO-GRS:C4.60?
NZKW^AKWK#LM6\$YE0P%22RY MND96=DVC8M>" A*S@A_EP8|ZZ:@19 * Q*P\$C/;\$C&\$|:EPJ0'_LG11IV::V
MHR:YGY;>.FK2HJ/*_G4==9'|>M'HZY^)^D)%"%+GC,1('NJWLH4;-KB4\$)&:% MZPX-
@Q|Z;).%B@'4&IV\$@H|*R;#ALEP|TR&09D,2LU.@F\$RW;=R\$ZX LU,NJ|AXYKJ-UB& MVV(9\$;)L-
MF4R@.)O>Z1N/D?G"012LS-BR 1?|)%/H|/@&I6; TS#X1AK) MZ!UO-
8:EJ_+I&FR%36%UR?;4_!9IS5@=^HV4&8J<|EN% C8MKW#681=IC5JM^
M@WVH;O:N:Y% "J=FY+|QYZP>T""AH0:G923">18 70TC%.IW2^|<FHL-8Q% MVC;6>.FW>Q&'S_&,Z1NK(=
M&6;8|QNK/%#"@U\$SDV (SYN| MN-K+H7RJG624EDZ.S3E\$#HM|J>4>Y*EE|K948X;G814N_+BA|G@|D|VYZ
M) _ID3+9I!_7C"X8UP;J|V62R<#OL MO9DN P"@T ID IX;"JW;W)K&ULS5==;JHP M%/TK5UDUM5+7?\$(
I2:22U>M4MDJ4+N':0|F7;"J\$S/;@?;?STI2\4857GH M"|&3>X|//XW.*TY%T|R@JC@.6:);%L3I:87MBVC"
<9\$G0\$DOK)B(N8*#T5 M8UM.!9)A|HJ9|3E.8,>\$)E;8RN|=-B|/#%45H@O<"9|K'1+Q<(>/SMN5:KS=Z
M=#Q1YH8=MJ9DC'U4#1|H6=VR3*D,2,2\|@0\$CMK6I7O1<3T#R")>*<|ETAA_M*#@;G|SD=MBV*
(&4;*4!|F6\$&3_-6L??@M0JUS3_Y?\$(K^TV6O\$YF0"1V M./M%AVK2MH6#%\$4J9Z?/X=BX1|PQ=Q)K-?
F!>QC@51*A6/"|6\$_.DOY+G MPH@E@%O?_O_*@+PK MH9|2C5A-0HZ(A9*"2090B<5
|H|;X|H0.2C|C%Z5\$Y|ER1Z4_7V?>@?25U+ MPY0A|;SL' D;J@NAAAY>>CR9C MN"*22CB^1D4HDR=ZE8?^1P?G<
1T 2ZE&|ZDE*YVTD6Y'18)?>8>+E@1_ M1NH/|A4/>K5| |N^&74Z'A017BABGNK=Q6'\$W?
F7_8;^*HB"RM4+@;M"IV8XW#Y^1/^ U|+ M P04 _" #|@7I9RD@X)|(\$!<&@ &0 'AL+W=O?59L 9K8
M\$B<)>2_7GVPW;E=Z3|'C+Q;=<J+ 2Y8R.?&62JVN?5_& M2Y)A><57A.E?YEOD6.E;L?#E2A"<=%\$Y9ZJ;@B/P,4^9-
Q|6S>S\$=|f5**2/W M LAUEF'OXP)^?;B0>_UP0=+|7^P)^.5WA|'HGZOKH7^LZOHB0T(TQ2SH @ M|XEW
Z|GO2'W"*S^IF0K;|<@A_+\$^7-^|SF9>\$&>\$4E)K/(06|MR(RD:1Y) MY_%O&=2KQLP=Z|>OT3|6X#68)RS)C*?
_T\$0M)H0 PF9XW6J'OCV3U("O_X M,4JE|OFVI6W@/@7%M%<|*9YU!1MGN&|4A:@YP/X!!U0ZH&=>J5#KP"ZRZR
M=8L5GHX%WP*16^MH^451F);HZ\$|;^C\$OI7JOW4)8(NL%Y*27 +&SM1"\$ MQ3 '_R_Q\$K,% 014/H|S'13=?L4>
|>I5Q|UBD|?Z\$S>>2*\$79 MQ(2;6+ MH7B)YI21774BUNB.\$WEI?>G@+MY=@G>_G|'TUIW4HYH8'DZ?AQOF2'
M7=+H0-+78G4%4/@;0_!6|QG;O>E=#ND(U^MUW*%8S+Q|*41&R(-WU^Q@%OIL=A2L_:=7P>VYHD|_2XE
MN,GX6L|&/04>2,P7C/Y'DM@Q|62\$(G MDAF62Z"1*6*" (WG0C>|Z F870|+A5);*C"-JH0|8R#GLBJ*@"%3E!?=6J
MM9M6MNRCS0;JWG|VSO@G9C^HLA|F@J%E MJ<%@KZ|6HRBR<|&H2GWD;-=?7.'4EM"HR^9T%*R!\$ 9&VX-
SMZ<LR3GWX_0GD-&GF9U0?E7V- XN8IDY&8\$ W@;@8;/_ MT"W<;GXMGIN=1L/IS"Q&
(W0@,2/+T*W+U::3O&XZA:XIB#E30N_S|4WO2'Y+ M7.<0R')HWB?C MTB8Z(BNCGV30MA6-GMMO
MW|JV0E1:T^UA+XFO?<_Q.7;N3=8(^R6_!J5(RK<;#4NCX/0U4LH2+J1-3 MS>;F|F2>B95FE,=1&I5542^7@ (3
MS3@8!&3HW2QU'8BS+;+;_!&(-)TT4JBPEK8_K*CB2,1^%X/S26KS7<(/ M"HW:&"/K9";\$LPUNRG\$064' H-
'6@9C7&B;F'4R,GYWG&_I05NCM_8KYOW MXV5&P\$>Z'E7HZ#TP"5,"7MFIQTY|!&0?'_P|&';
H3/.*G.VID23/).B0=)F&S8|<=&?CT,8-MY?
86'f0THJ3@=|'#U|UD:04.IR")I2I(W2,'A^FZ/#@"|T@RM\$M9OP!_="GR"&B;|FYQ|Q8|ON%? MW+ZB*54%\$VHE?
V|F"DMS??TR>O)8S|A+;&SE5-"A@'IH@4R#4\$^>=|@S3Z MZG|G|C>>1_VWH?
IV/KR|GY3DJT\$*+T7F6+3QW>50|Z'X|P61:N-RUXDM+T
MM\$|Z)RWNI<5H3V92C^F_+B6H@#EU=82)!O;CO#IEK3=G#3&?F5)KRS9J^R>M_*:-
\$A*F%=7LK/GC)X2|ANTEDT|@M+>V|7F?A2;);RC=N9D'FU?HB<) M#|85A1M=Q7;T6R(7E"O\$8&Y@TU?
^J|C|02P.\$% @_ (%Z643?^%6Z P;| ID IX;"JW M;W)K&ULM9A=C|HX%(-_BI6M5JW4G<0>"#_%I(9
MCUY;QK4|475"Y;/I/O>@YE,9&)Q|9-C%NPH/=W0+*S!?= @_*MCOQ*68I".VD0 HV,^|6WRQ(Z +R%?
|R..BC8^1*64OYPPT^QC,O<(Z 0V2<M|+5?>U@("YT|)^OBO%/6JG|P^/A9_>^|>%O.FFI82OZ5Q2:9>6;/Q;"A&3>/
M|O/E 4-G5XDN) M:EYM#7'A+LK*Z/L66;CS/QO*>.#XQO1\$:/|)&% M/|@I#Q9;M.:|K<%H1=-:V6Z(SLC-
VB9V-@.\$1(KD=+JM03\$UMTF|&+>B M\$GULX8RKM^A-V|YO9VSMT)/26.M.P^5-
I<%#9)B|T0W4MA\$HW^%#'\$+^_I M6W)5-WFN>T\$Z|3|'Y@J|X7M\$ C) 7U9WZ.V=QVZU|7UO,YUKW|U;|I2OMI
M.=5?S|5,6%T."TD'L_2.1C#S|_F0>W|F_ ^&PZ#%QTV|Y7-09?Z?%; M)H2|VO*J8C@E,%"
(LPEW-.JGP<^R3B<^OL3F8=5YF%GYF6V%|(CH"1E%A>:T M>#9MATG7?*=L%'K#(QMXU&
(BK\$R\$G29L%_YBIK"1=|QOB\$G'55H|VUVU9@ MK3&W=PT.QO@2+<0UCW_<1/"/>O)R|N4U#PF M??8-
'F;|Z,6'S61R;E\$)DTBXPEIZV52(YET(F.T348;/F+NCOTE9U!;AR3 MWGL+H% C4N.8|(|CTLOQ(<-
ARPVL;4SZIC%ITKCES4YJ&)-S85P*A-WE^T<; MT134-MIN:Q2YC6&Q)ZUFJRW|;+1K9<7_P?<4TMGH1&'C0T-
KD;V8%5LL8N! MD;M6|N6QFZ2||;\$_S*+;#G-U*YX%+4/W1,?24\$!#|!0 (/R!>EE# M,AT|!_)P* 9>&PO=V|JR-W-
H965T:E*6F;5F>F6&2&_Y(KUTQ?T17(B4Y7#'\$5UF&V9|H'0S-GK&=N&; M+!A%DO_5.
EW("X+;Z8G)FU2DPRR#FA.6*P&|N3WC<*+P&?">PX3MCD)S_M*U3DUD|BRU(4@A\$DH|R|<;SB%-
E9#*O^27N77N:8PSE-M?Y|8)/CS\$ Q+|J%=T|P4J/Z|2BVC*|3_.E%CO@X&B%1^ MK_*P0Y ZS02I(MB'!
<0)K|B|);P:D(SG.CN!5:6S=+|SIQ 1;8'S&Z04R MI9H.Z.QKMLP7R=4JN1%;OB62)_S/E;8;DJ8(YS&Z% DP-
_L%SI=DG@*;<Z" MHQ|T#3.C;U9&BHP \$)BD_EJNW-P\$Z>GL;H7%E&Z MAK5OCO4|G8B@&Q&V(28|#VK|@U;/
MDXPR0?YBW1G_O6QQ.#39&SRZ7DZO;^G?@&ULM5A=CYLX%/TK%EM5K;09L!_!I@E2FJC=2*T:S6QW'U;|MX
\$G006|0(PU63\$O"89|f#^=>|K6//3U2|H/O"!@9YX5?&;M MA-C?VC;/=R3'_ (N22&?;"C+L9|#MK7YGA&<*<
<|LYC>';_T|**INK>FD53 M>A!96|U _R0YY@|?209|/T/F_) /1'2|VLF1W-DJ0Y M*7A*"|(#9E-X>T"C4L'92%2H|
|J4H3Q0-J,7S^C?U+|RV>,"<+FOV9)F(WLP(+)&2#*YFXH?? M2|606^+%-/I%OPK6|<"8\$+FE?DD&>%J=+_+
*Q)D#G/OXH.H|O=1A7#FH MS-DG9BJL|18XFC)Z!*RTEFCEA|DT|3Z2>BSY0FQS3+ "X2 M\$WL"
_K0N|BFSYD|PY)X#%\$;B7Y9;"J| MYW|R 19%B0|S;1_H05QY>2f))BU009;@JDN'A@d5\$|T|WRV)P&G&WANW
M2|I2@G=OWH.W('W_5|E68O*1+63|91V7,7Z|10KZHGU6RQN_)!_>O\$|J_>^|SU1=J#E2
Y_UL7ZPE|H@QG4>QB;T2%M/NHA/|Z"*;>G MOP@%(O|GIN-Y*#HKWW5KJO;2D+D8"*R5 M"|_A3L^_@7|8?
&J'0^9A(+!6J#3Z_IGF+*L<YK#GHN&G; MV2NHUIP=0F_2I;HO"IP@|*Z 5H7C;C|8'%RE9\$R|(O"MH1K=|2DfM)?
M" MZ|71H#)A*+1V AJA,>OV5W0J\$.NSL5_+U<=(((\$FA7)R_ OK4FA Z"_ 6f0Z M;|?
U>XJVT2/0+\$BNZB_WLG%Y'A=JAHS3S98#15&5\$#C.AW|SG B-IER ZVZ M2I3# N=\$WUB#"HBAT-J1-
Q("J_6\$:%6,%%&4Y0 M5U|HC28|E=JH#&AHJA1_OLZ M\$%HIRD9#(B|J.WFC0KDZ%P.AM7-Q=JAA%BDO;|*H4?

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f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f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x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x?1O@M@N MVV#;-ICV0;);>#W!1T#8(F6+O!4(3QE5!>5IDKTY16W+_4<3WZ8UCTB2 MU:EX7Q7!UX2WJRZOELOM9IO&%5LYMI6;%WX* MK+8I<_')9I&.LR=6.DGFI&H6<MA*R*D!3!P!U!NP^=DY!^.#_5^.)FO!)+<_%3_4NL/C97M8U!O#0AV'Y3F? MZQ:EP!5FOE;\$_MI7U+^S\$?XOTXHQ_C?(VLP-ME!8R.L:1QF^!;6H=M!VM M9"G=2A)^FZ;IAC30^ZX/JN.GRZS>D<*8.GVZ"Y.BC\$P\$#=>1T(W^N#)NA MSP=##PV;OO\TWSIH_\$YU)--!S2F>!.Z2'0N3E9;/H6!%XXX#9;A.5EH^TEH MBHYE 8MV !8!VTKWD5IT>G.2?U!_9#?<_H2\$&KDZ%7>4A8"

DCD# *8N M8%(S28Y'L\XD99*9!PD)(&(&\$44A8! 23,FV^S!3Y7Y!S/5;E(==3YA
MLO+8\$V:~8S!9#^ 4M.NI4'CO1V!OVXOY;5K X3?I@-4:'T1QDCE!YG>3O?") MW::6-N 9":W#G;Z?L&U"B^#
M,PZ2'H+2""B-@M(B*)J<<4(HG.*7.VF"NF3&U.9^I= MI\$ /HF,L.1)"?7+MA-P60(J0X'20E-:~71EB9-
KB9:~NA&H!BK+A72D605 M"WJ6):"B#R@M!*414HM:8GUM8BS,HUW;^?5_L!L!MX~5#AYYOH+00 ME\$9
~124%D'IY-01LA%~I2Z?H0E8)~W#&0=)"4HH!5%06!1M'DS-:~W(KK7U M*KKLC&98M3!9LH=
(01U2DQ.TP19>=F>#PP:J MXX'2""B-MC3Y48 Z1-!@=#J?=&6 D-V0?8U1K\K+SA@<6%"Y#)1&0&D4Z>N;
M5%G>:B+'5 A;R"YL#2N\I+#!P86DA: T DJC2-?"#&>M03#K/FN%8(L@EF/
MRLN@TWC8GZFE%ZBZ970:X)E:>X*50V. #K:~SD40KI"=NFJG@(?;GZF:V> MS\$^YDS!YQFH? 5*(Z
T"DJ+H&ARM@A.#W?4<\$%~JF!TD!0&@&E45!;~\$63 M7 (0(IUG%^EZ%5QVQN#W.W2=:Q:H:~I
71*~2X35%29!^A4=(!KB":G-LZ_0ZE5HV1F# PLJ MD8'2""B->OJZ,"VJ-A.YI@=OT-
G%K&%MEATV.+BP:'!O@8'^QZ<0?PRG+6Z M5?
=9*P0RSRZ02^T/T%Y7"29JF67W.CA8NDMWHKXH1\$!ITCZ'&1WKF!P\$H5%Y
M=HVJGO3NWK.NWX:~8U52L*~8NGU(DR?+U114M@*EA-T DJCH+0(BB8GCO##
M//_15%P>J)8&2@M!:0241D%I\$11-SC@ASGEV<:Y?Q06Z2.TSB%M3-%=++M#% M9R:~7:5FJM/SZ)C+#D20IOS!-
H<<-4%"N"!TD)0&@&E44!~7:J+HTQV'3-MSH76YMG7G_6KN\$
U.EI:"\$HCH#3JZ20*U#>=#":8%~LU"SlUA<83<&UPX8&M%Y06@M((*(UBPPN*ZH87NDE7<(5(ANTBV?
%B"QL\$~UNLK"!&1PH@~4U-6 M-O5)>QUG=*QGCE.9"TL)O?4'3&&%0:0N4%H+2""B-8H,*IE!>(X,1FG>=
MN4(IPW:EK\$?I=-N:ZZG'UA!S(X5KI+;Z857J!;59^CC(IT:Q>~!<%FO!M6 M/#7!3)?!~
IFU6Z3UOVW@!VLKYH=G)7OK!TSXAJ^I^Y9M-NI6N!W&V= C@L^M&2J=E#UR5Y/
4^68K<7I>Y#E3JW6R\$~Y%65;YH_UQ>L:(VX+! YGGUXT/M M8+!C^~624\$~L#!10 /R!>EF#(&A5%00-\$P5-9
>&PO=VIR:W-H M965TU~23*N@9HFR!9 MU@-%/M#2V>)*B2Y)V5E_?4E*EBQ.%M962YL/L43=:/OI>\$<IXGC-
Q4<9 RCT ME+!43IQ8J>6%Z!HPAH3(4IZ\$5#^98H\$S"?);X(?;X6(N_**SEUC4RJQ
MH4AH8/!"SJ3!C!%K>>@,.)*)X6SCB"A:~Y+G@HBMAPT3K.#7SCXNP!PZ!
MPI%G\$!TGLVE=\$T6F8!72!AKC68N+~#266V=#4I.;#TKHU3J!>EE&&9)QHB" M"-VJ&-0*>*(+(C8KM0+TADN)3M
I(@0QA*.C:U"\$GFL1Q!~KM'1K!~C5^E(M#)X;%K-
>Y;Z!V8=HK<15;%~\$OZ<11'5_5V=0IN%OTKCR6P%00W6*~\$+Y'M^MOR&>X+^XGUGW7DLXO9+5GL7K"!~I3'5+;?
I9DWD&~Q&?~B.0KIL;I(52'7! M0*\$""#~!%0791&~#K!~Y+^22A#~I!Q!&))\$~MPIK_!@H?>RZ;L.P*K<=\$ON>A;M!-
XW5MA-&O(\$-CQ!>~\$=T8V~1/I=1\$N_2UHZ JO!BAI&;262\$Y%6*~%E0P M2!4,I'X->J!&9&2SFE(S,XG7R!%GA
~Z9U<:N.9I#~GJK\$+!Q"&-@2SH:~F M^RS?V-WMPEN6PS'+8FN7!~P2?(P^V8 C:@!W!+7%?E;&?M8:
M>Y"7K5F8/P5);,9H.OHGRSOX:~^;<7V@+M""R6_JA,?_2,?3OJDI..P&JT MG)>TG/_XOCW?
J^C=FF^SJ.6%Q4H)>*V90=-B<>OU!JBI?~KJ!WG:Q>S*!IZ MUEOZ!SICF1>3=45-
~VAU:OR*&O~EWH10VV:QXW:~?EH9JO=IN%VJFYH.8 MI-N3&H'1078ZK^=;~K(DVE,NE-
YUA5;G81'H'G5&BX4XG6%5J=FDJDX9! MH14QM&WWK2;UW"HAO!~8;W=->~IMTFWW!5Q!~K=8;Y=G6-
Y;JN'K'4RNT M@;~8O6(;L.4=UJE.ZPJM3D6EU!~S2C7WZ!7OZN8"N?0#ZS5!;3;~!F;~!M:Y5~)B88_KI%Z+~%7Y
M!4XY6AX)7MJ#L)WQ~WP1Y=I%4Q^SOB6B-5~)6(PUY#>Z9FE5N1=-F_XDM! M^C7C2O'~\$7L9 (A#&0#^?
&ULM=Q;~H(C%?P MKS)BJU4K50&;>S9!2O!~33=*U-V'U3X;~!L?&>C!2/_R.C6-
C+A/0_O;)/TJEHO)~CT*8W;6\$JYNFXVQ73)(BJNDA6+U5_F21H1 MJ1;315.L4D9G>5-4-LU6J!>~*
(~HYMAW6.ZNDG6.N0Q>TR)6\$<137_X^?M6=_.#5P4RH8..D)/Y/*V.6B0&9O3=2B?DHW'B@/J9MXT"47^DVRV
MV:~#3)="YE\$1;#;~@XC~V!~T>~%\$!~2TS1!9A%@!@<~3@2TBX#V7H!Y;H1. M\$=Y-Z!~!3/#>@5;US
~I%0/_<@\$\$1;#~@W8%@#;~!~%JOKUPKSZ#M2YIG MBT4E'=VDR8:DV?~*RQID29?JS3A<58?SS)5?
~4J3H!>211QJ1)>"D+C&1DG ML>3Q@L53S@1Y;S%)>2@^D'>\$Q^2!AZ%~G'3E&KH#&A.BV'L!3#FB6'Y\$!
M2T'L>~9F1^~(I?7Q)~JH4AUP>M_EZW>F%ORV<Q'OQ!~JH(NW4-3M6C2;~>M9A!~6?~YQMDR_/~%GG_!L.QY_~
MO3.IQ=Z=9AP!\$ZQ%Q?3>9-QS!J; YD%YF(R,7L3Z)F!5?K6W< M;9!P/R5"D7E7Y-4-
L27+!~!G1^RW8.0YF9!QKL;)3=MM0IU3!TA?6&/WZ MBI%K_78L!9&8A<1L).8@;1>)>4C,1V(!~N51:~2L+7H:2
Q"XG96ZR78!D4^674NFF^!L8!MSZ>=(!C)P*AOXA!N8K3VF "TV!64ZY8IU!6FW-UTFJ!9!C*G!>4;~)N4C,0V(^\$@M
6"WH!V7Z#1#7@0-D62 Q"XG9 M2.Q!8BX2Y"8C!0"\$%8KBV%9%0D!S"=*UFJVD!R)8%*&+) _!K"B?G9H_~E+
MBP*)6<CUS^!^CS#1@!H(#\$7B7E(S\$=B_0BKX;K!JMZM;VFSW6-IS"EY8&)) M/E67H3~)
(XMGZL107_F!G@CV:9U5A/VB?AXK!~V E!8#5+~.@F@W5'~CF0C4/ MJOE0+4!H!0+~7<9Z%~E4(;
(!~E94,V&@~Y4!+!~9T"~M*~; M!5+~J&+~3=M(C ZW8,B@~98H9H#U5RHYD\$U'ZH%~*~U>~!%6?U= W6JLB*#
!\$LJV!UX6L!Y_ MNN5>CUJRI^X"~@2= M+M?9^U'BU*MP*~<8JEE0S89J#E1SH9H'U7RH%J"~T>D%5W6JC!
!~*AS:NH9H% MU6RHYD U%ZIJY4.V:~@%~JU=(U>LVL UNR%4XM"U>~+MSKH@) (\$VO"&~@Y4
M.8B432T"8Y5+~.@F@W5'~CF0C4/ MJOE0+4!H!6~JNN7&~\$!S@G;H9H%U6RHYD U%ZIJY4.V:~@%~JWOK&JQF_H6
M.V+FI1_BTI(IM-V95_>@_0\$=TH9J#E1SH9H'U7RH%J"~T>B5407)3VVD<69Q.
ME%1GB,=UM")/V5=18U493P=SKC\$~3S)9VGG3;KT UI<~!6.E2SH9H#U5RH
MYD\$U'ZH%~*~U>2%5+W33!DRX3VD&~A94LZ&~!5=@~2-
!O!8#LS%10S89J#E1SH9H'U7RH%J"~T;0DT=VY.\$!~FD=1,29!H!K6- M!5TPRK7E#9?NML;L.VWC6O7.+>~Z!H
!>V4*GY!>Z<~FBYX+\$C(YFJHUE5? M%4:ZO6'2=D\$FJ_S6.)~\$RB3~RX9G;\$TVT#~!~9XD!G4A&Z"~!~7H7U!+ P04 M-"
#!@~719(26.Z3\$~" W!&0 _AL+W=O!Q!Y!SIDSDQDQ!ZD!>0. Y*GE0J=1@!A=AZ\$N&FBIGL@.A+FI
MI&HI&E/5H>X4T~!6A!&4.0.6!\$D"7N;~.R1;~(F8"- (K!O6ZI^KX'+0QI, M@^/!EM4-VH,P2SI:PP!P;
!~1Q@!F!E!U(#23@BBHTF UO5!K;IS^~;@H\$~V MQ&~22_EHC;LR#2(K"#@4;~!FH6?9P YQ;~(B/CU
9C"\$M!~!_9/_HY%3# MC>3?68E~&KP+2 D5!3ENY>\$S#~DL+~!AN79?H!>GR4OHXO\$GXI<\$+BQ1L21_&~<~) (~!~I9
M6)*9XYWHR1;Z*1~)FKR8Y5K5*~!~?Y+V!~S!9H;K6'2T@#~.0MSDH(BLS(%8MS3D<2Z~/B?25T"~T=G!W:~?S9-P2ZH@
M/&FF%~E3M!D:3008'~?5^~I^~4KGPS_G7W(WU/5&ULM5MM;~^V\$OXX MA+LH6J!>BZ1DRVEB8&I=P%NNXO~I>
!~H1!4F;~9E24012?~Q?WX4B^Q+!+\$ MQ!~!S);~LAXIT_~2C&7%T^5B(S^6&8F^~K;IO!IMI-Q=3"9ENF;TQ;~!%BN M?
KDOQ#~1ZE"~L^5.L&15#HF\$^~)YT!DVX?EH<5E_LU!L+HN!S.C;/@!4!K2;
M1/QYS;+B!6!\$1T!2?~+KCR~F"PN=V~F.W3+YV^ZC4\$>3~!N%~UE>~B)~@MU? MC=[AB]@GU8
~1_~'LNC SZ@RY:XH/E<~'ZNKD5==\$GH<~YJX/G)~9?~N.5.7=)R99%IE^~^DINK43A~"W:~?I#~YJ7C)~VL-
M"BJ^M.C^~B!Z;+>~*~7!4A;~K"Z@BW/F_)UJ811P,4#SR M.(/L ?&~\$#; M ?2E9_#;~?Y+SQ"~T
VK3)XWMM>~B1"~+2U\$!~(E&A%5OUH?9^5KYB^?51+~F5
M0OW*U3BYN&5K%7~)DGR%_L&*M4AV&YZBFIR9@U4LQ^A63<_5/F.HN\$=/_S!L MF%" YVOT413WO&&XR=-BR!
U4Z/9T!~DZ^L1#!\$3"8!~W!4?~+~1NB^S^B M-XCGZ~W/G6!G(BE3W554W2!MJOFVLG I=T?LBEYL2Q?
F*K8#QD7W!U#^~MHOQX<~9YGVWVGC/H86;1 MFH!~L_~L5TAZHER~G^IR!%1S>2;B!5~*~&>@U0UA<~R0?JE+
!XFLTFAE+~!+!&)(4>8GL73@153 MJ!7QOMM4;~!L;7B!)~ON95D.R9!)4WZEQ6;~?ZT9#(*)~AP@_A62FFOV!
M@@"V>W:P>V:U^U86Z>=QE4FLD(JO2J_~V@>0N5:F4R7!)5DT.SU#2*~Y#P+A
M.>R^~."^!F)~*~78IW(OJB52W>~5;"E2GLC:GR4!T)@2DRU:0~@YEB;0 & M'RW!QFP(%!+8!G!
!+G5!~53NJA2DXQ+OF!63+DQ)H5@_HP-RY#6!5+\$S&> MZNL\$P(2;5V!
@!V!98*!+~@WTK":WN=I=D!DU8HADE.F!>9D'2%TPURR&4%07 MD A_\$5,<(%2 !U01V6-VXG..A_FZ!
YED3I4&IVR14!8%5L_~*0+!WG% MG+\$E=Q4FEVR14!8%5L_3%UFCZUYZ;F98!O:2WZ!F;\$~JHK;I;M=!*!4%CK5

M50-S8IRMK[17>*.19FSJ1KH VB9B!4O'I(RW6>).VWLIX/UVR14I98E=L M_?ATZ3T.7E-&K,7#R6%RR18Y98M=L? 7#U-4DV%Z4G"LC9J&|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|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{PA=<5;O?Y@.4B91HA(G MJHKJ!3A1M#.UJL*W5I!R@^@^X"*SBJYT:0AD#"#C@T&>F69+(!, F;PBY\$=1 M"UW*J+I9773TCR:0*8!.#PCY- 2:0&8#.#M;.<_%^VBD#F #(.0@D@6+!I7 M<83;\$.@Y@)SS0GX43O5('RM=-,+4_@Z"!6AO>=&N@!A.RI*TV@=7!\$"CP_-RM%T6:P(I!C_FA;R!HU*WDN) H3 :Y;0.?>2I_G@D=I6=*I!&5?IM!RU5NKR;KX7FX\$S2XSX) 9LT2N M=-BZ/I3

-8?20\$3;8T.P6BP^0"X99K>I9!;G

5%V33G\$5=QS1*<5\$SI@Q2Z.K3AL9W8KO MP! A6I<5(H9.K:N;8KY\$ 8G9_.%6%N_6B@JH M.\$9"B9F%_EK>1T>+."IY_9\$0HF9A?)414='MR)!L?N#5T=\$3G M/IA\$O9!""BHAYA(-FS:\$9+ZK\$V3Y!N\$F;=C-? 6HYAPPHM1-!#('DR!)\$@X M";-P2)\$!&D)DF839.K#;H80>29A!LS+RG8TDD@S";-FH6X3Z 4\$VDF8=?. M>*4H@HFLD!;Q2@_LR1=9)N<fJ2C%*ZS.\$L' MEVUO**R3KL X@Y;+DGY39/Q@SH9C(02FS@S!F2C&1@U)V!Z%??!O@(>E MS Z'F.U2N2@D) CG!&F2\$'90<9^? Q.I103.2AIG:/...PT9&#LD.LS?S\$ M'#0ZLE#V.HLT>S!H0LK@>C^SA?9A/OF=8B(+9V\$;.*2.R4!0";B"8B(+Y M'+DG/^3N@6&V1.D)F=V#;0?9\$KDG9W8/QJ39LD#N*9C=@S%IMBR0>PIFH M M(Z,HT#**9B5.S+3N? A**923L&LG%;7_P%I;H^#>9+!W-!O=X)DE%;P M*V?_L +3*2<@GWZ#;T&T*Q>P.W.I-O")- F10+!V"6#IRE.U@J+Y!!"E:Y MX+45YNAS)) Y09>_*/D7SFS+!F%3E6^A.7^R^ ^"BE#R^HZ?(4+ MQTM1EPL;=0 !9L@XS;H-D:NVKL_"L<Z.R.JYW!V?I;Z!_4\$L#!!0 (M/R!>EFS1\$Z= (&TP: >@PQ7W)E;O=VIR:V)O:VLN>&UL+G)E M;^VDUNHT 0AN&K6!P@N*NJH@HSFHV8YR>2T? Q3;6!HDMN!Y2SL#!UB M-A?"C6(XI60'B^Z5R L!#;:K!L_ MC^4T.F.P.;?KWX==6.U>@W!1E75? UQN.T>ZNLF/5PF5XN7MU75O!REJIX! M2!"I(Y@I2"-+Y@PR"/Z@#\$\$Y B"()_*" HY@H(^B9/^@1@AIG#TI+E%) MD#3!FD#KA%PG J!3@IT(Q\$Y(=B(P.R';B4#MA&PG K<3PIT(Y\$Y(=R*P.R'> MB4!O0;V%0&!O85 :YD;H+BW\$.@MJ+<0Z"VHMQ#H+BW\$.@MJ+<0Z"VH MMQ#H+BW\$.BMJ+ <2Z*VHMQ+HK;BW\$NBMDYBOJK01Z^*JM!HK MZJTS>BOJK01Z^*JM!H.ZFT\$>AOJ:01Z&^IM!H.ZFT\$>MOD93>IWH9Z&X'> MAGH;@>Z>AN!WH9Z&X'>AGH;@>X9IF?4.O/HG5'O3!W1KTS@>X9IN?)QTH"O3/JG0GTSJAW)M HHZ90.^>F<"O1WU=@!?'25V KT=I78"O1WU M=@!?'25V KT=I78"O7WRLPFIWHYZ.X'>CGH!@>Z.>CN!WH%Z!X'>@7H'@>Z! M>@>IWH%Z!X'>@7H'@>Z!>@>IWH%Z!X'>?E9D\$#00+V#0.1 O8-!P;U;@CT M.E#OAD#O!O5NOE/O8?P!E.'6I !7&ZW!GU>/EW*['7YM7-R7ZXXU_<5P_-? M4\$L#!0 (/R!>ED2_6)0(0(" O 3_6T-O;G1E;G1?5'EP97=- M+GAM;W.WT!;10&1%>I_6MOG_&1?E>I^OD4**T.OS^F3;7+7QA+4#4!ERJ?;"OK&Q!%"PN M7^="Z!9NSMB8K4RK/%CIC\$O!U2CNK!Z1EMWW^2%S;1G#H_JH(?H67X; MIZQ- Y4+HN;ELLX>OO:OE.5S0EU.SG02K@OIHFRHV)L)TVJ_YI/ 7B@&+N6 M%KG\$Z M.9<IN;G/SM_+G.JL.R!C3ZD.K% ('XH&AE*(8JY_V*KXFEI-GO!I.T M6VK?F5VNJH" 3R/Q.;^7?YXQ?ZW^P#P'2AP3I0XTH4Z;"!H6) ^UB!H M7(+TP5&PO=&AE;64O=&AE;64Q+GAM;#%+ 0(4 Q0 (/R!>EDPHM\$5EPP /M! M 8" @0T(!X;!"IW;W)K&PO=VJR-W-H965T&UL4\$L! A0#% @_(%Z6;F)ITZ" M!;1(!@ ("!6!L 'AL+W=OED/FM&ZQ08 +H< 8"

M@1@!X;"IW;W)K\$" <" &@(\$+P>&PO=VJR:W-H965T&UL4\$L! A0#% @_(%Z67%SK?YC#0%9!@ M ("!(BH
'AL+W=OEE!OOGJHP(+! 8" @;LW!X;"IW;W)K"@ &M@(&<.@>&PO=VJR:W-H965T&UL4\$L! A0# M% @
_(%Z6=>QA(^(!0 KPT!@ ("!LD\$ 'AL+W=O MEE I6C1&P0 \$H* M 9" @7!'!X;"IW;W)K&UL4\$L! A0#% @
_(%Z6>B=3^K1\$0 ^A@ ID ("!PDL M 'AL+W=O&PO=VJR:W-H965TED4[MKC700 +0* 9 M " @;U=
!X;"IW;W)K&UL4\$L! A0#% @ M (%Z6?>K7R @ "P="8 ID ("!06('AL+W=O&UL4\$L! A0#% @_ (%Z6;K68EAP@
M6P4 ID ("!V80 'AL+W=O&PO=VJR:W-H965TEE/ M;L!M 8)<0 9 " @2N. !X;"IW;W)K&UL4\$L! A0#% @
_ (%Z69,8@/4@! 4PH ID M ("!%I4 'AL+W=O&PO=VJR:W-H M965TEE H2&UL4\$L! M A0#% @_ (%Z6;@G(-^J!0 H!
ID ("!/:\$ 'AL M+W=OIP>&PO=VJR:W-H965TED9!00=0@ #!5 9" M@;^! !X;"IW;W)K&UL4\$L! A0#% @_ (%Z
M68!2K?^! @ N0< ID ("!6!4 'AL+W=O&PO=VJR:W-H965TEGB)C.AAP8 +H1 9" @0Z, !X;"IW;W)K M&UL4\$L!
A0#% @_ (%Z64(DX#7U!0 ?@T M ID ("!PI('AL+W=O# &0 @('OV M>&PO=VJR:W-H965TEF!MOK MB, !0(9 "
@;G= !X;"IW;W)K&UL4\$L! A0#% @_ (%Z6?;/3+L!P DAD ID M ("!%\$ 'AL+W=O&PO=VJR:W-H965T MEG2!Y_P@
'&UL4\$L! A0# M% @_ (%Z65#;)XV! @;P4 ID ("!J/8 'AL+W=O M&PO=VJR:W-H965TED;ED!;-@, -! 9 " @<+^ M
!X;"IW;W)K&UL4\$L! A0#% @_ (%Z60MS M^X,> P EP@ ID ("!8P('AL+W=O&PO=VJR:W-H965TEG;-2OW0, -@) 9 "
@;^! 0!X;"IW;W)K&UL4\$L! A0#% @_ (%Z61\$-!;!@ # X ID M ("!TPT! 'AL+W=O&PO M=VJR:W-
H965TEF('BU'%@H M %H 9 " @<4< 0!X;"IW;W)K&UL4\$L! A0#% @_ (%Z6=T?P98! (A8 ID ("! M(BB@' !%1@ &0
@(&Q*P\$ >&PO=VJR:W-H965TEFJ&,"JP, -H 9 M " @1 S 0!X;"IW;W)K&UL4\$L! A0#% M @_ (%Z6>F?H=-/2!0 Q3@
ID ("!C8! 'AL+W=O&PO=VJR:W-H965TEE!;Z/G@(- ' 9 " @;1 0!X M;"IW;W)K&UL4\$L! A0#% @_ (%Z63!DEJK* M P
;!0 ID ("!>4, ! 'AL+W=O&PO=VJR:W-H965TEEICV,S30H !; 9 " @75+ 0!X;"IW;W)K&UL4\$L! A0#% @
_ (%Z6;J L8=X!0 !"(ID M ("!^54! 'AL+W=O&PO=VJR M:W-H965TEF9VJO)20, &P- M 9 " @?> 0!X;"IW;W)K&UL
M4\$L! A0#% @_ (%Z6<82HWWY P ZA0 ID ("!&PO=VJR:W-H965TEDS^!UX:P< (9& 9 M " @=%I
0!X;"IW;W)K&UL4\$L! A0#% @ M (%Z69!7>LP!\$@ H<, ID ("!&PO=VJR:W-H965TEFT MOD0^K@4, (J 9 " @2&7
0!X;"IW;W)K&UL4\$L! A0#% @_ (%Z61>LO9DN P " @T ID M ("!IT! 'AL+W=O&PO=VJR:W-H M965TEE77N9I? (
+8& 9 M " @52E 0!X;"IW;W)K&UL4\$L! M A0#% @_ (%Z643?^%6Z P ! ID ("!Z@! 'AL M+W=O&PO=VJR:W-
H965TEGZ0T!D2P0 <6 9" M@3.0 0!X;"IW;W)K&UL4\$L! A0#% @_ (%Z M65 X=OJ1 @ E 8 ID ("!M;!
'AL+W=O&PO=VJR:W-H965TEGOEQF>JP0 ! <9 " @7^Z 0!X;"IW;W)K M&UL4\$L! A0#% @_ (%Z6:=EO, 7 @ NPD
M ID ("!K;! 'AL+W=O(" WY0% !D* &0 @(&P@ \$ M>&PO=VJR:W-H965TEFF!(UI M8 0) 6 9 " @8;(
0!X;"IW;W)K&UL4\$L! A0#% @_ (%Z6?&NY,*0 '5P ID M ("!UP\$ >&PO=VJR:W-H965T MEE< B&'WP8,) * 9 M "
@6K, 0!X;"IW;W)K&UL4\$L! A0# M% @_ (%Z62'UCNDQ @ MP0 ID ("!@(! 'AL+W=O M&PO=VJR:W-H965TEDU,B
O5 0 -88 9 " @4;M M 0!X;"IW;W)K&UL4\$L! A0#% @_ (%Z6211 MR/) P !I< T (!T?;! 'AL+W-
T>6QE&PO=VJR:V)O;VLN>&UL4\$L! A0#% @_ (%Z66;- \$3IT M @; 3 !H (!4 P! 'AL+UJR96QS+W=O XML 108
Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange
Commission. Data and content created by government employees within the scope of their employment are not
subject to domestic copyright protection. 17 U.S.C. 105. var Show=
function() {Show.LastAR=null;Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var
e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(e.nodeName!='TABLE'){var ref=((window)?
w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e.e.style.display='block';Show.LastAR=e;Show.hideAR=function()
{Show.LastAR.style.display='none';Show.toggleNext=function(a){var
e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var
d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent)
fa.textContent=p+a.textContent.substring(1)}else{a.innerHTMLText=p+a.innerHTMLText.substring(1)}} XML 109
report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */.report
table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; }
.report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; }
.report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; }
.report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height:
150px; overflow: auto; width: 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */.pl a,
.pl a:visited { color: black; text-decoration: none; } /* table */.report { background-color: white; border: 2px solid
#acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr {
border: 1px solid #acf; } /* Top labels */.report th { background-color: #acf; color: black; font-weight: bold; text-
align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial,
san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px;
white-space: normal; /* word-wrap: break-word; */ } .report td.pl a a { cursor: pointer; display: block; width:
200px; overflow: hidden; } .report td.pl div a { width: 200px; } .report td.pl a: hover { background-color: #ffc; } /*
Header rows... */.report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */.report
.re { background-color: #f0f0f0; } /* Even rows... */.report .re, .report .reu { background-color: #def; } .report
.reu td { border-bottom: 1px solid black; } /* Odd rows... */.report .ro, .report .rou { background-color: white; }
.report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px
solid black; } /* styles for footnote marker */.report .fn { white-space: nowrap; } /* styles for numeric types */
.report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; }
.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */.report .text { text-align: left; white-
space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; }
.report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-
style: italic; } .report .outerFootnotes { font-size: 1em; } XML 111 FilingSummary.xml IDEA: XBRL DOCUMENT
3.24.3.html6993381false1570false11 falsefalseR1.htm0000001 - Document -
CoverSheethttp://www.medtronic.com/role/CoverCoverCover1 falsefalseR2.htm9952151 - Statement -
Consolidated Statements of Income
(Unaudited)Sheethttp://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnauditedConsolidated
Statements of Income (Unaudited)Statements2 falsefalseR3.htm9952152 - Statement - Consolidated Statements
of Comprehensive Income
(Unaudited)Sheethttp://www.medtronic.com/role/ConsolidatedStatementsofComprehensiveIncomeUnauditedConse
Statements of Comprehensive Income (Unaudited)Statements3 falsefalseR4.htm9952153 - Statement -
Consolidated Balance Sheets
(Unaudited)Sheethttp://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedConsolidated Balance
Sheets (Unaudited)Statements4 falsefalseR5.htm9952154 - Statement - Consolidated Balance Sheets (Unaudited)
(Parenthetical)Sheethttp://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedParentheticalConsolidat
Balance Sheets (Unaudited) (Parenthetical)Statements5 falsefalseR6.htm9952155 - Statement - Consolidated

Statements of Equity

(Unaudited)Sheet[http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnauditedConsolidatedStatementsofEquity\(Unaudited\)Statements6-falsefalseR7.htm9952156](http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnauditedConsolidatedStatementsofEquity(Unaudited)Statements6-falsefalseR7.htm9952156) – Statement – Consolidated Statements of Equity (Unaudited)

(Parenthetical)Sheet[http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnauditedParentheticalConsolidatedStatementsofEquity\(Unaudited\)\(Parenthetical\)Statements7-falsefalseR8.htm9952157](http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnauditedParentheticalConsolidatedStatementsofEquity(Unaudited)(Parenthetical)Statements7-falsefalseR8.htm9952157) – Statement – Consolidated Statements of Cash Flows

(Unaudited)Sheet[http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnauditedConsolidatedStatementsofCashFlows\(Unaudited\)Statements8-falsefalseR9.htm9952158](http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnauditedConsolidatedStatementsofCashFlows(Unaudited)Statements8-falsefalseR9.htm9952158) – Disclosure – Basis of PresentationSheet

<http://www.medtronic.com/role/BasisofPresentationBasisofPresentationNotes9-falsefalseR10.htm9952159> – Disclosure – New Accounting

PronouncementsSheet<http://www.medtronic.com/role/NewAccountingPronouncementsNewAccountingPronouncementsNotes10-falsefalseR11.htm9952160> – Disclosure –

RevenueSheet<http://www.medtronic.com/role/RevenueRevenueNotes11-falsefalseR12.htm9952161> – Disclosure –

Acquisitions and DispositionsSheet<http://www.medtronic.com/role/AcquisitionsandDispositionsAcquisitionsandDispositionsNotes12-falsefalseR13.htm9952162> – Disclosure – Restructuring and Other

CostsSheet<http://www.medtronic.com/role/RestructuringandOtherCostsRestructuringandOtherCostsNotes13-falsefalseR14.htm9952163> – Disclosure – Financial

InstrumentsSheet<http://www.medtronic.com/role/FinancialInstrumentsFinancialInstrumentsNotes14-falsefalseR15.htm9952164> – Disclosure – Financing

ArrangementsSheet<http://www.medtronic.com/role/FinancingArrangementsFinancingArrangementsNotes15-falsefalseR16.htm9952165> – Disclosure – Derivatives and Currency Exchange Risk

ManagementSheet<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementDerivativesandCurrencyExchangeRiskManagementNotes16-falsefalseR17.htm9952166> – Disclosure –

InventoriesSheet<http://www.medtronic.com/role/InventoriesInventoriesNotes17-falsefalseR18.htm9952167> –

Disclosure – Goodwill and Other Intangible

AssetsSheet<http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsGoodwillandOtherIntangibleAssetsNotes18-falsefalseR19.htm9952168> – Disclosure – Income

TaxesSheet<http://www.medtronic.com/role/IncomeTaxesIncomeTaxesNotes19-falsefalseR20.htm9952169> –

Disclosure – Earnings Per ShareSheet<http://www.medtronic.com/role/EarningsPerShareEarningsPerShareNotes20-falsefalseR21.htm9952170> – Disclosure – Stock-Based

CompensationSheet<http://www.medtronic.com/role/StockBasedCompensationStockBasedCompensationNotes21-falsefalseR22.htm9952171> – Disclosure – Retirement Benefit

PlansSheet<http://www.medtronic.com/role/RetirementBenefitPlansRetirementBenefitPlansNotes22-falsefalseR23.htm9952172> – Disclosure – Accumulated Other Comprehensive

LossSheet<http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossAccumulatedOtherComprehensiveLossNotes23-falsefalseR24.htm9952173> – Disclosure – Commitments and

ContingenciesSheet<http://www.medtronic.com/role/CommitmentsandContingenciesCommitmentsandContingenciesNotes24-falsefalseR25.htm9952174> – Disclosure – Segment and Geographic

InformationSheet<http://www.medtronic.com/role/SegmentandGeographicInformationSegmentandGeographicInformationNotes25-falsefalseR26.htm995410> – Disclosure – Pay vs Performance

DisclosureSheet<http://xbrl.sec.gov/eec/role/PvpDisclosurePayvsPerformanceDisclosureNotes26-falsefalseR27.htm995445> – Disclosure – Insider Trading

ArrangementsSheet<http://xbrl.sec.gov/eec/role/InsiderTradingArrangementsInsiderTradingArrangementsNotes27-falsefalseR28.htm9955511> – Disclosure – Basis of Presentation

(Policies)Sheet[http://www.medtronic.com/role/BasisofPresentationPoliciesBasisofPresentation\(Policies\)Policieshttp://www.medtronic.com/role/NewAccountingPronouncements28-falsefalseR29.htm9955512](http://www.medtronic.com/role/BasisofPresentationPoliciesBasisofPresentation(Policies)Policieshttp://www.medtronic.com/role/NewAccountingPronouncements28-falsefalseR29.htm9955512) –

Disclosure – Revenue (Tables)Sheet[http://www.medtronic.com/role/RevenueTablesRevenue\(Tables\)Tableshttp://www.medtronic.com/role/Revenue29-falsefalseR30.htm9955513](http://www.medtronic.com/role/RevenueTablesRevenue(Tables)Tableshttp://www.medtronic.com/role/Revenue29-falsefalseR30.htm9955513) – Disclosure – Acquisitions

and Dispositions (Tables)Sheet[http://www.medtronic.com/role/AcquisitionsandDispositionsTablesAcquisitionsandDispositions\(Tables\)Tableshttp://www.medtronic.com/role/AcquisitionsandDispositions30-falsefalseR31.htm9955514](http://www.medtronic.com/role/AcquisitionsandDispositionsTablesAcquisitionsandDispositions(Tables)Tableshttp://www.medtronic.com/role/AcquisitionsandDispositions30-falsefalseR31.htm9955514) – Disclosure – Restructuring and Other Costs

(Tables)Sheet[http://www.medtronic.com/role/RestructuringandOtherCostsTablesRestructuringandOtherCosts\(Tables\)Tableshttp://www.medtronic.com/role/RestructuringandOtherCosts31-falsefalseR32.htm9955515](http://www.medtronic.com/role/RestructuringandOtherCostsTablesRestructuringandOtherCosts(Tables)Tableshttp://www.medtronic.com/role/RestructuringandOtherCosts31-falsefalseR32.htm9955515) –

Disclosure – Financial Instruments

(Tables)Sheet[http://www.medtronic.com/role/FinancialInstrumentsTablesFinancialInstruments\(Tables\)Tableshttp://www.medtronic.com/role/FinancialInstruments32-falsefalseR33.htm9955516](http://www.medtronic.com/role/FinancialInstrumentsTablesFinancialInstruments(Tables)Tableshttp://www.medtronic.com/role/FinancialInstruments32-falsefalseR33.htm9955516) – Disclosure –

Financing Arrangements (Tables)Sheet[http://www.medtronic.com/role/FinancingArrangementsTablesFinancingArrangements\(Tables\)Tableshttp://www.medtronic.com/role/FinancingArrangements33-falsefalseR34.htm9955517](http://www.medtronic.com/role/FinancingArrangementsTablesFinancingArrangements(Tables)Tableshttp://www.medtronic.com/role/FinancingArrangements33-falsefalseR34.htm9955517) – Disclosure – Derivatives and Currency Exchange Risk Management

(Tables)Sheet[http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTablesDerivativesandCurrencyExchangeRiskManagement\(Tables\)Tableshttp://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement34-falsefalseR35.htm9955518](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTablesDerivativesandCurrencyExchangeRiskManagement(Tables)Tableshttp://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement34-falsefalseR35.htm9955518) – Disclosure – Inventories

(Tables)Sheet[http://www.medtronic.com/role/InventoriesTablesInventories\(Tables\)Tableshttp://www.medtronic.com/role/Inventories35-falsefalseR36.htm9955519](http://www.medtronic.com/role/InventoriesTablesInventories(Tables)Tableshttp://www.medtronic.com/role/Inventories35-falsefalseR36.htm9955519) – Disclosure – Goodwill

and Other Intangible Assets

(Tables)Sheet[http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTablesGoodwillandOtherIntangibleAssets\(Tables\)Tableshttp://www.medtronic.com/role/GoodwillandOtherIntangibleAssets36-falsefalseR37.htm9955520](http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTablesGoodwillandOtherIntangibleAssets(Tables)Tableshttp://www.medtronic.com/role/GoodwillandOtherIntangibleAssets36-falsefalseR37.htm9955520) – Disclosure – Earnings Per Share

(Tables)Sheet[http://www.medtronic.com/role/EarningsPerShareTablesEarningsPerShare\(Tables\)Tableshttp://www.medtronic.com/role/EarningsPerShare37-falsefalseR38.htm9955521](http://www.medtronic.com/role/EarningsPerShareTablesEarningsPerShare(Tables)Tableshttp://www.medtronic.com/role/EarningsPerShare37-falsefalseR38.htm9955521) – Disclosure –

Stock-Based Compensation (Tables)Sheet[http://www.medtronic.com/role/StockBasedCompensationTablesStockBasedCompensation\(Tables\)Tableshttp://www.medtronic.com/role/StockBasedCompensation38-falsefalseR39.htm9955522](http://www.medtronic.com/role/StockBasedCompensationTablesStockBasedCompensation(Tables)Tableshttp://www.medtronic.com/role/StockBasedCompensation38-falsefalseR39.htm9955522) – Disclosure – Retirement Benefit Plans

(Tables)Sheet[http://www.medtronic.com/role/RetirementBenefitPlansTablesRetirementBenefitPlans\(Tables\)Tableshttp://www.medtronic.com/role/RetirementBenefitPlans39-falsefalseR40.htm9955523](http://www.medtronic.com/role/RetirementBenefitPlansTablesRetirementBenefitPlans(Tables)Tableshttp://www.medtronic.com/role/RetirementBenefitPlans39-falsefalseR40.htm9955523) – Disclosure –

Accumulated Other Comprehensive Loss

~~(Tables)Sheet~~<http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables>~~Accumulated Other Comprehensive Loss (Tables)Tables~~<http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss40>~~falsefalseR41.htm9955524 - Disclosure - Segment and Geographic Information~~
~~(Tables)Sheet~~<http://www.medtronic.com/role/SegmentandGeographicInformationTables>~~Segment and Geographic Information (Tables)Tables~~<http://www.medtronic.com/role/SegmentandGeographicInformation41>~~falsefalseR42.htm9955525 - Disclosure - Revenue - Schedule of Disaggregation of Net Sales by Segment and Division~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivision>~~- Schedule of Disaggregation of Net Sales by Segment and Division (Details)Details~~<http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails>~~42 falsefalseR43.htm9955526 - Disclosure - Revenue - Schedule of Disaggregation of Net Sales by Market Geography~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails>~~- Schedule of Disaggregation of Net Sales by Market Geography (Details)Details~~<http://www.medtronic.com/role/RevenueNarrativeDetailsRevenue-Narrative>~~43 falsefalseR44.htm9955527 - Disclosure - Revenue - Narrative (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RevenueNarrativeDetailsRevenue-Narrative>~~44 falsefalseR45.htm9955528 - Disclosure - Acquisitions and Dispositions - Narrative (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetailsAcquisitions-and-Dispositions>~~- Narrative (Details)Details~~<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationLiabilities>~~45 falsefalseR46.htm9955529 - Disclosure - Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Liabilities~~
~~(Details)Sheet~~<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationLiabilities>~~- Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Liabilities (Details)Details~~<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurements>~~46 falsefalseR47.htm9955530 - Disclosure - Acquisitions and Dispositions - Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability~~
~~(Details)Sheet~~<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurements>~~- Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurements>~~47 falsefalseR48.htm9955531 - Disclosure - Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Receivables~~
~~(Details)Sheet~~<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationReceivables>~~- Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Receivables (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationReceivables>~~48 falsefalseR49.htm9955532 - Disclosure - Restructuring and Other Costs - Narrative (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RestructuringandOtherCostsNarrativeDetailsRestructuring-and-Other-Costs>~~- Restructuring and Other Costs - Narrative (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RestructuringandOtherCostsNarrativeDetailsRestructuring-and-Other-Costs>~~49 falsefalseR50.htm9955533 - Disclosure - Restructuring and Other Costs - Schedule of Restructuring and Related Costs~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCosts>~~- Restructuring and Other Costs - Schedule of Restructuring and Related Costs (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCosts>~~50 falsefalseR51.htm9955534 - Disclosure - Restructuring and Other Costs - Schedule of Activity of Restructuring Costs~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCosts>~~- Restructuring and Other Costs - Schedule of Activity of Restructuring Costs (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCosts>~~51 falsefalseR52.htm9955535 - Disclosure - Financial Instruments - Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecurities>~~- Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecurities>~~52 falsefalseR53.htm9955536 - Disclosure - Financial Instruments - Schedule of Gross Unrealized Losses and Fair Values of Available-for-Sale Securities, Aggregated by Investment Category~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValue>~~- Schedule of Gross Unrealized Losses and Fair Values of Available-for-Sale Securities, Aggregated by Investment Category (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValue>~~53 falsefalseR54.htm9955537 - Disclosure - Financial Instruments - Schedule of Activity Related to Available-for-Sale Securities Portfolio~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofActivityRelatedtoAvailableforSaleSecurities>~~- Schedule of Activity Related to Available-for-Sale Securities Portfolio (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofActivityRelatedtoAvailableforSaleSecurities>~~54 falsefalseR55.htm9955538 - Disclosure - Financial Instruments - Schedule of Available-for-Sale Debt Securities by Contractual Maturity~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMaturity>~~- Schedule of Available-for-Sale Debt Securities by Contractual Maturity (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMaturity>~~55 falsefalseR56.htm9955539 - Disclosure - Financial Instruments - Narrative~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetailsFinancialInstruments-Narrative>~~- Narrative (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetailsFinancialInstruments-Narrative>~~56 falsefalseR57.htm9955540 - Disclosure - Financial Instruments - Schedule of Equity and Other Investments~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestments>~~- Schedule of Equity and Other Investments (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestments>~~57 falsefalseR58.htm9955541 - Disclosure - Financing Arrangements - Narrative~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancingArrangementsNarrativeDetailsFinancingArrangements-Narrative>~~- Narrative (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancingArrangementsNarrativeDetailsFinancingArrangements-Narrative>~~58 falsefalseR59.htm9955542 - Disclosure - Financing Arrangements - Schedule of Debt Obligations~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligations>~~- Schedule of Debt Obligations (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligations>~~59 falsefalseR60.htm9955543 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative~~
~~(Details)Sheet~~<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetailsDerivativesandCurrencyExchangeRiskManagement-Narrative>~~- Narrative (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetailsDerivativesandCurrencyExchangeRiskManagement-Narrative>~~60 falsefalseR61.htm9955544 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Outstanding Instruments~~
~~(Details)Sheet~~<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments>~~- Schedule of Outstanding Instruments (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments>~~61 falsefalseR62.htm9955545 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Gains and Losses on Hedging Instruments~~
~~(Details)Sheet~~<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonHedgingInstruments>~~- Schedule of Gains and Losses on Hedging Instruments (Details)Details~~
~~(Details)Sheet~~<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonHedgingInstruments>~~62 falsefalseR63.htm9955546 - Disclosure - Derivatives and Currency Exchange Risk Management~~

[Schedule of Gains and Losses on Derivatives Not Designated as Hedging Instruments \(Details\)Sheet](#)[Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets \(Details\)Sheet](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandCurrencyExchangeRiskManagement-ScheduleofGainsandLossesonDerivativesNotDesignatedasHedgingInstruments(Details)Details63>falsefalseR64.htm9955547 - falsefalseR65.htm9955548 - falsefalseR66.htm9955549 - falsefalseR67.htm9955550 - falsefalseR68.htm9955551 - falsefalseR69.htm9955552 - falsefalseR70.htm9955553 - falsefalseR71.htm9955554 - falsefalseR72.htm9955555 - falsefalseR73.htm9955556 - falsefalseR74.htm9955557 - falsefalseR75.htm9955558 - falsefalseR76.htm9955559 - falsefalseR77.htm9955560 - falsefalseR78.htm9955561 - falsefalseR79.htm9955562 - falsefalseR80.htm9955563 - falsefalseR81.htm9955564 - falsefalseR82.htm9955565 - falsefalseR83.htm9955566
</p>
<p>
falsefalseR83.htm9955566)[mdt-20241025_cal.xml](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR84.htm9955567)[mdt-20241025_def.xml](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR85.htm9955568)[mdt-20241025_lab.xml](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR86.htm9955569)[mdt-20241025_pre.xml](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR87.htm9955570)[mdt-20241025_g1.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR88.htm9955571)[mdt-20241025_g10.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR89.htm9955572)[mdt-20241025_g11.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR90.htm9955573)[mdt-20241025_g12.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR91.htm9955574)[mdt-20241025_g13.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR92.htm9955575)[mdt-20241025_g2.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR93.htm9955576)[mdt-20241025_g3.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR94.htm9955577)[mdt-20241025_g4.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR95.htm9955578)[mdt-20241025_g5.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR96.htm9955579)[mdt-20241025_g6.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR97.htm9955580)[mdt-20241025_g7.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR98.htm9955581)[mdt-20241025_g8.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR99.htm9955582)[mdt-20241025_g9.jpg](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersandGeographicInformation-ScheduleofNetSalesstoExternalCustomersbyGeography(Details)Details82>falsefalseR100.htm9955583)

<http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/eed/2024trueJSON 114 MetaLinks.json>

IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mdt-20241025.htm": { "nsprefix": "mdt", "nsuri": "http://www.medtronic.com/20241025", "dts": { "inline": { "local": { "mdt-20241025.htm" } }, "schema": { "local": { "mdt-20241025.xsd" }, "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd",

"http://www.xbrl.org/2006/ref/2006-02-27.xsd", "http://www.xbrl.org/irr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/irr/role/net-2009-12-16.xsd", "http://www.xbrl.org/irr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" }, "calculationLink": { "local": { "mdt-20241025_cal.xml" } }, "definitionLink": { "local": { "mdt-20241025_def.xml" } }, "labelLink": { "local": { "mdt-20241025_lab.xml" } }, "presentationLink": { "local": { "mdt-20241025_pre.xml" } } }, "keyStandard": 314, "keyCustom": 24, "axisStandard": 34, "axisCustom": 0, "memberStandard": 70, "memberCustom": 84, "hidden": { "total": 67, "http://fasb.org/us-gaap/2024": 60, "http://xbrl.sec.gov/ecd/2024": 1, "http://xbrl.sec.gov/dei/2024": 6 }, "contextCount": 699, "entityCount": 1, "segmentCount": 157, "elementCount": 769, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1553, "http://xbrl.sec.gov/dei/2024": 90, "http://xbrl.sec.gov/ecd/2024": 11 }, "report": { "R1": { "role": "http://www.medtronic.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R2": { "role": "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited", "longName": "9952151 - Statement - Consolidated Statements of Income (Unaudited)", "shortName": "Consolidated Statements of Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }, "R3": { "role": "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "longName": "9952152 - Statement - Consolidated Statements of Comprehensive Income (Unaudited)", "shortName": "Consolidated Statements of Comprehensive Income (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }, "R4": { "role": "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited", "longName": "9952153 - Statement - Consolidated Balance Sheets (Unaudited)", "shortName": "Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R5": { "role": "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical", "longName": "9952154 - Statement - Consolidated Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R6": { "role": "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited", "longName": "9952155 - Statement - Consolidated Statements of Equity (Unaudited)", "shortName": "Consolidated Statements of Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-60", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-68", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": { "span", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }, "R7": { "role": "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnauditedParenthetical", "longName": "9952156 - Statement - Consolidated Statements of Equity (Unaudited) (Parenthetical)", "shortName": "Consolidated Statements of Equity (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": { "span", "div", "td", "tr", "table", "div", "body", "html" }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name":

"us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": ["span", "div", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R8": { "role": "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited", "longName": "9952157 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }, "R9": { "role": "http://www.medtronic.com/role/BasisOfPresentation", "longName": "9952158 - Disclosure - Basis of Presentation", "shortName": "Basis of Presentation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R10": { "role": "http://www.medtronic.com/role/NewAccountingPronouncements", "longName": "9952159 - Disclosure - New Accounting Pronouncements", "shortName": "New Accounting Pronouncements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R11": { "role": "http://www.medtronic.com/role/Revenue", "longName": "9952160 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R12": { "role": "http://www.medtronic.com/role/AcquisitionsandDispositions", "longName": "9952161 - Disclosure - Acquisitions and Dispositions", "shortName": "Acquisitions and Dispositions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R13": { "role": "http://www.medtronic.com/role/RestructuringandOtherCosts", "longName": "9952162 - Disclosure - Restructuring and Other Costs", "shortName": "Restructuring and Other Costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R14": { "role": "http://www.medtronic.com/role/FinancialInstruments", "longName": "9952163 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R15": { "role": "http://www.medtronic.com/role/FinancingArrangements", "longName": "9952164 - Disclosure - Financing Arrangements", "shortName": "Financing Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R16": { "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement", "longName": "9952165 - Disclosure - Derivatives and Currency Exchange Risk Management", "shortName": "Derivatives and Currency Exchange Risk Management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }

"first": true, "unique": true } }, "R17": { "role": "http://www.medtronic.com/role/Inventories", "longName": "9952166 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets", "longName": "9952167 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.medtronic.com/role/IncomeTaxes", "longName": "9952168 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.medtronic.com/role/EarningsPerShare", "longName": "9952169 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.medtronic.com/role/StockBasedCompensation", "longName": "9952170 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.medtronic.com/role/RetirementBenefitPlans", "longName": "9952171 - Disclosure - Retirement Benefit Plans", "shortName": "Retirement Benefit Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss", "longName": "9952172 - Disclosure - Accumulated Other Comprehensive Loss", "shortName": "Accumulated Other Comprehensive Loss", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.medtronic.com/role/CommitmentsandContingencies", "longName": "9952173 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LossContingencyDisclosures", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.medtronic.com/role/SegmentandGeographicInformation", "longName": "9952174 - Disclosure - Segment and Geographic Information", "shortName": "Segment and Geographic Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:NetIncomeLoss",

"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-23", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.medtronic.com/role/BasisOfPresentationPolicies", "longName": "9955511 - Disclosure - Basis of Presentation (Policies)", "shortName": "Basis of Presentation (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.medtronic.com/role/RevenueTables", "longName": "9955512 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsTables", "longName": "9955513 - Disclosure - Acquisitions and Dispositions (Tables)", "shortName": "Acquisitions and Dispositions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.medtronic.com/role/RestructuringandOtherCostsTables", "longName": "9955514 - Disclosure - Restructuring and Other Costs (Tables)", "shortName": "Restructuring and Other Costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.medtronic.com/role/FinancialInstrumentsTables", "longName": "9955515 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.medtronic.com/role/FinancingArrangementsTables", "longName": "9955516 - Disclosure - Financing Arrangements (Tables)", "shortName": "Financing Arrangements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables", "longName": "9955517 - Disclosure - Derivatives and Currency Exchange Risk Management (Tables)", "shortName": "Derivatives and Currency Exchange Risk Management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.medtronic.com/role/InventoriesTables", "longName": "9955518 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }

true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R36": { "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables", "longName": "9955519 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R37": { "role": "http://www.medtronic.com/role/EarningsPerShareTables", "longName": "9955520 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R38": { "role": "http://www.medtronic.com/role/StockBasedCompensationTables", "longName": "9955521 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R39": { "role": "http://www.medtronic.com/role/RetirementBenefitPlansTables", "longName": "9955522 - Disclosure - Retirement Benefit Plans (Tables)", "shortName": "Retirement Benefit Plans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R40": { "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables", "longName": "9955523 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R41": { "role": "http://www.medtronic.com/role/SegmentandGeographicInformationTables", "longName": "9955524 - Disclosure - Segment and Geographic Information (Tables)", "shortName": "Segment and Geographic Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "R42": { "role": "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails", "longName": "9955525 - Disclosure - Revenue - Schedule of Disaggregation of Net Sales by Segment and Division (Details)", "shortName": "Revenue - Schedule of Disaggregation of Net Sales by Segment and Division (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-94", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }, "R43": { "role": "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails", "longName": "9955526 - Disclosure - Revenue - Schedule of Disaggregation of Net Sales by Market Geography (Details)", "shortName": "Revenue - Schedule of Disaggregation of Net Sales by Market Geography (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-

US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R44": { "role": "http://www.medtronic.com/role/RevenueNarrativeDetails", "longName": "9955527 - Disclosure - Revenue Narrative (Details)", "shortName": "Revenue - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails", "longName": "9955528 - Disclosure - Acquisitions and Dispositions - Narrative (Details)", "shortName": "Acquisitions and Dispositions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-224", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R46": { "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationLiabilities", "longName": "9955529 - Disclosure - Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Liabilities (Details)", "shortName": "Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "mdt:BusinessAcquisitionContingentConsiderationMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R47": { "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationLiabilities", "longName": "9955530 - Disclosure - Acquisitions and Dispositions - Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability (Details)", "shortName": "Acquisitions and Dispositions - Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-229", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R48": { "role": "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationReceivables", "longName": "9955531 - Disclosure - Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Receivables (Details)", "shortName": "Acquisitions and Dispositions - Schedule of Reconciliation of Contingent Consideration Receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-27", "name": "mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-237", "name": "mdt:DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R49": { "role": "http://www.medtronic.com/role/RestructuringandOtherCostsNarrativeDetails", "longName": "9955532 - Disclosure - Restructuring and Other Costs - Narrative (Details)", "shortName": "Restructuring and Other Costs - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": null }, "R50": { "role": "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails", "longName": "9955533 - Disclosure - Restructuring and Other Costs - Schedule of Restructuring and Related Costs (Details)", "shortName": "Restructuring and Other Costs - Schedule of Restructuring and Related Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-246", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6",

"ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }], "R51": { "role": "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails", "longName": "9955534 - Disclosure - Restructuring and Other Costs - Schedule of Activity of Restructuring Costs (Details)", "shortName": "Restructuring and Other Costs - Schedule of Activity of Restructuring Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi", "longName": "9955535 - Disclosure - Financial Instruments - Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification (Details)", "shortName": "Financial Instruments - Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef", "longName": "9955536 - Disclosure - Financial Instruments - Schedule of Gross Unrealized Losses and Fair Values of Available-for-Sale Securities, Aggregated by Investment Category (Details)", "shortName": "Financial Instruments - Schedule of Gross Unrealized Losses and Fair Values of Available-for-Sale Securities, Aggregated by Investment Category (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.medtronic.com/role/FinancialInstrumentsScheduleofActivityRelatedtoAvailableforSaleSecuritiesPortfo", "longName": "9955537 - Disclosure - Financial Instruments - Schedule of Activity Related to Available-for-Sale Securities Portfolio (Details)", "shortName": "Financial Instruments - Schedule of Activity Related to Available-for-Sale Securities Portfolio (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:GainLossOnInvestmentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat", "longName": "9955538 - Disclosure - Financial Instruments - Schedule of Available-for-Sale Debt Securities by Contractual Maturity (Details)", "shortName": "Financial Instruments - Schedule of Available-for-Sale Debt Securities by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails", "longName": "9955539 - Disclosure - Financial Instruments - Narrative (Details)", "shortName": "Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:InterestIncomeExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:InterestIncomeExpenseNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }

"mdt-20241025.htm", "first": true, "unique": true }], "R57": { "role":
"http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails",
"longName": "9955540 - Disclosure - Financial Instruments - Schedule of Equity and Other Investments
(Details)", "shortName": "Financial Instruments - Schedule of Equity and Other Investments (Details)",
"isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57",
"firstAnchor": { "contextRef": "c-289", "name": "us-gAAP:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div",
"mdt:EquitySecuritiesFvNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestmentsTa
"ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true
} }, "uniqueAnchor": { "contextRef": "c-289", "name": "us-gAAP:EquitySecuritiesFvNi", "unitRef": "usd", "xsiNil":
"false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div",
"mdt:EquitySecuritiesFvNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestmentsTa
"ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true
}], "R58": { "role": "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails", "longName":
"9955541 - Disclosure - Financing Arrangements - Narrative (Details)", "shortName": "Financing Arrangements -
Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "58", "firstAnchor": { "contextRef": "c-26", "name": "us-gAAP:DebtCurrent", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] ,
"reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-23", "name":
"us-gAAP:InterestExpenseBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6",
"ancestors": ["span", "div", "ix:continuation", "body", "html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm",
"unique": true } }, "R59": { "role":
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails", "longName":
"9955542 - Disclosure - Financing Arrangements - Schedule of Debt Obligations (Details)", "shortName":
"Financing Arrangements - Schedule of Debt Obligations (Details)", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-26",
"name": "us-gAAP:DebtCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [
"span", "td", "tr", "table", "div", "body", "html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true },
"uniqueAnchor": { "contextRef": "c-26", "name": "us-gAAP:FinanceLeaseLiabilityNoncurrent", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-
gAAP:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html"] , "reportCount": 1, "baseRef": "mdt-
20241025.htm", "unique": true } }, "R60": { "role":
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
"longName": "9955543 - Disclosure - Derivatives and Currency Exchange Risk Management - Narrative (Details)",
"shortName": "Derivatives and Currency Exchange Risk Management - Narrative (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": {
"contextRef": "c-23", "name": "us-gAAP:DerivativeExcludedComponentGainLossRecognizedInEarnings", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body",
"html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "c-23", "name": "us-gAAP:DerivativeExcludedComponentGainLossRecognizedInEarnings", "unitRef":
"usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body",
"html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R61": { "role":
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrum
"longName": "9955544 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of
Outstanding Instruments (Details)", "shortName": "Derivatives and Currency Exchange Risk Management -
Schedule of Outstanding Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-538", "name": "us-
gAAP:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors":
["span", "div", "us-
gAAP:ScheduleOfDerivativeInstrumentsGainLossInStatementOffinancialPerformanceTextBlock",
"ix:continuation", "body", "html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true
} }, "uniqueAnchor": { "contextRef": "c-538", "name": "us-gAAP:DerivativeNotionalAmount", "unitRef": "usd",
"xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "us-
gAAP:ScheduleOfDerivativeInstrumentsGainLossInStatementOffinancialPerformanceTextBlock",
"ix:continuation", "body", "html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true
} }, "R62": { "role":
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH
"longName": "9955545 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Gains
and Losses on Hedging Instruments (Details)", "shortName": "Derivatives and Currency Exchange Risk
Management - Schedule of Gains and Losses on Hedging Instruments (Details)", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": {
"contextRef": "c-23", "name":
"mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAnc
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div",
"ix:continuation", "ix:continuation", "body", "html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm", "first":
true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name":
"mdt:OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAnc
"unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div",
"ix:continuation", "ix:continuation", "body", "html"] , "reportCount": 1, "baseRef": "mdt-20241025.htm", "first":
true, "unique": true } }, "R63": { "role":
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD
"longName": "9955546 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Gains
and Losses on Derivatives Not Designated as Hedging Instruments (Details)", "shortName": "Derivatives and
Currency Exchange Risk Management - Schedule of Gains and Losses on Derivatives Not Designated as Hedging
Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat":
"Details", "order": "63", "firstAnchor": { "contextRef": "c-540", "name": "us-
gAAP:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false",
"lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation",

"ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-540", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFairValueofDerivativeInstrumentsinBalanceSheets(Details)", "longName": "9955547 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets (Details)", "shortName": "Derivatives and Currency Exchange Risk Management - Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:OffsettingAssetsTableTextBlock", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-564", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R65": { "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsandLiabilitiesMeasuredatFairValueonRecurringBasis(Details)", "longName": "9955548 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "shortName": "Derivatives and Currency Exchange Risk Management - Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsandLiabilities(Details)", "longName": "9955549 - Disclosure - Derivatives and Currency Exchange Risk Management - Schedule of Offsetting Assets and Liabilities (Details)", "shortName": "Derivatives and Currency Exchange Risk Management - Schedule of Offsetting Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:OffsettingAssetsTableTextBlock", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:OffsettingAssetsTableTextBlock", "us-gaap:OffsettingLiabilitiesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R67": { "role": "http://www.medtronic.com/role/InventoriesDetails", "longName": "9955550 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwillandOtherIntangibleAssets", "longName": "9955551 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Changes in the Carrying Amount of Goodwill (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Changes in the Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-27", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true } }, "R69": { "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "longName": "9955552 - Disclosure - Goodwill and Other Intangible Assets - Narrative (Details)", "shortName": "Goodwill and Other Intangible Assets - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:GoodwillImpairmentLoss", "span", "div", "ix:continuation", "body", "html"],

"reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula", "longName": "9955553 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Gross Carrying Amount and Accumulated Amortization of Definite and Indefinite Lived Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Gross Carrying Amount and Accumulated Amortization of Definite and Indefinite Lived Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAggregateAmortiza", "longName": "9955554 - Disclosure - Goodwill and Other Intangible Assets - Schedule of Estimated Future Aggregate Amortization Expense (Details)", "shortName": "Goodwill and Other Intangible Assets - Schedule of Estimated Future Aggregate Amortization Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-26", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-26", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.medtronic.com/role/IncomeTaxesDetails", "longName": "9955555 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-70", "name": "us-gaap:IncomeTaxReconciliationTaxContingencies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-70", "name": "us-gaap:IncomeTaxReconciliationTaxContingencies", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "longName": "9955556 - Disclosure - Earnings Per Share - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)", "shortName": "Earnings Per Share - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-603", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails", "longName": "9955557 - Disclosure - Earnings Per Share - Narrative (Details)", "shortName": "Earnings Per Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-615", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["ix:continuation", "span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-615", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["ix:continuation", "span", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.medtronic.com/role/StockBasedCompensationDetails", "longName": "9955558 - Disclosure - Stock-Based Compensation (Details)", "shortName": "Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCo", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-23", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCo", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.medtronic.com/role/RetirementBenefitPlansDetails", "longName": "9955559 - Disclosure - Retirement Benefit Plans (Details)", "shortName": "Retirement Benefit Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-627", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-627", "name": "us-gaap:DefinedBenefitPlanServiceCost", "unitRef": "usd",

"xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }], "R77": { "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherComprehensiveLoss", "longName": "9955560 - Disclosure - Accumulated Other Comprehensive Loss - Schedule of Changes in Accumulated Other Comprehensive Loss (AOCL), Net of Tax, by Component (Details)", "shortName": "Accumulated Other Comprehensive Loss - Schedule of Changes in Accumulated Other Comprehensive Loss (AOCL), Net of Tax, by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-47", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "uniqueAnchor": { "contextRef": "c-645", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }], "R78": { "role": "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails", "longName": "9955561 - Disclosure - Accumulated Other Comprehensive Loss - Narrative (Details)", "shortName": "Accumulated Other Comprehensive Loss - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-640", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "uniqueAnchor": { "contextRef": "c-640", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }], "R79": { "role": "http://www.medtronic.com/role/CommitmentsandContingenciesDetails", "longName": "9955562 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:LossContingencyAccrualProvision", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "uniqueAnchor": { "contextRef": "c-27", "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }], "R80": { "role": "http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails", "longName": "9955563 - Disclosure - Segment and Geographic Information - Narrative (Details)", "shortName": "Segment and Geographic Information - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "unique": true }], "R81": { "role": "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome", "longName": "9955564 - Disclosure - Segment and Geographic Information - Schedule of Segment Operating Profit and Income Before Income Taxes (Details)", "shortName": "Segment and Geographic Information - Schedule of Segment Operating Profit and Income Before Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "uniqueAnchor": { "contextRef": "c-674", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }], "R82": { "role": "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGeography", "longName": "9955565 - Disclosure - Segment and Geographic Information - Schedule of Net Sales to External Customers by Geography (Details)", "shortName": "Segment and Geographic Information - Schedule of Net Sales to External Customers by Geography (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "c-23", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "first": true, "uniqueAnchor": { "contextRef": "c-686", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"] }, "reportCount": 1, "baseRef": "mdt-20241025.htm", "unique": true }], "tag": { "mdt_A0.000SeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A0.000SeniorNotesDue2025Member", "presentation": { "http://www.medtronic.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "0.000% Senior Notes due 2025", "label": "0.000% Senior Notes due 2025 [Member]", "documentation": "0.000% Senior Notes due 2025" } } } } }, "auth_ref": [] }, "mdt_A0.250SeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A0.250SeniorNotesDue2025Member", "presentation": { "http://www.medtronic.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "0.250% Senior Notes due 2025", "label": "0.250% Senior Notes due 2025 [Member]", "documentation": "0.250% Senior Notes due 2025" } } } } }, "auth_ref": [] }, "mdt_A0.375SeniorNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A0.375SeniorNotesDue2028Member", "presentation": {

"http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "0.375% Senior Notes due 2028", "label": "0.375% Senior Notes due 2028 [Member]", "documentation": "0.375% Senior Notes due 2028" } } } }, "auth_ref": [] }, "mdt_A0.750SeniorNotesDue2032Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A0.750SeniorNotesDue2032Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "0.750% Senior Notes due 2032", "label": "0.750% Senior Notes due 2032 [Member]", "documentation": "0.750% Senior Notes due 2032" } } } }, "auth_ref": [] }, "mdt_A1.000SeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A1.000SeniorNotesDue2031Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "1.000% Senior Notes due 2031", "label": "1.000% Senior Notes due 2031 [Member]", "documentation": "1.000% Senior Notes due 2031" } } } }, "auth_ref": [] }, "mdt_A1.125SeniorNotesDue2027Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A1.125SeniorNotesDue2027Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "1.125% Senior Notes due 2027", "label": "1.125% Senior Notes due 2027 [Member]", "documentation": "1.125% Senior Notes due 2027" } } } }, "auth_ref": [] }, "mdt_A1.375SeniorNotesDue2040Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A1.375SeniorNotesDue2040Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "1.375% Senior Notes due 2040", "label": "1.375% Senior Notes due 2040 [Member]", "documentation": "1.375% Senior Notes due 2040" } } } }, "auth_ref": [] }, "mdt_A1.500SeniorNotesDue2039Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A1.500SeniorNotesDue2039Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "1.500% Senior Notes due 2039", "label": "1.500% Senior Notes due 2039 [Member]", "documentation": "1.500% Senior Notes due 2039" } } } }, "auth_ref": [] }, "mdt_A1.625SeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A1.625SeniorNotesDue2031Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "1.625% Senior Notes due 2031", "label": "1.625% Senior Notes due 2031 [Member]", "documentation": "1.625% Senior Notes due 2031" } } } }, "auth_ref": [] }, "mdt_A1.625SeniorNotesDue2050Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A1.625SeniorNotesDue2050Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "1.625% Senior Notes due 2050", "label": "1.625% Senior Notes due 2050 [Member]", "documentation": "1.625% Senior Notes due 2050" } } } }, "auth_ref": [] }, "mdt_A1.750SeniorNotesDue2049Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A1.750SeniorNotesDue2049Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "1.750% Senior Notes due 2049", "label": "1.750% Senior Notes due 2049 [Member]", "documentation": "1.750% Senior Notes due 2049" } } } }, "auth_ref": [] }, "mdt_A2.250SeniorNotesDue2039Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A2.250SeniorNotesDue2039Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "2.250% Senior Notes due 2039", "label": "2.250% Senior Notes due 2039 [Member]", "documentation": "2.250% Senior Notes due 2039" } } } }, "auth_ref": [] }, "mdt_A2.625SeniorNotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A2.625SeniorNotesDue2025Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "2.625% Senior Notes due 2025", "label": "2.625% Senior Notes due 2025 [Member]", "documentation": "2.625% Senior Notes due 2025" } } } }, "auth_ref": [] }, "mdt_A2015CommercialPaperProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A2015CommercialPaperProgramMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper Program", "label": "2015 Commercial Paper Program [Member]", "documentation": "2015 Commercial Paper Program [Member]" } } } }, "auth_ref": [] }, "mdt_A3.000SeniorNotesDue2028Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A3.000SeniorNotesDue2028Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "3.000% Senior Notes due 2028", "label": "3.000% Senior Notes due 2028 [Member]", "documentation": "3.000% Senior Notes due 2028" } } } }, "auth_ref": [] }, "mdt_A3.125SeniorNotesDue2031Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A3.125SeniorNotesDue2031Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "3.125% Senior Notes due 2031", "label": "3.125% Senior Notes due 2031 [Member]", "documentation": "3.125% Senior Notes due 2031" } } } }, "auth_ref": [] }, "mdt_A3.375SeniorNotesDue2034Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A3.375SeniorNotesDue2034Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "3.375% Senior Notes due 2034", "label": "3.375% Senior Notes due 2034 [Member]", "documentation": "3.375% Senior Notes due 2034" } } } }, "auth_ref": [] }, "mdt_A3.650SeniorNotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A3.650SeniorNotesDue2029Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "3.650% Senior Notes due 2029", "label": "3.650% Senior Notes due 2029 [Member]", "documentation": "3.650% Senior Notes due 2029" } } } }, "auth_ref": [] }, "mdt_A3.875SeniorNotesDue2036Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A3.875SeniorNotesDue2036Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "3.875% Senior Notes due 2036", "label": "3.875% Senior Notes due 2036 [Member]", "documentation": "3.875% Senior Notes due 2036" } } } }, "auth_ref": [] }, "mdt_A4.150SeniorNotesDue2043Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A4.150SeniorNotesDue2043Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "4.150% Senior Notes due 2043", "label": "4.150% Senior Notes due 2043 [Member]", "documentation": "4.150% Senior Notes due 2043" } } } }, "auth_ref": [] }, "mdt_A4.150SeniorNotesDue2053Member": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "A4.150SeniorNotesDue2053Member", "presentation": { "http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "4.150% Senior Notes due 2053", "label": "4.150% Senior Notes due 2053 [Member]", "documentation": "4.150% Senior Notes due 2053" } } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-

gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }], "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of
 the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to
 vendors for goods and services received that are used in an entity's business. Used to reflect the current portion
 of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r88",
 "r1065" } }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "AccountsReceivableMember", "presentation": {
 "http://www.medtronic.com/role/RevenueNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accounts
 Receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for
 goods or services that have been delivered or sold." } } }, "auth_ref": { "r981" } }, "us-
 gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent",
 "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Accounts receivable, less allowances and credit losses of \$195 and \$173, respectively", "label":
 "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for
 credit loss, of right to consideration from customer for product sold and service rendered in normal course of
 business, classified as current." } } }, "auth_ref": { "r1221" } }, "us-gaap_AccruedIncomeTaxesCurrent": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-
 gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Accrued income taxes", "label": "Accrued Income Taxes, Current", "documentation": "Carrying
 amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all
 currently due domestic and foreign income tax obligations." } } }, "auth_ref": { "r91", "r154" } }, "us-
 gaap_AccruedIncomeTaxesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "AccruedIncomeTaxesNoncurrent", "crdr": "credit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities",
 "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Accrued income taxes", "label": "Accrued Income Taxes, Noncurrent", "documentation": "Carrying
 amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all
 domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer.
 Alternate captions include income taxes payable, noncurrent." } } }, "auth_ref": { "r96", "r154" } }, "us-
 gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
 "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails",
 "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi
 }, "lang": { "en-us": { "role": { "terseLabel": "Net Change in Retirement Obligations", "label": "Accumulated
 Defined Benefit Plans Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other
 comprehensive (income) loss related to defined benefit plans attributable to the parent." } } }, "auth_ref": { "r5",
 "r6", "r15", "r26", "r114", "r1191", "r1192", "r1193" } }, "us-
 gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
 "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails",
 "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi
 }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gain (Loss) on Cash Flow Hedges", "label": "Accumulated
 Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive
 income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in
 assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": { "r210", "r219", "r220", "r646",
 "r1003", "r1191" } }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": {
 "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails",
 "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi
 }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized (Loss) Gain on Investment Securities", "label": "AOCL
 Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated
 unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized
 in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": { "r206", "r207",
 "r208", "r210", "r219", "r220", "r1191" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": {
 "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails",
 "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi
 }, "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
 "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent
 financial concepts included in a table. These concepts are used to disclose reportable information associated with
 domain members defined in one or many axes to the table." } } }, "auth_ref": { "r218", "r219", "r688", "r690",
 "r691", "r692", "r693", "r694" } }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-
 gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Accumulated other comprehensive loss", "label": "Accumulated Other Comprehensive Income

(Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } }], "auth_ref": ["r25", "r26", "r115", "r195", "r794", "r830", "r833"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails", "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCo", "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r218", "r219", "r688", "r690", "r691", "r692", "r693", "r694"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCo", "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited" }, "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Loss", "terseLabel": "Total Accumulated Other Comprehensive (Loss) Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r3", "r15", "r26", "r657", "r660", "r704", "r826", "r827", "r1191", "r1192", "r1193", "r1207", "r1208", "r1209", "r1210"] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails", "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCo", "lang": { "en-us": { "role": { "terseLabel": "Cumulative Translation Adjustments", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": ["r4", "r15", "r26", "r112", "r113", "r219", "r220", "r690", "r691", "r692", "r693", "r694", "r1191"] }, "mdt_AcuteCareMonitoringMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "AcuteCareMonitoringMember", "presentation": { "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails", "lang": { "en-us": { "role": { "terseLabel": "Acute Care & Monitoring", "label": "Acute Care & Monitoring [Member]", "documentation": "Acute Care & Monitoring" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": ["r1128"] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": ["r101", "r1065", "r1365"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r841", "r1207", "r1208", "r1209", "r1210", "r1297", "r1366"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": ["r1141"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": ["r1141"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": ["r1141"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": ["r1141"] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited", "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": ["r55", "r56", "r568"] }, "us-

gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { } }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r1174" }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r1100", "r1110", "r1120", "r1152" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": { "r1103", "r1113", "r1123", "r1155" }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r1175" }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": { "r1141" }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": { "r1148" }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": { "r1104", "r1114", "r1124", "r1148", "r1156", "r1160", "r1168" }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": { "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails" }, "lang": { "en-us": { "role": { "terseLabel": "All other operating segments", "verboseLabel": "Other", "label": "Other Operating Segment [Member]", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": { "r278", "r297", "r298", "r299", "r300", "r301", "r304", "r1013", "r1014" }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": { "r1166" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/StockBasedCompensationDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/StockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": { "r598", "r602" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/StockBasedCompensationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/StockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Total stock-based compensation expense, net of tax", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": { } }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" }, "lang": { "en-us": { "role": { "terseLabel": "Allowances for accounts receivable", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": { "r196", "r313", "r357" }, "mdt_AmendedAndRestatedRevolvingCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "AmendedAndRestatedRevolvingCreditAgreementMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Amended And Restated Revolving Credit Agreement [Member]", "documentation": "Amended and Restated Revolving Credit Agreement [Member]" } } }, "auth_ref": { } }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when

the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 }, "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited", "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "lang": { "en-us": { "role": { "terseLabel": "Amortization of intangible assets", "verboseLabel": "Amortization expense", "negatedTerseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": ["r11", "r385", "r392", "r1021"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": { "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": ["r271"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": { "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": ["r36"] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": { "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": { "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": ["r36"] }, "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentParentMember", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails", "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Net Investment Hedges", "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, attributable to parent." } } }, "auth_ref": ["r174", "r210", "r219", "r220", "r1191"] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetBackedSecuritiesMember", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailableforSaleDebtSecuritiesbyType": { "lang": { "en-us": { "role": { "terseLabel": "Other asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": ["r1036", "r1066", "r1229", "r1235", "r1236"] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r152", "r168", "r191", "r236", "r275", "r281", "r299", "r303", "r352", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r642", "r647", "r683", "r789", "r874", "r1013", "r1014", "r1065", "r1091", "r1282", "r1283", "r1320"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]", "documentation": null } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit",

"calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": { "r185", "r199", "r236", "r352", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r642", "r647", "r683", "r1065", "r1282", "r1283", "r1320" } }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": { } }, "mdt_AssociatedAndOtherCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "AssociatedAndOtherCostsMember", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Associated and Other Costs", "label": "Associated And Other Costs [Member]", "documentation": "Associated And Other Costs" } } }, "auth_ref": { } }, "us-gaap_AuctionRateSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AuctionRateSecuritiesMember", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailableforSaleDebtSecuritiesbySi": { "lang": { "en-us": { "role": { "terseLabel": "Auction rate securities", "label": "Auction Rate Securities [Member]", "documentation": "Debt instrument securities (for example, but not limited to, corporate or municipal bonds) that typically have long-term nominal maturities for which the interest rate is reset through an auction process." } } }, "auth_ref": { } }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r319" } }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi": { "lang": { "en-us": { "role": { "negatedLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r320" } }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailableforSaleDebtSecuritiesbySi": { "lang": { "en-us": { "role": { "terseLabel": "Unrealized Losses", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss [Abstract]" } } }, "auth_ref": { } }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r1232" } }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Due after five years through ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",

"documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": ["r325", "r786"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": ["r1231"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Due after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": ["r324", "r785"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": ["r1233"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Due after ten years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "auth_ref": ["r326", "r787"] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]", "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat": { "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]", "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat":

{ "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
 "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat
 l, "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale,
 Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Amortized cost of
 investment in debt security measured at fair value with change in fair value recognized in other comprehensive
 income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in
 next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are
 reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r1230" } },
 "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat
 l, "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "weight": 1.0, "order": 4.0 }
 }, "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat
 l, "lang": { "en-us": { "role": { "terseLabel": "Due in one year or less", "label": "Debt Securities, Available-for-Sale,
 Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment
 in debt security measured at fair value with change in fair value recognized in other comprehensive income
 (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal
 year following current fiscal year. Excludes interim and annual periods when interim periods are reported from
 current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r323", "r784" } }, "us-
 gaap_AvailableForSaleSecuritiesGrossRealizedGainLossAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossAbstract",
 "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofActivityRelatedtoAvailableforSaleSecuritiesPortfo
 l, "lang": { "en-us": { "role": { "terseLabel": "Activities Related to Debt Securities Portfolio", "label": "Debt
 Securities, Available-for-Sale, Realized Gain (Loss) [Abstract]" } } }, "auth_ref": { } }, "ecd_AwardExrcPrice": {
 "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice",
 "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": {
 "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": { "r1163" } },
 "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardGrantDateFairValue", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
 l, "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value"
 } } }, "auth_ref": { "r1164" } }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label":
 "Award Timing Disclosures [Line Items]" } } }, "auth_ref": { "r1159" } },
 "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing
 How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": { "r1159" }
 l, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardTmgMethodTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing
 Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": { "r1159" } },
 "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing
 MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": { "r1159" } },
 "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardTmgMnpiDiscTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Timing
 MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": { "r1159" } },
 "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardTmgPredtrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
 l, "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing
 Predetermined [Flag]" } } }, "auth_ref": { "r1159" } }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {
 "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel
 "http://www.medtronic.com/role/StockBasedCompensationDetails",
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Award Type
 [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment
 arrangement." } } }, "auth_ref": { "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581",
 "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595",
 "r596", "r597" } }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Underlying
 Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": { "r1162" } },
 "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardsCloseToMnpiDiscIndName", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Name", "label":
 "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": { "r1161" } },
 "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "AwardsCloseToMnpiDiscTable", "presentation": {
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Awards Close
 in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": {
 "r1160" } }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

["http://xbrl.sec.gov/ecd/2024"](http://xbrl.sec.gov/ecd/2024), "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": {
["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"](http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure) }, "lang": { "en-us": { "role": { "terseLabel": "Awards Close
in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } },
"auth_ref": { "r1160" } }, "us-gaap-BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "BalanceSheetLocationAxis", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"](http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails),
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa),
["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails"](http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails),
["http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi"](http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi),
["http://www.medtronic.com/role/RevenueNarrativeDetails"](http://www.medtronic.com/role/RevenueNarrativeDetails) }, "lang": { "en-us": { "role": { "terseLabel": "Balance
Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation":
"Information by location in statement of financial position where disaggregated cumulative balance has been
reported." } } }, "auth_ref": { "r406", "r1331", "r1332" } }, "us-gaap-BalanceSheetLocationDomain": { "xbrltype":
"domainItemType", "nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "BalanceSheetLocationDomain",
"presentation": { ["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"](http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails),
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa),
["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails"](http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails),
["http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi"](http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi),
["http://www.medtronic.com/role/RevenueNarrativeDetails"](http://www.medtronic.com/role/RevenueNarrativeDetails) }, "lang": { "en-us": { "role": { "terseLabel": "Balance
Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]",
"documentation": "Location in statement of financial position where disaggregated cumulative balance has been
reported." } } }, "auth_ref": { "r75", "r78", "r406", "r1331", "r1332" } }, "us-gaap-BasisOfAccounting": {
"xbrltype": "textBlockItemType", "nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "BasisOfAccounting",
"presentation": { ["http://www.medtronic.com/role/BasisofPresentation"](http://www.medtronic.com/role/BasisofPresentation) }, "lang": { "en-us": { "role": {
"terseLabel": "Basis of Presentation", "label": "Basis of Accounting [Text Block]", "documentation": "The entire
disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for
example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } },
"auth_ref": { "r130" } }, "us-gaap-BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": {
["http://www.medtronic.com/role/BasisofPresentationPolicies"](http://www.medtronic.com/role/BasisofPresentationPolicies) }, "lang": { "en-us": { "role": { "terseLabel": "Basis
of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of
accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for
example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } },
"auth_ref": { } }, "mdt-BrettWallMember": { "xbrltype": "domainItemType", "nsuri":
["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname": "BrettWallMember", "presentation": {
["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"](http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements) }, "lang": { "en-us": { "role": { "label": "Brett Wall
[Member]", "documentation": "Brett Wall" } } }, "auth_ref": { } }, "us-gaap-BusinessAcquisitionAcquireeDomain":
{ "xbrltype": "domainItemType", "nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname":
"BusinessAcquisitionAcquireeDomain", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"](http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails) }, "lang": { "en-us": { "role": {
"terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]",
"documentation": "Identification of the acquiree in a material business combination (or series of individually
immaterial business combinations), which may include the name or other type of identification of the acquiree."
} } }, "auth_ref": { "r386", "r387", "r388", "r389", "r390", "r635", "r1040", "r1043" } }, "us-
gaap-BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024),
"localname": "BusinessAcquisitionAxis", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"](http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails) }, "lang": { "en-us": { "role": {
"terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information
by business combination or series of individually immaterial business combinations." } } }, "auth_ref": { "r58",
"r59", "r386", "r387", "r388", "r389", "r390", "r635", "r1040", "r1043" } },
"mdt-BusinessAcquisitionContingentConsiderationAtFairValueRollForward": { "xbrltype": "stringItemType",
"nsuri": ["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname":
"BusinessAcquisitionContingentConsiderationAtFairValueRollForward", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationI"](http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationI),
"lang": { "en-us": { "role": { "terseLabel": "Reconciliation of Beginning and Ending Balances of Contingent
Milestone Payments [Roll Forward]", "label": "Business Acquisition, Contingent Consideration, at Fair Value [Roll
Forward]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": { } },
"mdt-BusinessAcquisitionContingentConsiderationMilestonePayment": { "xbrltype": "monetaryItemType",
"nsuri": ["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname":
"BusinessAcquisitionContingentConsiderationMilestonePayment", "crdr": "debit", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationI"](http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationI),
"lang": { "en-us": { "role": { "negatedLabel": "Payments", "label": "Business Acquisition, Contingent
Consideration, Milestone Payment", "documentation": "Contingent milestone payments in business acquisition
transactions." } } }, "auth_ref": { } }, "mdt-BusinessAcquisitionContingentConsiderationRollForward": {
"xbrltype": "stringItemType", "nsuri": ["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname":
"BusinessAcquisitionContingentConsiderationRollForward", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationI"](http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationI),
"lang": { "en-us": { "role": { "terseLabel": "Beginning and Ending Balances of Contingent Payments [Roll
Forward]", "label": "Business Acquisition, Contingent Consideration [Roll Forward]", "documentation": "Business
Acquisition, Contingent Consideration" } } }, "auth_ref": { } }, "us-gaap-BusinessAcquisitionLineItems": {
"xbrltype": "stringItemType", "nsuri": ["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname":
"BusinessAcquisitionLineItems", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"](http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails) }, "lang": { "en-us": { "role": {
"verboseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to
disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": { "r635" } }, "mdt-BusinessAcquisitionPriceContingentConsideration": { "xbrltype":
"monetaryItemType", "nsuri": ["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname":

"BusinessAcquisitionPriceContingentConsideration", "crdr": "credit", "presentation": [
 "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationL",
], "lang": { "en-us": { "role": { "terseLabel": "Purchase price contingent consideration", "label": "Business Acquisition, Price Contingent Consideration", "documentation": "Business Acquisition, Price Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAcquisitionRelatedCosts", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome",], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition and divestiture-related items", "label": "Business Combination, Acquisition Related Costs", "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities." } } }, "auth_ref": ["r57"] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Business Combination and Asset Acquisition [Abstract]", "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "presentation": ["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",], "lang": { "en-us": { "role": { "terseLabel": "Total consideration for the transaction, net of cash acquired", "label": "Business Combination, Consideration Transferred", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": ["r0", "r1", "r14"] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability", "crdr": "debit", "presentation": ["http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationL",], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": ["r638", "r1202"] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, fair value", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r63", "r144", "r637", "r671", "r672", "r673"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": ["http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingent",], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, significant unobservable inputs", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": ["r671", "r672", "r673"] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": ["http://www.medtronic.com/role/AcquisitionsandDispositions",], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions and Dispositions", "label": "Business Combination Disclosure [Text Block]", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": ["r143", "r636"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangible": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAsset", "crdr": "debit", "presentation": ["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",], "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date." } } }, "auth_ref": ["r61"] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "crdr": "debit", "presentation": ["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date." } } }, "auth_ref": ["r60", "r61"] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": [

["http://www.medtronic.com/role/CommitmentsandContingenciesDetails"](http://www.medtronic.com/role/CommitmentsandContingenciesDetails)], "lang": { "en-us": { "role": { "terseLabel": "California", "label": "CALIFORNIA" } } }, "auth_ref": [] },
 "mdt_CIFSA Senior Notes 2007 Due 2038 6.550 Percent [Member]": { "xbrltype": "domainItemType", "nsuri":
["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname": "CIFSA Senior Notes 2007 Due 2038 6.550 Percent Member",
 "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "6.550 percent thirty-year 2007 CIFSA senior notes", "label": "CIFSA Senior Notes 2007 Due 2038, 6.550 Percent [Member]", "documentation": "CIFSA Senior Notes 2007 Due 2038, 6.550 Percent" } } }, "auth_ref": [] }, "mdt_Cardiac Rhythm And Heart Failure Division Member": { "xbrltype":
 "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "Cardiac Rhythm And Heart Failure Division Member", "presentation": {
["http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"](http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails)],
 "lang": { "en-us": { "role": { "terseLabel": "Cardiac Rhythm & Heart Failure", "label": "Cardiac Rhythm And Heart Failure Division [Member]", "documentation": "Cardiac Rhythm and Heart Failure Division [Member]" } } },
 "auth_ref": [] }, "mdt_Cardiovascular Member": { "xbrltype": "domainItemType", "nsuri":
["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname": "Cardiovascular Member", "presentation": {
["http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwillandOtherIntangibleAssets"](http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwillandOtherIntangibleAssets),
["http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails"](http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails),
["http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome"](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome)],
 "lang": { "en-us": { "role": { "terseLabel": "Cardiovascular", "label": "Cardiovascular [Member]", "documentation": "Cardiovascular" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {
["http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"](http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited): { "parentTag": "us-gaap_AssetsCurrent",
 "weight": 1.0, "order": 1.0 } }, "presentation": {
["http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"](http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited)], "lang": { "en-us": { "role": {
 "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value",
 "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r32", "r187",
 "r995"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": {
["http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited"](http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited)], "lang": { "en-us": { "role": {
 "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r32",
 "r127", "r234"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited":
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
["http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited"](http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited)], "lang": { "en-us": { "role": {
 "totalLabel": "Net change in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r2", "r127"] }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
 "crdr": "credit", "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails)], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedge unrealized gains to be reclassified over the next 12 months", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months", "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months." } } }, "auth_ref": ["r86"] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails),
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments)], "lang": { "en-us": { "role": { "terseLabel": "Cash flow hedge", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": ["r73"] }, "mdt_CentralizedDistributionCosts": { "xbrltype": "monetaryItemType", "nsuri":
["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname": "CentralizedDistributionCosts", "crdr": "debit",
 "calculation": {
["http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome"](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome)

{ "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
 "weight": -1.0, "order": 13.0 } }, "presentation": {
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome",
 "lang": { "en-us": { "role": { "terseLabel": "Centralized distribution costs", "label": "Centralized Distribution Costs", "documentation": "Centralized Distribution Costs" } } }, "auth_ref": [] },
 "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" },
 "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r1139"] },
 "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
 "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r1136"] },
 "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r1134"] },
 "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": {
 "http://www.medtronic.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] },
 "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt",
 "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r1140"] },
 "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r1140"] },
 "mdt_ColibriHeartValveLLCColibriMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "ColibriHeartValveLLCColibriMember", "presentation": {
 "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Colibri", "label": "Colibri Heart Valve LLC (Colibri) [Member]", "documentation": "Colibri Heart Valve LLC (Colibri)" } } }, "auth_ref": [] },
 "mdt_CommercialPaperMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "CommercialPaperMaximumBorrowingCapacity", "crdr": "credit", "presentation": {
 "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commercial paper, maximum borrowing amount", "label": "Commercial Paper, Maximum Borrowing Capacity", "documentation": "Commercial Paper, Maximum Borrowing Capacity" } } }, "auth_ref": [] },
 "us-gaap-CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": {
 "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": ["r137", "r431", "r1083", "r1084", "r1085", "r1088"] },
 "us-gaap-CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies",
 "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, { "parentTag": "us-gaap-LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 16)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r97", "r156", "r792", "r861"] },
 "us-gaap-CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] },
 "us-gaap-CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "CommonStockDividendsPerShareDeclared", "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnauditedParenthetical" }, "lang": { "en-us": { "role": { "verboseLabel": "Dividends to shareholders (in dollars per share)", "label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." } } }, "auth_ref": ["r140"] },
 "us-gaap-CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember",
 "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r1079", "r1080", "r1081", "r1083", "r1084", "r1085", "r1088", "r1207", "r1208", "r1210", "r1297", "r1363", "r1366"] },
 "us-gaap-CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares, par value (usd per share)", "label": "Common Stock, Par or Stated Value Per

Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r100" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares authorized (shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r100", "r862" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares issued (shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r100" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnauditedParenthetical" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares outstanding (shares)", "periodStartLabel": "Beginning balance (shares)", "periodEndLabel": "Ending balance (shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r16", "r100", "r862", "r880", "r1366", "r1367" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary shares", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r100", "r793", "r1065" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": { "r1145" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r1144" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": { "r1146" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r1143" } }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": { } }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income attributable to Medtronic", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r27", "r215", "r217", "r224", "r781", "r805", "r807" } }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r9", "r67", "r71", "r215", "r217", "r223", "r780", "r805", "r806" } }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit",
 "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
 "parentTag": "us-gaap-ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "lang": { "en-us":
 { "role": { "totalLabel": "Comprehensive income including noncontrolling interests", "label": "Comprehensive
 Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount
 after tax of increase (decrease) in equity from transactions and other events and circumstances from net income
 and other comprehensive income. Excludes changes in equity resulting from investments by owners and
 distributions to owners." } } }, "auth_ref": { "r71", "r145", "r215", "r217", "r222", "r779", "r805" } }, "us-
 gaap-ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": {
 "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLoss", "lang": { "en-us": { "role": {
 "terseLabel": "Accumulated Other Comprehensive Loss", "label": "Comprehensive Income (Loss) Note [Text
 Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to,
 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income,
 including reclassification adjustments, 2) the reclassification adjustments for each classification of other
 comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }
 } }, "auth_ref": { "r111", "r221", "r778", "r803" } }, "srt-ConsolidationEliminationsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationEliminationsMember",
 "presentation": {
 "http://www.medtronic.com/role/RevenueScheduleOfDisaggregationOfNetSalesbyMarketGeographyDetails",
 "http://www.medtronic.com/role/RevenueScheduleOfDisaggregationOfNetSalesbySegmentandDivisionDetails",
 "lang": { "en-us": { "role": { "terseLabel": "Other Adjustments", "label": "Consolidation, Eliminations [Member]" } } }
 } }, "auth_ref": { } }, "srt-ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": {
 "http://www.medtronic.com/role/RevenueScheduleOfDisaggregationOfNetSalesbyMarketGeographyDetails",
 "http://www.medtronic.com/role/RevenueScheduleOfDisaggregationOfNetSalesbySegmentandDivisionDetails",
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleOfSegmentOperatingProfitandIncome",
 "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]" } } }
 } }, "auth_ref": { "r166", "r238", "r275", "r283", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r305",
 "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r1013", "r1014", "r1282", "r1283" } },
 "srt-ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
 "localname": "ConsolidationItemsDomain", "presentation": {
 "http://www.medtronic.com/role/RevenueScheduleOfDisaggregationOfNetSalesbyMarketGeographyDetails",
 "http://www.medtronic.com/role/RevenueScheduleOfDisaggregationOfNetSalesbySegmentandDivisionDetails",
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleOfSegmentOperatingProfitandIncome",
 "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items
 [Domain]" } } } }, "auth_ref": { "r166", "r238", "r275", "r283", "r297", "r298", "r299", "r300", "r301", "r303",
 "r304", "r305", "r432", "r433", "r434", "r435", "r437", "r438", "r439", "r440", "r441", "r1013", "r1014", "r1282",
 "r1283" } }, "us-gaap-ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": {
 "http://www.medtronic.com/role/BasisOfPresentationPolicies", "lang": { "en-us": { "role": { "terseLabel":
 "Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting
 policy regarding (1) the principles it follows in consolidating or combining the separate financial statements,
 including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the
 consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a
 partnership interest or other means of exerting influence) in other entities, for example consolidation or use of
 the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for
 intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in
 consolidation for issuances of stock by a subsidiary." } } } }, "auth_ref": { "r68", "r1004" } }, "us-
 gaap-ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleOfLevel3FairValueMeasurementsOfContinger",
 "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration by Type [Axis]", "label": "Contingent
 Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } } },
 "auth_ref": { } }, "us-gaap-ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleOfLevel3FairValueMeasurementsOfContinger",
 "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent
 Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } } },
 "auth_ref": { } }, "us-gaap-ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": {
 "http://www.medtronic.com/role/RevenueNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Deferred
 revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good
 or service to customer for which consideration has been received or is receivable." } } } }, "auth_ref": { "r472",
 "r473", "r484" } }, "us-gaap-ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": {
 "http://www.medtronic.com/role/RevenueNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Revenue
 recognized that was previously included in deferred revenue", "label": "Contract with Customer, Liability,
 Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance
 of obligation to transfer good or service to customer for which consideration from customer has been received or
 is due." } } } }, "auth_ref": { "r485" } }, "us-gaap-ContractWithCustomerRefundLiabilityCurrent": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ContractWithCustomerRefundLiabilityCurrent", "crdr": "credit", "presentation": {
 "http://www.medtronic.com/role/RevenueNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Rebate
 obligations", "label": "Contract with Customer, Refund Liability, Current", "documentation": "Amount of liability
 for consideration received or receivable from customer which is not included in transaction price, when

consideration is expected to be refunded to customer, classified as current." } } }, "auth_ref": ["r1287"] },
"mdt_CoronaryAndPeripheralVascularDivisionMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.medtronic.com/20241025", "localname": "CoronaryAndPeripheralVascularDivisionMember",
"presentation": {
"http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"],
"lang": { "en-us": { "role": { "terseLabel": "Coronary & Peripheral Vascular", "label": "Coronary And Peripheral
Vascular Division [Member]", "documentation": "Aortic, Peripheral and Venous Division [Member]" } } },
"auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": {
"http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef
"http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
"lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities
[Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other
entities with a promise of repayment." } } }, "auth_ref": ["r1036", "r1038", "r1053", "r1066", "r1078", "r1360"]
}, "mdt_CorporateOverhead": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025",
"localname": "CorporateOverhead", "crdr": "debit", "calculation": {
"http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom
"parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": -1.0, "order": 9.0 } }, "presentation": {
"http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom
"lang": { "en-us": { "role": { "negatedTerseLabel": "Corporate", "label": "Corporate Overhead",
"documentation": "Corporate overhead expenses" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-
gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited" }, "lang": { "en-us": { "role": {
"terseLabel": "Cost of products sold, excluding amortization of intangible assets", "label": "Cost of Goods and
Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered
by an entity during the reporting period. This excludes costs incurred during the reporting period related to
financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r118", "r119", "r740"] },
"us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CostOfSalesMember", "presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH
"http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails",
"http://www.medtronic.com/role/StockBasedCompensationDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Cost of products sold", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption
encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpensesAbstract",
"presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited" }, "lang": { "en-
us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] },
"dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CountryRegion", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": {
"role": { "terseLabel": "Country Region", "label": "Country Region", "documentation": "Region code of country" }
} }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover page.", "label": "Cover
[Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] },
"mdt_CranialAndSpinalTechnologiesDivisionMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.medtronic.com/20241025", "localname": "CranialAndSpinalTechnologiesDivisionMember",
"presentation": {
"http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"],
"lang": { "en-us": { "role": { "terseLabel": "Cranial & Spinal Technologies", "label": "Cranial And Spinal
Technologies Division [Member]", "documentation": "Cranial And Spinal Technologies Division" } } }, "auth_ref":
[] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CreditFacilityAxis", "presentation": {
"http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of
credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each
borrowing." } } }, "auth_ref": ["r431", "r1280"] }, "us-gaap_CreditFacilityDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation":
{ "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit
facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } }
} }, "auth_ref": ["r431", "r1280", "r1281"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype":
"gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate",
"presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Current
Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year
in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelatedIntangibleAssetsMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CustomerRelatedIntangibleAssetsMember", "presentation": {
"http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulat
"lang": { "en-us": { "role": { "terseLabel": "Customer-related", "label": "Customer-Related Intangible Assets
[Member]", "documentation": "Customer-related asset, including, but not limited to, customer lists, and
noncontractual customer relationships." } } }, "auth_ref": ["r21", "r1259", "r1260", "r1261", "r1262", "r1264",
"r1266", "r1269", "r1270"] }, "us-gaap_DebtCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DebtCurrent", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-

gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }], "presentation": {
 "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited",
 "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
 "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Current debt obligations", "label": "Debt, Current", "documentation": "Amount of debt and
 lease obligation, classified as current." } } }, "auth_ref": { "r193" }, "us-gaap_DebtDisclosureAbstract": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract",
 "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }
 }, "auth_ref": { } }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": {
 "http://www.medtronic.com/role/FinancingArrangements", "lang": { "en-us": { "role": { "terseLabel": "Financing
 Arrangements", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information
 about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of
 credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements
 and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a
 classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of
 assets and activities, whether or not in compliance with debt covenants, and other matters important to users of
 the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } } },
 "auth_ref": { "r136", "r235", "r401", "r402", "r403", "r404", "r405", "r430", "r431", "r443", "r449", "r450", "r451",
 "r452", "r453", "r454", "r459", "r466", "r467", "r469", "r696" }, "us-gaap_DebtInstrumentAxis": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": {
 "http://www.medtronic.com/role/Cover",
 "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
 "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information
 by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": { "r23",
 "r90", "r91", "r153", "r155", "r238", "r444", "r445", "r446", "r447", "r448", "r450", "r455", "r456", "r457", "r458",
 "r460", "r461", "r462", "r463", "r464", "r465", "r1023", "r1024", "r1025", "r1026", "r1027", "r1064", "r1205",
 "r1272", "r1273", "r1274", "r1318", "r1319" }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr":
 "credit", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Principal value", "label": "Debt Instrument, Face Amount", "documentation":
 "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": { "r444", "r696", "r697", "r1024",
 "r1025", "r1064" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage",
 "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Stated interest rate", "label": "Debt Instrument, Interest Rate, Stated
 Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } } },
 "auth_ref": { "r93", "r445" }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": {
 "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation":
 "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
 information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {
 "r238", "r444", "r445", "r446", "r447", "r448", "r450", "r455", "r456", "r457", "r458", "r460", "r461", "r462",
 "r463", "r464", "r465", "r468", "r1023", "r1024", "r1025", "r1026", "r1027", "r1064", "r1205", "r1318", "r1319" }
 }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": {
 "http://www.medtronic.com/role/Cover",
 "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
 "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]",
 "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other
 debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": { "r23", "r238",
 "r444", "r445", "r446", "r447", "r448", "r450", "r455", "r456", "r457", "r458", "r460", "r461", "r462", "r463",
 "r464", "r465", "r1023", "r1024", "r1025", "r1026", "r1027", "r1064", "r1205", "r1272", "r1273", "r1274", "r1318",
 "r1319" }, "mdt_DebtInstrumentNumberOfTranches": { "xbrltype": "integerItemType", "nsuri":
 "http://www.medtronic.com/20241025", "localname": "DebtInstrumentNumberOfTranches", "presentation": {
 "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Number of tranches", "label": "Debt Instrument, Number of Tranches", "documentation": "Debt
 Instrument, Number of Tranches" } } }, "auth_ref": { } }, "us-gaap_DebtInstrumentTable": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": {
 "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt
 Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or
 arrangement." } } }, "auth_ref": { "r23", "r46", "r47", "r87", "r138", "r139", "r238", "r444", "r445", "r446", "r447",
 "r448", "r450", "r455", "r456", "r457", "r458", "r460", "r461", "r462", "r463", "r464", "r465", "r468", "r1023",
 "r1024", "r1025", "r1026", "r1027", "r1064", "r1205", "r1318", "r1319" }, "us-gaap_DebtInstrumentTerm": {
 "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm",
 "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
 "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
 "role": { "terseLabel": "Term of debt instrument", "label": "Debt Instrument, Term", "documentation": "Period of
 time between issuance and maturity of debt instrument, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D'
 represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { } }, "us-
 gaap_DebtInstrumentUnamortizedDiscountPremiumNet": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumNet", "crdr": "debit",
 "calculation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": {
 "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": -1.0, "order": 1.0 } } },

"presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": {
 "lang": { "en-us": { "role": { "negatedLabel": "Debt discount, net", "label": "Debt Instrument, Unamortized
 Discount (Premium), Net", "documentation": "Amount, after accumulated amortization, of debt discount
 (premium)." } } }, "auth_ref": { "r1285", "r1317", "r1318", "r1319" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss", "crdr":
 "debit", "calculation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 f "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 l, "lang": { "en-us": { "role": { "totalLabel": "Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost,
 Excluding Accrued Interest, after Allowance for Credit Loss", "documentation": "Amortized cost excluding
 accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with
 change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r1244" }
 }, "us-
 gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss", "crdr":
 "debit", "calculation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat
 f "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat
 l, "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Amortized Cost,
 Excluding Accrued Interest, before Allowance for Credit Loss", "documentation": "Amortized cost excluding
 accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with
 change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r364" }
 }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit",
 "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef
 l, "lang": { "en-us": { "role": { "terseLabel": "More than 12 months", "label": "Debt Securities, Available-for-Sale,
 Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt
 security measured at fair value with change in fair value recognized in other comprehensive income (available-
 for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss.
 Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r170", "r366", "r1019" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr":
 "debit", "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef
 l, "lang": { "en-us": { "role": { "negatedLabel": "More than 12 months", "label": "Debt Securities, Available-for-
 Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount
 of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value
 recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12
 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." }
 } }, "auth_ref": { "r170", "r366" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months", "crdr": "debit",
 "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef
 l, "lang": { "en-us": { "role": { "terseLabel": "Less than 12 months", "label": "Debt Securities, Available-for-Sale,
 Continuous Unrealized Loss Position, Less than 12 Months", "documentation": "Amount of investment in debt
 security measured at fair value with change in fair value recognized in other comprehensive income (available-
 for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss.
 Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r170", "r366", "r1019" } }, "us-
 gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss", "crdr":
 "debit", "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef
 l, "lang": { "en-us": { "role": { "negatedLabel": "Less than 12 months", "label": "Debt Securities, Available-for-
 Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss", "documentation": "Amount
 of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value
 recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less
 than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } }
 } }, "auth_ref": { "r170", "r366" } }, "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DebtSecuritiesAvailableForSaleExcludingAccruedInterest", "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 f "parentTag": "us-
 gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
 "weight": 1.0, "order": 2.0 },
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat
 f "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofAvailableforSaleDebtSecuritiesbyContractualMat

"<http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySignificantInvestmentCategoryandRelatedConsolidatedBalanceSheetClassification>", "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest", "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r1244" } }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "crdr": "credit", "presentation": { "<http://www.medtronic.com/role/FinancialInstrumentsScheduleofActivityRelatedtoAvailableforSaleSecuritiesPortfolios>", "lang": { "en-us": { "role": { "terseLabel": "Gross realized gains", "label": "Debt Securities, Available-for-Sale, Realized Gain", "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r345" } }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DebtSecuritiesAvailableForSaleRealizedLoss", "crdr": "debit", "presentation": { "<http://www.medtronic.com/role/FinancialInstrumentsScheduleofActivityRelatedtoAvailableforSaleSecuritiesPortfolios>", "lang": { "en-us": { "role": { "negatedLabel": "Gross realized losses", "label": "Debt Securities, Available-for-Sale, Realized Loss", "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r345" } }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": { "<http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailableforSaleSecurities>", "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326" } }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": { "<http://www.medtronic.com/role/FinancialInstrumentsTables>", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments in Available-for-Sale Debt Securities by Significant Investment Category and Related Consolidated Balance Sheet Classification", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": { "r1223", "r1224", "r1225", "r1226", "r1227", "r1228", "r1229", "r1230", "r1231", "r1232", "r1233", "r1237" } }, "mdt_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "<http://www.medtronic.com/20241025>", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueAbstract", "presentation": { "<http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailableforSaleSecurities>", "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Abstract]", "documentation": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value" } } }, "auth_ref": { } }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": { "<http://www.medtronic.com/role/FinancialInstrumentsTables>", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gross Unrealized Losses and Fair Values of Available-for-Sale Securities, Aggregated by Investment Category", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": { "r169", "r1019", "r1245" } }, "us-gaap_DeferredCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DeferredCompensationLiabilityCurrent", "crdr": "credit", "calculation": { "<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited>", "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited>", "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation", "label": "Deferred Compensation Liability, Current", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": { "r48", "r141" } }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "<http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails>", "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": -1.0, "order": 2.0 } }, "presentation": { "<http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails>", "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred financing costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": { "r1285", "r1317", "r1318", "r1319" } }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited>", "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": { "<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited>", "lang": { "en-us": { "role": { "terseLabel": "Tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": { "r606", "r607" } }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": {

"http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": { "r606", "r607", "r790" } }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": { "r129" } }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Amortization of net actuarial loss", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan." } } }, "auth_ref": { "r490", "r528", "r553", "r1038", "r1039" } }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Amortization of prior service cost", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan." } } }, "auth_ref": { "r490", "r529", "r554", "r1038", "r1039" } }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanDisclosureLineItems", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Defined Benefit Plan Disclosure [Line Items]", "label": "Defined Benefit Plan Disclosure [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Expected return on plan assets", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan." } } }, "auth_ref": { "r490", "r527", "r552", "r1038", "r1039" } }, "us-gaap_DefinedBenefitPlanInterestCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanInterestCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest cost", "label": "Defined Benefit Plan, Interest Cost", "documentation": "Amount of cost recognized for passage of time related to defined benefit plan." } } }, "auth_ref": { "r490", "r494", "r526", "r551", "r1038", "r1039" } }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "totalLabel": "Net periodic (credit) benefit cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan." } } }, "auth_ref": { "r524", "r549", "r1038", "r1039" } }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanNetPeriodicBenefitCostAbstract", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net Periodic Benefit Cost", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]", "documentation": null } } }, "auth_ref": { } }, "us-gaap_DefinedBenefitPlanServiceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedBenefitPlanServiceCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails": { "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Service cost", "label": "Defined Benefit Plan, Service Cost", "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan." } } }, "auth_ref": { "r492", "r525", "r550", "r1038", "r1039" } }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": {


```

"r11", "r275", "r286", "r303", "r1013", "r1014" ] }, "mdt:DerivativeAssetLiabilityAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
"DerivativeAssetLiabilityAbstract", "presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
", "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Derivative Asset (Liability) [Abstract]",
"documentation": "Derivative Asset (Liability) [Abstract]" } } }, "auth_ref": { } },
"mdt:DerivativeAssetLiabilityFairValueGrossAssetLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.medtronic.com/20241025", "localname": "DerivativeAssetLiabilityFairValueGrossAssetLiability",
"crdr": "debit", "calculation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
{ "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet", "weight": 1.0, "order": 1.0 } },
"presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
", "lang": { "en-us": { "role": { "totalLabel": "Gross Amount of Recognized Assets (Liabilities)", "label": "Derivative
Asset (Liability), Fair Value, Gross Asset (Liability)", "documentation": "Derivative Asset (Liability), Fair Value,
Gross Asset (Liability)" } } }, "auth_ref": { } }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"DerivativeAssetNotOffsetPolicyElectionDeduction", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
{ "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0,
"order": 2.0 } }, "presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
", "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial Instruments", "label": "Derivative Asset, Subject
to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of
financial asset or other contract with one or more underlyings, notional amount or payment provision or both,
and contract can be net settled by means outside contract or delivery of asset, subject to master netting
arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset." } } },
"auth_ref": { "r18", "r20", "r175" } }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand
", "lang": { "en-us": { "role": { "terseLabel": "Derivative Assets", "label": "Derivative Asset", "documentation":
"Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or
more underlyings, notional amount or payment provision or both, and the contract can be net settled by means
outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not
elected to be offset." } } }, "auth_ref": { "r201", "r204", "r669", "r670", "r677", "r682", "r843", "r844", "r845",
"r846", "r847", "r849", "r850", "r851", "r852", "r853", "r868", "r869", "r951", "r954", "r956", "r957", "r958",
"r959", "r1002", "r1053", "r1057", "r1081", "r1301", "r1302", "r1303", "r1364" } }, "us-
gaap_DerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "DerivativeAssetsAbstract", "presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
", "lang": { "en-us": { "role": { "terseLabel": "Derivative assets:", "label": "Derivative Asset [Abstract]" } } },
"auth_ref": { } }, "mdt_DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
"DerivativeAssetsandLiabilitiesNetCollateralObligationtoReturnCash", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
{ "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet", "weight": -1.0, "order": 3.0 } },
"presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
", "lang": { "en-us": { "role": { "negatedTotalLabel": "Cash Collateral (Received) Posted", "label": "Derivative
Assets and Liabilities, Net, Collateral, Obligation to Return Cash", "documentation": "Derivative Assets and
Liabilities, Net, Collateral, Obligation to Return Cash" } } }, "auth_ref": { } },
"mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.medtronic.com/20241025", "localname":
"DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
{ "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet", "weight": -1.0, "order": 2.0 } },
"presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
", "lang": { "en-us": { "role": { "negatedTotalLabel": "Financial Instruments", "label": "Derivative Assets and
Liabilities, Net, Not Offset, Policy Election Deduction", "documentation": "Derivative Assets and Liabilities, Net,
Not Offset, Policy Election Deduction" } } }, "auth_ref": { } }, "us-
gaap_DerivativeCollateralObligationToReturnCash": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "DerivativeCollateralObligationToReturnCash", "crdr": "credit",
"calculation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
{ "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": -1.0,
"order": 3.0 } }, "presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
", "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash Collateral (Received) Posted", "label": "Derivative
Asset, Subject to Master Netting Arrangement, Collateral, Obligation to Return Cash Not Offset",
"documentation": "Amount of obligation to return cash collateral under master netting arrangements that have
not been offset against derivative assets." } } }, "auth_ref": { "r20", "r83", "r202", "r1001" } }, "us-
gaap_DerivativeCollateralRightToReclaimCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "DerivativeCollateralRightToReclaimCash", "crdr": "debit", "calculation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
{ "parentTag": "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "weight": -1.0,
"order": 3.0 } }, "presentation": {
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand

```

], "lang": { "en-us": { "role": { "terseLabel": "Cash Collateral (Received) Posted", "label": "Derivative Liability, Subject to Master Netting Arrangement, Collateral, Right to Reclaim Cash Not Offset", "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities." } } }, "auth_ref": { "r20", "r83", "r202", "r1001" } }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun

], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": { "r851", "r853", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r875", "r876", "r877", "r878", "r888", "r889", "r890", "r891", "r894", "r895", "r896", "r897", "r951", "r952", "r956", "r958", "r1079", "r1081", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1311", "r1312" } }, "mdt_DerivativeExcludedComponentAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "DerivativeExcludedComponentAmortizedCost", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Amortized excluded component", "label": "Derivative, Excluded Component, Amortized Cost", "documentation": "Derivative, Excluded Component, Amortized Cost" } } }, "auth_ref": { }, "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative, excluded component, gain (loss), recognized in earnings", "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings", "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method." } } }, "auth_ref": { "r171", "r1296" } }, "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueAmountOffsetAgainstCollateralNet", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand { "parentTag": null, "weight": null, "order": null, "root": true } }, "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative, Fair Value, Amount Offset Against Collateral, Net", "documentation": "The net amount as of the balance sheet date of the fair value of derivative assets and derivative liabilities that in accordance with the entity's accounting policy were offset against collateral under a master netting arrangement." } } }, "auth_ref": { "r82" } }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand { "parentTag": "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand], "lang": { "en-us": { "role": { "terseLabel": "Derivative assets, fair value", "verboseLabel": "Gross Amount of Recognized Assets (Liabilities)", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": { "r19", "r110", "r149", "r150", "r200", "r1002" } }, "us-gaap_DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand { "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet", "weight": 1.0, "order": 1.0 } }, "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand], "lang": { "en-us": { "role": { "totalLabel": "Net Amount", "label": "Derivative Asset, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": { "r20", "r82" } }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand { "parentTag": "mdt_DerivativeAssetLiabilityFairValueGrossAssetLiability", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa

"<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand>
], "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities, fair value", "negatedTerseLabel": "Gross Amount of Recognized Assets (Liabilities)", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": { "r19", "r110", "r149", "r150", "r200", "r1002" } }, "us-gaap_DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral", "crdr": "credit", "calculation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand>
 { "parentTag": "us-gaap_DerivativeFairValueAmountOffsetAgainstCollateralNet", "weight": -1.0, "order": 2.0 }, "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand>
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand>
], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net Amount", "label": "Derivative Liability, Including Not Subject to Master Netting Arrangement, after Offset and Deduction", "documentation": "Fair value, after effect of master netting arrangement and deduction of obligation to return financial collateral not offset and financial instrument subject to master netting arrangement not offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset. Includes derivative not subject to master netting arrangement or similar agreement." } } }, "auth_ref": { "r20", "r82" } }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeInstrumentRiskAxis", "presentation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails>", "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa>
], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": { "r76", "r79", "r81", "r151", "r851", "r853", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r875", "r876", "r877", "r878", "r888", "r889", "r890", "r891", "r894", "r895", "r896", "r897", "r951", "r952", "r956", "r958", "r1002", "r1079", "r1081", "r1304", "r1305", "r1306", "r1307", "r1308", "r1309", "r1311", "r1312" } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagement>", "lang": { "en-us": { "role": { "terseLabel": "Derivatives and Currency Exchange Risk Management", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": { "r147", "r654", "r663" } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "presentation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails>", "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun>
], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "presentation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails>", "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun>
], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "documentation": "Disclosure of information about derivatives and hedging activities." } } }, "auth_ref": { } }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails>", "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun>
], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": { "r17", "r76", "r79" } }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrument": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskI", "presentation": { "<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD>

"<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH>], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": { "r17", "r76", "r79", "r81", "r84", "r85", "r653" } }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH" }, "lang": { "en-us": { "role": { "verboseLabel": "Derivative Instruments, (Gain) Loss [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r653" } }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH" }, "lang": { "en-us": { "role": { "negatedLabel": "(Gain) Loss Recognized in Income", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments." } } }, "auth_ref": { "r80", "r1181" } }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative Liabilities", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r201", "r204", "r669", "r670", "r677", "r682", "r843", "r844", "r845", "r846", "r849", "r850", "r851", "r852", "r853", "r875", "r877", "r878", "r952", "r953", "r954", "r956", "r957", "r958", "r959", "r1002", "r1301", "r1302", "r1303", "r1364" } }, "us-gaap_DerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesAbstract", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand" }, "lang": { "en-us": { "role": { "terseLabel": "Derivative liabilities", "label": "Derivative Liability [Abstract]" } } }, "auth_ref": { } }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand" }, "parentTag": "mdt_DerivativeAssetsandLiabilitiesNetNotOffsetPolicyElectionDeduction", "weight": -1.0, "order": 2.0 }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability." } } }, "auth_ref": { "r18", "r20", "r175" } }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun" }, "lang": { "en-us": { "role": { "terseLabel": "Gross notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": { "r1294", "r1295" } }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa" }, "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun" }, "lang": { "en-us": { "role": { "terseLabel": "Derivatives designated as hedging instruments", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": { "r17" } }, "mdt_DiabetesGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "DiabetesGroupMember", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoo", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom" }, "lang": { "en-us": { "role": { "terseLabel": "Diabetes", "label": "Diabetes Group [Member]", "documentation": "Diabetes Group [Member]" } } }, "auth_ref": { } }, "mdt_DiabetesPumpRetainerRingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "DiabetesPumpRetainerRingLitigationMember", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": {

"terseLabel": "Diabetes Pump Retainer Ring Litigation", "label": "Diabetes Pump Retainer Ring Litigation
 [Member]", "documentation": "Diabetes Pump Retainer Ring Litigation" } } }, "auth_ref": [] }, "us-
 gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": {
 "http://www.medtronic.com/role/RevenueNarrativeDetails",
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails",
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of
 Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These
 concepts are used to disclose reportable information associated with domain members defined in one or many
 axes to the table." } } }, "auth_ref": ["r483", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035"] },
 "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": {
 "http://www.medtronic.com/role/RevenueNarrativeDetails",
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails",
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of
 Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories
 depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic
 factor." } } }, "auth_ref": ["r483", "r1029", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035"] }, "us-
 gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": {
 "http://www.medtronic.com/role/RevenueTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of
 Disaggregation of Net Sales by Segment and Division and by Market Geography", "label": "Disaggregation of
 Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories
 depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic
 factor." } } }, "auth_ref": ["r1286"] }, "us-
 gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": {
 "http://www.medtronic.com/role/StockBasedCompensation" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-
 Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire
 disclosure for share-based payment arrangement." } } }, "auth_ref": ["r566", "r571", "r599", "r600", "r601",
 "r1047"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": {
 "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement
 [Abstract]" } } }, "auth_ref": [] },
 "mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable": { "xbrltype":
 "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivable", "crdr": "debit",
 "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationK
 }, "lang": { "en-us": { "role": { "verboseLabel": "Contingent consideration receivable", "periodStartLabel":
 "Beginning balance", "periodEndLabel": "Ending balance", "label": "Disposal Group, Including Discontinued
 Operation, Contingent Consideration Receivable", "documentation": "Disposal Group, Including Discontinued
 Operation, Contingent Consideration Receivable" } } }, "auth_ref": [] },
 "mdt_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue": {
 "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationReceivableChangeInFairValue", "crdr":
 "debit", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationofContingentConsiderationK
 }, "lang": { "en-us": { "role": { "terseLabel": "Change in fair value", "label": "Disposal Group Including
 Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value", "documentation":
 "Disposal Group Including Discontinued Operation, Contingent Consideration Receivable, Change In Fair Value"
 } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited" }, "lang": { "en-us": { "role": {
 "negatedTerseLabel": "Dividends to shareholders", "label": "Dividends, Common Stock, Cash", "documentation":
 "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } },
 "auth_ref": ["r140"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri":
 "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": {
 "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period
 Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.
 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or
 other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype":
 "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus",
 "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document
 Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the
 document report in YYYY format. For a 2006 annual report, which may also provide financial information from
 prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] },
 "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
 "DocumentPeriodEndDate", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role":
 { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the
 EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the
 EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or
 transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] },
 "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",

"localname": "DocumentQuarterlyReport", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r1095" }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r1127" }, "dei_DocumentType": { "xbrltype": "submissionItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": { } }, "us-gaap_DomesticPlanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticPlanMember", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Domestic Plan", "label": "Domestic Plan [Member]", "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": { "r1289", "r1290", "r1291" }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRwRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdNtOthrRwRflctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r225", "r248", "r249", "r250", "r251", "r252", "r253", "r262", "r266", "r268", "r269", "r270", "r274", "r633", "r640", "r666", "r667", "r782", "r808", "r1006" }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r262", "r266", "r268" }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "lang": { "en-us": { "role": { "verboseLabel": "Diluted earnings per share (usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r225", "r248", "r249", "r250", "r251", "r252", "r253", "r262", "r268", "r269", "r270", "r274", "r633", "r640", "r666", "r667", "r782", "r808", "r1006" }, "mdt_EarningsPerShareReconciliationDenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "EarningsPerShareReconciliationDenominatorAbstract", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Earnings Per Share Reconciliation Denominator [Abstract]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": { } }, "mdt_EarningsPerShareReconciliationNumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "EarningsPerShareReconciliationNumeratorAbstract", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Earnings Per Share Reconciliation Numerator [Abstract]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": { } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.medtronic.com/role/EarningsPerShare", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r259", "r271", "r272", "r273" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExch", "weight": 1.0, "order": 4.0 }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "label": "Effect of Exchange Rate

on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r686" } }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": { "http://www.medtronic.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": { "r609", "r1049" } }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/StockBasedCompensationDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/StockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "negatedLabel": "Income tax benefits", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": { "r598" } }, "us-gaap_EmployeeSeveranceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeSeveranceMember", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Employee Termination Benefits", "label": "Employee Severance [Member]", "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan." } } }, "auth_ref": { } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails", "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "http://www.medtronic.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "verboseLabel": "Employee stock options", "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { } }, "mdt_EmployeesStockPurchasePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "EmployeesStockPurchasePlanMember", "presentation": { "http://www.medtronic.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase plan", "label": "Employees Stock Purchase Plan [Member]", "documentation": "-- None. No documentation exists for this element." } } }, "auth_ref": { } }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitiesTable", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Country", "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r1093" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Ordinary Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting

Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r1093"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r1093"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInformationLineItems", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r1177"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r1093"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r1093"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r1093"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.medtronic.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r1093"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r1132"] }, "ecd_EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table [Member]", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r1173"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r1173"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date

Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } }], "auth_ref": ["r1173"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails", "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherComprehensiveLoss", "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r16", "r180", "r218", "r219", "r220", "r239", "r240", "r241", "r245", "r252", "r254", "r256", "r276", "r353", "r356", "r398", "r471", "r621", "r622", "r628", "r629", "r630", "r634", "r639", "r640", "r656", "r657", "r658", "r659", "r660", "r662", "r665", "r688", "r690", "r691", "r692", "r693", "r694", "r698", "r700", "r704", "r803", "r826", "r827", "r828", "r841", "r900"] }, "mdt_EquityInvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "EquityInvestmentsMember", "presentation": ["http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Equity Securities and Other Investments", "label": "Equity Investments [Member]", "documentation": "Equity Investments [Member]" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "calculation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails": { "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestments", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity method and other investments", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": ["r275", "r291", "r303", "r348", "r1189", "r1242"] }, "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestments", "crdr": "debit", "calculation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total equity and other investments", "label": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, And Equity Method Investments", "documentation": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, And Equity Method Investments" } } }, "auth_ref": [] }, "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestmentsTable": { "xbrltype": "textBlockItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestmentsTable", "presentation": ["http://www.medtronic.com/role/FinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity and Other Investments", "label": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, And Equity Method Investments [Table Text Block]", "documentation": "Equity Securities, FV-NI, Equity Securities Without Readily Determinable Fair Value, and Equity Method Investments [Table Text Block]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "calculation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails": { "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestments", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments for which the fair value option has been elected", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": ["r681"] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails": { "parentTag": "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestments", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments with readily determinable fair value (marketable equity securities)", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": ["r192", "r681", "r997"] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": ["http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of instrument", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r809", "r1241"] }, "us-

gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
 "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails": {
 "parentTag":
 "mdt_EquitySecuritiesFVNIEquitySecuritiesWithoutReadilyDeterminableFairValueAndEquityMethodInvestments",
 "weight": 1.0, "order": 3.0 } }, "presentation": {
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails" }, "lang": {
 "en-us": { "role": { "terseLabel": "Investments without readily determinable fair values", "label": "Equity
 Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity
 security without readily determinable fair value." } } }, "auth_ref": { "r347" } },
 "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation":
 { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation
 Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } }
 }, "auth_ref": { "r1142" } }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneous
 Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": { "r1100",
 "r1110", "r1120", "r1152" } }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": {
 "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Erroneously
 Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } },
 "auth_ref": { "r1097", "r1107", "r1117", "r1149" } }, "srt_EuropeMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/srt/2024", "localname": "EuropeMember", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun
 t", "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": { "r1368",
 "r1369", "r1370", "r1371" } }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Executive Category:",
 "label": "Executive Category [Axis]" } } }, "auth_ref": { "r1148" } }, "us-
 gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand
 t", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and
 Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and
 Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table.
 These concepts are used to disclose reportable information associated with domain members defined in one or
 many axes to the table." } } }, "auth_ref": { "r669", "r670", "r677", "r1053" } }, "us-
 gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand
 t", "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair
 Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and
 liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": { "r669", "r670", "r677",
 "r1053" } }, "us-
 gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems":
 { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
 "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContinger
 t", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Inputs, Liabilities, Quantitative Information [Line
 Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation":
 "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
 information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": {
 "r671", "r672", "r673", "r1057" } }, "us-
 gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
 "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContinger
 t", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
 "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of
 information about input and valuation technique used to measure fair value and change in valuation approach
 and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } },
 "auth_ref": { "r671", "r672", "r673", "r1057" } }, "us-
 gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBl
 k": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
 "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsTables" }, "lang": { "en-us": {
 "role": { "terseLabel": "Schedule of Level 3 Fair Value Measurements of Contingent Consideration for Liability",
 "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation":
 "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation
 approach and technique for each separate class of asset and liability measured on recurring and nonrecurring

basis." } } }, "auth_ref": ["r671", "r672", "r1057"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueByFairValueHierarchyLevelAxis", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationK
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationOfContingentConsiderationK
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy
 and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at
 net asset value per share as practical expedient." } } }, "auth_ref": ["r457", "r515", "r516", "r517", "r518",
 "r519", "r520", "r668", "r670", "r671", "r672", "r673", "r676", "r677", "r679", "r711", "r712", "r713", "r1024",
 "r1025", "r1036", "r1037", "r1038", "r1053", "r1057"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": {
 "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueByMeasurementFrequencyAxis", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationK
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationOfContingentConsiderationK
 }, "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency
 [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r669", "r670", "r671",
 "r673", "r1053", "r1302", "r1313"] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun
 }, "lang": { "en-us": { "role": { "terseLabel": "Fair value hedge", "label": "Fair Value Hedging [Member]",
 "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an
 unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": ["r72"] }, "us-
 gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "FairValueInputsLevel1Member", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 }, "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]",
 "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can
 access at the measurement date." } } }, "auth_ref": ["r457", "r515", "r520", "r670", "r677", "r711", "r1036",
 "r1037", "r1038", "r1053"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 }, "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]",
 "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or
 liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in
 active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref":
 ["r457", "r515", "r520", "r670", "r671", "r677", "r712", "r1024", "r1025", "r1036", "r1037", "r1038", "r1053"] },
 "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationK
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationOfContingentConsiderationK
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 }, "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]",
 "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market
 participants would use in pricing." } } }, "auth_ref": ["r457", "r515", "r516", "r517", "r518", "r519", "r520",
 "r670", "r671", "r672", "r673", "r677", "r713", "r1024", "r1025", "r1036", "r1037", "r1038", "r1053", "r1057"] },
 "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsQuantitativeInformationAbstract", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationK
 }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Inputs", "label": "Fair Value Measurement Inputs and
 Valuation Techniques [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueMeasurementFrequencyDomain", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationK
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationOfContingentConsiderationK
 }, "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement
 Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": ["r669", "r670", "r671",
 "r673", "r1053", "r1302", "r1313"] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "FairValueMeasurementsFairValueHierarchyDomain", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationK
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationOfContingentConsiderationK
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofDerivativeAssetsand
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
 }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value
 Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques
 to measure fair value." } } }, "auth_ref": ["r457", "r515", "r516", "r517", "r518", "r519", "r520", "r668", "r670",
 "r671", "r672", "r673", "r676", "r677", "r679", "r711", "r712", "r713", "r1024", "r1025", "r1036", "r1037", "r1038",
 "r1053", "r1057"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember",
 "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentConsiderationK
 "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofReconciliationOfContingentConsiderationK
 }, "lang": { "en-us": { "role": { "terseLabel": "Recurring", "label": "Fair Value, Recurring [Member]",

"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": { "r1053", "r1299", "r1300", "r1301", "r1302", "r1303", "r1313" } }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFairValue": { "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": { "r75", "r77", "r84" } }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "parentTag": "us-gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Finance lease obligations", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": { "r701" } }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails", "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailableforSaleDebtSecuritiesbySize": { "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r324", "r325", "r326", "r328", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r358", "r359", "r361", "r362", "r363", "r365", "r367", "r368", "r468", "r470", "r663", "r680", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r804", "r1019", "r1053", "r1055", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1066", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1237", "r1238", "r1239", "r1240", "r1298", "r1301", "r1302", "r1303", "r1310", "r1313" } }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentsDisclosureTextBlock", "presentation": { "http://www.medtronic.com/role/FinancialInstruments" }, "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments Disclosure [Text Block]", "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures." } } }, "auth_ref": { } }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Estimated useful life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { } }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulatedAmortization": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r189", "r370", "r391", "r1021" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAggregateAmortization": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r393", "r993", "r1021" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAggregateAmortization": { "lang": { "en-us": { "role": { "terseLabel": "Remaining 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": { "r1372" } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAggregateAmortization": { "lang": { "en-us": { "role": { "terseLabel": "2030", "label": "Finite-Lived Intangible Asset, Expected

Amortization, Year Five, "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r393", "r993", "r1021"], "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAggregateAmortization", "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r393", "r993", "r1021"], "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAggregateAmortization", "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r393", "r993", "r1021"], "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofEstimatedFutureAggregateAmortization", "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r393", "r993", "r1021"], "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails", "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulation", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r384", "r386", "r387", "r388", "r390", "r391", "r395", "r396", "r741", "r745", "r993"], "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulation", "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r370", "r391", "r745", "r1021"], "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulation", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r384", "r391", "r395", "r396", "r397", "r741", "r993", "r1021"], "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails", "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulation", "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r384", "r386", "r387", "r388", "r390", "r391", "r395", "r396", "r993"], "us-gaap_FiscalPeriod": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiscalPeriod", "presentation": { "http://www.medtronic.com/role/BasisofPresentationPolicies", "lang": { "en-us": { "role": { "terseLabel": "Fiscal Period", "label": "Fiscal Period, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed." } } }, "auth_ref": ["r64"], "mdt_ForeignCurrencyCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "ForeignCurrencyCosts", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome", "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 1.0 }, "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome", "lang": { "en-us": { "role": { "negatedTerseLabel": "Currency", "label": "Foreign Currency Costs",

"documentation": "Foreign Currency Costs" } } }, "auth_ref": [] },
 "mdt_ForeignCurrencyDenominatedDebtMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.medtronic.com/20241025", "localname": "ForeignCurrencyDenominatedDebtMember",
 "presentation": []
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun
], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency-denominated debt", "label": "Foreign Currency
 Denominated Debt [Member]", "documentation": "Foreign Currency Denominated Debt" } } }, "auth_ref": [] },
 "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": []
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails",
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun
], "lang": { "en-us": { "role": { "terseLabel": "Currency exchange rate contracts", "label": "Foreign Exchange
 Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign
 exchange rates." } } }, "auth_ref": ["r1002", "r1036", "r1052", "r1053"] }, "us-
 gaap_ForeignGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ForeignGovernmentDebtSecuritiesMember", "presentation": []
 "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
], "lang": { "en-us": { "role": { "terseLabel": "Non-U.S. government and agency securities", "label": "Debt Security,
 Government, Non-US [Member]", "documentation": "Debt security issued by government not domiciled in United
 States of America (US)." } } }, "auth_ref": ["r1066", "r1288", "r1360"] }, "us-gaap_ForeignPlanMember": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignPlanMember",
 "presentation": [] "http://www.medtronic.com/role/RetirementBenefitPlansDetails"], "lang": { "en-us": { "role": {
 "terseLabel": "Non-U.S.", "label": "Foreign Plan [Member]", "documentation": "Location of employer sponsoring
 plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not
 limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r1289", "r1290", "r1291"] },
 "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
 "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
 "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to
 Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r1104", "r1114", "r1124", "r1156"] },
 "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation":
 ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery
 due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } }
 } }, "auth_ref": ["r1104", "r1114", "r1124", "r1156"] },
 "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
 "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
 "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation
 of Home Country Law, Amount" } } }, "auth_ref": ["r1104", "r1114", "r1124", "r1156"] },
 "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
 "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
 "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability
 [Text Block]" } } }, "auth_ref": ["r1104", "r1114", "r1124", "r1156"] }, "ecd_ForgoneRecoveryIndName": {
 "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName",
 "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
 "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r1104", "r1114", "r1124", "r1156"] },
 "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype":
 "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": []
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair
 Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered
 Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable
 Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r1137"] }, "us-
 gaap_GainLossOnInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "GainLossOnInvestmentsTextBlock", "presentation": []
 "http://www.medtronic.com/role/FinancialInstrumentsTables"], "lang": { "en-us": { "role": { "terseLabel":
 "Schedule of Activity Related to Available-for-Sale Securities Portfolio", "label": "Gain (Loss) on Securities [Table
 Text Block]", "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in
 security." } } }, "auth_ref": ["r1194", "r1195"] }, "mdt_GainLossReclassifiedIntoIncomeAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "GainLossReclassifiedIntoIncomeAbstract", "presentation": []
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH
], "lang": { "en-us": { "role": { "terseLabel": "(Gain) Loss Reclassified into Income", "label": "(Gain) Loss
 Reclassified Into Income [Abstract]", "documentation": "(Gain) Loss Reclassified Into Income" } } }, "auth_ref":
 [] }, "mdt_GainLossRecognizedInAccumulatedOtherComprehensiveLossAbstract": { "xbrltype": "stringItemType",
 "nsuri": "http://www.medtronic.com/20241025", "localname":
 "GainLossRecognizedInAccumulatedOtherComprehensiveLossAbstract", "presentation": []
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH
], "lang": { "en-us": { "role": { "terseLabel": "(Gain)\u00a0Loss\u00a0Recognized in Accumulated Other
 Comprehensive Loss", "label": "(Gain)\u00a0Loss\u00a0Recognized In Accumulated Other Comprehensive Loss
 [Abstract]", "documentation": "(Gain)\u00a0Loss\u00a0Recognized In Accumulated Other Comprehensive Loss" } } } }

], "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails", "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited", "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwill", "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r188", "r371", "r776", "r1014", "r1020", "r1054", "r1065", "r1248", "r1255"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssets", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Other Intangible Assets", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r1246", "r1258"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwill", "lang": { "en-us": { "role": { "terseLabel": "Currency translation and other", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r379"] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r11", "r372", "r378", "r383", "r1020", "r1054"] }, "us-gaap_GoodwillImpairmentLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLossNetOfTax", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Impairment Loss, Net of Tax", "label": "Goodwill, Impairment Loss, Net of Tax", "documentation": "Amount, after tax, of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwill", "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r1020"] }, "us-gaap_GoodwillNotAllocatedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillNotAllocatedAmount", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Not Allocated, Amount", "label": "Goodwill, Not Allocated, Amount", "documentation": "Portion of goodwill not yet allocated to reportable segments." } } }, "auth_ref": ["r373"] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwill", "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFair Value", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments", "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r17", "r653"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFair Value", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments", "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r17"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments"

1. "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": { "r17" } },
 "mdt_HerniaMeshLitigationMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.medtronic.com/20241025", "localname": "HerniaMeshLitigationMember", "presentation": {
 "http://www.medtronic.com/role/CommitmentsandContingenciesDetails", "lang": { "en-us": { "role": {
 "terseLabel": "Hernia Mesh Litigation", "label": "Hernia Mesh Litigation [Member]", "documentation": "Hernia
 Mesh Litigation" } } }, "auth_ref": { } }, "country_IE": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/country/2024", "localname": "IE", "presentation": {
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe",
 "lang": { "en-us": { "role": { "terseLabel": "Ireland", "label": "IRELAND" } } }, "auth_ref": { } }, "us-
 gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "presentation": {
 "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "lang": { "en-us": { "role":
 "terseLabel": "Definite-lived intangible asset charges", "label": "Impairment of Intangible Assets, Finite-Lived",
 "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the
 carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": { "r385", "r1203", "r1271" } },
 "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "presentation": {
 "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "lang": { "en-us": { "role":
 "terseLabel": "Indefinite-lived intangible asset charges", "label": "Impairment of Intangible Assets, Indefinite-
 Lived (Excluding Goodwill)", "documentation": "Amount of impairment loss resulting from write-down of assets,
 excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of
 benefit to fair value." } } }, "auth_ref": { "r385", "r1203", "r1268", "r1271" } }, "us-
 gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "InProcessResearchAndDevelopmentMember", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
 "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula",
 "lang": { "en-us": { "role": { "terseLabel": "IPR&D", "label": "In Process Research and Development [Member]",
 "documentation": "In process investigation of new knowledge useful in developing new product or service or new
 process or technique or improvement to existing product or process, and translation of knowledge into plan or
 design for new product or process or for improvement to existing product or process." } } }, "auth_ref": { "r1259",
 "r1260", "r1261", "r1262", "r1263", "r1264", "r1266", "r1268", "r1269", "r1270" } }, "us-
 gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr":
 "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": {
 "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } },
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom",
 "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited",
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom",
 "lang": { "en-us": { "role": { "totalLabel": "Income before income taxes", "label": "Income (Loss) from
 Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income
 (loss) from continuing operations, including income (loss) from equity method investments, before deduction of
 income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": {
 "r117", "r161", "r167", "r783", "r799", "r1008", "r1013", "r1215", "r1217", "r1218", "r1219", "r1220" } }, "us-
 gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement
 [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": { } }, "us-
 gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "IncomeStatementLocationAxis", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD",
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH",
 "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails",
 "http://www.medtronic.com/role/StockBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel":
 "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation":
 "Information by location in statement of income where disaggregated amount has been reported." } } },
 "auth_ref": { "r399", "r406", "r411", "r674", "r675", "r678", "r823", "r825", "r885", "r993", "r1056", "r1333" } },
 "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD",
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH",
 "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails",
 "http://www.medtronic.com/role/StockBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel":
 "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]",
 "documentation": "Location in statement of income where disaggregated amount has been reported." } } },
 "auth_ref": { "r406", "r411", "r674", "r675", "r678", "r823", "r825", "r885", "r993", "r1056", "r1333" } }, "us-
 gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure
 [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": { } }, "us-
 gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "IncomeTaxDisclosureTextBlock", "presentation": { "http://www.medtronic.com/role/IncomeTaxes",
 "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]",
 "documentation": "The entire disclosure for income tax." } } }, "auth_ref": { "r237", "r604", "r609", "r611",
 "r612", "r613", "r617", "r618", "r623", "r625", "r626", "r627", "r838", "r1049" } }, "us-
 gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {

"http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited": { "parentTag": "us-gaap-ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Income tax provision", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of
 current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing
 operations." } } }, "auth_ref": { "r172", "r177", "r255", "r256", "r275", "r289", "r303", "r608", "r609", "r624",
 "r810", "r1049" } }, "us-gaap_IncomeTaxReconciliationTaxContingencies": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxReconciliationTaxContingencies", "crdr":
 "debit", "presentation": { "http://www.medtronic.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": {
 "terseLabel": "Income tax charge", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
 "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income
 tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income
 (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but
 not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other
 contingencies." } } }, "auth_ref": { "r610", "r1049", "r1293" } }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr":
 "credit", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" },
 "lang": { "en-us": { "role": { "terseLabel": "Income taxes", "label": "Income Taxes Paid, Net", "documentation":
 "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } },
 "auth_ref": { "r33", "r233", "r619", "r620" } }, "mdt_IncomeTaxesandInterestPaidAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "IncomeTaxesandInterestPaidAbstract", "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Cash paid for:", "label": "Income Taxes and Interest Paid [Abstract]", "documentation": "Income
 Taxes and Interest Paid [Abstract]" } } }, "auth_ref": { } }, "us-
 gaap_IncreaseDecreaseInAccountsAndNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsAndNotesReceivable", "crdr": "credit",
 "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag":
 "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts and Notes Receivable",
 "documentation": "The increase (decrease) during the reporting period of the sum of amounts due within one
 year (or one business cycle) from customers for the credit sale of goods and services; and from note holders for
 outstanding loans." } } }, "auth_ref": { "r10" } }, "us-
 gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr":
 "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } },
 "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-
 us": { "role": { "terseLabel": "Accounts payable and accrued liabilities", "label": "Increase (Decrease) in Accounts
 Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the
 amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred
 but not paid." } } }, "auth_ref": { "r10" } }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories",
 "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited":
 { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } },
 "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-
 us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation":
 "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting
 entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": {
 "r10" } }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": {
 "terseLabel": "Change in operating assets and liabilities, net of acquisitions and divestitures:", "label": "Increase
 (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": { } }, "us-
 gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit",
 "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag":
 "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": {
 "negatedLabel": "Other operating assets and liabilities", "label": "Increase (Decrease) in Other Operating Assets
 and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of
 operating liabilities classified as other." } } }, "auth_ref": { "r10" } }, "us-
 gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
 "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited" }, "lang": { "en-us":
 { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase
 (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a
 concept from the beginning of a period to the end of a period." } } }, "auth_ref": { } }, "us-
 gaap_IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends": { "xbrltype":
 "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "IncrementalCommonSharesAttributableToNonvestedSharesWithForfeitableDividends", "calculation": {
 "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel
 { "parentTag": "us-gaap_WeightedAverageNumberofDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } },
 "presentation": {
 "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel
 { "lang": { "en-us": { "role": { "terseLabel": "Employee restricted stock units (shares)", "label": "Incremental
 Common Shares Attributable to Dilutive Effect of Nonvested Shares with Forfeitable Dividends",

"documentation": "Number of additional shares included in diluted EPS for potentially dilutive effect of nonvested equity-based payment award containing forfeitable rights to dividends or dividend equivalents, whether paid or unpaid." } } }, "auth_ref": ["r34", "r1211", "r1212", "r1213", "r1214"] }, "us-gaap-IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDet": { "parentTag": "us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDet": { "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": ["r263", "r264", "r265", "r270", "r570"] }, "us-gaap-IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula": { "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "label": "Indefinite-Lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r384", "r389", "r394", "r1021"] }, "us-gaap-IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula": { "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets [Line Items]", "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r384", "r394", "r397", "r1021"] }, "us-gaap-IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula": { "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": ["r370", "r394", "r1021"] }, "us-gaap-IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula": { "lang": { "en-us": { "role": { "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": ["r384", "r389", "r394", "r1021"] }, "ecd-IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": ["r1104", "r1114", "r1124", "r1148", "r1156", "r1160", "r1168"] }, "ecd-InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": ["r1166"] }, "ecd-InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": ["r1096", "r1172"] }, "ecd-InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": ["r1096", "r1172"] }, "ecd-InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" }, "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": ["r1096", "r1172"] }, "us-gaap-IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": ["r384", "r1266", "r1268"] }, "us-gaap-InterestExpenseBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseBorrowings", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Interest expense on outstanding borrowings", "label": "Interest Expense, Borrowings", "documentation": "Aggregate amount of interest expense on all borrowings." } } }, "auth_ref": ["r163", "r164"] }

, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": { "r285", "r1196" } }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Interest Income (Expense), Operating", "documentation": "Amount of interest income (expense) classified as operating." } } }, "auth_ref": { "r777", "r1217" } }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "lang": { "en-us": { "role": { "verboseLabel": "Interest expense, net", "label": "Interest Income (Expense), Nonoperating", "documentation": "Amount of interest income (expense) classified as nonoperating." } } }, "auth_ref": { "r1013", "r1196", "r1217" } }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": { "r228", "r231", "r232" } }, "mdt_InternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "InternationalMember", "presentation": { "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails": { "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International [Member]", "documentation": "International" } } }, "auth_ref": { "r1" } }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": { "r1" } }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryDisclosureTextBlock", "presentation": { "http://www.medtronic.com/role/Inventories": { "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": { "r369" } }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/InventoriesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": { "r132", "r998" } }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.medtronic.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "http://www.medtronic.com/role/InventoriesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": { "r197", "r996", "r1065" } }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/InventoriesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": { "r132", "r1000" } }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/InventoriesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": { "r132", "r999" } }, "us-gaap_InvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments [Abstract]", "label": "Investments [Abstract]" } } }, "auth_ref": { "r1" } }, "us-

gaap_InvestmentsClassifiedByContractualMaturityDataTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsClassifiedByContractualMaturityDataTableTextBlock", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsTables" }, "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available for Sale Debt Securities by Contractual Maturity", "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": { } }, "us-gaap_InvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsMember", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi", "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments [Member]", "documentation": "Assets held for their financial return, rather than for the entity's operations." } } }, "auth_ref": { }, "country_JP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "JP", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstru", "lang": { "en-us": { "role": { "terseLabel": "JAPAN", "label": "JAPAN" } } }, "auth_ref": { }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": { }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": { "r23", "r90", "r91", "r92", "r95", "r96", "r97", "r98", "r236", "r352", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r643", "r647", "r648", "r683", "r860", "r1007", "r1091", "r1282", "r1320", "r1321" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": { "r105", "r158", "r797", "r1065", "r1206", "r1243", "r1314" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": { }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": { "r92", "r186", "r236", "r352", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r643", "r647", "r648", "r683", "r1065", "r1282", "r1320", "r1321" } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": { }, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Line of credit, amount outstanding", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": { "r23", "r155", "r1329" } }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Line of credit, maximum capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": { "r89", "r94" } }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": {

"terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } },
"auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "LitigationCaseAxis", "presentation": {
"http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] },
"srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024",
"localname": "LitigationCaseTypeDomain", "presentation": {
"http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "us-
gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr":
"credit", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": {
"en-us": { "role": { "terseLabel": "Amount of settlement paid", "label": "Litigation Settlement, Amount Awarded to
Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } },
"auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LitigationStatusAxis", "presentation": {
"http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by
status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1272", "r1273", "r1274", "r1277"] },
"us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LitigationStatusDomain", "presentation": {
"http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of
pending, threatened, or settled litigation." } } }, "auth_ref": ["r1272", "r1273", "r1274", "r1277"] },
"dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "LocalPhoneNumber", "presentation": { "http://www.medtronic.com/role/Cover" }, "lang": { "en-us":
{ "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone
number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities",
"weight": 1.0, "order": 2.0 },
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited",
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Long-term debt", "totalLabel": "Total long-term debt", "label": "Long-Term Debt and Lease
Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } },
"auth_ref": ["r23", "r791"] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": {
"http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": {
"terseLabel": "Estimated fair value", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value
amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical
disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the
footnote disclosures to the financial statements. The element may be used in both the balance sheet and
disclosure in the same submission." } } }, "auth_ref": ["r1299", "r1301", "r1302", "r1303"] }, "us-
gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "parentTag": "us-
gaap_LongTermDebtAndCapitalLeaseObligations", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Long-term debt, gross", "label": "Long-Term Debt, Excluding Current Maturities",
"documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-
term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r194"] }, "us-
gaap_LongTermDebtNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LongTermDebtNoncurrentAbstract", "presentation": {
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities [Abstract]" } } } },
"auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": {
"http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation":
"Information by type of long-term debt." } } }, "auth_ref": ["r23", "r1272", "r1273", "r1274"] }, "us-
gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LongtermDebtTypeDomain", "presentation": {
"http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails",
"http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": {
"role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]",
"documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-
based financing, project financing, letter of credit financing. These are debt arrangements that originally
required repayment more than twelve months after issuance or greater than the normal operating cycle of the
company, if longer." } } }, "auth_ref": ["r23", "r45", "r1272", "r1273", "r1274"] }, "us-
gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "LossContingenciesLineItems", "presentation": {
"http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": {

"terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r420", "r422", "r424", "r429", "r603", "r1022", "r1278", "r1279" } }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": { "r420", "r422", "r424", "r429", "r603", "r1022", "r1278", "r1279" } }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued litigation charges", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": { "r420", "r1178" } }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrual adjustment", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in loss contingency liability." } } }, "auth_ref": { "r1277" } }, "us-gaap_LossContingencyAccrualProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualProvision", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome" }, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 }, "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 7.0 }, "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails", "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome" }, "lang": { "en-us": { "role": { "terseLabel": "Certain litigation charges, net", "negatedTerseLabel": "Certain litigation charges, net", "label": "Loss Contingency Accrual, Provision", "documentation": "Amount charged against operating income increasing loss contingency liability, after adjustments to reduce previously estimated charges." } } }, "auth_ref": { "r1277" } }, "us-gaap_LossContingencyDisclosures": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDisclosures", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingencies" }, "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made." } } }, "auth_ref": { "r419", "r420", "r421", "r423", "r425", "r426", "r427", "r428", "r603" } }, "mdt_LossContingencyLawsuitsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "LossContingencyLawsuitsNumber", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of lawsuits (in lawsuits)", "label": "Loss Contingency, Lawsuits, Number", "documentation": "Loss Contingency, Lawsuits, Number" } } }, "auth_ref": { "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of plaintiffs (in plaintiffs)", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": { "r1278", "r1279" } } }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Number of claimants (in claimants)", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": { "r1278", "r1279" } } }, "stpr_MA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "MA", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Massachusetts", "label": "MASSACHUSETTS" } } }, "auth_ref": { "stpr_MN": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "MN", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Minnesota", "label": "MINNESOTA" } } }, "auth_ref": { "us-gaap_MaterialReconcilingItemsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaterialReconcilingItemsMember", "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome" }, "lang": { "en-us": { "role": { "terseLabel": "Segment Reconciling Items", "label": "Segment Reporting, Reconciling Item, Excluding Corporate Nonsegment [Member]", "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity." } } }, "auth_ref": { "r298", "r301", "r304", "r1013", "r1014" } } }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsandContingencies" }, "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": { "r422", "r424", "r425", "r426", "r564", "r603", "r673", "r739", "r822", "r824", "r834", "r852", "r853", "r906", "r925", "r930", "r931", "r969", "r991", "r992", "r1018", "r1028", "r1046", "r1057", "r1058", "r1062", "r1063", "r1075", "r1284", "r1322", "r1323", "r1324", "r1325", "r1326", "r1327" } } }, "us-gaap_MaximumRemainingMaturityOfForeignCurrencyDerivatives1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MaximumRemainingMaturityOfForeignCurrencyDerivatives1",

"presentation": {
<http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails> }, "lang": {
"en-us": { "role": { "terseLabel": "Maximum remaining maturity of foreign currency derivatives", "label":
"Maximum Remaining Maturity of Foreign Currency Derivatives", "documentation": "Maximum amount of time
remaining before foreign currency exchange rate derivatives mature or expire, in 'PnYnMnDnHnMnS' format,
for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } },
"auth_ref": { } }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "MeasureAxis", "presentation": { <http://xbrl.sec.gov/ecd/role/PvpDisclosure> }, "lang": { "en-us": {
"role": { "terseLabel": "Measure", "label": "Measure [Axis]" } } }, "auth_ref": { "r1140" } }, "ecd_MeasureName":
{ "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName",
"presentation": { <http://xbrl.sec.gov/ecd/role/PvpDisclosure> }, "lang": { "en-us": { "role": { "terseLabel": "Name",
"label": "Measure Name" } } }, "auth_ref": { "r1140" } }, "us-gaap_MeasurementInputDiscountRateMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputDiscountRateMember", "presentation": {
<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities>
}, "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Measurement Input, Discount Rate
[Member]", "documentation": "Measurement input using interest rate to determine present value of future cash
flows." } } }, "auth_ref": { "r1301", "r1302", "r1303" } }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis",
"presentation": {
<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities>
}, "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type
[Axis]", "documentation": "Information by type of measurement input used to determine value of asset and
liability." } } }, "auth_ref": { "r671", "r672", "r673", "r1057" } }, "us-gaap_MeasurementInputTypeDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MeasurementInputTypeDomain", "presentation": {
<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities>
}, "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input
Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } },
"auth_ref": { "r671", "r672", "r673", "r1057" } }, "mdt_MedicalDeviceRegulations": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "MedicalDeviceRegulations",
"crdr": "debit", "calculation": {
<http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome>
}, "parentTag": { "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": -1.0, "order": 12.0 } }, "presentation": {
<http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome>
}, "lang": { "en-us": { "role": { "negatedTerseLabel": "Medical device regulations", "label": "Medical Device
Regulations", "documentation": "Medical Device Regulations" } } }, "auth_ref": { } },
"mdt_MedicalSurgicalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025",
"localname": "MedicalSurgicalMember", "presentation": {
<http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails>
}, "lang": { "en-us": { "role": { "terseLabel": "Medical Surgical", "label": "Medical Surgical [Member]",
"documentation": "Medical Surgical [Member]" } } }, "auth_ref": { } }, "mdt_MedtronicLuxcoMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
"MedtronicLuxcoMember", "presentation": {
<http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails>
}, "lang": { "en-us": { "role": {
"terseLabel": "Medtronic Luxco", "label": "Medtronic Luxco [Member]", "documentation": "Medtronic Luxco
[Member]" } } }, "auth_ref": { } }, "mdt_MedtronicLuxcoSeniorNotesMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.medtronic.com/20241025", "localname": "MedtronicLuxcoSeniorNotesMember",
"presentation": { <http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails> }, "lang": { "en-us": {
"role": { "terseLabel": "Medtronic Luxco Senior Notes", "label": "Medtronic Luxco Senior Notes [Member]",
"documentation": "Medtronic Luxco Senior Notes" } } }, "auth_ref": { } }, "srt_MinimumMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": {
<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities>
}, "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": { "r422",
"r424", "r425", "r426", "r564", "r603", "r673", "r739", "r822", "r824", "r834", "r852", "r853", "r906", "r925",
"r930", "r931", "r969", "r991", "r992", "r1018", "r1028", "r1046", "r1057", "r1058", "r1062", "r1075", "r1284",
"r1322", "r1323", "r1324", "r1325", "r1326", "r1327" } }, "us-gaap_MinorityInterest": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit",
"calculation": { <http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited> }, "parentTag": { "us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } },
"presentation": { <http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited> }, "lang": { "en-us": {
"role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest",
"documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
} } }, "auth_ref": { "r104", "r157", "r236", "r352", "r432", "r435", "r436", "r437", "r441", "r442", "r683", "r796",
"r864" } }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype":
"percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": {
<http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails>
}, "lang": { "en-us": { "role": {
"terseLabel": "Non-controlling equity interest (percentage)", "label": "Subsidiary, Ownership Percentage,
Noncontrolling Owner", "documentation": "The equity interest of noncontrolling shareholders, partners or other
equity holders in consolidated entity." } } }, "auth_ref": { } }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag",

"presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": { "r1159" }, "us-gaap_MortgageBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MortgageBackedSecuritiesMember", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailableforSaleDebtSecuritiesbySi", "lang": { "en-us": { "role": { "terseLabel": "Mortgage-backed securities", "label": "Collateralized Mortgage-Backed Securities [Member]", "documentation": "Securities collateralized by mortgage loans." } } }, "auth_ref": { "r1036", "r1037", "r1038", "r1222", "r1229", "r1234", "r1235", "r1236", "r1360" }, "mdt_MozarcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "MozarcMember", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Mozarc", "label": "Mozarc [Member]", "documentation": "Mozarc" } } }, "auth_ref": { "r1141" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": { "r1167" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": { "r1141" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchanges", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": { "r230" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Financing Activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": { "r230" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchanges", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": { "r230" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Investing Activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": { "r230" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchanges", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": { "r127", "r128", "r129" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Operating Activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { "r127", "r128", "r129" }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited" }, "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to Medtronic", "verboseLabel": "Net income attributable to ordinary shareholders", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": { "r120", "r129", "r162" }

"r184", "r213", "r216", "r220", "r236", "r244", "r248", "r249", "r250", "r251", "r252", "r255", "r256", "r267",
 "r352", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r633", "r640", "r667", "r683",
 "r802", "r882", "r898", "r899", "r1089", "r1282"] }, "us-
 gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr":
 "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": {
 "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited" }, "lang": { "en-us": { "role": {
 "negatedTerseLabel": "Net income attributable to noncontrolling interests", "label": "Net Income (Loss)
 Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to
 noncontrolling interest." } } }, "auth_ref": { "r70", "r146", "r213", "r216", "r252", "r255", "r256", "r801", "r1193"]
 }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun
 t", "lang": { "en-us": { "role": { "terseLabel": "Net investment hedge", "label": "Net Investment Hedging
 [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": { "r74"] },
 "mdt_NeuromodulationDivisionMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.medtronic.com/20241025", "localname": "NeuromodulationDivisionMember", "presentation": {
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails" },
 "lang": { "en-us": { "role": { "terseLabel": "Neuromodulation", "label": "Neuromodulation Division [Member]",
 "documentation": "Neuromodulation Division" } } }, "auth_ref": [] }, "mdt_NeuroscienceGroupMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "NeuroscienceGroupMember", "presentation": {
 "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoo
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails",
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails",
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom
 t", "lang": { "en-us": { "role": { "terseLabel": "Neuroscience", "label": "Neuroscience Group [Member]",
 "documentation": "Neuroscience Group" } } }, "auth_ref": [] }, "us-
 gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "lang": { "en-us": { "role": {
 "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]", "label":
 "Accounting Standards Update and Change in Accounting Principle [Abstract]" } } }, "auth_ref": [] }, "us-
 gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": {
 "http://www.medtronic.com/role/NewAccountingPronouncements" }, "lang": { "en-us": { "role": { "terseLabel":
 "New Accounting Pronouncements", "label": "Accounting Standards Update and Change in Accounting Principle
 [Text Block]", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not
 limited to, nature, reason, and method of adopting amendment to accounting standards or other change in
 accounting principle." } } }, "auth_ref": { "r178", "r182", "r242", "r243", "r246", "r247", "r257", "r258", "r311",
 "r354", "r355", "r631", "r632", "r634", "r640", "r661", "r664", "r703", "r705", "r706", "r742", "r743", "r744",
 "r829", "r830", "r831", "r832", "r833"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
 "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": {
 "http://www.medtronic.com/role/BasisofPresentationPolicies" }, "lang": { "en-us": { "role": { "terseLabel":
 "Recently Adopted Accounting Standards and Not Yet Adopted Accounting Standards", "label": "New Accounting
 Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to
 new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to,
 quantification of the expected or actual impact." } } }, "auth_ref": [] },
 "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure
 Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": { "r1140"] },
 "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "NonNeosMember", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": {
 "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": { "r1104", "r1114", "r1124",
 "r1148", "r1156"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average
 Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } }
 }, "auth_ref": { "r1131"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average
 Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": {
 "r1130"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "NonPeoNeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-
 us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": { "r1148"] },
 "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "NonRule10b51ArrAdoptedFlag", "presentation": {
 "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Non-Rule
 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": {
 "r1167"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": {
 "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Non-Rule
 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": {
 "r1167"] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri":

["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "NoncontrollingInterestMember", "presentation": {
["http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited"](http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited) }, "lang": { "en-us": { "role": {
"verboseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This
element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to
the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": { "r65", "r471",
"r1207", "r1208", "r1209", "r1210", "r1366" } }, "us-gaap_NondesignatedMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NondesignatedMember",
"presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa)
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun)
}, "lang": { "en-us": { "role": { "terseLabel": "Derivatives not designated as hedging instruments", "label": "Not
Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as
hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": { "r17" } }, "us-
gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "NumberOfReportableSegments", "presentation": {
["http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails"](http://www.medtronic.com/role/SegmentandGeographicInformationNarrativeDetails) }, "lang": { "en-us": {
"role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments",
"documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity
for which there is an accounting requirement to report separate financial information on that component in the
entity's financial statements." } } }, "auth_ref": { "r1009", "r1017", "r1216" } }, "us-
gaap_OffsettingAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OffsettingAssetsTableTextBlock", "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables) }, "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Offsetting Assets", "label": "Offsetting Assets [Table Text Block]",
"documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting,
including master netting arrangements." } } }, "auth_ref": { "r109", "r203" } },
"mdt_OffsettingAssetsandLiabilitiesLineItems": { "xbrltype": "stringItemType", "nsuri":
["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname": "OffsettingAssetsandLiabilitiesLineItems", "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand)
}, "lang": { "en-us": { "role": { "terseLabel": "Offsetting Assets and Liabilities [Line Items]", "label": "Offsetting
Assets and Liabilities [Line Items]", "documentation": "[Line Items] for Offsetting Assets and Liabilities [Table]"
} } }, "auth_ref": { } }, "mdt_OffsettingAssetsandLiabilitiesTable": { "xbrltype": "stringItemType", "nsuri":
["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname": "OffsettingAssetsandLiabilitiesTable", "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand)
}, "lang": { "en-us": { "role": { "terseLabel": "Offsetting Assets and Liabilities [Table]", "label": "Offsetting Assets
and Liabilities [Table]", "documentation": "Offsetting Assets and Liabilities [Table]" } } }, "auth_ref": { } }, "us-
gaap_OffsettingLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OffsettingLiabilitiesTableTextBlock", "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables) }, "lang": { "en-us": {
"role": { "terseLabel": "Schedule of Offsetting Liabilities", "label": "Offsetting Liabilities [Table Text Block]",
"documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting,
including master netting arrangements." } } }, "auth_ref": { "r109", "r203" } }, "us-gaap_OperatingIncomeLoss": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss",
"crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited": {
"parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0, "order": 3.0 },
["http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom)
{ "parentTag": "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
"weight": 1.0, "order": 8.0 } }, "presentation": {
["http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited"](http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited),
["http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom)
}, "lang": { "en-us": { "role": { "totalLabel": "Operating profit", "terseLabel": "Reportable segment operating
profit", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting
operating expenses from operating revenues." } } }, "auth_ref": { "r167", "r1008", "r1215", "r1217", "r1218",
"r1219", "r1220" } }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "OperatingSegmentsMember", "presentation": {
["http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails"](http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails),
["http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"](http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails),
["http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom](http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncom)
}, "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]",
"documentation": "Identifies components of an entity that engage in business activities from which they may
earn revenue and incur expenses, including transactions with other components of the same entity." } } },
"auth_ref": { "r297", "r298", "r299", "r300", "r301", "r304", "r1013", "r1014" } }, "us-
gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": {
"terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label":
"Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": { } },
"mdt_OtherAccruedExpensesMember": { "xbrltype": "domainItemType", "nsuri":
["http://www.medtronic.com/20241025"](http://www.medtronic.com/20241025), "localname": "OtherAccruedExpensesMember", "presentation": {
["http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"](http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails),
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa)
["http://www.medtronic.com/role/RevenueNarrativeDetails"](http://www.medtronic.com/role/RevenueNarrativeDetails) }, "lang": { "en-us": { "role": { "terseLabel": "Other
accrued expenses", "label": "Other Accrued Expenses [Member]", "documentation": "Other Accrued Expenses" } }
}, "auth_ref": { } }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": {

["http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"](http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited): { "parentTag": "us-gaap_AssetsCurrent",
 "weight": 1.0, "order": 5.0 } }, "presentation": {
["http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"](http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited) }, "lang": { "en-us": { "role": {
 "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current
 assets classified as other." } } }, "auth_ref": { "r198", "r1065" } }, "us-gaap_OtherAssetsMember": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa),
["http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails"](http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails),
["http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi"](http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi)
 }, "lang": { "en-us": { "role": { "terseLabel": "Other Assets", "verboseLabel": "Other Assets", "label": "Other Assets
 [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref":
 { "r75", "r84" } }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
["http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"](http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited): { "parentTag": "us-gaap_Assets",
 "weight": 1.0, "order": 6.0 } }, "presentation": {
["http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"](http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited) }, "lang": { "en-us": { "role": {
 "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets
 classified as other." } } }, "auth_ref": { "r190" } }, "us-
 gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOf
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
 "crdr": "credit", "calculation": {
["http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"](http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited): { "parentTag": "us-
 gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": {
["http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited"](http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited) }, "lang": { "en-us":
 { "role": { "terseLabel": "Translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign
 Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount
 after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign
 currency transactions designated and effective as economic hedges of a net investment in a foreign entity and
 intra-entity foreign currency transactions that are of a long-term investment nature." } } }, "auth_ref": { "r4",
 "r112", "r113", "r115", "r684", "r685", "r687" } }, "us-
 gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType",
 "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": {
["http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi"](http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi)
 { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } },
 "presentation": {
["http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi"](http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherCoi)
 }, "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label":
 "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax,
 before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r22", "r26",
 "r219", "r688", "r691", "r694", "r803", "r1191" } }, "us-
 gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "xbrltype": "monetaryItemType", "nsuri":
["http://fasb.org/us-gaap/2024"](http://fasb.org/us-gaap/2024), "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
 "crdr": "debit", "presentation": {
["http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails"](http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails) }, "lang": { "en-us": {
 "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications, tax expense (benefit)",
 "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "documentation": "Amount of tax
 expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from
 accumulated other comprehensive income (loss)." } } }, "auth_ref": { "r7", "r218", "r803" } },
 "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAn
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
 "crdr": "credit", "calculation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH)
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH)
 }, "lang": { "en-us": { "role": { "negatedTotalLabel": "(Gain) Loss Reclassified into Income", "label": "Other
 Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification
 and Tax", "documentation": "Other Comprehensive Income (Loss),
 Cash Flow Hedge and Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "auth_ref": { } },
 "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax
 { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax",
 "crdr": "credit", "calculation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH)
 { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
["http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH"](http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH)
 }, "lang": { "en-us": { "role": { "negatedTotalLabel": "(Gain) Loss Reclassified into Income", "label": "Other
 Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain (Loss), Reclassification, before
 Tax", "documentation": "Other Comprehensive Income (Loss), Cash Flow Hedge and Net Investment Hedge, Gain
 (Loss), Reclassification, before Tax" } } }, "auth_ref": { } }, "us-
 gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit",
 "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": {
 "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 5.0 } }, "presentation":
 { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" }, "lang": { "en-

```

us": { "role": { "terseLabel": "Unrealized (loss) gain on cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r205", "r209", "r803" } }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAnd", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "lang": { "en-us": { "role": { "negatedTerseLabel": "Recognized in AOCI, cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r205", "r209", "r649", "r650", "r655" } }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "lang": { "en-us": { "role": { "negatedTerseLabel": "Recognized in income, cash flow hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": { "r176", "r209", "r211" } }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossBeforeReclassificationAnd", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "lang": { "en-us": { "role": { "negatedTerseLabel": "Recognized in AOCI, net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": { "r651" } }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "parentTag": "mdt_OtherComprehensiveIncomeLossCashFlowHedgeAndNetInvestmentHedgeGainLossReclassificationBeforeTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH { "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassified into Income, net investment hedges", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": { "r652" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleOfChangesInAccumulatedOtherCo { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleOfChangesInAccumulatedOtherCo { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited", "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited" } }, "lang": { "en-us": { "role": { "totalLabel": "Other comprehensive income", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r16", "r22", "r214", "r217", "r221", "r252", "r688", "r689", "r694", "r778", "r803", "r1191", "r1192" } }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" } }, "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": { } }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {

```

"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 4.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" }, "lang": { "en-us": { "role": { "negatedLabel": "Net change in retirement obligations", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": { "r5", "r6", "r114", "r115", "r803" } },
"mdt_OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedge": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "OtherComprehensiveIncomeLossUnrealizedGainLossOnDerivativesArisingDuringPeriodNetInvestmentHedgeNetOfTax", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Net investment hedge", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax", "documentation": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) On Derivatives Arising During Period, Net Investment Hedge, Net Of Tax" } } }, "auth_ref": { } }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on investment securities", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": { "r206", "r209", "r346" } }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": {
"http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulated": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": { "r1021", "r1259", "r1260", "r1261", "r1262", "r1263", "r1264", "r1266", "r1268", "r1269", "r1270" } }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Other accrued expenses", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r91", "r1065" } }, "us-gaap_OtherLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesMember", "presentation": {
"http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails",
"http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFairValue",
"http://www.medtronic.com/role/RevenueNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other liabilities." } } }, "auth_ref": { "r75", "r84" } }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r96" } }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Other, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": { "r129" } }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 },
"http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 10.0 } }, "presentation": {
"http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited",
"http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome"

], "lang": { "en-us": { "role": { "negatedLabel": "Other non-operating income, net", "terseLabel": "Other non-operating income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": { "r122" } }, "us-gaap-OtherNonrecurringIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonrecurringIncomeExpense", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "parentTag": "us-gaap-IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Other adjustments", "label": "Other Nonrecurring (Income) Expense", "documentation": "Amount of other expense (income) that is infrequent in occurrence or unusual in nature." } } }, "auth_ref": { "r123" } }, "us-gaap-OtherOperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseMember", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonD": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofGainsandLossesonH": { "lang": { "en-us": { "role": { "verboseLabel": "Other operating income, net", "terseLabel": "Other operating income, net", "label": "Other Operating Income (Expense) [Member]", "documentation": "Primary financial statement caption encompassing other operating income (expense)." } } }, "auth_ref": { "r123" } }, "us-gaap-OtherOperatingIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 8.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Other operating income, net", "label": "Other Operating Income (Expense), Net", "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations." } } }, "auth_ref": { "r123" } }, "ecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": { "r1140" } }, "mdt-OtherSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "OtherSegmentMember", "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Segment [Member]", "documentation": "Other Segment" } } }, "auth_ref": { "r123" } }, "ecd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r1102", "r1112", "r1122", "r1154" } }, "ecd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": { "r1105", "r1115", "r1125", "r1157" } }, "ecd-OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": { "r1105", "r1115", "r1125", "r1157" } }, "srt-OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]" } } }, "auth_ref": { "r123" } }, "srt-OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]" } } }, "auth_ref": { "r123" } }, "us-gaap-ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Total Shareholders' u2019 Equity", "label": "Parent [Member]", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": { "r123" } }, "ecd-PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": { "r1129" } }, "us-gaap-PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Other investing activities, net", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": { "r1179", "r1197" } }, "us-gaap-PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of ordinary shares", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": { "r126" } }, "us-gaap-PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",

"localname": "PaymentsForRestructuring", "crdr": "credit", "presentation": {
<http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails> },
 "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash payments", "label": "Payments for Restructuring",
 "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r410", "r1201" } },
 "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited>: { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited> }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Dividends to shareholders", "label": "Payments of Ordinary Dividends, Common Stock",
 "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": { "r126" } }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited>: { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited> }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired",
 "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": { "r30" } }, "us-gaap_PaymentsToAcquireInvestments": {
 "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited>: { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited> }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": { "r124" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited>: { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": {
<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited> }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Additions to property, plant, and equipment", "label": "Payments to Acquire Property, Plant, and Equipment",
 "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r125" } },
 "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { <http://xbrl.sec.gov/ecd/role/PvpDisclosure> },
 "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": { "r1139" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype":
 "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { <http://xbrl.sec.gov/ecd/role/PvpDisclosure> }, "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } },
 "auth_ref": { "r1139" } }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PendingLitigationMember", "presentation": {
<http://www.medtronic.com/role/CommitmentsandContingenciesDetails> }, "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": { "r1277" } }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
<http://fasb.org/us-gaap/2024>, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": { <http://www.medtronic.com/role/RetirementBenefitPlans> }, "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefit Plans", "label": "Retirement Benefits [Text Block]", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": { "r487", "r512", "r514", "r520", "r538", "r540", "r541", "r542", "r543", "r544", "r559", "r560", "r561", "r1038" } }, "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent", "crdr": "credit", "calculation": {
<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited>: { "parentTag": "us-gaap_Liabilities", "weight": -1.0, "order": 3.0 } }, "presentation": {
<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited> }, "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and retirement benefits", "label": "Liability, Defined Benefit Plan, Noncurrent", "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent." } } }, "auth_ref": { "r96", "r488", "r489", "r511", "r1038" } }, "us-gaap_PensionPlansDefinedBenefitMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PensionPlansDefinedBenefitMember", "presentation": {
<http://www.medtronic.com/role/RetirementBenefitPlansDetails> }, "lang": { "en-us": { "role": { "terseLabel": "Pension Plan", "label": "Pension Plan [Member]", "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits." } } }, "auth_ref": { "r488", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r537", "r539", "r542", "r545", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r562", "r565", "r1038", "r1039", "r1043", "r1044", "r1045" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
<http://xbrl.sec.gov/ecd/2024>, "localname": "PeoActuallyPaidCompAmt", "presentation": {

"http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": { "r1131" } },
 "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
 "PeoMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": {
 "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": { "r1148" } }, "ecd_PeoName": { "xbrltype":
 "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label":
 "PEO Name" } } }, "auth_ref": { "r1141" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation
 Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": { "r1130" } }, "us-
 gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "PerformanceSharesMember", "presentation": {
 "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel
 "http://www.medtronic.com/role/StockBasedCompensationDetails",
 "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "verboseLabel": "Employee
 performance share units", "terseLabel": "Performance share units", "label": "Performance Shares [Member]",
 "documentation": "Share-based payment arrangement awarded for meeting performance target." } } },
 "auth_ref": { } }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments
 Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": { "r1132" } },
 "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
 "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
 "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost
 [Member]" } } }, "auth_ref": { "r1176" } }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits
 Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": {
 "r1131" } }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa
], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Prepaid Expenses and Other Current
 Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and
 other current assets." } } }, "auth_ref": { } }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": {
 "terseLabel": "Issuance of long-term debt", "label": "Proceeds from Issuance of Long-Term Debt",
 "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the
 operating cycle, if longer." } } }, "auth_ref": { "r31", "r836" } }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity":
 { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": {
 "terseLabel": "Issuance of ordinary shares", "label": "Proceeds from Issuance or Sale of Equity", "documentation":
 "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other
 types of equity." } } }, "auth_ref": { "r8", "r836" } }, "us-
 gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr":
 "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
 "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } },
 "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-
 us": { "role": { "terseLabel": "Other financing activities, net", "label": "Proceeds from (Payments for) Other
 Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as
 other." } } }, "auth_ref": { "r1180", "r1198" } }, "us-gaap_ProceedsFromRepaymentsOfDebt": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromRepaymentsOfDebt",
 "crdr": "debit", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "Proceeds from (repayments of) debt", "label": "Proceeds from
 (Repayments of) Debt", "documentation": "The net cash inflow or outflow in aggregate debt due to repayments
 and proceeds from additional borrowings." } } }, "auth_ref": { } }, "us-
 gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess", "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": {
 "terseLabel": "Change in current debt obligations, net", "label": "Proceeds from (Repayments of) Short-Term
 Debt, Maturing in Three Months or Less", "documentation": "The cash inflow from a borrowing net of the cash
 outflow from repayment of a borrowing having initial term of repayment within three months." } } }, "auth_ref": {
 "r1199", "r1200", "r1204" } }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype":
 "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-
 gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": {

"<http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited>"], "lang": { "en-us": { "role": { "verboseLabel": "Sales and maturities of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": { "r28" } }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "presentation": { "<http://www.medtronic.com/role/FinancialInstrumentsScheduleofActivityRelatedtoAvailableforSaleSecuritiesPortfolio>": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales", "label": "Proceeds from Sale of Debt Securities, Available for Sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": { "r29", "r227", "r314", "r345" } }, "mdt_ProductDevelopmentMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "<http://www.medtronic.com/20241025>", "localname": "ProductDevelopmentMilestoneMember", "presentation": { "<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities>": { "lang": { "en-us": { "role": { "terseLabel": "Product development and other milestone-based payments", "label": "Product Development Milestone [Member]", "documentation": "A milestone in achieving certain product development target." } } }, "auth_ref": { } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "<http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited>": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "<http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited>": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 }, "<http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited>": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } } }, "presentation": { "<http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited>", "<http://www.medtronic.com/role/ConsolidatedStatementsOfComprehensiveIncomeUnaudited>", "<http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited>", "<http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited>"], "lang": { "en-us": { "role": { "totalLabel": "Net income", "verboseLabel": "Net income", "terseLabel": "Net income", "label": "Net Income (Loss). Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r184", "r213", "r216", "r229", "r236", "r244", "r252", "r255", "r256", "r352", "r432", "r433", "r435", "r436", "r437", "r438", "r439", "r441", "r442", "r633", "r640", "r641", "r644", "r645", "r667", "r683", "r783", "r800", "r840", "r882", "r898", "r899", "r1050", "r1051", "r1090", "r1193", "r1282" } }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited>": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "<http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited>"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r12", "r702", "r788", "r798", "r1065" } }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "<http://fasb.org/us-gaap/2024>", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "<http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited>": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": { "<http://www.medtronic.com/role/ConsolidatedStatementsOfCashFlowsUnaudited>"], "lang": { "en-us": { "role": { "terseLabel": "Provision for credit losses", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": { "r226", "r360" } }, "mdt_PurchasedTechnologyAndPatentsMember": { "xbrltype": "domainItemType", "nsuri": "<http://www.medtronic.com/20241025>", "localname": "PurchasedTechnologyAndPatentsMember", "presentation": { "<http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumulatedAmortization>": { "lang": { "en-us": { "role": { "terseLabel": "Purchased technology and patents", "label": "Purchased Technology And Patents [Member]", "documentation": "Purchased technology and patents." } } }, "auth_ref": { } }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "<http://xbrl.sec.gov/ecd/2024>", "localname": "PvpTable", "presentation": { "<http://xbrl.sec.gov/ecd/role/PvpDisclosure>"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "documentation": "Pay vs Performance Disclosure [Table Text Block]" } } }, "auth_ref": { "r1129" } }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "<http://xbrl.sec.gov/ecd/2024>", "localname": "PvpTableTextBlock", "presentation": { "<http://xbrl.sec.gov/ecd/role/PvpDisclosure>"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": { "r1129" } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "<http://fasb.org/srt/2024>", "localname": "RangeAxis", "presentation": { "<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities>": { "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Statistical Measurement [Domain]", "documentation": "Statistical Measurement [Domain]" } } }, "auth_ref": { "r422", "r424", "r425", "r426", "r512", "r564", "r594", "r595", "r596", "r603", "r673", "r714", "r723", "r739", "r822", "r824", "r834", "r852", "r853", "r906", "r925", "r930", "r931", "r969", "r991", "r992", "r1018", "r1028", "r1046", "r1057", "r1058", "r1062", "r1063", "r1075", "r1081", "r1275", "r1284", "r1302", "r1323", "r1324", "r1325", "r1326", "r1327" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "<http://fasb.org/srt/2024>", "localname": "RangeMember", "presentation": { "<http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities>": { "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical Measurement [Domain]", "documentation": "Statistical Measurement [Domain]" } } }, "auth_ref": { "r422", "r424", "r425", "r426", "r512", "r564", "r594", "r595", "r596", "r603", "r673", "r714", "r723", "r739", "r822", "r824", "r834", "r852", "r853", "r906", "r925", "r930", "r931", "r969", "r991", "r992", "r1018", "r1028", "r1046", "r1057", "r1058", "r1062", "r1063", "r1075", "r1081", "r1275", "r1284", "r1302", "r1323", "r1324", "r1325", "r1326", "r1327" } }, "us-

gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassifications", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "auth_ref": { "r22", "r26", "r219", "r688", "r693", "r694", "r803", "r1191" } }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "lang": { "en-us": { "role": { "terseLabel": "AOCl Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "label": "AOCl Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "auth_ref": { } }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAociCurrentPeriodTax", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Reclassifications, tax expense (benefit)", "label": "Reclassification from AOCl, Current Period, Tax", "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "auth_ref": { "r7", "r212", "r218", "r803" } }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Operating Profit and Income Before Income Taxes", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "auth_ref": { "r41", "r42" } }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": { "r1097", "r1107", "r1117", "r1149" } }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.", "auth_ref": { "r1292" } }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://www.medtronic.com/role/StockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "auth_ref": { } }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]", "auth_ref": { "r1098", "r1108", "r1118", "r1150" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date", "auth_ref": { "r1099", "r1109", "r1119", "r1151" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]", "auth_ref": { "r1106", "r1116", "r1126", "r1158" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDetails": { "http://www.medtronic.com/role/StockBasedCompensationDetails": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Employee restricted stock units", "verboseLabel": "Restricted stock", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "auth_ref": { } }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCosts" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Other Costs", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": ["r407", "r408", "r410", "r413", "r418"] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome" }, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 7.0 } }, "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsNarrativeDetails", "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges", "negatedLabel": "Restructuring and associated costs", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": ["r11", "r414", "r415", "r1276"] }, "mdt_RestructuringChargesIncludingAccrualAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "RestructuringChargesIncludingAccrualAdjustments", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Charges", "label": "Restructuring Charges, Including Accrual Adjustments", "documentation": "Restructuring Charges, Including Accrual Adjustments" } } }, "auth_ref": [] }, "us-gaap_RestructuringChargesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringChargesMember", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges, net", "label": "Restructuring Charges [Member]", "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included." } } }, "auth_ref": ["r133", "r135"] }, "mdt_RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "RestructuringChargesNetOfRestructuringReversalsIncludingCostOfProductSoldImpact", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring charges, net", "label": "Restructuring Charges, Net Of Restructuring Reversals Including Cost Of Product Sold Impact", "documentation": "Amount of expenses, net of reversals, associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to discontinued operation or an asset retirement obligation." } } }, "auth_ref": [] }, "us-gaap_RestructuringCostAndReserveAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveAxis", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring Type [Axis]", "label": "Restructuring Type [Axis]", "documentation": "Information by type of restructuring cost." } } }, "auth_ref": ["r409", "r410", "r415", "r416"] }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails", "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r409", "r410", "r411", "r412", "r415", "r416", "r417"] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" }, "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": ["r410", "r416"] }, "us-gaap_RestructuringReserveAccrualAdjustment1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAccrualAdjustment1", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrual adjustments", "label": "Restructuring Reserve, Accrual Adjustment", "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability." } } }, "auth_ref": ["r410", "r416"] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring

Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } }], "auth_ref": [] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Settled non-cash", "label": "Restructuring Reserve, Settled without Cash", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": ["r410", "r416"] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r102", "r140", "r795", "r829", "r833", "r837", "r863", "r1065"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r180", "r239", "r240", "r241", "r245", "r252", "r254", "r256", "r353", "r356", "r398", "r621", "r622", "r628", "r629", "r630", "r634", "r639", "r640", "r656", "r658", "r659", "r662", "r665", "r698", "r700", "r826", "r828", "r841", "r1366"] }, "us-gaap_RetirementPlanSponsorLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationAxis", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Axis]", "label": "Retirement Plan Sponsor Location [Axis]", "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r539", "r542", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r1289", "r1290", "r1291"] }, "us-gaap_RetirementPlanSponsorLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanSponsorLocationDomain", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Sponsor Location [Domain]", "label": "Retirement Plan Sponsor Location [Domain]", "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans." } } }, "auth_ref": ["r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r539", "r542", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r1289", "r1290", "r1291"] }, "us-gaap_RetirementPlanTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeAxis", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Axis]", "label": "Retirement Plan Type [Axis]", "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": ["r488", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r537", "r539", "r542", "r545", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r565", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045"] }, "us-gaap_RetirementPlanTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetirementPlanTypeDomain", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Retirement Plan Type [Domain]", "label": "Retirement Plan Type [Domain]", "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement." } } }, "auth_ref": ["r488", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r536", "r537", "r539", "r542", "r545", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r561", "r562", "r563", "r565", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044", "r1045"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails",

"http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails",
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe",
], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "verboseLabel": "Total net sales", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r165", "r166", "r275", "r282", "r283", "r297", "r303", "r306", "r308", "r310", "r482", "r483", "r740"], "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": { "http://www.medtronic.com/role/Revenue": ["lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r179", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r486"], "mdt_RevenueMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "RevenueMilestoneMember", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingent",
], "lang": { "en-us": { "role": { "terseLabel": "Revenue and other performance-based payments", "label": "Revenue Milestone [Member]", "documentation": "A milestone in achieving certain revenue target." } } }, "auth_ref": [] }, "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuePerformanceObligationDescriptionOfTiming", "presentation": { "http://www.medtronic.com/role/RevenueNarrativeDetails": ["lang": { "en-us": { "role": { "terseLabel": "Period over which remaining performance obligations are expected to be recognized as revenue", "label": "Revenue, Performance Obligation, Description of Timing", "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service." } } }, "auth_ref": ["r475"], "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/RevenueNarrativeDetails": ["lang": { "en-us": { "role": { "terseLabel": "Estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations", "label": "Revenue, Remaining Performance Obligation, Amount", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r173"], "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe",
], "lang": { "en-us": { "role": { "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": ["lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r1167"], "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": ["lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r1167"], "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossTables": ["lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss (AOCL), Net of Tax, by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r26", "r1315", "r1316"], "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": { "http://www.medtronic.com/role/EarningsPerShareNarrativeDetails": ["lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": ["r36"], "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesOfAvailablef",
], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326"], "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": {

"http://www.medtronic.com/role/AcquisitionsandDispositionsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Contingent Consideration Liabilities and Receivables", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": { "r58", "r59", "r635" } }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCosts": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCosts", "presentation": { "http://www.medtronic.com/role/StockBasedCompensationTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components and Classification of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]", "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit." } } }, "auth_ref": { "r54" } }, "mdt_ScheduleOfDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "ScheduleOfDebtLineItems", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt [Line Items]", "label": "Schedule of Debt [Line Items]", "documentation": "Schedule of Debt [Line Items]" } } }, "auth_ref": { } }, "mdt_ScheduleOfDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "ScheduleOfDebtTable", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt [Table]", "label": "Schedule of Debt [Table]", "documentation": "A table or schedule providing information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt Obligations", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": { } }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]", "label": "Defined Benefit Plan [Table]", "documentation": "Disclosure of information about individual defined benefit pension plan or other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": { "r13", "r49", "r50", "r51", "r52" } }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Outstanding Instruments and Gains and Losses on Hedging Instruments and Derivatives Not Designated as Hedging Instruments", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": { "r76", "r79", "r653" } }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Classification and Fair Value of Derivative Instruments in Balance Sheets", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": { "r77" } }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://www.medtronic.com/role/EarningsPerShareTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computation of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": { "r1214" } }, "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",

"presentation": {

"http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": { "r35", "r37", "r262", "r266", "r268" } }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Line Items]", "label": "Schedule of Equity Method Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r236", "r349", "r350", "r351", "r352", "r683" } }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEquityMethodInvestmentsTable", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofEquityandOtherInvestmentsDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Method Investments [Table]", "label": "Equity Method Investment [Table]", "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets." } } }, "auth_ref": { "r184", "r236", "r349", "r350", "r351", "r352", "r683" } }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."} } } }, "auth_ref": { "r1299", "r1300" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": { "r384", "r391", "r395", "r396", "r397", "r741", "r993", "r1021" } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { "r1021", "r1265" } }, "us-gaap_ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatem": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGainLossOnInvestmentsIncludingMarketableSecuritiesAndInvestmentsHeldAtCostIncomeStatementR", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Gain (Loss) on Securities [Line Items]", "label": "Gain (Loss) on Securities [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r1194", "r1195", "r1237" } }, "us-gaap_ScheduleOfGainLossOnInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGainLossOnInvestmentsTable", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gain (Loss) on Securities [Table]", "label": "Schedule of Gain (Loss) on Securities [Table]", "documentation": "Disclosure of information about realized and unrealized gain (loss) on investment in security." } } }, "auth_ref": { "r1194", "r1195", "r1237" } }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": { "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r1020" } }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in the Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": { "r1020", "r1247", "r1248", "r1249", "r1250", "r1251", "r1252", "r1253", "r1254", "r1255", "r1256", "r1257" } }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]", "label": "Intangible Asset, Indefinite-Lived [Table]", "documentation": "Disclosure of information about indefinite-lived

intangible asset. Excludes finite-lived intangible asset." } } }, "auth_ref": ["r384", "r394", "r397", "r1021"] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": ["r1021", "r1268"] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": { "http://www.medtronic.com/role/InventoriesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventory Balances", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": ["r24", "r106", "r107", "r108"] }, "us-gaap_ScheduleOfInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsLineItems", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Line Items]", "label": "Schedule of Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r960", "r961", "r962", "r963", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978"] }, "us-gaap_ScheduleOfInvestmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfInvestmentsTable", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Investments [Table]", "label": "Schedule of Investments [Table]", "documentation": "Disclosure of information about investments owned by investment company." } } }, "auth_ref": ["r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935", "r936", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r960", "r961", "r962", "r964", "r965", "r966", "r967", "r968", "r969", "r970", "r971", "r972", "r973", "r974", "r975", "r976", "r977", "r978"] }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "presentation": { "http://www.medtronic.com/role/RetirementBenefitPlansTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Net Periodic Benefit Cost", "label": "Schedule of Net Benefit Costs [Table Text Block]", "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments." } } }, "auth_ref": ["r142"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails": "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": ["r409", "r410", "r411", "r412", "r415", "r416", "r417"] }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs and Activity of Restructuring Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": ["r44", "r133", "r134"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Sales to External Customers by Geography", "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]", "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r43", "r116"] }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "documentation": "Disclosure of information about revenue from external customer and long-lived asset by

geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset." } } }, "auth_ref": ["r43", "r116"] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": ["http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": ["r38", "r39", "r40"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.medtronic.com/role/StockBasedCompensationDetails", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r567", "r569", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597"] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": ["http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsTables", "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Future Aggregate Amortization Expense", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": ["r1021", "r1267"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.medtronic.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r1092"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.medtronic.com/role/Cover", "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r1094"] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": ["http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails", "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoo", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome", "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": ["r165", "r166", "r167", "r168", "r275", "r278", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r305", "r310", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r397", "r412", "r417", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r1010", "r1013", "r1014", "r1020", "r1077", "r1330", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1361", "r1362"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.medtronic.com/role/CommitmentsandContingenciesDetails", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstrun", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe", "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": ["r308", "r309", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r845", "r848", "r850", "r912", "r926", "r947", "r975", "r980", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r994", "r1030", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1076", "r1081", "r1286", "r1330", "r1334", "r1335", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1361", "r1362"] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": ["http://www.medtronic.com/role/SegmentandGeographicInformation", "lang": { "en-us": { "role": { "terseLabel": "Segment and Geographic Information", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": ["r168", "r275", "r277", "r278", "r279", "r280", "r281", "r293", "r295", "r296", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r310", "r1009", "r1011",

"r1012", "r1013", "r1015", "r1016", "r1017"] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": { "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited": { "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r121"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": { "http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofRestructuringandRelatedCostsDetails": { "http://www.medtronic.com/role/StockBasedCompensationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative expense", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "mdt_SeniorNotes2009Due20396500PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2009Due20396500PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "6.500 percent thirty-year 2009 senior notes", "label": "Senior Notes 2009 Due 2039, 6.500 Percent [Member]", "documentation": "Senior Notes 2009 Due 2039, 6.500 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2010Due20405550PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2010Due20405550PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "5.550 percent thirty-year 2010 senior notes", "label": "Senior Notes 2010 Due 2040, 5.550 Percent [Member]", "documentation": "Senior Notes 2010 Due 2040, 5.550 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2012Due20424500PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2012Due20424500PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "4.500 percent thirty-year 2012 senior notes", "label": "Senior Notes 2012 Due 2042, 4.500 Percent [Member]", "documentation": "Senior Notes 2012 Due 2042, 4.500 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2013Due20434000PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2013Due20434000PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "4.000 percent thirty-year 2013 senior notes", "label": "Senior Notes 2013 Due 2043, 4.000 Percent [Member]", "documentation": "Senior Notes 2013 Due 2043, 4.000 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2014Due20444625PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2014Due20444625PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "4.625 percent thirty-year 2014 senior notes", "label": "Senior Notes 2014 Due 2044, 4.625 Percent [Member]", "documentation": "Senior Notes 2014 Due 2044, 4.625 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2015Due20354.375PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2015Due20354.375PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "4.375 percent twenty-year 2015 senior notes", "label": "Senior Notes 2015 Due 2035, 4.375 Percent [Member]", "documentation": "Senior Notes 2015 Due 2035, 4.375 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2015Due20454625PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2015Due20454625PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "4.625 percent thirty-year 2015 senior notes", "label": "Senior Notes 2015 Due 2045, 4.625 Percent [Member]", "documentation": "Senior Notes 2015 Due 2045, 4.625 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20260250PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2019Due20260250PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "0.25 percent six-year 2019 senior notes", "label": "Senior Notes 2019 Due 2026, 0.250 Percent [Member]", "documentation": "Senior Notes 2019 Due 2026, 0.250 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20271125PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2019Due20271125PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "1.125 percent eight-year 2019 senior notes", "label": "Senior Notes 2019 Due 2027, 1.125 Percent [Member]", "documentation": "Senior Notes 2019 Due 2027, 1.125 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20311625PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2019Due20311625PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails": { "lang": { "en-us": { "role": { "terseLabel": "1.625 percent twelve-year 2019 senior notes", "label": "Senior Notes 2019 Due 2031, 1.625 Percent [Member]", "documentation": "Senior Notes 2019 Due 2031, 1.625 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2019Due20321000PercentMember": { "xbrltype": "domainItemType", "nsuri":

[illegible]

"lang": { "en-us": { "role": { "terseLabel": "3.650 percent five-year 2024 senior notes", "label": "Senior Notes 2024 Due 2030, 3.650 Percent [Member]", "documentation": "Senior Notes 2024 Due 2030, 3.650 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2024Due20373.875PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2024Due20373.875PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "3.875 percent twelve-year 2024 senior notes", "label": "Senior Notes 2024 Due 2037, 3.875 Percent [Member]", "documentation": "Senior Notes 2024 Due 2037, 3.875 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2024Due20444.150PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2024Due20444.150PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "4.150 percent nineteen-year 2024 senior notes", "label": "Senior Notes 2024 Due 2044, 4.150 Percent [Member]", "documentation": "Senior Notes 2024 Due 2044, 4.150 Percent" } } }, "auth_ref": [] }, "mdt_SeniorNotes2024Due20544.150PercentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SeniorNotes2024Due20544.150PercentMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "4.150 percent twenty-nine-year 2024 senior notes", "label": "Senior Notes 2024 Due 2054, 4.150 Percent [Member]", "documentation": "Senior Notes 2024 Due 2054, 4.150 Percent" } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails", "http://www.medtronic.com/role/FinancingArrangementsScheduleofDebtObligationsDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Business Combinations", "label": "Series of Individually Immaterial Business Acquisitions [Member]", "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period." } } }, "auth_ref": ["r59"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 }, "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 11.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome" }, "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r10"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.medtronic.com/role/StockBasedCompensationDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r567", "r569", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "http://www.medtronic.com/role/StockBasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597"] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeAxis", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Axis]", "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r90", "r1272", "r1273", "r1274"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Short-term Debt, Type [Domain]", "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r88", "r1272", "r1273", "r1274"] }, "us-gaap_ShortTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtWeightedAverageInterestRateOverTime", "presentation": { "http://www.medtronic.com/role/FinancingArrangementsNarrativeDetails" }, "lang": { "en-us": {

"role": { "terseLabel": "Weighted average interest rate", "label": "Short-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of short-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r159", "r160", "r1190"] }, "mdt_SpecialtyTherapiesDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "SpecialtyTherapiesDivisionMember", "presentation": { "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Specialty Therapies", "label": "Specialty Therapies Division [Member]", "documentation": "Specialty Therapies Division [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": { "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsNarrativeDetails" }, "http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofChangesintheCarryingAmountofGoodwillandOtherIntangibleAssets", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofSegmentOperatingProfitandIncome", "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": ["r165", "r166", "r167", "r168", "r183", "r275", "r278", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r303", "r304", "r305", "r310", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r397", "r400", "r412", "r417", "r811", "r812", "r813", "r814", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r1010", "r1013", "r1014", "r1020", "r1077", "r1330", "r1334", "r1335", "r1336", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1361", "r1362"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossNarrativeDetails" }, "http://www.medtronic.com/role/AccumulatedOtherComprehensiveLossScheduleofChangesinAccumulatedOtherComprehensiveLoss", "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r16", "r100", "r103", "r104", "r180", "r218", "r219", "r220", "r239", "r240", "r241", "r245", "r252", "r254", "r256", "r276", "r353", "r356", "r398", "r471", "r621", "r622", "r628", "r629", "r630", "r634", "r639", "r640", "r656", "r657", "r658", "r659", "r660", "r662", "r665", "r688", "r690", "r691", "r692", "r693", "r694", "r698", "r700", "r704", "r803", "r826", "r827", "r828", "r841", "r900"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.medtronic.com/role/CommitmentsandContingenciesDetails", "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOutstandingInstruments", "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails", "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalesstoExternalCustomersbyGeography", "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": ["r308", "r309", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r775", "r845", "r848", "r850", "r912", "r926", "r947", "r975", "r980", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r994", "r1030", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1076", "r1081", "r1286", "r1330", "r1334", "r1335", "r1337", "r1338", "r1339", "r1340", "r1341", "r1342", "r1343", "r1344", "r1345", "r1346", "r1347", "r1348", "r1349", "r1350", "r1351", "r1352", "r1353", "r1354", "r1355", "r1356", "r1357", "r1358", "r1359", "r1361", "r1362"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofEquityUnaudited" }, "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r239", "r240", "r241", "r276", "r700", "r740", "r835", "r842", "r854", "r855", "r856", "r857", "r858", "r859", "r862", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r875", "r876", "r877", "r878", "r879", "r881", "r883", "r884", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r900", "r1082"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": {

"http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r239", "r240", "r241", "r276", "r312", "r700", "r740", "r835", "r842", "r854", "r855", "r856", "r857", "r858", "r859", "r862", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r875", "r876", "r877", "r878", "r879", "r881", "r883", "r884", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r900", "r1082" } }, "ecd_StkPreOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPreOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": { "r1101", "r1111", "r1121", "r1153" } } }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } } }, "auth_ref": { } }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares under stock purchase and award plans (shares)", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } } }, "auth_ref": { "r16", "r99", "r100", "r140" } }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares under stock purchase and award plans", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } } }, "auth_ref": { "r53", "r99", "r100", "r140" } }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of ordinary shares (shares)", "label": "Stock Repurchased and Retired During Period, Shares", "documentation": "Number of shares that have been repurchased and retired during the period." } } } }, "auth_ref": { "r16", "r99", "r100", "r140" } }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfEquityUnaudited"], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of ordinary shares", "label": "Stock Repurchased and Retired During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } } }, "auth_ref": { "r16", "r99", "r100", "r140" } }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' 2019 equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } } }, "auth_ref": { "r100", "r103", "r104", "r131", "r864", "r880", "r901", "r902", "r1065", "r1091", "r1206", "r1243", "r1314", "r1366" } }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "terseLabel": "Shareholders' 2019 equity", "label": "Equity, Attributable to Parent [Abstract]" } } } }, "auth_ref": { } }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedBalanceSheetsUnaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } } }, "auth_ref": { "r65", "r66", "r69", "r180", "r181", "r219", "r239", "r240", "r241", "r245", "r252", "r254", "r353", "r356", "r398", "r471", "r621", "r622", "r628", "r629", "r630", "r634", "r639", "r640", "r656", "r657", "r658", "r659", "r660", "r662", "r665", "r688", "r690", "r694", "r699", "r704", "r827", "r828", "r839", "r864", "r880", "r901", "r902", "r979", "r1090", "r1206", "r1243", "r1314", "r1366" } }, "mdt_StructuralHeartAndAorticDivisionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "StructuralHeartAndAorticDivisionMember", "presentation": { "http://www.medtronic.com/role/RevenueScheduleOfDisaggregationOfNetSalesbySegmentandDivisionDetails"], "lang": { "en-us": { "role": { "terseLabel": "Structural Heart & Aortic", "label": "Structural Heart And Aortic Division [Member]", "documentation": "Coronary and Structural Heart Division [Member]" } } } }, "auth_ref": { } }, "us-gaap_SubsegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsAxis", "presentation": {

["http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"](http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails)],
 "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Axis]", "label": "Subsegments [Axis]", "documentation":
 "Information by business subsegments." } } } }, "auth_ref": [] }, "us-gaap_SubsegmentsDomain": { "xbrltype":
 "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsegmentsDomain", "presentation": {
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "Subsegments [Domain]", "label": "Subsegments [Domain]",
 "documentation": "Divisions of a component of an entity that engage in business activities from which they may
 earn revenue and incur expenses, including transactions with other components of the same entity." } } } },
 "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "SubsequentEventMember", "presentation": {
 "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": {
 "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that
 occurred after the balance sheet date but before financial statements are issued or available to be issued." } } } },
 "auth_ref": ["r695", "r707"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri":
 "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": {
 "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": {
 "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation":
 "Information by event that occurred after the balance sheet date but before financial statements are issued or
 available to be issued." } } } }, "auth_ref": ["r695", "r707"] }, "us-gaap_SubsequentEventTypeDomain": {
 "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "SubsequentEventTypeDomain", "presentation": {
 "http://www.medtronic.com/role/CommitmentsandContingenciesDetails"], "lang": { "en-us": { "role": {
 "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation":
 "Event that occurred after the balance sheet date but before financial statements are issued or available to be
 issued." } } } }, "auth_ref": ["r695", "r707"] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype":
 "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
 "SupplementalCashFlowInformationAbstract", "presentation": {
 "http://www.medtronic.com/role/ConsolidatedStatementsofCashFlowsUnaudited"], "lang": { "en-us": { "role": {
 "terseLabel": "Supplemental Cash Flow Information", "label": "Supplemental Cash Flow Information [Abstract]" } } } }
 } }, "auth_ref": [] }, "mdt_SurgicalEndoscopyMember": { "xbrltype": "domainItemType", "nsuri":
 "http://www.medtronic.com/20241025", "localname": "SurgicalEndoscopyMember", "presentation": {
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "Surgical & Endoscopy", "label": "Surgical Endoscopy [Member]",
 "documentation": "Surgical Endoscopy" } } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype":
 "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock",
 "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular
 List, Table", "label": "Tabular List [Table Text Block]" } } } }, "auth_ref": ["r1147"] }, "us-
 gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
 gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": {
 "http://www.medtronic.com/role/AcquisitionsandDispositionsNarrativeDetails"], "lang": { "en-us": { "role": {
 "terseLabel": "Technology-Based Intangible Assets", "label": "Technology-Based Intangible Assets [Member]",
 "documentation": "Technology-based intangible assets, including, but not limited to, patented technology,
 unpatented technology, and developed technology rights." } } } }, "auth_ref": ["r21", "r1259", "r1260", "r1261",
 "r1262", "r1264", "r1266", "r1269", "r1270"] }, "mdt_TotalOtherCountriesExcludingIrelandMember": {
 "xbrltype": "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "TotalOtherCountriesExcludingIrelandMember", "presentation": {
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe"],
 "lang": { "en-us": { "role": { "terseLabel": "Total other countries, excluding Ireland", "label": "Total Other
 Countries, Excluding Ireland [Member]", "documentation": "Total Other Countries, Excluding Ireland [Member]" } } } },
 "auth_ref": [] }, "mdt_TotalOtherCountriesExcludingUnitedStatesAndIrelandMember": { "xbrltype":
 "domainItemType", "nsuri": "http://www.medtronic.com/20241025", "localname":
 "TotalOtherCountriesExcludingUnitedStatesAndIrelandMember", "presentation": {
 "http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe"],
 "lang": { "en-us": { "role": { "terseLabel": "Rest of world", "label": "Total Other Countries, Excluding United
 States And Ireland [Member]", "documentation": "Total Other Countries, Excluding United States and Ireland
 [Member]" } } } }, "auth_ref": [] }, "mdt_TotalReportableSegmentsMember": { "xbrltype": "domainItemType",
 "nsuri": "http://www.medtronic.com/20241025", "localname": "TotalReportableSegmentsMember",
 "presentation": {
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails",
 "http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbySegmentandDivisionDetails"],
 "lang": { "en-us": { "role": { "terseLabel": "Reportable segment net sales", "label": "Total Reportable Segments
 [Member]", "documentation": "Total Reportable Segments" } } } }, "auth_ref": [] }, "us-
 gaap_TotalReturnSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
 "localname": "TotalReturnSwapMember", "presentation": {
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofClassificationandFa"],
 "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementScheduleofOffsettingAssetsand"],
 "lang": { "en-us": { "role": { "verboseLabel": "Total return swaps", "label": "Total Return Swap [Member]",
 "documentation": "Contracts in which one party makes payments at a fixed or variable rate while the
 counterparty makes payments based on an asset, including the income and capital gains derived therefrom." } } } },
 "auth_ref": ["r148", "r1086", "r1087"] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType",
 "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder
 Return Amount", "label": "Total Shareholder Return Amount" } } } }, "auth_ref": ["r1139"] },
 "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
 "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": {
 "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder
 Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } } }, "auth_ref": [
 "r1146"] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri":

"http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": {
"http://www.medtronic.com/role/GoodwillandOtherIntangibleAssetsScheduleofGrossCarryingAmountandAccumula
t", "lang": { "en-us": { "role": { "terseLabel": "Trademarks and tradenames", "label": "Trademarks and Trade
Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect
exclusive use of a business name, symbol or other device or style, or rights either acquired through registration
of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": { "r62", "r1259", "r1260", "r1261",
"r1262", "r1263", "r1264", "r1266", "r1268", "r1269", "r1270" } }, "ecd_TradingArrAxis": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Trading
Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": { "r1166" } },
"ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TradingArrByIndTable", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": {
"en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by
Individual [Table]" } } }, "auth_ref": { "r1168" } }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": {
"http://www.medtronic.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label":
"Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } },
"auth_ref": { } }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": {
"http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails",
"http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef
"http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
t", "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments
[Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or
another financial instrument or to exchange other financial instruments on potentially unfavorable terms and
conveys a contractual right to receive cash or another financial instrument or to exchange other financial
instruments on potentially favorable terms." } } }, "auth_ref": { "r315", "r316", "r317", "r318", "r319", "r320",
"r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334",
"r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r468", "r470", "r663", "r680",
"r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721",
"r722", "r724", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736",
"r737", "r738", "r804", "r1053", "r1055", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1066",
"r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1237", "r1238", "r1239", "r1240", "r1298",
"r1301", "r1302", "r1303", "r1310", "r1313" } }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Adoption
Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": { "r1169" } }, "ecd_TrdArrDuration": {
"xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": {
"terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": { "r1170" } },
"ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrExpirationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": {
"en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } },
"auth_ref": { "r1170" } }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel": "Name",
"label": "Trading Arrangement, Individual Name" } } }, "auth_ref": { "r1168" } }, "ecd_TrdArrIndTitle": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle",
"presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": {
"terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": { "r1168" } },
"ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrSecuritiesAggAvailAmt", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel":
"Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": {
"r1171" } }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "TrdArrTerminationDate", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" }, "lang": { "en-us": { "role": { "terseLabel":
"Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": { "r1169" } }, "us-
gaap_TypeOfRestructuringDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TypeOfRestructuringDomain", "presentation": {
"http://www.medtronic.com/role/RestructuringandOtherCostsScheduleofActivityofRestructuringCostsDetails" },
"lang": { "en-us": { "role": { "terseLabel": "Type of Restructuring [Domain]", "label": "Type of Restructuring
[Domain]", "documentation": "Identification of the types of restructuring costs." } } }, "auth_ref": { "r409",
"r410", "r415", "r416" } }, "country_US": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": {
"http://www.medtronic.com/role/RetirementBenefitPlansDetails",
"http://www.medtronic.com/role/RevenueScheduleofDisaggregationofNetSalesbyMarketGeographyDetails",
"http://www.medtronic.com/role/SegmentandGeographicInformationScheduleofNetSalestoExternalCustomersbyGe
t", "lang": { "en-us": { "role": { "verboseLabel": "U.S.", "netLabel": "United States", "label": "UNITED STATES" } }
}, "auth_ref": { } }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentAgenciesDebtSecuritiesMember",
"presentation": {
"http://www.medtronic.com/role/FinancialInstrumentsScheduleofGrossUnrealizedLossesandFairValuesofAvailablef
"http://www.medtronic.com/role/FinancialInstrumentsScheduleofInvestmentsinAvailableforSaleDebtSecuritiesbySi
t", "lang": { "en-us": { "role": { "terseLabel": "U.S. government and agency securities", "label": "US Government
Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by
US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or

Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."} } };

"auth_ref": { "r1005", "r1036", "r1328" } }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": { "r1165" } }, "us-gaap_UnrealizedGainLossOnDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnDerivatives", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss)", "label": "Unrealized Gain (Loss) on Derivatives", "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period." } } }, "auth_ref": { "r11", "r894", "r895", "r896", "r897", "r955" } };

"mdt_UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "UnrealizedGainLossOnInterestRateCashFlowHedgesAccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/DerivativesandCurrencyExchangeRiskManagementNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI", "label": "Unrealized Gain (Loss) On Interest Rate Cash Flow Hedges, Accumulated Other Comprehensive Income (Loss), Net Of Tax", "documentation": "Amount of unrealized gain (loss), net of tax as of the balance sheet date, related to the increase or decrease in fair value of interest rate derivatives designated as cash flow hedging instruments, which was recorded in accumulated other comprehensive income to the extent that the cash flow hedge was determined to be effective." } } }, "auth_ref": { "r11", "r894", "r895", "r896", "r897", "r955" } };

"us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/FinancialInstrumentsNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Net unrealized gains (losses) on equity and other investments", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": { "r11" } };

"us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Gross unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": { "r605", "r615", "r1048" } };

"us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued gross interest and penalties", "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": { "r614", "r1048" } };

"mdt_UnrecognizedTaxBenefitsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.medtronic.com/20241025", "localname": "UnrecognizedTaxBenefitsNet", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits, net", "label": "Unrecognized Tax Benefits, Net", "documentation": "Unrecognized Tax Benefits, Net" } } }, "auth_ref": { "r614", "r1048" } };

"us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": { "http://www.medtronic.com/role/IncomeTaxesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": { "r616", "r1048" } };

"ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "documentation": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": { "r1135" } };

"srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": { "http://www.medtronic.com/role/AcquisitionsandDispositionsScheduleofLevel3FairValueMeasurementsOfContingentLiabilities", "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]", "documentation": "Weighted Average [Member]" } } }, "auth_ref": { "r673", "r723", "r991", "r992", "r1057", "r1322", "r1324", "r1327" } };

"us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationOfBasicandDilutedEarningsPerShareDelivered", "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "documentation": "Effect of dilutive securities" } } }, "auth_ref": { "r1135" } };

"us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationOfBasicandDilutedEarningsPerShareDelivered", "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsOfIncomeUnaudited", "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationOfBasicandDilutedEarningsPerShareDelivered", "lang": { "en-us": { "role": { "terseLabel": "Diluted weighted average shares outstanding (shares)", "totalLabel": "Diluted weighted average shares outstanding (shares)" } } }, "auth_ref": { "r1135" } };

"Diluted - weighted average shares outstanding (shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": { "r261", "r270" } }, "us-gaap_WeightedAverageNumberofSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "parentTag": "us-gaap_WeightedAverageNumberofDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.medtronic.com/role/ConsolidatedStatementsofIncomeUnaudited", "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "lang": { "en-us": { "role": { "terseLabel": "Basic weighted average shares outstanding (shares)", "verboseLabel": "Basic - weighted average shares outstanding (shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": { "r260", "r270" } }, "us-gaap_WeightedAverageNumberofSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberofSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": { "http://www.medtronic.com/role/EarningsPerShareScheduleofComputationofBasicandDilutedEarningsPerShareDel", "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]" } } }, "auth_ref": { "r1" }, "ecd_YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": { "r1133" } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "7", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7", "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "8", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8", "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1", "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12", "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14", "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20", "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28", "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1", "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "715", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1", "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1", "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A", "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2", "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2", "r18": { "role": "http://fasb.org/us-

[illegible]

[illegible]

[illegible]

[illegible]

"Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479823/420-10-S99-1](\"https://asc.fasb.org/1943274/2147479823/420-10-S99-1\")", "r134": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479823/420-10-S99-2](\"https://asc.fasb.org/1943274/2147479823/420-10-S99-2\")", "r135": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479823/420-10-S99-2](\"https://asc.fasb.org/1943274/2147479823/420-10-S99-2\")", "r136": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "[https://asc.fasb.org/470/tableOfContent](\"https://asc.fasb.org/470/tableOfContent\")", "r137": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481573/470-10-45-12A](\"https://asc.fasb.org/1943274/2147481573/470-10-45-12A\")", "r138": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481112/505-10-50-6](\"https://asc.fasb.org/1943274/2147481112/505-10-50-6\")", "r139": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481112/505-10-50-7](\"https://asc.fasb.org/1943274/2147481112/505-10-50-7\")", "r140": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480008/505-10-S99-1](\"https://asc.fasb.org/1943274/2147480008/505-10-S99-1\")", "r141": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483070/710-10-25-9](\"https://asc.fasb.org/1943274/2147483070/710-10-25-9\")", "r142": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "715", "SubTopic": "20", "Subparagraph": "(h)", "Name": "Accounting Standards Codification", "Paragraph": "1", "Section": "50", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480506/715-20-50-1](\"https://asc.fasb.org/1943274/2147480506/715-20-50-1\")", "r143": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "[https://asc.fasb.org/805/tableOfContent](\"https://asc.fasb.org/805/tableOfContent\")", "r144": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479613/805-30-35-1](\"https://asc.fasb.org/1943274/2147479613/805-30-35-1\")", "r145": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481231/810-10-45-19](\"https://asc.fasb.org/1943274/2147481231/810-10-45-19\")", "r146": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481203/810-10-50-1A](\"https://asc.fasb.org/1943274/2147481203/810-10-50-1A\")", "r147": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "[https://asc.fasb.org/815/tableOfContent](\"https://asc.fasb.org/815/tableOfContent\")", "r148": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480647/815-10-15-83](\"https://asc.fasb.org/1943274/2147480647/815-10-15-83\")", "r149": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480434/815-10-50-4B](\"https://asc.fasb.org/1943274/2147480434/815-10-50-4B\")", "r150": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480434/815-10-50-4B](\"https://asc.fasb.org/1943274/2147480434/815-10-50-4B\")", "r151": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480434/815-10-50-4B](\"https://asc.fasb.org/1943274/2147480434/815-10-50-4B\")", "r152": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478546/942-210-S99-1](\"https://asc.fasb.org/1943274/2147478546/942-210-S99-1\")", "r153": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478546/942-210-S99-1](\"https://asc.fasb.org/1943274/2147478546/942-210-S99-1\")", "r154": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478546/942-210-S99-1](\"https://asc.fasb.org/1943274/2147478546/942-210-S99-1\")", "r155": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "

<https://asc.fasb.org/1943274/2147478524/942-220-S99-1> }, "r162": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478524/942-220-S99-1](\"https://asc.fasb.org/1943274/2147478524/942-220-S99-1\")" }, "r163": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(7))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478524/942-220-S99-1](\"https://asc.fasb.org/1943274/2147478524/942-220-S99-1\")" }, "r164": { "role": "[http://fasb.org/us-gaap/role/ref/legacyRef](\"http://fasb.org/us-gaap/role/ref/legacyRef\")", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(8))", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147478524/942-220-S99-1](\"https://asc.fasb.org/1943274/2147478524/942-220-S99-1\")" }, "r165": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-32](\"https://asc.fasb.org/1943274/2147482810/280-10-50-32\")" }, "r166": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-32](\"https://asc.fasb.org/1943274/2147482810/280-10-50-32\")" }, "r167": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-32](\"https://asc.fasb.org/1943274/2147482810/280-10-50-32\")" }, "r168": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482810/280-10-50-32](\"https://asc.fasb.org/1943274/2147482810/280-10-50-32\")" }, "r169": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481800/320-10-50-6](\"https://asc.fasb.org/1943274/2147481800/320-10-50-6\")" }, "r170": { "role": "[http://fasb.org/us-gaap/role/ref/otherTransitionRef](\"http://fasb.org/us-gaap/role/ref/otherTransitionRef\")", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147481800/320-10-50-7](\"https://asc.fasb.org/1943274/2147481800/320-10-50-7\")" }, "r171": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "815", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480627/815-20-45-1A](\"https://asc.fasb.org/1943274/2147480627/815-20-45-1A\")" }, "r172": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147482659/740-20-45-2](\"https://asc.fasb.org/1943274/2147482659/740-20-45-2\")" }, "r173": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479806/606-10-50-13](\"https://asc.fasb.org/1943274/2147479806/606-10-50-13\")" }, "r174": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "815", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480870/815-30-50-2](\"https://asc.fasb.org/1943274/2147480870/815-30-50-2\")" }, "r175": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147483466/210-20-50-3](\"https://asc.fasb.org/1943274/2147483466/210-20-50-3\")" }, "r176": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480434/815-10-50-4C](\"https://asc.fasb.org/1943274/2147480434/815-10-50-4C\")" }, "r177": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147480678/235-10-S99-1](\"https://asc.fasb.org/1943274/2147480678/235-10-S99-1\")" }, "r178": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "[https://asc.fasb.org/250/tableOfContent](\"https://asc.fasb.org/250/tableOfContent\")" }, "r179": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "[https://asc.fasb.org/606/tableOfContent](\"https://asc.fasb.org/606/tableOfContent\")" }, "r180": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479343/105-10-65-6](\"https://asc.fasb.org/1943274/2147479343/105-10-65-6\")" }, "r181": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "[https://asc.fasb.org/1943274/2147479343/105-10-65-6](\"https://asc.fasb.org/1943274/2147479343/105-10-65-6\")" }, "r182": { "role": "[http://www.xbrl.org/2003/role/disclosureRef](\"http://www.xbrl.org/2003/role/disclosureRef\")", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<http://www.xbrl.org/2003/role/disclosureRef>, "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147483076/450-20-50-9>", "r425": { "role": "<http://www.xbrl.org/2003/role/disclosureRef>", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "<https://asc.fasb.org/1943274/2147483076/450-20-50-9>" }, "r426": { "role": "<https://asc.fasb.org/1943274/2147480102/450-20-50-1>" }, "r427": { "role": "<https://asc.fasb.org/1943274/2147480102/450-20-50-1>" }, "r428": { "role": "<https://asc.fasb.org/1943274/2147483049/450-30-50-1>" }, "r429": { "role": "<https://asc.fasb.org/1943274/2147482425/460-10-50-3>" }, "r430": { "role": "<https://asc.fasb.org/1943274/2147481544/470-10-50-6>" }, "r431": { "role": "<https://asc.fasb.org/1943274/2147481544/470-10-50-6>" }, "r432": { "role": "<https://asc.fasb.org/1943274/2147481544/470-10-50-6>" }, "r433": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r434": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r435": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r436": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r437": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r438": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r439": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r440": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r441": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r442": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r443": { "role": "<https://asc.fasb.org/1943274/2147480097/470-10-50-1A>" }, "r444": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r445": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r446": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r447": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r448": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r449": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r450": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r451": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r452": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r453": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r454": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r455": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r456": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r457": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r458": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r459": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r460": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r461": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r462": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r463": { "role": "<https://asc.fasb.org/1943274/2147481139/470-20-50-1B>" }, "r464": { "role": "

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

S99-2" },"r1370":{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1371":{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r1372":{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 115 0001613103-24-000165-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001613103-24-000165-xbrl.zip M4\$L#!0 (/!>EE#L(# ^H! !P(P 0 :61T+3(P,C0Q, #(U+EAT M;>RH7;C:)(F _ ^N@J=F=SKKO+2WQ2=U=KC=#JK9MINVU7L_3^Z4.1D.4N MBE21E.NJU_ U)%E^2"80:~?@XRA5=UZ,FGR+M_OAST2^ZY\$9YICZNY0&PPLL_ ^0/3U(W ^X7XG?% IOIE9^/R7SBC)/VG?GE M66+JFK/M.RK^3G% _O(#087TPLY/^(/1""+.S_GF^Z',3//7B MC,C6R|&VR-?54U4_U? 3Y3-J#7X3^&E26 M3|+-PR>?O+KT&8_RMU=O_.,@H1-UE_HID^KX;D|,X3U\VO|CLP|OEH6;HVEJGW\MG^ _? IOT1&GNG89SE7NRC^<?%&Y^!/I@|>WQA^%(D'TSX\$S)OIZ^SR_..H8/BTU_O_ V2I|@+^C^/4>XIX*ZG MZ/I^/27SD42Y|@YG#Z3/#C >*WOWIRD)Q_LKIV/^/ _B/G_PCU ?_ AT MKL>?/Q9 _EC<>=!\$KST? P|")R7+7R+TETX09I(>SF+DQCAYX?/9^1"E!8 _MAD&8OHC_OP_..Z@T| (O^/^=W:B7CG^*7RAVQNI.*#RIG/C7B|PXX%(ONHH# M|J_Q_T\$M""&M#DH5J>O8M7:FJ&IQL?7IVUPD,NIFF*G_ US^PO^B2RTLLX M^@I)D9282P2\$4W^_O,?7 MCOR&SR@X7H1P4ZG3 _P_P/G,T|QOK?XIB3XB0^6+9|IZ_3_IK-Z _!H MZ|N|G;ZNUA%9@8KS(\$A1EMTFV.BB_QM.+D@)(297|?3_ZFK*W _IN96>8YCZ M_\$DSCW3V|0WR*VS9*7VI|Y2.%T^QL*1N|7|6?01Y0GN/D_H57B";>(G&%6? MX%9Y@K7\$RRSPA,0+V)+>JJD_0JCS|V><)=H4G MI/1H.14>8*QQQ.<*G;=V|>FG2HYW=O'HTJ- NV:>VC;J6+3KK7*\$WH5;%K# M_ L>JNY5,&KB'VLVJU@U?@1Q*PUO>HS*M@U7H:SUS;J6+;F:OI>SZA@V_@9 MQA|/-4*UHV?0R485:R856R M<|O>1U96)3NWC;V>4=FY7LG.GMX^L|SIV|KA|/..2G??_ MO615R|2W59.97LW- 7V>4:ODIV>|JEYKY*=NWO9?>^*G>;@ MCLQ156/17A4|OX"/L|PJ|@Y|N^LG*KV#E6R%/|J&+GFK;7?Y6L7--VV<^ MMJ0J=JH|JBY15:QQQ;+5Z?_7K_I>J|E%Z3P:QN&0/H4|6KV4BMG+ MDW3/QZY|G_SQ^XJ3<1AONFU9T,RZQ/I> (#2+1|J9X|KR9)"LOV(T MK=T_ ^=LIEFE^Z^I^M#F@K|H|J2O?X|>=EZK ^ ^6>E>TTB+XSS<#C<^*+ M3RO=T|?? &F^|' VDTKTB|T.62*|S\$4*=4UHXZK_Q=7_>_W\$ _?+BQ&|OON\$+NK.2IMR+|W) M@C99=C5/5?4=^;? 6WZV&&:PO%133|DZ|>M/YK _/_+OU7MO%H-^:#',WJ90 M4_%K@! _V|(E"/AR_(^ (E"#G|+ZJ2T3WOESB!TW4? BYVM4M|H|H%89)>)SG*MODP16;0N|O3SQXT|6.AB.0XYM&-(J|W|P)9HQY1..WK7UJV6;,>23CM:5|N@ M';>1VK&ETX|:-9QU|?0;J|U_.NT8&^>=9FJG)Z%VI TOF|MD|C2:4?%148 M6B.UHZD2JF>#.VNI>@Z>EA_ MVV(V|H|AGI F=|ZC'T9J|/K| V|15&V8S MU2_286|T>QO48S=3/? (Q|OHF+M1H9ERM4<9;%UKO^364/7(QOEHF^8>4VVF M>N0C#^+^OGTD)'A(^2,CV/@I#4C'O1K1<&M5_&%- PES+Y)|H:PH7U)^=^AW MC%QZ:1S&CYDT@A^W MDX|02JY+T8C<|0E=Q7XR1M+H0MAUO9*ZN/5(HS|IQ"WL.EU)<5|G,7FC-(DB M|'*N|+NE*)- _.*NPPGC|O=G#4C692|?4;V7=CE_..X^203="L6)Y@#\$T%7 M(N2K(LA|N262|PI@N)DSY /RDH(H"|3|A3Z;|2&"J2/>T^(L?G,\$HX3-G3 M:TX<S/YRYO'YOC8R9XV3-M 3@^9KJ 2|JHXH84E:OX1ROZB+SGHO|H8>5%7 _+0E>SXJA" T'0_%R9|T|6VXZ\$@V;-B;K0= M#V7)GDD? C|9C5NEIR9XQ|Z'MV,E?|A3ZR+0=.\$+NY=3Y)CK0+J0=L _"FW" M3MRRI^U<:#MFXK=ES|R/%>84VWIZ3&0N?8;- (|GKL>A+KJ1/6'E15_RT)7L^:H0M:T|Q|Z5MN.A M-(FS8FZT'0JER9Y)'X^V>R7S6H&V|DS'J.G?QE3Z&/3- LQ\$|PK>XDS?J. MG2YDS _/0MNQ\$|P;L7VHZ=^\$4XK.9 KR9<(INE.O|+XBR)PL C<<((5|M@; M_-W@5|2? Q8_WO6UW\$65X?QYFN\$Y.LOF#UB>0?7A14&8/F9CUUYRNS|TT&V M^5&>?S=ZR4? C|SCX*)|1_506C=RT|0J7I0,J14(EGVS7%8Z; M %2*A\$H^AP2ZPG\$P@\$J14,GG^#M7.)8*4+EXU'V>3OUFGH1Q2/&Y7F2YJ'? M)A2_-X_\$"D* (OG\$DYHJ*)D|0% DGR^24T5CM@%2(H"23Z1H*8*1WX#))>/ M2M(D|M(7C,5;K-3)" +|U|?9DQI=3V(I_2X|EP)&E;"D I@4;2\$11W I8CQ_M)2SK|^7LD9WL*PB,BIXQ5:PK"\$R*GA%-K" T(#(|,45&K#|I%5%QC:9IDODA MBGWT2Y|,X<- >5.O#KT(1|SWDS#VH@?DC^(D2AY#E#6:N=*Y=D"AE?;<#U M S%*C/T8/L|F6+&F<#W"XW,^PGR,3+SEP="JDZ:'UT"SPIX%"FF!"X?|"A2 M) DK"X|D>)'6_.0&H_T;>,D)TC|4- #QYA*07_*\$KDJ_*#HJ1E+|1AT4; M_*H_..ZS0'J.D|9L.RR2" X-7+ 6K%((#@U=<|L%@@.#5XP|O'U%8'Q' M0>A|T? TT?23_/2O+GQ(91Q@+";3EX&_T#6_PBYQ|T|(N<=IP,P#"G' MA 8P|@*#|_R?YNC"2|'W)_S).5OW,RHT N'F# (/RXT@('4&*/# W@_&M L2&L)P4|C*&JO|^H+0L. 5_|J@M"PX|7+|O-"QXQ1; P%>\$Q9?0&Z < M90VN=3* \$1<8%)SB"A,8:H%|P2FJ,(\$O%A@4G&(*\$|C|BJ|X2'(OND.3),V| M081*CD#2Z,(\$5E4>/'",X#ME (>O"(,8#VE@>OV /8SPKPF\$|V'D4W^0BE M#0|H@ (5'QN|H@|@0<7|J^0^A0;!*=-ZPI&)%USZ|C|.Q&_?&SKI6U(Q ME#P5Q&GFM:1B"SE;\$(_ ISY**K^L05SF("9LT68| M*E_O.B)%%(6_&0; MY^G+V;_W^TD);(MY,(8*|_79=MV=8|6C?|ML4)RK8&D|LJ\$>4;4T9N/F MY_*RK80_HJ3_C(MB8"R&M(M|N0M@|2N6W|0Y0MB41@&\$CO:~M|JR,P\$S;D'K<=>V11# 72,RWY|L:QZMFW9;X/QZLBU _@; MZ EE6PF&@|1B6|FW4|P%TC,MV>;&L=, _DVT|G|MNPI(|&R@Y|Y1M|^0_-W"K MCO;IR;X_0AL6O8KVH|ZR;B=CE\$V99# (Y_IHZN;*LD,#W+|%V95LB_00V M+\$MV95L?@2FYTOY1MF43@&_CO_-LJRE-GY;=42G*|LZ"L'O4?FO;"LHK9J; M6^8*95M+ 2PVUR_*M|H"TW*C 15<(J?-F8MJIN4E83D8W|K9>>+F+;(S4<681'A&)>AL7=)Q9A\$ML M)1L+PV\$6X6(BLC\$C^81+08B"%LQ7U _|I\$5>|*/I\$4+YM|2G6EBJABX|G_M^ M.D7|Y?,\$?QD= (%L,8ZP'?VZ,21W2\$2A4|DLY T M8M>%R|N%Q3KQ138;H0N780N;=89B%RZ;+B|VBO=OH3<(HS^?)+KNG"ILK!" M9XATX?+@A=|G|7/G_N_3_0797Z/WQ-E-|K_B?PF#J1=+U7B,@|DT|*(- M7Q> (\$^CPE|J"Y<_BR5"@JE6,*ETORT4GIH7|XS+W|D%_OTXL<01PWG M68;R|/++=^?27H1>=F;4MJK^#9-? #RB_Y0A+5_Y|B;T|.*D@F1C#R(\$2f)M;R|B|T _BLH?7SY|&7K7Y0>0>G^V29 H6E|'|P0_/X\$7^)+/C.Z8T>OS| M|O R0_?0L1-GR(C3C) MUY:QN.@|JGD5SC%YA& PWY&735_*GY T>|3%|O6T;R#65\$AO?U2!_NN^D)FE,JY MPPY:'LL3ECH3W/*|9|_L+PZEBRJYV?T#A8^C' 7G3QB?C|Q_ "RP?18H M+)>5>\$HRW:1)_7R5QFDT+EN9&@FH @%7WV;|)_L_%W;)|R|,|=1MR*<J#>!(^!W5IK|K#H"C??T1C|VNIK#+ M H"C?? T1C|VYI@R<.>"H?C|"AKU0F=A&=RKV\$ _&+&Q?O-FLXLD RV^&JUYT MB'UF0H2DPM*H@NF'5Z@G+)98D?>J30/ YH*S|R3Q|H&QA^0B1L" _="&(+RSZ(92A"Z\$|8 MMD\$DJSI0);XM+%T@E|S<2OS"9OPL%M|U9H0O88RM*02BJYB @K5*ZZ?>O|+ M@D|TOH|(|GPMRKZ@07V|UMSE;N|H"LM" 6)W;UFK^ (G|S)HZ07@<|<^DN= M2C.#HK%ZF8Z)@_- .126&6*|0_UHD+A(TDF2XE!)5AP(2SP)A0,OYT7IP2 COH|+|B\$W|(^2?QI;_ K+=#8SMG;S2FV;_G MNRX1;J_Y/MC ^OT.&TW|P09;_7 (Q"<32?99QLO0!"|RCL02@^H|G.P0A+P M+X^X^|E|_9H R=#22D;DFWX9_@D' K+STJ&0T@2Z^%06_Y;.*R*NHF)&1_ MM=&\$>L_G1OG1UVCNON'3H?SH:S1CWY8-G SQ_RYO'A8T (M+V|4V)C0 CT M/9MB0@Y;F1BB 'AT>>=#R:\$'?+V|LZ#DT&LU12^0'H"B/O;L(X|R;"EC^W_ M|5)^HUGA9F_@9(B"1K.SL(%39.@UF@B PB0T|8^K>A@::P3&=#8SMQ.44Q MRZ*9|9TU-'\$Y_ >\$K|QAJ05QZ2=""#X;R%Y=2\$1%392=X75PZ|1|PDJ|@Q:52 MQ)QNV44ZNKC|A?#3+4.MB)O"SK=-I2|L+FLD- _M0|+F|0*=TR%+Q|V>TX MR_|N?Y_B|I240L%"32,O6*LS03NGNK.XS^SA>R"Y:6O@J'Y)_M1|X\$F)-V M3|

!D2!QYJ\$=@H.6T8!M6.PT8!J7.G+1C\$39D.K8!>ZJED7R7B.4F(3MOY^WILT>4R!
M.L5N/L13DP>4#HF8WAXF.W>?NKATM#E1C"YNM-%BPI3EO@8L0+!O")N^B
M+8='L'P(F^SULZ!,GM#V,R>M#WC7_?>=>.0B.V6^-T."O 0K.X^_IR.X MQ?%_GY+H*8P?
+U(4A/GY8XH0^0ZKL*VX!57/#R.LH<@^1.&8Z987"%/" L M80!%0V26%):T (0<^8VA>="BG!L5ADEXG.Q&"55-
8WD-417\$**TOA*9!#*.KT+XEL6.^M>=<=&88!E-81@64S3Y.\$9;.*.5L79H6^_NB5=D"@=6<-=^S=G'2D"0 A
M"Q\$F2D>=<=<4ISC1DIMQV\$=3TL4.[#RH)3?'TOIMLPM6++E9%5V=IP5=/K9 M(D5+;J:\$A_9^CFYV8!C"5^\$2-
&2F!K@H2E>D;+DO.,>FI(N=F#H024G.MJ@ M;8;BMS.RIQ=C1-/E;+DILKX2!|=KBWY68_CB-
!\$8(6VIB@H.B.,7SMMR<MPQZ*DBYL8#=UV7)S'&U0-L.Y4G).Q2B4W3.!\$A;(V9+3);R\$SQ#YDC,?QQ&^
M\$&&BY*P%ITWQBA/E9ASVT9!TL0/#Z4MNCJ.5VF8W7SIRLRKS*@(7D"=V9&;
M*>\$A?9^S!&_3B2!\$6(?!VYJOL>FN(4*3J2!PY!.\$JZV(FAIY6SBE)HDC(DE6VH1M>6;^FS)SE-PD'X#-
VPAZ*4QO835VNW!Q^Y3-M<*Z4FU.9*UO7)*R.<^5F23C(SB'NY>8!CB-!6)\$N2D+HKB%2,V@VVHH"CI
MP@.&DUZK7#.56Y1(?!PE>-(+EYCR.)7X#H MPU3E)BUX:(!0&^JFI(L=&T0R3F-FB;8-B.LRXXXMHRM?
2Q93DYPIX2!|=LC7)6<CB+M\$>(/77+J@H.F.,7TNN2!POZ.DBYV8#|=JZ9(3'6W0-L/Y4FYF1-FVC:E#%;D
M)DMX")^AGY;_SB2!(6(%.7F+GAHBE>D*#?OL(^FI(L=&T0N8F.5FB;7;B M2,ZLS#H@.4:W)U^D:\$A.EG
0/CL_9TC.?QQ'^"+\$X;DW 4'37&*Z0VY>8=I M-"5=I.#0@I=+1"VPR#%>F8E8NKK_?
GKU2N.H7*>W;7DFI'BR\$=8R*!AAZ M/F8\$&X;\$"(^JAO@SB%*L1?(JL.A+&B%8C*)CRIZADVL\$
MZW%@(V0L1(S:"L3BFHGC%B*S#7LH2KJP@:'4E)O>:(.RV<4IMMO!BJ.E&U) M6"MGRTV1<)
J0IS+S7H<1_8BA!ZVW(P%T5Q"N9MR=F&ZHJ2+FQ@.'5)3F^T M0-D.YTJY^919LW53TR3LUF++39%PD#U#W.O-
>AQ!4D+&B'(S%AP4Q2E&=.1F M&_90E'1A !NIRY&WFB#LMG.E8!D?&K1/=430G7FAW)*9+CRYZADY.<I3B*
M!H(421G+&Z0\$!J0".WVY!HJ0+&QBZ3IGIC38HFY<(<?2HA5G!9B&J4H8 M!A-
D7"0/30<I^1F/8XC>Q%"CY!&'E1NCJ.5VF87K+B2LRH+;=NZ=%6)KN1\$R?%ESQ#WDG.?1Y&I M"&&B*SEO<7Q%
<8H27;DYAST4)5W8P#JDI0C:(.R&XSB%R)&E)NRX* H/C&BI4K.-E17E'1A !IRU(EIS=:H&QF M(>I^E9CZ/(7H
8T5(E9RR.KRA>.;+D M;\$.U14D7-C" FAR.Q8<%.4IF-?D9AOV4)1T80-
#IRDWO=\$&9;.+4S2Y^919!DEYXTC"%R).E!NTX*\$17G&BY(S#HJ2+G9@Z\$SEYSC:H&UV
MP8HN:OR'05YFL2A_VWZ!^?E9;ISP0\$SIZAIR^ZI(+8!L3&800+LQ^>Z.E)\$7A8WSYI(^!^!%=
MX+=+/9J9+EH71!>=>OH;)3_*8:CTL&W^X(R_.!TT!^?_!>?9!KE^!L*M9('Y,P"R)\$_5\$ I.-L'V)01F^P"<\$-
@:K(IY*P8138".P0!8+QX3E2JH0K J#P89>A!5J\$.?ISOPL\$UTD<+! @ MCV."E1M9E.[0TH5.YQGXS1 G'?
\$G^#S\$FIR\$4IO M!OCSXC!R5B10L<J!+&%9.Y&5Q6QF\$!M\$EE90*8M85DC MD97%+X2EKU!
(!%#Z4%IB(OIM"!*\$M_.1MBB9>&.R63;+S.*K*D7TE9!G M&*!Q.6.V-'CB-.6 I=9/DSQ#^PXL?O.S0W0I.3)T<""
POY>T%@O26" MH/0LMPTL+M>-I D9S5?DAR+I#^32-[W!XDX;"3")E9VG7LI^@ (RT,OSF;X_+(I@'?
MT40!TY)S57QPS!H0!OE;+2SY/LS!&679?W");10@77AJ\$R9.7^=(2^61N;+ M10F97Z-!FF1^B'#B!4N;3
_M:AB*7=C.O838OZ.=N^GZ;Y+ R"NW8/+;\$ MT+^\$W@#E*).Y!FL@*X=I!VD?
>\$S7W%I!^Z\$C80%B\$R4((#0F;+.2.6830 MCI 9M0#3T(&R:578;%J.F>508I3)&*3TA7B;HM>
OOY.H>4'H/D_!WVXF!3U!0YAX!M MMBIL B^X.9OBT9f=587-X833+9WG)5H5-YH71#) _&Z!8J%;_13-X7L_3T!11
M0?7S*XX1LKO!7QLZUPB;Y NE'5!SC_YOU^X:X3G;.*2 \$!A!HPG+!FS1 MSBU^ATDZ+K;P>NDAJ\$D19AQ-6\$!
\$+UPFFLTV?@ #O:"99.1C0W@8"!>(RW@T5LL.U.PO(NPFN.UY0E+(BO.9XS6/" M;U7+GH_Q'73+Y/LR^DGA0%
MGU&?SA_@0TZ6PY D @^L+"S;4@8;IKWE& ML!P43#1\$J;YERC_%.1N31A+_.85E-
)ZX!G_MRFVC>%+&#16HFC>=7-MXNNW7BJ5?H0EZJL;RNO9ADY_EJ.L Q9=8W.)PX!KUQXV>AKE/R@5B.9D9C"
MDE\$23\$BO*FL"R1L/&\$&H3EL.1+@00IG"BI"!QI"!\$!8.D3!L\$0(36(MIBB.&?
7I6A\$!D;.6B;%.@W57/((#X\$S!M^=:TM 9?@HFA)J0G. 2)\$0^E MGP;1&3P)G8.L1K\$9G EF!BJ\$!L.IOE@!'+1B?
3D+IGJDFI<Q)OB MF>JG0=0 ORF>J48.E.QSG.*9J@2R>+GK?"Q(^.54&_##5(FD DRJH!YD%N
M_36(IN"TA1!+!C!-C.X\$DP M;=1@!@K@030Y4(QTID?7IV+AJ!JFW?6CF\$ZR_#04^9G0_ZOL7WUQP!&
(R;J!&6@&RZM!T/A M&!2!AX73_@4ECZDW&86^%Q7:R2))>O!IO+!^>8M@KDC-4"N;7_>168 M'TO!
OR/!..W%6E+9-7*)ASA",R#02B!ISP'H2^A-X Y2B!G8XC=RC"2-* M!Y@"6%1_>JR090PK&=
"@^\$^4J!9,E*N7UILHA6-X"3HN2.>>* RHP!P M\$-I,DS?X?%G!>-I<=N&GO3H"?
OBJ@<3@T6'>&87A&5PVEKH",DYRN::GV>9CC0XWE\$%22D?DMR+900\$B&)"E!4!*" _FL88: MRFOV")U;PC\$8R
KN(@?J#Z;J*M/J/"K!& U"! MAYICZNY0&PPLDO(IP>FJIN!.1PXIF=^B7IV7^J!^?AO@_3X?>.
(Q>SO!@+64*=?HAW*7C+WXSRR>9 M%V>G&9;)L+@P" _I>%1X@/37!1X M\$88SF;Z#I9-C*QO_-!YH@PC-AS1(
M4BS*4SRR)MDZ&S^PZ<@S:".1HX+51!J/O_1H!6/6%R#).@3!F1UA_<^X M9Z!
)5!O!1D5RY\$F6.5Y<^R;./N_BCC^M=WM=5!WD=K5Z_TONE!PIG M\$C F>8=^!I!>=>=(S.FY?
D!F9/LD5NABDS-4Q!0(R-YRIBH9O4??^6LG! M?Z2"%0)+SD8L_7H!7#Y!E_.'^XO'^-2P%>W!Y!>O=U7_!RJ5S"0?
+KX=^J5^JMOM!78@OZ.)Y&IT!EC>I<_K;E;5!_NU>8NZNW?I!>L!YU M.F7!HVVW=<-EF3YZ)\$Y6Y)5? MXI!/
J1!OH&0VW7S%AHJS("S;%T2)*HY<I^G2O*,DW3LY3C<@;J!AN\$S M'D!S=+H J=J! _= NHYI!J&TX!Y!J.IKYR+
!Y2#=%?)?FW7!_O'B!OOOU3 MN;N!O:E!4'Z!_G)YIV_!"IK*(9RLV=HED?@I^4FZ_*PUOE17?
O/#+YQ\$LEFOG/ E'^?G-OPS09* _I_!(W/G;NE??FO\$(M\$.N6B! ODO\$XS BEHGP<74BZQ
M0%>MZ853A%#8Y!UZ#/#BX)K_G<^NU.?VD^D_A=QJ147B;I^8/E!>G@2(MC.A.D"YDHWB9DDV03TCH0
EC)M5!ZY"BW"+Z4X M(VXU7\$7?3X< R!RDBTO>M6!Z!YWE4\$!3B=H4*Z3!H9I8U>:0Q; M0Z"DH*15G
=!BK)L!HO^!L.W"+<3Q _S-(R(F!6"!F)9(C)\$L%ZYZV^81GKRBVU_6X*M%*E%+&J!I M.S7N^2W!SQUB.10V+/I-1-
T^E6!AUV-Q\$+K.Q !K!WNZYGS^E!Q%.\$+> M78GIRY^0&2HZE!+&C%?
Q>HVIYM4WG'.8W6+>Z023JBG0.I3@#V!CRZ1!& M"W!OW_/_.\$=:M)'7I9)DL.4?+_4HO!C_F4!2*)&O=KUC*^AFD-
S.A^!A!^C M\$!EZ3>J!";E"IO\$ETWY.7:F.5!T4!M83"6IW^38I?UTM?E&R\$9YSL1)EX MJ?+D15.D_(G6NFED9:3X=
!FH'6RGAE88L+01/6IQ!H3;DWLR004HU!=@%JXN8KN_1LJB:P-
M9XL=OU_PT!H!Q;1C0Y09.4BIGAT;MCQ=A\$!>P8YR;@!RYQ0AU=MNO;?C M%F?(&U%6V9
M_.3M(NZ5.F2;&+!J;C;)VYX00WFX#>F.&#%*J;.<<JL/M(G+9+MV;+&N1M3)>Q5F6'H2Z.^W85 L!BG5M&-3
SM^0X5>+6/(HDX>5MDW6:(MO!;29DLYV!;LN O\$5>+4+GN>D_&IMS6VXS<07DTHO&RJHW!QJ5(OE_0G
MV9HMFVN!15!\$T=VU7O.LULM4VSP0.RGV!J8ZT9EZKVLG&>8G;U+3&VN=;;
MJ\$48W5WN9<_*O4RCS;..I.#+AH*OIV1(MJ.XI.U#S!5Y'AU(U7XI^70&FU>(06H=I^7.KY 3+5-&4J^WI-
QJ9(OQWHO MPEYO'MHBC.XN^7)F)5!@IMJF7?BJ)*1/&M"!!HJH#H7!IG%)G.#SHCK9-)
MJ^&U(W>7K=SH<I7E5!Q!ED33?/M7JHQO!>1NH35(SH=I.GH=0;XANGO>9A3@ZN<^>V3QO6#%A4?
(8RQ>E# F.\$R#GK MM-?LRC\$A!22E)&7*<.P0H'B1='L6"K2O;W:4A:U^.),D"S" _HS^C^KO;
ME#3T)=.4N0CVMY3T05Z)%RF?.#WPT.D9%-I&2CA)Q5.C^_*AIY.?WBLMVP ML-I/4HRQ.++LW?
X22'B0F(0%Z!XP;)(Q!&A N9Q>B;I#I!C!&I#3F!+*C MH&TLEQQ527.R!6!E9^4U3?+OB
3B5!;OGV8+5X!S!7^B;L+Z)+(*700 M6!E#EV;8E8; !M^TM>)#)8GC5&D=+
0;QSC;/Z+EW0%P6IO_3R!JLMK^F^\$!3M8@KP!8(C8I3)>Y'Y0/ MY*.YY-NZ-W9!DHI<&53#;X?
F5B.U1>4R3'_EH_G\$7!PZ(CBU PS"F020! M!8(<***CU!PROOJO!FE^V=H%L!I/YA=L'!_!3L0+=+;LD-.4;-^&>7L_H
MYED=+J.\$73<EQ0_!RL%Y/>1E!T>3L@!%!2_Q.GLXSPL_CO-T)L;82&B.)A_@>RQ M6.B9TVR\$?B/#CEZ(R?X(82-
WT")L>@2DFT_A!GUPK\$7^!20L&F!SF2BL<MHO>&F0*.TY##.2E%
<I6/O@_53!E+QIU7D27OQ&G\$@E+@12MD(1=\$!9%.^M>%E!ZQ3'T+I/H/S\$FD'A0F?

^\$H+)/BUDM.M/T2U)8.JXV5A'G++"LO@.M M^7J=/'"R>&0A4W7UA'0>-1>G-G^EZQOQX\$IC&82'6XJ2JSMO**;V#
!=V<123 M .5S=2UUP TLAXG.;V N*?WN)GF=&+ .1K5<3316F0Y* >S&^* !\$=T^%H
M0C%FIZ^=Z#T= _HU80<6S9SFP^WC*6G7R8 G<I>TNR\$4J0DRW%URQI6:S2) MZW5I75H
M#086TDWD^P/3U(W^ XSFMO/G7Z MX?SSMT0EYJMR<7/I<GJ<_G_.DI/80=U<(RNX;= MD_Y
ZUZIBLRK(TY.S IO4<6DX(9.1*\$ID1=UZL2X M/._L G.C.=CG"\$ZHZA9JHOOTC\$1?>#%YH^PN5R\$)A<";JP.>P
M^4E*RY# /IC\$V-W(5'HXGS%B444HHMALD80;>(8_ OWM0KGI^Z+U-E &>KR0 M!\$E;R45K=ML3;'UC(2V?
YM>BY? JSB6"OI/IO2_+I:7R4:KV4ZN#1/8FP9A MCH*?P#/*_7&W!KC:%F0V9T;084: &>&XAN62KF!>I#W2B8!LH&
<3YGR)<I#7*+*3+W#9)HK MW/WT-Y0K=V'V&IP6.%N(B6FS^=.%%=.%3!= -BVRZPYG\$7F*%4.GBMLT!5%
M9>>8"V N\$.P9D_>N4 \$F#;NA6#=-IN#KMF2I0K%P"RNWCH1"1PDK-U"L"QJ
M!_%T^M_OHQ<543+M/P=ALF33=7N@*G.8#.NU_ L;EJNVNG &A<;A%IS7KQ
M18BNNEL^/NOSEI7>TH11<35#Y./9E 'S! M!>#50R1ISRM#K)Y7KWN/2Z4WMQWJEB_IF>L;HGY>05I?
GUQ=7Y.^7J^NO-MW7?SAZN;ZW5(E)2TW=G^VEM;A.^8+I^8=L6@=U7-
GPF0^4JHLQ\$F2<'WY=V8I:C\$B*=FRFVW49 MG7JCI5V!8N^SI7IG=10/##K2H)P#_9S;.%P=Y@0")AFL*JY"N6:?
SW@ !#- MSTNDG=SKTO62"N(^?XN!AE10/DU/X2Q@N;D9V)PIZIM\$D)IWZBXI!"XT MO9I*((&?+E3BZ?
W&SY;?G_*=H8LWKY'5EN P7H4 \$:);f&B@C -D!0+;K M7Z7G_ :8)M.X.)V-UO<1&@ZK=LLIT0%'FP5PC;#^2-
G+6^CL>LG2&%5L>2P M.0KIT^>? 6I4_)(H5YIZI\$*TRO8.U?I6#U7X=2>'ZLPS4X76IR=H>>4#Q% M7I-
D3+>BX50^ (Q%L_OOI*+Y !:SKD;JG7IO MQ%2-M3.6-H?1S+1(JVDS>W.EKIHFAI<*POL;H6ZQ=T.R>E?Y-
@O6P8SK)S2#NG_ I\$H+Y(L M+S9LH.<)BK%BS!KP(GN!^A%MAW6W_UUONXL! FFQE)8PWV=\$>143K-!5+6%
MQ68(\$%I!%O G:1).?>PVL+L-Z!%;2HWIB<@OXK6B;X9QHL6/(5E.1 "\$ MD:_Q9@NIZ=6DMC\$HD7QRWD\$7\$>?<
#I)DB ICX-IE\$X?I%LKNLO;JSL%6IZ^2 MN".K\$5B_8!=(5)K08<3R@Z11HMB4(T-I&+=ZC"/_Q41Y1#%*O>B\$1H)>.
IC_.O3X@R!L!D M2Q*N'<'D3.R_#\$+&=G7^2L(STZIL/_E@BQ(XAN)J1UQY8\$P91).L5LH!DR) MA*D=\$>:!
(&41DLC4=(!4 R&U*Y@!\$*9L@BG==07!5-N(Q_#K#BW)/W:\$2RN MRO9F>+60I#D5I"9C(-V7-8WRF^&K#TCI?
IKAKU_%UJJ*VX+4HU24G%U7B"A!+)+8+1. MWQ"E<@*2XF;\$4<"EHY#/_!6\$X&U)<(!\$JZ;3M^!Q88FXFI-
_!@D8F=OLMJ MGS90>15WE^"Q>&&L1&\$>/A:\$7NWPL24U XBIUM"BB+B'(L_Q2I+N>^G4R_"
M!O\$490C>KSGO8?B_@M_.4)IL.A"t;_2C?60%R!@&3!FR!<32>N(L3M18;H M"Q'9/GVP(K3Z?=-JIR<"K
B(E5TLWQY@Z77ZFBj?9VD;S5<<099.%DICO^5 MD/_T;B/_IX%EI\$;%>C.7:M\$H?
5:9@#:=35;@=OK>L:RUCT6LF"Y<+(G#JN_ M\$UW%#F76>G\$YU!0J0KA&(#.D)O6ZB^Q N@: KI=12 #S-
N43UF.W(C<D)C;F=P MRO1TM>4K);J-W XT+63!00.04N!IK%7'YSLGO%108!'L-PUZMO?
4;"E9\$1.J.H*LB4DAIJ1XKG@Z0 M(A)2=D1=%8%BX)#+J=WT!H B(%!VA5T5D6)BLBB3#YM/VUB(*5_1HF*9JQ
M7\$KN/;!?ULEV3@;RR/1>P.Q^.;!Q.JC">8GG;*.4DSCY39137/1!57#IG MJ8=%&L9>^G*5HW&&
f8@!4UH_Y^YD56EH V++O!K!KIB'Y^\$%"859PH#H1M MNEQAS'DO++8KLL.*@U0W9L0K;LIC.*T3#<5\$-LN-
@28+M?_U%2*BHN@Q)3)3UD M;K?L!90(B)2@6!*XDB_OIORVKERC?\$.2 M CUZF%CKEEX)VI>@UJ3;572G=D\$M)-
+0MR.N&T5<>N@ (MVS-%;G O.DF@&I M'4%>#1I&=Z(80_8"X"H% C#40I Q=0G/K;4!K\$W8D07RI>GJ?A8)HY-R/!"I
M45:H6G(H"5JVW88"/M*%C<2QKI?57@#;DV9S\$=@!P<=(2H\$H8\$74CDI @_MF2"+)L
2Q@ (Y%#A+ACYP6%85K@=QW%&I% MQ%_ L-ZHWS(M_ G3X=I?I&=PL\$BV*YJGZ45C'D4=1L,V 8P,#"P6H'^)AO2
MYG+PMI!7EIC\$>*<1.4*MG(2I?J37;AXHB#"SJO2I+L_KJ*Z_3U%;#IMU_ ^ZC.L90.9?IZ!;>
=UZ1VL3E_MNJPVY)97"29(SI&Q5IJ=G5Y9BH MVM"LY4L837.4U.D.U/TEOF'Z@)HH'^HEAW.8+?)0IAL/L/*2A&?
G@6S;H9 M5O/#9XC06)7&)D<\$JP*K\$NO-CY COF-6.ILL!2AF MU9X5Q.(2G"QZ>&S>
(RKRQ\$Q)HGF6>5%Y&T;G+NIG/"2RH4)N.^HRK;2VX^9 M^+Z5I/OP.4W@RI+64W2QW.N)=JB_9VL=-.HW?
7SSL1D90A=VI9.f#AL1F M<7ZCH799-24!;#8(FOI!%J%V^QU6?6BIV@V")IOZNR.C\$UHC8/<BI'(&T
MQ.LMAPJEY3V9ZSCADS^:P96V;./WW8: 3&#R.D.+Y M?C+&HWDAG90B).?P^I2V/!(&Z?'U(N4B9?
F2C)4A"\$((\$W3KCD;:S&_9> MJ(2XJS<=(U1O.SZ=&1@TS?J+I#P5BFSRTRJZY31B%)%A(G;4HRO+P"7WZ
M\$0;Y;X?2U^;^=>DA M@F=>I_!R8AMK!H"OOP.N;1562&8_L^#E)C5^F@7EQOPZ?R6I3"4!10X8I
M/F.Z6#6I^X7!\$=N!P\$;IU"V" ^H IP: ^Q_@Q"/>=+I6@XLC P MR@;@X43>)-G!Q!^!6\$VB;R7LS" F-Z5?^O3;N1)
(O6VL0HRO^B)MJY:(&Y& M"R>//NXBS_ZN/YW2^T.MKWQ(I6K;?S!MEMI.M;=BUN/S5IL)LX=1BI RQM>- M,@7%
0JVON&ZUC9F!H(*XCYWBX&&5&1^34_A+&"IQJ1PZ;66HAMR@XK; X7 M6!\$W7H@!\$O1K1-%5W63UDHIN\$!;:
ML""U_922"M5WT% ^F+?UE#G8BBZ.UZI06L'ZP+I:GSSAZFTZ?2.!!SG;23N. MT.Z3=L"XP+B.=ZJ08S;G5"&9,K^?<
(037_5.M6L#?V""OQIQ.E1L4ZL_ =!M5H%TX5MQP814K!PDP;L?I#)&+ PU=:8I!;#+=#KYI?3">&+<
M2D+JYY0EL59B5#_C0-IQ_!J)JIV8KJ=IM5! ?K_O5?#7)"(" ^@4K@DQM M_!00G+G:9CACI@7^/'6_PR27"-
HOA@>1.9\$S.GT#ZQGD05G_!IR_+X M)YXX(WM\$ZAPU!U 3T*MR"/B2^R3X(9VP0H\$NAK>5Z CBT'Y
ZYQ&QK+2 MN'Y7"%FBT8<4?YD4Y&(>.&_IT7V);S9(I= MO\&*%N.65-%ZR)X0C=569LDV*TN(N./&GX?
%7D_M!%U!7MP!*EPL#M"+I@ MK&F=OJZOZD(.!/+S!4-2P^_O2T+I+(>F"M+B%I4L"VHT1\$*M=JV1J>W;\$(<
M4;=!OM5PB#\$L<(HE,O<#>_)M;8BM7"FWE;CE/>LO@"M*N*VE#7Q1IQ) M_#5_3A;(58H5UJ+3-
Z\$_.^R1HFC\$M(&?EXXV+ \$HDN&-K03=QQ1RJ6;.@D M/!5'70QJFEN4%.5A2G>)*D
#XIF&QGPI/#2H3#P.NJ(XKC8<+9IV&H'F>V"SB1^NO>0.8&L4V/L)V%-:23MVL?L0%0 M.O34ZL2AIV&-K.?<
HZ^4<H*M#3T+ S;UM.#_B;D%12L(8**-(DB)BLY5B% M65Z+UVRU4>V(3#?8TIR6KN9*N4U2FL'E>1H.IK2S_-\$<
R_4H15S;J5>TOX)S M<=SC (>Y"IF!6#+)L'E"UM=I8?LZ&KM37L VT;!=D>TS!NU&FV5YP)J;55 M F>L-
6)L^WT3>A!UHO"VHW10<=" B5V.;TL_U\$E&V3Y6QPWC4*W=89'5L2;T"/);<_H1C>X+)+O3 M%Z %2FO9WI?
QXN(TT3TC^IEQEP;609I.R4WIV4?E3D5J=EOT>J(1VL<*;RN MG+XZ!<7^-/2/6IKD1_B_8+I
M4RI2)EY;G\$XT0ADB X*2I'(4*_.PIF(Q!>E.X#V72<=1=?"N8V<-O5@+ MFR192)1_EJ*
(IM_YI".IM\$FJ1N!.1PXIF/KI=N*)X7R2AI&BVON\$T/SE MCV)H.-14KHEI@R_#\$K)55@PI_>7#_-1HWEM&;3-
LC:A^=)J65K9*%#.PLA&YYT'NB6\$C+=C4LN!>W.8!"RIGC?I2D^0_*QROBK&P(IJ=O MGUC;VI) K;J0"-
KA6YD@R"0(9W>*47'J'W)1!5V\$G/L^M?K!4U+D(SQA#B)THD0HRQ00BI(29'4D*!2%
5AKI^M_@OR5#Y\$TOW=#Y_MV+..UHWHP4T" MJ>0.Y0NM5!1.I\$'2B6I7;ELC3HH\$2"IO!"R1 MU"-
(TICMGH94HG(JG@=>)&N!9FEKE@>_USJ7X@NV@H&X;ZUHGL&HW!REF\$
M4.C9X4KK(\$=7"7+P7"PY(\$+!S!JKEZH3C>574Q+2LO ML)7HDZ91.V.KI"8)0MGVXFT77U+;^3!#>W\$-0I>^EV4
%AHDWV);A.G)<3 M91)Y<7Y"Z612FS.ARQIG2HOR"(+W!LOSZ9)3#_/S.+B<"W:?!-BS!H#/PWA
ML(A(VN%SF2+)IAPML08A@@@3&00O97Y(D^!%&\$;"R>SO3N0@KPIWH\$WMA-W)
M1I+%L4V'S0H/N3=L>A@VZHG;JIV)12P^5F@W69"P89QH6(-=H06M_'\$H747 MM.8"+7(W'#1JM'^0L#?W\$U-
409IO&"#_8*%&\$U14#2?C;UAYT9IV0.T3M XL9S:#6@&6!41 M1SN'D.E*B0IV!_5 MZ;LJ=@ "L8G&A2R/ HL"BJM;
5+8HN/ON2=N_2;(4/OQT/Y@WZL/UHNWJX MNKQ7SJ^_*)=^_7JX9^_ ^H6H8)MW!6P_Y;X:V
4ABFWC+W!%H3<(HS+M\$9LV7'4;4G=C=VJ(F)-IZA@A R58(AL_X66!\$6B27RJ>D4D5<=3U"-G70FCSV)X+18Z-
133);MA-8ZR^=>S98>"Y MIPMRDNK%LD2DVD M6.4I>I37%LA;=(I"/!#>W'H%LA-
..E%*V>"WDEB>H&H"/K8.DTV/5819J MZ.KXI&D_ 'B;HW1.IS!@\$-I?^6-IDL.WR!(Q>%H0DZ) X!#-TL2VHJ6PM9
M)3-!%6431P0&!_5W1X\$5;99-C_7*A@;+OCG;38AGM5I>B/PIZ86E#%". MAB'L9*_3L@!+%M!#&PM-*F^3+%!*^<
N6;HR"\$SX6822^R;"6@V7^GG457V=3Z MK7H!&Q8100VQ;Q.A;A45KQOTTVB;D>GU;@#;2IOI*Q.WIQP/B&\$ ML_U
2I6^3;O18G?ZEB;*0<-MB#Z+TH6ZWK\$E 4%JH4:X0)90SNO#%%.Z8' MDV?A0@TUAAMW\$LEIY.A>@9N%H-ON5#<
<2E;?>G=6&2A6D!YMY8L5JH+- M5CMIPSVQF!VZ %4*M1JD).QF!^/;-K9@0>_PHHK%NE0_728X4S?ZI3H.?

MU098V>L19^%9'9 Z>3P%+T%XLKPR2KNZN"7B-.*9=8=>=T8L+(%UG|S??F M;2"||D=>BD9)A-
U|IE V=,UYQ,IL2Q_@9X_0YIE#M?SIS3T@O!I?N_9+4I) M|6R-2/ HO?5\$R@M
"F_HG9>*ERI,739'RI=CH* DR|U1:A^,<9CAFIZ|VL7|6 MXX6U/YPH6P=>2+|F.D.L-
I|DI2K/M@,59W.5;K'=%M&4\$%)989@=WIZ|WU M0|IM#PJ.WR(ROF)8BK>X.W4A5GZ%FVF>Y3C:P*99+GQ<@8-
S!|%29=F4B+2B MT*BT*CIH?T\$|LR3C|K26@TD."KE=32RY||YL38< M6K@N|AG80RH0*QQD.8 3|7V0?
C2)Q2|+*8P)T \$|P'(|&B: ^KC7^MW&#ZC MX/0/E"8;V_#TFO5
'.KIHT&E;&P4|B)M+|+Q;1BCJ4TS821;N*N1BAR*2;#2= MU3XS07A:63SL'5,E.>^/QU/(T),D|IR|ZR| MW.R0?
@QJB=NDMKP J-(^|@ "LBF@3%643G-M"VB7&E026BE&-JE:\$0VISP A M)4JRM|73?JCG@CA_OBG#;7F*|L1;9>N
M;Z#EUE8W(>R5"V%K|D3PGH\$88;6XX|PEB&Q/\$5FV=8%X#H A M8"DS84 NV(MGRE"Y/X)95T9;AU6>|S|
E5>=;6ET2|-.MAMZ.2+L^|I|JIV^D|HFI?1: M%G;3@F|49I\$^+|^<302%%6KX-#JUIAR?_L9)BHWH:B;H3?:B=2JZ?
O S M3YM4*P&8.WHTV6 13J?JPH)EBRP/J 073CS:R|(T3T6A*1*;L3V MYWF>AH-
I3HS>4A>SXM+H2H^A@TZG:TYD972;RAJR-|VKE>|H0#5IG&|J MK|7"
|I=I&D: ^VA|W>:JHN2<7;S/V=MSH.&\$^;JB:9;"K|1CP.&) \$5J?Q
MJB>JR3CQJ:5/3BD16#%8|=\$WF+*Q8KO3|HDG;H_OKM.C6S\$-.C|2\$&M>F|ZR MWVGLI8|A|!5#ZMM|A"+|7
M)SD|(%+|YYB2?8|K2|V;?EZZ";|S@_ M_||H."W\$H_RA*WU_YV_&?5|2|.D3A: 5N1;.G0V_ ^%3\$&:3R'LY"V,Z;JE
M3Z|= (P'C&Q|+S;X> (93U^WV;)M=9;5S1X|0W\$70^S';_K5M|V'K MM_D3GK|T.QW|S1CLMX\$3H|_|C->63))@?
O7N:N7;8A%2Q"JN.D|KUR|O/G MN N++TE6DWL\$E;: 'C+5TLED94|8+>S/6 7: M4|MK"TIZY
MK|1G4M^"DWZT|ZLR3?J7;^_57+= '9)2|IP(IPN0-#7|6/KU?Q&W/6)|4UIT MM; TJ#VB*=9T-
B|ECH>8&|4D0A;M&R| MP|P.42|V;KN?7HJUNQ^P|D0P"=;XTQ|=(2LV75;M8< BQ<(F6.0NB514\$2W2 M51EW\$
&+%;2;L3(2LTA*%UDM&9S#9^PT6)Q;YV+DW& KMEZ K1B+BUN:X*|<"6E2NH;= M8-7_H&S-0'H: @|J 26
>HEGDIQO?E^E&';L_P) 6TE2;%BY1|L-L7#|@| MLVZU>BJ9M74PL|;K|N.FQW=4U9QLPX-H-
GU:0/8"\$4+9P\$37<2;|P)PT| M*TADTN"FBZB\$5<"H.NV@)#NT|!8|Z0#V@'E#|L2JG6^F?/C3>
|BX12G=Z/H^/O1W|LDNGCR_U1?D1_@_ MP0(5ZA(5>J>O=IWUFA%E@E(EF3=(HN_?0J5H|_@%#;|V
^H|J8|Z6JN>A: MGH|&Q;RU;I= =>EH4S|CD*|@ AS7"A !|"Y9;/369A TMV 0+E@0B8.%JZJ/O S1<|R|UX; M*);
(PT*|P|9NLPHT|6%: X%7Z8IV?V#AY4\$11LS^N|GK+; 4'DHSCSRR\$UF M1LKZ&W|
O@DJ4|=B|T.IA6C1Q2)LWA+Y M%I194\$6>#H@;:1N&;<Y=13 TX)Z0#W" T>B|"(+SX_-3+|^C;|>DO-@?K@|
M.=O|YZ=|SXYO|%;OT_-3X-LS|'JRA|'GU4S&%WR\$|>8WJ7V2V/F.1PEY6 MY|4 VL 9@'T|:JAR5SP;-76^"K)4(;
AU<:24N#A#&R|G;\$.LB\$|LTGD MO9"HNW@A*O@*C97 1SA*H&N:E0MF;_O.OWO 22BZ|;HJNZR;-VK;97A*%
M*)N+RLRU(UBW-ATJ*L=NIGF6>S\$12^65#H?TFI9|K-K7|S|0|AT 'A|T\$A|H M5^WE);6T32SN#C|Q(%RP-
9|:=_H#399(N|1;|O U@C6V#)K%& (8T-SR6FK M)SVM|O&.8)%B81;L667N'\$5BD6-ALIT56VYFPULMO
M2|B3K;I8=L|;3=;EI7+Y|J|!<%G.ZVRDE&6J4T_OBWJG;|HG+@P3X)%MLXB
M=YS;R.HBUXV.U(UKM5=SP>+\$PAY8W\$Z+*|_7X ASH(GGP-X)MCWA+;C%VSRN
M4;Z\$|P4GAL|5E1H8#T%R10#3MJ5Q5JU:25%(4'9&B@5E I*!;4*2*M'3O) MZ.QP0|=H#<>&XZ0;4U"&
|B0|BJUD@O9T6VLA@NQP84 VEZCS=JQRW45;>N MX) *.V@DG?44Q0PW7U"M>U?B2*<&AK5
Y9DS08W)I%X_%;EU2|H& MU>02&A=T;@+U@'I^>4C (@9YU8Q<%#0@N5N;.*QH.D%#O&N4WPP?O>5-4
MY^*HSJY|A= 1D#(|*(Q|H2.H0)D9(C.3)"IX=E=K^O16LB6?2Q2S2"(E+
M"K|XC%;)D^(4D5GACO+A3^ ^|XA:E=#OR^ ^#0W|G-O'CR_%9?D|_A_P0+;A+
M;B=OMK=0%@K\$Y2^0.05E67U.90K|1*O\$;@'U J;:|ZJFV|VE&Z4>'X=L,@ MQ|>O|DHOT\$*((6#JL;L\$|*(35IT+
;#G'&GAS%*8N32|TX4+P?7AHHD@ #8H%#ME@SBK3 M;V2|&."BV5S|H'54XFO+T5"E#V|>IVDM4Y? M-
|>W_ (C%1"X<;&I0#ZA'B"JFCY7|YK"6K J(56#|)"AYI&0ABU"VHA:." M;J5'Q|C_"/Z|XH=@\$H%|8|ZA&Z=^7P'(I+
LU;7|J= Y8"N(SW/6 >@17 M#|ODGX>SML|9RP0W| 9"JX8;=?\$.09I/(>R\$#1=01"5?|56RN M
GC"50)=U;B+V=SIUH_3P8H573K1-%5W13@4*)"MMAVL%-M'/(.S|S\$R8#H|DQ|W^@-
EDY;U%H@MV#G8=L|(SH4|=MT.WU=;>F|Y|L M'6P=;|V)K1 I?UJMFZ1;|HB;LQ;C<G|ULO5FV7FTCQ|K1WAE^
?R3(%:O M8;L T;WU1L"52QC|WL'>&VGOES);=UJ_ ^JP2Z"N (5PET%< 1 MKA+H*H C7"7050|'N\$J@JP".<)5
5P\$UVVS|'GWF_(H9L8H'"F3 M#)W-?_@T'V|84 J;?NG3;%@SDM;K&J|('QY|_A\$\$(H1W5RU(|YGQS9X|
M^|B+|_JX_G?>ZCKJYH_4KE;Q|Z9M5_K&MD%97=;P|N3W=6%&Y/3M2K>J9UR M<@7\$>*_K"C ?E;_#?
Y""*7D|I+J(T4C%&2A\$Z) ^99D M(+);R\$A)D4\$4E0N4 2*(FB%*V8"4 MS2&|H<('B6>|5|H0|XAL)WC?"KR>+|9I
M(7EB&|K; ^E&|J|%;7>=GHKN769V|XIEGV@SBE@C;QQ"=;XTQHU(?=7..3X
MEA+|+7= ^#18)%MELBROS:NSQ+;|NY 8+N=CV"10+^93HNLU"O\$-L3N%>*2 M7B&FN|X@;-|>
(6"50/93JNL9)0<G#NMD6+;9G%"=L?>2R9 YW;\$MxB6W_|S7*E1"K=5QF 1G.M|8)CPT
|H|Y03|V|54RG*6&N5^SK*N\$V389B3>M|P8#1Z3MN|3H'_.8+;BG MHMWNZ'G|OMV;8+>|<;JGO V|H&NW/018"
@+9T=EUONPL(F< 0|1J.* MAC=KENYMPB^W|J|)BZ6(B0;&+S;|WQ%Z7|2N%VC_&XX#UO"N#(<' ^I)-
Y1HBP(U0N%EG M 1CCI@>XD00W;|T(K9YJT%:LL|8K%U|S|K82_2TBQR'?Y+^|0&* XR)4^4
M;*4+A +A3^|XQ:E=#QJ^P#1W|G-NGCR_%9?D|_A_P0+6*^+6."|H6NO5YJ MK\$Q0JB3S-
D9T \$NH4E"V0\$LP(|Z0#V@GO;JHUKFLJ|N8#%OK&F@3"+|^*@=.&2#;:=;
M9P>B.1|F:9DCPX>5A(4S<H;HOY^QS@+|"Y.\$X|@C-YF9V>FS;BL&G*^8%;YHJU|H\$E#)OVMNSO'5;G;|F:FYX
?;&|0#ZD|5/2R|K>UP;O%Q% ^MP+R%5@+|+H">3L"F7<+6A|4C%@J*#B|@SN4A^DF M;F*3?4Z_?6&/\$#6"X<;
(N%5D|ULKX_ I3INF@I26Y|9|K"6K J(56#|)JAYI&K0EBU"THA";.AT0)=%>"/V
M|RH=@\$D%|8|ZQ".Z=^3PY|&_IUD^1G&>/23GP?R0=')&^E4|.R&=LG*#MX3W M'?
H&F9ACNY1^A3ZJ)BDH"?;T+EOG*UT@6AS0|LX U/J\$<%7|K|>?AJ M WRU1&@#9R" T>EAR|CR<@2F0;|A|!-@1A-
HF|S)0M|V<8J@'<)=!5 MC;KVBZ*IN|SNJG%&ED0ARI;RKQVG)JYLXROJNVZF>99I
M;1%+U7;@>E;GKYT81NU#O"OIC=|RV0%|) '|;5>7E)+VY0.<#B<=|@^H^#T
M#Y0FFVS17B2;8(U@C2VSOB;=3%IQ>G0Z?>T|L7JL#DT BQ0\$FV"1.RU2R(+ M>|U.WU|/H'EX)%BH7-
=EIDM9JWM6Y|6QH<^|)N|O|FB>V8|!;<|9K6&&+!
(MLMD7N.#N1E48&QVI&N|Q8-%MF4V8QQ_#M3I^C8K,Y"/9Q%MF";QS7*E9>.)S8|>*"|VLIR"98L|)N|8
MJS;M|@D%*L#18)20;F@5*%#I+6S(2NP6G/M7WX61MZ@X'8&HKE0=Y7+O@|DFYXJP.O+@@"J
M5(WW9J73PV9IHXW%;.S7D;Y\$&'UK;W5'K/N6T(C@J9"H|Y0#Z@'U/J\$3F MZ^T(X/8|A-XE)=(N|_IH@ (Q0D-
G|1^P+FIY 1B; (5*H172<=MM2H|@L>|K6 M2X\$;EN3"?EC|XR*.AM5;
=EJ(+PB00|L#AO5LF3XJ"06>6AN%|X'B|J5T M/|X-#?V0Z|>|+|5E^0^ ^|
MLJ\$ML;V^VK77^7)E@M(W|YTLO0N5*30D-MA<9)H|Y0#ZBGO>H|A/O|TH?T*H>IU3V@'B(%@WJH6O
.)J2*!1M@P9) M|!Q8:/54LN!=%\$;5"S8%L> 65"N0|V*|V*>GCQ;MTK"6 YRA9T1|RN)P4B|;
M%(.^EP;.);@QJ&0W;HZY5HUK^TF 1K;|L4; ^FRJ("N#>A>H>=*4 |O"|H4 M|);I_%S(|3M3M|0Q1|O #Y@WJ? 2
4(X7W+G|>V LZXTep@8M|H|8%LMS9@EA;IX8#N#E@HF3\$SH_IV?W7C>EFO5FP 8+|4>"
M>KB;LX.Q+Z>YN:2MJTK5=^@5\$+AQHP:E /J\$>(\$H>;/E<#GRL);L"HA58/ MTZJFD:M"V+4+2B\$H)HZI0?TN8-
<8*AV 207U@J\$(H|WY?#'/VS;U P| M7YFLND\$W;_@'I /;JAV7RS|_9F^"L98(>_AU<2>#A#2R1O;\$.OB\$(
MLTGD09"HNWHA*O@*C97 1SA*H&N:E3|E|YB;Z?)P.4*KISHNB|;@API%\$A MCK6.R#4.8|HB-
E2&K9V7N|6UD% =?-.|R+R9BJ7C8F*G9.\$ Y.0R5;9/K M6EKEM #*; 2GQS(4C22VO-F6F*'
1_B7;%A^ (R"TS|0FFRR1Z(*=@YV# MG3.R#K8.ML|+U(YW.7='6W4|?4\$|T|S;%"+8.MMYD-M6Z|4?

^BN^0R^I1LX^Z0756SU)X:SWHN^<@DCV^08>R/MO9^YIVATRLG^M4I? MTDY.^&^XL^6P=5:V7F:\$_
7S=GNNN@J0\$Q8.M@RV#+.UO><5(PIWG:H/V.M:~ND0P/TH:~S_>NRECV\$!)^=[D_S3I^"\$D.^1 M7H
BVX_#X3EX1/ZI^~.M%^(6CEBS/JLNO>~B&F^
M_2LK80<163+RNJ:6^+J+>J>N=OXXA^91B&H\$&4&:E?/KK^H^\$! @0.XJQJQJ0,B27"
MX^=>+>/CRYV^A@G>Z^+~NHB9^X1^"B>?T^V<9^YAYG|=.(CV^&@/EJ^NUBZ M(J7=)I+R^
LREMS.7.90UH@+I&+LR%:TZ!"&8^H/EIR^O/P-1:~AT8?2FIZ>2CH\$TMG)(64Y^LCQB93
M^V>!/@>~"PI@:~1^C7^N2A-?>)7TPF?^G:H_CII!"%0H|^*~URJU M^%K^*UKT^~'7^ K 6S^F\$)UBW8K<2I+U-
QX5IL="(*T.G%~1^%CO=)"TKJBM-M_194?~0#49+H!GXL%F%:~OI\$Q!K:&~%C^9-L=M(+A+ZF9&Q!~6QUX;WN^VZ
MA:~WI=%<~(M^Z>#-H0(9%PP5^X0.IK(E6_#+%PX5J=;~1IB@.(H.Q+RHM4J2 M^VS:~G^#N2!DG^70=?@Y_K5\$K!~L9-
V(9RBU?~MB=>C5V9!~H89-R/Z3 MJTKKD15V.TRP^%GA=Y0?~MK
M11^A:F&M%2K&Y!QQ@~"5VYJ!5\$J190D=0115=HY?1^~7I^P<1\$9L&I9H.T:G>~E\$~V.YI>
I_PUGOS8:D\$~GEN\$@IHHFE4NNTZZZ37 M0.^#DV^~60@J6FZHHK:4CW?~Z(RK?DS5Q0\$
>JG_ZSRN^Y&V8\$YGVJ4~.CY2.M/Y^88\$O_OX14^27!7YR.YC^S/?L^EF(MIV.2.J7DUS6XX4%LOBOTY2_6Q8S+
MJP!0N/DH.QBR^F^AO?EWY^UQDB_O8!%:H2.F.C.JFS0JX-\$!)#P14:~S)YL M8LF>~!OBC/\$X<~R\$)V089
I\$3!~%MX^N~:~!+~JL@G-0.3I=%~%C10:IP.M8)9CO=(PQ7_L!~4?M5^JTIF-UZU_~A~W7HBL^~GJ6Z+O%
<>CYD&OK^~.FY M^A6?&~NO+~T.@1@H2R!&~<~\$10QOI#35W:ZVLIHR#W~(A!#9BC_QGC^3 MA-DDY6P24^X
2/H?~6B%1^ZP5AQQ>~:~(=9)N@V2D^0TW6M^JTL M~/DE2I3DKZ#UDH?).A'ZYE8GNT8-W=D6J_OG-U">
I894DMLYMC0JFNPJ2X ME.S R6PT5_@RSO.NK?Z(!8/AN5.?Z5)SS2T:~ETIN1D^!<~S0(R~!6UD6XZ
M2?6)CU%~NE^+U^~(5NDZ6BN3CM@1#~:LYW3U>J0Q(N^
M#=#N16F\$!F!>~+@1#91<~>~%SWJRXJ_19_3YX\$W!U.%6HG(#!6P2H:D/I=ZQ^N MQLH=^!YQ%D:15_U)PE2-
666I&NTWR:~HAW^S4.Q2>C5BD:9^RPE!G5W^XBU4 MVD\$/G%MEI9V^~R^S_~26SMSI4%P@~\$JMR"&^A!A_~8G^JMD-
WY559>J=^_DJK M-ORP^WQ:OMN!~!L9P1M!&6~^BCX9G6J=^~&3!^Z^S=Q!^1JHR!P-8\$7WG8D M^HPY2!O=OQ?
#51P_ZF@NQ,)N^8,I^>~^N.JU9E9!S^G)XW89+&/O=EC^:U0>~E=1%OS^N57A^)/~UJ^M&GH!F MTGB:D^+&
@SZ#~:~"TK0.BC^=>RQ-Q?91=^&FZG=8^3^4)9KJU!^7Q62MK!F M!H55@X_~*~>#8V^1T!)!\$K^~J?
%HFR:A+W^~K.MPCH#R5Q1+5Q5E)FT^!96C MV^%#M!-1.(QESV68^~7MH)=Q.(XY^K7?8DY7^9&VH1WSP7:B!\$0)?
S@&BYYK MOED\$C!&9\$J!DG&^K%""X!^GDTESNP>~J^4^U^&~>I47?^S5J&7.W=P^4(Q)^*
M7H&~\$D.2DUV4T5R95N^!+~^NINM6\$W#~+G^&~(LWT/E!~=-~:31^O^QB^DDXT=3!H(XQ)^W
M4>UH8.Z42=YD.KT.NB.^N(6N_U)!^!~MFP02GL06%)2/P8X-"_H1?=@U%(M_~3^M^*VG.P^8A^"HZYB^MXO_JL^~7I>I
W5~"14SRA2/\$H1IZ?^TS%?:03@5 M46IY^0Q>EOANO:1/3R5T.HSWL^O3S6BL^ANE@>V_~*^+<6CA#^8^C7I8'
MZCI^VZUMT:8 A=6!0!NBSCH04FV-ZVJOLH^0U^!2^!4K\$4AXN^ MW3PI4,+XQ@Q1/TIV?8@~N.THV=H/
R_!02E^~.FX&~\$CX%EFF<~M9IWVW#JH M\$C=X.BG^0ZIZ:~IV!)SFC)-DJPL3K:~=-E\$IBEFU:~I3!)@2@6>5Q9&~Q!4
ME@VCS2?+51ZS^BAJGI9_Q:0_!N0_(N%_(3_~^UCXF_\$!HQCZ9\$5K4-E
MK4X_B^R9Q&4^~\$C/PITY@~(N)KWKD=^\$-0HPVG.I^"KNQFI_!C/7:EX^J@~5^*I
M+L4Z7V^X!BK>~VHH&D42;U&3>)US#^/F(^HJ!+TF66>W=16X!&~!~V!WL^/KSBS^=^/93:U0:A3TI^O7L:%5U=&#&
M2Y>@IBA=@H^&S9(S#^2W_~:~HM@F!FJP^I7^NJV>^%B=H!UOEH+>TMX3S!9SP6K71P>^=F6JA^M^JB)G-
W)4#Q_S^O%60H:~Y=S.S5:&R<6^Y^HCM!XP^ALH_~7K4EV4^MFA MNE/GCAS.^4C+>>2!+3TI@+M>)?@4/#!^!/:~"
IS73G^8\$=FS4K(3^2(H!FD M5M66O.\$R0_3R7SU!81+X=V4!S_j^?_B#7CAX23^!TR!K6%/ZO^O#@~RDM+Z^R
M@~O!8T,X^0GZ^T.SBL\$(ENUAJR(^L^!1YY!\$7.(BIEWY+9+V7!~8!"=1&LNGU(C^Q-\$B!QB!^@FS_~!8R\$20R^*Y
MD^!1!7\$GKA2KILJHH_R^*H_"ES<\$#N!~2R-W"(?)^=H_!GBOFR_ZJXN8C-!A
M:UCA@&1M@F0_IUCC^D^*ETIDY3FV92RYG:ELCD.NCNSA:~JG,=&?^~/ROJOS)@E+^D.MU6=YX^B-
EJBO/E,P)7T9>VP?:Z4.2_0U5^Z M%_(H!UFT32Y^0D7^~:~!RT!8ADWDTY5W5O=-=POZP>0L7L+^~?59!DJJU^#
MVI/5@Q=^!AD@H!YW2&G3T9S^@04OE!A+!G^KC4%~&PS@C-WP7~J_~O!^*M>~R!Y 2^~ELL7_V7/^#&=R9-TPI?
(2?2H!ZN+BOHT^5GLUE/ZY=SUC^=J2 M^*(^IRWW(?=E^\$9?PI.31&~!OG#W!"=8&J#^0?G%PS/MXRYFP^%3"
O)OKZ M7!B_~DRX!2\$6MW.(J&@_C13^VZQHQ:@7PI000_V5@~L&~4.FQ\$^\$8N_9C=? M!7NR!_QI!%~6^0^5-
+103!0G.C_~^!P?WMX^/H+;G.ID>~8V!B<~MC>~.9#ITC^08^VK!<6/WEH7/W!~B.XZ=W_X=>~H#6F\$G@_WSK_~*T-
UG?+~J M_R?<1W!TILZPI#~.X E83I!_2=DR_REX!@P:2PA^*)KU#7R<~_~LLB2NBQ5B M<%(ZM!8_YW@O306PZ:P
H6?T8\$.\$^X1+\$D=+G^TM1=UU@#O?Q9^M=HJ~M:~MR_U!P2G0G>9!P2?F^NO9!~D83KAH-
8VNO.Y#J7^#KWDME0QA0)D_F4^M^*P!KFX_X^R433Z_5J^!0LVI6%Y891PS8K2!YE6!~@K0!C:Z!XOT^JO%D9!H
MLJ0P^GAD>~"6Q5^U^9!^O6QLDTPX^@~^DC!&WD~/2E0PA0=N!NA^4X_)O M!3JA+~(6J^R":A_UV%~
0CEG0WDP5Q03_2YA!6QZUO@\$(SUC1BNF1 M5#10J=C^N!S!IG!+2^0032:MB@!24VET.F.VP!F.O0UV&X?
93RB!JHX^8L M3&^U!P^UU9%9^0^3)K!^~!\$0!B8^R:~HXJ!%0\$P\$(D7WM9YG8PB&~!CDD:IV
M5%~1UPJL!OKM.^*~F31!<~M!UPR^X:4.JQ7XXSQ_4YOAG'=?!\$S/^%?~\$WQCP^<~&^~*ZD)<#5
MMR!W8%F(H6!~8F\$0H?WV_R7J26+ALQZ^4S?C2:~9(WU\$)(BC8X=G(0.X7P^&^/M:~(=!
!^O2Y_)L">T7!OAHQ6!DMQW>AJ+6^#K^5LF%MQA!%CCM/@3N=Z/\$Y MMD.71^44S7
WS&T2MLT_~3WT4LF^4:0P0:&PL^!E0UR)K/MU:Z\$=~\$~\$ICW!D&&^*6#9NZ^W1@!\$0Y<71\$(11NI0Z:~.4
M!)9EV3O9:C)/J4>~#46N(38)!)\$A60!4T1&FK<~ZK.^!7GZV@~\$W)~L_C!M)TQ=1^OJ60/WW0:~%7/3!3IZH^~
Z!WHQRP0SNFCQ?VVG!D6!%=@~"+>M/SQ!P?3W>~R_OJ#_K-W50=WQZL_3~@L^CM?~UY&Q!~3QM@O@UN:%?
GMV_1^!M MA+\$!Q!~1+ZW^*IP^4+N9/(H9<+!@_B:~!Y^G.FSHY!SV^U T M>QW@KB!A(ZSP+NUW_EJP
VXSY!CU3CHVMLG.FRC%)ST9!M:D%^#(G.^?)T^ M%TX^6^?~\$IZ MD>P_!~!ZY4!8^CF+LPI^C^N/_#08T6>C26YUW
6X(G5=1MZ^@~!M(S@!@M@>~!~!78GA:~!3AKIDG.VKM!DBX!41) F!~O!67>7>U.G!@~K^F")
M!KT#="BB+SA<~Y_@~?~S>X.N+\$1?~\$=P!WVST^S_)~"9!H0<~(VF!U>~4F M_!0#60,1!H0/_0)CW^*X2.# X\$#
(!%Q/+Y^V!%!8!Q?~PYNU1<~\$931<~C<~M^T&!)H^NGGUC!J!~#K8Y\$!K^NY<~^N>W5?NFXOE_~+EK.^X+=
LCAC!0@M^X MLN_~3PB\$CR-PBT>6&XM^>B9_88^# X9EP\$?~DY_~T4U00T?BOKH@W^!="~&
MTD7!09^BK.PRQ>XU>N~KOR^5@&~>8RSV.^XWJ@OP/!WPID>U\$~B5_U!HCA5H MI~!~CGZUE!\$W.#NN^#I
JU^#Y#S!EO^O7PL=S!3!VK?JL(Z_YRKE^1\$Q/7W MX:~!^=-<I!9&D0^!<~X^~!&~UJ0?_0_2!^YAL
M+TY^"QSRA^PIJ^XHG8V^&L-L/P@2.SXQ_#UMH!4.^""@3L^~R#~E8>~\$!&~M!61=~08&B?F\$ O/YU_B3!F0!>E-
!^?29T^~(8CN.SW0L/9B_~RTP_~!R M:O.ZX.Z66:I=)~SHW+!~!EB?Q7C>3("GDA!@R6(U6:QF!&:Z7:6D&AGB46#
M\$6^#I#~!H1S%YW!9!^?~#W0_!)B1%X_~.V6T^0Z4!<~\$*!~!/@?~\$X_~!F\$^7 MKP>~YELHSX8:QKO!~^>R^_!~!0N^\$-
^*~.WZB!>~%MW_~5FNCWH>>~?J/Z!XR^
M!4%5IV!9AN:&>Q:~AX^@UX^8<~BQ\$PWW.54BL4=AK)QO:1PT?753XD.RO:~7 M+?+~2Q6^?UHQ
Q:9U^1LF6Q@672IZT!O3+0^"R:~<~#OI^~^NC!)U_M2
2D:9^8\$PZ^GL!70!H_EZ<3^GL3OH)O\$C!>Q0_G2BB6.A1Z9!+BM^!08D%
MG10_2EU^5\$>T.4L.GYTQ!LIND_K^%R!H_~0:HH=^*LS?D\$KZJH.3M?TWA!AJN+^#1I^~=:
H!4MT5UVIE5JO_T3F8>7)?~?ZL^~L^B-8)F^IT\$G!~WNH.5 M8EG!9L:&~!A!H9)MA01#8\$F!LR-
CP5MDPHZ5!\$VPHC>~BF\$~HB!V-9V(OC)>NT!SXN=I\$+&DF!\$NU!_O/F!_TS+5X<(J&ZT
M&G@ISB!^*~YH7M!LJ87430K!\$J8_@?L80-\$ \$P1WM^*W3:(\$P5NU^*)E2&L M6H!EE^%N
F&TXY4B=I42!\$V<~MB:~6^F@F-8B65W89F2?PI3_LITY^!%PC M^*~.99#^~\$R>
M^L=CY=GHBHBXKN_Q:QN:K9!9R5/_S\$BHR@^L#D4~9Q!E.0FPILH\$!NEC!~M9-@<~&~K~TIB\$UU-

Y?JMh+N7D37E5MI#.@.14>Y7ROD1J0130J=ZTIS&MMWX0)D_I09@@WDJ<&-F7FRV?H0F3^D1&B^K#)L,FR?
8K..@JA@V073#ID4M;B4^GF\$S+S;K;
\$KB\$T>L2DH5;59IY8%W<=HU1W!2EW>*Y8Rl@M2HlU!JN(E5)-GKM2;100.SNJA>T(->O0W:P4VLKUIK25F=/CL
Z9E\$#/H2HJMS8H5^W5%/MPT=E^=8@NRCL02VC.%R;*ALAT*Q#6FAZJJE3!4-E_5+;78-7B&E&IU1Y6
MWQ4/R+KY3.Q*B!Z#4+40;J1B^LBZ^4SH2D7NBAR?MO:@V18FLJ/ SX AEV2+7B*WOZF!F^==>H\$@0FJ/;
MG4T.FSW#9ON^1B^ZYQ+(389-ALU3;+9=2B&/\$YI465D5NJT_K>T!?\$@^H\$;:Y8R3
@UDB\$%DGZN\,R)-4@(>T7LA-I(3NO_UV&,*J_M15C(Y>A\$OQR=UI6N=%5Z47N07_6-I&S^TQ^K*
W/4#D85+9_ ^1A5RJE^A.7 MP7(PL&S_W\$G^5E;R6%9+U\$;7#SIRG@.GQTIX@ZOOU^KBHFS70,#
<.PIK8CV3MICX=R*^YRXNDOP:/Y M&_Z7_I2_TLP_G"@@ZCCIBL L_/2JD.\$T%U^.%22C>Y@A:) (-N2,"B3=
MO+P-PA#4200UD5(8%O#+-Q(3IL35230T&RYAR<-OA3N(2)C\$.BP**WO3VI(4)!VWTA?I7;U^E;=!"\$VF/HP""TCP
MYN#K^7SU;-QS8391AE?32=|XN=ICU(G4U\$LI*3TSR5%Z=R8QO)/&MR8JO3G
MH1@71S3T+;SY.Q*;/JPU/>B4+"6BZ3*=G0.,QI=C363VR+R!;#-<%#D5N6_M!PUIVYZJ(GT^&/R?9(1=Q.?Y23R?
D^G0#EJ2I2_1V3I_M.ZF0I>GBP_M9F(SG#<=E^C),=|=+F+W!Z;Z=@XA^!N&ICV-
8^#S5!+@QJ*>DAR4PT**EZ5G+XC#"?8\$Z;".5.G.\$IELN*13_M*>E\$1CJ&NDZBK%+>
IC\$9CAETI&AKD>D:T9IQH>.#TOR81W5X@KR(8!J*J.#QD?WBP?M^NUWA5*\$T5P<"ZK
^)#QX\TA7M5T6X4V&.XSV3NVNS2(C_MM22L^T%6=-^3S%%HOYEE24C&^."VB_#16"^UA66#2.82*LCIB1.(BP7X%;
M5<4G!J%N0:B.<(&^Q.(JSI_MVQEA@B;RLSN^R;"VC|=5;24A>J^O/%\$-8MA+5_JCR-"9FG4:8>V!+MZ
MU2UDX7PB*QP*JWWO/.\$05IE#;Z2EAK^\$6A<.@BC^4RJ^K^D|>8#\$(1"-5Q
M>A>D@QJBHDF&H6Q!J_U!&I8TG;LT*5@3NHU6AK^K\$=9^NJM^TUTUGB%LFAK_TA^U3"H3YBQ
M7<.P\$=;^D8XZ1Q%65?AVJYVZ85UU^Y&AIPUJ0;QXXU^VLA(1)76!9!;\$@(.6TUXTF!;V1G.T;9/*T)9;6<3C_M7
#T=8I&K+H)PY#RO;3LV8!HBH9>3Z\F@B&|

R<.><'(5R&D,C MU;H)=^ZI9_AO^I1V4X2)W)%1>34PD^JOI=&Q;4!5C4J4J2O\E>JLCfOH3
M7V!FX8-NERJ|>\$1?AF"?TZP7&4BNDVMO^NFKP-S%-S+>M\$TLT&2+EW@;WR MG=HKCR?
VRC68&V!|SN\$-L-M:DK)5#ADBT/RR^P^C^35;48?.WW;#RU/5D1+Q MQ-
JMU|U04X=1.9F^*W3#X5#7D>H^RPZ^A^/FWV&K^+F)CV2>@N"/>8^M^M)-
/A=).3(Z_Y_@J^#YM=RX^ADIST;^1M:7D559?(7)D)W)\$QRQ-4?D^|3_MJLF&
(5G4K4Q)H\$_\$6KY&W-!ELCT^&HPWV^*ZC^;EP|3^K8VS!O;MS;_78S
M6DV,K#ZBE0\$FT0/&+3S@D0EN|>^1X>L#_ ^1*3X/&DTE|6N5!EK(&^>4^7 MYE8IAYRSRQDS+9?
H9X>XOW-68X;E)QD_ ^K&V' _1_%DC/0.4!UBJA_ _G_M_BF8^5X3
Z%NB3!0G%&4Q^KV?;S6PMBC3^S1H&V69HXEL8,*-I

90TC,M5&!2M5 MKDV5W2CT6+A53)FP)>&<|DI2";>|1D?:GDHX*S*S|8/\$|83>;3B.*N!)QZ
M7C*1:6?JHO_@|X&/=|,E|%MX-U MZP49:D:H(G_ ^L'?6ERQ&XQ9>4|H
Y6!|O=,JAQ|3=@SYK17V3=*|I,F?9*\$FA(."PG)/A.P=#CGF VX M_)24U<>2#@1(1"
(X.5B.SOUA0E)*O9|R@ (I/U\$A9%|9LXG2%N^>U|ZB0(45-MCZ=
<5)=%X58Z/^*5_(B6SH_0^1\$ERH|0EMJ:=08|1N1^A_"JHIV\$ _|IC11^
M3^K^!)9.+>@>02Q1|DSQQIS-758-;@HZ%*R_0\$*0#H*\$B;KMH@3JQI>"9
M%1&ID1CK\$7^67N8\$/AT*)YMACL40%0I7&RMC!W;&I)>FV;>2CU)!8X>.+I_M_N9#
="K^(_WF&G|,F5|=^HZ*WTV!OOPDL)@Z=Q0**9#RZE6K>?^ONA5|5JU56H8PHSI_F::TRX-
7P;L52*V\$\$(HHF!DC&<|B49:*P\$F.I)/L|&KRN9O@_MJ!=0-4/=EE\$<|1HD+T!R);P8D/5/Q
MB4&|W5QPF/O_ "(57UR+88B:YC#UDF.S>:JCS6^T)845=K+16K31_-5);S2|_MT4YTHW7WL-
_9Q^_BM&|U!M_!23W6B7>|AH'=IHM6X9-MK;)F.?_J|4)F8V MM66A@)8^ZY3*DF\PIK
YNJCND;=HN|V1C|,W\$S0SG|OU3VD(U8W&!A#*_M0Z"Q"1O-
@;EQH^3V96;NP!VO!9(CB.^D;J.6!DDZA#^D8Z@):U@Q08Z2(&&G6=H,1I%M=+XK/_M0F-
DMQBHP8CE!^ND61-3OR;1%W.15.J^ZU?WT M.WN(*P"7_M"HU#IOGD13-
A/WA&&WAU@\$./X/1N6R;6C8;=@IV.W!|=MK54%#;NC@=T>7^W-!L*NTVD4^G;
|=+@NH5!*/D9DIHJY@DE04IZT355V MEHTIY(1\$OBB43|:GV<2HS|8JBW9%%!(B MNW%I-
EMG^W0JZ%\$BI+L;AV83CZT4Q5>E(;).B.S&G|G\$N\$A!\$'(*67HW<77E_M\$TO/_U\W
M.4XRL^I9P;POZ'^@5BZLNR;F_.AG+DR-CLIF3(6^!(8G5D_M7
(R&O.L3R.C|A8\$;)8&1FMVMF^R|JXT0CH^S(6!!E6!T9|;W9RXU=Z1_M<0)>>51D|9D3.G
MC>T;2U_3LX!^+TCYQ3!63*XF==B;^JK;QVR4Z<7(D^%YIC9"+?#P(
ML;/0OS9CBP679>5!UH<+^OY;^ESA<<)E64;O^G#I@EQMS.OR&B|')=EF;CK
MP^7R|(-1&+B<@N?L>EEG6>U%VT(=RZ|NU_Y=LK;7M+1Y.Z!|= _00K&|34-F M;#&ALD05VP
J=8**5!E1\$.E|!%9HH9M!7C|\$/7F" _YK.%2=J@L4<\$V@\$H#_MH-(J_%?6A<;I-
9KT?23)"|EEF_)D@ZM;^/W9I."#P^MD+R69+^N2.JG^SHY1=;WF|UL;H5-Y^O"|>408_>3Z|
MV(TAL^A7&BC?#V_W;-XC?/*9O)QU)(W-O^Y+SH8&R/SUP98_T!6^V9B+%
MQ|9ND_K7PDCK|/V#>RTEVV-NKJ@E\$=F&F8OL|= " _/0/-/F(<4RM;=MNR#F
MU/+>#>D_\$/FX;P-O+(&5HTWC_48P5!9^Y^R#J|)=(3Z6A^I7Q@?V!YIG:T!_M4G;+
E>K@P0;EZP372|I^ZU@V3CFW|\$M01HD4IEV4|)AN()"(PP6ZE1V*
MT6;ZU;G8%;N6MO@I^N!+07#CC7JV2^|/ #_NY7HOM#BZ-;X=(-&LD!HM^K7
MEM"IGWW(Z7.L^1J%0|W;U+?8\$CT&2&1|8+LL\$-JMVK8E=+"T3FV;T^P\$3_%M;JL!HV^_.OB3^%
|N5NB>0;LLVO4C?<%*6FL+>^ZG)+P90#FM;9A|9;3P^MJ^SQJFT^E?;9AZYVP!X?5)8H;IM A^H-
%X^MG(*K|;P<"A PR?%;P7@|@A M)>W4?&N|2PI32_J1500^7=|Q5I%TC9!?'*X8^U(\$'
|9)^=;X**8^M7LD^6P ME3NK0.L+;_+|^;) _JWOF+@WMF3MN**U8G78^4&IH*)4-
2KOUW^W#4@YFFMC; MZ?#.&(V4-SYU&9,IU4TIK.COQY|MU/MM KNXI.48ST!-!JPP
+^8N8<_ \$M M6P#5T5!YJH!2V!Y\$=;(L;|VJ_6|S|U.A5NS^PZR;?7XPE.DW.6?>3|XUD
M@""=5^M=|&;_8G@*N|H|1+#+>OH0^AW6T7>Y|C#|I\$|@3?M7W'(<8E.OY.LV;
MW&AT87CAA1L+H/^U@^55DX!O.URB78!A0/Y8#0#T_Q@1PQ@B2);.*:<=*M8V?)A)H!;
9P|@R@7J+|WSW|8%3R^H/K_-WOH_FRD_2QP.A6(V&^GTJKO_MJN/H1@

.39^##E]*H[=P'_BX8ZX/#=>%0&4%S]@B/IPC_5YR/P+U[5N],; M%-:=G\B?
D)=2[CAU07>M&LL7BZ#HD%NT?JH_XFLK?+UZ87J5%L&K@(-U8DL
M^\$0X%&QH\Z'G4V:5EP":SC)Z/L#/#4A\$ 93<^XCCPA:!(@(>O#7F I=;A!O0NK
MZG)WPH8\8.+%QL./GJ_.1JK.AVK6Y7>1MGH;12:WJX(F0UD,D/L'N4#-7D0
M^414HGJ&CG\+V%:8\3 V/<&A\%!(")3.%BMLO>=IKTPBL[!";*RR[1^L
MW/ZDIP*1@&!)Y\$%S.4."0FC&O.)2B/&97XM(BJ(("(9L13\$7_CLL7)%SH09 M1H49-:/)
C%9L\Z\$P50ETY9(U."=H\XD4\POH\,F,PA0,[E,5.=Z1G[-K"B MB>!\^P(!GF0+>6V_-(\$)U""1");?
4IW7F1-(^+-U=J.KDP^%G@5AT;/9/= MN5*IR#8H>7T+%&-B^?C^ IPK (4(I),O& JEB5%@14\F!
(4)^DWH3YCLS@+2 M"G\T/#-IE4\PT(.Z0C,&_.8 MY.=1?
O=:Z'&-CX%FGG;!)N)\$BI!'U1^(#D&S6ZX-JU M?@'Y^PN(3DNV_OEIDA*6.I
<^L.U'5)\>X6_.P2R_)THBP\$*JN*"FPM-A_". M1H!*.8;AA'XDSCX\PJSZH)%ZS[1;\4P?
1&0@>'3Y080R6TY!.E/OB*P7I@(-MOC \$->^B-/AJAEY/^%O)-5IJU^*MTU6'8P=/KFR74(I/?
1^H,Y>5#T07GY M_-MA4.T?;HU:?'^HH*'ZLKJE7;C4;NI5JUGOO\HE75:156+?_2
MHE;KE9**5=B(<9*36U#)OC>'.P-6F>0Y:"KS503DXE^R4 MYV9=Y-7)
<>P4F\!*MV"OPK&KR>=N@J->0*67;\$)06'1@2?%J.= M1\$;K\F>C-MS=//E^_Y4_-I2YM5#R\$-
XZ8D5QUHK\;->>P/6N5Y&9Z?6.OO0K#1J\^W2
M='WH8X#8DM,%>X\$8MIRJU#NZ\|%Q0FOI9Z\$10*QS\H%::71W=3!%0ZQ8\$%O;
MFV@/\$.LBQ&J7NF?D?GM&8D;>L^<[B](-)\$2K&YX^URB6*^UMGZ;)"N@U-(MB\5
DP2#Z4.CTNEJB\TGQ);VN-T#Q.IG'SJ5;F?K_O(8H6\$V-(VN7N F(\$0 M;QE;>
I.+5>6KT)KDHX>'P&8.9U28B.G)%F1+K6.%;1?^*OO&*H 7H-X@+T!G M5H,HL=C-
3A7!6=>M\CVT=LV4IFDN;J;HFRZMU?VJOE?XY\IE2R MW2_0\3"C9;5R\|*+*.+8K&U=
G/GA#Z0=TEO=;W5\U5=R\;O4L66W=K=X+> MZGJKZZV^8?
W;O>ST2S)_&_5=N>3U5M=;76_UM40=JF.O&S7I3.BVCV*OYU2R
M_7&FJEC>+YG*8HJ;370TS=;13"II_66Z'IF;BU\A/= @9E&X^)&Y\VF;";_5ZGR5N==OL_V M;/31,
M#ON,^4!<I'S\OU_P/LSPBCO?/!(@H;*UW&PW'E'3D\Z>V363*_A\SW_OPIY MHRUX!
<7\TI\8B9H52;9N\I.6)B3VEUW@?LHQV8D;R#B)7TKEWN3 (P.2_
M3I;+7=.F.INNI0H\PSWW5+B3;DE+8<_7F5R-FK#R9Z5>VU^_?+R\?WB\O+Q
M\LO/I.NO\^S3W9?K+S=WU\^PNR^?OMY_OGZ\^_KE".IP3E>-M*;!PV/@C'WO MR<;BPW9;A)2-
\$N"QGG\LD#8;5N_L83U-1SQA74?X9X2E-8,07D=E*?%S"03- M*0CZ*00SQ:OA7Y^%?%?
J>;YML\A\TJPVW\5\$OL"V;4T7)\ZE*NDC%39=G)+^ M_2PJ+ KH3R_RWU79)_B+LW\ID.#/CA: ^O-
=P*FW@1"X9>Y. = '\$LPP_IEU\7Q MX+U4 ?,-=RX6.X6IP0M
2#EPS\C#HKHNSG3\$ZK6+_TVJ=O9M%.M435?5 [P> M^I:C:GRV9:FD*KN#KUGRLVM-
\$D/_(^)PW:>;P\1<6!K6 M!-A07=J10K1\2+8@);J6DK#Q@8""%5EF-AHEQ6KA39Y+LQWQ"LSL0J
MP?CBL0)7E-NH&K7X\Z/'= GINW8R" R)6\P4RLWNRC)=*KL M=Q'K%!(.KPPZ5DZF=),H\$"#-^
M0G\B;W@%:D\:"!+%=D ?)I5.8YD_A16P0Q>4?"HJ8=H3""+FSD@;QFP4IW
M)R5CS\ELXWJ&\CAK(BB0Z\$M,W'N\A'DB M#M+&)&!.L&'#I3:|I>).F+"JWLOI%'0SF*D\7
M*!T\TU;DOPQ3\$HDN=<'(0%#Z6;'!HD7G")\&WL)#1A0>I@WLK@W3;Y76\ID M(I=-
GD^Q\45=>H1+JW!)RCJ\#HN7':U9*>-C\81P1)7;J+U?
M)B@K9^Q.M5NGCG45JV85/O8\EL\$KA5#^0L^#VW\ 7;+?KG\H?87\O6WV_O?
IFY/P(NDKI#;2G_';%)#@T\@7'I")B-U)655@I_!6J&5A=.FJ8QM MD"&>+QT\$(U@N-
3=B\$]*=ZXK()X_.'Q\&9YULRYA91%&!.I(O^"X<\$9*2SZ,1 MK\#;..
VRP;UGK2AS\MI(G/D/G_1H"K14OL>5)(05Z DT M-/KMH*K\A G8X MD/801"-!"4TI"V6@""+&)?04;
N&".%IY_VO:SD6N?) +J17>Q>E%L1:\$X@8;EOJLC MX_31EV-(A^5L^?VV_.R5C.Y2\>YF^3B&S"
M;C\Z>HC&CB;/LARQ?T.^%AORA^_JN*-F(C:PA7%X(UZJ71ZI%'+BPWV\$94[=.;+YTF)7X
MRW9&X6:M4@XZX\QLW:M5/\$"EZ9VHGS^*WI62E1I58X7"E@?>4=?+ #MV<6&O+
M9KVA\FZD54\QU6ONDS.'TM1)2IM'H:M(4DS2UJM'6M"DF;<"2.OY#FWW;"IE
MIGK%!=Y_5: ^3AG3_OHM^9C;R\$*4L1A\XIDVGX/! Z-N4J6A76RL,+R?E&0W7 MBT8U)
JL1BZ#@^"X^G-??+0G,'F= K.;Z7.Z4.I<=E,NMZX+;BC#KBY_3)4RC MHRE33,K4JK5UK5!-FWTL;9?
508J;+92V+;-^BJFT79M_1'0EMF#4>*932R M\27D\I_#J\SVWWWH^,%_19L'-FN MYV--05F
DU(H2J@J-TI3S7E>7X.7:1?GOGP"ZR:D:6_-WJ1_?4 [15/ES71E M39?I29>UE&7MV-
SAXG\6M<8M\62;V*ME@/58L^U^2J2>-4_3DUG?;SY'R=P
MASV\TY.@BDF8M75G39G\1;\$W\.;J?/FNZ9=73=[8S^I@X?W^IW"73OR;);F ME,J-
ZL"";2)XMN^*#*#JB4UP.H;H#K;.=B,N;S>EL[-@I'E?J\4K8T9=Y
MR=2T.5Y1)\6X+0@%3Q.W\4K;V'7=((U^B\U;U6DBE> M);)X\$&=34JMV*79O<+SF2W0@+6TO
A+&ZU;?5R/3H_N;0N+K>FVT*UW\IMIZ M1S4\TZUW-NKS\I\KG@X>)N^_BLSE*
;O/F..6PGW7);#?7N@_FR\G*7>X M.3&=KU<;FY:0+7K5>0WATX\PL\9AMKP&<*H>+(OJP=;=V/
M#>#3 ""MVMZPHG;1\$;Q.U.?8.MYH=W;I&MZY
M&^7M<*UK#KJE6KKQ;4\$IHWT\25,2Q<5+"AE0'=K;MH4DS9UHWJ@?7.JM08=
M4(&KIH#KD_\$(4*29E6KH=3\$ \$ILX&&HVFS)JH8C;4U M'.V=TGWBWK)/7'G-!9T+5E3*;
(4E#"&JDL5E#+8+4\3HBTP>[*I?9+E5QK MTUWCRF_Y-
+2_H**4T;DL\26,H=TX!;7;IJ;IDUQE37M8MM3&S-60GVM=9K. MML/B%)LW;ZVR;EJS3M#EJ87-
HT+OB5?V(UURR\J M':%WQ#OB'JEW5\W()>+\$WI"/6>J*Z=G%;^+7'D@85ZN\JAZ-^*H4I7OHC
M\6.)W>"9X_.(^P;C2%KP\NGPQ'=J;.\$10\JPQ?)O9KNE\$EF !=^ '&4>L7_F M_BK\ E;C;.:Q'PKR
;C\TI#M@X1\39J9J*6'_ \$CNT\;27Z;E\Y-"XF4L MW!_5,661,B>?3L4%UZ_'U39=!SD> !@% T CT
Q=1POA_!*(^W!&0;M2S M775Z#X%2P:=%'C-5<#"9 X\6 @T0#=\Y M5H@UB@:QWP7VP",\1:X08-
7^! HA%I)_2.+A3WA<0M!"2_RR'K"L<43 H:'R'X"@5@=>R\=2F5LJ<17,BEXIA\A-
9\$.AL8*S,>+GV;1)\-E4;X8@WQ\U@)T\04"@CM* M=!'K:DT0=H\V^&0Q)\$+X\J-?"

CK?KYI1W-7KVHZFC9E/(?/#AYOAI??Q-5!KG0#CM^|3:\$.X>P= M<70/1A2ZOT-45SHD92+G&-
+G>T.R&#W#C%A4_-D+3++G4CO/B>N|A)IP&C^ MAO EP(I:18XG"A/&SE:GF\$R7K?
+Z+&3Y6L1U,C)DS%T'.&H\$BJ(Z3PSB" ML"MBM|L^_01=BZ Z3OGB",+ZAJV.TF1!PUU 8Q)/6.ITV GDT,@1=BZ
F.%M MITNUL&) U*KI/H/_R_"2&:R&#:^Z*S)>AI?^X#5L>-5=CO\$RO-1^P^L7T<&# MAYK=>6J7H:KU
ZH,7M?"J^Z\$LIOPFC%XI0U>:XKA*W:XY.CX+=Z_/\=#2? MQ7.5?F\$PZAJ,BJ&H|E2OBU**Y LAI=KWL^:UJHHB9?
U2\$=1V^EJ\$3JL3S?3 M"TI DS3J(\:G<_"O"?V'DM/A_,O\$<-2.5K|H2WJ#\$@+|ZWG*2H5MD%EK)>C30?+X:TE-
*!IP:1%M="B19Z8"J_OVD+_M55DC9G,6C_,9A|?(X:WW)%5XE=9Q8A8_XW#&X35P%.LUKA5>HS6QQ+5AQB^
M.PYG|H|C_|KA2O/C-87&ZZ5WG|X0E>OR@BK:.'^|IV%N^3F:L_U/EEW% MKKK%IOB3LZO850_-BC\$YNXI=-
?"K&).S|JA5|^*3F|BETU|^L8D|KV%4# MOXHQ:;N*737PIQB3LZO850_-BC\$YNXI=-
?"K*)/_ZND+DX1EY2/U^|>Z|V18 M_-94VGEAH*E?SI_73@_ML;*^L7IU/S*L%;&|^SNVJ.XEE6/+% Z_4=^XHV
M_O930JD364 J?+0PZAA>X6T(MS%/_Z*46K|_R6D|Z:X|+#!|^M/>_O|EK^D)7 MSF|9@?BPN25Q/_V USH&+/@KTIV7
Y0L"3R7E|H6|@A3 |S2_@F626P>Q)XC M\$**GXR+YK,\$* Q^ WTK;YV*#\$4\$=_/O|D?I|^W% ^*93J<%A+5SC_=DM(G_X-
Z|M?K=T!>&M:7BOCWO^@6F.PAR&V2&09B.YOPD7C>4@QM_!JEL4^8%P)\$6JZZOIKPR=# M+0QY!^|XKV!K+7.
0W/_|^**G ?#(S|WQ^))6U>%U_.?6H M<7AY01F040;V^AEP&S,2^-%<\$>_9R-PVEPS0?7^K|5=V:XU!&*^J0\$F^),8S
M&K&M+CNH:E3PL+PT>TM_2VVAFSH|_=#B\$?UQ@.HF?4*2PG(<317%;C%4:9A&A+0L2>L12>8>WT%O+\$K
^>+&=YGC+ MN1=CY6W^Y.O?<7<SN8|J15_-8/9>^BVH<\$2,2|Z7C^CY)=4Y MD_6|+3#B@OR
MZNDN^1O9ZH:%GHBOQ*&YRBD0BQ_#/C>K"S2|L#=<|)AXZ&G04|UE"(AAOW M AJPF|^/k%Z2LH/2CQ)>V-
U425>I>"@08M:&QG%%PJ4,8&YV+J",?HB-F1 M)6HM|S7=M9*V|B5=+N7GIXSFHG)AAW6%O9=1>:
fP\$%48HBRD#_%"|WJA_WH% MOW3,BD|QXMLTY\$XP.|YFB3,*\$Q=>8FTTG|6:P)PKYS&*R:U^H|F
M,\$&C|4WDJ%YSI76M|H|^LK=VX|Z/P29*F8"N^A/@IXI0F65WB)60V4A MHZ)AS63F1W_LX#_FD^S|//_MB51|MY%
|&=|_/M'^*&=>|+ME7|JA6=1QI(>_M^0+|^OHSX2S;XUZ)QRT(00J:P.R.? B|^<^QG TF|!_Y>"KLX|^A&ZQEO@R
MTZ2^CF4_#9=|^7" I+6_|7|+|^2;_3 M@.6T'0/6';>J|U_M(CY8LBU^STB1/EL;WHT8U= J|H TX.9K*4L|YF0|<%:P
MUI%MTG&7E:!?%871?#D|+<% M4)HR:B_'PB|X>/_8\$^V#|HJ2M_D^@B/>* M5(^_7:P@^X V8(G>+&_N:>^!
|^I7SBS|_G |ZX2|28X;|2UL|4_|CS&\$f M|&TWYDG%429FM^L9")O^E+=0S" 2 MAF17|L(C:@+>^!|O:@L^**6C<^@5"-

=84EN\H7H(-BK1:#D&P1X13JB(0BB)X;6VD\Z@MV?Q2)+H#S,90

I-N%I+IF;/D2HA 3IU90N1#1%A 0Z MRIFU;CC

:SY3A&-LH90!U M RPE,C\09^Q+DJ=C\$W6W\0?X%Q%IXY6")\;IWHR/I*7A/X5B #(-=RPK(> M-X,?,>X3)
IN%AXH;1\TCXY/I2/==%T-BFY3@GT(77% Z/I M_MU8DY/9@NQ:***X>6H.Y7("G.6QUY4=)X#*; SX68H^FQI#
IX5-1"E MD;2%)>AEH64!*T" Y3LK2M1X8E>JGG:DO?8#:H7O#CQ@)I<@=8C*,X*V
M!"C9P/+ VNN:SM6(KZU&B03_?+5S09A)1CH>W*.XB(B/7_%0VV1HJ>0(T
MG6C*PA2J9"80PS"EW+=W=T\$.RH+PTE.;PXZIY&)PO;1% JE0F^Z;1)NW ML 4R1A@O-S1X^D3O.I%#Y)UC(T"
L_ \$M?(<=CN\HED@^DRZ^= NH\H\IE M_24M\$= <="Z-74D@W;QR 9P2L0%D%QJ^@72(//PN ML"
(/8W<(O@*XX/#HB/?L^,@)IW#@M%<_)2%(E@^ \;C\CTU_8/@KV3FC0XK MLGOPY5N!YI-;8F.WJ
5AC3@K."CG>UX@400L%?CPUX5=J#P&.JT/XDF%4@
M2E%Z=/1\$+DBO@GD9%F"/C%_U>K1<=%*0GWN(D<+E\T?;+X&7OMTJA68NW=1^MG\$WR;C=)FU\ZTY9\$,&J%"
I&SE4?2?7#7N@N:(1).2.K8B>.:YJHJ6C=Y.%<MO1 TA7 I"/6."KY.I4+5\$_%3T4HKHIG4Y6.2.I*8FE0J@H8ZFB?
\$C-0* M&KT7 AE!9A6MM#::7XA I<5*IT@ (Q.Z&IQM?UJNR&IODB K!)^+^XU\E<* M#N+GWI(L?
@8MS>+GWSVVP&W3M% ^H^X: &_03A07YR%DQJ"< YQ.G@ZBT(S(7&
MAR#+\$@O+X2KZ:UXN\KWK X8S^D*=%V>:\$!%41^Y#IY6U8X<2P*""WH36I/ M7XCI/&?
=1.@+;^/E3Z3J9 M\$Q1!"MXD.XVU9N\W @6^&"HTR54T^D0D&3< @M+^LH.A\HYX2J *\$E897
M3TF7A*T.Z1MO.+U<\$A)IU-Z'GNGO#MN18 ^2N\MV.-G<0+SW\X7>*E M.DY*8JXC&:/A^AB9<\$N\577J;H^IYD"
(BICKQI_33/94#E;+0+V."X30M MP;">1>H;>|TZAPV8R6HY\A(SF7#I3)^L,<9G0^%Y9K
M^K_\$IZH35>XXDWPI3;5+.^1*%=5L(Q2B3*#GZS4%I9_6E(^37QD^RNOLW<>PD MCI+PI\$3>.%M6;ZZ_
Z%-39ZQ)160Q5:9DI5Z\$JCAX9Y'%:WB\$#3I^IDU) MJ&9H#H-I&10L79522-U Y)(L JYI&7E/9'IC.?
Y>5=9Q@E3IXG4>%.C M:9PB,3Z%&68;R9,DB#::QP\C8K\$.UT"Q81-P.%3HPF<&SWYK9I9958-U@7
MY5_Q6_EZ;3@6D\8DIWI^IZ;57 (_&@>S\H^#XWYAH3\$@ 9W\0PL9> M19.\$!:=IRE/SVE^\$CY9?
M.7+NOP@4IB^Y&TCTM?YI2H;N;*B>"8C8C%_&W M#J% C%9XND)Z,^1U\$7DQV1%IP."I2%R9
QX_09>W.KL^O)DVI6L>#=#0HSX M;R=)JE=&4@0)HB+0>&7O;=V4A@:RL:RL.FVV.E>X2!%22X<5"I.J-02=CM4
M+WEJC^8&FL.WP;8V*=X.J M#;IV0^M4>>#;CA_QY/9H W)2?N13T&U\R_8NF308^5_N."S;3GAG^ITUW#-
M^K;2^8%-1(Q_18G\ X5.O&:>.AU.=;P##;C?L4()T8K5@=UT@^EN5,+WV^I MIZ#C04KQI\GIW=2D2_2LPNTI+W
IABTT)UAI?9>SXOHS4!^8HVW8C7TA-ED MJLI5E7-3*ROG-I*E.LK:>@Y:S45Y>S)0&YB(ZL)DIE8U*%\$J=L?
%0:E5 M5/;+J%14+)>%#-"/<511<7I7FH446\$;5!G07\ JU'39I5;?&R)W7%\$EK44& MZ05) X@:51-IJ+I1;W#>
(9&YGY1LC3\LA'F_0/I^&Q09?R+UU>7)T*. MT23X8I">OQ.F6MS@Q@9I^ "0G?S9AC5;& #,I=@4?HM++K4SE-
+IK^;OG/+Q_66/LM MF*OQ#(B3RH;B?SZZ>B^HS;<@7_OA"#8Q\$S91)/HA/HXK/6^E2E@?2AM
M(L2GD*#>NP+YGD/FP@06D&"A>5DWG8^G<^"PB)EJ=-F2MNL7)+ZIC_) MDO:#C216MM>A =FFCNL7);'G-
TAI^&?&B%:..K54B5I^W(2^1&WC(:Q? R: MT%?ZN)=.:V>@0.F*8IW\$*G%IHUB(Y%JCR:* &2GMUTW=
IP+K#FGC2#W\I) MK9C\RF@N)VWI7BE880AN>#T6C%H^UO9G?>UPGWP7:P#_!% M)A\3I^E;W\HB.X>X-
X2/IV2E;\$?&@8^17MC^%RE@T\H>.=2I8=7*FLL\B MUGL9/_K%1009<IS?FLVG&"A+&LK)<=I^>^&IW;7K>6\$>X-
%K(3I6_1S^@? MJA=8H^W.)\$@IO-ES8#R\I;@TN@#/9MSB6ER&IU<(^D-H\DW8L/*>H D>+8 MC8_A;JR;X_??
^6@?*>P.L1"1.Q^MB>!OZ7?T\NF0M_HKMR<+//AF3@B M&P-8">(.0EOA\>=HLK?X-
I^XVH\N3@0TQWPQ@O"D^D^ROX"#UL<_O3WL MKNV\^OW@-8-K(\$80+W08;MC?Y0\I.QP#L\DS9BS/5T!1%-
ZU%&8_0D5Y\$ MCKU_VE#_SX2CO;_SH)/O%"2/IUS3:8Y#FY1"R@3Y)C9\$A0?X=P-M(Z\$;15W*;D>TNR.
IW/VQ#&3P4M^G^#)P+M@!%D;4\$P>Y;I" BT.S3T0;M.2.G;XH87A9D8D?2+BI71I'={X0).((G4W;27R1C0H-
^"K;UB= =47\$05@L M=I-JH+AI_WK?VP<0M(IV-;C;X/I)<+NI;\$-K%.YZK%I-
MNJ0>ZUTY6.@@@1BV*L76+=1F?/YKP<#X%GW,>X\U:X+R7AK0GN\$YCYJ8\QWR\PG M3=MC/FR1,BO=;8)
HNTIU;^88UP^K(012?Z5;06&+CD/MNR26DD)OK&> M5T_F=:S*W3M5DUA\^V""T-
JY<5FG.%G7^Y@5L^7U>"0%<"THE4IB\$K M;W#%&EQU9)/+&ERU^YBL)0U7"<T+36=IM-
U(8;#5F3Z7L@?J25;6.AK3F&<1KKKVDN*)E@ND5""K'B/ M907@)>Y96DM^C;MHU
P2_MR;I&3T3YN@%;\$39*NXF@N04N\$79IPG7+ 6G18 M\$@C\3S8)QP79NNI.RP+Q.O,S=W::T"W?+\$ Q2C9,Q_?
=V0Y=%15FGJ>HK.M+3HN;-BNQ?7G86"%0.N&%26B;S#ACSX>"8ME#H2 K@8M0N*>M%??
HI>CY+2#174BV&CR&K"?=P7;=C&PF^Y%SZ2,&=I0F+0#L%AMGT3K8H2*I2 MX\ZZ;M(2,A:(I-O,FI>+)W
WD@LN=3&5?_B#\$EC6/N:9UGS+&N>93;SK^F& MK54N* @W2QO^8I/>'M
MALOXYT;X)Z7F1%^H3%/C^8 JP; Z24C2C&V 08B5XQC^?VZ?S(Z>?E M^WXT%IO//Q7ED^<I^")1^C;DG8A%^-
X\SM-76L Q82I^%0WC8QI+*+YS3 MIYIE*H;PF@>G1@.9)#0\$@E43J5 3AR2 R3(BDE PH^A^I^O\(@T@G(5))
MR)\ZE4=S6>T(1&I\77X;&+?T^V;622I%JTEM"=08)HKR0L4YTJ%6XX.K-M
M9Q)0*22"%EUBK4B&\$2&"9%*CIW4J3;JZ5U)H-(R)2ZRIVD&9 (J69CQD)3<I&NVYAU/70\PIZ?;29CS*I.
MK;IA3#XQM8)QF_QIA7;68UYR&ID)PES;B3;29CS"MWPI5PHB<=-XOSDRI MV)2 R.Q7DLP6
5)\$P5W=FN@1?;>08:SWNOFBOH(&AVKV&%SY;U-M^5+P2+M5\$KY1%:>8UO&DMN9RUAN(QF4WAP+U;&KK)?
3_D M57=DP& ^L3IRH;1 A^T0\$ QV1NZ5"E;/7A8;.F3B+I^OUZA1\$VO4J+1& M37I=F^1"/F)B?
G\319;RI^Z\RU6;@W9/W@R(+KX=-QI66%"4>M236\$;=S;6N)-BP*QJD7.A@70%R-
%&)@E"743(QDABT4PPH_F0KP&6Z\ATD<=?R\0K1^X M&&^KQ>W3QI%I2^EMWXGGF63% <OEJ#2V;I^>D6>Y-
L^Z/LPIQ8>P^J^B#D MYG;VNO? C(R2WOW;^E6= _FCIW\$N(K%E-X(6W%;RV8; 6<6?&U-QI\$BC
M>3QA.+PI2!@^F@&W B0ZX.QW D8-QT8\$PEY#1YQAI?^VU\$^_IA,IY+AM./ M/IE:FJPI-
IP;SP)&04XO^G3A*"">I>Z2_!@&G^+^2<>2QR&3HNS I^R/6 M;=<=G\35>+X7+XK3ZTWJ,)%3NS63A)?
I\K;F8'<043U?>H+I++V3N52TBM M&Q+R^FI59W6KRIHK2XIF""=IY-6210KSA5"";#2766D"QIE;ROCS")EMM(Y
M4\0C6I^Q9E>-6"8QE,2H2F)4(S#XT5PM71^X^I5.TG<)G>#I\P5^54E#FM(#, MQ9(RL>H*;T^%".IP(5*"URD%140
M\$XMB2%5+B5FNNA=1)W(^C8^PM-%4R>RD+\$BEVDO)?K^N9UC8*4AY6C'GB" M%6*6(I\TP^)(D!7OPF/@8F-
MD)5? N28)3_FU@ 9K\QBTP3QT*O\=FK;I=I@/N;.=2_//J<<4-G^%S M^1BU.Q1_SIZTM
I'=HG.)JE3KJ72C.%4PI8;)8@FN9"@F&THMT>8I67C< M=I*\$C8AGD+@42=I>30TXO;8H\FYC6VNP(RPGDEH>&
Y(=WYD-AEQU8X.2O;SN.F3PZ\$^S^I\VV\;=GH/Z; M=LX_VLL="C^YIRPNG)4)QI#L.EI@U>W\CNI;
I^I6IG>73">!\$4I34=S<2P) MLXZHR2I+3S P9H*Q(HJP%9IA650&*8ZYB6M"5197E))@!UP7%#UT4LZ<#PU
MJ#%#S;19S*\$(1%&HQ8M_Z\$U);EM/IN^02 IF009;1W;IVMY24N0/W*MU>M?
=@R7Q7/EHN^EM9N5@#Z8PN.XT@^\$D*.MPM+;I\$6^&I0718(Y\FH:E>&1)I6&@**QBV5 MH4B>A0-
%T49S0UJW_I?>LIULL?X\$VZ\G6B(49D96L@X^D\IYH2.^+ MI5I55>B(#XEY*1M%6UUGPC*>L#!(I012I7>U-
6\$J;U&I0 M(1;9CIB@Z"2FZ(:)HJ;RE62% H6BX**HIP2?_KK;Z.P%VJ\57C\UATIV"W+ M1Z5R@NK8Y&JC>>FP9^.)
I"/6FCI6E;M+1V.NR7 G>U;WO@.\$PUG7,K\BC>>D/P;L;A\ISUX2IK&^ M14D^6&G_)V#4X\JLJJ<7\$7UU2
+31HDR+2;\$B0* @DQC(LRR&K^G\CO\IET MO4^UO\$=P;TTTNJE8)@@@NU;8%FH5\)(TWMG=3J;*V>K"HM/-
^Z\I#? MS0#<I^Y;Y4=SH73L(<-AAW%8);>%Q"S-NFJ #;N\$)>(A5/&0BI".(M7E5 MNRV51^TI%9ET9;
@5E39DE8\$H.FR8I^L\$5DEMPM;K;YV7.VHK) \$OC?_
M%;3KFBGD<>^Q^IGI3=I;TE\$#WM?)"H^"BQE"=.;+5Z5T/*D(KGT\$IX@Q9 M)&NC8&LZ9TAEI2;H\B"CKJ;\$)?H-
/*1=P;5I?E66S;.\$FNN;DIT!!"U MW;A18XF+T=84TEG&MA;561PZK3&UP_"\$8/5^P>I/LA47):AZ818/C>C/

MI5X\$ZJ_L/S=R66!AWCH*%P=70IH!^9>62XP4.P32!#P\$4J?QHNS71>Q5-M
8:68DE+3>WBD)@.*\$J@VQ\$'=45D:6(5\$5F5KRSC/4X@F/V15U(VW&>:9@U M*Y9IL(8FS'V:3%V?
Y7^!\$.>JL/3X85CDV# M0L@P<(&IUSUS|WK&>M76#/ZM,.-=#G\$U|YY+|I)>W81DLPZ++3F|Z>_I"
MC+D|&SEH?_UVQ=CY6T0*).I#Y;@!/"IX<_#U!+|Z-?ZY)\$YD14G:CKA\$S|/
M>Y1:~\$GIGTML3&Q.W1R3*EU4L89Y.4 WX@A<2C, P5>5 (M"8KL9027EBNR
M_F'G&"8G*&_F&+J8D0SE"&7P)^3*Y=RZ#:M_JZ;>QWU:XTA#RS3B3=;("4 M>Z>;>%K(?=|0XG&/INZZOAK&%B-
F3LRU:C+GF_(P^+@J2,T(VY1J)%3"16 M&T^/;^60(1+MZ'_Z+Y=8XG:,F9\$8R(N8B)QD7|DL8%9.I^\$W'
YU*WC'INC'^*A:|6Q4:9L:OPWJ3_1#|V46#LT2?V;- V M*Q_E,N//YE*K"O%D3,&8HD:FJ*G#0)PH,84C"EZPA0-
5:|F^N:85=|M"*&MNL_IEM@K&N2@LS&38K#%(|@51D)VE-F,FDDBK8QB;>P:B/7M*! Z|HA5E5
MJND,./&6OG.'PQDG019 UT| MNI\$RM+.62T6>|Y0VG8|FFJ1V|YME2XPAK9,M#4<.,5>59ENV^*[A|J<|
MGC;#XV/67*(^>I07>8//F|JC:55MU1F*NH6BAFK_X 8BH:+H@9JQEVV MGBKOE-J1A*|V?
Y^@NW7\$>QW|W|F7.6.C/Q3JGR:W7L>;N8F4U5|F7LE=H MJ^E,6)N|HSG/(-432|7:7%"6L,PY?
6H_E^&S4*G|CH8KFVF")HK8TG4*G(+YEOW"KBD&8",MWC\$+FA>50\$!L,NPK#@+KLF'S,NLA5L,Q%"8N\$D<
_"+H*P065>44\$|L35:1 M20L|4|(F"\$P:K|*A.C0&3_2.\$F'Q-Z23Y/0C557>K'955GIGWIMV!>%V|
M@SP>/_8_N|_I^VMS>=A|VL|VO&?)?DTHFEDN_JB'@|H.Z.YT'0D\$I#%FC8* MMJ:S>D16K+%W@"OFJ*L+<5F..E\$ *
<9J_7823@TJRP*!*(("E=CH'J).@ M:KFUHB:RU.*!(ZRM#!|H"8JLAAU>D-KA|HX!&
M|_V+P+U5_8>7L"%4TKU,^;R&W>.CH7|_%9(H.\$(&J%41%|3X40BEL0E-TT9S08ZG
M+!9.+V.,S1C|1AB|4.^JH@M\$40YCE6AJC*LC-D9LS-F3W /=J&3KB9AR>6Q M.HO7?F?HIG_US|WK&^K5YZ-CT
&%#. #UTO)47(^S MU^>G|QRAJPZ_Z/ZJ;<#8'A30|AD0VY MX_2|F/N:~? "X= OMJXYF|?3%6WB:4\$Y&|FQ.C|?
H"QC-WDN_10+>4\$ MM(19GC^C3N3GQ@E'F'AZ-RQRB_WFGXZ'I06Z^Z*|NLG.44X\$|@X?+V@1)>#H
MQL//Z1P_D97GV):QY;F|G2ZK8WIL^W|PSR;>XP"IX-A 7-W>2^>_!EM)W M.S+@-
W|8.B@K&.40L1&=B6H4S:~870Y YW|=."CV\$V>|1*7_1XQ+ T6HBL*=
MX*MA^(_L'KSP4_&@NC_OMS#%Y9FNYHOIYE/_V=> KS_HAO-WW=R3'WCI#WCZ M.|>_GE4TS_V
LHAQP.PGW48TVVMO#D\$#0|1W6UR^U 2:'01W'IA#Y&L(U" M(G\$F_(TZS5IQ:R 2|XQ46/|A9F4H#8|2W;HY#=#KA-
HB_-DRX|2\$6 M*D(|7'9|WLU%TI>> ZPS0HY:T\$X8"%0I+KS.N:TIR>'|GJX14>|PP:EL|J
M6.)G3|SRL|IOBP|>T\$H":CO! M2IGZSB7WX2|OP|J9AD7|36|Z>PH)EG=A.%A/_U49L.IKY\$#0(R@C<'7T_@
MJU_CG|O3B3Q_FHZX|_3WL47_Q1Z9|+BL@C@U?R@A(N|R@CWN1#5XQLSS>SH MM*P;NN0|TC&DC1^=L6|
C)DIGZY.,SGG+AE7"7C%3@AP0^LL_U>7+0:KDPY M+9_2|0K2XGB|V+EF_0T++8_!/#/H=(PT^V0R|H|H6:
<|9EV^F:|V@J>: M8|VYL4/=W'2BS5&8(Q3:6(|8JRK'N M|%'H^W@'M6|/LZ?_V1SA\$E_F4LR|5.'?QX,K)=G3A2:F#
I'>.\$3 MM8V2S|3\$T5Q6|NIN).(4#L.31G|AK\$M..C#,'P)E=TH|GK)E#.V*#S7B;KPZI MOUM(K_YC|GW"/=DP)
(N>N^*HJOY\$K.4KZY^7CZU*1)4L>%3|W.1+UT^+!F| MK_,VU*|47CED-I:4B,|UO2LLI8-M<+.,9Z8BG-
W"0.*!R)5V9:Z6>5:E.%|6MRMR5U&16/Y0AKT:\$.S|0
M|09\$|L0Z:5(93U+6%JGS%#%T=LTD:A5<.FU1*S"5MO'IR+3@|0|T29HF69%9
MVM^=7#&F*=7GJDZS5.Y:HV+F0^@Q|DJ8I0H#(@-BK68I/>^)^^9NKJ)KH)F
M:./PRF&6:N6Z>C|/*60E59|P#DJUMZS3|V|27S'1PP|JZW1Y4|R(#8HWV M|%)\$30&KDZ:H|VB*JL<5;K19&ZPG:
(O|."IM)IAC4:25TF:,HN90K6XV|Z9 M5.317-6|'K@/%VL<4;'DC\$5:33GXY6WJ^VGP:B;<7=?N:L|
MS%TVS5!'IUC/B'"ERETOO*,Y:NHT*|P|2B@T(5X:O>:/2\$DOL%RA)CH5E6 MX:8C=5O9H/(JFX*M^V5=V3U:~
GV%BOFPMK^=">K;F#5;'A#SV*3J:"Z7SWEEZ.JF3=HH MO'+8|J@K8+C0N;TS\$8*JVY|K4R6NFJ65E=C/D0&/'N-
TNUZ|J).2#>'A|S MF*4.CX8"JVL%W05-\$L:A5>V6:HDH_F,>4I9==MN"E.YH :HDC+O%\$>%^Q1 MB0&1
%6>U1FU6U|!*Z"YFBCZ,IACB|JLNT0JMM.+|4-&GH0>O4\$ZK:(*51# MJ|9+V#G":35U--?
\$TDBBE:|Q"OC,2Z_(2XO5BJO43:/85=@LF8%<N9ZO?FP>70-T.&(|VEMX|ROGD>#O&"%1<*M ML:S7.Y;WXC8&
<71GN7GEEJ;NNL8:~\$1Q"/_IW+_VNN,1QWSE%KIKN|N\$8S" M)QB@8=\$Z00#+Q75K,Y>P&#?";TL?
X3#&NW|UONJ^+W:WIX5TZ_+IC5G MDF=BNJAUN"6LD@X7L ON!>#VP003|KYA(Y.H1|P1^6S7D.D&Q-
_!PE#LSA M|+V:~D=W|*)W H>;#W1YWD;AQ":L^L/X.*B1RQ5F3%25EZ|H(XO@839+< M*+WT|N5?
B_.N'JL",YO18|B6|_*B(\$6!&D4#M5WB&'SJ'0S.-D(!+(-! MCNGP8L^"98"AI7>V3PX7,\$8):2T)SA
_YUO^4M#*S<\$:P_OQ*|Q2UDTS2L4M MT=V|0S|U>(<=V);RP_D+G\$DB_EST_W6#*7\$%^NC|4Q<#Q_H_H
_WIGV|L^C MQC:"@H|HQ+Y|J#4-R|JQ%3X?4MRZGAP+W#H| MYX*P/|QONULQUN#|+Q.75\$O&G:~+Y|2/F^U-
M61+|f5:3%+@Z*U=ON7|G9 MDC69>U6O|@25@%-5|8@:D|)|2W, &"%DZ*:. "560.SC0MM.5:~|EH"!B8O MJYS.0-
8LR&XABO6K8|.@5| W<PMA|L(5C3YDYDK3%?(^9B1BAH#Z_A"/^"7 M|;EG|. @S1|B4>_3."JD%.M=
6M05>#0?7N&S(#9J2.P+TMY,^|V"JL(<*=- 6DK9E\$H7?NP M">UW"15|_N:8KLN%\$0;"NRT9C:&?
3:9*R;3PEEV5^5PN92NRS_CPG^_I0#_IE*Q%(L.9=LCU/EMOY<.:S?7N<)_ M_M>IE*02P^7Y?0|Q@P_LSE M");
(C/#A|'9X>=4A&|BOLXA_C"7@|B:J.GS^\$*4#^5|1+WXY8NHE/F9SF
MO)3|^I%:H6W&|=JW#0:Q1MU\$OQ;+M>=1"O2+!"|S7 M^SOFZ|U<_.S|/=4X8-!PKT1W:,HD<5E\$+
L|NK0K4B|IOBBX'(|PZ&""^V?7% M(O|_T#M|(A1\$|8.49E.90_0DC75.9|S(F+\$.Z)&|JQ,"JE!'5|C/B+80*
MH7:7UV|M'16|MX%)<(^TWCV/V&Q0_7SU@.N:~#6#Y X'X#VR&5N.9VG^H%Y MK-
&@UYOZ|TOX36\$G2:558&4|104D>_L7V0Y|Z02@CR_A|DM.9-R\$:_T@ M5H(@CS/_
_#17\$|HGLB+T#M9V(H(ZABN^"G@2HKW/VH'5|F=E4|>3NR**P"G<^NB0E>%"ZWE
M\$S\$B:~Z.U6G%7M|.Y%Q00?Z3"1*3"HU)A314|C9)61V>5:~3|P)9J^PF'BG MHA_#U>4.VEO.2X/*WG;3Q8-
SC&L0_'HF@9'GWA0@.5D+^_U_8VL_4&JM_9 M.^+H'L8P^B,?KJ6)YPSQFKX.X(UO8GY>MT2!
|41#TNLNP57.".YJ3:J9@1G&.% M7:W"65D/E0U?@R662R_Q:8@Q/@RG8UA^GX03?1 ("@FWKKN@+|<|+3L/CSK&
M_|/':=H#ZFQUOT|4B609=^2RS>L26UP@MGU(G|W#C':\$V;7>(_N<=|6W> MZ^+;_N|BOHTJ4|";P<-
E:8(D)|HW7_A6-2.7XB*|Q+6|I*)WZ.C5#@RU=Z<|'09L7M732+_K6W<0H_K3|)9O_82W(<775T
M/QWW:2N>2V/G5GL2MH/C"6X|B3QTOKQ1-2+_K."?N|LB+L:0<@11'D:73T&.#>T?/3R|+9#M|%;|_!
_!RKOC/>>#3V-VZ^\$ MW466P9LB;9U@E6#<%K4@.05Q:8.=M.A38_H:~#%|\$:
(+GAP3L3OH!^U9;&RH%4@."0|RHV/DO_U0|B:HD>L5+W| M^C)C|YTKHM_#E-R|I><@R|L#M?A^P%87?
4VTI9M;H N#B3)K|303=H=SMT0 M&-Y|Q>9:~WD%EZLN:(9#JBSNUS WEV3|B6RSF67R M(Z
MZN^?WZVK:"H5A*W":M\$HHDL^7KA(C.7#XQO_+=XE8CS|F6U?L)EAMXO:~# MXS/?XME'\$A-
(H|DFE.XKP9),PBDPB\$S%)!D %)J7|;+*JT>"J<|HD"/;59
M(BQK,*>4CIU1)K&.,|J7C|1GN:4=1\$E.\$9P+)2H(V*YTKG%K-"1^HM^=>3 M\$VJ8H
T:88C@E(552.A.47#^P7L5S86E'B+@QH2SP9Q1.\$_L|UUAHAW10! M.RH"M\$9R3^L^Y1A@UBEV#2I%>0WJ>-
LZRSV<&@|WAH(=,>%A<# \$1W2TY35-M=K-5NT6EEI-WNYZ|*V;E|/A.9%NG%B4;*D HEKFMR&F*O4Z.EJ|H:O
M@)=V3G_~X"?ZEX(7LAKD:3;+O2T&Q\$F\$T&U|3PD|9\$%0\$KP\$9Z0Z0FC8"" M2N&3_6_=67*?
R(HFEQ079@#9BPNM|X|="E7Q*TZQL(W7C)"#EY.H7|/5\$ _D| M|7#=#GB|8P.K6\$_)?F8|\$XX3)^9"U^H",|V|_ZL.?!"
|#)2=9@X:UADT.)FW8 M8/_?5JA80B_V_A"HR%|WL9PXP.=<."%429FM^L9")
(^E2<@3%F<^9("89/7@|9_A/NW>>)9U0NR1X?L):A6)9RBVM_9@I6|26P.# "A1R|F#; M1ZVO+?"|1|V=R^-\$=SA1-
">?T;U"/_KXO)H8@V'HT6YH8_)H|PTP|99V M2OQM|HA@_*-9E\$MN;?H%A&+0YR_P|*0+X|J#|L.>0)V_G|
*_+L_<>Z%>+ M5FC>K@0R1HB+I0|8NO5@2@?Q5G23HJ<+1X|0 M?S2?QK:~?:=|3@TB_U1W^E+\$+L'
3H|<\$.N4"3^#D@M_#WXA/N|7R"9S1) MMB\$%0V8312&|)=C:|BQQ(-FVBP>&|?

FN99W2L97.DJ(C8X;0A RN#>\$I0ML MUP""K#?L@R1B"5,401*R ESB\$4P>/OP&/T^ZTO_!;OFWVR>&4FQ.WS>P
M\$&IX.3^>\$;SIP7IYN 7 _IJ ^A^A^I^N^RY9PEST1Q/1I=F0HIL*:GE6.LXJ M(7PG-
5YF<.:7'9IDR2A\$IB+T1) \$DA;.4*#3VL!| 7Y1|F0 MC^TS90A.6M^!_OA)V1%CM8 _+;)HH(XNR*=CWPC1=4B3.
IY0U+^HTE^LM(QB MW#5\$)2B^,6^08#&2TB NL76SNP)O;+P&D4V@MP&:W1JG^+=+05 JOE/_^7 M)O#J6U
YTPV7^A2I>O^*B|TWNVS'98F2V'ARBH(7VUYFQ#JL M0P9I\$COAW:&(C\$F5HQ7ND&2?<
\$;L!_RR#N;O3ECAE "LD@'US+&H-SM=IQZ M|/M-W|M|R10 'A H" N9L|I?T>\$U^*X;WP)
I/T^NU&U&I&_IRM^|HUG|8E/ZA.+K#XQJT^<8#=#J\$ _L>_2 M?'R958N|:G)|C%K9-!|7SVC-7H;!CQ387@\$=ZBD"J8C?
\$++5*(8!'"K&# _'MH#U=^,KT4/M@D9JY|72'I|C%O3%>'2|BAZQ_U^?D2?JCLKIC_U|>XM|H6V MG<:"M53+?;+MU?
\$5?HB^|IPNFAS^OR9!(=V= DIMY|IYHL?@ M=*|T1@MH F4MVA=PN"(,DK&TX-?
@QYM@N&P,PUJYQ^_JI=@)P#+@4+|K3^2 M|=Z>#8XF^/=E 4BFC.+&7.7YG?K?EQO8D)B@P/&A*15 9;%,!=#V|?
K_2^76"793 85^L3HHH!D+RI^LIDUKVBB)|\$\$4VJ)R#NOPH5IYR2'49
MX6.0U^XU+ZX!>_YMNJV^2)|OBYVU5I\$R>?N#\$CVGJVDKEY+B_2%N|ML"5 M,^\$,-"5S=P@MA14S9<48V^W
>3BP*Y9C(\$NCN3A6^:K*Y PA?YEQU6UP54:2
M6|FNPIZ5XVG5S6KK*WOZYKGG9>IC:*E2)+N_HOMOP<:_|<0+VZ9ER^XO^|(^2 M)>|:_.4IJ'52 GJD<:Y|VE
032(AYYHK8Y);DFGP)=R)-&Q-@.%)@SRB+515=|5OU_M|8%;)0KQ+7KAB26.^0 M9NC,@%6HSJY0IYEVA3.8-
Z.33.&C;".ML|HJ0|FJR+P9W<)"FHK7:E7QJG3%D+)|R^DH.2:99IU5Z.U0EV^H (YRN4ZY#
ME/40>.:R+8|5;.:J\$|K*|EEE| MR1P>*7I>D6K5|KTB|B^|0Z)|VE;L.W-"3I-#SBPX/D3D|RAD>&G-XU*@S M8OT/ZM
9FD2WJPF>2;.:S&*C MJY5@0BN5L@8CZ/%"VOUA T&M7R5T2-JC5\$
MC4:|&*=KDI/6K3LL^M4M@HBAH:W?F.C/6A5A VFJTR9E.J.C3F!@F
MBJ|)U5\$3G^*|XUYQWU|HLKH@<5>N^Y)&.\$12%"=W3^+CAR=R12/6EB(
M1SN6|NLYE(6@61HSF4AE*1Y<\$|T\$T97|HP5|I+(HCVYA(47-:7&ELZN MB"W5ZHTMG='*Y\$|%1RU
^I4P/<BD(&88D=BVYB3DUTO1XK0&D,*8K(DBU6B-(84PT MA+3*A%AX9F8,*5P#|K;W0LPTX^5XBAK7O#,LU&?
WI@U\$40*X|*8;V/(*&HB MBA3&-6.^C6Z|!(479SVH(^6G_!5QI+^:XTAA3^GD5VD|!SPS,Y(4KA&.;D|N
MU:|A_|/K&C|JCB6|2X|*|174.&45-1)."BF06UM\$M,"0K>WA(S#RI^*TU MGA3&1-*JTRBA6=F1I3"-6"56|B=
<>4WJK_XSKS@^U<|R@.:I\$3"D_%.H^*M^F7^CTZB|F@4D 1JT?;3"DJ?L:HTH!"7#2J5IK6&E,"8:5ZI6&MTA9:6
MPC7R9?I^=:&EM^K_K)G_H\$|5P3<16@I<4E5L^?-=|)%3<26 HJJ^BYE_HJZ M#1^UN|2
\$+QZ%*)K\$6Z7;8TPTH>L#|9Q\$;TV|Y69|Z0-X3M M7Z;IGF;B3R4?SK#8)Y.|%T9BJ|%43|QIY+
<+10Q#TB*LA=KCC^5KH@_%.6N.MY\$YH^*E6K0&2(C4YFF5X0%B|CY(&|&OC4|J\$^*0(UK!WG^*GP,%R85A)A>
M+O A|ZS 1U_.BYKC2^4KXDO%FN+97\$T5R9RI?&E<- /&5.4> M/W|X L^|'.6.#-
:R14;M(5T999J@)6#G(6*4%&IYE!11::>C\$H3590ZA7|GG+-P9XJ+39;K0FAY@CV5+."/9D/HYP)(%F^*G7JAF:"/556
M;30*&HFV%-EQ48|H849;4^RI7A^LJ=0<|^FJH|E<<32&FB/84YU=|F^P
MK)%L^*P8(VYSF4AU*9<&>&NQ*!\$JR:4P:1-F%P9DD \$IY+&\$^C#1U77-MIW9%0*=2L:CD".C7YL@_CK&
HOYP8A6V(ZUJVL>UG+N6@-E.Q M5&.50P>-HF8JAFJL8FC^P)"B|^6:(T&U^R)!U9HC0:4:*H;.PL%*DKD?
X.)M7^I(O)PS8N5 ML_BI7%GE+^:CJ-?F-4;JAE/KXC5G-4;JAE/530PE^H:P_/3|A_+HS?2|L
M;A."S8S5YJX)FLN4M:\$8.U%ZM_-K2145V>IZ&^M^5 MIYK_4R42LJ|&R MOS5Y(2M4DQ6*&>
R*S@19VJHY&BG;S BG8.&D6-%.WD!5:TLV-@2%/V|09Z MD+Q0\$Y6F^@)R|@-9:*2|^=J
G+V0\$>E:8K7JC+A#YNFQ5MGG-I3OX1AJ^MT)5#=#Z9^Z23*&JDP3LO5-7@O1D7R,IP=Z;^B@,EZ:;UE7,*Y1B
/\$UAIZ^MQ4-G9;|FT%FOAM|9,4?HK^@H@WJ^\$;2L|VPIAAD+;ZE3I586/20"=DV5E8|L MVAE,JH5)
I=&S8G71LSUU_+0|@@^&I5M+PIE\$=PEG+V!\$;I+|U0V\$|HHWF^S<@|10-2I9I035H MP5+^MURHHWU?
D-6!%9CQ:WI8L&P8;JN=YUFNM&JDZ|2S<2V4 4HJ9^U10^M.1 ZCPCBSR19R^#_.N%PZ1>V?>HW1#+T41&
(H^:CYLMC4/D^K9^N)WE5H:| MA^EX8|XB^ML7-5|;M?2K5C|1^WK?|^7-LSTWV3U/H#U5X=LC?TV1=Q(4S|I
MXTZ|^*&I8|ZB9LA50.-7SB9JEQU%2T3Z+O52>JW^%UJOI#K3| M^E9X<9W^JGB|5.716?Y%6+R5O5^8A
O)^US@V;M|7%K7-HT5 M-3*;Z3NWX^I:O1519UNB|(JH6?T9_/16CWJ.P.8C^T.OAS=Y85C3^0!+^1I
MK\$RK2O2M:&5;VBR6FAUCZ=*D&1_%XA2KY*?1>|G<3P3A2;XN49FIB;3KYX. MKSI\$|?
@3^@RVH&L:3|4./RM|CP95CA*#58S^1^HVRVC_WKF>L7YO^D(8 M^J.^.)S1RP|
I+0X>^YGFXA03B@J&_P&_NF#.LLFGGP9V+P4%9Z^H<49 MKKNGIZ;4^W|_S/0T>|_J^MY!=N)QSR-
)^LM|^AFQ^M\$SIXU_C);>\$M&Y?G^N\$H4&Q^*(#3DN_X#^%.K^(5A|74_L^W"@P^Q)^R=|&S7P-ON^6+^"
ME<-DI8NQ|C:A^W<%;#L|B+O@|R|H|WT6V+^H98F92;J|YN7^T>STW^W MV_:I#;2-
0K_0%70G3MV!\$6#V.V^1%27H1G^/=L.N_J9>#|^""DIU|82 MK:7*S^*_YV2F-B20!!)
(C^T^VT9;YLF\$K3Y<:>L8+0%0%_%Y3G(XZ;C|^@5 M?_EXUD;0|N^ZCU.4 ?X;J!T^C-5GP|S|I?<
@XK)U8D5|(\$@SEU0C44;0Q:|+^Y?%@5VD761 |E\$H_+Y M<^XW|^14;.(K#=#P^M9^;#*C6|\$1+EE4|+>^Y/Y
+6+K|I+(MC9\$A59HK^K M.AER)87@-+^\$U16)K>+K8RNAC5DQ135#;30;A|)/11<|HGU5L>=CJ^*6%EE1^
M;CB3+5B\$NE|CM+=XCT.6#M8\$O|Z0UT%D4#SS #=#7#M|2> MU1_)F>S".3NJK2_A^CP6^|CD.BVUJP
|EM8SD5|!AHP0^_%Z%)^Q>|+CWD^2 MK9@_)^*7IQC&3GK1W;4\$?Y;LY F1H2%^P+|M)!K04|\$<)>D)*|N^\$>
MV6?|^#>MTK;|>:PV=8G^P%176#^+>17/&H^%56! TG62|?^\$4"=|_10TDJ^VEM.)+\$4(V=|^RIR>; M(838%G^?
0M:KPI/_^V;#R>CM02 0+UDO>5@MGQ^_127W&^28^72^M>63|_>A=RBW<^E+
I^>^^(8U=GU/6\$1+ZRK8VTF0&|S\$B^C&?81VS&8386^M9|AX(U^*XJP|I9^B\$;|JFSA7SIA92Y0=3\$A.);EXP#ZRK_S
I;XC6R5^=6V MOZP0<(6!_XCD^Y|P@|F<2EHBTF0>(RK@=T^3^L^F^+PN1|SW;"N&83\$! MV8UR(8E;E)13
!A^R^*K4DL(5.%JS_5-9P.@3-RJ6O Q>52:P3H^4PI^BX0 MWI8#+!!_CC^Q>9%@46YGI-
IQ00J4PYQ78.Y9^#*GY)3HMB"+XYV#^#?&640
MM+KK3+9W)9\$=6FTAP3FX^V|VBL.DB^MI4^1;^A_%|\$@>^ZE63/S>/>+WD4#3 MHQ2J22O_ZB!\$U^="
((G^PKN5^H=H^*HEVS_MDG%:I5);L9E@5B+L.MA>N2L_S^Y3%H_OKFEO='#@Q/0E;|H6;/#SFF2>UPEG M,2KK+
#=#/TAAGI6=1<.;*Y^T%.AU^*)>(O/ O4^/|<@^1Z|YZ#L^|N\$|_J_S| M0L&52 /X-OTO+8>J.4JR#10^72'.28H^8^L7>LJZ|?
>E5#<1Q|H3.M^1;L M;5B2^>?E2G-D(6N=V(JMKG?|2_2-JAB8>I^UC7^%H4Y\$8^RZ^NP5"+ALR O
MP^ICH_<^#K8^H|>J;|OR0?J+8 E;|EASH5@;|8)CXYJANO0F>Z+N^A%?0T0ZH MR01+|YU;3&FF5QUHK3Q3|Y9-
ML;MA@4VP#7#^%0<*|9P)R%B%5TIF^ME. MJSLC T^TFL>B3R_>N^>(F^86.*R|JPA+1 Q-55!OPEKQ(\$|^*")<(^*0JQ
M^!+K<^?46/Q.RGQT3>+B\$6+QRD>4WH(W6|_0JV#Q@HH+F3K4HL|Z11^J M=DIZ
94EUK|6I2_VR3D"?|&A>JPEHE<^1ZH5|8^Q%DDC^)!\$;L%;05 O;.: MI^7BZ^*S/T?4?5_;IR1Q9KX(S2^X<18>(%E^/*
M4L_SK^GY.%|<.<X(W#X1W^6_U^T|Q.X MS+5_.PM0T^TP\$*A
=^VHCNN03|65T\$<0.N^T%<H4B@PN^2.I^#ZG^K>HU M^J=0GXT9^H|S^V1@C5H^.)MB^O\$@E(H
|_E|/OCG>.^?A.G^L+;8W.\$LJFF M^O7-3Z^BSAL=U=3|5=Z0R9IZ^DGK=?L MVFV^|JKJ;3PF-
0=FCHNUR1H4^Q06%1<50T^;H>+&DT.PIAPMOA8H^(!#% M1M<2G-6_8>%YIV8.IB?
@=R7+ICM^4PY BTL+6C(1QH50LPR^=MC^WK#0M2^S MZ&HR#6W_Q:=9E%|6K10; &;>(PI1 F6^ZC;|LO (= &
(G^_M^?71^.)QX(U M8ZSVBMM40RL_18VW^48V@&(-_19>L NR^H#XU%^""B: V2Z56:9P?I5;ZF M..GC\$
:PDFAOW_T(|I86UBV-QK%3#2;.*P|N;.\$PX^9LV/Y0 M75)C3+;QH M?V5\$7|18F.)R^*E+|B6^J)
K/AWR^H1^9F6>CO|Z;7#9#;VZ9G! M8_E|H^K|_S&.0C^T;|G^8H0H|G|^<> X.S5)TR 9H|^%>N^*7JLALK8IF
M<|T^6GR:A3;^ZCLF^N)B1G5I#-|E^RTB?/2(N+LWY31;X0XYG|30TLJ9B& M\$N8KN0FEH ERD@XY#_+E2#
*D;#|Y9&-M2=%L>[|@1|#>|@9%K;S_>N^38X@#AX:/VS=?O J^887K@BCZHVZJW|E_?BI/YG<^4^W6P1YW@/J^*

(4Q1OUK>(D^NS'0+I7C'^2%&Z8*K34=Q'I'G".W&"KP8WL*.4/_MRT/1@PFSQ3+|FJN
=%|JC128I6MZ|HBKV|J32&ZX;Y+H&\$-6R(F=5:@^,M(W\$ZWRCZ%GSZH_F>
(V^J&3J+\$.2WE+TPO<^GCSF)^V(#;=P8<1P@5X7;MB4D=BFEA|F80VW7YZ;F%|^<33D85?
IG8ESI>HKH2_3+7/|7*,>QD\$Y1S\$4U\$M+2OE(56A3.B.|(ZRTQZP
%|D8I1FHE\$|U|JFYPC<95&|>WMZ_\$H\$HP>4&L+)+7->FEU!#6-"P.MLJ591BTS1+KE"-QS:140TD#^F.K=9-
NES|T-OY!1%;O-6.E'V270T=VK|^N/Q./52OS=(?W@|X:JZ2S|TJ%7?YI."SVID.+&@QZ@W|1CU|D
M4:.CK|H82Y"S;7X9MT3MUUYN,PLBVU3*KAWHMYDVE(Y)TROV@(|W^9>@=3F.MC1B8&L%-
I8U/B)O+^QZXS3W.DF^IS;X(|G=|&Z&A2G>3G.MTQ5A"Z5/RKQ_F#211_Y#1J>L2MQ'\$QILSUI<2D(#8MS=L)>B_*=
5@B|/CC8M"-B>.+F)ROW5"(#WLU0F4|2D'BNT>L'\$|S3&PWY6LRG?LOUL;24X693M\$YQ7VIN4.Q6CT4-
L!17="15E=CL|1\$49Q:L1ZIKV.POJ?)3?UIH';F%:@;XM.MDQ)J(V0|S01PR.K8|
|7>G"6LIUB|,TAI,5J0EMLBOK(7\$E'F)F")C=4I*M|?K8(HP|MYKYLLEF/E-DHV?4I)?*IO2>XSMI<"NC6QOF-
%40Q%&W86TUFR.MX0SING8;.%!1%\$M>P>QW7?11H|H9XO'DA#ETJ;7U<3CA|W4H.3PB0.*Q^\$Y.MK&|MF-
HE&8!7G87N9H@0)L.PQFP.PV9H'E'(Q95PBIDP.4Z;G!P8;.D#6.MV79LNP\$635<7AE>%(I&)2(KO
D9Z|9|V@.+S:@."C3\$A%EUEF,>X?&_5_%|/J%MYOUFMBWP/W:'##/-(#WUF/V\$TSQ-
|W=H(|@;#R|"/#8ZTE6H4M3(N|_#XPP+4DFRVI8+XP8;J.&YU2Y1HURT^?KS820XFX|,'^>=VEX14B9'%
MV;"S&.KRD=F'IQOEF00\$8GE,+|#1.DO!2@|SEA?N-5"+M3V.G";OH8J=U*)M3@X=Z92M#BSO:8U3C(=-RD
:Q5'"62H)I'(\$IUS.W3.S4KFD66N;W+>1A9.MWRI6X)
<^7_H.|DMO6Z@|H.6.R)PT*IM\$J\$P12NG|Y%YN%>*P3X.D%FP<:GODO.MOKT6@Q/18Q
::Q(M|D|O,3A.,S\$XJG|I=SIH|_\$.8,2^HFUKX/MLEFL\$=TV"RV:W@7X^J3R7*1%|A2BOD&S&S'BO@66&|7|?^%
(|#7|7UAJ;|^E8*PJ1-HLV&|J=|%F<_36U\$Y;X&P5SC:B!2_9Y?F^MCZRYQ?
BHVOR'I9283WK#R:2TLG>Q)K\$FL2:QIO+6-|CUAM/C?4=XO'W/AE0.M4IK#B@PN\$)E?
%OT+=ZS63NZA|L;HBS6HBDQ\$D>A(("%DV.M\$X4J;=7E7MWXT5#H2M2O9S9))K*P'|*|QCQ22R-J.M89Q#B?<
V2;D=<^?_&W\$X&\$QG:510/QDA7ZGJ(H"BB+324+7.M;5J3I3T!*_.8-
Z&V2C>93KTH*VM|81X2ANSDKG>#0*;NU6O:3.T#0"M?P7^-AFD-G|%C89I-)&XZ_&25U?CC6M\$QR^
3\$7>*N2IXED%;UD5BE-/MH@@(|MKMRC.O|K?H3MOAE=H+Y.M:H1*E4?XW%J;|Q1+>V+!+@Q|H=KQ;0.3#XG
M_NRVW^APP#|OAP7-IDWM4?F9V;P|N5V-BVM?<1.KUPOR1|1LTAHU?%Z"AC.M8|PVHD%CI^+<2J&#|>QFA;
(Z&M.^NPF.XJHO<#|N.M+1D>T#18|F62%90J|VO|6;G&D="RJ(|_U#2X|B|ON"X0KY8;7IMAC;#
M\$;CG&+."L6D6.EH*+FWQOTL&1S<8%44>JLM6O(D@E|W%6A|"16H=492M2.MQ9H<*8O5R|5+9&J;+VJ&%+);
.@74C5U\$JL.YX^RZ'MJ;>V7DX>L2Q#.T|MMV>=|<#IY6ALXJK.YOIGA?/B^=OZ_D.BAUIX\$-
W5|Y#2DSTN;W@44%U;7:Z.MN@92|&.@Q.|QAH|IF=E1.CLJF'H:|O(9SXA|ETB.MEN%TO(F(?
C<\$U8HQLO\$9B<\$EHMBDLY@.DB59@I'5#;MJH(|= <9OEGH++?1\$%M;S?J5:*(E8-Z.X%Z:4.H|A6|2;"|1K-
>I5HLV5@G|?2IM1KUV1K.^W%<1.MMVJ"R|62=V|A4|_9SYE-/|HSZ8<##J|+<8NZ?+0.TPIZ+&45*5;-
>&|L:"|2K6)LK!_7*BSG5\$6;MFD)?D?>U>0IG1M5#*EH('=-V+?S.\$)-0L;VD0-N(AWR2ZEC6@*A.RM6;.
MA>QL^8ZN'M<_%.8@^7:+'|RZGF*N.@K00|\$10MJ+L/K22-J&4O.N|9.>.:|/4+ZF|O|H:|@?
D'|@OH0.07ZL<"RUG(OH<7.M|U"N\$P62#2'G46.&<\$Z0M2|MLTCY0D'(MRAYW%D(?%Y0M*+L)UG@QTIZ
MM3TJH1=*>VG|K.=IFL\$OK@);A?|K^O/B5_C#?|&L9|TD^Y|%?J?K|SW'U5>|MLC%VT_|'69EF#|R)I&Q@?|3U(|="|
38XTB*J4D&X!|!"?#8|FS.55M_!COZ.MA+X|LCF18<.&\$O,>VJ3BT9Z%.A|>\$=^'K|.5QA&2?M)R4C|H|H|EIG
M'P:RH6A"W|_23<54=<40.\$|L.V:9^,|0/NVB;\$OLC1?TH;V/_D8BIP;-?M5=-;\$IOYC^5Q5Y+
|HIC>&K|R|5>&T@NO">YG9IE;LZ;@|_G"W">#S>/*=-M.25.T86<J&L67(&_|O;S7=V1K*|HUNTK.C#|V-?W"|35
%_2"|/9%U|PU.M|JA>GT4">"H.S*W(-+OR1.EP>|3_|4K|W2|W|T*L&=ZXX*L.SX<#LM;
MU*3@JZRZ*+E^BX(+M5N4/T-)O.CK|K(CJ>DCGH|!\$H)|GCHBM*|RHP*&)?M1DF9Y>HP^PK5@|<2*@@2:
C6DPG/L"M):9CY&@VFU-VFHJZ5V!1%E3
M|_WCR58KZGTVG|U1Z1.56GM;F7N_#>|HWQ/X)2"R#7)+SF|42#Y9(6*5I3N.M.V*700M:5%K*
|'F\$>E7+2<A.W#6PT.C).P;TXBL\$8@|_R)5_UK8ZUM|=T.MW#8H3T;V#4_"MZZ|6QE*KF|F|9)#!L-
3W'7>73=09U*|NT|_7^\$MN_|OQ^\$|_M'F4T|GL7>|@_AH#SY;|+G.OWCO_9|_R^V^M_LS<5|VM;8EB>6|N>CFM|
M9^VFLV)DEI7372VIS3|+>NF1^.);3)5|L4E7#)TJ2HWQ1#;54B?5|3XDI?M;*>*.BN<_3'P&42'K.O)Q-
VX0|JNKHGF&>3+*E4T?32#4-R7U0<_R^FK.MY>CXW0^&Q^/8GCD\$|PFV&|R)""3Y%0%9MX6/P-
M*I=0|Z*Q7"N:S.72.MHP-+!>=>XM#LKB4_&(<>S%XR&69RK0!_TC.""D.>|U+6@+4;GL9R'FA26C3|_M+|8)1U+
<(WEGUM;_CO\$_9|3Z+)?|DNO@13:1M@R3X"NX7F\$J>|!QW=-MZ=+WX3T.;+)\$UL*<5(|2/0"C
BO""X=|/7|T>XYAW/O|_N^%&XEF.M<(|=FT5^|ORMQJ.MVQ:1LU&HJJ="?
=.PXY.B.D9W9%RX'T25>6N@%J(7&*6*.U)(*2\$K0.=UL.MR?&?DEUS.DA.;|'\$.F|3I5|RI7F1R)0;<'&K^2%FG)68;-
=R|_|T+FB|_H#+_M3>NM2H|+A|6|B'LFLO+R)'+'6%8MOA?|\$|H"*7D.M\$RYU^&IO.JXWBF=E.;F.I72I5"*Z8(_E
MC"(|YB&8:S"/V5G.PP_2|%(9R*BS&\$_.PS|\$\$;25".85\$|L\$8|BT/430:B&J
MJ*KM\$0VLRBTQG6*Y^MGJHJ|KE+)WA*7R4&5|=C\$UA2(M'|BZR1W17=!"VO2
M6JYQ&X.SD0\$OKLW%F"C@S/5NKKB'-.#5<>E2A.-T.%V26B|QR.MUR.?H+K/D#VWD-(\$VDP.3
DJ|6UP&A7H&1Q6I9Q(0M|(?DFAL;+)Z.MM+K|278|RE4%Y=&_G.@1%&YVJ|HWYC.2|UWK|DOT|BB|9T?
P|.4C;Q.M_-|93\$9G|SUJ)Y=^WF|YYQTZ-ZW\$A.G0+59E07J%892SV.;D.0WX*K9CU_M8UGVN68.73|MRW/-
X%773^16SQ+CLZXB.XT2AAWLR9V1%G.=6AHASET.BS.M&"0G\$#<_MT2@S*2BI-|I&%FV4JU^2C3QG2D;G-
Z|6%U%9A%NOH@H4D+0X.M@3:3"O^1U-@U&U\$FS8RZG/R1EN69L@BB39Q/1L^_)L16+A808RK2BQ<#0K
M0|NK80f)0)E|*7F%*|O>*_|Z>@_W3;H>YK)_EM"&I
MJ<|CBJT&08JY2+&TW;AY#CNMYDE1CH;0.J"U2KC*,>1H5QB<'A9J#;S>>+YU3%3QS/RP?"M#>&4-
4PSJ>=|;CV=E|K"6>V94K/'T8A&\$4-)/Q.P43T.9|P2P\$|L0IBK8%4|TZLL^W/>.4_>QLX|Y7|&T|5-
STZ02XV"9YCO@A#?UO+T?&M-
S8QZ/&D|@1.2|<3#WPT>4)0#52)W2YLH/^Z4%2SVC6*!#L'(1H9TT8W_9>/9ST\$X?|N|JYCHJ?
M|O%WHKFY9>J|M#74^_|OMJ;|E@LOVT.602QLL.W47.1?9GWM4ZK)MP7A|_PJ8-B?J2X|V&?+W|4UT3P#>"
EMGPIWM3BPRX_ITHCF<380YC6#Z.M+G'6WQ1'=QZIG3S'^^W\$S+|5'R+&Q(3\$1KY%>K8|TDD#|N<...DR
IY97\$WX.MTW-M8U^(9NLA1&/(E3C+(.S\$P|U'R.MX.G0X|GSG"7%U*+=.NQ944FT@;#EP)_KW"">||=
(XO%61;|_|=J>|*_.29)=#M=M?K.Y;O=|R_OR#R|HDOO|W.^-^F7^KU|ZN^7C4H_JK#OX|FDPLN|JLR4
MH5IN|J+DB|&I8Q8SU%|;YZX+<6@JMTXA-F;+<1#\$>F6^=\$B|N;S_DV^4HW.M)7BK
<+0>9VGIN>0H95B:17|>\$.C5KK/7=&49->GCC|O.@0_6AW7'W\$|U#M7>|M\$_"VT=DBGV087!>DG:D0-
3G3J9>/4E5W1:_%PJB|ZQ_ZOY'#.N?%B"6RY.MXT..OZ6YEB>#SF(|3O-
O.@QU>08(IA(DN%\$&46\$7"HMR17\$5")2V6JDX(N.M|5V>29>Y(ZI'Q-NP@IPH(=|J@4V"C.HEHRSQ-
BH_"Z^T|VDRN%\$.Q(S.N6V.M-(BN@K(D6>Y60D>\$45M.^PK|*(2.ZZ;OP?09%);#Z|*;A:&T)|8QYL/9S
MMTOVN54|1)PV.Q\$%|E2;|*>RLED\$_.BJ40K63;CFBB.M;KW!@M;.*#>1&IM17
MH565\$>"8B_)509;"*|I'EAD>I6F_O45H=8^E"#H7=%Y:2=MA|3L=B*)T09:"
M+*|I'EEGB5VYM6>D9IOOQ\$M'&5G\$|6|OX|DY.*XY\$*)B3:K25N;.#B+DNV.MHK57JQP%7"^ZN|9-
^J@;+55<*H9B|JDIU@0?HW5<@#..PVJXNA)Y)J.TLH8_M(AIQ;=@A0T&EH4YWO/6">N.M?|S=(OWE
=|7.UJ*|H_X>Z2%;CT)|@;\$|SEI&=&+(|\$*7@8+6NX%WU\$;6LY.MM\$TNO-LF*H'U:71--ME;

EYA^U&P".Z9.&Q5W5^!6J+3QRVKE,(!% ^,"A@D7LNI^A7LCBOY@NG:W*5T 2!#
MQ%)4%3@MI3ZD3J!F6!<1U)M!1:5W Y+:MOY!^N:2A4L: ^@!Q5%:H^!D MBKKV;U9!\$!#=#6!5&Y.DH>QA+:?
STC"0%MY.X&1U%:JH!M:!=M&E\$Z>=H MVIO6KW(0+@R8E%E+K)E.VXP>G15YU3^>)GS-
GG0S,K(HP6B%X#:#!@J: MVU: <10^J(=Y04S)*GT&X,14)U6&4G+1Q?D!\$LD7+06!_&'?;HU003)M'FJ# M)OB-J-
<3"<1K0)2>A4Q.4J\$4AGNX0!C.YV..^2NB #4=B@IH*#<90NK;JQ8 M2RUH19!6NH&P7CSR\$S&*E7.32DIHJ\$AFY@)
[4]FPUAS/ET+Z8G\$G+NYJ M=SJ-EKF4+1KSKW/&6-YH&.7U9U\$?JHK!#U)-H@-ZMC\$T=I@YB/Y)2>G4=:
M.PCFC!RE::;\$!\$CQ-'>+:\$6!M-Q*=7X!X1\$!C&.Z)YI" ^H# #1+ :!8(>\$B:E(5!"HT@A=!8:;*\$7+= UJ/U MC;B>::
(UFTH%4Y *R6%B-2&"JQ5\!8)J\$D%=7+!B/@LF3*Z1!/#TW""%?:+:/AE,F?/Z,BK=DX6!6<!=FP ME\$8%A8ZG
=UV6H5GA,S*!;M?G!)2F8U*B!J(=+LA=#LEAC\$;EQ/#:\$8AJ4#: MYLCBXNKCI+,8#9.X7#=#!26.9FT*Y*NF:8KGVY-
/*5(F+YLR643H-5" T5954 M4GRB-&R;WGFK)CDE FDJ3YP(T.DNW&6:C2ODO)ME% X \!^3AN1@K.?AF"DXM
MR5?;6:DZV@M6_/2^IY/"VIO(HO* :DRQ5W^#5ZN7;GH#XPL?% ^: ^N&)\$12^H(W!_0BZ17H M,5!O'N.UZY-YM?6(?
N5M:F\$!L^16+?N6U@&(9-3U*5X1-- D&BA6 M!)?"\$YN C*2!X!;Y(VH* \$00FG12>98T%L?1**J@&:"0HJA\$4=7!JG@-
M'399GY?5/*5.*46B*N4FIQ+?I-WB6. R.O\$! = D73<6TO&MU&H^3JU8A-! MEAH&68+G1?
N9L\WFXW6T!;X8EN..Q6AS#E=V8;1?BKVU.FU(E"H*N>MPECOTFIQ+?I-WB6.-
MR;O:Y6NNJ&5>=G^!TEIU!\$6WCG* @TOYS1YY6WE)OV,=N/?/A);IUY#_#)G;=
M\$Q0KZ/=T^JVTMIZP/HH;SU!Z(+0&T HQ9KLG4!#16;+ W!XW/SR%M!R&7:
M3(!"9P">E?;KN!87!22J9!7=G!&/<^#1/W@:;@KJ; &PI0-SW* @6F M/PIE?3 =R?/58+D<\$WE\$5'4Y&LE#;:1:3D?
*>#J9_&<"^E78)!25+S?S: MX+!@.!"ET _DQ&YSY.7)B Z,=!DO U&/CW2&>P3RL?S6<,"M'>O=,=U: <
MSR;?;V\$G??:(XOV:Y(B!Y;B: %!T\$W= 1\$G/5F6ED@Y M/CF 5\$%WMT1W&0Z/*NANTS>ZFTQ* C=0#=#V55#Y4
M:TKYMV7 N+9FM;8\$=#+52RE+!B)7AX) /W=A^>9 M&L6PLOAT^W)9\$94:*!L"H8IST".(E8(SHYBW! 6!&-
NK\$H!-Z6_-ZZ!;L:9=50<."ABO4 \$ZBX0G2L#PX M6Q6H!0T?R**9)GLIS!\$HNC!C\$;H06PM1<^WMC\$H\$E/813!_\$.
[H9?OB(MLH1!>>[A1Q+QNRNE' QF!8R"Z)!%LHFF03;1V@Y#ED _D;FD3Y<=>=LH(=OE&:
M%V7GX#%!!Q9TTU_1>-9#N. ^#!#JY+!3S;4M4U>EK:\$FLBZNLZ;/E@LO2 M8FK2%W=-;"GW*.(@3TXG9?/!+TC
AF<#7R RIQS7A
MJ7B@I4@L>VYK\$P=Y+ATLRKK..9+.YHRJBFWO\%8E&+XY*/=W/JT/K&H1B-J.'J*K.Q&I",^*+:F6! ^*HWJ&8MJH3N!
M5,F-@@!..ER)!-T#\$:F&K/11C"!TY4E 4/R1K>?#+!<0OC^2\$JVR(T4N9&I MG2LQJW.OKE7W.4!RRFW?
GY?7E%YK&@KAIMO!AUR151E!SO+!:#E0T\$N0E MR.MER6M8%7D-@+SEW8&<{&0BR\$N0UZV0UZ@JH(!"
IDKC!>"N@1UW2AU9>7! MG\$Y\$M!DNMP"0-"Y.T1WF MS;5LG\$IR?+!L^G! HOA!_%W!9#FI
2/R".134KN1)5FN8B3429P)N*, M0:D7F-.S.FIK)Z(.9/8C J*S==H\$Z!4&=6'NKD!RP.UE4CYI)M#H-K7)&
M+4_D1S/@1L.Z3!*!A<2%K)9Z.5T4HN3N @!J#Q.9S^95^>!8!L.T?_7VU!WR M@-L"%@19-CYGF5+O?.!+*MLVEG!
(TXJTOB8:5! =B!1L.N!3\$ <^P-)VTEK1@NIWUZ*7K"VQ%1?+WWFA
MNT!/#^\$\$%Q\$VVEDVO(Q8ZDN;9M*R>%MGCZ6_/5VX2/62EKIB\$?2CB@V=03V MI ^6'Q/-OD*
(D!;K/8^_G9_5WX?04/P!+!N: ^8M5H3Y55T"/% "7JHP#=4 MPL8""(I _LCW9NF! =^HU _\$!V/2-M* @?
=_D3+8AB+!)R: ^)5Z2U9-=G) _M_/SA&5^A!7J-BX_5YBD'R144%>.:Q^2>."2Q17OZ1)P26-JE-2%!L%)?CJ
M"3^A&H!YJ%>%3& D6!HDW:5-""5P1 _L:6#2:X>C.G2B.HN>_)9 MWY78E2F!NSM!<X>:J81H"0=9=1TH)HG7-
H6%CPWG:L+!%3%O#AA(?2J.4 MQSVGNB/@BBAJ*JW!0S*A^G8.' Y7Q!9PW:."C4#C>9NN4:-
K/\$O>PY;0!%P^ARV6F0(5-.ZIH@E6_ C_0<5H0^ ^"&6C ME,N"0\$;+C_9_13ZB;MQ'U(WRVJ.T!U8"XRZ&<>W*
f3K0B8B;9W<&FDAO!B#2 M695H61AVTH02L;C:+.X6IM4!@*5J:0 FM"LYT<D).6U;+!="MB^V)QHSG&3TM MCKB;J.
N"898:K3!#N6A55)>"X4U!01Y/HX!6E""2BDT55LN(D.^@LYMW! M)%GMEK!-!;\$ (8KFB.,GHX%*^)&9;IFT:-
"KH(FT4=187(Z@90F3(=Q:P! MF27GJUUDG0A5D/^>CE&E! =!QUNK) 62!;W! ^*["KENPJ(!U
M?8UH>QJ!/:LJBD(59! =G8Y1L;K&6)!1+BB!;@:_RS&EGUP+5QZW0VY>A3#LR>DR=PF_&?
>0WHJ=4Q"F(+Y6,*!)OO /C_ MM 9!HEMP!TYN6!LHW) "Z)=KCLH;0".W9ESR=(PIPB'G<7! M"*5.8\$!-V,420
M>W+=& XG1!+F4!QOMF)X?W7FO&4V9"DI+#+>0NH>Y<3J9@G&:MUZ*1T!D9
M38+JVD%UA<30&6175FQK/*79@!-1LF-089>)H,%;H>+TF"9, ^!EWPS*OFF MY_?
8\$U0GJ*Y&&R!F^2H/(A8EQ#E(OG%W/D@28KTD7!LB">D5RV%+J7)KEE,Z
M%M;H!%;LKMK5W4*VU,>OW_ZWLMF^?2<*EIM<0U/:YO1P3VC0= _G!AO\$P 3 M!HE-BL=)'_3488N2OP0!
(D>^"0Y@6VU.9\$V8ULQH012;4!COH+(8SP7T% M=P>+W0VJ! _KZN=^5HE! ^*!OF/D>[XFX5:O">V2@;!/:C:
[CK)MY!B# MHDCC!(E<35-1 N<2KJ(5!R7_#&:9!SB#-4#>DIJB"15"MX(B\$7!FP9ZVX)OHHM@(+A0M;Y:
H+E)!>5.(!347\$T4TO&#>A@NZ/GPU!10=4;#M^ ^1GP,.(KY !1 C-L !"16\$(-
CLX12@C3&AD!)1W^!TPQ"=*H;:7+VH !M/#Y>H2P?>X1XSGZ"1VD!H.E^A)2T!T8)*K'#<>8!5CH-
#G3!YQWVZOV*! MR&BK578N!L=JP-DN<":8LP4"!Q90I%"@%L&%Q189^A M%X(<<1.QM0L2Y)H.56JW(.SH;NJ&
INZZD.RAFV00!YTW2/Q25-W M)KA# MZ.@:V4DU&S:&UYN)-3MCH!HJ2)8H: ^Z9,I<!)OI\$-Z/#(R8"SC4^<+M!
M:9^%!U_O4^EZAV2R@'#/P B#H1\$T?W_@^1.U7"P_/#!OB)%#T!T!TK'&. 6 M\$!^*ZT)\$AE>_ /A"C&?
R.S6EBAMZV&"Q.QF65:@GLJ\$S4 MJK1?(IYV?LPC='EO+4?&H0D94 !-#3_>X?YHR?OA(K2L0S/?Q(PO!Z MI?
CO8!X/2D3_Q.4B_NB#Z4B>KP;+Y9C((Z*JRI%(FJCU7(Z4L;3R>0_&'3E M#ZWMF.7!1.Z6-
E^"W"DKV.\$:Q7A1=@X>5#2VH9O^BL:S'L)!V37R1?XG6BN M;9FZ*FT-9\$H<!)TU?;9Z"7_UA
M*IX&_U!G95K@0Z_T=:E9+@X=6G_LCBPB!2+4CA2>28!OY1H.H"Y7R!4
M>)/YHJM&!"H W^F:EB.9Z<%DF>#E\$#R;.)%1%&P\$PFP"WAF@TW!(HBL MEN!E\$#K7\$E\$(DW*_V\$^*Z?
_PIK6T!9;&[JR!XWS5#4.OI<<72_K=TH@A??.S:E87N># ID6\$M@
M2<#>18VWD5SE9Y>'TT\$=.)PP)4GY&>2M&9CC*6T! P!_?X07J);!M=C":Q? M"5YI8!8!/#48_PW3U8@"
f_!3LW5'TYE:;C^R+!+U@!;SE=@FB=.3*#Q@7S2Z MI^B8_.*[CH>I#;!I^P7%M*O2E)P_X+!%&%&=IA:
!9.)>L8J*P!O.9>PI9L M"@F%JDSTN IF:U">'.P2?XU, FHGG00@4JW)#9-YH-7N::J8*P2H<!%U
M\$E/KPF=AB<0\$70Y6;I GW3'8AT!*)JF:1:6#7>RV@*8!@&_ V04O&.U8LDH MP0GY*98 SF@.!T8E>!*_B83YI
&5XWRO/HF.D55VHTF8 M/J!9MB*_0(^=PS/20P \$A!P"Y\$T2UIZ<(!\$<3+3%6M)G!|=6R&&+CW ^=B@_M,7^R@
H1#0&X0P> \$<7(>:Y'<@!1J*!#SP/P!_DE1@F9! ?WI%+KR6 MGG02_UW!
7Y7EHJ\$EH;C(H6:UTP)XY!>DT@#/QWWD8\$ \$ M2KWW5Q?B%JR0H9_!A_Q%EZEA:N"='&
<(6).+!DI_!IT6P77.JATJ3BWTDCR\$D CR>+EK!6":Q53D6. M4VLK!G--D=1@_V"B.107!)D\$E_89*4S W-H
#Q08@D3=)LO>I2!VT\$#\$"B35_M2(!!*33ADZN";T"X#IT MQE*,P0\$N6J_G@JPI%&@%*:4Q.0/(
&QL;Y\$0TY/CV.C:#&!=/A:2O:W?08L M/L55#UL;X!J*=\$\$X:7U3\$)CLS'BZ/Y JC\$ENWO=H/_O\$!P(T)L"=L8PF<
M)"BVH4J2M"0F6\$LN+V@KEJ>IRC/IOG.'Y%O =YC7!IGUXSCS"@:6!0XIKLO+.8912='RI!^"MD(!M?)_#CO:ZF+
f-)(P8!>5X_VDE07 !"!"!@S_S;!@SM(!57 !-A79AY)MC M>Z!4;2E..R_X16XBR(L*0W_CJ)
(2D;M)KWSB;/769\$Y)JN^L@32>F8> MFFAHQ.\$&?>D&A4KA:!" 62:3S.A^\$\$.10WYB!<:"N5_!Z:8(5!3*S P>=
MT=Q#A_Z9N.4! =@!Z!_688MEK!U.U*\$!W+!Z4H_C^F15'5Z)RP^+A:L?_MBL@5ZE6>+C)B6.\$\$\$0WF2:"/?
<08!#GT@@"=^IH(E'2E!)(BAZ(D8VJP8V M79&95^V%BB_!(S' M*J0YO/&0:1"(S1N&U8)P?
OW09H>F.T9@!QV3CB9:P5!Y 8&?_XK-OKVG: \$ M_KY64J!V%*M<^K\$FTQ!^ !#N0Z!9.C/FP:5M5"ZC;.:!/&X@
&\$!!" M8",#UT.(Z 9#0G\$@E86,@-%O'7@&P!.*YA(CWI MG6!0EYWTK5S?H&\$2:E-KOF\$?/A?A8?Q)ZLEFBAB-
I2P)::OHYH_OFO+!/D M?@_.=X%JV?XZZ-!3>^,31/35M)!E0N*K\$A*FRR!6QU33<1F-><=0(WMJT-
M_0KSF*P.KX!H2=JS: X%EY""@YD?<>.0'E14,P^V8J)) ^!A05#L!CPR8CJ.

M1+8@.1F.YZ \$!A.ZR 6!)2PRV!5!\$W5Y;+.&M2/N!\$M!&7!#H.3BJ_ K:9 M%!5W,)@X-AZJ@YZ/\$IRKD>3!2..LZ
M:\$L-ZD6@--4APCE>_Z@*GUY(R SQ\$ M!2"OOCE-&Q!&EVL/IW0-
FX5+%R M!-=554<#AL^+DUM6!VI7FI8A&NOI MWLPB!=\$T*! &7WJA(6& N+!GJ^_2*5!+;\$XNV,"!1-
"MEFY<P3C5!G32%!(M?7!JSWT_?%36YK.FG!0!/@PF=BI_R &CA@*H! P!&T:"KHTW&I7P5TZ *B- MAXF!9R;VS
M.S:7!T4"!!&+!L@L\$.>*Q8:7(CM&&AA* C2^#5@&R64L8M!L5^+5G M6UX:P62?@1V:(B:L\$)1A)5!36T*K-
!R79HY1% M37O3<=VY1KQVQ-K2?BK" CPF72?1# /T(I9/T3XHQH.UV5@F\$ZSWD0R(1!NO MHR!5V6!-
!_MF(^L7K15+\$Z!"S26N(G:TE6)5A=5:52/\$JKL0A!853I6 M99@%"6'56/"J5F/5Y"18-
4&LJDN>2TE&9>_T1>Q9@CU5:7<15!H164Y3&5LX MV^40P4Q+Q!C/EOD,P"
<_N_AOW5U_L.P5T>GU= _J\$KA%32R<=VHML4).Q+F4: M>0* *_I-KHQ?2LU8L!"ONN+7_KX-4?
^=78VD!"OFN+7H!"= _I@T/7!>\$6! MQIXU3K7<\$IO&FEC7.*PJ/UVWO!UC;) 13J!&L!CK5%"9^X!%*O@I6R:A'
MBL27UF+554(G@V\$ITEU@55VQZBJADP\$-G=0?JVXAQ!5O?EEU*G71C@WM)*L3 MZSY(262R0KGD0U8\$?=L4H?
J4@+CKH!6X=-.4+T2X/2+ MG*2E=Y>FU!/.>R^7D=- C2:HLGYH:7AYPSQC@/CQ;J%7+>3GUBLDEU41,F
M=CK*3=IU0XNA5L5% !0WF*YVA^# CCYH*~<?^"UY9P!M&/(@Y M#267E>:3 TOJVN+C)
9NFZ1:3T^C4^C)IR*Y3S,PRXK/Y#R&Q!0S5/1#1#2 MH!RY)- YU304%4@JCVS,@SJ(1.5)2KEU-
7.08:&YPOS,F!96N!WG9P!M6VPAD1YOS=;/+GVO97 MLU6>R-W2)LJ.V4%BWVC&"_SD&
(!P>ZZJ;_!O&LAR#YTU?2.9.X"JJB"W13.55=.:30+OQ \$S)KLN!72YB* MI^FPRM>)%04(\$,
!O'8\$T80M= _+JTD3)3=Y%VL=B@X%I-3SXV"5YFTY6!ZF> M\$8Q03B1V^L.4DPF>.(D2IVX!?
O,B1)!@!K:RW=K63^#H+C%V4N&XHP>[?>P M)
!_VO>@V=H!MB#M@VUM!+1T,DIV0<X/5N6!*\$C.7:2>GAS!^DPZ4+V9R MKXAN2X1U1'RQ/\$.3
MULD)X#H+2+KZ7=-C\$5:#7!:. *N:..H9/WSHWLJ!>4D62DBP2(-/G"!+SKR\$!>@&08PIK MTER_H_8!W5\$-
R_%L!F6%9TM,AY!9-U1:B?9@.:Z3*/AP'N&-OQF6^B."R@-& M5G#H1+MW_1 QBP00?XM*J^V1*YW=-VS
)_CV9L/M9\$%. M:TUE^&^RE.R")\W@-'BK-8)VXH6X>||?_R5M,=V.NC6!2M!0 M0'S?*\$P5%!K37\$HO3M_E*-
WVSQWF=XZA/G1)>OP/F ESRI7I9F!J!T^+^E MYUQ&D0-2"1AV-GHU%"1N'4+6!?
C_6!K!:\$L:P*P'SK_ Y@:)L!K^ M)!VIS-O!R03KH!WS I=9<..XMA6:T-ZUZ!VA+T%;6!(-R:6L\$M'4K9?G
MK ^F".N!5)45OCZ=JL:=Q>CL+GV%#D:0E""I&I!45A+!%Z20U_9(Z>V)*Y21U
M" _TPONU%Q43_X2,\$D94P1X/MJHA%/?+E;7F-7=0J(0 M-L:"IDA;V!AU760KA.=LX.O-
9NYV?T3ELU56IS>@M&4!&WB8V\$P\$003M!M8+*C/&(1874A"
!(\$ZT%EL2;C=@A97G/!\$(JBO""K!+Q!V+2\$6A#! M+3872..46QU39ND:N29&-86N^T>"M>*.(9(&D-E81 M:-
=.K*G_ ST'D2MX33NOIC*_U21)D>C\$^UJK:ADP;|^_25GHA);.5@+?05 M;.:NN/=:'.64K;90'R>/*TMPG
Q" _K.#GAMHYE79>J@?D>;!1^UE623CJ/ MRL_?V\$X0!/\$S!6&
<9>)_I.20N*87!PE4+\$DIK0X5IWV!B@ (5!VNN%6+BH+8 M)C,BI";>*B9F*;45HJ(C)@TZ>N%BL(2F^*/4HFEH=5?
H"&?);SPL>XIV70W M6!MSCI(Q1NUG9#Y7).Y!%1 MU>5H) ^UT6HY'2GCZ63RG^F!X!6'^PV"CVDV!Z6YX!"O!?
<(ASVN2H6BR; MIF.9C%@V&EG=V\$U+^Z.V%MQ!6)J!L\$ MBSNY!YISNJ83F>3!A5;V! ?R(H'.4D1"<-
!N7?!"!0;Y" QUS:(U+H+6/G S;JG XLEG<5HVV4XA^(W2V)^>X^JKW>69(X70 MXYI(R.\$4S9\$0U;B7_-?
H?<_M*CX:49WBSX!^#%2PNL3>ZR4_#U_&+M;V/>C.OT&U@/\$A6AQOZ;@*G(YB&#L)_I#^Z'WO282!QWZJ@UN-?
S)!EQ UX@\$ M^_ N+D9!W!4UT3R#?%D!T^/H/Z4-K& M M2.3\$9!^HKK4D-I-
AK@KR7UY1&^_7YG2!_W29KBI!>/_Y.VF.P"AW10=I!1"WH;_R!ZI?<\$'_T@N_SV1=?<-2H803Y3
M,K@_G'^97^H!5^2O!N3WKB??JG?&Z3^?NA5T!YH."STIL_ CR83L!&KFE8 M!\$UB3>U51"1Q+!KA/Z M+
TU*B@!YPIQ!3@2TM!HDIR!P1X!..4A#DWPREQ-E2!5/YBNH! (4G(F: M:>?B?BO!W/UFL!1:1O!Y5N2O!6 ^Q-
_Y%)E1!.'3 S3I=:Y+OLU>RLZS MVH6W#3LR%\$S\$21V!;)CD,*&7N"OK MKELHS^6E*#0X*
(;G5K7_JB0Z3>2..1WO6&29A!OQ:X*C&\$:W4O;YB6.YZA%
MJH\$B/BA(JA!94S!*\$Q2,YR56U;/1T%2M<!(L05*Y2"ICADAQDL+VNV>7P@B2
M\$B15HXT7(JEA1FOKXB2%K8G+FL8C2*16F"5(*A=)911_%2>I88E3W@1)U0JS M!\$GE(JF,ENC%26K460R%E!
(D=:LDE=\$OI#A)845R64WB!4G5"K.\$2>4BJ8S> M'<5)JLS)IDUH E9K(OB!73BN*E1M3_U5\$R0*QY!D%
!D!"FG<6HK"KY&K2K M\$-AR3IPD\$UMF@ "UGLTV!+7\$EL(A@ \$Q!252+;"ECMA2W+N=A2US#,*6-?9"
M8\$N!L*6PXS836P:=Q:RLF3P"6^J%+85!DIG8@.V" +VEG=A2V-V6B2VE1(4\$
MMM026PHDC*Q9835NF!_!>0@HW_ U27: @VRI_-B;=ADA3'(><-2VH@!A>+ MMW"" |@'IC<*ZR!F_G9/
9U*""^_8E+^6(4:Q"\$S WISE22J(-Q/ FO)F% F MJ1G>%/8!%<2;*<1/%GC3-KPIHETJB#MQ)O"?J;">\$.IVDDGI4"
EGMDSW5*.; #^%LV340A_V7U%>\$>2?Q! ML(FELQWTF&JAZ31@*3&H%)%?NMN/RK(WBOM_OI/
MHU_M_TFTN_12VTK9JSVEW)_EM34+ L6NG\$!5.HI! (HU#<7.=8=5+P^G MG<4Y_C&!2?
7\$I(1_K!L@E.;@0F5>PO*UWLS878:S>*>7:ME8UB@W! =4.P6 ML+VW7 XU ^ [BFVKAB283FWEAMV'2 EXBV%.
8\$!+\$U@_"!RJ(UZ=ZVT!%:J&J_ MC5=E>=BR1-ZXLY@)%&HE"17E6LM"H4F)!4.%#M4+AQ>M8IP;)H6!18HU 84
M.M-K=J!&-*N;AE12QAK!HK0W"?<.:9N-(6'K4T795>J=37^5!L:F,N-N:& M R(^M'@ (H_-L;VD0-EEJ0
M6U"KH%9!K<5#%06HM8S(J:160:UMIM:Y5@7H%NL5SNGFE!0K*!90;EA-P* MT.PHM9^QH%E!X)F+U
W4(!2OZG25:C%@EP%N5XIFER 7\$M)9+DRN69\$F37= MV1K*#C=(#E.WN\$OUYRZ!..*NRR: +ZZR-C!7!2
%S1XBR%CMW?1H_7#;+W"C_!9(7/5/SW"UU8!%HZ;/!\$:.IM.[F06DX1+!MW@Y^E0^%_&_! (V=9ZR?T\$Q!+0/H+2?
4CK_? M6HZ.MI^QB0''9.W+!KFKOW\$B!A3/\$^A^SZB+&%1GGOXD0CMJ_1G&5^")_!1!
M!_1!W&Y""1L!W)!5@1N!P3>414=3D:R4-MM%L1!IX.IG!9S;N^ ^M;7!+
M6^6)W"UMHORX4U:PPS>*!+_L!.0!\$4!L=-?T7C60!CO@ZO!P\$Q3_?IT5S; M.H\$9; TU@2_76=-GRX67N9;T\$ \$7Z#
!JIF"IVT_P>H!_%OSJ#U/Q@(\$2!75! MDMLH!A/@ &;SC+8N)X/%KTL:953J+M(N'GHM)!T9+?#?
RH5GPH4M#9#"N6"0< MI?9>P/E8FM9G;P.O4J5XGMA@/R!);.5-UL1T@ M^I!P54? \$1OG-L-0?D2RP
M:5+&PX_X2N*HRA8YG^V1*P_ 7E6!C6=0JOE"96%L9!G:#2.&(1!#L@DI@6
M" T+UN!HFFF>0+ZO(NNBR4N"-2WM\$72T-Z!_.\$="!>D8!@B>649AO6"R@75 M+J6M;3WK&GQ#!=7I"?
X/HEN)" 532!3846!C8.G5_9>^CZ^!H+RW%5^=B7% MU*3E+^E2ZWO@'QKX52&2:(@B!-I2M0HX?
WGK!&Z2==.WH;YQ4H@_8R!FT M9I=#!+3K.QC37^97ZY!Y=^2?X^E'M4L'5M6!QH."!W!L.^C
MR42L2:RIAFN;JL="WY3A+J%EL_19EQ!BO5+ %>&M!H@5)U&5&OKS*HT^;^M;\$. *A5_I%V6L).Y)
(\$ \$ FL_ \$<5%IE;X3U;!!?B*6!(GMY :.ZA4!I@ M(A'EWZ_-KS&8DG&OH7LEKM??F"P'5H\$42Y)M*>;11*\$Q0-
51%"/^D9.*L!\$GI0G+7T_32V!:=1M5# "G+.#.)@8X9'#%(W M;.:D: ^N&)\$^ZDMR71T7!7!ZL36HR5WA_=>[KJY@Z?
HX9^GZ=QN: ^M+COJFC!9GR!1V6"^PBT?D9^0_5W6%"@H_4"IOX=7T:>0HG<6P.YF=TSY1
M\$*#@T!IMO!ADEH*7THP#@>=Q6Q:UI@.07RUPL&.;Z"TC%O=^*R1!";.IS M(?X\$!;.# HL18\$;SWPKI;@AV80K=?
\$GB*^YQ%=(.5N!GHMVW"\$MN%PD-11 MZR4<VP&SY>4M!264BJLJB'?
\$G@I&G*KZ\$XCK?E1!VOX@Y)!-11B/M8PE0 MOU%*X?JL'IV?B?EDJ^C!3:0N!"/3;M'K#P_D7_*3T>
!%\$0%_9J<6F^+O:S.MQD'E^JH)Q&=>=L/EXU5.+UQFN<6+@EL4'HFB'4!\$H(-4L;RK0J>GHE&C> M>B%TFH-
U4L*@(H%/I=*=\$BD+E6(1J/V+P>#L*4EX5))>4Q-L603)W62@7HC
M(Y>3!NH/KL/UO^VM5OMHR0SZ"S!M06P#4K<"R_X5HN:N6? M^PTV4.WF?@O\$*Q?
Q\$D9N3!O*!"OW8B7UQBN7*IBL\$7@6\$-P!%P3^<*X->XL MQLE)GH6C>*O:H97&;9RY7@UZ2Q&2:9U<;PJ*O!
<:ULY.^H3G#WO/23^I!1 MQ2* 1ZEC6J9KJ1893B7Y.&_W7GL!J)BI!@37;
M>\$ \$3)3TUZNL:DS+JD:3NI=5"0(5!%J)HPH^K^88!QW%M.^+DAB*!Q%=0

M.B8J_B^OGTY\$RPU!@2VBP\$(X(-U=(=QB0'HJ6&X+XVD1\A<3?N.ZVX0QM M0WE\3C3U@BTW_\$7P
YGO\45GM.V.K'H(ZI(L#Z>G\^I9^JK;U;_E8ZC@/I/MQU%Q6RUO\$R-
74K96OU_8N2*&+DB1JZ(D2L7XS)BY(H8N7+6R)49S?8BOP/MX6#(X=Zl=%//%"<"CEP9B_"RH.#;L;"!0!7!0%-
^D">W5F*(UX0J)*01A)H.M.?K.J.ZI3C!;!D;YHV0AO.B">)K+O\$5E(YYJV4J)\$\$.YLYB.I'ZRH,"64&-Q.M
LPH\H0H;I=6Q"^@G;:RlM%;1PX5G/3D)4&S.MN&HJ)*V+B2@FJ;Y2N9)I/M/D_&G<7H^I(3G,8A&C6.I%&+D-
UZH;,\$!V&)6=(UO)9(EK-EZC,28BEDL+4>|#+/W
M:H@G9K&T'/'RMJ:H7*R.P*H1-.80'"OF),XRD'O'+1S\BBAOEL@5LT0ZZ*S.M\U(0"Z,0-
1CR(X:OB&\$LUPX*Z63;6'9DQ9(%N;4&W,Z+/QH\MUB_!4!;(UBYD.R<\$?139L'IK+M!-
MH%MI4>JGZ'9W%>@-9;@*Z99C'9Wt6>Q6V.MA\2&@*+IS0-U5M<%/337KH\I(H&:
(F.RFMR*>\$(ZYWE9X@2*46#.SGHYK&DX;+^)^IP.\$7"ASXOZ8+_P=??8V<-#JXE?XT=-?--?
M_-;YI_@XF9QTL1Y%?HJ=WELDV7^W60F.DJ\I^Y.BFXZDF)J\$B9KP)?A-M#^=),_@\$1RI8!W.\SS4\4?2X'GS28(G
5E_2AM8X\J1B*EABWT6V1V^0A\3.MP;+^B9+A8=\$NM*+@FN5R\I?2U(UDKZ7\6F?99?#GXH7#H'NS:9XN;/L.&:
M5_1DEGL0&-5-DKZ;,@/DLDOXY?T=-.IG2U0M*L.H\IF%V1'UM#M1(3'5K:UD>Z-/R47@A%4LU3X>?
E+D(+^+ST:E(A8ZEZK%LID-PQSR/XXAT.M+NZ4N%(@9)\$!N)/DWH&1PN-WS3U=A'.AZ,BFVO.CN6C?
C*FA%7)>^|\8WNPE;4.M"R8,5(T9VU)39_&4B%H6)7,HE;+6*/+JTG-9\XEQ+^FRYA\$%OPOX'OR%!M
SY1<40T'QT4S%573%(@H?_#G<6\$>H.\$(AA/ZIHDE.DX%^\0!&@4K61400#M\X/N9'98THX>ZPGM0"KD\HA<*<
(H_UW3^5"7TP.ILG>ZBC3*FIA0HHJ\$P8R#_MTJ^(4K3/(?"/S;+T=N46A,4LF-8I>^V<(C-8-
8U@8Q@02%FU.#D71V.)+..M"D?295"43BUW6):R0=/\OXSI_#G@NP&(GF*C\4J\$H;PY?B#5NJK>EJ0\$>J
MY;@EJ^>GXNAH^V1.#VVK=-.Z;YIE%&+A);?>7C0JH>KP'RF6AS<33\$JVC\$M\A!U4LO9;%E#%O);_L4=(W-
YVEB@4'O#%#.NHY"FEJNU_@OTHS2YVG00C#YE3.MJ8@BC+^*C+_I2.IK^+\$(VFW)D?
5DSSSJH%)QPNH*)ZQ>6H.^S*?9/T'#9G^)^M\JMGLEX)L->|4G=)T\4E-T%DDVSO\$W&
(GNXDKZ;HZ;I=85=//IS\$K55;G0M;3.MQ'K'E2'2&@W+2QUSS4MVI262I8MF8(ON\I3O#L;K2KZH\H!)NH(
HHBS>M;G&-MV.XQFRIBI6O*6!";.I0(46H3((I>V!>0);PIR7NM=\$T\H6LBL*AI7%)
MG#BG4!U;>KY\J\8>ZQLL,^Q4)X\4-!G;MX\SL;I/>\$V\$;XT9IP3P\$>W>M\7_\$EQ'@8UMXG6MH+;
>G1F;^4LJ+PQ1C12<378V>T=T21C^WTCX/NOEL<_M0Z5(8&MBU2.P'X-NG
DVAPD<5T>5PF+_9\A)>^2H*7+N^JXKDKB\+TN7>ZH8J,1#U#S3(7QTRYCM5VN5("=\$E^?XM,U?;_!@=H4+"U
M\0R78RQJ0Q)V^M\;#N7G;@CYP*K>ONB.N_93)/<0+OAX\H2Q_4<\$8"XG0.MCDHP\^E*I(-
::0PZD3_7MK^+4#V;@FJW8\906+2;.8+1K.P.2E*L.WL\2.M/HU\$(3\N\I.<N=;"Z0\$TB>K;\$FF-
MUUH0JAH.X_Q#5*3X\$.L7W0*>HR8)?M_6\$JP#E@E;_SR=(1H'L?EW;ORP.I'+M8J;PE=.%IS\5^-9.6-&3?DGYY9-
M@H'M;+H;1&9>UKJZCG'K%+G&K_S2D^XQ9-E.VS.X(/-2+23#K%(M;,>>+.#E.M/2DB/VEOY^E;!\SFMJ2FV\DP?
7Z82?+P5;7X9\G+;..V\^V)@+_0X).SM4PF.M<2SXX2\M^S\N6YZ)UY'0%.8\ITW*YH1<%1+!E#&8U'RZ#?
WR@I^MR2.M2#L.Z\6D"CF(+0\2C0>EZ+?0^G>DS\";_.'@7^7"2">"6KQ*8A8!O.A\I&=J.MK1H*V-VH43J\$)_T90-
WH31V\?0?#_7.CJS\J\3X*;!>8(^-(B.C0>Q5*
M8MWAT\YOI>*;I.P\R\64CN6G\$19.A5+C9Q*_#4#2_IK(5J(<*2!E5ZBI^&SPK.TTRFSP3("RX.LV8-EN%/I_AZ-
AV<#^I9.J.M\0;31W.KFK;+=@I&(>:QRSV^*(I6D2\1*VAL07*(4^"+)-1>KYD3PX">_
MRL3IEHJC.QL2/2;"B#OHEXKUM+>EQ.M(W0\$IK@)RFY+%;4AS0KY;&3D+JW>!W@#889@4727
1D4X)/Q2\W5";_"/T.M\3-IS;3\KT6(V6;1.99J@5IO^&Y.7H3.CM\$0HT@@"GWC;?P7<9P/7Z*J8.RQ.M)8>
B.P*!#)'QQ4N/9?RAI3.NP\I./\SAK\?I*OP.O8(I^I<|JS%I%Y5""MF.8\RL8<+>+>\$4W1JH_>MH3Y4-
TY24X;WQ^2LEK8(O\2_&+B%8B;I.M.V;V%=(A%ZE7\0\FY\$">GJH%*>_L;_4\V0'OXC+1B.62;XSLE%%CIKNM;
M.\N85=IS&3S#B@2\BK)GEF.HB<M*^&N>I>8T\+VD;Y"!&I'XD&O>I=(R'0>S.9#/\IQ\$@7RV*3)U=9Y;"SZ/>2
ML=<#^+/\TLV;1\Z,>M6'Q25Z'1P0#B.+1D'BH.G\2R3-ZSNC7PB^ALX4MU\$'_G.-8*K-&(>M*TYH#%V-
2F(KQ^C;,>O?LPM9Q2S'CL^NK\HESI'GD#5;_G#;A\$BX8U.M(^R7L;R8SW6KH+V+KDU;T0ALJ0?V7.6V.UJ-
I0^_=-8XV<7E.D3&")D#FXI?M7T0^LS00\Y8N.E\4\IR=(#U+R3/<)"QF5T77Y7CJFK\Y0LL)B8_F&SI.M4H-
V\JIC;1E.'P*%O9\$H\U"58XGF-QZPY5I\$#Q'DH6/GX-U@MW8!@+O@R_MIZLA(B9V_';NR65^!";N@
'+/4./17%U='2C0P(03=-00N-37>9R=I\V;QF9=M\10#I.WNWS_\$IMY\$J0PU=OG
ME@>ITP\ZXGUM"EZX\M#C';C3NSS(<@)+AN_XOIYN%XI\8L&\$D*VC%IRD"_MUF&95JP=6CH\;;?_81VR\^Q-
M#^UIZU'25&%K\A_C_%WIR@3@%T@HP.(9.M+X^2VM^V/@&I(->F2H\NX\$EA+@-&?CU(K_B%UT%;1\I
I3WJG(XL\U'ZP.M+!A\Q.N+'PAF8AKA94#K\I.P_7#>U\I=I\A/%?9X_@F8Q%I+E+"E-C7G-C)D1.M\$H;_94E8WJHJ<_"&
10L-U.E9\IFVP.A4B-7\;C@H;/(P347\LKVP-MC3H.M\Q3.L64/I.E6\I_7V;^_!@5K=-L/L.A#D8#6J;JH4\JKC*>PE+
I3;3)M.&\$.J*2@+_13S7H9N^H7C_HM@.T1XMFQGI6Y4YU5\A;J'IWH?Z7_8UHA\I-
MZ5>_"TLPIV#T*\$1YZW6P*8X6NU#(T8\I.IWM.K3H!(PBP\KC\0;=53W?C.MIB.>\$4KTB;_3T2\I(S(M#Y"T4P?
^RM/2/@41R+;HO>DS3)\LB/I=P*R-"2@QF^99H?8"/\$<2_I6=H!M/T?"I'(-2*&=@08#)6SJZIBNVSH%0;?/!
M9"1.XQY4-5EQFE61J/U\|KH,7/"X2G-E'G2V.*G<(&3R&6Q\UX/R881A=M\$U5@?I0B6'?>XGN)
IKXR1%28'I.COAL0SR>+A8(9X"-I+Y\I-HM*;7.MXL@VP7\CHS1D\I-XHL"@T/69>+8A=I=7Q3S,>>I<&-"M%XQ#'
0A/I(C(\$9:\$FPT=Q^<\$G_BOIT/Y*2*\$S'I"IBI@)OVEF.MA\$'=@;
M=I9JQ3D25U3#*E>48>Q:V\$<_YNT\I49JP>A=L0ESI'2*_.H0*2*SW\$)B1K/6.M08D%(8G^!-I4-
5MY4X@W_W%0E\IEN.2.G_EAE1BU_JA""^4Z25\TYZFGV.MM6\I=Y#Q\$NC\$<9TYEAZ62Y"U5FZ#P2
D4SA\UAZ&(5%(G.JD\H5I#CI*UP7_M3U1\$(<3.ECH70?NX%V(DT<4=2#>R\I+1.35-@J32B+08BTGVE\$P.S
M+D\6LD=IA0T^(<O<'<|L;!(5OW7ZVG@FM+AP%")3\KZMB,5!W"NZA+4WAA.R9QIM6P8_-V*89*5G^NTP5G.F>=(<
&W<I.MZ60"6F;6\8FS\KE.08M+F\$)N_D_YJC1\$|K<3BY;W@I8\!)A*BQ\9>+I*3?M(VD+#_*+Z9ET9=D\$G\?
M80?7;.V_&LM%G%S/4E.MCF/9+ C\3.5(K%29N-BPYE:B\$|L#9+C"9YU5)X00.MA\$58S\8_!CF@-0^08D&D\29-
;G6OF08FMT4ZQ20B6\S-VQ=%8SOR8A0&#D
M.RWMD6\FA!+F+_V'&!6AUXQ8%MY=\$2DV0TI+>8I?L\IH8H\CYE*(MQ(P"KM;4UA>(+MT8#A6/N\$H-
RG1UWFE;/SQ=,H>>DF#L)5N\$_Q(H9@DID;PN;IGQ:5U/M^C.M
R\H'MN;GH'5PI8P)\$\V2Q^DJLK4@^70*T&F275I;"LHH+Z'RH)"BWOX.MI>+OA+36CHJR)AO<,V??
%O"@LE6%O>V@%32GRZA7?2G)78VV@4!B(W9?E.M#M+D_K0Q"
FN;14/&*UG'2,2#;"QG43#E!^#;8&V.XATH7BS\IY*92>Z?(\$^M%\$X(J&/Q\$V4N_K;X4HT(3/B9-IGBV*KT'2-
2_)45(9?GOH2;CYQ/SHPV" MJZWI*1W)"K+^?6Q&1#1Y_<'^VWPXC7>W);7+Z:D.RO1W%\$E"19_4P\94)&X.M!
IY\H#&D\$?JIC6QYC@+1=V8B1#&2WBA?+2TWCF26\I-BO6\UY3%A0IB?IH.M\J\I-IF*)JX%_.18W?FEIDY\$XP;.
A+6=I+6V)*9IT"INU;_@OF\9KHHS&M&DN;9\T.T\$Q-B_OY/*36B71/+2HHHCY\Y\+00=H3AN\W.MA*,MF^@372Z-
"/A\A/H7X@F*B_8\2E8\4"6AR.#H\I.E8AVX8=#TS4\X&I.M@;8F"CNUP%Y.B\E@;H71Z3(K
&6OH#D)JSINW<2!;42=OXOG2J(F*B.M9#=#8DQ;9_*;JU\3T1XEUI>);6M*;UB8COSDK;>X
/_BYE.F*T".WU@LFA0LH9N\I(P=F3)S+;ID&^8QTM>#0/\$D6^EX/I.M6B)Y*^Z;9A+^SN\IQ\T^_X3T20C\I=F-
H4R^CT^9IO08;ECBBY*2TVY3P.M?&;/7CY\NM2*\$_V\86&7;_!\$;M>Q62R%^"M^CN=(?9A)6X'M=?@J15AL(K
M\I^A0UIZ\8%N.Z\J_)7=/%E)T\3F\BJ8;#4V?#I\I;)H90T&C.VSO@.@
M800T&9LBCL;/%ZD3\U\$H7WB8E72<6FL;J\IEG8_\$\GV\(^S_A1.0Y7YG;4_F.MO<2KM1/UV+>Z\$;_V8?
TTZW;%JIE4#;)I5D6)Q2VP=I_UJR?S=IBXCU5>+2RS.M.N@?H=-"P_E;+1#
@C%5@L9XD3Q97QU*2&CR4+.%&4/I143QTN?I4H&0.M;)B6R6JG\W?SI4SOQ&0"U0A%AO=^D16Y\W;CL'U8S?

%1NDJ-SOSQFK /CM MN^16HS82)BA@Q8=ETWJK(/&C" Q=[5\$1\$@D_ BE.8^~^IB>IQVTS_%D%I^M&J)?
^&6+=7IKIBVA0\$P&ID\$111T1B^F2X15@OGXSB(P>%5F+B=C)7REP?M#WS74@_7S".P7UI;V_*=^QI+^VP+BX
V^C<4">KV+1Z7OGH@5"SFIZY: M?K\$;1P1NCM[XIT@18N301;+C%>3_8;*O4"=\$Y+S5?#7UI@M3BP;M1 "IO<
MA1RS2R\$3%E&^:@(.9HMS=@)9!O M& "BFBI&67CH%E @8#-AW33B G6>4I7#E1D;2XL,Q.1+W319;S+*HH^R;J
M4Z>.">T1@E"8AFC//X*AI^?2,HG_%2GEY:(U+ACJ3"C40JG\$B%U8JW/I. M6W.#N6_-O"UP.FZ7 "H1"(C1&7!
M2W3RJHG3P+N1RDA25?3#M>QIM.YX7W?\$(\HB%'G#5T5T!MPOCY1=2YX&M^ M&P)RO#OPG@;"VDS_.H6(-
\$>O_.;V_7 IK;3#K1LT/Y@QB?A)J9//.H.+9 M)9T3(-!3[X3B? IC;1,%Z!FP\$Y/WT57JE<%25DJBZDF+ZR6M6B*13?
WZ6 M+<8GFX.NX+1^NPK35"U>X13V&LG58;BF221;A^2^7T#;AN.X-S!7%#9W>M.K
M".22G;HHH*SE=;!&1%FIKVJW?G&AED)@&^A&TR/RA01-Q9VIVOG_4
M&V0K:80/"_91(P=1!>W3OB[MZ;1S^/@GHPJ(-N1A6M^D6)4_ MV1+U1B"YV_M>G@;?H%;9-+
(!M68^SLT!H"+1PHV.AYF5^1\$0;_CE&3K#G80 MHDKP)DC;9Y20;KJLZ.A;"T<9"6ND.E9#BH8G1UB97Y*?
AAOR8?3(\$)TM. M<6)Q61#3&*P3MYA99=>1+XG*9<+S T^1BPUA0F1/I!>Z>%Q9RI+=BF0C4 M?V2AHOKT.L5&=-
;91\$_.6<7_;/K@#31T27YNZ=2S;.@%V/4T\$<EV!)H1W1 M_ZG#;=H;9(A.A09&\$U=02C%F1'DQJ9-JS=UO6."1
<+/83?R5R#=-W&CJ M_2H76.Z..EZ))11ZIB-D MM=JC6?QDV11J^)(E D.0T"-Y)1*=-
1;!*TE0/\$4"9&W\$>M3\$557Y5-Z5 MV>^+O0BV;=H)7M;+U\$ZP<1A.U?"7U^IH^""HB<16:U Y+2EX2,11,8C-1S M
=-1WD&?ZUX4^67TV%#*6?1;NG8>P^=H1L\$F+M%51UA1D)YLVH1#T5 M%YR:5\$MEI0TLR6Q\$5P+*EHOQ%&2R1K
FM^C*J#%)%F>?E MH+R+1\$;@QQ#52-J;T^I>@&D1PQ^&>PD"17%Z7Q)H18 M*-.26:C2;G=)N@H&6;H;(&>*
1&JB3A^(!U8Q"3.+JNWJT&F+A.80Q1+ MCSTLN(+K!^*ER?313VK55?0P9.DB@)0.1&-P!5CF&%8Q%
V7^S^A^ONX. MR\$1"6GHOYBRMAXEQ3K)=-1 [H>-T>.[2%Y#(C=))APVR*0 />^MBMLJP M9D2@38D1?
50&L4S/WNRV7+

1;#(0DC%19U&_F_)C,KRZ2^?RV^FOU'1LM/%UIX@T^1&140#,\$"19 M02A10.K8IRP0;1*L1^PR'B>^+F@#1+A^>I
3HK\$#&\$1'D&ER#S+AA5)O)Y(=OO:CA_6 M#R'0+&CST1/#C_?LD:VX)V2?6)AVWS89W0NXMSWK:\$?AKH1T7?
\$8@S MJ5"9WL"UT^93*23OX#1VC'C.)VB-@:9E^A%(1E3"E*:5HT10291MB (L"% M82@1ZDA.ZX09
AG5214/P1AM@AB212,3*5L)P:EPA1T B)H(CAB' M<0EX;IUUM#1I%PTF*614J@Q11B:\$GN8#H@,TT>1EZ0%9GM0)
(SR7Y&+U#; M%787^1SD*KL1R.&.)W?+W@?1GO%G6<^="ID*4Y\$QF#6>G+R?YX>11^T51Q1>
MB"#D;^H7=&GFLIOHTS0&GIR18@ "S9)1BP*VZ)8DPH^00T(LGU<(<@?) M%H-J2ML418%#NB %L@#4/\$KS
8;ESMF) U(D(A1U"/4C9P8P'NE:@CL->8A M%39VN1JJ_:/R1X3^R.A*R-/@TW/IF6?&*/ZU*G2)51YB1@DAZ-D-&#"AB1
M/E(W&0.Y1?J0Y7EWPO:="P@)"16TKA)QB U1!C1#JQ8.A%CH6:9:QTPNA1 M@75BI2/TY)S1..X3E)K\$*CV5N@KH*
<#1X?GTB&ISR\$O1 T621"1J*UXOD6R M@>10.141NP>=1QX\$Y4:N>T^\$ST*XJRLT2)/0WJ1D1&AF%DLM430:"1
MZ25_99BC%H^B*1.V>#=[@5R;*.E ?L"8>/W\$5_ \$^=HO;+B&.'GH_<&< M"KZH+R<ZE6K>?
^ONA515JU5DRZS(6VK:X&AG1*?L%AI+6?Q= 70 M#A:K-\$J9M0.1IH2&1YJQ6QZC/<_L5\$RR+1-^_Q_
?D7HZV(1C#."48+ MDQA&P)!\$31*Q1H&ZA">2A*)NZX%>Z-71/-8-OZQYE=1S2-RWZ1UVL)
MHRE,11=L&@YKV>1UEKS5;? 4Z1=GFVPS <*GVY?60/U1&>B^4<.5VX8>1#G1811J*Z&N1&1^K1%>6.MLKLT
MW%711L;XBG8/DQ10Q:E>PG518K9@S@ZGCN1<6#+/\$D'-CT%@.8?1L)"X./Z(LE4CANJ
M76;#8HY'B(JB=,IV,"DCQ\$12B83QJG2+M(/8?Q210BD Z7_#%'MSZ\$ _SAK-[N] M0%?
1HM&NC51V"80U#'^@0%;H%WVU.??=RH_5F1J8J5\$O:Z;&@18,M1^,&_N
M_B!_OZN6YR019S8_7E146+12)E"R:'BC66T?2321;(-J5OMKOFQO1XTB4N^H M1P74Z1P^107R"01N7)R-
#R^1J15W8:10117Y11E;Y:2/OQ3K%<4KOSQ1R: ME5)+#IDAL1\$3CB!;"<82&XK=2#OC?
*4EA196%Y&H=CHVB11?;EV30H>&R+ MG9?I=, X:=\$71B_LAGS+AU8P81.@WO!ZPQ=VX7(W_"GD@MZ@%Y^;
1'XX"81=5_M2Z1"/;MW;ENH4=RX#^+46QU-G&2 M1Q.FH(OQ*HVN=@P6ECA&NZ;)4TSBE-
MK6VBI1P&:Y7(GG&"U11^/14TRV04 M=1KK2LQR>H3*2)K;NCM?
DZ:@+/%D39F^V6;.UKB*CB;_ XM0T<01G'7=3=J1 MN4;KOU/PY?91&K+LJBD,381E;E1)^.R4N<%Y0REVM;S)HT
M>R)-MZGY64%)4U_WX'.OO)CTW7;5*J+1%(U_1.6KCE?P^1D\$VZ,2K.UX<1 MHTFX.3*1&MU33XDK(=E.
(11P5#NM6>FT3WVG'1E1614_QE/AJ E)M/GV1 M)(#C^1851IK6N11NV-)R2FIZU7VDUIK+;
Q#F01;V)LY0XFC#%)\$SRC4K_4 M?O3B\$J>K/>D%)L&2#)LV1HFMIPBQ/#1ICD4EC:&K;Q>4_ M^DX1-H+6-
G3;'@U12TBV8W#9ED61_FCSG@CA?2?FJVUW3Z_^91E)41=^1X*2
MHJZ1Z\$6E3*6A>R05ESCUNK1)5U3B(BGG9C1EZ;13_D/4P0_Q&P@V9*1"P MXLYV-5&/RF#M5AKM7;
<7+1O1>E0\$16S06^#8%11LIW&X>NCVFGU1@8;+1%MM;B_*O2ZFQ8.O1H*%I1NIU(E5?+?HK?K5YQ@=?=?
M8'.AUGXK^%0^,P;"Y^1 M.)O8SXX)L=,AM;NM%<T?NP%-E8*N_ (%E@O1\$N1Q2UXTZ.G9E>6!P1>-%(P(T>31Y-
'G>3!NX MK*VN#6BJZ\$VCR0/6S=IM.8KE?9;K:10_G>/1"1FS.(-CV;15?9.X.H!\$1>1 M"-*#%\$S11BK<
OUPT&61MB1M%MIKGYD;8>KD^1FBG4W; 41HGW MQ)%11A13_3/^R.(=3&5Q=XTZXG=KEL M7@9Y M_
PD3#TX?4EV1X M185+61HT1ZT4!?\$\$(U+MNO!";<*&#BQ0X%O.1G M0#<1P_5Z2AE61X1/1_81DP1HZVW%A-
^Q/V11<9R1PFO?D%9DX^#-^=. MG=F%K1>PN8(ZM88;XS/WOXN0_2R1@<'PTFH1>/ZD<@MSGD/FSLGG"19V81
M#@P(V(\$@*!G;"Z0/W\$ZXLP&CWA2X%FM13F<\$&GKW3H2N/J#9;UPH1/KKK=_1B7 1APWOMT8_%O@E/6^\$%
M3JE>_UK_&2J_QT/SAAWPG^N=RT014>O>?&+^G0YB3YD?E)??1M6 M.+OJ&/
@*C1+1MR>^G"WMOL/SZV>G3J?P3?1+1^4LYG^U2?KZ6A1ZH MEU&X^)\$1AQBQ52.F.2;S'^?
BK91N*BYPO^_8+W8;17W'GEDP17.8L1H.3. M&LY.2S%^21YUY*%@Q71BQ60YCO'<1(W
ID4GW0(91@/6W8P=OCDRG9IS>BA378LP*=:DQ12P4GU976Y"1=^G/^1 M"91%NYU1J5:MY_Z^Z%7MZF4M_1JB-
RW^O:G1=4T#;\$UE1TIQ1T1W+7ZQ3=*DWUS=F5V3.?' MUN37ZD/U35M5880"+J_>G>1DX35
_WU+9XDS>_PTRZ7UG)B1T+7Y/M+&1%1V1UY?26+C)PS'S&/@&54;17<T%_N1&7)W(+EYL>X-GIWZMU9
MFMUY>#?1I6;G91>/D16Q WW+=M1XH\$9.=R?J1.^*HKH_ S81K16G^QDV1 ME69CW52@=9?@0&?2-
(11L+&KMNO%3"ZORK*XBC86JSUB\$O\$7-\$#5#7)DA MMMN1M58\$(H(7PJ\$&Y>1KIB?4\$@=?+HR?=V.&*8-
K"-1=1RX1S1\$H&Q=71BPQ&FU==>1@)GPW&FC1Q39A.YQ"(S51 M5B&H7=-04E3J;WAU1=13QR/?
A1%A=.%7Z(-^14W50A+NGLOFAE&XDGD1 M2DE#9VIFC1031H=-K70Y.\$&Q1OYSM\$V0-Q6@?
JJ:)LXPXA=HUAU> M31Z M?A1M'E/A1^1\$W-&XT#>5W71H&E1*CK*%12;.)4U#"-=6T#11J6@7>H8
M04%)41>>Z.(HSZ18)IV^1W8NSYJJZ2*M*WL#).N;H425U-2O&VK6!WS:O M2V?
1:4G0>JM8V?2:850VAY>::OMM%1WPI9B11/3CHJ@C4JG4ZP<91TZWR/
M3_O:"^MK3^K91AM#LMNWJG/O#F*#H801OQO;1/PNL=- YO46E#1&ABT=-67> MFC+GAK%Z*VE-
E7UQLDN17XDF88.M164.N?RX)PLL/K1'04_P1_0^V7ONM- M8URRZ41PUR/O;W6AC9>D/7N&68G?E-L14:Z-
9:=1V70*N^Y+C=SC1VZ1 MLV\$*>Z&1>^0.1T?FQM147S.W3H1^E^MZ<K TS1RCQVY4JW=HS(7)1 M?
(CP=W&E1>=#V @RH@QJ15H4XOS_#>1N@1RFQPT/@B6%V&1-2.72*HGVH ML,NVOH<O-OOW JQ08;2-
16HML.#101^K<+<H;1+12&3=3%6W:13M&HNT@+1J9JMZ=>G<6=0%U.17MTND* M"?;J1J>ZF^U?
R+151R*MW&D3.MTA_1%0AW.D<*X77^~O1N81D+1DBYL MH-FB9HLYJ4W&SBM1%(0M:@B?1H2-
RJ7N11DGW7"9=1+D/PHYJ%MER1(Z MAZ#J1"=518VCJ609%Y8XM9:NY510XA2J^K.F31J8>J5E;.(4ECC-
1BX<5%#B M%*H+O.%57QV=U*U5UV)M74.WNBLN<>J;.\$4ECB9_0EC5(S+016MUL29)LZ& MP2)-
G+1=9^ZM1>1LR^ M*M^LW:E.DV91ET=7O5@1F7JA^=(7>_OHC=:M58^E15RWTFC1H^1=1;
MZQB+;1^YVVA#D16;.\$>UTSJ5R^Z&E::/9J<=&4%;ANY.73JR;7CH0)L+Q2.U MZ_-JR9AT>U7=^NXH*.

/4@8."4N:17I2FA)HJ&4ZF&T47E#)M'M-HF!"Y(89#=-HDV%M(X-B;UZM93I>(F6F@AB_S;ZD.UZ=8K.C M;J71W3
ZL:,%I#326).O3E62%=-NQOU46R.(?(B*JOKB5 37;U&QSUIF' MC753U8Z";>K-H3?"GFW9-KB* MA!?
(@-JW1BHMFL)-[RZP@IV3;G+980R9 K5N9>)%*_R?>3J!IMJAK/+9G
M9K9K.I\$%WPF@OWJVP&PV\$(0_B_NQ:C>T+A^W;H^8(JM.IXU(L0%&TA;^+ MUYPI#O.HGP#?
4^K0):"G&ECV;Y&X5=-J\$=X+)B/4*5S^VY^4W8D=-O_VAGP&H(C_%TH MNBUM;" IUBP*W;K5=E21S2<*<
+WNX#|VC&K.)RC-&3=-/^(.P'P11 XEYA.5 MD#3AL?^%3D39ABRXR;S(CB(&"JB:*=&X1V&.FFY?#/R
^9UZ>/3)A.K4\$P M>,P\$R<|M^*QO W4G@OL! QB8 MY;RVF|HCl IN-E44D@/H%M-"P#_2..9K|SIN48?FPFVCM
M8?%@YD@^4..>PR\$^/*,+,I*JTJT1&-T(<G;DW+H483>PP6WXRE_Y;/R> M/8QM!,"C.(YW+3^D MMAK;I5?/A
I3I8/!> ZLR-1D@N6(X1-WW00IB>ZXULDP-Q\$-X83\$ R%B? M VEIWI:18P\$4I2|RMHPS8Q844C/A%R%LG/=CCTHI
YH@."8Y7;/.5G);. M.N5P?G6G!5*CO7N!M.)Z8RZ%T7|_)E)H2%,+UC#P 4I^X"27"> ("V(%/ M/T<'KGF4'EQL-
_XG*PX8+<Q?7\$PL%GXR% 8P8IE@ 8>&I9Z1T-ZE7+S' (M@>/U \$@&F5CP/4"4&2N+?0<^2DM!NXT(^"QKCD!?
40^SWQ.3&|@7-IV|H8 MJ) ^S-DRGI&Q:3H+O\$SOK!O<@/B*O&C8XC|-Z* @JS2BC)O0'8Q I8&VP'A M"","U8>Y
I%9@LV'5T:WS1%P/0R:0FQO@8?GX"3H5?/Q/05-^>F(Z8&@) MHF@AOT#|^/DXN*MO\$&2/+_H7^6P^4+5) #
I@WO"6".(CA\$H> 7@-TD|I?(&)|#X* IM? /K=I'WJC>@A.R0:& #HCF%0 D8'
M44=1,VIEQ3(R*Y,L=I2J3&\$ _42TA'(+MPG! UJ-R!"O^A/P*M3C7"X^WP|MA M+^JF^O7^%2L+<03BNU1.9I
9P+P\$QQ+!^J X^\$@+3906_S#SZ-U1/7); M<IQ5+RD+P<=-PRJ|H A60PI=A26\$-E0"BEIG!-"DMN|_I1LB6
4%ET(CMY9W(G>5D8O.I>7:)\$ZGR^M17^A6TE\$*4.G MRCI0S8!&=O=")%5P&=- ON 4VDBD6H%JSS0-F;@V?
U#CV;,"H7+B9A14 MO^J6/L)H0(H7/Q(AF&92%;_0-RIT9@Y5I+YH|/I1X#<=\$#\$GR_XT8|5W MGD\$-0-
=NEG.#DYY9PIGIRTE^&O/IZ_P_(>U^BW)CB!@|LX@N@|VB+IP% M/A?_WR201(U;?;
@1ZQC).IVEP!^IB|JPZM13+^Y6H|>F(=GG3>%QM? M! RK7FG5;DS IGD3;5JN795INFM(7P"PZ%Q#R/M*U_G-
GU3M.X|=-I098P MFL(T>|VFT;". 5ZGR5N==OL_I IQ5A^O2=WEY(/"R8@I36(I3\$H4 ")Z=%(%1-15/YP@="&,>
B_\$O+\$)&H^7/A3&GVH_+O! UA M,\$ZE>>EP_-B#.OL)\$MT;=[ONV /%5W.H);\$G=@5X*\$A7T:3(O0C-ILB\$>;
M*%D@?^CX)N^9AIAU6?(ZLH7I+\$8A3X-2|TF> B7/GQ)##>108I>F5F_H'0L M_A-83<@^<=M!A2.96S(L2P1
7>D>I8X7@5D>J_Y)L*!# M*%5*KZ#L% ^F? MOJ(I1Z2.0ICQ% @KZ1EB+R5 \$W)16)-90%MP\$%2.M+V<
'<9W>..0I@7D. MZG?6/^GG*)W5|_>9 PL1^Z8 +CODL3K M5F4SB.1.X*4AS1L4)ZEECT T;.%5PY;(-800*=-NL-
*KYS>?'YX1|14(F05 MFMI/= @ SFOT2,,CM7>CL6< G?FA4ZZRG/+SX|_MJ
=27?)JTX^W(6FW_9MI6^MYD7_0B8""X=>?_0+! M9P8\$C.GD>1J*|+!&LV@.UWPWB0!W RH5@
3+NSTE0Y=-5SM9^43\$0>P9;U M37C;"B PRW70M2X\$SZ%3_ QZ3W1QYS@I25%> M5I9!PX 'T8Q8!_NI(2;N_IPB5&Y
HL|OIG_YZ=WNV!GJOE^,"ZE@HFPD>*9 M?^/D=WPD!236QS^*K%; 'M 0)S.&9'T:4?QLFSZ7Z0)@Z
P%*BAC^<)\$U\$U' MO@_I^ JGXXKWS@Q00N\$;8LMR; M#X)^BYO / @^I KYM4^V<*QTA?
I^&60D>2O)4P\$C@PN^!OEN;\$ QI^"V MGJ >)5\$O=I^UAWN?G3_||WK'R;FR.?DWU SJHQZGH8#IQ!
I'S%74"91M+* M!2Y2YL8^AF+ "TNKV"8"/OWI_R/AKJ"J7CHKRC.?SD 25(OH MB-6;N\$-EKG5PT>3?IR>IZC#\$OM
MJ9WRU#9+ZZDMS%Z^F;E| NLE08!QJGIVST9"L;^U^\$&5\$P2^8,"^/J\$Q
M^IXKS)E.,GD6)-1I9_8(C(PU@.T4=/@=Q8Y?U8",I8U9ID;DU^B!4J? M^ (V*55IQG&HL@\$J%>5&_&*|HB-
28"\$MK>%^<_!C=T2DINF&(PDR^M+B52 MDD1W_2=-2_I^HORP^HS@/@DI+PLE8!W8;L-J-&KDP-9T/3->?Y3;.:K:*
MJI^8>4SJ@ (4VC^3-0);.GC JW_FIVZ ME-\$JR/;,>KM4%\$SOP^0-@JD1I-1<("4IV"2@#\$Y>|+_Z.K8(#@J:B4SG3E
M|FXVSJNW;\$&(FQ)T=ML.\$B;AHC MNF!2RE3VK.S.1/J)XN0UJKWQ< (X<+S!_MA)W??
GL7|T+)YM.00NR;Z\$3IY^N8D)-Q""?>I^E?I*=K.;1KS!3G8%2/QV0! M(S^G^Y3.I^7W27.K42>S+.HI^=:D<|E'R*._)
M_A@ OTU2GA.W.AXQ4GC.YHN 3(7OR|@Q|H_P4#^| NIA9WT; T(7.F7GJ8_' MATSB827C4%*.88 Y&10EU6_B&JU-
\$*JY19&XD!V)|@8R|TZR|F M8A\$=A 33AZ_2IQ0@ "Z".0DO"E)F1K%83#I&A)Y_N|E|IV^TZ!3W1>"Y^U+I
M=GWSR&KU+K/A;^A>I;F21E==>H^&^ 0QX|BQUOED5|P|4ULI%7 MP6,993P+ (P2^0WK@|H|VK@?"I\$4VR
XS&K <^&Q?P:12>A(2;R12>(B1 MR32C^&076EX)^1-3BR(#@LBTF CZ\$9|X5|>#*|SKT<%(7PPB2A^I^8+)^C13
M%NUH!\$S%HH+JH(+X\$>KS%8ZE6N/J2G;%DGZK7(GZ5-YA) D#?2DG,DRRT_E;M.)^B_1H&V5;(\$M=*%4?
\$1.15|0YWE%/%GG #.X>&?A@(*6^<.T1)@90UH9% M2=E");.C\$.07ZK@<' MFBI_1JH&06ENQ*\$)=S9Q#R56IY5@3
2&LZ@AG0%: (55M4"RC&MB/&P61Z MX-2+H_-^9PGYJDOU_6QBFS"
H+Z8NSIYN%QQ_F^TV*E=>C4.DT#BO(Q8&-
&16/G7SIO&!#UQA0BZQ5#0V*PBI#V";2EN&A2*+;5O.*=QR.YOP#018VG&35LR6Z4X% 8P!AC
MSZ2Q3ZEB)4IB/P67YLT17|U+(PG%P"=0) <1HRCSZG0CTL!5E0(8.%MR; MG8_VS!1_P_WV%9U4X UYZ
MY_9M%P;7V>TXNIHS SAPYA4<I1\$+0\$+|VXY&MS8|ZS)S+|HPA^LYO<_MIC6_"4|;
I305SI@X^LH|QM9FIEBZ)5U6JA/#30&#%&H&-F3|@ @ (L+5YC? M4023XL-
1YD\$(VZBD/Y5Q.9'E!;XS>L^I7(KN,2AD|K6T!J9*(8^ZJ9W M8(*9E1I8;^Y%YQ.L:9< #SO0T,TH);@)?
X4IF9&B>%QPG2I)MP IXIM^1 MUI+T)TS5Q",Q Q1_0*LYKM!%HB^I^= TIO3?>W>823=\$OG+11UMSQG0*9N!
M,Y|>|LA|V @M0H|BVT|D=(>I4";CV55V#EV5?%ZH1|%\N|^<"6JBFK8DI@ MR?
@JR2A%N|11^LU2ILA2;KHVC;2\$W|IEA3BC|@>RSQBINO\$ M(FO*D*7)*5RY_LP5Q./R4/02|5FM!18-YXU=-%6B7V,
2O2SY9 MUL0-^>LR5?I+EXI"IK D;OUV+<=G>E>IJOG>IST5!MOX;9M_44^#_!.;17
MIR^E%=@=T!WJ+)\$6CG_"!T&U^?>7%|OO^C;IT_F5SQ2;ISOF-^HM%|^X M6P"IB%*F*DEJ3B7;)F NC:<*(&7T0
0DJE;-(46)KP,%PHR2/#12\$H4W_MHC3W+^CD(-KV&G*#>DVA;^A17T";I#@|T&.;ITUHF5N;\$)4D|23PNRN2.
M;6D72-2I4BMAGQQN2IN+9)SNZIDYQ8N%B2%WY;MQL+^%TF9GD*0<M)DBB45&^/S>^/XE;1J_>6D12^YD|E/9?
(J9R_K0YN>/#Y(W(NGB;JS&D# MCA!\$?RYN\$=DNR@PKS(FH|=)8VOS8;0F-8*G@N20WYA*N*N"E%ZF5/2=Y/5
Z6\$FY3D=<"^M^IV>N(\$G<;W@/ML^M"S;AXMA9698Q%^\$2"LP>ES9|FN"1GF*6DZU,1?^P7|N:Q?AIEFHHJFSRH
M>H%)SLIU3;.%F>Q-B:AT2_ KRP0@F*W^+36=F>);I:~0_MSC;@^=
A#Q6*IG\$PIKS3>HYISHR;TESM|2'D|27|CI^#^QL+Q@&1#RWS3 M6I2R
M.;3ICYP^VNL|V+Q+F3RN@C%A).E0RZ6*+4P_-L0<=<"7AN?^@)/Z MH|>L3H)!5HL;I?=@?
S0/Z6Z@3_3AI^1N2D?2JF)R+|D<4R+J>?;U8B(3.) M19/5HQ)N|QF+1Q*KRG(2-TY)\$X_H
I:~N;7>YC\$M>^C#JLL#*6QSA97S@+D)YM6!S72;UGG
MEWF?CO_ZA^9*TPN'OLIE/|V7SGH0QOJ>F&>6.*# 3H6N.H7G^|>V#EH
M&V^X_-2C|HECI#GV3|Z3GAW|C|A)6NAY3IH<28ZM/C",^&OG5EJ36QF);.76 M+ER"IU2G/HI98+;.@Y%?0)!G
*S/_OC_&O(IKUY8RPH\$%';&|V@)5^Y&S) M%RCRCQI-C|ZJHZ+K2Y#G-
LGH+G<3P!GNB\$OK5.37EG8E;Q+9)CIM.D=Q|TA M57P'-HPMG|VJ>\$T'3F4D)I5*&CO3O.XTX'0C=-A-
+5#2_CJ< ETN@ I?7I# MS57%GHEMJ_-LZ?8>Z@L6;G/2)X*(JL_J="BI5HHH|T@V9BV|Y7."\$K:AJ>Q
MBE+EUQ0GV2OT+BX@C@;O=M;YGLHR;3_(B|H-C42BC5%LB%RFXR^W09R+ MB"1W.%OF/4^>OTPIDL7""%
(X&M%JY0;ZU"IS6<@("IN7 &1F MOZ)%BH<@S!+X.6D;4U914D54^OW3;H5IK|BD@V!&.*#8C3^<(AE,> (=A0?
M@8E/;V22KV18%J7TT "<-&91%6390T&G=L28_PHL|J8D_OUO<MMRB.15%
5&-50I+D2S!P8\$K^3|_OHA;GE)@M M6=>ADIH&E108^|9_.;Y2!&O_!;\$GGU*\$3GT&-P^+9I3UZ>%@O;F!XBY&Q
ML6|*IF;V^X0_?H&Q.)Z'7) =+\$AHTA3P);IC|0.9R)-\$BBL>8_0Q MC0AK>P582B<=<=SS/'*?N8L P"IU MV7+45.
ZUM+@E<AE;)306IKL_8/\$OX&5.1U7G-*HIEPY4HLP^O MS6R9K'-YJ9.M8NZP^MAA
Z4>."S>=I6\$EBTFQ2(\$4BJ<8T=2Y I5"F9.PD M2.415#9.\$#3JY;I>*/;S1;P=Q) M;^HJ=O&;-
I6.UQ5;.0T0/<)T/RZ7_-G796@BL7! MG/L*5?FY|SI65)Z8T9H;."7Q\$@YN1HZ7EL&-"RYWS"ITQD+H_2N*=Z\$'7>>

MJ:2#3WOER&5I/& NH&6\$.IZ&?)DG\$41IW(?<>K/VM#D/#@YMAIP=R"2LD1Y@.##.H"?
L24IME%7^7BJN9X**LK^@+@+A MX06IC21*VIT'4_52*VP\G 28E.3&46..15^PR2 &N@ (L>_ (^DUT_56-?1(C
M7>_9_D\KVL3?Q5A<(&_?0S"WT-EF39(C)3/A\$.Z\AY(-1S4,>)X7AC%6:
M/MKAK@)B50JYQBQ_KA"6\$5EDXV(DW@2JXH@&J(DGIK.QG YNSCX2ZRO?M"O4"Z5A"2L3I9P9I'
M9)IQX (5@==I92_25+6E1\7\XC>O.2UM MI8G5=8)Y2:(S^S"U)H=Z1-KP6LNC).T1\$P
U4I/*A@&#.N%8YM3@=(1K ML9:3#,U>+@I-KF.C=I*\$= MI 4MF1LQ&GG(*K9IS\J_ \$B\2VQ261\O@1T6 M+;V
3A\'(BK^(\ W*DAZ9;LT\$GHH\$^L2%"M22J\$/OR%7I97:I"1I_G?V_5
MJ@""W\$NU: CWWIT6OJM>JK5K^I46O6OO\HXB#:C0:1SXXH\57_4C(DN@"" /,
M_W'6.\$MY"/EMKVJL#IOWQ^G;+I/>MS\J#>YQ=J2_?L_V* [Y4Q?L\$WS#MM M9G>IW "I9A=9?ID37)V8)W";
<+K44KM'3J2Y:N5"OT.*_?3:W/BE#*F2A& MI:8HTS7../TEM+BW"@:D)\$_9IS-
#7XUML7B4I2P3)FF\$*+Z/VQY>5J"/W_1* R('7UNJ7^J* M\H\GJ;">I%<75#"S9:%M:*RW KE;KW@0;-361&
^L=^_2Z\BV#O.RC0U90I* MFFS)XH<ID#&5.1P1VHQ)HL..H^M=S.68:2(W2\$HWWFZE0:3 Q MCIP\I0T5:TV9-
I=YZIHRO:1.O7:@37.*IN=7RO?ROM2#ERIO89:7*5J>[I\$.5E>=>R\WEEC\VLM M>6JD:VAOVBR[I]2KL&4-
5GV11:C &OY:7OR#A-%\3BV.CATBI:D4;O4@9AB MDJ;>U='+@I*FT6EKTA24-
.:I&:DS!_IT.@&)X\$;M5>J=5&.4KM01QF_ KO MTHS^:KH/W#=#AJ4G#M)F4E3_/7MI?9>%2^U1\K-
8@+A\K5SKVI\$A=AH")S M?3:..2-(G1_&?2U7+?#2ML""O?+J>&2*\$K4B:RL-KAC:V%\$E2D>TM25UG MR+R?&T-
>I=E)2QJH:5JL*.U M2C8HIG:86GQ(C4R)T6SY<H\$S(MFZ<*9025+I A>^+ONZ??%"P5D) QS5M%Y6 MV A:D%E.
I#8."^127ID@A!^H=^/F1P\I7)OU#CWY9I!#E@PA\$#JE &ID\A^4*HXSM1F2K>0E.?HTJZRQ=MZ=L_6VW'-
G0TV1E)B\+<MNU: &\$XFL80I%4LX (Y)1L@ (Q,3-2I3#&6I/T65=GUOPAWDJ"OV6FQ2B &M:*18\$92-
006(I:ME7'KX*HI* H9#VI>H2\$M=3I5=.%1%130(KV)605^2:3 MK_-I \$&N_.IEWGP=L9G15FG.QC.E\%I*Z_?
QP^K5FEX7180)20NAC=J4\$-A#52Y;U7B M/>[VD3:PPA=F_*P2&LI@GRJ6TNO58FZ*Y%\45* M#YI> [P-
BYV"B"!4>6ZFQK:\$@&UB MLY,@!M/8PT;JH:UVC#+&R,A)"&I@OSHD\$R;6K4)K/T?%AM96W9\>O\$#I K M+(->
[MN]2%:&0W:@LMG6D)(2GFPI %:TYZ.JG"5..6V7I+WYI\PJ:LI5H> MF^ELRNQFEV2:/V79'4Y(HK877QN?
6HJ;.+BXN%O5AQJ? ^C =1KOYOE%5"/VN MC#N-/CA7Y\$K6\$.^>5F3:=82+99VTDV697%Y)IE1%_N?
GZ^98I7OIH\B\XR M9R4D-OL5%N\HMEJ5.O%*R2[RT'I0K*["1.JGA&I6+<.%T&5A3Z6JH2X+
MJO""AYANBSLRMSW*.XJ2=Z_ K/9Y:Y M 6MI>1&F:ZX5R9#*^O03B%CV>U?
KZ^_I9QZFT>JL (ESZR+7ZW86VBH"LSYK.VAX\I%\$*2JU6E=3IYC\$ M:50NC753BS5QJD><_0:6MY"CX0XL)R+UBX?
U0\WVR#_808XO3\67-S0>CMC9 MKJ.W6P"J7=WOJZ\$I0&EXL:4'O@4.LV>S\^O.GXLAY:(89V"O'ECW; +WPI
M7=L3X;.0IG2%MR0-5I:Z?0LCIH1N\H5)ZYKQG:5I")S7&I7.2ML%:F"4 M 1A_9^N43?>A\A\& <2JH=-C'
O:MJDQE:<0+);I_ ^H/N\N7T,7BS;>F MYX*J9+(-+ZZ)K6HI\PT>#C_>GOS\1T:@RYJ\T-AL6^V@IT%T\HMFSA;/N
M(^Q\(#NANO-2TO:U/\^O#+*IJAGA;7^@2V@=/U5M_P?JT@L.I_QOY=F#9<4,J144:#Z!SK-H;
MB\$ "VA\YL2\$/6&"CAHDE:6%VW;
(O)*&O6G%\$MD6%:BFOD6<^K02GK2!+Z(I&#E5T3V.)OV96<'ZAJNR:N=\$(S\1:X_(#7WJ'2*+ M.%-5?
*QYZUH5^"P,4:CP4AR6JDT_70C@3B?MD9..(8,H,J M-5+HLI"WW:!
(:"8F28%6)"J566_ "8;U"J1R(GE#Z"V\X20KUA."OI2.?MRJHGOHAEP<1_WYDV299;%G=8&(KLB2-%0RY&2JUF
H91TQCB&JLT(SKO MY\QVOW0RP?.(L'NQ)A">B&_0K+F:Q.B'O(DQ:7)64:+_!LT"*QIA+("I;
M+I"US^6% =^RIROZW#^1X#U.G1F#_.UM=^W,Z69Z\ (F=PT)GW:\$K)S!:/ M'W)"&('JT%SN
8@LVAG4_%W"UI">::OVPI^:/R M>"S@#NKZ@Z\XB+ =.^417/%_Y%WH(\$JH=0H+A#I?&U& MHS
PH78I>P'(Z\W3>_U%EB;=S-MU67N_ WZIW'N\2_8I=?K*:ZV\W MCI>_L/O:AZ^ WMILT6.@ "P&=^T%Y2,H%:(
#U#P'F2Z9<<#8G"ITUZN.*6XJ3IW7:00TO4BOH4F.9B\AL#;.C3,MN M"M2RR!:->U_2&I-IN0+OX6ID
M_':L.R7U".JLFAF/HV?/_XYOCV="Q.HV M82-
>OZ@A9B4Q;"HTT%:"#C&HKJ>=VM,4B,DF@7I0\F4XC&.@OFG&JB*&LM\$3\$J13)?&EQ)V%JN1Y) VT
M=I.M6JF+ _YCG9(S;OF:*M+ M\IC;.75*T5RITZK6BM@R:&?E7!0KW^I)C)UA_O_VOK4Y<6I)^Z\H>CMVW!&8
M\G&QW3X\I\$8PO\;S?O8IM.IGS:\$*\$#30F)TL\DKMOOY5?2 M)H+(6M,\$G@1P_"K&23OG)00A&?<
%NQ=VNP^===_!>ZX:WT(BJ:XV2E\$J6GG:4'5=I.^9JH>=NMY1EMLY<@:\J<=*IV!=VL&LKHH>Q=U")<
<HUU5.G:12?9 M\$AMJ*=XBE\H@7.#'9NU0G?QG.NT\RESLIF#!@3.O?#PN-*/D@/88:1OSE
MG(#A@VDH>852D1\EG0LN569%6\G/# I<@D?Y I^#\$Z%I2D:#KV"LONO MWC%I2-W35_FS^&OU")LSL:9^C
FF6Y4Q5\QV:1Q68SOC31FV*1I.DK8:F;% MZ?P\RV\I%F*^M.Z9,Q&FX-%7"4:IR/#/CXW#=#O+D)1@ (7ZV
(PIW6YRQ3)^H MU+9I007I?&SDP\Y7&0V_ \NGC^V#YJ+52KQ\X)F9 M-(7DTAU!!'YD'=@2\=X\$D@O2
RM.PO(1GU:&*?)EATC6.(L^@1-&A#M M(X:9%,24(CMBV+I0\$UT9G"Z%)%(5IM&R&*
CX>6">I9B\$P3H&I&VKF*4R\ MZIE5!>8>(#8!(=V\$7H\O?EIXA M#XW,K/S\$S8I(50*K(IL_S\$S"-3 M;
#@Z@F")P;&?_I'8:/=&ZH-G\$1-3%XP<=&U322"T_8'^.CF9EK3DOE 01O MPPEG<&'.C0# +HXEJ.^!>N@8Y).%*!%<
<%V)GG#I MAU^ MC6W&H\VOY>M,@;S44RSN"4"X81L8M\$82H 3%C\$ OHSV>I\V"AE#T)W4
MML>1X\+WC=@#KHFIIT-F+S7\LP9RNQOF-\$OQ%6++%)!#DRJ.0*AI#19;- M8 "I"\$4LIR?FN("WD>7-
+&C&V%_U80:S>VH8.NP)O.#(8HF:&8N4+?_%
M/'@V^ (G#"A+4\$S.NGJ&@GACZ\$..HJ:J#18*Q\$WBV.S(1\DK6@#"#_F@>:AHQ MHP^FUJ+?TQ.CI.U>^ICA;BH62
MM"D0B&4?O@:0I:T_SQV.^UJS\RC^HW2S/&@J&S'U_! U*US/C'V\HDR M\$8EJ+_B?
TX<S0BERM3P"1_Q1Z\XJ2&@RX8^&_B'A)66M=X/428D:7IZ#& M\$2A&#AB=1OHV<I#42.C)*4#MP+=CNJ\$
(HJ_ZS!18I=O!&UEH=+8X+20^/_ ME8?WGCH!>\$1^ "P71^!PUP8'Z8/\$ISD5DY2U\JEK\O-I'KW'DYH>+Z\Y02<M
4@TF3?I\1;4\O@S'U9#8NU7-4Y7\TBSA8C4FS>PYH:IM% H9\$LBR(6(48A M.Z\$ "AE\LEB5>Q&@;
(I"85I)>A6VW78"RQ-63&1U9_IAG#M9W8ET",+2Z\ MIKXK9ESR=!SI4O48H#Z\GENVOR\6EJFI
8;U6P&J9R&A_XGCCJK".@VOD\ MY6IA>808"B:&2XL<@S<5R<)>J7(<87M).=S%#2.IYWU5#:3#T:L;.2%1@CW<
MV8R>FW_GTDY#IV<_I.3BV\$DWL56K">"<AH*P.I5=<OU=LJDL*8?U4W#QJ\$9R9MWJT741G6\5&\C\$ MY\JK?<
#P1.<0CSAE/Y=.=HMI?OG>XBD_0KB
M"XGG^/PZ'B@<=>J6D\RI\$M%\$555I3=ULSSP*I8HJTZ23"1NEJ*CTE>E M^HV/#A_GX1*GJU)
(&\$.KD5E1N=%7>+1;G\$#Y7NM3*K#/QX+I\BH7#@%ZMM< M;"I7B&H09X(*>8%8CD1%Z(I%<"&I&&NF8?\$/%0?&
I'!C\$)(+U!)RX6_@/V\$GY6I6\$W8Z8_94:>>Y0U EPX@IN608R7IRKH-E MR51@%6"/\XA<10-=L\I.)"6"JU?
Y1\4CR62\W)-B>(XDPRZ8)4E&0W2E MD>IY\H9#LA*5X;..6))JK9_CYHG5(&-
_S+CME"VN^L2T@MXOS64)TIF#V(O);#7ND?_3&D^_C6O?#I\NI%WWHK@WL\$! MI=W2H>?;IV_ ^7X?0QNBZQ?
K%H@)S\LK7EWKQI)? M=^I%2\W_H4^&8I MP7&B>D0I:"F7P>LG39A\I_0"1\WX-V88#^3O2?KOLM7-
Z)H#4FC">IDS.(^E.=_I\ MF2\I0@P9+C88R:L%V%7M5<4@K\^4-JY\KQ.%0UOX\#!<-6+XJ2C""3\$!
MA(5O)=1A.TEF2*\$.1L;\$XA1ZXU'J6@V-D/3;UG2AX8\$YMIS%)'_ZK'MU/\MI+_I4;Z(9CJDI@E43F
Z33@9)I\JWJ\$E3\IY96*%&9U")?2D%.2_#4I\LSB56@PS*2BN:G>M4.PIF61@81D"136G:J#0I(WY
7;FTE..%0&H\KD0I7%H+U1E0Z@I-O5O' MTA:0S'M'8IM?M3)%>2W)/(I50MS%Q>381"*D2(TQCXFU AJRH%:W
W\54P M&SG-I&Q<=>OV%SY&V\$1.B? ^MZ\H=YUKRYOJ47J:??V^DI>V &IT2U.C:??&
MB:&3Z@Q.S_&3"UR"!%&^&4@0I>TWGY^V_PLLU=@BEOIZ=77ZHWMOLO<@SEZ MV%0S-
I:@I9#7RH4^@ (6V(G\$O@NFFHP'8HPQ\$8S0'YS?CCZ!\$TBL">HE\I+ M7:"=H*KT+Q>HB:I(^&IH<%_@-I
(I.L&KD.8IF\$I@1V\?D44QXE@I>.&O>F M=F36,K,J\$""7J(2K3P*6GR^_3_2WW#^JFS"04&%%@HAVIE*C8&?

RM+IV!+GD M9\X8!>)0&XUG R"@WBOD:68CBE2G%"1M27HK@3V+2H 85UL|PIH@ 838.E MC(7<&I
=9[C\$Q*5!..IS)N^5.@HG.9@^FZ\X4QWCPYG5\$>:2YM@.YI@P*N;. M4Q:Z#IE&/A/A"?4|HVUN:.\$Z6T-
%/P& ^2!:=DMY5X%)SRBA!8L)B\$%T\F M\|F>.;#SAI=F<&UL>EK\!K>9*XZYQ/&%5++M=32S|M|>%.%.-^SS#P
MS(HDP&9:0?WP-?QCX#J&4W0KR:J?S^JG-Q4/ET0UP^OJ@WM1V&B/9% MJ2Z42DFD|15>C*7"F/= @&R-
50F(N>4!|O(G7W3EDNY+GSA-I%COX%0Z(3 MM)5(E"EI4M:AJ:;5:;>K2B>6M%1-BRWS?V^>#8I9H(C6+
|G|T/JCQ.&M M"E1/6U?PBM.QRHIR^3DY176UJL9Y'##A/7^GX'ODR.BJA9H:UOAD=Y(Q|LIGR>MA3PV4#2
M77Z&YR0E+(Q:2ZM|:4X2:8-NJ@?AP78\$5?9(-.6"X MP?1JV19Z607B!5-ZO):9TD5/TK.B:P6AT2!(8V9-*ZF?RF!?
8"GCK|@ ".I M!^17<7E31Y4!4,U%Y\$@>Q\Q2KP>#P1*IAI!+:&G%Z1HQ@.7
G(8CT6G.QF>U7/CR\$@.+1B4+4VS>:J9NT3'TO&(6TXP!/*NX%7:5.0+IX0K\$-5IQ3(%H+>"0@7XY;*EAE.C6X9^1@
M_@H>MA\$)D>@X%\$X:>01(!)=+/HX5^IX&*2;NT/VJBER?Q' S6A;' M2|P4GM
YSZTZ(K0H:1TQA.CXH0+J)..^{..}TP&%V?:OU.4!D:G:&8&\$P*Q-AZ*(3|HVC5AF2(B+>M"U1\$.OR!(=NO*|OKB|A
M|Y.S;V>7=|M@P80CHAZ1+>I 6BVY+.582P(AYIO\$0X|+>(DVZ_7UI?&-M/_CU>^>FW6Y
XR5%GZZM"LZL3:48EGJV-TWG>!"UN6A3*DT/D:)Z+:.8+!Z MOC\$|YZ9;BF6LFSR.16-=I^+3XOD>H\$R-
\$+G'G3J2^E#3%|:3ME'K5|BY M?#.SVFH@\$:|9'5:' E^5A!@4;ZX?
9Z5A58*_6#+:3J_!;JANJ289XG/BJ:K49*"DNCK4|A/M5R09+*D|&2Y+03M%7/NU U+&@A"!6#Q7?
G&FL16>4K'Y5S|6:RV|(C(9B)D:AK69.(Z-M=Y)%XZ4B> M7!4G64\$.M&&2B2%<3E154|:8-XY-
J\$>|@LL00:.%6"B_ MWG|@A;+!&+9I4NEI=%;(B:|L:7H.=<(G-0K0@2/%X+ #BKRXPX87R7 M^4G-^?
E)9:;1HI/DZ3"K+A?T774MS.4NO5|UDYMMZOM%6NGSBTNVGR0BJ>U M:N.E!W7X\$A5/WI2.P')U\$ _I?
<&J:5WXU1FX9N(B^+)U.AZ_ M07G6%ZG*NOUK/SHL3T+;R9SRC NQ.E3RY5! _APGHDDO7NZT9VT""CZAW M?
WW> 7YRHR9>KS0.9(2#5R-! KH2*5ZFP%G)PN^>#A2F491YO(!_ARIU5|P9 MY)S.@3_-5L:YVKP+A6|SF^<^L08L7N-
74Y#++%+;S:4Y.GR:E7D/?N/>A1^& M&*U2Q5)0;OV9
MOFUI^9?;.^ZYNAZPHBAP>C"7B_ #02|Z=@K|Y:01N4#L':M.%;>@3/+^RY MJ4="SSB>+@|HRD:?
|M|G%P+_Y.%/>>A3'OH|=..(1131|;M"=WYD58LEJL< MO,H2MJNM)08T;PD;U0)#K.EH8XZ,EI_ IQ'YK|7G'BS
M4F^V-Y"%UQ3|V@A#Z/G>UMO"YE/^Z|H&="K-MED>P6WfZK0JC<9NG!)MA/Y2 MRDNK4:;.&JSU*OIL>|<H3+
BUEMO=1!M64B#3 |H|BLX9/(B? M^VGI ZPSCI9EVRYE,IL'8FB,I>9GH%I'4M55S)M%CB0'4CZ(K(<=^DVDUO'
M0^8FIE!!\$=679P_Z2:~@1%\$!D9)E9EBFL6DLT^7"W=2)2CCW7""F'PNN;9&M M5Y&4M""X^-7'NEFML6WJ<18-
<<3>O4@>Q57>)6.DWFE2K W0XB-AV!#YTYW MEDE^&LDK@|OUEAE:4YI5|L99FJDIWT5%AG8^E|RRHH%F925YF
MDI>9Y+NO35QFDI>9Y&4F^4XDH&QMHER92?Z^LW#K|Y7&X=\$&IN&6F>0E#R^?
M27ZPB2S|3O.8MM86OM|_E:SC9*5RQ2F)U?GJ&*NC)/9QA2F#?'DMSL+|VF MDK*SV1F.R=&
(V=FG*7/(RE|S.)2|SRM&R23O.X _Z_3_ZX-3/VB:1X-ZK|<29E/8=J_9-!O|YJ|WT+1:|^WV_18/6A^VKT'P
MF@(@_DRM)A# _I?+_K7EUV:O|'N+RZ.S-NSKYV:DZ|EU^_ZN:' #G_L75U3-Q MW|=WG;NS;V>7=|<|@5MP0N-?H|J
|NX4|A03/X@.\$/9S/O@:_I=K^OUB*?=>H_ M/ 1.% D/Y!=OR_5;HV.'PPMCR_0.6A|H|H#L6@|T:Q<%%|N'1_Y0|N<.&0X
M|"+<-V&6CH4MS'7|5-%WROBR\$^Y@CER'D3%B\$/ZTX^#3W*D@>4""%>-W'Y| M:/6%T9O2_?@YV6|H_ A/FS_1
FU6Y/OI@Y|A>A(IZ%:~F@1L&CHW=S|D? MBYPQJ57|;P4^@#W02?
T_<^B)ZQ46\$% _W_7IGZ^J26K|6|M5U>BXF5\$R2:1 M<4|Z=6#
^H#.QAB2:~!L:#G0P2|. \$|AC'>Y>O5X:++@%U5X_VP26VY)XZ.U)8|("VN#JQ.U2&37LH|D|FWKWQ
MPH+^|/P'MG.OQW|'3O@3WAA|L.Y(XR1(^|E6("#>@)> (L'I(7UZSL#V-(3F9#- M@|5G)KSPA4_ZN#\$4* 0X7M=!*
)41B+F4^DJ#A;|GF'P# ^Y)*XP#9SZ,/ ? M0+R08)/R1A\$QSX.T04G:A%H2* 3?XHH)|- X|_IF;9XD\$MR:;#.^|:KL'
MZ8/K*1^F|&_1 ^PH%5;FG!="46:~9E5P/804V#U1_2+\$QWC*.86H^|E&D MHH_5_ F_XIT@%6*5A-_*A@E|S&-Y!?
0(K_G_9SH1(TW>=R:;#4 ^#%7'-U0 MK@+9'UB'P.C_R_#?U|S7A(4W|2%@(U#<|_Y_&O)^%F|_MQ=|L^<88?
6""/OG|_Q'MOBBTE\$T#J<|5).|XL4<|?'&*&|*R\$9_MD#L<%G??&_IXC8ZMI#|3A\$^_!|/\$2#QL^!+.#XS+WT%E_1<
E13)|B:Q.T5 MNHP(=*4U>)VT'K|((F\$E'2B\$<@5H;^6Z?R\$F3P9|&^ZTNE6C"T8^U2!
M6L1|A|\$IRLLK*18'=TG.0_!|*7 U(D_G#QP.\$|GT-6J|Q7RKP59;3D+SWA MHJ+)|7P;2NOW|147FF>LTV?
Q5I>#SUY\$#09EW*_UD@=S_@SSU|"\$S1SS0|# M|I9'LI>E'.|\$/A_%8P|!7_@&V2|DU6CT'"#AHY|H|F>HB
MG6OAI39&(QR1#?1|S_X9.ZR/*X6F_@M;*.H@F2*?|0/D1Q=X?A|90N<|YN;C MC((D1X#-4.)@48U) 93J!_4M9@LD+|*
f%|RBI/&<89B2_ 3D4\$F H)A.8" ME;\$K2/_ .Q.=D:~Z0AIFO!>:9Q41X|)K0U95>*3'GC1D;!) T.ZSWE+@'_ M07I(A;
(R=(8")I'7Z7YBZV%%%OQAN5.0&E:9_E(ZZ5BL^5-*6VL6?>9_99Q MY'
5_R^9AG19\$F.H+>M01HFRILZ8JQX8Q0'ZWSA.X0^_Z7>T"7QW|CM|(Z\$< M|<85|XX?AQF5?9PQ?>IB??>(+V^1)T-
C|WOUOMO|H+|OTS@~@WAH=|PMT.F M&*=|QCGIQTf-(8OZ\$J:95:KJ|^Q#7M<|
(|0RFC@#1XCR2+3DKE@_AO'L M0?/3QT-OCB0Y%\$5M@?
A&61_R21.M\$U(PD"5W.)JMAXX@DA8G_9QT65.H/P+3XWQS3T<"T2#P MJ>&RCR7)BQ.#:Q?HB^HRI*?
4:@@=;S94^D*L:L<=K+2K^FT3.5!+3G0(A#. MN!<(>|:T|VSE11/8#F%F5:2:2-YA@/81;X5-
78@9C6#V&,+|L>F0\$(@H! M+<G>@FLV%.:R?U581R"Y9Z<0/YW#11.3B@|KPH'RA|UNG+&,\$\$H0F|YE| MB
AT+9@E.92V\$.<|S\$K20|>-M_/=3<21F MF_#3"RBT@RQJ&5X|H&SB".H(K"SX".9#D+P3'\$L.WMJ=A5\$BZ|@8>_
MY\$98^E.5M.#+)=5C2L/N"@.V7:~+8#W4M8)>NV+WNO)D"Q9'^9+VORL9VD M>."@G_7:CL_1T33AJ*)/S(3N-&_
|QO|Z:2A0T@_MP_DICNA'5-<3)=J.28 M|Q|<^%RXM=\$7P)S*6VI6!(U*KQ WMH%*AEUX#2&JQ?Z%"4.:L-
%6FOLU3U675-QFO:QJORM+66\$W""TQ\$%_WY|(G^P M.FHW@-
P.RP:NKD|BSY(9#"ME*NRME7I@RO.Y:ZB(C%Y:KL3:5J(HD%W2?WWT MIUTUIV0"IED\$|41I*XIEQ9.)6RJG-2H)
+LZ+2J|R1#E4(HK2.3PN%MD0VR M94)|\$#F\$1HE.2AV#V>USB>38=7Y7*L<3EHS|=?'G@|KAT?9\$^_TLB
M*QC3^_+2L7:WV+%OIW.0)XX"2.\$O*K\$S...Q:|3.@IZ;|<^J<9=9D H|_MSL=5/F2IA-89LDVR02+KI_
H0=1ZI#2T.|KY:~#E@NRQM_2EJC UC|Y7(P MSVA.RE&Y.NL;?@4'SS.#Z*!Y9:G2VL-
L:N8ER:S<_T<X:;#7\$(QN4TGJL M?|QX_@L0I!*NJ_/2#BA.ME3^7XR68U@=YP/F>S^E@7?W(JWPG_0_P=4_Y1
MQ2#|^=E""O62%.*1N4591|I|=8_E<338'6.Z*<%&YOB EF4*+8'_U"\$>84'! MCS*_L_CU|VQHFB-
)~R"/ZV@YU.F_|T3|JPN_/4:@R81W.61%\$R9NTC#|<#< ML0!&AW?
L:~C5AZYN3C;BL_WTOY_X)K@>_UN2P0)0LS\$L68Q_.\$9W20| M.MQR=B2EK&5#K*. W12*1):91%A9;+>3RZ:M
V.6T&SF8T.LD<~\$343RDA! M.DDNXD2SB>|0CCPO%>7)58R\$8..L:;7'<*?>A3_@%HS=@JV=PZ|A+CLP|_
MB"^2>:3 =DK:~+V5-/8)*A.Z:(G\$)%*EF\$|V|-9_R'S|WE3?|KC60X%@+@OK M/_RP)>)<#+*GA+A&%5-~?<
&.#B2(5_1%YQO|U.GM%U*F0Z-#N79?F.P!6:1 M;95.FU-IX/O-S=GER?|89_||HF?G|NN9<=|!@/=VW|NU>R*?<
8I5QRAFF2< MONY9#|<>Y F)&"H|A#GG\$(Q|*X12. MT|CWT: "DS|*Z\$8.\$2AGSY>176N.^?
JDS\$QW"TWZ@JP*2I+C:|E#A*(AK| MI3U^9%\$9D=|3@>Q"V9)=*'T|H3?C2;U:~1:4?J|ZH*|FB+D9GSCA MPX*21?
L:Q""&M?^_ M\$B(CAC%3P0^8&%P3^C|CBD*F12C! KFO%I^/RTQ52YYP?Y@\$(PI>~_E| MH1<0W"80TYO2I_D-
+&|N7?H_#|@1BX&6>92TXHJM@R+~C\$^7"MDJ\$#OP/=GG"OQAQC05O0ZQ2+#+(>KF MB|QTW_(-?#NFL*?
|GC&W'H(C)\$A^&5Y(8W\$<~|ZY:T10_QF4\$T
"WLSULX<":K1<1+9#\$EDO:~|2_R1)&*4|A"EKI9/9|7/*#V<~5G)D&2IEA2@_MS\$7@<*9ALL?<8.DGW-
+CM(O N)|2.#76&3|)S)8QFDYP|@56%HU1!+B*!66ASE*SIUO+|E" '&XOVDZ_6*:Q_#2_%)/.#M1.4'4PKBR|F@T
M5Z|INTXM>Q;M|EXF(|R|2O?&POH75&S<@LM2L&B<^|HMA|G|&.@1HW+UOE0XK
MGN'9OSL7WSM8H|X.C=-N|WWV_.C).KR|N:JXM;HW_Y:ES2?)V45^C%*E.1^<U:|X\$HSVEG(R<@1
^_LJ=EXQ34:N0@M_7:>~*#Y6|48 M@=\$6%_95UM4TH2|B(\$&7U_MAK5?^V)3UJE3.T@X\$QMEY/X?Z-

)+H8U9MC0'GZ@W.6)B^7D=N3YFI8R5!H5 M8S406Y\$IK(?-/JB"P8IT>=&8-67/1N2?;\$@D_M58L">6WJL8?5*@A
MGM#6%#P=N2#DBM<5E19CMS#&4@A^, #IPSNIZ0< @^S\|C*++3^:(UJ@|=UV M.5QS8MP4V+XUNI<&f:
O.Q=*3QE7_SZL_MZ&A2/5(K)/&< JH48UL*R5_D'A5!?UM;I02%CLUG9H+CL@DP|R14%QW M;NZ;I?V
G7SV+BZ^Q,DH7MY?G7SC0S[R=I)QSP;=TU>15XT6,8G4M5@/"NW<"7R\$D"3<)>LA!
(2L+GU3YG5,.8%GD24UEH&M2!7 M15(ZQ@FUS:CHKY)YM7>48EXU.KG19Y\$7XM+;YAN\$<.%EC#++(EQ#CK_3-
S/0% M@^A0IMY^T7WKDK)V5-LV63.KQGN,7K*#FV.L(91C&P%?7<0"&_IPS10V.K.0XBU^?
K*"Z8Z5"#5(\$-38048H&Q! M28PT?ST)WP2@-;!=HFM-00%_%_7\$,6F'B6M, OCD>SH8>_L10M;".!JHU_3B,9
MU1L,V3S5/EE^7,5?OH>|UQ4*TU&H4_U_KU%:_WV^V5GI@WJ'IK P=U6&UO MW)@VDE#U=K5>:RYU1,I?E=LY?
LZO5(GS(E)&SG+/I79&+G=O"=G5IA-JFE M*."AW\$VB
7=DOU15#RF\$>LM:55F7ITJ:#HP%CWZO\$;5"A+FV*IH;1"%WBE9 MG,,A54?3(EI?I6D?OI>FZ)>W&ZY7&8:UBUFK/
M:SJ^"IN1;|XUUV.C1.6CZ^V?DNOV|M,-"L'M1WDX5+|51JHU(!;5V,BOM MHUJE>="J"!V:&C**SN9_J_K?
(GP7MLLA)YI#S\$9_F1N:FOK^D+2+&^C9
MDAL,EO>0.7"HMELO7DP9PLYM7U4KORNS%/%O++INIDM7!XPPNUVN3B:N3BE
M|&ST|IB55JM=,4TPPNW#MUFD%|H(TW"%4.GNMDOARIWF@?I6#FD53W&QN/6Q7S56| MF>W,\$'6:%H6|IA)-0-
HP|V\$UI+E%19?%330V%IA%*(E6U;@B_\$DW M39I?#D02O;\$(#E\$|6P:DUGJM_7K">03!4-#9N|BTFE=(;\$!
<(>%EMH,23U0F M3,-B&82QA@>&6\$!_0(SRE6I^KZ|?)%3"(&RO03L?V"|_C%|FW+>_Q#LPE|
M!+.^\$0.8W;X)1M.SQC|38?>_7/H>+@#2OPX\$|C#RZIRUAA,YCN0IL?H"U44 M D*XH?A
(C;8KQ^86|CBV=^Z"|9>M/2GS)4^?SO-+;,(A'A'YISW_OJ7|G M|>_UAHXDIUH;IU;2EMNRY68\$R4
\$/PP_6"526)OT>8V4:XX&^U|^|9|Q"W MF+St.)R;EQ\$O;I4H4Z;U"@WHE@%"X-|H(^DA|N_ MB8)8?-
A2,.SR%HM+GC1.#Q(34.BG8*#TDK3*#2+RSL\$XLLGDFEJ3SC:UVO?PF7 MM ^U/_S^1R"BR/AA^>X+?>
(..|KW\$CX|M:XX#?V%|&DPX==.2U4SDOV;D MX%)@83+;H=+.UZH6VFK#6D\$IS?>EXSZ<*|(^913))A8KKOK?
@BI1\$|P6_8<4 MQ*9J5(>62^(83U!NY9S. RY8B/4=>4;L!7R8F>71!Y!IVQF#VOFO#IW+|IFU M2\$&
G>&P/HOA_MRS?|+@B|5GA)3;/#57C.9L4|/%|D4&A
M72'O9MPUI\$CDHP2'I&_U.3I0B%8DO6I/&)9"QCHG#A@#|WH|83T.'>|HBTWX)-MXS'8C^GQFX-?
%SCL|2H8XI'3CD(SMZL&*UH#/#+5=;=7_M-:(K@:??*R9WU:"ZAKLV;=EIV7G;IT>M?F9JL_?R<
MV+Z"R0|K&4/#CP\$GWVP;YPF6VX"|9D%9I:P5)P_.8#-\$8!^I7C?K2|/N"? M9KWV|Z-X;-3KU5\$T_O|HUZM ^_SE?
VY=(^_E/< D&6(Q8 M1HWG5>2;Q&\$(O5UP&W,K2|LY.F;#BGH69X(IZ)>73%510W-6LVLS&L4B>6 M.G\$3|<-
=*)9GL1WN?1S=.)L=)2)Y8Z13T(AJG|1+|F\$|_I1O^2GWA4;XJU>Q3WY<I2"XTM.ODN'<I9_M_W%S8=S:(S&VC%/?
IC97U3)JOF-7Y MTI/SDN=/L<&)4|+|^V#YB|X?)P:B|IW,<_7HNYXQJD56<8YM@|?XPSMB"NHZUQ?1#A M
Y;JGB93S0R0RT^S/#<7;+C.O;,"-N-278^>HED9|F;DBR|YOG-1>3^;| M|;)SI|UTS'%LRI&LM=LG
U;|C)Q|)2_6EFIOR@|BF*L1786O6?HSMRZTX)\$L MTC(4|L3|O9DA1_LCCPF9X86>Y M32B *Y|04/52@!?
8GBV(F|N7)V|KPW MM6HK)Y_/I.>T>IN@1IGOB|/WZL_7\$YHW5F'|&/ M|S:&BVL|QO\$|6+2>T MD)M3(36(LGP4?
3FUG-|F3FA|6'1)444LH>M6-\$E)W0|FW/J:6.V%>Y^=R:W M.?QL_#_A>^3\$#K)7N0O1WIMX|L6T/96^%A?8%L88F
M)=7U>Y9KG,#S 6QW/9<"XARECFW|77A3!4JX*QI="3PR^<NO>"^YD%N| M2;=,=
I@JK<5AP|G|Z>.;Y\$5FU|^/%SS^|X3^C.S^O|4L\$#|H0 (M/R|>ED(681(C-A<_T9 0.0;61T+3(P.C0Q.#
(U+GAS9.U=6W/C-K)^ MSZ_@T5.V*K)UM<>NS&Q|H"B*M_*=D|VX)(2,(9BM""H&WEUQ|)\$52)&A M9
4O,REH1N=,/KQJ4!"|Y|I02=UX@="1\$/G?Z1|V. P,7>RB8?^|I|7S5 M_=3YYY>??OKU?|K=?
WUJO'\$NL1LM84"="P(|A9|SBNC"H0OH_(7)=_0"G NCX'NAI-N4^&GYX3'_>0I"FI9?>K10>@D|2G"
W",7+X^YNOW>8)R6YKR0 MA#L*0@H"=|_|>K2I0J&U33LYV/^,ZIGT.T.N|_B*O)NUU>ZRM^WDA
M@24,5|"%JWXY2?'X>"BY0H3Z@0EVAD(IT+6D%|!UG%BO|C|+J#"OGG).%6K M5/X8^C3DG|K|T|%;Z'6.16N-
PNX<@)51S7F.N;/D&Q.)9)94)48E"?_43>FZ M_*MN?|LJK\$.F:^8R9#2|2A#I8G7@.*B%)_#7<78.*FQ&
FED1C5GJN)14K M01B;5!A"JVB.7XY='64K'6_1\$R0M4>)?
I&OXSPZ"&+I)2JAD^F3LN#NJKD3,B1&+>OQ>H<&J:B-I M?IO4-X'4U/E&0GT_|K|0+?
5&I&XD9^&Y/GV_L=P=YGSL7F" T;.@|_|H'_M;G|350:ET|9I0PS^_O2\$ _Z3C=;8'0=0?
7K|7;9+2Y1"+W|X(OX>|NA\$^*D MB(1PJU6T78HN5\$F6?)FVGK1_@Q#|R./KJB>FA)A!AWAVS19D2_A'"/(43YI
MUIFYU/7X27,I.OH/^F..R82" R1AG/X0.GGDQ;^?G#?="_'<7>_E4VP!@Q"|
MP'VC*66NA';@#VVAH@/0.2M|3Y2,STM(*3A;K#6L%*"")2|F#|U8|X'P&I: M^0\$0IMX"4L0\$WB-Z1.Y**\$?-
H'1^+M335FCS_>*W_T2(KO?7SV|S4T(YUN); M8|X'WY0U^X.JLU<">W)+M>?
+4AP|AXLK'KSN.GPJ62EA#29#C+TC^+?4 M;|_|"\$+)%F?L@IH8U9%:T2G\$|_|<8A"U|=A1"#|(+AP+|)6H3
'7R=N")0BH+Y M VMBJ<_6Z@Y\$C(>2D3.MA%AW)R.G5/DUR)D'N\$+#+#"HC4);7M7B|JWM%D|H M6J2V\$Y<-
J'@%|H+ 8ZVOPLE|?|6!5|BT_-&C_-8>RP&L|HO#|+0A W"|Z!@Q58(VW@8MOUYT8FD%3EJ#PZMP
MLC|A.=UP*8_%;|9TI3Z-\$XV0;C1OUB|KY-XR|5^3|Z9;|S30)YFC|PTD8 M0H.>3,E(BEWD&T8ND=\$H 2BMPY.=
(\$>HH;^ M|DC AM+P_9*G|2#Z|IT2H;+)2POME(7#>#B"28L;_HEB|_M7P*CYCB1D2SBC MX%,-
N0J\$T|+&6S#|I'DY.GE6+H'B\$%|\$QZ?@*|_8/K">W62Y5TFNA**T|_8 M.0DG1|J\$103UXV67
J8KHSN_4W.#2)CJ@X*0\$JK<5S/#>KV|Q|LZV16_Q MY9>
(BM477S)@2|EDWJ3>:R.AQ*@T@(|ORU>9>3YM0B9)SCGC<".X#>(YP2L M%LB|!#OA|L-
11L% B5|H9YP%AD|T;C?FD(MJMR-*G906 U/< M%&F&3"4)32EV'#U|DH;L3'9\$C&\$K
%K)9*EF+|YQGLD;0\$J12UMF=;2^VYL AGC5D*OP&92"V.6=A#;B4;TG M8(B)E(D2F5)
H6Y|H8WX5&|4&*^6)\$R4^%3\$&ZKW"-|C|W++P#@_H<=|B5I% M.\$*|\$=%&|!7Q:M.N4(N;\$KT&?
V8I=\$/GDJ*R_R(9ZQ-@/S.8%S(1B>W4'Z M!%BC3-<9.)?H!&D7Y>0 N0;AVEWJTR)?"GLD49WF0TD-?8>
f%N_@VKW1'5 M.|UP5Q2\$9R?&R\$.%EQVBT@WR%-G6O|CN914Y/2-DIOET.V\$=>^Z476;+ M.T"
(B'8T1+M\$K|2P%")_PP:R4BD@V8QBB9!%0B5PK\$R+=W#GC6MGW61SY" M%P1|D<<2J2
M5#*G0|J3D^U@;G4XW|'^UA|>_43^!X\$;R'@H&S2R52"SB;8;=L:SPD^5"B5 M*0Y+(3_34Q12.D.'R^D(09V|I%+;9-
)N|+=TXUHD*L&\$008JWW(SO#"C&4
M%FAY@|Y9YB3K97F5G|8H<|KS9+|H875AM_4RJONGS3ELL|PA%I\$^4VA_4 M9O4H;
4HU390;\$|V"Z;R)">V#E82B5R\$YWU<3|H8V\$SRVK-NVQ0R121*YA=YT73;#_K'1TBJ=(("ZPX12|Q"2.YGH
M3BR|L.%LA2I6I17.D>GPBY-IP7VDRB|. %KYM-^F FO06%-<R0.F=,9Z\$KQ? MRIU%
J5%ED+T.A:YF62D72C%V0^V6<5#8| MK+N9|^_7_975J->E8+M.DZ>L.S-GQC.)OHM-H;B-95=_5C|30EM*8I=<_WE
MX.D5S9T|'|&K_NIC^)^C*DT=V)"|f\$MQ2;+H6W,*1&SX4YZIK)=XF%Y0;^_|
ME2C1+T6DS>|#M=WK30#*W/4^HOP%1O|Z:FYX?\$_CT*U;_3.EV'03FEW)CEY MBE==#|:DB>AO-(D-|C@|JA(?H3?
_9:E+X?2RG;/CKD=0N.R"YDLCL@/_CQ3G9< MW.)|P?P:77*_=>V*"B|
/4QMKPO*97VO(<|AD5|WMH|^Y9Q*N)M(*!;_|@_M|6P:8UK26CBF|>|TXP.S&;G&3T,V,*_//+3*SPF(%M MH;1D4-
ID*4;^|UH(U)=31IL;*8|_MQ@Z4Q*0ZV9H>MY+=+5F'9%#;0|5;>E M?<
9="NIP6MK|JP4UN1BV.G.V36;\$+0.B;^|B2OVG&5HX)%U.(WZ=V|164MFBT MLO%L3=-C@?<
BTFY5W4IF<6"BQ.\$V9'NRJC&SC"+|Q8Z4UE/9T_*VAW8%|?=<5
M|_&*/LN(<@E'V">\$HK^3" T67L920E;D.\$I'A#6MF;|N*|^MMWEUDI5&6MIH; M=%'Q;>!*KO?>\$.PFA--#2OE8#
JW(Y<2"9<=MBU;9R-9*4N|060^02Z1 M^F\$M;23E75%|D0#;*05SF M(O_AUOPW\$X_-%(D=W2%*)49%
_FTSRGL)*1\$N325D4ER.V>UE8GJS3%2LY% M"50|HEZ?|!%\$%97GJS2_G"KCHH2H%|ZL3WO90HB4>2HK

CM*FLGIQ-I4YE1^PU\K'61N1TLOFR87^QR\B_1LC9Y+_ \$E\2 M280_6&X5TCMD&S/EK+2-BH0I6E;3\B%>|D"
<*:8.K)0@EL*/TB?G6HF8(FUN_M8Y_.P.140=+(2A\$^8R/+|@53*0R.1NA^"2R->F#?SU^"!..H58:_%Q
MXLH|@&/905?L^&C^2T-N=TN_ GO2.OJ>T\PO)C<8H/Q+50.Q(>DX M8!J*FJJ?Y1\$L_.\$8_G9Y%1!%?
#=@*D/4ZJW?1>L^*%:XR)I7A3GP.LX M8<2J0*3BGWXC.%HJL3%\$87+CD/CXII^T^5_AN8>7_77\#?J'.L4:S7:Z*8
ME.H&Q09)X.QL6(*AL4ZQ_U*TO\52BFH+Q_U=H\+0LXB>E^4JH;.%H.6.DM_M*L445^8H=E+1OYTFI%9-
2V:18OZH;&/5/B.ELD.Q^J/24\$Q*98-BPZK^3.F8
M@LH&Q7I^V5O&0Z4O:*4R@;.%AE4=JW"D1\$Q*98=BGRIS(%\$)J6R0;%!U71V MJ.KN%50V/*_8_&E?
T;RK%%%1V*%;A+.;>4C\$E0V*K8[Z9;.;#16**AL4*Q? MU7&/U*8H\)#L8K)T5AMBE(J&Q2K_*IQ(U,\$1"X(?
7@>M^7H(+^GIV0+ #^RCQAW\IM>KIC^<^9:8L?*.IMAI/29M%_VC2_B_MLA_@%%^-%HV_6>(-4D#6Z08LIR+&
(=V:0MI6?CV>?W.7O\X_(2AD&E^*EG@0 MBK_6RM*)\1OR4+39.WBK;>B/\$V^!%P^O7>#(?!D% ^%_ "@E3X
\$@;Y(T69V_MZE#NW6?C;QAIGKM\J5R>;B\+('GUYIWUJG=-(K_\$7V\$P\$,^CT%#LD0!%WIS
M!7D2>#5+61E05S_.O\$BY3-HUJH^ZQ;.;/E^/H^LK^_4VK4;?_Z;?X0K M3^B7)G3A_)Q0\$%DP3!P_8B^!
L(>9R>R+6I+ON>^_AJ<0LA7>_163_Y=K4E/8!CTN\$9@RSP\U* @L.H_.PN*!^!A8T62
M=5F_0T!X.@<_(C\JE7*9S0YV*#Q4S(G_IZ0E\$D\X5<_7#UM=;EMT/0"\$ORP_M>043DDIY5FSV\!P_D\Y-
\$UP3%E;H3\$"_@_D?5JQ=E_ANXBP#Z>\R-2>BH; M<+!XZ<5Y^E\Z?J9@/I/2UE_-9X-V8B;LB52O,>NIYJ^R
^JTO^L6^"Q<1JO_MU@JPZHK;H.O\$C2B_)IO<8IX;H-@K@>U!_8,&\$4BZ_U*&G%06M4_%L5>
MN^ZKWTLN.RKF13(*&VSL^36\S_..I9^-%BKPBI)=ED>L>? M8?+*YKYU^K4[WQ\>7=;%UI_M&
(K8!)IR9I6OBO^DZ92&H0VZ*=O?^OU;IM<>I_|>7S\ZSK8!%T?_HI4U&H MQS
)0P66#QY2_XI4L7.6\$YDP=2R;K=K@ZF80*^UL>_41+K_MHUD^Q%;B_M4UR;=I&NXH>ZBL9/B1OB6=I!
(H=ESTOMY)C\IYN(V#^"W^&^I_7\$7C_MNE#&_HJHQM^I>79NN\K\Y_GG>7E458CM5I?=@-1X\I7!"2Q(VF+JQ
M\TX&O?Z87Q%EC\#P^P#CR^9\8CPW.WZ;WQ&ZB-Q?GCO.H-^7D9/I9J^035H4>X<;MNC@_M_*%>9Y(K_H/G
%L=P2UX0\MH^143@E^YBX_5<%G_7CN0;-W^P\>-US^T.A> M3\B+N^(\AV3-A52\|@_?BI(C/0UD_M%
XAT3#.#//9\W\67P1YJ0W&/<>=&%C^M/E_-W^I^S_L\&"3"BOMVYLI^Z2V8,1%!I:7(\<#925T=NF; &J&I_U^\$VIE
MY/99I3^YDS;-1MI+>_F@OKJ^>)@6)>Z>QQ\CL;W90A\$P04 MKAPOSP;IK_KR-VSYUXH\FC;EE&IVN^3
CUN7L_)&J+=/UUXB\%C7;7) MK=,UF0B-^OU=5GF5Y;IVH^G\J\JDD-2\CMTW687.P?_5OX2.BMTS69%XQ&
MXD)YXWE%;UU_&QV&K=PFY=<FT\O1N^&N^G+I=#U+|CKT&RUH9>36Z9J.
M&N_&\$2@9N7VZQ@XWVK%SJH;WH^*B1\>^_I^+W0T0V_N\+Y-6^<6Y^! MINU=(I^"M.OH^Z4/& MES#_*
74XMO<IO=2H_6I=^*7V\$+IX")KC><I%=-V3Z@|I^R(V8.F3 MH^"K2ZHG\$;!!5Q^QB8G)3Z MO^*VMJ&-
7\ PY+4:ZM5R1^|EQYTU2*UYN^K7%KE03QMAID)6@S@Q-RIC^N MU5<35^26^K8Y5^Z>*RI^IC/'-6%FY\T+5VV+)-
U5FSQ\$EOO_!1N_!F0Y<+ M<GY+3\DN5R\I\Z63EV5FEU@GT_"/#OISZ;"I.F^!2B_1V/C>9FK.EK;9_M0T3
+N71*SH;MY^5&#IMT\5='8BF2VT_!MF5(X#(3%:U\%RWY-4U_5\$&_9L?26I^*NIF^J^KX16?K3JRY6/UQ"&XB78
MU\WY_Z.*NWM*.AN^EG6L:\$J0R_#%1F^V7+ZY2+Y3I<-2\$MJ@W^<^0V1NXA>'B MAHTB\9_A5TO&88-&?<
Z\AVBY>N0//_60/#)+UM5/G\X&;<4B@E?D.MF%O.D_MZ5V\=O4\$EFHH<@PG;>(V1Y;_%6\37P\J0R^3P-
(4JS^P;N7R;N^P^C\CWQ_M^"A6Q+MK+ZEG^QYZSJR^D^RG_0_4_61T+3(P.C0Q_#(U7V-A;^YX;6SM_M?
5ES6T>RYGO_"HWG=;5^J)QNV\HL=R*L\YV%)^<^X2H)80\$-BH#T:9ZE\ MLPZXBPL(U^Y^\$X^!
(\$<ZL_"HK.RLKZS_^_DLDGD):3Q?RO/_LQ> MX#PM\G1^I+=^J^"I63%QV&%>8G MOTI7QTI6Q_CD^XONGI-
X^""77^MO/? M=G\1VD<10P\N48!"Q<""Q\$\$(C44P9J1@_>^H+YOYB\OIB\$HZ4"D;<(HG0)MT_M^DYA\JG_T-
ET_L^_U^"Q+(\$B3=?IC_<I8?CU>KC7YX^?WWW_1.7:S/R^Z MHZ?T/GT_T_G+W\U?
Q_UWV\^>^Z2\LR>NIS>ID;Z64TOW_Y^7TZQ\ MT_ER%>;JF_Y_83L?
T^+D:7W^TO>+^7(QF^JX/EE>7W\JGQ+\$K\7>@G+V&O^!E/Z\@^Q=EJ>?Y*!;I;_!#8SVV_MVTOV#C_A_!1?
=8L3&N;5%I+J^V0#7IPN5_2\$JL?;79:S<>SY1+I_PA?)X(M\FZH(\$K19.7TU0-
1DN;Z+G8H\$2RIK7D6\^VC)7>L2T67<;+0.3W\^M:LW.C.4;
<^C25X2\^E^WO^T?7IRTG\F\$5.SO^<^J.V_%DMJ\NU-7M(REWI_M\6^Q7+T\RT6>?
ELGMICIVF;X0B^E0)BD.5)2\M% MB8U9=#>;3<@B+LD"WQ1;BFA&2G>X1+I8XX)S\$LB\FSQ\9KR^S\Q/D2+IE;
M_G4Z\3_"GK_M%H1W6<68&.LRYUA_B\A_%<_>;0@I.W)HG4RN>V9VNXF\!_M?
JNTVI<_F_N/<IH5T<_X9P&8D:PG^63Z7RZ7_5A^81GR"<2960B9C!)2%_R_M%HAH.!BA=6998I;B;
<4V0I8)FI2WRJ8IE_...L_%MUJ^N\^6-Z0PTG>_J^T_MSK
NKZOEQ\$D9LS\$>K")JD^JF+R\$S(G.VFGOL;4_=#^B38BB0U6B_%3&S@2A_MB^B:P55WFE;G^Z52;CF.D\=3%<
M??*1_A)T9PXGC^Q02H;#5X^KA_B>XDMZAL@_90/_VH12YENCU*5U\Q_MU1&H@0^APGGZBRE\IC3,"
RG:4T%3;W*=-_(!E->@I<L\$+/68ZJ8&H MH1Z_M_F?I+?&IR^4T8PC;U;V-
V0\&Q5);Y^F9=8T!@0A:2MT;5B1@BL)% MOU!;U^W3&?\$(@SF8KYCF71X2H^)\G
M7\X\F;PS4L5T^KHOKVD\$E\NZ+?S%0WNK!=LA1V941(H1\$?HH3^N0:F2(0CO_MH;#_PCL6G_Z-
R36@.\$UF(GWTXE8^3&AXE.))@XY8/9C@P0E/L9%BAA5CN+6M
M0\IS\8TIDS86EMXZH\HOM_&7@MV;EFNH)O8Q\$QOV@#YQB2K)8%>0_1KO29_M%?B!
<7G^B&HDJH4EB'+M^CN_M?5?DP;S;^Y.NVJO&8W(+R\35?_1O6T)6O((9%/1>P%_TRNXF%.S)+#A8W9
M<_GT_3M0T6=2A!&_N6\>);_%2RT?GB#.MK@0^NK53>-IZL09_AA_M<8=5+;5N07(.^*3^RJ
@D5=0IV(P%>=Q=9+Z\I^CLK\$M2+I_LJZ;G>^IS_M^ZFGYM7THU8G^SL)B_I003FE=;=^IC\JVSVUS
1D7XWMSRPWYB\Q4Q8*\$H_M5@+7I>ZRB_C1%PY.F<1BD>B^*3QY\X&S>Y74G1HL= TMNYZTL329+8D(Y3B MW
)BZ^4"A^L_0)".%ET%R;/8I_-B^*9%LO<.OR\(^I_6&!7YW^K\$1Z\K_MZ_*E")IW;I7X\4B1_70^9<_V9_5/WFUN0#
<+Y6MON<-Z^O^H9%Z/"K)0Z MDQ\A\;ZMY;"Y.(F5#"AVY44/LKCR:RC9?YMW&&3?V/^<V)6+N5Q\GZ0-
M%\$V;.%I>VJ7L_ER&KIDO)_ZHMDFY^@HU^M;ECW=Q^EPZ#924(^A4\$^2Q)_MIC+\$1.*I0\NYXDYDH1(6>)=TR;?
(Q>I0\$V(O7IK: ^T\$ _2_EUO%\M5AZMI_MU^ZENA^F&P+5\4&V\$O_0^G+(!"1(#FMC;_FI=X3^0_M^J^S^4#=#G^_9"
IA=A>?QJMOB\GX;7^T^A^H=IEE8+J=ENCY47\4B@C?^KZ)(MIPX=R/R;HIC^?HY_IY\0^&!9Y^!"8KUG1@*6
%C01J-E)+9U_MPO3Q^O^AIECEXE1SG>YO=-YF-4N)^/>5?+5GN9=WOHYW+3<_WVJ<I.W@8
M:0AO;H)SGD^F6G89E;=L0I7K=C6.MXX\3GM0B7^<=&5L2G9/";!^*K)H
MR8;S:\$G\57Y^ELG1^_!F\B\6FOWJM.K6@INRO08C=JLO_3;D4?YX\H_ MIQ_/0J^-5_X7K?^E/BKH&2MQK2EH=
MKAV)V9=I_ZX0;=H(5>/4SX)"1A\2&2&8I8VF&L;W_YT%05A?"DS.\$8A_BIW7^L2Q>;>3N\&_M^474@!^"
AKUM@^F&@4*=\$%\N\<8#.U1Y0%'B\$7-!7?^:TZH4Q@S.1F0;"J26D@^B\^*XG^1B1^M^5UX#T>_A_) MR;"L:2J\I6?
^A1FM4#UY>I%Z+H09&K_*Q.<1)=5EE%_U9%>=;IQDV_C2^<^V887716+(-=)NZY?QXMNI0&IDM=S^7\$";#8
JB_M1PF^"T^K_+RHP85F&F@8_VB9R^Z_M+T;1L)P9_@FUX2;#+4CM?>@EB>"Y03_M8RG0VB-3^54)H-
83Z6E3^04RO\$!ZGN>W1R<I_Q30MHSC^I^J@34.S&A0E\4G67V9Z**UBJ*"^(12@_&3^G;<^C\$4
ISHR<4\$E8<3;TR;5.F?7=;CDK4FU1.6%6H^*XX)BM4H2>*29_PYVXX8_)O!^5\$^Y6TBWJ^
MDF^KK6^K=4;^SL#1\DW8;0EWPC\@_XQI5^*F\;UUG_0\$^9B\Z4&9=P\!%#I% @M3VSTL;C(R0&Q
A23\$2)R^"1%8JZW.#IN?RHS\=DD@L7J&BFO19@O>D5_P0_MF=4@8M_A">X;%VH\56^D2\^C\+V>00-
F=L.GN_*AF.5YB7/6YKX_359C\MC&&);^L>K1N^S/141LE70:A30;EE07GN0)1E_U>)N\Z\K^S9^=">C10M
M==*N#N.^XO676^9SS%=KV^<^R94-/(D5\$J20=2WIO5%'^@;%G(NE&.%6%S_MZ\QE\$^C79;W8MO^
=HR_H=7MF90(Q(E^B<^0)"S(3(<3^G\H(D4^174#6H_M:7ZAP3UXQ\O^T6=9N_7(W_5;B:F(H60%&_I#D)Q)-
=09_(24@DB1_VMT_MZ^S" Y#&E\$UKO8N66FB;3KW=>ID;69*LYG-MK8TVG.Q65.!^R\$Y+SB;BD-

C'YUOP30QC"AO'0)6=5#2@ M79XX&4UQ@H,7L1HBYI3LY-JH.R.-IWP5K(>NHM\$V9YFIKXW<F",P)THT&+P&IX5
MNPHCUC)CZ.9DL)<4-Y^>U*!&7L.L.;J:H'D1T>R2H% ECO#4%J#--+R8GBR MKO5)EH=1C2G=U9@?
C572,J5UCF.C4I>&8RA&UFQ;IC&(UD^4%#Y%FX-3OMJB M-4"6ZS\$0QY3X:FUD!E36\$/N3YSM-Y-(QJ6@EU\$S5YN:~?
B!)JV.LL9A">AUH!- M\$N1M-1C-BY?ABA>J(KFH,L)Q:~H,M,8,HE:LJJ+M)9GFZ0E=XX-5?9I'<
\$%Y:LSZWCKNC@C'0C ML 476@S^>2Y\$>MRUZOUT,2/NSE)P(CZB54#T;14_J;PJG3WO^Y;=EM0,7
M5S4^2ZOIL 6>8C&EY'K1 L.AI@04\$0*G.%LI1=%W2'F' :ICVA!=@!OGNEJS
M11+7_Z>GWM4S^;YU4*KYPGFUB9BDGD3>N@+2BG\$Y"C59TL7ON4.-JZY,I MC\WR!!G\#N"0X2?/"=HU!VPBC:
IZP@EUC+HXG-MLND! M@Y'),FV<:+VFW8YD3,'IGDC30"4-@Z;/:9ICX"^G^%9-!9G)W53!=IK9"YB
MUJP-N>IMK<4A/UTS^L'!(ORQ.K6-0R:XH3T+0GZC17UQ"7&S-?C).*0TC" M@KIN*US:\$RFV/!6JO\TK?
7!KQ:=R!5I7)73 MV?DR.\$DDE:X7MD=5.\$5RW(-#8ZH+Q*Z:&QSVW\$?GC%4/NC1QOUM+QR^8;7 MU\$=-%X*?;
<36,E#G.72QWJ_~%+*2T=?^Q-6@V:"2*J7HUN?R-D?WR#+,H3C M;:*[X:JH^L.(L+>G%*C*)!)&X<H3D/I7D";
MT,9H!>9G6PVU3107JB"4 C18RU_IHL(?>RWLZB@9Z<8Q JY>ZQ*30>1HVJ;H=V8 M=AB^?7KNJOZAZ?
EJ. @S=IU?C%@;?<78G1 BSJ- #H-1D?>WU22!9IH>0NZ M,>UB2/OTW%7IS>BY%O%-N2KVF_E.
SS1V4@:.\$@<^6XI:>"9!BBSD1.JB55&L ML-.W6PP@QIAV;+XAPA^:4(?F*6/D./X8O?
0G6FW+15;P6UO\25OV5UJ_G'TA_&4Q7QTOWW0_MXW(Y<3SFJ-&="!49F"B<+!PFB\$EHBEM\$F& K;6=,
(H5;B(AI=LO^U/S>WV M="!POIS6X9GGY943LQ/RZA2Y=A*(^&0KR^)*6-.92K"4E1;J-"^!)O1_1(YW
M@Z0WFS.KG8Y:U@)N=1+@8DI@4F3,6Z1% M+D_K+!AORM6^B!6A)!*,"FGMLD&!22DKLE
M\$RHS1+/)MCI&3"J;F_!^!3 U4U7^2(VI0RGW;D6")V%4CFCUCH4*RP9#8 M!"X.O*H8FK/IV3;IW\$?
AC5(XN8OJO*KI&NAC5\$W7L*L"A46Q!9RB09(KU M0BKU!J;Z\$%)929KW13,>,<A_?
3;48VIA=PAS=#VJCI\$HMT95K)V\$5+=K5;J M;@D87_H^K1S#CEK;8ZV3;1Q;XX+"!XE4D>'=JXJ/%%2*UH2?+U2.(
BH4 L M)8,0D4>C#9&CN=NX;IOX2#.KN2ZRSPWUMT@9KK.^7 O?K27V(QFV'J^V6_M*5=O< MGINIW-
<+G'=C:K?/5K_)M>[G;*N1=A>V\$*302 A5!P\$YA1TS 5%JL8'H'O M6XB(!S=>K?0W;N!NZ@NS%/EZONM!2A?
3K&?#K#Q=4E>SI_JBE,9I6(LBSZ M,*UFBMYCJFLI#5!HGYZ)^6:2(A_+O7H05'BVZ+Z%N?/9IUZIV.G@>9C7L
M>W^,I*196"HOUI2IUS1FY;7!V&CW@UCEZA)PXBQ^WE-.8VZ5%P?B'6H58
M9V=N*!#EZL?/9IO^%SUMUCV2GQ7ZHELMOBIXJ>_7)IOZ0IK&H!6?(M1&VQ MK3;B%I("4J6>F-;!
#BO1S@V9;N"Y@?;RD^)/'3WMMWF'85;AUF<_KVRK M:XDFC)/1#I@6R>!HDT#3F<&RDN1:ANRW/SBH";
QI0W/B+F7I4T:NAD?>V M;Y106L@)YI'5\$5R)1DO1M V4I=/5"DY/>8I2ZJ;RZSS\$=DC'E(H8,8W0(-V M/?
YG&T A>G!5\$QDOH ?/ MDD/& YM_56Y"ZDU6F8G6
TBNI"M6FVCVNTIO+@%+KU>_2ZF718P^VJ4W<_QPW"U.CXY733_A
M_170+;!),!\$&/7HR228I!"60C!,C<^0Y^)!""4U!V/74H#OS,%O-A<>6DWV MQYK!W*;!1/C='4!G9,,%?
AUW"Z@("B\$0;FIT/95L;344"@JCGY\$SF5SS'L0I MH_L(H"#4IP1/_;ZWYJU@EY-
C<_X/R6J;D\$=QD9@R(=B>!K68!B>3(%)#K MS!DOAS3H#PDPIM+@!X'MI5ES&+?CIM_1H^<0Q*
{HOY3M!}W0_-'=^7'HE"0M,29A1\$B M\$O)?PC?;Q.B ^&P5O#34DJ.H8&8?8K3;W_K5"ORW\$T!)#(*T
;2.TD;7BL.ARQ8>A_C;"0T.RM8&ZC!D9M?Z8%28 MYRO#J_U;AMK2>O"!>JBX>IS0.VY?TA.U@^!H_"K_KUJ47I/?
FJ7L(7A\$K=01#YCG8AJ@5L/5L0@=, MQ8?TMA>@_==N@GPTZ_3B=9D!TW4M=UK N6L
PKL+1C&\$U=:V=S!YNS;<(PA MC!H?VYJ=+2K!MOU+!EG&H!X;.KZ;QV6L4JX.Q;9/1-.EMAB>\$+W';
A00\$53(F5Q=ER!H4U(B<C M!1I*UF#'\$-J)>_PGO07'2FMK?(6*MWU2AN:(J@ *EU,#Q; MX9HW>'D\$O%&UHQB
5K>5UP^AN>975*TG.;-WWIB<^)#!JH7+-1CBOM*1!J M!2"SYZP(I9OKG0&+JHNBGNA3*!;Z09/WQGRY4J
{@4*1B!TEJ# M.A0/^!H>5_9C.#G%8O.K>Q^-;_?HJL;:F@9JRY*Q<5+"Z5\$GTN8+4RI>8(C M#=%I'FFE*.QB,E;G=?
GOW%D7!L%>^!(-W4,ZTR_Q&IZB3Z&/U_0I#C2UAN MFHM/E_-)LUXA!79I;R!;Z6GT9,T6'4>7ZG0;*0Z6*PDCE-
ME6&!AFDRO^-H&WP8!%=)) + M;!\$1&1D4\$!O!E\$NJD48ZE,^(9GP!H!;PYM2EKCJVR92I+SIH^C+
MBY3GW6W8#,T!,PU;#%>S!AKG>"IVJM+4RQC#V\$0ZBY0Z\$8.2^ECOM X6F@#?24HY.Q.3(6A5\$RX#+Z%> M@)
!!"XB8!2)!\$DJM9%9YMB&X;_2OZLZ^K#H79O1277D\$71B@H82LT%EYI<"HJH&RYI28K-LW3=TS MV@2-
N%>1%_#Y*@BR5<+CX.K>YX)HXR&!ZO:5YX\ MC&L,#L5>./(-W^'Q2AO_2C_DU6030_T(I7!X@L!/C
/L=BLN11&2EHT=)KJP.OPR4H-H:YI^@E15U(30;BB;9V MPZ
P3M"*7I*D(L(KF_>L3Y0I#*ZE&!31IU/M;WH:21.5Y;"*50.9"UP5C0J M0+YB@)*Y-B4'KH7>OI,UOJ3?OH@VI
KWPIK+D;FLOEXMWNJMDOW22,AG!>> MT\$8NZUV>BA;
J#5DI5%PJR@6;L*ZAX"/>5W-.8U5>&^DA>I+/=G1'D*BDQR M A!KYGL"H*+ #%SR3\$CC4RZMCSO#H'HO&41ET)>
<63WD0@.CBB9I/@2/*2L7 M;2BXYWV;T600#J.^K5*~C!B +RL!8>R,%>D_4.VPRY0\$SD8%R5J;-TWZ29:OJB7)6
M/L;A\$H""(TW="SD(IYJH="0.<,@N&MMU"W8YBJ<7#;=72W6EXB>HJY<^@^M'!)YJE*8M4+P;<8I2Y
M!PH32T\$PUD(\$BH#)A@&G@4)85YGUR6@IGRNY;83*.%/>::C&K_9PN?) MC1L #UWZ3'C&7OQ<I!B&*W!^/TB
V=I6_^R-JFNAIO+;X!L9\GLB+2'NH MD1AJOZ*=(B"DA9C >')U06.5D++_.93"*6KA48"3%+6DX
NIG#E3PZ4GFIU@&%_2XI';4#U MP!H<I:08>5S=3D>D;OF0)HOI0^:K&\DJ30;TP;6K;R1R,\$^:
MRBRGJ(1K2^LNOK\74W3O6>I"[-4MDV#;J;+HFW")E)STV.EJH.8IF MBM(E0U""0BJ+MA@D\NM!<I#J;T"FL
AYO&HK\$RFJU?%IC^L>C^>7K^MELD M7-X EK2(*I)2KEVMJ!;S*7D\$K+A7'-G8FY^"JD&L.9P/'@XFC121WN>O)K.
MITL*GGY;+/(8!%E*K892+)&SXG54S%=@\$A.&N5H/AY*)I<#6M.C0;Z21 M.H;U+X.W9P"1.5;I-X?
APXOH^JZ;OUTU3!A9Z'Y311_/UR.CM=8;IY5JL! M)6V?W2Z7&7!(&KE" ^@G!9GGA/!<?)
3TB=N3@K!TCU^>.5TM5P2/_VD MHXYJ!(VO1.PTATWKF;+LYOI'SK/ D1!WM8*W.ZKY 1*FR1T047/
MP9M\$CGUF)DV*\$41QWI1_0.ENI3T^"N"8W*PAN7;3= ZGQ8;+;>KZ-&68D34X M6_KKH.I"O_G-7\$!P&YD8OX;-
YTRM7SWZO U6^RCDKZ! MFJ?0E D+ND0*2(*I/2-I@JR.I<5(R4SK;-/C\$.YK1\$18?%3!T?8-.\$MS^3 MGO,V!U_O-
\$PUYE!;Y/#_F8 M?8I4FX M0VH+I[#U73M*)S-@K>SL,N%6_ =7L,%J1&0FQ6\$E.D<IY7'\$5G> M8C=+Y&DZ>I5>-
#-!+83D;*!>&@J90Z.6_*6.'T52L2"IO_P;X;MP4U'-YYS M9E;I!"<IR)B!;+ %X!S6DX^BU-
L+4TC1R*Q:YYCO!32F+;H@I+GEVJ-&ZFEY M-I8-2->7M?>8O#;LRQ_IJ;!.%Q(D!2UO"V7XU*FQ;9IQ=1B;T9!V;ULK
M:\$#2U#4ST8JZ+CE!Z^OK6L")YH+4917D);FA(6X!35WP\$MEBL=QYMI8@:@ MT-WX1G:&XR";J2I ?
GU;'VG8#^&J;7^ZSOHEPV?A(-I,U+2'LPI6;FA#D2.R%N;J4UP#7G/Q^W7.5P."9,I'2\$0
MK#617/B+X(I1&BVIXO.MK!M>@>X8PJ*FSN;?>OM%1K;^2A)IR;CK!75ISE M6I+L.EOY+B3(09/ (POHK&?
OZS+DK93@\$&ADNG6Q^S:8E_5<8!J?JP30_M!%XM'O4;T/A\$RZ.NO#Q>)I>SVGFK4?I^;CIB%>N+O;;
<@;XO^;BWG M>K;NOR<)=SD&3BD-CO&>QVX9DA!M3H!;"=,9.*#07!Y?J"52; MI_/0?7E-
FOZ11F/5WZJZS41.G062Z<&I)"5!*, B2YIHDSEYH'KU0) MI2N8!Q-GEWX3K^B1TZ/Y^2G;-G;I"0M;H;S-
(4)VH+C(\$H!8",WF#*+Q;H' MDL9=GSVJK>.04.QI^I2=%=)NQ_A;9JZVH^C;9R=G>N?6%D2X9*@2!WA)!T8N!
E894NLY=#^B4;WQ8Z/6_\$IM1K3^@KU^A(XYJ3!-E MI?M\$GA#W.0;(K^A)I5#E.C(ITK!R>C6;HAGP-
8^Y482T1N/#B>M:69\$&>J!%PW2>H;R;UFMC!-D>W"00-IWT#:3LADG(X;HJ3;O3;I9?(!N
MJDYLMKFVHJ02DF@DJ\$!J002V#R;75DI76ESFTX-B&8_3;&<%MG/=SBWK MY5-9+!D(V%I%P
Y9P\$'PB(L!1GIH3.K'5!Y"TP-B&2^X.OE!MKTUWU1>+ M!N."8_-3I@=8!@3P9DV.6E@PO)Z45Z\$Z-%#45DEQ77(-
_WV!QN3;\$HDB3)82U!4B_6""22P%8XF1);MB;8I4@V(M8? M-C/74(M-%K)?,D)1R^Q%HJJPZ.S72TGD?O(A"^0-
&2*HH";S"!E+QNW>9, M-G;#I>RNSI^07_8)'LSS;1Q=I"D^K!OS&_G"!7Q!0)R=F.DB_DKU!BV;">E_M %!+ P04"
#I@7I9%6UC/3N)+%_8_%&UD="TR.#(T.3_R-5ID M968N>&UL+U;YIPPDZ%M8C<G;I0EN;7GRP0X
T7+@U0!*RPT&I)(CZ*KI<59E9F5G_<C^<^7_Z_<XR3_MZ6+K>=I%?L+I_A*(WS8'3^W_Y^<^!@_O+<_CW?_F72_V

4W#Q1^>I' M<JZQ-'LNS<3##/W TQF%U-IO I XQGOOS\#E\HLPs,IX<@GPI_>S/^ M\4R.+^8?2>84.NW+7I
I-^00/HH8 G"+ A0J\CD#D)H+((Q(P7I?I- RIFW MR)R&J*0#E;(I\W@"M\$FGXA0FG^8?_AR_ OG7^B6&*7Y'TQM-
YI_ \VUN9K /M?_W^N\$ ^.^/5ES@90AI/SK^G >3WRW?_9?V+ROO T\WV\H /?WOSUNE@
MW1O18_GW_0775ZF"IP_!A-9V&4;@>@X7/LY@_OHM?? ^2WCH= '4Z_ M? MQBG.Y@0I.H7O-KZC?@?+MT'!\$7
HDK_ZLU_?=?>Z\I?F%29JA_@!RW>+ MEW_ \85Z6 T^SX+K12O.?
I!P2XODGS+Y^PG_!RW1P^6F(RYI)=3+!L1+^< M<@6E*YS_NW\!P=CNB
@DW05\$>BG.*HJWA#CND\ _//_9T'&JZ&LX;(5S^I M*=[Q91BT%/#*1S=_. \@N.3+B).64.H\AV<2Y
/\$=;/O.0\FXQ'@_0JC2^ _MG^I_ I#I:;%#7C%_HV\4?UR^V0(I?9CC*>+U(M+ <8CM.I-PWK\$C6^ ^#D\!IGZ
M@\$D\$*Y*!\$JZ_5U: #_T4\I=I&U=9F2Y9GF)Z=3I^ #V\GT527TQEI\TU+UO^MOA;8
3_:X3W\$ (=X)DR4(7^09<\$BC\$S@D)J_32EEG_3M\$LOA\N_!P^KU_M9#F#A;IOM&R7R?BR.6.S<0N171-
_F/_RW7B2<4*^OUJ_@S^_0W^4S_!H?9_ML_I0?S@>S4AM?QIBM57H(<+S^F)?PJ^FTE8^F9M KI,IF?& M2Q)-
I_79\!(&9QF2\!F43C8D^4U_Y12WA&F<+6I,8XH^_ZERY_N49\!F-SW%2JZY2C*<_OPB7^_%.^>Z>
I\Q\+Z+;+&W&^T/6Z9^79_M5A4X4.#^5_@718196#B120"/\NZ21@%SDWY)_MK;/7D70!"/\N\N_\$,IS\>(9&B?
YT;>V=6!QZ<-Z#1D_L:E(60.R?^*G": M>V08\I/>^A^E);?K3.#^B-V7B7\$08EPEF\U\&.;D3E5\$CJR:S#9JL\VOBPV M+J
V6&_VH5N!&19Y30<B7&UD^P>&6\$WH@L6^N=X1Z\EV2\!E%3M61=119:U
M9UIY);H0O^644R^XG1A7^18^\$11=R^XZRBG0^I_X2K\DY^PQ_P^F8HIE\1_0Q(I5@1X-\$IBC';(I3P
MOOAN!&19Y30<B7&58+@7OP&NM \@4RH9.W\!P6)#L>T\I(R.(#\$X.PY\H6
M;SH1O^644R^XG1A7^8^\$KQF';E\1K:24(9\MV\6(3.10\^6\ 26E'\D\I2I M&\%;1CD-@EN)<95@=^ 2O<_!NT%FO%512
4Y^\$*6&8>8D8&(H18)^95NBW1 M6T8Y\8+;B7&58^@%6U7-P\IEM8\^XY/00/M_XAAX@QJLU@PM^>JN&Y6
MH)913H^@F<=>@X+!>UOQGXA4BV@H1\6\4\X\ M-/DE\$%<(6;AD2\$4Y9^T_*MVC+**3#<3HQK&#XLEB5?N370S!
(MRK;D*\$\$(33.6S<08=3L6/9^*J8>GJ9O_M8GC+**?!<"LOKF\XL^66!<@H.MQ/C&H8/BV;Q5W\I-
";B\$)B1C21H\R")YZ:9F.M^/R\$+(9")(\$C\I\$; MPUM'.06&VXEQ#
<_A_/XN@U\$LO4T+ITPP40^Q.O\!/<096(@G0F**PQ_!6X_ M;QGE_!AN)<8U#16SU*O^_KRHN02FDI>%.U\I?
HE.0\A6E)#3MKH)9.8.T6D_MMXYR"@RW\$^_A@!_*TO\!5R>4T&&XEQC4_0;26KN\Z.7R@C9Z_@>*14T&DU&O?
<%5_@!G\$)DGPW90L/PCVP_MG'=P\X\VO%XI2D?>V_1-R#)@035A\I_)T/L(0)MF(U%)\DO_!F_!T^C_&.8X9D0299
M6H+^M \$M8#HO(><LW/J\!@%;+PO6#/AM_!A=DP_ ^K>2C(O)H^E^6BB^U&QE.UA=3&1CX9C@12<L;K-
M\ CP8XKNK;I_ M;^>%LA^M)6+(9/R03.11^D^%#*7PU;HAR_>%H/\$F^#G^M;+!_P?#\$F8K@Y
M%&D5L5P4F&\$0G8_IRIQ.P0A3(@R6).1.41^5^/A^8-1^DPV^KN^--X0H0&M2)(29I)O\!E?C6:3KV_&&
<128CH57B^IC/6+;_!A4M8MO_#E\>9H\!&5SW\$5BL/09CS+)PH&V#)DU.?(\D2O\!D M#BHAI_!Q:_^8?
@3X;Z%YWS!*?3Q3\UNOO_JH+_Y00Z&EJ2LBZT_MVSA/MD1_C-Q^X4L#QM<_?2)L^RK4ABE;^Z#>T.OWD\I_?
XS_*!7AINJ=YR^M2L>503.064R+T1PJ1W/MP.?%LM\^K1AUM8JH.MIY.OX\8W\!D)75IX\$!H\#_MI^U&>14C\!^A@1?
CWIB\XAR\Y6A70_D_U^BRTA\6V\O7><^>S?V%US(I_XZD:M4\$PIS^!_M9JYK\!L6^18Y)\Y\+CKHX
IS=AZ_ ^+Y/\$B\$+5.J^IC?)Z\$V)?SX\3*.AV=" MD;\$M:E8U\ZD>.9+I;2#A)(C;JV#.2RP?
&^X%_ \D_L)KF3=U5Z=^ ^I(NPN@<MY&RF)G.F=8);3/MW4@_LY>%OJBD;A\ZZU-E+H_FG=??&D^BS^EAF3MW-
MQ_00Q\CHKV=MGH=T50%DRZQA<>R2007_MSW45T;H.H\HUQE.0H-
/N./8186_!HET^_D4.566WJ@B%#5+1S_..DT2(*MY\H\$F->?B*<O\MRZRJ^X=8DS=AAN=C\J^I#_S;R(A&G^ZA("5
09HY^MR61*;\$#U04%/A_!I=DZF>H;ST^7.#FGU>5OD_ \$?LXLWX\!M/8?3U+SE0)(T-MQ50:6)S7\$
)M++4GB\$PJE+ BUTUE7@M<?B)\$R\8-7D;A6?KG%JO_S#X0I7
M4YKF=J6_!I(X)D6+OWD\!D1>5"\$+!1RV\$!ID5#UGN#G@C\^PMR#;\$1:06
M>"YP.%SJF8H^!I82IF_AZLM^.@2%)HO(I0!9=%BA;X\YJG0N\!8U\!Z4(QI
M806+_R_K.2_X_?/C19C@I/W5K+7KQ\>F2O6^"%_YRM1H\DR@/>@16.>_1U_MPKJ^F;T%PXFWD\$;I2@01K6&
I(")X=X=I3QR_ \$KV?."<60\!32^65\Z MEAD<3Q\Q&YZR+8YV^PQ^EP?C.PU\!X4Z^I8^#\!BD_U\DYL\$SR\8(6_0
MG\$ED\HL@(\3A^H^3M/B@5<^FPPX6-HS\XDEN(M(U\!4^7MBJ; <4SQ_H;S_MLZRTBH&9>M9\!D^MSR\!+T\!
I\Y2S*;Y\W^O>%>_/I^V\!C0<%09;)NM?^M=9V2_3\!^H6)4M\!W+B_.@K).0\3>@>S8>/0+Y\>-D)=0_5!ML;
H\H.ZT70\!1ZQ=D\H;>JZ71RA^44AUX%?.^E+\$LB_U5Z;RFD-D5M/I@?G.DF=A-U6_MPG;0G(YR&5_C/A_>I^"&)+_+4
W4\A^G&J_#RJ#IC\HR4>Q\! 9PW5C_M Y?KW)3&Y\63M+3U\!CK_!W\ICJ
61&_2F8.%WL_5.0P+2KNNX#JZ<*@M8"> MYK;@AL2_ ^Y+ZT50^D12A"(WQCB_9K^4BO_"STN82E;"05Q5>.2^H&-
KPB\^M\!D\$#?@LUIK1HDY^096EI?TQ.*5_Z.O")C_@47.WX&Z00K7>\$N^_?OP\I) TK&
MG>39L&7%LN= \X%EIY0BR5DAMS6(Q>G\!P.7)HHD)28\IC
M1H2_SEO2T^=A^VM@%XPI^T\$W;"QQ1+!NFQZQ^*.6\$ _W_M5=;T5Y\$;)/F4^000^
LO/G#OA\I)^_!@6@;MKBXT<4KBZOAC5H\GYV@9.Z_M@4WPHEHXG\&6>E_BLCVA5MM\!L_X\!P6K1_M#P\$-NV
M&\M5>9^X>D6R\$!\YZ_W1Y3LIBS+3\!P2LIX6J1^Y\K4T!
MCX1\$.R5Y;FT%W8Y^VKJRIY1\I)@V6>D5VSNR6@;1-8S^9EUMI\$WH3EM+6D^0_-6QC>VPW?3J=7F^!\FM0\<)X)
M>&V3S;_ ^0+!5;DN>>92F?>BL@9#U^4S#5X).DRIQR\OLV_MN\!\$;7WJFI>&71(?@?R?
87B%&Q\K\$U%7^4GR34^Q+L\I)C&1D.9TY^XG+(VG;_M%I3?I**U8JUA7\9IB#_@IZM\NJC87H_R\YP-
)NN>E+;B20\J2V#MA^\$SGIX) MEU(I_E)\4XJY\!I KO@^P9TJP^F&O;_W_WK_+\$X\$1\$C;TD2F\$0^E9T^"WBM
M9&/_!H5/\!2PY>3MF>S_N9K.Y@G#OXW^_#E3\^7&C_
MG\EL\CA1YQ\B2IGM0^3;S;RZOYZ="6D^195H4515AK1LA_GH^O.(PKECP\$K\@^)\<6-3X;^E=KZP)P2;5MSSGX#
M\!61K;.%M;)\!XR)'W^M.49GD^K)(+@V7K1/LNY71BY;=(!_R.(S\TP7F
MJR&.RX^#;3@_G^#Y_"D8EWNJ9_ UER(X72\BI(F MPI8H_VD_T_U^/=QO^ \+H+>GC"DZQE(6P.=QCGIM3LBT_2F?
>2\J;Q;/R/ M83H\JK;V\Z^S\#UB;(\$;\$!9\I.M8;EJ1ZL\!M\$;_M^?S9U;D^HJV>S\!K^R%&;129\GKUCO)\$2C06L72_ ^!^+
M%*U)Z)TP_KGT9_=F1XVREY+Y=H/P4B#Y=;PPRH^NC^7T_P^E=K?+6^I_E_M_V-
5\>*K;I^HC8#;DE8YC_YAZL\!M=I^E0>*C\$>DA">CTE=LITE(87U^K(Q MI58,I6A_-OXT8\I
I2F)LVRS\O\!+X1Q@(\A\2\$N^V>AU5T_I16X>CFB8(7 MAU^TF>X#Y-
OOH\ZLOF/>_U8\$13HE*7=QHN8(7\!K0Z^I>8\!^1_ECHHE>^
M=O^QK8\H\H\H%!_BZ^SB\O4H_P>&R>SG;A>37\YQK38>)R_-M5K_YBT-?(\
M;\$D+*=*EW54LDB/78RS\B_ ^P>9\!/>#VA;<B(D\A47\J1DA_# \$CYXK-TE1=);.XZZ_ /=1G0)K/<@S\I/^W@R^H7)
M5X)6TTD^D7T9AO^Y^0\!@&F%+C%7%T562Y_.55+;_!KGKES49#^W^6\!S\!D_M2^: ^+DVCIZ\F831(
P\Y<=/_@U\$8_H\H8C0>GL\^_V\J\!UY%"4ZJ(Z@LH<M\!T\&.5^EQJ8447_CN/^*+H\T>NC8,N^S\!A(I2SKH7I?
RTBHVE^RQ6.MR_M3.TGH.FS\\$\$\$XTGA(2NRU+_R#@OF>FF.FP8D\!D)UUZ;
M2=VR=Y^VG9K&J^P&G\#F8AR3^G0@=^L@+YG9=M)K6-4U5\!E%U\G41Y/T_C3_MU^5*\$HS;DI\YP^P)7@
9Z4%3%@R^YC)^<GRM^[\ ^)=.90N);_R7J\!>IZL9_MDE^OXY)CN.;N+X\3&\$Y9(YD9>)ZDU*57T4_LY12Z+^_C%T-
HXP\$FLFH\W4_M&18D32?5UEMV^"T4.PNF8)ANY_E\$05MQM)7R_P3MBJ\U^D\4VCI^W4Y.4_1+6T8@C018T.?
J4_!LR)H0RSTF)SO(M<>(M_O:~T+ M\ZNBIY^161MTCM;15&0S^#(R&_W")8A8TP97\!>%K=7.XIU4(ZW\!CZ6&3
MC09^_A@/79GG3V\!7GR\>42FBI1^?+JP\7/06E.VYG2^DQ_R2CMR;O?<C/W_M7H_!^HP7S^UK(??PI^_LEY\)"&H
51(LW\9A=OKJ;S\25.^OJRP)IZ/9TB_M_9\K^QBK@C);"!\$L9JBD?P+068;)PN^OK^R\2JK_!K;I@SS^&Y_KY4C?1.U
M<6UYLO^W7\DGSCI&X\I^ ^3Q=>CU+YM&/(A6\=9GZT\IC?T\$J54\$&+=GWP_MX^1AP.FFE8E>
(3NIJK=BG2V>^DI9B^E5S+6=O^+M.<2@A(M^_!JYXV54O>V@_M\!SM5O>TB\)=1169X^M^H KI06\!P9R^9T;

M=A%_IZ5/7TD_M_Y5:IM(IAA5:QS)Q02"J_).P\A@_^U>\$05\$ZVMV>RI Y/O>IM)I\$ _506V MB\R.5/7FE8EA?
A3#_.IFNW##P7&J0Y\U:6T3DND00X@NH>MN7R1:2.TK5FPX_M@^1(EK2+A:K-
T(F)_.%A6X"ZE+NLZSKWK;E\c#17:\$JK? 04R^*/#BYJ3 M0-N=@RRM<*@+JH+B0^1JZW?
2D15&+JWHC,IS&E"\$8T"E&KB6WH_QF3\$O MD#07NE7\JZQV\<::BC;QH>_P\,OO85Y*Y1R.BOGU) MN?7COQ\$-
LM2#6:3Z>_2WC6<4 U&PE^?)#4&L_>^E0+K*!_JHV6J@1M:-HGL_"SY+AYLVY ML,\$\$;RNE=E_JH&
CY52VP73MY12NQ-'7=(KIQ'PL5)J_XM<_E+H\|CY|BYH M")X5B"D(4C%:6F>8<_4VJ;
<|Z+7(^84IN2E\B3@LCG\V2:-HDP7!E%_14VTWXJEC2NTN0CYR2FV*(:%2M99.N\HKHIG*Q.O%0J5XYJ5\|V\|S MA%-
H^&^M9"?2TIM0A1%,Y"XKW?4>P>Z S16^(G&5FJ176J_8FDU\Z0EM8W M4<=-J7T7)G4U_(P)\JN?%+1-?M*
(^5U"JBD)D\U8F6GD2J4[P04)*+A9N MLA&L=CG%DR:U&H\\$.C+016Q>:<7I>1\$%K-):^#?0(XWU>2-VIZ,%:2:V\I
M"/RY)+7^\$(9AE/#C!>+LE_KNRD@USK-/CNQR/E(&DI+U)"66"Z"3Q=22UIB\ MZ>\$F+1R1K\$3V>,>A-
Z#\$;..UJ\LDX"LIY36S:B>)K^U#7L=5.(T177R(M2 I?@#%1:7I-EIF-F?QZYK625D7:NESDV\$KQ2
_1L75B%LZW3KE\IRZ13HDV ML_S3EWJ3\HX8+P(67F4\$QOM?S>\$S*SE,CD^8HUN^XOD^K#L;-
M!:=@PB'&3E)+FIUS3#YAP\+EN<104%&2%"E!H7(N>8(GI3CL6DD)O.K9^MP#A>?JIT%38?
40QJWK^,@AQ,"3\WJBFC\$H7'@)\$G6M3OJH%G2D/(13.25V% ML*TO\UZ/Y&04H(&&>VB%02XH\|'+U2@OH7Y\I
M0JAZ&YU7P:5:VM&ZUJ4\NF<8MCK\$>R)EAXVD75(\$S">Z924";2Y9<%X\3 G M(#)!@@@L.BU=9@_O_.E%9VX ?0-
JLI P>1A9MH):B&%QI?_8SX+O\@O'\$+@ M.8 J4KE@9";B=T+*HZK*"L)O27<HZ>'?>H&4!5\$9)V4N:P;J2LX
M'%Q+Z"QIPL63AF1K SU=(CBA+&27@L*LM?2MK99.P\$Y_=-J3T3/YP'(M=A^MO&F:#Y=B^;W>KAX?
I9.XDJ@!!3U\G-RS&@?1IF*=R&8E\$6VJA_>Z0KQ+6H M%X(VELBT/99IG?IK:C"=?YT?H7Y\|-
X16X#HH\=K/W%!=W>LVET\+HJ2ZC=P&J!6E%0&(J%W)9B=TA1?1!%@OPK015AP%R*._>+3 M!=FW?
BRX\$WO=CX#Y?2UQE2-QXW3(IDPIEM9;-B 68R%&881.CE:2UO"LEW(L MV)-
I'+OXQT+,IT%F>D\$0Q9'=KJC'3C17NQ0&542S\B\H%1Y(<=>".W'0\5AP M%P'V\$-=-
<=!!7GQ\$1X:5D%:"DDZ#MR\7G2^3O26=;9Y\|P).A:/AOZ&@^UCA M5RV?ZS4L%N4B8\ MUKY>4D\$,7-;
IT95(40JAFV=IK(?R;5B'#6CH(0Z\#E9\ M.4%<&BH= /9E(SX&|HE,Q194=E"/PWDXTG)R'RC+UJ_&K0RL39"<>\$
0W% M1>D*!_EA\|V7JBB\F8\|HB>|B+^7?IH3VOK>E\>C//@R%=A/SZ\O(RS.CG M8;ANH5U>JH"TV3+%;-
_5MJ;..0@N<-#(@M_ZU_OH6P?JL3Z\|9+6J\7VG0> M@,;+>N?JISQE1%GS&JLS_Z\I
N72M_9K1\ MQE^SWCR9ABFU6J0ABC8_80 M;\$"23Q(0.6WE,N4DE1.8FN?_I0#OFS"!J*KAV/&+5:O@:X+E\NGKP0
M;B>JY;M0K#W*^(\)G^X_UO.HY5YN0J+M.H)U MF4#6 EGO30;B,%Q;PNV/B\H\ SXQE:O\I
(H\Y8":OFIO"O/X3I&J\$LL72 M;+QW9/U%2Q9A+A>5EOGF;R4+\$W+KDL\PTU:@\MSTX\|Z,B\8/M2'\$
M(G_>@9\|M.OFC:<)!#;_*^0"EY(MB*AK"VM6P NK@&&BFU,O WQ?8,N^)Z%
M_=+D_R(WFCI80WZVWB<_O@,AV?"Q,RT2,"5R;7#;:DR" _0J<,+45K5>IE9
MCGU"U\ESN.L#+=JREFS:8&#;.@@WRIDBZ)%?WQ9.#'1*OINZK&O?@I+U2^J9 M3%;DJKS120=*,T:^*
IUB)7LE96TDW3PAYGC3.R'E?Y*Y>Y2YNI+N7GX*@TGU M<^9DRN\$>E=NKRQ7%N*P_&6\|<_!<I
(#TTI2=T9RT?H;.#NB\$U*/AJ)? M50S=2C^>C6>OA_WTHW62OLSXPUD0I&V%YYP"VJHSF(R\<2YB*U7CLUH
M3E A#A3YJC*80Q(1UTSWMD@82UO(S.26WON:AG(BK4*!30+E=J'2,%DTK:3CN@:B;5@:C2;I MOMZ*9GB*%;W
YMU\H\Y OFT\|)d6\>=T.CO G/&26/0% 5V104Q))\FI"IA,D=)J6V7NQO:8CH;S7I2FE;5 MS1^YAG29HS\$NOI2#(?
DSF6_&897^"N&Z=5D7DTV'9<-TR\CVRX_O92NMH?7 M<^UKS_)L5#Q\@VH1"1@7 U@>S>^K5E\I
)K7A12B_&X\FRV_"\|M/I|=2" M'A(-NL*H=/(D\|LTD<^|M;J8.O#UP=0FV\1E^ZY_?<_IX\$!&/_@6MZ(X
M*20R#Q;KE8-EWB+*7"8\HB9%2=[N]Z>GD?M3CX63T*R&7YZ(PSZ48><.B
M^KWQDX+RF62E\ XNL+;8N.WH4U%-E7SX2I5G3 M2Z@=C3WUHEH#L;);YE1T_A31N:CX)XF!
I.OJ=U4YD\&GD1U,*#I#7M"+5> M_(\$46ER2:4HS'LGG6U\H<<3JDE
Y.S@)4")FFR@U@#K98U+&X+A>AK_TX\OJC2D8-Y5?X\|LW?YN;\U6: MW4VN?_!I7GY0@_7C2=EJA)B*
J'CF@4<:B\$JDNHPP=\$LJMI=KX\K\|@>8\I
M7Z=4YB9(OH%\$8&)+W+).1SU)P+M/L7)@SG,JFBI/V#>:=!_1L@9%IEN,@U MBSHJH3I9:DI-X);+JORMXO
&O/V*TG\JNIR <2I&&2BK28H6R_AC@8BXQ&,M1RD9JWEXG8\EF'NWJ#O4)Q;I&6\BL\1V9OX8O=X"DB)A32""M-
T;?(20 ME 6.D7DC+D#G9(+R/O\J OD+R\9=;XR?L#LXO:G+9\+I;J8EI&&8 HN=LZN?)T@VVR\I MG>:NL\NB?
SFUORN+2AY<.2^<9YB36=IY&U;J'= -;?I0&FDX1&5:1YKOF MG/0&X,*I_*QKSKXQ^\$14>U\;VHWJ4YC7OJH<^I
E0DK!"L2Q+>B_ZPD*GUL3VD%A#F*CCZ9 MP_-S MY4/8 >P1\2-0) <8FK&>)>5K'E=QIH-
X+V+)>8N011\$JW#VA#HR3.DPR)S MW)L2>TLX>SK=ZFY2/0_5VH6E/E7H>C3U6QZG1&
IC&X@N>Q@/#6U5Y0"KR1 M%E@+DJ2C.:1;9&K<)Z'=6(R\$TJ3^A&-8%A\IOF%YV6 M"#&Q.GVAZTU1SIO6?
MHE+^:3;.>2.NARG=K17CTP593Q:19E1/8_ZT8:~# M2AP@^AZVHBT(E?
1)I\|@E.20>P\Y2U8K42461C&X@M7BD?LEF/KO"X2/X(N MS_NIKD:S#V%VC!,FGSIOEG3RS'+B6 E0.!8)E\$3
5EHM((CVARN;*_9^UD4V?1/= M9PSRV\I_7U>:\|F%VZ^2QZC19<^OS\W#U/Q.L1"FLAI+0U6I)-?7(9="RE,B4
M"XKK"?4&U\T(S#E\6#:-VHF4J0""^|HHT2S6D^OXVUVK2\W
M\W2T8O=&.GLIY>U&"A6+&S)+\HJ03\DZ9SA^@3BX*GUB06-UW>SBT77C(' M0N4,"DGHP9#%Y:3T"L D5-
)U7>^?Y>V-GX.CEK?OHC#|LRIX^F1C(\$VD)0@_MO1#).I8UQ2)K<#YID:Q@;_*2J2L'4KM' M%
<(^O#Q1_8LQ7O)'403"&ID^+ZX!))R:3W@8761Q.IY/J5OC5G\$SJ>JGY% MQUA4Y@R01PU*Y)? "A%C\85\;-MG=
IROD36'Z M\7X\WCR1YCDLR1Y0:DE9D,*(^T93-)B+;E"/GW#H\+JU?IC@Y_@R? ^M\$=/CD=8VYKVU
XN%UL\DI";6H+=PO\T3QR5%((1W\I&PPY+)|J3Z_&CTH4/ M212N&O?9:SE\Q>UT^>S\|L%Y+I-
'7 BD.IK\|<7)9\PUCP*R("OI7%)T6:A FFKK7 D@;H"W\IG8 UU.\>BNPIXE4-Z.Q MFWH6%1#COLV M)&GE(H-#)-
S#N?I"-*OSO^&(W+LAK1;OLZ7)-|= %K\$7\ZHD>F\NPI5\6 MD&J%8.9DHHE:09I=!(&-3))I?
|<+7P2V\$V\34I7^F.EAY;AOX%>\$R?D;BZ+ M5X\$7\$S\$6U=)H.O#10D L5A2-5?N6901G)*"-
)Y#^D3ZY"=&>V*IT3BJON M76 (SC_Q?B(E;Q;SPM\|<I+X&L\|BSNC?O*!;-ZKQ;M;H/9UP>1K2-\$ MJ;J;?
*RHWLY2.&943U@F66\$9N"H"E"4 VF%PH)VTTA:F6&I=S>>Y125X1AX8
M;_>E9AKMHRR105TH>2Y102T"O\$YXDCHQ M9C)X;LDW"++0IN
X""6.5E(X\$5LWJWTF\$TDN(HNVD"5NWTL8Z<^;KAU;HA@ MF?78 5A/T;V-H)XFLM>4PG&?IC^J@MA8&;:2
9FW\=V""Z12R#@>?T7B\ARDE&ZNW8\$RQ P\$Y N>MJ5\3D> M2F6P(<9<+&\$-56CMC&Z_@&*HZRU
M%:XL"Z6\$;+((K4M/UN%&X8FTXE*P.BK"3\!MGS*X+#+YD^|U.:7(5AJ_S |F; MSN;5#6>9(*F8 RV1.H-
*>9:U&!@>501 TK_,\$2\XA8/&1=HH\>(H;614;:L)R&_W MM;V;|T>L%#Q?
9K6.YLLSOLV\3(BNJ@|Y\N2LA2"IFTPJ)*BD^VF@+|
M\$=GI^V\|/30UW^MC63F:YQ(@++6T7%2YH\|M@N"LRR9J;ECKKK;K=&VAYX_M#T9A1\|C\|VH#CA?
_FV^MZ\N"/&AB.7G\@V\$-89?QI*8(-8AQIK\$6\|K M%>/7CX/ST;_4J@L9=-JX8\T/OY.O=W/_1=#PKIE1-
M1#;_&RV#&L8018B:G?>^?3KX^OM)*1F43VE\4\5+WU.5IEZIU.Q=C(O)_M M\9S:(YUG-
N0 |TNO>)^KF9""FY9&LYN BQIEUQ0<*B_95;9KK^5XOX=>YI'6"VW >3\HXJ6"#S4>VIVG\O&%IV"U9R\JX^T;Z
EX5! M#PKAS*_XY37VLSI%\$5\I=2.U\0? ^\6 CSS@9S05SC@2R-I>_U\$O\$IXM MRUYK\B+5V&EV\$J)Y#(R\$T6T
LFI;Q17;\$P:GGDVG ^CTI7 F\I8\^32> MD^U%IPS&#"^+7\NL2E":DZF;F0"390\8RFFM6YM\70-
U0\HOJX>FX\I9V' M<_PAI\B7D\$G)#-9B00:A0%B5UG\IS-M2\KD/&75NK?I=D3?L\XUI*J?J/C
M"0\I-H=KYUIMMU(C\L@_*N*J\|DLM6V.9928F6I^;T878_&P6K4GKH?3 MO7GWNPV*K\|SF@?3MG3Y)/CX"
(MJ#B\8U+!*\$SK\I*\$M<+YA36I%4@_?'*^O MTKSE\$^W"*J"2YT68ZI@9(6F @2I2+612Y%\$,9*

IUOJSS&:"#\$%.OWDF6M>*R\K\+I*YC:GHXCM6??.2.M!%I!_M7F33D0&#:AO9AZXGO\A&153UL@L0M9&D*F3*.6T-
&%J5@W:;%DCEW>KK5YB*:MXZG6+BP=Z2(COG0#0%#%)P2.UY+FN\$3E+@.8586"RH>NO=O@KG>1L:T1D
MAXML\F&ASXML\ID 32SN_U.IABOO\$J0LHH0XIVH\^Y:,%X8UOS\>#.<:TU! MJF'AR%=A:1^B3%B
W\$<R^S0F(\$TF8D)(E:5GTNK>;HM\>5=AM5:075CHP3*^MFQWVRIV\^=1%UUMEPH\7,@%*<%%0V1O^:Z%
M6=IU!MIG5TH@:;CKH\B+Z^C60+PJ142K0@ @M'DSD>_C\@PHC.Y MHI:M#8UC*14G2LNQ=6(7B2?2125F-
5QL8HQ+Q91VM3\8 ^5H_XJ&6S!>Z2*"M_*T3N==7% Z(50RM=70\1:P\>QKQ_?K6HR4@%U\+;FJ#;XVF*LW8-<
M0W%1:ZF\4:VC%RL@3H\OP\3;P_-1JCQIB3AY^N2A->7X\EL_-779)^ ^G*W
M(7SV1\$;)Z2IKPO\^WHX\41)49_6:">4\2FT\B@K1Y1\2)=K?0Z"CJE"
MS.0PHQ#&F=:69\;S.KXFHA=XS(IV\$1>SB?!\-Z>KR:EY\|<)H?W\OA M6*?I-V+EAUJ4@(\^+V>)8=8I%K
>+2CT\$9QQ\$CP/B=P"1PMTZ^VN"?34M3C M4\G#4K0O.JS=#N)Z^U 1JM-E):\$.*0%9VT&H9_-RA2%L76*81/@?
^KC053V M\$!OOIO60#DE?*&1(9:A%K\$M6 9O\!(87IKTHY/X<=40?A2D-X(9&T.M.OVSKGG-
X\3,,HW8=7IN*PLG+TCE_/S"9\7\RI^7;V9\MR^1B8^Z\I\KKD
MFUKTIDV3>B%!D+BXXU3P\WE5,3=GO&Y\RZ2?^I% H5WF\F5Z#H\G>_#4DR\5(GFJZ@.1.7+\$.-,W18
J^F=81\N>QJ7N6,S\ M1=V%U**DR+N\ 82J\X\RM\EE\HGSYLKWC90S\Z0\^Y8S\T+?TNZP5,N9SY\$H=H1=?
QR9ET*ESE\("X<M*65H80_%,W#*DGM5E(\^A=+=(29Y)%(D<Q\1FLM.#U\$A5J1U\$?!I9:1B>20\E-O4^C@.IY?
M&I\!IGZR8V CK6ZW73\;\$S: M3^BE\B9K\K#2H9\I>_#1*BL8^3#V@3F^MA^\$S\!>0#65VSU:9CJP2+>HDW
MX\%L+H:7TW73^<7G\$Y.OP@C+GZE=UY.SRS7(ADEZ^%AM\!O2#ZPB#JIT-D MIC\!VW%/976=P/&5\I
(A7:Z7"@5_Z/GD;XV^R6LW@_64\J=M0C:H1.O.WOE.MLZ&)-GB:\$N,AN\JR/C9O+M)V\G\J\I^X\I-V;AY/3:3.ZD_1
<3:?!G:\$X\#1:2W8+1<MY,,DS6TSF^*2H0 M6M=G)?T2,8,V@AD4C\?Q^\$S" Z7:/PL\JZ>DN^"A MR^PA*!-HJXID>-
^N\!SEJB+<.,WQ\EU0G\^"L\!%6S8;-OWG8\X+DTEF8#3YCG
MVY3)E8_M*ZMQ_.JFB8>US^*2^WYT)^ WYOZ^7VDGP0CWDN7^4\I_T\^:7 MLUIF0W\TOL2\,U*8^H\^&D\J1?
(7HZO:K+FU>5EF^R\8 (@NA-)VN^%5_L M^"2">1%%HY>*6E:GZP_:S;7=^R=@:765IUE?#%>N^".GE&E1
^"M&>%0JM^ MXK:4W-H#H\8+K^\$F2+T^W-U;TXCBIYYZ&33Y\K6S9S2*?Y_)E\N4\$#FRA(KREM>I#I\W#6VY)Q4(-
O>MIZ)I3M&#^Y\B(F<3NFI,*U/=9^INZ9>_EL%474ALJ:VE_125X/9U\6V M^"HR+9)
T^P6TF5\:_RF5I9&3^R0NYD?18BV?/P+SP,8B:JQ6V\$W\)/J=3F9G MI_18D5-N\I_F3X0PRFO.\$C@?:&*Y7J^QB\$IRY2(I
(2D3MT 6JML^RBX63U>FG)0.9^(=70>6&^_7\I\B^*QAOPK^/_I\I\WC\@M31H M^B2C^0=C\IQ^G)8;XW)00?
E.V51W/_X6^W\@ATWD\$H\F4O+Y@+7\9R?OGPB M<5W6)L^"5S\9/*2 65D(7T4^I YYE")&V,K4\%-
V%YRK/J^QDQ:TJ\#I\V MOY2/BEC/\$U:8XF@20^@I+@@"!X%+0W\$3F&UOI2(Y#^5+T=5\EQ7T4MPQ&
MX\G<3;E^0FZ6\I-(MB: M9CBZ\OQJ\$9\B;5A\I/F;SG+24>IC0&A3:W*P0)D M(SMRBI^0CQ2X3^U->T-
ID^MW5%KCZ,6/22W73O=MI+I^?_I\P8<#^"9TH)) M%PTD:VK*1F#@K;
UL320A9\$P8NNLABZX_M32^6T=G/HDG4\I:S^*_J=Z1 M<5\=GAX=L/_V3+O-N7F^P_7PQ^+L8IS7-
C=S62JDR.M%\$S^RJJ@?FB5@2,48 M=+RHU@4(W=&U2QG8,-)U=,P&+:QG"\$ZX^J1^*IX\IF0WQTYIW\IPKMANSX
M:0-167S\7XS.H+?_&IO(BR\R,K7=WD@&L;*A\H@N^"=Q^FWS4HG5^RO.I MHZ,=
f5WOZ\A^_>IDJ+L^FOHZ=V.M^_I^HC^N\I\W^_S^T^W^_PBWA\BH^LKR80F^A9\XL4\B8_U7(MQPIUB(
L1^&JMV^M^YA^C:48\B>AA?WB\A\I\$^L+5_/C6/LTXNIR, MYA4O-P7^I\4CF1:BH^S&M
LU^J4+N\$3KGA).N4+(K>Z4^W.IG4&^I\TH5S_T
M\19U7I^F8S)&\,2%PD#&\$#/OZEYGN)9%!QM+;U\4\$;H)RXSAPF^H\IFFX3 M_ ^ZOD?
NH\BAOFERNYABG%99YDIH2K\HH(H^3.EB,RF3Y(RY)5^S1Z GIW7/MC\Z-?)Z:;
(8G;^>3,+H^IL74C\RN0T/C:9P8^G^%59:O6QEMI>*I\GB<1 MR3^RNIY%6=JZHL\07\$%D^FCC68,/"DZW?
-(1=#16TPZ^C#6%U^82TV,M#>32\I:E1<I+V1GM46+WK3BXNP<*J^G\$HVOZ\42=0S4E;KME-I=I1#!S3
M&FAQ#45LFS\+3UM\$5V33A=4VA_@&Q\A1QB^A=N,3EC9\=TW)<"C M9)
M>L&LX^7X^EO^HP,=WT5HP\>X+V\$VC)\P5W.35CR-CZ0?U%;M7S-S^/A M9S*\$KR^S?
7T^P:E=L0SY,^X4@Z,3&05A>3^G(C:BO^E9\IE54^UJ7<=I03T
MH\$H1MRY\$63I(OUQ\2>./I.J)^_&LYM6Q:HXR7T28+3P!(T\$ \$9-44)+#)T^*
MA771@D>&.0^26PJRA\CDQXOQ9/8\3B\G9BW\T7P\<I86P44B4+K4(,"+VJX M^-&7/8_-8.M:EK5
3L^2/US^QZ\IH>5=8/5DZV^1#2F?@/2^E.# R3>@I&_ M^5Y2:_\$#EI9\KH \$I(#(5Q#^9%IDKK^HZC^L(CIOIQI&
702?_P\S=+\$Y MI^XA2V_@EV\,5 M;?<1+72Z^Z:>-OUU>)YFQS^4JZW4^R#H/M;Z==B\5BH+M&^5B>2^1 V1^WID
M:M>\$8-I\U\I?^(?V27/P:WN\BW\I\KJ=;I\CL:(K2
M;^"T\C.HIVMH\K<)^SGZP?M>WK4)TS+=NPJGO:V18B>9G<_G+%^5.MQVJI^ER0^EVD=LN2S@(*)=%
I3^F5%RJA06MA^M)C^L\$CN_RQ=&?*<1 MR5D).8>H.I<=P\IYRP7O(63)03>D?I1-1C^_
)HM+5:;Q1M6;T\$VM;*+>0\I\UZO6(TF_LXI^QRTL3S&LAI_I^X^M^H@>G^ZYH\7)&?J\5JG4AU\YC6^AH%UP=
BQ^>?S\JC^W94/%O^XH>P: M+L\$K>#)S+H3H("A^R^/J\>2\I^R7FF:;J.Y.WN5C/@<,-FVIO%.XBLE\O\3\1UK2)\
(C\I04LA1C8K7(1.%I1B\$VNDG\HG6)=G#I@C M+?G-L8LY6\I^J^Q\SSJM)W\GINB\$(030NEZ+H.&
(\$J\$4JQ4(CHH>^I\W2LH M3H/D R3:=Q;*W\I^P^E\$;P7W&23C^96?I^V&&I^E^OY^JC^S^B4)(I/#I\WVM+
I\AIE)=+;6.)KG)KV\H(M.G<=F0M?AYMI=M)@"I&6F?^Q:2E(OTSK\DMH7^W<4;K&\7/Z:2GF5?7.^I4<2^)
I^M^KP^8\+U+FEI\51+MBU\NI9\RTS;CK-#>4CT.<"P@*.8D>*4C&(W^"VR^T>7B?P/@X^Y_-&B(2W2=JQG-
ZZD^PVPT^T>T>_O^I>:5BSSSF?%H3-
MH#C/984(#J1\$N;Z3^M^D0U0&H<@Y?2_4@IK&^HP\=8 TOH(4I/I>N^&O3B%PH16.LY\I\$2#912F01.I^)>%: M_%
I\MI\?%RZKJ@^E83+^=BK%MRW3\B\IXR1^Y)Y330: MR.2RU3^6\$ \$QV8^EIO9=;)IO: 7CN^98IZ,
N4CY^@B47H6#Q&@JW&I2+GPB M:\$).%800G)7FY?+/-L%R)W8>3;#<1;0\1D\:/6CBH\>10%)9U9/NQAY5\$D2
M10&S<-)JW;IGZ\W0.MKHS\0OCV<26H_-(%U\?;FTGSKJVO\I^X,=L@Y8Q
MH6^I@QNT7O1@%SDWS@B\H\Q\QOQV/5TB4 M&^8T6\I0SN2P#8\J3@;-(A10^5F@G8X\SUHI+S\$X^<#16\ M-
MPSZ@KTD\<MC/L5:./4TGL0A5A_%^.,T/%8^&)9H1%=B^797\K>, M=VKLMQ)MGX^&8\$^L-?<78-Q75V3&=#4TIA
3^2@N1T1<1HXV%<60,8V^E7<8\ M.2H;B:A^*AQ@;*0HZ\$)CZ\3;=^5?>I4
MR&IDV(9)A:OZ^A.O5J97=RCQ%F:5&^+NE:1^3WTD_-2.4G2;W9X\I^?_X MI9^*J\$VS S@Y8\I^J9\I4CZ)+%Y
T\$4D1\Z\I(M^M^MX)T= M(I\$V3\I^E\,;>:R\RF\$84U_?4433L49\I9P&57J= \$-#M^%.COPV M@FV<,7@?
HH^E\$R^,BM^4^_9TG3K\7?2Q\$^+R@0M#>9=VKLMQ+MYK3" M=B:2E,P^W)JP_-K@Q\$M.6U-
C%F:,E082IK9I03AG>I^@XW,FQWT:P\IAO M&B3^XSJE7ZXO)GD2T%:H^K1"LIX\3\I&+) \$IK0S6.3N\I&\>I^3H;R3:-?
RW_MB_0M5R@M7ZWX)00"8\I^G^N\$K(AJEL\4TX\X\$YIMJK6>B=#WFVC^R_#<2\I^K^MVT7\N^Z
5^L@0V0Q>"&AD#E26\61<1IL\B>2DR>?VPNJB#Y:=YO%/COY5H MU_#2_-RW<\$RM?4>@F0I&Q6-
GORDW=*VU60Y)BQ28J\A)+1ZIV?_I\WCG1K_ MK42\AO^#XGUOWO\I\24H\Q>
(W7FE5)3C@FBI\BQGB2^PA\I77FR!<4T^@&R)T:8JF\@SL&2J6^0U:HZ\I^R^0SE5" MI86^QONX\GAYN%.C?
Q&E^U?2O.(H^"S905C,5;H\$&7VBL^8@0Q(W+0JN4 ME\IN9SM@W^G1GXCP:XAO\UT(D+,%1KVR-
=/\$>%8V@.&LEC-4C(8\I\H\Y.H M3(:=3_TV#W=RY+<1DIHM3C\R38-
>0WS&I#E(HH597)V6\U.246\FK^<2\^"P%4DU5\$,RC MUSLG^VP>I\M3C\R38->0W3\ICE^2^ER.,4#A.L4?
IDT)@PTO95J>/&FH^@Y<20J\$ M5.A^L=+O\$?G?/ZIT=I^M&OX;Q^YXS<@5\I(29#0J>L8A^3).E:BG4\IHR)*Q
MPIVCKSLG^&\>I\M38;R38->2W2_-Q*:57L6(QB13^@I062" M3%*W>.\&X<I.2+,"8-
^N2T8QDKA@+R6*OCL\$I2Z<5Z&1 UM^ MB\LF^X9\I\M3C\R38->2W^_(M#;I.SC

QW"K!0P\$4M935Z00^8(+JDG#19,(I MV+WLGL1WTBT: @_N& @W=L.R.P@HS-GD-P+FIQ5\$*6ER3IM:+),6=:Z?"3
MW!S1=V>O?>390|^_NRT+WXU'Z1K5ZT@3#FEVIB,IK_42M)+D;2HFH*860!8L M)>XY9M?|RMNMB\$Y# 1H*O?
<&#G=O,/@XHR|YL3B%*FJH?_XPVK.OBT=MJ%|F@X_K7C=VNVA&2G'N9!&%R\$M 0&D_0J4)%/& M"9I
UA)?G0E0:7V/ZE->2'T=^A9R#WT 5H_V3,E0?Z'&3)I0%" 9.B0*, MA102BKP(>Y0=Y*3H;R#L'BZ6N>ZYB|@F.
I0)Q0G#G=YG<@6>U%9A4 NEK>X)B M5+WRCLQ:9TN6EF6E6W>.:2@3222E%2 'W<'G,CUB0@.0%S#?
CZ6SZ#F=GO*A< M;V'"%FL-FZ|U; H9:%&4<%X*FIK;\$&NAG)0VM!!W#Q?-W^X CX*E^/)/#? MF|
<3%.|+N&W"5X.KBXX5..=R#EIT(S<(B55J'\$/#<:B)-;F|#Z;1BV%=Z) M:4L_M#2L-U|GA=>C_"9|&LS"<+|JW>GH?
A9RYJP:P\$AJ32@Y|X>8;HF4" LH4 MQU(?K64?1W92>M,#&1MKU-M>@? C3@:?"=YGG_8"/I=)^OK3EW11KPOX,)C^
M|HK^%8NK>ZT1Z# MQ^=R|L.ZV=:E9M|L_&0M0DP(2>M;N. +^*P|Q|Q<"8Z|/^".15X4C#;:>20CMVD7P/60'S>
(*#|J2 ML%T'7%9/DA<2N.)@6-3U-G<P3;6(15"1E2;TMU59_3W>V8J|A^"9H+O
MX9Q|L9G^B%".'=YPI|T3|(^EP(VG?U;F53L&L.OG\$M1;U%+;74*U'FT9 M'PW8Z.\$\$:Q75JGH@*LGDV;3J^M?
=R7&5XQ+@XIB|L(NM>#;UK0A)23Q<8;U?+F^QLVC>U MQJ|3|4_5FG?4A!1FL|E3/%AYG.#>-16.3G_XND#1-8?
7\$?&+P;2YXR)2*5HX" T(R0|MH"A!2#F""\$YD7-)ZUOX%| M'Z3?EH%R!#9|R+|8 VOO'4!U|L|LPKJ^41,6C.I?
EMK1\$M_-LX:@(|R'-1 MP)BH349=AL"3KSEE0F83""0/1LZO|&6/\$,J3J;:1 N.Q%8\$TQ MMFCP% C.H1#Z^QYISJ@7IV
10?L_O_5(GLS8.92JAX&4P^7<@X'S)DPO?AZ. M_|@/RB;6LJPWC@@::C81;:) "1XB|N)"CK#,6)XLHJ^W%5>?#P/I:
(WRL6Q8E#JGYNG=CT|ZRK#JL4^4 M6|+3^\$K_6Q@_24G#JXSYS?CRTWA4LX^6"68U,?
%._|%"B0*L|BEEGB6(@=Q\$ M|9@K7&FI>9?K0;J.RVH1V_R|V&|^35|&5Q>77|*LNZ|I(79U60P^_J^+ X5
MENE*=_2:CXLHJ|A|JP\$|X71@_.*0|WB6@G|=6@>@;<=CLO&|A>M6 MS|O557E|_#ES..
M/_1@:812N|5XF4F4Q|PWCRS|X|O/7=H@J0KR6U#Y|5T#Z?>^"7|_M|_-^ MP#0,T^F@#_#8S"l&
(Q^_P_G_7|6AV;:UWAV7&(E|38,E87+?2_O|FO M;VXC2=)W_B.W\$2+VM&J;JZM58M::6JZ4=8G|)F*\$
#@_I2_KUP\$%2) !F M A\$) \$)1-CT|LDC*_|SPMW#|16|9.<\$-|0?N|I26HZ9|L_JGPV6EN;:!!
M"YA^FI2A,WD5SE,,F0U5<4K(L9,84=:CZ1"8T M@;-#?%QH8,&&Z&P)?
-9V+IY#GEX37>@CZQ/EZ6D75;:.\$@4ZX|X|8FJ?;C X2 MNLC>25|;:K|P|+T>'|Z0H|>^@
;7V&^GZ(EL4&YNUFW@W@H|99I'M(Z<-P& M4.5B52G00*R|16R!<2SZ<*R FQ:*|4KBT20GXF.&H,O%J4?
3W0|7&XF2XHQ7A(T=82G&>P05-0C\$10%6?I MU+9?SCXW|QCNCY=R@P_5J|F7Q+|T79_1XH9>0D+C49;W9|E0
P#EPZQ|QFFVLND#;-)%P6" M\$@U>EDD#BF6Q@|72/3|,MV9%=WG7|7#>1*P5_X/Y;#%:SB 16H|?TO33S'W| M/
|N>M4|,MB56M0_*|Q_O:Q|CW|O@)=A M;=:CH&|:|+4*BWH|J3;5F/|@_IC6SZE(+N #&M,5B1J|VDK*M?>&W>
<93X\$ M|1E4_#U."BC7ALX1= B*(^B>= 'OY#<?7F@PBW,N_ WLR?F|F>"6E)G(F N M#^1E|;
\$8(@J>2"YRF\$#/KE?|L.GWWSGXL^)X:B|7DACM3|Z7Y/\$>0K_ ^|TVW^LGI@BW/6ZENPC^%-<2R;C;6".-<4K<88
QB3.&3*DC))9*Q65M4/S)U"0)RS6T^A"|J\$WT(MEB|%WN&LK MBFQS#1B(S8FD;%EY
<(Q#R9)"T&7NB7M,E>U=>_4_.,15)G+9DH\$6-SW2^ M>)< NNLT7P,RP1F3J0.C\$BW-
W2C83"7^F\$F/FEJ2_ NWCT|UV-O;D|3X2L_7YKV(|3G Z>"<\$C#3U|C|@=,4 XT5XK9XFU'5R9HT"<
MR>UNG=N|82E|L'WL.V*|M=WHJY31N|MK.+H^AB>Q+=M5DCN#ZP&M2J|L_@P M4C3F.9/H0H|1?
6YF547|)QN#JPXVTZUD|>RDC;W8?YQ|*|BNR,@N59=G; MG02|J_C@66-,|)"8_6Y8|Z?@J?BKS(|Q7;CS?^=-\$J
>N+FMKH|J|X*E M)WEEF(BRX(5B1AHN|J|<=K#Y2|J|<^|0|XJ|E|ID>MN@_UD,5VM|59X(3F@ M2.
(05\$#32VV2#=#|0A|XF-YJC26Y>SF. M4IDU92_51UO"BPS6^HRV|>:|ZZMKIU=H?
(27I2RMJ;X+ "W%W4OSR2=&0H8L MF2|CVU'.3DB(END@A;/9=BG';0SS8C3TW"C=;0F>8U'!O:>|G2|N^LVZQ_UF
M3UYN< C6|RE\$.%K2PY8H9"(|G\$659Q;_!CY|UOZUD|H|O+912Z+8SQ*%_ =D9
M*4L=HZ+@+;.%E|JC%70|H6XT|N|N&&9Z9_EBA4'E'HHZ|G+%'HHQ+G4|P+X/ M|;
X@8C30EA)P&N|*2.V5NT|F2(M;/%QM/8*Z/G\$ X&5Q1J_YX"3@_Z"K',YH|@LX| T427@DGJ4^T6K<|KXZN=?001
M_4DRODA\$)U|I:9\$+ 2*#@#>2%Q|/%H%|I3E2H/8;MV65|J2*Q=|97'P8;I&SL MK=VQ+&56(@|) \$XXKSQ|U
F_ \$Y710|S-8|JBND,H&+K4D@|+LS4;.%5X3#N+WX84|"RQS"4>I&?MHB_/H=2RF7;T MD?S@I9;><8K',P\$FRC5?
|I).4M|J%(O&<%DB^XU+|7=|U+?L(2B#|Y<=8;K\$U|O'+7;A+2Q|I#7|?500OZ>ZDFDB| ^KW4
M_!5W2<7#=#J\$71_|L(7<|+@ "\$-/DGCLXW25D^0WPNHVGRI^;W7W)?U-B_J
M_I%WZXO=FS;Y|JNBRPR|=0W)R7(*|@F&XTZ1<^""Y2CZ|0@M(^1T&PUP|R M';M|_R=_6=4KY(4(?
4BF"R9&5ZPYT=%@)B;" MC5D|)583ZY2SNO;5P|'7(\$DM M\$J2>5F_>|SFEC?B|,)#M;W(;|,|&7;0'7KK#
Q^W|CBKA\$R&"59>"3HQH M';VT'5@|HXGUQ^C L0)N&FS?;\$DM6GI@44@#;2M%BE@QPH_ YI&BR>DLG'7ZZJOC^
<6*=_3|?N^D-W.PF'_ EOJY|928<52-W%ICN%R MN71 DE*&2DXDJ^W";@5R05IPO*_|I
G;S*U5H|Z<^=H/P?)RJ#+B;ZZQM|H M3CCS3A@7J>G|<+RTS3M3UG%|A'|<@V;=W9 UL@RW8WJ_-9I?
8ZJ,01HA|H MGUDCC"R6|N(4B(X4|L_3|G|E-2B;(5*Z-J9D)KQ1/6Z_ ZT4?B#73A_2Q|
M=>_X3M4NT|IM6U=3+G(+%U7R>%IO^C=Q\$3X2/D*F)657@H^<@E71R4@BMZIV M?^_NZ(;W36IQ.AV\$D%9-\$|
%"B1CEE36MHY\$("&-8L@TBY)|S%DO/=HLCB M(A7A./%6;J"Z A"/I";=JN9&"S-
'PTD(H(FKD@|7P>F2R1|C<(^A;OEP6|C= M|&+K&YX|HQ4%V""N43V^|CY|?5R6.TJV+|>Y>N;R
T(513HHP#/&P%*"EKN;P_E3 MRW+R#L5@VPU_VHWKE &)|VIEBU7EHFHF^%>.&M|^/LO\$ZA*!!|X8Z381"6|E|
M4"9KP9.0|_|#ZLLMMA>D.X?OL=-R.(>L|033*SF5UH8;V6QSV(OLY-J;FQ;_|U*I9G2=7L>X59HF M=
M;_9A.M2L#)|#5XRC1CP=M&+C6\$Q= YZ=;5AJJ5)O)E|O.O.E|_@Z M=D69;9ID7'7V&800')P@*(F<#>
I93/M8.S%#A YSA7?N&1.Y2F2-9;1_5V@;- MK;'|Q(SG64,*E(C|ED|6J|^ID#ER'ZN/!=|Y:0IR" M_V|75N*(YVBT
MRP#8*#\$OI=#/828"83JZ.A;+5Q|_ Q#=#57AY*|>47PT#2Q2D|A|C"7R|(|Q|D
M2@%7Z|5X'9;_ \$"I2%E*UZ|EV#|A/33F&F;...)K_ +&05<&A9NBVL.'2GNAN9T M4>_#I'5DA'=Y<;|WK7=JGAD|Y?
H+=&1X=@|P7MI095R_6F|#Z'3>+9NKS|J MEV+O*U;1\$*^4(<8\$<^ADX8075;C8A/<^U8=|Y#|T
M65D7;#^K#WNSV*^>^|! *AE83+Y7+EC,PPACT"QGZA<19|(#FKCD'I>W2>IY# M|6\$S|>@C^<&K#
|GT07M|0'6P@74@O6'0@Z6|2LT|0^<Q=5?=>B+NUI5AWT\$ M|UCU|H1_X=FI?^|H%1_3U*%8IX)
(JQ4WJO;|6HPY72B)|\$S4TD5B>25HAFM2022M9BS"D|EMLU*C_/M;|C6#PD(|@|/|TWC;?3Q>J|C>3^| M'H?OZ
^?9?)BC?+WXRL07\$P&B&192)JE"7/8,W-MG\$?_R|G<9T@GAORE?_ MF;_|=ZOW2+-W/4|?
SW^M*K3GJX.RS+;=604-JD;M.E+|9-P|(-35 \$AQ"=K MOHJRY72\$ _>N3GNJTG&BH6K+|;R5K_KSZ5R;R+NV6-
;914B|LR14#8='V M,M)+2%S9G\$BBQ+6|C#P0|,6IV1#D/=8^T>3FE8T(E,EECY6_ DUMHJ>|<|'OT|Z3.@%+HB";
47N009'k,T M*9GX2ZR6.IK20ZNE^O#15&|N(3UIOC&=M|_4@1&E+E6+"";P"(A6.85GM";U M6T0=/_RM;D-
2P,9V1_&GSXOBD\$7KMWXRI*B8Y00BRH.B46'4HDE(A4XA*OU MX%OH|&.+ ?(M;I;G&Q?#6|:WFIS?
2I*Q6(N+,"Z|2.F#=#E\$C7<4 M_ D@+K U9>;HUR;\$5U=JA6/K'W8;A7X;|H?|C?QL9)0BWQ \$1B8(|B-R
MDT|E@_ZH2UX2\$HA^0PN48^2 M|J7MIS@|J(Z|J4C=PR*%+CK3^AE'E|C0MIN.H_|PN(+NX'1'E.4AL5P>/
MX*4T8#4EX*RGUC|*+V2B|HTD)>B354)<.&WFMDE2F|R)9.)&N()#_0GI0| MOPHWUL SH|9YS|OE=C:&>0\$;-
A1).XWANF40?YM.X|_|^""+=?+-9.\$FG|^ M^OQW/L&NLP_FB_|G|K_YM|+R;F-8D>4|_
S|M%1Z+7*."4TT<814G^WY";2QN^%&ON|N9;A*TR;V&Q% M&0QD<&VX\$G_Y_|"L_9#++7CH'O@#)4ZY?
C^VX@=60Z|F4/7QMNSAX_O'R'|.44Y5HO9 M=|H&1)*=P.TXK_E2N|VSFLG M#&Z|,3S)=5WA8R7;H|IF_VFDF%.1,
(TV3+|FGG<|K_";(2&3\$R4|MTW;S| M=+0>3.0.8GM)L8\$WLL&Q+N;<|\$_Y8^8F|^OE_C\$969;|!
I=ZN|J=ASF|'98"4M=;EA<9* M")Q10ZD21M5.AOIQ|QCVON&MF|V6|RKMA+>O6*(>X+|ZVIV|6_9U9+\$#-10 M=!*
<|Y'*\$|Q_2R48;|E|OE< FQ|J-M-86 M&)E8F SKPCI|(Z)+TO#8_7+HF=U|="|5Y7 M_TDW\$P.W
7,2|T"Z\$74WH#P(5)N3GU@SE*!%0@P;W9H.IQ(|MU%PEH1P;= M;M+%@PT;_WP7PS68M|I?

770|+U31Q/MT&3@ASVA-BP#.K M0'BM7K+=+88 WL9 'R.?J2Y4U1*M
+J48@4..*3'"QW2=)HO=2U\CV(WKNNE)1WCMOVDZ5*+VL=OHQ_Q?_TE4(M-
U1N2C)XO+_X,BISJ6<G/GIG2GXO7G#5PR17=T<_+IV<-R46L\Z>[7WGU\ MKF1H&3R8P()^3I, 7N9BT
45!=""Y^J3N&K@JA?JW?V5J(Q)R+F'C/8MZ?T?IK^FLI?7 M;KZ,ES\CHB<..(VL-%G-X
6)0)SRRAN=DJC=,J4'O-^E.LJR,^R(V;M&M^K M>S24.ZIOW=-8^ N<%L-INP\42C.UM1WUW%JO%V#NI&N.9>4J
<37:!!QIX M*="I'OA!J^>BW")O;4%;ISU;(>=#70KM?IO;V;ALT-C\H4 M/D^FU-
/WZ\F3V"G=S"L\H;Z3,'7*P%X6A\$HR +,,P+G7#U.<8GW-N.K\I, M96@AYP;[R\!S%],7--OO,IUP^4-9\IP9
BR,;@HB,E6Q^!\X8I7\HTK5/E;V MP+EL);G%0X *B#UB6+1E(9&I>SEZ+6J,(QHPHK\TQ?3@S)BICJ0Z2?P'16
MRE(G-%25AA9CQG?CVQ\$!D4=%Y; >\$&%5N5\N"ZM"9SW\J6A4W58XK\4;XL M5;I:58N;Z?WW _==QCL!\$9:EUX2
-Z7IHN.X;^KH(6M\,PU^F53\O\$0G/6" M^\$^!^1469\$IXB_XTH#Q*CH&*X),00)-
!6P2WCB#;=7+I@G'H8'YSG=H=W*J. MU#;+!0!_AXR789VLL;AO+J/(RI2WACB+180K!W"CH?
P#Z/MOUT;WLYE(\F-\$XY,I7D_A+M^LNIU +>V.Y.23&@=.F%^H-9*YKPH)7D/MKZ^M4IV/"^4W.*ZE4 M;7Y:)
(#0%K C-%")IH.)40-WN0P-DZ59\$>\$0JL='8CBP0V\7YU\ NI@_D)3 MVG;J6=USSE=(.((Y^_3L-G-
TOW^K=.OWR\6:Q3_5^Y^3@X_3&US>+!% ^MK<-S,>N^OT8Z94.)5.J(?/BN)90\E>;9<2MP^U.>+;4L@.&&
.H9IQ0)E/M M7,C\B.H%4+;^Y\5W).;+==+LE?>%B:@>#._>B.%!9YJC"K)=M.F1D\$.%42\JR^Z
20MBSB4\J\T62F3ZY?V;4@B&30(P%MJO>#Q_4XP%)H7 MHMP."J539=7Z <#IXOU-N^Y8\$7&PS%M43\I7F6(Y
5\0:B7P66EPOBP^?Q7\ M\H^=J +OUNNX&X9D_C^VDWN&;5=UM2J^+I!>DX3\$CE"31YN9>?"\7/17Z^<M5-
9\2(DO_7P/C@Q%._IHT@=8N)WP^>OM\$3.7.U;8/M0W4\5=T&Z;?4_JX MF(-?<
O>+;+V%T=EKTNSKU#ZLBA*P2J4F3<^"O260=(+GB.7%)\$8BY4=E M%-2I=H7\3N@_-2@*B15;BW\T\$ _ZD-
U>+;/K\5)6;V^~!%GYV\2SMY*6.5LF M(66E8L\$TD^W\1#V\+B%!(E"ORJ;+ M/U,989_BU3? CXE_D0;_RZDI=I
1.8EWX-N**E?9,>Z4YGI*9L9+>7OK% M4.G)QLEI3Q\67O3Z_7PG#;5HF>#L744&JUOKAZA/@J_M?^?+TUS:"4J+
M0;>LW(^B88:P;C,ET,?>\$S6^5@I4?=(R"1.IJQV:"B"4_CV=)%<->K*X,5 MYJL%>H#^9E&N#OZ8/O8=
fKD6HW)/KH7\$LULE4L;8"/R2H@ (T#***@9B'OY4'511'N5&#;IRD\RN#BMX.YU\2_>?YSO/C\VW26TWCYWW\9?
QO' M-(FX%O1MA;,&0FDI^ACW8)408)/15G(78Y"GT-B.^ JHB#._IAM=J@INR0Y
M(E9J1Y)'5ZN,UT#D^/D1\CG0)#)/#;YU>D)\<4=D;8:5)YN==M&+*40DQ3@_M7"IUCL%"&40#S^+M\$#AB-K)-
UN\7+*B" _YQ^H@:JO#6FU^0CLJ7%0U%40 M)\$9PC%B(OBIF!>?Q^FSR'5!>DDH<(OW'2B&2#JM,..3HR4>V2
T=9(C1U60Q MCH5+?._%&YFB#RMDXM3_TU\EX>ZN/LK+LH&J\$1" \$8I&)B)@#&B,B&F5
MET(9)6HW%F%O5X&Z9&(U\EM+^FT+O%KHLM)>>K _.(A)\FB).004\MG6-T5
M#)5\>A+=W9VE.CCY9Y/">MS"7WW?_H^E^I+E(1.9\$IBXK)TIM\62Y 4\0^J
M7\$[5S;V&RSE]>NWP2OHP_9,E*5\3&<[LGLI"WP-
0N,B3TXH7>ZVB02AHT;OSIE0R1F94<^X27O,16TIW)BGZNB12%PT&Q9 MRIP6+E.@NI3-AD3
DU) @=L_IH_4;=)HMFQ=WCIG0081>H.LHB._HM5, MB)\$T10&@ (UK;/*^4>)(N%,"H0+XY4(OK9_4P7XN6C9P
I.*0/5)R\+P> M99D>'B3;_JP.\$(>B"N%AV\Q-V5B'NG>Y9ZYR)3H&A\3*B-!LN5_O?_JL\;7H7-9Z>V?@=-
%0C538BXCE&6&F;)PT'8P4Z@1%0 M93V/U-9.;#VC4,WIN>X0F'S,9I4C\! "YM91E?>2P\$Z&P4B4K1O<:GH>'EKC-
MJ_QYC8U8L\1'CPBJ(5PO\$PH\$ 12TLXE\$5RBG07\ MGWC"/L_ZC0TR Y>E=U^7+C%4C2_EH10\5.0^63-
BH(,0CM%A#V= M+W\W==>W=E/V+CH52PLADT\$XGL_2GR%0HQC5%.'6/GD>@3A%;^QD#V,UGKML'?
(@)>D\;V8:6"C7ETO _RZ//.1#;\&.*24;J-@ \XRL,D MI/*"+3\Z0Q,1W.O:YTXW9&?H1;=-!FA 6(-C\#8&G6;?ONO8SR.L?
IB_7N%' MDL>+39;7PU5XFI5T+@-'Q&5V"BIAHH2',>\$Z\$">%)8\$>A3R%Z>6)R"1\YI
MIX_K;4*.\$=3^73V0RA.0R2MTOY=)HEFIRH9;L)"_IH7)6@M9.SWP2U.GO1ZKKPZ-P
M14U>&MA5>P&N7>XN\$!O=AW2=Y\DI^&C@:X@BC1?C,/?)&I>/. T-G\$E?L M\2(R#(C1EF:M9""U"UT>HQC>
(-M.UK2JI^O&GD(I)Q\ _WY<:2H(,0X\R:7 MW\!"+1CJ(GC#9WW&WS@/WI^FW_U@<47U^H<[EN_->
SRKQTH>I3(-M&GRPOTUG?QI;:0%.Y+0G")T!*#14H'R^"V=JFY",0E>Y^B?G MYB?L?<
8HXEKN6P\JA6ND0JPDBE4HA2R5-I43O183N2E^8\,1 @XNIOZC6 MVM>M%UR!^PAVF-M\7XPE\B^:1\J8\#;)7ZVON
G)DLF(F M*@Y<314(S M2;G^\$1)HG*P70T<'<\$>HROY M":7<\$D_OFI GDW?
*DO9K/TV(^DI9SK8T%*5"GA2L5*HW5YW= M^%Z<(E6BJD^EVE.L5U^FL\7XW^L.;N\11+<
f>^;K68KCQ2@Q;U?2""VYDGKE M/HMC"JPJ805*3>9UDX1@/SIBU.UZO0UF)IQ%.J_H9SG98A10M/1)1U#YH#Z
M@&>TC27ARE\$P4MJ@HTZ2UTY)Z0^OA:O7H43M'+I\WTE\6RTM8%#O?X=13 MZ;7^>_G/TFE;+I\WSP%
MRAI9H2>7;JT\OLPWN8(R\$BB.X12+VN" _MB M/#I-OMOI-L,<> HA1(1=I!F%*8=)4A*B=,31V7UE\I;Q/?--
DRFI1X\2H_O M1="Y9+>UNW\^C\WX\7=3K#JF\^),3YJ\B1;BBO2\FOP"K13A,B@'7?5JQWW_M 3K5^7(1-7B8^ER-
CA-ZW\5M&F@WP44HYODK8\,2KPRW^O-0N)&U_Z^=P0WQ758@L\^M<@_3+;3W_%%'^3/R2RY
MZ_&_4WRS*5=/T2.RD'ZJ;TWPU>*E11;1C_DF;C\L&C_ O\G4\QO\|EW- Y\BH29 MI7-I;
I\WLSOLU&G#S2(5F;I1):>EK\3OH8O!>K;4_OV.#& M\9Z\$MB0K/_I;J)\$%ZMC\7AJ<*5X M#^WFL;S_+6;?
_IM>OJOY5?OPT?@:6LTI9*8VCG M/2&^+VJSE2#>4/*5R\^7RJ.2S3%+PVFYBBW6%
TI=-,0A6HECM>KLZR\$^17\J+7H4?QI#G MMYV_IZN\PT@R\$U\$0H(KE MDLNEP%N\OIB
%AAQC.G.;^ZX\JIBO7L^#65D)5O+^4.X<IOV#XH5*#@#>BW=-M1\)'STZ*^FP^T'/(PDPT9R-H
J27!8OI(65+)H244F%)ZR5M>^?7_28"1 MU*!7\$F ?.@;+^H^ZJ4G ?8BKE/JUR%2'TPEF'RU @WT6ECF0RU
M8^3GGJ%5@=ICL\?ZA-(V,W\?EE"BE(8H#^BN@A."B\^AOJ\$YXNF12.VYR MKME;376F%@0C2D9L)2
I5;"8312PH.3M&_ZS%EF937=16ISTC_O MKU>CR;)46<=<\$-1.25+<7.MW<\$\1LF4H<4^7MIW//@_KJ0Y59Z5\O/^BIYR
M2Z&T0&A.@TU, @%"DI#_1"73R2N9\$T\&I/7P,*3/(&JF"CB_/OU&..Y68. MS_(?KMX\$SH"^=X4*&IQ0\Q\$@PO9
:=.6Q994M6;A7;%=N&*U82BG29\W?LV M%,R7\?*@GKL)6G^3\=J\$;1+&Z8A);1T>6N-&K2_V2E=H17%^>_<
F=%AD2\1& M-E.F\81 JSQN%A"Z0VF;#;C3\ICR/GKP*K,NH8C*HM4Q3CI;" M9;C&K\+5V7I2N\IE.Y*AKKHJ?
UPUZ@@WE-27\UGB\Q*_/RVT/L;95KYD) MG#89'<64O2AIS09*T'@26LAA(M<=H0?/PH<"?IC1C^YM/=3%5@H-
9%6 M#/8\IG.O_W873'VNG^K1?J1\37XV4GUD< (=BGB?"_K\$-H*WRUW\IS"99M_V MOH=C/OG\I;K;X3W?I+?
W^^^OU MOJN\$FDM;^>+Y5RY+B\@.R\$;@>AY0R.N+A"9.PTXN&\Q/J<3%M)B@D\$B\I"(R_*\$#O;O?L,QY
MK22ZRI_M+VA>9^FIV^>?U0W)U)FGU _^011BJ2(89)H#*\$PI#IS0(PD 1%1 M6DT46K"R
FU=W_?R6XBU@9W(G=X2\K#S2JOP8B8;.\$J_%QTH>\$S\BM M%IJ\JE;
I7=PV\=@AU<3\ P#4KS6^"ZI&*6#;\$9TF\^OXQIY0@2/\$W> >?@TTY2&5X(GLKZ%TH(^4VPP0B\N.)A^S MBH9DX-
RB54*8;6.XA<"SCZ(T57&U;YQV0\D^E^#J_ "J C,2)VC=X^3B; \$I\Y3@_7 M)J&DK*5<.RNT&I\B3%Z
M2"1E\$*IDCK+;(-M@N.99"M^L;I>+ MS\$SOM\VE;Q/@OL9P\TL"AJ"WW>CLID"7QZWXK\IAZOJ\<ZIE7\$O;T<\$G5
M\).7KW\HH&I8\A%XT+B2^ERH+GF8&+R.3GKM-AG>74CZNWS)Z\I&I_4^<O M\HRYD*7)D#=:AZ?+<
R#"3C_1^CG=L;*>E\$U.OG_T7UE%2#8,?&S\ _W-3 M*GF^X2^W Z&3;IXT9_/"J<>(1%#(,8E69&")9,\8&W.ZI
<@;5;4\@M&BT MAK4IP.L K%;:R>H\$Y4^UJ#N:74X0X-B^I_4JC(B\^H\ _7WM*7@F#&3<MRUS664E500?
CG(W*3E)P MH\238M\$Z\1=;3>3#A;@+TIT_P2">(B0Z1P7B;E9=P)VX5IR# UM\128K%*CIWZ
M.KW\7_E\!WQC^FRCN"IFRV^CV@.1"25@\$B+BBU*UV>?57OD.E 7#>OKY1IY MN?
8TP,O1G6:TM+B6_U'1WIX4D;W+I\Z\1@ (MOSO.13A0\QA*7*D60E@APR2A(M*3,FK>7H7;?
=:QZ#NAQ=J2K^IC6H#P"N;Q5?(XO\Q7:D=2\$AUB&4Q/&0+CH MP\$G^P#ATW96UPJ(<<24#"041+/'J#I\W?UK?C-
>W *C1B?C'40B M==%>M*14T6)FJ_&4" _PNFIK\$M_>ESQIHNN^L<&IANVYT ^6T*E\;TDS)*;
MIU_2ZI^CB(ZZ3ZB8CJ\$9+43V8\FUI?F'2UI2FT3MCAD\@WWV>C0L78_UK.F0 M^/7M@)O\$NPN"-

Y\G7U9&5BW0\57? #=UU3:D4X^H4.7Q^7OK>IF5Z72JH MX?XZIDZT:0:5:;#RJU2C>H:RX?TM:3S+2U\;P??
1J\$Y\$RX-Y 5PAR7:UF*:15 #U9K MEC28%:RF7PI3H(SEW"J6>X4.W@B36?IVTIU5=F<[VE5N5?V7J:.'+U@%3
MQ:R\73B&3JJKP=;%RH0\%#D"Z5IU\%C%)(H8BN&*0DBA^(1N!.EE\$?K0+[5\$V)E04>8N\A\$V*JN:1K. \E&7Y=;
M'W>+&^%>M+.SN7P%E&(HO@N8JQNJC)/8"NG3KL*XX+?=(5UC6GT87,*WR MV^X#;7\$[^.)>J@ "1TNYQ6IQ
RC""6)B#IPN8XR=5N!*"G5D(R>M,B).F^N10 MGO*N:2L;JY^N+7;K;A9:\$ ^ N7FXN7:5I3G%G
@VD014.%&:"#AXE("Y.T MU#.: 'HZLW=YA9\I"H:1O>;LMS7)*M\$ M\ (D@ "DBPE\$6G)\$:\$\$>FC\$7%#.U
W)9/U?:CI52Q9R7 F>9F;5>V09-XBA M3X%GCE9IQ" T O3\$'E\-'C'#(CC. _V>,G/U?*CI11BR;GF\#*79?D\$?6"1I_*M-
MOJ+_E=Y.). PKU-BY%07NOH8HF&=0TQ. _6I"ZX+THUF M=#0/("V/HON8?@-IEU:Z<@H9+(B&ET\>+T?
T06J244* M6LS0^5*6 >_E>M E-R4EZM/87Z>K^3PMY\@/15,H5=-,2YV2YE'^B)\$KGG
M60*_4=Z*,A^1!>H(4L%&F=-G-TBLW7TT10Y5=XAQE9W6FR@&3)51? G96 M\OZEX5J4E14;N\J\5*U(+E
A*HB\8IKSTA3"J8@2=2,J9IC3L8^C<;M\SY^S6\6\$T _S=-M?&GR6K3?B^PH,&BLO69E B*1"^9->;%
(%21H^2@E+1)9.Y\=D71N01XGM,MISS^TA3JUTU8W,Q*50QN+1)2:9HIM&EQIP7;U1%:H9X5+&DJ*,22NUJMUG9
MAN,"Z"FI\59A)\A\$4\8^*J\IR\NT2.OB.9J8MS"?\$IL.LPOBP%
MM&\>A3%"Y(QR=\$Z4TGC&643FB3@T.@QS"1.6>WQS/L179!>-*!@BX8<'6N\ MN^XHL5)7^10-HES?AZ
2/ZJ6^_4OI(0)Y\I\^)+>R2MD.ROUZN'MV\3XZ*YQ M&5<;YI-W/7K&_SA2YK_??-W_T^0+EM/R"%MD>(-*I4?
TK^&^1U\$E#E&,"0.BX@@@^4 (LRV.29TK)VUZ\#L=8K MP>Y)8)7<[6TPD@D%4K\,0#U68.XCN\2\6;4\F
M.=3MIFXK7T:\$6VMY&?&ATLR BQ+"3C!!7EI+>O6G>>YC=884@\$ZC>#H0\1@
M\Q>Z@'H(SAZ\$=5I\$,A4AY.!7A6FG)J4:49!^\$M.MZBU+5)HDLB) LFR1DGO MN%SYK:=9!M\MGJ^M'
4MO:?)*!;9+YJC8QH@ (DD6G'17E5O7(KW^?^R)D\$P;C MH4%FZJHKV40;9RXL _CE>?XX+K=K*\$X+_B_ ^X?X:.)921-
3:@P5(G\UBAP7"=M _V7.BXA231BV@1K^L X5B^Z"LU99P.IKBU6SF)\^62L3U?>I\ /> M?
5IV "ZP;K&ACKW'K>6M^I^9KE(Y\$@ "8HW,K'%8;K#3\JEKYU ^/CG/W\X M5FMF7^U\U "W40TU9FM&UE-
B;H8 _S\EC<=DY"62YDW(7;76RZ:TB=\$6\F% M\Z^XE4^ _IS1?ZL\FUGXC\$ LH2->&4%#&>N\$!) "M*6V
9P%L\#@V)P5-GLY!= MZE^?>LJESM%CI TUUOVAXXGX5GAD" T)JY& OB23>D3#4)Y
M:KCK\LT^>.OPG^A30K _>1VSHV.VXZO?>VORR\>O^ ^\ ^/U\+ P04 M" #!\@7I9\5\$ AN^Q "TW \$P&UD="TR.#
(T.3-R-5\G.2YJ<&?LNP= M5-?6*#O6%\$5B\V)L1\$>=WA ATW008R'3>^ ^C.D;-78DMODIL(4:16+\$%1(U= MB17%
H**C= \$1AF&_V^2&V_YIK?>>==RPA\G\+WV6G0UM>_LT9-3(JR>V\11^:/%D3(V;R31\ M*1\$U&
M3%)#8;"1;1D&1*%1L,FCH1#87 (%/A#3X(A4U#H%#AFY&_7*(\<JU271HN9.FK4;Y@UZK\@=GA=EO=H-
6\J(U)*U;FT>-R T M&-17;-U3>=H4G=UE57K2C%:E7@LQ.;3Z5,@?LW^A\A@I%NVOM\> F_Y;26W
M>XNQG7R*16G33QT5F*31ZI>BV=4&LJEM'E2(\ ^ _X\|E<8WAA\@| "OJQIP M^6IS#BAKZC^UE0\
J72K_H#ZR%&J_XOD@*VI+ !J\H/4J2TJ--_2-F@0H M&PX7 ?I&P%(0P" TJ\0I-A?P=[ZU-I\0\;11]>NAA2_4>;Q
ML%1Z/=T\YCZ.TB#UJ@W>_)P'T#^_O5WH+I9.(^TOX! %%9?PC\WOK3(#@3 M!
(G^X5F4.@QQ/P>C+>HB=*17@2L/'N\54@T\H^Q8645)R23F)\V7@|DF^V M#R_?2=P\?\$\$"!B))YDI9A6<8<%31;I"ZR
J\U8 MU//)>+R83-"*02IF4K@ROE\$OYY*T.M9)+R=2?3:F0GQ) *>3<+IVP>?A\$?R MR^@LET1@BR@\$OH@<I*NH
X(B.51+;>AVYGBD_% 7P* MWD^G M*%&?%F@ "M@34G_2UMTJ^L D1 IG&
MID%J90Z,C@8#ZQ\28I&"B&2646\Q:N561\$;14V1APK0W% M_#F84JL#;70XG5ZW2XGVV06_3 &NZ20""I
_OIQ;1-2O:I>3@4PB\$E" MIA, M\$0LX\KI>\$= KR,&\$>+N*YJ>P:0*DD\$.D2\A&M8\<8I \$)+U!*10\48YAD4D
M(A^CI9\U@ "2\$#0VCVL\$5B M%\$J@T/\$2">&(I-^)\$0
M_S<3_ZV/A/C_062RA/C_061RP\$(P%+)BL5LA72&S6#% ^M\$*"H<<\$ HYF"! "M8E&
(^\$X "T8@H\$TL@<&J0XJP5H1@/\$#F5YI@-T((P^2\6J;D:G Z\56ED2C@/\$*!"K"PJ\ISI#4C>?S_I BQ<*_&P\$^*J(B7:
MXN*8%#(<^7NZ7<4(D^AVO_2"10:LAJ%:+^40_4"D&NQ; MLTF.9 CH' J?#ZC&S\ 876\J)WW\@U5A_D*?
1RCUBJPP98FED0_QQ.%5&FY= MH..<*A34RU/2<2\$G00W\$H2&H@ &F@ _E8S*+Z\$^*
(PN^)>&P\5\G4*G!"#T3D_1LXK\T^4BD"H M030T02OC*W0N#H<*)RJC\VEN\IP^J16F\$TKT0J02IY<2^18Y2L34
QG0R+63 M)\E0\ F8&P;I\B71H5 MT4?BD7ADMYMM# 9X7K.15:0\$N+= H^>[F#BO1
VPA(\VC@^K=*E@\$_.1<#8; M%J\0<3HL7J+0_Q9+Y0I0>+>(37%;7% H4X'D4A4LK8=AE""\Z(-F;0"(E@*S M\$'R%L)
<:OX3)479?3X<7R#12-VB5PBL!(^V/9#U3\76A)22%\$6?QR>D8 MH"SR2BT"N5%I%J.
0INQ:KHQ(5\EL"0>HS(HX":Q%"VU8J ^;1V#U<\$QSJ% M>@F"(C2HJ&(B5^X0T&EF/P^+I3%P&)0%ZY9")3:-
'XZ%.=1&B5QFY?3X@_A MB<"",#1-"O7\@+ E#PF78@&B9QT-5\&,>M0?)^_Q;-(M40L\$_.12K17-E-R
MX6:R6RS,VTTJS>@0BH\K(A?F1_78C)"<")2R-1T\06AT^B0MTA%XVL=V*! M?*=>RV"\$R'^5U./Q<606(JI*IGA<%
N/*^<+! BVR"2>9END3ED^;ISV*1 M132MUEA\A.18#D8\I.R>12F3QN406PTDL3GE-G@,A&"0X\$QH1:C
MA.212LE&L0ZP20M/258%\$ B*&^IV6H1XF)\6TH&U9C_@ (3@4B>=T2D-B\&#
MD1BH*J\$QZ7;&'Z(\LG3\ROHMRW AYAA)@7\$IE ZI1POS"@ENWTZ"QVK0U" I M-)/
'C862.VP9H0:\$ZV@H(SJ@!7GDPT8JY;U\LD MEJ1J_?10#
ESFV2FUX4#B@5"%9BQ="K=I N&RN3X@&Y.9PV:0L+0)&L;"(M(G)(#*"8P\$&H7Z\AXL@|^*+FH7(P)(7_09)Q\!
+ #Q7""^L\$B'A<-!FQ*8Y*+ M\$#P84PK7> /EZ+Q6P_Z/9+\$ 3I&JCAV.DR1A*%XG&QEH""I586(9F*@"_7R M;
<#A+0P72R06<&Q*8M%CJ\A_) PZ:60562.6\$#G>A'@4%)7D/AHM21@ MLT%3K7#9R\2H8 NJ*8008OF6E
Z18/BP.&8>BTWP\8)U5\H4BKELWUD.(>B M8H@P?")3S&0_4"6\$7*V\ 6H=2XP\8TBN\@^K@A\AF4&E=;G-
H52?P22: MVA%0.L%PA94I5@BV+I\4J4?4TH&:7@RU\I^LH6M""IO\H?>R@-I-B">H-5">&"K%=3 M" 4\A>I^G@4
14(_34 RJ32.ALNA2M57JHIF@=I+6*E.HL6P\ F5Q&4P6 MML\OH*%P6(16KF_1F:Q"2%!M-OED:00(T<=)*31P?
&FH2"OP\KT0 (PCT M(G;J>BZ29+%(2A<:@HX@<4U#%-H?P1&(H"(C.3#;4\682TCV %GPN,\$LD\P(Q M@>-&
Z8;D\$O\$03\$32\IZ."\$D\B-^<714AIT(Y4.#=+>#HE2:4" (4Q32JHB* M\$%H4;" 4\$E0I<0 V;
64XU\GEH9Y^X^;XI\$3H&Q?P(NR6I "@CVAM"(>-L6CZ_K(8*%0)C.?U M4/D0:#!\$XW^U(-)R7;K;4X9"JL.D5PZE%)I
<&+I2*#"UR\$+IX?C17B"RA M#PND\$8^58K>KN6(3D\X**K=HL;+H4\1@O3*63*L&^-\$>VED-9F"4@>#7JW1
M;A8#AF7\ZE /J6@F%BKU.KA:P5@.8\MLY& 4W+02I5"17-BW2:2R_-j>5R MN87 \$I(I7;13 L
0&4)L@14P"W\$0%"QQN")/FTV*U\$A85Z^8QX28X\^1PBTF M%5\1&1ZE\I+<+%;G)R8?EM#WY8KCE),*L*JF^Y
M\$X)CHNP;&TB#;_.8N+=!K)7A+("D@&^&1 %L3*1+4A Q=2@M1RA\$A+J""5 M36;#G
R&5J&AKIA6HV\WE\I6\$)JIX.LM:&-4+2=X;)/&^ V'B^&("0L;I(4 M
/R4HT*"@SBJ".EHMVJ70VUUZ^PDCM..DT^P9)U*^+** 4P01PC!YN=&I\3 MIV.Z-
1H.3T1\$2K;7'B3\4<\$0X10\17%E9)U>AG9-!9E6HM72&2.9!+ET#
MY"QZ4!;P(=PX(%/0=%@4W:8&2F<@^JCY)@B>J\0&=!0H0H.S:2P*G5_LT4.8 M/BR<90HOE&B/\$\H.AB!2.8-
EQ%0B\=L#KU4:_4+2^N10B=JJD1G)2AJ^K78H#1\$@'M< M2BH5Q81"?(*@VFA^FYEHSY-
L.H)5)X&Z.OA#AY+^P=K@9U\0\$7@F.#VLB\ M<^<12W\8GA:E%8\$Q8%+(K%1W\I".F<>F8\ 6E0XK-
(=8&""%H.OPODPDU("7 M-^M^TJ51H""(B&T<\$#BFI" =L=WMD01*#!U;KS)=, FVNTRJU>J\G-P"H,, MHV<I8
@<6AH2Z?A8P="3L9J-*ICA*F%*+X;I-0BK43\$0\V\$"#MA>U;@-
M9Z1P:3;PV^=BAKPN('S155Z862J%>^DPB\XLT@%?JK8!*SE72\BI3)X%
M\ZLA8+45@PY:L5"@^1*PJ5Z7%,KP*E46_1W%9")?#)\$9\$5@N\$8MV192TR0T M-9V'A=(9=EX0B&!\\$L,DJ=D+L0@-
*4I+ MN4N\AU6H)!S&"XG;J%^ (0HKA5L:%+6>@ \$L)G' @H8-B=(U.+P4\V 31WT MAK1BJTV" I=NU.@B>!
I.Y@&@9(B,+78:TL&T\P\HM&I^,'M0A^"(=UJ52(KVZ M(GO,0*X&<18?_0%8)V@RSF73FH-^\$@^N_8 V*N""\$?T>

M'<+Y03Y9AA&(>3#36RM6ZIAS/6XH)\$.\$5@>2C*0^A%|C|9"1H S@ABM6CT
M?]>CBYU8.!|AEAD4KE*2@|AV|Z3VD|^ ^ VLY*B=Y(0-%|S|H(9Y*89D|J| "B_0%Y58L M3\$:(?@((4^*UYN|*BT?
*_9211HB#>)0L|!<(<(#*M|_#&H83C%>SO2*_S:~6 M(E\$^HL":?;\$|+BX?"H088G<|WH94-
%L#=#>K)9H#=#CF2JU_-2R@&4V MKQ*,LM_, 3A*04)1L8#?>EPT*T2(TV|AP9|*K@3LC8.&.!|N.X%|-(M-J@K MH-
(Y)3*F&BXC40DFDE6JY5+Y08(Y*_*B@|AHPYA"4JS6@Z+>95*|""*T>1|T M@J(P54)BLV!6&(*@@, >7"3@|M
TQ(A\$G=;K6.(C3B<6;KUB|0D8Q(?ACUO#H@/4*' \$ VPZGN':(.|L#@|I
MW"0%.P)0&\$^B@&MP0C<203";6&2*D":'^(">%ZT!6P0^O<%E)|."-';PV&Z
MT#ZA+@A/B(>R0@X7S|R3>O!8E!&EEVK94JO-BN(3D\$B?&\$DP%V;WD|L|@|MLCE(K9_5|B
VMX#L8I0)|A+@>2^RF42C NJ>H'A'K M|+I_-/P>K;Y|>33\$)|T\$0R!_Q|H5TO<AL5+6="8!L!16\$\$U M6(.5YI8;
|6RWUF86J|UR(C:0@|Y&X|H4P;W|_U^PA*|@|M5N,I9(G%1,2H MQ#0_"N
4R(M4|H|L18C|#+S#&\$&QE2RGU;2S0.1HG=|BQCFT|J#(|@F1PK'BE MQ"IS(/4H@1-EE|+-FN(0#9R*8?
A.OWF2\$AP\$|1>A^K|HN!;Q08;\$Z\$56 M.AXKQ|L2A@=#>4J|S_!K"<%J%:7V|VYND0"2^(A+EDQJ
8;N+S1&"7\$N8(C|A|D#1"1V%J_0AZ@.TOR%'YH-CC@+K,<62K Q8HBXXTJN4TB<&'\$J|I8)7-M@&FQ%\$ 45"-L-
I1.BR:A+>2@'4H@R(Q2E,W,28@' XTH<"S6@C6P,|#=5% MHJ|,H\$8PF9A#1RMVR,%6MV@TN>2NH):M|5"19J|+
T:ZT,(&#*SG0=7 D:L M<^G|2L 7&!2@Q'\$26JQG0AD:JY R%Z@8#H|<-I#,\$HP<|T&A3Z77MOSQ@ M:52(-
OD<<+O&8%|6J4)H%J_3X?#L(|L^RQVQ(KPP#YU+\$J07B|/M MA:~1:<"Z52*|A+X>)&(SK;|O /K|? 8C|N
+P|NS^W T-'P*|Z=,>Y MWJ|/WY_/DOGC; @Z>8 ZUGSFSVW^0;+7^Y<&SVR/0Z0XYM+O|<2GD|Z>E M
/CH/S:3?9|_S&:R3VOSC|/@"3:~G4*WN3U*U#HD|* B-6ZC#ZMAN*R6_5|^W4 M|H|_?X#>>|^E73^;NM?H=3|
X'_ER@U?R:1WU';_|L2_P W_Q5^UW|HG^X M_H>C_K7_Th7^;8W<%|WP+0;AU_N?>
0GC05BE*|7NW=RL|4NVG^F#N;R#_ M@4A:="P4|L_|H9@_Q\$^|8Z|D @F%)>|AORA.XW^|:G?H+7HEX'8A(*X+!
M4J#8%#AT\$A3Y KV.#Z#^9J?;KO/XE2XM7@ (-|YM>?;?L;G&J#T|7:M(@ MOT|_/O&/(^S_9F'C A<(&X5-
@6'_CQ:VVF|S:5V>?R5P_*/2JO5H7>XT77N4 M4SH<%J_:V0X*<=C=GE^3X4B|_!6?#;_!G(^M?S_M/W|>ON7>NCW
M6NK#FNF_WO-H/U_W(Y|/##K>|>_G>#*^12A1^GR>|T|EUUGM&A_?T_XGT#| M|H|T/P?>1>P
>P1|9Z7" RMB>\$|XG|2>1/(G|2^9/(MGT3^)/+>R) /^N6IME;K|(.3VM|3ZC'.K8H4|/WV|7IRZ=VJ^NG3MWZA+7
M-2ZN?73KWJ-|MV|QW>+BXA/BXWOT!*ZX|KT2\$WKV:O>C|H|>_LNX*|GMIAN M/2_35|L|4.|NH/N=BCIU&
7JV+M#|H|X=VLZ"DD"@#ETZ0+|OUT=;G;JW*4K M<*3X^@# X8^XW?JU!\$X;)?G8'5.<ZJ/O+GT^AN&
|H4KXT8Y^|S_7|6M.MVYC" J|^@NNU8Q JU|SN0.&#AH9.RXY\$ _&3T"BT|@L+H5(E.H-#I#*)+
M|H*Y0JW|Z0O&HGM?K|@6|H H(O%BY;O&3ZC5KUWVU_NL&|?OV+GKVYSO M=G|_X."APT?RCQX|?
OK,V9_.G;|P|=*F|=NWRFY>Z T<47EDZ?/J|Z_>%E7 MW_"FL:DY|O9=.U|=0)TZ_!|O|YZ WQU!"30.:Z=KPX=,>T
O3MW^1C6M0^> M'Z=T|AT%_|Q;A*J;?N+NH|&"&K|JUS7XP>,03X>6|?_VGO_ CW&YOV7_|L+
M8W_P50K|V:D#H+O.O4'IH_!HJ6?@X<|>_I<|V_/%3_9:|PNHG5W9|WKKAW
M&ZCHYO&F^15#7Z\$BF)V7C|PY^_5(Y.O+|!#7164C"R#;|H
MTHXVT&J|@TT6GIG7|=K0XY_6UC|21MH0|U|QZ%KU^F1|MF|,DLOIZQ/*FN M?|H|B|.2+&#V@"/|H&^C"K?#?
H1"V@?@-66^?;WJ|XNK|D=G8L|R|8EE7>@AVL MZ%&
(BWA|QB6PYM(&>H&:HYT#=#5|?|H|WB=D&Z|(<65|1W_4UNM@|8JF^=^>_M_UZQV\$LYV;+)M*^;3*1L|JU?
%FO9Q|+|ZP(*>_L+3N&MSY|XWSEA_-F B3_M9\$4|'C+>NB-C6|L.WW|PG6XWF*N|V^\$^VSXT?
OP8F|JS/^|L_|"ID8'C,B(C MC,M>F9JTS5CPT<&Z=35+)|NZ#|_MQ|_&FZ_Y.W8Z>Q_!3|TOP4-J|."KTA/0 M0?
&12Y<3%FG70#AR?D1Z\$C&.7)V"CDSYV\$_.659L Z65Q+HD_:3:O5?;-55;|3FEUC>M_2-%;#>BLC|V.(C
M66V@+X:515=0 Q;G|P@2&|N2VT#9_&B'|6^3#KZ15|*WM(CB)&9_.\$OXEHW M(S_*&).B"R4P+9|_GAN2SHV;E?
FQ?L(J_#>V_53W5GV>O"%JW"6;L;EQJ/U M#3+Z)&"%2;_V0:?'(P>5|_/AGT;PIAEX#F0\$|S&M#O_"P>E5X S|@I?
M'W"|52|8U;_~5W;_#%N;|Q;2#2-&H;Z|1*~XR2M^-#L|O04|J@-L&2D^* M=8+4I^N?>
YUVLN3DFY;*J6>BG5<_SAM_|X\$#G M1_U=3?7TDA?OIDX|^W>KAI<|F2#4|I2UPYQO;L7G=G=TOZJ?N/8@|_>PC
M+_|3<4XQY?#9=^|V7|RYLWW-O;_DR8LG#*AFO7MW* R-O*C7R'B0Z;|1AR M|S9YEB?B_SGM-G\$N@%|JQ>
|9YZ<1EE_UH'?W#;K*|T/OR?CZ7*RY\$OKJ*_M_8US5@X85EPL V|U3/>DG2H>WI=K+&D|MW|_9K1&U6-
;ZB%5.4W0<9R\$R*!2% MOYV+|5B#SOKN|KG1#^X&QMA|BWHN&E2V^IN6KW_I<=5Q:(L13Y_T=D;IVQ'C
M>BROAD64Q|_NTVKB86?9;Z^SO_TZ;_5B9F)-W;EK4W;|YC4G>2|_AJRG|TR_\$.FU=P|3#DKK-5Z=W3R|_-
C|)'7X|@|RK M.5.RY@BBB|J9;(|P%HXJ0"Q+Z2- MW6_PTH|6 M?8|HZ^DR;7KIUV0QZ?VR0&@O;<_W7QR-
NE_97IV|78U|OG_|KTX|_V#=#, MP>5586*|\$MJ#1X|H7A|Q2;L4WGN|(\$Y|P*AKL(OXRFLV1FGS1OB;@V)+6TT M/_=
<33%O6B+LNGZKM44K\$C<>37W&U|O;R%#%15G5V;+>QL2N5:>OZGB1U^S M9;(53M4,Q?>
Y%&L3YDX|Q9E:AYZ968Q&?_MQZ|?WJY)CM&C5V=D9X_H|3YGM=|;3|6|KMR^%>
RDKOL92\$;=|O5T_|POI|^F;7Q<6S)CQ">UO;|8O;3G&?|_M;X|W4=E'M'B\$|F'.HS5SC+4QZA;E' MN%^HB.:?
O9M9DPC|968_R-#0D1>B MYCH@|Q2|_*=2\$|_|"C"7;X+|%N<|NIL|^Y:VJ>A3_MVUH P%Y|Q&|GMU067L3
M.#LPZMFAYM=W=#E3:2JA9EY-SLOVAT(O1VHVR;1-F'#EXX|E*+V%YI@3Q
M0|Q(W|ZET>X;^3D3#CX|)+0_JH|/?>D4MV&J|D;JW?5_K_-/B02.6&ZFO_|M=X_K^4WX?
|>_JU|:YT2Z_K5)LR#%QM9B0L+RPO#1|DR6B9DGNUKC"6=,\$/Z MS^>')S8_|C|G5RRW-|&V=|H/6MH|
J|3>&6_|ROKOF7NZ9V@|ZYMV|_M6275&=#A|/|+67SDN)1SW?H;R(?V|K_/9O|+9^0-TATYS%6NRI&HX%I5
M|J3-J_#N|J?IOQ+|F;@OPN|JOY5=0)<9|_CDK;6|4Z?MM-VV;=N?S8_M>>VN@X=Z|HE35-FX??
|F87TOY^&_*K;E1|1|5_0|_E5B|<>S|J>U|+@W M5=R<%Z|@+BI9|?CRB0V);_9R\$GW2MV^A4^SR-1<-
T|<>|G|_*0&JN3T%_|UX MH'5K+&DR3PA_4;KO1ZO:LK<_9=8LUPWXR|_0#1R|NV\$S-W2AJR^RA?|J^>;
M.V|W9QHOD>SKJ;"9N99|QAE?3/6'(AV7/I)7K?F>4L_^;C|QLG@;@R-3+MTB(@|J;R
M:8.>+*|T_#JZ|OP=U+6LT^WY|STO#B|@M"#Z6E/(K9*M<*|?|_(^.HVD"EK MP:3:3DU?U35_?
HFV^_4S&:FXD+ITO\$|5>\$YUUI;6N|8#HG|H|JNAKV%5ZX+ MULS_|@;4M &>N)
ZH=WK;T;OIR7PP>=VQPI>_UAPXUGW&W=A6P-690RB MGH=#DC&GK9;B|F+|N|_S"
<>M|(U:ZO:E8K'Q;|_#VP_N|*>@154CFR3OZ MIS*KR^7)K|*|11;_//=%X>UICPB|H\$F-|IGW?|QU9OZPDW8^7&-
TR_IV|_MFOP=MS|U_|R|JMC|KZ|O;7;2W^4F>G'9WA9_?5^;E?S6X%7\$S:KKG(C'N
M#^O_9|>GW_M%<^NDFSNSOA&Y_F6TN^K-B|9P1ZR+GO_FKWR2?;X="L2BFWN^X")=|287MS/
MR|HYVY17&DTYW9)Z7)Q|?TUX|_H+7_|Q0A|Q0ZVO>"L|l%<C^<(MY2|S_I^O" M|PLGA/9E#9W^?>
6)B@|'OS_YS3|RTU3TLVIZ\$R0^+O|?T)0KNSE_|Z2O\$AOH@7MV2-HX&8LFQ\$N|BIBR-?1TN7S*D.3HF7,O_M7H
9H;J@NCEY\$HW_>%(BQ MPOL_9_3C9ZS(WO|J|/_ZG7?|T-T5W)X#3K>4_9^O%V4;Z,&S#|G&@0\$;L|_M|SQ6^M6?
4FZ_XK)|TU|H;T^NY%\$^AGP"GV|B+S:S-B|>_R8|L/YUU_S19FY&;7>M=' MUR;_P.U)=XN?%_S:27O\$GN_C06&Q^<-
#=#6<^GUV_QZX#MAVIC_V:L M_|@-&|@B@FH#J3N&GQ|#/RM|JXUU_P_XXS^8+;F6_@_Q)G5S3NN|K\$CE
MVQWO@ADGP|6Y*;LR@25=NAP|S6B|G;EXZ?RR?T_U/#\$'_GCC0C>N?CJ"V M.&_7WB56GVA|1+
(>|SJQ>/3MBD1M;|>Q-Z|_72;F5&X=NA^TX|_U8QU6A|'I MA_6OUU^&H|ZL>_H^<?K=;?W%QG4|DL9575+K=Y-
7#ZCH#ENTY_2C;CA|A^F) MKH|L1<_IG;IUE@W-|_RVNG668B;T|D5%|MBO?|B_M?&8|6|VX_%RW=|
MUOIT9\$O)G=KB_K3KCOEW'MQO>O09UNG M6VFW1G#K.ZX|P:*Q;(B(XM?
|_1F'_D|_5WT|/WHP8H\$Z;5K|N;TF_E)KRM' MW'Z34Y0W|U%|_>)RJ=5<_IY:'F+;N("Q>=#|TR)M6R?ISY4"MK
QWYMP)OS8-K MSGX|8|?L5>XICSUHL?%&QY7MD9BAKK(O-G'=|^W@5P9JZ+UPX;UOKZ0PN%6 MDN/B.H.Z=TI?
U|HUW)'T3?=NS|YR(YQ? UPSE|Z>.#Q|YN'7KC OKF|H09; M+YE8*Q7<@3(|?

%G80\02I7D9J(I74_26CXI^M"AA.W:MJ*8KYQV\I0 MM\Y)G+87GK\9RIUSX*FS4W\$B-I=H1@=I2A|=F
M5W0YV7.)=E:P<E-.4Z8QA=*IT3ET879%04\O\Z3.RLG MV4I>OVHUS>^U"&MG=KKHVB?K\B\I.F\K: ?15_I@-
M+"Y\+.W\B\F)Y_ M9\<\$)0V0ZUD5HW5+5%J3F7NS\>W2V' M9-NMJJ?4XE;?ZO(YIH9_D&5F;E?<?AD 5-
A:1BZ@)HMNS_QN\+7_PFTT M1*&0;L'C5SYC7>8;LNG8U;#EH\K8\065 MWR&!.#3+FUW-C8S-^GQ2-;
(6>+XR-M9>M16F7-?B7CEFFW\I0Y+JNAVZG M\I(HV>;20_VG>UV?%SINOB_F7WHXLF(O)?
+.04UH1@I(K^K"&L)ANU+HY^V'AV_)NVCX2Y.UV\%K^B.9ICZ3L_&/#0W_M+(K% TU'ET?7"S5\G(I
(9U)W!_848\$J4!84KENPT;Y(W)%UOPE.<.K\XG2 M9S_IO^IU_J2SZCU\TX9@UI>OI
IT;77SE8&LUV5Y2I.MKXBN3GL2J6EA\OHV M*6LH2.I)+#T4%;BIH#NM?DE-I\$)%N<I?
7H#J>WK_X4.ZAKX92P(2^2.OI4 M6I-~%9V\OQ=<7YJ;N^Q&K)QW^K*B<.I);0LU4O_JM;_Q7-VY_Q0K?
BY6OIKSU~RHYO/FFRXHXI:??3^GU\3\$0+;50QE\MS.'E+|C< MP5G^W 3C)U'OAE*+D\ M57=ORMRX+U-
F(8)Y>W="8\RTZ;+|XKL^>K>G.SY>P44;L2^Q>0^G=/@NGZ\? MC3XV14@L62LKFO+VI>Y?JBYI%;T.I:4WOR9-
OP^Q*G&T:TH8BED9;OCGN M%-1R7SG\RL3F74^*C-!Y;=3SHX8)OR.60HK\$^~|7CX;^F'=M%-P\I-
G2J^D&PX4ES+3#BMISOO MRPO\46=/_IT=*>VD"W\ Z9/M2TY.XOT)KG4VZP_MLR=6C^E\0=2Z6?#TZ;?
NT.2T_\$IXJ*=AKMR\>W@|Z+!HP\8M.5^P&T&:I\X MI>I#;DX45IMYL#)8.6G(R\#;'.9^W?#;HR?
<3&G\+F\(^++L4%6UL;Y3TYG(-MHO0E\2.C7S6?;*YKE\|M_UMSMJ52.X\^L741HY;R%HZLO@T;00GTJ70E=|3Y
M7\$=E_#'^+.7117)SUHFWAFNO\PI2^0UFE\Z;?D(7U2V;*/H\$93-I\RB) MPG*+I\21XU\I.8=;MEY-'=G"WTN\>W7
F9K\#1W8Q9Y4FM5I);EN5=;P/= M\1K.L76CFSI&EFLGX^BKJ\$?7TO?8QCHFO+BW?;E^E"G+V;W&LO_?BRN\^1
M&QTXK>EQK;ZZIC:J*52W7L&^P6.(?=?=;M3\DG\GE7O%Q\$-P\|<+AM\?JEQU MX;_TZL3^+
(IT*^L\>3R5;O>>R.&>FC7R'2OF_&I&I>3;29DR?^&I\JG\%\$5U9*;@H.SW%<="N?N,RZ\I3?XRI? PUI_<|\$@U=*
M\H-6\I)G;L^+!#L4QZ5WD;6_8P%;3CYI\$PAH;(-ZMEAE\$%G%IVH\#G_1_D;Z_NIH M;'KFM+BF
I(\$\XD;^A+@5#_B<&%I)K\IOWK-^<>^& M#|6\#F\$&K4YN2"V>.+G_ILO\5\0RYEL*ZN)H&="I05GD>;>V8/+
,Z)%O3-MNOK-ZC,X7QRD*;8?>_9HWG-S6?W&E.3SFY8.04J@HEQ.RX\NIZQFCJG+|@ M-3JLMM_3_Y3=YIRR-
E#WCVH\I>9X;@ZW?OG00A%\Y.V)\#N\TY;<79GZI\$A* M7451>H>%B?
8(I_&B\^62HF56K(\S.GG>P#B\I9ZXW>G"STX<:9VK M^WP_#JX\I3B65\YD\G4>\$;>A\I
(_004D4Y\WP^ZBP?E\JP8.SU&>SMDMGDS M;LPK8VQ0&Z@^N?'.* _ZE2#*K&XP<7<>G\5\IOWYL?
A5M9N;M4I\V'W@4 M6\U8?N31B;N5_X-BK\+ZIRMWV;C;
M\$&^N7540.GRJWS("O+Z1\I8YH;^W_&I3<IZE_0@=I=V?T\LOK\$#6\+7\$ M\JGLLO\RR\OFF"WV
V_|Z9R"2>U\;V'2^68+;49^PMZ7Y^(\SW<I;O2L.%< M9EU09;S.75NG6XW\I\N;I\P+NET)" ?
EIP;|MLR"W^A4L%&_Q#1W9^_OGRR9Y/ M\$C=-W=.P=O;3AS9*MN-
197;FR%#ONIEC"LH&B*_T1X3O%5_4_!0U577EW. M.++LE_0=29\$Q_Z\IOVV)Q4^?/4WY?01>ODU+_T!"0UN8:6-2-T
M_7CHI_1;K6N^<I>?I0"F6TFY\TH+P_4_IS4M;&VO_I WN_MLFW33WT^9C/Y+IOG3Y\IO37*<I3X-
)WQ*D&SOZQH2-GI=>IY_H\X;+Z%;3R_MENY?W;PZ.W7F1\N0K8+9WX;TC)F\CGTU;I\2Y3>GXU\^#TI%'\@5
M\ZT5MW16=AA@^A5^&^<6MS5_<I\PI+J\UY*%'\0_!K\I BR*Q.YK5F1.APH4
M7LLZGQ;I+CV_H7+X=I+I)5GY&;2>F(+U\%<6>'GIZM_4HX
M0R\$;57CFEQB5DK2P32Y+B_Y54VF_DUURYAPD3RS;V;IP_%W9O;MVW4X>|&-MTG7^WL0?3&W-
->>_OKKYM;+Z=S<.6_IV\$9_E>J="HZ\6ZB;YUDU;_2B2Y>*M?
L;W_@C?|*JT\$|NWUO6FU&|.S@Z;LOWE+^IK2>Z=V6;N8\8;MD=T8'3=X
MH>I9X'15;V9Q\OB#L6GI3_7\I\8_KQZ64/2847&I_H'VH'1H>(3K8K;X-
M%+0VS)C*^W(GZX_Q28N2(O)>7UFGDON\;D1OG^&^G\I M;B^<^FB65)^OD=-GP>9Q>^H;YVPA79M@L\U?
6\Y_A\XK"F"&L7KK^J\I_M\T7Y\I1YOVD_Z^OIN;I\Z?495U7V.V8IO71L4F?
;I=YY*AC5K\O7JZIC6\@E/KP;ET6+JX(F\I_N@75E\OR%V\SX3SKD=ZKO'R5N?>V
M#G@W\JFK\I+&3=Q>STLPSY\Y+KSI0\2VI4FUXK4K_7IHS5&L<5G?;..S=L3TE5
M6;1_8;Q^CPKN<|SS;S\I\8=;FU;4+CYM\IZ\I%+;2=@VNAHCPTFXOW;QTF_C
M;0^ZYRUF\ARVFOZN)#TO\$H\KD@^L>RN8NS+JEO#?;LNFHR_?^+F;U-W-) M=N9L-
A\5Z<;\$X?;8+P;6S+_Y;==PYZ-MI63AH;V\I=Q>8.(^<^<(4D12'ZU_M9M^&LOZ=OL;V\T#='F45YP_(OE,P)1TST\^I?
I_HX@;/>RH+3(N.CTW*J\$;L; M\3CAO8<5R8_3IEH2B<6#_#TOENJ063&=5K"TMJ7X">;7=
F\5\4\;5Z>7AE8D#&LL<>?26T32<^GI7SH;N MK;I\X1W\$R9-"G'2ZQ1\$2&="UY@+7/?_NY_ATL
<7SF<(T@W9)7OW=-WH&EV_MUDE/%#UU8N)@H*P%WZJ;L2NO^ECKG(CZK"1SXG6K=Q*ZJ81_LT;5=IK#;R#
M>;>*?7M7\MS3\$7&FBQW\YYD3@;.(VYL=MY+1_+F;CVP;75?S(DN;E<713^96\F\#+7BB7*1N_XT8)>BA
M^<4^OE^&8"&95>B(NCCG\5>E"=4?D\EVEDM^N1L95O08
M73ON\;MZEFA\BXUV12;=AW&J\T77P4G\IVY*_ZRP8B+0TY\ZAVN/B7EG2O\4_T%;^XEI@_)_
P_TDJM2\;R=L^C=BM5MH.+LZ_9P=%5=&^C5/E=S_M\N_58*
H\WIF^F\%9D;CR\+!_2_ W5Z8GWC47JAL_UNOO_X4%\UMD6:6(88> MV>?166J=B0_JKFI>X0\QIQZ
TBO*#\$GOK/EYZKRB.AXO#TO5E\$;Y#W18X\I6_M_)O3S(\$E;3 MTU_?
RKU56)H5B^I2NZP\I8.T.KIR#HIRT@.9L'FE#=#7I7/=+J\K-KOOI.#Z M-'E5QM;R\$4">O%PR.EG9OO"C)Z-?"
P.'Z.2>C\ABS&CGHT\O6E0J1?>O_MUEW.J_R\K&+3;E;8>)6XT\I\J7>^166\$ZS:4%PWY=A\$IDS9;E.VZ==&NZ/_
M1*9W;#&DF+GY8W\UEUC9M6#I_@;"E\U_8BUA0#>(HNA@_E+1NKSID>&7WZ_M_O?
2<= B89\W'EMMB1&.&L'E\66'E^I\I'6EB.W)"P^YLZ+K4'7E;ZG#I>I M2O5=R8V;CZ\4"P8\$WM7_MTM=H\I?>I?
OKG5_?I*# MFLR<.7\W\I^GC_I\GT0EX@IL?Q'9<79FJ\I.V.M<%)W1TMCLSX.6 M-
E^F;P1FD3EIV\6_1.UYY\$=&XI=Q8RSN7CW.%NNVT#XT_I0S%-M4B0K(3_MCN1(OFHR@0@
)=;G9QZ@F1%#XX?;E1O(XW^VC)62\I_J_B)=_N\4\I\Q\ZE6_8Z_&M>)=/OQWJ1&_MHL;5H\9FZ?
E%QWP=/WKVO5U_D'+U)"^U\26Q@KHC1FS;\$B%AI&?_&A.Y M*7W2"@W=@&LI#_D&R/'1_0\NPNL_4R>"">U"U'
M";RF^VI^Y;_"/3Z%\P1U&I_8*EX%G+28V9_9P;-?C&40>#V4XEZ+%/7M7G_?M_721YU6=WA\+?
=4C\O30F(O1>/JZX@AL;C20&BE&C9\$%||=>^&Y8J\I)2_M4MA2\I\KG5KR\90G1KHO)I2S+1GZQN4>X8U
26L.H@T.HHS_MKM^<?I\MA@%Y;=;I\V%;Y?;QBW_CU@;O;\$\$(^Y704(C.Y)O2MDZ/_Z9_MP,F6D>&VO>#=(CS*
(C@W8?+LTIPL>IPT7BJL;T_9UHR=OCD4N+7=^Y7I_M\RG\8\IO3L)V\I9VW&T.1"CMT^#I\VH\FS?
9UI;R+QJ1&0_M\$.7=N_\$>OJ M*)E0\OA^N)"Z_\$6#JWFB\$@C\$|F'ZEU;\$#L1H"<7E20Y"EEF\OB)I\TEP.5U
M)VEMHYJMPDOP#"/0^/M1Z^*N*XOMT^HVI_T(4^*V'DO.2.A^T0^Q9%0_IL_MY^XO=6#^5^8_EZWXL-
F=29K;)%DF*KD?KYRLJL4;UL_D T^D4HQ^T\=OG\+ M85_#/DWX?G(3^V\J48)ZZY=XVCE^B94I
W&M<#8U^N;KTIK7)" M^GE(W3FEWKEQ\HNSA2R^=379G4V=_WU\I_@?7QP) A2"56W\5#NE;@>I2'I
MG\$SR^SV0\$-7918\CD\OFFIVL=XIN7>6;OR_N;RRQ1K\IY83<V\D36);C.BO2)3*.9IE_'I\I\$P%?WG6KXPS?
CPBJC^OD7AG4@MF_&3M_&3^&^?6K\5V+ MCDQ\B\ZRGYQ.OP\$=H\94TMNH;0)Y(&L;JB2>M%>DY\Y\J*#5?D?
61ST^AL M+HIG_?H.18PO1B3>?GGCXO="XO\$D\$3\Q\SI(F^&E60)\&%8_4W;E<B%9LH_JMYG8#O+L?C_FT0S(S-
DD7@2)<^&(*Y+%">A;A@=IEW>=WZW_MXZ2EG_MC^I\A8+=0=-!\$O_I_Y0FG3MZ_&B@'MGZM*\$>I8FS;
(%RF+=I^AN^I_@ENIE M;LHU?#GOR.E4ENQO4Z<\$/'^B&L66V=&I\8P\$%((B?#8Y/B.VFZ2/_WP3*
MK5&\$;E\$IT>I_*2D&>84@8MM"2A\B&?S>4@G;A8_-I12_M0L;JZMTU5I3UGLSPX&I8\1P)Y_C#F\I-
DUFEA\GT.O3Y7NWO_)_*I@N;Y#@M;I)4G^FU2G^M%;Z%N^6Y?
8>#W+FBJM+ITI_F>WMZY\$6=A@I72^I0^V^<+;= M4'Y";2*@(X&XY4?I_\$?"O27TX;&I\Q(5;I^W'%-K?B3\6?

HC<6(.G(C%+>O+ M+JGEF7+H7M3"\$H\$IHUR^ M\$EIE;O/&R=I&+PA;5=SQJNF>V;6O/ 6YLL
LLUK;N<76^;3Y4;K M&%)'BJ#Q=\$:UAW\Q\3IA<IKOP5'^ 9.S\|^8H=">/%B="?=@*&FHXM2?9>E# M5^EIWL?
C;>?_L2;?%#UJ T8P\%78KY\$ _2V<0?PTF6K4\$ _Z0MV(VL =\;VY6 M\96RG<;75XANV\$=)!JOG">>"G 'NV=6Y(Y@0! "-
;324A"G76HJG(O<-VIAK M/2 _101G3?AE>2=55\$#UD^M7;IO\PI? Z&"MIM%+&I+I; *V=C\&GRP>2^E?
ML8M/2MK"8=OY I9K U2=JL'5;6;6!(OU6O@="SOEJ#B/GU2IX^LL.293F* @ M12Z@XW27U(Z.S _940S\ZO.301K5/)
<-+ "Y'7X\$H://>I> KR7SO7VKP>G% MB' LXF RM<&3S&"@/((\$L=:S-[BCSCQ%96+X@/M "(&GY'P'>#Y*DF M%;Y1.-
'&B@8WG>^88^JV_O^2AB49;GL+7;PGIO\^65?;62T2\4R/*_>*8=QNM/^*Q;V^LHV!5&V28.%CO::>"/.R?I
|XX6I;QOU M1/WLX7/YHH_L7) M\^\$ _7\$9W/SO\Y9\$9D\SW\ 1->4H(I|R\^LN;VX.'HONO;ZVF^C;X4;.'LQW
MYBAJQD3FPZM"@9#=-Z^=YY.C("2.-+I"(R^X"9".Q0!\^(\
M>PU/HG\2HX0FT^I9LOKE1\@XFQ9@WZ;J\@D613GLKKIKY;I0T3X.A*M?@8|= M TZIL9H= R5466*!&NP8|
ZMK'^\^/EBE?^N;OO/;8&);V2M07&MMW&"4.B M@L.(W"26-*Z)FKIM;#QFIF"3?
_8D5L2^L^LRIMIG@AC9^BT\3KI;#>1M\YE M< B=095.G"8T0MH;J\$".1DM;U6\ER3V\STI/C9L>#.F^T;
(#O?'@BIE7H9I M^;W#+2VE%+^ .F6.EC\$K#H&+3>%=6&I?P.TB^8##H*X PX<1\$P&#MBL(@-) M1+);
(3<@7F)1CGL\W4_%S>U8MTAEI5PN4/HY+2AW>2QF.H7@3-"C\$B&G5!UE\$R M!
W_H>P.^TY:T^Y_BA;=&GI3K(NML<1<(YAQU;EQ\$%.'!';P@^8!9@NY3%3 M.8C\$;'+!<)>)?
MP\$;+ TZX^EB^T;D.0L&B>54U\!PR^3(#\$S\$09B#J+Q# MI8\$"/DAT4 #HUBY(D?+Q9GL-6M#UI#)GO1-
'6+G9\$R!AU9?^ESC"/ M7 +Q8SW&14%*=) LWZ;JQSH>R1T/A6=2^IGZU+^E?+>2J^F=3%BU;X**L0X8 M9;I
>_VL2Q=7#/F.#L?B!5;GPF=(P<.3'33>I0>7\$OG>SC\ZU-HEBEM2V M-PM;/#Z&U\16.MOGI+089_IK/D?
Q3^NRVYK*>W^G9?+I#^N.VI;T#\$@ QR!1 MVW;KZ-V<..=FW/GU/KJTTOSSL\$SS\$".8J&VKUL%_=>_HY(E
M>H)794;E\$F5M9V\=^;_82LUY/P4TL365 SXU\3IY;^*V^12%7E.(I /SQR\^ZE8R'9;Z1
MI0N/*;.&&.LA3F(10)TP0\$GD(/;1*.;I.8QHN2@B\X\X)O^||<9_FBI4>M
M4ZH\Z\Q=..+0"OM6OMHA'X\$J&P_SYO\^4(*T=7^N^%|OJB'D"\(05##1^/%TP. M"
_IE*!/%R7AQBUXC8B./_J>7YAH2U)6M;.;25=3" @ (JRY_PLCH6.9|= MA3^1\$82RG%QB>Z-U83.\$64G=[5+LT
+U\B1.;YQ;PO\PV^5IA _N&V@XP52A M*M7WC#GZK@OZ9HNVW9% PRMW?C^6JEHXUGX8A_N'L06M^BG_D6F-
_8"SWGM M0-T26_9=T%;M\J>^G5;+T0A4YIBWU"(4\A\I@^@F+&^K@3F0\$P^&H\N&_UZ M#32K^O4@ (E7@/I?
1RIF\$TN>N)VT_49M#)ND>@);|3&5A;+!-54\IS-D0Y=>NXW6V\F_8 _3R/\$1LED3'(TAG8;T'8D'S>.B;H6G4R0#%6
M>";L'LG;0?PRC'S\@I0?1CI)+@^@SK;R2T^OO_*=.Q\$5^ONH(12;E4GQZ^ MPSSLE7L;3Z^R(=2E.2/OTP-
P5H\XG6EB AR;4WC/MS.MD" 2IDBHJUWY)X\$ZIU*=\$5T@R.CGCDKX8LU5W3\$+QRZR%^UD 2866=^5_M-
C"FI9M NSS&4;.\$P.;1"HBG\H\JOP-2N;V2**/=B8T)07LJH5HC'^1ROLK MRB/%148I&8J\IH+W;.#!N\$5\FRT7I*>5>^
(;T'#(T>^1UW\J1;=?NGDY>|D M)SRZ_@<U-"88M*TH9%U3?B;Q1#BQO;PX_YP4\$%=@?NIPN/|Z9L').Y1KY
M^AV7*;*Z)IY+1=A<.NT4\THRN\+C^T0\ HDZAUM%""=2!MIQ2A?6I793%1XL MG\#P856XXQ
@81HWU>E_PT.BMF5N-%?B?XMF89O)F&&Q3@#23\ HS:2^*M@Y @J2T;2="4NM_HJ/O\5CUR8*N)@T"6A-
OT7V\$^V2UY\4?3(BI= +U^9F M\A\1?H?8;I\UO';WL?7H^< K\;EIE9L;V;NO?#VX^;_GN)7MQ4AS52S.
M5G\$XHP\VRFX.C%IH\7.C#;?; G\$AP\VEN\U-E_JPT0B1H(C; MHFG9I2J>3\Y-M;.%VG-
IFV5_3Z4VT;|X=YH(=7H&OZXQCLD;U=JX4V-K M9E\?WMAKLA^|HY#@;MI^H>V54'1Z_186/F1\J?
S6K0G61_5MJU>X;A3MDOO VN;|KHC MO342L\;^/C^*)A/#\FV\B1ENY.^R?=\$=1ZIUW_P#-Y"B\HYQED3;XPI-B
MH+IZI-Q-LTVGL7"PJOM\%WX2&\$TI<36*L#;|8;1)&JA.T57KJYTH=9^8Q?
=7K03D"M7)+>V&#J;A5\4Q1XCD6H\K+RU#^CH_+R?L\3) M-3H"23J?Z%'.BJDWY\H^JW#DA?
+E2"/VTH/VBV(-1)5D#<-W;J25_%KYB 6 MDN-J8%44<@ ZC63=Q\7C\$;3\X?SCI\I9D0^VGHJHAMQ^KWE(&I;H&
(GTU MP<3I+X923Q5;HVVH@X#TMJG JO?^ZOG FCC+IOQAK\$A<""3&(4.8A>7MV_!
(W\;V%6MK%KZ+WKP\|H\DM'8=-%_#9#J&+?_F'(Z0CN0F3^>|?W38 MLBI/4KL;^VOQTROXX"VO3DI;IM;Q YCO?
LW(Y^9\&+1.DTXH_747%T*|Z M01(\;2^U8N544GS1LN)JW2\3M**;PFJ;6T64\I0+0*)8R;7Q/S_#*2JW1 MB-
_T8*50B-PI%16TOBC)R>1R/K1DT8VFT\ORDFA_44//>=9A^ZLGP"VC^K M)7L_W-
B0+M3\6&5Z9>JA>OCA.HEG#3R.ZW(Z9\TR\$ _PL)U>CX3%KJ^T25^E MI?_I;R.;LH (5Y\ZZM5VP=6\;?
V_T&JCW+*Y)+MY@C\;"Q@8WD\ZDZ6X2 M/Y(>H'C^C\H1#^F15\H\!+L_%M'8>;|6J\IE% =G#VXJ?N%R2?BQ?
*3#_J6. M.+7PS>?/RX7W_SSO3KJZS>3/Q\$1B5(JUX+VK\4+LX98.D\=*78G6MRQ;Y6Q MRD\$T K^<+6-
6*#//E>QW^GRP-W\$O;V^PZU\!&?P<*A;\$J;4 MZ!4EFG.
HYV@ "7X8F\<|&6W9J.N>3#HHY<%;!'^W#QT8KS)HLUNRU A\;X4-
M)5%.F(=51&OZ7XL"B2;./P)6Y*W>._|Q+Y&+A' M_30\PYM8U^EW-%OE+ |NS%%7SZ#C&SIW%MO9NRY#HP
(K_6&0>Y7OVP\$W;D M\J\$R=8DKTG-|NFDX_19'72X2+.\$22SV-8KE5?;E03=ZUQ_%C\>G^F;LR\$J%
M+L)&G2ONK&D2=E*^T\ _0F4/_BOT&(HO<|CN\2?AIT?@*W7;0KJ(^)&5N
MPT&\'+GKG^ODS7U"Z;VEH%)A\E)(LS'J(55KQ 8\HX0U\8).+I^L\$KW1=&:=78
MU;_##RDZ^_0OD#!+\$B9D9%MP!?!1=NNW(C_R>N^V=L*O"5-8AD!@.38/
M17O;7U>8>C;.>#3!..H>|660T^|^-+T \$W |T^9?K-RS_|UCGV3>;AKIVGB* M?=@3\YHV8 |FUMPVZ\JW\8/S
ZE.IF\1"/B_.\$+7L^Q^XB0\VOB^T+J;0 MMNKWQ#Z\$W'#;L3(J0\ZK@D4\ ">X.X\$O>'2H+1+IW
780A;46\>^#RD2+Z M MKU0BO)3UL5TFP%*?TL7(@A\+ME0347K.F;)_LF_HG;^4;+OJ\0YD)J\50Q
M4PI<^*\$7G(8K96K"XBT_4\3J8#C2S;DI_&_%"?+9;.#;19F7K2_3V)W5? M\$'63V.=GI H/H>5T)E\HY(V N\<%
|H7PA-TS= M+^U8XLS>)|=;PQ7<|_O.2&VLO<")|| YS.Y-X%J045;7YUL\4\FH=|Q\ MN\0MPQW5OU_BD?
F;=\$*C/%_A-6\G-)^*MZY35WN>98K6#XD;^UVLJU6\3? M\@S-@%NK@L F_/1AWFWLBP.4TM&27X"*\$CST0VB2-
1\ALK&V-V\^5-7\W M=|6\T_UCA_#5AT\4'5SO0%2#".G3T3C\$;|DH452D*MH_)|^<^PI?CK'+(E MBU1NY2Q+Z_
_?C63)R.AZ4FW;5&#;@S0Q\?_D*6_13J=RC8);MM=V.F@E#\$ MR4Z_?I?
QEK;# _=2/&WHKINQ'4GN\^D8\H\MT09INXMH\GLYIP.4O M3D/G*!46HZ3\YK"HY@&U;-
SC.9\$4#F*/8^*V5=@Z_|W2HK(H9.R^X7;S-28 MVV\GB\6/D^0QE%Y2<.>P\$R".EAFY.M'2N>&A%GB
M0CLN(0YB7WE K\K;E5P#UINE\|=6D\+^NN1U<_F\|V6Q//_MI_ MDVLHB^OL+^ (KO68WJ_93;W 2;Y9N"-?
|R0ODG>_I0E;?0T^=>=>(|3\Q-QM63 MA\$#9\$ _PGYVLD^YT?#*B^W+U^R>X;W_.5!^\$%*B)M^+8ZYXKM-
6"!TD\Q@RJ^1 M*(V@;4B;.#V;|>VGXF2;H\Z\3;LH2F5VY8J \$*ZB^R.WPPE;C_1_J
M_=:B;O.5Z;1.CY\&'_XIK42^J3C#"3TM^OAPS?75J+YYC&NUVZG@"EA7\35G?XR7ZG^VO;ZIK0EZ-
^\$;I@.5C\!\$A M +H2=5?8>+NFWHA1@_AS<==(#;!)X:44?"S\J##/NZ00V7
M\BK5K#MSWBF(RX_%K\4AHX)'0B(\;4 ^YZJ\$;9NX=62MS.8SRW#|X\#-
MO8;*MW(CYE/SYSF(%NG.EY\W^QA=YHZIV3B..&4K9\$7MPSC\;?IAXU_%M=9 M#KCF46%V&
<9^Q+D6K5AJ5/H\BAU\^2>6^W3'3TK\U^M)?BYD>9=X*!2M! M?X9L_X#(U9E3G\$<^"?2U?
E^4KV<&YHT7F2\T6YN^C^>^/;3;RN WW&G5 M>308VT/8;0\H\DO\%"#T%49XXE\&F;GP73;UNE^WF\;HYC%-
YH2T_TO(<@6@UP>SB(\^/9P.PZ<=X0 M4^5.)Q\@G;8<8^G(O;A\I\&V-
U\$!@>QV<60"GE_+\$J0U\I+>AUE\;=B_20= M@ 0+11G\ RI9\ZK9-&\$I?
*WCI\$T^2%0A(XBLOG(#*4G5>OD#XP5*&+O_51 MT!ORS"@LV&
(;W9.@N)"..+@CF#@.Y1.PJQH\2\A67OCWQ8\VC\F_UJM>;P
MGAM;IN;|D\FOND5E0)W0L_O\ATVA;XU"UIFGS;G*8V_ZF3K#|K4&YH)*@9.D MU4X.(FV#K0\IY?U\O6TX/X\$F?
^MT2_\$B-%1;(C P%@|HSR0+7FV.3WD;.>Y M?7\6+DP93TZZ3L5LQ./K-W6H(I'D'2S@F\Y0(M25T^/F\HJ2VQC\;-

Q;GM;M%J3+KZ5Q1EAE8#5,IY7+JA5H?FU@K39+V,GR"*8T@ID3SGI2\MSI<MRCRQ-
I>=W\YZI\$!>=@7@#R8Z6\3=7FF^GLCX&V=&XK%=7V\FFN'^\55PSMY%RN3FIL_YDCNFG0)\$JX8J^'\#+-\B5
MP_X\JFMAQ4\$>'"/4M)MGCF-Q<+SLEWGD/DHE?;A\@SP'RWR0ON+X?X?F'H'U'E%U#I-MFDYAD7I2L6/W2%=
(I(W0+);JPLFFGLUC6M90/'"=&6PI|=3YWL6+1<4\MO0N\\$_F=[SA8RN=G6)1:"/O>1"0HJ+>\$SE\;GX%*88
^VU76;N4XYH^F^M8F1<2ZCP0>>N\$F5/2OI(8BINKNEN2EZ52'L&%FE5+7#M_4J@M"WPFHWE MV\;2\=?X
Z;2MZ;)LHQ5;=08K@_9>P;2=?ZG8A:C^)">@W>|>HX2\=6MDJ0WHJ
M7*V\';WPY//KA^_4AAXB;CT08>:2&)30#F??MJ??8\N,Q3=I2-P>1&-K0RXM8NC;"A&P;\$
QU\$%:8?Z(BBK_4*ZI%\$;LC/MEBS"#ON3/RGWQ#O6LA_A\O6)#&(L_Y\X2*NSO6FMV)GCXQ;^43ZS)FKHWQ?Y
M'+P.4+#+<I^GXSUE\$ _RIQD\$V\L<%O:U"P_128DYMS?WG.1N88*A.2U%G8*ZM@/60278D^CL^8\Y@ORS\;E2R
FE(C<S>0(O?+UY";R>9>!SRNF)\O*N:\XD_MRL\$3X1P\$%-&ROM*;/200P6B_3K\$C\ S&E<(CVRB\$ _29E74ERK27?
H^W\;CZ8_MX8_AK<%;%R2D_Y!1*(A)EM;\IGF86\50%<^+J(75QO)*#T&\$/2LC\MD&);+V?L;@+;YW@S;P5M7\%;?;\$
X#_2^3(C;258_02P.0A\HSD"NR\$C_MRMUS^(2TGA9C)CBOGB*88/+3H_)EXCS_#Y
5;7F=OTTUGNGVX;#@S;)1MW^KDL\NOZ+3^S>6;M81\1&+|R1/HO-"|<A6^9JH><-
TFOK\NK&GGH_X%HS&W%&T/BW_!/'=1F)8>M;/A&H>YZ2%)B_>YUYVAP;GSGK6SA_E'1T^
MGD)V2Q@IZRC\DF;_G1L_@?W\8LL*U)M#02N>8?>12Y1JS/=M4+\$)S7\$G^T>|"C34Q5R\;:)T'M\;^C'
;""+0;YN&FX^;#YE>3CG2L\2R^U91P?27906"E;Q\Z\TFW&_RA2_MAKH*LTGFH\I\W'2E
^SW8U9N8'\$KCOB_U.ONK(9N)\NMZR3J98H;KQ1GB_M?O=#0-U;*H7MS_P\NU4QPHY_V2OB6+
H/>|R\X\?!"\$CDNY=&R(0\$ _MND0BH2P)OQY_4_RJ_<=IKIU_10"U77H35T*2L?2P;=PVX4^Y>Q+(\$0>+;W
M.O@;="L;SK#?QO^>Q><_MH.90(V9AL_F>MO4;Q453#J(P=ATP\FJ&7J&_4E_MOMY_6;_Y"(2;_1C30GR_5@RT"QA
=V+6A\QM&FW_P)YF8_X_X\18BBH_ _M7_EH=00R6_L11\3P&7UMK_9N*3W7^E>RJSZ
M_HCD&C^>6F/XKQ#*O5)1)8-U*4;MF3+;F60J8=RIC_AA=|3E2_Y>\$^749B/ M+Q"VI7=<)"XL9W9X"\$8D*"Q_14
YA#RSG/U(?<|HRL_+|NK;Q;_UWR^|_#MVW>.'Q'6\;KE\$NT;U.7*91)9O)#_BOVHBL)#K)_M#AKTNID>P.P#33VI_'
B;_H46+A3\$=';D>LW9/T'3R\>S.H@=SC2T1L=;
M3)A^&SR7%G<I;ISMPL;J5N0\$;MEGO?NRYW7SGDCV5<7=/W?)_>^|P+S6_MA3T2\|SX_#K"HH2\|UK7V=W-
*#"\$Q_1;UKCW\H#;H?";\$/GI+R_#NPT;_&F\ME1_T;S/8430LGQZQZW\LEZ;AD2#IWS^N\4H>S?/C\K(P5^|
|P|RCHFUV>NU_M/XP0WJ=MV7G=GU;_P2\N;M;OM;T82D;+;A6@N\$HN>VA?P^N3L@W?I\$*WGK-;
MB66T;9^VGB4Q6"=\$C_GDE_PBL_Q7-N;D#^2H+T0H\1EN81P\$P*_I^>9)M_OE*X""C+AJJ;JRJ=;MNHKBR;=
|>Z50<602\<8Q*YN=M=#;32_69DOWL_/JL3\$V)"PH80;20\$Y^Q?!"*M'2;(33\K*#ZAA\BN=|?J M=|R_K(WW;_!U
\$2)=5^ZF@ (4F.E5GGWD=|P_M76U2VB&J)J\A/_)GP3>|F/"4A543^OAOBZX\9RFX@0*!8;|<G;ELJO>>>LK
MIYE\$OEZ3>?1N\H%0X'^_@=.K7ADD\1GX5\RU1UC;6>_N*OH;#N;^3LF3*U_MNV\2W/I^ZXI?
KX<^+W\6)OW?)RTDX_T^)&|@T_MFNK2;0+CB%._@H5;3TB9&P*ZGF\+LHP^J58>L\;S4VEW#U_27>?
|OI0OH>0I>P" MZM#T5QI67OGS0BSIO)!E30_16/\LEDZ2XNARK4\U/L?*"MYVGO1W#O\<"++_>#FM-;
+J+YO*6ZI&91/+P%5_MVT)SX5U*'_L6XW=J_MZ/4=1N1<8M2?
S9%05LV\6W*^A^EJFA:T)YCJ&/6"5"(J2&-21;TDZ)TM\SH_M11L\#&CKS*)?>J0*5
N*K+;NXZXP%#H%ZTMOQ?7IW2T@F;=J#0M(VSUIUPX*)M^OGEMFY_4U\DC#/_47UG)KIN\$8\%7JU0_0LD?
%GWU;^SR\G?J-65@2Z1V/ MYB#FMRWOF@FZY.TC?><@!Q\W0(KLGC94XQ9X*(&YG%_ZHKRY(1A06#?F/_M>
(6_(PX"@&7+*^)|7<@OLW9=N%ZOF\$|I^/_G2\K\54C_M5\TV2D2N*^_)DDBX;@N_6LT\$T\^8\#B*|94*5\1%_Q2-
@1RTAR+EHD@KVP!=M>;V&|T;=&^<-X"&%/_+H_E#|AR\$LRTP\TZBR4^VW83_ ^7PAH)Z"<21LGTC3_MX"!<
(<(LL&KWE0D)0IXSVKS"#P4VP?P_XD;_#/\&9*N""2IS\$N_6@+5"X?/_MIO_9Y80)5;0H_W_3;_4A-
2\3+/_Y=%BC\|S(="0T\JSJN>D&-7-T)C\=(10;QFK9)IW_/_G1\1C&_)BX'E_8A;\$\D>|M;8\4_5_V-B+HH^>:=80\<0C?
B\$|G4>+0R;@F%;T:(23TM^Q^#^@R(10#" \$7_M4FI^HP&|/8;C>U\$=Z9\Z0/E1Z""%;?/&@&1F_8\;G3&)B;G^0
>G4A\8_MGKL7)NQ4;X)/&_1-CB6L;_X&UR_T#X=E%&0A9S1C_ MVVA?ON;RY\?;N_M+|M1.^+O_E^JB<|^*
<9X9OQYB@?;I&6=*#_T&W85^K;<#%PXZ^L\|PA;9_MFK*Q6QE#2?
U^4;_0Z3=A*OH/|^8F+|PL7H\6\89;#JL_*+U^H_&M>=E@_M-N7_Z1D\6TGYCRT;<8;#;_TZTQ%0#";5LJD*J%_!Y?
4Q\$@^P^+B'M.YOM2&-_M&M4\$R_1<49_+12_M1Q\$.6HK\|NT)P5Z;Q;^*/^|HYTK1MS;D.86;=|B.*
MH2RH;N51;\$U91.4\LYW68#RQC\50;8>_L_%N_1V+9&TEF8?L@3.0FS2YT_M<1SER_6A_\$M5%2)>|&;Q\$6+40P
MD0\AS87>;:#0?7RWI8/
_EB"9Q\H6:T\4\8"1D0TS\A\MSBGC+Q9&PKZ7U*1_F\#_RKUM.?|>M_4G8)LH+ZSTM//+7M!
MY>>?E;N&N\$JGS<;W_A^R6L'G=J^*V>@I<=';\$)1V12"Y";X+O^5W3\|S_M\@&"OYQ/R"FRJ22B\$-Q;
f5HV5<\$V;I5_M>FUA(3Y\H67V.G3GMVD+04<5J\N020/7C7LNC.'UNA=^G_MRSC;W6\W_MXZ;"L1Y*^6;#?Y-
Q\Q@D*1_-TPDMK^PU6\/_K+(3;TI6#A2)OH@|7S_M459S-N);&|EMV8H@N3W0Q'3^<
|;&GBFE=_GO;G*!KCU1J"3W\4)A>B;*/\$/_MOMEB>P2.NEF=_D@0\|VU)"PN>5HU28FQD^X?HKIG
EM5\!"NL4FLXGZ2C0F'6-|367VT/9JQE8-G^OD_M^LHH=OOZ_U66Q^85"=C+;+%'@?A#_DO\$*&?
KBZ6UK>|@R\;EW:S'E'\$3D&@=Q_M<7N+@|AB_0CGVC^G"HI/<1"P9IY\N3Z2=M/>I2DE_V#_!J@3\0=H)1<7X
MA3QI@FA7%K);>|<^>?2B\J=J\1TLP9VK.PFX;|FW\K2@XK&>8@Q@2PG>-S_M6#(*E/YZV\H\$6;F\1%_fL0TR)
((0&J@W"OLZ@DL%1N\1GZ(ZC+3>)D_M<'P@A5Q'78J@V&_M^204JE82XQ<3"UF50%+C;7/@"
(|D(4JW18_1VW\1*GARJV\|?_9D^MPTK+_M%+S%07PS@M);9#308!=_D>ZJ;AVG>R2\2O;S%ATK(7N;
M^OEZ3\|V2_EC\TGIN8C\HHSRPW&T\DI>-9AWQWC5FI\|H3WNMVA96*
MF^WY3*MOAZO5"#BD^7\|O#L79ININ^ZW0WZ;\$R8HELDQHC(0CZ)T6W1B4
M68;6.\$/H\Q\21=|33FL;_7NHN41*2\$EUNSYM\CW+92EZ36W7F0<|3TLOU%N7_MZ\$(OI
&7H24B)6;Z;_G4Z&HM=/'F_F3YWLVL+8#P^VG<59;SMV\Y\$W_VW^Q_ MSi6\$FL<|04|
_F7\$DX6%|F1/S&JUUL6=^=_7;QT=VYS==SH>N^H+SME8\ME\<*_D=B;_L#<|FPH4/DQEU9;
|7=Z;3U5G+;#JDD\|MZG1H&L=^V7@G\Z>_MY(#ID)N\|S^T&GHKX\$5L0
|KZX+^C=ETB^|MWI^Z8@W"A8TLU&?]*+OWH^N*^XCQF50PSNRD7(4Y9X\$S_MGZD_CF*_L_A)>?;=
(<3PEL\$+_LK1\;E\3XE78_(DL)B?_1_76"NS5TZV^&_M\$MR_?2*;Y1UX@Y9>OQEP\|GO+OF1Z-W=2VX2P\6|
f*)W&\$4H6P6AOLB\TXC;_M_12UDW;9\Y/+U9S_-5V\JS2XOIMBON_M2^C7<
@2F*6+|/MIR+H;H6>C=#G^0^+XG<1;4MN_ _F\;H+Q^PM=TO1\|S_MTI^>U^6;_JD*D#/_X*TC%*BH957%#_M&?
HB4/F1<;B_(TC23Z=W%SI3V9(Q\4_MH1_T@1.2U#O_*60S6;863Y_7\5JC);_BAP>JARKAH
M67GR<31A3@!!SA%>51#C7<%)_F_T0_1)6#_T5\|F=BBH0\A|<0^N^N;5=EY_M?_MVE^5G;?6B(GP(%BYVMVX;|@&C?
9LZ_N^U+M3V68+060#(BSN;_2;G^_MG&Z?4VJR3;|ZX?1CC8#N2X\+P_E_Z\6&BT29^I&8(I^NLL6?|L\PJCLMPNU0
MI_V\&C^|@:D\$|I^_DZ\|+9R\|MW<(ZBA>_P\RM@ZMXUNX_Z)H\.*OY=60;4@8PH^)#B?<
MQQK5W@/"#T(>?THD6f;==_9'??+J;JF%HM:;%@"Q"GI+ARR
S=41B@R7WKYU_Q_13;#B\|HRMK@5\>0;7&5(1QP4O%F%?;O
M9K)3TWZ2/BX8.9Y5CK'2E@A>AT51GW^PI+|N\^EC_"|MHIL\$?|A(C%9A>3;)_FT28DPA^N=GOV.)?Y\;5#TE/B-
1)HCA^1)3K;=5EOHZ+9VD1=329F\|K_.FTC'Q_1C2&L84J\>I32C;KVH>1V_M?Q@*D_TL7(2\3(RC\ZKTQK\|V^R^2S-
DL%0;A^H^RB1CCP3-DH8GV2KK_MXGVP2S%W;"A^<:@_6(G%N_4Z9+X4%_G*;|Z?;\$MQ^V\D5X^GB=Y8G;_FIXI
MU\$=<4;W@B2@|C+&10?CAAU";_IO?KU7;9Q?7CA;_ZH>;/BNH3\|+B5=5M
MVD^RK(9IN^Z<_Q8H\Q0TN.SYM0&DE\;#+>>TM@*_Q_10.0N^XN16;H;"P/<M_1(C_ZO;_SN#)#OU/_OTMJUF>&

<7P7 ^ 60?R3* @K: DGA? -IIV6URIU4VW MAB^)+ (@/5(JE+ _ .HH'PS#1. MSUT AAY7YG' :YB35YI# .:0Y""#33.EG
M1 '!?C-)?)W" S!D?N:O"H>)VW&&NGY#B#8^/!\ K+:0XLO&=T81-A\O\ MVCY3IBSS9%-K\JU!&"-U@%/
U<@M"/,CZ_-XL\9.NS'VUR7H'2P/WJ(4_P_-MI/\OV8'K&B>!D?_ [,6NX0SR*PYB!>.:1==N%#LOH\$HOA(=U0YPO>8%
I\$Y\I\MOH!\$Q_O.S,17Z\UFI\QD\J_9C>X%#00Q&K\47V^%IC3"NAZ@_N_8YV#1 MZI_- "3-Y=NZ
E:12RAOZ%SRJL3BOE\@DBXWGC;Y>_VE2K09_7!+2D;+ :\$Y MP7W\@_E7XDQQ\K6%:2^#B;_JN'6?D;_&;3;_<2M:J\$N+->N GS-C M(SI6(6+KR:9 /7\$9I33I%)LL(UTS:X\IOB_'2IWWM)R43% ^X
MSS+X0#;S3L6LVLRJ=)J20)9@_ K37:"W*EZI;?V_L@Z5.)&7S/?+F2+U+I+ M\I@ (TLUAM=OF:K+O)D;
(\$ _=NG8\0B\H)^%Y5A00U@_R Q48CD1&QJW8\JU5 M9\I+).? \$US\$NBMQ6(DTD_TY0JZ#_1&1%/-
K9&%T2*L5>""B8,&F\$B=;_M MEF'=\$L#R'@R49\J29_K32YU'T&^#9@>-Y\$NZ)1=T61760\I5&SB-PJUIJZ5&0
M4C:IS'&J&\$>A"ZR5(-N^WR>=P^_KF\Q-LF8AL<8(RINOW&^9\+T))Q=;_ME:A+IM3I?_
4SB_?1IB1RABHG2(#U_JS5@_X2ETLE&Y6Y-G.#=!_RIH
M5Z5RVS"JW**_=YZ#_.G\I>^%Y\+AOXL D\XF2G\=Q<=5#_HJYE\I\N+\$S
M#8+CZT 4ICD16) Z9#7=^Q^2#KL*0&I E5_ IY&MK%%Q3&%8\$W%U_6#M'KZ M(R2JE0/W\S);1E85B"0)I
O3+XF2\$SCM\!S8H5;?C)3G\$0S70NGH1TF@N\<-OE\AIN;AC?@AW75K1Q^T%
M_DN/2'X+M#187\96D>H/J&YX\$F'(00'H^AU!!6PX%(U_9N6-FUIP.G1\A\
MIS P"0S4;3_=2FI@_MKMMC\CV'WHFUB;_>AWS\9ST\$8FU.28'H:A@%2+H\$2*(J2;_R1=LIHQ MIMP&8*)H\@:&;<)6'!
(\$JO7W>>@O%40>BOXLR7\Y&V\6)2XS":NO:IDD"0 M&/Y&V_ JIC%&T&E,OC/_&N#<2PP+I?
KZJVB\CO7WIGBA\IG"^\VLD#JD MG6\$3C?W^M693IWE\Y\@:!.A"3ZE1N;XP<)RN'CA-9643QPO9R\JO+^J.W3Z
ML1R_3(NQT8&0E9DPMPE_IS'&H\XCN."7FW_2^#PL\$2"YO:L#_VMF>Q\7 -(D8_MF3,TL>U^SFA+;R^J
HLLU^JLO7?>M8GO<_%3Q*6Y8)I'OCY>_.\$Q\T#8208YAO>_O;)K5/>="W2*VXJ;_GM\TF MS)+UF6R5\LSU8X?>E,
C"-!1**AC&XU%V Y6F)N KWM,EX,R\ 'FG&C&\YX# MC@_!8"4"0%D\I^TIBH&F2,*>)\$M*N
IXFB\0*TM)N0\$0,B3Q_V<;@H1?/N MP4'F&:R_ ^ZD\!\$O-0G\&8^F**\B0J<4\$)N\^;"O9/-PZRZTO^2+M&Q:PL^N*
ML=QH"UIYT>^T1'=(S\44RT)I+2H\=*-DTR>#/=FE'VR+Z\JHO,\^<6ACM M&2F>-B:H#-V3U)
C6+0D4<&F<@SN,+&EL2"XJ2 M0ROM/Q+I_Z4Y^CHA6\9A^!%N=OPEPL#J14^K6J0\$/3_S1LM"#)+B-
>FIOL'>'C;9 M'MB\;E\$14PN4<4QZTYI>BQ\XU5H3Z0R3TI(25(-D6VV2CV<-F/QRT/BOZ-
M_=B^ISY@_W_+MRQEE*#"54">_YF(IO5%0\$U2\I)DJHR0_V6ZK\JO-Q(M*&E\1%EFO"QP-
"3N4IXHX;F_6(*;3=I\$#E@)066*M,3VM8 PDZ^>K%W* M:\$1\>BE)WHL;ZI98AM[E]I+
J8C1*KIC/"5&5Y5X^U51;" WL@M=@+_J3 M&1B@I2WWP(S69F)Y7_ "K9#^A,I=7B>B-
>WW2E3'=)LR/I\$OPA\IO=I>HDEF2 M70\H#.#_0G""XLO>5F8OZ_9_U'6NKH3_-ND^+5;NU2R8H_APTZK%I3\I\$19
MM#LR9'9DJ\;S"IT^5#E1I7" KUFG7H#A\Z_5GER;PISSC8 M-%ID\ _V).HM,O8GPLLO ML8F*1V\$=(/P#ED#_#
IMUE=JL\$)_PDM&_YA3MWH%I" LXAIUY<;Q_6I&:V_ M8*&:9JBHR_UW@WO0B7-#-"@P>N%E3\0^+T;_RUM(:-?
IQT^VA/G%Q\IA MOM^6/7NIQJ>=I X&84!XE"=;)&-353L'F8^2T_UYAYW%X&_LUR(A'6GVN@E&DIGZ/H\RVQ^
M8HLL>@PK6,>>P%)_RI>#;+;I%D:>MW\Y0SX3KFAKZGODXANQ^X-FR?(!J MV5\JR)ME^GH0E>'G*XXFP^S2QJ
M<=>78\I>+Y*&_X" _0GB(UHN,4*5IX_?W05<=>W5HYN)E8M_@1A)H>2BS^1M MIM,JFR@?V\I(&@KIU@>Z%4??
@&CN_I>5BS.CM&&I79\I7MY%S7KW\I26>I5SF MYPM\I_TH\$17IZ>@D_@RI2\5,K^AXQ184XB8\0_&W^1_#&I6
MZ:/DIQQM4U\@>><FL<_JLN:9_3&5)-N#;!@?BR&H>_WIM4_Q3_L)9Z7Y5 MA>=/ADX9\JLW=IKLC^D\$HAS-
M544=Z8*3.N5CAL_+E\$&S+R2GV%2O>WC\I)*?Q(&Y<0_I3O:I_-DPJGF*=@KA*=I+;OU&O ME/_=6Y"WQVM>B)T,
I\ID,C\BXGS*KU^Y\$T7T-I+FX2BXO5M+^Z_W5)%EK:S M4X1_?@YP0\U2\I_P_@O2T04\FV>=J'S8V3-
CSQ1\$^+>C@N8D5\ MFTOP87IC*J*89\^5\I-R) <%"K@_YFYDX/#=2FIZ"FIG^CGIAC(LC0V\$L?U MA0@J\$^0'M0Y?
0YGO'0.3#74A%&B\$?78\52\I049GL<I"W"E+3'0:7)G59/ M6Q,IDH7R.OIYUVDK\1\O\$!(H6CN)%Y0%>@N3
MJA3F4\$P\I'6:0Q+=*WU!%IX\9SE089^N.E3PTI1^*B/3_YC\HL70B_U\=_N M#X RI@/>F-
J\$561=C\JFGTBI=VO:I7FRE+;_&A,*IYMDB=E\FG_(O?+N33 MVD="LFN<@7V=_/MR)8(I\$^_VVC6#^"
BL&FD<:F6\I\$^I^E-BND;^BZ3_M_#(8JPHH@Q\$B\PI>"N(O9?>3Q>J9T5QYA:I?
(3E4N'ZD_IWN1Y^_I)QBB8/S23<7G THL?9AQ MP^K9N\I#G_C\IV_.'0?O+;_F6Q1/&@A.MZ MU2Q5.0MD\$2THRM2
=5JV@Z"3B\@'_%J6=IYX&K5,9KID9T\JY%+UJ.41..1 M6>_M^_XX.1H\?2->5RX?+;)E-S<3X-
%IAYV9C78/GI24;K9WL\$PUWP-3<""ETNX8@K:A;D/KSS;BI_O"\$S53CF;HH_@R\I0 ML\YI91.YDX91-
U"+P5G\$LET>:ZT"+O2&VKP6B%A=LIZ&/EDW+/4,N8*MNF= M\$NW7*_ED\DP#6)GB7L;\$=
?C_@/IKW&O)XP2V"UP2VZ67H.O>22B=EGG_-(MBDIX.NF?D52>=VXY)=X94P00\INUQPRO(X
M:66*R(ZY\UHK>QM;="RXRDB\OM>0^*3J\YK?JW#Q7C\+I)A(8NS15U9 MP?
7>KS\HDNIZQ=BREKSG0>5Z\I@_+*(2;+8E:OES4NES3PCQIM(25:0W6#X MW8*==_J\$WW%2_H"7R3;NBZ\I\$S?
OQ:7&@EM9XX'KQ(9L@D6.#)HV%AI*3K MDU>-910OC7G>+M;.\$\$J\^(-_6X?4@G"OOC;V(+?
TIZI\$&I^I:IT>AVB=^46G;\$%".#U1"ZGN\$>ROFV/C/LP*#A/%
M\$)6<\$L\JZ8R>S\I_"U4*529R\I)/-77% ^Y%9)T%I+K.CXNES&#J4_&UU_@I M2
(E(8Z7W6'H&E)3_ID>+62'DPIS\$<4+^&:6^"B6GI09=XUR:T6K59-S7\FY4Z
MM/87:00R3_&%%"75G0>H:Z09U&U52@LH1OG63NQ_N\5PDVCI-\$_Q0LNX%_M<IQQI20=VIM&YAYRM\$U-"0EG-
@J%=?S&JJ3=LLV@'X%WU\11#\XFE"R*M>>MOOKG/;_Q_"A<%T E1S#DB":%2N?LB6IV>=AIGBOVEO\KJ%<\$
G\HIV?M?2XN^K^J&=424QGL2J_\$74ZKT\KV\ST6G_5BHIEYK:5(I\Z4\+ALI6SIFI>MAQ_Q\4YJ#O:/H&5M^I?
TKIRI<=>JCPZ9M\I4HC1\((Q\K@L*KJ^GA-DQ(I)#_SD/_GB*BMP^ISDB(A+K\ML%YM@TGRCSW9VJ?
F22^?#'\&\$GN.+7%_+((3/CN(="I9G\&*P%N? M+!LF70J+D+;*8@@Q(A>FEI\$ "BONC_Z/<I\
IL\$WK,X\I:@J&?H;I\X.4,*I M'+3Y%I3+OLO3+LW*O0>L_9D-?A3IV'XO0GI96QT\HO\I)7_VN"GG3D%"Q_9B_M666X"
6;_@V\W0Y7)_K) WN8@/6XKM\KW_PTWE^J=+X\J?^<9NZYGZRU?) MW^_#I#TX#YN@P' W4DN\I'FXP=(N>
SCFE+ 2VLEP5-D0MA\$3*OACPV(&-B; M\GOZM,T\I97HDY6G528'<9:05@XE#? INF&\$C=_X='1ED\RIJQF(B*&R%7
O MA\4ZC&+@'_=X&IC0.D&8G22TS<"GMRP7.RRQ6%ZT\!*"E2\7>1F/97^QG MSFJ^91?D(2_GM8;O\O)6=^;IA:
(C+9_H2Q#E=Q50_X:G")+X/8MBYRQRMPL\K-A>S\&?^D^_QZU MG9Z9@>YV4;2;+(V+CW"\$X)PZK_+*97D>\$?
HIYI^TYD_YJ\I?X\I5(AK_PW40MHO=5Q\$S=;_RN M0;:3).M,J"1&")9\I3?R4J_7EE#>+I\6:HIQLY.WT&CZ;VFO<=>?
X_UOU_M55;K;O(CZSV\$80T_0-G IX8-X7\&RA'WDY0G/_IVO?Y_V* QIS"1I\I=I@P2\4_T_9D#C#40G\$R0T7\;:
(%U;N;KYM)*O>\$?C\YD^G.3A\IV M./VLL13S_A7:_+ZA2\$GKTGI6C>#^=E3JHCFRX1\ACL;ES.9&4)NP^:3\;L
MQ(*%N?M.(=9>R1;AUL,A"RDIE+2=I6\OG+V:OI\)<;DK3V"M)8A9)D= MEMV)UQY^L_ZF,K?
G12IV%^NZLL)G:B\JHd\$CW"YH.20\$S@6'U\$+6>J0"2KZ: MM\G4BPABV'D&MEME2^WH\UDK_IEY>H-9\X+;PL-
963C^MS/_HT\$SLCW8*Z+ MLS\$45=:@DH&>I\AFW05\5LZ;VZWU\N#M'ECLY0NJ5KQ^VSI>VR:P\$J'"<5 M\$;?
MX:IS?^I(72\Z+LLU<&G/O2;*0^L+)_BRQ*P'H97\6PN514CD7?3D M_*JS'#7G0SQ:<N)B:VB
O:R5C(I+V_8GH5_DH M_*D\I_6DL%Z(TOQBVS183T>F_N3<^5%LA UL&RZ)F#;IDR92NL8C_@'<9D?VSI\V5
MRL_U-B_XR5#6(O\13U\F4ZB)Q4\B\G?D_ INCN5O_I\I_OVK3&2>I" ^0E"N MX:I&B\L?
R%#:^NTXHH1OY'OPI#&'?KT.PI>VV?C.&SGDNRRQ9.C+Z*IHI1 MVT_#NY).9O_/4*YS<'CYZE/_
FFE\TN1F1RBK\0952<^*=N\I6X8T\I\I)FA&3QIE'PM,P?I:G&YS"LC?B=@)
I_E5A^G;_HOOD>/R"P(F5/<I'GAV\$S0<0?VP""W8D# MIIF>L_BE(8%=_U7*.Z9X%Q"DUFZ\I2(A\AX\A3TY46DS4.
IUs<4.Z\I1" M/_GAXYKG(AK;L)DM%(C^B@1>8IH M_C;_B;Q%6;JRI_UO&A9V/QO#WRH78_G-2%(AS&;C'=-
_F<#*VH-R@QOX3H() MF7X3U^)*H8Y2<=#U7""FY5HA_H'14J M_Q_?>V\$BVB&I%MA_LHZJ

K+^1GLO\1417_W7\5J\H>RT67: SX+LQ-8R MXK7#DZ2A1:P%BN5#U-S=)HD\O'HH+
6:O=SCKN#L&.:2!+6J&B6_V%B'WARI ML'X0*IH<#H0_KK.YG5%)C0(&7(.B'<@CR'.H(%*...2HF2"244IH*^
'F^00RG\16169!%.:61 M0JY#NA1>[4]UWY#.:@:1_)B'M&OC13'2D914 T6/A_7D=NOZ-<7\XK\ M_)S'J'.*6=>?
IS7/-5&5WMN?8DCXJA&KB+>I9R2(6)G(^DBUWC\QH_K_B)G\0E
MYA\N5SK2*QD\1^6BLLI&8 MI#1H8YF6Y&75D)NX_K_DRGCGY64J3RMI9\K', M)\DX=+2S+16VJBVL I #6=E-
/O1!\$!*<&J C:9D2@(&V:(K9BNSA^CGR9!>/- M%DRS\5 M'S-Q
6WJD")J^6Q<580FY5L1^@5:RT@%HLS1L: @ "\$W4:,RI-? M(HA1):,?)PB"9CA^M
=VQ=9B/65%\$FE+N+Q,1476R5;J5*E8A:IAFU/%_(M',J<"?^1> #T+M@XHG X*=MY+&2H5WG &H#YI,7TN0(DW
E0N"> V1-(S' 2-8>)A@:L9DWPO-1U7Y5Z8 MB0_8X=ZW>D+N FH&K;3S*J5EK0LRG@WZJ&JL,Y6\$-8,11FD<+N<-
>#IS B M443=Y8=U2&8^T^WNWKS))O" K 6NR=4#<[RWR A*M.H)?Q1-"K'Q\<X', MD-?T:8&142^+B4%4.
Y0=)B\BK C#FS=>S+RWTSTX=Y-.99Y\$%N6:!:> M;X KU.E?R^X?LO?:(4*\$,JUW-M+KWO\K.ZM\4(@O,9 8QAA-
U87VE=PY7 MF&E3T2PZQ^7O\FVAB0FGQ:YH8'W.KL'_N^SR5))F/U#:=1/G?F0#Y5E MIE" F70Y3VDZS:-
YCAP7-\$\ (HG'A# VON0Y%#) MJ@OKE\$(ISI>"12.N42\5U\$5\$+99CVMMMYC0?ZO/1UO#WP'28,@WS+)U.@M
M'IWQ+O17:3@-K\G30!S1C1FU5OLU:UJ'E&L:?:2SCUN; "H:E5&\$H=B\$ M_6)PWW*2X=CUE"NS<=%E\I+I5-
)#M^3_.C+(<2X>V2WT>(A^C0Q03JR\Q
MUI\4S_]>ZF7A_O561S1ZX#1/*J2KR6\$4(>GL)EG<"%F'KRP^>: #&OH\$RPQ%# MS2\$C9KME%+?
EP0L3'!P?:L\2D&PTB\$R<_L*^*K7U4DN>O MW#f\>C#K^!ZI@/H\JPO:4)N\$DC.I8.H_L32Y@!+=+C3F2:P=CE-
<B.G MY=H5\V7=Q,OF\NOJ'"E\JUR9E\8?VOQ^LBNXH\$;F0=#(Q7\$*L.P;ZOMH3'GC MU\$|
<12E8'Q\49S\K+ _UZ<#1?^0W:MYP5>VX_Z8<2UQ8ZR N\X\$S*P?> M7H\A+Z?SGP(4%:-+V8MJ_!P6O)
(DRR/4:2CXWU?EHJHWPMPRO(*?P_E@6 MPP\$TS\$ZB'F\+D"2JX9=1/B_MTP2W=* KSP+OC4D#4?
87BV'O13^B_P*#,NE:3<M2K\&1%1FC8+U"MI!#D-V,?YMSD(1D5O=IC M)V 6:AZU%*IRKX@G,:# V.)4/8(-I
G4E\$TUU9\5\$#>N,5TY9!":W7ERBI M:/O-B3D)^WO#K1_ ^YD4+|_8*,EM/F1M/4QAD>";N\AK5LNS#
MURNR%L;F;87U\XH5IT7TWV7E4>/^YP#0*AAC1N1P(M,% MA6#IS,>UQ(GL(R)MV" ^\$2444XW2O4+>BTK-
+TZ9C9IVBA=Z3:T\A\SWZGZ MZ@WD(MMH-2S\I#O-H)S:E-76WAVT6.L(*5#M;0/F"8)*&W0Y"!\7&IS'
MZ^.'V#A=A8<:DV-!WOMX@?CO^W.TYNTX8\R0S-Z8*05Q+6/#M_\$\5LIE2)CB
MR\TQ9#KW:T\1L(Q>#5QX5)BLT^('6'7#PJ\$J1:4(PNSZ\$RZ+Q22FIB(\$#H'9-A%S, '%ON)8*5E#>C%9A4_W=B,
MY.\$#J MOS\ YWB\TH> <2,^0#U)@F"2HG4PT3\X L=M%J\FFZ9IOD\^FGK5(C M^EU?
TS;\$C*OLZZ&H+H,2'9@16PD#1"C%F9=";53CLDVJ@%Y\$Z0=>|XA9F MY15\GDGRS!\$;BRSE9.K"DPP\$4>AM1-
%G@KHE_MA5/E&W;I^&UY\U=)2S MF;7&J^TWKP"OXQLNJ>BU/<|ZI9\^ZB2&42E-15;H;4S(0'Y-V8## ?2DJ
M#%,9.&@RYB55SVA@GBM9Z>55*/?+3T*&GEOT0JVL \$!5M2^4M\$=YWH\IRX " MI#>M5'XKL 3N@)*
:@3;C&+MP_YKP:T@UUO*^<G4W"\$:ALN0'BBCPJ"ZQ3 MI3^:Z EA
)%=>/"H/C3'0+CIYSM1NYT, G6OGIE74.O<^A_F^&I^K+J ME?LEZDC:>JA>C\SW= @!^86LXJ90>+;LRD&I-
/OB@F\IVU) C;?A@T: ^#W>_19> X8-/1:S U'9\G\ ^Q MDQZ29V! ?@R)1+QBIO@9<0L9+ISX?DX&-
(P:A)6@HRI&15>+&-B\IXA/ M(?R;:=B*XYH72N< &01EJ8C#P.*O;JVT\CXJUNIWOZ9E/I_Y&S\GBV\W<-6Y-
2\1'WH#E\^E9V2/+M_M% M27JSJN'HK_NH4IWWC+>K&5_%7I--8<1MZJ_:C7+I#5W-\$YK^--OB\4
M\2D)%OU+^H@ \$+&^HHS66V:(Y A30Z9H)*N"YVG\BF_EU+;#R<884/U*74 MH)8X6/H^=35AY #5.W\0\TFWX"N
:OB_T)2\3=;0%W^2YY"1NE%< MP\I@F*GYH-V\OQ;%99875AJWF61TML=*8.HPK+TT_A8EH\ZYC_NQW_:1:)
MMU\1T.8/7_P^LBD\3U:_@5=1H\I6MJ\$%(F>B_OQ%BE\$XZ>6J&)QWQQD\
MGFA4:UAQU%+WICVM>6U\$6/W_ _\$2H'R5>U!:(ENI=WSJL\$T^&P4FC)M_ M
8K#) CX&R593TCI=>|F1LSBT\O;^> \8":F4+3P=O@W<%SP*5?VJPN92%5 MX;03N>:;4*Y
WMQ;:3<(*E0SE1UQ\$K9B/4R#9YP\NF\,R55&: SX2 MO+B\G\2J\O49_5\=-C:/OE(+GRNFA,?P'O-WE>79\$?
6N\;T<> \$1\X%15+ MZA>E\ (F6RHM CURS3LZ&FO\J)C8B_4\BM3&KAMW4OF X\INH\MTS\^FNG
MM4\DA\3^P/M_B3Q2HD5'U_N:<1\$G\$>- D5T)+*C+D7_ ^WDJ_ ^MOX&3\A'H'C9X7M8U43_8APS
B#PJ:W0.B\3U.2E'N:>>?TI"16 \YJ9O\MS M>>YQ7TJ#KKIWKH5G@M=3,Z>0H'?EBY;DL#;:(4;"JVC)PY\SY4/P=
(,I_N0\FB.S\RP\HG"N9?A"GWM5^ M?53Z>#L\K;1!U):GV=W5KU&MK/M.)\$2QRXQ2VE FILW6"4VB/G-J&+D)K
MGFV* K\H&ULUNZ"-NS2BPJ0X+)\$QP)L>0I4 MYTIB_T^!^ %F\X\&#<@F3Z(H% =^B+7\$&.3W)JAT\$L'L?I'RG><
I_8DB%> M>N>W_3D@TX+^IVQ)0M#_4DL^1\HZ\I\A\$3M=V\7C\=W2K^_ ^PR;#5.IM6*V
MDFNIDT+^SAK1G"QPIR.ULEOW@-J81PL10:EQT T5ZPY*@(0/9-/EB-53WF\$>TYA=.=E"-MDY.
MT317#JKD? \H2C_0058M#TEU.R.^ (5_FC=;KJ\$%OW=7@I%?5IXC)WOC^R-G MYX\%?
MW^=S52N_)H\1JZK&#<@8&HK\$TN:2.\$WAVZ05WJJB?2L<<4;I&QB0/U4_X0S>T:X#0.7OU' M>"Z^?
N3HXHP@F3\$Z*N\SI2(H14NF?N3+I&UX0:/J7"W\1*73-"0<&@"PS3 M5A7DQ/Y,Q8D%'D80Q/I*&//=-/O_/\L50?
1^R"S)+1@IETA+^PG;O:3L MV.8IX\,9G\$G\I"#B> VBA9)N)81G1\D&)XBM@(*8%MV(W+1>:"E=!#6\$;9
MLF;.&G*SO47"C0E0\$?=>)*C8!>:;#)IM*0/V)\U_ 3PYR\4"U\B>&P44.= \$
M406\6432NDO@B" 4VJ5JD:S%1#_SC.A0.1C'P49?^LK&ELL)(Y6-H2MIEL M=I=&J&-BJMH,<0/V7T?
(G#VA6'L*:9=+MSWVQ0X?\$LWE!GONB+ ^CPHT.ZE M;D29VIO?IBW"-89+
%+11CF2^&*. 'C'D9N""=TUPOTQX::H7); &MJC7.2B^+);1W_-60+S&W_%IL\ (60TWXQ_Y#)8T+|L\N\K,1
<I^\$WBOXEV_M\$D_N;^F@ERTE'11R> /70-SD7SW_ ^DZ+=T^J\R4SOCP)DT#P;D@S#ONC;<<4YG021ZHGF?<
C\Y8TD#>'B1\$W\WY?EF:9LQB7B0-"=E M2@)NVRBK_EN0FK?XS\Y_K BGYEPL*#2);20\Y+I0)EIS^
>YE\ #/Q>@V M<1U*A0E,T_ S=60!%1L\K&(CT?IZ)I@&(SFW0^8_&H36_#;PUKIC0T\N\HCVKBN9YMT+
#MHNDNR*RR7\BJC92.K_WOT5%BKL=1VDAJFSCYYZ@I7C#_.29\$+I"YK7G@%LP
M00%V;1>10B88QUX*VBWBX+GX\% =G6>5>XU87:OXGF*0\ _F-TM2ZJ*GK6\ M4YU^76:EAK)T^Y453S=Q?
F=W.\$783GV'H8I8_V.O(MV9=MJK\^1+1HZ-O5 ML%2#^B0=@E<-56ZE\Q:(1+0ZH" F26>U
MS_F^1\12==CNQ0+8M0PPJ:1Z5N6=EE\0B_5+U>Z\PRM054M!>|O5<C.GW_MILY"O&:O3MG;
(3_XS=,FA6GC5KISA_1Z8_&?CB 9=Y M1+\$M.RB8"KT\H;BI,TN
T^UP;#)MX>\$Y9M6\$M&%;2*\$EWK8#Q&WJCH'5A M&^?L9R/V5PO%(6-RRUYCEQ7;>&+BJWYNV\^KY-
-5'V6FKR/R_ YE*DU@VE MG-I\J2RJD\23JF?6ONU\%<S9.MMJ_?"085/(%P.G4/\$JVVN+NE=C(QV9W MY-
_0.KT2DV0&:">,BP*84VLC8M7B*Z5G;K?4NSA90\$2=L? I^CDA)_5-U* M\$3VT>I=X&*A8%O_9PJ\$_.W<
UG@/_M;K#&+|L1<+0HM4\BA\$U_0YS);A^" M3JPHE\YI:|^P^ C7A3*W@U=80Q))Q
MG=LRMG;=I_UPTPEV77K_1;^%9^ LM?>7>^E<"_ B>G?+EL\Y\ L8.E%G/M M?Q^Z'YR(PW;J"!2H
(%B/&_30TPQ9L5V2T\3=-1#BT\;2+WP!\$O?9V8F6_M4NFQ\:#VXH_HDVU^
=I\ROQ>KP1KH\+^Q0N%N1+)X<9A\$+.&*K>_#O?U3Z M%&1Z0\7U1^QRS+2OB9Z\$
(N5M;E'+GA1N7G\)%52@NOH#X= MJ-18\;J M*5\$3U;HT#F F>@A;_0%?HUSMC5U;@:I: ^1_60+I&
C#>T6J&#103A_GL\ MCHBIO\$U6_ HBMA=&BX\CK4&_K'MAS7G@17KLF7D3-ER7_0>QR@O\96_X_F MC14S?
P*KY1H_B<9DI7ZJ=!1OL?&#A^NR9Z@*?! M?B\ S(XT* M&^)^N?@??C9ZI"+7-9K66IA\I"20^&^RV006W
DJ_*G\NL>AW4\$3@K+?D_MZ-%45Q9&@/(G_4V+L+IT7\#ME;4OTJ"/\HK+L1#^+TE&V2B;(^XY)^ M
Sj^DY_Y(8)_P+SR=JWUOF-?Y:5.GBCVDC\B31\1DV%I?L3&9K-%A:Z7 M9#J#DX\<<%(KTC_U1_B(Y92;#SW%D,
I(9FC@=O*.8R\ ABXV:=WX%B88PK M;YG6G+&_ WHA'Z\QLCXI63HK7V% C"PF2"123G.R\ZAI_7RD@Z&880\$1.QN\;
MG#?92VJT8\C4^9>+U_/I^&U&GXP\HT9U+6W":Q^BJS700))#E?9+M;8!

MH\$IZ#C#%V_!\$HP0^!14>1%23;+ WUD.S^RZ!(SB^GIB;C3ZN M%l=L\$*@J&G38>
(X>S4@<*EY3#FDYR(SL&UW^WG9A.G^#I#F3L#11W.0_9IK? M*8@7X/YGPN^W4I&D/=DW>3N^R M^\$6Z G
^391I879;J)(P6I.=>Y>--01GYI70OF>_ ^7J^ ^735I|N|32D) M&MN)5G_ "I?
%.RUC7#TY#*1JFTWPI(OXH#IQ%6L:VLQ*H^I^#&H@D%.. M_Z6>.EG%IY5<"O^AGN)IT5(2RXI@W250%)F_ 'ZB-
=8I54;.C.1N5W*40G2?K M8.NU*KIZURFV.BNKG^I)99C%LNE5F^C&_ .O+;LP (O.O^LBIE!3FM_QGB/G_ MXP=X/O_=
%I+ P04 " #I@7I9C<(*X^0 MJ % &UD="TR,#(T M.3 R-5IG.3 N:GIGI+QW6%-1MR8>I#?
I(\$6B5*6J@@"@ \$140\$)>B86.@(A(M^XD406H0!2J#2ID6X!(EU Z8+T)#1HD@B& RG\CM_>8WSWQ_S+UW9OZZ
MFV>=)R0YYZRUIHKO>MISSLI:GP;A_4R.0(PG2C^7(3_ (< (<-G /O.T! M8" C>E@&G(9 &O!# #IK/S
PZS0IZ#^X;17X. M81%@@%3Q^VH! R/(6NTR0)GHIZY9" 5M(E8#9/D-&I?C^D\$A4I(BXAKZIX
MXJ22IM99I7/G=2Y?30ROFIB:FUC:V?OX.ATQIWF^TIO;QS?X06U=24-CT_L/'ILI.KNZ>HTIHV, MCGT?
G_@O.44@+BPN+;17%TC_ JI>^4/9!;V_!%;&F^K?V+^2_ ZI<^, MV/_&Q70HI.17!%A8CYHF\$S2P9+15)"1S)H#^
+3U5MG+(<5B21V_>N43E M- GRV+^A_2.R /W 80YD^2?TSLA1UQ2\$AYD)^QF 0@.0J>I23H!^2_I?Y28
M031P#L7@AKXJ@+0IH#QFU6!Q#I/M42)(61>7^XIJ(%&PK:CCT.N/8T4I9.6L MY?..IGEE\$Z5LGK=K^/UO?
X#2.RIGB21&CBE@8=W2CY7T&^B@FYH#-P#:H: M>*S9Q%AYY&>(8QI09(5,1A,7L !+C">IP:@VWE+8(FL39RM
MS^4.DA4MZSJAQ_TNCXN\$GU8V_3T,I+7QWYI;80*7PWP.2@I&4'\$^C.&PV< MI6!P^<=#GZIJ0I-
H!N4T^%I8:AY>1A.CJ^&"HDJ<+?PT@LX^203GE8FID7Z MW^D_4 YB&=OY1H?N^SIPQ?>C2AWH3#DI#ZMY7N_5/+I
)&ZCF^7IZMGA+SA+ MF7/Z^(E%-UZLMS^VR>^!1.IHN\$Z;I+8U^6E-8;2%*=73BULXKOIG 6)2T
MOCCB(U,JIT+S M>J#_QO_ E^.*&GV^S+TXJCZ3ST^AC^,8X^AGI+KT-O))A>'3/E+D_+^
MEF240B1=<N|JGV8I)W&N C-IJ=QT-R97F&ZP1=+>Z^C)Y7NLX+"02=<.07_3
M<*1KN.CIG#9XC)M@IX0TS5ZWBUYE@EM4D(DW<+;L GB5NL\$SQ&DGNJI%+ MA<-"8+TD@;
(Y_P4W+B5++Q0+T4!B6R88IG.+1TMUB_VD^!&K3W^W6RK3 M:FK<+M6P2TUL;QU_V.L
Y.9627HQ@PM(Z&@5%71X@ULGVJ>^08G^RI("7C MXBRC-U N86>I9W#JIM1AY5\X0(>/Z(^A">TR.(^6
X\$4^Y)1^OZ\OC) Z6B/ M6)J(TWSR8)DJU9B38R!^2BG&/>W+=\$;XZ; X2\$@4KA",S^@ (L^7/@8IQI#7
MPZ91A^CY1/FOPQBV//94E1 ?PDIOEL +O#.8P9Y1"=?S_Q8&I4EA2SK|P>2Y M#S20):H^/B.S/ZX:N23X.'U"/_ %
I(D(O&#%Y&590Y5KE9^(H4;B^O6+\$W> MS#B1+&AVIG01.'1A5(&I^P^8X=S>0+RS2>KPYLKJG M9^#A_!+D6'-
+JH+!W?XFZ: IP0V_MGC/S^%Z>TR49=VYQ^!Q_ ^4EPWK,
MR&RQ%;1(E.SXI>CS^N=GS7H6I>523C)U=B6;R;I&+Q(
M^B>@!HWI+OPPIE3ZIO7O7P>T!^78^O.KLL.=QM.5FJ=#2,%UG,Z)IM.WO& M_H^W2^627D PCIAL6/4#QIVF
'7RJF=-Q_\$.BSG-I>JC.Y^D RKWF|>Q M^I M.&+JXRSNND0W> LYI^"0P4X *HS&3#&=&@VD8*=I1/(YW=E#J;LQ:T>-
%3,Z/\$"YV)DAI*=2=X,YADBY,X&I^Q%0_5^"M4FIP|Q|>X^9I3Z%9
MDA.Z41(T^QJHSR0K)AF6XBM%#P6XJ_POPZ0@.DAIZ>N>FQ.T;V7;_ M/^G^E\$CZ>Y@G#."R7PC;JH^PMO.L%-
&@=/A=SD-KOUU\$ M+RA#CSJXK%:@:N;M;.*W?U2TZH68^!^S\$UL+;IMTMJDT\$XL*&.8'5\$?_ G=-/L2C^#IR-
X(@/D5PS)>AY0 M8\$|SIH#|&I=@.I+1>G+>A!>.*R>GB+U|= MV?ITLT^*8B8%.?>*[R6(YZB:GDUP&K)RF^M37
%U4ZC4WA!>P>IE9TZ?W/B8 M:RK\$TF8Z6%#I\$P=>#&HJ^37)*C!D^C^XBO%&<.0HJF1U#=#Q8/MH-I^%&I& MIQP?
L46;#(H@ER8I+^2YQI^JXXI7I^Q2@/7DGI?HHCIG%_Y3@VHRE7(7.D
M%.;35^LR3D)1Y3&6T!)X^I5Q.E^&72RL_ #R!U#LJ+H.<6RH,TX)B|%) M9SY:DV^V8K.#IG54F29&Y
PD!\$YR" SIO^!2!_?5!B9(7CM#3_R*=IY4FFL MIO)F<+>^UEC(ITWID=IKO|UCO@=DO5,F-
#JS@H;553U2IFL2W+NV=-C01S M4@B&+I&JNP^<*K+9' 9AQ!Q AG(L6?I S+^B#H3B>O>R<I S+VWIR?TI,I
M^@H+Y.V.5^O9"QOQ(M84<L&*HI^76G|L> MAU08;L/43+30:3DOP2I@I^P^TS>:YQ;N-8_00T8QGIGI^&
(\$*+ICK3RTU1(M\$^U17)2UY?X."="3)_@J_9X6^:HH_/_V1>O2H;F.%^CEFGP>B9S5#R0^4Y(!;00BGY;"'
MI^+.^*LF&T+;C/IJZOPZ^LSKZJG)-R!EE)>SIZ(F06:V?7F5Q&:SBFF? M_8?
Y/O+CKU&1.EV|I)EH=G&MP_)O%5Q2(>PY_**Z8DHJPIXL%B2;^LB&=Q8 M.O8BYCI@3SAW9Q@L9IO*#H^ZU.KI/_
%R^QEQIATHCE:\$S^ITHL=<IHNO. M6<A-RV DSW=F\$EC IQCZ<|Q8LWXW7,R;2JHM " GM7^B_'.E3V#I<^!_7N
YB*LQ^74;1?>9"/HYL>!)JT M5;FTX|<5_>PT#IZ>8;/^W DU;G8^(DZ&N1GR@2HCDI!#.9H4;<I|9CJ+XY M@#R&
(%<^B64&X/;3&XX(0#^!_B\$+T YNN^B<5Q)-A#_*I/DP|@;"^IU\N(M1L^)^Z: 5PK\$8F;_)P6/0/9;
I#5IAI6G^YP;J.CWC.>T;./%5^;9)Q_IQ#"I+^LN0@/7?>Y8GIWW6T.PI@)QX M?T1U)><5R;@G>IPZ/415_WI_9/F
M%V-56>IN_#97\$U_Z&@3A|>T;17.W&;2B_ 'E2;#I#DM\$JPT\$69D@.&I MCJ|H@H?%CSO^Z1H=I0?X22>
<70K9.IQ5"L(+J#53MH<IX_=-R&GY50 GHD MXI_BMZ1FO+4_QA>LE@#>V9K>9_09PS;
(FOER9>*XIF^JMEI=I6!5&#=#Q1D M>5TBBX_V\$2Y+V.DJXZ10ERIK&GP8Y; MWMX3VWU!JAK"5;.!%ZM4O
T=N)CEI3KQ)^KJHROS(%)J2(QH\$ MO^AV_H>0YVVOICM0VZ#B\$O5=
I8QW1G:RTO7RJHNR^IXE.G+LIN>4VHXB M;IX|@IW^X7/T!<SDJ@2S4A^G!>;3;2@:5 /P-1G7+BW0_ '*ASR&D^\$7),F?
MM3;=YM;MN.#YN|MF40:#H_ |VR|ICE3^YIX*8YI +*4+;H JNWRSC(R.X1P M5)L_P.'SK^C^L\$BJH^T?
(+MN):DIY)?J#;W7YG@Y40G7WDJUM+Y>WOE12Q
M/WI_/_0@%H/39^MGV%52A5V0!P!_M^W^3)I8_ ^L(PQC@Z&B"=UBL1U*& 4 MLXNZ6)YN,F5=[XF7C7D=O=?
\$X#Q)HC(.7P=X219&I&C&:007\$(('26Z8F_K&MK_-"!%A|E.^)F^TC\$ _:=+1U53=
(^&P^NU/DB:3J^N^RWI|FS#3GBSX?5VP M^T1P?GS R>H<\$HZ(W4@&A0N0_-DN9J|32VB!V1T^U\$CLZ^B.+%DY
^82I M3E^H@<HJX10GIW+EL05E<('LEF6,K/X9-NW5P1 &_I9;/_>FI4AN681Q
MEGB4=QKHC710BZS>T^TXN^IOWUBKBEM^Y^U;7<3-C-IB)3:FPFUN_ '12:0!*&.#E<|Z@RYS>V
MITR|&T4^UL0+XT|Z=*.JL^!^@-2CAZ*.,%_>2AV&2^ZW?9>EO MSM\$TYM1GMCITH4\$FF DT6*#'.E1 AQ
%L2Z_ \$ZJ;E4|H#<I^KM\$VGO9|URU M@#QN4>O>A13#M/T_#BKO;3?EX!-UY;Z=I#6N|K&X+)
M!4X%#G8;&SA)FI^3YR5^*= 0!^7T2+IQH^HVJP^RZTYJ927X>QMDU_ E^8 M9/>E;_ RUZOTG|K0&4%_<-
#_/QSD(1_%.N154(3_1:HIO#^+I G|W&D3LGH M0FIBZ#>I\$ _I4_>Z1<I B?EY(@T9U_ =KF&:05?LX>0R^3 M-
H(B85=8^NG&8"+ADGC51;G1E^%U|@I?O361@;%)>TB;JIR,%FX&8>I@%L@;&.;
MTLS@C:U0!&B\$S8\$N>5.JHD(OM1NM^SC:S^Y7<&9F4NNL^HK!;F MT^U7^B-TGAVRX^JL^@8A-
(<1QXG^#4,OMO^"167M^W;H3 MJ\$LR>T!^9YTD)HT74^V^J WR4D;A^@-(BDYK11E@;=(2OI_PV>V!2=;
MIKV^N=<Q!O8V569IP+CLT6B&V25XN4)JD^L.P? @,CR;I)EM3>L2M_+ MJ>^PI@*AA0;X%E^1#T
R,VW5C#7)LAT4A0L9.&)T!;6;I08_16V
M*3&:\$)IQN!U(T9R/P4FA?Q^<(B76MIU|H%5KW@%|TDH)/UZZM)9%B!"B<)\$ MI/FD|OI>8!>AT;I 7B%:ZU\$%XI)
MJC6TQ-BDN/C|UHE=8OH.VR>1.GI%<^U|O+U5R7\$^#&#<23GP^D0%*"IN+L6 MDVF;L7_><.^V|-
A@^83S9;%QI&M)8^Y!LSB-VIFM-YCYW/G@U2Q.@:'DIS MEE^IS+S?"R:T/RXVS#.A!%6XIHV.IY)(0;G.FG=#+;_-
.4PYB^S4N9^3M^FR M;L;ELA?Q/SK@R#.1!"I.%@S|3SCI&@K0Y2:>&D5RT4_04W|^%5HRI^&KLI
MB(9QWKG^PV#I8O?VTI2HM;72K35^U.DI^>.@V<.0I5=T3;L3X3JPAZDV_!M,LWI?
@GL).I@CE.CX;/_@Q@HNT4^BOWJY9*#I^N.O.;R.Z.KP).YL M-85UTH2J^I6EM;I.VI;_VC>?
@KFQM.AL+ 9?IE_V7_K|QQ2CV9ID@TOVPU M@M EINHPUHT^B>9V-61MW.^I
<|XPW?;F8+BCY|49W_ _LFZ_ CUCPJ9Z5Z|C M?R?^A>56I=-.NQ2WS*3K^E|C|NQ;?IK6)B6H.I\$^I4GFXO-
Y\$*?<='N:3/ M.3+>8S2\$NKLEYK_OGG^HZDQ\$KE^&_-W&-#6Y;L.4AH^PSL^D PAG^IAYX
MJ.CJQ^6G^B+^4_ =X=G|ET4KLY*U614G^XHEB.# "K>8;UM2 N+S7_@= M2CKI23UW-
_FB!;UBI33@4ZT=A+?8 P@RKE;H;?>/_L_ MJ|+JHB6KZ2X MI_ "4P+S!^5T;+=\$TR83U8@QX28V5(W0)?

DMB"75FYL1M!,"5%.QTXI:&&WM=R\XIX;I4&98Q>CN"FC/ZW"10* 7E+ FVO2K.1-J:> M-09=%=CR/?)5U?+)<3>?
@A//IC2A;J0C.=IFT"!??QC5I5VE J^-+L*YV5-MVEI8I6%W1&A5^T12B*!VRVB32XK"/V.^+=U5>R/P(\$+ZF&-Y?
^74CYA, M7^-JU4IH;7%I^PX.2,N1N"60M9WJ=K?IZX; MRWS4Y;8>M>L^FW6DK0M2R?/4>
(WD+WPV^E^8=Z@92*MA:8SIJHXHOAA1&C;ZV> "\$O=89-ZYTFVJ MG.QCH4:UX58;*I! 57) ^J83C,K0V8>
1A;1D0^8.B0>70.(B&8UGK)DD MU^DKEB^E;C;@2>=%70=9*1651EGFIN\$JW,V#QWJO^%T@-E5M-F,56.1=52
M%SD\$K42%(N3/*):O5:Z3\$\$.=2/-HN;N8D@B6MJC/R\2ZS%"SXX-I\TM6+MNY+IWF<9TYS_=7,?
D6Q>Q#0@3(X7Y,&3"J11\MP)JHM37A=PO#=@FYY1Q-OAPH M+(F,,=J?6'NA_8BAXN5CFNVH\$Q3E^WZDB?
Y)6SQJV(QWYBBS6?C)*P+_20\$/4L8I;-&\$AR@I9B\$ \$-1AQEA10%DJ&6C1-&CSB0V)7 M3'LY,0TC^0_V8-0
F",I1\$6"8SC-"^R9PO(8SD":A1_-&%9ETO-UIYH Q M2:0>"N)VQ%I6>94+YVY"4L'SH3S/O=-M^I77FP;I>JQ5I1
MN+)*SV1"E-B6Y0:><*:D "J0JHX'O! P3#45N3"R97F^\$>8WNH\$7FG U\$-2? M>=@C%6V78<%C;
>I7C*UO<4N6K?I2:XX0+GD8=CO?IT4W?PL_/, M3F>GTF&BU:QP\$033>/O_3IGAM+QEFR?
5(SYX(AO+E5CF1S;VO_-+5T@CC M&BCEI+0\$;2V 78-/T9/+!/#I9M 7H=0_CE2W0I^I8E:W@#(-
)^75\$T7XQ9>KOW!IDU!:"Q\$<9I3_%^3K;2*#GHWQ@K&&I M4Q!B?<I\NM^A)2;I+G1W2@U78TNK_6K&"YZ-(
M%Q/?9!+M-P=DGSJ@IU^+=T#M%B! YUN"OI:A)2'Y1E^)%\$^>*NI;-WT#GCE M>T5GNCEVANW VM I4M
<6V%M%1M9;(#TJ^GTK MAUQ>1*ME2CWZVZ:A=X0>I^J&8@+V-VGF2/DD*V81K5'U?I@3IVXP;WZD& M8
1*N>=FF7X6Q>3P/IJG1B>+4I(XY-%>H&)A.WT27L7D:600V;#U7NIE*
MO8JTIJ)SIA4UHY\$1>:AD#1&M4;TM=Z%JLUR^LI8;IXY04GG-IG&MW;2^
M9T!>+!MC)*@YO+F>4T% ^I6B9I\$6K0<^I7?&A^*J_S&FQH2E2"YD#1(D M^?8>Y"ZQ 7D\$(0TXDYPH@-F!
(M!_!8+=Y ROCUBU=-I/C^YG2IW?>DM> MD+I-E+I^2G3&'("Z#Z?>@A?59H+ #)Q+O*
(GLMKI G!>P4HZ;2.D)BP322TR MO:I37+6T5/M9'9<I321%CN; MO:/U^C18)20C16?*\$H5PA0UC;4;?
M\$17^@SH>.U07I5&^Z!UPIC>9_)LNM M"MBF_7CZ?/VB+IVYJM=3!*IR%
+B0LUY!*B78I4^B\$/U2QVO\$A%"50IF M@0POIWR7PFK;G'AGG:L#K\$/CX^I5.&MVY2?\$/2/3PG^IEDPKY;O!"*!
MZ-Q@)X;V4U=7FC)V6"GRH#B+<I-M%2;2J;29"%"M/DM4JHO56KN;L#V!O MZ<>IRUK-L7,C34I/7=,,)
DDK7I0)---MEI>QTYD.KNI4?E0;I*YG'4 @RECA5IT-YOY")^5H-5PV;5Q? 5=XK3Y3\$4 MN;Y5.II@HE91+9
SL%KXALIK5/MEZC5\$&\$AIFHL0SS@IS+F&YTR8ZG;XVLL MKWIGCYX7VI/IVM9VZ4-CO.SY^I0^XUT6GU+X^
M@I/@Z--S:9?)%LEZU@L8?M>PINXY^3&M5+M;U5?>GJ3F G,3?UOAJGZRVG87 MMIX8Y4JIAFKS1^%+H
UZ3;"MFO22/_G<)AA9*GL;+QWM^S;BNWO^;IUZ?>T% M15H;@J1I/GZ^9YAHYV3XOZW2%;CH+3I0_OV)_9F"?
8%0/^0>3Q7H_3 MM8ZIFW8HH<IUKL5 H=FKP".JM6A;V-(Q8004/_R-(MW5IA6;@0*^1M^Q #)L M B_(V@=K-
EL'JL^F'D,5#,'0A;VYLOO^JH*GL%0>0HCHL\$X-J1WZIHJ M"*2_GI^G02E'WQU
1EWS\$3YPCW_HDJCIP%\$9@V&1R^B&R("UNZO@(@=9C? M>@M?
M1I;BW#=#&)X^YOSV/NF9X7=^4SIQ;Y(YV=RG@7C\$@V6X#AIEI576# M!J5;K40+ #V^28_TCT\$W*SP-
1DIML@P*HJ66Y@OY.Z6R7Y\$M&J#B25M>Z9 M% ^I4T#(BNU BH:E:C?IP8BOTTP)-?56E5)+\$<0/SK9B+D@?Z-
4_?F0_M/(XXJQQJCI#HH^O1\$!QI>IN&!: @ \$= VIX52IJZ+^\$YI\$+SIY8G6?6 M5S6^16Q.CNIYU&Q5X5'1\$YTI*7
I1XE=-E6X;%&S;%5^I27JF/OU^2J_+M;J>U^I0I1D;"MNGW;T%(@WS?DWX2P1>\$7U&-PM9?74"PHJ>EB(I
FBDR MLX7BDB2S"4C6V0=#X PC)A X7TK)I+I; 4"J9;ZIC30^OEI=@O+JY_KQ^EX;
MOTPIV8G:OWL*1L+3#%IK2.U"TO>A"&"Y8S*+!PV%EHJQM00YUUP^&I0
MWU)76_!KOY5XB;?W3>Z^%MLI-R&2;I"J>)# \$R3 P=[X81#(6M_?^?T(9P
MP%E)AE5Q\$;CIBL/(#^+L(F=#I-8F AEI2<+B).H.)%:5M?@WEGQ'GKL MIP/(B,, \$B/E1H6OH?) OXP!>I
<"> BHAW^@5JL'6C6QM? RW>UIU0(TO H MR?BW)51+>I*ZJ% 5H" EF<^UG'4ID:L_8CZC1;GO6E?RE56NLS
ML&YQ+\$H<&X(O3O;0@XH&-J:3G8"P #^H=IUF;TE/ K9\$RX3PK#TRKF^MF?/<"\$COY/FY'N;!&Z?
AK;:GLU9JA)C!@#":TU\$;WP@IUN0C^8J9JV.??A M1A9O,YCL;?QM;9I/9 I^? "JQJ M7DCU?8-3P.\$S8*3@GC;L5-;
(-AQ39=I4RMQIY:S5N03;6S70052D\$7V+> M#S-W.<(<=<@A5TD;G)I)W2J;IG54XY7X\$EOGB_M=I&Y3
I"%"#X; M+EQ4B;KU3_693)IV-R:=U4;5RX5H/IC96/"X.(AD-Z65U>_8J%;+I1
MC3D;N10(&L\HRAZV=%=LS:E2OKI;I.HW74UI.(A2HZE^_2:REIEP^F)DJ M0HJI&0*9-
G@NLPW#B#&DPS/F@RO"DM#;\$+P7X;P?I)5J]-H9O.) N**@"M M1 Y:H0B17+28HII'MDS5ZM5'H&KC@ZA M.
(41GB2_1L3"-C#B#@US96IG"@38F6R-U65/VURYX3B9=5\$N&MX_01)9' I M)<97'IDIS3*LEIV<I?
I6HOXU\$<+^XWWA.*#3H>)>C.L3U I>H(25%AMS MO(#A^CM>FK.@ WXOZY/+YERHUP>6.NNZIG@Y6"W-W"KQ"
X4O MA9*L<6DPDC4T-2-LNV=7T,-=9&0Q \8&J.TM-C1F!5C.I0X)T#\$\$63E'I6+ MB_@.I@U%&F+DV?
M.R8I5#ZI%959FE4=Z7"G9W;-0XI=IXF%QF%>*YHOT0 MA/LM4? TT/K>GT)#U_%;%IN:P:PKGW&QVI9
A.G9_@4+^I148;7:AM+@,&^I4TG2KD/7+U"2K)>+^VE-V4*0I,E')_XE1.6I2U(Y2-I&>%I^C MEP3I)!
&PDU13:EZGBIJM+R28I\$;#H1;>7=IXZYKO M.OL3AIT,RE-I3(L->2IG@9^C!;2IK=+A=*=?
^WV\YX[#D.B=#=:H2!(S M@^_O;I?V7%>VF0XO^!E):GST=IHP;+1YI;#R-1& G M.RCP(1A!G%I0R@I<:1M/B?;4.
(P6%G1A&NI72MW6IEI^&K7>@EW6EIMW1I)9 M4@H_#.<*6E7Z-N#67!-DB:S-O9!IG6KRG%^I#)I^KI%DY
E\$S'.53-C!_I MTMD+;YI("O'VGNE46P?L)ADR:P?=@06TM:FDZE4P
M67C#)ZR)*&Y4VZ=YTE44SQ50F7AXCBVY-4E@4QK"S;L7\$SLI_ I@?+"K& M&Y+4\$|^+E>
I\$Q1JXTWG:L=/(NLI+M>/KN_=HV>^S(0^D:6MTVL2-6J54V#QSBBP54I9;CMZHU0JF;\$_%T6IL!:"NZM?
TWJV%40>5E_E2 MH23IAY5Z2D_W.06994J1.W/LN DIXE^J(C07?_ \$C3Q3EA/YW*M4P=)BH
M0DS\KB625=3<I#TIFYR@JH14&U;_JISU5J*JUHFU)CAVMH3
M;^W=6P5TS=XYC4T6TOX4.IF%NA5/(G:BAIY043_*PPJB)I M+;,&^>*KTO:CCRGIT^1= Y3B%)X_@H+&"
'W_SIF JEM6"AB01.A= MD/ITC-R4L(TJ_-IK\$ \38WI>7.IYCQC,^HZNIVY'>)>@9&-'10):7^JW"Y
M_2;%DM68;.\$D+4/(G)3-H=WN.G4"TZ;J= _G(N8^YI|^_E MU#;CRT-IG"Q">P'A&6-1%<^&3OJE MLZBV\S"O XB@.
I7: R45DR:QI2.CFE&F+Y;U\$RRR73Z E'C(+IK(H.OI6ARI M#>= 7YIF\$6VW/I!
I<I%W"=V84F2<_FY<IBVYXL/3<"R'IJL*IB87Z@VMO 8 M<\$*Q6X,4BI IH?G0\$B"E,+F=FRG=L4S?
R/#A=V;H@ZV^VO45GB/VI(8;T#@ MMP?L_!&G(IQ7A)W/^IC9>ZN-IG45GT)I!UW;ZX?;+*6LIV+IJI.7AEIS-
M66:MRNM.V5J9G<C;MC NU"D)S" JW^4*#JQCI TC 6RUUC%_QP)KYC.MIQ*M#5 6S47:<WM\$KT5<I/I)HF"
D;H::MMGN6H;QOFEI_VI7I65P MAVLY<0*FZ7WI>VIU^PB,7=G@<4)S;=I4A@F\$2.%E'2IUXFVY;4>W&QYI
M;20+ET1@_ WO@=0-QADYI*ZM*.\$3_V+JQ\$IZB% MNFWHL?O1."CC4PIV.+@2_?W3TDFS(QCV%G!-.TC\$,*
(A@7\$@N!&RD^31A M5DTU6I<(I?VN"UK!2JHK3K^NX%<3%1.Y"7/X9VYF*DP7\$JIGH*18FSI!55V
MZBIV;RIX@("BHM)0%SR57REMF=I?)ZOM,G*DM*JHI.ZIM7I?DY" 3""&T%4EK=QNE/%T"*>A)?
ZFL;G7C.K0I^A5KV3=FIETZ MAUV<9XRDSUO&BSM;^#(8=I:0DSI26"=?\$H&#D<=@<^02G&=*?2_#%SIW+
M>UIR5*\$?&8LZN2(X60;UE;_-BE59'22Y\$6R.V9!E38_MK^G9NU;V7OJ_E1E:OO+I/"UH>+FZ4Z

MOAD3M+NW\$B*.DO#:%89+:Q)GFIPSVTYL3#L@*DNS@N*MF*PXV%HS58AW SC? MVNX25C\NH H\>N,8Z_Q?
X(1)17:!*I9\Z1J\DH3:NRP(0?&WN\$+*D?H
M/HU:L\!>+3N;0WUA9NB(O\TS)7A7DF1R%M5H#97TE#8_F:OQ'LUE_@W!!M=VDV8+)T4%)=;! MU!^KWD+R
0.4<U>16J\K\J/\^P=ETNY>4<?LD_'=K(-SKCSMX\NN M3I#0UDU%J\IV YNM:YL\3U+!1VJ)*F:J
M1H0?TV\I\!>O.=27=27(O6GJA7SO?>TP\$!(N\6PRDY^HLB-1N8>W_2CK\ MNTQ)F4HJ\JM3M;YV36#0U-
:60322&*Y\$S?>O_XCGI%<1\$1&K9MI#BXA>.(WN
M@5X_"OME<.*HLK\SHK+94PO=.FW^ZHUK@"!J6MJ<8GY.LIONO31F:.*TMV= M&'8(">\$9?(<
:4+@Y+K\$SHE=57P;U'E_:U:EK1'MUN>J>"HW3):R:="V8NW?21TN:~?O+PC MQ-HZZI*V MI85Q(CGBQ?
FKTW0WTF2+-59A^IW4:BF3KV0EX:W\:/CT6J%G+LLA2;K?N M?O)OG\DD?>U>^=K%# "DK@Q3OW_K<6/_C
%4431)+FJ:LQMKBW#NTQ=T MV^%B%*W\XE*100E0\ZA7Z.Y2TZ<+U>QI*XD1>V7\B88A\GO4UA#1%(J#R P
MQ46%3%@"+A"PSB&D" SL"0L\$1N\MC.G\%-IT*O2>ZXK0U*DXQ\CAZ3/&S9UC M,9PL\$AW8-2R#VQ\I8/
&DP5&!"EWJE\J<.:90R16BT*W-GR87T-?K^>OJ ME)1Z=U&OEEN;
<#URWP_M@O\&"K0RDHS&6_E1\B2HGY%\$^>UP0= 73T7XOV M^I=<I\BOHE..X:5J-WG?
U&&L=I<009\K>[*P)'C.TC\B\?%)T>B M#USH\$ES-3Y\$*-I:CJ@V1>STS(^YJ6O#_8%G3KD-/7I5J>\SQ_&Q1WH?
Q^B M_KMN\8;F%G"R="/\$BP@373N\3E9N0HEDKFZ\4YF1Y7VCHFP7_UEZ?@>HE)V MABD.9.1*6G^@?
Q^VY9(GJ@.*F.TJPGP:S.=#9KM3+*BD2V+S7DSXMI ZYTX M:(2#@PIY1IYP.OUH'6%ETNGK.XNL2\XK'RA5I)
I2L#YUVN+TY63Z#Y\$%I@ MW?I"X_Y CBK;U21M7QM36>(3^=I\JP6"3R5E4<\$Q@3L*WX_S'WHV?:?ON?Z M
F0SP6(T81<)>VKR\$G32B_"K_A8YH>N)1Q\6ZXSVXGK:)-T-# U29Q00K. MS26_G4+
HSLXOE5M)J'MY=I/#P"=L5R\ 59THX\=,MDS\TF"4X@>G>BZ(O M^T H8^P0.RT?3>L7K5SFU>"N\$V%M8L&NT?
E7&Y25\WQH58N\B K12_Y\H M#G<\DNW6NU_XCRV<-Z:!!YC@_ M5N%NJ\256\52X<6IE-2#_84M5WJ4"\"_O
MX\G&E_K\BVA1#0U=2YT\I\U:OL(DE:*\@=> B\7.4"W@-C.103Q.\#H7Z MG<61+-6G)#L.F4N:?
KI%PAFW)"N^ATN*1%D^(UF)L1X?+=+3%H\$J\R(P*ER:W6 MA%V>\8'3O\9T+FG7E6F3V04#'_Y92KH?
(5O(5^67%G6PQ"6J\6%#XE%\$4 MAAE>.7 JED\$&K.B.9\J\U+2K\I M(^Y?&M"4OGW#)7_1S\$5'1>9L'4ZQI
M"5^"BI\$#0KKWZ?G-3%:INC NB/8>%769'>P&:C8QUODL%\$AFEK&^7OMR M_06I&PC69PKX.3SH(T3Q-
V)ACV\I"C/*V8+I07#Z=JUO\#A=HD\$Q\Y\ M\>RY:(A\$"R-I9_4#S#C\$140%=1:N04DQO)S&96TN!%OAOB?
*%E:J.JY-7Z ME\$=7UI_4CNFYR=GVX7Z6MUUNVD:0"N5#7\$_3#=@JGXUT8Y"P9.OU?EQ#P(G
M,1NS):B\JZQQUZRD14B:~T<:R@SGN?<1*RLVA6#&E&MI>&Q5#17A25>M16#3GZ&NBE-ODI2_XW*L^_
04D#N4V(W=@BZ\HAGI7VID?^(VLW?Z3>*>Q M6\B&_ \$K"4I:TPZ#B1MTY\ 66X_&O\$X%\$S\@)\$S#08S)@I-
_Y/>W6)&CNE+ MAA2&WS/TC.X08WJ861I_1*JDH>R'I^L#G.4D2Q/8O30H.0M7I!LMCO!TVB2 ME9??_MR?
RV=E9+UU/OOSEW)JGN2\87O3\B=[3VT.(>\HJ\DOJ\#TMP^KB5 M:~W8CYK>(_YG_&J.MH>B5-F?3W\I-D-
:2R#%_A_OHIBFJ09#OIZ@&I8W:~T M"WH7"M3.I K\WU?>7>L:\$8J16J"<#9!*:#7=DS5P\$[L=<5-ORBL"CP
:P\ZI0GS4-WU9I6&:+) MU+L,S) >NX7_EML>^H%:3Z^&X>#1#/_R\Y+>S>:+L%+6RO.1+A3"E M0JG..<1M7&
I6G08H25'_Z_RID\9ILL@TN\Z=>[EO/)&K?>A2I7\5J?>O M@>=".)48Q8^_6AH%7'2%ZIRK%62<>SR:.(X U61>/
M2_Z%A+<@,BJ,+A+W,F\U(KT,\YF3^B<:~9V;3WL1RY4'~5FD=22NB).~8
M>YD'WS26\$C\I"ZIT)=0H\A'R:N;PB"2IRRL7L/G(3T9L\8C_+PS0^H2W
MZ*)+HQ)OI.OP*37>"XHJXPQ\LNKJF&9WX-Z*R.IQDKC#SY\ZW?US"SY\GGU\$
M5L\$Z33+I7>9GFXC@=:LX\$#.B5I(2Y*.ZB,O/7WEYOJO^0K5QRN-(Y??SV46H M+DXGL_'O*+Z.?>49E\!4-C:K*
>JK4\HK36.RGYQ>\$WCAXI7%GD1.HU-5OYV966"7LCM4KS22/1+W\U=PE_Z&4'G_E)&
MW3:7B6):KYM\BC+N0:0R73LO9O\I8)(008"B *9I&F(C0:GM?^&)5)*7.MV3 MVAD.=1^5#?
H@H&SY+8.NHRU"U\^%E8^R(HMZ-X:4>+?\$HDA6C_8N\I33%=\$#)#B+T=MJ9WA0%:MJ_6<^I\O\I:JL314I%RGE
#SAP1J.IB\NGG+MOR*>MWXHT MT7X&Y\^ M2:Y\WA7Y@^X\!^<1\I5A680%G
MH1+YX\LSM04&+P&JY83\O_UEX1HEI\$A74O_U22K+/#(OW7\&D.../V M.I^K7\I\$Q_#O&IF)A1?U
A&#%T>*WA\SVP_ S\&D1G#L:4.*+K=2JLOA" M6NEL"&3WB\9P2*.3?&?
I8AJX\54.OD"DJ:W8ZUJ00X:N:T0.1N&\N:SH MI+|\#@?:W\IC6 G=(TRY +*J^IW UV)7E#I/F.^>5_!LQA^J MIO?
R&%Q9Y_.6/#3.&I)6\$=63K%!=<69ER_FSWLO\Y\$N!>:04+/L XK?B@(' M\HR1"IO+
(//%@J.N:BV\YD9WQ\I5822<0^Y5\2D:@UH1?_6IG?>*R.LR# M0W2_12G_";WM^)R:8?+VQ\I L<=L32SGCA\J3I_?
N2GYXYN\I\$J0N#14YI0"QA M-QFIDIR6.O)CIC\ID=3C>^="IDGOCNV*)N:JFL6\K\$SGLFIO\5WB%OE<
MBGS8^&MMSJY94\42S(OLGVH ^4..LPZ\@2\3B8-S9A"D_JG\AE)N:HX&\$ MF8H\?IMS^WK\I\$<1:~
<%/8EMBS0HR1_#R.%IPG:2_'D0.Y'A#HYJUTS'L:Y MIDT X?I\B0=FIE.0"Z9GG P-ZWK\3Y5RV\X4\G96\^^?E#R?
A8C\I\$WHPV MW\WCO:1DQ_ORYQ*##\$JZ+RHM:I>JN?S'W+)\@06"IV9:\$X#HEV3T.W\XY30RW
M.=W=SLW;UM>BUZ'PLUC@1.C&.PL_+@.GM"2U"SYW)?!IS\ZUS/9=580@O7 MF13\I-1\$IX_DP(O&IS\5&2D_'C\$
13?15A#+I1>\$\$PLP_/.!2+R)#I+8N MY%:~S\7+QTV:5EZ_12*L\!//ZOEZQO4XTOVK=C%BERL'K4UT3GA6<68M'
MDJ0\I'D"1=U:A=DN^6_3DASE_U\1-IY\%":ZDOMV7#RH+R?L^C?R+:U\I7E8 M<:3X I-'GJ=N32+ "E"LOW<2ZQ6X?
40QZ\ITL1B-2\T'S.1#DN:=C2V?OH&BD MBEM2E M3A%9>U27IUX.G5@_GK)=;~
I&%Y.FKNP<^LB/XS\$KN#"EVAH^4)IMO(R96
M\(_1%ETI?#>4M\RI M>MS/\$\$X45X>KZ+:JK\U\ZK.G+3D=T("8/('=&JL=I"> M^ACYSXD="POS"7Q
_I"EH4CJ?_8+^Y@:_50-(QP#&L\63F(>2\$,&#:I? M@>^>W);=3+L-?>S\I'9A30PAU)1N_*X8VBAWV@;HJ6>?
O&_2SW0WT'8/_MR#A:7\$?H7U_K_5+0>H\T: MRV J\I"FA+LG@_1UP>14\!(PG ML)A NUAT&(<7I_C75Z-
YD%8ZTE.&?2.*2\$+KRJ>Q@QI01(?_I/D\I<>N& M:K>G?_L?>>84UVV\IH ML-&E2&I1
4&JTD4@(\B1-1\$2\$4)2\^D@3(TJ5D"@*2!=04!"B% \$ID=X)'9\$7 MD"Z="!E2\$TIX(\$^2+Z\SK;7WV>==
<9^>^IUG>=7_O_)?DR9QCCGO<IYACS.>" M'C4
8Q=4DGL=4^~3W\H4IZ+T6OS=7HYH\1*1/C7M.^@_W.Z.^4G_I>E#^J MTKEE_HM6F-7+H7/8U\4T"#9W#Y_K1=?
Y M?4B)TU88T'8?%0\I'D'9:~C3\$A.1>3OB4?-3R+>M;L'9\B&%S3X\I<7#%T&\$ MT?CB^?
RF88Q@WH*+_7VFNZ#>W?DGA.Y1Z(E5ZR\DFV\R\IS'D\I\$H3^N9?V M#(@ "Z"M?
5\4GW*P<6.K5UJOY\$GYB22+(LV)5KB\9C\+C037IE#22;40^5K M%+MYGF>D WT=OC'#>V?XH?
UG\H17OHL\8;%DUO\$N.F*P4&H\I>&M(BBP"&G9A2G+-KC\G26C*ES"@5SA*5P:F2LDGG9; M3\0\$WS6;M^5T.^K
M\$P/O&E4=0.8\I_%.17B35L<HXJZEA_P@+O:5)GS_Q@NN\U%?.H?29^H& MUBL@Y^IR6Z9SO".SQBK?I.R?
QD9D*@PW&QSIUZM32V7W7\O=#0:6ON^GI"Q M@'QU*X%<2#D&I).*E1O&*_\$18@N-
23YJ*NBVL\I*IZ(N0UOKU0I\Z>>)S;2I2
ME+3ZF"OCLQX\G^N\XI>;K#R(NV\$3=6H7WU*Q.*@7H\$JUL.RY8WD34GQ>@S
M\GO!E"SBKC6"1'W7IBRUO4'+J&J>.7+@IRWTFXKX.C'L)V02D\?SYP_ ^ MTG*
E>B0MRUI.RIO6_ ^L7:3&X>?MM=58DU?QK)UP7CE7B\=>CJX J3 MI3\5_&?J>/00=Z^_
#G%L.RYV\44^E=SP\!1D1.5"2#6=D).6A*>[X MD\J_-V:&2I9XCT79H@04\@R.O\HAWBX*KP,N8P3;Y0-
4=>068:YI?P23 MSI3>@2^X^#5FW\T!9WZ\I="*Y?N.'Y=B%K M9A2KU.59=8_7K.5_"TW&/_
J\Z&=0&9MGNI^3.C.(JPUR: M#W\+X\@X@N2#BX*V8TDFL>J&KD+L^FN&^_6V%"E-LP M\IR:(?Z)UM*.<8B7L7>
(E>@_"^_4&<6>D8HD(CPE.\$4^_UFD3SJV.L'8M<-7\EO?S=VR)6'>67&_I2W?LI=4+G_5/8QM(U-D0EZ/5 M\$Z^C
MLJIXW=,0J7\2AIQ:6&678Z\>@)S\SN:IRJS950:"M\0:FU8;(B8EH MX6FG85H-1J&S:9#HN\CADGW_#.<^<-
"YGJ4:X2:U\$WCDIB\IHE.8\ELMS M1I-T#^>^>?F@.19>9U>0-Z4TNI6")5.!' MJ43P)OI?

71"6J:~%\$U"E:E<%Q^H#IV7036D:1 Z:\$\JAC:~5N:KR2I*H4-RC MVT'H(C4B6G&IB- \F3:+D*/DTJ95H? A2:~F+E\,%E<FY7D*OH\$6:B^J'F1 M8"5B'V35V:1;/IIR=J6MK#Y6KF"VO/E8=O) :KZSPW7- <5VKD<13#V=PUX.1IA;".J&9(B5A^1+D MW%~X\XEY1\LW#W\$LPB_ .KNLJ^7AFZH2KV/2SRCIOSPO1IN^ORI6? Q@U22@^M 5:~1E+VX4XU"138CHZM-0J;IU\+87^1.WB 3:J9.XV4'5'N:Q-O7E.O MJA4P=V88B_&+!"1>Z:~Q6H? I.C"0I2I2>1 (L54I6Q0OK/JM^9L9JF1 Z M&RZLH(I7T%L.N?GZ2P9L.L."[M:DIQ?T0@2AS/KP? +3^D:W^TQ5_15Y0H; MK"U-? PR'+TJO"1587U#H R6WD+9>^BT#+J5N2//S\$ES X/G'&SDHN94S6W M/T'G<*:Q01RX4D->G:/I*_A_S_+6<^YTHJZ*HB\$399/0I_7>)R(09Z-4 M#C_/F-RUB.A?=:9 5!&2{3U49?2Q@) M;I <0^KH#FZ!CB_ 9I4DU\U.MO""=H@L>P_SJ:8+7W=\$3E=A2'S0<52U\ MTKY+;.&+%=> Q/=OA+W\HL-&UZGW#K\I"=V. (<&5 RG%@"@9 MW34?V>R\$C\I++&7S.00VDUO>Z6N%%<,>0T{60^:N'9KEJ=,ADO.I"=8F4. M- X(<%H*_AI/1/0DY2:PEP>LMDUDYGXT+O#(/&-PN*EAP/_ROBK%7L6'W\X\I_M_(>%XNG\KRPQO)5H+^@Y6^J_I 3J_/NZ_/S_DBOQ;@=:6'0FIP!*DD#C00RY ME@YKZJMT7L3";C14OE*JZB24V(E\?)"O3PYU5GB5Z2)XU =-2^H05ES.0F*2# M/IP*O.@HL(+Z3&TYC.U.#/DI5-M;LAA>8_TZD+@^&=&8=@S(U\^+Z?17ZPLL)RY\;".H3VAN M'TH3EKPJH3YK=&-O-X?>\$T_ZI?3%U8@+I.H'SWG9R>PS9EGR3POBY'8IED^M/U667[XKVJL%*I6E)B?C\ KC&EZ\$;U\?)JF{0B\TU>+B2@\$TB) H_KV/_MP>92\4<^DH^D.B 5@:.\$+E>0ZX H1QA"2MGE9R.MHR&Y1!7O_6*R5IB"5?^MI"~F+LZ5)#B=0W%N9CFM0+,YX,9\$(-18MTC@52%V\$#7^() M;8I64IE::MZH2X4C4G/EK.SXIL2"MX_7>L.KK{G9ET/L.^4YT:"N" M9).PN4>Q)I/6IHO:B#I.D) LPX#\$HISG:3*B&JL"?>4-2IJ#IM6!PKSR;UH M\$.LL0G\8W.^\$K*_/9^WIDZUF4"W8RLWP1.6)H J\?:C3J@4 ^+%#L))#\$C' MP^6A\H^I65YA:FHO;VTZ*(PD77^O@79:~#L'A_F\$;^9'7EI-8<0W=Q_3%XE< MV++I.F+^+8)J;_K%YU;S2U&5%W.C)FUJH@5J*H+OOEJR&1>PL)"DE3+H/SVC;TJ X^F%TOY;N4K3*6LE.KWO7#2.^M=#ORS3Z\$X<I{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{0IT"#A;6W:6511UAJ MWQGIEZY\B\O.DB+=V96CC\DSYA@PIW/"!)>X'QHYSU42VH4+9%/OX**6\GX;G&Z9N9F_-#)A\ MD%X(^ZOY\VDG=)LG+I5\WB_!B2A=TEK;.WI#M.ISVYQ7L/4@!Y0S>&76> MJ*\$S801P58WW8TIRW_O+2";.U(KL(GXN?>8L18X^B\4Z#R2\$FU MEY1@NE!+@JK;627L;5QC:\$3+/#X.&7\$FZ^U5YAU+;.)!"&E?T\$1.W>5_O'@_MO*_KHxu3I.ZV"OY\$EUZ>@_TC&ZG 1R;\$-?"NC#~WZ5/HU#^39OI\NLDry/8 MJ\Q\DAMUWVMIJ02=X2DILK00MAI\YG)C4_K\$@*VAS \$'70VYG)UX0J7TTBK0 MLNBAZCGM9";I%IR;I02="@7=I\$*26?V+ #P(5@_WQAA>HQM;I00B MP\I-E)A\ I4\+WCV4B+/_C'4=IHHV4O6I"TsWHY)JXZ4%K2W><-&=D*\$2>"LR M90M9,<6D-IX"21"K6I?T+=@&)- ^T#7NN36"+\3L0'I9J_!(M5M)=0<<(K M+*G)DMWVQ<>?O\IY61V?^I RQ><4N/>F*W;* (HI7L<50^V9A7S.G5#E_P_MDP)5^~28I8LN\WT3=;&P97\$".6^NXR*UYF^|\@4TU'P0I?OZH2Q\O8:QV>4B MB3;E:>6WAVI233* ^\$W_?9IF3J"74SXA9HX.4 ?"DFIG1^/\$(DA_ ^S:X5 M*&A\$.\$O;I.16)8YF>.<@>=<=IF? LC0<+7(2QR57-;LZNQ& MTI>98F4-9I*INS.C.)<'ET=C+ S(E79\89-S'9.W>YML94*F+NR2C&N^Y3 M68WYG33- H-RX9_~K\+@OJKNR'T-ESJ28)4. HG3.HBQJ (I2P##F;I)=N-S=I\$ACS\5\$M8U_M)5300T\$UA;5L(5;H: I_0HN.IDEXJG\ M&=IGC*?5(7J?P;.I05=";F*YID*B=FC&F3=VYE_I\ZIB?AQHUM'T8V8EBOL M:3IH22ML<*#> ?FLIDH8&^=.)^SC5Q>IR)B9_~7W9A;GA\^M5G\HQ_)&IXO-I#E@(\\$#4-ID;::\#3L;=^L;CG>(C9- J7G.LJ9*7^<(NAO% M^L78&K K%H#/6U9MI+9&R^?ITC_C3XZ>IQF\IYPIE9;35\HATV2VQ".5 MK*.)H (-7H'9MY;I0/SCR6B;5\37L?R>E/O>.W?QWQ0ELFYOMGL-0*.JL17&0I_%;I(WWB#7;ZL\HO891\PCK#3);MMASF\D0N5J M5&Q)>@S;..F+I"Y.*#G9\TF2DG^@I<+Q_U6I,BN M.F2I%=OM8/B\$6W.BBIQIYCIJ?MX5L\TXRYN\I<*>PB>Y<31M\T;_IR;H M\$MV'SZGZR\(&J;L.OU.MKEH, *)UARK\$CXIUX<<3M+K0I;E6; M=4O.FCZY*RG"TI"4.X?7(I_~F.\$\M7^O@<&8>I*6-^971PT";UO-H#C)^@I-M K;UH"6NV+U(3:9W_*2.MQ>L6JY^X&+L%;B'N\0UO^KS??J00?<14HUK MHHB;@JE<&-O)Z\1VH3G;YHNHS% =U=OB/SW>JZEU;2 R L2>9S")? MJ(O@0")=J@E*D*%=V^BT;(P9J3_H4E\$D)\UX.3G;D6U(0W\YQ*CL#_DQG- I&ZZ_8_~\$ M\+LFDK30-HTQC^'38'-EBE00T\I)=\$*JG/=(+5LIW3_K>OM=IO(8ZZQ6) M/J>3_K(X737M\TFQ- M@8XS2ZDZ);/<1*H @I[M%*RZ'8HA_)6GN.Q\$NE#K MOV^IPUGI#@OV)^.RIL.R3G;?? 0*YF\$90A.W%8+_L@>=8P1=S?@CNXW*/@W6 M&"_37P\K/NW8R3L5JY\$VODDTF M4W*ZL%IRI2';%C5/<2V=U1;D1L2/VNH;8VS\2;<0"800^IX*159U MCMD86XP{6?>IVX'7XU\BFPOX*N'F(;;\$@R? L261XD<I(98S)JSC\H/^LZ&\& MJO**@IY;P5W(ZN.I#-E*KQ(CYDN72-IPVOLH0K?(D-EOZ1*)V&N^RXI3P2-V6 -J;K=**4 4D)?= _MM8R^0)0AZMQ\ DG+ZIJ .CQFG/DYVIX8WBL MWJ0(VS:Q?I*J? TJ;I*1.5811A(E90QE"HC;NJE+A.EI>I\J-K_I2KG?QP\MMV. "XITSCP?00%!\P8DS)->:7EH&GQ.JF?F!>S4Q\ (HJ9WEZQABVZLX M<5M)>#TB#;GZNB\BX.7\O&/ZIX;=ME-9R;"+J5W\J9%#G)YDGN TIC<&I^T\BA? KA0(#NN&RR0/GTT\W.2I&E45-MJ@JYCTGF"?>I?;#(^MW%"/ZCRH%#F\$<A_IWEHJ8RM-IUF< M>=7W4D8FH5^4@DY(U*~5.UV7NOBQMCADS;\$FNE_6.O?'YSINO+G_.9L> M//;IX7*YV? 72ZGB*#1@2_5#W07\$24M=L^7"K0R(A)%O_O*!_BI=YK41_I T MQ5"TI4DS9P_~8.EG-W654J^)(_U I+^P%1CUHA7*GID5\6NE20R5@I_R) M5PJH1^T@+;4%CA4C01MOF@<7W/X;W5<5\H"4S3_>I7Z&- J\W\$D*F402"5-M4F8\7/8V4K0622Y/5.3%-IUDBX"C+4<^'=\$8""A7R83XT901WM*7L\OZH> M_K&5\Z44..TF %E3PPBO)CTG@%9<=\$L.NO<4(ID4_7Y9@_L*!\SNWFL M#K9@AVT4K"E8-3)QXSERZAO;\$IVVVR) L"~J2Y" (K=8IWCP8M>NS23-O4*AHZ0)4W/_MTQ&Y*!&RU5MSIP66CVZ5V#B#"V @\M(Z\$00>U\ MGPI9R5KO\NIG.6JTF.M1OUZ\I0C*~M+6_3*S>@OIR;*O.B1MTLX?5GBZ#; ME(CDI5JB#@4(I0TYKYW*?>D#- ZL/MI7PK MT#X5I?=- OGB2_*VY HV*P QA41 Q5HD@5".G2U2JE7Z&-RN66:F/7JH+I MLIR>CL;1\$8\I'MCM55#Q;=SD\SMPWLLAIKS&* >AS^I\VI6K1NLPCJ"\MJ8+I*KT>22;%VE% I%I7EMH\NRDEDMM MI9LCB= _RZLK4OE T6#XRH_'RODZK96R ML_JB\I=8ASG_7*"?E-P\I4R7IH(=UW/B.3".Q=? 6V)Y2^B7ITWOX?GZ4IH0 M_~;B3>3D13I.MI'A3C'2IH1+C#4<+JS;LYR'372/%;H1RQ'OYYED:WHA\$ MCIXU?IJOQ*W&I_C8XNA@K(CQ2-QPRG;HX-&FH";+7"Z4/A^5(&.*&<9LB\@L^E2IL M#^0)N\

[illegible]

0%>7LF>2L.U*!+9V6Z.FT1Y/&9>TLHICS6&SBOA7.34PIMD5-N.OY3)S.M-
@'XN51HF>*D=|L83SA3R/L*N(VAGBS^_.Y.WUV8W<=3/&^:I6<3W@/KTG9.MC8M+274/G0YIO
)1(U'6W@>V'VG>NHK02\$%7+|C;+@JMM8.SE!Z^A1^C/M.4D<EE?
G%J|9_S/_9_SOX>Q.=:4/B4'7D%158(SR@:P=|6.WG>?H.NM+C6Y_+2MK=|PWWZP_@"SC0Q(JSH_O-6F;R1@B#
MR^99C4155./<|G&=6"VC^+|. @&2KD\?H/&OXUJ8RIC2YQHR7OG!3(L|_E10_M-6&S:299YBG2ZYD3
Q^&'ZAH9IBPCO)<4|Q9:D8LF9Z_&ZKN\$=DK8Q/&K;+ M6_7:WJE07)"Z0+U-OTO_#ESA|>6-DT%H>4E(CFL5=?
WS?P!U>T7YU.T.+ MXKN1?>?<(VN1XP!R3U|P-EA#CH92#%\$L"6_Z"=(VNO!A)!UI.U3*Y6OZ^G3_M@D)C|/-.|S/O
M"KTQ1->"<>_LAI#P3^'=WOZ>8(B9C8D#49='DHG!<9%<R1|F*IRI&O^N!M!_!TW2OYA-
A07|A_-1YP/D_J^ET1>_CE.M!23D@9*_\$=4#=#ZL!_.)5*>|MCD*QZV5X\$K.FDQ/O1KI5_7K\1*):3=VKG!=LP_M;1-
T2::A14?Q)%VQ@UC5HV0#;1Z.G8=|UY.L+W;=I#PIWX|MZ9@|_B@V):0_M^KE8A:'DV*QYZPD+DXKGCL'JJUZ*/I%
/*(-?R#S9(S.:H2P719K0)_?KJR_M^8|'(&7PXHNX^"N1UYNA?37JSE)|C|Q:|f5=4.. "5\$X%55.TI2HU|?(U5K+N=MJ-
99.|_1V5)96_6R<9(H|T3_I&F.H\$Z|S.2/C)J5.L:SN3_?C)3VHI_M5GFD.NK3*Z+|.J=)CYK=(I26W\$SC82Z
\$+"B@2|S^VHC>5H?_B|1/H:R&J+BZ_M4%)JE^YS&V|Z#%C"TWI5K.YZ.G\$YR*MKV(?M^!\$#H;&_IV:(N%0JRLK
M!O>: (O_1^1%((M&24,04Z\$5)1&J%?)@E5>K9<+?7P<)"UB.N.Y'51^_M>KZXTN.E|S^CY5WV#(2SIBR.967X/R:1X
N!|5>=YN" _D+GIQ|WPI\$E@:\$E.M9P8T0S(G.Y6%EXJU"K<^JZ9*_%Q26H|>H;UG0);_@S|,\$X#(^&/\$>
MXK2CU|_OBT-P9YHREM;T4&|(DE'+@,"V8+?S<7|Q|B|L: @#CU%GHP|S@M
M7>|B53VHW*%)0%2%UJ5%U(X:2Y8+WAOZENV#*JO<*>_ZLJ?\$(NE8));D;"M)4BW)EG/HJ7|LL7^ZYW'>#>K9-
WP7HQ^HD.OA>TY.G^+31*)UWM;::!KEXS0!_M)ZH;O1LAWB3CA6\$UX*\$/-K\$RMW*%T|V:\$5_U^RAS8MZZ+;K|_
B=E6J);+;+O_M2-E3SGQ|8S^L\$%H=|/PS.W33_WY@^P@N&^ED6EQ7?J'E*HO\$';9A53AER|R.M.L|OY^|H#<3@K(I
"VJ@8+E|P#SN63(RSZM#ZIKGWCL/TMS<_-Z>13K^_*B=&|V|9@:96#&^#W*>@Q6:TH)=1WUQ|PB|Z_M-
9^JL1D|.?+E6F2V_(Z+YZZ!_@ON7^T_-P8CW<+M_Y0E4#ENW:GU3<13'E1Z=>*5_*YZ1%51^ZWU/<|>LJ_IR=IQ(O
MKH.N4B^#DM|_OQ+JJ;_#0M:~9\$|FW1|Z#S^N^6@.64X:HR)/FP%.NW2V:6I_4(P2)B|
(&A:6J2>G%12*&_H8XZY8UE.F_GM714G!?"T^N&7ZEIK_>RXFH3@P44H/M4PE/>2S|XX""K12IK^V%.ZSJG+C-
&N9/CX_N*N7V|PEM9/8ORVPH"VT=N_M*+6_|1Q14CX"GH|BR'Z<93B:|^*A>BP9*Z9SLUY(HU^_T+JL&A.B'A-2<%
M(|3VEUZ%&Y;>2U\$5).FM)U+T9.(?K0&_XH88#R%25H?2P#%3O7EB=0V!D2P.MBU.E.K?
B7#|R6\$)8)N:IWT"XFFN7C.;H5.GQ3_0!L3=:OS\$/("(&?8X^ABA7_MC0=A!0"
<|HT)BX'B(239(=54E.#C.#1W@S(>::3M1H^|ME_|M0ZGRW=|BC?
M0H"2R#D\$*^KW<,%\$/VF3L!1QO!*"PIR9.3|BCBY:17V'R|JXTUNQO\$%V7)_M#I5BYEYARC:?
XUVA@#)VG8442#E\$SEC.HVIVD5:~::27W1C&J56|^Q*X>_MCW5E'B5>E.GZX9G?J|_A2>9UM.4KX|H\$VJ'T:
<|G|X.M19R#U_@'N_X9'7R5R%>%V0O<>_)H_@:9*8%XL2)/_T3'#=6.7P|/I2Q!"N_M>_J@0W.V*8OEMV
MR|9!9M.=%"&D6*VZO_UXF2OD7_..HA<14M83|_I3_@%YQ:_O.A:_2Q%3/
M86F8|L:;#./H7X&Q%|S>QWC1\$H%DT5@IW00KPR(BMX_!B0Y+HT!&3O_'MAP.MT"()-_BLWF)?FBC*-'8+!N!_("
9DZ|H.#_70!|2W^#ZP#19D("6@_ZM_M*^K_@_7=1!0'>*+|>?HP@"H|FND?JN_.E&@:_T?
GK^_H>A0|_>O"@C%7KT=ZC*Z;("Y*"@T/..*#O>_M&S|>27P07AC4+<4>G@Y-US|TGD/C-!
I%SL8XYCM)7+BP2GAI_!W1Z_M#S\$@GE:~?&+|PK@5H.X0|5\$A9(S8PAQXD1L>&7WC@_FUGM#)*W0S3>O*"I
M_B7^O_!L8_|TW|_#Q.R)NP?|Z=BN#A|MFIJ4_)085LJY47S5SOSX"W*^|XTA_MP^F.|Q>VQ@Q(5!UYI%
MRX.6Q3<#;WY6:X67GXVM/UV5_)Y@,%(Q)GFY%!"&@D53_M0|0QR|/@\$LJUEL)3|_F?3|<_*/XO+DY6<:5XM6"
(7M|<3_YWK3C|L+U_..M5R1K|F0|)L)^="IK7X|>|(KAHCVC%|B;)=X|3N_9_G#=#7#)=Y\$)7@M-DG3^POD
M:5_P<^6S%5T=BI'_Q5:2EK&EZI.MO2|M_4G/D+&87=8DCV(IPE9#M'F767>VI-M>?
B+*U3S0T_U|^830.%)!&L5<=.KEZF)>SVAX:~(NS=:A04|/6YT=:!F4R
M|EC>FS5|@LV.7W#UF_65Z#T1Q676./896*5S<):..Z'.D2+7|G-A|1@AT(VT_M'?2<0(GZ-
%_K^!|_G9SW7NN_??JUK77_9*)H_?%1>H6O|DP&%58GUZAYQ4YJ34QZ_1QP_MH<^@17(|_JA+H\$|_#_#\$F?BPK+
(|BLVT_~U:~Q2_|+H+JGO@HS)156HMYB_M>)|^E&@_/5%4|NVO.=+7^AA&@1H;R>V2ZH&LQ993^%6|&8Z|)?P-
V6VL6!69N5^ND^G0:MDK8#XOT5/E+"3K+H?;\$&_3)2PAJ*ST2|fH%2D9HX^J|+|\$D5.'XM.MOH7^H
M_DH.#JEV(\$S
Q(KSJZ2M^V4KSM&12.V6NG|C|EIMN:K!0:~"S"Y\$4(#J^>#C'_W.C>#RZ^6F_14.6|@+WX_4GQ|_|#F:_M=E0S).?-
17#>+"42R1^30PY"X4E.|BT.WT|G)<|G0D:2G\$4>KT?X1L_ND_M9CP4>WYTA0<?
J(5)4.QN7/WG:7K33KWHZ*+!*"HHX=6RQW4TUYNEZ/VNGC_M_K^L^S|^D+Y"QLEQ\$"DOB2A_|/@.<\$=AG4-
QB"GW=L/3W2Y|1AD8UO@:5BO_M/;7T:VM.2DO'J_1^GUWO|OBC(=F'+6<_:8-BVB?
|P0|LX7VI<(D|J_S'_+5J8^*+;9L_M=)|1%%.T?#TTZHUS8E'|>YZ"0ZK<9?HY>%G2)N_2^I_MS<_|+GAGP6G"-
%*#Z&^A+7|HL.\$KD#F^/M/7:KA>_8GS8=9^GRUF="45_-J_M3LPWU=8|S>
|G+9V%L|I%UX%G04.Q/9W1(T:A*WPR*B#)|^IL|Q_M|3V?|R4|T|H|B&G)S_6U2R\$"-28:EPG-OT.
ML<@I.R*)P_\$S^C|D"ZB|1AK|Z!;/35=D.3WK!<^F?6%;Z|9H|Z=*Q.^!F!6K'S_\$\$O|5&P:??HC_M|R>T0(O>JGC
^_U9V=H/|D*>BTX)8:TI>#\$\$%Q%O|BV&N!B035HQTVC|F8.J
M8@C?/HR^|F4>Z2D:72A<R|R8E."A>)NO#/)50Q(9|T.2(D|P=HLP|>E6F
MZ)P\$OEGPM0<627"^-/4H.*7Y>L|RF)Q%(F#5O/^0*7_RY|H\$HWRL1*E+4NY:_M(FCZ:<5-
<\$JX^8#G61BR"2Y4XW0%|H_|%P(D9D89W8W&MIC_*\$.PS73&8I&JG
MFGL4APRH^CV).1>EH|ET:E+R.W.B).T&+^|/)&9A=\$6V>#TWH7&<0L|X&J?_M):X=%C?5_O!?
%|J#>%DO|_D%/S#9<5I8MFC>M^EZ_G4S%._@6YH#F"|9U|BSN_M|2|RDF?Z0'YB9*_PZY0E|7^9:N7BEWJ
M|=6.OMZ6A_O_#D..9|SRB0#J442*R|)49MJP_1#X<9K>E+Z"#":Y#|OI/4_H_MT.B16|J&NADKW_7*P_OB9OT6I8|GV*
MXVAC(E_6UBQ4_0?C_W:8D4*NSEP|1Q<+^;Q0WN0>C7C7_1_|L_M0FB&_M4Y

MI^YC8IO^Q^U0+ (1IW 8.1/8.2:QW DN &^@.5M3AEO MP1.OXM OESU7TBATM9NW^H)^>_3_S\GSX+#@D-
_W19\$9F0^#HI.27U M35I6IH>TMK5 _H1U\$P.#0\CHV.3TS.S?_
M>V%QB;^*^L.E%W09W=O_*M0=@V/_/A6_*Q0?M?^O&G#^E60/7K^_) "Q\SMR MG(/?P)+SMK>
S(D7^P7/Q>O.3P>= (J6>B.3R^7L)SFE#SEKVC_D.O_3I"@ M?Y=D_R+8_Y!K#.1AVP.M^AL?@ 081^QO>)_ZAIPO?
\$(3I8)C2\PMH5_Z M3Z@C0YXDVV%*+_+VJB.@FMZ.+A=F_.8T* M(+ "=J.;L8"@>Z
L13TC^GV:1@C.;\$ZT!.OWBJIQO!4D8^01J>C;/#E?/=C.T9 M:8^M9+3(N:R\$.YYDY+L8HM.M?
IAVYN9L%I>P5@IA"CZ^0B;(HR9-3C*1!E MIW\$|=NZI#W*>+//GO/ZI.C7WO<79LOZA18?
UBP7W^N9A2.V7D*0.%B^&4#(@ MYTT9KIXGCI=(^7I5U9P0.*X%I=;WV?&(3R"MB=E _^10V!;_.4..8")Y4V@S
MOU=*6 !_P.28VE2?2IV@W9KT.FEC9:~ME6)%#^RUZ>*ZE;? _^H+&V-0V" MD)P7#IY&
9(42N!!DCZARN)6(BAP4E\$!#D:(131)(ANIVI7^S5PP>SR<=JFR MAF3+\$=|T69I>|KTF.9U
_ACEWD!+XC91AS9P2N<+0+Y\$>+&;TH@^F! _%D/I+^&)02^IZR.CRS@^G\$.95Q/ M\$5F9H9WSATISX^)^|=?
276.'2WNLP_JNUH.X?^V.+2EQ/%?""3&L<8" _ME<9Z<48.DPL;ZIGIU?
5X05J&JL.ZH^*O\$VOIK8VIGH=>>+V5CO&_POD3BH MH< GH> _>+H MO_Y+YH!25@FP40SJ_4 &IS4W/YH9#-
%|^GJ=)5*.DV(H> M.OIT_;;>.+3XS/(_4 @ (1N2SX(%D-Y)28.L.YRY#AV*I 8(3IP\$>1SAFC M.M+E?XPW7R?
1J2>!.Z\$0I>?9Y0^G2^ _GM"QN.#5E#\$+WVI^4SA#^W.K.TY MN/S.7IT/EDNHFI.?RAEYI8J8(3CYGFT<
MVHH2;%N.;OFC6%>CE.BVI9Z=;.C=Z^T\$IBM_LGE%_V^""^0=8#=4%%+=_DEA_8>EZIH&^BDMJR+M.FIV

_W+>R&R9UR<8M: O=6. AA+A_NQF%(IC 3JTMJ<@U+<3)N55 ME:E.FL+=>(OMU_&H"#C9
#6"HX&5R&K \$V _!6.(%LTGXDMEPI "H3_2-I MOI%VLS0!D^QTQ-FL.(N6GE/7!UCODI!\$+>PSGU%6Q"
(XH%D*J8C/B1 M.&-FF\$QN I<.PO@I@ZSNW@=F8XTC.SK6_!2KV\$89%G ?^XHQBHF6U+"V!B=
O!8KT!&*4857Z8 M<_QW:Q&SG8I?55EX8 _R%O^9IS3+;\$[5Y)MV!88*M0_1C7R^A+4LIWQ6AEE M ?
OYD5WHI4Q)/."E9.SA2IQC^>#AA1>K#J1@Z9ZJ^>R/3/5.0JMDSCX^WBNQ M.;O..UIQY/J6#E||FE&I2UZW7RS
E!6IOCGW^6/ MB2V.#4^YLU5Q2_5ME-(F^I40_VPA^JE _MAC4E^S2IK.)OH!7W!;B/NUW1 M>V0HPU
<=>%0PRL#_.I)F!>_!\$Y@>.;\$4%3ACI:B07D/"K_6MU"L3W9B< ME7V^BOXIX>J(OH^=?
I.L|N<5.V9IZRIVUR7^9^7G _\$D?L65Q37 P^&E50W8 M YANYX^=;6ZDZ0B#J)HYW+:R?
_9!^I.&_R>ZWV5ID\$8^8!Z&3^WD+Q^O?2 MO@JYX.HYAI4IU"#=LD1+0#>V:5/F410^D_A8IZ>F^E?I1QQ#^)
I!KW^M6K MXC^Y1S&=_!\$@2^F(%V=K+%^* @OO\$IOHRX0SOT "P+5/8)4I)3?RL=+OTHJG
MMMLH#Z+R)QFORJGFLH5^%Z>=;3I?)TAWM%X/9A@OU_R)F KDWVB9E!J|<+6?H
M7BY/6+Y!"^/KN3MC8_H'.3MF2/7S7A%5-@+WFF*O.%D*I/9%|30..005XG<8 M^ZTR\$6KD|>7V
_94^2^L _>2:E1468<|1IT16:9\$F^V9O59N!OPHI2^@\$ M\$.!"ESA_!1#;S-B-K&CV1<9V9JHT#I
I4@1@ZDH+ZGEFO2:HEN02J.IT7P M.HZZ_G/_/PHNV%_A9)6L#?V?MR8?CD+*\$>K0FM%I@IHG^2+LGSN
MIEY3?P46F:/+W3?)(#N1OR7^ZF MSCOP^J _%0M?1ZCZNU.IC^2DJPU^UBMXELAL259V.M9IM+OA_U;ID=D/U26
M!5.NTY4I-GMA704YUC)^NHCZ^6AC/PGOFMV=.1FNZ^;G!^XK""70;+<6X## M5*(5HOL_*V*%&""*VF!^O?
R+&*)\$P _"2.WI5IOX: IHTXN%HOY<=&5 M:8/(L!;Y0N*^<\$S!G!&^XFTB.;FX2H4^>VX.L WYZGOI%#5?L<;L!<_
M/&HAGXV.4VN);C^=;Q0+WWN+\$(KDKN.F_4UH7^%D!VPXE\$+I@IFZ2PBUGVBW_MZ7=*I*J
IT.VREJH(=I7T\$TV6)?NJWUB7SLF|/%%B(I^T^+?_U&;YHR!4 M4;0C? _D9?IB^1J!C367^Z_KPS24E _MG+V@O6^*^X
2\$2J)I1HK*1HTX6X ME5P5^+^VJ:4@L\$CDHBOR/\$.N3.2X^SJ< _^3IT3LC)9TD!H1W\$V8^WC8<%*S
M@P4HA5YZ+K%-EX2 SCX=L)^F1%<\$ VGBS^X.LH< !^I.NIK(>V)-?IBZN6I
MZ7I3)WG_AZMB&N5F^GL7SGM4/NZ6TYI#DF VP%T)9* _PU23;..0 (Z1_OZ>HLO95|T=DORGAO\$Q>IS8\$DKR)
M=I04_&F7N+EH|RVQB6SWLME<+IK!1"%Z>>B1^&^P!NE FVU_H>AOJW:P(MIN0U?|3IT.JI%B!U?
\$5;+;=VQ.XBT_FUK_ALG9+OG_7XW3?J?^*A'G(4=YC
M&VTJUD!U0MO708&Z4ZB0J3AC1GIXTITVP9JNHC0HQ;#^|VKT8GV/<|..QQ_MIPUJE#>*
I8M5\$N&+IE26ITN=GI-V_VFYD%2S@VSIWE+VOV%5VZ.MX3.)AO? MV2N3GZQZ&6!/8SZL@D.5/K=Q@+&4Y@'3S-
2T:>+%)MPPX0@1?VQIF0!LJ&Y M)JC!*G%DIF)QVD2+|>N\$A<2G&+9C!_TJLW04EBK)I#*L60;Y @1@HXNI+41
M66H3I.WH/5H-BM>8X38<T=IEGEFOCYAS.6/PD/#W8J)!4UIQC_?OK4"" MV2FD(M+ # CSJLN)-P3(*H-
^D*4)@8^3IZY:A#J^*Z&/(I(F6;:"I587F^) M0HS?T7IW00(XO7H6I@D%\$?>_D=(^3B2)&P:?)
+L64(ASGF;>8T.EG%/IT M^H;3G=PD>4E3SG@f0<#2V/I9LNTBD*WAH()%(QIVK-
2A*5ITQJ4R16A#Q=T3SM4_M^1LKKV|C!OUI/\$CX8+)^P>B^UD%G&^/*&_.89VZB.EH=\$OP\$M MO06FIY?
9@H1CIZR>G!&Z.D^14%(T<^AC/Z@A<H;B: _" O9/N:B^XK-38I M5;Z5/ZW^U;V-
XM#I3E7(40R;ZWT\$7^%P@51+K@^ (CDJ;CB9W6H0^O6: ^/I"V0P9>APHQYM" M%I^*GT&CY/+K0;5:
<I8I%DZD\$?7S5@Z*12Y4"8.<)"S33R@.P8VI%W<3S&
M^ZS;7C1^_VFMND2|CBI(P8&AOI#BA\$7FYD^B37H49K%-N0_&!O_6_9HR2 ME\$Q%:6G-!:=?
@F!G65!UIVIM4V!"^.\$T:9U8^9R:"5/Z"32L^C2EL^VI4 MA*..HH@|+|+8I\$(U/ZO/VQ<I3-U68|ML6E6"BO0=I!?
>1ZQ!U5SC<%^NUL MP)4CZ4)\$YH&|=1S;&5;.%V9/_S^K&NPLHCT5:4Y+7N)RA094^/J _"E=GV& M9G9QI6I4Q-
AG0=CB3U=V&_?J\$M7J)81J)9!MB!(%|80T&>3^_@MPTM^I
MPO1<+^_BHLQAXJOT^N=4VNJ:*&B%A^|%)\$WTD<3S5%5;%N^3R-F+@IG@ M(I;BN-BDR8E^S_-F
#D|XVFO@E+;=%I-H>PB!4U#4M*(Y(O(5-BR)?D;QQAI 7*1HOIPSV M-I 22IF:~XV^U2!IFBYBMGM5GEYH.!H4GK8-
V6WZ8=J MH9_BI %JB _+|6VJHWK:8U/I-BA51%#| Q#_1 Y1" _3R(=4.)H?48R027.ZZ)V@QHUM-M^V>
<;SHUTIK@)O0KY0:N7;I9J\$Q^1U1@M^_YZR.7/#>E:3Y|IM05I.M.%N MNP4W.DWM-*>P@#:-
R*&K=L2;"V.OSV!"IS9.OQVSTYIQ-VM"COTXN73W#=#C M-B8MA;*T!Y\$?18*;NXLX^9N;(-YH((F ^H-
QE%B\$;&V<0)?^I&2HIVAS _MV(I=;G^7HGFNI^G(VKMX;Z?IT_IP%_HN=N/HA48ML(9AZ\$@;R0ASQ@E-4+
M7&=^Y(ML.^/.*6XAI;X5I6^PI4W7!S07PL.*<8RQ8%._^U!X:3_MI@ZR6 MXT=+0B^Y.%2>K6A
*0)4H;137I>3Q7CM2H3A?%81""?%FNO8M^/RXF3Z%< M1K?
QR:F _"K^O%\$ _0P7WD#GI0D/3.X>TEH4"E8/>7JCCISYR5?2.Y%+Q_UK MISX6";AJ4GZF?323;I^_#8I%5W.I>7-
\$IGO>_Y7I0.T":A&@T!7HP/VWE<5 MJANGEN^T!23)41+TLML_*PAFQ1.?>LCA54A.YZO&8CIME.5R=>^>I-C
M^4K.;JVRR%3J7.ZZ^DCIN!^O>'&#O\$SA^N\$>I##Z+!A.TZ3K M0408^DHNG^!/?E4 _"?_M);SQ7KI?EJ
(NXSWXRG0JJOJD-UXD#*.)^DY90#^@Q_I/ MD>?RJOK^OURPG6W(W-FPC6)XZ
(%)#^+C!&Q0I<"M1I.5%N:7Z.@OYF!05V_W M(F_2VH:3_82X@E7@C^&2JSMZ4&@TI9T%>"!!!=PJ9*_I^AEXYAYPG-
K^2)T^MMB^9=JZS(G%_ZG&^57#|_ZR/P" MD(60KW!"4(N(4D687^T^ZAY3XSXI&D#;+!@BY MZT816;4?;A?
M0L^Q+^E_UMITJ^7-I9BSPE>X7Q#MV!\$0E\$&S-Y)*J5^(:+ MVQ.&TIC+
(WMEK1JE6+KW^).79WI\$G:AK.F^K:7:#?^S(LNCIEF\$57V.FXE M2\$+VZDN^T2SI\$HS7L(WF-
TUI_!3-^CS4S37QYUFIW!%8F!+_PIFG8590 MEI%_8H\$BK(7=HW#^T.N F(O5I9+JDT^U!1T1%6IPRY(K/4N)ZF0HP
0^4 MOK.B:7_HO^B_Z+^I\$7K^3: S0D=IDQ!8@18J=29*+3 PHV!>?_IUY-8@-
MO7"!;9&"67.*00K\$7I\$>CMJ<*3H2ZQE+W_ _?V4L^I^REFK_A\$%1Q>D41^0
M9_00\$N9>J%=W94<6F=RCWM!QU7(08|F@;2X(2S_>OZ,V^A0L14E^ _MBI(7'.*KBQE||H)0P5BA513YLH44^+L%
M5=I^I=TT3.S^_)4%G&QISCK>H&T^A0M6=AR+!E^J.ATGET1C\$BBNKM4QHU_MU\$IR@+.^?
LM^DGRAO/=ILD_C9Y>|CYV15^LV^|ATIOC%3T_(U5V;D/8F8+I MAY=CGQ-(12Q_K\$Z%A!KC;-M53W\$O^@U_-
^I#VS|U!|)^W^GB2;O\$^UNYQ(8E MI_D83B:7)92M!E?X.18YB1.U&_O@55AP(5UN>^Q69G^E+^O,+^Y/01E")

M3M8!WW5Q;-DB/SSM61F*9!K6B4_)4(3U FS%|ABJURB74:CL9YJQ3DIC&+1 M1^!P-5T+2D)%!%+A)(I+D#GO
M_+'=X6'B7BOIR0N45VRM^N!LQRA1XIK3!QX6UJN3RSKW/OHONS4LK8Z-;+Q M179T1@=KOR_TUYTV7&(2U-
ER&;5+9,L5L_25#10VR6C' M-)5U')-+@(:\$TNT=^%OC1CM;<.2KR'W0>JLM%)J_3X_-BOP^K)H^*|E>E2;I
M3N+;_!4E9%27S#)4A6^(-?HQR:D;G/7LW!J.U.FW<=,PTLUFO3JH^C^== T M@.!(^%9
OZ3=FWJ_58CCN=RYA0_1^HKS5N^V7^V^V130!<(L(BJ!*)H2C^A4(\$%B@S590J M=-6I:'\$5=1H0IN+;=0@D!*J-VI90;
():K=(WYH|W0NW^!%|Y^'8UOT/?" M< NHV4SVJT:P03R==C78DQGR+ " M4982'N0^"N2@#.'< M6E))#(6-
115E;|&>_B^W1^LZ9U)6^Y&-23PG|/P)+KQ&&Z^BT%X-0G7K&7%&&3VIM MC8JP_1YAY%|S\$R6M3Y|V?
%._^VW7!DRGX:'N^QH/7O*T91;XL0#UOI^!%>N! MVXL*|RI|<8_H5!;5N-U^ZDYY=D>"PS0^!%GIB=8M-;/9B@15
M_+;=YZ^CQ4!/?^?|HHD(&*;WJC:4CT+I%245YHO3(H^:S#BC M?
^|V6V5|S:K&B;E^Q)HBRE_+ER_Q:&IQV)T^L^(:U4P918#2W.Y MT?;T)74G5L8W=|+G-.YC=;P7)S|
M@+;:H@*^D|JEO/!";O^A=^%N)ZY>NHL(^F-0L8W17N7D7R(TDD M%K!SR:L=1CLX^ETL|JH7Q\$5T+_OZ8!3Q!T1*
*S8^6PGV /LR)5RO=&*F5R MBOF5%/ACK8+M2OJ!;MTWF!^GZ26.13-)MDK?;9(NCO@_JQ\$FD_!H2B5/
MK2(YG&9&!#N^AO.<+;XLX#*(^&\$S;F9):TV)|+ON% !6K97W&AS5;W7: M<)EUV0NX,H-8P%T8J|= @L74L
!GW+A 4VX;JDRD'=|<^<8P=#Q^E^/P/IVCON M3Y 3!8(T6XJU^?9@O0+;"#P_3;-X">?2^R@\$71SZB8&Q99GW?
48G!^KRS014 M-\$CN|R5U|B^*UFZ/!L&9 _SZVKF13U_A".9#UG +3RH^T^M 86IF_,"LCIE M+XI+LW=2!^(RTR^LJ)>
|DU|%#?Q>C^TP=NH1U42/E?1A9!4&2@\$12H^!L)' M^V;DO^>MHH2?=:U^BKE|E8I4PLME_N?M;F@SWTIA!
<^QJO+^6^O^U=1K!:"N^CHZ*|A0IV)|RH;ZYR M-^|RI#JZ_8Y7*!^DZ.F;IV.O7I\$ 3HIDM4:3
MYU|=EKJA?^J6_7+^C|D)2NR;5OPF;AL1J?EJ?P83BRL44T0@A-X47 M14/);B<^1/^CT9FN@_5%
V_J+;H^%=/+CN^9UVN#CY|&L.R.7X+!OBCYS ML-L2%EE ^3YVA?|@G 6;Z/&L.U6X)/MA@-3(TO8Y|W>R?
G^A;Y^JAH_JNAGC%>|HP(1L3=NW(|UKGX3W|BH= MJE0GRMD7S9K006_FH7\$C_?^L;AX/RN^;-0!QQ)-
DXGJ:";310P+4 =*L _M;DP7|IT6_9,3&WAOV&@HMZ)L0:/M=J|Q^I5YIOC@4;=K-(-RM?E2NF6_+C1D|** (84PLW1_
"S99"> M^?^K7L^:RF)<(&)97CY/L-46-(Q=,84-7^Z-@_EB+V\$Z3OI6;EZN9,0_S3Y@Z M_2KC_V\$JEV":70-E\$4+?
&+PZB@W% W1?O7T"-|=N<12R_#|TG;\$f6XP\$ M>>AM?MF2D;BK=&78V_+/-Z%9M2^Y0+GU|7W^LJ|@-
L4LRG)TO^D^*CO:SSU/U<5^V|/"|<(CVY-AL(\$Y?K63?D MDHVZ|WWYDF\$O4VH;?XWY22!2!A\$ 9Z@O%
(M52YHVW;<(<#)PFPND;V+W^T^96 M39Z%=A.C!65VJ(8(X|;|<1-951C^UJ^7=,T=M7<0!0VZB/)=V2I5\$9D001S
MN\$8|W;|S0L+|J89Z>|VJFIQ_*1XJC59;|M^+ _PK&HF/X>W8Z>C+TV6^0/) MBX4 UVAN(|:TI^GP^~P-
_|UH^+ZT03J8^R+VZ^KS|W^6BUT_1Y|BM JR" M&6;^#>A|U(7F+^92F%QJ4_X(Q3|BQ87L)3I2V_!VZU;|AVS4?
MV%\$W682^JR MMSR^*!<14Y9IQ)AG;:=S@\$R\$|36 FYW91+^2@L_@Q%R>9;GMMJM=+&3D7 MXI>X.?ZD;V|;
(PHIAA&C|Y%G_ "3%I'2_23I^* 3":U.&"GR^;IQ9^W7.1> M=\$%>>Q|;:%JOB+ZX03|
SE)&JV4CKOQJEL>YEZ3GL;8592ES=J^|~^8%HG! M*(O6!%_6DO^S8_O^V("HO).EKN\$608*NH1> 594Q B!4_B#)PK?
&56>&.S? MP2L@ (M;6-!%TY^3(GUL\$=7%5DW;YE^!";^3^H!K1_%A>WDIKU|2S^/\$1%>QI-O
^|+@ZH&I90)G^JA5_'S."Y5Y%&=VH80V<<+@LS6V MU;2L.P%/CQT(AT|H#8^1+?+%\$3^GA:B6PSC;+1^U-6-
6C<=) |LJ)UVC^YM M0\$^KH.W:2^%|MC|8|\$XF26_."WY|&1A;3L|VJX5L^0N^11WU.6A%|XKU^FM P+E?=-S
=;MW^9^F^ZORSQXC/&.0.J.RT4+@;N|X|D!AGH-KR<)/T5^Q_%UA#^5-X_/8QFUG;MK7\$?85|N FT,H M@O@\$-
^N;3|ZFO?;90|=^/O0>/SHA?&Z@V4-1O|Z<= 6K6UAR MQS<6H_?<
&_7HSXDNY11!%6_GI79&4)4OF2T\$ AGWA!O%90#A!6^U8U3^9Z^" M&/Z?G<@OBC";VH8=- H(QG01W8
&*XE#MAMID_9L?;' +8QD86L)Y^C(53)3^S M@^Z'=V@WE//?+7C_Z|>ISH1U|6SF?B;D9U>DI@P%;5TA#^WV?
R9NB83S;IV" MT<6%7^5O#QF?X_V|=|#Q.(\$TOR:""%@I4H=|INU?;?9MYA/Q)K_+L M+/S\$|;62E-HJ">T?
39LGG1.+K=_VC|G|+W@_ML|S\$ML1.ZPO^" M0&7N;C#;"9|BR|M1>+1F6Q9Y69CF<I
M^=4^HW.N|V|IRSSP/\$E69=7! (^ALE>ZG.2ZZR%X^?V?^" &Q7|3>>V(CG0_M8F3#WW%TOWON=W%-
\$H^HXBO&2#9J^HG>GBU%@%_#O|-(P8^G7)?\$ _OMHEM M-^_/#%AW^%O+?E|Z?L;(#O!A^TIE4JL0^T:3./&|K-
|QTT^|S\$HDI=GYD^MD+^860!);_X QYFOTBDV|LVZ<QJMM&&8_-C72 XY33/ O85+;|FZU7|^M|/>=4\$;V-)+ZB?
^9M^@;VS_18HOJK|:1\$-Jk;8>%|T3%%" RIVR_13|>|KXKR+L_!&U;CV3^NIE=#O M\$+HT-MR\$V&|!T+I5OHJ;\$
KSMR/@"#^#^V40W#^#SK(#B!4EK^1|*|;...-5X9N^"IZIOMD|T2 MN5@01;K^~N8K#_=FRFLCCG^Z9X M1|+|^AO-
\$B3+-4M|HX2F8Y;RTF5XUMQ;XP9%0VDPMA1-((%WO8A|Y^6M4V
MJ6K@E<+^B_?O!M&MAM|FEL_S0E^G4LHTM-/KV:97BMHKL=MFN;#@SZH;^ M_KS?UQ<^4M;|+O)MSJ>
<=;J2^INVV(|ME^M83^*FK+6IZ/H@&/5Q^M&=TUE
M^9!KP8Y14VN@2/(@*)2>KLJH83+%^1%M2>B^\$+^!+&S.VW1?QJ|R4V>TIE:M MW; &W=|6%MAF_+KNS)^9_MK;J
!:"")S5MM?3;X;R^70^6F3Q)9P.E%Cl@_BP@LV=68+I#>=D^MO1D7A1.D MJ_DT|\$ %N|<-
U_WJWZ^3|TRP;PX%*86MG&_*%Z>FE|IMY7HP0^XEIN^1H-W M(22J^R+^C_KPIFEPXOCV2/6^|B%\$-
^Y9%|EQL6K+E)DBHFHO6TN-A%!"((%4 M2^SSL^OMK;2G>^?>^DY0Y8%8-
|>6/C<|;^+|I^>W+S>C+;UW8YC\$(0VI^ MQ1T\$|L_7I?MRF_+XV6A3>WA^5B!5Q|(I4V4(7RYN6(OI4+48KUF
^SMVT(^:MS;"AE6=,V)V/I-OWSB1/C|W9KQ?J^+BC|=D/!NN^ITYFC?;9X|4601UF;XI
M%B5T;TQ43)J.H0X0S%=N\$ _M13C%5_*BC48F/29);@9H;21|Z8ZD6U;1BW P
MW7KB^MP^@6|G_MV|)T^*#J=1_P^DB?;243%| 2'5_|#9Y%>O?/?FQ^!#S; MG7H5KHE 4_JLIG>S8V&|IT><|B(8|
(Z9G^T8-0\$BF4_E?/I022^HIG4 MA/^(%J>BI9P)8_3SY.86\$5>T&RD1R=N+&7>K7HU<%(09)EV3W32.F|FI(\$FD
M^57LT^2:456@A%|H&8^Y4@H@8V5D89^"=LD9R(+|1\$8.P|>|>T^!^ZF+(@ MO;H>H;'A=0@?LIM^508;0@=#
I=\$>#N(MV|HU/4T;|H29%6R8 M951%^EOI@2+^IMV1-2N^O;UV^JEW CNG?S0+^*8H-J_-^ (+\$\$(^!=WVI/7
M7FJ^")/E\$6JGK;-NM)=7P1I4T=Z|M|^&<+1;L (+S8RXXU0-60|3Q|P|7PC
M_MK2T+_UW|J D_RXZY?;^*O2/NOSUF1@SW=L;2A()I@O^@^LPNB".6L|LZHE
M9^#WY=U97Y>>5^P)W0D3%K6|94S1;<12|TNLZ5;|>|)^6D3?^GM|9HEHTOJ MF^OY3V?
>NKU7FZ@+V1-5CW&Q/ID?G_)=|&L;7Y%F>2JQ<|0JHQ6Q;PIOHX M&Z6X^R3|C8W?ON3BY|C6^~;
N03!^OAG|M(^&EIB+5UON\$(4V@X?R_LYKW0 MAE=|X/@\$;EY;P%O!O?7+A\$?_<9S6S5BFI8.L4-
_QF+;^Q.A@L;\$.30?Q^N MX7;--VJH@^149<+Z;26MX^P)+|H|
7|&N7!;=N8F%Q^FL?;S1;3DP74AA%N|J;C^~1H(^H)U|+HJ<\$E(95E9J%;LUB97|MYB6Y^\$|;34 MHW=5%X;IF@&&M^
|L;SMZ4HKO(UKB5^TJOYK^48^&^ 1^X/\$FJ08S|N)|X>V;BB^1 M65|JU_J^0U|T070>HPD
YNY/B8|1QYCS^*1I^=VU=<+;GL11NJMTANA3E MQWC.H46;VDWNG6?3=EKMHV4-Q?
6MO+15|7HAQA?^"0H=%1LTP7P|3_-A K;
M|H)WZBIO;CS&M|0;ZYW_"H9FS;.\$AGMFW<^8K1K|TP|89|3QLL&F%=(6'
M/TM|0L408(IQ@J^7;4CKIX6QP;0>INR29EC2Z_7B;F=I(>GG|HLGNA7;2&FA M*(Q4-YX%|D0SMXS+1S)"
/(<%J&B&HM9P^\$^_DIYD|D^?^RIT4K|I+^;8| M|H|VF)MK|Z9W=2>K_Q.04G?
F|C^/WH!+=5KS;J&AYQ\$9;IPIQ;UG:O^~^M>4D8R9UJ27TM|SMR@|SD|SW7=F1#+EQIGM MR/+T)MR(G>^5
2GR)AW^EL%WD^3/5I@^&^& M;PF)^3 M^AMH7|^\$AM|+7=1PM-B5PJ/^#W%M5|VZL M#^W6R"/-
%;H(9@|_Q_5("T^?EC3O-R_@%Y%EN4T|/6+V
MA^<&/G95AM_!S0CL9^N/9|2^J;N^C9SL76%MIG^@P5TXWQQ.^&^@8\$^&Q_ M.GSZOJW<2^4EF#_K6?
U^N_"=I9^*R-0BDP(+S>G/A-C6_&6R5R^698%G&E<MP9^T9GP9N@UZ)TIYWE|K@!M RU(>UQC/U6YXE2^
f41)Z%U(DO^HNNV^5A^M MJ_L2QG/^UG_)LOD!^SMT3ZFI-ZH^V7JZG/(7D|_ =8L A0(Z-0;S|0UV4
MK2BO_-^1A<|W^5(P^Y/19DEV^T.86|5=B1A_PD7HV9|^F23\$5%B\$ _7DL59

MX+NI/OLI=PD07L0&L51D17D*17R(!\$IL^4HFOY|ME/9X:2.%XE"Z2U.V D>YX:N MM?AQ*?A7=W\$+.-Z';9-
IR^=6"E.R+V(1.-N MF*XI(XIV5?Z!DWI|+@?|:6UKGMNG">".O"(BB/YO?U?NLO(NUZW^\$-@|I\$=C MY?
5^3:+PJ1.V#Q?7U7O(O:*\$+EOE|_D66%THSTOSN!2J/A\$O\$|+F0
M=RC:4W\$M&D0*VIA0Y"=,E/_MB69IS+8^YBI_ (HFO.,2!5Y!E-Z6#K#" +M->&7VIC3HSQNOKU_0%ADSLB1
M\$S:JL\$M\$=A(+IS^&PEITQI02F4@K0#CU,2&U/XI1DN,9DSXT^K?W43J^C
M#|UGZ3#;J|:2: ^3I'\$ \$Z|'38>Y&RZ9%PTMUT3G";|H@_2PG_-.S'Q.V.,?H
M1@P<1@7\$SG@U(04LLOU3FG8+S|3&Y-GATD2S/)CHW.3|HZVL7&6#C+\$HI#D
M2U|GRPUP|E7D*%LSMCPW^@P36@+|C;E2;A@>FQ|04L|>HQA)3KFIZUF
MHCIR+^@/1= @=/\$J2%+M1.8!&LUU#%2+EF_XH^|1L;I<7@>NV/+WZXQBFCYL85M#EBK?V#J_H.9NY/YR.@@
MBZ|VZE^UK?XIM+/,Y.*@%0%|P:ECFY,E1W">|N:M1LX H(2%|QD3G.1/%M MNR^8RL4JC=VP/_D_ DTLP/8%W1\$S-
C/C@9.JUUF:/%Y9!=*O1ERY*9/84!'| MJE!?'N0-|AH!'|/7L.^?0LW|HVQZ@O,)|VF,K^U89I_4E53JH?;S:;#7G
M8:2^35A1@V(R|L_!5SOYV<48IB_Q:N3/HL<1P.US0>TWAGQRHJ6)LIO M+3E^CDVRJZY_JEGS99@*KWGBNTO)-
F<_!K7^1R.#4.#/YXC_KG) O8W_!A MD96G?^S!2V3+S!%|\$:7NJ3C.B)-TC8/_JU#@ZN^MU|Z_ S6OZ1YP4#XB1FF
M;|R|<1NK6BYY0|=5^?&?HFFAD^ ^7J2>I01_!AG=+CI?(N40F783.M8(1OM M'.EVZ&N7>\$|1^JD65M=
<:8U_E!7)O/9C0_6>5VR&A!^ZVW?&1.)^G?X(NX@ MF6K=*J06J;^>_UB6JF#W;(RHC1QL+X0\$HZD_G_|-
E9&*AA0>>S:D:1KV)# M|)1@4G>|RVU*.M.S^R3_H\$X^6|@_KC|7#2@Z7|=7&J;IYU(V\$9\$+37<*M2_5M%8KW"
7(CYHR#"(3#_@9Q."Q""2X.WWR2^|1U.W3XO9/3:N; />^" M^V)+0US.=|>GDRP3|SI_#|,CESJGM.^U|_U^
M|JA3\$)|,X8ZIF|H^!^U63,CP.@2#V(AS"^(O.P^0-0S)5"BPEF>-E614|+W_MH_|!R_|FN8&U/J?P%U2#8_K*
XQR5Y+8U8))0V<_28>=0|22|XN;|VZ1YO M:T#9(^9@%LKN,9E_0B^N&I3^ (UND*#|0"=9F14ZD!@RH;B|G-
Y19"75Y|UO MTE.O)->|2!%G^R"-BYTL@6R&CD.1WJ+N4(2M.LR&W3O?ID%7SX|_R;H|Q&S0ELGFLC3!|
8W6N.BZ&?Q%|_BC;EI MJ=0ZU|J|X-W@|J<6B=-:N7A2|.8Y+.;#;NOX>;|JQGN41\$V.DK??|/2:;|P^FH2M%J>?/N/6
MJV^WI;I7-^?W2%2_4BMZ;S,3L;1=3XLKG (#^@.U;9@=NKRK2A1"J|X/F):O&P@'R+S!%WQ1O@|AKUIDV|1.V5K;^?
LGU;^ZK(ZS^ M|F_ %XV#;7 KDKI B(HQ(|KKO76YUC*[V; >4 MC^YISFU116YDA|')LV2';?
L6N5C7=Q=+SWP^|CK(@#|HH,K.A;^/M4'6HXY' MDM*0E4)=<4&;|*X9*B%2C
0:|TK*B*&J.5NA7@Y|LFERCXJD0^RFFW"9|" M(C.\$AF|5_GULX"+RC@4_FOM4Y>)T+?L9PG.MY<|?
AVU#Q3O.M?|H/Y^RHN=L M:7^C4C5U7)|WKGI@EO'=3.;73E|)E^,E1.T_HHU&*I3^YX\$G5K2KE/Q*;| MR1_FMMK&
2@AUNS0| MBXNH<HT30S_U>33\$^>R.2;^*1)TVIV23XQ5L3C=D,0IU^?6=@/F(7&
(Y%&\$|0|7H^K2CYA.GI'=^#D(G6Y.(^|T|T^1+ MM7Q4HS^L88.@=F@%E214P%
(K@+BN#CS+M>BI_MZ1%"RL)TB>O M^+C|^OE"D5M|7_52-)X6>YI?7 |K_9,R2\$|.W7CKD-\$MDVO>_3MK|
MKN&+GG/>0.K2K;U+=JD%;0=D5F|1O7ZI/_+#+NQG>6T+_G^"UJB1AZ&N#4: M'?
WN&K<>670S::DCQ_B|>7X1%4!9^K6HO|0>Z^*%&^Z03&\$-TA9I3Y4^X M1\$XK?6.2%2C;|W?-
:GPKTK#3JN|_G.RXS8C PQ4.4*.T">:(+G^*)>Z173#W MD.B:RG\$TL/>4.0L|_U<
VGOK^.).W|25|;%ZFXB=S">%K<693W?< MVS82|EBGN.B.O<62-0^Z#+(^D^IY1ZR|HA_HC^M@.52<'Y4|C^49A=Q\$IG
MW^H+25_08_H5?P|F=JY^V98G_?0|AC|U2\$|7>KL\$S^W0Y@3=UYL(Q410K62% M^+8Z!;E@EK+6%^A0D-%;-
K)3BWL9OW8=U&9;^5*%L+MRK9_5%T53|!\$7" MU;FW_6W^2R834W_R0OPND#;1.VU|^?Q13_W086#M-?
X7K5.F=#;8(BY7 MD% @_WXWE,W;)TD^I_7+?Q^60O09B2?&37^XK7SOJZ;2P"0B>.E7R81V>_A&
M&.PEI<=I&U^|PCTJWAV|1%|S|^"-:QX>C*^ PG*%*IV#+TW|_|!< \$WDD4|WTLXBI
M6YP+S^UM3XPI|>D&N(8(U_/X5GIG|CN^0|9T2GTRR\$%-B9';>#|")^%R
M8L37LK^72KM|IM3N;AR6SZ;7C=^DT(+F7W;(#_M3\$^;^%&|*1^Z(^|G?42BWJU^<_P_D/A2<^3NZ9/U%5YGF!;-)
|1:AA+^"-M|DRI^ VT+<5F";EW9ISPS1V|3T;SM3E_(VZ|/R|C11;Z/!_NW75LUTK?3 MZ5=WX_LBO;7A3J|?
<@|/|^G9SR\$1)|@3#;|4^Q+;&KZ+V;0?PB^L|""U>._M+^W%B^&0>NSHX;O'.B"|=(M^B^|MP)F_Z;I_NMI7|M;-
ND04?LE4L|_7R.C^ZC=@KUX^NPPY^EDC;IRI%445QI M@+G=?_4J?R=>ZS^&HM=0;-?MU3^Q^"ST9P@
^=&Q^Z\$|H4|FK9+\$Y4)H=6 M\$P\$8|K5-79U048V-IB@/GD+6HG|Y8>2@*|^%8#C_/K;#X^7W?#IW<|F&
M7B|1=VY\$@=-HTLYD@_6_/|U|^T6H>@903_**4^"U_UU@.;|+;5?VNCY4JN)3 M5?|I&_.YZX?PDW6^B4LEK?PB"
<8Z7)EW\$P(!?2NMBG\$ZGS1HDFM+/R<3|N|O_-J0Q|C%JZGP5FV\$CB3.P MEI*ZZPKG1|I;I?4*FG;M9&:
(1X^OH5IS_N.X2,XO8VZ6%)SQQ*%X0*>^ M:GSVZ9<_VZ3Y_6M5W_TVX6Y-
)U&/\$XVWGD^9\$D@1A^+9L6;R.W69|N%NTR@+H M_HM7T\$;EL?GA|U&O;_8B^H|QO|P!;EYQI7_**AFV3*1
Z^NCVO2|@_DMIO&^*TA1;%O_"5-Z+YW=5/-%5;CR;#M=(OESS^BFW@!#?'64 Y+GC|5|79MD7<_JW3Y=;P
M40W<^TE@NPM\$AJ|P=|U|MM\$E|!R3W">|O664|8Q6|A^N^Z2;)8U,3)I#W.3KEF_0MN1^|H|
M;Q99W;+>EY>GY&SEHR|92\$F|7 MK\$STL^C|EF%Q|?_D|'^5T873H&%67>D>;\$Q/T|LA2|!+/-=|U_|/WJDX+
MRH#)B+V*|4A0SB|NK6B5?2S|A==C^B^XV!|7X_F;SUZ|4DU=W6)QLGX+K|4H_M9?|HOS4;C^B\$;QJPG9<6W9;|
<:/O|MD3Z.XHY;QS^LW^9|Q+34.^;=SQ_Z MH5J\$3^LQ5DC3TA_S<_N?_05?;M3=I(N"?
9/P;)J/&)3\$\$(4(URA73G67|_B MQR-EJ1T#U^A.SD0%XX/MT^/"SUUBWP5?^DB:?)="48U2V)="9|UXN3_!HW
M712.UV|5Z|EXYNW^|^<5C|H0""Y|>2P|H_6%(4^M_0N.^G\$TA|5OH/(%T% M;_YI@C#"^EK;*2|D.A0-V9/
C7SC4|T;SQ^H=K(-V.LIF<7(V&.TZ""#6U&0 MH8L1Z|LALVZ|HHBJVK.6;WOBPJUN>_AB7<(B?
D_|>|L_C_H/A^*^|LL|(\$4\$ M>O|^#G#M4K0R2DL_W"-_MJGF|GDI_4IETL^4EIT4_5E+)|PK1WCQ@F.Y|;(K
M@9.MX^;9JG.XC|(\$>#V/RT=|7Q8&BK|OTT_-=I5|D?518B5")=|X^4|=M_T<(RP|O-
PZQ:H^7<|;6<4KLE>_5<|H;4;UU2SKLCPDE=N3_!N_+PZ%|W|Y'
M9(W)GG4|2A*RRS+3AB2IA!!3R1X3A;F8*1(10BC%5_8L3?;RS&_L\$8DPEIA% M1=89;=W.XKU|G^YOL^|^|>_|_Z_|
|_GC|MO<_RXX^N|SN7S.<_K_J_QBV%W M|Q9;>L:D#%P9/8=_OG^R^F;|YV&;74EIT_OU.#&2*@1?%C|_8Y=
|WGM#| M.TB^N>7?P\$>;OAF;Q>+4SQM4+I6'&AJT|^)+;8>?=%@M6-L\$;C_T5J3
MPL|_0K|HOMF#1CE34/^1|P|QTM|HXB1A<_OF|#0@A|HNG0(WB(8*PHX^M1_6|@&I;_4_0(V#X^"WM#%
(J0|N;+=5W?W,44N^)" M|L_(\$D5I_HR45W_U7*|EKJ&R0L1KEV4/9|U&QNO^Z/X)6+W7L=08#Q;_TW
MXP+|_313|H(OGG8JGPR7V?=\$&..5^Z#|2AWJ7JL2P+!7>I^|CNR^LCH+S=M9B=YIEGA"#|W?Q7-IG#;_|
(3BTL7C|M5|N0Z5Q3G#P3T0;=|H0;GPIKUQRH|U|H)5|7^U|^YUB?Z2;-"AM9
MHC4X4N2I+9\$@+HD.C90^BLE7|B39T-ZF|^|MN|8&#^VJO8A=-CSGTD2FR|ZI_M_~V7WR.#-
FT)|_|^"DI=P):1RG#A2*&H>Q|=&9V.M^@F=B^F9VJ|L3|S1!)V9P;WG->Y M
8%B:>WD>;@BD%I^P4WGH^AC1&7|A3N&_M=W;Z.N6%6KCTNQ5!%JRTS7AZR5">?7G|U(L37_M_!9NM,I1<4|7.9?
UYWH#-.OF&_T6(^NBT^P9-DT|G^MOR&E\$C@_V:0 MX_6.?<|?70@;-+&.6*(H0D^>UV+
""N|4^1G<2""C.3Z(&_8#)4%5_3L&2 M+@A|DGI?+VT^WT_ZIU)Y6LLDG@056(8K;YX+JG:(D3-I";M|M8'Q.)-O^HJ
M^FT;K|IM_.;D^42K@/^YS1@LXMW@W@V9%!"NTOT;7C\$1#WC^+>@5-E7M3 MG^A^9;J/W)GVFB1|5.!?N-V5-
X2(L2|/YM4(W)HMST?OW(^PIQ#H%G;>8 MA08IX@11;PANJ&SWOH1<^J0^_15|?
8ESI^*ID^VB>9";6XA/B#(Q;49 M_KNK;>10.U>7(X737|5*H7D?|AE!|=K";+;|T\$N^|S_W)" +FE;8;L1=
MXO&5;58/"^;_J13TWZEH\$A&PR/=^5T-BT^6^#SW2JD^\$::CZX=Q2QR9.G/+<^=|#M|_4^6LR%WCE0H;
&_QS(L:03|0 M8YHTC^FVX00^*B@SA^T#037;N|=U&T(^+>P.G(ZV#@"9,8<-|;"1^GHS
MRD)|SZW39H;%OOV|J|+.#;#4N&5P7|&|J_#*98^U.8IQ)(D8V|5;.*='\$?+
M49QS&M:%Y|4.KVORYOTKC38@WENQ1V&_L+Z%7F@S;"2ADW6&D5GO|BB<_ ^D1SXF MJ|I+ # VX9YK^B|R-
C#|L868X|9S_VPE^J=MDRYXD+G7SG6F27Z-^+;\$Y;Y5

MYBSRTN& 22.ID#0\OK^0^CX1Y2.TWF7CHIYLU1E^A=/"ZI M >"3XH"@3SQ7NZS?.XS\$%ND\$R7H0X9?
@TK1PY3XA=D6K\U\XW+IFO.I^\$ MYP0NNG'B+-NX@4.E1I7A2&T\$!F5* AB3JLC.T@L.#.K&)54>+.&1)T
M0\PJ.^40:.MUZ9@6?XN E/"/^4OH5-0GJ@L6V<641&04.'495TEU&::6FC2-M2Y:/GAN70@U?
W>@YNDI3=6/B1S1QFIB(##@1LK(@+T07924-UI7.F.M:31G M0'.0ZY6ZI+P.^3UZD^+NZ/4=&LG&+?
<6W67=D>M\JM+1K M^>A00364.0TI+11.I(PVW3DXM&8'KE0MMN7TL.Z9/IR'Q+VHV-ZF\YMI5L5
MQ:YI>F;D(+H(J(P.USVB5^BOX9XID+*4 D'I1)3>K?IY/T.#DL>L)X)\U(0 M%5R.^822.C2V77/>_D3@6._
I;F9&0T?/T^-8M9;K;ZL#B/K)22-#7%* MX#P% T41*XB2\?2/RS..U W1I I)X0KWRS<ZY_MA
M/;7)4PTW_8(2A0BY\6W3_#52M=\$&K1PCT"\$A\J?._ZG\$>12;@.L.I_RP#M M.7#Y_2 O=L8F/6_<(-I=_X>;C\^.@H-
U3MQAK1_K^_C.V>+XQ(4SSB?=:;& MG@#\$R)F\KY"&>EDH9A""U%LET@XIOG'.TJKP.C6?
VU.M7>M^US^+MG0/I MY%RAE8J_IW.?@^_@O4ZU\C&/@J.LZA.>\$;.*89.YDWH-OO=U\?23\$ANV%+
M5GZB\U<(LBW/Z, ".?JSE>OWM9M.? ?8J#1.C4\OLK'W&XV*;P+?X6? M=?G/7ZDOOWX/34KE>B2N_")
0M9N&X#^Y20\$A"J".K4BJH\U8;I08WDY>M314Q*UW*N\I^HX&.;I/<6.T'Z5""\$M5Q_Y#L.7/-BJJ6.6QGP_+T+
INC0Q*M_VN^1IQ^*Q=X)SYTVY;@?X*EZ3\Y;(RX9TKNXD?G@^6.HO**#QG5))66C#
M^N.\$9B9=8@CZM^K3J_7HYO;AEJ_7U9)S@H_\$.#^S+XDN)T=OV\I6/Y ?7< MM^;Y>1>C/4-
#X>>S:AXV.#OJ^C@+G-+X5J8-F(U-A;K3XQ1+!I=I1.;M;O^M^&;L2B^K;f53R4J)0LKIG1^H5W2G+O\MIQ-7I:=
<>K6-<820LF#)?SOZNO MVT<%LS_;"\$89+V!=-79G.<253\$(PG#H 6KP+\$;I^XKZ Q M&(V ".8\$.?&+1E/G;HS
JBK%OFIL^I>=GV+\$=N/U\<S39M7B.H;:/KO.& MFIc?L;+C_)B@;6SIZI#E2-
C^;X.^I@.MMS98;+PIIU^N2ETX/7O-UO50? M;055KJA/>_LH_ ^ET\$KW_ \X?CTUHV&5 7KNJ.L/A00U4
4WRJY8R=G; M\=IK<(Z8)0U5FW2+NDP\$K;52(O8CQ_-W?NN,IK&f ELW/ZR\Y19A M#)
+7PY5%:TS0YMZ2N9)@/I=FYFE.3W&=UYO/(^2N(E*6Q3A8.>_VP22K M\N<6\ QE-
R"13*&\$59OZI^TACE@CH@.\$19 M=OHB;(YF^ID"\$QB5:D4>=I3^\$.F=.NO <\$4FE4PIY2_I6(CZ9)%WQ.WOTL
M6_.EB7*/Q85BY^<1-27\$6J\<+-3O#.*NC\WGDMM0W3;4'DM\;0PT%I2I4.(X2&"0%V-AQ)=9%4".LMS11\7% M%(IC'?
V\>B+<"G1S*)V-O1>:8ZU2_*=IFA.0/.*"6?I. M7&BY@I6G".*5?I=/AQ\0LAX79/G5JA;=' RVCI\A3BCQ+PVT'M-
KJ4V(B MW2.^8^I38TRBPIFN@XY^X>_R(U2S7*6/H27*.8AZR@L((PW.D.)PI0\$7@
M7WWY\$+0\@C*S;+WBN^PNE;KT(3=\$X^RD\0S?5MM4UE@"EGA#8S=
M>B;E1".C:Y;B\MN:NW"VV7I=9#Y".YB6R^N\$^I.U9LMQWC<@J6D=>V_I
MK3WI\D7W@<f5;JS_".L#^\$G;K1)M.\$FJG9L0%Z^B2@.I\J+C9G/LZ;H;> MA88@2>*8#A\ @SR-
+D+T'5E\I92REIC7TM&2IUT\K4IR9T)"8F'ON?2LBIG MI\53A41OR&U#R+9=A.^9)+3B\RS8\$+
+I.O+^5I\^_Y.A*/_C/ 8Y\U7F MIX?A.>_1G.XVX7Y2/=EO1-#%^MPQ38'M-@+*@T.P?_W1905?%/BGZWZ+*0\
MT.V17^CX=8L_ \$1&!.T*.2&GZ1/CLW\I71/T%1.0P6"*J;VL9\8-?1ME/S=; MJ4NRY\>EV3HD4ZA2E\
M/R(&?)2*C.O\SVIPUM6#+2^ED@P1M(^I8P=,DH9J6+).B_6@CRRZXZ#(GJV MJIN6?K9_0=LI.M/C6%?
+^QD\NRD8+S_DJ^ID-G MLW3#=#OR\LEBJZ)SQ9JZ^H;AZU^_R8\+ZK+96;VRZ?Y>T27I\$YV?;@33B^XL8U&#-
JS%?21 MG2YGRSE^E.V71WRM9H00OPG3>#I\O1/4-2N&6/9Z/1CYQE9GKP2>+>+>)T @/ MK@8C0\4->
I-&Y\G\DLR1TZ;f7DCB.\UDY3U2+<93-6U\88(ZMQGF^U^U(CF5=P\TA@YI9RV MKUW\J_D_J:RU)\>+>
O.IZD=MCR^DR(IH)H\W2Q\^I\$9CI316UDMG=>@%15P^_G<_I68Z" MK.W=EMXW
>OBRMYIFU1@0J.YML5H1\O8GLVS4"Z5H\WPU;\$95AUDAIL=Z?N MV))<5G RIXB DR+7UG"H/ X_9L?600@@X
FNY7V>#K;%XFTUZ&R1U1JLE"2X MN.&KG34NOXU@VP0MFE)#!1Y?31ON.#.G _& MD0Q\RD,277>>S-RZ\$!2\))DB
_H3V\^K.CDR@/D)H5/Y="2?@\$ MZ?V=&M&1QS \$SU>ZV^EVFFOPU=ANJ;FA; MIMI-32;? RJE=<"1)QH+KAQ
34907QB\3\7#-&16;1/52GF@FJA'.U^E.Q MQ1?0?O(3XOPFG0I%A.LL*M^>O7 DI73ZT<7G"UR_OO\PIR=9A_ER'(S';
(I M."6L^RQ^#17;D073F I#?X<^I#;T6 MYGKAT0\$ A6^_EIE;.^_!&?9C6UIA M\@CHSI9&Q^A^JE
::5HVA\TMZO\H\I^H\OYLP M^IOY0? MJ/\$_/%WMBNVQ1.C 8L^F6^)*\WSL(N94*SAQ)=?;H9!'&-&,\$)OA\A69@:#
M_Q^C^JTKF^NGE=VQF=)XC7Q0Q_22^X.E?2^LC \^5KUAZ5(IKGCJ8
M&2%1QWKYBMIMMGUO.&5H)5IELWW(OI<26I^NKV)C+&V@^I09A%ML M8<0^R%&M0J#
(.A\$!9B12Y6)LWOT5;Y?F4DMNA;I>:%H9Q.*\$F+K8GHI8MBK MNG=5Y;C/"=O\7G>24 I+ M3;U^<0-6-?
@>X&L00=/3%1GYI=O0/=,T(V^PX(S-XM?7 U^*2_P-KUE^R/3 M\^_I^F^A+MZ^P;3GWQ
G2"@3RF;YI,89)4NO9G_BBK"YH/IPI;FP\I^C^X&Z
MULXQMF44<=6;XYCP=@MBC0(Z5LRA\KHH\#^K8G#=#/6S\XLW(*Z*2SO0XST) MK\;
fY9O0\BG'8\#=#;Q1;E+>.R".>L"M%#- M+U78!-+%Z-F?<=NIPKH?25(//T
R;Y2I@)3T)W^&7W^HN&^A8XS;@I;4G?M M7Q.W3IGRI+>I@@"HEEYGMVX)/DAMS25B4\$6+ \$A\URL)ATY.^6B&
MLA^A8 2B&=71@DEF.F7\$?9 /M?R48XF\ P.A^_>NMKLB7A3.97J_7Q?*TEGJZ%+"M2(1BHM"S:QO)!/"V
M<<@I-?#IU7M6F..APC@C@2P932\I\FO0/TZ_@XQ42;IU\U9*#;1.0.2\I"2"TCYB(FCOZI\0K8= KIX+ @RZX)\^<^<^<
X>@/D8YV. MIN6^1@1@/0 W.L3./V)I01XS.E<IH/^5R-DJCKG%&T(R(N+F71C#YN7R+?" MAHY\I)VVY5U
=L(&Y;JO4\<%Q? MC_Y26ZTGN'/K08E7(MX)<2^NV<IU(Z&NPH,NZO\ #IUG;4ZD,E!5%&WM;:
M/I_WZ"=3T0ZRG%7>*)\$18L.IF6-U.RIRIFO&5TP\IH71Q*>_7Y%72I.D MI< W^HWZ;Z^4+Y#Z 3%I^_?<_?
IR_T\!ATM4\=/F3FISOE5\;C33;);3C>J; M<4%B3F/>.G\$9J;_AA50&&?I@\$-3K^N.S4"<(M)@*"HN6HAN?V\HR\ KPJ
MG (C\$/A.09+ #W>^KI7&SW8KQLST5=1T6U?J_>(3X3KP7%&R;V^1J_S3PQ\$<\$;T^\$7WMA\I0E%1 TK;4MW_;
M\46S>1^V\^U2Y<^H\H'09\ BIV^QD?>DZI4G^;H(HG.VAOUE/R=7X<1RK
MC>O\&I)GVZ\2XI^*J3L\=\$F^+=Y^T7;RXXZ^Y=&^FOUE.F05#NBI\=I M_K3-40U@I\&QR\W\A8+AJ
TTNJ%UID3O+M4RD+D2MGWY5_>VZIRM)7DI YG M-W3@U8>;#I&I\W@>681V-
#^P=B1^D1#12S\$R^I\FP@J@+9^RF\I%K? M>2>;/QZSHTJK L"WRIW-
>MYZ\0;^OS5I@>A#FCSGXAG"+52=DY\32VA-JV; M-7GH5;9^60M^09=S;I\ 'M AE2E5U1SOQQ-OS^>MK" 2*8QR
MR^8\$17VFR\$IF8D004H>;(W+T2GAPF\$%Y+%;?Z725;0QZ\$2PC-^(-OH.CY
M.GD\43ZVN94XKB5E7(UN'.N+2M&PBVF/T'75;J_.'ODMY0..DE5-WS^>YV SI0C;@0_7D1&UIC;2*;&<
MG95788;UH\I/& ^T>PWR54A^_IO^0X-C MKDS\CGI7+.EHC Y3\DEP=G/I#_5NAM(\$&=T>^UHM W\GY.UK<;
fEP+X812P\$M1^E6.(=>M.RS\L7V X&D\ MP.6E.PWP;27OZ^>C.W3,2.T4_->6W&C(EI?
YC=M.OBEA6VJR4Q(6#5&YGBB MEM2LF@Y3XT.7&OYR=V5%4%G3#3/DWYH5%I/K;)>DATE\W\>#\$6F)B
M%ZC1PL.FEV.WY/OE\9V7V+R-I=2&A>R.QH=f48NRW+8.SWIM;#!?>JEV&Y MUJDO*Y^~I(I_?
5E567509W5U3:Q7@G#JT=>I\ \$Y'89 #D(@YU?.(OD_O/S _MU^V>;^T.&+FR-J_1(\$AC)O0#
<4NP7<<I^XKD^P>OC5J4;I1+A=J^*F? M3;W7\DI75/@&K(6I8=I 2X1E@^CC^G9@\$BO.L3-5'DJ
_ER3^B2218V/V^8 MK>Y@XIC=I23A?Q_7NIB6PPCLTJE+T?F>T9@&620&_5.*I^<
MV\G^<2\BG\JSR\$FB+>I>O+&H\JYX=Z?Jc3R.K3<_9#&&SEID-
MDON07L#D+I\FI01YV\8;Q&3X_)H131UA8I^ZM2\$QG+JP2M;+O=_.@=HM/ M=7.QDWJO\;I3C_<
AWB.=.4Z4^R0\$3BL6KUO= ".*.Z.^Y)#\$>A+S4+3C M""(Z\76ARIDQ.^M);PS9B^MFA;?
MH7U7)B6K;76>_7198?FI7NP^41_Y.Q9 O^+D6BOD\$&P%UX NGK2M+ND2ZU MI098@W+ (7_EDMW1/8<%R^L>
(/_Q_U?I.D&1THIP/1C;I) 31H#5=OM/(+M^M5-X)C.%^ OJO &N8>OL\@=TIYTNEV\$2< MR\&)&V9S5;LD-
O<7+I\VKC5;ZZ?N^I\RUCR.#8L4RD;\$&\$*8-6=.\$:TZ^VM?F M;D Z5.V?MPSPGHP?_fJ5OMUH6SQA--Y
(;D8HL\$EX=IPU(4(XH\::4*Y%<^15Y)SE2I Z>.G MZ^I0U)AIPW?HJO;1%<^ZMX#.6P%;LUHA\L,5<+**=N0 "M%I
MC5IO-D-3 MA#A& X1M_O#=#02;V*9)?T\LU-2^E>NFN_@&4P>X/HOOXEVYKT?^F@^M(G

F/LD/WX5FLJYY2BXXGALN4?%S'.-W>X2JY+O^/\$+ RH?>1\$!E,HH^Q%
MI4I^"YSZV)U43IAO>WF.'ZUUBJ@-I.FVL\$Y.2UI&5 M"HY-
)^QI6XNWT0HF== \$TPW(050,B+G.P5)4#S'J%DS"0"L\$?RJJ MQS_HGQ.
I14=MY9@'EUHUXD)T:NN&51+LUB=-78;M_3#N@WK>^O"4FJFP M!#-JRF&AJXAC "R4'K#Q5797 7Q'NWQ
M5M?>I.E)M1I03IMG^=9=K2+G&@6T+!M*L@2:6FKLGDZ/+":J10I7.Y*3 M&I&Z&?
N>C99\$%8QJX7)MWQ9>N/+M.\$GP2HE"7 &OAP<%VFFP6+ERIA'T2"#& M<&BQ<.,CB>I!#2V.WF'RB1#?
^X'3H:1*1.LDA6:B1O/8I+ (TIRI\$&'GTISU7SUA_HR@U7#;T=-GD(CF9'X>/8,H(SZ.+0<=)Q3/KDSB5H?);
MWY(NF9*/4R.QR QB'8ZC&,3>PIF1^Z<368%+"L;(H*.*#I'K"MB-4I.L^C8OI M#6ZQGFFDI>S>UWSA+IU
T:7/R@9MNV@+&5;"KD.^2XS@S5=<1FDU.(YDG\$! M44VV8.^M8HX_%U>CM^0^J?
109I'REQ)WP2H90#=#O6C#I>OIYK41%8AW:V: ME(1^F5K&W'ZNJ&EOVM(V>?I@+*T1 #
<&1<6"MI'UU!":OX0!:"6&G2I* MZ&(5 UM)W)I?^DF3B!6+V@/K+I)2EJRX.\$07?6!71K1O_.C>["N.YXGTLKW
M!#,QI=C%UHY4'ZSY>.6IS1MTI\$TY/* P6N!YX<@IQ>T22P>DU2#A>.:Y18 M(&".46"OH(00
-.L+LYWZOMH>.,NIM?Z&1TRIPLB1GA0VH M#0E7S:.#=3S%87\$&&+S&TCZPB|\$">#>H.=KZ&K65_F>G.:B56
753:.-/V762U-837I9M M/6.*D8#(HIE (WA6BJ.N8TO<-0FN8_IZIMIH_I&Y9TUFCK@P+X=IR\$Q1\$: M: @NZ*I+V;
<#M/1.%273!"O:9KSK?8P>4B0 SD)V-S&KR22HXI?GPT?>(Q3
M(./76+FL):!N=SSQ*3S.<@DDJMI"WOV1IG%1CIZ>3+SQ=EHHZ/EO%);' M-0I9P0*.60N2=-
W1")8B\$.MT.3Y:3="VG43Q3261FEISQ3.V^ ^?F4?3XW5
M-26'W!^V=\$.3JQ\$S<_1\$*.PE@I#8IZ+FICY_FND."W04E6)/?I#OG!'E<= MCI#KRUT\$Y^<<
9.I)0A_XNAYS%)IS5;BI1&I^!5* S.G:C4# M<.;L9DQH:4I-KIS^JHLF!."Z68I
<18.VH&)PPPIS0Q!8AE.%RZL=6JKU MJ:K31YG.#U%KMYSH65?QJGE+.%04AY%0?J4FIB* @)2@B05X)6N! "4
MCT.9+NAV*.X6:..SWS99+TJ\$)/&IUM*Y/I1_15!IC&>^*YNX1@=-=)'HIS_M9FSF45V90JT.D.V-
6T.10FXPHRW3K+FVD+VW>.;1BG?W!>E5?4*_Q?F:2 M6/5I8RKT"=P(A.(6C6*#@RD%5RF3UX>KB>!
(%YW:;O%4!J89KI06#F>I" H M(LOZS=;C!^#;O>=VU+Y:MUM?^PZF!6M(3?YIE+?@,\$."P(=@.SF)264I18W
M\$SD<7YH"7 =I^BL)*5?6J%(-M XR)6XI!AO?);T<.69-A#23-!SY M-R#I928I/8:FGB4.9G"+&*IY+X.@R9.FC 6GK
(2L3W#.I:U\$*_Z)LB(98% M2:5'OJGM6)Z=35C6) 9<<5VC!L6QV^JPV/RBB0 MS=X.U4YQG?A1' VOX)"-/
KN#*2NEY1;0\$2+\$^S=+GJM: &)6X7AB?O>?)Vf9 MTIJLYGNSI.J>F.)+U..RD@JN(S.&A0+LF'A6\$!ZGT/B=L\$47&2
'R*9&+F M^20QN+8^LO.G-W6(>.,6+TE)=OPMO<.,ID.AGDCSE.(OYSJPBWFF%0NL0&? M\$:-
UMIH+L7IUIPN2@S:Y/P?E>^L2PQ\$@A6DW>\$6U=T*/6D T/;>?=- M MDCSO^;9PO_EC(@5#QR'ML3VR+"
(+Z%<.;.#&'V(HUX2)(DSL;#031<7SO M!G1/Q94EJU(HOHAM.CRGN.Y+&'NPFZ 8N9)/Y^3.BOC%9& M(QN?
B*WH?"2(OZ7K5-'&=Y6YIH9.W9IW.Y_DP#77O;IGI30I?1F6YF\$).X5PS>\$-R4UX&H1"SH M;DOE?
4%4(>XU7EG6H=2@8UI9=28B?KI9@JHHMET*:(1&8B3_P^;#S:.;IZ MW_RP6VN6!"
IVIOV!2S##IBIESLF.7SQ*M#IL^LOSAXI>BP-0_0-F9I2..?I> M8,WI-?&EPT.<.;5(-1?VX*^
M9FZ;HA\$7TJF6KM.156_17.IOH4ZM?TIFYSQS.I=)A/XI>+>.;IRZBD=15JK M6FU(AA^.
(MOJPO/E<5X;R2JU.^L)>Z2?3I9+>(#18Q_>JHT=M^R)-JIDV-QN9@G?B3%&OK+PIZLVOLD4GE_\$C-M?
O* KML^.;HQ+X%>5< MR2+I^6)WSA.#I.VAE5D;IN8DL#8:VA T.T7FEW:0EHB53>D M: %FIIG_1
MRLW:/@(-P6EB? E=5F@<G*#I7(GOIL./FS%MF100*I<#X2)8G7<'R SCZV MZ.@W-)XC'IK0/3M^ZGU#;X(?
@9:59NUWZ1#=#IRE(WMVVZU\$&E!DG&I@#J?W78W)#-.R+51!FX=12A##M M&Y!*D_D^1>CH'S"NZ.846(T%
M'M4E+RO&OX@ITDI'X? S@3% MIV(I2SKUV=G.!USD?)RJ"Y_(9^*7L_-/1=MT4BJAG.TQ)&I'W<+&>&
M_/S493IRNOL5GO")L<.;?;R9*N>TO#.\$W/E\$7E\$M"14@8B"&_J^F'SI" MXQ_B+T/(4Q"ITZ @+7M'SX+I/E_/?
SW_I?R+^ZV>#<@UW)C7.6I2I@3TQ8J M0=6IC-DJLO4)H4:I7*=#N_DP QGIY%&Y!I"/LR>*C3GM?R8:O(-I:ZB=P
M_#<@I=U8^RZ_4(%2^5IXNSIG_@>.(I<.:G"K2WS5GE7?Q_G9KXF*&U6TT% (M&.*3Q:9?_JI=Z39*U^C""F?P-
2M0%9,*>Y\$Y5GY&*C;I3Y8HD MQRACMA.CI-6:E.373W4Ij+3+1L:VC7>2CE&G(KOF) \L^?J:E+IPEI%
RN>0I+>+2B M!5PH6IQN;#U VHU8'3DLW>\$@KC=2@YO>.1Ij.M:*I.P.KW2K76L-DK32L:E M&U88*QO+&\$-
'D982%??TQ?_4T*TDI'W=5PIK5L:7E9M03I9ZC%IL"P_@E^Z=R M%=0NSQ;5B@=-X;-"V VV-G%C5VIR23-
4W("PI\$F4(DG MB;?N08RZ-7>RI4I.RX\$K<);@7"6_M8RWIGFIT*Y'A38EK1"A+!6)V5C%E M&X>.;0WA-
^WWM.HE';-B.T=X^8M_B3FLFFH50N\$G^J'N4JK)T>-TO/P<.XND M:L98I^SR62??K_EH);T_G
9XIDEGS.S*B(7OPLZ?G>2FIS49<>*\$*#I%V1 MOYC.N%ZM!Q2YH MLN&KW"5I Y8%;\$C9ILP=2*)!2^E>?
@HS5T:|=;ZV=IS/IL6"A:/"SP_LM MJ^WCNI&."IBUXZG=*P)4%3IZIP&1I:3N'(-'JC&G>&VNV)5K3N2I&Q!_M 6I?
S!;TW=8(6*YV?Y<I- KP:27)*I&Y KFC'X3'SN1LOH*1.5>4U6DU M&)OS?3C-QA_MI?U^IGOLNOI<I>.;0BBS
MPDIL5TID3X;DHYT@;S\$A!#I+/MXDXP%GCE 27>..969?J1'T=VQ?Z(JM98_@IXCM8>KMJ9V(5)C'LF1G.*)/F=@
M>2)-&?0 "Q!7V\$AIML*BZ!7 % BQI0GI-IIC1Y!>O:9(QW04TH%OUTO_9H' MNU/?
Z)=BYC'/>%V(2F(K952+%32.D8Q4MC?A:1_G1GB2&RU! "XJ_X=OYPR2 M2U^R(HY2MWXXHCZIVZ?
L(OVRND1HIZI4JZR#^3OG+*6E_W= MGNL.2HO\$FP1%E34/4ER!.;T/8P);R!7FM%1Y4W/"?Y=VIHU2H!30IL# N-
M>R!_3.Y%Y(>05^ZIU"R;B:OKFY?EISVV_EK>?Z"+!&>)J^?HU%&\$Z M:3@+I/2YF#CIN@1(X8&1S&#?
92SA8'@2/XA>)17IDPWA=DE4L*OX.^1EELXXU#M3@13BF M&1(5="ATIN&-PO'9L=CVWF_9'@W6"BJOG*5.R-
'VZNQ!M4BOMGRYI/*(J M1AW;=9RI_9DW"MN Y&43+Y<I5IVK MA2V.S. FX'^<.:L>?YCI"?OIE(CI'N5RP?
GBUMC19,I2_Q4SG^?9U_3D2 MP.5:;@JDM%KZMN V/HNX6Q79>SL1UQ'JHOF&P>GIACKG4#JOJF^IZB;1
M#)LIGN2E0+6O4WA)U N48T MEH'8YSM/BI&Y QJ&-6XTZWB320IG?R3QM.I>QSG+
W/L"&S2/0B\$!8(E\$SZXMI@*B@-.ON MF !0I8CIN+92!T%;NI."I/E@H:.(RCYE:5.?KD;AOXO:1IT4=4_ZIF^?F
M&A\$!#0I*"PHX@ (C&^B&5@S#&+I8=-./95-1#(O4EM@+; HYZ'V(>IHS59)@ @#K22Z-#8FUQ) M#HML6*F6B:;>
I_?>E6;WLT&'IP7O;H_GW_%G!4)\#266Z_8UR%I&#H^#_ M\$NW>NGXMW.UTCN_V.4Q@C8IH?HNAR)2*S_/I
I2EV5I'XRX@KM/I8IKOR=N M0*0QHBF5G'+8.??%JO1>B4*?SIL;NDI_3=W5\$ MS;*_L-
60FX"X1HD>ABGR)#D810>X_96J0#>=TO(C@<4S!A"+I<#Q6!H64M:C MCN^#3+15/'E5=2.JTZYI^/#FRC:;?HA?
\$Q)+I' \$I/@WGOZX&52IVOM M^I:T@9UJ6V.TDIJWUJZM;?B+4"92IRHNXD\$S)7?I.OQGW@/'J<="LJ39JQ
M\$N@E&G?H6WZJ/WWF9O'I#^%=-SVI&U_K(S5I/9#CRQH;+9#8RPG=S=J1) MZ&1I*1#+%P-2&S0X<+0JZ
<.*I?N"#I3=-OYI>+E=JS^:#Y^+I<.. M(BIR2I!#4<=CH)U8<IWF82H!5I5'@HFAIVF\H*#;>BWU;UP-
V8YL6T!5WA MRYW:EODGK>I 8L-0AQKT(M:1 80C'/8: C-8RZ1!X4F:8R'O@;3#&7HST
M9<;EH%JH@#GU!9QZW?;SVILY=/O'5;=I*Y0Y*!;P<FIN.WD77QZ8_/D%DZ >X')FZ M%C4L5&RQK+4P^R^K>_Q?
SP(^Y.9M0'R7XI_U#LT4:4P?3*H(4I)??F<7P
MIHKZ@Z>^9&X!>N*08X8R.V>Y485^\$MZ=5Z73_WG6D..F!@#QH<\$V_3185(=2DG
M_/63=IVC1D//GGHOM2E/+YXVOFT0X_*V2UR@O\$J_-2_7L/"O>;728IR@5(JA5RH21L'&8@XQ!^#8FZFZU MAZ-
W3(G2>I"UWS#)&I%&C7(P?I=)U.^W:SXD!_M.=IWBNI=,R/S)0X6EXT,&*
(L2TC>9BY.5.4L5_U)0&*LW9_45#"ELI4+? M3Y??>9*E=".;@DVM.3I/KDI5=BS1*[N2UD8#_YATG&7B;
Z46MY8E838&RYF MATI8GG'1H*7WK)46/-GAG@P*BBQXUB:;X<0UIH!002<1XY7FHC_6EU&'ZC)1%AZ^
M!#*WOBUI<7'36X!@<K@L8RY%D7X/2_MEEQW2WGIA.&_I2F.%_Z7(&_OX^<^
M=&'OP'3F6C#)'&U0>;IAXD8XZ5N3*(ZZ6ITIOW;BD@%I^*7)KUW*6KT!==V
M##_#).5P%PVK#I!C8#MILGFTZ/50I_2^+M5#-BIF=RLXU;GPQ5&(L;AM&M:23;+XH\$3IG/3+QI3K_QQJ?
6F/46#+G%2Q5I/3-(6H_O2I6NITB*M-P'8B-M)0Q5_EK;I54#%6C=2I7I0I/?K@IXY2N.E^G;).5Y:;D(&#*#*+=S!+G&

%> MM"6HT\WJF)KS\$A7W22R7\| H38QNA U\+ M P04 " #\|@7I9TAA /LOY !2D@ % &UD="TR,#(T,3 R-5\G,3(N
M:G\G\+QW6%/OMBXZ\$1*XI 4)J(R\$V\44 B*B B(J(\$08B*@" 2(>0(+TC M74&
(4D2:Z:T2&J\I<(&07\+!,\$M\O7V7OMN^>YWG.66N?> \?^ ^,9\X%D MEC'&IXXQWO'-.6&,,O' P'4#(P. YO +\(\#Y S
V #Z\QZ\I %\f@#E8&\ M%> RY_Q9WO@SV\^C,,\R, &RL9^D)W\|+!+QY.=@YN/^W\^,K(\AYX.> !8%:6X\|
!0196019&P\A MZGCP:~JQ AR6 ZPLAUDYV\JP\X92^7XO>|B/*J3UZ\L+&+29^^(B\$O(+B":63ZAKG M-,I?
T+IR5= \)K1=2,I=RU@EO>L\|H.S@^<7+V\|+V\|77S#P@-"X^(C(J. M24Y)34O/>4Z,SBXHK*JNJ:VL\?
ZEL:V\H\KNZ>_H'!H>&1T;' MQF<)<|_F%Q:7EE=(O\>V=|B\X\^'|M8 %:6?QW J5V"3+L_)D#CC\VL1SP M_,.#(<
O\8V78A23,,\YZ""\ \X)3Y'+2N_)F+EFUYT31\|_N,7DU&?E27\, M^YME_VN&A?Q#EOW=L'^S:QPXQ,K"G#Q600
*T*BY,2> _Y, IP2#2P3/H^@ \ MD \,H%D\93\U&AKFDPY#B2)E\|?2\57<^4+!-,T'WM4-YL>1%-66LH\9\I2- M3J8?
^K""TEO=ZV4 H3,Z1PD4\W\$U\+SMZ"L%K8.,(=X7M7\<@*BXR508.1Q9 M.MSIP3&H6@T\$=3(-F,&\$.(RI+?
T6(1\RB>J&3&3-PGJ1)F"K).!(BF99 MMZOZO+IMPO/>?"IJD_B6+G^|D'R"Z=5EA2 ^=@<(7,0
(HDB>?Z5SGT.#XE" M5?F46*J0"85VCB7T05)YWF&?>2\MS9U4?>8\$;, &IE4&IT02&3G\57N.@MM
MRI6B.3.5N.L:05G3,I.>NR^67'#TPTPW\X#B M).K>X5LX V"N03#16\#45H0(UV\O.K6RU\I>L2V9(J-IT=UU\|M2/8
M54M.@-5\%:\$60* =HI5 \>'80U#\!WAEXEHT"8)/-Q#BC* E@|S@Y?|TH5O MEXR\|C)OU-
2HM1WSSI0\U% =UX%!\+S\|PX>1-7L"=J6PSFFCC"HDEWL"^V,\H MAH?8\H5CP1U"O\$|KV^6:,LGU63\Y6V_CJF-
H^XL<+Y\|DGK*+>+A4%!\\$S.T\ M W""8&8<,-F\$U^8HE_T@!9TP22GA08F&UB\NQO1?|L^|'EC:4)YN>WE<@|D
MD:U-\L\| "2HW-QVE%="YP/?=|+/"\$Q0Q^L\|?Y42QA
M<7=|H\$U23|E#2RHQ4\|P15.% =^E<4L6@.\|F4:!"\OZ"K#);6P+F\|+4H\|P6 M*)
(U&1FP(W^= #FTS90#X;&D9\|6:HPHZ@9H-FHF6 M'^1#LV=QQ)\>|W%V_Q^10\|7#)'Z
M3R2\+M>AS?2\#H\KK 21 2N9.R*K\Z\&Z7U\1% ^#(ZW* GJ8%W1MJACHG\^ \ M7DH +P%\U'5 _>=PBF\|MC:
|N#WH\H4=>CHUH%HY9WLY\|(\E: (^"M MD)%""\,5".N\|L)CD3 _@E,M4(9Z6)GG:9^Q3=WZ_0\|AAL"/G>IQ?
GS5PVK-1C""::JJE5!) M"\$2)3\|D^I MQC(-XBW345\|1P*NE3\|>78UN90 \2B%G>&R7N;K+@J8=N?^) MNW^-X?K(Y:
6Q>D0*FL1\UL&RX\+4F5PF-YIW"2YYID2.\|19>H31_*3C VB M+|9%'U4\|67F"-YE%M@#)RIPL\|@)PDW(G:U7R<
3AC(FTE:"%4,U)D\|T\|:HI9 M;H(8Q5C\|PY53"SV E=\$IR9AUY26W^ZV>'O(-D^P>2#RZE6\|ND13)@?2/D,= MH*
&.,Y\|8P\|'#Q(2*#*@8X3\|^D(P_7H&VKA@X005AW4^|/%TYOKX,W&F'\$#|PG-6:HH&+HYFO:66(E.7\Y1)4
M.7SMD5_!8Y(XA+)?(7_7UEKV1NUF:4VU;QNB6PPDET"3M5V@ZHB\|EUJ*|#KG7 M_|\$ _T&7"Z9:,I_YQH8\|Q^0)?
7^IAD%GO\O'7,"^DAOZ&)\YC.@D>"9GIU\#(M. UK34H53G2.FG\|OY:>XR_ZS>H?3\|8%R\H\YLOX-
|P8D\|KGUMD0>O)U8K^CV2UA) M405/#C.,)MNZC_!N5>2.FG\|OY:>XR_ZS>H?3\|8%R\H\YLOX-
|Y??CD.\$?LD_B1M3:TCV\INOXJ+VL1M\|^2Y=TSIP0R,2D,Q:_'?KH% M\|LSW2Z%S&WH3L ((S#M(1\|Y>?
92E<<3E^PSGH3^FS:Y624G:ZEYYO0DS\|= MD\$S\$OX6;O _F:O(V26(-*J9"6*IQ E#.K= M)GRMG@GOVH
%8GMVU\|4&X+F7+DA52OCM-8O";S24\|YBB%L= S=Y\|P.F)\|C M'#PO?)\|J-
K@X\|H.B_3SR&K5"@MI0%"FC\$CN87.F8H\|F>_LG7^W.A*FO.\V M4HX\|YK64:6FZDM?
6492C)Z:7%E\|L)XYX3PFW\|LO1C<8ETPX\|MD:\|D\|OT.% M:K7S5@D6^:8:/CIP_,IRY<6R:U@!:-
>OP%RRR6\+ME@70># ES"7T3A,V> MM^MC%K-U9NFH%)G M\|WK,'D">|,TSA\|N
M:1_60HS\|D>5WP\|AB:ZZW\|_M\|P5C\|V D5=J|P8"62SFU#5&TOG=|VY8SP M>6YH_!0F+IKO2\|?
-0.2+DG>@2BHAHB/%&CR6?)DQTR-%5\|KY)YX;/, @!^Q %:#M39\|1V*Y.PV 5RDSY 80.0\|RLTB@L\$KPLCUF\|LY
MXB&3\|A).OOP.Z*d+?O:8/\$A5_ ^8:, MJG@H +HV5>
B<+A@V/5\|WYRT3)H01&RYSSL2MD5:L.\$+A\|H@SA.RHF1/V=^?8M^N^2B MP^ ^.^V.R7^Z)?+KK(>Y0>J^-8X^F7?
*=C_ |M=-,;|&KK8=T:7.^N.7S247.J-8)UMES M\|'0G58B\|EY=2\|&O1P&IQ4YV\|XE%0:OL W2\|7#>1V+;L:,%="Z?
GM:\$GK M+&DW.R-D0\|Z\|V^NEN.9)-2\|5G5M2G@.\$HTP M<2\|>D3\|(Y1>T&KMG8:58F+(BV:./?S78"43PK
M8N40A.\|I7G0"@|M/M_3R>>1U-06Z%E>P\$X.WN(@U,9#"VR"RNYM,^!QWT@F M:8X61Y6_D7#
I9:.05TM\|JBH\|ZS4&RJ&C\|V\|9=Y\|O1KIP_&24DX_&WAFX @ M^L^*#T"4,4PG.30(N^Y\|T=O"5">EJR21S*
_V>K76P\|?&S3+>WB8")V R MFG<8D+\$3OC\|6^|L\|Z4@2SHOOT3K+IER>=IB2A\|91HX@X\|J1.0058\|H.Q
MIZZ\|7T;,&>=E\|JZ28 TG>+ZUHD)U9\|XVQDF-E)>716O_ \$*T(?>|J-Z5 M\|X&15\$S\$G=,&CQKEH7-
S*^H'/IE8X\$4R&J\|P\|MV#9AR?SZ3-K6^-&3VK\$ M?JPUN5^&5
MG: (10W(V6:./TH.Q\|04O^O+U^S.,OXM>Y\|ZG\|= \$: M4 Z8B<*Y2*I0(%TC11H_QYD
_B\|2Y**IME7\|H\|:"7B7MO.E^IY)"&32NL M6SDOM>D.2%M7EGMD(4BKU0>0SU-
U0S@\$V\|=GZG+."T)84\|100ZC.8_W;6XT M\|H33-1L^AL\|8,<==3&+2=HV6&W\|XK^ ^ ^3.W/B\|H\|JMV\|
M\|NT:4D9,BG\$93C\|N)M#H31<\$YRG7X%>((+/'M.B.O:'\|D6RJFG M#O.*69_W?H:I7*,_I
YP@Y<O9>=>"Q6&GEZQ5:1\)"HD.?N ML^ ^3\|H8\|I,2*U,3O^9RNB/P:S84\|(D8Q\$RP\|=#Y\|"\$S:.,8.4\$V8\|6U
MCBQ,RZMVY\|Z3*@7\|@ ME7K@MO6.,/D\|*./PI5:=J*@U#O\|8="QE3C6)TD\|+K^L:U@X\|5,881Y%1 M?
&W\|J9^V^!6Q15D)^3\|(>G\|L76>B2NY9,"CH>##T/Q3.S0_,T6)S0GM6(W\$MGC\|FMNZ\|O
MGAZ^T5GT^QA+^#)N3T_W7^&N\$,JXW%|3(Q9R/RC(8T\|2@A>HK-X^)480B= MKP6,4Y\|P4JBG(R7D!
(K6\|9.NBKEG\|DAQ(*1M)\|N*W\$3)0>B_?2XWM\|S M*(T3B9\|0Z.(SS2\|@L4.@%E**>I^="0N\|JL7.HMT-%?
8_%P>#1GNK&D#MQ_M\|YU^:X7.< Q^X#?#IMSR=M:F-O+U\|FL(<:(8XG6\|N\|I")QSXU'4MP#X4?
MTN5SV\|IKRPYF,-)@5/LVG1ATDZ\|H)G1T\|TIDA5M?>^>AB-/6\|Y9>=%SE*^M^ M-Q/O?
UMLF&X\|X?J06BSU:"R\|TFX:3\|C9OW4XF#-,V M#W?X53\|Q TN-C3\$IQX P5\|Q^Q^&D\|R4YE)3/4=Z%+RW34?
K.EH>B\|(B14,*\$MQ\|X.3.%3AF5EX M6).2E;W\|F\|Z_S:<|(-3@/W_20X\|I>K08PE/G\|^*L\|TF59E@=0ZQNM>3-LE'
MP'GF\|=Y@.\&Z\$U*#6UOD: &#-1^L+L8^ ^*##-LMK(8K"3:646^G\|A\|KKN6 M"O=.R7\|J3@^:T\|D^<6BH(?
_M_RW_+Z\|S)O?Z\|Q\|B\|V\|F\$|PP1C3#L M\|JRHTO U=.S>1^,ZSRGYX)UBB3\$^6)BBCH\|Y\|CFF" 2(XVN/&SZ
VW\|XD_KS^O MD)OQO2HA)V9OH ---,>-U;,>)/KY4ES:A%2YR1*H_-\$'=6U9NTDES"D2G^L MVU:L;8A^A=:J\|,0
=LPB\|J29P^L M6S5IV,^R M5.<3?Y2%:"H/7/>B1\|Y\|P1R^K-CN\|L:@Q \|D*EAYS%Y\|H:E938\|!68O\$& M^=R=&
(15QGM@K_001UOG5T=#-H* K^8 \|2OL%^DB#&?L\|B-3.E6S#.5BL
M(CFC#2:,"O4KY3*.Q:_)N4C"16&=8DVTVZ35AC#K#*!\8Z*K8= ^3?/@>U\| M4=|U<"U46UCZW0Y38?
\$UPKRI>%G>B \C^C9?^4D0?>XR_R=YWOM(V\|>Y")* M7\|38^O6OC;BF\$
M^EX7O\|KW\|U\|J5O_B_B*7PV\$5W\|^")=Y&@2?0X5T,(R7O_7V\|G\|+ \|HP>SB M8DAQ\|Q\|T8SMBBD\|
(\$\|7:4N\|J5=TT2U>W\$Z\|O,OL@W=A0IC%K\|Y-A+FSB&!\ MUB?FE,AVD_FXPV\|= _WC\$4\|PD9ZCLG_F
T*ODR7_0P#:\$GH% C KF^:Z.H MXI*VCB-K_*Z)K:*BYZ^<36P\|@9*R?V\|T;0\|YBG7N4^Y6^M\|A\$X ON7.7BDYFT! M#
/@@H6/\$X#%?IN+^W7O.P#ADP\$OE;\|A7CH:Z0\|T\$XQ_7RK:L\|H=P&%"YU
M\|9LBCQO.C_6E:"\|I=:E)24\|V\|JS^ ^ (&@'QKZ*4*TB5)?VAKA=J^MKTQ\|_5\|M\|K-RZP2S>7O)?
2(W^+I:="ASN'5\|RFED\|SD+K<1U58J\|V26*1\$?+_U.8YZ MU^E\|L_U\|^&@W*M:YWX\|YNGDD08^9X&E<\|VC2"/L0 R!
<2C\|G\|?<=P(C)0_4)C% MRREPLS5\|V:HLZM4@^G8:5GREBBAT8T&HJE%7@C*ZDQ\|H\|CZ\|2#C&?_?)K- AK75\|H
LO:LS7F94\|O0^34MFMNBIUN^DDZT@X\|L")%||^ROJ+2 MQ#7B0FA\|ZZ)SP\|1CD;ZCHY\|T\|9E3_17Y+LGLEB^ZE)
_FSFJRX<((-I3> C MV^%|(C:0N+ FQ9PX7^EPFTO+^G^G0NZM^4C I^|Y" M?DH+T\|F\$:*C6\|QXS,&2L\|J4*3_O%Q M?
1\|E:P\|>^7L\|UQO;^/H\|A33PYF\|F4HN?Z)>^FEJQ.FOJ\|?>A+K^Q67F2,P23 M.A' \$LQ?:TY&T\|+RP48< (B*ANA(CP:,AD
9S\|)O\|<|>JX\|&\$Z^OMMB^WJ M=?C88\|US\|T9<0D*LB\|8,RE:4VRGK\|NZY^V\|RIS-5K\$ _O4KXEO2#^X(%)D
M60P\|F,><%1>0@_PX?25N0*=4_Q1^67\|JIRE7W\|XAEXKGB97KG&_8^5E\|W M2YN%Z&O72.*MP-
>/>D#7@TA)V(=HWAN+S9DZ80L9G=D&8L<<E\|TW..6\$|^ M\|V_SGUOR-A8=_H4IPA(T_";X\|J

=@3HL&R<=%MK4*#FI.K0<759N+@/.@.C^:UUDP0GB0.MG1M.RB/PF.13S|=
N983T_B=IUW78C?/?#:%)IUW)38GXP-J:32!-).TLH MS_NAIROV%IKZIE 2?LW-DOS?C<7AXS#XIV7L
F89:BR.@ZXO9-28?1<:-=%?)%&YM5N892)L'ZS>.(D->NR\$;5CAEY:W/M/'D>3EX3AG|+0+>A)PS)*>#;?
OTRJDEC156*DK&8JDBGD1K7HCD9V_KUL MG^PDX930Z/OHWJM?R0?)3E6P)3|==@f5PC7B8!XG.<:X-Y3CNV?
#G\$Y:(*)3 M4M@M|U)UWF2M8:T%_HBL'OSX7<^12L2FRI# EGIW25)9I(A=/:C
MI%9Z:PUDWZ42\$Z^|AOV/GVT=J7K#Z*:(=V0%=9)9H>_W+_X KU&Q0/7:) MVT1AW|4ZRY|M??
<|H1D18YC:1^<+P.\$X0^006@BG|F:CV3KX,'<8 G"! MMTM*#J\$%)D:C|'C_*VV9Z?/'|T?6ZYM=G<5F6,-#J
XX#O/8F%MU<| M^ZEVT-5:|T@|I"A^X0L>KNJA>_M_WH7<3.IH+>?R?Y.A@+6^5)%%LCWH2;K(
IXN:0!758!ZEA1\$SZD\$!JG MCY&"XN-R! ?D#W^OF#POM)*B!O5SSX8406-.^KAEPVL'62|ELI5H(OWQSHR M@-
&4.7BH!J3>I+X1E.K?3'<^|.F>AE|5|:HB:ILJH6-.2"A6-200M)SF9 MI_!C(/030HK2&G;CXQO)*8((2&2)JNL-
HP:8;A@|DGF"8LI5|WSHJ&_7 M6EOR-R.Y7YDC12!^48R-U/?-5E179,|I#><%WXDBC&?7%;_N!U4GE)|
MS%WAG|6<9\$D)7AGM?ZLL2ET@59:5SA5!>(>#|!62!VA2>_)^IMDO(+GO'C M;Y\$8:>|5Y<\$\$(K%)JL=67.KJ?
W2)^7<9UY5//L:_.3LQA:TYZR3_4GPLOSPC' M.O*RD^3<)WQD-89/L3=\$H7L6:S(ZC=RS7YJA)HD*W9+|W
MW4@2IVHKT|F^,(|K>R"\$ 42@#9F|V7E#QY6B3O^!%6J26:(R(V6HG\$1D|2PO MN_4%=2B/<|V1:O3-
@^L#C\$H0:0KGT^/AA"? MN:_.4CQ6^P|KB).\$9S<*B85WAB%1ZNN.FK ZK^?ELU;K^|E=_RB|\$FIX#)Q MY!M!
(6?VPP-P(4)KV=RK/41L|R\$>X?FK>N.!:|BXY!>:JY85-IT"W-\$ M*VEZR4+?
P@5TH1"Z8"6>LAF)*:RYH\$9EP:G!%>T%+?#O|?V=O%Z\$DP^;^X/3 M45;/^6=O>_.
(5PW3R!RN@>J9&.FS#;9)"*V^Q4N8(F|VOU5.R48S44)5^MTA BMO57SO9U|!(? MF\$;\$S2YVF:YP1AW250:5;Y
@D=Y9?F|?>Y9T)|*"(OYK7 MF0#TWU^|2V.("P0+O=^H?2?>WZUQV1Q+@L/^7^@S|CJZ&4D6TFI&<%NO_YB4J
="GG>).H>(WSP:K5OSR%Y/X_K: M"GC_X-ZI(QA+2BVV|+>25;H_>\$.0.X|:ZY:>UVH"G M82(J<|6Q&6G&
MZ,KY09|QJ?EU.?G:E F)' MPIAIK1L|?3;(-RY*SH=,K-NRT+B)|_2FI3|3'=QZF62RHABE"|2^2L^7.
MF+|^Y.F<#8H>_C;?*,QVW0W|<1PQW@U'|JBVGV19Q_|&EV&Q+|L*W!7&GV M;_3Q%>Q|XFXE?#H9-
*=:EPP\$K*QN3|IV>T?Z"\$W<^U^/AUVZD?;KV13N93I MQ-P8FKQ<6A)U?
R*EGMDHO/AWO:_.V|+Z=RF1,_"4^*NUHQX2=TF=.S_|L M_W#)|92SCS-RUNFY+|FV3(R481-
XZ53:JP*9T/32M\$_.064E5I-5X47_S| M4.Q3(P+D JS_RLLN:N_C97@P-.)1A9!_%J'"W\$5V86MP:|T4:|1?L821M4:2
MBPE)-|VQ:%MLX_!FS=2X/4V+56B57WCB"BM+VJE|8:H5+)"BB1R\$0+/"H3\$6
MT",P(\$!Q*AAPJB&#SRDR|UQ9|YHIX,J&D8_*B|H+H2_QC#_B9S&<=PH?? M+ 6F4'"%RRM-"U99AN1.?
20,U2S+.#07W%|P@|JY?2A7U(2TBMHLKNTUY7K4 M1=) MR83NA_Z2:|W_)H4\$2H\$G2)\$^X0AP<9JNJEAZS*T-
3@.IEHCMM&R>8'0A2 MUDHUC#L-5SKM%96TJK6TVN0C+K2MV:#+G0(O)ATYA^V|Q#_.Y)GRZ2|M.GCXNL-
4X5*WXEG!_GM=LI^V(=YJ+U+2W3_WA3H).DJ3NV>.*<T&2GX2%3 MV|CY' 6P)-G/X.^M?NY"#/5;PJC+6,KV?
8W%?>|7'UGJD>H(JIP).T(E+^)^ MQ^;^LJWTA835.T<25LULP_A(5X-TM_@:Z^/I Z:P2N_Z|HG/+4B&AN3;(^ MOZ?
L.PA_/5L!Q=U4)E"9S:O:8N8_A@.N>EN<*JQ*OYD|0/L:B|HGQ&03-O<4SJ^W-N!)NSGBJ.Z_'M0J#4I3
M@D0SZO:*^EYS+I(6^12Z/>((EX"-H?|C9PM'W'FQ'YB|'H'>3X;*8O.OZ? MDAAX.0.@&J#
"VH\$|)KOZ0R%*GT,Z%(HSC2|^/;\$#1^KVGWG:?'%|MJ>_.?K7X2:/04W2K4\$|X7'K04E1'0|Q*EJ*Y:~X
M2G25*EGHEZ_UOK2%(A:~#6N8&:6+Y27W5|PUY7:~>?>^~L\$);B%U?Z%H<=>M%JH3:F8*5(CF=H%7B:_
SKS1P_Y%(3>#|MGP%FKR?8WK5|V:~L'!:S ML("I M+TKLB8'>-OH*/#<'"F=2NVEE*&=W(60_~RF?
S|NMN2/NKHUQ?9J4JK1OG3>6!|T|X=&.F**G%.L<%5Q^8.+0U* M:PJZ(I0:32DIB3<=1Y'?D3#K*G,*0|
|^TCC|J2(^S|U|9>RXWU.OG>|E|? MP%|UZ:~NXC|9WJ_G.71.@ONOF KC_9GZJ<9H|_.1SKLT0MW/?:"8;>K#?V-
M-AC_U?1N%:\$(SD1.WUOZ2?_SA^VA408^1RX0_IV|36+YJO.2#O_.5S|_&M M.NU7EJ)?
V^&|HKFV%HHG%B*%W86IH M(#7CC:P<0C!O*7,DJHJMP' MX':7>0JLZN-Y:EB>H|_*^HHBFF^,IG8|N M.
(I9>+S\$|U4OLN(L7OM*N1L(H6-:0>(>Y^Q?)5|>6|PBT2;DENTRJZXW|? M"K)^I8! M@/*):YL%N375'_TRS%/
L'K2U<@EV2AFPQ,DL615_U)ATB0%BXDN%O M(KBRIYB|XO,?IUUX.E,'4151J_MRNG%-
_V:D)=.2MH>.@|9N|U&IQMD. MI&BJS|DL@3<#X;9PY|C| MB|KIN8! P|C<:!"X?H9DC(;?2UDJ|3=Z-
T3#%:NI@R4T|?D9%32:7.WOZ|M-KA|_ER1.8X|RZ?Y3|W|F<2'<UWM!<K|'
MS>E|FG_SV\$Z^52*7X03=TDWOHN:#3./8PU#-6CJWDB<1%|O)-.6D4A:1!R M8HLL?
28D>052#H|9@|U|Z,>*2/5&|588|=FR#AB4|DJU*\$W6QO_(D7M&- M^BEV78H(<#>-
DEN_1!+ST%~VH!>|!PGST=0.9|_V|J9!<K>.OV-!2O4U% MG%X>,"C|IS:2:6LMIS.^EY:;(J-(9L|NYL|F|*BXM33*
(IG^_(I9)>*/4 M?3WGR#N/(IM)=O,U?>3SZ@54E?N:(T4).6+1=Q<5Z7H@N8=SSA|KIRKS3>4
M_X)NM6!9SG@3E3EQ.P4AL^=)H0M\$>GX9U\$R3 MIH M@_~L7<_~8SC| M.P.0D*TG&:
HDI+~N@BB3XZAK=)|JL5:IZ;RC+:()=X|C|H-|!MOPBA0M*Z)|L U<2=3E|Z/&_|P@A:X/L?>0^=&5G3\$1!KG-
1!6!@=CJC?L_A:KYIU|W1= MZ^IF\$ 4^%5<:~!OLA&4PU%\$S>|?GN+6,U2>"BB0HBA0\$
F>_2\$76U+QIH0C&7LK-6@+W%ZQH(Z_|>9V M@O|T(G:K9^RCG:YS&J1'.?|I68'RU2:W|1FJ@|PQ(7_G?
~37%RR)EZMK:U/ MWRMXEJ0O).XZ)D(2|<<8;"0X8Q4>A?R7:20X|?D+|7|>:2%U&5AQ"+MS?)Y*/UUT=0*
!^|+.^YJ|+LFFIMQ|VY:~0/8,~+8H4E1|B0N_U/A:~^Q.CH>=(L3555N%V"O-2|XF"@"Y"|(O0B&OUE,
M|H^EQ4/F8X/WTWD-TOX%VF%02Q'~#7516%YWZ|A)E)-GW MJ556^<"1.W("C*#VV:?(E8HAD.U."1+|!"*PWT?D?
VF'(T,P)|DSHSIT)K M<2*VN@AG|OEDL-."2IN2.")IKO-D/QV?|J%6XE2 HBBWJ\$IU?>UM<>KQ MR\$%:GO%0&BIF?
~Z@|WSSF>P*&=D I2.8M8XO|@>(*UV WH?BTX'P:5T)9=U
M3Q*RI0S4'FK#BHJ9P^XDCUUBDL1X|J|Q|HNRCSPPKOK&T=)QLTOBK GASIE,S1S_V2K,=14LXO.DR#!ZS8^"J
M+B|B9A/R=R9-^,<%>J^;.\$&EEF%.06(O83IU00#EFF|DJH(1:U<|:7B6+X3Q>|IM%4R7^O!40DKZX
MAB+>2|Q7:6M_+60(&L|37|Y.G.JQ<=>4L^1.87T+F<1GD-3W*PY|YS.WW' M&8'V|F,-
B8I=4SM|L.S0PGXYT3OF)Z#~#|(5AGEYP~N4C?S +DR#K_|M+Z)U:5|E|0V"=0|~#D#K/I^>62O:8'/?
HEM5B.OU12H.4^!O=((\$7Y5UG.*D5YB@1=|(IS89):"/38;(SDH M:=E;MBKP-01+|H).SUVK/MJ.105?XWRD-
5:S5^67J>|H'P|119Q|X.5X3;_M7S4#Z0-%BSYED(WH2^OF'W:C'B'A|VG5"LE+=(S1E0\$S|YJG#_4I#FHH+U_U
M&4Y?3;>S.D|ND|J|B2@4)0_.OT23"-4*~|BH;IE-N#RH(3EBW>441.N<M?)%L203D1L=U|4>?
*Y8GX@:<#J.O"V@YV3G_6K/L9|B9";G|6-IW3*I% MQ5(|CMZ%_303A@3N<_Q'S9T+P\$;|U|18%Y:2\$;E-
H^VF5@JE8PNL7:|U+|W=3T|T.MX6QW*UYVD|J\$^)|7 M3*00ZLOM%@*~14ALH=A 6|527MJGCGHQOR21(^6P@O
MLC#5850-2K*OWA5|XKQ_D>LJ.MQ_|G'_Y;^LXQQ@._\$-9@0H*YAUDU08NE-?
MIF;1KYK;V+^CK|3G:35Y=78N75.RI.3\$ T.9%_#A0JH@C_|MF(MJOHFU"|D M&&|7?@3J>K=^53|_KB:GY\$D@S-
|V@LP=)|KQ)"3Q%.53OWGV|OTAJUIYWI?? Y/_NO2 MRY%P|+S+V>9.T MM%6|M|+|^U"R+
^1>|>D\$C@U'F%C(|^T|H|+S)AQ_|G9W@%>)|#JOS;~7^K MF9C;<>O4ISKGW0+KFBT|V;929'=&.%6GE3R?0
=+!+4@*~V|JR:R)NZ-5:~*~#Z:1N"5S:SJ@^~ZLP*_PX>L|>(^MZ'|>Y.T\$0<:S9_%YE6?
KAD(+S6K'93H'XGKE5T775=/_90HH\$ 3BI7|M M>_&UX?W)FZ:/?5RI?5U^?
~ZY@6/3L69EN(7@F7VF&8+TQ&F353>#G M:A1)#B.1WT"K5&>AQBK;VFK#U2Y%
\$<3Q/OX_&L\$&|T|_K=|RIJ-'%|R(|*U#?~5:N7H971ZY MEL).BKI\$DV:~#|IE:\$'YL4V<7|57PE1R8-~1R-
HGQ3^WE">D)?E%KTVL'R MV|11'8N3|P=2ZFE".^G=D&4T/Y%~MV7OXJG*TX7=US.K;.#^FL,F*S.6S/3| M+*?K?
V=Q+;_I4K^X2-&?2C|_~PA|UHNU'&3?~*~ZD2LR4&D1EN<=(2?:8^M3"7J_LS3O5J(W7BU;O^\$ 5P_|?&-
L.DF#D&)P>Q.*@+L M.\$TG|N|+VSE4*~M1YZ+H%PKX@|CTH32EDLV 3T?@G&A&"2.QVIA_5E4|4N|S(#
M@Z(|WCJNC;&J3_FU2+?A^K^OB+IHQ.61,|O^SH'RZN||ZWVK|S7#~^ZHS3& MR/2ZP|4.3#MIH_X5.L|:@

MC\$\$\$GUIO4..571*1R?X%K 6)>..W?8TB>L-JG"<^09HN:Z6F&OME..0I?Z* M#LR>W:BA:P/H2LI0WAX9\$M
6J9*L+@BFE(AT^^^N..KO7T MTS_Q?C5K&P-PQ16Y\$A) H/O!MOURLS:5&@9#^Y^ZJDX. Q^4BFI>+K=..S9
MU25F^"G5MON0.CM3B?+QPQ0(I SV>H.(Q<^130M=G:NE4Z4:HP<_#MGR%/_8!?:
WO4TM8YX^=RIG<^SI/S9#O:F=-6AH!..) #JEN:VR?_8>;CG MMEE,O6,%LG6FTHI^\$R7;;Q+P:/LU0-
XVREJS_\$.;H&-2&S2 MWTVM9K8> MLB"1.#9<3H-
OZK_1=9Y@.4G+)O>"SE0"G7\$AM;YOAB2=370IUC4/GNSI^=N M0V!QI^G\D3S8(Y&C)+G/L1=2WS(SYNDR.)H
D.NZ-OK.^T=K/-5&KEF+IQO8)9,4 PFINDU0CJ- Y53YG:0&20ZQK MD9-566I-0TV(&?
RT1+_6_E)U^*9#%E4AJAW")N,154BJ<JHYAX>XPIS4WIOVZ+>D2#..MIA4-0S>XH M_)L %%%4DA7QT!"FUI/78=
I\$SFB*VTCPI)H%OMRHH/HI:39\$1)IMOS0:GV..JV@70?%6?SY&^ZJ\$TH?FK+%2QIOA-MJFH>4 MLN\$<..IL?
UC=L1/X^ROIRS@ZKSOMLS7YI9\^O9.HW!Z 11.20V1N=?E\$-T^ MB2>^!\$<PAT/3^X#==2;"\$A9A0 MFI
CD=7"\$+V;W?K);S8I:USDJMIHT<="G?N">>T0C0V1I231^Q>4TS9=*O MO0N? \$%30>X!O/W(*1%)J!N)I+I?
4KA=JGGH(G)ZJ<-1PY4E2S.~\$KP-6B MXH(QIOOR>?220H?0.<2/<3PNJIRU\$MD-W5@>[G>PY?J@!:=ISPWVH?
#?L<M?WCX!/(=F44XN^CN>=Z;?O<>I^X1X^A^,714NY0J(CWH&(NZ3X9V06;?Z MFM*6Y9ZOH/BW
M=0MC5+.;+H=B&WIL)>+F%KM(D@IEA2:925X1M-?/;("=MWFPZ>S CO%3@SWQ=FZ,IMXK!G"U M)>;\$VP/_H/
O*7S^="96E)*\$ZM!*1S;I603)W+=X ME7PWMP?WGT^IEMQ\P7%/IS*T"O;UY,G+XXIWPPG(84B-
E&^1+B^\$J9>F.0 M?R-C)4V2)+J68C JI^FU8H9A0FO T6GT?ZL# \$YFGS)2FMW4P4W3J;)J&>R
M4LOH.0S@R90LN9Z63)>BI^_%2<@12I/SX(&K>=2/GKI/PEICR26KNVR+ MAJ>BB\$ZUU44VR&CPFW8RIJRH
5;JBHI?THJ@91HFG&ZRG0^72R8&H>1-> MD@9VV(?OY^@62\$?7HAA6;TV0F).?
#SVOT2B_Y^"D&62OD>DWA6H\$*\$^/M(MI5A^L6UXL+L I_G)3P. @(:0R:@I^DWJ.J^ML-
NPE90FT4PA@/4ATK2=) MHWYIOGL^I^U8JOAYU6<L_7D+G2F7(1P:30CO4O!&?GEW0I7W@>JE3"S<5U
M&G4(Q)7VN_4^N#R> HY.17&M5*-V5YSY6ZGHL&BYZ*)SI(L0L^SYW@F6?Z MET"%F/V=C3Q.G^1LV>UOGIZI-
W^HPW#KH=*>X>QUU#FWE^Y,2?C<(:T9*1X8?OFN^BK+7H
MI=I<&+IX)VXHMJP(S;68S5A^YI00YE@%IU+E;CG,\$2%D:ZOS- OXB..*UXF M;"#&L)"\$;I*TOAFD5_\$4S..
"UIW.B+@9.W&O?H"QE=#. 2,KY!6I(P&(F5 MWR0L*L\$Q\$C5225P0SO! !4V.V.;
MEIX=3SD%&VG<I.2S.F>U0/?UZ_ S_Z(RZ*3;(43+I?P?LRR>N?>IO06S>- ME@S;VF6V5;('IV)-A!\$=8B6YO.^I#R86
?6>77>=NZ\$Z?NKO00=)B;Y^I.Y M*.*R^IL^PIM.IXV0I 8X:0XL==KI 2F/5_RWD7R-1" JJ^Y1L7Q0?&I= MYE?
*Q<J""5RUd+I<."D7<@D6CIAE^Z/I!<=:!TIOI=F;N^K=REBN#P.MJ?9I/UJZKB1ATPILELY*IMNIG(H>,5#<1A;
IDR=B%T^U.G0\$H0%112UUX MF5?DZJ1P6>0M;U^F.+C#-7Q^Y9V38UHB9PR7 W0H:HX&I&^0(&IA(2
MXV"51E*[T0C3P+O.L^E!#1 JN NVORR/T+6^//?%\$C:6^8+>K 9#Q52F1I M%TDL;!.O^<GRV=K6W
I>59^@E#V&_:"E4Z?7WHHOB"XZU\83R.*AI+YX91 MH).3WXFUYIDPR8DWEZUFPI;LB;OAM"/OK5AMA"64U+/?
BI=2I>*9ES\$17=E! MX(*H63CU12V6%QNX2;^C0T-5^:O)5+D1477.N#%9>D1IU>=2+2Q^*31E" ^Y<3IA_!O9.*M
MDJ%)1E3 YR^"L=IR*+PYGG.. MNC9\$T5_2JNRJ3X:P@?0!Z6.9WV5UU<35IX9.^%BZ&Y=QA7M/LX^=A!OI
MOJ+_NMVJG)LG T# ?K!>ZL HJ17I77\$MHC4T8/?@D87K^=) # (IXVBF5T1H M.3JOD +
(<A@58DUPE_K<8YBDKWFO&QD4^C"7-G4=* X.T7;.*Z^6@#6 M5VZM#31C#GFZU^UY*D,9>%
IHGBHML"2Y<="R2*PVC9NKR=>%5HFI\$K=7 M8.*^ TX:WX75!(HJZHJ@I=>V7EIHVL68?
V0EW!"*2<7T7C3OCGL<IEB0=?L(MDK5?D73S;GOLENU>&7T1_O?A+M7IY0J^<^PO
&4L9CN2DE:64AB2=3^S0M& M<C6-/3G4OW3INIZ#J;><2^IUR!P_M@1^I=KI^P?M0XO6+CIT6/K:NFZTH;.<.COO
MB GWD:SQ#KL^T1(NWNFZ@NAJ@I/E=IPI^DI+?#CNUAP!QKN8S^4 X!
M7^UI9UQ33I=NK\$@3Z9U(\$Y2F4E1;^0IBH" \$A7I C8D4K)1!*2)H(*B\$A7I M)=*5%H\$
(B+2FY^F=&2\$K:DW^R=ZCL=%%;G.9MGW^0KVN/1XJHK@^I6M6!CA&9I!;>(LY C)26>P?>62
03U6GVON)GWN^K0\LO(FSCKHP M)#=VJ!_D10Y^0D@F5K!\$E^FRWZ?OY^CFX*\$X_-?ZM*1DJMV?
B8Z97DB=I MLMB:(02IE28TJK(.3R8D.^I^TBW8IR^"Z9/S^9WI@O6%&E;GIFXHG3K;F@ M5I-/PVZM!O^MV-
XGF^=W;I);OI#^*^M.E.Q.->F=2?O;G=9%0B^%J*.485BT4T>)H.LV=T71^WP-ZTU4IN=3W"130&
M*#4\$.UC@BHV10#39+8@RKI M&347MI.%K@Q5+I&@WL;I!S5W*4OP#@
M>8"WdV8/J>#:7RE(K4E%!.C_D>J6^+>X94I65_Q/I4)53IC;H08*+I Q. M1;1XIX^N(\$5L>U5=IN+;L\$S^L=?Q-
)6M 5?@5671JW8>7RCFT.O _B1)3I421*# ML"W\$=>J.KZQL^&IXFB(EKJE@'5_ \$9C.*R%/I2(NV#1\$0%N=NR21Y\$-I
2C8 MV@LE^Z^G(@>^*^?W@#43X;H4^ID(5+ZC5SI%="8QL/SX DWG7?VCIG5"YFJ#
M8U;X%T4#=#4KIP="2KIA6H2IV00MZD?Z.1V^AKP3J#CD!MNB^P^I!Z6.F M^!;R_S2-IY>ZU%8T>IQ?F"U1+UOI
BII\$97NHFCA+GE.HZG;M>?FVH>IJA_U4?(S9MCXJ9EARFG7IX7).#;X^Y2^VSV.VV^#K4I6E&^F;XJ^M75^(!;.>;
O^I#")JFE_Q/55L^=(^I^RA.842\$W64S?"GO#GW*3G(UPI^X25BH&O.O^*2-HQG;X)1 MI?
XO+;M3K#E!4Z\$&&<6^L=G>\$R<^V1^J;0TX4M+*L/IXT4N8D2#Z8O MM86S4Q=2@A\$"
(..18I1I0YUEI/..#16^L2#CICLILG8D2*Q&&<27D4=?A^I M4M?&1=S<*/'.'%6 F?V*INZ_ ^YEU#QAL;#@FI?1#'-
X7=T#L;TA_L258^CW< M>M5=5;403K);# X%X+P2(0=&(?+ M(Z+9WCFYNETR=ID(CPJ/A/@-DIH>H*^1C76;?%>-
;*90)MP\$;(OS"84X7T6 M^P^EAKE,HEGRD?I)G1@<://<5&+8Z\$>>DP+I&2UO^A2YN#X"P=X%<>% C;C MUF=-
E9Z^A(D#\$ XIFI G:(.1%>(TC^43<(DS!)YE9>3^H' WZ>V7FKI6 M#PY^T UN=IU J^E@THUTOIZAIN;IB-
V#&JJE>7N^B9W!785D^2V0FI@U MO*!TQI(I5DC9JYF97AO_OFGI E3%JAUXW@H\$<9#?TGTQ^F.CVOEV"/UP2
MJ(25\$18@HP09ST^FK:9ID^F *SZ=Z\$5&;?UZJ>>KL^("PS1R^"06F=1S5E MZ3L>SU(O)I3(L+B^IZ;EO6?F7S#"2>I
X!^BTCM^DOA^L)6 GD)/ (VOQ)+K9^XF^9.>+P8(. MW9(22U;21551KH
7PI>EPLIQ&#LJ^O18>^P3#;7O\X@B!64R MZK(AI(D&NLZ\$%/7B%;9AKTW17%WX"<+K6=8"C YH+L+;^O+9R*
(+C:L/*2;."^AH\7 MTTTF5 ^TUNVOJCS/1=QJN\J6ST7D3O4/33_%6A&E<"7> RK5=IV_VJ9N^A:= MA(=I3_A+//
K/>^&L1&=OVFT)BH^G:OZ^W&IW^9I9R7A-OA=I)I?R8Q#^H*
MM55.YIZPFO:B)C^JV#AC;Z8ZMB +A/TBPID;RQ+1H7IU:B+1PPTI B1MX59 M;E%>)Y:OT2XB"(O"@WWLPS8!
<9(IB&;362&V1PT64UUOH76<5%0TK%0=- ME:5_JQ8:L9_IL*BA^8!6H0I>9" M 7<-2+ ZV8F.4?
TK+AW%OZV\$89.^ M+76\$8^Y"(4W;1XD;+UV\$Y3IB<(:F\$1;4CKU%\$4QX)5R^9D=M2#ITJGB
M#Y5BC&UYSV3U.E^L1V<5HN=%/M8_?S^0S-IN0>?BO9^Q7NEPG!>L^V748" M^2T)5W5&I \$O>/M.*
(E&G("L2,0S9>-O&A2^I(M,SC)<6A^IZ%Y)2@^#UBA M\$F3;^O(U^@
<<00"15_7N3=\$CMM=B/IKT5T".8\$.@T^I4U"00?F74+=@KI M.;KD8M%IU14&.-?
WAA^WY48LV!ID1#ID^VU7NJSUO JHVW/_I7Z=,1W%VL^S=*^5&0DT^L:(VT/O/N#.BT#@ "D_>O+1<-@61& MT4
ISS?<^6=DF#JEVQJZD;#L.*^MD^4J)+_=%^;\$"RJ^HS3IF 1_@9(TZY>UYNY8CCAT!.QL(>Q@15_4NF7/I^N<:9YZ%?
7K M:4GE7@&;IK=*L.P#/*J4;L=I\$ YIK^J@DPWSEJZL1>)@ T&;"0915;_H4 MD7\$;/-:XXI+
FDN%O H.KIO#?/I;J)#/=8?59TE!#@LDD^T5;N0>L^6MG^I8
MO+/@G99@HV:1W4#G/8B2CRZP\HLX.7I0WB&JM./I@97N"L5EPQ#>492# M1>=0T6V;0IGI9&WAL;
6I/S&U6BXL60X7JG^ZITKSHJ1QCF_?<3I"> M>5FF#^LT.PKE^R/I4?Q3I+7WMXGNZ=-/MEHDHD;B!@VEF?
IS2W19IV^9 MIRZ;4P=;"^.#PB 13)6BIW-X9WKS.?<6I?&^\$TG)Y=W"=GTAIXCF&9ID
M(6/#_5.E@&C5NCV;_A^7N.<7@7Z64\$U**@F(A*)UF9D.W32^GQ=>9;I) MU&%+I?F=[3R0DO4P%/@&?
74*HT>)C-6BK+=)BH/>V2 4J+W.^D7N1^IRY MQ:NEGIG2V4("8>I0I05IKMLMB=D\$8X^IF;
I82@R.C)N]5F_ITWIBPS+WLO>3)WI=O>=ZDD?;S2HW= MA(BL@Y=2^9X^KS?L.NP>*Z8XHNINFC\$?M-CWYUHV)
TDD@)\$H..A^6(W#VTG&QV*5>QK;J21A8H0-L>=AH_LNZI214VE="DI07K=1@2;VRR;T3

M>W6|KHRGO+KV^@DJ3-UI|3-|I5\$TD3|S@;*.L9:SKC/T6^>+ #R(B.O R%V M^|D-NN,AM4 "2RR:
(4+G;>8B=OKUH|X:|9K #FW\$0?Z%5|9|1%:Z2"RWG::& M^/R.B|XV^~.~9?9-
9:~OS*#8|97NSLOPP29\$-91MYMW.NOPT7PBCGW7#;1 M0Z4S#:@G6&-AUU#;M^U|V+B?TZ@R|C7GY1|YX9BN|%
(E|~1;~UBC^>~86 MS|B2S8\$MHS1:K|P&@?X<4VXST&?*(5>;EAV0W0_XP4KB\$&-#RR';~0(YB@!>~|E9*
(UG~%~1^NO Q17R_DH^@S|JHH M\$X)EP_XRRCM/*=@IK7>;' MWC:*2?_2I>ANW-VGMBHA&_WA|'&"V
1K1^/X9V*|0% (-#@?KXX3R&.#TIU..PU:~S#60: MYRTH&?I2X>?+RVN81:03B4|XLTPM5^FW+QY_RFZ|I?
+9UZI1ZN7C>^SMO9 MB-Q1R;J)#FZI-YT-N&8 M3"N5B_D//FI:74+LS'V:SL>~5RU8(JN\$@.11).X@2;S>U
L^IW\$.">~JOY6^ MNA\$>(\$3277,3|1|0*(#7#ST_4DCV(B6XOGF%VAL_7724 MHPYV&>X:7+TU I?H#=#J>E|Q55.1-
T0N,2+ S'9U;@K0@GPN%,6=*FXD3B: MZEU:EY:~5JW%|*1BPUPRGL<9|~|<H.NLB8EN5U^X7Z&6\$!-P4?FAY
MY8Q3ZD#4OD_W=AC2.^#@.C/YKU/">>8R6,*ZG)VGZ#|S9<'OL)W(FML%^9A\$ M"M%
(*P)%_V_2EDUY|CDE7.H<=|5+;3E(S:~?5#|WM"X|A"1FUG.H.<+~.I*"
M2UP9|XX:|DI,60>2B1^J^Z+J36^H;BO93KLG@84BMH;?..1+HB1VD?
JR(A"Z)109|:M/RN62A<|>3AGU2Y>WRHP|=8UUYB M_*I.G6E1-A>AJJ&('IZ-ZJX00&UTAC?
+1HFWRRA/6@O+@E8)N;T^J-8^Z4W5 M7=&X5&@8RV;M@9I01B>SG81/NV8)S\$V>TY+22*>=&"Y0=7%Q/K+U'Y
MM32L^P(|H|D|WKV|JNSQB_CEO M'|"?&@Q)1HK?2QDT@|0NF53?<"FI=JXPN^8%6IK5B1HN15> M>TP\$
D@FR=8?3F5=A*(I96=|3D5U4|;VIZ|X^>..HCQZ5VZ20=KS|H_ABY3;A M
/74N"==H>TQ^P=*DM1SM9&3^S|Y\$8QIRZ|_Z7#^/VC. "1>8@EK|3IP_3D M| #DRU3^V(5^00|
E>DCUO9YT.KT|/R1Y?+4C60S8:D\$/_W@6HV/A|1(|A"Y"/=|'CKDS3H|):1%: T? M&S7 @?NJ|(|C2IAL"TD)RD)L|
O_UY-|J|4KQ|H:F@;=3W,1HG5E+VD# MR+3^T V;1&XG_Q(|HHY>^FH>|9F7E388*~7(3E0.58S(>^*EMM^L)O+2~
M|VE|E53|_X|^~.~6PU/|1\$4>1Z50M|J^|H8H9CKC(%X#_FXJU8T+;7..~J ML O^19BF8A-
Z0^_UO(|A8SC>|"O.#U^M+VY1>VKYC7097/YSUHAL\$AH0DW:~|7+3#?DT|H#;MHI_|O0N_M_5<~
|N#|^H#M|K5L0U"YZQK+/@PG>.)S-W~*BT|ZUO1B-0-@H=,|@3J8' M9?8-5|:5>
|CQBNDP;VHJ1R_@&AN%61A(D+~*@OND4R)3|I7&'6N/O?)MU_JH'>\$/P|_M M7=3%) "Y"W/(@17|O)JT"S
OW>|V;MHO|JH6@|QL%V 4:~9-H2'5H?E7|6P:X MV#;~W6H;)%2+K&9VXK25<LGIB(%0RZ|U?<
O7B5U)\$S+E'U_U&*Z M|0YJX1+S)K8#>+|6#5".L NPAKX>(E68D?D%G:#0'9)G?DU5DMX0SU"G>7L\$ M'P=725
AC0&%P%Q,K#2|).#@R0|@X|3.R==FK;N>~8=^D,C/3 U@|IHL|QX@!;~"G\$ MQ'D;~FL9U64H#M'0D(49Y=L%#6G?
F0-D|%)EO)K_T?7|WA#XU\$%W%27P3^MA@~|JH_PV6MG \$GV/PHM)=1(E@6=PHS7-
7E=+AB|S|JOMV3R1(3JBK|F M|TB6?%>#~9=D|@30'.GPC|J?~|98%|I=09G6,4@O6#;~;L1D?4@)E3Y!
MX_|P|@2Q5%?OFPOH|Q%9\$|C/8|^K5RCKU6UT^OVF\$|V#2<(|RCM2E9+V M%3X40R_0UQ#X|.KY5*^_Y|O-
M+3IM_@ZA M0 ||=&B*)1EE11RA|E4|&_0U#W0QWUVQHHS(N|S FPI>~O'3O(%U/7(@ MxB#9^;3=?=T
0N|D_~|8T@;R|N12L"0X^LMP_~L.W(2%M'9:L M4P%FVR|P01(ZR~+MY0|%EO1?"M0TN.9|M2?>D3|@TW|5?F=
|5R\$YH:|Y+T M|TB4#6VM>~VF<6?+~;ZZE!\$C|Q_2NN^O1<4#AWXG~JYVW9M#VML3_JWU_|M\$AU>3>;
F+H\$MW^KK%+@6_FJ|*NQNQW:*M 8XN|*TFQZ\$^#@6*9MJYW5TE- MP9
_DB5>1SYN%D!!C06TAN54K;|M6T6O&80M\$Y'HW<=>V3)M%&H%#G)TK ML/ED8)P/%W-
VLS0@%VK^8|87L59KX=57~*@>=A\$F\$#8.XTWK79=PEJ|<4> M9,5H6>I>A QFN M|_M-ET~*|=S50O-
K4KQ(7KQ|/\$TZ/R_C%|J>~|V-1*|@V^: MT5KSQ|W/B+^489Q#2%|XZ1\$~)9=G?5Q WSWK(O8A0#6#550#;M|91AJGD
) (MD'\$?>?Y;~! A\$DK49L=5U9@L%1|O_NA&G^~L0MLHCA_B939^F\$|YDO.1 M(ZO|<~7A.11*?
8I|@X,O(&SB)MVAR0^|JT3T:"~M(|=^+>"KK-00+55 M&CP?4PU>E1A52|HG|ZFGH-ROA\$Y1005J'YX.MTA-
\$;*/<3ZK>W=|59'TVL*~\$*OJS|K;^VT_53S<2G5=+*~|~|_X<\$UC M=0MGQ5%86_+00Q=H5\$ \$COAMV0.51%Y+
<&M/I_~*E=-|59|H|F|WGA|BQ|):Z
M;~7&3VZ7_C:5T@=#:OP;#~QMH>MI(P.+4KF"6@=?~)LN8|K"/9HU|XRZA354Q,3+G|V/#(|(3P7SJ M9Y.%CYYU%QT
MO?SKD1DWNZ<~|KG/<_T8G0(2C|S?*"<< K|MI~B&JR%>%B"QO+D6.A?F?| M?
SJ+~7.DG#G""Z"3C.O=19P>E#EEGW&0G0/AS69K'R>|VIV""2JSYH|LU07|MD|^~7A>E1,2|A6Q9B-("XZ+2A-
X41DM?<~HLB(|?~NO8RL|UXPH<1\$A M_4OEYBU/4_F5"
I:=NR<(|#F1T35#+%\$+AA6|5U)9|J8(=HZI@L7_.P&BI=4 MAD-79;J3%EC:~I+VG5FG|3V|)8X?
E1YMARK6G+|^J'R|)S%) "YQ*P35D=| M0C_>OZ&>X'9;Q."?I"EHXLA.VH&3;+0E5JW?6N
M4JZ|C=..F=ANQ_~LOZX@*Q|7VNNDWF% E2AJ.M=6#_4'0_1^LB3.R6**RG!UH MIC?09!_B9"^."6WI(A-
BVZ|H8|6AASV#O YR^|OC?H6/~/~;J:3|F)"2PDZ| M)%L|+4SE4NU|ZWJOB#O_P<~19X5|B#DL%TB%K.1(G5
=+3|X|&~/ZO5| M8|N)W7+8Y.T9X|3M6100?MJ3LZ.3BJC>V'.3O/TY2+|=8>|MG0XXCYM|/ M3XA?
J)&Q|C|A%U5CW3NK4.TI^PQ^;2DOKMH8:6|S13\$6C2-8-W(ZA>3;Y MN@\$A|^@_BFZ7^>Q.%7@V243!
9&@&77R0\$S211^T|O:9?2SF8:K_!^T|2|5 M\$HG^H|_D^DM5&R8|DK1LRE&26%
(I>C95E:|)16G|'P<=BATMZN|DV@J|U83 M3).R4&|5|8&9VE?C'X7'M3X^|39+~MLNF:=\$0-
B/B&8M0E_1|FF|)587P8 M#|@O374X?20YP_G\$BFOQ=?|P;~\$B|&?~V|:0D^5*@3|K MRHX>VKR7L_'Q5T;\$*~U*BU
R'43LC9_F)=@W|(|K|\$Y)YB?A""C+=V^1)TWE|O/3D|0D=?_#DY0^3^~(S Y>2=N|R_B&|N;B
M=U=V63B885P6>)A|OT_2(QZLF?=TO>^Y9:DB M;|I7X+~#)OPCXWU.6:A)+|WRVB|\$5X0)-0%\$1-%
|V0L2ERO.R'|@LC6JMI&M\$|L8R_9BN>?2FZH8?|?@E6|F=Z)8|M|S1YKWO"@.CM=+\$G>^_I2=QF%+F\$ M@1*+|
+L(|LS@;FCA|I77'57HX@H M4C+>U3)V4ELIVK%*8CI=Y|SH8SVE MO;~/*7N*7=Z\$8"HD+~.C/HP8^R@/B=
I+1,B|FKTES3|S|ZL.T.FIHL5IOA| M2^G/=ZJM?KJW;+UYOMNT?>G-
/?="U6R/=|~KWB(|OT/^<(|I'R5.33^\$ +6F"V.M(9473>BHNSJ|S'IP'&\$Q58PJ"< M^FWW
+~PNY)DB6YA#&UH0|R3:5+E4%/B@M&I=)K+E1ANWW1HE|H>~_~|N|S M@3|GKC|9F|QMUC).W39N;N~Z+K-
HK83?|9.V('C@|"; MX|U+~*CL4C<?KVUV;?X\$8VN>/E).OXB8F/2U7AZ'DON(M% M=ADJ>|FX|U(|A9+=,~XZ*~O9-
NM-TU?7H_R)/4WZ2.I.N_BEY|C3|R2A%G M/F7R_\$VYZ~*@25J3=9WT"U&GJ-4-
\$B.HBD*YJQZ;CT>~M2|NZY)WC7;7%I0 M&#^@|\$|=|&Q\$LO~.2DMBS&-+W&1U|/I-YONYW|QJ_'S6U;X5D"Z
MI=J79;KH|?|&I9Y2>(Q^ZFPO"TI^NN1346KGG9JE6RD?;15KZ9B5655S.7J MZNH~*M?~7F|SIE1=
<~;C4|~=QWY\$&~WZ0NG\$UDF&5."(JT== M@%PX8=J|SQQ@~OW2..L-
|1A02+8363I9-2%X143N3;G7(K_K_~Z;S|_7 MW|58@A.GJ@;PWX"EXRAOG#|GF(LH\$VK5&0ENXAQ\$~|TV&H(??
C_~|^~56*)D MGOM|3|N|>X?G<<(|G|8)D:7Q"SV*)>W=8|Y84ZS^X-O&~.K7:KK4UQX5|2\$!@S:ZQ7.#*&Q.J|SIDV5'
M\$_(+~|30!AM6D#~NOR|8Y=|>|D..|O@;OE2|8W3240(0U="~+!&J@X(2,D:~W0|33J|?KMCJY"%5:
H/T4_3>N+R7BOQ M\$|+~41&_J#H(MPAW6"(^0?GJC&_#FG|0A&N|_29EC.4YVSH|BKZC=#:1'I
MA+VHY3|YN5IH8|ML|^L".HR3H%3"U8W*~<|D^AC2U^~(H_U|X6_TD5_%8T|
M;~M|YJW!~2>WWG&M|S_~5|7U%C>Z|9S_~I+~D&G&F*JDC.%H:)%88%|&(|F|E M2=11*;MH9:L:~#7>+~H|
9H,3AP|O5X0UW~KH|U6:H2;|YW);GUW5*~.X MJ7:7Y<4|&W\$59A;>X^CFVIB|9IQ0:P">9=Y?NJ|PV-
G|E|H|Y M'7Q'9/ZPD M1X.M2UFK-I3H|SM1|B|T7YHK_YFA|H 8(|HRB:0;"&LWGBR2H=8NV
MIS33F#~S;7#|RXZ@Q<%M#1_3O).U2MY4QCHGOWE\$Z"%5I"SH@AF_E|_12%' M)\$~W2R\$5/S%MJM2GSV|>T|
3\$G|\$N*B(C_P/Z65X|N_/GKB^SKO+G6|L792|A M GJ| MFKX>AYTFO_9>~1_MWR
I|JDU.D|)SV&>X'Q'BK/D|S\$>0LDX|X@~@%O7|_W M|_RW57R-%ES@YXKVPELVN|
M/@YB#V_9NX>^EV;~L7*.O>NZBIR\$>EIME<~%P10_~|2A;OT|3M7|@RV=&<|
M>8F^~2^+B|V%5(5G23=4/PX28/DVVL4G|IRX)|NZ|X^&CRV=YPICCYOFDLP M0?D2H-

TXEG@XPS>="HAQ/M=R50IN31IT<0\$5NH*D=X4 VM K/Q-6> 5VWTOR M66TPB|PIE;:L+6/7YQ&
:G"G2|RY@R/#.D8A|<+8G\U3.S|CM?K9+J.W/3. M=ZO7/3Z1|'#+7H92P1|CANY"5004-;
6S5|K(T6;BM&3LYK0|6:*E3W*_% M)5=D;T*K1VRDU(40R(^04AX|G:01A0:ELQ&U6"C+*|=\$-)ZVQO'02MCQX*GZ-
|Q|=QG#|/7|#!? MH6I0E 4-78.5MB5BPB?EPS+^6;(16"-)#8W7G*W3=BN B=1W^N8,U/HVNP M@O
8#T0\$WW+BL:0:IT>2.EV(+-H43K-5JRCSG*MD:8Z9R&IT"91|GAE4 MW((NW0A|J^E*+ZIB9?
CE^B|0:GA|O^EJEV/ADF_@&4X|X|!)67JCUR5+|BP\$KRHP-&SI<'YAO\$UC.&0&J
M8G&Y32WG(8#R+6M(=S^JA3%6998<%^'^6??|HR/L|:2UQO:BDR\$K>;XZJJ%K
M=1S+G*TI:80K;\$BQFR6JP=#. "'T\$RIF3#" ZUK'52<3-G XOWH=PHOCHO M+FZ|SJE:S4<(P(QK>:;G*X|6:2F-
QG:::ZQKFH ^H*2Q_3 J2|3 NK|0YN MX3'SE"101|@GT-"CT<0)Z;K|J:2V0:9(3G#7|NZ:AI^J|&_>97)QQVF|
MKE^I=")QDB?W-#H919>VGX<9O+D/#<|'C@ QR'_AW#D+;F%V&*GB|S?+% ME?>|M
"@%0G21C7C(0TAXHX\$RP0*W6)IB(O|/T9);VRKRFP0_*;|.29F M|GGWWFB":U|6W1|JEHO?
C#%5N0L@OX.9KTS7L?>+8A5Q Y@=(.N MINZD|+*9LBWN_9W! ?*\$Y6O Q;HZ|@F'BG|T7/8?F1%:0%8.T?#9M
K M6@Z9"19 _%|32| 0B|>=Z:D7Z# (\$GL&)B5)5U2*&|/""2R>QF O!<@%:-"V M!\$OT#Y-
<((&9C)'XS=2^|NJ#BLKY|A|36|_T/G6/HA@ .RI"(Y2&&^FDN<2P M0K+|^0?
GDOP;18=V\$V|JZD|^M*BYH^CME'KFW|/;(YO-#O|TX|/F%TVZE/< M1G<&\$
N%|YC6G=@|J|*N|5%KPI SAP7;U5BOD>9>2IU= M&KM=AI0A O|KD9/G<-QV75|"-FAR-ZL?@4",26F-
:=';|BLN(JZ*9<1%O+4H M.:VS3EWY^X<MF)#L:'R>W|1@66+11)|SSYD8YL"98Z%W|;
(JR5|30D).|KXC&F.9SK:#7 MEPV-;H7#4YRV@J&46HXX4'8;G_#06^,9K:8-|4BJP|ON);|TUB*M6F|)QZ#.0?
&YV|ZL0|VX#D>I9QM, ME, JU62V=>R>Q; |H|Y@7Q?F:G?2*|B|2|?+;WJ|4;DT 5|4):1";I'6+!?
M80|GNT>2|L139GFYQ^QO FAWB6;*E_D3|S1>|GU)3QAG%Z3S)(AYK6 M|X@Z#|
|E9;,>\$Z^3V>Z#H8\$\$\$NJR|KC^3OTRC_RR^R|U_HL"J'R?7N..)\$E MO,Y|!^9|&?
5K*2V,4*B'@|S\$VYL'XC0*&Z)O"JKF1.O|KHD=-='BL=/2_MIWCS?|3^6'#XGW(1ZJD0G8NXX\$E8-
|BW7MMX&K:'7|7%:PO,)RHPTE.J 61 MB_V\$5F07|SR@6'G:#-M|=\$L)-&62EFXB|0GS9N^YB-X^-
&&=G9L'O'&8GJY| M5%&2V6NYH"-PB15O_:@|T.1VVDXC*&@!(G<%_SF2DD1B*T#.WYX\$DG\$7W=&
M09XP4.)TJKKZ3)?4|4>N#N^|J|VPK|JW(I2.X=X|*@-|J5@-|F.@R1\$KM^P M;KR|4%K "%SUPLZ09<|J1_?*\$??
G+;BKT|_IS(5;#HISG<8 G5'5/=)G M|/_R_Z|6BF-F(J M@_R.#|&8AQD9Z?(J1YRH\$X+|D@4CWSRJ\$QO@+S MS-
'ED<^7/ES;;EG<>|KOS,\$7W24|P|4%,HH+^E1R|1)|E:2L,L8K|(R>Z M5DD|;AVHBX|H6C+OB|MRH^X6L|3W@T-
Q_V' 2Z|1%,%9S;%9S%045)|F MT/@8A7U;^|J98|O*O^AXIUCVUJ?R4* UT/@I MW)(J8L8^LA|S&ARG.C=?
S0/+|J#W7(1=B?99_!R|_L"93-N.^KM|MRM*M M2IAK=YMG3.A P7E?#|9X*/7GNALA6G@.O.LMAKN|+>7E&?
5NJ&R(B|!_!JS MQ&YR^ Z3\$!%(YK'9,(^S(3C^9JB1R>P9(S\$%3G8|,8<(4|?U-;<^5GO=#2 MM?
5"P;LBZB'W.M12|8X.W)RH2C_|9'W/(.996V7H3R...6%W|BGO-U2|V MTW?6J|VN^FH+*_4_>;SV:EGL&BJA|H>?^!A
'BC?<&3'DK1F5|&VQE&T#; M+|\$0RE_|@H2D3N.S3P5K>;U:C"JBU^|=F?7G7E<|J*#3HB(^ ^I@P()
M3/*RFUZ);C>ZYE6&G0>P<-|IR|U3.V2AL'+8;AS 5P7:BMT<8@3QD=+26 MGA_!FW|L-JKYC')H|KN>?
FR;MH27#%S'GS|+LRI'DO/F<=<7C&M0%1V@ M|C>A|62ZC|5MOHVI7#WJAI M|'0Q959+P
W5H8&94RH2TNU^Q ULR7.Y+HPT2HG3+ MLU"U=4^>E1A2VF4MSJBPB""CQ|&#-;|S'B;H|+;S|J%9H6-
|H|4C'PYO6 MGX#N'6>\$1#&JEUPLW0H917^..J&6@C(ZHMGPT5W>YR2ML_U'Y>X%(.;&M*
|*GB7KR3R"-Y77F6)=X3+|VA*\$S^VKOO9;85USIU=7>|P83) MTT*2M|:1(C(7TE?
#G8T*%|;NJ: ^I|H|'I>Z'W940|N4XQW0)?..|WH*_ MM-UQ@J5'%F"WKA?|X/;1\$K)QJ79IEM-
4PK=Q_G10A|NY_ ^Q"WEVEI|P>F MU'Y:Y(1&^CZ,2%+|H<-^0Z'S+G MS11|H>F#%L^J&=N9"?F%2#N|>LY'7J\$;
51P)J:2P>3F&L<817.44J-8"PZO M.A=Q"A(
*LSX'G\$|^|3^_X9|@*F5AH9VF,6|EDQ+,"PU;C-6|H|"%FX;>2JW*J=:WAS_W& MNX|_INUW\$?=?
+1.7F^WH6/L2C&DK|U'_=\$.#?YK;(24.5K+7B1S|YVW=F M7=#>YKH|2D;=TOB_>7#(BS#H%R CMYK\$??
EF^|XB)B|=GIP/1H(Y*+H.C""-|6E>Z MM|BN C|6QUZIG&FVWM6^/2FZ7;YO25+=3NY|3IH%C|68E|A02-
K|V^+5|V M+QF@XN1: DL48'@-KKJ7>#-M|@760H7T6D-N;PDO|S|H(C^XEF7-U%=S5+
M.LASUB_2625%8P'#X'*C-.6W2|D)R)N72A>._C>EGJA;"T0\$CZ_|P6LH_9|)P M|5W-#;I9B#F:@2*?1?PP<=B=?
QJPRF1AYQL3|A|S'736|HY\$S|=)%:Q?N_MK9N|B|F#O3+7FZM4COYZK|+45 M|OUD'0;%R>A|\$4>S-
\$&2)H|W|H8XC-5@;P/^*FEH7MQ|H)*1>#>L:E'=@%
M;^NW+P#VM&|'(D(|Z8.2Y.0FX6D2PZ'LA.9H>;W%N>9C.61R>RKXV6Z23Z^ MW<>
<(1|YB>T8>7>|T9YC++=TVO#|J=/F|GRMR(Y|Q>;103B#=#W,\$G M0L/+|5FPS<6|@N0D "R|+|ROEBG/XK!
M7^|NT->_!AX;|F7YD|G>;|3ZE2A7Y8S?>K\$H&S=OW6+CI8KDT ?<#YTRZV M3=X_'^#;S+^R|_T:"8,+D#PC-
(XBH"Y>=!*Y93AG+&+N">\$I<2F4B6@B; MH|1%EXP|H|P+
Z9=M7@Y_.WT^KG"F(H44=IM;DO|X9_HFT@R/&V|VB8XE M"\$284"8;=NC(GNBY6*D;|^T|YXSV?-
|5G|_(@/>_#=\$??^G>>_.* %|+ M P04_#|@7I91LE%",90-0"0UP\$ % &UD="TR,#(T,3 R-5|G,3,N
M;G|G|+M|/1_M_ ^2|+2Y)9032%\$Z")2F\$|H(0L|=\$3)(2))Q:9Y2R#Y\$S%N
MR75RSR63.R\$AA|AWD6^90PS|QYVONWS_E^ ^I9_9Y |QH|G=5X|7LOEF6<^ MUO|L|7FO|_K.^K"^LD:|7K:NMH
VR8VX|K|; 6@.UG|VO.P_.R0L88 M36 3V|_KY_=-/Z_-|F^_S+YY"|>6+?|BG%Q:8>'TM7.Z^I=,38Q-3.W|+2S=
|CAZ.1|T.NUSUOC(OH>|0<|M0D)C8L%Q2<|3TQ?2| (?)WU)CNGJ+BDM*S|745E77U#8U-S2^O'|XQO7W|
M7P<@Q|8G|>F9H|SE&6EE=6|J6NT|8V?>K\$H&S=OW6+CI8KDT ?<#YTRZV M3=X_'^#;S+^R|_T:"8,+D#PC-
QU"AI\$N|&N4|U/MWJ|BG9V_66 MXP|GU@TT*EW7=/LPZX>M8 "U"|&B|S\$WY.8Q0*J5|_&9|J|J|2C'63.X#V9EH8
MP\$P_I(|4@R%?H|1"M MF 5P(R A%L 0AZ2L)>@HB|!^OIZ|H33Y6LZ">5N?;OED/TW-7AVGO+ M=A9GFEA>|&
(|VRY|<|ND%?X|7EE;#*DQK" H_/_|F.FQ%G0@+X|)FB/O> ML0:OLP G9BS)ZG6D?(UW@E0GX<6|V_-FU8*|3P"SR>
<_0|3IK_O&STVZ;|_MZ-8C910,H94%M3= "PL;UF|_7+U&7|&3VY_#D.K@68 ML*^,&0|HTVLABG0=BLH8L(X-N-
0#_J0R#G*=R0)BVEA_-JZ#^X9I(6) M07GP?|S%L0#?|H"S"@ESM83E@_#D%431'D|R+;S%0N0N|0'IEY!)9.H93H+
M.)# L2Q#4;H2|9 V:G"->|/%#0ZL_)MP_|X'35V|G62|; PS%O*#&S| MQ0+^G+>#&G|!\$3K'?)&V_||H#
|QEMWQD>0^2;=@F|B_&X;#(>@.C M\$C7.3L.S|C+^+C'Q-%A ?O_'SE 5T+C+BT8P0.M_ SOB|H_G|0T%\$M0:@T^5?
CBUY|1WW|* JGUE.M(EJ7|= MME>|VIT;M=3DC?>MV^_L^J2|HNF2H>?K'/&|Z|9'LE;_UODA\$&@C?
Q>S).P@H|J|^9@&QIV@PB-CWP+^X|^:CYAH|L5>|T.VF@@:H;=^P@_FA:AA\$KJ>P.B)+R.9WV+D\$XULK
MF5%UR'6A<(')L|)+BYHU@D-> 88^&P<6D/DV+51NM7|=7B8M%/@WD5LY'G'! MNDL1019@Y|H//2G#>YYD;F;!
69@;SD|_6X>7BJO\$;GT 8+2\$LA>_#T50%...@SXU=7>?W2LP".3|PS-H?QHS" M.TCFH7)|
FE;N|6#M7)L(#9%AS1(H\$1E@L&H&-1B3 B\$7H%R|)^ 23V#5D6
M|_@N84K8|@;8PB@+M#>C*_(^>1(|!@1^>L\$; M|'H?O'XO.) (J5|BA3F *N9PC:3+R?B'H_3|*
|H52UD1Z5Q2|ZVO5\$|+/\$% M?QA.0144|2\$8R#R#IT3O#8=I\$DM;D\$5:N|X?VUZXTCF-
N3Z002_E>|=G^X.YORV9H|;R>M92+5|G>TQWRE;Z\$#_T M#YV MC^P.RQ63D#GO-8_NLDG;"P+2G?X2
O|MMDM ICQNO7|GK_-%T|D1>#>J4@82"&S 11-/(&Y_P|RP_Y51 MM|!#;"L5QD+^T*+P|QA9\$R\$TX@|;D
1XF8);5G|'5(H1&D7;@;@;@BBLWV9@;" MMI-7G_>=3G;_%I@|Z;|Z2>?
\$)TQ>SJC'E_V=EY^E5;TK(0@*7Z2*RA0@J|/\$ MQ;H1B.Q0&&XV|L_=?J91&JE39V_,2-YVX4=@_/=C:E2BG_UR"?
^%+S+4E.5 MS:2^_BHVV\$<+|JB%+@(|X|3Y9|S|S_DP8D_2T9LQ03L\$JW44XR^_8_+? MP&G0B+A^@054\$S^Y^#
5F"0MP5J39(P_|FU|P)MZ/(T># M=)=9|_JBM2H 8W>2J?QH1F2_|2HZY^_9L|DQ@M?VO'.U7 H<8)S|Y"\$NE",@2^<

U@!%6+ (EZ3GM81HBW\W%L* MKY&3H"N2YMXVX"V!"/3/G,2MX\IF9:T8LX13) FXQ"6U+4DIE/B,758?#)ZXU M>
<3VU?B%5!^9B\$2TQ9I2J2.3=-I2->[O];D*K?VCHT?H7:%>[9]^>K MJDN@IV6 MT+?BDF?<=35\$[W\$(U! S?
2.032<:QDV2K"-!KW:V818EUXC M+;#"WAGS=95G9^8I/.OF*S_!@!-O.ON*T"ZVCK07X.3+D.X-Q*X?!R0PB
M0PM)+M?8"WZ&TFU,+\$@1&KHJB;LOVR4^WP9\$,1U&+/,4LO6U8F?VYAZ=K%L.*0)75P<V;& MZL-
QH< <3S%!(#>)<#GXYW"5^MKN#^!O2Z?EH.GC":FJZB8XIFOS/2\$JF M "TN04T@6=-U1?@F#
M@W3SW)D^V2P@XSPC&0Y^CXX0'^=>,3G3MH;T;R?L; C"A^X@/UCS#)!\, M(XZXY+K&
JC*P^#WL)L;EPFO[SHAO3PT;0#"T6 Z(M4#QPK^"/PG_':(:#%; M(?XF(*?/\$O :L'5+VG:H>1C(9RL=46)@2Q..AC(5--
('I7"IX!_ OXD04PBL MK43#0_ / *Z,Y#WZ#7?IR+KK+C"\$&#RU3228PPWTH7AU4)UY (I%D1X6I#84 MW-
#2_ (%1A+2I60 I8_ Q^QHIM?+F-/8PC\$[PBL\$J.G>5,G9B7V/R?X&.G]*7 M2\$Z=*\$4.1*W<23W58"?7P-4Q^/_T_OR?
I'4'3_Z\$"Y(M:/\$<^*05/WC1*9* MI^5G2.V^V;1T(<,\$CA&ZSX-?)."N1VL?0&#(H&P==!@"T.2H_82_LF\$ _P
M0'AXH"OB\U%0B,Z%CO'^@9\$3^">_Q73&3J#^"/5/VO!.SKPS8 J\$VT@P7%J"+ M>@+/%
(9+ B*BC [U@A:*)^B0G&,OX?P4,X2=&!=,V@\$U#6 M(D&N*X*4RS)<12U9U9OWO_BN?#3;338#I!+_P
)XO:P'GQ'.A%""U\$6RI+*<=6#^V_A0.8J81.ANLWH. "BH_ M P\JA'Y+9(Q"1%R& G+_+M\$+A2AAV*!5M>+I,DUB42?
RG02OVO_00@/XB! MWCCBTN@RUGGQ5TR0&X+^FM\$P@7Y@7=2Z(8W/0;WO1R>I"O(=?+ @E9@D, M*A
_*DKIX I1'10R8>9 ?I^MA- <.K0_XG W63\FFOP(9)*;I_ ^6C%=<46<"6 MVV\KBK\Y7 D"D)H_B92,*K3MJQ1I#%S
B/FLAK! Y_<\$64!+*K;0\3&X M 5MGODF\$YVK;681:H1)G/ZL@_ ;ZW_I%X2>LB)*A9E#1< 4TFP>RQ/PFW
M<2ZJM1*.PB+ \$TM5?I_UW"1.KHQV/53X?"8.7# 1>!F6:@E M>(GMW^1W\2RI+=01NO&0_HD%TKS)0SC#7*
V! =717)J\$ _2WWK;&7!-O!<% MCA/GZ61D\$ZHDN%\$,&3C^"Z4DXO@ "WAP7+R+?G+/#
M;R>J1\$[LWET/16PM3_>+L9_2/4+*Z1HT%U%99;C^&^8_<(4_PIEUKG) MWZ5+3="PIK6A*9Q(HFZX':GR?<6;9L?
QN00BIR<_6 W M2G 7%>>8;MJ_2*JPI^AB+ _E8I_*!N^U07?OGA8D136%
(_:3/9U#HXO*VW4Z5"F6WS)7IE_ =!U157* O) W^KP6A/M^H;:KY05!@I MFJD1-'<6L/DKQ9
AB!_ '1"W6&"M)FB264#PZG.OW(@K)-,IX_ZD^TW\$UV+UHSJH:^FMV@QH1M(B_OVU^:)GUU0
M'\$K,EPXT;3*Q05F4(R@VK2,/EMLHFF\$H*6J*\$Q!72K6T?1V=V'OYL;X!@ \$3 MBR B"4;(S9_ZL1S89B00./H2Y:0THU
PSIAQIO= _2%OP+J) 2^W'U_5J3@ MNO*::!F'G8=7IZ^1DO=ID_ M5^NTB&+ BRA\Y:24?28YT+_ ;S07L;UFGO MDT?
7YB-8_%?G/('2:V@)5 X(3I%K33M\W=QO"UW<4=XSA^P^PO?(KA\Z< M;W79Z;YTB@AE6BD\$N3BY/QXR\$C/R?
FN7JB#?_QOIGP"UF""^=\$DXPS;?4)' MTNV@&O!8'_ EAR(UB@;J+6E1?WP_LQ"TY>:7L)C5(A@J%V&BX(RM08R_&
M9M4+<=>QTO+UO7US\+I^5T@6'7#L&)\$O=6W<J.S.C7IGU;@0#O*D;WHU(#F0G
MH;9+&E:1W>>GFX(N/#10_2EA5-'0EW+4UE9)2EE JI;BHODFC! WJ4SW#M\ MID0*&6_7E7S
@2W5\$0ANZ#)YTZ&N'DS_@+7J(Q^C9/T2H/8PS#? *L7QP0 M%I&B&LA+X5I"OP=H#^'0@>&Q!_>+1PKI-
TO6DA'S/G<^?N('5*7MBR=GN6 MS!Q&S9'S16A3;J9IRDV/;_JHQAH84D/Z6-K*!\$ZX=IX5+B=^5JZVZ!0V/
MO1P>6ZRO?L50.S5I0=,!)XMQ@!;X!G;5IQ7CD7_WWO6W<IYQ#;9/#>IS&I+
MN*P&CCJ15>H.GZ#XYO%>AEP8!%-13S@_FYL A9O>,U<+R_7%TZ9KMP8_J.7WOK7\ MIC!3^_ \$I(L2
^5_."0N(1&73<5WED,%5!\$>^(-DXW*_*#8PO_)I_5*^@Y GZM M0\$*Q5OU^CB^M.78FP*2\$@\$8UMH
K12,\$@5<^J\$E(GTK+I9XN#I&^@EA7R(M"WL1LI\WV^)=C00CGGWYPQHLPTH\@GCQS'4I M9XN2@HE-
P_7E!;CALEOUSN1PI;UHHBZY\$AL<1I2I+)YV134+P MXT)VCR=L=C7/++?
>ID7>NJA:3)=714KUY:0H%\COT(F^/P;M#<).2%/*2+ MJ8(J9S^(V&732)I/I3* G:"KF#4297Y=?*)LI>TNM+%
IOH^3SY-/%,BL2 M'ORP_ _=ZJF);\$PMNY!6TSUXK_-D^<32BCQ!056IFD%O6W+9BUD4L)C \$)B\1LNDR
MM+J,*V0(L@T_45?861"K>6E\$DG2)I4YU^G^0ID\I XHJ3P8FG74H&:R MIV=8)Q00EX9AU-
?/ 4!M2P@:G7>7GY+FUU#)*HS=^CJY'L L69\N/O.5_ M;FNFY 5S/L5J;=H:(9V9,9?
+DC!5\$B+J8^<G'Z6_W%*Z^QV7>5^Y=S;J3Q" MVTFRI
+!C=&!MT='1WFIITV>13/*EV+!^0@BS\@2"@=G!"+;,@FV>ELC(Q_M0G>)
(U9,J\N!>N>^XXDA!^O7UW0.MDK\!FHG^!YC5^++#+#IX,EW\Y;JK = M-O*=@I/64DF5E??
%CF3KW/D)#*%0=5UR5//HHBWTN==1HB/NH9R@T1M%I<=,JDN87A=I<4V4YMES M*D>N%66_%.1%U6%6*/%J-
N"*I,VIBHU\Q>SIV;SEERQ^C:0!*E>_GV#1WOH MD)6+(/>OU6;2B=4IWM9= _HH-
IB\$AJ32TJ"4+_M6+_ ^S!%FWH(CV=I1PT^X M9B\$;-(I 9+_4_ R:/<8K;68E0@ILCO:0
M+WD7.7YB\NJ%;6^Q1BD5(IL%:C^S:=W>>XR9K<^&0_61Q<_!H)?"17_ L3 M;ZR&<-P89I?I>+16U_T^67'A3JV;-
H>>S9?YRDFN\AWQ7:(OT\JA.AV+3! M%AB%Q=CIDO)#U?Y16M*IR\JB9--%H9G(_XBPYQ
MRIMZ::OXR^X:#7^I2NR)F13BR+QSE);YGC/^L1GGIEA2DIAB7OHFW?UK\)
M);XJ*=/MCC\$00#=#V4>=P#VA7VKPZK_*!N<6K^<=;O@OTSX?ZW":\$Y4" X M=ZZ;C2\DI<6"D(ZPE+
MEY^"0)KY0B30XMP>>9;"9=G.WM7.OW(I8;I8).K=[A^RSIP0+69EUQS%2 MEL E\$SCA-W6NL(
ZPW7E1#.F3I3<;ZMZN(AZS0)HH\LM\3PLPP&_YQ'=Z# M1X68/BMH>)D>@U>[+0*>@AY5VA"DK00GAXV?
FQ\$;QK2_E?OX\ID0_?/P3% H MJ\$G=\$2AIQ)2+*%0PNBPXKI6?R"LN%T?N%+X8WUQ5A&>12J_?^@*C\VR2*M:
M<\$DY@8:<\$5CXI9CJ.3M&>03LA?I%!/H(WZT)/58X^J=RJ;@,@EPY7%-4EX M;B*L>3V)?HK^G?K<+E?
*RE;IMGNA/8FL+XN2?H#_ N;(UO7SIE8HYP1#UJ MO&9D:6%0I65Y5;S:@AW?MSRWTW'L_4W3&?
+A'L35RYKL7K4W/5#@L*VY+M>#T<42"Y!#C;Y<<+U_@XE5B.)B:I%D2^A\JTH^CNSQI?F*E->+J(98;
M19CY!@I?TY3S_..B_ %F" I#M^R<50_+Y*OHEQDF8W)R8)8K-T\$[133\VX_TA MT^I_8;Z%=_N8TY>&
MY@&CRA=7I1_4J^1 Q^I^C5EOGNCR3KXP6H:PAYB\JFGW\CD7:0V/J>RL3 M2G"41)_7J1
EN>8>TOZR_C\Q&0^Q5XM!44T?M/T(T_ E_FL"DE+("L@QIO M^7_#XS\I2;SR!^CI^D<-89IB+
A3/=+!\$7>FIKCSZ;O>)E8?"=E1+WEE M9ISJUK;=15D/H%9T\$9\GT4-8\$8=O\ "PIE?>GDY(GW)=FW;ZT0\A7=8X-
MY1X6;@6&AM02W33/_ @6C'WTF^V68@BR!XLV1/B8@\$HAL"15QCF_MNYZ3^
MAN5Q%B\RSI76A5VDDMG\Z7%YY1>UF"J2^J/K)EO^EPS82\NV;8H1+ M\
(N>Z;5TR77+A9*R6;7Z5TOYV<^8\$!\$P?MAAG@OTF%!\%QSQ+BAYFI# 4=+-?W>>L?SCD,DQY\$WYP9# M#
<3F0%YHD\$@VO^!XNWJ!4>?KX%E:T\XICT2HH=>@OM^5?)1PU&I>8#L'9%!\Q9T3 MK#T&N!\&U\$[JY'9+AI*?
V!#I_5+E*_*O7WZ=E;B%<&2C18<_E#OEY.Z8Y&PO2_P^)V2 =>^@OI\$KXKP9\$7LS<^YI3N>.:T7 I5UN:&H
MPQ_ (7C@I4=EPWJYG\!K)XAXR#I>B>5WW=O_(4^ MIA;NJ&XYWS=YX.%HH)1#N! L(&U:'T3I%#I"XC5V#
+4;+@YQ4.5J7#UF&DN6^VZSOI0\6_8L3S0S^F08J<_<^RD'
M#5CY(HKP8WDP_5#>P#6^AWVL\Z^M9VG^K4MJ^C?IL7=CSMN.L*L=K#"Y^D D M//.E45A75IC3Q.3?O-
P^+IP,X.HIG4%\$C;YM97L2'WSXINONHO_/Z9N.8/ M8,\$&Y-*) #F"1#/R\2@+^+7T/(@*)8J+&B\ID!";\$J
I;QR:7*%>O!;&>67 M9IEEA;0<=CK@F^!0G6/J)ZH7W:M/Z\$W8S\BA;\$#_N+O:(VC>TIVFQ67O/=S
M7LD5:4_X4+IZCGAZ);U.PJ^@I)3_/ZDI1#&EHAF&SM@UI"#4#L\$B\Y7K M>&.0R10_<-
&D6G&81R\KR3VA<_O.%8/DIM M_< &F6#_RAR7E 6J?O"P\%); U\J+^=RA_@N/I1/I-B*>GH;M V MY=0HV*B\J@
AU6WUZ;Z15MBTTOY0D8DI^1)AX?G>_N1"1^+>D!;L'U=(@U9 MZ+_LO M;ZZ\$J6A%J#)W+1W+.11C.?
IXAV3\$3>8I"VP%KFWG+T4Y/P3(FE M;K;_<@7KW_1ZGPTUE7PW2H.F(E6+Y4 YMO(+)WZ\^DJSWF"\$PIZ)A.J
M'X_YZB4_VI>3O:M)V4OU_EPU:83SYTFULZC)109ZI2V<_GENXJC<_*YT_WNT MKV\Q99\TIZ;D'0
\$1JVV(2N9,%V! =^T_2WO/C;L\$E;LMW8HDBJ<.5K%_ _MZ!H57+I\F36\$RF8_?E)?
53M_0AD%#5MUJN*_.>44\$SHS(^H^P)@Q.P* =FD MYCY.%XF/HFYZ%L)@&F
(>ZF@:DVVY8B)R79.P)2^_KIR_V+&)&KHEYI&0 MIR295CI9Q=TY7IG^Z2+EX.TR44)XK^>V1FT?
_V+NDBD5\TZ+^A/C3!%+ M@^X2>U++K%SIC^Z)*\$6'PHB%ZKU* <3.5&4R"WAR%\7IK7; MS"J:N>KIXT;

<6U>&*H2LAI#A:G)CQ_:_L)*:KXK; IQJ%&SX9*?&:!HFU M0A&8H_H&MB#>|O_&|O%)|8+<9|2-
K"IFPMW%2%<|HXOJ7>)>|8K|2I>?B:-7
M+*3+X%_W%F:N;2/1I+U'=R*)5B>3F6H2M&M@^*NL>'B|J\$OVBH(76:QJW2_(-M5JL&:+.TC5_%)
<8KUN;:O07EZ:6^Z:"@C<\$>YI.B>HIC|4(W9J^F+Z^YK MKQ|0->#_DO&TL.@K5=Q*D--XS2R8(J-
JAG13^Z<1@+TJONN(N+A)."A0IVDU M9%4O&=.A3*G/D0C23&T3+8_TFZ_|7:RX
MA_:T0<=I23)VC_T^Q|G&^ZA1DV|M5W0E1)_26&B0F_-#P?T\$IL4J#|JTW)A_M\$Q/">C*L%FPGFN6I2V8EJS?
C.CLM\$+|XBN71W^"/0K'%EO<5V9 MS@+H8FZ\$%:U2?UWZF2A.1*3&(22"\$37030J|>WL_8:HYV\$6D-
LL=BSEW<2N M9B\$JD<?>?>G7P'2Y:0C/Y^_|JHOGG?|ULV!
NAW7|HHK46U|USU@P|RN|X7:TTC8#^&=RW;*N<6S@/O=E&'(TB%>Y_6JS8)%_M-JZI%.7=TKV>UU/)J7! MV*
B4^455XC|&=:B4O M+H2ALV?A6=ID=:S|K?<?|L3A|H^L"=SPE|)?+^ZN@4E_0.G/(|<#(\$\$:G_)
M627(WT+Y_1A"P|D<3|7XLE#?'*E9G3|4?HG#1V?*_JRFHLK=|PIHJS>R@ \$Y MB^L|A|J/GFG
#T1|W\$CWS|AS|Q|0BNOQ BM68|+6MJ|G6EQXA+U+ES:|_BL M*G#_&X|0BQ&DASHYOZ|>Z-2W9\$AV XF&
(N8|HKQ|8FA>4|G^DLH#_|K<)_M|5NG*W:|C|001G|7^EZK|:9Q|TWVB=7%APIJCA;P|TZA\$38"=R|K?E0(>&&| M:.
KTU@JN8@=WI7SC'+|2|OZ8%-69?J)4A=UY/'D+@6|U(3-C&G9D^7 L^)
M,+3FT+N0|>EVHT.GK^0DIG=TWK.YZN<6L)O)X0V2SS|YSE-P|P-T&YIC(U|& MTKU<3_72C::/SS.*O^R|.,,
<9E1/'C?F<^18TF\$|FF2\$\$.D>I8V5N*?C X M_+9+ZGE>=R='=8B|W+>S4ILL+HN|^-ZK-E)>R4>TGSFIL8594L,)?
8^Y 9+\$ M0:X?0S:E2S=CY6E=XV+|ICP|0?D%??)R.C&JU^FN=|TA>..1/IL^E^58FU<
MOGE|B6^U|U%<P3;1|/2T*)1,|^*|71VU3|4UKJO:17;%.>|96N5)UZNZM: M86>=CKL+6KI@
M12EN<5D|+6|WBI^&TO(BSJ)|8;J=^SO^KXTDN<&3;3Y:P82";XP9GS)GO M-|2%"|HU;
Q^_B|J=54X840W^5ZO7.DIXM=1+|A|XCL:9V@I5&TPI%\$&E M)&V)4GSB-22 B>?|!
<>:JLAA|2^>S("M86|O+9V?|.1T+|/|G-J7&+Z+|+R MD|DPEDEP0YV^\$ JD(1YF1|A+^DD7^HG;?
E^|7XR=;H|J1|:T=PT|G4W*>#P M&>88OL=S^_8V9|>NW ?A\$S8E.9^NZ"|IUEPB=Z'_A9_PFNVZ'?HWIU(E<:5U:
M2;%H=|V|7N_+H|T24G_KHZ"%BA967|GX MV/_3&4X*RP*#;KMS* AP7\$2Z6|@T1'+|J)?
Y%|_+|S_5.VMX|B2+K^C3 MV/8;R6QCXXUJQP^9300JHNMA^W|H&FHT,YV8^@L4LS#%X|PG^|OXQ#|L(0^U
M;#D=-6S+2ZQYTN^??
XJ1Y|50ZGLH|G:Z|GK^V5435>WWEI^W;A.8:9^EET\$=FFX|>65I+1LNY)=+80B9|3J5;..88+>W
M&#&46A|LWH4V2T|1N@Z%|D |@:U8;ZZ=ASDI^6P^F>XS|_BB5L6*\$NMQ(F MKV@R^|C1?^|CF8@:|:?
P|W&|@9D|V<|)G&^7XFP|>G.N|A.K.)TK^XS9'; MENJ=H|H^D|F#56G^|T7QW%M1=Cv8WEE(HLAU\$8|P4Q\$W=
(_13W.2%FMDT/3 M-|M.>\$E|A|C|4G9PRX-Q4RIS_2'=9V|TT7S_#NR5?>|Q-M7.CNC:|JRZ_V MA39^|R4GI^@-
A3/T_:_|WH6LU.?CO8RAZ%>_P9%9M4|85V1|A>|:|N7V M+7?LB@Y#6&+<.T|H%6H^Q:JYR&\$_-2?1_1JB3|J0+
+2_9Z:YOY6.2561:P M_%"PF?Z|H8VC_+|+|+|+|895Z70-QQ-N@^:|A|A^62J.^VX41T5?Z2*B M:|^T^45K|O(9#|
<:%&CN=J^0ZKTG|1F3N:9?XZBRW\$.F-4"C.&+AE3B#M6 M%W> M1:^FN-X=B?18*+K506HT-
%.XYBC:V|58VU;=%YA5FJ(|MTQ*NTB+&T|9;.&9CP|T=*C|J6>66W<|M^M>3KQ1(EEYH^="Y5|*.C(K%B M#'?
(F(A).9|?'ZC.#J|^"PQ|ZJ8MABM5'?_+|TF)|C^0?Q|-316 MRJMYOWK6<^1^K3AU|A|1%|T|P2&Y?VY^T|^GKB-L?
=H2|67.2ZXG|V|0 ME_2 IH9^?FG;N_-YU6JAPY>U?^BG9|H|:FK29Y(>9+)-N^|LAS2EFN^+B MY>5BYW^*
1&J_7;-83K)C/O-2 M^Z0? 9.OIY#_T6:"E(5*#_-VNZ!_IYWOK007NK:2R.#?
1_-&VB803ZO?>RU.FD.UV@BK|H^F_6K<)>5KHVSMPM<5*;\$R_K^W|=!R:(X^|+^R^0/D^)(*3)US# M<+TB;TF\$?
W|27R^6KA_=K|YV|/Z8(OU-NZV7+W2JXDNQ?^T1 ^XJ_*M^E|M MOVGFH|&9."P|K9GZE)9N1ZZJ|K8R/?
QV^3FTGLF|<72|023|>^CY.FVAAO MSX@NM=-1K7OCZ^""^>20?&|UTO|8H|^F D07S|H|PG3N%%9N,M^%+|^#K|^1>
M6|OD^Q#M5_O1D=-^V 8>_&3^RX#01<<^<|7K_/?OBZF>T\$?>>6.#S6.?T5 M>INZUJB.%>YI-
QJJ=WM54|WVT\$;F:DQ55NF.I/Q4P.E6\$W=A>-DY@K4^CH.T MF0|).0I2P>DHBNO^2U#-DL!%)VX=J0@8@R?
KXH7L|#:E*?>?>K(S|:255^>|>5M MR1GDKSV43#>#7)-1:/%ZEBAHZSD%B6;T-
6X)E(0&2)2F|K+>2| ODL^<=+3R/_9)\$6P>;B,K-\$MW|4O_7.KNW354E%? M^4!&5|8XFH|CZRA&XLBZN-W?1<?
(AET6|H|N|5_D2--1L|H<5^7;W|/VSY MPWP3U^GH7+)|F0B8TH|4TDR0G_-N#-;K.%&ND|^Y;V_N_'
M_2I76@J;#J|O^F@_VO|@B^Z^32XKL=|V#>8|A@I%UOTOD6R(YL|T*PKJDN7J
M^RUH|9+G3;Z;S|/|+^X^NGNIT_S|2RZ+1G_&83/C**_SHQW-BP^1)5ZU^/# MD504Y*6JQ@D(3)MA|6>E7?DC-
WH53_|:|\$?M|H|N|I|3|1%BF?)<(K5LP|SXVZ
MC7/M=)Q_|J7|CY*|AOYP.CK0ZY+X3N|G.EZ2YH8\$^9=SN55X^A5@#0_9V M2#1T=:YF:&_JQJL*^@?
4(SH|WM)|^*P:|(NFP<):|C^"L_:(|@2A;-WK%? M:2@3&L8|@Q:2/Q?J6_YUK>2YIEQ.\$|@MDO).^?
T|:E(R#H|@%9X<+>QB\$B* MHM|H|O_LPSIUQA^GE_Y2VX(4|ET.W<|^SE96|TC2MXEV#X1 MWZ;G&TV/72B+*
40N1N|^R|LOA_L6EZ_C< MB/*(4JN5@QF)HZA21X;_*6N:\$^VW/TPL AXR9&B)TA%8_8;>^XJ>O_)3+1 M(6?
4O;KU1L63H6^+_:|/)|MR^?2ZQ=>G+M<<\$^XC_23_#9\$;Z^X@E^3 MJ2#|OP6AINB1N>R7F-
2UJY2LABB^K|P:GXZKG(R8C-W:'MEE;3H|9S8;|M^|'^YE.Y|(%^U@AB^JD3Y(*LUU^+ASG-
DVK&?YWJBM/S7W|Q^QBHL|JBL2= M\$Z;OMD8=ZJ_|)-O>H|&"KA%KZ#K;HG;ZSAS9^I|SYQCH0U<-^L9Y99+JP
M=FX N;7_=[W0|8C|^H&R5H2X@0QK&AG%&::@+^Q:PP^Z|WNF2%EWM.Q_|
MW97L.PJ5^|@>CL7%/7|P0_|%)|^1=0I/C%G4%N@=KAU7\$CL9:TA0^=_|TLI? ML/3K^7SG\$FY=|!(>V VN9/CL-
F0|DGTJ4/47%M MB75F|8_M+1NHR5/Q.P-
MQF5X;LV R|L;=#%A+QDT3K%&E@_I@^S/A(W.O#_X|4MN9N|HVVK\$Q|...\$PP> MOV0Q|^EN+PM^>^>TOX@-
R2(H>:7#^L5?J0H#5?O19U86_195OQBUHF <6_13L%NP.)TYR7A#<-3V2\$?*_NY<|^KF1KZ%ID&H_N3YQ
M7|QWVML>_Q_8TO1=M."&0;_Z0LA)|RHYI&5W*Y>|7=^A^0+=CM<|^<1;_E*#|^F MN+
BAK6;099*U|UG^XUJ5O<<^*P|Z|E|W|MC|&JLSGN8B\$A;BN6KE\$0%N5R.*# MV|=1YCAD"(<^ZZ;-W#-O3#|PY
M+027RAS::9CN\$|4B60TS73|QB:|^@3))\$%4=-OYP-QN|VNFP<=69S\$5>N<
MEJG_TC|^*QV;|YNO1SKK)O%I.MKW=3Y;4I?SL(&2C@^&WV<|^B30#V7.FV M|)%?
%Z05V2Z6*^LROB@ZL%<K^P/^&*^&O07K8_2N9// MH^M;#82TN1SM&+(Y|)^V:UGF@A;&MIB+Q;^VQ;G|^5
MG17K|U6|_DZQ#ZW|I#_YK_7| ML;@8?O^4VMH|GY<323P4|1GBX@8J3.Y=7IC8(RQ|DU2V;|HU M)=_253_MO_IQ=O
SC?<1<#|G\$Z2|^L^R^6S:C05|A|O\$00H+|9|Q|C_PS3D MJ|H|QJ\$ P1D0|MVEX.K0CQU?9WW|/5_1<@N9.1MS?
E|8Y|^;S+?@^2RK=E ML\$-@<<\$CNCK#|E\$=Q)DZ|GK.K^=FJ6|PQO*!R51(FJ5|TN9JN-/5^5D\$ZD
M^=78F)K4;Q>|H|4R.<|VB.YE6A"=|DH9%#TY@OJFY|1;Z9G?ZP^2.\$TVZ
M&H&*C01|3|JT1NVA=>S)&PS79R:3UW1VC&^H^FWXXDU#+\$?9|G|E|^|)GC M_3*.7|<-FH?
&3K^>.KYKV5G|0?IR_-2 QTVWRT5%UT=2+^;CAY>
MB3M)R=+ZE^55.JQ|ADDJ2GU|!>>&@IS36/1PB#|C|^9Y.Z|T1S3#L|P|^ZJ
MZD@|OT#M%)H.MTYE^2U15W=6+G.Z:W.M?D*^M>;P:/D)^.NG?NOD#YIP M
750|HUA@I|JG7|3K87U;K(?ZKR=G+VQW9>VS.FJOQ^ MYN^MGG#LRG_|\$?Q_SK#|5WG_|(1V?
Y?^|I7RU=W^7L9%24QDF:SACX2.G^M\$|Q2A33S;1H.T|UP47IS_Y.P-C89D.V7W?YBNLB9|_?VUJ2T8&).\$?5YM.
MR\$07H?DA2?TO<+N^+|&M+RA1?F-VIB/|1?GT:|T^A6S<9_8A|^*|C9_Z0BB\$
MQP^\$27=">4+UJTD|IRFGWM7;.%LY.+M0^8HC%6|E^I@AN^0_1%M.6RW,T M4N\$)2_!KIS-
@@KZ90HX^A.1AVK^K;M03#0Z^0IV0|B|^GFW73LU;&F?&2R M;|)N?U5&B.06OK|C^IRT^1)G\$OA6YA;NATX
8NO(|7H.V^DZ%E^/0SAR MO7\$Q4X;?M;08^F3|&<8?X|^Y|^&^=+5_K_DYNP">|H|)^/>+B|H|Z#0C M2Q_D_A&Q?

J6(>Z=PW\$!>RD?Y!>IQ'<KI2U&#17:9DX^G3!IG?X #8,/N28 M(8 +='0S(>^2UI.L:CCVK/EK2+'E./DZ\Y,6TE-
:3:WSB_KIMS!8EI3V* M=ZZ6&=RS7/B"OU=>5KD^!S!+M.V@?PH.12@0.Z.*Q1DFL&9E!":KJF51T
M!HY6F/>V4^3:1OZ(+Z,/C/R-O&:,Z-9@(.A"+8?)P2.66-<&D61P4IT.:DO M:KKCG8(W>5Q>?X^7^1!AH9:,@6,R!KA-
WI+J\$-P!5CKI<C!T8! V,X@?J! M26EKCH>DJBB!+T2GPGW(!^XG;G!Q1'KUJ/5;W3\$0-)N-!>ZPY-3?YA!ODN
M.Y.L/P6!Y%YM='!10&C!T7SJT)J0^JRNYS;S/Q(DA!O)K+Q/7<.U2,;=HL% M-G!&(UPMGXEE!RK??B-!5W8,?
UINIQ+1OQWBH=QMNTQD9YGC\$/V^Y6Z!/\$ MN!J=852Y(F-
!^CAR/IVNK\$BR)>.H@3_9@VW6.EI!JWO/#:EW@O@N!H=?IB4 M9%_Q^!)1L<6Z RI9!XR-
H.6;*SPX)T>!&PP&=1D+98F-4B/LH.7B04% ^70\ MQU>@_&F2K'A9BW;QBWWWE?T?0UO<9321!1!7M6N&I="S?
5-M-R(P'Q3L&Z6T?(1GI^E^ B+ MQT)0RWYU>,% R M!M!JK.RCV9!U^WM;9%6-J0N!>G5-(TYD= *-
!V7U4XRX.WJ\$!QBW>TJ.4_ M2?+JF8Y/7H6!87)!&PUIE+7X0.?SH!KL7+=MNC)^&C#4LAD5%>!Z8& X@2!)(!HCE
M\$!H/9^EG(XIC3E3E R!0!2L+6.V:7HKZ."4RI+NO;5PG1!5S!G(M!<2TLT,*!HP=I@%E!,BE!/"#Z:3!L\$.^?
!V?03<6&2P<7E36!-!7FN MGHM."X!2* 83Z!Y:0#L!#5K>EOL^RU(8M!J2!BYV-DO69HK!4L!<"579
M"W>3LNASW!JH'D:#1!W4OH;SQ*VT 'H=JF"W@A+3!&)U?C 1V^HGS?(EE I=<2^U7+E-&70!/#9:4?_
M/J302MPSQ!A@UK#)V\$D7PD-SJH-R10190\$2_X'#Z+8#!4W0G;L\$B_X_R6
M<9@606EKA\$1HV/B+@T&:H^H7G=DC78LB0D8W#FHT\$0\$TDI^IWR!WI?
OX'@GZ8AU+71YZ!WID/<2#)!52C<6FZ MLX2;<9-.LM^VEBNH-7YH:7)9;J/R.!S2N!3+!-'1X&EG0!QQ>
3+PNL!\$W4 M-D?>JE(CSO=?^\$XC97RLG>>I=7>A5\$D!>")%I5!YP^U4E3R&((>=>-R#+C M-
/9COZV\$EQP(ED1#D1 CGU167=F;\$2;#;Y5L!WRJS8-WL-358@+)N5-+M MK(!C*
!I6+!H!TID/3!#KK%FDN^C;4M:9C3MT7E^<2+ S&WOL^O%YDA@YPVM.+&?JL.%6\$ "M\HQ^=5K_I-
=C#.^KYN!7\$=9PZ:Z.9D;JY:8 M-R!E\$%0249%GHO.2!HYV.PAYH)X@1H=04>8\$8H5&7Q\$*UH' 3KC+%1+!%@YB
M>&6K!NE.\$QB7\$N>RML,? <3BE=KSQW;G->V.9%D&V/K^V@!@7=,8-8 %O M=Z: =#7,(Y/!ZM\$D3.O.9WHSU.8
M=;>[D2Q9>O3>I.AAKW!&FB^'Z)5W M#*XU*P: AK'L\$TU*#&@5*5@V9V"J+!T>L:0#59415!9V%!NT(\$D68%<
MCF*W;4!Q_!31D"QY%NV"77B,T5-U^M5/CACS0Y!)&J2!Z)RH MWLB I?/\$FF=4;777:IWS/A?
VRTYK&N^D:LD1+H@A@BM/4GR(O2I"G!5 1E MX3TJ&^OYX!BLRYC24+I2O^*>QCOORUM#IX5W&)3SE?
B(12^=V?9DA6TUF)29 MBPF> !FHY.CJ!>9K^0UALF!6!&OJ!3QZR-5&9!4R:4!?
IW2AD?9ML/R)YYC/I=AX!GC<:K6B!8?J!+-,AR=G251@^Y'N)&3!H M92.+N?I64G8VG;JOTH!5#.8?
EM450^9AZ3P4!Y.P4 K3\$!UT>JTGIEY3K+? MN!^!6X'EH@NR0K.I(\$D_"^7A2CA\$-W(%YRR2V;>IVKS
\$K!T&W!TVS4 NB MAKDW.A*\$L)PV.F3K!MZ+!N"4B.M2O<(AU^0Q!T8FG8MOGX(@Z=/%&\$K;#7K5XU9-VL
MD!WB.L!AK+8V;HJ&'Y'4.N>1D4S)JTXM8:B_G+0NB"H8O'OC8W _LZB MT#2N+!)B12(2K;JFD12AY!G! ^LA:1=-
&F45_3RUF6*B)6A&FOY^&SO-@'^ MW:XBW7_K^G+L;5?10262G6GW!QNKX*K1=/NH4!MYGXDB>_Y?X*:V"?DO3
MV=4FV_"Z9A"N!PW"9E\$X8A2^M: W015TCY4(Q:0??J<200^UW=%>5GAFA M!8T&.SL!+Y5KY_D;
M@1^KW;+V/XL!LWG3UEFCK@QQ!RT"!>?T.U/*L4Q=146%5;\$*+!ZS<[HSJ=HQ M/M-W.B4*6V!
(Q^A*QOCV#JLTCASJ!JF*0)RG:*2L'BS_2!>_U%.H+?I&:T M!JGL32M^DOUWADZ4G&!*YM2U8HZ?
97!5!SH_MO!ZFN7=JYI-\$UB_!2A&M#)HAP30&@ZF\$V..!/@JH5D!@K0 M?QQE =%>[N0+2X!+^&0V\$C#!OHUL\$
(?7!W+>FVOZJ!/H2*%<-W9HL01A"S M_-L!10G/X+!1*1(B"BB5G!-FHZZ0+GUPDI'7;E\$;@I!>2&/EG4YK-1/(Q#
M\$-TI/M:9&"ER3!/7K%\$^NP1!=8E37LJWADJLK0A'Y:"P M%G*RI\$! WOT@BL:V*T)+8+ME;30?%IWH^!D1-
XDY5(AR>C4E8."=Q)W5#7> M?(A!_ =5X&W"L9O)+^FP SPO5^\$ "@YB!P'3MH3;5G92%&DDHUUF'ARPL<
M7Z!1!RP/MLB-/4^3X?&J#V0=6 ==COQ4J>N^7Z\$SD.1>X"B9'K!HT5)@W=C MB94! M 9=R%-
_M=%=S\$18>%;P9VOME.BS4!U' YHDS_OP+B#!\$*Q*E.E:>X%A9N: M&5WGH?
4:'FI+L^NL;NWN'23FT=*2&HX>"J.(!&DML>VSTK MZ!@<&7>^>&GG?*<
YEAD>9,JF@0="RGVHXU)UB2YXC3;=P1R&W\$ M@=7!2.RLCZV=/G_2U)D=-
Z+X+>JUV"TP!E#Z\$%LKW2%AGJ!H+!E%_!H^!_!=
MZ/4>/CM2AVB\$!3DFDRM^10>&)Y2:6P_7S>Q\$AP;J'^7470>8Z/N5OH%3H: M!F!S@>T>-
P\$Z_Z6MSO#/L'=WP%&JE5_H+BW?O&*BH58\$7>CSEKM=@J-N MK7MM3/K^&D7ZEL^<\$GM65!D3=>5>3AGLI
#!N\$ AWP<\$-;IACZ^&^FUJ>.# MG4C@D!P@XJ2ND%XB8)JZ!*^EN(_ V,NYYB>D,H/N:);8,9>(_S=E>"<_H0
MF4";)2G2!0E0+;AMVJF^DM/FIC14O3KS(H!7 =E>EW3*N0X*C M@<"?
WE.YXP8Y0&M8KEO*SRP1!H!OFECB3JW!C.KOQ>E7ZN=YC4S.OLOIH&> M&YJ*SWL3_-+FJ?>[P7L3A7%)HL7YJ8/Z;
!(-V!J.XFVZ1!X\$H_KK^826B MP>#>Q@E7(JZFY!3D!V=-!4_(UIK0P%HZ*!JMT=M3!M6M"Y!\$?_33.FR@
M<<#R;@P1CN+!JZD8G!2>DY5:C.MN:0S!DPG@>OEN<MO=;H:4!O!6!3P;C. MQN=;A9P2=CDT(Q0?
7?)B!ROH!XO/P5FTY*BHGD>6,8VGRH<<&74!OEJ!V M?2X-&7ERC?=%#>Z;
!L65W;H:ATW\$*+NJZ"26PDH3ZIURJ@'6P!>!"H_E2 ML3V_ZGBQJW;+OK"G.J ME*8P\$M
FLD02:F29SUSNZ;UO@VN)0^=VMN#*2?T0^V>J/C4/V8GJ_.D=:AEO M!4?N!1<>>GFI^U%"!J:KY;I9I07?3'
FS1>+UEN!YT6!A(7Z6P("A75GQRD97FI E 6@-
M6J=#;BM55K3!ZGL&JO^F+DXE5)DL190!ZVMGW6%5%!3/Z*M9M;_&MRY6S5!-G!Z!9AG.#(JS4!D)K23)C^
(H54?D.(4S FWVUMI&\$+!88^& M=ROF.GGU/-+\$+A'HNN*5;/E!F ZD05!C=6I_*KMB@&BH?(IK*/P_H;\$^J M3AP-
%#41G!E6>4!F!D=^MEWGUSUSC'%;F5G*.FYF8-2> M8? R)JG,P?1'5U*
<8'G;N.=X06>FUJA#E#=#OSAG#!\$+!UG40L."USPB EG2 M-L);P<?_"UXKPC.Z1,-(%D?&!@I:)H=9JH(SX M=,
<L>U\$+D@!1M<?>7-5.M09N1BV<@4#>IPTMU_@Y@2-ZAE210;Y)8
MM%&3XPO5"U15D5X=%>:#_4YYFAJF<4VXE;0W#-
S9FOJ5F!>B9+&K%8+0//EV7T09>AJ<)"NP5K>#>R>#4!/_JH^/A7 M!2/@5!O=4!QE33E(&LYC<3NZT=A+WZ+?%
<>5S*WH_IVK/\$3G@L:ORE@;Z1ST!A\$TN7!V% MDI_B @F<+AZ/5D.A!0Y!APU6;DPI93YLT00+>J!R4N!-DVQS
MSWB\$VT*NGY?IH9WA@STCTNFEWHC!AP^E!G!T/5(D5O4Y/0Y?>M!@RD_&3\$ MDRI7M!#4:S3B;I
+6YQ9;ORMS=LY!KZ+49J:3MWJ?C5V>;WFB&MBEN>B3EL M^6NK!H!F20\$?M^FUY_TA(*"=,FPG9.GU^T-
3LUC!H6U;H?J!HC!Z!T M0;ZO>JNO@J2.R.H)=/O=-P5\$NAK2!H2E_X+T@S3A"BV:)*5H":3@HBV M 8:TX-
O:A41!3(O!G\$>>S"JA^&592C\$>QY1-G4D!-LWS%_W87R&IM M.EHCK<M4&7L)2!P!K(AQ45,S7HNP>8C<
MOHC@!H^Q WY!B?THD9O!42P"!?(=\$\$9/L(S<1K<(F0UZ"!Z-WV*U&80\$YXG
M=A2)5&0&/H!B3'HT>JO!2:F&"NF/N\$;JG3MS58R=0HXEP7-C#";W-0+<
M5J!C8QFH)LNWS(K)C'A0\MFY!7VC^VFGF_!F\$)Z7K&7^A6%@3+;CH!XGBW& M!>X7H<Z9*%(OM!UR2B&VGZ-
VZ3!P!1^HYSW0+VMY;E!7RF&4=Y*/H) M5(#FOH!#"WT%>Z+%NL9+.15D;CZKZIFP#L^V=#/=WJV='SQ!6D?
F8+1;N!L:@7TYD)^S";OZ.A M8NCUN;GGNUT+59MHBW!MW\$Q)+Q3S1/C6#WN@SO)3!>=W!H6\$486!E^_IA

M5Y20->J9F*=N4+";.&3ML!+;#+06!UB!<G<[9K/Z2*WGP>->|'9W&TIH^_W M4N'B-
TS4&NZ+L3TM)S5.AKKT^ZFFV Y4%3PKCM':3!*I_!B)\$[Z(2.59(Q*M=-.WFSDJQWFLM?TB#??!NPF2_XY1(H\$L=I!
(X' M_!O.0/JVL#!?Z0-")C_UFD#7ISKIE_5_JK4!>W7/8_4!M^*@T!+[_WW6BW!M)WU\$-A<8@!Y*#+/-
+0U7F0!JN^<14_!IQ03D0078(<^!20Y_?M^*C79-G3XSF?LAYO.IMOIG+S5TM?D'=. \$03G"4E8LPJ5YINJVEINA!-CI
M)CK+?28QH!H*T)+\$ZML4.6D1"B.YUV&I\$V(#&:R \$#E.H8BL:Q CQWKL8Y CPTK@LH]=.%D:_MO@S"/^KHZ>+!
W7P>|K9?SSWE300_!9"?SK_N!:=;K@^MO^80>I%;PLH=9
M3T6\$Y4BFXCU.;&HBNJFA);.68I3PAV.&BY<.0Y;2X&%%&W5F2FSN::F*(?=-MC&4,^&/\$HDPIQ-2!*0D*O"L--
+#!@Y40=IENM)&<"5EL_F6!_G3ZW2!2O/H M.Y.VD)Q:("TUP7M8JS\UV\$2H%"
M(B@.#;.*V#9@!B@.3.@;Q>=IYOD+W!2!\$R/G>SP.@Q_\$(RPHEA1<_V.42K M3P7_#@^_Y/YP^W\$>-&C8\$&Y=6H?
=V;Q!VSY^H?>F/^9GRV;WC.0!;?PQARMW(87*9%?S?8_M_**AXO,?
7CYH_MO4"N67U(HJ9)+4,Z#A!Z*';W*D.O!#J@6L00IKJMSW;D.M>P30FO3);'->E\$F02Q9IT!W03<8
4"N;0Z!J.W4CJF=D+;.*.M\$!_M\$!&G&_T@T!G;J!Q^U8?6"9J^92)H8RRXYDCTSO'@P!F2K!H_!^OB7SI&W
M6(S6"Y4:(*T=BBF%?AVL= _Z1OY?)P_L.K!1V36(SI(CZ@T MLH!FA.%&H.L.M9A M>A^V_359CV7FX!9%PA
JLX7TR=4FR-#W^0_6F^!MA>&<.\$!2B0*OYHGT!
M!BV3\$K9!Y4"O*T'&77D((I+V!.*\$JX<*G%NLU1;20^ZQ80^5E#)LR\DB VS M+Z+PN_&S;YT1.W^0.%HY,U
MB.B\$%Z: 6C';JL&DO!/KC-%T4_JX# MG7:0?G9B6!;INH@[_N29#H)^&\$)4N4FD7MB;_XA:"^_F>"\$T.\$0)G)Q
M0H+ _Z1&V#JL-PS-?S_')9/S@-C!L%;RL!"ULO4VW72\$MFX!Y=R=96R#3!F! M#H.@YFD(I(9EU0:_J!(\$+U^C:2CDW-
UF\$X M(8%?XL^ED8)P?K/>(G#AC? M!@!RF#JEPUL/WJ!#!*!D8_#Z#^1GUH1(>^J#L*S #VFICSU\$2!H!9A
M<7L1D)I_!A(JHH'R+6!;HJWBR#:(9031"@1N+P5)!&0\$@!GL;N(C?I
MJ5:B!L1NVB)D)"^W&J2H!T0"TI0FCB_)%TP2^Z9IB&16=G%CVH MMM /GY\$E6)\$E!#4ME948/#?%4/Z3
SU!1.W*Y.U+(5<%\$R-"7@SB/1CY8MXW MA0QJO'4(R!8SR8GOEI J^N.NN.>>@7DJLY0+LLNNPW9
EO!D&RNKV+B_ \$!1 M@+ ^CN>K2;5V@.6+V!2 MP'_3 NE98& M-K0)0=ZKJPJO!>.5PZ!/%+(?
MOUD6!E\$3"0JC2Y(G9% &<@!+E=5!@_2DH7# M6A?+3CE++W\$
R0RL/<ILO"DXQYK!SV8GP'63!IXM'\$=E@OARQ=(M&T#ELXN;_0Z! \$!#;P:)*P!%#_!8W%B*D'Z!15JX3Z-
#R9_3L74@ MZF"^=QWV E)@E3=M00=-V;+!T=[X@AN; UK/L5PZ!)-KH"\$ \$*RGD%5!P\$_7
MX#>Z\$Z!F1!/"A!X#TR:2?C%;L_KCKNR:E_HU@PF_X3B MKZT(<I"U"\$F<I(/ 3L0;V+1 M% X>3:8@08.=:2 36)-
_5Z7^PO_QM-L!9"8/(3^K9;+@^"TL(F?_TE7^C)ZA M>5^X&S7681&RJZNLKRU=?
WY!MX_3D/DCS(LRW3=-050E=2KH!G-?C^M^W M.;5_00U_00U_00U_00W_#7M\$G5;K@,Q\$@.2/&>"H(J-
0#A)2_ WJW76>RQ?SIA323HK7% @+=DU\$!7 MKZA83-F(=,ZB_C(OZT9-
5P3JRJH!@LMZ!&!20<25^A!>^RWNN%;48^BOWF;E M\$ZZQ7H**/O,T4M!XCBPH.8<)63UJ,BDMPQJ;GGQ!?!
(P_7@GJWN";^O?5S(M<^=XGS0<^JFF+!>&T\$ZOPG)\$MGH=*G%5*\$S_Y=F@VR#?I.S<_1*7S(EW!;_M"+;2B?
J0%DE,IA! 2! Q:D<\$!/-C!N73ZC?)/90^!2%\$""(5&IEVM&T MG-P BORG5:OS%@5%/C@O.;63-M!>NYT025J-
\$W>UYELDAU2-WB770_F!Z+9!_4.6P^W334=T?_8R9T^@L8OWK^.?VN8MF
MJR6=2FX"LR6/B;L)K!&5WO;#GFI+TQOSJMTVCB MKO0MR4TWR?JMRI!%A_!KLZY%?@>
G!KPEC)XHT!0&@!E!>9!+!\$AS<M; 9HOP7T=9XJ0N&?
HWR%K#@7!):LCR/WC!OJ"LA/N9@W^!F50IR#%;TX MJ.3!\$C58BT!38!Z4QE,Y(O!D^!;SU @L2B)'D';
ALGYGOA00!/%?AM*_I MS(R#(PNL""!@2K@!786!#,\$='WY<\$L!&S-HG0WYL7F8"U0>=>^-\$*ULP 4V7" M94!B*R-
HS>\$9/3T_H-M,)=..X\$1 DT*;6LV^BJ@%A3I!)4"XYF>_GHCR7.^=4D)B?8DB>U!2PXF)E"L MAQ7\$3^!O'@^7_DL+
!B8PE!E7>T_."15S+6(!)Z?P!4 MMY&^O'6&A.UL;K!3=QR%^>^VFOQ6^@P%* YG!;8P=/6GY#(Q@GF#Y=3'O?
M5*LFSUR=MJ8_YOM?;0CVL1=OWGS@.204YV;7 M%A!H^(!J
3)GL#>B\$*W/HJ1K.5"PUFW.PK0J3DREA+!\$3JO'4SHG6VR-'=:9 M^EZ;EWF)!-2(?:(FT8
+L5A5!>=!600=MQQ04:5(^JP_EWZYL_E&693Z9<5G M=2Y2AX.^!EDO;^EFP<4X_"X=D#
!G*\$#K5/5@M44!4C4V_!JN+/P0!MAS?OBPCX-1#)\$S;E53-NC L MF-O688!>@U!_N^Q07R#5)N
//@92G20IM3MR-1S=JBO#GRK(N)9JTW20& M_R!=U_0!GG!90!1BG\$2+%K->
(YS78=I;WK)0J2!2R1F)=L!P/NFZF"5SJS31 MT_P%L!C6_?
H5VZ/B65M0YT#VO2!KL.TDZ'FY*#BX^*3&B\$!Q!B@""0!GI4+J M#H31?>S5Z)-
JR/3#4.2(!NXC<+PFXFMCI+H^*L>>?QRL=TWY!6;#T M8*E<*)XBA_TV(4""WDG!5D)2@B:%N#NPQ5-O
\$4R,\$&>'<^J:@!)\$QU=F(M9!5/1P=7J&5PAX^O!7!T.TD!2BKS)X5Y*T.2C&5:7M""#S,1S%TBTM!3""C
M).TEU3+G\$;IMO6'Y_'GKP^E1+<\$2_U?*:4L.C)*!&HM)A%\$!SM;+!<M=Z>1#8#1U;.@9E/!U2>3+,YPR/(_L-
JL)U3^U;7E?K!(!AAH!Q;JU"IF+;Q!&.;0N MG*B^!O4A'_=_JB+6=QB;)MJ0)4W^I2JPD-M4
Y!F!>B4)0GU!*PMUP.P_!0 # HP\$W8Z=U+E;SR9J)^(!83USBZ<^!N!%K MT+K\$>6W.W>R8CL8/PZ-
@#U.CA!WX\$UWNAXA\$A;6:L!W^W=XJ:T^*^OG;BUK'P_.!T?60=MDU; M&U5WIGNIVTH^C;5M?
MH3:"8T9;06JXCXAI\$!4&TITS65BU"#PW0_S0EOC MX<'=+!N-AK0\$NUN0QF>3+;0S63C!>?AC B!^I
3!S@_"7UFW6@9Z M^HC1(IGDU3K.K5ZQ(Y@:6Z?>=@SQ!AMP@6&48+3Q-8?QD=:7!P!@JV"<W M#NW!?
^VH2%XW%(T%6W"6UI/"L^W.7-.6#<("UP"Z^V+D#6+=.8Q#T9+. M-X\$>^MCV;<*R#13H
.:N(X!^-2<13M!AY^3Q-ZZX+AZA0!RB"XG(=5SMOC MSN!>&<_.9?X/>N.M!3PK@#2P!D.P4=NV;9UWO\$K18--
!#BMR8XX&=53J_M'9-K5Q!468C!-M'.UF\$)!GO(OH3JY<"D"4;/9;.%9D)W7!SFL8S!S)=
MB!)L\$NB;R.8%Z10G.4CMC-^MECP!XM.Y95F.OV<ZX/FL@.BNK!/T"N!U+2.DSOASDG
MDSNC6DA^3LH1(OH8B^CO!JXGS_H! T)!L?APK;!K&DP2A/9=W^*U*Y>BB MB SXS?FTBLXY_!A+ /1SXC@
/HM=J!P!>LGZF)DMSM;JMLWAEB2^T";EG&; M'+B7L_!@"5DO/Y J)="!7!U%6)-QEF_Z)CQ\ ZMOHUR"/&.1.<->6-
:NU M8@""PWO=QJ?&B>8.54^V->)4N\$@N)3!** X4&4Q:68B472JEU95: ^B%GTR5R07%3!/?
R!MB0KK0@KZ\$+ELY(=(^WENW5)3M#> M/>_8K"CQDUG-#!_FYGR!@XV0!FXJR"ADI2^<9<^!B%@XV"
(DGAZ_@O&J^O1 M11&5M#%ZT#I>MRQ^2.71+\$7\$ _\$KZJ+!UYNFH?HEQ!DHZYKB(M.\$!G81C-
@>30J=0FURAD;BAI;\$!R1(F-.88HW\$?3QYV, *F&=L/Z8?SJ=1 M 3R%@M<^"XN/!5!_2M (0\$66")/SL&G2ZN4!;3L-
H\$J@_RAW_+9Q&^W6B!UW8W_-(6;O-1J^>DWA;N9 IE4N;L4!;51G M*/^H4V>_>6!0!WT!VWO>A2;)S^/U+(!T?
H;J!8W.ND=(M=@>W@.AV+KRA)RNWH%+I978Q9!K!MAB%;H5!RXD!C>5S(_!P?DL@2J>5'
M.;&*4M!KME(7KE(V!ZU5^&3.9=X3#OWH1/\$!5(FOM^ M&A?Y_-
N=;3(L;X\$;_DMUHKC>.%Q^WLH8/M%\$ _!ROYK^I GM76BEH0@DN4* M)^!P5>
(3);.\$K62BLR9DOYH!D1AP7K%0J.KN&"CM;DO"34!"LO7OXW\$=T8Z53?&?SB>I/N^!E!E) MSRJI=-
%90#>S;L4+;V4-M7K;7P^07O)=5WZIN@>+8/B:=V@^G2Q-B!W'M); MV^I29YK0.HS:3&6!EYJ2UX(12.4.;F=+7I-
.:10X) K12FH8N^(!Q5MYEU M6/BVB^NP)RJT*(P8T'P%Y)M_LPL;U5FY#K.>#R1/!DZU^X2F*8V^E31UAR!
M!D+>_3B!T_1>B.SC">_G1*;KRPNS7&T!2JXZ%9"Y^DU!^*4H8N;BNQCG
M=RM_9=40\$=5R2GARME(=)G%DO@A:=!N0!&IQ(XXQ ELAYB6R?>-U<1VT;#P M!1.CP_)<=>D WB0!O!V?<
JR04(3;_*?_1/6=-.9 MO!9+N1#\$!JW#/IN@(>)XS0=X.8 P-NT0.0!X57 /X#B(8W.5+ TIUO*!^G/M7WCG9;(B^!&
=F!G!@_M6A"32!1G!SA0!^I-371HFO0QK)1Z%#X.YW_8"OH@0#FYWZ0L.+ #60_P=
M8!_DI&P&1U5G)1A.)FN^;RBMU5576!OA.UV!(&S2=%N7/9Z;R:4PZ!WD(SZ6&#AJ5C!SH28LS95LTHO0?
M!N9C!Q>^)U*247QKX7Q@%V(OYJ"K_T(=P#8=.^!JDU^R6'_ \$ _L8+7HY0L=O M(KZ\$?7Y8??.\$V!QU9ZLRCS
T22BR!JY3-B^2Z?QY+@.UW+=S2&DJJD=M7U(MQPK*!425;ANE)>44\$>OPC

M)ID1S29+.D:-6+.O(CR51;+1+9QCNDVHU3%./Y M#=-YE%>|STS^CWYUWF+N^61R7<?*2=K
M8A|4JX'O38=T6TZ#\$.&A|P@ZY!40.V:~^|K P^WF&AX#=#A*|2|'1M3E^V@*XSY|<6A,N/X^K2Y'JGW4UA8US:BC#-
+~ZSB=6<&M1-BIE'(<.2V0X207|HX+BXVG.O)'T/LI?7.YC)NT1!W6LR+YJ&'1F|E7-1|
MQO<5K3MG7%SC2|Q;~^*O|Q>*S?ZDY'AVS+=CZ=#2)Y25--4)C(Z&7@^U)N^+X7='YB7S|,-MW/%!>?
|A772G'9RB1*(TC)U.T%GZ-^B:~^01Z- FE3PG3?&C:))2WF%|_ MJFY:=#>*VY\$R" T" J2=(8@0FSQ6078
Q43'.L7*DO^P\$IN%"+KN\$O\$NT% M\$;DX< E5W!+CSLJS8R|+5N/N|W/URV=.(0 3L'QQ(.D)P'>::QD%,"|A
M|**/TA9R4(.P&D5?D&^R+M'5I94F*1|ZA;JE^S^5|1RQ.&3*A/*JU=I'5L2
M/4M(Z5R5E@H@7%@MZ9DB9|1H2D>^Q:Q+>'QQ*)&7|/.1RK7?X*|H F !(-MGOHM:V)S(FM5B|S=TYPM!'6O
DWP-GAW(4)ZNYHDM0P5;L..~^H|U;#=-F|SM45@.S*5D.^2VO;:2#U7.M7:2
M%|_9%\$4JHYA|HLRK>RT+5U'12|8.@OLH|H8?MN&PGQ MTU)H?%#HN/ ZSOV+:O*-"BPW8%F)0*W%J+Q'
A'3GZ@1NE-IS(B7%NL|O) M'7&!.GAQ559VW_APGC>|Z|37M@'10YY%BI=O|:L9W|^)3^<+2YD|
M\$D0G@O>51OAY|G<3(|YVU|1B|UY.-J.YOKG@W^U|PG5Q@>OL|529"Y M?2
2|1"B>=J24R1U\$|JTW%L1|Q1.#.^EH3U(TSTQ?4B.-Z.MUG-1M*C4Z9@0 MBE12%J44MHM;?69965!>2<""3+
19:LYY6R7HQM3|1:4.#Y8C8T419M:/P M 'O3EB8D#/#L/6R<+BYW|W"8E)6IC8!-C->N.>0YH,8%HX1*)NK-LI\$|V-|J
M-X=/TC(#-QKHU_@T.^P'6';(0EY3|3VR;76/U>PI5:M4OUH|D1L?|>(7E#U
M5I2Z'M4H|9%+9(-W_H|%;L|D)@^R4A5J;T;22|~J|L(V 0@P2L1>Y?AUU?>(@D M&Z_#|C""Y*7>""*_XW""Z-
X8W|!@^S7F\$K\$|J\$B,="Y91#S\$D|LS2UH"CG7FFK;|Z%|07 M#|;=9>TYO4Z1MWO:'R|O:~*3S>'1T22/V5!
(BHJ4Q%K" XUA7)Z;KV|P=3;% MK>'R3O K94MYN:6R^|F:6/4#%RQ0+;MO9^Q>_/J5|6?B@VI1Y@E:B(C"#3G:
MQF93TOWCS-W|PJ8<<26W/87|CA|H(JG.-/8M1C-FQ8\$DZV OJS RE MLX'\$48J;XSR147,5N
+69E.0|6\$Y;GDLO.Y2ER -&P* #5M|JDPBL&V|/N@ M3|X;=Z4F_7*~W^;D&4,8#;W';
|!XA^\$46;4V'9HMEPI|A,1|0|-.U+5'S|Z! M1EGNA! "FANO-(3YQLX|
^PO"3)>%B|04XZ\$;LVQ@9_OH!_8|RWEC(LMF\$(9
M&RE;|X5X=|)F@:6BQQ2'7#W1M'.0|K.N=F4|/k@;A<4UA+C=7X,&|1>7_:
MU4L@IX'ZX"MP#+NFD/EF/^"7K.J OR'X#QLZNV9^/PO2ZBNH&6@O(?&!;0:9 M"/OP>|H;UG|@#|D3\$4@O?R6AF?
L1L9XLC&C9/QO+4)Z1+7?6T&TE+-N;3XH M-|GWG0EIX+F=|!-M'://> K&PQ=-Q|A*Q/(-6MV*~W022<-67|3G\$;S;!
M7K#B=D:~%#U0WP)4 S,7|+H\$NKKGW|N;J=U3|G'.RWFYKY5 MD+2=2H:Y1D' MH0%UM?
HSG1|8X6MP.S1|!F&OE!:=!<7DH3Y^D3X.F&6"V+|J^"X"AA M_!|"0 ^BT<|)@1.RYN.N'S|I>9_/^3."<-
W_1|F#0VMU-WXV"1).YNZ9 MGQ^M03VN9>Y+VX;= M_2S4T-DY"51&:%W#|=MFSQV'XXZP_~RK|<70;:D
M'\$PVHSB%8*1H:0TI?V: %%8AJ%:ASA00+#+%)3&)%?QQSWZ.LNO|'(P62BRW M-6?
T|^T4ZVM5LI@J=C:)W#AF1OR)2Q.WPKHV(C&=IODE2#L"5%VXJPT<#?3 MO3*D45NQ;
(639WIMJ.@JUC7E|B/SF|OWT7'-YWB/EIS.GMA);IPI|=~Y M&3*<&T&LKL 7/>1W*ASC0_-PIDDX|VTA5ISC;:1?
%N>DBP8_Z>CINJ8#| M?8FU|TU|NF-8.TI37/'=F_25L510F_A|H9U::MBPST%UZD"3Q5#;JQ>LS
MO|6R?~1Z8,NY>:/#T57ZQ07%\$6I'9%;AYTL>.W"O|'ODUBEDB9:8 7C-M-?GD3MM\$~/OIT9*WNXF(&?
#9N@X+15|A&?/34M9AC=4R?7>*A9F%^-(15TOZ\$FEU5;\$E7_OBM<=>=?TUP-50XB^1X|@0(AH5)|4O|Z;G(^"9?
OUM|>=YH9*&^~|&A8|EY9F:G3%A M/#=Q#A|_3(K&E4P=|!\$|SE|@<8|Q6'H8D@>5>+DG:7O_-N2P9J|RLNW82-|I
M1VK8Y<=230G2K2|>+HJ M S*2EF84-|@XR.D2B5|K00:A((6)7E2EP<\$XP#UP@VX'M9&C
E:+%LAFS',0|9K|.D="AZK/ DB,%G!;IUIH&7>)>\$.LBQ
M9G0C_ \$81=|YY"JX%>Y@I2.NF7*ZTYZ_1=029\$<#%O;1807B6C*G2_9M;|P@ M_?GIV;|_O:~?>&|!
D5^>T|J>J3WSX6FR|CV8%/#T3\$K5BSG;Z MU'JQ|L|L5%&LNX;26|_1|7Y\$;K-MZW|
MH4AR*=X9+PS4ZI!\$;OL<6&FL%VXNC*>M/_9R09*CHP%>I1*~L9>9_*U3 VVK=-J#OM*2B |15Q==Q.UISI&-+~Y/C
M3 |A9)^P|ZN91#C7)2:P2^G<*R+%F<7HIW<5%|'9%>9,JZM'!%3,Y^~|JY|
M1""Y4|(-_51FP0YCCV'.780VJHY\$G34O9&6FS^/B"%KJZMVY=-XM>OBI M&|1NG>\$T28^Y+8QS;)4RFOJH8R%\$
ONTG4PY1|_0L#>J*<8"SM M-8FNKW|U; M_7H^Q_6YGEQ+C.O2R=>4""^O@BG50|_36='#EBK|FG6|T|H%M^;
|51*7SG-;JV=F_9(|S|(U-)H6|Q&8N)Z8X9Y*6|""|S\$Y&P;LS^ MX|JAYX|BYJ|2^G;=G'II+OF8O3PE.=3-
VERM.LOHJCO_~PI*KK;SY^@O;A' MX7>*~^NV.^9|A;Z1@%*M%<2&OD.|9;LC#|VWO_H&'+O6^:'R'EWT42/I.<&
MNK1OU/R1|)T#)U^R?TWBSS_1+|%J'VQ0KC%V0G/_F6F|GLML6E#P1#Q8&_ WX MJ^T 4X9V@|BPIP%0?
14(#UF^=COAXA+&|MDQ6|L2M\$N:#DZWW8D748.XY# M?A4BB)WN=MUVLF0--B1R(B|V%\$)SN5_TX^~UXR5
VXZ^)^T|@%W>)C13THG M|T-AN^OI7UZM_FFE7Q&04?E/1#GJ59QW6G(+YP/P<4H^IM=A4GC.|^2OZQD9H
M40/X:#08%RT1NH%@C>NPOB3LVOGHEG*(MA5P+MK|SE|^-(V13OW/WDA3Z|H_ M=7.D+|&
T3KL= X&WD)96_H)121BCB?26CB8_-+4LJ;<C(XV;I&^=IR-N67 M^IP+7F-XC|JR?T(7\$G2:0S|V94+6?
U6H|!\$T5G=Y;D)=XL=OFR>YCO|VT; MR|JG;:>P/10W;YE;A UZGOMD|2^U74J_ P+ZW*+U&MD|FN*
B0M|MI2_-&A M|)T7E)+Y3)2|Z&?6D>P B6W6861|30WSDCLLCT|Q>Y3K@BYO;W=@LP'7@30/)PI.H9AGVRB%
M8!@~BEG)W=; XG3T2J+8.@R+IQ_-'ZN+84Q-D+G YE\$A2'P>D-Q,F%~R1I
M|5X5R;19\$%KPP\$|TR*Z&|&LMX|HG78 L(-.9&C^~Q2KT\$9GG;_YS>
M/GWX|3|N2E%\$C\$1"ZQ9H|(*)X6HZ_I9WL.HH-BF<^(-ZX0W<|/L|? WALK|1P|Y5M=|PWN_65=|/1-DC(I-RE=Z-
<>KPOKN|J#0^ M| W+|WID| X'I 1=AT|ML+6-2H_GM3|&?3|H&^2CD4+XFC5OFHHS*130.VW
M.CST4UKG4AR*4HR3|8P8JOFS3FK_5FX6(-8N3%546BJW"4\$Y@MCD|LVK08#O MW
_7U%TMFX>AJR'&GOOX)3JX88N_H6|V;E.#M3C;IMEO*W"AM(>ST%610#A?T(V'Y|%+8W_139_/W;"1+@^6C(9BX-
HL_ M<'+CAO\$|WS"^W8,>X,4T|C|SG785PM0'X+"9YRT|QA9X"L4O|A_"@||WFG M7=DZ;(|I9>A|
T|>P6I8>SSYDF>M|N|GN-8|9_6'(83H\$QK?|O A8H=F|U M%MT \$PI5_L;-_%RQ-MWA.1(M_?)<|E9 MW9|Q??
DJNK60V|DZ+U@&/_D0^I6?2>H?Y2H|B)|@5%VQ;|N^;+2BEIF0 MFE_W;8AV\$%K" |&TD\$P(6'9N9!>>#\$\$FDO"-Q8
T5H;O<8;400K|I9S\$R6 M>0=^L@_T@H_7F+;I^//OYA#|0G;0A#0B|*U6;Y_ WCM:A_2XV@0Y|VAFXV?
M7"?TB1D2M&0"6%|3)"I (73&#+6O:@-;J&K\$QV YO|_2K 5S=(2^X0|+CK M_26BV1\$ |-=A<5#2F@\$(GYDF|
M**8E*SEKV|8*8AX-U'U9FG#QH2.)-H?;Z|Z\$ PX2'LLG1QCH% M-N<#|K#2JU50|G74M8_-18NH28;C0EZ;VO%
<>NW2U'515N697F)+D7#OVL M:0/C|H3F&PW|~|63|G|WL#SOQ6)E_|CM-(-?Q|8W;7R_PX760\$2\$(C| MM
4B9'0'08% 408"Y.)PMY@|E2 BH0I0@ZL|*5W>J=>4G%NAQN(9,LXU|HX MU-C>MN7%_D6C_#HQ%6|_W7B5|
|S#G(7@%Z;6|_#670|1%:U|>%Q<1;3A.W_ M_P^49\$8.HF\$(8-\$2>';O C/17WXF.M.HM|QCG3(>")~64&Q>B-B_-NE?
|!_V_F M)&NM,4 '@9F_'#L4@Y#;G)A!IOZ!)TU5

/4D|5P|>>Q%5>;SW MUP;N)%*+_Y%GV|1|9O3AT|3W<_9@%L|"(R|PIE%_QH#D81+P&O|P+Z?_U.C@1Q*10@B/
MCH'PJZOT:\$ER4@B/UV%#13.GD+-(VKD|!_E#?<|Q7KS3Y?>|7O"B|OK>" M3_~RS6J|(""?
10Q_A\$|%L*A*MZ@~MEU|VN&+|M=PI3Y|_M\$*MQ39EK7E&33
M.C#EXC241B&%L;C_X*4W>4|0FOM3"E&M0=8C_3 JVC.M3PLT(%E)B&8S^G|
M.A@H_MWDI8|;+.(=)S8M;HA3DIE4#F MI/W|104VE(W)J-
_3|>@|H^_0@/!G&NC3+|YA9Q|3BAY3B;X>*EY=\$Q%L MSQIUN?I*1ERR=\$'O5M|+AJ4."LE4#H%F|E\$?
2*@C9M#4>|4V2X7I#==3 AE M|T+90|T%6=|F2|)V=\$ (K9 |P;~2M;|>I5N|)~AD4-Z+Y|TS0! M^Q%\$28KB|H|
/Z=;|BOV2PB3-^G%4P"OP8|KBWT|JC6ANH'O1/L|_6;HDN
MNKNXR6|/|7=73|;RZI^@C|B.^QTBA_6G|!EB=15Y%>10?);#OI'I")O M+|FF+Z*_?

_,HK_*U5V 4#=-1\WT&.0\H3*!WK\$^' Q^(V20\$)>)(7T:)PS5Iz
MZ95ZHXR.#ZG+PL=@.N4KDY):Y07R#T)S/(#8F.,I2,@M<9N<,3X#3SI*!F#M M.,B\$?1M3
HD8#92\XL#OUC,"5KY"?7.8#<[VLWWK=<9(RQ:S01 A:W /<^< M2?3"-
Q>X'<9\J5I_8R3:%4L<96I2\NU@D>8)ZS.88R*2X8HC\R3S1 A&)"W3 M8A6O+* [U9^?&.[?3-83_-6CG3H+&=-
10DVY\JMP&I&\$.J28D\$FJ26#&\$X ML"B:#1.6.(V/C=\$1%QA_-L.O*2\$.9LV.41D9_4V6FP-6JL.I>4OKS"IF81E MFYQI3*7?
81SJK.'IY3N@KN:56\$?+*!7>\$^0) Y4AV3N.HC_9W2(_O4HMO/9I6I^M7*^!15=:02(Q)/MA8>M. R3M#.LZ/X#_EX?
%C5^:5Q MUA+=V@J8_Y@Z#)O4YQ")K\BB6%,7X1)'FV/5I=I S7E'B(IQYI;Y@A(M9 H_F56I\$)H+^O4R5G-H):4%\$
M'@H\3/O0M:U7A-@_R14:/<%F2G6L(3Y+H;H^+ MNL:%YAPK*H-
Y4\|SXA(3I%Q.&1B7*4@N>|K9!+Q(^D"DK.39%P_5AJ>5^E M_XE84ASWUD\@N!'&=?=K/(M#YO/F?*CG_KB/
P)K>84=HTM X=I M(WPH<_.R-1:W?)_PC_4%G0K!Q.JC@&UP!QW>7>O7>|*V\$Z*Z/&*I+6S3IC M#41+=X!
7<_Z+^#O>S=?OT-DK&ID7&\$J4K&2W05.Y1.UA%U6HN\U)I-X\ MB@C#-I9T"FM?@YSAP9;#(H?!"WB1^I?
K90DFV4*G&JDBO:N0L5?HD2%>^9V7!=/@.(38A)*+R"YTI<6Z2+ M+M-
&S\I\$&O1:3Z#/(@;HC(HM"D24! #U)"&N)IG%D#=C0+(B'R)GD\X\O\BLWC MH?
S>_ %19\$MC7\I(6:)5MD)&FR5\$*6O.JR1:P)"1.2.R+Q-"\$5-D"XU\I@|& M4DF*;&.9A5+99EK&G5E\;^&^?
K^_G_@X8I\SNMA\I?Q(^// M-6<%KK_P80@?R#%16&CX\Y049\FSC<4\$/:SP0,:%?V;I#M\WV\$N<^X+N1 MI
\$*M(F)Y5&.DN+58P&F+NZO*SXL>R:U8.KR:F\XL.M3HIS_JN:7SC62/M_HC'&(1SH#2Y88H"AQ9IG?-
(E:\$8V\K84CGGCD3'V)/O/VX3R+DVCHRJ MW3'IC(TP%RM8QU\LK-
_D+?!&*A64914V7I(!\$2D<Y_4IV9B\$GYU+_UR>M:ZM<^UO>_I MKWKKAZ&Z^I\$C.,
EQ&)\V_PQ"9W%NR":51H^"N\57VO)MXSAXW\5<_E'ST\?2'F"VW#>%O)P8DWE#U+ #U&_)C\$H:*Y/6
MH6=ZTY^15.Y4*H0V&Y4Z91B9&>IG'Y*G+^' OPHN*RG1?2L S6ZKO:3V# MR'1WO^/JE^8.\$TX>US3V/
M6==Z&_I>5L#W\$0\$+4@I\$;=(7\$UV\1.8I?Z3_+&+GK@C&=I ZO7_7EU(I BZ
M@M4+18X++B:RG9&_GL3>|UZ^I"A/O1 M:TIN Y&DI2"5V0>^T@.O+|1EK;E_BW_)@JR5#6N6?WYOS?
+ED=RNJ.<^&FRR?.%'U9U0*&>9%|YK#A-WGY\5-7US&NI(=ID8Q9IW
M.5=)XJU80E8PPYZW3P8(UFC9A@.@JIMZVNY% \$:2#|U\HZZ0X\5):MW)+DR_M93Z((N6K)IVED=-732R:|S|
(VX+R1&L_90J_-I P2D_O@T):.7.+|\$XDPX_M\!\$/'@=X7UL?1OBS3SS\$S:-CMR<67K3DC\SWI2"JQ6
M\$0."/VA\NYUADK>8J;SLU>BXV7ZRNU)JW@N_6:(R^RGFT6\$>OC90&3:N_?EW M\1)YV\VDX&1^45Z8LJ/S^L6CF?
M_,OZ\I\Z@1":FTP3RRTF[<N86)OW\+ M60X@5*^UD^N=0#&G05OQ1\$E;GFW\MAVA1H76_P\WXBPF?I?
AL;+*7"QY_M3,\$0AM9_42"JOI(42*4512OJ>%I?2 F*>A\NYBYHGCN M"!TGNVRWU>LI7 ^@5ZH0(IC60"
<_1T6/>X66@Q%&KL\I9#HD)68E60*!%L M3_%MYIFHFOF9\$8&6N.;UJU>U:
I7/XJ:>+I9^ODI^/YAD">+;_4'Z9N&L\$^M\?IW9_9-R*\$2*VB-.%ZH3-XWCXT-
XMSE"%*J BEB2E=R>W:RM@23%Z3G7)* M6EK9_&S>&R(OX:7A_JAQ\%4M^UC\^H=Y)XX.@61Y@
&&P8\$FJB*=T^9XF=D M8C+G.;RKX>|;#2U?AU@?&Z#%VLZFO(=I=F^6UC)MSDGL:M#ZKX3"C3>C\INU MY%I-
G"(@KVEO)'7_1%P.N=E#A*\$Z6?NF_7G34/\$LHN29MJMA=)M-H=_I\VM@1 M>SS;T2Q:8@?3 P9U0=GW-
<<@&)'J:YR=GIDOL:G#UWLL(MR'4)@3C2MCL%;UM\8&Z6>8\$(;%OHMCV/)E3?)K MYZ%2/>Y'G-Y
QK&Q_IUOLJO*F1%@EIJZ.G\$2VC/8CIE:1%#03U8_-M)6NBB7KUG/GP9K@*W_=G>O+H\UQAV;(+Y>G;S
MJ+YU'ZW1Y%O<2=-.S0#J#W3\5\HX;&H\O\N)DRX^F-TE#E\O?!\@T=GMJ#D46KRJB@I OW.%2.
(8#%*W(GBZBP_8\$EBHZ6BXC?2\$O# MH_/B:_OIFGGY\$)I EBE/P5J#R J#88^3ZP5GT&0;DO_0'NPD@9ZVE!CO
M\ M'67R.Q HCU?IXVO7VPWI2%I(H\7J9S\HJ&3";YJ6GM^I@X?0S8_3>= MO692^N%)N/K-@;_ ^IY.O:9(UPXR-
MR8^Q)?G2_-BU(H>?>JVK_=MG&)O7# M*7>(40"IV\JIEC?I\I\Z\AX%D@B=RC@T)@C?+K3G1H&1_58;"<1:P)?
_VHASW/ @(\VYXUCI#DIAQ.TD/N;=@R9>N8%3Q74=?I.&3G&/_L_2Y3RP/8'HK*.*8_P>CM;G MU"6>177!_.#4-JRL5
M.C/>|L"9>#+|I\$^XU_#^U7APMQ7\$%,74&#F6D37&5&-IFO+5E: ^U#O9P-L2 M7LPY9L..()&)LF#
(XA@N4."PW%HI1B)V4'4+AW\$KB4\$E@\$86NQ06NFXQ;D* MU/\$OSU^_V3J>R1=2WN;EG(K5J6>M_L4-
'J\GW:L@<VH1:RF1A_4'&9B03%_6 MH:)>R:4J8@>.9E>@63.M'6_ W5UDNX\HHD,\N\)=E3U^Q(45\7:K"R9
M#%...!1KA OF#6JK+O A\Y\ M6>F#BUN8TU>&E<+VH*P94\D(VR^J.5OBK*1O
M,S=SY%P.MLP314YQOU\G'D+C5W@/_UEHOW2B0Z6#|<^>+X*;>LFMME>2PW/ M:&H3*=-L_EH\$;LU=H "FB#
<I;#L>*^@E_2IE0FDM=LJ.S\=@8F/G2MK'Y_MK\I0E?25NK4F_ GK"EH+ #A4W>%T\^#X+&A<*,QYH\@
|8(+^AUFN\HYT\$ L M3IF<9VF&@VE'...+I26^LF6'Q'F^W=N#5X6XZM52H: "%=Z.EK+T-Z8\$U;
MU@TO@02"!*/D?;*SI5#_)JW)K&QR2RW2J#S\X*RB#HVU#4HC03G=W\N8_M52HN_-VEL_&7TT((AEKPM-
#D@+6U\NL+MV)"_JET@MC.I('O/2-F2FAO4_ M4&+;GAI'2=0Z1M1>)0P
YV*0>*T+_IM.C\1.5%T#66^B2I%D<^ICTRW) N\I L O@D2?O2;2
MV\N/(B19Y/&T\$G/R\ M.O9*>E)XMS\$.00D4#5D* SR.\$?(Z?R8(XCL1H
MKDFO8>@%2Q\$09S\$H4\89;X%"J\$SLWANT#8%: ^_DS3=-CYRIYNX\W6RJFO_1Q
M:B.+WVB_-2Q95V^WM^_C\1GWHIT9);#X:(A6^CQ.5&>5+Q<("VC^08QX2D\I/ M7'L3?/D?IS)(6C#0."A'-
RQ)E*MQ8YI=9>YAIR^_AX86\^QQ_IK>%*4@> M3=#OB>(I"\$KZ"UK\ P_V)JME\H9_MBY#Z.245=&M-
KR2W*7\K3_XF\ M\I?2WMUF@SIE3(E4PC9\$!_O6R1^(F=P^S#YC-T96&7U#!!GP<^@)U5;@RLO M)R-
CHM?K(C\WJ^POMKA4'651SG++B1GTL\SUN9K2(C_MWLLQKIT6"ZD?4B)_T!=0L*5"\$J*#\DRBF*6@P;4CRYT/I?
\$;XY>2"MGY= MP2\$V3IRITJ.6>?P0\MV&HZHY(GM@_QG_HS\3H1&IQMQJS.YL>EJFXGEKA
M35FO\2\^QMSE\TY+&_I\MAA\ M"TG>#S_*8M^>DZFC*V*Z57JEN9_\$ALW
MP8)U&SV"42R@85(MY9\YR<|O5\AHZSL0CN|=5>"IU1S5W5;_C?KW8E5GB_M9'Q^H_"/.KE\BBZ)D>:PIH&0D"?
Z@*%&.\$BP0%/I\N:05KMOG++@AA:S="H M4)AU5X?XH0\W:AL/_ TBL+5?OA(M\?)9+E408V4T^#R(A*BYCW%(W))
IPI MH\AUH5T7%3JG=Y\$F*W2B@A%:CAI%>_XBUC\I M+<I^1D5\TG_8="7J'EJ\I Z73G1(9)V)^?
7LY=W#6;^<2K%K#EX<CEEBWMA M03\QVF@F'2Z\,F%"
MDSDP4'K:&_>L\5NGG&="9R81JOT'B9.Z=1E6&+WWW6-6YK=M=|<6.N.J0<I M)V?
QNTUTPY\1_62G/(<@<AZ**>LPJWBF#X*?"@L@;&H\$7G@J6W="KGUBZJ-?M3@1T:"G%X_W8\GX\I
(\AFN\4UL)Q="ZV_?IM&G+O?;%C5+RGZ_8EKL'PA_Z8I99=#JH?>I4DYI+\$ %H5#^82"V\I%Q M*YQUD3E.O^T8-
K)=HN+5;))\W5)62&1S\OZ\ATGG3I6-L<#^Z^T0/ C&M6DO V+EP\$4B;I@/I\T+^SLJT>U7L6\$6FGCGEJ+;
MW:;W%7R.^U\5O7C=F.\RA(H(MAL_LVHA;WF_6TI*85WO3OFAX9E+KQ:F) MH_Q97.%G!/?<%@RU&MYJNLH\$^_P.
I&9+H+2_OO7\X.Q:'O\$(;_XVS7YH')4 M_CH M2YVUB7B=I;-7SMSR*Z=3QQ#Y&;@8#TS^@^@#(0ED\I
(T=P8&/_O8T>_<ME^S\A/*^4=I*WE>XE?2EZ\$PI/-J+1KMDK^D=>*E?QXZJP.Z#0^P Q?AE M.A_G&?PP-
A#W\$MF'XQ'40S<*4FD&6H&_T1891LEHJD\VHP9OZEAO\ MX\20\I>"R\I-R;R9*DI&&+LRD@H:Q*#D\W..5_5-
I?_YYPAMYB\CL'E0; MCB*7O@'X(U(0#&>_LX%Q\I4Q@5.PC:D>8HC4\03EF".^S J>X\#E%"1S.7\B_8C_VP@=9\45L:
MY3(1_KA=OH5? MKR13#85UJ?H52&\JRDD\X6\YNC\ M_C6; JH7CFR.G337H/9^/BH)TDL+I%_OW?>Q
MM"75+IQE\I7\$R9MAPH>R\I(F<(P+B&G<*6XE\08E\5->P_S:T5RU0IR2D)@ M:&T2'A(Y;&I&AGMMMC0HO-
OO%_3\K+&B'SH7A\SH_R\$IR^W"AZV0DS%-957 M#F"D5F3UP)0I&L37.UXVU%AE.^_5JS_6O2?78A-Z(>H&
<316F:#@0&I\$ MA\#6@M5_H+)|AS(&Y^@Q0?GMR=A.368.Z8)B7FL+IWEHQ)<\$Y.8;SP-6X\K
MR\7UK^W4<_C8?FOYCCO38\ VC:29#,%3I^?BFGKH=G4O_I=9WF"X83\,SF)\$@3=X=5D5ZC9.68LM\K(=Q.&Z
MC03FXSDT'XC=Z_&H4K&&3(Y7_XAMK*1J&\N)<9&@^U\$?%AH686I=-T0YI MZ74N4\$U;X 7"+%#1._FD0:%3;?
I^+5%IA#8@1F>CT&1_TPM;(<.=)X374<3R6\?_"9F<^<^_#NS)PX\A95\$1F8\

MB&2K7K..MFIWRKILE[H<)^A"+F..IG=J+CHJ6)RC;DCI(+?BU(Z5LYI&I&*IB:#1JOARIFI(GIAB6K183G&=:NF@)
M(LCCVNAQ/4P.I"@\$Q88N?IVDX.^UO+P@.IQ+<7H<=.*I.PH.64+MN+(RR MKZSK>JD17\$UFICHG_W-
HJHJW4G&64-W\$<=V<.(2B-6V)I#F+>_180,"VJ M.;4/-/+H3.9S&>+%FZ_U)I#J\$1-(-
XDD@UYHBOL\$)0T.,#H'G5C6&;2H3*Q M.;WF'PSAF2S/"?&H-8J.D2SN\$+9^2\TGIT>.OUP6G=);D_M-
7Z=:Y94Z(I\$<PFCG;+">Z?(<4-1/1+4)>UWTA4LH^?A8;=:7\$EBIY4K M^@3C0ADJ<A5?AO2HB_SN#1@)OEGB
M>.,/JIN#FX#8\$@&OG!O%U M1=9A9U98QMP6>!,.1?+6?6(3'V98!9-@ @A8U-YD"7.D1?
2",29NAIR>N8L^F.H'#K69/G\$ M*I)@IL4!>D?-BH\$HLLGA2\78.GJTFE1)&3+T!6+Q5LEK;>I'/SQ7: M(*TCLJ.P)'"I?
DN3E\$ZCHB@I+DM+KR8H&YYL'3-R7&*IS/N1;='T).IC MU<4(^U)M_EI?E4X^741J-8;/_1>^1:"(V7?
N/WTOGA#P&IV4_W4"HI^I6?GM2"+HHZ03D23OZTY+Q.I>OZ?UNIG\$%H/AP=NA_0Z8MJ-0M+ MZI06-J/
I!GO0E%859!\$W^;=.I..ONY.YAU..BSKJ7MSF.I MCU7N.3=^(T;IG%_93Y&'4^L)"(AQ>(.^0.YR)S(TMO&T)3
LLW'2KNX549_M5^OGZ!CO5DJRQ8#_HM/'NU)"_#VE%#H)U_S2Q&I66#-E/L+^;O\$@=J?I5D-
VWNIY+3JEKT+W@M.&EGV8E^!/"M-A6R9#-&H@_EY.XY^/+Y<8JW!#O_ITE\$+L_L390X=A+.\$P^Z^)JY^1/;.
M5N@PV#RQJTO<#W&VLEK-)M@S3H4ZSL1R\$DVL@.@*)IKP>/NHI@H15!
M'Y9@EDL6SN0DD;VB\$K\$#&U>G!)AXUFW D.G&@QYK!4I0-@I<7N1!>#14#_M6M56/P5E.D.\$'HZ_+Q"5I9B<*<
(8!5?KZU&./ZOVJD.&./'3CP;=_R/9D^&4 MUCQ_?>0FTG/C?'<6_:#JLV.A&=EOE.M.2%/\$03YI*=7=,&[A_B9QAI8)S5!+
MPI%GG+,4I)<6EU*IV2WJ==W.@8"V=:8\$!8Y(&"P1QK:B+F9@QT%98(%_IS MKY#=>_>^=N7T"&C+DN=
I^_UJ2QE#MYMLE#^9V-QUOG9)PX.@7 D=A*'D56%_MS8IWHXVYSU9Y6APKYAR.D06\$76\$*INC63?
6XWAVJ%M.7O=P^W"OM4FKWQ\$J7 ME3;2ID!%JF%A7_YPI^Z!V77;"7HN?10U3"A83)RS"J54HNV#J#.I:^6MI
MI*UOW>.*+VIRIN)9C>I>+!-HJWPR_\$B\$!2C O;8S2AM4HV=0H ABI.RJA>1 MOB_\$U
6674FEZ(SYHDSM+I5#T+B_!"I+U9^C<8%;JK>F2^F?A0NO<0DR@_MA@.I2DC+I/Y 1E"9!3.2)@D0&)?
B&X1NT!7H!R9IN;?)RTM=J?GRR<+CBRCK;+?^VI=4+*"A_!@W';OU7.2Z7AY0/O9ZIG;6I M-
#5\42OT.N6M5F4X^">0(BZIQP_ X6YTVG=3JX"1A0IP;.E-5WM(WD^S8D MK'!@^?
4U%!!K1I&"0AV3G#.OW/*WYJFW<#_Z9.WJ3S-19V)E7_I^JLIP-
MW"XPD56BH1D4CHPO39.CZ4!&A*#TU21XR3!P!/CUPH#HR,+F"2IP@TNXMX MF9!HX'U86_3P&'<..S!K!
(KQ!\$CK0Y"EMLI3E&WI/NF)N@<"6.2)_V05_MUICJM*>9ZR"D?A!N!YCEK34?G\$A", MLQL@DAD>HY*.T#
(X>7MW1#3_&S FG@Y4 Y4I&(G(E9.I^R2 MZJH.V)*+A*6IK'(Y5IO/R>TNSTRD^DRE!
I&J>Y.I@#9FA#TP6IK@W*/ M&UHWY_@EF=>YLR19&MYE.(UI&'5K'"?)DJTFV)JPG1.=(F0!26S96>YFJ
M0ZTW;*=8^H/I"/205!3RN-ZI@;6.S3\$SA"W5(>L^2N7CJ0\$T!K4%,&+ MB-EDWKXCW"*.&#.1%4,
2!4<8P.ZAN:T"V4YV1)S7#?"T4QGUMY\INWU3NY,
M_MT+ _Z2C\$T/3EOIS/OJ_SVTS8:QU;CJ<.@'+PC69KDW%^(^5'T8AR_?94!3T+ M*V/9A%,8!8
ZF9JW>YSR3.FJHME5H!M\$7D\$%JH%31C.KZ.P*#W#7F\$K!HXOK*M/4>%N.*(K;AIC8<=IL' M'X!PC'E
MWC!3IV+9>*3W=D;.L%=-,AEF)K1CAVDRA7*7.ON!9.L2?)V1\$SORC0YN_HN) M.9@GUQ_B;Y+!
2;8G@G7IXLA'5>EE0.3YAW=K%;EY_Y6DRD8Q219AL#AH#R
MU\$#AC<+YEC=OVXCOC/FSTD.J@<16'AUIFB;S8B#L>(6DZR.(HCL!IG5> M>(IY_V\$7.4I(SIPC>8E9#01K;
(JH6I2T(0TJ-PH)(+XD@3D&+L*)CLGEH!MWA#JN(=72+G(LB-19FAI^I/3RN+RMN^6YIEG'+Y.NHO_NRI\$EP
MPS_=(IA*X0M\$S';?8(8^+9U.YR3G^HE;UII MZ9@.#7FM)GCJ3IA*1+06HKO?QWA? #VO!RD2.S!&(Q;
<9\$V?)C8I-)I" M+K5N*\$,&0!0015DU^?W(B/*H!_=:Z1*-&),=9.-H.4 I@:L"XS0.M!%VXM M.=@ PA'YO
2XE7.L)T.LQ8 ML>.'VHT*!_Y<.E/N).8NQ+%L+0HV^WM;H\$ L M*WA8M7JVJG6^F!@KX9N^<8+5Y?AA/&>.,^M+8
ASCWB\$T"KILL'UIEO7G#T.SIDQEI M.H>JH1PSUGHIECXKQ.969-41C2I%EDP8"G/A.DT3>XTLW%-)T(D#G\$SZA4
M_I.I;N;/ZH!"GEH#/4%HEMM8GMCEI_1P\$EPBO=^H=W8WP85B;U_M9Q0U+IX.G80G8T1#6IR#0IR\$X?
L41KZ(N-*T_H2_KQV7I7^I;W+@)V*K!6 MB95V=?)ESU7/(1H/)5W_O0YI;2SU_+I4-
1XH5!HPK(ZSAF&8%*MR@3*9K\$8 MYM32WNX5%PT?T&K+AFNT"\$/(Q1FMI:BDJCG@-3IYD70\$SE?O.K1W=4NA)
M&-1(U"1L2"Q\$T&G/+4I X5C^M<+>O6!DU<^7;D4EAMX+6N;('=.0S!#1.8HTMN\$!_YOQ)_G=9#
<7<707#5G(IY3&I<-9H@L(C<-H!NZ MCP/I7AJ>Q9PH5!H#EY4VM6MQF!7!I!18CZ\$F^U8&^T27TZ>.<U;IXSL
M9T;J2A)'C5X)!I#?N/XGZ;-7I0)Y?XS'M MS;Z'U8=[D;YQ>^I_1YE3+\$<&/U03#-7\$-AN(6A^<86)ZF.P23R(V9)+LV!
M8ES!2_ B'E+CSK9X-A&JRK62;.&36V)4%2J4IP3W#DUG!H#D40/#?N@?S3>/T #M1 M.;-R00"\$0Z
GRKWQ2I<4T/TV*K;QON25)OXM7&X?&&.6ZQ_/7- MJ7UHAJWPVC^9U^Q.ST+!P_4*A2OV_\$(=02-
V"/S&"\$8@4RIWCJMV?O&Q; M/WIEIBNVNA8\$=Q1WW+/G7IXKT.I^J+^F/#6!7#YC@BC_O.6H>&Z;ZS9D
MZA9P.Y-ZS2=H?Q7G7J+/WH#Q1QU_&RN(NU;F2*!<10!M3EDO>Q#0CZRQ MPPA)CWLH;I-0P7N+8F?
@T3<19T!PJIX!35!AG.42VOT9JM7=+7>+B.O;70>W:0QM?Z4IVH44WAC9E MV)J?12V.1.1FH-
K2AZ\$2P>V\$GPTBOXY9VKMZ(868);_7P.4E*J_-L>TY(I\X6G MQCI-
MH"5.='ALD#ID/WXVF/C\$5!904=GQ#4A.Y_4U/=%8*A5L%W=2KQ^ M' '4E\$UTRNHBR&%)=)AG!XN-IE08E.Y
MG4(3EV.('GL\$(8LLG9AP^CNFUZ#8.XI8Q8<#>.(AUP+\$CJM-Q2ID-4+R.OI+W.>(<@F4)?/HAH<;>-4I3V/
MN@>1-69SK>1+=(S!QDI/)D.+ IM;3K_5YMQ+I.7&L-30HHCPIZ7?)\$4.O M_ ^*/B6%.PELV2 @HRAQ08F-
0NL!3IODY:K6E:I#;F?Y";\$8\$700TA5&CMUAR M2MJ4W#)^!0I86DSOZ+S_YE<1K*SKM.)IYSA@5:E+&#?
Y)U.U8_2U!+!+WV5+GDD@U!;!8!MB A&YX+*)^ M.;4!6S-E2Z_ %3IV=Y4BUX=("RJ?9IW&6IR!4>OGOB=HDI/O+
(+O;5&I M*M*2IQ@URX.K.8OP55.&UV+EO-WI(9XD3(FCQ6!UU.T)V".7NSK&I=8U.YR*M>W4C+^5B#H!
(IYUG2GCH;+WE">(6%!XPFGZF2^!\$@)Y;ZVYXTK! MIGOL^<8X2<;?@I&Y-
0GTE)ROSLA)MW01MV+I=%&=)7'ABEIE/.95WUW# M2YHA'G.O%S/A>?
D%UIUMWZ5;JIV5Y#0#;1ZK>Q\$SW/HG#GV_*!BFADE%.R MFJM:"I(F1170*OJ)A=?)#/#/2*2(-85*D^1E)Z_0?
I>WP'MA L*H%JZG.Q M68V-R-V&G+0HGF5M0UHRW'X;@.GH?>9I13O_X)A9S!MP"(VJ5SWRE2?S"
MWZ;L5B72T_VKU4E.G(KK<)"LQVUXZ^JRO5_&PM8RU#AE#;8+Q!13I)"!+M#3&-
H(>MSK^<^^ZCR31(B9CA>--JD9.7M"5\$FIE;/0&_O9G^SS!&TK/"@ MG7Z.-Q@+!)WWH:\$S(?Q1-9
*)I277LF6"TD_#1&@BVMAK14X1V7FT"^(M^A(U_PYR6IVW/C7R?E'I'B(S8CLD08!"TRO\$J2.4BL7MR9*M"P*?
S9%<^/(M)?>Z5CM;6RSG.&8!";J6HJ(ZEJH MGLD@SY(10P8.R_"&)&\$U46J_?
S!55T4@A:RRIFR_ \$N2TXQP9A5)YVX3-!6 M4I23WQV!*KL/>
(\$3IG;&Y^J!S!ZD4YL^8NB2ZIAFLI5Q/Y83;EQ+JKW+ MK^FI#6F<-OXEMSH%9OY>[Q88<'ATP-W2?_4MI
(9;D)3D1:OUH!XLF;J^'M M?DL>N9;R&J.H(S1*W<0.AENRPB.Y&)OMRQWYW+JU3 LH@F^HJT@(:@NXJF
M_&4.%1QHI%9+V*%N=^C9T8WYS&FC=Q6SXMER=L3\$.(0;25/<*HXA=7I7 M/VGO-5O?MU?
TQJN&.*L7NE" 4Y!5B-V8.Z.I<*N72OW6++MF8*+T/ZNW.3IT"2!;8^06@/CXWJA+Z.;#X#2N_J<7IS\$D\4K_!D0?
I*44 MUF!@ZR(6T)CBB)FS_!(^)/HVRVNO.I! A20JMI6\$=1XU?KZY&[VKT7E4W] M62M*M2F9%@IX7.E8;."V"W-D
&TZ#CNQC)HZ;+;KT)1N%48MVB3^YB" M'E@J@'YI?QI_NK-5X"Z= WACT^SYP%-QZ6:#"6;/LZ:(R'G(1MZ8"=N-
MSAY4!Y95LXTMHL3BH(E.MI.VQOIH!K71+7R.G@15#QK>J#=#2E0!#P.W
M10\$+8H!398UMZ33D.%&W4Q":58&10G5HUI#9I?^0Q\$!BLKDJC9EZ_(JSD ML*%IL3?IYJ"=1I;8;IE;
(4X\$APGZ_#J<_1.*!K1WZ).!ZIRR)MDC_VI M5H1.S*O\$!5_%YIHWIA891^1'5*6*2.I0Q."L&N8-
I=MF+J5<;I<^YWL_ M_LU9-K064T='3H:8VI\$1JKVM(_M5!SWT7I M<#WSY8E_I^G!B#HIRA;fDMB@I
<-9W1G.IN&B")&.FDB T\$ M2JUDLH^U>I5O3;QND\$B^V.LKA X5LYI'E@RJ2!>?
_2X@1.OKHAGBT95@N&V_Z8>;7&OX#;%.49>P9*)C N9.H(P6W(GD<<4P;O_4W>*T"P\$B>4ZF6;_R^F!I

M\VRP6<*HGY+O'DCNMFWWKH<3,QR\7 WD#QWR^2R_43I3VJLG89;Y>-TL M+CP^R\$ "2>@K\$?
^TQ(2GHYPJ?IR_ =5[1V^9B5Y:0N/+ #MTM:HY-\$&2(U Z=@ MR8-I=<-0GU(@.Q<)+>@:8;3YTVS:/\IXY:>-
NDX:9@A'-AV""*8'M?M0XS>CT\$P5IS,T\$M"A2U)\TFKAIEEA7 M18S\>..M UU)
I:MK*038N:C#I?U7R!\T,U\^\$ES+3.1F5?OM*Z_P&0@/N0-J MH'Y030QC"37_>
(Y*EDM>B@)D(D8<1.10Z3%0:91%0%?X(128"&,-*KKOS M108FYHL.FGU73%V:C/I>Z\^Z?
5A=I'NW@.9_X_KJ'IOU?/SXV MI-N\G;L'AL"2P;HW",I1 [N7WG2T%@N^?FIKL M\$F\>-JXV?9=@Z"\$F/+87K-
=1*',"ND>V E\EY\$T_>BWW6GSPN=:6%TBU5LM?!11&I1N'D=WH MQOL#,\$GD;WMOPP\$IA+OH <63QW5?
&,%CJH'M+2J1MO+15<^?L>>61)5K&SX M_ 4K*#3@**TPPVENJW>8-CSA H82B_CY#_\$10KHS\$VT*;A,M/4W?Z%
SJ73+*1R:3,VED@9^S;+GVIL+(L^DQ**95;87=Q(M_Y@/1_?'^+I?F8;L1 MR^>Q#;IJ&-LLYS87S*_
ICIPA1/G+R2\#G6*47I9U0G9\,@RGZK1XNS\I'S M?Q0H0#I\U&
IS(OKZG\M\$H3*MC9JZ%,2.^1MO8PR+^: @#U_#(I)9B>^">
M^C8DS(B'XR<7&>8HPE32Y=TBJEJH_ MOAC5OPUY?ME94)-H1:0L&0GZF"; M082#^_3FPAC*B#
OUKS:H' Y79B1GU+POHN#43I95^*NO97Y-P#C*,TRL6\< MAQ\$(0'TC\7YK3=ISA&Q?DDI69H4NT<4H\;6&8QD+?
B)#+W-)HV-H53M1 MJJ-CE7\UTB" %T^D:&?U2./+E\;L3C/NB6Y(2/=4L"NVF\%Q5S/QI94#V,
MBS+S35QF9JVR(D7\;M=:L,B^#(6Y?MA T'9)AW3R;IA+_C;MBL9E,0YY0)9/\$
MZN5VH^70DQ2&YPI2EHP9E\ZC^0@E?I4I1BBA2IYI57;A=XYKZ+-E/8V1#C M9WOE>L\$IYVJ1?)
<^+5@<)S=W,1M2.BH7_#O\!>6MP>K&.2C_*#T\$*9J5\I MI7FW0^=\$O+S^I>-/WUMI(3)POS2I*);_9A(H\;%)?
NPP^.>+=AA^A*<5F;V%< MY:@+>^J4%\OF\$5647;-%)>#CC4BQXC\PS9=%N\#FT T;O1M0V;/L_*8_M_JL-S-
+70(AW(4?F2>2IHA>YHBOI&(\7RO\,"EP"/HPOL\@%;_I MM1Z1YHU&,
I>6RW\I\$GGTG7>HM^?/P6LY0@N:>^I=H8E&VZ8>W^M;GHSQ\$ MPWJU="4+U M=KIJ?7H5WW 1%D6_!0(P\=@
MP8MBW>&28C(@&B\$V4-6?Q@8IK" ^BI<6N M\2=RP+5OB\RP;O_*&4HLOQ\IW8%09@%AKVF0GR@D@#&!
IB1W44>IA5KIM,IBCTE.7_FI%Z=I2-I M1D)Q1M79;42R&D^,"325@Z;8A1&I%1C0G;)/&E<>J=3N\OV% @81\FP^>+
ME+QISF&C5XWJJ_QX_E>DCQ_25<4?P)T#GD.SX;>@P*&SN-9-GE19/Z)^8VB4 MG.W?
VDCIM(O>4Q\%/,9V2D9YUAX;T@V3Q4G8JFC0C=*WUKFN9R/JF.6P8WMVY MBX".3VPLZ-
/*_52&D.J.=)R8>DHOBH@LE-JT1Z6_/F**3CC"H+L.I@/@0F3^)<3+ MD>IKYS*6^Z1^F.@OV>8&\$4+N1-
I1&Y@E'23LONU.OW)I3,859L>);_I8G&);_MT8L30 E&BQ% "NGDQH0G+S>_H2Z&">?NS6KX_
M=A;LW<K@2"K1H\;@I+LH.6X3)@2;;_FJ5_4%4HLNI@V)\F(D+.#)>@FEL4\$ M9UZR,I"8A^MION2D)73,0\;K0S?
&A20\>H648S=I'8(@/70&EYJ,C\$D2_E) MG@XR-9\;.\$&24SRIXYK=.28EBN6-IU>);E?^E=PT^EPX;Q#U\$.3;)ZD-9N
M*FY&AR>\$H&Y.DWC"(TPGEAX_9_9J,"L'8S6=6YB;_I78QJ2EN7=1P8=JC%R/ M>L;5-
,"2X^G;V58PIZ;/@96^*I"IL0(\$\$#7.#0\MPX\HBEUX%4*CY% M4-[R^N62J3Z\;D;_1PT*4K>K\$1.4JFN(O_W-
Y\YVHAYN#>+@I<_.1&G MMF+I\$8_&MY(CN0VA.W&D1VUQM,TD8^IUIXOCM%9_HG@58GS8QO_"Z_9#I
M_H'BD=J>YD;=-Z6\%%XO'\$S,*?#KE\FU7EAC:Q?SHL7_-H'/\>,YE\$!A>B MZPXZ^CT.3P.O;
(4M6>)+_M9\NK_S1(\$'.!Z+N+=HW99_4LPK+WG^62(P\$G-C MZD@_JRG=3M5?N?<+XTS04TF4N-
PBO#K>\$#);HM(?;D5MD:C422'B9+Z?HU MNM^&<0F&7N2\^6^-8G'(DG=(H6J3ZJN>E^D/HWHL/WY\I
I@UD"3VORG\; M3N3_IY ZG.SB<M%MI\4V?2%0E>Z17&.2'NG8DFY\;F0;#E\2_R=W'KEZ0;_MB\$Z^0-\$?F%XG\$+X/?
BRX';RC*&-N"T^"-WD\$=83IG'? DIRS8/QYYVR?&3)^ MYEO@"TSCR2_8T,^=.2IU-R59'WT327;I\$YH&^>W#?F/2IX?
PC02TRUV,V=9_M?JG>'I Z913NA.060Z<%S,C17WI^,O\C3+);%/0?&;V6/_9T?&I'TH\9_M?;-YTC"Z8*#,\$
KF00'M&S6,.04X MK;D1'P5#(SX7/6@IR2V*!,N\$%*1Z99L<0_E_P180OHYYZ_Q\RU" 6RU_'R M^_,RKH\UFZ?
5)0;5\(&>1"MP.H;QJOA&* &40DX)I>@!VR>HRI<9*4K\$ITG,"36804ULMMZH0G;VKY% IOFL(X MBTVEM"
X,EZT48X,I_*WT0BQ;X%CT#RNRSE)7<\$FWJ6<,_XJGOAY)R>G4W/;
M>WJIFU*.D8@)JC(O;TOL"0:L5;)5D\$=XG9N0_R(H_/_73WI#;Y5UMN3,5Z24*>HZW93W;I"DL_H MF("GRN(83E
)7@I;?^>M&I#L_&D=Y05+X1RJ(^-WC5LLOPV^OIGQ%0H^>GC M9>KYAW(7\Y1.W%&JG\X;CV"?B22"6\!#-
#&C:A/3QW(=-;7UJ96(;;_M3R@YI@;P*9\ HR>NE10KI\WB\OCL@>(K01)ZEP" M*Y
+^O'FACAOP=/D03#;#&EGY&U^I1\$XJ3X6/J(I#5DD;+U5OR!0.8;K?F M@WF;D&%%=-
E%*I@>4*01J>F>6(YTF"=PD7T6@+>\$\$(HYBQ_8*UE\LB#4S, M:-(4*V<>W6R;ZPO_INR2V;D4<5_V0>%C5V^S-
C>\$)H\N\$NST3&13C(XOB7 ML)D@T=#3XP0S5NS'F)4_<")#K'IOCX7YJWI=S8YH1=%C37%GL49XM8_LQ7VI ML\I
<4C*2JUI\TG5/Z30CQ#@_(-7HGCSWT^OBEI06W#?R+@I>.%#%6;(\$V MF3L&<8H\Q543;WDW
5IS;ZL&K=,UGBNX/JY)V5)3?<.TT^F@>U M@_L_R\$'-/BC-U?IA^_90D^"J@M/%AQ4Q*^D-G@BT7>H\;IXT
M'M\I;H\VM=)^%8LT;Z\$PW\ (P#Y;BWWZ8-MRK/06Y;G^++4;BMP NX' M5200_1)37;JP9_-+Y::I'F8^%H\N<?<?
8V_T;#SOX\$E;I7UU=I=O@PB;IX M%_*0YSE@80+*M&2IMRPYV7\I*CI4\BB\$721(MHJJ)=_XVYV=O=5H+JIN(
M\+J@ST_)R_IQ",L TA2CR<1\$KC>FU@E.2X BU<,%00.+)#ITFC H'!2+D MK?
EU/ZFK3I(KSN:8/HD>ECK\!&>N+G(7PV&CSTHW7U.@:DH?MY^IF9?PUF
M3R_/_AO(5:9RO>QXH!*T?965I6N2\576WS(P:9DTWVRTM;NBUE;XT&5(YN) MTGP,V\I8(-/_FU#@J'3P536I+:/-
VMO"IS%&^9DO^*(H M/I2XRWNX^X3KY/S+*168;)%C>"U^RD)7& MP7%LJ'C^F^G/4;9A\HU3W09T8\$)
Z2PA\$Y%D&=WO+&YH;I+LRLNBG=H3B&(X40_W=QCZ\$GMJY_6YCG3U^ID#TT!;'8K?/NCLP
M'TN; &F\N%OGHXW7M_8\)_H&ZDG(5,P:ORR94SG>E.D(TI6\$DI\ (=JH'?3Y8+KM;VA=U5^C/0.30@GH<"<#0
6;2/0E M_IXK 2= @S^X@9W_@DEJY00+W.=HI67=Y,^+@1D M#6BKYD3%0Y;(U&C_XPQE-
H8EIAF/N8G\$4*+L+VBM7N99UQC2&Q'U>\$AD8&D> MP3*8^?EOVRU4^_U#P9@GZIEEOI0?084\@BQM%#
<+YPEE,F&L9G_@KW;N8(O M^;\$.57;I-7@N^1'2N3.V6W(:(WNK)B@G6&BQJ;YC(I54?4YCIT@'6MP+2
MY7Q+!4RO!\$^=Z=67E'^VS_S\;\$S\;@6_O3%COY#TL?L<I MXWN0F_NOT!;SH59GM@_+BBG;AH_6G+IQ!
XH""D=X%>WC?OS_XZ55%F#F5\$6;T3U;5+>?%H"/0-63K M-%AL9Q@XCK@A7;7\^CH-X#5VII%Z+
D4*K6SJ&N.2IL&%U L2^=\$4_82G!-"HINKG MOH_?^RI5T"331@N&
6E\UXD2IBPE7RZ^I_3DIXO#/_/>"0\FLAFRN\!W-A-^+S.<-R_)TET'=>AF0^- M 83.>ZL/
J;J2W^M_KV=^MU6#JL;H=53&R\;OZ6^<1*N'14(-&C%D4KO MP3#<1#/8+OB^6;
H\VYPO;FT9:9IJG40;:=R6;2W>ZQ7&LUB\Z062'8W;K9N MP_)3W&3M5)UDHQ)M2-
CIE.XVO\PTB417N="@J\$A^Y2U00 N.D>I\%92R39* MJ\V*;N;Z3T4=&;JP;_8\^B^GO-7X(B9J(=MB\$N(C%Q\RC-#&
)5)@(4IX M;(P0/B1I5I&^VU2_8LHV1_EUA(DGS*5S9?SRU;=BG\$GLOX&-BRZWI&Z'A0R M6%;TI<1%#+
"@& & >HBWPZ N GB>4_XB3L4WC-"5B_JJUFU^;WR_1KVA# MU>_KW XVU?GK5\OD@99;YB?
_AT\ARZ,L=IR\!R9&QY0L;L_0/3VH\$ \$TS.@C.N M^G&B?<I8\;CJ-E\I0A8\$TL^W?I<^?6RJ7E'S208Q^P_8N*IB.
I-71R6A1 MP/5_X?Q5X<6S)'9AK">\$.2^X#YC^%J_\$MDM34PW\I6_CIG&?D\!PUD(8OR
M5^<64IE7\KP96D/252\2_09*J6(-H?686DJ8Y_C\$T"?IOMC_'A L_-L(H
MQ49N*^C0_3#1A\$IT4&294W)WRON?I3_UN_0+^FTZV#30IZE,L<54Y5_WJ^M^OV?
+M106I8G4"R""(KN+DC*\$4@I6V%FL\B3IHEAKLVZ.) M5_=-D^Q\WM35TZM2IN3;/>"IOV\$8 WN"!5U#238E&*->
C>E+98=WF^9@MX? MQCJ6W2V1>FSZP12I9F\J98IF>^_.8!3QP(2A1ID/KB^Q:(?24A@NYSIT)?+
MPP2#N\/@&^I06=;0:&.MO.C)K0ZC3IRKKJB\?P%V\$#0"!.S+,\$H""-0'Y2V9 M'RW&46 VT3^I
LI#S16OY+A4K&.%7G^_!^?3DF2.V\$_)^IS1> B+?B9.&UZY MFNA#;L1S0\H;\$\O\F;+!ITYW,%H\$5#SE&IAR,\$
TM46L\$3EJ\$6C)8"M5Q M\KG-4WF3VH6.\$+N5(ZR;U2_3R\4V5T "(?W^&4*<0";B./+IF_)9GI2
M9U&4+Z37F^T.OC\$+%HYP3<(3N@S^Y@GN<I1IQ@^75(S0GT&<^*3^FC\$<%"!U6(%

MVKBWH:WY@9I5N-W=YY^8V:~XR-V#N\$!<>X3GAG*#9YE8PXXJ:I9RHL\$Z&1P-MS*O\U@K:IBHSWSO=+W?
F-JE|'^#61JFJ|S@Q-9\$2R'SFXMY7'B&..SYA%W-MAR/B9+A^K>-%9:4WBC+:RIAL1PCM5/D-35BA7=W/^Q-(9&
H7PESR00*FP<MK\$2/P(7-8:1(-JV)X("Z7:9)(V:2IZX/Q/1FPZ?>1\$P0ICKO/11)(8FT&V4?DP^>@8H7D\68IN+T^XOE
MKAS,,LOAO-4TK3W\H&(Z4)R2N(+C=;~M|,%CWN|%-GEP5/^"H7L""',6P'=C9(8+-MX=C">~
MJ2N|K.\$2R>..#SG/MUDY~..NWFJ6D12Z1%G6M|>OI/T4T%3E+|V8R-XM\$W)T!FAH%23-3
G<7(Y#>>~;=OQU&9<7+\$J6?;6N-UDT N"R9GDQEQD\$4VGA|CW
M*S*|VP;6QM#3+GH|XQOAWGKR6IF/|XD/=>B).FV88U!|741=7M1S"&D#T^,M
&12,8|F<"J&DGL3O>|ND4AU3I&(B60>9|?>QI4MH)8>4-\$O^|QJ8^HM-M"<*^=Z5MC;Y%@PA:(1OTP05!
#1@-H>./HXT=F|N-#%J;FIS-YZU-.596G-9\$3^S+6=APVSH!OH.?AM;A\$;T-&)0N4
M77PFD6G9@9'02#|B1|K.;U#>UX(>WB6EL|0=J|2N5N/4*|1IWW&M2S\$A|F!Q)=W|G>9Z2#=#|XY@"E:02"
|AYF|=158\$N|&9=B3B792%<"K&E|MI^<QC.F.6|Q.(ETN+DB)|DH!?.+=<(CPV-H^ZUV?)IRT.*;XBN_KE>B4V?5_-?
M8K|H%4#Z@57:ZAI|0L|YJQ1@|J7.O.D6*TO<87FP=@(7-MG_-SZ0|MF|>=RJA|QE!:=#J0?7N|S3-;&4%
|E3|0%UCDCN@C>?Q3\$"-M^N8M5T-QYWQ9|XL52+I6DONWM'ZN=3V\$>;PT5S'0L'N*+.|4WO>RY^06/(1
M*|FFH2#D"-YXQA1A79Y\$A<91YS|J@/2W,T^NC)=*&*?)YXN\$G|37U4I_-HZ-M4?O#=#U8M|W7(/>WX)STOUUB-
3K>CM88'2#Y5_EY+\$6-GYTYW>@SZ,N-U:YV-M%5C.;@6S^5N.\$Q/+D4FPX|9;1X-RLF'N?1U.A2I9IEA+W;#>%2Z?
6E|/YV6?MPP|IM4|:#4Q?^C\$SH|'7<59R@?T|9+16.TP-#T'GENLU!;^,;)OY|TA
M5M.X039MWZD%*T-W@|6G-#VL7.L2|1G^TP%S1BCO-M*Y9Q
@(^*O)'<#9M=I;DWL6^O*>_9VOC|IU%NG07+~"FY+C?#U)XK#?-E33V-M='2X2F/@PEG-.L0J.&(#3WD#*LL
(XD&C;+>V(6;VY3%<|64VRBC@/N4ZE|MT51Z^Z-3|MT19|>+-6WV6CV6.(\$IA%/6"3X+9)(F&KLBM.62-
K|J#ADJ%5?2*1BWD\$B-34U49.HT0H%S@<M-S7.Q'0ZMP7.0#DWFEXHC.>;EP+.%AK5C"
M.=83|E>B9NW7OT.F"DZWPUF9>*M\$*X'WJ-W@S/Q3!>6X1!WFR=D|.;|T2V-MHR/1(LI^W!&|I1H.O:O\$?
%*;;.OK#5Q)E6#|9|R+UR#&J@M|L|;|NVH0P0%(2F9/31L8TZ'"D%&HP>|2|T%@!MCK|C-G9C'N8PW|JV)|@1A
ME|\$(7|VV|)99|RPLHNJ5Y*%RZ5.#3Q>6R|@--R67FM8,97?|36#?1\$J3|H?M'9-!4|0V^G8N?
(S(|W'WJ+~HMH;PU@)E=GT*E.U2IR'F-#10N9|HJVOT-MJ?^JZS4!^YV7#:.0%AX&
<|E;XMB\$A&"G>5YM|C(77C%.D-M^M^D8)XU=L-MW)|MH6&GCBV>E-(+>U4E-|HA|UO?
@HM/3.#N6BL&EVP&5|N83MOVG;Z-M\$P6LH9\$V-3A&I*!0@*XBM(M-*?27Q4MT?3A8Q?7UM?
L|MFEXK+N4Z7K>P;Q-M841-W;|@G2;|J\$*6.4|Y|N%..O8XH'0B->D-9X85/AUB1.,!^IE\$>FKIMQBT\$=NY-ML9QR&O
UD.H+T&H|K.DVOP|RK|S|J|W|OM'=XZX\$|>@#..(U@|5Y|%R;MQ#(NB|FR!D;@)M*>2|
O@6T+7@LN%S8^>O@PCMSX?X-0U7C8|0H1|A18M-M*RERA5X|@)FA+3&=(C8VZ'E8G0
A>P;|^L"M:MM'(R>C=T|O-!%|R-@R%L(Q-MK8|NTTP@9UW\$25RMDJ2W(INU3YE1.9L3
FX|IOP#XZP|BO=&@'+>@|HL4-KM\$*|J*(F)JH61X\$^BBF#0P<~VM)^SGJ3Z9*2H|Y%.%1EI=S^FX1-D*C^(O*\$M-
!\$?L-1+1+XG'+|GC%-U0/>.-&=LH'=-)TP-3-1-W|9GG02^DM2*Q-086/M?<3NC'-M(QF6SAP?)4;2MKKROY/"2H|H-
W:HLO"-..(*NEW\$0-W#VJ+8?@\$>L3QA#-MT|4^|Z@FIYMH\$169;T+U.0Z*=?ZQ-
>OO>")T>1UR|HG^K1#;A.KK5WG?Q=MT(.#JP|O|E1XW
E015B8#_TLNV0~Q8RAK8'EWBUR4G)X(13(%NZ-ID|MJ-3H"2@\$(/-\$E|FG.>=WCJ#P'.GO-"A|)=JMZXP?B=1N
MIBO@|I9>7|HMMJW;OC?RM=N:1;-1;MET=|UD-/C8-M|9|TR(5@/%J|+O/=MZM4|~|4P|3:"KW|0#LI?
\$N|3E&C(;WMF?='!@M/Y-M|O<.KK9=)2@Y:EPP57-)!P.6GO+(1H=;A8F|;R:=H0%&)%J\$0E09931OC8/MY=8U#=?
ZB6|AT1|H|V>O-R7K3E-?Y0P+>LY"1-U^7T^#-\$3.6E|>C&A|U|3;
MIC"A.)+%)BTYNZ'A831..E:4+M+1;7\$LO>LYRFO_-GG?Y-F.O25-5EZTH'|#2.%LPN-(W*1|A6H6T?A6N_*
"Q#9%80TC<M"3G-F&^|L-9B(%4-1;.%O6#597;<=1G8Q7S"\$R<#MFPP7F@3AN.56913;-1-866M*3-|
|U%RM\$Y_-ZHF|S;+|F"5=3^T|DW/YJ;JK-MP&A~DX.&=|;..GSHA)V3"/L+F%*J*.;'62SDF+3Y^Z1(D7EW!S"VL_RCB?
M6@|;\$*XPD_*"WH4%9EHZMTYH9-\$V|Z\$J9A,|_MVZEA@M)AVV\$ZK^IQ?&CS0?MC-
360A-M*R-S-B5+I=#G|O\$7KW-9CK-MS5>MTDHI-IGUC-MZSJRKZ_|R7W^LIX;/%EQJ|E\$#LUUV2XF3WKD\$"?
YUV.?-R.A3J|MA7(I9-MS5-!\$S-;^R.1;VLX|+I%N)|^&Z.F?31-.CJ|^FE(LIX\$BV?_ENI%*A-MT'+;F8#|W-
-)R!|T291EG6*#K"WONV55J7|PW|D+\$NIX(7-1|396W+<8-M"A;*<"16X0D?9?JP/\$9M+'G\$PC|C/5^DDY:?
5G|^)Y4LFC+|>?<|42EVK+M"Y-4|P4YEAQAQ2N_@)|WPR"@27-|4K-\$E9AR-/FOAY5"TC|2?R+40PH-M5?|QE'
NW+PX45-4.GWF?+1P*R)CW=-1="FJFH?8MB-M^NX6.G|5"A@N1'ST""M>6%3Z-|A\$Q2N7D82@)>|A-
@!|Q#V#8|H(|R(K<3RV(0*QG+AD%@:H-M?_X|CB1+;D+#0Z?MWN+KFU?MPZ(XD:0E@MD?;W#_G(@:~QQ
M|N|X)V:GD%Z'NDK7B6)?0YI27M.SN|/-1|<~AF7>M+?&A|8?)E^Y*P"MD>VEO+PL|1\$AOPF
K1|"M*XR#K\$+6LW1_-#ZSUZ*UU2MB%*&..*16(2^-F-M?6AA9?-VU*G.5EY^GGYYA4?+2Z^2CT@YM#O(-L&|
5Y\$;|;#XV|Y'RV9-MC(V//\$SYEHX2R!+|NUH8ODVVRV=#9|>D-)XVV|/!10.YK-ZOXM^&7-|9%|&\$
MZS\$<2<+;+8H7"X@G'UT'=_PFRXO-M'BV(DPUKF.3FUQ|NW!%P;M+A-RL|^I<31&4|95^CTHZDW@+07-
N?|*MTY?H:Y)(KA?SH)AG99@5'YNC-M<8|W-EY+MC?3-KX^WNL)2KI79AZ=42(F
8-1A\$CUJ<.&X|+|RC@G("7M(0-M29AZ*.\$|3@#ESFAXDT.#)<@DT/N^AMV|^C%MB-1?T)M9E"3|A7
M9*|KX;Y|&"IP;HV!;|OA?D2ZZ#&2-^TPZ7L|@-@%X;+;DX(9.S2C")=9P-MV|T<20TT*^GV;8S?#2Y|@0
Q|J&ZG)B2W|1|S%T;Z4#WH2!^5|2\$|X-M.O:R?H*~K&P*4-|UN)O>H+~UOQYC2|*NA'WMIY*RU(GJ014VM/'P?
S-'OH-M_-Q|S|X?T;\$%#BB-|H1@!K\$1AFW?BZ-AN\$94HQ/%@RF=2N58|28ZQHS3I>#G@L2P=+1;Y|35:33
M\$-^LM0VIM<6N"A@UE=^M'W"PEE|SVZ|XG..|B>2|L|X36V-T+1A@B."J
M9?;"L&+;D)|M^)|THW/9"Z0D&P|/%SQRC32#W/SS-_%O#%O|QK'GNMV%|HZ0(F7D^L\$5WC1-DK<5XX^?Q?
8VXL7P(=DD-G7U-M(<.FPHK;%OLXCOH|1P#*^&X/M4*MYHQ;_U&'IYIOBZ_D%LH-0OR.VWP)?
_LJWF*NV;4-UO3|5UOHKO;M;P*3-OI29|57|^U65F>"CW.21K62)CJ&N-M.7YUB+O(>U=H
&5WHD"-PVPE8=S|E|BT-V|4T3(6NAY%8;NT8-E1"Z-M?
O.2^83%>H|OR\$+J<&LX3JHC0P|S3UO*Q%=)|LZ|/I310:T/0BX1&RM1-|V-M9\$:@B|>+T?;K>93?
11HPTIMCVO%VT-V^>736(2L|3+|_18Y'|2= M+~Y4U#GZ;1Y=UL-4!5#Q%<^OA7Y&_L|H
(A|@US4S|Q8*.G0MH<X)|+~M3?(>UG/T^=SJB6|F.C0BQ8O/Z?<\$6?KLREOA.*E.2NLL^X.WF^">F-G0C|;M8;
M;'S|GE68P8^F;ABKFY@|L5^OQV=PG^IM=ZHS|ON^G9|E\$E(?)>2&M#KMT+W=|XB+L4.E.M&9YP#@T^6|
|*|P93JP1;L&A=N@:6;D|LP?C1QW86-V?X@0?|HC76UU(>M(C-MJ<7MHW=;=6D6|3|W|@O?
Z;CE|S"G^NWLVM:Q1U.LHH&|?(1BX7*>H|2!-MO%&^#RIG6)?|E:Z;G-A3J\$|U2H-SO"/IV:!!+2>WTZK%
(9S=J|;#M.C"Y-R-MK^#1'ZS@-QN-L|JH+="%FJGU|*US4|^|Y92#;17U003;|O9NQ-F*8'R7@W;
MAJC"-1<|f=9L|A6DI/EE:(OYCU+|F|E%>CRWPY5LZ1DV&%CFI#KA'Y>/_LDS/X'NUV.1;4+4
M2I4CXMIR7KTY(V|EM.1-/2Y;Y4V4;O..@#.^_8ZO@=E)V.%M.|%&LZ.1?;%P>7.W4D'E|YY|>L!4?
4|5X;W'C5P1ZO;-9H"|J<@&10|?<\$J-M#H%ZN-'W-8|U^S(3MGK-U00=-Z\$5L!:=78%0;|>->OF|<(QR*~HKMM89++&
MD8-4K=%Q;2X;C|6A49|H>XV8-P;BR<<0|LD-|773|JK75BGIZT5F#A*MYGR9V@:'
JPKY9B"HA7U#S/S1AS|C|*%/B88T|7P/Z43<@*#&G61@|E>A0-MCCO1DGLV|X7Z*3-^9\$<&3-RI#OMC2*|^|
-|'|+?P?>6\$R*TWQVVLBIG-MU\$*2=L&O80(@EMJ5PH9"\$S'XP;-)T-D;PBP).3"<|F'U?%EH#J=%|NOXA
MB@GM(5W"!;S|+|QP*_3'WP/5)T(63,+E14H"Y/-(1-?#K/|_#O:M=#D-MF|VC53S14)B-V1&4%PU&VJW3#2^|~;|?
HQ^Z;B.*^36O51^..|D>|P'O\$9-M6J|K|N|B67M'7@=#B|'5%D4R.3<9P52|U.V;N-E^R>.*@N|VTKS"S|I|O&
MEQ2XWS9P.^V<-&VLD?(&%;7E.&O(7I-MD;-J|I(2+^|@3U9NEZ>1.WQN->G;)|NS:W|/QAQY/0I??

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|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|TPCJ|/<)^AJO^F! MH.;DI>5K3(1KXQBX>H1+FNX? 0IGFTX^JKO^NS2E_Q9.VC\$Q4MWY=42J92.A M_!33_IKN/C#AJ^%N4WUB!D95C7W>0U^8- %%%&0CH@T\$5X2TZR5|C;6Y-G|> M/^%YX?M3'!.IZ@;J.4 PJAMK@OB9:BZ<&NVMHO#IUFN3H>\$Y M6(RG\$\$.GZ8F M#M0Q+G9^*!L74.3@^M.OBB|G)SN9D)\$XH3YZ06I@Z>^&U.(# M:Y7_-+^ZDMJJ&CW>3JT^W;XG.J-V8P?Q'!SZ=I. (TN^D\$3VB6|9TG5;"T MI23+HX61WHMGQSB^K_I VY9DF^NJS3=45CL;H4X^_N.E823K2F#%YC?X M0F^AL-4? M00K+>A7FY.G M1NL&3-89AD5OER^U.P@ZIK406XCA")2A0;18V;C(YV5P."GF#^I4I)N==SR MH@=O)\$U R+HQ>PNAD9GB@11Y)|KY?;G?+.#.G|=G9=D_6D0/JW(=D8J?W.GN?6S@T%VE^Q\$(92BPT@ H@74L4.;@B7V4XPM&JDR4>;2&G7P=I=.%JPK^ MRLQ1XU-W^9I5OB3|Y<4|IT&|SKMZ|&L(?88PK7)?+W^K8-3A) M>(I^+S1&.DU0^M/*B|=DDTU|%/<|H8=I<1G08&@ZSS.>R#5FZ|Z^04(F_M1D)!.#^S_@ZS? J6A9_I^%ISP_+CU^B4G <==L5!^KC6+T^P9W>DSC9MHOVP^+ MRC9)Y2^0_E3YQC<; HRP|Y.;7C|G^WOC/R|U5.ZF\$R78!OQAGCF#4 \$^1. M>3UK^9H*.;C11CU.#F@? Z_IQWR/78>Q.6JAV^HS6\$@EK^!^Y.HR(<)G_(YFZ@GWY^4HRJHY-%M+!\$!GO>53" _!4=QJJD M\$0'+6V/CKD _!XGG-1G+<;1FMEA5P_T.^NDMKI+A OJ^EY;PK;D;ND3G<1 M9P4608S#115_/;.%D _M^4GNL/D+CG^5HRCE^S=M3M%#FMEYIO.ZKRYIZ.M9IR+24E)KWUEQ /H8Q+&%E@CK56P!+DEH(*@.FCU)E^E939MLL4I3XZ="6 M.K_I XR|+!O.^JK1RK<+SEC-I A_PW|J^2N20+X!1>04Y?07(8PY2.)TN@+9^ M#U\$1N4F)6|F3KZ9|H5U5BAP|37.:?6')=HG;|TJ\$ _5Q?H7MU1? NNJBV57H M^S./8N\$TO1) MI^>#;0X.%%L+PIYVF.DK)CZ2|_M%CC(HQ<|3B667|H7F3.H6L+AVC.3QI/51^_#.^ =#I6P.Y3X|*L6E|U6X+ MI(+ WH%I!+*<.YQ#@!8|!#U8)?XC<@X5E&#ZU^RX%>LF=CLJ=_B70Q6WM5 MMZ^CSUMTMD84TZ>&^!RX^PZO^%TO-G)HF=CX?_X5/CIX^Q|8L.YUL#92F/ M|H8>SF26WM=&RGBOM^_WL|RCH!;&)"B;2\$3KRL>|5\$T5&K=;|Q>*R^J22|63L|^NG S|Y4YMWEGJ:TTHK54&.! (-VPV8 M+.;@^R9Z|TY#&AA.G6;4C^00.4&R/RJPH(1^P^RWV;5EK?" +4_6+|T M#(A;G_MUTBIX- LDZ;_NN|@33F6;@8SK_2KHQI^L%WHEEXIV8=UB@9IQF?D) MHBK.;Z9Y-V|H5#&=YZ+)|LC%/(@Q=^D ML+\$&HL=Z7+IRO2A^/;&31L^|IX.4X|;@45ECF1+|HOD<'@A*^6FAUU4\$D M^BMP63PM<|7|!|@'^^|LSDR= <|<|!M9;FF/B=,HP MI3F\$|G">^/WC|HR).X:~ PW6E\$&#CP5U9L6.H?O\$;.' MF(0DQV#^*F^0R7QGL;9;Y^=81:5 Y&Q64#\$/M M=-.6MI55CQ_#QM@WE7Z|I5P+Y|U|=FJKAD22-GU?R8***N^6H3WFD4M?<. MAB3#BF\$.^6DQ8E+\$B^R+ICW/&5K3.;<ZUI?N&/P4.@D^ W^8GXP;S_V\$8R2 MC6E.I@>S\$>B>.8BLC0YZ%"- XU>=X3+>?26B;/8(6|J;Q/N1HUJ>6^F\$F;VL MTW+5(^JC^|F^G)&6^G|8-A@RK|VCL7VHK2_UU3L3\$ _?3*I- BA)AZOD1R^*1 M33T^C%|=RR^XX#/#6N>.|U^U603Y^5?^V69-FL+|E>_I>|G;A(5.8 MO6;8A\$)5P.FE+Y+YBO>#Q.S#^T;H%#U#|>=^WZU?%Y1!_) _D&U^_M85 ME4HJL>.9IO #)S)3.CE^0>"F^"5M_#;.*N.'GW|44_Y5-\$CZP5.M&AFB^ MJC^*MV?(Q;BU;YI?WSQO/^*LI>2/H=Z_Z^=I P>(^KJ; |W^O)|R_7^D_K M&|^*WBV2\$>\$M;ZEHDZJ4XKH+POK\$H.N7J?0JNCH\$|<4CGF|ZO6Y3&(+5(|5|O_MVBR- @H)VH;D:5_7GAK;/O3PP="OBMI%;_4|XCQ'_.N#F6@>Q+P-SA^RJ#H MQX4KZ_3\$^?1X^_0 +8A3G;YX|H43D25O;B|^OR6V-Y;W+^XD/DR;MLD^Y MZ6@E(C.9IH8?_48\$1I7\$Z_-H5_6L=FYBJYF=7B-I4ROYG7? OD24RTM@FJ". MR&@SCF.56WJ3|HR.;|YS^I&ZP2S?7I7@5X^I8&&I8/PGWB>"(8=@_H&=OI0_M6_Y\$# RRW+B|S8D20W&^).P=FJY.Y5Z;#*O)J5J50F2?+X3WYA(6!9JG;% M_&7;|_P-5;<Rj1%";.084>I= <<M&DS6H/1M(ZGF^I)R3=EH@WQG5C(KX|T)FR<=I6KTLB#06^P:7MS^GG;|S M- JI^4N>S**T.C^E'(8<#^H#GO^LU2S!^+)=L(*!45?L\$Z6P|JR^*W^&9X-M2JD9">&=&=IE TILM_GE_OYHT& |YO=->20J-ENNHYMM>DWU^US&F=78WMQ&/_M3CLC\$2;&KL_61&|5;8L\$S#&|PAP;HB^DPH-IRW24B(0J). (Q)Z>A1679>MT M\$C M=|UHF2<-OH277>:6Y-CXCDJ?2^FN<+@G^H? %H^C7AJYN_87D/3@8JNM-5 M1\$;| ("7>:LKB_X-(G4ZQV4=DI/LPM^B MJ3|5FNLQ;BI%YS_K_+KIEHL^ILZ7N!+KEO0^Q5Q0Q+ @6^ZVYV><|MP9/ M>0Y7YFDX;D.\$MR\$|V;\$PDN^+Z9;H5HC5\$TF_*&B^BZH>9\$Z9SBK)ZA_M|Y_8K)%GPIBX_0(U-66I8@;+R^X MM^&Y4Z;J+;O5T3Z_0^3)3?G^=W-QEFFH(^UPB(PX)2=(3P)!_MB@V)^CM M#U0_%A^|*34.RD1^61C#R XUTA&T^/^1\$BW..C?>96TL+T^X?I_/KU M&89\$%VQ&\$\$S:1A<@GF.P^I_Y|UH5? E|_I30WTLW^W2WT+CP6|H50YI%_*S^41AN M\$7K_25JVP+|N2W)^0DPX3_C)SH5@0&9 MAPG&9T _L02<.)+XQ;%A)!HN/00;Z2BI\$TS=KP^D!E!=PD|J>J>_ \$ MV(NK_X|GGG_MVIF@:SA008|U3\$V5@^T;_6_HL? (2%PT4X2638 _M^H%;V.BCW)BL3^I9-0^&S;|L.T.<_/O|NYRV.VHG1.OOOR@_|C2O>ED#_T M&|L _^YL^H<+N>R#ONMW.MLQ-P:U00\$KIW:AAI8A32L/8W&88"#W 3* MD;HO^MTN3O2^X^WR==C^Z;=J>F@EX<40LJU/AQ8FTA^A0LZ#OQ=S"-G^@_M&3NERC _Y8L8\$DMOD^S|/%LP\$F%|52_@+*9!6|_?N+DVI_#D?N;O-IEAAKE M |J^Y/_YHETH."ZJDE/E#21_!^HA.FOYTD+V6_.'PSP(E4F?2^*M/^WQO_M9O\$3!&G9@P^T7#@R6 J|S^WA^<83<* (MQU=A|U5QYZ<1^GS7R^|HL@ZQ?L\$ MM4J>-%_0_.R6!;^T(=T_U&3|515J|>F2V3FF^Y&G^745\$;N0&%M F@Q^0 M.LVL;.(E)I0;<&09#;UYKP\$^C|D_(-8;SG>&N|A7>@!%;W8W?3>K|HMK_@ M;#|_|LS>|=IV/6XM)X)!? T9RP@OIR#.;+O:A-2;OX^"HD^6(-I M^UX4^7\$. _|B7UQ?RI_3#W%;\$F^!W4T^|I^1Q?K59^+A|PP)%LNWKN\$PPE MOUV1^P(?3+Y1P=JK3%X.F;T30(4G@|_YO_|D^&=L9JFD_MZO816G^H|+NQVI">H(WYVKVUUF-IIM\$ST;+%;&|)P- |H^N|WP2A5L_9J_ML;P^_L7^IGEOJ3?<|XBYYP+O9\$O0FFK%|*^F/_5^"G6.RMU4ZI&_K^QXN4! M<_KOH62&\$^P!G.&2+<7|H6)>)%=%WN^%214;_LZ++^KXLE^?W%;_+WIVR?VR+KI?5;@O5B_MG_CO_IQ|&C- |AQG^*XG^WO7|GS^W^D;9;EAJ;\$I@^9#E|F&2.SF@33B\$;O/ M&Y^R#?FP#;.%>XI9OP^(_Y|^_H5IN#@^ND)!_A 3|67RBX#<D32!S;%90^? MXI@M&M^P%1S!&I;>//M@;/_OV+JFG;(Z@_N^L2WZ^U&SP;_MX&O;L<&N8^_VP? CVJ%I^Q2_*SS_!(EIQNI2FOK.#B/3DC_6I^K;EE_S M;6K^KE^Z!^.#8N)HOI|9E|AW\$W^/+(4C?Y9|RX?U;_ |NBI;LEA97_MHKMUM:1HR8Y8^7|B>L%/CHM%|T8J^";_WJ^D^E0QE8N-HH9_!ND3W!M_-2N= M;9S5R#^9=KR8!DSYJU\$_.@ND^L^3AD(Y^HPWK16Q3@IS#<GB<H.^VXG_MDM7E_HIONP_X;/@2/AN+1N&Y(8L2@^_U%G_HL.D|;\$-A3|U7W<4^6;<6Y_MYYR^*X_N;=RX8T8\$M&_9UCH5H._=P%>^'=^*3KUQO:VHVX|_5R6D)J? \$+N%L M;|*M%ZKOLRY4_R.#E5L_4T1_"R|A<1|^3@VOF0AR).^NY#O&9!^CVG!|&_ M>;H5=*|P^JHP&M8% |F.W&\$|_TILKP3SL>|EGZ|V|H^7+&.5FIH^MDWX;_8 MKWJM0&^H7.IQIQVS77^M^D^DH8:U>?

A2G2!;*~>Q^D12YYI&S7PM%KX.C.U)FAJ:DL0217>5I3OYT>JIMM.M%6ALW+@A/V&")44IO@7*I9<YP^#HMWF+
(G"YY*[*&D\$, 'M#M7X/S8(N!=Y.J)<0/>|0M8/0RKRILOBB|UXD-8YRQB>DWOARHD&DSIQS_Z MH|K:YLO1R4!|2.O)
AT.U0H%0,<*.#(#++F&9F)4W@*?I9^U) 0Z1.*1|3 M26X8?SE1HA@Y*Z.SM>_JKU_4'E)3(,):!%7I
MMWHLZK2AS1C,7H|N<-S+&&X13\$JF_&?4|V?+L^::HA%Y6:HCA)-OH5CJHS M&QF:HU-!WR_!F" NR3*!D&GB,3
M0(O9<\$.32/UG7IZ%LEI\$!CX"6"4-.49_.X.6?>MJ(K0Q_VF1E!_02Y-RZI(N!\$G9"ZU0BH MXZ!<:A=\$R;
<|!UJ1|DH/\$,Y1>WK2YGRW3V;5&D02.OQIG|<|D%(\$NIOK-Q) MV"7\$;/MQ;>>|L-FM3I\$
|ZXK3H"6:Z^KQIY73A5XB>BU_J@.U#<ZK%""&?U M\$V#*%D63=FF"(8"6|I<_!HF-S)ID=JNVCHL8).7*J? E-Y_512-
DW.ZL08 MOM/IT.:|H2)W:2Y&6V3LG74W:7!+8N9H(!=|&WD15%T?<4.#U0GT3!XY3J|
MA62%1)Z)=7|K1.OVAOS%|G^@+<?'KS'(KB^!|3.=|ZF(2^TMVY@W7+B: M.-
T!0K\$MROUA.34/9|7O77=O>5|, %SN^|A8G/Z<+M?^*~\$7%\$K(? M^/41MS:3>=#|.#3TU|_ "R M!Q="F+0Z%XL):9/L?
B+|Z"(QZ2>Z>QM2M|F9K8:RFXBN-+0G_-/8+3WDMT9 M55'#JDW*U82BXZ1K|78F OY)CKFZI?
X_#<|&90VS0DA*H|V%VHR3|357F3|MZ>>8<+\$/H1LRP2B70PESV*VQ5|TSBL7Z,."G(+U:RHL0V)-M3A'@G^|S-
GI@?M.MA.G4V:EU@A7!!PM!::#YD\$F>NY|*BE^-.!=LG4^=)X MS8J4GG2@C(C WO-
X>XM.3E_N/XA<2U8(|F=|*8).|PL+?%DW|<D?|C38D& MBW73/\$E"7?,RI^|J+8?
7|H:.\$3ZJ#&8E2T)F=U%)62"9@_ DICAA=,SKL%/LJ M1'XJMTN+R.(9J?EI/=<|)B>="(S|88F_Q_\$06D|E&_X/CR2|,8NQ
BELI4L MA4R2+5!-6DB6J>S\$5,+(-&OH408BDK-FS-(-OA"2\$K+H9)G(9 MO| G>5X|+_ /B^?
%_<*+^=RN\$J0XSR.Z|ZN|T "%IE?1IEU/_ ,Q#B&A+M=?926&H!"6+OV8:9>'@5/7'LNXIA:9-
(HO|ROD:H3,O>DG7#<3"ER&WOK- M(#?B>W#I'HMMJS)\$CF6#6>8,.)X"F3:#:R%N=E6;>RJ0Y1*VI4+E-?48|
M!9>&4!>_ FEODYUT4#2P/@X18.M91M:M.W!\$8=&JY3Q.FXZX?=>|MJ|>NYAKA|
MB|XAQ10UN+|B/CQOCPZJ8LP^=W^W)6-!#:DUM@W6'FR5JB|ABBHME65*@"VX)AQ_XW:5)*X=30MZ,?T#8<:0:
|I*ID M#J!|.#|NZ250":S7(L06!=K0&91M"\"N5O*=2Y:.)@5H*HT|NQ-L^VMD|NR(A7" M78,#)ZIK\$,Q@3G%S'^G|
112:8Y)Z=C>2GV6!\$PR-/>8Q-H!"H&2CA.X#R>@'OCO||_?4.CHC=IK5|F: M#2O3V@_N_G?
|12:8Y)=|N|HLN^R3#|HB4MXB&XF|HP41+;K"IP<+@|O4 (=M>MM=NE4!2A-
3KSDG^T^:3^5WD9(1TKV1#=#58XPZ9B:UN@?#M50W|E(L%< MEXK?#6(G>CS%_T"5ED_('3+
<_1@1)=+U61/K'\$YV1|'2*"C3.ON+;S*1X) M9?-M0Q+*)W\$|T#T# +|!"#DGMJZHIP|RQ;KTMU5!O8'=?
Z+&B8M*%L@SMS51> MJ_@R.4P|YQG|GQNF?FE\$T15_U|P:E6N\$\$_2@>9Q:>3VH G*;&>5>2H>T> ML|3>:
|F#U0_":5PY<:(U"4|V2S3L MXV;/GCO_."Z!L:9H_-L&CK(50|DR8"1!&_2H|D4(HH/XNIZ7"2"VSW
M!9:0.C(Z=E:V13Y|JNSNH.Y8;".N.AUVKP:6?_#;BZ3MD7:F&%Q)40X3ROT ML6.>H|ZY9|L|485|(*?
W94EM4^;7V6|R_0R?;<N&Y9??"Y!A".Y.\$Y*W MEBGP!X|3|8OL-\$-%J")CDY>UCUA7|J-Z=>:|??
>ICOL#>W>Z.M(PC9|X-V M'BREUABS^DN\$QHV2?P>-19:.5_4NY|*|UHQ/&A|+#+@5K|@8C3<\$>5F63%
M=.*MYAAB\$(0^|FT*\$)1S>CXD7|J^26&Z:2A9>ZIG+!0 M&:=8WQ.CWP@U3GQ-
=CWW^6FPB_XHX@C|GLSI#N^&KRH.!!=H@(-1-!V7+ MY'!.35CRV\$||=JNUO@%/8L_
TM*~*AHR#2>A_|N:R.T?"YNXLT_5/70Y4|) M|P|?1M|JZ6WR|?O(&*S>_983|&\$&6*05GH@#!
|N/HCP10A=0RH*8HT)_T7,\$& M;@B|?DET#0<7|7R:|6T.2@N92_KS4Y\$S MJ4O3;"D8|R'(H"!!GGCK(L9YGF|
(2|Z1G3C)73HM6S%|Y9V>@0>|4!6:>X9%.;=)J#W T2#EM4P< M>4,ZA|YT='>8XO=HT|2.#@=15|3&3Z|8(8V
@X5^<EG/%'5Z_0B_9B'|(I|AS M6^Q#SPO8*=@B@.>O#6PI MN#)F/_5H?
U(EXIHON:O*CU(|+EAD5OYA106%"9J|H1O+|+3U&+*U|_~8 M2!%8!=MD8';TC##4=XYF,R81UIA='FZ%'V;
|&<C/+7|&G M.HPP<.<)'QM@(-G(S+32_8Q/G&<@<C.CY7|NHQ>,P\$2*1:O_<@<4#<6+F9J%4^YN;+X'>?
YK0LZHK77C.O& M#NZNMX|H(M8L8_|+&9%"_!X_.\$%\$23L%:=SZR5@1%V"4/SQU9|3EQQT5*Y
M\$AK/1+H8+X%6M)HDI.MP.A#|U->90\$M*=<|3B(E@::|N_/V.YR6 ML|0L\$;SH",&\$X|KOFH=1\$>|A&%N&3"U?+V=|
G#085DNOZ2/A0FWO?J8^@ M OK(^3%P.87TEZMS5Q>_<^C-BB|JT^*|+KMG/F8L\$%69/QN0?7)R%)"\$8) MO\$;
|X=|@UI(HTL)_F<^\$7AFHQSE5FSJHWAB6%K|O|OVPSE#E81#G|G M!"|X/M4#4\$5"@=YJ5V:66-|&1BIZ?
T52?&UW5Y#YIN5*XKF\$, %R-|+SAX MU:QR4P+QU5 4X>CTH9=A&E3O?D|S3\$A|08QQ
MH3!!Q99ECHYR=+3I|UJZW|4#UCR79W8-7Y>,*JO|U=22+D7E2D|XLV76YB04^+ M"#=A#AL>?
|Y:FR|RAJDAR=+GRW50XN0SSC5N&C|21:=+YH8R^!HKM_OY?S1+X|B|H|CUZZD
M&:>TO?EVGHBLXX|E247GT?QO17?X,<+FU|XMEANL|>|Q1UPO+0_?>M M5H^P"NXTO.%(CZ.(8-D;+U\$?
Z:D) @EVN).W#JWE FF:~.X:3>E?%M(H M?HI=*U>)P_40|<(-M.VA%5+?740@V(WR=W)+1W|H(?O?
5BOY/V")X*.4E MY4GGDI1G'A+|>57?;SVJ=%B&NMA;_?VQ|=\$ M)X)QUV+>PW'F49:8H?@C?
GLXU!2QX|_48|V|XTY\$NAH1^Q^759T^<O2TA)|8?O^XD<1UR&*FB60LDJ>A%Y_|1X,8|&
MJ=T7SRLOJW@UW"%"9O)@|L_!|831TAJ^Z1EB9+P|N@P\$32>Z"~18L_8'.U M&#-D02*,MYK3W|;5.|O?
FWK#H< MVVZ8D|L|9LJ(H53Z7FUA*UH2O_NWMW|H|H<8|~R58#)R?NW!CP"=Q2
MXHT6K(N\$A:JT>S|H|3_7^2K;L;_G|O'3_'L')='/'L426=H")TL+M"!2|'O0+&?>=@9^J1_?OG|YE>-
2^2^OYZ|PW8?9-ZBG>&K09T<-CNF8.W@9 M?5U4|S0?S5G?2|O44|HR?SP7|NWAWS5;@7E?""4+B?:@H0UIG?
F%L_)2| M0P.%?2|PIT(^G*UU_#|F|_X(G?ZY|* RF&N!/>\$RX>&><3U68B_ H'=JEY M@1ELZ|Y|W
SXOI+79+8FW_/B2,\$S2>X_..SL'2X&^(Z|O4%ES M;_2*(=T7+8B6:V>|OTR|O;_U4|L2FU5E_Z^, @:#@NI\$9|SU:\$AF-
5.%XMI>/_MWYWE65>PG.2XO3(27/W+(!W|T(R2|66|CASH|TC%OR MWE3?L9*.KDO*@5R!0"!!(1<\$EZ%=<^D-
KO@VA%.(/TE>F|9AHI^E<#72B M2WT1R6)/(WCEAGSK"W=AJ?+.|B7U_4?U"AS1Z|HDEWYH|6C.|L0B6V(
M'S\$:*11&1_3Q2H@". Y5|T.V4\$DP|H|X:B?A7%-|Y.>>78&|&UE9=G+A' M|SQ_=MPH2BB\$KD=%A|2\$W)2V-
+PETF#ZYG^|B.OA_E^97/?C(AX(WU9|GQ\$ M842RCM9#!S6F&C0%Y|V8LHV;<#U_BCW|CZ|L):|O_Q|9D

MQOUMCBGWK#KEQVOF90A_-#2P)UKX/JS#"1X0(LM\|T MF8;3'BIEKH\RX+26>H^&2>*\$;3/A-
!\$ZE9RW5+IY+//+O1D\$=N PZQO EKI
M(>E7"QP&8E>ML548(IYB:6,QDITPP2Y2C)49<=N9KU,M0.FT@7B\1V0H6> M73EI?
I_YDWT^@;A&U#JH0UOC=92#\AT1V /OVN,OC3N>B8I(ZP?> MD6R1_6<-+KR^*?)4*N_0_U<>
FUNBF41WAO&P#PIJEZ^>DUJRR.>H:~%1XG2^M^>R#_?YK:62-8-B^9D2#2)2WR*7,~
D(K,\$EZFV,A05:@\!&VIO%JFSSIW,/715Q#IW^ MJ"@Q4(O\$+)\$&_!O&:9K(Z*M,KP*R M
H8+W_L@:V"N28@:15/WF^S8[36]D
MJ8,X"11M9%~%LD;PQ,3SI/N>>IZW%=H*M3MB\$/3LV9[B>4R>SL<2YI+A+7W+I
=^IQD#I.OM/#@GP7>MRM,E7L,2Z64EM(^*M+TX@AD;C,9;5*^H\$UC2I-VGKUOFEP1YI(-JR?
W6;LQ9W*1!@V%\$R<-ME MO9L1Q\$QA3.53;O8L4_Q2JKVGPQ:NZ-|HFWQVFI@U_*"XBJ(*I_-=;BIH?TM9
M^S;G8 V9I^WBK^H,V;YSDI7D@^R&(@L@|NR+N^|UF5=WWRK53>F6L(#:W M+A=>
<=151VQK1%YY@P;EE;Y8HGB#DYI,X!^I#(DW\$Q-F6YIO= M=",\$M/G4=*C5QJKA0YN4?
ZE^0\$^37*=WMQMWLKO@7I;DGT^P6HPI^B*A M.T.9YHO+\$^9.SIU6Y=24IBYI%"M.7<|ZZE?X&<
_Q&A1!"5FT?"NO:T331IJ M/PI^AS&Y6VM+2<I^*2HGJ!4>08=WN;AK0,3SRG&O.FBM<I#7&&ROZ
MMK(" \$3)E&?<"QK^D?X=KQ%D,E|VVIGD_,ERECH^F.>5W.\$= M ING1,">^*61F+9-M2>-(6MM<(*NC^WYJH9*,B
MU^ILIS-60BW);**)@T3@I2>K_||L|O?>0>65+B3L_\$N!^QJD1*TDL;@X;
M7;QT)G(%V\$J_@8R&2JE!|PCE|PI&7DQ)GO#JPB?"UUGMC5@9!^V=F#!WIJ M/Z5JE.IX#IHP\$A_^(<IY,?
^.&Z^DKRXL_- \$UC(-=YCPTB-DWT;U/!"N9%B/ M.KZW=4+>9Y_XG|N^|,H&)L=? %2:RTMI8N-
J.2V;"D)&E&@R(39(CMXVJBK|IQM2!O&DW^PYF=B\$V%HO @\KJR-75/3H+P>_7;, X7ND_24MG>
<+,\$Y73(H"IOQA0UIH^I,F#N,5LZ3CF&W#0 M) 9K@)TKY3W.E4\$ISH-S;R8YUD?H^4!^4!_4T&4-2N#-'H*3A_LQ
MN^>,357VVH;T5^QJ7;IC7<7(B-E^CT;N18LK/Q MND9AT TU%|3S#1VSH=KE6,TH\$
9=H>L@Z1IS^T;,>_N_#YIY\$V>* _8PLR| MK?/MH|^%3^V*^+YEV_A%2KA^R>|_*81L;L|PW99PK1%Y
M32\$8CN;..HVVH;JD.Z=, /OG)=MFC'=YDI,2BL_+Z6ZSI;KF%;BH@ (N!&DR^%| MN&VY.UASXC_J14/^T|^(!#O',CG
ZF%3_P0)I5Z,+|L_VH4)\$^%,IRBG_N MGRH='<(O=">^&8Z?NM5#S(IH!_#OHV N!9BN5_ B8\$4_4ZGYX3_G*B_Q
MR9K/NG(CS;V62WG&NPT,GB9<%_ZM^F3(I_IB7F<|XU18&CA1D&KYE M.<:0^_1PI^IVY(8B?V(B;R>M6NP-
JO,&N;D!!M4O<@I&J2YJ+GUX^IV)^ MEDIS:\$@KKEL#!??^SFIST8H&PDAV,@^M3L_?JH9,S,C:MJM_6Q_Y@"
MG1+KYE76I^7X/B#7HLO,3Q+9QLRUKQSP+C>^DN|B126^H8,ZVP|0\$S#I MJ6LJVHY-
%UO:L47^CRR%-N%E2^5PU_8_ZI@KFC64IT(KMMN9^INR& MIQZ=,>EC>FL13
3IXA&@R&ZQF\$E#L2AYVYOZX42^HO*OLB76&WUFXM^&I M/4U\$U8%\$M?Q+-'5\$A5."HWSJG_!;\$O<-
_P3KI7KXNHCH7\$N).<)L|P:OE MOY6?>HG| VRTR(;75;\$5@4N4:5*FU^KA*!@Y)"4).I|I^!%=:F/IN;G5_5 M?
JSY&K6!_L^XECE<8MNN_!^?^O<0XSRK@W!U7_~%8|CF0_/RA_0K;+ MAQIC|HJ^/945@Q2(V07|CS@
@9K#R2^|U39;|ARH;W.<7W%&^|KRI#V8=&E%)FY#&HDQI_0EWI7>4HL|HG-ITON3K&MI1KK_U_#MR<02^65+
M=5"@?>294*XP#G^AP=R"7E05QWUL%ZOSL^_HHN6H6ZWSYFO)HLCITYK| MGQJ(O|NIAS;N;7Z_!Z#_Y?
_8136F!)7(K\$6P^Q5/!>=\$J?>4\$TYXXR M_SPX/^C@5,X3KY0LM>+?*(C)XN&^*K|N2R;)U7R/^6(=OIGI"
M=W3&2\$ UN^?>#R-L0GM7<_B^LKAZE|O\$>D5/H^|1N#EH3I\$#7&_D&/AD^E3L_2_M-V;49RC\$^J+RG0_T-
&3YSHI1R5 MI?_?#QM>/C2P^JYILZ;Q7@/I&A\;AN<^NY<_7+ZMIW@Q^X%I.#K(#0#K@
MOIP+;)E".8|M6Y^X)FE^6V+JKI_892_X_|>V|OBF6W4;W<_U1E93Q|L+X| M.G" TX5EB1TB-
|FL3^<8GP+37>|L;9D|Q%CEG=:O2CA@_!^L^YFBU^XDTI M)?3UE-G%^6;UYUW;RYQC;%%CXH;D;Y(@HL*?8-
AE%Y#%~%X&5(3+D_FS_MS((?>_OJ?QEB#J26?^2^&57EEUWV@TIFY.4J8TT8E#FS#1UBZY%V9@H(?) M!%<3--
BGQS>:>+@105/)<|^*V).32_4Q(P_GE IQ5^_\$QIN|T;^I_Z^YGT>^ZAI M-%.H-%G<<8S*_H\$'_MSL-
YA3)^(:CT^FYYYJ#%-G&>T+S^8Z.+@T(JSYAF3X6SYEC)I4(^UCFGL_ME-2QI+B?
+4YRZK^RO^X^413K@=&F958K4FA^86T0/K>_H<=&ER| MJ+ON=-=JQ6=0Q6DGP*&J28#R^"1 UA1,(JIVE?
@|3%HGZG%K/N<-P &2%Z;7B^<X6;=F<&|OP,PYQ@^E;%AQ9XPA8|I M"
I6)>|ORUY6E>PV&\$Q9Z(2F^N(9KNB0U1/^G0<|A|D.%<6FD;\$\$\$-"CYSE7Y5\XC# MX^U5EX>RU|
_FSKE;E;1>*NT2_44XVJAOHKJ^2W@?1&^*77V^*|FB(OCOT+PJE/O&RMCPX1@S)W(7MY%F
MDW7\$G(C^E^S8!^9<H)-4D830) MJ;LH/=AP|&XS_F%DMXM)J^_)W;3|^P37BF^*A|LBNS&J.A-UX0I\$ 77I2? M
+@_IEIV/2(#NDY;H#3\$.M+L.B1:2D^QF=-;\$9U;JYUO;J&S^=MK&B^2XKP MWJ/A^=BI^3WXPDP9"FR%)?
=QW.TZ45RWE2\$^U++M#;Y\$5?F67K;DJ_ZZ MRQR^;TL;Q1134CP&O90_BT8UFU<WHK!%LUAC0^MYB38\$-\$
&#=(0HL)A/M& M@%5PDC;I^S_CMIK6>HV6)F^*_@DI5YI%+.*|9/7I^#Q-V^OTZO*OM-BSYVH
M+>9)M.4W#G/^7O^XBCUQY;2.E.U_7/^6810D<^#<(1DYQI^5FNG3_3IC7W
MDQKT36EUVE!1P>E3B4O+=!+K(>8;PI\$|Q#&K8AO)!!P?R!^?W_R.GD;\$WIN
MW/^!ZX6%>=WFH>25>_KFSI(?2Y^G@YM&)WIG/=(+43>SCT2T^7C&7)=Z\$
M^V^NC\$|K>R3AJP/EGRM^>KH!6?HC,TO3O& M^T(X0<|D);?@ Z.QN;ZAI,#XMMUN|PV& M!N+3^<+
(4%YH#7K+G80KH^YNPT1Q>YE1WS:P%QL>_6^T8W0F FI.Y2I.!P MMWY\$TZH\$*=ZVSN@OAQ>8#^#N
2|WM7GA:>%^AK6;|D>8EN5WZTO7D39BE4Z1 M1X.L;PA3NK|^C?
2&^@5WW6J="2A>9EB5^G/Y@2#OAVO0^!5|IV>#|/(-69^ (MN;7M;01=_|RB1D8L;1K|,T(1Y7?O.
I;6L|UON76L;5)"RQ>Z4^D+SC;Y M\$+3@&3+U9W|G| "E)T^JD@8&+A^68Q^H4,X5^T^NFUM^00HMK#\$?
\$U&TV2 MG-E)I2D;S=718<^ME;IK_I08,MVJ^IESO;9H_YBB(CTLI^SL.#Y_G^|,OH)?>L;9IWX;<
MPLUV)D&=CP;V.G|I2<_UG68*(5<3(8XR26@I5V;Z3@|/I_6@Y;?Y0@AW| MJ7#3/_OCF2?P)I%1!&
<@UI=KL/\$OH^UJ|HTB|+<^H"+SF++A\$|Y>P%<|Y_@3B#W M_48*#)TSRF+|^FGORS=A-K5.2X^(!
KYUE|NLZY;F@4U+>EZP(. MS%<|B@8_4XEK^H|/R/N 1.7\$N/^/#0N)LO|B#T690^04VT>JQA4&8@?>C'
M8%J;2ST/44CPP WYG/ I9LXN^84_0N_G^Z<3/D&\$&%|>6ZX^MYOSR>^ (6&W=Z2NQ2_||4R1!0U>L-H,1QW:%8
M!70F4Q>L9UUVXW|@FN?TPG>%S7%DO>#6%).I68|AJH?2N:~%@UO>|R?^FP64 M9;S>O;?
M/5L^X=O2O<102;J\$4|5W;25YZDS?^OU.WI\$Y>|WI<|/RR|C%*:/ MC<:;&6=>'(EU_!V!MM\$M&EJ_..RKE;L 9665-
9NM46@>@JX14U3/3Q| MT E4E7_!XE4TBRT3OOHX6_K^I M(O^A^Y0_R&2D#&?3?TJE3^@M.6.WYEB;)1-
ZZI_P5>G|V;ALS;WML^A16 MB@OER|5E/CSM^XW|CDA.(E9BECM-K(HQ7G^X^T^KO^&94*_RWC M2L)+*7?
#|V1B#^>_DOUROK#W1;W|HU;?%KHT=_8UO^L;27>QP<;C3W_WD& M^2478A5V U^/H^K#J^!V!-|L1R+^F|
!=PZO1MS<\$&,+@ (G4N1_W.E.)\$KH8 M?J_GJ_ ^N#^F;5_S\$CNRVH;D.GTC_LDODO+&|6^DG0L"<"ET^HDK^4D?
|K\$24\$S49)R.X<3R.6*;I;_7=^?W9I M((O|O>MEIWH^CG.D^N.TFG72ZS/C#2^_ZB;Z.D%|H)E?
@>6CL#Q_>7M^*/@TG^I4^8\$XWN^H.ME|N^D|E5,+Z|C2J2N@V^_5BK5T5W/3+0IF2J8|PEX0^ZX\$E2-|ZQA?>)|KF
MY^_WV^O5N|^4F#^X^0;Z)=2DVO+9D|RA8^XWW\$TNL2N2F|YK%X|S='U55-MP0^J;_||.78.WCB;H-
4*87_K13V&XG7O5U119M|CS|8G>7"8M|SXA^ MO6L>>?
>M.R(IYV71N1A;GK#8|4MO2=O=4H|8TXECE\$^L;YO|V^RAWL0;5D MVYTIZKGB7"
(X^0>O@/YU=;QFIFKG9^>9M^0_KU^G_KIZ|TKO M)^7%*=2O1^2|SY5T^>8?-=|X
MK)N;=_2N;Y.W1=QV15N4|ECN1NPV1-Q"\$VW%(P&9V_!|L@4#"XT3#\$.4+GC M4>NUSKQ/?|=VR;
|VG.#ZGMIC>U)-E4!4(K#\$F&R."IS&_+&EF|\$.CWG_@6I M1O-L9NQQ9>L?F^Y0B#<,"I:87YDUH|H0L^C188<<-
|H|A<^IY|H8YDLG5^DW" C^*^ MOH2SK7W|8;X_QX7A;R J>&8^RV(<- CMB\$^|FI#^IC%M)|IBL# MGJA#G-
8W_WOQ;ZG+YN3MYY)+(I51_2|^|=J+^R>KAUS6W/(SU3"+TJ|YQ@ MS%%&U|H|E:(?X%V.^V+ICQP)?

PLO7BPT"J">J974/H3W1/N/FA@^U# MI!%>K/^@ZYBQG%RB?IU,'5?%@UH7G?V >9?WTC 0=
<(D7((FUYB+IAA_\$5"1#4FJH)OI M.-VS!5K(R*6@-/+R@Y3K^1#9%!LO+Y\$SQT;WM&)\6.18CT0H,0 NB'UO<10I
M"09AP&A/IA/4@%8D<,-;XX'R4W>:J6%Y8 +1CFI1&=-/M&@BSG?I^ULHESYN'0N8*#VCI(ENN
#XS3?^<ZY1?1U"PIJ.WWN2RTP 1&AXI# .UM=K:(C9.G=0BX937O%4;5M-M,7 MU859K*IN5'ZH*H,R;-X7B%66?
#LZQ?VY 1.*B16.HR Y6ITW1EAAE3 MEDP/I(HISZ (%Y;VGOPKDN.XB^D7SL);W1XT.IVQ?>0B,I^HLE_U6@X+3%
MY@N" 6. +=?1BQ>"IVPD((4)IEP2P0Q DLAIGKJ9/60HIE#0 >.;D#^1B?IT M3\$S=0Z;-16 ?
^?7=4"1I_58;M:E*8(.=C;@.7?I K:R&>AO WIB6 <1;MQ MI3U0"+R;QW\$'@)OGNWFCD/MKJ&I.I)SYT*?
V/AIV_#+EIW14<5ROV#K(^S MV;1S!4N5?9ISE&T;:/>6*(30+I72A);!AH63Y0G/I%7K=O>&V PF+V>O MW.O-
CP@6FE-5_6J4I=9BMDI@2M*M%I58I26Q\$164<:"ZLAB9ZE4 I#C? MQMA35"Y^9!2A7);UJH 1>N^"&2=
I+\$1Q%^;C*[NX;&R2RV/NV#;D?QBA1B!! M&=BB*S!&K8&/KVFLV^..417S(^?V)WNUQGA>?&75-AZ<I,U>O=T
M+Z_J(C.\$IT@G)+B#&AK^M2A?S\$V8.F+JITF*MS;J>CH(^30IL"+_N+C3IP(@65KL@N.HHQ_B9R(O9-
89Q_NL>6H9IPGE.O(E3 M8A1O 2A?S\$F+JITF*MS;J>CH(^30IL"+_N+C3IP(@65KL@N.HHQ_B9R(O9-
MN!"4*MAIB^B#)N(EM>W4 PAMG)ZQO&6WQ UDI\$OE);BI-BJHQGM;<\$&)
M\$4EIY9ZQ;TO.F3O/H/9C+DGKG,8_-4SD7P8*<9J,2I_H20BB@?37)+/= M;7IDD\$17S'M^G1+?
I=LG+W75FBP)TITJT,@EW=;U80!.<88Z'7M_98X5I. M!P6"OAGG.?KKIIVKN/8T-C?"BBB6XKI-
+30"14C.L.ZYF&T!UT"SXJ MN-SFAOL=%5F@9P37+>8?W&D(#-"MJIM2&IW!
M;R!XB3I!&LBX!15;@IOTUO=GO5*2ENW00+L3I\$/I=%!\$?(7IL+IR7/E M5%P73AP#SR^<IQ(T;WP.OX^
M+.M5;J9NTD.\$<379-Q@XICX<2Q%I;OG5=<)<5%QIMN I?_74G+%"='F8(IK=-?72I)/=);E9!6O^_80;(
MJ0!S)/1K1&H:#7(J<#(J/S!M@G,S5JG!-WR8;"2JUNW1\$I P\$YI2Y\$UH^6!9V8!NRIYHAKU,&\$9Y_6# M3"
(J!M3><^RHS3?3.#C5_?Q+JV#WW=ZN29)=6;D7(L13+PA.GQM""7FOE9O M)J(EN.YBGO-
YXBWB_E9O9OH%R^=@5+>GBEWVDB=CIT%_U+5C&CKA4Q53K0K2 M0UUCT%IP4D<9/3.OJE&/G-T"D?IP_?I?>-
&Q3!F=0)<*)/ZH6BO?_KEIQB.60BC0*O^ZC!L04)U.GV9Y<2<7I3C/);L MLOCYIC?C3;A9_5Y3%6Y5T-
(GT8@.Z#0N2BDW=O)-%GKJ!>_F;<H+ZV93M6 MO5RT\$#9#W&XD/ 43)GH!US73Q6(?G;R%P/N> M!9IGW>?
T<I75"FF+ (15X MX8N L4FPY03)^Y;*7EEM-SW1R\$G="0K IP4X.65;ZH/CP %8ML-F%+FU\$% MZ9<
9)H#6C2"JGKERYHO38^*.W5.KKO+/(Z^Z7EV)>8A+C;=>=IEF# M>+?ANEAR,S26(Z=1KYQZ1U)6.(/%M?
6I@;M-4D.J73>_>/8K9="RR8SP MQ>4M.@ORRK-BD>[LL@!>=")H?W8^&YAY;0S:6KX!/^%)%D8 (3&H"MVB
M3)9^E77* I_U"-Z!M7="99%94%2-6M^P""29X+OJ;\$5APIBBA8!^VX>E1?
MYNP+M.A;5D;R32 Z!5^#NO;804.X\$3)-?0PS#5N/I9VJ/2E4.7G&0OU M WLAT+9_?%G-74;
(N2O0#C"!.WP*UNY'UR=?RVCK&)!4YIYQJ:LQ%7SKIS4 M96G7);@N^IK>--W3/*W1>OJJC=
IC;4AU^*MTK\$;L:NR&2;Y^IV6L(10BAP/HI8% M6.IHG!^HB>N3+ 10IA^KWI#^+=IJS.C'RS;T(^JW%/+0J!>
C)I.C^R_NCBQ M3G-GX W(="2S!7"C=C.6-5J#^6JLZIOI25IV=J42M&H<.2;I@.DJ!8YJ65;> M/F6-D?O_(-
IA06PDCQA&<0=@37YI@Q9&V'%RXW(1D^0! O2RY4+G.MTIV3U MIR*
IA6^@U"ARK8R@YHHWH3&E39EO=CE_EXKR927L#>^~A2Q6\$O=C1;4B+ M"TE?"ZO?HO?#^PQ5;S:5=
H(O)QHH@I^H)~%2EC MK#C.\$_A?HA=)F>;8AHD_AQJF<200!(S!M%X;I,7I74S)O.G8WYECDZ\$1PA
M.;>I293VE/WM"S;FJ8!;U.OV.XHK-G=)WF.CV.OI?I@I-XS2^U^K*MY=(BRF!#G,U"J
M9SQ/YZ5Y,>/>2)I!* N\$GMS#3^4IM2;+=%=%7E"3FKN#J<5=?2;@H) B#V
MD=/AP@0^I"17#>./)KX\$_6S4FD+\$/W8#_.L@K8^@"4B2,R7A65#7I SDUO2BV0IDC+3&HO7I_I0W\$""44M?
ZCG2(AGG>6..L)3FOJV(5?N MU*S(>#;W;ORJ@D!H6I" 6D9#*IA>?J%I!_+2(C%T?(N:#J)9-\$%/I M2@R++"?
9_VX&J.=0H3-@E-W"4D_UCQZ2LB(WEZ>C#GY AV^U/=OBN@3I+6 MI=2WJ=-=AH+FK\$(I/Y%Y%IHV_VA/-IC%?
I(;\$).ZO'IGT@I7MQQ9@IE_P@QOM>7NK741U;4+7*K%U:73WI&16I#_M%5H\$X=JCS!TGH!9RF^+EX: M?
QIW:7TD9X(6IUL CJORGB>TEI V*_F#)PY8ZL#I <@5A_-/<7%"R)?^ MINNAID)78IO>%^RY&G-
\$+>EMS!?:OPD/&H@Z6+4@.. "X#9GE@>\$6(#W;#_#G M@*VSC(WN.BB8L;O2'VM'HN2,>H,3?
C_VA8)*GV;XSXUIG02.GH.X\$//_ M%?_ VAQJ^D1-93)EK7B7N1CC*%9*WG_70CW-D*WP)ENVL@9016PHQC3
M P@PN&X=#SJ;>IU>(I @@@)K;4@H^&G6Z;6""<<<=ROH!4IN9!&5^R!OV8(
MCW*0HJR;HIQ_+O^DA<.+G^KYY&0NC0 MD^0APZ9@8LJL;4@OUFQZPX6M1-Z&'J&!(Y>I6VQ#;XIH#?:94-
X"XLG+ M)IQ9)N1NU;&ER5SAM6V(Q!0' RT\$JF&W"E&>O!ISEM.#?X6V1+7AX7 MD:1RU;&&
(+N_"N"7I&MZLIENJ7CWC3OA8?<IQ82%V"AOA ME6A@/L%74-FLEMD_XLG Y?B-A THQ_F88!>=(QUF/N%O+
EF\$DX/H8Y5HJY M!+2T6:37K>4DZ6Y#FF_5&OI)&/D>+M5_..5G'.AJI I&G!4#FF-I4SJ_NJAIK@DGHJ1&
MS4R7/FXH;+>J5EUKS4'I^R<.=I=70TH6UO"P/GD!H8+QAF>>+ MP_QF_EI?
JP4_F7&4*~LHOVSIB&^T62=.#.SYSMRB(99&E\$P!QI>XIS9(8?3% M4<>@VE 6"6DL(PO,O)SWSES"!;U9J.>_&
IVIH50=)#V<.59'3(E%M^&\$1; MT=-.@-H2Iz_8!D\$P!L@?@N<@MX4*=TE9N_.D!?
N#Q;4K#7%)I1)ZOARI/WFZ!19WN@SB\$ M +9ZB?SS)HF\$(Z#TXEGGL; @KVIV8-W"?
=5EHKVD(WM^;DG5_W8AD#9;J C MI92MTR1;&R"2VGT6:VO;FZ?P+RS%\BM{X4+);7Y-;Z3FI^5A4"%0\$ZL=;
MC"6P1=F(QZ2_C_<?I7WI>%0AV^X(M8&IGWJ6REI"0*&9(I2D)E&R7KQ*22
M46/&OH^9YWWN^WY_O^=^4/.*_=/3+7+?#_.*^001+I^V\$T!&MGJ^AM_Y MG(30\$!ZJE?
%B'7.43I.EQ2;EV^TQ5Y5G!UW0#\$_.?U%09RDR+@#^#>_D=, MZ2QAJ;EI+!(M/FDG6;JB58P+Y/-S8OI?
FT5%;K\$CNSFG67H Z!18\$!ZB MJ_8H;*9JU=NAJW_>VEV)I&O_OV12W_2;4K-I(^7NTT-V:UYTYVPWR4 NN
MUGE;OFC-IVL/DWYU/ Z!_"GOL*M-CWS/F"Ts_..2LEJ7GD_38Y@RUCS18^TNB M4,8L8G&8H;LZ!
(Q*>)EY#@D)7;ZD*2=2I8 MP_LIK1WIKW?IH!FD15XIZO;5<=NB3I;E^ FWGRQ>CI7LS=AI7_7DN^JNWXL
M_^FR!E2T"W.G0N/#RYO:F2*39*JCYOAX3G MY8A@G8&S""&!"FLO0\$QE&5QMKB>F_*' YGP!E1IGLL(G2IWJNWJ
TY*!0 E M?>@4WB4#EE(,C)1/^J""^BA>HP;.:22@KQU@_ M0^0MCX;&>"W_X4/O!_24XF/
W3'6'BM&TG0I_4@QPXU@#&;2F'K3Y7A\$CJR1 M?;HI.N!MSW%PO=ONZ^J/
J;@.\$JCKH^IIE!.%PIYV17""8NLXJ5I/68=S ME^=K%IS;Q>?
FU>^Z8\$;WM6I%MB89=TIQ&K_V86';9C976J3WJYHK_IU
MU3K/OL+XZHABBN6^I732LROD2@VX#VYJH66;FTH66(P3W.%+;G!H3.#8;= MKKR5K6<;=X7?X6@/?
=IUBAB&GF7Z-D_<?GV#BDQH#&LM,@NIDH+I8KY5" MIQ_(!=^OQ_>@I=HIZ;P<K);N.J_#\$29R4YZ>6\$R>
*_P_J!Y6;T>575<I/KI4<0I_M-K1(!A/VVQD)-FA73M4%_#TKX?5H*ERX=>I0LSQI!\$N:Q6Y4X;JAJ4ZB=PB
ME%\$5OV"!\$5SIRPOW3S!AG%T="KM I&Z;NFI1QCA0\$%_+I4Z,\$L41@40(MJK.^>Q\$5X^@!1-
Z=&G#.#0#1MLS_034XIH9@?K\$SL88LLMBX!ID81U@EYD8 M8_00HF#M('63IC62I4NE,I=0VAISH
Iu2Viy4S#E.YE@ZZ>_0Q3">^&)E MC)!*V@R MJAP0=-LIZOFOP?"K!W!^0DJU8B%*!X("1-IUE%PF!>-
A='OT(82%NME0J2_ MCK-LRGMCA*!K58&+Z0T+UFO:3'_S"IESYAF/F&(I9QQU?"^"(S5GS0^ MY
-<I6BC.PZ6!&)LQVR;IW6(+OUSS-+G5DK1.#.M5R3;CWCMM^0.IBTR8<_M@2+L!^@IK6I^G8;S)0IQPG-
D(9;/7AQIOLOQ2*!I7ZS^ZIK716")8E5_M=K6I+CA\$;79ZH&5DK@NMV/PXPA3^&E!C4F;5CO-Z)HH
MAG!H510' 4X1 @JT-R^^_L;25^_TV^5#ID^NJ-GS9=N0S=%IY_>9*&8H MYO/Q14HJ"P(^8N138^Q;3&PX?
UZN'DO(ZB!NJP).IE(C_AEY.7M/PI7N7 M+ZH'FC|WBMCT7H^Z_HIX1A/@J#^!M_3)Q0IXMO" @BU.(C_123/9IYT'
M)2AOD_HI2_+T.8\$8E!C+&+WE_&O(XPZOTG"=XFWXGA^8T6)9.ZZJ_1V? M>I2\$5%?
3HPZ*O=A&\$6YV;ILQWB3CJUKAOAU56F5M(&N5<7Q.*\$S6 M9BJR>-B=Q.OX67I'8*P'G@1O:TA9FD<I
HB\$LHG2F=I9\$4H!A+Z8*W+I5 MY-'?KH+/M'=I_Z\$%I M.ED*&VX\$CR#7?S!E6#I S%K0TE@2L4TVCF56,80H

*EZU?>J0#3A?(=)RI+ MAJE/34^_KSE@G-8N?G|HN.(Z^|KXG|NJ X86#<32T+RM:=GIX8B.T&&(V(#
M1Y|FG(U4,WQOWWR7&=|>V02/@ YB^|IUR|SON,*MR\$|P0PRKO5\$ADC,H5Z&-M&WTN=)_*L6@%DKC021LUI-
XE1ITN45YT#;|Z*U#%<|7HB|E-Q.7U-Y\$7ST)IH1FCE|0"GF V. M2#;S|/<.9#;Z W|9)TY-
I.@|FTVK@94Q10S||56VYHTCTX-W AJH;DV?1+R8-VLDC_W3;A7\$\$.64^@T+L2;KZ.L7|OG%|JU5)\$BPPS_1|H
M06ABD|V&|CGG.DABW05|H|2>K%B.*N|JLH@-CR57(48>4W7C.6ES0FQ|S_A|+ M4\$>@&N.+UAI%\$8X0|TE4|_|*M?
L29:2|L_7^9MB<:HS:+D^%8.W|IR=#+ M) A9C89V).L5K.E|H16R7AC')P1L^.;SK|MBJL\$30+1#4\$(7G.V9A2@;6
MC%9=Z*6SV^..AB>W8-4F_5|5X;>>/3??+|=!S).WLL0Q=TSIX2E1M"SIX%NW
MBXOPO&8Q5.LRPW|JR>X|V|V6_U%|JUXA.WJRM)1@B:2&(E 0IK'T6 (- M&|1E: M/9|S^V#|S^WS;V|&H|7XG|/?
\$TWXD\$ZA%7*369_3\$8?Y|0.Y>&'LF/U8.F& MOEGT|R1*|E@|0%|6G3CKE"MCD+O;W.K 0LV*YMR-
+S%LQF17B&%^..DX^=|H46|2%-_O)GL;9/M+T.WOT|B0_.R'|@-Q8-G32|
(X1.4L/+|Z|K|BK8/'L52U)Z79|&^K9H/+|ZM2^ MPY_*?4X|RF2VY K"%!D7KK 7W,BO#A)Y%6J@>762V|
M5.VHBL&?ZYQZ5JC3&@Y_16)GH9HU|IRB8<(R|LW^K7IWH2?S2_J|(|T9H_0^*VB M8;WP>-|J0&BHKM_)|J-Q>?
TF|>2FE|@MY"M'/C|WH?^WHT\$7*F@|3"MH M@V#"++?>"#W|4^N^)-KHS"!'@ XUPT\$3.RC&M|N::M?
UA>BG|HU8WZ"N MKK|<7JG0X\$V.Z7C|?63;UD#6)R-J?FRW-E7.G-90|K<-\$3=6IJ%| M9:;&#&OFO-4R9'/YD&'W9
M/YJP<>6&O1Z|Z=@P|DM")C L-<^<=,=0XV) M' 5ZZR"".)?TUH.H&WV(|:|#?P|N'WB1-L*&
MVB;MRYDWS|K: ^6^DE !6*LSA"5@W2" &K<=|3CC)*2 MQ=5Z+T|OF4>/9X|E1V?
LV+^|2.I&|=KE:=.L: ^'26\$C@Y>=U(Y^YTF|C M%|P|PW3D8N;L;5OY-10>S_>>6<:TW|9>C;6L*A_6B\$B|CF|Q0MUT.
(D@:@@NU6DUNO;J|CR5-X4^00%RX;Z(C MMD4PA=62-M+0Q|Q=+V\$ _V+9X6ENO7K;|5|+|^|Q?
%+!|0A6"*TX|+X80N) M: H.L6CV; ^H\$RV1'S'6 *?G_*|D.6:(\$_.7|9|L+I9VE=T4F?;U^4::NW9CQ"!|?#S">X3B*
L7|J|AK6 LMSWDOC.U|M6L+2;E3>7M=XR#Q| AF(1VOQ*08_5;H|_7A08_C|3207PK21
MP^ED.GEA= '(SEKB0)EIMH5"DHO340AO+&1)>@G>HK.60LN*HTAWQ|7.9| MG;*IN+V52?
4_LZFOM;7K#J_557072A|N'@K_Z1MSAA\$27K#G;NT#O%D|'& M.1'&(+L\$?TDG|A|Q79YI" Z:.P-|S8ES>?CA?
*YR<2ULO5*EGZTX#X7<8CH M.U?I MQ>\$XMBLG<*P^8690RF""!%#PZN;RP'DT MD9)@NFZ|_W_K_?
#9H|N\$F343)J1R><:P9"FU0 MQ->46D>I73=|XJ5QU>E= |U7LBIAGG;S%+>MY: ^UW> LHKCY|/?B?7A|
MMWI@COG^ ^V|712U>F+ E.(A-(V.I&PAFU(@ YX\$DU;67^U^SA"15|C|C MDZ|_01G>PWZ MS3'36'|0L|7L0M
9W4??;C|0+Y|V|(K?P.NA%VK0|Z=M: ^.4;*)|*+C09 MA0Z#2_3|H;1U(U=P63'E*=<=,Q-Y>-
VZ2(%J_ ^O.MG(2BU_.6T= A/*6S4 M;7-G5A>H#E WHJ=OT-!#B;G4CF&:(P|8;T ES'R Y6^ M_LZF9SGGS@?
H(GH@|D7W^00K?T?|ZOT8QA=DB_ C5YLE4|<*/@|)(D'4#6 M| 4:FSH6CQ_LB7QK|Y6.1NSF" 5_?
Y>5"=C.0513P;4%J4B|+"KS_P_#) MLO)1PWM-TVGAZ"J|J2LE;QWS3| ^7/65007=|< %2\$EL>X^VI^NWT6(-YW'
MR|HNS|D%/U" I #9>G_ :P%P>?P;2LTVY).M MGBTW5>1;7L<2X|Q;_ 'F#!&V-B6W>PSKYC;/KGP>6C(8B"N NYM%
|C.KPM.E|>7QX M-K.FTU^32;R'A.V.EK16L;2;J*2U*J_ SF_ +|'-60|#=^E.2>3E?_K\$|H>|
M'9RI'R|GIXT."CY9R14>>M6>WQ.4YJ0|6D.OF'9/|L.CELA9Z9EH |=R;|0' M'R.=MXK45JT"PH(2DJH?G?
U3>)|3;JZSU;Y8!'QG_.F&|L -|9LW>4.TX! M|0GC;7IE\$*W)H?W3V>)O(XIG23L^K?
M4T#8\$JHXC&9Y>|4B36\$=TE&\$M0Q>|H|_ :O7_R S4?+|JOG MFR<(JZ#-CHD(E|2'H|\$XOAT?<%"G_|*#
#RDP| GNY<073KTY_BHO^VN\$6. M|=XRC"Y^7#UX<|ZK>3U@%=13KN;R|6TGW^JZ_L
M|NPS|WF5LK0>Q31R|C(I8\$L?B2/6!=Z|YF|&XG+8QAL.65>|V\$H_"C#
M63D%H;| ^9ZA5O.W.=QSD\$)K|'|)RW/Z3I0PYBG#Q)/2/T%BM?\$TR|K\$KG/
M7+2^\$&H=;+.KF2VBC'H;3V3;N06|6AO+>#%:A#-MA#@>>|8)'SHMBS@RZ M;9Y+|H|): (H+PLN
%QX^ (R_9GM@:FO7QP825H2)Z^:E29.L@76_>QW(? M#26V(3?
1WL465|"-J#*#6B0W80ZP4&WLLC|ZXZS33#NLT802B37*7Z1*_O| \$7PCM.HYMHAHU@;V=;4T|V*1P\$H|%)
(N)2|P MT.P.O(*CNOY&)_A_*IJ?"^|YO:|@7MW0%(" @=@S|)D#(XOH|A|(F-5_ T1A M#L3|
)RV+YEG3|&C_ (53@AWB^KPOIG"A5@:X#63X_A>#D4 MA01*X8-
|0F\$2WS<"4\$MC.9(^WAFMOVAWRT*D)UJ2G#|KA*C5T\$K'. KI& ^'^3VA=|B|":WOGEX>TH
|>L5^+G;N'4IEC|+*+UNJ. MW*Q%\$S#)Q|L3&\$?:<|<8@P|9F_VQA% XK8)I&FH-6 M|)^PG|@+|O96*
H|HFA6FG;7<76>|3(W+|DR)6T*^=5A|XUO|QY65G9_7>1
M|7@00/7C%#|BY6F4Q&*Y|O\$ _B0=K0|P|Q;K=9FK<0R3/|MK2K*VVKYWD.OITSQU54UMC-QYBQ_R/@=
MEY;|@+|\$3L4%U|2BT|ZJ=6C5N=F;3*N=U"RW?ILPE;J_2F0 M&W;W;|D40SR1P(|@(|%XYMGBW;C?
NVR|V|U|(G17N|C|L>#|QZLMRI M6B\$OD^9JRF.%\$15N7(+|6C&|P+1%.:P7G9>| @2Z;N9&-3H^_LF">LQ|6QP8
M4KZ2HQ*P*>|'-H3=>M981=2M#B3&;X'U99-6E|J_8"R|VXO*1*W|6|?/ M/DWS_N(6O'3UT5*!M.99M?
6+|E>6-#>9C FPB'D\$-P@?C^BSHL|J|D: -4\$
M(F\$;HH23^L90\$;)O96)59>|K@|@V""M2|U=&=).JE5_6""^|H|T+8;L|3K(F"06/>| M5ODRDVFX3FR9^*J(X0T>_YC-
GL;| M#=#A):C(M8|<(73+R#D)Z|Y.R8M\$X|VE)7K".A8?M.\$7\$^O+KV(|S|8M/QW M|M;?(N/77>WT+GF2%_1?
4)6T_8*_1U3|Z|6GK@4VMQ9M6LRC1_?U7/F;"&\$OH#VM#R@GCHIBO;L0|AHR12F"L&+|KUN'/F9
MGM|PIZ= &M_ 8.82T8Y0&RB\$Z-U02.P"KF@|86S0&Q&#U+\$<\$X M8|"+>1X#^U"PSU^/H^ (E0|H|5+^"VZR-
2:=FO#Q".M*+DMX4W2)7|G_ &(\$R M;0 WF# VK_#|4^@&AUS*>9JOH|Q^XVZ|L|G5N75K)S_-P_R'543-Y>|T9
MKNQ|EHA_2"6HR4_#;EEA53_/9HZ)KKA 6CE|K(|2|+9=1&0;XDY%IN6<%33 MJ-S_5/X0V03/('\$VK|/"?I"
&4)LDN#LLS_8Y3 Y"EB5/7ZC:=Q0^/3PR3^Y+6LENX:A8_RP*8 M'TL@|
6M|&9N9GRV|4/4V*%CVDOWGS=%@WE|7&)W@P5H|YXZ(O4)0@5H(22Z M\$;O'?
G)EIOL8'75QXNIRL; ^RH#;3/|9ZL R+>:=%V1;9&|RU|U>S%4!) M+BG28#|S|H|HS*/ZB9V%_4?
T/4&JVR>8SH&5|0**E_7|+E^NV>/1%"E9^ M36G;"0FK_1+G.XG&T*|K3"9;U\$X;L;2E#U|PY
3Y; >WKU@5F\$|*BNC6)| M0|4U;SZ8= ?2*9|"+\$N.Q%&4#1"E8U8KH|P8;|V0|Z|;W4_#*|H*+7Q(C MO)H|8U/>PD-
@|JNG25D/ 5PPG_B-07+*HM0^2-8Y@V+|^\$OF+90D"CK#;Z MDB1&*+T_ 02VH_G;SK;* |K173|1*W;NPFW&|F
L5&."%K8X|2MV%9' MF5_3X_'N/16>J;+N""(MR|WSZOGYA3+1>|UGT?OBH6(CAP;|S&"CV8Q:2 MKC*S))MA
@U\$7>B1V>8|BT^L^MIOK+|L=82;#(48|2KE|TYT3HT;6YND(MAODV).\$2_1J"4|I9WWW#XX"KOD|O+HJ-
/N%0^&A5 R49"KL;5|_Z|1W<|Z_ MUZN#H'7;|F"Z_N2TN5;DE&)9S^AN/20(O="AI".A3T.Y|U1@=%B5A\$AD0*
M#TN--6KUN22MU83MQ1L|F7WQD"B.T^8;4H|M6+)&2QO)1&HM4&2Q96%)1O
M.W/381JWFZ5*AR>N&4.7X4G%2L0/OU^7S|9J_TQ::U<^&SA0|'(X295<|9PL MP+/W6C#OFYWA@|=9BQR
1.VMEX3K-#V>IW@.(@7.1/8|L@P374BK#Q;2%G> MYZ+|V=J#4+X|OCU).9ESABQ*;G|LG(9%=BH).>8F|8F-
9*UPA"|*UTM^)|L435\$ HK2%7(PGXT?/).Y?N|28Z|3DN?H|S84.WTQH;S6|L5%W4R M?
%4G)FW'L>JTXS>JAVGL8Y4P@;AG>9%;5^*_+T=K&?Q3RN.H3S2|H_> M|TK6*\$P3D;3(-|KT>7@H;
|S|_5DF^>LF|1407E?|(B3XL^;ZD|VZ25BEB M'L6|H|S0|VBLP(V|@_ 80=;>@<>P=)|V@BE|8>
MQ\$?+FK0F@YU|)GNM\$3R/6;7|H|F LA#>X|'|V|V5%Z<_C8<_0RC.%WGM|R MGN5J7*#F'F|^88 FS5?NE6R^!
<+Y>4R|I9_6SIR-G_?JAG(WW|&08|Z|YB_P|Q)W|HK^L=^|O&F96V| MOO;">1Y+|E\$ZD_OZ'6<2QT-
/N7;GY48; ^K|GBF AW"/=C^_5N|F|JL'_ MP|6)83H"8;B3.KOUHE6|H|FW.25ZQC|N1#SWM*OFOM?
%Z;#AU(OA)#2H(C MB1Y5PY<1#_ P8&Q(-\$0.8""?"/L>LH>A| MR|RHTZ;OGGHFM|NY"| \$K6P M9Q(?)NMM?KH-
4|W;I9|KC5LOAZ0ZW;8D6FWW9U@&1.G2?J9|HYE)|0; M0SHL_@7^2PE V"3|9GNHND
&)"0|5M(7L;\$A'L;|@#J|V=B30%2<7|AF_X>YMF|W065 M@_P/(2C+)|OY|PI?OU|H|SO
W1%8;11*|+^ZR;M_M!>|M';VDIR9=UT MI7|Z+>W|6LLVQ**^WML0P3GX)P37H95O+^2.'MM0;;S

M0ICR9"KEJH^;2DK@3B, @?&.@)L).E15IM4:P*FT_@31;_9_%!+P04"#\@7I9&5OX#:H5_@!C@0(\$P&UD
M="TR,#(T,3R-5IG,BYJ<&?LNG=44^_W+G@0\$ \$1Z2-E2E5I*E*DO?*AB8A(MD0H5Z4U4FH1\$04"1(B @-=(14D-
-9\$N(B=0@F\$WA-.*"3=^)UJ9^>S-K MOK^HJPU: ^:0_4OGG_2Q^FSP.G; ^D;Z;1,3\$ _"0!0?0)X%;_M
+Q8W_ C.(%)6\$JP^D=4W!0Z+YA:65!0;6Z MSU_X!P0&+!^?Q,1&?7V771BTL?DE-1!>FY>?
D?6ZPJ+OGZKK*JN476U3>T MMK5W=";HJXU_#0L.GHV/H&9P!TO+ "XMKZRN\$79VJ_);I33#HJH^,3! _" _' M_Z%?/
R-CK&P,+P_76+Z5C@WP\$!+*SG+A GO6'&JLB/3_+*ZQA-Q-R*EK8
MI53NXP4>/OO@)\$2^_B=#^_O:OSS/O^=8V' (L_5L?_+POPDIF)\$3QF'@_ ,
M4,USH\#_#_JISD)#;^(RM9X.S+Y'SI'3@6@Y&A^9_2;I@.7?;I3,S;H@ "L= M^,*/I4V,I_+>S@9TO^6B%13AL_4?=%K?
(\VI+BU1I7YV1YU"9N!U" /H%*H MG!"S7T"<:'=27CN2C20*#W^ODSHK65!_G'CHIZ?+N:14#@GJQP:(=MI*IU
M/QVH16XZT(&3?CRVX14BB06GT)MM^UO2!8B1HW7^H8%0WMI%FE=";& !C-!M02VD;?T);1V
M:\$/L3+A/FW!1,DV MX& ^ (G^N7(G^HNJD"(U#J!%9C)37YB+1WX+%IWFEDUV2F(G90BXF@RG;0\$U?J
MG<:#RAJF5^#H@^VL3WKMFO).A"6L\$H1\$YJA/Z&T33Z%QDGEVKA%M8M5
M^ILPN:GO6WD0XGY.MN^3!Q2N2>M_S.T#IDD<9D.1"K2@3=RM/;(TAWXG-PY MD-
*!;B/Z5E\$1M\$ _&Z\$",3@42%00ZJYC 3SY8*W"N!T M=
4:D=^3f@OE\$K%:#@.4(OS/CF=UVAIGL_W6X351FZR,.*+QQM:D".IK.L"N M3H02!0P A59M9%
FK+0/L^T_ =6Y0AS(#/G_ \$5\$JY%PIWB2UZ9!QQ@:_PEO M!5%?JU9K@6MTIY@*ZW2_VYT.Q"32@0C&LG\$4
MTURP)#T4_XGK'ZA?U5P333"?BLG3K99_LZ*,?B_WDP4LI/A9!_CI@._&8
M^DD126PI=FZ"\$S\$.OR> \$1GH&H:MH8TO'FE>Q!+0W/L:G?_L:EP M/OC; >Z@;F+H=.ZE#).8^!B(<1E-
_>VST5=HWZ@_L_Y6P(G%J9&T0'3K!1 M&^%U'5P<1DU2JXC-DI+OU+S(VD'4&9E;-(E_ E%5ST,E1^EVI,I^>E#160CI
MH@%B%6%1C8I\$XDM07<3-%YXH#R23(21NI8.(2XBUE-45!MRJ^&IYXSIW" MJBXLEB1U@X'F\$0CK@_PT90IVA
ZT5.!)G!M%B_J5BFYT(>?X+@=#G\$4Z_IVG M-QN;O6##(S!9!+=DOZ^2M&_WAK7I\$8>1%VA_%%F)#J(C))\$E
)A#"T_%_MS^&T_&8K_\$&FI"1%!#B#? 4@;&^ID>I2'/GO.!PI\$O4CJ_\$X&^MD#8ZJH M<-(SY";
U=NSE60#BG0&7U\$SV02IE,E=J)3WV^T.MCG@GP=3)I2ND(5ST5= MI98REBH7@>|!"TCB72GRVR0C2J^F^*U-
I"3D2>=10@!CG;*T48V->^7!=""J M\$#XB3@=Z\$'2@;NU<*LY#|^IE@Z6>|CH^JHC;+Z?)+I.;=IC2_4!9!S9P1=RIJON
MB#;\$!\$N=>GP?G4(D?IALVJH7DYDSYV)K:9?& S)?6"H7AJW-LF(%#L8-)/|FYI
MT8%4;_!WP&_AOOH_E43/>TTP(X)_*XH<|Y#0A;LH8>1J_*_-RRK5C209T_*DF MDT\$'G*G(CPZ@+Q^MVQ#L-
D2+)=V;(30:H=HU0P&ZR4_R_759^LY#7R_F#P MXGFK&S/HS?%EZI0)R">KK.@-
H8N;#F*\$E|I++Z29I&Q'=UM_+?VXS<_7DR_4@G9L5JDIVV^A3%_.9BK*H M?)ET&F&\$!_
(+1D+ZT/@+6/9<CWU>7L)&3+0;8R+IQF^JHLS\$S_5@E^<1 M5C'G\$ZX8BK'M:XA(?;&!R5Y>?OI*;YI)3=Z-Y+23
_XIPPB01M\$X,VYH|#" M5(O1H0JGP=M=PC&_4C*^L>>"L^\$6&51G"ELGW+K;W&\$G;9|G|>_9ZI^+O
MNJYVZ(O>I-E*VD6!_LS!7&V8I%7DY_E;SDO9.6KT*)B(+0<+(R;0;!#7=O M+!@HH6R?)\$*?P3=TC(3?
K!4(#_XG0>>Q_@_Y\$,"Z:O%KIO_XJ_?RZ++W K M8YI'=OB2S.@_&5TOGP#O5F^8??(CIA="2P1X& MX3(Z>5"555@
Y?EO!#%L MUFK5K0?K(R.@IE2U7-1)DA|=8'U)|L%>HARIY_K?%0E4MZ:Z09#9I\$EJW5 MD4"-
A15"EIDA" G0.UZ;IQBED?8=+50UZ)1-\$@GW:C\$S_4MRI(%:8278 M5%4OU7SMONE7%<+:KY^+O@*?
VT/L&|W&\$5^2QAO_>R2NOM8\$ 2A_ZMI>G MR^!)%2**@CT_U4BAA)+_ ,
(2@AQY/>|^V(&F6+4Z#T@MI=^G|\$!*9R.&KQ_4'TG^5"T7(+8/59(\$=TXUMQM#S
M)?">GMMMDA=+0KO^TX9U%._!&1F%G|B=-8,C_H_LGOJUZ#61!JBU|6>UA
MEJHYW(1%_6<6HGVBE4GZO^!ZOC)AC/F<|>|U+Y;3_-198==|KWY",Z54I?
M:9BK;4N;TK1\$ZX0C/3/(IB8X8ZDY_F2FECQQYILU*(_=77%(EDI&P.S-F;=IMZ ROZI39E?EO*JJ&_ ^E^8D-
+17U/E^@HX'H%\$4.XS M2@0=X-2&_D0G3A&D1.|-H2W!/*F+#+;C_7X9NVH)X6K^ (34YG/M_-X90D
MKJE_Q"/OX\$162GGIR:"W;E)'KX1STC!_!XL25^!6=|_O'Q(3L&2'NCX:D@ MB,J7F6G!/O=/&N?
9!N6WRGMC)/U!F8+AE,TKI"36L&OW6V#=#FYENA+(4U& MOWCB*K!_HZ,HT\$!\$T.C">HMMLK13>
7RE=#;4>42@O\$ _I332I2N9'X5?RM5 M_PTFEL;3;5E;2KGME,C)KMS0@\$ _&Q'9H81=R>;*JG5BD_I9\$UTH^6VQ
M>6U7@2P%='NA%|E?T#/S_Y_3K&7X+)>Q3HP9V8?UWYU8 @6>+9UA(OB4_M;MEL@I
(6HY/YS5_EGK|HY=U!PM)GE?KKBU>_Y^ (MI5PLRA7LO68#1W2@UFO M@O_VA3P&1?I@ "MM,E'
IX"9CG=N&^4>13QZIG!>Y RB\$15\$6Y1L\$11_OH=O M#R2J8IOC5;G4IT5Y3E:%5T?
9YWW%C)H=CKM>NOZP>&Z^5V_%2.=I/DRG@A^ ML^NL_XH!+!GT^!RH(X.3#"RPM^_SIZ(I.GHOZAK75XE?
1&3OI58;_J@BNT9YPI>0 M_A_W>Y/ZF_8?2\$2#5R6/N:YNDV2|HU\$104E M=:80'/6E^_C*KV!7&^Z_56V%_!04S!G;
M^EB5WMG=S+*1_X6?#X(2!+WO2@7SU\$0(=V!"E ROX_/9E;YI3! JOVV: MMQV<@54>/9XVQ3;&8E&_P#^4!?
C.U3=IT9_I MANTURUK&PBKHBI)'=0I@^6P!\$2?6(DJP;3UYJTC_A+9 ML^R_ AGC0_V;
^JLVL0\$IPY!)#NB'ZE_ OMMNF^<:NSC WVR0:JSOR>O M@5R6MP*;3+ P;I+^L>9)8C=)%ETMM(&=A!IU
!F6*;^G5Z'/E,1!%)Y*3*8% M!*TLO=)VL&K\$* 48^K'%U3!_BZ!3YTH4!|=9S!9*:Q#W;K58=V/JHM_E
MF/4.6)2F_F%9T/*ZR7>L.PH_# JVOQ/>|Z&NK 4ZY8I1_VV52B.+5\$AIH*_MG_TD-ZY0:V?2QLR-|K)W#>"^|=:@*Y
MOP_||\$!U_>36_T%>SOIA2B!E_I.G@QK)(D9\$)R(G-1KN+CXK(=4W-(27>_M-
G&TISEL+S.OTH^B)'XIOAPM!SGC M2PVUJ01MW#DXE*\$I.<\$8^_W&T:L-
_PX1=VQT5Y'G1E2@D'F=FOR_H_ OMMTH.M1+ F65FSTI7>1EW/R MI*4S3DHG%?
#67<^ID2Y*LF.K#0)&X'C;X_/N0><|H2Z?JXM#LWI&I_O>B9V M(.09=CKY4O-382E0(P21S4%>=|HEYDM3-%(QLC
M!F5,SVKI72F^7B_UNG'N;4690P=4IQNV#=#|XQ#752MKP-BZ(2AH\$X'RF12;_M!(N75):'W/T'SS.?B94OEL.>?ID?
UD*UW=C'IFL",D+S>N!;*AY)Y745YO"G_@4PVYTH!KR MI!Z3'O^_6R_P'@+ID.5A_=&%MB%/D'LI&?;/QMI&M=@-1?
2+D-%R79MK7' M%QH7OK_U_O_P7\$K/T\$'7Z4#2-0*\$"G.G T>6XD'<%!XX!09< MD_ZLUZ;2@<_38W_N?
IN43@=,5HJ78I M2HQLPZOFZQ/MI;G|_ =EV%=)1S_6+PR;|; FG#6^1HJFN.ITEX&_CXN70Z M6W3HDG_-
TXY>|F3BHTV_.NG9XO.P>_L!|FEW00D# +7!CZ\$X2*GFHILY<;2= MSA_3%=,9I27&JDM%WYIOAJUPZ12XH?
N*9@50N03E@N.PF/FV!2F.Z.ZH-K& M85H\$2;+^_C/_5!3G!S7<:W:SBUKCE|34PK9M_WVV!0."MM@_UWYN2A13H
MP)|7/I&81P?_UYN291/@JQC|>#_R_#=#F0LUUK4"\$(_WG(C.O'B&D!6*\$O M?1E%.WD2>FCL7
SU>J;E!\$6*,"M1JR!TPDM\$S1C_/DYC_#7W(0E'ZIA MG'!|!OCP7.T4MJ9T&224?_HYH-
)=Y3Y1VCN(CG10!KE_!K34EJN21Y&L M625(UXQM8%SB4;Y#XO>'C?F#0).|=SP0JH+_" CVNS,7YTSU"U167UZI
/= @LV6QAYSTT?JR9;HJ);UW;#|@_6'2U4YE2;_ M9&H62|YJ|TEI-UP3")?GSB@Z>X822FU&+VS3Y.#C>O"!_ID2=-
+7S4&|MQ5_M_8_.21\$%.1S3%_&\$A!O(B@Q68W|RY-)/Z>&|6MEQ;DV7H(8_.NEKV?ZQ MDT;\$G&|DV_O!*\$##%_-
ZQ_ =A5\$S411>2*NC#LES3HG/NC M@9A.ZBH>N%L MW"!O1?6? (@;VA|XG?|EJ1>_Y8TQO5U_-
1%VLIY.MB#"=E_.M?^Z%4.DK MD7\$'F2X57HGM0OT&VA;+WR)GZ-J=2"0N6X-S2F!1U8Y!)Y-
GU(7\$;2&G#\$MA#K%/8Q>%WSF;==8)UNU)IZ#_HV"P(T2KH==/F\$HS2*AM&
M#90YAIG#\$WST.6!*B_1*=ZQQG6!AHJ3^6F#2;M+B58S(Q\$0S39>\$22%4IZ MP!;_%CK|<6";J!"/_4
A:H=W%A|_J+!_AQDN6*LO<4C=>^&\$2<|L*!\$B\$'_M41P'83JTH229|CDK;P/#B+.#)662IM3R'F&E5|LLS)|BS
AN,*+Q;YB^RU_M|SYKIO;7"1%H+HW'DMK6G2"36?DBOYCQ.3D;0+>5ZX91/UYPHV84'9 M
M)|C1.GJP5/Z1(2@;WGNL#1T&X;O(\$W"!VLK*ROJU_U.ZOW@7FU3DT^C?J= M#BR.T.3AX_4A=" WOR-
>+4U(F6:Q_+SX+6(<_L!"/%1?;HWRG3-(L3!QGGHH(Z>%H;M<"I4C
MI!^;T(YK0GRMOB^XM+IE7L/W+^F_*A#1%&)^5^E)#(K&+X)YR_-V\$4%BV2 MELFPHL|83K!NT_?
B+_Z)MC"+VA!5*K(18YB8K*ST(37I?HU_-I<|H\$7^#&6 MUZN4S).%938IXQ.G?

[illegible]

VPPIG07@KKBH%VS(6V;Q/&)7;N&*BF2Y2"B?_CL2-R#;BZ MUYWC\$Z 7KZ5B>"2025@X+2R^1&J9TR
QC:G*LZY!99FA++QX3Z+6C.I%X M*%#IY)9-;=Z66M3F@O M&3S1"?-)30/#0SKXIFG3'DG&>
/^\WP!_\$7GH+5?)N&=H<=;\$0!T4Q99 MU^PL(C9UY0T-[MIWMIS>=)#R!0Z5N6>ZS*X-3JTZ2?(Y>1=_K-
;34U/M@2 M\43DH6UL00I&^AK@;XW@GX;;M;SQ01IX;*JH2W3)^\ZLE+SIHH(E_\$*? M2DR8G@N!-0NR\$(I,(I
R)@A/Y8\$L210*#%L216DS#TT.P8%;(2>I0G/- M#&Y%5A*74JRB-
LU%3Q(YI4IL ^09*2)HJIK\$G6^T_@I3P,%SB^A;V;@" MX2B+^=V!\$-IO#U-Y*U(L6?R9H,DDD?-\$>VJ?R?&D0(-
HC&WX_5(OJ1FK^1 M>=;! HNU%Z^H3R9,SPJX*=@+*LF^">Y4=ST-ED?K8/VI"?))@>+;N5Q1IBX
MJW!>\$OS.4/FCVFCYD"5\$GX3IB1@IKRI4;UJ";JB/0I.KMS MRIM9!={U"2H R%QN0UY1BEM;N#EX"1#I KO_E*7*T?
IKQG3\F M%PFXP@SG+I8Q#(XIJ= <6YL"PZ;JQ=C SOI5OMC\LO;=>@TU"189 M% ?8!2E%\$9U+JQ-YOUI6?>Q6;
GOZ;E-Z<,D8L^>-"C>_JTL%GL/XYE3NZ M=)T-V/\^BM-L#>E:"%P%/A)NIDP4D_!NQ04).G\IF M&&<)W&4!GA<;
<=Z!_j;MIDXN4_9!_X9Y/UME#%NOHR^EF=?F9D;JH(B^T^M"ZKIR@PN>#Y0C&EPN9I^*),8-
KI^6+;\$GZ!A5\$SL_8""#D72>%"^A\$X^C^P M T A^"1_PJ7S5F+6IH284!%&;R15S0FTKK^OPVWRM8W@#\\(82/(D7-
U051 M;N;%VD.?=[@7YJ>[OCU">E=2,]*>[@D4"Y0D3.Z9I+6JMVY9M"FK3L"Z(C^4^M:7A0F-ISTE
;ZM0HY87J>O/= _G8U*WF_YRQ7!'8&?&0BI^T@&:_J 3+R-P*O'^9;.E+I>G?2J.219B M*/4XIMTJ\$OI\$(:8N;\$/F-
H5?:QX4CSH-Z|=8 M->+'S#7!T)EO#M>WQ<^IGYM6L 6XA 3X-74GR
MG/E#H+MFE0U#S89%'KL>UEM3_YFBI.V^NDQ?S_O3FEY080<#RV7%..Y) MY5;P;
(7GFINMXYN&FNPJG(HL47#"4D/879?2O&KZKG<6+D.R_/KI_.80CT/B M8\\$_@JAW+KGU.T;Q%
=X8HAHE099&7>Z6M=OABD^Z^?PV?%BK;(.43XH G M/X-RDXOPW^"V&7G"PAFKJOS2QFE;-
B6BV46<_LOIW=OHB^T^D;\$8E^_RS/ MHKB3CU/LX12C5GQOM04H"4(12=0A;56JKKM_(UOB1UD)J%?'RZ85=>S
M^#Q\$IDA_8VIME/!W75IU8;RN+5DG^T@_D3=.MFX@I.R5_LPBW^VKYI(=O M=ZGX102;IM8
H?;4KGA6).R)TY'Y5!4O3!;I7H;0J;12P8*.H%LIS7#FL;6 MOR)A8(2SFV2*J78#>E>JG/(+)A^3T%I%L_<6GO/Q;%
(^GJ7.(10KV=7JE_H;YX)" MBEX#G;580&-IV^(+O&P%X\H 80X""P8Y1K@W!Q\$B%>@2V#@@@(.K%Z1A>9
MFWIEPE368LKA9ISS+<&G;5IAAY^7H[? 3R 8\$UU%6,^HHP;!>2_@;#2;+KJD_?MVT;^VL7?
!U+7;O*\$GFI4T@>%!R MT*?U@S_9^Q_0I?E-W75!O^CCY WNB=FPM2#.N*9D=>QBYUWIBO8;Z.@FB7IB
M"FG@_U2WCA2AW 7F7CJ+HJ&&\$ B4M-EPF8<I-B VQ) U>;9A*S/?@?O?H!O M!"71V!&EI#;^<^AWN@)04X)@;-
TMW_AB0!87%G!;/&O*+8KM;QF30" MGO6BQ8?@EO+IU#@Z!A::Q8+D^2ZD
MU[X^53I]"35\$U[B(A1J+0=KD#YFSH,FZ^_B6_=CO1(Z#J55J#8^Q)H+ C M8ZH,
I^G^)!TR#I[W@M<5*Q!4\$ZIRPK?ZV"D!6UKO0_TZ=EI-I15*0\$9IBY8&;9,#MLVK";RQB5/V=FVR6\$5! MW(/IEO*!>
W1.NUTX"AQ1CHYH*\$6D36+>');XF:(+ _J X^GJ@L^_NU;Z* M(XOM5BD52JNR6;V2W/>
I7LG_H@,>RAA10VH:C67GCV_@R0+MJI;7J0VW2E57IG&%&""AJ_ZTH;JQI>YIC9_W_WGZ
M>36I1V^C^"V^*^31%ABF_H\$=@V_31J&D00P^C;_I"18;2_J>%M=UN;+E;"5 M2=%3Y2W18/@+9HP;O:X56>K??
B*6;"JE16R! M5SA34;2>;&9(9_KVB2+XVCC=;!&PT.4W-D_5XW41R\$"IUZXW7E0;OE@O;+ MF;6K!Q(-SOW)XE2I
&Y#3I-@R"V#0GEUYUN!&9!NV=KB59L7/*<(+&IWL1 M^C1HO^!D@W^190=IY78C>^KFERH%#YNWEE;);-
=I\RTGCGV390S^B;(^J MY9& M2IJ(BIV!O5&GN-US"7BZ;9>'X;S;ZB TVLEG;+JYC6C,KLE00??-TI M?
I)TNE;7T3\$(&+!/" 3Q(EG;=P;J#I2;IS!W%>OWYD54OI#*IG19N2BAL M@?
%H4B,ZHW"BDVIM@ZN:>K^ X^G"WR(IBZ5;17\$EQ7^!7#Z G0#-H=M-(^ MHR&8%;
NHRLZFRZ;Y5VVP*>6OF;MEWS9WC0.8MRZ;CD)R! IE8C0M#WPH6 MV- #D#=#H_%WXH?9V)!W8Q^S2_4,?
^0./)&(HP*14YI3IGQU9I P2%4_I<\$6 M#MYX\$4!;L?"B_OK50K_NQACJYIHDHAB@_2X=W?R+TOK_-B!V8(49T_KI
ME?UO#%GUM>9G\$X^ODI9^#Z<#M7;EONL+3S.;7;#5M@^I@?G"J!N^JY6^!\$?S;PYO%;_GL_*2P
MPJ9YAPM#0SC"%U:NPLD"I?"I+VME&AS^!AY4^F;7I)*(&I>;+UY64I;MHK^T M6%.7"=G@KF;C>%YU^A-
DQ&+RJ\$;"L4H;Q\$#;X!>O(2WUZNLWRR\$&=A^ZT<6F(42;3Q+GJY511I87GXJ6N^&CT;"IO^9^O#%:U
M=I;P&I9CDPN15X143I?>I\$RTKZ?E&=G&EziJY!BMIVZ/3CQRZ6R"=>X
M=*JX/R&""MIR^RUY@C8FI^ORKMF2=>="N4?7Y)?*27*0=FZ2*2H)A*7G;LM6
M==#B0_.RU@FODELTRJ\$!H;P3C1""R5\$4X^T-OC/ZA.O%B.%Z>)F79I!B2755!6?2!GZZG\ XIL9&I^G7BK*
(;LZD(RZ+FA&T-56_M26)WU2UPLJ8#KZT7(* W#N\$>VY.W?YN(FGKCROFI0_U\$V.1=EZH^E0<>ZC.O
MFAD<6_N5^!\$D!Q5>3;JR=UE50P.YSB?^&K_ZP;#)ZMPA1@_2C^U98)KIL> MUJPI.TVO)HODIHI!M_<\$72)0S?
E^Q\$UB&%VR-L=;#JH%>^B^JO^W;AAA;9)Y?;K\$+O=664AJ^0W#>_IBM3?BRJO39^5B0.6KC
MH@;SUW@WE@1(%KS)=I.@&/_SB%;!94W3_C/VOM_(L_FEUAA;=!!ZH/8K;I@%?Y ML_*T4DZX/8=
<3!JS5;ES\$9P6OKB+S!OD<)WA!;/(BZ_0;IZHUJ12;&<;9G M2U22U2+!SMR#+H&^G-6IRIV^<+*(#9;)-
G\$1G;AST=9M^HR^U4_8B5^-2 M;T>OZH F;H7^IBRU*(G7^;535-F(,L7Y>F23U@O(EB)1G8\$E@P76_!SHH
MO%;^!IH6RD;YQS+6=E9ZO6Y I@5%%=V!(H&GDC\$^!9>G_B@7_MVZB^_1)=!#M!4C*> M?+N>H!9;IMN?
LU%PI>YLEHYS^WEA)\$ (F?-%=C/QC%I(RF\IE7>_I.16WF M-2\$)QP3<>NCWPI@ (X_%;VJH9QQ=VK;/_I-
!S^\$WMO^@_5_M_Q) M93>%C!ED9!8RACESY0?V>7ROI?C>U_>ZKON^O_?O=U! S_.AWF><I\$JOI^OU M?#V?
I^6<5D;U/_OKJ(E-QR6;G^7MIGI;ZT0_R;ANIS;G;3T^5=_IE@ M%EH/S5FFCPM#8++C G^!G2!HK;4%AT^K&2K-
VOI?96^Y2?SJ*=11TH=3 MF8MEX^K(63I^OL/4IKI7?DQ\$KX_6QR698;L_1L5+X?C!9CIT!9EUD%7)W
M;B8GL(P^M>N)VS)8N@;8!)^G5>-C&<I6WKE8".G="H!6OV7KEVT_TZ1 M*@5;TN^DI_191OW(#WJ8M;F?
M;B8WZV9;4@N;DJ;3NXI^GPJ);U!^9">X^ MW?
UAA!ZW>J57QY^S_H;DL;^!TDA4;FJX5ENFCR<\$A4@87*.TP(PV3"Z5I_#+"KC0;V^)\EL;2R2Z%\$!SXW>GMJ&);S)
ML3D3("=T!>6GN.@\$PH7C*CKE!<^2*JO^Z=ES^24_E*^<+U^7Q77*&F\$!6A MI*MG?>
R;_N2H&#;AF>I";XSQHA5EW,FE^U_9^"?=)X<'>5?F08_W_6NX MMYK!P<+5R&ON4QID6""^*?CK_#L&OM8??E
M6K!FOS\$/2J.RS\$QF^V^VP10G+!R_).4"W<_X\$3@FQP#V=ODKFKQW+*OBHS M!)_T?";E;62W!HX\ZF!/?
L^<D0!%Q@T:B544WIB\$.% ^U/B>_BA;5A1^ZZG MN:@XM%;E&FI+^RQ>;V@W6_U
M@QVYTS6;P7%*O6PVFDA(D_!JM1P E%DI!\$;\$J!>?TA!\$U/A!ROPA?4W!VW M>1.JG@VREW_(^F-R;?
Y6_-""KG3EIV.TUY8>UGJ<;2J;W!A!_U0MJ>2I MS;ME;<8?CW/B>/5R)3P??N6"KK%U7?9M_-F PW%SP"TO;
(8BV1#^KK3!5F M2D3?VOD)85H_VOU0X-Q6.G;ZHQ=NT>P&JT#_**87Q!UN>Y&W1F+2J?I#_ MHV(F/K-
7;^CGEZ=W^9O>U96O\$7W1!3Z@);.N#V)I-I-N25^HIQ!7SI_ZP^E M85R9LI/6I^V!^C9!XO.DW;\$DIW?
LPI.NZUUP)P0MM?8_SX9I.ALPR*/^/>F^ M4FK=(WM7?7+#+.HKG!%HE)/R_F4!3^P;+>_S2I57BVE!%;#IH^...!%
M!4F^IN15G!*=+)(?NM4^RZ2.EG&TOS;_4N+^" MC %5S.)R2^VMQ\$E3W4/<_M_OD-^NIWFJXB@;V!L35F?
+ #GS#=#Z10\$N\$>7*>*B^*/2D_(I!PS;DOX_I M9++20945TNS8%I%>=>Q_\$FEMUDFYM_H+7\$C^76_*76U2U
<3N")55N3BW# MO^L274O_H-78;_G WL*)ZR_EN&M;Y7;^R+I#^R)%4QIZYMAID(X=&9.V MTB^LV4Y7;\$QS99-
/YI>S^XHLHWM#OD)#S)RF=(GUI2-91ZH1E->N8_GP;P^+8P(@!EWT4ISU!5;6UF0I3L6BIU
M;IT7W24;V)!A7<_H2(Z9J4LK<#ZJK)2FRX>_TGYI?L?I_>TQA1^IQ=
MQ(4;I+4;=B2/BR^FS%Y9OCKJG.Y.I=C%#)Y9&BG/6^0UG=M8GCL?V!+*\$Y;,>I;Z=IN M=\$
PLFG)DUO8KLL^X_@CIM;<*WG!8I0+)S=-.R%NZ.Q2Q&1-&U?^N9GIG/ MG8;7%Q%
(ZV17IP;H50A<^C6*^XXK&XC5V_21&MV4CB?U4RI_UWE>-U/C1ZJ MV*IC<&^IPI_!W(A(7ES3/&3QF%SO;3
D>\$&8!="/@IFRSJB;^@W+(>JHD MDCUQU6-36DQ8!K7D0_QIM!%3T^I7!D2EVI2C14T^+6LKJ5/^%3EYQ_-=+M)
ME/91.F+^Z9P!8>JGZW.TP3I+Z8Y@WQ?TT4XH16N.I5V24FI64+!M\$+2^ M5/UB>
<75F/7L;KZT7)%VW;%O5;XBYM^4/9DYZ9JH!_!1R;W);IBXZ^2X5=

MNM;#M^(T6UK;0ZRL;J;D)#O&X1DN)I<%ZC7+^U*BA6ZB309JM91PI3V\0T-M4G-)DKN<>5;M?
7.='(Y;W/58;B/Y@/#Y=JAKO+Y"IR^W M'B'ZC;IOA 1">_>Tl3;J;...X&!"BjJZl\1(HK68^>D_GYO_6DA!^+
M4XDIB--=\$06D=X/7!00^UZ)J-BEST!"#;X7AW\64DJK75+WUC*ENE_R;G%YA M'RVK?/@^8!FFHL*P5Q_<'Q4,?
_V%HI^K;SW/K/ D\&BBF653NZA@J^U A M#^J)B'R\2"l"#!
Ft:Z%B<@HJU&T;L6Q>6MY4;NDF4.2_V7B5M0@USD&T:< M1W..993VO-E5E)VO\$ITU;)O&C9UB:S/4=H3?Y_-8
JG*9\YDC.T^Z/684(M M#UJ+M4),1%C7U=/:L^OCISRL\NLCIV>"9EDLT (W0WM6..%5T%89QM.8D
MYP2E=\$+SLZM(OZ'G^S:XW5%39C)@Y;6E_AFZICOLQBLB19T6%*+'&";T3#W M2D4#*IK6-C@IKY-2I
(FW4\$IQ'O_8&_V(W\I#L3IB>G9IL>/BIO^2_-J_P3 MS*WJ1HWS&9Y*\$T952V%YHV9F!O_KSN/D>2?
93GAH\$NJS\$Y*XRU+%X=<%RNK MRK?6UM70=#;ME=L5NES\PQ*S1BOC3(-@V=JB)9/C52;2L-V4:N?M5I64F'H!
MBHHY/I3K."<85P\|>"4=M'LW389=5;IOF>X7+99Q19G/Q^E%\$JOW;S-<<91
M\O)A*4L>W';I0K0QQTU7,9ME72=3>FJG1;,>T\NO\ P<>CKCXYPU_3V"0 MBL:Y"IRVBEUDE(3N6%^,OJ:C^I
MVO/30LC^&Q\$ (P2T7A\^9*SXXI#;)^6?S5;+39QOENT;O@(@_I&>^CG1ESR(MO
JF*L/E+&8=ZT93^U*9L=UOW9DC81%D#8>A2ID?T\$ZG46:6Y?.@^Y) MHW;+*WJ"%;
I3/B080+/(AN IOI5#J&J/R(@V_*KLIHI"J.CI63V)&IN.*J(9NV4P+8#L/UPYK:1K^<6'_N89IM/I=7MH^IRFCL&P-
C^9;BD=K)QX3;?7@Q2"5("UOHK M,X&MMXIHQ8PVBBOBP^C;OF8I\UINN3)FT>&+1=Y@HC5W)^(?
EN:M.8D&R)+ M/^1(PRGHGX2%N(O-3"96*IU'I/QF*(W)ZU+*1D?L+A<6A\J2S_WB/A3
M\$YJ>V_*)^4CKP* UC*-75W>8^GW%1A\246F?O.@W=%#IDXFONEWI4OIM:2IN M^O4ZUTM1+<_UOCG\S=W5QU!
IS9I+9RTLEDL+T\$W.*(R^J;O"*@T@_W;C9)IT M%5G\|S%|=4JU<;ME(F^N/AIH_?QNJM/(T+//
R4K@WTL;+018D928 MNK>.X5+6JL2^2D7LS,2;^H@5I?TJH;IIP=9<4,_=S^&JDW/LFKO0U5JC MCC
F!EOZ>T>N)P,KZR.O:08%.*Z8 USV"l^E^C^MJM.V\9IY(M=6HBRKQ_H%YZND?>W%_<5K"-6&I58>#
M:6IUQ>=UAT>@6QY7XR?K#^G0AUL@^@9X4\$ *,P.9:)<;3N97-"#Y\N;!S)M"OGZE7\$C>;&_JHZ
M9FCVDK;_VX@KIWS+M XS=|K;CG*2)03|-AB^G=EXE75WWL_N=IDZ/HY"\$ MJNCXM|B?
6LD7W4GK^SR5B3U>@EG\$93^3/OTPBKX5-ZHD^LW"+'F|>PC);\$
M_3PHI0JA@%U)Z*\$B'DONC8WC0G5>5\$6)I25%T:\$YCS- K) IV3EG7=I M7(*2T_>+|=B-I-
LWW4G:'6A/ZW5AU<1ZT0;HK=B"<^Z170\JURV\$.63K4X M^6372Y;N\F27?&9
I/Z\$J^%//&)T\F(TUFEJ38;)U^C)D)LWPL>U*T_V_" M%=<|Z|#;#C;H/16Q.9I7IFE-I+K6'KV=1_>KR2+I7P>>
MQUP6C>=L<;TCU?D EOZ;#_!K@FWG&'ZZYI\WAV3?8A\$YBBA24*\$FJU"/X;B(EN\$JLX652
M9V1S3NQ;7CJ_1T2ND;DL#2IPD9%6D@#CA.O>3A\$A00E8F#O?W8L;Q7E;"C M%"6+X|\$8'94SB-
WE\JA:7Tl.#H)^4%+US>S\U(CX\G6/I ULI M8BN;7_2^@!G5=D?Y@_/5W*3F4;<_0D_KI-
I^_79#N5\$*M/KO8INRE^PK%U* MCJ_E|SYI%1/-)^<^3H0^>E.OO-;T>8B5JE_IV\^IOW\$?9%L.7&'HO8CJ-
MANIAJZ*4&8CL:'^_2I-BI2D&F^IATK\$N\$D^<0GI0K^A^B5U80:22.8Z%_MQ\A\INN3VME4.
IA)FC.>\$*V'KV>7I(YU_H:7I6:8-MYX M<9ZXOV-8-7\$[VIE;_6<2/S+P|JZ=MHZ_G9M^I='MY>OI=W1?
0M;KCI.G5\$8/7LYB<C1.*A"X\MI#;:7E7T\F#/(^%)ZJLT M5FU1/@_";>PF|&'B0T=2F/U!R4R%;J(=+9XCE-
=P(2?7@J7FO-IGWHKZ.1 M P?77K^_4(7:L8Q;#(&S;ZQHGS;GB>"OY#4H&+V+E*E*6IK;ZN<;UIB
MN*HG\O3'G09*>S12AA=MEH_L5O%"%2);O:1.;_4OWDD9W@/@IR#C^1:324_6
MEUV%.;WUL1@;'AW.4\$LAT&XY_SB3*UR8Z6M7F)?A:'RFU&)R)HZ=>1SRY0 MW39(+=/KD_&\$S\$U
IPCO^*UL>_AD?X9_8;CDA;E:6_9RPK+D<'-\$X\GI&\$; M3#F-G;I* >1\$-DT_RH&VPL@V\A_C-
*Q'T;+B6W17EFG^IV^/#%TEA#A,Y M\O?3=SI:5)FNW53%;UHF^/Q3C&=#YV77NT:4E%4Y?T%;S0N-
9K4IIP>7I^7T_D4L MIGXH6H_Z%MIVZ;ZGGSC|E=E=DPM_Ci6VMIPMF+7H15IE.7QJ=UO^6U7-EQLG MS&IM6+;
<T?@UJGZ13+@_*!EA&EKKA.HZ\$O!5/LXAH=\$2N?5(L@RE_JUY M G9I3QX21=K
@RBG>=#4*5R"E.UQGE6WG8G#WKSC@<-D)R:4HS@SSH+NJ* M%6?JH<=:R.;C\%3P,V\$O2)D@?6=ZU\HU&5?
|HY;_"LAC?7B(C27_9PS3& M5@.CG*JWNV)7I=;JAQI^<^N1R9/M^E3F"7&";_?HNID<_E;@9/B94+2^VJQ* MG4;+*
<7EY&4A^6V\HQ#OYINCXIP3+4X7^A@PMS4;2E8>=7+5AWK4^D>/5>_MC/3J43&AWR1ARXE0I>
|LR;=>NZ*O52A6G..04Q.F_O!5I1K2HZ%G6OD;2 MB3^328<#K_;/^CT9&\QE=0VF.R?
AFGTCO,4JHU6V5ALGB)^FA%B:7'F&/_!> MO^&#&*4<#TUL.7X5HMO^_B0ZIO-A+!>-83>N9!7X#D+?
I="EY">T)X=DU4W ML:(GJ_9^+<+\$.W_R#_IJZ_N"JX2M)\%L5F3;I>ON.&*Y/-5#*3N6>?U_CR MM87*=J
MTFN.NQ+KEOH)= "\$Z+D3Q_I7@TU#;Q.5)E+3TJ!OQY6&&X\I^CI9T&NR\ MT!"X4RQ@U5D&+!
<2TLQWQU/6J_"0;ODL;QIC_3AO.?U"7:N7V@&%3X3Y+ M&3\$RLS96O:C;2+!&_AM.XGD>_BV;NI+DU5_*0 4/PS">
M#..G1.B@F-2LF5.8.O.C.W6.S"(TSA)DWGZ:9PX>./;@9I7.3\$8W)3BB M?C;|B+T);%TJUAXRD;>|AL;-4#Z^?
M1I(PA;M\+Y21Y4?7B;25Q^/* M_*_*_ "P.Z.^O42A#X>(%^<P_Z%V'>7\$<"EW+IJD@ZL,KO1VER;>0!)IAD
MD1*J#%^HF^5!T\$ _B\$';/3LP?+S3+A|EL>!*0R'K%"JV(FT26?9BF\$N\$* MCGU47JLNTQ
JL.LWV;)9(3.5N.3SFV+|EZYVCA4M2B.O:F.00Z+_I00!4^97# MM9\H="JK7BN0@G)?
W@L@KU'&GE6\$P"/Q^.;JH9JN6\B ^=%1 6S4?E+S;
M'4DA<|FLY6RE;DRHK2)SOV>I3.X7ZQ/QX;Y;R\N8BX861ZU)ES:EA!OUK?=-MH|>7IXS%JU=E+=?;4"7%1 T?
839WJJC3MWDE510_ZR7I\JU03)!S1N?X6OF4IK MQ?<_Y(H*V"-L\$)YH82U\IT+BTI\WW\KH?D-
M^R)4HJ91S^I/HQ;RY?Z;T;NGH@<=>+ MUUM_/+A7=-?R205_N73.6=T%5"TFE;?I2.GW.J\U8C0_IX ?2JG;8!PCB
M_!@T_GKZS-%2K\HAHQ^H+!+1PMT:7J6?W3Y;UM\A**Q-6WQ:6""MQ M2TMJ7F^NH^1HLJ A
MJ6%DI E(QR+G<(6I#V#I2.HG|\$9\$E=AV'R.ZE3I@(%@;S\H\N5)Y*Q_Z MW<*(10S8@JC?K2906A#Q_2QI
FN&X\HIU91Y^02YQ_6\$#+)@V)-%IE^);8& M;CBK\I/30A\$UFVD*0=8_*?>\$700*I%DUE6UJ'S_81=>_QYI?&Y-8&
<%YRCV M\$V.%"179C011>!"-\$^@UE;+UZ.'!;I_ 9X.P D%IY3V%YOUH1J6I06N"Y
M:2I+@*E(ZA'X;OAAKK0DC>KHE5/343PJDL;DXYQFBY_I@M6LW"0DP#XK_* M1F6Z-4S6=#\R\I0|<"HR+
+17=H7+KH6B77U&=04PH\$|NSMIL6IG^T-TYJ5 MR#I/P%IE-VFXTNM@2'56_2AE5?
R8N\JSI2XR(IJ3;RM=JLRORA;I&3PNJ< MWB+?^V5!T!.*FC6_@:(S;L4P&I?QI\$0FT\TR0^8F489FB8_XGX^VSCF
M^Z#CP^1! BOF-Z,O/@&=V\?&-+BJ^CJ;)&KX% D"=,@E5T6L=AG=SGKKI M%4QI^D_6(I:6?-/I8HY#I#1 XJ
<7>2BN\$PD8NSI_"^ABE<>|F8&G=U^PJ M5ZA;&J@TH7F!6!"H\$|4IOXU5T! M=R(C-M3%UO!6RJY\PW^&?
G3VYMJV09=LRPT\W6.O*G+=R"C#E' KXW+T\$N+5G5I%"N1\DHX5U.DV\$ZIO M\^?)@*#R13J5J5Y
G#I?I'E'9XSDKK>U*((\$0\$ _3W_%B>|AQ.G; LUN9! M-A>I9_7QURB5U.UD0
#T<(<X.O(THH9&HJRCI;B7A7868%3_\$@N\J35(N MYJ8ZA&Q8\9>G\I^XJC!M9)/&@X@P?J:3W>'%VSS^W-
(0B+*&<#I'&5 MS^H^|K7G0\CCRI!!^JR.;|VPFSN_J*6@B2445BZRO))#!<I+S MX05MF0Q060/3D-
J8\QJR0IDDLNZ.^7_N8& #8)HRI^5=&@_*K7C)@ZY2RRZR MZHC3+K??RIT.0S^_U<|A.C^9J2.PPIE;J3Q
I+^&UR^K)U&\$26&|DQ4TO^*E4HPWW\@5/-V3QH_=5HXYD\34K MC|>B(=%S-IF%;V-"FW0?YSU;<_.P\$|6>%?
RHL^O\$!15-C&6:5B7(M ML;QJ7GN^J3E6T I<;_?DI-?>N%K|>= A;Y;EOB5JMY3EMW\$?+@Q&O;#O;
MJRTNQ>F&3Z3D>B^Q_I&8+?P=78E3I235I^VO02;\$2_QKM"TT^H^C2.H9@3
ML'XI872KLVG=-6_*4Q^%|G3S4);YH_Z<\$00PIY+;00=)LKI<9YDSM+ "MIY MD\$1-
W;5UY5J9F.7A=,_W/(\$XR\YY_#^@VW2IS*)=I D@P.B"%VZGJD7.%8L2;>QUB|M8/W8 M/^8HBV1%3>Z^\$7;OI
I*1;RN#PD*V-8OQ8=&_Y<;_S@QO8^3J*OI% X^NE2/WU9\XIBS2Y8:2I M\$?+X)QNI;#D\$>_0 W^E!!T*X
-5<3W;@P=^>)G @U(.*>YGE3I_LSN\ MZWG0R-EFE30%"?>=RG+;_1AAI
M#>M/9J2A4FPW6GT@8JV8R=R\$4*JFL=^?MNUJC3_#0E>/_@8^I5YLT\TVTO"l

Ml^6MZl/*6)SL8"M"S;T96!_QD=#G"TI/7(S_R2JOGCEI&1N/XFL/H6.J\$^N\$8?_7GU^VO>Z:\$2X/D7GS85Y?;L4O
M1G+(H#!WOY\$G0*CKX3' NU|Vt\$;2!%2L5Vl/^?>|JP%CJ4)W2:/RO(@I7ZF M&5IEA_HW\$?Z|(D|RV!
f>U\$Y>|OK|_XT."V'+88OJ54)_R;#E"O+ORLY8_M_#|_13H335O6(U;9\$)XLVl B7-L/M,(-G??
OP""4|W""PKH&1=W^+3MW MN-K+GV;H=K'XL_O-9K+M-B_9+6HOUR?"AC|P>HJ%_SR"/N^%@S*K1
M8@<2U;/(UGO4F;-+T"Q);-6Xl|"795OIKXO/_M'DN7GC2X4-G_4"<12WKX^M@,IX,56_YJQGGP5;
(<_A;I=C7\$%^Xl2@G8WQYFB|TX9_%+0+ZXl'ZJK=OX#_M"H?
+!T5OW;C2()N8'4BNE1OK/UMKUMMO>56U|Z=5^AE;E*2P_-W#>=@,<'=-M-)N(C,GRH^|&K81,Q1*'EQ|8LX??
=L9@EK?-=Y5E/O_8SO_D2GL'?@B_6_O-M&T_+R;O\$B@P7VH65|COFUZ1P_N^M;7!#0O|8U/'Q?P+
HlG|=MlQl73JL ME!_QX;Y\$SM_%N&NC8PSN9B|O(*;5+QTD;9#8=ONVD3M5)6^RF#7_M>NZ?
A%6>XSIL;:HDAUAT5",9l"77%?^=DTRUATKB_MT;B_C_-|V_N);R;B
M5^+JW_MSL+9'7BKS;PE'Z=:@NM3%&EK1#_6Tl'fC\$BmI(BNC8T^M1SAJ/SI)-BW&92;KM6Y?
A6ELVFCYV7IA7%A_\$T%;^=,|DIW6<^OF;G*W Ml5;S<32X;LlEA=C23J#7-
&UKX3|V&E|=A:S<|&AZN%CNRL_8,DPTe9 M|HKFD'3U&L>M)G(C_M3N9!+W;WYP>BOH5STW_12H-TUU?
&>1H_1#+_OHY>+??XWHQ;+S2H-DME2 M)"0QKX+("88'NPl+8\$?-6 M>"K<"EE+HF+;S5"C>GHJ-R2.A#ZJPl^
XAIV_Q0+5T(<)S1.5-"#@!5SFL)-M5_O_.,UY;A1>?K2B|ZAF=Dl_,O\$K_H+MLSB1OJS"-1\$X4:"2*
<18|NEFFY|JE;&A;Y8#JN|Z;R_!l;6@K23H|@M/2|7XFC_XR?9S;M!_Y+4AE| M)+?+?+G8VF*YJ=WN/O=T7'V-
_3.H@(-LZV0E|&:%9_7S(l_WOl_DH%2%;9T M^";=P_-ED%:\$^FOL9*?PA7W%Y^1WBELAE6LMB?
XPT,>Z3'861^|SXICXD0"U2L^Q4XEZO4MON/NF|:7O573;8A_G@;8K7F."T?%8N?>4LM|_<:"l?FD!_00OJ#(
MHJ79|F#-TSV2|LR\$;_?B^)|KGP|'O3_GZ|)|ZN#SXX_9N<60;AF_%L3)*(+ ML+=W9|A3/>?Q^RF_-|D@;
^H|IB;)"DPC_E5W7l+A>_U2#@R#A"Q*Q*TDV_MS#GVGGA8O\$;UDVZ86>V
(H8TUO_G\$:=W7Z;_#R*Y2I@_EHCL(l;^7>GLO9_M73@N0#NG4+^'\$>G&(@_V&6H@-
USFB|A|5L2JG4V5L@GG|NY;+(1(*CEOWK5_lZf(Q6T+WW3_7O2C_MUFIF3%D4X(TNM*FS"FO^Z8;+
&P|1G%KWJW/MN6=<+@B@K?UKB|VGRVFUW|_M;1D1;|!^I%0NKJWZ*?+&BP^_6>X=TD6XV-Q-7)T;0K@<7^Pl-
NV&|V'7^+@S_M-W_-)6&|5Ll;HG%:Z9WV>MHH:=S>UW_7%PO/-X'70#R0K@\$V'J96LF^ZOB_M4l+8V#|*2HN:%
<|E14FVl_|lC=V%;R03M_lQ39U|N\$A>L_N.^\$K5J<|K|?3_M45>HD=Q^VIF#@FTOYJ<=|@E"\$@UT;D>|F8?|
HK);G=DM6GQ;46\$_99 MT^Z;Rl5L99WDQA=CF(|_*DS54,"Y\$E_D'E<+YZ1RC;+5KU>Z;PU9C?4 M?
1\$2_);M0_CFU2KJ45K|P)8;|_%H#CUK|?FU2TVYUGO6YF0?)L7^QXE
MEK56:NTCNZVNL4)8YW|85B0=2)H^9H^W%;3|A09S;A"O"W7L^CE|YKB2_M7WJXY#_1PT)P^FUI|A+_1LH
N|C|>HQ>(3R_R_83#K_GZ;AJC;_l-JEZ"R4H MX||&*|_.;?E|Z3)SC'Y8OE-2|V;_TDZSM;)*.Kl.=)=169I8A%GY3ATZ81
MF+YB2X!_.\$%-Y;|)O|HW('KRY4K'LJEF WN=/H5<P4<88S|AWN|_CNM|0)_M-W%V=_I4GB0H;_CS8N3_-
<+|Z7WT8@<(2=X*1=5*D(B?^!|1=H-7|9_YG|L_M7(PQ_-G"TO_J|L5"2>6&7"\$5;|?;X@8G7H|#!OF0:X"
M7+6S%+J6(OPQ)(+K&X\$^_CGU%E-%(Z8H!A\$T?&%W|WV7&X|"*V_YMCG;_
M8|X|W+|OPK;_*!Y4HM<_NU\$Q|_14Rl8^0L3_2*482>PGOWH_./YC|_G|H%_M30XF|&R0K1BN+9;B9V0JH8l
<OY;_TBP#l'Z^F_3\$;^F>DV0);(C#E#;_*MC+|<9OP#S=04<5|3Wl_#J235^|V2>@JPHDY>T+O6H*6@GC0ULKX
D+Y#M|Y#R4+_UEJ;_#K2DR12_#6/0\$|_E5(G|N|_#Z_3\$K=AN4)1K\$Y)E(ME8+|*MJW3)""/<3%_?2*
|!S.CGVYB_L>"3B>P6JkO@#*IL=|&R9^*T+ECA)/X|MSZ;|L>Y#|Jl|L;_8|V=|4|>4.3(TDMNQ)TLV\$=;
LS^WIN^|@FKK(P#*/2K('!E<:Y4>%\$;1\$;MCH|S|I^NN03"4%^OAO|1>H;#U>1|?|@|/<)=l_H7MG%|RN
)|XV|RXCH_M2GBS|7;0>VBRWTC.*+L=%K|767K%;|9NSNN&_.5|'5%(l^H5K0#Z_MVJ|N%W3<QV;"5_/UHS
M.\$>0*XR|*H'V9YX=1^&^&C\$Y;JN7SO8N=*_Z\$|HJW5|NLMX;L^JZLUZR
M_;N50JDY9HYM|7V5Z(HB;|KT^J&9S;9^YMN0G*|X^)|RNJS:<&O!^G^!4 MU@:N"XA;9?KD<);14W@ZS:>PB|1|
(-TF|6C"&8;9H3?C^|M<?|?158Q)ZP_ME3W(%/S@=9BJK16;|KU*Z?
MXD;|R3TG*|+^/R4Z4S+;W>Y+5R%="F"W%;LP_M^@^(|QHMPK)
|QJH|?;VDA)\$Rl;S|QY^LFC^&GYM%GT=UK"%NS@*^MM^SQ|"6G4SDB&"%#S|%;05_IYFI4(l0W_TlVEW3?
S0+L>0F%?|H|P3|P3|MSR_H_R&F=&6_#Jv.YVXP4|B;E'.4.KW5>M\$N9+|L_K_UTTR2;<1'PPOV_M73|>E|
@\$BKB=GS|'9_|FTH0CHH+A2D62GPW-K26M;|R0.KK;^_17;R(!_MKNC1
BC6\$4S^=3|@+G7X@A3Gcy4GHNKX)91&ZA+L;P@R;|P"#7V4KA+R|V;_8W|R;I-|G01T"!="U"!;H_LB4S&%M|
);5U=;^>JVL&Z|H4="F0|0(2;^=G.^X>8C|94|&N'N)85/49M-PU)
MV=|M_FRWOAAE|N&FQJN/YW1U#;Jl+TLNBZ+&|PTYLWWL*LESFXIE9|_R(&8|_MEL8D;@)ZR("1VN?
&@VH<=>%WX;6(&4?;DT4M)PCZ;2Z)5\$UT+JJE)L3K+??_M8"C#PLU?=%GDAR5?M)T9SE9MA+T"
>CVPE\$H;T3V4PK+KLYJ;_Rl_JZ= MW_*O%9S&%W8HE|R0TW;1T?7J^l5F"4G=|
|XW)1U_VG_RC5JP6G_UNJ0>>6(0|3M|OL1O|_7C^/_2|TOJ8;8^5|C+M|3|WKsCTN;0)|4@E|JN|H|F>.<#;>JVI
::B4?U5YGU_S&\$EDMA*Y5|F#_M_MUHESV0<#AD|HFN|E5|7T'FLG;"M1B;>Z\$WF0;HZ/"5!%^16(Xl0CCH@_M>>
|OP_O;%R-/TP_84IB7WUB|+|5Z7l">#|ESI#_%N(JEAI)*VS(DOTD@5_M0.R|2)|C?78@6T'N35U8<*>?
00&GX7@.4(|#K|8QQM_H+D(KZR6^&R;HQ_ME77A'P%HI1D94"|E19_\$R@_XN*L|_
Y%>CH6+^PC5/C|H1F0AE|V%Z_0A.Xl_M?=#RMZl|&*AK|0+|H0'FNC*=N0|B@|VXH9*_.9PF00X0SXl#ZVJ_9Y^*C|IM
M2PXN|@Z;2P8*YCHf\$_4N8>N|J<@'U#W^SLW^*|W6E_R%;P")C;N;|fC#_MU_%O?R%3F_)%|?
UG3EHP8;@ZG9JR|C\$15VQ|BQ*YD_M'H2_"j3N>8>?B8^=1;C|Z@9M'l%&>%XEAQ*Z?5=0".?;11X|T3l7=@V
M2!D>-YU%QOD^9VP'AEX_DLV_.C0U9F|*6J02X@5Xl4P)2D><DI%|;_M&4@*X4RR?
QGYE?|MC+L_YlV01@TH@>3A#_*<|/"7S^"&4\$?Xl|K|0;"O>X@_M\$Sf@+DUE^V;!(MDM/-A_CFW27?"W
M@E>@*Y2CD'Y<2RlY+8l_2QO-5>*>T>A5'X(O|KH;E;Q;|Y(|+|J55_XNC0_M*L6;_C\$T3B#
|U|D2>U5ZGM<7D>;/XEKNC%L%5_"\$4AM;OS=,Z7XNBL^MG_M+Z=|S3=PB<+G)B|G
|Q;_0_FD/N\$+_9A_75|9ND;0A_YN9;H4.&MV%>>M7IY-G+8W+&@WM_/7APO?Z8>;3WY5'l>5'O|3B90X|
M/+|GL)?(79@MT@%_B|Q&<B|UXQCOFUyG2_IK9);?\$/_<+|95U65(+YE*_M_)DN5#%>SPCHT=Kl;4+S_YTJO?
SZYK18_MFW)95#TP_W2_-LO;_M)1^N0Q<3;E;_BV54?2SV@Q#|_|+3;)=%|A%UDQ?5JDG#RQ@|T5K7(2X4&=>C??
X_MGG6;F'E'Z(-GBG#*)G;G+VSOX(l'|"W")(\$S\$W^H-D.6QW)?"QQUL^F;\$#_MW'Q?>(\$\$K^R2@&M-
0WA0'G;TFOE)\$SEX_SXV(1%0>;?WV=|D)9\$#6^6(%E_MR8|WYTS;_C_RLIG;@=;0CV;G5L(KJ82|YQBG0&_M|Hl("D:
(|G4Q+D^873A;H0'U;+3%>|l/Z)2P0C-5|D|OD^+ZA=N;l_DH.U!_MH<8";_l\$GRDZ;H7FS#6JZl?W6CZ-X8A)Ql
QR8U(Q')_O1XYK=BRV)M4*_ML/?8(3&8Y?"W?.S4RZMN/_M5|H|_N;TFOCK|W9|R'.U%|H-B;_EB";
>|E@_9;:QW7l"5TT>R/^?F=-_M|LP|*SRLWE|G|U7FWS|WD=M#Y#@#_FQ|4'A286;"RP=*8A>"H%|!"XB8_Q
M8G_;\$S8W|O"C_WZl>044>|B)RR+-4\$EO@Q|LMU*)Q|S);_KO.F;5_-US^|A'_B2A3|?F/HB+0!_KX|^Z
M^QH;_NK|YF+K7\$";#2H|Q4-S#VCXV0T^ZT#*Y#X_1'|8"REC@SQ;8lQ^_"OSG@3|6LVDE."@%QVO_"_8\$A.*_M63C-
UTOCX" M1457'NT\$>?H0'P'G_Pa6|_AU|Y@(|N.Tr>RAB+4 F;_?1_0B+X=1XML(|
M0;_HHYX;X^+)_4VOGPEYQ23Y'G;44 W=-R(C|TM+M+R|HRDY&K&Z|H/D@DC'S|>Q_ZWFG|W\$FT(LWT,U?
^HC)_8%>^OXTOQO+_MWD=?_1#<'X=|_.(=O_VWYUP|8/3|9&R^(|#Y+|0*6|L6R\$|WXXXV.L%H+*|H_R_M#
|GCC|K|B=S"U_W6_9-S|Z6XC'WY|);>(|B1@00&^R>-|&REL>(%N\$;PB_MC^V='V=.(53|PYOQ2(F@5%(!^Pl>/_BK
%|3BO>|JD%'X=@5@_MH5S1.W|00SL_Vl_|PH6|<-T|Z8LD?A;=%&E%F-WE6V@7?K5=W?M
Z22(T=&UBX|V%)"PF2|P#W|K*|6@_lW_MKH"DO5S-Q9'H5INPO;^JX|BW'7lQGGR_J2|GKHC3HWH|@J\$%;AD<=
=Q|3(3-)Y@&|!\$"|9<5+?G|#U&(#1ZF+_M\$9+=|XD"(|#R7^l;6;|P"8(1/4;|TQU8_EQQ)3'+V|R;8#@;YD4?_8N;_M5

AYE-^O+IC.2T\$^-&F 1I^-8&5Y"^-L.\$49 1B1TPX/&+IS%7IAON<|WN3 MY9-
_PDHC%-(B&#%0TU.#/|P/(K(4KV+GC"3A0ZW3AY0JL#%#=#@I MD)2-OSB MG"\$E7[CW"\$\$.5&I*NA.9G#D|,+4 2VY>
EO&Z^20TKWB,O" SOW.ZTX2|NFO M@|7_ IRY+V@N7?2?WCA6#Y+9E8>_TA7UJ|_:+M'5I@/(K;8&63E|38|Y>6@>
M6L_?6>R=/#2"J3(HJM C.AZ2)0HB0,*E"EW|X,X^2|VY(I_Z_!*"T%AO MT%MDI_<RX.NI:3Z|P1%?
&S#8K9.41%|&IB3:OG5I*G.MSOA<|L_&+DPX2@ MBG(O)JTQV<|L.67RET5@89RXR(
T^H(!>UV+|I8@#P\$25|_UK@P<M|&|+U"JM;L\$Y(=71/W\$+AN|_<CQ3=^79GW#ZRX;B(R 0T(PQ>0K|9@"_
M|PR;|J9G|J\$OAMUFJZ_W|FK?YWG+4BORR4 M'Y"YTE7|Q&'"M@MFK.K#QAK(SSDFY:\$
IE+A"&3)#>+G%)SV)J)#|3O|T|6WV&*+(<4 MD|AFW:@:#S(?L^@^|>SXM9F,5>@/YM?(R" MH)H%
<%3PG|B=|U\$1.#?QJZ0P=WNC|DK,@_8GYIQQ:AIY^0HSMIG4 M4(JG-(VNG"OBS-OW|_9_#LV)=BP_*FWW)B|
MGG)8IU(WZ2+|_!^* O|_?|@|PHJKFE3H M.MT7^~"I-QR:|J@_9XT\$5VQ\$7|1D1BM|6|6H.\$F|TLO<4H|T|_<
<%"|_I@.%7(48> MA.RCU@C.26K+|P|2Z;I_?8=WW A!%|K0RW8@?)CL!_940-OPPX|89. 'VIP M(-?<
=1PA|_9N%B^ARRB|GFLVVD%\$S.XHX<_./|(OD%GXUNDOD4|_M|M;Z
M%>F:@6S&4;EE*0W<_Y>ZC_!CU5N_BVU27?)OF4HF)N|'7CF'2L.HSVU1K
M_GE|7LX<7^78HFZ*Y/>1(#.B.WGOHSEM&/_@+ M1%CW2?!=0A._|>1/T'R>-3^/DUKTD^MWG0T2GJS)P2*E?
Z|2EB.F|I|I# M<%8"PUSSWGF6^)_*6#;_WS B59+UQ"GE_?K M3E4UITYM^>08DJM|_<
|N56_4R89I&|I1.S".B&C5LBV|_L.CYM9|RXDNV|X| M54:9|U*1R#_<
_NOYXE79HCSZTI%_*#*#@U+1Q5@QMEF7AT=1^X-|30%4EO35CB
M|I5E"1|=B_|!|+2A_A5NN_ZI_L|J.AX3R|W\$W%<_?;_/'YM^<D_?D0_*XC M+(<H1|U@B7CV17(X9LK_|C8KP
NC_CM_ G_|!GT>R:2SER|T|IX= L_Q2ZT M|YES)6^~5'D(|S8+Z'F_AOHJ6.I53|_:/:1GX++|7P:GEW+&-><_G.YE_8
M/Z_A|_O"Z|6|=6U|<9|EL8WO|<%+>?W3F#18|CZ2?7D|.L\$K|<N#?2|HQC7?2_CVE2>>UAJ>D&:5DS|R
MRL|6:L>C&(D;J|O?#_7_C&Y;5(PMLG<45=6VE=PA&+)(1H^9%\$5^3'7F|M?O9")I_S5>%_|R.8^K|_'"_?2
&B5'2V|UV|;H|_I70XOF1K5>_U|F0_' MG8.S"Z9^7#3._:TYR)K-|6C8TU_<L%9U|+U*Y=1NU? M_2V("F\$K3.:D"4(
B7S0)D#7H_#B%|&_*#>@H;_Z*|2&_Y5;"T;_&IW%&K MNS|7E >5|H(|3TV7DYD2^2"CH('27_:\$#J?Y8AKX3
'E3;@ZF=|Y\$RV.? M#\$C|4@|NZN/ 7"ZUEM<"F3SH MSK8.U.T?NY^<(41|6TCT|"#IT!NDWQ3=&+/@%&Z#C.NQ
ML_L(MH*%*B"EJ M.D|LF_)&3.0M_P'B_<H\$;U1FIZ"H%_AOD=3)"C\$"@OO_3Y#|55=W&|+<
M>|<+Z3L;Y=*P%|_#1*NN^X(6^@M^0_"U"#\$SZ8G1|E6C?T11LKBNU.P4|X MV (A3|6X\$J\$E%XD#6B?
91MVPX)CZ|_U=S3P*9?>_TZ:R4G2|5RWIET3ER M_QD\$U0Y_:_Q|V69|H^<|2A?O|Y*?L0F2*Q#X|S(M%
5N_P.S"QJR|49FD|Z|I"|=I=\$9M%G<343PMSH7H"\$s_ AV.G@|2|PG+^ M0.QASS 6|_|2Q|8B"
|@A0W|J#D/&N7|H|YGO|_@"*1_/H%:_@5WH>G#_D"K|Q MOOK&)4++9|9<3UA7"K?S_RIC.2---?F'5XX?
7P04^IF_CWE|@YGV=(Z>BX MHXZ>MR+EV|2_&6OOR?F5|J2GJO|7ZY/%E&N=U|3)9|CJOHC|UBW#)_ \$8OI(<
MFXL;Y>?H7=V"DCA8GWY_5FH%=-|>8H4Q.A(C_<B";_D&-|J#182+|E+\$&+C*K#" M|GSNO@JL1|ZO|7H;JFS3Y=?
T8M3^+>DYQH90\$V'7_PEZ*2L;D|CYE%HR% MYCB+##Y"#\$E%|&ZV\$;3?MRC>|2L2XS&^+&6MK\$P?Y2-
B0E"Y.F>|?3|G5V|N|8>Q<=+(JM;??3R|MI?M_MYSD29/>(J_@_<R=T M'6HE7|&&6MD%
(7HOB0_@3=,R.77|N0JLE9<"W#1N=;#&U&-|S|L_%"GB=_8 M|4@*C5A_#J\$F151B
KIVLE5HS@>SC1#7XP|N=G=VD\$WYV95OD^U|>|7|H+|_M_XN|X^<^G_A=BBICL64/^807 M=5VOZWJHKNOY9%
|7U?O5|9%&NLX|PE"AA\$+D1HQV+TR)!?M+_"#0%\$OE-7& MDDZ/\$AN%E9Q)
|6^5DX.R.KJE|Y_MO<0Y\$YZ8,463\$9@K'(HT|Z\$S6>83EB9T MI<IX|O%ZOG?00B%E;^TACH|4U8Z+TZJ#OK_<
_DG^BL1(\$OLX\$9=|#M#40: MJ2+XMG/:PM&A*E?<8=R8QR=\$:/R5;_ZK>^)'2|03^<YY\$6=#G&^>I6"Q|@
MZ+4|C'ZJ.R6\$&_&9TNXZ|_K\$DPF|B/55UZ%|E-W%AW^ZUWW|_D^8AF3^Y% MV_@|H2=H3T4@|H|&#_?<8C22?
3HJ&Z"G7Y^?<6T5|Z)+T315K'25O?7 Z_<MFN\$|K(60:RGZ_Z0(QIDXD|9+E|J|Z:0VS%|HK>BLR#U6_<Z:7B
M:XV1=%U&_)@S@WZ90#ZE>*Y1H8UW M-C|^MCJ.WOJ G;+<HX%33<74M_#YL1AJA|J<P50FZ/W|0U_?E8."AA4=.
MPH|_#J2ZB_@FF>ACQ@5M%;PS#0|QAH&S'T\$(<^?U;U;4_XO|KDN5_KQ^<=O=M?<
WT6#VL>4383J%3M6\$#7JMQ4|&4O%>CW\$<G#C+4+91#2|5PNQ"JQT_XO& MB8C|B3KARE!
L|/W8U9_2_%1HA1G/21! MFR3.M0"2O+RYUZU6S_7Q@59"QR >XIJ#0=|^L&=V6 C.TOPNA; S+@_QE-SO
MCC%*_9/V%7'5HT<3+FDWCO0"|<6\$MW;H^<#"ZH|5|+=#<PW^U<_<C\$L8DO64 M|O89CM8"|<5NK'9O-P*Z3.>?
+<=D#ET M4R0*W")_R2UEJ|K3_H^<IN\$B2C_AX,55J*(_I5HEI^/YV|5>&6K.MA=5KY;X|Q M0?)>"+P(HKB(=|9|?
Q6\$NKB09"PVG4%J49XE2Z_X MD1K@V(=YGE|Y|6?25%&4JYK"8_<T78L@O&ER3V4-F\$55O8H+<B1<|U>_*&^ M63-
59|FS_O=6X|6S>ZR*RT04THG;9"Z0?|HUQ1\$C|&?<C2J(5O8.F0YH|Z M?4NJ>OLK^)_M_7?AFV:@HPM/H-(51)8EJA
MYB@+<O:|VW0Z|?K9S_UUK_|JB+9\$C?Y7_:N.|1-5LT_2A(|(A_<E&B8K% M'4_Z4@0^)_ZDL8ZZ5,8>^L S&^<
QW@;TUV+|I MU%F8R*Z4?XJ.T|6<CR E+<Q;_P_ES-RSE+R=CWZNJ2FO)%RZX+|C|M3T MP+&XJA+G&/
#_N(4TA/L73QT^B8_80IZ;RS_:=H5 MT_(?<4HR52)1FJK)*_@BV4G|<LUG%3|=DS:3X9L5/+0O_#OW^B|3#T@I
|MRFHL|B@%AR=8)NA226A11T=RPY!\$CZKEB6|J|C|G+PE^L_'Z|F#^<"R*_)ZN M#>))M (*|S|&=L.Z^<
F&F9D8;|XLW+S+1-V5>G; Z79_YL1QQ|*5*|S< ML6*6&QFR>N65*.6LOBE|I*
|K|D2PLVGAVUJB0_VIA4'8|J0QY^Y#G7\$F'K<|> M+GA&0.6|W^BWD|(@5S'!<|*0VIT6_=%)(+1^U3(L_B-JUW>
0&|X0&| M|&.(F>D.LA|=UWM2C#<+2KKD7X4_|P1=+6L29_#_09Q7D'DJR(&)RAI-/J|NMI;Q(M0&4B|==
M)B_VSM7UC91&|_#YQMI(JT M|VY@J_<QSI(%9|T)PZ MWX26N_%"|AH%^<DR1>AA;_Y,7)PC3+HEN|LK;3OA?<
WVPGM>GWT'Y3FEK-T3Q-OR= M9093X"UEH'2'2'8@SYQYZN_VG%#ZE-#KL>=LTN7G(Y)_>E|PB+522"46-*>
M:DU;Y_T2LO_LFHE|JL<|H_J@2WM3" |Y*1EX(EAKG^5U|<OW#D3|<^<D MUY0P%974|_<
MO%M*YEL+"CMCPI0=EH5/M4_A3)A/#P)Z) M+WO^<(<2L_<WQ|TVKZ*|0%E@LM*)|<^/EG#@7L
*_PJ#|EZ%:_|Y|8|D0\$D8S'ZPF"DGB'8^#_E12K M01E|G>_BND8Q=3_FOGWG;42NG+E@*9
&|O8+0U6J|D3KEL;KV^<+<RU-RZ>6 M)HA|FLT|>2_J>?2.C#5|JKUSX"C^U,UL"5'65|0_RPAQCK2|PP;_X|&?%UD'
M|J3K)'(AA.F1H|H8Z_-YG|PE<_<H5_@S=B|>47P+=4'3_1YSFA2G3^0M== MT.=|HH<7_&|%\$X01;
|XF"GT_R3@|XO+E+7|S|OL_0DYHK2_B?LW&|_#*J(I M#-
|BWA)87|3L@EVN9^|E+RT*LF|"=&67|Y|_P|6N|&&7FIHF0MG/ZG0F|NG M:))9TKC|KD4ZCF' X1?
G<5Z8B><XMPY>|/XN+4S|FEBFG37;AKM'"7L_ M9Q2|<SELH\$KE#QY6:9|4ZC.2|H6)1*FEDZ_(P_#1#;KF?
H)7T%+C3|I25HR| MRZV^#S?ZU8|5|P(=N+<|B3?VR@_&2Z9&2C" AK0:F7W7.?Y|K2W9W;23|C M915DP?
UL|JR5|V?JYXA=?B>W2C_|D#1'(<=:K9Q0LO|H|O|"4H2H*7AP_MN|L'K'<(
HG>W..GO)AC&\$)T|T|M'6M21#<I(IMNS<_0'_S/7Z5N=Y+FR1.4
M+2*|=2|CKUYX_Y"||GA+|M^I+|05GVB|M=A^YN_Y>U23QX2_0AM M%JSG|E*>J)Z_PPE#4=|<_#+8+6S7|E
F=SP+CYQ|O"BX7M+N|G TX>6 MK_XF 3_"XV9\$C(|P'A:C|2<\$(C@ZA9|H#GF'|MTR7.K2OPT_Q<^>@>K
MTPF2EM?|)VWVR|& M/Z>^<BI?X%3#|4'4"J9FB#&4104_X4=#J5A.\$(P1_<_<
UK#6S@L\$1*YU1EU;2K|H#*OTSV&5E3QS\$%WG|ZV;_R?&BT?&O+B"Y*6|GX1X;5K7.5^YV>_M7X?
%UJ.CEHBK9\$QG MT(W6+|O:QC*2|76U8/|O@<JPANDX6J|D=ENZ&+*WL= MHPT^Z_<T%N>R;Q)>+>+?
D9QJROK&6>'4HYW V#M*PBG=+7JZ?+Q:BZW3 M'WECQX\$-
+RAWT8*H?5X76H=ZP>:4#6|*^XSE!:_9IU4OP6|M"W M#1=W" F#VEG#/8#HL^5@|; "RPG"=|_U0I|/2Z5;"P?
AO9|JZWVG|6LU(GMN|OTC^|A M_/H'>4 A2'6IE+|!\$VHI>T ?<R/2VXP.1+?NA_5_<EAXJ).V<_SL_M6GBAH
MX@<\$9S8BS/5R&^<G1W&S MW07(XBJLQ0V_|B^Y>5_U7_YJZQ|D.DEX1WS>+<
MPZ^YGI>:QN2<4M+K\$CK1'33%QP:F7S4> (DEGB>=I3F4|<K&Q.W?#N=(>Q|L_M)DEW3_M0S5\$B|&OGX?

(RMZBPO58;3AQA@PUC@3'H%00V+9JE"XX6X(60I. M*8W6R9CIF WfVQP>
[NOY*)M""7>CF"G>6_\$P"J2\$M\$K(\X(%%>P>7@Y/8&EX M.[P3]DS3C3HVV.7NCMFO#B!"?K)A@2#XGQ*=Z-Z
M'TI&\$.E7.N!4N[C-%UY%#2>(9V!D00RG\$@)Z*,7/#*.^ ^0[W]7?IY8@!JH M.%B"O#;<?#F!-
JH8EQ7N*T_\$+EBH5419OM0:6U!;7T1.U!:=D~YM0! M?
N:G"NQH+ALP+M11E[G,=X%Q8H[B9=23]UWG+KP>+;_P/^UFD015F2H=840} MV#@3_C 70PI%*@[#"/,;S?
OCJ0U2@W.TI4G"Z\N+5JYK M5Y;#FV;X="F

S%S8/8YM M"*GZN410\$?ZF.O7IS+.O?)4(C%1: #07;(C_?9WA& DN:4+2DBH^>CH?&=IP
M17VS6*X6<>;3I9NUG<IQ6AH# 6.6#S'D\$W0K4)5VC:(F?X2:/IDM.#0P2O#; MN>FE/M'UU*U*L4Y#W-
C)=I.0W/I45A/HR2GX+G1K5K^S\$+9#_P<4TB@+FCM@_M6/MQT3M^~09F.;1::?JH/Y1VEI.W2H"H%H4<.
<=;/7.5Q"72\$GY>4.4OE: MIE-5PBM^R8)YV6&%M/(K2D)GP3EM0C_.PW4~I.F &NFDK//@I~ID"P4O M-B#>*
->:I>_K&>IXUIO(O3*5W#Q0U?2UU~0DPU[0A]5HB[3#6-U5'T>3.I02I0L?-\$2_7I>KLI#;I76L6
M/YH2W885;^3YG0):FJ2WKH\$^~|^<.7RB;@QFKY.33PD-60;~H4=XGCO*4I~V MM
_4H84W0G)E454;>G=AWC2BMV_N5U\$8C7JH4UQO9WRJ1?6=Yu>")23U5<
M2NEY+8=+6LN^U_%2)BLSF=8JRXZ_4I" SA<#H!"#3IP6/*EM40JW=&~!"! MHO_@H3/=^VWU4Q_#9*M\F6^%
(TD:NTIY3PI.5!(S>(I<#Q) KUD6>:1KM^ MLP2J!^=J^KOF6BR(C1JWSP/) WIFT2W HXN9WZ#>D
6M//CQGH:W2!G M%G+W13RY^Y6B9NQ^8*TJ:NNBM.7R4OBZ37?EK\$ZE00D(8-CYI+S01*.X;@2
MYJ?3L18L#YHHN\XJN!+!/(4J6^:R>EHE_A7H0&*_(2M9_+J=6(K4: M#JHMB-W=#!'
JO~NI7QI;8:T>S+I8W^B^K" I MT.1DX:A).8)#\$MD>*IA=3V2KM?/+IAM*9=695Q?CZ^CVI961S(C)@2J'9
M@2I08A#1ZJ;~|_09>E7Z5=F7LSR=&Z6R@+#+37A)DIP#Eku7!D:~NRB MB1"RW+U72P3!7GRHH>"
I4AHL6G"\$+~|K+YK+NH_/&7E*Y)":>ID-DF'@#5 M8-<) \$T=/YZ.%4&+@H!-EHX_EG\$E5R13+W?1UYVX.(P-O_2ZB?
EKNY#Y~? MMH!%!:UO9O~RU~
L#;."#"1JM;)04K'3NQ8H@LBQNEJZ7^2EE;O!SSQ5%DZ_<29\$IPQ!\$O.!>9@_QL*JHR&D.QR#8X;>>X80K#^K"U?)%!
YZ MYR9EB=9OK)?!+O&G<*=~DIB17T^RJ<I<=~-67ZXTJ\$H7 U7/@Z?5VA3"3IT
MM!~X^%12)NOKQ+V8&5+U;RM;!6Z_577YDT=21).5C69NNNG 2I?CJ8_. M3A>::?
G7;IAKMN/\$L/1DWGNO@_0X/H0MH/(C<+&4<5.CW%J&D;\$0P*LN5 M>WS"Z>;Q&A08L?)ZT3Y@KPIAT9EBR1#
I2(OE&@:G(IZJPIKJ3+ DU>JROH:K M'W^WCYD-N=OS/+KUHO9>^D'4:AU*CIZI5%Z GO-"2MM&?#2?&A Q
M3ZA>O=MUV&1"X)V?I6D3JH;F6TX\$49((4.3+>D7\$THV24KI!%XCZCN#0/_M8D\$7ZBZ3E9DSWQN=NL?P4I%
<03@%0V1GDJH:\$%;^YI_5S;~|L1\$Z8#3DDB^IZ%F;A C!UB7%L_%?8I-G?1AJH;.@02K2#>_2U
MA4^0V LILBU_@H8H(<~Y>EZU5@D*);GFF%Z#>>?U1'206S1@4'5H!>MG*> MPP!DO/0KIG-S/4L Z0HFN4S?Z6/
IU>%O=,*IUDG5#E!W?XECN!CPIH;R#WVK>4/ MH!6?
A7NQ:"DD)+,%T@GDG/I2*X2V!WJYJR*V9EXXO&>=P77*JK!K7-J.75 MYF"BP!N:J4D9TT*I'7'HJ5;~FY1CH5H+
D4HPZ@D+(RL-P3YJ9*ESD62 MC%?.I;~C6I8?#7C;=IU"% ?_S<9<;R-D;H3(IV<7M8RB!~M_<D<%4
MRI:3W8_*\$W@Q"(2:B9BW!5EK>#9TOI^X)!:=<I8_!B=08!B"1"(N"54## M*!PHPI
<=..EC7""IS_2>WEK3ZY>J(QROO6J:6.WI4LY>~|:(3;I8) N2FX MCMZ(LH6'T0DZ3JHJ>Y4F#9^?%\$N1=KJKU&
M7&R@V80EBWP?B%A=CE>S+0>O3QSOC&I1"HX#C&3;%9XL+C/D>=ZSZB,BN! M4FT*K*KDW 5::;2JHYHJ?
XD>J4RWQ!B>IA@_70 I+LHX8F+I2/QY;+M>PZGK M3G(6%~|6HDL;^36!C.= MOSI?
LKP5/TK.W%XBPAABBNLP_!AX<+Z7KZSU\$GTI_C M#7^?%;="&S?BH^%D7I/^#^%C'.O)!':..9KF^ M7>K?NU&K?
CZ!_%08B'&!#Z:DK3^N#JIV!)6802 ?V)B4^H(FR@?=ALNCAH MQ4!&!O:~MYDJ.2CGB<(")J9H
(~F>O/G/W4I5>5T+@8 D+%YHB3W U\$PI=W/IYD6% MOE^7%D=4-VLP>(L/?>I@?_~\$~V2"H3;~LR-
IWF&NZYJL%&~2M1Y\$&*)/F" M)D+VZH;~HJ!GJ0!%<&)GMMZZ@V3Q!TRGOVQ!
<9Z.C8MG\$W*+NYL^*NQD5 MFC KC30Z?>1YT!HKK==&_4_55!2R_!(JRP9LG=%BSS)<
MYI_L#ALBTGZ;&0!>J:19DI_X2GVA\Z66;I/Y.F:IMJO!>L;7XIT:N9COV8#'_M5!Q.M!(G#Z*O_~|.#B B8"
(W(I'5#3K"O4P^~?CWXIJ7_O//9JSD!5I;Z6N<2HJ!:=,ZWw8 M!_UW#U1:P!N%B#~26=F+U3_9@A^
YI3'5J:WU@*VTIK_&H+1B3W;>H:P M.IG:3=IC;B"W*86=RA0IK@
MPB\$SQ>>_8#QE:P#AG"HTA/FATC(NTZ.93I58GJ<;@B^=VSL NU!7KQ#2W-U M3^/I9_%+;^11%I_Q?0N(_3-
5"16#%72BG&D(I'G5Y\$N#\$~|YW;2) 8R<;# ME4/I?*FL\$L6.(~9-8C9@!1GW9E:C)V4'4!"&
M13"Z3.7?QEC.F/7@5N/7@AKWVXF%~|_#>1H;8)K?9=XRIW^~@2!IH>%&8Y MHE/DPS!>
BWF:2SM!6L2(P!)=I5IE^~2+P!QO5G*=78D?>%N!HC0S-MXV1MW9FI?9IZ>GC_Z#K2HHD>H?
DQ*ST_/3G2(4.V&LB~;3E~7IXN^R M!K\$0#ILLC8?)_PISG%Z6/P_Y\$UJ_YX!8"EJH7+3'G/G)CXZ<7X!E'9NBM^
MMFFLP6_M5+FY)S'3;1E;)HZW3"3 MW"NJ)T^UW4(UHRO2\$!>L%T(O!7X)-I+7P*7AXAPDC_>+V48
MIGNV?A;/+?=25\$WAPWP;)DY+~T&A&K;2L<^RR2P@=O>A(F)<6GTZ-WU!STK MT73+KLC15Y;?
~OS7"\$>8ER;00D.MP*~(<6OEI3@ARIWW~|;.(5I)#CYLTGD M&'=MTRFY7G*5A3:IY10..9Z6>DA#P-
A.#0;^W9FK+FO!7A#Z^PIL<#WE6 MI"Z/40AT_')&2%@Q1JA/QFVH#)S;MXI=ONQ"IOQIT&+2!3"6IQ;S>WTJ)
M!T(" >>5!4NKTX?:11!6+?(~U'3(@MCU.)CI"W>*1WF&!V;<3 TJ5/!-5SX
M!~9I(KP9>;!|>#>>B"7XHGVI;#Y<~|RH<_I@?5UMY~M!)~85XG>M MWNZ>I'G:>YNE
~ZY<7(KS-0D\$!&S;H!)VA=RI:CGU M/UT?6=W0L%*XLN*~|&X=5?3@HHGPMLY5;~<=HOJG!1"B38&@TD_@I<~\$K2WZ
MR+H?O<;N7:QJP_CFVNK29"56#DFUN7(RXNR9)6=F+8H7A!~7HY&^Q&L@4X! MZZ H)2L8;#HU33\$~7J-
<^Z*YTNJEE!4!="5<@9=I>C;~H4).DUUPJ=R'_M9DUURLT*_B(WI=>Q#KGJ9BUM_P5F9_JH>ZF2H?
41(?IHH@O2CF)+WOD\$J MIS;.25#09.IX""6_Z+I9G5/P5?EY49_SR8.W;~(N_N)U:YY(^N5!@AF!CZ%
MZDK/I*UZG'3;=+~H1!24IVF(HM6B)C+>2&C+ZW3BUE\$8M2KFH/R+U4GF0 M.I0H:P3'ASKE(IV>_ETJMI#3!^I-
^~!\$TS?USS>= \$LL3^~W.I~R4&MB8JFH M:R2(JIY6&J(S09)(NR9~J49%B3_0I4ZGF;.
<>M_LWYA3ND\$Z<9WAT?I_ M+J;K;>XPWS9J+CHK43LB&#*#I19AQI2K:22IV_~PH""#<)U/ M=OS?
CP_~K260Y06Z+;~^60<6*016B;>7OJ\$5NA)B5_~|H!0^&=I.S MO>..!5X3?BFSV5-B7+0K&AMI/Q(XQ\$!_>~(5-
N!&;+GT""RC~RVO1IAW3HDBDH^_MG/^4\$;1CH>Iv3_46M5YQ=MMI05^~|L?@HJHUX.*G*F Q#=#;~\$WQ5?
D7:DZ"~|M_@WTT#~UY5HJVRQ!D_.WPl;~U.&8I080\$2X)QNH"\$DD;V#YD%~|H>~|X) M^EEI4? C1X&Q2 V;H@&S
FMIK;"N=V9?I=IG;_ \$BA9GO4#JL03B7_Z8_%WBO M^~|:PY?J!5K;RHBPC%#)S3Y5+6947MU7=KPM="E90/OY
MQ4A1JFET3A/3<~(8+8(B_WZ&#>P'S8G.&~|<~QFG)#TS/3ZRK7*X3"R5.W3
M!_K33>0%);V!\$KL^X=G!Q5!^HJIT30%2L".4%D=EI6?&C MQW)E905O.7H3ZEV)!I9WJE6;VHP;ZN\$BIS)%V"&H
MOF6K47+@FEEQ?CT;P*~H!WWDZ!~_9@P+3>C2BILL4P8QG&X%K!;#?XZ;TX MV~+
ISA'E0Q7&BHFWKA:G2H_UGO5JX+3Q2+ITDAVXUQ!E2D7T!R9TE9-X<;WCIP\$NVNB+T59C=IQNG;C!
IQ!&~(\$K.YD_EI+7#0Q\$N14ABJN154E\$S_EKDZ1IQZ@&H M.:~|+~|+~W#I7A0D!G/L(K3^
MZYU>R&0Q&_BI1^QHFXIN+>8P;JY"KBD=4P.6W=\$8QYA!@+7%Q MYGG9*!768JGI@LQ.&YJ2=U/L;~\$G;~
UW.EEXIT8!E_X8IJ9G0378G.2I3;"M M.MNMZM"N*9!>2S1D.C5#~\$SKU9G2%?QKT@1#QA7D.IX!4(A?P.N1@G<~
MALN_UG%_0B%@KR%UR;KO?ISL"&T(H_R 2;%_X+;~(??(IE8.K0A;3#~U11 M^FR@)7F+~22.J*~
=K!N6YY@0J!>R~|O^~B!XIDJ3!\$E\$~7~\$S8P4_&~M!;~(=&V?^64725\$8YHZU=7I?MB@I3JH!
(H&Y>D9H!6M.BF7;C7XIMGB6S'_M<4Q.HWGG4"E*\$X7AAI\$~Y"W_8>D5>~(G?&E.\$#ZR2J;H/JW4ROKIM\$ M*W@D-
F3.25I;K&TF;~KR:5@N920ZIYON";K\$S))E;Z=J%B&-1N(CD'U83>I

M8&MOA6Q@I0R40M4DB+|B^5A7H|EFGL|HD/(|WTEG|8:Q:/^4.D>3&00
MX;LJU9(EKTS-"IU_E@U|U|R@:|:.'PKSM-RYPAT^|(@&|B6QX|/0U<9?UX# M/K9D ZG1(PL/T"-
=S*+7.#\$V0"3!*U288A#<ZP4VP,"8,@S:4YGG,|EXX MP=A TF|V|,PTEPWT+L|)SN|OW_A;|_|ICND?8@
#C*4Z@N%"PHE|H|'D<|D MC%OI-QH8MP>08WDW|H|^|G|Q6.|9;==GZ/W;?^0^6_=7G>))0G=@A-@
MN%/B69+4Q SFY|QQ<|%|>YD8%WML&L^+MOPK|+00\$?M4% XQZAX@P7|%^MYZ%G)3EB?CV\$ _809?
QENL=#7V\$ 3)Q5_ORMU,.6YE!#R*M/|@# +2Y"VO|/M_?S_MWP5VB*)>Q/#9ZE.#|_|
/07H7T7AUD*F>VJG|KL7R5>5150?_N|?K% M>26/W
|^|7%ZN/85N69#E\$;|6.=8LG#FYNQ|)A*M>N|JYFE'L5;|%Y#Y=#OT
MM.#N&5Q*"LQ|U%5M0GM==L6F|5NLN|7C>-,LV8W|&%|U8|>MU32WT9RVO-M<7%1=?UM+|VZ:
(W3|)Q67F\$#|S",=#90 M|0'CH)O<_WC@=6|F#(9:Q|K\$;TMA)#7T#|@_7G|!^KW_R(7|6-UYQ@:^H>FW M.'|HS
:L8|X|6|'ZT),(&|F#&+2JR 67.BB=-J_U;|7|56|K0O=TPH+Z M|D,WS,WAS|V&U-Z^TY9QL&.&?YTC.?R-F|S=
|L65R-CF-|Y|N7&??^LJ M L F \$0FX|FBB?91X|U@UC|)DR#S.M&5|28^CH=N<#22K+M2|PERZ@=D&6315
M|J8:7XGV@.RHP+90_L|M|^*#TK-%H|A|&5#Y|B69U7MC11H47X&#%R|)MKTB"1KUMT@W^&M@W%@\$?
|HV/5|N|G0V?.\$ K#/UMG8-1)<|G?2_Z_OL3.DC|"4P"/4M#MA)"X M|L5IW#|V|^*DOZ@_K+??
8WQ=5)E6RGC^:Q3RVHCIBN>\$Z\$=\$M9:602L+Z4|M33E^-DD|(O)|6,Q3C&>RC< M6UK4L7\$)M*8Y,?
@S="AW3K;K^XG|K;T0:C+&?"PC=,@&-L@+N(U8D, #| MWA; G0, 7PY<&48SXN ^=KD.)W|J>NHQCI+
|EK@|RQH3>95W)F"AM0V*F\$SAH=90/1EQF'V, K3/L4*.?| M@6.5;|Q:E#"ZKV/&GR%4SHF*
|TA%C;BOZE">.;LZ"^-H;3ZC|/#_GB*NF_|-| M)XL_T" _PG^VJ9|S|C+ "VS@#0|1|OY6|'|(|WI^PYU6|83SQ |/,P|P:
MEH/| MDHV#|_*SX G2|6|@-|WEP/LUR>K+&L2|H^-,OUG Y560LMG/B#| M=>Q01);QIC?L_|+Z7XWR_%<_5=
(Q= EXZ9LP+B< 20ZC #H%0^_WO^|UT2LP MTF"\$AOR;ID 3SM71 "X\$QMX&GW:
0N7*6O&;K*X;=%WA+0/36M(7_K^=-O>5 M^3|Y>CN2M%|F+O(T70?4V,++|_@RI+FLLY"E46|^A="?+4>
|4M0VW:2VRE_C|K^P/PK0E1.EY08."Q\$-XA'1^R.YE! M&WM^VJ^&|4PS5% _;SDN=X,5/P5#KM4>4EDOD|!%?
WK7;@ 34L(&9%VB|X9|^VWE|K"OC:;KW#0&#FDJ! M4QJO#%YEZB8=B'>|^7FMI?Z.)1)Q0|&SC|4%4-|S>#F&6R
HL)R897FOIO0W, Q| ^7YG@? M80UVH^NWV<"D0//=-J&^|V?SA*(W|G\$*9|ZW _;=X9#MPT^V4#^D7|6EOK|
MQU5F82(|:Q53C)V.WJG|@7=)Z|D(2L&4.L-^<@|@+|0==7+|^@&'8=1|D)^|J^ MB/-K#-DPA, Q+
(N#73|AL:S6:_OT=,UZ*1Y&*7WSQR6WUOL(*4.R@C"),P MYX0+4)BE>,QV)|6P2_1'VOU_FW6L&(|^|_|
TG<^5^D8|JM_| CO8_RX^ ML7%L:7|JO>S?J6C#%ZS^U_O_5)=N|ZOC1R;*W-A\$;@7;+5|QJY78LY^V^C
M#7Y|P8"/|Y" WZ\$H(F.D@0|2^|VP&LW|JHKM4|N7;&\$R|N=0KE;TX7?5TA| MDCYA:@6E&XW.NK?
#A7S9:A299IW+|J?P3ZK*PIN.AFU23L^F|<_|4RT:Z| MGL\$|DY1J&^XI*G|5%.PX+%U'3B?Q?"
<_XA"i@5Y:YVF)WY|/00V=F11A M KAPX_O>|!TMH?N5@=#%# MV!2Q(U>|C*RH@R|R<"+WFKWX|F_?
87KN;U%|H: 41B|C7+)|9RM7?LW%5F^I+K|2CH|/"G5X\$;RRU#S MTWAN)OCBQ_U|ISNLPTS2A_
M_Y_KO2GQ7|NCYEC?02UF|EB|RYDB;% LI#13|X|H+D|@)|3*7^GJ_H=IRC MWR.NF?
6=^BD7@=O_577WMW|TN=2S;H9Y*TF>LO>AFJX9 BBDM|Y)"(FJ MJ-^2ZRI-M3|AO|Z^KJ: |8WAI?K\$@^?
74K2\$CHK%CGC@W|SCT51L^Y>U| M#*TP)5^|?K D0?5|DH7F"RZ\$NPUP8C1-"(|^O480|H|&S#SG_|B?75
MG8K10XN7,"X4|_|#&\$X;"PI6?Q^R9J;ULEN|8 @434H7?J6N 768 PD|E.6|2&QWVU6.OM >U?;>&%9K
M@+V97,S_&6K' P"L_NQ_)Y@:~SP| |Y|Z0P|M"(&"3WZ|S.|% ^OCV%G)V:(KSI"=<&H62 M(K?_
#EM|5RL&FEV26&|Q#XT4O>WT|?|3HHL2UUY|JN04OR>FGE66N^UN.Y^X M10S4H(ZI.CG^>:4KJ&O"3"G7 K7*
MX,#39+L93?JN24YRBLZ#X/VY4>|PRNK6WOUMKQ"6|82M9Y495|~8RQF85V:Z MVTG=%CN7S?6MI-R660>
|BQZ=;Y6 S'067QO2>)RL;M#6*|H|1&H(=E\$S_|
MU|ZTZ35M0H,HS8SY&D=;|198^&RT%,T2P1=YC#NB/8(JU|_.OCYW6=-L/9\$ M+O,**W4D5F&|T^PI!\$J*
(5|HD^M+^A03|LH79=(UC|?K>V9IK4W(EV\$5W; MTS*)8A=X3 7V!T<7:%^<&(|^Y|?|OAJSOQZ=.6?
|JZ^DM^&|A<|)PC<@^F=L:|@%4Y;TB'D8B'5|Y MLP\$OK|HQX^?KMZ64|C4N|KEQ _"!&)|LFX20G3CA-&?"1M-77"! "
|9DF|6^| M4.(C|Z2?2G%-U|_|D|O|U2|N=>658M*O?7?";V7*G;W|SD7'RE)-T-\$
M|3;OL%ZP>*G%P|8#> UXANVZ>|I<_,IO>^DL|'0=|_|@@
MARV.|EN|+V;K|>|T) MHO4Y@FOQMNRX4&U")JP>|3D%,4;&HV31W%-(0THED?Q|=|DL?_M;Z|OUNUX"-
KK42|SG={0#+|F+5?+|B3>PD^JEB2\$^|_|1E^?YC&| 2^4W@M M4|YBG8N?VX)E^W?H>=|JBD&?#^U>^|?0|CG?
D6YEL:|ZOB:Q^=;98/4&W_ZXN(UDG|_|ZF|;GRVL:X>>7<^P^1/PZY""7WD:09N4.KIN|F_|P+WHK=L_?P
M;SCXKML_S+U&|S\$#IP8+-25*R 7-E|\$*LB47>?KX_*FFM+L<:UR8FL4Y1WR M7+J;XV(^*JB|^0EVFP8CN;
SFD,*M2GB^|4\$J8AN<_MER8;ZBH|V^EZWJZ8N* DY%)C(WO41>;CD6DMD>_N:~09#+GL)P^U'GI^6V
M|+U<^W52NMMKU\$CP\$PR=86U|Z M6S&R3G|1%AS>T#+=XHYW9?2M=7:7SY-RO9FH7?(@#S)(^|Z4|)O|H#X|H*Q
M_|^P|F%\$E|UB|&.#?NUIQ=(7F2Q_/KO|6P#<+6C_O*#P=|J2|4;NR^(_ 2 MCRYB*^V;#^A,"|HJDB;XM^CF5Z*
(\$*P0EQ*_ON_MF|3"LN@J2|5F|4N&U>|@%Z6|NM_'MG%_M4#P^XFEZH2/"UH\$WKE34MDD6V/= M)J92XU-
'3H,AK<|P"|4K=Z6R5W4MTGOO:3AD<&;5-ZLUTNVA|4=4V=>/_R M^Q5G71F|GO0C9>?;TZ:00|'16/K4B/8
;&=P3H8)\$XN\$T/583B!|LW|#F=|1%5|T+*K|O|QPM?#S7>UB+/_+U|)^*(|2B)Y.|FF,
(+WH.A_|@>^*P4?|")*PV:|%13*.V=|HUTJ5*|1LV7|&SNY&*-&<%68-A@A?::M M
Z|9N45(C8Y*OZYODE|PNWQ:;W%0*1^Y|79MKXEBP+5F<9L:;P)VY.)0|HP' M)8F MYY M\$-
V@78FPQO|2DLE^(*Q|5|@2(N)|JFX>P;)M|H.G.32*6MEER/%IA MMZSYSM-
9<4C7UQR|H@^*WIPK&M.YQA?|CHR>DU93*YGUZP7BN^OZ^X-EB
MOM.%\$O*G91^NX&2/DL(-;58D7+EXUJ8V23%A>%KA@.62PE=9/|MV7H QQP&\$ M62B"M ?
9@%0L29P/5TROH;1'(P<\$_Q)WUR|8YQ:9/G;ZQ#MWFU,=Z4|!\$6AC MV^0F&RAW+J?
KL6J6W\$C|(DMC&8;|6V;0J5F16>26<|Z-?UWZ1^GDOOH_/MC>Z#^|S9LEQ L;B*N|H@VGTX+0GA=|ZL??
M5C^MRKK.^?<C&C|G4#?@O(B M;S%+C+3-WOE,"IO>,11XW5=-|OBDWZUN"N^+;G_9
WPU7BB6L9*FD)\$DN; M8+|2Q1#HM.1Z7T&-32>1GAFZ)%|K63^@^|WK.#KK<88G"@^|G;
M#_Q_0G4F>HY34RN8|2=1|+E=,2_4Z4|&#&66=K;H061O7UWCCZ8F60|!
M/2;4"N65_A1GWGXS>TAD\$YX+;.&3DWJ.NV^9|O670?H;XN|HU>6_BC6_S MG<|HWF83N=@IZL_*|_|^_W_W""
XXU\$|T|H08@G1\$S<|H@C2E)X6_-E M=U*^W;(|VD^0?U/2N@D^PQX|57*|/%;|H3Y\$GUWZ@E;\$@E|ZRFOW/B)
MPGHC8;H_X>5;|"-2"YGI>2;|8@?DE5Y*RM;-(E.AHW XUB_YRM1F5B\$@R|
M^JGIFV0^_YQ,F'B3;|@|OQY.8'/P)WPO5(*|_|"K&|HBITZ=X?TVYCITIA_M,2/A1NSWLLJ1(G?UPO+I8S&|_|^
%03^LN^L5^SRV5|M=X;T_RJ=K;4D6=W M#PWI6%P;)?N1#TO9^H\$G,\$\$F"|J\$F^S)|@|_|"(L?
ET!\$@95BKQ|ULU%)Z_ML|<6W#PO2L-W|HVNZ=UJ_8;|S^+|JRC^K2<4X;BG(|(RVG+6.&?0K:454 M;UL?&?C-
AC;NV_OA-D|M5&K6E8@T/A^=G|DBTPX,\$MQC.8&|M85OGSO>4WG^RB5-&8>E=6 E;
(ZHD9=QYB\$9ZP=XXYJG|D;_2G M0EE|IR23S|Y);BSIZ58:54;|J|Y/MC37_MQT MB3.WF\$HW
\$CMN1|'SQ=HC*%6 _;|3;|7Y>U M.W.W%A2E9R.7SZRN+2|
MY'/(%4|2<&"-32HP|^Y68J|C;SS3XVK41U*O^EC<|_|P;ROU=C^Z.3FQPX2,74|7-|AB6128MA(|9G>?+6KKSQO_X_
<&>D&LVI MIP<6.5%MJP=-1LNW5UX/SWGM*Y24@2"=,K2%>;C2;O_*;#|L;B M2\$X_C|7J2+=>>_U)2>+&;0791|'
AN8S-E#F3PZEPT#X-6K|J.22PRD%K|J; MFA4PL^IO_@=;UQU\$|O^V^L@*V0))&W.,T0*:3^IV Y?4S@8.+T|++|HJH|
M7QE529)GS;H|S\$E+RASM>R MHU\$J8#Y|O70|DNK4Q22J;YNH<59=S\$Q|_S.G6YJA2.%9?*>K^T#EM-|
M2+Y#;P^F%K0=*|N|AA|/8L70: M)/GT.^1>D\$|_A%2L=+MW;>(\$|STWP'?T\$|@_MG^|)X5N5FZP>

(7JG00&'Q4L1505\$M6#>GSJ2Z5+HPI+(XF'7.9U^9V(MU5 MY%U73.HQZB#L-X.NBPYK3DJ8?#EW*7*!5^
M==!LJN5SK9!-)2/\$QW?S>(@RW@L9".FUX58)-!0#I(AR @/0\$+0GAQ&^=^C/?ISIO.><[M_YSU6ROSS|
|>_>^YYZYKRN9N886Z*1ZGSFMJ9I?89&A7W>K\$CL(5MC12*EKPX#RQR!699F&^W'E>A\Y,I78R>-ZSI*1*_GMEIY2
M'5NF=@\E4W71)I"1N2:@ZITR7?>6R,85P7>>.(B.N2=^!W3#)XG<?6XI 9 M+KGQ-J@+YHR-VI^3BC?=@3NI-
_35MS9:'LCONE,D\$:G8LW:@R#:.YJV10# M! 8A'8S'E!ALMO.2IACY^F/6!>:F+H2<=
=9RF'#W?I_%3D/LK^2<3ZKT+W M +\$7?CHPU*^&EQ6!S_?EXG:AON2B?3'Z5*WZ+P.2T^D)!WV=L7A9+V%KB.8
M^R0 T%P=B9YC.EK<.I41#1_8Y'(AU.77%TU,NK3IK!|F;-BM(S)3RZP4XG0
MFVZ7<&I\$,F490V,L&UD^?)BK^MS/=X.0.Q:Y\$.R_OI:D3ODYD)W8;L#I&#H M9I?7:/(YI6?
XI@KK':IH*DBIXMF<'"ASB|2@+IGS8H8Y4GNV#Y1I!/=QZIH39ME?K<^HU5 M%_!_CLQ3F:_MYOXXW"4Q=O?F2-
EJQ)9WSJY6I#*U_Z%R\$T=7E'_|Y.%&LK81 M59W'_+=ND%ED#E"
R*KGB1P^!Y!8Y!);%;;^QS\$7>5%0PIS>@2J0WF7!K'
M:SVUROP6!;Y4<795_K:RH"13VL\$6@8B,23OFFH:PAT@M7115R;N/W;*PI;# M.IW->>8U91L*BQ||>0(M-^PFW
*_5*_C(I8DV_15%(4YVC1HK;8H T=V0 MXZ2^K!2?F<)"+=O_Z'_B_Y6"S9^;.6G'(G>35^#UN7"YBBK;QJP2U^L3MZUM
M|_1N#%_ZNM_->!P!%'QF'L\1SD,%4ICZG1*!<8QION&R:
MD'E=W2)WSN:M1VE"HUIVQ2^OS:'O\$^5#_NK^(5U1M"6):P=7YV&9V\$P8+\$J_ M>;B"/GS;
(\$+Q13E)3D|JW|IS26#LIG,XGN&HP_:3;JCVU#":9A6%&3SX-
MFQ"EEG@CHS4M|>/'=^N|:~^*Z)+J=1!WUY;G.WM4J2QRZ.AL@)9!_"4E5VO1 M(*=XWZ\1EW1^5WPE(W/0!(Z2-
HF05!BVU,W\$T9:F>8=\$S:8W|^&GW M?I3!*15?)'(E9.J !+?!N138_!/+R:.)I94F'X IX1FHAVT:KXH@/PYTN 3MZ
MACOWU6^WQB@/(Q/T^V>8:#_~O^S&IOD56V96,/FIC>5" 7PCML/LODD!<--MD,4D2H='X!0
*2OFF98B>Y\$_.|H<_14LB?GTI#MUIS^D^4_*L9.^~F2@D)_MBL;L5.K>DTEPH%|>:
[7.1T'7'3,T#I|)Q&A5T4PID'Z1NQ-UI":R*"2(G# M^K#<#<_:(5?1UW>6F"8VT@/&3!0#_.32,Q*7:5E*Y%GX)V?
&P)|0NTK8M1/I MQI8F)|%"2I6POI0L_|_=&J?33GUCU092:&-
%|_.DP<5|A%D\$WSE%>@*(KZ7K'LVJ1UI5P05L3+T2<7.(Z MJVJ_T1A?)T)=Q0>+!
Y\$3WA^5YK_5HX*78M^5%TD1_GHSN7RY7J7W>_5Y-Q! M5^"#!_R6+#7U9SY+P8E?*N+W=%>_.+L0R:IJ9W?
^AL+E9A-?I(9/5O;R?UI MI"L#BWPYO:UOW@0;K)C_P|PO7NID*KYN^AA15GXA%&2!+!#ZA#C-31-R&8A?
MW2_%G(2B&P3?BK<72?) (MN,E^~V2= ESUB?7>"-_|M2^NO":(8D-0M@0Z
M5W\$2'IV)IFU3XHX'G;^DIW4(YBY(2;4H|^5R#US;(I3IDPR&B=IWI;ZL M#;P\$IB_-J!/\$!_8%_.0?5L4_8L\EK?
7IB=ZKDWU!\$-ER=5^~!<=MD\$S%BQ!ISD&T2\$=+O%|RO;J#IN|G44^VU;I8X;*HIB"B5L:CP6.Z)/2&_1 MV+,&L:
(ZD5%L+!W(: "YNK%%4U7!#_/NYJKHK"ZUY^OV;K;V9+U0&V8Z2YH6 MDSNXZ1\$JDP0H+K_+RK.T\$
@96P_6>#)FZ+:@NU_#ZV6!;W M|_1#OH9PGU4BY(L!9(^M(\$XN?WW!?'9"IU5!&6_2MK6=E9<4%?53IH90M3^Q
M/&^?D&/35P|ZWR#>47/BW%<(BMC=\$)8)V9P-6!|3)N1U70|S73>|M/LNP3%2_MNEYODEC8,V"GK(
1MDL#D,"N=1&IL%/_#6.^\$-.&,\$B6ST_QV_Y|ZFAUL M3?IO>2/XXG_^4S7<:
^&A!+!H89;MO;>RFTRC(X(0.M5N&N,0-IQ_'EYID M*3>>TJ|!%0)\$%BN^J?Y79YY0!%WP4XEYI969O9O+M6?\$_
Q6BF8K0!|O9<=&RW9)_MA MM96_)?EHL|3T_-3.#)4+T.URF@*ZPX,B=2!YR#!&I72^B/;"JCQTF>0=R)1%|
M2/H|T3:JASTLR+P%PGI^YU;8C=W0583&8Y.QO;M^M@:8<<^<40 QI:FHM2 M P%)E:FA'_R&
M|WWJZ|7\$%QC)Y"SE/ICC2>59*RL^10 E\$;-0?H;PDZ|*%%/ MTX37^(I1W*+(GM#A6?_202>PLOQE7A*JO
NE!%0|B^J#HMI:/J-3;3'+TP? MI9N::G^~*|@)NLAY:#2TQ\$M"(O(\$%IPX^L/V;UMAW_|_Q5BI\$!H=W M|9G8-;S3O--
XO|MCHG?A(IG6;WM*LRT&L(:?ST6%^1YP.%UI& G:CU_HU 2U#9SP4>J@%>508T;KTM|7NIG>@ M@%=-
VHYNM>_1_#>|&K>R88KG092<#A44O-E_2A_3A\$ M6DNL<_<.&^AO4.K06A+@1W0_>XIT:P7AB7W;\$/
'M'EITS^G^9Y7"7@>^ M%,\$\$P?L M7?*J+X|_*TAX>AHILT W|B%1X:%)T22ZX1=>9)BN1\N4W79T MW:;+TS6;
L,U.GQ000;_#F"X@<)&E+OX(" /HZJQ@MXXZZ;45QPK&5F'3XQ&2/ M"TT"^(YN|X1ZJYT#.YWE|?
YGH*^M857B>XIDP0\$%LDT M76'21V|ZZC|T_AO"0#02>#UX/HG\$;#_#W/_-3X|+70F?CU"|\$.*^%F B/J
MO9;)51B4L70;EWM CW:~CA38GISUQ;(+;N(0)*5;E3(I\$/'^NE"HC'VK M6&^YT.5ZNYMCCV-E.HI.9+
(!Q>A273PD?4/^&NQI^E.+UC:9NO" MB2>I%ZV,=\$!&L.2C6#JT'P+)=O#F)&^X6ZGZ?Y-RSW_P;M|+V|B/I#I3>
MOE3COD3|GL<'!.\$<3N*RD2_9Y!;Y3MGU|'TJH'YM;?SPIKN>#QJ_5I6.VH9 MIA0Q=789T.C|K8?-BW7Z;?)2I3?
7>|G3A903TRK=,='7*8BR1Z6L.R0LL0G< MQ2ON9;QC_OFI/GT7%^18A6.V#I=";IV#OC8/-I74)IB*/+MZ<+GF
MDB?_KKN4IA<3!YYRA3Y)\$TDIBT5Z+EQI_"1LAF>F)(ID:~+DJ\$CT29PZ=L.WW2E.CM^%X=?O5?* MT9V4JJR1"-
K:\$4_%5WKO@+;+AM".TJ B_-#GU4JV|K|W_8/B|; M;=E=7'IW.^=2=##*16|XIE"HXD@2UP7>RV9;+FOAY-
=9TI9HKH|H1P|>15 MJHNW)&ZCES28N!Z_3!+Y0!_YAQ61#*GS)"C+Q)NR%SEMD!25^1?J=47"0BX
MF^>2^K;Z_A9I;EDA>>3 Y>E9@2KYS_PZ_XZ_"%;H8GE1-W=S;2>U|>0XK;J M#8I*YI?Q?
_7L|EC+.)EKVSSQ.@LEA\$^V14_X|_15;_TASTQW^?SIFM|TW/@_M X_-U(U?9'ZA.'QVYPY5/V5!R#_2=
R>K5@A1J_8T%"9#2O/SR^VVIYL?9'Z MMOSH#J6"J>D>-/H6HH>_VJC@&I#AV-1.3B_(E4 M2*\$_FGEWHG|OD;
<9)P53;)|@UI_67UZ+N&.*S3"X%Q;).0P*2.IU FZ?@IY(M;)"\$P|X>|WC21R>*@!;SKD!B
M%=X1CGPT_NIMEI5IXFY+V|_201W;.9TUE(=V?+_0+R_U\$QISX^U6TFM2%QT);&+N|Y4#_BA"84QH M|;?KT4?
W2?9\$;C|9Q^_G_C"+A_VW=8^|17FO1/R'45V1KM'5N_AIH=9 H M0W=1&TH;(@CW8^4|V\$SL#>
|5B|0;7.O+Y%.Y%MS:O?SD^8TXT"%"JUF%-N|OK MHNLYB)G|P5E!&P07V-5EEEEAJXZ9#K;TOMG|A82SF9VT|_#?
|6L_3S2|JO M"VM^C1+!"|PK DJKM|WGZ|JKI X@V_7B7S_&TI&KDZN>Q1H"JK?CJX@>W;9
M55N8^6<|#RDE>@*U08\$224:QJLJV.ZK"N.Q9*_*23<#SAID^N|O21U");W(U M3LF.BPGB2T=
(X)>ED.V^ID.2V5U098JEJG M#XODG7O?T5SO^N!Q0@OS>%F|=XOL.MF38_YJAM.39P1Q77>0W\$@5"X
MF(;^!;F);K|&^&5E|^|L.T(KV,DLVR2UIB%>#971CY.%5NA"K.8VUA M>ZXQTH|Z7C_C\$|P_D+Z0OWT+!"
M3HM|B|6;JOR**OFLN<5XXK;RKLS'B|H|5+Q2OP(%A)?>K7(*KRR|"<#=#K8^7
MB++E;Y|N.Y"'^=TO@Y/"30KTS7I>Z/F/D|:4!T_9 T D |K^*#&|DV3B*9R.QVFD
/U^ZQ%=%5G8&C/S,FR|TS2|E:L_F_-F"33==PW_VO^C_MPZ(L?=(6/U_+9<:YZ@|f%>
(VWG14V_A_WX3<4.1O(G37"")P|6O\$AM71H@LSUHUIL6&P_Q-C1(76EIQ|Z:&R04SV
M"|I04R0X(&K;H=)W09Q1!K%Q_S@M9"O<NA>ZH/V#HS,*VYI9GIRU_X06
MQ\$2V@6PTH_*8GN2S2;7I5%EWGTI?;ENB D SQMQJ@M^W(I55%S6&+EZ@W1 MN(IV)Q_Y+IC-
Q/W.G|LY*:#A/KE;A_*DW|F^IU64QFA\$;VXL UU0&+4DH" M4RK_T65ENZF@:F:TI2H?0^15?IFA2?1Y M=>
1<^_UB(I:|T6?4SH"PX;2#CB;R_:Q-TVXD+(8QV@LLE1R\$|")|LGNG; MZY?M#R(2ZQ++VYQ7'_E
SLGQRU)CX>0\$X(R;J2P5TQOWLDZMFV_EFI=Y|H MEO_U0|LAAD1Z;0_%"(331E0B5+FY;==O\$CV)I?
A%:6BD\$;B_61FT|= M'W_1C;+>@)T:2**P!|C5L;QQWQ2OQ@?Q06H)#!L7/02@IQ.N""8|&84679
M&8>S+=5L1DDHWRT"/6\$)QV:I LCERR+FO7HMIY|OD30^A|_IO6#_K7^;RXJNMOWQ1_1 MAE==F@=@^=
"/V;!"YN;"*0W^2Q8+>=>NX>ON)NAJ<^E|Q;R:H7FU*HSO M;9I:Z5G|UJGYCTC4;CKNRL@);H#CB|;(5KCFLR D4+
K<+!GCA!"*K;D|:IT M+T>4N5Y:YL@G2.3H=@Q;@J\$-(X;S_Y7(GVO;#T+=|I'=3M|M88|&_J>4UL+IO7K^QP8^H
&O>AR;.(FL|N.(W/#Y;Q358TM9^C4CT\$_O M\$!_*@Y%G&U+DS=^~)D<."#_D5;_9IL@,E"A-WS01"#"
<35M2KV+_Y0IKKY M VKXHS^>XK+!+;TUI7C33;CD/O4VHE|ZSQOT_R;*'=Z\$B|+G'F!?"PG@5
M1?'3EF&RG8^@B^~3;G&)\OU@QN!@O%;_11IP=*4_6/'_&E(T%DVI!)+2JY MC1RW>1*.178NFD_157V1*
(E5ZO%Z52A*OO#AW;5;DO>@1?""%3<>6X>1N"A
M7F9IOTXP|1CQZ@@@58;>M!\$KP3C?"SA#X;6|F;I:7>ULP(f%5M<A_%8|JRI0#.T_7M=*; MA;_2OTCD%)_VAD?

*3="?)S6RXF_P2B&CT\$|C<>T7X7..G4LEPH!RH!%MC1K77_&^XCA*H&JUIWD36000-
P6Q*G|QKQHO!A!^VL>X4E0_M/<5-:RQI_TY=>GTIWC&B2.39SCKX-;5.00@/?*C+!O-8R"2Z7@Z%I30!-(H
MARIP*^,EKIZ0_1R0O6_U35DJ0\$Z=:2^:HW?_M:=6+!B<:,#ZU3=K%23C>.:C4Z,0!8" M:J^C@*X>|&PT|Z8=
!+XDB_W6N#*_#(O=LO(QG;8.*==^>,?DN=HG1^*MA3R!^XCJT?MMI%2)SU2U_M@9W%*0R|>-N*.TV_-!?
R\$!-6!/0_!Y)N1+!V7P<8AHTA0FR1>?%R^AG6!_M!_HZ0KJYT#FY:FG9Z_F94Q4">+TOGQ)(K_-^*W
_XR0:L=|XV2'6\$)&|- "MO6|@8_*@M&*;T3SW_YO@7P5J=3>O-!T?IMT(GP_!#H/@VKW(N73,1=2>;C7!
M?/37F0&""7#J|(-!%7O38?Y2LTL!|OU;F^#JL_S:O'-4CP)"D|Z@WJ.I#N)L_M^;UH2").BIV'-HVVU>>\$D+!/!Q|>K\$P2
W9QVS5QT3HAY*^<^DHOT/X5YN0_MJ%&X%*H^K\$3#W>0_#;9Sj32%K|@G\$G8J_B@.I6H7_!Z7|A"7VU^6+!)2-9%
MFW2WHUO>:9Q<6#"NL'<8!H7!DCQFAIW/*K.5TWAU7G-&8!#1>|S!|&0=|S_M07HA5"\$:2?
=8TN"S>?VP/YI<)#I>+LPG_-HVB|8@WW6_9VT3_TZ25CZ_G=0_M|V!S;=K|H9%L'!\$/\$%+!->CD%>!=A+@+H'#DF)&
(@SJ69MR\$%TS/ZR3NLA_M1WF?Z-@M|5|5FK7QQU@TZ.3'WK>%-6'6;5?R%_-KV,'_X6N-Q^X*=R7'YM'2892#BJ\$
M(S""3)B?_!7?PS2W!Y4YPGA-IN0V12W17(^W6\$^E?%PIWH/CLM:+D+G)S@O(B@K^TQCCEH2H"5!&*HN?
(*@_BF?54T'^=AFQNH-429VF(C@SE_!|<^>AC_P+!^TC!@W.O_M9R&1+7!-
XHP9S8E)'!+^Q,&*4%R=R)3CK',3W=Z=V\$"!|#M*4_M3T)C54D..U7\$;X^&Q>O+^|P|:Q)!UXO+@P1!LY!4>^
OSS>JP|+/(!'^F_MP*ME(5)_^;"S1"9LM"\$%VA#1.H(A+ZIS/I"N4L|E"0&|N)?@D|EH;OG/(M=I%_&)+_?,\$?
\$|Q|I3_S'Q'Q/_Q/QHM.3KX!L1CN"!*Y@28HFZ!..%M_?>?2D(Q-R='9Q1*INH/3?RN2U3_!7_MM_S_T^V@?
K='Y^#^F|S"OO&QK4?>|&'Y|3>|!\$|W_1/<_T?U=^A3W?|S_M|_?^H_MOM!F.S_EC6|A&(M;|!)=X?+XQ7VH7^
#LAFN>V-U)Z5XNWA3K..K3*!7AK_M)_P9?KM9L+6!WE08HP#F?
&76M0YV|6Q=7W=_93!5?AWL1W6=T.#H3X16^SP_MUG:0#0/5T<|OFF'\$5R<^Z|(^WKTXYTY"U/4+6
W5I68"!_Q|J2MX^_HB!_M4M2!8Q4G?-*N71_2*M0(9_199!_NXCYPE")P21V|0(AL+AO*.DM0?
>LOGH,2_QP50X|B)+TE!^*AU_M#NK=(3&55PC!FR_CT4UW2GKF1P;Z',2_M#-KZ1QQ/*|A^O_^/U?|S^C|?_!?
H_7O^?Y'6HJWD|J9*;@#XQ7'F_MC(0+26V:UYD;KZN1#/O\$@LOLMN>Q-E4-9P9C2O(BXY('50BGT|Y,*ROMRWL
M><(&G9F?C_9;R%J3G7^CU5QB"W3\$J|J|3\$_(H|MWX|5
M>R6A|Z8)PE*.FVW1^H|W.4H|*3Y'E9|PB|J38155UC5YOK(6<29N.E_M=-B,BKF^JU)C#
!%UM;^*J5YCE6LR2S7FM/D_>_!4*RLD\$_<1"GCM/NNTG42_MA2?;E\$!^|PHK++N<=
|SLKNAX"K6B1YE9T77HVAV6JZF3'K)7#7?K7KA|5K'(5,N/;#SX>F7%*"D)N#G16V0
M08Z_QQ6BC.8,N#N"6)AG\$Y/MX%|MG=U|>|H31036!2NM^M#A2P7&HH_K
MWMGS\$T09U^RLKD7&7DFK;>H2|YF32P2H|N015#K|3(+KSDFI00/NOKF^U7_DW@|J29
MPO0^*E>0C1\$>X01"N_?"ACUAZ6M,4T&G<:YOP^-%"|LDR4Z7Y+|YGU\$&|V_M|B\$E5"L_('(=VU?>B!2:@V)
|H|933_#9I6G|J00L>7LBT_M.&|"?_^S_50,?K'4)5:OM&2RR7-L??UO;Q;2^+F;?J9X3KJ5>4LCH&WU3Y;O(
M^9\$WW*G&2N|0P.1_INN<32_KQQ0|Q|9|W>M0P,%F3?S;@+==+5S_L6NQ&LX
M|H|H|WU^)|OX1&^NIGG#ZEFZ4L&_!^GHTZQ"RM2.6B|3;RBG^X^ZF^%_C|Y\$J" MVN?IXZEIL:
<\$%8XK@X|=_%_L04NB;KYDC#1_MFO:~>|=!#QJ4?|D>S%MIUP%~!T+|^'=RU9_9_2!FLY1U"#N32_M)?
IQZNNTC=9|40"Q1DDB|F;\$S(=)|@M!<;XW5DMN|WT=F%Z\$|/*|HR'K|3XU_MZO.P.Y>_SW0%CH37&
|W\$KD_A>+M^QD0|_O|C>|Y-DT)|@J_P!^M|7#NP+^M%KH-
^WH=3/"NK.S(W^&|B4,%MDD6PB>*^&K8BU\$M6)G.SQ\$V"LML..04_M@S\$?
IGMIY;K.5P+/0=SP^|Q=;,R.C*|L>^_D>C3C10_MAW!>=V93RS<9CS^"MEQ1@F-(UQS|
P9W(N=4&PL&10T|=8Z50XLE55TM#;BL_M^53BD\$T=;_?"6>B7>|SVOF^(-D|!|O6;|8_!%-Y-
;#=#0'GY>9QDW.P9HGK|O-T10E2G2H4(3.ZOH@O=M|9.@@^<8VO@;1_ENMEFZ^YIEFY>(17SRE)<>2C
62&&P2PQ|>:M<,UK/8=>M^|5;H+TZK1A)S#|9|AP28K|LE_YMJ3O@44#17B(Z-IT6#%#51XR:74_JPS^
M%AR!;)6+7@U6K|OS|Y;\$S)W%&_E=|OG_'B;SX=;|YW9Q&@6\$#@AT>4)6|R#!_M(@N0=S"7J_!%G-F+?
#BN\$J*K6ZA*L=_%M(7J?>|_?(V6/(T2)9|L_3DC3=&_MAR!+2C&U??G85|96N?..Y?
AAXW;OKI&2+RMGP5=S'M&M028_M/4
7MV5\$3#JLFI/+E1Y6G<;|N<7Y9.L^#SL#TYUKK;3'9&E^T64H|;Z'A;I\$N5)V2T70@|SW5LJ/D_.,&@&A=A)RU;&
|EE2!>|!%-#T#;3(C_M6;-|I&E-WN/0\$QUD8Z)&_>E<=DXYQ?U=")S!;\$ (4/_B;^0M"B-FB!|U_D
M|J>MKQ;4IDEPO#/_Q9C,B6LJ&FNZY)#68)APAI^G'2*8;NB+EMZ>!W24%+3U_M&"Y;\$@+I@:
B0KAPU;DXH|P(D8)UQ|JV%W%;ZEE|M|TVT2*=&C#1,+RCO|Y_RL:D?W
MODAR683|HD)Q"20*Q7&00PZ6(1.MRTSNG,##QH3+=+N_>D)O<;Q#NE7;?_MX.U&J
I7'(X|ETG5_P_.,%#)|@BOY#ITCT&|!%>32N=A&B4)X@!|/XPWXE*_M_>K+|W"R|"?5R1;
E&#DFL76\$@7_.*;>YH(WQZQ^+!|(JKRHPO#+)^^#JT=M%)P<|EF_ZQ|GS.NR52)G09@QC03H-ZXZJN0^&
|ESU2|^H7C^3PIA_EPI%(M@5UJWO3;"@VTF|3Z|Z|_|+QYRD|ZR=@V+;5\$7/2D@PT|IZRY8GLW.OA.,|
ML^NH+|>|OWS7J|_WGSZ=@Z2M*=5V#)7AN\$>S3|!C%(OC+DRADU\$F@9T;Q
M<+570N'1UG;|G,1XUFRO)%KY+7(K^?_3U%|5NZ)R_)C;*7;_JLGS&.M%N6-
=9G%6|9IH6)#Y9D/CZ.8;LVX=1.UNY4_+L_2_J0IE7V2'!7_#""L_M(=HN">6"/#|H"-SN;SR)NL='O:|?
HL.FB>C|8PHY_CU>VR>X|H/C..^MFR_M|(&\$'CLU.O)0YF2Z+MC%W.9LI5A\$?=R-
C"N>|4&WHY|)8XX"_DUC4CSKNPX_MPM@/HR)LB77Z;46HJ&M.
|42!RM."NY<+!0+H@U<+^S|V+TO>0RLRQ"EPO)LMX&5PWY9&^MR..5JA6PE(_+7C;%MG|HLX)#N^79H|K/@+
<\$'D0Y1ER8+FAVU+!|MG|C2|KG_M+9&H?W=W%(YAM;286IX5:(QLT^..025WX11%L!9):HML30X|M-MGF5=6K0R
M%LZO!27.MUN!|?KF+C\$BT2VFY%/R<6-C@33H-?A*0C|(>1+=N9/749"/.DO_M96TAQV/K<=>S>Y|I=-
&N*I>6.W|:92QE5<|NR+6|"A1=8H'!UZ>N\$^|9|C=2_M,26S7T^<-MSA3>_5M;Y=^)|ZIP7OBPKA<|>|"?PI=IO)-
FM>O0^EMEV|T!#F_MF0R;P9^FI%~?Y;D|>6X^1);Q/=2"@R/NRUEM",_.\$CF6HJGLX#+EST8YQ=AV
MG%R^IT#VN&^#&_QR:NKT@CXOSH|@IVAY_WX"2#7J?1L_!!<=..F_MA_5#W%1C5|F%;NTBV7+!^FWZ6Y.?
=X|DV35H*3J_W|1_ZX5\$DKXF=L<+1_M11.%XOAORN^JLN&4W.+10HZ2ZZZJ1%QMLOG|39EE;)%1TY
M\$TACK+;2T+X/5D3_Z:SK6=\$<>2Z">FPI|NPD;SHE%Q9\$|2AM_VZZ@|!>M|W9_N?7H|26;+URO6@'WZ_\$Z|:
1>;S|>^<^WK&9(K&M52JHDV>_|Q|5,2_Z\$M2ER_(OKU6<=>|U8_/@#|GS=KDO\$Q9.69|=2TYWI9WC"AH
M03TMGHJ?>MLS.P&Q|P>F90NOAJZ|WR-3C7L/3'AV;6FO@#EZ+2<4AO^*F7|
M42|WJ^P.B2&W.>RP3P'Q>GN0J7K:'WJF5_MR+CI|M3ST04Y=6X|VW0OF%..A."/JL7PP_L(ZIY^#+D|HJY
X\$;S.%TTW_M:'S8W9H|XVX:23ULWH@KC00AA*,?8HWB_80ZC#_5?PP3_LG(>P*T1U_MR-
C3/D_6F+R_W5<VJ2QFULF1_?D7KE4M>\$9^|RV991-WTYYO4>7N;)|@NAQ(C_M|HT7HNF?|MC?6_GP|4LGRV
=\$%AMJ&J0FZ)=.&_UW^_QOE\$U+ S2|!|^@8H9+MYBL4KLIN).Y5"SWD/^)J#;|NS%FE"H"M_?/H|R2"CK%P\$;.#
MO+93C|TT_MMLYB5|;0D+?+!&5^)|XN_*F6^%5+LPCC\$+|+7|5!ON;VU>|0(H-1|?|FS_MC_V?MX&_?/"Q?>8<-
8|^;T5@#5LGV7%_HJ_|UDF|I7A;4H6G/!|FDF=|_R^L4?GR4-!%Z_7G_-|Q\$8;OE@(|S6&QNT9KK1+5%_MZBN1:
|CS@LQHE0/Q?;PR%6\$E6H^UNC(O|DNG;0_#A5W<3;)|2WT991RYI4Y_M*0M?1EBBX#/=F2.5!_L?<
5S:B\$!+5I=^#O6_POI&2U8|;9|C0ER8?Y=|>>MZ|_X%|_H9*M|6T;LDC*+"Q%\$=8U<@4D"|OHV8K*)#A(?<
%_292EK0B|_MJC#E1G?2F\$/#_K_7_5KA;6F"ZA5X86?J#I=(^&YW!\$+|0U^AH7?%|Q7
MV=;_HZA#03HW&DE=|_K=3!#%@L^<.FCFV(KT"H_MMTS)+|@05#;L|?RWXOZL|0&_&3H^1J5U)|-
UW|LA3TA_RM#|4V=|Q|LK00|MP%;>89AZ.C=N03;6B>>N?^+9Y<;Y_1-9|AC<-V>YMK>M12^&2N&^SS5R>M
C"Z1\$|G';_95YRD|N\$|95O3S^TJF|_PT4M_YIMU?^U^W+^B.#W/A|2|Z9K_MP8;^PR1CX\$M>6KABN?_?

5'93QNBPPP&=1.77;-13/3G(G2V5,R0ETE+M-LK#;Q-(5(UWS!E'IV+D,>@:
(!H"RPA<(&ZM,N!1V2+.;89I8)MTOL2*6R-M#M5?E0X'47X?'F"G::A!;NA&Y/I9KH=,L6#/7.?'
M>1,1D7:TVY>^T.:@+I2S3M\$M;(@QF\$KODNE@I6S3!'43N+!OL)1!R>P/JOOI-M,9GW4CP,IN#
I-@FET7D44KD2=X1B0KA&W1.I:(05PHVZ0V0G?7^N93UFHY C MVN9)INCJPH=;*K6@V;OT;.\#SJ*B IO7-
&BI1=15\$<*B=&F2VX=W</6>J2F M+M+C&-1M1QW*!S6*>6ZF"J.I@Q?P=;.\$=H%HIK W:I7298OHN+!Q>18/9P
MVQ-1 5J!VZ*^!V MH59IJ+3CM7/06JM4K6QP18-<>'8YSU&^YAE_J?"=J1&IN/6Z^DX!\$>ZD@\$!MPEVI (RKYU.&T!
IY!X<.>1MWF:2DSMYAU \E62 "6UF8<1+D!75R0*KU2=
M'<\$ _1YU&R _;E=@5%R7X=H8O<>*80B)B|BVRZ5=9M\$7'X_1).+OUZ1*M1)F1G|ARDEV*FHF!
MMOJ.5F7"3:KU#IT>:Y<:7 J\$J=% (BB|X|<+ A:;\$HB M&I77GZ8&J9H-D8M/=C6:.) MZX@G\$ZKL
SA^JVGQ?7SEITEUR#>;F9G?FU 8!.)JF8<&MCBEO/9_12&V?+<# M!\$M/9%A9"3?_8%(6#DTWH/C?
\$E!13FWG)\$P@/GL#VT)M92OF)Z(FWBUL MUL(YR*7^T8IX(F7U-.^H4*!H1-QMD91HBBDD9^6S2;057,OACI&3G
M.DYE|I|>DS|B\$#-<M7+M)NY4#JDL9+!.)3!6HF Q-^*FBRB\$)=;N4#<I M=9GBA=+G&#;./6-F'&?MS8HT-
I0;K:N""W9ZS5!EB<%K_9@:(0I&2T'GYX| M^HJ3RH.Q^&S*W=VN?G) INO/ZDQ?
IV1XP_4W0Q9IMZ7N#>4XT"EMW)'\$'7/ M7%|X@=\$MJ'C1VDTN;?L.9'MNO2I_!GW|*
<0_QS>5Z9E>2D5SZAAYEM_M1%L3 M\$K_%>,4HR^,%9^%=#W"4 8_1AT5N9\$'K5,1TNS!&AL652=&8A^9'DL1S:
<M&*XFL_Y_&T!7IA/%B1W^'=2.A:.(PABZ%ALX,N/MT8.3_9A+K&;E|
<I@L0\$^!LUG@1QZTQOS\$*G'_J=F'XZ:%5_36N+4+M<1M-M> C:O?
\$=I&8RJ(@M37P+LFRK|O|O|P_CS|PSRL|CMH8HO/W:F>S#8\$IH>|XW M?(?/CAG?M\$)D8:_X;Z9-57\$;|NPW*:
IO:O6!H\$|RP|H'UR?V!#8TN9)O*-> M1L|YR4B6@!W;>);FQ&;+&ZR^6XE&_2!1610)CR*MH*89DX7F3O#E'% "147
M.993<|H2^RW#YEJ\$SWER63YIB*GE|@B"WRT;O:Y6"7H(CJSA=0&M2H+IK|
|ZYD|Y4_F7NK97S^|HPWD)>W:;+ZCC^TRAYAL>|*<\$?L|X|+>5(V M| _;^A1!!'.51^_
WMER#V!"NYXX#S;N|C6P6|<_?Y\$|CPB/N7&IU_Q^*G(D,MMQEB3\$?D2(8NVSZ_/03"EVOD;|VINHW-
+1/6M69U+ZF?F4?I 0'O@BDBR)> MG5M 2. DHF2-J%(QUKWG6\$O'X>5GR^ZKBA#R*3^>+;66:<)'|U?;V0X'A:
MO41V%/4!+I.S= ?P?|HDDM_5LIQLTFT.9&XH#9HUCTL(OI&I9^XGM49X>|SN MS^GIS'BSU MKG;=#!?
I@:U'1_AR,UKMT&|7I/EZ>3W%H/\$&V\$.M/UO:>CN&/+X<". C\$J M3.TCIE",1 =|4F= M;X_?%|!:"&W57MPIATL7%*
4SG@HBO7D&ZMR7\$GH#G|H?+6T3|BMTS\$%?& M|@:QX_,E9P=;|@XIF4:Q=6/3_!S1N^#_.L4YBF<7BJ9>JH/Q-
GS7>@2 MPFX2D2X0S-)L'O-"0"?RZ1(O:>>NA5^G+1+\$ _%|8|JX!(1*V;OESX0PORJ M=#CC=^!_VF\$QA/
!S5X>@K=5SW&AF97UDR&\$|3)8DHVLK*WU' MN?95C\$|G;B0;O3NH&HM|T>=(D!%D<">5&_5FR;|AB|D3
WITHUQX"HX;6& M%)NRU+P) (E:SAC7XCG6DX)- _|S6JE| M8X'IR"5NM(NJUTF9*B=_%?<
K=V+5GJ_!2!HOK;V>LOI&@Q*XX+7 \!01D2GE/\$H|1.U7@=*^ZW/!#8GO@/O|AYPW+;R M"/CM@E9
M#P:~+D.OE3;#PW>|I%_IO_*Y6%_+QYD#|D<:4\$4>Y+L|HE|SSEC*TC|RS MX7&X 3|J);|F?<
6A8ELC4OP|*W\$.^!E%9"YW*E*|J0*QSC4R8^LZ82.>+MX MTU"1&I+\$>WAOW-
B<.GG4ZFLU,P|TD8>V.7>Y8NXXCR.1)D6T2FEHQIC6!& M\$^S94-K6=>'^
\$O>S&F= TUV(F'QH0Z2#N!1|>@;PE'DVQ'DT>07|U>W1 M4EL+Y_2G3^JW_R399=|HOIT8*;KD3V-
J>L5KLDWP&^")1VRH6(-N">1-5 M4=4|S^X=O@ZX32R/O/KU/+06-Z#Z#ML2'DJOE?QU|J@PV1%5"+,5YM6|2?
K&9|D(XS6)|SOI M0+D1|;8J TYO+ 8OIHAEE9 L;U-FM|UB;TFR661H3P;3>CX3AI?<|P3,)+4
M+JF|<@YBLX";&V"-8@@NE8M;A^|. *K2&JK)1%*G|@G/I^V2YX^(7|@LNJ|2 ME-(H#C|8+@*,7Y8NM;0|CO5
<\$0|M45&'SNL3<8KM/Y1|3;FAV3;Z7F^H7 MBA\$^TSO:LC4|5^I=XDK6FJR^&B-E^?N-M1;#T6Y>W|
<*S1QUJ7MS<2FA9L2 MX3"IL);#G=CZTW'Y'(M>GHI2Y2K<|AO|)\$/.O6.256|NO9-UHJ5DJ*7P5TLE?P-QMODLW
MOMK<#R9_!A^/B9<&5=GKFQWQ7IK3,7W:D6' XH(8*9V?Z^K%)@J M&'G_#MB>@PRF?3|S=UNI-
C+O|F6SL"E+1DKC|HKE0K(#U4_EC2;&X>XF8R M"G_9F_ =5@L;?(\$#;|H9OL<7DN|P|\$.0V* =4F^_
W8&78'7G;U&7+Q.>*M6(-_LH57W|AY%&*^<+JM2\$ M.UN4@ZH%ZLLC.)QR/7(P%\$P\$_49T3:C=UMSO6_
<|Z+&G-*K98-4@&I M.N.&CY2..DH|';@7|&I @ZG'RO!;*G08#|5ETZ>HCM&8FJVY-7;|||% &K M=*29R
ZEJ'W#8QIOOY>E6F^4:%W'K)VE*9L'O"?|S^.;1Y:%TO%EM.%N<_
M4JZR9;W&M&??%"389Q79SNX0@'T"R|=WKY)_E7V/!1-O)6.\$8Y"7^O"JE
M|&%C4O3HGC'_U.'G)'|+|UJ1/G5E_+J<_U>\$S<>5>|'+8!)A1%W1R0DG@?! M|J)VFI7;#M1?
&B&@\$M>21D<23@64.F M8G#"597%O:X+G3<=;"T*B25+YHZVY<7>13\$HPE\$;J5?27;#IER-H)2Z11
M)HKW2U(=QVXI* TIEN;DZ)5>M01H82P@|H'/72PSV>KH?SE^QD|KY="KJS MR&2@?<
_+78<|LB _F;N|BI5O|=4(J|CU56|DO\$A+B(|;NN0!)?C+5:36FV M|L_=16^C"
|H#06|.9#V\$1UB;XWG&|OM'#692R+S90Z) DW.%AWF|_RZOXL MK=>2#T/I
%:=UGC%T">_JISY_HJZF^=@UX|T5Q;_W1VZ7T%YS89/P;G/V^
M8"U8UYC.Y.\$WW|X'|141VM;8U_ED@ZK&>LTV7@H* (P?C=*BRA#H@O'9!M;./E4GDLMPU,,FN-;M2>YUJ)
MJJQG/WIN+UUI@-5I%9N'QZF_!O3I&03P>;W*:8G)_LMONCJ#&R;3.IFEL(-M>)Z#AEK'GW|+B?FF/>/*55_YE!+!>
5+7S)9NRX M3(3H2>9ZIH/W+G'OZ9MO#2&D16XS%^=&4G?|=BD;G|H7J.V_3(I\$M
M5E0>+0F.UNW|P@GEH|X6 R=3XX/NF| _"405=84V|4KOFEB?0B+?2N-D* M2\$ "DB0@JTHM*#2W2-P1"D=X\$!
0\$1)I(DRXME(2B-D2A)Z34 @2(#A/S// M7)PY,V?F(E>YV-E|K_6NW_L|J.1|)'1*&DD1DY=^HODW-.K7WU/_8)AV
M8* R=72#OF3Y<_!H>|<|OW*^T^3U%2_K>OQ9<+Y165.\$_%<BR=40PW-Q?Y MQWEUOR,26ZF+9
<2.2KZM@+3\$U>=>)3K3|HCOL7*A_1TSA.5)Q8H^ M8D<2+NG9J\$N<=#616L*HP.OL=YU3X/H(M2:6;R:A/PS!
QW91A'0!E|G MB24?FS+|6*EI<)R3|_K/%?P?S,>IK3,C+I^;=@:IDP(" ?IEA\$3NH+@4=(E M(71+CR9)(!_A5NVX
^%,Y=*+72V6;G(PF|.U|!\$|L#OL#UW40J.GRR6_XV^2ZY(& MXYMKRW+CMW>L'"<.VIXLR=0>|)NK-'7G*88E-'D:
(-=D.&"ZL J&Z_!LBRI J.)LY+A>0 M;W.9H6HXH|4F9|3Z>;7E)5G_9EHZU/SZF40|G+(BC_Y""Z;_N3O;%#2N-
_!X>D_6+!-\$ZID@|UL#XK8@8\$J5-IH MVNB"#H*9!_!K-00P:2OUE-U_0>YNFCM\$X_@5FK6#;@8UG8=C;- "&(UHLV
MJN=^V5)%_4S3U8T^CK_!|@OE5>3L_POAW6%PK45.9C M-5H|W#* MOIH/7US/M_%@RRG%WOPRE,C'A#Z&T*
R/Z-;7Jc15..6A@)KR|;CY0!3 M!%YJJW^NHB.UWC?%\$L6JT|MQN'H1)5LM?(GS!)+)(1M^_1MH7"DON?
_LZ6H%@DL@|I;N>G7^\$EP+VY-17V MAR&GJB/N <<L\$5@8(#?2NQN|9AQK1|NWR+EV&<
M_-C|9|H|BOKYN>=B2E&M@ZVSWF(K|@XG3MQ^O_&9Z(E&O4U%74LT>|M MPIYS)D:4L2N1^DW1JGJ|U-S;
|H^?I#^?R(U\$D2>^_YLLW5-C1T'(H<.=R: M"TG9*2ACB01;M2|*G=FVHCO M3VB!-#;N\$+88|0.U4| ^?<
_9YS&WE-I%>0|Q|4E+I3=(OJW,MZR@ZW@.8YJ6 M(MTN7G0)8HA08\ N""D9>H;_J|*5.UK7V#VN8(M?>
I39EZ3YX_%<9K)9CMW=U&;@<6EOC^Z;=XG(=|A;H4_|>SPB<\$5-X>- MRI@N7|H7, #9H+#\$A|3JK3I>2W
P@*P7|3C^G"1^ZY^;R).IHD87D@R1K3. M^X*E_1BY|BNE|99|H357HC@XJ-
Y1+^+E.NW=2C8X'K"XB9I;W05TI-N8 MLUF!\$S/I<0) L;3Y=*^JWBBR7MJZ_ (^C7L|B7_K9-\$S'+E?
B#;J=j*#G/7EX_IY7UN4F\$V4_ ME92&X_0P7*93O=I|J:G^RLI2E?HGF6|B;&*VC_GHIZBA>MG*R?=
NOHE>EL9;G!_..MG)W&1%P&L_!GU'9KI2.IXO;F0^D|_R^6 M_ VQ.E\$ZS&*54*H3OK|HDM_4Z4O|FC|G/AE;VU-
RG38^B?7H^? M_KCY0K&\$/#4T4V_@EL(-S.M.C*F&;DGC;N|E_60"KT%UDO"X&!U7U_K,V M)|%JR='H9G"
|EF2" MJ#6E|7 TDSU#|3X%-WX:OMCH7(Y.P)|KHM"9-96| MDHL ""O!\$OP0WFL'!Q,8)J3KKXH=*
>ZW4RC>WE";4'MPI@*Z467Q@00C*Q_M=*0C+16"GJ|85*8ME1">E&5.1*>>|+2KL(D^1)=XH/3&+6|?
^XX@&GG:B" MNKYRLDTXTU0Y9;I+P.G^U#+3=J|S7H4F7K|M|YT7\$X?D_24IL^%JE13 M"VW>_I
(&GJR^P3!_P6%L0_GU>|H0;_*#!0RLRJ'(9F;+8Z&=(449PHN=L)H>4^@S#8XM

M,=,)UFYBW)@?^CT+9./&082&V)038_DU?@6\$/41%523&/3&&1*%_FP:#Q1^M?G(@^KB2FB8U'N@55BMNPB?K4<,-
@TZ0!&JV5!ZD1..TL6?#HN.JYZ^@H6A..MRFR(*#9%)E?2<39"/48A1^.'ZY##+7-IV"UJ"6PHMVLV07-
V=^BPPW^HG=MEGO:F#KYCU&3Y\$(V)*E.NZ00\HXK:~KFCUDW'S\!^I1^E33Q7?IK':F/IMW" MO)_,IF-
2HN&L3@2&GD8""1T5 LO/U""2_V44#7_."OJAU>,,1M,+^,P'6
M":LX7+GVST/F^/WO1@_7/G?IX\$P67BY4HHSCIK_'=B_/1P-NFV4NQXV+J13_MUR
HYD\AT^+35@YS^NVI%&)\)GMG-A/4\7QA1<\$H-14)TP'RI*,BN8I>M_-M*@LH?U4X^9X11(CILH'WH2&H2\#-
Q:~8?"Z"3A%IV^MOC_>I%)13:1Z^MS9O_M>'A?8,F%,_83NZE\$;>B16,PEP)E0"587GE!&3M(D_M-U?:(TP;FP_,P)%
I).T1="I(=<7_FMHU0WGA+WFB_R,Y_6H!2G="IK)^IKD_M.FW6#%\$OYVGXM2)28?4-77L'R.N+3&H!
I/4H1M1\$&/ZH% C5% '8'6F_\$#': MB:~WS5/!P@T1CLT?108KR+E>12A>S>_88GO!P+*G
MN5YOAY!9ZFN^W9W:SF^Z=I)/G_UT0L^IC% "W+&X(DL?P2D!2R?1R\N%1X3?
MFLY38&OFTHV31A,%YST.VQ2)0DQUCRP/0?L6C!9@!OB%FV?8)_0X2@>/EM!O0J/G_ZT8VFBC%HI!&=%6% ^
MDB(@R/ET/@-FL) V31!,3+!P2R!H@>!"SJM!FHW'K=Z!%5>Z=D,9V1ZK^X(UG"2)W9Z+R
M6ZJE_O6JVO(%QUE/B!_G^ RF_!)U0VV4^_!Z_M%X5.1J.RBPTY~(Z,JR15;H7^?BA!A5AI*= MK=,(VX^Y;M754
!4YPP*6-3Z+;,Y-%j7)!WV-!YGD)"EN\$6L=282IN!X' M"!I^0;V.%> F<*FM32_4@=E6<_54*=?
LK=S>VR794YU>SZ!E'PL0'0E!":A_MZFZR/EST7VO3%8?*"04H4G!;9UBK49J&K)98F<)/YSP8O=^WW
M<:>I2M18WUTEA?I(>>MY8;LDB52VXD'P)EC8%N#@ROK'8?JMS/*S:MQL1P_M-7%IJ\$.M@
!PS>+HFV/V9W/IQDY)V_C(ZYIK_'F!@'^H=4!0@/00JO&P&" MG_PIP6Y_A'=\$KC6P;Z_+YPAE5GDVGS.-'ZM/I
I+!T:H:'8_<"%#JBO" M@_2C9*F&,P^@%CYI847%_!LC062M*#+4%2W<'YVS&_S-7GWX4/D#IY*HFOQ=
M2!8"/OQF!9C7RWMWLD;&8U^GUM\$>PEHD:(1/*YVF6GVW+3LKKDZ*!&@_M8B,(TKWMEIL@J':3+!RE'L+>+C+
U!)O/O/RA!ZX)6F-!F_Q%#N>22(9_M8?9K3T%_XJY4%GP8%+>8!&K02;G0)CNY_N K67_!V;JH_"A_@K%@HA%
MKND=DM:WN>V@C_6B@=L/FK0U3#5:8X/3?<6!S3O_RSHY!OA5!_"M!QD\DOQA_!3-
'9I^Y1J=FK\$VMLOX2I%6%3N@,1HD2T1\$7N_MU!^_Q?#)C9B*KF3M_?U!C0AJ>TM&
f6H,^&L(B(+V)COC.G>V:C9A_M>Y-?&(I"_1SMN.2?R?Q(8D,ZME>*_-&PDNN'RR1!_J7X'>^S/*I;W:ZW ^
M4IH.%29JXE)NN!V"+6FY5DGL~;XL)H7U29;ZQ:4#9;B!%YA(P2W+C;H!3&I+!"\$JKW=_I;JMH0Y>0?
K"2H!\$+X,ZH_M2!EHJO-HNG!*02*JZR(-<1!W@!17D:P7!&BK#7MNZMS9EK7T19XI+=;B8@_M9;E@_A5G_>PE-
MC@_IZTB1.M:7A(7^S6AT+D+O?SB=P)SL=&#)###Y-0QO0_!69RB(8W.!+9QK&!WS,IF_M>";U%;M8PNM:
!Y#P8WN!R7*N7Y+!5.TJ5+=^M?Q=A_X7PZ0_9%H!J,%KA_!1\$)=LB=GV.#Y>I<@_NT)PG?87F-IGR"S3HT_M)
IC<,9/#/XT_R90_J8%=5>A9QI&SL!H7?Q995!0%A3C;%>J(\$,%(OGF0>'QROG9A-RB18_MNRFWOG.C;4X?I-
@UM+C#I4T;.X9W(.790;(!\$S_A0F2WRDE2ED9*=VM3*L'_MR>;Q".Y%9VM3P6,+H23ZC;1%
I=95FITE!HLVO*:=3^4^D^O2'UZ^R2.OQ.C9_MK5WILP4
M0XUL+@'OBGL;E>I70G+!/=X!1X5"+P\$R0TEVGCNTN'LCE%[CC5_)>@N)'KB4
M:UMDYL65MT+Y9N*CB_M!%YZ8DV6G_&MODN6@5_1443@_BW%R7!2HWQW^7K@P?L.TT\4;B!>L_!D;C+H\$%
(=+_<>6Z;"0!*T!A(D(EIGL>I_MG30P*HN*^S135Y9!>H"&F\$FJPO2?Q)!C_MS3!L;JFNJ^(-4)=ZN_:YI"
!ZB9+OH\$5,=<8K!O;Z5X!)I6U:WIOFJ\$G1_M!M4P@A_*I#
!A^2HR5&B3KAPL!UHH!FNJ!UTUJ@Y.V)!LLW>GNZ08.C%FB_M!H/HVFEA9@2R!M;L+*MI#)+F.X:#-
^ER3WN(L_KO4,5!O^DYS:N+P2D,N_M4_^(^M_5P8#S\$O!JBI'!/1!H8,J^DW'53\$!GOJ!W.A%MS8,A^MHS.V/Q18
MX3!7P9;_GM?;_&!8JB!;MX7@%=XXTE!DBD_M!&T\$+8X_G")DJ2(7^_) +9@=?
8%'9\$!*ME6N1.%!2D"CV;+!L_O!2.BL_*_M3XECGL;KH@V_M7V!2>#+4/NQ?/3V!*<8_M1ZPJ#23F!O<)/SUF!+BN7?<
C2E2WF<-!4R:5YW&_~W.GO_%;#YGXW39I#">_M-Q>79/1X)O^YDYT<-?890%6_Q&UIC^E!2J!@F)^F#&
<=4T=3KZ?I.C.*GR#_M^+TVOIA&O14+H9;7H@_S"-9/\$%(CO>_!Q@>S7KM!2^CAT3DK4KXO\$5)F:(
MH_8@&\$3+482W.4!5GVWQ_TV25Y*K_&_@Y."+YCA+IGY04ZNZJ%*XAS18DPUA)!N_M=":D8T5+
<#+4^&WXE!@2>P6XCAA!;~3W_/DEVO;G!Y:~406RJLJBC,4?>_M'RQ"~T-
6695I2G6^&#5SZEZ!^#00WJC*2BD;QENXYGI@G!-IXYXR:#C%YC8*H_MXCIY@I-
B\$*J@OHKS"3.17+!)P^3/LQ7Y8D^:=25;ZU(5K;HT!_3O3PQ<IY*_MFU>*A_!OI'3>)!A!6\$*+8S/ZE4BT@I_8NR-OH?
L>*_!Q:SNROLB3<6==!M@/L!G??-7-V:8:%>>F!_O^!/7>R9ATOZ&E\$(1\$!#/XCR/E6/^@?IT7-
\$;YW(\$H/7WT833%,CNUY_M+_94^N^!HK/TU\$EWS6_:=/B!4\$L!8J#K_3L:94_"US75\$YN(86JCZSO*UP_M5:
!M0+&P7%3M@H4N*&8UI?M;IZ-L8H_BTM24;U<1>#BXWF/KC=H=L%I?TH
M.&TGW8CB!8K&UB+XTJ!>UVGTNQMURSA9Y-D?;KNZ3<_MCKIZ:37ETD5H?+I-
SMS0E+O=U6F/3H8W!U9=T!KLJMY/GI^#R:R:8CQ!H3_MXHKQ*:A1_/3B&-
A60^N"=07Q+SDVY_)YX_E4K5/FZ+I=GB1D!%_W_DWOS>I
M+7\$70XYECVK7+H+;J_X#)>RMC=>0I7^>ER!BOL/O#3N)"7IX8SDP2HL9V!>_MS:LKFCZ94A~KHGBJS<*IUW%
!X5#BHE99RH/X+8\$5NW*6XA?X!G#YA4"+:8N_M*&CV%;T@AQ/9!18&AKG-?
YT!FX2EAQ.*AM*2"974_QFLSK+!_0G\$TRIZ.%!M0W71G-?IK!_'DXX3"XCSB8BDYM@M;/IU0^T!XH,8V>*KF;H
MOD+!R.F!+_5UXUQ_@Y3:3#AJZ!+@\$LM!_JBT;XZ="!T:PQ=B'4!&)Q_!O\$ M2-
!L)&J6@7_.YOI*,"WJTU4&Y>V4NE1+!6ZYB!<)F2<@(<)5:Q45Y%;_QG!_M89W^2EHP_MP*2C5!G8W_I
I=N#N!VU78W2>:(B2OO!@5")=.UB_~!VA4ZM_*7YG(!0RXJAB!~36Y(P?' MI*NO;HI?N27%U5B8Y
41LW"4XU*>D!N;K=2#W%BJ0%F!_~FG3!Y,35YS_M?2\$XF+WN_G&2+!T2%&&\$5HN*~D+9".S1"C8JNM_KH4T?
315:6"!IS:F+JFYSX!U!KJOS>0UI9Z!Y05F/!Q6YH\$5!&MIA27HM6Y_MHE.D+QW9IS=18R_K!2?+PT)G<&1
M_*SUTIV/!HSYX;GVIS^2K1QRSCS!PGF^B"R0I@!V7P+H8(H_N!_O'_!JO(M+?0!L+W!S!XX!7\$2MF)-
@D;&GKJM@03*X3WR&L@#J!%Q/G>8YT!07U_MSMFK?>5MGD_E\$W%BG_N6D!<.!A+P-3T%+A^F\$!F;PY/5NR.%
(+I(=)PBM!@_M09H!\$&"6QDYAD!Z&UE,++JOB"2R8Y9B8'SX2,Q2LL*PG'B!\$^>+!1HK;-0
M3N0LXONQSE0U4\$!A^GPL2KL)4-%_8&^0@C;0MK0_6;&=7HW'!B-!>TX_M9O^4?D!S-C>52)L&7=YJD!~9T
E5!^HAY8,MPQ5E;X;/&PY%V=IKJXC=M#0E6*2S!%16::&5>S#!25((<\$Q6,6SCC;./<70++R!D_'L:#SBMT,=I*
MJJBO*N!AM:Y+!\$(J>_?#_!@KDTF)Y;1,KRA<"13?N!N",5'%^&^VYEP*
ML"Z2W9A'E!;6J;B5OH7L!A00(RFE32)HIG7!H8_UX/Y(*G5DNA08ZD>?G#7_M&6.=!VRLA9_S;X^V.K96G00*"GN
KPRRSCIPG3F8-PJ!2QW(I1N>)/&BH^V&=M5!J8R#(C!_REM_J*&2DKX;H_7,2!>D>W-9JA6^~
UB8D^E<,+!)I4Y7!G=S/!\$T-(!MG2E)!^8Y&UN/R1QYVJ*5U\$>)2WZ_K!&Y63I1)!HG/S_IY&3OQ.TEJ!H8
M!JY59NVO'C4<>ON>&Z_A=11=/"LPW..007OW/8_U1B5#M!XF3K<+3S?V7H_M2(S#UZ_N_8R^?
#0&9;WEH_8!E<2T7PN%R?*.WK^UA2>D;!&P);>2U7ID#YFL_MV6,O_9B7EX!>Y)5XYAW#B59!D.E+0.W%;,N:-T>2.
<2L*V<<*KFY%2!Q^\$ MR>,(A"17!+4UB^8K&J,++ZL5"!C6/+XQJ_0@W%\$/7C:8F/CNWF+PMDEXN8
MY?9>O6*!L2&Q:A<#8KA@AVY?_SZO;AB.(^OI7>15?2.OIZ_@!7XB'S!MQ'=
M7!E\$M?F;#;\$ADVRIA;QU%7Z3!@07*!~1_3R46TUXR?T27""TDZ30V3DL/O_M9ORY0M-
%.SQ4*ZRT)!TL\$H3Y@R%76D;_>AN@>V_U5NRW;RA=JQ!LED(2J_MB+8N'KB+03QIHGN#07_4V,"010HUQFG-
6"?I#IKJLR?I^>_Z_D^7D_N<M"OZWV6*U!^5@8V-!XBI(?+I^+UE0Q?J!4T"P-HET%#_HRL;_&![Q;=P?;
MLIZ!4_5E!M=>_!3.N4!PYI;!09R)!IG>R?N?T!N9(70)(Z,890W!U,4ZQ9_M17!HBH>E@Y5R/C!(-/7GLJ=OH@P_S5Z
07!ME)&SG50P^+RS!;#)!M!=WN_M7:3%%Z!8JA;I"ZVWU8\$YZZBW;/9+P;~\$G&F'J=G5Z=)
MM#!NG6Y0W7W!VE9T(U63E)3+8YML#C:%75;8G0=IY&5F!_H!GSC9BP;TO:9
M^37V/4*)T(&KLNJQ!HSHC_8M^(!\$V&O_>!%C8CP;_V*S7\$!RL);#3DF@RVK_M35UR#<_Z:C.5!7?2

6ICMY%REK8)\$MB#U0D):R/N?Q M0F^*Y.\$NU5#11HX+I7ZND<=YYEH9R\NJGH)F"?#PEQU@9-G7=*RC?0?;D\$
MWGWD#(O-AC<4L6(Q?^K50#LPEJZ3)U"MN(9I<2HQU-2>S&I/M/#E(E+2A7X
MLW10;+ZBC:I%2WI7=AC10ICI/H&)Z2EX METI%D*PJL:9C:/8-1LOMH-2?GX1?3M XG9_Z+X7_BMS8#.
M^O6(4%J17P7Q:&9624+1+_P.L_:ADG1+-=04ZYH E<*P5T')-/1S1V MBY3%\$%%P=
GX\ML#H1YS4/GAXF=2D-&RGN@35IP"4 GP6O M\$5H-B=E9U#BXF%N%=:J=Z:6P->;3I>0".3G*U+
(S\ANF%JJ\$FJ"383#0GF M1(NFV)/=G/TI7LNO2NI G*X@-1A%T C1H?5DJ287?ZX01\$D F/);2W"ECKIM?
R:I@%I@J:(2Z)E2#(=_CNG%-TB,V>_N,O.Y8B6"IGI*JKWQ M+;/T+HZU\OZGY_FAO.C%T%&V GRB^5#.PJ?
RZH8Q2@^HZ\$>G9U^YX27A=R3# M#10/DLTF_U@3-604K67L-Q)1ESJSK*T38 LZZGS\PC*UUQ=J5<;2I#7=!CE
MNT5?@)#IV6QL#@FP-6HR3B3^%0%0<3%2P/-72MYD?%-1EJT\$0I_K@U&E5AB6-M9=JMG%V9PQ)+F?K7LEZ-
M3P\RPY:.->^I:LJ.D_#V!_AJK*!Q#))1(=65+2 M5\I?+!\$[SBH]>/SW5A9E=>
5WAEW192L04:)DQT7#?;W@XZOA%O:QD6^=! M;V?IGN>*0\$18 &M+_#_=NG(:?JX%8&>2Y ?;66H*S="/\$\$6,0-
/BOZ.H ME5U=4QSQ.H>5G?;M.780H8\J8TE,LT\I+X1134JTYSGN.7X"\$A1:_.YA4 M?#.8F&>
I8?168Y3#HOA&RTZ!%):T2C"SQL(9M1W*Q"W10"FMJ M%)WI(.F7&'GOE<^AS:O3*(W\HGR-&U?<5M/"SR
M3WKW\$Q&B4PH)-D9F\$[ZJ M.CNG-8(6VA*XL* B\$'ZR^;GR2\$TG7CIV1/Z_*)1KZ<*2Y%!!5;Z"MPN/SJ<9@U-
@::JAN;VO!.X6E MJ\H45(I?P='8I&RD\H9BC=6_3X-#/N0W_8>.Z4MM1E;ZIA-5/2;#;VU\$7KG M;JI+&%ZC/_
^P&I_&E4D^&49I2V.1-03)O&4ISB_ ^G:I+OI^@8+Y0)8#E* M8KV&157%WA@.JRP-=*\$YCID?_XXA&CI>#?=-
MM\$3S'%6U;I(+I0SEZ-SX M+#!_5F)\$S>;C" E).R84\$;RR14R5#(\$Z6>.RW#\$1J<+O?LHFSAZ5MK")T.E
MS4KZ2"%XY.%ZI<TO<*&I'(GBU:7V+JD5.XD=5:G=E0?&BX3Q*4I9TS1%
M:Q.O9NH80.H14TW>G3VQB^E;L<;I9PK1D^>3W.S#6;4CIRFROGPCIR/KBU M(MZYAR6^X\I?;3E
(@&F/W8\KH7:;D\$;+O&D2S\MKC8X; N\$>2PBY6X ML5+?%AH@5-6^13#1)?>U=FN6;7H207%*W.B=?
MIB0G;NN-2^W"7&!N\IR\$ MZY_9^VB2?U^NCN1\38?+J@IOAI\I7TW""; GSXLZ56&+9Q8 ^2T\14YQHW>
M\$)XK'W+\$/+CTV(KI5F?26N*5)CT;I5HDDCW^I.V0%"\$SA4K>5R+^0@30\2_&+.#5968)7MK1FCO+IQ6S;<8V;^P>
(D=?Q;IUL M>JL4%RKRVXIO-LOR+P.&@?I*K@E)>?%@PU)#/QP9A+>\$EA*W;PP^0URI?
M5EHHDR9QI%4\$>&'@I-IJ&ILG;F4T(YT MVG^SPYTSYP" OG2Y^LSGXT2Z'6UU46CUW\KH8#_H@HA(%)-
C\$^15"18:8R M&KW60N\6BKHS_"X=%SUS50UGSPKW8"-/QTSEAH9N7.VAYN.H9!?
\$=6*5TS7(T"BV=BD,55>Z\$CKZG-/P#DO1?JK*O(162L)QG2H M8I%K3I('I.#%K;IPFGZPD>B\6I+ID04RS_P.&*
<.H9V"1;7'EB#0<=J. MAZIV_CEL4% M>A^K^G_4I7F.L6G&1.8+&6;Q10?4/('E.X'_F7Q^XJ^M\WPMQAQ; 7PWH.
M+L+6;1L.M 9PI+Q6G/VIT.RPX-5*W.GC6OYGF\JNY.ZMVID)SYRZZ5>.5=*;I86F"TL.%;Z>%L0AAN6L'
M7">/L6I^F^U>5Y6.CJ7(=N>2#;9-4W1^2BF08QN(1/WMO6SF.%IN(-\$%.IXGW\ (?_SXP73_3N%C9J9B M8 M-
KX+I>Z6\$(6YI."D.OL^E;VJAMV@2B6D)WFR=)%E@#*QMUC\?(QTI_DU- M!^VIVG3U1D+76BTLLM?>#)UK7-
;@QD24OK>\$Z_RQ:G.PZ3;/P#4P;A2A\ M=>7-J_N?^U1GIM" AHRJ=T215?^(CEC=-X>R1BCCZ+8J_W2 MN)LO:
<1*+1PIZRD(O:IS79Q*>ECAPEA/_ZH.*NMC8(4)\$FY\NZ.A.VYV M5O!O!@<9'!=AJ=(W8A"\$8BK0?9UJ+HN+P
M"S+@A\$W>)5ITLN\$/+O.><"I/85/^O9577=RM31K=N/C.99EP=G6&F26.N)V MEG7^&)-E6D^UDTQKKH8
>;NOE\UHKD;R+!+EQ#084\TR2A\$1?W.\$7S('J M.YM*ZKD=-/8T4 M%*8C @B^H&ZH:%%@;=9=XIJ>4GIH_2I5-
(M6<#B.OIP"U-IU).I"10: M'@I#8H/M&(A\<>L.ULM5JYLK\$W#;SBEJX;T<0QH1H6UH615W.;DCI(EF M6#I+\$.
TV6ZC<%=9^3V/O->8F28DTM.00E^3>PI+1. M#\0IOY/(<#B^=UE4W4JCV\$W(D>ISDOY*S^|OCG74?6P#55% G8!
X('P6EU MI/Y9YD&NRA;%8)H(<9P40CO.58WV4 '>L9.+5DH\(\$F<.C56L&J6X_B5H. M_+;AC
MJFMAI\$6VM^5"G5&AO)W1\K5M<:8GSGN%D\K5D@=_0A_SK-? MIH;K@+5)M=I OG@7%)T;B)\$*L3%KEP 7X9-
=I(M8)=;E.N&V' MJPKA3E\ C.<@4W/5FO@YICG(88M7FL@9#>.E\X=CUIU@Z995JW>D\3H@:
M%SY=11*\$DK6Y FN9S\G6O_2->>T+;\$.O91/8M1KQU64E5T1/_%GBRE!N M86V.ZG5V67/AA\I)K>
IKQ;G2I>7E&V"LBX_B&-W8P8ATNWX?BTSKB_8^! MCI::P5;LTQ"K;
Y6E\PWJ\."RNP#O)FV?;RIH\ C.@8Q73&I")OI\FIK1 M.M'DE'G.SI8X#82K8\$TSK477Y&35GY_7+E+Z;C?
#^S4>9E;9I19I03AC29 M@)12& W+MH50N\IBJ>21LT9_JF&U^D^/LOIUT.9V\@&_.6%40F47.SD!
M)"%;B9;.9OSY2 V&6+DG<@EXYX.*P>+K-)IS+V\$V5/15FN3V3%.7PZ?1I26;0>YIS_)&IK*V-
<%%0E*9U_K)+V^3Z*0;CO<& MD-R#<C=A6NG(H\$1;2E_+P%\$O3+97-5A9>07&J'TB<@V#E3GRSE"O^AIJ8 M1-
14I0.PY=PP3W<IGC*Q_"L1" 8P8YS>"U%0\HAHK_8E>MRI^2D^(EDA M H'5-?
8QN.8;L1DE_R6U!:"DUC(\$\$@WCPR5XL"151HJN4F'9DDO\$118;Z\IPOIY@ MI%&2S8E^D\I34A47P93;IG#^XU-
\$1^!S9N7GEHW38RE";&8@H6I+>Z^97;0* M43O_8)VNT\$-G2B\ E^WN;N)NK=<@ M(E)'R&I;3)
9#*HD0C3LG^&+RGIZ M@-^#)M-5;+ZB*F?_BTLG4+F;C:0C\$_.WG.)H.R\IEV*FHXT.J/JQ<<_KF
M(CP.0K\$1%&R*T\I#'+NL>UHU\X0\3+H';J=N#(3ZJGIE8_H_&U.HS M5^JM@6KCKS=I#LF:/9_R15X"P\ F:(P1?
BFV\$030+H3* M6TI.+*GN;WQ>\$B#E+>B='.'+P+?"FT95# W V.1\$J3TK=E4Q
MZ72<4*AAJ(FINV*.GJ4)B04&%7W\BLI.7/06DN%71CI7%4)8U420*WDZ.#.1 MC>6BI7 EC=OV3X\I\$J;
I:1L;6P<8QW/G;T_25_>0P*"4OBHM%=%^2BE;^>4 MFHW?5Q?I\G\ -U=(J?F5=;AFLIWSF>HV(Q%QD
MUM!Z\$807L\$3?2IFHG=RGKQ1#2XY?
XCR0)+P6.%TVLKI3\AI+004#>65%7UOB^OXI&LPH'2I&\$@&@Q#C7\ C.XI-5;1
I2W_4I&D15C6O)5246KN;VJZ_S^L+!W\O\$J@R^ MPC2(<6*
I3(4N*K;IG^>A@B=>9RUFYRO=X#HHVF;I_8#-8AAW-VQ>J@3YR MC\2FA).=(RP#LRU).T6#T-I
M6EI/H/E4:QV8#93D::!S.*Q "UXUG_!0SA;I150&K%#Y8#!"007^TBCMU9> M-
ZD32^CHK7="T"?7.PKUYJTGJ4=85HZ?XF22IR\$AYOAM\XVRK2LN\RD*^ M3&.IY;?"
57M2I5.B1FOI+0BRBCZ<_G:3*"MJEV59QF-3'#C^6L=;#C%5 MM4+JEL;DG('&POP9K((O&ZO%I*!@WE 2
SZNYDA6D^X#9(CB9FI_0B\$G' MA.C4WTV% X=>.*41M\DFWQH8/RX^D)-US7F.0>&6(WLLZ6=(D5TRD_ S%5
M585^D#XFK>K\+AZI;#G+G\JX&O"*D=E6_P(I%*.I&>>KXDD1VI9C).50
MFT&A\I>^LBNS.WA(NCL&O#2N\I9L_ ^F13/"B?VKMMO\PI&5Q50SW^NI@I MMS_WCES1&?
Z\I^KIV;%K+EJQX\1*4.GV>0E6IZ<_ \$I+F&JXY7D"@F;)J+O
M/8@ (KXYV)HV7?7EEP=ZU)1;6Z8^QRZ;L);8R)W%M(C_?2;G!=(3 K&UW3!
M6=P59V4.APVZ31299X'E^59YC)>7.7=859E'>HN5^N-\$\LFVXP\Z>;>X\H V MK%) V(M=I_7L-0<*KK)?
H"4X;7W#EOL.Z9L\J.IU8*QIX/LIREI_2_ V/"6I3OV?=8VR"G0^K>#X.P&I\$5H J<1.L\$S
MST+P:U*ZV\$1;Z1^M^JL*\$H#>4.W@X*#JY9TE:E0K-4-46X\ T\K.8OPP MRP;1TYZ*!E7JACI8PYN&W\^D/_OV;
I;J^LI@622K_S\WM^YOF;8*M;2^I M"\$ 6T\!>O*YH&'VI%VY-8_(1SIAF.L;A5.3Y(7/6^6M Y\X\#9I\$W\I?#^
MOY;U94FO2904F6:D^2QI!&KS=#ZC%T O\ID* J.Y3 M0IVZ+VAB;-LF23\I/V04EQ@'(73MKO9;W(<)X)5 AH_+
ZUT%MYRH7_499& MOY>F*.\L.ZG-N4LVYS?I#&V;^I\$;>=(E?C8C160V\$X/T7\(#8E85\$%/T>4U^CD*QNM\I*
MM%7(NZAI\$?51@O)?+4K06AN?-I_K4974.@IWU&B\1H)\@8WP6Y>2BI(UR MKZ5M>>42VM6;"U+@)JR2A)I?>
=O."K%7H)(M6TIP=;BI\&C.146^T4G\U\$3 MZRXL2A"1+2I35\$OF2N>F-
+W;I/HD"8@D^*104>TGLLVJ.NDYLSM4;G^V M\I M^N> &M.OA#%)VDU>PWFJ@6LTF-
^_ \$OQ6E\$*GE@O%.;K.DFOA@.S\EO+(BR M%9D@>541LIH6I>OPA\3(8\W_>9C<H\CI_43\15WUV\$IXUIP?
9&U%V3B@H5% MMC;JC.0\IK!/?\$P99R;C;K%CI/OX^5Y5!\$.(\$-3U* MS;NIV%I=(1;J=Q;.02.-
L\$H)G#Z@I;O;NSUI@K M_%3<3V=@7C79#M/W3X%VI""7)D8I=N^ (YB\(<1H\;\$Q=OLO8LBALS3\HAT
MDF1E;N3;ZH4_FB2&?HS_+77-0-R\@BI\&D_-+2WUHOYDHS)C16.T7 E6T

MT*1#UBN)XPK_PR*FIYK:@D/A&3!8'D4GRO(MCX+5GHW4?S&D3>(.%I'+U/MIVY,?
DY'Q73YK36@S!9>%!^)G..C@>K&9>(M7PZ?88KIC#^TB!2&&!)RZ+MJ!UT\$S\$F%<->A|<|<6^W2=Y@-
O60Z1=X_M!;NHVU)H74=R=LBA@39Q=.,8#COY5X'!\$Z_L?;>T7!&:_W'''&"Z+TE M>O0NT4NTB A)1%
I"8\$ST\$8/HG2!(?!=,HWZBA!1&CR@P!WOP\$R;C^#UG
MK;A6>M=ZWV.NIY IOYH NZOM KL>JIT9S7C,*+U&8U^Z?P72=L#_63F# MM81!"CMM
G||A3TF<84%D80"0USKUW9R/V"||H2 T\$ZC")DEL;@)/E W\$*C.J-Z,D34YJ!W.3WGHM"/
MXD<9OUI;+V6LM\$O?-B*F_6H(O%TOP)%\$WFLPX,3P:15;3 MP8KW(1R!.*%Y FRN!!U(K0_/&T%U<7J7T:@ZP;7*2-
f;S8/+73?TT'73TC M9Q_Q;W75">Z_.?|_ DNO'U8EI#;PIT>JPK|_@\$;YO:2K'GL4WGR#_%ONM"
MQHR7=I2D&*UVSXWOC?-Q6WZT\>F:JHD(PVH)"HPZ-U!9X@H0"45%*BT MGMHJ#*3Y_7#
IQ%6W\$39.V6#CUV,U5T02_F8_4"JF1W":X%(-B>Y;DVJWEB#U8170Q;2I(Z7*;D#^O53U7>|T6=1)0(I52<@BC.7
M>2BK.SIYDAI?H@!)YDL6<77LAC_*.!|ZZE 4PV+C.VCJ9L>?2DU6VJGR&7! M0F_9T>M)BA&L"%-
L^F!0!A*!A%KJM.L!R7U_<3G.P%7F*4R!(42D9;2C/+E M0!A.B*JTY5%3"W811M!16L7!MR.PNV)?/EV_!X#
!|MARDX_W7Y.3:1F)0 MTZIWRU\$EG8! T8&-6>-N!\$|ZCS&K'B=3&3!6(5'AP...#EV='U\$R=|C M_AK=,=;QGK-
SA8!JC>?(*#=5C9?6/\$?|E:P8*OY6!|UK\$LD)4QU4;1<0 MI?86F6!YT5E6CTK@2".2=XDW3X?Z"2^OX1^
MZ".KN5UZZQLSJ8I3<5 MM?9.,|!#CPDK?+*=)>2;9*3?A^CQHR|D|V!I3B WH9IY!|B>1?M;XX\$'3
M=>#)1%&XKG6&S!S!L>XT>H+|!"%|ZK4Q%(+0>)(W^OP2X!|@N0*(P!)>3 MS!V!YX"BV^_|LXB;D-
C.\$?/OWM9+2.37K*#PY8J=(I+L85<=H3/4RRL%A1H M&2WQF=L>_U-FG P!>MDB/L;GK(VFKU;BG1CQ>1L_)
(<((Z<M5GA_*M/2/FEBWU>6>YINTUW>T=T3M+2>>X.M9!O<.)N!#_/P#BAA"IO_UOKR&M=V<|?6M-AIVP3-
+!K?%8G(C!SM_""J;XK0=OF)"<^T!S!C;8RV8+8>T_M!YR M!+!O6_H!8:9RJ^1#HJ3?J-
I5E3G|SDI#@A9)|^!^O%7TJ9|Y!>4)-ZYH8/13DWO+M!K05C4!H!M+GY!M C6.Q=I9?KL>38EMKOL5P!2
M=05KJ!TGX!%!(Z6/=U+D||O!5IB8O.RW=|'9:S^VS_#OIHJ18-&PO8ZTKKGJR6IS?
42%XY=7PH>\$N%E+LS1"8S-GLP|B-\$Y/B%^W.KV7 M_8/I0!@KI"6=E95S>||3!_I30L<0BI(+3^*
<2;4_'Z7OUK|H|_C3R(6 M2OT%ZS=_82G.1B!6Y8A"&FZ!|5N3Q+H(|/+>(<2?RF5&J!P!N;G-B P' M-
"U*(HY@:O!JU@O!BUKHVXTG|H%J!L9FGO\$U%/H@B0XBV;+M_Z5V_*^MV=JU!16J!AF!6CZ2IVK_\$!%BAZ-
L:A!58TQX"ZZTZ&P2&9)%O_F!_S0U1+MK>E P!_I7"HNV!_7W^)&?5L!W!O!_K9ET#7 MN
)26IK=H<_|=X,7\$%)KE^4WR#=#;...O!..0^"RGE?H(Z^<|_9BO MX);0\$(:'KL!#^ND,FOJ#<=>|I-5WG7-GFK\$MY
T6.P)CUK*\$S...#U;B%M M2?45P,>0905'0UC&8A*ZZ3*O#5S2SMSA1^P@VB<=>+HXUSQ;|U\$B#^T%M-
Y+76X!00+609Z5G^ED9RM!OEN-IP7ME.DIC(<7.&_%30M>=<^10VJE<MZG^|K@&R\$SXY.OYW(G\$6H^Z;
|*\$S\$O@WXI9)_4TN2Q7)/JFH;J5N!A!M.U@5W5 MX#@8B@XHY!#TP!;9\$C:N=*<4\$>/'625^6?
B35CZD)\$Q>*20%WN6!MV975Y1 M9(BA#!3(IP3!V NT_0TJ&'8^H?_:%SNI_?/6)5"iUP\$)P76,5A;_94I8F)SVY-
9X.0T4"TS'2 M'O5&?MZ'S8&=0S%W1'^@H!_CHK!8T9/'N5YA-K&^JWE_=8+QGZ>ABK/O/IZ
MM(>NJ6XC\$O_.'R9\$!W\$=M#^%CY^%?%QM2!3KXGB)!+S1/93MQ\$<_Y U2ZL M!_SWBS!_EB5O>(9FW?V2A3"
|PW.+|T#VSL4!"ZIT"*=VY!A!)!T^+PHGY! M7F^N""B2|DCR!K(OJ?|H!#Z=J!QC^=(59)?6!G%/_1.T_203JL_OA?
M\$S_D)DK^QOI!H641MM=:(DV!;V4RXODZ)B7,NE!4*#B&XO;+!|FOJ^_8T MZ?'R!KX584Q/4D!1"&\$/_D7*H.
N!LVY>_444!TU>=F3BCV*%&|_8<0 M#52!JRK*%<6F!R!;H8D9M@).Y\$)L4= 2B47S\$FN_0^!PWB1&=!(N!|L+T!
M+M!3E9MT&+"4.IQM.L5R7A3;T2(6RD*F.C..S."7J!G'HK&OFON*6= M(*D;
(17%GXQV8.4Z=PN^6)T?I>0#@ORW)!L.6&QC.|_1<:DM_S!K#3 M"W1@|@|3U|=XDZ=-!1&G40<|?EW^>ME
A;ZP,V6)TO(Y4>WT3=^^?2I?IB6 MM@:2CZ&C=B1B!;82!8A7XX^@LFW%XD.E!>SWJ3L!|*+XR?W4SJ+!UZVB4
M)C7!9>H8'(#!7_4<26=H6HUF&6FT!(S.8Q!OJZ(CHY.POI:A7-B>5!MF^U>1GR<_!0D)S!\$RM!E/
2&/_Y;^JP:5H|&W!XXE%Q^>) WZ.T#;O_9 M2.9W+R7\$|V!EE!AH67T^)#1!"24S9+O!E9X7!|9(+@V.E;S6?0@|6-
_U1+Y M87=NOT_*JP;?(\$5FOC=SD@?P:(T7K)G5&79!&%=S2T!&IB^B&S'=V-X+ MYM!7BV>|W5.U_9 F_?F6
KUQL_99Q*5%O&E7)L+!)ME7M#DC=?HD M!AYZ! "RMOPHE)(H)JP>^I@ M*|WI20V<8;.RW!?'W&'C^!\$*49CM5-
6Z!X5(-T^!XBX>7P%:#K_1STRGE>_M8^FU)HT:KOYBQSDA-U3(VX+|LY#^+V(FDG?
0%1+9L=86X^*QTO3PX0:IBCX^ M:W.T(A0;C/_1;O!XW>)|\$7T*-W!3RKS78:|ED+>0?I<5_LMW^<(3
M;F2\$38!MT:"#^"-|&.<=(B37|ZAP!6"1*6>=S;D/GX5ZJYV.9\$<_Q.T! M*V_HHOWVFS_?0GGM,,G@N\$|_9Y
|O/M2RERM;94UT!L.^N!HS%;?%7MMD MC3!U_NH/70Y8)!7=X>&WXQPH&U25+0N&\$!^7R<("5!K42,0D3G!-
>QA>MN'E.Q??=>RO!FO9E)L4(78CCZ:A X=^)#G54!A&FBA!(<^!PG!FG.FY6 M3;L;P7'4?;Z+Z:N
|X3*B_P%IA>EL;|S"EN..V=H5W45.SXS1D!OW7TL-MB+!LM8F93QH>#48>9V?D_!HFJO-BUV4%
|T=EF&LEST!D! MHUF;BL1BF&&WNP!X!9CKE#^VXTL4G2.SHY?_AJC>&|2U:RA+Q84"FH?X!P M;|6">:-
C9N9ODL@/_!9-*%:9+W\$-7M;^_%92BM;|D8TD9U=/'WPI<78 MJ\$BQ_#23&N>*IS3S..U#*=UY\$ Q%|C-
FYIK^9Z#&H>2DAMUW.,6HV.F M%%6JH#88&UHZ^RO@O8MV!RST!+=M2>R,B)V%#8V M;2!9#V.U73B"J@_K?
G2_G1>X!AM0TGVY+8V?G*5%P!J2MBW4;?EV#\$>GGU MT;3L\$/_OY)NRHX^2=16&Y5XTE4/R!\$9.2J5EGV-
&1#|B5%XHOQNA'9)*#J>^ MINCG5P#*7X2GZN/7_1%TXB1VNMX#X.I_L/U:D4LCW3H#G07@&U<4!U!4N
M(W+ Y9:L S6<3ORW_Y5!6:E.7+OG-F"4/Z!#JFV2.N*DT!|OR!<+VC;@H
MB'Y_(7L+3CB!82A0960^4*=|_7D%D#C3XR.+)|PAC"R/E!-2?G08GNCU>91D&ISS|BI#JG>(C!%FB:PB_!(A!2A!\$
M.2Z58^!#HG=X(C!R;=KQ>_ZDQ!H4^!IOX7/5F;*Q)B+V9?^=YKZTA!@K8%
M<^/S/*308S=DO6G!%;CM#O+;3_G"NA;7)Z@!M!X=UON5*OHN/N>TU-ZJ MRUM_730SNECZ!B*-M%5-
ZJDY7#2!QUA#H4MFND)PNE#UN45"NT3AV!UYE) M2!G(+&#&5""#1945<2LXE)RC#|B"Q%TK#B\$08S_ZW?
*XZ%#_G_3!A0!HXT M8M?YKZUTMAOOU("O33\$A3!N:%55\$!L1PL%155@R.%C(Y\$J2QSN<7!L'AV
M!1_D(2!?'TU:XV!+|E_ORB)|_P;68-M5%Z;68)=!6160QZ'V5U?5LZ>A;RQ"BC07G4+<9Z_K9 UC+('HZZ=8LTPV_&%
MQ#H5!8X+QQ@O\$!_J(7Y9X0DDDX! MK6=Z8FE==CXFJ.#A-Y%57ITE/G*0 IG;^<^>"8-!J&'OO8W4@U:DP*6B
M4;-)MJDZ_'SGVD'>*FA6FA>%GS=X)H0SE5=>|ZJO?W))R2/84D"SO+C!0WM M."L;JU/_^#"E33;+JR2JC"97
BU*TZPN/@NH9/UFV=)L#X=Q/4A>Y;JV M!U\$|1^2*#@=<^EC)-5(5D_D(O!&*.3?J.W*KP7!P!5)70EV\$.WSO:@47
>-1R M4:|S!JUFZP>63!4?>M!WJC!U*#E;O!W>?<+!^GU>NDM!JVS(8&Q5^PI4 M<5)&|O6_/L?)V3?^%
JK!PQ8U%\$H3BF;T7+N!+4!UAJ7!8>S!L!NO!F3 M%OL;3?#@!/_<*(D4RF#6^F&N=[ML26G"4!80"&=0Q^>QR.#
|568+P.90") MO>|2J!JG%1.R!/"N=|G#T!A!|OK\$S(8-13K-C6)<8!J*D#M!9&"!LXT"
MNCM!LV*P)!%UJ09BT\$T=|*5BY'O*O7E#N!|10<130:4P.71\$>A\$^?P.D-&AJ M95C>W9_#?
E#^>A#LRU1/9W#L;C_YJ6^@E\$J;> M!0H?@PL?(B8NNT)"@PZ//^&2U%D@%\$1F6\$Q\$7/!7!D5@)!J!EAC!1W<_O!
M*S4_6&GU-B7ZN%W!M>A_E226MB_T\$J*MS+*,10,BJ2+ \$>D/ZVWYZ\$E\$?V9M O\$|<6KT"W_K;+O(Z,YE) M&%E??
J%X>*ENO+P-J*M#|+A@HY%A5N8F%IH-@VWMY*9UE"OI#BI/'NT> M97UK9PGF!L.PXL U\$XR#R!='D3.'U"7P-
L4GJEJ5X8^1G?KH-^|MR_#(5)2 MXBO:K\$SU)GQWW^F!G!CY\$S""Q2(1!NN=>|*V*\$FWQ@C-
XWV_S_6HW\$4A@CB M!ZRU,SH("7P!M!VJL"E,3PC(3%PRC_NHRSE*,GMI?,"XO^*P G;C!1XA6 T M#PU!H_WM-N?
A9!MA>O(SO>LX!WKC3N!K!<465C 7C;2!Y#IOS*0Q_!/_O+&#DIV0GJ3)HC MTI3.906-2*4W0XMIWA4XZ7ADN"
BV3*)TX8F+RV_2D!"T8'I'(H/O*R7'7Q MH)V8_QAN#>CZ3'B.DTA!;3;Y SD>"%+G;%I)=%D-
LG!>\$=XVIB4T%!,86"O;@9?|!#0WXT_U"N#P M<|5E)+LM8KQ@)=AUDWW\$\$\$":?
Y8"IM@)5!H=N1"\$Q02NDWY;XE,MR\$5XC>7#D MTN6<^?^FUSN"KBL?0UH?)%P5!(3>|MXCS+Q3;+N<|
V*V;YYNV#5_P#H0 M+EW:NU%YVU!L<2;"!XWEH!35HIQ;U\$;I%*7J?F!27E_T#1_!\$1R-DXC+
MJ>)=*GD!_D;L:'81YR^C51"NJ19 &&OF^E@^H(OGQLOB"-L-NV4+)..MAFW8^<^<2!T3NWU_&?

5LOK4FOSA,9MUOLN:6+662KN3CZV#4F4681RE^I M(#G,*&XA:IO!.\$X("X3'-400 W78+ ,R8(DIY*H1Z ?
CS7G4\B1/7:HL*AF M] 4.*B5IV,O&9K\IK5,"+=-8\9>?FY*#R., NI9M\<@K#Z1#?R1*)KF-8 MWK6XL\$.P3/A6
6\MZ4/9ZT8,"&MC3P; M#U/I,%A*O\BZ\>X"..QV/<;26^2\$BH\$YJ4>/5.KL\5 V!:#RPC
M&+7.JMZY8Y@RU"5%5%9X\A" JCIQ:PDKUUBIO:/RY81S-^JXL+..G<"#DZS M3+M\J3#C"MKBX%!\C% ^:??/<4*
_.7H2HXJ9HD^@?11=.TDPH/ MPIK/8) QK&CB%<Q.9WC:IO#0\$XQ%;KIT?EObBYK=QO71Y+Z"<-EKIR/\$
MG%CC@^6FV<2\ZE@IX6PU2Y(7OR65:CAOE: ^>M*TWIUP#M?DE\T.)\AK M&&IHFEVBS0N(^ZWQWP5%G,%
8S;3@:CI%IB?L4W5\SI-O8&MK*L\BK\IE+&UGOO^EGJL4P/=PE, :RA9.\VU, _H&MLTV+8F.ZVJOIG+ M8HG/W-
2TN@(\T@)2N7\ 93\IK?(*&;\U-V\ 09=45--O'H2A)&2X+\W)R MX I TU_53OL_,*J1+?@K".&=)U3@TV7X+9?
IH8WO,+.YXN1#47*OMPW.*@*E MF",,^4/J-,WXZ%X\$;K\$H\=M.WZ8#>U@.\SLC??&N;.&/ MMP"H\VI38V
<=%SK\$3\B\$B\C\CV.W "U/I+6\A#)OE15D=8O\TL@G4U-IZ MHH)7ZW@BV36&JH5\IR/0UU<><=>H5YW:HR<)P_7J
MQL\FVEO9PW\EST+VA4)#8Q27 U!Q""IV%XC052\$:0\%0%.K'M6&KH@IO41R;U7 M7\;FKZK@6TM-
ZIEA"MV#9/?O=NSRDWAI\9;I=L HN?R\$ONEK1#CKMJ M'PO.H\O6Z\?O\WB\$R.'\XTM/;
(08J486/1A9R8PLK.#LT1\I%=?@&\$#I+ M-8/I<:C8D4%-FF\$Z8B\IA,IU2E'99@^=#;H9?E:O6WS.\$ZIAPNGD83I
MF3^2/#S.?-8TLT\!E4\KE49XFXSGS\$\$(UH%2:V23;E;J9^IDGHH2X9*\\$PXT+
MF_9%@<&\$U1HL@<;\39#OGN=SY*VT?#Y;83TH*-E 7>Y% N#@J321N2,YWKS
MHT);/B(D6(&HLAS0ROW#,MVXV8\TU*UYT*.@1MSM/4.F*MJ%@3I&6D7T++ M=P-ZHXDJT?
8XUL3C<'ZKMJ26 SR2UIHK@MV)-VFR"2G+UFS-Q%@\$9GUW>|<>
M37_.HY'K8YYI*6T""+MT+9N4\;K\$@283G"%JK27H57KY2RJ5I0VZ&ZT@;.(% M@_..E9\2=S/J1T^R 3OJ5(0WS?
BJ&BJE^:Q\A\$S&W%>MB>SLIO,"9IB O M.^@?15?K\6\ZS-5NW:UW\%KPROW+A 4_C\?HRI00C#R5Y7;-
LP-R.AP0&MONK0=^ZIO)GA\0+YQ-POW\# RQZ=?M&21=#4-MGZ%CN&-V&T>.^&R2H-L MS2
CARD%.Q9NUA=V0BR=G;H-!;7&#;\$T1#&TK0@H\M;DL?;3S9VZ+6*@\$ M9IXX\Z""%7ZL^L9<;SL7\4V-(CW188?
@X@K%;K7\L7(X)\ M.XSIV\;I*UE>+4*W65PR4\$+*+.;T*L\VKZFO'R-^%1(H;-HU;76)>OHXD=-MO-
%09HR\$ KBEZGY*)QA6_0A\ JFWEP,M,BPPAEIJMN2@G;P%;#K1FR\$,-MBP4H\$P\93R1\$00VGE;HW+WJH8T(7&
IS\=L^=<9J5\+EC7'W.T&G/+ "6.6 MIAE0=\$H-U6GENOUUN-^Q3W-+AVKWV-%6K;=B&Y91O"PI>6TC2=*6M?
K6\Z MS;=#;8L-L)*0E)^0\X\VC1\$9*IT D^>V&^/7;KR%G=6C\I) MQW\8B3ZRRL8>\HO(6EM7#)\$;? /%7
OAB?;120>"LYMI6Z?Nj51,AFT?IUI MQ=SPX*.;UZ"HYU\I CM=WF V0"!JY\$F&HE2<2N9SA5%;1\+(->8=I%#
MVWA%5"A9,8BE@BURZP"MTF%0QHO""L\#<QY'8)PK,N;3D\+.)SOM90 M#WYAY.PP0Z9V.*VOWOH#CE% ^-
_.\$XLV5P+J51=7(E6^%0%27-2#FIB+.B%M\2/3%)\$0B7P*K\8\$C\&H8SF98)DFS4.5WS>WQ"V**
I=YX3^>9CVU^P4UQP MUL&.CB%8GK3\^HD@-U5CP.09_Y\$GDPO\$FJJH5\IR/MVF?E"R1#=#8Z
MNU/0A\ _N\4\$TSX2_Y@U^X*0\#D4%KZ8\H\Z;7;"#3FV3\5Z9HU2@2;&7S
M(-7+NT%Z5O"27\7AWEI:OGQPI<&+>EQPEF""^V*P)\\$IUG;V^YF3 FX-I M#+.HHU\A3N-/Q2EX
X/(M<.#&KM@8H'B'7-N@QI/>=VI-(O_.;G%G#F+ M^*>O4SOT%""MS#HKQH=I@20/A3-/H=H4>;J+30>
<=1D)S;_7CZ*>EA0DLI@ M=S3\5^IK^TT=J3INVNO.3 EGQV>XN+FI8T 4SW OWH1UKU65-MP1KZO)CER
M:&1%0?I>C4P\$=SAG\$9?#LKI5N\Y1P=ZVY>V;#IM%;KF_+R?# M\ALV\7OH1&7L^J Q\Z7-
0_&81Q64@JZTISZ%+MQE\ICZY-YPYV=O:O M%U*!M.,X-IVQJ^-&>0.;0YB7<6S,B\PH<#;2J\X_%/O84?
EKCF"PLX M1\$FW>S;"PROQ>'@_L)X3KZ;Q> HCl721Y+Q\$C\8IAIGHRDWH\VO\FP#@X
M\>MZIS79(3FI>0_>C50@-8%PA26^09_S6XH\YOTM;.:C=U72T)Q8O9;\Q&I M-UAZ(3L>!"KFW/FC G1#+*C/-
WB7THV+FIYJY97N\+^G(7MXDU8E\G6A;L;G
M^POD\$M;4;..YO5E=VI>3C2=ZO=J*M:R^XAA(080\59)^J^"\U71TTI.^ M*.0.K9%50NN+TYIHW\VMXZI&
I%U@U_F4>O9WP?C>J%Y@+..MPIB(Z_K/LZWN\$)SB>^H\K0K;FL9#W7G;-QO\$M\O+Y)*.LTIT9;%82G
M\$CYG;=G&HX3IV9L@6>IE(2\QT"NP*^>EBK5\0L^V(T247*ON(T&H1Q3\FMK# MT%-4 1E8MYP-
^E.E)=!6P;HJ\4(UC05I=#D78%;>JZX6KE\I-P*%QJD8>?2? M?ZO<^#59Z\$J;=OP146C9#6A5\9GK&BX%KC-
4_Y;8;OE\DR_.; M-2Z(G)6(G6Z0+-80(=-)B.9MK)P/N9.@5%2\I SUGOHYL M\$^C%0I4/PGA6W>C" WM
Y7>H DU0)=I+FU/;(&\HLW%\LDJBG#\V=>NF\$X,+ MX(VIKMO%REF\7L35B.)JH+NC7OSJ1Y2HGL\Z7%_!BT
N\SENJ&1#AGKAN(M^YC->(44&@P;2*66D8_T84\U_&9MC(7XQ\#-W\6*.C O).*O\NT>);.0_2
M\J>^AZF#K3I\$(IGFGK1002-K#X+HF(KKBZ^#B'HDMV^ ^T"1&?IB=U^J"1 MPI8D^M;2KR^XCADW_#0\$IG^
208)^6B M^#R;RX4L20N1_O:P_@UG#V.1?+LX<0R,+J5\$ 4^U2.DIFFG%6EX%TN2AO MH;Y7.E)\>OQ\
=DS"A"V#5.1IRX+440.\$AGG#_Z\$R>I)OU\LDWFZ,"K\I'D P M9#GJ<5&?ZW>M:AVY_\$ZRX1#0\Q_6=?H8V=3;
R/R\JF.B)B%P*)C>F/6Q;4F\A,^OL>X_@4I;J\30(M<I\^H\JM%3I9\ C4&0.N(TQ_DI8+P#*NLT^S#;.\$M_2R)16\/
2UW=4TNZ_MMTARA5OUX\8XV=92(TF^3?G\6"&8V20*@_||>B?(<?J#A;_F;Z=0.7.1P#J5S8,Z M-
L*L%RUQV;_7&H75.4I";.MBT?R'M\CW-JSET*KUA ^1S+BRWQ+4E#KV 4
MU=MFD@,>+OOX&7X3HYA1#K&QG(8;HL;/&4Y-B7,S/CFIUA ?\$&I0RK3KWH/MU*TC;
JCS%6,D@?&Q\WJS\$H8-N+ _L*O+4'? M+V.TXZ7ACZ^DI"NT,EGM;\$R"\H3N=Q;O2+?;+A0NG
M\N)R\Z\$ZWGZDITZ+M"7)1#>^N1P\X4*6O@RP^0W2VX.C @D)2IT-P/(@ISWS M1O^HF-&B"^;=12%
I41QG\I D^&+>B7#;Z\H1E\>M78^\$#8#J;R.VK B^?1W MA>LO\+4>RAMP82%5";5 X.JB"2^08=D\6N"P*7'=H"-G FI
6VH\>Q>)NWy\MA;R3@GTXD M^G+=06Q-419F+GZR.Q5C-IXWO@;I*859GAP(MN8@'F'SEQ1%I4\$S\BDE
M7^.#U<2/E@G?_YM&/(+BN\JF;\$#RL#UCWQA,T1T(E4KA2JK\4H\&E^P
M^GV,DDP3716QG2JHT)%GD\$2.'A^_HNWKC5\I(66-LGVN6NOT#&/RF+DX"U/8-MJ^Y(T\JSX\40;Y^GB-
\$^G;RK8>M9S1&?Y@FPFX*P8L)-5%;4SV;73&?;^L
MEK>W;9YZ\G7GBHH^4B1ZN=ZSXHHH.BT7.=555X8YW6PQJ6@GB.GKP=X;7+ M_G9I7WJ\$;
(.)VHS2542(5%6:E)^"5*\$,C9N?^*^U5-MT%;LH8\JN&MI\$@U11""U=DR_JYWV.(I;*Z.B3H(GSF/\HWL"6\7;SP;
M34Q>M.VO1X<^62RRNISY9=XR\I\$DW-%SW0>)W\$(56/ <3WB_)B=0U>;^R M KU<_1\$5V2H#XYQ?7"DR%&H-
#NK\>6?Y&+PGUL77P/*Z1)MWL*H5.RJO"^ MD+J\66J*.GU-&+F\2TA3?
(9QQ#I>I^9C0"TGULBDM2IKSTAR1JJP72I3T+ M-O57);X^5A\QOG9\ITD6QV.8(W\&E^P<06;I+4Q?D0FZ.=
<&G MPP^T*ZDI,?(HACKQ2<(YN6-JM3G99_X\$#LR\FB?&B\GD_ K.RGI\DD55OEN^0X3Z;(441"OIQC"71= _#U9
M;+5 _H<^Mv5JL24F;==""@VR;?^>+7_DWA>K2DZBLB7?0BJE"7%<2 M==O563\VLVL6^2&>M#I&J.G;
(BN.+.\$TSBMV8\$NF?EQU5"RMJ*J7=-XRT M.M2FAY=NIOE\ZECQ'MME\YNIU=;0T8/HGN7 B\6)
M\I@;>VLS!=TP)_U>6_9RHC%C.0/V3HC@1.;4#@E4H.>("PX-DU Q\3\A^ MJ+>B00LG?
KYT^&.G\$D;/@_M5L=NC&.#FA9/8-J=3\NF2N;N>>ULJF@ "L# M&VD&(WPI\5Q@D52N.FO.E.Z^\$OM9^3QM1,OK^
I=?8W^Z01P QZX83_\$7&8MWXS"<'LB;WK)9EV.CN4K3O70&8H.SHZW8\X""Q\CL\DI)+ MUCR?
#87X%A;:BO>OJ_?KI-I9>^ID\$JH@DY+0X7;.M&IX&Q'S_2 MT6N52^ M @1L;01/0\J(4)\$SKH\$(ATNIM?
@;U43^+JM%A@-H\6VM\(\F\HU//IE TK MV\$R\<=AE^JF=.675SWYF9A?&@8ULANYN
>8AYLW"Q3+KN\J\$F8-M=R;W MC<4< (MMRD28M@K\2,3T" T\W OVT-%I;0\+ _RD;^X?70<^MNX-VD
M>5Q\2K.)\!1A4OSO MD_0'XKPP;_#0HH DI)=E^JL< C5>WZR1YF9^D^>2BIP4Z%\ X;A5G50Y??_TL-
J0H5=W<+M7^M2\$Y&D?1 MMTJ C<J\N+!TKUN\425X">5\W M\;V BV7<I8.R_ "6-JD(TE5L&1%\$#51
MGN&"DYRUS:\$1&B\O\VH@CK5;N;2)<./035;"+ M_SL3_OU?3*AC M&1FUY<=;J?G.(E*#&
<&X;>=YJH\I3Y&G";5HU!^*O>MLW#C*==++E MI^JKH\J3Z9^I3"-X\L6GUH>^%+I XB%5I@P<.5\OINIX-
/_R^JFDQW8J@EH_L M#Z8\I)5"PD-%2K/W3_34HY0NR&B*5\5J\$*4Y&Y%KJ;T3(7PP;#*Q-E^(C-V MI-GMW0?F=

ICDI"^(^L,^T0(Y*#L,^R>7VK6+7|8&RJ|MC|>O6\$.37LZW=M%2^V,^YJ8A|BPN*^5I6(W8T4,^(23E8/Q!|,?HV;
(O1"\$0YEGO^73K-W(N1M%87:K|A.G?G?666@ZFHSUB*H1Z|D MD,^|&-NHP*|7RUJ|2RSJ\$WXV|0B0|C?
OT^@OUZS^:0 JEXN*^A>:,I^.|P& MN?#&6TG6.H>%EU.>*T^5\$XELC?
XCWA4S71P^OVY/^(1MW0QA|<=6/AR03<51(SQ MSV0-HX,
(^)/<1&W72.D1<:,W,9^CBB)HN9>RX/E|L.G9EXPSB-(H M.I6&TUANKX3_+Z+Z&S;4F|S&BN??
R|)DPK>|)N57XG0END?W0N"Q* E PM MD/>|4%)OR#8XZ3+S0HD2-|Y|0|!\$* C|^(2),_E/P.TC=MGW\$WD)
8WA4\$E<::KJ8|X)X(B1C4 MX/+DN8<+|^Y69\$;0\$NUYO&EE2,N7."J+9^
9W+H=07PLOQ7.S,052M|G^ET53QN%_C>,3;PDL-4>\$L
MI+&>#113|WK,;B= 62EU(C%EL=7@ \$+V70E?/V7+0N(^VB;\$*^NS4E+WMZ9@\$@64??GYP>,%BAU MI6GXG^,
|NWF|967SL2WS""|H8)C'6=9 F1:E@^2|'K+(C(1M""@_)M?^K,14R,;UQ|HS>#3.HSMZ&->?&:>^B^XY9/3)V
M3SV^B7,V+>_IF1-EY9/8M>N\$?TX^G2.90Q6M+@&+|^<^ZB/0.S|Z%0I=DA<;K
M9^HE-,0+Z|,^XFTX0WL,X@?^WS/28C<\$JLI&C^7G|C.YE3+VY_E2(?>9 MBU=1WGETDE>::,\$|U D?4;O/RU
2/V>"/2WARHO_K8,M+QW_V8+TM#M3|X(C M\$*|4L|>'OK#HW_.B7A(4L""K1W O#N-7^T5K;5P"WO7#NIMG?
AD:WEB\$ M@U?2,-L1W|UE0&N>KK-I0A|U0,T+G7M(@SW?).^HW>5AP-EGP#V5U9_Z"MV% M)6^5KY\$N0I""AVP?
,\$6.MT@Z+(-^EW2N,P<5 M|?VUG&,D@MA^9S,F. 20S)|VV|UUM2.MJ2_BC^PS96(CCT_Y",8J&,,MT
M|GFD>|^2S|S*HF|IA<2_RZ|M?|J|N.72CW#1V|L1S8:%5X^%H9,24Q>QMO M=GUD:Y56I^DIOZE<*H,:(9I-
|C17E?@),/UMP964_PGFF!"W|JV_JE=RJ@B\$OD^._P(I5OD-#^%*S|KDJ*J6.Q@:Y|F2?&TTP0K+ERQCGT M8.
TBG5_,/3"ZD=3 M#OPYZ>|I(WE8-8V|_TJ#(2WCE|OJR%3M@)8K(L_8?0OZ(8>6^*4\$PW0
M8|8^Z\$9*68D9_#1U7|S^LQK^T""^C|T^N7O8F&2.X^-+G|<% MVJ?
LSI7.UFU.ITA7C|Q\$8\$|A@M/GVP4SVRZ*O|>2^S4IC65N=-\$+;,J2H MV4*OD0@TW|0JY:4F|EBB|D=S|P3HXI=%A?
3Z0"C5/,J5RY\$'(QCZWL%UE= M^D&NT\$^NCDUO^4EF@^@8V(AH\$EE|_@CGR|L"V.W=/(C|BX"=QXG?
WP^M7|>SC|#"N LLVB;%^D'E^AE M;C9F9K9BR7PSCE;3^#4|H|O/6SXE4'49|Q'8C.">K_S9VKFFA:7F%5W.E|
ML>S4Z=7T^#XA,;H#|^<3>XQZCR>RHO|S=2|UHMQ?Q*+K^TM|Z)D:5|I9N2U
M1\$2+4^M:2^\$LBSP9T|O#9R6JY|7G@ZF|Y807^&QWR8P:HRL I7#LH?;L)|#R@ M^SG9RC5*Y5A|J5#>^,
|K1^|X^R^K|F59SOD<28M+?PS/5HL\$J4_6,A\$7 MDN1(>A>T(<237NT,7|/%2QD;=1>9Q5@172.L^=0RQ9
M7C=HNFK|)1\$TJC-?1|<"PB9:>+(6B6&(V:XPXZ/8(QVGV0WL?Y1_X?Y@90W65/'C|S^HCGG M|F@:UW6G)0:
|+|QWT_VOR?4_NYH)5=81AFAW#A>I^Z'4;>'90K5Z'^^>M81
M0Y8;|UR.IF\$)0|SV_5K.TUZA|72|@52K42NA45W)H+|L|B^RM^X5HID??) MF%6C%WI>|42_Q)M@_?MA=+
ZG2#W@3:~*7M@JH_YWM|PR?8CCY=|SSI=?UP MQ_|G@&35^A,;T7<"5<-|%>_XC_|R-
&3|LXHZ,;VOXT|:UTA+47K4HN2N-^=S?TY^*PUD(EF|,|&Q* MQ?
U>OP?Q|WJ9832A(74J4C^JH|MI|+GL:|D8O.K==|I^JKAZM|E|HS#! M7*,L#PT^S-<?%\$VJ_8
MB@6&L4*85\$+^Y|<:,DP>,ZSSR,"7?H=7;TVU=-#(11U+(-S<|N\$/W.9|?>^ M?2"ZFQ|JCCL?6/&M@|1N:JGUC*|Z<
M=QS^R(|EP\$IX^93ZYQW(-NKMD^_E4>?&? WF?NLB
MS_P+96S\$;BP5:RZLU8\$C,^Y#0RU^UJD&.VNNW^VFRL3U\$FF|%>K)&T8Z? MAA,%,1:|Q?F=65
|&ZN^DNLJY|D|HDS^SWY8^LQ?T2LOOY:XT|VD< M%3/,R?@|75VQ9|I#S-
&8%M1!\$(Z/S)^C^65#2=#^M.W>O^I+OM|^-,:(M?
^6(FX\$8&_M_?A|FAIR|R7UCZ\$BC*:W(YU|^+|\$MNH*&FT\$757N04PD.\$W7|Q
M=3WV^L|&D,|Q#8HGQQ\$W2G^5/Z^#.U^KC<+QNI@)|H5O^GH#G|O)|+S4>UU M# H+^;CGF)?>.04:I
@^A:PMR4|Z6V,")7<F=(Y:6|_EB2,?>5CTS^H M|C|Y*|L<0|L->=|_#K1&3N2)&AE|HZSHQ,^|6
YM^P=M2|^&:"6|2+|@ MRA0A743C2S;&T|E|8_BNX5HJF=ZH-2K001!!A%V@ORL<|*LLX|N\$ND-6*^+
M5Y7;X&7SU&|D^SSJHF=0*>^G|C_F&1WHY2|33RYFN)ZV7DD|Y,|8F&4C MK*2|)_3_K
>G,\$LU%@P=64W|^6J|+|^&=<^560V4|TU^L4,0021GVUK#* MO_?UP1QKDAI8/<^&+7).>4CBT^R7+
>=X57^S&,^/NFGGA)QBCWD^*|QM0? MLKYR|S^|HG6+|3? M^S4|TL%-(#>|E^MM;|L<=GO&?
YS^Z2&:3D/P_9T*+Q?_ZS2*X^)?_PMJCGF5^" M^<(W6S=|M+|^K^\$R%MAR1<^*|T^5T(+)|A.PVMG^|/FV-
X3ONWFXN& MH:5E|@JSL7N>=LHU0DX,JFQ<|6^#L MXO/>Z:-|7W^%L|DZUH5DV^M/*@O8B+QK/X|AF2_,W?
0D2B&O5F;L M4M5,H M>|D|X?WNT6:BK|XF^H;=|>3_U2^"C@0^?_"1UBI2"(S|F865"/S7'=1?#-^
M,%RX,VB^)^L=\$Q|NZS|IRG\$7N^O#90TQ(<+_,D6ZE1)>^)" MOYM7|A2LV*K_VISA8J|;
|_@Z6@5/T\$|K>|SWX^~6BMA|YS%-|9+ _P=M|C49 M=EVC09I(|YW0B_3>|JA(DZ8HO0E("1Z^1)
>@:~UUU|KWG/M_~H1JL#&)/D,5>? M2FWQB"=E.*?G-("UZ;=|,XRL36^"C #S^:"GLIV@P:B,Q)R0)-<4SE)7C
MUL^VSO?KWG=N->TW7>MZ04>|VQEH.W+V_|M^#|U+|^E#PNHP7) Y#>-6^=W>N(@Y61E^TO+6NL?DC^|WNL)1-
YRXBQ&^Z|OQFV98Z|D: M|3L *=%9L.BFWWR|OD=P\$7/B^U_8&(WTA+F211N^I>2^C^L=ASE62BKA8
M+FEH3T= OMF W%+|L2\$6O1C52;&R:E:3\$AG(VZ(>62TGR4W4IUA|J0UD;P:2 M0+OZD0\$1('74'8
>C,RO|*MP,6&Q.@^7BYNS-GD_DY,GBF5@V_T31L@=(M'+5FQ065Y%D,6W|.WDB7D3#P!|=8#X,|_M?
5|J|DZ1%A^Y#M:"7#EC:K8^| MA#S|Z|6^S:TS#KT6:R:Q.#OK6|YOD^P?G6<:,6\$F^9*\$272CV LB7|V_(_# M?9BC#
|>O(|=V)F<^>GS9OWI9LWCEGU;3H)LH59M<^FVH1.5EN11_*PQ1-8 L M^NZ.>%6TC^L"N1OG|&
(N)|VLN?"P,HIPCY*?)(TGZZ,*(|^?X1U29Q|I2 MERN3TT&Q|I<^L49ZFR*^0RF.X@,+\$\$T|=U))?"(8-?
ZK2P21KSH/M+XF2?HJZ?^?1.M0CR M0DU3XBQOZ:<Q1%GE.%^=^;K7Y<*<#KRM-
)9=CA\$D4FQ VM=@%M^APFGS8@<@%2 M@-2|5J\$M: M_1&*|DFR\$>.%HU=K^TLS-G+ILM=GJMW CYY&?
6P|6F);FE,6E M|8,8U|Q.#BOT'6;&5KV_+||RM;K8|L?%L_13^HVNN5^WVTHA7X&&7,IE+AGG&K?L;|HD8T)!=?
@<=)0 M\$*EKHPT2|HDP+ON0.MST()&EH\$@_WT_4F-0+RL|J|J|F:U/U9^6/&X\$^TYWK MX;YYC+
^ZL2^1@K.63^"P_NZ>EH|G&3,=(F|9U|S\$T F13AKX64RXS|XBP12Y(3H>5%JEM>VYR,P3|K
M/L|VGCZ|B:6,;|8C@A@_82C@J|@RZ+:4K(5G2S\$XJ2J\$Z3AXY+JWYFJP,^7
MB(8H>*VM#^#5^",N=K.NJ8G9ZV&NN|H%,Q|L_ F6A|AXM(C|L1\$V\$9Z
MLM22YB*,|),U0*6A.N<^17^L4QH9FD4^_17FUJ+O-Q=2RWS\$YFU M4&|U2T-)O>:07O1.1\$A0\$O3%5S%
<M=C=40\$|/5E>6C7)+G|@/C828SP^_MSC?
>4HKTOW|ZRUQ|V^56X|TAMHX%&:,3VDM3\$GQ4\$!*|JR=>0MM2IBJ^+Y52M|1W3)<|3E-(3T9T_G M8Z*~>
T2|B6+V)X447::XO,U3 M^ER) 6:Q^|EOK,)^D^_.V8B#\$=>Y_%GO M1NO GXB|^3*+|O&.A3X58_Y5MG&C^6.QT
F1DR.?EM6&L(T8)8H|@+TF.Y M8/GARTXD;G;V1)72.80ATAGN1%&!K_E%^TM+26_*W0H:6>U)N0376:1/D^E
M_|BN@Y^TALHYF(T7C:4 IHRE|QXX>J707GZ&<|O>TLAX)?U3&^#&0S,\$ MBV#SK5A;GXIV,LLY=U,\$)-=|2;7=
M3EV^J^(^%4Y)_M.C|ST53AS6^RSV,|H^Y67Z^O>A)40!AU&<^>*40+KPTC|S^,:(BY06|J T=
M^(^UC<5_,2|^"\$MUBQO|J|0P8.H2F5CWQ\$VWC^X4V_AJY?GL3>ZUT?RW^,"F MJ2|1U|UN?"\$F0J.
(*=MSQO=2NX=?AKE8L=2^Q0L&*N^&N^@QY0WE,AM7N_O MS=?YL3-Y)#
(|L&E#^*TGLRR1SG;J^FCX0.E#<=KC_D^O|M6?|UH M^8LUH|NPY^URR3VRD^/F|B>K|OQ_*?
N2^*C<:EO^|GT2P.F1AYL|+1) M5N\$|LSA%M20Q#N4S|S^O*,THGAIGJ^3AXW|JXW1/|4@FPC9 M^I#
:UWQ.)F^|H|TO5D>3-|P9^1Z2|S:V&OUF_OQLAWU:JFWNY%A@|2@|Z8L
MG+V,;6;N|J.Y#D(V_L^/PTE44\$G924^Y="=O*&5N9+("^T^WX.1O)Q",2X/E\$|5(*BB/52LN+85*?F.9MNS|O/|XEZL-
MAGGT:H&TO*7VWM|V83CFD)QR5I^DA+L|J%2.F_|R1EP^9%0D3<|H9W1E^H
M@@^K^UIYD|42,9NR406KF|4|P|0,|1|^("U^0WNCF2|Q23(MRDO?T|Q|F|YH?< MGI06^*QZS(+2T_0J,1^CE&J|J\$9

BC:HIVA8" MYH-7ZX>9W7R2@JJB4(&W\$)2EHQK1\$QD@%,3G\$=>IRN)L1B9S|=Q8% I G O1I"83D49?
MW8F8OU'#Q SEDZOP8,NNXF#RE<'5^O-B%|K"6HF,B>%!@0\$6@TQ:X8.@QQ** M4L,9HF, RX?"D3@>N.NM
ZGPG6=)S7H(\$7^9'AF\$8#XK:3D:1(0T?6V&=' MIJ)-699=^XYG&9V+6491#1;AHOLD>RN%|B=W(C@IH*O0
MLM(K@-BHE),"3 HJ1#4F(V^,P"UGT=LEXIHNDFN>LQ+S\$V.PTZ_",8I98>P186,/G"AG;-15,^TMU/9A8A
MZ@%Y9:-5)Y\$41>W#TJ552HUWL6NLNE-XNP1KOL9.#^!@M&@JDI&I+:+OTX&MLQ?LS\$<0T:/5FY90
^9_PVHF6M-6AV5GS,C3Y32\$ _@.40 M.LBRR(#C'U\$9A2-'9)H5\$P.X\$P3IBK!U^AY1-^4.*NHK?!\N&1RUSH=
M<^AGIX)D)=SE_ZAU;:6QN'1*YLN'A_"[5I #@-6@I=R+GHRI%UL5I2R(L[_
MJ@3K\$^NDM0Y#3NR=UFEK!;WH#"1M&6;"=|^KQ'8MR1RK&M;/G=0=0^I.)Q*4
MS+3I08TK.0B_X86/5+=MR* KMB|+ B+D?A|2+'\$=\$#_1JTMXU2.6=\$W./\$CXJR!(U4 M|6::0(W#8VLSH=W
%=@)#-|+!PA^H@YK04|SP+3G0*+8B%\$|1*7U(#PP*2N M#.OCL>W7K,\$L*)E2#";P\$ MQBFDCH@;|,\$\$2A
U|7+&C,3#;FA GWE^->:4-K&3H/KQ;V|C2UAB5M K)
M|3|D&EO=BBOE|+GR9:<4+70387A/>RW*BI5\$X&ZPOV9L(IRE8?(4)_M,(-MM;"ZHS"F^H5OWYSQM_X4I=
f8D)URH&:0<)A@\$"RU MLG&%K|UY9A9_M=\$HE|KS@8;_JK-V?H@NH 11NJP5-Z|44UP|_UP=5S2
MTGP*H25JG%|G<=-HR;:50_OX|&<"2HPWHOTI631FN|;| MR"H(IDG=WTQ<^F;"0;D #Y&|
<9MWP|K#G3L86OYM_"H"+|R8QG7NZ9F:BQ M5:K|O?C48\$@;1W,R/5(45-"D=-(#Z4VQW7>)/U^!;S=?;|<<?<
N.N9>X M:FHMOB%>O@0I:0<0|4(>52RBGM>X0*PPNB|5\$AP1#E6=H>BODP1+5%'^4
M9R>9:~^ @839T_9/&R3V"5YD4Y-QT7%/D+W& X<-O1|O4#\$RVI;J*HB@;:AT2<MO.D"DCY>SB&?&6)(XCT>
)HXZ52?P&6-G.%H4?I M6;F';>:5L:/^TW68MD:@H:OL!_#HNWS)F"TR'=X0;NI@C21&@@OK7_|Z MPOM+|XF-
LYC(%>)FKQW7H7EM6R|YZE=4^A_/H?#VEMUYR7:6P3!/@FO/L M|SYSOD6,LXDK543Y"(B)UD?
QF*ERJ"9H&G%Z&JOTI0:4.#|+3HLM*38M MN42NLJ,Z)#_IG>'03UQ+-,3")%SD/I79\$W4M^6B0@7H/DJK?
1R*~7O5@-P;% M@5#1NAL" _2QI/"|7+^")DMY:4HVP U+=OE_FUT\$6I9W*H^Z_8-30AZ9<2T
M)O8J3B:%X\$82XQ%=O&C?@<5;/"LP?P|GP;1^2|L;B<W_O;R,PH M2"<5J?R\$UT1Q|S<(C-4Q6H2I\$R>?
@.0K|G,N=C/;H5VI5E7,"=SNS;/NDQ#
M|^00IN7I=|&NEUNH6)\$^CCEU*\$43UF3(W*#?)BF\$J^#UM4H9:DW'N&WVA&=-M|=PWCFXEJ?WP%ZN(2M?
VKF=KIS>BC)=9C16G#A MY#^O|1S)E#4VOL|V1A>|TH#;:/@#|TEU_4X7>1N1(@);Z"IRV;|J,IU^C'=
MF/(4ML8%^?K9,(A%MK\$%PA*D/K_-8A)BLE.?2A)2+O+65|6>1<|_D?N:O& MO44&ES^T^K#+N0X'2=,) ">
(5^CZ;%E#%-L?_ M5*1W\$DRV?'L)I>?T|S|H0L7Z#6:A-OQWSO2U'W;2|S\$X M(#HT'F95"5"/|>0H\$F9/7I1T|N|^#
%ZXCXU_2WXY)=(4688@1@H#G(SNNE>8=>1D\$1#3&:YVH6#H|T\$Z=V\$Q@%|/NM170T)&P.#M&FHP'(H%F")
|D7|?FO5|4JV#-=S(#|O+B+^8&_X#G ?X;7I ML?|88;TL/JE_&G|X^K3;^2|?;3N'^|S1;RVQ8V/-,E"?
Q;B&R>ZCMR%OFTP7;6I_#M Y8X? MHV\$?|N\$U_@&+|#"||U865U'EJL(=,9K%P3)WOO;N|DSYB(Y#RS;G&IN*4/A
MP6**= PD<|L;2Z/Z@L4;:BH-J5\$7\$"(QV3ID0BUZ^45(MO_O MG""?X*|L;DI';G3I;3;V6F;
(G"/>UBU6|YS22@*H?89Z!"F&?4LA MNYUE48^N1K06,<3>L(?RFOSY;
(RU_KOA|FY&V/SRV>LW\$&&6_+MO?Q|#R#N M:9/@+G?
E1JWH^Q^0%I<.0Q)WNS/LK:0F)'PU>=>Z>_6W1(PJ25,%TM_JQG-SUCQOB0;H3 M?O4#Y6K>I
I08Y>F3:6-16T.CC'BP_5519T)P|+PE>=>ZQ>?&5?S0I9W3 M3"FY#B\$;4)U*Y'4 MM@C|Q=RYG5J2=Q*H8==?
C%|;O9"G7U^/CS(ZWR@;:9&A;5 I*Z9D|4*4 M=\$A.16Y.AJL2&CZMF_62(<8H|>9)TJ666Y\$JS*2*/C;?
K4W*~;0AS^GVEID ?IT9XJ/_ MY|1/X? _&C| \$CK10*P"8F'\$;W M7V;AGY69?I?+K-^\$A47MI4DC\$8
;S:6+NNA;BKDC67B(*L|/K(NV|@,F.K>| MMZ%J?G6>? M;|_7)G'IX^#V=3WV-SO+;_R=L<)>2#|>2G'K*4POV=GW-
+LX)HGW;)GD/_ M-OV|_>E:9.L>'>F9DJ?X---O;ZG|9D)Z"ERRANN:U=Y89MSFC3\$2:3V
MLOY#H4,F46=MX|H6""%K_8"H@C)B;L8F_F(D ?PO6KFX5AIW-.NT#T^O);M@=*N|Y;S|??
AA"1IG?|HN))O%3_SB+8_F&W""9;K|OJMF<8*I">DU?|;: M*36\$\$.2_|+PVR7P>F.^_H5P@|F#%F63
ZC7>8E;Q>OBCAQ=;+X&83WR1<+D MD""^CMNR_H|<3EF7RS8|5N(8'E|U6=HX%P61;#/+0C1ANF<_3QWT^?
6X?GS ME3P5=Q)FEB5--(I7 T.)A|_ O9LHAZU/@C>HUI13ZE%\$@4F9-R)T/JY%5 MO_Y<=JW4&4AB|%
532;Z;4AG+|LVK MYD8+HQFA53+53A0C*N D^5I_-I;VXF7=04@5=0I"R|B,APCUH;VH3FT9EHL
MP|'6S%.BCTSTA|A7K&_+JRG\$;SR8|/*-#<|;BURGT";VC|>:2"TE<1T.D*BVU9|
M|PA;7K*U\$6LMT=W48W9#6Z'N5+%_R.)ED=#\$G(_VQ*V:O+V<?"M|+TK|W|R M|>#E=VJ9PY2=^PNRTK-W-
4<|P'&#+W_-|E+|V(^"WJNC@#"('F>3OC+SO7 M;*>DUF5P<450#|3H/RX1XVY9M+780BD"*U=*Y\$&X@E1G_&1L'-
"-2TGD)7% MU6;S>SEFV>XC&*8/&_!QB=9S+T;CH1H6F'O&' +O%9CGNA-M"5X0I.MX26*/H8S14RSR40 D
6AC3GL4Y)N7Z-U&A3|C,Z9J+)YR|D@95 M\$W5U,JR|9C_-LZ2\$%QY%76?0QJ4UBIAFOYQ_16X,X(I
(WYU;_IC5Z<M|PJE?THS31NO7S1T)749+_SC&_ELY=;PWBAB;GO.R_|<#;)0IU@&=;7=H MP<\$Z|0Q"SM?
FZ*^P>M;TG&JC^HC"6%\$Z|&)(D@1 M(I^O0CNGEYQ5G|ODOY|N';SD|_6735550DR_H<|NTP1_-T).6W>*|I7Q,DW
M7IC.PWN|*GIU5#E(;%2E|6H99WA7=9JC5^6W#0,IFDE0GVR MP\$Q<+DY&
A+D;5E=>^X(T:7*=&+H'MUG;_NU/63EM+F9|_8,C|8L>|M_HS ML/Z,WU<,(=(G MY|_O_8A;T/7S*H*&\$2-U35#'
^6+_1U:9NST(S?=_D^?ZUD2DRJ#7X_%5>QQ:S M*/WWF?_2F_PO80^=-FA?0 !K?R!=-|/AKNNI#IEL<(3I-D?
5S3%CN| W5OY58^E?42%/DTRO:U>>>J2-59I_R^P&*L@U|T@V;BSM;O;U;6; M#@N;@LN62_Y\$EK?0-UH<2-
WA|E4%QW_CR2C)*YGY*G9CX@AA2BC-Y_GWN MM8ZR>P|L3J6X.'WV9QWAIH5#D@H\$@DQ;+ZU.@_|I|CY9K?
+M.&L;VYL;TC M1&EQZW571^,"CHRK%C56H M'=+CLCP%M>H0LEL03I+KGNP&H;W3I^L7^46I K)
<"HCE)202-0P"C\$RT#;_M|_5RVZ=|T'|CS_-|B|VDTYK59SL;B;4R;74;_7*E'I?W@CW4MP|D)@
MD+I9P|L^HL%KZ6NUH+VCZZNCE;R.M103M63I9&%B.QSI9K>|INSYOH@?Z?WF M0?
EE@5G9ZC657=GLJ_ \$"YI9LOK?^_8*FE5S0WQJ'E+%)KB?_"G-O3-Z;|KM|/L%;L%M7J*Y4_<
@L(DY1/0&K'TB/'H;E;0IO;WCB)_276% MJ%AF8;XV-E-L*/REMPAHHS\$.T<=|H*OW+J=|'<2AN#)HQWU**W
15@N\$ M*SW_\$(M|)|2I+|TP\$IPV|N*?S=)WRE<_<|;B"(B-X|;7%CI2?8FS1\$M|JWY;7_7
MNYOG|=0004C@YRUDN&4 M+^1.&KL.U5&:%S|V %!HQP%*;"?FRW% ^G|JZRXE+|97;D3(C,^&P.WV8P;7Q853-
G M/BHUR%M%+2G;Y;531/;@EG?F%K3/J*0:5I02#33#9);@YNI/RT";1VZ;10H MFS|=3HC,3.P69|X#14_?
PR|>H%;K"GXY:8)B83Q53RHL719;649_/(4T MD.O|KGV+5U+EKQ%02A,30<+7FD &805QE!
16XQW73>K0|>|O+|BC9@R<%2 MSLVBA4H^VSRXO@_TD|@/H0#|U|H R6DKIU(S|H=%JN64@GPI'X'6&60Q'LL0
MH_/C;LED26L#E W2;G0X|6?;X&8!@ZD%-Y"/16R+;VYR9 M1=;QI3?7JX@SXXJCOU@+;UP;BC7IE34FI AEAN|N-
/H#%*C'QCUDWFLP=61 M'<&99'1U3-CXRGOS.^"O_D(4F D!"0CNF/_I7*Z M?)Y+D528K;^1L0_B-/G01#%(4YTN?
4&M;(^S(98W89276K-HH;|<1S_LNM\$LEU>R2ICDA+*A=?U#|?Z7>@TNYGE+6,V1=_; MP^/ M*#PB-/@/"%|HY
TVN+0&#=#SH910NM.A|GT.T&P/+L1H8*A_75?_M_S9P/-0:8C291+ MHT?@*BRL;6YT_V9=U@&X"+8|F42?3%-
/X96SK5H67|L M5/(-#|PD<_L67S8Y;6_M|+_-48C.OK^G|5>&7WM53KOS"ZFFV;_CA_V7OK.F.M+K-
_Q4+ZE/PO+8UX M6198C""^|H5J+R?09T^W.W36_9K|4R""S(SXXR;SPH "9G485^5I^K22)"K M:CTUT;"?
@CEBOIPA\$|SOOD,ESFE87=2TNELS3W6N_-|L\$?C8E M"9GD\$S_+|L&X|RV=|L?M);+|SF&P9WO_11^KOUM;2C9-
7E?0V"F9R0TG;_ MSPR_"<"LPF_2F*+V9_E31F*WL5"><950U2\$D87F9'U|F-OS_(0""S%TS|_M.KLBP5N=1RA?
I%8/B^+@|HU)L/*#M_|3;BE MQG(S*3J;#|9^L-1/DR09|1GE%AA61(5OC(MUK2|=08|L|JA_9@=Z#?
M*%6|4I9#*I2|QO";3%;0YGYXM|KMKJ#*8VO|217 MOO+^_EG;ZOY5&N,K5M,P|AN16\$C
9J0YV;I077G|S|LOB783VO*7&OD8" MHRZ(YEHVJ|8|7"1%|WS;+YQ)Y@M'Z;>BQ9Z\$%'&R/D>|YC;#|U|6M9X;TF
MA#KJ6JXDZ*H^%L.XN"=A#^BI79:B?T-ZF?K;RQ1,XRS VZU^",YV@%L M%|D|8500;_|J">

(%JM;F;.&0(Y;CJXK#)RE=P-6P^>M6@O;_SC>+37;=.7PA||NEQ4Q0=:%=ORL_0>BQON"SD M.7.MS%?
0X1;V>9Y8H?0)5-"ND1\%Z\2"TEPUIG9CGL^8Z6/M\$EQV!"M?;!ADU'0=D+^(OE?L.9&<\$Q_F3E;.;8L;[*TKU;
(8H@;_IALCXP(Y;_9Z%E)"WKIT5J;/MT6>Z810S)D
M@TD'LXR&78GBX=X7^DL;H5KW_9U75EJ+ #9.LU61N=U/6OZ805;={3;)_T_A;_M#%)'A4.%/,1R%&#;:AN60K>F
'&\$K;S=015S&^"JCSEH2DUFTFMNS+JT)@ (6.MP.F%040(I2*
(QP%5>3YF/WOD3KZ3W=+3WM;1_+FI(9/UTI99<>BZECO/I(S#_M-
Q)Z38;_!0C)"JCFD'6S'O\$QBWOPL>0B5S>BO2/I17!5U%ZF&8LV4Y6@HR-?
MPYGLI/ZM"#F*"\$O456Z%TQ\DI9I;F>:N5;6G"3/ &8A<4A@-0D8/^(?(-;T
M4F(I)JPXR(F.SXF)@NFA\GBL\R#-5CX6K>&L5DI--*#?N2?G^KY5^2=|*N+-
ML\$'T:Q&U1800XN3\WLV_+VP#^8\I\H-TER0#9IZXF8'DO&O)))<"L%/_B@_MHBKD-"K5&L^I'34>?
_ZMPJ6"R3Q?4SY;O9?ORRO^5I/?L\$Q_6FAG%;S9W
M36+7QG.%;B4<5YVKBAQN#'_O;_DF&DMGYN'PG26G;3\N=;15DV\A\HNP&K4\I_M-
3M!>6*W^=GO!_%/%_"10GAQ1S(%;"[K-#;P4G00LZN247?W_OIG@|DHV4M=MMI%UR;*DH/;P3=V-
TINBH44<_WK)+_@XC*Y@D\;D.<85XY9G=AN5WO^4X"X MR)GR&(_M.W=_0_9UG*W'E'0"!%R!S>5A3F6XIX?;_DW
#I+7/GN\JC^7;_7<JHV ME46;=+I\$>R9?U_S\$1IG+;V2Z)&Q..N;X'ZU*YW\Z903M-!JXZ9HY@N+8 YE
M72\3HJ4XF71+3=;Q-H&J#)"/7_4AWH""8F_?2LN#/#A5;_AKTWO6;A=C M+Y>V#V;67ZNJFO1+K>O&194B
M0GIRGT8GJ85;<0+X>"F4?_I+601DI" LAP-L;?C;(&C_9HSZE2L)(Z657_M4D*GU8!3\$B?UEFMVOD3R4QIF*)!C-K;?
UX;_IK5H_M9D-COU1+3+0M/N/^;?_AS'0_D_2JYQ&5UUKFZR&_ZXM"W&_?@DIWF MBJMU_M_#(W/>;YZ\$ "FZ?
P*VM<7_G;_2@5S\OS3QSU, V"Y'NW!;JOEQDIM.@2'QU MH\$E@;A'IOBGV#A#U^L\H\WP;P^>SVP(OQ;^VJ M;?
Z>X@150IRP&I84ESRHCF;G>8OXLB&5%G6YKOGBSQQT7R%YD<;LO>B5X=
M3GB;_ID5<0=P_JMC@J&,\$#^!98>F>3#@ (G109Q(>SR47\H0>*TT+JUL6O^M_M0W'X;:
T+2X9I'69;F0"7UFR>RWW=R>A?F(XRD)H-A)FN_ML\HJY5.C0>@0AQ_)<;PI;*V_L6U'D*[CHLXDDPY@I)"9Z+
(HRW;+H#9_-M7+9@RMO>G\5<0M\DY=D\2/Z?#I\W)J%JS"&S\8_%IT9UA\IS3\0D/QEU_M01^R""
<3Y6BS<&J%J'/?T=K)B\K4=DCGG0)'\$=!+X_M.+IPE0S_E;P7
MX;VS_C_D)DY\CUOZT.C0>M\OFOI6\Y.HYMW>9\Y8+V='JZX]=M#@UTRCI).PMS@3RC@0SY;VN9Z@%337IK&E\;
NZ4\5&9V=^=*MK12<&L>ESM1!_Q;_Q_5+PA8E<|7E'B\$12WN'='^[*=G2ME;RYJ=)G?TL/ MN.4.%";V8T:W"/I#
(<_H;_CYM9J\$/_R%&R^\$2L+I)YU\T3I7.W79\I;ISS#49R?#FP_M'@BXM\J3UH7G21XV^PVWB<^Z2F(O^3\OX?
2\D_F_/7B\J*9-B3LM%*=H\;_M1_H309V;3.CW\I;W=E^P3;_ID>5&S51=XRXY^/QJD%;C7WY4E\56E\Z8
M*#F<^"(V6%;18VQ%3%69>BNF56D41\$*XB)%Z7_AHU@>IP;H\H(8@04;G6A2_M'=#MD)F_%>L\((5L_"GU*V;!
(%)9\HMS\XBVIR"%9@UVAL;+3HV\$51U*_M6)3UE!_H>+TVK4@SS1TGV\I\W18;<<9OGKUEQ?
EHL%#^_)A^3XYI0_V3Y)4_M3O\4B<\$6^!#;_JV>IOU-WR43C@GH1^ZDQ_A')4?JE)&L6*TD6_MW_IC\?SM8#Z-
SL_T@FL2R;B@I_NKR56A2=T*DQ-7>2/M(K_2C%UK?@^>4_MTD A>2P=73(B4DB\2A-JYQC^_E*HVAV>)\N0-
XCR&&ZIN\N21U97&7FFZR8R5_M\TD>RQ>*B;T2Y=M)M#_QUH_H\K\I9;M-
TLKTTYXJHO(ULQITG_")'_%#H;_W0^QWR_MIF=^9P;5_MRO&OR-MUW23+K#F#"^>N\3_7
-43Q9HH";_P;RVL""=L_MO<#UCK;K#<S+H_7FH(40Z4HU^+I\Z-IS&IYJYWHJPZ_M;+Q<73;Z2V;NP/B;(57;VHB4?
W-HDQ\PYDV0LE\5*Q/#9_V=TN_*9L(=NC1OEH\PV*RXKX7K&O#9XL7U
MO_'U(GR\IX)_@2VUSH;W\$18?/ZJ/U>3.^LX^MS5.1'4Z'M_9(X#*V(#HV_M+?_0-
_BN=GQ_X#6HK0_2C;15WNFJMR\PY)6H>&LNE\3Z\I\LVH8.R;D8?_O_M_ OYPFG\$K\IXSYV\WW""701C\!)9PZ1-
C=...?QG?ZP_0=ZH7_CPYFD3+LSI_M"!11S/DE6I'4=9R4\$"4V=#P83V>V=K\IE9*U5&?<Q-3+!/3;KC6-FQLNE
MV\K?@IA;Z?W\>1A/6HW\QOB8=THE2L3\$^S6H;8\CU&9M71L2_OP\$*6(\$_M^CGH6J_RQOS/SF05_++VW\IVO.#?
F08B?#E;C-OPQYN=I'^-UDP<&_IRF" ME@RIX^_)D>ZLBAZ_%K\&D\&C(9BY_TLEF)'6B\SFW^;3;Z0I4VD\BIU
MSBF(AFA*6.96%J*#ZA6H?)*MC064M;'S"<54?J;@>C2E77JM1#Q^3#B\$K_MHHYE+A\IE#3I-
*Y'D;/_@9L+&QMSU9B_>HA=T>*E"N;14^0/V%1>FNNG_M5XQ5K\QQH\W)BUEF5%N;6EO\$%<#&LR2>IQ/X\I
I_=&FMU1R7\GH)0;Q;R8\$ _M08ER49U6HD_9WJ7\$3+0%1*+L;H51.8)@YY)E"&T_MZ9QI9%Y454D_V#"=B_8?
\$C19"9;9DS2WYOK;_20VOIHK'C&N@B;_?9_3DI_MEAU8'\$.U\$TA1\$1?_X3>@RL=+G%PSC\O0;_UM\HH3>HP
5(26<6K\IF;L_P3;_M'6GQ;7(3ET+YDI>;Y>7^O=7;B6KBD\JP#B6A;_L;SBK<;YMS5ZG_WSM_M'6X;
I++_0H9+I""?>5MR;2I2WK\DCM<=M"SU0@A&YQPN22-<%\$YR_A@)MS_M0I0"3Q/F;2H^<@"5IZO7W-
F&*XD)!_#N0;W(&B@;I/G\BV9*I_MJL2W^B-9;UQ>#K#J\$ _&/(N3_-T6H;&#%8YK_I?XKN4GXKQ_#T%!
M#'^@;Y#_R\I^7Q?V5_M-WVHTD8'/1(8S;>>YBLC0_4!LB">LKI_C%CG;_MRN;_6.0L_80NS)I^Z^\$/P*\$?
910'TIRL;D\T#9_Y2PX;>26X\I^Q7!6L+M\WQ1A3GL;G3+)=09&JK4IB&SI9)=N
M@S9I24G8\W8MV_1P82#IL/I#M;4%IV2>_P46T<9!;G=FZ>K6>*I_5H\>WO&_MM;'H4<"9W\;X(3\39\$@'WFC;O^?
E0H0TJC;5N+FU8JK\$RE;_N\KKQIS4V#_M9.YDL<^W\IF0?8"R.WU7ZH2P7BJQC8W\A_D^IV?
H*#1"L3J@^7>%P05P%7_M>*7/V&"SDD9;ZB!1.QPC9DJ%ZD805<4\1!BMY=NE'W\I)W0N&.CT;6Q;@2OWX\6;H'
M**/_I4GB3+X1H\$'&KQB+YE6PIMZUFK"+P#K%02Q\$LYW;9Y9'L;_%;P.6.^_M97/J<;D8C6S;
I64PA69;Z/U92_!R7!E;9_T01<+JFQFK_IY0CU&D(2@3LI7_ML%-(HTKQ?+*H0)#ZT+=3?%"?J;^?
DVJR_EV'B3>CXLB+0>S8BX_Y7B5(I_M?
RI&G\$KST5M;M;H\PIYV_MIOSNNX;_T3>6^A\55G>M&=S;CKB%ZVCW_Q;I
MIZ>Z*1XN4T>7%#*MTI';85>8\4HMPR9IP3YIC.P;Q'#D<9\^9\$(*V4%2\$ _M*TIJ=#;_@VCO
>3OB71C\9\$9!O;_K;G>@>60^36LGBG\#6@NIK(&%!)0;_I_M!&S63_7M=(5Z#;_S8C\F%NUMBG.B-
J1.I\ISHH8CK\&CK1CO98>\KX'-0H
M\;+4H@;@JB3HR.@S\F6"@M;/_I2+K@_UI200*&/>#>AU4#BJOEZ%;_H\4VI
MO%ZH7LZJF\$J\I'V8\>JBB0IKE\QW%5F7'2UYQFM2;O5\NW&^D@/_MGYUP6A%|*9>|B'^.S**OC9&1!=)3Y
/ZGFO/WU1C\9+&QAMN&\NF(Y#;C.OX_MAD10*_IM+@M/5P*2EF<"JSR;GF-F6K8CSK9V2%9(I\T\7;I#_?A;_CGVDD
M7#/3MX*|1^/J9*98!3XL?QY%>NA3@=^EUD00;F=@BH\9_-F.C^T\Z(KT_M7W8\I_P;FKL#;_Q'(ZV+2JT&B\<;?
RZ\H-XW?G48<&83M=8UEA\9R4P^W' MIEK;FK\JR\4X;I\I_KDN(^FAYP4&)EE\A7;_P&#%=V;<;
<(L""H\BV+*9Q05^<^C;TL9Q*7IUM=K%G+I_M>G5T<L@86;/_I^_@A;9) 5I0;1IR=0CRC(G=2P>L-
1(W"OD@FJU';95E4_M=Z8@2KG\6IOU_'O&\$Y#@@|3P?PG\$C;I><MRC&_E8NS"IF_3G;9;RY\MG-Q
U2"11T1GQ#GJXY>=K.G;88?F2HJAZ\I_P*7J\+;I&VEMBW-EK_MC;UIWRF?P=L'6*NV*#?>67Y;77U*KN
T1_ZZL%0'E;9;G\9?<8HHWN^0IE_M;I2I8'I'/_#;JBCB?P)7>?D.@;+/?9%PH(6G'O4XZ3JZ;_&V;?
>Q#'_AC@Q@?;T\7L2W\$;4_M-6\I9@F2G;+;X\Y=;IA#Y>;N^I2;*SF)SI?QO\!+@^>*CY3SKE2_DVF"8_M>-
>8\YR^IV=I\TU)"3_P(4E&_ARK_WT=V1Y7EI42=DYN?G.E&Y>)73WD#>=M_M72T5R"!34;9SM\$ _JU7WYF(T?OFEQ?
9JTSHQ_I+&E\HBI?<6;D*6?7WJ23T'L"A\$""/IG?KUCW/_^MX\XQICD?
UOZ2DYQUESS<IO98^UZ.MTPRP=VBKK*W&B*3F=5A_I%G+XG;_M-9+"6
3I;3U#&1;_SIH8%_9%=;3K;_&F>X;_S98-Q'/J*8KJ7_KJO7;EX_M_L5\5I-)=9#L;S5T7?
QS\CX8"CDHH@^5H<@46_L9JLT\1.3O9;ZEH_B_M#AP\YI*P59)9_DX_IB&LV(+PT_4>0ZI-'6D2>>?V*
(6A\A/G@))YCUNKA+_M=QYGVH\HUK1U-7_!-
JXK9'R&M+L\T;XN4RT83FUO')6S(3*JNYM.&IMP26PD7K;_XG;="KJE"G8DJ\I'(X);<%UKS?S>2UD;
M55_6N;_J1F;VA28%=AZ6);_!_YY(QZ^_VP37@I5WIQRS"65H1*?Q&N<H

M1HIV7:\$>FK<58R"RZE.U/C)F VM400QE\H5#I<8'\$8.4SG%-@W>?D)K= MF 3)WMIH\$O&S/Y\$1-
K\$PP^U5OIO.,>= M4\XA(8(S!2B^%QU7(A '8>6'E9P"6:WYN)CJHH&IVF4)IO: ^:N84K&XBLJ
M\$S_OA.\$?!V"!L.#)OZ_)PF&!*R.AA.:G7FZ#48!.^@@V:4+CJXCX-Y#IEL)>
MDO+EX6/XSP&_4&YBW9'3.G%'GAKW?3.EVFE\$W?C/H/T<9-\$NW%J3D+YN MD+@8CP@GS&Df6X7-
*03%Q>5I3 8EIO2'.E\@ E=>62Y.=202%XMJH8\$H<MYM>1"33L5KP7HEXf#G18P8>0L5#1A0FIV%9/5-Z-"
(9B5F<"D?K (*^*)* MTM7f)\7:(WM*M(BL(N7!3%FEYKM>.76 GOY U L9 ?I5A62:@R7Xl+&I>I MM=-
M)Z="9YTR%JDWDZIB?Q'1JU?-KWW"M3@ZN^9&:KTF"-EOMXOIOI M?;)R(6=7?FGf75B:K:U>||?636JAD1T,5T-
NF*Q7P)&&=C-6#6.1KA@9C ML?)M5R5&!* 614N\N#6=&K;M\$IOI\UYE5T?>X.<>% 4>\$.S+=XPV0?VO*Y
M2LC/F*L"O/C35D8X8!J2TPXLF@ (02E\#Ff)>E=3A:W*EOI7VIQ\$#IC5Y&L(M&5"-UFQWRSX:SNL_ ^E!D#F>
<\$<"HY?)RZ8SI\$444 9LM=4I7/WVfZ?B<5.Z MOYf\$BVI7Z(""/7TUT/B8'S92I1A!_07ZFM R*&
(. \$Y>O&_T3I0H6UK-" MJE*3JL77UC#JG&*, MB=| M4"Y-*8.BZQ3V9*9F\$Y1M?
RYYVG:LS*7V\BT1#JCK&*V(7+DQ\$=JfE% MEKPVfS'O&Q"PGO7VfE:=Kl.VfEBP%? X "\$.\$)T<% " B?
E>V\KG:4?I2V MC&G8JfZ+'#%+\$C_H(M3M=\$PEFKMOFL).T35 DGD)Z^T=XAI00#@Z#4NF(1
MMPMWYfCfJ7f!|*7BQ>5MCSf/*#7I7)HWWfL\$8U3.+TCI7>R>\$&L>4@#\$*"O M>J5C4:Xf*4\$CZ'-D:HTN M@/2-
P&S5L.5X#_ /QIU5f#6f7GfHCGfH"Y.Q/3W-W;P_T:4OVP/Q2%:&B Mf@8@),? R37@%DSQK.O\++K"*3f
HVfIWL%@D%+<)M)X7B6DCP4R*M?1UYGQ
M.1.T:X=+C^G)\$#OFO%LY>I(2R?R:7"3G_2Wf_T.L7MPBE&..ZP_%L)-KNf MM*W_?
GOO'UI>|. \$V@'TP"P"#>3)E\^/\ JE*5DA6K.0\$OS\HN5.)Q%V78@DF MN-Y.7Z^J3M9%V5MF\$*:8^PDfKOZR5?
%3JR(2.6/PUDOEFG=WC9JW\$R8 M>^;M>;RGV01(&3LF?3EA!'9f30"^5H2f+C#G"1D'J-O"B@C>WK_ V:8LK
M=:@fWYfEA"35JHU5W?2C Q>=E5UHPU\$R*6G3:~OC5A(\$+05N6Z0E/QPC
M(IBAWOC)#.'2Sf&_K KPN9USOCO6 MM+<-5C.O5_H_@.OEf7 *5DUDC>_+782>S"Q-
fHBH3P^3#AGR5K=\$1A7FN M_<=SFG 5N@:fT7A_"&f*M=|*"1YYPAWFAJK:f KS?F:V1),=#2TS"MN&
M;ZY5<35V_ ^@ (XWf>R"Q0L*\$EFf);<(Q72f+L:COQ5^69F@Y^+Y+0Cf&8M M>+7>\$%3AVf>
90*+J0F")JZ0(+1.XM#VXf+K_.3/&NfD6ARNVA)U)G%L_ M7PS@F73fEG=A2*U_9<3D.f: @X2Hf
H^K/?f4M55&L3HL7f B+PD)fTLTA_/@ MILZZfLA@4\$.L(7*9?@'ONNB&CfP1GSUCR8)\$KU1M6_16P?
V%#3JfG0B"N1 MRf;C=:L4fJR 4>>B\$M+SO*Zf6.*X37N+fJQ7?NCR.<:(U2f@=)HDI?/"
M)B>L3"7Q&f/=M:Q7C59M+f/@10XfZVfHfHG%9>*?SW7<3(F*E\VT3;L)
MPAfH=,D:B5Gf4E3%Of^M0Cf+1)\$fE*XLR"\$RfJ:W#+HXW9.65O#ZY4f.L+ M=XfV6<,ZW&0YZ
MTfQ>.LT6>:QJZP/VDO^D)6"4@HZ5DMGC&G Y.MY7"*2)0fM^ T\$ KfZRX2MZ M.O_(C#O&@K\$FX#E&U RE?
1+&N>f8B^&CWJOYP&Z>1fV3fGB-ID'J:0FKfH?%3H?&'P60SM/(M"Z:\$&Q_ %3KGU,XfW3;CfR
5#Y:BOA)^JE*.2)7'C5"J4OOSR&MfH\$QfGC M#S_P06Q(Uf
f(9f62\$3fQ03JGf4JM2*FM)*PQ%0VA6fAY0f:10YHfCDfATUf- MY3fMG
@^f.0T99+@)ZfH64\$OVJTO!\$f5*f22.V7fTM9_R:..0H.O 2W#XM/- M#O_SSYCC=B:"PF3=
(9O#EU:\$f3'\$>V=3LND_AfCO4M5JfPGfHfUK&f*^N MO6+%A MVMFCVfA\X_@ "D:~_.5<).7P2)M8?
G#:\$f"FO5Df0QB3=E:Yf128&LFJ2Z:P4:6MZ(NJY@_Y*0&?CYV2_M2f\$-UM0M%7A>f/=4 @:9)KW6W:f)7.CW8SA
fW+ "T(MfG7 f-7'\$2fN-B MD&YXM>GfD)T*f.&=Pf"ZHHVVU 7NC:E4S.PWX\$8LY_Y@fJfL(6X7'S>25
MU_,+85HLO_ER3-12JVO5XF9"W"DC+N6/T'DR*2GE=*JNf"ZDE,fKT&7fOT// M<K@C4(=\$V f79ET+:T9_XGZ&
(CV2&OMP&DWWMI4WJ(^Nf MG<105D7HRC0^A'\$398_@<\$0f;CDAC&%1,DU>3VO FP/?6fFY@W5K8Sf!@f f
M>"XCJ=M5f\$TYf\$>T9?F'ORE?2Y8fTUU3fX84+Xf3fQA 37>:~4UV3fXfHR MEWTES/35Q-
^8.W"-42D_FMDM@SF_Z+RXfQfEf^U\$ _fB\$2+:%XPfB7&Gf@7S* MWVYf+^#f\$10AWUQ(PN7/f5f1,N"N
4\$%fVZ+;#M+LJ:@fJON..5P(EK\$Y_Y8 M-O: GWf"VfVf:5B/Kf6Pf!T<f49(P>+NN8,f8U+)TSRHNTfTXUV&/'=E9 f#
MYD64"0\$+1:FR.20JE:(Q5#30f.0HM0%6MG/G2S44TAYC AU.B>+fY3-GYfOBCU>XJ?>fGfS3)-f/*_* U3A 402
M.4."O:XVXL?K.9XW(OWL_2H+))fZ M3ZfE3DMX8ES)WVQ>?
O#CVL":3XG0NT72f"M@00A#X.NZD^3LUP39_2)>4. Mf5NJC">M&:/fL.K8:M(P'EXRELf
JfT:f1BN/0Q9X@f9\$<2+^C'K9 C+TXf; ML0G=&Z fJLOfOA5=:4NZ5W/64/(0TB3fN)f^f &HL6JU72::T:1XGY5O\$?
ZfH@f@fY7WKW>A48-\$23F5:R)QE8+G4>5:Xf^3Z?_1H#f1XMfEN MfJZK "8#ALR_K.D.WK\$8#@Wf9)fL
MMZN%22U3=&2fKE)@_D^M6@TF_@KN'FDf25+QfE:PR9fA^5.%B.>WYf:"fFO0A^6TC\$#&3Hf+
(84&.'1)RHfJKfK\$<:52ESf.O M 4)P%RR9f:1f&fWEf)UGTNW18%+>A&7P/NfO*5f^0fL:f.#DfL2DBVf+LZR MQ#-
%_+f"DC>>G'&_Y9OfM_1G^9RLT4KS>H"96)_7UA)GCfI(MfKfL>:D MFZ/_XXDY2@f^f.XG#SGQ?&1OPfH^AQ:~
M T1Q0%U5f18("HfD)PCNfYf Mf2FI=Xf1"ZfL-GL4f<8"5F-5445VGU:fWN-WRC.R9fR'&DfL_V M47W2J29-
)Q34fL: <#5@7B+C72825?EDW+O3DMfJ=R5fJ?"fR2^+OTQC2-/23 M6M8D:fLA><0G8f3V2Z26?B^O.fAK29V
&fIAZWf+UG8 M*?8K.3=HfE5P6>"1@5&JZ:47^7fFY@8.?K^BfL-XM>PVNR@27fRO_PMQBQ MN^:
(.:6O)XXf("VFfN:HNN DB(NfWf5"8E4TCf.+fSQ1'PPU3_>5X?G"&GLf M>"5.#Wf/*fD54&f!&=QCFT#&=W_=6fFL)/C-
M\$>fH9Y6/\$fF_O:4@DOU>fO M</_=^H^@8AHLfIOW7Uf/f+N\$W NCM'fPC.%EP@7fJR8fLTC8(fGS^f:R QZf 4:VDf
MfL7^MNfUXFH:Z#R_A\$1X2'Q8-6(?C63f\$+:f05U":6'\$6(^f#GV_)>3T= M&LYWAf10fJ.?
+/5"M5S5>f fZR.OfWO&VY?=_\$^6#_A X<3&f?fM)=C*X_Ef@ M<.HAS&_K4f%O.NQ+*fK\$!
(S32?f0f1*DP8Nf_W04#fJQ5 M_>@f?f.fu=6'N>f3. (MAAHLXT'SfJBARf1.#X59GP9B7=4.)9RH7P_:C-4 M60Q_2"-
CQ#NMN\$AefFIR?Z"-_0f!#*fNRP7:7M..=f\$ /K5U3R6ZY:3B2N+5 MS,CABS:G93QATf_'D7)%-
2M=7@f/NOFX"VDL:)X6A.fX9fF#>2?FZW25D MT:9AfO70-
Df#NL5fP.G8VNS>3ZZJfK2Q@Hf+HfB5RWP6M3=P=:fU_*fK==Z\$ _L
M+M^%#\$T'0:2>B=^3F\$_)#C?..S:./>8U(f<12Jf0Q;E)"O59;WE+fF'R'G MH>S+)KNZ'QP_@fG'##f#fD)E^T:~
>VXW+6 DFP?MfH_4U8/4N98^f15:).95E MB/L2PM-2ZMSf+ fA:PH5TM=4<:LL6= _MA:H'F\$FF^&*0/M3
MD^f(=f"=5LS>""%?<>'2"/50TRSXU&^Q=/_^.(X>fFF?86+E<fW?&fP'fP.f M4DV#*+WMBO"2)LD&
(>B#f+Y:"HfRJBBQf4)P06S8G'ES8L?f!f*5KG)1WM M.O.ZM8CVR:6*XD-fJD"9&Lf10RWf
f7BBM\$SD6f":.095\$^X:)=AQ=8G.NK6@3D:~?_5) M9\$ZGO?R5KfJCSO9F:RfH4ZQ_M%TTDf5O:Hf-ATf.\$fE=
f^>:fH35/XC?24COASD7f&#@fB9U L=UK XXfL.MVXZf13EORG"D*L/N.>&#Q95f
M:~2_W0/4CC=SO:973V<fW%N88 f%FWf M\$LfDPK)0fOBL=E*Z/f=X^_WfL63:fI?3%4_7_O#%=Q.fLX%7
M<2QSF&EQ+5_W0/9fIB9+;SC?>Z/26D)9\$R)fT4T5Q-N8JE.V#B@E)fL4Z\$Q'O MQ5#fVfAU*>3?
1%_fE&NfJfKfL.O.RK6:OW6X.U"YD-fB^WfL(f&:fUf9EW4+fL MG@:B:N\$=T9RMGOS)EV70^f3.
MCZ^""U.XXfWfQ'ZfT+f5HfBf5f15.0fWXf1 MN9F.R9T>HR(GT(ASf6fGEf0f5_10?AIBf90XfD0G24(+68T<%M7f-
7+^Bf3BY2_OUJ&8f&_M0QTN&U<6:8>ZXV_)(BHfN6K^D&fL=R?F'MWf_WK)YBVf1Q_18-Q&_P:KACf
M.WS99>8U@?<?KNfJ5K&?U?ON0FP_>\$>fFNQf@CENW6fOIfU?&325)f\$B* _Mf1:N%#(KGf5LEY4f^0)3 JB
XO7W+>fX+f5ZDN7f&L6FFY*H025;fA^B9" M*MR "K9L.0K.5X2WZf&@fJf9-fJ24M7(AVUA29RQ:~+&L:X^<-
f5J35fHf\$AfH MLf%_:LZ>V4" G*DVVBf%<D<39C8-RD_AEV3R2;Y.9K_.\$KGLfH+84fF'3\$ MA+
QGWNHU^>.=Hf1\$S4&_XN%_E^fCH3Z%IK(9?*_MK+IH*"MLPXfBYZ,2(R+ MKWY:fTA:fX'TO("5%C'&_M+M
Bf"7V+%B@:LfL^WQS/f14LQ94XfW.#54P+U M<#:\$>4.D\$LfOUPf#&fC#D%Gf@_7C_..fU>?KR:DJ86,HLC:AE?
#YAf=-N M.&KTUHYQ&UCC9U<1G\$&QTVL:4G M&UTRf1324U>%f4C")f3fF*B43AW.+6Y H5:3QR7P=f-
f4fXN>\$f1.O M:Y^HfS8ZTPfX&>H05_AN+fHfJ9L_Tf14>HE>_BVO><:P.Q^2*4++801N>TSG3^2F@)_8C0R MKSAG<

F@>M4L5(Q\1D)95? TZ3XOFPI<SAK*.X'E'. W\HJ_5"(H>W
M+,4VCA3'3J&R>'CKO97V5'';+Z*K7GL+,*%>QI=S2>-EB ?EI6F8 Z MI'57M8*POL:FIW@_X_0&R5N
/9!U_FYJ2,00/HI>0\$'9S7&@2I97_?2EP"1&E^H5W.RC5NS' MJ#79
L:V%LMA(J:'S:WGY40^+Q=L0QN7DI>95JFQB-1'AFI_YIH?P.MR'A MI6F#I*IG/(N4A-R=I"@V77H";CVX;
/G:~B':ZL:YD2B1TY#<'I&Q=9QV4D M+&=WH,1R#?_%;=,,"\$,HQ+9GB\A=N)-I:P:CFYT2;D.FV2\$;/E%\$=667\44Z
M4-UJB_#0+3.3DTPSH=I\$ASY2JQ/=-MODW/NE;2(*1%4R9V>K^_H^JAM=(^U%O-
YIGW4JJ1I905KV"!SEKU%ZBH'B)+_MG^N5V!\$&N OV./_""9ET8S-""\$OCZ%QD+5^FZD== #'PDSL<+'6QIR:~3K
M7_#6?HKJ*X9WYH0X%9Q9%K+7V#1^#7@+O-6\NV5YION'J8H_3KN)<=K9I_M.IUG4:4 LPN^8L-
#+2X+0=X8B*E&W>1)NLR\Q@7)3)QPSH"N(&1"F85+U(#1 M75^C55"N\$88"&7\$K6-WUQO%RSXA
*4U4N=+GT>P#>&A->>A'I^N'V)H0I3:>T/B5S\#DE1K MK92K+J)EMFL"A-H'+N2"E=)\I?Q:X:PN:J^8+I/8I5L:
ML>T1^#/1B@'7:~#W!_X\$P_Z,QI_JJC9A#B:VN?>V4MI/0B?J6Z8N;=:U)@ M\$.)S#FP:XBK"=K8?;H:~?
IUVR'5H@EURKICE/4VQI_U\$!=FR:2CC@Z4+GMJO=1C77NLL5X=88 Y MC7L4V:9J.21X%%-^F6C9NM^URL?
\$W7G2MYUH:6%GA\7LEL^?"2DE6*V(K31 MI<"ESB)C\$V3N9?3I@3W1\$=OYBDZ_3_L/W\H7:S-R3ZY-
E\$N6D%0/16*&^_I\AFC7"W0:16Q@_D>Q52:P6#R+_D)_MP(I#7#>1NIHEH7X "I^X1.*G6SR2N-
&%&KE#DUP56KGF?_I#Z+&KI94&/ M(T_21D)+;BJ\ID#\$^C-*D\H,<88?A\I_R_4P\I%_,,RNW
M1P(VI">'2.NI2'346XS08F>_2AU) @^'&XT'P=
M%2->M:~I&YJK0=16Y(VO2&RAM:HHB>SOHMH2#V\KB:LR)#XH6^DN4Z\HJ^G-\$=4PF?L*
MG(^8\HTWW_CO3G^NFARS:&WHZ/ MX\WA70M/M:/E%-(YW+U!G4?59&*%*G/@L<+;:\$W^ONLP6)6C=?
\$8EIQDQ>+X2*3T+76\$3.3F?_U3@HED MNKI@IDOC:;H)@<=GB\4NRM;HV)K@>CBP288XYH(*E=8G_!
I.PQK4QX+_1+MYCFL&84IB(XEQYJ^UEHT+I\A5JZR*%;%6M\JNECKW*_XP3L_TF62RH*+,P
MQ@>:3ASG2YD\$S2JHWE0%65+C.XKPEI-W4H\$51O.L.T7F>\$;>BWOP@VD6_P8 MMCVKP\$EW=I\HAHJVU+)-
IQ2A\04WUO6<@?3:5"2L2\))I*~.88+%(SN7V2OJ_MIO7>DJ:DXSEW3G=>YX>K<@RT_*IU)>:UXU2?
#3N!%+R7N4BZD974.,#3BDI_M_^^3E;@O*IPR2L.*T=\$DG0+9T2\$CY.Z2%;,~#D;)X(N&OQZ*=DPP_VF&2A
M2_I\AQZ0Z0!"FS,3G5F\YI.8E\H.6:I*D,UAXS?KIS?V7L*ISO-Z>:H=G? M)'OR IKTB)0Z+:/FDGN8DLZ?
4KZLQOQYWC3JW*=S=I09V?/B>NRRRXGOW(K-MAK37LVKYFD? '\$G:(JCG5&VY<=,O.C8I+VVZCG/B\I??)
(;\$JZK_VUZF\4N.GR M7&CLO-EMZ\JCZW?&FF_N<3^10Z"?V:MZ: J:02T)34B77%#+KVK5-DZ_%#C3 MO4\$2M7:R-?
^J*O;^O=2WUK"FJYWHTOCWEOP^@RF^I<@7^1VP9%*B=D>C9@3R;@72I"*)SA/S?<(7K>T5Z7'A(.^I
%EBU\OZO'405S_MR%X0=QUNS(SVKX_~23UTX6J+=O)2PT/67Q@*UVS+)E_\$W/;>NP-M?V-3^C15SHR?GDZ_I⁻
WO:~1%W6T3\@-,#0L_~ICWK.EQC+%4T0%XF*+L/= M6C;%GJ8!XQSO?
6&:WV&^O25!,B^2E%W\,8V1321=H4"7TFWW7:/PI_P9 MG%*X6ZO'A>I\$YH3(OPF\$?KJ^F^)6LA5VI-
475#%I\SOA\I\U2X7GYVX\HG^HD M/7*9M@Z0E.PI:~#+T#@Y9?HV7L&8Y#_PMC@:_U\G/L:*D>?GG#C\A&:%
M)8R1H+MB#Q+/O6.XYZI&= _D/=N1\IV:>"352(OPIQ-4?<)K%'S4I?#;O"%-D MNT%=%4S)I=V%^MXUP
%+.&.>.6W:~W\#&@EILM&/I6?B\^IY)D?8R1RDHXK*L MX>JN=V+C-2#FTV4#&_P4=G\$-
+D&6+8KR2IVPOVI@)\$6.O@8='M8.TUM?DV M&_553(FYE:K\97%I_1?C:A,S#>L'GPK_A/8TI0E?:@LTC-IU_9B>L:~
(9P_M4*.83F+=O*P\$3F1\NNR7F<_UX&/3>HQ(H,H,7L>YM\$Q_9UT+;_90;>W&*H= ML_FVHM*ERI&CF;\$I?;"
(;DEI/S)W/Z<=3W(CY\$MENHB/9I%\$XW\$'8F,@ M&^I+GNZ+D2-4'XIBE*>6I>V.W*^L3L/RZU_P\EMD?
63+;O.>>1748D5FK M'X)L9S"!6?7X45X#H-I6S6DW V2,>3>Z3I>89S:I\NJMOHN\$9I!1'Q'-AEGY M 1+-A;14P)P%0
C/"WZI!7OM"X3+3;MI9L?EQO*6'/6S"C7QWL.HKB=U%B>8 M8RM,&W%!\1\$=\$HRD0T^SFUJ7/0:4.26_-E)3"1)+?
X1@_D%I6ZTHU ("N MT?2935&MO\XTAZ1J?<-4W?R.IT&*U+;I4Y9("5HUJ=L:3#U\,8CE1FH
MR=D7I%\$KY#!NV;4.VTBA1S>#B^AY*+>)?L=:#^Q"^\I-1-L%8Q*K:38#I%/5)(;OHLCA\N.M;9)LXCK^)<11V
BO%F^I&V#P4LV<)'96_/W<=)+9H%:~O0@4H/IYKCY*\$%I\BQ+W<I\A7\$KEJ4%12Z%/KD3&/8B^I
M90/QVRO1("856E")_H#F3\$5T&LVZ;~J\B81E6A M,8+LWM9"#)T0A_R/40DXU\$0
/H@;T(T%Q)V+=4HQCS(=LA&I4FH03&>^W% M%<=>XE#&@D>HQ%:~I.F2%>RL0S:50L8?)"B ZE?
FO2.%G*^_AUD;Z2,)X MTYUP^2G &R;!S'YU,(+G\$3.3I28F*);H%(=HC0-M0U)""I?3F%F36ZBX, MYUY\OC57-
>I_X1WW#ZMSMY)0Q7B,%D?CT@,@,Z&"J42YLU5G;GIN0=<")_I
M1=S*1*XAYZ\3GK(^S_I@4_Q+A=Z8\$I.ER:HP3>209;GMKIY:SKH;GM2+-D@0.GT*A_I9'I M9RI0&JB53T,
<,>W13U2^I;~J\P'D"?G8AW\IN^F099%~^M_U/;CT^T5SL MR5!PW:/XV)WRN5C9#N;M8;H\K#-<)
(KW'=6H\MC.NBG-M52P_M\6VQ:KW+_I=77;@^AAGKG>TNB1WBH
MEM2YI=CD@~I,YJ4LUK&^;^F@""ETH/H5T)X#6+%;G\ MNE2P9QBRH&M ?=L-
YU+8\$F:6?2IX#ZO_95@_UL"68\3*#>6V\NQWP+6A+I M%\$TM:P>29&B(-H\XE-9W4UJ6;TK1&*CSS(N\OP0>XJ?
YH^P681N\IF=9LGE MP\$4CS;4WI*~L,BE:YRA7_I-G&SVL;G)B'+MR>3KHWN\IK2^IQB_E?I?M*~. MI%UT.I?
=HZ#Z)I!;K\$JU=AGF/YOFU_A#P;G)R;,@_B\$>X MB^YV>A'I'N;,%I8IA.^KI
6F,ZW\0T%I\BA*IPZ25J9JC5I#>YJ#*SR_I3I6S M-I'2X(H!"*Q
4&4/BME\8X&19H"WCHJG;X\I:~%IN_#Z0BUP#S0EP/MFB5+I+-(D\$%3UO6CZ.%&V+;&<'<
BU/UB>ZYR/Y>"^IW?E0_D<~WBX;20*" M/'HE,,^~1L@_?X7BF5>6:M M4 "R%)8Z8GC39VG^NFK'IWQE5*
<%LQ_,L>9 M:E4XZ8;I7^DN^7>BH\2TCPR@;_I\$Q;?7.(=*^05H^'OONDL_HC8\=C=9H M>NH>_~Q\$-GF:#I-
D@0FWIV^S/=VQ)WMG6'=I8\$E1AE7'=~#2T,IW)HY8/
M_ZXRCM:A_DI=T_8&E78H3^XE:3&N_#V8,VX\$I_C;I\NCB;+;\$LOL7V_-MI4=-
JTV\J+ZG">I(C\$~L>~ME:ANU&9U)U%0A9;>>3XQF@EZDYFEY,HR3H>OMKA1XXPQJZH1.K MXX;H
<0ZR>X%*3*AO),Y(CYHQU.D4M*UQ\OWZ/IQ_7H\I?>M>R5XHKTW
M)B03&I\$'LF^_H"AMFX:~G66I38BH/X,49#>.%=8F M%=~KA2G@5&3+U>(O.Z5?T\I R+?P?F)WIXV1=#Q>
H8G6XEUR<&69\$C\BC," MMS'A\$@M#1.KAQEX_NUY50K-)J1A)H?2C+0VWK)D)T^~WF, M\X/D/J,+6V:DC.J0
*_I8IVZ:(/ZIZLOBK?IY&ERKK!_"I\2A9@T_~(M@_T5>7*G+T,#CC,?
8WIQ=PM6OF@MKJQUE!"84&=JF5%T122R)!\$S7K'\$^V> M_%I=@F@U\P.ZLY=9=Z:6EV&(BW?
DBQ3G>LB_9AWSS=#,I/2%7<7Q0W<3;G6QW.PU\$=_TZ;=)A+?&I
MU8I+^EAC2\$GYU\I7QPS(8A_97!!WEFPI=ADRI\5 FW;V#VX,@CTH)I?57 MI^J)KOZQF*Q76G_2>%8=R\FX*;Z/F-
9<)_%*1E9XN9SIS;C?&&J";N<&G M3)Y5'?=O?YHSUBJ_.S1N&#!1X?F0L"Y(-IGQI^<6^~IMT>#7^I,KOI%Z(
M0ONXNZ=I04SHCMN+~U9WZR5/WX"JYJR/ M^%\$4)95^?WNZIN&(\$/L0"B-AR^?9YU%?
_I\I\N/I_H:V=JHN@)M;~?#UY M"/DI3^F^+~#VU4,+PIN)5314_6)RS:E19-UDFI;"@IX4G59QJ(O7-
_I\XKNJ>9IN36(C@UO:3>~W%C'VO-KU2)VW&C@@30 MV;~\$6 OD7%A\99!U\AW^B#\$J= KI'7HI!%4D1 MF4-
I^~(EN^>NLK.W+~\$1'ZJ@JRM\$VH+IDCTBQ<+OK&@1\I(6GD\$7:Q3 M.^8&)2FW,T1&3\CHME?2AM@F\I-
IS=I;~E# MD2^I*BKG80U0%;I=H^G^KQBC??2H2>=B(MMH,LMG^K1V,QW4I/I\B4IV;5@=L%\$B(5FLKN4T?0B-
_Y0@_Q.MI@_Y.U\I^4%;~CO/KH?2 M^N&K&G"Z\$6YBU+J^VR+K4=)PGM^IUL
+XE_5DML5LW=7%Z;2HI=S4Q6^_V8%I)V/DUP&P2I-DN M!Q\G/*5V>5IKV'ZORI#@U%>;=HEZ8:&R_VXF\JB1R?
>^~P HSU^I;5"+I M.T)M1^T\J/F*F1_\$L;CW?V&:3+;0#>V.?(13I3I6=;~GK)?BAXL^C;O, MC/BK
1>TBCIPIXS26?Q0Y;\$Y<>H/I-8_HAU;A#H%R&*BV'M,I-LJLARF MY3<2G&6?^Q0LY*/H803C*~IBV?
I5(#W\YO>*YEA-Y0.2W@I#F?_US;~89G M<+7(IGL\W6T'SI2,(C45.2&J^_ZN+MLF#6*~HC=B'SEI-
~BW\$%)WM/U\+I4\#~*~\$SIH(CCUT=+'8(C_A0S0C9+\$,(QAIKA>H^U+&V^F-KR4A? MKI\AWK1-UY%?

#G@RIT@;GGF/IW-NYD0-(f@?/1#W18#X=)KJFNHG2IU*AC(?!*U?NHBL"\$5K8EIS\$G9U:D(3!/W(0L>ON-3S+20
M7+?SEGC'L5XK\$F2/5_S-?K+K22SU^<+T71A)'M9->>6W8JRV..OLZS&&T_M+>QEQK1?K4-
RW+QZG9K1@0Y=YMV:I0I%\$S-89R\$;X_?B7IF&H85!<*\$L=HTVN)^A.2J7LE=>9_M_BC.W*>_C'IA_U+#+FTJ?
J1%I>HSTNI>1*%,8&)5_EX'Z\$UL:YD4U2G<M3B7IPW131Z&1=JM8U"V%/@&LBQ\RS;
<02!34IZNB6I5SD"POHD09=%FO3N'_MD<-W8N(9Z0TEIKI5Z&5.N#SNU=4IQ_S!\$?I/17:2C&:EXVSM?)>8P-"RPBI
MR8_21%-2.Q8UJ9FWA\ZWVX4F">"N(G_AYF,@D2)U\BMF?T,+2G_0(IC\$*U0#//WK.4*;CDRY_Y89=IA.AJ-Y,EK;
(L_&'3*(@>4Z(83I:9UR5Z(Q_MW_8XU9B6R#'-5'ORMAZ*O&_?;0:PW>\$_\$DTW_,!EO8,+H?;4:6IZ?7!<I.#
M9:ZD02>E+2?/1+Y4_#LN6KEKG2/42MNA>IPR5:4G2JH4>E_/_4_!
>IG&O(X+J+!7FU>LOJ/+0_-'CJD'<6@QQFVV_MZ=SWDDI04'^^(V,MO!HIK%TT&-Y-
(-83&^8R(C8NCA,)!4%:Y5E;TLK?2V_V;7%(JV)X>AWOQ_M+LGA>I*+6M,\$\$M!XX4W300ZG)
<)ZH"BA&LB=%OF5JW9R93=LJX/UC/K+WOH9_MF2\$!>G+)-%K9_%G;^I(QS=ZC?
&.96UR_ZI@5=FIFGO"B&J>87@0W;1LC*/#_MFHG(46=)JFW0_Q&+V1B1PM:%)I.B+O<>W+!8DM3,8"0Z0S67%
(3&FEIJK(M6YUI_A0@_MD^8N&4&_62XZDF2#_B-<IAK"\$W_WF4\$-^T*K#+!NQ_2J:(7)6ID<1*N(OS1
M_F_C2Z;%D>T@I_!&0\$<+I\$Z"@8I@RW6Z3PPX?HG_-L&JYC^8DS:<KG\$MWE,F=ONH('E5N!&7S8_-4L;U!>S_=
=CPG8SBR_XM8UH*8AL+3VQGR;F^XR_M73H7>59&_!6T8DI>+6K"212,>FL?CDCB^G%66I_M2IS-
DW2G02K05Q_&P<9G)HCDEP4L\I^((H!A*W02.)H@!#Q=U.OI>X\$*C_M+B98(
!0%=K)1Z.X49C5N9MF7%=%6TI.BF4_5^!4IT.O7!;0!U>(\$KM#>#)A
M/0DRO9'OKE,ZI:1DDRf"@8NDGQLH,BOSTZ0B\W!.*"?YFOF"\$89V\H85SJ_MA_XPI">9TPDH>X)-
>:>HJKH(ZN*Z'_M+P=IN!(=G,I&JBJU_E(!#Y_ZEUDU"#O8*Y/6;J7:@_VH%_T1_M%GG;I-
038+!6&7EGB\$FXH.AO'C\$S='PDC;,<QDS77HPP_M/<^4L_*U5N.)#S=<_-QB\QI40-
IJ@NRH";DP4<5>#)9DT%QU^;7I>_6_MJ;GNJS3=VH#18>N"(5C%1ZL@/H#4;2*4I3Y?
I3AESA,'SVXC1HE5WNR*QD_M/_IW_QO=>S1!>G_'HTC8UY_>)/%:(H<8;=,6N)XJ*5(K)K8!V;>19C*\$72_M2H!
!A9YC%/(O09%G\$.2)8K)8.OYPIN79SU5+!N6!#C/U_V5!#;_WUM_*M'DXIKMDU_!OI
C9INH;Z/6SIGD_M.UDB&9"CBPKV#"?I.GI#DIK\REAS*!C_012.*_M#YD^+O_PNG:9Z>EZ;4G)G"G9UN0S;-
G"O\@452\18D0(>55RF9_+!9SI_M2^/\$P,#N-CGV0I#7=FTQC#N>.775CK:5F*JP'NP&*0?
#4+);+HZOITVO3^";4I4N;<_M=;'AU'9D-N)9\KA(LU1>(&T^EK&K@.8U\5:K=1?3EYDPN%*YKO"V9X\4H5-<
M=>C"(9%22?")3^(>I.WH!>_E.4)2>@AI8;.39/LGTZ_MFS%QZWPQ
I+IWI^VM7ZH\7=7F@BH#FCXG5_I_DFBOR*XPI!9(=MOG4YVG@Z.A^WYU44TM_M3)RN_Y">V?
VSP;BAN&TM'AC+;4SD;5-8ZFE-6E26\T#M-1@C_4!E5):74
MTEHK5&4H*2V;M;2D(4DM%J3TFTCI1M9:04!>30>?T^MS.N3KS.VB_=\$Y%Q6IY1B!^"B.PUJ_98S7LMUM37=27*!
<<1\$6IX(-_6P<:6*8+V4_MT^U:H#1BF.WIB9D1\$+>Y_3UT@_2_+V?7LO.=O#R_+K>5L7BDQI@I2&0'_MZV(?
BE<:&\$K?K62M_+NF%TCW.BA.RJU*!M8X*2T#3I;@I<_E/9\$GS)"G_-M/QB:M&N-5JD6>%N(I2CZ+?
1N;HGR^Z=LIA_9;DAM37"15P\$==_7=CVO(M%9(DETL)"PQ5X:K?)%LUKTN>3S\RW3Q:(@AIHQ3^)#_E:STUA?
SBQ\Y&8_M-U_=\$0/I_R%34*_5=GLZ12+ZD1B*0'DW\$[?Y%?_*@2XZ%_KC,X_/PJ2GOJA_MM,7BZ
43J4GK\^O^\$^3=IRHIZ%V4MJXN.\$@05H)\$\$>_0>B/=T9\$;5^2ECIA7
MA8VT^8;T=D5DJRXU^H1&Z@/NR&BH9&^H4;_B/%8I%IK?PB9?_%OVZ;=M?=-[26^_I&Z2?
JZ"!^HV"S';L'.KIR?QWV#-1>?HD9_KYT;I=96D>?I_M(OKL5&A^%0=-K!WIE6L2=(V\$-6Y%F#4FL;!!^_
Y7I5K#EH%4QVFW@7I:MA @8>"CR+9&>?66K6L5?B+;_P_79IS@ (U023JD#)+@1C3#>.@\$;!>X8"L_-
SU_CYW_746V61M5M0Q1R#YNKF_M;JU_M9@TFJH_61\$*IG5_%1AF>D\MK#060K_+9\$KKIV(#'V/9U-
%KV&^!O#ZWFN-NWXS#F\$57G9'I9=[12-25\I_M/I\W\G.OZ/I^S6NY..N=
/I)FPL*DYKUP/9V=5!3\+W(RI10M\C)"T>I_Q;M:6FYG+!P%*4QH_FI8;PHYBV;I-
(2C4ROB_/90+SI_KJHSI=CLWX#)#=DR\$P%*>+J7(IN#_-V4;L*IU/:6#&M5=?VG;O%-MADR\@Y)>G=24FF@&+_W;
(I#7\$^_%W7;-_Z-I?TX<#JZ:D*33WJ%Z2.Z_MG^BM^D_#^GE3)+%_#VEVEBI!G:%;G"+*T.OINU08HC6
MV(:%_OZV+72!KAI\52%19J!>%&444_\$(=6F&I^IH^@BHE.A6VF.4>#I#FV_M_G_MT8,565\TE_E-X30%L?
6^RVW>Q?E.*Q="2L2'3;VZR0!U?PS:S>+MGU(-X_V%KH_I&AW.MOVKDN)W=IV)^ZU5T96Z"0G2ZF\$R\$);C;5
KDJP;&J_MG\G7_(!<;4W;"VC^@&W9*EDV;UBD0-
AJ\$_.IGS7G.>?M\$N*_%C/Y74Y2.85OD1#2YI(-5W;H"OUDE4A'M/EJO_MMF!
4.)U:L5\$&HQ=Q:>JY?IGP/3!5E%I_I>YI):9+AHB:"BMU9P-L7I+V#_MF\$(XR_M4#AJQ\$'S_5J87X\$"_L*+
(^YIT4F_JZC+QSGX3;9>&WV@Z>(84VC\$\$(M17G#C03UWYF2\$CK)A>H-L!"I-K'Y1AIX(8"FU8YK<H
<#_!3Z*XU2/H_MJEI8D&_..6.C9Q#8'W9BA1>)9_MWWWF1.26A.)E?TD=I'4ED6_*51^!CTD^VJ<_WYVH\$0(V08<&
IRS@Q63I_P\$CQ\HG+ZS?4_X&KU'JO@7+F>X)G9N2RCRAR?V_M)K0QJDXG;IIR0@52\IE@X\I_R.C*N-
81@/*9G%/_M<9>_!%DIO(JTOV^?Q_MKVAD_0_&#F.ISVH\$J@H9)3R2W\4=PS'Z*M>OCIS\9W\G6!<!)>I="16>3@#
M\$SKTB/4C_=#R=<.&)&I*ON^K\8VYM500I'=CCM"\$D)INFTY;W=%U\$!K^Y.YC)=H
MI\$IT7I4OVHS!&2_YD^&PM&)>X_41=N\$Z(J%8+FK\IP4>TD62K1I)^.G5BL_S*Y-YS-
M'C8M06%FFFN:>ATXL_K\7L'BC;MOI@*!*"M#17%_5I#*#<@VIN)A*L\$Q<'M%_W:*HW99I#51H#*9G64Q?
R\7QHGF=U'1_MG!A.Y\A2O>\$R%C6R9DD@))M?EGX)G_HJS;NM6ZCW8I=-/59E7R!^ (#HXX1_?8?EVT
Q_KFAA)#582D_M=VL#>W.LNVC@?I?BH?_7XZZUGX=K)^SMJ+(@?(_?JEOL/\$I=-;Z&7YK
MA=\$IC\Q/895\3V\$Z;7%API4276PJ*Y)P>91A/A?)AOWBV(+P0&&W15NS;ZIF3D3TI54#I_M&US//_S#/_Q/H/?
YUS\4\$L#!!O(-/R!>EE.3O%BA+L(#3_3_M;6IT+3(P.C0Q.#(U7V8APF=-VYZ&L+&S0:Z?Q#6
M3XC016NA7CX0_PBXV%@SD).0=K;_Z^C^I_!%R?WD8N3DX.3FXN;^Q_"PI/L/M%IYN\GW\^WCY_B\PF0_G\#?
%WJAB^LG_O<#Q?I7P\$SV\I%ZL3(K*!_OMI_M+>:(H1=A(U#A(U%@!_!
0X.4&DN_M4&PW1C7P20BG)??
H0;WCW/L=KO(HA

M8Y.IP< S\WT.G\ICPS&DW=_RC6P(%O*^P2\,8K0X'0.LA6>.)2\DZ/+S^.%
MOPW)&74DR.IKUJD+9K.IE6(XP&#QE0);M O8+D46 M)+ ZR5.&<9_N0\$GJP\K0\$=5K'2I FEL:O13/S.IP%.:?
6KVM1KBWG.K3.5+ MEO<5&_.SN4XX+!PR=2I.WIED0+BZR_ZB9?P0!\$!>".3F2<.<) MP
IW**#*(\$).&B=6HPEY\$W(!%!.P'GS6Y9*8J^N5!BW/G@>/'7*%.P!;S0 M<?09V IQ\T;X)HR+7/7!J>C2SGJB\JP->
M2ISS9BTHCQEO8G@PAO2UGSL\$)&MH?Q>|HEF3J#Z;VE/0#G>>8878>LNXD\ MT;+>+H0IGPI@29J'
UBN@Z3BE+/6V^DIM0\35.DI(VNM9QH-ZJKU29>29\1^G M@4?9\SV7K\+L%YO^9E"BA"=(OG\>W0W@E\$O>=
M0XHU;") M7)(X9-AM)=<8\+PM>YSY\$NZ@.9\$.ZCO)#\$Y%&&UB(TUME0>HB6IZ_'G <=
:GH&2U8K'"SLN\0=O/I#S?"ZEIK3C1@6; MUMTP;&
FLR>I9&E'P)C149%!\^!#G\$!D5V0"AO7KPZTNDNK>29M8D75DTDO&B+8HT\YS<#4I#"*TOI7,_D)#
ME%U4WEW+YXG.ZK8LJ4PMO7I68 G7"YM)80*. \$4L>/E BT.H("J5D0/W=Z(8
MWJ5N>#Y\B5"/51\KMR8_17T\$&EDL8+HTV4Z7#2Z>^'XK%.N0KI+T\$0D_5 MD7^FARY-3\GV\!P>
(W)Q1LN*KR%5^!N\Y5.UR-B\1+OR"2\$AJ(L+XOU\5\YA MU.GCB=7RS\JTV;_E'0?N6'B<#K\ES+X\FLB-
)H_>Z) 7;/_P-EZ_3W8I^_&O:9L M%F7 M^VE^XEB(K)Q\L;I OB\=G.O\$*>J-8IP2'AT/S=:I=PRIKOE=-E%8IRA
MSO;I#;AJOIU^;XZ&H"=^;WTJ# MA*5*)X*O#R\J'.A1AO1?OY;I?I&H\1Q9\$/>%LK-P>71XD.EQ'@5&.:ET-
MB*).@F(Q+I\I^<UM;?O7:K91K5TH\XBA;4 M63JUD?^KJ"UAKI;I>>I WV8;CJHOMYT%V75P
0W\MDGR)\TN/32. MU2;=7;TYEDJY-A5;(219PBX\8-S.9E3.=ZA;CDBPD4=C^?D79'Q/2WSIA;FIV3-
O\K\1K\JE_SRFK>H'6!NLU9K(/)*=562/F=4\ M>6.1\05_0VA_9N\N<67\7/ZH5\ M#."J\&O(P!-OXTF"18H
%\$@D@3\V(6 M"BX@&CQE)\Z%L6O;);BQ.<+A/2+&A:C M^Y" FFY:P\1SQ3/>OXA"@)N7
MARX@X\4HYJE2)*#R\I>R;T\1.T6HR-OR9+P)01RL_F/>+!/=H0! MJH@N.*YM%&%H63/5KSSK0E+H?
#I@%O/G;2R\2IGI4L&EK_&GWI^F4C M=^&8_PQAHH5!..#I=)JX"ENX"AIV^&AID\$.
SKM7ER\$70/3"GJH4"W1*P M6C07.W\I9)*D M57S#%ULO?M8:#?^+G_?76)/_XY\!P.Q.J*(RT&CXX^BQ6??IW;.
I0UDI.0M9 M'KGNPDB;2*"I0=O.=VT(>^ M>+(6;Z^!4+;I57B> Z)R;K_7Q?S9#I5VBU5\YJMS M;%LSA4
,Q&O)9L7/71)V%IDM"3-&\$F1C*W2W1U\$JMSI*.>Z/TG=T^8H)>G;
MU4)6*4=O>I6FL"%;+C%\$;%>9G;AZ.%U\CLE;OH".Q38.)=\$UR)/=P;'&ZOF MVI5Z\HM_4)F28\K>I*KO6K<7:79G-
F_41ME('V.)@S.HA\I^HYM#=4\ M.U M1W;2\&33VU\!P>P7U6%!\O\;#&*+M>/_L.F\0*U_N26_US6YJH\I0=2B*U
MRZ5OR>DJMG\I0.GB9A?;!)40F2N%!\>'GY_J=HO);TM3=K>P\$FX\QRI5\3 M'2>=_2/_?OYRU>:OQ?
J104^U1NE3W+5Q\F2\BW7;I2I9@=U+WP).Y\ M1SX+3;1SU8+;+H\I0=).IQD<I69#\ZG;+I:HSE@W;I?
K+2I%+8V^TJIV# M.FT(7<@F"MA+I2\FT&2.7IY2)30\&S(NFS209QLE^U?)"JDG">T4ES*WTW8)Z\I_HFI
M\UF^>I4V\IY&HHYB&Q"IS;IY3T";GJ;F\84'Z=%G+KC-N;X2'QW#))\V M3#(NYDO5N*N-
24*QR5'E3TA.MD0*I5H:(D0^A)8U(08D*LXX@Z3MX&F".H MKHPJ"V&KXKEO*.H.(=^WM125'?/9Y1??4T3S71?
Z\Y2M MAJ2J<^S<90H_4\$P0T(8=1W\+S;2SY\$1V*0H\@K\ \$R_<<D=:F.M+@%&%BLK
M#FJ46HM5985N)SW.HGUO@CJL<#D^<2\I C(/0Q2=ZF/Q#\UML M2&@'F.E=BLKDB/Y LFS>JA6TLLJB2<"+3E?
6\I\I6H_8Q6O>I KS?/4/Y4+LQ"U4BG*!E'WE^G%33
MDKIY_3;Z77IM4);U%WN\9ZGN*O4KPQ\BH84M8)HYA\$)\!0\DH9C\3\ C M6#
(X;A)Y;B(+ORI;A;_%PLP%&GS8/GWYZ;#^D_%;V2_2G_30+J>NJ#L MFTX5%?P%O"14'FT))-
\$.Z&9@""L+U""^C*MS)1EFO4/F\$D\ML2>"CI8T9_I1 M-W.>I6>=X1FPFM9D%@6)"#HFRP"Z*GXT8)+.'@Z%?
K&C&OE5/ZYZDB\!L.V MIH*.R'9&B+RP<3C(9)>E*2>*%&I^=I9L-H(-PYL%TRU>)*!UUDG%@@9%
M0(MN+S0Q\J\$G2L;C>%N%VY2*36\3NF5Q7FL*D\Z^42;H#X=%X "W(=#JCB M-D&\L\$M0.20I8?V M\YH=Z\SI1*
VZBI(+U4_JI5SXZSP-2_J<+I4+U M.EB52>8")FB"+4FY\;..0WG_S0.IQR\SYQ_8DC\$)+ @GJ\I=MOU*@L;S MU?
TPXH4_L26M@DB(NWZ=00ERZ=3BEI+G/4TW1)B<'ZS';I>^G-7;W8\$V+G M>9\0\$8Q4L.IATV?UV9\EK_8\I
Q^HO_I>;BY>GZKH_M*7D;)\GSF7HP;Q-AAQ\!D4.M>O#R(UW ZE.9 EV;\ZI\V87YN;TF_4;?)_I M;P_8F5R)-Y\I4?
I\SD>@C#)BB^K2)TO^<36\$#P(\V11*5D3\I_C;_P4H90+WTOS\Q@/X\I2CUS M\$#/+VYG). "G.P34XM\$VYJB\N;
<1W3)J^/G9Q?#%>@QU&RK;9>7;E-X(NAD>0 MD^@BV"XX-SXX=+KJEL^V6&ZJHG)# 0\$%DQ=
(L%XX7/*'<^&N5;'(MZOO-82FP\B8K\$^U5R\$20LEH(ZRWN,I2V;4<-SZ M<@7;I#"U?S?
+3HGA>Q5BXG=8R"P)H2;KH\1^YT8>7A?7=\$/I73+2;3D MJW77R53MQ_@*0E\A1Z6K3Q9;G;H.FOD?
L\$^ULK6<#;NMM@?FCVMYF\7 M\QB^ (RT6ZR9OP_E*;2S3E5YNH02RHB6Z(F\+22)X^@5?^+I)@QQ"C_B\$GI
M9D%J_7;A3S?B9R\I759&.;)79XBNP\GJ\QYV;=574HG((L=..87%J\I>LA;/_MZ+<.+>*<
I\H/L#;X#9(=+7K)GUW#VAR=PL=R"J*N1-JMF?+HJ^_0\$2EC<3_-B- MOK?OS'?DO60.P.AN0\I8@;FZ0_9\Y/4^&W-
9-M5\$LUD>M.5.71)@I\&_X MZH>EXLFV6\$ZZ"J.(J#<2C'F)"YF\$!&RR(+VPJKN< MA\$!%BALD;S3
I4N\I08Z\I;C\4K9N_81VYUAG2HTX3GBB+A-Q*MQ=P CP.MW@9SC?
V;QHPR@4H0\$1@I5\$+V5#%FO1>CW^3UAID-AOH=CV..90>4E(LUM<\$'0"G+B\&:(WW\HEU=^AM5
M6^FB6%X=66;T)Q:D8T?R)@Z<4_-UF5_X_=@0/*"&B;/ZPI(5Q^D>I L3M\I\PUHRKXWCM;D;ZG(>POUJ_-R18LP0*
=8T&ZFQC/ MT2JT@^B#0\$2A/O\B49\OS\IN-JPYF7 'Z?T_4PNU=(CV0_5+&^G9Q>Y7EI
MI5;8\TZ&CUX\!"/=FUE=8AQRBYV>Q"IZ" M&I-V" L7=PV?RP>3NP8\$C+E
J_QM_L&14\!E^G*"I0.40(+KV\CB7F1U07>=@IB\Q>SR^DGW*90%US?9*PG\G9_B5\I\H
MB&B'(F)'*@08.1BY4\$Q\I#9Y>NY8I955SK7H\I^GEZ217U;I1+3#>=H= M1OPW"P*VPI_.\$J8(YBM6;J\#';>+
(2\;@SD54)30HE.=I=8BS<%>)\MCXT4XWY*?JG\$>5*!4EW_6T&X DGR2X M\$IR.X_* "IP^?H\6T2-
<^"\L6\NMN@O#>5\$2S;(<#I9\$)<#>9H?Y>DRM"Y* MYY5\I"/)%J(-E#('"-T8G(O\H;K;OC;FIY?Z\KR5Q
2;XGQBEBV*N8L M13DXAKW+^XB?YS=UYXC?)=IKG+4RQT/G6\#ROR&J\IG%K">J_KCN\I7I^G!>X6DE M\$F!
I-7+I.308_9)*6FX(45)HVTKL3AE_Y%3_6Q9^IQCI^1MZ-A@O4 M&<#M#;K_#>EJ*F0\>%&+3J1_3+;M"
(CFJ\%Z\3KLX\I;Y^P5U)VY%(. "Z3 M>W6FV.Q;#)R\I;V;0BL738WKBG\IPT>E&LR+2 M.U;UH(%\?<
B*GGO>8;D9F\O876XKM\;?U;3Z8T77H8L/T@W\I.I%D;3;&C M)XC>3V=@D=G;."ZH*"2^Y693A-
_@U*->#A\OR(ZZ.V\$A@9F\ORW;."J= MP0PJ<(T;J-5YK&RQ\DT9\H&\$?UP3;0JUE+R06)?AB_WRF<&>BNO!6\<;
M_YRH6;A<4@0;1.\$T=5.)^G2>DO\@Y8_WZTY(M?MRW"'/_M19=I.FMN;- MD^"U;_M G^0H
_02H=*5=08;4>F0_I\I^O\3ULHE4.(XCR#EDT)QG; M\TCN_0;@LH#7;N3Z9&OCAM5OU\?ZWAP'6F?YFX-
L%THU>LCS6HS)K"5F(MDBY8CC\O%V;A-7S)\PDKRIV<4;(F_?T5+0VSHX\FOC&DF5\90;+GA.S0
M^NA&Y_QNATAP+J*>O7PH-I0+)O6Q=LJ=9.8061=9A<+;BTYIYR(IP6GC4(Q M^W=COM'>PLSRRJKE#1S
Q2L(U1*LFWEER+5#OW\%&7X=B22\SA/U_0MV@V M;'9@D;S(Y*N;AP+J>W%;A4\;/D>);A_E3F\I78@8C6L#T
_7F>B)7699 M5>H\$76?LHKR7XED*7=Q;_2JYX2O\@H\LVHU\$RX\I7%1HM2\IOM#C5\I3\$YE2-TO2.KI\$^NHI\$;
M<;HOI8D_I0JWVJ44HOD2_A9DWYJG_N@2KMIHW?&R.*6?4J88'OFQ\I MSX-2\I3*KKF\IAT.LG@B;)=K
2HYW_"G;#H@87\$%)K)&E8\$ZX_D M2T9\I"0X7Z*\$)M%5?+37&ENWT6N5P4J9Z#Q\I65^QF=Q'SP_X=+IYD0JAP*9Y
M2&J9\W'NC*!OS9L R>*45*+I\8;H*8W?B\YD&%UY1=-VPHBYO_<7%2Q5.@W19R MVN+;RG3-
7_0@IW5L\$YZF@J\I;H\$UIH?G2EN\^FYFYZ*XC;08CLIG;RNDI@ZC<*&I'W\%9)QH2=W5=3GNY>I3_/M,PPU9-
>GP M9;QY\$6T1&G+;I\B#S *BX7?^ W=+;"W#" MUPLD)9MI%G;TF=I;IV+ IK
#S7U*\$I^3E.F0@I&XNM0\I C+5&V\I^&M6QL M.->)"I(8'PL@)\OAI%OI?56@X5NEK*W45S"."4H\@GW6TP#8J.
<5TA)RQ MOYGM>MSD;7^UP\I\KF;U01;UGN0Y#N<159I?7 R0D73<.@^K1MVCX(^?D6=K@8L2OW(W=?4E-
=R9 M*70V%HOGE4F0J;^ \$O#3>0N)2 M8\$Y@^#%3R-JD37E16S*4^HBL>S_?ZOW='HQF?>L3U&>9HFLZ2?
(G(59WS+\$" M3GN2\$@I+QRNWQ&J.HI;24VL/FW""O#^P5_T2\I@<'I71Q=;IEW/W;?>CIBWT MC"0

D=59)3Q5JN82K/MD0?2>P47W0\U\HX>B1(%?QT&65T\IDMLPKD)5Z MYWKGK>J_5M+=OGC.G634LB
^FTH\$HYZ\$/(("6WLT?ZD#W3\HYHBU\HSJDO\3 ML4NCFH%4YCNV2Q\G%@_W""\,
I")OHU;XN%*6\ESGW\JY\$N+H;V;H;Y;H M+=(<I8>F42#1FND;W5/;\$:~_OJ>J5RM?M1(I\$~?+3:?
715<BX5F(AJKY#)3S M&G(Z)_2,KG\MN+69*K=>_!MPA)*/EJA/.,BI\AC\BWVEP;Y)J#~@7V\IM87 MY>=?E/8+A-0-
FJ20K6P_SFJ>%R\;V\#\$(G^>Z\NL\O96BQ-4<>C-I\IE!%
MM1(2BIK'S@H;TUN)I+3,\$W=PA\$FXU;7#_S>6'DW6WR*Y,IMDH3IC C(9_0 M2=#0*FSUW<.,;5S-
LIX'QXV%!\GICCF*G(GI8\$/N(<H3-Z_N1DSE,N" MO&_)I)1^*Q7\!,M%1.P_V9W;=V.C.% M,V7K?KCZW\<.'+W\I-
G<I\YGFV7N'SR4WXW\IM;5<^Z\$HW=;,>I\?E K
M&M9V5!;QJP5F)HC3XGIA^K#D\G;9H)^%=AN+HKV(GLH!,BF&'MT'+%/Z!/7
ME:S^R^X6HDP0"X'S"/%3C77;)0%"ZV6OUX\J?2OEHE;UHE0R\YIZ>Q_0%3+ M,9I8D)"AZ44F+XWLM;(W^1:Z
KB&91+R**1S-EP32HOU39&=>7GZ0+3B M(S<9XI'G08,,Y/@>_3;=68MU3%1_M=V_TF?
<<2S;R50\2ZIT<I\XW@Q M\$F+E%Z;52\3TZ^&H;I56T.PX\MLM-I6N1;KKRLR#YV7UQ_-5S'ORH\7)F^?
2MLNI^I_ MFR-? MA(%\9\T.)"#A@R?T4ANNT2%.C@T>+I*I3A MRLTOM69#H4MMJ>)CYH\H2="A:\$%0
M=V+6UC@+DO<INH^?Y&Z"3RD<3.G9*",ML\HOOWPD\CI6A2TL,05KEI\V&Q\ MPW3_CND5F_03\Z+
X6^PM;V+D^V\5-Z2\EO-&OTP8FB<3\I\5QUECG" _&8C M*3^RW+_T0.REV!.U#Z1MNB\WD>H;..I\I%7\D2\<-
BAPW6^R5E&*79Q.; MQRQD\I_VG+2R9>P&I9425\I8"Y\Z;?U83=HWAPM>,I>HE7Q\$G/_.#2<>KFDX
ME==0%81U=1V@("SD3U5UTC*=<I\IW*\$1@-I.NWC-8B;2\$ DJ;.%?;<59MI?\$.I M^R+G5\9P#I9V^1
MB+A6RW_JT9RFG>E^!%MI9.(EFS^9&67 X62X-SRK\$)+Z#>G^I\XUAV%+6 V<M;#,"#->0^2YU_-
CD62^Z^40*JCC\$6YK+(C(XFGV%/\X(ND MTH8I&6(8.ET/*;O+)"BZ_&I2%ZST>H\$)H\==?UUPG,E%U,U_I\I"D>MCR<
MPM;G_UZ\FED3M:8SUQX;Y0T\F-4J@D^X;&_>"B2\8QSF\I22<>1UMZ%33\WZ\I\H6&Q
MXF8FJ2%_OQ^EB\0#*S1CU^XO\I,1^6)1S X^25NU;#T.CMRGW+?X3/C,4=FL
M)S:&&^_E\^\$JX_ =R*IS>OD(1N_<\$!P^L*1+I\!=7Q7)J#;O\&"A%&2%FX7 ML2#;I;K!)^B?VV?
1%==V_H+4&^CFAP=+I6+V)*LF2//I\I_F#>J=P^X#M7 M&EAU6L^MD051&6\J<@XN22Z_(9\Q?A;*D)80C0J;I\$
JH979'7A!*IR\9P+NKYN)40NV=ALO(9SOSVD9*FKP\SK-X=I\KB MOEDML+V<_"/<9J.VR-1S
MW4(\R8_:\$K\7_\$V@A7#F%>%Y V/OQ52J3+22\>G&G%\$S2T\)"@3\A5#=-WIZ M&0B1J.\$847P\8N)IA\$>4G-
MXW>;V)Z^<^JS^9*L4\)/Q)GX,5HFRM);JYJ'= M 8T0%7-1Y4.8MHCJ\NBI^<2?;7"ROD<<>PR&JH,W_X
CU);00^7WWT84@ MYJNDN(Y\$9=@VRD+1.D^I.U9JF@I\U<6%)VVS7FWFC3WM7D&H962#_) +U.W
M\$[7+DXZ(6KK4\W).>X;Z7GMSITTO8M3;K;=F#)G0SR^*C4^XHN\B6MQ-KRH M
8\QPS;H&&T(&FIFA_E.W>JK=I\$^=X\784;WM;4&>J1^Z(^AT'+:K%MZ@ MNIE%"Z-
;BHLX#;?)^1^CFIT\Y\BU.C7D#YBW\IR)12*O@HX+R#X GF.UE!TDL^NZO4CLV\I+XA M9Y:O 3.=GEQ
#NEWEP\%MNO..7RINX\I0\Y\@?BWMF+&J\4G)IK5G=M^I_9+ MTG\8_C""FV;O%0/A1?@*766;4\3I
%S*A1DZ01D@W:4^5U_=\$\$1M83ZYQ\ M84-I7_19QQ^A;^M^0XJV(+N6K\$@0;@SB2;.%N;I\I_7NSVZDW*JLRCH)
MVT\$A\Z1Z;7C=(2_N+8BOBMU3NTCY=Q(GA*3.H>9BTFYX4^_7I2"OXIG\I\G M?F8;-P/E#F2)YXD>&?R27VU2.
%HGV3.HICUNG=HZ1)S9X^FAN=,0?N5^_M;BTZD;K^H\DE;
<>TPUO;MH4\ZG4\K#I0UEFAE.NUK=F7G2IG^L;9<_PPGXZ MR.U5G.P7ZM6DTSU*6I"/@^5_OY\6RC8R?VV T6I-
&HX;&X25DQNH/>>ZC MI2-O5\$6\BKYGT%>D2R1ZH;I9\ POIROWI2D M60"/IG_D1T>YNN).2.O^Y\Y\$Y7I^?MCZR?
IY.T?>.E\X\JG_/V,9=2"U2 MPW7;_C.ZB4?;I\K)HC8HD\<7I"-00\9\U&8W=T"BOEW*&HJ;)DKX+TNP+7 MI-
C\I4\4791RNW;T(XDX\WFN;\$;_U*LZ4\F446-5HROB\5;?N/^I#^<(SM MI;%S=7GGQW2*XY?
W\$6U7\BW+9=0^I7F(6S*A8I&@J?9.C^CV;_>L34S+QN M,M8_SU_M>9+&I\$7Y_99Z6I5_ZL@IFSC
^4\J6T^S\+I%1.\$Y>\$#=>I^=I#) MIT;S"D0J8+0\A^V\H_*ZGG\I77FU&C?POFVJ+I%SRL/(VYU\I2%&A_IQT%
M^5T9B".?R+*("H_4D5&&^&8+2R@E2\I69^IY>=JIM3^_&A7&+B37^VY MT\$K(-DQ8IW.P5L*>4^XQ>M
+I^I2A5Z\I2G>J^G\VOX+PN=G=^U4MPFG&FB>G\$R1A6&-2FR3_H91P>6D\A;7&L MI9W00083VUMEL;RI_*I\XW
T\I\9N,"^<EV\I%NM9C**5IWE?EACGP.RU&= MO.0\$I^4F0X)SS2/I6EHJB2\I2HIO-FA4NN4^2O?
GN0AZX^<)E.Q^B@SH-43?1 MYLF8&G\I\V+M"EP,1NM09^_5NAMI.#GF9NVLKS^IHDGX.IT=
M&P8\JH.UZNFN5;_I%O<;MR.V\;V\+_Z?O\A\;C^00M&2)W/WU.HMOE.3VGWQ9^C(&*#PE% H53^&T<1V&?<
=,GH7*A6 (Y6E_LP*&_S MJ+;=I+2*N-&>MRG-P0.VKC5G;"D_)Y9W9\IROQ>8W6WQ\YIXJ&("DF+I%"M"&K2
0BC(+IE;C^?US\^4RC*IW""BP;IVN.%I_ YWS;7L*P;_)IC M907@^5A 4XTN4D=I\Q\MC\A\I\HHHZWFS4^0>TASR?
F&K3\$9JIM.TE^R)_D M3Z/+E(UD\Z+8L^&G/J+N\CA\0K^53_-C8DQ/O+(U<(&A-6<I\9ZQ\I3)F\I MB P5
_QW3+&C93T+D@C\$34^4WE.M&@&+H;SURUG_8=I\GASQU A\A^EW M.CQTW9L;R^CN\$,%L"
<2:T4VA^RMD\^0S01%G51^M8J\$D%4H9WAKKK&@ MI(ME#ZF(Z@5?
O^U^_AL2T&);G\I&"" Z00.50WRW06)DIPY^W#=GW23UT=% M>E)D+L1\$W^",8I#_U;Z=->*+9I_"G5YP&506E
?HDHK7F1DY\YMJ/5)LE MV_-V^Q.=(<I4;IY4FDALB9&I^HNY^8*)G
MB++\K010@2LV.D&I%CA\I\I/^5;:QZ6>V&2F5/(I\LF>K;D>:A
E=%;+&NIC%G;+I6C;^1>N7TJAQP\IE/4)+X0FHF3 M;S%4Z^I#0&AOS0^F#H^HJ<<4-
Y.%SIDWRXN);W6\G\ZNC-KT_9*5T_CULU\$*6I3_/N&?5\F3 M#387"19D_BY&C^NYP;+?"9?AGIDD/<
M9UMS6^5GV?;PU98C0\$*IW;2^5J&K;_Y^I3.A\$7_JERP=0^=\$+6M#P0 MSU;U1^/EPLFCM_Y?
^IWP^9U;I\GV#>P6%YKG9^C;9>3N+C&F?>V;X=8\ MEYEEVYG^B7L\REF\$7;R75U\K^SL%<6CKMB?J32BTP9?
D_M<+G;G#I6T;2;65&A<""<4IC&D#IS+ S_I.F7/15^R\$;V\&4D\I7^BE)W2S M2N;K03J_YTLVIE;IH_N6Z8/6E4-
#+K<I05@2W*AL2>^8XJTE.DB^/8? M\;^&P(+4V4_-V&>C;?J8@IE2\K_I2.9E0;R0Z19*^@+0BAG-0S&7GS
MNX=?SP^GH\A=IPN?"/U^M7^ZYX\$EF10\^\$>0_24\+<5#4UFYRY;4L.I^V< MH^M5J(S=;W)V&G0P3IF.@-
IC>SSXAXH3)@9R;V\#3K.A^54@W1G;QQQ! M\AKJU@/8/IE#K@DIOESSA_241;WC#EW@2>GW2T^I^D;#?
\$IE??"2^F_I3 M7;B^_C4A*_RDK^9.\$F_2AV\LHXM?9)QT^10LLZ,*CK(H#B_W/4\$>\$GE MN1YN+I.F.8
Z5Y^2&W\8>5_F06^D\&="^4\I\Z_.I"U;0T3NZ\$6\IYZXT>^I,5S
M@6S6A#27P10;DS8S6<@4F%XG\H_23XS\I3Y32@<I\X\$VK6VX^Q+N(T/&Q<&; MK F(F4RG;?I)FAC=8.0E
Z1%P^H+TH;O^T^M\YJHE;I=I/G2CT^5494IGX MT\I;V_TY7N=^NH\HX\44=9L ML(I6^+I5 MF%XX)T%XM,4;?
02M5TMTHZQWA69 M^>MW.R_N Q#T\2;K;6#ZX?O_UJN3N;KV4#J^GKMF?BZUX^/R?H/OWB=9G M?!"6;-H-
J\7=&%U\$SNWZ\RV#KQYI@#=-M_I\A;@W2#2;K5P"?S\&@LR_IRAC
I\XPH)+C4\X\I;4_8Z^B%5>M/%N3.6IST&7I6U5PJ3-3L^B5SX32> MXX? 7;E^W\$H)3RM.+>AZMR^E&R5H@4_W3
5TN+3^*@P\$G>SF<I\WUXY=(2 MMK?4.6Y=N;SS;*)CN^85S;TKA^KPEG9"?A\G>N^I\&72YH^WK(@S@IN^/_SQE@
M/B^K\@ASQ+G^R42X^_*>S/G62?K%JK2E_3?2\$600(U_/6^IX\I\&RQM<8;2IFZCBC*=F)C0CNDHI
I_JP=AWVU0=AEP;IE;I^I^>OAA4\GUQ+. MOI^X=X^Y>R^R@< @/K17/6QYMA(OBM;_R\XK;-H+
AVR/9E5MNY&5HUOH+K M@?5261#I\X388^S+3%*G<0%;YSD0#9/_I;2C9\Q^PB;CW\$1.2+0QL)N/6;I.(I;***=8H
0\5\I\$);C;X%6\I3=1;I^S_+3K^T_3X(=510H(HFR_Q2\I^9QKZOOQ@6(B/\$2=6U2T(2GSS>*F@6OD(S_9?
M;+MLK\$>D/-80?"&+TKJINY3&E^CVMOR9\Q\&&S^QP;O.(C1#=#39>M.6\@=, MI;E 6\I>BH)+@X/\$O?C(NT_+?
T"?3O;2%M6Z_-I4^=09;_9(>>7;L<;G;N MOI\$19X9F7H=;I\NZ&I_T(P_ZP5HK^WV-
3E41WZU5L\53\I\14.VKKFNNQ MO/G\$&UD"9&YDK\$NIO^QF59\$>B/OC3AB\$^5BOZC-LN-3.79+98&IKOX7U5EF
MLI0>)E\08V4F6PA00=Y_@H5^AIJUZ_MWHAID/O=-WJTGJU^QEG\4@)N_Z MS;
<5(C\$HFG(F(>"J@<LR\I%I0@9+/B^+08\EAX\I#Z;)Z?_C\BL^BH%_6U7@ M^ZWT(@07N7I(7_C9KQ?I0LS%WK?

Wl\$C&%(>2/8SA>)-!0M(O"AS"-2-%RU MT"-#.#RVX>X8V>X4R"TT&-"WUURT'FL4NG<:)P>I3IP^\$;H U"IEG9P,2#
MYA74!/#@ (V@MX"D8X^01D)2ESD'-O"VR6)!\$0E7T(*+*JM-1T76.B(=?M|^|X?GIXHXV(>OUZJ@5!CC)=:O
8CTJ5H_9H"7H3MU MJ+UMJVFO' TYWY.K+1CL&YT75+Y9!C4'-R67/!!|,CKHSQ?99S*KU:M11 G MFZH-
KOUV6Z6GK!4:4ET6AD3*!MJ44T!L@7N!(\$A(UK(!^S0S-%V%+6>MS\$RX!\$S_G)##0;H%6;)X0>M2R!L P<1/42UH?
=L@Q=)JR=<9\$TU(V,5X"V8+ADD="D_0WVYN-,2A+>|F9BJ7U=L,"D97 M1:-%@,|ZOKT1U@#=#P.MD&XWW("(
(8T%JFWJV@./5X5:1)AUZ*/SYVOQ1ZT9T MQ6P 5:))!)*NGQ^NE7OEN(D&JPO3!2R,(28(1B>S-V7RE5%P3+|HDA^_
Q_KO MT;DH?KWYSO=NTYZ^4HRZ JO 2+8W!V;6F6'3KV&G*QKOPG/):3?_WD=.MVT M@.R'I7>P_T-
G/60IE<616W!8OLA>!%.:9! HJ.CRMU129<|H-SL(R2BW6YF M?PU.)!)*H?0-F@Y\$39Y0\$A,I5'U
%T.:^SC.3&\$%D+|ZYWK\$0XFMQOTM>/W#19EC*#K7N;A!2^&VL4T#>=(D3 M;J'VVH(+D4)E\$D2!;
(.^EYR.QG_6<)V=A@GX97_WPK:E77"18+1!F(2ZC&%H*U|J_-R_SFIH3P!(!?>
M8CPZ?Q03;0LY!\$>6ZLAX!8YSTTCVVW B;ZQ.BS!>5#:D9+>(B9?1%5J!75\$Z MYB&*)GKV8L,?9_-8?13EUQ#
1#*X'Z(!^X5_052&_OLKUH=H\$!^O_K5S8I0I M\$!ADHT0FHLUO^>D)V>0A6YB17,?,9-WH!,-%CV1@|GXZLY>G%-M3?
53=1\$SO M1B3"1>C60DE%Z>2F"K30(*!VUK=4L^K_E#1RBAI7Y^P!%L^WD8CBU%&=-9-
MF'8(S3/>H:4VR!%*B6A3:1IM@|VW6VQ>>4=1: C7!/(IZU?B%GGB>UM0PTGD MM').W&5BK+E1ZF!UJ@2C_3M?
JM/ZAT8XF:.8!FV0?@X3|GZ89!6A&0@5NIZ M0!VMV|KI2O49\$1!J3J>2)W/KRM\$?MCP_-
AT003VRVYK09#C.V'B!\$S:GOYA M967 TB2.*|&|S_G%G%?1-L_5O&040>2^G:-(6HA0+3NW6L?FZ:!!X,7J1
M\$D5AM (/S!2!>^(5SIRRN8R8W!NSU"9Z_?BBX)>&WEI&IPJYC\$:R9>G'(OU6 W_VGSJQ
M"C0KE.2&.>VZ/>WB.DZL0Q2UWN4T*PO\$D8/Z+Z""^NZO0!>:MS;7IW@L? M=&0#UT?WE:;9-H74^H-G(WI>9C:!
Z,U3?H.._SZA^L;K&.+O^\$YHZ*TDW(MT T4M7%*DG:<\$ID;J<4!;1ON7Z;Z>%EN!@IC_90A31+Y\$4:7,*86PANJ
M26+1!^JA>?0E37U>I=1,1,2(^Z?Z!+!OUVNU=%QGCI^MZU:XID8AAO2S+Z=(9% M22B A^?B0 &M2O)U&!4Y!^;^8
!>F7)P.?GG'PKLH58NA87'T7R#:OL/D M?4B3'F1!FOHW2^>'IB>O@|MVSMHH:E;|!M=AW*+^+Z?E9IRYRD
4IS"ZK MBOK=&!#_X%.SP.*WJEF+2\$*HX^6Z*%&P!M9S\$ MX+ BO|SK0|(*KMVXO\$8,+G%JE'
:OHKZK6IK1C/HJO_I9W2M!ORI1Z@-BIO5\$UVZF7O-H!7<(!?I\$FJJ MRQ0NRPKSSM\$>>WP8!C"\$\$_FY+M+\$B-
U2J&#EC50>:XZW4*2V%TBZVG K/ M)WTYI^RI:6C;M.=+ZF^J<0*7G(&N3!947#G78_@U/J8289%I(N
MCIQ5J..2N")937!@|9GN/TYYIE+)*?9<6"1;8%E%|ZKZ%F,3@D86&57N*! M+
<4VK.A\$0GFS3K*!;RE9WZ!>6LU):X:X?4!QX_!0Y!5E=>0EY?G2_#I!;\$_M^!5^.&O)P'IV;*T"H M(%
!A^_DJOBJP@!1A23C RS2!UF2EY02BJ2.P^!|JDB!Y>1JVLZIM742TS.MW0BCJW3^PHE!>&OX6-SQ*H^=6';3-
U:;T4%#U2ZL;1+RPY#=#>H MV+R3:;JHM!EG #V5RS&K X#?(>6NZ2E0? MQJ
D_V"!+M&U_@1<%H!A=PM\$3S!!WRH*O%+^_K7+^!B9Y'#!?5*#&.0J>;SY^ MQ!|
!SPL#N'Q7^LQ:;IQ..!VW&8U!L81'U:L!#|0)T3"P_-M;)JM.+F+S; M/0IMO,=?BT7/M9R79H'#U%&-
KWR(4!7/9#M&|H7L!|V' UY6&=,B!PIQ4A3;;J MCT.QGR#H69U86LE7FO2W!+^>N5M/H1>WZT71.OYO_!;
(KH\$*T:7YS6S ML9Q(CY:1.\$!E65&\$J>(3^)WOPY!A4U"WVGU3!^_CGB(H#Y-36_E"LE/0A M\$R0(MR87?
RD@K*SC%"BU0.J8@^BOK0+9^L%ZLQQ7^!OT^7S#/=7M'@ K>% MMYTG^G1^V4E9I5_PRKN!2X44I5NN1?C
/GDZJ Y2LEW6**S,J!+K+AZ.CH M?+_AR+;M<\$!=-.EOM3DUU*(H7)8YRM!G^2;O@F*SK3!D-6,ZNV;5K!P%
M4!&!)H=BCT7RNI8WCN=R=JAM(N!;56#<:2\$353_0JF>+@?J:2(C):!0H5 MAG55!L3UI2K
(QT@|H>2LD%WC9*D!|Q3L_*3D|JO!/=//DF/=C>5 MR;;S+GUY0BLLWNR2!7G!A>G(
WNEGCZ>09X2WAN%;R.H8OL^D/W.CW2Y^L3%12;4272^5+!|@U(-U:(+K5_+O:6 M_!SL2 D?ACU>QE!-
&/4*!7U)OF>H!_?KX@C?/!^R,*Y SFA!C+U:%,\$_KZ)^&43%M=U_!|!\$3PYMM\$_6!Z3 MFT1R!826ZSSB+Z^MW-
KT&-!\$WSW_!LNI5ZTR2?@HG@K|X|^_ \$9!F-AOT+ M!2X0%(3DG!H7^!4HP_!0Z_64?B!VLR0='2_C\$ZTNCKY=03!L
MQC1HF!4!JH-H!A2?^*?6PFR?@I>>9Z8^>L&:??TFD;BZ?5*?='L'GY 5HIG MR%B,0Q5E*,+M")Y!3=-GAVE\Q&
(M\$U+H^!3!M9*K!S=/RF1J:S!7EH;O!=-(*2+L+4JWK1,
M>AWC@9%4Z\$|VF4Z2!ZY_D!Z(C!7\$R+6!JL)P!JFE,T!1^CQ)P:T+L!|3 M)JXD(\$_-/NOK?W>:..@0:E\$&
(W/S@+0+G!8KP6!9R+LX^F U-"H.O.O MB!Q2!HY!/*""6H!P(59>04DEH9W"< YY^&%*TK9>|RT
M4%+LW/L\$ZOG7.@\$V/=MQA.Z_&78X1BTXW_@D MZ7 ?K0!M+52+23!L_&8C6%73V6V,*Q+C5(%S2@X-
U&-56!)8ASB556JK?. M.WR?@WOK!(*,*TT<@<Y4:PL_+HW R!4L5Z/(0TI7+Y.3!|MZ18@*5^DI+ MZ3-
HLEOA3*1J!>F!&F0%4"GGRIO-;3&\$6+!*, MMJ\$!3OOG".?4%#_OL""L_!Y+O3YUDKG GW&UE(##=
(GHTM9=&4"1P MN\$)^#"5U->SNS^!H!L:V!PI<_JE>"0:1+*_.C!RF!95R:NC!"^=*^2K M!^D\$3T=>?>
Q08+F+=%&|GV>T+1!|HU:2>KZ+ONZM=0=-" M88'6NV=F>53OK?/H!>M.7Q&DMA_8(^B7Z9V!AXV?;G2>9N%
)M.W_XE5JE M,7CV_!%GV2@X8RI&0NU9)FVCW.SSO!G9CV=TO.Z&J"-G!0Y18+XS1) X0
M'H!&4=GR>QWVW/C+M!H=#(HDE^G6#1H#_!@2_5IW1&8Q@:..0Z/Y>\$!TE MOP/HOX?^!FLP);!N0W64?VJ2H-
J)=Y(8FAB?G)66-^<280WG/0^+@ P!E MU\$/N&P%(RA*@A-\$_/58*E!_ZPKROIF?
6L>U9">=O\$EPDEQCZ=FB<+FOJ*+%-_M!<_.\$ZQWNJPAYY&MMO IF^!8"2!3L15YO!>3%!TC6JOHT6<<72?
%>HS+TJY@?I.\$S3)T2(#2!Q=BAK!&6;./;\$@N,P!R2;Y,4 MV M/_L2>#|^2W=GPUAY8TXX)Y5QM)B,!GUP@36?
5K<9AB9CZQP!\$_#2;Z" M>HH M0!J_VMH!#_W46#LX?(R^ZIZRR8H9!052" T IO:)<9'A:N:TZ!SZ'Q2+?Y! MC?
Y6'X+K)P287X'RJM_D98)@I+;L6)&DZUV0_QE'3A#V(JM@!M2%.UE_7(MP>93S_9&+?>
RNW:APO7*#&LZ":R7_XW=#,Z0/N(^NEY^!OO*U7/BS05&) M+^4%Z8J(9:>K_03"=&&QL'8\$AD01D!MX!A!NV-
!79V;DFS0F2\$3RIN7U76SO_JFM M_H= OCK+L\$!D!:(L12!0V!F31*XH\$P!UJ X:@+Z:)7UC3-IF>V!&C8#,DU
MKQW8ZH!A@H01Z<IK@=U=/4Z=5(V!2;H5>),4*VNPFXAM@?A8BU M8F%!4?
>%P<|Y=UYNMJ@B=S55=R>R6:X!R?G|B;W:X#=>U?"_Y0!@|=8#G! MT74:7WDS&KRV,*\$9R5# J1>@L=
!>CH%K3%""*!NL 2*O%8?"\$25"!T_0#(#7/_9#3QXJDM4>.@R>0G+O1 MV*M(C_ %A_&J6"0(4P2\$;LOR)*D>!
(+O1Q!)X-B?9!2MQ+6C.P=KRL!F!:@4 MZPVD_MX3C<9,! FFO^>X#.+.>U!NP^@',?2?V8:&\$F1EO6Z!JZ;/@1U\$
MEXX_!QE6>O5!CHQO4HHH%UF1?E'Q&%6% VRW.W5E'R!NS!XIA4C!+;W/4%(
M62GO<6DRVF.A\$ZQ1+'Z@U"Y2!@35.JD)!+!#&(.41;R"NG\$+9!1UX_9.4RU>|&C?A>+O!&--OOHB!<-
B!UK>_"02H*6V9>| M);M>:[11^ESE;SUC6YF8,W!H M9_3*>ITB@VHPQ)5V!|DQN"=2?
M'_D!8CEL^LR1"2M@FYQ!>975 M/_<+!IT^C' O'+A@I!M!K!WR1>\$OMR9U/&->Z=FI5R*SJ.9JZ*%OUW9\$)LE?
!%>W+D..L!H!J?#-:*2SG)-M0V^YLHAST>|_!W>G_!UXZW2!>800@!EK#41C5(WVPB!OF9?@N&"D2!0
M\$JQ_#ZC!TFR@ (KKYRY-&T;-I@)N;Z_?T8H=G!R.#&FXCN0Z8Z%^E\$YZW) MN@B?@+RU3\$EV\$OT&FXZH4Z^?
=!9:..@G(VW")^ S2*GA(K<5 K=E_!CW_, M8@'U'!A'+?3W.NSKB"6 M6V\$4Z8C"M;_/E(+7!/%8G\$?
SDLQ@@(>5C0;7H6"L=^E;X9)BE?TU0UYN;^E M5!O9V\$MD6\$A.YR173"X"IT",
|X!@|ZBKQ\$Y*O.WE=C;TDT;KFO|SZ":Q='D2/W_ M6!UM2\$F!VZ!DHS^_7!D:./-!X5OOLY.XY8"47L6QM6V&<7:!
(KU*?Z M>-1K%H*U.M^/5 X-9T#(B+.71JTH/GRT!#:.Q?RK=P2Q_ TTP.*VI MID 2@Y+ZAXP2!D>DTZ?|K<;KD?SN
U!7A!"S)PXP@AST59H!5%) T99TG!M=-HEO!V<29!9BC-%|G?CC*%>"!62!(!O:2-%RRH7XUZ?DXQSDNV;6VNY
MXN:!)?>E!P.O_!SO.J8&Y!NL%*7U5TGJCRB"!(<?4SE%=>H!O(,3_57M)?! M'B!@Q/>,OEQ?J;<_Z!6BF?
509:O7W%BDW!1 YBYG.W!_!>=0 SIAW5Z6!>W) MQ2A?8L.#'N7RMD^0!# M!XC%+T^DVAV!\$1U,
!;*@I+*Z2=&X".Y*1BF;BAD/J MH!CDZ=5N%\$M\$FV\$/FW/M_ D2V/31YR_-5&'Y"O,6!2WZLN>7W8&ZX&P,AB
MLH!X=28H'U!S_LU_4F6D&4T#8:6.TB\$OV9(.?C?14C1=!,FV/&QC:7PL
M!NM!M4\$Y7_JUO\$YG<4X#>AOL\$C*GLN!^VS_2A6+6N!N"VY47KPI\$J_!H22
MQ6L1QY#-.DA!+!H:88>@9J*CXCU*K;T;JE!9!+G:7GOD%AAW\$>H@^HEF%7 M=E(N7)

{CK1^~/.T18.*K6^@V8LRN^\$=I(Y)NF@TH?I>8<N=XL:)P7GW5LP MQ5;U8E%^Z?
K/TCYXHG@.\$W7!2.HL>.:!D+C%BB*!&A/2!\$:-.9P.*3L-S M!2%B-7'FB<Q.3!/?>I^#4DYLF/P1UOHH(:)>I9C
TGC+.F948._0^JR).N.-!T\$!A583&-?P_6!@&B;-YKNW<>6VOJZW=,K
M^#6+BQ<:MNL:)@QVJWK@C76>7BAC:I/H9WS9NE/F=+JGM=SONUU^J^=N MG19+!%
VOS/E<>RZ\$H!^8M!YE%F>!P%D)#-FGJ^DTK#^40^2.B;GL%5B/^MG;AN0Y3TWX;6 (3.0 JB(9P-%;9@#.H%F!<@
U+F@W1WVUC<7)\$\$.8.7^?7 M'(Z3% C++3#WN^CEQU^XCO^VXNB#YIGE1F^PT:Q^KF0I-2/\$^?B.WI64\$ _JOZG>
4\$4VC|^~^1COU65G<(J0U@U|^:X1EX^P.T:C1Y|^MFZZ^UJYZCL<;RIU&F@_8;#QO Z5-
UD^@6U281OT,\$/>U:T@(*AM|^>:"PC MYLNNWW6%V;@Q!D9@UNFI><_I=O/ MFAW^F/98;YDN^>-V2O096\$)IX
G_*=^RDB6!^U8!SYLTOY1%V.;(7J6 MW@7&..S\$D;CC^XFB^Q#3" @FL:8O36XML-|Y5SPL3PJG2OHD!"OTRUFN=
M^W>PN7^T=^P3AL>6,< \$DR MD0>FFF@^~%T1Z.TCV-9R1.LL;=N 8=^:PS%JH41/MJ
M7Z#T_4AN\$G\$UDIZKH69BZ^UJ5%.:!D&)QF&(J#^XZ/MI<#^UIA/IR;8XR MGI>A^LD?I^ZIJH_X_FX-
Pl;K>OJZK^UB7N,9>.%M(X^|9!V4U%=#!UDDB:"M^2:W!^T^6BI&DJP4!5YJC7%B;43J?EQ@S_! MMS+4?
BG16!#L:CH6GN2KE3Y7^~^778MZ0VCDIM*.SZ1P.6(JW^T9!P!DD-M.VS2FNR(WY0K!C-"&AX^H0E?W
A9_F^+^*U^H.HZS9!H8 A/H95OJ? P! = M_1_)H_1L^O^6Q+1C^6@Z9/KB&.1%L:DL;"*M\$HEC!L)(O49 >^*CW_ETA9-
M<#;DWEN03^0&\$=D./D23)^F.Q="BW^3PIYNZ!3WAU9="NL^!N%82-1HS%^' (Q\$ _+V8>+?1NW-A^9_-VD>\$7L
ME05T^~^MV?>M0PI=^6!2^N>_WZ2:TH_ Y625J 7=75C9TH@/+&6LT\$D34"-ZTP0T*:D91(2QW/U)^&+VOC(
M23^6.>1&<7!MEMN;@U/SM\$H(?U9Y \$1I>:~!T6:P=7.RM^KTS0VE#6! OL MOM6^Q!^!Q/7#RPM.Z>V?
D6XU)6SG;93+AJ(K6%;%XG1.YMM0.0D6S=;-QLM MUQJX>15V!>[?^*.R!))#9,@_%;
"XD^L(%#R3!+MYN6!>W/O\$U^>;C2^WI35/-;M&V)K9P-%@W3/ M=M/+N6S!6?2!O!Q'=0NE">L)-
%.(E^1V=ZA1^!H^K^=VE84.Y8)^9.6V MG!6W5 (A1N)5T^#I=T:4H6&KQPI/GH+!2R5G)H^DDWM=?VAXVEY^5G.;NK
MK68UVMN:Q!HW-! =4BR@4VFN,|/<_3O>\$Q/PY_M3PZ+(YBL4GXTM0N:62RN9);T/A!1=:Q.TDI,ITPPH-
S0;JAP4ZWSL# M.D.RL3%)=U(J(#R;_-K^O^@\$PEGRE5O.^*O!L^~^RA=Y=YB@YV8\$[UV9]4%E>[VPI]@&
M>^61J8VIS^@!027;G#2L^SZVM^!F^*!D362C>3VF_M3X%;T!A;M+AXFKAN)\$_5^!O+3@>_00EF4/9;-HFZ*-
P(2HTTJ^R!H!FIS923 MZ_1^U;J+O!;\$^2^+X8KS*(E@4XB+,I+QW\$6>WOR.3!YZ+!%=86!7I_-.=@;LO
M;H.D7F&&+UJTOK!PD^?Z!^!3\$<@JF4U4WI%KLMK:M?SYBUGHN"-V^V^L M54&?
QXV;_9AXZ@&#&QJUU+V^P4E3\$H!OZ06>@#5(1GD/G=>7 KR%-(!UR MD!Z@X^7310^);!(-6/PJ0Z1!H6:G5N!9H(1
M^QN5\$G-GM^N8H^XGB0^*)XPAMQ^MR&J_G1;_!L"&_&+^#LMUB?W3(W^Z=2L
M^UGK8^JN=951^?TP0V>S^@!^H&Z^3M@MZ+12^X<7/GZ2WJXWXT=C56ZWJL M9@/E753S(>?TD>I>?8;-F#?
L.J.#6_6W@720H7(H@&BS#6;?-EU4E)^W_LR M4>5NOQ)DN(1^~^?
+G!25F.N_="RB^~^F7K)V1:W)YO;;GDDS5OSK(T2_-/%L M_#U/ 2V,M4F%R!C0ZDXXKI/ @ (W;".<4!
(-G3C!B.\$BZ!D!S!WT!E XR M091-EL<17H@1)SX+7;K!FJE?H24R^M ^;D>N!J3&O+W7M/N!H!#<;UR
M^IE@&5D!2HR\$IV1!O4^;#W_IUG+ND;*D* MU<,>
(Y^T^TTO<5H=)WM^~^OW.SK(^YE^3DI-7>3LZ/CY^6C&\$8".E)!(UW M\$(E3(9JB:Q!E\$A2X_J!^*B%7%.ZY1;T+;P98:!
<9>^XN\$BTF^4>?5/Y&>+M)JG.);K!8%6.QB@MN%_@\$PH EE=RY MWQY58;JV/N%6OX^ZD>+8O^ER_1/
68@6A!SXWS UYK)EX5W WOVJG^~^*P2^M1+S_=\$.@PI#^1=(S!+R>@3!@E-
R#350(O2@O;_ W^T\$!HA<|P4ZQ&F6" M^F.E;MM2NK5^G!T92!KJEL KWY+23!"\$F^OD<=APYQ-0^:HQDK1!-ZB5>1
M6%+PSYO^ (A^HP@^7Z>|G.C!QH/I3YG;-"L4^FP MY(!B0@HVV.DQ OARLE39U^D-!4;)N!Q.ZDL!03)QQC3OV?
HUBJ^")&P2 M/69K/^XRX/<&Q>\$GK O>>73_5<|B\$H1N;|^!05#VV)9YX7L/SVV8OTD>@HU_ M5YL9(C!^I?
E.;JK\$&&^~!#OFCL!E2H<\$8_5FA0C 0% M^~^99^GP@H6GO>*(!4&9F>2;KU=M.;N5NL@!5G#3I2;!4T9@ESOT?#?
^2!\$ M+52-(LE!QL9?5#W?^A5!K!58-!N3OD7NATBZR! RUO=*ZN_#Q!_8<4R4-)
M<0NN0!KU(C+N!)0FUV@^*TCENUR@!NH?!4N?Y8^0P#UI0C!(-.VFL-
M!3P;-BQN(C/HJ^P";=>=#).)*#P!KWZ2@1Q?F>M!2;H!F4J>4!);4!OS# M&8EPCHR.<[WO2,F2M^Z?D#/-L 5Y
XCG@_.\$CP;D!U+9YV7OULK.Y*TMZ! M5R45@^TU.Z#K7!2!QVCW/09;V "-);/* NXI>13^_H1ZUD(X_+!IQMQ;
MT2W)H!Q)NN5J!^5\$F7^DXTS<!"RI?>@QIF9/H>5@9R/+ ?NU8O!A!&+P^PT M2!_1 !&S +!KJZN(L1S6N;
<(O:EVT^SRI7!<%!^*>L/U6_WGO6(<_2!^6! M4? (^728X=U<_3!9!SQP6^KXP+T>E4C!=[NZD1,@-VIF)?
A^Y(5?).OYV8 M3F^E4\$^_!^E?(%6VMQ6^N^9F3GWCY_F<L.NZ#>JRME/ M.;!L_!+&_DX/GH^P);
(9)1&8(6=FZIVD7UUNNG^A+^DZIGR^LH9YW.NSYT^HB5)@(^YS^YGS^G>J?B&+O+/-PVAS
M&GU.T^L6DUXJYZPWC5!+!|=R;VZH0L*.<+81E6PQ^="NOS.UN#L.L!JGH;(-M9S!A.O>H>I^
563BOVD+XQ(\$RK%7S7^_8;\$_2E.^(\$AVPJN/^0<3 T3E MVZ?^*FUS(I3DJTGLHH#E5^+;2-
(93(V3L>S@YPB60QSC\$!N+^<3TQDT3!H M?49EY_8_KESI^?1_M6KH@E2IQ"
2!_FZ:45D%>28;SQ9%K5B@M(!O8=";#> M=F!^!H;+MY)\$_1@^!61DAB<'GACK"?
RMY6I<@!QMB!GO)\$S^H4+^OPUWBGCMHN#;K)B55=/#"R.Q.JC^PA4H(#L=1AZH=WI9\$A (3
2(>|D!HJRN!+98V!4Z MD!E);AJ5#XS!O6_?H6@%;?N=,PM>SEL_(\$(^ADS^ZR!NJ=;!U8+14U> M">G+)_6Y/V!S7-
^BNM&O<_P0HV07&8M4MM.*WF0?F^A1M0C4\$QU.IOTSIG4!H?;D,M(M K85?9 F1>);D:H)J+^B+3-P
^6=*OAH.*I<>I<>GD?<85-/R@!E7R/G_9!OH79S!6JZ!>K?R!HB
M@3+;S!8OQ6ESL2Y90PDC!2!^?_P.#+0O(94W0T1TQ/SP9!#%KI>.SU75VM!6 ML#^IK;
H+OH.KK046Z&UATZKM)+3>+ZM5.I="FB1@1!"HDK>(-!>F%TL<7^O*.\$2^(Y(-T=^6KS=5WY?
M;4H44Y@!D^5V98YQHW>8^L4X>-USN7C^R3BRIYCRBS4BZ=G9\$("+L!A^D M5Y)T#>9S%+!S08WO1TWY+9H?
+&FW?+#.MGBW&WTB\$8L;GVIWY!O<;"PH_M;
!;)U!F^OX5PX9TN%>9ZH4\$!2LK6\$F7%G=AD2EPRE:MZZEZ\$G".W7QRZ)> MX?),T#AA@IX0-
VWHE^7!_0@W!7Q2V6)M^R5ZF;7S1CX^6QH!ZG+!68>G^!%+
MDW28N!GU^TCUN8^@M37^Z0@.JB2C7>^!T5OC(LV&F(R^20JK^)U.4AY7^2WY
M_%2W3CU3Z&/7#T@V@X^4&D!C(O1 CP)!&N!MIM_>&+BY>=7.M83B;1 M6";JGC_HO;M(%V^6L4\$0!3
M_!OQ#B&LE!)JOK@)+(!^8H^XZ!JWZ5J!TUX6!W2.B9%B(!AUHZ=^~^YZQ M\$A?B=
Q!O9YE^_K.8C)V!^?2^4S#EYER)^9%G?Q57.\$O>D_<;78(C_ZMHDKT3!_7SK-H!8?LO&^*2.C;^*K)R^I<9>WK;C-
!UYC;<<1FWL^P;7Y^EMO MAI^;S=7<^2.V!T>;<_U9ODGT/6_~^7Y;/_=LB0GS@+V;="^+9D/N;
M6!%._ MKB!GAAGGLJ3FY1S%YM_P>?SHT\$2A3Z4FY7F^OV=(?R@3Q-JH#R3H^
M!DE6(=&X@>:T7P!5_*=A%S!CMR6:%RT7M0RGXI_H.O#;\$411=|DLQ79< M;1%*5<&^6XMH/=0LM7^C!T-
4!Z0A^N3Y%I0W.T\$E8@LXMDEU2!BB=FY91!P8(4X1S^@+9=~/CP,+QWO&DX/8+VC91!_G!LG_TR
TGM|^#K^T!;9A?#6 MBWCI/^~^HDK@%GK*_INV9_/0Z9.HDIA*>2DYE<C/QAWM^4KC(!^TG?069;JP
MUSED\$6R0%/E;Z\$4^>^*^=)U\$0O!X2FN8=<<^!4T0^U%3A1#_LG(.#AOQ^10 M!HD^2^0&17+.^/6A#%C!F
TNO#/\$*!TX3-C^!72JHR<_D1>|V(^P9O^_MAM(>^*#9!P%\$!TKZD3^BIZH4%NZTI=^N?;1E-
!>Q2!=\$=>ZG7!QK1^&(H MKN2%+/_K!H(L3HX60M^K8)D/&MZH^53Q!-PO:BPI?S7E_YVGPI+K1WQ<> M3-!L;I
ZF)=B^W;)JDL8.+5FW;^~^OH=9WX;TYN/HO=9.);F8^8I*=TQ\$ M1B!Y^*)L3R9^6S!7!ES(?CPZ2-U^Y 3NQ2"
<57%#3QL41!H_!SM\$/N!B! M5!>O!;X>"2!S;".S62BH3Z+A7^Z-#@C#FD;Q\$3Q\$8^MM(*GXQ&%LR5VD;
M_S;F&U-X9FO=WHKH(8FS&JL2@MWV6O MG4/(XQC^B!U)7!OOQYAV!O^(-J-?OW^H@DV SJ&M!O4?^!^B
ME52FS+!@Y7!7E5.A)Q!EW +O&QTNWLIW6#^UIKLNN=>@EL_F8H\$>HKH=11 M86/7=M%38N5_RV!<15>
(1QKS4D;8\$)6(U9E M!V.C^B^6F?6=H!3-"Q^P! M?_6NX>B=Z6E.4(F!H^INFFU#N0SD8

M'&ZP<20W7,@MS^MV^538S#,H=:/%OO"(?R+@I7+"AM%\$%JD_3*Z^/T&0W MR'?OS;I-
Z)>+^JTG/@WN2F.U15,\$#H9QE*?4G37/Z8C={O<+4 QOIO:0H
MWQX*R!;W4HLE,DQAIM6UD=O1\P)^M/>|V/KJ.J;?H3L)*Z_V>S8C;6=7%-! MX3I0DOKMF>(76I8&QQQ4.-<-
/LR/2W^V&KE,=G?J<>S(C=G6'E;,"HEZQ FAR+X=BE' #TQKT1BY'N>YEPFZWQZ0)
MYLX2=O=D9S80B8H5(HATF)YGE5J-U ME63"7(X@JROBI#;O^>/?23^T8Q<
M:T^;TB#17&%6PI&68BU)N9M!KU=F\H\$Z;^;W@1+=6 M;V!|!+!D?3F1"3J72U@-<-
L_+IDQB0G"*_O:'RX%4/58/1G29ZL0(4@!*/& M_G;CQ'EF&8>ZS5;L\$>@O;K4&7?=-M.'''WS!3X=.R!H#+(
%=@7GK=F^HO;7 M&PI%V_XI14GK%.?NWS>.;?1"6"7=N7&2U!A<^TVP,N@Y M#!TN;\$.+V8VZYF;T!B#@XIT M-
#LY4^X=A_34/=C?25E5;Z)9:CGP,,YB.ZW@Z2HIG,CFQ;P="Z7\WQN>NG M7NFU9->@XJ 5ULV8\1G"1I?3RE@5
EZO7Y825&IJHJ92/X%F7YBD1E<6Y#
MKK;YSB.TP12=AHJ+;YX.OY+;OCJXWHF;RZG/0#16RKF^:R2<=OOQ_"@W_<5SR MCF6"V:8-
UOXW(J2N(HY6B@)-.LOAHJKEG5SSYK>N/FZ0?%C M36^OAXI;9%>&M(A%;7?PPO.{YLP;A^A?D>|>(>G2B*;;
(\$HL_2/<2AW%8"8 MZV>>)/%F^>2/6I+5C;*7H(-6HR2/Z#V@T7IV, BX;_3@T@V8SL+A-2C0P
M5V(OU8I/*M*Z@_S98+"TI=(@+;Q"QN>#H&|7G|C|VG:L;2Q3KL_&V76% MJ%I6Y6-PBI%?
S!+D;(\$4RKEA/=7E@ZT\$5FR\$PRV_-X66,^4IT#6WW\|@?>T M;)>XX@&@&(D4I?O< MI?SIEI7AFDJH-
Q9U/<;X>=^ICI7G1E;YS-KT^<(-J@@\$ _18H0WQ)\70A-P MDA1FW*H<@;7^
4;3R5<;*.QYYIE TI\G|@2/W2|_F385N\X0AD<8SD MEK(U@L3GX?I71UQ(234GAGOJ=^*U
MZ_/TO>;3XY?/OCNP=X88MWVK(4*CR|>J A)E+<./6E5JF;O-X7AK?;L_ MOG@\$3Y;|1;B"Y" 12AK-
JL;L72&&D\$PQG1A!;|0>Z";6;UN3==#E)2.=!#9PV10Z0V;Q2G>W&+M+S#AJJ3)NI+\$FQ
E&UQOQH\$PIV7H(")96CYSIH(U1/9;*QW*#&VH4A1N0
M|+6I\$26^94FY%\$NV+MFZ(>ODYNYXQE/*CCGT(FWS8&'99;/8D;AY;YK)TG M0"; ^ LQ5".X-
HF!R0;|VSJ(WCQ,D+=-AD M.R-KW^P"RHV<|)+DT*3ENHW&%Q)W0B05XM(@7<;BR07*EK6KIPG#OBT#E
M#/'8,C;|H&.5V.HX^G\$YY_ BEL/' #?J38.N\$5)/M8"?UG\$5N0.N\UZNKJ; MDBBC3NIA!C&|*2_@Z|;.
<#LX\$+_UY,^)MW29/D0%HZ> ?!4ZGD\$81HK%=G;\$ Mx-VE NHGQ7 XF94;4(HGUEY/PY>9*OI?
VFKZU|=!^MKK5+U<@0Q%\$S!=IY*MRPB9+;IC_#*2"Y2,-AKG"3;1/Y?/? A|>ODV;8XMUO
MR^E!AQ+BXIF4WAH,B1I>#1(L_+0;JA/MZF/\$\$>|M5#FVM<#VJ+OU66GWO M4U48_UDC4;G_<N))V^Q7YI?
I(Z8/D/6P7P;6^/1@6T)"\WG;@F%N"Z;." MG87ZT@6N47_01O_<WRCS_GH;E(?!&.9*42@249KT_-O+T?
>*LXUFU;2ES8Z*M;80L7QE3C.+V24^G32^>?G83^BXF*Q;EOZL@IVLG(1.*P923S0U7+CGQ
M|QFE9NV\$OMLOM'&4U?A|BJKS40*8>23;|BZ#A.NLT<;M0 8.V#.+>4O; ?ML.EJH5V3YVDIF.QO|H|
(FMY=WIZ|U|9M_PST(VZW*CIR|)HUKCHHG-GYH;L&)/1,2FP/LO;.
MJ@4D47)8C/GA%|_1I|*S;9T'L(7PKNCQVVF_EJU*4XP2Q2IRIZ%@3Y>P?(G|
MM<@;KYK>@HW^#/#?"7HT^&=IOV_!APID@BD7)' MH"C5;
I#H1LLX/#\$S!;3;1"GL?AM|_|JU+_ \$GCK69J+S!;Y%Z/-K*D>D0E39L)RC8JIN)I-?XZPS6S7.XZ6Q|V^'EF
MOE)P+;AIS&Y;L_-PV#K|ZIMN.A=;8;D&F=M\$27)4F2O?
XWE(WHA52IA2+>UH+N_?"%8\$O>N3C9MD3I2>F(8Q_+UH5?/F M)Y^V#TN1XXMXJL;?SY|
(J=Q=7,?*5"OUHYIB4"AHJL2)V)SIVR/T=,F9 M)QDC67T&3L FD3U\$3RC=J43PEMOI9CM2CG3N&Q_-=*6
JVKEUU\$.73|@CG MI^&NLS@0EO4 J@4;V""8";IFC+6Y^Q3&*#04#WL2?QN;>UJ>UTB^;Y"CH#<
M13_=HYATZ%5M6X5^QOI;"N-FKAJ3\$ACG6"4)#L E) _=S&&|>BDI>8L0;' MA|<)EIN^J7Z7(@@HBO4?
<.6CR@Z#F1IPU*FYP52.&Z3%IL\$"%>O"DE^Y6 MMGX6OH0)30DD\$<&X-
;P%5N)EH/7|W*IQW& _=9,>W(B>NUF1+\$N\$SK(J*3 MTDGS49E7#.WUSP@L;OVO70(8E',=TQ05SE-A DJ7=Y-
^/U,*1>)?TPLGD. MNO&E)*?0JX%8)FCP)*R_&%0P@1MG(XHPEYP@D8J|"8^0\$N+^0DH4;YS28(F;T*C+(,UY
MUA;QU,P0&RV^%4HIC6;Y58B+9W\$SLYVNCDO|<Q)9=LJRPH"040AS1@BY# MOX&Z0")L9>09#0<=|;2&IQQ
WONQYY^&3J|YGS)"\$IY^J3HG3I+M@46AUC M<R0P0_-9;@<CG&\$*2)#N&H'8V8THZ=@1=66\$%=TVKA#
|<E|HFM(H@CXS7 MPHNN?G|<|5R7B|<QP 0=MJ*G8;T@XTR0 ?DF\$|1? 0/#+PI5_%YKE*;ID;EI
M+T2K(I8#WLLJMG^M+*,08\$|ZVS"196QO8(IQK|W9ZJ|N+XZ;SOE2Q/FV5;FELZLV
M<_0L_ QO#&&+F(Z4"@ "ZP*81D7<0 0T9-QQ1YKA+CGRI<#/?GF8YJ;+O*
M)%%5<=>L4*X<|J1\$.WF>H382\$;_4(C|N|H+;|<08;L;T;3V(I3-<|SB1_\$;=|LFG;M 71Y5^<
MB*Y/|+3BBI*1JZ543QJ4'JF"?2-E#PYVBBSE)XY%J8IHQP2W"OHBH%=:ZJ
MTJPB=5/445QY|JH_)LL^|YZ7/|5A0|>|V=3/D(N\$1*!;./\$ _19<|8M. M|'"FF4;:=G401C2T,QZN*?
W^|Y>^RA>_YG2\$A N#M*TV>3J=V&QFAMEU?G3HK" M?8;SB7R;P3#%"<6452_6G/7Z|H'7;?EVON(^/Y|>
M"KPU%KP_N-B"(+>&R_E?4)OZ;!6-/(?TM7(EW!7ANG-/L*9Z)6P={O)M2;()/M>+&."81 M^|H DPQ)T-
HXAQ4P8#J5G2%?XB?A-@M4G6|XK;\$B|;VT?)|=O>GEH(A/R;.
MB;>5_AQ.+9J=KZ|0OT9^N7V&H0&3TX=5/W;LY)Y0_M>4HK3RX\99^J/4*OZ5^8.LR'5O_DNQQ:T2X4/D0?
=QD_5N_9\$KCJUMKVA MUG'@P;|&3.#(WXHU%A:<\$F ?Y'74'Z^R58EIE|935L0H(B1HKP?XK|" MB@2;>
8^+1+NEP/H."!;@O%NRL0AOW6>AL2_C2&NCWC"/?S;4,+;D|)%RZ&|;1P(I>D 9*IA0*H=B3MN M!+MWH9A
R;J>=/OZ|P?>HVF'OR)<<+;L;@/;|K<|?;2&JDL83+ZG%MKR MWJO(#|+62BR&M@&R3EM_KZE*T4A44\$|
f(=<=|;Q-BNW(AU;T.B)0#(KC^2 M54+UM&D;|AU*NH?/AC(*@W7^BCQ"S+E!GR6;1\$Y 2\$K*MX M|Q."PAF_2'_?
W4NTM1R1H3IZUV6JW@(|;XS6|JA|@|ZFD^RY6G7|9>DW(|S<5'5;,%_?S.MP"JZW)HFFH\$WP|X"l88+\$=8+
(L"8M=;N4->7Y)|IE#@>X>^;N01(42EKWJ30
M+O)J3+ZD|1"M.&"XV^V;MN9UU@O3%S6R6&|XQX,&7K":|S3|3CB&IM/#U
M>|F3HXS BW_/L^2UEUE391"6&|V=L|HYOTVB)KV9_3M6=" M/VU==SP
_ZG'00(C'7VCX^U04BFZQ.GJ<3UU4IR'C\$X(GP-PIV09&YJ7V&B MW9;R4L->=/\$\$<724/4--%
|NOMMA/>+;8NM'5W%|7H6)*L.Z&H\$XLZL)% M5KL/.(MSS=;UK MT9B|560_I+|3GZCHD%FB\$FMGG|;=(?#Z<3-
Y FC\$ #+ MX%HAM9JO/=VA>4%UB3J@I1UZ792K2;8A2GFL5Y_?JGNKWAS|O?>_NW^<^YG^=^<^\$ \$
V^<^EX|&=>L 1 Y)JQI|=BM.3=JE?B7\$AJWB\$K5_B5IV>Y+@# M;1C*6S06ZG\$CG1>Q
#%*M1&^7=G;D\$O1JKAFAFX4W J2+TTHJW(8M|WUD M_ FRY4R\$R'!AAKNLKT*|W3B^K|X\$CW;;J=C_KO!\$7
6VHU?<|NIA<|J7"1D00EPJJ6| M<"TWK9|UA%IFR4 9+'8*1Y>ERZ)ZT=)1|KGWH'B\$?O/+S|N?
|W|W2/D+-025<<1\$*82Q3D3 M<'&XY_"T*0.3UC>G#9A2A@P>8*>^S|J3E+.BP).D+.Y U/-1%9%\$8DE2*4(
M#01^\$=#XT8;< GBWV;TJL+4)HMF1/GZ68|*5E1U/GP)(G92;&f R3\$^<C
MS2"OLN88L;JZ1_B&!MOE6C;W+GTL5N|^M4+TP&)'BQ_N'.A3H'S;<|90 MC^M?#O.@B'GFA;.<2:P4R_C5-
(@#HFT&M-|)"&\$MEL,KELN\$MA;Y8NNS;N/* M"7_GQ|P;4@UH+@3P&-Z|2C8IP;"+4X2@Z<9<;
M.MX+7KS|KP4ZJLK;G+&#Y;(/T_<N%SAAS;)"J9 8/DLT?L-E(O\$;L_ %7 MGZB_2I%W%+?#R)Q'M/2.!?%(BZS)F1
Q7;8@;AAJ3AOVEU7;HT#PQ8*D M*3;|NL |M0>5HX30>O.W*_.2#T;3D FNF_KW M=+@O4+H#>;/E;
(H>*0MLX/WB>8 =KD\$#@O;G!?IEF_Y;+=95Y%C76A;B' M=VD=GK|F-IDX=YC0^&YBC7JVK%#U;-
M"@A.U(V@N.VGZ?NLVI6LP/@Z_WP* M*T P Q SCY-;KT)U'Q|>_9KSF' ?I/4=7KU3=QW4Z+KY^%.UD=?&|FWU0U
M&7<;UEY|MP5;LT|Q7OX|>|9J;#|0)EX#.N3J<=&ZNY@(_ WIS30|U6|<^9; M4;)"TG|<^R9J\$_'@UHNBI;5\$K|@CE&?
DC|>^'SKXD(7_@O42(05P^"U/\$\$ \$ MU)D2P&'K85;.)ZPHP5@|B2#G1K96'05TG)EQF-Z4Y84*;I6)#-A3NVM_6#
MKOFSP^M(NBGC*CL;J^<T;GL"2W*;RQ>(X\$&@7XOC;.%XE7UJ4I.5V=-_IG

MBWVF7.6+DD2IN@385+B<2CH'O/O MEUZSS&*<+YD&MQ_Z M=B.G"UP:@2Y:A0/I&'^(?P 2&7PWZ Y2)87R(?
5"8WJO9=*#WL_DK.\$I8 CL M^NTO@A2VXIB6""!T+H=ITDW?>^I?B|PD:J86=U|'Z-/
M::MMO9>XGLU^N2OC!*"TI7>=FRF(FQ?25!=97ARM*JR|@6_5C"AP!>#DE&UT MCWQWKA0-
I920MX_E\$GA:*6#U\$-74>*/LC|!=%I:Z,3=&Q!A3 MG5@9S"=L4Z*_2FNB_R8K*05:IQLMX|COB&F%FL'6KZ-
Y24Y5I>C3|H.:OUD?<#0M<"9DMD! M1D3XL_5 DAWP=*#2.!\$-40_8\$V8I,3.#"T.<#-X2J75=\$29YR0T,FE
M"!>W\$J27.%KV9..EH%+A(*CU)=?HCV:0NE#R)@N<0YUM(!"=\$)#0.5V>W M-LLT0DU9TW42VQ"@4V.123Q3!
MXU)I3\$!+PZ\$A0"!f&8,%|X=R%=-OOC\$|Q T?RF/T-9?|RJH0R4/S S;W:* M-
1:7L,1:7<1_T3::RXLSWZVW>3_0KRR+,VY'\$.B|f\$#!+Y:0:K""0+3JB_MMI,4!1"A>(F(353_7X/^ ^VSKJ|C:K-
5VR^)|J<^|0Q=W|<=>W>K:Q"H3:BS M6H|1^Y|!%S\$14DMG#7_-M|_Q7Q A7Q(5B8\$!f\$-
VT3B:K0Z@S:MN1(NC!8?7V| M&-2|V#@9T_*|N1,^|956HYN=SP6|9AHNUO!H:|C5.6J9.9M&6<9_5C'+ M-
MU_|Z?RL2F8KJZU+^4#K'?B:0^71MT^|VFI_7Y 0V'W:0R_...<_EBW>*L|5J^X)>
M>^GV/_5FOKK5K)*I3FY82DZ:Y|W(\$W#<5@OX9#N'0BDJB0Q(DWN.E!.\$KX5_MJ+8L6ET76&
(%W:A|^Y%YGYB3)*36%7W@&6IKR'G|Q9PZ|M|>:"1K2!FD\$ M+1V5X|0PN1632^7N!0HSAFYD8ZQSUTXDA?
\$3G4ULKA#V:Z@|K?(-RS)B MGN&0H74:G0@^EC?@66)!@4(!E3X\$2V"0?HK+OP!2M7+>199|@5WXUWTA0U>
MNEU|67&<|QL."F)9'4| 1.!|Q"FK9X#!?29V@|5K).9PH.&XHL;<?M& M5|E?|4U-J4ZMF3X2,IK|'H_ACUH'.TUF\$=-
Y'(%H'CPH&#!MLQ_U2X='1!9UD>Q&5|XO|!f%2ZO#>OD>:AFF|N|W@'PIVSPRT|f\$S8::%P M'L'.(P"&|KT=7SR
D&*T?N(9S^|>@0H:7HK(L^4#1M(16?%0K:5SOM(2C+ MWR9U:5YBBN5#5X^K ON^
HTFP4B+A6|f\$M=J*SL:ANX6F*K?#Q(|&?KYWO>#F MZ?3B+4FN#:@H=KY868,XPM\$ ^AAV|OE \$LPLJ^=BVI
MK_Rf(GLX8#5>AH_|BF|6RRN_D310W.#|0*X*='*P 5Z8#2XVV'|J1R_|
MJS<|W8\$4AT|5DWT\$Y|DLGY|^&5SP|f&.\$?T*VP.7#X%2KM. MG|CV|18MW:W7<"OC0SC-8*49#UB+9!G?
OP=GH6Z#5OC.Y^Z|GHSF1,>>C MX|WFXRNP?SG5|D68=|0ZML,H^O?9|K:Q.Z7@03/Q_4#>AX925-L%X@"@2X
M*|C<(2A/K*?f\$!-&E'XSA|4NZI|f\$QV\$%;Z=4|B340,Q:0/"P:20::YCM^GM M0
|UNW4'FKA=G(D)W2)6:8JCC%B94TIS&6'9|/"E?S.3:H_EJVA.|7B1?7| MR5K=?8L&:">\$f.<361\$^GP2%8OVP/&_0V|L
%&C(7HQ>%A?09P4H\$|9S*^: MBMH:"SQN<56T"S"2BVCJ_U7K|>+.7S:8GIU_^Q/W-)@9:0Y_5,"+*+ M+"AE|+>
&9=WK OSH.1?=%W7NA_H43GMDPG72I+BO3M#(MS8@<1?P|YCPK?4 M@=4=B*
_%DC6@*D1|NRYZ\$.0E\$S@Q+QH?5|O+SX|OGGO M|E|?O7DV_V6"E:V#%<|H|X>N_:|S@'SL@QH+K|(#.8|)=f:
<1#>X&MW M(+>P7TOGD6LM%-D|H|=<\$Q?5RD|<|M)9L2L_*=6J\$&^|fT%|f+%7B+P/N|XZM8Y-
M79K0|LOV|)5"!RA1O=HXL+O)G2=V)-
R<,U=:7G^LTW7ZHVYP9JFMNLXN.OY#3M%UDUVCHD2"N^:A.RI1.5T2.M.637| MHCI3?67;^V"W&@BZ+
QPD&D\$7)^+RSWX\$0 U-TK^A^A-#KE57VWX7TWKTK MWSS|_<^A>A.9M_/@2VIM=T'VP*-QHGI*53
|83BT88=B.C/R^|M;B.R.WWZ<65^_2.OMB25.)?X^H|<|YFAN3:5;R+ M.VXEP|9.%F:4
*K"%&>ALO<%F""H^+938#8^&BVYA)7|8W%2P|3U/M*YP_M|K#OR+S>
|17|Z_XA<>|7'.9W+==G+HVS8KZL9CS/Z)4(5|HAIQO.V\$VQS MW:ZB>>|D4(S#Y:QVR(|JAR@TH\$58YT(F)?
%8T1'_ZPKV<=\$?UJTR,*UR? M?C3V2G3P'Df?#J|^+<7Q> PBS5KIZ0D.>C;%M36-\$TBIS-296P>^R-2S3
M+V|LG\$LM<5=5.1'f\$WT8|f\$|5:U3:|LD1H3|<?>QJ#5|0YK2)JK=C-U|f\$MYT@UI^|O7C%W./8V|N?<6IV'P.+B)0
KU+H_Z1>1?U#N8F@|S.|VSOD' MJO4\$OS3.H5:7:54C.B\$M%DL);/O.S2IMOU#D="Y:>&)0#KCH<|2SE4.1&Q
M72=)H%D7UYZ0N^6;YH7>ECXIK(|K|^=067*|8&IQODE|X7?@4;)BZQ#F8;
M+QT)E\$|WB,WAA*HNWS/OFZ^79L|9S=ZP4"QSO%Y|7DER4422"X|/-W"" LLAN\$;BE.>0L=G.K:9|&| MA3\$7S-
KM#2%<7ZZ6O1)XP%&BL0L^A%\$S:0^:IER2(|Z^&UYQ_3PHO|_M&MP^F#NK7(K>|
|)XOZX|B2#%LAK7|T)0U;O@(|Q:#Z6F2/>-JP+HW|_MG:-(|@O)GM@>?>
P_8'B#|2V65PW^%|1'4H*N1=:C\$@9+T(|U)68JFNU)^X=F07ZP9@T3|<8@|^N7
M(=WXY>^|L>KO#JO*#2PNKS+|B(L27=90|H|f\$6EK M|>@A=[7D;O&5QB7*|L|7XD%#K|Q|L7-!&1#C?JR-OM&Y
XE4YJ2-M9>9-M>Q(GZT4|H|=GO|T^|'S3S|IKB7OW@(|S9V""OCI/7%|.YNHL<*|UX4HZW.|
M5&L^IDP>VO4|P+3^/FTX'.9MGK7V0|Z."\$@/_#PL1,OX""@7:|\$|f\$M'|_TT1E7"|D|6C8O_3|D). M1|=R=Z6-
|!>1P9|PP3HUA+;DRGIR2>?J4JH%5T2#S"G4#;6|L#&+Y^3-1348EJM+92(-7WWW3J1)
M|9:QX&H+K|f\$F8A7|XK34NK>VY>KC^DAATC>|PX"KXLS3_8)0.1@)\$|0<7M> M>_0MA^8LL"T2Y)/TWB&^|
Y_C:=53V(VG><:W7|H.7OTG^%MN_L|G+G:Z|MO VO(f=K#HFQ|_R(f-
E='|WY>|=|f\$^4R|'IC&3MYX>F+|))%NE3+T+7<\$
M>\$N'MV/W\$N10<0OJ|3IB%L6H@Y6+BPA|(^_KAJ)+UV0EJU/7LGR2;VGO')Q% M%|_*C0^A
U@_BC#9|PXI5N'E\$1MY>_K>...2.V^5MCPY_9L.%M9X M>_Y>E'SJMT|E;LGTQ\$S37RWO:GS7*T,|
\$^2TDC|_1GE0-\$ZH/LA=C3Z.? M\$V^;VF^@.R|_XGOPT_-36>77 W(=&AM*AI=(|9U4.L|(- M0:
|_MRU\$4"KOX_LB"05"XV@>ZO/%1_!K3<=G*T^NW7L2W;4_7L'2YG&O2.S MIX3B68H&@%-
KP+_NA_M2@BN!"T;Z1M>5Z,"DG<@,>RB'<@78L@.!.OXX=+^ ML+S%|H,PM?"K26&WM8K)
(4N_JT4H02IX^_|O|/!#>^Z5&FKHX2_..W-K#%|f\$M&>LR0+|_9=NP*P3|6/H+PXOYA.#;@?CF.S*=-:005O)?
2DO7O:"Y%>%C91(M"14|)(@P=F"V_#M/P\$A'5"QM39DZ)FJZKQC^_BZLE2B7|Y4%5|PP+GZ7'FL%|f-
KGF(^O9WX;K:#S|F/28MJ_L9R>EGT#4|f\$A M9(XL=B_+P@_B9>TWSO+=U;%|f\$S*Y\$?DCL"=O*)\DO%8-
SBV^1'SN0IC22 M0M<&E1P)EV>|+>0?5><_7#J_QH^W^?G@|f\$71B;)PAZUDML+E#)Q8#X3>4ST M66?
8^9C:)Q&4:0OW3'B|Y|T-KW|GKYAY?66NWB#^|H6TN/WEQS|D15+U\$C MC;\$*%O.F|f\$
(BZ:)4+)AYN/Z@f\$73LF|9WDK?6BH|RRTD+QY5*<XJ3AR=3& M#))\|H_M"#75N>M(^2'f\$VH6T*
(f\$9!"UR5*E9:+-*#XT(7F&5E_%=4C_9U;_M;OJ|Z:Y)C)@>|V%|X%_'RS(+LB6H96H&R*H
MW0*N3JDL|)^^(N36U|UM@;P&@N_JY92O%(8|X6:S_&0I+G(P,N1A|"+H&M M&VZ'/D9&J?H"/:(f\$)N!RE<1@H
/E-V|H>|JMG5|H9X?^<7KW&PC*|8081 MTQ|+>*>^/1_T9M0CKT|B.*K|HUYR_*R:M70MKCIN?C
(L4RAY(&G|P8:79/ M&|8*GH_H|EVNLP5'3UJA:T|DTNA3G(VKM:#HCR0GP34Q'39_86UVW:*|f\$2_MHH7|
f\$P)_B_CR_4:~(f\$TP&A)M\$^6|U4LQ;L'E3Q/R(|YPB|JH|B9_M8<3HTLVO_P)EG*?
0!@%A8:7|8^C_#U|DX2L_EI^?7VH|=+4:5C77C"=TAN(MF_!""0:OS>T:(f\$Y%0:C?|X^T<f\$)D|S<+;;SQ;APPOG
/5:7"=G M?VWK>|W9:93KV<8Q:N|520M+6X#Y@62EO^#==HB'W&<0?9|@BPDZ=(OIS_MUZ0|(**|f\$P2PW@3^
_8P1V11:20=J|V|)2X)M^-=@%4\$27>J'=07A5X4<3 M#^!7#C"(%0^=5P|+P^_1/7_/ON?_%CUST|f\$|
/O)U1W(Z&WY|X@_@G M|@N';U4.,P)U#*/ M.-X>>QV%8LU&@'4KL5D447G%<;VBK.(^Y//-%|O;D/6ZK|K?
Y3|J5IK0 M#?Y'3|!#D|>@'S%+M8')HRIUD.PP<4D(R"?/B|f\$C>W9?^6%U'WADGLZ^MR7N8L)O8W
3%DA&7DA<8GX4"?|L_5C";_7?EU|+*OV(K(\$8?R>0Y|+YI M+B|YX45C5+@.TG|H7_|R;?>
NW7PB_|D(QAH|R.)EKGBH&@VWQJ:X0:LY MQS/GKKP-
IP8Z76FL&UV#RGX|+9C;TP4JA>4U#2_+4#>4LMXC\$>N.PZ|P MA-L/A+S+-(G|Z&""19XJD/DW|<6S7|
HH95MQ|Q8LA7_ZWAWX&^+O3=>AEG#R|41H<0ZW\$OIVZ:5|C3&J^CZS_MNL94A2/MR_TU5U|YRW&T;|85>5A
%:Z&9-|012^":P_O0U\$X7B6")4-WY|L?@*2G92|f\$|F2.07HE69S?>)D2G*_D MNF+<_CIV2:?"
|f\$&UZ:8OJ%|f\$C6OM50*C*WAF?LS6ZZ^XLY@B|SK+|G?A M0>\$RXX<=V;V1;&('&#56?
OBI|H\$3>SJR_W5PGU^TC|HU""^\$OW(XP(PW># M)|FGS)|YWXI2.:KYN=K9J8/HBR19R08/|H80-#|T!(K12#<3"
M_G+V.IN(AS|@17A|W8@=3O(RZH&*3|0=W_RCI7E.0RQHXW.SE_%A4SHK7 MY:;
(f\$1.M\$|EPD^+A2HLT@S4|H@/F"QTM0/=YDTUN0^2&OF7QE_9Y*E<)'9ZR MS:7VLWA^9>G/>9GP=OA5SM

A9U>+H(O,H)U0\$1^1,1,1/\$8<3MV=!(5^B/8MI" E6)'S153! \$W7SFK/Z^Q=B5U0AR="|+X#+#A6*(207@5
M4YGO:/H.NOB2,H6O!|>C14=*AW"9'RS*!|V#UQ\$P&Q-BX4NCUNV:W_W_GO_MZC?
C06N6'9V7)>+/(V!F1>6U\$#<-%PL3LL%)5Q!9YXM>Q^F'1GS:PH(JL M^,&,P07HT0N?
S:4C38P1,CGS|CVK\$D^XH(^#W%L!MO\$&F#U_
N4B3B=XRA|28GZ"431224NJT\$9W0D\$7>M/#J#MP#^OK\HX^ M3L_JPU_S5Z9B-E4TP\$<>XY2) 8AH7(-
(GOEPUT0.50BV.B<(:%'6'6TT M')>@59G|TODH|ADU+;VVT-;=9/'2%1U|_X<|J?P"FH==;B*+F470@C9Z
M\$*0FBEG)%D;)WM3QR-2^IG|BU;7WC:?,DV/OO4F*XZTB|>_U7BF>G-JE\$RS MA?^UP+4CF2K*H*&,V31@'F#
<#F.%"J(-_2#IOMD2T=YI9EFFPN.1".DSZ10|5#_Z=MY5GG5|VR""<#AV?OEF%TVR1D0^S,|#" M0VVX?
>@3|_Q4IU>E^VJN)MS2.1W*+;\$ #0G&C"VFU/-8-ICAHBTJX\$R|XXE M=,%*04?2AW#.00!A9?2
RD=+&>E&4EH=H5&MAVM".9F3MNO@=:Y;.!&-|<H6 M-4X5HJ>OHA|=U|SKO=3JV8UALN%S/0+J3C!A=UZZ?
&=!8T|YYQUK1=OL(MD^#GO-YA\$50ZN@/OPP-PCJ0TQ&,(2^4J8/&T L2*/GJ5.P3_8 J0;D N9T#:76H&V|
fTE\$RH1|086EE'7_-=WL?%ZU_M+O:26 M2!A9CC*GN=*Z"69&DWD68#ET%+!-
H_!88M0\$N@3.0GK#3|_K84*R=W>6L|EL MP-'2A3\$1.I(E8)"@O1_#J*Q|@VUVON/<4%\$%L_(*Z&
MADM"F_+ODCJF F"E32WW/B5I8/"CTI7C|_*/L&-VRK'/KS3JO23 MB|V|0K#D^ZEIPD-2ASL C1!=37*WJ8C>@0?
9\$|)+\$FH,2|^CH0%I8STJ\$S8 M8ZA/67O>A)3!|+K)=9CZ9|Y_K/2T#GEH\$D\$WX"KV%LMO0EMOUJ(+HY-) M1YE
KA=>_W3|U+Z|TK*YU@_@WO VDNEQWJ_\$W61J+5.88D;E "I"TI",2_ M\$SW\$'@N!!
|^OL+4KA*);.0\$G#T4F9@CCJ_9.E=)7PT M=KX(Y..@B=B|G@S;|^>@8ALW%=2I^Y+>FTZCXUS\$0|^@9B|?
3K|0LW(G?3P MR_VZNLG|X+|^*XPE+@HRQ6A3|+3B3YPP\$""BNU_3*LPXKZ8'\$1)=.(@+%)O M&+D-
70*_J=|KJ|:JO'AKE;S#="IGV-#O;_G|/P65QX %S:D HV;N69>/M_-*(+1%R_DN|W5:8(DM,G>UZR?JFIBC7
M|/7=8LGZ#I=Y)D RO::;.=|_1DPCO)T2+;WB;N#MU7Z|&L^NINL:M@>_)| MOW-N7|IRTCG4VNO;Y"
<=#O|22@V8B'1YN<07NR" T#3G\$E31\$DP@NC2LJ9 M%|+|/+=-Q146DXPR^(PW0-%BS9KJ@
MICKAX(OPQ");_6(B*+B9'(<_ (^MXO3:|9EFE).+TP'U'0_*Q5V9X4?(1 MA5FX"2N8|G1P+\$V:>1H4X9-FT^3;_8;
MU9RQMFG*?QMJ;3D'S9|ON:\$7|:GS(N0;2*@T|2+AV#&P_N-%M1X)26F18 M4|@**
(M.%T8L|W788/VZ;DLO5L7^JU8/H#3PC"@>U%3A!>U;3>|/\$*00ZF<'R?TWU:Z.4Z=T.O2RO#8 M?+\$ R4D6|T|
|+L#;|.#3>K|'F.HC|_J)G6...>|R=FDL;FS|_\$%U|>.CHJB MY_*G572_Z_GB|CBQ_VS<=W(*M?=R GW*7<5^E0SH5
_Z'M-|2E'LO)RR_MEV,J|>.T.\$W.)VX%L-/E&GWN?ESC^JG_V('LH_F,N/'&0?5N>%Z MU:B^>EW-
HC2:\$C\$XTIGFL(J,2|IW?>@|99Z5>@K'\$=D|V07@#"D^HWU MY6 J+M5\$='3L.KLBE&UA=3HG(? FTSO?4J|?
=)|>GB&J+G2O:8_KX2P@*\$Z MY5<;=(|O_*RM@B-XE2G_HP:PHXDBU;U&="1Y|^H2#=#B|\$:K;^7>TSEXR4+U
M>6.FRD&%_ESUSS|NYZP|Q%HO@XA!_I_1#A..@C:C888|@_#UIP1# M=<:|J0.VH@VU2V(%6>%
1VON;6C"SN0DC75^3R;2PH53;G4D;7NH3C19(K/ MB8=-+D#5QH^#@2%|C#PNDF|N7_ZA_@9LUAD|!O3Z
M1L=3F^Q<2K5V28(UJU_OB."OYXHQ?|<15F\$ \$L^T'8 MT.N'N|">2G'A7#-
\$HR2JS97COA\$V3R|_P^Y/#X|L.WG9G7\$-)\$#D&*@UV MMHRH3/0;)E4L?(?RMNG0W@V2:0*9|Y.M(>|Z-
U_JC2G'=(T:'HSZ%1G|JB> M..?H7/T4>FR^ (986A+1P|V%K(M-MVZR(TSX|3G|A_3E>.N|K|218|0#^3
M;_>6N555EAL|S>LN>D8K3E7G.V4.R>|3B(4Q|4\$K^BW(U?)?# '>MWN,G"7 MOOE+!;
(T3DH\$O9_260|383E+1EM_L_ "T07#|+|W+K=F<=<)>6*D=2\$5 M:A?A#;<7T|V8'7|W*BOAND^;9
56|OEZ|A|VCZC<#LN)|=K4RK4J3-15 M#+2)/8K'+U(9WDSPUFN@ V=R!%FC6(\$T&ITY;2%84F6,^!+
V3940;C@OE M0VJ'YOLOU%|6/)(ALV" T|\$L23PE M-8X* MFRO%91R-)4-
J)#8R2<1#2>35H6GSA6UKA0Z/&4JBVOUJA9X=|37?4@=X M-24BM&YKSW%O6#%"@1M4!>8S36>"8=V-!3<|X
M-XD6IE50U1.TZHT1'|@;)ZT@=M%8_61&U_6QHK_#L|46|^=^9CF(?S;P^X-MD..8H?2
%8_VP2IPA;)U|QR/CWG_&JUA_H/WIR|P4SQTNDLPB.9_\$ZFR# MM)5EDY;.% "25K*_DY#|=&A|V@SX^C?9-
1@("FE/0Z|T"RZ\$9)MUDB>AKCV M9H|SRG"E-Z=YY|H|/A=4>;&SE|3Y1?|>GFESCG&ER;5@?L:|17 T>T8
M1|G0|'30QEXX(Q)7- RV1.I<|7|K:VS 9Y?|>93GNA
M^J6|==VTUH'005+I.WGC<\$8N;%X+LJYH1&WAA7_ ^J@H8^3CV/0^R'O2,0#CK|=;|SIZPNIG|U_Y;
|_9K56H4I99WY3^MAB M;.0.A|LT"0&F8E&WMB&%M?>N|D.LI.9#R9^?G|X_)^*N)BR+6X#NNFW" AH2.!!+.CN^
MN?|9|W5T#9%MH('@<@'KN@-H|"=A&CV2X+Q"KS> MM|N0H;C1;@W;V|3EFN2ZUN;
|(?|RZBEO4+POI>^G<_AY?|>X;%67#;A| MN0B3|0
9&K;=FBTC;|C2Y1=OQ)QJHDL2Q_ ("^3)Z<_%Y4+C|K2/U2Z+&4) MDSJ|Y+<(C*-/Q8B@|A|'4-
|P+!+|"6*#M>/%O<_E;K^G_2C>_NNJ<_|.2/ M7+|=9V04\$^B4Q#H^DP|VYLLR'(M|GT@":_C.MQ_*C-/L_6D08|!
<9+_K MV.U=O=W4X!_FJ0^=^A4*4A;20\$ _CQZC;(4|ZI2P.)BI5N%)E_YJOW2W^J|=
MTGS>YB1_|@A/384;"QN:BFGMV316D'R7PL60XMX4'7LBD;2\$D46\$<4-C^F21VQGN\$K-O@EN;
M"GTLY/>M3N0.#;E/RO1):|3H;95|JLD\$)CZKXA\$.0;QX|G\$|T_HQ+<;_ M86^V*H3K<*31< P9PN%|B|@LS;
|D/PH_-/OLG;I#H2/&*U?P2?;D;E_ Q M|=TK|VNT4Y|4V#M 23HNCVY3FD85;04+2=>?Y8_VB|WLIDRX-KZ 1;
|34C" M6@%VX83ZHD|6;CNHX^X@IW&,"5|ZP)Q.H Z&Y>|A1^&"K BM_15YPAUSITQ
MEIU98'GYNYD\$E|*\$@UI*YBRZ1*&1>^P(|_T^9R.>+36HWD_C|C@H6=C9Y^Y M|DR.G6V4;H|D|
|54G_P_==35H6OW-N7F:M VO<.<'7&D#E)*JH;2NM#@7 MF3A*V|VINS|JR+YQ*;H:5XTV-2_2GA9M| "^|@H:|=+WW2
M|A%:_4EU4ANM3VEUE=-Y*6YZZ8OYFZN9X7<*;O|'\$P;&ZW*\$U|NGU5;PNS.L|)G<@^|GSN"=V<6N_
M2#_'S|H-#5)1JH4F|CTA'S;07X%A>O7SLY7*9#H:3F-VY K&W/3Q_MMTE_*34+X\$^/%Q+< @3W6=
|JZ2R#DGPZ_9(DLR#82H(=%Z^4|_*E2E|I MUSJMT3TYV)\$K|L TOG>D|CL>R.">\$-#XX#Y|FWWS0E--
|_#WPW;J\$P%\$;|Y MDRCKSNR' 6XAN#D%U|@6Q|H)B5"EDQ4T|*+CW6YB0R"
<4>6'7LM#*%7(*6)P,*VI*|^E8%*VG|_O| MJK#|L>"&\$0U.NH.8V*6|FK)7=WGNW|?
G/4&|1F,%/(*K>08A&#_'Q+*O_FO:KW|DYWS:C|<|#UY=| MSB8/'|Z62G|P4(U.A_S0O)<(6<1(LP0!%=JHS|H
0U:2"=H&E<?N7QW<8Z>X*<8B|0_Q_U6J&G^J M>-FY2-C;)7|"M7;N_/CO%*CH"VE+(-BGJ9@3VM;1| XI"|&
|'B'DPU""O MZT%5P\$W9Q2T%W6Z|_A%R^|0/LBV-6B9_+|=F"6|K?+6Q@C;<>U/(P&@|H)GCRD^+*|A^GTD|!
<%D_MVK-S'F^C8#+%|/4^(<XE@P-EIXBH^H|H003=M;#|+TK-MYEM+P*QGN+L/1&02-9QDUYN2=680+Y0\$
M93N2(VX3+700(3;Q|H(1=JKS2ZF,2|Z?<")7?9#H=NVLE7JDD1J*GAI MV|Y_3PB|_/_HE-
5#Z=RB_O|WW%PRYC#SE;+6T|WA">|OP<\$@_I W2!"^?>+|XZF=K;V M'_*GIQD/*"37,YFF(GO33PR?
K3P<21\$<(<K6SKR?W=6"OKQ#H0'O00)#|? M@3"%070M-\$+ (1Z"Q
@!_X2!>=T@8#W(P|/8|^%,'1K,E_18WA3.\$Y|,=;
M1+W5+5#E@\$+Z<"D(@QZM9+0/2|XQXY!;%_8C|Y730X_M@)5.HH#BX&600F
MU.MH04G5SD;_6|U72'|,KQ157FF>*1HF3)<(QV.N(ZYAN|KN<+OS7/(8;
M2&G;&F/30WUM+D4(9>80408T\$76*P.C.O/GP|F|F|8%5D'M\$)/_4AT/'^ MP|T.^G
&V+;^_L83(N|=LXT4EF;U"U#7*>^1KLY(F@;=5,KKS W-FTE:HEPU MW&<3F<|OL8:M,5AGTJ|9G>SL^XAD&9/C-2-
M9F|63HRCZ;|3WQR00"N\$C%| MYDCN'1.C|H"4*)K|_4F7M>;L;B;L-H Z+TNQO>|S5*K0Y%D=TGA2A^Z
M2_F^/XXMW_O @_ \$P8(X = M2O2"Z)OL7\$WZT?;5.CB75W*9CDI-|^%\$@S+I<^/1:(#C_V>5TUTQPR>WAD_MLW
A S'F24(&CDL<(<81P OST=;F"|)=8|X"#Z4>B|?Z1KF!"TO.=#U;4B M/3A@#WE8X8;VI_-M %M?F|*GI_-#;|
MBPKIS F#W#Y=TL M38V("&VW|K>|WSSZ-4>XG_-!99008-YZS*\$ZG"\$H M#S%@@6F"Z2%HL1R?
V@CHE08R6&LWLUQV*JN|L9RS8+URVXO.=.C5.NKL7O
M/\$Y2C|/E3/X|J#|F;S,4|H=X|9^_H.D+;2^4HJD\$|D&>D'L'VH MVTP3K4.RVT|R%_&FKM%M%L^T|I?

&F.LQ36%~\F@>=EVH IRZ9EB1".T M6^E\ P&4K%Y=JGDG DYG*:R*UY\:"S1"G'5DC&4#FO"^\LP@5)\$\$%I2WI
M0%>@>XA^*@O(I&5!;Z165\X<+<F53UYG'T\N<I(^4QP)I+V0#KYSE_3D% M6E;9Z>UV^F9@E\K8?IPA JZBS^Q
8@:..7#". \$0)0%#RM6L;+YS;T4I=OQ# M25=X3?FZ>/?&\$8?TR\$8:C>=<@.N.\OR!Q:8:F@E\16<|TL&Z=J?_+FUS
M1*(OCXE0V\$=M&AV.B/QB\2-V\N)J5:UN8"G-|>|*WC=#F3=AQT279I M6P!M#O&UCA\$!G%=@@QK=D-
WN6H2+1TQDKL\Y.A8+B6ZIERA#16LZTF70KB0!M-VTJ\HZVXYX(OM,OY4*5)@*F1X"12V-&8'C(ZIOEA:NY
MF=>?D4@WGY1EGN01\|>YIU)F7 UC>% UL(W0NPNB03QA&:LU?<: M R:A.V5UKL@E_?AJ7\IKI=S"4I'@S
+BUPOQ&1 M^J%GO_9;FK#Y^O1D M:R)H(M1%DI:I>#CMOC#^;+&0GSJ(F@4UR@V)'XIH>D-2^B9;!(YP9P"^\
M3B#:I\;*/N)V_?A1YEY.LEW1HFX8(6 VY;=&S?^D|>@;CS^SQL@A!\$<VO M/Q21!"SFD=%;5;;3+ZH:E
RZ3M78B7D?Q2@Q(,*N0(SF_Q*JS7_|^N=_?/M_X'OC\I7P!02P.\$% @-(%Z63NR\BLS00_*4!;!M9'0M,C R M-
#P.C5?9S0N:G\G\+MG6%-1MRZZZ I(,*B\X*B-(2\$1\$0\$4\$%J4\$!;4)\$ M!*) @B"!10HH*%&*2!0IK1(ER;2FT 25)
Q6A8D:7WSC?/N?WOLY\IR\I_M_VS\|-(D6LL:88XQWO&/N9C33#P@:/M MY_XIH>V-R?_Y^R/_XZNL^QI-
BXYNCX>EUTJO_UR_X:DAH&K>_9B_ML7"Q"8E)F8^29&7G/V66U185/RZY\$UIV:O:NOJ&QOC_U18^
MC4I,3DW/S!*(2I^~^UA>^E*WMK^8>R^N^IN_+6+!6!C^>?X5^T2A.OB>L# MKKIVL;"&_3U!D)WC\|%%.(1-
KNM!PG+^NP3.9/OJJ9IOIR.'4GTOTI1.C\$% M78(B^:H_|#L\RPZ\KR_1%L/EURS_R\8".8!-\$(#=#!D@KPW_?)U7#
MZ>)<#('H8)M"MAO.:UX_|#LQTPHFAY%Y=I4!-)%)&HOIF1HU31>E\$)6SOK1 M4=.SJ&ZIELW\9A5CLK8IP
1B%HVDB%3DK X>T27U5.F 8S.ZY)3\YPLP3>2A M%LN;UH.XOK7K@JL\NQ02B:X+RE%?TY(B3U&!,N_6B+?
B=K\$^A:713.IH_%A88GVOE"9.UL(%1.YVMO'7#5H5N"85GU&1F!NZW\$7 MKOI)-
J:KP(#N!REPUJ_)N!92IHR>5Z5\4O_EXD&^Z/_U'O_G!='/N%LDY4X8 MXZ>^I=-@JF6^YM;TW+N7Y?1(V.
I:AUP_+H*WJHUR:NOH)?179_Q&UOA@ M1"C(3!>6GUTDNDRI.QO.
I^>X%H6M"Q4^~.1^!^JW5YV;=MNF_~F#%?Y@A M4WS\3@~GPE(&JN8D)P)YANO2'-
=LJHM&KKSPE;DD(I:/PXK3K'I'!=\X7*_MJIH4ER52.(|B\$Q=6EZ080*<6AH'MJEM95@BO2I*X^O_G>-
JFO(YTCJ7D0& MK#_|C_BID9+FT\11A%!\@.Y+X?C8W&B(9AD_OW46+,H&.-Z1S MC_9D2UZN6-
V=RWK0T*#3=3@D5YYWI(45HG@&#NI=O\$ @ (24;<>27)Q.-(% MW(.IG'9\$M)M.#0\0TPUZGSYLZ%2>H.
4G0+L:H\G'7PRH\I\$D_AK\5_0\MC"9\$?T\$;B\.(LS;R_+K2\0S*!B1\$UO)=9^>X28\^&IX:MRH7?/#.ZT5:34U
M;F=JN*2GMC>9%)D4O9G"#\9UM0F.;>@>0;MLT_-LAX&66/D7)SE MC#Z72=I?W36Y82'-
I_X+!QKP\$P.P.-\$=QGZ9,A)1L2&=2!6?-%8*9T=HJ/ M/=1-N/N#*MV0D^P(A:M&?;HG,>T<1>%) *X0LL^&">!?
R\X"GV*YZN\ S M&\$+D8J+B.1^6.X\K56-Z""7D0-F)QQ\#F5R9%0BC@ "4C"9=J;HS J>_V I
M6>K"AZ9I,E=LY>_F8;ZU^P?LJ2N1PR7SYC*FVEWS_!&H MJ9(L9"71*62I%6JA"Q,3AR>C/B-
H=FA!;/1YLB_3WN%I(?%7YYLB7\>_K MX24F(^HI355R>1HU9!-IW//.#5.1?..^?I_+A@2#+OVMSCRP0\$C*50059D
MSIAR9\>K\$J?W(=A\CF&BWE4ZN_%Y3+M8BN8 M2++I-
\$BK)89CQ.8644E4R3G;U0CW@#)D_-6O=^.%5)466\;G#IN1'@S#J#I
MS0P=&M=?.&#.R07O!9A>1/7PKY;@I\$ZN/ZI=JE>MT#N.(@4G?OLF>_G.Z9X MR^OI_Y\I60F0+ID;QV&YTH;
IN1/Q=9C.YD_#RKZ*(^KK\%44L#^+W""&00V=W M6+^#T@RI5W*/K\+WO\41AS<\$J7
:&ID.US6!Q\^I8^W'2(C\$RMU MYPX695B=2SS5E2BEHU:KM6-R&Q\F C4).+T"C
MC;W8TL@BME'N=13P2H7MIY(=-&QC&8E1+M5U>PYX)P^X>X""\|BXK\(@)768
MS#67G^68&L3Z#52QIW\H6N6W:(0_6R-GJ\&IK#XIK O'Y8L1!)-%E=A,ZIM2)/#QD4G5\@#C0!-
T(1/T09T>1%4XDIS
MID#S^C#^RNAZF^JB+X.K833DYZWA>"WC\|M<#86^%V5C6C1B\$=%N4\=C_I_=\$,\$9H627L#IT7?;TQI"/&Z%O@
M\IS2?@ (TFY)*DNRK\+^K07^E\I'R:7+=?U5&LY2O"SA_H>>9\JH\X60S=?
M:J52(@4VNY:4)S8J*.;7IS+7+N\$;WUQ(VYVWWCS@'P-B^5.0T+@-4;D:8\UM>8H.@KCIAD M:C*MGFUT H-
CZK0"T6-"(+DAISE9W\K0\5\Z=(WC\|=7_R\$=D4DE,KOI&M<(^QWGA(X;QZ-JEF?TY&=YGY0IG:ILX\$^?
CM14=HA\+T(I9G^;AQ\Q A:8-9U_/1^5^G0WDR^X=SW0.8VPO@>D>QM>"
MG1>HA2;IQN*MX>PNLQ=R#27XTPIZWIU24KTOM5158-5XIB>>YCV@5RNA\BE MI79LS53'KHS=I@1G)3E?IY
H32\7H(XE3\$)0GK; RJ3NWQ^T6R*7 KAA=:NSL X/:0=DY^7SE;9KIP+ M5+C):G-W_@)80Z;*NB*1QA&
>@>8Y>H\ICUM@Y\$5;^E3(?)"7N*RXDM5N5SOGNA
M+WP5)U\AP@VZ#10)EH9EFH\@E7NC<>T1P)Y+*Z8G8CP_X*!B2;I:&<I@J2)7
MG<9>!IT0SQ&H&*VH7XMJENKUOIFN@29Q?00IZ&0HL7\5+L\<NV25/(%E
M'\#I'E3M\<F\@G903BQ1_GTGS\BUF=RC MD<@"QVOB9Z2\;E\Y2A;R:1%-((\$5;15-1.SU+NN^ KWD*9/*!O-
X96 M0>E;09@I_L\K4@F"SM#L;39,V+5^9W*XD\>Z* MH_I-^
_U_I7*TI<9?ZEJ=P*N0C\!\$EW\D")DDP*Y;E:Q+D>189F1.C M#=#/H<"R@GLA9C<9W @"\$^"/8*7GP_W\13&X??
76@+_L43(3B\!%05A*//>4 M.'6^X6R^>372)LK#X*ZO^IO^M>BO"/Q>Y;WCMSD.X;VHX0;DS+^&D;AF78+3?
H)>H&3_0D&S=^&R\ M.JOZTL:UUL'O@T&P_"V8S;10ZW\X0\Q (@@Q3QB2#%ZX.^0\$ "L3 A=-R'\$U
M10A4W*0C@J13Z7#G\;\$\RR;X>I>R%?6^5A);2M52O' Z(V;DI^64@WMDG\$9 M^\$WIKS\Z37'Y/U^#T-4.WV?
VFR.RB;HO%..%6Q3#S98728UH10X\8Q.6 M24@<3;3*@MX084NIX(<10\!S;GOG\A%HB2_U^P\I*
<3(WTVY_&E08_.'MC M5\I)_. \$KNXPHS"41.WGD;:K%I\2IDE.@I!TG^H\I8!-72;<+*>"Q-U)MB
MCZ/G;3F\XK=3.\TI3^.;^EG(*7.=J+7+H#;+ MHN#4/Q=-.6CJL)747&=<@*MGR
I_1/1#9>E.K;T+IG3\H;HW="O2;TF_I\1V2\$&3T M"8AVR^;G=<)C&ALHKQ5R?UTR^&Y;MT:<#99_M353I;8_%
I6\5Y-N6K; M0(6-D YH)=*\$.<8W"54D6L1\$J\J^;^%+DDZ@_I.\$F.1@4I?HPTXEK)V M43=
IQ@9+UL7>_GH5PIV&QG\54E4\MI%\#)YAS\>H\#<8@H=(+LI>WU> M>
F6&&'M6\8J>>X)OZ#3C*/K>6VO1#Y-VTD718Q5P*WPIJ0",NN"/2^(30/ MHCA_?
E#U;0X)1ZQ:3X8:%S#YHWW.WLTJ0BOB2G2//S4\^H\6#Q# 7I=S@ MZ.FS457S:N@\$>C43<+>9A3&X(7;-
DI6_@B2^YDB(#^2ZTW5^2L26Y9A""M/^\$8GE6QF@2"+O\I023BXM#WCD9%/+ZA@+I/W_@OHY?XB(VL+=-
T%U9-"MN6\4\$1V#^X.3K)&@J\$S+!E1R MB_XIC-61.5T?7\B<CX\AX>%U5JK\$I
M>@1VON#DY3)K_XB@Y@O%K*TU2;2+G0L0\6C4%?7T?/@KE9-5>R%\$13"B2;K)/#O5Z#3&!)O-M?57.S\FI
>1GX&=+N\JZGFOGD M29MWSIW\3G<9C0UNJ\OD_YH;Z#N8JGHF4#V\<0_299;>\$6%#U41(8O?)
MC6S^@F_1H36<1UM,?>*!#;2F;TV1W_QT&ZW\B=^"E5W;&M\&7\3-H."" M4H&+B18)4DC>F9Q?
P7&\$PDJXSI)?DYUBY5#GO\GHR6IAD M_ZEQUW30@KZB#OLJM_~8\PL_Q3BXZ'B7==?TT3!>IYA"EIRB%WSI(N
M"(FBSK)'&BSGMYSZ,22SC"!Z6U* LB!UTZ!UY5LO."S\$7#).%FTUJJ;EDI M7:D0&H7FO^VI_I-
K19,BOD/_ MNKHI_7S@_T>J_RH\X6'P>8/7(=AV;\$S MA@K:I!)F%Y8CIQ'4P-1>/56CYIC\ E3>I(5&UYI*^P(??
UZQA5>9W>-H^5H MQIG"^\P9/6.V< PA3W.G0?2P)F%J;SF\$8S7\$T-CZI2IC-5S(^L>*L;7&<7;
M)*L\$ "H90QK\$G8;K\KZA-U0;Y*=FM(W5.6@K;P4O&S9&K>W\ MKF71ZLJM_M_EKG@8@"/^&?BKD MUATPK-
\$W^HG^@%)D9:=6=G\Z_ZO1^*O1)T?D8_*F3W\$F&M\H4\!EJEEQ MFC.P=NTD\12B3V_JYO MZL#6\$FW=205T"
I\K2TUM4#PNU5_?M>EQ<5WRR#F.1>6.V\I7;WC)@U603F;Y<0I8SI?
I7G4L\54BVVQ7UB;RGB@8D.FL;=/RXOUOGX\2\EK*9X31S.4D;6@LCV>Y MI-I_7Q.@\40T_==^=BS7"H)T
0.;A"/C*&Y;1"(.;|^+W#C.4R+7OK_6U\U^D'7X?AJZ.PK2?_*8H4.RE.1*2QBB;M2\$1;%.E<39\T=P(P<7;O/&I
IS7FPA5D6#\TD^9YYS5P_7GIY%5&#J2O-O>.;*6Z\HMX>QM02. MC8_*X8%Y^?
V>V9%S1N^C%A\$OKUQB.1Y;_DW131OB5\!"=LQM;S2X/4;H\0 MQ+?X^DA9?
Z2K>NADPVW#PT;+P3R"B(LKQYB.6TY\4;(00'8IH;2L_9'1 MB_IWH\UZ3NY\IEZ<\WIHOV?24K#CPU-#SFR'PM

:KDV*S..5;I?.\$!"EIJ MB0X;C505VF'RS6(, @.\$C?=7Y@./9AK3EKN/0\I 07E-
P!=[/\$^4/_@<*.63L9I&3W1G@(@)^BLT#^-+4V!Q680T&..5F2I^B!WCG_GD96_(BZXI,I:1=D9UDJ/(B1%#
I@=650JBN/-_0\$04^BLC/)-M#Y:I0IJ/BW;3BNE<4)NL>Z9+E^H^XQI40:=,'VF18L>,>?KMF,*I2YN2I9Z!
MUH.F;3&/P3K%#.SXIU8V5B3@%9==K^OL0)B ^X^3LV8W M(ZIK&G_MJ=DIVCK?
Y9R(N&VJ)>*0\$D^ON^O+ESM1P_!-=X(3\$BI0I" M9+5-
BM0:EU>&RG.9IVINF7AJO='B>W.NH.B3\$M7QYFGF58.@UB2W?#<&M&A M@PFD(@Y
J)8/>R=;7.Q\$NPFVY(A7\$2,#YIUK2+"XRJS9;=?WB0F.+^Q5LQ>4 MY?2SE19NOU(-J%)IT-
%%/K0T>A@'&)F1" _&Z7J+R;.*8RW*F)-D9\$*+K_&'MD,JOG?N?=-,\$&?=P=LO5DS=Z9="T6% '4MLID>??*==,-
TW M@CC%&#<6)>OW5B52X_4E'4@!MY^+@=7)B#&.*GTDX U;U9#_BDZ!P^(/JK M@#S_2JO(R)
IL.EBL8%0/9PL(XA1%QI:HQ%THH&F;3:@R@NPFG^?ZP6# V# MFLM=IRX3N3:JJ"*8=F/O8.588R6:^^N8\,Q9IHJ?
>K//^GMTK<,DT4,G7J MO?<=SJSGLM7?5X\$>_WJ&_T_O=[C2#:.C1V^5J1;D&%9IH=!=>BWB\$Z!\$#^JPJ:
M4PZA)"E7N"%J8SHW_0K0\$2_8:IVCUQ*)2*UJLS1_Q'D^YHLYE0(70_C_-8 MG*DE&!<5,{2},B=-'LP*
[SD8JU)P<ILA?_"9=C0B(+GR\$T'IPKW_..!@/MDTHVLJ@ZX"*EASRS;D-
)\$WF8\$4BQ%_.,LIDS*=7#0:CNNSRHN\MD\YLRO< M<;ZP5B7WV\$+&&@EW!<,\$0XEV> M*Y9O-
T,SD2SN\N7+,.S4^6_/D4KAIZ9ER2)QB?_ .Y1&'K*NI9=>| #K&>|W\$ M;Y"-Y-"M7TD4)C4N#<>U>)'C+Y)6K8(#D
3"VZ^(^5D3"==MT>10:Y?>|/; MGK-EI|WB*1;T7)SW(JCJT&XSFT.8HHEL=C:A7Y'5,%)R)!IA9,E%GK;G#_M
MG_08E/0I#_EZB9;74;..U?Q7K?T!&#^3&-Y(\$Y#33J/ 2-9P'A1R"9N"C+"2 M3:SR-T!\$T2Z7JN _@^-
U7K02>W8_+|/GY%+UY4W3;X|LCBG4FWZHB_0K^DMUE=C2J?|HK.TY?7LH>|6*|(^M)R!8N,&Y4?
(-;)%HI>@/&1.3H;(0I2)NXNLH(If3\$-W^HX60U@?G MX)I _^FSOH;I&%#;9>*F9_/GYR00>B6POT(F>"8N-FFS!-?
DKS5TN0R@!..8"JU M4YCN8KGE1HB172_&_SHC3\$E&5O;DD38LMEI*0!VMNB3..JT!=EG5IF
..4VXI5MF8ELH'QGHF;.!5^VD.IN?N"02 E3\$ ML;8=H4&|(3HH@I^|TIN+5"1G5Y\$ZSS5_-0H1,IL:/8IN/UCV/A63V5?I..
I-EV!IKU98:CYC7YVS MB9R-9|BL;G|^EODU_2JL1+2C(|A<^,@F8=24#-1^X\$A"/.58^LZQTN
M=3E+V00)SA/I0_K?+)>LLSVHI:5|>_U|;T,1%7@=|(^M)D/|G)AE."A'O_MLC:D%
(AQ:B.#FTOI#79BC3"D05_W6@Z2N=JG+K67 M^28:W N#>..-/@2&_H: ^SG8CNYYI+H#D@_83KD#*G.M6T-
D2*J\$;^|70.J M^V6\$EA_-3!PAT\$Y<|I-"GZ>_K?N\$UI_#33=-R-!2KH^0'F&ZDB)E"=| M4VI34W#7PV64ES8IL5"-
!Q_22Y_ACT)S)7?J93N;\$UY?^Y#%CM8ZLSJ? M\$P;3C;Z;\$.3:%;>| MJHH/O_ ^JT^&DT%P;Y)-
Z&M2V?)3Q6I(RD3/^?RB#U7C9B M'4:1 ?_IN<5FISY9PME/>V;_O21*5N9,|P(ZYAA%"W4W*6916>=N'QIQO?
2(A=8T=VMH%;M*TR>OA"13SM%3C6H M3PUNQ19_PP16V^3C-
EU(A;|H;&^|E3\$JH:ROV.QMEMG\$J6/F\$E6!)U)\$A7\$ M)#YI^G4*G:3RDK6PI;9N7%.Q&E>?AE)+L515@^ M1^B!<-
)C_-<XPO"=0*U;+7H%SM.=&KTQ|@K|R@:#=A*&G&K M\$!+U KEUIVM(_V.3'BY1S^I\$H1Y3,*PT&.*K?<>1;-
L@M%1WWM!@!;8|L"V^> MEOKQ43|_IH0L;+ %WNLB-EG(#LDH+G.8/6MCP57% H&9MJ-&25KJ;./@ MH-L-
H%-W; 71L-&6X;6AY;*J3U9H?>5,BT#L;X6YISW0N+926K&&D&*P@_MO'LGHS(6&"+%6'?
T:S2Y.%K9/G#8\$^Z<#>+O)3I0Y>_@|V^3*"AZ;2Q1 M);|;"9JVI/^6?U14#V;)-%<#O)DVYP\$G|=RI-
@V4SADEI0VY;14FD|WJ@6<& MVL\$X+2VI2MO;&#FZ192YNG3. +Z M;9H1,E&U,B;|Z^N5N#);->VP?
+Z4O'8&2'WK)H4#N&=SYOUJ/TJR 2 M.H890TD32"UI# 3.-/RU.F9484GKVZM;K" M4B3+|>XE&5^D7E=59-?
Z? MU<| VCLONHSFHU=&6!%MYF#7Z_ ^T;(>|I-/R1*ID7S _^(S2E'ID>|PIA+0O+RA<;&
2,Z67;S4|BQ|B/\$\$=C%9<;>Z.|NWSM33*#? WT" M.QW;R02L0T/(Q>@7.01:01OGDV4K|XF&3P3#T3V!|_@HJX
MBFCV)PI0I12G5U1W;ZB#G1W0J26I2S;_@_T@N9@&|OL#S5'E2G>J'IX'7W M>YD-S_E&0F6XIEQ1S/"D-
ALJ6&J35+EFU;S!|WV4.B>NY_KZ9Q(6;..1;3 MNG?D;2H_?A.P.T6<1W_&DJA0-62I2J_-1X2A_Y>>AQ4'EEEE%
(KW(O@|<&M;#ZLZ>&GLMB\XLK="I(^J%MUH)65_F6.TROJ^K)=\$>C8<3I9.140I1_)3
M>NA?>|L(ST8+N6(^3J67N);MA#8'Q_97JIBL_O_IE*.(%:RB6D_!@^PU-2U
MB6<="68Y<33ST^L>D)+T2|JZKTU"=7VOM=|>IE8/""VA8EG_\$I^ET.""J MZD0^V^)=1Y?2@EYM%|0;-{BAPBMJ)?
_R14);S2(W JK%5Q;+8ED71%2XJ
M_MUMVIAV,YP'X@&VCO\AQ!=Q"3CIN^5(&.#W2E+GA2^@G4;MOI+^JBV%Y)M
MY==3C3IXZ!*C'(*U2GK6K\$/GW"S2;G|H@F9IWM(JZDFY+"E| RIP/Q^=7|_
MEL;:JO8^HA#OJY\$Z""42EP8WIM9(*O| M_UMA"\$E'G;D;L'MJ;X_-9"RC.XIRJLTOIL2#HP@3X)<*C/0B6H46;)/
MUIV^6IA-C&W;@%HEQV+|+H|CHFN!\$ZYR7_!S|Q||G030;D/IQ48(W=| M;=>D152M?
^Y2.U60"&2\$PD0F6N>%72(^-?VH8EOCG|8P>|!#0;83I#UI7_5W5_M#6F9H&G|7<%T""DI64_!8!M?>8-
%7)*WJM;)6|FTHNAJ;)|VL=Q-6\$;I&M;3RN|V@(&OOYM'I3X?NEJ@>J?CSW@GVI7-93R;9 S%T571L:4NC^4CS
M?M-2/M#8;7JBIESJ2AP(P\$IR>S;_W)G5U*;M@?>|MIKWM??)9='1G/M'CD404HP&^G#R
M1HW8@8#JYZQ&8EL0=>WL"M6C/T8R"HF0\$_%X0M""..V!9S"(M=Y (HV!= M#OUVC
O!-=S=,|53I.##2GC&^INO:'X=PM= Q+W>Q?B0LOE,9Z&9PG"S3T'2 M|E;T?TD14>_W4+;F5+O|
(<W@7;7J|D;_LLI?/POY)*IW|O6;GJVSCN303R*FE MF/8A8Q7R)B7G(PY4OCJT\$%_00(TT)X8,VL9;Z%|:R?P**4!2/(
M(QP@J_9:XZ<|V""DB5YJ?K-GK\$-ST-RN:2|@9WF4#Q:_\$4|@ \$FW%(HW=9 MIQQU;234'FZ+I'S<&BJWCH4(>)W?
_HYY)3(Q^PMOG?%^X|:HO'Q5^_R\$P M3/CY=BX#;FOZ?#&?"SD\%/T..TBK3S@^EM"L*?
PDI(2.6LJ)JR;S1^WX>^XTZ*W;-|J=TSUI= ML=\$@YKY2D-?3X;C2.W8%28P-
UC(G9;9)KGV^H*7W+&87MI;U*L)N_S;IMU;JUD0HYDP M?&CS&|I?I*_*A#IYXM%^/&\$(- MMMVW3"
EA@EVXJ3AJ;7F<"KYL-P+V@7_U8YSW_..JSE-D);Q>8=;I;#Y MIA.<?J4'7&QG/UAOH;=&A=E53UN5*3PF;#?V7?
JYY+7&N+-%|E|L6\$F% M#Q?3H.2?KCH9WR<9+>#>4\$TFF*1BZ_U(=U8_!LMD<|X\$1\$C_@1+4)T5S!
MZ^0EPD(6V1_ E29I6 CT=VX0E|2O+W+5^>R>"E.9M^A|WFBS"?@Z=G?5(+ M,2_9#QM&JL3A)R3Q2M77?
0H-!%?&_"/(O|AH)\$B8AJ;YH(A4?TC>_%M=KJJ, MWZM=7(MV)KH8)AWB..TF..1B-0T,7UFC|J4TR,U9K3N--?
DMWP1_R M;,>)5K3&LEJZR;6;_JW|+L-P>_#78:#JZW|;=|SAF>(AXXPLV6W-G%BY ML,Q|<|
|C=V9P4"6")N*/A|&\$P_ IBZ*.HWX(PEMJD?@Y0|X#>MDI^>L-6P M?Z4H^Y-
+HFVGC|F\$F**91>V.;>@)H8WS8|A)#||^XG1(VK0|UEA\$; M?YX<|M-G;X6+V<|0%JE2BC|
JY<@%N&PI8I9M"9=@//F\$;9N_920U,W M3T^AU_26PQ>9KVVH%(H?)L<;9|_ (R;,>:Q0DM^7Q-
|Q_VNFWX|QOEF MW MJ=H LKJ=@>Y&_UP;|<361SDI99>L G97J;=H;JU(CYZRW)?%N;:Q-0|0^%+
M(\$VGTJ;0C3I7O*/M1.BJ1*091@-6Z|W!19;G7_8W"8+2&TTC\$(D)_U MSCL+|A^|/*_/%XDE79LAAK
'6DIXWL25(6*Q4FW2C*_8=|/I>|G79RLTHP-*3D*UK2K='D*V.R_.'Y*FJ+;|\$VP^_NWM(XVJ@=P
MS_7=Q^*QN|WLD)#^MJF?R'IW>_PEW.QIE?QU8**GOSSY562.6Q5NMP3H0W M"PFGLZ^HIR90DGX|A+R^X)Y"
GFNN*0A&UJMR0_X4LR#W=RUNO08QO|C|X5 MLANIY'D+&X8|U%D Y*+=F=Z"W5(ZLDF%"LOI
JHUR/8G%<OV^9;QYX|HKT|EN^>SWZ8>O MMAMQ#OM-3#%X08@CE>G'TAXA9K2>%.EQKHQRW;'BFW#
M+K|MD/H"2P2W<_&HA4T+4PY=U9VMON?>|I& MLH4Q(YCG@CWWE#-
BR#;2^D;X@>>2M"64B\$6KD8P>D|G7QT_IKNA54&\$ MJA0B%6-5Y_#E\$O'6&I%7>*8K;7ZVX1"VP?
O'L3U*M.FQ1P8UF4+ARGY|O,K"WU\$EOE80D0Q_XI!M M7>|UT6='7)\$IV"BL%-Q:6VJ8M+BTV)\$N@(*|
O8|MB*+96D6%0>GKBK8MO)| MNY3SF N|22JO8Y^ M;E'0+|>K9IEF4E.?
E9)CRJ>T7#*I""GO#K0N5<*G>R;.>#>S;14\$WY8P)# MA;GD|\$Y" M7X/5.&P4 MDYK
M3\$OOCVI/>|R.EHPLI.%F8PI9P^O2U)?W@25AFDBSG@.3.27\$CC&.!4!;O%K MK-
FH)WO'_E+F#WGEQW*9)D2;+I3^ 10N""MSFFVQXG3+#!?S)WVPLQ74_+X

M7QX|^)IP)^='@&B+M=%6F9RJ=|@M#K92Y>K"VR>PL^:41/ R59DF1.;?8"-7 M=?F^1@5WAAX(#M? GM^0^!|&MJ(#,-E+=P'8-I8)I0N%!SZC@AQJT@^>KEB

@:NS&).)(*XH\$62;f52G*@<@Z5.K3,300VE7> M/EJ3Z3WT#IB#<*9\$Z_6V_7,RON-"JYSA-H9D:H^%
 JAM*KKN7>"WQBW"&PWU MM*56CI>V35XAX&L2.BC/#*)W!7MC/B0#I70!1C>\FFOI Q6(T!>)AJ>F=H1
 MI63K208F:4.E:YN:=-/J/KS_Z+VL<&A.TG/=C\$N45OLICESUX/97PR2"7W> MI%IHX:3^93LFN&FJOIA)Q@N:)\/-
 N'O+LEPZ4W:;+/*YSC:75HXZ*)YV-XB_I8_SG_M1A(3,+*I^+=64\$ _9^4I""H^SMF?
 HRF02HXUJO:;EI\$ _:;>+1HX_?/:C M3!(/9912,V")#LS>"&0Q408W5/YO4K,M0"-2Z5UEN,W1TF#70W)F@=f90Q
 MBIBI2A_84#UM04Q_Y>//I>I
 #H:AJ.F*R8L'M*ME>M>S"XH@<\$7(-CRVK%UYE'R!O450+E)5?Z.W\$R/\$391%L=,I/+M2#ON6=,3@_M5(1Q#83-
 SF%,^U'O/,@XIA+JN:%2Z5J12T13WZ)RRM5(%*,)H(-M9NGOCOA*WEB;881.MM6&W%(-
 H6FMOTDQF4LV:L@)6BFYOH?G?E6L+X\$N MK@J1+6CR1+<,#A1)20/(\$CTG(G2(J:<"*f0XV3.DLS+W.R@/Y.H?
 D-T^K4@Q M="*K(8JPL JFBAEB0+07^,@N7H6A>LP^J""_2+TKM&&N=384!9IGOI F M5M<,CWW:?
 QC^H3.B4=C7^U=UC_X6!52E*L_B>ZI78 MJ0YA%9QO35" M4RVR#-0(IC)"A23NE:&LRV3U.R@.Q%15.R+
 GUIA)%OFT9HDX_I.X>J>I4(8<)&6W> BW W1S MIT.DI8OV3IOV16V/HZ:Z=%?_1WY!&JW8YI/^&D4H_J?
 WV+Z")N_IW*R(3 M("57JH/VID6,"2,0D)T:ICK""\$Z.FR0I_%?<6E?IA/73%-WCW@U'MOE,KJAM
 MUD#!^O2)\$E>|D^D.F6!7F.D)I4N!\$G+Z|^XYRLD8D<-IORG=I93UIU(I-P.M.V?
 S*TJ(L=TM!4%%:T%)O^G9_V55"FT0YI3MJLE*< M=J%_7)WISS&PX>Z\$IOG7:5V5:C2T74A_8P8G#15N' M9 L:2%
 IG)3>QI=9"4I",.6IQ4Z(G)MCW MF?BUCF)Z0NAYBRGKF\$+AZK&^J=_M B*" "
 J=_V15JZ_X4IBM9DN7S):&\$"L(BC8_*,C!U>#DQ=6.Q5_MR0?Y".B%W1QDT+EI NVJ7HQ335?!TQ
 M\$JWFB!7E*PP*|BT9#0%RWIELOF_TO*J,)(0&QPR:**9G L!+N"IO?TCL M\$PNG2(+ "84R
 0XI4N#%7XA.A7097>R"UGI"R^C(TK#_)I2*(9VFE*A@-UNJC"75E*1%AC%^"%G+^?F,^>
 MNG0A#8,2AVV1+O)L<^J,9@0A!ZW\$*XFBETIF8M495%=4<6S.N#1Q9_HB*"Q"U"9"CN#M#)\$=B)B-SB2-
 6S2HJL:7)E3!-IN9L)Q_9+14D!RM!E)9B M5?K?2IF_%4I^G*.0BI> (PMQ\$M.1^TCN9QVJ#:DL0W7VOC.*CZN?
 V&!(TWIY&O!BNN.CU0)J7:,@%)D)+.6T M(T'UT!(HO^?!"OC1S"5.1!P=2#R00F(-!F!_1HFEYHBI!>7OK.D!)=8I2
 MVM42.793_VO2&=&K_/5!\$FD_0BLT"%RD.IF1XO&,"="6F1("7>:P)JIZZT M\$S\$W!_JSJ%"ED..A9FINP:.\$#?*/AS
 8K>@_!N!?,XR\$NP#O@/Y/K)DLTL MO)>WY""O\$H+LE*M1XO>Q!W:W/S+)"WC1QE3!24H8EE1V=O<76ZIT:WXM
 M6L_<#IBVRTQQR2!\$Y0",.5P9%ZZ).WJEHJO^/W2MS%JHP&DX!Q1D7*)Q MK(XA(D3@(-7AL?E!T4CRV^)^NUDK
 C-GIO)\$S\$E'Z693^12WJH>'D:9CJENXVD&7W-2!\$JG/5AM7LFMS/CO4
 M4Y*7I%,M)RMN99X)3+T!XJ(K5EDZ2#M?)HCN_64(\$A*BF-E_DZN:E1+QYP7EN1R7J>S?F&K;6>YU,PE\$N
 M@5#FSFSCQXV8>);CKX+G!BS6F9MVE15_\$L!J0YF=^ZIDWB7%KSO1L_.,L MR!-) &F!P%!806|@Z!9Q6K.G!-
 _FDSA+6@M^_W9TW/#=6 M^3M5KD*RLK"3LK9V>=A4*=D5%E^&7_5_12U)NDCIM,;!O'NL.&7IH_VB?
 M7'GE2JY^8IT_C@^5;MF_&_O#XZA9M8YT=[S^(7:OQ?NB-I*OX6:,"00:>:"
 MU"B&\$QS?I4|P>,C/U5Y"F&6'J"C"P1\$X/6QV6TG+RM;TF/0=W9+!Y<5@8X M?1S3W(YMUY/R**/T?"-
 JFZ\$ _TC;#)05(KY#2,-#L@%% M'^/B5H5.XC3LV#/XY>_P1N_G_ID_3T3!, DPZK-PR)F)F8)9EL/6W^A10#
 MMFGJOYR:,:=SKS: SXIO>69%?HVM,=2!\$P2(@AZI>R%)O+C7?R!FLS9B9VJ7-=(P7-KU-@%I0)K&P*ID9\$T*
 O&PSO)#Y MI+!E8+'GRI/#=0,/RZDTWM_#M.L/7H@WS_55XMYV7AQDS/A5/0X#P^?&8_M'P#4X|WDH1#
 IL\$XYI=GUZ7U>XW/56D(SR)3.EU52=[/;#IS,\$Z_D) K! M4CO:"ANUQ#B 9,BC&#=#6 T:78<+R*,&^CPA8*H?
 %Y>:=\$UZVUBCOD6<># MOGGCR(W*8SWI^OXZUA)95JYZCOMFE.1"?<#I/OY21IR_1+^TZIE+Q3K7&-
 M_DCHT9,+:,*V2T5TK5W3*O7TEJYU=2THDAO=6N\$IQOS+J*<V+!&_M7D-D) PLJR"\$M!/^S.??#&BHD???
 0QQ&VJZIFM&CVIFJ03.Q@8R(-ML0K4=.A.%T4OP\$@VR&GM2^3YAPN2L%>)I#"8,42>8^;"YB?I\$OY5OXLK%)
 M:"JGL#IXL&6:8.C_!8ZOE4!(4I%_F&JC0_3;H+QJ\$I9%#);I&E6RG?BZ?C*Q/0EF;ZN M379>RO! FEVB+)?
 UMDD&#AT+K_@>EF(RTG!6)?EB;UYGP6#*W-I_0CIRH= MY4U5;A7K6T4HY?*@E\$B/2<*255=-K'Q\$-HGP
 !NHM:K#)D6\$P!+;XF M=TF*+&@WOW7CIT3QOF#T10C5&RIL*NGS,JLDI+TLI9PIAVZ9UCCR#LD!ITI8^
 \$^QD.IA=)R13^/FP@8R=1TFGQOJT<M_9Z1_C6\$HP>C7HOR6N?@3)"L.%FJ_@/NIUS#M|CC|RWR=*,0RRIL_IY9*
 MW^?#TW>R "Q'ISBYWARL!G\$XK74RPZ=[@_MI4)Y:W:/>8PG_XSP1QQ\$BJ/^5/&CD=;)OI P
 OG46VJW3\$YL\$12<1?N2^ M/+G\$XJ?8QY:\$!\$GCR25+YI10IH=5=I<?7O29@@.45+ \$J)4@\$=7TTI)SBA
 M2:5K1J<(GZX9V5^*7QI*#9C2/T: ^87\$C_4E#/_HHLJB):G!&+TFE"Y129
 M=Z3U/2:P@,'00C.E#Z<9RSNZK/*_J_L\$(AU1C>U63Y_COT1OPGC!\$G/YXUL"B_JQBBNKDDW MI='7'VIROIK07PI?
 3QZ4(>TR9^\$B,:=J=\$NDSLP4>Y;^X.JSK"R8=CC.@PEP MHGMO!T+""TM214H;MA/&2IM/%48AKLS
 \$W)=>6K)^EW2JF"77LZERRA+I0 MIDIZ(JHG:*PI3K5G"%ROLAYR69ER'M.(0OSPP"P_-
 _6/IH>J\$|+D0Q#3AI/W6V/>>='>?/6F7?K MI6FSKIB4S<1K_P!C"JL%R3MRV;PN^VTIND(R)\47P=+Q#?
 M,7)YSOZ(BP3 M/P<_I V05S3>=,SS"TW_TOJ??K.C.IV!SI^4\$^M0,U65=_P_M(^=I?F'RH M:#UCHJ30GXA3WH+.4-
 DT)U6*F^#;UJWX3;W\$>#PWOYK;WL04FKI3=6!4&V538H7&L(XJC= M7050%8=),D)_VWJ#>ZT.A:/".YN\$66?
 !*(4CB;|86>S2G!4E^V.F-P MODVF)Y 4H:PWK_UE7WH?4KV0Z26MF6CU7S_!101HDJK4F I=3&#&JAM7
 M4Y(4XJ?42AJIOA@E_:#.18A:@WE^(CJ|<^>4JA7:N#6"PKMKB.E3:.^A'=1>B/!\$ _3?XC#W<@=!G3BS7P;INY>"*
 IVP\$R9L.4S\$ _M=;3"SB6.68\$V1),B/I3<1%\$F0JH^6U36K"Y!;.\$Y!"V0O:Y1QG2IG1-%WCO M8AI#_F3#OZ>9E?
 ^2YIXY*F!7L:H2(UTJ5%I^DVI2HN*=!%I M*8(0>D"(AU"HBG2!*OK")\$NTJ2+8\$)FU>2T(3:0DE,\$AAPG?FK)EISLRL
 MXYWUW7OGCJ_*6EE9.WN_Y7EYI??>Y=8UX@!&8AB&B!E>B9=G.F'H(ZTRBP9"U^_LO/ MBK=-PKQE-
 3;>9AI_3BUR*3/E3ESQ_N(AZ_0?1#.FLJX3.V; 'XDEV!^T:B) MA7%YP K^!Q=>\$B!VQ;_N_V4_W3CV)
 <2D^;29W"TT7N%^1Z!L8^X6# M4-BR@HL^C4HVP!K8LO%7F*%&Z86?0FAD2)I9I?+MY6JH@F-"DOD=A)G:N
 M""^DH.?)3OE_,9S34.O#B9B9BM6_U+ 8AJJQN:E0TYM/05D3 &GGA MZAU^P"B-
 K2@#WQE,+U!R,"JCB*69^CI!"@1KX=B&HZ!+7

JKA =&VA\0>=3QSN2BMVLV(LIREQ&!ZQF'CX2(Z5=J1V?0"X M^V (F10GR!;D##
(.15%! 4*O@!&0:H8NE;B0;U2DHO74.OJ<@WQ:K#J3U M:FT48** */O.;@KWH@ (HS%Y\+6JKHW
MFNH8|3>4\$^HF%SK|3GS8<\$ 1UGI^>1 M3.1Q;LUW;>VTM:OE\ AC)?!2/-%(8X1#4"7Z+@! (A% 'M/R0NN
40+E\$O MDG%BH%VLI&FE%OI\&J.LH9R.TI@;DBXE(FR<.%!% 0@3(SI1+XH2*! MM0H+<F)*LGE6;MAK"054-
B.=2..0%8S;H\+&GW|DOJ8+62=@Q@.H48 M^PIZB9*FOO\$|>M(\V&<YI\$R|L^)\U^J)*|G2H?
E|0YFVYQ5|E4&ZQT M\$A-KA|YZ'WGR&D8 .9>1Q0?4T8/?N-68'3\$"\$4*+|I 0+2S&|(%)=#K6=LS|
ML|O5=@\V#.7.6X+1J4|SYEVN&2(+W2IA|U6ONB4|B) M?2\$ 7N>RPQU-FYJW:82QK=B*U8XHE8-
O%"VX+TW*6TI,*524GMU/TS:V\$ MSDI7OEKH"A5? KI@D4+#8@C&8"*. "\$\V)QO#;P&M>*|M(C_OL0:X&N9P\$1E
M5|HV514RC7IHKE;H"!\&\$|*ZFKSXJ96>SSTIW_RDI#GI2NL?;8I2R1""
M%)ZP9;@F#T\$H/3D:S#%\$F_Y>284W7#3N#T<86TQ""=Z..5# \$DHPQT05G: Y MUH:EFR<|H=F#EZL=4.9LJR
=,P(EG'KVT*.;_&L;VGPf8S>=SJR*4I85|V2 MZU=K(%C^(\9Y<+|C:*\$>;H?PTM6GK-RH396F?QKIUH9\$
MT"%C+|KO.NTXU(D6TPO)JFC0JV_9\$YR|PUE MY&+5\$82ZGFO\FZR>GE;5 M5#A==X|XJ4:5F
M7\$Q+BDZ_YEY1ED^/03#N|+PF*++E.OT*M>+YM"5B"\$HS/=EO@>SC51|:FEHRPGB|TH|X|N-
M:JN|>NW@%R>;QCL@&V&|O(XO M_-W/?AJU_NZ%,+33F-'PY<(>?WDH8;|B=U#4AIF?7M?7+7R:6OET0F
M'7CF:OI:CIR_(GZO^#)3#OIT|XZ1UKC0#8G7&J.I.=^A&WIO|LPRG.L GN MHLZ,-
UE/X320Z@R/7Q"3MD=52.=5W0C_PYPRC\$AFV7GB,RZ;XBZ|NA^I.0 MD,=AO<@5<43;.>4X(6(98^A
UH8<)/!;%PBI<.#@&<|:8 MY(7R%K.I J47| 7:AH!
M4<8.)HEXN2>@N\!>P_)D^U>J.#.|ZAO3LFP05R@=@=D:TJW;-0*K>/^/M<PI0FM1H@|\@26->)T@^C'/@S^A
/HYBEY==+ZP1?7(X%L3BV>0.;|C^"" ZWXUPIV6?E\$40_?N7YX|M3%GH7 (|L3>@D|%(AJ#RXH""W=Y=M?AJ
|R:C\$P.2 5C0E.^6?RVL|E3V M*?/SXIR@ QQS8Y6Y&C.3S"G2W=\$Y(?VZ|FM=&XR6\$5GVJ|@4MF0KZ1T#F5PS"
\$0>4BGV|)US50.3 MA5EHIX>)KQ7PZ|+=|C(6THD"AE/U7|&0!%|T)@G
MY_8|/^86;>|TC|:Q|I00QCUDF8GE(0+7=88-OP@+H<|.%92|@2%)X.CH%
MFFNW/A'OQN:ZD5J%Y*EA4A9VNZDC6KM|H|P.H^.=MJPL|5CBLX7VNQH9%#H|E7^|?@12X#_-+;;0
0D"CJ'LKU\$X|X|7Z:N1%0E MB#TDI^|Q^B=F4YYPT\$690Y99M?4W* MHW|TMH?
^1\$=H_M20VKN+Z:;CXU:1HZ;TIVZ|E.3SXW4(%%)0U#2=;D\$TKZ9 ML>N+B%24SY'Y!#7._+<"I&L3H.|*Q.O
DK4+0Z9;F:70J2+?@ M2L|+Y=4U<04Q) WIP|JK0QY\$?3 MX*S(2VQI""Q-
=|*9.IT=4PI=^@("7G&C)W#)^W|D<&C/2P8" Z|FS06)H** M-@K|/M|+7K'5Y|E*GL)
&:70Y5*EJ|H|Z@K5+WM|!" X>64'E7S\$" L|SF=M O4YT M10EK"*4 MQQ154|+2H|L6ACXU?H@|
<&CRHE'7A4IR&GY1S\$4RI".G1ON#X08OW^47|A2N.2J+9)XZ#.Y PZ?R|4L%B#%06.K=D+W M;KI\$4KLM?
UW|4&Z\$H|W&9-&FY2JUY_4'Z)P2Y>I. R|J?J|H|5PAQ_-5X*" MG|)MN|W?OWWP-
P&|VH|NH/7CV2C_R0VTD@%8EP.08#K)G 9 MVS|+_Q"V?^47GX|E'(77^:TUI0.W%=|K6I2!9))/S|LVV\$GAAI\$^?
Z5& M0^W|4>+M76_G7%|R|>+U|>9I2|X=4F)9MZ*%6CQH
M3.40+3FFEXO.TEL_VU*=-)/UQ1)#W=-IO_8P8S^\$UPZY=^G@#%U4|A78 M_6/KQY#
<B(%QEA.R\$3G^31TTV|@0%W4%ZF= _94%#%/K2=&-B@V0ZDWJL M"5)HA@|BG>&-
AB%.=F@@"LJEV+|GUKHTMA5S#=#S_J|HLSIK">T3|4X6RC&A M:;6M'Q"^8|C^NH.5U=X*4\$;40Z@2|T|+#?
M>RFA=D3A"ZEY*1NFLOC:S<6 M=EIT E-|0C-AYN:0XPXT?B2-V77>?2*|ZMNI/%I0#:-"9>& JV1/ZF?79U2#A M7Z
^:.'N9.\$_L>T/Z M"P:|D" H4W?&O/%UQ\%6D.GR|1^I-/4*%4.MLRN#FN_H'^7C(0H.0AD|+TU2A7*%+R@| (FXEN-
P&J)V04&.|1N-|R|N|) M%)E7884IYU|H+'N#Z;HAY(9; 4BQ_-8M4Y 5JY1KY.NZ\$8IW+?Y\$+XE7_SE^
M8B%)G)^M|Z"QE0G.J.U->|AMOC(^"B.8_/A#
MBJ|\$1X=+73J7UU"1|/7B"FS&9U+X J#N(|JL>T3F.DQ_ZVBO"N.YI.*KZ MSD|D@^?
8'W?"EQ|H|YJ42.2|X\$;TE2D?D9+&!"KU&E^OXRM_'NL?L9;O
M916Q4A(R"\$XX*YGHWN.M.DBX|7DDY<7'7'E.IV3^K|WW\$Y;@=Q|T|)ISLBY.=2X|&SB/HWY2?XC>\$=-MK-H-
P*2@#Q|H_OG37*MM0VP&X|2^@|J'(YYD-VP|K1.%\$>Z6_C2LHF_!96H4Q|WH|IOM=TF)%
M=A.O5<59IWRTOK;VQ4GIR>C?DW:4.X ?#AQSM|^|&0X|H_@|I01.'=J;T|M.5.R-
DLY|C:INV*YSNK@UTG|1V3WOY@U?R-;>|B>1|B+7Y0Y#7S2YX|4' MO)+@RUY?
#D%OH&|5I0:13|O'D|H/0168|9QSL'9,>B MMM31<_Z<340|1@|@W=81MDIB% SO_?J@ (M#UTOTBGHM=3^?
%TMV|'CX0-|F M2_)ITEU7EG.K^K^U|@S7#XWL_P|_5|Q|HD MDEREOD+=;_CF|
E:2^O\$J'=7@#J|&>\$60_*6YDV|E-2X9|2CY3PJ-7XT/B M DU@_3R-?U'X70\$#-:4^3-SB:"YCB|E7W|
|7%|H|+2;|F"?#ABTM M#D)(JLC?|H(WKQZ"2D6?>4D*T08IEX%I0N>|8U8VDH|MO^KE|9I6,+*>JV-: M_O;-L1?
B8#7KLT^N%(059^4SPK.E7^|K;U>49 M^+_Z+;W-V'_G:Z|N|B4JB E4-KX42/^;R^|N&D|K;;M""R6L1PC^S
M2V@Q-TH|IG.5DUH"|"H|ZS3W|!ZC@A<97*F|^H3RHKTF|X/Z|Z>E.BZD)62G0
M+HRGE'D.3.B_1|Y5\$Z@ (8TIB"PO\$TBC5V|I*8\$YPJ&W??23R_5;9?9 M@,M^RB1="GN 3NY2
MFNXML|6WB3=WLM??52(|DDK^/HRH-PN|."SR+3EAXJOWOHZ+,C>N7?*"VI M')_6//#ET^,DKH)DFOUN-R8-
8(R\$59IG_-BC= @|O6++0""9|_9^E%?_?7T6IS\$ MQ-F1:SDFXV8|*T*8|HIKH5S7O|E.M5;VH|01M|J^98 W7"L?
6^@NX->|* M1H"44B?C2|N2Y M:IS|EWCA270VD3DZ9|PO*B|C#53W6AYRI541:UJ26_LBE_7D#M#MF\$&_3KY@
M\$YQ_*6UZK6D/B:3R-FK'>25@PRN2J'3^ZZ:8B;R9'E0?A4.0@5|W*5JT=1 M|JHX?YJ=I3&A_.V|11*TJO0%E2H
GW)40Z?0Q6!|.88@#E97S=^DDO|^ (D M:27Q\$(3;>Q^4NS\$JK*AE&EU1L7)9IYZ+AJFH@K"">)Q&3 V|B
|U2J^+ M_R7UY|E9*|CO\$|"1H29HH+ (K4P7@MLP2%K*:=E6P(@21?HEQ_ZI##|5B4 M%&&5|H_Q
RFS=6*%6X0?QOU?2;WM0 A3FPN|_+/(/16@#E+CZ?";COH* MI7 @6V|17)JBL^WSV)@D:|
(ZX9JG6|1A^5H9ZVQ>BA"0KU_|-79MIPC+K. MRTV.SDFN0|FP.%) 8@-
&=%U38YEC7X#)\$E4BX0|DC(*,|>|A7|F=;??32UI:#6*+RU2|_R#&QR A9IH|ODQY M'L)MG6^1P9_*W??
C)=#6*G&_X6#@90X;W==>|_MYC=0RXO|5|;VBXE|5\$UD_.07F0+F12S<@FM\$KQ|*T.VZ5WSCQRG_|H|G>
M^3A+T.GN+PO+@B|OZB=U")UBFX=\$1.1E37>%&\$Q^)"0EKJP4+1C-VQ=(=Q|MC|H|H@6+-N)R?
VHCFO|3)U=G5W0313E(%X""1&DZ6"N|>FI-TP6(X^<|4)*_N3B%9BGZ* M5O TP_*0E;|U&|XYCF|LX)Q?VX=9-
:D1=|42|3U=*=^J|V8-8|M5/5OAN%|JX|LNK^|UP|H|U: YHZG<03.A0,NU^C&N2H MM39Y&|XO?|_N' 6T0^=
(^L-C+X\$=KOOT9DM>V#_*^0UC_-|S\$ZQLS-C_RZ
M9'@..GUHMMU:9VMK8M+|XCIY|/GR2+Y.ZC|F48HER>.@ZF:GK<9(M;N7@.M^2_V*>SYZ#|M^Z63D.2-
\$"%SOZ%8FW(4(|2A&1M'8AQT"?E7TV7D M;CE|S3I357,+6^/ETHHKZUQ4=#N.9E+7% :F^W;6:
M4"X*M@W,\$^COO(6&"-7A:V|V)ZV:O|>_IMS/E.G<|RS'H|CV.2.RYRLEMSH#K<70/T5W,=0*Y|TR)P0)+\$
RT4(+*8:|7*A?|<^&_UI7_G-3B_R%ZT ML3H#9.2P?NWQ.5^89/^?L2H7-MGE:|2XW&SPMQ7E%?2.BU8A?3AKD?
JKB? M.@)F9I9K8BMO#1U6J|KK;IR%P9^O+Q9P?|W_0|K2(I\$S@UZ_Y/4*31H%5* M; &V#|?|A%K58^OGM(|-
KW7|F6B|!&S"7.\$HQAO\$<# MZ#P@;|)3C@W/U\$;WF6VSW|J;^""^W% ^VY%>N\$13|E*TB4;==+D78Z|6
M*P3<*)H/L#2K"J_|Y+JD^RH+W.UP|OE9|I|5|=:|T>*B=F_1YBX|/EQ#D+9QOEHS1F&|+FA%SKPN-;
M6C+PUAP6)WQWG_*YS"XA^9\$E|MR)R"G0WV?^70(|K|MD|V@2X|/I8|O|ZX_3 M^--
|*9.T1=C=|J4|>.;BV;)J1ZM8U9W.ZZ7|^R@R)UVXBD+ML("8W|O%0U< MJKJLP7%^-GI2?9*EJ_1\$PL_
HPQ<4^H|L|TAV7|IVQ8WTP3"U>J"BH=5&
M;=_/?@V9MT4.8|PQ|KYC(%|8=*K2UBU9Y<>VSU7@=C2@S|=T301*%|/S567 M'57Q3RIY%A@VO>#*E@OBO)YV?
9(2IRZM*Y?7G%:SI_)MW+;O \$:#O>?1RMF9X|@ZK7^?M;^S2|>G|INK\$.2K>1 M)S^@;?U'SZ-VYPK*T#|H|

JFRGC=B,A(Q1!V.O9TO\3MM#*NG7AFH!* MT7+/, 8XQL>G|=J#4GAZ8IOM%(2DOP+O+
f58T2U02M88U1KH5GB+/-=K.KJU M4).BYDE.MBW>
<5T_..ZNDPZU1C#!@P\$/(EW9Q^!1\$=!'JHO_OB:P>+MM!#: MQ:4>T,I:.'@N?6V5N(T,;<,(422(=T3D@5"!5*S*O5?
AJ:RXT>@JD2A^93' MNCQISFOH_@1 D*)JFK9HJ-NQ>,>?I.D_R4_) (37(5 5M16/P54F&_UH
MRO7.1R18SKK|BD+O-E=9=\$ M>ZBF0NB|JZT.GY20(B|T4|^2W=+04"M-P==16.)|JO^D^:8WL\3F-X:\$7(M)-
M5+""LRV?^H_(\SK#WD/<7_,-IY6#6LU\HM68811TK8>C_/CDI8U;Y M\Y7RCGN^H2+U)^#|\X-*YG+%V\$A"/D
QG/>=<137^43W?I2*VHTO^@>D Z\$ M,S6=%MUQ&* I0X(9Z.ASSQ8.#|L^?Y068:"S2/T7;6+#+.\$FXS=|'">@PCF
M0*^X/G&AN_:9E|6VUJ_#T=W;P20;XV4P%+^==16VEB#\$C?G(H?+/RYI#<.? MVZ1|1|5M?(0|)-
^F#Q0),,N+5EUP1-C;,"R6)XT@;VITBBDJZ4WU

XJ76: M!G@<@A+Q7.LQ!+*YXQ% NMPJ.A2=?>YT.<>4_/*)#C2F;JE\$C|KWK,""V>> M:82J\$HUQ\$6NA=/RH-
T:14.QNBO/G"=L%&FD|/LD2F=K@X7BVK^Z2B:78[" MV_*U>) D4:1F|L)Y>%>|N+3|F9Z|= \$G.S
WW>SZ1M7JE"-N;-Q)/I:0 S M1YVKR_QYX|<@2(8TC&:3NA? \$DMI?|2/?MIDSE^P6-898BV* @0UJ4V|J_ N
MO"B9A_-&I^<35ZDZ^HE9E15H|+|F^@5C?D5076/1\$FMH7 4NJE8)9_3J7K) M-!%D=EYV74QHTJ9
7_ "T>NU4L3RXJ1R0AE X=,<|*9PI>*1^+)%-(UK525? M >K| ^|+|EW\$&X|
O-V!^!UWS%'U_ O"M,Y|I=&.5&M^..NOLOU.G390@'6T6WM M7DL.?F%V-QE#N(BN2%P1'PY6\AU\$G-Z;CFB/AI?
F#QMAJ X+UB*9GW12?>CAX2;0N MN/YL+?'_N19TXDVJ_ GOADD^A=H|^Z&OC+&
|TIXO/R0>8N(O8E188HV!*&9B(6 M)/"0.CI?IG,>OW\$<56+84(-S|0X0HI>BM?1E)DI3MM.V76
MLW|)R+@G(;\$)H0P69U_#_#|XA_ |C%O&N3H^8;#^D*,,,UM!MD|THZ6IZ? G
M^OD/R^%|H9=4E2NJ(H3A'Z|2R5^=#L.S#<:DT5U>|LCK7L*|EQ|/I-4_.94 M8+QT\$-
JWMBG>"P0H%JJ#DWG|^V7Q2H|<=>|L:*+)|QOGY'!_?|OG>;#*> MA,T'-\$\$E|0=JLHM=O-^Q1Q1?
312#Z66HY6R^*/2|Y|EHLKIW"KS?&U>_--M*(Q#|3;8KH*|J7SOQF% MG3"%?YM=(42%SP|0C\$>ER|3GJ-
L7J|NN,&RRD2 M|2KHU8MV6?U/Q+3|7LMW2RR.E;(^|LKM?6)XNW.K0Z\$ *|!+@T'PGIC&X
MXN)2SOK>Q&S4UGBY\$_.3FEY>X'R|@X>LGVK<5|6F\$/_|B|3DI(SR@"%59T.J M|(+I0)_B2PYN/|S L4^DX0I0.\$A8(4;
<_)2K)1LUXK+0RX"B.Z;_R,8OQR^@-M| (4LL#!.FBK4A.^=FDH=Z*L|H5G;,*| \$U>;9NVX1_G!|LA! M7.#|C:@I?
T|NN65& YJ1+7Y*3>9BO^<?T1V MSXA1B|IR4WA"Y9/^;,"B8|N3Q|LWKK_/@0Y;8|W="JX^%
M"75OYI5)RHM/|H2"1"74KNFOT@9K3S_X: SH/Q|?&N9.164<15>'3ZIZ(L M|=-
Y.)JH34D%X"UPVU;U4T.KK/;|QOD|EN95AJZQJH|7%7FD?H\$J5AZ;7 MN@CA%2CAGCN87YMXW@OIG.PT|*DN^%<
M2?J6*6S@RG;N;(BY)-1E2GRK/U9(LZJF?^<.YW|A M_4 ZT<=<):6VSS+;|DIT"8JHO,D|)%NM:7(\$F7_I:
S|Y+7H|HX)QEON;|T|5 M^=<=>F*8;%0&F2Y|NN'D?R<-|2A(C%^|OE-UV|@/|L^&CU-QKE/0*0;J/
M^&I5WKTO*y7-0M|BZ^!=|L...7T.RVH=B@Y/1%Q%U1@-E""|N5_D\$N MP7 M%P;?JMK/=-NJT/FXH-
++Z+;3Q8M?;*E=VXT-FLTE=|GA/5|6^28,\$(=%;9...3Q_4?+<40<|NMPC?NKA.55A3)P.9LEM_GH%O%>WC4
MESLK#M?*=L-%#Y)#!6%)*LM_?6HL\$416|TX<1"Q(CD=6B,N0:IL,CM>=#W MURUD<O<)
AJC<|+|K|K5BYL\$O|8F^U"OR|YL6FKL>_#MM;O/"*Y>S;4 MA2Q|T8H(L:=;J|C(=-3AYK9*2|D|_GIUPO?
U|AR#LK:O4WU/SO_H4GF(D M6M3ORKM=A86\$)DYCQ\$(H*JW|RWQ_|W|VOLCFZ_M/2)7DD=Y.F%Y2T4CJ1|P
MCA@1V@|:2L_@F7|ST@E>-WCN654|'3P&FSSI^YMD?IK0J.KSBVPUXA3@/A< ML=?Q0_8|VLU|^_Z@J>L|YP6S\$-
1/U2W6&@YP"#;K,M\$Z&PM9QU_E|K5N5! M9Q;ZU;.C\$P_XQM*&GZ?92B4J|^69%5#&6V?_G3-)9"
M|T/O:Q0+7+Q;_7ISR\$E"WZES;:GOU+LV8BFT\$;-BGTN,U|7Z\$^<^Y|^A^O9
M>"*|QK0Z!WE;ZC/B9|AC@&TE^B2YE;_O|KV:L:;|QC(^ZBX7HSHSP M\$ZA|^_/OCGO<|_IAB)4(-O&WD?<
OCZ;N|KX!5A MM G%U>3"|<V@|:/8U#27Q5SW9,R,AHC=6-O! MQ3N2"33F+PI2>7B9_F M(QC9MM?Q\$2UAHE-
E>SQ|BGB6FT ZR|L|SUP=8H|AER"V_#%XFA87 M|L7CXXZ
;MX0L\$%@8S3Q\$|DI0AQ<9*;WWU3OLYMA^AN@\$9E^<O?O\$PY| M43O6I:H^XZ2IAS.3U:8ZH<:ZZ"< MP|O?
CGW_VWE@LJ=2T+=,R=@:<2W^LS6VYZ>7\$B3GTFUF(H>ST:WC|KW7< M3WQK-GF^%8R4+"=KOP,M1E?
4|APDZ7W3>J018|R/3|^FNDZ/I?8RBZ@X"
M3AZ"300""^KSXW2KMJHO%,,,17D:9WM16<\$62+*4R%3Y34T+C@GX\$#0NB\$B M
GC@#\$,UE1G6^4">60OQ^\$2M|>NKS=?XYXZU(HS;\$&*+;_<7_U++;K62,V MH:+++K07<^#
<96|B|>SHOJ06NRST%G4M;>|Q3?_0I+@^K;-' AC:4Q5_-1Q_M?8|YK|A8KU*WGI??N2102/ZE0T\$?#D&VK8;
I(<)*&FD0F?;_|D@LZ|N^D M#_ |@ZYWE%\$22FIR_!*,9DV?QI:6L>I#|GH-J\$0\$2LE82A>\$%4*JY)G@WK|
M20*Q40_HWE^0Y_#_RB&O0N7MX#;8_UA|3D.XVSD=JTS>^H8'KWFM)GUJ#0=WH_?U8*D_SSTQ
M8Y_S/15WRJ646U*Q7E;2W(+^#;#/?@W;XC;7.W171C"\$;.&H;29/?@EY M2|9@#J"/V&^X5_9;U_3NY#
M%*8\$UK|)-^EUN899>D-GL|?W3>=MV&<5_XJYKMF|D|G47>E=0|KF"Y|_E MC^|5:76D!DLWA-9_410ZH|+IV-
#@Z>#WCMNZ(99TSC|I-W#R+;(+6&+;_ MZYYEL|X?#EU\$Q?P?Q=&SFG.)\$SM?L?1-1P+UMEW;C@|_
VX=,2|S6\$**9@?IX M32W)W8^UN8;K|VU'E#>#X2/I8|1T*>H7EY78M_;*5*0H-
#>\$(|PR|NIMFDXZ|J@SJH3MWW*L|JXV|Q.\$ MT-H1+0BV83|=AW CM;NISXV_ BMQ%=U_#BH8L
T6Z_<VYC"YGIW23_*F;,@ M;*&+P4^U\$A%Q)>Z=8"9CQV+7X9%??2HU|P#YJ|^RB%B9YG|XD>_SWQ43">
MH^Z(K7|3.XR)UML:T65&@I3"UN7H2_)XDT|AE6#5;_YR+;R&L9+?\$@"_N5A=B^<0KG)JHEV2/0A
MR(^QX8S4A1A171^<"DIX_08M3TXZL#|3|+)|9Q0CW25.BK.P@Q@UJ10B5U
M|WP%3^<4@@UK*VM>VTNYZ_%>^QU|AZH_%6?NG7S_-O70QE59A|_R2F39#QB
MM|6IW3A|9OZ^1H=H6Q5VS/|Y4X2 MK T'^)WKL:;M3-6_8;|M2ZV"7TJ(H1+_USY"(TF6IKZB_5VA@|I?&|N/D|
M)GV,J|>%;&CC;#)|\$8@4;7TOMN4B|>340Q|IVWDGI72@1;0E^OBV(|_MY?LA4\$1AM|^>
{6@R6NHGW60|23LW_B=10Q_R.L<1)H4;H7%2+A.EJM&B@#.. M>C-C4VDCYD0>->A65CT0(K;D&/?W;MR79-
UXEG|C*"J6L=+A7)|H3U9=- MJ0E0R.SGFDX<%OTB%(W;IS
MIU7CUTJQ(H|)W84J|9H,*KU8;AGL_Z^<T%AZ|K6<9|PKDB|<);9LSU1>0
MPL.MR26D;4=T@G&4DZ(X/@|CHIE+&HS(|3WYWHBUDAF4/FJ9=S=S|B>B| M@S'>2UE9K+Y
^3P(2|HKHPUH\$)|X|H3EEMFV5W75)52H|PX(O=S^|2S+@O M7_2Q@A@-
K*2PQ58U0;9Y^U\$97ML:4I<3*|B)\$0^/F|0%L/0;2,E^NE_UXM! M_H=5@A(&|H|02R-
PD5P+2|M7EBN|>!4O,NH56U=*.S3W=69^6UU8L|Y)H&X
MQ4B>)6@5A,*M0!*A5M5X&+;_5G;N&YAA/Y:W49XYA;X|X|M|BG4.IOGZW M)-
_&OG+|PSEGB1<B= %XVA5\$/_0\$XEA9*HH(>Z7>97_3."B|737T:A|6U MIU8\ZZEC%?
FFH|CN:EHHJ8@^TX3X^=\$W^41D.R8RW2)RA^R^(EWN-"C| M.M;93T2|QW5PLUG^B6?TC;)Z?
@;_%8T/I#RA>&*&M63>|S4L|*KE>^V^YQE M9O(S|ZMN.E^PL56_XG>1;_Q7V-T"<|LM8
ZE<+ZB>H2H(<@=<G|Z6>4W MS/"SEK?7N1M%|Z=Y23N(HM|0P_*D|&_@U+4D7<^?G<#4V8<@JTM2|4\$!
MWXVKENS|H8Z=E=6|9^0W"Z;=#^3"=X;Y8J|@K'"| N|5Z1THJW+P4Q|FO1#*U36;F
M5+5""59>8Z.=AZ"*V=9,T>893=6T2#GTA3ZL|? M>|;6|L>O>XZW_Y0&V
>AF/8VE,LP3E^7G4NN""NY%|_P8O|M:@R-JK&WX9 M>X<@<W>0X/8U|V;3T!74=M_7@&68Z.Q\$=CPI(\$=,V-
2|)FZ"?%ML^@ (M|Z8O56A% DREZB63&|D)6&-BCKQNE5QOW<*O.LC>M2!|7;QBMZ+*YBY/RD
M,>|H0L8A**PTT)#&(|\$XL:A) 16&<-|DHER)PG5&4F|F3@C^Q(C%CMYU"7P-|Q M|HT+;6462|_?+PZ<723|_FY-
S5RLR+*AW/G|>|E?T11,G)@F^<(|D;|<|T9K&|L&|P\$|J M")6TO0L+J^J9K|@FE*_ZV&2\$VGO)WG.HQT3WM5V0F.J?-

J;ZIE*JM8H%Y4FHRA7JT4M<PIU6EKG619Q&T1PJCT<OZ3%BM^IX5DV(C)H(@E6O M*&I=A;J,IT@DR-
N0O163ZIYSI-)B8>>.:0BZ|+1M"GX8:&I?#K^&N7,II^E
M'^>A3Q'=J%K=-2S9*Y#;!%,@E2U\$JLHAA07N8%QJW>/(3E'J(L_1C>?S&Q0 K M<+6E2_4*+I-
&I1U7Y\$T;H4>K:VIF<0F&_0G'P#V?A M13D18B;P.:7A'5B%FM,(S:7UP B6FRJ@<C0QVS\$-H>@G-
JC9VP5%42)2V@ M&^&7E|ITVK3O|,=\$JN)EL MS1|\$,XV7JO)<XNJ
M7FY;07JA("MU9UPM5'V_>S>S,1_PZ@SN,/%;V=CKC1U/LTJ(NW)HADO)?\$W|
MZ(UWYR@W^:|=^JED1G%|VA#F6U-H\$#0 M'%7NYH#,,=YT|YC"3G>/TV*)G|=3S)|KJH,7U%S|Q
IC@%|#@BM|JA;@.N< M'E|KK8K*MNW4N(O5(^4\$0Q)%SU1_010MO25MA83Z>+TC%L\$:%BC3(D;|3P!
M^YKGARK=L7Q1>4P2U=B|W+^LP2Q2TJM.6|^C%R.O"YVOWI\$RC05W\$
MT9=P0:)|T%:ZV8D@K|RI%K#OG_ =ST/2Y(6A5Q#=#6W73W&=-6M_WSN!, #?W!RXN! FV|P//
MOJPD+*+L@N%\$#\$E+DR?..)V2V#%U@_[-NISO?5GD2|VN,HAB"/YB(|L.""H MKFVFI@\$6^6^ZMJ5MQ.UCE?
\$TICW'Q.ACI+U# VT*2|R\$H5X\$X2@.085HP
MYD>M9LBZS5='L(^LL;NWYO#1ARDO7DJNYO1=IWWA|72|0+SNL2Y>|L;<|O1-MEB6%5YI-
22DK6YWNTXBW7,8.LW|R>Z881|OF.=.&P;RR\$H7%.LE&NDL&_SR)GU;Y|1R'82BOSLU'I|OK_E;L4J0."LI^VB^(^V
XNP4@'#&*PL2Y#L\$|?&?;?XV9|3/("L>Y-5@212|@A=TT|SX3UJ.MLVV0\$K",>D)K>UVD0QV@_240*/
M^_8|_9TG;U89G,ITN!%TSNP|G|6+ENHL|0I:*77"Z2K%PNMT_8BL)BK181V M2-AI"KQ)*A%|N\$|22,
<#*%H&8='9K;><6%,>LIGF_8_OS_Y/R/QHFZ<M:PS:;GR40%(RFS)2_1O:WQ D^YBW0C2;.)ER-HIT-01 U%
|1'4HUN'G/_5VG\$* MJV0Y/V"T.G|Z|)X|CEH/B%Y(K?;I.MZR/?OI|3L|6O_GQMD2;
M*=\$(<ULEGRCE'IT8B1(VX;F27'|>KP,"XM(G<1%KYUM(GD9-I;E(0LM|9@ M6-D^NV@A|1,V:6G&<-9?
=H.P#>:4R3+|HJ1|'T6AAE^"NH3>NS^T87|V M'&Q3K29XO\$^|'9R9F@=UGIU XU:(02"9Y_9.X8Q&7U-
\$^1Y_B0"W;NB\$/?+V9 MA8N5GC#*(ZE<'LEK?AJGR|AM|3HHHDF2QO&5.DVL?D8\$D8|P? \$BW(2X|+|'
M^>@89|R,IZ'^^\$M/'=PDW*K_*UY_#|4F'2C5|Q50-2|L-|9#=#4V>6>%*9JA^ M-/8K=T|J4+|SfV<7YN|RA**\$B@D
B>*VP|1|5.S\$9K*8R/S=(%|235J*RKRI8ZIUB>?/SC|I)>%_F|@_#|Z'&|,|05U5%_XZ MY?UI'"#H\$Z84C-6NH)Y'-
B|"MIX>@4|BU8;PA:|_#%N***+7E2V)B|*,L@_T M4NH <0AZ|0"YR*D*I<9;S=|B#6B/W? SE|OX\$7T>..) <5YQ@IC-%*
(\$<#|Z M527|=|U7E Y|PA2^\$>NIQ MWMNXZU8|TE,U'B\$*\$(%58EZ#76&1%B)-S+J#-AIGALR.8:R+;AGH%-Z8|
M+,@(2;5=-MHDW(OA.1ZX5DACVB."_?D+,%(O4|>O&A_? \$K|ZI>YV5N#|DJCAH>A9^7+EYP*
MK;W)UR@G|0#N'T" C8003M8L>ZFK@2(2(SBQ7>^S+XX05(^_GZ4G2#G)7ZE(#
MI^J|(O%>J(C#>G_6IC1BF)\$&DCLQP81QDM7>_JLJ=)|^HWZ?<N^_ MMJZ|'8FMZ"\$^5VK;\$MGU_2^1_.
6<*1VD:B)E@O@B_.S2&;ES\$.8|24|P% MPXJ&N\$U4_0WV&\$LR&E%2@A#WH3* M>#6=\$POZ9A&-VF;NXYU/?
91M:C%F+F2=-1:|=F#_J5&RB&?8")%SH^@Q5;2 M,T?#E6)EE^_R'E37|L9?J:TQKDI;%K_3DAV|_7+Q=9:/_J+HE8
(S%Q1|&Y= M_<OX'83XH0XPH4|1.EQA|68_6-/L'27K|OIA);4_<W69|L8_)<6JGY|2|909| M16>
|HU2TE^|4LAW<#3":AP|RG6ML^\$,0*^760-G.#XOF&6B2\$<:PAF_:UR=2 MW;^RPU|P/C|AM:Q|U3_'Z: <=|FT0KR.
<8!TK-K2('Y7G0NB:KZX%\$S9".D M%\$B9=ZHF+!5^MM87|OG59_ S3|_WT?R>_R|D|A/K(2@.PJFY)1!|8|>AOH/+
M\$.OFQ#39AG>0QP/QAB#4T;97% H*(X|TCTX|@;B84C=SJF)|PRF9|B;L+3_3%|5723&WHWALYP85TOA\$#+&
(HS) M7@(<J+673K)9(EE:#OH6WYKU_XJ2"DF<'BC>ET.KA|:%AA0XCD8F@Z^6BO=
M5L|H8R>|78(\$8KVT;N.5NGY4#Z>_9<6"??+|=1MD2VAL|0/PM"*+X6V|-(D+J_U:8D)4HI?GA|T2OC
M>=LYAE//+VQ#HS|*42398ERKS35*\$K4.\$7PBZC/<"<@_J>&Y>S#Q6SRE):E MX/Z|MX|'JKX_O|= (7OV?
9D*24*%D,E4LB5+BSTFV1.3)"|3C,B^4Q0Q98FR MC+)|E:<8N(=DS8LP("9F1QJE9_ (H|_?IW<=|/X_IWX?
CWO_N7|_#_XSGF? MWZ|GLMYO1?VR: KN38?S+5?^7L2\$#|R%JFS|_1_57"=;LB2^\$W|D+G05L< MD0*?
3YS3IS*X%VXZ07|")|0@HK9T\$4^H\$3%<|H0?CUVR79SG%|C>B%:"T^X M_#U1ENLCS"@
V4&D.9Y.)U0|5/#0:P|/HI@J;32/5_33VTX-(WIHLUO(U_# M*,S@RPM"Y6;O^|G6CWS#U_00XJ3/G.MX>J<6=
(FE(A>Q*:=B|(LBHYH/X7K MFG5FW)D,|X|3)Q,B|N:M^|S5+EJRJ71|)=2H2(WFY5LL>S>R_?C?R0&O/
M*SHP;BH6Q%&C9TT_ =R_4%&X9781#(ZS(224Z&5+ @GM?AOPK?_JHE>6+*%R MJOM;MW+G,XLKV.5EEN05QB-
VNJDTL,H1M'R)(BS9BP%.IQ&7Z%(#Y7H|:P'02(SF_W\$&UJ;IAZ;EN*,UV M8^80D|JQUD=?I3Y(B%_'B*|R+MMZU-
N8=-=&G@H_)@3DY*Y09"INMN_NWU M6/S'O<7=@VL\$'13,D8|L@/_O4'I(D37NP;X*@DMM
YL2/<5KS0ZCYDM|Y29 MW;Y>6*.;ZNY1(EYU2%4%N"7,"RWV=9DD4SA&:W0>:|OT^"K%68YU"L^<(<M@_#.R|?
&8|WM@<.&H%1+D#4|"2R|03L_452|C"3V)|AK:LSC?K_7HNQ4K2;
M7TAP(0WXAB2UPXDT3WB*TPZDT9ZEN\$%OI(|L.O@0_Q3K<%N5WYWY*;|HJJOY MYH2&5_TGWV2>TNKC-
FJYZP>7S9|KYR=#/DWP%>@6QX'_>K|Z4PZK2=
MH6RDY"3O(KF^KKJ%M"=|^>^*#T_/7ERLWZ9VP9)C.J_>X6=@5JAZCB"(E2B|&<"+@_W'IXV8V R^N9T
#/*D*\$CG;F*T'80'!4P MD%.)4A1R-1VZ/25|N3..XYO,(SRE4BF\$19X\$-'IXIW4J&?>N<)|AKK3%K>@BY+ MBKRP
UG#;YU842D4T7B=")K@0!:=!8#0|8:0|ER3Q;4;_D)|HMF&.7&.;LZ; MEA-
#G8L,7Q:86K\$SC(|CC|<#HJ&XXQ2_LM_4,"8R.A" FV7/YF U\$ _L>/_A_7V*E&|HSAC|<_W+8QX,<^"
<(@SB95FE;R8|G%_K_V0|KL_M(+:15)|T|+RG_?IPX|&2&LO M4.#@|E1K4%&380Z'\$4WX:*A4QV?96_!GN?B?
3QBEC?X84C+X)P'.W|UF3,C"?BO MV_Y U#%"G#;L+^NX|I%(@QX*B*3N)NL^!IO>=H MZ3P>NLW*-L*#%;Y)GCG73_?
U|M*(2*^|O%IZ,(<=7/6_1MY(6R7YH>|!<^\$ M|JR??
839C>5B76>08U>(>KA7=|J4&3#;_2'(TOIM8HYZ|*%8|TK80)!\$7 M)6BCDP'|.13X;_8AJF;I MYCJNVWGQY9-
(9^L#3^SVF;E%;X|@M: KD;+KOG|HBO_Z|SM,UR|Y|G @G|L.D: M<2QSYMF EO*\$REZ|\$WJ_TDWGZPD)ZL.G+W,K;6G=
_W@5H9CK>+%(I/N/J M=-NO|5H+^,1_2@_L_6K;ZN592LDG:>_86*V4?>N/'N)7\$SVB3|>4+^_.3I MP0/W6?
@O6|14A|'P|+,\$R_@RD)'+(9%N_ PHH13#12"/(>9|NU44#7.<5V M/*XW;4F)HF9_A?AO+VOKWS007|V>|U)-V-
<82=AY|LPNO0|EM0VA2|>SY%\$ MHP#_E^;SHHDJ>K1|VH*7_YL<<\$W#@73 M8_|=/_ MNW8R7V|+T-
KR=6ZF&9B=RK;:R_M+E>:WA5_K_K'/%@_%(\$34W:Q|0K=^1XTCY/RVNL+ADN0\$9E/|0Q|O>O=0%
MZ/9|!E+ACMIF*5@|4TS;"N)2_S8>PI9GOX//UQ DV&EH6YJE&1VY-K&0YM>W<*_ MMSR_Q,E1?
Y|6&>O8|7<;WE87|QGO;HOVUIHG3Q1CN^@S@2&3132VA=R-
M(-4QU(\$4&KX;BWZ|W%\$XH>U|>H=60\$L7&Z99AB,24^&%,+Q|O_&"8PY+IRV
M;2AN@<@%#F_T6;XN@00>/U0VUU0?2|L(D'Z_87C=@K|9_'LO>FW:(DS=Q_ M"U%+3R3/^@G>1N%|;HJ-WT^?
ZL3*8CYAFY(##4D)7>2'9&7M0|HX5_MV X+ED@Q9I_H@#%<10B'|\$106_+W0|1BH^H^\$3_'Y/WL_|^ZZIJH=IM-RS?
M%W|HJDS?_7W=J1?P|8;_?4*#W?)JER_Q(|BZ'7(X8_G2ACHZG0^|4W(|VTC|71|'0|;YU:UK^ MACT-
%4#7N(K"Y%P?K3TV_KCWZ#WA<);N);O52=FVK>M_+TNA.QI(=\$.PPO MF|8V<)|ATC)U,H>VS#
|MN<&|ITS#|B?L.S2\$|R M'9M>|?_%6:;|VVI|Z0ESYZ_8|H2|N_.NF0VG_'EB*|MKG'4C3<+6
M1R2L>P<"J2Y+CLJ0=P&*2"(W@M67Q6KJ@LNLH1M5S|^UR+Y|DMZ%*_F&|1L_M_S7L7,\$":ATT@|Q7
&/:0(|L)RG-N&-W*2Z;235X*EN",7.O\$_.0L6G-D M+HL>;&OE"(OR_|I%=G/GF<9,TISR-"ZC4X\$AL7|"ZSI\$"A&H?
0B_XQ"#_MI=^3+_|IO+|^>BVXEN|B*SSSTN|*|QO<_!P6QK_XG:"|OQ&(T%|/D(+
M&7(IT'KMU#S.'OIP0DEC_H|H|H|OM@YVFLXCI M HY@+|I6># \$HQ3@.3BS.">|>7Q-
F^J7+*RJ'ND#VH*L4ONG!!Q0OKPWK%GBI M99F=ZNIX|/_=L< M^NB#Y1,6THG)HNH|7LH|24D)|F?7%>Q+6W
ME9V-O|>+S51O1D@<?"Y|Y|+A|5.9I5M27|M0,>QJ8HF<82C"70Q|GYRP"
M0HZ5C6"8GIPD|X2N6\$=42_U;IESY=UGN4_|JHBP_DY78-K986O;JHH_F|OO\$ M&A"@1S&L
7>F(TN=MIUH4\$82;%Y M?>AY<|+H@<G| ML"P^#4J|1)SNXPCTO&#=-&Y#MAIYACM%:(0ZP%M@SKW MX?

7T+!K1C.?=-C3T=S.F/3!\$WPLI?<-IRNM6S".^8=6R'+T8OL.^,G8V=-MKP
%GI!-!P!H@%F2S0!0.E240450F5A/BTM-U;^S0+V=E&7Y)WL**+XMI:SBK.O:B&D;\$G>A5YS';M-?P<";-BO-I
(DI!-,3>F6!>I3!7\$RIQ&AML(MRS:(/.,N71!O(7BIF:RSXF.&562'S*&OUK)&J!SO!^O&4S!-9
MGYO_=-J<4!3G=GF")3.IYH!@06E!\$X.,*,3G41713!""[KVG]>#O;JF.,+A.MVBG2?+=G2(1K.Y#\$JHCY;/B6!K"Z.Q\$*Q
+)VQO_3A+&MJ.H-G@N5#N2833.M@LE!HJ!7W((QS.R!0IV(DJ>7WXG;9Y5"\$3(I&X/1Y.K0!-(H&B-3G2
M_*\$44AJGK@/K<G.84GQS:O7'KLSU-@^SI@J6AERVC5^-,=(W>N/L\$-K\$'MXPBYJHID/8="M.O!L#?IM#N0&
!FOY/'-EW:2S\$"QBXX:""%9FXZRXZ8.MO.FI'6Y8:+(WYD<=^K#AR2B;9RJ@Y!>YJ2)H(6-T.1)!#-!89.-&;65!+!
MG8P9ND>LQ!6P!"J.IVKSJUC4Q=JS?G!6A.V:IBS7WJHM(9S!-P_%NF"M'6!RB#RYU3M->B76=-MG6>JC,*
HR#SJE!Y'3*R4!9-OZBN5^Y!C!8C0:"@L#&+Q>!WPO+/3A1.MP.#.B?2Q+RG;./=N74A98
MZ^XZ^5KJ4D5G<86<(^OZY!CO'3?L&H4)"S3=UP9\$E*0Y:1Y-"7!4.M*5\$5-4X<&=#L5F92NC?/J7!-Y",BIS*?
9Y@TJ3!M*ET!7HR!J!<=81NR.@J(575P+SF5RWG1K^NLV:MNO\$0LVB7+&0&\$<;SL>"-M<=ZALGCLOQ.=X*;
<=O&#)H9MDEGOADL!]<*5L.#5!0%K2)ZM=CUY.%VDHVIQML7K9P/HZNN?2!FINP;+B)8!+U+MMH&1?
%!8\$C^8G@BS/FWKE!O6\$@.S.IK5Z7.;U4C.B&M%DN%:(O.32H=OW.M#D=#%.;&)0&.COLI2WE4>I&O72=
(I%DWIYZPVV+V+8H!K?S26!<7GX!<L.MZP-3GS-*YH'?@L8HB*Y#F4;+UU)E&IWB.VAI.HN_I/OFUW*L^?
L9Z!9*E4X.MN92>4Y9:)%7B@G.H.XXVUH.^=X^<7=4&I1):F68_K5R.H
M&EUP7=7M^D)3I+LFU4\$6.3IM3V@4=P74KTP?(-/8?N"1!GH!JX_"T">6-MW(L@N5/GTN;)(JY*MF^"#.VYFU>4
K@B2XV.T@W!C(SVMN@F@):T!U)68JE.MNU-
^X=DO7Z!PY@T3I2:@!NN7)=WZY>7Z.L.G34U!27APS9LNH_U*R1!_UA%R.M")DJL\$>
<.:3)&O!F.B1F6L):*/53NR56&I2(1PV9T*=9GC8N>#M.B#;V@;?;-S!Q*M(D";ZVP!"9.UHL*3D-/GNY_TEV@+?
S.2!<GB)S5V"*MOCH7*;NYJLR*IE4HFI/5!/L^ND(QO4IR*SQ/E.T.L9CF7+!+>G3%!M28-72!S!
I'3!""!XH!TAL@)QO!-%4=UXTK+(-I7+I.PM-."?ZEJ_OI!<I.MPC7R)8).)?
3SR@3NS>BL7LX)VW*A^EY!TV/VJH.L.KH.;)^TC'O;V@-/#4JYR3L:17YDV@;V-@)%EVM2
>P328<\$##9O3NZ2"FM_GHUH:@P>R_*)"KSO.MK(%C";#;G6I0K3AJS-/1(8T9W@'PM4666-
#Q2JA)6CI=-MWF.B&R!%2-L.M!SL*OBS-/M\$G")&07C#QQWXX%&T(I3V0+3/D4A.PR);ZA7G>;S+JC.V?
5=1M>1V!7&A)G&432X!V;*Z.WI.R!+B)IMX.M\$32-G;SV^/CZ"2+=.FWH6_X()H.;!
R\$.11"0L;KBEJ6HH.Y!4D!5<OI.MH#RIR?2H?)"FU5:1+BZ5(RINT\X!(&*P"1@Y45@(\$K_/#%Y80JF2?UP.M1-
GFS_0UQB7W)IGQ6!8!1U>QA30**84N:F;1L%>IM.M>:68H.V.Q5MSPZ.;97L;Y-ZV)#@*!*)4GU;MU.DJOIA-
FFOAN>OU.F^5H;J3NY2!&G!@*!\$VM<I0=I#A^/20H?LG<IZX!4!C:4#2^1
MYMQ+&;K6@1#AT^WSZCN3^;CLU6.MG5B!RBV:U^A5@^6.HUI!V:O"<>SE.P!Y!:@?IWWIZ:%5@T)6372-WRNQ
2E.M!D#BV"4!D_"\$LIT(UNG#Q7T!8N/9V!JD5=2(FYJEY+EG!7B%)5/\$*?U)
M%D;VW"DWTM3!QWZY!\$8N=D(W4%6-E&A+I0D!@#"#I!V4+!T_06\$=4/&U-F3XZ>J:@J!M^;MR5&./H7-?;)J86!
M-J6?C.PBJA5I@!^@.*9R!M^75:E+S6!7S0&E.9\$!"IOPUG#Z4YD&./4;-6.M-D>C+
<>:NH28G4+P51+D.53Q4Q7P>TG*QCA%4%GIS"^C2!R#JVIH%ZNG<M^UCPD+2@6PL;Y!%UZ+.X=3.7)8'187\$
0*+YF=U;OK\$M1>18QG(G"/CC.M=E6/4KA>;7T*(6=B#M&23%K@TJ.IJNP%)*#RB(7"H?X'(N^V!Z;/A-M;)*E
VHEOQC?M!3"9XZ@!MH->N!A2ZOH1W5J(LZ8W4P)!DO-6490@ZQ@JCY9!2%
M/ZLUSPV3TEPA=P>W7L@^GK84\$3X.K9^>3V(>9+3BQ"N.3V.&4?C2%X@7M?MYD-?V>.P.&M6HB;AL?
-ZH>1<IYGI+)4;CIK.B*UZ!7D0M453OOC81""<.'\$E!C(Z'OUT=(-H(3-ELW7!I"\$R2J-#IR%!E!9V.T3Q\$E(0)NR-IOH
MO->KK?(Z_OFI.I5%I9Y%#.(D#%8I#OWP*<'VC'J\$S+AS)UQ5#G/FW.6IVI.MJ%'+/Q3<<4E*Z3O/I2^"X=?"+H-
Q!-J.H%CI+IGIYBMHJ!25K;IE#;EIV.MGWRI&IBV<-TO.UTP*S7490/M7AX\$LUB\$"OG599<0QG)-%"B#;MX-
(OZ(SA.?=-F;J.K8L%6!\$;N9V+26IO8-OEG4YY%\$)*EH>LD-LTY"&F/MA!Z?(P2R5!LGI0#GSH8=-@!;=A!>!
(Z@N;>Z397-#W0!"I"<^"V38S_UG'O!&'KHPA.M_I7ZOM02!&X!VK"NLV.VI3!0-
:/U44&QU>2JDU5YVD!A!1^W_V99^7V3X"0.MF>XTLSEB>U#AQ;.AJTA!L.OK>M!_5FIU"N9QK!J/E7)BYMQ+D-
F>2!6OZ?M+"3!\$0>85!)LARFBI/OHC!+=HI(HHX_PO_UQ#^";.XP06!7Y!=I!V(C2\$-MOAE0BUT-372Y#IH3A%=5
3!Q/WI%D"."0N5CIQ7P!"#X/P.MO^+^+H!L^N>\$M!-I-8#^ZL@.9O.GP!&!^\$D?(30!2/P@/JANL;TH-
!S>=>FK=KFGFRK-N.MIH4!G%'IYMR+HYF)1#CO+N#%F<8I8.<3L>+AOCN0MUM1.72A>?6AK=(^XC!\$
MD!U!8(-9^!F.OO<+J%F90C=X'_T!-TW?0@:SQ?L4MWP!H.O)!.W5_%;'<M55^!JO!K8D<"2C-3!Z#IYOF"E*3GC7&-
LKW!U&#GRXUHHVM0N6-IQQ8)K5G&BC5K.MBL!OW8@CXCUEM%87QQP"#2N<#D
+>I4!""9OCH+E0(A31!/OEAFH!HJ!U9.M%M7.O5P)_PP)JZ;K4.DXA
ME0@MS>6QM!M52H.4:5V&M>UYBN>+AJN_V2KK&QSMJDUE-190@ZAF==_M\$56N!-;
-1.J&U.RR6!(-4EP!16N>ZZ!_0_+B;4D)N:QN!O#J;Z3TG+1.MHG@R1S"R"JW!;H#Q.24Y7EUL;A!^Q33D;
<0>00!9Y10S84.KFT-J.K?R&M9-'D-EUX9QYWF%YGI>:=Q\$!1!3+C)QW909%J!@H8.Y58>Q.H^KN.FI!W5E_<K
MC/HI/YKN%_BQ.M1QH3AVR'X!D.63UQQO*#@>T?I8UJPK.MP#VX\$S(C.MQ<619?8<\$BX.G*E"RY<5=T_%7
K4.VCZU.MASZ_#FY^!MDHP?#"P@:=-V(*16BN\$;8F&8A&7L8S<1COS.BG+4?^Q_ZO<2%U0-T_Z@IGYE.MG2W!*<
<1E.QQHJG%I*!9Q0S6=Z>3D!5:(+B0HN*BS3#-5&F(^8+2U!WN5.M2VY!H>_9@F4!WFK5-L?FK++M_&S*7A:W?
WVT/S*THSL!M"NZH!!"ODA!\$M<6HUSY(*!4)-6ZOI55XWWS!0Q
MJT&03X7G9?9X(7CBH!^:ST!;SERO!A!+P9IY&NT+R+ZTI@A8N'BMUA(MJK*H'?+XKZ/UPV(-6\$AE3F)@UF#"!
CYS!R\$3#;6\$4.^?IB>T8TF6%P.MYQ3#?KQ-U)<^?70.DTV49!HU57%SKOJF);==37^L(/;:HCUALI=,=A=O
M!D.7H(F7U(#.0FJ2(R!N!U!B@69MBI!J2OKK8)V+66X!UM4O.GX!ZW%Y!7&WEJ;(*H&87'W?&XMV^S(
M:U^RTDB+1.EKS2=JUZ=&R30!^%I+7#N2!H"!LJ8;0/&B3.(E^=(HS(XPC-H
M_H^V=%56FMP2XDW%5UNPB<&49CFZ?>."(\$8Z!Y7"-X-LY.W;.N<5S_+(M<3QP*/HUU4XS0X9?
3!W"RLRU(;BS!^+D!M7W7:D!J*NS7!P'HTUW5VZD.M.6!-4LI@-FB\$B!\$BP!HUI&-Z.8=J!B;0<
!#6!B<>*&^LE!IH>XG%M!9G.M#;UH1;H%Z<+!+6R+XFL?3L."5P&.EJ<1Q?2U_4;W.F!+=LQ+#!1M!0H.;
M&#W7J9!9T%S3N7!+1LEN^S"3\$."ZWF\$94CZZ.PG.X!ISAA!>-A=&8>I409+\$JK+
IYMD+GISJ!+>=HAG;ITYM=SU.ML0AJE@.P0.MCN((44#A#-5R'TG7/T0P38%Y.A1V(+Q#5!DU<;VM!60TAT(
MR^VDWG!+C!PL-GXLX^M*WPB^MJ0)=7D#CS;R3=L3&LP(K&)OJY#R^A0@*80.MH(*N8&^P
B9TI&1ZLY!>%MY;CO%D)>X6.M4HB13BF8%>H?2!282&6'.FASD-H<7_=^7F3K5H@E.'DBDAM!DIT4&"FO
M%..CES.#LI3\$)JOZV.C!7.EX!Z!01/&N+/_FS1V(Z.9=90WJWI2790/8.M!#?
AT&N(N9NG.L_7CMS^C+S4KZ?@_@3^J;21.JGXI"?)H\$.Y/H!P<.);G8
M#L2T*B/AB^D!E&0G#L+R!X\$ARU9SIQQ^*J3^>I"V2728N!5B(^S.U!A0GWU)M_1!<#<@<-&<(A(7UOG/HJ3?
BB"TI7(R2X^W>.H!\$=TBVA8!&W/3DWLOY+M!HU(1#)7(M?M'FNI88US_U0!^CD)UN!@S093M-1.FCV?
(V9!ODJ.=L+U-MW!>^+MDC5/W5T!9?2N;IV!GW-Z&JU:1R.9GV!@M(0*L1#X!U/8WV
M9A>H3F3H8229(309^1Y_AGX!VV-1N=9P.1H2EECTKLA_4!.MUV55T8!3^X(O.MPS8;IAIKJA(O^9^MH!>
<>43%4@FR>TWY^I_8)<@VVV!M.M2<>7!KA0.4HH.F.+&DIK#@+V5%M.H-783U@<=<I*!+50#!CV>J^IY/C
M82+4Z@PQOS;-O^&L4-6X5HS-K9-^8_K927-B.FS!4>#ICYE'T!LDT\$=)MZ.M!1#.&\$B@P!O=IB0HI?
6:#86LB++L=&/\$U^(&S9NGYK+T!OOG_Z8)7M(8P.M?_JXL4.1&^!CT7".+T.%LL2?\$.>Y0A>T1/E0V!CI2,\$>93J
MN7%"_QWEZ^/4"?T<[2ROS6<+D+Q4B?Z;IX+L;\$#S!0HJH.HL*IPFF7HE.>I.M4)M+6HH!0Q!0='IY*0D=I9'-(RRP?
^R8(3!ZIL;X#6?VZ.SGN*>VY2H=R.MS@?;GW*8.9.MD5EB%LIWVOZ!\$.8"1AJ47WE@/X"++1*CM
5H!^6L"F>Y(L5MUF2\$>>^Z(Q-MTXC1'ZVYD7!H!%2!6GC=FI!Q3!S4^_!B4MSZ<0.0YX!0PG-D/AK^SCEQ

M!^*GC;PRCM&O?C.PCTAR3K"7D4D*?L5^M39SPU7G48&*7*82D/ F MDF)E4SHU;+!%I*\$\$LE>YW 'X32IK0G8;?
G3#7 !*OAXR'YZ*L7IQ7(\$59DA+%VP MW;Nf.C0B0(- F1OJ3BA7PAWHSW^XO'C_IH5R)*KMI=V5<1XT0D.0XJ
S:V@JA"!DF52YA_*UZ(+=MCY;9U=566XE-ZRYZ1RE-5!ZYQG)IQ!A3!E10+OF M-
MR\$!>5YZGZOM)*CQ(=*MCG;9U=566XE-ZRYZ1RE-5!ZYQG)IQ!A3!E10+OF M-
:C4AIG!,\$=ZW>XP<+>^H8M% U5E-4-6>U7>PT# 1!DPDE8ZIU(4+5>%!&4-MP!23@G;@!%?Q>J*..Z3YGF!%?
U^7L'0%7>/MJ-Z,R(OSV=3.MRY.UF,*L!8BIBL>N4!G^3(C6>Z+9W(\$6&-8@31ZG25C(5A M*98KX\$!ILY-
E3!M."='ZH07!B!47U(ZG!K9>+QM!VUI7!#L!QH2C4P*L@,T MP
@%0%4+,8Q9D=UM7?4!@0K^V;*5EG,TE(QID/C)W'ZD4E5IQ%-9!6I4> M/UK1MR0HES1-
6#LAQL5HZA(%M\$03.5H H4H!\$!9\$X9'VPB8;H!X /WB0* M&2"E9Q1/VY%0N>Y!J!&V5!5(^GY8!ME
SA&@G\$;NN'=/,"C!6%KU MEDIKS*S(!=F^A7I WOYP>I#GIWD1& &IB:Q#1DL!7@%IQ=;9Y!2U69.1W81 MQ,8-
/W;22;L!DOOD@=Z;2M.?^6R\$VV7AJY=-R^*H>I8UK7GN+IL&.%!C MZH
OJG_,B"3TJX^PD6H162=5(TJXW02@;)JFC==&\$7=3&5TN8R5GM!V? M+6>/?
TOPTMODY7!R"/,4S/2,0&8)4Y0!@ZPXX')KW MCMG-6P^T^Y.C. M*IT!5""50W(EB=;9A>BHR*4^&F""@I*SE?
J<@!>C0!HP9L/LWV;48" KI0\$.N MQ=\$LNQ%2;39(WH;\$!F;.Y,IPE0W^G?>;H NKD8N3!0S>ZEB?
6*#8RVN<,"T5!EK4,MD7I7NUP;VCNV)R7^CP78! MZ8?J!GB'^!7GQR)Z (RW>^QR@C\$!'!";6)WX#%!4K1
M,JW!H!#^A/33WZY!A!G'>0;A!FZ>OF24=-KTW33D^U_YH)4W_ZWI9S3!
M3#E'8(O!L%OXAVF!1.DR!%Q)*TY%#"@U;2X!L;+7X!1SD-P MNK
A2Z*)\$P=7Q0!)06R21+CO3EIH,W(//I#P8F(!YO^_.JHZT=<7TC !F,E? MG^0!FG496?/L4WE=83!
(N#4H_WF3J_=,^!JG)JBVT\$#H#N0!UGT^MT@Y@.PFQ!<\$DQ5X0?7^4!1XM;P%;4XY!BOMKQV!R'WD640&
M)>1#;\$F!;C!4N2WEB) ZNZ^_2W\$;3Z6(X^H_1U#2;1H2QEBB!7CQ;+!-6Z M_K)
TK5C!GHG#24E#E^VVVMGW!LG,(Z""^9,(J>;+1R?X.2!0%#)F0Y_3E M6GGBK;03/L1@^>A^!
!&;V4)ZZ:"S=+O_&TS4H\$0DP M,^WB\$V!-0&9'O5'NF7X?2U(MS!PWML*!=!XN\$@;5_\$W5%@!503N;4F!MJRB
M7UU6HUZ+?+=!0=7%.)N7.552S^S)X?2!(KY>+!6M*+KD61S=A"2*\$B'!& MQ@S(HC>S/%UG7X6V&!?
!6/S9Q+=OV>I2W.W)\$G5PW"=2C:>#B.#.PHD5E%~;Q'4@!%)SI=\$FG??" M3TS00KL#;;322!C!F!G;NE8?;
<.C!H!F!7:# K\$!N0 M!E,&7!O_0"+ R8L;..(W!<8U\$U)I!&WD-XQ@2MJ'6!;!U\$G4U(W4*(M
\$58T9O_0*\$_.=6!A=+!\$Z!-U!R); M^!% \$8<1*WM7?(WH%<'IDZTRC3%"">JD_!C!26LMZ!HYUUV;:NTB*ST% M
?;_6L>BBCR/V!33;TG9!ZO;/,G4TP@9W0..@J240M;=;JWX6;G35UGTN87?QB>I'=N2MH!L T8<
M9VBW(=""\$V;9\$HYF?W!KISXL.6.@\$RW.G_9Y6^5T4RKRL272V>44C"LX') M'9,[D'WD>=PC^X2U7Z2?
8^=,%1N82!*-U_%24^>L ^;f3Z_0B(-WLZ3N0!% MRF0F&DYC=N3;Q5WW"1-3RLW#Q+(C!9;2W*,\$-
MK=^*VEMON-&!H-\$MT0:YF M/STB5K_046)P8Y!V7WE=WVCU45YHD-!PL#@@_ME3!/?-T!U MP?? =W?U
(!8VG#;G4#9=;,>#_((P!THL;P_9T#2D9LF2!B!8\$!1.COMB>0
M*3@!V"JWD@(!P;\$GK@E%+7@!8=>#28M@CG7K!FP@>[FH-6:S#3A)#0VE-M7=G6U->J6"F3!IG?
5T44CH8VC&AR.AW%Q2!6U%:N.U!ZX\$WW\$*-!8KR%0%0
M;"7"(83;CE,&9BI@S3KZ;7N%0D!T*0%3G!5W>_!\$E;A!MH)FT\$QO)7;8'ERG(M=3+8;\$;JA"!I?>
H!@D23!COH!E&N6;W\$V\$ESBL M:C7AZ"C!YT0RY&!"PX =S9%"ZXZPD%1!D)GR^_0Z6?
HCW2F_%8+6HKTO\$!L!BW*F)'0A!OPP-)6F678-B5J! M;GC_..8=K7!O+!L=R9U6.FF=)*CHU!L)N2'UTUDR")&AB4\$J-
>+PD0KK9S!TD!6;1!DT!S1%!UKCL_D@ M\$(<!Q7'G!1Q\$H)8%7?>J@Z!++3XZ+L5_7,\$V_E-
O^<&X_.1NV7H,^5! PO!_!_ YKS NL#JP+=.Y(U7LU MQ:=QGVG#\$+;S""@TN\$F?RGX#>EHD1WBO_03(5NM9;ZY!
<#OYG)0 M24R5D9+XM1N<3 !WI&-WV04P"+!Q#^!4W_X="G-Q@^P+4XY90%N=T!9)+UR
MGR;YO_JH">SELI#V0/HJA*^VOK!;!S'E!GY?R^N>,P8T*;I!EPL=?ZK&#_!M/XOQW9#_HOA?L9NOE;A-
!3&2M!PU!;IYE!AU&@%!=4!3X!07!C(>#/?F=?@ MTO.WM4HXMP8*#@LEVYZ;=Q!;
Y.M;1EINSH+FC+!#\$06QHL/\$\$V!ZTY%* MEY_O#^W+GRR-MJU&G7^;ZNT@A!9.2/
F2;4X2D_V7#&HJP*A>UL\$5VOIY!M7W#T>&5_-I=)TH!T6D@_E3V5'Q<#5!4;M;8IBD;L.NY2!7!GR=;!N.S2)H
M/LFJM8B4KC.'^* D*=O1!!G ;H!R+<)EZ*"CO_!G*CFVG%ZER/IY#-*@?N#<H!#R*; MQ'O5-MT0L13'RQO/I
(>F=KRV&NW,E)QCTZR>U,EKD\$3 +A!2/%#Z,A2A ^N?*1 !Z. M5>B'.Q!>I XD.W1^H(4
=&UVP!MC;@/'B.\$_!MS%)S3!0+>CRP\$KP,78G<1 M<_)? Q.X4V0_/(47IU"W0YH)\$^5 !"H">L6.0VQ3!H_M5BR.
MK425SV..0TN!UKXYC3!2\$J-J!KUG!H5U@HC^YL48UYNG2D)%4JTG\$!_A+" M!=-2!7A?!.P!>P4;-
I@!9NAZ*#!XTZL(M.J0=8AJ!XE-Q.X7><)>WMJ8!KVU@L/&(R'?+?..!57C!M1U*GAE;C#2)JK" MS-7?O-
W!ETU;HEPQV!L;G2G@M8A-M5QGTF(9G>S'9K.C9!"!)+W."TN4<^+H;B6(-NH&TNIS)!I
MPU*Q0V'D=D7A/C^Z;=G!P(FWTU^!&I+6YG;C2+;\$O(ZLK=!12?+UFI_!2Q MLN3!>A^>)D(1@&IE1@C%T+?
8..NUX^TJ=(ENKI4S/2KN>*!I-FW"Y^>B@8 M&WGT!L;M@5D!M#(90%""F!"^X0-
+8LH0QCB!BGI^T,%^^QJ!Q\$PHC5!^ M!C7,<3H!;=C!>942/3!H#WE8!9J;=^#UC \$=5!<1!"\$WD6!>I*!(Z+K730X
M5;9.6<^;G!&\$.#T!BPKKS(N W#Q5UI;K0XY*"F7VWW#I!>HY\$Z0/3?NB;
M'F)WI3IV)4.7.P3E)08M,\$TO/00M@!/@F\$-J(Z!9Q=ARKIW_MJZKK;5.LV0! M#PF^;E3!Z2!>^D!KQ/48W1YTW^
!QAPYNQ"S!%.N^<^L,L>_7!R&Z%M!#N- M3G45*223C V"V!4;::HD&Y!429BW@SJH@VRR M=EUX
!2^>E2!_T6_E&LP@5(D%I2W!0E>@>X@!J@O!4A&Y!6=I;\$<+<"F53!ZF!L7MNA\$(^4
MAXZIS^2"!Y A^!SD%1E;#>J>UV^F9@E!K8_!QAJZ@3^!X@::G.B.\$090%#V
MMV!+YXN/\$D!>N0#65=DI9MUB>Z-PXZ9T8.PU6XX!1!<I85""PP#=&[FZ,& MLES!\$=VZ,??
^7=SFB,9>&I/8<(C9-#X4%?W%F:M8,ZX=SI=ND;#T\$J&Z!WE M9_"Z'O>6@E/ M\$
D.EA!5^Z1=KRK2!H#/_HEJL;GIZC\$^GB!/_ RC8385J.'V?(U4_Z0^8>A M6V-6<&38RYMOBE?
MLEY>D\$C7'U5DG^A1#%2H!UQ"R/_X!7U_M2PIEA@@VF,MUF.7Z!>(R%
(HJ_K7!C;)G*ZH;SV6N=9J9Z5\$!P11;M^W?GQ!A1W!ZLO@O.* MD%@<;!JO TGPY'S";O&#RD)V9P="!2Q_0!Z38S_!J\$-
PD)!YHGV^53K2=" M;H3Q'SZ!+!\$O_*QXL>-2;5?RV-JH7W!_,^3)&IQ\$E>J9!+NW%4^WWNI !M+*2!@W
+BYPOQ*5_JOP'._@_J_616MN)T;9MYOQ!QGW;@FC+ M!H!O M!&^!
(\$Z@)<W,B&O)QJ(RMS\$B=P5*G1V&IVY.1%N M+K^!9WJGLG705_94L8 M'7^>KM>X.LH^X/U/_00O'HV'<8G!ZC
%^O!H!R)DJM 1\$41!> 3MOCQ#';+4F+F(F0DS&R@^)'\$MK! M>L/2^B9;!
!S9P^3#B;%!"JOB)V.L10)EU.BMTQ!BZ886!FY;=&J?^2!>; M@3K^SRL@C!\$)<,VOWQ>5 BSGD;%;U7;3SZH;E
V!3M;_B_L>N? Q*_!RV?WS MFP+*JH7_?UU_/_L?^!T_P!02P,\$% @_(%Z6E-0\$!1B5)\$;9\$N+;&C(-!20B!D)10-;7?
!S7QG MSGWNNZ;G#;S!_YQ-L!#"3MIK_5;:FWK?7_9T\$?I>;COZU>-KT(8CC! !H%? M\$H&A.O@H=
<#9X@!S!#P8Z!;0RY C#^/O!^/_#V8&!^9V9B8F1B869A^8>Q MLK!QLK"PL;)QLIQIP#_=923X^C?
_RJR!YZQ*F!D9F#E865H_Z8/>".%A M.M)!Y 4C@R3D)!#(P!O!14"!7UD_H={#)#_>C <861B9F\$J%W>_ \$3Z@!#KK/
MR_@ZS0QZ#XV!PIA!F^E?24.0.6/O!K)+_*HODS^S25TJ;1*PZ""*JSWP
M'6/G\$!0Z(2PB(RLGKW!7>_!Y@4M!&1T;'R&_#LWO!^XM+Q"VMK>V=W;PX_!;_%&D M^?Q;+!% !9UY&!6/_&Q7
DX!)>\$S;AZQ!J8LH!WY!42H;4"6OD_7&+L+)!SJ60=5*B\$A'70(DPD=\$N8"2.U!H8AM,B^MR"93G#DP3!
(D3!5E\$GI(&@TLBP@D6)00(\$_?FF0=H0B!EK'?(%SLS#W7O ME>-W1..2BV(2@!V=GL\$4?
Y!MV9K4Q^!#EQY5*M?#CI30^V5M2B^01_F27P M;JV=*7GY?
!K+GD!7W!R#P2!;I0X&YD2LU=EM2@XAJ^W_%NG"M-*?S!D/2 MP.C!G4_2^!1ZF%.'P\$!B@_Q5>GK06

M0X+BDSh.0@7HD:~0Q*NO#R7R/RV9!O)O%%5I=9ZRBj3ZFA?Q9%K>5V0~W3 M-
Xl!O\$!GFU!\$!ZH+!/\$&IN5A1A~!S%&M%~OL\$A)T6SXM5Q6+K<~!\$RCCZF52<~M2A.~!L#V(93466j5
(<~%4!B17^~@0%IPXW A#~\$EJ!)5!~A!)84!F3:~HZFTQ M68jE9+!~W2N?AJ+~\$TE+~2Z6L8B!~FW0!~SF@V(011!>~1!
!~H%~@SOP!F~8U!~MX~7CW~MIK!Q~D9+V=I~Z?PI\$K"P/#!~Y<\$~^~2W, "VMP\$3Q2%;Y~&+EX>~.V9
M\$~!FX+~7!T#8&JEN;G!R.OU*~?~!9#%Jc(RK(Z/G@Y!F/AS(B7HW&J!,"0\$FP&~M9T:~X#I*G
3>HE@K8!/(F!~KM7GGG!A!~1/85CEZ4.S!PH MJB,\$7!5N43QN@~Y)TZ\$(~D&YX/U2GQ!C
j~VB^/6!40=~!0Y24j!@T!HUD=~!M)I~T(Uj.3?8!62W=VR'D5E"~8>~!1"AZ%\$%~^LDQ&U2N%WMD!~^~L!5KYIW?~^V63
M!A O5X*~XKIU.Z?S8O13Y.%Z3\$!6!QK(O!A)IQ_Z~%1X7^~@=~>OD~AY6S&R%~!~M8!H!<0<~&WQZN#RH!~(S2X>~<~.G?<
D"~KI+~9U2!A!~0!GQ~!~!K~!~D!CM~!~Mj~63S9T...XO&MAA0FO+!~I3~D!K=LM!%6~"5!~K:6#)3!F&RV?Z:9~@~E&@
M~T7OW0?6P~I6\$8*3@~!~XPEFP4:S=~UCWJ*~.(U9=~(QIR=~MK!~5699>~(!PI1T+I=~!U"BL?^~&~B!9>~>AY^2:~@~?<
H~V.R=5BX~^!A2H4C~CB?~#1~WHNI7VjDTM5YK~SVj?~<4RIQ=COEMEH)XUL:>~.P%5B6JA0S@~#PIYQ
M.KAKC!1Z?LKL=~CYY99!~116V~!~IOW8LBT\$2~A9YR~*~*~(Q\$0VQK3R)~*C~*~
MQOZ:ZA\$!CSE)~HH!5!H0SDTVN!~JCUQHcJG:Z7Y8"H~47B@CF"R~/&~"3:(%L~MDJ!#~!J&C~\$6H~11S4E0!4H!BAE!&R
!Q~M.KW)3O=~\$!M0*~MV)^~D~O=M&.MU8(W,@C!C2+>Q@&RK(EV>~^"ZO!JZT!^&4<~YTUBK^OV6'~=\$*>LW?<
>D*~^&I7 ML~""7>~M7?V~^~I,=D!~AB>N~56>~U~B~@I95~R+90~_V!XK*!6KX8M9<~9!~M#~!JU\$SG+KV!<
&UQL~Y>N!C\$1~QRX!W!Q#~D:4=ZV~.~K.9JNPY~"KD&XX(M/N#~!H7W&M#Z!~*H)
!W~!S=~&~R@R7I27(~/7!~1T!K5O&H~.~#R~&VP~HN~Mj5(&GCN"9ZY!CIB&6M!~L67V..(=~%>~#T<~!HIP@P!~LDL'Z%<
(~!NB0XH!T~K~MNO@~@PZ~RW"~@~.~S:~T~QT~A23=~^LMD~!~#B!H~55(L~"M%3(C~ML:~?0!~!L;C~R~MKE~
SU:~!VOL=~&~#F3@OB=~7:~H8&G!S!~!T?~!~\$ECW=~B!G!Z~KTV~Z~%72(*~.4,F~"MB8~#~!~\$~^<~@N/ R\$5+~Y!VJCO;"4=~>Q!<
MGXSI"0C0XB"~RSL>~<69:~>0W%T#M4&G8BBL6O!K5CPIH~TSP1Z!~U!~MTV!N5B3~<~*7~GT6XUG!1+~Y?<
I&XM~/!W8!3DGE5!4S~!3K2)V~N!~PY@72!%~B~M!@O=~:6(?)I6.3\$!D~JL^U7(8~>7W!AG>X#3!~#5OLAL8SB4^~\$VI&
M*~"~M0~C%1#N!R9~93ZKW~'OY!Z=~\$?~N:~24RQRUZIQC!Y4~MTDN!~MBK>~^~.~9=F!~+~1J!~5).L3!<
<~.N.Q!~!I9ZD&~>~7!~FL5~L73NHLNEZ~MjW~5F!~G~RUL^UBU~
X(9!4~!~M!J!H@>~\$D\$5!W:\$P#~+~\$CFC&~U~^X(DTJG~S!E0/M+V0S!9K(:)28:~X9.GR~MXZIG?<
Z0UYF%\$VQZH&Y:H%~6>~1CZ+~""2^~J~M~DHB(!~E!6;~+W~N%F6?6O~'~FL!~MS~
Z:~'9.N!~*6N9M=GR~T^~&A=~!SFG>~AQ~4=~Q!N@0ME@F\$&*C!@~\$D*~(?~_YP<
M"~@~N:~*8KN:S/GS9BGK&D!~!~:~BYBK@Q\$~<~RA~P76M~MD.SPI~T4V.SF"WAYQ!H+S%~@10#~!V~!~!2HPX@~!~?<
4CWVH"8!~+5S!1FHEUT~MBZEN?~.UV3~+~ET!~A+~UTS4~639;6@D~/M~BQR0!~WE"XH;H=~!G%JWB)IQJ~M/GX@~!E~?<
D5+~WFL?~*?W!10BQW;~'G@PU90%LE~.~()JO*34~9VIYP)\$!G!OY!~M!LF(^~KZB^~\$C?<
VUW<~:~N4RMO!HL3Z~\$!HCU/3K"XO(//~_VFG\$7WIHE1007~MK5X'2=~@4!+~"J?9*69V,2!~&U%~!RTUFS7N03KB!9%)8?<
M2YTB"UR&Z33Y#Q~.~#O:8#~#CMNN9~0M~X~M%(L~(\$@!~#"1PN\$~\$~218<0Y~9ROQH!~5K~H!~&Z4!~T/R8*P~16K!~(4H3<
M2"~+N=~^A+~"B!~#~@~HW3@~_PT&7%CUF0!~?HBY~MX?~!>L~!&\$BVA@~*Q9\$PPXW~.6C"1K4AS!~H7!~H!0=F<
DC!3SC!Z=Z6M!GR~MD!QPM?~WR!5K7!%~!+~<~Tj3*~D%~!G9).R0@8.W09.O5EH3Q^~M%09%/EB~/(M!<
M!2L5Y*~00;D!&~!J!5!~"5M03#~ZGGW?RW.B.2~H5!~H!01=~T~RH*3V)\$~""M=1UD).P?P(M~\$+6\$K<13~U69MKV9L~
(VM+~*E&<6R!FO"55CTZ?Q?YX#VM/U8~M~E5X3W).B\$89UY49!22.&2S!HUNL+6~A)P~2QS(H~F9!M~!<
<~!RB~YZS5DS~MAA7V;Q2=K!4U@6A%IDA3?3~EXUAVJ7~&TQ^3CAHQ7V;<~H+PWH!9IXA!)(KB~MLQ+(C)0'@<
!QM8G&1.R~C!7*M<~X@~:~%Q@~#80!~B6;MOU49!~M!~#~\$ALB:<~)/2B6&6G&HR~/-<
M.7YD;U~^).!5S:0.LD2Z!S!BQ@&>~.T=~*~_Y!T150&C"~!H!~!~!~?~(JXH~MB@)QI~<
Y!U!5~.Y!L24S9V6!C2HY!1\$Mj9N:Y9L&X!~#BIZ=~!~>S&9&D!~M(P)*T~Y=~^QEG2+"W0~I*9GSE?~"Z!FOQ<95~N^S3O?<
!D.L>~XRP!G!U~K'~&MX~21~&~!~XG/Q!~%OP*)!Q!OHH!2?QO?722K1~#X8&&ND0!L2IV0;9B8N5M*~*~MNW!~YS~U+~!E~<
UX.G?A2A!U6"?ER\$!E%QZ~M6K~D@~Y!~P.2W~V^+~B7LV&!)%2MjCI8^~#~D9+~!BA~W<99~.~UA"/X&NX*LI<
M?"@~:~P!HAR~()BZD.UP\$H4M~Q!HFL5!~+~9G!~4"~>KECO.VEH4GW4D4TD&SR<
M!~Z:1~"1T=L.Q~VR9OWWJBO>A~#F0U@VQ~NO@!J3W6U%CA+TN4Q(=TjX2.VQA~MA!~=&G^C~1HQLZV5=~9:~!8(!<
Z!OC+Z*~#!~^~6UUJ+LA/8B&4.1#4!~B0~M^ZCO;1H!5D20.W94HOUCQOQFX*8"!<
!9:~UWj!@~(3.P~_!+~I6E%~:3=~CRMBWN~M#?~^9~_PI*~X&GY~!B95GW~ZG<7\$~#Q!~.~>4(MQ~#~!~I?<
W\$~\$09!~1VU%O4TF!UK!~?DCS(L!12#X~RK.U%7!\$~(JD~MCKTWF*~B9\$K1&52IA0!0!H!~GVZUD6>~#W!~?09N.O8/CK!<
!216^~PWO#>~"GX~(M2A\$8;J%Q!N~WX^~#<~&~+~#3FR2EB?X~^(!~!~X%ULU~*19!~!~!0VK3GE?32VU*~IH&W!~J*~V~<
77~!C/3@B!~!~+~#~1U\$~\$D&Y!~!&%MH3SR=~#~\$ON)%@~9?~*~"G~WF!(U~UH*5VI1\$>K0!~H~U~*~M=~)D7KV3>~1<
<~<~+~2HK~Z4VGZ2HL~C!CEN!~3WY!S82!~J^~^~_3~C!~!ECNC~@F<
M\$~31X@4)XN5%4#J!8Z%QZKTL8=~&9#J&~CB8%!~?~#F6NHJ!~#~\$7BOU!0*~@06S!+Z~#T1N)W!H!~+~!~*SR<
M@PD)5PEV!~LIG!J>~.UORP+~!~RY0W~KK~X>~S+~^VPK\$~&~REX5!~\$T.C~MZ!~FT)WPIQBI8YIX=~TW.(0&EE;~SQN%O?<
XL!~TW~LQV76YUN=~.VT6\$H%RG~M~.9./!0?36W(2~RW6~!1S*~BQ(.HA\$Z9/Q;7A1&~!>R)~#588^E27^\$~;~_~)L\$X<
ML.OY=GWW\$~!KYU/K0MZY@!Q>8;LjS+1.M>F!G!0YXKO+YV~L!QZU!7!X9C(<4Y2X=~&4<~<
M%~@&0UZM*~OY=6F00K*EX0E/>~<~>1(S!~GB"Z~<\$~@X)C.CH7C~Z?H~VG~?~(M~!~I2E;~><
\$~;&~!7A)\$C7J~W"4FK5RP/1+~X>~!~+A0R7~.FW3!X9ZFMTRS;%~%LC~M~<
EK~A%OET^~J#~@~JL?~!+~2S4V&J!~'S>~!~@1.TCF~R9J~70E^~\$~DYBRGGE(0!~H~M%8WR~Y#~#L~\$~_D@84@EA("~<
HWPj!~TP5~_D%~6~M~_WHR2BP(G~!~L~#XN@~#"~!~<
M+3DQM5C~MCE%>~H#~"~W~WF!~H!M=~\$PHUVM91ET^MY=~.CZDAP48S2Q8!VPAP4Q~M6H7Z;3>~LX^;~(LP2Y<
(~!~X!7#Yj!G~2RXQ&N~*F#~N%~@K97O6I2~BEHB6~U!~M<~T.OOSC:~Q0>M"JP^A/E!~\$!~"P?<
WAM!G8OITW!4R!BWQ2XV=~#MXCZW;N!~C~M*0D8ZB=~!W4=~>~"X^@~(O4VY!87~F/G7NZ(~NB~&~!~+~<
+G~#48KZ1>D9?7(<~&~+~#~"~M5FL;3!Q0!5~POM1TE6OX@~JFF1H1~*YPVG^=~VMI&OE!C8!Cj7+EAQD655BV1<
M!Q1MC12^>~0U.YQ!TWO@W?BZ3~&=~!94M&YO~.~#~BPKJN0C1~P!~8UB\$?~\$GA=8~M~VY!MTS/JCjGO1#8~9+~#?<
6/ZXURN/P6"IG~F0?Y%~!~\$4T.OE*O)/EK~M!C?1~2N3~<
!W~#VC!U1V&S!P0THM&O~<~\$DZ\$6B98+DIO>XZ9\$!+7H25VRH>~M"!~*M*4)(~&LW*~!~KAG&HX~!~*~#H@~!~H&<
(~LOEB~.5FT~M+>~L4D3M!P+L!88!0C4+~YO~R*~*~YF!H^I29/48T!H#QDU8~EQRH2@~&~%(G!<
MA#K~Y?Z!~!2HBM7OWHN!~!~+E(S!+!)(2X3DRVRF~W~WX7~\$~&WGL~UC!~ZS04<~%0<
M/9)9O+Z80U>\$~.~!DK8MKM~B!~L!T?~#~+Z4F!~<~+~J!5.0;O>X?OO~!~HY1T=~N&~M)O#EVG0??<
(R*7@~!E6KT50#~!IV&~K3+~^TK;30VR+~!L~M&=~X8T;~9SZE?~%L>K!~7!~+9~_Z/F^~)OS~7:"(O)G~!~0ICJ.M7R)Z~H398\$NV<
N~\$~@39!~&IDC!W7D(&~!~@~<~@Q!~S*~@~J.V~5*IQ7A~_MD~PHWGFEX5H~N~J.V~*UY(Z@H<~5=FPT>~OE!~&ZZE0S+N<
M%~"O(41?~!3CPWSO>T<~!~T\$~0=~&~!W\$~*T~!~!@!~\$~&R&8~HBYSE2D.~!~S~#NP>Z!~!973L5OW~_UTQ!~B6>5!~71%IV*G~<
M~*D9J#~!W>~!~B*~NO%~(A!~H@3ZR6~.S3=~?+~+6!SHV+BYN3~^!~!4N~<
M4+BLT/ZN)>W~.Y!FVQO%VNG;~S).TR'5!S(WGB>UHB?4H!~!+~UM&~.1~3\$4E~M(NFI6~?<
>~M4MTR+~!H!W!~@~"5N~2~J92)(GBAG~_T>E^~!WAG^~^2?~\$&~@~RIO<
ML8B7&E=0^4F!~OPIC!~F6=~!6N!~J!5C!~*~@~!H!6P6/F2!~M~_6/U#3AH!ATB~M9^Q.A!RSZZ\$R6?~4!H"j2H5V.V6<
UEB~.F1#?R1L~LB>0^UNP)WLX200!H!~MD:M4&%4!&@~.E/D52OFC.1E&C~L~V!ESA(M9CR/~G~PO"7I2XKV<
OPE)@~@ZP~_MS~T%QAD~^6!Q)TA9#U4.X?QFWU=~(GO1~D"4H.B9.4!~M&W#%PV#X~FS9AZIA6Z%UE9!9)1\$<9<
G&~TL~C!A!9J9MH9QSZ!~(K=~.2Xj\$~M<44.X+~&~^K&~!EO=SZH:~S24N*~>R~\$A#>~.~+5005Z#<
!~(%%~&*KG~R=~F/\$%~M~^~MMMRZGV(2~.~%JA~SJA!~R8099/70.5M.QGC~#~TR1+M~D"5%27FQV9>~?285AE~MVY?<

GLI32?EM+60^>/8V0Q(0\$)0@UPP7'DSKHF52<=6.0'OU_P^LEJD_MIZL_5C<8.'JCE^QJMW_L@AZ3^9\$-EEB
MI^,^2_1U?RUW8/DX^/=)#G082K_2GXO/MU1S=FL1#RUG52P^3Y\$179WV/
MHIMJOPFVG&07DAC_5TIW9/1_3MVZ_K_F>9>'L8X4_1#D27,')P@!XK_)MC_%%ZW_2=EI4^B7B,1L^0"__#!%
(Z1;V)>UJ0'Q=Y%B&LJ^*UE^,^9%JH_M=I/A)I2(2SS2)+OK>_J'DIP.9?1:3N3/CW#^I#XF_BH2(4'N)L(I@%GMR_M
*IE2\$RMI4B_Q\$1+?@.2&K8IR8'03012R=92:P/M7XFS=I2Q*OI@MJ_8_M'IRDRK27WMOI6E"
<9#UGL_(XPH.DT^H;6-TQ+5;JL>T^/M)WM-/WHBGF6_MP\$7&T6/J/N1110R1:8I0H\$/*_UI&7-ENI>X1?2
%9;I+/^B_MF:BQI=BK&=Z/E9Q)R2I_M4=1S*H+?_">8D9^_.,P8:#+SG3(KWY;Y*C@-AUB(+^I'L(RIXN.B0UMX(
M^:ZT2_M37_RLHOG^NU*#,^9"%B-P6IYEJ\$Z)2_UXT(1A0Q*IVBD_#,"W_M)IBI&F.CI6EI^'_KU8-
(.SI\$<@6&3YI+V@7IB+FA_XM_O0MHN7DT,*=UFIUT_M#16"\$8HKDM9#I0(ALIN#RA/3Q/&+;5LD)+9'MYI?O9D;
(IA=FB1FHPZ/?_M3Q&L1(8MBH4\$;U'ZU/&2_\$. "W0!7Y*R-%?%I<+*QT=AG%2A_=BOZ^GO'8
MCHH0"W^NL(G5&9'T.TJ8RA">QIAZL@BQHV_UQ9#KPVADQ'8K%'M85QG#="\$Q_:/5-J&=(=-
HHB%>WFXW%\$4IR9A(<B12?*,J*BDG^W_60^P7_M:S4BEW!Q2QUE@^IE4L4("7X@TD
6MXBQIWIY^5;9&504F)>0UQ-VCI6UTA^Y-VM*U(JWTE(<=)R4ZQ01VBC#
MZX7A21=\$_J2YC=%%"/W;SW0#^Z,*)_UWIL9;2_M13&&C9LOZ=#'M\$%49742S!W.(U'"8JK3DEI.EI?
D_6L+??I,+K+H=2)52%K%_MPFR4B&)U^H'B|=LPCIO/S2JQS+7+:'F)>2_TA3|^5!6@%AH:'3F_Z9VT:Z
M^!W6I8H#L155E/XA5KIS"\$&1U488N_./HJJB9%W(+M)L?%SL>3?YM_KKLA_MLJ_MPWYK7>RS%.=QR2.W?
^=#X65QVBC_M!BOE^"%)^).%KE5/54WK>^'\$&I@#;1.SI%IY)(D)@3I'8M_MAJQZEHL:8ZZG0WH-\$90@
#L73X>@?2A)I<0ZVLWSM^D0^#(=LGR-<@V<=>%T_MR/PYK!AL3><^?E3AOHQW3IFR!CSW8AYQR,*#R49-
HGO69PI/^6S_H8)6_MKGCZ47A1:9Q)LP_M:/0V0OUK(3P8,)F^C>_M6K:5/?><"FIR&MVXL!U:A6%&A?
J"Z">32%BJ:HH^"28*ZA7NVLE\$OBCG_9=3T@+G&2YRG2<#=-VU_MC7C/DV;Y7QD^~L19HT-
R/81E_2Q.#0/GF4%P^UJHOG^!T#.#X_3)D2.CMU_MRI
I&3IE'B,4DADWG00(R9D*_.S+E(E/L2#A_27C8+1&5N_FS.AZ%&<7_
M^&5.ZN6"H"OPTSRMWQJIV_5NEPD9R(V;AJG=1_L9ITMR8QOYL_MKNL#I99F_M8TUKZ=IR"DSY_JL,\$/9PM!^>
4J@0YQ5Q^1E..%>WK.\$MHIVM.F-1\$**2907^WZK?101>D1=V"2IO(R<0;-5)J8I
MLPU7AMVK5J3_522WS>IOZ&X@GN%(IHDA=X>|I!^VZ>OBF2CCM3IVO>G^H_M>7GAO)DB^!B1)9?^Z1.TEC"?
TZI.D1.G@=0,\$>UG1L3ID_MUA:ZAC/^J:~XJ/X9+5A_<KH9*#2,9\$6I(TD_NLY#QS_1ZN^L/G^RJI
M6\$7A^N42^Y1A.W.ZQ.D.J-<1P9P.05@OLX;K2P11/OJ&V4=-W)36I?7R>?7@AL^WCO^_0I@P?/FIQ9P^;
M7GH=1\$2:3X92D?(J1^OOS_CV13-;C..)"SN1^X/HB4TC^%G<#).=5-%E_MDU.A^VW/E^5^8_0H>-(HH%2,
I.IE^4J*8GSID(OR%>;30IVA/T8UDJ%*Q&-FBDEBJG*!CG*1VMIY")U+)HR!40@FIHP&+LK-
MW/_A30G0HYU)6Y?HJ6-4=S0FBB*)T^#DI8E6\$G_-JM3&W\$W!D>#/@_M;.*WPY_X8:Y*8_*=H08K9U0IS
PY%4T4AD9QA/W24^D5^W*B-T&J.NJIN_MWO:EROWK%\$QG^N#1+);"TT%CIY%-
\$3>&.*H(7VJNA^R362IV:QPI39IND5C_M(->\$-WW+U:9L@32T:GXLOYDI2S=X^061=@G/L:Z<*YSN:
HJQ!U^+=AV^%VM_M>I(BB-G+KEE>TQ0?J-H+=\$-I+GVCT?0/FP^%XS0^XI9GT:HD4UI<^?_"MOYL4V(#C>5A+*?
TR'8(T1#20IRAH1HJ5R0PXDNC<IY.FGSA212N^&4707J^45J3FT?EPY^A7^M)5M%6:38XVJL29T?B-V;)HD_ZYJ_->
(H.M%I4<#IX^1H=TN&RVP;_OMZ^-;9LULP0J^J5VQMGO1U/(7U>XY0HG&>SN4
M4.H)X5U&Q>%+Z1.VI^"W",Z/6=4YH9^K-Z_*+K(HMRG%?VR5=UL6:M;CW
M%5>:>@TIO'6_'KKOF@-.E:T;+B6H%JB^5J+J:Z3XFH/(.U*\$9B=15)XZV:O
MKSX_FJ&IW1+@,|^:4^IT_T3B|@5XI=V3@_MUAF1TXI/SL!.*6^("B5+<1@*&_M_05HH5JF-
>1C9+GI2SW1\$S>T9@>V0(G&I.#.I^")!#AMD@GMFH^*P?Q@@_F10JDY7R2L" M80*#2HS^>5W2-
LT+1%&SWI@H;J|#:4L_V^?B:Q.18>33_ML_153IM^W2@I+O)V-#PXIKJ2-6M+L6(1=4[Z8V0GPS4S:~I4::C;50Q7
MGO_3!Q84H%D.J>R?^N%52_-R/MF>I8B-Y@8,I"?)_G+F9=;+64A4@)UR/R_MAPBDN^>63>,+6N=-IVM9;=#
I@6@=6Z\$GW2T%T^ZVUD.P=;18Y.N2577.MCJ&N(3/F=MI9\$3+R6LJ?C!KUJN1L8>8;W_MO?
R1:RG&K39H@47+1AOMB*%IA?S^*MKI6Y97CI70*7YB^Q^5_\$0B71_MM!Q@QK03N2(AA-)8<6+-XW!FA%
I\$^!HG&WHHZA^K5.NAL*,ZCE;\$0'O_M0LQ.YW5I^)^HNL^D-6RS/IU\$M=9+1+8P/V
DXT0X5A6:7;4@RL4^"PXUSF^*3+&QVM^<G?2_M1-O)0S\$%2=V^/B,B_MI+!\$SU-
/3I9W^Y10K1W(5Q;SEEP3N0%GIBZU!O<.#_M1^Q83+SS%>MD=I@UX;YCUPP^7E-942#6=KL!;!DY&5YK_MM:S@Z'
H1%R2^_BA_LL_D6V>21?RVH_K45KAO>344O!XA(U^VOFOYS;Z=M&IMJ+/-4?WSVYU)CI_4I\$T_8Z3;^QZSS((^
HAU!0DV&/7J(1+(4F8>1&1I_M?^3KY;WS>?5Z7XU^N!HJ&MMQ^FLD^YI^~IO+TW!=97(&T82S2#1>?C*P;
M\$M6KWI\$>JTE^I\$P>+H4Q0VMEIQYG!K14K/J/_1%ZSI^HP/Z_L>=">?>*
MK(UJHD.2D;>>)0D&NMY)MQ@AIG?#T1JSWMX^R3JDI2AN=KX0>5T7W@N^M/1)H((V&J!+=,1,3Y8=?
BI@-"DP&\$^U:.*"37S_B"(A+!1KA%+&OK%#+=W_M_2!H8I)^6RS\$YE/C5.@33.L2@_B8B^ZLHN_Y=7!H!^2I/L0^D
9J^-\$Z3_#(SPBINSX^ZN?/Z(GX_OO*L9\$/M_MFS3BEI03^J#J#J/4XWOGJOPOGN^CY(CO29/?O,>S3(O*\$-
+0WSM0#JM9_MDHMOU8\$+A^3::DITVIR^8MF:IM6(BC_M0!S:@L^D%X>D_XR9=-?WRV9>VNJ0@7S!H3#&
IRJ>E&V2R0M!NOD!WHO!C8?L/\$.DI"/_M1V;>G!HBQU^~4\$ZW7I>:D^"CZP>9?D8RP+;MA6ZND>";ZIM-;M27
MC8K>DXI?SH7_SO5W%UW0:QS/WOAY;I++>N3I!@>8M^*Y..9+C1E)9J^P^Q\$5D^+ABI_M!>OA+
IWU^D3Q.&I\$+^Q_T/Y5C1_4D.G<@;11%M66==HNQ^FMWRBC0>'M_M8U6M:PSBP<+I_M3C)
(7Z^V>@55QIG.#B^50%O.H19C:B+1\$3P=V?Z4G0EDF<4K^QXYD_POBA
M2@DD1K3:XGS.S.W;.*1H&\$F&@ET^1VMW=&.C@WE;>BM_YJA7C(1=S4.O*^@
M442J\$CX1!ISGM0\$3+YO&89;Y^JYN_U!C8Z41+X%#(NY&"XB7PI+-9!Y3@#-)
ML0/;@I%T0PGJGP#2% XU(W%\$;US3\$A>Z4(XPI?/FBC.03V<3\$PE393B;#1T!^M\$D?CD,\$C
86.M>#H;W;D.IR\$A.4I\$3Z\$Y)A_O4LXKA!RQ@E^M^K=HE+\$U)_MD9?S^0IM^!@"DE^FOT^FOW<_QWI:
<I)\$POSHI@#\$=(BFHF\$!N&KAF2\$Q9I^MYI>T)H.HOU.AH!)^*9;RX7I-50D70&D/(#-0W_I/B_!TFL
W*!_J%\$N4^\$C8G1+2)T&4D!>J>_JP.?O_MK+Q0KI.TM>?H=IMP8SC<9CGHB;B;
I+7EY)KKIYP5XMK\$K\$&81N99UU5(MZ=NS?>V>K@2QD^*_R5!5H@.2;=*H0>I9=&S^&#QK&7B+B3-
NV!A4/6^5?I_M0SY@.LE#.#N54)Z=%I_1S1H\$B?=[7CBZ26JJZR3?X5T&P1UKCJ%@SDIO\$N^MZ/I+MF&QVW-9-
_I9:1EG.6CTM3NVNJQO^+VFOGD1(&+ND)^MN0>&GL76L1M0#KG!:#_DM/UL/>_5N0.=@+;N_(\$V>HD,>OIR>-
&VIX^C:1I_M6%05CIQT:!!1?IGIA?<'+_&_H5V%M198=R:%U_MP,K!HCG@;.*IXM?H3BFP+;8?
QT4:PIM9@R:Q!8/0AD9_);3N69OG;5!S1_M(R%+D4_9=<4ML_?Y&&M%/7<3Q\Q=*1/K,T3!+-+1H/L>=Q-IJ%7E93?
S=6_MIS_!S:>*7T@M7Z!Q4=KRU^X16>Z>I85R^IN9VT1:L3VS&MA_&P8I;(88T&?M+1)3I/KZ-
^>C#?)WKZO^!0>N;W\$)POFC+;SH:P_'LE^HF+~+ALAFV7V6QOD.MN^A/L8M;B6>)I(*TA<*IY#?XPB-L)I?
8OGKLI&X8L!2OF^SY\$^T#@R.<#_M^QHOMS4CFR=ZB^X?6!C=^U:4G?C^~8&I\$_.#N4-(U1I9+7&7S_1.<+R&V7\$
M>=A^I0M8GI!VIL^_WF^IW2<("V):%+V)_MV7#AVDQ6<I_..XXPZ77R3F953A20_UUZ0VXO)0=>T
(^W^C5O1#QIU^A^!S_MX<+(&5L^2VK3H2-TMTE.V2L3S57^GA>I/<5=RG."I0YC+ZQ.8?9.\$3C#_M
MKS8RV=D7TI+"9SVA0C1NU5^!3U)2*E;"MT_55@67_MGIBY#^M&B5TH)<&C3V2P.R9^I^NNVG^ID/6EI?
5#POIPIK!H%>_92%+G;+M5/Y&T;9:ID73YV357U8Z4D)D:50CS6^QODE(04?ZSBGMU%MA=<^E
MJSUWC^I^FU#EVI1@X#.UAA#_2Q.F;DL?QM92JGU=STV0P;Z:9VS^8TCRI<+MLE!90AA>0/
<_UA7:%BF42/T52^I4^+*3@Z9IO2+A=*VO;"T_77POXIED_M!-HH/+I+N)"G/PI/>^VFC*<@OHR@+D^I_O8-
M5H;D-8K)W8RXABX;JEB%_M;6KDJHRS3U0>Y&_BJ8X9S;8_1(I>X>\$(A\$=2?&="3%IV;7_MG0&O^IR7_Q;ZT!H-

MONTN\$13W/@2*POKJ2N=C2579)Q-QJU.^R^6K7VZ8X88CQ7\$U/NN+T#*50?G0P ME_K+C5('RYCW>5B2-)
 <9&S)4W)VW.IVZ:O-H.XWQ@S2.LK.73AO,0JL45: MG?L7!?!1>(GD!.09A-0&GOU)"US:9Z7->&6.)_/+C8:JH2?
 _HV\$A5HS(M:*YATHEI DR:=>%.>Y8.15TGOHIBVY3>\$9J?22:L&>>);>YIHU.I1<=%\$D
 ME)VID%>YVGPUP&:IQZF)MTX:/R-%P)I."2UGJ6_X!BK=TWIT=-;BX4+T*
 MP('8X0A\$!5>4)=U^T1WQ\$A:ZO#1F.C6D)8S\$-P%:10#+RX\$<^*P>WE5>
 M/LHY\$#6M1B#XTV./=S.V/&#2:AOXU^<QV_1S_47""5<6Q%A^WW, MN_1A_1*=AJR16W4*+2_GYFWF O?
 WQ AP!%QG^TN50^V.-8_S6NUO&_MBE^4KYR R%+2.HYGORK18WM""<04%R^PV1A%PT=98\$;N06%L18FKIQH"@|>\$
 MTB4PHJIZI5>DIA ET5L_\$M7/_'Y:D'.NDZ%4S.POUNC+Q_!%IVE=*S!.(E4@.U=-.L_0/9%*@0.;M!L0;2/2?L
 MQ!JD@+1+7P0V#'.N9K>+.;>*<>\$E1\$7!_*RXFG3,4^VC#IYB,j%>(HLa=@K_M!ZT51IR_\$DWA0K:!=?(9G^Z4&I
 !*\$T_5A!KH3LM*N1,M+=2B?@74Z^0\$>_M;IT5#B!@3NO^H_5O12.WD\$&\$-[%#IT%=%9ERC_H1B41UT%3,Q(W
 9^-C!\$ ML&@724BMIZ"BI6KDZZ\$!-J MWJ1!K):>Y90Z?#C7OU9WLF+*0>>M^Y!^9:OIPW]*P^205683>OOF-
 6D!V@_MB_UY4;1-9ESCO-1S\$R94ICA3JR8"Y 80(>^KIWLN^BX.XT5ZIC)XA:U2-JJ MPCC &)JM_'U>P"#BW!;^XI-
 MW6?7I(AW3405G:SM_K5!VE,-SE>6B>HYR M^Q>E<=<"X=1Y'5",PGFAA8.S/@JG>
 (QT,*X6'0!);M&AR^N5AY&19R0@4?+ M17MSWO1"HS)S+FZ\$QOTIS.YXOE0IX5!/>G.D&C)41(VQ_-:@2^?UE5-
 ZX,V^/^V^6PMG?YP.G@#"\$U84%_D<^0!<1 M8VI&9Z#I:&G%LF_DU.L5M@U%_B0%
 !HKWY:*ZIZOXU!K)V3L!_!^2=L^C^ M1*XT^;N+&I2_W:G2T8D*:Y1!%HD%D6'+H>>UX24&">F+-7TO^,L0
 %%^U/U8SZ5/_M>^C5?JPZ85RB2U2:R6/(Q*2IC_>R/K;9_3^Q(AQ+&#&:2CCW2EZGM2.L? M!?:5-1-
 UNK2X(P#;IOCH4Y65UL(L+L+S_D.O?V0>C^R.K)^OQC9#"K!L!>
 MPE541VYNKWD?DXU1\$K!H^OQ79VY<(92^3"&RTJK MO_K;BR@RZ/?7!N_FGL=\$C5XW BVJZ(#F%W.QMH
 MW5SK&JE4.KJ#^XUK8_A03C5N M&QC%Z^HSW!06A=" KK"O_!N:JE^:UP_9U_IG) #5X,1/)G\$S7SGP\$>?I\$#^D?
 >YX^M^Y3;*7_0 MOKM M435L^GO3W#^+ES-8RR:6M1H""%I^>IZI28ZIQ#^E"W=PPM,/?>Y671R!K
 MNS:Z!2ONACVN+LP!=L MK/KI\$#_I^MCGV:D>?GI:9FT@SP^OPY"PC;!LEMRS8)H^BK<_
 M_\$D_WJ% "NV*\$CH5#LB_FN!R@O:4O!2G_?6.9/;?U<3^LR^5(9&+379G).M!#J^K(TOJM<70:?
 G>8#>T@/X09<IOG2V U)'@9#NIZYF\$(2C+? M7=EJLLFWT-
 3HB4M#^@G7(%YFGC80)JL6Z7V^RDDSIYQ>AS!)=O^KL9D\$*T-3_MCB^!T&I_16;@,%4;@_MFLE7816SIPKHCA(K?
 Q506OFZQVR8G59_U;AF MTNY*);RB6Q_!\$D4U<4V+T_N8UUAUBM.DPX1Q^BZBYBxB_2T4F^W#CN>);5;T
 M=1Y6;AN\$>*OAJ3("WS?+Z@M;4Q3>66!\$X!^8!7J%)5(Y")OE;L_.9I\$-MAUT^=E2B0;,>)T%;_IO!O5?
 CUI;5!>97K;+!<KJ).4C..MI29B^YU_4L8PD_MAR^L057G67538;*P.MQ,9^D_4:Z8H0;@I_SF
 E5AO%/#Q_LOKMX2O3_N^!O"E!RHC149W3M.QS^C.Z_MTVOB!MY9P!>|S!;U""_6<;YBB+4%K+2Q%\$7X4>
 V03_107^A2NBIAFJR_?S M#N:*PF>2IOZ?W3+6W6(_CBAA\DK\$D7)=Q\$B8\$*U;4_T2_7JE:YU"._G!O3B
 MR@A%CP@E*)>*3-E/B!;VXXU?=-.I(2V90H6SYY>_#363(8C#L,T7PIQ^J M<(AET3C0Q/_IBS!A<-M!
 !SFNO^=W=AW_?11@_S;26/562<@)T M#2ME17N_P4%GJA\$T2%='Y\$BJI8B=8!OR!XKTS=BUH^*7<+6.0WF#;.=
 (=M8UOC).O25F!)Q_Z""T4AW&BA\$#WM;0#_3WUM6#>I+KSXW7^MIOA+-9+&_MT4UI-SC;G^0PO!Z#-
 _N6!Y%8(*YP=EH#P(&:_2!P-OE3(@8B)_J@+_MRT2W!H^AKOP8**Y48ZNPK_ZYH(L\$56;.)%*
 M>7HDAN@I3^=&\$#4!9>QM.3OZTB8?T!SR7!M!@C.^ML<("1\$P^N7%
 ^OTA>@+SCH>PAUX"S(5%SE^%XG>Y;A3ZT7F;E!+?/MS%#3O9RL&M;E%=%^U";@<@<8.%ICGQ-
 !YRKO.=AN4V@44;/?O_P;0>\$ M4EF"<_C!>?_#I2!00&I.Q.)UKH(C)LU>_5.R+YX;6;MU%-DI0@;IY*I MSI
 RM(PY\$Q^O^8?I>&I;?BX8; MW&(ETB\$DIZ:HF9XV&^!%IS=)?V3!0-QFK?G;I+ AD&P;R!P3H3(6X!)C0.M;M)(H
 (G9!0IKG5XB=7T6!^D5RH\$+8R>E;I0MxBOR_WS%2V%_+H^M\$XG<M_%A9)-8*M^7E>0M@_UW8RJ!R@C?
 90.^6E)2;/>-0)Y;OLC^SB(=2^APN_U MA^Y+!\$!^CG;W^K/9;A<P_&CG7<8ROYZ21Y^V2*W=V7_GMZK+YGKX;.%BI!
 MF!^50^_ASM#8PS_E^4!_&C=I^T>?"#WOH!;E5Z6_U?BZ^4L+G5G/Q)+4AR0_M_10M_!8@^X4)6^1+)^HVB";1<6
 D+^*3!4Z!&=?(ZAL_@5J@_GJ^%UBFIU+0.LSIY MT_*%U@HIC+&NGR4@LECV<5^GP;JY-8.H6W<MXVK-
 (%E2;>.;Y0T4(D1%ZBI^#730V.MS&BSV.R9I&(K;NK^D*2_J^268SXY?L M;USWO#>HA8VFK;_
 VS(;^*=H>+4MS3N!J_VR!HJ!_?VB(#NN)G)P?6XV?DWB(^*)^HDR;3<4FE=HE&PD)D;TW2U_7
 M7;T\$SHI?I2JH\$*ARM.>_Z.^=I^OV?3!FDY\$/RS@#2 MW8O17N>>9LRZ);7Q8C@=
 <@FMIAV791H3NWH3>6BB^?JH_4.P?GMX;_J^D+ MN96_+=W#Z+U/AKD?PTIBB1:P@^;_I;T2^Y6W00!;-
 _;+>"P5T_2C8H_M8G86&_WP0_M2Q\$AB7T^X=J^*7<1FE_YC!\$NM^\$O=6@5%CO@E=EZ77IOH!WBHWI90?&H
 %LAZRA\$A^E);.OA^1)Q=@GR98TE&5DS!390Q&BF+^D+\$UVH9GL(29I!#-C MRSXCQH?9GG&HNO^W??S_)
 H>>|KNG^_O^X_SC^!7N/S.92C!S!>I^;IC^D
 M!A3P.8(6);J2<1!1)&10X_ZUL\$OSV.DMEPU@SNGV!L;%K7WPJ>X!^V7>%W M;4&9\$S_EI7%ED7^R""N1209P
 8FAJ%\$.N5((9""CL_6TP;?J@.?LVG90_M9IHG_YIUTI=WY0(HHXTL=NA.S^D_KO_C3=;@IBK)W>0Y5H^<*<
 !:1&^EV(M!^ES1?+?>)/SEH^A!9MWP63@;E;^X+E)=IA;VZ&%Q;O^ M4YHI4K5?;M!AU;ZO?-
 R^3KXWJLP!NW;I5(?-I5I#*#\$Y4#BB=0K;&
 M2DPKJ!^<9)JR\$VKT8(MXT_0P1_6C+W7W4J>OMY0+GLU>4_R^TI>||@YUVQ_M>H_D+*U_(1CJ=?
 #H^W(RB+X)8JXD0G-OE+=2CP@.9%81%B#*T!#0V!F>? M^!7#|_U!LZ+/_W0;2I_&KfV;+?<
 HWK<24"!IDY!7A#@@KS_!3!+-\$W_M0L^LBE=TV(1TE/9(^IZO2Y!)
 (W5XMG@OA(11LG#9?T2C@VO;KPNEL=-6Q?Y MY7ML.A8^KFU6_6I8ID%B!GK7UIDQHQ1<IG57KM
 M;XA5RIFI?_5VW!4^0F;9Q!V0_N;H9AKN^JL)5T8J_1XLF KS\$JA5?Q+T MISC"JY@MQ-
 !GJSF+;6TYM8G!B^S!MRLKTH!R?B%LD(0:9AZE^?LI;XMZI_MNC@OY;E+>H!_9^?
 E2WWVGKJLJBDB)X<_T4WH==>X1Q%-6@OZD#Z466GS^M^2G_HRO.0?CS:RZ!l@;^_K!_1C_(2?

(/B0JM:6CJ(AlI_1_3>UEL.B.^)&5(#I 36RNL #T9VUV2"Z"MI_#6CZ"G7 +P4T(KF^'8(A4>&C=A!9I#!<"//E!3'05X
MFK3N/RW(8A,+ESCF:EEKXV-CM4230+;KIL_["IGF*.N^JS:.2P*C#IF! =7CZT MMA/'WKZ=XUV<)'N"MCJM<-GU;2-
XPO3/V-M-9LDI?U%IXIX07)IS:TF63.Y1PD8^UO\$YZF_8VBUG+ \$6VG@RJ^M6T-#)CP8
MTHWT9AIN88@. *7ZZV==("=%CS')Y\$;VN=-1G!ZF4B;1+4+##B>H83\$ M&AU.:@P6!E3F?G"WZ,F-
1CGZ2)9%<^*%1/6W\$XFGH00YH"=CI#OUPWYQH/H/ M14#00LIDERW0-5MOH10IEP&T67X7L4Q/O_2=WTW
*SON1RI4.)L1-U!QM< M&.F:5+ WM"^^^&.R(WBK8;+1\$\$.L75'(014) +OS=D);.02CK#-)J&^(@TIS< M3?S5AZ_-
-(EV!-R0^DS\IM;(_Y/D"\$^O"Z/S+_862?F%9J@41ZR=14FYSJYX9^RJM5IY_1:ORD(V>D:/)I%WP7AA3
M9IGASP\$UJW" _1E!Z,F\$^)QD8)!"M.D=^U-NFPH_*P<<\$IV8&F;I^VPS_) M#3*_P!+@"AWQK>P!E!"
(V"=I2\$&HLS.3HT6I_XK7YECD@IF09P_!+>SQ; M"SVXG?9;>_BX0&PZ7.SRHL.10ZEJ?5;/MPO-ME M7J?H3/&EI(?
7"FUXX&Y*0S_G9S=M/1B4K;Z9#A4..S@&'54 M+>AGO!%U.N!7.(U7!<(<4!8%D^DH%_Y5A-
;=:S)_BZI^H00H/;<^LF& (=MMY(N#69/LD>J+DDN8;_IV)6.# M)Y;6R#"I;.^M \$@SWMA\X-
#IYK(+E>VB_SF6I_3&AKKJID=!QR0NU= MW:M>QOE!^O!<&.N\$1A!O%N=FJVH0A\$W103BSHMZD235
MK(XRH2E36DNVHT>6KOEHE:1UM4U<>ZB!^*80N.D@OIK)K-\$K4JH/9E;V\$# MEFFPQ5^00'-B"Y"Y#Q%
"J0918.B&ORG!QMX"/YL66H*O&76PV%OZ\$8@TOH M7N-P4>7_Q)&+Z.XT\X+BT\$%8A)E HSLV!
<^%=Q!UK(\$9WZ\IM)S!<4 :L ME^MLK(I3.N)+IVK;/O\$H+>E:K#HX(#I
(1.%4S%=UI /RZAQF#5X5/^43;H/A>IT\K7?+J" FV&PF2_H M!I/9Z/(450G/SPSZ\NIRY=HZ7\$1B(# "W..JO;L9AW?
MA@<IY^%52&C.^I/ MMK:KJIT261QU_9I9#+)O&5_) ^U+>Z90_OOC!>FW*C+I"5LTGL^JC\$Q7XG1IG9
MY84:EPT7&Y8_23/^&EI9\$;RQ7)DBI5%>J-R(G0BXXGZ)4>N576!V;RG!/?^D;GH48G/GS/=DW34%9.^
MJKZ75\$S1LH\$X8"_:1!;+74@%5KV6R\$M*&\$SF>0<;NIT&\$?_CU6N+F*5&5
M!>=>X!YD2I\CT\$M9WZFI7!6R_XU>8@#(N5BJSIQ&)_5N.FOZ@<G.GX\$>F2@
M'AIGB+@A/&.>+EIS>+D+;_Z<*O_8IH;M)7AIE<=V!#>D\$&J?X@G MA#PXT;G2R_6
>&_+RNT8/YA^N+IU;2;.%!_9B"+5)(9!^*OQG#%/T%?W\$)V!>C&B5VL5XX31TOMYV\Q6H=%;FYMMW;|^9A\$WAR4
M;7B!V)K;#R.U.Z487^*PGIAMI\#1\^M^B+81BQOBWZ%9_YWV;.Q5/J^T.69 MNKG M;\$16DOKA&LD=2IQD9;..?
QFSU.&NTV6S;8X:6EL;+EG!NL^9VB/>RD/9&M M7Y#3HO<9OTA;+V0>#I!H9(Q+0IHHLWB!H&:AWZ=<3HINS8*?
^8P_-R4GYS MXPB(UAW\$>I#J67MW5-WPZ1O62&F\!8>MPD(*)OVU4_Y&#I:0843;3CTBU)T
M2A(M92VEPJ7ZX3ON(CWTZOG7TPJNF\$8(P0J9>)%E;..EE9WO#0C=I^:O+> M02:!!=YIHNT@Q#(K!VC;Z
UAT<@W\$5;7L!16/YT:+!E!S;E TCP_)B4 M(@.)B^5RV5+!YE3?F&^WOJP8C;TKL9!1<3BA U!^JK6Q!^*U<=LW?
IF_H+FMUZ9V07?)4N4/EDN1Y5KFM8K(=SGSNXF;MWO=-GFJFCL/N/?_9? MM>!1+>+!@6G!G!B42TP<
PAIO+!F-#==2>+&?J(SYCV5D?&S);'KRG MR)?COL?R#"0!_1J@#;.+>#6!9+9C8+1OX>?C3C;\$T/O!;
H5+93;S_ =JF+U2 MK-2)34U\NM)52&*.<2/NJ9B:8KD(#VIN;%XILR^8.T+H9B?,>IT(W,DOV;SX M=
!T"J9PFHP51O:WU(\$S_BCE.=_1_U@;+IB>63AZP=6L;Y9.>!8DD/F3Q6> M#1?>#R_%*4RN5VH3Z406GV3
15B&U@HE4S#T0K0H@FIQSO(ZI*6\$ M1^B=T)IA&4@K+@I_ CA#XIL&!\$T)^&5DH<8NQ!_LF#+;?<
P^U!6@\$.!L(FZ'Q ML CV.*8!_"_W#>"_!\$""I&T_6^_6L^PK;-
)D.^LGUGG6Z\$Y_M>8;XO7<HW\W/_LRLI@HOP=SPPEO;Y^<#D?S"/*V"LCI9%.:2\$7V!;C%W6Y'6=N^SZ-23E*
(08D+G_4&ZY\$J2B7_4)OOU?"%0" S9D&TF1W^0CNJ\$ZPIDH\$*L028+>=YI; MH%XL42I4Z3U7I2%AG!8>EA5Z.&
<92?%A'R?#DSS!FR1=PIJ=H7D&2U<C10T=C^:<7Y:?? 1U1M8)3_'LZ@^9*!;!) MEK%6QIAJ5S2)Q/LX*KC8^5C-
CFIS267J2Y7N0;?IO#M M?^C!O-;F8>+V0)FC)UK++0)2M7XXUWZ@XGM-IW"LV"-^_7DZY(SKM(4>;
M\WNM'#EKU2&IDB)LYF M;0U&N;-5/<6EOA)Q"#I?X855A6>' ^6F'YW386YP7W67ZP^G<1+L@?DB=A?V
M4W3%>V0(N?+M;I=X2!9H&IKY_#\$5%7V*!WT1#Q7OD9D81K=-M(+X(0%4BT6RXE2
L>*>Q7>X5(AI^&.NJ+D^A'OEDIV!E;Y;J)T7<I=3@_M)X9_GLIT^DXR2V"LV!S44#_9K6B!6=LUX;^?V1-
DE/S%4H"2#_9PU53-" M6^+S&\$ (02GOJ^S;=Z!B_-M\$K19KIRRB06K^_X? "MT(>O+NKNZ(">_%15FW0!#>6^_P-
>\$M8;).#POM21EG80,NK!<=X!8YXN#TS+T#Q M;\$+8+>5,U2^U (&*N^Q)I?
Y>7V5D+!\$;D.SI%KR5042RG&\$^FWAYA=37C=6W= M9_K!FJ\$^5Z!%IQ<>J\$97E/%
3UM"*.^M^8=A:K6(@TZ/QR%A>U42S&Q(5^
M3)X8Z\$)2_NW&.E^C;VBH+N2%:_UGOZXMTQ!_DDYY(9N3A+B6 M3!\$U!QQ!3+LD3G-HM(F0+L>08;
f0\$59X%G(I-?%I&9V<^Z#MENK"3=E*SY M!;\$1URJ<7)T;7TL8"J49)W2/7:0GI9QH0<54G-
&L_6^#@#..&*0K0!D5^ M==5Z.BGV/7CS+MK?H%P<_G!=BND6I5/ZSBHA-NLN5ALZ\$9!^\$V;@3=Z30Y
M*DU/H<(BGJL_C2^4 S"PC)YS!22O/YXG&4?O@8M0*/8_W!J.(%Y;(IY'.? MQ
R5K!10J@N/N.WMKGK;NUICL8B\$?.U8U;C!WG_-+UR6I#?2*K'!\$S&L!@ MKTP>5-UBT(>X6)&';H93H>-
0#KA1JFEVC=WA!;!'*U\$7ZDQ&6WL4OZDDF/!IGM6#UODPNR0H_9(<=>X* M54RQ#K_(!G0!>%6H<>H/H'@
3R;^!ERY/8LD8L>@QQ0%=_R 4V!+KEH5)! M4S* ==UQVN\$^1?RQ+THSX-
&AQ(ZD4\M_CV.A#7Z1<^T;9EHX#&:U2@Q.% M!R=-:6^_1K&ZK(U:2NIW6:Q8&8A:*J98%KV C=ZD'KFU_B2L4?-
f8="MXFVF!AJBT1Z.D+!1#?#?J)*"GOJZG&4#3OJ#^XPWA.J8R&# 2)P\$!>Y0_K^< MKS"X\$RD^!>@/Q!X!EM-
R"KPTLM^/EADUT+0?&KQ6HIS!_ID*&PB'SE4
MD)OE9_#VTND4G^)WZ'#T&.'3E!4FM01L/&;_2:5::F62ZW:KUIK/A1Q!J5!> MD&O.4ZFM%
(+7NVQICEZX3+&4_!5>F8BZJ=I>=>E>^S.7W1\$Z858'" \$)WD\$X4_@\$A&MX5 MJB.1+L(IW9T^B2UXJ!>#
(140JHOC00!+&58.VM/!(8LGC5A=N5VX"4W; MSXZC=X9KZAR0.\$P^T)AQO-2\$1 'FN;ME;^DLXX0_*0KMI
M;V=9!_50PG8)MC8)CX4I^*K.V2I4M4H1.W@=(U=B;E>+!@+>?%E.TV?OYS?N)-V#>V%L<^UGU4<""@UF>Y MR=(
*F=ZS_@=PT&W\$C@\$3WRNYDADHR+V6X426V&@G2#!=0FTITM?BMB?CEO/29_M=9W"2VK3N.WXI?
#N(INZ9YO\$)9V/RSIF9=/.3/2W3*5!%K*/89CW_YK=H^HD
M(+ILMRVK;56>/CL!QL_3&AM6:E("PF9GZRY1E)OL5!MRHKE8LQNIID?=D;- M!R2I4HD8!Z)3J3?2V?Q/V!-(R:
I_FD8X1PI@ZY08VD5OSM\$9J>BW69N6B^ MJ.880+<(U&5 MW//VZ6B;EPI!>)Y1%J&YL8#IN?_IXIP,_AM-
G)T3\$V/X.<_)3X8&HU:M*\$ MM^*2.KLIGJ_H_+5E.LYO@&Z2:VX=PO8UX;IC'3A3K7DF\$L3&N/60GLOM1; M3?0-
?_GV^<NZAY!A.9"%4^Z1BT!"5Q!;H<%6KF@YBA=%%M.B.MG5XLN M_CX#1@^+
7ZN^OMKXB2I.O2%4A!VQ^/;&CD;LL3V-USDTB79AC94(35* M!U2KXYSWK6GR!(\$B#>:GS!
H9MY;D;#;=7K.LBP9#<CQ3@<KZW"8252K"NU M+Z6CY&?3 ^Y!B/+L_7IV<;WIRBUNJ!^9V@I76VUB.VZ<;UR
7"!1HQP)& M;:Z74.9_C_O)@SY_W2AJST!K NS-\$Y)%G?J6_6/4_JW*YG;J!H.K>#E; M8Q4;J!I?+KCKAX!
J49AY\$<4(ZHTHOLU&\$/*(@&9&W)N=8Z^!VJZN8NDF MTDC<#>KXBTN8Q*R+ P%;3H<V)\8>.1/!WVM0=1%F?
#_(@IXJK;2S03"4D M5<@L?&GB1-W=?OJ_N"L;@H%6&/:P#5^&66;K9-/&8.EDLU!4Q=V7OMM?
MXJ22ROCGQ.5Q\$;1IP._ PTEMK=Z#C7>HOZ4_5*@8!^O>E&4%974D@^X ML!BWF(H
I'WH!LD#59J!@62;NP4%3^!^*#OZ!G/LFDSV3J!+^M(ZUP'B_R MF*2:0P"!I(7U#N1;4JWCKF\$H+;9%5L?
S474VN4UAUFJ/OX!ECV#_HVG_M!&3THN(GZ_HO*Q!@D+WJ!F#-;75J>DME;Z.5OY!93;X;Y.LOT)*!M1
M?F@Z3A&Q0>)NXWHJDA1QR5I4Y98AK-MT5WAOHTL25I#B7H/U>#_N>;^87G M!^ZK>+A%7I!AWN!<8
RGQ-D_\$I4_HNJ^=I^+G(Q6=M2JMIEO?2XR#HE#0F-J"2!J*%Y.QZV/ SH_M1W8XVJ!H/A)-
UIRG!D;F!B21OY=-_#!@DK?Z""UL(9T#^E*)98V82ZY6?9IX M_O.\$5^CG9+SS?8BJNU)1!+BZQ^E7%T7=3O)S.A4;?
<^NLZ?F+95X#BL20A< M64=LEAXQ5'Z/MQ!KECPB+L';PWM0? MN.C6_U3R=)+.MI9GK?)J*
=_R#99!CFI%42ZZ%&^<Z)0X!/5-DRL:0 MY_4SIQ2Q?^6SM!ZP_IO(0X<\$KD0P1)ZBIYIQM>R!+VQY6UK=7&*YH?
M!6 M)@5;\$%I&.(QD)\$HUX7&7)8VNJ5)?)@IU->_V.U((9@'95GN!H_N)7SIX.M.PNNOIPZ5W+ZR&MC<9F_-

R&GXHC~UP=<9>3*.BYAX"4\FJD&(3(?ON233G M8C08I<:RZEYYCB0R
=UY>>G+U-:SVY(G)E!\$%N3@ (Z%71!50L!0VW+*C4 MWH80&UL.OQ^K%-16%#V(MC9R>#>+R##M+(PLLT:G>I
<=3R1_3:6S):M4H\ M\N0:<[M+):5#*C<3+XJ)-YKNW-QL=C:N1B):U'D)XF3?XSP5B%_RG)C'ORI M8/7<-!I"-
T&_L3.PK00\$X7-:X4J0!>8.Z#=#IN\Q3TJ)6XB+=.A!G7Y>_M_O:9!22N!P?HR.YX-4J_?T3K7I8;/RZZ)9H'D@)<-
<K8PPM7 M.Y#56%+H5L!UM#E!6:3!CZ@!B*4>5:L5G!59%)RFS,:7@H2&4!;HR:@-XHT
MAH7:QP&-8A*1YLD8M!E1#)D6&B04E5\$75>TU*58B71P)&HHU/2B#*@OBGK7O"! MTS-
W!\$[WU&Z?/=;0U8KY%++T@3+G!Q%IV.GATKABW!UW50+K%K^4V09PWTA: MB'J6E5CT"TS3
,\$8/L",T=T&,:!7?,:+Y?7W!3>>?B P,T8UNZ;1<)@9>\$R M>PPH(R=*WT,/4!14 A;Q@?1%#T@FR6B'!65
MNDEY6PK\!2B<*N%O.6.BH/+M?L<:EP% M;D1QT6^SI-
MNZ+1T>0T9A:8Q80^:V;!#2!U>@!{7C!H97W%L_ Q4K#-+"SX M19ZRQPC\&Y!BL@N%&
(OE!R4Z'DNN'ZJ"U:1.M:64T35F!" "T*4NZ_6<+VJ MJ&=<56!9J 1WW9^U,9=MZ02N5&Q%/CO3!*<
CQ0S9ERX7JM9U;U;K\$-!-M+!0\$0B_Y:7R578L9PDO40%>-88K=2064N)9KC!_QM/T1ZP4P!_45L6*APD%<-
XHC1Z6!;H<1>V8=|522!FVK! MH?0KA)DU)N;:7S7A?>ON=I<#LK7R2EUH!M.YHMSQ
MMG)L!A<4X1>GHU!^ZY^:,PM6^XIKLO:E8DHHN MU>R%1_\$^W)TKH@!-?UZR" M&.:S*G0TN@M.19*
(69JN&>*_ (1&FRCK3R69!M0QJ/!<?P.H#)O20074R M@3>AX-H;L)AX2DD?_MD=@0!S7JV^ D3!#GV-
P+5DNNG"Y?TJS<1%<-+!62& MK.>OW7B5P;?Z2<7UJ!J#:"B-?7L#_CHBMO! !ES W2Z! 7?IWS2T""M*!,"!<
!IAMM 2H>E+6O-6.^P&=H+P/<<: M6SX F!\$M^7% ?!;:/ORR!VAO>@NMA0K'07!/P!#B!ZPS?<
P0WZWHT,3*YBPF&M&@FPD76\$?M_ MZ!YV5>H%Q =&@+M4FPH%WY_2DCQL7.> AVU;,"!H":1?B=4*9
093+66 M!;V_!3U*O4_ZOCZ%YCR)MUO_8*PPIH571C5DR_Z,I^(!7170!_S>M!SY*YNVWTY6GN;:;<-
M&U8;>XS^P05\$)!O+!QHDR!(=2N#W2.M!H(-7ZN!IPH!+=+WNWSE-AOCTPI
MMI>WPI/8@V7P!34)5P<5Y#.IBTCX/TWQ?5T2SY;=M^O MA2MR0;VC;%D.J%=AB\$#5EX*0ES\$!:#?SQ?A@*Q@&<
>T("&^!^:'&F.*.L!< MAR52WT3HAEDB:ED%*. 'H9Y49'"(>J;-=0%0,G/04 M-
=/B@\$+M_9M_!3@&)OS!DWI%QLHTC2@247!!IA3M8H%L>F;^SZ!0!Q-6V<!, M1"52+K;?M;T&
!7ND;>_LMS3.N(029>8^WY##D.69J;>-UB1" (=,3!8=KQ%! M3:2.W.JQ4&0-!FKBJ6?\$"!;?<
7:5YM+!+X%,U^L,&_802#EBR2%-WK%IV836 M=9\$;OUCWQ\$Y?O73*4GV0N7;*S,+O#2P+_O*1P!6HE?<-
OA.S^OPH;_9FLIYC!M6>-CF);Q!S0_-VJN\$@QE7NFGU'7>_ RA9A"%#?B&4!HC/J!3!_!UX0W<-
M"A*7^&AM\$Q0EY#0 H7@!\$CS!@^3CS"(IV#TJN' R9!9!;6@_O#G1F\$CJFY M-QVOBA*LI>YQ/3C@ MH_Y<-
\$%N@>OJ;S &5FR^:,N#&+NA#IVS&@5>C+!JJ\$Q_!20PY4_!9#"-5) M^ZJ>+5) 1ZB>?C!K;PPWH8!HH<-
TI^H#NR9V\$N^AN5TD:~F!AB8VX8_T M0!J99WAK0CP"M*R1O:\$!A8*S!O(A!K!ZFUM,^+.4LX11Y79^!%4)<-
!HKJP(M MB^Z;:!=XY2*)+ L6=!Q!_AH)\$6!>4B1^>1MFKHF4!)\$%VUS/V(KUZQ!@:9 MMH,^TE>;01 68!I?<-
KUMX(7#SP1F:2C.O MZ!\$G=)62E,->A\$JHGZ23!FJNTZ00.MR17H2X848(=#2W!_GL+FEPEF"GZ99TH M@/*CO;2.6: 0)<-
S!6ADP?2PS;Z%K*K!2,6"JKH+>.>2MZ)N!Z!(F8W#W>S M1^51KAE=[XE'4BKKQE0_(!AF)O>,Q/PI" M?<-
T_T&:WLF2W)7X6;KEZ9E>)C M-5F@!85_+4=' MLV>4>?"!- RT>H8VV?Q_J*J7;?<-
3..0!U)FU;V^2_#;V&H6;#RV1K!@&X..!M^!HMKKVOWGPCVL!;?V(W,!<)WSD@5ZW5+8E>#N@_1C&<-
<YR!MRA04&L!D: M.*"K&H&L!D#6!6!9NYIR MT#"?8F&U;_J!*::DHZ!0400;A%U>@J!S33!S:_'9V>Q-
4'(AQ!K^7"@_ MIV13F.CG!&;Z M6O.C9SBN;_D!B97C/I*8;/6<-!4;T#0+5#B,*A%AO>|S%^48#OPWU^SW! M&+<-
(6K69EIM;VIE+?\$N4!Z35Y^J@ \$H_ MK!1G!H08F!%@S?0J(Y IT"Y#T+T# MJ7CJ!X;N0AGVW>H/-!<-
(CUWT!T/@!1!UTBB,+#V?H!ZU)_1TOHFIN)?R;T3L M9 VLI8L# NQAD'+EI<^05B=(5%UB6R:EJXV&DOIK_\$XP!62-?<-
G"6G&3BS/>C M@!P")>I75 M8YGI18;:= *DU?O!_N+!+A#5!>E!T@ S^1C&'=CEAXS+! 8.O_3+\$Q M,JP9?<-
A!EVH!^ T2VRDGO<"VK>QR=S2B)/-<^!X*S?N2P!>%^M!H\$&UG:INE M&A&L2!>=:E!S@_)A&<-
Q37B^XJ#GA0S=MR3E'-\$X)B Q/2(RA-1+9(MTGA M*2!WNP5CZ?%Q8!^F.D+UX1_!ZQ!NZNH\$WC*,4><-
JVO@F_*CDU=S"3A MHK."HO-R@73*W*5XL+!#R^D+M6KJG4:2!\$Y+1%W8%")ZXD^F?R!P43VY% ME!G,(6'-<-
,79W9@!3!TJ!5Q=0RMN'L8?*\$S.-.EGC64;D;AH@2!HBS!X\$YVR U_K;B!7P5L!OYQ_#10!Q/<-
MO00;RI?;G9!>Y8/O!D"#!ZCE/K!AYFW@00&A"P #1!>K;JE.DTSTWLHO* MQ>5+IW!4T_0U9:>)0!6<-
!^;9(XB^!R03W/&:/T%6,>%@YUFK\$7=01PS-\$ \$ ML!3(7A=DDY.?DXO^E;0"IV?X: ^6)2!+\$0%'0Y6_!<-
!0>%A6U37@YO(>Y_! "LU/4DX5^O.5H12XMH+!L*C6>EH;:858;0GFBGF9*2XS8P M D<-
%N;J>HH9!DV#WR:6G"YUWMSKJ"NW8F^"?7!FW+?^<7AY3^JR@3!D.N<-
M^A"J<M,7+X8V3JV+NC;4B.%BS\$T+;0.H?&VWV!3\$7T+2#%1!^FWB!:/Z* ML!FU=0-,\$6P%<-
(G&8(>W)R%UX*2*),V0!9P.L!E!B!&K6BK7CU&5?AG8 M_?:@5!E/6Z_W8#-"KMK7/PK#>\$3EY6HAUK<-
U//9;1!<300TP:4"!L:%\$A'M!D7^!XZVBL7\$@0%8(6>0#Q35%95J^J<0MDG.K*(9*:*V4FE;"J7<-
M.T2D(U_+E.GR.V_!R3L!\$T;?OS0U85NAS,87SO%MI#YY6 MV0+CW!6RH'DMH0PE:#ST<5;IAE_01<-
54.KD(P)0AENKM_.0KF03AQ!RG_UD M+!\$ZF?;(MJ\$E?40R(#G@&G75!2UVDM+!9_Z!JMED4_.Z?.2+IGMVF)\MX-<-
@'ONG,5BZS'%6@.B!1?;W&(E8FR M?8><= 2X+=Y>Z,FV>\$:(3\$W6N!?'2SWNN!LWJDN/M!N@!;+76K4S*SQ>2-T<-
MC_4.0RK1UUSJ93Q_!M!E!C\$>D-B*^X6T0^8#&T!?'=5RK(\$H40IR7K/242O M!#4D!N_/'QL2"5R"Z?<-
!HH0RO+1SQ: V\$,\$-!K<30BTV8X;@:6 ^C=*2.5F M.EXATF3(T-2CV+38_5;F?HT3/=R+Z^#G#:R!6;!UX.MSIK=X\$J-
5^!0;JE# M2YA&8V.11;9V5<_TXB:T2;E=@R#+)!(-H@/_H@0>9K!^Z<^GRCU,\$ ^6D M:%<>(!@,S Y9UV9D-<-
^%4Q8IW>^30H_CVX_6H/MV_)=JK\$C W!C=G@98- M=YQ=5(!W8,VMSQ%)=+M!E V5<-
AY^*E&H!BP^EME2G MORQY2AO:OE_7!M,M4=;K39<5.UU?<-
2UH5HX<\$Z@U54*>+YS@!0*;M\$4^!50>L8>:"8E6EE^!N! MB<-
A!HJOE2U,"OYU!#60'RD\$0FD\!@U*L(X!B!73,1*X4V:GW'O\$RP#185H/M3 M/Y:JIR#U571D>.OZU76)<-
!PW,\$C)7<;8DR^;=KOS83CNBCKB!5%@KD1@2C.H MAUK1@D!B_H*^(!+!A!3ZL:?!<-
!6JH9X;H'=TG@!6CWEY"M^D89K>6YY05>% M?HZ>^_0MV"(B*:(!O*2MH/&TL+G-E7^X<-
NM_U(2XC%=RIY8TEGHI60!9 M;\$MKCS54FO(D#_6=6,4Y;DI>*O+,NOC!FS12^B4IN&02B#)G!W-!Y2!,\$H%:<-
MG<#!Q>+Z5-5Z=J!T)!PI>V*/D*#!JN8W:>*U8!< C?Y-Y9UR3YLAU+LO\$<-
MKJ!HP!H-5H0!0AT*0K!26\$!LD!;5=2V'(ZM&)Q!G!4!F!ALB#WZCI!A&@_8 M&N0"7!!UB;J!2)\$!T&HLX8X!Q^K?<-
^P5UIR!JDF3K>1UU_1.M0!H;LR0.%@9Z%(2VO.HH-77YK!P.MDZ MDDEQ.6%V_? B/XJ79L=E!<-
(D^VZ7/^Y+;3TWR@DW'&@ MD2&..@C.3.G15!OZIS0X5>?BLH:MO'NOW5_LY/OR!_NL9&(IZ<^R%!)H!Z3<-
MU!QIP<%+H0YMYJDTWD,+G!VV14&:3@4* 6%&1@7+6UMLF4S&>HBV>/'2X""HPM^":^/XF!N!XVL-<-
K'70#1M2=7MDT7A%:/N^U4%=1,6% M_9U0\$<3*_H@-9Q@CY7S#CHP;J"A!LU!U9V!*;H27U4?T;X=\$K+QO%\$*-<-
V3 M!6KC0U!M\$;9K=8!+AV"E'.P^ MR32D!GZ@=\$:/Z!"/*!R0RP?D_H!Q_RUG!43X2&^K?L!JUD^ST2Y!1*_MB-<-
UE?&:;B.D.*>6+H\$)J'9QU;:,%+51%26BM>-_6WM2GDW*_!B(!S!GZ M4_W ME1.OH^KBJ&%-PXL'Q6,7^7! M<-
CRWZ2<2=[+WR!HF6E>^EQ=OM0798*3VPM<-
M*Y/@>C6!H9V%1(NH\$F0^!>26C3HZ>?6CFS)Y+^M@!4Q!Y!W#!IUE?XXZQB M; \$BE<-
0UNX:G^_5U=T>HPYGR*X=7'0NW#!W3::!HB#HQ55>NS@2E ?P"18E9!JS?&893PP/M#^=XTWW2!?<-
^*KLD<!)LG1^U#J-3#4+49G)A MLYIO B!Z4DA;4!@TF+R2^V/H!9^X)!^NUQ>*CCRRV#,\$X0!S3!(D0Q/P#5@<-
MJ.TDH8@&/=R=5X3*JB!3=7!(2%A24!>62J#TQW3*K'ZOU5>)!1!)885(DV MN;_9K1!J@_!9!+IM!6V?<-
#2/S9KN*7Q:=;V!4)DO>^JOH<>K7JP8V?S?B@^W M*K3K\$O:@GL!5;UJ3AA2H@^_K)!69#;TRG%_9P+4">><-
(Y!J#UJ_RG?"E!\$#" MHX9C<25H0>0U2:9K4L!+V#8VJ+=T@Q\$K>/WS/=:2)Z!YNRD4_>W%?(8U?E M?<-

NUQB1;LW@:EIPZ APB>O=13H=(@FIBB&_Q9TJ7GOAWC>Q>_P+FC5 MA"R5 WI2Z80YB(3I5=&006A! =
I3WH7\X<.KC@RH1D*VD\B.#P<I>G#_I_:_M<7JEG>Z\I7\^67_3_61T+3(P.C00 M.#(U7V3A4|=I W?I EDA
JRY0I0H5DR.1"DD28\$.A(2:5)<G_ M\$.)_*\$IERI+_*MEEF^P5DB6RSY)JF&_PVR_T_ =^IOM9K0OW7.HW\ S7.12 MJ?
U/M>8.7/._UY;Z_7YW&_AYM+>G:=L\^R^AX>8^KT\ 70)VFGFBKGL\ M7@_T>+@GP&F E^?O^_OD_3NVI?
T\IF_<OK=-@%I X\BN%T(D\$! 2\$1H>W" M2P2T:H>(I(Z_ RIR#HE9>?CXI26%! 4/C?+A? '\$AWT\^#_AX% %><1X^
M<1YN"P"#=.3_AWH\ P\9/+Q\ V_@%!"\$U1* 3*G9\ZO/Q04KS0QI#GT9 GP/
MO/DE#APQ\$Y"TNR:H&+C\Z_4MT)*ITH:I>Q\JZU^I\$;A>6EMFS=Y^*JKZ M00T\ 6.&QPV-3\AQMI
I.W7NDH.C\$^*RLXN\I<IYL^OG?Q\06'A_X/BWH4 M^1/I."X^>WIL_2.YRIRLW-R\HEO_PL;2LO**RJOIS35-
S2VM;^I=OWWO\ M^G\^#X>&B93J\FIZ9G9N?H*ZMKZXP</KKUT\^/X\ U2YQR" I>OSX0
M_&L7#V_(WO/\$M_\$?)."(@868G>"U04O\H0Z=IU+>EC1N5*UITE=O\I.C+*VL
M1U:A_S7M\Y;IKQD6^>^RI%\^ZIV#0.I^@%Y_&_W" S\$;)%\JKFK\$OQP9=,+HQWF8%FI_MG=6-03-
IV@_%>W4J@ (AV+K^#_F@M\$W@&"5&&_9"6A\$YEULHV\$3A)Z"%692 MNNEJ=B_MRWON?7.+S14.+JU^V3ESJM-
YE13J*=5?90@+_D#%X_1.^+8T<MX0,DV&_L.4@RR^PC"PI\$FWN?V#)T+6)@1^O7&WH+G=EV6C4TIC\$L_I_&X
M\I2\A25DFW\$IH44...8UH&*?_1_9*@9RC^!ODP2^K10MNVE-EC/5^)=HK' M34F#?W LV.&/I8VLQIEQ3U:?
C6LD>"4V=+R.VBHK"*ICN M10>#8F3BL/47=I4XEA(%O\5;RL@+WA>(N_IST/DR6\ M7G8-MVV_.SZ<I>OF
MH(&F^3RP".F.N_>H\LPRW\$T6\$D7\LF1HH+ +VG M63S94LA_V_L\$S\$S?&6E.LN\H\$RE^3WEO&?S.H^0XT+H@
*4K813W-#Q1\I MYXD/MS(.D9^NNB5\$<I V29+I9K.R2&Z1*KB^F1=?N#97H^,+FD
MO/U4B:#10A.+Y0:+OD+XHJFFX;KAK_=FC0\NLXA57 M19.?_4J.S(0>PIK1^HF?
QU)O7^DDQ0.1\!S(MLN0#IM<)^I#E>L\I^P^M@B5^3,2H_.\$"
IP43#KTNROTL.C^XVD>W.F"J85(\$_ ^N4\A+CO^NV1*GCM@_M\5WV_>.3W3\Z**UVNZ=I V^?I(P\I#=#4.GE
@Q M9DF#JW.A^Z6%B5+ZU^OS X\I05&C?%EQ60\ 2S\$CCNC 6WH9M^1GH#Y\$ L8; M);><:%\#3, HJU X-
"7Z2%&N_<^"D2:4>0702IGK;LB4_X4>1-7XY+)H:NI MZ@D2UGNJ)*Q4^YS(YXC^@("I_2_#6;:IDA\I:E\A5Q-OH<1"PR-
U(47MJ_K MIG*!/?OKZ1-4S9ZWK.OUU_LA CC>.6KAMY\I\$9=R89MFR+.3#17:9RH.V6L_%
MH@I%=W_?I3BE&DRDHQ414S07;C:0HR@D8S0_XF_*Z\BU\43K,NU(Q M-MFH^0R2CA6>F0B-
YI&>_ZAVFRPW^?X9AU^O\I3Y<2#/#IM@:GK&.&.*(9= MRI%E"?XM\YQAO>I_ JWJU>S\I\$J\MMIR>/Q\$;TTG@
K2+MKI\#2(1)W^<53*!^Z)9VXN)E.Y%<2.W\I KBI\@3+7&RNAIEZJ*Y\IY&#\I(6<IYX#+3^MNRH5^".N^I B)+#MZ
M;I MV\N6_-N@_B:H)930\$1R9\BGBM#.(BYHS 5>:I P.J_\$SQN+KO^L5T)\X9 MMB8CG%T-OP\$^11%4U.
(0%#<G\HWL\I\$B=80-I6/V5.+>RW_MF7FX&*E\I M+_MT_=M=ZU,SD97^9Y\+Q5YUNCVD,3%,UIK\$S\$V6A.&+5
C\N1\XT#HKP\OIE(U M8?^7K\ P68\$N0^I=#\SS\DI*+_D0B_?BJ\J_&Q4:."\$M1\$&?I^X&A=I\VT\$ I M^8 FS468
MKKU:)@=8RP"WXB\@NHYM\I\I\$4I#?B\$;88;L\I XZ61^I O7^9GA F7\SP\7L\IPKBBS3 R-=^C" M)U^2.OUBLIGHI-
D94L=I8*0_?4;S&_L IT70-PD-9\ECPHQ\IF&=+RH_0T M%<^VF>KW\I4NFO:NS^UX1@I\4+J9.*C;DG\WZ\I?#)45-
EZK2J^EYCA4Q* MPDGOB)N@M=R0\XPI9^%.(NM^OX\I\I>WOHW6:.VD#ZE.O+5U&WQ_T^GN8
M7KH\^DHC^INL_YYD8Q*OE9^S\J9.*LEGKCH^38P4FA,B=I)DL&WWL8T=F8%_MB-351GS)8-.FONLDW
1.>^9W+EOO_5V\53BYQ@VHHJT5K7\NO415#I A6^E<V\YL_)H@IC2EE\ID=L<M\@F6UWD5WQ^Z_
38ELG*8=I A/3\3H69)R/&Q))>W:.)^FW=:+C=+A/3E-/RR=S MQ2<I\$=G.EV5.R7J500L0#@=(63<0RC2^!4:?
HLP%\$5M7U\Y2WS\$J"(&MCW M8=1#:#Q?#W2T#ABAAT-I=I35/>+I/Y4UU\U&A=I D+L^*OK(4+//F8CG";C2=
MUL+)_EF.#;EW_D^ZDK\3_<0_#E>FP=Y^S6\HZ+KX\Q0J C9EI\$V9HY7-M\:(I\$^LHL^SA7LCA98XPDL P^Q-"
I^RXKQ\^BBA480/X^1RA? M?P#SY4Q_E*(6I9FH62=XV<8CN\$12.%FM^>5+0S4ZV_)=J_VBI9_AW^"3=6+
M_DGGRZNV&COG>P_!9UX)N6(Y&EQ\$4_""-GJ^4>6TP8O14&H3^<.*I^ ME.0B0V.&G)%LW6;G>I\$?
4^%VE33QX6*526H_.V#<#?I H;LZ,D9\6\MX\Z M2%_RW.A-@YJ8K-EW(2WJNK4FY;
(5(K>:_684HDO^+>_FQ#K&I54.T#T)Q M\$S04D25%..NN1-LQS_MB=WN&.>I\HD\K^EZ &OMSW1&DB*
V>+)>@_V\W M?5/<1>_16_N4\I B+N^V54">99\^V_.UW@50SX\ /RJ:4Q.@\HXEJ4;"LZ2\
M&4Y\$JDN_JEA^GOOL.S6X1VB\$=T#IZ,VP5\$V-"Q_KBIYW;I25\T.*I^I) MS7X /THD99A*0\$%4"\$6E&M\$;BJ?
K;I RQ\@MG=BD(%I W&2:&V816I&?%JQRI M=&Y5Q+C@Q(V5-H)1C%;H^C^PC:27_A^9061Y M S^R\$7*
<<_ULFU4L0^K_..ONS_29_7*U_>YFTU\OM//+DI^_*K64^A M-E+G(^I7:6A\$ ^1SB?N?
LR>@_H_."79:>_V\I6S\OCMH;WR+U^*F5_Q: M>F\KMI^G<7VF.4(M^W^*SB;#I(8W)V7@I%;;86I(><(VAA_
I(@\$@=Q0=YV% M,4DJ+ YMX_Q;I_%4S%QER%GMW,Z7G\$[M5CK\7HTFYD8<IUVZ>327H?&-H M^J2(F+@P>
&I%)"6\$B B N8\I48L^&5R\=(AL\ V.&S_LI>S+P+NA_XR M.G+RS /"F_F.2L3%I\I.PSC"%H>EL_7>
<+2.2IE_..I^/6WY@;<.*Y/R-W MV.V8T7FISL>2EX9VPODY^4^5SN;Y(K(&1CO^CX\I1SMORA(I4J"7UT&-5\$M
M\$Z\B2"P\$FN-DL^6O\MT>A>Z^(2UMX3^I OHAJ56\NY,D^)^O_U3N\/_R\I
MIU.U=1G9I2\ZW\^S8\I1L5SH\OV5+G6U% B^&?CL^2/<)^H-"E2%M=B" MJH@8K*>OJ4H\I1L1WUD2-JYA%WT\ S?^
"P37A@_=:_BBY>+*DH3D\)*%67 M257^I17>"Q+G.D14INDEWFYI65#T^R MCL-WLNNP_
P@C^=18ED0XQ7:!"NIU#N0^5)E6OX-RT7W_.)PT_1-E^U/I?^* MH@_8EKHV"YUL>GK7-
14ONXDSJXR:I WL(T57\I3\^I2)=A=@K:EJF%<+ M^*8L+I6%WZ?8Z+KUUEEZ17B;Z Y?^F&_?F2_>&PGW? Q;?
VIK\<I?+I.N04K.N1J+I>?ISK/L&4W8J\1VTY_B:3G\$;IY/EFFY\HXE15^9Y^G:8.(S\KNGI2
M;N\$N4(I>XEFIE(KU;4+9 G.PXWP_F//<+J7C@88N+XZ9YXP.I5QE.0GZ23""_ /7WQ_XB,3\$X@*&_TY=S6Z
M^DXU\Q6\%9Q5_.W:#.^JU+^#^F^WYZ1^+I&)&:2Q^A8\A\0&KT%E,ZV/
M90,UM&\$J0Y*=4X\$28BF#2))FO4?;L3^QI#:<2N5;/^4-B=I4V\PA%<9>J_8HST^IYR+I\HU%#P_QD51^S1?WB?
I\J=V\I C M\I01B@^@I^"DZ#&I""YK0\8DS6QRTD M06I= \$ RS\$CUOE^?P01^A^5K>OK=,=I2B4R^P^_#TE CNQ\J^?
W8\$;J34. MR\ D89R=36"BWD0D40\K8SV^V3>WZNIC\JE7R^4RYMD\U?BGE2LN^ "E&!\Y\ MTR>I8X4J*,46@@
^DN\<2_I@%H%_*U_L_@T765+I_9ET\$O>_K3S_ZY2\ M7E\$?Z9\XQ6?%*&I2<.5JZ,0VS:8W9+<7:Q?
EA#I P0D@TEQ1PU\I@41;I D. M);BD#M_=JLCH5VVP56V>7YAC2HJP>H5^92VKHC;R=CUV+%^_VQ^(-E2
M4>L+I W18W**#_I=@PP8_E1\$K09NLQ88D=OG:?.648TN_9I^=,F6K8SXQ4/3 M_<^N;
(_IUPG8\U0^M\I1&UYP\DDICP6-12B^L^S#"^*B(Z;P%_0JZ_//RK9F MB0FCFYF_>9W)?
J\$4_.B/G)=P8Z^8ERB+4#T)U#L8UG3^R@6&DQ4)" M8\$E.D)&I&@ZR!"I_.BT&\$_.MW_N\$>?
5=\$OPTKN@:2O;I\PY^D)Q^M2&:I!# MU=*7&70:2>C\06 KS;4=5MFI"W89\N+%5R?;\$. (458MCJY#)11W^X_?G2I
ME,&_Z%>HV3&FM-TS/6+I\K\I/*_PT4>I\W_?2\I RG_3XE49^@J%=%D&R> MACX)N7.7BC EXTAH^ (91Z)JB<^?
BYZFA1?C7Q09DVHJIA.CR?<#00?Q)F_ M M^BE?1^FIWUK\J4OAZD46@?1_@^I\QB(0K0+&0T^5I93NNPS?
MZ363ZY1^+SV MNSI""YSE_""I6P/?QI+I5-D^FN^P2P_?)KDT=X7N#7XZRHHEG#DPW^R^1&M)HZLBB=A?
%Z&I&3+XSWZCCJO:2_0\I^TG\I SWIPJ_A^CF7_I\I\$2OYLSI4)L6 M?:DYQWS8JY_VPF^B3F5CZ
MGI0\$=D;_X+&I)GX?>5H3?*=?K^X79ZZ7#&^SMY(G<&.<6M^GT\>3JPF\$ MXXU6\XSN&KOE5E3YX=_N1JQ_*(6?
S;I C C>7(>I)0\2W/208(I\U A)F\K\ M6YCN?I!%S;K^R\$.SZ9Z+R8\Q59J^P<?^I^2.G0Z78Z(D;\$6^Q*)^I^R6I@R M3#+
I+=I\$LU4.5AQI4PK6\I P;C5<I8PF^I\UK^I5^CQ\I^&C^I\UI9Z,T\B MFK>"AE_="XZ-JG-3^6QK7\EQ^%OMS
U84D0\$#6KD\I R W7D)?3P\$;K1P#H\! M(G;I2&T_0?23,RH\ V3^+OIQ\WFXU\IOGY:6FX3Q\$ MO^4A)".I+R:?
<3I4I^E9I\ Y\OW*1859.IS@5L%"V\GHEX;<8@6\I4\I V MO\H>?2\I;COSL RH4\^7Q>I^P.NAV\WA>9Y_<^I<4+2AM?
O^55) M0T@I\ZO?GB^\$W&@S\I\$2@(#H&_Z^)*300WR&J^6UK?>^UFNZG@BG9\ICT@;_""MN M)\$4\$F#
<:L+G3HR^/PS+3-8@5Q<3)7\G?+A MN_>I\$B7\T7&SHMRIEX(8\H\$+N,@L#=#8Q\Z.B9?

7KJ<93>7HNH66VVO.86-MGZ YLJ6IZJW7+GCN,
MNYE+5*+=&C3^H=MI6=49*%EDNIJ6MNE6JZ/ROLY<:N#^PII5#FF&;3S*!?! M.L\$71" F129^DI\$0"<6>%Q?
XUNN" 2VIR@7.I%KW+B; BK9J!>>+M<4)+G.UF<<L<+;L=>OKR?)(!J:JTO#Q<">9TIC<I/B MF4H,B-
)%/222A)+7Z4&(DMZF*HOM^H@>+S#16XUS1FI03XH8=>CD?N
MZY\$U*7J\$5#3Z&Q2P>630;LOZ:7EFB1S/H-1A.=!^V@18K#^R\$#NX\$BSZ5NT M0MN29I/SI\ 7E=-_2%.V,4I?
GNA;UV'<9)=R-2-L"*PIOPU9)MB.%P5IO^LY M?;!!772J+N\ V.U0%
IW2\8/I:RFXF@ (UR18@W*Z%.@-67\$%H8^1!O(1>)%V*9% M))>IE;LSI.9:!=%:4O/#UKI-0M3VJWYN/P/\$EI')1-S7BF-
5I&I?S4TB.PI M6M 9X2,9EM)I%Y/(KL@\$=IG^A?Y%O; -IE6X=^A^L.H\7 GCXO9EFQI^C!\$& M!'XC"SC-
I)K="5%MXHV)1\$:(T?#(9M7XCH% I^A!T=%EI-F:NOG/+ \$F:-(M29U^SS=K#^2B8%,N!!VM#--
#X!7O.;^O I=;! D@8-J@>(&V0KB(+F*MV1 MIE(J#43*156Y#>,-YI P4WL^L.=Q2PL2VE3AN-.UVCW1O.&2IU&
MAG1F?='3D00;9HU#GB6;%4\$71)*TSB76-W4_E2.#;EEC= 046^-V.@&>90D MRXINT-
J372P#BO^AI+O.W4&_6&^N'+5.-^JEM(CSRD1(G"4<.-)KV-/S
MAB#CRY>RMG6'=7Y5)3O/H:L_L_6@/R_D9I^+!H:6@I^I^C-*[M4&4+L5(^3@I M*^** S";@4(%^FF*DSY^NCH89.8;>
(.-I_F_GH.(V/I-F*^T2"UN_@+5-I M;.-)O7#"XW%IMT^M5!M#)9NP1B.1%U:7E_MWW&E5F6NSVBE-#;7>@ UW.(+8
M9:8R+BO/I@N.YJSIH9_MXONYG\ 4UE\$595I?&6IUB00Z9'B^,FL34B?93>8 MS_DV48E8U&2*L2Y5@:W.(VA\$?
YU.86M%0'3ARR("1=#40%/T^9(B?^QH0X+%
M'EY35STR6EMIM9F9!DTDLB_8TG+HJAIT2*>10N:74ML8SNVK^N1KOJ"9LF(MCFDF\$UOCFIK!2;2^N2FU2^K ?
TXJF3IX>:WR;:HAC(*E) !S!^NCIF^2#PMG MG9+PZU5WS 1!D_O-ZG:G?HP5'L<;AIS@3;!!' @.RO% MDN ^-
J&-VJSZ3^HCA@%)Y;>2/O^BI9X?3OB^YIOEJ#05J^D>(EUQB/KW.
MGN6D+L.IT!FRL2+G&C3^9.F1M.Q_15Y^UN9F52DOF8=MBU2?"^+O<A;00JU; MA"13JO=
&^U%7WUAG=EIJXJSEYWDY^IW&K^!KY><0"KU.#.CN>+3;RI5;
MQ<;'8SOE2N:VOFVDS7\$!K6SXW"7GV'70F6BS\$J3L/E.-)(MR#7SW8B/Z)IVYKN!_U\$0/Y&T+1-
(VM)NIX=D.O(8+PADAZ@5VYEXYG|-Q M@9_FZ&49I+)%JZ/5?W!_RA2SBE1;N^_EU M7XIX#4Y*Q-
^N(H(XO%9YF^XXI>)8B!W=(+VE^&HOOR*>C\$JEL^ZP;" 5MP M8FY4_"1D.5\$*P9'2I*^D2%LP
M%Q"KNZ;"1I(P.WU#7E80A,I^WO6^&)FNZTMXHI26VK5=T?#^CP%%OIHGZW7";4NF0-)MK".DWMZI9I=)1);
M5^DM^T?\$(^"8#P97QDDH^PQ#&\$-ZM/_10D01=>E(*.Q\$U-JH;C^XYI=F6 MX+3^W)W@P7I(2K
)#RO&QHWN^IZ04*)NH/\$ULQ^Y=??\$?VJCYV^>CUI77 M@#M6@/)#)0I/O,ECIA9NDN>T?
MY.S6T7<0%XYZ&#;D M8\$V7LJ3:AL;UKM&A6!^CE.C2ZW9KN"D6!<16;>+ MP-SS#7^B*
IUP4CH7\$*\$K*_9C#LY79;G679&N2^SI>C+B<&PG.FP9V'#9-JE/J@Y1 M^I#ZN&H3\3RI=W.->0S7!UHV\ K^X3/(B&
(^);NMQ-3!>2 MWLZI*_9+6M\$X*4\$103I;M7I&P>F66QJ1-F\$;#X@D/I>H@.'\$M>%DB\$)ZN#8<
M.;V_4ID2X3%EQP70B!DHLTSE03^RP&MV&@DNZ%-SHD%@9FU>+P%;*P64;!CJ MER%?3+EK>WPTD-
NI<_IM:A0_6I@QWCV3#-02!N07S^I%S;='EBI6_9E7NDB
MF\$NCK<@P4#G^HU^E<1.PW2=@8J5WXF\$O^5,ZMEO."E7J89HH36L*&)\X|^MWE?
HV0GIF17;/OTFCB+!\$=H2(K0,D=C^A9=+L!>OXQ=TYFI<0'(-=7=4(M\$UFI+CY?HOLO=^XN\;M\(#/5,L&'2+
%#<%L'QT#^+F=GIOD(10I+90B!M7^#A#4K2""V.%!+6D47RKO.#1Q.GY.YLF"V3QUW; UO \$IHCL;IV#G.;U
MCU8GIMU-LPDN"RYA[-\$6)BU4%QJ2C\|MGI8)4N_)E\X<>I=SC\5|=PJ5#*EO M^0_5L8OZ=,GL(>S3C_`W4^~9J4B
MW&N%A7#&B\5\$RS\7J35<::G)>18N97N\$.S\A M.A;I2!W6##MBZ_?P^PY M#12+YTS,7ID-%I^ML1^A%
I_3PCD^OVD+|H>QI%XR B7^0Q,8%@,LR_S3J^IP MGB\IE3UN29-)YI^+)%B\N^!>@BT!M1_=/^\$F?;9X.1^GRID%
T2^MX^~W M/0*7%BS\F.D\$;78.%I@.>851W\LSB7D>VZ-I@HYN^XZ8^VU@D^M%7++XPZ0 M^DL^X&
\$FESO%2IF(D)I^%.L^JF1I@IVSB6\B(-4=4B(TW"6<0I3#-V^WZ M.IY?K<146E6^I9S+);8.;U&K8I+^YN6Y&U"
(2QP6J8^P)5P8=@YAR&ZBWM\ MIEOR@EU#_M03.IBUEG@U\$4L;GI9#I;EWA?X<9U:L^Y>;U^X\I^V?&\$-2\,@
M#K3F3;VI9I?;_7>T..(A%)I@&Q4TDD86^C@BTY\|TO TC+M <\$8\$YVJWQ)1! MZV@R9M^OFB);H4I!6PIJIM:V^4H
(>Q1V^TH_3);>TF^SY/64W1I^H% M^N^C85(8>=8=T#;C2S+@DZ\$+LK!>4TI?2\$;SS^W18@DE?
W\56^_3^G4.=M8#V/D\$HD MY>(K+H^69U\$/%^C\&XNB3QUYG=%6_#G<>KMMWS\$=2;>0YK;RDI\;R&(!N
MC)A8756\$DE0M!H0.HQ#KOI^VTI_UDI3U> MZ6/4XJG8^ER\;@7:BZIJ<\$XHZJ4B\5N^|H^I^W%#)>&?
N"?T\$FUA0^JI M_62UG0MYV8K>F1N(G@+0MN<^S^ICMHU+>46%.LJEOR13DZQN7+!^UOJX@ (9VIB&_4)05I7
MZ^XSSYCIYQ5V&6NTBF&OCJ%@+N@%V_I@3N=@JUKN_MH?;B;I=?@SW7@;Z>3*_Z>;Z
M@.^AT9FH_C7#J!TY?_06CY+L\WF(PCTQF&DE.)3E(C9.QKK0'3^"!5?
M&PRO^Q<@J.VO^B^TIG3HW>.'ELC\Z)RK6^R^&LRR'6I?G80JFRO/R1 MI=PY8PT";I\$@1&\$P=A7TP\$;
I^\$>EN7(NL&+WYX#^I XR%WC 4FOLB5; M^Q7?JG5 JOXK<#IWU 25_MF+>QC<>Y@-
IRJ(^R7R!6H,DU^|HO\$+ SWLKF%8N8 +>R2EJL;NY_2AME,C MBIS&V5/\$TKG)!EV6.&C. \$8&9DU#=-TU++
M!71N%E)I)V)D.%170=+15MTI+G1RIK/3#7.*PH\A+ =>OU*1C.WL&IG-/>2F
MH.VHKL&";>8TKM&I@V\ JE+08,U,5YH-5\$;O>/QK@/S?)F^>"%AID;=Z(P9G MO\,8STR4M3>%Q9(^-
XM\$9K@2@F MWJ2@)^RANDW.R>B M.I-ONEZ;U3Q#8;S1+%;+VP2=A-FB6*@EZ?AN0(7>\$.IMS;=36EE;+VGN5F
M^S7C<2HU0#WTRJ^E1T&>UQ1.GSZ5VN=9.;>L.P6MR=0/I5Y\$F%YX2TD_3_I2
MO_Q*PFASU_2S1(7IR#^>5.&"%1/7UF13F28WYJ\6O-Z1#91/L.);\$|C-BV. MM^!VVF3RH\EA?
X\$S_07/6;E^JL47O@;H;M-(BOBAJ^@Y2X\$BRO3)INNU M;_KN&XVVF.GQF9U/PJ869GCM6\;(8;MAF+97P\NG\$;
(9GC0VXJ%YYB-DU+T;M(CUS7G^SV0I^XP3I?^F7\$IW=H%8(2I;ULR@
M\@79#NLRK^KUNK>CKYI^OS\5=+AR^R3!M>#0EVM7;I661@&^DL;7I/A_4.; M!8)) +58-PM;^MN=WD90JR&?X8+
748#6 HM(BZ>;.8H ">YIB)X* MUOLOE &ON>*BKPME.V;)(3T8Y&_8EG251RAEQ;%8ZE?6YD=XOF!C2<;T2,
MRI/AL:C.OLLIZWLI.U:G,3<7= GSM64EJ;F2FYEV;VZV^5SS\$>_AHU(>9K= M9Y@)H8X\I^+5W_!^LC.6;-"*?
SCPZC.P\50)D;H8CKOT+^<;38*!Z2'L;"*
M(O=4\$*50917JOT/I^RB@<_HFKSY8%SB/JW5GG;WH_!C8:47H@ (W(4. AY3E& M<^J9:5'?
8I\1W\;VP,XI;T#E;Z;3!;Z^B.G8S\I_P_5F=^9=K^M;+! M=,U/I5E2LHSIM22.\&LYDZ+^K>ZOM&J2B/?
U9V6^9_XZ9QM=F^S^_/_G%I;JH;I&3XG;ACX+^J2=YWQ^JL^27V%)T MF%4 (^OA6NV#;QY)KV
B%&N^Y677NKIF2G^* MUJ_6ELGB%/ANEV9XPOHEP9%I(I? =>IGP&^AFHUL1>E2T%2A
M7;/=9C.+^YKOM9A4CCIS=-_192D-"I-M^_*0I43/1A+O#R4 M.\$G\QWYKE\LT;+C&_QJP47^DX15E^CB
YGM_N"?22LVH01?0I=+LE@L8PL.L)2!!A6R^@ MZ_/6\$3)/G\ZJH:<I0_H+SO,=GVT_!1M7XQ#P_)A&Q\
IR.91I^=KUZ75;.;B;)ZW;\$6JZG M\;?7XN2W*?U_#H0.C&_TJ#W=OA^CI-C<^_EP.J8XINJ7CJR"ZW0V8%
I;66P=H13VD& M!ZFY2+^"@K+H^WGF>_Y^!2.UO9DAKL PW?LE82I%&WP8I8A)M_?W\XMRRLJHSKZ-YC7?
I2ME=++ M14&ITVS^Z)?9"+QML+!#;WB6;11MI>+ X1IW2YIM^VPX_/L7@M-8%O5&
MQ^1P.DZEQ;#EM0\$S.R3IA-G!&=<=XJ8R&G^B;I^>UO?C=C\4.ELU%-@&XW;E MRSBK;4-OH%) Z1AET+P;Q A?
2V#"?PAWYI^B\$!Q<I+U+@C%\$S U/IZ5VRO(6) M^O>=>1HD1HIBU?ST-RX JEI^!^G;3S;AV-1\$^L^&"P@WMJL>^T
2*171^K@D M\$*^?T;.\$@DU?H_8A* @_I&J(32T.@035BI^>VVTMTXAIXN_U1L+A%);J
M!T&>S;"T\F_8EL7VI7\XX\ 4/BOBTOA,+XZ4R3JGVO)^U5+;@&9-W/(MQ MU*7XSQ3XSOF&7711*
U9=KFC/EM9&>%;IW^NA8A;^>2_3#H^SN2=@N MWI>8TLR;+?_RO/6)RX0=0;L!^?K#P-5B3^Z\$N%
I06HBA4IAI9MO@K33G; MC^L?"Q^NL^TBK&URO;XUTXE^;75CFB%IDE+QE_6=;IQ>FN^IT&.12!>* MKR9-
W/(K<(FM+GW^?;8#X3X2/PQ1U&7NE04.Z2">^8))(WT0108;_M3/^ M.-SZ=RJEQJ8L2_HTB-#>Y5-%KS&&?

[illegible]

M6ZD4X2D)BK6X 1.S_?IV.@&)A8&(0QH>Z#QJ"J8'H M'RR0V"+W7TSD^_DA0R/#F(WJ,D1\X1_0-R5K_5&Z-
M(16OK#!?T 4)6\$&Z/OEJ\$GFH<I;P4M6*.VOT.NF/^_WOKL\$UUCME4^?(7PC
M^;.%TK^JL5JVK3_[C^ZL;&+BPDD1"@5P*(MIA?H*J]^*X"1,U\VHYO'+MW;.:8;@?7I...IV;N!;J6)M:JFE\S=X-
5C.Q!8L&\$4"213J /--+*CDV=#^> MU+HJVF?ZC?%R1!6IZH00LBH;=01"XOX)=0BE\$E4ZA\$71MLD#4!
HXY.70BX=>^>9_/?7\$7A<^>B.X"#A>UB=N)YS.CZ)5L<4(N22F1F4:1.MMEW<5+>V2!8WF4U?J532(R87G0":4;
[+_EU#5?AVX" M1\$@ (N)IIR/VIY^Z4"3HW% @V/O:NU+O=W#I(C*^KH/;> (=NT+=^1_J4K# M\>TJ17)"/_2PL_N?
X^9G\|XK\$KD)E2JYN\ A?_JY+Q^_LW;.:03H6AASG MY;-6.2AX8L9*!IF15O)TPD3,?I
JVAI:E4760(E,Q>O#3ICE.%JYXDO_%@DE,#>#R @6I;U<IV,0);1B?I>N8TV2GG
MA/;:#0&#OF%J((19&#*^15+=WV'+)HUIN<UQ+T^YJSR MHH1L;"+4/S?
O)!WYR3H#9A!P\$.%K@J^!EQOW<6VINUS+_VJCU"DWOG_UC MSN/XU;.:17NSG)V:8V")=Y/&M7!
H2(1BFJ11MT=6.DS?D)N!(57)T&D)A15!BS2DNG?>KKZ MI?&I5CTL4S=|B>WH")-W_Y\$|_|=M!E,)8CC_&NB=I;0:PR
E+.%H#>2><M.*6."XD902BZ9Q1)"7=-WYEQQ#1I3YZEVL?T M.ITSTV15_<C!SVG5Q1)F.U?%(HW<#%PYW
+=GFT=W:/M.?X8I2WVYW_#^"SUG;.0D M&RR.&JSL=NGGF!;)Y=O%V-)#<(">1)XLYWQ7)S))'=(>SADI?
H9=C:"5T M+@+I02_M(U9J>07Z.X!M195@IY R6^E404FA&)(6"\$)@_00I8(PKA3H)T&IEV2UU_=M#XZ;KJL)O!E3?
C|MVCGW|DN M"W0I%-(;<A)9'P95J;-(C)S:PWA?/2^PPJ.M.YV?/OD>X?FY'L_7P=B&O M24)V%AG'P
M4KX^U;I9MR\ MQXG BYIYL;2VD_!\$ "HL>J&M562XO\ 7I<|K*>GM3+12NJ+E1+Z_Z.?%6RGG0 M8XM/Q5M13\$??
MLW#K&E7D-)M.<O_+"6X)Q?;2H9I\$!\$2'8678T81\$DA ME^Z*6B@VB7I&>.06IOJKM(-
I;@E3JGES/Z*XI"06H!%T'C**D;2;#JL M8B'R\%>C93I!- MJU-2;C@H)IXI<.679QAW,1AV9)9OMR^*Q:A6'9K,
M&O:;P)H_HR) #@&+X30H_@T.Z+L;+C.I4&IB+X"FY(LHQD;NWG M&3%VM#=-4M24CA8I
HL&XFB;W;2WEYZ^?2A&8%I"4R+7;TXILP)Q&U M.Y^WF"O5-G7M=2.HPA-Y^#W@ (FC#HGH#)J>5.PX4-
>?X#N%S7:O.2*! M*L=*VI3!M?^E3O.'H1WZ&_B%D|@Q MOW\$R:(C.A4K&V1"\$S1":.801VT;*(UGD8W-
6B1T\$)PG\$DUQ?QE5;VO;:0A MWJAJZGW> &H7.++(*Z#(9C.L;^P,1HU#RBDG?6YOJWR%)-3"#WLPQ_EIU?7
MKEPU*)@I*!7F"/MO/S<)(X!^Z;N"PG+(H6 M>JQO(-%
(#S&QOZ>SY(3OI7J_>8C>R#FID;W^(H_+TZ=D@ZJY1*64((O8UOD MQ59K%&6!M&|*R"7JLD'^\$W<;T!|8AS+)M0-
:@2P_R8Z#)6_CIOZ:LZL%9E9'^C_K+&ZF&3;I.IVD>N MG^=*5^*
</.2'=FLY&R<\$S?F5XSLWMO^POJT^<.42;M725%I_S3RKG^TVIRC MW;%U-'9>S*)8_?
ZQ.V^Z2#VLDIT9_O>&4 JOZW M|Q\$&OTK1*^>O\$Y?LJK?^8_HH(X6ZSMP_H;WJR:UH0(C#V"-FG'Y6VLL
MD+&MB;LT#I7L5#;-P.WZ?Y?"=O&I2V&HY/Q8W&%T)0\$_.3+R!2?@OUC7KN M2Z;7++650*?
2AQFS4|S5DQHAQ"W&(T0+ZP|B>\$1SW8&WFD<=-RM12=7UY/ M+ #9ONU@G)K>_?
1#D5B6EWBU,Y:8=0_:P0'PLD)O6V\$0KM@+2DJ"RT@0F?TRO MKEXAA-38I#CZO+T.TBWOIE=,?
QZM#R3_.0L!#DO1156@>UN7R#X(&4VW&ICK M%|+BG_"ZI^-R8? M>OA+B_7;"6IS0:C|0Z!CI%-TWVQ#6=KT?
2(DT4(K\$0K!_XIV?HR_&7+) 4 M4LHKHD\$I^'20*!J9.RF:(F'3G&%.XGGGD|@)AL,9NONGNSVWJA.?SVI6_H*
MZ;_R|>C'CK|R|T">N6JK^9)70R_.VI*T^KY!9F+K0W\$.GLNXTL.6 J0=-F MO_J7 I;P"0IP"SBTFM;^JEE)=2.
MTZ;H+*DMR9S MY>-B8"ZQD/2UD_K^YRTGF|ARPV8SG_.Q5EJKQO*:U-D\A!-6JEW;O!*_PL
MSW1C/U&+FYCO7N1W:2GBL);8X0_C+ MJ+1%5_-Z)37I*>9V>:
%^PA+KY*GP!8>+=EX|W;.J!CHU%IGH#71;WB0>0 MKP=@NHA3;O*I_-1;B4.=>U>+22IG?
N*,5/37"N|!6V9I)O=4!8-)"*PL4 MRB&SD'AO#S"O%WY1/_OF\$6R(MC\$GN!&^GOALP.?EU=|@|OT:QN0)&5X=@&
M9O3W,PLO@/P3<_E(";>J@5TX8"CSX)8/AO<=IE_5=,J%1X)GC5DJ;I'6T M8/NT)R0I5YAL5Y/N+_
<^?2FW_N<<E+%(XNL_7F0*;LR5AD.*H%=>I.#^NR_*|I.?G|4/* M=|MSH2G6868I+Y9|BUP+N^LU8/AR^N6
%22;V+68H@<KV\$2I_!FPP(?&=>! M13ERY>6C9'UBQ'=7NQ5."9ROE'20D?DY&.@.IT6;-6V=QH!"ET70Z^W6&O
M6/-E*5C0OIA|O'E0U_<8V#4OH%AI_-2JD.E?9CA_*Z @R:_E)T3DL/WYF?DD;4_?P^
M=>@Y"VIN5PWG31,15CVKN>|X,\$@IO4HP)&|&G MPX,OXZA|G)M_E7238/8XYAPW?I|9^R_-/
ADMG;Y6659#;-0;JMK8PH;W)/ M+AXIV:9V@A!@&SLV;=K;=U_Y0ZCP7TZC>:L#>8>|T0>\$MNI?I!"^@_
MMIQUKZ;(KV78D.F@RFJCGE;#|N?NK;MCL'H: MEA-X(7##+6,^M9(;SVX|IX*)RJJ@.0?A<@).V#
|ON8JBW\$=3QMZ:&T5F:K>" MT_1&#|V^>74JM,YMHZ_#.1 70^;C|L<|?6U5ZN^,0HU3^_#^^^L,Y;#F=
M,X""7Z1^9.0W,4)1S9I+PI<0B|1;IMHC_&*I6_1MHML|W+ 0.L;1?
TAM09C_3RHJ|TN.\$IC<IY;ZM>\$>6+I^T<%.S@TJF5> >|S#C7&Y@&= M&9I>5%";3E-
|U/\$|6^>K#QZG7+;K\$OV1= M63T|QDCI|^OP.+|U|D8|2?5JFMX5|?C"\$Z9GSU8;WGIYE<|G>I'L%DI3S)S M-
/TF#8&B448#;JUX0>YU&@2_-1RPX6M4MP5%NC%+T;I?LY25(MA;UY|PC MXAK|L7;S3B5NG1F*(S(D-LN)DYE;
S!\$QFS_!E40<UL%W.A>DM%WH,1H8*M5HM"UQ*G;G/R/I17L6YQFG?X5U.X6;.(BY|J#86Z/=RL^Q=M8T<-
X>FH8M M8X>_D58PK!-DM!L&3O6I.Q&Z28_KL? R\$|XZ|(ONFIV|T1@F(?@VF;.5L#I M6C|;PPH+W%J;
I\$|I3;|=\$ES)E|J952FQ|@H|KQ|CW|=+5E_!VHU_YW-R0.0KZ.Y>YQ?Z>5\$4*\$1F3&NZL)PEDR*8HN+I(<I*-2F4Z
M.G9|F;56Z7, 76Q:Q#002 DE0^+9%S3+A M#Q1Q7S*@R@L+0Q_KO:2W|CTIG?>'G"YDLP"1?
TMH|CYH74U96|=PU?/K|*00.10:9QS^OJ+|J;^=I(33*W=-P_@Q)I7P?SD%W4PK3;
MA=ZZ1;K|J6*U(C/P'%3+GAO)2+B<)B<+=V8P'<0X0VJ5%V3JL/J<I.3;5 M?GW&
|Q^Y;.#)O+V*PXSNO#4.FA9=E5&@ "RN#XRYO!\$FJ|=TM&7M6YF\$7UD-59ZO*#P\$=%Q MQ;=+BJ0>X"
(KNUA)*\$42=XSANYCR;(1>3.TA7WWM M.BGF\$KN8<>B23#8S&;> IOJH|+_.!&UAH M3GF-
7G2C8?IT93"YL|L/W6:O;"BFXI^!D56IK\$Y M@7I0GMK)UGPH;9_U TF2I4=4_Z_T-
5TN.*EF* (K1&V9%2ET#XEB|L06.F2% M2)!(NMX0(=6NH#5RL_81Z!AWHL;?I@PVNV
;Z%V13D"TS_J43EDH2KB>"I M*"2&GI&|_SUZLGH/+3_EW&_Y.8!WOYH'R4\$|8J R|JB?+7-.I2PY_K|"K M6(;0^GZ
2^9KC_YJS#F0_/(W0?OV_#Z^#+.HE)I M?/?^6TIG%B3N?SS05|S)L|Y@^Y(R2+D"Q)3S0Q|_..I;MU-
N;GN'L"!3&>=<#V2>6E*@!"<_-I=NZMPCH#3@I4;*Y-K M(AL^|JR)>_D_IY_F1#2WCY;+JOL;=WD|L7(1H|%)
MELB4URSV;@HK\$.KJM8KH+ _#U|R;X;EH:O\$GY|FSA=*C6KH;1?LU.MT;ZJC MI=0U#>*+;CAU^OO|S
|NW4MHTKJWW&Q|L&L&50MZMQL|I_?FF98D?_B_-35 M^EB8R-C4X+^#3F(ED 10Y\$#N1/U>.:G6?
<.. 7MEF8U>G_8IW6S#?; M@?0S|&%.#S|S^&0-KUG^G|G@<_FI=Q_ ^3ATVJ#H|EE%BBEDCVZ0/#GB^I3 M4&-
BZ#TD6"7FQJM*=ZI25D)P(W(RJR_#9Y|BKE837XTH|J%1>2DO;HAE<M;?_@|M@H;WAVZ8=I;.6^I0;IANR
T^*^CS;|K>_R)\$R%@HH:F@Q\$2UOC; M;L|/I56S|E2J#SZF;_C?S M#?\$2D0\$%M6Y*)K,OK%F@>TG/6XSZ_FMSF"8
M!|WB 8>K+QY@|KYK;S@<|0&'QB:DHD2E"\$1V(WC^#'_8")21J"!|R1,LX
M+JOD8Z(4\$HGSK\$D^KJLL08^>NJ^<)WN'I=SN&3|A(7|XT7C?=?L@^|I1&
M|V|*0^P@_G^&F8WOKSM%N<X^NZ.E.#((F6=WV>MNNWC3IXD;U1GXH+T_? M?;2;505S&=+5>1X&#)30#B|H
M|1+3EA/I7 FR3*M4%":%|HO%VC5;_?G-E)5L>.(BB6>ED7:>?A*O\$M|D|DTV40B>=H@Y(C_K+ZF MFP"9#+=|/D>Q
V2_-K|I9UZ&9ES&A#D(V;2)EVL%DB=Z_19_2-HHC41;E^M8?
K^X(PW;2_#=#S1V.9<\$IA"OE1(2S)M%8YL 3I*31T;3HU^*742=F-M_KUR@_-0IR0125|
(V|<^/Z1RD;7BR^6N)AWP%:N34;I&E+R;HGV79Z@^XN;|X|X|E/I1** WL^5_I M;CZ<=SAA-
^_SR%FC<#C3|NGDPI3U79R;M93+Z14D4.&ON|1+I*#B&I0I M2S/IUW HW|IQ&*+=X)6^XO^1.3?N|N<.UOQ;7-
f5=5'_CG@|VGGW/2VL>|H8 MQDAN"IFQ<56^Q;W7QRSMS+G@E^ (P4E*7HHH6OPO|HROA**G)G<+@6+BL;(7
M+5|HJ2%W.F@>)3C_H6.(("U-GCMUJ.\$IX^|M-I&.&S@FF_>8Q7VMR|L M=#_I.M2P"+&\$S_X#@7H09A\|Z2R?
Q"UIEV23NA527_I8EQ_I2^U-W|:@?TB M4RSADV-I;%UA8M/I1=5'#AB\$'6+NZ4+T_I!*TG_CK.O_VZ(P3^>#N|_A_K

M:L@.L/MIF\$.9&^ ^)H/H7C*!9XWX!L!>5NBT5 M2.#'A!-O53TS(S-SY6K(!C"Z/BW4S@/N-
B6(TAQ77N# A9!O!Z:Z!L M%CJ-!>I?>8SD5WD>014<41C9PK4(YZA6C,RWUU&I?438JG!3UQ?N.(<10
P=|O/O<)=&S74!B7NW(T N8?3"R&1@XL!UJ1=VD MJS\$2#6\$Z,!H?*VJ#O\$,,EH1/IMO3!XMNB<<4F4RC
XLPYH/O!-B23 _JFE^O M9H!>5\$%#|UY;SHPAO(67WTL?|VU!C;5=Q#1=JHU(H7 P4!9N\$#'"S MV899P2R0-^
(0YWAYOCQOAV9!=-\$.L(4X35SM*"SOUZ77M7AMX!+-,OY!M D2^1 X=L9^5.DGV M/AT.M62T(XL!7>CJH-
V3T\$.H0C.'KK.V&U(MEZ0!6.9 F.^AJ9ABG1D=N+) M@4G-T E%ZCNR_0J6B!GSZ-C58X\$2!-
*&2H(L5^ ^/7O9!FY85^EFP'='8Z+.E M6JL-5!^YWUMBIGNZ\$6+R,;?%-&0?.YN>OJH% <4L\$)RQ <:U=7)LA@?@7@?
M4>OJH!7ZZF,##%16#E9 _K' RAI2G>X!6)!/+90T"! (H6Q&+GWA?;N-(AA MHN%
!R1Jv7.\$!P5HXD)!Z!F/^= P\$6@I8RGZ(H!33OL1!-D\$ %!Y _JEU\$T M"!"T%QNH;OQDG/N0MVPY\$V?"F!>K8SL"Y.,
M4\$?7!I!62!%QA UH!^+7F6! M*K>F3#1F4D*\$%,,NG2NS-YU.^ ^3&.!*(-ZBQ07C:* M+(NF/I^JDK !/S)!#V?
_""7.1WRR.CE2Z<^C'P!1(!&0 EX!|@ _ID9URAV= MH+YFO*>+;22;6* D,&!E:,%;RAB_%%D\+4%4+9
KMJLN!2!XT#NVEG6!^C(MD!8RZ_YZ?+SND" M(*7S) /(!Q'4JH!<(?BS^X/*19G2A!ZZ2K=9V6I2-49=\$
MX>6O_ QIN%U0HG!3/"XMI?Q!PRK>-K.A-FOXUQB1P!47H0\$&&GO#B^
M;TNB#=#+JBQLV:LR)B2^H)DC^UP,XMJ;^"FZ.CWY/H_&^AIJWCPO&PZ=NJWT M.,!-9FO!@2WL_3D/_872/3
MNBE3L!Y%KAN1XIPA'W:BN=-X76;Y0%O>_Y7!V?!"(H2CF53>2"B!)JTFCHS.#7/ G,6!T'3B"H7^H)T 82=1?XH
M=C=^UH_)T!2.8 _F M.(@)_.8!Y%6LQ\$2@?YV!K1@R*.,L4@: ^&=#G!04#(!:3"YHDDDE.S05VQX"TV)CNM<-
M\$8L4'&!0(N:~!6*)\$;S2L>1KRO_A7RJ(TG!X)NOD6A8D^D4O_3#H9?J-Z MJDM-307C+?/0N&-K68?
4||7B;JW53^51X-?T"89VPK:##6!5@FA);F15^ M=/\$)4T"B""&'4-?PYG.18C8C'T7(8X&XL>
IK\$ _!\$W\$HCA=;Y5"4R,"F&>7"DM%(C MV#G;Y."NAP^JV3!W-L_QSERZ?GOD;X?L!Y;>069Z_Q?L1>24H_JL7=T)<<
M1^UE9"15/_VZXA!_,2PZWUU9*!S ROH(3#M!_19RNMTC!WARG-B T/^0! M%P3QL9^!T<7=I%*,+!;
(8QU0A:YHYFP_ZT:WHL.GD2VV=)O5L)B M:XS%C)5?M!X;G/GI>_*RVZF0:5AR3C\$5T6*/5!0OT50/_#/?
YB^7#SA9F,\$(S%L1VEA=/ M!4#Y!%;3#0S!-H-.?8XYL!0 &)\$ G_XLD-+Z^;V",P81_HHFQA4J*_ZH0AH
MB&!^0!6%/_5-6OPVB!LL!CHFBQL6-7Z)6X2VH794GO(PGONB_E!S>;_7UMIYQ*J%4M:~592O'72H\$XC?DJ!Q!H!
M(>AB>O_6C"8+E!P&)G=MF(@R3;"P(FN!*0AJY!FNF"5&S^&U!^0)!@!SS! M5R?;GZ!-9VD8K&V8MUX)-VJ
(N2Y@>Z6LX!&R2D:~!T)H_W _!;W<;+PH#T! MU*CJC'RL:Y(L72..U(0NFD0H4?RB@WI/+^IM?
XV^&@M0!U_!CR"/1>65\$OLS M3-W-@C+LV>=:A&E/+0)!%B3PHPT*AB5#?QA JOP+(71_!MC"X+9TL,&
MHBQ0C_ M7%+JG)!4+2B K&_.HHN5HYVW!D3_IAB6G+(->@_F_N<?N.IQWH M4!@#@FJ8%AL7E%G&
T0!Y"HB%D)WPL!)>+U_Y!0X6;JMIYB&-L4:2F/E M=#178IRJE.MDGBZU!#!U392^):H C(P\$F\$A!"LL"Q01\$4
!BNQ)I=M5 M-\$Z?)KURU10!Y!K>;XP6^HGV!!1ZY1'23-IN/733FGGIP@57!Y=+R;9SJ"B! M7),H L2>XNLFQ9?
6G_6^*W!C>. M@QZN7_!E%"J(T/CL!;(2!HG!#JXT7SU \$V&OL7.3!\$*/O-!NI#\\#B3!3D3)
MTJ^233^TNQS_I>6_JTF!P8_5\$!Z?&W=WNI0EES!S.&\$!H_916H0.8.N M5M/"UK-?) (P+X34CS
6ON15U^9NGICH!1+EA4V4#.">6C_ _W^JNJQ7DLLWC MN\$HH5SPDG
C.Z!CP14+;>@X%D@6JAD:3KE.O:0"OFH6;@ISP* M=J!0N&5X^63!!+>;"/P&U)^OV _"/J_L!L#;!
2!#6YK&&!"T)7BMX(C0!M@_M_\$PY!Y!L@U\$HH4=#L>VKY!7E)SXHL=.;JRT\$C*_EW\$V_?EA>NKH:X+QR"Z. M*
<1-D7R&(L2B*8*22;ESN\$Y;177(EK?+A..457GWXTT;Y&?2! Q3 HE@_M"34&4.W.^D!H)S0.^Q6=5)G\$!CJB0SA
@XIMMX*_V+4D11206*(I2+;#Q2M7CU0-
MO5!TO!G#W376-.#_!L!5"H%T25_W>2(JUO"8^@K3"R(T8*;@,&!/L)R#*M
M&?7)T64;P)M:8^!3"ZJIT.C:H!^!IT\$BV4F681Q!" MZBG@5099CHB)7M/42W-CX6/TP +
PYW2V9%2WB:4^Q1W!""P!<!(@Q%.(+&.U@^GGPC21+9U=: " M.@CQ08!K@&A9%R7!\$AU,CA1
^"DIUD_8EW3Y#1E.7V@/?R'\$!>C4A#DKFT MAPP7TWT)+2DCKBUMW6#W
_!\$832M*)+FR2!)F\$!>.J%P1_I306"D-O#30,B MIC^_KZ>?G70!H3^F%Z!Z\$!CPW5K)5K9!H?
!G;PGF2#J^K@^DZ!MGJD+KM%_ M!KG;T^U!;)"EU BNF0: ^1Y;"Z^#J!Z^VNX1D;R M-T*N!&D@;
!%D6VL2?BSCBV\$H31CQE)&&."&C2,"A"(@/Z8SN6;VTXZ5!M4Q
MAG&BTZ8!IWH/NB?/E,=+!MT&K=BU!@=H%Q;K/%I!>Y!L%YLA*F!G+)UZH6WX M XB!YUO6S_BRM 1/_
B<Q9B!+ZHO/4M=W?+A2O%+^V.JNG3O>|8%L!4MK! 8+8-8K\$ _OB;+>A>E!6WPI!\$2,C/\$O@U
M>2%#|Y(C%R:043KB#O!>^6(U_Z.@5-EJUA^!DGRD*!DP>_J+5Y;0/ MP!&/_%RNO!/'W>>|D_KWG^+9"NY=-
C6^@""F0ORK_@O\$!X4"8AE!"OLE MLN _S.F.HH3GK)AEW"@+XET)30T10.Y?%29GM"EH!;7GB@ZGTS3:1TH
M4+Z?XI^T9*Y)WTV2V'87M]=4E(CNL+A2.9FYMCG9_R1WH;U'!Q*(I>CL;%5% M9F
!MSD;EX9#0362@JO!>;L4"W _!V'2R&MFWZ4D09Q7Q!C.F?L \$&/_IRG
M1=+!IGQM#H=58J!SH7@!G;)>Z4+!Y;_ \$OCKMP2Z*UM>J!^%\$?MK2L;U8_!J
MF3XRE+*F!GYHJU='K582GFUH\$SUW!HJ?9IUIG??!>'7710#A9J9V+(GMOZ!0M?
@<%DN""^E!PWQEK^N;F_9HL(KYMFT*BWT!Q>BZT+W!(MT3,T" S>-%UM!CTYP9_0="<*U3^W-E&?
!9'Y^U!0HPV>"91_-ZHL!IE) M;~)O98R?<:A)\$@RX?3A5OJH4-R7>R&0 M@W>-BH>B_
_MIG+M+&WKZA8*NU!HXACZ!(8U0ABZ0#UQG@81^_M)9H#!B M)2@("\$=O:%)J?Z+=5PP:#?
W0*F5S!&6SE.O!&7R>*\$ (M&Q?"(8T JU5<69E M-P!Z.KT_&?G@572>&13)'="D#4B0+Y*.E;%!X3;A5!@)7!^!J
!Q!^!426E M'W! _5+EJF.S08@W_/9F2(V'UY=#U@C!@!%QMNE#;B;XE=Z;JPL?%;7S% MPO/YFK*\$@O)PV(&Q"
<^=43R3Q!E=H<^!H0VT!AUF@^WYCG6,2,5"39 M=+/5A*F7V"1!@TW?A5>=SQ7C)>*=A)W!Q#';
!6;_&0S(O!HK1 DG!L^1 M MN3.O^\$ "WR@!JCFB6G+65DC^49< JC7!W0GA.V^TK\$BR7!DAB!T8?RCT 4LC
M>>\$.S(RSZT!C98\$HN==M2=SO!4.'S@>G9!+7;YSSNA@\$X!#QO#6;..PZ+9 M?
H\$X2H?;F9Y>O2O96C%OFH!+IT"7Q!P.VYVG%-\$"LCZA!E!1!PIS<+Q_@_ M\$93OE7)JLV((Z,(GF
MLYB'WYZ\$/QYA@JNE\$%V<|_ACZU=S %N7OFDJ63AL\$7H=^NAQ7IA BY^109H\$C&41.M6U%8 O
M>?."^_!^0X4E#6&+R(!=T!M%_)B^9Z9NT&""%J&-E,". UK7W! A0:WM* M+JG63K!0JAY>
0!UXUC.4CN%CE7B4!JHG*?W966_39C^5 W"7)(O)^!#C M@R-Z3!F;-MAA)Z/47O!9PG+RY1T)=5;H;&+ TK2\$O1
2J&9VZ M6IGD_B\$2!VJCG_!AW/6#W=3X)R-M _;BGK^1_ZML;^%U!+ P04 " #! M@7I9(XL/I*". #5I@_ \$P
&UD="TR;#(T,3 R-5JG-RYJ<?&?LO=84^!Z M-K@&Z26 (WAE-Y\$!004B0UI8@25D1FA@&1
>F)@O0F74&."HATZ4!+<! MZ4T@A%XXB4"(I^V+6?O!H_GNLZWS!GFYD_SN)Z0T0!>>K!W_!W@5SG(D#
M!\$POFUP&#K< &Z#/#P\$%!! _AIRKC!/@(#;
>849#W(SL;_ K?P<4)#@YV=DX>3B!N_0U!Q!O#S;O_Q_Y)_H!#6=A86=FX M.=@YN/^7-^870)"3Y0?
+!\$!8#1P\$6P0.L@>8!0 4E)"M;^ (= /YM.!#"">I" MG0,4@P?9#%G-G(V,3T^HV; M5M8VMG9.JYQ=7-
W<|_OX^CWV#P@."G!6\$1D5'L;DJH6G!YXF76N!R!/_<%
M'PJ+*JNJ:VKK/GVN:VUK!^CL^QJM>W!H>&1T_!QB<@X_O!XM+RRND;ZO:6! M0!ZE_-G;U^!
P^K@HL_U4LOU(MEWP<<^WH=8"?WT'P-N!\$^Q"YRTX!G@? M.GKR*?PA>2W?2U" Q_HHP_B:*+9O!
!S"!%@6T! QOV+!/&=9H M\$93LK5OC%"4D7!@EOXWE;2UP7CQ. 7VIM;)S5M5\$)8/WPKZ/J?B80/JLO MB:IKL"54?
^U6CB(KXBUN7_!Q1 X1V,8 DP@_MS(4B2WY+CP0!H_J@6!QG+2B+!)W!=\$D6O!^D;)M63W@^!TA(N PX!JZ9/Z5
M"JM!42V+BB,G,=DHG&%3 _"*=4NBG&IC6\$@3 M)1W#>H>^MX=|_FO"=A(1B67Q"0&NSOYPE2_6H2WOSM-
OP!<.E^O4\$5*\$P1 M;M<2T_P#>+!Y%G&YT'DU=/#75%6AS5-<" +231H,I!%D;F!\$S?ZT>UB9B. MJF<<2!85N67P-
^!#8W>VWT!^ (L/L,@:B(8!D#GLI-D7QZ,O_%DIAM?>8!K M _&Z4!;#!6YQ6_MSA_#^'=Y^N>/0SQ\$
S7X^A7C;!0.E!T3!2/"6^>)4 MNXQORDYK6!'"\$SDE!U7TV_#;XR&W<+G+W!JDC_FB<\$;F!2=7YYHXO!>C

M0#M6IC<7H/-T.D/K6VU#W82I#(EM*XB/3=>|A^K2.G6M=_\$.E/Z7STHMA MN @L+PSW
5&5M!%#@N*2NOZ@1)A ZP?BY>=|.@5O5LQIQI*NU-9JMA-ORY+E M':AF,<|O 8;T5*IR
4A0V!8;T0\$9A25>P3!=RVQI/A#EJ5F I_@\$.8WJH6E M4H2Y E'/J(^GB-Y8X7Z%(W156"0B8/TV(-IX)N.Q:(HR:2:
Q+|0+5+M.R;.)Z?VFLO^JY?D835S3-GIQI+O^PE).0 "> M&-JA70:7=1\$%2883+R?@|
Q4?>2VUJ%L6=;T.Y+5*K:S\$QK|>.J8?<2OTZE.M)IXC@L&0K&YH.YP)H#++D?F+|@+40V;0L^%SL;(#-
CV+Y\$M3&>P..|Q7I MICKUIW"DE"#T/7L#H#2A0=MGF#P/*+4D"2O?*[2.*(-UNZ.=?
#-)|:M8;BG3%2^O;GZE8G+B=HA0G9"96)V2B|.1L 8.O#XSP.%0?
MHFJ7)L33VBO/_X1|@(.0\$!%|2;0PNZWK?A|@Q/YJ;\$I0./^B_>XHU8?#W#S MT;S.I.C60KW MDN&I:C#T_-
H12C6+M%ZCZ MO)X2>M-F70L&I6CCWLI# M#MHY+-D|J%\$NT3X50/2)7DCIG.IF/RG_P/G%
<|BT1AP3(%Z#C_OC.1+|VR) MF!L&Q/@0@|P>|/@?GHLU-5J_S7Y=V#V#HXK<^<@|N+WF*L/B^PF"5!B-
ME6B<|/Q\$C1!%8ONE^J5-/Y&0.;5:4^YR6:78|ZVQTAJJE0H:4N3'!!-C8B&Y# M^B:X?LA:|DJL%N-
8/2*VH|3@I0D)JE0K.NACHF<47?TW!/@K1+KIKPE:*(M1DLJHL6L?/R=*9%1H?HWX|E<\$<+,.L\$%,#'M*2|6E4)4-
O|LL%@CRGW;-H^AD>%RN+S M!+XV/U^W./@JP_P_V14N*K^?|&J.R.V1?U=4L.MSM@E3E?
0%&@6MK/N"YD+UP3@? M%-OU,25LL^:#-QM^*QIOG#AZ47CYL4OY!#E|MZMS!D#4FT\$9-+/\$\$7WLXLIR2NY_U
+BXI^G9#F<7L M@_>EN.(8PK1C1 T"%HR^;72+'P/*^#8#H6Q^H-2=)Q7\$^BHM5|8\$WJDB><45 MS="?
5Y-94O|3?_5CUI*7IU=-|B\$TXW6ZW_%S(4*.;7R|@JNEGKE:GK% # M-N7</TDG-W.VUKJHSB |)N/&>5KD@Q>TEH
|X/J=+>B9P\$@EUI4G14 M0_L0"7K"-GHBUY2>JX6(.+W;+L|J/Q>'E\$FOS|8|_|9|0-7OQFCY48"NYAL MGK^?
FSF^\$5.4W;(G@T4KW|M|VGR;#43D*2I@;XB!@1WS0C&63S0|&|2&5O M/Y\$|20R@M/E)2=#UP/UJ3#F.3B(C'G'2-
YK3D Q/T+V|L- M4BYN>|3|^5<9XAG?MHE>/G|FH|'F0R/1WF9D72"5>O^5HRVYQ&.DL=V7YX="OQ'9O-HJ-
N7&+M%RMXJ3U|6Y3Q|+YVG|'J5\$7E|C|'68*21JFC MS0.;NU.NPH:|QNO2@YI>WJQC-
C&=+Z'|@%C^J>.#>@7F9O|+E@*X|U*6@A|T=3J9@)*\$5>> M2.W2I\$&BPZ9+&.(JT10H51)1B|*UDSLBF:HF?
MYXSW11H=D)Y:7;Z&9QY MEA(:U6;J+|L7|J3Z|LEI+|*(=OU0-RP1&45(IQX/'-J|8A8B)YI|OV2\$| M(CRK/O43?<
5=|&PXC_S"i8VLG7>-F:(/;>|M:3SC%0P5 5W_=KH&&LJLF8U2 M|ZHY(938U)8>VZ?;0)PH|D)E^MHIXT_&D?
T(HJ\$80 MWT"&+1EUXUBJL/^|338W.831%47P=R'Z#|WN/-GU.G 8RX#7.7T3<>DK);MM?
J.VDJTCVXSUX_8JP0ILVOC-&8OZ3CC)&5UZ1B(^|K8I4C(+V|YC("M
-!H#3_Q=HO)/Q+W#\$2&IX+6CMEW#T"EL=9'EZ2E+8*1.=8U6Q2CF\$|
MFUA"S|PAGLTE=&SJT0OL@K7|Y9FZ3NU"4H\$2\$HSHJQ)C=WF)6|0H?ZZ
M@VA +4L\$C=9X|HW?Q.A5>+5GF|K%EBXC4KHBML @/ID+|'(87|4|T+|B5W_%TFYV"*(>P"DI
MKAO>)|#2#7YGB#T:."44GV.)CW"4' TY89#|P>2-N4B|A4U|G.'479V! O*W3W8)T>6D3 MCF1|8<#"|_OL
I%\$F|"*0KP%AA%i7^C%\$W5H3DT9)HV1B|Z03DI97W3SI^ M|A9WCBJ?X#1#H.B M|Q(NSJ.?Z@",^E|C:
#/(8DBOY=)\$X&3E3Y23A"K M+<=>A|I:X"FEQ7J|HBD2K(W8+K)N(6E"U^=V M:5(Y1\$G|^B3F J+|H%Z3>87S:5-
H(K..KD(|MX@FZMC^IDPOE>|5%.21O3=D.\$O3.10R)'Y)H6I M"%X3+UV+\$SILK)"|I(R1"J.D96-
A^U"X(16ZW'3.!)>8DYA MIT:LJ*7|K-W*9-H5.3W61 D^C PM>3EH9MY?(4KUB=H" M"&H>3.
9G*+P55#4K|D.WHI08"AKFSTP'DK?8LEX|@.3NO:X U^J".NH9 MSOPMR|NC?3?7L@+P=\$MKUBE5BWPAG|
H2F"">|K*F0S;K|-\$#HJ2\$N& M9_2M|2:Z67&XT=;=U>|H1'E2"/ATE3DIZ@7R=025K|/^F&7.(UXG=|HP7|/"CGLC
M?D0('R|RT\$1&VQ@|_C-. 2D&EQY^R5N? B.I MVEV^00ZIT5(-0_2FS>V>WGI9X-
7B#%G0J2KA8'M\$N3*MF=WH|U:M+\$N3|3 MED:;#1LH3.+5'FN)=8&(A9RC1%&U;/@|"SMRE&P"BF1
M3R5_"AJO|@8%WK|0S?O4Y(KD9#^RI,0?Q.2.*MD D^8@+O"M"21Y;ILRU?RKI:|L|K-
U8URV|Y96B+"CM.7G>Z_O:O-@+A76#_U|Z|N M&ZLZ!|U&R32|A4Q0.+A?&_Q;B|
<4.54ZN0H%;U99B"X^_@1@)6G7.\$J0).2 M|HHRN*^H+B%R'^G).-OK+|^UFIY(Z84ZJ*^O#"@;+OU.1F?
^_M\$#>+1L M|K(D)\$17!! Z"XH1.);ET&5=T\$G+?>@D?6-HY/PN |B\$J/B M'OQ*<9UIMG-Z1/O4TH^&('R-XR4-
3H|40^=,DKF 6 G:O/Q*E,*F,K%/M^GJ#.00#L+PGS?UTM5K=|E'7HC^MCGG;_BS% C""+2J_K#<K'PU"M:!)
MT=;Q6T9?24NY7-0B|4=U>|ST:H=IBJZM OC4F2?+@O 9^CIY!8HS5W9 M_XKR|5.\$@C.MK?A846L6K*J>UC)
<|Z0_F=\$G=T\$<-&'9?|<+*/WW^_Q MW^/_1Z.Q>'Z9T\$658?0D?Z*_0;O#V2E6%06 M>)A5^N5=\$5YYY1O9D|?
CTC#O3"J=E5H-&=N9_Q|@DL\$2HA(%T.VA6050_#&F)H|^@2H+
MAO|X6:%^%);G|U*Z>;@Q:P=;H"4;0CGJ|LV-X5;/46L""=2YRL|JU>8*
MLVXK;YI9|_@#_9QFO65+\$F7P>X'DLR1@>KH>WZ6.T#_U_F*|Sxu.4!DDU MH:UW-CJ#H%X IO:|LM'@@:
|=37@SFS;|/E:A/KX7FJ)+HEBO?(*|0T3;/N/M:9|/9S1(X)<(-JUK=\$\$|=Q0V('MH'6OX;/99P.0^>Z2"ID6;|*2"/\$ZI
M096_ZO(G25|W:|^D<('FOI%;&%L"D'TL_)F(\$L;)_W.A4Y\$0-Y)+\$RA MJW3Q|*T:|N|5-P6.2|RI/+CS6+
<(CW_U"MEIEQO6I+MU8^+B|&IM:CY MJA"1UUCIGAW9ZC43FM8IEP*+F00N@_E NR.G=>;*B/2.V1=&
<*Q3|F M%;*19>-T#*Q0WSK0|Z#MD-JW^E;|X^OSOFIU^H"%Y&*(%A.=K94 PF43Y MYEJG:X^J2|JW S#NK5
+1#|KLVI4.+U53J+=E>5ZV5!>LODST-T4=?M9U-|JIT'Q\$YZG@DN;OFMZ|8E;KR.<%Q@L)1@<>D8D>^GT(|&F:
M;OWS"||AE>|XY|ZK'78QQ(ZM7"7T#Y*2OD:5O;-WN|BE8#U8(/UJM^S| MF\$14P@AF|S-A5>4\$15RYN*914ZD61-
"WT>@SQW(4IO M|JMUZ9J%|H.X?FN22>D|I2D5^/);CJB+HL%|^|XCA.Y:2%UJE"1 ID3.
M8Z/1|^GQ:|>L0+&#*78I.+CQ8-"CAT">-K>3^%3+U>U".=QO'2Y?H1&2/&-MC3=0"48?
FFB+2)@!O1G^Z|@.1QY3'9GN7D0|3_R5B;G9-X=L7@QL=CUE8INE%FAWC7%6|E?HW"9%.2.)M-|U6H72@FM0
M9VUG L^E^H;S9U.WDPY|<(|98K?HUWT(|L|A|TS|I7ANF\$;ZS6Q 3J#(-7 M?H:|A^0(T07?H?
3MJ=JHRCIQ^E+#+|<^O%H>QIY^4&W#|?I2DI'3.))S|
MJ9_0V+AD4DOV%|H2;VW&.HH.HW&S&C\$(@>K@#XM#-'B|@5SL7;-T#>(Z7&Y M
P|U8BLM_O'2\$X.EBA.)TH8014E0@0%=8;^R0J'M>|+O2_^M|&;>RP='N1 M^-#T=-8?53)
(%./<4.P6@3A4\$F(%7C^|QAOQ#_%LJHSRHR8%-;1TF07EF(MU)|5H_G|BW5_6H1-SXK|I-?4C;G8|/Y>D+H+T?
&K.5\$G0F.G9V&V MNCOCAWZS)6;S|78TQFW.>P L#%+4X.Y0|6B7-"L.&5Y6 MC0_*|B/45=/O@S?)"
(U#L8E.)6|RGESM=UE&UT/^MU0*NZ.N'Q8#*B%&<M/4T+S_Q(&%B-V'WH5&3X2'.TF0V+
(=,>VX0E)ASM^G)Y+R?BJ8/N8>Q9D MWP3#AD!=[B]1 IOBO|FQ64X3H(^I2^+X^U"!TU2,X)8|&\$"CR?6"5+?
6RS MS"J.F%Q114XO89FP^1.3W//&QQ%|6(JES>X|.0T3_!8&7A9A|B2Q;?IG
M!\$8S.4.#/2)-(C*RI.W%"C|A59&CKK_O;K|T3-318Z|TISH M^CKV &PH#^)|@R\$525'OYA"PYEIX-
MMAPSE.YGY.IN?=>5?@DX1|I2K-OL6W- MF8EJZH? ?RW!6UWJ|69^9PRY.1)OU-1\$'+W4>MEZ&(O+@-
*MF.F.U11AQEO MFLOKR=T.O.%FW8#PN:5V/(^989UYD*2X8&D>X2!L7.*^#7CF&="LNDWK6X" M4,N!/_D\$D(5-
0.EVFL>S"XZ\$B?>R\$6E+3ZY?@C%Q<#1%LCCNU(4W#F6YP\$ MCHO4Y0OGNXMIRSO14|.\$?AOZ9|HRO6?
@SVU%J=(59/5|ORU1PN'L/MC5(-M3|P3_.\$\$+*KN+)A?2L6!7@!DO.#Z-(B3J.>)/PFB+Y&YWQYZ:4NE;IRM
M>J;-2L3EWWYLG'Y=_ODEL_0AQIM2L#W>|F7)5KE(73X|IG!0J.MR5W6G5/M|-?E-
PMQ83FKO#4.A5PO^4F);H;FS^_07D^F?&2X& M>4M%UCMCG*&|QV2C;^M/7Z5-*YM4QB 4
MQ1:"U=^Z17U71U.KO@C+WD|PT51+D4HU?P=|FUE?2)SIU^SUCW'AUPBRIV<K.Z7Y&K"EM MN_P'EG)*DF&9G|
<\$QE+^F.1*7GD?|1832+WS"CU^%D&7SPF|SZB/OR9!2M=M4(E.VD.F)\$0Q|YAI S)CX;U3SQ:M\$0" MK=?|
VJHOHROZ-JZ2"8PIT3/A+E|^0.Y:-?%P+|#>J|'Y)3(E|S8W/M';&|0T1_1/7G8A;L4H+2)'G/99'INA1:Q^Y-
G:1EUIP.YDZ0JGJ_X.(1 MV@ES:FS|7PM|/5?00S8T>)GXQYM_*E C)HK|BF"<3F|BUUV|GC)QV+N^\$
MWF&\$?_"L2%Y5"J5XU031^1N/N4(#UCXXNQ%*+ YP|G>^4?L MVUS\$L<(F?&.4PFC'=K\$%6S\$\$ ^U0ZMF.O\$;
(F#>7R&A|@.#Y_D0^-?5VCEF M#L\$O9&N3CRVY_3"3N 3|2*|Q|ZL|EYR 4>6@+%)NP\$7QQ* C9V DUS9X

M9%93/V5%5K0:4P(^GWA.?KS:K&2HIH=IDOIF/S^HMB\|@Z?)(%YM6+7.A@6N?U*_(1B2+T8\$(602I
(Z>Q'WJR+XPZJ\$1J3^1.+Y&90@%_.7S2I(MOIL:"B:IM=4-%\$XL_1BC.Q60<+0#R#/'^(@Z>*NZ(CM*T#IBL\$;:90T
MJU.ZI.<^O6WNNK7SC4M8=C.+*5EYU+.-]>^(P^I^Z)O@?Y+3V> MIDR|3#M^2;UF)/A-B.:CX;
(C6IHT+CP/9(VOPSSZC(Z1_?Z N0E76L_/8OP M99,2&T@>+M=D=#"IBO*V_O'M;KNB)OZ==9ERC#S'K80<%PP
M+!^2DX&ACY%>)>29?CTH7B YI?#>JHMMCM#GE^YQ6T1>V#^I\$K:1FT53_M|06|0;=|P|@."3>0#&G4IW4?
8NZ7+.^8IT-E6V5K@C*ZH/S&U_BH<=X|5/> MV|(%0))&*YY,Z-BDI#SF,SZOTRLL+TX%:%|L*)F(^SROVG1)\(A(
MORDEUMA%5>IN&R(WD^OA@SOQO9;==T=R%K|'^/2O9R<9|M,K6==W=Z"W_/3/3;7*SX'.R7&:%7IRJ=_D=M|;&*
(-U+TG_S?EIGI-M\$T#N_TGT+W9T?_GE'/7/7R\$%OS:CGUA J\$%:TDY3_"8P)_KB"|(C%3^_ MJ94_6+8MU5!7=,L/,|2S-
K+D_OB7P|FO1XL+N-096#N:X'76&4"D_|D|YZP-M.32AZDX@'='B+1P|_Z:|G98?
S8G^KG14F9N0KASWTH.ME!M:1#W+D M*#@3/A^IN?VF7|\$.S%JH7*[R#X*+\$ML|A?
2<^5G4I0Z+9_J5+_|+3%PM6%YF M?RE_T:OKO!5_U?L R:P4#|BNX/P43?/I=YYAU5#XY)GB3ZB7V:GQ+?(G|)J M=
=6S90C|X6#_0L1E7X;C+H)|PVNT7?&P=IQJ M|E2%0Y:N^:6=
=<=0V/HOT'QO6YWC_(-)|@D2AC5A^7=0<0C)|O!"RC(-CMU M_:Z'M_-8Z-'&#'=ATDS 3>-PV4Y
M^9.08YW=4F=G"GW/*WMX"O|5HWJ;|+SH@ (M*T7?8RWZ*ES0X MXR>)/N_VFG>PS*%1&6VC("S%8.07V @_?
O)/+6N|=(\$LOG|URAOJ;+|>8P^6.VOPL* KKF@_M!S6#--.I,FTDK|57B|=VOP>" EU/=F+7>MALX(M|
(M|2OLO5;#NH#_33K+|" MV;_-=MF6?BDMO(\$1V"P625\$GE26C=?@|B|A|M;MS,2|57Z"3+D_71Q89QK
MG^|L_2_2A/@611."GC,2\$R P>5*%O3ML3T68D&LLVZR)L&'?CMV7/@5>V.E
M"YIG^1M7BCR@FB@XM!_'3V<"|=S(ZGEK"SY*3TGO_^SG(*T2=KUN?2XU^_X MZ_?3_&T'|^?/?GZ,S|L)*?
B^N<L^+OS3>U1B#LJH8JV)!L:O3.PE \$G_?M/M.P *O=)"PEJH(4B_?:\$4\$AY2-3&U)*UH6N>LD|4Q9^E44W?
A|O#(2BT M|>_W"X7:6.HUQA"\$.^:T^71RE|H|ZF|A|0?YF2^|P(OZ_))T_?QED+R MQZ+/4JH2
#FT,19H64Y1FNU\$4)2_-"P^)!_|I?Z"EOP%,R1P%7QGJF54<J M:E^ (YIR=[4.>CP",X27\$3_W#Q&!IO-># =3P2?
L^0|=O#2!%:%?H;@?@|PYZKOUU:|1_#6|YON9TD; *O'G<|EP_)(*FIG%&_M4IW_QZOH=QR2.1_?
FOA/R_*^4KJ)X'@'=BOFCQK+CWT|N6;#RR9_4\$K5ZS#_M5@Y;7+OC19BNFE?4&|Y.RYD"4;SAV|^#=-55C?
\$"H<&2'MG=@5F0W@|VCZ0_MJ^N|*YJU2.*G3E|Q|T5W|5/A8_R|S_HA37_M9@5V;K;UOEE)W'_.*C7?
\$N|@GO|D+A<|FWXRGU>)|Z|12|GR^XG|?IFT^OS_-M8:Q+ZF(X\$Y:ZYW^GI=-41 MCN+V@E7">3)_MU4F'U)|PS2
YH#OH4_*RU\$ F+W@V_|&J@|>NV^%KO+K>N:|6L\$S#D&@_"*|MX?
f=TCR|j|= /QK8Q8|0XT?|A7=19&8*8B4U<5^2^M_O7P|X_M_)*%SYU752+ M;5A"DG->4,<"\$=|?
F6S7|WET7_M;2;F>9&+E|6AG,2XL;B=M8&@|JW+|_3Y&
M%CO*RH"%#4"CQWKX9KLVIZ"7ACB!_CM@#>4S#VT85ML|>:YN|2L=_.BW!A-M(AML=C\$:A.-Q| T2:-
#5(R_ ^F14?L|QLM4F\$,N.QOORG5XTQ M<%7QJ-
%MS6GVCLYFP8;)D").\$GUAE<25IV1C="(0)922#V+Z@V"@M24|U5&MKH|5OZ MQ:O/.*|TJ'?\$|?
M#6X2(8DQSLR'C.:OS/OH&QJ:RMUUY@8%M|H/ZI"UY3X_MMO%\$AC?
>SOP&U0S97|@:"Y|\$.^S+RV.RZCKAB>A*EXAR2JH#)Y.=T/L>U^&7 M>M^8NY8S5U9T+|W|(O;'.!':.-|%-
DD7|IDSU1-.|5352K|>R^3S,? M.2>B74TENB|H:54.J>ZA(D_4HTP78Y2\$QZ8">VR'W\$|NA|XFX/&AWF>A+D
MYJGO|2WK#U|WKH46|<|%_LIMM^Y0+|H=4=Q#D\$35X_M5Y/#J|3OZ&N="|VTS"@>MV^M4\$U|_OSKD7MX?
G|.*\$EF5R4>QG^VV8).R9\$UZ&LS#7&H%4UVPL34'E;AT M|52;0<_|0_7>>B8P)|D?^!\$3_ %O"@YP/%F44R\$|M)6("<
MQ@2;Z_?F"!Q\$%.*|B&YAH64B/ZDTAQ:??NF"LGN0T^B'LA.D)3|H%6|3&: MO+B _AXU"R7"
|2=^H=W@3W<+|VBIZ*B&2%'^=:/T)74LO_12N8B6UY*KWK|L?_M0|T9AZ3|5X1C_49@A5|H|&5GX/8N5G5\$X-
^5GV\$TF726HE+754Z1+^BZ1 DG MK@5JH|GN_S8236B\$^#RRFK*NN|Y6N#QT9_4J2|"7"tHMR2_A|6E6-
UF*>8.L@7AT/D_/KK1KLLD"=^&S5^M/FEI*9_|WVOB5_M@&|MRG*/Q_U45:%7RA<0#"XV\$.SN46K_7/E(2Y-
+>|RV&|3?1D"YO2'MAELA M,WX##X_ =YGV+G1?C\$0_*=_R|LO,%K>633G|A3TE3N*1X=;|_GH|L
MN^VO|/5JF%KT(^|*UY:7;G|=^7+R=,7^|X*(J&5;|2M%\$S5E#P;"/|PR7@?2|_MT0&P|@C_E|4|Q=^F_|Z
MJ5(49J(|R@)|&_&_XE6HGKWR\$|_|78P|IKYB BWMJ,J;W! M^ _/L|5JK;V MR|2/C>0/+|H(^=6?C;5@"?
7\$&&WF#3K&R3@>|C%&A\$R@HTI&NRK?/6P.JS2
M9\$ZK3.57S0KXWH>OUUBU(|J5|TN'=8|/U*/7PM_<%FT|4RUTE/6J_ ^:*U;:
M4M>F7%M'2RV;C/0;:D%M@UWN_*E5RG69+LIE_H\$6\$<40XDFY13LW@H<*> M35HGK|<-
TZ"XPL>WW%\$|2+^BH+^|AQ&2H(H M|T.Z.%R/'+#00_ZY(|T QD-CEEVW'&DXJ:>)
(K|OZE6'DV|=2JZY>O*21_UE@'"Y|6;:CD+|%HDI_MZ_0V2;R|PM;G?8PQ)94;>^L7#1)^+Q:SVZ9
KFUO)UUOQ*5;:>>W=V59(M.('|&:9#=#&\$:8>)|" 0;|!|X^?3G9|6_'V*|V?MOQWWM54)F0B;:0|9\$
MCAB8|S0&O0X\$5_HW"#)|#R#|\$=-.5S\$|IXU|_W#4HYDB|OUPU16UC(9|2 M^_J&KE;P8<(3F&O#NX)1B3?
N1%I=;V/A.BC#9VX(H.ZA6XS0N" H M>?YD_UF*J9_O1OTN3_?G|A+N2%|'"I90|5EFR?%5E#|Y|=-UI+P%.H5E
M<.52;X-1J\$|+;N:F%QB(|MYQ|U_5B;/G:?'T)1<^W"1.UEMF(2H)|MC' TCJJ>|C7P>O;_24EQ_9BUD@_-|H|
M:4_.'V1%F&1X^A&5:A\$K>F@V #C(.?%- "OM8;&)K|O|H/AU30|K5&8Q+ " MX,+>^4#|M)
(X|HY@Q'M5;|YOO|MO9O.YO|&=>T|D?PN.NW*|LX|_MSF)#F|8Q2YQ|'R7Q_-S/P_*G\$|Q?
GP'C.RFKR63BTK'A'7&IW?GV^|D)9 MK^S2).%6E"UI|C+P4HR"LV"?)F=;HDBKA8C
MP/GW\$DF|K+^I0&EY%QD5+I\$57BPM;.:^P3FYW3"3D:A.W_|>T=#;T|OH1ZD M|&G@S?
NI#O?6A|"N14UL=I8QN*<42K7=),^|3|L_T-^6")L|M4=&,+W M=X>1;NOPJ6G\$>;YEV=1':20:VI+A:O>N3
MC2G>^V;5@9|ARFL9:VMM?T6FXRV|MR?2=|F#>|BF393E13QF6QT\$M7EZ%#)7@'R M,29?;X;^ZU4PD|6LU/?
118>X8;M7P)Q"M47V+|W|+|SA|_|18QE' HJO\$G6>
MAN@%EWB<;EIXG.68^7Y*:TST>@.A;SAP2JA_';6J.1TN#JQ<%J+6G9M\$'_ #NQWY|Q_M9'87|7*6:%=.T-R:|<^FT?
^Q7Z*_-179K M13|YWK4RDA)|B0A&HQ5WS|8^B;F<7+1Q02\$5%@V+ ZD(0S&\$A9)90|F M|
(2+K:|5B32Y^W6|DX5|K793;FD@+|\$WHV+=|PX@R";U5G3:.*>WZ?3_N>C56J2SV|W^;A6-%?)\$Y2T|H9=;80)"
M#)F_V'7CL6H^4|Z+ET?4|J;4|H|2DTN|<3;V.IQB03_!D44*9BP'4&MR=5 MT@TC58KJ=<H=|NW)-S|MG;YS:Y@6?
A7M8EEE_-9;Y5+2%|@:9X CP&U M-"N^X;G:T=?E@2TV=-(QFGW7P|T0*;&!5_V_Z)"198DZ=LAN+|_|#33S-\$ M<-
|U5E52DFEB6#YKC_-6ZM(-AY=TX\$K=9_J&NK,BET?+|D;Y|LEM;GN24 M#>|@L HPW_K8|ZO2Q"D|
|U5E ML_PU|+|1S;(MY%F1|H\$|H%&E M2=V=1|_RH08*530+|BCR|8XSGB=P|Z="|OZ|*VO9_>H0F
M)|4F3>XAG0WOHM)|B:A9|5U_+H+3G;B:GNBJ&M|+9+*%.*|H;G"PA_M3I\$ZK43.VQ_V.=17E(|>R#4"C&
(I8U1K\$9XYHM7K|M-BA@03J^NP1)L7WDZ> M7|8MOQ.YD|A|:'&EB0-\$F"ZO(^WY;C9"IKFR%K
M6;7_|DJ|X6\$6>FN5QY|T?2;=E5|"_7CX FX;2_M>%+V|VIZAWME#IX|_NO^B MOOL5;_
|39ZV<|I<133"EBZQ%5"|@(*A&E#L(2%=TB8ZIG?"/.0RW33=V|OOL
M|2|6)-71>^O2@P=KL|5I66_|J_K_3/*PT>|EGJ=|BI?G|T68Q0|HXJVFP MRZ|E+\$_B"B+S"EO<0>70|*Y7ZH3%
B#)Q^_6P2K=0?|>NM.*+>N=-8KN&FLS M8>Y;:#Z&*K\$@)H0+GV#48J#YPVN|U.FX;:/GOI<SJV@^E_MXEP|
<1V+5 MPL"|@;8_Q|4T2P.SD5GDFI+5A1_-O'D^@|>|CM5_&L<6P&^TN;"SX?*"MHB;7I>|>\$F\$08"N%>Q.835L
|80|K|38ZNU@K7|U+|\$7IW\$|L3_HZ_IU@A5_MIB?N8_/UNQN7C_Y|J+MEC'SF/"EOP&NOS|X"8H|_%M
|6)HM_B52P>FE MZG8K|KD&13.3;(A&3;%)PZ1) UN74O1X)GYB;X|(M-|4|V:&B|PN0QCMW M|L3^5ZY;
|7H(9|3=K-V7:%/E(>L4"7&+5_O%>3EQ87H'K1<;S3)#C8|H MQ.ZZ%NVL=-+|C_|+Z59&(&L_F=NOG\$L^=.DF
#5M8<((2M7T+;_%80\$)_A MG#_|PW_10\$9=8C@OTRC1Z_4|R0_A33\$|C(%XK\$J_433&"\$@-PIW|FRDY,\$= M#5@;
>4S|@?M%M;^H)>|# ^F:%M|3;Y)2GR(6^|5X.<1N'Z.JT6KSSM

MZLDC9I9NF.0Q@39^FYH@^6VI8"D\$B>YT1I#WV"JI"?=UL" UO.. 0S1##X. MZ< 2+3"3RQ6\$*P;Y.)HOUDNCSQ
M6S4#1-P9A\$*U)CB0=QJ&YV&O%F|<>XNX1SEF?LZ(PJH,"P/Y M,JJ" I6 M"#S>
(R#-IM:8SAW\$*72+1J|>7T(M'&F0!-TIF*!>0;><IH7R!13:4JWC#2\$NZN6-BE_Z5P3PVIS-?BY M9VS"JI-JGD?
%|.1M9FC<%Q>=UEL5X.Q3.V1(I-G MGT6-Q!R-^K#34,X1IE0V"1H>5?S1E"0VHP M:O#4;*7HA@<)2DY,1Z=;YTY-
EG.NM=:I+!(EG<%ZS= KR0"00W!1!"=L\$, M4:7A6B"Q GHK|Q@|C|H|ZS8=DWAVI/6|I#(47Z@^W?TS.)?<
U""3G/A)) M^W7I3I3%7I3VDR)AP5=*A?;@HU/ERJH7K>|&F1XBCZU|3+QJ)P/P?S.!,+< M,8X\$2^6A4J>MID*O7VI
(P2|MN63@ U|5?>TP<;D;")D@QT15!9C \$TX"#| M(6+|AYO9 ZI:88?
49+I%S@Q2J:H6#|>J3JN"W*BRYO1XRUR^@*QN+SH(RK_9I"XO M;7IY6:GV5@ROYN.++&A|.")S)K|Y)QU^=O-
TI"Z|4XZ%7"=/(P)NUS)C MK^"76S#IK0&I3QJ@:%S|YZT|@Q4M6RY3MK"9V*5(T).\$(-8FF0P5@)L M*|H86J4R>D+
=GXWB^DPV|^*TC|TH2\|V^OWUTMW4|\$7&4W<I2N"3("1\$E MT_%XHU_NNU?>MTP>+X.EPO,^|H.M(I_6NF
<;Z+H0H+* MWLD+^U!19R!NTB"MB)B9*44ESPUGM!MJS4AUW%LFH.95NF3|(#MTR^)^S M;5T-
I%|2JHEI&\$D;H48QHK\$4X@:IN%3J"TB\$V)?>R?H|U>R&\$4;=..G08 M;JR(W5C?
TFPF=|S|U%&H^J2)H|5HY>N@ C""\$SE4YXJP.O^X|9D)N|JU MDS3>ASL#Y4J-0T.D#?TQ36?G'E|8W5
-6T_L_|*5#6-PUST#+QN+17SRV+V/E86Y.8/_7B3-CME%&WINWSP MDF^J)M:%C"UA-&K|4BYF#Q.;US
MDS9_51U+>IF2Q00@Z>(2?A0I""P.Q;OBR#F-?)JUOTA-DHQIM_I;|HH)\$>\$|C(WAIM MJH|L,@VS #
HL.;>|3X&G+|+D1L60QI M3\$%CR% TYJ|AF\$=8SIS0H< M\$XAVU*<\$|TTF=5W+7(;M;_IM7SYR^-
Q*>U@I^"I6O/1I>FIQ35.CI8K'2 MPM\$;- O*92Q8ZIBQ+ZDR9MOI:N6|NS&*!K?
>U)JWHIX<+TX|^G(P\$FD/>A2R_>EO|MT#F_5FT9&" M' IF|Z97QIAEEDO=>Q-OLPX\$UF6?=(=&EZ|S2W3A*?("<
<1>?6SLXB#-(\$4 MD0&C2J|H;W|C7T|A:>R:@@%Q!#X-Y."C>|GCL"J9I"|N8=L: LNL=>1X M4->I%GW/7I&
<^5-/2&2-Q*Y3I2WXN|*%Y.S|H:(2LL/4(E*M&1B3_-BG& M0.2)N?>,WH#?Y30^QZP_7QD^3,
)C%E32^%W9I%4T2QY_KQ#7"/9S|M"XN
MU55KU"|AJ:XL/8HT%NO'"&3EM\$Z\$KZ0&#|7/+8?/N1YM.9C|="/>0*=:X6T MI<,^)#S"!E4)V9-/E!H063-
JMG=WP>3-MAW GUV5893P.VAXI'=I8)W@P MG59| M;_+7:Q%/1A3>^_&AQ+%NGS=|LT14W738V0;5/X=!
M<%I@?&TC@|_EDV|0G/|=|>X / KM68((7A4WH|SVCZX>\$M_2AF>R#K_!&ZI
M|JV6M\$|I^EDSUE78C"Y>;!\$+|&LGV.HDQ0)#NYPX=0=PV6-J<|>MV*9) M1KJ|_..XR4"
<5"A+;BU2>H>|>O(?/!N!QO7?DP8#SI|*\$G4T|(P.O)BS_EWE%|L.E2*-&F.\$|_R9K|P|\$F)"*
M_|_+C\$D&3#4%RD)>|<5N7;\$%?R&M.O@-FSG|_|5%+4"NS29?R04LN M=09|DPD|X'M("2;?
(36_D9IQ>I=BUZO3GGG/H2*(QX\$S4XI>I04Q_QO* M8L|VTUH|J2TQ?2PM?G.S3A91B-
WQ1&C0<I0W_""^!_LO7=8D|&7+AI%112D M-RE1>F@%:%:5 0\$U A(%R(BTCL*2\$@\$I9=0!
24*\$5\$2D"J@\$0(552D=TA M0'I""1^DW3|S?G-G|CG/G3DS<^|?YX_I|30K+V6N|ZW|W77I_9/QNJ,\$DC
M0S|_4N""50LQ(YV/1W)?%1A|%>%UMF+5 M^6LMLDQ4=U0@O|_#_IZUT09Q46A CJYG&DN7W"?^FT.Y&D)MI
0/V6.) MGS@V#Y=%&^!_6|RX.EB#T5|V%3J|+XA;FBT<|4.SL|X)0_8|PHG^LT.N
M4(C@:8N^<0%A3G*.D6.G'6)_67/&JGV@A/H9N0|P63Z0D1=Q(K7T^E)_#GZ*MS3|*)|5\$&8^8E9IM@(^>M|&*G?
R(V9M|3>^GC.;M>+BS;5R-|H6|A(5)_/S*P%O<=&=|_0/9T|K(. COSDQXKDZN=8R MA&V:M?%A0-8(-%*
>J&R*NAAQ QU<|>LT0U>I?KFO I<^/VR#O"A6%|O T%NK.D"X.23M@-Y\$*KIT>Y^0V|C IEA)?
M9BLI+LZTUCO\$;|LGM9N10\$"LQ.3|&?TAN>U7@^O.^NCG-INL|)@W3K(>TBB MI_|)GDG&|C.LKW!&PQ.6=-;?<
Y'RYN-<%G8)=W WVI&.>VRF^Y2R\$SS M_OQY/-ENY.KS03*I*_OCVTYBUF%2 I>.(/ MYWV6_N>*IC8-00EP"
<)/8YP|B3.N>N+D3TLG@4RWT#|1,X>;F@7&;<(B*:T1 M(65R)D/4&V!"IVAP6Y1T_=NDBG/+>ZJ&\$F_8_GJ
EAUY)XB3;|^@CT27'5K MY+M.C+NO'S-7'Z-JFY1EI"H Z4/I:=2!4N %)I6AHP|=6-7C S@S M MXW|H|DWNK|?<
DSM@N KU+>.;/G)^1JTTK |M.RR4F1)78.\$WO|^HOC=SY+ M9XE4^Y^?E_2VLK04TY-E37;^>|R_C.0?
>44TCGI>|X>5CZV3A9I0_FXT M(C.M?-(Y1'/W=)G=):N\$J?K&T!55@LU2 /7\$D.'7-#/*AGIT_L#85;Q-MTCYA"4O-
S.;=I+;^WL5_*FK0&D8)SC;UNT?K&2O|_#1?>7/^"/Z=ONC% MU9AP;|S\$D3:RW^+4/I/=^\$._#-|?A-^RL@TX*&;
I8YB\$+^)_ M1LZ#P:088 Z9|@4X_539ZC@_!A""8PY_@BOF'=U&J4 M3O;S0|HRE46YL2.7>+F1VRPU\$LA^V4-
M=9J|HD@-UNA@>|*RI4I499 M5)VHAGTY95\$=|V_1<^|I^>GW.;KZWLUZ|H MIO9=^%"T"*6\$S!_MO-
|F0'19>B=2N%D&SD<2SH/W<0T2'S-S#(F/3X)J.Y")|T-B"|QU*UJ?MGDTN01|_|."POC M|PI4O&VS&C
FEVIL^AM8EU*S@OX>\$5PZ7Y?QX J/N|/5@Y(E)7*C2+4X3" MW.;J\$Y(>F4"KI(LOT>5&=6"9^Y75>?
8U!@M\$>CU@HH4DF9#U;9J|V>&CE; MQGL(O-EN!%= -D(5&:'844UH1|AKN|XW)^D-KZ10.
<9BP|Y"R\$Z_X7MR=& M:@N|)^N3WV0D3T"JQ;JEIFRZ>TX3D/CQE2A;+A_VG9W=9&4/2O&"P-82?+M
MMJRHATT^"M;55E"\$B|?_900|+SP*\$Z"?GCWD5>D+|#)J|^T<3H4EVBEYN700^O|RF2>Z|9Q^R*/PUG.8| M-
(1L8KU5 V/G(200)XG|P CE?GGAG2#BEBJM3.NAB|E4|>XW;+9 M'D^;LZGLGXWAB=O|JR
&F_!2DLOWHK>T5|I*B%_I4IE1U;VH)U=#.; M+M3C93;>ZW#+CD-E_Z;\$ (8Z?U74<%&I(KH/\$5\$4ZQ-8QB21">|<
<:Z2<B2LX M39IV'4.;RF9B;15K# (OTI4^ES|K#G|6.; TJW;=<+WWN7G0.I/HY.Q000
M_UMIQX+;P'50JH!=""X1'05<;8(F_UM|Q|Z)U S2)8 YLH@I6MS;L|AJY3C MJUYKI='CD0NY KH56&^%?
15YIS%4X1MK9&>32>?D*=Y#(U=A)JL-I:Y4 M@T_M.)YZ4J;Y?7HIGP%Z>H)Q=TS_0.XX2>M|/K7;N0
K1TE.@#E=P#D"6|M7.@%MP5_|W.6\$H9\$ZM9=KD?XY(2*|\$!A M^*9|HA"OU#23Q(I.F:P=E>.\$X/R>E>GH#
|PF|@CBQ""ZX\$E&Y!1*U#VZ%1CF MXXV)3*0)"U5RSEN=\$I&Z6Z^0EM5Y?
*OMJ|+FVIMWU&6B"FA\$G?;RZ2;@CL M\$'9)5BY<@H_WY34H1|WDLGX=G'0,DWHH0'f8YK8R^WZ1#YD1Q
|H|ND MGR.YPV2|WF@^_6GP-|Z|@C/F|8_3;0RP78-? MX*YEV^CL|6"768UH|H%D MCB!T>\$W)YNN1
'F7|5)C.;F|1%NSE|5NF*8)#H?@^S?D|8*K1SX%&X=Y?I% M/4_R#IXA0*.:J1NT
=^ERG98>#7U7HXE,Y^QODZ,IEQH'RQJ_JXMWVRS AW M)MAB"Q;S=O,@Q)F"|Z>;J_*F>KSI_S^+U7X|*_
EHU47H?JMG.SJV6=G/Q MI86P) 4D9|N<2\$ VNN.&#;YX"1 M3K|7;R|*3VUB)
I'X3(I>ATS.NX4S;|&Z8H'S&J02%&NJ8Q|*Y I&(:N&WY8% M3US|/|+.)?=(;\$|NW|2|)Q@J%&>ZAD578';WWP>'.
XMHM#1V\$Y\$5S|2CA" M;ROFB)N#Z&^UKH1GB,2|44.O+^>+|*CL_)E0IW5\$QX (W4Z_1|(9SMZ%%5 MLC%
F+;WG&5MZWTO/|^?|<7M*":VO;DHR_UK5CY8Y>R+>|5U66>&SEV|:W> M|WS7%R1JH4>BD|_1RFFU!-#D,<^*
A|C(/% M#=#;|57W|I2-V@%I%YV3@.;WAXX\$|_|C|(H03W=\$J0N0;Q8 M.X (<2'E@98
M=#7'N3&O|3+>Q5)P_V_N|OYR4/Y6YR|DD#9;."X'1(L4ALV%Z9D
M1T\$==|T;P;7I2ZU5V0/9/E6IWQ<2RKU|OPK@_M@Q0*%^@="|P\$TL9.PVX&.
MSAYH8FC|MD2J>:%|I'89N;SA(1G.I4)Z3>Z\$?Z\$0.%-NM M MW,3Y.VE|W?>4HP%>IO#
I(2|@(#Y(^AFP5IMP+SKZ<-W&L2-(V@14<^B01 MH=&YX+(T8):%1X693WK0Q-EV=|>>#>9@@ (DHU^;G2/
M<|^C6IZ_.NC2I&@_IC\$+C;S+%(WZ|B2#IU9IWD3^9;L_'.X?Y|K)GE?1Y M-X-TYIQ / 3M.ZC5H61+@;H5I-
@KU_N;@#N>G-(DYG96F32;LM/I|_@P.2 M>|PI9_Y+O.%_":<^3P.N V.RZ_H FW:Z8G-F*50;J(V/M.;EV+IHO^Y\$-
MIX?Y(NCIUZ;+4B;^\$H)DU'2|2+|F+J+Z<|^UZL ASRA0R|CT>|>UDR3
MC+HDUE4;=2B4W1Y.6""2.199N5*CWJ^|M><%C&9IW;#&H-Y)XWK'R|2|_@2 MIQF@.7_C
U^MK|NK*3=0;IB;ZV6^VR_092GS/#S:Q-C(R-I/Q6%;11*DE M^7?IW1LO7NJ#Y%_I0/S43"9=Q*3,P54?D+|
/1ZD59;N|H%4\$BE%D/RD MJ<|OXGXOWPF=4:N=AC;+|W;|H;#3S_?E>;/(!DJ93_&^|X+<
I4")>W9I@7|T4*DGH%&8.M.M6@J\$CM*6/O M+|+C#IPTVH+2|MP|ENNE+|)_S,+5+=<\$E;R6E(.7I'4O:
{89999R'D=C7^M1_0FIM?_7J=%_KHM|93;='6H\$7+OQ#S(I>V&|/QB|_H4U6"ZE0-B"JM|
MN3S<^WH!%1K=TF"!NSW.6RGR@<^NV1-'L_>@RUGBS(M;EB"Q;X5<|)W M@%YPN|_8?

H!^MF'F\$V!=GO.L=,QQK.&ZY+IOM_NI%VL05V:TRP3/B\XVN(F M,_.E?^L8I?
^(&W^".L_7_.\$">*&"ITM0FV1LW'5_5M^XADEX8^?7I E%:P M7TEE+D!5NX.X43FR!B(2W&@9A3/IV/
I#U&BM1+4I'2=3342(EOH/PR+1 I' M:F76LLOHY':SC;HN,=JE6@2.FYJYZ3U^2L>'M?GO=XQ0+6^"J:H1_RT@XYS
M_*SC4EP6Z'XVKN;7>5X*91COF7VRGXCB&S6:-+OV57XO M"?
I&_)TJ2^47W\$^JN.MK&IDC/%##3V3+I&UC5\$HEUC8WD0LX=-M5%#EC-*6=R.L.;H)SJO.J"Y^Z<5)'5?
V^9E@&I@O141(@,%2I4;6.Y54OF>&;BH:IN3K0578.V3I,ION>7I31Z^~Q?0DKV4N"V/I MU.WY-
K,^FNASS*&R17F_E.5P?RGWCNZ?I%#BX+K"A^~:(1IK<%?A 3Y9I M)I7<I:/EM\+A;XKJ5C=HD8
6")JBV#5SA%*F")ZC1L4*39YSV6=XW@I0S12 M:4B& MXW"?KTU-H9X5&^&?
5HK'D8I**%FBUESZ^V%OZE=>V.FBY?:3+Y42=-I0R.XI."Z MOI3;Q7Y7/?%:<IG_11WF<5-VE<,MIL@<I
(CQAMU5>R5LTV_M2Y66EJ3P5YN M;-I/>A>G=-&2SYI%/MTN^OI6TEHG1%+D&>1UE2C72:.F(O6/&+&\$ 63541
M7.V,."CZ6=M&UF3Q+SU@G&I%)%D62V\$?GSOZSKF<@7W+T94E2 MNT&DSA_Z^L?:
I2OE""5DBQ12_XVY+Q*MW3(I) OT+?S\$SHBA?2I4A8T M/M:EPAM.&2 HKUK5HO"8I#L"CTEFHKA'N-
I%4>I/WQV7ZVT9_I=+OO.U36B_M23NZNJ@3.WTT-BEF#L(SYCK,4>7?L>R@ZIS2 MM\$21.?!:&08QW"S5_R-
HS6,JH/OZ!P<4SI3D-R90)RVKVAPEK*9U?:I.Y.D M^.#70AHN7IG"4B4;P3WL;9N1#L(A#B I+IN=V)GN)M.Z+?
4@KL\$/M.7MY MG=#C(2V-R:MSS<,*>W5/Y43RF=I\$!+<4)H'W5/Z9%&I!EU^*)MU>3P_*
MGLXY3R+5X&3V.I>1#0M8F7+%=44ER>J&R+D:5E)?R5A(5&N:W^O8<;&#IHI M1B123Z01@CJZM0,*%;
IJ+8.ZRKQF^U/+RX6S=Y.HXISZ2YA1JDR018^*K<^ ME?0CMB%MF4W-'C#*DUU(6G-
:DP#)FAW"0C2,*01K*4;T+HAQ.YFZ+*DS3_<9 MTIMVS8&*?^RDK""=-
A)SSP&2(900ZPV:~@..I^*~2BIFFI81/W/IXK5*5X M#?9IFI6\$B=:5"#:SDCI?UAQM&*C1X,0'O"
FYLSJ7"Y> @92A9;V5 Z>'I.I2LK"S/S5M) M.OG?ABJO5DZ MGLZ#%)%64M1WN_6?N
WJ:EP,4I\$C+T)9Z<;Z&1*/IJ="?3.+SN.Y'=% MNA.5<8_CVZ8ON#G14'U=<.S7SRI",VB\$BHI
IQ^@WTN*GR^+81FJ6G,4'LA?0I M7UN54%;IFF(O^2ZOL!?!F. CJK3_MWB
)/*1'&XK&/=G9'SW!XI;4W70I'DYMXEGX+N#J;ZSS;?Q:PDQ%_&+8I9 M:WN)%=38%I3I!'+=
(OVO#J:9%'X7'DV9Z\$R>XWUG@+I3D+FIYFIJAD+S.D9 MT:WW#P>D&+9*!2/UHHQZA&@L61-OA:,OKRKW"
(FT&^@HR/A1%_<#2""(90C MKG6IDSM7I2AAG?_) "M"R^_0I""/KAA#@0/V=I;:-LL')_.PV(*D*JDWI4
MR6TAQ%,YS.4H1V> 3*~J0_/C.:R.A.WS0MQ:_0L?IJJN7:5?J:NI?9F: ML>M0ZL:QX1G/DC%?QS<9*MZ:J5
P4.D7=:8W\$ _L<: SM6[PT513)M. \$ M:K;P%X9)'7=IB=JN8)S ICFK528+4C8_J^Y3"5<7WM"5FAI*O(9I@><"/
MPA+3I1%8_*RUMI=*:(1H3VBJWWS=LH4\$(D904*6G+ITX=/49H SI%*E6 M1#1HP:
(>V7CD+&2^BGBV:KHMD9H%-TWAGI@/_WVU_ M"OM^~.*! YIE6?-'5;LW_:D10I"\$)3+I68Y^&"WSAYLINA)&O
8&L.%4 MK1(R=[^:FG7UIE9SJ1L""MUOKB;I-BE0N=:74RD?*KVR)NDTUC>7'4 M-
Z8XO@VXQK*TK< 4SISG:Q"Z#^~W_2_"@6*B" XI/GT#BTD'9H0: 3SE:Q MLGZH9BWT+E.<IVN'-
Q@I.FLE^5PE1/0ZM5W'.OR!5AG&"!3MZI!9EQMX6N MOJ?<#3:I%-S71CPN_."Z'T.O:I*+V/O
=KA!WOM,2/C31^~04NRCF>ISW_J/M_!F9_R:+@/0ISLM1A*PHI8<9=4C#1D%YT#?AIE/NZ7:EL-?9ICRLGT\$Q8&
MK:N6VQ8%8.S9>HL?P>>E\$! ?UZ@!<IT+FG+BY#BZ_4N&8VIOY+S YHVUDGZR8IYI-#:[T!@S>W
7KIM38_0&IOWI! MTKQ6&I+9S'0912*+JF(C)3G.3"IEEJF=&6 HIWV@/_CV_8UM1L4>[BT M5S>?R\$;
""H0K6#ZOTI&^B%G3,@BZ.6WG28H;R>4FYW1%VVY"0>QEPIGH M)"
<'DEJ#YS4&HS:+%H9!DIW#&15;0G\$Y9@.8+83KX=)WZO*F%X>?APW_ U(MCG2S(J2-?G:\$>ZUNR/;#>I&?
QD@K7GAZW=4+%V9L/7P^BLFTI#;3G@^I.= MN*.U0_#PI*~&7\$S7"RCY(54QYN0A^M""HJC0POO/><+
(QIZ>5S%?2L4FTP(M80IGI@YL2/#8.=@:BU1:3>"Q67)WW^*D&TXKD)9!" MN
)239P%Z*LT%N6K642.LOFJKST8*49/LN?I7F(4E.'VQ0M^ACX_-(UJ&9I M==@MMV>D6IWOW'G"E:
I^:9MDR!3(SFECA4P5XX50A-50^I?5A^71 3I;4<4X&1/H*X?2>@SP\$0@^I@VX\$N+/MON,73_-DA&I_K6;DXI2
MB8 IT/#IK= 7C'Q2MTRH)V\$D!7IX@S%@"65>YIQ*EK9IG)IRCXY+5P*UW M8IM%.N/Q900IHUQO%>2Y??
ZBQBF(EK'4@NB?2E)HC162I3;BJM7%16Y8 MW8WMA3G)-O#3-\$BX.6WB>IYMDTELLWHW M^O-
B.WI"COQ%Q*X.\$*Z%)8;2./9=7L^#W+%) "M1_%KEEJ9?Z)-[PUIPY= M9J4*0)U^P1O);2I(AR'76YLI)'
M'V_>2/TL\$9%G8'2Q6>:/I/G!PA.H'/C@X=HDYG9?H)U#QV&IPHH+GA'R2%1D
MH"5&4G8G9^\$;I_LSH\$;QS+I3IIE:5:6+A08I/D76I)X7(EF<,T",#/*S
M5;C:S;G@U@DIDF49*6(I)R#K(3HM'#4N\$NIFGHSU\$GQ9UM&7^/A'W78SO&/
M&=)/L%+T@0DZVT%)!..!9K3G8I6:;#I!>0PQ.X<0<(*P8;EB);\$/G!\$W^C2*&-V7;H>@8\$+J
M:QK000(1\$1LJ69?)9WF7."VI:S=O)Y@V%O3Q^~JG&I+U?F>I+^DX CKN=="15CNZJ>K;HJ
MDT:OIGY<*J1S@;#_W2:16E)T&(YEJWK_!..57(XK?P8)9<\$U\$S0<+-_* MW18Z%
(WGWSV.5=I0L2=8/HX1%W6%W5YI\$Y1&R^7_% MP0>G=IY:DFGCINVI4E)!8S%*4.B\$6'(%C'(XWH&R
DZ443.I^4B'V/XIY;I M55\$YH7G+XH*5V7OEGM0KLR:O"II^LO.2T9OIG6IE)I8G)ZZG(G^IB)&' M?
ALY(1^>9535G7HJ>Q!C:UA>@_ \$7;Q_=(UVH2;HFY,60&3,%1^M<I+I/R>:"^SN^K25 K-F+EOJH*.KB M-
7"H.UVYRX-LTL(^0!2I(DIR"2LD_(\$ER:8#W13M<96GLPT+I75M;2;/@X M25O?43I^_?Z&T?"O!WC#;?B7^7* 0*/I-
:8_084+8&_+1W/0S_XN&M^~) M"~T<45R(5>%0YL?DLES! M?6H2QILZ5?=@YY'TO0;HJ?Y M-
"FZDU/O'5G7VY;DA+I7I?E7RPYJY61?)JF9!8?B;O7(I:AYO>?I?R)?TG?QU MG\$4R,WIFWI3).D0#^R3%?
O1^I)ST95!A+YN.M.T0JHJQ?NV(XG5I+DR)K MY>J)CV?I*K"E_%OA?
>1SHGTEFL1+I)LOI;Z^P;4."2R)QC3EK2(Y)I36 G.M3)2FHY?QM."TO_#."IYYILRT)\JP!Y&LF3L&/>2(BCO5L9;N:D-
4,>VL Y M@T)(C02EM,8;63I;%M*IT9N<_B'9ZN#-MMR;8%_T.FUFJXY9I\$C6@16EO-'
MINLAIZ%TEE&Z%FFK92I@<#8A>U&B%41_~Y0',T\$(M\$167OZ3(I<+QWCOBO
M5IT.\$>I#I33M;7^0>D2BDFZ,CG\$F0A-KM"1?M@A'+X0S4I7E10'~HX58% MG9&"O":?Z5+D5R0E'5%OR
S_E@7_.*72U90?Y;OCQM!%XZ)+HWWJK7/3VI M+H&G^@Q_3KA5;I+)ML_R2::QPVI(*O!BI""B0C\$W82H!4K6:
<(BETU83\$A4Y1?XCUK)<85N\$U!T)G9I42; MI?)LRRR'KC9G!I^ZXIR7D^*S-P'Z_E6(I++IIP_!5AA%8CPIXNY\$-
M7I M!BG8<\$DOLECHJZRV?)V<5L:7FI>RJD_KN#J>%2?_F" X&R%*E;E"G)Y MJ%+P+P.GWT)SD-
IIGLM&=SISOC'8YD.YIS;8&O^~.IV10RZ'Z5;GYO MHE^I)(I0AV4_OJ^!E;D>7#*%
Z(H.ARK&I^R)G2*PII7GR%#7PG0+IV(I MFGY(R8;."M/GLXH?2_XW"L%I;E7*=&1A.R'7T&L%5QCHU@!(CB-I_BI
I-L+ M6+IL;#\$_-VZW""(>+>FOH4J-D<1A*M2IL12Y:I.G289M4I>U2S7+IQD@GMN* MC<U12#1:~
UKGLZ(NTA=R/+Z6-N^~>Y.*L5M9@\$T4T4_L48XP MIZE=080&"!2>3^4NU-@!""OJ=EO;=I-C1@V 32UK2,J?
QQE@EO M_LXSW_\$C"QSSII/Y(4KO/H;Z;1MJH7UJE:\$B"799*\$D4XTD=SI^Q52UJJBH M/PU_=28/*IB^~C2*%
D#OZ;O3+I A IPR85^/L25V.O03IA0K\$S1+S3Z_Y_M4L3A_-9.J*YI\$FD:O%TC0L'_#%
SP>PII^M!8\$1V;7K1FY*~C&(N M<;ZIJ.7K.8HFXYUOHDPZ_JE!Z_B(Z\$BPHO-I(?ZJ\$OYM.SU-.TH'W;@%KB
MN581.Q-K2Q\$!I<-(OW-WPY_D/AZZI?P*Q/#M^~)9_/3&4;9&D.VW2B_6J MFAI6*S.9PH#N?
YOK_2C9K'12\$JFH:2=H<~20GIR_4:I9G!7F-8K4H4I M771?%I5D7I8!UH(I(F88=6^4HPK TQ&E>REX33IY.Y;
IPX:N)=#IR=5I M^RH4NHUP)\$X.#O.Q.?C=>VPZ&SIV.I>-2;VUF.IR*C&@G/I^I TE)~Z7Z
MTIOO*AI32*~K;="X%KUI*6W_*6ZGN4.II=N?&I.UIU2:4MU?^V M._Z-3_.C^2W73I+;(2^4LFOXOM9X>8I
<5%6*2;NK=;&I%K775:O M?V7H,7S\$,FOMETC)H:ORDOXR_D63U*U9S#<J<I;J0^#U(O>6:Y;U1G?
PN;7XJB""YMF4XQRR? MAI\$5A(>6B>M@6*BL+JUPI+PI.P<6;F(K?OGVUFY4L4..TR?3N&&=^7EE1M' M2X-
0C04(K;Q7\$04EAXIKOS""749W_TIG/_WOO#*I*H9IR63=WD3Q06)T>R*B M0XU22W)/?

8T5ZI9:HH..U^V.+PXXOW%KWU.IYWLETMTM.-H(CYA:M3APRH1%Y\$M
M>KJH5">@1QU5B608J7VI=KQTLV#DTJ6:3CFYZYL&K=ZT&GISW283B"+ZX8ZQ?R8S*H%G M0E'/.% WL:4^)^Rf 5
T0.15ECE10)Q(HFM1TTR@H/OO MV.3\$L.81L5DLH TA4P>HCE9\$A8(#:U6N(C(OF.:R=D.CT=#%31=PUK\$\$.F
MUW1F1K%K^@C(F+NA0V>)9)@PXQ43B".*@RX3HC&LAYTE#F;".NF:WB^XLO MV^4K68AWBJ/-
CXIYHID#MNDNQY2 PLA; &QFO.E^C "93(E*F0.16IWTf@Y7C
M5)ZF.W&K^9EX5ZV!0OZ_R>6C/-89#XVD4UWSXE.Y E=K659+T50N/VX!P\$ MD('\$>B+=.,<
C_VZ9Y8RLS)2UB/6FS?ACU" W 27U!8&D7WMV2I(H:5^" M\$/50@,:)=EAU30>*8DV?
=CC=U(<016:FBA!UNER5X7>:5&H7O8(E6AAB3TO MFAAC,:_FK@8K0W!T"
<8!^0UF=BN5F%2I4IXTOCWFC/BA:/(^JYY+4#IGR M7SUT%00"81)HZY/4>\$\$^EA^Z9.I/Q*38?
&4\$HPI(7.#X01:FM!SY*G.I MR?M+K59LK7.1.R8&+?K>.&FTW?U^*=W(-"WP14?I"Z7G5/W9E!?:. WLKD M?
QZZIK2R@IHKA C0+ C72!HZ\$N?11;^VE+@PF9C2D:2FB=OS1&TE"-\$J-9QS MCO.84/1_-P78F:BFOQ;#.JL\$R!3-
U9QW4^R/^0H^XNR2M5KUP>+(QIA(M9+5!)^US:DI0T+?#F==W6IOFT8:Z?SQ93GA1&HK^TR\$NX0?
NCYGN=I^:YE VJ SB?#92ZU" C3Z M0Z0_8F" TJP3.&ZFJFPR.WWM 1!5\$;E.7SA:1P; M.;UW8KZ5<(L?B0HPC*
M!Q!7.#X(HQ0PX?QW23PP:&P+Bl:TW0@M.VJ=N.\$(H4 MD/P0K=9<5YCO> I?@QHW" ">?IBA=Z?"Y&IS
!U7H0ENFR2W_C94:KSFG<# M.;?VK!PEZPJ:9VX.;?)^TRKWNN(D_F6/U?9UF8W?_H^AL_4PNCIDVT<6=D22E
MAH+8+H.RZ4Q%E8 E>F(CI"XY:IAQ_ JDP5+T!^D27VE:BC(V^2MM5DQPR3
M5)7.3#F_2.\$H%39QM_5\$Q*H9M*YIFNNAQ#"||2INEQB1+R=B;K4XULD[U^YD>#(85I+.'4C("FE MCEI?
0.>8%K^3_S_@!RKX>PGXJ/B#RTCA2.DZ?O;S@003G\$>I09D=: M^M/RV;J'2^OH:B:DK9A3I?
N!0W80T>519:MUAI0YFR2+CY?=[7^E;U6T M#6M:IOF061G^&>I= @00Y?..N67R!^EX>1SK4ZY>=C?
4X:~J!P8V> (9#J/11 M&f\$;XK<-EXE^FW6GH\$%9A OOKL&4X1Y,U10!>-L>>IG@T3\$SUQH!*_IK MI-
S6A;EMR1AYMC1\$[22LR1SI?9"\$U749_26?#TDXS-JMF/^JCOB"!HO"J M4E3+?6MCNSOKFZ5W!_+G &PO@
?,>0)2!P@/ZC34J7XDJBL!_ K*M^IE\$+DYT*/_P3IE6,+JL4 MFFEU^/FEHJ=I-CYI?N/(@
0I(ELDJAD@U;9FC.%+.#%:I0964!9*.IDP%R&IG2 M8U!8)BW#4:~TN;A.XHJC; >6=E^16/51NMS^RO<4
^4FLV*3JS"6:~^RO M3!ROHL >09(+D7(SU5\$US&0GO<8!+U.45F@Z!9V15C81-EJ&L3P_G-H8=5;P03338F
M..3MP=D79%=:K0I7IULA3V_/AG:IYZ:XO(B:"M\$=C15-C:52^++E=>L<;O! MXJV19&/=
^T37PW)YK1XB#MT(F#V.%SMX'O*#J*^W7*XWJZB8!T;Z2GfY
MXE!Q44004WGQ^Q\$)5CM3X4.1+4UT^;H.H>:8(EJW.UH+47@.ZT_%W-3\$ MJ?..9fV!#2D1.^*E!CN=^(T6Y9?
@JGGI71!.#O@DA=L@AL^&6/OCK@5!_+ M!ZID 9I<%;YIE@f%J^<25;@. Z?=GB%<6K!^V^N*_X;0MY>)O:D
MME_12G)">M4@U_AJ^H^7RG=>P^9:F..IE>I#@^)^7J1RRO^1REO=%HIZ=> MSP#55JY#J<^PMA!QQ_UG^
HYTS;#=#0SGWYQWBV#;)H3R\ LJQ)U7:3%8O- M3TKW0=PXJ<<0N_1I-ZFP/*P=U8VB <^ HC8T\$IKY7#4&C;7T7?
TWS! \$Q9_M-F>|B15\$MJ@.@T.XJXSR:3OL><6O#JA?7T\$7MG9W5IOKGF"= _65HVA-M'#B3 M7M!_6*
4M&HA1G|=976.H5CUOF:7Q!LRDOK@HQ4_NC<'B4_U2^B+1HVIHV0!2@7Z:T0!N:C MB!IT"
<"C1(1M9V508UV!C@NTE0Y13+T<1;HE%-%:4=J12*)^EJJP+EQF!(X M/%>L7J@WBQ.EIEL7K?~GKIG0ZZUMXHA
2@/<900VN5+YU=I^7B)VR^8JR MP2.C"A8:~Y+^O37<[RJ3L0!52.IQP8H#Y^AGK=R\$.%NX@^GXG0+99!8
M15EXB#3^VZ3#_!UISR^NIYQPH+X-KJH+YXJ32=BM5F%(!= GB&V<3.LQP MPW#*OVK++
(X62(11A430RK.O0C(Q.G@"3W2(LK^PB.H+ #U7>(\$:4I3ZR^K!|=SZ MI; @HC2=K8QR"/%C\$Q="U"+K
LAW#BTH>KI*TPQ "ZD!<(TSE26B\$BDMZ#)+HP0&MN98@A!D@U^SUUM#
(VNA:V01H@REX#GT!T(8G>/E2>&.)QZH"! M3P2*)-AVJ=YY1%?R5T/RJ2O?QX^:Z+?&IULP..G5M;M(="*?
D_ NT2C:~R MLEGKM:6U63:1F DG/N5^@MA!E G5^;=>)UA*^!NZ#_@C/ M2#UHI=/S_B4!_M9_R?7_&QQI6?
P3;D(#6!-D/""""=I^0REG@L<70%AM&@8^U.2:5YV4OZ9Z MX_YAE4/R*6C;#@8HYCOR.7)?%2*~Q-
HJ@CIR%OU)8T5:HW0NQ%\$5JA"V! M8X88B/H&G9 @OR:K6(f#&7JGUU!BA1/7V@H(G)VN/AFUY9Z3FAGSC:X%^
M>NS(U5!5K_YLX_JWVZ*^3:AJP6_0"P8+Z^Q#_W\$D%D%3GT.T<+^UT!IG MNJ<+>=G5ERR!UG;^Z2GFU0*6;
&B(-_TT<E-HJ<N=CAQ9NT)X*Z?E MIHFFIY>3C^X?#I5V4C%1.OE<6=ZIG!HWBG08GVY:2Y!P3;3-11%:A9?NL
M;F!)<@?B(+AWNKFwj_-IG/YGA=GOPPY_6WMHJ8(6PT<9;O!HN1FM\$/D2_ M"!7X3G#8361-)B0QPIWE!45)-
XOO&QK%9^@VSK\$OAO!J!5M7Q9Y@J:)1Y!H:N0/" 4@:!(TVU_4IB2GUJG.V.F9CTX3G;GXX#J*B9 M;HOL
0TYR:@AI@VRP!%_JTF!>I@=LT3Q6+365=>U.1K6+ZO*7IR/I4_UQ MFI#(F;K:51,2KFT!H+.3A^:H!\$>5Q:D-Q<7
CIMET;J!-QSZH2=(L2R.SI MX:~8:5E*4W58Z&S=M"IC @KP1D9"QFWO=XA!H0S0R^7.WNIDGD(HU(HDJSRI9
MJH=6EHH^B?WYU!^!9@XQ+-W+(!#:#APA!T: (SEN9YNKCK96^@:<&L-M4:
MS:GVM+D1Y!LH8"M\$GHD+@>_L?:"HH#X73EM0IOFOR"B\$@S>?BBC%\$) QX>_ M<"Q5U;FDL-
PZ!_BB&_FX\$ _869YZ;_/R0(@9<*5R.S+6"X:~*)8 M42\$DSOBR0M?UIHOYP9^&%^&#T5<2)W64#DO%GUO.7;?2
2"&G^N8Q16_6QF' MQ&Z'(KF"D:9QF!_7STK5\$*#2NVF^6!^N-4WF&AWGW#82#^+214+H>C"=4GK M7_#RO6-
:5:~KME??Z\$5VVR'WMG8"MNJ?..9KM/5TIA@+B?^XAMUT1!S44 M!VC_J6:RDKR+E_!IS@5H):9/329RZ+NSV_!D
H?? Y8-6" C51:.(51G. M02N'N\$%9\$3ISQ6A9338L&"X5ZH++<)-1B9ZS9!+,\$^UNFWN-W)%W@RfB#WOAK-X
9^&K MTF'2A M\$0.YPOWYM0_%@Y#90/HPQ*.*%7)JMU2+WSYU1L#V#/Q4:M_?" M:5(&(PM,4+I'9 J"Jf3,H-
Q"#1.%&OX[U@EJ-@?)Y1Y^Q_&R!HC.2#!_ M5BL@\$3=<"N>BU1QT58/9-
A!^5DF4>W!M4D>1DW#JK@FO**\$4L^!U^X%/L/Z M6ZN4+2Y6M4+@U:)P6GT\$U*48P!D-H*18*M01)G;I>!,>\$
(HFF=9^G9NW MQR%5:A^7.RLFTAS>SF"6_7E"J\$ME^AFX/LDB*!HDF_?@;FT_W22^3*1XT/H96"0^GT\$E.C?
BLF7#_RWK0Y!8!@T_8!3K0-098NE9_3<5PR^U7I2WW2V02BG M-4B:8D;I+:TCDYC_-RE@>0.XBZ\$6-N(A-
J0HF^QQ_XFYH&_@' R3K#7_R M0\$Z#L^TY6WI3R=:T"@.***#A!)Q3IMHLC0I#^EB"L%_158KMRLGG%#W:4;O
MJKM\$YP*L"".\$!9NE!<\$1P:OVR!2FU!LHKL/WTW.)6..?70-/P>6!NYBB8& MD:=H;^6%!5X(%G;=&[X^SCC*\$Y.5-
ZU_W8GS.2H#3Z:R(3-3%35/IAR%N.1C L/DX?43SI?@9(KJ-=I600YH9^P6I&CQ+(R.L M?ZH?I^X#)5=.6^5=:0D
+!&2D)!@L:F69QRYQ2XDB"IU/O2Q%Q!XD:4^DWE M&C#7^0.SDS(2!^=Q0B)1#TCB0+7=>P9FIT99NR(6D_M8\$
"D!HPDI!3B\$ MXHPBU>?ORHESIR:T!@0!^6UZT^@:2UJ^XSHJQ;+\$.?@?%BF;KA!99X M"!FUE*M_*VA2)!WI-
!AH7_Y+YG2XZ6&006^K4>#/FLF4@4&?90\$5BQ0-Q8IY1-7@
M!X!03FM1U+9NMG0TIGfWEX +^H TX\$U\$!DG08<5U#41;H M8WW+Y\$!)^JG'5BTV
!DK(P/V2**!IN8SGD^@AX.V MZ=O2I7%K+V +YW#>YDSP3GGHR!OUSOP360+XGT<\$!HP63N>9E#*^ESJ@9!+
MBMH+!+?GR!_S2/QK)-< &\$SB/Q6&^YVK%+SR:63+U6965!0A1*)):ZWMK_A/
M<,N^M?)2^XE^1:/@!U\$FR23C5%8K@T/IX4<.)20_J9%^7)I4-2?=" M"HUO!H-8(ZG7B%0E5)E;IAM_/?
^MG!>3SESK>E5U=+/KE(C>YHJ M!YIV:J2WOD(H6+/H" MREQM9C;M&^;C3KPA!0=UJXU7B@V#@T_00
M>0W/H=DVO?L2#Q+H^!^?0(C^NPEP85GH8_BJIG.7&59(D.E>IDRN\$;N!*;
MV2Q9AP**_YR03&^3W2G+O00P=?;>B?V<28DR!^=^GIR!022 M<<(\$)!2.(^*7T4.1(69<*%1#&N+JV/1.<.-
+09.Z/LU43#8ETF!\$+!GE- MB0^#/_Q!6MH6+2L%_00S/46P7Q(F_?><3!^!UR)9R3N^RPI&ZPP%IL96T
MY+!/IHN^~735LC_..MRR12+!JQ*%83NV%WU_Z_P!;) FZ7FF5SJ68&BB M0_%V!H(GSPFI)!-S!?
3^M.VCYD0S0T^@!^FH3?)\$!2HGT(9ELN10A.B"; M@:EL#%!%/P/T5Q^VR6+CB+\$ '7W!TO3<28;T+L:1+\$5?
EH)V;4<30ME@"8* MD%YA L@_**8+^F&_)TLFRQS5FN=9)MU M@"+ZB6N4L!/
<.:P.YD^34LN^06;ZLM)V(>).ST\$;MUJ(PVX8VPAGF4%&."XRFIU6@*>WZ!<WGO> MOC=3
+Z<(WJ1!9Z!5V:"+4.P)EU=T?IO:U2OAX:T!K^!LL?UZD?/*IP&CG7&2_0O:Q+L#HEI70Z M*A*MLK_3YU?F6HX#PO?
8N::C(1G50_WRf@;PH:U2T8GU/B_Q\$?V-"Z\$)NGB: MZ*\$\$.M.Z#2=X<=<%P_G&99%F2X-H Q!>2;+ #DM:LT'WED=9

?=.82LM.FM M*R<.T8=77U 5.=61R?
\$U.QTZ8*2KMJ.G%BL?"D^6.I^D2R).A\$6MIOGXZ2!J^3U2W&HS.3)3)-7D1L=Y7*O M#O&6C%0L'I@%JFV?
!YW=,MDEVTEQ>!3AE&_#11@AT)I+B+;MIWS6")K?=-M^+%;?IGIJQ5:HS.RZ=112 KSE5DF 3Q>.:KWP@N-
2&^41)("8%>XE=-I.M:XQIX0&9%&AWYIGC?Q.TA 2/4.:YI+A@NJI#AUJUJJB.U&="4"Q.YE MH*.8%4Q;+<@6G?
?"0.+8G083)0H.9.:P-(+<5D5JZQC!5N@EC5U1/K3 MQC6G<I0DM5L221=IY\$4B29@&?
AESPHW%)J68;IZ46W=?^U8.UPH/ZNVX=A MYOKP-U.3.#X&LA5\$2*6TL>AW!QL".N+D&SNW.G3HW+7H*WN"C
I;W;JS9I3T M(DOW+EMPF*!#(R0 \$!2;.F3Z)%O!_"(OIY1H?Z4" E?I- HW3 MDHKL)0EC3V-(8^S%_E_R9-
D8H<8.QRNI9^ZI 4 C+.FY2SKX%:N8+60K.11 MMT2QN_4P4-P?@XH?R%JD_AY?VD\T%0AL
6^T.M37^8)55GF@R3BLR/M=V M82R%HB@8SW%:?\$?=2%/_RL_EV&?P0*AB5,"DC*G=0(+3RKT*EY;+:CLD#('I
IYG!_P->HZ-&8Q\$5W0NF7P>%"MN9/>-EW;IF2?SG42/5K2.9@F4
MH5P<("ZIZK4S!3MB%NMXI("C=R^SEG5EP#E/M4-LIU W^UQ#ZIAK;-O#.,G M@;&+4V
I&HV!STR^C1#_7;L+4?I^NYLWHBS3EF>^_W=V=OXY_IH_V_VS"
M95Z14^M=2M@50#_2+;"ZA\$2&OR5>%.1>^6UA/=;57G(@Q#A):\$IYFPTIX)
MD.):8MJ&K1A!TMJT.80\$W13M^F&R,>E>I_*G>SLIMR0_\$%PR KH5G:A'@9 ML!/"P=P./:-
D9N&6H1R!4XZ@S9&^5ZA9F6Z!9S%.1:H+J7J3XB!^Y>..I MO*4E)0,BI")W6:GA8>JD(X.AL\$I@# /@*@/%H/
MD=CV5G069!^7;_#FJHS.>=ROGYN T>R^AK59+RIGN&=C%/I_1DGCKK8+=MXE?
EYDJB>T09MI/96.CO!5^4NESL:L^M*H(U8F.H-IR4UP12B28T0^#(Z MY4>M^3V@>*
(SDF">CM8NJE.P7D^8IH.NDDT>1.\$P8RU^6@5Q0^(@MX R?28 M<"%2::Q+!)VRS8<V*;T.J=?
F^HJMD=\$>:0@.Y5Y_K@2^X#"(8,<6I@7B _M%:YX@FYFY=J.NO^UOGSHF!7^,-^F"%2C3!OH6KU2,-
OYH8%QK3QWVA-(EQ>SSB)"="M&WS84Y48Z25X(H5!TS3I#>DL=FR!4Y2^LJP^84.GW0=6)(R7"HZ\$UXKI_-
MLL>/5Y2TO8X)O(N+1OSLY^UQ^Y2+^I^OR2%M)V>1DKSK_-F+G*3H_5^L.*<
MBV^DCAE<0JI*\$VDYGI89Y4M1\$9Z&I#EP!9#16-S!/?37!OIV?60!BHM!_.MI/RJ^4OZUIY:SQ&7Z4A8^Q;B?O @%
!-<2*3!5^<4MT4HGU)<X_Q_+N=\$7 MJ1IV/I SVC*^OO/&-5?M+%;!:=80!&GFD>%"F'&#*^=D+=O=C^R/F"%Z!
M5H13_5^8W*WJ%!"@3#C5!318_\$AV:*DI0!2H&3!A3S?P2H!&=;?;L;3
M4M.7K.XAG\$3X^R1<*BQ^L^G<6VBPC.XR00SZ_EG@DM/>G";<.4Y"#MKC1B" MBACMFKSF)%22,
(C3JH+JF:ILVLAU!S=?@^OX?_0KE9RY/L)"<I7MM_2)=V MO5V1J^&%5!6W@&L<>-
+*QD_AK!;IE/EFQ?J!>4&^!&RG-TJ7=I-&:/^?UY M:/CS0C.INL^3V?CK^BXRID3L8SV?
7@NUJVO8ROA\$:O*Q?@?>=\$4I.T@ MT4UC^T R6L0:IA*9_5%1TA<SER#^!/#><4YZ\$9.VEJH!-B?Q?IAA 10^97%
MG&J8\$NH(ONV+%-T56Q NSRPS^E2@&C-5R-?HTA>DK=^0!ZEWMQ/)CD_GT MML!)?RU5\$)B^D^
B7M;.:9K091QM.#00&G-BI35L/%O; U^9N7/V?;,"18'
MD0AQGP38(+Q2@YZ.U15N!3;_*EVJ&D*U6!C>32TN^8F%SM)G;K<%!S!%)MM15R;\$^!^ZYQ;C;V>XXTJN^X=);
MA!W;_>)&-!5!+ P04 " #!@7I9!0C=F\$V_-#DI \$P&UD="TR M.#(T.3 R-5!G."YJ<&?LO^DXE/-;
SS(6K)G^U/V):ELB4PJ(4ED%I-FCZ&(M.F8L2^80BIBR).MD+V"(\$FR.Y89(V3+#!H7L!U7O_NY?I^I_!OL?SW?I
MO.?HOWTYSCEF8N>:ZSOA?KIG^?EYVVO8XVP21/C218N+&Y.#L@+?"@W9 M;W('WBX>7C^8;S!?*#Q
MO#PI>7C% AI@+ MVRNPI^!2R_R+V EY;BXA:@Y>\$5^-
I^V)A(GR(GH!>I"FGS%TPOFIE;7+IF9^_@Z.3L7MX_O >"0 M!Z%A#Q_%(Y!\$OE9:5U_-5-S1^&^C4WH^O
ML_K^TO-U<&X9^1L?(P2YH!^P^&MIF;JON?6^M@WLI/Z-BP/"Q?&OO!9 MEP@8%^?;>#I&Q<^9^C?
\$T3VUP\$R#XN#G#PN\$0@, B349"@ M^ODO^_L/VIP^DT:R_T!O2IHSVF#X&>_P@RO\$M@5^X?GT+;--5G9ZV9
8H!\$LF8X@:!)@>-D7RJ>YUZ-# MSIS^?AFJB3C<:;\$! 4NJ.XAW6*L>\$M^ANRQ9\$.B/0\$%VAMF(M*?A_9D6T M
>:I^N3IBAQR/U7%)M>V:B^XORVVZ,"#FL-T;_??7.6EM@ISQB@LE&DTK9 M\$^C..Q70ZY
)"%!GZ)K0E.8)F4,"%!88O6PE"%)/88+BGCK:NVG\$!0L!^O_ MEU81GQ+N+S:M2=M
M26 @^YX_I0Q>QG^@J5N9C9L7;_XFKTO!=-88^YETPKRZLLGZM.3IV<^NU MT!0B!BUG+(U C-
X@B6GJWEXQD*0.P^5I! =@.(^Z+%SW! M ^/(Z3^YQ;J:V!C YBCA+(\$@GUN<:6:#>YB@+S6)/96H(NTN^LU%O>Q
IV MK1W.EM&Y@O!???"Y\$LC+<6QZ;XHSB^N8I9#B/%XO;I2_@M.FK!50H*;5I
M!R7!AK2_HUQIMBM7!OJ79?I8SN6&FWAD9 HZ;=_FCI MZ?&JEHJ4ZFKW<I6!+6-OI?)-COF-PR/IA?
XS<.."U\$JL&M@TVB9R.(4K#^S\$N:S)I?I/PHX+EIW*N-V2SIM> 3?RIPN#,@YB
MWW:X@^YH1392J;_IY8VMW/K4OW_ED?/K+%/R/IRB?_ID#LAX)DH%:7ZXO\$1SBR8:&F-JJK>\$ AN.^>U;!7<@.
MP:F!@)5JVA:YJ(Y9VJ)"H52/IU3D=>H.Y(R^\$O1V(V9BOL-KMQFB>IM:E9@?^<10F^A
MUT;PZNZW;/L2%2AYM;DI5-7N WI-UON^%V-!>="O3^G&4.*&7Z=SX<-
M\$3:6#>NVI+&E+MJ=F56>N<I#G7(CM9H(9^C?"?>OMY&CP>2G&CV-I X\$U M\$)6+C^LM0#S%NN-
T2BTY^U@DAB60#+=HOG MX1,2BR6(8GYB:3-X Y8#D^ZZI^2N+NG-'&R/BIN^TIUZM0I=O3#*_*<_
MTINFO^X J737X!4SH6FM1#:\$JVJ8#J^OC&*^OPL@6)@G6Z+;I-G0WRQ
M<>XRS^2\$N^RW#L,8NM2H!B2J)=5^DXL#E:QN&G9-XU?_I8H04H_TFI? MD+EU-7E_3@-
ZR.GZACFZ&KYZ^ZSXCEIR2N7!+@?5R-!BV&G#XE%(!C!4\$+ MMJ%E5B/Z1P*:-
=8@SH/5@V&^TWZ7^6Z;RHO6I54)/SYF0EVL9R 3U M#4.Y1@24>5-<:6!>^?9#;ZVIA%I6+P-
@R%+=_OCCAFW0>T?>=:MJ^2/Q?2 M?E(!:5205G9;WIB^Z8V13,T^EK3^!G-C_H.X!M!3+9FU3)0!08N/7HH!5
MSW-1Y1T^US=-J#T(L3P(!:5!58S!5W6O-_.3FL!BN0%:I.ON2#^UNIU M!EC:D.L\$""\$S4!USAT/L^M_?
?73J<8IME^T^XV0C13^R.TLA!-/P2EWDRE5<2IZM)P2^X4^I^M4<(!G8'
MCH#.*U0MBP!KN8ZD6^G!B/MH#^C@%CKZU+D!J45R=^L2&U#S(KSMI*=JZO-M-4L*B!9!QG6H.MWRY5H^Y-
N0!J- XB0D!\$YQ1XP+L02TP?J V.47I+^JA_U M...
4A*CH!%VO!M8=SCDTYKQX;ROIWHT>I*WDECVOBL^U^&^*^N;?)TV%00 MW+E&#P+M85P7I^IG&XFSY-
RX8;H21HOF4^I#>L)+KK MCJIM-X?W;6YNLPU3!:=^H^LZ#S."43+I+A7HG)H+K =+ #+;NI6);R4)<8P
M^P59AREC+5!-"6%WHI9+CS.WSN1YQ(PUC0&'7\$;6T!_?V M9Z%RZ#80Q+=3)U8
L(Y!-5%#CM13.@ONG<^JC5^#G+P^M6R8P.SZF"-I-M^2K1.^Q>QB@Z.EIK<7=3QT*FQ=IWE!C
MERW+!WUY^3Y(V^08>?IA2L\$RD-S3!Q2G_HC3;B>^\$8Q.QYIYR;):84
M^!HPUEXL%7L6P!L9FL:3I&=QVKI!%.EJ^M*#_8WE;UIYPO^R MK>./!24ID\$4<);_#J<N)D1GUEE!YHC?HG>I^\$&
MA>T#^/>FL!&@J-(XA9U;I M';<2<*H=5;_FM/WD0Z/2IY\$1SM9!^0LWV%\$R1-GTC!0M-038GA&FTH^1 M)
IL469H%:\$@L!/4*)8ES_-6&<)P&?9\$"\$D)S;YNN^B<^OU5M!_.1.4-F0 MN#?
T^Z7DBR_(8Y<+N1+1DI=E^YZPG+%4ZGIW8\$IN<*8BHONG?2%!)#/ MVCI?
V1#5V.N14%I6D5B#6..EY8<8+7;CV\$^R>&S^AVYN08J5-Q3C_I3W6I-
M_UI_1^O&E!5F>^O:E@=DVI_!%@01!L6TKT?#;W!K?B^E2S#.6+*L+5H.M69DH0#2A/JDN@H<I&76&
I4I!^=PLDIY^M2SIKAJU(6G4LHF9WQ#JFUX*:MDET.^&J3>9)&6C!XY:W?I^1_Z2T WJWQ0_I7.W@Z62=A%-
@1FUL(BZ2C) 8ID6BKXK;*B#.TLY_2>ZD> "42U(Q^HJ&M\$0#V5 M<9^PC DO&@..8NZIAT;I^7M-
J8^1CEX!-5/>CI(UU*^4F6J>^A.R^OR M7CREWG8(E5X0^3N)(V4;BX(@J@!I!8+S O^T^YI*JWIPAHKEQ-
I @^50AU&MRE/\$Y3TKEW:W&M8?L9SH!MN0N&CL AI^R YOF3GYNXY.X9(#^T3O.IW=-OY MK7!@.V3VD/XLO
T<..>.FI/6_0_DE.+L1W5EO>=IA#^IO:ZFBQ^P7^EFJ/_MEI5_4%?!CH6Y9I-
!8YU.TIY>ED?)71Q)Z04X%SJXRY++8G!LV>8=:@_1#H! M+ &X00FCDE74N2=MC2/S2O<3A>@W43N-
+^XU"IVU_PH@2+&^R(OBG4 *"\$D MD.2&N6NM3HO-0>.15CYERS(7GPN)N\$PXNUW2!HC?K!GXDZ#&#<%:4(%FZ

M>(2"/JH(FS*R*QT^JHHSW,;@;P*4)0"RZSW#5*W/L\$FO#I8XX#?7XKD\ MZ4\QSY SML_D3CMZl?2
Z2NSZl\$X0L[CXP0=GHZ*!_4-A;\N+>"FAJ_RDAN3-M83?6
0T\$G@C(A;:H#E>\$EWJ2L83YU7AXO.HNW,%H11%.IRMSU+-E7YNHJM! MPZSAI(I4M^4OPF+8
QNO\$@>DIPK9/48^441,1T)DB9KIF(=4Z19A.WFGN MUI8/"3TA5A>MHHW2=JD\$ATGQV*G;+_UBOO&A-
@!G95N384.*>8J6A2&8QB-MA0"4H7AK0-GQ"7H.Gl%26#;^A.12"1W?2*DR=R2!_!0+2-
<+1>VKPR8;RZ%ZX;7=,2@!A@HU;PKESWHSEZNI/DTN7T&J!BH"MN1YKW,\$VX M9^9C/;\$SM9,A?*\$ TG6Zl2PSW>
FS(G&2GGYKF>F6P_Z5#L.4 MG5?+=S3SJ;/6-.X=?&?Q1D/?UC04;SF(!M-(AIZ+9Z-N1!_H#T!<,"PUH
M3==<\$C6+XY?62S>/_R1;L-IMY1@9:1.<)HEYCVUW2H_l>05<)(THB;(-17H.PA !=?1(B/\$O7*ULA\/%UMV/UT7BIEF
M^SY8&&"PY?&G?/2S)F_*!3HOS&^W_@2"l/OY\$G_S+4,"F*?@!^GC#GF M3%IQ_9/C(E!_SJ.P0D+2L!V-
I5^ECOY0!XMM0H!\$S"9-HO(M#CFE*_K>L M^ZB^T0Dl48FP"WLB3!_@/+OKV(&AG&-
#QC=I3P%NDE82K*YD+8_-8M+Q,FA MCBYJU"54Y4+\$0!V^+17!>ST!&A,-Y^X+12X+/%l,1\$JWQNP\$RUI6?B_@
MQ@V,X885F!#(S10)B%l0@^AB(-)VFTW.l2>R24W6JU/#&3W%:=&KJG\NL MSM;)N_E\$^X7"1Z>?
<HJZ_A&CW;#&X86>HFN M. JA#.?IV+BS^GXN^YFX^H+ MODZ-PJU"99/>C!\$Y=,^=.5X%-
NA8@1.MJ&:AC0Y).MY:7 M)C\$X7'5C!F>DX;(1).P4C@94ADDAQ6)T MG-5-74T&AW4;""TT(7X2GP\$LD1EIU96?
>7?6M\$<^R">DT< !O9PWAH"=M M>K2)2AM!DB\$&9>UO!Y)TB-&X@V@?RUHF>5-5Q!CS>KW0-I
&>6\$WVG7;4! M\$K0(S*=-G^3>C3E>"2822-P.\$J@/D.DC T!6RE=)^P1++J!C> <17P>JBI
M&%4!+/NUOB7;+NFZS;IF^G>C1MAQ#T;l;IGW5XBT7l50K0/Q1<440P*(M3<:=M9Y(0<3
JOGOHF<#NNW&FNV*?8;54=#E!J2"=W!>A.YL:ZZND%J6 , M38^DE.EK?N;.
!0\$!_8_!0!B^FE2);_JM02;\$&QKU!6+L:TN0QK!%1%+O9 M^6M^X<(/ZOHF4_?>PM1FT^:L M<\$;fN!"?J.LT:6>?")
(T\$E_Q!88V!^N!K9;QOZY.RP968;2(LPZ'5C!&EN M3D!ZU71N-2!^1ZIQ7XIV1%3!HB"3"7JM=Y3
5-R !+ _LO^ ^52+>Z#l87l MWL90^!%2!H@W.@8;U/7R\$9))Q8P_\$2.W>Q!4#1H^CITZl_K6*XDlW7>W?% M)H?
T%'YMRA_ES_8PXH%U7;DTIU1K_74?5!TJ^>L7l5/WO!\$EC2O+V%_MHN8^X^T(/
(PP+\$L^AGl2Q5",HB3+1G;_+6LC=C>B>0KSO=FO"TYQ00/J MV2D3DZl.QF8_'L8B7699TQ!J76,F!Q-
@2G)l65+W"C^O/O7Jc_)D3A%Fl@IQ MYT3/43l2JU3C-OHETW4_D7K*8ST&M>(2=@6\$D_-0@!@1VJ?2
P*22YLVISE? M4GA5HKJ56!V\$!_.L(L!L^>L\$W778"SA-7?K!RO&"DU-<6^Q M@9-*:=D*U5V^W)_?L;
+BC9^RJC&5;fG!_MUB!(# MLBYO>CP'.5P0IV%? QS>C_-9V69Yl.2 4WU16NOYU M!U!8UJ
D^N^2^B!3%.HVX;UP9C;#OJWK%ZGN">G8!J>X\$0&-QD@/YSJMR<:N M:l_Z>)J?<I3)9H!9ISGZ7TL_7@I>N"SMP
2\$Y^YVU!O^D-5B9Z+0P!O MK2NGMM>6MDL_1TF;@A.KCSHT(@\$H\$!)9PD=IQ:7FOJ
BRNNT;_L)C>DM;8">9.TXY K2@U*^YF8M\$\$.6DF<:LH0F.M\$23XDl0_G M#Z9lV+G/N%*ZGK"l5.Z12@A
Y6%\$AS?4!E#>C!421l7YD9.%l+W69F^MH; MS_#PK2Y9K*#)=_XX7!+6YC^W!B MCO\$XIC
L0DE\$KA7CX^H(ZOZX!SBZ^!G"Y">\$SVM805>PN=PG0J9XX6?CE_ M\$223%UGl^9GI*"Y02%-L7*&3?K-5!?
ZD%3TJ;R+;Rl(Z=K2W;.&+)9O;WX1CG M!_ICB^W.GO=NS(A!l3>TP=FLS&_l5<-D\$+;/%WS*;3RX&fM2R^*KIUU\$C
M!^H^W-JA\$M9HJ;_M!H^V=0U!6R8K!5"-=M^Z^KH(>L\$PIGW7<fSXX.O!WP; M!#V!>?QZ)(2NTC8C0AD^R17?
DCLG03UY?U!AKYR!V2N8_Y^2!DE2(V>*K^9 ML)>P^Q=@L"\$@RD#lLD*_AYlX X ZlZ+!66B!l67l.X+@-;?<
\$-GQ0*+;UF@M;JES**9!FL6T(21Q4<=&KAWT.\$>O^PE)FCN^l@WY.C3R-5S5!C@8^%DA M_6K?
D3P3>_B^DU)EN"-02Q#DZZ\$*#7HQV<64O?"TOV FC%lX.43ZM.5K;^J MG.3N9W99ARC40V"=(<(HK+E&/2+%/<
(5#*YL5"IR0H1+L@>&1?7!%R9!<1?49.4V8_@!l;l3\$;ML" T_+!%P\$)8WJ3"&F!EYNW/;
MDGPLR%KH/L%8N!5K7D\$E^UYE:"780Zl2ME1X>=B=YGM_H3!F>^Y+Q!P MlZBP^*WIBHQ3S*;Z5\$!-
JlV3E_ _UMU!l;0:<6G)S%MX&?2S3_!WM8VY^1 MZV(9l@H3WRK.lXN=JB@JW>TFHl9XB;YG2WNX4\$-8VV6S-
@%IRH8XB&4+ M%QEW!>K!%XF_?7X>_l5*&ZX=CVIN4KGBZ.*4(WK=?!&:@%HJY\$UFA^T
M72L@)>JOV\$;Q&6^5#&A5D!R;C MTYGV5LG!5L.P15H\$TL%8*;N&3Z%MGN,X_-R\$^P?Y 7%_/-!FK@FOM1EVFXL
M?76%3?R.CYW76@>O79=J.EUO=5+!lKRK3=O^Q#9+TL-9W2P.lA;47C=IPF1 MHG6B(3,l1#5M-4#4+'IAZ@/\$8KY?
O^KlY2P!D!@Y.RH!_77G/^TG3@;_! M+2P0>Q3KQG\$O9%5+2KYK*.9Y+(=JB96828D-
fEQL;KM=Q_0^Z@)OU1X)FEAV-Jl^X.Y MP2R%(3 JLY<+&2AF)_&%T;%TD?+=RPT=M7TF-
%8FB(XO/"DRl_ NE1V(G ME>Z\$;B.@!@J?J!LKS K33T_Y;JA12;_W^K!BO!9Q;BK+X?>=_.NK+MZY(P_G MJ^KX?&4J-
E^\$BL>AL+>JH(DYD;=L_5!T*_UXQNWG/>?QW70K6^S*=-^=MHY1C%E(CWU6.^MLWA99<8EU-
7\$#3M@CHKV%22>L2C!2;B/6=W>@UU!#.(H+
M^!S7'-4L.7#F^5_>E0L7J0QHT@3L.HU3NB.9_ODW0RMNGZ5L2CXL>O7KlM-
MG9F>6C!_&A8EJB=K6!8D;/XO9;&_B/B8OGT^H(G+^T MWK?4%=>JN&S=0(-1GJ"*=?
KYC!6V+2Y6X!_VY^l#XREN_+5=8;2!HHT MCMBYE)7!AMRZ.C:B@G2<(!
4^R^D\$!MRXP!Z^RN\$!"/Z!l8NHH%3_-8U66H' MJZ;INNM7BTW66,7lS!Q;+WHGVYF#1%&&@T;6)"@4?<7/Q;Tl;V
_5!<?l0 MJ_F#RS.F2BU!>6!_Y/O23N;JYNlP!l^>6!+2Q#PHQV-8O0WlZ&U/4DEOD
MB%QT+K(4:Z(Q^)"PA0!PJ73M!0R4LYHS/EJR !WC96-ZF!4-8^TZ:42UR=X M64+!@&YI(%"7&ND&_JZBS?=\$X6+
3*WWSEEG7%;!0P4H6_/YPDx^ZA/8B3_M<3lS9AU#FPWAAZl^!MH!^!S!H_GC;+TF#XlD5L^CA!0;IOPINGDBO+/8-
TRK M6TX70)#8;(@T&5OEXYC2QP%82;#BO6-S4\$#11F^3N>_lVGN^DT(K9<30F M\$V(\$<*PO.9WGY4@_LACL-
8^ZN9#3BOEW>;9>F.WC2#YH!_9HlR^XVM-.Y*%)4-R7R.lA7*!#l@0VJW.X&5*V.l3=-M\$!_0X-
+9RN;JK"T26?Z65!l7Dl(>A>N!6FYFIGN!@IA;C)\$>0N!H6O!>.* MC:G\$3W%Q&U/(?Y;=9%P>-\$)C<=&CP=:QlKKO*
<3X8UM+-P=TF=873C^>A5 MXS^lC@^41!_2@/+A+!68OGCP@+D&;*1.=TG;GM!%M_PEVl;_H-
!OHON+F=:L^FY< @83O/XN"NF76S <4<.#BRH_J/OHMM.M^J@VHQU !P6P^R*8LI=>M)M=BO;D;LG2Z%T?N(O-
6;F3&XVQ;>4^0E.2T03lJFM\$OJl/\$DX M^MPL-/&+F^.;G!<-0!A&?_/#IC:3)Zl2)CU8;@U) RS#
MIDE!ND&;_PU"G7FS!N7P!>))H9WW.X07!6%/Q2!0YU!l)?><@Z^Q;_R M9J#PQ.K^=N^X-
2UB"-W%AL!J\$HW;\$*WWZTHF^E6V@?R!PN>3;AFD(@.C5? M!l2(O4
"9UF42CL4H861QWJ0M=E=U8^&*@&C<1)^2D4OK@JRPYRl16DZQJ M:"lR8KYOY-
L+V9>A3N%J8_'R@;_0E48X;#l/QX5_ZHW-72O0IPC^BZA5*G\$ M=C,*-&K7)U2K?@Q<+)"3_A.FG/?_OR0&?
%70>AWR6>72FE_Z#^B(GP_0!MATA#M07F!J;K+E98KQTZ=I:"*98K<6F+SZHO;O6!^MN;MG;^DBK3Q
MQWl%%/P%FF(!TZMD!97BX^54_Ql.#?#J(P20N!Kl(VZL!SS0Y!l^6@8 Ml+!+ B>7VM!UH^9IES*B-%VSHY-
AE!S&NANXG^N/3!^MUUA-2-TZ(1XX MO+LJ/IE3!)&V^FP&X2GVP@;9C%*-5Q(5_XF;<-FM9;C8J;-F+ZOV/_E
M^T#l_2SUCPJ4;l_)AO"JX4;PM1U3!;*HGKT&M\$"#.ECOS#VT:1#Z^M)U^R!_M_9!+OH!0?
UK!XZ+BXW-U.T)H#KUE2U;?)VYM<5"THJ053Q.0VX4F!;KF M22.\$12GS6!SJKLD)TXKMNC(P"?+<2LNU#2B9?
M3M!6A&IE5GEKRNYN^DO39#)IY1%Z:4SO?2Q!VE8!@49QE ?l6KPl!%0S!;T@?N!6!_O=@_J@SY91@H6=J?
7BLN(W;Z_HQ9#P.AL-0>J? M^B5LQ_UQS95=,1CU.YPT(*C=2+MB/S
<7<^W1_@>7!FPS0WAXNXD/=ZLG!8DGAJ4G8XK%P%U/GZ KH"9A MM;QK0Y2O6HFPFNW.%GWAKK-
XP_7CY8MIQVD-PQJB;N-XXFP_l2CT.8!B# MG18G&FEO
)!^D">JP\$&Z!CVO&D^ME0!^KD\$HGYs)3Y9KH/4\$UPGOE3\$
M<2E\$P4_D!;2;WZ%9!@)8M+;_#WXl2_&8!T^&RF>0"?ID!\$Dl KN=ERIGEV23HF?Q!?"M/Y;82XQMZ6@l M22A-
+66_2U<JLZY:2KN>+C!R!9_XGVGJ7\$N_Q\$4!?"Y7@V9"\$UA_##_CL MVH&1JA"WV_8?G6XT/WU1-
B>A=S#1W(H^BS"?2(B\$<%+):CC%RP^8!^IGGGG MRPW^lWYEOW0;KPD_<&V#@IKl^#L#HXQ(?FB?D/B/FLO%
l6?)>!#W3/NIMO! Ml^7&1!#H4UZ>NPDOS3G;VlV_&IS%6B;L+5>[_9D/=AUB1;_!EUNV_08-00 M@U)G+\$91DI

+5ZWT:++=I\$!\$'A77:7V8*,6L\$'KFLGYNV9_V"VTNT5IXU2?@<\$Y'5HY@./ 04HIM CNJU*!LZX@&IY/ID
MS+U@JH)FU=WL6:&G^YG)5QB:&% X 1699M<1\$:IY1P8:!*L)~9UQG0S)N MOD*/GX\$SE?+"A+8)I'<1-
9~(9)0=3\$"P7C7XE@YJRMSE^A:J:S;B9N*:MI VHUM&*\$>53(&%;^?W88I 05KQL%LJBO(->"F0?SWANTL
((("BNRL6>M/F#WMOY^6H1WMB#LE;KB?
EV9IR1=58G/HJLN>>P53"Y8LC1^7&2_L&@Q6I>F:AW1:TOM/)"@I7GCAP MF^1<1-\$*^(H%G#&@...:AI-9
N9I*#\$\$/JCFD)IQ)LI*JLVO<#35W4Y#M!(MS?!"LX18@S4K#WJU/R):%VZ\$'+(-H-M:15E104?;\$%)\$%IDD#OU
M'Q.5.TI?"3@_L3VZI?NS7US2G@/>RVJ"2@QS"98GM7I7FI(D-^H)9/Y1 MFA:1169K5A17F@Z@4,%
JOD+UN57&K)VZ6M+R*F2=-C_SR#EWO.O.CWK9 M-WUC'887X\$4W0FJ.&>LB:U/I&^JFL?N=-&1501T(.?<
JH5.#7ESGM1M;Z(HP(*C215\$BATN'BQKUQ'10F0_8KV/.)B||.V2Z**Q^G=-?VB;K2GWW\$*NNF_BFHH7:6
M&Z7:&1.HBAZ0VOS=CV&_-D"W74:IFE*(NXK9)Z>4?1H'A%K_W>Z|IT52QY
M|8=E((E+L)@.3=78W:U*LLMV|;NW:|!#TNT:>#G"87K2 MOV2JW.XI'3M_=Q/?PO2VI,VIN*0?QK\JH32C"3.H)?
)TX=(*H7I4ZRC V MCEH2|SNGU")DKFI/9ER@QH^&J@N8NS0'N@G:82P#%H3D%G.;INX MRIM)?
M!MJ^6(^(E%5:+/?"ZZIQVFI2UYU=6I=P2_VD)D(?;W8 A3L(^G.=:'@CM1I3:=UJ2Z?U)MT.
M+I6DDO^F%G1+'>W^L&R'@FC(+89\$K YQG%?I)V MTHSP4\$DWX)1Q#NSXN?I MVY605!*Y-(KIN97>B6Y)5?
4"B<*GUUS&?^TX,8AB/RMR*Z|! MNH8L_HE9|W3X08:|JHDX=MRH||.8IOI AV.^B_U_GJ_&ENHE@:IF_N<5\$@SJ.
ML9>Z7_VHKS6H(3LF\$HDG/9J3CN5A?DTLOYP7H M6DN0B|Y8&N\$>3VW<IAM'>V\$!9=BJ+%T-
>3:57+*Z3=2IA9*B|M.(YV)6|FP5 MN%%Q\$G)(^VB2>3.G.|O+4?I+'>O.FB79CTC2IO1&>X4'U\$Z4#^4F?/6XR?
MTI(324>L#:.M=&@OTM)>T"Y&W%&H*+Z2*2,=I,M@G!*=>_128X;L|/+:I MOBIX209?
W/SR1^#3L@3&PD;4|ET6V_Q+IVL"V_L#SYMU_86IRK2X?/H!^HIZ"N.*Z"89Y%D_)G5:H?HJ20/D#A
MK9|J M7G3\$Q=ZK#?2*Q-UT*W.TMU8H(|VGZTQS_6%CIQ:|"I"#X@.UM3\$)-H MI+M2=
(ZO7DX_+WK>T75.S0:*TJU.MG(I)7-(WM=RI%|CU:IF%TBD<@V(7>IY^%3G0IB.&ET U0UO.)!#"W3
MINN'67;MNI4QAOL)?DR_NS?IED;=I!&PNM"HS1|V|C>4BM9/ 3C1?>)+M% @ MB8IT=CF9=3!2/Y@ X^-T>
+N)CQE>T.H):)?Z\$#:#.9)*T)A4I)\$05I|MY; M'9SY S#I=T\$0'L,%: \$JW^MH|+KNSRW65H-
J+M.HLXW3/U@47|ZJ=\$U8KI M" 2N9HOP1SCP&O36"JI9SQNH2DHOR.=A8O+J@4M)MSB-F?_1\$;8&) ?1H
MFO4#2K'L3SV|O_98/R)DOJ5+ID"E_77?UG|K06|U.FKT16)P3N/:(H_5I MJ:1I*:O3K5XWND\$;OAK6|UFO)8V
C2D4C(C.P;-I'8J7|UH%YWX_>:/6V2=%3YX|SUE5G):96CZVP00>^C5XZ|<4!9%N|!^_!>HMC5
M+K<C2HF\$+OSI_G0.LI=:%I_2)37=(X.N&B=O.AMD0)W2MUQJ4\$DYK %1> MHWY@.)KA/(VSJ:++>Y-
XY)"YDIH5LY6/WA3EB_E>3)7B6UT|=RV7UH.(9D"4N B:: (UW0D:@H(L,*@ "EIS32VZ/U+GSC7G/H14|1B|G M9E;Y?
&^L=;^*O9/W&/ 587T|4F*3=;YK\$Q=A &L7LVX)F.\$EUYCH16+=7^K
M7%ZJ7PYRIM:G^|N| "HYOZ|1M\$+XPO??38B|YSR(9_0W=VQ?QG"&-IF'VJ! MH/;<(D.<<^PJI3NV>"+H+= (H/D?
PFMT5/K^&V8H"V.W6P_V+/9|UMPXZ-5I M7?NS@67WHNZP
NU6_2OB1KMA((%.8X;EM4*AV.J\$TAXK^C:99URU\$\$.LFU8' M9B|&F&A6HH"ZN:00H_:6IW&|R:*1FA8|O)J3PE?
7#WX)E1Q4E|AY<.(R\$ M@5"V9#5(+IR|VY_M2L:0S%6_HH>V7%>D|>C(%'73'0019&- \$ 23I9Y)5_MYL-;
<<|P>Q|HPP*9>V(VFH@=K:A:G="CF;N Z7:10% M)9KY^?
GX:WZNK:H.JMLVEFHMQV5X^+T"AT;SC+Y6&UYFU_U4Z6V6&'9D*ET?6&LM: ^9QO|4I| ML>^9/KA9GTD-
D+&0|HDIU:N=|I')K=Q?6(DQZR:@T "IG4IR\$ #T_G\$U M;7|) 2P+H/|<>@9|
(4G7^M(R7I0/_NK^&CX6>)N RVA|S9%4+0O';)PJGY; M1G*&@JF%:ZJ75JCN5L':/I+\$C0J3/XIDI'H-AXTJ7KFR-I_&
|@ JUJOIF M.Z)Y&YHF;"W^(<^H&?LV+V43Q7I+B=TQZ?QW4-I'"1GI7(1T.DQ_&|S M;9&%77Z2>YDU"WPH_
+U2IP&:UOF49XDON.8|920IRX4M-Q?T_"G:7DX6>_ MOHGX=TC;J*:<<
NEA0."E*ZN\$HE|S\$ 4Z/|@HOPAORHU@(|N:>G4#N->R%I MWY8AF?2%5=2*XT_G++BK9F>3IH|Q"N|A
(3AWR@B;-I'/U+=MSAXHJF2UE" M4>V)SY_0Q1^WS\$4N_D|78XY0IB008Z,%^FV|+_M.ID""E2>(5(94)*S"OG
MHU|WTKBR3K?W0_M0?OCB40|>&2"=J*/55&VRRM.JD(AP^H;W*BN8?>T MY@B^RMU";C=+D1IX>I_
IGIKH^M_%(8E@_WW0/>&AVG"S_+C"2X0=M\$N15O_M-7%T\$T(@|AB|_7K6CTM_-|N\$41#K#EXB1Q;Y^L"
IYY\$1Q_K+G*Z\$Y@SB#XC%YSW#F'VMTF%LR)P^7E!A%M|> MSS^STBH ADWO-Q|AKHFN_XN9ZOVQYD|N2?
G;V%8Y6_XA%|DJ\$//@8- M88EDH=0-6.LK96L(R'3\$8Y(EPMW.?QDYG?VFCM_?2;ZW?
9U)|#ZQFO)#_V7I<#07|C0S MH6(+1X#2BH96C6RH'FD|1X^ZW MU%QSHEQ<:5I0?#\$E#V0B+!FI"ML@0-QA?R
MC|9YQ_YWKY<+?-(NI46W99+>_P@R=%C>=* D2:|^;|X6&UL_@CA:L I2:
M&DX11VH\$ "^5V#.SW13V"D\$53_Q'ANQG6!^V7:9C"OC|2|+>|&@JNHF.4G\$M M^N-6M6)YFA7|ZKF
X9BV6/VWH|@3LG=%XR#;|ZV_*/2'D/K|J#.4/E9R MY;_M=!!?HLEOI3K+M:R\$F%R9_O>|R.YOM2|94%9|1MW-
_U+VYA^B|OI"Q5V_K#MA|O>:5+V6EN2X385UT& ME27)=WJIS=J*MY\$'8SEP*|6'RI(+1/#^!
O: #JD:B4D)5/8:U^@N=10S3 MH5L(ZMMS%6C| M3<JG=M+9MB 2:|FZ\$7JQ7@O.GR_+VX4&ASZ&1V+6B
O.J(VGGBYVY/'&P MY5.(YM/UQ:F.C_ ^IVIO#K'V_5D)'1"C*:92^J/TNVO'8CD|KXB9RE%?(/+ MU:M:56'SE@H5
F\$&KVI>=?EM*?L4_97'5.R2Q:O_ =3 &=6CF|^>|X'"5< M:|?6Z>' HWDT=32.L;\$H
>KG7+NIU>TIZNY^K?"QCP%RZ|EHU4T'W:&E<+@ MDM.=^W+KQ/%665I?VM;13#8DE'=%Z=O00)>HF|667F>\$J
P2LT:YX#| K9 MW7M(IW^5L7:I.GO5ER26U.+OZU#0T-/G?S|Q=)MRBZ)6\$C87(4_PQR,#WH MJN.:&4/6
AR/VTI6G4\$29H;VA@ORFH9"!>K|2MW:RVG_) 3.+O-S|2FCUT#B
MCOBPV&YGCSD"4?I-(WLGAM^MJW^O^#5BCUY|*|ZZ"|"<.>HW=SFAMDP MFG(.#2B@DNF<2)W\$N?(N0Z)
I.4ER:D+=I|ISEYD#9U1-RJ|F'@|NG^N| M5FHL2MK'L&R#8*+|QIY8_YU5YZI<<7|MS10#.XR2\$>"8IV9I^
&4XIY2F ML(VIO:..MO^='@! :<\$(AC"*Q;.9@97*V.U9=*&%R3NO)UMK8 |V|6#FM
MFOBP|B2ZEZ"/PEMA<1^V"# A@:@:Y;O)V\$B| ^G|>#L/IZZ=RAAFE^Z%7;.ET
M|TVTGZ)8FX*9D=@1Q^1A4CG7%W_FGU\$ _S?P_H W,%R%DJX"01ZI M6G|N4 MR#C<#.&-8!(H-H;
M*:NH|>)>&31GUYX560: ^SX-U=W0A78T_4O:;%6%(9)&Z'HK'|>U&TX>O->
MQ^";D+RY3&7TM%M;2FS2Y6|O2>9IC90QFNXL7#PLO%M.<@CI-ZOI?NCH=&C M1UJ&M-
8PP:~C&Z_3#>RV'2XZVX86SAHG1UA#5V|T4+(8>RR(9AOH_M_X4(MJAWXCRQ5(4W9\$%Y.U 21|@5&N=
(O.A\$6;D|'2|Z"V"Q".<1KV#Y&^%PY<27 MB;M*5^<=|JQUU+|N.14|5/^&N: '-PQC7F-G|JP7=NL@STFG|P_K3_O:J_\$
M?V8R-1#C3BECRN;)=HOI:;>N==) XU+DIRD7|JNR_X15A;|)B:ZRE MCP|WK:T7\$AGX(PHU?/Q_Y#\$EY^PI|_
RNJ6E|^/9ENZFXN7->.>KO(H9 M7:K^2@|X1S_4.QB@ARA0AB/XJ:0K|S|/7|&C4|<I?%./5 MQOU&|6U?X"=-
.\$<36"5&K|O&TLN?>4I-C@<|R|%5ICV>?Y%"/&<"8AH<(QONGQFGFKIR(+_9)4KL_1HK|_V+:S3=GH?
N09RGY)21K66^I MJHKDBJ5-IV6"QY:|>CYU8@RGZJVZ|5D!..#V18_LX
MEBCU|4.OL.532=RVGHI+/@*YQ(UVT_VKZ*_L MH2 M=|M8KVYIPMN.#PV2\$4^
A47|T\$+^OD:NA<73>S6)4Q^3'H9|X339^VHG9#V0 MY.VQZGL-|..Y8:FW?
AXTM%LP|K4(L3O_NW|2IEKS<_Z|L4J|I%3_#95.KI MS(048S.VW'7DGU5C";OP=#\$+>F6J.^VJ'Z4UJCQ
|D>X|A4|K|MUL(6LUH)1""%<XKIE:J^&C/|S17T>@2|+1AD.J|L8^&K*)&_M#&@?
V"BA(TVWF"3W.+@2726A^_Y+XMI^&*|_N5#00S%?W%5#;KF1K|WGAK7 ME7/X(R6NW9P|6H426-!
(MG^L;RU\$F7V88L-N0BAC.PLPH<=&<+7;/JI"-0
MF/>|BT.N0WODE*ED(0G@>=,MT_!W/R;/3LPG/IE'7Q+XC*KIH7;_H/H.&+0-O-7|+ZFP MSX,ZC1B=*2>L|YB-
#0VZ*L%>85PK85Y7-R74A1|)/+P:D*EJ6P4LXC5CJNK M>DE_R>I&"(A/4GR/U)2"6?">0XL'>Z=QC;Z|_OLJH;
(XW+'P=) 7>B/6 MU-D04?3-5"E4Z'R^&5#2G_713^I'394(B23^%5V;J|I C;I7|L9VW3?2 M&J;^4=VRMK8:(P7D_0

K=20Q2I<7?F2A V^3YIF52KUFBDENR/H962B J/ MJJ*O3W.?)0\4H>IR^V.WQY/QFOL.R+Z.9^ED@F.YWJ
M.+M^L(N.+W^AJEW%G*G'+IHO1687QTBWF3AOS21FJL7 TOE.Q6)'FJHS&@ M_FIC>.#80=+)+I*Q/L5B
I).9N(H=H?^H8J8-X6S5#G08+&W97T:E1G-MEH-2:6YX0*BLJ A3G)Q6CX52E'5_XD1PI P8Q80-
F>3M^T*QVY\$8C%9)'1FV MPIGG<(&)0UEM%*,@95=Y;R;IG*CK^EC&5*T^UH+P_HM>YW)61:W(-131J*
MFOC-M^VMML+*F2D2QKMI*OE=,IN(5CN2B9QRIOJHY.FCTNEFH#2*ID-0L'9C
MI!ON1\$OJYV=*C|^\$JWYLV\$QW.!.?X@Z2WDA|F%?>O|X6UR^|=?"K<ZXWN7F:|*NR8490_OA5.^YR-J^N=
MM:PI84VFT&A/B\$W0Y0R_10IZIOI/\$OZ:KD"5S2?4;20;PKN+1LBRT"#_ONC MQK/*2U#CT)JLU/NA1UWAMJ-
&9WA>^W=?@N527Q^ZG<"SH6">XJA!'0S1.&T M0L=AM BXXZ;RT>CXI#)\$9N#Y?7J4 MXI9FRX/>VQ\$
L7W0R#1\$CM_OLE\$HO**REQ.,8XWT ERPG^Z.*#Y=2.*84.*)1BXK42JE,E^IGQU(^L'4(G;ZK\$OF86U.4R#H
I^W^S8N5_M6#W_WS1^11U=O7'C?^:R+|B.(HBAV*,G3EJ/H(\$IE+/TOI4#_6U9A2' MI5MB:8\1GR\YGG5SCGRD-
^YAW@/ME-U_(H'5K4&19 D=8N:R(>I9VDAE9H5. M)4PD+.(L)KW6AV_R-
J7EKBO9F*19:30%6:U""84J^VL"W06Z,7(I/9+ MS@&.UBGMVH/I?P/5'A26H"M"U.JP!..T2RJY-
;?JL?"JG.Z\$CP)5CO2)A M^CIS2R.%(*6T#>3B-A5ZN7'84S Y* 2: M9F4&X(3ZX&U&(S)TS^3=E\$M?J"XHJTG?
S/8D_70:?.**6D%0@K<IGNJ MST"PW?I#8>G64@#1F1J.SQX)<4WL GAXI^?4I>DN=Z0UT5'4;M2D9G<8*Q.95
MN4,M'WA_%.TG#N(EI/6>2DK&9)N;.@I#39\$&.\$%2VG-?;\$%;GG=2W+I40?CS M.PFM;HX2O!
IZY5_U%.I2*D/L:S^^AWI"QZ4_H7Z%OE-OV9O(I5)Y^>U'.I3' M2.RAX361 (%3.SV_297GC\$QC.-
&TA3#-F0)\$VOAL/^+O3>/A_IM X:G5\$)(MLL=42/(4K9)LB5-4G:FDNQ)\$HJ9\$+
(GH2A3(CNOIV:L0IKL&3%)D06&3\$^MS/;ZWJ^U_VHOM^GN=W7;_G_N_GI3K_0KY+^>Q_)^|=O'B??1"X)O#I>
M>WV>I<8>IAU53ZW8_%T?I6:2K 3YM;.) MH^V:K9UNIVA8Y/H2I;\$<; M^I=8SC05C&Q7K;S60L8ZU-5?NQD>Z
MR42?/>Q)O-0+362.I.IUTJX.P(->2VPM>U3'._#ZU_.IV=^<<""6.17.8B M\$>^9;G?2**KT.G?2
YUCX.V&1=&_*0%\$E(8S0I8\$TNC|^*=T^(5HO)GAMT&&J^H MK<0(T2_40EW32R%"3_-9_#?
J+6ZX880G;6YRK!5Y:08:IGMIX*44+=KV|C MWUC&T<;I>W^OAIUE"17W,=(V#*F0G_L35OR.I8 RU-V
M5I%L&UJ)@:X56B%6V*IANYC_Y_3?(S0+CT6JXIGRAEV2U/KJ.1&ILC;3/T5I M(Z\$^E>(9WZ5^VXRY?;L3WANB9WG"
IHS^Z=.\$6@+H 19^YIEZT:/A.C G^2%H?PC& M""5^VC=2IQ)UO;GRIT5N6Q8>/H#IV&-&/0^9F!#1#3&O4V*;;^8?
P_?S>MMZ1YYG;)SB86.T@\$AR%0.GHD5?@I#NK!" I9/KB5U=49Z_ME_"#Q'NIK7W M3B2;XMH\$BJDB9E(RIU?
5&N"AO_IBLD"W6*#AJJXZ_BBR,J)Q4_H=AIC:3K MZYO+ J%5""Z=(RJXY\$N|GJYN-*%B@?
Q09A=I/ISG/I,Z1NNT2/J 7;_X> MHS9C>OJMI4IOI M&Y,ZX-IJOL-
_T5=@0F84TI"E,TIOYTFE>K+I4)P(O94(I^!U%VXM0/I/I MT"D9;"ZIY(LG6V&25Y8H55WN+)"#UDUBX&I
(K6TL@G^6@6(JIG=I03_**7+. MS7ADRIRB(I!6?SCQ6CB>_>#*VD)SUF2YO/ TT7>^CB*8|C=TRAJ>P1T(O
MC+V%9WT"L_7C|M(&^5&.FE8YI% ;6 ID5!;..IEU'B9X6;W1R4(I3(%O^ ^ M,HAINZU;..B19*O+W+W>3;A%_%FY(%
(I*Z)BEI|^I4GO#D;3YA=.)>20C| M9#NV_+.@_O_8M(YTHOB\$!#<07C.W3@57EP2W?0PYJ.IU>55Z7UK4@OA0(-
MG@O D&S9N8J8\$+G(B(+H!#5D%;Q).JC;4Y@D@&C(5Q0=?>P=IFL2^9N; M)A%5CAIEC.8F<7ISFMT!"*=I9LI
_4SN 13I>#?7DCC/CIH2=HEP%B?_NT M%O=Y_#<4L:NS@=>_DK*="I>DW^O<6O1^48:IOY
=^+I4G5BC<(\$2)>C<6Z%P#C613>U, MBHGOI9PS=B-1RU_5%RMQ\$ /+X1X_QXMJ?I<1;IY#36!
M:08\$9T3G5F)C3CUA*_BC>JG\$WFOY/>V48!%MR M\$|=
<>C*ZS)K)S2I8&K6QI?..#Y#KT@7M>DB6T4F=RXLID@JE?P;)6BFS" MW8TI1:I)*)8Y6SXB5H(=;0_11%;5"#,
I&7Y9"VI8Q/G%'WHP4RDJ.HGN# M0K0E|W;.:8VM P?DK)R@T4E ""W0/HFGDD:92@R RFP6U*=C"6L/4IT)TH4
M/W7FO#+D-FS<*)OYY?@K78J_VCNS!!7AIZ4O4Z(8T@!"9AEJ|W-'2QI\$?_D M3-
X%6BAW^GA@!Q:TIZLZ/COK5UJ&%#A_@I+:M2R=/LEXA-W_I9LYZFI1BI\$ MU>_B2.KAO2-!FR_5K;-
%)R|JVOW_3^Q_=@MB2G):8>WF^O;Z;HKO AB^CF3O(I:9(<7?AL-PO\$WQYZ;52#1U*_/Z9L\$<
MRNE1|R2QI0SIKK-73=?B8<96WT^ETQ9A7I/+:T!A7>2S!^DTLB+!OZ;_A_? MM'3RM.ET7G*8FLC>LFY.P3G&I?
R3Z=[9IL@DZIG|A8P*W3I^V/F6*5_=H% M.IN21N1I8LA740EX411:QE-
*>I&PWK69;1%A:NPI1W@42NOT/E)17B-IE M+IN^2/I+WX1S0%A/I Z_K.I!!+""^ADUGLOD=
ME(C(LQ'HT.OWAV&O^K-K3)(YC3;WL!;\$?)_BTL:3(?XNEN.5;<34B)N<-G M^G*A&29_PC>
I_&D1^PUUKUT|K|KTRJ|@F;:/YB;+)MN8_?%2QD5:2)G_8+%(F&*. %0M0G?G-&D94^OK3 MZN|X2B
98ZCWF)FV&Y%E (L,U);!\$.6#?>5V|8W+JU)CE#WG@O#|JHZ? MYH^>/XV;Y# M:CK\$*5)7DA|I
P@NE3)YYFQ9!A=H&FZ37YM?="2N.3Y+CBDA;"MDZVL
MN0LA_I@KT2;%EK*G)S#Y%HC&Q&FNC|I_GFA/MJ/M^0DW""1#(39M..D""0Q M%""VHY;IG6X?
&THCYIRT|U9ZAG|N+|U\$ENM^B_-Z|S)NZD4IO&FVB8V @)CB<&RV M6_YO..JRF_'ZQA?(Z?13=_+WBNF=BUN-
IR+FYJB0|^+GGX1_CYD|^Z0L&+ MXHG!"V|YBA;PL^ID%K^;B*H|&01D^TL" I^R77.XMAGRLWZ|3I)SVU@00-
MFM0;J:N=8.HE+K;.*AY^JXDA4,I+<2AY_3B5:@Y@2)"CCAF9"L.^RYN^ M?AV9KQ_K?%S_?"IY.44T=&W!>EV6V?
DD5K;U_4C4_/I*).@CED:D_S (JHW2G/I'5)>O28:O\$H<6-5H.5.?LN)|HJ*VMK;. M_IBB^0/INLL7J8%H^U M7<:-
#M2Z#*C\$JL^XQ02=%'MV=:DNZ-"E_4YTUI^%C07\$(Y*+;+PY3QCOR; M9&3"H_SR;4Q:XEE&75SB:3K9K|NI\$@
SD>I98MQ(#+D&A<+LJ_Y=&U^C MGLQ4|G+8+VJNQ^4YTZ+=B5.P.)=UJ?N^UBJQZ?JB^JEN?_?X;IGE;I;I
MNKS5IYI)0A|GP^Q09RY)?)7K|&.:5AQ#<5Q;S2S-CA:/YO#THZ9M
M2/(+^C.5*>_3XQI7=0;C(=\$E)DDA)CT2Z;F#09Y<_WT""H:<5|DNXL%>OV6 M3>MS^I^EHQI8
<4TA3+5WAOQXVO>=DP&RPL39/_O5?MS9SU:X4DKI\$!*M|K|IOP.IWM:3_6T'(8ZIO_LR2J;FJL=0LX82.
<_QWAP-8N%<%2B.W%.;TUR M9R1>8)Z*0'W^4E*218Y1*E+|S)T=V4IA".\$. #AY19N3/3?_Z<H9.E+
M(YTX1#N&L|TSI\$BMC?I5#4:90UU\$@=9E4UT#=%%?_"4%>@P|YIG#&-82(.O+#+@QI^/HVX;'+OUU
M(J;_JQEQ6#U9)CTE3HIW|+C9K|JR_B/MXT+0=Q.RTA.WA8^!H%S^2>)SIU M31_6D5>K=&.I0DDQFM%2VTVP
MBKW8)=8@;U;S=P8ICI_GG(Q#MH=E4H;B1D83X;(" M2?I#B+B+.(E|XF:%0|8X4POFEJ?7_T)+8.<_<.6;I02!
IWC+ZJEV=P<I?FH_+ M^EO"6X(M.G=,ST.5)X;I+M3_+FO M\$"TKE=E;_CI4L%.;ZD:(I&TM@;
(SG>_H#N3B_X0A(N#V;XT+>I5;W7?IL ME-26*B_!^PE(I5^J>C2WTS.;W!55-5C%R#<|SHZIO=UE=0G&#WNF
1_PY MWMBUZ*=TTCLVT_>I|JX>KA-Q|&SMV;K;H-V|QI MH>1;=O_8>_P^XKR<#^-&N(\$TH5;)VBTZFN =>A
MU!0EPK1-3N8J-H.#WB^9^15LZ-YO4&G(F6+P041E*.P3W7-8V9^OE)*)^+AK MYGD1|O\$&:9.LN!&-D\$ME8D-
Y+S_14@M;R|M-M9G4%\$2F&E/2,"+DA!A)
MO;TH&5IR'!&"S|I+9<^;.@VJHU_K|6P_0#_"A.O0^&ANP|9""I7&G.BT9Q M|Z8/7>\$ZH)M&:&6N*XN>-7
:=^ZJOOT)4&X5!RJ M|2ZJ/Y!.)6EHN^S.\$:DD8-/FLK04^|^&|<0HD_)BU:A6T|C#FIJAA:R MC7<_I>VYX
W=08:IQI0N'#F2|WEG:Z2JP:I?IV(CTP3I_-3\$ M;_DS69:U71:U?T/+!Q_5^X3J3+3DJ#4&+@%_7DALL&X16WN?&?>
E.Q?N;N M2D4N7OQWEJHX21R=1F"<6G(9#Q3U62|QS2:NK|Y=2&DI(N>Y-I><_U<|ME^M_U00#-
")9W\$S*>"A%9J>(|=P44WF@WN(8;%FQ_+??Z.X-BZHXX?S-89((76B2^F<4L9M/J7-/@B<7ITW
MD\$@BT:1;U/OAF69U-ZSXQONTAMZ4^YO^&YH#CG=1KU8V\$P/R9')J-E0U_MFK/
REBHX&1Z2+4|D4_5H7Q;ZVZN^8IEE M2_OH_|C(U<=\$# 4GNR1L7Q:KA.#R^K"U")C-UIPMAUA.KI=),O\$3:?.G)+
M^;ZEYL|U.X:AW^T=H|Y5PG<@+VC0TW2?#Y8(B"/?HISBZ9^W41#U:PH|INR|N+D4.MACX"L M"
(4F:VI63VS06=1(JI&W2?/D=+4^N;_VD;^?EX^SODBI5_P|OS M1Z--/=<?G+8F_H8L H|F%|G%O;UIF|L
\$+&J:(\$C&K2*D(N3^Y8C5@N^I?MZ)G.|PKT MI|^*HX\$|OZ\$^0?
VZML(\$S%)^;^%8|W)HOW|N&*E'0612.MBYTR<>|G|S? M K8?>SX&CQI99USVBFI MR8S.YL|E'&|GX&6A#-?
#=&E|N%7^&2I%3>GP4788QUH5\$D)5.KKL7(AU MLQI.98&W%\$*T(WU.%3N8N.HKS))0=-NJU-

Q:LL:HSY^ZF:XC97#1W/(+/MJPNAH4%3)/Y&F92L;N5C_R7/(@3ME#K^O5GN SXXOTNJ^SI
M9L:5Y>.E'+2T>UOIOD_2JKE>|(\$)>&S'3'5XPOFU&*\$"#+(C0U((>!*+K" MZJZ0-U.T.D.2?ID?>:\$&D3W
fMOG*_DS#0DY K9!=,HE&K644&B@R<9IJ:IS" M.SG1H0>WR0(=7:0,T#EA<#/WPO|HLMBDPBRT:\$9%Y!Q!D%SI
Z4 # M'1I2B_\$10C@,>19%7V,X Q)*+G>H=3Y1-#. MV3>^>.Q!*&OD?IM1>I/6"^^>IVV:37:779:OQ_ER9OR3VT9F!
'7'R3^Z>|=KRJK24 M>/+FFK\$/V"=131F'V(&AP?D?B%KD^F'.2R!-) +RP9^!\$@\$IE.'9"%UIV&\$ M
fF9/0C >VA+K,3KT9& 382%JHB,@6@:(=,NT\$5&Z\$=2Y*BO+:@M?ZMZL3D@_LK9GJNU0^J=-&G&+^
M<34LZG.06/<1.4PI5%>|KIQ^SM91M=LT,1VNCWS\$W/JMBA,*ADNY(V MG16B|K| T?P0^?(@IE#1S9S J*+ #A?
H/ OD:RZGHC@KJS_4I5@)\$8VW#V(LIB)LPA<1SRI M6D2D_1N2/D)CJ96.6-
#L.7&Z_RV_4^*.7IE@ZSL:@E8/80%|/%? +F%G#2' M"TYWD2.)29J-HO8H"AVL>S=ST?5LS:4.-B>Y<3@AXIF>
(IO<<&2RK.N=WB MKGP7P7^1%W|&=A13OK5"DNO 5H:"@8%"C4R^2PXF5?RUMFO_0)&_K6^5,T M3+(-"
f370G3Vf6S%UM8f\$1QSP_9/\$.PIL(P%&JWF#|X_5*0!\$\$\$*O72MBN7(MC_,UZ>3.L?5ZK1>ZFQ6)L9)<5.13-
PD2H8NL@|DT|BQ1\$|5FVH.T!HAD&:=
ME/Q"QZ<+!EM\$N=TEI54M2MW^2BIB+IWRZXZCK4H2MLQ+.,2IJ7=V0C &_?EE M\$WW.N_63U.Y.U-
5;-VZIGU.RJ+5CD?;TM)FXU^9)B=N"IG^O4I4 MBYOAS085|HB9C &.*?SI^*840D1|FR9MD/2T+JL_&
>7K<6ZJ113@+C5I6_M/10ZW2PJYQWWJX^YY@PUA1I/N!:=,;Q8ISIKY2? M4<7N)3,0(\$F+>#>8*B1/I!f=
HJ47CTS# MNXA+;F_?A08>W/?HOM-2TY M^K&E5OUC1_QNY0:2+^"T9A9A|EN|S7WB01C).NG7<1.-O|@YJ-VH6I
X<*HQVFTR|S@4Z| TECO?P1T+VZ.F+Q_.UZ;:D MM><-.?&??T01.M|Sj<_ORL^\$RMN>M6E=#?
W16N\$F/F^8Y%6JL&DMLR, MA\$#^F\$Q\$7/7VYH"-V|KQB"AR:2ANJ|>TX;+4%R,#=Q7Y08LT-W0MT|6P^4
MLA&5* MT6(^+@(|%QH)W4^DI0G(HTH?X/T:UJH7.3WQ^EDK|:G4Z+85A333 M\$P0?&VHY8G_.2+/(f1;D"?
+IW"Z(&CDD.1')-|J#=-|D><#|TR'5B(|* M'3YK+P*8D)2S|.P+J.#'M0&_1=8V2&#YD_O8A6-|NA"+3-
=EM2.,+E04EMN0 MRW096901&7LL5)T%A9MV.0 M8Y!:-O&^AJUCC 3UTH./>ZD>+?JGVI!=X|SIJR@17.H#
fUY^NEGOGPI'.MOVQ"&_M_.J6PI@U3#@H#J1^DR +|3M^YO_\$2V|&_9E>D)BT:O'f#ML7 MO-
0./A*JZ4OBY "FIF1G/6Z(7I08YR|*&_5H^#A.DJL=A%V2.8@XBG|'MF;:9SIDK*_M+ ?9:2!\$@).K: SXI@'6M4\$^P>
MO"50?KQH\$7\$1^"-IVZY-\$FW_|HM6^G)K4+S\$!@Q@FFSEFM&^W^!TA0B0:H0 M*PWD#&S7:0IS6L!+N.VUY*/>?
NM(-V0-9J9|03L4D|XEB|S.E1XWNXR8 MKN\$F6R4JCF(TOS(Z\$V9W|8^_DOI<4LCV;QNI%KY-4:Q+G&P#-
PE0@+!+^!% M(+8=,/(**!6 |<|=YQ/?Q 8=RYL;V MF>'#A@(|KNM& CXJTR\$WK'!%Y
_Q8A*_TDEI2^SGA7|%|FQ"\$Y%@_VG/:"%R M=S+_6T3Q8IV\$&SU4WCZ^Q.D0^QGR^/O&?>.D"Q'M\$&UWXL.GJ(&
MU>+Y(5|U4I/%PX^@LW1F:MS#1.HNSL)3TZ|UY|= MF6TW=/?TYC%76F|BPYUK%F750"!UC1%&^"7C@CK 5?
QM_4=P MZ9A@|F"9N,/0R76|XA4GT=)KZW=AO<4XM,#.6G|&F(>| H1 5V>9L FT#-
MH:14FO4)ELK*RAQ|YIP@RLI?QV;UM#(OZWJF03=6<6.FH.PGC^|MA #;P>_# MD626S%5P_-
J.*G"KOE,K^612_4A.4@EPQHBG2SS-0>JZ?ZK_?<5&E\$ M-Q0N)(*YKCS'12<8'G./M9E1#@'W)&.B|P|2I
Y/S1(RRX2 M0Q_#<8|1WK%&ENH?M+7YFY_'G7-QO:(5#+R(#,U6N *Q(HK@:900=!:N5) M%@
\$VW0V&WOS@JN'HY4NPD>1G"5)U<%L:/+ #D)9:H_0Q1(+)_Z'3=2J:9 M|^"OEXP?91@F#Y1F%XRAGF3_>?*
0NXQ=GAH4CXMOWF(|V M3|2F1VZCO4GP5U<16RR&+XVD=^)\$-1@#RB9^V'Z0PD85/?FQI:14Y)O%R
MEHRH2OT.Y2|=!%47*#T=,;&OG^1% MZJH:MEGENOS,+F=70=WX.G"%;#3D,1^C4!^!&2VN%J_7A76A"JW2.5_#
MAS"5J^D8B:ON^IA/1'.90JT_5_22C\$JAA;)X(=+/RI M\$4/N_5Q3YB=>E&! S"&I\$P"!L+LP-?%I Q*/A:;>56YHLD#
<+K*#!1)"S\$STPP2^C|F M\$<&QR(:?GL7I"2JG+?JT-(M9AH-U?6?P&=_&D-
P0C2I|HA:RX:2/I6N=JH0C+WS6VLK4EP.H_9?SFD;YEK0>T"
M6&JWZ@("M#D12=CK8KY(.*)Y +227I/A"2@96\$36VTR:=(SN4CFN9)*6Y> M99"@H^O5PUP')R2;--LZS1S0\$XQ4-
_@+L|>9(^0IA1.6Z0Q\$DG@M:| OF*WZL_7&4Y|P(MJP+8VRZH7U4NB-"N=%TID|P^U8 C0>)J+|UJ=L M)|FFE,
:%IU1;&_.6EDJZ:@&)%?RY5.2P*%L8'B2QOTV:)1:|E_LJB> MJP*XX?5?&TE2=@)823)4
)+L3V8:/OM=QDM.GAV|=O4^T8H' |SGMC_*_M01Q)2+*= OPP'HH\$R.052:CK MF6UO^E.O.6,5/DD8EU
TE>_HWN')!Q@>3.0=X*>@A|G+H86&7F*SN|KJ MJN):L1+E^\$;_9WUUGOZ\$88D-1=
(Y_XD|Y.LK%IE2|OOIZ)T(W;T9|A MI!^)-^+9R.1 (S;8YH_Y U4F%T08;Y-"OSXQX|+7/HUZYX\$ZJ|&|G6)
M?|F^C5IB(8R:80G|A\$) \$G"<=>"QM83+A5"2Y%-LCBK(H,2UZD0^&8A^"B" M@ZG:GA(LT?T@T3!#-<=+&-
M%_XOQ%#WM9+^TJ W)5HLKRL/<+&U.104F\$ \$ M|L_#TAI1WH I>O.W'-(A\$)LM WDI*2=9.NJTK"W"R:4-IB
M%GVG&6<_H6& &_O6EH_T4J2K?E|BR|B|>?P#^*L_?7&D OP_2JF'9' W MICE.G'#NOXQ?
R*!NEP_S0F@|W:VC8>X:2HR|N?L&R6ELL4 M.G2A#&Q:Y26^R\$|W+1SQ6_|SD"V"H+3/&+)|@
9NM=QG4_U,4#"7,^+!KMF'E M.=3|YT""@7^X|(/,MYC9DZ?*|HWYFZ*1YN&(M.PK6VF=#HM68 MZ/ZU)US5R>-
>VZ|45;V|>^6=>P\$|^Q?<=>_D3A+:9A+|HK62YJ+|WYQI<<7 MVU@|V=JGEAV=^1ZBML+C"K.#
\$+R&-74JDM!Y9(1I\$&Y(%OLRS0NBS")_UE594#42T=8.(5^4P.#& M.OW<5VIH3L%6). Q=YJK68I0|BS0%R^(H.2F-
!U=K_2|RP_C:)@LXN7=#)CJHP8Q/ODH^\$ _PLVD>RHBX4_*IMYP|H:J>A7DY|7MP)P(D7O3O MOW:9I&ORQ-
:=&13"1I@P^P27FS(3LH|*V('LYV7D&H?M#2Q:C&G1C/QGN.^N^(|8B@WH\$B9M^P<,"M"@GR+/QZUL3+8%?
38F M2HI+8J<|H1K&+HY2AY\$>G^L_FXK3'H5N@YX'Y9V8K)ODY6C4;U#0.%Y M_TTL Q?
X>+?I#?:2.U""CQ%G|E_LT^6R2PD)|^XMR&>Z0AM13\$/T.7C:Y\$; M4U"|^M\$:"7Y>C^|31@%AYP|XOSTB=&T(/;H?
*Z.0% =+|C #QE\$N!/%//.U M"LL!% (+-#<2C70:LCVG*XYD?Y2H^X>-Y0JLR*2C"?_N@B XZ|U(|SOV; M>8(
f<=T^>UE8WI>@^>_04+#E2DOA\$ _W38J9VXC|L*_ M+V|BT|3%1650|L?
AS7ZSY6NE!+M2E=F\$DY>BCM35'3N&@BTIW5Q|Y#I#Q35 M.|D3D?
\$SUQIAE:V=+%TUC3T>OPY7^8DEZ90C.'EZ>H+)|N.&^|XBY1^>0UW| M#X6>|M^|_4-12XO+<-
X<#1|A/!;W7U4Y)X|NA;LNE*&amp

50). XE08."0Hf6EDX+F8?RMJ9.T9P1! 6-0WMDH@V M33@XU-B3#B4)/(?6N*ST IWHO)\$LT"!AF? C 8C?
JS!K@ZZE@F GPN1DIZ! M5<06L)QU: < VV#-KF.G.MZY/=OY!>3: +?A9VZVE9#1(K*P.3'E 3<)M0? \$ M*.8ST56,>
(IBVY,4UT!OT>V82W=NCT*LYX) N^29FQOE894N,N2>#W7"!@! M+!1@DYD6U!>2_8TZY9;8TU@N35F!J=)W6!CX
#R=Z=59&BGZ<<7+30/H.5A M^X8-VSD5,8H!OJP3E M&JG14F!RTR!^20!9)IMG.Z:@:GV S4TD-6*(G,10QZM-
VA23>^<= MC! 6^LT;AHUSP(W\$D2\$8GJ!KSYX(IU))P!FV0/OE!FVZ55RZA*3)G2!E
MTKGZWM#,W4+9A7/ R(D5HJ5 YD=A9L+QXH&>?(AY/SN@ R%Z=,+/#-MNM5 ML)'DE8E
%N@@@BY103GBL_P'#7:28^Y-\$3 M#=#1LXV8 VWJN+FGJ*!N;||9 M!G2&&VPSHU>\$!-4V*&=JP.BCEJY%&I^H8?
H346J**.?F2)NL)HJ3F8205D M9>VP"Y!K8D90V(2D)YP"<1^(MVYTI+Y1.>^D>S%75J!%OC>7:;JH!>W
M!48U9!0@O#"32.)>NC8CGF%86*,7E82:7!*^0^N.2BM* V2:7 6!Y9L.#3FFULXM(J5 M&0=OCV!V>3:,,_Q>_1XW-
FP%=D1)MB>+34+OQ\$ QSC!@4^+((N:3DA0(<9+22 P7F!YH1B=6 MZ)*-1RCXCF0HY HG46!4L8O!-
H+XOD3G_RC46,\$B#:#!Y#<M24D.)4!M!4!BHJGA4_[B\$!N5ZZ)G04M/M7K&^X:H&((=?;.*^=4B!EMU!/*/^!
MHJFA_WX5!CK61X!+XIM#41!_S=3?19B2#W(R\$(K!K2L_EUA.AO3VUU M2%>#MBIR;UYV#0RC<)ONJ
%=A>L!13?@>)\$!-\$%7VM;HFWW(2053W.@6Z/PV!Q4GAD.E",MO^TI24&@!FN3AM#;LL#T.
A80729U,+TT<+HU(7D-41NU4Y.XA9(PH!CN%-M02X3R!)\$KA 19W*J85.Z%/(8R)E4W07+E9H-
(0:#QDY@VDR@2!HA7#;/F8 MN5;/M*9\$KDJ9R^:#!O&U;8%5Z78# MNX=8CW@3U\$<#=#J))O1'D^I/C?0TF&!O-
:&^N-Y!-L1)-7Z MK\$B/HTIM(@G)XURP(M?YM,^%7.1%Y8!-Z2!1^D!MR(V.NA7P.ST&_WMI;
M.%OY:HW+&LE,U6*!.,+89JAW"M\$NRP(=F UNN+R%'D0<#!A)%C!SVD#W.
MB8@SF@PW1)L+Y@X"QTDMM9!2.L7LP5118VX7!E?A4+J-ZE5W7M!)7RZUY= MEWT=Q0*EZIF+H3IX4(
6A.FCYJ<6!YZ(O+^ ^@MD+!H>52>14*7M34UY6R MSK:B2JHFV>7K5*67*DO6C+!
E!OR)@/GO+AE76 ^N!DN+MHGE!K<"2.MCK,MYUB/ NK4 _L \$W=,YTD!N<4\$)XCL+%)Y:AF/,=,C.*
!33J^IHJWH@T! M@N!J5?7) KX^6!%9SK3 AP1- !OY@%\$8J!M=OM3A!Q!V&G!DO: @V+JZ> (G/\$ZNB;
!2^H:7WXE+9^X5W!K!;) RCYZFC.R M"4Q!H&ACD)#D3!2%J!D<.<4"R1C8 ^..FJ!4E^RN3=;<9@\$WK^E2)*JH!"
MV3.D V1?7+!+LVP7/<%H07C; M1, FYJF6E+H7RZMFAY?4/%!^<5Q!CX _M!.WQC/OYT_H (&X3F+^@,-
JZ.#K5!L9MW/ !S#?X _O!H !&(6)WIS;G M4 @W"! _!A#>>WPIQEU _">#&DK;#HW\$!HK;AZG/.*?F5R0?
7AVR0Y/\$8.N M8!E4WYV\$HH.G\$%/%6/^1)<50EH0_4&(6X%J!F8CTDF7PK 1:L+Y'B9F30 M-6E*,8\$0_E4-T?
USIPL3G<3Q_ M06/XQ^DR5^)^6-RIRIY"=!#+XJ= X_.'8\$C'F\$!Q0&EPJDUTWX0D>C'D567A M8VGN#ZNNK?
O&LSSQY.N(U+W^DC7&AGY?F53!WSH06(!N_!XY0!TAW.S.% M^PEKU5^Z8%=MV!L2ZCO! 3*E@DO:
(V0VKLF1D9! NP4>F!Y*5NS^*O+TM M\$M!L!9L!H7V@C!P ND<-2.P82X!\$U!DM0V!D!9KF/61%;@/3>(-NZ,N
MR=,1K571W++>^A/V)<I!ZU?S4W7!I#PX1@O*5\$E!^Q)D?JHGN2!XF!H%!! P M^Q: ^T41L%*/K/3@K%W-
R\$Q5@Q,+!6==(!/D+BF M5BFE,8W70:;&#/@,XY*!+!3%)ZT*01_&/DZ>"J5G_%;2:6= M@@!G3A<34!/#U-
=D2%*(@)+=,JD.Y.3!VQ6^NW%36ZK.9<+!MN)<!>U!O/KGY
M/P(6MGW9Q!FNL2@40F-V/TP0.ZW2UDN^U47(DP!+IHC)!/F?Q-"6\$'PL4 + M*4LP0)
(W!P&P8+R!D&S48!@ _" _0KN=K>)00H!TY.NGS.?P%27E%5X(3-<!D^W'6;M-2ZYM2)#Y^: ^TD!
M^V!H*O"OF=^R",@DA(2&8?MV.V0C5(!^STQO60TUPES2F!;(HJ+1KB6_\$R*M=:@DHQSAEHP3UNV%IV-
^APM0?@Q7CV)& 3Q!L.M6H?7UXH/K 2+8V6MW4E MA">&BUTW-XPS1ET.9 AGR1190\$416!WS&6\$WMEF"
(Y!QE4< YQ!V!4, M7!N:8(\$FYSD&SG!-(O^P0_#N#@ZEI&"F9E="!24!\$S(SZQ-5'5@JK3C->+7 M1+V6!B>I@ALJE;
<*VO!OO:IF _C,%<4B<'YD<%9\$14OV^>#W4UR20-'Sj3-M'J-6: ^LL)374COJK/?R!A\$W9Z:Z@5
)!@!7FB>P!D3!PSDJY_KZ!9SQ6 MT!G-&5R-?^MHD+&G3-%?^Z(N0VO=17D;)30+D4#<1_!HH7IAJH=8
M((!D^++597_IR.D 2B-<J5<5K10<)HZ". M(C-HN86!A>E6B_@H4:%@<10!-FD164L0!H@Y MB(3?WJ&S;MG?POT
KE@QKZ*OR0ZZ.%FG1TV.*SUS,1:;>X^EAE!OW! 5 M(FM37P)!%>#;6#F-^0XG!H/?"JF^*BB"t9<\$S>UU8/) U-
L@M!)Y(=SW M_VJ7@!HW.CA+N!8"17X-O<0"52S9LD!#\$!Y19404CRQ0ZAL@E@5R'4.O0'F5
MXSR@B'FT3!;V!;#ANZOZT(YV)=RD=8_(3R'M:P=ST^5#J?KU=1TRB8L+4Z7X+;?S26:NS-
^F12!G!PUZC0HK8Q4IE!S\$E, M57(B)UX!X)ZAS!A! M?GFC9!LB\$!RZ%QDYNOM Y6H#X^_O179*0+(@KV9-
DBB108GC \$ M@PFYGB!B!S7E.Q96A2,&N1+T@E4-JT:5F'+(S!CFBE5!4Q)M+ MGZ'/K^W;S95. T+!&4>)4J. ^*!Z+
(?28J7!(M!B'NW*!D-JSCCV&!O,!< M785+9!NC9>T^(G3N?\$.1C9-FY!#/OPN4V3R!;H=V FEXA!RVS?\$.3D2B9*
MGNU!5F=\$H^4G%A^CU8"!QGL3Z(7BH! ^V0F,@KO5K_XF64><7F&R'D!(&8%
M.C/G)QZ.@Y'N)K!3!EXBEQ^0M9PQFA*PIX@K^U!* Q!%Q856!P+GSPQSY.YL\$#Z(WX/61K0=1&N%W@7,
M*4\$=S.-DS L#<3@9NE9ZR2S^RXA'P4Z#YX_DGX+;^GP^URQ\$&4!_O*BIZ-M*KOMA/96:A^BZX=5^X?N
ZSM!7W?9&IN!)G+RKQ)28C*F)2U&?X!KGU@N (M!GT6*(L2>&DXMF71X1!>#R)OG).WS*BMF(C!V\$@!<:;
!Z:R8AP!H2&U^!L RP0M?A1;!/M V0!J@>>^N(S93GTP67_7 =CZ?:7K@'S;9D8^C\$Q&L+.\$ZXP7";7G-K>/B3J
M!Y")J!0U: ^N"SOLI7!2@_D!> ^#!L>+W@T:46ZZCN2UN(>NVEFG>2HIV(KP, M#D&/3!2-COMH,
(P'97T^57T:.#9W!HD,=N1,#W!_9PI">@26K(Y@.*E^+; M>:T=FD91=V*B7JTO6BNMDRI"Q-
Z1BM7TE!S^\$8&'2,%E\$+V7QME*K!G6KIS, M"F!OHBG!M26"V6\$+VSE?+(R!?
H!9_X!2V\$;S4'6SY0RY>\$^&V!>IA74!L@ M5'\$88W_QYF6.(L(5O^T#W<^<"?!\$; BC1A7H\$EW8;4FV=4(A:(^25U"?
L!04 M+^S>Y!O_0S!0J@7HWX3 TCSTX5S2)P!L.D.PH\$6!#F(&E%)7!D+9ZK_%O>>
M5HW.&5!/^"OUL#E=EUCR6:1M!>DXR!DR2!H\$?.*S200.H4@,ZL\$<99LN,VA= MR+%@6Y?JW/N?SUJ7R_OYV4
M""&""Z:&^!O!@AE&SEJS !O!W<^W@D(C^NFJ.TE2DK-6U0T6T1%_WK= M.*G<5A_X'P\$X%3G!W: S\$!;1" ^
BCOGK2PBD!)(2PO2=7,,DR=M!:8=&L! _E! MDUL-TL>S!Q4BVGO8(&_!CWG!T8)YE8+ # 4QHP
N'FJ_!D9X0_AZ^R>"";MQ M<)>1R:7;U;OO1DWZQ1=?0?T@+M\$R/),KC)18!%/!H!9^7W!H MV!.0!HL!M9K*)
(F7SX!5!9TX"!.*CSP1,R0D!)L2@&N9DL)% _@%W2K_1Q8, M5W5H"QJ" F?
Z:Z+CJ=Q<3RVB5G=6!+S>H74/GDTY^S\$-+_G_!7>M49#0;_A M?
!DMA\$3388@2HV2SF5R:TNZBFD;M84C.6YIH3Y.VV!0T?XW2SJU-RS*W.18Z:ZH/IT/YQOY/I_5WONY!W?9!U
M_M;O@8R!% "6B!V)%+N%2*U562(*VD<:9;"UX@_K10/FYE4UZE>@RZ!HW!TY!A!F^PZ6
MCI+1900(!8!34^LO,XC2S?57^M&A!J_5MI;XLWV!D:&!=!GL0_%9!;:3\$
M!QG_!^;+PMOVEOW42UKC!>_AFM)X@<#D=%L=E^EWF<3N
M!MI#158H>#EKN8+4%L#ZW"QW#0%, ^T(!A8@KR@W!W_8Q7!6NK=D_/HP3G/ SSME,VANHH; M-A;CVI\$8
SA*VH0H<:1J\$8%\$)H@=N-E MV)O@!P2J,? 5!O.M^8!+J4J=^RK _C45KW?FPE+3@>4#9!/_UZ8#
MCHO@RO1<5FVZ4GK/YD;)VNOM=TO!,XT;V?WTWV"TZ _L/L M.HWZO\$^RW-L,N_56/F.+
WRL7=+E.16BPJXE,R!OKISBZ;H:X<^WH%!HD5 M6V!_BMM:?.\$L!>#>&)?
&=,;O5=34(KBK,D!Z!Z8/)3!PLHF%FZ#)%!HHP>+Y M!H!<XW"TG5^Q^Q^B+9IHGL.#"3E"U"OW7.HF9_D!66(
M^X!2H55C\$NCR.&TV;_!LVWUH^SD?NP:K5_Z-U78K!K1KBNC+&TR?_08ZY) M3>Q_DQ/Y'PS<)-
M2!;3!G^HPM@PK33PRYXD! _&=#U*/OO0!C/<{M0G)HO MXR(OVA#-EL!SR)=8.DHK!(!Y:(!?
>L7>T>7UA9H90V&2*(2?E!M ME7,+1K2 M2!>16_!#D!<4MW;84'7537Y+>8(>MW+0!15@!\$7L,OC-MS/;=@K49Z!
<_IYN^ MPW.Y!D+6FZV!BY!PQ_0Y!H!&17A(!1BSB*0SG\$"Q=K>>K!>?=\$^"!9398G7! M;
!R!Q13EYB@31?/_CU@!/:&+^W'0E^*4_!\$\$\$!5 M:Q2%2M.8F!C^1TU^TJ3_B-
VQ3D:EZ^50VKS8=F=R)FN!&9.YF.3_X" *OP>B M6.FV!>"YN59^XC3:F>N&5\$!_KP
ZQ: ^YX8WAW^3AWOAGF7WJP?DZ=HN^E;) M5U^3P_8!+ZD *Y!6>^L2E-/GS@^EYFC-,&OJN@C;A!7399S<7W?
Z:CP M>MA4AWTF%T!Q!\$08^7@G!%2_-06/&?M2^%X2/I_T_#1@Z-7)*+!H7F<>_%_K

M,7B)T/2G<%"&G@HC4+44Q:UZO%N^23AM#&4=, HV^#2I&Z_@)C9=)^{0}M\$6XY8F*[88K2A]-1)E-
TY7N"WE='1C,-CM^OFAVW,S/57MS:P/%I88\$6(MA&HU_Y=BD)C2:5:
[B2Q]D3C5OCA_/->CIRD7DPD_VO)TX'K&X_4/(EP#M ME6 T>B*^OQ:-(*<0,)JU8%0+LW3XBV#:5=&I3P\TA23D?
82"WAWI* M*Q?ZP,...>OH1_U^*I&H73L^E%://I8_8_9Y>(0K;,X_U#D#S,(@YJO,;
MLA%))&XWBAM5ONIX700_YL^Q76L'=66G_RL<);-'R2_UL-UPU3I@88_1/M3U""7CJ6+?
NOCFWK:_^DLIUL\EL;JVGSI_#4P6<#",'MHR1FYI&#>_7P(CMX_P?+
{6M6[F>N"RN5H\$U>Q,J%1;NDIOQ_A\$J&: @ "QXV9=Z,5JZCV\FW0 M8F5155X:4\$%)"(^>#5/1?
JR7RI;N*2XAFNWGQ+3:Q%6'O!; M&'G'2A3TCKJY_K6R@V/'^,2FT;31^K3UBW0W!6Y>U2,X95F#&SZ5>_I3*^O
MQAMZTRR-'^,;M7@A+TD..^Q5%*)B&5+6Q6@5C;\$97Y/"#Z1\$CFF;*&7@1 MH.O8H=VHOG<=A?
+TPQI=0I+0XZHBTT,18W<62@Q9SXJ(=48)_K;1Q>NKJEP_M2"F+QL_LM/2=U#8_-(ZC/*65P+LXF4W)1UEC=B?
M9I;N:FW8_0NV5+4F_M4GRGTF.H&F)ERTC:~?S="T9*ZX)KGIF0HKH;JF^(JC+Z=YS7DIRX)FC7P(MWV%
{YQHP;1R:=46;KMX8N@+^X'S#R;J50T4YD>I2.H3TR#%-^#N5"IX#8H1INDH?K=_XGR@4,2%2!81Y9N
M)"M6TSQ40&^<A<,'CU\J_GW8\0 MW\$K\$+D9Q.S:@_B?_O#ZGSQZN+"K_GV&WY9.*CU8PS9T(1?
8.XK<#!_7H+JZ.)FH")>*798.WG_M@-?OI#407\T\$M<*3ZB1C\73;W6B4C#(S5KIC?K1Q8ZG-C_N#-EZWIG@A_
M_LV"4TW\U!+P04_"#1@7I9O;OF4'&_!9I@_\$P&UD="TR,#(T_M,3_R-5IG.2YJ<&?LO'D\E/;+S(OF7;I4U;X4H,DGV-
)7L_B'9225BS)1" MIA"BF_HARV0OVY2=(F0\6;R_P;-I=VW.>[_ASNMI_SCG>V^N: M%_?<<1_7L;F6]_OZ?#Z#^8-
)A!RT,K,T@["PLD!N@#10YA^(@/'-8_0B!<\$_M/M84Q_3""O+K' RKI_'&#;?V4<(#M<[I]>""
(*Z@Z#Z;&R@TNR@QN"i4>#ID-"ML)3AASB%OOYSP:(GKR4=H;+OGS56UB5P=)"MH>=Z*Y>
<0E#DE**2HHQO3_MU=\$H=_(HS)!5;S1;GG\^/K=O1=Z/RS\0<3C)S&Q_M<4_C\$1
{SGF=F9;_(R7U;4%CTKKBD)U36U=2_MVL4#86Q_Y%_IAs"i6=JP+EO_M%PMKV/X%0@?8CYS@#:#^PND>
(G+TY",NT?_LZK:N.6UKY+\$/X;H@KZ,PJ_MDO=-^Q?+_M<B_X/6?9OAOV\79,0/C86T^EL0A_8A\$Y\FZ_"^2_Y?R?
8@51_M\W@A98P(6U*;*I3=B3^UD:;#&4O*OK#T_C>\$ZXK;B#14WC2&\$263ESJ;VJ_MFZ\FJ9K%5]**
OZIVN\$/'882L11@R>UB8A.Z1=*9I@WHD//GNF_"4(MQL_M>40RUR%)">(5ATD"L^\$'+F0)O_?4-
_1\$Y&GJ772;#>\$*L\$C6FYLNST;_M("M?>7FU=O#>U^LQA>+WJQO2!Z=^9T4&SKO_*H,28;32QE0J_XGU3@5->#
MYP@1^A1="99".WY/@P_%Q38/2FD29\$U<2_0I%[B_3LCJ04?IN+3R^)^1(7HJ
M,+4O5QYWOUCU#JP,5N.#7:0#*O.>_A*K)1OMB3M>X#;2NG!K_@KAS5_M-R*+Z32H,?
>^YK;T/OV1H5)6&Z;IYP+EE4%53"7VL,CJMOOQ;+?P8+6"BN_%BYZ_EU=O%KHJ>5UMOP'KM'O_P' M&(?
8;X(C^8S(5)&*L8DEUGS3>D4ZY8RW;M,BUN30AH=FL;1H(5V+! M5(D@R>\$3)U?7JMB0CAZ4.
X5F>V%J,+L;HJ3JUN=0YUK\MD2^E<_M"@Y<>_%7Z\$1#)<6A;_HK>@1G8I>!B/X/A@Q)I\$3>I;IE*3,7OHL28D/82
MDMFS;GBU\^L\XWG7JROU^X\SIHKSS=8RVI1U_L9/JUZB1\2#"K;AB%=#X\#_MD2[B^NUEMR&BW;2K<,#?
N63#CM%G("GJPP;G;N4_362?P2W\@BFP\$EFR<331FH_L;1M8G\B<I3>TM4F?KL;?)XZK1-U.^3*4_&(&F)PA6
JL&9\$*>W&'@18:S_M%C:%GHTBQ"N."&X7G(FJ_H"S_UX_PW.@G3.I&\$8V!<_I#JL6)
M&^DJB<+6AQJ+94>GBUFV/>#99Z(ZD?4I-"\$>=M;_%>D?<0!'@N&1MF/-D97X
M=P/3,BAP\TMR4K&+SHW)=UT^GDA=G=.FOG+?@18T_RHS@IF5"#ADA^_M_MR1R/RUPTNC,K?'*?A-
EG/VNP/JK=-#_0Q_#1\$01DC7F_HL_Z&?7+M\$LM_0M#P)WGSF;E18N\$BT^10A/H)HGN"Q0#?D"14Y/6^,7C!22CK%
_3F6/)#>#X4_M08FA3>/<+P>_R;_I>X\$FEP!=XIMYV_GZTN.77RG5/A9/N/EU(IYN\$3BI
M&.#UXIG@M%8B\$T*Z#A11N1,&>@03;483J8\$-IPZ\;UWW/C"<\$OLIM\SI_M88<%0Y=T<_SM;?<
SUV)FQM8%Z+";&PD4USG0_I&AB9+O/%/#B<;CU,#HZO_MT)F2+\$RS_HL_VQDOK;U;H?SB)?A&
{#G<53!&Q0KZ+;CC(A?M@X-REZ\$NT*_M;X;+46#8U=;%8%Y<3;0YQ3RX,5#P%NZ\IV*IBUXVZ(XOSI-E^
MT=4HD?2/L^LP0=A/GAM@EA9R?Y#;M:\$@<\$5f_0A^HQ_K6CAWXI6@_2\$P9
MJ/I^P_U+0XN8AJ/G^D+>J+!MSU\!RB&T=:(+&3IH%3^G-WIN!5(I>RKDI_MKP:5=71=*4-
7(=8PHMN^B>G5"Q\$(_S9&CA:#_KDI\$AAG3A.7_3!5KGP8OBX_MCFQ0N\HZU&FHJ'<05H:C1K\$RLX");#DV?
M&T6SGRL5C>+M1(P.QEH_HOQ9!=95=15^4Q#BX;+HJ_MCO-
7I4H@7=,"5,=0'W'@?7\&*D&NG5B5L2,WIS)S'ME.=37F2>1UYZQ
MR5:E6^>L=T"^\#;01WHJ=A\$1ZTV1.4TU=D^KTY&WT1(\$5O4_'\$7-F\^P^3,)Y-M#);IW?C2V?
BUHZ";FY\$INC\GM9KO(&SZS=7A12EMIRH8"@I3@I9;6_M"9&FJ8.^(H5'XF>\$JH\IKA9
KWY2<_PJ*>^0L#BHJ'((G2\$RDC13X/7_MU8-AS&MT-WF:6@^JR6-1-#?-#^8)0_FV_Z)
<(\$5AF36UVU2D(*3XJ>;N9QA_M:>WG"LL3BMP0\BU@NJ;3<0SNT_L1"SI>ST@IW)\H6"?S)>H\UZKZ4\$SJS
MQ(.1%"XNWQ\^ZWJ\$OK"AOU8LX\84+2^H/T5=RY1+?<\$7:DA_DH,7)GXX_MXP-
JA>Y_R90RE&4HO0P6"15..B2L;2481C_P7#;N=6';7G*172;"Q6IE6Q_M\NO/J<+VDI=7P=@5BL^/;#@"IB+83J
YIS7L2;CHWB90Q+8_XP#K5F*^ZD_M_@>^;"DN2^AIUH*Y@JO-M;I>0JM&9I-ERJ4TJC04&+@;&V\Q+W0>T%BCI
M.CH.A-"POPR#52;-ITC?N3R>TVL5;HX!->WJPVXFQIG,RO^RPYIS+&K7E1X_M>K+*_C_3?&AD(.S2<(5"XXC6AK?
CF_IH7EM&JMU5A_F034W^M7T%V\$D9P'H#XX_M4G#<>B;U;#*<_J16CX2)H1F_6W4.
IA+D6+G;_!>B(>_A;K+EQ8R_WJMC;_M(H'QI?V\$9Q+T;CJ+ILME&LFFE\^I>M29'D?KJ>25'E02R-
&ZM+ZJ;B>FJ19!>"PYC@&/>:V74Z_N?H%F_QXB;O#K_M-G=)8;/BL_Y;N-
8*1MF.^HH<6PC/_*9>=I+TPX;PZ3/%DK1N@*&1%PL_MYC_I*MTM2TF%0%AIT,9R"IM>
(<11IX;^_5"17LO#*Y*W73")G>I\$S(P3+MXQQ\$V\+3U&DIR^IB?(&W69?MP%HXKI;6*;9A%/9E/-
Z2IK*SS81!OI*G(-M/3N%")QI>6DI*=-QT(L1Q)*P>Q+#+T&=M2I&>^/D'RRY3G3\$+6>8>K\$??9ZE?
@AS(9=P'D4004%GN9D*FLAD"1^DOD*N\XMB9;#3EH9=7*,YO7X..IHIEDK;P1O)1BBK_C#D>R@!*\#0;H
M#J05H*EZM.M-V5;-L8NA4"Z@LG_-Z^/WOPKVU_*NI2V9I7Q+OV_AD'3;+OH,
M7=\$4@O)"MVBDB%4'3G4#7PU\$#@XO.&I3ML6XRCWYB*/_@CI\$<I1Q@.GI6U"K@_M7>:2>)A11-IB4FFU^9WJ8S?
>SQD*2=4I2.U;1>0YUT%&POX*O\$G<+UP=@2;Z_MN_U;
<#ON,8.K)K:C'<.Q9F@M4%;N=VJP9_C.C.M\$50WC@;3XS+DT0J=S.UK_M<;2>Y21H(GYR50VF@<@1OK=QA_@-2,F
M&I6I8<)-IK#B\$ZRBMS1NNKJON=NO<(R+KN_17U8U9O;1;CN2ILF^8_3&
MHM7VR;M=:U9!=B0H*JAR\+*S0VNY#=#2TEK(GC5-V-B*K6MJR&_R/KW_M\I&LR;K\&J_Z;SYA:&\$V,P.
NG4;1-E3T^8U=IJ_7;U_PMQ;#IIS*^I"22EX+=@5+H=H0'M"/(YT_M84,0S_YA32;4U^G#S7@6#OT-
S5Q"VPIA;IR2>KL8'R1.)*89A&J>1=F1.O_M;XZT\8YB_"5\$")T87APQ)GINPON2ZJ"B_D<1MS5\PIWJC(+^TU=RD
MW,6*];_SM17U*MU*MXMRLE1&.2ALL(+MRYP+YB^ZR(\$/OH8FYA)(%V%/,;2+M6#I&EX-(^I+64X_1X<L;B
CRR'R+TM2Y_L9HK>-"Y,)(10;6TH7RH%5I<&%MSZK1<;DI@H#;#NU@\$WCQ\PE:2_8YI5HO;M@7R8*I&;F*Y_M-
GTP0"-O1-N<IVIOO*2OKU+;!Q8IZ&M0%6(#303#X\X_VR\$(NDT_I8N00AK2_MLW#>JIRT0_;"1-
D4WP9IRMBLE\30G8J=GEI'9/NK6J@&G_5;5V\=-;HWOB215KP=F*#"MO68_M(2_A(9\$D2O:15Q9PAD.#HN
@.=ZQ-RZ8IZW*(U;OMY&I\)"LR%ZU(M"IZ>Y%&-6X/^Z@&C)0%2_OL#U;TP(A_E_CXRG/6^F*{&Z\IES4)*">)"
M;WTJ5\2^667-(KPG;K19+VJ.B-(^+I+B+M_0.EB8QT.W@B1B)"L17;1+;C_M"J31+<0B8LGPIMFWU6(Y_
U9G\?_JKV'H"??_6;9H\$IV?Z,H&6X\8*4W".M5LPBZ(SE8U)JP'W"-I_MO#.XF>-C*>QI?
3Q=9>=HESSL!>;IX#EH*H9T!|^*H.C1#T(5=>2J.X66NI%-D)>YG2;+B5'G_?4+/Z9ZDI8S7P6N
M)HD)H*JF9"3(BO_f0T'.@H6VW\$Q.B\!%<:6)%0,\$W(5_?QAU9Y?CTB%@^=O+H'
MC6ULIN\$)P8\$&"DXFL6_2IT.*J\$A_%9YI=?;0_08UH4^+WJ9,X<&IR>_M50^=/_DL8L@!;LY\$(O2&GU=G=
(O;JLEQS;E_?%<GS_EPLU\=_DK_?%I/_M/^I#6:-

&\$:1@!RZ<+!BOH31!ZA6:#/UYJZ03H! Q%G9V%VDR2_6YUVM!^D:T
MKL2;V@^/O/@^+X@:T!I3QA(@%06_ILSC!H\$!J^M^ZJL^5-5:1ZJZ8NK!Z: M!J2I5>%Y^A!^" X&_/DV:++R7_)?
!E_R_T:P&88F8#53(O!6R#VZR0\$3<3; MEOX"6YNLUX7B&T6:IL^WN'2*8RD_@TI>8/I X;\$!_W&KW-
)SM_L(9OHZ>|M^?W?F9";,%P\$ZMAFC(3P@U+;54!QENQP@8^M9E16G,+S;R?+H3Q1X9IL MYO1Z-
%5U6#;C5(D)289B9^28,,H\$30/1!^5!JA183!...5V10:L7^T8MV, M2&ZE(1H0W14!S=_[3S[V8T-UI80,SE^W_+K#
!%#^JT5KUD3=GIW8)(*)1M+>EZ?DFI?/F!Q2AOX%NVWB5\$S5!X!)!;I7 MGC<5?
4(VI^#HMK)6PH4OEFAO%2.59SB[N^V&;74% M^M!;UY/S%!/6:LZ69_L(K?F^T(5BF_/25JY@.#4C0/
M&#"XRT@_GQ)HX:19(I%_TJHF'3,M2GNDH!CH3AY=FY;ZLU%MMQR(!%9#IUF1PML#K^+SS!(>HHD
MAH>U?;"L6:"WT&?6W%W\$S9|<<3W1J|<H#HJL39JUWA+FA&9X_PTQ11HNW*&)BE^V
MR):!@"4L#4Q;+F>1.07/KEX)#/H MX_-+M6?P?)^\$L>F(!H98EV^QW MPI+EU,?+8;"HPM4@9HY@!^*2L*
<9-4.7E_60NPZ":0!";ZWA(OQ!^5?G5? MZ2E(NV=672H^G)&M,28&Q0IU_J6G+W>^O+H!9I8WJ#37\$A-2&=6P
:MG=M6#Z E_*8!";LJ_N8IO)TJ-N-B?^ZQ!^HJO.PCAW0X6RDVYX@<Q4QKJ!M6CU?EMZ,NFT_NL9TF;TO!P-
BXDV>HOC?_N1SX4;=LMZ&PICWJ2GDPL#;6 MP#;M%&@3FP@^LOD)RU3ZC@L;_1O>TAJ41TN
M!;VHN4!B3!8+;0Y/40D=O!O%#?5E+;+OD<^6E^FZ3#^B^+;V^8H@!20"!P M^!O2AB5A@/^0'A<O! B?
5QINT+7!;9,S%7B7IV73WQ=HYSV0:<%HLL8@97D+ M^JW N:|Y32!NV\$G>#S)<3\$+Z0>9D+IC;977--Q%
(%EL26^+H(H^I^"PCM<M9G>1."IUT^V2I\$6IH6>#7+/-QPI7@U_G)A^D.N4)1P' 3ON=,^=A^X4AG!^
M2FYS;6/!8Y5NYYV^!J5IHGH%5.+ SE/ L!(-176TPKKZ>0D^PDA&F!OL MNNTNVILPZ>I\$QIX1J&&.;S!>??A3"4(-
KG-YK-F.R;12MGJF/O7^!-!8VG+M.!OC>L71LV>B^GGX6V&J+ZT77X1!BQ%L>#"X)S,P;NN"\$-@>D^4=2.YE:
M>;&EQ^LM6>1%M;N!0<.!QY.Z0Q32/O\$1#JNR1263?;RNJ13L=DS;")^F!L MS_MF2H?
YR#WJ%>YNNZ5TRM+JN5H3V!J8/2.1>A+!M2EXJ99!>@G:J!J.Y MC7AI5B0*K@0U!F9 M4OR:
(K**JLUH8YR^U:74@6%UB%Y3-ZWL M24^N!^&/%_UY&^=(B^H3!X0 M4)@H^*2ZY;WOY;P>N!L/5Q;+A;)X*
!68)SCQBS9E3YRZ4(X^LVKD<IUCIA^:0R"9"D)0D^CZ6_OU M^?;P D,"-<2 D@23C520-T?N-%V)/C?
2NO^*E)#C(LD#^I MZ2X;|X V<-)DC2!MOITP;0W!4%KN(O-U_/=.F3_*JCY_CX57;X/;>9H867Q=Z_YQ@IW^%3).3R?
M5V!UD7!AU2:7 MMD.6F3G7/CD>Q_X!410CS-&"=OO^<\$6IV.H!J&%^4\$<#&\$#/\$GH M68?
HOZ5_9O&S#^ZRE^F)J<7?^O#?EH?;KA66U>797;RP^VI_\$/T=R@Y5%L\$ M)A!M34WE K!S&UV1@ERNR&L
M1(P&NKC!S_V8T=|X_UV,LL?WM)S<5BY!H M^KYV,H(O:4^0<&_/^KE;W2='CY8P/J=,BZ85JFIO;JH@W^7OUN6D
M^DWLC^!726=1_3>(M.5!)ELX&8BF(!.*\$!A_H.K3,"QTTJJK<^>WZY35I+ MT^QY4Q=3^VCUM/R(FC,P9ID2%
<+DOJ/E_9PI W^*M0P^X_Y^Y:)9^U3-IHK!U.15!BH7%YVU! OPV+^*DSNT/U!EGQ!HM2(L M^#CGEXP>M!T/0-1
RZ.CNQ#M_IZIF6+Q(H!A2>|O^C9SS+L!#G<5GS%+V M!C-NNZOG^CD;O!8BE!^!X+\$4>^CVVI W F
!G3S)+P;&M_/KSBZ+3@HV9- MX:UK^F8.W!ZU:3PB/M9^9SX!8239\$("X#3J10B05^IB52!MNT.F;ZAAW-
M\$T#7^FN_F=|"IAAF?;\$!N^U\$!Q4M!?!&BZ/_XDL0^#^41S#F!"M!S_'9OM M7A40S\$M(_U!X;WBF?<
40Z;0#M#F!U\$NLK5^B!6^KT^HW.16,,Y8Z^E^MU;G? 2.;#F-J^B8#A!4=N2H2#L.D.;3H!^/LU.74X)
M>^27\$HE,T=/(K)4L!T1SU7^VTG.D!4ZW13(\$DFZ05@1H.&M9517;26H3&E MX-
!60,B1U0WY!^A2+!?)OHZ*6!0^!|\$=4ZE/GG=8>.!\$=%P%H*-
\$;RC%_HE:3Z%UXDU0%*WH^K!SG.G^D6^S%O=F,RE1XVM M\$OP)J!H^Q!IT;JL4!(G04T\$!W=B8P_-M
F>Q4L;\$2U5\$@_ \$C^F3E&(4SE2 @ M#Q0>QGOZA)XPOAW^>P!;"JU^70^AGD2_HPI^G;G,\$Z^!W?G^MAIM;5^J!/
M9@OZQ!4\$NCO8BZ3N_2K<<"7#)_S;DN5=\$9> \$S(G,ZDU18;U/(ZC.#JG8GI M<^B)+^5!2;R!X7B?9!@YN-
FO!QH="";.78IVE;06Z8D6!BT5BVT)RM.3?>TR311L!;6I^NIK@YI@)2?9^OP MHX#!(SN+7<=,LZ;IA27=\$
RK!QWS#BRWXG_++XOY!;GI MYJ\$Y5AXL!N."6%:!AC)+N7H05>?W_9#=#3!E!)9P6FO@>1PH!;Z+@1% @ M^"2
8W!J89HELA@N1@;7Y0XIO>|E?T/;>MC2N^WZHK2K!E_-B)^%:_?K+ MNDXH&^_1_/7U0UI+K_+3W!L;TH.^=
C%#06#UR9@8RQA^UA+5>^A!^QU/_MJ,5V2;E?7N+@49&8A!7^X1G5A?#.;)NK"\$^!FE!^! MNUN:8^JR!0-
26=05K/@Z?IGH70SHYSO_HU!VZL=RO>;S-ED!COH MZGE; M +V8H4! N@%TLMHU,OQF0>=4?
#^9!#P53^3Z2%\$YJ?2GQ752&RN_B4>&^MVA&SEP233N2T.WYS^J!^YF+\$!QI<%;YHY;5^6&T^!## 2K&@;70-I
MIR3Q!>C3,B0T_A#)B2J>#4U#|P.D.7N7@S&^U(%?J!7*OM;=#5_3LUI0& M\$Y(6^B69;Y!MK0GJ%1^YU%Y^_#?
9(B\$3J(A2%N=%*3).Z\$;@U!IV%ED97) MUK0HQ;J^H^O/K-D?_I#J>YMA678^HN MGEFO!^VHLJK8?
VA>|NW^M&0HUMKGL+G@<|!\$ K=!4GAM(AN&DG3@=;|N0H^EBCXG2(?C
M)17^*CQI8^;T(@:2SGX77;>|B#2!^+K B?=@1_P;Z2N0^K7!EQ" |@_*=7 M7?;#;_G#Z@*GK?D*>_8+0
M!UF9&^HLNLW&Z,B+T?>L6.^5U3#N#H_Z3 MDH!X>O7/WS^<^D5KKR8)%S^X82A;'SWRPX@X=I.ST(M?
%N7M6(I@%|2_7!Y0QD_VT^FHA%DVXW=#(ADWM1<^+G6F*)GYL@<&_JO4!V MNN7C^@23JP(7D&-CY?
H^H^M&^39).O=#%;Q1B8IE?V#ML^N?=#A&J>;M,,M;39<>>_<
/4S71+K91.#S4/O!LC8>ZFH@!#+_YIC!(-1=SV@;"9J;Z;SS M9D);%5\$1#K!0-
&E^)^N38U2^TFN48>ONJPS)*\$ _WU0S!L30!+2.I0YJ2NPZXAMH?(<3(A/9XH??2/^V"!MKD?
2BZ^ROZGH^Y\$!&TQ!)P(&^T!J_P&BX_"? MK:12(^/O:W+G)/>|XF^Y4^V/-YX;#Y><(>C!XT1/HMOY)
<#W5";.U)+K_M@F895@X\$K-5!1QW!5J%+R3);Q9?;JP5A&_Y^NEH6X89) C\$N;P7H!K=V!_MA30ERJ%
^A#Z\$Q/;#U+D_0B!%VM!^?+_UY7LZU_^6TS4ON!^FE?R5_4I
M1U1_!1CS<1^026A"!;H0OX.WC!RX_U!17_X8R9\$7_E^F!SIPYL3Q_XNG0=
MB,JKWG%^X/GPI/793T=D^BKQ^OB!0_8N686OBY)C_#1DGF>LY!1+NJ7I7 M?T;Y_6?E)N&^XW;S.W9G0YQF-
G;0Z(Y^R2!X?;9N;3."^+=E3H?^= MB%(@<1^ZM+K!^IPZ(15;#/TPC*(X ZESEN^RO4WC1&IK!^YWKU?3TXW
MG^@5S;H_8;FE^OZ;7NMI6C^H.HA%<=1^LA;9*_6^%FL@%/N3&F);I28.8N8 MN99!U;4+KC4UJ@!M67^9J8
JCB8F.H>GB8!/-^>?'\$ _N3B,F^SC=(;&^(->^*
MDC_I_<ICOOTG%V3!NAAPOV2@34&V#Z(ASS;NM;BR&_>\$N%:=/OM=G!OHJ9
MHVY;HUW6_!^2&VVPTYGLU>_88%CO\$AYU-IHDWS2)P02MZU-6>V0G?WOLF=+.09&GR5C&M-0^!T/ MP=;^*
!HHV^_7FE^*RH45WAZ7Q^<\$:.78V0QZ.WG!S#Q/8&J8?^K!^IE0JHW.F!6 MD977H!@&ID#R>Q5^S<<%-20.5G*_OB53
ME/N%15>?7Q!FYE!^!0/DG<4!#)X0 M\$80BS(O6!G8J?K!\$JH@AM^?L1;^;T%!0SAFI4(Z0(>#Q6CU!HH!L4;4P
MC.QBFMGN2WKQ>+60ID;^YORI;RNV!58T^SV5Q%6-7>SL>JNHHB.YX-K@U^_M5?
CU.W^A<5!;"\$0^G!T^2,3^5!&=3!^D>80B21L;6L!/=W^02A!2E=;M@<A27YA-!L>T!&_!GB!A>T6?
KL!Z!S8VG5IM%)D^1^O;R^2%YJ-OJO M>6FYM73G79-MTK&IY4.E49L!VIZ+CCR1YQF-&!'<
A<\$_#;K&!/!0%*2JUA>= M_/MOU-"!W;)E!>VZ+1,BBW6GYZ.)+YB0#^!K!?,XQAC_%^C%C>;>K#^#6!\$P
MHN!5N^!JOY&6X9_2.I8@-|BP!ZY^D/OR.#)WLJ+^C=P&V\$K M;_"1?..7TM2M7+!F<7(E?&2#JF!|D.3UF-
"#@22(YH<&= _TD4^Q!D!&^;_MGT6=M!Y!5+^#?_!/_K.WXQ9)H^N4^A>P=S.Y+!V@&011&_X#E(L3#ONV^J+=M
@IF7=X^+=+V!6CVB\$3>F5V!2*=CLUMUT6TO8=!:;J!^D^"@H3;4?(A6;&_! M7.URGX;XH=-
^AR_P&J8E24JNVQOFTJ(8N^F/LU_+5D9->T5V%>EO<1^ M;)(!?)1L.^>!:L^U8!>R?I<-6K(;^@!=\$8
N^A52#^X8MS;VH9 M@+^N&N3!>V_12>LK!8IA!V#=#J^WS!ZN/LUMLR^O2>+S4(-@ER6X%D=U6!\$H
MW)_ (K.E^@KS)Y^8;EMN=+.UV!B/^3!\$!S!C=&Y;9<"JG9R!WZ3O,JWO!\$X8Z
MUL4_&HEV%JE/UM_>=0;#4.DJ%_H99;^?@=B=|4HTVUO/E@2MSO^!A!U^Y>4I&W17A_74Q;O!4(>UU.C1;V
M8!O!^Z%SMF3N5Z.=W5R;_70J^S.;C!^NG^_V280\$^OZH5;>#&)I@!M^@%|Z M<|=)E-33@_9;.+E89!Z>GY?<
T=)16C&X31!_K4&#;&=>U&Y(3)B!4Z!(-M85T.7!%|H3V2/&F49X1L=2O" M!^K!A71VZB4C.6F!4TZY(-
HJZKNU7KH!5S@?V4!25?7>G5NQY5Q!NUA^BH^M(M0(^#*3AB\$X^D\$ AG!^"2,UL%#D-

+CQ:FS@H^#)^X5)2<('B1H7JF3E&B^(>YX M,?-
@MKXO#W9Y'40*7'OSB>>WYN8J/0>Z,5*KIY0'KL:Y:5<%D6IKC82;XEX MD5:9.%,...LJHD(*,?%B"IF<IW=_10"AADF?
UJ2?K63M<-7_-M-7YMEN+9O,2\$9-G-P\$DN7XM*!^,ZI+NN+;S#ID\$Y4%U0\$EQK\$1?@89LO(&(G M&F9?
I26=&GJ_RCC:HD2P'GJT\$7+;,%1_P:RI(2(#1#:\$ACH'P03 EX6 M:1@HJFI8!:=&NEW1O&B.1UKR8@YZ5-?7CU,;
IU#)IY/T48@:0H C-1 U'NH MPX3\$8#B0:\$7AWAV UIRNQZ853)0?IS1XL*:.DZJ^GN5AZ6&IU&C%)#E5R2I M-;
ZG9TI^_9036NGEI!%:HS8^S\$AO:P: 3I:C.HXG|N3QH|35U|0!7-O:|_B M25-W=W^9@|92>+|CKZ|EBIY0?209
H'(JEH8)=CI*|R|I_ P_-%S_D(IR MGTGSI_?G@|H>SJ_B8O:|YRWPJMMV="E")%Y'29&'?K\$PW@7_290B2#
M_Q8J|>W+!A#30+.C/M"H8!X&AP*\$|S+T>A@1@ZY+I8G,SUD"OM3+--7F0<4<#%79*6YG+ZA""C3*VB536O'0XK4?
4K3>+./T.C":7C'==B#OXC=@(T1#W=)W6CK)M|Y:2^H:W#39-M*4BIFYG&TYAO|VBH:7Z7_M|A+|G=GEQFUT
8WKID6&?EV#&R|U39HTA)D M6XJ7%&:=C7I@TBI?GW3^\$|HC...X|F|GOBC'KDLW3NX|S*^!LJBN
M/F@^E4O<_<(HJ|CO)<4W3W7SR@E#O(O*R?B>KWR2 M=IYDEM4+!E6T/9'1*:5^30*8"TS^T@JW.-G0P.4
7LW1W6424J:22_YY|O: M4^R65HH(W3L)XL_/_7|C|G%CQ|:ALBFSX-J:PIOHDKSW|MADE+Y8>0C2_Y
M'XSVOW%5A6X|WZP-HC"1GE:7FI3^TA|KYG=A!75@/ZK_MYYTJ&1R9GRS>!XM!=3,P9/J\$=#,?
-A%X/=AVYA1NM,_BJUQMZ5RT|W>'L M1\$X|S'FO@|\$;,"(ZL>"OXE%CA4/^|HDH|T4@BHC/-B>)-59M+CU"
I(P#C+^= MB8MTRHXE5"QW M'M7PM:1)(O|KJ2/K+U;|2TSE"\$B)&@69+OOR1"XQB2K6.A+1Z;|C9:5L:|
MN:Y BN_6R5^X:U"U^75QN:|GE#90.&^C-3O0@>_A3_SIR%*.C^CR|;
M^6:EB5.X S3*\$S@+>LNN=D*^ZD' H9BM!B/K-QHJ:OE:F3;\$<#00:|5:_.9 MZ.2IY^23M:&W^F"#)E3&X-
|C*:.% ^1>AAJ|U?|+('4T|T0J(I&X@ M!9#VQ&2E/@Q39MN:|C))XW@|N\$73W|FU??N_SN6MNJ3\$>#'|
<3:S8|39|:4SA|I,DJPP.6|"0 M2=5'(DC+^_#',XHO+VS<#*X#>=4Y00=B|6?DT85PB6?Z@*V:H5EN=M|
M'L_Z'G@DAH?!"|KNXLF%L.I*8B)^TP|(THQ|&D*!>1(HFT%R>)K<^3:|&O?3 M?
N#*|A.>|OYT'^6N%:TTNCJ_K)|MD'0VNB=V?=:UQU6F^E6CYM@I58J:W&:
MI_XI\$|SO"&T.5"H#1WPMC.K|57VG8PQ9*J71DC1G|HKU|Y:Q:5V\$+<^_/1) M#I?0_I.*STN_A>YI/W@
XI0U&AT*XI2TH(9=|?2.#|D^/X|7:01+^|D) ZI=^8V M7_A
RGOB9SL0(N^GVH51A^|EF=DN.ARY"JGOIQKQ<8LIG9IP+|M5H:|L\$ M^/P|=E\$|Y>(Z|O/O|1VTV:?)V)\$E68V!R/7
L:2:9J%|D&|IAN1EL9S|_O MC3-X%*DFX9|?|FM?=D_YMQ_-5#V+|\$|M(.AF28T?Z=N4#W2I:N M3I=^%B?
4|JR+S+XH C|_66|=(/B3RIKW|GLF3-MQ)JK(2U)% M|8|H,9>1|7#S\$W|XOW.WV8*\$M?E:_D-
%LYA:1&G|I2,RS7|MHAY:1N|4S1@5& M:64:|S#|=5-00W@ED>2;T-I_E+R'=|D*O?T6(|(%|/_/D.^B&:KN(
MNX7CQOZ?TJ|3(O XQ9=JKZJSP,R3JB>6*DYLB:QG:846_J-E-9U=905E';<>?4=E5+809A|IT&PQ&?";G3FYX6E?@
M#V*!1:LT>?KTM&4GB53H>E3X5#05Z8G_D06R|I:|6) NQXT_YRE@O:|S%5
MTY&O|:/6G0CL*)#*R5_7|1%5(PH^I^!7B3H"\$YAO@2.1+8G)+AL<+N<|I"AI
M8"XUX61#K_XCZ3F+=87SXUN/QED)HYQDRGYV^|IF8R>#@=,9E//|@_D80D|U MM.)A_&|NA|P/^U6C|D
MUF=3V&9|:0)ZG8%C^|CF@V(|3+TRFU\$|?>E|&V|P378;+^|S6_+..B+*
M|@GW=+FG5DKNW'B0B|9C<|)+@3QA2@)X5|(|XEG7*:E#G|!E|?OF+_:D|!O6# MARWFC2?LKK%L8U-QQ"
<\$|P+=P/Q_WO)Z.0@_ZX3"E4_0TB6LR|K5"XP(68? MSGZ_/F6075O=|SA:;=V9"3E.0Y-5D9=PAWNWD@YL8^V|
<9PZ7+WT:2?B%I M2N53HJ:|>6:WD-MJK_:F9=&?
E&Q6WNU26CP4='T8T+5DI*:L9M!Q(8UDP(|1|T_5I6P9W!O76 M*D*P&>9UAPD1;+Z*+4>>?&?%6W+HU\$*|^/3"-3
3&0<=<=:|(1%R)(^KF)R5X3! MZPDBS0+8AA,+<1|H_*4Y9_6A:P.ZV+BW,HA/PNZ8PIU91J|4?D^=EGUO)
M_1<|6F@:??(NR5;PGUFIVVBMGH6OUZ%?1L4TUC/_Y\$2>RBN9M X."58S-Q3I MOC(?JN_E91C=?CQEZ-OL:/?
SQ^#|/^*88#> &4N> ILUVIF96T|&P466:|SXWNKU|_DP\$#15B'=1,7IN8E/Q* GTUTIY9MF|BP(6.=K8K%|2W
M|:.*^_D|85KLCET53#E=IT^_\$>=&3OD+L|@|@:(MH2/X;VU695FSS0+^? MV_%|%=O/>.:?8Q7L_3LND
TXR#|!%+&|EM:F.Q4QH|C|Q^LJ*T3M_)B\$|H MNWHS|)^O)N*0+F4A8|L5NU_YD#LOLV=XHOWCM|\$-
LU>%S8O^ILA%KRVC_ N M>#=#=U^EN:9(EV>??:CLXL89M%|;K2M|/_M/M3WMV""QD|R"R=(4BA)O!?!#GP M
^TS:S/6"3)|@S^*|UJ=5-|P07#|BM140>2Z#OS0EX;Z_|>+1/4YKY M,2E|>%G(P|)NW1W4A?
4ZB&J:VGY,C|%/>UO^=,E9D/"|97N@G0PNR?TR% MY\$AQA7\$K;>4T(D:ZF-A%42\$N^0O0K:|T>LT*B2^\$';|NO4B?
4)=S-|&J9HM>P(1X\$";!?! IO8#VE?K(4J1 ME|1K*Z,7D9_?/30;YQ.4<4DRO.^V/XZ;ELCKJH97=U \$VDP(|K>
<>?%M""? MLB;_E?|Y<:|VC?6'27Z3>:O\$|OC=;|&U9'RGJS(|X.T@EC6>M.K|A-RUNIR>
MOI.Q_K5|A1="L_/>2L:PVGZHI|ROKYLDF:|7\$S|O|=A-!%3YQC3?DCX1AFY5 M_N\$6WMJ:RS|8A1|M9-
466'X4#_JRP+._W6_!1\$X;Z4R M^/I181Y|\$UXP(+\$45&RNU?<(2@T IQQE|HEXF.=|7D:R:2-7
9L_3QN|MN/Y^|_D6%<#*:)K03S9TP0619Z=NPI MUD-5. O!";%/UI%U)H2|>-UR7M9&|6?69|\$/SS8B|SU" M
1CQ2A7?QO'0H6Z4RI<|ZL_-W"0@E^C4I%&A%K|C^C5O'ENH6_J|
(33/QUZ@S8V)A8|_3DY_&T#IF'IQ/*KZ'0%@^L|:|^#5:T M+6,Z' M<0H>&>DV4_G.TTJ3:AN:8|!|&.O=
(.6|C^*G8|.NCSU?5K2IS:"\$U(GZ*BOW M%Y4M|RRMM-C562<>:0K_|@=7|S<_HK_*4P_O_2X)V
MF9ZO0X7*FP|C+^RT2E|&J0S|&0VJ\$(7.38CV"LD#|4\$ONM>H_O?>-,106Q MF0=I+*Q|)%MTE&R0-
S=V>0@GW\$(W%=Y4B.G06G^4Y|Q|3:|CQ|^2)=9TYG M%;YD(|&41)' 4W(|_I|0|^B_Q7V|7L-
K%E(=&\$O1BQC%&WYD8RA1: C@S MY?HAP6S7IA|3LGBRA+%EBOP6,F(|,"U&YW:8W-^8+ "_@(|/K(2Q-YMK#*9,
M.9.UP^L^L<+_=T551J\$Z&#_G.N?|YBZO8HPTD^D2J#T|J-8@R_@TWP#18 M|V/I"SRC9|B>R:M>|
Y9-YDI5ZL2F,SZ;?UKU_#0*BF9|.02|KR|(|LA"=3G2SH3%:=SHL1*"FB0RYD1.A M| H-PX>ALV?ON5N5X|8-
B14%RI|Z>A>6KDC?GTA96|X|_J|S@V7O"&A| M|DY\$VYE|U|UTB2^C|ATX.F3.X.F3Z1%L17&_0|XK_1L,2\$3|
XAP(023+)_ MFK8&(Z5.N5H7%*XN@QCG)5W>_VP*2\$|+P>#>3ELG'89--|JDZ?_D|BJ*9:2 M=^|S|^E?4:3|4M|!#JD4
8.6;#J|I?J@X'V^+^Q|YYQ37Y=NG_4%6FB5_\$A M(E5I2A\$42\$1\$0/Z(V.A\$1:H|I4B_D%M>A,0D|JE"\$J)=
5.I\$N3WH("2(=M\$|S02#OAF?>9|LY<|X|HYO|V'#EW'3>^VUUG5=>Z^|=B'J\$-RPW8T,V|2 M>|T8RG^F=4;(W?
%4/?>GD\$@G)U7|YU85"Y:.\$U:Y8A.NI_KX1EUD+:/D:U
M39|^M#O>PO"9ICJ'_H/^T#V0\$1#VAI_@D|GB&M5Y|QW>:/;\$XC9P?(1-K0?N
M_5W^_\$.0Z0|H(>9RE08\$9O4N(8Z3A9_>+LF=U)'R|L'9^8/PAX|H4.9UBLQ|733E<2K7K_BOY_-|=|
T#^\$+5|U/58 E:/06T?8A|_@Q^HW9D\$|2_M0>NVU?7K%GEXOT,W0EK7P1%(|A0D^+
(|%BRY2&_2;2RJQ|5_8';&HQOPDC2C M*5%NDHO&5KV:YY@<@<9-YY)8(|=,CRWC-MNL_V#I*_3UN,GWL_V99
MS\$|)O'L|0WE5^_*Z^?DZE*2-?|&9|_P(5BEH|I3(D3|G@LOVSTH@_ZX62=M>%S; VG3D+<9TZLH|&+0;7&1-
=|MMQY7UV;>)|@%F\$#36X6Y*|BYU7_'U^ MVW5WY_#5*%39>G1;|L8_:=|J8T#W>&
NTK"*H^R1L=@CT|U,V\$|I23(R|O M<|)6YOKYS&9Q)SPA1SX>,"U<'A?Q;|QXD|9B@;E3EK4%FZJ_5C| P%F@^"S)
MPN|35=12HN(|_J9K+26T|WNW^|9'2|_+74X#%UHB54L_:?RBY4HYF\$)8B09 MH+
UQJQCV=#&:Z2*5CJ:7T/&Q|/T/7*4,+T)*LM&S:5ZUN.8H=V%FD0IV" M?/=FVUGVI^Y/H4
I03NO>G8Q4?_SMA9|3GENV>O)NZD68;/'8 M@V.T|PHZK0;3|Y%M4%J^_#M:E-H?|J|>4 MVB|RV1VXR6VF=,|
-D'J0>7Y5^). HWY&YO_0\$/TZ2J_-M\$B87 D:|H"0W;:2N*DXXBZ:@U'1|XA'HKAEP_A>MEWLO+VEP_K+EO8M#1
MB&:%&H0*87G<@|PC<:|HDXVWJ.5S:XCKN|"(34S09MLIAR|7:@|!S B|E4-IQ=4 JYCW|_4'M(|N"K2
M<):&.V14BG>8L(|O#?0,YGU25N+S/_C?NONZODP4\$BP\$5*_+/_DL2Q\$@%O! MQZ|N|W1GGXNR0/N9
O2^483^)&00|1|I7%OR"#)EB|*M|7L9281PMP=2D"E*05(MRI
LU(40SZ&J.FUR:|JR&O2GXPIO_E5)RW|_|+G8KO:B6FTUM_R9
MCO:821H06(3R&%|J|@M='5|_#5RG\$RG*|>OCA"0L4^D%M"|/P(PA91:W^HMZ M5+%_0> R\$*LW-\$X4.

!A#=#H4>T^=O*7F1R2?|<*M*D+*L#HYJL M'H"H95RRF'I'2NRYO(D+)|IRGOR% U0.AJ=9 "DI9^G;>EWI/9
!E=YWL|>M M;|58=%L3U3YH)\$RW|RH(PWJ L4GAS#5K-BP8'0V3=@R9|UCHFQ) W'D|* M&>6^24--
!JY*7C|62+-1NR=AOY+UD'8Z)(K5|5QXL6LR4TM#QP#35CX#.0 M|AN6 (V=YSS^B,*;,- E#IP
FB684B+V'4KM)!2GG_5A^@?(?|CN7F&OR5 M+"OZ,8
@E*HJ MOH|W3Q\$|6%*O(C0|B3FNZRV|SBH?%X;LL,F"YXNW:LWA MJ*==Z0(H|
>U0;)\$"W""R0LT7V+*TX7(Z&WCH^*SGX0 .OMH|R\$5NL)G(<+D1LH;!A8BB|K|D3|T M-@
!&,\$X=4^3OX+ 4Z>2:<*> TN,CZ&#U59,|W?F?Q2.1P0"+WAOUH+ "H0SYW-7|OY0G1.'KVLT M*."=57S|-7|?
N*VFDV HJR3S#&EF)|H|BQ?OH.E'AY>VP6N^1L2=1,7GEM M%GH?|5 ,<5TQQ9#?
U1H/G4QOWA9DRN|W107|VDMVY@83VC8B|'5T"DYULB M4HT&>0)2|<SZLLL|N|KXBEM<
MBA7O|H|G|K2|'W5B|)^OX@MO2|D5??6*9;|S(O'ZU^\$#J3VJ*<8L4(0K>|NS03(C6D^WU
81H66N=IN4GB;@WM>" +\$P&@"LJ.6\$S| M4YT|V&4|"(#RGOAOWZR4:>)H-
_&F5DYL'D.K%;RN|LY\$P*JYV|02H/5I
M&+J0U5QORS9)&2M.|=8.I^+;+3>^4=LX^B|Q>+V7O@;61M|B|Y#QJ0.H4(P>B|31?T).NH|
(A0DAOZJY>8.|0/A6|+J;|T M++Z\$JRZ?W4-D'64>'5ILY.8)-RN,/\$3FZAYL,*L.K.O(E|1 E-\$ #|)3(\$ MAC,PM^9<\$S7-
)2C|5+!4;.\$|8GW9#B:(8+8_58OP,QF1Z'*FOL9EVL#7+G69 MRFL?*\$|SAVBP||%#1FB3&7F&R94S4V_&C.
!PA.|P:\$L|1|5\$YU=7|? XW7D|\$)5DTW3T_7EE|MMFLJ7KSBOP%FX)D;|*NGU;#=#0.RA.J
M|CEX#DP7X>^8(5GVN1*BHI&BL|_LR#O5C3_!*>NUV9F1.OX%OSZ|LKJ5%SG MB0/E'P-
)NWOP0/>4/C_-=E;.>RS#RA5<4)RJ_ ^U6;L=+0Q.MC# E59S>>B M&N@!@W9MP'D=>=>4@M-I';Z9.C.C+
JFIV=SG|4VJ;#B^GMB3S+<+L=>=, ^PT&U FP=PK M7\$OPSU(#_9&8=YGTQYL7CRV*!(H;L(F-
MKFYMEYR#JOUU@Y,DPER;P#O5KD%G T;Y|Z_4GH3\$4?<6@"TT&W>#G2|C MMRI_Q#M/QV5%*EJRSAAH?
4ST+G=B,SE-VH8D?^F.)5D>Z?K.V%J;\$#U0/" M MF2P;GVTA_M\$A4+UG5J+|U/2-
B=J^586E_E+/(MDINM:A_S)1|HBA|TV MGC*^H8^X(8-T*6)4)\$H0U0X|C!*>MD;*>C
M|A.2PXNO/;^W\$641=K|_D|L+8LZK?|ND9QB0^K@PWZDO;^=;@|3?_1ZQS MJ(7ZIBFX,F'_F>66|X#
!#C/T\$|JO|R:D4P%)6#B6H<(|^04+=(|1 M@.G|3*&H;Y|AM=IQRBDJE;#IB@(>IXV0-
R)6T&UR#DIX= NY3BUOCV'D-S\$|L M@|F? <|UX.Z9:_\$5=SX".KT"3&%3=D+|L)6:4_R3-E.M&%;/OG/N0,@VR|E
MY)(QYB&|/X|^-|BT.JK8>A3KD\$'@+R5AJ:EYS?VM=)_K7GGCJ\$%>K) J?) (83#M;)? M3Z-%?
N/BB1'G^+;8/K;63:6(PUHQ_I_KPJK)5T)J6^P.D6@E*J8GDGB+(*
M+L,UPZRGPY78K/>2|3H/;8LW@U ^R|VP388./QM|C1% \$TX2?3G5>WFL0
MJE+"YEC6;7|WJC6HRT;\$./TQ(U_O.GD1+Y)B(8KH-QNT%"R5*/WX^@L+A%VA M>;"G.>9>F-
85(^|H@GV7%D%KL&Y.NL0;TC6+A|F255+&\$#7/77Q/4N|VVI|+" MX?TOE=<=>(MAB8' "|S;Q|H*A^61TIP>.9R!=6?
39N@^++2TBO>O%\$%B.(Q|ST%H&^7\$56C?_1KQY1D?E4 M|H(A? &|TST*9QXZ1|M)EEA+|^+N =T9C|JO9E1#*
MAV3L\$PYRI38<9TLYJ_9\$UGS^?B60 MP+SH_D|MPF5VN(2"3=FIEWJ,T?+?
V9N|A|Q+523PA|WPZAF1PXE'WBK7J'Q O M|@3553^=^=T|_BV2?G=;^@9Y&A?GC7>=P|3@W&?P8#9GJS&.-W
PZ">QHY MW5|P>E+WEU\$&K#Z%|MC/O2(%BT&I+DNK M\$2-(+?TQ)1O;8E6?=>FK9|#"3R.)<J7?
8TA<|SL|701ZTP5E|7|HCNKKJW> M=GL>=,2WP_?Y|HF@'14 TT/L_#YV&HT*"%=9NB/G1KWDD;53|WO/93&U_P/
M|L>(&4/C&W"D)/O#4|Q>5XKG7OL|L|#S0^_M;RC2|C.F|??&SCU5U4\$|SN MS%
<08CT^K;4C\$ARS.^9YU_/A*M96PLB&_8|=#0S^\$15Q6^|6H4^C0TIL|"E7 MWOK+9CE=>^@L,T&|/TF-
(=RH%&L|FJ|U5^QO_=M5PC1)?F&1Q@?%<M<6*3|L\$1T=6?>A68?MT|/(\$,\$)
M*JM4.A.SS|HX.XJL RV9FSHK_WIQZ+G+ULF|HNOCNL%?=ZJ_ ^W4#?Q9C^' MC7|+-
G@3XV/V2|GCE|HHP0|DEL'N@|ZW|V-(V@.2P' MP'AK#55/-(RS+|1^SBEUE8|GD@G;F#|*)
|O&Z"N^>FGB39ODATD#67>?;T7 M=#0XUA|YN;<9&/FBQ(6#E)U6P|A"|=S|+YEW?|_VA|OGT#_0|O,+Z9C"
ME1W!"IV58JN5@=AQ|1:6D5"H-8|9C\$10V|6|Q?U> ?+1TMS(Q;|KWL)RWF8 M%;+F7|1^GZ;6Q99_1|1?
CVS1:U9|M|*?<4_.,UD?(L+K^FNA.\$/TM'Q3^%|M&F/K|H0510#J'1^N|0T|1|NC2.XMD|5;ABI^|&L
MO7+;?/A=/6@KP>OBT=KQT.;13N+<98GZ;57.3_G5"10^FT XL4#>2DE41?3; MYAPX<=>!/H2P';J?CQ
0.Y|R3|+HK=2YU9V96_3162_RHTPM|L.\$V.6Y/T MQ^D:CTFI#&>)9%PR=_6J(*T5R-
HNMOX2@VCH(F#ID6U<19%;9+-|J*KWPZ M|'E*&A_C#&1+V 2|F(9W55F"XN3|,S|W-
2TL@9: 7\$\$(6G&23;M8MJD6^3 M=>"V6U#D8LB#FB|Q^FHW/ KJV7Z9/7-W.3T/8T1-4*K>Y21%1>A|9Z%<2ZA#
M|+QLR?2T O9 MH>J@-%#|MAT9|HU_+0==8X'V).Z>N%S(XX?/*KE|CQ%-LAGHDE>AW|R,^RH3F29%K;BI?_|
M|5|F^2_FM=ZL%S|.T;|Z0UQ;M=6&;\$FXMF50;3=,LP<|06MZ&82|>M.N_QZSX&M;G|SZ<#0ZV;-
+T=4R|J%=?WT|H#M4; M Q_1%J|YOCG52?00.;3^&YFTZ?8?TEASZW%K9+X8-|H#>TWRW9|_EY
M8_!K'|=5|@L#28-BJTU4Y^Z|+(|%|@O1%^M|W@T5&2^<<^X.%U?TNS|H|K1 M'O#@KIXI=.O4>L#3|_O?E|BF/
|)#GZ4'J#|F*,S7- '%|/#;6R8Z.SH>VCK MYB@VC?B_B@(|P>G2Y@8T(9ZI&L;#JND7 XS)|I-I#U%C8"\$6B"7|+?;@9J-
M#GW#OK\$FRW>+)|"+L;P2C_ ^DS51^J=BY4S&/_&DILNB|H|KOS6*HR@?'Z4+A ME#18!"I-8DC6"
44SH>D>K5#|#82G+B<7@TP|G9EKO)"&0K<& M&O:0F/CW#87.S@U7DIK_-YMM7<_-
_47|HNH&9+GGR#I>BX#|_*C*|;|,%-YE<L6SVP3P@R|H|G=ZCY4.PZ;H@^ MVTUOYJ>L=(SPPQORQW6F|+?
BIM8 M(C?M.Q;|MDN\$7/MSX*G23TFXL)H(|1,|_|4J-|)3NPN M)\$UO&9V&+8>9>Y&SYO|@_E\$6NGJ>(Y#(?
H.A5KP'G M\$K;WAG&9_2H7(\$?HUL)1%"K;U23I)=W@WE, #SQ@S#H\$)+MAV%KBK
MR.;G)\$CAV=|G)R2*#1TT1JWTO#OZ"S3N8L74U?NBD5O!4<3|0;9?_.,%6|1 M|DT>|W4>Y)1V!%&)#O'.F<^PO(B?
<9 CT7X^NTU5J?6JL>WUX4.1PO.VB MWVH|CWMHKUVF|!R6L'5LKSH&'R8-Q M(D=L65_5^E?A6_/(\$8U-
EAA1VM&L/?CWN002Q|M;MJB-R|S^5:Q| M|H|F%-OWB79@H:7=A55M&@@QTG5?_|
|B8FR%#9.F"C;+FDFB9:UK*_43 MSDYRID_I\$P381K|V%;TUI;Q"M?C/OE>MJ|36RLOHO|BCU= ZN,YM+
M5&RTNP;^9"N|E.5BI+H@(\$4(=)X<|EMO|XYE7N_%)28W2DND=J_Q|SLI2N M
YXGN(TYNUV|JWHN|RIE.CW'W64GZF5_)X|V; 7"6W_HBNM(#&+P+|L@ M#/09"W0?;D?
H#UW|P|W'4\$^2M<^S3R|^(AUV, MU?>.,UM%QWZ<"XWL+MK-M HZE'3D?=>|@)^#
(SX4W|95LM%F^FD9S9+|=H9K M8O93K=K\$WV:0T*U9VY%OL=G\$?<,&-A457BF_-%P|G;3|LHL,^*|LZ4S("8@
M6ETLF06;_%Z|'NG" XRD|&"- ?DZ?KT*3-R9+I+AOG'EWH- M|H+7|QPI M|'L6|=|8E|8)>O|@!81FYXP|B-?<
C#FR;%LU<=|ZS@XU-B^A"VZTSM1Z=X;(& TW&5=0H^S" MYBQ(C-)V=|AP78>L;MAQ@&Z-
|4.9L8H*&"5%I+BP"1K&%|7D)' +U &C9&B MX*C.EOY0*#CJV3H*;)ZOF8&5'ES#K/K1&9KV,=G?
VB.OS4Y>C)HQQ1G)|I M&HBAF|TITEAY=X|QDB81UQC7?G"@N_!T?ECO&"N|&5|1)15@RY<5|E
M6|N^|>QNN.W;=|<@LE#)=EAB-SB#&^ONZ<6JRR%EK\$N-B8|>(2*2J<8&0-M>;9HJ'4?DRV4CKG-
HSG>SAR^C+)|HXCX_*YGX^=%9W?(7)9R+|/F| M.ASLL?VN=JX;
|L5.5+U1QYWFG2RM^&XT6ZEU|Y.D0.35D.JH'1-.,^\$A: M^~|S/+U^6(O&#|F)T\$#P/D0M8<IMHP#PW74|_-
ZR|/CBGTE>|Y4Z4X;033 M'7^*;JK;HSQ_<|EV1;|) X|Q|UHZ^+E_|(-D)MF<&D+=,Q9YXZ;_..1|M
M|Q#74;_*M\$|3|(#D7#Z|^7|U?WB"KQ44|B/?TL|QB|N|&C%WU> M2_A^VT|P|=|'"NB|_J31S.R&+;H/C+;UW_C\$=
H'.Z M7D*_*Z1|2B-LK|H=,ET1LY4CRCPH7*|>8|7L++P|!@>W|IG;JZGU\$OQCCT7 MSWFRWC2
L98;D2I4|1#HM0IC&1THX+QV8^|4FKIHM-X_SHA7V|NPP(Y|FO0 M7_ T5?
5N\$4D+TFY.VH_S.KC; UN8ZKMVKKXT) M|EX|RJD#|I=HFXB3&=K|6;V IWJ2;|G*C;|5QMI G|F*\$Z\$1Y-K?GW"S;4
MB*-C'RQ^Y>3S=)G9|(^1VVM|K|T|^YGC;SIX4@-/&

M04P/2MHVS;PVKUP6,=WW:QDIF%G8)08/TI+EI!>%3%OU23H/LA:RTVJ&T" M8?
2_BG17V=@9I:8+JNW=)/(\CG@!\$Z!= MCL.<:O>?4ZK%+Y@IXQM8LM29>Q3X0T:_[1>5>'#D 58QA,1:T9!#,509IU0
MGfW\A!;G21.LLGfL_L_27#,0:"(@#E,+%-X.8M_E4V-" %Q'F=?#BL9TB\$
MDJ\JX1M)CfH#QOJ>WZ&B>6F/>GUX4J00+@S1:S+W6O'-,26)E,)P;/7Y,T M,*E&@47-
UJ2Y10!/*J^V.\$HT4;@U!@%XL>KC^K&KGS!%OPT^IC9P3:H&30_ M6HN.8AY C8-)?
UG@M9NSQ)\$.5'#Q1'22&/7:CV0)WF<:TCPD>+3)54YU^*
M.=X16I7:VFKW5_,MEB%@JD%53JI^>IPKKI\$FPLL1H&:-E57M_NF&D5_K.O M6DY30(=**>VU5+ 4ZMFVM
"3*45D:RHQ"9#YV()7005H0G:B0G:2XY78!P MH#L!C5\WE(NE9T-96T2008K:<)(C:_)H='3)T=JO?D! M4+(D
18' JFO6.SLSNO^9%B;A_3^>4X%N")G=ZNP!-T@.82:H-RVHU:-KG:\$.E+K27H\$6S M0,>0AYD2?(\$JLUGX!1#,
f=H-XO*TKfTfJ^14f^X.QY=RI*XJ(W)=3&JL9> M:SiV"#Q44IN4F'.UL@.L1%IXZH->D70#CNKNHW-S4\$17:N.^
&%<6/KK8 M/17^61.86*OWP8+=1P6U.X3)5P+K&S1D+^GY@SjC'U9OU&9K&& (/+JUO
MDfM+%OHMCAQSG0RY^%4F-.2'%2_4DK:6S2100\$;@G209KAM*&8P!G%-
_HFTf72BX'2#>Q.%OMK;F@<>fE,>LD1=(M&>'TA=NHEA\$!+^\$W/156'5!W M-RCM)?YI@?
L)RO8Q3=IfI4.FOR+%K*4.GWOA@/F&G@JG:."H/170)"2GLS*3 M'X=^IMY7U-T9;JU+G7f!_O4\$-
CL/=VD.<^<5WRB%*PVK2*M0.GXC=M0S1W+ MWJ";SO6' ^XN'2':IZ/793=L7X3Q^f^ZM%%U\$G7.LJWF(YR08H,
YI># M9F);=V!>IBLM_L_1f%OHL@AZYH9!^*O-M);.V="f70"U9Z4A-L21MG3?
MBR0TV.#32)JP"0ND7"X6P@+Qf/Q&CfE+ _GM.E>9("7=VB#(J%?#N=J_YHC M=PIZH+?C%B%T=G*/RR1V8?
2MRZO_QOT=4JZ=fIL?+HI "DN=1/CA^Q*#4I_M/2@1X\$/46S 6K#2E2-KX'7H6UW3=2%KR:8/@U>M%9W<4I
<@<6+0V10_P=14 MZ)O?#\$"5A5S1FGJ3P6>FH?9Cf74@DV3SVS.D!7R;W<-B33J2L3NWfNY<(D)HLJ?C'SS-68
M959BD#;CHfHx02XUMHC\$0.164^M036WCXWf==KOR_ S)U+''' %*0'83S' M&R=(022M):A0YPI#
fV7Q(.+WKMW)W%7.VJ=fY'=&GfA"0VZMWf?>J.RK". M0@+MfFFHAN(O'#H2H-Y)(-MHGCF4-
UXGC:5P!>0+D7: ^G9#!?FV1:FF*17N MQBNOJ^"9,IV)Q-
J=O3UQ!+J#>,*1D)V@9PR4+M=OBF&Vf&^2UU55^HfFLK* MY2:JDQT?F45SR*8#H+;02
MD)5>1#S>G\$0C^CfT^fM@QDRE4GYUI9B)f J_VX0YAf^Y?Y9H1U% f6^W<f? MX7_Kf-
A_T_D4HfE:C3I2J8>fU,1T&P"l>3G?#F&.2E(TWZ5G2(f_F1)Hf-M&:^T\$2;fXKOAKf_18A9f#=>Xf;#;Z_U=?
6%S!^P.O:S;N2%X0JCSC fA9)f M%DC&J\$6fQ_@BfMW0_98A?OAM f7T(fBfZZ&Z8R<*6Df.OZR:B6KfJ4@f19
M(f:;#3EFM;=H@/H^fM^fRK_M^fJUGf 37f@_fJ.KOJf>RfSTWKS4O&=Z4 MCM;#)O17S_P0FCMf^9KE4f?;%N%
f!V/f^f+6<%D@_HfVK0fBN_0Uf6f%N(f_M;:Z)_DE_M:f3/5UO&Z5.O=S^BU050+;#fU>P-
PDSFWC(f_OfV@1L_2%R>6A9 M/O87GGB6Wf_U_fLY+DL&)>^_?6* ZJU6.4JfJ,"8&.%3FBB-VfJMf?AL+H6-
MNSfM8HR9-MBNVN?fV f3.RA.LOSBXE/K4*!=0T>f!ZZf;f T7H/26>PIA(H;KL^\$/Y5C*R
M0KH94W\$2&3&=@R_#;R^>^FDf!f+07UY-TUCf=PK6LS:"%YX 7#E_<_/6%
M#>VZ7f_Q<f29N')^>N_WP'TH_f2>WT@f^ 2SQ^N1\$0U2XF/f_1^470-G5f^ M\$Hf+B=UY&DLZ9Z_0:CT>f-\$UA
_1YMS>fP(P+1-E=N/Yf,?9C>?9>*@7WRW" MUJ8fEGf04M3SBTQH0%=Y4/7E1?/7M=?
8F>@fET.2O)YC>Y*P:CU+^f2KF& M;SUG@;_ 5^P%;^ERBCFZ43TY#VB,Y*=-K9:<82_J2&P7>E0R)6:M8/=f_/9@>
M3KfLV:RX_42Hf#R.O4)FE12N;fCP6ZEf!_A1=fJCQ&%M%\$f3@&Q*W=>K*6
M:=N@ZLXPN=6(f/&5Q0F>+1016.+1ZOE%G81" M>_QDH-O+V'M4 CM9S;/_4XM\$V<";&@>B+3Ff?
W;*AG#=<fQVP'3f3>/_L" M!4fD;+4CHXR>#G;f=fA%8#9%.W5fVQ_.FS.6XQN,"Y'9J.LP(N5H)O>_CT^Q MN'00)
(>j8:QfVYVQMR74CM2DS0E2ADDU5#_W&L_f3"fb+MDf0MT^VZ?JfAZ Mf^GYYf<%W'2RM-LPGY>^>R0
SfEFHRS0#H_f8+Rf6f?^O;ST4_/9^O1f+\$ M2%FX;=AM_%#^9@?2M(VXX01,VYf9V?%8ESV""T0>=K(fLIR)
f^SOWZ,8@# MQ\$W-H<4(f";>E_KfL""0#0K)U9HRZ2P5*UH*6)9fL.#DV8\$JS7)PAV4C"JfH109\$HRf.OR
M=1/%2PSGN;RNfMfUV*:.LM=J07fTJ8 M"M_4f;>BR)O+IK.UH"XM/0f?
15R0RECZP16'9YKfSTN=.2Gf#LW>O*P'V MS/<%>^HBE0f;70N:7<fR@H#-fMM0*N 63PFNO[A7%JEfX+A"%&
(5B@S.S)fS0U+8V02XSL W@S!>;+fE158#9T MIDZf+I2XVfE9?X7%DIUD VMT-O-3)
fW=NJ7L:B7LUU+DNGM;CGK*T_X0(AfMOTfZf7MMR-(MU4B_-Df^@7S#f!_#W#\$QNZf-2<^
(UH6;)2WSG".3"Z@=QO_-PU.TPK&=(#&V/@6K@'F"HfOVMMV;Y)^L)NfW! M-0)f0'06&YLMN/_X@05Df?<
XUXCf5PI32KAD:0Q48,X3E4<>?H^9JfL;P;fF M+;C.J)^POCHf?
_Y'S/QCfE58D5*Y<f16fU+G\$9TFQ@f1YD*Q0LIZQTU M=H*Hf
9F2f!ZA=Q63M+R04)f@)UJ\$F.#Y;+^OP<_fEBfKYQ?TEf/YfIS.8A6X>M_NF(@?Z6f773E;)1M>P8>4?ZZ&A2f fSfZ
+f7fR&H0_W237fYA MfBfTD02P:f1G/H52"/C&0;O_Q967f6f7:T8?)H%4fD0f-4_5BE7EY#E9P_M%4B_f\$
G"#\$fFKfTZfS9JUK7\$00+13.Jf@_#GL_f+J*f!>f4"U_Of&Y_L7fB
Mf^;+*%RTO_f^Q_ZfY^P(OQfID9ACQO+7.EfSf&OfO?BC_/660^HfUJZE%
Mf^%)*CASfX2<8P_f/K2W86;PY9_-H"W#2+?GV6F_N0fHP?%YQ4L_*F8K_AN_Mf;JG?P-G<6#CW<
B2H26VfXMM4"2@9.2' f7\$ B^3EJ#YfJZ=Uf^_ \$3;A_M_fLN/^;^&F?_W%OYW7W6+*7EL#578P_MZF*OX6;,\$_fOf#
O'9fT)6=2f_MYS.+#D!_#JfE!7POV;#X04RZUET;f(P'4V)72fHCOOL0V=0#_Y&FG.0+;f_M_9Z>\$DV_?
GS\$/fOMf;%EE.PG6+7fI>_+?VWf/_ Z*3EMFYf13>RP6K=>%6_M!3J4@_K*G%=(79"ZV#Q7EAE1*Q
5>ZA'XZM;J&=NM>4 K<1^Cf&CSf>F'7B_M_NfL=fF4X@-0@%26%0DX@H&8#FN;J^XfDfBS6'1^_:(f)O?J
MB3^W5;2_7G_C8;@4HfLMYPBfB_V*>Q?5@f5Z-6W8V_AJ&=f(S0Nf)*SLfJE_M^O_2fVW1=f*#;94=0@1VMS4??
B6%&XCPf/97<5E27AHfPOYfL)fPIHVS_M00N^@fH\$A@B3J\$U>2D6>*O45+IH_f2JfXfXfG.ZS_XfCf%<?<
9(f"MHf4V+ MW#ODM^1H2+Y%\$6%DHYfJZC.8fUf;_>U32fQX56_*fQ3W)20U2D.V5OY8>?&<
MZYRO#7DK4O9&E0P/HN/_);_f5D-@SNE&@3O&"CfM&O^f);=F_1&P8fK^f)f7)CW(6C5?+^+&f0GRHMBfO;
MDXG46V^fL;?fH0K*E/Y>0#Z%LU;\$XfJ0MX@G3EFVE8PY>J;#DfXL4)<_U?MH MB#A"4-
K\$+Ef&NT2;_7^f+G=VER&fJ7%?C@9fL;O<8Tf13\$8WHY_CCG&
M3f#/_#Vf9>54f+f4V%7R_(!Z?;BINAT@F<fLPfMf^CfL&B+CUT_-E-M>Q_9H MORH@'_N
M2GYE@NMLS0f!&VAU;f&)4_+&_6CZC=fI0NG5T2W"JAfQ#PN'.6(f3PZf12 MPBfZ?K**#f#@7-UA@2/BGG
N4EN\$P.7?)7:L0@_V5*AF%<f;_<5JfV9NfMKTf?f*# SMHN0V<+6*^fT#4NFBG0+fD+GD 3C)f3GfP%8U9?
O?E#_#B%B7D2 MIL0f;% K^_DfG9fDV.E.f;_4%<M^fUHF?R\$!fU.KfV6W4+;HRA_H#A.ORG_N
MG/^f_8G%EMfLG;J54P4?fJX(=NZfWKN3C3->@LR,8JfDYf_3MZf1.D_S5O.RG4 MT<_
fR.K472M3P@Q5TXS)'5JV=A&3Q.1?LD@A!+MV68f_D=;3+=LS-Pf);D_MBO\$&M&+G(BV<>fPFF*X,fFf+XfG
#N@f4^DE_,_7_6FE/K#*7O_M\$"%V&&AJQ/3R>AX<%U20NWHf15^U&=5fEB%DC>Q&fM8XVfL@J*S0Cf7MfL^WV-
f>^MVCf#Q1<62O#0_H1\$J(fTX6%=RXZB\$Lf;fW=+O@/_TfYD#";C(fDfM_)f(KM%W?>T6-Z5>30D)^>C:f^"
(RX&?NJO!^O!fLZQ"?+TfF^_WFUM"4C_Mf!)^N;?4_fJXf6_#>#GS3#CK^@f?OKf>B97.DVDQf.@+f
E.fM7A)fE@>f3HNM3Q8A@_M+G."OCC?5>*#Y0'Z>>C\$f*ZC'5_U\$">*9L2f^f!fAENG<6;2151_-5fOCf_
MYV2fQL2+;fJPy;fH=fHOHS;G'_%f;_4^E>*DSYf1#>=f^ZX,5JYfB;<6X_MK\$Df3WL>MS0S1R_W_BfZRM;f("S9-
#Q"2F#fH61AM5?RfJK)YEfHDC><_U%>_!%<fL_fL"P60#fH=&"B=XfF>?0NJA6_MfFQ5WfV\$5M&UWB"fNY=W-
WfB?J7VA#W@P4f)_7_UU@f16Rf^E_=2(007>_G_M(fF&E\$;JfLEfKB.L7f0'O)fA+9=fJ&#
f0."21=fY>FZZ(fHH%;="ZO*QfBQ05"U=EP7*_RX'9OVTMAQ#2SN)?(=Z'"_%\$M3@_Af)_GZ6
M^/_NHZ^_S:Q%6%V3CYf+S9XN""8J#O:M#^CTC\$2O/f1W^fU;?H+fE*_RB=5CKM_M."TEQ(fLEEA,6?
1Z1fT.K(fB"RGZNN=MA^_9H@LfJR,R\$3Q'_M'Z;UfXCf3Yf!>9Q&88Of4G/8_&@^1KR&fM>+PWBTfS%-8K)fTNC

=,;>'+4T25A MWDRLP>=//T7/OIPIWZHF3D\KU4_ZE@.@:U 6&GZ/X,ZKVCJMM4IRIV7\B MN4PK\ 1GTBL_-SU""2?
4M,(/1K20EP#+B\IY6\4JG2V9,#G 6#1H\$6T8 7 M>=%*I9:6/PKWH\VEY\ O'<:C \W:R *C\:^+');:8V9?WJHRME=05?
8\Z+ M9>G/(AKC%)\$*E?>\G+4#:0\F\H+H4=ZXWH' VD*B&XB7-#JT_#I0SC;
M&AXE0Z6KU005\JRA.ZJ@1%7,9#1S@:\JCAH7S0)Q.YZBGS%51M\6U; M?PW
MAB;9\G&H^H^LU01ZDDP62V<+TOL9R:C9^8U07&WGVNG9C_XLI=92FZ.Q.#\A1XV\$W\ O*DPP78\B::O
MPO&1HKJM%\44L-S>\$C+68 MY#O+JTIS0*B\$:C.L\56.NN0LQ:A9:\$8EJ:K2EIL#>YQ/62F2*H(7S\$RI3L
M.@=M\7I&Y\$<31?>"030"3^*&^5@U9IG+TQ,\$2G&T.7P;M_-1'CS4*>Y4:!" M+-0I:2+["ULM_IF)SI-
DE"+W%2*,K4^Z0Q1'Z+?@A\!"!+PH#K8X0+ZB+F>[M+QS'F)*>#T%,DI+D&L2DI-
HQ^=I.%9#I:X)@9DUFYAX,Z7R.9"T=>Z) J4 ME\$Z?##OIFN^,4CQUB7:5#F*TL,4,8/BH7-6\$4U_V?D6R2;J!
[M9H)ISN>PICRRL(S\Z#OABS0*8-IN.TKG42H/XXM8^/O%JOS_#W\$
M)N7Y^<K&K\XO>;RC>H\;CQJ>H33"NM5GU'DV#)@BQ1 E\@SV^P*\$ MUJ.?G+O=<_AF04(H_?#1.>D6E(E7R\K-
\$-4H& AI=4*IH5CXM&N9@SI@^"U M9\DE23Y<=>V@6:~ZM52LC7?UN/L4_BG+RDZ4R=,,,&(&LJ?O=:_*D"S\$T2'
MYL/DEB"A:PC6*.R+N""PC^N<2.M_H+SSSD6G--@3I@%GE+\$/DM3?6)PU M.M4K"5A4L\$>X.@L3-
MGZ.Q"RV>/S@Z(7)Y?JLV'@5K%7^:'6E.V.X:./IJ% MI_-V\X+/'Q:0L3\ 1FV'S4)KJQ?JR4KS%G0\1N6OXO'Z,401^!/?
<4D?HH?(QFB1-V?XU_SIZE3 M-UIWT1&_-I^-IO%M#^PW^R4F# 0RW\$6\IFD#I/>M3-V:\C6EK*/_O=M"l MB^S'F
=):U@JG00"W2\$*85PZ,DZ4&-Q'/TQV3(4\4_EL<+:=/99% TXL9K MD)(HDXN3IDK5L:"36\@DU_?Q057XU.V5EQ@)Q
FY\!D&RV7@W&#-=7RW9R6R#4FRL=(M1C15'PR.LDJ->K@X75KXU=SK P.\E7WY(-/0Z>/>_.3\$ W_-S*Z8Z?
OJKJ8GBLWPPAQ +I\$81\OK=P7\$#7N7 6"/.\$G01\KEUM1V<2PP>=L4!% M9S\$3>SVF?
E_PT_CV>I%M.PG5F,2*HW"R2\<8DM0U4TFS!A;\d8' 8CV\IO\$Q""?=>C_V0^SI=-.S M)&53&AFO4/*+MO7QJ".(W-
JENJ8Z\$>.) (7B%L M,C=66O\H3A:I>PO5\ TQO M3AL WP0>YHJ9X^>K\I5U2:" N^K
MK,2#.ETV=0_/"1H%G\^B\I+<P:M=L<9W(I7B8?>A\+-IL\$R:2TV2/<%5 M(1HM,Y)T\W)B\I\POHG
P*N\+2=\$6F7<&O4\ZFKLC:D>:SOU'094K^V2\^ M6"1XLG,")PS,5CY&0A@->FORB'R*+- MWG\$SW,FJ2 <2K4-
IX%O7/=K3Z5;?X\>SCF'5^VH4!:\T?ZL0\H.E;J\-(M_F032428>1X_5 W"N&)O6#KCRF9^RN*+))\+1*!_ VLU.4-
MI_@J'GAE?053IT*18P:EP_Z^#K4LT'-8I04&MD:-G?ILR6I?%)TC@Y\$;!!Y
MTWPN#J=,OX3&X\R91AKJ>G&YMO>@=U7K3%\05A\$G&SKV=X#W:VIA\&I6?=- MHAN3O3M@_-K1\$+!:%GP9;Z
:-<%8=WF\7OTI33*E;""D:34=4;VB:X7S\X; MMG&@;7_?'09C9?
J20\$8>X<<^HCL:)\HJ3N\8I"SD\2)@^I\WS8BWCAG?M&R\$3D,8 MF:(\$O_0Q6Q_V0Y&0D\+"TL%L MHB6)/8OZ,JW-
R-7:,\$*WHVIXNP:6(I5,1LNW>!PINM>%T\="C*JIHHK8I*M.N'N3U);5W\!G5@ZIF-U26R'460BFY_T>'46)
(30(&7%ZAIPO?C;EL,(1 M^?1FF:Q?3V-'=@W=-K:4=VGJ1*<J,IU703C520A@?(-*>XL\J:,&4_P0"
MUKIK#9&EAK\IAOT5R_C\A\WEZYA17;8EF>#K(<^FWHJ\Y^X N&\$QI_28M MF(S6F#J=>R(XZ13=O^+_=KM
M\$H0.W6><^/-HTEW,4:H%G'>XDI"5WWNC\$1*T*XMGP_R;ITYMH0I%W?KTP2L
MYU#7#W6C*I#^HW6\@U%GS7Q*)GE:#XQG,W\,M_%(3_A7H\+DMJP0D(HT^I MT+OZ\$B4&S<2P'G\I-
J46V2J)4YFI\$#ZL=1^E_C3HPB/<%RY\4R7=,J2C:GP>I7X8&O\G?N\HO;_-%K.\B#>HM"8GQ"PMC\I
MI8_@H75U*)>!\\$W-7\EGHW1KI,%7^_?'7JEWZ\GV'0Q
M%EY#5RGOA>K;T#6=:P5D*H\GJH.WCO\$NZN9P^6\UI\$&\I7\$5ZI7"PY.S\&?
MW\$LVHRHX6NUR9/M(H..XMOSGMXM_Q_JH\SBV4\7.H63DFK%6NC\HY4U:E,
MEA#5490RJ#53F:E6D*K=I\$1BJ:513+5H*:JVVA)J'5MH5%H\I2D&6:H8K>.O M" ^IOSC1B_YY^I" ?J=-YGO?
I>S_/_Q6KY-"G4UN5SYJH\OMH"_%6R-3K_L1NT.S6'=JM M4_H WF@E+IRBH\$#.Y@ID3_"HE0*5\$,B40I?&
(P4#X6#B4:,ON+ _J5AAY"RK7 MSPZNS5VP"?@C7"-W-U@>_A#M&"Q\UW58DLOG4ORE@IW
MA=VO\$OZ:JHJ\VZI?/'V7FG&9@-+I:8\$+I^WWQ(52H9D#W"=G:L\QTI3/ MCWWY2U;%=37 @OU&^?<
6BNZB7(X2O@5*Q\1YANFURHF\N&:>B= M7HZ;P3%"M.A-\$&6IE\V_HDQGL AD)EFL_L#%3&G(G'9^%*9(@H5^(?
&4 M\VI?U4^_04T-GU\^?ACI@^C4'5E6AWF=YHDC 9<(&9' W"(4#H73+6HF MD\1D)\^ VFM6>6OR?5NU\I M-
=AYA+ZLW1\WMRL_&O?&I?U)B@1L.P.M*ID>'E@F" V>1%JTAC M*70A4OJUB+(U:SD35C,5@PQ4XHH_-
LZ%F,8%6D:A*9TP:HACP MK(%?+@K.E-'BBZY/\$MZN0C8\ X=N;<_*L6P\B\I\I\74\B+!^P67I%WS_2W
M87M)@G7\I.8TD J8LP8J,^3R,^R\A6R)S\J3_7N:Q'EQ:F36 MI+VU_2(I4&)E'\C"R\I\B:K\I-S-Z*
f0BSZ_52:NO&M(9SIK\I-S(I#.OKK M?D\N%JK,%"=<@"/,FH"P%:S+1\$EGYV>E'K;RRO9 M#3#%*7+0V6E_#D6'K
WT...5VI-0(Z'6K1VYVGN&=>")K*KJ=U=&_I&_@9YR MM5:EI
7LDH2:@4.\L5VDTX\CG\<L2)Z\ADS>Y=V:BK&ZQ\I\#L;7?T?I_=-Z
M405\<2Q04,K0&BYMD:H5^JUQ76Y+MLI\;E5,I?UAMTG/#@0IU_V\@*RH\ M+&I*O(1M7\.)PO2P9O^S>8;A-
SURW&(V.L8395IF?ONJYVWJ MIZT+*YW;Y\6(8OCZIAMV-G\$7\$EBX\==J/>P*EEP3V@MI3\U_15WJ\HOK8
M1CM%U1\4NDA\S7ZG2@I\VA)A,X6IW-6">T4V\O68@&I_1XP8;+BS='&_CI*H(@0S)?-R9\$WC(IRBQ\$*529-VHH
M21X.&K+O*(J4X<4F:JZX=QB(K9I-0FC\W%-DQ+E:S'<I1\$TW\26Y7O"L07
M4ZYP0FVO58UKWA<>V\JU^NZ;H_T74MIZ-LC:A"\"C=4"#>LHH %G&>_6'!::I M\IX<5,^B&.0,XBKOS(F?
V35LFISKHW _UFY F\I\H\9B\Y\I(3;:<^:~+E M\XTM3I'>*B=7.4#^>Z2CI@=CVO#SXLECV%)3 22-
OZ02NSX\!Q+LU@(:.' M7_A.WO;\$^UM%B@7)3_I.P&*C'(?\$@%'<31H%T0&8I:~*+0EU)HRME0NI
MNBMMK0>2\W"N-7J7G>:Q%PNE*TLTAXH)#+\$86R&H.UNHO88_BB*H>U+'OXIA&W3(M"GA_
MCN:8J1>MG=XT\8^*G S0U&-@;#I%Q T3:DI8\$Z6_54_TPQGEW?(@QR.A>-M?
D4Y=IYGO3UH#EWK\I\$)LK"FYR.^K=I%SC<17Q4W*T^_GDR?%0L4BD2BL4"MUUYE;
ME\I5@E#HB"B@^_3\1VE;LL@CX#UGV7TC:S)&RJN7A02=WI+A6I\V:(2R03- M-H0R\$.8\QQ13-^0FA_I\ISMF-
HIPMH..3L6Q<0 M7W^G%8A5_HBUIZXJ55Q1&K,WV!%0I_1I_/@&C\JH0T?UZFZ4V%7L)Z5Q0
MT)H<&F&DS;V2;AVA,IE_:0@51&TU",-X%,ARQ">I@)XVK%A\LIKGR.?XVL M3M1SHV^>/-I\VU0KD(KD)QQ;-(AN-
@;_*C<>+&+L\BG#;7EL\LR\ZOE&I4^).B:4A6;+U_OH%>%2Q+A: M\JG>B9BVI""F\H6A.)/H?
WU_7\G7E;YJOB//_D>7\O*KEA?W_&G MW^I>P_1/_L_ ^5?_OW_@_#_O/GR;Q=T?4C+VIP4W)<7?
#Z\%C97^UF6=Q\NKFTRH\=?U?_X_OW\X2A_X(X9Y4=6XH(I_E?^Y M:O\X845QW:!\^EB\PI@KU&^PO@^I/T
I@Z\ TO6)_LJ_:"%HUPM^I?^H W MAY*+X\LRW)G5<5EIKCT8I7E_SAF\<+V?;\$WW(JP/F&G\$ _NN)Q#-./SMB\I
MDQ:"3\ P@_S%+ +=?J<%F^N\NR%U>O3<@S\H\J7*5&K166S(#EI?K#I_ E3 M1T8M-
&)&S\J=Z1ZPRK_70&M\98\2X.<=<?Y\$^+1U8O/J\+^B\MK/R*TH=B MM5S=OUP7\+/DKJBK7_DCX>4BYJ" _22"
4?R%45H"+. 1S_1SA+4YS\$PEO4 MFZ_X@A?PMZI\PU)(W\I^I\J&_):I6DE+IY\J+=^RI9;C@_I88%@_L&
MGEHF_OWG+=^78I><&Y&E)1A;ZD"2\QUH'O+P?_O%A76>5N-HS_G.CN\$G7UE M?
CDSHKNT%@JWVA5\LNZHI:RMJ9"W@25\^E\I0=38%=U5?CYXA=-ESRDNZ1DD
MNRM^IBOI^CW5<_.9\K.V_(-RL_P_-IYSVO+).@YI\CH'C^47VLV:2\X_J\6Z?)X_
M@>WW8,L^>+T7X\H\0LRSH'OU\K, -N)7I\$&XH^S,K0_V5=I7H3&JC M=B=E<19;0?O8&?
A9:96Z\$JZ\47\H\Z\TXP3PC:08S+&TXB@2%J9_Y.QI M/T:4^XP0'4.^M^I\$MO>K8B:2\^_I+?%5^7-6\4D_1\9H'
M'D+HDS_R/G.HD7=>8\1EK).Q"D40I\A%\$&<@..H.XP&\$2\$D&H:NO8E^C\$ M:G9#\$\$RU%\$&1%
I\$F\J_7CLOV*+AJ^ 2%8E3?8FM#>OZM.@50AMYZ'T'#0@N* M9 (H+JY BU_'B\$6_61LH_7?4%(#9O6RT@7/S?C
52:30:RIUF\4V%6YH>HWO MM0Q#/\<_KID\U?E5\SD;SFIOW*Z+MNH\I5?H?52\15^*4E_ZTH.5\F_-V9
MLNM:9PPG*;>_9Y%#.(H0S\6\$A2#A*AOG&786PQ\2\I%_%WQ9:(G,+I&6 M:K,CTK6V;L'7C
I\JB5O5;L@_T_5V##+Y2TH>)8_FW+)6C8\I\P*W_@ET MKB*J3GB_-I3K\$L:~6*

I3Q>ULZ5M>YL_R;2N=X/B;.&2*FINL".(R-D9:0CHS.*U9C8>6V/M&0>|F.V5G/%_Y+Y(H5KY9WE/JU;RAZTV'.XTB^<=<?%*#7MDM,7V+W^5\$!(?_=/I=2ZY;J6/4+EROG5+YVU0?7!=OIP^#*.M/SMJ#RQ5S)MMW?IK_QIN58H^<^TP=U;O1%OL+?"<E=RI.1>(|#6'L>P2B.(Y@%E\$&DRS\$M24Q(O^&PJ.1?S;P.^T;7Y,HV*+4F0%VVBPH)-S_P+=MF|B9|I#>2_~M^|@,+9CDK(OC#QA4(J?>=|>HH(CWAIW|VB%KU4X(=>KA^OP\$8FTL&E'"@ME4JW,BLNI%7-0<3-2MKIX>MI%>+TPBAN(4,D8SB#+*(8GGEW#H.95;XM0\$UO7;O**K M=5\$K?ZG|&N+.#U/J1=#WB8I7;^#+G24X=K^X(@E)2M-^F-.#2|V3<@F!FQ8;YR@WQ*|'|I-G_N?=A1.5UY;|H\$)S5>|5'8-JU;C3MS@2|7Y4|OR|^R^|(7V0I&F\$B2W*X&2*0IQ-@+YX|>"M,@RGRSWR,49/%M_2")%|VY3WZ|*4OL5"A"R+_2""8>0GTNHD*906A%"E"|"AU=P;@C%".-/T4ME5E5^HRH^|HIG(D)54I:71U7ZBDM#O|_0TOIF0^O^Z|^MUDMV^B\$:=T>M:\$A#(2|1VX\$%B7&4A5D"?9\$BB#|C.\$TIARE@<MN=|OV_Y/0LQ?3HFAF2'6-E-?|F|B|@|^RMI:39<-1=^&0/6V.A:(3&|'KSD.AQ9.MXUSZB|M^I^W?CZ|DA6T6^:@E!|H9^<4>|0F5BL|N3\$APH|8XL=|JIM1N|/RQ"K>MT0(M,?VDVEW|Q57X(IG,U%13*4VJ.L6Z74JXT6TKM40&*&*7+|_|)I M=0KPA3^M2M5OZ+90#;-|Y>N+(Y)84(IP^P9OD*A\$6+D%|'5"/|Z&8D)A"A"M_M_1.3HE.'#%|L6P(8'&#B@BH3+3PU@X..43)330<F8<#\$21V^0C4(3EO^_|MA@.@G|F|EB=|29F+;L_@2?1-\$|BQ_L(%(&*|'5^"/CV"4H#1F<8+CP,A\$M^"F|J|I5>PO^"L|S@RF@=^%|MK>JWK2+K*\$YQ|CW_15?KQ5:1I=0?N@4Y;|H3>1V|S)I^"YJTS\$P6'?|C=;UE(=|APMZ2.O/XD|_U3Y?|9N1"KXK|NRYRL;W5*>+?Z*.52%;6\$8MFX%UA>540A\$|2MN9WVH4<3C<C|H8I4R-A|_I*K?3B/I&E7)N^3.R0>:E<+MIT|H.T/FF#|K8-MX4FU.6R8.BV-<S(|\$S8\$SX(VLWVKM.U2K*5X)D>EB?UO\$-AHRK3M"IK(>M=X>E;I.ZJHVS3%W|Q:230/M07791&3.K#FG;'&17;AH.NR5)|0XV&A88G-M=VZ-J8|LED00|P&'Q/5LXUDQHV<2IG-K-4L1WNP72&XF,RB4Z@T'9UDZ<M77@6A=5KJ|=<|>OM*H/J^+^CI>|JBG0=<%N|%.NW.A5-QP|+|D|@13+0C'MG&|D)T6D|=F2/X\$0IY"GC*AF|S&C9*#@JPL,LFUF6CB%K(CM1SB(8)(\$TK_T\$)|I5HE%V4>C>,T8(R;^)<3X&N-C;|L<%R>O3T7*WWF)C9.MQ.9KI!@3:LU.M7BY?/N.<_7:;#.^XXI_K-U*4?^BZ.3IK31VL&F8C|+P.Q0QXKGX;#*;1|W^T M\$#KO!|D&QWSWIH4+^%UQQIV^#E))I);.4M;|&9SFD\$3H/10=VMUP\$R'_M)+9_+5%UC0-DIAD&2|'04|UZ8BW;|ZCI9KL,Q;|>#+UI7Z?%V3MOW-|H#7K|B2WUJE;^N|K>FF|^TG(>1=4W2;|(^&Z:3(R1?2?D>1!.MZ#4MN?2.0A|TR<@B(.?XB#;.440O\$BP4.0PB%)?M2?"D2.P"P5GN='PD|3WVX.MPFFB\$QOFAN|F#\$\$(MOWY).P.A<#(#803/<6.R%4IFQF2_E7_0M?/(XBO0@N=J M|L((4+8S\$-P.YF8&PDG@HB!<%YPI|D|(TNJ|T@R\$|I*=GH&@<_Y%O:CJOC(M5X8A^9V;|)K9RJK|QW>?#&+NNR*=WUQ:2V-FC7H!'?\$1CW)0M1/<76FV+=|H.M.89|N^77-J7X|TN"~E%JFZ*7QIPR=*_@?J|UJ^7*O1@.V)V"9\$@L;4>X'MD(M(I0>)0Y@10:~L!>*-UYK#5%Z4(^)M;U8:<"M:->M^~|6O#5MOZKV4.MI(RK=P%#H6+=M66#V*/2V.3;+B.#+|A.|J".|M3P/@_*3D"!|G?0|N'BE.MA@=64)WN?&"WG&7^Y>/3/N>4|_1VZYFV)9#O)0K#3|ZU70466922MC|,"?1Y0B"A)8>|J?0SX(X82(3S&S.D1O&M.3VDD%77QW6'MME+CIY@'H.M&:190:6SA8HAV'\$N:7H)C)YK3<7UK,EVTF/J%|Y76;|NF|HWC|0ID>9.MIF7-J;29%FVO=(Y.OOYC5;4FK|7Z)|W5W22=NG|B'4U2!(@OIH4Z|C@/I M;=0IZ<|OJ|P(C;F9/SL@;?E?D>VWS@AGM?;ZM>9L>|S0@UW8^D|H"\$B+;5|G<"?;XX&%,MS\$Z&=,A.?C*TH.S;"I%<FUE-15X(>|&RUE&Q4*LL?FAX~2%K)Y;X1HM.M.R5OJ8.&O&K?VC%P=Q\$15PXS8;6EME=BO-YDG/G+6N#<~096?|>BPS;IAD.MU6'MZQ+W=;V'CF8Y>;7E.M|EZ=473GG^<K2ZFY5(R0R\$J>0|R&1;G0H M/>@L2V%_AYC@3.6&N6H&5&?^IW;|U(|L6JZHC9L@'+#A^&\$K-B^I+OW<F#%&"R*(\$4I MA18N;SW%71E/&I0;):ZJ7.1T<|+;+&Z.MH/Q.OGL72+4IW9WS2V%Z-OP'?=2.3U.43X"|=#;T9CE5?@5@G9I)SRG#*YUH.MO|)C.GT>_AK.F&<&L@W\$;&0.M44|\$7AAZ,=7J0WZ;Q-3G1BW1YN6P;OKK/_&RZ<|6J%&NC75Y.A^~03|Q";3&M|0;#R/D#KQ-P0M5EK;HP.ME1TZ-2|O>7UZRI11VN^XM")OB=NG"VE=YSQ80+OF2LOZ;7V*Z?U|3H9|ER MHY0+*K@QBH@2R.U"@"&\$.L|Z:1%W.2>%2\$1A|Q"3H3VZ&N.=AC0W9@C?(M M|S8MTP|ATO.5'8|>9H@Z^5N*X%9#;LL>."=E9FIR|W.M/Y^2?LM?U7E7_R;='FHT&RX|JG*=-|C21P|~FJ|?G|T8SC7KN&PEJ=T^BL.M|N|C8&PPY;D|O;?Q2;O+59'3#^OO=#6H0NF=72Z8P#2F4<3Z?%Z*4PQM3Z&7(2|C?DI(I#6N3X/6Q&^;#770D~9YZSO^)W#ZIR|ZO%.^4>|#"|3Z'MA+XO|!_1.Z28ZJ|MA|KBCCB"9|;83:76%.4H6^L>XO%.Y?S|I=RM7YJ>AA|MW694?F+Z|=;S'DS#(36R9%'33D0=N*;<^,+K=5ETW03T|T;|AB+C#M_Q_~N1P,R=\$3U|I^3.VO,Y'W|TC@>FK=85;)>F'|H>H6)=565=CK+NQI!MX;Q^NH'3#4UT>;@7U>1MORUU?PSXOVEYAI#39V%WG_RH;V;9(>|B?WJX>M<2X|MIA3+2'E\$<\$HE102%);(2C!>8X"Q*3&).RE-K+|5(DA8?|2HP.M|Y|L|0B3\$X@,-8.^F.XTQG)7.4:3I-9|98TUEQ|Z-YV^X-"%CVVCG=C-P MHK3MOLJM4&.3XGW>8\$+FN/EYU65*RXV;7JVI|J\$QC1C\$%>|DQ|1409VD\$M8T|@#~J&UW9^<(OSF3*~)S;E1T>C"J|EXPZ%UD\$@=JKS|RR9T|O6|<1.0.MMNI|JF>870\$OF9FSX1_Z_0-VW*K+OR"GN&KX9.<)TG""S.TQ<.&UPEGUVID<=+|)K("S"M*X1S'BOK31/*MI1UG'LQH|;..(^XE(@UBLZ""VI0G3UT8)-\$8Y8X3L&4%-XS8^C>Z<.K9U4G.M.P.S&?U.G|D:DB.GYZ._GI+ZNE MFES0#X#Z5&P'1%V7>24>MLP^5D:S'7KIY\$|D)D@9D;/8H@H@G6%HDCT*>M9"3D&<9>@ \$TLTE2,3FS MNR!^V;HV5)-|@+2PIQF8|JPZB9.9OLX>G9NS."M(S\$SCYIN;J_+O_#Z737SSA? *J|0BE4)OV)5+3%X;IT0PZ%UFZ:TU^SOZ_8A.M7@L5.M.R;|JSHUPHZ;1LSFJ|SIP9|W1/3L^RY|KN|5|E"PP2&(Y>M|T.M:MR04Q7%2BUW;HD_N.Y8&97.O|X8.5YRXA"|71007SR0CMOH^G40D18" E6VQ@>|1148A#8N(OG"8U|H8D1KX?O=HMYB;HZ;V8.MW%34C.K8B#W=;.2SPCEZJXT0FO6|= %I@_3>+QAWVUI9A.@0X|K;0(G|*KM0'8GFO?;Z9'@CA4H.M6ZQBWS8ZD5%._WO+VWINB<L_/2 \$2JU\$BW60PU9B#QR\$7?DR@FCD/\$4XO(F7.M0L(#A(+8)QXQ|'"J3UQ+DR|H8MH0|JN>S9XR;F^AB|V=|'-E MVPREH0U^Z+GX41TAM?AM..D|S3#+?XN6^<8HB'NX8JNH3G;K1B".B1|BRF.M*UPXFL9'S?&A-#!@! /41S':083'F*(TC2_611XT09(WR?P|2%)9#69YC3-MB3XD9D()\$.9G>|BH2D';^"T|5+N?2C;|D.M.9.Q.IM*FRJ MV4*|A(C_ZECE|EM>MIG15IS#_DS9|22UL;W.5FV_8J^;#*_O_0X4|KO^3K.M^4Z-D%LPDL4J301RGQ*(I^+ (N1=\$H\$RQ(4X^F)C%62SXF5ESY|4G~CJV.M>.KM>F9 R4S76X9@PQ'8LM2/Y52,T"9E9,=#=5".@88S=QN@"Z%QM|NRY6+6MK=&%4.WODRY= I^D;4;X%Y@>|YZWMVE*0D)#SX>IP#%#0@00^SR"&&."4LY.M%5I&RH#FQ;_)TD2W&Z;OO'E|V;D.4P91ZDL? \$T;\$IF&|OPG_1|=3DLGVM.M<5G/B|I^86T4W_#10%#C'@T'L&FP\$Y^Q43\$4AARYD&4^02A".8HIC@+A\$ MYO7802LTCR=(M>3U<M7?M%FO_TO?>!*QC.7@VLX|PE=@0J204OMI%7EV|^L"O4@>4%?/O/&~PL.M)K M\$)S5!;@#L&|.Z.TI'GK2|RI4+GT>;98=WY'OM4?%U.EWEYL=54?;JCGP.ME;J_7#;Z4.1_W|JVT(@^"8^:D(9; f3&E42)Q\$&+(4AXP.5)HOHT.C\$2%G9V)XG.&#J;NNE.MUF""KZO|D..M5FPU3|4G0=CNW/6 :K;62K|O!Q5.T#ZAX&WW;ZQ\$6%:=/I.MS=%4E'3K8#7+XR5.&I\$5|IR+UTK#A596&#? MQW'L".@B|VIS'D'2|9GJEID2@EE\$D&|60.A?7*OZY=21;HV76|4GR+3@D\$#M*/74VC|\$5KJNU2ZH9Z49J.S;|IC+ |I@P&|^U5J8|D00BQ6L&W>V.R(>RJE.M4&Z%ZM7VM|Q^N^E+3^*1EYO>@B+?#?DQ%GV1A!1:5YP2C|; E19%)Y\$0FN.MI""=B3V?2NBB>H2@YP|DXR.GI+^C;J|C;MG8R;R|S.(+*HF6CD>#.&C;J.M49VY7;1%(?&LUN-S.HS6CW|F7QV|<%5KGQ0F20\$^9#%*HF2=07D'L^0G+O.MG (4+9YY25;GK.5V49.O|G|H>_W;S|H;T|B6IYZ6A%)1|M4^%*.Q3'T_M@FD8|OW|BWX>G=H^|KY0;FD.61VK|NXM9T+=|LK<9@J5D.PB'KO;X?^<0^|MOT.M#.KZ_JGEI? RIGM=KM4I9?LE;K|UP6|+;E|J|S;|>);PS'&|HCR""OAK.M\$48PBA+?2Z2B>\$2KF^HE3\$SN;5I-HZ1OJW*|5/G(DC|W|G;L4=N>4VVM.M|H8G5;7<05V+!&0C(&..XO2&6MD|<.^"W;|)+(^)

I>|\$+^4^6ZWIEY7.^R&#MR*>Q-O+H<<0YBS#5HJD\W?*(+6)#7A'''5!)RC1N-(1;JC(D>2FT.&&+.GH M
D7X"O10W(Q!81\$-TA#160!HC-.,1-L0-#/#HWV:GTYW)%6>5VN=5M5:
ME2H:L)GTO19GSA"1XFA%8B4#Y:R&%68HP)!W4.#?L:,@CKG24ZLW#U1MY:&M=LN&S'1=SPJA7<+B9G6J
I3:E,T6FO(H^@JCE@-WNJOK2,#H\$%P5BN@M#1""^*3"XIX(9&FVJT481T5YDTLMWW+EFW_AJ^MN8.I"MI3W%-
AQ@QD=I9)!%Y%T@CQ@,11DPD29IK<,<7<#Q%RR*UXLY<=3QJ@#7D
M0;FEKQ^2.XG6^6#F1<).J6HO<\$L2? '\$JL'Z,T87@=C%\$ "P",0H/G):L)_9V M=::0WCGFAZ&|L|C:N3"
MGR,XL2/09GC=X+):.5J<+W0QU89,S1-W"82941KM?2C=_X+T.=P2=OI-A
M2^Z/TK)P1WB#WH2HUTZ0WV\$4#E>N%1FL9">ATDP@%\$<8*A&HD.HPRGE(8^
MBI%13K8^Z:ECI8.YVN,JT0W,-DS1,L:8SV),@YR9I3ALE:H#W3F@+A@GKBNS-MTGA9PF-TA:P74!S_?
67L%VTMVW:JKDC*CYC.6JD#_2IA:6'3#>(*A)1I5M M.,PF+VC^M!Q.G4;<3Y(27-"#9?
NA_0I2@I3)B7)&I^+F%G<8<1#2Q69(<M@BUYL,MC<|C><G*KG8N!FU3BIU<#T3-G,C|,Q@U
-:HZ^&25>W)R8WMO0A3?_29ZJOIR<30.G*91P@Z@.IPUJ!HA:G0L,+:.-TKZ7MM+2<41P%, "11"A&)\$4R1M*
LB\$1".(I2@G33YL9)36P8&JK_"G9_K*FVZIN MKWL-M.X'D=QA8&.5OL2WR&P|@X-
^,D='G81)JNOA5&.24_"D4C3F05FBS?I M"3*,FG>83E)5=I"EB_7JG'-MASI(WID;U>/. "16-XC% C+HX5";CUIS&\$:
MT0QFJ1+1S *>I4:QIW,\$)S9@0_(U72*_!HRX,ARW860SU_S"4RALI69:"8 M#SISE-35J-
SY.8=JHI_,\$X4IWL,L\$ZISMD*22U.ID(M?2VK!2IOPC") (MJ8@RD(*"28(9G(#&"1AP\$*G1)1\$ MG(<|@B&-
Y6|G<(T"4-(PS@0"9/ HT,1X1-TIL|QVLR|,*7>|F+UF!2J>6W"=)A&F"(4PS20:U1\$Y4I9ZB703X/81X3'+4JNK"B
M/K\$V#RC^67I#:(IA^5C!LB8Z7S/BAJ(U+,:|O<7(\$!A8A9#L\$!.,DR)I M%WB 4"7*I_D?
I:"H#+IZVTJ4+B6#_D%>#+YG7\$X\$0343"&HV1(7YFK/% M+:S%'88R!>Q/&+G2_GI_2^D-
9->5YPR:R8Y&IMM8WJNK3WGD*0(I&DG\$(O M"D(UYR2&)\$ \$4BC@3W\$ _3-\$+42)3=A/K4!^TM+U?
@ON7FJCE%P3L,29UL.#(M8C?6.,FPPY,WNJ:UCL%LEQ70|S*!IV:%@JNC=R:VYZ^V!R< !OM8CM
M&7RM&L9|+E?/./LSPVNR!(8/TI-R M;6CU+|T@)F9'855TIGQIP"K'Q0C("I^W\$YV=?G4;XY38%P-EAMC;AF<^I
M30\$Y)HV7F%J0I/Q_DE*\$\$9@IQS:7#BB.,4"1#D:61QS,69D:S.U9F"VL MM"6MN2,I
%:7OF:ZO:F%T9DHR!86DIGMT&OET-@9&^77&W'-EFUU3NU57Y
M!&==*Y3IY(2)I+ E_M""W5^K+)+@SCW^LW\$H%_(B@.),)"=5I3S=A(1N4& M3?D)1.OPQ0'+#":='4A/U-
OV0.YT:OIA CVKF|Y V:;SJ_@A^M/OJ^O)* MJ^7M=_CIE+)G=>6JT&ZH^JY:6|ZYGL:AMQ
P8.XAW_B\$ QIY:7B@T4CZ!A MQE:D@<LA# M"20I36&8A2B+213IH7IZX2BIB4VB=SK/+#)(NQM'Z_R1@CL,S
S1E@VZ82C M.LBD\$K#P^X4P.IK899<J^T7A6/KA^+SHIJ";*3JAWAX7I0C YT<"4=A! M_5*69;
I'!\$0.JZJ3(&Z&C\$.._G5%HH*SC:&D8 M+6<8F!FM,%MC-8X#@9&RQD>=D;+ZFMA9K2T)!PS6N,+S&>TM
39,5IZ=UAN M8U5_307 VZY=FTU5U20#!B* 4A2\$4.Y(542-^A CGT"14)K01#.!*?:-ZABU MB4U72W*[;:RLLB;|=+
<^I"PR&:Y@RO7>-DWJ6BF>|F9:YB88NCST,(HD"X+ M#F@\$L<")GZJ93+%1A80U)Q;,@XX1@-G?UU6M/ISQR-
,\$S3\$,\$P01\$F/N(TU8H G28QI3%>\$VOMVC->V@GTOK8- MJ(6L9@9CMP?HS80-
0&^FIOYHJM/V^T^W/N7VFF=9RRQ?4W7+*IQ_M?>?VP M8MN##PV-
&KEI/0>YH@KND=UJMN2UM.H.8G'5+##* @M1" @A4+I4ABG%:,IL*(Q2:)<|H\$9TB;>^JH@A^D=|#R^D=
NB\$+B9@=SC:QA%|P7BC'794FW!:=JNMMT29RFX-FX7035H-VL:#GS:NR?R6I"VIZ7F'N7801/H8XD
MD#15IEM3IMNDL4GZ^7/UGBIOV\$Y*OOYW>U9,EZ(*S MI5?&Q!EN5D:OL^V?4M7EFM,K4BZL7)3K@LF_|?
YI1&290% C)0^@E<3>)2 MV5A,#0*),|I#CW|JV\$AEF-\$JKE#_9)^*N.@Z;W@'4)AHJF*%CT5|&2S5FC
ME7%J,W=G18Y1,=+M*T#_N_,KB^BJ<A&Q7E|I^M#<-"W^!6VSE?TF_7!5?ZQ7I1H/0H/JTKBO5
MKUC:GD62.,+8@X|\$,YC1\$/(I1+^0)5APO>&;>N2F/H#KAVVVA,& LNFP MKU'0QI7?I1F>M^-
6J)@X;ZE0DB%M.=2I8_38Z/(SSP'3\$25P&)C67>;,
MY=NBRN65W5;A!VJ9TYQ7:HCGA|S@MS5_//FTEQENF|K1QSTVJ>?/"HAE' MRM;JF_NIX@4TS#C:5QJ(;:7-
U%E_MEVG@;##3:C);7,ZIMU)5>JFQZSW5> MY2HJN?FQY)ONOIPBN?ND,151)%(?9AFD8+|J,
(R#)D5DKTUQXK=43QI, M\$+@/"0N6_7W/PZCG6L3H%QIP27Q+L>NJ+LCQ_4I05G=5FWQIYU6_1LMLE38
MW^|6*L9_5AKIZ8,HDZ'V635PKJ57>PHNJ:XMGB/N0-3S;VE,*J3@',8!YD'\$?+D9@|S%,8A5B.0,:0UA
D"IH3ZUW@'X)EBETX_HW M,2"71'0I3JH AI<^@1L,N)D.,UBM@D!M*MNT\$<-F96&W8W-A5
M0E|I*GN2K/944/1A0;3I%;S7=L@FJG2@9YY^6*XASNIPM2>I<\$6QT3NQLZ M-R*F;\$!3= 3G6Z7=UY"JSW?
R+*SIO#BS;<#VI<:1<|W: *VPR/5_E&XV7 M|C^W&22D2I(3#T(L9A2CT\$D@RDL+00PFA\$?
(8%HN"WZN64JA5!/R6E_J MK/U2#YG0#UUTI%6Z;T?S"A3>C:=OSE08|O>7& M7:S5!@-
'85|OZIOH|K|ST55_!4Q;XNOZ?UHI5 M=7%ENI7Y?
73DBS_J^R!5=W@K>G"4T=XI^+QOH,QC=EM52J&8)J(-RWOZX65?UZI&77|A8
M%Q#CDF^5,D<76E^%HHT)8+.,8)1+|22I7"8RH"&CLAQG%IU^|4E/-
M<*)4<\$66^7VC)X:U4@88ZGE0TR!C9HZ'L WR03HN5%#3XH/L&%D@I8(YN(I M<2H^NRY8VB#>NW>&V"
(NY)>I(PPZRL9Q MOJ-RGW?L+Q79I_5DZV1RD M.#3%@\$UX0Y4&5H/9,CZ_)2&T/=C#)%/.\$P#L\$|I
(C@QA>GB5;MO"7IB=5V M.,D-S5'A:8|CHI.,6VPNAQH)W)X?7-I?@804>AMV^=\$&S,W\$.SWF&P!B!
MX'SHBQIU5OKR8@3-Z.\$N9LM8=.,2+WSY8>|JO?F)^FVZ#BUP,3&L,+.%.\$K MTZ#
I:G/^!#!#93JH&LDVBVEEQVK3E.KCI?2XYS@NTTZ3A|84E,+?T|JN M/O!GONS'1R0!BQ(H#"U82Y4/7K2
A1\$^90\$&Y%1/0(K8F5LB\$%->, MZ\$C|U9V)+ "94BJB|1&6RC|6=*|)_|8|DU1'1=C7^\$TNM4X9|6^63U_<@M
MEIZI*O|@ZNY7U9_W#AHEF23F97O)9_RB_MIT) VPI=LE4P1,V2_8I:FIO5=4@4^V4M"VJL_4|+L3I#VSI6I\$9H
M>6GN"&9I"8FJ|@7VC>8#>&|I.PW\$.XP<|6GN)RA>;<9S@|VFX6IE|2I^MA=)^28B_RI*1142H8S:F012%
N*04IB1T"=)%F2G3E4Z&'9B&/30 M!\$/LKF'Y)(01? U9\$;KHD:GYT5>8K^9Z>)OEX;M+-C'9#.W^W^7"WWA^
M_U!S=OW,2WS/NV")^*0HH3#2/5:0Z\$O'.PL)E"DF72V=1QE,+ \$ MZM_3!|U1_3..XWBR|M>>H MS?
J.U11|_<6>|N%<:MT/G%RS((HQ5!\$3:#!4!\$9_@3SKM6<8#2C%FF=%L"F9 MG=C2;*.8-C6LXU;->=Y&+EK.S2;CG?
Z:&\$=I7?E*V(5ZG#ID^#LA>JZC MQU.P^CKAYPE!|QF_GI^F^2^QNW_6+I?22E:YJO(S6'+JH,NF0NF7\$DOM?JM^
M^C^2H|N(C:;FV3|T7@IF?/Z4>B)|S>SGM-ZKO'R0,SJ1-R\$SFQGY!;" M#T_-6Z_8,SLCE%L%"*TB1+\$M7FFF.
(XE#N0&D004-R\$;RLY|HJ-F#IA, M:(G:..S+5+56+6;.T@X);+&8:6ED"7PV4,B|P^@/2GHT2&T MIZV;
IUC7IR(V_OE*9K2-I 7I6)QF+R+(BA\$F\$!\$B&U+|+RUP(C^02K5" MI.=)3:R?
#>U_!3LMD% C7_4B_-=09M.;5U2T&9BH)KY% DZPS..CWQG*AUU+ M+*NOA5\$7+ #T)1YI?
G5E@MIY7>H6,6UUIWF%NM/I"RR+^O_+JX8.T@FU5=&^P MLBS@7\$20QV\$*448IAG!D*1>
I(<\$!;ZO508^3F9B8|42|HHRV)+65||Z; M*#=2FYFGXP|;&*81R?6-DAL\$|R2X;W.D7GY1HQ0R,WSV;"S@LP-
#1:5|OM M8U3<7I6LY5LQ>H.QVO;W!90L@_AOD!?=9EL99!HG-D:HMR F-(T0-SS
M?)@V&A:HT5UCB07N=;?G64FC2#-D-0_?C'I9O|VH=-ABH2@?IY M*K=2<2+0X(QS*B'8,2C-
*,BA\$SFOEG1UB,&6DQILR5Z!#4M0K\$|8814 M_&="FR\$LYX1F0P|V-R|KBOVL=4!>H (#SJD=VJH4\$V@
R^F*0)%|(Q0 MIX:~+>CJD= AH\$Z**7M^CM1@ECHP(P9XP2B *M(*X|@BFE"411/5>X8
ML9D|D:RA#6I%W,R.C"*E9S5UW" M>RP56CHM+%^N58+0UER|^ZXF+G#V7K*OSFO6I3;SDWB'Y:GN*|^M I
I+)|6^/Y18^3KAJ I9+*2WP3,/DCAE,"*IST08LP,I?HYX6H\$S'@\$50; M)@'ON 3JV0.ZY5.=.?*.4S5|
52*5_!#|XH*J&:YZ9IA^9^&H8&: @MOR! M=SL/XF:W0?1,JHD\$;9'3V:%>YO:-
>6ZN#*\$3GN:UF"YA/#M3A>WL|%=K50E MO:=-HA%R"-I606'_\$L2_@|@9F7^3-PR1,29C@|/=-
W_TK>LI>EHJNMNU M_<|<:M|@Z@|\$1=2R8&V30.G9L80DMC)/<6F9?\$.37=6YIQ4C@S'23*SVH)S

MPNZKHGK+1L'EYSEI7M,F^:AW=I5GH1-1P88^FD&42)2F&9)"GV:D@@E*1.)M443V&)&)?
9J6).A16LZG/8J.GHI>*K.9>AJ+;JF=T0>5WUICY&8MT/OB)'MO7C'KK5410E"4?I7^8+>+>*G40='U7+505!TO9&&?
QA>KJC7I>UINY>PI/O)WZ?;I/7L,I3I^H'OJ4. M<T(O||+Y>@H5IDE86@"+GHF\$44D(UX&N;=&IL7JE!U'/DQ0(OT)?
E"5>V#^3 M=X7F^J)9GTC/EYOGP>7?7^5):%KMN; U. ^2T!5H@!W0NP);5D!I2=LC;^>/MPSLM=0Q64#5E0
M2;G+VISCZ.B9HHLE-C.QK:@M;- (3I"K"/J2(YV-PG;:L2CXJYK|RCE|LY1M MO%+M<;LCQ&9>%-W6SSS
MKF5;.^DY)CERQ? N%SM,2^:BAFA:F^>FJJ:'OYO^0I>-W F;1'.-KYM&*^<^
M"JJ>*E'E9DF=I5&PI/QIW^%"VIG&(\$R)I@C73Y*8E9U'A-R7YM'K|4H.O!_ M2HXD!F?
=BR3(Y(L4AP@&JIT^D2<|F"+B0RZ\$|R?;#|,HT2XZ\$-4UL6(WMIG MEV<&R?;C;(WKJEL,S#1V3'R;HH-Q'
R*#ISA89?C;-6U,"LZT)PK.A@?('Y MB@ZT-DL.M"IP|QHIOIN#MIE Q3M#X9/(HX CZ2YHH)+A|23FP3Y7I4WPTLR
M'DD/1.NIG0-B?V 4AF=FY'D1M(WK;:%R!%KN.\$0NCIPN3006; "XLZ@-FQN;:"CWB"4 M76DV*VDHVM!ES*
(0I;"E(D,BMCS M.,EHI'78*"GI&)6I#^1::@ WM/JLF"-T%|J:IS=2%PIK9N);<9J!%?N).HRC MC(KD*KWF*
(UYTV7&QOQ(OFIV\$X;?UFMV+=|N5SX04@'C\$-D:E1B0;.%SVS.M 9Q0I,L0DGL&V4%|@M/K;I&3-EVTB-
4)0107T8476@R.3.D@11^+FL.C%A M3(B0FOHVLN?3.X9GA|H|H#@&JVJCF @F1R0V3&"9Q(U5GJ00JZ|"S@27
M1AB'+A,S 'L@3^DLW7(Z|GKFUD'9G0S;*S6LUJ8?8- MY<'GYIV);U9%M5KFK'0CFV*;9M0@87%;.8A1EDD-
W2Q@&DFW10/DQC3+@\$@ (MTDH;DUB:AJE2+2M'#\$>Q'@"FW'E<2.QF1I9"&04J'A+96Q>."
M#7L5GJG2SBFY+1@7>9'7 \$/ ^K\$H;OE4<|+LYNG|BO^&^F^6TLW^B|IYE|F M=RDL; (B@#)-SG!\$<0L26
H4OE^#Q)/"/*.\$/@L>)C;:ZCF"2|42V/(\$>I>| M80LT? %F&52H.T#T'MW3@RKFT78(K!';+&|8+,"T&K?A8-
8W_@40I3L' MERQU0@|59E0|@=>5))J6QRF"Ms _OJ3N;/?/S=>K_OIR7"%W_+VWTT<(\$T3 M+PO#&
(9IWS(4PI^T@/11(TR8I<|B+|Y%+\$ULJ^78V_&X9;#P#6;W+|FMJ|%)>(>YOHJT;15_13ZV\$LE)PGON\$/'90Q
MRQB:OUY@P\$M|MA9TL|L^"C;_ GU>7E;5U3J^|HTGEA^UTBC70.3|G2YO)/-J^&52K/C'41UG \$DJ@YPL\$8HH
MS&*?0;E#BU@4T"3RM&8|G5A_8G7M*>|?V|I#8%P|4AFH\$|=10LSB7/B:C M AGTA;+;G3>;RFQTNCPBT\$(=IGY;
(+WDM-5P;|PNGKF MTOBL^=U*6J|_K0\$R%SGMJKBEJ_&&W++5E?7C|7N7*;M2IR?J M5V"?K=|G|CD|V^O
#;#C5FD.3.W;UF1P&DT;N 03JH\$#5@1GFS|P"1S#0007 MK6-FB1C/%^&*J|?;@NQ*A^M3JL>L.%44|X\$;G-
1H\$'\$\$.0|P1|H/A!"\$O M#9A68LHXF8E-3TL8#"A;I-P|I2X_7 G0HF5L)5*0(3|20>KAD#"S.KR3M\$R^15;U>#UE4"G28-
70-@P.G\$8JS"(OS\$@&8T*8 MW'KA!!*>\$L@CCC.1HX(2H0BR\$YPLC-G7*<#1YDX\$=G;@#6=BV SIAUT#5+
M8(S|'6C9F*"4;RPKLJ?3M*9MPJG+@'A5;G;|"S=:K0Z|:K|:~NM4; H M2|0'71GB3H/RF"6>2D4'HF")(D|/|::6!
<^K0BDZ?8)NIF3PZF_8Y_ MHS0Z|8!="#ZPTD-B1="A.M9;(|@WT"8W&K990QA5=9WO'Q4H; &AM|64@MY
M57|_?D W27/|)%DF6J(HG#&*|8>DN(0IP* OTL|AX2L/4R&28,C"Q\$=D; MIL?
=8/JXP&4D@G#UN*FV.H9D2D1_4L)"=0L0(4+U=@@U|'#NCY 8JA*Z"V MXD#QY+ #5N"4.KKJ-FY*?
M^&X)3@/'<=MU|FLL#+;JFF1JJH')SF/E)&& 8 MIZD\$1)4?|B(BGTM6/76K9I+9<4^+^%"H@_R+4...^3:(>&J
M<;XAI7G|Z=H<|!FUW*9BRU)/'CEEUL.FHD;Y=3.7Q0I7<;.W:HS(SH<>>S.05H&|^_P5 MW;
E72^|RC749MI@('X.D%S7?)@S\$W"<+Q*24I&J MSNE^D\$A;F78L)A\$H2\$!90Q+TD6M6K^IV>+1V@9&=8-
16V5O3E69X#KNLS) MNFVM5Z_ KYS5Y;K(J6%/WQ\$5I0R?(US.K)AF9< 5N-Z#Z3-VVX|/0WI7379' M*;W;00>|R<-
JLHISKJDFIY%|;JBE2""7-*|(50 M>F-G0IY<|K20G+/#E6RRB9-W?XQOD#>FLR#W;S"O MJFE;.(K&YC=.;F)IT=
^WC/9.VHA8;6>40B#@.SHS(FOETK|3\$ UUOBW|0/2G*VR2MJ MB*25X0I@|078B-
|>@ZFSB|DYDJK=X7X+!GY\$S/|TKF=P6|61V,ZKVG9;Z M@6-UIM;E9%4T?|I72N|Q75H+QM-.2G?
I0%\$84B#E/HWD1 M0!F)(8OCA&+D@&@9-0V_A)DYC9-F_R9/UL|S_7(B;
MQLVV4 "V;)"T""2C6NC0;.%DGJ4M15*FK+O MY+U-LVL1Q31"9-G<&|H|U|U_)F7=6K1ZE+UP7IL"KNFQ;<;>/M-
R^_15IB9|>QXMIYBB0"68IDQ E5D<&1*GD/O8R|+(XRG2F@4I;LSID54*|J;@50JH+G M'6R85SYSSZSA|F"/)ZEGM?
X8S|#"P84Y|WP@7|BP.") M*?9|P_ ^DVOI@79>|."9T9>|SA=5 M6R#S"Z+|P=(OPD3!
814UZ,4WEGBN|_XE(&F'N9UYHE&BL3WJ3|&C#.HM MZ<8ZK%1-GEV)N0:>>E9X&I3,K&K/PO7HN ;R 9|
_5(5Z/@OE9=7W|)>P; MA%<^ELET?D%;(P8K|Y^EODS5N53|W%>_A4OU|QM-OD"&G@F9D)2X27T)2@*%;3!4R-
(UYF|B<4KE, M)BV%+T%3IPAR4HQ.S05|2J2YD>R AI^&3;IH60(=3V#+5%;6Y?0TH39R=;
MYAS;?)QG#='A&9W|4I=NE'MC|ZD8A+=OB^XD|%=<_H.WU76#;|2"#2|I"U^R MZUH=|I;YE|KR;/ZY
N7VWS5ZZ>H|JZ?GS\$Y*YQ%N(OH;4'_ M@6D0X8V+08E=#PL;H?@Z;V. M0W!R=)C&K=;|
I)YX6;^H"NA;&JAW_USG3|H*9MU'/J\$>)Z 24J#2.))-I M=R "?AS2&|AU;IVC-C\$|J G?06>%/(&K)@#(>_IVG>I.
Z=G#5S|868&MD@T M=|L@WFFV|<+K+U|076^YTZ3F;B1W5N@C7>|.WV.GX|HR3)EUXF2AH(C%W|C(
MDD@UJ"8P98)#(43LOH/PM H^C98>^*HVIVZ|2RW|RT=0B"GG);BF:FBQ|T MY#%6NB.<|.J*QX9#KQ7QK'=1*MD
MY+Q8K|;5;T7);5+5=JAM^=5E;NSK6M^UX^J^6/|YU;+1+&C)TA0'4HFI
MOR&A7@QC/ #"(HP"3.CE&+7\$YLL;+1.56QEUZG#|0/20QJC";GEQI5.SM M/0;0L^PRSWHJ.%WE;COG;JY|
|ZG@/<@9GXR0;WNMM**K&I&_ M296QX"425I'L%.BIP56^M1 9#D(6|2'\$..|IX2&&&"441AZ*\$4ZIQ#2+2)V"
MR8FM|FZ|K2N3?<\$SN=1JSX/T|C|9_*J*6&FC9E6H9-6A-UJN?W"Z)E^>48 M3V|
+V#Q#V+0+P=9WZ8|H&7=G IQ530C&#_C|E/9G%&Q)G^C;X;|2+S #_V4 M0(HCK+KC48@3QF%"TB#)
(Q\$ID5%9VE;_1_52R0.#E"Z@4.6D/GG)GA4# MX(=UQ<
3+|N/3N=|6J.I9U|=8V1F+EOBH*%^I|I2RZ|4;#EHD|FVP^<|JG6 ME=A=O^JS%.?N6ZT+P9'^U=JWFEF*
(^@DWUW71RQ=U_S;OR=EAW+;1N=>ME4J M&B;|>O&)#43\$^B94HU/-FRI<|I|QO3LA#V6XU9C%AC-;
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC
M")TGAU *UROE>#N"|W2JMBL"YEOCN|Y).M(|SLN&IHK6Z>Y|C|I|L67<\$FOB MV/K;U|
RGM^57BJBF8&Y*W;FW3|X(&NQ\$8|RS&OK#;.1Q><;5|X)LYPVS=Z MG9VS|Y'7-
|AZ^%RNGG.F>M|5JFVG>V^9&>0|N;.\$*B B#0.;>09ZF*) 4)C& M40@%"7"B4Y9%S&A09|I"Q\$JZH3R8\$/UG,^_#
E8I-V-L;S47=4T*9 SXWR M%WY0#;G+|C @&@R3'-398^+(0;|@8%9/P|Z@_5?^!2O9V;=-.2 M;2NJ_ ^|
MQD6=UTVE|VTAM_2/K;?1*U\$2<(%|I_ (D54G87H1AZ@L? \$LXB/T;AD#^8V"8S ME-'Q3?5_*|EQ|PF&4*I9X^F
|@PWKW%YE>JW79>A|M5TU(37W8^B%WG#X4 M^3_7\$YDC.T@>M1>E).2< MA %;SAI
(@Q/DN|WH4Y%T;R MTB=+KMW9%JYV9L6>XBQ&YF)>I-S^4*3S77>Z@NF/O,R|?I B%|;C^3# M "&?
>SZ+0QX|O#|&M6+P8?>:96.5K?E D0CZ?HAXL|ID&^>|9TBM>GY MPMLXUC9EO'PL;W0?RQN+QW)!5KDC

M+T.!R1>F)EUCM).6*UW'BBO"6L9M"MUG552Y=>H>S)AA'3N5"GD--35R=X MF.YD.B@ZFE?-(?
3H4IG!..VZND4G9D/)T1IW"LTID:5(.1VVX'ZD7>M@9)M0!%9)A#.LG8"*8=/:XDAIV.QD!6=>@6-5@F3_F
M'E="!+IDS=>+F39EZ'FIY>9?@ZJA<;6OH9BROW/-D:QMT4E M'W%Y5!+/JV5.LNDANA=L!63_!7^!)W2/9LPM-
H0T!"?Q*3GHOD-.H..MF?JZ@HXC_8!PB-FTSGX)AZ.\$:X@+!5.XZ.<+7%MCK./Z..>ZVH(.#WCU M;f+P=j2YH
!<X^5?."!5Q+OKU0*=OLV2TFLY2X'V%N2S MQ%#FY'!H(-9 M)+DH..#=#S<#!7VA8?S2!..4YVGM2?JEPUI4%-
FN@>^/J(F?DJ1L'N2IZ M"\\WGT1@)MN/DF-UY0;V.ZGA7!@>YSVPZ4*CC(C7W1YWE0E^NOOV%LWO>CS)_MPZ4?
JHHV!_3NE!+/Q*4ARR\$<:0VDR*.8(KDKS0)B @2PC,2+@I^KJ*0 MIPQ+;EPQJ:5 6:M !ZQJ*YJ.WU?-*
<;JHORIYM;N4E09<."!@H>%+,VU20. MGH1>I&E^X"^^HEFMGA\$W1GS3!HKGZ!;IM!79!P^!5<I.T^90T;(-
JOAL+*#EW M7(#C&E"7Q30.>)N !+AIP3L3IROIT\$-#ID!;^M^6.U!_8(X\$%#%J M0Y1\$""8LP3#R4C6!F0THZ;GZT?
H3'Y&1E3?JYXL^%T1!@UEP[XAIW#2/2N! M6'K3TS(+P.T.OQ2?\$(Z(>..H>NIP\M001W+VICNG.W4BITE(
M'R#UP2+!=^Q"\$^MD0QJL&J!S9Y_!>=1.1.AV*"4@!M>:WB2.=7 MGRV.I"WH.(ZD?Y/=^_8+K^0>C#
f(E =.LR7JR=E(+JSN7ZGGC(L1."!>8C MB.(DA#A.&OPQ)E\$<@!8/9EL>^D-RLW>Q#H9ZIV7)RAI M_PXH
!>M0G/5%;@#! DO=Y%8SZU"5!>+=NEPH5?E\$*/ MQ@&'<M22TM/F YG'52822@7K)W!J;#;
<+/!S2HA>24Y^!JA=UO6Z?EB5*^ZVX+X(O2R- M8.!2^7XD80*)1U3G?2_D7N CXAGE?
H_0FEA?IMMFX0UA5ZVS:K#IO1!(=6&F MS'P>QU'F!P)KM7'0H#6U6K?E!UW?IOQ',@ MG7!D).A3=5(D'A*
D+3CEZFFB!>17H!F.V5JRGJ"VL>XO=B!D:6%7=K.YI MDY_V9EWE!;J7GWDI2>A MC=)VP1QSQ!)XA99S(-
S6/849!#F89B+E/8R M87&.9!+!#/=T#;4J.V"^^@60FW)X=52\$.S!WN-&*.NIV)V#9F4D>BY4PF)'M#6P9N0(?
6^B:4!K<1_9O_YM.'#D#QB1GM5!L %EWV.P6L/+W!55Y!M6>4 MJG;>7?)R!MA=3%WV"(Y#WX.L23.
(>3!3\$0!#B\$!&8^3,*D)GTR\$!L M6#1,*/WX\$CR_..LFO#IV13WH)A9DPT>6PZNVJ3..!H!>DLXW-'!>D0C2)
MSEH\$!8S-QN&=JL9C+Q_Y!OM.OGWF)G_M?2*!HEW^7(1M_HN<#YM*!06 M<1H222..
AN!U1!^9@.2C&0R"\$;T9EX2&!6'M*?^DB!)0N^=5P!W++5AR"&MM6IV.0A3O\$D6HTPZB##V?0&1E_D0^W'(&
4>I:@@?L3!1.UZLK!^WALNC/&& M?R#5!8S!A#B:6?F>\$=!Q EI6-J..*S!@XPIT#+HSH9_++ZIM1G-?^6T.R_
M!VR7,4^C^+5XRM7,E+O!D;WJR8-ZZIX:5*<.+!\$Q+;IUX^?;X=S?H.5'^D MW;'E37-5_22*,4C&+85#-
_PL@D03HMP*2U2IL86W>VA D-X8:I\$CJ76PXZ
MS8N!YA_R9WXP!^CZ4:6N_W<VVI/7K!PU3^5*8/07K*#EZK+!')CG&0"J:1% M3"!BF0?3./9@EHF0>
<@3RQ@:@P.>D^R>.RJ5^57*S*Q* MRQQLN#L8H7;5)&0QA\$9<*K:#G5,*H^D9;/!?.YPC*H!T\$S-5G7 T;P#5IU!
M>#""U>2EHUH5!6!B5OBICE!LUT@R)(<R2Y4(\$4 4^#'\$<1'00>R^8&8DS MDAD@SA&9&*3IDBV)?
B*Z!509*VFM1X%2,!@72JVF05D+XSD!B!^R(2*YZ MOAXC,6!IOUQ\$A#WJXCEUKIY+_
Z7DI/ZYJ>WXO\$H("QH5T25*<0809@P1)YX0(
M%..8IQIEPB30<4ABXE&.WJPVDI&J_I_G_T@#/_DWP!ORAA.4#Q'2T!C+Y#;3 MQW;J'W!=UV5.UFTKD7H%/DL_7
Q;/'^3J!'AP3FG:Q!4L"#\$X=% MOBH_KFI>24C"MYL>>&&(2HH!S.7C!RHN!0*P1.N!/^!_2P2?Q2"&9A1"CC M61S0.
K#6.MM.4)TXK=G0U!UM5\$4U9 DJ(8DJ=U!"*J&1=6@1K=U C-<46> M"B.SU6XY T++2AJHI3BX@JTT'6.V-
3TZP)E4_4_6!V=2W:P#FJZ#<4?RF M7W>I^:KZ#87;J>LW07?:F71_R^N'O/A4<+6AV8Y)"!-8VE7IY@0H!+=K\$0G.
M(NS#@#*?1CAA,==ZW/!SM2G:U(1!^L"MX,1%/JP9!FF@NW0G !9RH^6 T ML!H3S5ZK)M)):>8?
23<Y.PCZ4PX<<23<G.U(NC.K6@>N<4%SO-S6 E..M8XIM=DTH&.>9SV\$;7(G^!^9>I<>N7\$D7?BO\$#AG%IU
L5!)*<(DZ^ZE!FV/ M;2NU;T8I(<".ZK23%:F1!IT=^VO/Z0NF;J2 PFI6I@MZ=<)3\$B'BE"PF!<
M8DDPX3BG(LXCE(S!OLT"\\B2!LS&+!_%H/(<:/L;2..?N&!1Q//D5D>'#E MM!S746Y_(6\$KJDN'?2%0G GM@FYW;
<)1E&LE7ZFU_F!6;J"PICQ!+T:E-M(Q#3NCIB:<^UP8AH&*&B/2B<*Q)@FN6QWJ-F*DY)GU)M9SP_U*TTY7DR-
WMDI6R*!J0^L#8DIYX=X@8\$A.^X7 EX!78'W0GLHL^!K5K=G("D3D33I"-HE2:0Y MB4).65^@) BYY%RED; N-#Y=?
NICH3U!4S_.QFZ@>X\$A>2N!H\$Q 4!5 M93FNJDLZL^ABI5*7!1I61XU:UK\$9%<T\$)J?5!J^V3!=-.S!C_@<(N*^9EBE
M*M !S#*#7.LO+E(5ATDFDB1EL+*A!X1F5MJ.+&KHHIZP4^K\$1:CLM-8' !S MG:W>=S2=)ITK'X'_GG3UF?
NT:A!4J^!RNF9/96#W2!S.(50./"GM;13\$SO
M9;+4Q!UZA!U5S!05W0FM023*699GF+ "5(%IP%/MY*9!8R\$2H\$J>D9HS:S7 MO!EFEKCJP9)/0*3J4IB0_3ZM-
A4D.ZLXV3.B?&"IU MIA9XLL9M_O-DL&O9GNDF?9-L8B0=5JK/^CO!U:F4U"\\JXDFH;?V.083;
(WKL!;8*H)KY#KL4\$#089%OP<NK M<'HM0*D4=A*.)%!.++!8VH2=(.D"< M81'F">9*VSRN*(E%:BJ3%YE!
<)%#AS. J!<>E VOBP!^N/R4!HREA4%_F9\$' MQSSOAR"\\I+R#22A?;MC!9<;^VL.)@&J>LS!-
7:5/SID+^_3;RCW*U&F1B M!#36GE.\$!8)UA8V.3GY"8L:%TF8@CIB(L!5AJ:EV9.>V RT3^B^9>.FR89DSSAQZIMN
MB:JE(2".% =F!#!U'#0H/>>A#S5YM L@H7V9"#NBRUH+!\$! GA@-V!R&2%7> MO5UOR^W3K93Z!;I?
FVJF71!R+P9@Y#1EF."8DDYFE"<) GA L!H!P:CMI MB<#=-J\$EB3J:VJMOJ=J9@<(N@C"N!#U%A:@V5TEJ!IT09:?
NA:VWU5!J4,^+ M'RZBB%/B!H'HW>9W!V+7NAK44-ZL:Y&EIC^!>JHH&8L_@ONL02<(B ONL;Z>CA#I-
;NO!S)^9X8=I>YQ3EB M!N*SP8Y\$.C8/DT92_LV42E9 M;IOZ_7T !289XT? G?8L;Z/MKTIE)PU6P"85HU#;V0U?
_+LQ1ZI+P/L M6+\$U@REZ!J.>2UV)@ !P^?>1GA?M8!CD;M;+00^J1NT>8>UUE*!29388HA M^RDB3!1Q&6)-
@HL-"XWTUM9\$F!5T"1249'F*6C"X F%N1UO3<^H^?>J(W=" MO^3U9@6;1_VFWZZEZ3;5=(MK>1!V^3S@D7<5
H M3\$PL;)S@ADM"IQ%N2Q00* @GI6NC(RNRO?LH7.T!8VC/6?A;AJAM8T8 M6^ZN&_!M_\$#L3.
(2...LOYP(.PP=00X>;Y-('=E8>#SI=6"=SBRJ FF2;!0;HS!"CPUE>(#1X!P.MCU&#\$.3P..=DOYD#N^C;f-
EVI>5W)BGTS)MNOZT/L-F_JTV/DU2-SBP=O M_0!+OX! Q7!)&F)LUH!6WW#TR!_5.L=E))Z4P65N!;5=
f_195JMX_5E5 MS22&@WM\$A\$41B(25>DM TQWF69A)LC0."LEI"FIKXNQN<Q S8!@/U
MC+9>UX!5LXGKF36!J=JQ)5H&4\$ZP6>?S#M!0C@02!;/G*V#FBZUE M@VN>P3P)Q!>E>WVD)@?
YDJ!)^W48&Q=.WBJUK)IHBRK5L_K5J..N3:F^KLC8% MU#MS^J'9+#+>RF MV;0/F\$%L!_93YF!SR=G9I?
_8L!#9M(M"A.Z.5 O"!I(TH0XAHIS4+2_H%0 M*Q%J1=H/GUVD<&&&9S!S18-/CO!2!0XS/
+;&H@Y2..H7U>U^M;^<_ZUWU3;LM!;!>NGIE\$?S8X:GV^W9MG!O!6! M;M;->/JV_C;%/4R992+D5#1C@4.!
MMCT'5F QU078_~*RVU!U)OR^VN4KAJN4&EV><"NTG9_VVWQ_&F!L8^HX' M-&#B!@T!H/AHOL!>#(f
f!+Y:3!D37K89%1B0D_94!7@CQ?M:07V3R6:&-K MO>#HBKW>4B6W0?8&G.'P%_#L3MG>Y1_*8!;U^R
X;.!3V!#;".?D M=8!NO)C2/>T/^VNMMZU9YQH!V92JO!XV;=3AH?SGK!MFE^JXK52GYF3^B MVZHRU?7-
!NLNR?3W74A4A!H")BH..6"XI ISL!R@<I6Q=S!+NO^V^H) MPF3!Y;Z<-!R4S_<<3?^ZS^PVNA=S=#W?9!
7C.E..ROZZZG8MGB;A!PE%== MD&\$B:88I27!L"Q.<) &.28)CS 50N%"ISG&4LQ\$!8!J>(S7T6;*8=V!>AG(1F7*!J
M"PR_7^XIM!G@Z*^!J9_1!SU!0%/.233LVW+Z1.6M,>>UZ!(Z=-J*.!ESN<=>\$<3ZJ!2!A!OW;!#C-R!\$?
NG;AB("0E"8DT+Y* MRK1)2Q*\$P)C0H?O3:AWS_ SYIA6V>7M+/D9"OQ<8?)7D LCOW21KA,X9PIW
MW=9Q'C%.;E53LO->2!26!Z5^F=KBG>'(L'X'EAEN^NV/S5VDC9@J(H9C:@Z6_M29CBG\$J*\$Q6DBD-NJ
I9V)FATAF)UJV>G* 0X_MM2L3=I3ACK->2MFY:L^?(ZFM0=%G^#2AUX6!IJ3M,9X:87K\$8_2K!3XK M/RM5_-W:
f+Z_6Q^ZQ%>H;TL..5Z2@C0QHUM\$V>Z6:WFPMMV5.03!JO.5)
M>IB%&f/<YQB2QF=#KG&UEWLC,M"N.S!1E!WECIN=5LO!33?+>,DR&F\$!682) M+#+,LI#C/&=)%F21C&-
_X!O>H!>O;H!>X GLMON:MPE@fX=^BHCT&M\$.9%!.77/UH6;_1K&G/OGYJUS;>6S+IES\$S.7HIA?
I0Q2*RY00:L(!5&"2 MIQ'.9;JT2@4JCV1&50C!LG>)T.OZ=2#;S)!%&AK#C><9%J.P4SP<_!5TD!VA M!<X8-
Y:7%P@LW+BW% A3UM43%Q_51>>SZHJ_M6C.0KYM_0^D;5HBJ MQ5! MW!T_ NN*/L4+!'"DA8!DAG!2*
(D8&D4@'IB>G/K.1=0O+FAW;N_M_G@HQ0/2D&N03?G3!P.+PRZVR!3\$JGYCN-T@KDPCOGXL#S-
M^IH1G9KQ6#17 M6!Q&H0B!PF*39K^!>0<*A!F!47Z*W#A2:"RUU
MP.OX'RVV+P>0J+ "4+L>&4^U!9*8D:C6/LD@521RF*5%G=;J;&/-H);DYM8XDIEQ2!91QF#1MA;SC!S?

XE %#/YD^J< 4/2L8I4RU;W!@IMFBK'C).N!S0B!PF>R058A!#@3(M-
+ \$K2V&A47&-;S+HU1F"8LOCU.ILY5@ZI"-9.1X!EFF4Q*(DST!B6/\$YE:80UY/M3ILO!#&*F-
UGT1<.0#US@<"A>|VT;-YZT8V06KBSW+30IWWB+.YQ!0+^~*@JMDZK!F>D=?S!=",U*)"H-0>
!ZY!G03&F(F9(19R&@:RR"!+!B%VUDJ=H?2.QBM!8KKJ!;%MMKZ5_W0X&
HP^+!P!Q+!WR"NU5D6YK8=-2%Q.R""^!.*YXGN2!Y9V=Z#.&1JN/7*V*5PU6MR^H2J(?-2M_R9;O^K=Z?NX-
5T7*YF56S_MX0(-V\$!U?97K=%O!2";PUXU;4&:5M49!(&IKATT.Z@N4'(G5;:EL9AJ_X4> MJCKT5CDVI;W/U5!ZFA3_-
R.JX3YR*.XV;G*OM ?KJ?_ 'E M.1!OOH N\XV\$GKRH\$=)+>I(VPAH\$!;W0.O3?Q4%+7;LOU?9O^P!;RKQTJ
MU6"HBX@C2HN4X8(E'!F\$!PG28"C.!A99&2Q*J>!T!S!K.>!/1?D)=FOLN! M\$8=6XQ!\$QORW 3#@!CWU>&"+"
!AP"TDPM.#PFREME0("01BI!H2 M=17%RB*!H@VK(Z&WPNWH5!4N-15'O:6MHR#;W^R4J;P)PRCYK/2;LNX;I&9Y
M(O.\$21RD288)R2).E: XH2S+\$IJ;PP!;V)DBM<+Y""5F?Y:/N!=7FZK;
M_*M!J60VGB8ER^W2GTB@3A^LF@X9022TV>0Q%J%&/Y0J3F.KCF\$ FLN=OWPW M;-
R@QY81Q'M.\$!TTYWM!8\$MFM-F?KUMMJ);3/X/4#J^!WC4 SF:9! MS E.8L\$PR8L84YDS\$G\$PXC+. !A!72IZY-
W7!E?C\$CC6B6\$! (EP=&& M.;0T%WF\$@SA.M>.;G@#SLG>|/#-P. M>T<+P6TWCY+OWISF D&/:FSRI#"S.60H
MF8*QS_JB_D6%!H\$^!L5N.W>5J#!IM9?R0.QSVM2D4-Y.;A^OOW GYPOBG39P MOG2AF^9!%0!*<
!E;*)%H4>HLBNW06HIKUFI(6JTV!TV! D0A.&=>PTG!:#1B:/-3V +;= MML!&("0<1S%C*;2I&@&K!\$R QS)?0^*
.&*>\$!SU-0!;%YA:T66_K;?G8-!MN M>4.W!_ =5.^GO6?!.U/I9KV/#"885OZ,0"#6(G;I.U12%=_ES-/H3"6: MQ7>;
TG/1M4+;R!BLDD>Z7AF"3?M"/O@T!J(8T8IBO7&)"E- 11E6 MJ2
F^!0%.:@KUG*QF2WF2>U'_9 _BT9AJE_HL!WUF?M9U&Q.VNNLL+.TFS=
MX!^QIRM_?;CTLOGJ9OZR4! =XV;+KU?2^A75+HMY^*U4!JK=W?-AOY1!E;
MW8DL!*29S@6A3+#!@+;4NWE!\$S(5Z9!1PT; +*P.PZ^;=J8!;DLJH;M*(M 5E!SI#.*>N<0.\$4^L#))?!";1G!_7!Z.
!GY#BSPT*.P/!@.07'M_G!L!H ML#
!^=6"&J*ZV=UWB3C_)B)O+K(IP*7"4.3+WI7#9_!^R+S(H+YIH(SZ7P=%/!%UO\$0V!\$*O
M.IY!M1/4&MGO!4UA# !A7?1PZEL9)P;(!TR(GVL;0 N>!*#
C*6VTSK !NMP^O= _5VZBJ_5S#NX)GB8AXBEE!&@- (!L0YR4(FBGO#-OCS6
M0Z4"2\$)OO;K&:"W738WP1L)M2\$WIAJU@_25VCTW;IS=EH35 M:8D<6GO!5IU9E5MFT)X;=& "AQZ?T%!&I
<!/?%#68\$H)#-T'C(#0JG_-M4HNU(7*#8-B-R'XQ)>+O;?1+&B6#!.*V.#7I@A9A\$G&:Q2DNB"HP*3C%/!-
M<_&\$"Q*K_ FM*R;2L!;+M@HZL<JQG4!KW\$!XQ0!F%);\$=ICU
MG<#!M/7QYN>;Y.KP4HG==.PI%DWHD%\$DOEM1-DE,AK>8?KP99IOO^_?E% M&>;U;J4!>?
T+XW&5ZWMM(TM5WQ59G@6%WM9DR@Q/CX(\$LTQ%F%(JPB!+LKRPMJG8'TIW9G'4#(!LSZZ8\$WJ\$90>>
!3!%NIU;W&@?Q+^E)W6B1F.%L M%;=9+#!%);=)<@J3K;B"M""R2*TI9M@2G=F- 3W=.%UIU9"D;/PCGM)LT!
M\$LRD7*HC(;U&+GMV#T+%;#7%8Q>"YC?@M\$3X.8K&IT3"%@P>G;I%RT8'1-N MJF!TI-YK;SI>
!>IRK>KZ5NB!;UTFV\$QO?0W^M32.6_U376H;K4?AUFT(65\$ M9(7!;+)+79;KG=E!255B5S46I4T-4!T239CIW;;
M!FCR+;O.U-Y;?T;W&;ZMD%;O!LZSM&\$^TN)S\$6<11A(A*"YPG.%Q27@; MA"&LMG9&7N=.;@!D01@?
Z=#&UC<-<3L!/?Y^G/+GCH GODP/SB^TB9F MY'39G(OY(3I)V%0B I
!;RNVZ! LR7@=KW>5J2>XRU@D(ZK!;Y7S&).BB#- MN8E.\$IZ&Z'
_FR!OGLS<9K0CBKZW5(&&!SPREC;O:GF!YJH7M2.HWK TWO.Q-1^;@S.^!;UB:~T%UG>< M!H!Q*G"!<D9
G.&6.XY04M."OR.+;*)TF;-VMN3.2FG;\$;0/BTU@-!TU MI"1Z:D549S@O*L98!%9RRK A2B\$MA07/! M4-Q@WLB
_9C'88.BG?OA&1N8C3L/Q:QA+8"!GAP5&XJ+>BT "(Y=&BMCHW4 MNK"5WN7P1+L P1I(7(9! \$AH.YJ
M5F1GWX4.@L F!Y9^+H?@%LO68"HYV-!L.S\$SLH^0#!@;IK.9JV:2VE<7 M-SNBRI9V P%QTN-
=C?;DA5WG7!J'=Z4;ZAV+5V!5P!J3G+"@X#F."IR M!;6A9@%68HS&HD)*E204JO!SOB1F2U"1Q:U=)\$AC-
X;P!L\$!-!H7?UJR MPY3=261KY;:1.21K7_->K^X;"HXLNHJHV806*:76MX!G!PZ;:E/5X_OU M#16-
\$K^C4B621""DM!4Y@<)SDDL!YUF%\$9LSB\$=3<10V3VQ.@!)> 1^#E MI#ZZUXH)THJ&C;DD(VP!-D\$6E!0N?
(!L^>Z(D<"M6/7NFQ?2S>C_92! M_:\$J=J.C2L;NM=BS-F\$7YSUU+H;732W97<@#5\$#.<9J9 MLHPD;R8?
YCA(8Y!E&0U41"&*>B4_ ^MTFIYK-N3!P!MZ?USR?V!J?BWR=A9A M03QAOJ-G#'#6<#8)R+5!HP-@-
ZEB^00<>T>|JEQX=>\$!X>3)/UW*!SJ"7S!-VQ
MT?;U++Q9T!2!OJHF\$R%/21A%L!QQADF7.V!)>6YM"2J"*+@S2W>K3IW M^
!\$R>MM:1SB7Q4S.Z=.;^R5!ZC;&YQG&4#AUN8H\$Z")V(<47WH;-BW4. M.F%_V#7HI
(PBN_/O.1/5KM@P>7S_R^?W!!"1DRIK77O1CCH6C!+"W>D)Y M4.'S\$;M.%BO?K=BI MI3M!
<8&YCI!W:VP(T.9ATC3@KR'35VW:6DFG7BG";=W!M4XOJ5 M*C:5VM?J\$9>059C3W"@A34WS*&_90N2_1
M4!X9S_FT!;O?Y%G +;?P&9_1D8+T8\$S=&!J2"6F\$S"OJTFGH?3%ZA GA7RU7+Y)TZ/(2_Q)YT88M+5F5*>)G/58L2C")
M(H%99J=(R&S7!;2*ZLC^FE2_ MM#>VSI3QB NAN.HI6N GUBP!_HZ)H+E M91P0)
<7;WBXI2(ZO1:P+B!6\$HYU>1E?8+DN+U;"/.OR8G>'T^!1.\$5YO;' M?3-*PY13W#YN 9O'L_SL)Q-!7Z!KS
:8/#""AM4.FH@ MX!O(ZS&_B!A73=YY?=.GMXZA8!O!6M=4P5,M1*KE1P^O\$%;H!U=+CF
M.WMJ#@+^8)5L_O-4!U=2S;S823WFP>6;F^*X(L%9E@6(@BQ"0(0LP4+S#) M(E)C_0R",
(E&OAG;&HU;RE:5(SF!&IO4=.L2!LMB!><_9J/Q?29NXWC-BI>_F MI%K !FY6\$HIMW<876&
!O9B7(LIV;W1WPO=L@.<3T!);@*?W:PDYOKZPMS! M-!IHBB@TQLS/S+^"L.R)N)WB!_MOQ1RIW>H?D!\$!6SVE3-
K+L8MNR;=&& M&S.+JOU+^+2J4>M*2_E""^!;9!;T5JRNZRZ;4?CY&_OS+@NE8"PP MU5A^!POAE&./17^TPY %
<6!FA6@JDTG-E6XX8D(9<16=R/ZV;(Z+N*!Z MYNVFZ;O;#5E"/_%V-
OGE^88^XW=JFM^P(%&I<'Z&4/H^7%^03&9CEN1(4L(&QE=23*9DDMZC1L!7^V#Q8W^<8H-YNQ+>U_5.R3>I
M2CM9GU55;KHT!/?1G#L5:A^D@07(M%^\$(T5IK'(<1+^C%"I;Y(4/P9SL; MYL(PP_1C-3I1M!4=N!4&%=6&5?
1=W_@66JHUUD3(VN!Z_13^W%0'?Y1E8 MAIKG119F;KHBFE9;=FZYFIOM?
W/"!NH#@.&GR!K%"!T!T;E.5JMSN*^!+ _P M^ (HN.W" P;/#8!;3V/
52SG4RYOCT>KIB!HWZD)ED\$1"ACB/(FE.EOZ)ZOU; M\$H=AD5_6L=A!;O;)RC;HHX6:HD!;N&?
23N!+*Z2"68"+6!U;F78!VMN/W9 M2LM5M)3X%D9^JD+W+!W_43Z!X_?65D9 VOV&7>)HMK99P7;CC'Q'09SDD>
M8L7R(E4DRQ("FO1SGLS,RM(31>6>*NQ#? \$ _!M;"Z2!T @!2*+?N7&13W^D\$U<#8_X-
!DF8KMCJH739U;*W^K7FZJH<16R;YB M\$#R# +!+!H!^O8=Y2QO.R3*\$?12!-Z(NMGU#75!D:7^0
)O^FAA+NB@WTHG MU&:82NJ"AI/I(C08N<5+N(3S"<IG?ING!V<3^G8MFZCBYTVIK=2V; N;
MWZBB7"OYJ@W)FOR+>M#>SN3-=QV=19'F02QB)"@.>*0F*51@>_Y3(PC1- M02/-07 U=T*9\$)7>F#1G'GNM;IOI
Z>H.P-5B3Y>29V/LCB2;-VGYVIPWJ MF\$=\$-!BPTQ82^6!3!1433SZ!YX6=9&PGCL4?E=W/%
(!5*KR/WU46W=-.VY MI4>UOLIU M3T4:X93\$&6-YD44%Z -F0W!FO7L;O'H7&KB&)5IHF^JE<(S.+%WH\$9X6B
MW:?.S8P!6R!X8!M!O/WPWJ&4!&1A?2!@\$GOZ\$EJ17/2;"^A^L(NA=> M!?'N4ZGR?
MUVPQ5;11ZTH6A.3.P^EH(HO?X>;BP5*EHQ73G+.<8^W=;!K0!VX
M&7B=A!P!M42O=GRJYF8!;X01\$Y)R";ME%BNB@^U+*4 W0>W?L_&>8=Y
M6Z>1AB/1L;G(@T3;10032..24+U-E!E=8+9J!^%I%.E*T)M*0YLQ4T)2KH M>TL0U>6?
V/A&R#" \$ZK8H.&TXM%=Y6RBGS>\$_. \$LXK.JJ:2-VUI5!J#FM(> MU#B8!EM8;(WCC/Y68?K6'S8R>!H1
CF9J!S/F(*:8)EDL14;2) 05PHQ2F_OT M9T^L.6#%>A?9D0>.2!U%\$&L_Z TTF#F!#(';K1E!35\$=I+3M(U4;LDWFI
M5C>YGG64Y0^V;6L^DF(!=18N6Z*3YI^KY+W3=W=JTI>2B MX!E4A210.L
M@E2KQJDOH05/L10T27@J!&6@!B1N;QL\$SJH;\$C6:>"(ABV!RMSOP# !?B\$!OGW=-;7\$YGY=_H^2WIB?

70)5DI4C2\$RYBE.L MF#D0+N(4YI2!?'?#WS)*6*9IC9&602'AINU\$GZ!Y@I8C^3T0G*,CF'ZD
MAVGB,1%-6M.KO>ICB4T0P>TCDWX< M&.@(1BD!RS<2=RY>,\$XXI0 P!B MQ=6.E>8I7JM-I 0S?
OM#-1>T^NOIF<99D\$,"XI#?)-("4R3),1)%K*|R)5 M80*J)I\$69I=*" +&L)7I2>|B).=[^X% ^"!BIOX|*KM*=%\U69?
I+-L1?4 MN"=UUI,W,1:7M,7YI?BC>EWM;23#M_W*RNZ|*YH7K 0\$YHET)(B2EC
M,->9I0Q(@I5D2I% =KT)= "23L1B=HJ2+G|8L)0|N^)HNVF10+QL%EIN*#U M^ ^,PV,FS|RCP=OREJL-
L_K+\$4%\$F!|08C)6%8" &'7 MN^D)B9*O,3,^ .E5> M%F"!KMLUG,S6N_7HB71S\$PEK!L.G.
IW58EWT97ZEOFX^,9B9I/Y\YO\OM M0I=DR/OI\TKOTCS/,D%2K^G1>|Y|/3-K MSS| -V-
M3H_ ,87_ W3?_O_ FM0W|/\$@3K_ "1RFE)BV71+G4N:8B8(+E7+&B553 M|&E2,QM2@W&Y,;=2HJO
@8D2.N%T!^X|6^@^4AE>R8O.I^>,%M&3D1DA MM*(C)F!,XV !8W.&FSA_5I="F)9EIL5?
M5GKT4I^ ^7S9E6*I_ .ART,8Z2(M"!@|^4@=DWB"8A= _6\$;N7FN_D\YA#7TUG M>U_)UBA|W&S1/1V|/\$*8K0
_ "SL+,B?"+NB,1G")R7&I3R@7I0_G<66^ ,*MAB<+!":_J%UR!>?86CFOX|P+Y*CER.WCIMJ6_I,U8?
Y< (Y3C(FQX4:29 N6AN,R=I3)@P>PI0ALF M4-UR@<1F9.ZW3ZSM+-7I" +LU2FV1I>0-
ERACBUD^\$(M9Q=WFFI="VY AI_ M^4U_-B(NRG9QI,;7,QWN<%V4^P_FVDW M>,>,&/ 6656N|5OU954THJ0E?
*GF7%PF7B9 X:Q(E FM)R+\$:9PI\$M.(1(+ = M_5 5WIBZ3!^01U1?YI+A%2>7)-+5!;U/29\$/78NIBYWRR%F*Y,V!/?Z?
%J_ M7^L/M;JW7Y@Q%O7#N|7F#U|AHVJ|1H|HE8FUV9LK_5^M?U4F(EM6MEY3B3# MB2A23(*"8U:0" JRW:
I25!HUJ4NIVY MI^J23>_ &C2B;5B3-Z8I0,J%""X4>NKJ|E"998;SF<I,F^2
MW)=DUOKGKNQO^Q1INJ.FX0;I5""!_ 0^>VXE.V. UW%R> =HOK/I\$ _'U%BP1FA_&XSF!^@G"
MY_7I=U|OG_57",*FOTI,TU^2XP8^:9(&_I(1%FD081(5#"/_ "AOD_%0A";D, MK\$,H(C,HS.R0-P7WGJ.U#66V?
^N91088;5AU;2,\$ G0859H,->,+0+4^4E# MU79^BND:-C%U;RH% _I^@SP;@&X?6""0?
KXB3AB,2I5@ZRUFEY9W\$%"IMMP5I
M=S:N7SW|ROZYJ5Z;L+2A;XWX\$VK800T_3OUI(#C;A9UF0@|FD+T^YI\$G\|D4(9F^ -? \$KY+|I(A M^2(DIHV2+R_AW?
@,?-^AT=U=IO* _RS|J2)*VZ DP;20^&=*|3O/PG|0 /?- MBRFPZ(F53CVOC/OF?3""DJ?YF@ "C?FM
MTB4& _BK&:0(@@ (V:6@G>+Z>,'>1/5KE01 _=,K/K8DC8=|_9BC^N^XE=(=/, M?J3BJ""@YC9GV^9J:3<9I%&-
F>8^I:0.? =G^ _SNM^MMN7UJ(D&LB1.^85OV MNH|,*&B8JDOAR:((\$|WIP)S1
*=!GO\$@#Y5(K|1@BM#,BM&21@/:R!#O>LY; MYL|_@C6N1#XA_)X1.TH/F@IN(YK3D/#1A1>,&6XCWG"\$N-
7U#KEEX2IAE SB M_6TGCJR+064L4VF>1YB95%BB+S4C|PAFG(5I% F_1J%U@MDHJ9D5MJ|I^ ^#
M4KM>YX|,JW&T9H.=?K#_*Q8^*|9)R-XP|(C_&AUNHTNFU@ "6?64DXEH\$V MOLR:6A6@CS+1,;
|PVUL|YKB?^I^F*KFG=CN3*)UUXIY3QA@1E^@S_4ADSR7 MF)\$@QP6C>4!3FE-
8,ZJ+E&8V64WSI4V|GE%V:\$9U&2VIO;@7#& FRU%|_9Z M4C1/^ ^?+=!;=)D^*>|P;GK|!L9NKZ4I0VZ&J|_ -
_JY^*M7NWJ_M^ ^|ZZLF_ ^Y=9_ T^D4AB_ , \$YGEF\$0BO|E, "8YY3#-5D(P+4.IZ5T9F
M5O^>L,DCXF:6\$KR)M#|\$=D9A">|@_J/ER%B-(4 HP|3:HSID:X;Y&=BXZL# MGBL;RS;
(NQ^LD_YYUZX^#^,9^ZC7;Z:=|Q_|^T7I9>OU!&Z3 MX";I4Z 20&:Q_ "9<I&8T^%N-Q>G273IN#^I>'>5<9S:/+>W?
WY7ZWQ=\$2:3 MI_ YCG,3^R59AIG(% X%)5D>YH0(XG#<,\$YUF:/%-@:_R7_NZK9G"LOQF0#;
MSCWQ@ (3/6AE^Q)&I6D?T8=<7|^AIV0GKR)"6*+^@QV@AH|H9W.3::K#9" M^5F_TQ^92N|;
IKIPC90>_IH5J3A_4A_)J9QCEA EF*XC9^B; MO4LSS;G P@W;LX>+387-
91Z;_S|^X:NDI3|LLTT^<\$Y;+IN@|I0:=9.F<4 MM""7/(BSY^EV,>>4*1FE6,9),**D.(^|I.21I")6- M;YN_.*^ TZ
MD\$>&?EN:N@&4IEK"9^> ,^0,%9AVOPP/L==F)Z^E.^TL_V;:5O3%3^M93|K0%1U5RPB/ZV_I
(6KBC#G3CK5DL0HS*H^96CZYFID;I+RV0?V^ MSTI?
QVP:Q@X1CW+B&V1D0WJUG8.6B.&ID*^@1@I@&IC7!VIGBE|L,0&#HH,G M=,#190(IZ8=R|)\$C0|PWAW2HGP5-
7REF7GE;_N|L#EA/DM^F(>+8%; ^LV?U| MI>Z|5M5?U
^UWJF&QIT,,34Q3/RF08;)BHC>N24^YX205,4QT4>U/M^A-C, MAO:2EPRS8*FYTH
4&S+RYXP|O1FAH^6IV,DEFTL;R^T2?MX MFWLC#+U_0C;5JJ/-0H;E| RDZ7/8@/4^&JY^N*,VRS)J3RU9/Y I5E
M>S^BWK2DWGB9|HC")|@+3 M^JO*\$1^4UFDL0:*BM@0G7M3M\$^6-CYWSP3JN7" JUKA;EY|8P2<|JR/4#P
M#09_8E_|IAN2RVX' ""<>/F0>|T,1K-K>,7\$OY0|9(OU-7&"A210"2ZBB&&2 MQ_3GA?L RYP4&0N#C!;K.GT+6G.?
9;:9XX8^Y@T#J_Y\$ +,(8X#9&0)/,,#T MOR&*6ZJ#-
9/OD6XGE2|C%*B^JXA(I8S#W;!!SU^/,>OX00>&YA_>PTFGDR-\$PN+VJ|K0#HV3E>MY6:U M^OK905WZ?
@SQ50I4EWJMYM=I>^/I^VX; ^C|^OMN>Y>^&_9;"3I""@0F+\$HP M#0J^0R\$DSY)4!0GH5,@#3S/_M_I2 SYN4%FYD-
9E(*MS>"8#3>#.)NCA_*P M!;1W/AZ.G?E;&*8-3S7I.\$ |I^Z^?8_ B#1HPB1HN_5E^CY|Y,I8^.%K4 M=GJ\$|-
B4^ES;21D)GJ|8K62PWR;NXQ27)"\$I^DA M14)!^M|Y,K_??271^ _H_-5F)\$U/%ACD.8I0)- Q-H=+@J981)F%-0!CA@
MDC_2T3_E;+!;_&N@S;"7H8<_@N@S^VHL|&U5Z4L;#;IQ M=7-A+O5=3GDOH^*)TGLER^U30DZ#6^4.HWE8)
(C"W8 >_)&_8S#DLQA73AX0PE7Q_ MS67DS3DI_9-MKI36<8"-W2.%S:<9D61L#,VYVY;-C/"I-.A,F/7N18>G^6I
M3#>ZOL|CF"5YK/1^RU"3)(QXRF#&=Q1E/INXP^&S<8(+BZ-Q=I2B;NK|I M\$4>*)-IC8(JFE,0RQCQ.3>E D!>
HAKDLQF,H@WTI79;E7RW;8*9VTVS?=-&0I;F>|D<2>ZO2TV_ M|+|9XX\$.M_9YO@*Q^R"PV2;-
ZHPXWZ|U+K/^L^7M_M;OU@@"P5VN.BF&CS_M_YHA",R3P(2HTBP+PCAE,04E'(#+I^Z^J|KQ|W.&5!Y4-G|BJZI2;IJ*
\$/7 M3M^GPPQF#(.#KSI&4,<):EA!!UY.C.)G5EGUG(\$G-SBAXRO? 49V100V!. MLB+<5H^C-Z4I?=-S59_JS;
H_N/C#G6;|S.G9^?OG>^Y@47I)(L2JFR.U.Y(C M^# FM/>0LX|API3V(8MA:M^V;MISY99_! =
SXIS^0N04JEZAA<|A|&^X^JQ>/H^7U|:1E^K^_J MV;A^NI=I|J" ^1Q_C@3:09);+\$ _!TC#P|XLZSO6KNX+Z-
^O3NN5IA=J(BXWF&DTQ|J.Z.@>L;:<87#&_M M^&"IF&2)6"W;IV;)X=< M@7I2=#I.>FDUTSB^!^7?
Z/5FB|K7WQ\$(NZ_AG8 MI6R7P=7MJW;HXS @WW67 M)\$5^1)9C*^NMZ^%(, >-
Y@/_BHSF+61I^4%F/>F9E;XE|<=W=NNIX;@K8/F|UZ>Z?= 49YE&(148J)8APSF628JCS/HSR)DP36PNL"H9FM
MQ=|J\$ZY8=R0I_VBZ1BJ.(((&(-P%=XTKF#J^3O+;<WFG?
N%ZAWJ^3:77J9YNUT;YR^V|JF*KW|HTZ3=ENU_MD^H8/KL)5@4
MF=Z04YIAG^AJT.TB^E.A@%Y^>PK.N;|S>WXZM9D&HJ;(7^F|!|O:KW9U0#L M8)4<<3&^CP
JRU7JP\$75DYB_/MO@ (G^I7V,9VF(M0ZKW580\$2N^PI)I+!0-I>()Z4/0QE8(C.Q|Z/(R&)%OS_ZAIZ0>6CV#, M1?
303Z|K)*Q7.2;+5K;|/E.\$<*IR"(< M%Z,C^8I2G\$5X(1F^8UEF*=9ZK8U;PG;,%A.VM>I;LCO MN|XRY9A(P3_5_4B3,
(EE&I);!5;/DY@Z=#D84#;BCWPT#I.\$ VBEU^#T| MU2?2"4Q1KX+CBLS+8U)ZGZ1PEM@+C488\$ _SRK/(INOR5?
O?)^ZHPV&KUZO^ M>+?;_/%^76RJ1_.LQR^/LCB(S:F)&/H4A%CGJ0\$DR_6(N6\$%)JLC60|MQF M8_%,FP@PP<;
(T I9H6EH#_ Q@!S<(D//T38;)|E=NG0PO7=|H?" _N_NMP^;W?+8K)-2BFOACT(Y^X
M^7E8+Z_&)S#J|IR1%YIK3>#EMYH\$RMBOSF#NO=_5VZBJMWIVU2TF0J_-
M3WYC?IZO2G;I(BF.E%"8D\$)@GJ<1Y0I\$S_*14\$.VDLX|+ #B4^5M#9"BY@
M4B92JIC\$7\$82T\$ISFD18)HFH0DFNO&:QUSCE8|79H.T.% MTCZ*73&J&>'22Y@?
U#_DO5L|2ZGDR>|>|>|4|H^M53V<@X4|U3M#=-JH MWGVI:X/\$9VMP^A*;I^NSLWM4U>PI_4R^N1_LBCDUB?E#
M%=@=2%00T1|I|APN&HC_MMO66M?7RPT(XL|4SC^2#4I0>YIF%2<&3*;TX1R3-%3:EHL4IP63+M3E02"-LGR
HW9_M_?4#5?LPRR4|IN>^J2\$F;AP_8MA4/NX|7G;QT_|B"W6PCG5^X_(98)@48" M(Y?N7^R<,<^Z_@Q=>G5LUK;
M#;==,2OU(/:ETW=J|Y;7|H%B;AC(LHPG%D MFI3&C8^H74;|HR3B>L^;2= X1B#|N=W
X8#29VST/4\$|S^"UPMG2%YL//> A M|0_@KIGM"A?_YA7^<HO-?5\$ LW|A%?0.HY3WHM"B>U^5;U1-B5F;?N=G=XI
M|3ORU^=L^>#4H M_.\$|&S;L|LISOCTH@RX1AHVFXIVLU=EU^2KJT3T.#P>+Z0>2+VA)<=,0I& MY&3J/P%-
WOR46U-PL5GTS|)%OGJZ>^UDN_7|<&+B)6E F\$@R'(AF MY\$9*, "6QPBR1@A>49'&

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xu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

M27-V.1(Z)OIT):RX:%I6@>S&-/P1041*LP%9IS\$F.1AC/H"~&>\$YJD19#I
M'R#1:Z_@N73760XZ.SOK%1"7L,%AID^_9^S(^RQI!0LK2>S.DUO48MJ+?ZQ
M.:6_T:9!6^Q6MT)L=MIFWXXDD4E%6H6LI(FI@AI5); M@U#A(LA5D08RDRR\$V(
Q8C.K_YTT_535\$J66J32R3H0+%1P.PTWQ<_.*70_M*9BJDM(?&Z.AUZW0#3^9_=.H9^~*/UQJMGJ%
MG<.<\$M7#Z2R-93LYC8EYTHH\$)Y>RKY_N6O^U.2_."Q@%8YD(LWDQ>YE4_MIVKR).19FJ9Y%BC#.^3N3WW!;?
RI^H?K^S2.3!7GJOI!?:?VZ?: M/RI9ZU_+I^O7/RKYCZK;^J.2)0%O.TJIV>ZC_M65!4ML^9.-L/%;A1XIE24-
FR(73KUB.A=;Y6#EYOIQW4=O" MNQ!5%3L&U%Z&_J5UXPCR?^&:S*6DA,^%OUJS-5IKLRHQRXB69.&-#&@4.
M(NY'/-S#..<OIH8GMCVE5I@Y0F5H!;97OWZ4-&C7?&49J6+;A&P/7/I M7"UO;Y9Q1"D*~<QJCT\$OD= =?N-
A!!HF7E"/!?"JR.MJ76#- M;LRME-FQOWPI/US8>IY^_?+H<=!S^9#9@OU8/MGLP!OO2!+!0KS!%8^M9?74?
GHQQ8IK/=KF\$2I/C6J1TV0=D.3AMQ+^84I!+.)@E@2CP\$DRS-HIC M!2=
<>XL=)#7Q5U!1-C=PT!6J89(06JPPRCI;-L/ 3^6&Q+?9.4>^?I; MK3_!
I/9JZ^%V6ZK)>_0=CN!P\$!K98@!QNNWA07-@L.VY71K!QWS8JMN.<
MAIRF09S)+#D.29I02%\$>_<^>_+98*Z1"-OLG30+^!S MW+Y-9*9I3ON>Q>V?>^"= \$:I%RU"OP RK9?H!O-W#0.O
C<% T#QP77IA@X ML-1/ADX+MSEGH\$;HK=\$!S#POI?/VS\$FE!2<=4;I<:##/LYQC*# @Z1)RRG_M_#?TA!%-
XBCQTI!H4MU%2E-)5NZ!GL+%%&6S>X+^".E="CB1V!SXG8H_IAD MFMRH;YN!"!3F?4Z8%3Q7B-
8TFN&*VQ6YKFL1K'(R.U#AYPG(C;TLV_^M M^"C>O>P=KTP./ 33#&:<4(@HXK*GDP^!
(. "\$(!:D=\$%IUDJ\$RO1GB901-U3_M;IBHK=C72VMH:M^).@.\$=2V#\$KE*NCM+8IYDNR\$Q3Y+L!A^VTT852;19L!9(
M8=-F^~F410QGN<0!T0VCT8Q)"P.((G!)(DOCE*/FBCD4)31!S5E92!G>_M MX?P4!N+
EH@NQ#8/M.XDIFN"/CJH#!1T3S)&.7B0SJYJ?7N!J!/VRGK_MIV7!OA>KE5CY;EV+^!T@*H.1!^/2MJ?~C*?
YSCS0L@C/X<(^P).D#+P!M1+S0IX%1=KL9^8D5NV.F=_9PHT7)EINB&Z>OH_69E5N\$ KA.@#B=M37"N
MM_!D1\$Q)#ZK;.\$#YMC@6*YB'L'O^@WL1R7IR_"0_IVP!V"MD6<8M-Z M+;%?BC4U3<I/3(CI.T1Y!_..11!YE.
(LB@A.4S_49#XQ#F#WRS^?:(UW/P43SYN%FRW/=H%.<0AV\$"\$:4<8NHA2%>^!DIR%CM9M51+MF;V!
(S!ELN4?ISCV?9^&>O4Z%RG,<3?7=8EH*)KVQSC!Q;BSE92 MBTLY72'M!N/.">+R+NY@_?GOXXX>*XI
MHU6VR="ZLZ6>_C7ST!1>=QRSVMTNK7M\$H("Z!0YK&:5!1CGB&/D02^AA*9Q_M%G\$?&^UW_=6GWNNNW.@.@-
#7>V<6"<I/VMF' MS&^&G)64+SZNJT>Y)IM_D/>12GO@=CE(FC.8J\$*K&<0A(G(4KC_."!UKWQ
M.4MA8G5J:8*_J/IMP!DQFI:KI:23^N.;2HKC@OJ?HQM42V!U;F\$MN=;!Q M*-7 !Y)L_!75Y:2&#Q4B&^
M08JZ;)Y)O#8WRD>0&+<)W8#&J\$T9%_ MJX?78KUWA@V=D!XW!^HZQQM+V M@?H4R1)8AGS@(^74RV J7&&
("\$Y@E@4)9#E+Y.YGR5+SO\$IB8FU5;7V%=-H M)D.I08ZR>=#!"/CIP+>IN!;ZSVQA=)/MT!GZ(X#IP?
\$9@!^"M>P;.!W M/ M7ML-4&5Q?2KKSWDN_G)?K@KZ^FI%J?1UWG*V57!99ED8A23DD/FQ&BE_92=C M#&.2!A*
<_IY^7+-!^1= 3>;/H%;;&A!E;/FJWS"C/;7^GVQOFLHJO>(!S; MUH%Z;KJMGNTKFTPJ#A9"">7_\$N0EW?
J'_%&3J#^O.OZ:(M>@!UOTD">PUF6 M&8-&JBDZ%1KAYKOYH!HUGI3/T B:RRT.S9:O.UIBBU/4_@.=I*^>O-45G7Q
MO^JDUF:RRZY!4W>>D+&5HB&&8!0B+PWDE#H*28J8!T4A3GAJXEG8L3&Q MIR&^?
IF9K;)4!D38^1F>5J^(&*H9;184J;:&JP5J/N473:0DRYLF70>_M(!DR<2L%NHZX(X-
U96K67H7!WNUJQX*=~6K!H6@HJ16!^!Y\$Y!1:GZ9! MRJ9SN_=-78>>L!O@97B/^J M?
Y21F_K! S\$NVJ5E&41!6_."3"D\$54^AEDH P9!%;=YPK(@_!HO-DAMZEF! MCK;JG*KE/I>2NMD>/(R8WE;M#
8SG3Q"0/T3*.H3E^UKR>AHL>JB7V M!5;HY)-6DHM@WN7I@ZY>3=9Y/DE)ID!2P\$R+!^.=L3IBW30;YI!ZT3
MQ@!3/(Y_:=#-1!O^\$?^_+?>55'GH.(PY3RG.(PM2#Q/P!6A-K1#M@5I^J_ UK&73P4QOBW*\$A)EJ68-
@O#MIB.=H;QJB_.O.I"R M;ZD!XJ94C->+^M;Y4<_4TF1B!S(G0T) T@RR\$".93!3
M"A6=K#RQPG:TP!^*FJ;"GLH_K(Y7266F?H"20;1>8^IC?Q3J-5XBH93H= M:1;5N2A
IRB7!#M+2?=-!+W.VLMU!XT!3=>DC#M)->_ ^ZY64MB?@8ZN2O9_MZK!H) 6->2;+JBG5RWTL\$=Y(X\$&TF=_R
G9>GJHX_E>OR!"#W98P0!3** M("4.0Q2%"*9!&#*LC!-4CEM/>@N1?5?9LK4E;ZORS7<_0 *Q<\$" MK=NY&S
8RF/6>1AZ^NAl)!SF!FTP12?C98EOD12Q(3+J)!:=/96:\$!@!%QE M=W"8F;(&B3YAT#K0;UK;#L?3ZPGIR<>
(3;KVZPG^+GK/F6;1.%=D3OYWR@_ M18#PJ;.@!AR&:9!E(JS<8;3)(PR%0>!G6G-#C*A.K/P!F120Y^+^JN;
MX&H8M;#5;|@.\$?S"XX 9I E-L_90GB?E(0IR3Q*6>I%9G&U<.*S^ W% M/@!^*TXLG
8M!^6C;&YQ.0VW"34/7.A4.ND!M"R C@>'CH2)R,Y"/>*PIA!"ZC&?9&M"@2YN_4+W!323OV-LP?>I9/ZC>=EQ;IPNA*J
M5>0%5?D=ID8+_U@&.\$/RM""M2"H.<+(K>!"F.(W"V_!I/@DM,AJ=<^IOH(SN_/_G<_6YZ;IK77=PDESITIC! M/<I
T DNW=(T3Q#HZ9;V!6!0)ZDH'5Y6G/+XPGO\$D /GLJG6;2>97Q
M42+Q1GQO/Q28%"L5S!LW)8KV1"PPJO/9%4**IU^877VVIHS>/2QPRAF*.
M82(ERAE"4QC\$%5/MW30/PP83N;7M9X-6S3G3!E8!YWK&F;\$5D)!%D!A2G
MPY6EXR^R39184!_DIOJ/8=A"SX>JD_J&C6IQYTROHL>V NPYU\$6031< LGF MG*CK%T7/BKY= ?4!GX)1T_4SU
8*M^*C.5LOMS.X^H7?IA:UK"!1?4/O-KR MS9Z3S6!8?#4I_K(>?VA;#;IWUIW#|@>:C!DW0_.U5H3BX/6;X!M7JV
M32N@V(MY2J!/&(H2S!;20!GK TL;0IX%6MXKI69TX!B\$9!PWGH;?Z K3_ M!4IZ-@7CNUK!SG0B0"D#&Y#C-
!RG!D!_&9V>V+VZL9F7U\$R.J^NRF^D8 MG;R4.3_L^F (XU1RE9%B#HCCT;TQA MQI\$XNZ
P@Q@L@N";&419Q2HV!C3KB;>"OH=;259 UC2VYPU!8LZ!>FC1 M:"7<Y2@V
1^_!B2\$!#14ZA/7"O_*Z7G'VWT7!6&YKZ>_?2Q)0RD(@ G- HB8SV"-80;14.XD!U(O M(3;M*#3)SQ-
_PFKK"*J4!.\$HY.^I=2. M!)(NU5DMCR\$40!%;!7SP!70B!ZE-9!TW@^=G;+0!Y/F1Y!US!97;#;R- MTMQ+?
=6^AE*(!8)2HD&DQC3*(T2E9\$Q;.&=VH/Q?4!PW%\$!7?Q_U?X M*CL62*;1C\$9/M@>WE?NG".AWDG_G,=#0.
5!_XG@_4@F@J#!K!F7\$HC6E M+DSZ<=D)X+^+OEFK#YB;R:BCW0/Q4>Z79HJ2!H05CH;OVGE=OVTWQ9IO-K2E
M\$RG6W46>BK!>T#^W13;&8I=OF_0)TG&811A!!"U HB#W(>\$Y#C. AHR;E1_M;T9^8FO;_0-
ZW*AI!4/Z#%DG=5I"+>>AS8=B&6!AQ^BU/P%@K3_RH+87;_ M(!LJ12G#N>L"ZRQLZ<4".?#I#XK.Z=G;
"MXEJm8--3YCBNVN5V5&_ZM M_+A^+F09J KA&3?TU5AJ8FO3< 4"S+GZE0QI;2??QT?I>K-MXL@&+H!V/
M!DK#AF4"@_PLB2XV!44"<_!^UT!ZN_8^&NO/U^U"7!B#YC!&KUE&UE
MZ002S5C_U6*;&LF_?/S!EO0TIV@!=*P9*YBZ^>)S!LL!Q3T)/HJ_+2YG>_> M7E3>;#
!GIU7US^K=FGW_W_U9O!Y!>_R!VI=L!N^LWF_8K!8U_O^V!+-=N! MK<1?7BKVS!JL1Y(;A;N_M*1A14.TW!
f=AG\$B:L+8^K-WU?Z_PNF!ST>O MH!=F_8AK^>I*^O(RW>#F^7E54.4#_(-OE/I(Z93#N0%OFY#Q;2GLCEA0KJ!O
M1CGZ\$;<I!K?D-/S/H?>YZ!PWN7<I+NY47Z(B%V10%MY#U?4G*YQ?(-SXOW!> MUXN!J7A;Z+=;+PFE#_A!
4HA(!\$.2!_T*(^B-\$ZIGU+=JX_A4I/?&C: M_P8.(KQ!7=#7S_V/8+6^_V.PS;_F0^!9W".XZ(?^W>%A%_&W^EH8!?
GU M)!R(!8!L,%M(7T^0?B1?PW;M(FZJ%2-JKWX1+!^B!VSK+I4N";68ICBF&4I
MA#3Q\$XA8S.19V8L@39"_0030@.3 L&S8G-Y)X#(%D+0^H%/+94Z8.H=
M(AU#9&EKD?(E!"6UYGN1+C%&2.D!"X#1^00!5B!#YPT!KE)U?C=;M7;\$ M_."MJ;-
A#P^5R!8"@F2YVN56W2+Y)C3--;FJ=R;#+H!DEDCWFTMKF%H^TD MS<+89X6RBU@?+C5?+Y\$/D1A2G'&
(LB/T!3~C?J7Z1="?\$M)E)"MOM;Z!F\$PWU>LINBX-<43D*7(0+Y!>0F((R_9A^_O6L>-KCELKY\$
MY4*_+02E@FRES9>_LL@IM3G'H)DX!S!J!@FK_)D&\$&6A\$.ASN\$%Y@MQ;@ER\$+4>+!+H_@JSN!5!^=.V
M26OQHP@3G.(L0N+L11/A5(49A5Z*Q4_9I(MI.YXAN%)S9.BAQ0!\$!#4!&
MPPD.PP;H6NG.3(Z!8\$;S&BY)8#6NX62QV28V7!C/I3AXC-V88S!BC_C@K7M MG>44KZ;5U!JA.%LFJMT>6*
<(920'(9AG(E!W!<0AXQ#V'(\$ZJ6T=PHF%*/ M>F)U;_J!\$;W!;Y!%KLP0%\$O@C\$-F;*VO(.B94%*
M0=ABU;9<%90QOF@!P_"Q6N.H&0>SN_3U6RX4JE8RO"">_!QEH_!9!3J!7 MG(\$!U8W#Y>Q.KJ/<*3XUN*4X3
!^ZS! TPN/92XS*!GW'5.2KNA0N0!??_MXP8?..0%=Z"@!8_#?YJ-1G%_@3S..2!IR%_.8.AGT89PAI/4JUV-9<(

M3&P1=B2IHJE_#X+QG@PX%HI5;3W2#I+4_19,27/^M>*.W?"-Q;:Z'0-)/MF?IL:1.=Y(>8H_?IY^S.X*Y3D7/(C;S6P
I.2XQ%'"..48LIR&\$)D@<D)M(TA2F@5YB_1\$C)*21NA-,%ZZJ#&A/H3JGLP#&&F=XIPR\$29G9G(T)O;NIQ
MSU9WAPE-,1V=(.HS7ILT/3I^*R@^YI%IVZQI^Z-O?;I^*"\$12V-\$.^D;*9I*!&YND1G7=NGA\$0C)X/SS-ZVLQR?
3CE9/;ZQZ)M91)"Q#"2L01RV(1U1MG.UMOOQF8IQH#5,QH.X3\$S%D=M?=L)41*B.PU\$MC\$V&HR.;,48M5F-
A*HQ19JHS7;P\$07_7S7.0USOQIA=^9L0H-/N>YI-.D MU*DW7D-W\$PPIS%D8>!!%DA)"&H_1
(-5KQIS#&8L65.2W6NGJDD#8Y)MV8E;_5#/?/!>>TPI1TK"OD=;L=YRENDKUOR+TYKU1<.;VHY09S7JAW_356)
MQ519U+@7/ZJD4#9^+=B@Z5NCD&3H.DL1N2"YFC4PYA/(UAN5SM=HJ18_%S5>[9K-9UF>(XXXC#
A=-.3<)GE7/Z3_M4D(113PSFD"G3WIB\$W;[,(LBGAOM4NWD157O4S5-1EDJ(IWW+FX>8_#J M0C;KW_R'F64S^
CTS-DTP)K9L(X1*CX4<1)+Z+;_?\$**>G_1\$6?>+YP6CZLY571'1.GGR(OY,5Q4I:C MAFM4G-
T<3\$D7OHL^R1R_6GSFA7AXLXPC%B6^CV*SJ&3Y-/B6IS?O@+V9M3D_%6C/,@SW94>=FPK
MWZO.&@Y7X*WPH6N.P@_#*9\$;39-*I02Z1GFZAD1,N?_8<(I=0:PPL?
BDY12<AV(CAXP\$\$(TA1L7V2).HAX/(R_@MI@H136J_MV-1_ M&QJ/GG!
I!KBUN6JZ7^Y?)H;X^X@MIMFF=3US03%5HZ@W=1_S9R?1 2\$
MOV.;P.5I!/?;1*867QP.*OXH#EIBY;V1N9\WM" T.YGP41C5D<M="9+SU1-Q*F%
<3.S:S)+B^X"?NV0\$E6;9J^X4W\$5)^9GNWIF9_#%>.K#C@&M;QJ>?P&2ZP5X*QB3'0):%M5=;Y?
1)?AE3B."9>K07+=1X1(MAW9T4GQM>1 MT9V*RUEMI,10YOTJRJH>./IB'4:YZ?)C1.,PQ1DL0PI7\$(QIY M-
(H1F/O:C#199H3^+QX6#ZQZ+;#Z;WG RF'X!SV-1.)9T3R:L.YU\$1;# M;
%BEX/IAIYU=H/IW<#E9#19=@F&\$P_+K?N8/JIE7I.8/IQT2X.IM=X14J1_MZ7<4 G\$4/ P&AV&*.8F\$R?
0IXM4>0Q)SACT,NJ/(Y1+V5Z(TX_J)ARZW FG.16FGQ_5WA?V<I?2>V M-G1!_%C(*S=Z(C@.@:T0'50HY1G1,HJH
MMZQ_"NDFQ1212\$1=A<1TVX@>6J03./19IAA9@QQ+RPI*IA9@QQ9H^0(= M8RYCR=<XRRR;7\$S'E'X ZC3H?
M=J5GG00-M,\$/H1!&A0Q-Y:9YD)(0L MX E\$F3\$Y./%S2&F,8N8G:9JE5B&(-:(3&WA%<.'KXLUHSH(C#A10_!;>A&
M.P+I*CI:@-(ZA,\$"--@YJ.(@+)TI!T!YL23O@S)D\$>8HJ MACGSEVA-
GAVG6C;N2%17&SB\$F9IKY@(@)0Y.XDILNR:6'>4% ^V+AREW7A2H
MG;J1/6+E.9.613^4R&^N@KE@K^1'S.@G+1S_D^G:O)BFG2#%"07O&MIR_P1@D3HD)X""C+.,PX"V"8I&\$D
M\$_%#3RMM4XO:Q\$;C10_8GH%>X16GCA=(1\$;8E&?1M"%30-11.64XS.[4' M3X1VV!&W.\$Z-
PZ%_CG(*B)T!ZF;_#9%)6Y@^%0Q%KPHKV2?5?1YNM5RVVH M_M7-
74H;A'(#U@:LYVB,7IY_T7I*?A;.,BJW&PKOJMQC; 78NQYT=2 M809))HY,09+ #)
(R(%PCWBF9&C6S/DYG<;2(UV%/5J7(UP4@ NGV=Y;1:S.A
MK0+3EV5R&^@^0V3VP/EO<1%C@>>ME/0V_+H5Q_K4OZ/ITNPM,H" T."EPAB9E2M\$24N.&Y5NIY?
9I:Z13/,IVO6S_W:UX5)5-)% MN>%P W/@1?;R;>\$T#,8WZ#7<+)I4G46SLT/!KAOX@KG&@6_+ZN;O'F<8EX&2,
M1#(B1'54PRT_256JDE"4TS14J-")LIP-BFGY0LLV4*C+!NC3U0GK0.A2GB0Z\$^J\$=8! MXG*%L-
..MKD%NZD/N^1/PLLRB'O/<2B+COPRO(4LBS).3BYV&C5RD.S0F MSR7H#6^RC(R=0T;/9%PIKYE1,135(C?
@HC#.<@).*07SFKL6DC=1!K%_O;.^U09;\$7A;Q/#+* M#S1E8&(CTY_?N.OSUN=H_Q_3FYBN-%?
QSEJ3ST*YQVVS1 MAJX=88^0S;<_67Z"UT1K4E?H6O(F>8W@2>^G+511_J_N3.OJHORH<)/M;.<9"3I
7L43899XRB1\$818&4QX%F0T15F4>^8CE*.;BR1(PT4:=2UT^_M;=KV# Z1\\$.S\$G*XI
(*%EFDXW#H9Y\$ZA<4NB_1*>(SR1;7%<@751CMGQ1 M;7'Z^+Z+IEYJO^\$0_PYOZTX*IKJ4JCA,@.4 8//3_N.BG-
-2A@/DI%T6QI\$+=(K%L_M90&/9&1)UJB=MR59"J^!O'5?T/O'KA'SI>@f:D YI#^J\$>0!X00I!_V7"4XB<)?
MP^2HTP3Q8S1BS(?8#RA\$&0TA(0TT M/4I. 3IN*> R3"P2JE51R1;=4CT'/J_%X_RG_77K1N M4Y1+2K&J5\$;R6,131C.)
(3>\$Z2=5JW#95D+6=M.E27B>.N1K^12L3_*JM;&716U3E1%W*4>3Y.DR"&*1\$GMPPG\$8SSUJHBG-& MC*9\$&=*?
6*7WW+112TZ.*U_5_X1\$6Z^/ MWIA.714A("E9Z.>Q7/H>)(5)=MJVE1-.ET08\$KCM^833DNL-K7@4N/6.9+ MP2Y
7WASV4ER^-VE3R4ABG*)(4IH;LF^1#&@H(C.OBD./QB/PN-#B>7"\$WL M%+1DP8ZN=;G31.3T3A@NY#?=[2U\$-
1J^T+5?;3+S9AF/"N233SVO&TL M1V;L6N&5%G1^_YZY+1B&FAQ1Y'\$&41#[501Q#DN9)YH?R*EA+6R12F"?^
MUQ(%BBH09\$TC21>XZ.;KI#6*MJG+ZA%G.-^,%=\$^Y7G#FV=T&@TZC@10R_VZ1TW#Q57-0@=3IFG;Y!R.211
10L71 MFN80,<^GB5#_*\$#;>9V&Q*=.S6@RAIYCJHKK#=(934\$<=1GA;9.DUM.@&% M=+R_3-
=NM6.'9ML4%(X#)##)X31LN-H'R=V1;=9H@E'D)I*9+SI=;BGL M0;JH1K7EG7*9/ZU^"!;f=5)?
ZFJK"^1_U;T*1_UEF#.'4CP(8J;'KF1?" M-&\$IS#(49B02UI@:#4;3)35U;.:97?KACHMW8-J:2A=+S8/-! @9'G3.@;
M+1=M(2;0C_#%R20UF7K".Z_%'"IDVHPI<"X7'NI^;Z=+?G1NN*T?%@7_109 M_ RCG2V^4J&Q_N^1JOU/2O16I
5SOO:TD1X=.%F3_OGH.*3.H9H)C3-K%? M*5FX""JV%EU%I/SACC6%<=<-U_0G<%R))\$C&W8-)
1.-0>0'50LZTN:=1/Y M5*Y_%13;f)O^896Q;(JY-1M^9I=;97FM@Z"0;@fSWWN3%XR1YW\$49@^11=J8X(
M%Q5Q55LY\$+?;O;5@W?7E,9I&")2ADOH<(H1Y-/3IGD61VF<1#A\$1J<@/);3
MAZ\$;%F0K@1X38,^%H3^BB:6>Z^\$>(<-HU)Z^f\$S+BX=U>P"BKSV(P\$U=5P79 MUNI(5)?
@'E=NHREV@#CR*32)SNH^F %QI'D8OFWE%-SSA,O;UX>9;KL#;VW M>+5ZO<<%,VBK-1+.#.I
-/O/X)X1^:%5_B!@WIK8="Q_R0_QIWTOC#2L51TLK&8JMMF(YV8-[MID*^8G7
MG_#7WSAXGNPP2MYW&BFF=^6&_%0.VWJ:IEB_%\$)O8H;PPU0W85(VCI*IO7^1.XY=C/Q%G.ZMT".1M M;ZIL"?
4Y1X>_W;\$+=OP"R;1LIOB)WD&#=-,1/1OWW1B9^3f>6PQGT=J7SX(;/CAA&:WRW1V>8U)+Y-
EL4RAU_44B<_DA@RS'.(11"DL4I3*.@DA\$@UROE>%U;Q_#Z18 MD'.R5=1.C05K+T=7>S9.JUBM\$->+14Z/HYG!
f/@;SJ.21%#17?(WO>0f;Z= M/V@&:U'I>@TPS@I>K9B8N>fU&JL.RU^O6LTHGDCL_9J>WKK6_G1X_JYN%UO
Mf/BWZ27G1'13FQTU>1/1201U040+(/G^10Q_%WO2D\$"+H3OS30&1>N@/ M\$SYC#@1KCCU9+6*68XL/5O(4D_\$?
L121PTIY^=GUN9N51^/9=KX7.^+9JP ML51&89J&24I@&F61XLU7LLNPG=K M&491TWED/Y7.XX3P_\$.4
H1S0.8Q<+4^6D>^!H04!YR\$1610&=BU=Q1!7NR
M5NUH+L&DIYX.A# =34!NYC55T1"12G)DRJQJ.B+JL;./>ZFAOMML&K4F8@ MI/V1F/49V(#S?Q
5HD&L=A/20S301S>?1KGG)A-1ZG;.*\$=^7-1M3X.Y=- MSH?R'J^UWE9/611\$
3%/6TVC\$V9AI^6061)^_87f:0=Z)J1.4?VIA^_\$
M8S7B0Z^_V0=UQJY=E_1UOTOYR(O^LARR\$*@PABRBA\$\$.HE1.42WUWR1Y ML7;_UW1S2<H>Z):R?
=LR;J1PWJH=YW1+36+2IRR MWGWC\$S&(K;#F)J^AE=B\$WLY9Z1UPSMC"TT=X=G1!X*!R^_1RU07!G%Z-
M<(Y+)Q#/.@31=T974+L SNO1,1Y=00_"/HOV?FIQP.WW@N6>_FMEZ9X MM361
fPJ2J9N1M6D01Q)Z&4Y9!QG\$*4H@BGU_O/(N1F 4S2PF;KD44MM M'(XY;#@VO(ER^J'H^<>S8VR9HW;09
:OIYH>".Z+COMNF12V,G<[N' * M'!TYZ\$Y9F163GP+48Y= _\$AIV-KF;Y?91_05LW>8&?
1PNO+=+YK_XRC.29(TI'89^Y;.(P9Q1HFXGMB1#A1UZ&Y1BHP M>;351O1D /SW+ _A215_R_FZT=T^!=@S M! XX
GTF%F#_>[592^1NMAE.#AH_?63X'>T5!S%1;S;R,P?Q?\$.S=YN1WG M\$ _>9H(*O=5N19_10TK-
VO6<+1998NH9XHU+9Y7?+_WWH4!0R%/DQD>!O1 M*(X32*8\$"1C 6&,\$<1D9W"U.3;AF 1L.F#0R;1@1G'X'>YC
WL(1B#V>_M7VN19KAB&_#W9R8<G7?T#N?>1;#B>*K+N\$S)&U=L+2K*;8)8C'=M;1V18M M?;UH_*?
0A'5A>K6_QO124-P>+ M+TUG\$OG_Z0_NDR15:5S6'.PT'XICF1&8183'D2XI'G2N;SY0N02*G=3F1B
MEDVL1)1Q_4NV6GQN4'\$:(HPP8\$4WIR>G;YK_11&-KL^1O;15"1P=4AW&/ M7YLV1WNO1K59:O*ADJ2@=1+ #KL>#
3CJYZ)4S-[KQ=%F8"_Z0_PUQT;3N% M?WWDJ15N6"#S/9)'\$61>[f'DH0'F*24@35'0)CR(*=+RE<1O/W4Z9=,Z6U&T
MG0QX@.;P>;Q>1C-C9B2>15?PR M.0!_E0UO;YO;f-N2;5/(XYSSL3QDV.(@H#E/(@HJAE'.OCWVMR<6;1.91 MM
_6%D Q=0.JA@!DA-3_1N&45YC=BU;f.O""W;1LF06%GM9L&PC%""&8P03SC*(
M0C^"F/13).D97F09#CW=6N\#6E/7JZ/V?FFS*7K#^C1Q)H;VH&5\$7O-V M)Q!PR,L"1+@Q'CEDJUDH&70Q(@#^*

HS3V1YQAINMTZ!*=-.CFVHR6V@(-8-%6=5?..COH=H(MCCL>4^!BIJ=I#A9==RRVKI1<@#UDDH)0+~W.*8-R\ZU<
2..D4JA*OV..Z&I-MUO>A*EP???'^%VI'['?RY)]+U:K3V5JLU(?%6=-1L/2(S1F?D9AG.6I<&-M4QPSZ'O.2V*2\3S0..IZ-
DYK8/G:.\$%[/+/\$MC17ABUMM4 3..&R0T.9N:0%@'C M:YUQX1Q=R P0FO4J95S@XTL0C3EETXZ0F5C-
%~VP7PL@S;..HXC;X>=<\$=I:~..''2~37/'81P..MFE,ZPI\N(&#UM3;K3JDEX5:SRN%\$YFM.J27(07~*03?LJM?OWBU1C
+BQR.%MONJ#%*8I)(&F%2OWIV;V.C=R6;5:~T>;3UIA^V*?MFJN/N MRJL/Y_>NJM@WS-I=06I6&K6"08JZ|
<5I+W76'97PD6E\GO:45'2H+VO^~)H:
M:~G'/?"~%L..JEV(A1C&&*)5)!>*, "H..\$4I^2A'!FY.UJT)Q8+7J\$P8ZR954BU\$HSTR\$UL!D\OSA= M:;
1#4/?"K7X%96R"YZ.S^<?2^~X*/O^XL&?A#1@L4PZ8=%8?IUC;..IB T MLQASHF?>G5\$+%%=M&H>)S=NO44OPD|:-
>FIYGT..H*+\$.#..LASDF\$40YI2#Q MD\J3&N&\$AX@2..M2V..0*~J2/@:BIUMCIE.P.61TH/
MB7:LP9>H\17F.U..2V:~'I93U3+N^KL-#?V3GM..*3\$*H4AY!R)59IZ(9#+W.O
MCR/..334!RTSR&&0P#%C%&?2)"&R:~(S)5M.*G:IY\$S#%BQ%.U0='PTZ M7I\PN!MH.V@HKOV8I
S**A.&9YSO6!FP..\$Q 2..W&S..DS>|CH:KZ\WOE M"#)=NU;F:U?XZ@:..3KI8ULZ>..JEI*9@7EJF
J0JP\J38>.\$&9QF'..0!9Z M'").4IAYE..XYU..8LJH5&L"UQ"1B=V>[.*^VX80!E\$:-@^N9+;U.A8B*QM
M0'1D&K(*XOV>11#_VEN#P:5G47\$=X3JU7K6O'SJMJA2;RJ.58\$/L-./)% MY*..(A)R<>K(&?12+PI1P%G&M-
K0'B\|M=+JLAD)R\#FZ4#V8=6Z1B)#== (3 MQJA0Z1SG5A5)!PO-
5GITCOU^C= '9WIOY^;T\IVT\MUT%THIDF>PIC*R0J..MB"Y*KG0E\B.*"~#;V6A-6QXG..6ZM+T/>I/1-(N&-
%#2\Z#~R&ZF6#V:~^Z/ M&J4 OK\NN'..W-@!0K-ZJ..''SN?&F^8H#T+K@%5%YSR>W\1#~<~&56~M
M5D20^7GD8P(JG HWTPIJ3)'8Y>(-IR'+\$<9(*)!F0'..I\KPW%"4I5A5..0I? M:..fD<\$V;..JL BK7D4C^W1!?.88V?'"0SU3I
(~U&00&UR2..P%+IK&:%(P=&% M23\79P*~X)D)RM&C%SDZC*~'= JH\N2K/E\B*UD>..7W5=13L"V..H'3?UYAC MH
<\$LIP%\$4D(E)8QAF#&4^IEF<&\$Z\I/(P=8I/GHH=-C*/1\FJL+~G M/5+C%LMB#..1.909Q-6#U>?^AJ1?
\$.YV+>NE!.QV\KTK*..=O(=M)?^~/3"FOS M.? Z6%:U-UXIO>6D_HCK;7B;~\\$/WCN:X?~Y^K#WRS6;..
((XGJSOP(140D M9E FU\\$/@2CPY0"K(*A4=..A\@)*LBH>FE?X"K+EA..9@36C/T'7'6\..M LV<..E/DO0/\$')8-KQ.21
(6A@R/AN'A1!\$D8\$>C\ M89J'C(5!F\$..3RGI'P..27#%W38;U&=1"~"-?L+P=MOHY\SMV:S(JNWAT^E=FV;3;Y
MX">+/+SC\8..91'L..JC\4X@LA\1<+J4:0R@N=J7S5\$..V7J9L)!PJ3#..5(MV\H/%CB\T?NQ131~*11:E2-2I3^Y.?
_D1P6+0QTC..f6DID>..M"0%+J6F9(MT\IVLE49A\U#~..#Y67U%9/<@6A..\$9P5\31"3
6;JW<9833"\$TQ@ (JP9A^E1FZQUF+~B_K9CY MRU=6)MZMG\?UY@_..X2N..C5.3..*T03ZDS JD^XO3F0)ACS..Q;
f4>..5B2> MTK8:BA2P+0F..4\2..G;FAQY\$+A@EH0<96DMG\@BCTJ0>Y1/(V M+H
Q\$18JHIG95F0F5=BN.HGIMQ\+JL:=K1T/X..2L.O\X3L;L..!7\..L\ MJO:0C/#TY#9)39..S6IOY2+J
MOVIVF;..''W&:R\$DL4R^3I\$'..<8\$IG5>1~I M-..<1+PDA2BA&))0Z!E?^J8W3HZ>?
SGRX_L7XI@OJ'P3/BCQ^\$KQ/*3*44 M+= 2LSCMGA%0_X1HG:V\IHH#@=T<8R^+;7IT/?2;..?5RPSWCZ@#3UDFU+;I
M:..+Z@M..%L/(IYPL\FK'DMJ\O..2Y0Q'D9RCZ<=R\@9"D~#<%..IE7IB'A%"\$
MNIX;>AOP.%&MHQA5PTSFI&G*IU*~5BQOM4KV..@618;..M:~\$>KNV(UCL4EJ\ M#%8YB.H0G+;2EF+
8;JMK'"NDE'"2Z;~>JH\O7=BE-IXM\IRME5..6<8)#H(IY3)9?N^4/@262J<L2G/B~)\$.=< M\..'\$%3Q..f&+~%R9B30N\
G=K<+=+96M3%V"K9SLEALO.F.R9V>?0+<#7?F7 M8\$VROF(-
^(&D.UTZLY7#0^I.TYAF\EZNYD.KL#D7VYRX616@W4%1<6 MDJE:~TJ?~2H6; 1))\@<<"#R)Q^(&(^3G.9
-2%F\$..IQ*..&#ZZS\#8^K(M GT4^*S4-OVA7#..N\JZZ=LHNVD4)G99B?X#B\!\$P) MRFA\$2:@U2W.8S-2L3M59;I
f\$V^C1L'W(>^CT?O5YH\QTHU.N#G-OV%K\$IM?W*..6SLL\O^(>)>)S-L\9%#0D\XAPT\!;NU;~PY;X.3XF
BQ\W)@C9QHGO2 M:~#?7MM?~IM)Q#..4<8*~GR8!1"~@2)P:4^C\G'.2\H\B9J.NS'F8<7ONPGD\ MID'"/177>A?
PLYJ=92\$!;..XE3-NK..6IO#E'S6PEI3%S=6UAP.._ACU\$)W2V%2^LI^!/'%~:~?^4/4V;~JHG_CAZQG?
OIQ^F:NSW\JR.8JV^LG8;0?VW+7V M&C@MR..@IB+I..Y^4YY^34#f'QW-Q-
7T6XL;YH\ING\8K>..E+OW..J)J63*Z"Y)Q\HT^fG M.QM\K6>WIP+0S/RZQ"%DN+!%\$@JSW.?0
?M?>YI?2);SHOM;D.XD-5+^1W>~>)U H3^6XZK76;8PUF? &~>@9JUF0;~< M#4M@S\..V\8KT&
<+I.O&M8&HMC56X?K..Q\3\YK&..B;J6S21NRFV\ M3&(>A;P2SB0Z1\$DR&#FTQ1B+/Z>ID^S\^*XXPL-
VOP5OQFT7f.4JA0..1:*8'O8.KXI%~\BV= M\C:O\SD%K"?>Z21f\{SX%R\OI&G36U\@UA..V@/JH"4/I
..@)8#PZ/QO^YZAM..A M^F.F\^I C(V6HB.S..8M5D-BZ;HQZ9"JS7+2^DMV;@!UO6\%WDO)%:Y^5%L
MEDGD8\KH\..8Y%TH?8PQ5T6C..^..E\$6>\$F\$(-=ETW;\$.~P"QJ\XB1FR L\;+1+~#1".6&D-2M5T M@~'34\$?
BFFEISV>4P4-V0E*1#7\$J~fF*L2ZIGZ1)'&H<91)..!7A!>..8;#~\$O\MS'..)-2L+~
..N\I97..B\2'FH"JZ7(f\JLR+XM@HEI4;M&1!HG~\$.099f M..40I2V&*H@P2/U&MG0@.C7+~+Q&~V%7HR.KO/U"\$K?
LV781SU2X..#;+MC) M;GXM.R*8JU072V3FO50=\$?DSG3L^6N207?P(OP3&C&(/LRH%)\\$M(5E.
<I)B8C0EZ?~XJ56TR3"~P5LM#*~25T5L10Q74ELTR&Y(J93M<..?D+8PJ MUOFG\>~&K@7K'0(P_2&/GB^PX);D6
MOV>..^3IR29\Y1N6.XR2GOJ+~"W\%31\A\J..@ (7+IG:9<@F)ZH6\H+(*8D5-(M9@CRJ-
&QX'86J9ZX#H>3CA"-7D\>PR?~P&JX&..^4G5..^D\A?ALDW)N:R@;?I-C8LU9\UY
MD>X..I;G\2W\$B9JZ3";~P(3(4;LR6";+09F^CXDOLVXEF\$<#;..U;../#KK&MU=?"~%R+ MEH1#XUJ&%YAO7(N6(-?
C6O3>F/(F5-57-TL?I3S..0)92..19S;~B"%8!~*A M..*1^C+W)"DN~S.P*PK>..I>WM.O1UK\I7\$.W\07I%~^
M+Y8GNB\$JA*!6I%_PCO00%+M+TJ.US\TG6;~f.VY"7S..@fYMM46\~;=4..M&*..T12E-(%Z^IFP7T-
IX>^..B6*G:~)2..2^1C8FNGAE?E M@BWP*/D"VW7V VWGS#X+^C>R.33BH>CR"~D78Q..J1@f7.N?0#~*0X-7.Q;#~I6
M\6J\K\K~C.IN2\A0+~)4J?DI(&XSYG\+~>~\$-A^";6V F\!\$AE'..I@M%LZ
M9E="~>RE7;N<99Q\HEOZH+>BZIC&ZN@N'O8CFE;8!D.44093\$60@I%*.8I MCBG7BG\=)C&QT>H(
DG1L(X*1OZ%N4Z(OTOS?KR35"=2)VT-U RYL..fL=A7W\..LHC\U**"(9'~#..(>(X@YID'21;Q M2*B?EZ'
+~\$)\D)Y%!.9.\$WNTC.M\!F#24GK1;..G:7N+R.S614/ZK\I6F\$RA)AFR-01#H8ATF..(MINS\JB.B\^f<9TCH#;BA\6I6:9
M(N)EA\$209AZ'"N\RJBSQ81@%S\<^M)?2V&PFSS#J;WGEKS8M%0E96U>/#H* MF:9/I1-(0P^fPZ!?
0*ON0F1=;40>Y6>/4&=3>D9(3?SR\XIX4..G\VB^9SG;
MIZC;G>TKK^N5Z@+>..fID7U>..M6JOKT>US5KTL..R\ID#2.8ARB"R(^4#0A@..MY\;1V'NOZ%O-./A/K\$J&A*~>
fS8X7\ (P+9CC^QPA0/OLQ4R&5R(f-L"> MCZZM)VA9D7&\L.XL;AT";~\$%S-\$C*B/>^^(1M83B8/62UB.
<&K&CQLX= MQL..7DI?T92IKYTX#HA#&L4)@;C%\$3'O..4!SE;(^K%/LEI3(RB?)OR\ GHT?4..H MG2
..''2RJH516C3G?MOL..L\YV;CERW;4%4>)%W\KD2= ESNKB9>;4+;15f*JHC\YN%IU2I~f4ZIG)DB;G/ M=^V/E;K8V1?
>Z5FQ;..HT M(\$Q?B88>LSM.?~*U3\$6ZK\J7@G^VV^O?~S+(VFZ>ZX<;6AJCK\%*fR@3H(+W<..Z VH3.G;~M1%
M";@f\%@#>~I6#FIAO JN?33P.6F69+G%3J8L>%&'Y\N\;+^~2..@9APU8^?< M'!'K@!X5G=;~
CGUIBQ7;=VBU#..Q\S.K5ZT-OH=WER\N.%N+4AR05-^ MG\B:AB2Y\H?KYV(;~;BB0X*~f3EWA4-
N\^~JL^W@HX+U\..QA^UV\WM> MJ7GC@MNF~MU\$7F~C..\$QCZB\$.4Q1QBEF;BG^+..(0N*#\$^7+IPBI6\IP(E
MDR\HGYZ^=..GTO"i?..0?>P:~DZP70I=TQOAA1\$FD1>%D+&X%Z;~)PSE+H M95XYWE&%
fP.T+~P8=30J3GMC@OW.R\65N*\$YP5S(BE2'XQ*56;V..M\$5&/78JOORVKME2.QWM.YO3L5S7Z)<>~>
%T44IP3B+BP\1GF 41Q&<~)IDF> M&;7V\;4QL7(V\!\$?T6HNSAE<1-3R.FG---)04;..fHNRN"~L.B4P;^7110%/
MBHHN\VF9#5G(D\&..6f+IZ=RK4K+Y9%A&?N\$XAX..(XAB@E%..*4NBCC(6\$ M.P\Q9-%0XA\K6_GU1LG
M:0)%=*\$..^PIS'D<\$(G.O'F.(^*Y#>..f6>H>%ML7DN-WCU>U5NG^..6 M=+65ER%R)HB\JN!N?KM\2 M8=K/:-
C@..*60-f58#~M\0UVC(\YV#^f+?KJ\$&fR#/?OBH>..CO~L#TYZN MTW^4^MTQ_C(2J5UWC;..1VO4I6.6N>Z?
\$Q+?H8N(;~V.R.@fL\UY;6)Y M(U2&2;5YO\2X(HD;TKE.JCKF(9S.5AUT88B\DHSA^&NUUS\9>>I.DXX6
MD.3TC.BH\HUU4R&4;~f<31-AP761^~(HMMW&O=7..&7OJ9ZN-(O*7A2@4f+ M#U@6Z)3K\W&D>Y(9M?M=;..fI2(B

IE1 E'HJJ9=-.V.M41R50ESEL.%2I# M8IY4M@P^+Y+O1.I8OWZA3I4J-R77_"3WSDW'LY2F!61P2.1LM\$-M6D\$&? MD<1'G%(41HJ:U3D"4RNB(@GV-(\$DIKJWG<5D? N!5E(S!304TFA'&Y+\$.F.I MN^!L^!N0./UM:O YBX0)HJOY:=R? <-+3IRI+9+>WZ-WS1)TDR:&%IG:JINE M_DXBQ8NG-W&7P2_TD^-^K3?->EV6I+FN##.1A9(8US2DHALZC&1Z.IQ=K M"VZ7>#&X!GS)%SH"BI@:+UP162NF^?GBM.B.2@6#X UYNO-EZ_Z&2/2H+I".OH+G1@<>BS8R M^O(Z:R6C07+F=C+ZORVE#%XUS+Q^7=Y(B+I:Z/RYBD/9^~/K%JI^Q &ID M:WB \$@6#%.?STBNX:%?+ I2A:Z!2GO=".@U(4ADG^U9LUYQ&7.4!3DS:GU@S!O\$RMST'Z)HUKHV:V!6JMDX4?SU&KI3 MF^Z.UWP:>GOI3!B:V8X&W@.NN@YR32_W18?O"7.I8;+7)X5PI5.SD64_DSQ4FS\$GIU.N)E(967QI+|"0801 M@5E 3I"<>9'PA<+H FA?PI.:UOYO49Y%TGV7T%.94.MV#74/49.-PYB#X!HJHS6:KBFX4/>7? N.^8>T\$DQXURCZG/E/ZX%T2IU!;W MTN-V*JL!C:V93_-YS?)<=6&33B33"PIR6F4IN*%> 0HA!1F&51"*.(X3I M- &91:+"NIZEJ8.B6Y4\$7JXY!6D!:=Y@Q3>&FN!>#TC.2^<%09DSI!BWYP) M"N!92G878.>+.C@+T+!+GZS4@:EG6:Z5=C@%= 16@5Y%D!* X14IDR4.T = M63.'#UJ^- P!>&PC'.YLV>JWBWK=K9^W!>8#?^&KH*O.9UD28)9 OFD"498G M\$%.?0.8OD@2RF@XCHP.-EVE-.5*1 8- NT=@\$:/DCD2V.Q\$!:/(\$!#078!6 M_BE: XZ+Z*HAIP"E>=OPCHM TGO7XQ7:\$PRI96' JMQLJH@&LS#.\$>\$P"2. M.\$2>3-/8PI3/T\$^AD+/*.(A@4Z4U_YI-LVI=LD&H8SB.D>V*Y6FX+V-/ MT7^E:98SDXMYZG.?&H9%/7TU#++^)^7: I\$>.Y:KJ>ISIX=!*7HDE'U_?ED^X M6"J9Z(5ID&8P(1!1\$.\$4XX3&.9I:Z!>G@69T9PN(^KSW>+N""MO^/-A? M#0N&K2;.P#7B_7-V?I-8+OH 1HN8F9M_5PM M/IXL"6\$9SGD*(TI&.\$C*(:BIT_2GB:1L*KU^I TZXLW4GXB# <:3!^W"3JLS!;LFZGGQYNO7VIN_.WK^<^?MZ0IH>|3N0@"&?;)1*_FV03-T* MLZC\$O:0%.[XQY9]E::NGSBU1>^D@&3NW4M@="2?EF(IXG7:~^(CL5V2C%.8H2 4I10P9H0:M5K2H3Q.G0P*!APK#ODA9N>IN@L3#X(OLEJY\$-E.R.YGUMU(=:8.45RS04UWQKIXE. ICV!%NOCGBI#5GKX6OG M3=^M&<^+=5'S#|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|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|84)8M^OP!YJ1EWV7@9FC9IR&X:LN^L:5>IV6?AG 76_!W&M9!#XH M9%6SJ#_CNIF%H+HV;-JPE(5%AP< ES%*(DO1PFDA(2HPTPO#Y!.*6!0#S MD)>(E? S>DXVN3VO!A8DF#G15X1E.K?;ECRWW"A_3.YO!CTA@7P%E#K>:DS.MPV=F>0I*WYOYYC>@9ZCMXK)CZ>B'M 7-7#6W"P:SV/40G=?%7+&59 M&X_+0CH.E:2\$32^-IC*Z2JA.0WCA\$.U\$9/^ QF'B2JGOTLC67+V.2 \$!E>I'W8/AURWY_V-SSC6K!^-:8#Z75C#5=N'UF MY9-4MZV!@!/:S!7WW.5!C-7P\$!+S*V"BBYXR)!5 M3#@SE_N/@^2N@=I=%!%|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|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

MDGR1UL;QUB<^>_)>1H@4S<%U'0PT:7X9DI_1O+=-'N:K.44%@;I2H>8
M6.8IK|&+&+\$>I*>Q86RDIK""0C=>^QF%VP>?Y^2^LM7JH?IG'. EXU MTU(^.NOZD'I?_9<2O:WHNRJQU3EV/VF
MS2WL)DHW49'1#D0)'D0H(IA2C%5<@'4(08YP2)(0A|G46KF(CGC:RM|;LH74Z?;W:/6==Y>
MY0&:GD:9;1'CO/TW-X,6RVU\$50@U'+_**4S_1\$=9PO|FLSE|>RXP'D>^_019E M*J#_ \$9+?2J_
13/*&0BH|B*%>_>^UB^&5^1JP>1\$UY5:21.&@R->HFV016RG M/2<_1L.S^S17-P*|>#*.PRRL|FY&HS=
(<+18\$>B6HAS&EUV+1SC?IE&.2KQNF MNGE2*X|CV<^AHRES8_6'V)'0A@*G_FJ9ES_56H?%:S14)6&T_1@1TC8=
M#^H6T(T?|>L|>3-?|@PT>B|9=0*?4 'M'8SW=QY1)38G"&P|J|R6.&9-^_1: ^OU_ED3H=D|47
M^N|JM*^2CYLGZ|61S=*<|%R5^Q@B#<2_01-P/8;_> MDR8"FW\$<)RS1|BFM375F^15N_A(#VG-P
WO_."F.T'45|/=>_5E0C;Y M+4|M".7M|J#WQPI9Y.|UD=)WAF=1S.Z=8>0H#AC69K_E&<"(H())\$DHW2E&@P
G628=+-WJEUV\$1>J+3DV M;1#32JWG*9G+8F:W;L<%,&_5/43U)M0H|@%&0.BWXG8V7|H'73UU_Y.S.S4>G0@M?
JX?N=4>3M#)F|A^>N MN%R8Y')&M0\$^|T^OU'FSS+7V@_X@XG7)JO:F3MUKK_IVZ0F;G:G;MOFS5;
M42I0B\$41D|X\$"".(0X|2DGC|1F|A\$4JYFV3L7Y15K<(<W|L_V|Z_I6D M.223|_#F=F+33C=MJA(CF.H9, #=
(F1FG|J2&A_|Z>D^1=B=19D6SI'E&2&T MJ_68%OC8(FC<89LY*?B=>%MREM>KE&4>(*H92I8BB_(202R"/
(QF\$PT1J MN(E^#Q>?6;_5*?6RTH;8C5)@Z1*!S7X|G6G.9("+;K;\$3EK#/.FF>(0/O'P&
MO<@M19>YDE,YG&5)!DLOG|Y%>HT;W+F&ML*JD>LPO|9+%/O8A22!.<0I22 M#&8105
(BG'L\$Q;04&_FT@<5DQ?;J;2;=&"DZ*D4|BFXXD.(##304IV@U(+ MXSCA)7E-2V2NDONJ4A8C^2T*3"Y*-
ED(5F_W.MG6'=5&-5):O.PSQ_1&*(LAHCB|& >6J_|">DD?|H M%MT5;35Y'I?>GWB6FHUKZE0Q:T0V6;-
:6QE6H6_>UCXP9|5XRTA5_|Y|5P M^)|L^P'H;|L>@V8UZZWA08'5<@/L=:/=|T-Y|@F8^XLU8?E>3W?0)+SO0S1B0
MDSENYB08690F@S|H)>DB)>QJB^*4"!+&:H?I'4)|@+3@&'H9VD4)|B40I|J M\$5#I'F:?'
HMW46)=<C4'D9Q< "<YF#UJ9#XJOI'F=J?ZT:(Y42830HJH|+?'Q M^FO<85Z014'RORGX5TY5)"=^_>_V|SB2^?
|_>YUJW M7.MTW9DUMV_|/P MN7J"|I=C2?G-BJDNE?T")%LW*LR^U=T56*\$YKO=S_VF8
MFY@%0Z;R+>LPK*JPC(DM5H1E"|.P|LMZC60;F>U;JJC(9==G93_993|EK>HZ
M\$HHP3I&0S@AF\$40)BF"&:08|GT02MS3@46;7|H0DYE-U*_V("Q9JO=|PX; MS+19,&?7V-
#^>CM51:1V@CXC7J|_|(&9)U+H_8V@:)1YJ?Y@03V;YLV M_R^2X*6Y-YF3N3>7X9P.&H
DIEA.A|@DG4#7"|+O|K38N9H2!|ZNZ?12Q#@D/&_#|!*"2616A*1UNQ5*#0*S;Z\$#FF#7Q3(P(|_M-
2TUN0R=WE;_2|F-O\$8BP.R+DM-)F5S5FMRF=+"Q2:3(IJ6FIS?8EE*Q|Y M?
CAV7UN|SL6+YH\$U'3AY6|H.F6IG);W5HK|Y'Z;|O70*UG*98" T.R4W_Z|_7@# M|M|?GK&^>R_O#ZYP96DZ|FY
R|_|C7I=_.6J2A;5I8M|7<_VLE!|=KEH?=>M'TIV6Y8&7;\$M>E51UYU8^MC;YI9_@RH-<=S|6|BYT6=#GQ?
+;69D7@H<5/H M^VG*7_/&RFH+;13\$A7_*E)|?L7%PM&C @UCSN;76A|&V;45:&"<0=6_15|'Q:&
M\$<8I1@\$Q*FAWRMW<_)AHZF&W6;C/6"X|^_*@%2(<_54.N0<_V^\$TQ#AK. M#6/3;1^IWM;EU9Z481+N-1Z2^?
&A.S(C M^DT06|2LZ_E^_|!\$|L/A5ZY>#Z9_/U7?GJ00)|T_9|LBQUU|_M2>*)<*)H|).\$97(?ARE;8RYU*_-\$S&B;1&)TQOI*?
F8V'=H20_VL&0_|*M@<"LOUL'L"R)H(F(131#L0_|C|S|J#;F0_:X715#G_E^L6|B|H0TP-&RUI9) M|?
9A=^)|H<%U;47DOB9F;SCD90WX&1'WC_LJG|MRWY MG=-:7E^QI5D|DBPZZ.HV0W_00VY;
IQ;HQ=8C>R3AWR@Z+YRRY>>5"JBN MA.JR(=6U)"IQ92^EZ|H=|FYAS)D(4)3&G&(4)Q"G&04TLO#!/\$\$,RY;G1G
M;"Q6"U|HLCB7_S;|@<9GS?Z\$PLP*1/T'D.T1V|T9\$S;45C4(R>)*S@8Y>_> MJ2SC^>H4>?)
URRUC|K%7;^6/=^7#YF>QD@Z9+QI7347;\$5;S<_GO73N=3R6'BYH9RSZH-DZV-5;_>%D^4ZH+B(|:=F
M#Jv""\$DIB1&_2,3D|S3UY<448BS_<\$H\$K_-)/Z#3)F96S)ZL_*U50Q0U
MED|^58GIB>H|/2^HVX1,5/.F0Z'+DHFP""*C5|5TG289; Y6J4%J9Z=<=V484C4 M^4; &Y|)\$:\$<&0XODHB;#|
(1CHV%TKV7=|M\$TPOW|H&S29USW4PM5;_BNX_|/MY6;|^/1|NK2|6VYFUBQ:L@B#F^HM"Z
6>#U'\$\$\$Q52TG/8Q|E%&6>: ^2M.^_L M;A|_R|O(F3I4W9R&JEM6@%_1.74;TPI?9PI\$SSJ|"M2F(4Z-^:S#HJ.ZQ=Y
MY;HQ5=V8D6|Y|2@M8?_GLAZP*WWV_7=)|R|0\$CHL%G8-LZO*86=|+5M&|K. MDYIBYP3LIW/O(V6W?
^35B@5;1"\$A;1"&EL_|R")@P@F(4=Q\$^@BBXR_|2F)_MV2.CI#X(CRF:QD??3W#13>5<(ZY%<X=
(7U&HD|E9\$YV/B*P^<(#F|P*>F|+MX>|32+Y82.52Q_00.75TRH(LXCZPH->ZB&(4'0@YB&1;8M2_M07";\$(SZSGL/
DTNICC0>H/V^|V6)QLE)3_GA7PRU=_.N6IG_|L;AB|7M;W=M3@*L|JE_|7*4C=7.O^Y9O@%|IM5=+>N@05|E4|H9\$
|YD-) V@7I M8L_LXR&D@6_19P()\$9H4G|VL0D#Q6-X0|BNRYQLZV92NOKBG
MG1V6UIP3S\$51S<_RY;3G|/K|D)#F|\$57-%N^<@R|WALH;:)?=#7^J5S@.TY"\$ M&0PR+O=LD<
P"SB".8TREB\$E.\$W.VKF\$|3P(C>N-<@|=MV2>%_-E6^+>Q)9OS3PI^<GV\$-WV?2* M;#H3R.UW\$ZK4;A(QO&MN?
^JT><*_FW2C(|P7_FOD|U_X<|UA' 5A|TLAV4+ MB(E%NS|
<=\$Z\$PZ8/9ZPIY_Y9OE!>^J9H!!U8STV6BJN5/5X+4J**J;J6\$|H'G'2_VK6J6E=|_?E_|
M@XXY@_35S^T<6NPI*PLQ|I9V#_VLT0Z/N;J2+4A%OO|D^JU
EX3>KD&AD.GSY+9F;-4T0/>U2;G2FX@>^)!>ZR%|D1\$(5A1%;BC1KF
M'"8|CI*66&9U|VC'2|@%V3#>_P:28;G(%AF&PXEGV6CZ>9E*YR M#>)/\$ELTU:
E^DFO0NM.V|^XU4UY#7_1\$J|Q:U?/"YM CGO|1B%.1";FM3BA\$@6H-YF.&O3|+&\$8X
M#;E1BYL+^A;A|^U;|BN"R:<0IM*Z(F|3C;9|E?EW7^|MDR3LN&EE@<(PS8 M2V.U#|HY2GI69&LS2S.\$/8/H_#_NI6X
A/GAXGU.7BEL|7&\$%T^>FR^E'D* M^<BQ6(4FE-X?673=>G|'ZSSNG+^S5O^M#M&M*M.)?F37_*@XA*7R7@<09
MOA G*>\$1\$ \$*L|UYF^F:52=,691/9B7NLKG@Z5'B-?#X;Z6<7KH1|W:1PSDG_>XZF9PRN8&M\$R"GDN-
MH@SH*Z?S^T42;ML|C|P2C+ZPRUD33O_MJ306R_Z@V.8Z'6WJ^ENY_V_ZI?GR6K;MGOE1H'I?
AWO|ZO;SE5^L|IOFY M?%&)L;HN_LBZ;Z6HF?2Z6?WGF?2^Z9JHCFXJ_RH1|/IMFL8T@1'4SOHMC;E
M*|N=|QR;Y<7|QW'35-(%NA.YYCF|=;LNV&):?W\$S^<#JL-GE=3A9L4LR^V6 M|
|*8I@8NV*5|;KP/"B:2_1;MM*_5QK) B_""+"(4D9CB&F(H?|!%&"/N
M>8QYLI?7.GYL7L77;_@Z|GW2|+I>E^6*.OSHX7H)BYHK>_H|U2 M_YU15%^CCJU;N>3SI8^2_7=IMO-
S0&IN(YG_R|DOY)9E4W;%>2N|Q MJU=^.\$XWG8ZQ_9J^J" _F;4X=^#7>J+I>U">_2>F_> MCZW^WXJ2M_/?5#'+_>:
ENW'\$I^J+C&M5X(E|J9ROYK\$J=RY>MR'):\$|C\$@: MD-
A+Y7Y6JSL&40N_#IL@|F.'HJK0*Y#U\$;#N2|H+!C0=0C+85#7Y<*VHT@^ MY&O^9=OL"FG&N!|(#_5-
4H|H5U;/0@'3@413T2C_JYD0><6GSMRV|B41 M2|TY;@ AW%K?ZUTAN%3?
<=L1HN<2G#%3)'18|L|L\$SD5XW2'R|EKKF@|MQMQG_2NG;UQ5NR"O8_XCY6@+ ">*E4N9_BB MF&.
(.4I@B_.8^X0'B=D_9Y?;S;RR@P_+>^OFP)B:C*9<-ZJZ_0K):3/HRW3| ML|GHQ>G?W4S4S)N2;+!R?
V;MH^F8K;9M"8W'TAA|TV|HX|O5L|QC7_.RL|?%>^@Q=;KJ;J_|@JOTC|Q^>KNM;LE0 MN:|S1'E/(HHH|
IQ(%>C70B/(I@E/DI) COC2RP+N&9K6Q'AIGIU_9-SRS_ M_869R>LX: <H3R
GYOT'.QTPEE4ID=V2=MLHO'E.PCNV*|WFSM"ISH/_ MD%<4KU70|XA3;7".(CBB!(8|X\$;)LUCF#
(LO_.\$Q0)Y/B.15K'X"(VY.QD= M5="2;0:/#6%1%^D2.M>D@.9#2=YN(C;4X3_EGY3Y?67.R-FA|JZ\$U_76H|
MQ9@JS=ZLU2WO_/F>|ZKNLE6\$;19&Q>1^C C\$@A(PC2#<=<\$NSBL M_.\$%=E_0?_#|:GF|9N-
O%CE|A\$|UXB^IN6U'1"&8A831\$2LR^<(|H|K&JY9%;|G\$G1<=BTD=4"W M910_5/6/MO^6_IC>IW_YQV|F@>9^L:
|'K>_>=J\$&)|J3V+6R"/MSB. M5|1%^X+2^>^_ H\$^J_ E7N>&Z;T;|?>^I'M.?>*W_.GV5|E*9IXI2|8?;
M@AW^8G#ERA-1%&&2PLC#2_T+RF"."0P)B;TC#P>_V)BAV?@<>|6_.Q|@^"| MXQF4DFG0_ESM_L
JKIC|P/>LF5GB.9Z?GEE^Y=BN\$O7;#X50|'|="E MA0>LW(|_H|TEZF\$=_?+PCK8GVU99^6Y&Q*9P\$))=^!-
GX.#A<5ZLDA#C-&\$8.HQN: ^61CW#80H|9C&6|H|@<F3|+Q&:
M.TMT.&WY|BC*X+>6|E7C|0=8Z=E.%P@8YHSLA+IRY/2I9+_.GAZ0><7QTZ?"

MC@^A/G./^8FV#Y+W3<&55R&WD2?":Z6U3VD=OIN#250D= "W9:P'\$!'"9(V\KKT7'S\1SP 7I&P'"= *ZY'!%E,,M'
M=ISR*WYWM2_9_Q3K+6%G7D9ZY@U:4G9C!)MJ\$WGM*08(PR@A4.ZN8XA2+X5I
MHVVPR!!/*%>%, "@1>>+GK@TLT: S- !@>:BG&:FRV\GI<603 MFZX<3-!CS@9= !XPC\ S+?L/<%4UU:5E\$J.(T(
M@2Q(XAB(<_>)&A%&!!X_!7A*%H@>4C)>_K)5NB:C\BTW\&O*CT\$)2I
M2/C5TAIN5\$P%M2H+I2O.546AARLN7A)Z5!\$!:'G+W0Q\$.2EEM)2.HKWY>9' M7C4\0/I_>9Y4#1!?!?O!%"2#V&
(IQ@009!0^+H9)P3>C.KX%M>UNJKF M^AF/ND3+A_5D7!C-V,*IV1BBGR8!!Y***(HIA#3E,*
(H9"KX>B9% ^/Z_RZ+ MX%&'WS\YD\J)H=OEIFY.QI! (ZTC=@1WRN6407I9QE*-\$IM5><3G11/\$Q
M19=OLYW,>78*Z)N7!IE>,Z0CRC+?IRF#C*2A&H*0PHP&!'9!@%+&1(P3HHEB
MDQ3GMJ\$79@H#)\@ (4"U833J9AU#,"3L\$Q.P/7XF(QFE-35F>S..?H+3R<4UA MT^F:MYNZI?I2H\$W7N2;4HW\K-
YM>>"%?G=:Q\$^(+TB60>FRF(WQ3E, M>1;"",O=%8YIRH36^+)+I4C,:@8:V_P(MI6;^;
78E/!/%@ZWH@FTQE7>+09F MNCXF_03Q&E,<I-LONU.^J&!/I
<397S<:I0K=WXFOO+_E#UZM\$NQS3(0/8Z*FLF4D@R3"G00% M TK#+"-QP.O.\$DW2G-
F.183\HZ)L>IHH&C&138MC'.Q.V8IX# =BAT=I0D>J M5*WGP>5Y(VV\G9TIFJ:X\#DD:0A.SR3IWVK9ZIT=9:%JP?
9MTIJ/498)+T@% MA90\$&414_H<0+Y#>#<81IU'\$L)\$1&*\$UL_)WE-N2V&F'V\!#^PA4>MKO" S
MK>IE;ZI/IV1G.:JL(9ZKYN8CE);M6CXMDDI&EIG MIA5MOCJ:NP9C'=E?7<)&Q/-9'S\7 MW_.W1<5*IF&-
'W4+*L_?/?2W5!\$%#_FS.GGP^N-%>LC^TS>BBQ.MIV6Y.?M\J(IRJ:QCEV^>4X'K:\$.J) 4E4'-9K)7N
WQ0!H.'#TMDV+:/7&C2RIV%LW M+=KPS=-.XVKI0IW(WZH.9.
IN:Y.4W6JBF.1K&O.%B4W(UV>@GEF*K<0G2ZN2U MRG6M<("E'X80#!A'\$&5I+%((&*0(\$KI@,:+!6OT53*?
I=L_3&O M'YIS>EM^/I\$)L9+*MY7?L)A9T.NW95-X T8H"=I.W4F\$;2IE_VR+G\3!W M6!@)I!>+%U.O /VYNPER-
H^CY+!)IC\7K7K:%X;+Y 78 HBP_*DA"IS;M,X"XF")H4"AYXDT3"?
ZPR6'KF9W8=O_+I&AP0:S55&I.X\B:RK>;4EZG0GC2^ZRZ>IV\V30<&34)H@M:I/T\#IV*9IW M79FGV_?
AV/6Q(7X29W\BP30-L2J0CF**?I"F"<-I%K\$X\;6J"S1HS6P+=I3! MGO05'?N0V:8H+L.",O\$G"\$&IMFXR*YSL*=H?
0ZV;?+(E_NHW<8AZ-&/37 MN7U\K-^735/_V^=;-)DW<8&9-7382TH2+IMX/9#D-P7?;*O*#8IR&I4M-/Q
MXZA.AVB< (&8AW> (A5&L9E)6JU#-Y547BH."C8.U\$Q?;*Z7IWQ52^LM7JI? MU)A30Z4I?_2.&GG_@IT5-O9K%?IX
4\$IA7P>N'-M.\ZN8WT:5PT*V6\I.1B MFC8NTE#-JXTKY7IMBT?CF^TOGHJ\$@I5\$042@WK)DJL_A3J@/
M*8!"@:R(U^*K#^X(C;E=V8XJ^-_X^?Q_13OB^A6AE\95S\!\$AOZK+VP.XH6 M%; "7Y-40?74@MUW-
ZG6;BI=)P0.*7I=;BM:T3K ^+6JNQIFK0\$^H4\$,G6@,("8AAPC%".(0^9_49QR MAU\I4_R;IL_!&
\$M)YT:K@!30Z:FF Y:1EE@XF-W:1Z<% M2?S6IE\WEVY(PC)PUR#GI@ "WTO^Y>_O_1^D+%ZN4?P(P+GBIBH-
*FXF! MAN#K\3:G@I30+)=&'@# =KRH/\$@+^X=MR*S2@/CB9RS-@3EWX-)B M%8NB2?;IPZ9Q3-6)8=U:R>%-
_UL-240*WZ3IZLU!G.+?#2HD#Z2<#LA8"VBF MPY=ES%UB>Y*%-!E*JA?/?ZC*AG\2'Z9^ MDQR,F9=)"
(TPS\IT(NRU:0B#\$SRA5>(C2W0G5DP9ZNX?F=2P#I24!=B&VH M9J<2SW%J9T(N5T=V+I%9IKS.A+
GAW6FKK>H/F-C M UDO.U74%IZ34:/6"IF6M9?2&-Y#H\OI55!95IH\$PHOI%CD0X8B"A&-!234 M"V 2\$!9D!
(^T6K>J\$5MYDW'GC98\XEK\N#UX-(S+Y.#_B_EW:MPLF4E: M\CDKIAZCM7
IM<8IX7.C=9HI>E#Q_+H9;T_W^V4N2!^ZOL4)K\4R14 M6WKJQ3!-2IJ&?H9P8N1*C%*.WFR+CKN# TS'>-(
M\N=4f4)THT+1+=6>I>5LDY8=L4JZ.6O=9-JR^<\$.194W00B:&005!8F7 MIDD&<>J22&F_V3-\$9)S+
(X2@DA6@U@QXC_ ;WN^Q'OZ785\N:MET_P&==B M5U<?I#-
!;9JP7Q)HJNZ;)\LNG@CYDMBG>O%?/?%>O7\KRTNY5N^?NG>L\$@(\$ M,?)#P9 RS* JEJX\0%RF-:HU@F&\$QE(*N"-
KK7_X.BKWQ4B6VJ? MMK16RG=IGJMT\WC-Q57O@E#G_-2I9:IJ.3?_LS@>J\$X&=<IR<\$A:1Y5_"MIW*\$S?
7Q2@PI4P(\X*3@RHM+CO?P(#A&""*78BY)Z""@R"2.^*84*T2QEEX MFUO9MOQ@Q0=08IA>U\20NF4""4RJM^8-
MER^G T(NO\FI+VYQV+KC_N6F M.5-53RVJ>;YEA>:/HJ>|*1?ZQG#WLAQRV8!>MF-N?SQRI?WG^I>
|BI7OV/>!W9O*^K6V55 M/^V5M%IA\$;4Z8K=7A.-?&JZS&(O@RA) M!&(2)'(GX3_%"S*F%:\AB1F5_R/5DUK-
QTU/\$H.A.*\$XAF_&TP%E=2633D M&?ODR?L'GSOYKX\$6C2VIC&H"+?3-YUK+4/=_"CM2?KY9P0;A\BI0%D2I_I4-
(HE#_J8Q M0I>16E@!9WQ=G,ZJIX\ VC3?^EGJSO1RR WYK># \$IRN_NZ6@&WU#<+
MO1NXS8/VKJ%Q%>!WOM>RR0#7<)XD#IP3L*Y(W#YOU\KG;/FJD+'DC_QHI+N MP+Y@H6EG_H#_6 G54#S+N-
S!)PPBIF'Y4^BI?N-1%"/D96:G" SISVPL\IR M3=,EPIY
>NOIF9.16.ALR'FIFY&P+6IC\^8.6PN&DWDPD"RY+0VT@8+=R63
M1M27KJ2T@>9;@:75.N8YE_=%G=ENM.HP2WX)\#!\N2\K M\RL? 9IGV<9IEZ"/&:>!DC+.-
_4F#CO:^MQAHJ>OG8\$;IFD\N(+ S M2F^4D)\S1S2HQ\KPK8MD9'?
&*&1JMZ^VV#W^5+H2_!M'-61JSYM4#_R/\HUD MJI^KE\$0'R3!"-(>1\$00F G"89QZ?B9"7WC\$:%S\+F9%?<:?
>JL^J"W9+ MZ_R>I&_!O:C5V_AJHSSN>IBLXW9ON""8#UM@ON8#-3=D6W+VS>%># M39JH*U
I@ (8)AZZ0GK2.OO\3Q\I\W.L)?OQUUIS+SCY\Y6HN.6?O<5E(F\W M_8S20*P#&\$4H\$QZ\$GT(I"TS_E\$E\$4A"P3RRY?
@*+&C_S-R^&YA/:2%)#'+*80L&(@ "BEJ51=55-1)QQC#_&(4Z.F MQI:GYOC>_I-IM*FLVJ MNJ52<IN:T
NCIK*BA\VI1HMLZ(1"E\$D*/15^W84!=*RL9!"DB%*)82S+6\ MW5EQ,+9>V_?Z+HX1 MC%NY18 ULVXI.V#
S\T0R_..LNB\=_:G94I=IQ MQE=7B3WL@77=0A;I@8NJN&6_5H^T+=5?Z!+MSOPF7MG-L+W*G2NFN'N>K14
MX!LO?^24-R6A\FV\SPD^;D!=R&QF'Z?=\$>A+3@EGUQ3XW(+M00>\$>>@(#?8
M=79>XKZHIPT6=V5>7!..5&-/U9\+D3*(8EY @.2LL/A:%1G-NSI-9K@RN
MI6I8">?;D9ZK=KWD9HH(2QKS4NDR-Z@*11;VD<4&/7:")JRT5=%\VO#R
M615V* >I3?LVA;@.I.H&*4PH\0(HP03\$F"81QZ@TCWXMCHZ\X^3F5EA) M'KIG@&3Y
V5=!PG365U)KVATBK!%6&@*I\G.JRJ/N: EGZ/N@HJDSQXDM MJ^%:@HHNMY==AK_#YX_/M6P&8P
M!..7\G>&85HSI\4RSV0B""?Q#%\$<4(5T@2&'0\H-0Q8WD2F3SZE@/N3!\$ M&_YI-8SV;-A:&:!>S9
QP=H&5'AMI85..#E\I3E_2N?C*IU6=/S<;R<^?MJP?3&(9L!#9ZVY2VEJ20/<
MERH"L"GIPI>08;!*'.G1#X)H@3;=%&'BV&*3_2)O3@AE3H-V")UHS%@NF MF(@I#*X8W6?L&I\I'\$;/MUNMM7?
BI+CM3J?JZIVIC=M>-4//LLKGJH4FT_M>3FHV6V&G =1EL0X46W TEAU_Y=[PDR=QI5\B\$20\$2_S^MZD>ON36?
G5TK#/_M%J9F%NBS&F%>/^\$""^%X;EAG.O97^VL>EMJUY_402.1%YE&?RVO?Z)9I(Y@-YM\$IXJHW>B3Z^JW3R3
MO&CS;+N!#1!9EIR7""2Y36;A2;E(/#IG)QVY?Y>4#XR(OH_RG^H?VH= MZV.^NW2%,6\$(13Z,DXQ#E.
\$IB@1.9N&A<6QVX&M\WF?>O.ZIPI4BKVK# M.OH -PR825&6?IZWY< Z;_R^IKLZ@<&4MP.YM:
H2"@Y0;THC15.@A0"?-M#1@|_48@L)>H6\3==^<5GH.CK\I"2G" Z37J%1W+V\A7H-%NR^5-W)F3O1C1>J M/DA
W\AC6Z\U_T.HN80M/Q:-ART=-OF ((%8:8^09BJ4T3,PQ#I#.%("I'B M-).L&T6QKV-G\I#(X)11SQY0IQ_H&=P-
Y*!ZZ320ZT)ZHR752^*Y^1W@=E M.;>0@R_S@VYLI-U@Y4?UOCF(+H MDL\#J7*^T_%KS4?PPY#A-
_YA%3#6/#AA.@\2+/9\$%&5\$ _E\$:TDV-UYJ&U E_ M1@9UQYRV:C^H6\KC&X8FT0WJ6?0ARC &8>9EIF4S_TPM5W
M7N8;JW&9?UGO?Z81?T=^*IFG+2%YJ_R&"8IK'(?I@F 8;(#PG_""0TSCQ MDQ#+34_-&X7FC'0UWH(8/:CZ KI\I-
_#5W"(LC:K93:'E2IE)A.-QM?SD M)K=0N=HHN&JY0V4R/I-@YN5\<IAU) &K3FK&'G;I+3JY^<^UL_H:"0JS
M\$":\$1+IDGL\$(AB#21.0\I.IE+I#CV"+69_?WS\7EQ>N1D^W3\JR-UN M%1NE9I\8L\LY0Q3R*YW*K\H@D\$2"
Q3DF8!(XQS'YO5_#@#SJK&Y^L18BZO MTK/^SNOW^H#P=LT?\$.8_")5_XYH^;J69,ZI9ZW?VYKEW8#U-T\I/5
MG.5Y6=IQ\$^!\$4\$.W\1&I)NBZ*@J:UO:JS*\RLN5GZ+;H&8!YE\$@0B@R/X:(Q02EF'(Y9\$
M,268ATRW\8,NT9D5L2\$(NCXUH_K_@.WX\42J\H60:%XU&J\H(WFN,+A9%A MTJ>%H&&A\47-2E)&ON./F?:
MT@4?5 P=E!TQ\DC8R26M3UT\ZV_0NL?@G>6(C"Z\F#^B(HI0+=&ZWMP\Z70O M?N5TC:LJ%WE3>
I=IF^KO^A-X,>4A\R@@.(2*R&?D<4)HC*.;IENA-'=,G M.;/^_J^X^+4IS3%D1)50;JA\$?J;4T4IWT2\HB8Z?Q%6#

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|Y- ZL'+5KAIX@/W(3ST. X:%W"N%/LR"S(<(4Q*+ M& G/VK%/\$IM9HO3!:)WQ\$%/W;,% ^CAR>O;!&1YF=F&/P4:T? j>JDT_5V>& M)NM:XKHKYQVAM73QJH389TIU-6ZR;<"N^FITDTUHSJM/><\$ _2D+5*^I8C%@8 MP!AS-27!9Y H=X#X811E/(DB9-0XZ3*IF=6!'"2X>4:,*=J@{6XZ+N\$R8!J* M!@8&RVW1<"BT_J4<,ZZK%DM'"J2F!3|NK3|YA7@|S=O.-KYL|V>.55F% M21W,V9MGULFWF^? ON^@/670D1ZO ->B4>UP1G8ALIG|VTAK5NXQ*9%7H_!3ZVJM?78RW_2)I+/_I2_WY MZ|OT\$;:"C">+99BEN|B _^+U0| G:6P7\$GJNW3H/_WZG>P^36H/P(N0/(? MORSRG_H7W|X82V.^6R"; I^4/_|U|>OOEGR"O-R/IN.TX|H=O53_8V?GL(M\$43KZMNOW|"/_|L;|Z,-'SS!L?SY3U=Y"56GG E=% P_U_N|MU|AUQ M06!9!DK >#FG|=3%J!|ORQOFG'-V&.)R2Q|TN3*M;9|_ ^C MU: <^BXOE/*3E*.=HG>0&LE,9E#0(H;@="W)D<&9=;X .6*|T+(GJEA06F'S_ M/O|S'_ Q3E4/PTH@*V\$|6FXMF- /H_F6Z'"_N'@?X@1PD09(G<0=\$F@&/_@ MG)#@,3JEE'76L;/H_F.Y;^F^K)G_3#;)YQ3I9CLUZ8IT?J_1:S-|QTZ :SJQ:6LY;R&ZM&+W3S|0VP7G<|R_KA6SD|L5:TLRJ+CZ MS5.5?KV #R%|&KW N^Q%UF.^LKK|OHP7(^_ECX9V>C:|>V^_#%XDDHA.-B0= M34QOC_9+6.05N3=+K"& D^5B|Y, |+.RFHC|0G*!.65/9#@X=OX#;_?;,%Q8MK)&WJW_JXGQD=>#!>0:./?EC05D(.7-R*@(G646& M)7M^P/=7&1(H3M7BK!.1|@.OG9SXE1)Z*P&3+;N'9LA!%L 7<#L,\$;MPF'@ MV+/*0>_03PD"03P<<[43:- SCXCWP+);&\$QDQ9LXM%\$>R45IR*%9X= M_HZ|JQPS#05TP%.I^V#@_TH|6_.W TG.D8D+).>"0;*, "ST, EC%DYK5P M7!UVK.Q9Y2!PZ*<#CG8B|!L<#CG8R|!L=|S?|^ (248N,^L>#(CT; X#;=DXZ|-ZC!;LW0 M!EM4<8>@8^|JAZ'C2>5(6|FT;W3C;9&75#>D!|JD>U8Y#!U/*\$G:3J;|H-MX<1L..%691LR%*(%)0)YV/4N(#M6?+,* M\$3.H0V/*H>AXPEE2=O)M&|TB&TW17(3>R52N4B1N.6^9FT8Q>3)24@LH/_ M)@'6V8Z|JOR&CB>4)FGT|H|P7_46_SK#2="J.D\$8 L)O*O.PT<_8@|J\$PN M5/8#T/'WE4.0|<3RI_VDVG_Z- AR1BIVPPE73IA@ (M'/_S4#|Q|E8B"="8HK M#\$|OP| "Q9Y7#T/&\$S|J7M9-HW.M2/_ +\$55'+#B4I>%.U|J? HE.0|A6D() ^| MR23F@ZY8|YR&#J>4*.TG4S|I@??%GVIC17,"0.STD'269&N.(H@P96@DXA MR:BT/*06F*%B MV4AG#ZKZV;O*8>AX4KG25C+M&QU;K;#>6\$&TT9.WQ('R.F.=:'=I9*-\$SG MY+- V|_D=>U5*V|FT1W3B|VGVQTI%30:_M37&XIP54" &<0 DR9ZYLX4\$X?Q8;|H_6| N\$|H|-1#C0_3_?U^'.7WBY.M; M_#2;+T?(>49/94HT=9ZZ_)!888D7>2)G&H65!D/*BX9Z/0#2C.\$>Y V\$& MY^_9 F6:7X0ECGQ)L@0RF2ZK0 +1 J+S'G(*) ^C8A2|'3J^6:;NN*.L7&Z M8>"C/?S,%VJU|NT.VM|J>1G&63;U EZ\$ _D>&E \$UV(BJ5LSWOZN&OE?DJ+ MNSY0SA^O(S.E^_) _GZ|CJC(N="68A6\$KQCR3TD,C?BCY(\$60NYTJ#U?L MIZ"X(TB<!)6BR PE%/*3.VYV2\$(80+YY-9D;QK MX=M5^RDCIA029XA5+IX-4VS.1FWE5#>D3+P^>OZNIQ_?3|+,\$)JZ51X@:0R MUK(3"K2)|A@|"1DYA3:.P%P!|E! =W"IV0A|\$AMZ'+ZRR7)PL;L6+Z?RN.<="T(-S+,<21^+ MF |4?"15 6=RPET- &0ZLRYTHCI/OE9 C-Q*X4L#M&Q9NTRY\$Z1&F8IS3%VG|HXJ_ :A;|I<(+K7#R-W"/=4B7P(B)TIW M4 :9YZCXK4W!A-(7G,|)B#X&"*=H|H+IG@,5C9\$QWK5G@J1+P*.\$^3;,RYN M2*Y>^6Q*A#.+S\$3@,E&01B*!8.F34HSG8DM(P=NS /'_ \$A_-EV3<\$ M*H#G&%; ^='0\$7(8;,'\$?:82HC89 @IM>)(9F- _POW5>JHK|@H_I|JQ9_W_M2G|V>?_Q-MVD;HS(3#AE@|M>7|9DHIUE#C:5*!1Y/RF=E_EZN&)/%<0=X>_I M>?;A7>8KN9"9ZWK|0W;10Z)9Y^+ #CJX|T+2AROV M5" <\$1;DF?/6@_# :50Z|N05W\$V&0E%49"H+ZB83|6\$A(A|OITDE|Q1.QW.M>3_?SD?P_0#KE*V,3.=,YDS:3.Y-L@8>%GHBTK* MAARTWMLP|G"3<|_5GD|L.S8+)|MU\$ _D| ^MYE=WZK|_BFQ|RO1A9.M^CP60 MAUHQ\$!_V/N0)Z8C>*IYTB2VBRNVK|U04W&ETV4#.@|_#|JRE|6DC+|6=|S9:A MAJTT.4).8J1(ZOM#%#DB(H.1T=\$&"VB<*|_G/X|/+;#;/YUY&5@WD8&#-%0"'T\$U*)8R!B%|SDF4T(#F'RS:\$|EPIW? R9|F MU4& XIR/Y3GZP5)9;\$8)8PZ\$ID@&=;>E^1E M11X4,1(*Q> E)|.B?OR:10|#QU|>9XKU6& XB-)AM(Q^A#|AA6RM|W.|J" MCRY! (?SD_O|I(0%Z^OEW7" M2@W:1ZY8(WR=(*\$0\$8DAAF0F\$?B6| ZIE|L<3L|\$Y*V.+VHP'ROZ&DZ>2.SU? MLGU?K*T*KY?C10J3_P?#_+9R/@@6R-<&9Q)%8B) ("Z1^4DV4BT*MA|MA|CIV MK7P80)Y*6K6)?O&R+K.G.9: _|R\$CZ,LM|J|F;J-2%Y4/4_#G9AB+V|)Q- M&XP- N5G:KIDAS(XY0UGM=O;?|2SQ:C*%D*VE|<|HD#99V\$+@| MS7.N*6G&|F7;SN7/@P3R6- VD:"@X)|-7=K%K3D@N40(;_H|O M/?=>|Y>|+CX<.@|E0RIRVD.PA/|*84|?HF5F/S|&;ZIXO9 M9)SK+- :5.XNZ)Q:S4A|@7.%?I^\$ZC^FOON7CP&&>AWURJW&?)_!QYD#037./M|JWJIX.G"P|F:"P- BR6FC"7##AR1R|RS|520A2Q+R8|98C>#E+.G1/X%C_C M|H|TFFXC0:| ^|C _RX_/KQ=+6F|^RYM| &KGY_=7CR;YE^ ^ M2|(I<7\$K_V|^"I|<*<.\$F7E'85X|Q#R:058KTK9#|7*3,+>+EGZ'T'4K"92 M'PAZ7I>_S&_Y\$&\$&=S+|5/29C;#N;#SZ|^LQ M\$?=J^F8^2ZL'(XOE2'O+|^">4C6T2M6FH- \$9D*AI_Z&WN_+|YV.Y;K^& MK!87DIY |#L.YQ.ZK4^3G\$>)L3PLWPUGJX>Y=RH1N>1RP;YFR.@*';/(H M:M&O 25YML(D.C/VE?"=LG#%,MW7&F+AHWU>?G0"K MH0IZ|AA*|GHYOT|+ZSEME.BV(M\$NU\$|^%&@|> (V|N|S582;)&L5K|!19M'LW^E M#<_CJKT^TUFOC_U|EIM+|DRYOT<_C17T@RBSMMJM25;OZ"H1Y|CXX|A&9 M53->|RH|HC>77@)KBAYK7 M;@.L|UFI&V:4F+489V9:%=9H0*.;^)\$,VG)WRR86GO_6|CHU|7O(F-VKJQ/ MMT"S99BTLT" _SZ:SK3M@1+948:Q3PJU\$4)9.ZY 2AR28T49JKN.^7JLG6Z"= M%/7KUG<"HG8:& (0!6CU6(H|P8T3O<39"BXXQED*0BY?G6<0:B6/SB:89"S3 M?%_WHM-NS:2TZ|_W@666LE^_*|I64G=W'2-H? \$QXW-G4T7/V.9S7|>^ _# M%US|H4D2&H;3|AZZHL@_20ZAW9;61V4AGQ(OP5DH|04;4Y&7.CTA@!4I M%6'0-I |Z|R0G7|=-&Y@/_S=#^|AOF7Q9DQ_C%.LX^5((2;ZGP>5"XDW1P|.MBP0)ZV33JABZWS;#E+ZC0FZ@HY.A^ :6HF*A>.:59V&(J^T.59U"0V&Q MHT@8>-3%6>9V_04|A2TW*W>3QO2+@%RHF0'8\$XHI+TSKL^6R_DX7B_KOKW MLQWVTEMGT=3Y\$- I&4\$9|"_@3Q=,%*9_U|6)?I>|IT#F;R|E;W;|L&|U=&Z< M+Z9C2|&SY%3WBEE\$5)PLA|8|CXI"RD*7F2B;&? O:XFSL=93D|.+>DH_0_M6OT2YE|^ ^.(SE=/'G|.BW\$;H;LUB=+_A.\$;%@\$(2+0\$&R|5YX^V3K1/M6 M0GKJ>|HE6LX7^_#|GH=O!A/KLEHC8HUQ1CDD+.U!Y!%C)Y" |H;&9)V.HNN M<7-#2DH4B^)G%.\$? C|V/N_!SA|AYS|Q_.\$C4?Z/_C1|N.GX^+H>M*WAK\$ M\$*=-0.Q91M&DQ#K_A|A%9G-! |FQDK<_PHPC|J2KETCK3D\$#L%TIF+O938_? MU4?)%^-%U6U6BV(VJM#*M LRTA4>X3_M|2-%^//V- VKHKW+=/O\$Z'&|TWNEW|_ "X2Z_ SHEMB;C M?V#^C|FD>AM ">-I%?6|:8<\$7DWIKY;5/?@/S|_P5B;Z MF@_#.01F'A=(D27!A=)7BBQ&7Z.R'C>GMMX:U1STR\$ _^+BI4GA3?|R M%*O? JMUEYK@DU1R9L)F9|G^_<NU|*X%8.PSF*R&K@M>=1."5YL_%MDL L5."Y>S/U:&X/8@+;1)WY*; MA.7B=MIO/7.)>V=<\$=(QR(%Q4%\$PB-D3|!"L84%FY5OG@%K2WV=|8!W1*=M&/AA<;NUK9-.92' UOL(55CM=2IXO3+0Q|_&6|H7.(?2U6&0|8M" T+,4O6|BQVFI M=9JRT*|S? |G|:9^Z'S;T#V(WF<1U|@)D\$5@#>0719P|6>8KCA8DH6U^XG4ER MOT|X0*#=7+?#J;=P_7(D1!E3@6DBO0K>- f73@>\$(K-.64NKO6CNSWD|_O| M#&@2|1^FDF<'LLB3DYT"1:L)W"Q&7BU8%(#L^M^VYOR'4MR_N>#F>TJKC,*0 M?|S:108,4JM&L;=<MQN)9S)XV%UH/*F%|VASK7/7(G")QM*Z@^RW%_RFG*_-A|UBSI=W_(EM?4 MWXP\$N67")LTM#PX*.EV9(F\$8H %4:SBRCCK.L;_T+ZA>1XF%RV*_N+JX6(V>5S8PE

MR#XR"A84:4\$K!8C@.5EGYK1LG?/81D>_?M 72VK>EV8D+8 MA9SD & \F-SL>K1\$|<|)HUEK>4Y2:=^16^8>>OI
2+7'3S/9#P! M=0M,Z5>^UFYDR-%AZP-LR*!4CE#(A#X+!\$E)3I8N+\$W?KJ9I!X^1DV0X M%ZLKB6!\$,J(0 47T!2R*
(IE=Z""%)RSJT-B>76)=1C*OK-|H3'R)ER!|2 MOB7>R?Q(F-6K/7UXO'XZ.P>L8.SYF3I#N BY,V! M|@=;?
JUE)LO:69/<|4WA28CYDPT01.X02:#F 1%E1D-.)^#49(K@:V=F'WT M#,)1)Q-Q/Z & Q+?7QQW@R&:EHT043(
M='1FXIG!CXYG8,+7K+6&)*R#N:DP+|X*9/2*/=|M+!#RQ|>-WZ1J"2H\$:/V5. !@O:A9IK8AYRUK(V&TU9)D(E3%:>
<.:<|X:N MT^1|>Z/G8W-4P>9N-J"!P"=>VYIO>C?N&?>>>9#|>XR6G"9:|C! M>|YTI?9Q,2^DZYLNQ
M=Q6D!&EF? :N:R^CY*#XA)&".\UEMJPVYVX,D\$-I&|S3IVYNLCM1T0 LSSV^ M'N8DT-.)BG34FB!X?79+^|!#(
E(P,J"1-E%1'7WOHJ?&|NM+|,8N>H8@@" M>H'QIK(CY*QE5@8DKI6.0M-^,R6"B#9@C+!\$^IVON)L>CH4N-9NS-
/K(1SY- MO- QN9>|!\$WX6B-%EPD!"A4%L"9(R|HS*?#PU!"9.)E(1LGO+>2DF-IUA' M>&D@! % 9Q:9UD)6G"YN"BI7
OMZNOT,*RP&#Q85^8Z-H:WD8'19(J9E-Z5-MUN'5(73UFR#LS-PU5L@-0+8:YW8O^W-KL5%D-E!\$@E
ME?%:HSM(Z3=:V!% ^6HA-.C9P@&S2(\$K09!53U)+!4 EP)/#H7C607",3Z-M31AVA)DSA3V\$U-
%L^J'6*=:886'7Q^FE@1(T)RY=10.P4WM|AY|K.)YBOM|Y)ZH-M| ^7I>TUDFA-R0E#JG95BB%F\$#&P\$#GM%|?Z)
<=W2|L,F-=P%HI90-8>Q@# MW=LMG,14ZN,Z*L^BX"JWAM9N:P003W2&KD2H&*|H3-2A-M%71Z6P:~!))
(^7:OLG"0).5&FIN<<^L M/Y5:|,2H,W_X#155I(OW'(30:A(9|5W'EP5CBZQ2.F1%VP=?^XAI|HYH!?!
M42ME#,#^D@+MYH8Q.D6@VHE"H0LBP0G?_G("IP5A5,E>^L:W.PHZ+L92!O=M;C%\$)PMZ
\$!YEO.JBBQ.WH0QQ0DWZ:N1SSI861AH)2L:68 K%"BXPDP7RBA5E M6S^\$W4%*WY5WG<"FA=@'@)ZWN
PU4:893ODLI>NKZTGM^%13:&E|VD=T8LP|5-4/L:2*\$HT20'MA*O M.\$AP(1L(*)2TREI=6O=?
TO%WXT>.|'2F<(>0)|@M_%T-B>Z:QN>1EN83(J# M<+6^ISIQ|K6!+S=96.V|UK+UOS<6@C|_|
M:0|UE05"R\$DIB5-NC6W02,4-YONO-BKJMS|O YGTO.S,RA5%0!GYC*5V M=#\$&(F,%>#*.'\$+&9K&
(T>38>E(UA7^+MTN0Q603A-LEO5B|KYS.MQ"IO-M^6G4_G:%2|50'D/7Y?
LHJ08LBP5#8S7L+*@A6BD!5\$RTYX%@Z6UAW.1LJ3 MR>R/*067L F+V75!:&=*6L KN*|+ # M^=?SE33S*N^|N?
O/I(*1E+|%&H3?9OJ MM5=T#&)0\$;3PF!E2;"U:WUT?0%?;V=N.4=,=,62| ME%:ONC?6YYC<*HQQH 0T49-
OD@TK:>V|R&G|RSNY;!UEB* & B*E7B|4UL<%% M3\$R"Z'NC52@I@ \$A^+HE!19-
GAK>14OI.S%X:2RGV|7"S#M<7 M(R^%4"*H&|S743*1(O:~L<(S2N/@DIUKL%TCYZ^TI.71M2|HF@&JRI#REMO
M+FE9E'3JW&L&S|Y:AY\$|H\$^?R3XHA*9(X@G0JT)%F-%DA'R%\$14X2G6O> MM+ZW.XBP|S.~XN|K|'R\$E=DD-&+
|REFBDUL/D7&ND|1)V-8&ZEL*!A," M-L+^X^3KR?(>P.%V2_U:(O46=39=53A^&2|&=?C"J)V^5.&NMGPCMI3&
MY<L5-29'ME&T%"P=(F=X'F+\$/ \$:/>'@ONPKCZ0B1%&G;N=D6Z00Z1= M:0AB(9>HCGV>&MA*R\$
P<|ZB9ZVE/@#HK')O^%5OQ/DHH2//S7A(6BE0.CKP M23)(P2GC19^M+8V|H?O%R@-U/GPL>FILAT+NX^C<,B%
(36A0T!E\$!7%O MP!F-8(TF|QM09-NZ3>,C(OI%R.GZW!U%G2#<:!C1R'KAAP?,+4^ZS+LK3
M"1T3TIZ)&7E*SN3V3XKW\$=1O-KH9:MH)?0 (>EBV>L,%LH@F4@@@5=9T'EM+
M7&@.10?!"K"FOQ9|93TFV5NAID&8AX-6 XH:~UAC%NEG#> YU^B&SX)C3 M@%%+8|0J7O90"WP\$I#I+K#?
H3SP#0M_&\$)G'(60-9"D@S9JW:JIQHH9 MKCH%PC'7J|=HY62\$?<+Y>%80#.2+(3UWX-
9P7WU"LF+5(I'EZ!2@>AM(6'7 M*KI6,^8O^~RALP/WDMCM0=#0?F:~R.E-6YXRC&3.Y00\$ M.9TTD:|BDF@|4>
(#.'D>BSKM(R9>0U,AWC*0|>,0EHM64L M1Z2-T|A%PW-(?E\$|=72)#W8OQYG&:%?<
M_M8AHSHJLU+GZ&OUWZZ4%|=E%UH:V|G-7L-7?%\$-):\$B"FEFLP4^<XD M6_~%91%|^+G@|GKMZWE|&YO;
L.166C.J3-NEZL&|^G^VHCUGMN/CP3'B+ M).7%>(GO89A^FJTI92T2%(\$I(L4YZ^|1/R|8A&%0A>\$6NO"~&?
#+TK=36!^:42*WG MUIQ-|?/?^JSC%K.S(C_~FUCEQO=!=A"@G,R@;<:,^~*8X0^+A|DUVJJ:%I&D^0Q'=7*?)^
M=JPH43A\$(0P(E2D.8HB?!"TS!;8<224PW|Q;|8*/?LL>+PSAWH\$P@,WP FGE M-%ZIF/X|P>5ZS/'S|YH\$^,?
Z'C9XB|P:!"KX%&KZNP-|K+|Z@:FEAX:ZMZ M'"%WIVMO^T?H?&QC50X GBO9U=6AG?
H|G'XX)GYT29&C=Z"9.K2M9-? MHH'\$9(B1&Q9#ZRN8|H'4.TWYX.#85(4#@.2.DBEAG)'&)^#.~|HDT|H+(8&P
MA?~:8L:RUD~|H|~MLY+SP<@O@:H&+I5=7V|'2+K27YRY?*(Z<|24Q9<H
M2XSM\$^17"~|6!>X8Y<47|M2ZVW\$E,OI7H@X>&Z4-IYKM2WIK>1N:D-NQ1-L MKRV3\$3):LNEH!(1:'<6D4UX;
HFWSM-N'4I=O?2K@8-J16=@-1|SMO&#R0/Y M2~;>R,O1DX96R(C5SBP#"H"*4ZS-LHH6|3D/K6!_@Q|
WM37<C'P7BHT4 M-HCBR?@H:V M\$M"@#M5)0-%V&_O E?
ZZ:16:F4YM>TWMW,LQ%%_3:C<:6%8NTK@P6"C|&L M+,ERZSPYQ1VB?1|FB:3YO1L# M%AW71JF
V#K#N(<^>03J.%P|=J8H9|LSFLX28%R|)K_!"|+R^MY?8LOS<IG MDPFFJL7%ZW*?20S<.%Y?3S R|LJA@#KC+R-
BNQ|TIB:~W'DIEQ.'U4^L MQD&H-|LO>S^7U^5PE\$+8(=K@1ZA8"//NX|=3.9@I
M|!?)-|12UQ#R/ >L_EO|=X#TA#^~39VB"14?%U^G4T-.)@=65'HM% 60L@%5'ET~F?|H0NN#9:6U1?T^ M58-
~\$ET'E V4-38W6ZL:8V,1|7^TR=I(OGREN~+T-B^ MB@:9'NH;NV4,XB@9NOVF=
<H&F3ZYZ(VIG0E#|TY=OSWS+XS)C|0YV+|3C+Z5@6I*!A85_0#OB4S-T.F:W-MJY|9-)!;
N^19+C.)&17M6*U\$;8|W|P|S='SDRG|G:@H)\$@.H#G10*C&>1 M*V\$29ZV/|0|8Z-2|H"Q)V?~?"IV""(SV)VWV4 <-D
?>1.C2.U+M @EUC2Q M8@C|B C&))-MK:0)K5V;|@^#SCSP84+|*4.9MKH>2QGS@HYDAPR)DI.I"3O
M+J8\$Q9BLC!1^~|W5|WCMC,O?:"X/4:0YD)AW%EGDAY-~6/H|&?03*3/8B:0TYU?LRSAQQ08"T4X;R.M25);-V4Z#\$5
M->"H"QT-?HU|GL-9D|D53RR?J5'L81^D5*M(&CP9X\$9*EX2S/K=VL1Z0-MT\$|QQ47
&JSSM#)8D-4| G"TAOZ2-IC6HOM!-U|H:F+~#Z6UDRO:L M5Y|K3*GB|M6.*O?&1^2%3W.DHX#"9"*9+K6N|?
#:@8-'B/|K^?+|H.PGM2WL^36O%119ALVJN<I\$2X.U*~MV M HO5B.L:O|H&S+|
~KX|P|K^10V%NI@>AM9K4W3F>>SJT@1PV8TRF*|RWND MW+/LU*0:0Y:~^JA-0A6P|2Y:A#"D7SUI?
\$QU%\$=M#Y>#7209K.%M=SO-L; MQ3JN+4Z?>=7062~&X\$|R^|~18M>8?-(|!"**^K52'+|41S:7E&#-6*K>|/K
MM|B1U9A57C|?+8X*3;=|V&MG*S#J&WF=|U;G7)/~EUZUO*30W/G.N0>5D-M" NVD"LM% B>
<@G!>U;O^\$ZF+CS?~O+~+1M<~L):T.1)J6>>DU^ F9CKP MK66(G%O6NF""*73V|9-U@:~'7EG^ANL<:M-
5+Z:5A&MHEP&Z(#,RX6-MY0&QT!;B-M8NR F2D#8@^AA+Z|N;
TGK>~|##>IG=E'8R.C4Q-GWZGZ%DW")5>D\$9"R=G2"20F1&+~*R4V6"K-DIOVD
MOFV4G#^3V/ZGWCLL>30\$70/(D@)EG-2?N0!&4 V61:6?~KF#E+Z-24-1/4X
MAN#Y(A~L|7B|~%G^IC/JP*0Y|=V\$#1|O7TM.%|L~L=>X)1>KCV|B- MTSEJ9H(V!-PI?
LCL_0-|YYNK<%|YJA9CQZ4(I^~FH|H4O*1.F@~%G+ED+KK:6SXY+1!84BM9|G/H|=LL7@:3 MCVWGA30|6-|?
ZC51?;ST4BLL|WC3GH:1GGU|HN09(W5K% %AC)G|>PL&| MY&ME84F2*!%,ZX\$G+KR-|H-
%WV%5.2&|X@821L.L\$A196%&8HLP|!#~9)H?T8=~/XSK*YZI7~*2?GN M1L:Q!~1WL CX;9|MJE F:|+=
+P|J"OD^AC(OR|4#P%|0I!!ZTUJ=1M X* MCR+P7-UT&)W&X:\$833Z#~;7N<#9:|J\$:"|B|PP\$D;S(>+~4=BO\$>L.6P-
M6H=Z&ZRAN_<0X20WZ>Y?MW*3=M#3S\$VZ^?QM1R)WTG*E@%FK0*S-26)H#%)
MX8K2RK1^4|F'G&8OM+8>TI@~TXX3=@T%&\$Y5|/C.6F1-/CYQZUN7B^VCHVW
MJ0TF=C|9.E<#@|4>OX3YE+~|V@3CW4>2|0DFY-'M+~C^REK9\$P>+G+7@HI0
MDWQ.L(*.LA@~@M)P|~9Y&1'UW=C-5HV1=M|R=M^H|Y|H|AV"),?KH)900Z/RS
M0H%/@A~"G7+|F5QX|~Y|NXC|UX TP<&C DU-|~18T|L?ES6&~!^/KOZA-/M MJ0-Z=GQ0&S-R")6MTM>WA|2J+>?
M8C3HW&\$&M M#H%6FKZXE"0HXU&92\$YO:~H|/HOBLV/8AZI~^ W5|V4YCYU3VY?
#Y*)M|054/UF"~Q>5XOKH|~QF66;+CGO MM%+~K1-4JDSS^U0V,ICWD;"J~NLO.6-C^2X8Z!8/9=Z\$!8(!
F~")RXU.J MR\$7S-F2'DW=V(V1:9|W~*N7WAO;#_*\$>MJ8PE K6Y|OKCV=&G@23M4.K+R M"
|+~\$SD:C<5R*JW|&K^NL|H)_ (E-#E\$<

NKZY5-ORG00J/+_EAEIAE_MG2U.>USSO<|I|<3F*-L-1."KB0%WV<I4N(K)0:W5(<^@50ET1!F1FR*0N0H06
M+56^I>#LIGWWL;..G_P^6H#..4.1 L. \$@^TN:Q")\H%D\$;I1'&13*YU|<^W M.;HY|CP=8^>
I:44_FN^3!UY,%X70=8ZI=GJC31.TVF%_OL^K8UA.9C>=F15_M9KUG#1;EA1%K2*R#*
(6^2N3\$SBC&/BH4E3%Y")E^_UX.(G&J1JN>^6N^?A MO1A)\$YPU68#SA&M<I(VJCJSI^;# M-6T!ZPCIG%'
H:03MO5MPP#DI=S1LP4V'O6;R:P5JA+;WLWLPEXQ-IY?
MUEGKO>WT#JH%7Q(H.B\$0A)\$4LT=>P!H!G6TH%8J<=6|A_P6_"M=/5U_?5N M)IED)J\$Y!QP\$D_A
@)!2(4\$772ENG6KN5AE/TS_.L!GO?;=9WOOX&T)IV M&UD^Y"44Z5.T"63(Q(M6_PJ=0!9TL'S++AUS<.2
MG(@P68^1&04K%!/UIDH0S%_+5^TW\$*Q@7E98F!9%P?_U^Q_VGZN3=3\$ M'.WT!"IC=/CO.G+^"@V2%HF1!IG
P@O:)<);C""UK_CZ6QW!%L>_Q4YT.M-OJXZ27W/L3)2?&M_^^8_>31=N_.C32(JBE0A!ZWK4)L\$/M0&>HH4+;7@
M.K90KW.13H!43H+)^9^OYG=MILL4/S=6R3OL2"D4X! MTR0DVXC1#J!0#G14B%G*O6CYXNV_+Q7?
J(^7J"K!MFW?MZ^?GKO>|N|S.6 MUW180PN3L1(13R(I:-68MU)W-.CJ62VH!T20_*?5/((7#Y*
M#>D|@\$\$R_#>ZVW^F+>2Y\$OYU")XLNHQ!N&F/KZ=O.5W/WK1_3Z; MSC?2KC)*!=-?
2""IG(I^QH7#XX6K.BY(1>P)3HZ6CQ"L:~#D/0#^SBZT+R/ MUR48ZS>=<|S=,CR8#-8#V=WOI(RXZ#L?
V76GUDZCIT/I:0;NVG4 !EERKXB2)?4=57:JMJ_07FN#M6_>D6>;-GV?%AWS5HIM&;&G/&XCQ6FM1L
M7\$U^*P/4UR-B")<@@-MKX.I!E:VWJZZ>Y^OM(SF,)U6,+V?S=V'R.)60 MK*#FM1-
5LLWMPD2VYIU0>LAQ2MU!R)X>!!^5C^Y)Y" H\$EXETIK&MOB_Y_88:E!5L=WH=
*3_\$L3RM;KZ3VAWBN^\$/1_OB3P"-M2Y/J<+ \$ TH0 M=.&+
^2I>HWZOEUL!K*/T!8.D>#H!G8;\$8ES'FG|N+A*NP^2W4'W2Y=<7 MY(X^C+;#MX%1>|UJ)YOY! =?0DZU_&?7*
N71HS#KW!7BFWQN"%-3KR^05KXBM|V>|I=HVE>_Z0?D'XW MW|^IWXK&./2U(IA*<.3?2-K*
(00#T;@2H18)!Y>|231\$#V0=C60!2VT/4I M!)#ZVY!_Y!46S^MP^D\$4:5NWK4LUJ_*BSI!EG2!
18)H!%7F\$9LWPBD MDQD%=WFD^OD/C7VQ".73(&5!OX8@A-%@94BE9"MC^IU^F 2/7VWY3X;".N3 M>&<?
I#FY9@&_R=;G1.6N?SX@DYMUD_XR5F!^XWMY+ P@O^_.'8P_B@C=G=@&2VD MR0;\$!;VL""V2XC
M+9TA*7,1>N@OC\$+_28Z!H1.L7!H+;L94FJ!2AUZ; M!Z8Y" F^NP0D5@6JCF#T&!7D*(UF(IG4O-
YC/T7I9F/I@FA#+0T*^>V MUP.61!32JL")4GN5\$!#^4'/%O'G\$D)4^M+TP(ZC=^VC_ZVNAKL F+>R.W
M3LY"/Z.YN/_.JXCVC4_2@2.F2(9**J^TRFF@&=HP>DH"!%<^!IG0!N M3OW;1=8YG(>I!-=KA>, MY"!*)SU*!&
I5;):!5V1BDY=1.F(V\$^!&-3CN,ZAI#R>CI?X*!FBC!3WJ\$HN!;STDE068Q.0 S<@662"9^Q M>_-=BX&#R>PW^=
<^&+O1X!<^H!EW(PFVAJUW-^\$R;#%I1+J!EL7KDR\$OP M).SF/2!/(?7.%T78.U.DP; "I&S?GGQYQ:QBO:|H|
<9GIY4@<|/"S1DZ88 MB5%"TBF"!LE J#LV;(<^IYV=|H4EO3WFIZ!+0OKO!QD&|H>=&O?L^!N MI@1V&-?
LG!&7DY+%%P.4!IO@3D(1FE(#(-)(1C7_%U75L"!IRS!PQ7JU4IZ M5IN13*Z7F!|V%:H2 R
W)*W!%D%_.V)FY)0%.:DZ:XV!2A2!SIG!@.I3Z6 MNU/:8.W4IOE^)QNK01_7Y43"+BO2SIS)KPI/C@HAH(G2T2-
F!"49%I!VS MOG5'RWIG\$M|MI_MKUT7KL!2'4^KNESX_FZP^?
=5;Z^X7'W!^XN>O=;..0Z#7AA!VC.0C|@+NWT4&\$U6"._22:A M&6U4IGQ1>3SD
M9#BC@'FT+G!H.RKQ;@/LE>IZCM^M.;1=5AGAL,ZHL9Q)4#(7<^H:R%A<"J(4 MH!OS&\$\B>5B#%H
SV!U;WJ!F03OC,Q!0H_#*O#!5:PS@6.O.C;8)!+7N/VQ?CS>\$%_<P*783PY8T3(>ZF^?K&XWGVV;P865VTEH+*K
M45\$92!\$%_0MF0!^Q^9%EOI(ZOW2I9>YI-S90P!\$2M.7IQNPKEZ4C%+T)
M"5(A1T69P.!K*R%&;912.7'=O#;|/@\$|AR|M%+M!_00)4NZY@=|I|V3).UJYM MW3<;@?R&5Q'GHU(%IG(&-<6YJH\$
\$X!E*E6*)CCC\1081S9ZB MN%D74NP9#L_#/(IGG;B74_"(9^YWQRFIPKC;!L!P0)!Z ML(EXV72WA^ M@FV?
W8_R&ZMLUE!/^>O_=IR>SQ9IC-.\$?YG/KC_=L""+B\$8LHB^OEM1EJRD M-PXPRH*A1.T2.P
_.SZ^G_B^_Q2TD&+/0|@-<|TOO+N>ZC_W0C\$D2%D&\$FS MO8-B9!C2@>L5HHR@-
@L/7#^WGNT!T(SI=@SQ!X;..OE|BXCVI!Q3!T+ MR2@P4X;(5PF32:KR|<\$@G! MJZ15!_=JDCVQVH;\$<I#;_4-
"RFV0B#>3LD@TL)G>(X-Y3P M+R|CHO|X91+ M0/KK%61C;..HI6|UUEIXX0!##PLG-WD'F MO6-%
\$_A!)D%KTH&@*7UNH&G&^>7U\$1.I1Z#DJW0V/\$^0!A/@SI+W0S("Y.5/W52;_VN30!Y(NTK+@Q(6>?QF3K-)H!
MH(R)H+5F_&\$OY*VH.6RUGAV49HC10+9IVYG9?#8^Z_\$RAN3!AJN"UI&K7FK@Z(BU^@!3!P!&>9_*EUK8
M0^%;+YBOR_K&T*G&QGW?4A!PMI8>?GU?T*GQ!SPD_*OEBDX%\$;8HA.7<^2 M!AE,K* !O'Q8?
+W!>/K..OTVN&OX,+64YQ!2IU>S7^N^;P7/MXQ\$X8/!;WL M7:2SU3 (RF7P"6TNQC&IPJ\$)^%V+^!0*;WQ4M)-
DW^B)G?|RS3?%FGVZ>O& MX@4CL^2UV;(+H 0/X*RT@_E+9@4SQ8B'6(GM'WA0#.SP8=!">CT#X%FZ7B+%
M;_C;#JN76&G'S9722R'S)&K;_A@Q80_RFF4ZW.HS2>06M&)9:D:Q.S!H M&JS3-!@?>TAS_\$
M:2+&C/Z@YP!0Z7/H&HKG>Z^R D"D_2_O9IS8.DVOKD%?K0"HZ\$14=B12%
M>P3+D#&FC^@Q!7CH!0;"3*GZ/AA<_T&A^2L2_ZRH\$!6B. M< M1R4YF1VE59@8DI&4IQ^D&S'(ZQ.8_)Z"?
GVAPWK04^!)NSX!S^=3S%E;1& M*+=IG#^+Y>"611^!AY!SA;"TCSPPE57KIMW?HZGG.31=72\$W5<4 H/6=9R;=
M?F3ZWPS5H?^/I/7T96!66T\$!"HNU3_/U)*\$A^G\$1'7UCAH3';3B!SD\$!L
M3L3)HS>_W2KM9%Q^QGF<#>5UXVIA_G=<;MY?KW(T!8=U!7>_AO%_X4;- M#/#!(S_ZM.M9!L'Y+;F+\$)
(77ECS)UA#>-18K+/%T!6V=\$^C!F_XJ!UA"# M\$BX*U7SNY!_U^@.5HYZU'B;-@9P.N!_F5X*M'H K!0;:
(P9XC2TKI=B!CQJ/D2*@\$6*P)%Y\$+_Y4&5!\$JE^A:X71V2?XWN? MIJ&HQ1W!*&8Z38=|W.MD=YS'.G%!+57G-
0(03PN;I+4<5\$;VO!^?CH!4_I M4>-1*OO>H!9CY#>\$RHHMS_&L.C&L!B;6ZA/*L#SU90N%;PM(G)IR+O6)_H
M!504M)M#B(HUZL P5#<|8NW8R**"\$G)8KQ8I@)W(1U2<-6D^C6>"H+S)3C M1XV!>YE!4>""%|4@A-
PC!IAD:X5!7511AP#<@3UJ!7!YTIO_*#CL=V!\$B M.64(QM-Z&5M^TW^MA M%4=4P9-09*F#CL(Y/WP
%)&&AQJ\$6+N!Z=;! SX>;I28IVPN!YCOP&I?>9 MN-E+Y"!+U.A
8(SUC!3@M\$IT1F)TAE!1#YN_!#W\$!"*@OWJ*1HJ=M99RCU!) ML^OI!_Q#PXH-QLGL!@E(QDDQ2C0(-2Z2\$UO
<(> "1!*Z2T!2!1)X41+Z2"!D'I,%PY51"),L MLG5AT!IX3U*QP?
6!XC!"\$9ERTEI2F&A\$K5)W""U8B?)",3A^A=*9YY*1V M_/S_20WO*;AI+?
IV)SO#P0B!04I:P*XUK/I3;Z9+@PX*T(F^A.R UW#VZ2@
MHZDJ!@"MD!|B<^/3U!%2VR3TI&!KH432BM.>TX4L%HGKEP..LC+^!Y/J(KV&*P<545! MC#8&<#
I^""9AFO#>=13EKS>#NU=Q8N6@9YTV@|5D'HA|HA&|B&R,BD@P*,"9J?^); Q_R;FM9)61=O;|I- M3:P;J/M
R!T@NAIKIY9W>@_2VE^C?F7+W6>JX&LKP(7F 4\$P!=\$D M0BB(+B=DGXORCH"3P.A#P_ZWTUOB"AJ
MYLZ"E8E\$92>=VYL;4HN%FZR\$;JX-DD(IE/I=8Y;G)350P_6MO"TK=8KJ=Y MLVN^/K^>5Y&4J03F5B)&
(!Q;V\$4.UO=%X%E^I#J!9/T_ZG;I!1V8FHF%U\$ M10.%WRU/(YV2.H%|PRP8KTFL!40F2""!1>ER^SA(*9.^9+T"
M6G<0.TT1 M0T?5C=C(F9QIF(I_@7D4>#%>.(3_9O.KZN>^CI/Q6J*CJ(D/GC0D6WMTZA+!"64A
MNQ049JVE|VB\$^!T!"GFEW_9V|I4S'+1MY>4%+M)_&DMRO>U0./#*)G\$E4) M*!B"\$BJ2K^
S%_!";_F!;_%4WN#N4Q'X!N%!"@9THJQD66!E/TO_?3U>C%>E M06&;2<"29C?2-
KAA/N;3VIPZGQ/HYOH33_.YLK>_%R5ETVZ!H7T!2!WVW M3@1HRY@JN4!7=ODLPP4)&FR|
(XYHS17LK5\$CJ6QYQN!|A#VJ!%+E!H:P/!&M!;-YFY)P^CA#JK(;Z6I3\$EYC*17,*L?)>I/_FH6P0<>MU|C#H&"JN:
MO'GBQNF0#9A2+&5+M!%C.19B%\$;Y!ASK?_U3^ZZ^RAM'W!=\$8SHAWO=S706 MY;2V;(X*B=(7Y_+ #G82?
H^H.H80109ZG^_#B=KH9ROPV3R!|=755:5QF&R;8-NAIH@F7:F&)EX86NAI(/@_@>+ BM<I2F M>>
I@1%J"!S(G;H?^L%I#< G+X<3!+=_7!&?K4M!TPYA.AE4BADZ.W)_ MS>;)V&Q?
C0NA#\$Z9@_!B1Y)&@1T_\$A4TY2.8&I>47B\$>3U//CYDH=O5TH; M-A!O&/L!7&WVN+5)=O5;4A!H!O'9+
SSB9?K=##;VWX1\$YCT"15'\$5'V8 MZ;T!@!DQ_.YMP=8IUX.(&RP\$SX?&K&L!#0!M_/O_X<%EN\$>#I3*/QWI&G
M\$2UY!\$@>;5L;2B;2=O!^KIVP'\$=904'Q)\+77TP# M!6=N2M5!Z!5Q!</p></div>

M64XG1F:E%#DZ1W\$JDOW(LLMS5U>|V>OHM+>HJ W*:6GKMZK?G/K@V?QG5=,@
MDM<|3!=KVOBHI"A+R19\$U+5L.G'GA57.)\$GNCG**UJ?89NUN|YXJ\$K MV)PDV@% 8@O<|PJ&7V42Z;B.P^W9?I-
YRL N'D^,<4%=WU5'8&9;R5E;23>O+<CR)TY3_#POSOF.L'R_7D MUW"!D0DIY.L9.*SD.=
(5@*""UW/H(H8C6G48/H:O?VOC.D-E<)0.V<+U M>G7U*8SG-
WUZVRQ^|V7KTMN>>+YXIO69N|RCJGQH%ST@/33M)W1G+1.C:2 M31%|T#)/#EH-U3 @4/T^6SZ;K'Z=
/-5;90Q.M9H\$:4 M4=YQ20.Y+!9 R.M|Y%;&VQ=E-S\$)CLDP73F>+ON?9SBWG>S,<)Z|/\20#"?B;U,%(1(4:A0(Z
MR4M)?F!@L4 VEJ1C\$Z*/4Q=;RT(/7+9@R#DG@R\$NA;| (S3)AS4-L|N'IDK M':3CN@!B;3X=C;:8JR?
==|L1+8M\$7!'1UKJ?'22'6\$3"8(J7W4MM# M)MFTL.FP5#9L,K#L56<#;L>|Y|TYE)K5FHD/TVTIU?KS7O3Q:EH4@?T
+@G<0X(NUP),(15N*A_%IONS=X2OM4,ZSY4N* M|X6)M?X=C:9Q)S_PCS/
)6)55\$|JE+15P&J)TJ1:5&%0LT%WFM=Z%|W# MN&_L_%'?<6R|4I83171UL#YZ4: \$\$>ML@ AVP#<"Y.8D5D|I"
(H6\$^W.5PO MCZ\$&GO Q"CT9L^3LC&?YW3+EQ>/^WDH17AB*QMFR1ID#^|_8^+_NMLZDC1_
M47AR7QYEEUWM;+DD=U39YX6+Z.C.B12;WA2S&+9%8/PP"WITW_!T7TR|(ZMFYR33NX^FUVA:OK
MQ1Q_#UJ|KF09"9BD**PE|S@P4|P5|TA&2M\$1E-!IAM+W GU(P\$=X;T@<0UW# M0>EO03FOMZ@R|U+H'XD2L3?
-.?D;.PNF \$|L4>J13_/_|3YUT>UM|5^2|X'_#L+I9WA|W MG;FDLGB8=3IR"JX5>2=.R(TBT6G2WRWFR|O?_AA6LU7|
|V+ MU&MWSNS_W>|JLS_422&1>,"H*+HNZZT-3H#%#)7<J+;TQ^3FK_.0Y#XK MY>H%|UX1#OLU8I?_Z0?L.
HM3IDBIF(C<@**|9"5D30|K3_XFL+;8>K|QJ M41.WHW:#GRU#RILILUIT5G8VW988T&V&M#7X661)XA*.W-UTO?
>26=;|R|^ME:AIT=D8|/M|I\$"-3)SYV|RZOL|3W35W<^>DE Y.S05N"9E\$PPU@#K98U+\$X
M|8KON_NG=PF.0|6W:"K+B='P^W*1;|+UXV;_)RHM.ZH#>"B|71PO(08BH*@ M(OI% ^E="|P&_5S|T;2??
>|A|K^X);:)\$N|K|FQM3U7F)DC&@441@%@DC&>> M@5F6@G.9L VN8/HISZZ?^AW#W?/-Q^<>|Y";H/XJOI
R4VL+|F|HGF|P|V* M028RH\$%9UXL?GPA| M\$3&GD\$|;T#5%|B0E
6.D7DC+<GE>W6AO|XQQ^=YLYHIOB#Y3>OXO^!L|N/ MM0/G"WE1|V(OTC|_@4.2J79T220OQS# I\$O'^(75>PV)> 4
6S|^3<5 *R< M+|LAKW'M2/7Q|!ORR1/*#YNGK^F;T6#L5/#G"W%+3>URR|O)FG820W>>YU@*
|0FCVQBZFXKK!"L2,C%Q9,C%R"* (E.HG;\$G.09DF&1.>Y-B;/5(^Q#8"?&LB%)"K&73=35\$Q9_G7^ ^ MN5|=5D'=!6"
(RGDLX(QU=0ZI F^D!9:#BY(DJ?EHUO(Y.9W@K#T|=L'M2(UT M
Y|EHS<_16'8U@T6\$&FW(")4N\$F%@5E|H|U|S|IG6.L8N6:0;=7OS-E%=MIQ#<|%(E:YN(9Q|!K?#;.JM6=:B2BS.
(RU+@?3 T &B|O|\$ MZZD0_-/K#^Z/O6)@0F?&4069%WOX|\$5.FN6.9UB2 F:3%*"OP7S6#KPP=42*.MDF+J-
MOJ|H9)ZF1K8 M|7=5%90Z?KJ!=*QD-GE@/74A"+H4"P+ *EPG(12:13M\$ T.2^A3YPU;|_ MHO0.%W6?S6|LTCJKH#
(|P5|)Z|^|>"E2B"U5 2NKJ?K18,N0Q:%A.9 M7^UGK+0%AKTKS?U^76ZY|)(Y\$|IGDEY.\$ QY;DY*
MKU|S8V3K3L9_|^L>@-R3|NL. 44'7M">KY@R|K+>*4&*(8*RME9|9 W.9R^2 M%2SFUFV1#()\$C%UBR MR:-
%|.T1^;L|7QB\$D*/%X;HJR|U8WKF.L*G,&R*,&)>@O@1-C%CT:5|3/MG51S?=1T3| (M#(=4|_13\$|H&^M-
QDBA8A\$&.%X|_8HN\$F|U<(2H\$XN"U'22#;452-N7C;=|9R(>_1'10RH3/K"
MSD\$#TPI5Y>T1"VX7&R=1D)NFZG+XRP\$1WSG|*00CL+2H+EFBUAK7)X+.
M6(O5ANBQB|4G+;F_&^1^;Y.NHC4B<^?|VD#B\$5@0L*7\$H%F2BFAB6#C M|AS6J02&|^T_3T9;ND9XZ@CL%
D:4\$|)|TX+CS):8\$?>9 7ORPSWQ=I;> M#@C(UVY_<J^OE3;f^j>Y=F.?WUQ|Q^=-B=;UZ%Y;+=0'5X04Y
WYXF^*.M0E|E5"CSS>2)=2Z5^O-YHD^O@P'PK0K|_C6UT M3|MC8_1 F|H^72;
<7A|N|IN'3NVS^SD?Z3XUAR89|>6PS=X0<3FX#>9:1 M;:1+LW!|0.P<"(D<9.:8W9*N-
9OC2>S@7=Z>%|V?'*M|JM<8# DA\$CQ7T&/ MH%@=#\$>R+V+|%8XGPRFUA;J&1%=N<0!3|; MDG*,M#N
RQ|X1?_JN|XQV6XJG7|^=-L|JO^0 WT?|K;|Y7|R5NC@FU?\$. MF=<%CG7T1W81C\$U1;JEY|*T#T\$\$\$3EOC-A|QM-
2|Q#<%FIO..&R>|5X 1%D MM>I&0Q1H(2 6|XOF:MP.SS?43%M).1ZX&LF_.R21.5Y|GBMVP#;H?&1<-Y;Y|J|F-
5VG|MR;:Z@|U&U2A4:|(LDCA>(J M#X\$A...X...+B(S%9\$?-R_27JFVB|7VRM\$-\$?|99VDT"Y^N3/4)LK3|?ET
M6=K|ABM%*"B=BZ|4"KY|T/MG:05#8W^<;K)<.<8%9'5CX1V28(L|S\$PC"4#_F_K MLDPZH8GB|IUY);:K?
M<+5E")@52|<|*(K=(2J5P888<|f;56GM+P@95H0-5+THKW4)RZF?+;+=)|L
M|1P=HCOEB42V4\$(3R+1E9&,\$\$).D|E|R|J53MM70H!7|S)M|J(M,-I*M_1 MLE?4+2R3K+
_7|5|!|E#WF0@23EH2U.L=QZVO|WE04;R2,Z3\$.|H6|f\$S..* M8VX<5R(9"+H&+<0\$^*0*L19CDXE74;UOI^3U*V+="
&7@+9D0KI%|7FG\$4 M:RM/OP#%4=9N? ^6A5)"-%GDUE..MM'1\$9*.5?0>(|HD|2X;KK;EB>^;|ZD
MM+P)5V_R_|U97;^|Y"R;)B#N1&Z PJ|;KZ8V" 9;C|H3^?)^JPLU+|3
MWGUCH&ALV7=@EGX|7V_G)BV6WW|ZG+7024)D1R145|UHC%0|8E^N@E8F@|_M|&(7+=,^7(|GH(C?
SB*_ "V*YGA9G<C_1|WC_L#KZRO_YA=?US<7A45A_%
M:2N9Z8*|JB&4^MKOP1N6@#DO&|T@S7+KB|X|29MV9^6I;|)C==,W|X99WX1
M:KSD>180(M>@QUH(PENZ_H,J|J08Y*BU\$SLFEW9CVZEQ=Z1E.K@VM_J59FY9 M1;
(8NHZ|X'1^0K8)@K.NFZBY8-TW4ASLS8^V1NCDWOP0J7?=A?O+;|fE;1:N M?IU7-M>_P4.1P* S+|CO.6?S-U"
|*JF<P:4807/4IL2C=RI'!*|UYQ-7|L|ZW*AFE&2L8UV_) |Y)Z 8*V<D?ZG M=89L"QGMRD\$>_?#;E*E6.C*3R NW-
H#*Y|I%JTO=N\$P|1B:9;NVV|J9FZH\$ MX_2_NZSC**EWX|ELL0;K)^.47+)U)I8(L98B 7K^7(YBKY|+)&G|
|Y|NV+J*^J^|_O'86 MG8+5G(\$RKLK3%_R_B>9^70IQE-8|BUT'_B(7DM /6T|&_J|7:|/_X^<+ M+
|B7|P<90/5E6JD"^3@\$75"U5 MJUUT+\$7@S+&.\$C-3S5?4|48M"XW4"RO1(|0.9Z7O6.0Z;0&|H(UTC9D|)"2 MX^
B&7XLWC&I8Q2F=2;H?7F?<_H|H6M%-8#|JF2>OPG>1K/6\$F>|UE?H*1
ME145(\$A%QPB%#D4(WGK)H|543T54=<|B#K&6Q5R(IRV
M|@R=RZ!>L>1(C(6X|V81YB"\$+4(L+B|H|6+Y,YS14(5GQP%|G5(0JTE M"i9L)A)+ "P65*/MY|L3B_XZ|4F ==#0>RN
:4XG1(MA.*5#R0^DN7-9TCOHF5:6(WD|3<1?*<VARQI%1*=+*!_)%PT:O>1HF-C M|_9M6Y|_|VF9EJO|HVV|X#0
+O \$2/3M;C#(N%5/;U;EE#)0C"QH-MV" MTD4\$8:1|5SU+1'10>80|3Z;|WR;J#O
RGHBP>VRR3L&7\$1HLR1_+O@Z_*^N M_B*9A.*BUE)YHUHG#IX1;U?|1)6CA-
U|UC9>G>_O>|H|MUDD9(%#X(6#2IY^M)4A*(AO&C99|A>83G%<D-KWQ|S|G89*Z |2WSY|WM?@_W);@_FTV)Y?<
OO MV^\$8/_UN+;7|ZIS(H.\$|*0W|H<72W^60|M_9<\$1LS.KBKU451(?)J<_C|_M=%|PO|3Z;1T
M|^EFW6|RIR5Q|Y_S)8;K*IZ_TQWU8^U@P3_#7Q>|8=8I%K>+2CT\$90Q\$CP/
MB>R/(|DM4*NOGB;U)M0^YZM79@X@JENH|Z;C|P>=>5H16A*|D1:30CO_1R+98/5^NQ+>TG<%AV74T7R2OE#
D9M8@UCUEH\$V= MML0+TUMZ4%KW>QQ&8<^|RD+|K0HSD M+R^7M^&#M6@_(|.#Y%"_+)93|BDI%|5PL"7
O|_ER|LG'=@%LL_J6T11>=\$8?0+02|WK@D\$FR2<2H7%<C_W'S56^ M9R/R\$/EW
*.F9;PA2:9="L|3?;CWV8\$KEH\$F61A,05!_V1A|FWW|C|B|_C=F(M/\$2|'2|H^Y5)XR7*N-FL1-3"1SG!;3-*+<
/G#="|_l|@C_(@|H\$B#Q\$E1U M|_6>5B8)_Y_@\$@A@5*R0(R:3K^SV5B%_LO6G7?_*HW(QX"QG=(Z0_K:VZ M% "YSIA
V^YY"TW&1V&OD<(ZP-|#_173|_0#9P_O%62Y MB0:RYW63#RA=*|U.SI "3|QO.EFM24<L."TIN'8Z9|Q=#7OD|Z7!??
M:|+O MB|6L*O3^0>\$^.;MMIH-&LF2R\$j\$|>J\$F@<=K;*"%"9GMDQAZZR.*)L3T4M;4 M""B+*;76@;UF>F?%O/KV?
QF</:SOY;7*W^_!CF7/Q&?+_CZL)R+9)1@NX(M|HZ*K1-?>0M=4A.E.8.^TS^E_I@/Z1/1*(S*A_.B3<H|3P>I
M|7<_I33%<V_2>=S+|KKYNU->+W56|JOR^6UY5Q-5N.50Q|""VG*^M)JL1 MBW=UH;B%Q0";TW"3AP+AP-
C#I@V;EM\$Y5CU"IN|O.K NM/SS|H_K&F!@O MC00TXW&O.*AL:S G\$VCF&'KCO1&M^T0)+6 (MAR-
D_&B&GKPY<_M^7BX28 M5|^00"N;+T59|6ZZT\$%)9U""L)ED*M|L;&_(*^_99.^KHSDGXE)4!_*B?1>MW_ M3U
MZNFA|R1-LY6B>3AHM59%O9\$N_ ^V.VO|S">UG3;?IF'LN/835| M\$S\$V4HI9M;+F|N/O|R^K'E?2A/3C.I614EC?
<_XGS+9#G78@1-8R*PIEH" HYS.OG:2:5+A@+&2?Z9;_*|Z MD2!%XRPWB|J4P|L2VX51|VRUVWF?>@;|AT_/P&ZPM'
I:19TB9>U N M&XA&TE\$LB)ABX|%-Y>%LI_@4D%PJI%ON%P^&ZMEC)E|DK7A

MVP8\$OT.!@UCX=\$H/E6N\U7B5R"/,PW.VVK^W"")4Y_8-Q3?Z,\$\$ L2IHS M38*H8X0B>59F0G ?
I^.,\$W@=:KDC=%*2 W58 JY)A%:==, MZ^"C\A.6X=XU%CI R9,D:1%\ ITV2W"FI SO*BW?SY MAJNM M:
IX0WKF+9+B5". P9@BER)"X+26W3GOMOU= J5\#.,+%\ -%0C371PA>X:1AUT MSBZ*#12X13+A@E.XYP(I,+GS#-
/K0LWNIPNWUJG>XZ7ZED" #G#4=&Q@R3FI M\$)X.I/\$>_3@BO,08C*92^%:1U2?_ CY0_W-80PX^IP^?
(HKSE+X\RH\50LUQUZ" +\$3(EYS M%772 M3)WYDT.AW#;LV4=I&0_4^X13K@3VHIO"1<+91%)DLB,3JX(?
\$(^12L)R# MJ): (5V:OV3O\XF+*,^I(Q6U3_P%2G/A2^6WQW_3MC4%+4DN#ID RFNAFS(13 MB1AC7WFI?Z^&=VH-
I#E+)H(*\$.%'7C-ZO\TT"Z\>P_ "^\KB;P4;9K MGA_IT?_J_SFNI\T^T^T(1_D!*Q_IL/^FQO,,\YM\BIO; W7SZ%)9?WSX,
M6D-T(7@.2K-"\$LL"O&0">)&%HU=*FM:QV_1<H(R=Z0P<7H!\#X)5!P?Q+C5\ MR^7?ZW&^0K?
85W.*E3.UH\A=,\H(OM=/(E(L\4(EU\I26PNUVT=)W;Z Y3 MBQ\$4W_%0OIW8_DP-%XX\$H;U\$4"5Y4%)8<,0"N\2T-
Q\$YAM;9D%=(ZCJLZ\VV M+=7=7I_F\T7RW6L?GL\IWV WW&9*BPN\<>OIQ8DW_DU?7JJA/6?^0B)QVE M-@:\$-
G6%#A:@61!?:/Z.O,B-8%10<3V\5WT3OB3P,1#L!;=:j0?;_?DW M>SHFY4)IP61\#4^V3G5R@8&S@M=9I
("F8016T^IV\>N::MESASAS17?#,RG M'5=S*EXE!^=A5QX4I%S^IL= M+9F;92#2V
MEK\$K"+D@E,"MM,E+5H7TNRBI9?D0#N\+T900J=@VF3 I7,R<,8AR\1)10D MJ\H&2B.*TKDT'Q\FYJI@54&VW0
:\$#1-!B-^PWK?ZOUR7V^SXHYO2M48
M&>QHBP=F"AVX8IB+K7NIGA'1'V0.T>ZBI:@G+2O8VSH_Q#4N2R41B3=6%PMH
MDEE\$XA)*#L:@XT6UWGWZ\W6I9I)'N^&4E0'IFM;S'LA#=-*F);U,VK,=")
M3,5!D2I;.D5Z181R#8Z.G>=#M3Y'DF'00KH\$43_ ^IVO-1-XLZR"O@(@^15)W M
R\ C#E0).C.PI\$ _3;\$ (40VD<I>JHLXHZMUMPI70(L=JRO\BY_H ASZ\H M#&'N,/(N?;)-
M.MH6XX5VD0B0+ZRE3KRP%)'(Z2W24748^S\W4+!;E;I^V")D#13ZQ" Y& M,*Y_6GSZA,M:00)
I^ (S+I\WY>+RV7XME^<%G%JT"9K6HJZP\$>0.LD40F\I' M%+ _)?JAWJ"QJ&Z7(PEV*E1FGMGI'W_8\I;IT\^65QJ
(2?O=H\OF\LE MKAV\NSA"%I*EE\$%M4\AM#03IL;8^A.<4^=:/A M7>#P\N:OM/@#YI^0\MWB&N^;J8N3W"?
TG+C^M73SZC\97MK.V"\$Z10:F94@KT%7A1 MTZ6)N^QYU_9;MTAM)60:8S.&[WN\G'L\$R^8L)84&3>"@E76@C
I@A.Q0&,@ M4^2NM.\DV\$*Q_ ^QROY=@<(/\$./\$2=N8RCH%VS&D(AJ.D\%P5MC06OT
M4;.L;N4HY*2&>@.43%B\RI@ST;_KEYIF5\KK^NCO)1#5@L;\$BN". @9
M7*)0.FLOG369G*_6"9GG5\$SCT(QQ*1TIX>XPLCDY7BN5\5JPRD1RP.*&R\5" MKL-\$@D'O48^*DA\NHF-
U^R)4#A'T\I'V"13VSORRTG=PD"*Y1/EM^XB\J?40* M\CF%J=M;1\$/J>B)Z++_Z??0L.^L4#)K9\<)HJ9;7S+%2
MG\@ MU106D%FSH40'03E.W^23A_#D^NJOY95UB;_Y*^_KOW'7YO&\$;RMKD4#
MV77U8+Q6BB%,%\$B>^107&AP\F8.X;..UH:S0Q\^1"O.E";_ WM2(HY0%P3 MJ_M;2 ?VO@#4)\^3B
+0ZCH>A.X\WV&X HB4T\$;S_0^X?OY?23<^6O97L MDE;_TR1M^&OVZ>;3CXOE7DG8_.4+*^>#DFZ?&?
^#L\I.F.=A_8%E^\$2\X;S?0C7^)\^ MT9^S3WC\K&#;.,J9H&-IG\$5;IC \$/IZ29&T0=YHFND, M=20D9;DF_TIR6IH-
>7K>@DSH8XA)86S^CO/H^IV\$7^U1.TBR;#BSIYN)H?? MHWQU(8-14JL,3M4^QQ \$>(\$B%*!N50^?;+
(W<0LQ=>I+G@I8W.)P\IC^!0M814ICKU)0_!E"N@L6DI2;U9HF>)"\$!%P@U\$WT,*H/Z7AT3&)\$+7.H.Y=-
X&A4\;6%NGJ+L=PS%\$Z^DJ0>+N\I\H%G= MH NE:(R%(L(8228I42#@R)WC66GT5KO<>C+IP?
6W)^JA/T^Y^I3@#I%TAVC9 M5)5\$!LQ;_!KHTRGTT\B -\U>#.T3<8'F>7\$H
M%Z%(@1H*MQJ4BW5)\K\$BM%5!";9;=IS2\8UN(GT^VH\A O=X"3+?L5-1 MNR
@ZPGG@5*#@3C>\$X_AHZ4LK=X>31G(F*17K M#61>Q<(S0C0H("G0=A2%Q;B\;)T_-TO&^DZ&&"S\J M
'ZR@8\W^I0=*E MHMB M7"WA\LA-BR)'XS0W_+DO;)"%_SEIG.OXK@60E@6/8178FEV*!>>#I\5U*
MK9'32LQ=08?>G88?&'MR"1V3&=#H@HA@;+20F3T%Q&CC85Q;QKJ;TAW^MT M2E0;Z#025((27=
D)*"2S3@K;.>0(W&*.QTVAUZ6SW_ MW+2#Z\$S1S6QTIY)YP(^0M2TH\;P&=L8Q9LEX1H=T;.>J?AT%G#SE)VE;(
MDI\I>I..A\ 9Y#026(2Q)7G2B@%* L\ 6"C*CO_M,1F%>VT&V/
ITQ3IG0@YC<3<\$W0VOIOD_%FX"+OI#!!Y^QS)HR>OR8S*AT9(G MQU36S"@G#^GFV/S^V'G^--(>1"9\$AK1
#*>4^MQ@R1*TIUCD<3L MY^T#G7%('C.7>%G8TAU?9P\$CT8PQ60?<)R207I;_ M3YR#P\1SG58M\;
7SQ>^MQIVSC2+I\$K;6&ZPU/ZGE\G.(80)0R%VK R;_ MPIV@DE1PD>90'I;..6'FISI>_ MAYTSSR*WDW\;
V\K(50I@GO+\$4C8J&@7H M9_8EZ\$8..BARY3(&DF%&JP?;G=W?VP\IYI\CB3GJ<=T_?K+V^ ^88S96\<
M^4\$ _2U0+&O4"A@72IY_C_XG&EJN9&4 M#P;.%US&16OHL#NFS+@0 C;_5CRY0RRVLWH(
2ZGDNHDX+0>I\X3N MQ^ MT#G3Y(C*7=HP+.)N>L\6\^;D@_OLU9*J;=&5\DO_46+5L8;+H\$ 4N!5*N3!//HJ>
ZP=V? MVP\X9YI7;B3EKH\SFRHGW_I9TRX/Z\$QP'(ETZFRJLIS/M0MO=J4.GZ;#R^I
MV\FY_8\SIDGE1E+N"3B;?)52Z@?^I/T-&R(*9,5K0,95""@2E(@I\$7BI7^ M@+>LW=;_#SIGFE-
N)>>>L/O>7I6B'2C4=\$S#DF0WZ\I\$?>I51D.6C\5N?UU M<
_6H_MAYPSS2@WDG)7P+EI8%Z.4MH3*#E<"R5EP'2*58E^5B,9D@4Y1R M>!9PY^?V\Y))"D')7P+E-
_E\8^*R8Q\$7)8ID.BT\J.D:DA\$UAHRH\AGK M6HMA\IXR^?V\IYIX^/E7)/P-
G\$BGL;S:R15\5C(5FL3RD.P3LIU\W03.M2 M0CRT%V++Y_8#SIDFCOM)N2O@W-Z^>IO?9KA5@H<*"HD\Z<3^(
)J3(9.) M#T#.[N_MURU\INGC5G+N;BK*V_N9F\4RI\WS.Q(8E-Y_S7>F\A.I(2Y_FW< MT7\O\VU#.U%RI_4&
I7YPIJKG+M;I^T^V^6\S3+I?W0S-U)\J002MI" _C.FH MD6B0\4N)>XI9M4;*RQ3U_ZE#7@;J
#/'TKH7+WA\$B^P,"Z+ M\$ \$>OZ\^6R:WWSLH7FIOZ'_XTYD6C2^LEZB;?FI@*TR\>)TU4U\WT%OODM_% M2\$N\$
Y(G\TI2;_ \$3V#K<:=B;^21H78WA0\1C-9)X/28(W%)GMPKE0PNM; M;@0V<8H(C&#&@E"C
6;@AIY\;UI\$>\$3@/!=P"?VUGW^!8#_G6&R>:(6G;R4XC_HJE^CI UMV MGIVPI=-B=;UZA\<70*A<;_U28^W\I
I4#7R\$#+8H2SE.8FIK\3M)E7;2TZBW MYO&BXX@?XN@.5Y6)^S\D9R_YR\3XOE\>R;=<."76ET^I+_#2\^50Y-
Z) MG);&S2AJ55%FD358"Q*BFZX"6S78=KM9F^M\$;F(N0_V;+U\$XD-B\I'P%._@;G5_TI=-M%/_* @DI@#B0?
KI"FL^+>;K M;_IHT4XIY"WGPH")D\$%_%HMWKH\ GD@0.41 N;=I/2'M<.TOA_.1ZJ@ SC\I
MLECBI')^YRO=,7173\$W.<."*@V%1@_+0?";_19A54*&'EM76;Q(4"^_E;O M3\YS930;_
(VIOQON"*6;G53#US1/L@<&7 CR6IK6\LI'_.=2;).BV)\Z^6+ MVRF9^DU\B@NP@4ZZ1;FI'"?18Q_QHRX4HQ04-?
&%\$W@;I;X MM.RI@?OT*EF\I0>H0_3_SH_HJHPM;3L?R=I05VL5C\^W7#Y;JN4XT?9Y_7
M1U.D4K1P\H1DAJQZ'A\2#F""\$YD7-)ZU3@421NG49;ZIO(V=-=H\PL3GB MAL(@GHL"QD0=1NPR!)Y\K6\1 IM
G(UTKSXGIA?7?SPD;+I\XCU1+!_CZ)"&H\NQM848XL&X\$^ID0\CL=;=*%_6,3O&MRXZV4\+%;_7JLEH& ME;?+O
/D_!16"W^Y6OSS6R9L8BG+NGA*V%!!+&\$BB"QTAIN)"CK9,3FI.G*V\$ M3\MI(CH;XR7>_6P.<I>WE>W(XDN^3K4+
IM8;I L>.\$C."DPFRRYE7@*CVQ? M@J=>7IB-8S;*ACN\W_.EQBN;HG.G=GW*RIUZ*N_XI%>)J.N&_W@>R?_TI7-
QGS3XM/GQ?S6I\5S\%5 MBP40=I LE"C JEJCY5F")0^I9@K7&FI^3Y+S;IWOEE;X^#UFBZZ,"P_1;^ MFGVZ^?
0JHM2O8UP?;.<77H7S8/(G>5\(_.\$+I0V415DYE9"0X*HP?GE0;_ MB\$4AN_I-
DW0'\$7I^"9_VIG\K4YL&K=9^<>=98H;%R\2>GFAU5S76^O_Z(MRWITE_@IYZNU;M+B\$18?
I0ZOWY<_PUA7&C(P0H\I?G@>6^QMFI^3QY^')_ (#1*JQ6LS+#_ (9I>@SP6G2FA)M(X8N@I@=>K5WE-9IU-H
MM@;_O^I2W3%_#"NY_7_SK_2SK5;ZL%KIA**^OHG;6.78I8E-/F9ABQ;_ MF<8
44J1>_3P7@4YBV&8"G+I/W_ (WW\$?_%B+ ^YGIU37^FU28U6DZ O.E MXO2-@?)IX/^8KQ)+KB@)LB0,58(&+0)
I3JHHZ\I'9I+J\I 9&F#_A(X M>@1EM83;_@3VMH2?10IR.G<^P>&H+%=+0W7;@C>PHV_*
M;15I>A89\G^NV3R\$/T?4#(Y1\D=X.O=@ESE.ZIN^E\DM&K"#G793;PC2_M)S"UR,"8&*)N;9>VD-%;4=;_!PKI
IPW(L@=@E_H_8W\I2#38R M+,*KUE60WU>)\I2 DI%UB.TOM>I K1EG0\YM1@J^);M>1XA)JD@8R\N&\$^> M-
V_?L2VT^JWJ_\$=HC.T#_CHD\@48(66M&R1U04A;PR7(P@N7HC13)M;XR
MSZK\$IAC<"_Q#F#S#J\G7_IU76UTD\0;L2%MJD9L&Y5B&8+(\$\$=#S*(I/ ML75'TVYJIBW"&0=C63?8I>G-"@Z?

YF.05(63-B* L(-B@0PEMN%4=GQGMJ M/7!N2E2E7..XYP2HRNL:1G>@%I0""Q#C8'IW.1DC"@DGY+S(H*36;'VVT3.
MLE\$-<+!*%>\$##KY7?%>G!%-*)00BAR C\$@Q1-DN*UC+NX70-%7'AD>^MV#T7F1@/K#C!<4VJG
MB:GAA)=/6;::!6XB'F16(PCL21M(62?7R;ZN!@S/*)J.-:=!\$QS=S54!""U
ME">RL!WR!5G0%M%R;G+4BB04M5UVS7!4XJ1Q0Q)@ P>(GV)CD54VGFKG'UJ-L*
MTP^7BR_8_3;P&P^1GT?K25=-(,JR2BXS:I@&Y!U4K7^Z=Z-B^R\$B(76!^A MH0N>!0L>)0F4!#='!PENY?
3+^-"L)-W; >Q/T90='?K8-NC!'"MBH5L=^#U7='09%&3+7#7W..CK-R MBNGQ4W9SO%#@#N/7VVI: ^UCM;?
T(-D89%\$!%I8*F:IESG-8>; M1RHA)=*YS^DDZR-&X>[L/HR#!Y!+=E)T-.5G/E28>3D#5%*T"DUV2&L!2" M6
&>&RD,*!;:198&G,6"B@XP-1E=HA"NP+GEG2_"SQ*A0\$8HA:Y!*>#DH M\$;(HWD8W7C3V;J97:0UH>|S
Y100=P>OE14'M;+&D\$Z" UA4>1O)23X'-(M!+I2V/93! T97:0W@>|S Y1PCFIS**S/HG
0%H>25(Y@7.HH7!1DM6&^?Q: M!4=O,P>@I=11-R!\$=KA\$MQ6K&VX;IWW?)&@::' M9FK?#TX'Z*
#0*WGF!W_C'6K;DVI5=9^_NLSSE=WYJ!>^8C,\$8J)"E00\$1QJ M#G6)AT;BC2M0?4J45T"ZQ
+;4Q!P^H!+&N&C5HK)87;O?X0K7&U8<"DX M5!@%9Y#7^5^-! OTF! WOTHDOQ!#1%AR!+
M%A*0GOKKK%Q59S';VE4=DK-181ZOY/LERCIL-C/(1M!R9/NAH';1M/I^(<MT?J"Q+G/'")E0"&%@I(>F!N:
248A01O20SVF%B,85Z M.C"B+PVMW3HBI\$,KS7?;&BV#(-!FEI6K5R.N!6I-".96Y
M:K!H!LRD#T^#ZQ*#;YDA.@H#A!/>W!)_C917*GR!%I9T*A(>O)C)A7\$SC^_9!DZ A>D/117_WD:!.#00*,5ZGT-!
MX\$;42>A%0&#&0U1&..VD*TOX<>;3^DT?OHTAZ!#W1H(!7X;JESWX_?W7 M^?
7B5C3W.D!8DV\$H(9E\$/UCC/Z3:WP5@(- M1W?I20&Z/5;K31*HLXJU,-.94/L8.7A7V;>*Z*!-
MZQ4(IZKMPM)OAZEB/MNHV2I<1\$157^UC(B9+6RB2MCZTGA#1FH0M'>@J MCZWNZ4?SF7:+9&
(\$05+1EH6!UM23M!;V*15X,7O,QRE M@9*#!<!)@IPW M!;9VA_OL=WGT4JXMKAI&(H?G(\$G!X0YA-
->>F2.EG4!W3.N^B14G>*D)RE M5,QE\$;A!*(^"/-2I>^Z>P;)MSH9#I(S7_6>3)/48;DL>ED\$2;ZW3.G
M!YX9@O<)NV>&H*>#Z/RE,K @DW%\$,CCMZL,*@AUF'HNT9.OJE/FK9^VCBWF M_!YZ9P8A;\$
QYQ!U!HO,NW4!/C\$5@(@)R8'=-YXA%IM!DNNHE=|8NLI0F=: MS#E(I8.*.8?HH -O5X^R#)%1<8:R%(INF(H*
D8%625>#96,I-KTT!ZV+. M00-87,PY1!L=P.O%:C80L(@:AJ-EDB159%T5AW0F3;\$(\$DZH"?P*0?UH7X/MC1"W*7-
%-H5.+2%.@&*;HC@24A:MSU8S,YZI^G=E^P@WZI%#J!+ M9RM?WR26M^PUO&?1'5Y?";Z-0?)P!/\$,KFX&W6(+
(DBI-P29!D8?;0HGLQ MJ^VPM J<1U/KL:J02D8L4!43+??:1-&RV+"OZYH!T>H>"Q
MGK9=UH^JR_LK J&>U=OK.X4SL>-QW> M0"/>=>=ROFG1T4!0L&_N: 81T?N0\$=6;JXB@Z.X'5@N.A5+419O_8"
fG9)I M=D+3E!=(#J8:5U!>Q!U>RJ!IM^+Y3RI=GX5_@<(O0/PI+!O7LEHJJA)
<4H<#\$(C@4\$U%:AY#1\$W;ZYU6R>H/4 M(2! N6U548^JW(C?2ICJL"SYXY7*)J068^%"I@#>>/XD9X-9FIUKG93=
M0D872V_!XN=887> EQ??/\$QD#FO)E12UD!-H 62C+=!5;S@&6W0YQ6*+/IXN
M_6IFBFP*S!N>2!111F#==NAI*4NL9/@R)V 4\$+F6B>?RGBUF6?U5#E(ZT.> M*H>HH_XO?Q*IK2V&
(GZHC@Q@W4U>5Y/R)(4*!#FE7KO_*Y/E4.TON@HHA M2N@ 4>MVD@IX?;<_ 'A'G#A\$04+G_%T>6U"T'BD3H
0V,"G43!H0-\$WP&@E-BYS#+FW+=^N9QVRZZ?J2?K-X?7=@\$WI"FI=2R !I^+DRBG !BM^?B&@<29#L*!G.M
M@%(YD3/A!60N(Q.AUUE,0KV!X-H-(-K)! =)^K)QXW>DI_2!@:O#!(=YHND
MZU!X+5Y4%F9(=A:OY9S"DF077JJD!/%=CZA6G=H9X:"C,7@S(VUF(LZOU MP_Q=J2P&5A(K(#QW%)?&
%X(A2FQ)H+T9RUH7;3LE>T%G IV&0N!H^"MD?TLCY>UHE6%V%#P@CX'X.@*4HX?
AC!HH!%9^U+!\$_.0M"T0.HTA&NGPIJP M>_+^T<5?NNKFQSM&B=?
+R%"A=7Z"29."!&#@#6_ WH*YW73UDN0!&@8! M=9Q_ WCLZN?ITH+MJ4D@6;:-ESI@Q%QL&"
<<4JB4J3B3!MUNYIZR4E>F*! M::;|VRK^)/CMQX"!@7";4L,X?KASKI>?B B7XZ73!_AM7LY&7HJ2B>LA!H
M)+EW4(H>+\$!Y Q&)"07Q";P4DNPPGEO'4H&?T=:R^_U_ CU_P_<_E\$?7QZUO!@E2KQP!@B80GH-
95WEYP!YIP"9 MCL9;)YUNO>I@/AHZJ3L_+6QV@;>=#GM"YD::U/PG+!VD9*RO\OM<3_ M::A;J"Q\$+JP0*?
K2?/E(-!P6E#A.P"87-U!83%7^>?;ZY7:XGQ37:"ZQ#L@MN1&ND47&+BD7AHP6 M;\$!"KT\$+
f2H"24QZ"&D3@+7\$1!HQ1.8<8ATE"2 MD5SLXC3\$(!2T#(ZJX5QHFI+1CH!;J>(LG1T0'Q^Q!KN9"ENQL*
DH9C2@ MC"7ZA&P!+!@&ZZPM8C"5X81=0Z9D";LNY M1 /H05?&%=8E#;CC4
!1,CYFH6*#M42I_9L!/4D@E=3+IMO3UJ9!\$J-F MRC3_?+J05A8^+J&M'KR=W_<
<(07)6!^_9%&D%\$XRZ7_<5/ZZANM%_ =SZ M3!\$8QYQ+\$,B+I^_N\$'Q!^DL,S*-Q*I?7X+WGA!XWG3X\$=_4T#66?
U\$5%_&W76H>P2/2KP0)3NB0XM-!LW#8^R>Z^YXH=T_@f!0E>(VM! M%K4)Q4L!3CF!E!(!"QXB#JCM)
(8XN/5,IU5Y^!@K0_I_!VB@!@!+3J=0Q MV:@8:"EJRHH!%Q*F+Y)5E!>EMIR_!3M(HX,Z?
X@Z#CA3YI_!J+3L!#"!\$2!7^\$VP6 ME97((4;MP=3)#=K%F)>^>^W^!QI"UK'O>P#E?
Y!)08@#72%I>JU\$N=C,T"Q;FJ ME%HQ3=,PVU(#D7@UJ4>;L!H!Y<P"#FD:&*;+N9+ZJHC^OKB;
M!_7V%:=Y=AOEG_XL!@J#Q#@9"M*J2SKHU@!+SZ%\$G.1X>-N+Q%ZHU&(MUUY)TR!HW^:87EW1SUZ&J_?
Q:G9YVU:VN'4MZT!K"V>D*!%1Y%PIFU5@!8+A M"iAD\$;U+F/68BY!>HJZ7#2.C
+!I.GK\$WFI_C_N;3XF: ^7EO+NNBZNL:5SP M009=\$!&=&G*#/04!3D<-* VYPPPY"^_!Q1I
(!+3=IY=TN!4>;B7^&33?>-W M^X=GD,*-JH \$W6(LZG#!0.%!<@SQT!2MMR_C@+R8
M77Z!KNYON@J53VO_5W Z%W2!\$4).5<H)0BK6)BEMD#L!*)<I?Z"4O& M@UXS072%MIVUITQC|<_YI+>\$+
HQ(O!V?F!0%:07MO!MP1C'!60"F4(JMA"G#L\$4 M)UT.C1R#HI6I/!YS65NM!P*F9"B;G&SA!EQ?+=CEU)Q(2Q0\$
>2C?Q M3C0/#@*W.ON3>7C:V!@/WH83,EU&Y53@&UDY7=Z0SWG>EGB_?IOXYO;U=29! M3)%XUMJ!MYO!J)%
f'SCS?>_E*;)F>Z.G0Z0394S;2!>=>?1\$SK)NV,12,K M%C)+=6\$JDO"SH>L@R2*C#S!K!JR9SF@!C")>2F-
!NW6S6-.EK_0SUDL MC^KYVO)VK!H!Q49=HPZKN!H=W=(4ZQ07M9NU*(U*!LHK@!@Q9'F8(I*=TZ M2?";
<<:IOL? F&@V M(47)AL04(GFE2HD#7MBT0KA#RU.ZWUT4\$"HZE?RR6_7K_?E(N"J'4LD M,61)(22?
R6!B!>!%*"!+9C\$6ED)H>:P!UG3OC&.#K%&^N@)8A_"/W^K%_L M7#WA*\$21#%W'H%U=4DH'I;Z?IQ
Y%_4%3W07NJKD=JF?4D8'6!MM-\$30JJ; M%Y514F4+UD8%JI@(<@="126"PL>L?6IU/03Y01'QTS0R7_#)(&?
UGUBJH<_MA/8;G!6G;ZV!C4>Y^RN&^&#AT MM"G3R"C1A!W3?>S/-3(K?US"?\$/
Q&!HJBGD#E8RA_-BI/ID>+V&5;J!V("ZF14.93:SS=WBS7*S2#>I M/KC?
W/74.X!9R%HOZ6P"10T"QT+=ZQ>#YH,YUYOSSM^+3YHS::R&YB97_
M&^99"E= W"POZ!W#C"N#4A0:S9+97KKW(f!Q%-S%RVJ&_W4/W6'SYM7J>-
MXH^7VM3%3S/Z_36N!J,6E0W&1^+7(@DC9H2_@H.M46>/_@OW>RA!RX>-BW3
M1N7'2JP#W^_)7Y!7P=HF9%#J2!*=7HRAMP4EI @BH+3#\$66C^C/R-BXHM@ MA(#A.#EW!)0/BZNK7Q;+?
Y*#PGJDZXU\$4!PPEGP=V;K' M;PL9?:0N#E3L#I@<N6.@)A1#"9"08-F/>[L8%_JD_!756B=_ISOX!6*U
MNL!L%==1@!VSJ=F!CS+"GC6UCC'G9*MEQ'M3!VT=)8F&JLE9IL#!0BJYL MDHSF=);<5;Q&H(4W"%NE#.M6Y
&V9_1XIG1L!0B1YI?WZ>YPG?&M^Y7)= MS#C>_&S3YSFA?IESB9Y_\$06%N;H5B094L04A #O/
<>LA>V301KWBK8Q^-? MX!8M.S!^#=\$QW<<^_4>@<@V;> M@!H@
Q2@!AX!8IBMB!(-2H?I@W1/X!@F;3%>2P?%U(KD MR_?SR4"03M=D!TOD.23;O%;K;H_!BGVQ<>_(5+N!BW
91>3AZXE!KV;T@2 MBA@&LXZ69X5AKZ;IPI!303!-TA!KIX%#%);Y:A>6;+"VXURP7!5G"Z>R.#
MIP*#A*PXZX06^E!U-7S\$=7*S_YIK:GGW%Y8&0S7M;2YCC11F"5QHR5X&5\$S!VK0MY7Z9HVJ!-MMC&K*/N&
_6G:ZM9#!YME>\$_J.W*=UNJE=^_FOP!;E;YN#&&K;INY40JVG MED6!P2!.*3?^H&GM-J8Y+\$OR!H^
E*\$!G5J6(\$FVP&R,SCE4H7F?_2) M_UIVJ^,V?N1)1N3DNJ> M0R-"0A%6'ZF:1!HYA00^U/41/!7U!IG@::Z MZL#-
>(&?^!^%O!O8OG355AMTIS"N1Q9_FSJ,O2"D3%K!@HHG.(JK6HP4& MD-2+;T):A#S=B#B2N0I&X@-G!GNI6
FDDKH^_93W!)#T(6!GGTBB>R4 M*IT.C=M(G!;1HT%E?T@>K;<8/G3S>IZ!0F7'W#M6SUC<=/(Y2-.6H04E56

M8H1H. 6719L<,+&86I>HD58MO\AJ+L24T\?O:IS?+I#&LZ@Z#I'&^N%I<M?B5YW=B;G/CC?>Z5@DD'
H:DTU52%#@1E4625LGYE4JSTI-FI4I9#&-MD'D\NO9:~#@9UHS%AA7%3'TI('SQP4E6L51(#@G%#DAJT)K:~&
M%#B9-DUY2H\UTDD\T:~\WU\H)UDD:~3OBU+~\$6H(Y))"49VM*Z16?
MNGJH2I@J+~#U,07V#;IV/O#<~&QYI^~M)1N="JEH\$T#8+)ECQ;#F<~!>HZE;M=J
%.P/L^~JZ1MBJ+~Y%JEFOW(RP*0CRVWJ)DA:EQH\$Z;HRE/S=J/P*KL-M%D:80NUJ;/SIN^V>.7EZ/8&\$49%
IW(\$*T6M C\$9(BH%~WYLW0B4_YSL_H MI*,TY3I%=C6O=1320 MQ%Z>+MJCY=ELTO%4USIRMX9X+C:;Z/^!;~Q-
%1\L81%>W M\$~+M H2-52LXH4G8QRVKG@A,Y>|CTIW>6~%;_H#XO,M8D0I?)39>A3N// MN@YR9!
(2C_2/\$S,RA=."I+""\ZN\~-1,PRFOZFP&42GJ~WJ>74I^U33I_K<M7~?X_)RN4XC/\$Y?
/S79YR01AQY<10YIZZ /59BDU34NES(L@M;~*X^2&)D MZ'@Y&H4;>"RK>NW3MH1>U+;GG>OF U3\$C2U??
158I7/T?JTN9.4.%G"5) MAIYZ4I.~%;=5D8#0S1NJZ<4.2,+>Z)JG5<I(5#LJYC:~+@#IV.8R^~(L/SY
M3ISZ@KIMYMB%OC/7A#4;EPD:AG+6N>Z,XR@^I SLZ;A ME%
I/1#L7UG/YSI4%JZB5U1*TXW5S\$4~WB503UCIT0TZEI42I@PCMHI^R~P>MHL7SA"IA#RIL2_K;^~+FMO(077?
M\W_!;=~*R\N-D+<>I\AM7~VBDKDIR&12&0FZBC3K)*NIR/Y4O+V0I</TAC%XTSR-MTQ@TI#~H@Z10 M&C?~T?
HB_U23J(KLU_(ET/QO'G9'O\W4O/!6^B)D@92Q&G#B.%;42&>B%U MZJ"=O?GO<9(.8JOXCV3KH3A6&UGI.(6?
AF_FSI>=7\V2*Y7W?~+E^U5I_5G MMA"+86JB(Q+.)8@+EVJE.#@IGGFX&B"-8WY'W7=~<I-P#KH;\&UTU=.VF7
ML_100(7#6#N'I"O";878)5AASF#&2AK)4%1)3=Q\$)9I+H&N8IA;~6+>+UKI M>~>ICP/Z^?I8(=GV.P;4FS
_S;_PFM("907E1^B7\$YU=.JZU8Q\$C3*V\$ MF4G8^O6&DY:C&\$81Q~#ZZ7/ MO=;~PH,YF"/5IYI/3F9I
IUB^#!*Y3B;2)MRDP'Z(\$_U (I:489RZ:T+~#<M)8@GB%OZS?A7I6V_V JEZK?O9OIW;C'OJ<>FGX+~.3L/_<5W
MTA)=LK;IOK8KIN_?;S&S%IGIOY=.UG;@I_15I<~^/)>T_L8T2=9 J;~IK
MGN:6&F03TY%:"X,X5KIH6NU0\$&""^X;3/YXW?8.ESI~(D9<M61BYN?D6@+0"1_\$AE7I3J4L+~N86K,IU-
UVFJJZR MJ1D.D10.46"2P@0-G/DM3IG53D8207#~>*T:PI9EIXEF+2S-G6.6"O@I5EZ
MU>~;~.5E*90+/"AF/~;~@+=#8X;~IP|<8.Y36QDN9.X SA;~BEM' 7LS;~1 M1VN^ MK<~27XY"V%Z6P-
4F^F5I\N7CV9O;A_~SKFY3;^WG/'#M*?^?&*FCRJ? MK#" T;B\$-BR\$(AZPO~V)IM6B4(IGI^CXQCI(D/H%6FI:O-
~85\PIG&ZZ MVQ NYIWYIYY@.O DL(KE#L^FLS=6'E@~^G8;FS;\$HX M&QJHDW>~81H'IUI*);AL;AH;Q#E+~JW?
M6Q+P=~5=C K<[XI MR3Q8-TS G M)"Q=5F"FR^%\$27\$*H8);4+N?+~I\$M52T T:AYB.VI2^4=F;
I:32RQ#@A\$12QX9%SO%\$BN?6:Y<#/UA4O/7MIG54 M7I~^3G.5Y=6RQ<6B4PF4>4FGG
B8PDDIX<~E;I^@~60N9>~PB0ID&C0XS METOGI>~EJ7T+EDRZW;Z1%*~.@S^(F&9I,12864\$PS1**0W%C?8L9--
T98/ MEIWHBABC4I5?>3D;&E5?ZO.22BLD I\SAIHZ2:<7\$4RCI W;XOP+YO^2I9S;~+L=;~@471A~4IL7."C!
M%)\$2\$9IL?6 ^;&/HJUP #Q>YC/LA+@C(5N!~06OHU|>IUD=~!S?%L/NH; MNYBG I>WIGD?OVIO6AZF'N5MAN-
\$* MN93 SBFS2 O.D0Y*ZH89IUWN-CHYY2_K U?/^S%84,\$*V.&I=+)=;~#A8 M;HV!'&8*2QU3%T)/#
(P@~WYP>*6"9X7HDID@FYXXG9P2(+U9^24-P/C0<M&1/20Q=.(TV%1%0S2R4'9?+32\$&[2 M8H'U@3CV'AF*~?
+~"ZHYLSYFKR3=+DJ9XI7R=#H&B8RG +&K\$SZ/M7%WF0L M.'@VY#~@U/I/LE'I\LL0%JGD<8Z<9\$Q6.0R 0I/#.~<~
+&Q;G<~9"QR@(>+C'/MIO/6)IZ#5B^~6_1M*BQ<I>~\$-@.LRD?E&L O/PN9XXYS>WVP=8YGOJYB)N7\$*~
M+IOHZ01;104\$~YB# Q9?PVIH.+2GAKI_2S7SO2BA3I>IYE#?E63I:6LE-)(C M90>U@)~%*44AD)1@O;<~\$SITQ)9?
LM612_NQI_W%D^~D7P=EUMYC+ONEI/2 MPZ29_6GPNN(E&"+5=6<&=S'~R"~%ZCFI2;G@~9.3)GBHXI%
(% B8^~^34LGUE^VWFLR4UI*/+^^(=;<=FHQG 'IAFG M9^TQ:9"U.BIB FFB(K&KW+?1ITF<+I)V?
'+~G_31DKI:E4.6I=2)?(FJ M8U@X*3\$5)G>F8#;ARUK;5^3L|BC<~)?@V?OI\$P::TTI#8 MT3
6F%8;*YG=0ZBQI&KDFIO/XI#*\$F 3J-4_178:(<00U>INB SZO(N"U> M8DE8H;ZSW#>M_I0I(1Q\$J)HAW
(QA7P?~XI1%1<6I#PC2IHMTHAI3F_#7= M(4);YHG.G;5;~7RK/\$I&Q00.T"INTOI<~2\YT1\$SYE*JU?(I5\$&0\$YI8I
M0F7(G63WGJ8-X106Y@.OBHJ57>7U-I)K;~1C\$H@I@FX0*~)(C5"A0F0I/I MZND IQ_~*?S+
5CI&O6U(9\M5I)#YHG?07E)1^NY8"V\$%~IP@I=WLSA FG'M.OI;H.A;#B?"096@+WRG;~%OS:IB5'9(*MMA5U?
0%H+E4Y;T?T)YD_L;I)*M.(XL3BIR^72ZBZHI>3JN?>21XQ%*~7)4IOE4,DS>GG2W;X AAY MEI2DC4)&I<~;
(31B0L%US=UM;~I-3R3E_V870Z H,*")7"IK ZS>1^IX 6 M>~\ZK.E(N*~I:33BW*~\$F)~"IW;KF1I5\$N<8@+N(%8-
KV>~M0;G)TM=..I2Q7'AE;~O@.UGD^7?65?VIOZ M>BE?ZH82(I5:CC)0J@IP^GO DK> MWI;\$ J9=QR*?
S>WA%~JF+~?65L216~1 OFB+C5+(4M IC7F\$F'3^~7(N)0N /IAE-
BICC.PDKOUNIP2X?I6:V%AJYLV^_AGFI:G>S7IHIQ#I/OMV M_WAYLFV/D#E3INT3.DH@PI;'FO4U#;3B\$~!L
VC"ED#2?I+09%~+82&YIY MC1I@7KZIVG>@~6GP3R"X_IRZI;=)"I'9ID61^E.5(%G;_C=K+~4RTR\$0VAVI'H5\$
VD#K_YZQZG7%#2&\$8MHG>@U9 M#C-0%&E-EF2-(DCD\^EZ)B&AT#)=5ZP5YXU)%8^H^=O%I2 <8V4.4C&E
MYF^FD2+&(ZM8#\$UCK(SIO*Y99X)438>K:A
M.\$WG%>P03Q5T7TC";&R63LEO)T0CC2#16PE(*+C9#6\MP)2=LEJ24-IG4I MY*~PJ))-
ZS4&)U.OM)8(I\U6KIWUPB\$?J6TT7@;KIN=3?0IP<3B_2)TCE%XI M><I#~8HK*~XCY?;W8;N!5?
&PP12.R:A43*8(6.5LS&H&2(N4-J+IE4&YF.M0?
Y9(4%&&"J@U7/+_6"X'RX,HH^"246041RV;2HU,HVU2*C8T("YXT+G/E0-M\$;R6O(ZOH_~%5)O<I^A?
AIZMO.M6_I\NRBQIZ'40'6TXX^R+EL>~B;A8IY^6GR(A\$S8E8E)I>7I6E2ERH*JKQ@B#4;)S_\$(R/MRJ>7
&2#%5C^I+&E?0+5QK;<7'B1>~<"4R7+/DYAI#I;ZNI22*~%16L2+^M"0L1O?
#P5.AQ#N<~F?)74V_7Z*ROIS"/#L:FB)EO(S4ADV;~>~?OIEZ MS69A/KML-&2*HT:#NN'FU0+~IQ&E##A.
~G;I;~;~OK~7F\$29H*MBG2P MYI,IN^I?>OO=1~_0NB#A.TK(%TH6)FAW**JWHTUG^8MKI+~TU'<"Y-
D%2%QD"~H\$GHGU=3,\$ MJ;~13GH9&I8F>~<~A3I;E?OJ?24U(C M*~XN;M;~%MH3TO*LG;
IX;~Z^O/T\$2NM24K&I37_<35.2X-\$YN"6DS)/96UR MN=ZR^M>BG=;>+S!K'
V.*036U@'WOW(/)~PUI;WPRBN9_1+LJ00GESGLT_~J M8#5I^JXA/O..0I"15= _&ZIA("D:YIN#~5E>K&=I.O
^OJ_74I,YZ5*XP% M2@5^Z7WYTI?IXMVJ3*+QTI9+RG"41.8C%1(R.O_+CQDG.3/8"GT"%>X\$ M.AH/O/(LX%2
<~YVG"?D0XC80AW02Q7(5(28H1I\$S\$P%~P3WHQB)J3<\$*9P? MG@_HS3KID)5>
74&~+~BIG+~H)2/\$HV@('HJADQ*~%~;"I><8ZK)'7<~<+~P-M^~I)1#A.SP"E;KH;FIL;I^F\$GHI^~+I^@3\LT'?
B3B;~KW&S=;~I0IH(8 M<~H8@^~^IZE3GPB>~;~M-I>1#I2Q^AWS&*KL)F1^W.KBY;?>3&>3%7I^?Q;K
MV=UE#3DMK;4&06*X1%~@I#31B#~&B;H;M;C.WECLLK)7Z_P5P8U<~"SK7O
MOM>+~L6_~I%K*MXVTZOSF9_~XJW#VC=+~IG"16<~<5&DI'34H"AU37UR" M++@M*&@=&~%E8TGN*^A3Y"UI-
_A*~TM&O@I~H~MZ36/5N9Q#8D*~L5;K2XI M11UT>C_2(&J)9H'RV/1K><~"";ZZ%RHU47*~4&M
M3P^IGTI)"6L+Q08G%R8RF!KX,8W'WBA,8%'FKA\$X5;J'WBSI;M+H;O6LB=I1H#~U"C.I/!<<<4PTLDAMTH\$
M&Y00<)8I4C3&~H_UY_O&255X5I4.%26#X;I.V;~*RS540I@F^_OCNYRDC M'6"2S_O6+N;)JGSK/G>@~^D
K;/(B)@IL81.IY#H.IQZG(H#GE+QN7JYX5%~&J4FKWJ*~MCGV&MX&%I.%+N.49\$TIC2(
6RFL/QH^B0VE.O?;MT/D*AO%JXI-V;~EM%~W%>W M2A.K#6Q4G,+~;O)OEJ&HFFT(D833G*~I5?TU4<+~E9^0)T-
%7?SH7&P MZJG=GTV>B=EQ.3L9HXI3J_7;~)RG;-I\$JBAJN*~IRI0B8V) HF**P9G M0)+
IT?P~5HICWY;~&JZDON3\$0J/61""7;~B10N(W=(T)I\?~H09IR4%T(M*~I4 M&V(C_BN#I%5B*~I-
~5P\$UCT@921>~.0G)8948B'2A'7.#46ZP)2 8K0)M8<9+I M->?C)/TI0GI^LN?TDI#H.R.L%MO+~I&5?
G(IF>85@DO;CD"";=B/(L(N&@0 M(T9JZFD0V3OU#Y7MIH"=4@Y"ES9;)C\YA94>=TN/>69F<+1;3I' UV8NC;< M
(IM@'\$SW,T>*GV^%VWO/GNV^=GGKX\ZZJQ*5W"4Q?1*~3#&*NM0<%IK)JG3 M(G?
#G8;~I-6^I:7WYI;K'Z;QP@<%ZX%~PN#(I3PR5E.D312I'R*~MSETIO%V2 MXN_4CL253<~5 8>"N^6LGU|^~N?
MU1(9.\$BMGOAIP)\$JNH!"M#P5F2B4^AHC M%AK)%3>>R4\$~L@N\$2.OA^I<~>

I5\NRYH<6'.9%%L5+1XIV&.#!E=0>V2U6K.%M=\$A%\$!4D8&&L&5Q4#SX(*4?
A.KIYX\J7&D<@L2!)P/L+&3UO\MWX+IY\^MR4WXJ.GM^O?
N;DE2DU9N4T@YNF&QB*#4;6.9"B)QM/F\JS*D9!%*:*/L MCMU82BW,D+^%?MJ:7\VL^X.>JYIC2"-X.\$=:9LJM!
('W#HL<=>86^X\& (M-79_HIZZ=YG<=Q/@\!^*F+L>@_/SJUL-570B8?)\C^TOHKGKS
MXXWOKS&2YHB2X8X\$V\$L%~JA!O"/CH2GA\$52.CM8Q\6B#>N&=1%H.);HI&9&5MTN8PK6...!^F3Y'Z+T^
JU/T08*I<9>U* M;H0\$!\S!B806-A)I+-K/V8@3PUABTP@I7?.1JO@#;+/+*G^UP^A7W3;-4@ M*197\$)PCK6P
JHOP8I@P#N>N;=@M3=DRAC%B\^D47QV%;L^,D=^.%X6J+(PPBGT\8KZN+6^ M;GT+|
fE>K69WV4C.G;..5K801R4/PD'7Q>Z:@LSUQ=99NH?HK(^3F/77R-'SM;0 MH
OY"G9/&E>F>HWUS)\#3I2L^;IU4/YG72-!<X^85+RY7?_AZMJ%6LFD;S@2/K6/DFGZWJ6>+;".O>"-MU-FG?
fB8E=K70\CSL.9S9+*Y^;"TSOK)JU?3F/11Z_2"YR6D@;).5^#JKEL9 M%4@HS9@61-.X*.;
f0F+NIJ\79M'8@=9M5!=?199/EQ(B6WZ54 G-(IS\$, MWHU35@JAE&V4)/@QE4.K;I\Z9*7*\$@BL(CMQI%W?
NZ5T+4R@+J0=@9\ MW^C2^=DX9_YA=,T-8?FDYWAR@U4>88C#?IG650>6\^=7 6^V9? VNFHV
MDNQTPTM=ZISU)C8V(HOZ3_"8(B^J.5)&='B&*DV>RV<3) I\$15+.1^%11G5
M7P&9\JMNWBQF\33.9G=K8VFBF5&.."U#) MF8\PC M9E:A*# (U\H@)D;J0K8=Q_D>VA.?TDL M)\Z&M/B80JGS
^R/4B'L8%EIXV+^=1^WB%_%D2,CUKNB\TI^Q;#9MLA;\^T%0PTXFG)B*Q&('>39P%0>0_#PX78F' M,T^O&#
-5\MW&K.9D8I3(%68S5=4?Q_GCS"=A<_M+OC^..S^+!)I"Y-MZN'.X7\;VIDKGO=+9+5.7;L2I+I<%;A\$9I=)3?I>
MZN=+)@2X*Y+I\W/9K.PGUTZ90FG@L.ZD3\$=+I(3MLXCST3T3C9L8.NY\BU M7Z(JCG^CD2LC'/7LF!??
0;EOS&SU_BRLDN7T+J/I.A)A\$&W2Z21=8VCA&I= M9'VC;IWSWW.VRI)V3JAT3F50?WEN;3T(\$%->IEIW?M;-
ZW=K'LBH-8&E@ M86ET/B(6<.H&*R78W<8@9E..Q'&-RW5=H\SS?^UO*;ZYS64FT=3/G0I.&I MFJ>A7.WJVF
7V>BUA\$'M(#3JD^3@6\/*8B883PH2<^VP;@Q SU\$)C)-5 M69X1=WKZ"D>#2N'EB5Z5U8)5Q
JH3F7BJ8D').\$.)3I+\$%<@=I)&ET(FWN MQGO;Y\CS^/W3.2B;ZDJE418"W:5DP*YJV^D*?>
>O13MKTT^_AN4SF*L5XBC5 M(7HX\A@.JH-KW. '44>CIZ*.<5(I\RIX=(BS;BGY9M(^4CR5\J9-3TRC+ M.&-
(Z/2D.?.\$F.) (I0XQ8D('M'R"P-M7I>""=.1.KS\%\$ZP;MPT\KP-5RE M1WYA)K\DA&N<#PHUXAA\H(C(7%0QOK6
.">V&9%IM&G\84Wf.&@6G9;G MQV8HK+;W.-GH3#G&24.3IA"2-C?OI>7">2 4. C.PC\PA*#5_2HD^P8-
19SC\2EJ/>* &NM?/#CX7LU/OYV\$&C=21HLC'SZ+1T.EB?I\MTQYVW2J<9-%Z@WI
ML0\3\&ORLLCC9X0BEAJ8\8A3...Q\$QR@1Q3736BA<<I\X.^6.-I<8P<_';11ES;2*(W4D; M/2&2-
A_5>P/V;>?I+W?Y)AM**@1&EL<96I'1B#);2L\ZBAWDA<>+JG/=6 M\^M^&=,R/H=>#9.*4DL// D\Q
BEX\ZL#DKYTAZY-O#B.84=I\X2P5LLD= MW\A6UEJ.CKS;J>M5P.V^Q^XB890.&K\I.2I:0=#9I.&W51"4HI17_=CKS?
3Z8-H8L4L1XM/5\KHM*@\I;I>#?DMX(ZABQO(M'@70=-T\$H-"V V%MSD*V\ M%\$S>=IS.NOA?
&+U(G=_@2*E.O\$<"<8RM6R9T*L\$M(I3W\ZT?K%.S3@%J(VA MRA*INN>TD\H9?29/(@UUT#\L6T;8\BR&T0^?=-
54\$&M=K7_XRR\LFJ.Z M2CP9N^QA>= JVN4"L#;WE7@K_-I&J9N3-I<_OP=I-I?)-IC29AQE_?G\$ M3#^;ZI#.-
J+^2@B%HV;..R?#H'X/>9"I@'COKW\NML0+N;@I'WYD>;VHBD_ MACV\OU.VTW);=+L#55T\9;RG?V
S\MVJ8JOI=7W^>SB\O%*+1X^7MEKX1? MD1Z#55\398-"%JW3*X
J5>Q>SKO6^C4S3_M\JVX'M%>@Q2^=4F.I@Q7GH MEW4_4Q>6LW\Y4'. 'W9H6R?O%=DP@MJ+L;fE(IUM\^
E@PI7_3N\PY36H;M\$;9FN+TX1-F&=;^I B&*+ /USL7G6;30\^TNX&+M+5Y_18VH9>2L=MDHB_
M37T_N;VZ2*7M\;P-L\K^>FX;1VU3>ABK3 M1^9P<)Y-O@9\$?@&I/W\GYN&#;?O?S621
9HM8Y;IX(X1K0541BLIRO\H= MSI=4>OMJ>G7N3C-I+PQ=ID/*0=-4TZMN9CO^6E4AYF;I'SY*#^8+0&?(O
MTXNI-Z&_1*??>L9&8\B_:/G+IDUZ/>?>;T&JHM-Q;I7#H\$G\>+=9I;"AO9
M%)H85QFG/>#DFHMXQ7#;Z_>NT%*^(^<0Q_%.QD*RE^WYW_ =GA^\$S>=N^CET M.4\Y.E*Y;)-JNNY>F'A%^TJ
(;-7+6B3?VJ*(S/G4\3;fF=M;..I^X\RU6\$7"B\HU3/871NYC_ M\IOW7_IOL_H;ZNNN_E+I)4;I
(%BY0+HGJ(V@HC_&4QGZ4^BZFD-PIW3UJ ML?J\8I%44U;('?'N_D_POU.'7+5\@SY0+@R@R;Y8MJ*XSP\OBTFX;
fF>;X M\$-TQ9+&R@F-1W*^NG\IMPC?NG6?YAGZF;KEJHU<^VD;4N^S.A/0)58(M^&J\M-UD^&BW\GJLF@K=?
C)C\IWH^5NSC/R8 A^JRO\C#C2RW;I\VM6TO_ MS?SYDQ#;.GK;1\$PISEZ<I@R^XED\K&N MH_3C<^<79G
N_IK^M6C\>[N2QR@?)E\I(%<5^CIX3-D\ES;FY_GSVJ\$.B=^#-D_I/6-2CGI?R?^T&*7;@>@,+C%;DY^I(70G\&
MMYBW_^\$MF(FKKK\I.75D^XCE8-K4=S=P\J4#R9)IGCM@&JK04DDNPABE9\$)R\KN\DR?)
(B/0Y^QR;8Y5KB'\$@*#N4I%>N MXFON-'_E)_Z5GW@8-OY_OG7+I_BIR^/I2.72J;MCJ\V3+0W_9'(O5IZEL3E<
MN6U\H\H\Z.O#5 M;L_R.SM44\$MX(SLCASRG7)QO#TP;4\SI_!GDPLO7MT\H4UQ_IW#^?0NX5
M.NQSY8HT#\3I8_T6AOX?_?NI_Y#;77R)IY\X\I9FP=>I/X??;I+H\KLZG_M;7HSF_L;I#CZHW4L_HN3)??
88)7I^9;^@IS@#^<IWT&FAS^M6).81YZ*W>>JS(V>Q+7\$_C
M2UPR^X;F=EQJ\$>+E7EFMR%*;MTQO=X"MYL\YOKDR?;fF?CFW\MIW4S\H\U M\)-OP<^9^?^R_1^<I_GZ??_F'V-
M\$Y>F16T^20I*KS0EHE2.IQF7M96=O.TNPB2DUN\K#IU<(<);IQ^+W_I?AM5C+.BIM4;^GCOW^7M!
<*.X;MYC>;OU?5E'O==B\ZV;FTF.KW- ML8IU23EZS6W517F\$SMQ\82;3VW/3^DQ
;1NR6#^4X_-'HYG2.57IRATD7)X; M;YG&76.6;W-R)' OZ*:TVWF7T\IV68B<
M(&X;NUQID0Q8fE%6#;T7M3L\G7GR.4;@YQB5UI25/\$\GT4\OTU\FZQ4"<>;MZ^4\GN;";(\$F&TN=_\5+D^(4"?
9PI2Q\;S;H/E)K)\NUI-P\$M?YWG
M.DD>JER+4;.CMT=HKJ\ASXT"/&J8D='J+\$P\EO.3YKY.OB5!_2AWQB\$=TW1IP.55\TB_S+_'OJ1U_?V M;PR"NJ;
U8**\VJC5U;3^IGQ^2-86R\BJK(*1W+Z#?.^Z?NMF^?UH9G8I MQ\H?KI&SL;GO>IRV_K@/(@JBD_M4MI3O4
M)H4\$YM;X^I\$Z;T&9WWS M?FR\U>="1582."<.)3\I^D^5=@I3R/I(P;./I;/%D6BB>8-DOE;_L7)3M"
fH9J\^4CU\Y.OHXKR?? O\H>Q+_-9\6_-Y3E\I MABUFMP\SRUY63"O+\$F5X\7;IR.5ZUEPJ_>I9?JU0/*MG9\I'DR5+'F
T>=" MAD0A5^YNI@\$@FU#DB?INQ_SX#I.S-5);.P;LUAC@<-P>D\$EY;I0QL\LS\#% M.@D6_AHR&+I M
XXWA<I54I\AIYUJGYI\$JNZ_?B\O1V;Z"^BEI M;I/S8_>OK?HZSI(U@S" W_Q_4\$L#!!0 (M/R\I>EEE%/"Q@<"XI 7
;61T+3(P.C5Q.C\$P<7AE>#;O.2YH=&WM M6MMRVS80?>I7H/(T<68DF;I9MNOX)DW33A\YM*9/G9-8BEB#(I
\$I6O\ZI M^F+I)2?RQ'443_/@B_2PV4.SAZ N.QN\5I7"R.GF6/H#JD?VIS+6<I#E#OI%%PU=BY/PO/E
MB>_D.M9B<74IY(Q);(ES>CLU%Z+L1H#;-\$)%9E.)PS&\$PB\JC8?17KX5-
ML7IH8JU"PENYA+X);+XI^/fJ5Y>I+ASV9\H^G; M;I0C9HKV8NV5<96W"LUVGV\$1(SR#J4TPN@VW_R.W;2-
=GZ_4!@ MKQ)'KO>CJ^GZYLKXG1S\I^GZ\I=7C_IUP#<.Q\LV^P5TEAHTEJL?QO?7-
8>E%W1/PEF4U'E/Z/T5A#.ZD-DK58+3=XTIZM_<-/U(I=;7 MVZI00+6B>D;JF;88YPV;"Q8OU87BZ MH\Q\Z
\$ELH"YT0M)KF-B(2JV.O62N718H.\$^2*+I)5";2)4%J;TS;"4!(K ME8@\$ C&^6ZD52FN V%M=XT(0D@RWJ4;EL_)4R-
^?26^Y-PE\%4Z;EM<&M@ M*JTS)TXO0Q^HY?M-?C9QIDM;ST^GR(AP<'P#\V9NO9T5F_-fZP<I\94\$L MHFO-
2/XEG\$#C&(&DKH)EE@#"E;095=-f.3(HL2@I^VD3I6V%\f8A;C58\ M;J71^0A\;=DQ(D4_0B_X*)2D-M4XL 6;+B-
O6D\R0I;fLW5&ZT5&*5&.7U0)@=I\VC=O#U5"<- M&.SVS\O1F;A)\^X-
I\UGP\HAJ4X).>+7W;T*9;@;2=U3R+VZ;F@_Z6LF MK2=%K
6%MTJ>T6GZYHLO/\$O#KYYKL#3KNE;"B52*_IBM9+""U\8*K922&XD M\2"#1/I)HB\+E;6T\=>H3G>4ZBV@
XYI&QJ5*(6E4FE.#\$ AN6=6*5_-'\$ MQ+H&PE\Q4\$4D9VP\XB')^*" I_L;I'&6_B>FI^VX+W_ERX_IQ92R5=-O2
fNZI;7F@>@QMCQHV25Y0FZYJ0.J M*U.BQJW7+TFBC?>.(TIAO)EB4*H8PF4M(C'H^NKW_&=<f)\$>G\0?7M0B\$X.
MH\$-5;^9<55Y/JYAC2E8Z@9SI3=(I:7fF/?@Z/N_6C1S_V1&ZU0:7&NG)W M>H\N'+VD_2/W\H\K%C;CWBQ+^2*_
8#4P5.\$H3@<\$#;T&J9W&R;TO_ % MGR_9B<5\I'D'E)JDE2\$PK.7;59S;IV^I^5M&43-/W.#IBQYM-GA;%5@8)
MfE;IVF700B^)-QNY0E1(T>_R\ISO C4?Y@BEY#;H^H+A5-MO_W%@/_/@F#^H2=WH8#_#_9?LZ?Z

IFN727C\$8\$>HZ9%=-D1M"IAU+9TL!+USCJ M8*>-78H#_P)YKET#N 3Z2+6*#^H7\$CTSQLY1G@C.UMB?_R?
U'BS&N'O2J+I M?N55A?J8E_1OWU!/\$WP2I' 0\I/*A3I093R0@5NJIOMQ&S8%?4ZC.@L^G M:BI5_8%K"A%
(_KR1EP!)\$U9S+2_ M-67.@D_K8WJ3LR?DI=(+P-)YI@-E\T\(\X>1%!T'R-5?MF7T#T\Q8D3VV6GX^ZPW\NS..K>7?
8ILX.H.QB?IV7V MQ+LIOW.V@&HJ-&);U6R6'N SI29;?>QY M#.;94>TNNB?MOVMFUO76NI!>HIV8M_2H-
QQ\^C D:DZ2A?_S1?>@W/B^WQ.?) MYIY7G7:GQ2XYJW+?2:6V_@T'P&F_6=;54081+EHUX3&NYIM_G.#<'Z M:
IBO>.+02?X+4\$L#!0 (-/R!>EEUMBX3V0< #TJ 7;61T+3(P M,C5Q,C\$P<7AE>#_Q,BYH=&WM6EUSV\82?
>^00.5IXLQ(CD7)MBP\GDG3\X> M;HIFG?:Q#D@L18Q!@&5 R;J_ NX"i#XL.9%;_U%\FP=')(#%+G;PI@#\$5>X*
M=7V5_Q?7WUQIV^NQ'W1:%U ZEAK@#&@2KK2RG\DYMUH!&#G_'8NC M>;1^U^9&SG@H=HIN&
IM7)V\$YZL3W!E5HL7B^DK(&9B94>_XN@L&E\;Q7G_ M1-L?#&&_!KR:#PK(I3B*#@2IHU9\$YH%I7 C?HPC'8;
MOH\N^Q9:D'Z@+GDKMG1Z?CR_MG=#.BLIV(Z+!B0B!9IA1D:C(A M:ZE#E@(_D-QE\LDZ&_C>KSHXY+(.HIR?
_+F*#VZZON@2)PFG MHUBPFU+/%8@I=;..LF3!70J;+I4E;#>UP63)>+EA=E.#1H!;PLL*G\$3."GPR ME
4R3G1DF"ZD)UA?;ZM""2E82ZL6JQ3\!CSS+FU3??"20&>Q2>4W24\J#6H0 MK%9B<_L\$8+J9YS+ E:WISZK\! PT1BB
0EJ!%8H5TSURZ_-T%3C_14YV*W1_ M"POSALT\$2Q:KP_!T03G!>D)+%L*C=4T=Q&16\!V+S5JY+ #_DF*!39)FJ6J!_ MA-
+;G'81AD)8J4(D\$(@)W\$JM4-H Q-HA>"D&2X2S5JA140FAKQX\NSW\^4 MVYQE2LIMBUL#4VF=(>L1^!0!_#HX
/ZZ_5O/CL;Q MX/S2-A!KE 6QB&I\$+LWC6\8>_0@_F2B@&_6<(T4=+F5)VJ%W:<I!+*7BY\IY66&_PY+W\Z3&I
M!\$T\IR(A4=) K4,D"7IC+AM#3+WAUE&QUEV!%>1?26(T@%=>CX39 M_@N9@G%7PBS_&P&U_THW;AQ_
XJ8\$HIGP4ICITL).N6UW;1)9%+\$6E_XJ>15G:Y3L@%'/?_Y+L"3I>A:RJ42*WHB\5* M"GJH>O\$2B&YD12
#I+I)XF2+66TK9?H;G>\$<^AV@(\ZY)"RJ5&6E2FM>+\$ M_!B6=V*5_K%\$!K&@A_)4 5D9RQ/8C'..# G9R..
>I\$+>Q/7>C+8%[_VY M<&4XJ824^Y19WG43ZW""P29D2HKD1+;H0FY(G4DFW(#VPJUM;OZ(F/+ M\$Y9=DB?
DEMLF#HYV6<+>OY2IMH(IX#7N%_H498HA#160\$5KB*!@2I\!PQK4F M*Z3W1J6W\X7HJ_0W5+UFQE7M>
IH(8P\$^A_2/T\11"*PP%A M2ZMA>K=A0MOH\OSYDIU8?_9D@30:5H;L_ OMUAM=#6X7LZ5T5;-D5#?X2C
M(W;+V>OY46!MD.#NU&M@F@_*_6I?WEP'AWS\!6O.ST8S/^U?9T_T\3MF_KJ%/M!E\2\6FKR^ MW\$;-
@=10H@Z"SZ=J+U7I\6MI"/4@!#8IGG" L8/ZN;"&%L;=R!&X&+31!R MJ\$;I02U8E JV+A
>_SH^F";7I#RN6I+B4T3>X>VO7F&^SPSR2A=A_)X*\$4C^ MO+Q\7#&5ATOZXO_13*;Z8R-)/IVITN?T1=D;9"X50
M\VG;IQ>*FRL4%Q?I>F0:E\$X#_VMN/F@D7?7I X<6*H_R\Y^/BV.^H-I MRSYF=HA).3I\R^R)=SFXC0-C*UZ^I
PI;8-FN'=Q=&K WR:QJVOW^HOJ;1^"EQ\$SS&XIR\JZ@ MV"\$>W5 (-HICY82IRSNNXCUSPA=I+IYPX%O#V)I?
\$YIBGW S=>8F\$? M(7'GKE.EK?^L/ D?1V;P=?MQQ7_14>K)CQ\IJO=I-7)AL_H;KFR?^VNC_ M%I+ P04"
#I@7I9V8SFVB8\$ IH\$P_%P &UD=#TR.#(U<3Q_%"X M97@S,C\$N:1MW5C;N;V\$ W05\ _FDT 2Y9D^28\ 8HT+?
JPFVVSQ3X6M#2* MB*5(+4DY=K^0TK*S7&2 FD2Q ^")7)N9PYG1EH4IN3'BP)H=OS#XD?/(I_ (MM"Y!&)(H
8R4FLF+LC7#/0WXGGMKA-9;12I* R)@B@F7Z7ZQE:T63?;<#CN MI"P&S?UBX(PLEC+;"\RMB(L_ ^JOT1AE;
GS(=I9G(I&4C&LP""(IGH^DX M_#OLH2AN;V2TV7 XZI5;> 58^TD<^9-19>;7+ #_%\$@;13SVW\7B12V'0GD+Y
MYF^C9EL951>H;RF-D65B=;5/C*S^ID)I&A3+FXV;_ 0/H-HQMY=-3/4PYF M+L8PLE&=K@NV9(8;(S^I=*8&
IXFB+ZH%(DV1-0AN4LI89)061.3@H&3E= M0UH;M@)REN;J*/+F(E<*UU3M&LD.8?4Q3+QC8F4#;I_ ^:DP2
MWQ_#E50(DB"-_2E62;/#^L(AI,A,PH*5A**IZ27\J7_E;@_BP5IZE1BY\I>^% MXV >C?JN.O;=QAHW*
(ULP&T%*%AN2_J<\$=HP@2Q3J2THBDS&T+US@_SUY6^
MAZ6J524UPH3+X93IY9_D_X57VA*.A;I323E2WJU<.DWLT9&PPU^WNCZ7PW MI1^MI!7_NPIH?
<)*.XJH\$.1(F8;C5Z/'07C8A?7RYF_C\$L7^,+9_?,&_ MM*3;XX,3659<>1-
1U^I_+UF"FS#=12X3OP\23(CW!TD;U>I1Z;+IG5BM#&6V;&"1<*6J MXP)EMEQ5"K1-
NRLBE;"6)A@Q= GIGKUEN)I+9S)^_AG8H-1B;R3K#L;SJNWEU8++M MM?"\$CZ-PYW+@IUY\2.TP
(>3V9/4#IS+C=L(C*ZH..H->YU "W<256L2WIZ3 M;0;N8M/=STYSNO!RTHSQOOVQV*#I>_%DKMV5 M_
8RSQ5V_7.??3AIJ#D'H2>2(W M5\\$_7V!%H H@HCEYQEI OY_4+^TC" _M7R1W#;IO\$LW7P.?
@LV+8^"OL_5L@78T_U_@;7*M\Y;?"^Y4IQ<=#ST+X4N1& MG40IS;RK0I%UW7(N11EE#\$\$UD.@0 P4 7
_61T+3(P,C5Q,C\$P<7AE>#_R.BYH=&WM M6&UOVS80_KY?P3E8F@^6+;GRF^P8&_YVZ(K^1 MD0+FE.LF&+
FZ^8-A^7C'N^<>WAVU6)E^+!GZX,B8(H)I^4 LS!";WW A8=G86@^9Y,7";
M+%;%ULL%XV>\$LX,>9^F\$Q6R81C"#.&:SZ70<32?AD,V";2S\ ^PAZJXO-&I MS%K 0;_@TEN!W3^)
(W\R*LW\G#_S2L@(^*GGBX7N9(&H.HW_ QLS&P;H_H4 MI;7*%&4DUE;ICU&E>S1P83PJ^*E,7 RIQG:GGRFA=+
(3N_<2KR<%ERLDU0\$5^0#GY#=#54/FI7U%9>15HGC<+* X7H_XB7L;V*;H\W\!70QAI&-ZLW% MBJ?<I-
"M/(*_EIAJ3)-9\$0ZDT@B3) M6Z4+\$@;>KQ:QI\5DGI!09R95VZ6_5"\$B&M?(H,RH%O;L3CH-Y_HJZMAW M"VM#
<=JGO?"IK M7;H*X4)Q_6_ ^R?^H7_)VW X"OK6.&6JM,6IO)O\I)Y^ ^YNX1+\$ _C"T0'S\$C+3GS M6B\3;U64
QG3T=B*OJ1<@VYIC@)7B=>^C^P3Y\$8\VVY\YE>B&K-326PIN+;\$7E M*70Y#F?#N&%X;B-F9I-
_97L^IQVI*SS26>Z;+IH5BU#.6V?&"Q<"6KXP+E MMFR5&BJ;=E=;J! \$I= =K!@H*)\$55.(LM* @A89=
I9M7G%5+1K6J*TV\3; MJ#+^8^4_G-I_O_WG43K+ SG!F;WE&1=OQW7Z-N)U;9S_-AK:X=1@;(9U&
I=SI^_FUH%AFI+QQ(F M\59QX(=;97>9^0;^*!H_R.S N=RXC-WWZ%K;I5;XWX)<I3ED=C?BR;QRW^07JM=X
MT<_C3I^!S_Y\$5B >G>BVIXI&WA48L1*<\$;Z4+I?D)*WG^*X^_@<@*2XY#R
M!PZXY!@;\$K<%VW;G2X3^NJC<^_CYD M@+GUZ@HO;&X,2S0(^+O.8_-EUE6I="X%5RHTQ7I9FTV5>IY_M=-
VIB!>POX M%5!+ 0(4 Q0 (-/R!>EE#%L(#_ ^H!_!%P(P 0 " 0 M !M9'0M,C R-#P,C4N:1M4\$!L_A0#% @
_(-%Z60A9A@V%P SID! M (+!>H!&UD="TR.#(T,3 R-2YX+LZLI LIP\$ _% @_) 0(:61T+3(P,C0Q M,#(U7V-
A;"YX;6Q02P\$""_4 " #I@7I9%6UC(3N)+% 8 % M @&F*PL;61T+3(P,C0Q.#(U7VIE9BYX;6Q02P\$""_4 " #I
M@7I9\5\$ AN^Q "TW \$P @ \$3M0(:61T+3(P,C0Q.#(U M7VEF-P@KCIY "VH 4 M " 3-G P!M9'0M,C R-#P,C5?
9S\$P+FIP9U!+ 0(4 Q0 (-/R!>EG^ M"3IHW@ **1 4 " 53X P!M9'0M,C R-#P,C5?9S\$Q M+FIP9U!+ 0(4 Q0 (-
/R!>EG2&^!^S'D %*2 4 " M 7EQ! !M9'0M,C R-#P,C5?9S\$R+FIP9U!+ 0(4 Q0 (-/R!>EE&R44(MQF!)#7 0 4 " 7?K!
IM9'0M,C R-#P,C5?9S\$S+FIP M9U!+ 0(4 Q0 (-/R!>ED96_@_JA4'&_! @ 3 " 6I; MI@!M9'0M,C R-#P,C5?
9S(N;G\G4\$!L_A0#% @_(-%Z64Q_16*\$NP M@_,!, (-!2G\$(&UD="TR.#(T,3 R-5IG,RJY<=&02P\$" M%_4 " #I@7I9;
I+RR+I HU0 \$P @ _+D;61T M+3(P,C0Q.#(U7VEG+%N&37W\).7 3 M ">/f'0!M9'0M,C R-#P,C5?9S4N;G\G4\$!L
A0#% M @_(-%Z6=IH\$&EEGQ"-V838T_2D 3 " =%X"P!M9'0M,C R-#P,C5? M9S@N;G\G4\$!L_A0#% @
_(-%Z6;V\YE!QC@_6:8 !, M (-!3P8_&UD="TR.#(T,3 R-5IG,2YJ<=&02P\$""_4 " #I@7I9=/"4 MW)E9 0#>+T % @ 'QE
P;61T+3(P,C0Q.#(U7VQA8BYX M;6Q02P\$""_4 " #I@7I9_FI B4W_ CPD % @ _&I MI@T;61T+3(P,C0Q.#
(U7W\!R92YX;6Q02P\$""_4 " #I@7I991?SPL8' M N%0 %P @ \$IO X;61T+3(P,C5Q,C\$P<7AE>#_Q,2YH
M=&U02P\$""_4 " #I@7I9=;8N\$ID'J!@ %P @ \$V MQ X;61T+3(P,C5Q,C\$P<7AE>#_Q,BYH=&U02P\$""_4 "
#I@7I9V8SF MVB8\$ IH\$P_%P @ %\$S X;61T+3(P,C5Q,C\$P<7AE>#_R M,2YH=&U02P\$""_4 " #I@7I90Q!>9#H\$,%
%P M@&?T X;61T+3(P,C5Q,C\$P<7AE>#_R.BYH=&U02P4& !<%P#I!0 &#M4. end XML 116 mdt-
20241025_htm.xml IDEA: XBRL DOCUMENT 0001613103 2024-04-272024-10-25 0001613103
mdt:A0.250SeniorNotesDue2025Member 2024-04-272024-10-25 0001613103
mdt:A0.000SeniorNotesDue2025Member 2024-04-272024-10-25 0001613103
mdt:A2.625SeniorNotesDue2025Member 2024-04-272024-10-25 0001613103
mdt:A1.125SeniorNotesDue2027Member 2024-04-272024-10-25 0001613103
mdt:A0.375SeniorNotesDue2028Member 2024-04-272024-10-25 0001613103
mdt:A3.000SeniorNotesDue2028Member 2024-04-272024-10-25 0001613103

mdt:A3.650SeniorNotesDue2029Member 2024-04-272024-10-25 0001613103
mdt:A1.625SeniorNotesDue2031Member 2024-04-272024-10-25 0001613103
mdt:A1.000SeniorNotesDue2031Member 2024-04-272024-10-25 0001613103
mdt:A3.125SeniorNotesDue2031Member 2024-04-272024-10-25 0001613103
mdt:A0.750SeniorNotesDue2032Member 2024-04-272024-10-25 0001613103
mdt:A3.375SeniorNotesDue2034Member 2024-04-272024-10-25 0001613103
mdt:A3.875SeniorNotesDue2036Member 2024-04-272024-10-25 0001613103
mdt:A2.250SeniorNotesDue2039Member 2024-04-272024-10-25 0001613103
mdt:A1.500SeniorNotesDue2039Member 2024-04-272024-10-25 0001613103
mdt:A1.375SeniorNotesDue2040Member 2024-04-272024-10-25 0001613103
mdt:A4.150SeniorNotesDue2043Member 2024-04-272024-10-25 0001613103
mdt:A1.750SeniorNotesDue2049Member 2024-04-272024-10-25 0001613103
mdt:A1.625SeniorNotesDue2050Member 2024-04-272024-10-25 0001613103
mdt:A4.150SeniorNotesDue2053Member 2024-04-272024-10-25 0001613103 2024-11-20 0001613103 2024-07-
272024-10-25 0001613103 2023-07-292023-10-27 0001613103 2023-04-292023-10-27 0001613103 2024-10-25
0001613103 2024-04-26 0001613103 us-gaap:CommonStockMember 2024-04-26 0001613103 us-
gaap:AdditionalPaidInCapitalMember 2024-04-26 0001613103 us-gaap:RetainedEarningsMember 2024-04-26
0001613103 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-26 0001613103 us-
gaap:ParentMember 2024-04-26 0001613103 us-gaap:NoncontrollingInterestMember 2024-04-26 0001613103
us-gaap:RetainedEarningsMember 2024-04-272024-07-26 0001613103 us-gaap:ParentMember 2024-04-272024-
07-26 0001613103 us-gaap:NoncontrollingInterestMember 2024-04-272024-07-26 0001613103 2024-04-272024-
07-26 0001613103 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-272024-07-26 0001613103
us-gaap:CommonStockMember 2024-04-272024-07-26 0001613103 us-gaap:AdditionalPaidInCapitalMember
2024-04-272024-07-26 0001613103 us-gaap:CommonStockMember 2024-07-26 0001613103 us-
gaap:AdditionalPaidInCapitalMember 2024-07-26 0001613103 us-gaap:RetainedEarningsMember 2024-07-26
0001613103 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-26 0001613103 us-
gaap:ParentMember 2024-07-26 0001613103 us-gaap:NoncontrollingInterestMember 2024-07-26 0001613103
2024-07-26 0001613103 us-gaap:RetainedEarningsMember 2024-07-272024-10-25 0001613103 us-
gaap:ParentMember 2024-07-272024-10-25 0001613103 us-gaap:NoncontrollingInterestMember 2024-07-
272024-10-25 0001613103 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-272024-10-25
0001613103 us-gaap:CommonStockMember 2024-07-272024-10-25 0001613103 us-
gaap:AdditionalPaidInCapitalMember 2024-07-272024-10-25 0001613103 us-gaap:CommonStockMember 2024-
10-25 0001613103 us-gaap:AdditionalPaidInCapitalMember 2024-10-25 0001613103 us-
gaap:RetainedEarningsMember 2024-10-25 0001613103 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-10-25 0001613103 us-gaap:ParentMember 2024-10-
25 0001613103 us-gaap:NoncontrollingInterestMember 2024-10-25 0001613103 us-gaap:CommonStockMember
2023-04-28 0001613103 us-gaap:AdditionalPaidInCapitalMember 2023-04-28 0001613103 us-
gaap:RetainedEarningsMember 2023-04-28 0001613103 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-28 0001613103 us-gaap:ParentMember 2023-04-
28 0001613103 us-gaap:NoncontrollingInterestMember 2023-04-28 0001613103 2023-04-28 0001613103 us-
gaap:RetainedEarningsMember 2023-04-292023-07-28 0001613103 us-gaap:ParentMember 2023-04-292023-07-
28 0001613103 us-gaap:NoncontrollingInterestMember 2023-04-292023-07-28 0001613103 2023-04-292023-07-
28 0001613103 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-292023-07-28 0001613103
us-gaap:CommonStockMember 2023-04-292023-07-28 0001613103 us-gaap:AdditionalPaidInCapitalMember
2023-04-292023-07-28 0001613103 us-gaap:CommonStockMember 2023-07-28 0001613103 us-
gaap:AdditionalPaidInCapitalMember 2023-07-28 0001613103 us-gaap:RetainedEarningsMember 2023-07-28
0001613103 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-28 0001613103 us-
gaap:ParentMember 2023-07-28 0001613103 us-gaap:NoncontrollingInterestMember 2023-07-28 0001613103
2023-07-28 0001613103 us-gaap:RetainedEarningsMember 2023-07-292023-10-27 0001613103 us-
gaap:ParentMember 2023-07-292023-10-27 0001613103 us-gaap:NoncontrollingInterestMember 2023-07-
292023-10-27 0001613103 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-292023-10-27
0001613103 us-gaap:CommonStockMember 2023-07-292023-10-27 0001613103 us-
gaap:AdditionalPaidInCapitalMember 2023-07-292023-10-27 0001613103 us-gaap:CommonStockMember 2023-
10-27 0001613103 us-gaap:AdditionalPaidInCapitalMember 2023-10-27 0001613103 us-
gaap:RetainedEarningsMember 2023-10-27 0001613103 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-27 0001613103 us-gaap:ParentMember 2023-10-
27 0001613103 us-gaap:NoncontrollingInterestMember 2023-10-27 0001613103 2023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember
2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember
2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember
2024-04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CardiacRhythmAndHeartFailureDivisionMember
2023-04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:StructuralHeartAndAorticDivisionMember
2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:StructuralHeartAndAorticDivisionMember
2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:StructuralHeartAndAorticDivisionMember
2024-04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:StructuralHeartAndAorticDivisionMember
2023-04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CoronaryAndPeripheralVascularDivisionMember
2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CoronaryAndPeripheralVascularDivisionMember
2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CoronaryAndPeripheralVascularDivisionMember

2024-04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:CardiovascularMembermdt:CoronaryAndPeripheralVascularDivisionMember
2023-04-292023-10-27 0001613103 us-gaap:OperatingSegmentsMembermdt:CardiovascularMember 2024-07-
272024-10-25 0001613103 us-gaap:OperatingSegmentsMembermdt:CardiovascularMember 2023-07-292023-10-
27 0001613103 us-gaap:OperatingSegmentsMembermdt:CardiovascularMember 2024-04-272024-10-25
0001613103 us-gaap:OperatingSegmentsMembermdt:CardiovascularMember 2023-04-292023-10-27 0001613103
us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:CranialAndSpinalTechnologiesDivisionMem
2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:CranialAndSpinalTechnologiesDivisionMem
2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:CranialAndSpinalTechnologiesDivisionMem
2024-04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:CranialAndSpinalTechnologiesDivisionMem
2023-04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:SpecialtyTherapiesDivisionMember 2024-
07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:SpecialtyTherapiesDivisionMember 2023-
07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:SpecialtyTherapiesDivisionMember 2024-
04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:SpecialtyTherapiesDivisionMember 2023-
04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:NeuromodulationDivisionMember 2024-
07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:NeuromodulationDivisionMember 2023-
07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:NeuromodulationDivisionMember 2024-
04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMembermdt:NeuromodulationDivisionMember 2023-
04-292023-10-27 0001613103 us-gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMember 2024-07-
272024-10-25 0001613103 us-gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMember 2023-07-
292023-10-27 0001613103 us-gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMember 2024-04-
272024-10-25 0001613103 us-gaap:OperatingSegmentsMembermdt:NeuroscienceGroupMember 2023-04-
292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:SurgicalEndoscopyMember 2024-07-272024-
10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:SurgicalEndoscopyMember 2023-07-292023-
10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:SurgicalEndoscopyMember 2024-04-272024-
10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:SurgicalEndoscopyMember 2023-04-292023-
10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:AcuteCareMonitoringMember 2024-07-
272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:AcuteCareMonitoringMember 2023-07-
292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:AcuteCareMonitoringMember 2024-04-
272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:MedicalSurgicalMembermdt:AcuteCareMonitoringMember 2023-04-
292023-10-27 0001613103 us-gaap:OperatingSegmentsMembermdt:MedicalSurgicalMember 2024-07-272024-
10-25 0001613103 us-gaap:OperatingSegmentsMembermdt:MedicalSurgicalMember 2023-07-292023-10-27
0001613103 us-gaap:OperatingSegmentsMembermdt:MedicalSurgicalMember 2024-04-272024-10-25
0001613103 us-gaap:OperatingSegmentsMembermdt:MedicalSurgicalMember 2023-04-292023-10-27
0001613103 us-gaap:OperatingSegmentsMembermdt:DiabetesGroupMember 2024-07-272024-10-25 0001613103
us-gaap:OperatingSegmentsMembermdt:DiabetesGroupMember 2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:DiabetesGroupMember 2024-04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:DiabetesGroupMember 2023-04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:TotalReportableSegmentsMember 2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:TotalReportableSegmentsMember 2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:TotalReportableSegmentsMember 2024-04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:TotalReportableSegmentsMember 2023-04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2024-04-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember 2023-04-292023-10-27 0001613103
srt:ConsolidationEliminationsMember 2024-07-272024-10-25 0001613103 srt:ConsolidationEliminationsMember
2023-07-292023-10-27 0001613103 srt:ConsolidationEliminationsMember 2024-04-272024-10-25 0001613103
srt:ConsolidationEliminationsMember 2023-04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembercountry:USmdt:CardiovascularMember 2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembercountry:USmdt:CardiovascularMember 2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:InternationalMembermdt:CardiovascularMember 2024-07-272024-10-25
0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:CardiovascularMember 2023-07-
292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:CardiovascularMember 2024-04-
272024-10-25 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:CardiovascularMember 2023-04-
292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:InternationalMembermdt:CardiovascularMember 2024-04-272024-10-25
0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:CardiovascularMember 2023-04-

~~292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:NeuroscienceGroupMember~~
~~2024-07-272024-10-25 0001613103 us-~~
~~gaap:OperatingSegmentsMembercountry:USmdt:NeuroscienceGroupMember 2023-07-292023-10-27 0001613103~~
~~us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:NeuroscienceGroupMember 2024-07-272024-~~
~~10-25 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:NeuroscienceGroupMember 2023-07-292023-10-~~
~~27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:NeuroscienceGroupMember 2024-04-~~
~~272024-10-25 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:NeuroscienceGroupMember~~
~~2023-04-292023-10-27 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:NeuroscienceGroupMember 2024-04-272024-10-~~
~~25 0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:NeuroscienceGroupMember~~
~~2023-04-292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:MedicalSurgicalMember~~
~~2024-07-272024-10-25 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:MedicalSurgicalMember~~
~~2023-07-292023-10-27 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:MedicalSurgicalMember 2024-07-272024-10-25~~
~~0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:MedicalSurgicalMember 2023-~~
~~07-292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:MedicalSurgicalMember 2024-~~
~~04-272024-10-25 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:MedicalSurgicalMember 2023-~~
~~04-292023-10-27 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:MedicalSurgicalMember 2024-04-272024-10-25~~
~~0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:MedicalSurgicalMember 2023-~~
~~04-292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:DiabetesGroupMember 2024-~~
~~07-272024-10-25 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:DiabetesGroupMember 2023-~~
~~07-292023-10-27 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:DiabetesGroupMember 2024-07-272024-10-25~~
~~0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:DiabetesGroupMember 2023-07-~~
~~292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:DiabetesGroupMember 2024-04-~~
~~272024-10-25 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:DiabetesGroupMember 2023-04-~~
~~292023-10-27 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:DiabetesGroupMember 2024-04-272024-10-25~~
~~0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMembermdt:DiabetesGroupMember 2023-04-~~
~~292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:TotalReportableSegmentsMember~~
~~2024-07-272024-10-25 0001613103 us-~~
~~gaap:OperatingSegmentsMembercountry:USmdt:TotalReportableSegmentsMember 2023-07-292023-10-27~~
~~0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:TotalReportableSegmentsMember 2024-07-~~
~~272024-10-25 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:TotalReportableSegmentsMember 2023-07-~~
~~292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USmdt:TotalReportableSegmentsMember~~
~~2024-04-272024-10-25 0001613103 us-~~
~~gaap:OperatingSegmentsMembercountry:USmdt:TotalReportableSegmentsMember 2023-04-292023-10-27~~
~~0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:TotalReportableSegmentsMember 2024-04-~~
~~272024-10-25 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMembermdt:TotalReportableSegmentsMember 2023-04-~~
~~292023-10-27 0001613103 us-gaap:OperatingSegmentsMembercountry:USus-gaap:AllOtherSegmentsMember~~
~~2024-07-272024-10-25 0001613103 us-gaap:OperatingSegmentsMembercountry:USus-~~
~~gaap:AllOtherSegmentsMember 2023-07-292023-10-27 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMemberus-gaap:AllOtherSegmentsMember 2024-07-272024-~~
~~10-25 0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMemberus-~~
~~gaap:AllOtherSegmentsMember 2023-07-292023-10-27 0001613103 us-~~
~~gaap:OperatingSegmentsMembercountry:USus-gaap:AllOtherSegmentsMember 2024-04-272024-10-25~~
~~0001613103 us-gaap:OperatingSegmentsMembercountry:USus-gaap:AllOtherSegmentsMember 2023-04-292023-~~
~~10-27 0001613103 us-gaap:OperatingSegmentsMembermdt:InternationalMemberus-~~
~~gaap:AllOtherSegmentsMember 2024-04-272024-10-25 0001613103 us-~~
~~gaap:OperatingSegmentsMembermdt:InternationalMemberus-gaap:AllOtherSegmentsMember 2023-04-292023-~~
~~10-27 0001613103 srt:ConsolidationEliminationsMembercountry:US 2024-07-272024-10-25 0001613103~~
~~srt:ConsolidationEliminationsMembermdt:InternationalMember 2024-07-272024-10-25 0001613103~~
~~srt:ConsolidationEliminationsMembermdt:InternationalMember 2023-07-292023-10-27 0001613103~~
~~srt:ConsolidationEliminationsMembercountry:US 2024-04-272024-10-25 0001613103~~
~~srt:ConsolidationEliminationsMembercountry:US 2023-04-292023-10-27 0001613103~~
~~srt:ConsolidationEliminationsMembermdt:InternationalMember 2024-04-272024-10-25 0001613103~~
~~srt:ConsolidationEliminationsMembermdt:InternationalMember 2023-04-292023-10-27 0001613103 country:US~~
~~2024-07-272024-10-25 0001613103 country:US 2023-07-292023-10-27 0001613103 mdt:InternationalMember~~
~~2024-07-272024-10-25 0001613103 mdt:InternationalMember 2023-07-292023-10-27 0001613103 country:US~~
~~2024-04-272024-10-25 0001613103 country:US 2023-04-292023-10-27 0001613103 mdt:InternationalMember~~
~~2024-04-272024-10-25 0001613103 mdt:InternationalMember 2023-04-292023-10-27 0001613103~~
~~mdt:OtherAccruedExpensesMember 2024-10-25 0001613103 us-gaap:AccountsReceivableMember 2024-10-25~~
~~0001613103 mdt:OtherAccruedExpensesMember 2024-04-26 0001613103 us-gaap:AccountsReceivableMember~~
~~2024-04-26 0001613103 us-gaap:OtherLiabilitiesMember 2024-10-25 0001613103 us-~~
~~gaap:OtherLiabilitiesMember 2024-04-26 0001613103 us-~~
~~gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2023-04-292024-04-26 0001613103 us-~~
~~gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember 2024-04-26 0001613103 us-~~
~~gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-~~
~~gaap:InProcessResearchAndDevelopmentMember 2024-04-26 0001613103 us-~~
~~gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMemberus-~~
~~gaap:TechnologyBasedIntangibleAssetsMember 2024-04-26 0001613103 2023-04-292024-04-26 0001613103~~

[illegible]

04-26-0001613103-us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:CorporateDebtSecuritiesMember 2024-04-26-0001613103-us-gaap:FairValueInputsLevel2Memberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-04-26-0001613103-us-gaap:InvestmentsMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-04-26
0001613103-us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-04-26-0001613103-us-
gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesMember 2024-04-26-0001613103-us-
gaap:InvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesMember
2024-04-26-0001613103-us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:MortgageBackedSecuritiesMember 2024-04-26-0001613103-us-gaap:FairValueInputsLevel2Memberus-
gaap:ForeignGovernmentDebtSecuritiesMember 2024-04-26-0001613103-us-gaap:InvestmentsMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMember 2024-04-26-0001613103
us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:ForeignGovernmentDebtSecuritiesMember 2024-04-26-0001613103-us-
gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember 2024-04-26-0001613103-us-
gaap:InvestmentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember 2024-
04-26-0001613103-us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Memberus-
gaap:AssetBackedSecuritiesMember 2024-04-26-0001613103-us-gaap:FairValueInputsLevel2Member 2024-04-26
0001613103-us-gaap:InvestmentsMemberus-gaap:FairValueInputsLevel2Member 2024-04-26-0001613103-us-
gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel2Member 2024-04-26-0001613103-us-
gaap:FairValueInputsLevel3Memberus-gaap:AuctionRateSecuritiesMember 2024-04-26-0001613103-us-
gaap:InvestmentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:AuctionRateSecuritiesMember 2024-04-
26-0001613103-us-gaap:OtherAssetsMemberus-gaap:FairValueInputsLevel3Memberus-
gaap:AuctionRateSecuritiesMember 2024-04-26-0001613103-us-gaap:InvestmentsMember 2024-04-26
0001613103-us-gaap:OtherAssetsMember 2024-04-26-0001613103-us-gaap:CorporateDebtSecuritiesMember
2024-10-25-0001613103-us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-10-25-0001613103-us-
gaap:MortgageBackedSecuritiesMember 2024-10-25-0001613103-us-gaap:AssetBackedSecuritiesMember 2024-
10-25-0001613103-us-gaap:AuctionRateSecuritiesMember 2024-10-25-0001613103-us-
gaap:CorporateDebtSecuritiesMember 2024-04-26-0001613103-us-
gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-04-26-0001613103-us-
gaap:MortgageBackedSecuritiesMember 2024-04-26-0001613103-us-gaap:AssetBackedSecuritiesMember 2024-
04-26-0001613103-us-gaap:AuctionRateSecuritiesMember 2024-04-26-0001613103
mdt:EquityInvestmentsMember 2024-07-272024-10-25-0001613103-mdt:EquityInvestmentsMember 2024-04-
272024-10-25-0001613103-mdt:EquityInvestmentsMember 2023-07-292023-10-27-0001613103
mdt:EquityInvestmentsMember 2023-04-292023-10-27-0001613103-mdt:MozarcMember 2023-04-01-0001613103
mdt:A2015CommercialPaperProgramMemberus-gaap:CommercialPaperMember 2024-10-25-0001613103-us-
gaap:CommercialPaperMember 2024-10-25-0001613103-us-gaap:CommercialPaperMember 2024-07-272024-10-
25-0001613103-us-gaap:CommercialPaperMember 2024-04-272024-10-25-0001613103-us-
gaap:CommercialPaperMember 2024-04-26-0001613103-us-gaap:CommercialPaperMember 2023-04-292024-04-
26-0001613103-us-gaap:LineOfCreditMembermdt:AmendedAndRestatedRevolvingCreditAgreementMember 2024-
10-25-0001613103-us-gaap:LineOfCreditMembermdt:AmendedAndRestatedRevolvingCreditAgreementMember
2024-04-272024-10-25-0001613103-us-
gaap:LineOfCreditMembermdt:AmendedAndRestatedRevolvingCreditAgreementMember 2024-04-26-0001613103
mdt:SeniorNotes2019Due20260250PercentMember 2024-04-26-0001613103
mdt:SeniorNotes2019Due20260250PercentMember 2024-10-25-0001613103
mdt:SeniorNotes2019Due20260250PercentMember 2023-04-292024-04-26-0001613103
mdt:SeniorNotes2019Due20260250PercentMember 2024-04-272024-10-25-0001613103
mdt:SeniorNotes2019Due20260250PercentMemberus-gaap:SeniorNotesMember 2024-10-25-0001613103
mdt:SeniorNotes2019Due20260250PercentMemberus-gaap:SeniorNotesMember 2024-04-26-0001613103
mdt:SeniorNotes2022Due20262.625PercentMember 2024-04-26-0001613103
mdt:SeniorNotes2022Due20262.625PercentMember 2024-10-25-0001613103
mdt:SeniorNotes2022Due20262.625PercentMember 2023-04-292024-04-26-0001613103
mdt:SeniorNotes2022Due20262.625PercentMember 2024-04-272024-10-25-0001613103
mdt:SeniorNotes2022Due20262.625PercentMemberus-gaap:SeniorNotesMember 2024-10-25-0001613103
mdt:SeniorNotes2022Due20262.625PercentMemberus-gaap:SeniorNotesMember 2024-04-26-0001613103
mdt:SeniorNotes2020Due20260.000PercentMember 2024-04-26-0001613103
mdt:SeniorNotes2020Due20260.000PercentMember 2024-10-25-0001613103
mdt:SeniorNotes2020Due20260.000PercentMember 2023-04-292024-04-26-0001613103
mdt:SeniorNotes2020Due20260.000PercentMember 2024-04-272024-10-25-0001613103
mdt:SeniorNotes2020Due20260.000PercentMemberus-gaap:SeniorNotesMember 2024-10-25-0001613103
mdt:SeniorNotes2020Due20260.000PercentMemberus-gaap:SeniorNotesMember 2024-04-26-0001613103
mdt:SeniorNotes2019Due20271125PercentMember 2024-10-25-0001613103
mdt:SeniorNotes2019Due20271125PercentMember 2024-04-26-0001613103
mdt:SeniorNotes2019Due20271125PercentMember 2024-04-272024-10-25-0001613103
mdt:SeniorNotes2019Due20271125PercentMember 2023-04-292024-04-26-0001613103
mdt:SeniorNotes2019Due20271125PercentMemberus-gaap:SeniorNotesMember 2024-10-25-0001613103
mdt:SeniorNotes2019Due20271125PercentMemberus-gaap:SeniorNotesMember 2024-04-26-0001613103
mdt:SeniorNotes2023Due20284.250PercentMember 2024-10-25-0001613103
mdt:SeniorNotes2023Due20284.250PercentMember 2024-04-26-0001613103
mdt:SeniorNotes2023Due20284.250PercentMember 2024-04-272024-10-25-0001613103
mdt:SeniorNotes2023Due20284.250PercentMember 2023-04-292024-04-26-0001613103
mdt:SeniorNotes2023Due20284.250PercentMemberus-gaap:SeniorNotesMember 2024-10-25-0001613103
mdt:SeniorNotes2023Due20284.250PercentMemberus-gaap:SeniorNotesMember 2024-04-26-0001613103
mdt:SeniorNotes2022Due20293.000PercentMember 2024-04-26-0001613103
mdt:SeniorNotes2022Due20293.000PercentMember 2024-10-25-0001613103
mdt:SeniorNotes2022Due20293.000PercentMember 2024-04-272024-10-25-0001613103
mdt:SeniorNotes2022Due20293.000PercentMember 2023-04-292024-04-26-0001613103
mdt:SeniorNotes2022Due20293.000PercentMemberus-gaap:SeniorNotesMember 2024-10-25-0001613103

[illegible]

[illegible]

gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-25 0001613103 us-
gaap:ForeignExchangeContractMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103 us-
gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-25 0001613103 us-
gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103
mdt:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-25 0001613103
mdt:ForeignCurrencyDenominatedDebtMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103 us-
gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember 2024-10-25 0001613103 us-
gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember 2024-04-26 0001613103
srt:EuropeMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember
2024-10-25 0001613103 country:JPus-gaap:ForeignExchangeContractMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-25 0001613103 us-
gaap:ForeignExchangeContractMemberus-gaap:OtherOperatingIncomeExpenseMember 2024-07-272024-10-25
0001613103 us-gaap:ForeignExchangeContractMemberus-gaap:OtherOperatingIncomeExpenseMember 2023-07-
292023-10-27 0001613103 us-gaap:ForeignExchangeContractMemberus-
gaap:OtherOperatingIncomeExpenseMember 2024-04-272024-10-25 0001613103 us-
gaap:ForeignExchangeContractMemberus-gaap:OtherOperatingIncomeExpenseMember 2023-04-292023-10-27
0001613103 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2024-07-272024-10-25
0001613103 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2023-07-292023-10-27
0001613103 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2024-04-272024-10-25
0001613103 us-gaap:ForeignExchangeContractMemberus-gaap:CostOfSalesMember 2023-04-292023-10-27
0001613103 mdt:ForeignCurrencyDenominatedDebtMember 2024-07-272024-10-25 0001613103
mdt:ForeignCurrencyDenominatedDebtMember 2023-07-292023-10-27 0001613103
mdt:ForeignCurrencyDenominatedDebtMember 2024-04-272024-10-25 0001613103
mdt:ForeignCurrencyDenominatedDebtMember 2023-04-292023-10-27 0001613103 us-
gaap:ForeignExchangeContractMember 2024-07-272024-10-25 0001613103 us-
gaap:ForeignExchangeContractMember 2023-07-292023-10-27 0001613103 us-
gaap:ForeignExchangeContractMember 2024-04-272024-10-25 0001613103 us-
gaap:ForeignExchangeContractMember 2023-04-292023-10-27 0001613103 us-
gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-25 0001613103 us-
gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103 mdt:OtherAccruedExpensesMemberus-
gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-10-25
0001613103 mdt:OtherAccruedExpensesMemberus-gaap:ForeignExchangeContractMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103 us-gaap:OtherAssetsMemberus-
gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-10-25
0001613103 us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103 us-gaap:OtherLiabilitiesMemberus-
gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-10-25
0001613103 us-gaap:OtherLiabilitiesMemberus-gaap:ForeignExchangeContractMemberus-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103 us-
gaap:DesignatedAsHedgingInstrumentMember 2024-10-25 0001613103 us-
gaap:DesignatedAsHedgingInstrumentMember 2024-04-26 0001613103 us-
gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-
gaap:NondesignatedMember 2024-10-25 0001613103 us-
gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeContractMemberus-
gaap:NondesignatedMember 2024-04-26 0001613103 mdt:OtherAccruedExpensesMemberus-
gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember 2024-10-25 0001613103
mdt:OtherAccruedExpensesMemberus-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember
2024-04-26 0001613103 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-
gaap:TotalReturnSwapMemberus-gaap:NondesignatedMember 2024-10-25 0001613103 us-
gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:TotalReturnSwapMemberus-
gaap:NondesignatedMember 2024-04-26 0001613103 mdt:OtherAccruedExpensesMemberus-
gaap:TotalReturnSwapMemberus-gaap:NondesignatedMember 2024-10-25 0001613103
mdt:OtherAccruedExpensesMemberus-gaap:TotalReturnSwapMemberus-gaap:NondesignatedMember 2024-04-26
0001613103 us-gaap:NondesignatedMember 2024-10-25 0001613103 us-gaap:NondesignatedMember 2024-04-
26 0001613103 us-gaap:FairValueInputsLevel1Member 2024-10-25 0001613103 us-
gaap:FairValueInputsLevel1Member 2024-04-26 0001613103 us-gaap:ForeignExchangeContractMember 2024-
10-25 0001613103 us-gaap:TotalReturnSwapMember 2024-10-25 0001613103 us-
gaap:ForeignExchangeContractMember 2024-04-26 0001613103 mdt:CardiovascularMember 2024-04-26
0001613103 mdt:NeuroscienceGroupMember 2024-04-26 0001613103 mdt:MedicalSurgicalMember 2024-04-26
0001613103 mdt:DiabetesGroupMember 2024-04-26 0001613103 mdt:CardiovascularMember 2024-04-272024-
10-25 0001613103 mdt:NeuroscienceGroupMember 2024-04-272024-10-25 0001613103
mdt:MedicalSurgicalMember 2024-04-272024-10-25 0001613103 mdt:DiabetesGroupMember 2024-04-272024-
10-25 0001613103 mdt:CardiovascularMember 2024-10-25 0001613103 mdt:NeuroscienceGroupMember 2024-
10-25 0001613103 mdt:MedicalSurgicalMember 2024-10-25 0001613103 mdt:DiabetesGroupMember 2024-10-25
0001613103 us-gaap:CustomerRelatedIntangibleAssetsMember 2024-10-25 0001613103 us-
gaap:CustomerRelatedIntangibleAssetsMember 2024-04-26 0001613103
mdt:PurchasedTechnologyAndPatentsMember 2024-10-25 0001613103
mdt:PurchasedTechnologyAndPatentsMember 2024-04-26 0001613103 us-
gaap:TrademarksAndTradeNamesMember 2024-10-25 0001613103 us-gaap:TrademarksAndTradeNamesMember
2024-04-26 0001613103 us-gaap:OtherIntangibleAssetsMember 2024-10-25 0001613103 us-

gaap:OtherIntangibleAssetsMember 2024-04-26 0001613103 us-
gaap:InProcessResearchAndDevelopmentMember 2024-10-25 0001613103 us-
gaap:InProcessResearchAndDevelopmentMember 2024-04-26 0001613103 us-
gaap:EmployeeStockOptionMember 2024-07-272024-10-25 0001613103 us-gaap:EmployeeStockOptionMember
2023-07-292023-10-27 0001613103 us-gaap:EmployeeStockOptionMember 2024-04-272024-10-25 0001613103
us-gaap:EmployeeStockOptionMember 2023-04-292023-10-27 0001613103 us-
gaap:RestrictedStockUnitsRSUMember 2024-07-272024-10-25 0001613103 us-
gaap:RestrictedStockUnitsRSUMember 2023-07-292023-10-27 0001613103 us-
gaap:RestrictedStockUnitsRSUMember 2024-04-272024-10-25 0001613103 us-
gaap:RestrictedStockUnitsRSUMember 2023-04-292023-10-27 0001613103 us-gaap:PerformanceSharesMember
2024-07-272024-10-25 0001613103 us-gaap:PerformanceSharesMember 2023-07-292023-10-27 0001613103 us-
gaap:PerformanceSharesMember 2024-04-272024-10-25 0001613103 us-gaap:PerformanceSharesMember 2023-
04-292023-10-27 0001613103 us-gaap:EmployeeStockOptionMember 2024-07-272024-10-25 0001613103 us-
gaap:EmployeeStockOptionMember 2024-04-272024-10-25 0001613103 us-gaap:EmployeeStockOptionMember
2023-07-292023-10-27 0001613103 us-gaap:EmployeeStockOptionMember 2023-04-292023-10-27 0001613103
mdt:EmployeesStockPurchasePlanMember 2024-07-272024-10-25 0001613103
mdt:EmployeesStockPurchasePlanMember 2023-07-292023-10-27 0001613103
mdt:EmployeesStockPurchasePlanMember 2024-04-272024-10-25 0001613103
mdt:EmployeesStockPurchasePlanMember 2023-04-292023-10-27 0001613103 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-07-272024-10-25 0001613103 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-07-292023-10-27 0001613103 us-
gaap:ResearchAndDevelopmentExpenseMember 2024-04-272024-10-25 0001613103 us-
gaap:ResearchAndDevelopmentExpenseMember 2023-04-292023-10-27 0001613103 country:USus-
gaap:PensionPlansDefinedBenefitMember 2024-07-272024-10-25 0001613103 country:USus-
gaap:PensionPlansDefinedBenefitMember 2023-07-292023-10-27 0001613103 us-gaap:ForeignPlanMemberus-
gaap:PensionPlansDefinedBenefitMember 2024-07-272024-10-25 0001613103 us-gaap:ForeignPlanMemberus-
gaap:PensionPlansDefinedBenefitMember 2023-07-292023-10-27 0001613103 country:USus-
gaap:PensionPlansDefinedBenefitMember 2024-04-272024-10-25 0001613103 country:USus-
gaap:PensionPlansDefinedBenefitMember 2023-04-292023-10-27 0001613103 us-gaap:ForeignPlanMemberus-
gaap:PensionPlansDefinedBenefitMember 2024-04-272024-10-25 0001613103 us-gaap:ForeignPlanMemberus-
gaap:PensionPlansDefinedBenefitMember 2023-04-292023-10-27 0001613103 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-26 0001613103 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-04-26 0001613103 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2024-04-26 0001613103 us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-04-26 0001613103 us-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-26 0001613103 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-04-272024-10-25 0001613103 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-04-272024-10-25 0001613103 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2024-04-272024-10-25 0001613103
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-04-272024-10-25 0001613103 us-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-272024-10-25 0001613103 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-272024-10-25 0001613103 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-10-25 0001613103 us-
gaap:AccumulatedTranslationAdjustmentMember 2024-10-25 0001613103 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2024-10-25 0001613103 us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2024-10-25 0001613103 us-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-10-25 0001613103 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-28 0001613103 us-
gaap:AccumulatedTranslationAdjustmentMember 2023-04-28 0001613103 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2023-04-28 0001613103 us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-28 0001613103 us-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-28 0001613103 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-04-292023-10-27 0001613103 us-
gaap:AccumulatedTranslationAdjustmentMember 2023-04-292023-10-27 0001613103 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2023-04-292023-10-27 0001613103
us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-292023-10-27 0001613103 us-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-292023-10-27 0001613103 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-292023-10-27 0001613103 us-
gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-10-27 0001613103 us-
gaap:AccumulatedTranslationAdjustmentMember 2023-10-27 0001613103 us-
gaap:AociDerivativeQualifyingAsHedgeExcludedComponentParentMember 2023-10-27 0001613103 us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-10-27 0001613103 us-
gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-10-27 0001613103
mdt:ColibriHeartValveLLCColibriMember 2023-02-082023-02-08 0001613103
mdt:HerniaMeshLitigationMemberus-gaap:PendingLitigationMemberus-gaap:SubsequentEventMember 2024-10-
302024-10-30 0001613103 mdt:HerniaMeshLitigationMemberstpr:MAus-gaap:PendingLitigationMemberus-
gaap:SubsequentEventMember 2024-10-302024-10-30 0001613103
mdt:HerniaMeshLitigationMemberstpr:MNus-gaap:PendingLitigationMemberus-gaap:SubsequentEventMember
2024-10-302024-10-30 0001613103 mdt:HerniaMeshLitigationMemberus-gaap:PendingLitigationMemberus-
gaap:SubsequentEventMember 2024-10-30 0001613103
mdt:DiabetesPumpRetainerRingLitigationMemberstpr:CAus-gaap:SubsequentEventMember 2024-11-04
0001613103 mdt:DiabetesPumpRetainerRingLitigationMemberstpr:CAus-gaap:SubsequentEventMember 2024-
11-042024-11-04 0001613103 us-gaap:OperatingSegmentsMember 2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMember 2023-07-292023-10-27 0001613103 us-gaap:OperatingSegmentsMember 2024-
04-272024-10-25 0001613103 us-gaap:OperatingSegmentsMember 2023-04-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:OtherSegmentMember 2024-07-272024-10-25 0001613103 us-
gaap:OperatingSegmentsMembermdt:OtherSegmentMember 2023-07-292023-10-27 0001613103 us-
gaap:OperatingSegmentsMembermdt:OtherSegmentMember 2024-04-272024-10-25 0001613103 us-

gaap:OperatingSegmentsMembermdt:OtherSegmentMember 2023-04-292023-10-27 0001613103 us-
gaap:MaterialReconcilingItemsMember 2024-07-272024-10-25 0001613103 us-
gaap:MaterialReconcilingItemsMember 2023-07-292023-10-27 0001613103 us-
gaap:MaterialReconcilingItemsMember 2024-04-272024-10-25 0001613103 us-
gaap:MaterialReconcilingItemsMember 2023-04-292023-10-27 0001613103 country:IE 2024-07-272024-10-25
0001613103 country:IE 2023-07-292023-10-27 0001613103 country:IE 2024-04-272024-10-25 0001613103
country:IE 2023-04-292023-10-27 0001613103
mdt:TotalOtherCountriesExcludingUnitedStatesAndIrelandMember 2024-07-272024-10-25 0001613103
mdt:TotalOtherCountriesExcludingUnitedStatesAndIrelandMember 2023-07-292023-10-27 0001613103
mdt:TotalOtherCountriesExcludingUnitedStatesAndIrelandMember 2024-04-272024-10-25 0001613103
mdt:TotalOtherCountriesExcludingUnitedStatesAndIrelandMember 2023-04-292023-10-27 0001613103
mdt:TotalOtherCountriesExcludingIrelandMember 2024-07-272024-10-25 0001613103
mdt:TotalOtherCountriesExcludingIrelandMember 2023-07-292023-10-27 0001613103
mdt:TotalOtherCountriesExcludingIrelandMember 2024-04-272024-10-25 0001613103
mdt:TotalOtherCountriesExcludingIrelandMember 2023-04-292023-10-27 0001613103 mdt:BrettWallMember
2024-07-272024-10-25 0001613103 mdt:BrettWallMember 2024-10-25 shares iso4217:USD iso4217:USD shares
pure mdt:tranche iso4217:EUR iso4217:JPY mdt:plaintiff mdt:claim mdt:lawsuit mdt:segment0001613103--04-
25falseQ22025H91
VY19P6YP6YP3YP3YP5YP5YP8YP8YP5YP5YP6YP6YP8YP8YP5YP5YP12YP12YP12YP12YP9YP9YP12YP12YP10YP10Y
Qtrue2024-10-25false001-36820Medtronic plcL298-1183488Building Two, Parkmore Business Park
WestGalwayIE3531438-1700Ordinary shares, par value \$0.0001 per shareMDTNYSE0.250% Senior Notes due
2025MDT/25NYSE0.000% Senior Notes due 2025MDT/25NYSE2.625% Senior Notes due
2025MDT/25BNYSE1.125% Senior Notes due 2027MDT/27NYSE0.375% Senior Notes due
2028MDT/28NYSE3.000% Senior Notes due 2028MDT/28NYSE3.650% Senior Notes due
2029MDT/29NYSE1.625% Senior Notes due 2031MDT/31NYSE1.000% Senior Notes due
2031MDT/31NYSE3.125% Senior Notes due 2031MDT/31BNYSE0.750% Senior Notes due
2032MDT/32NYSE3.375% Senior Notes due 2034MDT/34NYSE3.875% Senior Notes due 2036MDT/36NYSE2.250%
Senior Notes due 2039MDT/39NYSE1.500% Senior Notes due 2039MDT/39BNYSE1.375% Senior Notes due
2040MDT/40NYSE4.150% Senior Notes due 2043MDT/43NYSE1.750% Senior Notes due
2049MDT/49NYSE1.625% Senior Notes due 2050MDT/50NYSE4.150% Senior Notes due
2053MDT/53NYSEYesYesLarge Accelerated
Filerfalsefalsefalse12822856818403000000798400000016318000000156860000002946000000276100000057070
19000000111000000-38000000116000000-926000000218000000-91100000035000000915000000-
170000000771000000-1000000-1000000-4000000-27000000324000000-
93000000294000000161000000295000000690000001200000001439000000120600000023960000001828000000
0.00010.00012600000000260000000012825531501282553150131133753113113375310020824000000231290000
3250000000-
3318000000048494000000502140000002220000002060000004871600000050420000000900420000008998100000
331800000005021400000020600000050420000001042000000104200000060000001049000000-92000000-
92000000-
920000000.708980000008980000000898000000100000087000000870000008700000030000000248900000024890
341000000047947000000213000000481600000001270000000127000000090000001278000000161000000161000
32500000004849400000022200000048716000000133100000002459000000030392000000-
3499000000051483000000182000000516650000007910000007910000006000000797000000-175000000-
175000000-
1750000000.6991800000091800000091800000010000007300000073000000730000002000000148000000148000
3674000000051178000000188000000513660000009090000009090000002000000911000000297000000297000000
2000000295000000.699180000009180000009180000002000000350000003500000035000000200000018900000
337700000051460000000187000000516470000002327000000170800000013370000001344000000450000003706
3600000024200000021900000098000000-182000000181000000117000000278000000616000000-707000000-
69900000080000000048600000019440000001536000000220000009240000008150000004019000000340300000
100000059000000-604000000-963000000-
67000000132100000032090000000179500000018360000002320000001490000002780000000378000000-
64000000153000000-1265000000-59100000035000000-214000000110000000-
232000000128400000015430000001394000000131100000013350000001110000000513000000476000000Basis
of Presentation<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">The accompanying unaudited consolidated financial statements of Medtronic plc and its
subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting
principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the
consolidated financial statements include all the adjustments necessary for a fair statement in conformity with
U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to
classifications used in the current year.</div><div style="margin-bottom:8pt;margin-top:8pt;text-
align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">Operating results for interim periods are not necessarily indicative of results that
may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with
U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets,
liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the
reporting period. Actual results could materially differ from these estimates.</div><div style="margin-
bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial
statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company
has a controlling financial interest, and variable interest entities for which the Company is the primary
beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in
millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of
the components may not equal the total amount reported in millions due to rounding. Additionally, certain
columns and rows within tables may not sum due to rounding.</div><div style="margin-

The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. The Company's fiscal years 2025, 2024, and 2023 will end or ended on April 25, 2025, April 26, 2024, and April 28, 2023, respectively.

The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year.

Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding. The Company's fiscal years 2025, 2024, and 2023 will end or ended on April 25, 2025, April 26, 2024, and April 28, 2023, respectively.

New Accounting Pronouncements

Recently Adopted Accounting Standards

As of October 25, 2024, there have been no newly adopted accounting pronouncements that materially impact our consolidated financial statements.

Refer to the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024 for pronouncements recently adopted.

Not Yet Adopted Accounting Standards

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Recently Adopted Accounting Standards

As of October 25, 2024, there have been no newly adopted accounting pronouncements that materially impact our consolidated financial statements.

Refer to the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024 for pronouncements recently adopted.

Not Yet Adopted Accounting Standards

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, Improvements to Segment Reporting (Topic 280), which requires incremental disclosures on reportable segments, primarily through enhanced disclosures on significant segment expenses. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2025 for our annual report and for interim periods starting in fiscal year 2026. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740), which requires incremental annual disclosures on income taxes, including rate reconciliations, income taxes paid, and other disclosures. The Company will adopt this guidance beginning in the fourth quarter of fiscal year 2026 for our annual report. We are currently evaluating the potential effect that the updated standard will have on our financial statement disclosures.

The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, urological and digestive disorders, ear, nose, and throat conditions, and diabetes conditions as well as advanced and general surgical care products, respiratory and monitoring solutions, and neurological surgery technologies. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. Certain prior period net sales has been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. Refer to Note 17 to the consolidated financial statements for additional information regarding the Company's reporting structure. In addition, starting in the first quarter of fiscal year 2025, the Company combined the non-U.S. developed markets and the emerging markets into an international market geography. Prior period net sales has been recast to conform to the new presentation.

The table below illustrates net sales by segment and division and by market geography for the three and six months ended October 25, 2024 and October 27, 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.

	World wide	U.S.	International
Three months ended			
October 25, 2024	\$1,578	\$1,492	\$86
October 27, 2023	\$1,578	\$1,492	\$86
Six months ended			
October 25, 2024	\$3,156	\$3,084	\$172
October 27, 2023	\$3,156	\$3,084	\$172

Cardiac Rhythm & Heart Failure

[illegible]

[illegible]

background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	3,193		
background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	3,187		
background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	Acute Care & Monitoring		
background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">	478		
background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	462		
background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">	930		
background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	921		
background-color:#c0c0c0;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">	Times New Roman, sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%; Medical Surgical		
background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">	2,128		
background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	2,103		
background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	4,123		
background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	4,107		
background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">	Diabetes		
background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">	686		
background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	610		
background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	1,333		
background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	1,189		
background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">	Reportable segment net sales		
background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">	8,366		
background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">	7,923		

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

23 19 37 37 45 38 66 Other adjustments(2) — — — — — — — — — — — — — — — — — —

[illegible]

[illegible]

(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.

(2) Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.

The amount of revenue recognized is reduced by sales rebates and returns. Adjustments to rebates and returns reserves are recorded as increases or decreases to revenue. At October 25, 2024, \$1.0 billion of rebates were classified as other accrued expenses and \$639 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet. At April 26, 2024, \$1.0 billion of rebates were classified as other accrued expenses, and \$574 million of rebates were classified as a reduction of accounts receivable in the consolidated balance sheet.

Deferred Revenue and Remaining Performance Obligations

Deferred revenue at October 25, 2024 and April 26, 2024 was \$467 million and \$453 million, respectively. At October 25, 2024 and April 26, 2024, \$369 million and \$352 million was included in other accrued expenses, respectively, and \$98 million and \$101 million was included in other liabilities, respectively. During the six months ended October 25, 2024, the Company recognized \$196 million of revenue that was included in deferred revenue as of April 26, 2024. During the six months ended October 27, 2023, the Company recognized \$216 million of revenue that was included in deferred revenue as of April 28, 2023.

Remaining performance obligations include goods and services that have not yet been delivered or provided under existing, noncancellable contracts with minimum purchase commitments. At October 25, 2024, the estimated revenue expected to be recognized in future periods related to unsatisfied performance obligations for executed contracts with an original duration of one year or more was approximately \$0.4 billion. The Company expects to recognize revenue on the majority of these remaining performance obligations over the next three years.

The table below illustrates net sales by segment and division and by market geography for the three and six months ended October 25, 2024 and October 27, 2023. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries.

[illegible]

[illegible]

Neuromodulation 480 426 937 846 2,451 2,288 4,768 4,506 1,649 1,641 3,193 3,187 478 462 930

Neuroscience 2,451 2,288 4,768 4,506 1,649 1,641 3,193 3,187 478 462 930

Surgical & Endoscopy 1,649 1,641 3,193 3,187 478 462 930

Acute Care & Monitoring 478 462 930

2		background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom	
921			
Medical Surgical			
2		background-color:#ceefff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom	
2,128		background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
2,103		background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
4,123		background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
4,107		background-color:#ceefff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
686		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
610		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
1,333		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
1,189		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
7,923		background-color:#ceefff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
8,366		background-color:#ceefff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
16,333		background-color:#ceefff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
15,575		background-color:#ceefff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
37		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
61		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
37		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	
61		background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom	

[illegible]

[illegible]

[illegible]

[illegible]

Reportable segment net sales 4,286

4,151

4,080

3,772

8,350

7,983

7,521

Other operating segment

(1)

18

23

19

37

37

45

38

[illegible]

[illegible]

(1) Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.

(2)

weight:400;line-height:120%;padding-left:7.52pt">Incremental Italian payback accruals resulting from the two
July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.
</div>15780000001492000000311400000029380000008810000000173600000016330000000643000000
900000000840300000079840000001631800000015686000000143400000014270000001668000000149600000021
9000000000430400000041750000004099000000380900000083870000008099000000793100000075870000001001
yearsAcquisitions and Dispositions<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">Acquisition Activity</div><div style="margin-bottom:8pt;margin-top:8pt;text-
align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%">During the three and six months ended October 25, 2024, the Company had no
acquisitions that were accounted for as business combinations. During the fiscal year ended April 26, 2024, the
Company had acquisitions that were accounted for as business combinations. For the three and six months ended
October 25, 2024 and the fiscal year ended April 26, 2024, purchase price allocation adjustments were not
significant.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-
height:120%">Fiscal year 2024</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">The acquisition date fair value of net assets acquired during the fiscal year ended April 26, 2024
was \$335 million. Based on preliminary valuations, assets acquired were primarily comprised of \$131 million of
goodwill, \$150 million of IPR&D, and \$29 million of technology-based intangible assets with estimated
useful lives of 10 years. For tax purposes, \$51 million of goodwill is deductible while \$80 million is not
deductible. The IPR&D was placed into service as a definite-lived intangible asset during the second quarter
of fiscal year 2025. The Company recognized \$30 million of non-cash contingent consideration liabilities in
connection with these business combinations during the fiscal year ended April 26, 2024, which are comprised of
revenue and product development milestone-based payments.</div><div style="margin-
bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</div><div
style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's business
combinations involve potential payment of future consideration that is contingent upon the achievement of
certain product development milestones and/or contingent on the acquired business reaching certain
performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the
acquisition date. The fair value of the contingent consideration is remeasured at each reporting period, and the
change in fair value is recognized within <span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other operating income,
net<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
weight:400;line-height:120%"> in the consolidated statements of income.</div><div style="margin-
bottom:8pt;margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-
serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of contingent consideration liabilities at
October 25, 2024 and April 26, 2024 was \$124 million and \$149 million, respectively. At October 25, 2024, \$77
million was recorded in <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:10pt;font-style:italic;font-weight:400;line-height:120%">other accrued expenses<span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">, and \$47 million was recorded in <span style="color:#000000;font-family:'Times New
Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other liabilities
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%"> in the consolidated balance sheet. At April 26, 2024, \$96 million was recorded in <span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-
weight:400;line-height:120%">other accrued expenses<span style="color:#000000;font-family:'Times
New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and \$53 million was recorded in
<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-
style:italic;font-weight:400;line-height:120%">other liabilities<span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated
balance sheet.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-
height:120%">The following table provides a reconciliation of the beginning and ending balances of contingent
consideration liabilities:</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table
style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top-
bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.633%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td
style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td
style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:400;line-height:100%"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-
align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-
weight:700;line-height:100%">Three months ended</td><td colspan="3" style="padding:0 1pt"></td>
<td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-
height:100%">Six months ended</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-
align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-
size:8pt;font-weight:700;line-height:100%">(in millions)</td><td colspan="3" style="border-top:1pt
solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-
family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">October 25, 2024
</td></tr></table></div>

October 27, 2023					
October 25, 2024					
October 27, 2023					
Beginning balance					
128					
206					
149					
206					
Purchase price contingent consideration					
—					
25					
—					
25					
(8)					
(14)					
(3)					

[illegible]

weight:700;line-height:100%">October 25, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unobservable Input</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Range</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Weighted Average(1</div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Revenue and other performance-based payments</td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">\$58</td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">Discount rate</td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><div style="text-align:center">16.5% - 28.2%</div></td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cfe2f3;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">22.1%</td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" style="background-color:#cfe2f3;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cfe2f3;padding:2px 1pt;text-align:center;vertical-align:middle">2025 - 2029</td><td colspan="3" style="background-color:#cfe2f3;padding:2px 1pt;text-align:center;vertical-align:middle">2027</td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Product development and other milestone-based payments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">\$66</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Discount rate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center">5.5%</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">5.5%</td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Projected fiscal year of payment</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2025 - 2027</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">2025</td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1) Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected fiscal year of payment, the amount represents the median of the inputs and is not a weighted average.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">On April 1, 2023, the Company and DaVita Inc. ("DaVita") completed the transaction for the Company to sell half of its Renal Care Solutions (RCS) business. In connection with the sale, the Company may be entitled to receive additional consideration based on the achievement of certain revenue, regulatory, and profitability milestones, with potential payouts starting in fiscal year 2026 through 2029. The fair value of the contingent consideration receivable at October 25, 2024 and April 26, 2024

\$61 million and \$58 million.

and was recorded in other assets

in the consolidated balance sheet.

The following table provides a reconciliation of the beginning and ending balances of the Level 3 measurement of contingent consideration receivable:

	October 25, 2024	October 27, 2023
Beginning balance	\$58	\$152
		\$195
Change in fair value	3	—

[illegible]

[illegible]

[illegible]

[illegible]

12800000020600000014900000020600000002500000002500000003000000014000000300000004000000-10000000-11000000-7000000124000000220000000124000000220000000<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:98.533%"><tr><td style="width:1.0%"></td><td style="width:29.075%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:25.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.973%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.977%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value at</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unobservable Input</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Range</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Weighted Average(1)</div></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Revenue and other performance-based payments</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">\$58</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle">Discount rate</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center">16.5% - 28.2%</div></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e6e6ff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">22.1%</td><td colspan="3" style="height:14pt"><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:center;vertical-align:middle">Projected fiscal year of payment</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e6e6ff;padding:2px 1pt;text-align:center;vertical-align:middle">2025 - 2029</td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#e6e6ff;padding:2px 1pt;text-align:center;vertical-align:middle">2027</td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle">Product development and other milestone-based payments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle">\$66</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Total Restructuring Charges, net

2024	2023
\$30	\$40
\$77	\$94
Total restructuring and associated costs	
\$46	
	\$91
	\$182

The following table summarizes the activity for the six months ended October 25, 2024:

	2024	2023
Employee Termination Benefits	\$108	\$182
Associated and Other Costs	\$108	\$182
Total	\$216	\$364

April 26, 2024

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

33

Total available for sale debt securities		
6,968		
7		
(252)		
6,723		
6,690		
33		

The amortized cost of debt securities excludes accrued interest, which is reported in
other current assets
in the consolidated balance sheets.

The following tables present the gross unrealized losses and fair values of the Company's available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 25, 2024 and April 26, 2024:

October 25, 2024											

[illegible]

3	535	Other asset-backed securities	—	212	(3)	Auction rate securities	—	33	782	Total	\$	782	(10)	3,137	(128)

[illegible]

[illegible]

\$

			Three months ended									Six months ended												
			(in millions)																					
			October 25, 2024																					
			October 27, 2023																					
			October 25, 2024																					
			October 27, 2023																					
			Proceeds from sales																					
			\$																					
			2,087																					
			\$																					
			1,573																					
			\$																					
			4,244																					

\$

3,320		
Gross realized gains		
7		
6		
14		
11		
Gross realized losses		
(6)		
(3)		
(13)		
(15)		

The contractual maturities of available for sale debt securities at October 25, 2024 is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.

<table> <tr> <td style="width: 1.0%;">100.000%</td> <td style="width: 1.0%;">75.166%</td> <td style="width: 1.0%;">0.1%</td> <td style="width: 1.0%;">1.0%</td> <td style="width: 1.0%;">10.500%</td> <td style="width: 1.0%;">0.1%</td> <td style="width: 1.0%;">0.1%</td> <td style="width: 1.0%;">1.0%</td> <td style="width: 1.0%;">10.501%</td> <td style="width: 1.0%;">0.1%</td> </tr> <tr> <td colspan="10"></td> </tr> </table>	100.000%	75.166%	0.1%	1.0%	10.500%	0.1%	0.1%	1.0%	10.501%	0.1%										
100.000%	75.166%	0.1%	1.0%	10.500%	0.1%	0.1%	1.0%	10.501%	0.1%											
(in millions)																				
Amortized Cost																				
Fair Value																				
Due in one year or less																				
1,488																				
1,478																				

#000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Due after one year through five years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,322 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,248 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">Due after five years through ten years</td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">749 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Due after ten years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,148 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,117 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total</td><td colspan="2" style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td colspan="2" style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,708 </td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td colspan="2" style="background-color:#ceceff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,592 </td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td></tr></table><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">Interest income is recognized inother non-operating income, net, in the consolidated statements of income. During the three and six months ended October 25, 2024, there were \$137 million and \$249 million of interest income, respectively. During the three and six months ended October 27, 2023, there was \$148 million and \$259 million of interest income, respectively.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">Equity Securities, Equity Method Investments, and Other Investments</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The Company holds investments in equity securities with readily determinable fair values, equity method investments for which the Company has elected the fair value option, equity investments without readily determinable fair values, investments accounted for under the equity method, and other investments. Equity securities with readily determinable fair values are included in Level 1 of the fair value hierarchy, as they are measured using quoted market prices. Equity method investments for which the Company has elected the fair value option are included within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. To determine the fair value of these investments, the Company uses a discounted cash flow methodology, taking into consideration various assumptions including discount rate, and all pertinent financial information available related to the investees, including the timing of anticipated product launches, historical financial results, and projections of future cash flows. Equity investments that do not have readily determinable fair values, and that are not accounted for via the fair value option, are included within Level 3 of the fair value hierarchy, as they are measured using the measurement alternative at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for an identical or similar investment of the same issuer.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The following table summarizes the Company's equity and other investments at October 25, 2024 and April 26, 2024, which are classified as primarily<span style="color:#000000;font-

family:"Times New Roman",sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">other
assets<span style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-
weight:400;line-height:120%">in the consolidated balance sheets:</div><div style="margin-
bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-
bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td
style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td
style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td
style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td
style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td
style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:"Times New Roman",sans-
serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">
<span style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:8pt;font-weight:700;line-
height:100%">October 25, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:"Times
New Roman",sans-serif;font-size:8pt;font-weight:700;line-height:100%">April 26, 2024</td></tr><tr>
<td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-
height:100%">Investments with readily determinable fair value (marketable equity securities)</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-
top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$</td><td
style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-
align:bottom"><span style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-
weight:400;line-height:100%">34</td><td style="background-color:#cceeef;border-top:1pt solid
#000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-
color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px
0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:"Times New Roman",sans-
serif;font-size:10pt;font-weight:400;line-height:100%">\$</td><td style="background-
color:#cceeef;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-
height:100%">28</td><td style="background-color:#cceeef;border-top:1pt solid #000;padding:2px 1pt
2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-
color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-
family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments for which the
fair value option has been elected</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt">
</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">
<span style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-
height:100%">311</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td
colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-
height:100%">311</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:"Times New Roman",sans-
serif;font-size:10pt;font-weight:400;line-height:100%">Investments without readily determinable fair
values</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-
height:100%">826</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span
style="color:#000000;font-family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-
height:100%">859</td><td style="background-color:#cceeef;padding:2px 1pt 2px 0;text-
align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px
1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:"Times New Roman",sans-
serif;font-size:10pt;font-weight:400;line-height:100%">Equity method and other investments</td><td colspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td
colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-
color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-
family:"Times New Roman",sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</td><td
style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom">Total equity and other investments</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,265</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-

bottom:3pt double #000;border-bottom-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,282 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">Gains and losses on the Company's portfolio of equity and other investments are recognized in other non-operating income, net in the consolidated statements of income. During the three and six months ended October 25, 2024, there were \$10 million of net unrealized losses and \$7 million of net unrealized gains, respectively, on equity securities and other investments still held at October 25, 2024. During the three and six months ended October 27, 2023, there were \$7 million and \$70 million, respectively, of net unrealized losses on equity securities and other investments still held at October 27, 2023.</div><div style="text-align:justify">Mozarc Medical Investment</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">As further described in Note 4, on April 1, 2023, the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50 percent equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction.</div><div style="text-align:justify">Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in other non-operating income, net in the consolidated statements of income. During the three and six months ended October 25, 2024 and October 27, 2023, the change in fair value was not significant.</div><div style="text-align:justify">The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at October 25, 2024 and April 26, 2024:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Valuation</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet Classification</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cost</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Gains</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized
Losses</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Investments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Other Assets</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="

[illegible]

3,384

U.S. government and agency securities

874

(28)

845

845

Mortgage-backed securities

772

3

(33)

742

742

9

Non-U.S. government and agency securities

9

[illegible]

[illegible]

[illegible]

[illegible]

securities			692			1			50			643			643			643			Non-U.S. government and agency securities			5			5			5			5			5			941			934			934		
Other asset-backed securities			692			1			50			643			643			643			Non-U.S. government and agency securities			5			5			5			5			5			941			934			934		

—

Total Level 2	6,438	7	(227)	6,218	6,218	Level 3:					Auction rate securities	36			(3)	33	33	Total available-for-sale debt securities	\$	6,968

[illegible]

[illegible]

Auction rate securities

Total	782
(10)	3,137
(128)	

April 26, 2024

Less than 12 months

3

21

9

	More than 12 months (in millions)	Fair Value	Unrealized Losses	Corporate debt securities	661	2,448	177	730	582
				U.S. government and agency securities				Mortgage-backed securities	

[illegible]

[illegible]

[illegible]

height:100%">Due after ten years</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,148</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,117</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">6,708</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">6,592</td><td style="background-color:#ceeeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>148800000014780000003322000000324800000075000000074900000011480000001170000000670800000<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The following table summarizes the Company's equity and other investments at October 25, 2024 and April 26, 2024, which are classified as primarilyother assetsin the consolidated balance sheets:</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;bottom:width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.366%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">April 26, 2024</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Investments with readily determinable fair value (marketable equity securities)</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">34</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Investments for which the fair value option has been elected</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">311</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom">311</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Investments without readily determinable fair values</td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">\$</td></tr></table></div>

826

859

Equity method and other investments

92

84

Total equity and other investments

1,265

1,282

3400000028000000311000000311000000826000000859000000920000008400000012650000001282000007000000700000000.500000

Financing Arrangements

The Company maintains commercial paper programs that allow the Company to issue U.S. dollar or Euro-denominated unsecured commercial paper notes. The aggregate amount outstanding at any time under the commercial paper programs may not exceed the equivalent of \$3.5 billion. Commercial paper outstanding at October 25, 2024 was \$899 million. During the three and six months ended October 25, 2024, the commercial paper outstanding had a weighted average original maturity of 13 days and 14 days, respectively and a weighted average interest rate of 5.23 percent and 5.34 percent, respectively. Commercial paper outstanding at April 26, 2024 was \$1.1 billion. During fiscal year 2024, the weighted average original maturity of the commercial paper outstanding was approximately 20 days and the weighted average interest rate was 5.45 percent. The issuance of commercial paper reduces the amount of credit available under the Company's existing Credit Facility, as defined below.

Line of Credit

The Company has a \$3.5 billion five-year unsecured revolving credit facility (Credit Facility), which provides back-up funding for the commercial paper programs described above. The Credit Facility includes a multi-currency borrowing feature for certain specified foreign currencies. At October 25, 2024 and April 26, 2024, no amounts were outstanding under the Credit Facility.

Interest rates on advances on the Credit Facility

Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company's long-term debt ratings, assigned by Standard & Poor's Ratings Services and Moody's Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The Company is in compliance with the covenants under the Credit Facility.

Debt Obligations

The Company's debt obligations consisted of the following:

	October 25, 2024	April 26, 2024
Unsecured revolving credit facility	\$899 million	\$1.1 billion
Commercial paper	\$899 million	\$1.1 billion
Other debt obligations	\$1.1 billion	\$1.1 billion
Total debt obligations	\$2.0 billion	\$2.0 billion

(in millions)

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

4.150 percent		
nineteen		
year 2024 senior notes		
2044		
648		
—		
4.625 percent		
thirty		
year 2014 senior notes		
2044		
127		
127		
4.625 percent		
thirty		
year 2015 senior notes		
2045		
1,813		
1,813		
1.750 percent		
thirty		
year 2019 senior notes		
2050		
1,080		
1,070		
1,070		
1.625 percent		
thirty		
year 2020 senior notes		
2051		
1,080		
1,070		

[illegible]

interest expense, net

in the consolidated statements of income. During the three and six months ended October 25, 2024, there was \$252 million and \$469 million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums.

During the three and six months ended October 27, 2023, there was \$230 million and \$427 million, respectively, of interest expense on outstanding borrowings, including amortization of debt issuance costs and debt discounts and premiums.

Senior Notes

The Company has outstanding unsecured senior obligations, described as senior notes in the tables above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The Company is in compliance with all covenants related to the Senior Notes.

On June 3, 2024, Medtronic Inc. issued four tranches of EUR-denominated Senior Notes with an aggregate principal of €3.0 billion, with maturities ranging from fiscal year 2030 to 2054, resulting in cash proceeds of approximately \$3.2 billion, net of discounts and issuance costs. In anticipation of the Euro-denominated debt issuance, the Company entered into forward currency exchange rate contracts to manage the exposure to exchange rate movements. These contracts were settled in conjunction with the issuance of the June 2024 Notes.

Financial Instruments Not Measured at Fair Value

At October 25, 2024, the estimated fair value of the Company's Senior Notes was \$25.3 billion compared to a principal value of \$27.4 billion. At April 26, 2024, the estimated fair value was \$21.2 billion compared to a principal value of \$24.0 billion. The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and hedging activity.

	October 25, 2024	April 26, 2024
Total debt obligations	\$27.4 billion	\$24.0 billion
Less: Current debt obligations	(3.2 billion)	(2.8 billion)
Long-term debt obligations	\$24.2 billion	\$21.2 billion

[illegible]

1,000	3.000 percent	2022 senior notes	2029	1,080	0.375 percent	2020 senior notes	2029	1,080	1,080	918	1.625 percent	2019 senior notes	2031	1,080	1,000 percent	2019 senior notes	2032	1,080	1,070

[illegible]

12

2037	918	6.550 percent	30	2007 CIFSA senior notes	30
2038	253	2.250 percent	20	2019 senior notes	20
2039	1,080	1.070	1,070	2009 senior notes	30
2039	158	158	158	2010 senior notes	30
2040	1,080	1,070	1,070	2010 senior notes	30
2040	1,080	1,070	1,070	2010 senior notes	30

[illegible]

[illegible]

over the life of the hedging instrument were not significant. Cash flows related to the Company's derivative instruments designated as fair value hedges are reported as financing activities in the consolidated statements of cash flows. Cash flows attributed to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.

Cash Flow Hedges

The Company uses foreign currency forward and option contracts designated as cash flow hedges to manage its exposure to the variability of future cash flows that are denominated in a foreign currency.

At inception, foreign currency forward and option contracts are designated as cash flow hedges. Changes in the fair value of these derivatives are reported as a component of accumulated other comprehensive loss until the hedged transaction affects earnings. When the hedged transaction affects earnings, the gain or loss on the derivative is reclassified to earnings. Amounts excluded from the measurement of hedge effectiveness are recognized in earnings on a straight-line basis over the term of the hedge. Cash flows are reported as operating activities in the consolidated statements of cash flows.

The Company's cash flow hedges will mature within the subsequent three-year period. At October 25, 2024 and April 26, 2024, the Company had \$139 million and \$229 million in after-tax unrealized gains, respectively, associated with cash flow hedging instruments recorded in accumulated other comprehensive loss. The Company expects that \$108 million of after-tax net unrealized gains at October 25, 2024 will be recognized in the consolidated statements of income over the next 12 months.

Net Investment Hedges

The Company uses derivative instruments and foreign currency denominated debt to manage foreign currency risk associated with its net investment in foreign operations. The derivative instruments that the Company uses for this purpose may include foreign currency forward exchange contracts used on a standalone basis or in combination with option collars and standalone cross currency interest rate contracts.

For instruments that are designated as net investment hedges, the gains or losses are reported as a component of accumulated other comprehensive loss. The gains or losses are reclassified into earnings upon a liquidation event or deconsolidation of the foreign subsidiary. Amounts excluded from the assessment of effectiveness are recognized in interest expense, net on a straight-line basis over the term of the hedge. During the three and six months ended October 25, 2024, the Company recognized \$47 million and \$98 million, respectively, in after-tax unrealized gains representing excluded components in interest expense, net. During the three and six months ended October 27, 2023, the Company recognized \$50 million and \$99 million, respectively, in after-tax unrealized gains representing excluded components in interest expense, net. The cash flows related to the Company's derivative instruments designated as net investment hedges are reported as investing activities in the consolidated statements of cash flows. Cash flows attributable to amounts excluded from the assessment of effectiveness are reported as operating activities in the consolidated statements of cash flows.

Undesignated Derivatives

The Company uses foreign currency forward exchange contracts to offset the Company's exposure to the change in the value of non-functional currency denominated assets, liabilities, and cash flows.

These foreign currency forward exchange rate contracts are not designated as hedges at inception, and therefore, changes in the fair value of these contracts are recognized in the consolidated statements of income. Cash flows related to the Company's undesignated derivative contracts are reported in the consolidated statements of cash flows based on the nature of the derivative instrument.

Outstanding Instruments

The following table presents the contractual amounts of the Company's

outstanding instruments:											
As of			(in billions)			Designation			October 25, 2024		
April 26, 2024			Fair value hedge			\$			1.1		
\$			\$			\$			10.4		
Currency exchange rate contracts			Cash flow hedge			Currency exchange rate contracts			Net investment hedge		
(2)			11.3			10.4			7.4		
7.5			7.4			Foreign currency-denominated debt			(3)		
Net investment hedge			Foreign currency-denominated debt			Net investment hedge			Net investment hedge		

19.4

17.1

Currency exchange rate contracts

Undesignated

4.7

5.9

(1)

At October 25, 2024, includes derivative contracts with a notional value of €1.0 billion, or \$1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.

(2)

At October 25, 2024, includes derivative contracts with a notional value of €5.0 billion, or \$5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of ¥322.2 billion, or \$2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033.

(3)

At October 25, 2024, includes €18.0 billion, or \$19.4 billion, of outstanding Euro-denominated debt designated as hedges of a portion of our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.

Gains and Losses on Hedging Instruments and Derivatives not Designated as Hedging Instruments

The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three and six months ended October 25, 2024 and October 27, 2023 were as follows:

	October 25, 2024	October 27, 2023
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	\$1.4 billion	\$1.4 billion
(Gain) Loss Reclassified into Income	\$0.1 billion	\$0.1 billion
Total	\$1.5 billion	\$1.5 billion

(Gain) Loss Recognized in Accumulated Other Comprehensive Loss

(Gain) Loss Reclassified into Income

[illegible]

[illegible]

[illegible]

	(160)	Total	\$	(1,384)	(1,278)	(89)	(78)

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

<td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">589 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">110 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">659 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#ceeeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The cash flows related to collateral posted and received are reported gross as investing and financing activities, respectively, in the consolidated statements of cash flows.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amount of Recognized Assets (Liabilities)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid

Financial Instruments			Cash Collateral (Received) Posted			Net Amount		
Derivative assets:			Currency exchange rate contracts			574		
(107)			(52)			417		
Total return swaps			15			15		

[illegible]

[illegible]

[illegible]

[illegible]

April 26, 2024		
Currency exchange rate contracts		
Fair value hedge		
\$		
1.1		
\$		
—		
Currency exchange rate contracts		
Cash flow hedge		
11.3		
10.4		
Currency exchange rate contracts		
(2)		
Net investment hedge		
7.5		
7.4		
Foreign currency-denominated debt		
(3)		
Net investment hedge		
19.4		
17.1		
Currency exchange rate contracts		
Undesignated		
4.7		
5.9		

(1) At October 25, 2024, includes derivative contracts with a notional value of €1.0 billion, or \$1.1 billion, designated as hedges of a portion of our fixed-rate debt obligations.

(2) At October 25, 2024, includes derivative contracts with a notional value of €5.0 billion, or \$5.4 billion, designated as hedges of a portion of our net investment in certain European operations and derivative contracts with a notional value of ¥322.2 billion, or \$2.1 billion, designated as hedges of a portion of our net investment in certain Japanese operations. These derivative contracts mature in fiscal years 2025 through 2033.

(3) At October 25, 2024, includes €18.0 billion, or \$19.4 billion, of outstanding Euro-denominated debt designated as hedges of a portion of our net investment in foreign operations. This debt matures in fiscal years 2026 through 2054.

The amount of the gains and losses on hedging instruments and the classification of those gains and losses within our consolidated financial statements for the three and six months ended October 25, 2024 and October 27, 2023 were as follows:

	October 25, 2024	October 27, 2023	December 31, 2022
(Gain) Loss Recognized in Accumulated Other Comprehensive Loss	\$1.0	\$1.0	\$1.0
(Gain) Loss Reclassified into Income	\$6.4	\$6.4	\$6.4
Three months ended	\$7.4	\$7.4	\$7.4
Six months ended	\$7.4	\$7.4	\$7.4
Location of (Gain) Loss in Income Statement	Other income	Other income	Other income
(in millions)			
October 25, 2024			
October 27, 2023			
December 31, 2022			

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

214000000127800000024000000890000007800000014500000035000000-9400000045000000-92000000<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The following table summarizes the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at October 25, 2024 and April 26, 2024. The fair value amounts are presented on a gross basis, and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.700%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value - Assets</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value - Liabilities</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">April 26, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet Classification</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">April 26, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet Classification</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as hedging instruments</td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Currency exchange rate contracts</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">328</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px

[illegible]

[illegible]

[illegible]

[illegible]

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">659</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">66</td><td style="background-color:#cceeef;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table>

</div>5740000001100000006590000006600000015000000000589000000110000000065900000066000000<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The following tables provide information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.700%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.033%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amount Not Offset on the Balance Sheet</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Amount of Recognized Assets (Liabilities)</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Financial Instruments</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Cash Collateral (Received) Posted</td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net Amount</td></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivative assets:</td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Currency exchange rate contracts</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642

Raw materials	1,022	907
Total	5,479	5,217

\$

Inventory balances were as follows:

Finished goods	Work-in-process	Raw materials
3,729	3,668	728

\$

642

1,022

color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">907

color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total			color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479	color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,217																																																																																																																																																																																																								
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and Other Intangible Assets			color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill																																																																																																																																																																																																									
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amount of goodwill by segment:																																																																																																																																																																																																												
<table><tr><td colspan="5">border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%</td></tr><tr><td>width:1.0%</td><td>width:38.233%</td><td>width:0.1%</td><td>width:1.0%</td><td>width:0.1%</td></tr><tr><td>width:1.0%</td><td>width:10.500%</td><td>width:0.1%</td><td>width:0.1%</td><td>width:0.1%</td></tr><tr><td>width:0.1%</td><td>width:0.466%</td><td>width:0.1%</td><td>width:1.0%</td><td>width:10.500%</td></tr><tr><td>width:0.1%</td><td>width:0.466%</td><td>width:0.1%</td><td>width:0.1%</td><td>width:0.1%</td></tr><tr><td>width:1.0%</td><td>width:10.500%</td><td>width:0.1%</td><td>width:0.1%</td><td>width:0.1%</td></tr><tr><td>width:0.1%</td><td>width:0.466%</td><td>width:0.1%</td><td>width:0.1%</td><td>width:0.1%</td></tr><tr><td>width:1.0%</td><td>width:10.503%</td><td>width:0.1%</td><td colspan="2"></td></tr><tr><td colspan="5">padding:2px 1pt;text-align:left;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</td></tr><tr><td colspan="5">padding:2px 1pt;text-align:center;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular</td></tr><tr><td colspan="5">padding:0 1pt</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience</td></tr><tr><td colspan="5">padding:0 1pt</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical</td></tr><tr><td colspan="5">padding:2px 1pt;text-align:center;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes</td></tr><tr><td colspan="5">padding:0 1pt</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</td></tr><tr><td colspan="5">background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom</td></tr><tr><td colspan="5">background-color:#e6e6ff;padding:0 1pt</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,644</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom</td></tr><tr><td colspan="5">background-color:#e6e6ff;padding:0 1pt</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom</td></tr><tr><td colspan="5">color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,121</td></tr><tr><td colspan="5">background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom</td></tr><tr><td colspan="5">background-color:#e6e6ff;padding:0 1pt</td></tr></table>					border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%					width:1.0%	width:38.233%	width:0.1%	width:1.0%	width:0.1%	width:1.0%	width:10.500%	width:0.1%	width:0.1%	width:0.1%	width:0.1%	width:0.466%	width:0.1%	width:1.0%	width:10.500%	width:0.1%	width:0.466%	width:0.1%	width:0.1%	width:0.1%	width:1.0%	width:10.500%	width:0.1%	width:0.1%	width:0.1%	width:0.1%	width:0.466%	width:0.1%	width:0.1%	width:0.1%	width:1.0%	width:10.503%	width:0.1%			padding:2px 1pt;text-align:left;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)					padding:2px 1pt;text-align:center;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular					padding:0 1pt					color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience					padding:0 1pt					color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical					padding:2px 1pt;text-align:center;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes					padding:0 1pt					color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total					background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom					background-color:#e6e6ff;padding:0 1pt					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,644					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom					background-color:#e6e6ff;padding:0 1pt					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom					color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,121					background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom					background-color:#e6e6ff;padding:0 1pt				
border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;width:100.000%																																																																																																																																																																																																												
width:1.0%	width:38.233%	width:0.1%	width:1.0%	width:0.1%																																																																																																																																																																																																								
width:1.0%	width:10.500%	width:0.1%	width:0.1%	width:0.1%																																																																																																																																																																																																								
width:0.1%	width:0.466%	width:0.1%	width:1.0%	width:10.500%																																																																																																																																																																																																								
width:0.1%	width:0.466%	width:0.1%	width:0.1%	width:0.1%																																																																																																																																																																																																								
width:1.0%	width:10.500%	width:0.1%	width:0.1%	width:0.1%																																																																																																																																																																																																								
width:0.1%	width:0.466%	width:0.1%	width:0.1%	width:0.1%																																																																																																																																																																																																								
width:1.0%	width:10.503%	width:0.1%																																																																																																																																																																																																										
padding:2px 1pt;text-align:left;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)																																																																																																																																																																																																												
padding:2px 1pt;text-align:center;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cardiovascular																																																																																																																																																																																																												
padding:0 1pt																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Neuroscience																																																																																																																																																																																																												
padding:0 1pt																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Surgical																																																																																																																																																																																																												
padding:2px 1pt;text-align:center;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Diabetes																																																																																																																																																																																																												
padding:0 1pt																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total																																																																																																																																																																																																												
background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 26, 2024																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,966																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom																																																																																																																																																																																																												
background-color:#e6e6ff;padding:0 1pt																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,644																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom																																																																																																																																																																																																												
background-color:#e6e6ff;padding:0 1pt																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">\$																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom																																																																																																																																																																																																												
color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,121																																																																																																																																																																																																												
background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom																																																																																																																																																																																																												
background-color:#e6e6ff;padding:0 1pt																																																																																																																																																																																																												

[illegible]

#000000;padding:0 1pt"></td><td style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">41,161 </td><td style="background-color:#cceedd;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">As further described in Note 17, the Company had changes to the operating segments and goodwill reporting units during the fourth quarter of fiscal year 2024. For further information on the reporting unit changes, refer to Note 9 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. No goodwill impairment was recognized during the three and six months ended October 25, 2024 and October 27, 2023.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The following table presents the gross carrying amount and accumulated amortization of intangible assets:</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">April 26, 2024</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross Carrying Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated Amortization</td></tr><tr><td colspan="3" style="background-color:#cceedd;padding:2px 1pt;text-align:left;vertical-align:bottom">Definite-lived:</td><td colspan="3" style="background-color:#cceedd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceedd;padding:0 1pt"></td><td colspan="3" style="background-color:#cceedd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceedd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceedd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceedd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer-related</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">16,523 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">(9,164) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">16,518 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

Legal

(8,689)	Purchased technology and patents
11,727	Trademarks and tradenames
425	Other
254	Total

Financial

28,929	Total

New Roman'<div style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">28,755</div><div style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</div><div style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(15,915)</div><div style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></div></tr><tr><td colspan="3" style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom">Indefinite-lived:</td><td colspan="3" style="background-color:#cceeef;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeef;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">IPR&D</td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">235</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">385</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The Company did not recognize any definite-lived intangible asset impairment charges during the three and six months ended October 25, 2024 and October 27, 2023.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The Company did not recognize any indefinite-lived intangible asset impairment charges during the three and six months ended October 25, 2024. Indefinite-lived intangible asset impairment charges were not significant for the three and six months ended October 27, 2023. Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of clinical trials, delays or failures to obtain required market clearances, other failures to achieve a commercially viable product, or the discontinuation of certain projects, and as a result, may recognize impairment losses in the future.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">Amortization Expense</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">Intangible asset amortization expense for the three months ended October 25, 2024 and October 27, 2023 was \$413 million and \$425 million, respectively. Intangible asset amortization expense for the six months ended October 25, 2024 and October 27, 2023 was \$827 million and \$855 million, respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 25, 2024, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortization Expense</td></tr></table></div><div style="background-color:#cceeef;padding:2px 1pt;text-align:left;vertical-align:bottom"></div></div>

Remaining 2025

824	1,639	1,616	1,565	1,488	1,356
2026	2027	2028	2029	2030	2031

The following table presents the changes in the carrying amount of goodwill by segment:

(in millions)	Cardiovascular	Neuroscience	Medical Surgical	Diabetes	Total
April 26, 2024	7,966				

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

height:100%;>385</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">—</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>16523000000091640000001651800000086890000001172700000072060000001155700000006868000000425, aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 25, 2024, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:top;bottom:width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortization Expense</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Remaining 2025</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">824</td><td style="background-color:#ceeeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2026</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,639</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2027</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,616</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2028</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,565</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom">2029</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,488</td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">2030</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,356</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>82400000016390000001616000000156500000014880000001356000000Income Taxes<div style="margin-top:8pt;text-align:justify">The Organization for Economic Co-operation and Development (OECD) published Pillar Two Model Rules defining the global minimum tax, which calls for the taxation of large multinational corporations at a minimum rate of 15% in each jurisdiction in which the group operates. The OECD has since issued administrative guidance providing transition and safe harbor rules around the implementation of the Pillar Two global minimum tax. A number of countries, including Ireland, have enacted legislation to implement the core elements of Pillar Two, which are effective for the Company in fiscal year 2025. We will continue to monitor the impacts of further legislation, regulatory guidance, and regulations issued in the countries in which we do business.</div><div style="margin-top:8pt;text-align:justify">The Israeli Central Lod District Court issued its decision in the Medtronic Ventor Technologies Ltd (Ventor) v. Kfar Saba Assessing Office on June 1, 2023. The court determined that there was a deemed taxable transfer of intellectual property. As a result, the Company recorded a \$187 million income tax charge

The first quarter of fiscal year 2024 and has filed an appeal with the Supreme Court of Israel.

The Company's effective tax rate for the three and six months ended October 25, 2024 was 18.0% and 17.7%, respectively, as compared to 30.6% and 32.0% for the three and six months ended October 27, 2023, respectively. The decrease in the effective tax rate for the three months ended October 25, 2024, primarily relates to the establishment of a valuation allowance on certain net operating losses recorded during the three months ended October 27, 2023, which was partially offset by the implementation of the Pillar Two global minimum tax. In addition to the items discussed in the current quarter, the decrease in the effective tax rate for the six months ended October 25, 2024 was also attributable to an income tax reserve adjustment made during the six months ended October 27, 2023 associated with the Vontor court decision noted above.

At October 25, 2024 and April 26, 2024, the Company's gross unrecognized tax benefits were \$2.9 billion and \$2.8 billion, respectively. In addition, the Company had accrued gross interest and penalties of \$45 million at October 25, 2024. If all of the Company's unrecognized tax benefits were recognized, approximately \$2.7 billion would impact the Company's effective tax rate. At October 25, 2024 and April 26, 2024, the amount of the Company's gross unrecognized tax benefits, net of cash advance, recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheets was \$1.9 billion and \$1.8 billion, respectively. The Company recognizes interest and penalties related to income tax matters within income tax provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheets.

Refer to Note 16 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

1870000000.1800.1770.3060.3202900000000280000000045000000270000000019000000001800000000

Earnings Per Share

Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan.

The table below sets forth the computation of basic and diluted earnings per share:

	Three months ended October 25, 2024	Six months ended October 25, 2024	Three months ended October 27, 2023	Six months ended October 27, 2023
Numerator				
Denominator				
Weighted average number of shares outstanding	187,000,000	180,000,000	177,000,000	306,000,000
Weighted average number of shares outstanding, including potentially dilutive shares	187,000,000	180,000,000	177,000,000	320,290,000
Earnings per share	\$0.91	\$0.95	\$0.28	\$0.28

(in millions, except per share data)

October 25, 2024

October 27, 2023

Background color: #e6e6ff; padding: 2px 1pt; text-align: left; vertical-align: bottom

Numerator:

Denominator:

Weighted average number of shares outstanding

Weighted average number of shares outstanding, including potentially dilutive shares

Earnings per share

[illegible]

[illegible]

[illegible]

October 27, 2023		
Numerator:		
Net income attributable to ordinary shareholders		
\$		
1,270		
\$		
909		
2,312		
1,700		
Denominator:		
Basic – weighted average shares outstanding		
1,282.4		
1,330.2		
1,288.6		
1,330.3		
Effect of dilutive securities:		

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Selling, general, and administrative expense		
123		
115		
187		
172		
Total stock-based compensation expense		
159		
146		
242		
219		
Income tax benefits		
(25)		
(25)		
(38)		
Total stock-based compensation expense, net of tax		
\$		
134		

family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 400; line-height: 100%;>\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 0; text-align: right; vertical-align: bottom">121</td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom">204</td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td><td colspan="3" style="background-color: #ffffff; padding: 0 1pt"></td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 0 2px 1pt; text-align: left; vertical-align: bottom">\$</td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 0; text-align: right; vertical-align: bottom">183</td><td style="background-color: #ffffff; border-bottom: 3pt double #000000; border-top: 1pt solid #000000; padding: 2px 1pt 2px 0; text-align: right; vertical-align: bottom"></td></tr></table></div>300000000350000000420000000460000000680000000550000000111000000093000000054000000048000000006900000 style="color: #000000; font-family: 'Times New Roman', sans-serif; font-size: 10pt; font-weight: 700; line-height: 120%">Retirement Benefit Plans<div style="margin-bottom: 8pt; margin-top: 8pt; text-align: justify">The Company sponsors various retirement benefit plans, including defined benefit pension plans, post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 25, 2024 and October 27, 2023:</div><div style="margin-bottom: 8pt; margin-top: 8pt; text-align: justify"><table style="border-collapse: collapse; display: inline-table; margin-bottom: 5pt; vertical-align: text-bottom; width: 100.000%"><tr><td style="width: 1.0%"></td><td style="width: 26.500%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 7.433%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.466%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 7.433%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.466%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 7.433%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.466%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 7.433%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.333%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 7.433%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.333%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 7.433%"></td><td style="width: 0.1%"></td><td style="width: 0.1%"></td><td style="width: 0.333%"></td><td style="width: 0.1%"></td><td style="width: 1.0%"></td><td style="width: 7.439%"></td><td style="width: 0.1%"></td></tr><tr><td colspan="3" style="padding: 2px 1pt; text-align: left; vertical-align: bottom"></td><td colspan="9" style="border-bottom: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">U.S.</td><td colspan="3" style="padding: 0 1pt"></td><td colspan="9" style="border-bottom: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">Non-U.S.</td><td colspan="3" style="padding: 0 1pt"></td><td colspan="9" style="border-bottom: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">U.S.</td><td colspan="3" style="padding: 0 1pt"></td><td colspan="9" style="border-bottom: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">Non-U.S.</td></tr><tr><td colspan="3" style="padding: 2px 1pt; text-align: left; vertical-align: bottom"></td><td colspan="21" style="border-top: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">Three months ended</td><td colspan="3" style="padding: 0 1pt"></td><td colspan="21" style="border-top: 1pt solid #000000; padding: 2px 1pt; text-align: center; vertical-align: bottom">Six months ended</td></tr><tr><td colspan="3" style="padding: 2px 1pt; text-align: left; vertical-align: bottom">(in millions)</td><td colspan="3" style="border-top: 1pt solid #000; padding: 0 1pt"></td><td colspan="3" style="border-top: 1pt solid #000; padding: 2px 1pt; text-align: center; vertical-align: bottom">October 25, 2024</td><td colspan="3" style="border-top: 1pt solid #000; padding: 0 1pt"></td><td colspan="3" style="border-top: 1pt solid #000; padding: 2px 1pt; text-align: center; vertical-align: bottom">October 27, 2023</td><td colspan="3" style="border-top: 1pt solid #000; padding: 0 1pt"></td><td colspan="3" style="border-top: 1pt solid #000; padding: 2px 1pt; text-align: center; vertical-align: bottom"></td></tr></table></div>

[illegible]

[illegible]

[illegible]

[illegible]

Components of net periodic benefit (credit) cost other than the service component are recognized in other non-operating income, net in the consolidated statements of income.

The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 25, 2024 and October 27, 2023:

	October 25, 2024	October 27, 2023
Service cost	\$1.0 million	\$1.0 million
Interest cost	\$7.4 million	\$7.4 million
Remeasurement gain	(0.1) million	(0.1) million
Net periodic benefit cost	\$7.4 million	\$7.4 million
Other non-operating income	(0.3) million	(0.3) million
Net periodic benefit cost, net of other non-operating income	\$7.1 million	\$7.1 million

U.S.

Non-U.S.

[illegible]

[illegible]

[illegible]

[illegible]

130000000150000001100000010000000260000003000000002200000020000000430000004000000013000000
 10000000-100000000-2000000-2000000000-4000000-5000000000-8000000-10000000-10000000-7000000-
 60000000700000005000000-14000000-120000001400000010000000Accumulated Other
 Comprehensive LossThe following table provides changes in accumulated other
 comprehensive loss (AOCI), net of tax, and by component:

|--|--|--|

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">387</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(3,377)</td><td style="background-color:#cceeef;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>-212000000-3686000000878000000-529000000229000000-3318000000102000000218000000-170000000-1000000-370000000111000000-900000000-30000005500000043000000111000000218000000-1700000001000000-9300000069000000-101000000-3468000000708000000-529000000139000000-3250000000-258000000-2839000000245000000-74100000093000000-3499000000-490000000-9090000007710000000404000000217000000-1100000000-400000011000000095000000-38000000-9090000007710000004000000294000000122000000-296000000-37480000001016000000-737000000387000000-337700000019000000-8000000-2000000300000000-100000000010000002000000-5000000103000000-22000000-34000000Commitments and Contingencies<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">Legal Matters</div><div style="margin-top:8pt;text-align:justify">The Company and its affiliates are involved in a number of legal actions from time to time involving product liability, employment, intellectual property and commercial disputes, shareholder related matters, environmental proceedings, tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state, and local governmental agencies in the United</div><div style="margin-top:8pt;text-align:justify">States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company's standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of legal actions are not within the Company's complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. The Company classifies certain specified litigation charges and gains related to significant legal matters ascertain litigation charges, netin the consolidated statements of income. The Company recognized no certain litigation charges and \$81 million of certain litigation charges during the three and six months ended October 25, 2024, respectively, whereas the Company recognized \$65 million and \$105 million of certain litigation charges during the three and six months ended October 27, 2023, respectively. At October 25, 2024 and April 26, 2024, accrued litigation was approximately \$0.2 billion. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation inother accrued expensesandother liabilitieson the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">Intellectual Property Matters</div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify">At any given time, the Company is involved in litigation relating to patents, trademarks, copyrights, trade secrets, and other intellectual property (IP) rights, and licenses, acquisitions or other agreements relating to such rights. This litigation

includes, but is not limited to, alleged infringement or misappropriation of IP rights, or breach of obligations related to IP rights, or other claims asserted by competitors, individuals, or, consistent with a growing trend across technology-intensive industries, other entities created specifically to fund IP litigation. While the outcome of these litigation matters is inherently uncertain, it is possible that the results of such litigation could require the Company to pay significant monetary damages and/or royalty payments, and negatively impact the Company's ability to sell current or future products, which could have a material adverse impact on the Company's business, results of operations, financial condition, and cash flows.

Colibri

The Company is a defendant in patent litigation brought by Colibri Heart Valve LLC (Colibri) in the U.S. District Court for the Central District of California. Colibri alleges infringement of one patent by the Company's Evolut family of transcatheter aortic valve replacement devices. The patent asserted by Colibri has expired. On February 8, 2023, a jury returned a verdict against the Company for approximately \$106 million. In July 2023, the Company filed its appeal with the U.S. Court of Appeals for the Federal Circuit. The Company has not recognized an expense in connection with this matter because it does not currently believe a loss is probable.

Product Liability Matters

Hernia Mesh Litigation

Starting in fiscal year 2020, plaintiffs began filing lawsuits against certain subsidiaries of the Company in U.S. state and federal courts that allege personal injury from hernia mesh products sold by those subsidiaries. As of October 30, 2024, the Company and certain of its subsidiaries have been named as defendants in lawsuits filed on behalf of approximately 8,800 individual plaintiffs, and certain plaintiffs' law firms have advised the Company that they may file additional cases in the future. Approximately 6,850 plaintiffs have pending lawsuits in a coordinated proceeding in Massachusetts state court, where they have been consolidated before a single judge. Approximately 500 plaintiffs have pending lawsuits in a coordinated action in Minnesota state court, and there are approximately 1,450 actions coordinated in a federal Multidistrict Litigation in the U.S. District Court for the District of Massachusetts plus fewer than ten one-off cases filed in other courts. The pending lawsuits relate almost entirely to hernia mesh products that have not been subject to recalls, withdrawals, or other adverse regulatory action. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Diabetes Pump Retainer Ring Litigation

Starting in fiscal year 2021, plaintiffs began filing lawsuits against the Diabetes operating unit in U.S. state and federal courts alleging personal injury from Series 600 insulin pumps with allegedly defective clear retainer rings that were subject to field corrective actions in 2019 and 2021. As of November 4, 2024, after a number of recent dismissals of individual plaintiffs, there are 23 lawsuits filed on behalf of 76 individuals. Plaintiffs' firms previously notified the Company that they may file additional lawsuits in the future on behalf of thousands of additional claimants. Most of the filed suits are coordinated in California state court. The Company has not recorded an expense related to damages in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Environmental Proceedings

The Company is a successor to several investigation and cleanup actions at various stages related to environmental remediation matters at a number of sites, including in Orrington, Maine. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods.

The Company is also a successor to a party named in a lawsuit filed in the U.S. District Court for the District of Maine in the early 2000's by the Natural Resources Defense Council and the Maine People's Alliance relating to mercury contamination of the Penobscot River and Bay and options for remediating such contamination. In October 2022, the court issued a final order approving the settlement and the parties are working with consultants on implementation of remedial activities. The final court order did not result in a change to the Company's previous accrual for this matter.

The Company's accrued expenses for these various environmental proceedings are included within accrued litigation as discussed above.

Anti-Corruption Matters

The Company has regular and ongoing interactions with governmental agencies, and its practice is to cooperate with such inquiries. In addition, from time to time, the Company self-discloses potential concerns to governmental regulators. Like many in the medical device industry or with international operations, the Company engages in periodic discussions with the U.S. Securities and Exchange Commission, U.S. Department of Justice, and various authorities in China regarding certain activities, including in China. The Company is committed to

regularly evaluating and, as appropriate, strengthening its anti-corruption compliance programs and practices. Any possible future determination that certain of our operations and activities, and/or those of our third-party distributors, are not in compliance with existing laws could result in the imposition of fines, penalties, and equitable remedies in the United States or in other jurisdictions. The Company has not recorded an expense in connection with these matters because any potential loss is not currently probable and reasonably estimable. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters.

Other Matters

Italian Payback

In 2015, "payback" legislation was enacted in Italy requiring companies selling medical devices to make payments to the Italian state if Italy's medical device expenditures exceed annual regional maximum ceilings. The payment amounts are calculated based upon the amount by which the regional ceilings were exceeded for any given year. There has been significant scrutiny on the legality and enforceability of the payback law since its inception, and litigation challenging the law has been proceeding through the Italian Courts. Since the law was enacted, the Company has recognized an estimate for the amount of variable consideration but has not made any payments under the payback law. In July 2024, two rulings by the Constitutional Court of Italy found that the medical device payback law is constitutional. Therefore, the Company increased its liability pertaining primarily to certain prior years since 2015 by \$90 million during the three months ended July 26, 2024, as a reduction to net sales in the consolidated statements of income. As litigation before Italian Courts is still pending, final resolution is unknown at this time, and it is possible that the amount of the Company's liability could differ from the amount currently accrued.

Income Taxes

In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court (Tax Court) reviewed this dispute, and in June 2016, issued an opinion with respect to the allocation of income between the parties for fiscal years 2005 and 2006 whereby it generally rejected the IRS's position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. In April 2017, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit regarding the Tax Court opinion. The U.S. Court of Appeals issued its opinion in August 2018 and remanded the case back to the Tax Court for additional factual findings. The Tax Court issued its second opinion in August 2022, the IRS filed a Notice of Appeal to the U.S. Court of Appeals for the Eighth Circuit in September 2023, and Medtronic subsequently filed a cross-appeal in October 2023.

The IRS has issued its audit reports on Medtronic, Inc. for fiscal years 2007 through 2016. Medtronic, Inc. and the IRS have reached agreement on all significant issues except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court matter for fiscal years 2005 and 2006.

Medtronic, Inc.'s fiscal years 2017, 2018, and 2019 U.S. federal income tax returns are currently being audited by the IRS.

Covidien LP (a wholly owned subsidiary of Medtronic plc) has either reached agreement with the IRS or the statute of limitations has lapsed on its U.S. federal income tax returns through fiscal year 2020.

Although it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company's consolidated earnings, financial position, and/or cash flows.

Refer to Note 11 for additional discussion of income taxes.

Guarantees

In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of the Company and/or its affiliates to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising as a result of the Company or its affiliates' products, the negligence of the Company's personnel, or claims alleging that the Company's products infringe on third-party patents or other intellectual property. The Company also offers warranties on various products. The Company's maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees.

The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company's consolidated earnings, financial position, and/or cash flows.

08100000065000000105000000200000000200000000106000000088006850500145010237690000000

Segment and Geographic Information

Segment disclosures are on a performance basis consistent with internal management reporting. Net sales of the Company's reportable segments include end-customer revenues from the sale of products the segment develops, manufactures, and distributes. The Company's management evaluates performance of the segments and allocates resources based on net sales and segment operating profit. Segment operating profit represents income before income taxes, excluding interest income or expense, amortization of intangible assets, centralized distribution costs, currency impact of remeasurement and hedging, non-operating income or expense items, certain corporate charges, stock-based compensation, and other items not allocated to the segments.

The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024. Certain depreciable assets may be recorded by one segment, while the depreciation expense is allocated to another segment. The allocation of depreciation expense is based on the proportion of the assets used by each segment.

There have been no changes to reportable segments during the quarter ended October 25, 2024. We continue to have four reportable segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. Prior period amounts have been recast to conform to the new operating segment structure in the fourth quarter of fiscal year 2024. For further information on the operating segment structure changes, refer to Note 19 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 26, 2024.

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

	Three months ended	Six months ended	(in millions)	October 25, 2024	October 27, 2023	October 25, 2024	October 27, 2023
Cardiovascular	\$1,164	\$1,117					

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

>Rest of world

Total other countries, excluding Ireland	8,374
Total	8,403

The following tables present reconciliations of financial information from the segments to the applicable line items in the Company's consolidated financial statements:

Segment Operating Profit	15,636

[illegible]

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Surgical		
774		
795		
1,464		
1,521		
Diabetes		
116		
101		
218		
186		
Reportable segment operating profit		
3,079		
2,942		
5,956		
5,773		
Other operating segment		
(1)		
12		
4		
26		
1		
Corporate		

	(448)		
	(431)		
	(903)		
	(879)		
		Interest expense, net	
	(209)		
	(180)		
	(376)		
	(329)		
		Other non-operating income, net	
	173		
	154		
	330		
	230		
	(413)		
	(425)		
	(827)		
	(855)		
		Stock-based compensation	
	(159)		

[illegible]

[illegible]

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,827 </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6ff;padding:0 1pt"></td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,510 </td><td style="background-color:#e6e6ff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:2pt;margin-top:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Includes the historical operations and ongoing transition agreements from businesses the Company has exited or divested.</div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Includes the net impact of remeasurement and the Company's hedging programs recorded in other operating income, net.</div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3)Incremental Italian payback accruals resulting from the two July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015.</div>116400000011170000002289000000220800000010240000009290000001985000000185800000077400000209000000180000000376000000329000000173000000154000000330000000230000000413000000425000000827000000855000000159000000146320000004400000029000000460000000910000001080000001820000002500000058000000130000001070000000650000008100000010500000012000000300000002700000062000000009000000001559000 following table presents net sales for the three and six months ended October 25, 2024 and October 27, 2023 for the Company's country of domicile, countries with significant concentrations, and all other countries:<div style="margin-bottom:8pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.333%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six months ended</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">October 27, 2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">October 25, 2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">October 27, 2023</td></tr><tr><td colspan="3" style="background-color:#e6e6ff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ireland</td><td colspan="3" style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$</td><td colspan="3" style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">29 </td><td colspan="3" style="background-color:#e6e6ff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>

[illegible]

height:100%">16,259 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeef;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15,627 </td><td style="background-color:#cceeef;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8,403 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">7,984 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">16,318 </td><td style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:left;vertical-align:bottom">\$ </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">15,686 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

290000002900000059000000580000004304000000417500000083870000008099000000407000000037800

style="margin-bottom:8pt;margin-top:8pt;text-align:justify">On October 10, 2024, Brett Wall, Executive Vice President and President Neuroscience Portfolio, adopted a Rule 10b5-1 trading plan. Mr. Wall's trading plan provides for the sale of up to 22,287 shares of the Company's common stock prior to the plan's August 1, 2025 termination date.</div>October 10, 2024Brett WallExecutive Vice President and Presidenttrue22287August 1, 2025"

=9&MVAL[WP/&+.Z%PICG,MU;B+8V<-O++MQUR,4<-\10^M"W.H?"73?
A3I9/B+^PGX^TCX+_\$W5=&TD_%FJUBQ2+3K[4HPT+?V<6^V26:L
M64W4D<(<(7C217B,GMOQU_,N/@/JKWPQ^P5\&/A:GB_XG^(\!5UXPEMM6UTZ M3I6E:):22,
<<44\$A)5BYC7!/PE_P_%JO%WA2'_(\ @?K M\$OB2P6UNM2^&KVMR;L-DH5O&*. &PB.QQT'DI:I@:_^X*
>"M. X*\$SZ-^ MPS\WU:7!L;54CDF8V/I<2/# MA)(PIW 'JGPC P""HOB3IH;IEGXT \$OX1?LFWL?Q0^"/B?5_"BSX:;
[XBMX MH(M6L%W.RWZC+:+%3O\$BH';8P\$?W2?..?^37I?/I4'Q'_P""4&F_M: M!_LX M>(<(%V_0-:2W&J^/'\$.G37?
B!GU6^FQGCM+J+J+...)-RK&[OW(E1?E4^&+M\$9_B%!\:QQ^&W\I:OAKXCN+CE-8-^+?B34?#/AN^:IDU:XTQK
QQ7_#70QK5M!\$?CBU;V^J-X7O+D\$V!>N6T<2"R5_ML%6EM;N) &&<9/!YE4\OBQ\&^#17X&>?
@#I4OB^Z^%OB^#Q=XDT+2R9_M9;NPT_7-2^T1%R3YIECG<8R\$@9L<5IF_P#L;XW_!7I00\X(JWWA/IF7Q5
MIGC?6OCQ<^&[X3Z%I=W'+>:J\$FK65R8UC!+10;Q1323IL>2L\$OE;=IH JN_M_:9_X*PZ+^S1^W-X_81:1).
MTKR-(J1.UR+6*(YKR>4K,+7I&O_4TUKJHKJK#QI^PH>OV5?5'P?^)W@G MP_:(X
IUCQ#9;M#JVB3R+\$MY%:%@I<_.Q5POS1^T+INE?""_M (+L?&^/A'K_C2UO-3V/?"7QAIEU<37 \$ES(
\$_"2\$&3;GEB"!D@UT M'AKQ3H%O_P'5GBZQC6WENU_8IA(@G'<)YKSKXAMY_)"D_ZSRB'VI=IW=.: M.TI7?
!;T_9E!>?MX_#/?E;4?%P'&?^7C"YT+7?;\$>*XK36/R.VNDM;K M4+^3@;:=0RLJE0+6N%_X.00%7AKXD?
+OP!00"IR+K3-8;@ MC4M)N6C*E)X)D&X!Y4E'Z'GG%?GOX_+R^&/_10;_@B7!#HH-1P-NM,M:
L^H.T6+F>^O5>D)OE6_JI7K+P5J^M.GP2?!_I0A!/?%?@WXC:3J.EIXR^5E_:5M=J>2XMHHFN8TD^[(8MDDR;
M"1&\4J-AHW50#IC:*,#-<0I<6JRI1R*1T;(8'D\$\$=13J "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** /SO\&?&?P: ^?&?j/'GC#
M5?"B#PEXV:_UG4HZI+QE*IE:;1F'(&W@;F.IVK_XA4?^"2/_ \$)_CK_P MMI?
(BOTBHK75G&:):65;7WL7*CX3_9P_P"#=+ @FM^RM<_#(I0_P)?#B^M^O)X2U);IY;
IQ9)/"LP4"/94!AACQ7W9117+B,5B,5)2K3&IGP;00^&EZIHIZ@6ITK6=/CNK:=0<@/%*K*PR<\$'I7*_ "+IE3
MJEHG^_N-5^&Wl-W@'P3=7B;+NY\(^#K+39)UX.UVMXD+^#@<'T%=I16 S^<M_#OXZ_\$_1%&?
\$KP+HWB3DNXKI-/US3(KN!9XG#Q2B.564.C.K8RI (C_ M1^_ _C&*X@17>#)_U5+NR:SNDU+3HIQ-
..P9H7#J=T98_E#P2<<5K44<M3)\V:/VW/P(9_P#!/@J34O\ D(R>\$O"EGIK77.?WAMXTW\I_-FMY
MOAW\W\>+!5!#..?Z:6=-3Q&=,B^WK9&3S#;"XV^8(=_S^7NV\N<9YK8HH M **** "BBB@ KR:XP?L6?
fXY>,W\>^/;#4I-0DMXX6:UU%HTV(,+H^O7K-
M%=F"S#&Y;6IKA:CA*UKQ=G;L>5G&1Y/Q\A/JN94(5J=U+EFE)75I.SZJ/GW M AV9^RW_-G6O\ P<-
_A1_Pl_9;_Zl.M?^#AO!^@J*!;_%MXG_Z#*G_@ M3/E_^(7>^/A'T*:' @N/^17TG3+71_*M=&L5806END,
(9LD(BA1D)\^!7.^,? M@5\\$/B)K'_ "0_#\$X-^%=O\ REB^W: SX>MKJ;8N<)&OD1FVC)P,X&37545\|V MY;

[illegible]

OJHFFHVIV^G:>KLEA9F6WDDCC98PIPZA7.MU)U7((KJHHH(+@YG^&'63T_Q-X?|VN/V\$VCM6|("3X7^KO6&S
M-GH/C<:/):.A.R3W\$MS<0ET_M%)8!;POPPD2C>CJ4 E);|1/V8/&'Q^(?I-/MP||?
-%G2A8>*M<|#:1J'B:Q\$/EBWU":SBDN(JG|.V5G&WMC%/4/CS^R_X#_:6 MO=&T_P".KZKJ?A32;V&^N/
7G1)LKW<.JS6|M|HC|VZ2*1\$=:L:LRAH(MI":J2*/S@_X#_(#2%:OVSOA-8 LC?|1/7X=Z-|X+UJ%;GXB^)|2|66
MEG/J-K(2FE1Q2MD6_P H>8D?Q05C^X))\|^.% P3' X.POB.--"OOQ_4OH M?
AKJUMI/BVOL/B181HFBNZ17.2LA7V?9JZ^6F-R+C|Q71"%%'Y|'|W M_|&J_P#^"K7I-
^AZ*XZMINB_%#X9WDUYX&EU|O*M_V"5(Q<?:?(Z@^4^F|X MWPOKPJ#A79E)?:#_P"";?I6O_L;|K_.?C;|L3IF.;X-?
%#X.:?/=;>|-MU|Q1H6IWOBCA;B6VDN+&R33;FX5;-C9Q)YH12&.1R(MP_ZR44 ?F_-';
MWPP%_X*V MF?"2P_9\$ _X)Z_#K1H/!6M0KOEIC'_|1#Q)_P % ?@C^VIX7^*O M_|/?
X5^<\$OBG\|K;0+>UUOX5/J&EZ9=-D)2W?@?4?%5EK6L^)=6(B\$ _M_J|V|>UMKI/+W2.)9)9IVSRX@-|?H%10 4444
%%%%%%%% |1110 4444 %%%%%%%%% |M1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %% M%%
|1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 444 M4 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444
%%%%%%%% |1110 4444 %%%%%%%%% |1110 M 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |
M1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 % M%% |1110 4444 %%%%%%%%% |1110 4444
%%%%%%%% |1110 4444 %%%%%%%%% |1110 444 M4 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110
M 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |M1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |
|1110 4444 %%%%%%%%% |1110 4444 % M%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 444 M4
%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 M 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110
4444 %%%%%%%%% |1110 4444 %%%%%%%%% |M1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 % M%%
|1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 444 M4 %%%%%%%%% |1110 4444
%%%%%%%% |1110 4444 %%%%%%%%% |1110 M 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |
M1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 % M%% |1110 4444 %%%%%%%%% |1110 4444
%%%%%%%% |1110 4444 %%%%%%%%% |1110 444 M4 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110
M 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |LV^&|7APZUX@d"-8:=Y;
M9/NTY1@/<*.|K|4_|%:?\$T^Z/P3|+"VO|R75-4->/N4C6"/TW'ZUI5@^ ^ + M.:DXX9Q7|YJ/X2:?
X'YIFWC9X8Y.W&F)|RI4U*|YP3C|C|?HK|WM?_P"" ME_|4^LLOTF|= (TG=T&GZ-&VWZ>?YGZUQVK MG?
M2.VYDO?C9K2%NOV.5;|5IQ^H^_+** &I?_P_E/U2H MK|CK|HH'X|;F^_4/C5XLF/\$/\$5R0/H_
_%>T_P#!.3Q|XZ|1 M.6NG>(??FK M7IN='NV.%YJ.LJ:@HP=K.1FGF?A?C.KRRKC)XF+IG%RLHO6RVO?|">'?I(95
MQ'OQA'JI?|.:^._P#P5Q^-M7ACP^T|XWT33;;7:/|VD>*[RV@BSIEF3MCCD"KDDG@=:^;=_X*3_/1
M+PLZOX=:R^M.FP5QZ)|A3=553WY7S|17S=#A*OB,/K&JO>2=K/JKG|AY_M9K17|BW@K/@N_P#1%=_
J2Z%^W9XQG*8VC6A.ZD#H|>OR@_C7N/PS_X.MO^*M'LW@66_%%?B+P#XT5=J^|Q=)|:E/4K.W.FIZ&8?C7UH|^ ^
M#J:_|O3?%PPV?CWQ/XP^%W)A67Q:X7>:##Z"73VN_\$ \$X0>N*|ROD&T-M94F_2S_*|S19^D=%><_
|KH|E?H+3AJ?I.OI'1@WOHG|FY(O#OB*WNIH1 M_P|-(D:'#|K7X(&_)|?QIXI6?5_F8|\$TT'.Z:C(RH(\$8/8N5H
M9KXY^_O_4L^~7Q#>;2OATJ>\$M+;*AK1_.09%|6F(^3U^0*1_>-?6Y%P3G^M?VG1HM_,EHOFUE|DUYH+_N-?
&#@C@?FI8|OI6NO^75.TH_P|H51A_VTI M;)GW+|3OGH(@_W9_/B5XJT_2R4W1VTLN^>4>J)EV"N%
(KYG^*W_|5_|.-MI-
/^#P|DO&&ONIZ|EQY|1#&=S#ZN|H|^*M3U34|OY=5UG49|NZG??/_4MYRDN5?|NP37|QZE|2_VSOVD?
BH7AU|XF7MI|/G_#\$1C|DB_NG MR|X_P|FKR^222;|H99&9V)+,QR2?4FFT5^AX/_8+|Z7L|2C"/.*2(-|L
MUSO.|Q'MQQ\$ZT^|Y.3^5VI+RG MB@4445UGF|1110 5!?!\$R_P#DZ2T_|MY_M_P"@BOGVQH+
(OE_P#)TEI_V|;S_P|!%2..?2|).8S_KW+|CISPN_Y.-E/M_7^G_P'E(\$C_@X/_P"4QOQP_P"P|8?^FNSKXTKI+_X.#_|
E.;|HK|(-9_-P"#@:_@JK^RC);.6.@_M.W_C'1K8@'0?MB-'_&S"ZCHGG2D74:@<1S(.?05|7T5A7PV'Q,>6K|27FK@FT?
Ts_L@?'|@_MGP%|2VOAG|M7|G_ %7P3=/M27Q/X.F.IZ>6|R26SA;B|/9#<-_3I2_V;VR_M_P|E?HL?PJ?&7L_QY|^+^*_
%.Y3H05KBTST\$|NY)K=C=D13f5_%76UV|MOB|H0OA+XMM/'WPL|=ZXQ.UW3Y_
ICK.^ZG+:75NWJDL3*ZGZ&OFL;PE@:UW0_M;@_O7XZ_C|BU_K<N&HK^.;|@S_@|'_|^ ^
YLO|/H8WA6U^+7AN(K&VM1E+#_M7K>|IGS47R;K|2(KL?O3LV8
RV^V|D)DCSQOKXW_DS#+M:D.Q_F6J_X'S+4DSZ*HHHK ML2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@
HHHH ***^:_VI_P#@HAX-^\$4ESX(^%26^O^X|QSW._=9V#|'_M&*G|ZX_N*O>K
@K7IY3D^8YWBUAI'3R7=O9+^EJ?.<3|69|P=EDL?FU M=4X+;K*3_EC%:R?DMMW979f|/5/C|^_@KX=:Q/A2?%-
OIUOR(AW.Z6X8?P1 MQCYG;Z#CJ|<#FOB#|H?|X*5?\$KXB|X<^\$\$\$_\$+XD>./BKXFF|7_\$(Q)E8=?OG#7A MOE64*_
.&VK5?->Y%^2>_K+Y)^0>(T@>)>*93PF4_X3"|H-/2WIKX4_Y8 M>CE)#
|FYN:RXDN|RX>665RLLKEF=B)?7B&S|6^#?5H&JZ=<+/I^I MZ9=O;W?K*IRLD%EVPQ>--2--
>L\$Z|IE)6_4#'+%)>K&20X6OWA_9A_R_9U_|^%UK|_M9CN9_BOI7BSO+G"M4 @F.15;!!Q@@_U_%?7I_DWI97
MJ2OI#_Q3M_C%^S%|5|2|+ZS%M6Z%K|NMK^C/D7_|#9AV(C_=2>1A@/"ELT MX7PN+O/#^Y/_E?RZ?+IBU-
K<_MIHK|U?| @D=P<=_L| M|2:9|\$VA8;# MX;_ %B<+#+;6DMR5TCQL>|/FD.8I6/2VE)8Y
1Y3D#|J|_<7@|3@:SI5HV? MJ;=S1_.****YAA1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% M !1110
4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 %%%%%%%%% |1110 4444 M%%%%%%%% |1110 53U_Q|H?
A7L.GQ'XEU.WL"(SB.MU=W4H2.)HU)X%9_Q&^)'@ MSX3^\$+OQSXIUN*PTZS3.DLG+_OZ(BGEW/0*.37YN_M7_
+8/C3H37C8QF73 M"/|L3IVC+)S(1TFG(X>0IAIU <#NS?7|*^(8_B?.\$^HE&+IZ?Z1HR_|OHG
M^5^)|OBKDGCAS@+5+5<5-?NZ2>O^*;^S|/KO)Z1ZM=|'^US_P%"_\$7Q.DNOA_|M%|RXTKPZKZ MR?>3ZO|
+961_GIQ7Q=G&F:RS#;SG+|+%;+.T400>|;=V%%%%%%%%%|J?+1 M110 4444 %%%%%%%%% |1110 4444 %?07_|O_DZ2T_|
MY_Z""^2.^@O^""?)T MEI_V|;S_-|?2|72|DQCA KW+|CISP_N_Y.-E|_% I_P#I2/Q(P"#@_|MY3&_#_L_V'_*
|.OC2OLO_(_#_P#E_|6P_O|S1_MCA K1M5/OZHKKCOV PV84?95HW73NO_-;1<_X_|>\$/B_X3T

NOJMS.#15~/P"W'P26-Q'P""E)+^T9|>#KZ?0?-V6WC/0SINT>?2)PO>DQC\$ M+,>D%>UVNX MXANT7HW"R
/!XVLGQ-16.(P!#472JH7T!Q-^S9^TE!&^VN/@MH7I0P M!VVO>&/\$-J)K&I@.&1NCPRH>8I4,*/&V&5@0:HOY-
O^+7_!87XD-!LO MCD(I7>|UOX4^*+N-?&-A6.3A JI^%Q5^M^?QR^&VB?%_X2^+;/7?#7B/3HH!M7L)-T5S
XRK#N#V*D!E^D @BORK,;>|Z).3T3?OVI/VNY_C?XK?X<^! =3/_B6D7&/_B:C M4IA>#_76-3D(,+ =P%^=,*_J!^2Y?
#^8-HQ7S;ZMIY^O! D2YB!4<3 M9KQ?GE;-U27Q!^W-!-JUR.V!>?M\$036EJY+7PPCE)H
MU!N!&-8_Z9KIW/7!|!&_! R5A-^WQD!<DM92?9+KZ!+JT?6!<#1! =9G! M2RFCS-?
%)Z0@N!Y=V!^GT3/G_X%_LR_%SIH75OL?<P!P!4%O^F4!RO! MY!QR,C;TKW?0= T!PMH!OX?|-
L1:6%C!B.W+2\$1QQ^*RJO JW7!_! \$?B MG.=N5*=@8T>T7IS7IZ6 R5EWN?W+XZ!
@/PGP=&&)QD5BL4M>:>_!R+ N0=UI MTE*!N!Y=A^544(B@ # '2EHHKX <@HHHH **** "BBB@ HHHH **** "BB
MB@ JOJVDZ5KV7&B.YIEO>V5W^T-U:7<*R131L,CHP(92^001@BK%%&PY>
M_P#!1!_@UT_8Z:_IMKW@_LG^U^#WCB0-(+73;4MX?U^"3KMDM%_X!G WV^U M5&289#7X)_MP?|X_P!K!_@G?
X!7PA M12^:ITB.YE=-!0VA^T:5JH7^*W MNE&QSC#&-MLB@C>BYK^RZN6^_P1^\$7!17PXU+X12^/X=;3XJ!-
M%Y=-HYM M6:S0R>C 'E'4JZD,I^D\$ UI+EG\$V-P34*OOP!UJZ/I!^!#<F?Q\$45^P7! M7C_@UZ? L^V6! M^"2!
!6/5?&@Z?#?<K!V!W&L:/%U+6K#YKZ%>1LOYZ M@# 7?R_C!D)^#(T4J!64D,K#!!^4\$5^AX+^X7,*M*\$KKKW7JC-
IH2BBBN M04444 %%%% !7ZA?I^Z?_!J!_8: ^*=O^R^_!T9XK; A4^C^4L6->R_)X4U. M5@!A!ITZOQW_X?O!
@!L" OUI^6!+P3K_&A_ \$YE!8^>_9OA MUJ!E!8TEFZZ,V33044 M45QC^BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
^7+>D?9!&LG/_S=, #L7_=&^!P!^*GOBORL!2>(M!_7: ->*/\$FHR7=J M%R!Y\$&GU#4KZ41VMI;N9VA@!DDG@
\$D@<G>#?1OB;X@^*+P9X.TB6^U M+4)Q%:VL(Y9CW/8#)+@ \$D@<OTJ_9(9%!* LU>&?M5SY.H>+^#\$5-6"<
M1CKY\$>5C!ZG@N1DXPK!CQ:Q:@^%)=^!6E!/_U2:*_9=6OU+PO!+LY!+MT<87IX6FUI2K;^Y#Q-
KY16LNB>|^R^!PMX4^ MK;^O^\$<&K>+G0.)BNZ#3 MK!C(>>RX&=WT%117!S9IFN/SG&2Q6+FY3?
W)=DNB7!J3_13A0AG).\$ MLI AEV5TE3H!^!3ZRD!Y325OT5DD@HHHXCSCW@HHHH **** "BBB@ HHHH **** M*
"BBB@ HHHH **** "BBB@ K!O/^"UW !NS!_VX!U3!HSIDG2,)!&!% M>YU"PC^V^G>+6ZLLP&%@NR?NW
#L<2YR)8_U#HKJP>_O&KJ!E9_@)IT ML_ A!^!<PS^<(P!>2M!>2BMX_U#P_XBT!>TU211M5MEAN+69>JNKA!
M!!(^8=2U8?%K?^")OPN_X^A_#)_&O@!P!_?&P_9_/#2B=XID6IQKDC3! MX!M\$3G9)@M^QR,J71OY=?C^!B?
^S!3!<^#/OG!%7WAWQ/X=OFM-8T?48 MMLMO^OZ,I^#*ZDJZLK*2H/ZGE<4,UHW6DUNOU7D92BTST:***JG-
2Q_P""@_@;_@I7^QYX>_+!K;VFE!H!A;Z%!)G^RM7B5_M2.B&23Y;EEC)Y;I:EEHWQ^!0FW^&
M7Q(DAT;OHLTFG^4L1;D>P!FIRKG GC^*<\$A_#5>:ZK_+MSI2HNS/ZK;*165U#HP^D9!^X(I;_+8**** "BBB@
HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O_?
M^"AWO!X/_!9_"VA7OBUOQ5OL!4HV^AM@!YH!E8(#U!DR/NU!2%19B_M2:_+!L7XW2??"
XZZMXFLH!R:38O!@T0_+JFC)&!H!%I^7YP.U?>N0+_M!C.HKTJ!2!_975>OFDTXBGQON^#^"IT?
87AS*Y8NMJH!HQ FDI E^K2!7M>_."RX^XCIY7A(^%4G;Z MA!R?GTBNLF EHKM>G?
L3_LBZ;^SOX!B/Q1:PS^+!5@^V^?AA91G!%M&?;@N MP^!P!A17NM%%?RGF>9XS-
! =/%XJ7-.3^!LEV2V2!/_!^!JX5R;EEF74^2E M35EW;ZRD^LI/5ON%%%%O_((J^O^"E'PF/OA^#&E6EC;/_!6 MGL-
&N25B3Q?9KECIMPYP^2QAD:A^8JQ".67!\$**Z<)BJ^"KQK4G9K^K/R\$T MFC^&SOX;A0^#?2\$5_P^\$?
%NB7>F;KI=Y+;E!U_M%;W\$;E)(!\$8!D=6!4J M!D\$&\$J5?O;_P=|^!\$;1XOT>_P""E_!7A8?VKIML^&+6AV\$/_
W:HH5=711_M^H^"SXZQA93CRY&^\$J_6!LS^CF>5:5=6V_R!C^HA1117H""BBB@ HHH MH_JC_X/JA
@HTW!/_H#=#O@OB!KAN^WPA2WT75FGDS+Z65(L+PYH^7& MT#GDE!>W^L?>?HO7!BG_1_!XN?
^>7_!0PG6=9U5K2P2KLP!A_CV.O MBA LNZ=9V_3^58KC!A91HXU_73%!"<BNCJ&1U.0P!0@JZ_^^).N^
MHY@Y17NSU7KU7W_@S:#NAU%%%?/E!1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444
%%%% !1110 4444 %%%% 'BW!>WQC?X0? ML!F=-N_*U37S_9>G%3!R^8#YKCN,1!^LS+7YD5!)?%OBP_C7XZ1?
#ZQN MMUCX4LQ\$R!<@W4P624_@OE)!%&KYMKG?#K)UE7#=-.N_L6?LX3_M\$?%J&RU6V?_A'
MM^V76O2C(^IGY(^60@CU^"AR_0* 3VUM;RMHL.SMTBAA0)%%&H544#_4<M<8KS3!D?
X^6GI/7P/L!/_/O+_MY A8 TE!&^#Z_?"<%7C;%UI3JOJM=I^D\$!/_^ MY/9H****^/_UX**** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** (-2TW3M9TZXT?
5!^&ZM+N!X;JUN8@!W9U^Y)+1(\$Q)8L!_6%7S_P5U_X)!/^"D_P^Q+XF^LHM;Q^ M!2,ZMX!U;_<QZQ
G>2^Q^!^*&>^0X29FOE5O!>OYHMQ!C(#NN^\$/\$_P"\$ %&DW&GZGI=I+;C87<126VGCXLI#IE?M_!KE!^#B3!?
7,LE)+WH>|OE MO^Y^0=F?TR4445^5&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M !1110 4444
%%%% !1110 4444 %%%% !6=XN!3;X+!^:GXPUA!MH6GS7_M=R<_LXT+M^@-:>?|!2/XB^P/^S1>Z:;S+GQ?^
0Z='M/(GR99#1^D90_MH!>EDV7RS7-;&\$7VY)/TOJ_DKL^>XLSRGPUPSC,TE_RYIRDQ.27NKYRLOF?G
M=XQ!4ZIXX!6;GXRUN7?>:K?S7=RV>_!CESCVR>*S;* L2\$(4X*\$59+1+RA
MH^U;KB^LJM1WE)MMO=MZMOU844451F%%%% !7T7_.\$V?@>GQ+^)!2?U9^9 MI?A)\$N107Y9+UB1_O_<-)
!%!)!<=*_4+!AWX/CX_L!Z!U!>5J6K!_!FJ_M97#"28 HA!^L8C4CU!;!<#1!>3V2A3=JE;W^Y)_ \$ NTFT?
MG@<P="BKC MRG6KQO1PJH+LY)VIO^MU46CZBBBOYC!& HHHH **** "BBB@ HHHH M**** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
5;H""^>ABG!/_+NU MP?X37Y85_7;_.%N_P!BV!_!X)O?\$X5:5HP0\$VC6!1^#L>Z4;G9^T MJQQ_!4T7G6W_
&!&OY\$J_4N&<>|9ERA)^!#1^G3!_!D8S5F%%%%?1\$A1110 M5T/PE^!OBKX*_%3PU!8Q
MH!FUOPIKUGK&D3!_N!FV2;_! =MZ^N>H!_2L! M@/!<_@)8O^W!0WPO!C^CP1+NTCQEX;LM;T!+9*PW,"3^K?
!2AH^8@BNMK M!U_#^5OH=-CC_P2^L_A?J!9=3^%OBBIT%ED;+M92D7MLY_V0+B2%?>WQVK
M!*_%!=AG@!94HO!/_+^73!#=.Z^BBBN084444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 44

**** "BBB@ HHHH **** "BBB@ MHHHH X/IJ/XK>-/ @9^SKXU^+ P./A-J_COO#X=1.75IH?@W0K=Y;O6+M(R8
M;:-4I8IWV@I02ID@C\$!_ \$?_! X*>?MNWEU P17^+ , O\$G L;JK:P_XN!>7
M6EZU00BY3C0@I#I&CWFMLMK&G2S7%S.MJ*UM!M@CM+6\$*XBC2U@!PNZOWTKO M3_@HI^Q3X7_X*)_L;,>_V-
O&GC;1;9XSL4NM9TNW26>V^S7I0+M23Y3N M:W53GLQ_ \$!H?I,OI3OI_ A?>X"?X?DME/&=H/6J)_X*8?
M\$<(2V6_V&_B%16/D;2+3HZZ/X M\$M8C^IN/\$&HRI8:9&H_B)NIFD#^&\$,>9K0U;JEWX&C^W9I7I75O^UFXUM?
M">G^9?#I0\&891_85Y=M.T@U-UW8||*P7.P0\BXD^ID:Y^TQ^RO;_M_-A
M/K/B/OLIGH/PT^(D7C&1\1Z>)/I2D%Q.EUC8^IX(Q\N-U M'/>O| @GI!=_X)UZ^_P3>^)OA:W\0^"+7X?
6OAK7:9V9/I09(D)VZ#J0 MR3/&N!(I#+(0PP0*)P^C(WP+T7\9-^)!2%_M/O#GM;J31-
#LSIHGN9(I2WMXUL+0R&\G)3S+FX>WA:4O/%C!*KS'X72L^7GA MCXY>?VBOB+XHBUIQ-XD9-
T%X\4Q0^'#T!W0:=K.QW22F2YN)>#+*Z @)!M!'J'S-HWQ3I^7PD_ :XTI_ @D;_QJ^&Z5>>#_@K=?\$/QAXI>Z3-
JTVL:G=: MB88HY4BN+2A4GFL7X)!L^_ \$G\6R?MR M_LR_73?_Q%NOAA=>M=FUIPN^KV%
HCW(N!;X\$=:U;EY;7+*Y=ED1FC9 M0-K+W'I'G'7PV_8"9_!%2LB?6JO+O1?INFOJ^H%3OKB6:2XN;F3:P&
MDGFEDYCA=^T<4>MT444>?MAZF^D_LP>_H#>OH\$T/X28CA_Z%7Y45^H M^T-T;ID?QC.#UM\5/^&KR!?
ZU^7I?T%X1TTLBKS\U&ONC'_A:Z4M9RXT MP=+MAT_OJ5%_I:%%%%?JQ_@4444_%3Z782ZKJ=OID'W\F=(D^K,
YU!71_M!^T^W_%OPM8XSY_B.QCQ\A!_6LJH3V_="3LF_N1U8&@L5C:5'^45H2/UZ MM;:&SMH\2W3;'\$_@1%'8_8
H%%?Q8VY\I_UY2459\1110,**** "BBB@ HHHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ M HHHH **** /XDOVCO!O "NOVAO^GP^!KR I^!9ZHVS&-ODW/_XRO> M?^!IFFI2/_P4P_#T^&
((B_&KQ.T:*,!5;5;E@!H8->#5^WT).=" \$GU2_(YV M%%%%>@%>%%>%!7I;2_!O_*.618_!\$>/@;JS/N_/AR\I<_P#7KJ-
W;8_!A5_)M)7I4_P#P;):D^_1E^%UJYR+^4?&\$\$_OZW>R?SD?)!81OEL^VFOR9<-S M\YHHHK\W-0HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH \8_X\$?!)H'B_P"EA_Z7VU2F-7ZA?
MY6?V\HDKOE M#C.VUMY/^&+I%_+V6OR\K^AO"22_P!7:R_Z>O|_I(@?PAI*+7')>%ET>&C^M%6M_F%%%%?
J1_04444_%=7!2%^.'@UB<8\5Z=S_P!O_=P69#_2N;&Q<^4BNL7^3/0RBI&EFV'FIE.#^Z2/V\$HHHK^_M#_70****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH ****
"BBB@#^_K_@KO+!3?_!4C\H\I7H^+MNO*2\X7LH;_QX&OG2O:2^"D6NQ>)_P#@HA!>?\$_=O,)(K\XS>*)XG!X*
JUR5_MQ\8(KQ:OVS"+EPM-?W5^1SO<****Z_"BBB@ K^IC_@UZ61?^".O@_R=#X@UX
MH\I3G_KFOY9Z_JM_P"#9W1WTO\X(P_>XD&#?7?B"XQ\?VY?H/T3/XU\KQ M>[97'_&ORD7#<^!Z***_-34**^3_
/@KE^V_X?I_V0_@AX?#VOI2OAWX3>+M_BQXEC\>%O_B>"&>U-1H#>ZNI_Q5A_VZ;\$1R\$XGMD)M:@O;/7H\&
(;7%U97LUFIO\$DVI8^WHC,R@D^*0#Z_MDHKS?HOP9^T!22!%O\?V>OBO;+^+O5;S9K?
C@:,%>WNE6(1BWV&WF4PO= M2/LC5Y@T<2M(^UV5\$/OI^QAJ7_!0#IEK_@KOX@_8"^+?I4>O?^7X5ZM&4!=
MZ=XF\7:7;1:KX6N3J+64=M-/;OHLJS&*+IS+>^)M;Y;=[V>1H98K6,_P"IM(B_E01\5BC3<6?<I=00_4444_%%%%!
M1110_4444_%%%%!1110_4444_%%%%_G?I6VE-K\I.WCFS49*>&IF?_+I(M9A_V2ORCK\AOB/H3^*AYKWAF-
S:CHMU:JOJ9(63^ZU^/-?O'A!64LOQ5+MM*+^I?^VG\3_2IPCAGF6XJWQTYQ_P#)_ ^WA1117I?RF%%%%
I3HI9(5_MFB8JR_&5AV(IM%&X)M.Z/V4\O!X@T"QUZV(N^LXKB/IUT#^!#5RO_IVO_M_%2>_OV9O!6M+)N!%;%:2-
GJHO^L^&8S7HI?QEC\^CJN^>!)2CIS:/I<<MDS";9_AL=%Z5:<)_P#@45+!0HHHKD/3"BBB@ HHHH **** "BBB@
HHHH *M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKZJM=-
MLIM1OIECA@B:2:1CPBJ.DGZ_5+7A7_I3WXO?|*!_"=GOK^*L5UY%SI?PTU M<:=+NQM0);5X;2|
I C21UI2INK5C\MI?>_!_9\1%MUX_|B!KOCN\W>=K>_ML75_-N/Z:5I#G\6K^HHK\O225D#RY-^%V@6_M\$ZD8/F1:?
CD^Y8,3\FOCN_IVPE*>5_N7_!+AN>LT445^>&IYH?OV3/V7O_MVJI^AT^H2|
9XI>_!6VBECLD\6^&K;_T63;OIEYD9H2=J\$LA4Y13G\&A M;_@G?^R5>2!_!/_ (+!>A_IB2\G/7M4;X!>A
X_+&TKPAJ#)D0LPCFC>5P2=[B]58MY&X_47\5?I(\I3OQC^_?A7XX_LX_|!0OQ_MC\!6T+29_U?
PE;^K36=#UF)I#)YTEGK^+_|XKB@3Q+X\!31P&INTMO(+V2*WCBAMK2\$RRF.WA1%_M#2RNO>6625P#F?
VS/BC\0+1&-93_9U*_/BIX\TJ6^RU(H7B\G:7(3#KJ^T M_1A8LL+>(D-5VP-SR<#-?%Z?
!\$4\VM;XB>+!BEH^_!XU:3K^C M;5_I\13Z7X;=TJ(7\$H01QH\LR**!(XAI D:C" @9.2:2A+!\$|_(D>_V*
M/'WLT'I'=WO_U#QYX_>|N+SXXZA=AM>LKF6..&%X-C*(4ABACC2_-DP-I^R.MVX_TSJ=I/?Z;<6-KJ<IE+-|
<=Y;+&9(&((S\$B"160LIY&Y67(Y!%?E\I^P MX_ _P"";_!<3X";6^!9&*V2+1I2M\I D?
O&=E,F1(#ND8L7;Z\3V)_V0\W1/BW M8?M&?M"_%Z\^?7Q_T?0Y\I(ZI=:Z=I^@6MPT;77V&RAR(I;@O1>:-)) +*
M5B5%=(H0#DOV@?^"7OI_7QQ\2?&3Q=XF4>*O#FE?%BQTV_XQZ\X>U>WM=/M17P>."(2MC20/-?)_Q
MWVCX<_"/P1=6GL?@N!^LT-S9%5MO\9V\2(3J#F&WMGVDPZ>_Z@&FCKZK_ MC^!L?M)^
_3X_S>_O\)^ZKJT0^(&K#_QN_:T959IM+CD#^Y^7+B_9\3;_MM&H5I%D2?I_:_9B^G\5_I^B\IE+XF:8I?
A7QAX;FT;BTKT@:O.FU)(M_'J\$PITRI4;BY!%"SC\^?V_VBO#@H8^PB_9/_N_X1\5)_CC\Y_%_AS_M5/"6BSV
TC5K18YKW2W2_YG^T6X@F#13Y1IT+AE;>"GVC7RA\/_^OC^PC^MTKX\$:@_0^-/CXYUSX4_"^!_AY;Z/X4;2H8(9-
BW6IW6^ZN#>SQOQOG88_MXD4/A"7&SZOH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\@?
MBYX9:P9\5?&OA)HMG\JFZ\=VRKC^%)F48JL_&OU^K\I\$?^"AWA_&\$_VJM>F2^9_M#J_MJ\$ QUWQ*KG\9\$DKJ\9
(6J)>XC#^I<\$G_Y29_+TI(X6P6_2_A M57%>2J\O\I\$OFCQ&BBBOW\AL**** "BBB@ #H\^"5_C@:H"M2\%S2YFT'
M6W\I_M_=@G4_O_D035\5^>O_2Z^ (P\+?J\I#75QMM_\$VE/^&A.UQ\I5#_M_P\I>|OXJK66E2TU_VIO_
_3*1_I%X#Y\I/#/)N\Z_-M1EY+H\N1\$+&UEFA;_P"1_K\6%?U MD5^>I95N;%4\79_->|_@&M/8****^+"BBB@
HHHH **** "BBB@ HHHH *M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXK_X^U^!MMWX1^)=O
M#I^_23+N3^3\$10_|>F_*OM2O&_V\AU_P+&_9A\0100;HK1435K3C.TP\$F M0_|?
DRC\^IX+S%99Q/AJS=HN7*_27N_A>_R/S:Q>R%1>'.886^O_/_I\ MWIM3LO_J+C\SI^PZ***_J_ S\$ "BBB@ HHHH
VOASXVU+X;/_=&?03\HT?4H M;N-BBBOP\$ _N(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ****
"BBB@ HHHH **** "BBB@ HHHH I?)>\$>A>#_#M_XN\4:I#8Z9I=E+M>:C>W#;8I>)"DC\IJD/H*_C%_O_
&FM3_);_<^)_I3NI>_MZ?#^I^WLOWEVD\IXI=(8_P#@%?T4_P#ISY^VY;_LL_|!;4?@IX*_C M%L8HWQ(FEJ)?
4H=T_12VA_U^#TX_EIK\X/P7)0GBI+XM%Z+?IW^1E M-ZV"BBBOLR HHHH **** /VK_P"#_SIGN35/BY\7_P\J?
4+>+&6B^J\POI4S MKD)=S?KC>Q1;2WS\3>YKJ\^!^?#>?JF-OV_-/_@E%X+U;4|_P:M1\VZ
M\8:B&7DQW)6^T>_H\X+9QVS^J?QJOR+/L2L5FM62V3LOEI^9M9%6B%>%%>O M4%>%% !1110_4444_%%%%
!1110_4444_%%%%!1110_4444_%%%%!1110_4444_%%%%!1110_4444_%%%%!4.HZ?9ZMR\^EZC;K-
W+13Q_!1@0RGV()344TVG="E&_XN M_E=_ (XP_#V\^%Q1UIX=7VXMI&IRP1NXYDB\;S&_P#P)"K?C7-U\?<
!%5OA_M\$=%!_=:A9M_ML0;U;_8=291P+F(9C8GU;+>@T-)?=UWPWFL=.700_P#)6D_-Z"BBBOO_*Y<:@Z&88
M2IAJRO";?H_ZT\AR?<_D>:T.PPDN6K2DIQ?G%WU\H|=5="I.P3P74"7-M M;LD#W\KHUZK7\#_4_A#B?<8\X?_M
(=JONUUC):2B_..KKS6C04445Y9\I(%%%%!1110_4444_%%%%!1110_4 M444_%%%%!1110_4444_%%%%!1110
4444_%%%%!102!9B_2;*_#_@Y M5_X*6#I/B\B^X)?#?Q\IG^ (OQ;@G\TK3;RXFTS2=H6\O>.48JX@C/IW3_ZG
M_1KIP>%JXW\$QH4IY_AW\MO_V1^*G_I?+@H_OI^_P#P4)2>?)?N"!\#>"
M_&O\!ADW0SV\#MY\XN_&^2#IT5\4T45^R8;_#T\+AXT8;15C\ZA M1116X\1110_5Z\^RG\
/S\O\57\2O@7IG#PB'%_XU\4V6DOS(FH.DTJK).1_M=CC+R-Z*AKS^OU\X_\$OV_Y\B7^U7XM;A
\$^D%|^&VCG3/#T\B?^VL7R.MCNA\F^T\$RL.WVN.UPYEUB<#4KOHM/79?B_*I/Z#_W@OPW_-!C_#OP;H
M66D:#I5OIVE6^M)M-FC^+^H\;%5PL=SD?_M(_OI@X\H0.U?LGA/GBI5ZF557I+WX>J7O+YD)_G\I_2>X,EB,%A^E
M_\$2PG-MN\N_YB9B\$GC/#Q/C^%E)4^F\I
M>"LZ>69A.V"Q#5VH=393\H02_.*TOLZ_I314=K=6M\;QWMEF>&?>DRZAJUX^"1&@X1%R-!CL51\$^+NZJ_2*_C_

M."B?I< Q- X**2M8^>)OVG?B6I?P?VG/IG/VZ-YQ>/11+B)%M:Y^526= @!OD M>1
N: ^W/^#D7_@LK#^VS153^R#^SIXH\WX5>".38ZKJEE-F+Q1JT>5.H845+.OTOAG)W@J'UBJO?EMY+_!?
EYF4Y7"BBBOJ2 HHHH M **** 'OPRW\$JVIO\$SR.P5\$1 !U?U!?'\$8?V1_P_\$_O!@GGX%^&
MM:8MOXHO:4ZIXW^7#^5KL1+&WJ84\$5MGN+<O7X^!_!MM_P3I?IMC_(?!
M:9X_18Z:GP)A^IXGURQYBN:Y9#_9IH>QWS(92I&CM9%/WA7I3%2!<7X_MFG'"1>VLO7HONU^:-(+J%/%?<
\$&@4444 %%% %!1110 4444 %%% %!1110 M4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 5Y?
^U!H?V@_MO@MJA.TA3^U!A TW0I6P,7* X3/8.I9#V&X'M7J)%=6!QN(RI&4!50=IP: M:15^G?
R/SG*.#GV55\NQD>:E5BXR7DU;3LUNGT:3/QBN::XLKF2SO('BEB< MI+%(I5D8^!IZ\$'M3^HO^"E?
L.\$G@+QX/C9X7L<:XCGQJ:1KQ:7^"2QI!* M 6_W@_J^?<_KG).WPV>973QM':2U79I4_1_?QUAM>,>%L?
P9Q'B.HQ:IZF MI'FE%ZOFO^2L_)W3U3"BBBO5/F HHHH **** /K?_@G_/MJQ^#Y+7X%?%G5
M=NE2R"/P_JUP_%DY/%O(3TB)^ZWA!..#I&WHIK^7Z^Q/V^NJD2T^I^#?QSU MD_8UVPZ)XAN7SY Z+!Q_@I+(!
NI&^7E?QCC_@.5:4TRV_Y:S@NO>45W_F7 M7=:WO_77@=XUTJ)3I<:
<05+05HT:LGFM3FWTZ0DIOA>EFOMRBD1TD4.C!E8 M9!R"60PX_LK<**** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHH MH **** "BBB@ K1_P#@Y%_X+L6WAC3I<_X)U?L<>.=^K7"O9?%/QCIEQQ91 MD%9-
(MI%ZRL,K.X/R+F(97N?%I?^#B/3OA:ZU^Q_~P1XUCN?%TBR67C M?XB:7"W)K%8I:;QB_S?Z+YFW@C+O*
I'"JCEB20_IR2:BK18?^#6Q_0232M*2M&(^W) M6_#GF>IOA?2I/#45U%F/52\$(>_C/WDM599B?^>K08R
X)CL92P&%E7GLOO Q?1?;5V?L_P1_X)VV?_!_!A/PI_=?TR*/QOXD^ZI0: @_%AJ_R+BUW=U MMXPD(
_TLDCC_6&OKRBB0QS\$5ZF^KRJU'=R=V;K0****Q **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ M HHHH **** "XG?#GPU60 6L_#OQ;.:^8ZL&^*0@#=#&W5)%ST96 8'U45^
M40QE^\$OBCX(2\$;42AQXMAQ<6.OH=5(2YA^*3) LL.28YIYKJ>^*1+_E_97 MB_:%!# 7#%J@15:.\$SZ8P
IO(NK6S'WZH3T:C@.OKI\$V^N*UD.825L1*U^J MI?HME+TZ2\K/H?@OCMX9/C:(EF_A?&X9.R6I2GO*FU4/4?<
M77YIT4^Y MMKBSN)+2I@>*6)RDL4BE61@<\$D\$'C%K^E\$TU=^>S33LPHHHH\$%% %!1 M110!I+_L?2M_<
I^OLWPZ^+_UQJ?A<8CM+P9>XTM>P'>2(2W.JC!O3:2OKPO MXA_>=<
=!MO%'A+6L:4=O(PIM=VDH='7ZCN_A4\$S'FOONKT7IGHJ^XI LY
M:V:WP7JOG:=(/OJ\$O'6MKCL3CJCXZ.N#P_Y%?EW%_AUALWE+Y%Y?;%9ZN.T M9+_R.GWV?
7JS^D?KQI_Q_"L(97GO-6PBTG>I271?WX+M45!+_2B?JW17D_M_P"SM^V+!(OVB;2.RT74AIFO>7F?0-0D
ERIR8FX\$RI>5Y Y^*K7K?>@F.P&- MRSO#XJFX371K^KKLUHS^WLF\$O*(T@0;GDDDDZ/X1E62T12?J-6@O=90
MY5H;\$#\$VUN1D&8[99.X41KDR2&'_5'_P""V?I6_P#P5!0R:)XTU3_(1/ MXIZYJ=MHEBZ=>7EY
M.D%I:6L+22SRNP5\$15!+_20_DD_4_>I?L0?L=?%C!O3!HOPO^S#I^+=J M?B&I
NM0DC+0:79)UQ>38Z1Q)EL=6.U%RS*#_8%^R9^R_|"O!_8R_9V!*_MLS_!C2?LOA_PH:VMNS@>;=2DEIKF4@-<
++*SR.1@:G_!@#Y#_X(I?I\$B=/_M_P""_I/_I_"?%7186^+_CZSBC!53_I+_A6OW+PZXU56_IQIO>6E.3ZKI^:~SW6FIK
M_P9>/G@_+U*G%&2T_<=Y5Z:7POK5BOY7O=^I^SER_-%%%?LQ_)4444 M%% %!1110D:W5S8W,=
I97\$D.T3AXI8G^LC_Y#_CD\$O7TM/_^"F'O_~^B M0^OBW:XJTL^MX9_M_"O!_OGB;Z/AC^PKYEHKRIUR7*!<
IP_L<24UTIKT: MU7R?J2!>_<8<2<8WZUE&)E2EU2UC+RE%WC)>JZ69^LGP=:_6^"_P=?:_9?
MAIXTMKILINETJY;R;N+US\$W)_O+N27WKO&^UNKERN4O+*XDAB<_+%+Y\$5D M8=?:_0?
>O<A) P42_.*^&0BT_6-C^4EH_FH^I_5G"/TH!7C&AQ^AG3E_S!>I%~;@WS1_MI=<_1^Z4T5!T?#/_(*B_<
KQ6(I3Q_I.I^~(EL:Y)(S=VP/L!0W_)Q@>I>Z M^!_BY+_ (EPB?P!A0-(U?Y4MK%X>4\$N
MMKQ_!^5XOIS^B,@XYX/XHBGE>.IU6_LJ24_G"5IKYQ.BHHHKQSZL **** "BB MB@ HHHH **X/XW?
M2_LU_LU:2=:_&@_CYXA%6WEET:Q_XBMD)I TS65PT MA/O!023P!7P%^U+_<
_6_P#P39^="OI7P0B13_%G5XIK%_8.G-I^C;QV>ZO M%1?I44.H/BNS#9?C<8_P!S3%SXE_<
MC^/_B^&Y'A.ECHAG_4IX<@>19Q:H 2..PNQ2?F91S7!_I9'_!TA_P4A_:_M6BN_#7P?U/2O@_X>N-RB'P>AEU1HSV?<
4)>75A_?@2_?260Sj6>+_ %GCWQ= M^/_/B?4=U74C^?ZHU)KR2R\$LI>Y)-?48^@O_J6*GRKLM7I^R
M_\$AS!ZY_P#117_@I+_+.WQ@BOOAK^P%X.E^6@2AHG!..XD4^NW^*C_.0+06 M61D9S-)T97C-?<
D:XP!8^+OB%XGOO&WCWQ3J.MZSJ=PUQJ6K:O>R7-S=RMUDD MED)9V/7T^6A!+SZOU>Y#;X4445VB"BBB@<
HHHH **** " MOWA_X F?^")_AQ_(-X*3_M7^\$MEI^+\$CX3>&-1@YMT8?+K.R-T=?@1_U(X M!<
J8F7PO_@WB_X(77I5^OZ;^VU^U_X/>/X7Z7="PCX9U"\$C_A++E&XFD4 MI;&-<
AR.DI#;RBN&-HQAAABMXE@@B5\$10J(BX"<@_#H^^(XESU13P>>OVG^B M_7INYI"/5CJ****^"- HHHH **** "BBB@<
HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *<
MBOI^QU6QFTS4L.*XMKB)HIBWGC#I(C##*RG@@@@D\$&I:.;3NA2C&47&2NF?G
MG^VY^PH^P7OI_B9!+_&:Y)SR:KFV3+OI+!\$!F\$GKG!OW6I%OFNOV=NK6
MVOK:2RO>.:&.:I+%*>974C!4@!\$<\$&OA;JLW_@GU?^#Y;OXI?_C29+G1SN MEU+P_"TMCW+PCJ78>VLI?IG_<
_#&EZALMD37I5O; M:3Q_HL(+9S!IJ4?4U^1^?8^+I9I@:\$.4YNE?M= MA^KG3/A+:SK<>)_#MPK17'C!U.0OZ-'8Y'S/<
MP9N53"Y<>H?I\$/_#S:5O'EQI^7/_!1OP7+9: OEWGA3X6:C&4GU(A.EQJ2 M^F*#H5M3AY/^6@5!LD_>^PL+2K&'3_<
LHK:VMHEBBI>.(D2*#Bj.%4 M#@_515GW\$D:;>PCUZ73R7GYL.FNVD8I61Z-HVD>_-(M#_-(TJVL;"PMD<
MMI&QLX%BAMX44*D:(H"HJJ_H %6:.*^ W- HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH<
**** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH ^7?VNA @GCH?Q.DNOB)\%XK<
M2?_#\$YE0_*.M=0;J2O.^4^OW6/7:26KX0I3>&\$/@S7;GPOXKT:YT_4+4Q MW-<
G=Q?C;W!_'H001Q7I(UYU^T!^R_!OVC_?^Q>=AG488RMAK=F MS;^M@W8^=, _P-DI16BEO*/_<
_E'RW72^B/YL4OH_Y= MO/*>9Y!RT_4IN4-J=1H/@F^ZIV3W2::SIQU/ M03)BW!06\$9.)!/<
E7DPMTX;@GA6:O)Z_>I#C!F6&CB,+44X/9K^M'W3U74_ MB/:4%% %!1110 4444 >D M_L?^~^I<
A*OVG?!.E&/<\$UZ\$Z9<=1/F<_I7YI|^<^Q&M?&'_!4#2?IUCJ! MD7PE!+_+L;JW\$F5AN);JNR<=F.5Q!GU 7VKI0?<
^"8WAS^V_VGX=4,>1H^A7 M=WNQT+I8/:QK!/_^"JQ0TWXO2!%?CIXKTJ8/%>+8I\$8CM)IMG;Z=(PD<
MM7'X5^1<55/K'&(<=(=1922Z6/I0^C'E_U;@3\$8IK6K7E_X#&\$S_O)_N8^1*_M***P/Z_"BBB@ HHHH **** "BBB@<
HHHH **** "BBON_@EY_P05_&_P"" MDUJ8^_\$.T= 7PPDE!N?^OB"S8"CSR/MR5+J_X^P@@@R;AM.&(Q.'PE)U<
M^TE&*(@DV?)P0^!7QA(3^N)?!OX#_ZU3Q3XGUB;RI/T2?8R2R>K-VG MC42.8;_5KE1*WV3_<
_\$.P#@F+_R1_P35^!#_LX> 5CU& MA12\$B_52L^K:C.PR!YFGVC" |B&)&IY"Y)>@Z/_XKEK8U.CA =AWZO_)>7<
MWJ6,+A1117RI84444 %%% %!1110 4444 %%% %!1110 4444 %%% %!11 M10 4444 %%% %!1110 4444 %%% %<
!1110 4444 %%% %!1110 4444 %%% % M !1110 4444 %%% %!1110!'=VEK?VLEC?6T.1RG_KN#_#E'15W9_(7&OT_<
M_P LF)'D=ORI?S?RY?2M*2%7_A>W!fGC_XW^6R2V)EXUU77-CCYE^UWDMQ@^_I MROZ>?@;XPO?V??I @EK!=?<
VB+_"12/X8I0ZG8:FV^8IGI3/"_JLRI^~?RH MU^X)RHI9XLQI:HG"" I=C9_B?Z3^~67_<
G>%V70:UG&4W_V_4E_P"2M!11 M170?JH4444 %%% %!1110 4444 %%% %?5!%/_1%W_@HK^WHUKJWP6^_%_8>&<
MKHJ1XTI79TS2A&?^6B2RKON5!LZ2D>E95J!#PYZLE%=V!^YAKUE^Q3_P M3@_!(_X*#>,1X3_9>^~^HZU1%;<
(I3I7_9M*TW)JWB-2ISY8+2_=:J> M* D'ISS@!(CIRI&_4NTM+2PM8K"PMHX((MUCAAA0*D_8"J!P_<
_I**^(Q>.Q6.J<I>3D_P7HMD:))!1117C. **** "B MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@<
HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH 22-<
J4:*5_RL^&5AD\$>AKQ_XK?L)?LW?%=Y+V!^\$C1K^M3)_X?<6K\$GN4_3/7.2A/O7L_<
%=N!S"Y;5HA*LI2IQ:7WI_F>1G.09)Q#_MAOJ^9X%:_<5*WEKK1^_LSX3^)?_I*+QH327GPJ^(%AJ^O*V>JQFUF I<
MZID<^YV"O"/B!^RI^T#_!GC+X4.O!^G?>6I0IH@_I3+"60?B:_6.BOT#+_M?%3B")I0.8UEYKEE!@/_!>6?<

AG\$T:./&GP4^\$/Q\$#MX^&>AZG(6>|TV-HD):A^!KR5O3_.\$V/V6/M\$19M/-
ZGHS/U:217D.#Z@3^8!L8K|3!^+>2U5:\$T9P?E:2^~\7^!^0YMI%MSBI#-O+|91K1-OKCP#9>M!T^~&K2:-3-
-%:6L!6L8G@QN>5)2X:AHAI\$O^4?C+(-.W/VMK%I!M/?VNOASJ@!_='6=.O|J>S>G2Q_9'#
M>53R3AS!9\$%BC)=.*4+7O|@T>_X*E7O6G^*OA)JF#P;Q M;+>GGMYUC^!YNX_5_~^N5O"98O
G@F=AC\$<7C>_?^~^@!^M>PLYRJ6U:/MWGLLCX:2.W_X_3_~^MLSHLGA+P)S&(-X)XUB(3Z!4/3VS73>^O!@T6_
MX*A:Q(JZIXZ^\$.DJ<F%FO?%5|Y7KGB&P?)X_4<|<#SK*8|UH>'(+.BOV4M\$+!FO^TY?
RH/B/^V5X#TI"!YC:)H5|J!7UP)?L^?S%>Y?#/_@S4_9STIT/MQC_2|:ZHQB^&?#EGD)/K@SO>8_(URU.)_FI_!O;^B?
^5A!LC^?FGV|O<7M=PEK:P/!+*X2..2S.Q_!R23VK^IKX_|!L5_P2%~%#17.L_!#6_&MU"0M4N?&BV|D&?
5HK5H(7^C(H5I=?!#|CCIDW|FJ|(?V?_FOP-X:=-OVGP|MX7M;6=^_9>5\$CG'=F|IZ|ROQC@X?
PJME_G^0^1G|H_|.7_!&_@H^U_MJOA*V_!%>GW)!CUKQ-9#1K(H?^6BS7QB651_TSW\$!_>*_0|IEK_@SG^*
M.LRVVM_ME_M3:3H=L<-/H^P^LGO:EEA|NH8XXF|J(9EST)ZU^~%>^BN+
MSK:4|07DKOFW(D4H)R^!R!P0M_XD_L626VL_#2|G#3M>|0VYUD|5>_B-7MO@XZ21^_L@>_
KE:0=9NM:FN(M=LPLK03-\$7(R_2N1MGUK&P"(RG|F?HS/OU_X|+|"097#^<-75)_>O|R>.)^RU%?EK^QM_P=(
M3|LC|J#P5^R_X_99|7Z-2|C365TZUU2^UFUDAMF96;>ZH-Q'R|O6OU*K@Q
M>"Q6:FH5X|K>O3|!H|!17D"_P#|0+|AU_BK_P*)3|K3X?QOYGE|+"#Q_M5:2VIN|H|OV7?YN=OS?=Z<|!GXL_&?
X3?_2P2A00C5|1|&^*Z#:@FZUG7|M02UM8_22|LA"H_|D@5RC.FHKG?A9|7A?|O@O|LX>|9/B7|>?BAHGA+08|B.W_
M+3UW4\$MXY)Y#B."/<QT%%%%_!1M110
445X^~^T^!WSX0_9Y^!)\$OPWUGP|J6HSQ6D5P:FUN8T0B0\$@8:GC%>AEF5_M9AG&)HA@Z?|U!*RT775KN>%Q#Q-
D?^F-6-S:L|J|R4>9|OWG=I>ZF^CZ^OMM%)?/_#VOX=|S_CUK_P#H:/^M?PI_Z)_K7_~^OUI_~H7%W_0*_OC_!D?#_
M|S;Q"S_*22M^C|H|WIDK|E>UMOVE|VD_|!/%K|_!2^\$P|26VG"X_<~(9W4.<G_R>^*1E
M%PDXO='ZE3G^K|3B|H|J|&>F45F>#?&GA/XA^&|7OAX&|0VFJZ5>|O|I0L9A_M)%_O|Y6^#W^10%=(L****"BBB@
HHHH ****H^)_\$NA>#/#>H>_!/%&I1V6F:M38RWFHWDN=D\$2%Y)&OSA54D_2@|!17#?LU_M*?!+|K_".@_M'?
LY>.HO\$MO@OO_#|+HFMPV<|N+E8IY|W5PD:7YB_65^%|D_M"@#U:BBB@HHHH ****"BBB@HHHH ****
"BBB@HHHH ****"BBB@HHHH ****"BBB@HHHH ****"BBB@HHHH ****"BBB@HHHH ****"BBB@HHHH ****
M@#^G|J^DYCXB?|CUJ_L+7"UW7|4/)_S^Q\$|K5_2V6N%K|Q|PH^B.
M<^KO^~^Q_*6|X#_|CUQ_Z^EK^O^OY#?^~^Q_*EN^_&/47_HJ6OZ|J_>M_O|?J?
^!L:PV|RT|ZPL1_P=RW|Q|D|C\$AD42|H@SO_M_--V779|N?3BONM3_@H7!#
<|L_&WN(E>3X/^)=&0P.E7((|B0A7|K77=-8E_X_2/A=^VMA=;Z^P_+|OBL#;CP!%XYU1Q%ING;
I'=RW26US.WR0&1\$MPC.0&C=HW(^HMO^~^E_P^U+|K;|D^QO|!P%|0=%|2?
\$3XI^#>2|+_#7P5H>J|76H:WJ>H6DMMM|Y<_3_D(THDFG(AN&)'=V_6OD"SV|HEZWMI|/F?
X=VEK^L<47@72\$CG1<M^JBRB_Z^O@A_X+P^~^C_/LD?M0?LV_!%-M%~^!6I?%#X3?|B|UY2B^X7MTE/;GT=
I^VC@BUA\$(*|HH_VRN_L;*>+Q^=O^V=|:2VG/V9O^~^I_7AGQ7^MU9|7|PKX8TS^R_#&MW=E<3>_>%Y<2!
((Y^X1.Q::M559F^J|YS|HG_@MH?|!|E|H|LWX=?LO?^QGHGAG2/B?X0U:ZT+7>=G\$%N^J6ES9QK9|I^)/S
M8K6|O|OP&>(#N=58|T^!GQK_P^+@_YXCGU1MH;BV%OK^EVEUIMY93V%S
V)8XG>Y|HWSO|LN^CMU|AM7XU_!%&V%_Z_P!G_M|_J3^RY^T^_\$.KWTSPM;2&Q=M(2&_@?
P!|=JMGJ7A1@TNJ:M=6D)*6UND_M2^7*RA\$F%R3A|W5^HT_|97L|K^UC!^PUA5K1?BK<^\$SXE@|(FTN/;3|(
M8S-YWE^1G9YFT%M|NWF@#TZBBB@HHHH *_^@H_R=)=|@6S_/03_M7Z/5^Y?G\$GKZ3/_^F_7^
MG_Z34/GVBBBOZ^X/V&^&_"300A_L"VO_HE:~^_.(S+UO?^~^?/PVB_MO+9)5_X:_+|(H(YM|04|?
4\$CZ\$U^E|PW_Y|WH_8%M?_1^U^9?_!VWX|_M>'OY_AE::YKUL:2S?M#^9HHKBX56>^*WOVE<G)5
06;H_C/45_%V)_PIY_MGZO|S_7C+O|D7T?_?R1|72|%(^~^G^AW_@F|PXN^/|IWC#Q+I7Q&^(&E
M^~^L;Q^HKVILM.N|R1|)*@D>|DE\$.4T|QO6SK)Y>S>K\$N=|*P#|5KQ)9_MV
M^~^OV+VBOV^&OPMB^~^~^GZGPB\$|Q#|:6DLC:?(2^~^2_MSY=%949L^X^QS_(-./&A&V^%G|)>HW"B?3TMY_VTO
M|H_.UXF06..9YPV<M&-0Z\$O|= =0A%_O_P^FL#L+PL_P_~^C(^_!;WXH_LV:C^SC&WA3P%|/)_BTW_M0|?
QO;1FUM;Z|2636K@D%)9I\$^01Y:1!0Q9G)^AOB_~^W5|3+_(6%<LB_M?
LN3_%6S^%NHW&F>+|+QO%|&D+=:G;Q++&8WES""59_D1^0F)97D21_M4^5_A|H_OA)|A
@Y2^/L^QH^(&F>^YO&/P3|(Q>\$+;5+@1S:L)4A|BRC^M_=S&3^K%\$&=BK_*=|QX1^PO|=|@FA^R|^T1^T)^Q^_
%=0A5|?#GO#TW_MXS^<(^%A?QK|3O!%I<1>*_U^Y:YMYH|V>|!M|S_%9AE955_/|BW6(=(N6@N+^S_.\$W2^4X#
|5^M?^#>@7Q%H|_X(J?G61K=H_|!#QBSNA<*8YS+=6XBV-G#;MRR|<=);5M=.DZ5I6B07^V;
|1<7_V|Q(7DGS^"%!(258N8UP3)!?
M|H%JO^WA2^_@WS^!^L2^!+;6ZU+X:O:W)NDV2A4@D8HE?|+X=1_!>O%=Q|0)=7@TF^!8S27HC71|?5I
M<^QM52.29C:NEQ(A.\$DC"G<=>J?"/_@J+XD_&_99^~^Q+^\$7I_-|V4/@CX_MGU?
POXL^&VN^(K>*"+5K|=SLM^HVRVA4|Q|Q^V^!|TGS'_O-?M|_M0?S_M'_@E|H|6O|0?
I_.B#Q=OT^60\$MJOASQ#ITUWX@9|5O|HXX+2ZG@6VCB3W_P^+&|27P\$|0?|!G0/A;HGO9T_M_|H0^#?
A+XEF|8Z1;7RO-H^*|U#^VX#_(!X;=&LNPRHKN@948@^D_Y>O^M^G_L=W_.\$I-\$X^6>)/!2^CX>9_M\$5(T
&^95SC+55^W_!4CQ9^Q^!|?Q_:=9/U#X>_#7QOK5M|S?CBU|6V^J_M-X7O+D\$V|>N6T<2^R5L%6EMY:N)'&&
<9|YEZA|OBQ|6A_@T5^!GC7X_Z5_M+XBNOA_XO@|7>)"TLF66|L_/US4OM\$11\$V9?%6F>|_!/^%SX;L/A/H6EW<L/
M?^KJE7Q|H_B=X|/VOB.#0=8|0V6K0ZMHD|BQ>+17-DS1|ED>^C|8*7_#L_M5<+|T?M^Z;IGPG_X+L2|^\$^A^K_C2UO-
3|2?^QAIH<37_?ES^_*2\$&3;GEB^*|D@UT^AKQ3H^O|!5GBZQCU6WENU_8|A@%G<)>YKSKXAMY_)^D
M_P^L|HA|O7:=W3F@#M/%W_|:T_9E|>?MX_#A_96U^Q1|_#_AUXPN="UWQ&
MGBN*TUN|CMKI+6ZU^RTOX#^+)*_FW4,K^L_RUKA?|@Y^|5>&OB1_P2|!_M_\$+PO">Y#QN
>5)1^AYYQ7QY|>A|OA#_P%|O|M@B7|HH-1P&NM,M-L^H.T6+F>^O5>M|)OE6_J17K_/P5|^GP?|_+P;^_
3Q7X-^(VDZCL>_OAU9?VE;7:FW_MDN+!*KF-)/NR&+9(LFPD10%*C8:_U4_8VBFP\$0W\$*7%O*LD+X?
\$GA+4EOM^EOO^DD^*S!2H+QE0&&&/%?>E^%~^B_X;N?|OQ^|(7KVCWJ|;S2M9T^_ZMIU|R_|4J_MLK#(|P0>E?|_
U>)|LN|GPCX_LM-DG7@|7-WB_M0L_|P?05WU^%8#_?QS|_A_|\$1%|_?KP+HWP^3DNXKI-/US3(KN|9XG#Q2
MB.564.C_K8RI((-1^1^_C&*X@|7>#)_U5+NR:SNDU+3HQ^_P9H7^J_M=T98_E#P2<<5K44
<3|U^:VW/P(9_!\$^~^I_2_Y^_GA+P|9Z:UU_MSG|X>---/S9K>;X=#|_B_#1_VCGQ.FEG34|IG3(OMZV1D|PVPN-OF^"
M?|_E|MN|G&>V**"BBB@HHHH *|F^_!%GP_~^7C_~^OCVPU*34|+>.%FM_M=1_-B#^_*!
|UZS179@LPQ6UO:X6HX2M;|79V|^E9QD>3|083ZKF5^%:G=2_MY9I25U>SL^JNSY|_X=F?LM_|G6O_!PW^%~^_
I_9:_@3K7_@X;_"OH^B_M06_UMXG_@RI_X\$SY?_(A=X<|FA_X+C_)%?2=M=\$TJUT_Q5A:6Z0P
MAFR0B%&3WX%<|XO^!7P0^(FL2|"0_#\$X_~^%=O_*6+|=K/AZVNIMBYPF^1M&::G_S@9-
=517SS;D|O<^|A^_.*C%62T1Q^W^S+^S>=V=K|H^SYX^FM|&-_MH|*^7PG9LENC.SLJ^8(|L_Q|DL3U)HUA
9F_9OUJ_XUG|G|P1=R0VT5O_M\$|SX4LY"D:|XP6C.%5%557H_|@^NWH|&/?P|_|IXLT_Q|J?@;|HG7
M|@>#2M:GTR|NSB<8=(HBN^6Y^D_IZR|B5^SY|C|I6G:Q|8?@AXO|67
MFCOOTBZ|2^&K6_DL6SG,+3QL8CGG*XKKZ^_<|?|IX2?^N2VE^<P+?#GB_M|K)&2S:6|S_MILP^V-P0RHVT'
R|C_|Z5#J/P_~^FL>%K^P_J_P^O^UUHFF2
M_~^FZ/<^|9|6T9B2S11_A2;DLV2H&=Q|:ZFB@#B+C|F;|F^|TZVTB|_9|!\$2_MVEF7-G;R>%+HX^Y!%S<
M>^+5_P^QWR#NML7YOM7TT_M>^L|L?718_9YH|FV63<=|MD_YXK|_*_+PA_#X;?#^VN+|X;?#S0Q#T_M-
VX>ZBT/28;19F_P<1^H8@\$@UC^_V;_V<_A7XNOO^_P_/@#X^_Z|H|F|M^TM;T^PK9V=W=|CEO-FBC5Y;GD|B%

[illegible]

[illegible]

(LOA3CTE6;G+UY8N"B 64T>S1R"FM:L|FA^"P>_X-\$?B-2+#+='MHL?1-(,|AXA|
#4U|N|0L|S)!M^IB/TKZ0^7_-|J;_P_\$|?"T22^?_?Q_M;|47&/WBW&N6MI?IU(+8./OD-?
IO17XWFOCYXLYM)|^9RIKM3C"G;YQBI?>MVST:>58"GM"KJ?\$_A2-(-W?^"0WAF)-
-|*K;E,G6XU3Q6K;A;ZH+M8_P#Q MV08?V>O^"8_|HO|^7Q_C^G|/7|>A^&/\$;-G);1ZM937#RK#('3,LK#D-9
M_|U|O17Q&/X|XW\$6C.CC8YA224*TDE>?>9M9Y02\$|_@T%_X|X>*+=Y2AG|80BCX6NB/W8DU2R0I9_M?K);+(?
^_HKY@^-^!_FO|==&MIKO|GSH|PKXAD&6ALO%WARXTDX_NF6W>Z_M|/OL4VK|_J*|J|/\$6<4=JM_5)_I?
+1WA>_JJ=L133|XZ?@|_FB73|!5=%?T+_ME_M|A&A|_GO|^U^*/V)_C|JOP^U%|SP^&?\$_5_*8|HTR+F!?
5G;X?20Q_P#V MY?|_@D1^WQ_P3UO9|G|H3X|WT_|OR|(&_AW_HTV3A2;A!^X+^HDZQ_W4|_IY\$-
R@)_S".&UMXT+R2N|<^J?"23P_*O5^M&_+P8=MY_L9QY;A00/#C@+_
/\$;BBEE.\$IV+|ZL|U|U3HKX|SZ17632T5VN7&8J&#H.I.M+Y+NSY%_X+4?
1%80%7_-2;X|HW@_R_NK+X4>\$_R2+P;I#;H_M|HVTW^"K+(M_|I%|^JC(4_TA;X|HHK_%=XOVZ|?
4_|_@J79<:7X+GS|J_M|H0TY/S64#<=<\$>^&MN|H>89S75.&T5O;_EA>3_6|FEJ;X?#5L54Y*O^GJ?|_P"O9_P3Y_-L
M_|_>|_""LV?#*XU_-+>15U;7|PF#3+4_Q7%R1M4XR1&NZ1@#M1L5^YW_+M?|X-L?V00V6C^Q|^TE|H6?
&T6V4|JMKMT.ODZXBLVS|HP48?#I_M2G|TOP^XCL|TTZTBT_3|6_""-8X((4"IB&C 50_.E2445_-;|NSU MPHIII
%%%%%%%%_!1110 4444 %%%%%%%%%_!1110 5#?V%A|MC-I>J64-S;7\$317%O<1 MAXY488964|_""00>#4U%_YD?V%?
^#8"IC"KA;|XB?LS+|_?P;0IHUB_M&T*_DZXFE|C%N2<#?E_EC'G_|'IN_@FC^V#_,\$X_J^"OVG/A?2-86EU
M*R;+XITUCY+8Y;3A)5&"R#(K^R6N;^+7P?^%GOY^"I?"GXT?M#_27%AO5X?
*U'1=;LDN+>9>O*L#A@<=%6&4@\$\$\$U)EG\$N-P+4*OOP|JUZ_M|I^!+@F?Q|T5^R?
170@US;?R+40V@<_|AJ/B?PO\$N_5^&5JKI_P|77FAIV9_F7D5Q;7\$2RV|Q|(^25&596'#M_@@@C@@U+7XI?
+&MO_-|7|_>@VW_31_)|4E|8TBU=AJ|H-EKRRCA|M|+>2|*AGAZYB#HP(D#?M;7Y%F.
K9=BI4;G39|UT9LG=|1117",****_BBB M@_HHHH ****_BBB@_HHHH ****_BBB@_HHHH ****_BBB@_HHHH ****
M"BBB@_HHHH ****_BBJ/BCQ/X>|\$_&=19>+=8M|_TK2+&:_|U/4+J0)%6|
M2%Y)781%55+\$|@*J5)5)*5=O1)=0V/D;_@MC_P4KT|_OR_LF76K>%-2A/_MQ&|9+IG@.S;#-
+M'G;@RGJENKJPR'&E>)|2,2Y==4U34M;U_XUK6=0GNI_MR|G>>
|N|F4R232N09G=FR68DDDGDDYKZ_X*M_M|^O^"BO|8FO_-!NEEN(?M#-FQTOP+I6Q7^&25BTS|<-
*5R0JX^*U+|W#02GX<|O|CB(|M9B+3K|JG;W;?I33L^|W)K1H^S(&|&8C3X5HO_|F%%%%%%%%%LYYP4444 %%%%%%%%%!
M6EXA>*_B%X|T|P_X%|L_7NL:S|JY::7I>FVS37%U_|4CC102S\$D"G">M?|B|XD^+|_+>
/=#YK&MZS>QV>E5|U|N|TL|U/(P5(T1>68D@8K^D+_(Q M?|S3_|_3T|&6WQ|^_G66M?&76++_N|^66#PU#
(OS6=JW0R\$^+/_O<M|HAV9;GY=XI^*>2>&&2_6.3^|Q%2ZI4D|_|O^6\$?M2^2NV=N|P_7&U++1+=_MUU//?^"
|!OKX(_90M=*_4;_(T6Q|0_\$_"76C^")L^G^%VX*L>JW^%XO7S_M.8XV_P|7N*B4_J)117^8O&'&?\$/6RVC"/2,
(_9BOO;U;|_|^T MP^H86GR4U9?F%%%%%%%%%?+&X4444 %%%%%%%%%_!1110 4444 %%%%%%%%%_!1110 4444 %%%%%%%%%_!1110
5^9W_!;K_@WH^%7_!0"RU"IH3|FFVTWP?|&2_|LH|1#IWBL@?M/L_*ZL|C_1@Z|F96;_R?D|L_B#^+_P'_B=+M
OB7K/P=^_W@C4/#GB?P>_>ZOHVIPDK>4<|F4@AE=2596#*2"">;K^L'_M(++?
+5\$@_Y_P5^&9|0;3|B|_0O0_|D|^*^?)PET@RPL+|_TENS\$|7P7A_M9BR9>_3^6KXZ?WXX?LU?%O??@9|O|EWX?
+4>H|K35M+O4PT;G;I^HR ME7IU5ET964D&S&OU+)|XH9K|NM|K=2JO+|C*4>4Y.BBB08)"BBB@_HHHH U_
M'CWQC|+|_C_!+^GB*ZTC7M_U*#4+U2RDVRVES"XDCE0|BK*#^%?UT?M|(?
(*.>/_^"FW|VB?^*U^S6GBO3R-*|Z);MC|J|D;+O=)R(9E*S1|<*M^PDLC8_D_K|9_P""#G_|2Z|_X)O?
MM;9K'C#6Y?(A0XZ;_1?B|_SGRH(6<_9_M|O(_O6TCEB<\$^4Z@985X'\$5K,
<&Y07OPU7GW7SZ>9479G|8|%,M|BWN|=+M|UG26*5_U|T*0A8CGD&YF0K|OP3*1A_MQ7ZD>-?
&/AKX=^#M6^('C/5XM/T?0|_GU#5;^)_B3Q|JK?V-83/G|H|L0\$=K;|<96%4W\$<_Y=NK&O_MZA_HT<
1XKXU_M7%00A|>N|TJK_AK_+=LYOSC%/21X^T*_9?AKI%Y#E-1U")L-J3+|_%X*Q|=TR
MLW'DC=|OYQKE/A_PS6SC;|L_(Q3UG-
_#/'F^KZ13D|S\$HPN&|8NLH|_TRHHK_*C#B|N_,_K9OF<^;I4>B^S""&\$5TC%;=16|MMO|G
M#X>GAJ2IP6B"BBBOF#<****_BBB@_HHHH ****_BBB@_HHHH ****_BBB@_HHHH ****_BBB@_KX#_X+I?|
!%WP7_P4W^#S_\$3X;?::7|90">G/_PC
M&K\$+&NM0+E_|+NF;M8D^5(W^J=NH1W|^_*Z;+B|^#KQK4G;2_JWH|I-|_
M_BOPIXE|">*_|\$^_|N|N|UC2+Z6RU33+^|HH|2XBQA_Y"FGQKM&J^H9H%_M\$O|>A&|X;_W_P_M?
K>69C2S/"M#1|_G_/_L8M684445Z(@HHHH ****_M/Z?XY^#L<&ENTF9;|I&|C/S|XQA&MFOG
MAB9CF2OTPK^0+_|@CE^WC?_|_|_JOGP;+=S4)(O^|H|J>J^_7YFT'=\$E%?%?E!1110 4444 %%%%%%%%%_!1110 4444 %%%%%%%%%
M%?%_!1110 4444 %%%%%%%%%_!1110 4444 %%%%%%%%%_!1110 4444 %%%%%%%%%_YG?V^M^V?+|
V*|FIPG|AAU_P"+=^UK=^4^BT;U*271XYF.UO#@_|DDH|&OYV_M^AT_^^_7|6|O|6'_4G|9'2|2|_P_X<>\$M
5^RF+1W%U|C<?>M<\$;_|_|MDX%?%E?ZI^!|T>#/#?>49QM6KKVU3OS5\$FD_P####EBUW3|GP^9XCZOC)-+M1?
+_(4445^PGGA1110 4444 ?1G_!+3|@/O;_P49;YT/X%Z7|HM?#UN?|
M2|_ZS'/^/#2HG752H(|\$LA98H^#|_|@)&U6Q_5KX|>#0A7X^TCX;_#SPL;_M3H6@Z=#8;HEFFV*UMXD"1Q|/0*
/4JZ^/_^""_30@_82_8MT_7?&FA?9_M_B^|LXX=+7--B;SB*\$VE@>X|J-RS*>1+_*0|C|BK_#&^D#XESX|XPEA;
M)_#PC<*=MIRVG4|_M6B_P"1|JW_S|3*L|5P_->|+5_H@HHHK|\$/4"BBB@_M_HHHH ****_BBB@_HHHH ****
_BBB@_HHHH ****_BBB@_HHHH ****"
MBBB@""|LK|4K.73M1M(KBWN(FCG@FC#I(C##*RG@(@@D\$^@U_*|P7^X);#
M_@FU^U|_P#?#7118_A=|0O.U3P4P4E_-D#?|3IA;_IBSJR9Y;L0)9E\$|_@I^Q;XF_9|U6*WA|01Q?
VGX&U;8#_B7ZQ"C>0Q;M'(&_M;_&3_*9S.1R_1H619F|LOJ*M9^U>+/_A5;|NM^;^99;6)_UA>Y|MBL6X
M|LM(;_E@K|+?^#6|L4_LY_1%80@GX@U4P>^OC|H;)|*DCXC75(=TJA(?5 MB1;|J|6|KP>)|_%HW|2-
M^R%^QK|1_VGD(UN/"WA_XGTT9<_9+|P;2_Y|<20J?>|UZ_M|7SW_P%*_V+?#7_4_9QN/V3|>^_
EWX*;5=1@U%+C3X89Y+H6Q+^X)&4_MRQ_1HW(5E_Y\$^8=#|O#\$_IGQ%A%FLN7#>T@ZK2D4V_=OLF8XB;A1D
MXO?97TU>B_#_DPO|^JU6^GU34|N2XN;F9L;B>9RSR.Q)9F(Y)))/O45?IK^MT5_P:P?
M^?_"S|2^|GBSPC|3+^|)AM|2^_LK47_18;HB\$?07#^OPE|>OV_MVJ?
V7K|K#|H7|GOO=X0Q|L2ZUK0YHK;8_P#3;?Y4H|T8BO|9N'/\$#@CBN*6_M48^E5;VBD)3_
/!>;T445|B|)%_RQYBN&BD^V2T;|V?;64_>BBF%?E?_MTK_|&WO|'\$7L?|
P3TTOXFZ|H7D>)|OBS<#Q%|#R)AUT_|33XL|T|G_X|I#M
M7XOX|;RXA|14H2MB_1^Y|TYT|TEVY8*33Z2Y>YZ_5X;ZSBTGLM7_/_%ZG_MZ_T445_FF?A1110 4444 %%%%%%%%%_!1110
4444 %%%%%%%%%_!1110 4444 %%%%%%%%%_!M1110 4444 %%%%%%%%%_!1110 4444 %%%%%%%%%_!WW_=<P#|RV_9|_UTO|LCX?MZ.(?
#?Q<60;ZD\$>\$M=?MU7S6;_%^T1%)1W;2_X8U^4%?U|_1%FOV(X?V^+M@GCX|^_F.8MQXEL|^W?)V9=6LU;2*
/0S)YML3YV6X8U_(*RLK#64@>X(M(Z5^H;8|X\$+E^3|Z&GRZ?Y?QFK;2BBBOHROHHHH_*W/AG|0_/_PC^)_A_X
MK>|H|VEM>=&M=6TBZ"_ONK>99HG_T4_A6^12;4E9@?VY_LZ?&OPS^TC|M_?H0@UA_9?
C3P08ZU9)OR8DN8\$E|MOH=Q4CL5(KLZ_W_@U_-5D^~7_M3^C^\$NKG_F;C|+2%M|HRRH|9WG)B;Z!M;LH/
FDS.Q^NUXQ_P&OT1K|E|VC_!7_)Q|>_&B=9=|SXANA;MGK\$DA2_M/_QO5K|3|)|J^>U<0UI3@|>LFE^2D?S7|)
|_|8|@O#X"#LZ|57|XTXMO_R9_MP9K_|_|_3^&16+P|A6-3FMU*_P"AZ|XO(MH_@_F#?!_N%;|Q|_1%5;|M4+(Z|_|?
@H^J6=P#>2Z3|M5HB;\$&WGWK)GN"ZCYKY"HK|CS#A+AW_55|_MF_FC|LO6|_|_Y_V0>*7_|S;|S"IR+
|\$_W|2%NRC/F2_|=L_^BOB^Q_M|_P0D_::S^+?@SH7@?7;M6N?6U6QXA_B%X|

M^MZVH^!/&>J;-^./,DTR_D@+XZ!MA&X>OR^!_V_L/JL8K:G6M6A;MLN>_*O!
"K^9^QY+D)7%Z0SS+H5/I)NG+U<7S*3^<4?GE^T5_P09_X*B_LX_M>?>Z0^S5?^+_,ASC5O_\$\$ZNC@=6\$\$\$A
I^C'.7A7I#7R/KN@ZIX7U:20/\$NB_MW>G7JY2YLKZV:&.%OIK(X#?*8BOZ_OAY_P4V_-!C,EOXKETOO_-!QO_M"S
M\$,X4?PK)!M\$?==EE7H*%FUH0+25X;8>L>+FXOUJG/FT_M+!KE_,MG_LLG_*_L/VZ#HWA70;+POX?L:?
!\$GO^"80PI^/UA^VW^QSH_U:7VGYMY96EG9Z!_WBE@_\$C_)#_PI4Z:_.@PIJ149JK_7OW
M2Y^V9%2HK">WI3C..!5*+4HN/1K1KT"BBBOP_H****_BBB@_H_MHHH ****_BBB@_HHHH ****_BBB@_HHHH
****_BBB@_HHHH ****_BB MB@_HHHH *_D6_P""Y/(P_8Q_P""F_Q,^&FE:9!FT^6M5_X27PLJIMC^PZAF
M<1H/ID4QF@'_%PK^NFOPT_X)?V:=!G\^OVOM^*L_8Y+SP?KMSMZA@_VQ7/M_MMU_C!^FX5Q7L,SIFHHKYK5?
Y?B:NC|*|****_3C|****_BBB@#1?2^#/_M3X_2>#OVQ?B/^SK?7WEV?C?P-J=K\$S<27NG7_"JZF""N^&D?L*_HCK^1'
M((8?&@_C_@K_|#_&_EYY.&H>,DT&Z):"LFIQ2:2WL&N5;GH5!5_7=7YI_MQ;0IEF:J+!44_FM/R2-8;1117RQ84444
%%%%!1110_4444_%%%%!1110_M_4444_%%%%!1110_4444_%%%%!1110_4444_9?CG7_/A%!!6L>*0/I-T
MNXLGI^!C9_Z5^,DDDDL2R69B2S,9H\$U_MMKG_KMB'_J5^4!20^A!A^7_8JO_#2C_P%_+!MQ_#?TJL9;@!_!3G
M/_P_2C_IC"BBBOV_E(****_BBECC>618HD+Q_51U)!@.\$FV?H^P3X^3P_M3^RSX9B;+;JD,FI?QC<9G+(?I
OUIY8_"08JR_#AN#P;X+T?PA:_"2M+M_ML_#IMBC5!_Z#6I7;9KC^F&9U!2_MSE+!VV?ZT<,Y5^('ER508TH0^<8
MI/IVKA1117>X%%%!1110_4444_%%%%!1110_4444_%%%%!1110_4444_M_%%%%!1110_4444_%%%%!1110
4444_%?#7_!QW!\$?^?>V_!\$AOB@EK9^=?M^\$TL?&M@=N?
+^R749G;+5!GIZ^Y.XCHKX90_&OIF_X@?RXXM5G3Q9X)U71_MVA89#_::26"_C!=#K?
5!73J_RR3^YB>J/XEJ""I*L""#R#17!68!1110_M4444_7PW!;G!-
/B)H^Q^T4D7GA_6K74K0AL^S8)EE7GMRHK^WKP!KNF^*_M_L?&VC3^:9ZC9Q75I^XXI\$#J?
Q!K^&NOL!/^9WCY_BC_P3M^!GCV>72/J_M/PGTHMB(=&+^SAX+_R>J_U"BBBO_MTF_G0****
"NE^#&BIXD^/_A3PI(N5O_!+8VI#^9!A^/ZYJO1OV1!)+_+M_!#P_%.!16!GXHV!?!H<_.9U70RVO47V82?W!;/9X"!?
X;_M5_M_\$WX=VD^E!:_!0M:TZ*/^XL%|-\$!^60/;^A?^"M6B0>O!_@J!^T^IUMC8W_MQAI03@_=#+?S2D?
FYKYZK!NPTN?#PEW2_(YV%%%%;%%%%!7!;_!OMXID!_M8?;_!3X^:M+)N_/A^!L0<IK;4!NV_1_?A7!DI?
U1_!&O>IO?_!/GX:6_MKOD66J^((5^T^6;N3_YR\$ _C7R?&\$;Y;_!HK!P^PW/OVBBBOSBZG^8=-U>UN^5=S)!<*Y|<_J*
+5%9NL^,M?"/AS4K#10\$/BK3;_"U68Q:7:7M!%)>2#JD2L09&Y""@GFM*^_HID!%K_1
MU=3)^%&A:221@%50,DDGH_!9_A7QIX!:=Z8=+!\$>+_,UFS\$K1&IT_J_CN(@Z_M_>7?&2,CN,Y%_&G167J^C?
P9I/B2R!&ZKXNTNVU?4D9I.TJXOXTN;I5R6:(_MMN<#IR5!QBM2@
HJMLZKJE_::A:M:7MOYTD7GYDZR)YD:M^(FY21N5U96_M^4IY!JS0_4444_%%%%!1110_4444_%%%%!1110_4444
%%%%_SU_P%_M_Y_9>G^C(&NV>IV&7K!Y*_2G_@I%:2?V3!_FOGI/?V_GTS<(O_+7YK5_M10A3)2X9DNU27Y19
7TFJ;AXBTV^N^IO_R>HOT"BBBOTL_G@****_"O3_V_M"@_!E!\$!S@?VROYI&Q7F%>@?LI7R:?!M^!;AVP&!3V<?>
=Y50?^A5YN=1<M!GQ_5UIS_P#26?0!(U(TN+_OFIE7H/JD3I8****_CD_UC"BBB@_HHHH_***_M*"BBB@_HHHH_****
"BBB@_HHHH_****_BBB@_HHHH_****_BBB@_HHHH_M_****_BBB@_HHHH_CT_P""R&S_(>I'_8P(C_X6GJW(?
!0V:~^J!Q_P""MG^B#_A^O^"C_??\$^R;DN?C_XF:\$Y_Y9C5+@)_XZ!7AU?MF#7+A*_NKICG_M>X4445T_%%%%!7!2?I
P_Y*1_P1!%GKXEUXC_&M?RV5_5/_P^R6E^M3O!_@C+!+KLIC!^J/B"?_N_
:08!_P#D.OE>+W;_X_XU^4BX;GWS1117YJ:G_MYT_!^QVA!>I/ WP#^&?I?
QF^*P4!1ZC/JGOQF^\$^@W4K1:5;)NM;*6Z_MA>,0+)>&*XD>H?+LMA(\$V:U?^"
(WP9_X(F^"_@SXD_!_X)2>&HK#3==L5L_MO&=WJ&M:A=CI8M0TI6=Q%?32O:L_!/@F%EC<_
(H1J^Z8_B%X!E!)8=.74)O#RZG\$;Y+1G*+<#&=Y@B+@J^!201G_?#^J^OI(G@/0?^"LGI_M6/BK!G^TATOX;+>_
/A_H6E>/_2!U^6+^_9#>M=K\$B?QXK_6WEF_Y\$FH9;YF;_M!P'_!&X;?#K_@H^QU4VX?
VQ_AH_BK7/CUXWURSM)M9M4GF!/>@!3!M)8Z78.P)M\$MV2656BVL9G,I)?#5ZU_P;U_M;_%!K#_@GG#;?'+Q-
KOC/X5_M^!6^'_B/Q!%_!5?%8_B^WB#_@HW^QG^PA0RH^%_Q4!6>(-4!>=<M_P#^MX@ETNP673=-
G!^6:W!EB:2!H?)*#0_FV!H!S!^?^=W_5Z_90^M+M+G!_B67AK3/CYKU!_BOX8T6U2VL!>3%L_OH(P\$S;2W#?
Q!>9Y>(IYP_ME3!9?MQ!\$ _/V:O^"D?PZ!_Z!4!IUFQOO^VLP>(2A!0/_NLK9ZOH%ZNUDN_M!&ZVR(P5#AE=&VHV-
R(R_"7PL_9=10?MT_!%EO!Q(L/CSX_P#BE!)OV2(_MM=3^(_CC4K9X/\$^C:8!7!L(I&WMK_K9!
(7FGAA#^;_%YCJK^P9I")&N_ML:QCE1*?I_!*_VFOV!/^"3
M7QN_!DBU*^Q^/QCE=)_X2^7;%A<1>\$K>ZU"WL;_PM^P8-MKN4(^LER!IT_M5!G8_?A5!+O
OP3^&^A_"3X9>XM^!A_AW38K#2;"\$DB*&_0HRS\$LI^T_MSL2S,2S\$DDUOU^C!_KQAXV_9H_X+5!?
L%~"?_BKQ!_O\$W!<7C^IT_Q7XG_MO-9N--UFTUAK_WR7%Y)++&ES"P\$L88(R^0_SEONZ@_HHHH_****_BBB@
MHHHH****_BBB@_HHHH_****_)?VZ=^_MO!D_QE!;F.QBN!>5<12Y_1
M^*_FOUT^/7A!_%7P0!7^((4W27OAF^BA&X^S^W_P>Q7Y%U^>5=2RC\$4_M?Y9W_P#_HI?^VG!/?
2GP;H4X#%V^_BX_P#@^\$Y/_O"BBBOUH_EP****_M_MOX:_VGAGXC>'_SDDFO=/UNT6;T\$-
_A3X;+8)+O_M/0K2Y=OIH^E+^X)(TKHJ_B^M_M2G0K2I2WBVGZK0_UVPF)H8W^4!13=XSBI+T:NOP84445D=4444
%%%%!11_M10_4444_%%%%!1110_4444_%%%%!1110_4444_%%%%!1110_4444_%%%%M!1110_5%>WEKIUG+J%
!L4,\$3232.>\$51DD^P_J60#_/_@IA!9\$ _9_?"M^QG^+RW(BN_!^&^K_ISDX^VR2V>^V^XS21C;T!4W5JQ@MVT00
_CN^*WCBZ_M^!)OQ!12_\$FIW>=XAU^!U:~?UW3SO*~^&^7K_HHK!O2459_%%%%,HHHH_*_K_M@_X(%~%7!2!\$?
O@7I#PE#_X7GOM!475_9(-4B0\$A8!ME4'_!%=#!?OV8/@_M^U^!M4_9F^//PQT_P
0>+19MK>WU#PW^7@>_.6^6%5,_(T6R2^E^!4H_M5WM^!>_OV8O@SXY^VC??"?6_HU.U!;_#IZ6&GZ!H?B?4-
M^9I&D2VTF5G_M!\$MS^C\$5!_3;D8PQSU^P3#X^&^O@!3OAY!/_NE^M_TBv6WTK1_\$L(!6_MTLX1TCBBC
1%_HH_K6HH_Y;O!&O_!Q_!5^%/_C?2Y;^X!%:O)JOA^WDNG%_MM#2-
!^W+P@!9(XY91&7!MI^RX8!A<^)_PQ^_WOI^FM?";XK^#!#7_#7B_M+3L;#6!%U_
207EM(!5XW4!B#UZ@X((!K=HH_!H^!4%I/?I_GB_5?B+!_M!#FJ7^B76=)L!)O?&OB?
Q+?S!FEV@(!MK%+B^FEDCMX!O8!J0&K_MF44_%%%%!1110_4444_%%%%!1110_4444_%%%%!1110
DD<)HXHML&IR1:C_!Z-6<_!2_*OUWPBOBIYGB<*MP40_%V_P#;_MC^6?I3Y4Z_#F5%+^%5E!^E2-
_SIK!SQNBWBOWL_B\$****_BBB@#1!/^"MC=%_P^RIFFO/OGT&N=GR>0_FI^250!VO>*^&/^"3WQ&33?
&OB3X6W_MEQA=4L8!^R1CQYD+9_/_=ED4_2*ON>OY5XZR!Y;Q3B86TD^=>DI7!S;7RA
M3+P7SV\$^AM@*MIRIPIE+R=+W%?S<5&7S^BBBOD3!2^BBB@_HHHH_****_B_MBB@_HHHH_****_BBB@_HHHH
****_BBB@_HHHH_****_BBB@_HHHH_****_M*_OS_X.N/V@;?X3?_!+F?X4VUWMOOB_XRT!2%B5L/!EMG.H32?
IH:UA0_M!=@_A?IC7!ZO_!WW^T!;?3!LCP_^RIHFH^;?#?PH!JT2_Q^J!DAC8=
MR+!_"U<\$HSCJ<^WP!AOK;4UTCIS^6WXYVDF!R)HHHK!9.0HHHH_****_G_M^"GPWO!_XQ_&7PE!
(=*W2:Q%7B>PT>VV#)!RYN(X5Q!Y<5_G86%GI=A!IFG_MVZQ6IM^L4\$2#A\$4^HI@_!7!E+P_?^!
OCI_P5T^#>AS6GF6F@:_!+XDO^Q_MD1?V=;RW<3^ZSQ0*/=A7!_U?GW&5;FQ_?EV3?WO_(!I3^BBBOC#0****_B
_MBB@_HHHH_****_BBB@_HHHH_****_BBB@_HHHH_****_BBB@_HHHH_****_M*_OBA_X^T>_#!KOA3XHVT)^W-
K+I=VX^;,%>^!\$DO_2?2E>+2M_#E_MBB+^S#KHM+?S+K0\$JUL=)!M^T_!^6EKZK@G;?I,XGPU5NT7+E?I+W?
P;3^1_M^>,&0/B/PYS#05YQA!2>I_!EYMQQ^9^9%?UP@T_45^VA_K6SYCF
^<^6S8!5^M5O<07=NEU:S+)%@_M>.1R&4C((!<\$5^,5?I7_P_\$!^C/!5OV?K+1_!ZWZKX6^Z;>JS99HE!B3Z_M&!
<IS&U?CGBUD!HX:CF<%K#W>CUB_DIK_MY!9?1>XLCALPQ?#U:5E57M:M?^***M-
+S<>5^D&>ZT445^!H!1110_4444_%%%%!1110_4444_%%%%!1110_4444_%%%%!1110_4444_%%%%!1110
4444_%%%%&?XL!5>^O_OA:4_M&WB!5H;#2=FY21^!U^_!N&Q^6!2&221CV545B?85_&^VW^TGK7!8!7'Q\$;

M:UPRA &2BN[U"U@F.6MK0N5MHA MG L48ID%?T/ P#!TG^V_ ^S+ P3WE^ MGA?
6A\XI^,EZVC1QOR8ECT>+;)J\$N\IK*8;8CN+MO2OYCJ_0>#1%LA/%2WE MHO1; > R.106P4445IF0%>%%
!1110!S7_IG%~SZ?S\$!0G09_>U"PS#X8! M*VGA\3H%~4SW_ GRE/H(I)0?03_P"U71_U?GE_P;#?LS2?L^_!\$J?#7BS5
MM^SZK\3_0?%~V7YQ_Y6VM\G^ZUO;1RJ.G\HR_0VOR3A\3:S;K;)%V7 MRT_YM%6B%>%%>4%>%%~!1110 4444
%>%%~!1110 4444 %>%%~!1110 4 M444 %>%%~!1110 4444 %>%%~!4.H6%GJMA\H6ZRVIS"743C(=&!#**28@
MD5-133:=T*48RBXR5TS\@OB_V\ISX5?%#70AW?!\MVD;G+;QNX YDB#9C?_@2% M6_&N\<1#_,\$^K1Y7Z0U\D5_7?
M#6;1SO(Z&,OK*/O?XEI+|4_D?Y7^<(7#\$^#^,L9E35HPFW#SIR\Z'_DK2?FF@ MHHHKW#XP**** "O:?
V\$QCRGP_ ^5H=9N_+T37PNGZL6;"Q;F_ =3'_RN\ M>+45PYEE^ ^S7
5_)77NS33_S7FGJO\CAH_ =PUG> ^S3!NU2C)279VW3\I*! M7Y-G\045X+ P3+VC%^~
GPD3PQX@O= _B'PS":WN\OFN;?&(9_ %>15_ (N;Y:BTHOSB\Q?F@HHHKSSW0HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH *;--:00<7\$JQQOJ6=W; 4#DDD\3J_ M;'_ @YZ_X*9_ \A?
LECFE?X7^<(?!? %RSEM;A\7\$NEZ\HRZGXY5IR3;(>_ @MSL#1BNK\82KCL5&A3WD_N\OY";LKGXN?%Q?
^"@G_!0_ \X*>*2B5X(\<509CBU@<%4KO*TI>GXC2N\I\$^PN^7A2X/_ #3
MPI\)?!%E\FT;POH=ILD6X_Y96UM"D_2|>B(HK=HHK\9;XM+B2TNH7CEB(O@;\4=^/ (OA\ M(L+>5J_
GNPMW:L1YD1^N 0>S*H5^JW@?QKX<^ M(WA'3_ "A+4%NM.U.V6>UF7NH\$=F'R".H((20QTKZ1_P""?
WI6P^# \BD?" M_P 2;GM+ZSE.H\ \$WVC\A2Z\I2T7_S\#Z*1 M65U#HP(R"#U\; G0_OH**** "BBB@ HHHH ****
"BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** BOI^OTJOFU\4\I^VMK;)\B\XGD")\$B@EG M9CPI@
DD\ " @#>?V?>VG?A3^OK^SWX\;5^~6LBR/>%=;ZNM\FW,F0L5M M\$ "I NEED9(T7C+_D#)\?G\4?
M/_&")U@QK>DU>G1REH= M+LD^6WLH<|(\X\+G +N=OF=B?K\ @X/_ P""QMI_ %%;_ CL_PI3X*_ _OP<|
M":@ZZ_8G*KXB\+_A) &R2\H9\$O\Q98"4_+L\$1'3=\$Q'6OP+_P"#>G_ @G\+_W?1_1% M M
G\5_!J\ " #9HO\$WC\H8\PSF*0&SLVSPWG7_7*!\T44_I7\6U?"<7X\PPD M'M\TOT7Z_<074****&_ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSC\JSX&VOI0'P7U3P
M0D2?VE\$OV01)GP/+NXP=@R>@<%HR>P"SO*ZV7XR/-2JQ<)+RDK/T?5/H\3\9+ZQO_09M-U&UD@N+>5HIX95*
MM&ZG*#0>A!!!%15\7_+!37IG_ A\$0%D7QY*6&W3M8XEXZ"0
M#D-WU)RXXY0K^N,BSC#YIE= /&T=I+5=I+=?)>K/J?Y;<:*8_@GB7\$91BM M73?
NRZ3@18R7JM^SNMTPHHHKUSY4**** "BBB@#1_X)^ MKPK#9_3XNZOM M*{8?
#_KW+!\$=%M)&3TC8_IG\W/V?7XO@D'<?;!\\$/?<=|EG\?CMK 2EME3FWM;::GI;W7K9O\ (HHHK\4/I "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
3W_8T\;!\#%O(UK\3/ M&6EW&5UB13A\MI%/-LI&)\I ?WK#RQ^I#>;I_P#!?K_@XE@V;6NL?L1?\$/ M">
!1Y5DL_'GO*TF00_>'W\K% M8\;IOB_ S?Z+YF_ \&QW_!+IOVP_VJO^&J?BMX<_P_ A/?17,"7.68=7UX8DMK?
GAT@&VX MD'/@5@5E-IM%??V75&E=GI%?2\\$\$?^"/#(F);;2_29\JP+>(A2N2/>Z1X8<_
+;:&XU;7M>U".UM+2/(&Z260A M5R2_GDD_9) H_W*!6_95_X*+?L_ MOWV\;3^RA^U\X2\<7^CQ^9I6F;H(
M^UV\6X+YI@D'R>5N(F'=F2\G)%=A\7_17X_ ?4_*T/XH^/I>QU77C+_8 M6@VMM->ZEJ0B_K6IG;))
<3J@92I(A;EW\$9&0N;.*Y;X0?&X2?WPK)XU^ M#?Q TWOQ#IL%+8WE_ \$;X;+^_U\0_ %GC7Q#1_#?
B6"IGUHPHJGB*S@#-|@DN8O.AC MD;T2_?MDIO.Y4DC9@I(A8_WJ***_?QIX%+?2SP;J/@Q28"YTI5+9H;F(
M\0#T93Y92_P/8@'M7Y4?KX_>)\@)\3M0^/B12YMG\RON\F%N\9B?+E7Z@8 M(L_&^OUOKOGIM\IERQ_>A
AV7T>*.+O/HZ/+HMRO_W/+6SG^Z^!\@G\K_ 'MINS^@<<5?ZOYCI#52_<5= _JLNDOTEY;!\\$?AGCCX9?
Z\9"L9@87QN'3<_12& M\J?KUA_>NM.9L_6BIM1TZ_TC4)DU2SEMIJUF;*XMYD*O%(H(96\Y!!!!'M M4_?TNFI*ZA
_490DXR5F@HHHHB"BBB@ HHHH ^H_V/ P#@H\K\PP6V^/Q MIN;C40#R@1V6JX.EQIR\K=Y8AZ?
>4=,@\!IX>/ \$F@>+!\$MO\$0A?6+;4_/O M(Q);7EI*CD7U\Y>QXK;*\C_9\;G^*O\;KFX\&ZH+C3)Y UJH=Z2UM/V
M+ =8WQ_&N#P;I@;5^6<7>?&&S64L7EUJ=9ZN.T9?_(R\JGUM)JS^E?"SQ_P?
MPS^&5Y_S5L*M(SWJ4UT3_G@NWQ16S;2B?JO17DWL_!9'PA_:'M(K+1\3&EZ M4S/H&H2@2Y_Y;3<"9>O*_
CDJM>LU^#8\ 8W+;2Z&*IN\$UT;_JZL_> M M\; #MOXAT3PIK+_O^&3MTFT^I\8EBMY\B)P5FD22LB."HD9);,XH
HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
MR\1IX7QE6OIAN6Q3D_YPT\!2_QDC?#X;OBZJIT8N4GV\;M(^K?C%19_A3^SY M\15^+_QM\?Z9X8\Z);&?
4\9U>Z\$4_*!\GEF8X544%F8A5\ K^= _ (+6 M_P#!QG\0/VXX=2_9\9#EU/PC\G9\?6-
6D)\U/Q6G0B0#FVM&_YXYWR#_6D M F)?D;_ @HM_P59_+X*>/%122M^~1\H% A<_
>X>| #Z+NATK2@AUQ>2XZR2R%F(R0H(4855^_O\ @W8_ MX(^I_P\$^?@_?C\15E8A)) ^GSJD>
M/W6YOTDD\RXDS=8_ \$>Q\JW#17W\%LOO_81L@HHHKY@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
HHHH **** "BBB@ KSWX\LR?_?1_4O_ M M\; #MOXAT3PIK+_O^&3MTFT^I\8EBMY\B)P5FD22LB."HD9);,XH
MROH5>#_!%!_ ^"BO\O\ P3;^H^+O\0?C2Q\IM2NA8^%="FO5BGUF^_ \$;\$@ M\ (DW\I9R"L298Y)56
/D?IKC\I\X=;5_P7K_&2OB'^R5X\$TWPMXPMM#\5:M M8+GP08LQS>&8;:&WMI+Z;(16.MS<26T;L"S\$X)
(A791_X*! M%~O^~37_ M 5FT_ \X*_ 'KP/J/B+IGWXE_#;30A\KOB02;*.7I/V1A
@K%_P2MTWQY)JMA^V/HGQ3^/7Q@UI3=U_P2HE\ M)+>7#R>39;1HZ31(MOIUKYS\#Z+T\Q.WT2R_>A\4/TWO/_
_"YGB#X*_MG M;3IUYX*P*A7X#^&_ \$T"2Z3K4US*17B"6..8&*> \$;1VDS(MH\84)*Y8_Z\ M_@E?X.UCXF_%GXX_1%;
134+T\ (C?M'Z\H\IX_+V.HPW7E;3I6GFQBU*Y;F MB2\O.EWA5F;)(H8Y#YBNB?6GQ_?>#A7X&UCXF?
\$7Q;Z/H'A_39\I0UG5;V M39#6L* &2255V"J\X5^?7_13FNA_8T_!;C_9Y_9A5W>H?LX;)>Z+J
M'A>QFOFN;PYXDN819_2JTTF\ (RDI@RKDM&MUE \$NWN\COAI?@H7R7=SLM(+*RU)EDC%PUK<@NK*Q
M@B(^!LT?'_4\ \C_ \$7XA_MO\ \\$/O\PTO4=(UOQ\^TK\HCX_ \&Z@610_M"GAE(S);P319PM_*/CA^Q7_,\$??
A_X+UCX<72?S?X@^_>_ MA^#PWU^_2WFB34_1NINS6ZCOOM\6"U_E<<;HK=7_F;8S\N_LO_!WP;^SM MX
3X06'C= _?13M+)K/C76\R2;_AK>J73HG4KB_3E/-DR\$4?)^&D<282)%_ M?LN^&O&'QP\7;G^WS\1_#THJ_O_<
HWP@+_ZO\$T4GA\PTS+*LLT;8;5YJ_D M<_S_" T<26ENP#6\A?+_+X\$ZOXUTG_@GI^O=^T9H\;@_?7\42MN36'Q\U8P
MA==U_ XUC6;?6\ "8?O3;BRAA66_ DCB@/@RA\$ _!K4444 %>%%~'R_ P% M#_V.9/%=M<_ 'WX8Z86U*WBW>(_<
@3FZB4? \R@'610/F\2C/53N^&*_#K MUKX/_X_8EE\#W=Y;OA+I\1)G;NN;5;I_R#W)YFC4?L2>2\PG^H\W\ M
M.N_5RQRG_R\JYXZ_5JH*_P#3B7^/ M^9KY\HHHK\KX_ "BBB@ HHHH **** "P7\JK_EU;S\+&X;_2-B&5@<@@CH0
M>|?27P\$ _X*6?2?X<@)X?>*%L?>DQX47\$TNR_B7VE\N\ION\H\5\U45Y>_Y M-E>=T/8XVDIK?
=>C6J^3/H^&N+N(^#;!\;RC\$RI2ZL;QE;I*+O&2\4I=#17 M/@W^U\1#OCK#^X%!\P2;W7+;/?GR+M#W'EL?
GOW*%E\Z\K\88I98)5G@D9_M'1@R.AP5(Z\$^L;H^\$W\?O\1_P_*Q%8OXL'B#3X\#I#X@4SD+Z++D2CCIEB!
MZ5^19SX2UHMU_KK77\LI\4D6?S2\3^J>?2\0X6I&_#B/'N.O^?E'6\JZ;C*7E%Z;45\ M?#7_@JG\ (O\$^EVGO+);GX>G;
>YM_L MAZDE0L@^@1OK7_MNW@X_?!\3XFI\$!"?%#1=IED^L_QWRK/^_38/
M_@2NOQ/ZR#Q\X*XHBO\Q\1_D_9YN6?_@N6?X'7T445X9ID%>%%~!1110 M4444 %>%~_ M" _P#1\A
86_93\$!7\0G\5_@;PS=VX/F;3>_%)J'"7%!\\$6G; M\;\$^GM^U9_P=X_L7?#H3HG*GPA\4?S\$W4(K#JNH_1
DTMNP96E1H==K M01YX&X9XA+EF88Q_N;::I\VOO>@G\ (C^OF7ING_@KY_P3_ \$M.G@^A M\;123Q"%NM_
AO;?ZS.<9 "!\#SAYVB0X&SQ7\W\!_!QA_P_N_ VQ M4NO#TQ;3X;>&@;%&V_ W62P;1#QB6\+M=/D<_HD6-
LGY\TKX6NKJZOKJ2_M\O;F2;::00_.*Y9G8G)8D\DD\DFQ\;P?_M2Q<I>4? \ /)U(<^Q^GW_!10_M_@Z_>#_<
&K\6\^&O\+5C+!^?EP&BEN\OO_U^_C'/SWBA1;@C\VVX5QR#* MX_?F#>7EWJ_
Y+J&H74DIQ\ (TD\SEGD=CEF9CR22223UJ_BOL)\@L+@;?10@_MHK\7ZO=D MA11174(**** "BBB@ HHHH
*_ _@V9_X(F3^*M5TC_@I+^U;X M0VZ39R+<_ "PUJ_ \I^76)48?ZI"/I\^ ^P^X5(F?PO_(-^?^"%FK?M

MX>,K3JH0HPY<6GP:T&^SI^G7"-&WC"IC:F%.A^QHPQ+(/OD&)#GS&C I8T MI3M/T?3X-(TBPAM:2UA6&UM::
(^)#&H"JBH 50-.!7Q7\$N>JG%X/#OWG M3I>2I^_::2:2>I-1117P:H%%%%!1110 4444 %%%!1110 4444 %%%!
M!1110 4444 %%%!1110 4444 %%%-BOX=#_QVT#>./VCZR:4,+8ZKID5 MOY.I&I.YBG;G:N<=<#TK8HH
YG10@M/!#FIPZWX>^\$WAFO:=MUO=V>@V4 ML38QE75 5.">AJSI0?AAI-/BUH7 BWQ5^FA>)M.1T2?
V=X@TF&I@WC(#> M7,K+D9!..UNT4 4?#A?P5X+T*V1+>#O#MCLF64?EY>G:9:!! F<I4C0! M5&2>
I4@WP+X(^6B I(W/O!NE:~IWVB6?!!HVG16L/ERN7DDV1*JIG=BS M-C+\$DG)-M% %>+5?#2AW7,FTO-
:T&RO)M/N!/82W5JDC6THZ21E@2C>XP:K^ M-?_@SXD^%
IOP100"NGZWHU^JK?;5JMHDIO<*K!PLD:@JXW/*#@@GBM6B@ K MB=+_&: V=M#^+_Q!>M% ^W@VS!
<78D^U>,+7PS:QZI+YB*DA:Z6,2DNB(K\$ MMEE101MU^S MD<YB'C AR,*OIGP-
XA1K1CE^:SM+_:1I>RD^_:77KKJ_XQ!90 FIA)U, M!X:17INJE&*UCUU/"Q8U^QC3!MO%JDIB_&_DH?Q%>
MB^>O^"CGI5VAI5N_&UGJ:+T34'-@_4Q^C^I+Z+HKRL56D2XYWQ&A)IW"?+W MVN?399QIQ?DT5' YA6H=(U)JA
X#>WX^VQ^S% P4_&_OC^&^_"IOIX4I M^C:K*K!DUS8VTJRZGJ&O3VTJRW\$1D,95(V& I3:X)KL_P#@G-
82:VMO#L^ MW/V6VOI3I9M4+9Z_ 'K @Y7U.74?I @M!88GDW):Q^H8AGH/ TYBA
MOIFK!>XDR#):%D<+1HJ/8J32NE\$<I5I^UC^Y_H_P#\$7\$!\$O!:=&9MB)5IJ MO*,7*UU%0INVRZMGUE?_
/Y:~T!)MTOIB;P;#) ?N/%%W*OY"-?;O7>* _M^#P_IOS4:=X/WI_ P)-+9N!-
>6.IW:*=L7D8SGU!M7Y)45C^A_XI45^ M/^9^XITCI_ B+_P= ?I_!8+QU#++:|<=++1R@AEI_&";#@JE:ZCF9?J#G
MWKYD^_7_4C_&@I-!8?VR_B3KEK.")=N/%!TEF<I<6T:K"/P2O\$Z*
M!*.7X&@ITZ45Z)"NV!)8EF)))Y)HHHKL\$%%%%!1110 4444 %%%!1110 M5^F'_!?"
_@GXS_X*#&^:"H#H?2KW1@/KIEYNBC.Z&Y7S1MAK>W/#):A@ M5EN!R<&_!HQ>D_!\$./^#
<+Q5^TM<:/^UC^WEX.O!^/R7GAOP/R/ XDF(V(5= Z&O#GASP_XA #JEX3)I_Z'9Z9I>FVD=KIVFZ?
M;+#!:P1J%2*_-%1%4 !0 *^SIB_-!/#X5WEUEVEY_EZ!7&-!61># !M_A7X?>_-!^!/?EEI&BZ/916>E:5IMLL-
O:6!A4BC10 BJH_P *TJ**_M/FVW=FH4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** /FKIK?I X)I^&_C%)=?\$X5?9I!3/F2YM2-
EKJ3=RV/I?>IXX8 >&2 M6^P/XPI&^*2_ B*YI>--"N=U*S?9<6EU^M93V/H01R&&01R^17I&UP^QY_M9K^%?I1A?>
V7XIT7%W#&5L-8M.)=6I/IU2_N>J_!TZXS@CI/X1!L5DZCA_MPO4HK1/I4A_Y*/DI5T?0_G^Q2!
LLXKE/!CY:&+=W*U^J^K=O@F_YDK-_M\$KMR/R>HKU_H+I^C^XK?LZW!Y M!7H@,PP6:898C"U%.#ZK!GV?
=I5^IYWD6<<_9C/ YG0E2JQWC?BGLT^C3 M:2!A11178>2%%%%!1110 4444 %%%!
'T9_P2L/MG!3+W&W/V3PW=R_3+Q M) /I7X=2I^ FOIXE_P""Q/ORUS-PPC!0V=KD^O!MI_1^<>* >#_().V^F?
M&OO%JFW_ %/A9HL^F^YA/ LE?SS?I%?M:O_ /!4OIH&^+I0+^+6N6V?^N-Y M)#C_ /3X<'#L:CAKR8<_NX^
<"1XP0:QKXBCAJ3J59*,5U M8)-GS!_ AK!0?C#XZTSX9?"KP7J?B+Q#K5TMMI6BZ/90<7-U*>BHB D!9)I M DX
)K^&_ @C+_P+_+^"OY=9_*:6_X""Z3IWB?QW\$4NM\$!_DN=+T^0899+ MDC*7ERIQA1F&,@D>:=KKH_!\$U2^"0?I(2)
P3"!&"R^#A8ZMXPO:41>(/B M#KD22:E?I" T:\$#%K!N (ACP#M4N9&&_ 4U?GV<<3U<6G1PMXPZQI_P#)?C^1
MK&#MP & ****^2+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH ****
&7%O:WENH=P)+%A22*10RNI&""P01VKYA M_+_ _"/@Q^9_ \$ _P %I B#PWISY=I=3I@N&I@_3
?IT?2I@=:^H_*17*! MS3(1I:15%'!5T?DUL_TZ'S/%_!W#G> ^J9OAXU(I^M*+IQDM8OT=GLTUH?
MD5!50@C!40@GK! 8GQ*!W6FNS\$07#KN@N_!T8^BOS)%!3OI@*_!A!5,NQ:5+X^RG_KN#^6LH_BO-!@I:?
M1HSI+!2Q^#M3ZS2WIG)J-5>CTA/_D?119!T5WGO;_&9_C!\$B0?#\$P% M>06B-A=4MD!ZT?T/FIE5SZ-
AO:N#K!HPV+PN_HJKAYI<7UBTUIZYMS+_!QR MC%2PV_HRI5(IQG%QDODTF%!!PA1110 4444 ?87_!(I3
#/\$OC?5-O MJ:&OBS_OO.?_&G7IT/ 46UA/\$7_!07XI>((WW+??&3O/<*WJ^U_Y_~M?T M)!+!
(VPIOP!XUXU?_ KKPVPBS_N).?_E?RK?M(G_U_P)) ^T1X!0!HVV_P_ M:I<I!|=IW*V?UK!2S&7M_-L>^RIK_P
D7ZG^C_@/OJAX4YWEI5_?6J6_"QQ M=%%I?^NA1110 4444 %%%!1170OI" !+HNO!034XH/V:V>_UC3^EV
M3>)HR\$6>D6^#AMUY/MB))*(6D_%)XK_K5I4:=222!MV!^"KU!E/BSH M3!MSX@)!-V7?
@OK/BW4MR_Y+^"WVVMBK^DN:ERL_NG^U(R@!ID!5^VW!O M_!HG!&?+6?CCIO_*TGC?
4D*R/X*!S2V>DHW=)KHA:FY^X+?JPKI.%7.^ITC_F_P!2U!H3I?^":7_IJ)!\$?@M-8?%;_(*!^(K3XB>(-MXMLT/@?>
2C(FA6:10)W(62_/_E(GBZJR2CFOUUA_/_/#WA#0/PMX3T&RTO3 M-/MTM!#3M.M4@MHE&%CCC0!44 !0 *NT5!-
C85->O* ET7HC1)+8* M***XAA1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!1110 4 M444 %%%!
!1110 4444 %%%!1110 4444 %%%!1110 4444 %%%!11 M10 4444 %%%!1110 4444 %%%!
%98HYXVAF5T=2KHPR&Z@CO7C?Q7_8 M*_9N^SR7TO@_P#L*_DR3?>'F^L2?5H&(!D!GUKV:BNW
YEF&65?X2K*_M\$O!K^&_O!SQZX>R/B+?#51SP^T.TXJ5O_-ZI^LSX_&G_2F^!6B^9>-
M"SQOI^N0C)6SU!#;7&H.6C8^Y*?2O!O^W!_QW^&X! "PIUFACSONUM# M_C_+QID_!>K!J*_00_U0NN?
I<+>)QI BOML^LY^6LL1 M2G3?E:2^&Z?_)*?C^?;?1>XRPKXA M_*)Z^BH>("_.(6F)2I8R7YJQ!%C?
SQ3P.O>R9R7>\$ZPCMH6/_H=?R)ZUI(A?B:QY9RCRNZ:2 M:NC^Z?#*^<9DGA_EV"Q5-PJ0I^I%
HMMM/SU/SUHKJ":7 @UX_X+\$W\$PBE^! M7AZ!3G.DOCW32H_IYF)_2NB!2I_IJ_ %9:(&I:1V-(SU.H>_IV.O_/"
M&3_)KN><940^7T?0!HURL_2BOU!%_!&=?I=NI%7I?_+2GPHTA&ZC2YI2O MG7ZAI2\$9^C?
C7MWPV_XR?I!LT=Q!7_V!M2002#_9^&_D=KMJ0)HJ7/U.8 M^E!6_HF_TRR/P=HK^G_X0?&I/_2@^&
IPW^C_0^GCUTP9!3 M^+V@C=QJW3H!8>VX^Y-?7P_X)K?L?LSRPWGP_8^&^&@7L&^U:"PU!_M?+CI_I4RO-
_X_7FU^_!#&^4G!DOU2X#4&?RA?LY2!_!O!O+_!U:3IGW MIDGOMX@L!@CR=8 L=K33CGI_IESY=N/QDZ5^A?
I+2_!G_P#M:>/3::U^U?I M^GPO/K^R&ETC0(6UK40.Z,08K>_GH&624#K@J*_HAHKP!5Q=F%72DE!>_Q MT_
I01!^?LA_!&YO_!+?IDJ2TUUO@H_Q%0VN&77/B3.NI..5) MA+K@2-
WKIET_3I#2;&2!L8::VMXECMI>WB"IO(HPIJHX4 #X%345!YB,
M5B<5/FK3^MI^R!XVN9M!UFZTZ:XBUVS"RM! M.TI<C(I*Y&?6L_ (C*?V9_&C_ '7 @_LO!JEZIOAE)VYQN^K1!>
VI_M?V) VA?%K>_/@5^US!_?&&OK\$9#H7ASQM8WEIY8&XOY\$4IDV@<IMN.#S0!ZM M17%_&IHWX!_LT^&4!>?
M^"/(PWX)T9WV+JWBG6(K&VW95<&65E0+J_>?2P M H^&W!1OP%^_GPID^+7PD^+_(>I3>%XHVD?
Q#H.J1W=F4M^_@S^U=X!6:QI*_&J:7X:4VU!<6:JNW&6_MV:&Q!H^_5(I5B?V0/^"O=M:F^%L2/97E?
2E>)FF39GDM-+&TW^4E=)M/3;HV?8 M<-!6I!7X6>)R?*\$M^\$N5M^2M^R=O>2>S045YEI>VS/V7/V9-9TWPS|<_C9
MHF@:OK_+SZ5H2_G MIH/PCXQ&G::M_J7_C6N0WIL!&GD0_-(F8Q^?%*NO!_#&P(RIKS#Z(I^HKR
M3P!^WQ^Q+!5_B5-!&OAC^U?/_ \$/BZVE::Z!_XJM;G4('5@C^2WC*+PGN*=+T6UU?4-
!6X^VF"QN99X8+ADZ^6!EM.H/K&<I!D W_ M*** "BBB@ HHHH **_*X@_!7GI/GP^!>ZYX"O/V3O&5Q-
HFKW.GRW\$6M6@ M65H96C+ \$9)7/XUD?I \$75^SG T_XV_P#IY9_X5^NT_?QJFU.&5S::NO M?L/_M!X^FF 3MS_
)_Y^ZI45^9_I(W_-773L!4W!5:2*W8JS:F51DCY>U?IA7Q/%!O\$W!6.AA<IPSHU)QYHIN+O M&
I5=;6Z::FAB*.)BY4W=I:7,2%IXU?I_P#9^!#7/Q_&_?Q0T?P?X>LV5;G6 MO\$FK0V5LCMIU/E95+L1A5!W;>
!VTL@I^PG?265QI%U^TYX9T!VTZ24 M^*BN^TMH!6&_R2S0+>+&UPB("Q:G_>XKY@V/<***I^OI=I&I-5_::7
M^TI^U/X"!W&H1>981>+O%_KION4VJVZ/SW7>_I.W_P!L?I#IM!ICOH?
M6KKPU^SQ^U1V!&IV_9DO=+!*>,K*_N:=!@:WAAE9U7D?0!S0!Z=17C7B3 M_@HE^P;X/^*+!#O7^V)!I-
!9QW7V9_="XPM(I2\$W:/LT@D+L_N37IWC MOOIX^&A" ^C(Q%156&B:I<^GZEJ^I7*PV!K%D_O)
(Q^HN2.2<@"#7HKBO M@;^TA!_VG/"LOCIGI3XT>&/_BPW)MY=7!*_U#?VRRCK^YL+_NX=QG(KM: M"BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH

[illegible]

AKTKZ&Y VV/V8 ^#57XV LV? !07P: ,!2> #/ #^J62ABVGUZTU1CH@>UN+0^: M;2RJ!-)(\$B%MR) @ "A*/TXU+
(*% L&Z7!%+KJH&;JLWX73> + +53IES MXRL?5A>*=/ MUS0=;L(KI1I9TJH2>VO::5
|VTG7L: ^+C|HLMWJ%NJB>>XW6|3 ,D MH"6BJHKN;=^|GL/P!^!"*WP")?
LX "&PN+;PSX*T&WTG18KNY.TWD0H%# M2.2ONV"S' !+ XH ^?/X8OI;I&H<"8+^%/PN" MO_!|O1
MP77^' DW@ XIZCMT'QIXIT*,>RM7EAL %NBZK> 9"TI DTCT'*=XF56RY22 M;K%6(//1 NZIHGA?1+SQ
XEU>VT 3M.M)+K4+^JG6*&V@C4N|LCL0\$15:8L M2 "37Y2 L2 LES?100^"K6O?1 !=?XUZ!/IWPK!)POZA
LW:5K\$|BEUFU MLT>,>O4D,=L9)+F>W# ,S3* RB%3(=5 P7F 8# X*+ |I3?XU #+X#?ZL
M: \$P #GPIX,T^>USQCXUU'6H3I2|NKR9(+6SB-HC* \$Q: ^)5AX!)> /# B26EN9; MFYR<-YK*HAC/EASG(J=L D?
U'03P74'7-M.DD\$O^/SP9^QU|+Y 5OE/SP)5K2J(T.. PM7@E7NKV3=QB@#1% M A/L^k^\$/PL!-??"
0KVZN;+POH%GI-I?1%2 P|CC|M' @H0FE LN !?JB| ^"?PO?2Y+|Q|XVT*|3JVOW# MN8X-MTCGB>!"%1Y;B1F
DIV" 0X\$P71*7A=X% ,? X-ZA @NO| V3O! Q
MWU'Q;H/C3Q3H4<|E:O+ #9^+=%U6| ^R%ID|F6.Z5QJMERDD096*L0?ZC|=U MW1/" ^B7GB;Q+JMI^G:=;276H7J
L L4-M!&I=Y9'8@ (B|'Q8D \$FORE 8E M9+F X*A?1%6M> X+K &00)H.^%?
A.&/1 P|F12M8,4NLVMFCOCQ!^D@!CMC M!)VFCPM \$L\$4BD.%IHEE8%T(9; .F<2&O*?| @M9X^T7 (-|VRO
MY8/CQ^PEH;^\$ #2B#3=2TWXH>#+=G+;+O=8Z? IX;2IB|V37K17DN+M@9=X1 MBQQ@^(?|D>EZHZ?
^"EWP+16LY?1K|X9V<%C.IS&|L6LW;RE2.#|D| ^A%>A M'R|BG6?V9(NXMO&)/XMHO| A0! ^GA P4L_95_-| X*7^'
J OV>/VIK MGX. "-+5- &L> ,? ' (>A^TZIXD;8XM=*MD2>%X+<1AHY&8"0301J"G!P?T
M^%W@7|M _@WH P""Z_P_9.1' '24?%N@^ ^/%.A1SV5JL GXMT75;WI(6GL
MFD=8H7\$RJV7*21|E8JO! I#_9*8 #+|A|X9A2|3ATT^OA3HH07NHSB*, MUAC3(C/DE=R BKL@3Z=|* "<,
M>C LW:5K\$|BEUFULT>,>O4D,=L9)+F>W# ,S3* P HA4R 'VK^W|^R: ^T' M^V I5C^SIX0_8UIX2?
#FY|Y) _&B#P).L?B+6W+;8M-MYG4K96P4)-+AGE MS'\$ \$N?PN^"7|* |6O_1O P"#D/X; L8 LF_ 'P 2^
J|N(OI@|XAM99 M7 TSPU=RW .+|E C&|L> "XF\$N./+BE4(6V#^DGQCI>K^+O!&H:1X;Z;XBTVMJ|B2RD=?
DN(TG22&QJ2= 64JP17R 4 TS @J P;| M%;H(9|42M;G|48 B7<&>7QA?
6HA7Q;IT\$D"W6C7UJ'8X'CC|A46+Y\$5H7 MA*%2D8! 4!12(V| ^TC(SAA@BEH **** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@ HHHH *^?^?^J/ !,GX) |%6?V5K |MF XNW"(U9O,?C1_P1@_% P""SG_!0_1?VN ^"G7A M'3?A7|_ 19PV'A3X-
Y'B6'5=8U&VCE:9UO+FS+6T'GR.3*4COY.K"N'HG MKJ|Z* |AC @NQ_P2|LO^"J?
I/%A|&/A9J6E>& &G@/4\$U/X=SW49BL05A.,F MGR>6L4\$D>T|E4|AB."H8YM X)*?#| @Y. ^WP3T;|@?XQ?
KX=># =X M7B LW1/C'XE|36FJZAI&E|16ME974HO98D.+?SUBC0!%EWA"E?KS10! ^2/ M <| P#!%;|K# _@IKI?
PO^>O|(O|FZ XB|6E |FK^&I7U2"QFO|>Y;|TN;9 MI-D =^B<.C% 1^"OW2I^B/VP P!@3IH? @KO_P
\$U\$OP# ,9|/^%|AKX|UF MZMM6|Q\$Z5X; W 10! ^V W MC3|@| @K;|3?^")WA |X(D72I&
<&F; 9ZQ::7K'Q>N B%HS>%VT2UU; ^T(+ MJ-(IEM2,N8X8S", \$!&?6"#Z* ' X(| ^+|A5 P;VZY P \$I/V2+;|Q3XLN M-
|TZ|;ZIN(K)=4U&37+6|OKQVE::%&.3.%+;RQ1J@WL!G|Z* /R(8X 8| MX^H |\$UO^"8?Q\$ X)E>&?
V0(B5XE|0Q;NG@?XF^\$/>DVV@6O| MHLX?|\$?O^"W@?|@+ _@G;XW_9|^ .6LV?B3Q+|
M9M.NH/BMJ&CEEM L|D;+86SNH9HX8I9<2.H+232-@ JH 0>B@#1%Q^" <_ M
3G_P"#@# @AS^TKXT^G|+7|/'@WXV "2QG=Q^?ZAXYLM*M6.3,+>^*S3 MK^M=&U*3I"/V?| !KID7Q/^RU^UI
((M'O|KQ|>)),UW2O\$S=E?6<|,H8V_V=A+Y MJ3|K9VY0H5(^<Y3^C=%?YP?|!P?|!O|
@K=<V=|)K|D; @GO|J&@1% MZU"MS|1? \$I>+>2SGU-5D)32HXI6R+?Y0|Q(>@K'IP2"3X.T+ _@FA|'87
MQ&F 17XX M*7T/PUU>;VTG0;8V'Q|L(T317=(KF)4MPK|/L^|?+3&Y?EQ@X
MK^A"B@ "Q|I6FD6.GLR6T|FUME4\$A5X1 2.F "0/I7PY_P0O| V|/VB/@% MX" ^/I2G|9W@ ^& B|>?B|J7B?
Q)H|FHV|V^G:>KLEA9F6WDDC98P|PZA7. MU)U7 ((K|JHH (+ _@YG^&' 63T_Q-X?| VN/V\$ _VCM6|(^"3X7^ KO6/&
M GH<C<.);A.R3W\$MS<0ET_M%)8|;POPD2C>GJ4 E);|I/V8/&'Q ^(?|/MP|I?
_%G2A8>*M<|#;1J'B:Q\$/EBWU";SBDN(|G|V5G&WMC%4/CS^R_X# ;6 MO=&T_P".KZKJ?A32;V&^N/
7G1)I.KW<JS6|M|HC|VZ2*1\$=;=I;LRAI(M|J';?2* /S@_X# (#2%;OVSOA-8 LC?| !?X=Z-!X+UJ%;GXB^)|2|66
MEG|J;K(2FEI02MD6_P H>8D?O05C'Q|)!| ^P3' X.POB,--"OOQ_4OH M?
AKJUM|BVBQ|B181HEBNZ17,2LA7V29I2^6F_R_+C|Q7|"%% 'Y| |' W M |&J_P#^"K7L
'AZ/X*ZMINB_%#X9WDUYX&EU|O*M_V"5(Q<.;?Z@<4^F|X MWP0KPI#A79E)? ;# P"";?I6O !;|K _.?C;|L3IF;X?
#X.;?/=>| MUIQI16IW0BC4.B6VDN+&R33;FX5;-C9Q)Y|I2&.1R(MP /ZR44 ?F_ ,!
MWP%_X^V_MF? "2P_9\$ X)Z_#K1H|/6M0KOEIC' !1#Q)_P % ?@C^V|X7^*O M_!/?
X5^\$OBG|K;0+>UUX5/J&EZ9=-D12W?@?2?5EK6L^)=6(B\$ M_JHV|>UMK|/+W2.)9)9IVSRX@-I?H%10 4444
%%%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%%
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !
M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M6% !1110 4444 %%% !1110 4444
%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
M 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%%
!1110 4444 %%% !1110 4444 %%% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M 4444 %%% !1110 4444 %%% !1110
4444 %%% !1110 4444 %%% ! M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% M%%
!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110 4444 %%% !1110 4444
%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !
M1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4

MGCM:&8XHE'95154>PKI P# ((P#(Z MR2IGU^_ \$9!0^B5?#OP&: M9^W /3/H7XYZ;^S-
M%:E!+OAG!%O%[!^="U;PSX?TO4+SQ-XCMXP^H7- MTVI6MPBV4#/#" (Y)0S2&=055?N*OS% X-8-
*O_ "W")7QW\#>)E:Q#HG| M5OBRU1P3#JW:V^G*Y8^G.5QDIU(I4 A5?N_BS;?1\$EOB%|?K;PCHEA|
M= AS14#1)2%6FB|Y+L2\$XU*Q;4\$C9MYMO+F^TI&Q/S@PEF"ES|;^S_ /M' M_ '3X7-
I6^Q/ P31^+WQ=U+XBZ5>?>P^GA7Q3KNE:2ZA8L422KVRE_L
M^WMX9(WF"3QDQAHISIN9=@7Y) X)3 LD_ #CINK6/^"D/PI^ FFWMQV?/?I5 M6KV5G>:9<>3-#?6=|/<["IM9<\$)-
(IG,K\$,,A=RLI^GZQ^-(GP4N_V6?C-?? M#PKX_O?B1^TY!:=M/ 7/35?=\$A;PVNC:59YGFN3;6J((H+V+O?
W3\$YFF, "M&-IH8Z/7IKXL_ \$XT M_Q_?+X_ ^-(FTIP=1.95N?BGKUO:OR?VEJDUONM/#L
M32*P79%*E|=-2)AT5K.)6_ ?RI/(<^%|*^_ WCGIGWXI:G_ \$R?V(I T+4I=^& MGPAG^ (C P-8?
\$%;BYDU_ 5+RZ18ND7F*% @DSM3Z_ 8_ M_ :+!%_ M| L?^ ?VO? &C7&FZ;XXT;7G|EW4HD>QN\$D>"YMRX
\$GESQ2QI#< M\$#8&< I;JY(ROF(&"6RGJ&F;,\$?=W^BOQC_ A_P"#F3|MSH%|OPE^SPL
M/PA|+RED51\$N/M&LW"=-,O>LHDI"/(2-EY&IA7ZYP)X)G2OY0 MB^9_ I03:2IX&(SO%5=*.Y5|_ KY^U-
^TS_P6E_X*5?M5R3VGC_ |L_ 7)TF8 MD?V|X-D_L>T"" EFPMMLDR^TSR?
7@5|N7%Q<7=P|W=SO+*Y>221BS.O.223 MR23WIE?T-E&OY)D&^KY9AJ=":G",%|^5*
|AWJ>34JU^K0.3;|PHHHKUC, M**** "OT+ XAO| E^EI/ 8DZS_Z?2OSTK|_ P#@V&_ Y2I:3_P|B3K/_ **2 MOSOQ<_ Y-
AG_ &#U?_26=>_ WVGZH^= _#@_ E;|WP|/ (8 MFW=IT023GI1\$HZ8BF3CCTKXVHK&OAL/B8|M6"DO-7| M-H_?
|H|_ @|)^#GB|L;PW^VW^SMJ7A2Z6BGIVIK(%GMS| M2(M?Q:5J>_ "C7X;^)|/OM|_ %^J;#K.GRB6PU?
1=0DM;JV<=&CEB970^X(M-?8WA+ 5|;#<|Z_ '7|2U-K<_ N.HK^:W|@_ _ZO_::9YELO|O|5VCVOQ@|
M+1:8WO|MULM=MX^F5ND7R|C R<31EW/!E7K7L:2L%?A_ !7S|A'_ @HQIT=O| ML_2%^&^Q+Y/F7?
@7Q|V6L6^!EL0.Q?P|C|J#2H.C+|5|;F&1YAEUY5(WC_ M_ #+5?JOE6DGTY1117D%:1110 4444 %%%% 1110 4444
%%%% 1110 4 M444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 111 M10!A_ \$S2|^_ O_#
I6=\$^%7C6P|_ ^)+O3I8=>R_ 4|S.I0:??@I1_ @1^S3HWP@U7X MWW^C/QEI^FRG5?B|XGTMI#JVJS2/-
>MV3J4C-;1RMNDP<<R)7 O&O%O| M@FQ_P3J^_ |I/C3XOZ_XO>:1.;M_ ^7Q1U;Q_K-C8_ #2?1YK_5M096F2&9
MM5NE-N_@:"HT9?_H7U|H|XRG?_ &E%_ M?HJM_VM:QO44W@_ :OP_ X1^+ MR%U7|HYGH_ |V_ SY=NW/_
VT;:X67|@WXI?|KH7XE?|S|B3XV>'O|+?&(MVUWX|/|^O|VIBG>(@31/OCF>_ R4(??I044>3?L3?
ML<_ "W|A|GW3?V?_ (4SWU|;W=SJ.MZ|H|BO?:YJEU*9KJ_NG4_ -+((O/ M50J* JJ))?)@:KVA_ '3OG^TE|6M=M-
6|3ZZW|D>&(|-7^S^_O#<+|H;*> M?GES=7,F|OD;*YH|6\$UZK10|G_ 'O|@WXP#|K_ ,2 ML?LF>/?#>E^*/? MPD?
P^XKTSQ=;W#6BE.8RV6L0M|EFG@W.C6|).FP>9^5+Z|P9^R|X* 8'_ M&O/ 7|H(P^UFEXU+3/
^B^S&J7<0CDOKAY^GN+@H^0GF3RRR; 3M#AT8+^:N^R3=D8 M8C\$4<-3YZCLCH_ :V_ ;5_ 9H_ 8=^&|GQ1_ :5^*
CX?L2&73|_V|R|U*51GRK_ MW7;DS|C.T:5SEBJY(_#'_ @HM_ P^+W|3G|3^V|X;?LDVMMW|* _!1+?W|H|M|_J^IWLMS
M5V.69F+>\$DDGDGU%117I0)"R/"BBBF 4444 %%%% 1110 5^A?_ |L_ RE M2TG_ +G62|T4E2GI7Z%+|L-
_RE2TG_L2=>9_I%)7YWXN?FPSC_L|J_|M|+O_?H3I42_ |P<_ /*8WXX?I|VP-P#379U|:5|E_P#|P?|H?CA_VM;#_--
=G7QI7^>V6_| (NH_X(DC|5|A1117: 4444 %%%% 1110 59T?6 M=7|ZM;:|X?
U6YL;ZSG6:SO;.=H|8)%_ .5='4@JP(!!R""K44;@?J_|+|U/_ M^#J|HW|FYM/^&T; >GWGQ7|&Q%8D|0B55|1:2^TR97(2-
:8K(2>9L+7| MV?LC?ML LP?MT_ #*+X|_ L0?%O3?2\$^ED*M|L;N4N|E89|EZMWQ);OP>^4;@:
MJ64@G^+2N^_ 9M_ :A^A^_R%|4|+XT?LW?%+5??"B.Q.\$OM.GPLT>03#&P;< M|3\$#J^YEL;1_ ;%17Y6_P#|(|X.9_
M@?| M@2;:| "OVS|H7PY^).O2WL_ :XQ: 'X@E/ "/(3|CG8|>5(O1CC9)|N8|C
M|4NO2OSW&8+\$X^M|O.&S_ !^CZFB:84445R#"BBB@ HHHH **** "BBB@ HHHH MH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#^)?Q_ ^WP_|Z|B3_
(J^=A M/^M% M6N=5UC5:E88+:(=V9O4D_ |G5OCS|?O& MD&B>'M(BRK_ #2W4Q|V6|\$?669R_ *@Y). "1_--
P5< X+ _'/_ @H038 M737^AKX::1=E_ #/|B^XR"1D"|O&7B>Y(OQ_ !"\$50^)^8|T+
MTL'3=JE9KY|D%|J;7RBM9;I2|_ '9A2P4=9/9?Y^1H_ ,%?/^#ASXE_M97& MJ?L^ L=;G|A^X9-OMM2UY-
T&J>)4Y#9(|_UM6^E#&C|?WA_ 8Q#|P|* TL MX|X_X=X&R>_ .6Y|15.FMWO* WVGZH^= _#@_)3& M_ '#
+ #MA_Z;L.OC2OLO_ @X/ P^4OQQP_P^P|8?^FNSKXTK_ #VRW_D74?| M|^D?>O<****|O"BBB@ HHHH **** "BBB@
HHHH _57_ @C3_P*4%%%% 1110 4444 %%%% 1110 4444 %%%% 111 M10 4444 %%%% 1110 4444 %%%%
1110 4444 %%%% 1110 4444 %%%% M 1110 5YW^U1^U^U^OV/_ @CK/Q_ ^?BR/2M
T>+G&G09R#Y=K;QY|EFD(P MJCW)^JK_ SXT_ &X29_L|2^O7/C5|8_ %MMH?AKPY8=ZMJ=VWRQ1C@ 7BVA)P
M;J<*=K74H_ +\$9^""2*W_ ^R^#GA^F/B?G7OWIX^DU|6HNO7V<+Z_ \$J^FDC|&>_ "M|>X+6^E0\$XWMT\$MPX
DI&3|U0J^JCYGHHK \$|R;|LKX>RNEEV74E2HTE;_ M8|)?JV|6W=MMMMMGQ=2|K-SF|MA1117ID|1110 4444
%%%% 117TQ^Q1_P M2);_ O_ :U>#5?@G|)|3PU*^|;)>)V_A|2C_ "R2NLXP>H@25AW_K|A^VO|
M@U1_97^&D=IXD_ :Z^|6K_ \$254>:0D)=|+TA6ZE&* _HF /|A)\$_ Y2OROC3 MQH|V>|92f8_ %J=>/_ +|E^|J7L_
)L^Y3E\$|L-EV+Q6L8V7=Z+^O0_ !#PKX0| M6>_|=@|+|^"/^HZSJ=TVVUT|2K^2XGF/HL<8+?_H^_OO@#_ P;_?
|%3_C_ #J M5M^SC_X0T2?_ (P|?A^I93|ZVH6>YD@V_ 4Q^Z5|?#O_ @U_ X)V>%HDE|<^/OB9XHN_#S%N-
VST>58^GM^_ KJ? \$ M_AZ?_ (W2^GM^WAF_ |C^E;G6XU3QGK\$A;IU078C|?W;|A_9Z_X)C_L&_ LI M?;\$^XJ?
L|LUZX8|0PVZ<7)H|K6.F&%PT^>_ \$ODCYF^_ _1Q_P""9_I3 M7Q_U;XR?A
9.T/7_ %&NW""3:OK4U_ >PS73I&L2EO)G0<(BK@#^RBO(?&G_ !MLS_P1M|7(OLV8K_
\$*5QS/HOCG5E(|PDUS(@_ |YK|WHKP;>8YA224^TDE_> M?^9M9^Y_ _%#_ (-?^">WB>W>7X8?&GXH^%KLYV"?
4+4+9?K&|LDA_|^ XU M|N_ &G_ @S;_ :\$T.WGN_V?VQO"/B5ERT-GXL|W.D_1_ =|R|H|NP)"@HO;^
M@2BNZCQ%G%%Z5;^J3_ 2_XBY8G|D|40W_ 01_P""L|^D=Q|BW|D+7M=TVW_M|;^U/
|D6M1L@ZOY=HSS(HZ_ /&N|STKY%U72M4T/4|H^UO3;BSN|:

!11ZKX!^&!(>XU3PXZ>=K7AZ..PV/H^TH2NOO7DUT,VF@HHHK\$%%!!1110 M 5! ?!\$&?^"QWB' OF '82#
[XH:I=7?P\A:W]:>\$.I/I%N3A\$U6!!DY4 M:5F1>9(E'# '&^*.*Y15A...H2HU5>+ J JAIM_N5T'7M\$14Z'9>)_#.KV
MVH:J-I=:??V4ZRPW,\$BATEC=20Z,I#1!@<\$5\$;K1*?^#60_@L#)! (KG5!>U_4IK_6-30'W2W5
MQ?Z>21CZEB3@<#H,'OKO_@NC_P %&!) ^@/7!95^W@O7&G^?@-I='1Q1R9B MN@'VG4.YGD4%3Q^ZCA! (-?
%E?Y>^'AG'@'A&.)Q<+8W%)3J76L(IPI^7 M^G>7HM.ZBCXO<.:I:Q'+% ^!_, ****>3RPHHHH ****
"MGX> #SOS!6? M&^E_#7X9^\$!_ %W7!O\$M=*TC3+9I9!J9C@ (BKR3W! 2<\$U).OAEX_P#C M-!0-(^%?
PL)WNN^(M>ODLI(TG3XM\US,YP%[#J2OP%))! ?TJ!_!&W_M((R_#?_)N?#^+X@/^/8+7_B_KEB%UW7U7?
%I\$;_%K&R)!"#H!O#2D=E"J M/RGO6!5!E!+GIK6M4Q5!V5)/63_FE_+!/=!M21UO;NP.!J8VI9:16!_KJ> M=_+!&_
((#?#KIBJSTOIH?HJ33!#Q1!66!BPL6VSZ?X58C(6!JLITAI^
M50!1=/.?I*J**_S(XMXOX@XWSF>9YO6=2I+;I&,>D81VC%=EZMMMM_4./2P MU_0JR"BBBOF38**** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH MH *_)+_@MS_P;?>#AVJ8M6_:D_84T'3_
!2!JKW60>#H@EMIWBA^22D71+6 M!_!JQ*W+!&+2!_!Z%CL3E!:=5;+L_P?DQ>G\7C+P9XN^'7BS4?>CWP-MS?
Z-K>CWDEJNDZG:O!<6D!_%7BDC\$?*,3!_A!0/M'C:X5>_
!6^&OO!+WNB: H5_+9:OI&HP&*>TN(V*O&ZGD\$&&OU/*?\$.N^\$?%\$CXX!+:QF7 MD5WIVH6.=>N!
M>+XA^\$S%I/Q%TV(!?I+!9CO40?=BN44N,*ZROC/EY/AD75_P#P!I_X*:_M_P\$T?
VUH!^+UU>W#^"M:9=^ (FF1983Z7*XS_!#T!#8F3)V.FO)&KPL_R MM9E@WRKWXXZQ_52A!%1=F?
UXT55T+7=&4:)9^)?#FJVHVHVD=U87MI*)(MKB&10Z2(PX964@.@C@@@U:K!HV_@HHHH **** "BBB@ HHHH
**** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_/_3_@XW
M_P""@!_9\$ _8MF^#/37/L_C?XL+!%D8),2V6E!0+ZYXY4LCK IX.9RRG,9K M!9IHK!)KBXE5(T4L!NV
H"))OY3/^"Q7!<\$W!>_! =BWXM;J:3^<=)E M+L+P0NI*2V9;RK.HI>=(TMOZCSL?PBOWOZ_,>_
>/(8C\$POAL':K_ ^TI7_ M'<'Z7R,T!'&\$EU+!S;_%25! *U'XL+!6?+E% %?Z(7'64^?#%?7 M_
! =K;2\$+V=2H!L%ZVNWKRQ3=G:QTX3"U_765./S!D?4?_!?"_@C?HW! GPT MB^//QOT2"Y^,'BG3Q!H655<>&+_
P&^PQ'D>_8K;XR^&I.W7=C;1A!XOLHEXMGQ_RHHHQ#(?O@"" MN/+;!/!_*ZL'C^*^Q"K4G9K!5V?D)!_!_ =Y9W>GW_
MU."K!@.@.@@!@CK!N!_@Z\$ _X(V6?A"ZO_+!IC^S5X8\$=A?7;_+!9T&Q@PM MO<2,%76(U7HLC4G
_C99>=!K#!1Z_7.NOI'_L'JU/YKL^J.6K,****[A!11 M10 4444 ?T=_!&IO_!1EOV@_V7!_ /8B^).O&:Q9!85E!_<
<2YDO/#LC!44 M9Y/V65O)/98Y;91T-?K+7!_W_!+_!M3O)_P3!_!5!#?M/Z&T!EEHVJ"#Q+H
M!YODG_ =7<=&A8Q;C)G@2)W!>V>?%?A!QOX7TWQKX2U>_4_*UBPAO=_O MI9IT=S;RH)(Y5/=61E8'T?F'\$^7?
4!2!6"!IVIK!^O!_G!S6#NB_1117S184 M444_!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!11
M10 4444 %%%!!1110!1?_!P)^V= PR#_P3L!2V7A!5?L_BGXC\$^%O#_EO MB2-
+A&^V3C'(V6PE4./NR2Q>HK^82OTH_P"#H#!K;_A>G!>=M!_!U/SM#^\$ MVC+8.B/E&U6Z"3W;CW"?982.S0.*_
>OI/OHZ!+A3PWH5JD;5L7^ ^GWM)?N MUZ*%I6Z.4CXO-!H?&+;_G^?XA!117L>6%%%%
!113!6UN;VYCLK*W>.:9 MPD442?F=BL!"7A7!L:3M+ MTNSBM_T^SA\$<M!&@2.)%"H@*_.*^5_ ^"+_ /P3WL?
^">7!%NC>!M>T MR_/_B@)K?CVYVC>M!(@V6F?IEO'B+&<Q*XYAKZUK_"Z!>!/J?B#QA.&&
MG?X9N%)>3.OHJ_+?T_N'6Y!ME>#6\$PIY?%+5_Y? (****_ \$#T@HHHH *_M**** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HH MHH SO&A'PQ!0">I^!/_&V/VNJZ-K.GS6.K:9?0B2&M!4*21.IX965BI!Z@
MU)_/ P %H!_@F2KO_!3!LC4OA7IR7-SX%!OHVK_#S5KC+&73V<@VTC!&FM MW_ =W8>7(0!*!7!=-?
&_!_@."00N<^77OC!R^6_WJY479G!55%%?DOL%%!!1110 4444 %%%!!11 M10 4444 %%%!!1110 4444 %%%!!1110 4444
%%!!1110 4444 %%%!!1110 5S?QC^*/A MCX'_D!3_&:OK<>5!A/P_>:OJ!;@ \$06T+S.!GN50@>I(KI^*/?^"/A?I
M:A B'_P3=8?2"K!E_X6ZQXLU_Q3>66GWIEH48DN8_.\$PGN)%3!0_L(A*H&_M8B?@<\$CW>%!KP^=128/
5ZBITZM2\$92DU%1BY)2DVI)65V95YNG1E_*!29_ M7!7?B=XG^?>
Q6!2_&+OK<^=K'BK7K05!4DR2N+B9YGOGMNRYN9W"BBBN@0444 %?H9_P>?L*1_M7?MR0_&'QIH@
MN?""PDCBUH!T>8KC568C3X#ZX=#N/3_ \$8!_7YYU_45_P04_8WC_8!_P"" M<_A&TUK3!X!>(!%?
B4NF)>ZC0VT#9Y7R!58%*GI(9#QDU_!C?%22&XWEP:X>_M5>:_E;_8M^QA:=*22M!+TA=)K:4HL!/*<_
!8Q;_VCJ_ T/LZBBBO!P#!4**** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M****
"BBB@ HHHH _F" X.2_X'0?Z25 PE?FY7!8G_!P5^Q_!VW?^":WC#20#VD?:%?G@)? M^\$L!*>6F9!);2-
S<6ZXY8RVK3H\$'63RCSM?R=U^J!_X!XW+DIWH>Z_T?W? MBF8S5F% %>^2%%%%
!5G!H8U3PHHK^AW!MK>V-REQ9W4#!7AE1@R.F0A M@#"#ZBJU%&X!H!/"OI2NF?MA_L_=#?_!_TOXL^,?"5I?
7!4/W8+W9LNI_U MSN\$EC_X!7J!DO!_!&AO!2K_!_) 88!8?LW:K?>9>?#/OD9K&(M_JM-U)6FC
M4#_KYAOF_P"!BOUHK!9S/"_4!24H!\$!3=?@:IW0445PC"BBB@ HHHH **** M* "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ KY9_M;C_0^<_!/_Q4T7PE!HDZG!C=ZG:ZE:&5;25ECY1E92!&QP&&0_>*^H
M_+S!NSQ:_C#JGO9="=%8WB6\$*YX001K&P_!H5!2:_0/#C)L+G&?2CB8*=M.\$&VGJFW:_M>A^&_2
XMS+A/@JG/+JTJ5>K5A%2B!_)4Y;JO=47W3L!#V M:3_@HO! KXS>'F!%?
M2_LS6&M:7(H\$UO+9VVJVLK'@DV!TJA1_P)C7DOO&_MX)_!\$'_L'S:CP5!:_! =N&_!POK4FD-
O:HJ6MZKVY/2*GIGI7BU%?N M&#X;J9)4HD6-KX.6H527(-!4&V!+R>A_>322.XZP24.QA2OZ=IEFUCPI"NL6P0?
!M&:S.AB7_M_KH\$(!@5^GO@/XP_%7X82K)!OB!J^D*)/."ROW2%VI7CSL?Z,#7M_P!_X* MB?M_ ^%S%;>_
=/TCQ+!JO.LEQ?9;EAZ!X<(!J8S7W&7>)OC#D-E5J4.PIK^>
M!JCI"!T/G)_5LF^D'P!F5HYCAJN%D^L;58+U:M/H^W%W:75A=265!;20 MS0N4EAE0JR_#@.@@!@!@HCK^F_P
!_ _O?M2MB6JZ=^V!^REH5=S:Q;7U+6 M!#T&H&W'3\$=W&HN4_Z*OUKPOXB2&I'_D?JH_7U!E!XX:QX)U*>_R0:9I
M6O+!5O\$#W>TO%.)+?V3F%*M!1YN6!_X!^TOP/OZ_X)F_LO^!LGINWX:?!L^7=BUOIFL>)_ M!O\$*
%;BRTZ:UN86EGCDG MEEA?>D9V0HBE)7)\$D@.._P"E?R_!OO\$ROCWBO#ORFM!7"4*249)-)SF^:_
MM)K10BTU>!6?HN482>%H/VBM)O!%L%%?SV>L%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!1110
4444 %%%!!1110 4444 %%%!!1110 4444) M)&D!_<
%*@96!#*PR"/OU_)_P57_9_D_8C_X*_%#JG:UT!V^DZ5XDDNO#2! ME.E70%U9@_HVV&5(R1_%&PXQBO!*_
7_@! =_9O_+#+_WPF_:PTK3!1> (= MN_#.LS1K@/+9R_+*=',G2>TU^*U7X7(FM#!6: ** M*_2S(**** "BBB@#!2?
^#2CX^R_#3_@!J?P80+W:9M?>CP)>VL_N6P'OK(K> MQ-IE8(IP8_VS7!J?QP?I\$!C+!)_!A @!+!\$?BHL-
O-VQ^TRWU&8-C99W_M4RVMR?!)OO!)G!P?F_!#V>8!J+!4!Q6GY6-8;!1117R984444 %%%!!11 M10 4444
%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444) (Z1 M(TDC!54\$!3T_K! =?7B23QCXWUGO=,27U75;B!>
=US+*SG_T*OUH^..N?(S_M)!%/B/?M^P>_!VX!H"D#M_2OR"KJN!_!N3%UW_ '(K_P F;_0_CKZ5F!/J
MY5@D!\$JLVO7DC"U!117!4?R %%%!!1110!^F/_!/*S!3)^S%I6L^*M>OI M^;5+RYN(#2W:S-
#"!E(UWD!40%N"CCYR>YKV^N0_9_!_#P9!#O"/AX%=F7UOJ^_!5.TE^>HFKH_M_CHHHKKH, HHHH ****),"_O-
+OH=3TZY>&XMIEE@FOX9'4@JPIPO#7JNW MP9^(-!6O@_X4^*MAM!CQ_X:L=6AV=-ES:L,>V!%?Q"5_8/_P
\$90A^<_M_2!^7B-!2YA^&>FZ:S\$Y)_E%JC.??,%?%?%9TIT*53LVOO7_+HGT51117 MY^A!1110 4444 %%%!!1110
4444 %%%!!1110 4444 %%%!!1110 444 M44 %%%!!1110!Y!^V?G3?V7O&JP&QNT*2+_!FY"?S5^55?H^W!\$CX
^)/B'P(69CHFN7=@6 M;J?F>/G_OFL.O7/^"@&@Q^%OV!C:X8B_Z=17/\$EJH7IB/5+!E!_!O(Z_<* M4N>E&7=
(YPHHHK0 HHHH *_JR_X-J/\$!^)/^",WPEBF?)=ILVNV3G/9=:OF0 M?@CH/PK^4VOZ@+_!@U9U&2!_X)&:!.V1:>-=@-
P)/YN:^5XOC?>XOM) M?DRX;GZ.T445^:FH4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!11 M110 4444
%%!!1110 4444 >+_! /OHX_8_P#%_O!_8A_TX6U?F?7ZA?M MYVGVWIDKOE#C.VUMIA
OB!A:_V6ORIK^AO"22_U=K+_*_>O_P!(@?P?I*.\$ MEQYA9='AH+!JM;_****_4C^:PHHHH_*!#IGL@?'WP.2<>_,-R?

#WJ/NKH M/A/?#2 BGX-U-FVBV1064L:TVSH?Z5RXZ+G@JL5UC+|F>GDM2-,-4>RJ0? MW21^P%%%?QB?
ZXA1110 4444 %%% !1110 4444 %%% !1110 4444 %M% !1110 4444 %%% !1110 4444 %%% !1110 4444
?QE | 12QMW /1 MOX_MZ_&SQ6? "KW5>)UZ3^V5XE_X3/HK_XK>,/,W_VM2==O^-?O>,J\$FY
M!>KS:QVI#IQP|\$^R (YI% %%%; %%% % !7I/ JI\$! ? 27TIW/\$GO UIE^ MFZ(?S/K^8>OZDO| @UPT4Z7_
.\$?/!=5Q_-7B;7KD^UQI\$/L/_M^OE^+G_*E M B7YN&Y^AU%%%?F9J?G_P#1%VO^-^AWP)_9=|_#HECXM?
M4~^O@Y#!7-9E M^B^XC> TN3K/AW1+/-DEM/MHI9(9KBY^S6RR;#B)HOEHPPW7_!)|_9:_\$ MGPI|
WGf2GP3_P""H/QO_:2|_+1+GMM(O) XE_%I_\$G6*I(6D-O"%1(K@L M%"1HZ^8FPIA,N#|;>*O^7A3QWX?NO^7C?
PSI^LZ521&*<TS5*;XMIB,I4>.0 M%74^AI%?G |\$Y V1=" 84 X*| M# OIEZY?3QO@OX4^/ASQC?>\$IR=/A M-
>);NIO;?I:H21#YMO:/8UQA'A7 1(@ "' @K-K OP^&_ 4< 8MN?'"I M2OCBR|+-OC0VF^(?-IJ\$-MI-PD50%
(A=8(4FN/FWL5N)94RP*JF:7Z+5^= MO_-!:#_D_3|@'_LX.X |2-*_1*@#X@_X+!?M:\$?OX?! Q"_9|_8)^!OC6_|
M#^BCJHWXE+HJ|^*=^EV7^C^&I,PRZK+;/SY-TZK%8;JB%M^U2T>JFE MDBFEDE>"
<*X25=KLK2*&KE/^"OWA34/I_P#P6&_X| M(ZK"W_"P2\$#7?" MI=N,1V^HZC;D8QDI-TK";_ DFE_P""
f7A:5OB_^W3_,\$ _@9X2B>?5(CI MH@>*9(81EXI,T:D)=WDW^0+\$2<^U'BGf2^Q^^WC^9C_W_?CU?XL^)#
MGQ_9_|C| AIX2-9(^JWM=IT29=;%NB6:R""2_-%Q,9Q(C^X6<*V0D87I
M(CA^TUOI|^"G@C0OAIX=MD^+WO8LH+7P;H-I&SPZ9=/) >;A=ID-IDLC(V
M:67D%V6!*6SEQ+:0 8V 8(=O%OI37I1?@.SMM-L/Q;X_FNM=OK?2-4,2
M5|RVNI2L(IEM;IX%C7:9XI&/E1#YO+C"-_GI8WI2/OB_8H_8(^_G_!8SOQ| M#)|\4-4T"OTWX=>\$M>A)3P=HMWJ-
O:Z?9SH",3M+M:W=F>JU.ZD=L:B(N)#|Z6:9Y)6P_H M9R%"J HZROB_XA |IG|O/P_P""IVF_|\$ZOC^8K(XD:1XM^J^
M:13:SI M%A:WVGZO:Z@;|MP+"WMXFMD^SC^OO&ZL@8HP";_% !1110 4444 %%% ! M1110 4444 %%% !1110
4444 >= M_:2VM?LS>.+1DIX:N9|#_*9(9? MV2ORCKIA_B-H:>)OAKWAM(IYU#1KJV"?WC)\$RX_6OQXKIX|(*W-
E^*HHI? MWIK_-M/XG^E5A^#/MQ7|I.)2CIS:A M7#)^ I^?:L1HET/2+G4+G)Q^|AB:IN?HIK7KYF_X+!+_ICA^!_
2RM^..OO!EG\$4C?>VITFDW8*7H@?*"PIQ)=(1BML/2=>O"FOM+|W8#^0^6M7
MOQ&L7>O:I+YES+W:EQ<28^I(I%FYDU6HHK|NV.<**** "BBB@ K^M'_@WG M|
(GP7_P1P^".E"/4.YT:4.JLCEOM6JWEP# WS*/PO7IEU?V; P#|-KX>2?"C
M_@GO|\$AW<6_E7&E?"G0^V,C&+C^SX6F_|(A<-C7Q_&52V"IPIRO| 4N5G: M1,%@@%"L0>R_X_9("MI?LK>)/V2?
B_XS|46VB>*M-MH/5M;|.E^8ZH?*F MBF\$B2I\$8U9GA7>OE^6RLZE-K;|4HH_I|^*|&/P^*_I,VF_LH_\$_2-1U?P
MWHIAIT&DWUSJTHU2RN+|_9+^*|4B5+R_XDD\$X.XL#G(9@:/PC_8G|_?#CXR MO^T2XV|?^*_B_|0ET#^PM.|8>,
|BS>XT03^XD>UM(G^VMK;W61PK22")92J_M^9(X50/9**_.!_/P_T^X_7GA2R|<|=GP|X|2PZY?>&HE7|_
KES;9>S2Z)_M!+OP7^EW0C&TMO^6RJ^6D;_9P^\$OI7GP#|5?LT_'7PZ=5|)^.=*>PUBS6
M4QOL#))&XY22.14D1OX713VKNJ*/_/@!P^X4^~WIO-W^U9X_@+?BCXC?5 M23P);>"-I-
|2^*DLXFTI0H@/EFBBM((4.DTYZ:9@6D<+MM \$KWRBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH ****
"OR"^./AG_A#/BSXG|)" M:NfZ_>6R#|^*3.JGZ8_?KI7YG_|%\$?I_G_("(M3ZW<1Q:(=9MI?48ICKOC".M?
QDCD/XU^L^\$>+5;.*^&?VX7^<7_)29+_TLJ>(X5P6/BK^RJN+|E4BI?O MA%?'A|%%%?OY_#84444 %%%%'Z!?)
!_WQPNN?|5/!,T^Z:0=<9D3/W8)_MT#K^'|_#XCIX2_+F&7EQLM_\$VER0Ij3@&XB_>QD_|JcW85_M^A|?
R_XB9<|OXJK+W:EIKY|_P#DR9_I^X^Y|//#3?^I_O/#IU&7_;CO^RF MX|1117PY^R|1110 4444 %%% !1110 4444
%% %% !1110 4444 %%% !1 M110 4444 %%% !1110 4444 %%% !7Y2?|=GO^MOAJ_P3Y|_? FTO=FM? M\$3OY
9(-V/L+)-KB8^~+A|_OKZ5^K=?S4_Y|/I3<^Q?|^"BFE? C1-3\$ MVG "OP?":742ME8|303|KG(|?Z^V2D=C&O>F!
IO#>+^LYM^M^WG|MOQL3-VB MEK1117ZN8A1110 4444 +=|&AQJ7QC^|/AXI;+&XXJ|2VS&CV@09/F7_P
MD^*XHN^* MTITS3_1M-MH(FRW6&VM(\$AMXDZ(BJ)51I_"OY-/^-#27X^O)= ^M"N?P>T>6FRS;ZU-XEOI-N\$-
/MY+J^Cl_B:|?JXK^M^OSIC^MS8FE2DOI MW_P#6GL%% %%?&A1110 4444 %%% !1110 4444 %%% !1110
4444 %%% M% !1110 4444 %%% !1110 5|6_|%O:B;PE|3K>+*E9M+NWQT(>PC|9_MRK|2KO|HO+X>+|?_
V8/\$5M;6_F76DOJEK@9C|W2\$>_E&4?C7U|^>8_Y9Q/MAJS=DY|^%|_ "/S?Q?&B/Q=M^KXS1_K=XO_
S_9+7_EI*\$5BPQZD)"X/H^05^3^*^3/0%973S"FM:3M+_|#| MKI6^IGI?2IDLCEO\$=(ZIK0Q>:'_7REFF|+%_ P#X D?
45%%%?S^?W,%% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 444 M4 %%% !1110
4444 8^Q5^>A^X_#^Q^7O^I+9Z^X6T_Z;6+MB,16UO M\$TLK^<BH-_BS_:0^.'BOHCX_P#C3IH30Q(3JOC3Q-
>ZO>IO+^")KB9!\$|_N M(\$%^*RI/VK^<_P;X_Q_VX|I#^V+=(-9A(ZOY7B#XMZE_P35(9;/#H=FZ2S
M9QOROFSEFWC^9T6=><&OYNZ_L\$,\$Z6%EB9+6;LOI?YO)(RFL|1117V| 444 M4 %%% !2?
|&_ /)UKXV_%SJ;4K+JWX>|V?AK2I77(6IF-S.5_VD2SA M|/7\$ N:_?RO@+_@VA_9C;IG+_@E^X-UO5--
^SZO|2+^Z|7:B&3YC%<%8K0YZ_ME6M(+>0=AVALQ^0WQH^EU)_BOX@^
M^5Ts_P")3JDL+/U>'.8G_X%&5;|YBOKG_@JO|(D)7Z|+|=M<0ZM#_9^MJ,J|XB|)B25HAK|(^IJ_KKAG-
HYWD=#%WUE&TO|2TE^*?RA|+Q#X8GP_M?QGC,K:M"\$VX>=.700 |E:3|TT%%%>Z?%A1110
5Z|^S%|KKX|^&2?B"I M=K)#;Z0"G66TDP|CN5X<#^|BUY_17/B|+0QV%GAZRO"...FK'?E>98S|I
MRHX_"2Y:M^49Q?9Q=ULNZK0_9K3M0L=7T^#5=,NTGMKJ?9;>)>)LK(C%6|I M@<@U_7RI_P
\$R_VC518^#9@|3XHO_=&L^F^%>E1>|^2.TE.M^CVHSJ;"BBBO(j0HHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBBB@ HHHH **** "BBB@ HHHH *KZQI^E>^DNM>UW48;RL;9IB|N|FO)! M\$BEG=V|"J^I))X
%6*)_7_@ZB_X*_|#_W|/%O^PG|)_\$/E>_?B28M)XJEM MI<2:=X>W%'C_/NM=NK1=|QIS@<@/E=F P=3^XN"&
|_|=6)NRN?C%_P5V_/_S MU7_@HO|MV>/_V@HJN<^&X|C^R/MI-D?9M&MF98#M/*_*2|PZ|GG<= *_9J M**_8Z-
&GAZ;4%915EIC|ZA1116H|1110 5Z|^RI^SIXH_|L_4|?2LW^#5<
M:AXT|3V>DQ3^FI|DLJK)_P_NQQIY&I^0UY_7Z_?|&B7I&\$GO+_:F6_MI^)_MI+W:5|_D_E>'99\$X?
5IY&61T/A|K|G;_/_A X*- M R3X7?&V3QOI-ELT?Q:OO(F1?ECNQ CST^I8B3_MH0.E?L?A/GH8BIE55Z3I
M^~^)+WEUK_VZ^Y_)WTG>#^BLA^)_G ADW%_XXICIHHH MKH|XL"BBB@ HHHH VOAUO/\$WPL;Z^0/I
IY&H:7VIM2^7M+A<>9^WN#T|2K="*(VO9 M/V_?VHIO_9O^(@<KSR^&-7=8M;M5RWE=EN4|Y|_@?>7(ZI2/S_
(_X3_UA MR_V^?I^DM/IT>L?7K^STZW/W3P_|3OI<|>"OT_IBQ#

X(2?#H3 @FI^PIX=^\$NN6\$~M> XGOQ|NH\$G4IT7 1@P MZLQK' :3&C&U|:445^8B04O-
>56H|N3NS=:1116(1110 4444 %% M%% !110 4444 %%% !110 4444 %%% !110 4454UW7M#|+:+=^)?\$V
MLVFG:=86SW% J% <+ #1:0HI9Y)<_ O|L#|DH^ZU M&Q 9M :!>Y|(-Y'D'@SQ?9:FIH'(?
C516/#GA*OO+H6ME=>)-.@LDN9R'1#&9F7S)" 2\$7+^2@#J:*Y X9 % MCX7?&CPLGGGX/_\$?
00%6BR3/'FK>='6A0:8RHZ:B3S0RIAF7: ME50 !|K3^+7QP^#P\$V|1>+?C?
!5_#OA#3+BZ%M;W_B368;*_#5AXS|\$>=UG1I4M\$NM;U;2K0+BV0
H(4,DL4L9^2(P(9200<@U%9>./FI>=0^FG^*M/GU|2K&VO=4T>+&|1KFT MM|AI5@EEC|WH(T\$P1F #&)|9VG
JT444 8 P 0/ GAKXF^#-1|!>+1 7.G M:L-#)1Y= %N6'G=VMG|UA#!
M/W6P>FI/Z|P|Q7 J F/L1+|Q5>OIV727ITEY:|#|_*120RL# MR''''''/H: I=-25UL?YWRC*\$G&2LT% %%%.04444
% % % % 'T+^R#^W9XG^TT M/@?QX;C5_ "3-A(PVZ?3L9..ZD'(-|?'|CKPA|2?#5MXP|#: ;Z MGIMVN8;JV?
(/J|56'0J0"#P0*_6NZ^!/?|1?Q1_9Y|0_P|M_# 6RL\$S W^E M7.7M;L#LZ9&#Z;I#L<\$@_F?%_AYA<|/&
M9<'QAEF<|U?|K2+WJ4EY7^*~ E;NE|+LN5_K-17C|/-L;GPE:~MX^~VKH M?B1E DT_F&96_Z82'E MP_IRN:~JFK
S#+L=E6)>'Q=-PFNC_#71KS6A M P% % % % !110 4444 % M% % % !110 4444 % % % % !117PU_P5\$ _X+W_L=?!-!
JSO? JZJGC_P'Z)Z1D6 M_@/PI>K_ %%)C@ZA<_MFO3Y_001'M.X;X;"XC%U53HQNMI/E6W=;
M8\$|002%CM2/Y1_X*\$?|13K|K|X*6_ \$M?G|IOCC=IUE(Y|>\$_)#0Z5HZ M-U\$)|8|G(X:~0M(W
+0JCY|K|S;R;ANE@6JV(|ZIT712YOS^|N9RE?8****^ MIC(BBB@ HHHH ***L:5I6|:
|JEMH>B:~|>7MY<)|9VEK'TDL|KL%1\$502S.Q M R20!1L;ZG^PU^QK|6?V^/VG?#'/L/P#|J+Q%H_*L4P;B|FOT
MCC3)OD%F*HN6=0?|/V5?V9?A7^QS^SYX5_9K^"^C"R|/>%+2TM P'F7#|M M+5VQRSG@#BOD/_((#?
|\$B|'_@FG^S>?&OO2TF|_B|X^M8KCO; M_=KG1|7|L_E1N|/A_^4KPIQ&66*_U|~U^7|1Y0| VAB?94W^|A^+|_HO^";Q
MC9|1117S984444 % % % % !110 4444 % % % % !110 4444 % % % % !110 44 M44 % % % % !7F2|4|/*_PY_!|+Z+|
/C3|_?@RS|01:IXA|)3(3>:(Q#~)Y% MI>#-->|3ZU|X|TOP|)46FV.H^+~.TCDO9KJVMU6(15D\$(D*@_MN|S|I+D>W?_
~"CWI>N?|!-| (*|?#G_ (*?M+~|I3UC|GS60A)_X? MQ=|HBUVOPIUR?4S110=8RHW>4(W|7|GK_@H+_P \$W|*^
M(G| M0?2%O|NGX2>+|C_X|A|I#TWPOX(|_VFLSZ/8_/L7A02H8'6X9KB4~M_J W_
P^|A(HX8X;QQ>R_4 X+4V'I% |6/A^SU+X36/P N\$?@3P3KUNLFE M>+~EO|I+?
7.L;CR|R:TM#M2!@QA\$|SA02KJ=% P \$V_#B#XL M:'G_@ MHGX*C;2OA)|9(O#L/PZL"0C>(O|UK)#/XC> ?Z@7!|=
(HM^V:2&W1Y%7IV^Z_ M_@M/^UAXO_8B_P""7'QD_3^E|UIXAT;PREGH%|GWI.^O|H#3X+A?5HI+I9
M1GC;8S07\$| P2>_9H22|\$^O^"E_Q^_81^_C/4|_9|L_ "6C^_!T:4+Q|H M?
^MZA<3^*CORL2|YD;3W&OCN|K|S99FDD|" X*76|PL_X+#+|!(CX|"? M|BOXFZ/X_NUAEL;0^KH3|I4?M*_
MLNZ|!O^#9RTTSP?OTK03|OA#|/Q\$TCQ|_MOK7Q3:10ZM|JB3?>%Q+?|I#W|>'Q|U\$ST?P%XU_9AU>73|IU"98-
TS MQE=6M0<7TF;1#)|:I*L>X^ND\$H7.U-?|P@/V_15_X-G+7Q%X%+E MXA^|GP|T;P+H^ANS7?
>WOB_12#2YM+BB'S<13_%;#(C%O(2_*^SOV* V9 MM_9|_8_^%O|+?Q&M_U#A "A|W|L DZZ+N-
):2ZMK6;7\$F'4IYRNP)Z#% M^O|_.\$?OC+X@_9: P""4^J_ \$C7??"6HZEIWB/XR^)|5_9H+1CR;C7;#4-4D;
MD65|KCIW%/*TTPD(V1V|<'2\$J^V?V3O@|JOP*| WE|I0=?@UWX^_~3;7/ MB/XF@C*H_JR(B%
(0WS):6|216M0&>4@MXPQ+EV;S_190M9?VNOC"G|<7B&MV;_A"M%@N_ ^NF2)A);*0>7=^|60_+|+2|
|JU/5+%=ZD2;14YB>%|BU|7 M+|A X)Z?#K_@HG_?WB_M*Z|~VT-&UR^_K VA=K+KMUITGA9^=QL|9|JIV7^K
M38LBJK@_0|^YE% % % !110|D?|10W|CB3Q=;W/O|^&F%M4MH=WB+38\$YN MXE'_!|
(UD4#YA_ \$HR;5^X6K|H*^\$ _V^?V)?!MU>?'#X2:5NT>9S-KNDV M|2|
QX;3EIXU^+&GEE'W#R/E^Y^V^7&RM*^Q_ GC MYX/2C1X0=2|;Z|?| MF8Y\$S'I("3TW/**<~*|S-
GRS:L|/^TE/2^Z|NGZ_@AX;XKXBX1QWUO* M1^E/K9^D)=I1=XR7E); 50X;?M5_ X|PI%X&9PC4&7+Z-J&
(+M/4|&S/X| ME"PIZ|K|889L>59X)61T8;CHV"|"((Z&O:_A' P % ?VC/A5Y5C<^)QXC MTZ/ ^O>(-9F" P"S.")|QTRQ
|*_ (C^4EH_FEZG|5|(? M2@PM2;~\$F%<);>TLQ|94V|KS<92|HH_3.BOE_X92|14WX,>)1:~? \$GPIJ M7AJX-
|PB_+>~Y)|J+|/UKWCP|;A%|3T4^/B/H^J.PS|GM;Y#;OUC) M#K^C%?F69<_YYE#?UO#RBEUM>A
X\$KQ_ \$ HKA_C|@WBB>68ZG4^SS=O^H22O5R_~F P"#OG|CKX= :~\$ 94^" M2BGXD7R96'5M7<~|IC>C|9%DN7
ZE6ACSTW#J_ "Y7F&|FFVN^R^|Z"/2| MUVKY8_~N P""R |P3_.">=MC|L| @X<X*<MD_!|NOCOWP^~L.W.Y?|
A& APKZ;K1GC M;=|VNI01PRF78W/R_?%\$Q<7%W;|^O MP&BD71+|O MKFH1G@=^?2*%,"D<|+
<(1DJTD@KIT+BXGNIWNK|9Y)9^R22;S;3DDDI23W|ME%?983|87 T_9T(* _/U>|G;|"BBBNH04444 % % % % !110
5^~7_!LO_P \$ M2Y?#D.E?|%)OVK_!Y6^FC%Q|)?#.10%'C^%NDW@F|)^&|^" EMU+W~LD4|&-QSVF=
M2G***|^C6***WB6""|)41%"HB+@*|T_85~1Q+G|BG@~|?M/ P|M7Z_~W-(1 MZL=1117P1H% % % % !110 4444
% % % % !110 4444 % % % % !110 4444 % M% % !110 4444 % <9|8_V|VB;2Q|V@?@~X+|=0:7(AFF0>?"|H;6C MN'
(7;B;L%4\$KC_T9Z5V=% 'D'A'_@GQ^PIX|4:2XW| L0?~#1_7FI2 MZTO5|K^&NEVUU9SHOR2Q2QP|XW4@\$;I!&0;
|3XK? KX*~3;+2(C3|)O#G MBNWTV|WID7B'1H;O|<~8\$DE4F*0#C>F&P>M=710!@?#CX5?#X/>'CX2^
M\$WP|T3PS|7+W+Z?H.EQ6D+SOC?R1*H;1B-6% M_@|+)_#O@_3=3UBXU;4;#PUHT E#;50LLIN% C\$GF2* K
MOGYMXEBM|>~(D2*~JF_ ' M KS2+|BOJE_#XQK|?
XO@3H^+4U>35TU06IV|JNNK_C+QE|^F'G4SWAFE>#O*10BM8 M|7*FNL>|~K'>|N/1^~
_*5E9&*!|P01R#25^S^D|1110 4444 % % % % !11 M10 4JLR_1B"#D\$'D&DHH |?P?| M) 'WP\$%C|^2%
|7|:|HELVOH+/'/T(6 M3|^1|~1%*OVJ_#KJ'B32|6|IM1T>_9^IA|LUX'17D8KA_(!>.*9D25A|G<#?3T+>R+ M<~?
\$.OY+M1OKC5-0GU*|)1RY#CPSX+LMVT|@JVD|+|00?>OFXS?|%(OV_?VAO|XR_MD_ \$ MC7K*Y!\$VEW/BZZ2R;/7-
\$;_UA^X)7BE% =M^+|~A|~**|\$A7;"BBBNP0444 M4 % % % % !110 4444 % % % % !P|0_5^J?
!|3@!|XD_8UK2_P|K|K|K|P|=; M9|/|^<3Z+HDX;*X|8R(W_1H|\$58>48,N"D9QN=?1|@AK_&VNM?Z;2/ MVN?
^"A_@XT|PD#~^=?A|?QM%UNDPP|".S*>H89|'O) M?L97"?3IG+X6?M'Z|_8WQ T_<1(18ZM;82ZM

MI^:LSX+^)W!*CXGZ&9+WX6>--/UZ 9*VE\OV2XI@^2T:24LGTKP:X@2L|^'M^X6[W]>?"
[6+^"&/IV:0R6X-1:1HS-WU7ZVT=>M^H.6^*N285*.*A&LN-PR M^1:?
^2GX3Q\J&:;@C.Y.IEM6IA9/HG12" _P"W9^/ Y4/Q\HK\^&2\^P&^()M>3Q=)-:NY9/OW0T\YC_P:M8PK_
*UY3XL_X)_LT:~\3:~_VAD=CL-3\$ MD8\N\UD8C_@0K\!>+15M,12G3?RDOO33_VE/Q\ _HP<:81N6-Q-
&O\SOV)_Y?2VJ2\@D=L>_L:~8:EXLEAIV_V:ZU_UA9+*>WDE(E ME(7_)8\9QFOPPN0^#8_@LQ:S&*JF+3)U
P:9%0=%"G+ZNP?TK\BR; M;|^"OK\$ZE6*P\WRN/_+^/_@2/3Y6?G#17ZT>"|^@SU_X*#ZL^W_#7_(R-
CDCNOC#^W\G"UL M/#7@)8S^\$|VW_HJN:IO#D\|>JGZ)O\)#Y9:X445_3\^O^#3S_062?F2 M^Z\>P_-\$Q\I
(N#^+X\629H&/?"Z?%;N\!%R?>OKSX#_|\$PO^">2L_S0W/P2_M8X\|+>6^/U90#T5U?ICTNK@23_
/C\>97XPR^~\$S\Y)?Y_@-09^)*SE M_P\$V?V\?VM6@E_9Y_9-|>(\Y(\$LQ:*IOIQSTS>S\+=?QD^K7Z?LM?
M\H%^UX^DMM:~N^GA:X>Z>^&FTG0D:6=2|HVTQV\9/0,LLH7:~>A_HD M&_==**\%<79A5THQ4%J_|IT-
I01^?2L@?|N9_P2Y_9(EM=>X+O\ M\$7Q#;~677/B5.FHA7:4M_B6BX/()B9UP/F\G\ET_3\#2;~2\!L8::UMXEC
MM\WB\1Q(HP%51PH_X^J\BOG_1BL3BAU;D_-E)1117,****"BBB@ M HHHH ****"BBB@ HHHH ****"BBB@
HHHH ****"BBB@ HHHH ****" MBBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH **** M**
"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHH MH ****"BBB@ HHHH ****"BBB@
HHHH ****"BBB@ HHHH ****"BBB@ M HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"
MBBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH **** M**"BBB@ HHHH ****"BBB@
HHHH ****"BBB@ HHHH ****"BBB@ HHH MH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB@ M HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****" MBBB@ HHHH ****"BBB@
HHHH ****"BBB@ HHHH ****"BBB@ HHHH **** M**"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB@ HHH MH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ M HHHH ****"BBB@
HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****" MBBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB@ HHHH **** M**"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHH MH ****"BBB@
HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ M HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB@ HHHH ****" MBBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHHH **** M**"BBB@
HHHH ****"BBB@ HHHH ****"BBB@ HHHH ****"BBB@ HHH MH ****"BBB@ HHHH ****"BBB@ HHHH ****
"BOR"^(_=|?LX_#GXA M;|V;WID#QM^OV7_#7|+|B_ M1K_OIK^Z=:Z\?:S:R0VS,K-O=4&XC\Y>WK7ZE5P8O:8K
S4\>507\^@TT\@H MKF/B\;O@_|L_>|KGF?/XH:|XA/6;*MSK7B35H;*V1V^ZGF2LJEV(PJ@ M\F/!-
>::= P4G_830K^XU^"Z_<|B;Z;=|J_ %17#Z6T\K#&9)H\O%O%K:X M\\$:8M\$' /<5RC/<?*|I^-O\|=H&7_-9Z7^T1^U-
X^|W&H1>981>+O%-M MIQNA4VJVZ/SW7>,,I.W_ P\:/@|W;^Q/^T+XM;P\|OVN?AKXPU\8C(="|> M-K&|O?+
W%_(BE,FT#G=MOP>:/5J^XOXW?M&_/IFGPRGC3\H7XQ^&_!C_ M^Q=64ZQ%8VV\^*K@RRLJ Y=0 3R6_%PV_:-^
QQD^LGO:~^GQ2\|>)O^14 M;2/XAT^5\NS*~.6\$T9*_|@Y0Z4=I17DGP N;_X_8E^_B;4\!2P9_N\> M+-8TE^75-+|
^*~|N+~4W;C+^|L^C8^=P^D=JQA AZ!_P3D MR_|? M#<_P\ M+2YC#J>G_/_=6/GVD@)4I+YFZ-
@01A@#D&@#W:BO~?@^V3^R9^ MTYK>J^&OV=VE/_CG4="B236K#PIXGM;^P1R51IDA=C&*&D L!D@UZ50-4
M444%%%%~!17RIX@_P^JGP_VZ\>Z#-!*=8D>RNY+=Y%O8@&*,5)UO53_A M\7\ P#HD>M?^IT-?
71X\$XMG%26%=GYQ_P#DCM\J>-7A2J_LRBFG9^I4W7 M;A\45U_7Z_@I\X(^+7QCTZ;X=|
=5M\I8NQ;QW_UW\$R1D@G) Y/2OI2O M\$S3)LSR6M&EC;A*2NDVGMT/L_&^+>+|+/\$Y/B%6A"7*VE)6E9.WO)/9
MH**\R^/|9G\+G\FLZ;X9^.?OLT30-7UF%Y\^T:9IK^|A0X>:UA5YFB4\ M-(\$V*>"14WP=;|_98_:%CO)?
@3^T^X1\8C3M_6_U+ A&M&-&|56MSJ\$#JP1A);QN9\$PQ^G^O%M83W.OI_=I,ZF3\Z?>S\X>M_!E%5-
IUI_ \$^CV_B#P_J M,5Y97<0DMKJ\I^AZ;#W%9MG\3?AI?_Q)O_ (V?C^PD\4Z7HMKJ^H;"MP/MM,%C/=
<|7G\|WC^XFT35\G3Y;B+6K0+*T_K1E@;_@\$KG;R/^ (NK\G/ HT/ MQM_X/+/_K\=I^ BW5IJ<KFTU=>_2V?|
V^<#S3)_VY_S_P C\=J*_ _J MD;_@Y>^!OI7\I2G@|HFSPI^S_XLTB^|8:NNGVVITWKNKVTD5NQ5FW;JC)"R\J_
M3^OB>*>#>N^L9#^YWAG1J3CS13<7>-VK^ZVMTT= #54<3%RINZ^BN8^+WQJ
M^#_I/W@Y^Y^GOS^*Y&@>#_#UFRKX45Y3\;2VZ?V;V^K^TIO\|:(_G\!>L;C4(O_L(O)WBFUTXW*;
M5;='Y\KQ&&4G;G&X>M6/@A^VM^OW^TOK5UX: 9X_ H^GCC4\&R7NE^%&5 ME?W-N@P-|PRLZKR/F(YH
I.HKQKO)_P42_8-|_%%_@AXK_:\$^&^F^X\K M\ A_|86D>I^;M^|F:02%CV&W)KTIQWXH\%?#PA?|Q
^(OBJPT30\+@|_M4M7U2Y6&WM8L@%Y)&(5%R1R3@4_|!%<5\#?VD/@|^TYX5E\<_LZ?&CPOXYT6 M&Y-
Q+J_A36H;^V64=8_A9EW#N;Y%=K0_4444 %%%~!1110_4444 %%%~!M1110_4444 %%%~!1110_4444 %%%~!
!1110_4444 %%%~!1110_4444 %%%~!1110_4444 %%%~!3\4A_RM7_P#2V6N%KNQVH?_DYCXB?_8\O_P^ELM<+ M7\|C2_A1\|5?2
R&P#|#7_E+=|_P#L M>HO_ \$5+7\>5?GO&7^_4_P#^#^K-8;Y3_L3^L_F_X^B?|Y_Z_VA?BE\8%&K>#? MV1;FW\
(&?"OPI?>S+|3M;EN+J^U<1^Y7NO.TZ\I52Z.HDD0?_2_TV_~|_9^_K M#O\O\B\K\IE3XZ>&;4\|4:5+;N9\=7DL9R\\$:
Y^3IR>%R)\$<8(91VS7YI-M?|N_T?|X(C?|Q%O?CEK\3-U_P(|\$?VN=0@|0>\$_B2*_5\I_B_)HFXETZ
M^N#|EHS27U\59R%*^0LSL(8E6*%_.F+?W:2N\Y).!R>*XK_@X&|3?^O\OKXG?L M_P#P=_X)C^=(,|>?
M)>&OBG9ZG:~^?AS<)?_/_&Z^L4WFR:C?VI9+2(W)M) M@DK@X@<@:|H-Y)^U\X)6^U M-
O=4|R&R*K2%5&&4D#=#BKW_4^*&OBC_@C=^V3;2\!9?IECPC<_"/QBU MIHW\5_P_T">7IE+A+;Q^0KA/_
B9P^QC+-U N)Y%_I#_@OU#%/_P\$;|VA M\$FC5@/_\$K_~|B:(@_@0#^%<_P3#_X*8?|_!2X=|_!C\GWP%XT_X^!?
M\|0M:T;X)>+6=%U3XK;|75C>1Z1;|!_#)VO(8?>7X4MI9:6=75)H=(MHI M8R0>&21^EZR\|D^4?&G_!N_P"*_?
Q\~?_?P^"GO^&GB;2= M:5KFAWL5S:7\O)+J\$AITFN7RVZV+I8,TNTG\I04G_>IZZK_@W^<^#G_41
M_P^"AUMH^BK3\V2X^A_HMTMKQ^T N=3C_J_YDW#;N&1G/(H_P^"4CG MP9J_|P9^W\8:7XJTZXGO)"/PM(8;Q&:?
|+;O#<|_#EO^D(1)?=8@^!H^UO MV/OB)^RW^V7J\Y^W\^S\;VIT^H)J\@Q/%FNU=|L_/U%T25LHK.BS1SF(GHD
MS\|OPQH\6+X^'?@|X;V>H:2X^T2^P@U36K05KV^A9+RZE;L\N.O>1FMJ@ HHHH ****_/OY^')_1-?_.PU=?|
HYJQ;VOB1_R437_ ^PU=?^CFK M%K^T<+ NT\I?D?Y#YC_R_~W^*7Y\I_8Q_Y.D\ \$|AI?_06K\4J_*W\|C'_DZ M3P3_-
AI?_06K\4J_!O%S_D=4\ KW_I=(MKZ+|_)XW_K_A N:~!^0^QJ
M_ CUO_@C#_P6H^_OU_P^P^&O7_P=:"LO#MMX^~ND:~|XOAJ\3L_O\|DB* M^4B\UH7AC\F^8DPCEWG;IY?LF?
#S\|DKXG?^OQ3_~%(V0_~A77M+^+@_M2\+UW5\#?#?S=OIS>|?%L<#)XAT>YTNQO\$N^AN24NMLMQ^X0\$QF
M_L\|T+?"_L;|D_P_L_||>SXL_"C_@G_XL\KSJGZ?X1P_C\I2M^|J6>_M\TCPW^XKEO=MMIT949F=(KB5"<*H^Y.?T\5?
V_VFV6_P\|E\@X M;_KU2\A V@O_P\LAU6T(O;1<^~%EEI^7CC38G6%KJ2;2\$;D9@N2_@ MGJ^?|
|%L_P\KW\|CG\H+|K+|@00OV=OVH?A\1\|3?VL_#LFIV7@KQMI^KRV M MO)?V;|I4M99"B.P RP)&^*|?
_@E\|X\&ZM_P<8?MZ6&F>*M/N)\RQ^*K:OPW MB,TOM;*&Y^" +>5(OCX^ZOP<&E_X..?
&W@_PQ^T_P#L^1^(-%&GV)M?VK_\$ MU^Z%W=I^Y-G#>V7FW#;B_L;:AN<|_#)H_4G6=8TKPH%UK^N^ZC#9V-
C;27%MY=W;@2")%+L>%4**23T_K\3=^*Q\H_9) P^"E_P_P^"X^Q0\1:E;_#? M\J_5KOP1XLT?4 8X/#_@W3J?|
|_!"Y3;P6H-D91TNAURB)\S+ M?^0&V;Y M_P4T_X(A:3^T7^P)X_ \$>I?M=?%4O\|3:CX5T\Q;XATXZ5;Z MC91-
+9^&:LHS\$^14+^Z\49NW\|T#H\KXN_XO_1%\$|^"P^"BW_~7P_X\U_MQ?2WCWPQH?
A_XB637^M=)J%JHB%U^N<@7.OCN_V\I_K^4\VC0_4444 %%%~!G\I2_<X9^+^QVU7_TLEKBJH7H_DXSQ_-
CMJQ\ Z62UQ5?| M3Y9_R+|^/^Y_(.9_&SZ@_X(L?_5+X(?_8\I?^BI^_JXK^42_ (L?|I4
MO@A_V.T7_HJ2OZN*_@GZ77_)8#_+|_OZ(^?|_8G\9_P5_M\$X+U_M^_%+XP*_6\&_LBW_OX0^%?A2^F6>G;U-
<74%WJXB/RO=>9IUVJRD M91)(@.8D8?H;^V#^R?|_!W\|MW\|G^Q5^S)=/#_M\J>@>*~EM7;|NKR6.Y4B&
M\A)^Y^Y\$B_.\$H\9K\TO@W?Z\A|\$10^"WOQRUCHEZ_P^\$>^"/I7.H0>(\ M^?Q/U_%_T_Q&D\|S<2Z=?
7\^2T9\+Z^*LY^E?(<%S^E?CG\|I\GCP7H-GJ-MEG\3\|0ZAK(V>_%_#OAC5(+|4?

[illegible]

BAYE4'DD5L4%%%!1110 4444 %%%M% !1110 4444 %%%M% !1110 4444 %%%M% !1110 4444 %%%M% !1110 4444 M %%%M% !1110 4444 %%%M% !1110 4444 %%%M% !1110 4444 %?O_!5'_@F M3|\$ ^'K/I^U _^S?
I7;N72KR&Y74?'/BNSMUEN.#U)94G521YD;*S))\$2 Z,M<%6".OTE10/^97_+GPE_P%6?| @DJ^SI'^Q#A??
V+M0^-_A#PC>7(^OO M^\$7C/LI*,*.5YA9W5GK-Y8RILD=RLBE@JN(.\$1JS>8.&C.@CI^V+_P%GA M@H?HOI7?
-13KPICIOPK^#@BSAL/'GP:L/\$L.JZQI-M*TSK>7-F6MH/D8F5 MXI?RU6%<%1/7IT4 ?#'!=C.@D#9?
!%4_V*+ #X,'?"S4M%'|^/>)H)?PI MGNIHS*8@K'89-/DM28H)(H#*IV/#\$<%0P/S,_P24^W_'IR=!O@GHWI_QB
M!1/PZ|^'#O!'7IFZ)18_\$OB:TU74-(TH'B'ULK*ZEFI|^+\$AO;>L4:(LN4(MKI)>.* /RI_X.=|
@BM^UA P4UTOX7_%7ID^SU=>2I> K2 TS5_#>KZI8S7 MIOLW5MJW@O2O#FJ/HOX7U"UC B:YN_C^TM*
f7"R>4@6.&YV(973S7^Y MJ*/Q6!:?!%?:?B; P1.V/ P#!\$BI_- & X_U^SUBTTO6/B|= \$+1F|+MH
MEKJWH074:I W+:D9.TK:8HQBP9PI9F6*-4|@_H_10:^1' MI'|'O)_P51_X)K?)\$P_B)_P3*_L@0?\$KQ+XABU=/_P
3?""CO2::0+7^ MU;18Y'ODU*XMKV-K:1I7 BMY1,J@H>;JP_X(?!\$+O_P"P%_P3M;_+) MQORUSI2>)?C-
IUUIA5MOT+VRTWO_M P#&+XK64EQ26NC:E#1^A>'S.8IP6SWCK)IDMX80@8AYFYG:5DC\$K"/LHH M._3-(
K_P!AGIKS.^FU^R+XC_9_:T^\$\$6CWUXIO/\$FF:H7B.ROK.>&>T ML:?!PBEU)|@ULI:&,27SLPDBCWM(L4CYB?
>=%_X^?!"_*_P_X+"+=7!_?M1_|\$_ H^4?!/P:_\$WPIN=3I4 M:5X!:_?138WEFTSSSO!T%;BW@B@Q*T;KL
E:12OV8/Q ^(?I/_PI MA? Q9TH6BK7/V D:XFLI^Y8MI0FLXI+B/9_#ME9QM18Q5?*X|LOI_@A
M:6O=&T.XPZOJN(^-)O8ZXI>=\$FDZO=PRK-,RWRB/S,I(\$IUMVD%NS*&D MBDB*IM(H_#_@X/^W_
5N_:.^\$UC^R_P3W^">C0>"I:A6Y^^(OB?4O%EI M9SZFJR\$H4<4K9%OH>8D?O05C^X)!|^.%_P3'_.#L+XC#3?
@KIOEIC'H_@KVVFZ+I4/AG>37G@:74&JUO8)4C%QACJ#Y0?R8' MC?!"O"H.%=F7O_+|#_X)I_M_:+!!JK_XI^!
OVQA8YO@UL_/@YIHUXST MW7O%&E:C>^*_1N)::2XL_)~N:A5LV-G\$GGSM%(8Y'(BW_K)10!^:/P<M'?
7_@K;^V9)+#ID3_@GK|.M&@%:U"M0Q1/\$^I>*[2SGU)5<^7I4<4K9%OMH>8D8E!6/I@dSGP?H7_
3'_P"#L+XC#3?>@KOEIC(8O%WQH_M9,&^?B_5H+*.SAU3QIX#T_4+F.WCSLA\$L|+,.(UW-ARLK.I8H;>%%)"IB*B*
J(Q_ *M I5FBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@ HHHH **** BBB@
HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M

M1% |\$V=3_9BOM(TWQ7X,U7Q%^_^I6I06K_8;3S\$"VIK;(55GC SNF='VL,Q M GCT?IMGLI0_PIDPIX0TK3_"?-
D_CKXE>,K3PI."/ U 6BZGJ<->27G MV2?9K6&-7EFF;\$E\$7"H/BL =>V45H7'I>_Q7_9Z;,"^')D/I:P|" ^EP M-&"&
IB^-&7CIP7JEQ+87&K6RJNCWD-S&KVS(ZM#,)9R)=@5&**^K;"BOGW MH7I0:10A-V+96NBZ4CA-U;5ITQRBP
MLPOV*1++*Y"112\$4?VO VT&+I WH(E)^OCKX=T+O+XKO_ZL_%!^%?2_L MDUL;7NIW||5M:V;7-QYC%1(SO)
<>6N(D8B\$LH# TA17S;^S7^VOXY7_MD?_M\$#|@7IH3PGH6G>/?!OA/2_%>E:IX7NIGT_7-
&O"T3R+/,/@DN4.%@68.&C M=2N61>|1-'_%[4?VH]&_9I^%&A6FI2:=IAOUXFZQ=YBT#3I%DCL;90A&Z
MINYT9D0G"06LCC+0K(>JT444 %%%M% !1110 4444 %%%M% !117EOQY;>_M9_9@AD:X|[2?@WPK/&NXZ?
JE00K>...OR6P8\$/P IOUUX+ 8LL0J&\$12 MJ3>T8H45^.;..^#HI_@FK-C-.?#5/WQ/N5R(9_# M/?
8I5F'IZ2^>?P/<1M)*^5/BO|^=-_Q2O_#;?X& L:ZH6.B&/I6>)YI_ M '>A.*WCMIOT\$A^M?JF3> WBQG:4J663IQ?
6JXTK?INSDI =%G#4S3_4YW|M_P?RW+W HK^:SXB?|^IS=_P57|_;QX<|>>\$/"(?.X=|&P2;/HN-R?SKQOC_M
%10^>"/CG?;7L_WC:#S/O?V/=1=CZ?9(XIOX8KI?P_T2_=P5?|);OI<|>>L/^ A3M_Y,+>L/^>3I
M#K/B.ZNH=XB3#;)79;URIR6'IRJ.,Y5>R;EI? MO85_Z=:M&FH/5VW/Z(** E@_P""I?2_P" T'=VO^"N7QL_<
OV@/&VB::; M:f8_9I/TCQ7>6T\$6=,LR=L<<@5>23P.IKYIT#_@I/P42|R+)X=-_Q^EGM
MZ)/A3=5""ORO GX(^HK^H<)5|1AX58U5IR3M9]5<JGG/I_.*_D6|\$_|!>#_M(*!)?
#^5)M"_L|8SE,8&MK;ZF/Q%Y*#^>Y?#+_@ZX_P""LG@1TB/S7?' MC15QQ'B/P8L)8?
73Y+;!J"G^&91^&47|VOT_4.=!1.%?A#|^?| @Q|30&* MS :_8=L;H"C:EX_7O!MZ9VVUS#)NH9A_6OK_. IU! P
&HOB|TGX MX|8>+OAS=S*\$8_&A>22\$A |=;!KEON?XGV#N<5YE?(WP^LJ3?IK^5QJ46 M?H_17GOP+_S_9?_
&G-&J_L?M"?>#?&L0CWR+X|16IW)'/^FD<;EXSZAP M/"2O0JF<")TY"+G0+JVM_-
*2_G:WHCNLI1R<8TGE>2PB.R1RIQ^PE2+! I_M_|| C8_M8ZU_P%&ASM=TG6_BSJB V#X_
T#099)M&^VA:BQL,*25\$>ZN M969GN+UXXRY=DCCCCR&HT#Q?^W+/^W7KW@KO%)O!<I/L@2"Y/A C"WU
M5VURY0&9!);2P>9M6\$1FOYL?=0B5BS1H?f=P10|?MI_MH.?^U#_,%\$ M_A=^TOX?|^_/BAI9-1TNQU+6/
(UN|M_1:8V)::Y1G:-CRC&D9D81(?) M,P^K_WQG|4O| @OM_P3>+_/X|66C_#[X|!XS]|> JW=A;R2Z7%XGT*
MZBN(GD1RXMYOG@D3<64^:R_P+7L'D/J^*O|OW_I,XM?&P_|\$ @I-1 A! M3?&IUX|&6VB>
(+"ROO"FKWB(MIUTEI-"K6+-%\$|4T#22I@.K0N3N/I7_! M-A_8?U'IBIX9^
M2|?HU_10/BYI3M;^/(O&NM+M90ZKJ4_F:6K2*KM; MP1A(E9E4N5>0JF_8H/Y/J_PO^)^GL/I4WQ" X*;?32?#VJ?
%XA^AM^&P M?^%7/O6HIN&=UD>X6|VXMK=Y&FN=I O+(+>4M+6UED8R!&8:GACHGX>?L%Z
MGXE_9_N"/BOXN>?P|(7'O4^/NN^>I2S00K*=CW+!"N8LDI 8;.PC+R);64
M:M_M3?:PY+IB>'GN_#OPC|+W4IJ2'3=.WA:S690 MC.HNKIXU"#):&SBA7Y'GN4/SO|>?
V6_VG/@A^W1^T|^U!|\$_@AJ^Q+TSX^?! M&RV/6%CI.K6%M+HOB*PAFM;>.Y%|<0A;&:*9_!9D*-(&CYOl
?;WP;^+_P_M|_|^\$ ASXX?"Q+#K'ACQ9HMOJN@ZG_K*MS:SQB2-MK_IPPRK_H|!(K
ML|_*_P""9/I*7B#|AW|@7X5 LI>+M2@U/6!GA.&TUBIM&9H7O&9HUB+_%H MUDD=4)55) S@>ZT %%%M% !1110
45|O_MV?|@/V?^"?=O-I(OA

**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@D9)K|O?^"JO |O M P#"#IEN:4 @;^QLNF^//\!>WO _!"TGFZ+H\$>^")..
f>T8+^:NKV2;LC#58FCAJ?/4=D?=?I77I;? MLOI#/#PX?XG?
M*%&QT"S8;-L2WFWVIRJ/I5;6ZY>9N1D@;5R"S*N37X8? M%Q^#EKJ#H|OKIX; LG07GPI\%2EHFU*VN0=?
U&/IEIA#BSI&#L@+<@S;# MBOS _/CS^T+L/VG B3?2?IX 2\$K5/%B+4& ?ZCJM0Q*+DD11H,)##N3MC0 M*BC@
5QM?WYX;?10X4X/C#&9PEC;6M?>7J# N0?Q?S3OT;C%GRV.SBOB+Q
MI^|7|B6^OKW4|V;4M2O);BYN)6DN+B>0N(KL6))))))J*BBOZ. M225D>.%%%, HHHH **** "BBB@
KI" ^#8;_E*EIA V).L P#HJ* /2OT+ M P"#8;_E*EI/ 3DZS_Z*2OSOQ<_Y AG'_8/5_P#26=>_P|H^J/G?|X.#_M
/E;A4K|!0-&@1-9LDZ|KF\$;8FU0.99?+EP"Q.S"%2NO^SK^TW| MOVMTAC9_&A 9P^*ND>+O#EIQJ&DW.
IRGP"8IHSAX)0".QR*KKGD"OXFJ|_M_8X_ F _A_8)^*<7Q<_9?^EIX>U*KJ-DK>98ZI"ISY-U;MDZ?LTA|P9PAF
9A^BE?GV*PF(P59 MTJT;/^MNYHFF%%%<9)/4DD*%&69B)(%R_P SWW_@KW_P<+?\$_P#;^GU/X ?
LBZAJ7@_X M8-OMMIU=28-43)T;>1UM;L"'''=3^;_2_ F3117^E?"/W#W^3QRWZ
M*TTUNY3EUE;6|N|N|MDDDDOCL1B*V)J<|H W84445|8|1110 4444 %%% M|1110 4444 %?H7_&PW_*5+2?
^Q)UG_P|%)7YZ5^A?_!L_P I4M) |\$G6 M?_125^=^+G_)L_X |IZO I+O ?H3I4?_<'_P#*8WXX?|AVP+379U
M|5IE_|P?_IC?CA_V;#_P|=G7QI7^>V6_BZC_((DCI5A1117: M4444 %%% !1110 4444 %%% #
f>XGM9TNK69XY8W#QR1L0RL#D\$=\$="#WKI MGO|@C%_P|OAI-
I7L;G_!2/Q)=ZSX;RUTXIS*TIU8^ZL>HXRUS#T T M@ RI _Y@_Y/O>HKBOV7X7;./LZT;IGU7HOIM^IR?
AKQ+X=|9^K'O;X0UZSU M72M3M(HK3=2TZZ2:WNH'4,DL)"/_B"S%SL;L;+NCF0|\$\$_!1U8%61@&1E96 (('
MY=FY3XG*JUIZO>TN_P#D_(UC);ZFBBBO)*BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *U_U_S^"7I\$ _P_U?IH^X^5TW0I*3;)%&_U
MSJ%RP/EVMO&2/_F<@+D_%F*JK_ |XY & X7_LW?"77?CA|90%EOHGAKPY8 M=ZJ%R>%4|I7%2|_&M->2+P=X-
M|@M;.:1;\$I3T\$MPX_DQ +\$ _BHB_-I%?Z=Y/D^6|;NVVVVVSXNI4G5FYS=VPHHHKTB HHHH **** " MBBB@
HKZ4_8I_P""2?|=G|>TT&I? |X_7_'AR63;)|XTI2;_#24<=&K_X+7&#_MU6|96<5^M^I(A_P;G_++OPV2U|2?M??\$|5OB-
JB@+H;CL^E;2A|HS(WV ME?Z;)(^|TK|LXT|9_#W@64|6/Q;G67_"ZI?O^E^S2?+!_XY1_|#9=B|5K"
M.G=Z+^O0_!POX3|4^.=M_"@KPUJ&L;G=OLM=.TNS>XGF;T2;_#F/L|7U| M|/^" _5_ :2&_M?V<)"&G3_?|_ \$P|?
7T>E|_WK=R;K|H37I)_P*_9 M@_9U_9C|_CPK^SY|\$_#/@^RV|94T^2(K=Y|=Y9%&^9O|HV8GUKNZ_F/B3Z76
M;^/GBSFTGSYG^FNU;_#OG&^E|FST M;:>58"GM^KJ?\$_A;_@W=P""0_AB)0_|*K;E;O6XU3QGK\$A;ZJ+M4_|^IA
M_9Y_X|C_#P*%C^X|L|L2LUZX8|0PVB0B;0DCYF^_M_P#P|U_X|G_M-2\$S5OC)^_V3_"U_P_4|<|J^M37H#-
=.D2Q*6|F=|PB* MN_?%|B|:?!&S?_1M|7H6/L_!H4S|9I%|GBB|IOAC|9OBCX5NB#L6;4K+4+8?6 M-
I9)#_WIKY>^_7_!FS|?M\$MIKO|9|_))^(W&6ALO%OAZYT@D?W?;@>|/M8\$JH)ZXK^@*BNZCQ%G%:K?U2?
Z7_\$7+\$_DE_&_X(\$_1%9A;H;G4_#/(V MMZ_IEL"QU3P_/K2;@ZOY5JSSHHZY>_<#GI7R%J^CZOX?U2?1-
>TNYL;VUE;M=U9WD#12PN;JLC_%2/0C_2W+UY9^T?|L0_LA_M>Z2VD?M+_+7A^QD#%Y<
M=YK&C1M>0+C^FZ4;.\$^|J;|O"|955IB*?G'3|?|_-\$NGV/X|J*_H*_+M_P"#0^X#^OM?
BC|AWXZ;CX)OGW/#X6|9|M1TPMVCN5Q(+U&|8>#;YB8X4W|EN.V.Y50;CA)E4(^#"^DC^
M*PQ;C;HXBZ557BP3L?VY?_?X|_F_::>A?3X&^_?Q#X6|1V*W6E;I M9/E9%|**RGYHY\$8;COL
R.K*P|!%==7HW_!#W_@LWX|_P""70QE^A+OY=WV ML?|WQ5?)_P);H\$9;CZ9*<_3M\$|2|_|(@XF1=I^98V7^IGX??
\$#P3|5_VD M?\$_OX;^)/6M_U|3XK|1|6T^8207=O(H9)\$8=000;_*LXRBME6(Y7K!_"_P|_ MYHVC*Z-BBBBO)*"BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"H=0U"PTEP MGU75;V&VM;.%L;FYN)0D<4;@EG9CPI@ DD|_IJ_&|_Y@_X*PMX2TBY_P"" MC
MD^!5G+6<|75.FOBF_39+3FDU&^IS8K\$PPE%U)?|_#L^O^"IW_!7;4_ ^"@?Q ME;X;?|O7IX_A#X-OV72EC8H/\$-
|N4;49%|O@#EA4A"7;_D*K^?M%?ZO|*|_M;91P=D-
#;LARTJ2LN|GUE)|92>K?2;RLCX607J8BJZDWJPHHHKZ\$R"BBB@ MHHHHH **5\$>1Q^&I9F.%4#))K|7_ ^"3W-
;9^A_X^P;+>_V|K?4O"7@V79 M<_9X&CW0;MK;?4<|UE W^RX|YAG^E?^Y^2XRXXX;X"REYAG=-4X?9CO;_M
)81WD_P6|FEJ=&^PU;.%5.2FK_H?|G|%-|/+|J_@H#XZ/|K|FWX9SZC#;2
MJNK^(KTFWTO2@>|Q<\$;5;1&NZ1@#M1L5^YW_!/?_@VV_8_&5(|^Q|^T5% M#|6?&|60C6+0#1+&7KB&S;
|G(|.1OG+@X#";_U|_ "3X/_ "WX#>_A A9|& M?_E>&?#NE1>78;1H|FL_0|G"CYF8|L|99B26)))KJ*_@#Q(^D9Q?
QG.>\$R MR3P>\$>G+!_O)K^_45FK_ L++6SE^R|9V=HH%86%K M^!|&L<;_*I4C11@^H'
|2I*** GAMMW9ZP4444@ "BBB@ HHHH **** M"BBB@ HHHH *K;QHVD> (=N="|0;5;7UC>0M# =V=Y LL4;##
(Z;_&4@X|(P M;LTA;?EA_P4>_X_9OV2^VC_+?|2/V0+ZW^+\$/C2;=*=+MK8R>'K^0|X;V7Y
MK(DX&ZW^11D^2Q;_!_!M|C_@GW^UG_P3X^>_&G|A|TJO_?EF9|DUF^I IN MK1K; M+6Y4;)|1@^E>)|\$W
JGBOL_*Y#XZ?_X+?M_?#74/@|H?OAG|BSPU MJ;8O-(UFT\$|L9;#MD0_>CD7.5D0JZGE6|YKZ;+)|L9@FH5O?AY|KT?
Z A""|_M_B.HK|_|/@K|_P;_%3|F4;G^T#^P3;|XX|_1|IG4_!C SZUH;?5C%@9OK M=24#SD&-RR-
+7Y(LK(Q1U((""0;_0|%CL+F%VE"5U^*|FC-IH2BBBNL0 M4444 %%% !7ZP?|&WG_6KN/V1OB'9_L1?
M;^+MOPM|4ZAM;_|Q|\$WR>%M M3E;H6;IEG.Y^?/RQR;|E5I6/Y|T5R8|4.2A|4;JT?X/NAIV9_=" _@T5^
M2G_!LC_P6"2H/X6Q?L'_M">)|S+|0O!&E|O^&J7TV9/\$&BQ_#RF8GY|FV&/_M|3PI6P3*U?K77Y#CL%6R_\$RH5-
U^Z-R;:"BBBN084444 %%% !1110 4 M444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!11 M10 4444 %%% !11 M10 4444 %%% !11 M10 4444 %%% !11 M10 4444 %%% !11 M10 4444 %%% !11 M10 4444 %%%
3@_9&UCXR2FYN0%6ISZ\$X\$T>^?N=5UO7-1FOI6U;|DWRW5S^Y>25SW9F8D_6OK#_@MM M_P %%%K|_ (&?
ME;GKGA?6^E^W@OY=^!6ZL?+F@5_WU_C^|<2+O|P#Y2PJ_M>4KX|K_3_P
#.'A_PC&OBX6QN*2G5OO!;PI>7^G>7|O=)^Q6;XWZWB+1? MNQV_S"BBBOW4P**** "BBB@ K4|\$^"?
%_Q)7;X|^_AF^UG6|8O(|32|_MTVV;:>ZG<|4G1%;+2>@IW@/P^XS^/C32_AS|_#_YK.NZW?IV>DZ5H|DF
MNY&^I&BC|237D)_!Q_@BKX#_X)V>"+?XN_%VQL=<^_FLV>_0U(8EA|/0N
MOS65H>F|!Q+..7Y52\$^|>6>*GBKDGAADOM|1^|Q-2_LJ2>LG_+^6\$>LODKL M|L#@;F;J66B6|_KJ>>|\$_O^#?
KP)^R^Z5^TA^U|H^AXD^*6\$N=*T_RL^G^M^FX^D=5N+Q>|O*1M_|E|E*WZ>445_F-Q?QEQ|QSG;|SS>LYU);+;(|
(PCM& M^|O=MMMO|/X#>EAJ?)35E_6X4445N;A1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!7Y2_P#|+ @W%|!2MD)|W|30I%FE;=X7^*K|K6_M2#@*V^F^%WY+V6UO&_YZI1RM_K-
I8RC|6J*Z|C<3@*ZJT96?X/R8FDS^7 MQYX"|_"/QJG|PY^(_A6_P|!#U|1+V2SU;2-4MEAN+2=&VO'(C%6!^0UDU_4
MS_P6Y_X(8?#+_@IEX(N|BY;_>O|_&K1K^&EZT5\$=OX@B1?DL;XCO@;8Y^6 MCX|W)P/Y@OB5|?^OP<|?
ZQ|+|BEX2OM"|1;J\$EEK.CZC"8Y|2>_L_C?2?N M;_,\$\$@U^IY3F|_#_-'22W7;_@&4HM_PZ***|8D****
"BBB@#J_@+|/B5_M^SA|7_#GOV^#WB6;2|\$WA758M0T?4(3_*N5#G;PZ;C#*_AX=&92""|7I?G_M37_Q^?|
P4<_9%|_M->_)MKF^A^R>*_SCEW-H^K1^HN;5L|I02^0G|_M;*_2_L#_BOXY*_0S_(-S?^"G3_L#?MEV_P_?B5XC-
M|OBE^H7B(W\$N(=+ MOI06SU^GA KN8|X^E2EFSY2X^7EHI|+?WU|!!!&TDT MTS4C11DLO|_)-?R?2|?>?
VYKS|OGN;QC|<+ _EEI_V|S_8_@F^R>1:3 M;_RPL?NE5C)^_O9IV;OW_Z.G_>_>XXO\$POAL;K_&T|W_ =0?
K).36S4& MGN>5F^*^KX7EC|4M|SYLHHHK_34^."BBB@ HHHH *2;6US>W;=G9V|RS2N\$ MBBB0LSL3@*
_22>_4ROV(X_J?|_@DI_X_UFU_X*)?M#>^&T;2;QA|+I(O8
MLK>WD;%7U1E|/2%P4A|959^/*0M;Q|QOE|A|PS6SC^NZCI"-|I_#"/FIV M|>6*^I*G!; (****^9_@HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS4_P"#@#_@B+X? M_P""@WPRNOVD^V?O#L-
K|O^G9CBMU5|XLLXQG|%;>|H50?E/7_5;=I5H_M_P|*Z*Z<^BZ^|Q\$;U)V;_R?D)H-

!NL:J.CZC/H&KV\$UK=VLS0W5K(*M***"BBB@#^J#_@W-X*.22MYL)V7A^OIKANOB#^*(T#Q.TTNZ:IM0A^PW
MS=R9(D:-F)RTMO*Q^1*0"OY^A_@A+^W|-P3|X*\$>%O&WB+6C:~^?%TB^M&:'R28BCLKF11=-G@?
9YQ0,6P3Y:RJ/OFOZUP01D^(OBORKB/+E@,P:@MMS-(\$XDCM)\$+7X'7 MJT61RKW,9K^9>OVF_X,9/V M0O
@H:~TE?:"^)/PW_?&M;13_O!&^%Q:Z7-X99;^+=+N9S+>3R6D1,Z9 M0^A8(5VVX,X9?>B1?VW;H51-HFJ64UM-
P<%64!@!\$&O!+ H MTY1DN4^&J*6%K0J5ZAG4JLHR<6H(0E9MQ<8)7B16DYQNF1L-ZJW02RL5ACZX9IV"-J-
715_@?P3X3^&O@W2OAYX#T" MVTK1-#TZ&PTC3+/-%:VT2!(XT'9550!1^/^O^"SW_1/"1@71B03CXRT06_MQ!1?
+ #K?C1Y(12VNYA 1K 1P(V.Y>TLLV#@BOM6O!/_O_12H>182PV%G M?1X5N%.VTY;3J>?;U:~) \$FK-
L^TRK!K"X>|E|TM7_D%%%%?@YZ@4444 %% M%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!1110 444 M4 40\$GAOP_XO!_W_ (1!6:+ZEL>JV4MGJ6G7L*R0W5O(A22*1&R&1E8J5!_ M!(K^2_+X+;
/L.W5/^"9/I9NI?#P_97+~^4J^L?#K49R7S9L^)-/W/MW1:9SY9R2Q0Q2"F8K^MVOD3_@MC_P\$Y'-
"DO!#VO_#;2=)B?QWX:CDU MOX=71_#KJ,2-^KN(2_X3,+G&:SDQBO=X?S1Y:C4H/W):/1^ORN3)71-
MU14M!97NF7LYG:C:2VIO;RM"/&4->U_5E/(((((OJ*OU 1_P (GXL,LFZ626U1LUPV>6, MMJT#_Y^1O1SM-?
R>5^IG_!H^V2WP*_WU"JE:QJABT+XOZ(UM;1N^\$36+M09+BV;G@:H3=Q8ZL!D8I
5|_Q+@OK>62DE|T/>7IU_#7Y0=F?TJ4445^5FP M4444 %%% !1110 4444 %%% !1110 4444 %%% !1110
4444 %%% !1 M110 4444 %%% !65XZ!6Z;X!%ZMXWUAL6ND:=>3C."5C0L0/NE_ S1X<1V(R '(5PIPZY_A;
(H7T3!*^"IGQ M>|B/3OBEX:1/\$J!A|J("SNN3U)13&V1VY*3W:OM;H2/%KA:T9U*>945IF MHO9UK=E4GK2G-
29^IU/-Z\$!4?VH_O:2H)37HHNW?O_+17I(M_P 7/V4/^) !1837/Q\$^%NG>!?%EYN9M:TU5T&^PG!D:6+K<)&/
MIQ7Q=^U7_P&GOQJ,Q3^?V.?CUI/C.P*F2W/^+&GWVS^%(H/=;SL>/F M80+_ % 5L@^D-P1CZL<-
G\$Z:F7UWTK1?W_ =JQO&WJZ2>CIGRW\$9=GN&^L93B M->(AWIR4FO*2W3!GJ?D37W1_P;Z?L*1?MH?
MZZ5K_C1?M7@OX9UXB1!5_M07%PCXL1INQWSCS"IX:WE?>OE;H+8M_N_9\$UO!L^H+X!^)?",AE,<M-
WJ>GL;2X8=H;I-T\$WUC=A7I"-|P;J-L:Q_LK?1\$|=#1:;H@A!3?%.5?^_MK.Z8=+21
MA#GKM%OMEP>C7,@K3QO!1<)PWX9U<5EM>,ZF+~'4)*2IY/G MG%Q:&^E9IZ2<3U5%%?Y@GVH4444
%% %% !1110 444 M4 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 M!_ =P
_OG_1/^T_9*_K^Q! Z+IF' &6*26%2*\$5KK4;J-OB&.@=H(KG MGJUS(1)7YH5_6;_ %^OV(L:IM|_@FMXUT'2_*\$_BKP-
_MXM(LD>9&N+~ MVF@7'),UL9X@O0NT9.=HK^3*OU3AO^O&Y:E)^|W7^C^|C&:LPHHHKZ-D** M**
"NH^"/Q!6_+XR>%/CCX"NO)UKPAXBL!9TJ0D>?;3);@.JDH 1W!(MURI%45*+3V8!O?P8^GA?
XZ?"PM!_!%QYNC>+O#MEK.E2;@2>Y@2:/ M.^UQGWK:~/_@UM_?2X1?1\$LI@:MJ/GZ!/\$=
IXN@PBU_!>C>H_P#R;|O!+**** HT_@**** "NQ^&107QH^C331H2L^M:M^T#XEL/@):/_@ULNQ>(H#
M:S2VT0:1XH9O.MI@ZR* K.Q# 8'"FOL+3M.T_1H/@TG2;&&UM;6%8:~VMH@ MD<.:@*JX"J!P_*^#A
@EA/DUWXN:W1+JWW1Z!H(AMV(^|/,<0"/? MRXY1_P #KIYK^/\$+99EV>O!X")&*3DDW;GEK=)MI>IRI6/I\$ _G-
N)^X M%CF&=UW6E.^M&5" *+NU6ZM%_BV13+2\$XHVZ8Q7!BU?@_P'C7I- TXP_"CIKCI/-B M0Z^<^&^FC7
\$H)HMF:U9XIF=0>N+<#L^IX3Q3HYDZ3>DU^*U7X7(FM# M!6**** 2S(**** "BBB@#1CO^#_G!H
^%_VG_BG^S3J%IMM_@ZVURPBD;Y M34RJ/!S17S,<=1!S!T5_0E7!D'_O.^-3? K_@KC!%O\$^+I"<+
(-2@DLHU/TFGB8>ZBOZW_~^+!LTIHOMQ3^T_1&L@HHHKY\$F:_O);B4 MDIEG^V=)?%D.)M?
UN=82\$<_TCG5Z!7A<2XQX_A57ISE:T3LO MP2!4_#1HY!P/EV"2LX4= 13BI2_1)FPHHHKQ#I\$**** "BBB@
HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH *_K_(D?@9_PM_
O)+^(%MM9^==_#WQ1H7B*W"KEIAF-C+CV\$5ZIG MV3/85^BM>,%&?
A@/C1^P!/:A:EMYL^M?" 7+>R3&?)^PRM"<=12A#^%= MF7UGA! =2J=I+11/5^18U%%?M!@%% %%
!1110!T7P@^(6H_ "XL^% BOH^1 MI7X8|166K6NTX/F6TZ3+@JCE!7IN^E:E9:SIMOJ^FW"RVUU DUO*O1T8!E8?
M4\$&OX9J_L^X)U^/9/BE^P%|SOB)/<>:/K'PH/W5TY.3YI=- 90?/_P!FK!M: 3' (**S_-%^R_XE0-CS)!3!_Z9"?Z5^9U?
T-X2P2X>K3IU M7^\$8!_ \$HJSGQWA:72.&B_FZE7_)1117ZD?S6%% %% !3HH)Y5AB7+P5 M0.Y-K9^5DFI?
\$!OM.DRW&LVL?115!;BK-4Z MI^Z^Z!4A:~+9Z);_P"JL!6_"A W44^T%6J** BN4G*3;W9_KY"\$<%% "L
MEH@HHHH!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !111 M0 4444 %%% !1110 4444 %%%
!4=Y:6U_2V-I LL_11RQN,AU(P0?8@ MU)10!_#KX|1-2^" '&L^#K@\$2:3JUQ9ONZYBE9#G_OFLFO5?V!*=MI!_?1
MC)H=I^LBLOBKXB@B0?PJFI7"@?D*JK!QI2YZ<9=TCG"BBBK **** "OZX?^ M"!OBAO%_!_!>K+O!GPM-99S_P
^U!OD^,8WRV#_OK!U#PW/O2BBBOS4D5 MMR.AY1U93@@T
=C17D7!5W!H/Q2^"VEZ;X: 9!_9NU/XK>/M>\$IZX6M:~@T MFSAMX=GG7=HJ#P#;PI9(T "R2R/(D:~9&3Q+X)S_
/4?Q3^V#1;OB5^MR+^T?^ROJOP8^,OPJ6TN?\$/@^!01_O:7=AT5!+_ \$C_@MI!^?PQ!1VC=.^\$%_1
OX2_2X<^/?K^*6BU&^ MT6UI=ZA;~>+5DGLK>ZO+>(L;E);YKHF(U\$GUY!_C3X\$_9!^X^M?&XC7TT
M>D):~"65+_S7%W(S+!#;612!S7\$TKOPQ1+TDDJ(N2PH ZRBN>^%&N_#\$Q/M!_=#12?%7P!&?&
\$5_IL5OK^AVUUO7!9,ZIFM_/"O63.UF50I8^D8)Z&@ M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "/?1
@I^S+^R=K8 X M-18@^W^DI7YJU^FG_!1&U^T?LB>*) .89+!Q_P"!L_ UK|RZ_HGPF:~#=-1=J MLO!
TF!_!TGX_/B%0;ZX:~*0L>VV53_2L,5%SPTXKJG^1VY;- M4LOHS>RG%_WD_X*\$?>2T;3?
&7Q08CZK_ USC!*:KT+!K;7H_%!5GQ-13Q3"1= M1^(6M72R Y#"2^F2/ZUY!7!P07+0@Q)?D\$)8SIZO65@3Y|BWD
MGI\$!/=G!=%Q!OVG?V_ VY;2PF^/2LGA":JM/&?AZ 16OBW3|K3KJ?3!1C1 M%55DW0?M5!AZ HKK(!%?&
HJ!OCX3?M2_!_#?1!-W4OB5!+;W18)- M!^#_B!I%M?6VH\$MYT%U9:E/!8QP1(DAXY&I^*)M?LO_LO^M(^*?
Q+~L M: T1X&_P68-T^!_#NF7)O+31^#T^&6.TTXSNB?92US=33R!%00.(U# M)"LC@'SQ_P &O>@Z59_1\$-
@T422G5%XCN_09AN_Z10&HH=V>ORHJG/IVN M_X+1=U:40^~38/W!CGZ9H_Q41:?
X>#L2%LO.CGPO^SYL^Q^I=;^R? ML!MH_1;|F/Q!^P+|V?2=Z9!K^LW/P|<6_B/3;23=+L=2=YX!P6/ MM-
REU"!G_9!_8%^FG?&M/XC^#K:WWZ1J&L1Z7#K=1=7HEU&IR5E 5?F-&<\$1HBY)7#_V+XLO?\$FF M^&
IV_P#IV@6^JZI%;LUAIUWJ^V6.XDI(TP23RP?IVOL>AK!U_P#@F1^U)XX/M_!7GX!2 SINSID?
(5G)??NAV7B#PIHUEXA35_+U3PEIX6TM:*TF6_/!66 MDF>3K_*UQO6^R\$A7ZW_~:8_~^"OBGP&/A?
P3OUCXI^'=^\$?B# MI5MJ^AJZ CV116NH/I?2T@P31@;G:D9YWX5?LV \$+XT MY6O_!17XZ?" MJ_LOAKX:S>#_
_@K4=0M:O58H!JZ6YO+4)+*66VCD.R.&""&=50RNTFZ4 M)&?>WQ3_P""G!O^B+!G#XU?
1\$Y"/&L^&T^M^QO^H!>7CB?5I4U^0="GO MI^4!3!LOLO(FN1<67EP2>:(VBF+2%&C^O!+6_VA/@WKVN:W^V?
1= \$RZ5^S MS^SM?R1>+&YA_!2BCO7%)HGD0HXT!YCLYG_A(H/FWLEQC_3!2^VWJKU/C
M9XXT31OV>_@?JND7^CNZEM?\$WC^Q78OA71(U!O)XL@OYE9;>U R4DF-P05 MMG4^_+!63!@:Q+|=^"9S?
LP_LB>#K"WOO ^H>^!4!%^#HIA+VOH=(NX) METT22\$*A>&)E1G(7S FI@^6_!9!|VR?AQ|=OB9XE^!DOA7Q%X-
!2!A^3K M^4M!#^~;WBOX/O%8YUI&UK/!"Y21"8Y6:1"DBOM@UNOB7IG_X_ %I MXQ_1% @_&W_!S6?AAXA!^!
!P^Z!_2?1AXMLO9W^LWIU-M3NKK!N+QOP\$ MK:AW \$C%C^O0;SIM4 %%% !1110 4444 %%% !1110 4444
%% %% !1110 M!Y7^VY!+S^RIXTLU7.S2UG_~4T!M_7!4:@<IFMW" KBOR^K!H(JW-E.)H=H_?
%+~VT_A_Z5&\$<.)!BK?%18!#CM&:~FMR8#GW\$7!5?QGF&M>#Q!7#O!\$H^YM^M^19A^LDPN-
CM5IPG_X%?2 4****XSUOHHHH ****_ MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
** M** "BBB@ K%^)/C"U^GPIU_Q>I?T/L:K4)MOXVPPM(<_@M;5?+_P6H^M+_PHW_
(4)?7QXEUY,LO@&ZTBWE#8*2ZB5T!"#ZAKI2/>ML/2=?0IK!3 M2^IV!Z!@E!>76HWDVH7LS233RM)-
(QY9F.23!2:BHHKJN.<**** "BBB@ K M^NW_ (4^&G!%?1!(SX\$;194S>"EO!\$=KJXFN@?Q\$V: D2K^TW!AGX?X3
M2L4_"X7MIY;^OACH.G2H1@IX=/@C:/N64D^YKXWC^L_4H=Y_+1)(ML5_>KJ+8^HH197/_?Q
MG^X5^O>\$+4.RQ.&^"E_X"!? MQ_*WTJ,KE6X2R_,\$OX524'_Q(W_+M<9Y)1117IT?Q(%% %% !1110!^@7_

2M1:G6_@9JG@V>:=+H>NN8TSIV"=%= M?_UFKZ>K\I?^"/Q\$A2XIW?@>ZGVP>)=>.<;KB#|ZA_{XIX?
C7Z%5+ MWB'E|P%'59VTJ6FO^WEK_P'3)G^D/(@_GL<|1|(FISH'100^'G|?A/X'?:>^7>?57QW\$
MUS#N_P|I^GQ>>7COBXDLCD_5^L%?S4?1901447QC_X*):9|J%OA+IWP|H_M)PV=RBMD#4H:=W!!Z?
Z@V2\$=FC8T'Q<-X9XG-X=HWD_EM^B9NT3MJ**** M_5C\$***** BBB@#M/V:OA=A|J+T5\$3JQKN*#_P"^(
MZ_MJB|BBB@B6""41%>HBC4#H_U2R@21Z?P2D^W_17CX5036?FV/A6YO/\$MFH_MSY0L161X&_1
HVP_P"15_6#7YIOE6YL72I?RIO|W_P#6GL%/%/%?&EA1_M110_4444 %/%/%!1110_4444 %/%/%!1110_4444 %/%/%
!1110_4444 %/%/% M% !1110_5+?1%9? IV/C_PO1(8/W>HZ5)83.HXWP2;USIE9N/9:/ONFO!/? M^"C_
//^\$X_9EU#5K>#?<^;V^4HMHYV_F?0?0)(S' _*^NX%\$S:9;Q3AYM_MZ2?(P#M|1?
C9GY9XTY"^(#;'T8*Z_10RM^(K):J_0W_@F318_@\$|^"DOPYU2|W_MZAX3N^*C#_1SV/Z_MC^C#Q7^9_BX-E#;-16-?>
M-?D6>XGZUFM6:V3LOEH;15D%/%/%>04%/%/%!1110_4444 %/%/%!1110_444 M4 %/%/%!1110_4444 %/%/%
!1110_4444 %/%/%!5#Q3XJ6,M|=)>CD0HP_(FKJ)5",DTTFGHT?CIXZ_M(:IX|:MX^UI,7>D:C-3!8!:-
RNX>QOD>Q%95237_14^X2R>\$C1: \$RPM_ML67BFS;F95X6|A^HXJLY3>YW>AKYEK^OIAS;&BEBGB6;&171U#
(ZG(8^H0_M>XIU2-G_3=:(7XG?#_"SQ^2A|:1+1+!YC?-7GEJ^D_MZ_D3_361J?PEQ+@+^+;ZNKF4)^#&BE_MF=F"/J
"23P*GK|O|_@Z9_X*76_P"S3^R|^Q5|+_\$8C|^S2XE_MTWP|N^*S%L?=-TZFW_/6;CH0M=>|P=3^XN-"&|?
W+J_D)NRN?BW_,%C_P|O_M^*X_X*)_M|^?COI=-)X6M)AHG@2&4\$>7HJJS+\$X4J9G:6X93R&N".U?+E% M%?
LE"C3PI&_*"TBK(P>H4445J_4444 %>C?LA?2L|^QVM/VHO_/?A991=^M_/%_GL31+DVT_DH\$UP1_ =BB\$DAJD->
MI>,R*!ZE?2QORIKH*_,|N/X&?|"COCO?VFEV?E;+K>=1T?:N%1'8^9\$/38_M^X?W2GK7I7X39XE|7*JC_OP_*2_)I?
XF?Q|H|_@R4EAN)L/:U^K;YNG)_C_M%O|P|^HHHK|M/X|"BBB@_HHHH_Z?X.2%;Q+1%/B/IGQ(*RXN=/G|D@+)\$)
MJWC|U|U1_0/@_XGQX_SEY5F;|8/\$:_O:G4_MV4_*M(\$|6C+|^+O^D_%-@GAN84N::99(Y%#1R(P^LI&001U|HU?S?L?
Z|H|_MUZ^BBB@8444 %/%/%!1110_4444 %/%/%!1110_4444 %/%/%!1110_4444 M4 %/%/%!1110_4444 %/%/%
!114&JZKIFA:9HP6=E9P//=-W=U_L<4\$2*6=W9B_J|H))P_P"31_MN!YW^U_ ^U=|V)/V=/\$_P"TO|_-9%IH7AG3VF_*N!-?
7|^6&TA|^|^|++(511_MTRV20H)|?|9|6^Q3_&W_-I3Q7^T|8|0|W60%&I-^A_9D3_7;UZO|NAC*_M5V%/%/%?
2DA1110_4444 /MK;YO;F_SLI=YHG"111(69V)P%_')/&* _L!_X_M(|?L00_1\$ _/^-?G@3X|:C8)#XDDL?|8|;H&7UB|
DG0D?>|H>7;ANZ6ZFOP_M1_X-H?|_@GVW|97|?>C|6/&NAFX|\$2"0Z_JOECS^Q>HTY|R-M^MJRG|PK^HJO@>+!?
S5(X2#VUEZ1%|VOS1|!=0HHHKXDT"BBB@_HHHH_**** M"BBB@_HHHH_**** "BBB@_HHHH_**** "BBB@_HHHH_****
"BBB@_HHHH_M**** "O"?VZ_V?#|>|@O/HEGYFO^|J|HX1-Q#D6_XFR3\$97C8W15HN+|J^S7G%VDGT:1
M^+Y|P117T_%"_P|G_3X_%"_A"AZPV^O%|KW\$^EKIMM=|98?0_D|U" M#\$#|AKYX^N?XC*;<K5^4FK|
M|>+;EY2C:2IF%/%/%>B> %/%/%!1110|H|_1|O|M2^0Q9_ /XLZKMM&81>&_M17N^X|^Z6LC^HA"/,?NYV|_
NW|=K17Z^U/V&_P|O99ELO@Q|C<|G|4|0_|D3E/_MC=|U(+|917_I2^:ZG|@>|GC53I4Z_M7#?
\$%2R5HT:LGI5;:Z=H2?^%|#!,HHHK|2|/\$"BBB@_HHHH_**** "BBB@_HHHH_**** "BBB@_HHHH_**** "BBB@_HHHH_****
HHH)|B|H97^JH)9F_!ZF@!>G6Q_MP_X_00^"Z|C|87U3_@GS^QMXU\$WA:WF:W^)?C#3)_DUB5&P=,M1%|S6RL^W
ML@XE8: ?+5C+T'_|?O|X|_|Q3I^N?L_-L>-3)83>98^/2B7I=QA:L5DL
M_-D7K>5DN5:'&5C)4EV_#ZOO.'>'W|K%XI_9B_S?Z+YFR?M_ 'N7|OGXN: 7|'?#74!%X|@N8ODU/Q
%#"89^|EHK|)G_M_GL|_|/EN^X|?C*6_PD|_&GXOHA|79^P'!&#_@G|8_1\$W?V%/#7P:U:Q@^C_M+6!:_GQ
NXB&_FJ3HNZ_|O|H|<"D<^RF<8+FOJ^BBOQVO7J8EM^C4=W)W9_MNM_HHHK\$ _HHHH_**** "BBB@_HHHH_****
"BBB@_HHHH_**** "BBB@_HHH_MH_***>?VNA_P4E|=Z|_@A_86U:X<^H/3|/6?4?"Q|TJYU_ZA=ON*6=E:
M6|B>6B*JM+6(B+W-MYC;RC|YM9=Q&5#C:'|^+O_P_-;_,_M_P'"^@7PB^)|7I?O|6L>#-*|^%?
\$&J:7|)_#FO>&IKZ;X@'305FNKFZ2YC-G_M|+;YLAESY(^NVO^_@?|LWX;?1_07|D7P3^UU|*;>6VTOQ
MAI9FETVXE#RZ==QR-#(Q"1EGXEUB:Q|FDQ9)8;>=P>F5Z@_WZ*^2_P#@B3^W^8Q^"B?_M_|OPI^U;|=I
(T73O\$>N^=(;@N_/V/KQ6EM%:_C|!%&@D=W.U(U|9F))R>^M^*>|BQ_P6%_:T/IG?XX?|?|_IGX?3:
(TE|XAT>VO|3|M_40MOG_PW337ID@0(TC@VR+*TF5/T|HKSC|J+|HK10V?|X0^XB6>B3>=(
M7U6YMI|)\$>&+*4)<>=(7NCMM+*(MJS>WS/(1MAA269)|\$Y'2_"/3/B7HWPRT_M/3OC+XHL-9|61Z='_P
)%|6DV/V:TFO'_R^1\$22D(8E4#5ML5=M+Q+9)_BHHH_MH
Y#XZ_!SPW|>|AEJ?PW|2J%2|CW6ET%RUK<+S^*ON#U'=2R|":_*X@^_-\$
MOPQ|:CX"|86|MM1TRY:&XC|'=(3W5@0RGN"#7|!UW_P#|07|E|OC+X1_X_M6?X&T|?
XFT_V|EP1)|VHV@R3|_@=9\$Y9>Y|9>25Q^F>|/%:R;_&_4<3*U&J&J_MHSVOZ/9|M^M<_G?
Q|H_9<6Y_LYRZ%|7AXNZ2U4U|X^)=(M|2|:L_WMC=Q"2UNI64/*AZ_MK#@BOQIKU3F_P#;Z^*/|VI>3H%T-
1T:7=>:|>R^R7|=HSUB?|0X/&X-@_M5^5<8>_%#-12QF6VA5>KCM&7FOY9?@^MM6?
TUX4^/X:A3RKB#RJX5:1J:U_M*:Z)I9P7_@45MS*T5^IE%>>S/49RK_LLSS_PQN7UHU
M:4|5+^NG_DUU3U3T:N%/%/%.7MO_TKX<^TTEU*J_%"XK>_|_M|>=\$M&NM6UG5|FM8+>UB7JSNQ^_|U|)(R2|7|?|
+P6Q_#D+QO^V+;Z_MQ^R|^Q3=W_ACX6S;|77/\$|T&I^*8NC(|PUK9M_S SXDE7B38K-%7R_P4L_X_M*_?M=|
|3WQJ:WXQ>*/|1^65T9/#_P|T_9TTVOZA9)>|J?|_9LD9:8(U_M.P?+%?H63<_T|&U6Q_
I3Z+HO|W^"_\$RE.^P4445|80%/%/%!1110_445:T31_M-9|2ZU:>|/NE7_-J&H74=M8V-G"TDUQ-(P5(T102L_Q_@9)(
HV|7_8_ M8M^*_P#P4|_|B|_LP_"&T87NN70:4|4>\$O#|&GH0:BIFQC"1H<@9&IRB#YG_M4^P+IE_1FWX5_LA?
_PM^S?1%M#\$AX<|)Z6EG8QG|DE:EDY2-TLLC|(H8_M&7=CQC%?)^P03_."1^F_1\$R_V:O|A(OB3IEM-
16^=O%=>_KM=KG2X-MT_E1_-L>=TC+P|+|^D9^WG7Y=Q%F_JHXGV=-_NX>;_|Y?|\$UC&R^BBBOG_M"PHHHH
"BBB@_HHHH_**** "BBB@_HHHH_**** "BBB@_HHHH_**** M"N_/_AWAWXZ^*_A7JF^_LX?%#0?|WBYX@9-
10^("SZS:6K%2-WV9+JWR^2" M&9V5<*X1FRVUD3_VL%2|@_QO|_1\$|BS^UGX?^1^|7_13|HW_MP9H:2?WXZ?
>WH|9^\$K=D3QC)K|G?7L_IRD@&2|EE|E>4A"WGHI16C?|_|MP:XG24_X(8_1|M_=AO\$90".HE_X2+4L|O?
&W|_5|_LK?LGGX\$>*_^_/_O_M^_BRW|2?SOXKZQ::AXZ|OV6G&SM/+M+86MC86D|>1HK6V|^15=|O(|RS2,V9-MJ^%?
#S_@GI^U%^R3|/B=^RW^Q_X||#Z7|_B_X@U+50#6I^))>P:E|GU)<M7L%E:0Q_#J<*2%YK99)|4Q-(5(Y_
M#V<|39%X%>3_&?-6;|QG-?IU7RUK?|S7QM_9_X|E|3^Q7_,\$H_B?H|@#Q_M5X2TVSL_"OB?QKIBWL|Q=+-?
3W""&13-<;KARWDLHDF.%7@K|ZZ_P_6|^*&_MB+X4L|UOQ?2%80H?|5O9M.T^XN<*)"T45Q)&F=S|_K\$|+N&=P
/A^_@UC_Y_M0V>"/^Q_M|3_&GFZKK_B|_P_8?|7C+P7|3?@+_P08:1#|BU7(OBA_\$7P(M_AL->2W@FMKN|M+?
4_M2L_V5Q(|OB^VT75M00|12>#|Z|?W|O|HAXL|>W41|H>?&K^YX\$#_M8N,GV^|KX+_
|_|_TG00@:9:A^6^P_UN=OBL_?B_?V|X^?7P2|02|@_C_X9O|5|^&K9=^_9R|&
MV06:6/M|=G_/*A^EU*5XXH)"#Y.G(91C|7/7MOP!_>U_P:2M;^*/V\$M_CY|M_|)?
\$KP_X&T_OG8PZ|XCDU73M7T2YF:V>.*:6VMI%D@NT:"1&C_Z_MU8IV5(^"G|^R_MZ?
L6:U^S1X1|V7AG68;O3=5|&:E|EK2QU?3|F^YMEE_MCCYAC%Y3:02J2\$J"5
KE_V>OV/CEJW_1|H07_P4K_4L/#GA_6:OX16^PY_M|>#_#&NS:FEMIZ7QU&|NKBYDMK?<|EV0L:|^1L2_L=SE\$
/K&BBB@_HHHH_M^%?^"AW|^_11N?CW|M_*_XE5W+O|1:;_L_OYS>;A0/^6:D_/_X6.>C?+1|MDU^S=
196>164VG:C|SV|Q\$T<|S|R;DD1AAE8^@@@D\$&OSI_|_@_8SO_@+KC^/M?^=E+X/OY^_LVERL>(7|4QD<<<P"Z>
<%OWK|PXY6+|QORKR^+>2\$GH2R_MO^NG=;|L_QX|^&|J|KU|I^%+I#?Q+I#U^X%>H|4445_M^O|K|1110_4444
%/%/%_C2M6U70=2AUC0|2N+_|MI|O=6LS1RL_C*RD%_M3|BOJ|KX_P#|4+Q:X8C@|_
_71WURS3"#6K%52|C|JZ<)-11M;N=QKY_HKQ|_MXR#*
<^H>RQM)2MLH+T:U7|H^J9|7PIQOO/P3C/K&48AT|_%>\$O|4^H_6UU_MT;UW^%WQK^%OQGT@:S|_
O&EEJ:10TL\$4FV>#VDB;#|<(&>Y:ZFOQJ|T37=+M_:G%K2AS6+JPO(&W07=E<-%+&2564@C|^*A_A)_P4Y^/_@98M-
1?V5GXXLH_M_O<_Z|=>@TJ_JWU9&)I_-Z|)|20;GEE15(_P_LK1E|_P+^?2UEPA|W)M_|&_B^NA/_

[illegible]

Entity Registrant Name	Medtronic plc	
Entity Incorporation, State or Country Code	L2	
Entity Tax Identification Number	98-1183488	
Entity Address, Address Line One	Building Two, Parkmore Business Park West	
Entity Address, City or Town	Galway	
Entity Address, Country	IE	
Country Region	353	
City Area Code	1	
Local Phone Number	438-1700	
Title of 12(b) Security	Ordinary shares, par value \$0.0001 per share	
Trading Symbol	MDT	
Security Exchange Name	NYSE	
Entity Current Reporting Status	Yes	
Entity Interactive Data Current	Yes	
Entity Filer Category	Large Accelerated Filer	
Entity Emerging Growth Company	false	
Entity Small Business	false	
Entity Shell Company	false	
Ordinary Shares Outstanding		1,282,285,681
Entity Central Index Key	0001613103	
Current Fiscal Year End Date	--04-25	
Amendment Flag	false	
Document Fiscal Period Focus	Q2	
Document Fiscal Year Focus	2025	
Entity Address, Postal Zip Code	H91 VY19	
0.250% Senior Notes due 2025		
Entity Information [Line Items]		
Title of 12(b) Security	0.250% Senior Notes due 2025	
Trading Symbol	MDT/25	
Security Exchange Name	NYSE	
0.000% Senior Notes due 2025		
Entity Information [Line Items]		
Title of 12(b) Security	0.000% Senior Notes due 2025	
Trading Symbol	MDT/25A	
Security Exchange Name	NYSE	
2.625% Senior Notes due 2025		
Entity Information [Line Items]		
Title of 12(b) Security	2.625% Senior Notes due 2025	
Trading Symbol	MDT/25B	
Security Exchange Name	NYSE	
1.125% Senior Notes due 2027		
Entity Information [Line Items]		
Title of 12(b) Security	1.125% Senior Notes due 2027	
Trading Symbol	MDT/27	
Security Exchange Name	NYSE	
0.375% Senior Notes due 2028		
Entity Information [Line Items]		
Title of 12(b) Security	0.375% Senior Notes due 2028	
Trading Symbol	MDT/28	
Security Exchange Name	NYSE	
3.000% Senior Notes due 2028		
Entity Information [Line Items]		
Title of 12(b) Security	3.000% Senior Notes due 2028	
Trading Symbol	MDT/28A	
Security Exchange Name	NYSE	
3.650% Senior Notes due 2029		
Entity Information [Line Items]		
Title of 12(b) Security	3.650% Senior Notes due 2029	
Trading Symbol	MDT/29	
Security Exchange Name	NYSE	
1.625% Senior Notes due 2031		
Entity Information [Line Items]		
Title of 12(b) Security	1.625% Senior Notes due 2031	
Trading Symbol	MDT/31	
Security Exchange Name	NYSE	
1.000% Senior Notes due 2031		
Entity Information [Line Items]		
Title of 12(b) Security	1.000% Senior Notes due 2031	
Trading Symbol	MDT/31A	
Security Exchange Name	NYSE	
3.125% Senior Notes due 2031		
Entity Information [Line Items]		
Title of 12(b) Security	3.125% Senior Notes due 2031	
Trading Symbol	MDT/31B	
Security Exchange Name	NYSE	
0.750% Senior Notes due 2032		
Entity Information [Line Items]		
Title of 12(b) Security	0.750% Senior Notes due 2032	
Trading Symbol	MDT/32	
Security Exchange Name	NYSE	
3.375% Senior Notes due 2034		
Entity Information [Line Items]		
Title of 12(b) Security	3.375% Senior Notes due 2034	
Trading Symbol	MDT/34	
Security Exchange Name	NYSE	
3.875% Senior Notes due 2036		
Entity Information [Line Items]		
Title of 12(b) Security	3.875% Senior Notes due 2036	
Trading Symbol	MDT/36	
Security Exchange Name	NYSE	
2.250% Senior Notes due 2039		
Entity Information [Line Items]		
Title of 12(b) Security	2.250% Senior Notes due 2039	
Trading Symbol	MDT/39A	
Security Exchange Name	NYSE	
1.500% Senior Notes due 2039		
Entity Information [Line Items]		
Title of 12(b) Security	1.500% Senior Notes due 2039	

Trading Symbol	MDT/39B
Security Exchange Name	NYSE
1.375% Senior Notes due 2040	
Entity Information Line Items 	
Title of 12(b) Security	1.375% Senior Notes due 2040
Trading Symbol	MDT/40A
Security Exchange Name	NYSE
4.150% Senior Notes due 2043	
Entity Information Line Items 	
Title of 12(b) Security	4.150% Senior Notes due 2043
Trading Symbol	MDT/43A
Security Exchange Name	NYSE
1.750% Senior Notes due 2049	
Entity Information Line Items 	
Title of 12(b) Security	1.750% Senior Notes due 2049
Trading Symbol	MDT/49
Security Exchange Name	NYSE
1.625% Senior Notes due 2050	
Entity Information Line Items 	
Title of 12(b) Security	1.625% Senior Notes due 2050
Trading Symbol	MDT/50
Security Exchange Name	NYSE
4.150% Senior Notes due 2053	
Entity Information Line Items 	
Title of 12(b) Security	4.150% Senior Notes due 2053
Trading Symbol	MDT/53
Security Exchange Name	NYSE

#P/[ISLNB:4S?=7H9I,<&5OR4?*Y/V/!\ "6)X MGQMG>-&'QR JM7JY @M7T3 *%?Q0R_PXR>\;3Q=5/V5/_V^? 50C)\GJJZN- M3]I_I'QK^TMXR;5=7D>ST6TD8:-HJ292W3IO;LI'I5OP&!7F-%?%?T[@L%A< MNPL,-AH*,(JR2_K? NJV]6?YR9QG&99_F57/YA5=2M4=Y2>[_ \$26R2T2LDDD M%%=%=1YH4444 %%% % !1110 45ZG\%?V- OCU3(+2CW16'N*^KOA)_ P2X^#_A-8]O^~6N7GB>[&"ULA-K: ^FU#YC8]2X![] MK7R>=<; <.Y&W"M5YIK[/,>E\^B^;1^G\(^#W'O&48U<)AO9T7_RJ^Y"W=73 ME)>>(R1\$:/HFM>(M032? #^D75]=2G\$=M9V[2R/]4\$FO7 _ ? !/[IJ3QV(Y M_P#A7XT:WDQ_I&072V^WZQRC_OBOT?&?#WP+\.M- C^<!\/"&FZ1:=XM/LTB M#^U;: 6/N:46?>\$OA_(DEK)=3D_B\$M_%A^@CB!_'T:^EJ*^/Q7'O°F+?O8IQ7: M*4?R2? XGZOE0CX7Y7%'S,> MN*]JB0\$Q&?YWBH.%;%5)]Z-.O>']>\`ZQ<>'O%& MB7FFZA:2&.ZL;^v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v;8Y[^#2,>LYOX8+S;W?1)R>B9X]^WE^UY-ID?/A1110 4444 % M%/MK:YO;F.SL[=Y9I7"111(69V)P%)&/*^POV5_\ @FII7!60%SSB**^L+[?&3MV2UE)]DOUV75H^ MOX.X&XCX[S+ZGE5'FM;FF](03ZRET\DKR?1,??@1^S!/?VAM4%MX\$/E;" M.3;=ZU>YCM(/4%]'>W^R@+<] .:'X_@#_P_\$~/@M\'\$AUGQ+9KXIUQ,,;W5(M!)GA; IE BDXK^S&N5^-^P/^\$/[1?PXU'X1?'3XC 'E'4]JZD,IP5(!KZ7+.)L;@FH5O?AY[KT?Z/\!"!,_B)HK]> MO^"O7_IL\2?V=(-3_-_"P""?D&j]- /!\$.^XU3P)+FXUG18^26MR/FOX%Y^4 M#SU&,B7YG'Y#.CQN8Y*\$LIPRL,\$TK]#P6/PN84?:4)77XKU1FTT)11178(* M***"BBB@ K]!O\ @@=@_P60UO_@FI=!\\OBWKU< !KQM?HGB2URTG]A79P MB:K"@R> %69%Y>, @,T2 GS17/B4+1QN'E1JJ\7_5_5#3:9_-?>+?,/L^BV3G_CXNFV C^ZN"[?[*GN17Y7 M>(_\$6M>+M? O/%'B34N+N_P!ON7+N_RYE6DD8Y8G\3TZ"O7/VYOVN9/CYN89X MM%(OC)X=T^GL]%56^28Y>W'OO8<^XJ>=\UXM7]-\ <,K,(I56M']J5LY=TND M?EN_-^2/Z/' +Q\$EQOQ0\ - A9WPF&;C"VTY;3J>=VK1_NI-6YF% %%% %?>GXD% M%% % !1110 5I^#?!GBCX@^)K3P=X,T2?4- 2OI1';6ENN68]R>R@#)+^')!(MI_@7P-XJ^)^7BNR\%^"M'EOM2U"81VUO\$.IZEB3PJ@9)8\ DU^EOI_)?)A# MJFGPJ'VQ7_B6^A U?6-GX^3%GE8@?Q8C)[!?D.+>+L'POA->?K2^&'_MTNT5 M][>BZM? JOA;X69KXCYGI>GA*;7M*EO\ R2'1S: ^45K+HI<_R+^PWX1^ %G! MXP\81V^K^+W3+797=#I^1RD /78R\$9/0;02#[[117\S9IFF.SG&2Q.+FY3? MW)=DNB79'^B7#G#62])Y5#+LK HJG2CVW;ZRD]Y2? 5OTV204445YYIH4444 % M%% % !1110 4444 %%% % !1110 4444 %%% % !1110 5^5W '!;'_@W-/[:5 MIJO[2W]&^D;:X5^+6'NM5T1-MOIOBU^2V_HMM>;>1-PDC\$N"WFK^J-%=6#Q MN)P%=5,K\ \^3A-)G\._Q ^"WCCX4^-]4^&WQ+)W^A: HEI]9ZOH^J6S MOW%LAPT;HP!4@UCU_4__P %NO\ @AU/-\ @IM/YOBC\+ [73_#OQIT.RQH MVO,@CAUV)!MA?\$#D=HYCEHC@\$;[0? \$?A M_4))+6='U&'9:-SH<,C#]01D\$\$\$\$@U^IY1F]#-: '- '2:W7;S7D92BTS"HHH MKUR0HHHH ***** +_ (6/4>(_ _B;3O&G@_6[K3-6TB^BO=+U*RF,6- j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l;W_@G'l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

W= T [J21R1[R:H445_8<(1P48JR6B\HJM617JR5>4FVVJWJV% M%9A1110 5]+
\\S/@ORR7SY\KZ[%#/L,(60 MFFOU. 8T^#X^"W[NA^&[NU\O4;V+^T=7!&&^T3 -M/NB;(^ 5\!XCYV\HX M?
E2INU2M[B]/M/[M/62/W'P X.CQ3QU#SUXWHX1>UEV<[VIQ_P# O>\U!H]2 MHHHK^9C_ \$3"BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "MBBB@ HHHH **** "BBB@ HHHH ****
/YAO^#GG])@"/D7]O27XX^!M#%MX, M^,D;:M.@=9/+.#M%?R>5^J\X]XW+4 MI/WH>Z T?W?
BC&:LPHHHKWR0HHHH *N^/\$.M>\$?S-AXK-:E+9ZCIE[%=Z? M>0-AX)XW#I(I[%64\$>XJE10TF@/[4?
V_P!HW2/VN_V2_AW^TOHPC1/&?A*S MU*Y@B.5M[IXP+B#_ +9S"2,^Z5Z?7Y1_\&C'[2TGQ1_8\$2_L[:M?>9>_"_Q
ME])BB+9/K3=1#7,0QVS]JY7XQF6%IX^I12]NWINOP-T[!H***XA MA1110 4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 % M%%% !1110 5(\ 16+QR^H \$GPUV(9LQ:7I#WLJJ>/,GDVX/N%A!_X'[U]
MW5J_%G]F\ 9O\ VR/BMXA\2^?VH]/N_\$>GW9TS7-+T?5;+4ETNYMAY\$EO M)#\$XDAD1D8/&[;E?
<#CH/L>!B7:RVLC?0!9%S]6%>9^+/V%/VJO"&Y[OX2WEY\$O2729XKK%WB'DUWBLK66[CIS2_[>AS+\3R.BM/
MQ'X*9>#I_LOB[PEJ]>E29QY>I6\$D#9],.HK,KZ"\$X5(\\T'==T?#5J;#;U'3J MQ<9+=-6:~3"BBBJ,ST?JDGX7I\7OVA?
#7@^([M,_LA? "[U%2,J;>\$&5U;V;:\$ M^KBOU9KXF_X)+_#Y9M7\5_%*ZM_>"/>"2!0CNYV;0\$A_[ZK[9K^?
K\E[^+G*5^O)\D5]ZE)?X@ MHHHKV/Z#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@
HHHH **** "BBB@ HHHH **** &RQ13Q-!/&KHZE71UR&[Z@CN*_C=X* MC?LL'JB[@H#5/V<[73S;:9H?
BN>7P]MP!I=R!=60![XMYHE]=3Z5_97 M\ _?_>+?LT6OACXJ?"S[K'1;:OBWP =>'M;:>-
,+JHL9%E@D8J]W>*Z=!_LV MH]*^IX2Q7L5CPB*"23] #7\ M1GQ?>)>K?%?XR^*/C%>S21WWB7Q/>ZS-
(('=9;BX>79-H?PI\07MLP.#YT>G3M&![EPH_&OXOJ^X,I+DK5/1?F
M9U#Z\$^#/_!6+@_I7^S_%3:7++Z*VG2V:GW;,:2OS M)HKZJMEF7XC^)>2B_DK_?N1=H_>SX0?\ !Y+)-<5-
*_:2_8>US3K=D"W5YXO M\36^I"7U(MKJ*V"CV,K?6O?O \ P7!_X-?VEUCA;:S8^#M1NCC[XM]#7
M%A+D_P!\ZLTDA7ZF85_K17#'(,)1ES8:!OC-\$[_!7_@J]_P_%/V>)>A^\$'[:7Q&TJUM>3IDGB>>ZLDQTQ;7 M#/#_
..5W4J_%V" W'X'N2[5\$]B[L/_LT/&O#'-KNKEL/O3_
75_V=/@W"17=E<:E+J5Q=WTVGNS1,S\$*FTNJ_Z NTCSD#G(I]Z3 MK@/V4+_XD:K^RY\]-J6^,?B%]6]77?
/@2)_%.IO;10FZU%[.]:KF7RXE5\$W2ES MM50!G KOZ_)LQQ>(Q^/JXBN[SE)MM;7OT\NQ^A9+E&R#*:&78.-
J5&*C%- MW=DK:OJWNWU84445Q'IA1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444
%% %% !1110 4444 %%%% !7YP_\3WP#_X7#_P2CUG
MQU9V7FWOPW\6:9X@B*+_DO(UA,!_LA+WS&'I'GM7Z/5XE_P4I^%W_"ZO^"?
M'QK^%>=MYL^K_"_6X[%_9_TI;*5X#CVE5#^%=F75GA]?2J=I+[KZ_@)J]Z/XS M****_:# ****
"BBB@ "QI&K:AH.K6NN:3=-!>V5PD]M,G6.1&#*P]P0#7]N_ MPD>6GQ4^%/ACXGV"J(/\$GAZR2\$(<@)<0)*,>V"%?
Q 5_87_P \$OBN,Z5Z%&4;7WK_(!=/<^E M;**** -0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M **** "BBB@ HHHH ^1_ ^"/VB7F?_P2'^.VK0R;3-X)%B3GM&;8J]>A#ZK;+C]:SJRY*4I=DP/[+_.TM
MM/M(K"R@6*&"-8XHT& B@8 'L *DHHK_.@**** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** M"HKZRM-3LIM.O[=98+B)HYHG&OZ_,%3[\$\$BI:* /X=OB#X9?P5X]UOP;
(&#: M3J]S9,&ZYBE9.? \OFLBO6_V_/#T7A']NWXU^\$X -FE_%OQ):CIB/5+A!_Z M#7DE?N%*?/2C+NDSG"BBBM
"BBB@ K^K3_@VL\3R^)?^",OPC6XDWRZ=)KMD MYSV36KXH/P1D'X5_*77]0? P:LZC+??A\$C-
MI&R+/QKKD*#T!N!)-S7RO M%;Y7%]I+|F7#<_1VBBBOS4U"BBB@ HHHH **** "BBB@ HHHH **** "BBB M@
HHHH **** "BBB@ HHHH **** "BBB@ #X\$ _P"#G%93_P \$9_B<8^@U/P^7 M^GJLV?\ 7%?RM5_5U_P
M#W_P2_QO\HF4]PHHHKZL@**** "O=/^"7KQ1_\
!2][GAYSA1%\UZM^PCX@3PE^W#\&O%4C!5TSXK>;MF/81ZG;O_2L<2G+ #S7D_R];G M]I5%??B)T!1110 4444
%% %% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
QF_P#!3(8_X*0?M!#_ M *K=XK_]/%U7B->I_MS^AXU_9^,7C(/N&K?%/Q#>AAW\W4KA_ ^/5Y97[=
MADUAX)JE^1SL****V **** "OZ=O^#42.5/^"35DTAX?XA:T4^F81_&OYB: M_J_-X-
:M%ETO_@D!X2OI@:EXKUVY3W O7A_G\$:^7XN=LJ7^)?DRX;GZ)T44 M5^9FH4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 % M% !1110 4444 ?? !O^9U-PHHHK[(S"BBB@
J_X5\OWOA+Q/IOB033BYTR_AN[H37OC^,IVP-.'>5_N3_ _RX;GNM%?%?G9J%?% !1110 44 M44 %%%% !1110
4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ".B2 M(8Y\$#*PPRL,@CTK^C)C]IOX53_
K]I'X@?!*YB*X/\;:KHK*PY'V6[E@_P#9 M* _MHK^4#_@XS^"+_1_X*?%&."U\NQ\5SV7B73VVX\P7EK&T[?^!2W(_"O
ML>#:W+BZE+O&_P!S_P""1/8^J***_OS(**** "BBB@ #^E\ (-+_CW\3?^ M"9MY\ [N^#7OPV=7]C%;%LE+*
[VWT3^P::>[_ZYFOU^K^_\$_=E\30""GZ?\$7_UFI:8SS1J!_P!>LUZQ/7]V/P_HWK\GXCPS MPV;U.TO>7SW_
!N;1=XA1117AE!1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444
%% %% !7YE_\7WQYB^ MG_!+F3X6VU[MO/B3XVTW23"K89K6W9M0E?\ W0]K I_ZZCUK]-* _G;_X/_OV MF4>?
M>_#_9=T?4!):?#(PE)J>IQH_W-0U*13L<>JVUM;,.!<=37M.X M9XG-Z:Z1]Y_+;:\$R=HGY!T445^LF(4444 %%%%
&[+? 6J)?%3XF^/AAH8 M)O?F06>EV8"Y/FW\$R1)QW^9Q7]N_A_0M+^Z!8^&M&@JSTZSBM;2?(P11H M\$4?@
!7E7_!|3X[X]_%;?@MX8FM/M=&[3GQ>;1,E8UTR&2^0M[&6")J MXK^N&OS_(RKZ;8>?
JWP[N+;QCI@Y*K:%DNSGL\9373?51]:?>(L3]5S6E)[-V? MST)DKQ/Y4J***_73\$**** "BBB@ #TS]C3]H[7_V0_P]JSX?_
+3'AL2M<>_"_M%5IJ4MO\$V##/&'AOXA>#])\)?>#=5BO](US3(-0 MTJ^A.4N+:-9(I%]F1E[JC7\.-?TV_\ !K1^W\$G[3\A
P3]7]G[Q3]XF\4? M]71V21\R2Z->NDL)?H@6:V '1;5_>KXWC#!.IAX8F^*^1^CV^Y_F7]ZV/T MSHHHK]-0HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH ****
"BBB@ "IKVNZ/X7T.J]2^=(2BL]/TZTDNKZ[N' MVQP0QJ7>1CV55!)/H* _C'_W_:>U+|LW]LSXD?M/:BTNSQ?
XJN;O38I_OP6" MMY5G"?>.VCA3_@?T7_\-G;[\?]W_!.'5?AAX:U@0>* _C!_AG3(T?\$B:<
M5#E,IW7R^+CXF_5^*G[3NHV.Z#PEX2MMITZ21>/M.H3^+[_M+^9% M3Z?WK^@ZOSM_P"#7_9D_X9_\
^"5WA[QK]FG>1JWQ/UR\3WF]G%NS" U MM%S_'3!];*H_P'FY]37Z)5^2<08GZUFU22V3LOEI^=S:*M\$****[8H****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "LSQIX0_\$+P=JW@'Q?
IB7NDZYID^GZI9R_=GMYHVCDC/LR_P_&M.BF

'L'!O[9 Q1_8 _F\+ M?M0 ">?>Z!>8U'2WE*PZK82?+<6'/%6F)=V4A(\R!ONR6J@G9+%(C=<.\C#GK7\3M?I/ M_P
&[O P6/;_@GO\&_9]^\B%U^#_CS44^UW\A*>M38!\$U #M"X"l..R
MJD@_U95_F.),G>/H>WI+Y\5V]5T^XN\$K_IYHJ.UNK6^M8[VRN8YH9HP\, MT3AE=2,A@1P01R"*DK\R-0HHHH
**** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
B+XY_& M'Q!|HWAGPMI#H 6*J]^6WDO-]?^',IROH%?%?%?5\$!1110 4444 M !P!DGH!7!)O%S2Q MYBG>*3-E9-
V/G7"@E#JZ*&;TK^K*OA.+>FXX2#VJZ7Z+J?N-(+J%?%?%?#&@ M4444 %?%?%? !1110 4444 %?%?%? !1110 4444
%?%?%? !1110 4444 %?%?%? !1 M110 4444 %?%?%? !1110 5\A?%NO^="MO_P4@_82\0?"_P .:=\$_CCPX3KWP M_G8
,=0A1LVNXJ%N(C)#R0H=XW.?+%?7M%;8>O4PU>-6F[.+N@>I_#?V%I M=I-IFIV)U.&5E/*D\$\$\$D\$5%7ZO?'\2/_
2]D_9E_.3 M]M_X2^'S'X&^*6HO_P)%?%;18CTKQ\$07ESCHETJ\O.^ IJMQT!05^4-?L>!Q ME+X'6-
>S_!J5\C]JS"BBBNL04444 %?%?%? '[>_&W7_7:MO"JZ)_P3I_ ; M(8[-/9TLOA9XRU.?
Y;4DXCTBYD8\1DX%O(3\I(B)V^6%>_OX7P2#D&OW: MX("'_\$]I>VNB?L/?% O'EW2>78^
B9JUS\LR\+8:C*QX<+!'!S.#^Z4F;O&?RMO M@OI_P #VE_FTUKJBGJA'QC'=2.1%>R\9^/M-F#1>'
665RS.Q.2Q)Y))YS7V_#O#[FUBL2M-XQ M?7S?EV77?;?4NB&4445]Z9A1110 4444 %.AAFN9DM(>)I)&"HB+DL2<
M#J;7ZB?\&Q' !+UOVO/VHS^UM\5O#YE^'OPGU"*>RCN(LQ:OX@ \$EO!SPR6 MXVW\$@_O>OI!61JY<;BZ6!PLJ]39?
CV7S&E=G[\$?&\$&_<^@_X)S_+^6C^%_ M&.D+!0/&S)X@>LZ?O+>XDC AL2>N+>+:A&2/-:9AP]?E%?
CF)Q%3%5Y5 MJCUD[FZT"BBBL "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@#SC]K?JEKX4_MI?LZ^*OV M9_C3I/VK0/%6FM;3.@FVDP(:&ZA)X66*14D0]-R#
(O)!_C]_8_9 ^*_P"P MC^TSXI_9A^_E@4U7PY?%+>^CC*PZG9M\T%Y#GK'+&58=U)*MAE8#^TNOSY_X
M.!/^"1%I_P %)/V9!1110 4444 %?%?%? 'ZY?%3/^ M#DSQ9^RQ;Z1^RQ^W=JFH>(OAO#LM?
#_C7#W&H^&8^6*8^+L?!"W75\0>!KVZ\$NO?#O79W-A=\$X2P,_,M M:7!'FQC(POF)(%)UEG/#-/%MUL+[L^JZ/_
"?X\2XSMHS^NVBOE;_ (O M_P#!8C]C+_@IGX8B'P\;KI/C*&UW6\AYX@D2'5+0@?T:YVW<(/_+6(L "
MN\1L=H^J_:./!"MAJCIU8N,ET9K>X4445D 4444 %?%?%? !1110 4444 %?%?%? M !1110 4444 %?%?%?.\
P4&_X*J_L;_\\$U?!\1U_]H?XC1G7;FV:71/\&BE;C M5]3Z@%(=P\N,D\$>=*4C!!&XMA3I1HU<145.G%MOH@V/H#Q-
XF-^" #U[XN\ M8>(+2M*TVU>YU'4]2ND@M[6%?%+))Y"HB@\$EB0 !S7X(?%L/^#F;5/B!;
MZQ^RG_P3E\17>F^') IJXD^*4!&ZU1>5>#3NC00'D&X.)'Z(\$4;Y/B_@JA M_P %Q?VLO^"GVM3>%=?OCX-
^&4%UYFE_#W1+MC%+M.4EOIL*;R48!&OL:\$ I M&IRQ^+^*_0,FX8AAFJV+UETCT7KW?
X>IE*=[*S,S%F))R2>)]117V! 4444 M %?%?%? !114EK:W5]=1V5E;23332!(88D+,[X\$X"@DDG@ 4 >B?LB_LK_!8
M;5_*!+?LS_!71S=Z]XHU>;>.1U/DV4(^:ZF('RQ11AI/7"D \$D _" _L5 M_LB?"G]A7]F?PM^S#\'+#9I'AJP\$'P ?XW?&
[PXD?Q@^(C&^K13(#)X>TPD21::I_AD)"R
M3X_C")SY(9OT=K\QXDS=8_\$>QI/JW#7WJ)%LOOZFL(V04445\R6%?%?%? !111 M0 4444 %?%?%? !1110 4444 %?%?%?
!1110 4444 %?%?%? !1110 4444 %?%?%? M!1110 4444 %?%?%? !1110 4444 ?AW_P"&YA>VN85DCD4K)&Z@JRD
M8((/4&OYRO\ @X;_.#"UU^R/X@U'J]M;J]D(PC))\+=5NS+XK\6\$);_A\$KJ1 MO];&HZ6,C'CM"QV<(R!?
O>&L]4DL'B'K]E_H_P\N\&XM95.5 MDCDC(9&!Y#*017ZV_P#!.3_@[#^/WP4AL/AE^WMX2G^7)7AV;\$_GC+2?
+AUZU MC^&94.V&^P !EC%(>6:20\5^0=0=<>-R_"9A3Y7\+^?5>C&FUL?V;_L>?%\%O MV-OV)/" "?3LM_'?1?
\$CQP2B_T59C]J=@#(Q).4+-&,G&KL8CY68I:'K&GS"6PU;1Z2VN;0='CEC(9&]P0:_1_ M8R_X.GO^"B7I-
\5GX7^_3:3\80#UN%1E\39M=76,=DOX5RYZY>>.9CZU\5CN M\$*\&Y86?,NST?W[\^"U=-3^F^BOS9_95_P"#IO\ X)C_-
!]CM])^+&N:_P#" M?6I0%>#Q;IK3V+2'LEY:"100^W,L(X/MG[Z^\$?QX^""Q^V+XM^!GQ@>,= M,8 _;"^NV]_\$.]
6A=@#['FOE\3@<9@W:M3\$=*0\$MJ7B;6X+^" 8Y/[R=U M7]:^#/VI_P#@Z%_X)=?
L]17.E_#OQMK/Q4UN'*K9>"+=86@?MOO+GRXBG^U# MYWT-=6&P6+Q;M1@Y>BT^_83:1^C%>3_M8?MS?
LE_L/>#?^\$Y_:E^_FA>\$K5X MV>SM+VYWWM]CJ+>UC#37!]?+1L='OY_VR_#^KC]O\^/Z7?AG]G/1=%^#V
M@SAD6;2@-1UAD!/!#7DZ!\XZ_%#&ZG.'Z5^?Q^<(WQ!^+^BV\>_+>QSK'B3 M7-0DWVVLZ]J4MW=7#>KRRLSL?
J:~HP"/&(J-2Q4N5=EJ_OV7XDN:Z[_ P#! M1C_@[5^*GQ%BUX#8_P#!.P+)X,TF0,"P 0/\$T?/B#X[^*GC"_ B%3?
&>J>(>=U)X&G,\IZSK5_) =75U(>KR2R\$L MY]R>U9%?%?X+L'E.6A"W=]7ZO^D9MM[A1117:(**** "BBB@ HHHH
* _<# M_@V9_P""),^KWVC?%?%?VK?"96RMV%U)?#&HPMN"/F;]J P M%B9O#O\ @WR_X(3ZC^V_XLLOVNOVJO"UO\
!_1+W=HVCW<90^,+N-N4 //V M*-AB1^DC Q+G\$A3^DRQL;+2[*3-,LXK>VMXEBM[>","(D2*,*J].% '
MKXKB7/53B\AWK]I]O)>??MMZ:0CU9+1117P!H%?%?%? !1110 4444 %?%?%? ! M1110 4444 %?%?%? !1110 4444
%?%?%? !1110 4444 %?%?%? !1110 4444 %?%?%? M%?%? !1110 4444 %?%?%? !576]!\$T;Q+HUWX=1:3;7^GW]M);7UC>P++#
<0NI5 MXY\$8%71E)!4@@@D&K5%&P'W/_!>K_@WY1_L9ZM]JO[7]'I'GANYU/X1W4S7& MO>'I8-+
<>#W8Y8XY:2QR?EDY,7W7X <_E+7]S=_86.J6,VF:G9Q7-M#9[W0B7N_%7PKT M^ (R3Z;U9[C3\$&3+!U+6HR(?
'SW)(D?W^0\2HEAL6]=E+OY/S\^O77?4; M:H_%BE='C'8X MK/X@_"OX5^*HD UEQ+HM[9W,G_H;H1#\
(J_*>BO/K93EE=WG1C]UOR'S-'I M@>\$O^#SWQ3;HL?CO_@GUIJVV/FFTGXDO;@?1)+3/_?5=K8?'FOP>DM[VJ?
ML)>)89<I;^<->1>@_B-LIZY[5^!5%<4N&LEE_RZM_V]+_?/(_?:_X/_@ M['&T]A/Q+)>GE9_&UO&,?46S>W:N,\5_
]Y]XGBB:+P/_,\$][*UE_F/(_5WXD_P#!WU_P44\3 M+):_#OX/?"OPQ"X.R8Z3?7URGT>2Z\$9_&*OF3XT?%]/^"N?
QSBFL_\$O[:GB M32+67(6V\&P6VB>6I["6QBBE/U9R?>OCVBNVCE&64'>%&W7_.XN9LU_&_Q M\>?S\$7Y?%?
Q'\:OX@U2?_7:EK>I2W=Q)_O22LS\361117H))*R\$%?%?%?, H MHHH **** "BBB@ HHHH * 4#_@A!_P
\$!_%W[>/B#3OVH?VIM#O-^'##A<^9 M86\$FZ&Y\8RHW^JB(PT=F&&))Q@O@QQG.YX_3_P#@AU_P;:Z]4/<:GI[1
M^5I/BB3J3,%'^C73'_ENH^N2?4EC'O\ZGQU^ GQD_9E^*&J?!?X^?#G5/'O MB?11O+O](U:WV2+_
'74K&PY61"R.I!5B"#7J]N5>?M]?\$T?V2?] @I' M-CX_:'4^D=S>6L3KH/BO3=L&K;[?
Q6]QM/RYY,3AXF(19"0"/JLGXEK8)* MCB/>AT?5?YKR^[L1*%]C^-RBON[_ (*A_P#! +]L?_@G%+QOX?
LFWV\$6>/[OM@6:U([R O#R/W@8[!\(U^AX;%8?%TE4HR4D^W):& M3304445N 4444 %?%?%? !1110 4444 %?%?%?
!1110 4444 %?%?%? !1110 444 M4 %?%?%? !117VE_P3&_X(7_MF?%+>=3M/%7AWPW@OX;&<"^ (B.T=8)4!PP
MLH?E>]DX(^0B(\$\$/AX.&(Q-#"TG4K248KJP2;E'X1_!_XH_'OXBZ7)/@O MX"U3Q-XEUYJ\$&EZ+H]HTT[]3A1T4
%F8X55!9B _":_H8_X(R_!M1/V\2 M9]+_&DOVX[32_&'Q*AV7.C>%5VW&D^&I>"KMGY;R[4_QXJ-N4#LJRU]I?
M\$[/^5'!(7_!SP#_P (U^S]X^SVOWMNL?B#QQK(6;5M5(P2'E BBR 1#&% MC&
2&;+^Z2K\^SCB:KCZ.&O&5]7_DOQ_(UC"VX4445F6%?%?%?"Q@_X+)? M&_PM[8_%GP]_9_
^"3'QR^+/_ASPMK\^C)X_>+6L,>FZG=VY\$=TMN91F18K@_M2P%P2I>%\^C/NZBOD3]C[_ (*U>&?
VB/VO%/P9T#X*ZQ?Z M;XO@|87\$4]RDUC:+2SL4 W BG^-/\ @I=3/@]^S9I?|2)&)" MR%64 'UQ13+>X@NX\$NK69)
(I\$#QR(P*LI&001U!%>%?M!_MN0?#?)HGP M^QG M\%/AW'X[^+?BO0;GQ!'X>N-<_LVPT71Q)!\$^IZE>"&=
[>!IF6',1P3222' 0 M_P />*%#^ /_!O'X8_%33/BGI'Q/TMO 7C#X&W3Q?%KPOJ5ZMR-'A^RFVA
MU""=%7[38SVP,T,VQ&958-&C*5'FGP(X*WV/Q19?!%?B' _I!_@_JI^RU M?X-^(Y?\$_JW=SY!(V,48@\$ ^QZ*W_:9_:%
M3X!>%M*3P]X2/B?QCXLUR'1/ O@^_&^S/J^H2!G(>9)Y%O#!'-'B4Z-^TU&+3M,EN#%IOBS30;O
M1]0;/RKI!M#\$#E/2;O.J"OG^O[C_%GA'PIX]-WG@WQXS8T[6M(U& PZAI6 MK64=S;749ZI)("KJ?0@BOS _;R_X-
3?V>OVB!+SQM^REKUS'?LQ:OZ=9P M^&T]X<X-J]A]P,P,R'1-TB-?;Y?Q=OJ6ABXK[K5?=NOQ,W!]#^:^BOL+J
MM? X(3?%)_V&I;K5O'WP(N_%'ABVW,?&7@\$/JE@ (QU>5403VRCCYIHHUYX M)KX]
((."^MH8BAB8<]2DO)W(:L%?%?%? %?%?%? !1110 4444 %?%?%? !1110 M 4444 %?%?%? !117U3^Q5_P \$6O\
@HO^WC:ZC\&OV?M0T[PW=;3_P)IXO5 MM,TH1G_EHDLJ][E?7[.DI'I65:O1P\>K)17=NP6N?*U>U_L9? \!_LJ3]O
M[QC_,(?^RW\$]4)0)#,L>I:XR"WTS3LEDT_0H".&56\^P1U9HT89#1&O MU2^_P
.OA_)O""C\VOA;X'TCPYH.F1>5IVC:%IT5I:VR?W8XHE55'T?%)Y MAQ=AZ5X86/,^T7W;O\ M0?4_+K_@FI_P</p></div>

[7]-7L-AT_XH?ML:E9.9%?QG? MMFC/B/E%Z?(<4X#WY![S!8R#S#D!J_5C3M.T_1]/@TG2+&UM+6%8K:V
 MMH@D<.:@!455 "J !P *FHKX?&8[%X^ISUY-O%Z+9&B204445R#"BBB@ MKS[I^XU^!?
 V0OV8_&OQ^1V<%MH/P_\\(7VL2V<"K\$K1VT#R+!&,!G*A% ' M+, !S7H-?,_ 4K^\$/Q)_9T;X6?LN>_%!Y?
 >\$O%WQ8TN]^*VIHH^S6GAW M2BVJ203-G(^U75I9VH4 [EGDS@ T /M2O?V.?&FNP6WPQ_:%M?#9-H!^
 MA<4<442Q0[OHJ@J# [>U?F\\ L%:GJGC?_@Y8_6U P 42.UQX7^ ^\$-#
 MT.*4_P#*O8RV=K.RIGHKRKYIY":^N/B9XW_&HOV9M8^ 7P(^ ['-U4/" MVI7\\A_XC^-KGQ)#92^%].M[>&-
 =1DB<\$W+/^J]D?>L]3[TJ\$>6_O 9(:) MOI,? !5:X X*6 !;X::GXSL?\$KX,H\$ "R1>)I+2Q^R:=-
 ;H55K2W2W0W%RUQM*LOEH^7,PJC 8: 8(^ M)(,G^-? !3_/:#\\2>&?&?Q/M--
 \\>!?!EW=03WGA_PS8Q1*#=O;O)\$+F[MGB6X>&-Y%B"HN\\L6"^C?M">!--&7[5^QLTO\\ 9MU?PKJ%I*?#\\5KK_Q&U*
 [M M^C@\\57 E+6.@P,P GMQ)%[IO2N5*];VQW+<3J@!YAX8_:#%:#XYT7]NO\\H_M2]9_M_XIWH\\(LW?
 #2UTXR:NFCR_Z076W^_A)K,\\T>D:>Z#XBTS4+1K>]T75[.3RKJPNX7YBG MB? (Y!#*ZED=6/SE_P_%'_@)\\4+
 [MO]DW]NCPAX2U;Q^X:^"7BKQ-!XYT+0
 M+&2\\OHK^6])BFHQ6L0:6Z%M+&A>.%7FV9ED1MK4_P#X)#_L]_%X9:E^T/^ MT!\\5 !VH>%X/C9\\?
 -7/6>_<"^KQ>5>6ND(B(H+XNH>MO/.(C(T+?.B^6^PV5 M4 ^R:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
 HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
 3@_:=EN=9^'.[FB#7[K]?Q7X;5M+U,R') :236Q3[0P_Z;"0 M>U?3U%:T:]#SYZ4G%[T!N?A9^U' P9P7 EN=:_8O\\
 VLT*)MO#OQ*TX@K MW - 9H<^G_\\L/J:_/3]HO_@G_P5>_9HEN)_%[(NO\\ B^3H,E=7\\[-AD0 M=7\\NT+S(O_72-
 "!SC%?UO45]#A>*\\TH:3M->:U^J6_&Y#@C^&OQ!X=\\0>\$]8 MG\\>*= "O-,O[5]ES8ZA:O#-"WHR. RGVJG7]NGQ5^
 GP,^_NE_V);?@SX4 M\\8V>PH+3Q3X>MM0C"GJ-LZ,\\7RA\\7O\\ @W6_X) ?&%YKR_9^LO#JY*21=^\$ M-?
 [L\$4P@\\XQFO)X#)+\\/^"@ MA= \\Q6^M?#IX-OL9(KZ3/UV#Z5Z5/B?)I[U&O5/]\$Q^P7>J7..O\\ M?
 LHL]OS/IR//H#2WL6/KM/TKVSX<_P#!G7^Q%HICE^*?[3/Q.U]TP632/[TV)SZ\$!/. MV/HP/O7-
 4XGR:&U2_HG^J0+O\$E>[\\?WH#M,N? M^_5?6/PA_9J_9U_9]L1IGP(^ W@WP9 \$V/PMX9M; ,/?R(UW>Y.
 <[Z\\VMQE MA_PJ;?K9?YCY&?RC?L[?\\?/^?J7[3DEO/X!_8Y\\4Z9I]P01J_C*!=\$MA&? M^6@-Z8VE7_KFKD[@:_0C]E[
 (,XO&VH2VVL_ME M8?:IL^#7/A_XUS,P M\\V\\V[5%C8=\\6@ST) Y_>>BO#Q/%>9U]*=H+R5W]
 [O^2*4\$CY*_9%_X(<_\\ M\$ROV+\\K76_A?^S3I>K^(+7#)X\\:L=7OA.(DB&?_5N_O!'"^M?6H P!117S
 MU;\$53/FJRF45^-/_9 M3^S/_P!&9^_O !_9?X4?\\1E/L,_ \$9GXZ_\\]E A7L?ZO9S_P ^7]Z_S)YH MG[+45_\\\$G?
 ^"X_PJ_X*P_ \$+Q;\\?2A\\[\\#/\$A*PGHT&HW%QK.HP3K<+)+Y M011R"#SS7W)7F8G#5\\)6=*M&TET&FF%%>(?
 '\$_@I\\ L&?"KQYJ7PU^ (7\\5 M?@[2]7T.X6W\\0)<:H#!HTS8Q%>W"@PV3X(\\V=T(!Q@UVEA^U!^SKJGPNOC M?I?
 Q\\W,\\@VRN;BWN0%=OJ\\3Z=&\\#;DV;A28\\(R,&.;T%3SQ6 SNZ*\\&TG_@ MJ5_P3U^Q&IZ%~W?
 \\)KVV8D"XM/MC(AZCB_S\\H_\\G_\\J\\WPKE=^? MVVO\$2.1[=Y(695D5)8V*\$Y D4XY% ':444 M4 %%%
 !117RIX@_X*J?#_P_KU[H,WPIUB1[*[DMWD6]B 8HQ4D?7%>ME619 MMGM?^!T-=%)?\\ @I/X(^+7Q(T?X;Z=\\-
 =5M)]8NQ;QW,UW_M\$R1D@G) Y/2O5K<#\\58>C*K4PK48IMN\\=\$M7]H^:PGC)X:8[%4]-OS&,ISDH
 MQ7+4UE)V2UA;5L^E*****4/TT**POA[\\3A]6-\$N?&?PV\\86&MV%GK%]I5U M:=<"1(KVRN9+6Z@8CH\\
 <\\,D;#U4]L&MV@_HKQ^6_P#@I#^POH/BO4_!=Q^T MUX9NK[0[AH-? LFX>^@TB5?
 O1WD]LKQ6C*.669T*]5TUI^V)^REJ'_@_6/B) MIG1[?@RI\\>^XX)-\\06?B*WFL;))H?.B:2X1C&H:~+X#NQM(;H0:
 /2**X\\ MX?M#? ;IJKP6WQ_9U^,OACQUX?2]DLWUKPEKD&H6JW"!6>\$RP,RAU#H2N< M@,I[BMWQMXW\\?#7P?
 JGQ^? (BK3]#T^1+"6^UG6=6O\$M[6QMHD+R32RN0L: M^H+%F() - &117\$ _\\I3]GW]IGP)XP_9W^-AGQQB];
 [\\U7PKK,-];LL M17S869"058\$ \\\$&NVH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@
 HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KY1_X+E?\\
 *)X?\\ 8BR_M^C8J^KJ^4?\\ @N5_RB1^/_8BR_^C8JZ!_OU+_%'\\T)[^AM%%?M)@?LM_MP9K?\\G;?&;_L1;#_ -
 +37[_Z_::G?Z%>V.BZD+\\FM)([2\\,8?R)2I^R;3UV MD@X[XK_/_^#-;_DYCX\$?B+8?^EIK]?
 \$FHSZ1X=O]6M54RVME+-&'&065"P MS[9%?EG%'_(Ygz1_)&L/A/QK_P""/_!4WX/_P#!.3PJW_!^K_@K!X%E^\$/Q
 M%T#7-4+>-?%\$!?!1/&POKV>=KZ>\\<8W2^:R :)2894C4F56_ =C]_V2?V5_A; M^R5^S;K/PB^#B;:_ ,G;?
 Z[KVO>'K/2U!M+;SU.ZFO5MXL\$J8D\\JFWY=@4# MBO_!OQ("P""6'_!>+_@GQH/C+JH]?
 A_XBM)O#45UXIL=0U.*TU^P5J9@7[4 M]KE9UGL&20-B3<%DC"MEXVY\\P_P"#/_ OQO\\ VE/"?
 AC6;+Q3KMS=:9J^J+U%/'\$UTSJY0X^C\\UK) _V' M_%WP(^-OPOU\\KJG\\GW2/LVC_!@UV7Q!+=*NT:FT*)ID-
 \\L*J4::VL+9R&&X M< Y)KX\$ _P"#4K]H7X!>!--_ @C[X:*^-?C?X0T?4[3QGKOVG3M5\\2VMO/%N MNMZ[HY)
 PRK*PR.00:<^Z?V/_ -H+JFKQ_P"+O%_\\W/[=YI6M>\$_AQ*AUCQ! MX?U1+G3;?
 5M0N+F[DTNW:,,CM^K"20*VV\$7\$8!.1@_O-%%% !1110 5^// MQ(_Y*)K_/_V&KK_TG?L8_G2>?"\\ L+_ M
 .@M7Z_GG_(EQ\\ U[G_ .DL E7@S_DL,N Z_P!_P!_1/U2KQS]O7X]^*V M>?V9-<\\3_#_UBNO^6NSVWAKX;Z?,,K=>
 (M2F6SL PPQS+BSTY+P\\G#ZJ@W!HV_\\CL_U@/GW_@BEIOBK_@F)_P_?'C?_P_\$8/BG
 MX]U7=>)UJV@^\\)WP@\\0ZW)^_U:"X1(M24D>D\\Q1P/XK2Y?G<37= _\\'+[6/Q M=^\$O[/PQ_8[^7C&[\\-^*?
 VD\\B5>#)\\\$5C(4GL+>=XTN_*92"CNUQ?Q\$CG MRY)O_@CQS_@NW^SQK?_3KN_@M_P
 A6A_!/[OOCQCXJ]^#Q^L;+5K+QOKE MI+J^AZI+O7=G;F*WA8L^XQE3NPEQ* &TYI)_P""\\OP-\\3?\\%_V(?@_P_%
 M!_V_&A^(.M?!!OQA8?\$PKI^B/YI:YI9\$Z MN@JX4"XC-N74#F1)7)D.,[IDO\\ X*:?L4?MF !:P^-?PC^/WAE::Q6;6M%
 MU76H+74=\\F'FVU\\;R.'@DC;*G<-IQN4LI5CV7@3]I^P)\\5/#7B;XA^&+J ^ M =%M";/Q[=JFGZML21KF:V<@+):1
 1@708QR,90A(BW, ?CE_P0 UW5_P#@ MF^U\\+OV7_%FISI\\,VQO@/X<\\= _#^ZNY28K3Q=#I4)U&T#-
 @!IOWK\$>C6* M#)-??:P7JUG5_CA^S_.)OV^O!^I3P6[GPI_1_\$7XG75I(5:VT^1.62QM M2PP5-[JRV]8S\\%E>C! -
 ?/[O_!^N?M4_&V/[.7I0_P\$S;JBM\\5/V>?AC MX6<_#_5M*823Q76F:?!]OM

(B8J2DY25EI>8F9JBHZ2EIJ>H MJ;JRL[2UMK>XN;K"P\3%QL?(R;GZ.GJ)?+SI/7V M]_CY^O_\$!\;! 0\$! 0\$! 0\$!
@,\$!08"" D*"__\$ +41 (! M @0\$ P0'!00\$ \$"=P ! @,1! 4A,08205\$'87\$3(C*!"!1"D:&QP0DC,U+P M%6)RT0H6)#3A)?
\$7&!D:)BH*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZB9FJ*SM+6V MM[BYNL+Q,7&Q(C)RM+3U-
76UJC9VN+CY.7FY^CIZO+SJ/7V]_CY^O_: P# M 0 "\$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M*
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN:~-'Q\$ _P"%0 !WQ9!6?[_ +1_MX1?PS?
ZO_9_VCR?M/V>W>;RM^UMF9MW;6QG.#TIQBY226[Z6BOPO\ (TG M_K&Q_P'9C_\
O/1_Q&D_J8V/_Q_>>O<_U:SO\ Y]?^31_S)YXG[H45^%_ M !&D_P#6-C_S,? \YZ/^(TG_K&Q_P'9C_\ O/1_JUG?/_K_
,FC_F'/\$ _=" MBOPO_P"(TG_K&Q_YF\ ^\]'_ \$:3_P!8V\ S,? _YZ/[6L_ Y]?^31_P P MYXG[H45^%_\
Q&D_J8V/_Q_>>C_B-) _P'L;_ 'F8_\ [ST?ZM9W_P ^O_)H M_P'8<[3]T** _ _\ XC2?^L;_ 'F8_O/1_P 1I\ UC8_'S'_
>>C_5K._\ MGU_Y-'_>.)^Z?%?'O\ P1O _.'L'_#VKX.>+/BS_P *_X5_P#\ (OXF72/[M/_X2G^U?
M.ZWCFWS/LMOL^ _MV[6Z9SSBOL*O(Q&'K86LZ556DMU_P ,4G<* M***Q **** "BBB@ HHHH **** "BBB@
HHKR[JM/I+ _ (9_9=8_M)_P#" M&? \ "1\ (GIR77]B_P !H_9/M6Z:.;+YWER;/OYSL;IC':ZL#@L3F.-I83#Q
MYJ24815TKRDTDKM^:U;2[LBK4A1IR]3=DDV_1J'-%?CO_ ,18W_5@W_F4_M_P#[UT?18W_ %8-_P'93_\ O77ZI_Q
?Q7_ _A= _P'5J'_RT+> *_IR'_G] M_P'2R_\ D3]B** _?B+&ZL&_\ ,I_ 'KH_P'(L;_JP;_ S?; _JZZ/^(#^ M*_ T+O_
"M0_P#EH?ZTY#_S^ _)9? _") ^Q?%?CO\ 18W_5@W_F4_ O71_M_P 18W_5@W_F4_\ [UT?18W_5@W_F4_\ H7?^5J'_ ,M#_6G(?
^?W_DLO_D3]B** _M'? \ XBQO^K\O_I_>NC_B+&_P'K\O\ S*? _ZZ/^(#^*_ \$+O_*U#_P'6_MA_K3D\ S^ _EE_ \B?
L117X[_P#6-_U8-_YE\ ^]= _\$6-_P!6#? \ F4_ _M +UT?18W_5@W_F4_ ^A= _Y6H? _"T/[_ M6XW)\QJX'&OY:M*3C)73M*+LU=-
IV?5-H]NC6IXBC&K3=XR5T_)A1117":A1 M110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444
%% %M% !1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 M %%% %!1110 4444 %%% %
!1110 4444 %%% %!1110 4444 %%% %!1110 M4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444
%% %!1 M110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %M% !1110 4444 %%% %
!1110 4444 %%% %!1110 4444 %%% %!1110 4444 M %%% %!17FGI:'_)G?Q8_]IKO IOGKTNO-/VT\ DSOXL?_ 9--
= _P#3?/6M M#^/_U7YB>Q_ %51117[>8!1110 4444 %%% %!1110!_0Y_P9P?)_G7Q8_[* M9%_Z;X*_82OQ[_X,X\
DSKXL?_ 93(O_3?17["5^2<0? \CBMZK\D;1^\$X/] MJ\ Y-N\ = _8IW_/_Z(>OR;K]9/VH_ ^3;O'?_8IW_/_Z(>OR;K]C(?
^17B M?;_)]/XC^E1_P E+E _%YE_P"EL****_7#^60HHHH **** "BBB@ K]#/_^ M"5W_ _;??_ 8VW7_HBVK\Z_OS_
(?)?FWW_\ V-MU_P"B+>OSKQ1_Y)5_MXX_J?OOT;? \ DY%_\ L8]9_P#2QZ^Y MJ^&?^#+= _E%UX7_[&6?
_2QZ^YJ_R_\ \$O\ Y.%FO_815_\ 2V?MN3? \BFA_M@C^2,+XD:SJ6@># [K5)-N?*GC:;))L#8RZ@ \, ".AKS#_
(6Y\0_ ^A@ _\E(?_ M (BO1OC!_P_D_O?) ^+_T8M>*U\>F=) _PMSXA_\ 0P?^2D/_ ,11_P +<^(?_M_0P?^2D/_ P 17-T4
=) _PMSXA_\ 0P?^2D/_ ,11_P +<^(?_0P?^2D/_ P 17-T4 =) _PMSXA_\ 0P?^2D/_ ,11_P +<^(?_0P?^2D/_ P 17-T4
=) _PMSX_MA_\ 0P?^2D/_ ,11_P +<^(?_0P?^2D/_ P 17-T4 =) _PMSXA_\ 0P?^2D/_ M ,17]P^U;4-
<[\V6J:I<>;/*KF238%SAV_X_Z_5X17M_P_H_P"2?Z=_N2?^ MC&H_Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **S/ M&GC#PYV\ /VK> \ QAJ/V/2-#TR?4-4N_)>3R+>:&-
I)7VH"S816.%)Q@_ GB_MOBK_ (B4_P#@BE_T>C_YCGQ)_P#*ZNBCA,5B4W1IRE;LF_R%=(^Z**^%_P#B
M)3_X(I?]'H_ ^8Y\2? *_ZC_B)3_X(I? \1Z/_)CGQ)_KJW_ ++S/_GQ/_P& M7^071]T45+_/_/2G_P12_Z/1_\ ,
<^)/_E=1_Q\$!_ \!%+ _*/1_P#,<^)/_ M_E=1_9>9_P#B/?_X#+ _""Z/NBBOA?_ (B4_P#@BE_T>C_YCGQ)_P#*ZC_B
M)3_X(I?]'H_ ^8Y\2? *_ZC_R\ S_Y3_\ 9Y!='W117PO_Q\$!_ \!%+ _*/1_M_P#,<^)/_ E=1_P_1?*_ P12_Z/1_\ Q\$XD_\
E=1_9>9_\ ^ _R_R"Z/NBBO_MA? \XB4_ ^""7_1Z/_F.?G_RNKZ'_8W_ &^?V2_ ^"@@[50'_P"R_-5_ ^\$MT
MC0]3&GZI=_V%?V'D7)C60)MO8(6;Y&4Y4\$SA*=KVORQ;M>SM>V]GZ'>45^+]%?LG_ '\$? \J_ _I? \ W0_DO_B;#_J3_M?
^7'_P!P/V@HK\7Z^ \B#O_ %'?^4O_ +H'_ \$V'_4F_ \N/_ +@?M!17XOT4_M? \0=_P"H[_RE_P#=_XFP_ZDW_EQ_P#
<#]H**_%^BC_B#O\ U'?^4O\ [H'_ M !_A_P!2;_RX_P#N!^T?%?B_11_Q!W_J_ _*7_W0\ B;#_ *DW_EQ_]P/V
M@HKYK_X)7?)_M]_P!C;=?^B+>OI2OR;_LN_LC:_V"YN;VG)=V+ _/_V3[5NFCBV^=YG&TK)VM.<7LUJE;S/OQVNC
M_B+&_P'K\O\ S*? _ZZ/^(#^*_ \$+O_*U#_P'6A_K3D\ S^ _EE_ \B?L1_M17X[_P#6-_U8-_YE\ ^]= _\$6-_P!6#? \ F4_
+UT?18W_5@W_F4_ ^A= _Y6H? _"M_T/;6O\ 8O\ /V_R_(F
M:+=YWD_PYW8SC8,9QD];^>XF\>..# \N6.S?">RI.2BG[2E+WFFTKOG)]ZVL
M=>"SK+,QK>RP]3FE:]K26GS2[GN=5=8UG3= T]4U:YJ",@/)L+8R0!PH)Z_MFK5? \ 0P?^2DW_ ,11_P +<^'_G_0P?
M^2DW_P 17B=% 'MG_"W/AY_T,'_DI_ \11_PMSX>?]#!_P"2DW_Q%>)T4 >V M? \+<^'_G_ \$,'_DI_ _P#4? \
"W/AY_T,'_DI_ \ \$5XG10[9_PMSX>?]#!_MY*3?_ \$4?+<^'_G_0P? \DI_ \17B=% 'MG_"W/AY_P!#!_Y*3? \Q%'_MS
MX>?]#!_Y*3?_ !%>)T4 ?1&DZMI^N:?'JFEW'FP2@F.385S@D'@@]'#5BN>^ M%'_)]/_W)_ \$8U=#0 4444 %%% %
!1110 4444 %%% %!1110 5YI^VA_R M9W\6/^R::[_Z;YZ]+KS3]M#_ _],[^+_ _&337? \TWSUKO_CQ]5^8GL?Q544
M45^WF 4444 %%% %!1110 4444 ?T.?\&< _"9U\6/^RF1?^F^"OV\$K\> _^ M#._ _],Z^+_ _&4R+_TWP5^PE?
DG\$ _ (XK>J_)&T?A.#:_C_ .3;O'? _&*M_P#^B'K\FZ_63J]_DV[QW_V*= _ .B'K\FZ_8 _""_D5XG_&O_23^(_I4?)M)2Y?
_P!>9? \I;"BBBOUP_ED**** "BBB@ HHHH *_OS_@E=_P_FWW_ &-M MU_Z(MJ_/_OT_P""5W)M]_ _-C;=? \
HBVK\Z\4?^25? ^./ZG[[]&W_).7_M'_KS4_\ ;3Z4KY>_X+2_ \HNOC%_V+D/_ *66]4-?+W_6E_P'477QB_P"Q
MOQ/@G_DL[M_I"* \ZON:OAG_@W2_Y1=>%_M^QCUG_TL>ON:O\O_ !+_ .3A9K_V\$5?_ \$MG[_DW_(IH?X(DCF?
C!_R3^ _]_MWXO_ \$8M>*U[5/8/^2?WO^ _%_P"C%KQ6OASTPHHHH **** "BBB@ HHHH *)
MO^%')/_I_/_W)_/_1C5XA7M_P_H_P"2?Z=_N2?^C&H_Z&BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH ****

"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH \T;0_Y,[^+_9--= \ 3?/7/55? VJ_MH?)\ G?Q8_DIKO_
*;YZ_BJKI_@S^!6]5^3,JFX4445]J0% %%% !111 M0 4444 %?T.?&<')G7Q8_[*9%_Z;X* GCK^AS_
(,X/^3.OBQ_V4R+_P!-M%?/?<4 \B>?K\RH?\$(?L)7!_M1_\FW>._P#L4[_-\$/7>5P?[4?_)MWCO\ [%. _P#1#U^>93_R-
*^./\ MZ4CR>)^2:QO_7FI_P"D2/R;HHHK^R#_ "7" MBBB@ HHHH ****
"BBB@#]#/\^"5W_)M]_P#]C;=?^B+:OI2OFO\ X)7?FWW M_P#V-MU_Z(MJ^E* D[C/_DJL7_C9_I_X2?)\ M,J_P"O,?
U/E[_@M+_RBZ^, M7_8N0_\ I9;U_M_A7]-_ 6E_P"477QB_P"QOYD*_KSZ+_P#R1F,_ M["_.FZ9S;?<
<C&G_@_5A1117]*GQ@4444 %%% %%% !1110 5_15_P;I?HNO"_ \V,>L_P#I8]?SJU_15_P;I? \ *+KPO_V,>L_ ^ECU_/?
TE_P#DWM/_ +** M?_I%0^MX+_Y&TO_SB?*T444 %%% %%% !1110 4444 %%% %%% 'M_PH_Y)_IW^Y)_Z,:NAKGOA
M1_R3_3O]R3_T8U=#0 4444 %%% %%% !1110 4444 %%% %%% !1110 5YI^VA_P F M=%C_LFFN_ IOGKTNO-
/VT/^3._BQ_V337?_3?/6M#^/'U7YB>Q_%51117[M>8!1110 4444 %%% %%% !1110!_0Y_P9P?F=?%C_LID7_
*;X*_82OQ[_.#.#_DSKXL?JE,B_P#3?7["5^2<0?CBMZK\ D;1^\$X/IJ/_DV[QW_V*=_ .B' MK\FZ_63JJ\ Y-N)= \ 8IW_
/Z(>OR;KJC(? \ D5XG &O_\$D_B/Z5')_2 MY? \]>9?^EL**** 7#^60HHHH **** "BBB@ K]#/\^"5W_)M]_ \]C;=?
^B+_M:OSSK]#/\^"5W_)M]_P#]C;=?^B+:OSKQ1_Y)5_XX_J?OOT;?^3EQ_P"O-3_V MT^E*^7O^"TO_ "BZ^,7_<
&+D/_I9;U]0U\O?%I?^477QB_[%R'_ -++>OQ/_M@G_DL[M["*_IR)_?69?\BZM_@E^3/YD****_U1/PP**** "BBB@
HHHH * M**** /Z*O^#=#+_E%UX7_[&/6?_2QZ^YJ^&? \ @W2_Y1=>% \ L8]9_P#2QZ^Y
MJ_R_ \ 2_ ^3A9K_P!A%7_TMGI;DW_(IH?X(DCF?C!_P_D_O?]^+_T8M>*U[5\ M8\ DG][_OQ?^C%KQ6OASTPHHHH
**** "BBB@ HHHH *]O^%')/_]._W)/_ M_\$8U>(5[?*/^2?Z=_N2?^C&H_Z&BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH \T;0_Y,[^+_9--= \]-]?Q55_:K^VA_R9W\6/^R:
M:[_Z;YZ_BJKI_@S^!6]5^3,JFX4445]J0% %%% !1110 4444 %?T.? \ !G!_MR9U\6\<
LID7_IO@K^>.OZ'/^#.#_DSKXL?JE,B_J-]?/?<4_P#(GGZQ_J' MQ'["5P?[4? \ R;=X[_%_ \ _1#UWE<' ^U'
,FW>._^Q3O_/_TO]?GF4_ \ M(TH?XX_ ^E(GB? \ Y)K&_P#7FI_Z1()NBBBO[(\EPHHH **** "BBB@ H MHHH _OS_
)7?FWW_ \ V-MU_P"B+:OI2OFO_@E=_P_FWW_&-MU_Z(MJ^E M*_D[C/_Y^K*_P"-G^G_(2?\FTRK_KS')3Y>_X+2_ \<
*+KXQ? \ 8N0_ ^EO M7\ R?%?TW_/_!/:7_E%U\8O^QL_P#I8]?SW)]?_DWM/_L(I \ I%0^MX+_ .1M M+_ _SB?*T444 M
%% %%% !1110 4444 %%% %%% 'M_P */^2?Z=_N2? \ HQJZ&N>^%')/_]._W)/_ M_\$8U=#0 4444 %%% %%% !1110 4444 %%% %%%
!1110 5YI^VA_R9W\6/^R:[:Z;YZ]+KS3]M#_ _M),[^+_ &337? \ TWSUKO_CQ]5^8GL?Q54445^WF 4444 %M %%%
!1110 4444 %?T.?&<' "9U\6/^RF1?^F^"OV\$K]>_#.#_ _),Z^+_ _M &4R+_TWP5^PE?DG\$'(XK>J_)&T?A.#_ :C_<
.3;O'?_&*=_P#^B'K\FZ_6 M3JJ/_DV[QW_V*=_ .B'K\FZ_8_ '"_D5XG &O_23^(_I4?) \ 2Y?_P!>9? \ MI;"BBBOUP_ED****
"BBB@ HHHH *_OS_@E=_P_FWW_&-MU_Z(MJ_/_OT, M_P""5W_)M]_ _C;=? \ HBVK\Z4?^25?^./ZG[[J&W_
)_7'_KS4_ \ ;3Z4_MKY>_X+2_ \ HNOC%_V+D/_*66]?4-?+W_6E_P"477QB_P"QOQ/@G_M_DL[M["*_ \<
ZON:OAG_@W2_Y1=>%_ ^QCUG_TL>ON: MO\O_!+_ .3A9K_V\$5?_ \$MG;DW_(IH?X(DCF?C!_R3^_]_WXO_ \$8M>*UI
M5\8/^2?WO^_%_P"C%KQ6OASTPHHHH **** "BBB@ HHHH *]O^%')/_]._W)_ M/_1C5XA7M_PH_P"2?Z=_N2?^C&H
Z&BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH
 \T;0_Y,[^+_9--= \ 3?/7/55?VJ_MH?)\ G?Q M8_DIKO_ *;YZ_BJKI_@S^!6]5^3,JFX4445]J0% %%% !1110 4444 %?T.?<
M&<')G7Q8_[*9%_Z;X* GCK^AS_(,X/^3.OBQ_V4R+_P!-M%?/?<4 \B>?K M\RH?\$(?L)7!_M1_\FW>._P#L4[_-\$<
\$/7>5P?[4?_)MWCO\ [%. _P#1#U^> M93_R- *^./\ MZ4CR>)^2:QO_7FI_P"D2/R;HHHK^R#_ "7"BBB@ HHHH **<
M** "BBB@#]#/\^"5W_)M]_P#]C;=?^B+:OI2OFO\ X)7?FWW P#V-MU_Z(MJ M^E* D[C/_DJL7_C9_I_X2?)\<
)M,J_P"O,?U/E[_@M+_RBZ^,7_8N0_\ I9;U_M_A7]-_ 6E_P"477QB_P"QOYD*_KSZ+_P#R1F,_ M["_.FZ9S; M?<
<C&G_@_5A1117]*GQ@4444 %%% %%% !1110 5_15_P;I?HNO"_ \V,>L_P#I M8]?SJU_15_P;I? \ *+KPO_V,>L_ ^ECU_/?<
TE_P#DWM/_ +** M?_I%0^MX+_Y&MTO_SB?*T4 M44 %%% %%% !1110 4444 %%% %%%
'M_PH_Y)_IW^Y)_Z,:NAKGOA1_R3_3O]R3_T M8U=#0 4444 %%% %%% !1110 4444 %%% %%% !1110 5YI^VA_P<
F=_%C_LFFN_ MIOGKTNO-/VT/^3._BQ_V337?_3?/6M#^/'U7YB>Q_%51117[>8!1110 4444 M %%% %%%<
!1110!_0Y_P9P?F=?%C_LID7_ *;X*_82OQ[_.#.#_DSKXL?JE,B_M_P#3?7["5^2<0?<
<CBMZK\ D;1^\$X/IJ/_DV[QW_V*=_ .B'K\FZ_63JJ\ \ MY-N)= \ 8IW_/_Z(>OR;KJC(? \ D5XG &O_\$D_B/Z5')_2Y? \]>9?<
^EL* M**** 7#^60HHHH **** "BBB@ K]#/\^"5W_)M]_ \]C;=?^B+:OSSK]#/\^"5W_M_)M]_P#]C;=?<
^B+:OSKQ1_Y)5_XX_J?OOT;?^3EQ_P"O-3_VT^E*^7O^"TO_ M "BZ^,7_&+D/_I9;U]0U\O?%I?^477QB_[%R'_ -<
++>OQ/_@G_DL[M["*_M_IR)_?69?\BZM_@E^3/YD****_U1/PP**** "BBB@ HHHH **** /Z*O^#=#+_M_E%UX7_[&/6?<
_2QZ^YJ^&? \ @W2_Y1=>% \ L8]9_P#2QZ^YJ_R_ \ 2_ ^3A9K_M_P!A%7_TMGI;DW_(IH?X(DCF?C!_P<
D_O?]^+_T8M>*U[5\8\ DG][_OQ? M^C%KQ6OASTPHHHH **** "BBB@ HHHH *]O^%')/_]._W)/_ \$8U>(5[?*/^M^2?<
Z=_N2?^C&H_Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH<
**** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@<
M HHHH \T;0_Y,[^+_9--= \]-]?Q55_:K^VA_R9W\6/^R:[:Z;YZ_BJKI_ M_@S^!6]5^3,JFX4445]J0% %%% !1110 4444<
%?T.? \ !G!_R9U\6\< LID7_M_IO@K^>.OZ'/^#.#_DSKXL?JE,B_J-]?/?<4_P#(GGZQ_J'Q'["5P?[4? \ MR;=X[_%_ \<
1#UWE<' ^U' ,FW>._^Q3O_/_TO]?GF4_ \ (TH?XX_ ^E(GB MB? \ Y)K&_P#7FI_Z1()NBBBO[(\EPHHH **** "BBB@<
HHHH _OS_ (7 M?FWW_ \ V-MU_P"B+:OI2OFO_@E=_P_FWW_&-MU_Z(MJ^E*_D[C/_Y^K*_M_P"-G^G_(2?<
<\FTRK_KS')3Y>_X+2_ \ *+KXQ? \ 8N0_ ^EOO7\R?%?TW_/_!/: M7_E%U\8O^QL_P#I8]?SW)]?_DWM/_L(I \ I%0^MX+_<
.1M+_ _SB?*T444 %%% %%% !1110 M4444 %%% %%% 'M_P */^2?Z=_N2? \ HQJZ&N>^%')/_]._W)/_ \$8U=#0 4444 M %%% %%%<
!1110 4444 %%% %%% !1110 5YI^VA_R9W\6/^R:[:Z;YZ]+KS3]M#_ _M),[^+_ &337? \ TWSUKO_CQ]5^8GL?<
Q54445^WF 4444 %%% %%% !1110 44 M44 %?T.?&<' "9U\6/^RF1?^F^"OV\$K]>_#.#_ _),Z^+_ _M &4R+_TWP5^P ME?<
DG\$'(XK>J_)&T?A.#_ :C_ .3;O'?_&*=_P#^B'K\FZ_63JJ/_DV[QW_V M*=_ .B'K\FZ_8_ '"_D5XG &O_23^(_I4?) \ 2Y?<
_P!>9? \ I;"BBBOUP_ED M**** "BBB@ HHHH *_OS_@E=_P_FWW_&-MU_Z(MJ_/_OT, P""5W_)M]_ _M -C;=? \<
HBVK\Z4?^25?^./ZG[[J&W_)_7'_KS4_ \ ;3Z4_MKY>_X+2_ \ HNOC%_V+D/_*66]?4-?+W_<
6E_P"477QB_P"QOQ/@G_DL[M["*_ \ MZON:OAG_@W2_Y1=>%_ ^QCUG_TL>ON:O\O_!+_ .3A M9K_V\$5?_<
\$MG;DW_(IH?X(DCF?C!_R3^_]_WXO_ \$8M>*U[5\8/^2?WO^_%_M_P"C%KQ6OASTPHHHH **** "BBB@ HHHH<
*]O^%')/_]._W)/_1C5XA7M_PH_M_P"2?Z=_N2?^C&H_Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH<
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@<
HHHH **** "BBB@ HHHH **** "BB MB@ HHHH \T;0_Y,[^+_9--= \ 3?/7/55?VJ_MH?)\ G?Q8_DIKO_ *;Y<
MZ_BJKI_@S^!6]5^3,JFX4445]J0% %%% !1110 4444 %?T.?&<')G7Q8_[M*9%_Z;X* GCK^AS_<
(,X/^3.OBQ_V4R+_P!-M%?/?<4 \B>?K\RH?\$(?L)7!_MM1_\FW>._P#L4[_-\$/7>5P?[4?_)MWCO\ [%. _P#1#U^>93_R-<
*^./\ MZ4CR>)^2:QO_7FI_P"D2/R;HHHK^R#_ "7"BBB@ HHHH **** "BBB@#]#/\^"5W_)M]_P#]C;=?<
^B+:OI2OFO\ X)7?FWW_P#V-MU_Z(MJ^E*_D[C/_DJL M7_C9_I_X2?)\ M,J_P"O,?U/E[_@M+_RBZ^,7_8N0_\<
I9;U_M_A7]-_ 6E M_P"477QB_P"QOYD*_KSZ+_P#R1F,_ M["_.FZ9S;?<C&G_@_5A11 M17]*GQ@4444 %%% %%% !1110<
5_15_P;I?HNO"_ \V,>L_P#I8]?SJU_15_P; MI? \ *+KPO_V,>L_ ^ECU_/?TE_P#DWM/_ +** M?_I%0^MX+_Y&TO_SB?<
*T444 %%% %%% !111 M0 4444 %%% %%% 'M_PH_Y)_IW^Y)_Z,:NAKGOA1_R3_3O]R3_T8U=#0 4444 % M %%% !1110 4444<
%% %%% !1110 5YI^VA_P F=_%C_LFFN_ IOGKTNO-/VT/_ M^3._BQ_V337?_3?/6M#^/'U7YB>Q_%51117[>8!1110<
4444 %%% %%% !1110!_M_0Y_P9P?F=?%C_LID7_ *;X*_82OQ[_.#.#_DSKXL?JE,B_P#3?7["5^2 M<0?

\CBMZK\D;1^\$X\IJ/ _DVIQW_V*=_ .B'K\FZ_63JJ\A Y-N\=_ \8IW _M/Z(>OR;KJC\(? D5XG_&O_ \$D_B/Z5')_2Y?\]>9?
^EL****_7#^60HHH MH *** "BBB@ K]#/\^"5W_)M]_ \]C;=?^B+:OSSK]#/\^"5W_)M] P#]C;=?
M^B+:OSKQ1_Y)5_XX_J?OOT;?^3EQ_P"O-3_VT^E*^7O^~"TO_ "BZ^,7_ &+D M/_I9;U]O\O^?%I^477QB_[%R'_ -
++>OQ/[G_DL\M_I["(IR)_?69?/BZ_MM @E^3/YD****_U1/PP**** "BBB@ HHHH ****_Z/O^#+=_E%UX7_[&/6?
M_2QZ^YJ^&? \ @W2_Y1=>%_ \ L8]9_P#2QZ^YJ_R_ \2_ ^3A9K_P!A%7_TMGI; MDW_(IH?X(DCF?C!_P
D_O?]^+_ T8M>*U[5\8/\ DG][_OQ?^C%KQ6OASTPH_MHHH **** "BBB@ HHHH *]O^%')_]/_W)/_ \$8U>(5[?*/^2?
Z=_N2?^C^& MH Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH \T;_0_MY,[^+_9--=_]-]?Q55:_K^VA_R9W6/^R:[:_Z;YZ_BJKI_@S^!6]5^3,J_MFX4445]J0%%%
!1110 4444 %?T.? \ !G!_R9U\6/\ LID7_IO@K^>.OZ/_ M^#.#_ DSKXL?]E,B_]-%?/<4_P#(GGZQ_]'Q'["5P? [4?
R;=X_I[_%_ \ M_1#UWE<^'U'_ _FW>._ ^Q3O_ /T0?GF4_ \ (TH?XX_ ^E(GB? \ Y)K&_P#7
MFI_Z1()NBBB0[(\EPHHH **** "BBB@ HHHH _O5_ (O7?FWW \ V-MU M_P"B+>O12OFO_@E= P_FWW_ &-
MU_Z(MJ^E*_D[C/\Y^K%_P"-G^G_(2? M\FTRK_KS']J3Y>_X+2_ \ *+KXQ? \ 8N0_ ^EEO7\R?TW_ /!:_7_E%U\80^QL
M_P#I8]?SW)]?_DWM/_L(I \ I%0^MX+_ .1M+_ _SB?*T444 %%%!1110 4444 %%% 'M_M_P*/^2?Z=_N2?
HQJZ^N>^%')_]/_W)/_ \$8U=#0 4444 %%%!1110 M4444 %%%!1110 5YI^VA_R9W6/^R:[:_Z;YZ]+KS3]M#_),
[^+_ &33 M7? \ TWSUK0_CQ]5^8GL?Q54445^WF 4444 %%%!1110 4444 %?T.?&<'_ M "9U\6/^RF1?
^F^"OV\$K>_ ^#.#_),Z^+_ &4R+_ TWP5^PE?DG\$'_ (XK>J_M_)&T?A.#_ :C_ .3;O'?
&*=_ P#^B'K\FZ_63JJ/_DV[QW_V*=_ .B'K\FZ_M_8_ ""_D5XG_&O_23^(_I4?)_2Y?_P!>9? \ I;"BBBOUP_ED**** "BBB@
H_MHHH*_OS_@E=_P_FWW_ &-MU_Z(MJ/_OT,P""5W_)M]_ -C;=? \ HBVK_M\Z4?^25?^./ZG[]&W_).7'_KS4_ \
3Z4KY>_X+2_ \ HNOC%_V+D/_ *66 M]Z?4?+W_6E_P"477QB_P"OQO/[G_DL\M_I["^/
ZON:OAG_@W2_Y1=>%_ ^QCUG_TL>ON:O\O_ !+_ .3A9K_V\$5?_ \$MG_M;DW_(IH?X(DCF?C!_R3^]_WXO_
\$8M>*U[5\8/^2?WO^_%_P"C%KQ6OAST MPH **** "BBB@ HHHH *]O^%')_]/_W)/_1C5XA7M_PH_P"2?
Z=_N2?^ MC&H Z&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H_MHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH \T;_M0_Y,[^+_9--=_ \ 3?/7\55?VJ_MH? \)G?Q8_]IKO_ *_YZ_BJKI_@S^!6]M]5^3,J_FX4445]J0%%%
!1110 4444 %?T.?& \ G7Q8_ \9%_Z;X*_GCK_M^AS_ (X/\3.OBQ_V4R+_P!-%?/<4_ \B>?K^RH? \$?
L)7!_M1_FW>_ .P#L M4]_ -\$/7>5P?[4?]_MWCOW [%_ _P#1#U^>93_R_*^ \ ^Z4CR>_]^2:QO
M_7FI_P"D2/R;HHHK^R#_ "7"BBB@ HHHH **** "BBB@ #]#/\^"5W_)M]_P#] MC;=?^B+>O12OFO \ X)7?FWW_P#V-
MU_Z(MJ^E*_D[C/_DJL7_C9_I_X2? \ M)M_J_P"O,?U/EI_@M+_RBZ^,7_8N0_ \ I9;U_ ,A7]-_6E_P"477QB_P"Q
MOYD*_KSZ+_P#R1F,[""_FZ9S;? \ C&G_@_5A1117]*GQ@4444 M%%%!1110 5_15_P;I?^HNO" \ _V,>L_P#I8]?
S_JU_15_P;I? \ *+KPO_V, M>L_ ^ECU_/?TE_P#DWM/_ +*?_I%0^MX+_Y^TO_ _SB?*T444 %%%!1110 4444 %%%
M'M_PH_Y)_IW^Y)_Z;:NAKGOA1_R3_3O]R3_T8U=#0 4444 %%%!1110 44 M44 %%%!1110 5YI^VA_P
F=_%C_LFFN_ \ IOGKTNO/_VT/^3_ _BQ_V337?_M_3?/6M#^/_U7YB>Q_ %517:_L_ ?QC^TA\4;X7># =2TC37N\$>?
4==\1ZFEE_MIFCV<:[IKV\N7^6""->68Y).%4,[^I^ \ OCS_],&[6H>\$ _P!A36?VZ_V5/VI/_M
GQKT3PK83WOBFS \ Z>8H[> &W4-=>1<"X\$KPH?;..1(6L\$@9]JWD)7QV?P_MU2_*LK.6BWZ[:[+YV,4FS\W**^H?
^"67_!,'QS_P5_ ^+/_B'X>^ ^OBEI^?2O_M#&@#4=5\3Z;M);(\R10VH=?WDF96^/W8']*]4_P""G_ \ P0_M?^"9?P^T
MWXQ>(OVU?""C6\UGQ#%I6F> &] TITGE)BDEDF^&9@L:+_R= !_4SS#]PQ_M2PSE[[Z6?^5@L[7/]@JBI],TV^UG4K?
1],MFFN;N=(;>)>KR,P55&?4D"OM3Q_M_-P0Q_-^&_ 38\4_ \%*_BG3?!EEX=T:VL)=#\ \ A_68=:N-4^T:I;V#_M;
[BTD:V@5#.S';)*^Z)HV1#DC:MB:&'<54E9R:2V]A6;/B2BOH?_@FA_P \$MX_BO_P %-/_V@9?@G_-\$_-
AH%AI.BS: SX]4:I\$ \ D&E:?\$R(TGEIAH&9U5(P_M1N)))559AM_M6? \ !,[7?@5^QQ_-?""@?PH^)DGC7X3_
!*O;G3K+4]_ /C_M2M1TO4(9KF(V]U:K<7^!7-I<)%F<^'RB&"\$KNF6,PT*_L7+WM-/6[2OM=I/O
M=G8^7;?]F^F^M[W(G/[+_Q_I;Y^>? \ Q!_X1+PCX1DATGPW(=)^US>?*?D^ _ MBTJW4RQ]OD >>>?
+>3&%/EN9%60&:(VA4A-M1>VC]1']^Q!_G!_R9U\6/^RF1_M?^F^"OV\$K>_ ^#.#_ DSKXL?]E,B_]-%?L)7Y/Q!_P
CBMZK\D;1^\$X\IJ/ _M)-N\=_]BG?_ /HAZ_)NOUD:_C_Y-N\=_P#8IW_*(>ORV^'_PW=_%3Q"G_MA3X>>%
[O5K]T+^1:IG8@ZLS""HO(&YB!R.>:_7_":K2H9/BJE22C%33;;LDN_M7JV?Q3]*##8C&
<69;0H0#QG!YR^*QJNE5IUJ<:E.2E&2333NFGLT^J]21F6(P^ (PF(G0KP<)P_M;C*,DU*,D[--/5-/1IZI[A171Z?)?
B^J'A<>-AX<:UT=F^PZG]5Q%:03L_J_MQ/.R"509.FCP-)/B# \ 1[*]U3PEX?ZRTXQB_P!0N;N^VMH&D8*BM-,Z(&9B
M_%W9.> \ !6;L;@X0E*52^479NZLGM9ZZ.^ECKAE&5*L*^/_-RFG**4)-RBE=N_M*M=I+5M:6U."_%?P] \ 1W/A^QKH-
QINI6;A;BTNDVNL1D'T((((R" M""""=?> \ /%5CX^M/B^>Z5Y6D7]]:65U)/&IGEC4,^R,M095R_7"[02%SGBM
M*B*#C&2FK2^6W6MU=6[W6NGOP>]QL:E2FZ4G?G7*P[PL]/F5O=LVD[VLW; < MR*_OS_@E=R;??
_8VW7_HBVK\Z_O5_@E=_P_FWW_ &-MU_Z(MJ/_%'_M))5_P"/ZG[G] &W_DY)=+L_MLQ6X:\$SQJT?FRJR21*
[I(DC!A^V=OR[O]+_J_%W#N^SVGD]6NEB^E^6-I6;2N_MX\]N3FMKR\W-9K35^XQ'_8R> %>
(C#W%N]/OMO;SM8^0**^VO^"?_ /P16<_ MMT_E_CU=?M">/'>GS:U<6&E6FNV;227Z0A]PF)\$&SS& >/O \ T3UY#_
,%#_MOV(-/_8&^_ ,G? !E?CMH_CK4+G0TU^*N-\$LFBBLA)(Z1Q,2[IG(C+D<85D \ M%6.\$XUX8Q^?
SR7^XCFQ,;F@HSTY?BO+EY=-OBWTWT^*J9;C:6%)G^"T':SNN_MNVE[_@> \ T5Z9^R^'R? \ %G]M?XVZ-
^SY&!]J6U8O)+=WKE+;PMHQEN9F_M)6-/Z_EB55068_ ^J>.^?";C7GP#?^M#_LU?%^7Q]I^PJ\2OH_C^TN_#]/F7
M-J%!.?VJBYG\$S9D[OG8Q2J]+-%!(;Q+D>78Z.#Q-91J/DTL+VDBG^,TG
M&/),>9KF:LKLS18+%5J3]OC=: @KNW5V6KML?+1%?1W[. _!/_C4/BI^RCX_MM_:=^+^Q+?
P;/_/"NM6NCB]L]"_M.^U&]FG@B^PV[3P+Y+DG&SW@H.:4KVF]G9V?6QXC17JWQ<_9C_P""(_7P+ \ 3/'WC?[-XK]?
I]J>E_M> \ 5TW]Y;:#]V#4KB7-%.4;V_M:5XMQ=KI72::NKI]&S^I2G2ERS5GH_OU/Z^O^#+=_E%UX7_[&/6?_2QZ^YJ^
M&? \ @W2_Y1=>%_ \ L8]9_P#2QZ^YJ_S)\2_ ^3A9K_P!A%7_TMGI3DW_(IH?X_M(DCF?C!_P_D_O?]^+_ T8M>*U[5\8/\
DG][_OQ?^C%KY;_':_9^?]WPY_MF^+7[10Q4TGPCX?@F6'^T-5G(V5@2L44:@O-(0&(2-68A2<8!KX<], [JBO)
M/V3OV[OV1_VY- _U#Q)^RK\<-+ \ 76^DRI^JD-M%-;W-F7SL,M0<1QS(K;6VL4_M"MM;!.TX]1UW7=% \ +Z)>>)?
\$FK6UAIVG6LEU?WUY,L<-M^&I=Y^=B_JJH)+^'_M @ \$F@ "U17%?L?^M#_!W]JWX/Z1?/@#XR7Q!X2UXW
TG5UL9[87^7\$MM+B. MXCCD7\$L,BY91G;D9! !:T %%/K6]N?
M"GAI;>.:6> \ AM(7FGE8QHR0(\$BD^M^R!S^RH692\3^_ '[8']_O[-6MZ^X5^,'_MQ#^Q:UXE%PV@>']_TB\U/4K]
((FEGDBL[**=HXXU9GD";%_.2*/2Z^Y;X+_M_&WX2_M%?#73/C# \ ^F^)O#.LQ&33M8TJ?%*
Q5E/0HZL^K(P#^P(8_@B_MH-*^/GPFUWXX:M^SCHOB[7XQT^0K?6-J_)F53<*M^*^U("BBB@ HHHH **** "OZ^ \
@S@_Y,Z^+_93(O_ \$WP5_/'7]#G_!G!_M_P_F=?%C_LID7_IO@KY[BG_D3S]8_F5#XCIA^X/J]/A_Y-N\=_ \ 8IW_ /Z(
M>N^K@_VH_P#DV[QW_P!BG? \ _HAZ_/_I_P"1I0_QQ_ \ 2D>3Q \ ^DUC?^O- _M3_TB1^3=%%%?V0?Y+A1110 4444
%%%%!1110!^AG_!*_L_DV^_ _QMNO \ MT1;5]5\U_ \ !*_ _OO_ \ L;_K_P!\$6U?2E?R=QG_R56+_ ;/_ \ A_PD_Y_M-
IE7_7F/ZGR]_P?I^H^E%U\8O \ L7(?_2RWK^9^OZ;_/_@M+_RBZ^,7_8N0_M_P#I9;U_ ,A7]>?1?_P"2,QG_&\$/_P!-
TSGXV_Y&-/_P]PHHK^E3XP**M* "BBB@ HHHH *_HJ_X-TO^E%UX7_[&/6?_ \$L>OYU:_HJ_X-TO^477A? \
M[&/6?_2QZ_GOZ2_";VG_V\$4_ \ TBH?6%\C:7^!_G\$^YJYGP?^D_O? \ M?
B_]&+735S/Q@_Y)_> \ 7_HQ:_@L_4SQ6BBB@ HHHH **** "BBB@ HHHH M]O \ A1_R3_3O]R3_ -
&-70USWPH_Y)_IW^Y)_P"C&KH: "BBB@ HHHH **** M "BBB@ HHHH **** "O/_VT/^3_ _BQ_V337?_3?/7I=>.:?MH?
 \ F=_%C_+)I_MKO \ Z;YZUH?QX^J_3V/XK[> \ N!;:"WNY8H[F,1W^QN0)4#^*^U@/O#];J?5/B+^>>)+.4+ \ ID_M56T)8)9-
IJL\!079#K*3(HPN?+_ _L_X)_P_ \ X) \ &[XD>(_!/_!0/I3_MQ# \ +=.E..?!G&+1M-^TVXU7>H478\$,K>4\$W-M

C#8(Z,XW>[?LN_M0_#K_M((XZ=;Y_@[^U5X8^+7B?XA^~7)+>#8?MIJ*6%F)90XUB^DO+;!4DACW""
MWB,Y,DKAV1&?][4S:-3\$QJE1NIQ<9)OVH?^"(GP MV 9!U][F[_@I3X3U05M5\8>)/(J9U.XDT*\?3[2&VMGM[+]
[8RBX+1BX07RX\$M^U\$#C-6_P#@M/\ \$<_V2_@/_@S9X? \ ^~CO_!-?XJ?Q!)\\$.J16.HJ:2^
MWQ:>TV136UPW[PQB1##<6ECD(RQRRX^@R5^RK_P2I_:"_8U2_ C!^W MUJ/PF^.]EJEP;3?%.BRS^';JS
7R0#;VSR9;D-)=R'/[AP 6POB1^U=I/P M<_X)_P _!, [X9_%RV<:9K7Q/[B_P 7^*=M\$;N+3\$M=M%!!8V*WL4\$[H+1^
M?+*,0+I\$JIE#.V?L*BS#VN'G-/F]Z,D^5KNM+;;-,AJU^W'@XD_!F-X MF!/36%Q_X7%K7PU_P5M)&?)
!GP^_PI@_X)6^/=7OFO-"F_X6%-K\$E_)'"_M[@6TTOVF/%9= \3+H: MQM?
62F19(KJ%)&59'I5E;LN5D)IRH4^K:K^T;I7[:_][SWI/_P#P0I_8TCO= M530/\$][KGC3XD>(I :?
9QJ;G4;R281F1VBL[:&][GFFED*M_HZA5.?F_-^ZAC MM[J2WANHYT20JL\08+(NO%X*BZZK1
M70MJW:Z32D_*;]=%082>AZ\?0A1XU_';C*ZGIO[(<5CX<_97_9ATY=&L/& M_BZZ:SLKJ][N9D6XU:X"
(LUJ]P%RR2>7^&QB-BNC! IN^7OVN/V/OV@?V&_C1 M>? 3]I/P*^A>(;6WCNH56X2>WO;63/EW-O-&2DL3;6 8'AE96
9642:0#[M7/P*?;\$. CQ_P2Y0^/=!((\$3QXML0\$7A&\4'E^I^G:S\$M][LL+7_\$K+061 NXJP&)_P<6_MX_L_?MN?
M7>\$;#][FWQ GB^0/ASX%AT"?Q M%; |<6K7?G222&> SPIN55<@/F,A7*!6;""UL73QOU?D]Q.60DE%J3?5R;E M?
@,;M:Y^BO 9P?F=?%C_ +9%_Z;X*_82OQ[_P"#.#_DSKXL?JE,B_| M3?7["^5^?10?|CBMZK|D:1^\$X| :C_Y-
N|= _P#8IW_*(>OS^&GB/XK/< M1_#OX5ZU=V-UJUZX%=.01:2W4BK|B/+N7Y5^8A2P +\$|<8_3CJ]/_DV[QW_V
M*=_ _B'K|Y?|['*Q?^)7PBN/C%X|TZUU>SM+U|:2K&*E&*2*3GV,X^|?;KYKU1_'TB,%G&-XTP"RZG
M4J2C0G*2I-J?(I^_9I-K1VO9[ZIJZ/??^"AB?%02/V>_A[X0|>:&_]);+ #)K MWB@2JX-^L#)Y"S9(+L7(??L3^&M"|\$?
&'P7KGBS38[K60\$E]?[! ML)Q9Q6@5]U|X_ON5*1]@|G_#S)T/B3|:-?TG|AG30@?4Y+@^*;060+.QO
MP1=6NF0LLD[&P_96T_2];O[M8 M;?7AJBR26NR\$JNU1^0 10@ (& !7I0AFN!X4KX6.'YH)U^:=QBFEJ|6E)
M/E;|NHWARTVU/GZM7AG.?\$[!YE/'>SJN.'Y*5>,YRC-Z2IN4(-.I&;8V=3EJ MZKSMW>*_P#10C_D|_Q?];#_-
(+;I V^O@)HWQV^-BP>+;03Z+H5H;^_MG^ M[U""0ZIX@F?]? M;B*;.=7* 2RQ@1*NX|B|R;|7_V/I_-9+_:X|3_ (!;^+
[&9;^SAMK35U/ MEQ27 "S1QMDGRV99&4@D_.H7)R#7?+-ZM/@:&&PK<<2L-"2BM^32#FFM-KM:
M|RTT3/\$I<+8:OX55+87-TD+WL1GM_P|ZA<@/L'"< M_XKT#|FI|OJEW30CAJOQ6LY=/TZWO\$M]-%
[&474IQ|KVI|N_P|875XC MQD8=2>.:^,(HI9Y5AAC9W=@J(HR6)Z
#N:ZSM9ZW>IY_%&84>&|1SCV;^LYC1Q=/\$T92?-&|25)3@VG*'-;|4TT MN6R7*SZF :[E]% M3_M666C>
/\$5H=)T+P+!XG|3PD;VUO#);+--O'#JB.# M!|PSL*|Z5XO|7_ \$VM?%S6&U3P1X/U""PAX;M1I^A6L-J|QV-
HF2&E905\$KDF M1V)R6<|D 5L_\$^6+X&?#?%I4BCQ|JWDWOC^YC.3\$P^&#3 1VCR)),=9"!G
MY,5]/^!5TD:A^S0/AGM_L4Z9J0| :GV7_5FX_L^/SO.QQOW^?G/6ZN=8N'# MF!P|J<'4IQC.--
R=E:_.524V|;U.7EAVAJMW%|TLKJ|?Y\$CJ>[JJC7J5*|0 MH*[YJU>G1A2BFTW'#_/_6UJZK|K^&_U|U^AG_!*[_DV^_|
^QMNO_1%M7Q) M^T&!/P^_/BP?#_R/[&_MZY^P?9>>5L|P_P"KQQLSG;CC&;<5]M_|\$KO^3;|_ M
/[&VZ_]56U3XDUOK'IL:MFN:4'9|JZ;L_-%_1|PGU^Q9GAN92JG^"M^F6SY6 ME=>3M=>1]*5|0?|! :7_)1=?&+
+R'_TLMZ^H: ^7O^"TO_*+KXQ?|BY#_ M.EEO7XUP3_R6>6_JA%'_P|.1/[OS+ _D75O|_OR9_-C|+>+)>*O&6D^\$OB7
M|2)O"_AR:];|=K0TR6_73U90&F%M&P:0G8@ (4@D>E?JK_P6A_9|OKG_)= M_!|Q|^S-|2;3Q;|_A|IMA8K;I;_
+V^F=#;1:HTN|DAMT)^*H86E8<_,\$^) MOV=_V;_ V
/C5^RIJFJ>.OVSV^7QHLM7E^Q:1XJT29M"N|(*OECS+>WDD5V) M;,@=BN,>21ASI_%C|L;1_AY_P3GTS_@FU|_
?|B|+CQI-XB|6>+*""XCT^) M,H8--LQ=J;U)< WQQ%1QN>|59=7RYU%+!XBU2G4HM4W"
M49*=6,Y05WRNT)1FTV|\$G>_Y5A)4|+@:T:UK5(-2|ZZ:M%I/:^Z:/L;|G|X MH_|
!OC^TK|Q%OAQ^S1|>+2_TWQ)X;|_VN@V?B?Q">Z4HN2|DT|I<6|S01*] MU/<39GPF9/FSTKXO_P""M|
P3H'!.7IH>T|>#>&?%DVO>\$/\$VE_VIX3U.|" M_!:#0*;S%_%>2, @?H'LKH<*25&U|7_-DK_@F1KWP2|.?
\$KJF/_@H?;Z7K MYTN ^+/'7Q/T6^\$J76Q?.|AK"Q=AM?(\$>R52.1-@598KK41!:O_*7,L)>6^.:Y\$*%4)=(\$7Y@VYAX^
M083&9)F|LRRNOC^N\$M7E7P|>\$W)227'MN@AS|]=_|\$]'TCQG^S9^U[X9|41D|IVJW,|M?K+RIBDL|063.?)
MDFOG+|E|J|NC|D#_@F|P5A|4>-_V9|K5M5^ VMVPT2:8K-+!/;R);RO<0B8" M65(C-N@N_P"=H2V-
S\$\$Z/|;M+X'_L#_+(?|07PP^?QJTGQWXM^-B^YMO M"S>&K;[6+2M'DCEB^VW3\$7E3&.>0+ NYU=5+8'-?
+|6Y|GV>YAF57#4*B_ MM".7RH|T&G^V<[U%/=4Y4U|TE)JU|+L|L|B|+A:5%3DOW+K*5GO=-=T|E8|
MR_9T;R^\$4G_34|;?|\$W?CR=5T:#50%%IK?AKQ;I6G"CA"W=K<6T|.]' M!*P.4==V6EPP4*"?
5_VE/VDOA;_P5):YUC|N#XI^"|JOT;X!_'PU;6|JA?N MB7OB;SYI;33|L+*MQ>7\$C*55F\$50\$[E@1D_G9H&CR^ (=LM
@OK2V>^NX|= M+G4+I8((B|!0|DCD+&@SEF8@* 2>E>]?MK?&#X>:5X?V?L6_LX^(HM1^'GP M|D>;4-?
M|M3Q=XCE0+>:L?|T0P+>V!SM@C!|>@OTW_.#LMI9|&K@ (SC7K2J MSE--
|M)5%3C7G^M4J*G"\$V^5N4XJT9)^+2S&M+^N-5IQBHI+K+EYG/R5VW MWT3W1W/BW|B|N_JO?
QI|72_BG2=#LM;^L;ES?S_YL:;EJJV2VFHV\$Y\$ M8Y;:>-RDD3J>596|4@|@B|OUX^%O[?]D|WQ8E_8P^_VL_&?
P_P"\$;?| 9^V M:UIOQ(T|5|OR;RV)+);#:(! (5\$H#_-\$C|ROVU?CAH/[2G|6 MGQ\$^//A71Y+ #2_%7BR|U#3K6=0LBP/(?
+,@&0)&4!F)&YCR>M9|"YYQ'C

&_V_|M.PV5O++X6|5OZKI0BN:AK=7FO# #8%B=^:80%A(U+C?@=@=)JW|I\$G@_X_VGB
M+Q5IV@:7>ZCJ2:7IAM/\$T4^DWK.AD25;|XX|D859"Q>(.#P57RFZ72_@_X|M@UIO%XGO?B-
9MXJU3;/3K:73_#HAT^S6WFEF4^VDN)7=9/99_9@Q^W^C^7 M;E:7^S|/Z3J=Q<=>);.R|6W/B&+O/;CX=T1-
L+JG@ \$Y;2RE3UDHDCWK-OE M+2^1L GRE0^H@>K3XJ:OK.A3G0/K M1L^C:2NY""P8&O6:Y?
P/H_BS38H7Q:XEL/\$Y.5\$::3|T|ZU@49Y6_YIY" MS9&2T|RC"KSGJ* "BBB@ HHHH **** "BBB@ HHHH
*X/Q|3+OPIKFG^&? M#F@MXI|77|W#<=@;D6MM;6Z\$*9|FE;|JOL=@^|>6"WD1@/F).93_/S=JT?" M_P 30!WC?
0:07/#GBS0|T6T+^YU+2|2AN;.:NYM|B.57^IG)X^>:?\$#XK MW_C?X?ZY^X|>%(M1|M8;N>|3VR+\$;B-
9S%9WBQ37\$|<)>DF1%*8PN2Q M"-Q/P^T_5I9|:2%358?^\$VUO3=0(6UG:ZMXL/QZ5/>7"/?PQP):6TA""5 M
/_CW"=|IY(|HOQJ^C:/JNK#QYX9.E:3*L.H7PUBW|BSD895)GW|8V(Y
M8@FN9M_C8=6U7QC)H=SX>UG0|TO2|1TV_4Q|:W0N7N%=FNQYB;_0KM*KU) M&3D8X5?4?PWT?X\$ZK-
XOU""^|>+>=%DM+G3_TV2|N^O)+>W\$-WJE16E>.:?^%ZZOHG@SQ|IMEK%GHJV)U^2)274Y(WF)V6.
M"11(N.@%616XW%<.&8 ^C/\$7QA_10A^7|_T+7?%NAZ+K>ID"QFW4=2A@N;O M+;1Y4;L&?
+%;_ASL;GXL2:1X7TUY!\$MYK51%:0ER^0H>1E M&3@|9SQ7S)^TE_PD^M^XK:&=;166TM_1K6FA:=X2|+0WMOXAC-
E|Z|O|29(MBLSR(\$:2!E6)2N|N_@ZS_@#XLZ5XT|1>^:UK29/"UOI5H&DZ3/JMQI5T
M)9^N4:W@22=1<*T&71"O^BX\$KS7|_XM2M(K)|Z%>X)08YT M\$9=2KC(PP PPSUSS7D7A?
X|>_Y_#;WXM|"/H_AKQ=)9P6E|HGB2349|66_MZ0_-B>&6RM^Q*H3&|E2PXVY8=-="/50A#|0T00;K14NM^N?
L^DRVJPSIN|1 MJF%="K.3G;|X%L\$|L@>!? "WX.W^PHU+X/> (BP|4>(M+NM&L|O_)U>|O|4;
MPWJ9M_EO889WD^SH0TEO+M^B_-'C:OF4>P^>_COX>N%&K^&^/?B3PIHNO# M7;C3-)TN>^C@NKV-
M*1 ^Z1B6(^08XZ5W_/PE&C38|AN_16L2LFE-(FH3_M_4V6:(H=UE;.(RJD.OV_@GBOG7QA|
KB/X)_M(M8^&)Y/\$&O7FIW5NB6+2 M7%_(E|&ML|:I29_@V:0?F'':D^+7A24^^(7_""VUM(VA_%9+?^U6A3^V=K
M0*+|Y#V\$|F(H(O%?A70/%NA:CXKT73VNTLDU*WE M^T2".9VCC1)=|M^Y).BX|4.OKQT/PO|
C^X9^)%C96=GXF^4/%4>GV|WJFC M;:Q2W%FSQJ6#PAV>.!FQ|WM7\$^(OM.E_%XDV+Z|B^C_ ("K%I=S::7<3V
MLLD\$=IYD;3OHT<+CS(|+(RE|X"ICQ6=IOP_E|+Z7^S19: X=EL;20|CR+Q(+ M@V\$+;=JXE.W.8;R@Q;&7*^Y)%
_IL?QU^&TNJ2::GO^"Q|_N|X|FN M6 MQF6|06>4IOR\$|);&>_W/| CKPW|1'_ M;PKXATKQ-I7F-|NT>|BNX-ZX
MW+OC8KD9&1G(S7S?_P*?1O@7|_-'?PA)) +%X_MM80;2P9GC)U2622XD4KE M1M;<6/&T^E>M>#=#O=

._\$^)=|,"XMM*U#2!%DCNFA98;BX3!6DA5!89U00! ML'(&S/44,MOCLC?M"7_...01 LD,>GPW-
IK378(NKEU>0VOE!M811R2 | MCN\$!#;RNO?'^R?CYX9^&UMHAOH!3MI9;S6/M6Q,*00RRQ1"+8?;+K!(3!R
M!04!X5PGCKP'KVJ>|OBMKFEZ;=KJNG0Z*#K&@7'DN\$N!JT?R!P(W;S\$9H' M' "SG/45*#X9!(Z-
XK^\$ _BZ^T.^@UC7-5U3Q!K4T^FO;V!Y C,42V MJODXRT9!F@#V_2?B?X-U_P 5W_A?
3/%NAZCXET!\$WFC6FI0RWEM@@"S!58NF M'1U ZBJU!A80 -CXEMO#MOXW!_6_B"ZF-V@TF75K=;N653M;-
(B^YF!X* @9! MKYG!)KX!1>-OA*^H:=XPM!8TW7'N!%8='T'0'!G>+(!>Z^R!ZF254W
MQW,JMGXOI\$M8A;/&N,R\$- M&NS:#RO!:/>/\$7Q!A!OA'7!-T+7?%NAZ+K>ID"QW4=2A@N;O+;1Y4;L& M?
+,%_ASL!;GXL!2;1X7TUY!\$MYK5!%:0ER"0H>1E&3@!9SQ7 MR_ | M\$XJURW^*&AR;=XMM;G4*^RZ)IWA/PM#>P>
(\$-D/FO;Z6TF2)EG>1 MC20!JO KO+C/HVL7?#?#_+ND>,Q\$7AS6M9!TJ7PM;Z79ZCLD7&JSZ5=+*!W M*!-
DDZ_:%>WRZH1_HN^!K_+D !:L_!A?4- N! =M?#FD7.B6@S<:E#?1!0C M8KY>0-M7Y'1N3T8'H15;1?BGX+!2>%Y?
\$FD>+!H!U7P!%)Y4FKV6IP36B/D+M M,RL4!RRC>I'K7RR!E!J7A+Q+X!T4M!TG2_BH=9U'2=%M;:2!^S&RA,CQ
MYAR210(DTJ7!B*Y8R%F!16_P"(=MX^/^Q2U'R!C!Q3!7!R8R)"!\$!^9A7(5OE)SP2?NFUKQUX!+
^&1XCU;Q#16E^C&DHU;108 MH!0HP!10-9@F""#CG>=>3>X4 .HT+7X!5.6Q!%7.GPZDMIB.%C>0%81!)C M
_P/A7!BDM!(M+&Y2TFMYGDC\$2,@_32!;A2/D+F@#ZB7XF>\$!+VGB5?%>B-XL^/-+UF!7Q5!26DCF'R@;G!D
M'!"88_W4>[S8D)9"S#G+=[9^&=1C^_GQ5N(-,GBL-6!+Z0D5SY)2&ZNE;44<M"0C:SJA@!YR 4S@\$4 =M!+?
BIX8^_G@VP!3^\$!7L!7TRZC1F-K-/B9X0^&!5G+XM!5Z)X6CO)#%:/K6HPV8G<+!+5?1OAB/6+S4+EH/L!Y'M;A M;:>
(*L)&18T8RL3*A-/8/%Q!+!>+!&_!1^)=(T"SD!H4N-40XK;-D4 LP-M9V(-
9M.LO'GAK40"8!46GB'2KKPRT1G&M0WL3V1C!(!+<^&V;00>O>;Q+OPW8RR7.5Y;-IMP-/2>9M4*C L5' &?NCI6
M=KG@;5K76&5!-X2O!8,Z3!;7!C1H;L=8M!D!MU:>")@!Y5XRSD+DEK M=JH+@+0!H!X<^,NE^/_B-
!&F>%M8T7Q!)X8O!1_M32;L!6GAN;>+8LL!E M,3/D8R!R!0:WGLXF72AW7-A,^!;Q3XNOX'NX!
W(M;VMT(4SW.Y5O+ M0LP4!4=V).U"%) -TB/PG<6#->U_ M!(N9;-?#VBSZ3:
MW=T\$(CM6CO!#;V!2\$V8R"ZDBO#!#T_6O\$'CZQN!-'6MVEKX,UK3!B;7O"<
M>BVMG/(M!Y=G;1BS@E=28W(RTJ?# KL>@!H-Z9!5!6M;?J!_IWB_0;^QT<I M=2NK74X)(K(XW8F96(C...?FQO7)V?
ORT!Q-XPM;?PEJ_A-Q-X;F!ZAJRZE9 MZ@DD#7?O!&\$-S&S(Q?O6W'Q&>O!X570A^V@-OX/6EMX3N-
2T+PK<;7=Z MKX8M;:2!\$=JZ\$# \$#T!^ M0 MT!M6U;0;O31>7+30E(\$BN(TE+JIGED&X"EMAV@'LFK?%SPGX-
!:/%J?C+Q3 MX<!^?VM%&8#?ZS#'-!4#%(0)9"@F SPP R,' S6EXO!B)X5^NCO;MXH3:
M/X:TJ5UCCOM8OXY2!V(R%#R;%)!(&S;^?O#^E1^\$+&W MM!H!PGX635;^!O#D3V-RTEK<"VC54A_UB!JOE
MMJ8_!CTVYMUMY(5)!)&Z-20A=VT!C/S_(&SU0 4444 %%%%+1110 5Y5XL^ M/GAV.VL?"?B7P!XAU'7M-
TK4!M;_YFLX!FZ2%S!)NC;#-C=QD<@!^Z M!XH;)JOB;X;^+-(T^Z^Q:WJ&DW5K8W.IY4!PLL;
!AR;0<H!5!^ZYKV^)/ M#_PI!^*^OA=XLT6!T+Q#H!DUE)X;N+6UT*^*9/_TDH!D &TF!Y1R'.%4L M#Z"U?
XH^#/#_ (H!2#;J>+M"TWQ)?D"TT>|U*^*N;H!+A9@!Y!@=XP^)W@
M_P""LUA%X!H6:'X.EU!+LTUC48;1KE!@;8Q(PWGD<#45!QZAX)OX;KXC^\$ M/&%Y!1P/\$^MWUQ!;^&?
#UI>66IV<f9@/VXV.GV=XXRL7^D3Q!AA!OA=AKT%;
MBW^%Q;+=WGBCPKXA!1Q@H(K;+3=9TW0YM8;XM8K6.)K";!/&YAO;L!N90D+ M?B0V0X4!;:
+B*.*4F!64E"\$9!\$(2<?&?1C M#42B8GB3-4AN!FUL?#JH;..XBNA*+Y-36Q""8"5@;GSR'964L64@'U!-13
M_!MOXTC!^R^+=#B!6R0\$T!H2A%^RE2P80%O.(V@G.WH.T^W^)'A*Z!93>\$8 M?%&BS>*X8O.ET*/4(6OHX!
fV@#;PN".2.H2;BUHWF2&WC\$C>723.PR3R%9V3\$8!"' MN.K_!1!&>'<
!38^&=4!7:%!O!B2_(!H!Y!J4.5Y<9Z>7"S!WS!U=19;Y/X
M;L!WVIVZ6\$DUNJLJZG?"RMSE@/GF*!Z_P!TY!WS7RQJ!@F ANOB/X0!87G MQ'!3ZW?7\$%OX9!6EY9;G9SMF
_C8R?9WCC*Q?Z1/&R&\$%""V&O>/CGH=I M??!+7=+L(\$S5;TVT;.(J!&6>8K)'DD*/E;).!ZT_7B?XO> O!H!8>(O&_A
MS0+JY5A6U!U35K>VE;1@&5 KN#N((!4@BM7QAXRT3P!X8O! Q#XAU2ST?1K& M/S)!V^N\$@B0\$@*"!D""S\$;D9+
=Z!ZTWP!:=2%KXMZM>Z&9!JVDZ=IRW4UN
M2M!"L_!^!6(PP#2!^=AGM5SX)Z3!J!7@C2!2M+FVUQ/"=G.SVEY&8HYO M;*H!U;15@W!!Q@!;
6W;G!;Y8^!O\$>D>) #_A>M!IW5_#MTXQV MJS""6593!0(I=5=6)QG'O7J%EXH-
EX3'BBT!0Z5=>&6B.XUJ&B>R,8)!? MS@VS;#"SG%">">!"3QE9?L!?#&K+)X0BD@O\$UC1KFU^PWL.FB+?1
OHU# M,S*D!H!D8_<8D5A^./BNXN/&!Q!VG:S;18_\$NTUR6#2;"!KBH!/?#MEEG MMHIXGCN"ERWFD;9F@<)FQ**
H?P2X!-2\$3!_!6!^*^=(^!3;7YC!2;M'O8 MKN#>_JHXV^Y&1D9!TR^!4C32\$TEC=OIEMID.F!\$UU_*!I<H?7'DF KQ\$%R3
M*7P";8!UYW!\$='LK!Q7XD!76V!>=3N-0M;6RFN_%VC1Z0LXB;4HLMOLMM*6 M3S&!D>!/!#* S!7EE!Z?J5Y!2=;NK?
3!J>VD!#7EHDT<+C3M,"L0(&"Y'(7 MJ;_!U;_%P3XU!JT?P!XPT?7M7L!DEU8;9J<S! IQAGC1BRCD-&!XLT-
%JYX;"N!O""I=VXP.O.QCG.WIS7CUG!90#NG?LSYU!M>Y!^090LUTL-HW^@-0-HMTKK+QF.3;
!(@=V.O!M!Y!P.O!3P2X5!_?#O6? M>O!1^+M/G+7UU_8,DEA+=Y9I=4 M K!F8RL6E P;YV9.%V5H! =_P""I>##
MXS;P@/%VA'Q8HSH/HO_!PN;Y!C=OQ@@!AJOXF^_/@+P3J*?XB!;^!O MWE6%;74!6M!5!E&
94"NX)8@&@=2""^<&T>!D_9!C^\$S\$^@C7;XDH!O!_9\$ MZ6_U\$7*NVM?VDJ&W)\S-UQ)Y^?EV;_EKTW4/
N_"QMU2;07N9!6V!6>FPW M.EJ6%Y&MO<9A3(PXWRU_!2A_XG>#O%GB#4M!T!Q9H>LZYIF?MVF;M?J4;1S;8;:-
B1BR<12;!SQ20_%P9<>_W!(1>+M"E!6(I=M!34H3?A0.DF# M=OP!STKQ?PKX#O?#^C LP16;@7-@VBVAM+!8!-
E^P!OHTH=)AC!V#_L0!F'S MA1UKB!AKX!OU!>?&?C#42B8GB/3-4AN!FUL?#JH;..XBNA*+Y-36Q""8"
M5@;GSR'964L64@'TG!6_B!X7^"/@F!4^+=4M!TVW^5!<11K.T>G;G/K5LEM>LXP!PRE!LA
M!!"DX(H!^T+HU_XA^!_CC3M+LYM!U&XTF=(+2W&Z25M!51W8XX(?%U!H.%IXUP?PO>#?JV&H;IX(>YU2_N3/*)
!#Z2!L!6M(@!0D>=\$C^ M;A>_#Z_X2C1OMMU9_P!K6!VNTM4OKBW^TIYD-N^X).ZYRL;_POX.ON>
M#5K3=2L!TZUU#3!J'_L+J)9!>ZMI!)%_&P!5T920RD\$S\$<\$&OB34OA5XN!9 M?7X6Z'8^\$=5M=!*%>;>7Q%#?
*UFNKV)"B3P!)_%!GF;&6P-D7EH#@35!H^ M&=6M!>_!Z9J-!75A;75O^!7UH!H!("I4\$))"X#1L.A4@\$8Q0!HT444_%4!
M6UBPT#3Y;_4!ZVTZQBQYEU=RK%\$F2%&68@#)!C!U(JY7FG!27AN3QA!#O%VB1 MZ2-
JQO!46!64\$;2/C2*4*O)^7/3M0!T_@_XE>\$?B)N X17Q5HGB;!)Y- MW_8^HPW?V=^?DD!MCL;@!^!X-
1^OBEX;17;J!AZ\$XNT'6M;TT\$WNFZ?J4_MJS@!^V-+!)SO!P^-4?&X?
Z!K(Q^CA)6LFES7GPZU_18=5@A*06UPTF MJCH_!(03^R+UPKD#@USWPG!1.YK7P_M+^?XF6NK>%!YO!
9>1^!;3!_TR M06SPO!KBL88!B(AV0"VFD5B48C_# !^&7!0WPI!&N;H!A+Q7!K&M;CH!
MPT.UO9ZC;SO(@6.F>-8Y&)AS*\$WD;E8=N>CU+XD>\$M%|5Z?X7U#Q!HMAXEU M!=UGHUSJ\$=_YZETCXB?
\$S0H!3=5M+J!UQM7M;F73 M9Q97%JUI!1ADNMGDE!Z.#O!P;22N;1^!^!^!S7WAOXK;E_P(O!B34-4UK6=
M.N!W0!H!^*F_T34_@C@C-Y%J"(M)XHEYFG&UK<%8"6!<JRF^)_@VW;1^#Y M?%NAQ>+9\$B;_!10B_92!8;
("WFS;03G;T&_IZ#XUN=0^C7!L!6T&G;%"9 M2Q3_%6Q+&[N9&+8P_@Q@# SG-?^Q%BSQ!T!H!L^F^+
!76U!6EW^X>T/PM M!-%SAU;H!0DU^K!10.D-O&)&NY60.Q7RU"G^<_&3P#XJ!66WQFM=!L;PW-
M_%H!M;@!EPX)H!H!_!1?*\$_.D!+>+M#12QV#^7>/H^!0W8MFY^60QL=AX!@QT-
2^#OB!X4^EO=W!A3Q!H_B>"SF^S MW.NCW!5VL;E;L;_!\$V.QYKP/3_>C?>;7+^!D^*7BA8?#_HMS;SX?M!\$
M\$MO<*@DM(PUI;-(=^*!;_2K2_-WS=1^S!K6M;IXMU^_6#5!5T"#3K.*V!2
M>?)";Z!JDDBM+NM90!B^/_C%X!^DWE>*O"AO MPS+N5-FL;M;VC;B-P&)" R/M#Q1!00"W@?
P_'KOB/Q+H^@;^!45-3U2_B MMK9BXR@S\$KL%;X=;>+! =_X2+1/ G!0^Q.U!5/#FJ7!DNGZ19C4=%T2XU6X"^7
M.WD&*VCDE523NSMV9\$S\$;GC+!3!%2P_!^#6!TW72?2AZ;_P! =U_7WAOP^ MEM;OH*3W;26%F'
L!R(E,\$SAV6&14!I8!J""0#Z7O!"WAC3O#MKG!WXCTFUT M&Z57M!4FOHDM9E92RE)2VU@5!88/0\$UP'A_HKX8^

Q\$VL^&-"WC2PSKNN6-MDMY!"#KJ8;S*2N5C='-CY8B)D(0!%93S7EGA#X>:CK7P7LZ5K7A06)HO
MA9+ZHIK-C"<"U_M2:XCGFBA18T!!20!5"C//>N!2-=:!5/B59RZ1K\$O_M DGA>UBTRZM=+N+BUED@COO-
C>>-&CB<>9'A9&400 7<:/0-6^+GA/P;X>
MT+4_&7BGPYX4_M:.*P&_U6:."0H&*02R%!,!GA@!D8.!FG>)/&=UI/CKP1H MJEO-
8ZZIVY6!9PL4!D0H0<^!)^%DU6_O:PY!IC'S%CBVWA 6Z;FI9_KK!-UBPUB.=!'"IMYQWMI6M MI5D\$X!_P)A/?
AKHNASR>=J21// AU/HOA*&2VT!13J49O=2NA;12I*.;@7&U8S* MIP^6L+;6C.'SE1D-HID^SW'!(C/!&NVWQ)1X@;
I^R)TL!J(N5=M:_M)4-N3 MYF;KB3S_+LW_+7=>+O^"LW'PU_-M8M*OI/K5;FY:PBCMG+W@.DVD8,*@9D
M!=67Y<_I44=MX7^,OA03?^A!H6_\$WP-?7FO.RZ?J6FW45C9;DV_:\$M4 MDN9C(02%.VILMV7.!T_B_P"*'@WX?
7%C;^*2%NA>&HIME!%K&IOVC7#9QB, M2,"YSV&:4_&2XT'Q%?
ZMH6G^!)90\$^H>?TTY+*+PDVO;)KBH\$1V=T(T+6Y-M#3.">[RV!96?+&0)F1KVE;IX=^*GC/40\$MQXXT?
30\$UM8"P\$A!P!;Y 46U6_M*:QF(L;F2+9*)S(4A83D>YWT>Q;I^T/A/-%+G!;IQ9HJKXKNK?SDLIM
M1MT<.6B\$!=\$A_X0K0;X3LH;OL&U!F;+WS M^6+>."W,H?>6"J.CDMD8!M>=>&I#?PL!?"VW&G>)
IC0H "C^*!\$U71KRY6S MMMH=1AFMYRVTI)(K%6.5LKK%>V/K!;WMN=32!;EK(2KYRQ.Q59-M"F=P4LK-
C&5(I5HMX'N/C1K?Q+UW1-*O! POI6KZ5I.F7.M:7+8SW.LVD MLT5^;6=4E01-
IF4,ZJT@C_NHA/5_LWW=SX^MI>^&*I6\$VFW_BAX;."TG'S6 M!G:*T:(/4&=KJ0'")5-%R!_::!77BGQ?X/T?
Q3HMXWQT"Q>X_LXZA;NTT MRLSPK&LGF;7D'S5V@H&7/7C=^%_P_8_#/Q(L;*SL_\$V@ZAXICT^WNI4T;3
M;^*6XLV>-2P>\$_.SQ@.V/FHXKQ(UUIOQ4^!)5G+I&L2_))X7M8M.NK72IBXM M99((HS8WGC1HXG'F1X61E+
IP^W&LS3_?S>%!)_9ILM%/2V\$&B3^1=I!9_M\$&PA;1;M7\$IVYC#3>4&+8RY4')(H_I?
A^*/@RX!9OX0B!7%;+XL12!"FI0F M_"@B);&I?>#GI73U!<_#7P#?KX<^!_>^&&H_\$Q/\$>F;I#=-W-K8^!0:8UQ%=
M"47R;FMB\$*.P\$K_W/GD.RLI8LI^QJ_"BBB@#GHQ2-1326-V^F6VF0Z9^H3 M74VHJEQ'M<*28"O\$07),I?
(QC057PS!5O!/C76KS1_#WC#0->U>R0275AIF MIP7_!^G&&>-+*1R1W%
<5X_T/4KSDZW=6^GW4!M)X&O+1)HX69&G;8%8@0_M,%R.004US%CV!O#EA^S+;3X?GLXM;F^S7:PVC#
H;MHMTKK+Q^!4S")3NQ MEIH%)^_L_C+Q_X7^;EIJ7BSQ)I^AC3GD\$*WFLWT5!^SG)"AY&4%G@!9SQ2
M>*/B%&X6!#^X!=-1^)=T#0Y'BH>J7!5M;7&4 E=@IW#ISS7FWI0\$<&F;U MXA00R>+;UBQM!VUM-6!^&UZ+_
Y)>WKN6.*679(88V#H(4>4094W;7Y' M7M;176?@WX4RZKH.I>I!3^RI6U2^!&^%UU_ T>I\$<2PV!O+!#=-_9XI%:8L1'
M\$!M4+.#.X@'KNI?58/XK!_6NBW%AJ>B>)?M3F^@?SE>..W.L;PNK;2"<<I@C MIZUIP_#P9<>+W!
(1>+M"E!6(I=M!34H3?A0.DF#=#OP!STKP+X^!%?%\$DWP_ MDO=%URSCA1!^!HVU;R2>*&=>2=H))EA18HS(' #
*JC+8ZUSOPU WZ^!#/_M@'QAJ/Q_3Q!FJ0W=S;V/A^DWF<170E%FIK8A"CL!*P-SYY#LK*6+*0#ZC
MM_B1X2NO&4WA&'Q1HLWBN&+SI="CU"%KZ./_!H_V!+@CDC'(J?QAXZ!_#W M1SJWBKQ!I?AG2A(L1OM808K2
.WW5WR,%R<'SS7@>@M?>'?C)I^C>-'(27 MFFR^)+^_U+2_\$?A4_9+!Y9WEOK'5E1(L!)G89)Y"LD B;
A.Q^/N!SIGB M#PFT*;UIGAX)>=^)/_"AX;UJMC<8C6""*!I/<%\$D5IBT@A<#RE4E=V2>DW
M7CWPS8^!37KGQ%I-OH=X%;VU.6^B6VF#*64I*6VL"HD&#R 32>\$_B#X6!>;M&^M>&?&ND>(M&C9D?
4=)OXXJW5E&6!DC8J!"UYXKYN!(?#S4=;^_"AG2M;1-MZO-Q_-P+)25'L=9L8X!@60!_DUQ/-
""BOH">DAVJ%>>>I:OQ<^N:N;IXT^M+RZ;X=N=2T14M\$-7\$UFL8CBUH6H=O>6;R/A'DDM46\$JS8Q(@;./21!=
MM!2>+O!Y%>#/?7A_P5;=J>J76G;E<+72!WAMFBLIK!)NB&_A!HYU;Q5X@TOPS10D6(WVL7L5!;
H!Y&"Y.#@9YKQ*X!467Q M\$^WPHN=1\$^*K2VT66_6!U74_#EWI=O9(UC*B6Y!^./?EB,,@;,%<;P7;H
MOC!JFLZ9X@!)M"FM;9X>"7C7?B3POX>&M;K8W&(U@BBA^SW!1)%;8M((7_I
M5)7=D@'KFDZM8ZHMKJ.F7EOJ.GW4:56!W:2K+%;C#*NCJ2&4CH0<5S7BOXK
M>%/"VJ0:KQ3H=GKKGMY)K+1+O4(DNIG;A8;('P=OP?NCL;XHE72=3T;X6W M.;JV&JZ;-
)KVKW;4.M6T5O=&&6^FDCD>.)\$C4NKA!(H'S?6N#?4H?A_H/O!_M.;!X_!3;YXBU_5-208;C!H!N+V'78YBS6F;R-
#/"T41BM_12)(MGD9'RI6(M!ZQH_P_9_#^E_";PAXP!>=(M!)!K.F6EU)/J5!96WG2PI(R(TS^K' W\$X!
M;ZK6!"ASP_X7/B35/\$EZ;X\$=3'5!R!CBM/+;&U_.9@FTY&#G;R**7K7PW MXD!&A!/\$JW'C30!#B!
:=HYF+Z#JMWUJ!TT4UJUGK8VT8;;_M7*!(8C)MFWYQ0""@MMW!9!_G^&K/Q%=>./#=#MX?
O8VEM=6FU;W2TG12 S) M*7VL 2_2#@%92>)/BYX&1&K!;_XS!/_&NJA3IYU+58+<7@;&TPIW'F9R;+<MYR*XO-
T!XB_#\$X6^<(K/P;J5CIEJIVIZ@)-2TA!-UF-HT:W4D3_/\$7+,%!Y M4#_AQ#92^+!/%>A^%XKV0Q6KZUJ_-HL!@9*
MH9&7<>1P/6E!3?&OPAX+N+@!0^*M\$T&;59!%I>IZC#;+>2_%A#L!;/S+P MN>H!;^?=:T_5!_GAGPZD?
CC2!/%CX7M;/3=2T7PY;ZWK%I-O<26%I+HEN(H M\$2_!EECC8R;?^3CC+7!H9!?"7PA)H?<
BZS!+%'FW9&E=2S26T6V;)+A.(?67B_XH>#?A!<6-OXI6Z%X;GOVV6D6L; ME#;-<-G&
(Q(P+G/89KI@;12!3K3C1!;36U@+>\$? M#UMKD!1;58IK&8BQN9(MDHD?;A2A.2#G?7T#1+
#X#_<^AK0K8ZEJFT_M3X;)=9D!HQ5_%25H_E+J_*=O"?K0!0B^+7A_1_"=IK7BI7_#7AA)_/S' MUR)H7;%
(58!XC#8&W=P_L!;Z9/2^?&ND>,%M=8T'5;+6!(NEWV! IUPEQ M!;N2,I(A*L,@C@H!
!%_#^INI/@@^K>^HFT34M;O^TVKCI'(RW"Q2/D?<M2)/E+=PQVKO?@OH=IH7C#XOK-I^GV%WXL^V67F0-
".CZ;8^9+&2_4S"7 M+#+(W!QU!H ZI6/B=X!_<*A-KXLT/3/\$>HX^Q;/>:E#%=W.20/+A9@fY(M(^4T1-
!3_!MOXTC!R^+=#B!6RQ\$T!H2A%^RE2P80%O.(V@G.WH.UY#X10 M!3X=ZIXO!^)?
>O:OK>O>)+K4\$O;'09+^TUB&6?=:O)=*IAA!F+RH=MR!97 MI/E!0OM-GTWQ?;ZVOC2TNX_#VA^%HIHK6<.IP-
'J\$FHM;-Y MDAMXQ(WEW'R!F*^6H4X/J;W^!)A*Z!9>=&8?%&BS>*X8O.ET*/4(6OHX)! MV@#;PN".2,*-7!>
(_GAI1=>&NW&F;3I<H!:=7L;/:4B M=JTC\$!L!@QQTKSG0600#QQDT_10#FD>)+S39?&E_?ZEI?B/PJ?LFE^(>O-
3NK=\$L6DN+^1 M+2;9XUVDR89!LV@;..!I9Z+8RWNH7?%A9PC;EQ6ND;H=2VW)7!XL;SIR".<<@UQ
MW!3HNI?LY^+6ZM5O4N+!Y;:7@2AG0.C9Z Y/(UKGI7N%!?2?&X<0>%?"F ML;:-
X/OIY!2O=1T6;3;VM#93P_8HH\$5+@/!^!Q;F2;"<6X3!(ZKI/QA M!NO^*
I_POIGBW0!H!2>";S1K34H9;RVP0#YD*L73!(Z@=12Z?XS@6P!07^L MW.D;7I^DWDL#W<>IK+\$D2*IWSL500O!
=T9)VA<(O&WPE24_M;186^L;:KCW>N;@/'L.GZ#H!>SO%D%O=?95>=3)*J;XIF56SN;&0#U_B;PCJ MOIGW^HW?
AB_UW1!^)#ZW?;:EY;ZR%OLCFBB;G"*=H9PJY+79SM#,">MG>/C+I?CCXC;1GA;6-%!2>&+!1+S4?
!4TFZ6Z5IX;FWBV++&Y3_\$SY&"<@ M?
M+XDTGPXDTW2("=Q9S;WK6AW6EQW;YN!<EB\$=RD+KF;0V@?>J3Z;JL^F7NA7NCI>Z?H!Y%#>275HZ+;84
M;R4*QN?;DVQC;#X\$P;@%VA'Q8HSH/HO_!PN;YC=OO@_M@!AKIZ^06T>ID_9IC^\$\$@CZ;XDH0+!9\$Z6
U\$7*NVM?VDJ&W)!S-UQ) MY^?EV;_EKZ!7(4 G)!F@!;*** "BBB@_HHHH *** "BBB@_HHHH *** "B_MBB@
KG/&WQ)!(#2Q@O?%_BG1?"MG<2>5#<:WJ\$-G'(^!5;5E!..<"NCKR!
MOMX%126WQ;M?WA;#1!;U&23HFDZY);J(S_YOF07*1RF)CDAU;3"3;"R M;D_I
(T!4K36+&^"L+J&JLKA!)#&SAF%M;26MJTZ!60AG#2RL!;&V@DJ!M_T217BNH!
M^+M<^<7P!LOB#JNC6^CZ%;ZK>^((+3Y-6U;2>>>)&^V-M&B"W8OMMADR1 MX*8;
!S!OBWA0_"WA;4M\$OM7F!5>(I_B"WA*TV;2!&RAGBM?L2W"LL#_AC!0I9&UJV>RL+>XTQ!XOCTA!S!6
MTI66&+3R87A_HAO+!L(-2%;NZO-3!0_""Q)X-/B/QI?>)?#>I2;M.U"FU M.RM(C!>.@GMY=UO#&\$B"PSQ
_#DRQ98MR0#V*BN\$^".M;_XG^".G;IXCD8WN ML23;E!;M\$D9M;.65GM82%_RRP&(3DEM37=T
%Z9XX!2^#;N*;PL^AR6LD7-Y?3&YN!B5R!DTKGIS;Q!8 M_"J J@#I*** "BBB@_HHHH JOI=G)J4.HO:0-
J\$;3P1W;1*94C;10N-)!Z!6LGE75M83S128!VNL;%3@!^! ZUX%8ZH00!PW!#_M
!%U;XBW/BV35YM%AU^P_)IEE#ISK?SV!-H8H5G5T;X=2!TBM8%1N&T^E MJ^>^!QAXTT6W^?CO5?
\$!UJNC>\$;G4TTKPM;VEK'!-!);/E!DS;^!LH M'4<;@YR;GU'5!/POA!\$^)-5!2-

XQCU_6= /T04=&>QM+>R47;>6'T01'9? M+=T? \$TL^Z^&03N !H5+1M;J;Z5;VI?VSJ7@_31/GU; !TN2ML5MHF-
HWAVK*\$4 M3S%A%M&"YH^B+O7-.T 4K#3IJ_M; ORXL16:95EN2B1G\$;DY?;O)P#@0V'C^XUC4?
@/H8Q'K&GZY;74MS>#3_LQNJEGO#^5(#)=V28|@J
M>S>/_MG|_#4^_&GC5I\$>TBU@^_ L5JFEBT;12;02>4;K15Y9*>9YVWSN?*V_
MD0H045M>+/%GQ)TSPM8/17CVY@M/!>I7KZ7X=33;(VEU;V1.TGU.Y^RQ75Y!80MY;/NGFD\$<2?#C+L;D!#J)
K4KYK|<>'M?&E>'? 6IZH0)/%K.EXIT|KJTDLK6WLH6-W&V;RHA+MSCB:68E>=P(YUM_M9^*OB+2?@K|_\$.^J?
9I2;ZEJUOI=P1O'_HZ1(IMQMVX?188+ YR.YH|H MKYO|5^/O'OC+XG>+|1-?)=HIX7>T@5_!&A.MS++))
<%KC^T9_YC_@0 M+;\$J?ZM_WA)PGI={#XA7? MEUZ;Y|#^+;G20|VGM;30:7 3,JQF5)HBK\$;O MG("MP0V&
JZ+17R_+^\$LL2A+!2P2WCS4K9_\$/ATZM/KIY9V.EY:61O; M68%G9J+=80=UPI#S1S; \$CDSN)#+Z;+?<
\$VNQ_//&_@77-8/B9O#R6%U;ZW-% M%+9UDCU#9\$62U679%CY") QR={240P000& MCPZL?@G_
&XURG160BZ"/3;K1FT^VBL|ETR6ZC:T=(UF_V'78;DEW;B1M M/O ^EZ*^4_AW|2OBY|0M*|_
^_J)TSQ5=VNK7\$;TEA7?Z#%HD=D|P64*XF_!_ M8XMQ\$;W.B8;0=J_5E_!1110 4444 %%%_!1110 445YH?
0%&K^#?A+KFL MZ%<&UU2U-N8IEB63;&N(U<|6!!^1FZCCCK0;Z%17DWQ(|>ZKH00\$&A;2J7V6;
M^#=8U=H5BC9EGAEM4@ERRGI0F2_+JTY;P*XOP/XB^('A>+|^#=_XEL;S^*1X M|V74|_FT^T@M;*8Z;-
>+)9F%*)0 T!4B9Y=9^)|2 M?&CQ=?;MK/C"/2=/L|?3-)GN|BL6MQ*FN6VG-J5YJIP6UWRE=K MO%&MY;C:'
/DRGOS6H?^?*_A;13_@ZKXTQ?6F^+O+5=7M+."YLI< MW"RP?98(@8;1NC+('8&2_<9P0P!
I369XD12;=X0T.ZUC5|CDIUJ TTVQGV@ ML%RJ"3R1T%?./AOQ9XW7X76>MZ|1MGOAJAJZAMX9_ \$PL(KSRW@
MM;E?M9L&;WRIE8;HPOR;\$+1/_%6O;_#;+UYK*VZ7"2;IC40JR MIL &1D;&_ \$FG>+M^@U72;C|783.ZOS;&3)1V1N&
/##PZ=JLU_&M7?#>QIX+;_197/B13/>IM15SI-W8VL^V4AM9YUFLC#&DGEJ8"&2=YCL;+M%3N1ST?
QIXDTCR3;?OAJ+68|GQ=;N9K|P^FGO>Q1VUT?DB^WNL 9C.&)9 M9#MC;"<IE /K*BO.?
@K>>.)MDU;T;V&HQ&TO FF:AK#6(OKVV;'=<)9.T" MR+(9%R@4.H0|0217.>#Y/&GQ2U76?&4^CNX|-Z?
IFO7FE6GAVQTZTFMI(K2X M;|S>+&TS/(8V<>3+/"1X^&(,+>TT5X#K/Q5|1:3|?%C7XAGU3|J7AW4M6
MMI+N'MX_12)%-N-NW#X+;#18'.1G-;FBR>?&WQH46S^;K30".@V^FS0;+ M9V=J3=331R&59I9(6?
ROD0@1LC|BWS8PM_9^_ AO;>_18T.YU/5M2_LK2|F M.^L*R;9W=O%O)9B8C;3|JNH|QDJ-RMTKKZ^7=-^ (OC_P
&_L^ZS|2- M;1477BC5HJ_+L_ *6RLHK2S5|2^R0S |(F>0(RN_F3+&2#CRQ|U;NA;M5
MO#1VNG48_%SH+)>W1U7Q8NA+<?>HH; MUT|B^C8>9D2HQ;1/F(+@#Z%H
MKYQ|\$(_B|X5NO@YJ/B7QO<>*AXZ7|+J>F3;?;06MG;=-FO%>S;4*2@;H"A\$
MSRY#1;2*Z#X21^_JB9X7T^X@Z/Q^NK"+7+;18/#5HEFYGV\$JDQQAfB-P;B M,%=SM;4+JW|H*=H
/J7>N;=I^I6&GW5_+VU_?EQ9VLTRK+ M3@'Y->(^_B?
XI7;E;O#|O@GB"QEOO^\$SF%LB^8+\$&V8!"N(Q<7\$D\$J%< M?NP=IQ7?
^_M>OM.^)WP|TVWE5+/49;+7*&)&+A+8NN&O7|_ND9Z'(H IRBO MD5/\$^O;_%.>>\$_%?
"T)QJ&O^TT|M;1H^K*"SFO9+9)E @67|2B|7W&0Q M%A@Q%;Z^Q5X|^>/_#-SXN|W&EVWB#5/#+SX#7^CBW-
P\$ _B0&>*50&_M!(7&2Q M6-Q?J?W"\$&X#AT9C@9!4_&H;*|6|XU^*>J;SXB@|>7^AK3|_UZ|TJT/6;
MG6QUM%;7#0;QI8VF9Y#&SCR9(OJ?PQ;9J|/_@_5M^7_13N+|QQKW.B. M%?&LMN;34X_-/2-
G^<OY;>>3;VL3^9@|L;|@FT#Y-V6(|O1110 4444 %%%>A MC|XHZC|^_6ORZO/LL_7^AF35-(M5B4.EY;1<0!@
6;RW%L44DG*28XKAM M;18?&QO\$7A_X>/>^)|M2L "UIK.M;OX/M|6XN+J662)U4;B1\$12M"W"1.Q|MQ;LF/G
/IFBOG.ZUKXM;U PK/0-0U;X|!;HJH;L;K=16UA<7<|G#|\$VR+ MB>"*=@L18#<@+2?1MQ7A^)?C;"*_P#
J^)\$EUV/QRGA_'O;>V;|F6U;34U' MSGB14A;XV%|H5(14WLC%#@|JP|12>)M-B|36_AYKG&L3V6WS01NB.^|
M&T8;5!@G/S<#@UJ5X7X=T76/#|I2&D6&J^|)KKO;(_JU_)%?ZG%;Q7IS?6FY9
M!;111%1@;2L;GJ^DC)Y;Q_XIL_@;GQPD;M(CVD6L^P7|BM4TL6C2*3;"3R MC=?;O+)3S;V^=SY6WY*
/J"BO!O"UQ|3/\$5|5-8L_%|NYM*U#4-+>YI M.VCL2VZV-;N01>(7UOXV^ (QF;Z'8_ M\$C4/!^@;:)=;VVB:?
82W333)*7;DEU|/+&084(&R#|X Q69#|7M;UKX/6 M@NM6N|Q?=>
(K|P;7^A03H)KK4K2YN(F>UCN6;\$3/%;O(6F+1QX?;<"#@Z M^HKY/M_B5|3=0;ZEX>CUO4M^|0V/C;3-"&I>
(+1/3)=1%G=6|\$T@G2T.EJ95_M\$S|&C"CY8IR_>W=2|AYKIE^T_P^O%GF^)_BJ_6^PO=3/'<6VDA9U2|L@|3|+&
M2\$D)W;5*L"!L9;D\$|ZT;7-;1Z;%J&DW|KJEA*6\$=U9S+-\$Y5BK;I;.&4@
M|1\$=\$JAU#Q)IVEZQI6E75QY5_JC2K9P|&FF-|@8&%Y|SVKP_?&7|;^&M_@|3|6M?C|6ZM)J-S|E|
(;IK;A<6|O<C;K7H%I"BE59G7+%U"IDFHOAS MXTUKQOKWPLN0\$FG5|'6_>E327"0)|E\$T^M*L#O\$)2J#?Y;:-
V|;%R@_M^A/#?B330^VCP;KI-Q|KL)F=8YMC)DH|(W#_AE8=-U;=?-WPO|&%_X#1.? M#>|O-0|KP;JQ-"NRWO#
(@G;6EHC|5?@GK60^)?A MOI^O^&(Y&J;U=|Y2@MVB2;VUG+*|VL)"@998#&\$&R2V|D|H|RN|6?&PAX'U
MYT|UG4Y;+AL6U*Z;^QN\$;X*U4.2.N9HXVCMT/E2;3*R;BA"Y(Q7B|LWC_P> MV?P-
3XX2>-6D1|2+6#X+^Q6J;6+1H%)MDY1NOM7EDIYGG;2_YK;|EN7FM_'Z|B^)_BBRMU1%V=TVGPPVE&%XV.HXMF+
M|9^\$?%EAXVT&WUC38|0BLYRVO=3TVYT^;@D9_-Q&D@!QP2H|&";@ULU;Z_ \$M^>|?_#_|\$|WB|Q.?GQ(16;-
X4D|66NF^&S9Q0S^\$X="DCO)K5+CS)S;N|QD_M2JH6)4^XW|PDX0^DZS-0|2;=I>L;5I5U<>5?
ZHTJV<_QCYIC3>_(&|A>>2;MJJ^?/#_A|QKX@;_")ZWXE2ZUX8UJ7P?=-;CX;L5TV;RAD2XLEFMDD-M)(8
M9^RY/FEQP%=1D5V7QIBU"|^*7PGL|U6/L;JZN|2A^VLBO+&OV)RQA1P5;7" MG;N|4_-&
I&"4RWHOP|;CX|^&(7C"|L|Y9_+G16>GZ>L; M(5N+LOF>XG#XW%=DJM&G_*2<9H
INUUS3K|H3;_M;C4;\$1FV|M(IE;6W\$ M@)C;B_Y3<2;@9_*NUX|5_ BOO|XSMX>U*"QU/1K'3)-FFM8W2&64-N
M\$X;+|QH^MZ|>ZNLVY=H+9W%M.M;A;Q|D1MH8@8F6Z^|C<%|YR;_J9;*17^#>+>_B)H7A0XBW_ (N(K7685OC
MX3M;M|/L_@MY2D;|Q_?2/0%0TAGVEU;|T|A1YCG_ \$3XE;|)_#>NWWBG5?&
M>L^_O\$4F@6MGHAID<>FPK+=,DL0E6(|<_!"9I3^OD|6;X" L_?2_C?PA9^ M/O^M_H&H2SPV=ZJH(|LRK(
&#18\$=5;MVOGG3O&GCIP+X|6^Q=XBLM(6 M"UCT77_ \$5H-SJKWT|QA^S+;Z42J2;|HP&3|!_&GO;_M;XA>\$I
M|I9O=>L?#L;K;\$WCN/2DN3=2M=1(LFM_*|>WGR|L;ODGC;?1M%?+=O|; MO\$GPZ|^)_K|5/%&J^++-
_6B^+|&L+>ZL&N|H6WFQS6OE6ES_K/G D.TQD M;_XVZMMXV^*PTL_ \$^MZQI7BK7_
UL_A^_U667Q==\$BGANX\$D;_ TU_FB MD42@^8A92J;U;02*/>_ \$B;3?^|O;3ZG<_98KJ|L(6|MGW3S2");|E|QEV
MR>|GD=5J5|U^/_#OC#2O#O@+4|>^(\$GBUM2|4Z_UU;265K;V4+&|C;-CY40E MVYQQ+;2O.X\$<_2E_!1110 4444
%%%%_!1110 4444 %%%_!1110 4444 M%%%_!7\$>_O@WX7^&(F16^L;M%JEMJ4.)MA>Z)K=IL
(PDEO*DDM)HFD0\$DA7 M))&37;T4<|JOP;|ZMX3T;PV=%_L_2M%EL_3/DNY|N+*3#|GAN+=TE MC9A)
(&97|8.V|XY/#GP_|\$^\$|_CI>BFWMVU9->?==SR)?JJJ+AW=RSN=B MEBQ.YLLV223W=%_COQQ|+KK>L;1>R?#?
7_%|6L\$D<&K>#O\$*;1JUH792|7F M&ZM&EPB\$A9CDJ;P#4?PR^)_M_||\$E^=-LXH_\$.M2ZPVBO\$<_<QY;6X
M\$ZX/GHL\$4AE0Y64DJYP/LU%_""9|\$?;_E^14T86=?VN|H%O9M6UB|O|J M=4;I?%+0;/P#X\$U^WTUM^BNEE
M;|N-6|Z|8VL?FW5S83PQ1Y.W.T;1D|(#)(ZUP^|_&AK
M0|A);G;E77|NZ78VVRGU2YFL+2Z6(^L5F93;1R|M_P"ICC#99CN^8D^G M;JEIHEFF7>HW|Q;6-
I^|Q/<2G|1QJ9FJ|_>V7GOA_P"5KJVO;58;EX4 M1^&K36E>C;IK45LEQJ;@B;RT6;=YHG;X6>;
(D(1C(Q0|VVD^%*=T-4 M2SM%C35+J2O%9F<2RN_KL0Q_0H&!@<=*Y+PK|? W@O6K/4M)TFXBDL&9M
M.M;C5+NYLM;1D/V.UEE;&U^1W3|RB?Q7H<5AV?|O<_B#PO?ZWH/P|77|B MVF_VIH|X8K)(-7@)7#Q.UVOE?
*ZR;+GR^90VU6*D|/_OP|0>(&A^X6|47GP MS|3W&N;O;P2?V|HL"TNZ|)&N\$D;|F*\$ECM\$TRR|LS0;WO_"N_#O|
PGY|_M;?V7'_PEH|L_ M#>^2L^_2LVYVYVW?Q8W8XSCBL6?@+X+UO2=+TZ2QU"PBT MP5?9|I
(UJT^YC69|J?;+>9)61VP2A8J2%X^48YX@?&*UU+P#X013Z=JYV MD0_XLM-

/(OK)HG2\21+AX9K22..G>WF*4VJ65^~I8\$\$!%Y80I8T_Q1H5\H&O M>|\$.T.C7>H6=KK'V?2
=01KM:X@EM9YHR\$=XP5+B1=Z\$J P).STOX:&~M#A\ M-0Z?I\$-C\X;B:2H;*MO%SHH%=K/J"Q:Y(3(#YD\$EL-"
<*P>X2#(R@W+D\U\X8^~M6\>)O#1 MWIOFZ1XE:=M5M /E'VDS(\$E^8-N3%;58UN3," MTJ&2M&
(HU01+BY_M@JV16<6JWD%E>R*JHL MTUK'L,DJA\$Q*R%QY:\$,"JXDT?X\Z1:9+^+?
A&XU3701^H>?%9XKYZMTF:Z>T5PL=U-\$I& M(GF9@R"-522ML\;)3"? &A2#S391+0122\;F\3=7%S65J(NYV8X11G-%
<5KW\0VG:/>ZXUGX5\3: H:@/0%K/B'2K6\K.Q> M)=TJ\7F2>X*#[WV:*7!ROWE91R'C:Q??^?VA?
A_H5KI'BV\|R:7<:Q%J?A M_6\>SL+MQ+9^51S301K*RM&RE7\T\$1R@94\7U?X5>&\<15R>(HFUNU
MU6:R.G7#6N17-O#=#Y#@)/#(LZ\;OA8/89'A>03
M:1^~D-T9A;R6P/WOG_=2R+|\H\IV>H\#/'C&Z\V5M)8^%M<177MQ)Y<=AH: M0"0 #)=I+B6&%%_OR
DG"@FF^#OB\9>."/+;HJE?Q^6T\SVFW.2QW<-Q"/ M1RP.N\O5T99Q8"7\;)2_SF3RMQ8ELY:|"K@+^~F@:UH_P
/=1LHKZX3QPRK12(Q)8@ M;2X=IP6^01H&RM@DAB%YS4C\:(Y/&%CHFI>#_ \$V@6FI74EEIFMZG:VZVEI
M,B_<Q529IXMR12,IGCB#>#DJ">C45XWX1^)^B^&IC7UUI;4-0%_X\DT&QVM MYOD%XT;_,PVQC#
<+G&>1S7<A\H\&OUKO'T*:2J5\Z'H\JL-E;B5IUG: M98XXE\RSYMWSD #!2?3HS50#P^~77\A\;\$EIXOT*SCO7T/
M50L_=00/+NW>.\J2'="ZLL\$C\3ZK= MZ)K L6AM(XYPK3RS022_O HZ+(R:#DX8<
'15%>5Z^~T%I^JZCHB:AX5\3>& M-(UZ=+;1=-BS-/SJIVBYBB))51\S\3EZI^U%I&EZAXG#^ M\$?
%4VA^%10;3M=10Q6\KIBTIU",78&X\$TJ)\$TSO;H.H:+K-C#1>DZA\ M=6=R@>.:P0RL#U\K1K%19>,*1 M^&;
%_6\AK;3:~\KQO(*Y)(542-6=V8JHH+;S \$F@#DO#?H/7@7PMJ=
MSJ5HU_=G<:=+L.NH:KK5J\J\RUG(RLT'FW\$SN(J'J@X4EMN-S9Z63X>Z\; MOA8/89'A>03:1^~D_P!\&86\EL#1
fY_W4LB\N^IGJ\1SGA7XS0ZYXFLO#^M^%?@\$C5M2AFN-,@10+;XU"
(*9/+;VGF574.&N0DM#;A6(XSPS^U)H_B9
MM+NOX2\4Z;X;U'4SHL/B.^M\5:/=YI6X@*I<-,S*8Q)Y7E\$D?/SF@#L \$' MP:\(^*+;48K_ \$R7=?ZBNKR7-K?
7%M"P_B;_ M@7X4>%OA09:I;Z#IK0)JLWVG4)+JZFN;R78L9DFDF=WDHF\CT^UT&\MH)\V^N):F)
(#;32PR;L;21+A K-(4520 M;?A_X1^#_ #/P^?P-8;1:?(E)^#)I5T#_5.IZ5:W\^1>2UK">:QJYJZED,,9:;\$QO\5)1>.:163
M8?S1HK;Q% PDVD:QX'U+0_*;7+W2\;C@DG^P+OW7\$;6LL1%_A7X\1Z?+2%
MJVDP";*UU9;#RGB97*W\!=+W8T8*8;-M9\;7&I\ECTNON#>69M;ZXMIFTG+QEAN8Y%FB M?IY(-
R.#AV7;"15'3_V?O_.G>\$?7AE-!^T:XB?S-8AO;RXN9-0?;J%YY99 M&DD8JBAF9B6QR372Z?XL#>\$&10:
HEWX1BA@DN;NTUB6W;6TC3<6:1H)98L; M5W7*!<G;R\Q;A?M\;?JFH:*FH>%?WAG2>G6VT77-
;MHG;74)71GC0(LS3 MP;ZJ=HN8H2257\;S\2_W@WX%#?>M1ZMI5C?27T\$)M\H4U>1U\;&^&^I M<32+;*0 "L(0\$*
>14^J\;P=K/A?3_<:2Z6&G3O=6\$EM>3V\W93;7+2 M07;K-\$Y\QON1P=KLO0XKSKX(G\K/C;XR?
\$K4\I\$M%)"^*_&6LZ5;V\ MU>+HL5G^%#%,;,>=7,*\$G8PV\B_&=N.;.T\>="(1\Z4VGZ/#')#)(9I9 MKR\FN\B>0@
Q+;\R2-A5&YV)P_15SFM?7P1K_ (GFUZZTNYCO;F5)HR&S MU\JM;_D0 *IW:Q2K\HU
MO1+BY_M@JV16<6JWD%E>R*JHLTUK'L,DJA\$Q*R%QY:\$,"JXIO3_SINEZU MJ>K6MMY6H;DL*74WE?;\$2E8^"<#
8\;YYS7\$7WQ^~\GPSX7U;0;35%T_B M<VD;3HT"-IC8NZ7<)GC2_1XVN9GC".0A(8A3OFF?!=&8?SW7;M=LM;
MT?3M"N@7C)>QGFDN490JRM#N.Z(LT;LK AFP*/78A\X\$VTBWN M?#<1\$UOA9VVI710+9\235M
M;OM1>_W2&ZC>KE:0PG<^2;J\QP*^<J^<(FC^&3D6D\;E)M;O>\DVBW MAM\I9H5E+L3D\^~\&^&^GBA A?
FHZAX?O15TOX7^~H7\I\$UYI=Q<6IE" MFHJ;\$%4DNU>#Y3OVW2P;54@ OA2=Y)V= F7PL'L,CPOOM(^?2Z;PMY+8
M\IWS_NI9%^?>H/4 CG8/@7X*T/Q" _B.PT6\%Y'/J\$>F6VJ7*Z>;ILLTR6) MF%HL5;2WF>6&W;6+9)-
)O%OB#3\1BT#3C\ F M3P1QV\374;/>^4L.ZYC"D*)CN'R<&O4-0<:9HW@&Y\8;F+K3-M;5+H7
M=JZ3V\1F1\6-X=5\RN;Y&*_)^#2@FIM_%7CGQIK7A\^&M\157<33918I M+BWM+>%8XQ;89\O-9_-/1-0_
Z=JFL;5JMU>;?Z6TK6.0<=JXNU^MI:~^=UOQ/X7\1^+1/28XYF MBVAF;ZCD)6;P? M9)9Q\H_BB\W+
(^@W+EWA7XS0ZYXFLO#^M^%?@\$C5M2AFN-,@10+;XU".(M*9/+;VGF574.&N0DM#;A6(-
O A5_AG^P=)T7^S/^);15 _J=G\Y\OJY M24S^*=EL2\$M@DCG&<5S^QD^%)M?LK6RG+3X%Q!"*S1H
M0H\YB67GC;IG;17^ _G#_PG\PL\);176_&B?26KJ^AL=;TL/>W7E7S19 MB\TB11H&B\07ED11E%SEE!UOA7XXO?
%_Q>1?PW;J;6EEINC\IM#U1U+V\$|_V MD7\$;O%N8",EHV96_7YC@4=-X=^#/A+POXC;Q\96-
U+J@1HH'U#4J\BLHVX M9+6*;5X\5" 5A5_0", "LK0_V;A\XNZ;VY MM+!+!+;PDF26;H+\$6\NM+N8\IYE2>1A
ML\3N\6SOY\$ "O=VL4JP7+*HS.CG"J.@ &U\PYT+0?&&K>)\AN\75-6^V MK'J%Q\DF<*B^;7S\K\$NV-
%;H0.0H\;%"^+ B\X AN8=4T MM+!+3="W;JCI7L)W^UM(N(W>+ CU.RWNZ^5<1YV\I&X<\J\5/&O<"J?CKX3^&?
B-<65U MK-I=QZC8JZ6VIZ3J5SIE\CXWQK0 M37FIS1V?AR?57TN&"W-NZQR@&O.V)/- A'EA@Y.#S6\X\;TOQY?
AF-O M"WBBPH_BBW_QH&JZS\;LZF:#YQ5%BGDEB;R@S@3I'D*<9H\32_AOX:T94J4##9-9'A?XWV_C+6+=-(^)
MKOPS+5MH\JTSJ2"50S2;?+*0)OAIN""D;D\40FERWEGDV5_+XAFM#82ZMJVL7NI7+JGOP%#X MA_M>/HT?18-
1&FKJ5T+^V)!*+D6'F_91-Y@\$GF>5NW_-G=S6;XJ_:\$MO#O MC37
Q8>"O%7B>_T&U@OM3ET>T\FWMYE=DDW37;9?_%<@M TGR'"\$\$SY MEK^T#J>M?%IPSH&A^"M6UGP?KFA?
VQ;^(K=D)(WC9\;950LFX;3@%0\@8'M65X"^ M#_A?X:WM\>Z+;7FH7D<<\$U_J^K7>J71B0L4B\$UU+(ZQJ68B-
6"@L3C)K\$^& M_P6-U;3PUHH7UKJ6J6UO#YRVUTL4D3"\$A0Z^~FT!>44DG(-ME'Q\TB\T6VO="T36\?
O+Z_OK#3M*L(H\ M2U^UU&UL+Z+3TLK_ \$C6:C3:F01QN)8-M\HY0F2N48I
M6\IP<=<9JWP=1ZX\TWPO)HRV>C:6ZRZ?ID\MC+92*&_D@F@9)(GPI@NC!
MB\$8G<H&_QOM&U33+G\J6CZHL8NK&?RTD"2>6\QMF;2-PT M;LI#*#G"W?1ID7\JM>(K'2?
A_XS1\VOAV\>QU;4M-M;7L;J\I(1%1+8181);H9)>ZGA4\@ MPPB\I#_ =JWH'Q>T+Q-JGA>TTLR2#Q+I\$FLZ;?
20>7\)&ABW1-N(=9<3*VPI M_ =2*_*VK_ GP7K6DZ3\FGWEDFDM;UC=;5JUY87EN)GWS*ES!*DP1VP63?
MM;:N1\HQ<1*ISP=X(M\@T\18\ATB>ZNK)(YI2(I;C/GOROW%IS\$|L\DD< MURL?I26DZLT=MX;+>
(_%VK237@CTW28;9)&M\Y>V>Z;L\4*1_+&XCWR*1 MFTE4(5L;IG=O#E\HNCZA%#J&14-
>AJ2SDA5+BQOISJT=PA8;=I0G*E@0RL MNY6#\$ YKXN_1^)/.F2"S0O"TOPLQ)%&@2-%JJC'
KA_~WQ2_L3Q98;5H&IZ_KF@Z M9;DUE9FW3SUG>9\$"-&N5\B\I\$F;OR@;2Q_*XGP?^T?J6K^?I_E_?PZ\2 M3>+?
\$&F?VC%G&G'3_G@CCMVFNHV>H\8=US&\$2243;MC^5AMQYIOS+@_-UX&73\;CU#0+25OLUY
M;136RW\Y;XM72Y0%=VOHL;@XZ%<9SQ7;7\>(9KR\ M-9\&=>*"EVEFW;K64_ML16F=1MX-OFF(PW\$@1QYD?
IN"/@9X^)^6H"/U2ZP099FMQ9S MK9;M>64=Y;@DB&ZC@EL;F\YF^28;N<8PQR\Q1\#?OBI58-3N\N\#4(K=+
M1KG014N*>>WOD\;66\SHW-B.3\CM;~XGLD\> M(M3TS1A<6NH^*+&*!;"PG2(LZY>9)I2A(#-!%(8\$@\$J\V
#K=0^%AC4-2\ MZAJAGL;OP\Y;FR:9?7%EY<4/D;(9\$5L);<9;4@9#L&5XI\B%)?)"OO2&EG MQ+IC7TNE3-
<6%Q#=#S6TULRI3+%)Z.C@9_2&&3@BL?X>ZY\$ _#ICX\5>.?\$ M.L>X\;@73X;&*2;W'EK)*TL;@R(2N0"7PF<\$
VT\V/P9\ZK)X\^MZXIU\;D#3PMJ8NKZ\;Z\^+F MU_Q%=7%C9^~X\>U^UBXAC;C(IM<"*45F\$@E;,%/S@X\;
RU;X;^~ M\H= MIWG-NI\J\^1?76_-%8X8;<9_AQGOFKUQX2TFF66'B66TWZW8V<1A;W M7F-
D\$SQ^FT'=S01)\(VA\$9;0U_XS16J2Z=IG@GO_XIO;_*758=-6S M\IF>8F)*TUS&KR\?F;/%7C_318LUU"&X\
M\16RI;LH*N\W4\Y\^(\K4M)P2DH DT_X""^*4C7\2\FVN5NFOEL8M3NU
MTU;EB6:X%AYOV83%B6;@BW\B6SDYK3O\A3X3U#P3_P(C@YE2TDD= MC')YIE\$B2%MZ.LAWJZL&5@H'
QRUQ^T3I%TNFMX\;)>)<=UI=MKHD-Q/#O?9AO+BWN RG;RY)+/X\$^~17PWJNARZ=>:I9ZIY?V MN;6=5O-
0NY3&V^~(KB5Y@8V^9""&QN5VGFF>?@%X&\KKGv?2)H;7+;# M5+G6M2NM3N+VW7?MCEEN99=0)'RW
1@<5MMXRTSQ\Y\%CZE)H%W\ M;A:ZA9HK2>48BZR(L@QN Y'N.9X(ZBN%G^/D.BS>\$ _#ICX\5>.?\$L>X\;
M@73X;&*2;W'EK)*TL;@R(2N0"7PF<\$W_#_? OAVSUNU71YM8CUJ MU6QU\O\$6HW6L27%I-

V+2RL(10<^6"\$RO,FKG@WX-^%O MQ<7&FV^H7\1MD)MC)K.L7FJ-""2"88C=2R>5&=JY1-
J1#CBM7P#XXTWXC^\$[+Q\I/GK9W1D0 MQ741CFAECD-.6*13T=)\$=#C(RIP2,&N6D^-JO<=>)KS3-&\(^)O\$FG:??
V?J M%&7:0&RL[!\$!T(DF2?;9D;C:Q2A3E20RL 4/- &7/AM>H:1=PZ+>LNC7 M45\I5E/K=-9:9-&V4:UM7G-
OCIB)%&TE<=2025JY1Y02&B/POXE%CI^@_O M-#H7VR#3W4FWMOIZ3S.L<:E#;+DJ9'1/-6 Q@MG?@\$B3P18H?
%BQJ*TP MMXBET=-RZTY2\$X@&G&ZMW=-)HB\,9TV0%(GF/L99A45Z-!JH MR^\$1#@UG0 %-
Q87&K7&CGOA=QQ/9->&IEBCA.Z\I21OVQ"7R?*\$@+5\1-10 M'NF-" P/K'BO5X\J73-@^T7"647FS%
0#L3(W'GH.3VR:-.DHKS7PW\,H\6 M2Z;HNM^#?*\$W@F75BZZ1/X@BM1#J+(C2-&AMIB4QR>6C/Y"/#4R1>
(O&^MZY<7<.GZ?!\6J:C=^3))YC, T5O%'&%+MQW1>8P3O<K*_%|XO^+WC^&YAU32TLM-T2=H>J.I>PG?
I6TBXC=XMS 1DM M&S*P",<@"#UVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "OYX1M? MB\X\0^@|Z22*RUK3K39Y(OOK^&T;\$X#&O_A3\|_P'ZOI_UX"> "S3 MCI\$>Q?
\$VYB6)\WWSK&5658\18M&)PQ GGJ#SN'OU% 'S\X#^'\BK2O'EWJ=
MSIGA3P5LNGWMI>V A&^NW@UJXG92MU+80%#-.I#L2&FD8R%3+C)*N_@?X
M\U3P7X\TS7/#_@KQ7;>%;"32)O'NJZO<'2=50101PW\C&R?9,@BE A:&50)V MQ)D9KTOPO\9O^\$D_X0?-(D_V?
X2;4(O^/K=JF^R^9S\I;IWE^V\JZ\,H M ^<-_9H: ^O@SIGAW1;SPKI7B.Q\7/XEB6VM9(I+BB-I)<_9TB50P&U_+X
MQCELYKH\2ASXX^("B"27_&-OX?T*YL=%O)TC2\%U&>_C.EVL8DN)HB2W@(P M(E41K&0 68LQ("ATT4
>2Z9*M>TNZTRXBGTAYK/P6/#NV\CDGA.Z\0\GC&W M?"=I!^96/(05P.B?L\>+AX<|;=>NG>&? ^G:O86EG8^%I U:
JO_AFBEO\;^&^&-WAGOC^;#3-,T'4M+FB9F\YI M;B>RD1E&W:5
MLDL#DK@)QR0^&^MCX^&^/#WVK3_MNA^)\K;6;F3S\MX8\ MU\AE0\,E\I C \$ 9\XYKVBB@#PSXG?
L\77Q.U3XE2\KZPMK#Q+IFBP6)F@-T(MKFNP9I@&>!\@JR1%WB\3=RAP=O\!*>#2@O?
6MOKC7'PY^&G@B\GTNXL+>Y*H MTTTDB;=I3&T@,??,860G(^?C\THH \JNOA3JT\?P85;BR\%W:SZAEW-> MJ-
+N;3\$/R_?F4_M^4\$|<Z7P9*)>)/FD;IH.M0:6^FP:C=W.FW\A>2R3
M7,=Q=37\I2%Z\$H5\$+YH7"R2AL\$Y7I7H=07UR\IG8W%PEM+>)/%&TBV\&WS)2 2\$ M7<0NX\|D@9\)%
'B\WP^)\GA:T4>&O'7H\;OJMS/%>:JY\ MLP^S)"Z7@6:6\IUS-!PP0YV\FZ7P5\ (SX\5>!\9--G5\I\,^%I_#I+
<.3,M)T^_ZBN-"BRYDM\O'E\OR\EF M6"<.\02155X6\;\$\5%2 3I_L^?#/\4/A\I_#U='BN9-5O\4\!H\I@LH\$N+
MF298HT&T("AGO7;ZIXFTW1\6T?3;RYF\U>:2"RB\MF\UTB>5AD A<)&Y MRQ XQUP*U* /(A\I&=5\)_G7-
5O+Z^E\T.V_P\I\ANV@W&>U^W3BYO3^&T M8E51M)PF0<=*\W\%_LQ^*!\8> M1U+1? JWGAG4?MFH^(-EN-
=1_Z<0 M\YF>W4P.6G\QD\Z8\$|J\@_4I% 'BGB#X_^(H#U>73+2G2UR/QDOBO2XIR2
M46T@7ROY.SJNZ.LHD7.YOK\$ M\IG)?QVWEMT\$;HCONOM&&E08)S\W X-E 'RH?L.NR6?Q,.7A_P)\5\4^ M' (=M-
)*|\EO#/'<.\9IY?L\!EWF<9(C\4#&&ZGT+5_A7KOO*N=1G\70Z;H MT>L^\$;SPW?
VFCZA)>>2TTOWHI9(MP\OG)12&..\$#)\0TC59M4:_\$NF7FF_9 M;H=#>>7_I"J_1^L=OD;.&I:W\RHXSH4->)2>?
B5XZ;POHWC5_#_MH>@ZG M:;G\FB74\W6L26K>9"#;20JMF#*L3L_/PK("VX6/%7P9UK7/A%\8"/T%U
M8)\J^C(34GL)))\$40N(%C3S2\$)&"#G:&XZ9KV6B@*"VC_-O%&V"50*<>PJ6L
MQQ\XFTWPO;VD^IW/V6*ZO(+ "%O+9\T\T@CB3Y0<9=@_G@9Y(%E\7(-%;P/ M+1/
JWHUJ"Z5\GYU\97LD/G)#=6UQ'<0.!\Y=Z"2)-RAE\7(R.M==10\Y M\IO@SQUXT?>%O\$CFW\Z/:^%VN9\Q\ZA-?
FINI83\I))> "RD6.2\T MH?+LGR8:A=?\77) @QX=|(K=>:-2TIQ%8:M+*9\EH8-62\=5.S)8Q\JO 0 M\NX)
YKVJB@#AOBMX(U7Q=9Z#?A^M M+/O#X=U1=6T_ ^T\$9K:=Q#+!)+#M^
M95>*>50Z@E&*MM?;M\;X0^(-CG2M+U;4D\+^O%/A_5X\5T>PL\HXU"S;\$ M\$SL\$=Q<-
%"Q\$=Q*H9(1Y1VMB7&T^H7\JS6>K;:9HEY=Q7AD\$EY\Y?DYFU= MP,NYPWS'Y1L5N>N\!S6A0\XH_P
/_&WB/Q5\J7C+Q_ 'X#D_\$KQ MTWAC1O&K^&%;0\!U.TU.25-\$NIWNM8DM6\R\$&VDA5;.&58G8"?A60\$;MP\JM MHH
X_P">#\WPOKWC\JN18)(M=UH:E;+"S%DCC%G;08?(&&W0.<#(P5YSD#SM M9_&=C\?:
B9<>\$+&0J9F.&DHJAKE_-81@^5*2.6>*"<="ACYX(9<5\I56#2 M\UOKJAM(CRZ""XN(XU628("\$WL\EMH) STR:
02\!P1U3PG>>"KJ;4K2 M^N=U+6-8U>9\$;9B;_LCB\!FPBQ*5 9L\5\;R3FKE_X3\>^#?7B762\=OX
M=US3/\$T\%W>6>O7\IA)8W=O'F6.2*"<3(T4;/IA&0R?.._"D:Q\JVE+ M9F+3+S4_M%U';N+/R_W"L<&9\I
IK\B\HNYO136A0\X3IOP\3_#W1_ ^H>%=2
MTO6_%7A^/44U"/63)9VFJ#4)EN:O\;2M;'1'&Z'9+M12A#9W"E=?\;Q\X\ ML_BG/XKN?
#FDZAXJL=.\TNWTJ6XO(=/>T.S)HG=(6F'E.K%E6/Q7;-H9QH.MB@#P*+A X\^*GBI4;
IQV#^AZ">^\$-2\+MIOA_4;B^E5KJ2\$M<"66WA"*Q MD;-GRE1\SI\CM\#POI_Q1NX3HOBR/PG'I<5E);R:QI5Q)\$M1
M_\$5\Z\1 N@C\U=A2?&G "O?I&J^(-L?JH?845_LWF^70RZKC=@X^JGH>E9\ MGO(F7Q\XPTN#0+S4Y?
#1=6\66R1M=^>K"K(45=NNW (SJ">577PC\=7W MPL\^&J7%?#WQ/<^+=/B2^UF\8"!
(HKZW0\$LVDM92%D#1)&2 XO/P0W MJ?A/PCXA\ P=T PW?ZM:Z\XEMM)%G)\.IQ2W%O<3"/F56D\RI\,\$L^IAD
MDY)KN**/FGP\^SCXGFTGQ/;/#X=^%E=1Z;+I&@^&|ZZU33+2^L\K\3'=^3 M+^)\\$I=(E:'&-
RIS(3C;W>F^#/\7C3Q\X6\0>.:?P_H=KX7;YGL\^P_J\$U^ M;VZEA, FDDEMx?18Y)OW2A\ZDR?)AO6Z*"/
I\X>.:?I^E""=4\|SZ)>>*M/#BZG:S6&HSS165\;7DZS:@G6)GAD#0V\!_*&0;40&.UMOL\B\I<22\UEA(9M
MP?;^Q:5X%O\XC;:K\IDUL;V\;?V0\;LWF&SD?^)\M*U7Q#*=O\B:*SO;#4\0:Z\HSK\$SPRI4MCO\$4@!
M61<?;&7?"KPAXWL\WC7Q7XT_L&VDUR#3X+33M\N)KA;1+<3AD>.6*;RDF; M<")U(VC;N;U*B@
HKE?!\C3 A;9\$2_K_LG\I;O-I>?W^&Y;HWF=!\MSO\ MN\XQUK\J "BBB@#SOQ\;J2U\Q\>KVAJEM=>%
IG1\$61V#B>20.K\$12-FIR M%416 MRZ19H@#Q_X9^\$B\A_K'00\2IX7Q?16CHMK\KKW5PNHO9\;10-9B+RQ(\$H
M9OM\!VE_*&=HX;X?LOR?#N32/#_/PK_P"&KZ)H\9-R(I M M\FVF95POVC\3RR_"^=M?3-9.YOK\$IG)?
QVWEMT\$;HCONQ MM&&E08)S\W X-'Z5X)OK'QOXYUF26W-KKM09Q6R*S;T.44B-O&W\!+C&"> M_2O/_AH
/(&/PW3X1M;+H>JOX>*\IX6UJ;^FMPBYM6;XMF\$#^0;=@(W\$6\ M<#O7&*IVHH \U+X*^&
I7X1^=.T#4=+M\7AW4+B_TZ\N&D-IF9KA)%?%;+P=;^+Z&Z\67B--KEY\;-TY\J\$
M&14BAD^TC^+RRT/(AS##;J\55L=+L\I-R;T@M#;*0 7; ^9C M@9)YX% 'SAJGL;J;+IX6TS3\I?*\$C0-
'L>A6VG^D\$ATZ\X@9RU_%"L\$ MZ2R2\HJR\$1\A^4 G#?"#6/A1^S\;M\LM0L4\2\A;3=-T:ZMXW6VGO
M9<610(H\;\$QSR9!%# #8^2OINL>^!\;J7B33O\$YH>FW>OZ;DD5EJLH&JU M:HXPZQ2D;D#=#@A2\JZ/+8?
A+XD^%FJ;H?PX@T35\$@T"TV7FC\I=RV"31V MSRO<)>B@#R#P\&WC7Q\XD\92;J8GQ\I
M=C\UIV\BW4UXMB(!#O#>K^"OA M\XGN?#ENNGQ)?S>0;I^D45\WB6;26LI'R\HDC) <8GX(GZ+HH\ZTIX?>
M)H?@*O@N?Q=.GBPZ\$VF_)%)YCRQ7)A*+."IF1RK\$' MO6/C\;_X1'X?>"\$B\;EHTB^&Y9;BYU*>Y6)\! M\T4
>577PIU>X*MQ9 ^"M9\I0R_+U1=S:8A^7YCYDRGYMOR@GK@'I MN??
Q2\06BOP\X_A_ ^T6IV^OK/4\;O+F"ZTHQWFF5K>.\UNP\I967H\! MAK\3IW"OAKJ?
AOQ1X_U*YGM@TWPG%HR.Q9IU>-BRY4 IA#R2#TXKTJB
M@#P'0O@EXR\#V^C:WH5SH=YXGTG5\$;OJGZMT5G>V.IZ@UUY1G6)G@E79;G M>
(H'E'7;0P<=G:~\$&B#Q)X\0>)>T.R.O-(N+Z6W1M+GFFCBGF@.<.)!;F M9@>6%XY\+HH ^>O&W\HGO1\2>+.\\$<
?L7B4VTES%XRC\J23IH8 M5@WPRBUN#&T;1GR2\K\$=-P K?"P\UG4=;TF>V\+> ?%^C6^C6^FQ>'_ M
|#\$):Z9HMTDDCR7EG:K\;CHZ QGRV @0"7YCCZ'HH ^6-4 9L\90_" P & M^++2?!\;KHWAZ\1X?%10;S2=1T:X
PTH\;Q\;D9PC" /C;,>"!OEVO\$O M\%|!0=;2V_A^P#\2)/\$;=H;Y_&D/V>X\B\;(&FAD6VN\;C=(XSY!\$>UE
M8ASO^7Z-HH Y8^#S\;YO#5G;Z;FK;6\DD.GV_V6SCD;K^IG&\9^N)(M\YIP5\=-3\I
^#/#>I7;JH&F^\$XM\F6)V+-KQL67*%@.(>20>G%>E44<)& M\&2_M_+?OP?

=Z3J4UM/<3:WJVT*UJS.GEW6H7%\$S&"64"<\$E4.8!P2.3S6 MB^\$/B/A #I5=4TGPRGA?40"VL:O.M8:6:7\$M40XI
ME:&.(VY\$(2.-85=)INU ?*4L2.PC^# BOOC59>)>8*)^&K.4Y:V^Uf0+Zf MAO=:MS\$:6fW8B-878'HfS232D>2"B(2
GO-# BMUf1%=>.O#5WxJ30-)T+PM?2:E92:->3W-Sf5R::W1Y(Y(46V15GD?8'G).T: MP%.[S/P7^S'XHT?
QAX"U4M%)"K">&=1^V:XT@>6XUWQ' HUQ#OF9f=3 Q: M?S&3SI@3P"H&#f3T4>%V/P>f8^#f1+1\$ZIX?
GT2f4>)"Q:UfL-16FBLK2TO M)UF=:L3#(&AMY#^4X^5UYG<&f12"KPAXWLfWC70?XTL&VDUR#3X+33M"
MN)KA:1+<3AD>:6*.RDEf<")U(VC:N;U*B@ HHHH ***** "BBB@ HHHH *** M*"BBB@ HHHH ***** "BBB@ HHHH
***** "BBB@ HHHH ***** "BBB@ HHHH M ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@ HHHH ***** "BBB@
MHHHH ***** "BBB@ #G?B-KD_AcX?")=8MM*Nf=N+ #3;BZCTS3W9+BI9(V811L MOS:VQ@%03DC
)KY4_9YN/#=Cf2fP_#X,UCP+>V>HZfJ,NK0_#W29+;f)EDL MS&E-f77Q&fF2%V6*Z:3;<?:DfT:ZEU%"00+;H*
MZ%&f&E>* @M<^f6M,TY= ^*BKSYSQ8DGfE:5fL4316DU_ \$&0/\$T=G^f MD98S)=+N:&_9E%_PfX?MfU?f
9T^_.A:9fFEWGAf4K>'3:GPG82:9fB(MfM9fLFGO-,(X_-+L&C XOA+|3+K2/A)HMGX:U+60AfKUPE
MGf4*01W>fHYfAF+2>11A7fF#7#CS'8Af\$Uf144_?2*OA>3X4+Xf1UL?fK^SO^%Q M-X;Q
OEfCKOYKR"5_M2/fT2^;M_X_= 3FL+X"Z"X400"A" P#=#7C3P79>* MXfYNMZ5X>f3VNNW2FW=9+?
6>>fED4ACNW7*;O-C7fR<f'fHH ^?fVK=7fM M<>%-f61>\$;#0+
fH5=/KWQfMS=:%;31",1PRVYfABEFDFUfCfR1< "&0KEfW Mf+ZBES^SGX:&K75UAf/;QO?
6NM/86MS:0Cf5N+M;=2)+O+>9>;fD#(6*B#(M;fWD#f|+K"8Z7KfKfA?AW78_#VfJfR+)"SPW-N=fEHC=K.WW":f;
MLB/.64"N1^fMOX:L?fWf@S6/ Mf9ZCX,UF75H?AfLEM DRK:&-+X^TRK< M7*fEL&1\$f9R0 Qf^fJO OPfUfO2_&-
fXOf8>(f3Q)fXDFL5TN_Z9f9TfZMf+82& Mf1ECB::9RSMf+LfK?ZM-H49SZ)0fNz)"* "GO.^('PYCf6:'9>(f"V^f;+ #3
M=4(2XM)fL&UY:f75V3YMI8';O;fKf;fB7Wf->CVGBGQfL.B:fHWC5K&(fM;+2fT6YMK>^OK>"SOP9\$40B;
fC:CA5DB@X8@f(WYf10f1)f7PDI:1+1&_%2 MBKPIX)fTGPU9:fH6D'4KR.ZfCLfL-Z:f;f=7.2XMfF*O'f&&95CRfI/OWf2
MGE_f(OX;_M3f9_PAfMP_P#f"3_8O_YfWDS8fWR_F^S^?fFfW^RO,W_";Z Mf?HH ^f1OB%+X
_X5?+:f|&Y/fL_P_'B6U'BF:P_8/>Z%:'&*4.S16LD4;QB7fM_9_*<
+DS97<#A7'A#PSAf\$OBNOA#QGx6U;PG??:6YfT_P"'">DG3f)Lf@3G-MQ;R)<31"X8_ _E_"#%\$6_?"
M:B@#YfHGf%>" #IN=&NTf MNXfFTRfMWNfM46ZM#"f64;fJO:7*fD\$R+fD=ZfU^fQB+f0_4^fPTfO:f+XfT?Q5
MK>N2_PfNz#H>f3MXBL(Y+f;f=X_90C%fM#QEH>fJ:fJf;f+8W'Q:@6:_'ETS%N0D?PLN48=fU9AT=f|fC_#_D?#OXf?
\$3PG MX7TRfV^&fT31=4BT;385Mf."YEEOX9(X4_1"ZP1;MH&XJ":N'1_";5Yf MXDUK40%P_9ZU+Q?
fJfCfX)U_PZLWB/40^&G2:ELfO6Lf=K=fYf1<0f\$;_22G MFPI9:9<6MS;^fT@T3f+
MfYf5+Q+5fDD6T<+OW&W;QC&.*fTf* "O.OV@_";^&OA'KUW)f2fK6f@AM9X7EEC
MABAff2*2>=HOG\$ \$2NTDFWfJB."0.D>BT4_?&7P7:0+25OB_fIA/5?f^K^\$Vf(C MPW
_X0'fSI^AM<fUZLAC07;f4DNQ8ED>;C.%##*X&fX+^&OAOX4W?fL6f^&- M*@TO6<<?:
K;fJ0H%NM6B:fLfF<_YfIAK@^;#&X_A.TCC%25f1%_fT?Q_Y+f%)*MO^NfVf|fG:>=#^&fAGP1&_f/CK2-(Mf7QH?
&MC&? \$"Hf?&"XUT6fEL9@- MYM_)E;0YVf0_.*^fTf* /E;29/Af1'XfUf BM_9_ M5?;\$=R=* MH;=4^R_: M#f|@_L@?
ZTQ>fY6?LG'F>=Of FWU?_?#6"WfL_COXPf+Zf1:W'Q_?4f7@T:4YX MDDGM9?LD8CB@=Af-fD^9E4@.S\$G_235%
QM"=%fW?C7PEJfAGQEF,M?%E MNfFU0f_#OAB:UWfJ7fLXDMM79fV6f12&.f|=(&fV<->)P>9f^)- U+XN_#?Q
M#HDOAf1_%.M;M;U+_Y@Z#f|<f(f"2SNW>#6+TU9fR'6>7fO)fOfL^Z?N^B
M@#X@^&fHfV@WGB700AE/X6f9>_9_>fIF/Q5X>26VUE+R_4fA=MV+AKEY"/W MLfDYBRA8D#;fL?_70_ "EfXXf(7
f;f;f>f" f+Q7"/-UO2O#WAB>UUVZ4VfK) M;ZPSWLLBD;=VZY3=YL:X.3@_8f1%_fF?QR_XfL_W_&fNF?fHPUf_>fOAFX7
MA^&?fO_CfZf1:R^f)DU35_0TK7)\$fNf+E@MHf\$-K+C="ZEF"\$;BS9SFOLVB@_M#S3XfVfAJGP9U9-7UZfPU8;+2?
4fBUDN;6-5FC%-+f";2XSMXM=U3PE;W&H>&KS3WM=TDZ6f3Qf;(5G_M_NXfI&C7;(SNX;HKfBHH^f;f+00#NG_
E^f)MYXf+7^\$=f+f+S6=fE_9?@f1 MC9;);W"Wf+3f1.MQ_97f"R+&P_U<98_fGM?BU_S7C_KST3_V:fOf>B@#YQU7X
M^f^_B1f;_BQ?>*?fJEKfT.FZ9:fC4(5F6S?R)B9X_P/E3?="FKAP\$0_C%TSQf"OV?>5^*fV+OX>W_Af9f>H8_M<4
>#_fG4OAMf+&P_7>=f3V^G>%fTf1;Z?335:6P56%VO^Af1Q@&Q,P&U_M059V;";6KOfH:2?)_AMM7_VO@&Zf
f%V3Sf;_Q+S%_)2+&R/M'V;S2X_M2+WfL_DW5f1^%_@K%&NN7OC+4Df6;fKEf9WUfUf/?"?QLCU*)f3B3PQ.?
%QF2YfFC>0WIE>TD_*fM_*^SF&0%0fH5Of16FT*;Yf\$H^_O'WPMf+P_#fH?Q^=(MY?&>DZfJfFH;5KDB
MW>ERP6T4B&UEQN@f!=2Sf!"_Q9LYS3OBM;Z3fJWQf5f)3f9f;Z-8_8MX6?X@;_M'fY");9?_L^9KR%Nf!
<>=N6)?&8B204^RZ*/f700A+HOBKXfL_#Z?QEf(M'fINC^fE>fUNP*"fF%U%Y=U_
;2fBfE&2" _S*SN>"37E7Q+f12Z#fJfQ\$NM>@? MPAX=^f(KXQfLf%_*;3)KKQ@;>f4H8#fGf;R:K=?9EQ_'4VG6P\$;R+
<2K'fL;f5f)Yf)Z_DD_ \$CV'LS5_ M#>fZf>Zf1=WfMfHGTfFZ_Y9DNP\$4QB>+2Mf;8f)7_W@9R.0"-@ HHHH_f4 M?
#+PAJ7f6'BU+7KKPGH=UKHf;C=C4YfA>Yf^&XfL%AEfTKNWHfK;JMG*ABfC) MKPUO^\$)_X5O^C?9O^F=?;
<f>f)M6TBfU/6=-MM(fC37D2RBRDI;= _&AN5AM4R+AB MJ*XD8_Q_fC_#7fL_VL?""B+Q+X?
f+V^KZEhUREAfJf65LDfWfJ<=Q9BW2*;10_M7N5C#"fMX4';P#7fT7f10f)?)?WQ%H&fJ?&X>(f#fV'ZfXfJU0?)?
f=T'0f;G_M;Q%81R6=VfP;S?&Y+_0XB&R>f?WB#9fT\$=+ #)fD'QfCU\$R3#X'XED6T8D"Q_M7Q=DHTAS_P
NOFAU4_ =^W%CU*fOLBB@#X2^% ^AV.MZAX<;7?&G@SPWf;(f2B_M?4XD;3^Q<9DN09HWD-Z97M)
N ROLYADf4*NW_9_%B^f^f%_V@&U6fN/"_MBfQ7f+J^fF'fVf;f;f>fHf#(&fOfPf+f;8fE;_*-8RQNf)+@fLf_75%
fM#O#6K;fHDI@TS2f26fNf10f8f1%&A=S@=<*fKS_S^_BG2fKPI>>?_D7AGPW_MX@08-
fLKfJ'6fMEf;33@^0Mf;Bf4AWOLCS%_-%>f103MRPf;f4>f{fQCX;U;0= M4B;^fF;f2V5U\$&*EXf\$*;CfE6->9V?
P7f4Zf=>'KfQCXfBf3>&_#HfJfE: MPZfJCO;N:'R&OK@3LDVQfHfDf(H8_SQfJ2_N5(f77XQ^f)D>
M&f3DTZXNK_QfIDN+THB_QM(f1;2*fL?Q6B2%=PONQEAfE>*fVMfAAf-
fXN;+ #X@A_X3+Q&F@VZ6DQ(CRYBF=fI&*N_BOD+Y9W_N5W1>#?"_C/6;SXBK_MX6f96GARVN?
%EY'=B^T;128fR+_fFO#L^fJNWU^_%SX+fVf7O MPUf0P^&-0TC0X?#936M;5+;fLH26AfV)fH'fU&:0K(fJfCf)N5fLC;
9\$7f3_MEfXGT?P1+X*f6_B34O\$U_?6T4VLB"TLHf17_KO<fPRfXfY;944E@T9"/
MfLWQf;2N/@K<f10fJUAX4fLX+ #f|=OZGXPAL;^YVfJS2HfL) ^TE0C8fOQ-O&M'W(fRfX>ZC=:QX;U750\$'U/4=;
fDfF^fQf\$+fHXRF%56Q&f9X'\$S@#)fRQX7_MQf^SUX@f27OQfCT#QQ>_M(f=P^7K_GT3f9?
Q\$6fJV+6Yf)4B38@.QXf<fTA_M4KNX_*f12OB#f7Q^&f)GZCH^CGPfTVB6fH;R660Sf1WT<4D=VR2(f9*1)*(D
MfW#SL0f0f4;0DUHQ_&#Q1?>#/"W@_P7#KUWfA>+7f;f;fXAEfMX>_3&ACGG%M_M(fAfQ<L)fO"?
A;50#B6;2f;f;GfHfMfKfP_fE8f/(8fHfE;8\$6_MBNMfJ_H+>=>+f;f&C_f1+1_#^fI7/Q*Lf2f6MfVfKZU>_M6?
B#6f/Sf31:A=O=36=V#*BA_M#M/GQ_S0\$5f+)6U^SMfJ\$SXMf=2\$?Q6_-M_M%.EWL6F6\$.OZ?&WfL+Z:"_9YfFLU+f/f?<
M'"&\$D@+f!QO8@X-CQ9XDLf!WQNO_MM>U24P;9f?>@ZQ;f4*6*11W*NYP.N%4fTVf^fBG2;CP_>^?<
<7AKPWX@08+_M"RNH=8^V7MfL_#Y"WfUN(f2?>^R/f4TX#R*"0N6'4>*OA38>_f\$Ff7VJ3f?3-
M2f;_W^AVZfX(07BF<f;f>8&X^7*XQWSFN6M?>KXfJU;20+QAXfCf1^f/#fY#?V_M-
OfHXM+ZfZf@fAKZX\$SOS'V28BAA#f&fY4@_P5^fVf?&fZfO/M*MO#S_MPMf#<?:
KZ7Mf;RA@#fWfKY2&VNfDYC5Y0K(ZLRD#>F?#OHfO&fAW6O%FHZ1_MfL^f^fT?24f+^PUY+ZfHf1"-TEO?
VfHB0VUP%#9Cf1Y0Kf1KfL_fW7O"OP3U^S^_M%*MXUf3>*fL_UfL_N+M+G3f#L>G7Lf;Kf1G-
fYfL@G*^4f58TAC#f%FV= N;_M%<fSC?^)/%UWfL_CSQf?B6*3f1+WPfJG3?#Z;f>7Ef<fXO;@32><0fJ#_C2%_Q9_MMG0*
4/Of6=AXHf8;fL_ZOA5+_Q#(8=-_L#Q;fJfUf1)fY3fJfMY)f\$HAf5&7=M)fHAK;ZA<*\$*(NY;S_Mf(P&fS%#fEADCf)*G)f
f^f77K'XfJ6G;QfXfT07f;f3fGTRUfTfPZfG7ES#*T_M;?Z;f;fH/f*^4f"Qf" @8LVSH%<-
fQfXfP3P)f1M0"6EWf;7f3^fHf#&C^.(BYC30ZR_NZCE^MRM="f(f-O&L)4^K_6?Hf1^S_&KP_fH7D>f1N
MV^9(fW=N&<8QMOSZUf1N/AfJHC^%B_VMM_X0>Y6X_P"/fVW&GSV>fO_+O_M%<f/S?>QWR#

^7C;XC^&_B;_M*(Z1H_H^K75Q%=?VIK,EF\):7\$AC_M(6RGV(HC5PZMEF&PI%):N\$T/XL>)OAW-
+6I8C1P7_@W0? \$MY=;MJEQJ_P\F MN?+ \$+_R-:6_DLLXC3EO,EAR00N!%>R_\$OP#JOBZ\+ZKH&MVNAZWX?
OG0+>7_M4-:/M15D@D@D1XEFA;|DI(82##%AAD5C>(?@B=>^&GQ;)60/(C1FY_MG
MV3=IC^TPK%IS>|V|<>7;=<=;|XN?M%6'P\46GABQCI+_P\O36*ZF+_MPEGB5-#M\$MVD;-)3%,(NS))A5C(
0HF7^|NP<?Q/THXO>";?Q#JH&AGGM_MXHYU\|H9&CD^2K\LD9^|DD^#*RM@9P,?
Q=|*|N/&%KXO|&^);7P|XD735_MTB|_+5TQM1L+RV6H(|^3P.)|W>QJRR@_2N&5LC;W^ANPU^3-%MK?5M4_M
M;BH)FO?LZ0^1BQ.%C7A5&=H&2<_99CDD\2L_P|HWQC)X+O?^MU|-K6T|_+MUTU|=^Q|OU06|O+
(DMS%:"V\|MXP(RX#3HY4^"|fOW86/Q6|1;|H8-3(-X3_MM+G0|)@L|N|H0W>K-"IBN4=E6"";=_E|C;^*LZ+M^*G?
DI;V^~7PM|2_\$3X)MYOA|_+8+^P/K|U^#5=;DF749(9+J<20P7?G^D2,I.G^Z^1P&;R_+M|P|_|+M4|_|?<?
\$FN170>/5XK.);18MHMQ;HR#YMOW9W>@QCO0|YQX=^+EU;^#?^&F^%_M_#MUKWB77GU|L,QU?
6Y&CAAM|K/<^&3Q=X,AM|B|T^QOS!%>13^*2UN#^\$AD5L2H|-OB8%5!#&VG MP^U#1|H|+X>|4KI?
BKPXUZHJ=QWVYBUN(-J75)K>XMO-5GC|6C)^*C|H4_M|&Y2DGP%N|6|_|^<?
^KOB5=0|5^+^%M8|H5K>P_%M|%;XJ|&WMC^Q2,\$RMAI78M_M,Y+\$;0
#T/P;J^B^4|CN/\$^CV&A;H|\$FRT_47OD1/X=TC0Q/?CJH4@^HS=;MW;*"LKQ5K,OA WPWJ6IP6JWLMI^R P27^6Z-
M&?FE>^;3FDG MKJ^X\$0F198)XYXQ)\$2|)&7B4.A(W^*6&03D^GWP
MU_8A|>6_C^W^AF|UCPY|JZH W_|^)^TUG3YXV|X^AN1#&T<@>W=65HN_5(+_M<@2^_CWXCUR^|R>*/T^A?
1_&|);1H=9-W=12_96NA%>0&WC6\$F^*OCRY_M)>5P=N:T/#_P_|2^7?%FN>*O&5IK6J;-H<6AB+3-&-C9V<<3;3LKQO-
<3.23<_M,6W2^)_P5<->Z^<^\$VF/X6H=5P/_|P|_|MGL;C3Y|/|_|=Z_?GYONX|Y_M|Y|?7BOXF^(|/?C+7;?P7#;>
M1TJ;^S13;52^13QL=L5RUF(-B0...&|M|N\$8%HQH|H>^*M9E|_|^&J2U_"U6JEM('F6^2Y2W1MHS|TKD^BCJ6|O_G|Z^Q
M^7A;2&5Y|;SX=;72L3/_+1&WM; >3P|)H3MK<N2U^U2^1&T^>|_|%_D_MV#^F;OGKU/XL2^N/X|<HOP|AVG-
);745P(A,BRP3QSOB2(D^2,O\$H="1N_M4L,@G(|/?AQ^U)|B|J|U9MK,OAN-O^NFKK%|>=>\$?2ZJ8?93YV|H|(H765#
M;R;HVC|_|&)|OA_\$#QIXT1;|)X^N|\$G@;#PSIFH>*|DLO)U1_M^!\$@;Q^|EF&XX)!/7Z+|_#M6U36/%^H^A
Q1;^*3XFT^P|&|/QWKL7PVCQ_"7@O4Y_M-/U&|&N^7?72J(V,EG;FWV2X\$JY\$DT6"&
+8R>@M_BUX@;|U|PUXV|^6WAS5_M#X>N-|H)T9XON|P_X(|#_!<_O7>I_M^%XM<%YKOB&6WAMXU;|&.>
<6T|CR^S^PVPER^+;<9-WPY6;7QJ^PXU^S-M1T^|U^ZU;SFLUU)ECM;FU\$D5Q^+&GR7(\$D3A^V,<_#P_H|^_|_
(1GQ|H6_M|VGH_LOPYX?|^*S|/-V.C>=G<<9V?>P>O6L3PA^|SX4N/#|HUTW|TG6-M;U4;0(9|1GGEV^M
M(U|Q;XRMEH?7WCM55;)+C|3)9=UQ(|H&Y67;K\$|E&^%_M|;?VDKCY^W\$;ZM8>%(+,"P^W7<>I^<?
|&_N=|J|TJ;^"/?2M4(V;_#<1@=R_M^5H2OB^|J7Q^*|&GZCH^CGP|VB6|L;R66O51WT<4D=VR2(|9^1)*^DW#SL0
M|04:0DU?|??L|>(|\$E|08|_|<6WA|2|^/*7#-(5^|N-^Z^#^K)XJ|U;_P|A1VEOI6M;_%#HVV-
UL;33,T,\$K%O8DEO.1C@FN7|0?M4_P|CV?ABRET_PUH^BW5|SAUZYTKOEXJ31X+&_M&4D)&9C|
(|DN5<%5AP#&VYERN|H?&W|/|<7C+PSX^TG^W9+|M|MDTR|N(|4_M;6G;D2W-H06_=K.8(B6RVW9T-
;C7X7ZU>^H?&?@SQ);^&_\$GIGC2;I=4TQ_MM1L+NV6H(P|^3P.)|V>38ZR@8E<_K9&T_U?A)|4--^+G@B#Q%IP2-
#-/:3Q_MQSK.B30R-^(\$E7Y9(R5+)|&5E;_S@>|/7^VKH;J;E|E|)^X5E);C>Q65O)_M;^+<?
(|M;^FS^&_9|6+Y8|S^S8F,B(51@A@/H^PH^H;HMO;^MJAUK4#& >M|ND D);.%C7A5&=H&2<_99CDGSCP|
(0%GPY7M_T2QS;+X_T27=;9-H@D_MU^*%N%K|L_|EF0=0=@_T25_|S<-U%;#|H^XF^)(^G_"|R#QHNHL)K+|6
M?(CT<#<-5|H^8V|6;|H<^?F;|_|E1+|8_'^N;WXXB|_|#6QU/2/#>IR;=<7
M5_XC^R7%Z41^8VD(MI%=MKXQ+)"NX8W8RPD^|A>+XTC|=+XJ8>|AJC2R;M_MIA/D2;225&DF_2C|R(|&WY\$X|
|)C.^#X|+^_|90/B^OA;QE;>+;Y|67D= MV+|1S?RHOE0@M;L)XQ%)CO(LR9_S|VX_E|4?M;Z|;#X;3PY<^&GN|
(#|>HZ_UW)-|C2(733QE;^JMB_4SP|E) &23EB_XM,UKPHJ;|JNGKJ0>RAF?R^DYNVC3;B.ZBE>9XE^
(^4^7|CU;|HB3_MP?|_#>T1|>*M.T#2|W4=232|_|XFBGTF|9T,B2K?O^LC^K(6+Q|@8F^J^4
MW=%;"W5|_|#;XA7>A>^*0TS5O%&L1;Q;W+Z+;GQ#%XGMM1;Z(FGV%G>QP^_%;-I92ZR1_M|UFWRE|
(V&3Y2H|T^P7^5H5-8UG0ISH^|N;7|_#=-R-X7UU=9T^6&5G52ER_M(HCO5HV^QM&I7^4+M9^
MM|6255EF5;RB\$Y8+|N7|_XW#|6|_BCPW8>_2#>JZ#JL^W6E;G;RV=S^XR^CD
M4JP_(FOFKP3X=|8_%;0/'MS=W\$EIXPT^PY=^_#_2|2?|=I)?A6-S?(03A976_MS.03M,3#J#0|H|>?
BCX;|7;-J&AZ%XNT+6M;TX9O=-T|4H;BYM>+^#U^Q+IX)O^&M-2AEO+;|/F0JQ=;\$CJ|U%
M>|_|"OPZFM;MX|M;R7XEV^L^\$U|Y=)U3P|9Z=INF2BV>%X3=Q6;_Q\$0S)BYE_ME5LHV;_|>)KXJ|1>-
QA^*H;=XPM|8TW7^N|8=|T^0^|G>+(|>Z^RJ_M|ZF254WQW,JMGVT^% % % % !1110_4444^% % % % !1110_4444
% % % % !11_M10_4444^% % % % !1110_4R;_WA>65UCB12SNYPJ@I=(899^D|M\$5|69G(0^8XZUX7<>^+XB?&|X4
M7;@>?"%5I;+>?K>ZKJ?AR|TNWLD;QE1+<^?^"ORO&&0-&^N^X+@-QMC?ZUI_M7PU|%^?
#2^P=XIG|0;1XPL|1E;|&^*SCU83&|6|V^1^C^A0(V^=0^75=K|
M0#Z4|7_#P;|KBOM_%/BW00#4|^VRTBUC4H;1KALXQ&)&|/K_#S4|^GHOB1+-+G|)^+>
689H4MUBDM)O|N9(<2^1_P|X4A(G);SO_MKVGP?X07PS|&|_|6_U^TM-&6RMH|8DC>|51%M2.5D^0NHPI(XXZ|Z
^OA/X_M_?#|OA|X^?|GXOT2^PJ8HWN=0N-3MUAL795;R;B02%(Y5WJ&4MD\$XKKO#?B_MC10&6C6^KZ|JUCKFDW
W0WVFW*7\$H|5D0E3^|KYL|_W\$MOX>^?2B34_"B3_M4-)^%Z5|J;JZ?)X?
NS>:9J7V;VC2|CM6C\$MPI^XAS\$ENLG^P2N5WD>B-!>P
MNM0^<G0^86VD7V@>^&/\$E@;^*UU^UDLY|RXBA99|UK;15>^>@B_>*KMJER5_M_VD@^9>)_C^X^"|Z@EAXB|_|^<?
OWE6%;75-6M|5E|94^NL.X@&@=2^"O>M,OB)X5^&^FOZCXL3;X7T^1_+2|UF_BM(F;^Z^D903|9K@=-
|P77Q;^+>K_MZNAF0;MX.G;+|H|G|^*7B&2Q_MQH6F1_#03="DE|^X|4Q=,U^|X|H|H5K;YN(-5HP6CC
|M|2\$?)0|I|=67B_M;|12N;6WM-6L;JXNK7|2;Q0W^_|UME1YR_+^1Y91O^S#GFH;7QCX?OK^3|V_MVUW3;BSU&|?
%7PZ^&O@|O+M|+M^|1ZMK|5_J=AIUFUFUC6^BM|5;@_K10(JO0QW?V6Y^%;%V1HV0F^"|<^#OP7
MUCX=_&C2_A|T^XOPO^|I-XDT34Y(V,\$EW=0);B_>#)&|E^*P|^XC/^&0#Z_M7|4^_#O@;Q^V>)_?TOP_9|6?
HJFY;|H5&6_YV_P|R2JND_\$SP?X@|^*GO_M|T^B01-2|_MAUFTU&&6SW;@F;5BF=Q^XSU.^|Y^_|L8?BA|K_#19-
"%M8@|M;|>)_\$TW2DT_4)_GLKK5;F^>?|1|DD19E^E2PQ;G1681|955)/H;XN>|H0_M"-SXX3QIX>?PO;R-#K;ZK
^*)U;RO/OV^*0Q_0R"<5K;#XNT+Q5H;6N+K_M6GZOHJL2/4K^ZCGMG4=6\$B\$J0/7->8_%O2QX=|>?
#KQ3/X^8KZ&6_MUTEF;JFTVXE2%;>|2UC#22;2>?JTC HN^%6G;GJEUVI7&EWT=;X;9HK^X^";HG(1|T;Y#
|_|#K7>P^+M-^N)|MM4BUC3Y-;N94@^O4ND;LGR>6B^<=K;SD(|#DL<=;+|N/%%E|1C=|
M^+G0|/B|JMM%EOUO=5U/PY=Z7;V2-8RHEN?/CCWY8C#(|&C;7&|P&XVQO|
M6M^&O@KX;0^#0%;_B#2/&%A_;;S;^<+90V<>K^8W;W>WR)4^!&O^(|J^RZK_MM?;_?2NL_\$_P=X<|4;?
X;U;Q;H>E^<(M0P;2+SAH8;NYR2|Y<+;?)^R@|^*MY_X9?M#?#WXP;YKND>\$O%>D;UJ;CW#0S6|GJ-
O;B|8R9XUCD8F;H3>0^N5_MAVYX^PC?VGP|U3Q?X;|2^>|>U?6|>|276H>V.@R7|HK\$;L^ZU>2Z53#Y;7
ME0|EXROV^?Y4J3UOPGNI= (^GQ.T.^TW5;2ZN|<5|6YETV<65Q;M;6D89+MK9Y)?
>C@Q|_|&TDKQ|@#H=)|>23>?&EZB|G9Z3X?>LYUNG)CVK+^|AC2NS_M;QJL;N|@9SFM#PO|3O|WC?
0;07#GBS0|T6T+^YU+2|2AN;^N;YMB;57^MIGX|^>2_\$2R|3Z=J^Q;OM^R;JUXNB1QB;3_M2|^*W4L;+?+<?
<20QL|@C^M;M4T|6_!|OI=IKGC+0HM(DN;@/?QK^M|_MOMC\$R#;J9^;@E>2_?3|OZ85TUAJ-
IMU;XL3YZXNSY9DQoS|_PBL_RY^52>M@KGI)^7@^70\$D7AW3/&_AS4?;\$L9FCTFTU;WENG C)+B)7+%0>
<8XKQ^PO_MXJU/Q5KOP^T6UA^&K^_-(1Z60;|H^K+3_U=6^L6_CFPU>6WCLW^T1LVN|H|PRXW>2|MC;OX^\$GA;^/?
=8^)W@|P|XHT_P_-KXLT|3|\$>HX^Q;^>E#%>W.20|+A9@|MY(|(^4|T)^%_COX>N^/%&K^|/\$2B3PHNO#7;C3-
JTN>^C@NKV-!^M^*1.^Z1B_M6(^08XZ5QOA&_M/AWJGB_P-^)?>O;OK>O>)+K4O;09+^TUB&6?>=O)=*

[illegible]

HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M* "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH ****
"BBB@ HHHH */C @X? X+'ZC_,\$F?V7=+C^\$=I97?Q5^ M(UO5YL*QQM\K22J6#*CJ?
T^K^H06!N'D:R)CGMI8W0_*\A1@|2B.OUJ_P'''1&JZ/K/_ M 2J_9NO_#D1H%^\GA6\$!8\$D>DVT*;TL-T32_%UK+
J!4L&%MA\7."CY\HO\JO00X_H_@IQ\?OCY^RQ_M_P&RGI'_P'RE;ZG?Z0WQ:TVZO/\$TL;M')<:;\$YO;>R8J1'(M_:5IK
%/RE M@?TL_:L X(6_#_# @J%^SC^R)1_@C\?Y2A7_.*H\$;0^AZGH.A+=->.3+:V M_10A=9HC#&T
DBERP#3.2L#0!O_P#I:P9_P76^O_!OX^ZE\%?@EXSL_X M\>*_
/_:Z;M_.WA>"5>=4NT(9495.8(G\IQRK%6C5)_=P2_::&?VE\! MOO\$7L_/I0G@?X@?:?I=P(300!/BR5U6&TE*
IA*IK(ZOL5Y)L0<Y\BOXH\!>N77A#2(=,|+7 MEU<9,"J"9(I\Y)Y.P\JOZ/_%/_P#@G1X@^)B?H0_VW_A?=>^)=0.
MGP::\XTLV.UX_VJ_)CSY(DJO2?&W->|+|*^FPVW_1R^+7Q&TRYNK#Q M\X6M\+O/#NMZ;>26UW\SZO90R-
%+ \$RLN^)\W1AG#*Q!!KX^_.P6^FD_P#! MDWH_XOABR\$SIVE;)XCLIG\N\1N_%<,"M3UKQ\KL>FS^/_!@@
MO+V-)D&8Q/(97C3."P!50MTDBFB9DD4_WE)%?B1_P05_8K_9A^_W_;G_\$Z\^(GP3\Z
MCK\B>W\6V\HXBOM^BEOD^SP_1HYW4O^Y#XDC^D\RX&YF)\9_X?0V\CA M_
@F_^VB+^*FU#30@UX*^C/P1_7>98;+4IK#4V>!\SB.22QMW*^C(E;&68 MD_ =+XO_/I03\AWX>_S_/C9^UGV/
MX@C\$+76DZUXIMH\K_92!\$JP&? M_1E^_Z_XL M\$?L_/_P1_.\$SXZ?/P=X+!-W<|-KX@!6^)K33;
M&:2KZ?/)<2)&S.JLR@-D@C\I7X#_P#1^J7X\ M2?B_P\JK=>&OV_%^Q MA\9_&OQ/K^F^)?B+)XNT&?;Y\&M_L?
VK^T\KZ&Y VX\8_ ^57XY LV?|_I07P_:_12>#/#^J6?ABVGUZTU1CH@>UN+0^;M_2RJ\^)/\$B%MR)_@ "A*/TXU+_
(%0_L&Z7\%+K\I&:\LWX73> ++53IES MXRL?5A>*=/_ MUS0=:L(K\119TJ2>VO::5
|VTG7L_/_+C\|LMWJ%N\JYB>>XW6\3_-D MH"6BJKN;=^IG\!P\!^!*"WP\!)?
LX_"&PN+;PSX*T&WTG18KNY.TWD0H%# M2.?ONV'S'!+^'XH^?!\X8OI!&H<"8+^%/PN_" MO_!|O1
MP77^_DW@_X\ZCXMT^O\XIT*>RM7EAL_%NBZK>_9^T\DTCK=*XF56RY22 M\K%6(\1^NZ\HGA21+SQ
XEU>VT_3M.M)+K4+^IG6*^V@C4N\LCLO\$15!8L M2_"37Y2_L2_LES?!\00^"K6O?!\!=2XUZ\!TWP\K)POZA
LW:5K\$!BEUFU MLT>,>(04D_:=L9)+F>W#_S3*_RB3(>V?!\#G\15M_ V\!_9HTK\HS1?
MA3KWSQ\70>&+;Q\KINM:0:IT2M>@A>O(A*OE0+&^?02UZ@&^?>8M1@&MW0@&QKJ&H,L!<&2-7BN71)2@8
M\G#=#P: 3G_(*V_P#!"SX?2\%C\$?A+QMA7_VAO\GAW_A#I&N+3P\H AF6_MR?3P:B19J;EDF@=WD<)
I*R*I6%,#_2?Q1_!A_X).?!_I07_(-J\BOX_:_V M_94_:%;Q_X.MM MBZ;X:T2S\Z_+^39V%K^6D1%/B
MU;Z9)91^*/#5A\=G*RM7EAL_%NB_MZK>_9^T\DTCK=*XF56RY22(K%6(A_4?KNNZ)X7T2\3>)=7MM/T\3K22Z
MU" _O9UBAMH(U+O+(!\$!\$506+@\$@_DU^4OI\$O\))M?T>Y:&IM_!A_)8(I%(-M+!1+*P+H0VRV=,XD
>4_!%K^VB_!&^!97L^OX_82T_-"2AOQ\HNL;!\4/M\NESNMEXNL=(F\!>1\$)DKUHKR7%VP.N\Q8XP?A_@|CTO5#_
_%+O@7X_MM9R^C7WPSLX+&=3F_Y8M9NWE*D<^Y)X#|^*!#_X/EY%_L_LR1=Q>_2?Q:1?_M*/TY_X*6?
I\ M_=_P#12_P_X>^7\!4US\?A#JF@#6/&C_P\#HU3Q\ MTQO:Z5:(D\+P6XC#33R,P\$@F@C4/_ "AA+O_O_|P;T?
1%U_A_!LG>_P_ M_CQJ\B0W2&GBG0HY\!U>6&S\6Z+JMH\D+3V32.L=TKB95;+E)(@RL58@_P\ (M?D)3^X9?L?
#)_B7\<.FGP\!*=%/B^!U<<11VOD:9#Y\DKN0\$5=CEF) !K M\!V?)V2YO\ @J%_P5:U\ @NO:|
GT\X5^\$X8\!_9NTK6(#%+K_K9H8\02 MI(8\8R27\N&_9FF5_E\$F0_5?Q)XC\A_@P\?^+O%FM6NFZ5I5E+>:GJ M
!\L4%K;Q(7DED=B_B*JEBQ_2_ G_&H/^"CGQO\ VY?^#CG\F^PYK>B; MGX<^%WA_QYH6H?"_P\J^M%+?V
Y*KIK=Q\$>4DNXPDD:_ T=NT0\$J52:ON+ @ MM_ P5C_8W^%!\6?@H@G\H+OQJVA?"W_(1^U:2\$0:1HDU^WC%#
<_/_T+!P_M#LLFD@:XNF_:%R1Q0#*2S8_)SIL3_@J9^QQ\7_ ^#BGX=|!17X?>*=4D^% M7A06?
#\$^HZA)H\$T5Q%#8Q(L^VV(WG:0< #GM0!_5E16A/?\A\XG^=#^)? MA&XDETCQ%H\JM\>F2RQ%&>WGB66
BIY4E^4D^D5L4_%%%%%\1110 4444_%%%\1110 4444_%%%\1110 4444_%%%\1110 4444_%%%\1110 4444_%%%\1110
4444 M_%%6%\1110 4444_%%%\1110 4444_%%%\1110 4444_%%%\1110 4444_%%%\1110 4444_%%%\1110 4444_%%%\1110
17_N72KR&Y74?"/BNSMUEN_#U)%94G521YD;*)\$2_Z_M<%6".OTE10!^97_!+GPE_P%62\@D\!S\!^Q#\!??
V+M0^_A#PC>7(^OQ_M^\$7C/11*;5YA9W5GK_Y8RILD=RLBE@JN(\$1JS>8_&C_@C\^V+_P%GA M@H?HO\?7
13KPC\OPK^#@BSAL"/GP;L/\$L.JZQJ_M*TSK>7_F6MH//D8F5_MX\?RU6%<%1/7\T4?#'_!=C_@D#9?
1%4_V*+X_?"S4M^_/_>H)P\PL MGNHS#8@K"89_-D\M28H\H#*IV/#\$<%0P/S;_P24^W_!R=|!O@GHW\QB
M^!7PZ\^#O\!7\FZ)8_ \$OB_TU74_(TH^B*ULK*ZE%!\+\$AQ_>L4_:(LN\4 MK\>*_/_R1_X=|
@BM^UA_P4UYOX7_?%7ID7^S=2\1> K2_TS5_#>KZ\8S7_MJOLW5MJW@O2O#FJ\JOX7U"UC B_YN_+C^TM*
f7R>4@6_&YV(973S7^Y MJ*/Q6\;2L^2\%;2B_P1\|_P#!\$B\ _&X_U^SUBTTO6B\=_\$+1F+MH
MEKJW\H074:1W+;D9.TK;8HQB9PI9F6*4&!_H_10!^1^ MI^!^O\ P51_X)K?P_B)_P3*,L@0?\$KQ+XABU=/_P
3?""CO2;_0+7^ MU;18Y^ODU*XMKV_K:1I7_BMY1_J@H>:IP_X(?\+O_P"P%_P3M\;+)_ MQRUFS\2>)?C
IUU\5M0T+VRTWQ_M_P#&+XK64EO?6NC:E#I^A>'S.8\P6SWCK)IDMX80@8AYTYG:5DC\$K"/L;HH M_3_(-
K_P\AG\KS_@FU^R+XG_9_:_T^\$6CW\UX\O\$FE:H7B.ROK>&>T ML;?L.PBE\U)@UL&_27\$LPDBCW M(L4C/YB?
>=%_X^?!*_P@_X+^"&=7\?M1\\$_ _H'4?!\P_>^WP\N=3\4 M:5X\;#138WEF\TSSS0!T%_);BW@B@Q* T;KL
E);12OV8/&Q_?(\P\ M\? Q9TH6^BK7/_VD:AXFL1#Y8M\OFLX\B/9_#ME9QM\8Q5#X\LO\@A
M:6O=&T_XPZOJN\^%)O8;ZX\!>=\$FDZO=PRK;RWRB/S;I(\$1UMVD%NS*&D MBD^IM\H_#_@X/^W
5N_:_^\$UC^R_P3W^>C0>"!A6Y^!(OB?4O#EI M9SZEJRH4>4K9%OH>8D?00S^X\H)!^_%_P3_#L+XG#3?
@K\OEIC^H_@KJVFZ+!4/AG>37G@:74&\JU08)4C%QACJ#Y0?R8'_MC?!"O^H_%=F7Q_+;#_X\ M_!|!;IK_X\^
OVQ/V8YO@U_/@Y\HUXST MW70%&E;G>^*_1N);2XL)-N;A5LV_G\$GGSM%(8Y'(BW_K)10!^/_P<M'?
7_@K_>V9\)+#ID3_@GK\ M&@!%;U"MQ\!/\$^I>^?2SGU)5<^714<4K9%O M\H>8D8E!6/H@D\$GP?H7
3'_P"#L+XG#3?@K\OEIC(80%WQH_M9_&?B_5H+*.SAU3Q\X#T_4+FE.WCSLA\$LL+(UW-ARLK!8H;>%%%"I&B*
J\@*_M_!5FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ #XH_X+Q?
MH_%+ID#ICC2/#WP\0?2/B)8?B^I/P^!\ZW&@>329M09_04 M4\7C@BD""^&22
N<8/E/\2_3_""!%_P3\&OVUOV:WU+3_77XFZ5X7^,MI M=ZO/<_!_8^!^_2.XO
1:5R;K4I8X\HKM\RAFD4L4=D*_!_W@S4\X&?
M^H\LFEA?!\ HCMPK_C"7R6FEM.T3W#GH%69K=,G_GK1_P=*^\$M6^/_!/_ M@!IEKP7\$USXC^+OZ\>&_#H
SR2R?;9#)@?P(L>6;HHO(H_2ROE_P#X M*1?+XGP>!_6_9>_9B\2R;7\0=|%ZCK6M>*+8;F\&^8(H\J7HMU.ZFULU
M/68R389+245\|H8;I+-Y&)VA+I THQD4@%L=2_2H)2/6ORI/B/_(-D M_ "+X2?&^Q%XX_P""9?PYUC6?MOJ\H>
/&LGQTMUF^R^WEBMK>&W%LWEVH; M;8XH QR5DD8F6:5V_..^_!0_P"T%!_ ^#_ZS^_P0\3:K^XW\AW);ZY;W
M#M>6D5SXC;UNKD.[EDBMH\H^D\RA0_ "N;H^" ^EZ;^RQ_P6\|)2LO?LRQ
M_#KQG^RL=>|8>|=GM6O\5!;VFN_"3_I4Z.T\$DY^?AG+LH88/_LY>_ 'M^XJ_!\$E_?PE_:(_9R\</p></div>

VOPO7PG)9>#M6DUZ+4CXXMM+B|U|;Z.L6C MD0I8 MICEQ(LAI#%>| \$|X.2#X|^)A
9A_8>|*IX;^*7Q4TB.RU/QFEY?WOA'P MC8XCDO1=O*|<< E^SV%0H"(1=7""8_+BGV@'46,TW|;|3?|HPRI_P)?@QX
MA9+8HW|KQ7XSMV*N_D;:6VY|U5|0+Y6T|2WTA7P3K&O>*)/^"FOA3_()M? SQMK7PP^&'@|F.7QKY_A"6./4-
00FU5+LXVND)DD9HH)+AO^>|S_+|S M%W^24|_@B_^V|32VZ_~^=|@7|H^XTBU?Q=-J6D>
(KZOMA#|J%587|Q9F| M1%P|>:L^R%5_57=E4_"#ZFHHHH **** "BBB@ HHHH **** "BBB@ HHHH M ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHHH **** "O M\$/C|V3_~*W_:|!)?LA?"X=IXS^~C#0KW7K?1K56Q|FGZ5HU|"%+J%|=
MB&=XHS_+'#&L4\$TCNQ^4*K;Z_-S_@MU|OB|X<_~;^|J9|_ Q(AMOVH_M%>|T#P_|F 3P?
\$^0FO<:A97"EE6""W0O,UQ(|<:F0+O69K=@_76/P&_~;MxA?M'>+|V-OC^|. \$|&?%#PGX=L_\$.:58ZW_-FG:OHEU+)|'?
V5V88))\$6>)X M9\$E@A=' P'5@U>K_!^*(O@|X0_#S7?BK|0|933M!_Z1<:GK_^Z_P@MH(VD MD?:H+-A5)VJ"2>
"2|7Y_P#_1#_~3^\$7|% MOB+|=TPV_G@3|I2>8VNFV<3D0_ TQEEEN7_~2VNX5DC9D=9\$)5@02KJK#T*^|J
/SM^*Q| P7S^)_ LFNZ' M|0_VQO|_@E|I6_A?|\$/6L16_C|5|9U6RN9|S3_\$4NHZ5;|L|3U^22&0_*\$MCO|)7U_
^TM^W#HGP9^*PG_>_ACX2M?&QO|^~W?_/"\$Z3+KOV#3Q8V_M|HLO_0NKQ(9S%_D10+LBE>1Y455QN9?
^O^"VW@B|_J_98C_~;?P_@BNO& MGOUFPT^T#1>8FB;9W|K>:EKFZSX=U+P9<:C';W&K;J&FK:*UM/+B(7-
Q)%%(\$D M^):\$0&1""R?>I2|_ MG^%/VY_AKGC20"MSX_-6|&_/O"MW=K&? M
CPZ;JOC1M0Q%8/6/A9^VS^PI^RWT=M^S1X%U36X?"7@?QM|/M7|>S.?)T%|IXK MN"LC65|2DH+V;:<_
/HO_F_:J^\$ _!G M|G_X4>|/7Q(Y|5>*M5|#:7+IOP^E|<^*|K5E|+6Df|.1+|9V(21HU6)KA| MIPT:|{#5}4^X44
>_)?V%?V>_~%O|:GAS_@H/K6C;H_Q|)^*^Y_"VD7L>LS+ M;+|LDLC|K8'8|@SS_1_P M.02B%?4O%?
AG1_&OA:4O|OB&W:73|7T^:ROH MED^%X94*.H8<@E6(R.16A10|P7|+_P"S1C(ZV_@X<_9|^N@SZ7X1*6LE
MOHEA1F=Y78|O10|XQ^T|^Q# M|.OCM|5|&_~TWQYXL|?2\$^1/#=IX=MO&_@6|M8;^;|HME>:PE%W;W\$;D7FH
MDR\$Q^9%(N^T);/7?LU?LX_!P#9%~!7AK|F_P" GA1-\$|>\$|/%GH^GK*TC
M^I9|D=V);2221WD=R/"\$P@U#X=>+?#&B3P?VCX? M_VHQA.LVL\$|D:W(9D^SS)&WFJ|1D23|^QJ*/CKX;?
LE;UXU_X^V>(_P#@MIG%)|HP#|S|OP9C#^29M66%MXVH1W3:E|/"F**&""WG_~V>0@Y1(X8
MC)V'P|_L_AU;X5_&QMA0_~^=>KV6O>"/&-HGP0|_".E>_J|DG|2|_!|7 M/%?Q&|5;?|242?M|^~;:
(01%S;=:0|9#;6.&|MD0=V9Y)99&DEE=V_1'X=M>_OBAHGL>E_\$7|H7PJ(?)
%T'A5=4|6^~"5E+>FVN_)Z:QM(X|ETT;9A3; MEI2@(&7 KNJ*/\$?V0?A)X|AGUS|J;H+1_LGQ)^ (R0/=Z1)*LO_
BFBQ%V ML_!C9|)#Q" M|^E;14_W.L6;JMK5Q|C'DP30|2PR6K_+DR|?+CD5@|2LM M10_4444 %%%% !1110_4444
%%%% !1110_4444 %%%% !1110_4444 %%%% M !1110_4444 %%%% !1110_4444 %%%% !1110_4444 %%%% !1110
4444 M%%%% !1110_4444 %%%% !1110_4444 %%%% !1110_4444 %%%% !1110_4444 %%%% !1110_4444 %%%%
!1110_4444 %%%% 8FO_\$/PCX<+17^K(T|H8|_MG?/H<<#|
<5QNN?|JDS%X>T9(AVENFW' OD<#|S0|Z;534\$&AZ3G^T|8MH" M.TLZ|2R)S7B6K2\$#QCK>5OM?
GV^K|"WEK|+C/XUCDDG).2>|H|HOOO#X\$| MB534Y)R.H@|8_J<"LN|^/F@)D6.B7^*A2_@23;#TR?ZU|ZU|
>\$G|SPKIDG|H3X3_~" M@#|@O^"C'_|S|H6OV%?VW0'W|^*_.D_LG^/\$=AX.U.VM|?5K6Q)/:37*26D\$Y MW*L3J|H|E89'&
_*|Z|_2|H\$HD6+QC_P3R4J0_+|F?2\$ _|TC?3N?^~J_|/S_@ MxA_^4QOQP_|#MA_Z;L.OC2O|T|V|X17P_
*\$|^WQ|9HHH(%_&05_*|2|F|)95/X>:/H_|TQ|H|6 M?@M^V%~RA^T=\$DGP#_~4|^_FD7(@|_~
^*K2|F7C.&CCD+H<=0P|!>CU_#%;W M%Q;3I=6L|Q2Q_.'CDC8JR_#D\$<@|Z^F/V<_~^RG_!3K|EB6"/X3?
MD^_386 M^!HWB_~MBO5|_L%)4C|_V H@|UY.(X.FM;6_E)6_~7_(J|^M%?@ M1^RO_P'BOQ;T|^|?
0_VR_P|E|2|\$L""E|0>_~U|^Z5|_SUK^Y?0?C9|)%GQ^UWX>_\$ B3H>I>+|/#-I<MZ_X>M_
2CDNM/GF+B(S(DCW;#P|D_J2_~N2.O^CCQ;KE|I>L2&VCBD*91 M""@|_|W|X|>E:UJ?#R4:L7%M)V;:T:NGKT;:?:
5_Z\$FGL>@>*/C%|X9T+=;: M;W|H7_XQ^V(U/N_2|UY|XB^)|GB|Q(6BN_1,\$#?|N|K|BX|">|_ \$US|9# "B_MBB@
HHHH **** "O>_S|_!NEM_TX1#|E KP2O=?AP_F>|M;_~2V_~(D4?R MB_!P?_~IC?CA_V^#_P|_~G7Q|7V7_P_!|_RF_
^_~8=L/_ \$UV=?&E M?L^6_P#(NH_X|_DCG>X4445V@%%%% !1110|J=3L/2|_!<3_(*_L%S6>D? M#XXW7B'PK;
|5_X0CONSZEIHC' _+.(PEM5|H|)(QJ#7|I3_|\$_?^#L|B+|J M_|+P)^TW;+&_%TY6.3ZQ=-;"NI#QE+T^OV?|)
(N%1%&|YKFOYCG|^*|Y#E MV87V5W_LUI>6DRR13QLJZ.I M(92""""#@@U8K^0K_OX_P#|97|N/_@FUK_
O9_!GXD|JW@X3|H|X>^G>ZTJ M8\$YK?|(%|2WC M_F|^)+Q_UV^,DV%QA4O%Z_*DP_|.04;C|^F?#V_RZ|U|_ZZ>JZ?
BQ.T4D MS|@HHHKP"|HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH ****|<_~?_&|V>|^/"?OP8N?
C/^T%XL%K|AT6 MC;+:%7O|9N0.BWMHB1O;IEB0B_|G91S7;EV78_~|3P6"12J5:C48QBKRDT M21_YQIQ|V;_
:&XU36-6NEA@MXQW M9F..20_D)(%?AE_P54_X.70'_P 79_
1^|W_~|B|O_"OAZ5)KS|Q|92L|RV/SB=;|*&D>_5_P"7YGNW_!C|NWXD_L&
M_M@;#^U)H%W=ZEY=V|^C#3Y+EBVMZ9_X-W|\$,|8\$B_V0)HXW(W_|HUC7 MO_OOP^&.@?
M'?""6HM5V^|(D)M|^TOI=2|^<6T|H|2" 5C|^!L|92,\$_@U_~M97|C_P#|K|_P4E@TG5KS_@FM;_95M_UAKC4|AI_
=NO6*Y(2|TS)"K(|Q M&E^F"~9914"/Z3?ABN(A7\$N7P_VC^QM427QT5K?ULR_P.5|HH62XWV57V
M.W|+;U_X)^F1%;CCPKX0|02Z6^3?2GMI_*|OG|^Z^W%8|2Y|GU@4444 M%%% !1110
5|A|*W|SP|IS?L W^Y2_~|KV0X1^P|H|8R_^C7H_E/_P"# M@_~Y3&_~#_L_V' _*|_OC2O|O_~(._P#E;|1\$%V6^G_M
|^C|H8TE>/_MBCYK^\$<9D_X^%&2?..%|^_#_XH_~GXT^ M+^*7PD|_Z9X MC|_~U:KS5^>5*=2C4<)|S6Z9J%%% M0
4444 %%% !1110_4444 %%% !1110_4444 %%% !1110_4444 %%% M !1110_4444 %%% !1110_4444 %%%
!1110_4444 %%% !1110_4444 % M%?2/G_!2|_@HO|&|^~|_!A_B5VVD|B*E2%*#G_M_V2^7_!2S_@IK|^_~^/P?2
X@_ \$R|74_ \$FIOR1^#_!_IG3OM% M=9;S>KLK17QF89C/&SLM(+9?JPHHHK|O/_ "M?P^XO|3_~^|6Z7X|H\$ZYQ
K;H9PA4@X35T|&GLUVB_M_JD M_P""&gt

! = ? (*L;I_P4; M&D) ?#(7)1)O UD\X8@C8JFL70RDNJ2#ON^980?NQ:W6D.C%+B=COU# M0%941 23F2T=DC
X^O^GW M0BU OJJINQM+81%#H8%&# = 7&TYM2 N5WO&&4G^BCI@_3_OA_LG7\!\$Y_Z^' M_@3X&277;FV6/7?
&N&KJLVJ.F> "0TN\Y460"(8PJ#) !;+^2_I+!U>!)
M/8A^VQR:E!OM^YDNM26RYHMIPUDT!ITDO>R7#8I5E66D?/KZ?YG>^&_@2XN M&G\47X,2N0D%L>7/!+=@?
0<H172Z1H>D;.#BST23XK>/N(UY;W)ZD^YJU M7^2YI4%%%% !1110 4444 %%% !1110 4444 I2RO3M27T6;
<(V!S!/\$_O517HX#<=>ETKT M9:=GJG!OM1.*9_#S1/AQ!0/A% XUUXAK^K^P_ (*)2!\$JOV0 ^"F" P^?PQ!??
J0;.:VY3P_X MZT>.(M6TIN2 DN#YL6228) T9R2 &PP_FG_X*B?I\$;/V KO @EQXRW?\$G2U M1> 100#X#X#^(FC6!?
8IHHE89T)+6EQM&?0*2/T3*>(+F=H/W:G9 MI?11?3_!127XO?1_!3HK3_(X?
M#B:6_P!\$NREIXV)M.5@UO3MV6C/99DR7BEQE'ZY1G5OZV/V:OVCOA%^UO! M
IPY^T1!"%>K^&/\$^GK==*.*AR5>&5<_NY8W#1NAY5T8=J_B9K)O^#M7_@K=?
L!2!V>OC;XF?*"XA:DD!+=2_N_#FJ.!%J SPD3X2.?H<_@23/ MJK#?+<29*L=1^L45^C_ .3+_
=>N!PE9V/Z>J*2.1)4\$13AE8 JRG(CI:6 MOSOU)BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *)G_(: M/^G7=I+!^GZ,V0MID?
=>Y(X=1"!&E)-M?HW^V%^U%V OV/V:_%OI2OQ.G'F>%!*>X2T\$@5!ZY8A+>UC) CEE9(P>@W M9/
)K^2+!H^XZ?3HG XU>)OCY\6-9;_!0^*M6EOI2G).U6<+!\$@).V-\$"QH MO1415' K^GOHT>&
<>*N(GG^A?)"X1KE36DZV15YJFK3?FX;IL7.<!"C!^* MIZ7X+ @ YG'T445_HL?(A1110 4444 %?I+_
.\$6_P#@@WXQ :GNI#IHHW> MUOM ^\$4%QOL;_2T-IXK9&Y2\$!8K7((<</'U!RJ<+!UA
M:MJM5;^RIPA_T! FE_RIV7O_>JE>5>VM6K+W>BI^OE^?H9GPX^&_@'X0>! MM_&?
PN!Z=H^A_1K5;2!TJU6&"VB^1511@5.\$EYVR2?F)7IR^LZ-H_B/2+KP_XATJ
MV0!^MGM1ZQO(%EAN(74J);HP*NK*2"!H!(!?S;_P#IP9_P0DNOV& \$EU^U MO^RCX:GG^#^L7@_MK1K<-(WA"
ID;_4YR392.0(W/^K8B-CS&6_0N'^^?K+6& MQ3!_H^_D_/UWRE^VJ/RPHHHK!\$@****
"BBB@#^D3_@U^_P""JL_M5?) M_P!B7XT^(S/X_P#AGIB^PI=W^ GAJ99=6UG4?B"EEEXN=+!P(VJQZ9Y#>1!R
M'6.1S-Y9#RI-XC/T"HKF?A=16_!7Q=#GAWX!^%_09/#GBCPS9ZHMU?J(C M2ME
KOPUKDUY%&T)1KS1GSH8RUQ#%+*)T CE MD&R;JN! ^MZ*!L^_O!O&L>#?BIX(^
_PLV6VM^_O%JZ;N!MIF5A!HGA^VD3 MI=JESLY &I+>!.#+<7\$8X1)G3U_@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
\$00(^Z<'@13F&IX7#Q;+!Q V.#Y%N^!_KI@1E*)&MWXH?CQAI8_B1K_Q9^(&K?/!XEBYU/
M5IQ^LUS/(TDC>PW<#L.*PJ_UY/^\$.)P)PAA;FH6;IQ!^2^U4>LY2.3=K!1 MLNA!B1+>8B51!?
RZ!1117V1SA1110_5H_!\$5/^"4VO_!12GIH+!9XTM; MNS^%G@>.?QGJL1*&I<_!L#C_EI+C+LA_5QY;
(9HPWS1^S%^SE!3?VM_C MUX8_9U^\$&E"IU_Q3J:VEIOSY=NT"TMQ*0"5BBC5Y'.#A4. 3Q7!8O!\$W!(P
MM_85_9L!;2LV_"6T'V'1+;_J.D06;5+Y!&>FQU>1^<9(50J#Y44#^>_I> M++!VLA67Y=V/Q*?
*^M^&Sj>M_!P!Z!M>H^ME6 ^MU>>?PQ_%IO!_!&!
M'^\$/"WP_!%;X%!\$>'!32=&T>OBL!+TRP@4%K;QJ\$CB1%X554_#L*T:** MS1G.=2;G-W;U;>I?>GV222"BBB! ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M%*212P(964D\$@_@UHT4TVG= ?RB P#!=#_@D3XE_P""8!IAU/P/8W=Y!)/ M&ES+<>H6D+2&P?TFESN2!
EK\$#E&8_O8L-DLL@7X9K^T3IN? 8T^%?I?7 ML_B?IF#XP68_L!7L_8=22(-!5!F6MIV/22+!&0&4LA^5V!_C!_L_9C
M^*W!&_!0GBG!FOXU;*+Q#X5U-K6Z"@^5;?&? P3D^(^O'D)K8F0_#K!1+Q'=QIF^LDS_'XE%PJC!@G/5Z_\$JNQ
M_9Z^_7COIF;XY^\$OV@OAE? V;7O!VOVVJZ8Y)VO)#(MP/O1N_49?XE9> M#7!F>ICF&"G0>
IV!FMOZI#3LIG!MI%<1^S5!>_!14GI/_@HHKX<7&_1?&? MAVUU:Q5G!>31AFA?22-
BT;#LR..U=O7XY*H2<9*S1N%?"G_!>V!_JF_8 MO!IZ+^S;^S;X1^/(\$V2W7Q8TR!87-
IK>H;#"XFOK*SMTMP@66"-D>9;AI@ MCN!4)4(3\$DCE59L<D
D#/?!QZ&O3P!&_AUXNOX+G3!#QEA5;'50D<%=~/IWH!@O3K&+\$.); M7!E2!L@^/?/CSX& M^
9!&!*^_AOH_@32K62=18);Q7MC>->3/L_""WG#SDDP;H8A!OVA? M@C!)^*_B;_P_\$B+_."6WP!8SZ1_P(=H5@?
WC"ZBS+;ZW9/Y! =*H/_G M.OFA>BW\$@3D+67^U+^S!^U!_P5!_9*T!A_HG!GM?AW9;WK.C2_&OO6OB>P
MO+&IM/NX+R6+0UM9GN7;ZGMHU5KN&V!B)W)\$C*J_?<&E;I8:WI=MK6EW_F
MM;RW2>YE4#QNH96Y!00;_?ID*X^_G_2T_P""E!3G@KX!_L!2\$OO)!/_ MCS!0V!??#CXA_#IP#J/B*U2ZN6D-
SIMXNGPS26LB^8B(9%5;6L2\$96K!6< M^*?VU?#OI8WPX^/PE^""@^!^UUX=OS!02%IWK!BU7!H;_<
L4K!;P'C9A M\$I(1^?+1!%RA^U!K7!OQ+T;5/@?!LK?#!_A!KW5%>SF^_7B_4+*.TT>VM?^O>:386MQ+
<7EVJY_4=PMK\$&LID\$8V/S6_8"-9TT!_@JG!9^"GNDZK8Z MQX3!/?
%GQ9!7A3!FZ@B>6SUG38;Q99RD4K!+_OM9619/G\$H!89R/JJ;JFW MXE_!XV^O!
@HO^WCXD!^6ME^SU&)/"7A700A!>WFI7'B'6+XO6TUV%GM; M5R68X_VJH5551BZI+/_ O!_S@!92?7PW+IWP
M!^%_O'_X\$TFYE1AXC!02P?O_9E16.(+.*5K>V1!_9Y+!F8K^ZM9*/*?/QG/ML'Q1TO3_C+V+!_M+?M
6MSKM(X)!7?E(^@Z!IL9_G"YO+BW MXK*R6< M0AS/(M5!>7\$J)^!2R_H;IE7H+X1?ME?
G0_VA_@AJIQ=:KBS*D=I.F"ZLK MF&9X+BUN(CDQ313!R1NN2,H2"RD.?GGH!SG3XR> O!_@J=1;?_@I+2AG
MJWCS0M/^\$6K^?%WAGPI+O\$&B6_XMS#H!VI7CSK8K*GR2&*M/RPDE#)OVEEPQ /RBBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MD+ND&XJ.D_!45^_BI_+!6?MB?LE?&7P!G_!33_@F-B M?
\$!O_B79<(4T6^FSY;_HQV!2K!D99F5Q44D*";8VM/IKWHHT?LL? ?5OBOI MW@_!77!);?
3O!_@O3!M8+GO'K5U*L%EI!(^!KM5U2PT/2IG6M5N1#;V=N!S,P)"1HI9FXYX_) MH_L45^=GI7'_63_/_<
&*!_L_VGOCA_P \$N!2TW!G;36K6TU/Q>?"IN_B3_M2K.YF6*" _N!(6\$_9IY= +=IBZLZ)(A O"EMXG M!;?
&KQK!X<!7>;BUG;#="UQ<7!S^L!2L M/?ML3?
M3ZY!40A)XZ!%6WAOX@?KQU)X!9Z3I^HM=VDX;)9!34+5XXW_%Q M"P8(ZAT9)\$X*;K?GI0.I?S\$WH7Q)!/?
AIX;@N_#!@33TM_&BR2X;:NO3 M^*6+2;90;2%;MY!PY.(M%J@#;TOE_!J%0%% !7XZ?19G!7!/_#GP#^Q1 MX;U3;
<^(+IO\$ _BF*_!C@+OV<;#NDDQG?IZT0U^Q=?RA_!%C?VGC^UK_P4 M>^>)_Q0L=1-
SHHGKK;X=97S!AL!JF!T!%D;_YOK;_HOZ;?"<>(\$;_K10 M3P<4N=^!37JFW>><#R,ZK^RPG*MY;?
+K_EISYCHHHK_2D^."BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
IK;H\$2!_)Z2 MIZUY^;9I@LDRRMF&_ERTJ_93D^T8IM_@M%UV+IPE4FH1W>A^PG_!L_!P3E@^M"GP(N?VY_B=X?
V>*OB'&W!))%_#>EP6.G;:16MA96T82.W@C4(D;.%55_'8"K=?Y\$<=<7YA MOUQ3B!67NQZ0@M(07^&-
EYN!W;/O<+AX86A&G^T^84445D= 4444 %M% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
!7Y&+!5O_M_!LA?GI/MG^WI*O#_!OBSX969M_%!5M%F2_V%ROE;_6:UD9I;*6=B? MD45^N55-2T!1?
%6A7OACQ)I<%JVI6DEK?V5U^BN(O)*%&ZGAE9200>H=F M OE3_8N>_3!5U0FKJQ_#517TA_!%4OV'M_P"">?
!*_9%-6>E&H4WE=?P"BBBB_M BBBB@#^A;_@T)_E^?L'C3!B;QJWF7_P!U;UX7BE?YCI5ZI>?\$@_NQ78 M9R?
6!6OV*K^27_@G^UBW!(!_!42X;=>=2U_VYA^*_!A3Q!2^UM=M0*POLY MD)<_9IB3YAK^MJORIBC!_5 M^_X*52!
!_!_P#@!IX1!);#? M22?X77_@;6Y=;!;K!_!ALG74F@;"_X MF+0M^QBC>94!J6(@7\$F2#_P#@D?_#ZY4!> M_2!
B3QWXH^/UC=W&KZI(JHU!>1#'\$74*J(D,11(H8HX8@B1HH^JOVB_C'_P
M4D^!C7X>:5!^OV;+!^GA6XT_V_Q\$U>P!<6&@;Q;_B@0^YB@OGCMWA?YF; MONR2/D"C> >_P#!_OXY_M!_LS?
MS>(^_2/_!0WXG!)4)(?>_@_!8_L? MD76MZ21%=1V!H>J"!_W*#X!7IKXP4OXQC^SS.?MQ4 MRM8_OE@4LT2E2-
?22".X!N2!"_P_12VN/_!IMK;H&GAGXH?LZ>_!\$&MF;I!+!^W!RPZSJ.EV-S%=B!K5K4)#K'_

WA:RT318&->2BTLI9(E..H(HUS@KIHKKIKKXEM=>&M#TJ26TKPMHIG:K:QW<DD<3W,M&GVI:>>0QQ+/-/!
(%:-FZG0/VIOV.V"?BGX'Z'H7C?6-"7P30\3I/XMR?%UM:6YLI&U?591-
+=E*JPES=W,DMR+FIDM8)Q\$;DF39AE3UWJE#X5>/M
M6\4Z1^UJ^T)X>DTWQXW<2TTKPYTTH,A9/M#DFZNW0D-<2^6M&>.V@(^%OV@OV
OVO"OPN_5_9^%P200%(@_E^)^(^C/64+6/3-CU M(6R:BFI)*);!Y\$GJ%CDIY6C\$6YIZ(2JO:7-
M>VT=Y9W"2PRH'BEB<,KJ M1D,".NBH\7 X** MI?L?L,%X107WV:IT#P;>-I\$VI&W4)4BSYHB6\$?C
M7B#S,69B23DDGK7I#/_!UE:W"!L#>/'@187ICN?'?CRW6ZAW8\VOLHI+ MB3ZXG-H: GEK_1#Z)^0+++\1FIZO?
PV6G6DORTTKA(T M'N68#;_I*_96^OA_19=9M1#_+//AE8_LG@_PQ9Z9YL2X%Q+!\$!+;!M:DDWR'W)!:%%%
1110 4444 %%% %1110 4444 %%% %1110 44 M44 %%% %1110 4444 %%% %'X12!>7I%P^(OI-?
@HMSPKI_4_AYJ8T:Q M/_%S:1>N!#(YI(KO8BCUO7-?SS5_-!^UE^S_X>_J_9D)>_LX>*4B^Q^/_
M'EIDEE3<+>66%EBG^U)LD4IF0&OXL?%OA;70 WBK4_!BK3I+/5-'U":Q
MU*TE&@N(G;&:&0/#+&Q5D8'(8\$<@@YK^T#I@?I;A_!W_8M^&I2"S M(HQXN&6-
H8CQMC00"7<8Q=>N\$E7 @-?Q=U_2Q_P&E'QIE^)?!;4 @I MJ5IONOAOXIO;*U@W9,=C>*E!&?;MX/^UEQ?
AO:8"-9:Q?X/(-BX/4_M4BBBBBOS@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH
**** "BBB@ HHHH **** "BBB@ HHHH !/_ (X?BD)K7I47PL^M"Z7>Z'PIX%N-7:(A);^:(YHM@A^A^K7Y)UIT?
!^GC^_QQ_P5L^(_F_/_M_@_HVE6ISPH&G03NOX2SRCZYKX7K_%H&L64>%N44\$K7HQGIZOFU_C,M^\$S&?
M_4?G;IM HHHK!_ (**** /LK_ ((? %V@/^"IWPULK^S\$NG>\$KN M:Q3J&5SL^POF2W;_
_S;#;_J.K)/^#1+X10ZE\6OC!>;FVP^C>='T-R MF* >%Y/+<3-'V^PP9_WA7IGU_FS!*/9GXXGRP:?
NX6E3A;SDO:M^MH/TI MADE+DP7_-V_T_0**** G\$!@**** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@
HHHH **** "BBB@ HHHH **** "OY/OI @XJ_9IA_9Y_X^Y \$^TTS M3A:9XPN+Q7IP5<"0WT*Q7?IRVTIXI_!JH"TLA
MYNKZJWA^N_BVDI_S I^OVVY(^AKZ;A2OI+-5#^=-?K^A\$UH?B?1117Z<M9!1110 5^RW_
9M_&%!%_5^/_P%EO"(\$7@FRUV&%FX+V%WY!(JNH\XZA M?:OQIKI ?
^#8KXDGPI_P6%^^^D23>7#XJT;6M'G;/ISAUR@/UDMHQI2*%K.MZ7MLIK1_NM_=K^@X_\$?U/T445^0&X4444
%% %1110 4444 %%% %1110 M 4444 %%% %1110 4444 %%% %1110 4444 %%% %1110 4444 %%% %1110 4444 %%% %
5S153>?I @IU_-=7GEWM#13-4L0<IK6=K8#1!\$!^%?M>I?MU:K-K MOI:GOCURX_9+SXJ>(9W->IZE<?<
YUY77^S'#&'6\$X:P51;OHTX_="SRL^:MM) ^; **** JPR"BBB@#^A+_@TZI_QZ#^P-XR!>S6X6XIO?
%YC23'W!>WL;_M4_22>OU&KX+_P#:#OP^NC?I\$E/I_HA /6UJ7+LGUQJ.T&?(-?>E?Y^>;
M.ECO%?C>U>I^P4B ")IYE>7!4UY+I=0HHHKIV.P**** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "ORC X.M^OAW;>(^< @X@)#FZ!_%S'F8^L;W-C>QN//BP?I^U^KE?GU_P=>&K M???
^)/QIU28#>HVNZ!>19!3;K;V_!33=/_+O)??I^HI"?RR44 M45^PF 4444 %?2_1J82>IOI @JKI_-BDVF?
XH:5IY>UW.+4C1I.1^M2-%>L L\$;OX?_I^"VO0R;7L?BSXK"BBB05("BBB@#^G_(-UA\$/^_PC;9)Q?I MOIC_
&_I/L5ILU!+_!M9X@BUG @DIX(TZ-LG2=>URTD>A.HSS_RF%?>E M?Y#>*.5+Q*SE2_Z"JI^K)K&?28)WP=A
PKI@HHHKXOZ@HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^%
M_P#@Y1BCE_X(K?&S&V_P#".LI/K_PD6F5IT5^?/_IT%KHTC @CGX_TIR8_MM37M M0_>OJEO-C_P
@Y"N"E2_Z^/_YH3VY9;****_93 **** "O1V0 M0Q_:\$^%X4D\$_\$3L.\$2I_7_#7G=>M_LI;WB+IN_X*>TC+M??OPW;A
/O%I M4MUQ^M95W:C)^3 (%N?VBT445^C'0%% %1110 4444 %%% %1110 4444 M %%% %1110 4444 %%% %
1110 4444 %%% %1110 4444 %%% %1110! M_*!_P66)*X_P"!!7QOTAH=GG>/_J^VD8SJI"W.?QI/XU\$S1_?I_7PV/
M@G @JXG10"#8OBSPHONK+Q@_MM5LB1^F?OS7P#7^P'AQCXYGX?Y5B4_BPI M&_J<4_Q3/S_
ID>3%5(^_****^T.<**** /Z\$ P#@TI?2KK_I OC#P%/_ M&G/2\$^Z>_-=MIBOLW7_P B)7ZBU^%W !H17XI,^+_P 8?
@+=7@W:UX5_&G^T?B!I?V=I6IQ_8_MAS40\$5I_K??Y<1VT#>\$WV^X_WVKV^!+K9Q27:I^Y/J29"?
BG1117ZR8A M1110 5I_P#:%WP=+XZ_X^M_+1(H=Y@^)>G:@1CH+23I63^A) "OF^OT)_MX-2/AH_C_P#X+ ^_
>)_DBI(^M;UF88X-C)9J3I)+M"/<^N+JGLLOK3I ME^OUN?U+T445^,&X4444 %%% %1110 4444 %%% %1110 4444 %%% %
4444 %%% %11 M110 4444 %%% %1110 4444 %%% %1110 4444 %%% %X92I_W=I)/I M^P<^JO:Y M;PH6@W
/VD-%:(+XN\,6UI=PPG*VIWMV7_!_:=98 JE?PKI+OAF5+IOS^MG^W9Q=&I2BW.%_2E/YI/I@K7A.D^FIZ?
1117:GT(4444 %%% %1110 M4444 %%% %1110 4444 %%% %1110 4444 %%% %1110 4444 %%% %1110 4444 %?R5<
<N#>&Z;_@7XU_3W^V M7^TAX>_9I_94^C'I3/B?RYMO!A:HU**WE; NKA\$(M?/K+8XAIN*_BZ15>
MDI=I>*>2I9^*-I>IU/5I^:IU&ID^I/*YDD<^Y9B?QKI7@W"N5:IB^T7*OG MJ_R7WFOI(*)KK)P?C?
IDRH+WCI_.*.*S8 M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH ****
"BBB@ HHHH **** "BBB@ #SWIK/X%:9^TI^S^X^_9IU81B/OAX3 MOM+BED'\$ \$TL+#+-
I4DV./=17>6LZJGA16+O0_L9+;IL;F2WN;5/3X^=HFPI%XSFY4=A MB(2Y Z+MZ5_8_T1N)XX?L?
D%66E6;L%>A/LTO-OE%>D&?/9_103A5731 M_/8^+;*** NT^8"BBB@
KIR_#3WILZ'7OA_XT_86\6ZOFIT&X;Q+X/BE?E! M*9ECO(4)!_8I<=2;J0I%K!_*I9_88_!P17?
I0_M7>"_VFO:Z232>&M6634+ M!^V_!&0&*ZMCV_>00(H)^ZQ5NJBOSGQ7X^CQJP+B\JBOWK7/2?K#6.O3FU
M@WTC)G9@<3I5Q4:G3KZ?I?16%+_B5X_>GPXT+XL_#K6HJ2TQ)I_OJ6C MWT1^6>WFC\$D;>QVL_@I@YIY%;M?
Y^U:56A5E3JI<91;33T:T:Z_>I335T M%% %9C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "RO'7C?PGI_!L?>QYKL&EZ'H&ESZCK&I73:8I6UAC:265CV545 MB?
I32>=D!^G_IWK^W!#X(^!_@H@KPEJ@&I^KM/\$7BZ*_FCTNUD(M8G'I
M+=*9I&QIZ_GWKW;_@I7^VKXD_X" MJ_/_VHM10XJIKI?R: PIG9?"D BW?I NV^1A)W84445Z@&HH MHH
L:3I6I:HMMH>C6.ES>7MPD%I0KN>65V"JBCN22 IJU_5^Q9^SY8_LH M?LD?#CIF^Q\$9/@SP;8:7=RO=)IF.%1<3-
/F?2+UTC9CCEO+N1;D=E664I\$=-FL))O+*K=1 IH;E0>B2Q_!O^S(*^K_7 MW"80#8_413AY*5.1%2C);,E=->33N?
2BX2<7N@HHHKH\$%;WPS^%_Q&^_ MCC3_(-?;P1JGB/QJTXATHI^LGN+B=+91_3@#)Z DD \$UI;_!\$T/^
M"&W167_!1&ZM/_FGOX%>&KR S^MH#R+^W)5KH10RL0(+IAM/I7_M
9^#^!/_@C)V!\$ _IGPBFH;_JU5=4OY9\$N_!U4X!NKC!;Q9P1&H5! MIY8V.2?PIQI<_AX2Q\$LIJF'UW_090?NP?>K-
1MUBKR_FY4IAC^V7Y3EIL MPS2M&A0C0*3M?RBMVWT2NWT3+O! P0Z_9)_Y_8L_8IM@M^UIXITNXN8I3E
MOU#GA^QF-Q+X?M)LJG+<^7(2+R18JAD8"1P0%^QZ_!XB_MX?M ^/_B# MI_CB/QI^=MI
(OEN=,T73V9;9^IZ2C.9B5RI+^&8_*#BOT&^?QM+?^ P^& MME100^I@7S5I04+(OEI.Y4#?WTSD^N14IZ_@7Q#R?
B*683SL_HPYI3-RFJ: MM&\$WK:WGO?6IO=MZOSO#IQ:X5XZS'\$99EW_&5%)PYI)U(.45NK/=6S3LM4
MNSHHHK\VUD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M**** "BBB@ KI9?I @ZI_
_GIM_OAE:2I\$W/A%KP_O^+8(=1^IQ:2_8Z4 M^#VIB2/NO<_HD<<\$0QI""LXKI%_>^FO_4)^%G_33_93UOIHGXB-
%>:@H M-EX0!>=LDUK5'5C#;KW""#IDDP?I @CIR 3M4_P A_P>?CC!2OVEOC+XE^/?
MOA100JGB:Q9JNHZQ>OP&ED.=J+_1HN\$1PJ*JC@^OK.%I>)Q^UJHO@>\$M!M=
(T>WXRMO:Q+\$FXCIS\$+EFZEB2>373U_9CB MY8I&SKO{3TI.GX&Z5E8****XAA1110 4444 %%% %1110 4444
%% %11 M10 4444 %%% %1110 4444 %%% %1110 4444 %%% %1110 4444 %%% %M^XR?I'57I_IU70I!_X*&
#O1LS:=(^CPI8&%;C>MC^ZI&W9CDGS+<=%M-?
B%7IFGOB^G@+X1?"KQ#I%_BAH::EX>I3Z3/IVKV3I>9#*A5MI_A89W*PY M5@&^(%?
@H!O^#6GHIKQK^TIXFI&_&GOE#X7^%WAO7Y+>R!60&:_P#\$=ID/ M\$H_1\$6C90\DORQN655E*!_='@%XV9!E?
I7+I4J3P203/C;^U%I2;+X0_L_M TU3Q5XBOS^XTI2I?<43(EDCGMB*L?W!_+IG>WVDN)^(<<<?W_
A<%;&8U:63_4W M_?DOB_ ECKI9N#/H#IHG_@I/KVNVK^_V=I!O^>CQ1^0NL&)4N9(P-H\$*#BW M3^0OC&-

A&*^5[N|N|^ZDOK^ZDGGFI_71(CKBSC7B3C; /K>;5W-KX8I0@NT(K1>N|ZM04*I M4_9;_S6EF.J.%:D^;+7?
L^Z:T;>C3;>C/V M/A)^+/#OCKPU9>+ GJL5HVH0+;74)RKH?U!/((((.*T;-A 8S; M^UOIG/Q/#2B;2>H
(7V;RT7YGLG/GQ#_T)/X@/4^OT=|,;>) #_C/0+3Q3 MX5U>_ TZ^A\$MI=VS[DD4JP?
T/(((K^7>^%*,9PQC>27O4I?/OY/M)=5U MW6A_I^X8^N4^-(V3JK3;AB8)>UI7U3_FCU<T73X7K0?
HHHKY0_30HHHH **M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF?CA^X>2L^ "2Q# M;OBUXA32?
#7A;29M2UK4)\$9O)MXE+,0J@L|^J@EB0_2^F^)_00\$ _HP M;=>_ 'VLI96%JO4|O_#^MCC7HMC@#ZG!(^7?A%_P
%*O#?Q&?ZKX&^_A M:PL?"^N2-;Z;+,@DCMXG788;L-E71OG\$N%|VPV6YEB8TZM=^ZGLETE-[0BW|J;XEZY#
<3X^T^S;+X?^%))HJF6;:7|VMIE ME|J?F>|LP,F6RZLT8RT ^89BSY/X|U^BY57P5?;1^JZ16EN|G|GN^6/N%
M%>>>B(**** "OWC_#1Q_@G;)HV@>(O^"D^Q+T\$K-JBS>OAN+BT;^+^+ M3A>D46R;,\$>5<#HU?
D/_P3T_8F^-(G_4)_U|_LO?#I9(6U|W7-6\$6 MY)_TR+75V;Y\$R%!(WR-F^/E|*)CTSPYX5T:W
MTO1K&(GRK>% BY/3\$#+,>68DGFOD>*R5\$#+"P?03W|H_||KEP5W)KZRU"V4SSV-B^UM3MU4^9;
|A|V2D|^X8C:00W^K5=-F7XVIEV M.IXJ^3<^FEDU=-W?UY;GE9YE_#/LGKY=6E*;L^N+<9*ZM=-=5|SV;:;1^+
MY!!P1@CJ**^J/^"BODA^VO2_/PHN-#U6X_XG5K"GRV-TY_U@_Z1R\$-17
M..C*!KU_6V29QA_^RV&P|TENN7UB_-?BK/9G^6_&|^>:<\$|05LIQZ|Z#T METG%_#_/DUISO%ZIA1117K'S 4444
%>O_LK_M@^_OV;=:^Q1A|4|-7S+Y:17^F&7X/,-)+#8J^G^6Z?YKLUT:U1ZV1YHF
MW#>9T|PRV|Z5;#TDOQ36S3V;=FUHT2KU|_C|V_ (V>\$H?&?PIU^_JM)_+
M^G\$MM)C)CE3JC#T/7I^00:Z:OR%^%Q@^(?P3|51^/_ASXBEL+I<^9|T5RF M&GCUD/%|(8'-MG^#8S;5V|U'
_)X6_Y)_2+ET^A^_02BOS@_H **** "BBB@ HHHH ****M*"BBB@ HHHH ****222.&199%5%4EF8X_ZDF@-
A:X/X^_M%_?#IG7PH?#7 MCG64MUQ,K#3=)MR#<7CCLJFE=S|H^I/CGI3/_I2/PA.TN?)"P7^S^(-=;7; MP1%;W-
&C@K7PKXY|>_?B7XEN&^COO# M7Y#*(Q6JW<^19H23/WG&YSR?8_*/J** H#^83^8^#1P^@HPBK)+9?U^_<|
|X9S3_-MQSK_*F.OU5U*M1WE^3NV_P#;)+1+1)|TY^Q7^W=??"=|X6?%V|EN_"SD1 MV-^X+R:7GC;>
|P_|/5>V1M?%G_!=?|X_U|5|4_VZ/^;7A.&YM;F)M2| M7?#70HPZ2(PWO?;4B<\$99K5?
6:9.K5=YT^E3NTNDOS|= _Z2|&_ M^ID?L|CXB|J.6&T5;J|72|1GU=-/L|X;:Q^~^7|E9&*!|P01T|* H*_X+B?
M|&_/A#|K+0+_/S_P""+;V|M1|3>#-(VK;>*5.6>|LP.(|WJ7BX\$Y MR2EFSYW|_FL;J.C.C<;/K%4/;7=L+
U:W_1CDAD4E61U8-JP(((O7S& M7YC1S"DY0TDM)1>|V9;_)PJTU_#3BU=-:H|/JF04J|CB_"S.<^H&23_MZ4E?
KO_P;(?|=\$)_VB_B39_!%|/VB|_|[P%X/U,GP)|5|_|FOZO"W_R5/WK M:V<9ST>=0N2(I%-
X_&TLOZMC9^R"BBBN884444 %%% %%% 1110 4444 %%% %%% 1110 4444 %%% %%% 1110 4444 %%% %%% 1110 4444
%% %%% 1110 4444 %%% %%% 1110 4444 M4 %%% %%% %Q#X>T3Q9H5WX9|2:9%>6%; M|=V|ZY26-A@|_|_O|H_|E;6_P|F
MOQUM|UFNO#_IR_VBZBPR5|FWD/;11W_B7YA_ \$%_4^L#XG?#+P;|7_!=YX"|= MZ2MW|ZF&7H3C|LB-
"ZGD^8)%?7||5XCAC|^SO^C/XX_^W+^|OO6CZ-? ME7BMX98^Q&R3DC;&+I7=*H_OA+KR2^+^+|Y=4_P?
J^I)_:9H|9?LU^_6|V_MZXX76EW99I%UA()=1@|_|#_ =D7C(#+VX(R""?_J_J#|XS"YAA88C#R4H25TU_7
MWK=/_IG^<;_93F.19E5P&|TNG6|NTHO=-/4|TUHU9IM,****Z3S@HHHH ****M/_@%~W?;O@9^H;ZBOB#0HL
;3JTC^Q)Z0R|M^|E^I|VOLKX+ M_|L^_M%|C_|X|1#P|JTF=-UUA\$K-Z)_JWYZ D;?IM?F517Q.?<Y|GC=1P|G4?VH
M:7?FMGZZ|S/V^GOOXXX_C#|JK|8PZT|G5N|M^?Q1HE=Q7|A^SZLKJ^1@5(|
MR^#P12U|36PK_>^_WP9;+P%|1;^TC|SFW+^2;X1%|E5SZJ?>OHCX<+M%9M:MPER6/A=;W(Z/?;#^"?
^"B^|/C)52X M;7&BSOTM|L_BQ|73?&/^H|0|_ %CX7>-\$#^\$/B/H6|HN@L-6AE/T(5B0?
M:OA|9DV;Y>VL3AYP|8M+|H6/V3^N+N%L|BGE^_I5;|U(M_-7NO1HZ"BBBO_M/H@HHHH **P/\$_Q5^&'@H;?
&^Q^T/2RO5=0U6&\$_3#;_3|5Y=XV_X*(?LL^# M0|5OXVN_:G3.8-\$L^ES|)'V1G|&KT|DV;Y@TL_AYS|
(MK|H6|GLVXMX6R*_M>88VE2MTE4BG|DW=OR2/<*_#;PM<7\$|QOHI9W=L|0.D/05|22\$;_@K+X@
MNEDL_A1|;+S|R(|I7+DS/CU|J;/_U=A7S|4_VDOC?|9V=/B^|1+^|ME/_M|GON(4>G|E_*A(I2^?>ON(8U+|N-
&F^+7W+3|Y(-&.)?*<#93&4 M;LC/%U.G^G^%_4US?|@;)+S/O^XV_!%"O@|)8Y=;T^5O^\$JU9_A;+190T M*_TTN.4
I2+08=Q7QAI?OVT/C5^T|NF:UK(TK1&/RZ%I3,D+#+*_MG=> MGWCMR,A17DM%?
K60<#"Y#D#52\$;55|N>K7HMEZVOYGN|N|^&W&|98>K5|A MAW_RZ|7BFO|K|T_-|O|U!1117V1^2A1110 4444
>T?LD?MB^+?V;_&=DZ MAYVI>%+R;H:50|F@)ZS09X5_5>
X&#@X8^KXVW@<;EUE+U^T5U/M^58|D8E^YOP%X;5%?F7^7#^%H499WAJBI5 MH?%?X:B_E_ F?3OL^C7|_<
7B=Q|^LVH|UJL9?AG_P \$A_|@BH;O|_@H+^U=?_ ^&*WA^6_"/@7X>ZOY/Q1U^LW/M MKF";_N=*B60
B|?|R/W^9=@3L|_ZG_AO|? OP@|ZA+?ACX6L\$|V>^|_ MBL_&TBPBV0VEO&H5(U^H_!Y/4DDYK4M=_T^QEN)
|*QAA>ZFZZ>*(^9I-J|M0;2|H^TW@;_C|X5_2N4YOE^=X_8G|S4HO|T^S71_TM M#_/_7B?
A7>#|UEE^:T73J+;^62Z2C+;47W7H|_11117T^SP4444 %%% %%% 11 M110 4444
|ND>_O&WA|H^C^5;_%1T6S|U^6(#_OE46W_ M#?ZS^C|T^7C^M|_|#^XENE^Y^2N/HKEJ8+!UG>I3B_5)_H>A0S;-
<+^EHXB<5Y3DOR9V%Q^T_M|?KO+^N_CCXPE7^DXFNF^ZR5BZQX|=>(5*^(/&FK7P/47FHRRY_P"^F-9-
M%/%|8.D|PIQ7HDOT"OF^XJ/+6Q\$Y+SG)_FPHHHKI/"BBB@ HHHH **** "MBBB@ H10"Q"J^23P;7UE^R#_
,\$|48M;?;\$X^:3Z3D26|AY|QSW@ZAIN MABC-GAV_V1C=Y&=9YEN08_XC&3LNBZR?;*ZO|!=6D?5<(<&
<0<<9M^95 M2YI?_DI(07|TY=%H>T4WH<)^Q|^Q3XF;_(U_/Q9XI6?3/"%M-B_|^I9+I@>
M8H|INS2=%Z#)R|^B_A/PEX;|^+^/PCX1T>&PTVPA\$5L:6ZX5%ZDDY))R22_M222:M;7I>FZ)IT&CZ-I-
I:6T2Q6UM;Q|(XD_P%51P|^V%3U_-^%|>XGQ?_M_4IVE^X8+9>|R|_DK(T/A #;PQR3PYRSV>^>8B:7M^K6LO|L?Y8)
|I2|M MMA1117RI^EA1110 4444 %%% %%% 1110 4444 %%% %%% 1110 4444 %%% %%% 11 M110 4444 %%% %%% 1110 4444
%% %%% 1110 4444 %%% %%% 1110 4444 %%% %%% M%| 1110 4444 %%% %%% 0^_S9|ZBOEHJ|_@G^X4^|).MSXW^"
|VVA:V^9|)+9 M=ME>-U)7_<.74 J3U_R6KZAHKU?#|OK|.?SD_A^O|X;NM+U&W/MSV|U^C(|T^|J>S^2#V-8U?KO|5?
@O|_C7X?/ASXD^%+;48 #Y\$KKMFMV|_M4YD|3;4_L=/DVK?P+Z<+|/5PQ_M_N=Z>N^|G^*6ONK|H M%?WH+XK?
S00W<8H^7J^GU+3=1T>_ETO5|^>UNH^*3VUS\$4DC8=596_(L;@K M|H(34E=;|^RC^*G&2LT% %%% %%% 04444 %%% %%%
1110 4444 %%% %%% 1110 444 M4 %%% %%% 6|T^6_ \$VJPZ^XZO|VX?;_VEE_TLLC>B|H|X4H2C^+E)V2+|TYU
M9J\$VWHDM6WV2^E=-|+/@_|\$XT^)^4^_*#?PQ<C=|^F=|B^W4_QR2^Y47W
<M7A^X>Z&/_9I_P""8^BGQ^Y^B7X|ZD^C61PZZ8R^UW^N^Y6(>PW-U|VFO_ML_X>?#3P)|^/*#
|Y+X>+&+72|^+D0VRF^_O|Q|O|Z>)/\$S+;L4J_ M7VK5>_V%|_M>D=|Q_17A|J?
B+B^4;7GM+|A|^7 ED>47|_|YZK^1K4Z_ M&6^V O?P^S^_/36_B#OOF^CF;_K8- TO1A|S_ |M&&>|M"Y^A***!
M|TS;_YQ:Q&J_-;NJ_!Q3%KEL_E=*U1E@N@/_M19.(Y#|GRZ^I:.*^FR3B_/AM^#5;P7V)>|I^NG_ K1^=|7^%?|^W-
/_*E5 M?_+V^N5/FUI+ M|27D?CYX|^&Q#^&_I_P|D?*\$P9J6CSY(1;ZU9^DQW1B-K MCW4D5A5^RNN;H7B;3)-
%|2+;+A9S#\$UI?6RRQN/=6!KQ#XD?|XOV;/_G ME76D;#=#&|MGSM\$NBL>?>*0;@_LH6OU3^O^K
54HYA1<'WC|T?N=FO_"8_MFGB7Z+N=X;4JF1XN_&E3W)^BDKQD_ |B/S9HKZP|=|G_(F:89)_AW1 MM(U;
(9^PZC^|H^1ZQ;YBD^Y^CZ5X|XQ_8R_>|R_-7^#FKW|)SYVE1^|4CU
M<=<#ZXQW7WN|XLX;S)+V&^*@WV;Y7|TKA_ \$Z;/_\$#AJOZ|EM5)?_C^V MD?|P^*_|3S^BK6K;)K6@79L-
=TBZLIU^|_|#=V1N|P8_U5KZ^_HR5TH^&G M^=_;C-6;Z|<****Q(4444 %%% %%% 6|T^7|_T+0_ %N|Z8|G;V:5OR4\$T|2C"
M_Y_R+A3G5FH03;>R6K^E%>I>"_V+|VH/^95M)^#^J6L3=9M75;|0/7\$Y4D?0 M&O8Q
^_|)WXA|BZ7^Q^>^&EZ7\$<%K?2H7N|2|H|^+6JGW&X5|C^+>+&|M3|O MBH771/F?W1N|S|K)?^|O|X@;^IY;5;?
V|H|G^_P_"J|2U>7<%=K.V+1QD_P|^0_(@|V(%?H5|_O|_@G9^S_+VGC0+P_ M7^B^|CY\$VOW^FIG_
XH^C(|F5|JLTO2=+T.PBTK1=-M|_UA7;#;6L^QQOCT M55_TKX^?%O|4DXY?0<\$X^8^NNHK|JSKBS/<;_6
M|JOD_E6D?N6_SN_ _ICA#PPX^X(2EEF%7M?|_GY|WZC_|>?PWZJ^BGV^BBBOG_M#|I**** "BBB@ HHHH ****

"BBB@ HHHH *** "BBB@ HHHH *** "BBB M@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** M"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
MJJ(18KF%77F!%E3188Y# P-#? MK7:T5T4,7B!T:DH^C- (X,9E>69BK8NA"HOIT8R-,\BO-@HDO4L-:/
M@W+G_GWU"ZB_P#0)169) P3H_9'D4JOPWN\$)Z,NWFI^1589/ *14I ?RG\$Z+^S7^SYX>(2/@GX6B=?NRMH<
M#N/^\I/UZU^GZ9IND6JV6DZ2L:PKJY&WB5\$)T_3T5YE2%KK\$N!P:7JIV MS/HL'E>69%I\$O/\$WB76+73M-
TZUDNM0U" ^N%B@ MMH(U+R2R.Y"HBJ"Q8D \$DU^G? S_ @0% P \$F VC CS: LU "A, #T> P#% MNI77V,1K6\T?
4+&VU6;<5\$=K=W-O';W#,PVH\$D)D) CWYH ^NZ*WXW?M ?" M+IG/PK;> /C#XP72K6_U.'3=*MX,.;>IO-
3OI<^5:6EI,))<7=P^UBL,;N0K M\$+A21A?7IL;IGWH^O/X@_ #/Q;>Q^*/"9A/B:PAXEV/7VBZQH3+NAEEL
M=0AAG\$, @Y28(8WP=K'IH I/HHKXH)= \%I?^"1/PT^GPKT^B>(L.OI+N;"^TC48=IDM;JUNHXYH) K M(P#H
R.KJ65E8@>45RVH_&7P!HOQCTSX"/JDLWBG5-"N=9CTZVM7D%080R1 MQ-<3NHVP*TLB!O(C,K+)L#>5(5ZF@
HHHH *** "BBB@ HHHH *** "BBB M@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
M"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** .6^ P'? WOI^%'I)OB9H M7N@:J:MJVG;AY=I#^#L:S+F2.\$RSW.A.(I>)"?FF MFD;"J@ZDY.
"1^:WP8_X.\$?^"3=[XYN_VO/VBOCEKEU1+K2);'PSX5T_P"& MFO3P^#M)=ED.FVTC62QR7<I1O/=765662..6F",D
I\$_X*&_%VX^\$G_!?! MJC#4/C+J L/AQ? AGO5IOAO4HMEG#XGN19X&8_*)GC:U@3/;D@8#-5#_M (%>.+7X8?
!%"I%J_ "O5X2^G8^&/%GAKX@:;=3*9;G05@6XM5N\$4IO+ M2=KF=-W&ZW'W37UW^T JGf\$Q_<
&8)F X*>" !5EX:UK3K7570)?%L;2 M66TNVB5A#^Y>[I1#;\$!ERQ*IG=@ +/ !.# @G7H_B_1O35?^"GVL_LU6?P
MDI&:X:PM^SU^CH*:=J\$=A)O! M?B+4K<*KPW=V) \$2.;J^L\$FV4 JE 'Z M*>* #B?PSJ/AHZM>V
U&QFMOMVFS".XMO,0YID3\$#+(N2<2I<2 *ZD3ECQH^IE^:O@JW_X.# ^"3?QU^/\$Q<_) ^FMV' MAWP#K4K-
P!#M!:=N5>I3=^PD_Z8K)HYG^LXM(6%O)(TKGSJOEJ=G; M2V-2VD_A^A^QM^P^XJFI5_#GL?CSPC>_%K2I
(MY+^>UMH!_G>I%"DN4 ML9) 'RU9 *WR 85JZCID#Q+J/H/W1GI:7 !23XB>%I?TIX:?\$7QIX7M/AGI
M\$^DRP7_B6ZT13HK26-L,\$DD:_09H8+*.Z:\$_-\$DPC,J*WS>6Z%@I)5?, M_AC_9M?M#I^T1??
OOA;L=4NK'X76S0/7OB"1X+<&:RLST8FIC M&Y7MG !_9MB\&? +6'UGHJKXO>#M.^GOENXM2UO1HKO+;I-
M3,=GHNFQR_MLDIK9(OA0HOI/V9KBVN@>\$+ @J:HOI2EU&GC;6AH3?#V MWOF TJHTQK\$1^1HZGYI
M^"JB'.VY#I).U^M/I+J2%" /F:X=1 ^XS'QHO@_M72!XO-P=YF?>@#NJ*** "BBB@ HHHH *** "BBB@ HHHH M
*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** "BBB@ HHHH *** "B MBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
M)!="IDC500*K8R>X'6K% % \$<=K:PS27_M&DDO!FD5<@&83WP...DHH MH 22..6-
HI4*#P(96&00>QJMH>AZ+X9T:T!>@!M=/TZPMDM[I&PL;=8H;:% M%"I&B *B"H "@ 5:HH QI
<^'W@'Q/K^F^*_ \$O@C11U31I" ^CZE?;9%- M<6+JT.CJ6B)IE2^V*** "BBB@ HHHH *** "BBB@ HHHH ***
"BBB@ H MHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** M "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH ***
"BBB@ HHHH M*** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ H MHHH *** "BBB@
HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
%FLSZ=;V^C7L_#0 M_#YI=C+P01QQ7PW_P IE/I_P#T9GXZ_P#I_92X5Z6&R2.L7256C3;B^MU MF)R2/V6HK;?<
<(RGIF?_*S!=?^#^R PKI% P#@FG^WIX/_ "E?I+H^U! MX'^^I>&:"IUFITY=+U:YCF5K=@I?
=|N#GBEBLIS#!4O:5Z?+;JU^C!-/M8I_HHKOSQU_P4\$_8Q^/O_O_(4?)?VAM?Q+I./I:T/2))-1N=*SG^VN.T2
M0VCG3/H9QSTKSAGL=%<1*AVE?V>_CQ>W&G?I+XU^%_ %TMHEOJ%R/#>MPWJ MQ6TID4,C-"S
IGMIU'.2YD;:RE3;8"&)W'G.FX !=Q^OZ^UO^SKX MD_ :CUO)
8MT3XFVUQ!3O#OA:'Q'K/A1.X\$EMIDLBH<4QB%LO)&"BN742(M2H#_D_I'HHHH *** "BBB@ HHHH
I!8_MP_LF^?VEO'_I'7BCXY: # M3_&)F&@>"H&DN+V416LEV!2K\$K"V7R(G<_8PP "DEE!/5J "BBB@ H
MHHH *** "BBB@ HKG?BU1I++X2_#?6/B1J.G2W<@CVAN)+%PKR \$#)X'6 MOFO (>U_#O_
*)K7_@=#7N97PWGF=495<%I)/\$@IA M#%0PV<8M495CS)-3=XW:O!L6MTSZVHKY) X>U_#O_HD>M?I
@=#7J'L'I9G MAGH!7M4T'0?IE_L:Z7;)<227=PCAPS;<#;TKIQO!_ \$F7866)Q.'<81W=XZ: MVZ.^I//R?
Q6\I_L_S'GE^7X^-2M4;48J.TVTFWJXI)O5GLU%8_CSX@>"/A=X M6NO"Q&\5V&B;/8IOO=3U.Y6&!"I?SNV
HISQ6%)"OVDAY??VH"/,WCHF_X MV^%/'FB6UUE%/"_H:Y4_I\$S_9_I'J_P#2(5_/K7ZIP0!IB:K+IV
M8S^(*_I^P"#5'_E\$CH_8I:W_Z-2OY@:_I^P"#5'_E\$CH_8I:W_Z-2N?B MI_D5+ \$OR8X;G62?I^I>GQ)_P""?O!_P3
U_P=_!269I+I9>-M2M/I_AO6 MK5B)=ENXYIKB,CE9I;6MP(W&"DC(XY6OI3I@GICWX) EW#-
:SE95C\$JOLDVI67T8J_F9J=;1M3Q8V!_O!I37%RFI,L8R;PMY9XW."SB.+JO<^(2+I+>;PYI?@_ ^MUM1OV4M0T?
X2;?SQ8?;#X8I4P>+8;K5I,^WLZV-WJ.EK J0PRI'QIFZG>.\$ M97<0H?^/7I>>A>OV<_B_I
/7X!^!D^&)B_# +X?:MJSZGIMV)-UC4I:"23 M^S+;1%87001M!HEC)6\$E8QYDGF!#^1GI>_I4_P"SQ^T/_P
\$L/@)^T:XE_;" MM?/Q\$U#XE^"-<17^I"UEH-^ ^UL96:>P.DVC?9M.BMG!MTGO%-Q_Y3XF<\$ MJ
#I0_VKO^"LFG_LL?MM_#_IB"J_9+^(B'6OB3IFW7A36+^N=.%OJTM!/_M,+;U3I27QIA"
I70M8HA)YS2>4C.'>O^"I>O6WPI";+&3IC7QOQX(^+7 MQ;L:WOA2P
I\$-5N]=M4U.YMBI2W8G)2..PC@0W\$MTP" I&_J-T7F?/WI87QJ M^\$WC'_ @OO^P_XO!
#/Q"TIJTO5?IWC^33;I+M1=1W.E/:ROEL;XYV1A"XR MLW!C+!@32_X*Z?SYOV?^"S?
I'_I=QR>?T^&GZ9XB/ZWXE>-FM/#!FIZA; M21QSSLB%9I)%ESCJW;3'^" @#A CAI2/C/XO_X.1OV0?"WQM^
D/@W5I" M_)+> TCQC-7TS5I:229HMEH+>7S(WBDB62*2I"N!&4NK@UI9?ICLOCP+5 M/^"G?
Q!_8;:IEW6 "WB_P9V/+;6I1;:ZVG;I6L'NHTMXX#;2S.T!|H%|R1 M&5@RM\$K9KY*;&_#_92I1_I'
GI%GBWPY^T=X)U^IM.++>./+4=^L/\$UK-8 M6US=Z7MMH)+E'.2RR\$H%C+;CYL7IQ-W_\$7-
(SZU_P4:_9F^"7B'QUH_@|7G_?>I+N+3=>I.O9+NOH)H9_Z&_M:W7\$CQAQNB(="^0#|_I
!N=1+3IF/X9&K_@G=^U#XFM/#OO3^%7Q;UK5= M8M=?NTMI-6T>I^ ^LATCHI2^
MT8A/CQ^T9XEUOP#8W5O_HVK>"VGDB34\$C88,%UODV<8>*-&5920#Z"TC_M(??
V!_P35LO^"CNC_F&ZL=1#P^M/A(6_B97N;BVEC62\$S298^AOFW+ \$ M(, &BT?B^H^WB"IRJO?>%
IAOI0;Z46);5=4D^V%ONYTR6/C%>T?M.MT?MI^&_IO_!5WP1^PAI;C=IGP1^U^I^KOQ7JGQ.NI0MI,O?\$5P;XP+X?
MM M4N,+IT.R;HB62)EG_?%P#J?PIU7 MIG+6=5T_XM;=W27Z60L+9IF2ZM;B\$+J;X8W9&*1N=A!O?
*6M^!OVZOC9XA MU#X0:_XD_9'6S!%?&HAC.^)M!>OZC+H!4^FW&H6IZG;BV186EB@VCI/-< MQ!W"F4932^?
G_!3IH3|CCX5^_O^"D>A>+IF3Q#X5CU?4? \$4_@W5HRXU+7? M#-
MH=U)=S.+PFYDAEB;0W.OPI7\$SEIHJVOX#^#WQ;_X)?S!G7Q!_P3>_M)OOB!^S!>OB?8>&I7X-
>)-235VT2S0\$EGDU71KH\$N+6UA26:0#9LVKYQEW MT/T!6?MO!BSQ5!6_/_P0_8+ @00Q.USX91P+XIO+
IQ7^HNFV5!_#Y!6E MOW!@G:XOC%M=HQ&L40EC\$DR_VT>"^+^" ^OPPT_ ()?0?I52P^SKXCUG
MP58-M_9'C3PY?;G%8;QH6?;(K+R0+&BN\$?TJ@NLBD*Z;G>L2AOI GI>'P M3_XB+!02IKWIC3_@H-
I1+X<7C;XXZB4AIXJ6;.23I/XM6_P!V3_P!&IXK_ICP=?R%I)=4T>||* MBUG)\$N:1;ZUIDVJLZ!
<#_.IT9AB2");@_9** /K+INS_ (*%I'A7O)(MDI5?I2ZIO>OBYI3=&I!V.M;:KL<4VF;KJ+R>49K>2AXI\$HT_ ^"ED,2_!
I=[_ (VSB;I^F^)JL^_2!H-L0/PR?S>.;2!Q_V_/V_ CA M* V1?%PD_:(I+^)=
(T;IKOP#XB!OZSH>J)=66BV"P7IEKZXC)CLY" FIA#_R M2%89F"XB>QI+63I<-<74L%_F6*! RAI@V0.' X?7?"76/^
M"5(X^N?#_+9I+=^(O")%C=2:UX9LGLG!HY;Y>UG%R9IA%,23)C?")7*_M!K&X+YQ^WI)?C+_P4W^/_
RO^U;>XOA#X; ^%8T*R!_ ^)=)UAI&UGXD2 MW-LTK78J#XX_9\$^_7PHN?I @TO^?PML?&I MA_ OAZQI3IK>D--

B:36NM9D^RQ3J?I3)*"#&^<D X- 'ZE LA P#I1KXF M M9_%?P|H-E^PA|00#?P|I5?
#2W|5:#|6M4N+=|*NY7\$.ZS5%(F)S*XCDD"/ M L7FI%Y+I*?
J>O/'^="NNZ+XF_8#^".N>M5M|ZSG^*OATPW5K_1!; IP1 MQP001V((/(KV.@ HHHH ****
"BBB@#S|L| DUOQM_V|6_|1"60RMKJ4OVS0 M^36_&W_8%;_T):_*VOZH(^1)7_.OG ML3^&I3?1)7X+_KQ_|DF%?
6W_M 24_P"2B>+O^P+|_P"CJ^2^MO^"2G_ "43Q= V|8|_ \$=7U"W_)(XKT7_M *\$\$_O|_ DZ>6?X|_|
IN9IU5^#6E6/I0G_1Q_:\$^(O| P5T_9 TJ^|1_M?Q3^T|XT|-2M#_#+2;95&C6MMXF0K:RU>SB0*BB)"JXV|2A8)
<:H?WE)& M2<=2:~20^"8UW|*OCA^SY|9?"DEQHGBG0M0_:'^)^FGZW8%XKNVN8)_ \$5^6A ME7E722&53@Y#)
(#R#7|K|^EY% ^UE|4_A5^T5H?D|OJ^&_ B23_\$GA?Q%^T%H MNJ>_48LSOBGB21+9)%R_JPR05(##P*D
@BO6|BY^U5JGA|XSI^S+|_ ABOC MKXAIX:7O|JVF|W_NKI>G: +ICS/!->W9BF:~YY8IDABCAE=_(E9@B(7KK|!_ M9
::X)1|I3CX)_L3^"9+SQ#^RG|0OCLGB|X97=|+)+X+U>+3=2%QHWF M'_\$D2=I%#?<
ZQ8@ZGS%N=W<_M_:%#JE|B7_@O^XO|9?|?/A|X:O_A|>/AG MH47@#X@>,"\$JZ=H>JZ4)
(9K)FEBD^SB3S7>1E"F6|A6+H_?4P_ "R M^D_+X&?^COE:2LW:GIGQ&_9GENV@/PJU7Q+
ES:6MO-W%P:F0O(XWA08Y\$ MMI#&2(MVOLI?D|S7^_W_5J|HX5?|SLI_X*MZ7^SYJ.M>#J2|+::KVK^'\$_
M|00V^L:2;7TD\$46S=&8YRKSKO&Y_97=T' 75Q^PI^T#^QA^U1+_, \$P?VC7?
Q"^&_@RUTZ#Q1K\$FEWP7389+>WC_~8 T1:0.T:O=K&I+B4) M|4_'/M^|EOQS_P:26/P-|?&W0=<|:VOP?
|ZJ|7A+|KY:K4=,ELI3L\$N^O M+>+<|G\$C*YLP2,F2)58M+&&/T9_:(X^Z^\$OV_?\$_WP1T/Q_<S5XXUFQ^V
MLV6G:_K^DR6/?#^Q5V|7^C7?QPT">#4|36(9&C6SA MB=MZL0 DCHC?W68*^BO0?|_@X8@|=?"<
Q=^RG^WBFWDVH?#WX"?2UU3XH1 MV%N|S:~IMRT\$7|L.B@DI"\$E7/9KA|P&)|HXC_X*6:O|_?VE?A|^SE^VW^S
MZWVZ3XM7K:=|O&ND>*TUK1KS51MVZ7=R_9|>2SNW|H(P8WBD8D+*=|QT_B# MJM:QOXXG^/?Q&^
/L_P.L?>K?*"VTUO^R:EXUTB|L_F M2MEM962|WFE%Q_ M28Y:9K:_&15\$|82"/X>_X+K:X2_?Q^GI-/L
W|_7C72_\$OBKQ?^T|X?|3_ M|=>~0CNC8Z%9V|T|H|K^<)CMM88ID|ESAGFC50T_~97WOR^6H_!|8ZA_P4_|#:_^S+|)?
C?K7PQU|/%?QK&G6O@/X60/\$=6N MI3NX//F|2,D<2V|8D>XG&X1XW!CDB"G:3OY3?|_G+|<
MOVWQVB)|@Y_P3B_X+@?M2?"|T_P_P""M:|2V/Q?AT32I##HOK,8TJVUH6Z MY*PRV|W28^7,|2(?WB|OTY^!|?|
P4L_9_~Y^+6D_#G|COXDZ3|3H|H|NH> M+~<|S_+9^&|L_>5|HGV:%N)KCR8TM^RRE5FD(|_0#_83_>^~7|6^QW_ M
&@?AQI7|_N|J?#35OA#XFL_~9W?B673UNM4N9+>8^=;*26+|_~J^D_|F4 M9?N@8KDCA_P5UU_X2_LSO|_M|^?V0_<
<|3_~"MI8|HCOE8^)|_#6|M)><0 MKK-MI4D?|ZRU027BO^:BN9M\$OI|7)!^4)/E2?X64@|BO+O^"7|_?|P0T@_8_|?<
L|M_M|ZL_~"7PC|92ACI4?A^Q_X(|=?"6UN_8U_~LL6R211FT>34)YPB\$HU#3><M74JQ MV6\$+& F|V%4S@\$|?<
|9O\$GAZW_~#|X|_~KEHEV_|+&KPK_<*)#(V|W\$BIM MSG)2-V ZD^3T%
^O^Q|_X*0>*,_1_BGXQ_9/_9KG^<_AWX_7=8^M;?Q7^I M27>HV_/G7NGZ4A@F:_N(%PCL_ (B|T^6DKLKA-'P#_P_%2?
@)|7OV2?A|^U7|_M)?#WB#6S|+Y_&_@K|/%;ZKJ6|_P"D>=,;)|!%\$MN+2ZDFG+F)(K=W5GR@_M?X4_X(T?
|%&_VO:G9W?C&1K:# MQT^|<|&YBO:>9AME=V9G"@JG|CDB9=V6"|7_~97XS:<=#_9)_X*@_ \$CIF6|U_MX&^
OB1K2^_~"FM>Q&=LOA|5|8V%CK%SHQ&+^E+H|CBE4-&|Q|&VR|L ^MO^AY_P_%.|FS_|PT_P#X)T_M5?
23X<^/O%_AB77_AY?Z=XGCUK1_\$UK")#<M117_A@EAN8UAF8Q20C*Q_P:E_~U77PO^RM|^M?<
A|J_BFQ3|AVGV|OI%Y%"T#1Q>868R<\$<5^6_P#\$75^SG_T:XV_|EG_M_A7ZEPQX;^?7\$63PQV2X2I4P|G)1E&<
<\$FTV|...>Z20XZV_P="R5|6?2S/5|_M^<5)_@DC_P|?XZ_|+7_P|K|^&2V*2@:_^P%|&#_?JGC|GBPU^V|_V|V7
M%|1%|JNHM=3>=,~P:0F1@#C(&|V|K|Y/^<N|K|G/_HT/QM_X/+/_K|_?|_@G5^ MW3X3_P""BGI=K^TGX+|":CX^Y^+?#<
|Q_M+X8RM8S/L+G0)G&_#/_&*UOC^?O@A^SGX_M3/CSX^?%GP_X-T-6VOK^B758K^U0Y_PTLK^J|D#D|2^T/A=|5?
AG|_O_6F_~%M/X_?.\$#10%7AK6(FDTK7_~J45Y9WB^|H(S1S1,R_ZLIP3@J1U?%FIUFQ|^E
M:9|L_F0Z+I6FP6UG;0K#_YEO^T|11|J_*B|A5_&_~5R6G_LX2L|3X_O|AW
MI7P%|VWA_4:X7NH:~%|^K|+ZNOX<3R0B/8|@=5;>06RH_~=:F|2>+O@7X_U74;G_|H|O|2|_6D||NU0|H|G>_LV%55&_<
|VK=|9_M^"/!2Q^|_?2@GXA^&+U|1M0C|N_TC6M/CNK6Y3(CV2*561QD_X(|(K4J|KN
MO:~X7T6|2)>M9M_TZPMGN+Z_OKA88;~%|+|/D#BJ_26)&30|S?@|H|G MSX"?N;2+CX?_!#PAH4GA^TGM=|?<
|0#5K:G38|F#3116YCC7RAD95+*F_O4\$@ MXL^G_X#Z7XH^CC3?@6X1M|:6Z_X76(|#=#JET|V)+2^<
(|~|DDEL|Y)|YKE? M@%~W_~R=^U|^+O%|OL^~^QKTSQ/X2|V|ZQ>:7XD|0V_~RVMK=6EO%3|U<1QRH5EBD0AT4Y0|4
3_~\$S|G|^GGXU_O|_B#XR?_P9XMO|)_MY|=|XF|+VE_~9|OW3SOLT?//RDXAA:1H8Y)_SHAFF^J20IEC>#?#5D<3;|K_<
UL#N>D<:_%YI#<XCC5F_M_#&@NB^"Q"|(?%OX>:~|50A|H_|H|:XGT6UU_O|_P^SR1?::YA6:&79^JN MFZ_<
U::ZJPS@@(|H_9_PJWX92;M>U3_A76A2:2%_~"P^|H^C^R(2_U)>8S\$~NFV MYN%\$9*
2:@%..G%8W@_|FG|G+X5>+|SO|+|_(>?"#>NZA&8|_6M|^V=G= MW*\$@E9)H8U=P2<\$GD59^?<
QZ^"_|_!^63XE_~GXH^X2T&_XCM_|3UW4\$MX MY)Y#B_"/<H^<|H0_MA9VGA8PR3@&QE"W"|@Q0RN&:~*5C8@|4
=0|3O@^|_C9+|L_QE^"V MA+Q<~D3&72G|3^~|G_<#>9(|(SQMY:<#E<~@5TEH|DZ|H_VZGHEO<6-Q;M M;W%E/|<
KQ2Q_NUHV0C#*5)|4C!|Q5BB@#B?#O|_L|_A^PH|2A#PG^S_X)TO2_M=#UK^V_%TO30^EG|Z?<
J_OX_MD\$|A8|H|DCKY|@/M=AG!_6|/?|/_P_|O^FN_M2^)_~"P2(|ZS|J4Z|)|H0U;PW:W\$|@50JAD|ROPH_&3P_|7744<
<_>_~"7X5:E MX_M|BOJ|PS|W^BFP3;6^B6?18^U^VA.TRO_%)C#?_7@7X ME:U%~!17F/|5G|9O|+G|_#_PW?<
XM_M6_&O1O|6@|JQ6^YU21VEN6&_I!|K\$S7_M#CC:3JEAKFE6VM:7/YMK>6Z3VTNTKOC=0RG|_R")_T6***M*
"BBB@#'^<(|^70/B9X_U^P%XICE23I4MS#=#K#+L|_K\$>@:_<S_~"TBV|>|D4X)KCA_A?VC_P#00W/_~|604P_M=YOE^<
T)|7E3BW=J+;3?<^<SK@_A:B.O&OFF^"IUYQ7*G_~"DTKWLF^EVV>>?|_M.S/V6_|H\$ZU_P^#AO|_~"NY^!W|7PC_<
&=>=50M9^<JG?Q3ZC;K#R|_W4JK;Z;+8(PY_C@YR<=>JVQ7>?<
M8VA^A7Q_Y0ENG)M|K|CDRIP_X(RC&PQ^RZC3JPU^<J2NK_~+31M&QKN@Z M%XHT>Y|>)M%M_<
1T^|B_5W8W|LLT_Z|JKHX^L#Z\$8K\$|\$_!_X:~#34)=6^" MPF|_~|J>~R9|G1_~|M|222/|G8S1(I^Y_#QD^"MO7_<
#GI7BGUY|H|6BZ-K/V)=&@O|5G7_&_4ZLA(R<^&H_~|H MX_|P(^&|OXM^/OK|>=.*B<)|J?@_P<
26NIVZ_1D*9+1U|XZ9K&^*?|_M7^|_OP4^?P|_9U^*Q_MM)|9_~%6>^A|Z)+9W#MJKV<2RW_\$D<_1Q;4=96<
M0_6^KN:B@#M_~"GA+PIX#|_6?@_P^X9T_1M(T^<0V&EZ391V|M;1CHD<48^HO ML<
|7^6|/|+G|_V|F_~KNBZ;^SKX\$M|/Q3>1W?B:T@|V21:O<1R^5)K|H|BX=9_M^#2|B&_8^/_=W7G?|3G|6O|_<
O|&7PRN/C^<U%|8|1%|~%|^8X_~JY#3/Q^|_MAB0_~)~(2-68YZ4_~BOX"?_OQYJ^QXX^" _A/6;N^W2".ZU;PY:W\$B1+G;_<
M&|&DC|C)PO09KH|Z#%#H(|^*QZ)9K|_V7V1=6V06XMF|SRO+OMV?^EVXQCC M&^A|>+O#WC_~(Z5X|H<
(ZAIKTK6|_@O|NO>|>|SK>+9(WVN_RY|E_&_&(S@_M@M@M^#&C_<5_L|_<
^X%O>R?|+X&^#_!S:FX;46|^&_73S=..09/L|_>8>3R MV>M4_'|+|^L_7Q8UY?<
%7Q3_9R|_|^)=46=9EU+Q|X0LKRX\$B|J^XDFB9MP5\$4_M'.0\$4= *|RB@^"EK/AOP|XBT^X|^>(-_LK_2|NV:VNM_<
Q+5);>:~\$C:8W^C8%60 MC@J|C^%8_P_O@S|_~@SX8D|\$_!_X4>^&O^FC2RO+|^I^AK0K>QM7=AAF_4^"A_M)|QDXKI:~<
3|C~7X&?#_~%I?>?@/X+^\$|S^U%(V1+_2/|EK:3^K#~*^C0_M_1U&~>:CU^|GKX|_O|3|?<
XVZM#O|HUXSM^"VOBZX|_VKZ|^_H^731F50_M|!ANE=A10|R7BW^|_KQ_K3^)??<
P6|)_WJ|J^DE_J ARUN9W51A07DC+&^<M9X_7|G?|G^?Q\$&_P_|/JPEN|JC^&OW(F4AEF|WR|V|\$ ALY!_KL:~<
M_|1<|_~^*BK2_?Q+|^"2A^Q^KFAL^T76=|_VMW^Z>Q08&~"6-GBPO)_M^4CDYKIM6TG2M>TNXT/7_<
_M|VRO(&AN|_I|A62>~@OR.C AEQ)!!&"#5BB@# ME_A9|\$/@O|_#)_N|^!^?PA|^~^K&|N#/=V7A;0+3X|H3UD=|<
(\$0_W^T1FNHHH MH ****_BBB@_HHHH ****_BBB@_HHHH ****_BBB@_HHHH ****_BBB@_M_HHHH_(G_@|J_Y_<
S^\$/_8|7W_I&*_|VOWB_X.ZO^3<_A#_V_U|_Z1BOP=K_M_\$Z^C3_R+|^!_XZW_*=D?%YS_P_C^"7R_(*_I_XAO|<
E%:_|_8|S_Z-2OY ML|_I_XAO|_E%:_|_8|S_Z-2O#^E9_R:"_813_P#2:AKD7^<OT?Z^T#_P_M5|IMK>Z_X)3?<
M)Q7_~R*/@5XK<*ZY9=)N64_4\$ CW%?&G_!#^#7=7_P^"??I9 MGQ|_X(A_\$74Y_P^Q|N3|00@)|T|F^~|89^OD#E|1>_<

T60L3 M (+%:WH^@?1!*#H"JUS5+>SAE^"/B>VCEN9@BM--IEO%&"3RSR-B*.I9@ M:R:~2A @O)/O%GPV!~? C
(+?:LHZ>NM^*. @#K-C-K,>D2: ^\$A\ (Z@4B MN+?>FXR)F:."N0L=[>)]M5U*VL|+L'QC<(-/EOKN1.1NN|L=^*^|
(2_M\$>?V6? M^~. _\$ &B03KV^FU^P-X1T^PMX;T6*-KW6|5N|*VAM+^V61T3>|'|SLD<: M\ACLB(S^XM_X^T_
I7 @1_P>?&07OCYUN93\$X:01^?M.X%4PLV%1B #Z_? @IYK^PG M_:4| L3_MC?LZ2?#05/BS9WHN?
VZ0%0Q.~./C|X.2L< :XC3 KNDL^FNZEKN31M^AU M9HA,=TYOLIP;J^2-D:566^"
(RHKSJY95|&_9V_:1 X(4_M) %/X=CIA;X"? M|CQ|1+O4(=3T5#/PRLK;4?^5JC|)^*NA_# XEZA M_:XR.WC?5X=-
C|0:7J^P%+ M^~:Y9%F!\$E)!SY?#^|TZ=L|)6%O^DSVEMY5| M3D.D#%'42, NY&7.017SHFA_\$ _Q!_P:9_LI?
&7X%Z%)XFN?@S|L/|QOXAT/ M3F|Q|BRTSQ#J33QNJY.(S)XQ|JL.Y&%H_33Q?_P_%/?&'P_:1^\$/P'_:
MU_9/U+P/9?/4Y=^*|>(-+4PZS|EU15C9+^#5(8H4%*XE4|H9+^F/<&^?K.M'^?^"G'B:6_B|L_OA_~RS^S6WC|?
L|6L^PL_U3Q^+_,+>^ @MX>U632M5: M%:_/K\$ _V3;J&M/<.,@6*S^|A6_08_MIMZ00;Z|_P%:1?
VJ/AA^W5_P_N_#7|JWXA6E|X=|:~?4-0L+35H%2XMG7< MDD,J67?~&Z\$J2I^94D8-2W_L_: /E'G|O^R,>%_|TTVU?
E_#S#19_A5X MC_X/Z/%GA/00^NFW6H> &A^KNG<(< &Y^L^N_5OC#;RM|U)W5HW\$). _9-"
MY4|++&6_4K @FAJFFZS_P3F^>L:1?PW_O|)&?#&R:"0.K8TJV|P1QP00?0@B M@#XW_P^"V|C3X_|D'|4|_O_!3;1?
@5J700^\$WP8N|>7XA^%|)3S|)^>_M MHX(M81^"NZ^/S=LK@+&RA2|?G;O|!#/_C7_P3F_X+*>_
OA%^V;^R|13M:UCQ M?|V/\$<^J_#<6PM|?TNTNM-O+*>PN8&Q+^\$|W^/N^:%GMP4=NI|_&BO^"AW MP6_9>_+_
^7|+WQ^|9Z)X9TGXG^\$-6NM^"UW79Q|:OJEL P#|0:7Q_M/_P4I2_!\$T_%WP4N=^U_0_AB?^5EXGMM>CNI^4-_
_#91J\$|N.2^40^*2RL_M+Y:_%@58YOL_W_!235?CG|2V@?V9;G|F^7K;QG^SX=\$76=*T3Q|8W@UYM4M MY|BW%E+<_
_QCIU^~?M%_K #M(-?/Q0^_OPE_99_P^#G=OB_-T?2|2|^#>_M/&^|&O_9?A|O%XKU6^PL+N^B|1|I|)."XG98Q^
(H7?6|QC^N+^VT|/O|Q|S_ A^!SXJZW7|3_!^F|)^+ M?Z,%W9F+P=MN^6YNESNEVI^_F\$8,4^"09F=E0^!-
_P4MUOXE|)9M>_9)_9Y M^2XC>_ @1KMYH^C+4|O%2Z9_J>L64^W%|H^DP_9YA=RP(Z^S3O;(TK|!\$9AEQX
M7_P:R>*/#2B+ @EW);Z#KMI>267Q7|4+=L:7^N83)?M^*8_|HW1QCGJK_C@U
MX3^SW^V+^R|^QK^T%^V#|!_@K^W%|(^!&A^+OC_K4W|B_&C5+C3=1|_ ^)9((MX=50|_)8RFHV|G
6&|I+=C|E|/S:0S_V+|V_P#@L7|_C|_,\$I?%_4_M|_L5_%S4/AQHOAZ|U+|+J|T/AU9=;TZW2Z^W3Q1K|TBF&W-
K^*DR2;9_AU_M_P\$+O| @GU^W)X|_72BOPS|_/%7@0Q7|0-)T8^9TTVWM^MIB?_T3DQ\$G_M_5M_2V_K\$ _Z)6G_
4L|2_#W|MKX?2L_ M5_LU7|/?6_BUH|>_#G7M\$|4+ MK=A>2V<;2W-E=,+>|K6X2(|OE\$|LW_7D\$|UXV_X^
!_O/X_~7QC_9|_&7; MCQQX_\$ _9N|1:GH?Q^UB|7H=|@>83X;+ M_VPI^(%DDGFCC"@_W3|_~G|?^PD_:=_9*_
D_.*^B^#2%7A>X|=^&/_W|_M.GAS5--O&>UTR9=(20;2TVWFLSS2|WF:7?90K_Q)|^*DDH_H_X+|?&KP|^MT_|
|&WOQ\$ _~&|7\$OAWQMX1|);|H9OH!^MO.\$LF/F|KID@|H>G;U|& _">L:/?PW5I=>
M&K^6VN;>0|^+&UNA5E8<\$\$\$\$54=-1110_4444_8GQ^_.1&U^A_Z|C_#%> M%5|K|1_^1&U/_KVAQ7A5_!7?_
D:A_U|+_Z%7_5W_P?^0QJ^_7LO|_MZ%0|ZC7Y>_|!O!:_VUK^U!_P4#CMK=(U3|KSQ_B!%_PHO;W^"CV^I7Z@LR|J9
MF&22>E?DA_P0#_&BOV? PM^T|T^WG<>?*CCX0TM_8_ MU_4=)_I>):6#|
M99M>WA6XB|R0>9\$01AURO/6@#^X_"2AH?_2F^* PJ_X+4_L:Z+^X2|36_MWQ^"MO#?Q;T+0(Q:V?
C32KF^:3Q86B6VF_:LVV)9+H2;^AB= M6B@!\$P(=P^"^^/_@K9XAL^~|OQB^&?_!_G|B&|Q=|_?#7Q_M_\$OQW^&A
M_RZ^HL%O+^NG07RYANKMX|B<^7\$S8<2FC^7JW_!4W6_"OA|X+7?|Y\$=
M%EU>RM#_:WX_1.9YU4Q|^I^E#_,\$|Y|Y:2WF|_R10|H&^/_|^@7BCQ|^UAX M^_8R_94^&|4TG3|_!|)307>AZ|\$_@N
MM-OK35(H9H)-A^MMEB)5@?F4J<*25%_4OV_?A1|6_P#@|+>OV3/VJOCY|^!_MO^" PLLI_M_#_(3TS66T76?B7-
=6S3-0%+ZZ2(R0Q06-DZM)H^<2|O&/ MB|HEKQ_X&|7?|&I|/0_P8|\$ZRM_XE|_77B.XUOP_~QR27>EP2:VLD1N8|_H^
MT:LZK)M9ECD8 A&(-/L6#_@MKJG|\$_|WP@|5?&S_@GW|5K^X\$R> &/#^C7OQ_MR?
I^+>YF>TAB%RVF|C=I9E|!9|A\$91S\$DFZ_/_H_#2|_ZTSP|X^_|!X^> M\$4|?^//&^AV?Q#H^DYVLOV=C;Z+^\$T2-
J=Y>%9/(MFDFBBC,<?Q_~\$WQO_X_)^"GPE|1Z/X|4_%CX9^~_G|_?#|AW4C^RYUG6GC_MM%\$<*(QYMC&|K'
A6W=G^|!_::T|X)|_+|_+^(*4_#Q7_P4K^&A^+^_M(^ZY^RKHOPK^CGQ^X435|_T#Q+I5PIE=9(I\$|LJ;^F^AB)V;|L_A
|HK?#_M#_@K^XA^"H?^A_9|T|HEVAT|^!_!^UC'=;K|+6|5VQ|3MIXEEMKZVU_-M5^Q0_-)>|&
|L8EE02(+|+|_7G0_!&W_@HO|60^P#P2OL_VUOVX?#|6B^%XM_|M3^M^:_^).VOQSQ70_M|4|)+>*Q4--
D2DPQ1Y8E88T0^*B00/V6/&^!?XU>M)?B#K?|_P30^/PTO%M_!UI_BKXI_#?P79V\$;UU_(VMI&2|@MT_!Y1#_*B.
MRP>7;ANF3;^=W|+U|9_M8_|&C^H_L8?LT^+K+Q%|6_#OA#4_4UGP-H|_:=1 MLHK+QDVH|;W\$^9_*2>W1A#%(
UP&RU<*^#|\$_OV@_|@K^XF_8ZD^~_1_MVO|_ID^6?_WPJ^ (GB2VT_U|_XKM;R|_7=TC|;#6_.C0^U5E1R|03W(CV\$-
M^V%|IOB7|L_QCXA_!^=LU_LS?|23O&^O?^"W2=+O?^JZOXT3|O|)|L4DH9
MV@^S3FXN^AB.A.OV>|!)&^+;PGQ|^/_V|_~#?+|L^X>&|0|&_LA?|^Q%|4
MO\$MO|:6^P+G^&G/K\$NOLF/L7EM9_P4A63=NO2#^\$E=E^"L!U|I9W|WP_: M_:8^)_Q3_8J_:
(UG|GSH_X/6&G66NZU|+|JBU_2Y_M;ZTFU_Q8VX?M;F7D+|EF|RA8E_H|2LP?&Z?H^X>%?GE=>
=1^S>)=+6|F|_ZNZM=:8Y M9E.WF^|>8A4A@_01DXS7>5|R|^!|HXY MC_/_7X;_+0_|1_A^*STG
MOAKME=KJ9TZW|FVU\$07L|O%|J\$*=^CN8XDG&WY^YNY/D9: ^FJ^"BBB@_HHHH M^**** "BBB@_HHHH ^****
"BBB@_HHHH ^**** "BBB@_HHHH ^**** "BBB@_H MHHH ^**** /"OVZ?^"=7|_2|
P44|)Z%X+_:3TS5|JQ|_C>Z8ND:LUHRRO^MY:%BH_X>U?/_\$ _P2M_Z%/QM_X64O_P37UO^UA
M3Z|^RSH&E_K A6_MU5-50^MXX|_9\$.95-V3NZUX|P|^~_1|L_|+^_K|^/\$+CCA_1P
M66YC6HT8W:A^"QOZ|J?7_OFS< &|R<9 MP_U>?^|_#WSX|=|> <: <28/ZIFN85:|^ZERSG^2NKV=FJU= _>_EA<-1ES0
M@D_)^0>_>AC^?B;067Q|^FA^&(8;60O_Q_YL_VL+^8+^*)58^2_BG>/_A
MQV|!_AQ_!WA+P^HNEZ1(|H|6G:7#|_S8W_QO(H4DX&3CG%;5>+^_#(M_L3?^_Q|JG@7Q?| M&^EU;07*>
(^399+|M&8#)6|_JD@LSCG\$Q0XYZ5|D; MGHWCCX/_E^)^TIO=?\$GX7>/_\$ MHC):R_YHD^VT^L06^&5&V@D#
(^7%3>\$? MAC|O^&BW^ASP|^=#T33KR1GNI^#2)_AMH9V90K_Z1J^8E0%)(Y_I|AM|3_M_(-?&7P38?
\$KX1>/_|%)4>=5A|W3=^V:I%>6=VF<;HYHF9^01P3R^"T|/?B1|?%"7B#7="8-HFM:YX2%_D11,| M^M>^?A;|_OAI:W-
C|_AUH7A^&|8=^PZ)H\$ M_HL| \$ N(E4,0^1SZUNT4_!HT_U%H_ M^"W.SS2F_N^M7044_Q7_HL|D|FYX-
^@WP^X^&^6D^P_!O!FDZ%8&9I38Z-IT5K^9" M^"R)57<0!DXR<^"M:B@#)|1^~_C&^X@|7>#-
|U5+NR:SNDU+3HIQ_~P9H7_M#J=T98_E#P2<<5S_P)_V:/VW/P(_9_|+|@J340^OC)X2|^6>FM= M&WC3?SS|V;
!B@#^F/B|^\$ _S|89_F^+GPD|>^7T6Z^TZ_B|0>+^_A_M/Q^|A_R_Y3|^YEP>|SQ4DWP>^!\$ES_K|Q\$?
@W|^_AH_N|^%7PN|_>^+VZ@|N2XTC08+ M;S_6GB=Y|AW2XD35WAN+)|8XFCMTB882^"
(U555%_4RB@#YA_8U_8#^ M&7POT^QOXD|<_LN?#7P_!1_LM3G^%?A32K>XT31/LMMY\$3D^"_.&|<(-|T
MT<^+|R1KYGE>=+|!>%?AA|^? N@W/A7P1V_#T;2|UW>|TW2M)AM|^>=F0(S/_M^&H5B555)(.0_@KMM
M/2Y^Y^>18\$0.W)Y.3R:FM?@U|(+>OAJOO^LOA5X;AU_7:7|+K>N1:%K>A! M@#R|Y@F^5_#_Q(P|Q7244?
L_P#P&U#PMIG@:_+@EX1GT310PT?1YO^ M=JUK8|CEA#^8|D63UV@9K=|^*>#_ "7@30XO#^?2PMIVC;:
6_&GZ58QV|\$99B MS%8XP%&6)|P.22:T_*"BBB@_HHHH KZMI=IK6FS:5?|C#_FV0^V^CZUS7_~ ME?
W/_O<P#^0:ZVB@#DO^%~!O^?>Y|^!#6IX8|^~_C+G7>>R|L_0M4FAF7=KHX^L_I^P1_M7&+^RC^RVC|T_9L|
@Y|^|ZOR#_~^H^B@^O16DZ5H6G0Z1HFF6|G:6Z:(M+6UA6_~2154>PKF?^GP_~_CS7)?\$WCGG|^\$=U^*=56;4-6|
VMS/(%4^*MH:22_L0_!D|_5UU%_/_ZA|)OA7JWCZR^*V|_#P_<^*=.MC;Z^XEN_&@?4_M+6\$YS^"<%#(B^)|R|L|R?
6K7A7P%X%|^!6EW|_@CP7LCO:A?2WM_!H6G16Z7_ MS^&=U0\$E MK^A PK:65U=@D\$^+^#&KR9(|XG|6YX|^?<^
P_P#BKX6N?_Q0|^Z_XDT2|^% MYH^OZ9%>6L^#D;XIE9&P1GD5LT4_9'^@3X?>_OA;X6M?_P_O!&D>^_!\$L5^V
M6CZ%|L5G;YX)(2^*)51_22>_31X4^W@+P&^H2^!_!&D;_YK7K7F|L_FQ6
MYO+EOQ32^6H|R0|W;)/K6O10|Q_AC|GKX|^>^?B|J^Q9|&?^P?^BK5@PU7Q_M-IGAFUM|00-

[illegible]

#FFLY) & B#P).L2B+6W+8M-MYG4K96P4)+AGE MS' \$ \$.N?PN^7/* [60 -10 P"#D/X: L8 LF' P2^-
J\|8.OI%IXAM99 M7_TSPU=R,+|E C&)L>=>"XF\$N,+BE4(6V#^DGOCI>K^+O!&H:1X.Z:XBTVWM|B2RD=?
DN(TG22&QJ2&=64IP17RW_4-TS.@J_P_|M%:|C_:9|4ZM.:G|48_B7<&>7QA?
6HA7Q.IT\$D"W6C7UJ"8X"CC|A46+Y\$5H7 MA%*2D8! 4|12(V| ^TC(SAA@BEH **** "BBB@ HHHH **** "BBB@
HHHH M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@ HHHH ****
"BBB@ HHHH ^~?^?"/J/_|GX)_|6%?V5K |MF_XNW"(U9O.?C1_P1@_-;% P""SG_10_1?VN _^G7A_M'3?A7|_ 19PV'A3X-
V'B6'5=8U+VGE:9UO+/F5+6T'GR,3!4COY.K"N"HG MK|@Z*/AC_@NO_P2ILO^"J?
I/%A|&/A9J6E>& &G@/4\$U/X=SW49BL05A,F MGR>6L4SD>T'E|4'AB."H8YM X")?*#| @Y.^ WP3T:|@?XQ?
KX=># =X M7B_LW1/C'XE|36FJZAI&E |16ME974HO98D.+?SUBC0!%EWA"E?KS10!^2/ _M<| P#1%;IK#_@IKI?
PO^*OI(OIFZ_XB|!6E_IFK^&|7U2"QFO|>Y:TN(9 MI=D='B<.C% 1("OW2I^B/V/P_|@3IH?_@KO_P
\$U/\$OP#_9V/^%/AKX|UF MZMM6)%Z5X:_W-10|^*W MC3|@_|@K|3?^")WA_|X(D77I&
<&F_9ZQ::7K'Q>N_B%HS>%YT2UU:^T(+ MJ-(EM2.N8X8S":,\$|&2.6"%#Z*_:' X(|^+|A5_P-VZY_P\$|V2+:|Q3XLN M-
)TZ|:ZIN(K)=4U&37+6|OKOVE::%&.3.%+RQ1J|WL|G|Z*"R(C_8X_8| MX^H_|SUO^"8?Q\$_X)E>&?
V0(B5XE|0Q:NG@?XF^\$/>DVV@60!:MHLX2?|0^"!%W@?|@+_@G:XW_9/|^6LV?B3Q+|
M9M.NH/BMJ&CEEM_LVD|+86SNH9HX8I9<2,H+232_@ JH_0>B@#1%O^"<- M
3G_P"#@#@AS^TKXT^GI+7I/'@WXV "?QG=C^;2ZAXYL*M6.3,+>^*S3 MK^M=&U*3I"/VF?+|KID7Q/^RU^UH
((M'O|KQ|>>)-.UW2O\$=E?6<|.H8V_V=A%+Y MJ3|K9VYOH5(^<'Y3^C=%%'YP?|P2|O|
@K=^V=)|K'|D:_@GO_|J&@|% MZU"MS1?|\$^I>++2SGU-5D)32HXI6R+?Y0|Q(>@K'JP2"3X.T+|_@FA|'87
MO&&F_17XX_M^7T/PUU>_VTGQ:8V'Q|LCT317=(KF)4MPKI/L^|P+3&Y?EQ@X
MK^A"B@!"O%I6FD6.GLR6T|FU ME4\$A5X1_2_F "0/I7PY_P0O| V|VB/@% MX"^/I2GI9W@ ^&_BI|>2BH7B?
Q)H|FHVIV^G:>A KLEA9F6WDDC98PIPA7.F MU)U7 ((KJHHH_(+_@YG^&' 63T_Q-X? VN/V\$_ VCM6(|_3X7^ KO6/&
M-GH/C<:/>:A:R3B.\$QS<0ET_M%)8!!POP2C>CJ4_E):|1V/8^&'Q ^(?I/ MP||?
_G2A8)*M<|#:1F'B:\$SEBWU":SBDN(HG|V5G+WMC%4/CS^R_X# :6 MO=&T_P".KZKJ?A32.V&^N/
7G1)LKW<JS6|MHC|VZ2*1\$=:I:LRAI(M'I_J?2*/S@_X.# (#?|%;OVSOA-8 LC?|1?X=Z_|X+UJ%;GXB^)|2|66
MEG/J:K(2FE1O2MD6_P_H>8D?O05C^X)!):'% P3'_X.POB.--^"OOQ_4OH M?
AKJUMI/BVOL/B181HFBNZ17,2LA7V?9IZ^6F_R+C|Q7|"%% '%Y|_|W M_!&J_P#^"K7|-
'AZX^ZMINB_%#X9WDUYX&EU|O*M,V"?5(Q<:2(Z@^4\F|X MW|PKPJ#A79E|?_:# P""?16O_!;;|K_.?C;|L3JE,X-?
#X.X:~/=>_|- MU|Q|H6IWOBCA,B6VDN+&R33;FX5_-C9Q)Y|12&.1R(MP/ZR44 ?F_-'!
MWP%_X^V_MF?"2P_9\$X_Z_#K1H/|6M0KOEIC"|1#Q)_P %_?@C^V|X7^*O_M_!/?
X5^\$OBG|K;0+>UUXO5/J&EZ9=-D|2W?@?4?%5EK6L^)=6(B\$ M-JVI>UMK|/+W2,)9|9VSRX@-|?H%10 4444
%%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
%%%% !1110 4444 %%%% !116:XP|8_M^\$?A|X6U#Q5X^4Z=HFB:3/=JK&KWL=M.V<^#+RRRR\$)&B@\$EF(%
&E17 MGWP2_K_&=?VCKB_L?@E|7M|OW6EPPS:A86DY6Y@@FSY_|OR!9!)M;RY= MNR3:VUFP:|H_*|L^?)7|:
|/PA|6:E&^?(QOT6PU71+-Y|OVBR./=@D M7^YTVZV+(;FW E59;>0QNC A94E75AD\$&M7Q+|3O_7A#Q?X=M-
|(\$O\$L)MK7BRXN(?#VF,6>:|:"%IYYV55|V^N6D;"612=TB|@#>HHHH *M*** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **XWH3PU|4_&GP2|3>"-
M@EXN@|V>*M:TF33|&1W"LPT>2?IT,Y44@R20*[3]'E0|QJI9_Q8?EI_P4|_MX)2?\$|HC|C7Q9|=??W_W_6F_AU_P
7V5L;:X.T6;X|3|JWB"^N(K+3|< MQK'O:_W=Q%N57W|_WS#&X '^Z^T5Q_P'SY|_>^#WP(A&?"CQ7X|U7Q3JOAOP
MO8::JGB;7-1ENIS5KF&W2.6|FFF9D))75G9F))+5|R2V%+V^OB5|+_(U2_M#2|X)X?
LAZEI5K|9OB|EQ>OXGUNW6>Q|!^&K97:UVXB8A9G58IEMXG(C>6 M)MYPH20^RZ*|^&WPY^"|/OP_|1?&CX.^/
=^+^B73Q"=..2%OB+Q|KEU MK=S#"93\$|QH8%>6-1Y%LD42/-OM&D,%\$V|AB,B1|L9485W#_'D MT5|_M0^*?
%WOZ^)|C^P|)O\$%|HWVZPBUTXO^)|DNGACT'PTZC+3PS(OT5 MJH+QRPLI|Q615W,I21(-_T#;6T%G;1V=K\$ L<42!
(T4<*H&_|^% #Z*** "O_MS<_X+>?\$/5/B|^VO^Q1_P3YC%(B;8)/\$(CO36_U6|6>AFVN8,*=>DD\$D
MDC:T9X)|OGH*_2.OSM_X+=?"K5_W|27D)?_4MALY|_|OXJ26?Q(NHE)_M&EZ|K'V>VFU27T@MFB|D8?
=6*FA.W^TI^UDVZ-/C_6)#*GGQJ>%D&XSK)%\$OWF_M"NP&U2P^S_"G|97L_C?IJ?Q3^Q/X5^*UI>?'P7H-MK7B?
PDEI<+8V-P(C M%*96C\$+Y\$|)*HL_HFC+|UR ?EA|_|@H94MG|O|JEO&D.FSW4S+|%.7*(Y4)DG=88ERKM&B1--
K_M\$ M2L(C_M_LF_|!%?X_!7Q3>MXA/PM^//AKQE|8=|I+&NW%=VD\$8 M7?:.637.|^|@1V9DVJ|X7H?V2/V:OV??
^"E7P4_.E^?_13OPH^H?}\$3XR_MU9^H|G2#40|NE6G&A|DGS6EE%NTIO,O|H4SW+,9?FW>|?|\$"(OC08?
M\$T_"WAOXY^|;WQ+HFO:SI?@/Q3J2L|_|6H+|%IEZ=Y+&2:082?O0>20 M2^&(P/H^OC|PV?^"K7|7H=>B>
K&+X\$6OPX|+66L/^(H/HVJZXKH|+(-2&7BZ_9_|TQ|%|5^/5=-| M^%|7(CG|+&0WG6|@48 +?7)47EX|PD|J
EELXV.=XS_P".WOVD6^SEM^^^ M\$ PCURWNO'\$HYA|4>*82EQ::1Z26U@?*N|D=&N3:PY/D7_=2&/3NE:#|6V
MW/A @H:;_M<:2.W&F_#O|FCO|_@S+K2*?|(TN:2-ONK_%&P+_ZF4:I'FXC MPXDMHANS&F #|8:*|X);^_OC#|2?|
@G%|#_WQ_EO)?&6K_##1KK7|G40 M1+X_#?XL_|47Q\$T| MJ|3X>Z5XETZ;JF/3M1^_.E^)
H+|JSDBBOK.&9TBE|CD9|Q=\$_@|26<_%0P^| MOV|?
V'/A;^V)XK^%WC^XC^_&6DW/PF|>VWBWP_%X4|0&OBO.R'|L

[illegible]

M@U"YF5)U:/9&T03;Y^Y0#&M?='I8'I' P&_ 97N?V2O'FD3:/H\$45HWAB/M_%.Z'-W=GM-E=V+ 8BD@*KM&-I7
6T-/6=-MHWCM-1U(O?70E/F.*L\$(@B\AV#*J1H M?2I?CK P1* 8Z\!MD^)/VU/BO\ M)^*?42B?7OVHO\$&A:
HOASO_JFA&". MSP\N7_L^>!\Y#\$UW.D.S;|<8B^1%.XM^DEU^SO\?9_P\NZV_>A_A\UN/X<0^M
&T.7X*CX58RZD;@R#5#<|APA";?+W?7/WTF*XRJ_8"9_?JHKQI^U)^MQM;M&1%A6(I>XD^#_
HX+EUK2K_5;=&2+5K98+ZSDM+ED8K_IQSF#%5_M<>90!H2\$M_IWC\JM7X"2M82\&CO^@6C/7?
B=X9^\$ _Q1N"/^C^>_OV;5K_M_2BYGLGDNN6>|MWMXIUE;&|8O_>U_P_8>*|HQ3X^|6ZG&B76OZW>N^N+ITC 2);!
M(XX4 6_.*_!D@LTOPJ_9_P!8T+X|^_VD?BGXAMM8|2ZZI^AA+6)E@V/>('M6#Q64(?GS9IMUS9(8H^4MH<
'S9HGOE^(_P_>2/_!*KIAVR;SZ_P"!M_@|<_\$/QSXX^(UE7S(D,B6UQ;-JKO;EIJ>|+D8D 2%|4H_X) MV?MG^%?
^"A?I%?P_>_&|^T=(M?&VD//I\$TXE-C=PSRVMU_)+YBI<0?K MI5W*H;N<#A?CU^PG4KCH/4VZ?V4?
B9H/AIQMXB^%\$W@>Q-9>*|*FN;&: MW%SHL|3B|B1'%S;2%P8VRD;|2T14.71V/!P!CCP%_P3^_8+G|OPUU
M>ZU?2?!.DM;#4IR,)>?7LTES?^#LCJKZ?PO|_GI\$WA?5-D_B>X;Q)XKBC?#&RMW,5G\$P|D)YTG^|9I
M7|5_.*%_P6;_>DG_&N_>^C^Q_>^*M^JVC1|^7T+PV52,8T^QV^_TJ%E9'
MG^LOK^B_HR<)|XB|18X^M&|+|+1=3RIH=IKU3;FO;Y&=5_8X3E6M/EU_R^M9\4445_I2?^1110
44518_!\$6OV%F_V;P;?#KQ#DN?|_AUO^\$@|<%T MS&|A;N!%LWKY|S10D9SMD=A|TUY;79U@.'EQ&:8V5J5&\$IRI
(JEW;V2ZMI M&E*E*M44(HL_8W_@W%_X)RV_|C|DL7|1?Q#T'RO'_Q5M(KV3|1'B73=%^_>M6PSRID!%Q(;
IXE89B?>HU38HHH(EAAC5\$10J(HP%_Z_#L*=7^0Q%_&8|9|M28G;
<< WE:3=ND8|1@O*4HKR6NHAZ\$/_1C3CL@HHHKYLV"BBB@ HHHH *M*** "BBB@ HHHH **** "BBB@ HHHH
**** "BBB@ HHHH *+| (->_P#> MF0/VO/V4%_>N^>O^A_P |X@?"2RFN;I+>+,NJ>'>9+J#CEF@_>A|V43J_6D%?
MJ#3+>FVM|RWDL|RW26*5"DL4B;E=2,%2#P01QBNK|8NK<5&O3WB_O75?35T M?PQ45|92%J_V
|C_>G9^WYXL^#>BZ6|_|6|I?| R|3L_E7+N5@|HF"19; MO3Q_ "6#TDBKP>@4445L 4444_2T3?|&BG|9C?\$_P#9
M2|6_L_>*=6.FJ?#36/|2V12ORVD7|_|(|B*|69F;|5&*_7JOY^A_@WL_M;QD_9_X*G_#05-0U'R-
#|>M?|?>K17|(EN6/0*MXMHY)Z^C=,M?UCU^ M6|3X/ZKFCDEI/WOGU_ '7YFT'=|1117SI04444 %%%% !1110 4444
%%%%% !M1110 4444 %%%% !1110 4444 %%%% !7S3^V^Q^A5^VX?B!%X+7_M0_\$/MX; "O1|&B=-+^\$ _B0;1J?
B+5D)?>A0%1Y%M(EA\$<">2.DED:0D1O@_2U<_MA?2?COX8^/|>N/Q^J^G7>K;M|=XNG>%"NDA6O^Q|J3JS165LC\$
N0K.SL5-MCABCD FE9(XW=0#X0_P""2>H_M6_LN+|2'X^?|+|XJ_M#^*OB|_|_WA?
M1_7@>#QAXYO>:QI45|0|IUS6_P|I MN(2MR701QM\$K"1OHK|CK|FH_L|2^*/BS|9_&EWWO<^>
'B1=6|=G;S8A>>* MV^6>GV)D^O);V-G\$8H;X.CXFG95,CJOYY?|INA^P;^RM;V\$ _BUHW|7?|
M_A3QIXZ^>.GB01/B& BW1(KN|M+M|L_K+|SCR@Q_OAE&/_G<1+2>>TEYJEQ>S3N552.DGN)))96*JOS.
|>X^'6ZK^|M+|P39^|D)-'^| MV1^6A3S&=?C7_@VIF^+^A?|_92^+7|LOCOQ5J6O>|@|^T1XC|/_ZUC59C
M)))HUBT"ISKG|_|2M+M(X7<47_C'Z'ZQI=MKFDW6BWL MRD_Y;O#*|G>26|R
MJZE24EB99(FP>'1E93@>@>@&@&#|/|^?2^P+_|1_8|_P""N_Q0_96|2M%?\$3X MD?L^P_ "+30\$5U_PLCO)-
K_A7Q/=7QCATV&|FRV7M89|EHOC|W-"SY.QW|3_M&EOCK;_B7|*O|_@H^U7|_QA6^%_&7L WC^2?
@|^I7B2ZM+;0+73(+X_MCD6T2003_>WD?SC.DGG1RK&?D5%>)>_V3/W_!_|@N_P#"W1/V9_C1XYUO MX8_M-
Z^XN0|XG>#?>B|ZUG^|S|_JQBF34Q/=|K%Y9;_*2RL|@W2(9"KH MJ_9G|2|/|>GBV;Q2|
'WHCP;6^?7MCG9Z|29;GO>?>V6GZUI;UM|UI M%;EM?+;JF0;B_-DC56W(BJ
|GCW|K;OY|_|+|P|2>?>?|H|A6_BWHNG6_@K MPC=;Q#^JMU9+<3SW_IWI964?FW%PV<^7|L4F62-6|1^?
PC7X&?>71_A|+XS_MU7Q)>6,3R;MXDURX,EYJU|_(TUS=RG;:29Y'\$;X2;_(T5415^O9^T_>TG|1
MOV5OV)_C%_P6E|=2#MF|80^#DL?@_P"#>MW4>%)|N;RW@LEN800R7-W<2P7
MUZ@>N%CM|4D&T#G|_@Q^U#^>T?|?>^COP_|V&|CM8+GXC;|3_/_%XMM=
M=U+1;"SNM^UVRG5+N&6%O|&.&.)IZ+(KROO^CS75L_*>M%%%_B7_!2^H MJ3|D_P#83^*7Q^LKS|/?
Z#X1N1HTQ;&S4)P+;T/_ (315_(JS,S%F8DDY)) MZU_0A_P=<_23P)^PUX3^"&GW1CN?OCB-
H_ZRL(FED&|^N^EF?PK^>ZO MJ\$?HH+2+5I(5>F|S<M39^#|+|^_17|_GP.^\$WB/X|_&?PG|\$O""M4|7>
(+1H#Y|D5#GK2J0|WJ_>|^!>9NT445_M_!44%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'Y5_|V|^Q3_PO;|A02_VI_"ND>;K_P(=6|V_>*/+R;+M>_D-
P..6|N86TO/"HDCQDFOYLZ_M|^_P|_*_7X0>*>@IXYMO.T;Q=X=O=& MU6/_)-O

14_!3QS;>3K^A^O^>Z_JL>"+>MBVG>&3>VY#CVK|%X0QCJX2>'D|8.Z|'_P &_P|YE-W::HHHKZ|@**** +&
MDZMJ6@ZK;YHU);WEE<);7,+7BE1@RNH|\$@^U?VF_L9_'ZO_>H_9_>'M^1MB|?_!6?@S3|5N8XONPW,L"-
/%|4E|Q#|H_|BJK^F+X_1OCTWQ7_X) M;12#_!OC@=_#2QM|6C|S|986LY2_B;_>W7RP7|E=+|=A#M-Q;>3(X+EF-
>^T4>%^_|@G?^SOXL_89U;_@GOX63_M7_!G@+5|^?3Y;GPAK30;I%YD_P|HEN!=RB5DY9=SRR3^0S&23S-
^|LXOO|_MX)N>%_BW|+A3|/_#G|6^QR^LOP?L(+3PYXD^_|_0!>ZAJ,<5M#;_|3(SP_M30;@62|2QFB;)>3&!
(X/T=10|Y|_>V3/_GP=|97?Q8U7Q=XE|<.>_|24TJ|_M|=^+^*YU^|_C^8+2%8(H;TA,F)'2WAB\$CA7DWLJD;GQ|^
&@_M\$V^A_P+M>_>=O%|Z5XDM8UKP|J>1KYMLR6|K=\$@DVRW AG-<>:UNB-3&9\$?OJ^*_M+;_*_9_>%O|57P-
14_LZ?&SP|_5|^*_>FTW6K(2%&.*0?>1QORDBL%="LJ ML_17E2|/O_!/#PGV|OCI_M/?
\$+XP^)|OB+XVT7X>6_@7PMJ_B;TA&DZ^%*) M658|6&-)+J>0*TURPW/L556-
60B;O|_|!XYXY7Y1ATK7H0F_6JO;A9L^#S^?M M;4?G^6@445^D^&%%% 'Z"_P#|L|!\$^?_!3|1_&>H6(FL?
AWX_U^Q|+Y_MBY3SRBV<^M^2|S^B|^_|>U?TU^_|_H?|_1?P3|9_CO=6X8WVJZ7H-C*_M|JSR(YKB=0??
|L;G_@(|K|EZ_S+^DQC.&A3|+P^VDO_)JC3|_|M|J7L"GW;?Z?H%%%%?S^>J%%%% !1110 4444 %%%% !1110
4444 %%%% M|1110 4444 %%%% !1110 4444 %%%% !7|MO_!T#^S|OP0_X^R>*/%C8>1_M8?7P_!OB;U5\$PGF-
&_X(|YH.60|H9|BOZDJ_#G_(|OA%)HOP_>_MG9@/#=:SH&HW
7E@ZVUQ;*3|>7='_@1KZ/A;NZ;QCTDFOU_0F;IT_"6BBBO MU\$Q^BBB@ K|L/^#_XPO8?%3XV_"YN"RZKX?
TKO|9Q\$<-K/+3_|M?>(|M?|P5^)|?H|_P;L_>7P/_P%<|A_QS|!8^"M;T=US|);B_P?G8@_A7DY
M|2|ME%|97^|7|!Q^>(|#HHHK|A_PHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** /MYC?^?|?BK_A_P#@D|===\$F|?A_VN6T3Y^|D%|+
I^MMC%>"UZ%^UO|PU_MCH|WXC;L7W&Z^>(6M3%L|=ULV?UKSVOIG;L"/"9|A*"VA2IQ^Z^1^=UGS59
M/S84445|F%0%|_|(|>_Z^!|O^7_|+N#Q^D>&|4>|7U)VQH8(+>^DE M?HO7QC_P;WZ_#HO_2^>\$\$44>&N+?
6+B0|V;36KYL_D0/H;7V=7^1/BIBY8_MWQ^SBK+_*_R^49RBOP2/OL#^EP=->2_ (****^!_H**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OS^X.T/M_EOXK_X)70>)7M@TGACXF;1?
I+CE|)%=6AY|_|H^KCTK|_|^O^#E#0|6O_M^"|_Q@DFCR|D=|N8#_>9==L
3_WRS#|_|!*)N&:47_>C^+L^6Q_*11117|f&8_M|1110 5|_|!"/Q<_@G_@KM|"=9CF,9F9_8-P;B|MH4C|1-C|_>2J|Y-
MX)9ZN=#_"F^|FH|?C3X81R|KZL|HWZ;_YL;GP=2/>+_)C6Y_9/111 M7XH;A1110 4444 %%%% !1110 4444
%%%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 ?Q|_M%Q|_|M|^X)^2R>_M45B
M>I(NY17&UZ3^V7HDOAK|K_XK>^QAJ/^).NVS@CO^J\$ZG^5>;5_M)E-
15(^>"0_PSM&DW2.5>:Y9R^|(QJ|W(H_!95K|BK_ (M#Q)HRH>(F<4Y=,57_P#3LS|_|OA*_+J_ (****^*_D**** "BBB@
HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OBK_@ MXGDMHO|_@CA;FNFPTS20#-
+1UJP_>^|5|JU|?|!SIXDAT+ _@C5|2|_MEG"K&J^|_|(\$_78;Q:3D#_@_#|^K3EF=%?WX_FA/8_E,5|2|
|^1)|/\$_!3O|GO3_MXUSM^,WAN=AC|L6I02M^B&L_4|8;_>G^0+<_L@HHHK|2_@**** "BBB@ HHH MH **** "BBB@
HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M HHHH **** "BBB@ #^2_@K;X/G|?#|^3?XZZ)<1;#-

#3=50U7^l-W<=? MO\$P-2.7=- | P'V/6:GZl8Q.W-E.I0.5lR+Z/L@I*-=O|K ! R MJ64^+690MIM24B:l:OC) | DSDOD?:Y54H(>6GW,**** &ST0HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH M *)_|_/_|_P#B+X=P"">/@KX=P7(6X)2?%UD>/=RJM:6%ZI>TDD%?K#7|M_O|P>3?
&D:S^T!& V>L|R#WA& U^IAIN-U UE6'E4HY2YX ^23BCXO.*2L|=)H/^ON" MBBDOWDL**** /KC_@A?
^T/^S=P5"^%WB74:P0Z9XAUI90#.JFFPICU|#:1 M%CV5:AX)"3OB.OZH*BNTK5-1T/4L:6M'O9+:
|LYTGM:F%RKQ2(P974CH00" M#f5_7S^PK^THGI8!(P|_1TZ:)I/%7AFWN=2CAOMAOU'E7<(Q_\$Z3I?T?
Z^K%??%?QD? M11110 4444 %%%% 1110 4444 %%%% 1110 4444 M%??%? 1110 4444 M%??%? 1110 5-(f_
%XOVC/AH @JSI?2&5E?~2FA:_,_(SH^ULHL.F MHMHY0IU>:*4H?)'%?T12%% VJ+ #IBCIB#XE_M.74127/A?
PO)HRS8VR MZE+B"RC/(4-(2\3W:L/FV/*+_1H+)O|2>YKYSBFO|*)1_F:7Z_H5!>?H91117Y<M:1110 4444
%%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 M%??%? 1110 4444 %%%% 1110 4444 >>?M:_K3?
VG/V8?" f/NJ+L18> M\$K(2X9)IQ#/+ "RPR_5)=CCW45_'GK&D:GX?U:ZT'6f&2UO;*Y>WNf:9-6TK3?
L^B>/Q^XTL:F%)NRWVH M# Q>1W_.BE260f&^B-Q1#YOC|JRtJO56'^*NS2|W&47Z09|IG|&l-5 M=
_lSXHHHHK^|CY@:**** "OV^ X.OVSH-O|^_V\$ _%VK_Z3fAQ4>#8Y7^ M _R*^@/7/0))Y\$H4HK||5."X"/C?|/_/#_8?
AMK*:AH'B?1f4)(MO\$ Y:VT8="1 "V#@/5((KH: R2K4:N^K2I58N,HMIIZ--=&GN?>)I MJZ"BBBLQA1110
4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1111 M0 4444 %%%%/C7V/_ G#X,>'CU5-7%CX=|(Z)
<:JUOP6\$,,%BJ_D: MG8@*Jf69E4"l8^:4CQ9XX2&3^\$
M:X=MVOZGf1.R'^L:MCH:"JO3OVS/VIO' f: f4/C3H+XF2G^U/%^M278M
M1(72RMAA+>UOGJD,*1Q*>I\$8)Y)KS&OV+*<"LOP\$*/5:OU>_1A)W84445Z(M@HHHH V/A[X%|2_%QIH?
PS|&:>UWK'B+6+3-)M5ZS7-Q*L42#ZNZC|_M: M^ 7P@|_L_ WP=|"?"2@:9X-
|+V&B6!"XW16MND*LIZD)D^DK^9W_@V)_9 MDE_4 X*@:_A0-7TSSM
^&FS>*0=TRAO/Q#8QYL+ B59QZBU:OZCZ />,< M6IXFGAUJE7?J_P#@+|32"TN%??%?&F@4444 %%%%
1110 4444 %%%% 111 M10 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% M!7Y?_|
fTK^QY_PN7IC72VH?#E>;K7PKU_ B8O&F7?1HUDBFSGEO+G%LX M*fIF&37Z@5A_\$SX=>\$B_|#K7OA3|0-
(2_T+Q+HISIFL64G2>VGC_:1/* ML>>W6OK.!>* <1P5Q=@|ZI7?L9IR2^U!^L/_ &!R7S..506)Pf/ZK_(8_
MC#HKTWf|LKfF3Q?| L_ MO>-?V:/&P=KSPGKDMK#=.FWf9:G\$EM<@=A+|4@' M:?CM7F5?
Z_8^&X7,L%2Q>&DI4ZD5*,ELXR2:|FFF? 2C*\$G&6Z"BBBBNH**
M*FT_3|_5K^#21+LIKFZN9EBMK:WC+R2R:0%15^+,20 IR2:3:2NPAT_X:O M^"DL_Vf_P_\$Y/BWXA=#fJOPPGNI?O
YDO_-7/<='=%?M17X6_|M:(7 -(Z/BWHHWBGPI^V?^VfXLU#X:6'Af|@U00?"UG>_9-5+PL)4GO9B?|B
M&T\$Q_P"M(W|O)QS^T_PJ^-WPQ^-EGf|_ _%,6IQ:9>FUNVCIE*OC(8!@"4/M.UL8:,P3BO|
/Q_H<)&OCQ\$9APY4IK^5G7<%>E&LW9|LUfKYf6NN>^K:C M15EV84<.Z6#Q_2:L|N\$)*FR0:K|5+FUER)KG
ELL)|41@K<2#D:V@'|C85^E" M6? P""HGA+ @EYR>:>|2>UN B#Xf\$NF *G0IR&ZIVC?=RIU-O;AE=^S
M.8X|@R C^3#QOXU|6_\$GOEJOQ"|>^C(K5M^OVf?VRO GI+GAA)DC|L:RG|N7T*|V&EQ?O:RXR>
4@1RH/#.47PJ*E2% M&FY\$=DE=^B_H_X-7?V+&_9O_X)f-|??\$^E&#Q|9-4&K\$R)ATTBWVPV""V M:-Q<
HUND|*_3:LWP=X1|-?#_P(Z5X#&:/#fVCZ)IL%AI6GYRXCMK:&-8X MHE'95154>PK2K|8QV*GC<7.O+|3O|NB^2T-
TK(***Y1A1110 4444 %%%% M1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%% 1110 4444 %%%%
1110 4444 %%%% X ?|47 -|_/X37X<:) P4 ^>B:M2*K%HOCQ M8(^9M-DDQ:W:8ZF*9S\$QY)6X3HL=?
A17fG_Q%^W@WXL^=:^=_Q#T-f M0Z7/fVL:=?@= T:XX\$L4@ S7|_1+18YOD<^%L9/f MIADY4K_-f-
ZQ7G3D_P#P&44E+/E<|PGLZOMXf/ZU_X)X112QQR32+%&S.S.M *JC))/0
5^I7_fO @VY^*Wf0508 _JNF2_P#AfX""ZMO##?N-9U:\$#=FM7>f| @fZEQYI.\$0%9* HOB_C7AK@7*WC|XKJG#
f*WG-_P_L(K63|_%O)f:G MCT_/5Q\$N6" R7JSX?_8B_P""7f4?_f07XDK|.OV 2(U#2/@f4:|KJT_V/P#@fI^P/P1?
f*VGQ_^(f_%X|^+DUMN MAUNfM\$:XB<@@KHfQ(M(OO SN=f|,-^&\$==IXR_U^Gf(PV@_9J_8#^VB
MZ3|>E(T>H?:_6=N_H(P(&_N7/B:Q7K5 MSJ.H7DF^YO+R8R22-C')/H IV^ K^2N*N-N;?
%%NE5YL#EC_Y=1=JU92f M/9+X8O| D6GfHVDC|4Xf|<ZNfLXGf/f
M2'f8/O5_-fOVM=;O/fT".3=:^K&4^2,'(:5N#,XXY8 C*fJN3G&_9Q_-f|
M5_LY_\$>W|_'^B9f9P(=7TUQPEY:DY*GT8=5:L1Wf(/ T5Yf.FRJEKR^%&*H MM6<::_XWfHZWN?R76XNXEQ'\$,
<|XfJ-V2Z**VY4NVEK:f|U M_#;XC^?BSX+L?'W@C5%NL.OX@|3CAHV_BC/O'/Q_)V?C:P/K45_I
MMf|O(N(C^L#RK f%3@@C|K^:^+?&\$<7PQC+RH2?NR IMEVDQOQ6fZfZ\$%^7 MBEEGB+E*3:IXRFOWEA
#GAW@WfXOW7TSM#<3)\$S10PID8#(7 MX&3QD|#_8WQ+^)^G@OXf>#KOQUXfUJ.RT^T7YG:Ef/W8T7fJMV4?
Rf?_GMf M2A @H%|:/\$_QJM_B?X.U672=/TOFBTOOF?=|f(W^X4\$C@/:C_X&TC:#
M7U7#?"&+|3<|LE&\$4 _>E>SETBO_|>RU?1ASf0/?7AGPHfC3QSEfG.AE4E76Of"OZE?VR_V'OV//^"|_P15DU)
M8?""Q=|V|3fO\$d_*O=Z<22f1,M-Y8,Y)P2"A8E3&S.&_F_)_8O| VAOV M" CGf7f/O|2?@>3fH6f8B_|MDL 30/M.&
f4AD=4=^f'M'M="MBES)._|Cf3<1@^|=M\$P_*'_._@DM_P3U|62f%OVf?#?P"T^YA|-6|@U3 MOYK\$
Qf@T>)%UXAOX9)25AC)/f(fJVfZfO:WA#PO/VO".E^ O|.AV^f-H MFfGV&DZ:9Qf(K2VAC\$<42+V5455
f7QO?f9E16\$@f9:RL-B^-_ 7F7f_W M*BBBOSTU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
M\$Jf7_@I=^Sf|+fDT^R^")WA"X_A4fY_*BN89&47%C/(2(W #J<')&O0_M^?
M6BO:X5H=G,3YP|R&GDx,ISSMP\$&A(+Y&D-HP 2.9TY3T:Bf:P5DG>,N9QN%??%?>fU|1110 5Z;^S3^U+0?
V:O\$Q MO_#TQO="NI =5T.>0B*X'3>fYN0#HX'8 AAQ7F5\$S3NfM&fCL?@Ef>OAM|2f
MPHOBGX>ZTLVT*+VPFPMQ9NfHRL|=|_fV#@fFNSKf?AU|2 _fPF4P>,OAl MXBN-
U"#A986X>=>Z.f15U:.58\$<5fV?LT?|_f1SX??\$Z.W|*_%UK;PUKQP BW M:OML;MO4_Q_>:ZGIT^&7 MCIDG%;
(8#.W'#8O92>E"H_OX)/^63LWf.FWRKZ7H\$)=|\$D;AE895<@CUfM_ _S^B=PHHHH **** "BBB@ HHHH ****
"BBB@ HHHEQ<06D#w5U.D<4%(fM)&#"Jf@9f))=Z\$fVfM)78^N#^/7f12PT_9Wf+fG7_6K W.J_-9VDVY#7-X
MXf(O9?5SA1ZY(f6_-7_"E'@OP"/X3^fQM_\$&L#*2:Lv6L:4^JD?ZfOH=MG3Yfy6OAOQOQX|f8?\$KQ+
<^_/f7B"YU/4KfLS75R^3CLH_X5fV4_#@_5^H<^
M>&^_S24<3F*=*CORf3E|OLKS>O9=3^Z

(FSNB[X"G:DY*FOLOX*|%#O@%|5O%IFO M:JWA757P#::U(%@901+@?(1 0I">PKUZX*^
Sl@3C^J3Al.H M0T:15L_5 MJ_F?K?/C3QOP3&-"E5IOAU R|JWDDNT)7YH>23Y5_*S|G;>X@NX\$NK6=)(Y
M%#1R1L"K|I"'.HH?DE|+ VAOC3|&I?AQ010T^=>DV7F"6V8|R89_R9|9 MJZ^AOAU_P5B|;B6?Q1^&UCJBC
:JTFX:VDOZE"#JQ^A05^3YIX5Y_@VY82 M4:T2?EEJST^Z3/Z=X;^DMP1FL8PS2\$|)/JVO:0^4H+F^>7F?
<|%>|>." P#@ MIA LO>*HT75|?U+09FX_6K:8Y/^|YBX|R1^%>G^&_CH#_%ZK_P (U?2 M#=#X\$J
(8M9A|S|4+;A^(KX?&9#G>=L1AIO|W^V^UQQ/V3^N-N#|BG@.2IJ M7Z*IF<^;AR^..NHIL_T-
Q\$LUO*KHPRKHV0?H13JG8^G335T%%%,N+FWM(6 MN+J=
(HT&6DD8*H^N30DVP:25V/HKCO\$W|0WP(|HS>)/C|X;M63|T+:Q"TOX M1JQ8_@*|N|;?|%+_-
F|PLCH6J:KX@F7@)I>FLBY|VG|L8|QGI:J2|V|YFF
M#MA|-.7FHNWWVM^+)|MFO^|N1Q:Q^84:71U(|WRBFY/Y(^@JBO:VRTVTD0I M1NXK>")2TLTT@1\$4=22> *^%?
B/_%?7B-JZ/9_#X?:=HJ'(%WJ4S7*GT=09T_ I+G^Z%GW/O M'XU?|%' (\$_#(3:7X-N7|6ZJF0(M+D"VJ_ M7!!!_7,|
A7Q0= VPOC; M^T |ECX|0_3M^9|H6EYBM|_|^2TIZ??)&>0?7EM%?K:0|Y#D#52E#GJ+ M|<|7EM'Y*_FS^8>-
O&7C?C>J&(K>QPI_Y=4KQBUVD|N4_-2?+?5104445|M>?E(4444 %%%%#
|:YN+.XCO+X>*6)P|4L:E61@TNMP+):ZQ\$V (:@-PLN<%9..L 2,F.SA)Z_|3M@A4ZD^@|(^8XKRC
M)|SRJD_|%|K#QE%|2%O?V>49M5N|/"IW<2?VN)T=2FD- M(|A|5B<_ :PE|M&C(WD3?IGM%T71_#>C6GAWPH5M8?:
86L=M8V-G L4-O"B MA4C1% ""|@_*|5?PCX:M?|OA:3_"EE?7=S#IUG':OW% <&6:0(H4|IGE ME..?TP_*T_ E|YAB<==
*K/F4=\$|6NN|7=|3_3BBYNE&4X|LFE=709|5?2|N MJE<****|U"BBB@_HHHH **** "BBB@_HHHH **** "BBB@_
HHHH **** "B_MBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** M* "BBB@_#|>^
O"7Q|^*7G@QOQHD.HH;?1|I>8?DRGJK|AA@C(K|WOVLO_MV_|&G|VMOJMFDT^%+J;%AJX3+0D|K9P.\$?
L^&Z_48.5^Z0F^ZM+|J|*AZJRG@BOK>%+L2PQB?<|ZE+X|Z|NTOSV?2WY= MXF^F2^(^7)5?W>*@OW=5+5?
W9+|4&^FZ>L6KM|A..*^I?VMO^="WB'X'=/? M\$'X(VL^|J_-TMUHXRI|UIZ|24|S1C_OM1UW_%J^6J_L)|
|RI/L&L3@Y|RZKK M%|H+H_SW5T?YY<6<'Y_P5FLL|FM%PFMGO&_FA+:2_%;-)W04445Z|AR%%%% M !1110 4444
%%%% %BPU;5=*D|W2|3N+9_|UO,R^P:U|?XK_%*TOIE^|)6O
MO8:1Y>LSK@^O#5@45E.A0JOWX|^J3.FCC<9AU:E4E'T;7Y,WY_BK|4+E2MS| M2?D!2'UB;J6H3W#_P|Z>4N?
S)J"BB">"C2^~*7HD@K8S_M&8A6J|U)2|6W^84445JWV2
MW|D>PWPQGG^V:0R_*J+J5)=MHKK^3VC%=6_1:M(XC|F:|EOQ|^TKXK&G:'
M^|GHUK(|4UR6(F^W7KL7^-(1T0>N3@C(K;P)X TA:6SMQ MNDD:|EN9"|NED;^)|SCKT_P-'P5X)|*?
#KPS:~#O|A6^G:9H+>UMUP_M%|23U9B>2QR222236K7|U|7<98WB>OR+W*\$7|L>_|Z7= @NG5O|_T|)??"7*
M/#G|>UDU5QDU|H2VR_DIWU4>|WD|796BBBBBOC#|<"BBB@_HHHH **** "BB MB@_HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HHHH **** M "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH ****
"OG3H|_@GK MX|^_K7/C^X|2R9DEVIBSOG|A|Q%|MB?XT?^NHE&Z:D8?C?|2D\$>M?&7Q^X)=^*M|>?Q^|_7_M>
MS&7_+"U"14NHQZ1R""2CV:W;YC7|OPYXF97F:5'+4:G2|?#^?V?26G|X_B MCC_Z.W\$?#TIXO(KXO#
|J7|Z^|XKX_6&K_D2U|DBBKOB#P|K_A/5Y_#_-(GT M6ZTZ^MGVW%G>V|121GT*|
15*OTV.HSB1|=TS^=E.IJ_|%1-26C3T:29H^M^*H@**** "BBB@_HHHH **** "BBB@_HHHH **** "BBIM.T|4-
7QHM.TEPE MNKF=PD0%Q%Y&|155\$ WA_MVZU34;DXBM;2+Y(^?^_5TWAC26PQL5
MP|_OIMY6'ZOE^A_OAMX4M|C8#|1<_HDC^*20_Y MZ|\$X&> !Q7YQQ^XDY1E*+=|VK5?)^XO677TC|VC^@:
/H^<4|42ABLV3PF&> MOO+|H)?W8/X;_P T|=U&2/_V7_^;|AGP);>-OCHUOK6K(1)!HD?SV=JW4 M>9G_-%
|T^X_>&X_?5*(D:A\$4*JC &|2T5^"YQGF9Y|BO;XRIS/HND5V2V M7YOK<_MOA|@WAW@K+5@LIH*G'|3WE-
JYRW_6R26@4445Y|H0%%%% !111 M0 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 %%%
M!1110 4444 %%% !1110 4444 %%% !1110 4444 %%% !1110 4444 % M%% !1110 4444
OE+XQ_!\$K^&275O@9XW2:/EET?7CM<>R3H_-Z_J^|&OM>BOH5>+F&FE';#B_YH:K_P!=FOO9_-?
\$OT6LPL53(<|&<>D^RY9>G%;+? MK&|S#HK|?|?|EM8AWW/PO^+@O.A EG9Z|9M\$1|98MV?^_8KQ|QA^P#^U
M3X|WRM|-6U_|%6^CWD5QN^B|A)|X|7WN|X5X85%+Y6*BGVD^1_*=U_D?B.= M>\$GB/D;G|9RVHTOMAU|6-
N|Z?_YV/&_*V?\$?PZ^|@YF7Q;X%UC2RAPPU^3 M)8>AK1H5L145.E
M%RD^B3;^Y&517K_A'|@HJGQ@4>W^%5S80MUFU>YBM=OU1V#_DIKU_P)_P \$ MF/%MWLN/B5|5;"Q'5|1K-
|AB|3S)/+"GWVM7SN.XQX9RY|V^A?M%|S^Z_ MO|OLF*|\$7|I+ZKEM5)|9QIG^UO4Y4_E<^0:Z^X??^?XE?%74?
|+^?@C4=7 ME#_2&SMBR19_OO|=0>|S"OT/^&W_!|/F3X>>77HY2M&+|TH^_|@_|.J|
MO&>L/%JGQM|70Z|^%M+TAEGN6'=6E(|N,^X|ROK#X0?LX?|GX%VHB^|/FV
MM;DIMEU*;MU*^_97RP|_NC^U=S17Y=G7%?Y|>).K-0?V(^|F|EO|_JO-G M|)<(>?|?|_IY=A4ZJ_Y>S|^H|2A
VXHKR"BBB0F3|"BBB@_HHHH **** M "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH ****
HHHH M **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH ****
"BBB@_HHHH " 1@BN?UOX2_"KQ*|2^(^AG MX?
U|F^|U|HL\$|UW(^Z"BM^5:M1ES4Y_|G|CGQ&\$PN+AR5Z<9KM)|K|3SG M4OV1?V9-
5L(^|6;+^PS^RA_07^#_GC|RYN%_E)7K% M%>C#|<|HJ.T547L7^9X57@S@^N|U.NH2?G|H0|
_Y%|^PS^RA"2R?|G3SD_M?QW5PW|Y*T--_9|_9BTG^V7X^'^WQ_S|V(F_|&J|HHGGN=U%:6*J|UG+_
M*7|?|U"5Z>6T(ORHTU^43G_%^#WPD|_|)?#GPM|_|>PZ-9:|Q\$?|H^Z)55 M%"(H_P
|TL:*|K6K5Y7J2_+U;40#W|+|4O@OQSJ6D1^J.F:#K4&I?%_P;^(FE>|4MKZ2R0BM_NA(UG=1X|
MRVG3|S\$R9Z^Z^0?XY&0,T=315/Q#XAT^PCH%|XK15:U;Z|>F6|/BOX|TOXE?#^QAOB#PIK=DEYH^MZ/>I<6M|X
MR|D(+|XBS>\$=.CLH|CPE9VL*RR7R0*(9|@6D;L MNUR\$R0B|/M+INS|O3|G/_@G2|#:CXY_M&^
K33+1|A;/OM>ZCCN=9OW_P|7 M:P|V R3RSL0D2|I^944D?)O|+_|P57_."7&D>.|SXJ>|/VT?"/Q%|^/Q3O_M=/T-"
M3;SDQ^Y7Y^8Y=(8Y?2?^"8OAK4OC7^T7|_|/|J#X;U"VM|A|>\$|V0?#K1 M|2|CEDO|TFUEMO|NEB9EBFN6|^#?
AGQ%;I+I&OZW=-FWUB;RY08|F_BLW\$(B;X M\$M=?
LK2Y)|O|+S4:>S=E^80SOJT.@4AC^*X#*2&P3_P5G_X)R_|\$|/"O|V MA_L_? S|@GX*^O'OOK|>Z-
|_|>O:A^M(BOM^6|F|S4-0BE2V|Q_M|_M|Z M82J=RLBMG_|_|'|*G|9|_|_|W@#4OBC^RO|5|/QAH&D>
|(|K0=1U&RM9X5AU_M^V^&K&C^R|L^_*|BLK|HKO|I3_(-7_P""R|M|_K_#O|?
PQ:|=1=:2:"812S2\$1VK36,*QQEV7S|S(D)&*YO|X)._*XG M?L>_|\$JH=9UOX=ZA/KWQ#^+?B-
O@%|=31|XOH=3U^XGTVW9'72;6Y03WTK ME?W-
H)9BI^X/Z0:MJVEZ#15SKNN:E;V=E96|SWEY=3+%;\$BEGD=V("JJ@DD MG_)_?/G|+6DZI^TY|3I?
V^?^FW\$&E7.G2Z9|\$_"OH61M/T"1E:76)(V*7 M6|&_.09_*SCM8|(|W"L|=|^RO_|_3?V>O_#^#=8|8Q>(?(VMWDFO|
Q^1 MR*L<^MZQ<^I/=F)|<(V)!|DB&W@AA4D1B03|_"3X=^(^B|HW_!CX'_M>M M:&|J?
7|V|6TWQ3JROXUF|U&76|^RO-
\$G(ELBYLUW1X+L0%|MGFJVW.U|O|7PX|_6_@|X>>#|+T^2+0\$6FE:+H=K;0@DDA(HE55R23P.IK4HH_Q? M
WPX^GPPT|200AIX#T7P|8W_>W_EH6EPVD4MS_VZ6=DB50TCMS.1N8|D
MFIM|^|^O"VL:OXA|_|#|+TZ_P#\$%XEWKU|8:?'#-J5PD20|<_BAIG6*.. M,Y)"
(|@X4^M2B@#)=>|?|OQ.'ZE|OB^X9LM:T/6+1|75M)U&_2V|Y XP| M4J_PZ..&4Y#_D\$\$\$\$BM6_-(D\$42|54_*JC
|^6B@#A+7|ES|FRR^+|?M_V?P M#|^1>.7D>10%T?ARV&HF5XEA>7SPF_S&B58V?YD54)*@_N|HHHH **** "BB
MB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** M "BBB@_HHHH **** "BBB@_HHHH
**** "BBB@_HHHH **** "BBB@_HHHH M**** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_H

MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH ****
"BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BODW_@K%_P5B^O_!)
IX>^%OB% M00A-K/BV^Q9K_ G610HU!# T#1P^:78R!\$<<5!_! \$93^S/!&9^O! MP?
V7>^%EALGS+^%TE5HTVXOK=>YB! A_17AFPN!90_7216N8YIE:W3*7W1_+@ MYXI8K*GROVO=?HP33V/?Z*!<!=?
1%:/V_2AS!0+ P""/B7!H!O_ M!2Z3C^VM#T2B34:G2LYOIKCM\$D-ITS^V<<1^X9!17\$? "GH7!G0X!7M0!MWP2^-?
A?Q=+::9:ZA4ZY^W#^R:X> :AT!BS4?CEHK?%(O):W\$^E>"K1!+B!N"WDN9&FI66V M AB=OYS)N 7<2
^A_M!UKYK_P""M?P! P"B1ZU_X'OU!F5!_YYG5&57 M!47.*=FTTM=[:M= SXWB3Q!X.X0Q4_ G&+5&-
VK^!%K=, ^MJ*^2?^ M'M?P!_Z!K7_ (OUZA^S!^V9X9_>U!5!_!T:P9?Z6^EVB7\$DEW<(X<,VW V M!Z<:P?
Q)EV%EB<3AW&\$=W>_FMNCONSS!G!50#!ARIY?E^/C4K5&U&*C-M
M)MZN*6R:U9!-16/X!^!^@CX7>%KKQO!10%=AHFCV*!IW4!3N5A!@7^!M@*/M<15A? K!H!|GW!H#PC-X^_9O^
O0A3OYHEM?97_K>\$->M!1MXKE55VA:2!V5 M7"NC%2YA66"5#PZ_ 58>Q! M!H EHHHH **** "BBB@ HHHH
*!X^#O!F!L_OQ_>?Q#^!GP@^!MMK?BCX4 M:K::!0 *AL!B-M(NIT=XHV>2-4EW" 3YHF=04920RD5Z/0 4444
%%%% %1 M110 4444 %%% %1110 4444 %%% %1110 4444 %%% %1110 4444 %%% M% 1110!^!^!
>4 P#)L_P9_P"QZO!_P!(A7!^M?T%?^E!)L_P^?^QZ MO_!TB%?SZU^J<+_/FAZR-F_B"OZ?O!
@U1_Y1(Z/_V/6M_ ^C4K^8&OZ M?O! @U1_Y1(Z/_V/6M_ ^C4KGN_Y%2_Q+!F.&YUG_!R1^W!2! @G!_ \$P M-?!"?
P7UF?2_ &7C:7!3P2X:U!U8B739:N.>::XG(Y646UK<"_O@!R_5KZ M4_8)_8!^!T"GI?A#!IG'X=:):P!M)A/B#440&26-
5=%Y?W\$G66::>Y9B M<A1A54#YX_X.^?^"?QO#_X*_.!L!7_A!&M/:!^!\$=VN:_!1CH9-BD@'(H'X)T?1!5:IE:IN!G_
\$7Q3A_%+1? M#WQ_T!38!XC_#!Q#?QV&K>17B0)=PS6LY658Q*K!)_NUE!&#OYF:G6W!M-/P/_93_
&@_BE_P43LH:3P!XA^D:?\$16-@M+PZUO4>-S@_MLXCBZD/B\$O_6GF!_?WX/_M:?\$;IE+G_
!^#QL!7V&@&^!&^!BY&ZU23/MM!MC=ZGHP*D_NPL2)N!WCI&5W\$*27_CU^WGH7!AHG/XO_!U^?@9/B!H
MOPR^!VK:L^!Z:=B33=8U.V@DD_LRVD16%T\$\$.2!)8R5A!6,>9)YJ0_D9^WO^MUA_L!2M#_!+!#X"?M&^)?
VPK7QS!1-0^)?@C7/%_A_0M9:#1?A!&5FGL#_MI-HWV:3(K9P:=)!Q3<3>4^)!G!*_@_4/J!_@K!_!+!/?P_8@O?
V2_B!XA MUKXDZ9J=UX4UC2!G3A:ZM+:6CS"VM4^TE_81PNUT+6*(2>"/BU!3/&M!X7!#?!#5:NW:5-
3N:8NTMVR4CCL(MX\$-O+=_J!C*B3=%YGS!^V%!:OA_XO_X+!2L#>+_S!0M*NI+U7P=X_DTV_
M2!41W4=SI3QVLL9:&^=D80N_K-P8RP8\$TO^"NGO_!C7_@LW^O_ ^W?!(O!^M^)!7C9K3PYJ>H6TD<<H
8A60219+^#D:1D'PM!/?@^#X-U?1_GCB2WO!(!2#5!U>VGTf?>:Y:"WE!R-XI! MDD@0K01E+JX-?67P8_-X!#?
%3_@HW!0?V&V_9=UOPMXO!&?#RVUO4?&FNMI_MV_5K!H+>_VDLSM?/12,D1E8,K1*V:_2OVQOVP_V40\$?
!P!@Q9XM!>2 MM>="1L:30"WCBSU?Z:#O:S6%MEL:"2Y15\$LLA!8RVX^%Q^!3=W^P
M2!3>')^#I#XSZ)#KEHUXO!+VC1_K<9!(NH6TC+MSG<\$DC8CJ_X/O_T?1 M_!>?%W6_B'9_L3?LT-
!4_ ^%OB"XT#Q/K_YXQAT6#4-8MXU>ZT!2!_WVN M>^>L:M_!F@!QMB\$ M8M=G_ \$'O@+!(=(_H:\$_OM&#_#SX!?
M&>)=+!Y-U_ Z_JWAHY(DU!(_MV&#!=:Y_G&'BC!AE64D_ ^@M(_P""@G!O?SU;+_@H!H_P!ANK'42!VBK3_"
M%OXF5!FXM!8UDBLTF6_H_YMRQ"#!G(B!S^*H/B5_P%O\$O@SX!_#7!CCO/_M@!FH?&XA^!\$!SQ+_
X80O%:VNE>1_MCMEDN!12VF9V_A\$2!L:R!G5LE4"NWQ_M_P2!^%_OA^&_P" T=XL_X(C>-/!#V!3_#G!GCXM'XAZ-
X@N!O:WWA>X_!^T/#N_ME!B26E75)/MA:IN=,ECXQ7M!^!^!_AOP_P5=1\$?L(?&CXW:9!\$?A!_!Z! M5Z!3KO4+?
3+WQ<&^&^!5+C"Z=#L@>XEDB99V_&J!1VLX!D!S5_P5 M_ ^WQF^\$ P_YDNK6XA"BZ@> M&-
V1BD:G804'REK?@:JNKXV> (=0^\$&O^)/V!UL_!7QJO88_#OB:1'D_HRZ/_M%/IMQ!N^!VXMD6%I8H-
H^SS7,0=PIE&4W_GY_P34_:\$ 8X^%?CK_@!H7B^MYD!0^%8!7U^O%/X-U:>N-2UWPS;!=27^*O%CFWT_7-
*U3;MC2Y8>6#%#_H!(;S4'S!M=;_P7C^+5O! MD_!M&^_QN^*_P8!7!OA275_!O/"FHM9R1/KFD6^M::)-J!0.BO'
SBZ=&88D@B6_MX!V2B@#Z_R_!P""A!_85!22")/7P4NO\$!A!XN?SW1O=CK6FZ!%-!EJZB
M!GE&:WDC^>\$!Q_!^!)RI4JOREOGO_@!9#\$O_7>_P""=LXC=IOB:K/CD@:_M#:\$#!_G!S7CG_!-3_X+E?1!35_M=-
!9Z5<6MT/B'<6US!^?O!_#=#Z!1VLBL#ADF<%8V'#D87_'TAXL_X*#>*_M\$O!5/Q(_8!_90_9^C!?)>+OA#X&:)!^&
MT>6VN7M9QX13\$DR8WPB5RC!_ *QN^!3R?M^!_7XR!%-_C_P!LK_M6_N+MXO^&OA6^!LO^O@G2=8?
!M9^)\$MS;_#UW)=6Y2_058O%18V3@N+@>8LWF*^!M_!V!C%!*+G_(!+CG!+!QO8?V!X>L?
\$Z:WI#38FTUKK69/L4ZG_4R2@(@_MQOOAW_)_#0!^!P!(!P4:!)O!6?Q7!Z#9?L(?\$+PW!//%7PTM_%6@_%K5
M+BW?2KN5Q#NLU13YB2Z2GZGKOS_@G:KNB^!OV_@CKGA!M5:>^LY_A+X=,_U:S!T?&FP*
<\$<<\$<\$<\$<B"R#R!CH **** "BBB@ HHHH !Q_+M_Y-
!>?l@5Q_0EK!K: 5+!L! DUOQM_V!6!^6ORMK^?"/_D25_P#KY_L_M\$ AGZ4W_ "5^" Z!^Y!A7UM_P\$EA
DHGB!_L"P?_HZODFOK;_@DI_P_E_M\$!7?l@6#_P!^5!1O!_R2_!%_P"E!S:P1_Y.GEG^*?_*F?>5?@UI5C^T)_M_P_\$-
/7!0_PRTFV5!HUK;>!)KZVLM7L_MXD"HHB0JO_K\$H6"7Z!Y20!DG_4FODK_@F=_"KXX?L^?&7P!<:)XIT+
M4VA_B9!^MV!>*[MKF]?Q?EH95Y5TDNA.X.0R2!@U_*Q_I>1?M92%/X5?M_M%:_!R3:OA/XGT_Q)X7!1?
M!:_+JGA_6+!XIXGT36F21^Z?LR_?X8KXZ^!>^U!0_M!MSKJZ7IVBZ8!SP037MV8IFC M>>6*9(8HX97?
R)68(B%Z_*_0?V0/VFO^"4?_4X^"?!\$ _@F2!0_L!_\$+X! M)XN^&5W?2R32^!17BTW4A<:-
YASA)\$G:10W^L6(!Q:G=W/!6_Q0_93_8E_MX+Q^+&7_!3WX0>&K_X3?CX9Z%\$X
^C(C/PA#JNG:JNE"2&:R9!8!LXD! MUWD9!QYENSX5BZ_U!V/P#@LO!Q/^!GQX!96W!_VIZ9!1OV9Y;MOC#!M5
M!2P)E_L^:CK7@_4O"VFZ!H_AO/\$\$-OJ6GVU!1%LW1F_.\$C)DB56+2QA@#!&?VR/^"N MOA+!C7Q-
!\$=#16_LU>_9L?C=K-EIVC_!EG:VLT:2&W\$22M=3W(61=D2_MP!DI_U9_@@_TC_@JMK?A#X.ZW1?VKV)?
B+!_*\$%_#W!>/_J7?C>:CX_MXU*ZV?8UT^246!^86?<_FF",OR_YSA^!^4?^"COQV^" B^_!^P""9GCWPQ!5 M?
M!_H_W!<_G@U_TUB&2!HULX8G;>K\$!)Z(W!UT"G!XKT'_&^!7PG!7 M2!L_MXU_H!P!^!WQTM=4^*\$=A;O;VGZ;
M>(^"EFK_'H7X??LY?MM_L^M!D^+5ZVG?#KQK!BM_:T!U4;=NEWWDL!M!Z'&-X!&)RG;
<=X@:_6!^)_CQ!10@#^S#!#+'QWJWPBMM;_O!F MI>8!
(D6YO!7!9;65DAMYA<3&WV.6F:V@!D51*6\$@C^7O^"ZVC^\$OV!AY^S M3^S=^SEXUTOO+X!7_M
>' \$V@77AS4(HV.A6=O=/?YOB8!6&*9_9>SXP!>7A^(!K6DZ!HJR/%*B7)@_MMGAN\$>-P8Y@!IVD!^4W_
!R_'!+IM!H!B3X_?XO^"X!4GPFN!A!_@K6O_M\$MCI7X=\$T!OPZ2;ZS&_MM:MM%NN2L MO_!TF/ES/\$B!X@;1!>?7_
_!%+!V3!_MVN?BUI/P_8!^)_D_Z0:2+J!BS7/#_S2V?AO3S&WE?!)JFO:B:X!F+0LL!M59!)"#D
P!V\$ _V_OAU^UA!:=P!H^X<5^S!JGPTU;X0^)!K#3O&=WXEET!K M5+F2WF/G2FRDEBVQQZVA9#)E&7!H&*Y+XX?
1%==2^\$O!L_+2AWID#7/\$_M_P_K:6*>X!96B>V@UB;27G\$ZS::5)!^!LG+*Z%IB?9HF\$AB1>:=/V-" MF^!2!6Q-
53^#GPR!467_00)=7M+=TEXKQ08KF;1+^T5R0?E"3Y4G^%E/_M(KR!_@EQ^VG_.\$-(V&_#G!/?!^!OPE!
(_&7X8Z5^X!1?^"/7PEM;C6-M6OK+%LDD49M'DU"><(A:_0TWG%U*G*LP!IR?_!X+?"CX*?&+X#?#K0?@+
MXX!8:1^T+8R7_@+QSX>CM!K+4+9:&_!M!>.5!N29A!+LEA@3H!N!S"/MU? MV9O^"H/B/XK_+;^M?L!_M&?
L@>)_@YX!B!%#QAX2M!^!Z=JL6O:*+GL!O_MFV\$DD4_ZR<(\$!IR3Y_E&YF_!QU/P7X3_X^(!1_08?
AS!PUBCUCO:: MX?VWJ>W3P_!+H!E%8B*\$+^"L=EA"Q@)O!5_X!7_&:Q!X>M_P#@Z1^#VCS;
MY:)=O^RQ!^VS7^B0R_J=Q(J:F_"_QH_ BWKVIV=WXOD:V@!1Z7?7!N8KVWF8:97=F9PH.YXY(F7=E@NU_
MP65^_VG^0_V2?^!H/Q_9EN!2^!O@+!XD:TOCOP!K7AL7+X>U>V_A8ZQ2!13_YL_V!A_!^=!57P\$D^!G!Q
M!X8EU_X>7^G>)X!T?Q:PB0W\$45P(8)8:F-89F_4D(RL3_&Y3?15U!+LK?M#_@BQ!2?VA_!6=K=>!"!-
M,#=3W0M% M>TDED:U6W+)-ASMVIRE?NB@ HHHH **** "BBB@ HHHH **** "BBB@ H MHHH **** "BBB@
HHHH **** "BBB@#P#IOW_@FG^R_ %*!_A_P#_M0: M5K-W8>&=2EOM+71M8:S99H(+8L5!W#;VKY<_P"
(5_@DC_T) CK_P+7_X MB0?O^"H_!4?P%_P2Z!>%O^OCWX6ZOXIA!4ZO-HO:Z1>10M T<7F%F_G! M!%"?%Q!
Q%U?LY_!&A^O_!Y9_X5^!<,>&_BEQ%DI_!DN\$J5_!R491G!)M-MJ6CFGNGT..MC<0!H!T!_ MU2YCEE5H&"EMT?

&#GBN?BWP^12^&K6.SI"SI")10*<)+F.:2M&3>R?0=#& M82O/EI2N F>ZUYU2?V/OV2?C-
XI3QSI8/V7/AUXKUN+Y>L>)?!%A?72;?N MXEGB9QC QSOBMB;XS_!X(?
LY^%\$X1^/GQ9V/^#=#5MKZQXEU6*RM4.0.-+*R MJO) Y/4BM*X7?%7X9_&[P%IOQ3^#GQ T;Q5X;UB)I-*U_P
/ZE%>6=XBNR.T M&.:); P.0>)M6BLK. MW:218HPITS*BEG=5)Y+ #DTIX4_&+X5?3P=; \$/X_\$/1_%.@W8!M-9T*
M2ZM9P5#!DEC)5P00<@DT:4(+OI(UK3XI MJUN4R#MDBE5D<9_."#R*U*J;
IKVA^%1%N_ \$GB;6.33M.L+9IB^OIZX6&VA1 M2SR2.Y"HJ@\$EB0 !DT L7F ME^)/\$-C#.MK:W5L;Q7-
PJO)&HF5(9HWR+>AW\$!B0P&1^S3^TM\$VP?@AH/ M1_/_CN+Q-X+3132;)K<-G;/BY6*>2WD_ =7\$<+;_2?^07?
>)O"H?S6?;HT|;-SS!^=C#=#; MP!V12QOHH5\$1A77VG0I MK6M&@NI.GX >P-*C&%^!R8/ YK#_.;:@_9!_9\$^&-
W19?VEOBWHW@WPU9 M;\$VJ:S=; IGI^&@!>:0X.(XU9C@X!KHOAQ!00"Q;^F@_%X>ZO_;&@>)!% MM=6T_!|
L1D7VFSN85FAEV2JKINC=6VNJL.X(I R*^?1*M^&7V17M4 X5UH7 MVGQ3 L/B>X LB'S-
7B6;O+IMN;A1&2@&FX13C1Q6-X!_9I_9R^>7BRH>_ "M_P" @GPWKHN1F_ UK0!"MG9W=RA()62:&-7<\$@!)Y%6?
C71>Q@O-SAX%D^M)Q?QY^%&B>\$M!CN(I?^TI=U!+>2>0XC@CW' DKD86-78!*;XGX8?1!0C! MB;XR^*+P%|
PHKPGJ/B/4+X6=IX7.I"#57E.DX!L90MPH.4.KAFC"E8V M(%'; \$IX!_ OXV2Z2A9?
@MX2!7!\$QETI_ \$ ARUOS92'&7B;+>6W Y7! MX%=)?;1I.J:3-H.IZ9;W%C<6!6!Q93P*!4L3+M;-D(PRE205(P0<58HH
XGP M|^S3^SCX1.L7X0!)_L_ ^"=+TG0!_ MC1=+TPI9P6^GZCL>/!9!&D86*?9(MZ^:H#1789P35CQ7^S_!|
;QYKDOB?QOI\$O".LZE;JB24-6!_VMQ/(%4*H;22 M.L<* ID! 5UU%
/_WOPE^%6I>/!3XL:C|_ #1QXIL+4VUAXEGT6!H0MH3G. M4=P4!Q\$.X_*& Y/K6?<-L|_
*!T1_#5Y!#_!NG2:G+J4FGR>&;5H&O9?19< ME#*M.K_Q28W-W)K1^*GQA!_!+X9>(?
C)40\$4>D>&O"FB76K^(-5FB=UL!*MVB;;;4K&K.P5\$8X4%CC!;5;X)_ &GX8_M&?"3PI=O@OXXCUSPIXKTJ'4M
MU>*6);JVE71QS7HYVDZ18;Y15MK6ES^;WEND MJM+M*[XW4,IP0",@G@C- %BBBBB@ HHHH
Q_B!X%T#XF>#-1!>*8Y7T_5+

;Y93="/5Y4XMW:BVDWW/FZX/X6XCKQKY MI@J=><5RIS@I^H)OI=MGGG_#LSIEQ_*!M?1 @X;_ KN?@=^RE|
(P!G MG5!6?AO9W4^HVZPW)N|XR@HK;A@\$<*N?#WB;1:34=/O(C%=V-;+.#.AZJZ. M"K
^A&*Q!|P6^#GPTU"75OAQ!)O#/A^ZGAIF>YT30;>TDDCR&V.T2*2N0#@ M!9 K;US7-
!Z1<_K^H16EE:1F2YN9FPD:CJ2>PKP0?V%;2^?7)O!H/_!0
MWX;FXMBPN8!1L.WQ%3A@R^=E<^@YZ5XIH>>^ZEHNC;S!G.L:3:7?V2Y6YM?
MM."R>3.N=LB;@=KC)PPY&361!20A!+/C/X8?P3!8?AKX?1_ %FBR2+))!B7 M1H+^U9USAC%.K(2.G!QOFJ/P>^/_
!VAO#|^+?@#! "7CG2HG"2:GXA M\$EKJ=NC\$9"F2VD=0>.F.QOBG^UQ^SK!%/C7!V?=?BA!3;;2?&?Q5GOH?_B
M2Y=P!JIG\$LMP!^&T<6U3FE5D#%#@JFEXH_!2PIX2!>_#EGXA#^&=/T;2 M-/A\$-AI>DV4=O;6T8Z)!'&J+I
5REC^RY^S-IFZIHNF-LZ^!+>S!4WD=W MXFM("'
DD6KW\$<@E2:Z418N'60!PT@8A@&!SS7=UYW^TY^UK^S;^QE\ KCXQ M?M1?&/1?!?AVV.#?ZO.OTS!?
NX8D'23OR/DC5F>E &QXK^GP+!>:BFL>/_
M@OX3UFIBMT@CNM6!6MQ(D2YVQAI(R0HR<+TS;Z!/#^@Q:"!L>B6;Z6MGID M735MD%N+?
9L!KR!:=FWY=N.8XQBH?|WB|PIX_P#"E>_."H?;!*UO38+ 3+ MKRGC|ZWFC62-!K@_N493A@_"X(K2H X_P"%?
!//P!^!;WLG2^!O@_P7Q5!4_V\$+*N!(JJBNI)HF;<%1%!SD!%0"N!HH L:SX;L_ ^ (M N/"GB#0+*_T
MN!MFMKK3;RU26WFA(VF_XV!5D(X*D8QQ6A_#X;_!X_&)/!P?^%AKPI MHTLKRRZ1X:T*WL;5W889C% BH20_'
<9_*Z6B@#D_ "P%~!GP_P!;7Q_X#^" MA/1-12-D2_TCPY;VTRJPPRAXT\$=#1GFH!1_9Z^6K_ \$^W^~NK?|P?=>_!1
M0MKXNN/#J^J0@#;ETT9E4 8;I7844_*CE_9W_9_G!#QAA#/#SZL+L;D:H-AFT M-R)E(99?~O=O!(-.00*
!B&#>D?^H/_P!_ BAXJTOQW!>@GX1!1:YH;!M M%UG7?#=#K=W>GD;6!@FEC9XL;2?E(Y.;Z;5M)TK7M+N-
#US3+>JLKR!H;NSNX M5DBGC8\$;CHP(92"001@^U8HH Y?H6?1#X+_ S2;G0?@G!(-) @ZQN!@SW=EX
M6T"VT^*;.419?2!\$#- M\$9KJ*** "BBB@ HHHH ***** "BBB@ HHHH ***** MBBB@ HHHH *****
/R) X.ZO^3<_A#_V.U!_Z1BOP=K!X MO^#NK_DW/X0_!CM??^D8K!^_ P!_OHT_!FBP?^_M_P"G9'Q><+| (PE|OR"O
MZ3?^#8;_)16Z3_V.VL_ ^C4K^_*OZ3?^#8;_)16Z3_V.VL_ ^C4KP_I6?1EP MA_V\$4+TFH;Y%_OK!^AI_!%>
!;WNO^"4W!2<5S"LBXC%>*W"NN0&72;EE M/U! (IQ7OI_P0PUW5_+@GW^Y9!;2^?^?Q%U;?1L?1HD_ \$+X"7-
!>2;OPY? ME6GM\$900&&1T) Y;47C=%K!\$ P""Q6MZ/H_ 2@_ :00=W#H_SA/KS@_+@Z/U MG5_VC_V7_BM!+I
U*>/PG^S!X5T?Q/XPDMY2!7GB;5=2MK/2!18W"#3Y;Z!
MD3D;KNP;2ON_P#@OI1^!JEG_@F_P#@1/QCXKTZIOIM1!#>#=\$!+>&!%BC;+ MUO5;NRMH;2PMED=\$WNQ^|
!)&B/(H;B.P^2+^"M/PNU_X\$?+WGQKUIX^7-I M92?OXJ7^G>* _Z27 RVO;CKFG2G3XB<&1;VCALHP.?)L%..;J?
!%1+JYM_M^"0_!&_!8.B_#6#XF?#_#_ (C) #^+?B/X8M!*_ @OM_71GM;F4Q.&CD\$?G M!3N!5!+A48@
^OW_X*>:Q) _VU/_?!\$ _!8W!_DGP!U3XLV=W)!+O%.F>+8
MM9TK6+JV" M/AS^1!);W2K)%A2CQLTBJLA++GJ+GJNKQ;30C#X^<#G!^P& MA^T_P*H!+QYKNI>+DT;38=6;
(3!L;|/!<&ZODC9&E5EB@B;J^ZN65?1 MOY=OVD?^"%H2?Q3^8_86^ GP8!>_ \$2IU""4!93PS;K^VU^PE;HR27.J74
MQLP^F&%0 NXH!LYAB3EIR^~2!\$+ _JIX3?L7^//VG_V#OVWOBKH?P^)>C_M+0&O^C-
XWU>38_ \$&EZ@L!2_@FN619@1_920<^7-\$V;L_%|X(->7P M-^P/^U5^T/%!O%FI!;
M5^;=:G!";2?8QZM#";73H+9DN;F*W\$!2;@Z;U M0A=YP#I3_LW_!3S!FC6A @E=X>_X*;OX!E^GP_O.G?
3!"5A;QSW*_ M2EL+;RMX8%19!B9\$5(D^&8;_6KY_."&OOV^#>M?LB_MP;-8_ \$K1C?0_ MM#_ \$?Q#-
!U^D=Q!L;H>5?/\$Y#I Q1U\$C+NIESD\$5!_9H?QA0?1&F?I
M/7QE^!>A2>)KGX_ \$6S!_ ^ (= #TYO>XLM;10ZDT;JN3B;R1S_..?D3.1A: M/TT!7+!3WQA!_VD?A#!+_VM?
V3!2!#V7QSU.720_7B#2_%;_L_9=458V2 MPU2&*&1;2N)5_&2YCW!OGVJSA_C'_ @IOXFUOXD?&IX?
_LL_LUMX_!45K#_ M_+ #O_4!7+HQN;QI5!HV.FC;2!5.D2'<9C;1HR%5VZTWX*2!%H/V#2VM4! " MZ#^R;4!X@^?<
&EU;/:>="1_12T6V9E^VW>H)L/V%+6!I69I2JR;JO1L!2 MIN^7)/V^/A)^U)!>OVM?@Y^U#!=%^!
^&7BB_P#"W@OX+>'M5DTK5?&K16CQ MOZO/!DVZAK3W#("%BLX"85@""6*;>KT>O?1!07HJX8?MU?1&
IOQ5_!M^%6% MI?1^?&WP7U#4!+TU;4N+9UW)!#JEEWQ\$S1NA^DJ2F5)TM_P3C_Y1Y_M;_LC'A?_---M7Y6_LP_&?
X5>(^#_CQ9X3T+O!HMUJ^ACX1Z!H_B&WAN0?I M/O+C5;XPVLK?=2=U;-
Q"3OV30N5"RQEOU*_X)H;HNL_!\$YO@J6D7!-S;R2 M!GPQLF@D#JV_*M@<\$<=<\$ \$T(H^~+|@O#XT^/_
_R1^U!^S;_P4VT7X%;E M!4A_!&+O7E^ (A?24R?1WO!_."+6\$0@KNBC!W;*X"QLH4O^YV!>P? SXU_<
M!\$YO^"RGC;X1?MF_LN_!\$0=8!7_!SQ/JC0W%L+?7!+M+K3;RRGL+F!L2QQ_ MIRC!OFA9!<%?J?
2_P!HK_@H=1%OV7OVS?AU^R!|QO&>B>&=)^ A#5KK0M= MUV<06!Z!7-G&MD!SL(X_-BN9"F_<
9X@.@_YU5OSV_P""C!^_P"S?^S!_P_% M2?V7/V@_ ^5!Z9X6^~OC#XNVD/C?P/X NU6SU+PHP;75-6NK2\$E+;W2)?<
+E9 M0B3")PTBH/T#^~O! P4&E!3_!%?%0_!/_O=1%+G1!T/X8GQU9>H;7H MINQU#3#?
PV4:A+&DBE+RDLK#^6P!8%6;^SM_P4DU7XY_!SH!FE6Y_9AU MZV19_L^1!%UG2M\$!06-X-
>;5+>>XMQ92W#6L8_ =0AOW!1?ZP_!2#7S3!4C+ M)!?V6?1 @YW;XC?M_ \$O00 WASQA^OK_ &7X>1!>*!5BL+ "
!OHO\$;3R6PN)V M6.2B*%WVE@<8_O+G- X)4_M)_ Q;_P7-;PN-^ (^G0^QE!V/M0!)P:E+!D
MFUBSL! "N!/NK;.*;T*)D)%+YB@J8I8Y_2CJO_/3?V4_ ^"Y^BW!M#PIX#!??L M_P#_ 3<^NM^%_ \$_P_2IO"?<
BWQ#!=V9B!;:;CREN;1<H=J?OYA&#% A4&9 MG94/!3?1%+;~^)^2?&;7OV2?V>7^<(WA_X\$!>:;#XRU*;Q4NF3;GK%<E
MQ2;?I M/V>87%_!&LGBCPWXB_X)=R6^@Z!;7DEE!5_% "W;6 MUPKF\$R7!2H&_/&Z-T<9ZJP(X>\$_L! MB_LO?
L_!M!M@_?X*_MQ?"P1H? MB!XS;U_80QHU2XTW4?#?B62".5;^VB6;H_@9P%AB;2W8_93^!VD;P!JB_M#_!

X+ % #?X^ P#I.WQ? P #?#?!2!%?QO-2^RZM#X=676I.MTNO MMT4:ZM(IAMS:RI,DFV7)PD4IW =KX- X*? OPY_P
\$I/AE^VJ_P-/IW0= M)^(&BZ%#X'^6@QQ7% >:CJ01+ #1;)Y4&:-\OV0 MOV8 ^#<3XG-!7IDCIH?0/B%X\$!*>
/QG9?QOI>N6UU#J&HSZ?>SW+,\#ND;O M-/#EWXK_- #Q5X+15_ \$ M#2=& F=-M/I1>XGP#@-\$Y,1) U;3\$M@*Q
^B5I_P%+/%OPJ_-^WI#OI M5?I-5SX^UOXM;?WOPYU11%?"ZW87DMG&TMS973"W@:UN\$B;Y1+\$=P EYI/M->
O^~"NVKS^#/CU8_V>PIEYK<>I/V:O\$6IZ^H8N%?Z:7?7-HD?3ZHN MF6C6THNEMHFRS32V F%2(P-1/;1C @K-
^Q+^UIXU\ (#+8W^+&E?%#QIX MAQ>75GH'F\$^'+5-IQ>ZB3'FRP-L*12!9))YHXPH&IT /OQY^WQ\)/VW?V2O
MVS9/VBOCHO@WQ5X7N/?ACP-^SIX-^~^WQJ\ ?M/_/M/I1/VA-ANUQ+X=1>??"6O:&Z 1 MS+;W.MZ3-
&)\$R=DBAP&)PP(R>M?H/I ?1 Y);X: [% ^S_1\$)7XS?M/_&X M5^//^#-**PI'>/=-
U*310AEX(T+40LER*6#4XM4TDRV18?9XP?7C1+1CY@*M_9+X*;GIVM?IOPGK&CW_-
U:77AJPEMKFWD#QROM;H596'!!!!1% '34444 % M%%&)1 P#D1M3_ .08 P Q7A5>Z_ \$?_D1M3_ZIC_5X50
5W_P!_Y#&H?I M>R_ ^A5P%=-' _D;A_UI+ _A4 >HU^70_ ;P6MM: M0?1% X1:W2-4_ ;
M10@10,*+VJPHIAZ5^H+JH69@DDGI7Y(1\$ _P;HKJG_ ,+?M_ MYW'B MGXX^\$+36/VK=?
U'23J7B6U@^V6;7MX5N(O,D'F1\$58=Z7 M_P
\$IOBOI*O^~"U/H&NBP^\$O\$UM10K;PW16I" T",6MGXTTJYBFG(O(4Q'))BV MDB,A&F:)\H49?
MSX^_1%"OAU\A^O@#^R5XC_&8M;U/4?BY)JLO@7XE7 MAT16%HEMIOVF\MB62Z\$FOX8G5HH 1,""<BOC#_
(*V>G/_@O+18OAG_P3 M)_8AO&172#GPU0+?Q+1=-C\H0_N@Z+1;Q2PKIT%N8;H1>XG/EQ_V\$(SA M9C%ZM_P5-
UOPKX?_."UW-1.719=7LK0VVM^/T6V>=5,22Z190P#1/ >0>6G M1Y@0.D4 ?1OC#_@H%XH10?
M8>/OV,OV5/@"X\H8_ "SPOI^L^/)-16#0K*V M_-&TME8V1OV;X:XNI8E+_,D<*KNF!R% ^7_~^B/I:OPO_P""COI_P:9?
%| M:H+&7A05_)T_60%4T%WH>NQ(+K3;ZTU2*&?"382K;98B58'YE*G"DE1?U+10 MWX4?%OI X*B_ 'KIDSJHX^0?I
IPOI+10+?P_P"1;UEM%UGXES75LTS7+WD M12^NDB.D.4% C9.K22;3G\$N1CXN_9A?^10^W_HJ3^TA&1.LK?^)?
#EUXC MN-;A\VL7 MA63R+9DHHHS"-)*I_)&RI*?QE^WG16 A-1_ ^#?S2?@I)?>C^//O/Q9 M^&?A_P
)_#GPSX=U"&N=9UIX11""B,>;8OO/*OP(5MW9RNVO#?VFM.^"?_ M 3" P""E/P 15-1%*ACH?B_P""NN?
IJZ+1*QXY11^%\$U?3M 12Z5)9;_ ^MM350KVC1R1N1&)94\$B#RRS 5YI_P1M_X*+_ %K MQ_1
1\$KI/IM;IN_P_%HOA>+30\$ _BK6OB3-K1<15T/H>U"22WBL5#30ISL_4 M>6)6&_ \$IRHKT#IECOA_P37^7B7X@ZW_
_ \$T/@#1+Q;2P/=;?XJ^?PW1%V M=A#=-3"-K?1DNX+=#?_40S2HCLLEVVX;IDV_G=^RI?6?I6/_H J/I&I-/MBZR1?
%OPIX0U#5-9)1#:_VG4; **R19-J#V1Q F6BDGMT80Q2_ -16)O?#EW M=(SVPUC3HT M594W\;QNG_0^~^A7XY
M77@'4?1LWB72UNYO>KKNK76F.696MYBO'F(5(8#&@S\$9,UWE?O_1V_>+M;718_P#P3E^&_P"TI^T?X2L)1)8;
197;ZF=_M_)MM1(I%)Q:A(G18(F_))Q MM^0^;N3Y&6QH/_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#PKING_@G5^S7_ ,%"/>A>" V MDI_U>ZL?#FHR7NF+I&K-
;LKO^6Q8J#N&WM7S3_Q#?#? \$K?^A31;?^%E+ _1 M\$UI_ M3_ +4^@?LLZ;H6OZ_X50-535;OI>..SF1#&53=D\NM>?*
1/2AQ_T1 M_6_ /A_P^*QRCQ"XXX?P\$<%EN8UJ-&_VH0G*_5=W=DG;5ZLYZF\$PU67_ _M";1#SA XAAO^~^5O_OI^~O
PLI?B:~M_V.2V.?@K^PK1%8/@%1 K'4;?PI_M;ZC<7L<>J:@US+YLS;G:1@&0.#M7BG_11^~_ \$1_6+P/A_PKZ#_9R^
M.^D_M&?#;+XEZ+H-OIL\$MY;BUN15=P8R 3E>.D2.SR:5IVEPP6S_V M-
Q.2*0%1.DXYQ6U7B_O_P""B1\$WPO16ZIX%17_+10AY=6T%RGB&QTV62_M;1FR5O3;I(+XYQ4_>E?)&YZ-XX^#_P
?2B=;W7Q)^%WASQ#1+;(R6LFN M;1)=M"K%(@AE1MD_RIUQ4WA^X8_#;P;HMQX<1_#W01\$T2D9\NPTC28;:&
M=F4*S.D:A6)4!22.0 *3X;?\$ _P"~WQE1\$V'Q^*^\$7C_12%'AW58?TS7?#VJ1 M7EG=IG&Z;)F1OD\$<\$|@BM/7-
=T3PQHMWXD12ZQ:Z=IUA;/<7U_?7"PPVT** M6>21W(5%5026)_1H YSX7?/X%? 17X^~^OP61)>#_15E\$N1_1
"+^+73_M +9(X>7R(UAQAD\MD\GUH;_+X\$ _\$SQ9I7CWXD?17PEX@UW0F#;)K6N>'+ M6IN1/(<#1+&SQ\$;2?
E(Y:P1V7/VQOV9_VU?>N^_ V6OBW8>1%1-^Y_ M#YKZKI<PMX11AA@GDA1Y\$43 1W,+>9&6C_8E6 1,H
YB/X)?1B'PM?>1H M?A'X831-3U"2_P12T==MA:W=W)YLEQ+%LV22M)Y=@6+?;3GFK7@GX6_#+
MX:6MS8_#CX=:%X?AO<.B:1#;+.P!+B)5# \$D<^M;M%_')?#7X_CX,W
M^~K1_@IX2*76LRB36+GPUX;M;2^<^\$D_T\$;F4Y)Y)YJZGPF^%36QX-1!^!OAU11 M/_#IP9LA6\F:4V.C;=%:PF0@
OLB55W\$9_G K6HH R2?@/P/XQBN(%W M@S2=52LFLH-TZ*^36S;_%PZG=&6)01\$@1%"<1 "3JFCJG'X
S7MS1" M/V?_3X*DU+ _D(R>\$O"EGIK77.?WAMXTW11_~FNVHH YCXC?1/X_&&33)Q
MBY1)/#BE1%NOM.C/XCT"WOC831?O83.C>4_ ^9<^@<15)-1OA)*I(W14.^B6Y.L&BQQM=\$I_1!5\$1%.FI"HH'
%='10;S'A_X_ "OX: M&1O?A51+O#^ARINH/+DN-(T&"V1S*^B3R50NH/_E7YM? IP+^VW1-(N?A M;^W?_P \$-
_#GQ^1>X=TN)\$U=X;BR6;H1=(F& M\$B@C2-5551?U;HH ^8?V-?V_AE1+1^~^)/I+GPU&Q_\$361+4Y_A7X4T
MJWN;T31+;>1\$Y @CAFO7#2/-"B_-D:~9Y7G2_07A7X8?#7P+H-SX51\$?# MS01&TN1=W0-
TK28;>WG9D",SOQJ#8E5522#D_#H*W**_.5^%OP+^"/P-L1S M3O@I/'O@^WU"?S10@1+>'K;3TN9>?
GD61\$#MR>3D1EIK7X-?""R18;K101_M+X5>X?>UYU^RZWKD6A6ZWEH08 1J>8)OE3 VL2, <5TE% '(WG1A 1M0
M1+;9X&O_0)>91\$T4_-T>PW:M;V 8Y80Q&/9%D1=H&:W?"G@_PEX\$T.+P
MOX1+;=HVFP%CI^E6,=O!&68LQ6,,1EB2<#DDFM&B@ HHHH **** *^K:7 M::UILVE7P8PSIMD"M@X^M&/?<
A_P (SRW.C1R1TR17R7=P#FMFB@GX@1.^~!9HUQX<15:9ZGI
MUW'LN1#4+5)H9ESG:Z."K#<=<\$5QB_LH LMHP=N;/(.01X.L<@_P#?JN_H MH
KZ51.E:%IT.D;)IEO9VENFR"UM85CCC7T55_ 'L*YGO91_/@X1UR7Q_XY M^~^?A'6M2G55FU#50#=#K!2 EI=Z M?
X(1%Z3HT&H7TM1?P:5IT5NES_/A71 O!7AG6M4!&I:OX?1*VEE=78)/FRPQ1F2_3N)Z5N>?/AW M1A XJ^%KGP/4/
NC>)_ \$O 1>;/K^F17EK/@Y&^*961L\$9Y%;&_1X\$^W M@+X6^%K7PA
#+P11AS1+2MEH^A;~9VMN"22\$BB540\$DG@#DT>%1A1X" M1O1\$O@?P11&C JUZUYJC:3IL5N;RY;
1TTOEJ;D=VR3ZUKT4 (O"-E>S"1555?2-\$S;@J(H<@*H1"N1HH M 9:6UO9V1=I:0)%%\$@2**_0JHH&!P 1QBGT44
%%%%% 1110 4444 %%%M 1110 4444 %%%M 1110 4444 %%%M 1110 4444 %%%M 1110 4444 M?(''
51_P"2<>#_ /L-S_1 HD51%51Z_P#17S_DG'@_L-S_P#HD51%4 %? M19_P21_Y-3L_ ^PW>_P#H8K1TZ_2S_@E1_P FIV?
&&1W_T_4>+P#1S'^W M=14OV^O^~^7^K>?*@?KEQ1B1Q1XGL_1NBZY9.5GTS13#261_#YM_P""B'_@GEX_P""D21
P34U1X2_1VQ%1XW1*ZY: M^+/'&F&0)_U:QS126JL2_ 'DMKFX5_X1DV D EAI^P-^W1/(VPOV6=%^_ M%SXPL-
&1:1;14'Q;1;UP2E7MBDJ0@M^H9-KCAA012V MOQ"U+ @G1_P#+K'9V/BNVBORH;1DA(9 M+A=-"R\$;5D>
1W/GRU^~^D_P#1;1#NKK1MRW10JN1H/PM80Y78+310"/QL#/M'D67C6"6#PC:VUI,RH\$@>WDLSENTEDD8
W2;1U1+CD?@1;1?^F7 1>^T X*M7^ (VN/@1^S1AY?"@GO@BG1XQ103?;5NIK1SQ<6L"W117"YC:6"(RRX)
M99_~^3OQP^\$?PM_X* @MP_XA?5'3-1)9>)OCW9W7ASPI=W &HZL;R6+N)I M>W'IR6)8QYCR*12/YW*K1U'E_<
28_ :M^+ _1^P6_ :^H/G1%OBOXOZH M'19?Q U75=.T75;/2;.PL\$CL1_O17C 3SL(I-EM;1+)A,N(P1D^~^OA=_P %M1?V=?<
BK^P%X_P""A.A66M'PIXY6TM?#GAJ^YCDU_ UFXQ?1/BTB&^>\$DN6O MOUN#O\$>5+LZQAG'RS_P1/>_1UUN1?
VS=6A14;<H% ^V10=0FN1>(8TLY+; MO9+AF5@L1J.OY^4A&P>#7Q+1^A37/_N?LP?/P21.8O^~^D? KIH(^~O
MB1X+2V216_T2S1O;W1JMIH&#1DV7D.CA@56.F1AM4D_ 'ZM>(?^~^H.O? G1KG MX_1I?MF_LU3?#W_ (7+1+;?#3Q?I?
B^~6=YO-2BV9TV1"PP0?7#>;"J11+\$ M1RA5D(#_1O\$1_1H39HIE\$C%)"T<4<
M3EY(S6= P3D18>%+W_@X*_X""+9+)&61NKX<-6T5TC/*+;0C91+ #KWIEA Z1&M_P#@Y?1 PKZ(HH ^=_1
AUI^RG_T"-_ /IR_P#A M7KWP;^#?@GX\$>"8_A+1#^"XCTZ.XDG5;1X.K1W.6^8_2NJHH_*1^~^)/D?1 M*WQE13Q>-
OB_ ^SA/O>LP11J_B3P98WUU&%&%VRSQ.XP.F#Q7H-%_\$.GZ? M8:380Z715C#;6MM\$150;6102.1%&%55'"@_#@<
5C7_*/A;JOB#41%FJ? M#70+G5=6TMM,U741C1H^N+RR(P:660KNDA(X;,\$K15OT4 <19_LS?LWZ=W=
MGI_1/O@B""_@\$__##X4LU2YC\$B21) (1.HDC1P#D;D410#6OX^*^\$ _P+/AK!
M=VOPZ^~^OA_0(K_1NCT31H+5;C: "%1P1*H? 9L9SC6SUIOAS1GGX>#M M>@14^\$?@;X/TK419F:VU?3?#-

[illegible]

JQ@ * M !5FBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ H MHHH *** "BBB@ HHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BB MB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** M "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH M *** "BBB@ HHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ H MHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** "BB MB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** M "BBB@ HHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH M *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** "BBB@ H MHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BB MB@ HHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** M "BBB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** "BBB@ HHHH M *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ H MHHH ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BB MB@ HHHH *** "BBB@ HHHH *** "BBB@
HHHH *** "BBB@ HHHH *** M "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH M ***
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ H MHHH *** "BBB@
HHHH *** "BBB@ HHHH *** "BB MB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** M
"BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH *** "BBB@ HHHH M *** "BBB@ HHHH *** "BBB@
HHKE 'OQI^?\$?POOGX@?;\$!1* <# /V> ZOD\$ MS#VC!+M^- :T:?\$U\$3HQ5^*O^"MOB>?='X)^#
MEA:X^Y+JNIO/GW*1K^CZ:CI^JP?2?>.2<<,XK^U^)^A#TS:QL,\$W\$-17JU:2+ " &T2+I/E/U2HK\G;
HH#X:F F:A:O%DOI>9X MBN2!!O XKV K -OR^/O'7B/HIBUT P 0^-6OI<8*3G'3F=KM
M):VI7/T(HK^6#_ @O!^TO^T=V-| @KE\O#/@+IH#QM HFFVNV/V?3I(A5WE MM!%G3+,G;"(%7DDI#J: ^:= -P""D-|
P42+2+)X= ;R,EGMZ)43=5"G0 MROGX(SV(KYNAPE7Q&A5C57O).UGU5S^D><_LUHK^1,P5_P7?_X*(^)4FT+
MINSQC.4Z#6Q^Z#R^H1>0R@=C7N/PS_P"K#_<K-X%D1O%GB/P#XT5<:U1^#\$ MAW CHEM@_YQ45.\$,RC\,HOYM?
H'.C^GBBOP>^#O -YAXKMVBL_V@/V'M.NP M<=>=J/@IQ=):I?Z;W,,FHA7UJ^A @ZF_X)2_%PP6?
CWQ3XP^%W+A67Q_M;X7>:\$/Z"73VN_%S_\$X0=SBO,KY!F!#65)OTL_RNO\T6?T'17G7P(-|_98_M:?
T:E^SO^TIX,+)Y>^2+PYXBMJ:\$?I-(DV: ^./C5_P_%OC=|13-I7P_\$?A+3'RH M-B_F7CK_+4Y V'O^| "D>IKZI(N"
<-S^TZ-/DIOI<I%NLODK>:RWC7OBX(MX(=U&DIVU29IS_! ^_.WPA^#=#H:KXD^/MTQMF MY+627?
<2#U6%,NWU"XKYG^*G_!6#2+1Y=^ @U\G.NR.A-3U^3RX\^HAC.YA MI74^U?%6HZCJ&KWTNIZM?
S75S.Y>:XN)2(R,>I9F))N:AKI=RCPMR+ I3QC M=:7GJL2N3N_FVO(ECBKZ2G&F<.5+*81PE/NK3J6Y27*O\ MV"
IGJ/Q* ;M_:1^*:R1Z\3KZTM7R/L&C-JDA"-P\TB+ #./M7E:DDDTG2RN69B2S,

;7RMNF?NW_P &Z7_*+KPO_P!C'K/_*6/7W-7PS_P;I?HNO" _P#V M,>L^ECUJS5_!_B7_P G"S7_
+"*O I;/U+)O^130_P1_)',_&#_))_>_|\ M7_HQ: ^./VG_AK^R5#87/[1_]6/@C2-) -#.K6VE02.#/+ #: >7+
MB63]VKNB%RD:KPH(V\A8\ DGJ\ OQ?^C%K\^?CI_P5R_8X_9D_ ;\$T[I]C#] MH+Q'JOA#6-
6T.'4K#Q9KMBD&@.)6=5A-VTF4?Y&R!((0?E,@;Y: ^/3/SX_X M-RI?V0/&/_!1?JHGR? #QW#X?M]7>]MO /PL-K)
XVO?QS_ ;L,-F\$9(8UA MOLT*R,P"IT1_P'7(^?)WCSXY_L9_&[P+Q!(O\$USI?@CX::\$/^_U^P?!UO6&E MA\$>A0O\
\\H4E\$UVR_KQ"WR7Q^W7^R?;>GPIT MCP6YUK70#K(=)U;P1>1207%MQ0^ZG"Q%9YVB+*DY*MAV('@7[>?_!
(S)O'J MDO\ X)W?\$/70\$'_!67Q#XJ\#::I\$EYJ?@!O"DEM;ZKYUXLDH=S>R?;TKZL[
M*Q9R2\:=@WFN:G.WEVMA;J>#++(0,GY47=(Y5\$9A^8/_1]^-/C7_@G M_-P0>=?
AW90^1_82+K5SI\L*3,S@12W#&YDD\; MS_*Y'/L_CGX; &_ (+@?LY? 7]MOIF+II+Q%^SI>:1%KUT+"31SJ,ISSR)9
M>8DBSVXPB6UR(Y@N7BO&X3/?"6M:I)V^&^H:*^O;I<|[#HMFVFGZD/LLR0]I1>:R;&("NTY4\$E6Q\ M)#|C|IK?
PM_P<-^"/VVMZW\0S8K>CXM3:.Z70M4T:YNGM?)^T\$[7MX MY+8GS.%F)P<;3_0W=75K8VLE|>W,
<,,_9>::5PJHH&2Q)X Y)- 'Y1?=\$K M3XW?\$/H/^"2NM^/-VA?AOJZ>+O'GQ\$9OA9+;O&BU'4]1O+>VM;*S,3X>!YY
MH7D=2_8X8S*1U0?;7I"P\N\ _L>^#8O"OQS^,GAV|^?Q,U5O/CW5+W588;
MG7=8GPK1VL4C!VM8%"VT\$:C"QQ+@ LV>+ _99M+KIO\ :1E_X*#^++:1OAYX M1^V:) ^SWI=PA"W:;3%?^)V0\
[KD]8+8G!6V1GP# /FORO^/,GBUO#_P#P4^:| MJ'?_)NOB?PF"QU7_CX&G_ /"17^V+I'N^:R/ (^PI-G\&S- 'I! =>W_"C_
M))_IW^Y)_Z_:OBK_@G6?C.W]"7PC;JH?MV^9N^?;NSSFOM7X4?D_TL_?MH?)G?Q8_)IKO_*;YZ_C? M_9]^
_C'I\#XHV/PN\&ZEI&FO<(^HZ[XCU++3-'LXUW37MYIEBCN8Q?^#=#K4/"?"FL_MU_LJ? MMV>!/C7HGA6PGO?%-
GX7TQ1V\NH:ZBX%Q*)7A0^8T"!K'IC:9XC\97D7GZWJFU':ST^UDFA^U M.BRQ%_WB]?C
W\$D#I'OV"/V0?!_Q1_X(#_&X(?\$VOVW;3Q)XR\2W4^J?\$ M6.\.26\$8 M=4U[4KR^CTKPKH44KRGSKF?
Y8(\$)PF^:0D@8I9B3U)KV,%B,7BH5Z?MO>A_U MW&S2M?
5+;TTV):2/IW_@K9_P1R^G_)GOSH&G^_&G>+O"GBR.;A/%NE MVCVXEEAV>;:SP.S&"4"1& #NK*V58E75?
E_X5?"_QU\;/B9H'P?^&A^75?\$ M7B?6+22] \$TV\$@-R^VOZ>^J&Y\$ F-!V\:(OY95W%CM'F?I' /!/
M]I:|K+|MWQ5^Q'>3V/@_5?AX;Z3XB:WJBF>WT6"TF\$,KJL9_TAF=E\$;J0'#; MMP4%A_0+JG|/W|+?
[9]'5^A_MG^#_ ">F>=&?VM_A%X/CN=5^&>N^*(?_0KJ\ MTR3I#I!K2V8E,D<1N5=+B# #;2JOT6-/QL_8B_X*D?\$_\
X)R_)\3_ (T^/?\ M@H)V=30+ X@W.JZ\^6++0H8OM>EWK77F>?:QLXCDCC9614#A6B<,K-M4-XV
M\$S3,.70J*D|SC!.SM?FOJXVWC;5;I"FDf>_M6?/\$SM=^!7I"PU_P""@?PH M^)DGC7X3_\$JIN=.LM30_ ^-
*U2]0AFN8C;W5JMQJZF@>)[W7/&G MQ(\1V T^SC4W.HWDDPC,CM%9VT-I/--+5;_ \$=0JG/S<3?0A1XU_ ;C*ZG
MIO|(<5CX<_97_9ATY=&L& BZZ:SLKJ\IN9D6XU"X"(LUJ]6RR2>7^QBB-N MC!
!N|EB\2HE9KYGJ|7Y.:T;K^:6R5N[W1-D"?-?T.? \!G!_R9U6\A MLID7_IO@K\VN/V/OV@?V&_C1>? 3I|P/^A>
(:6WCNH56X2>WO:63/EW-O M-&2DL3:6_8'AE96_964?N? \&<')G7Q8_]*9%_Z:X*Y.)9PJY)*<=-QLU
MZE0^(_82N#_ :C_Y-N)=_JBG?_P#HAZ|RN#_ :C_Y-N=_JBG?_P#HAZ_|I_Y M&E#_ !O_]*1Y'\$_ "36-_Z\U\ TB1^:?
P<7X%:79@9(UDB23RW(X++NQGO@'_SBM|]C/XO_"CX M._%FQ\0_\$SP.+I-P\$M-;%TP.E%AM,OD_=D
R_DGIQ'0"C#U,3@^_GAZE2I MR5*3:4FG^4E)7<;/W.5-*UE>_D|:N51KRST..UW=5228;V'_"#/^UCO70_M ?1O!?
[7/@KXG^\$OB9/VO#UKK.C7KSV&NZ;H5K=1/-YY#/(@#.5DA)8L3OW
M'=(GK7)F_\$E3"9U6C44Q\^'5/GY79N55V4N[C14/KV/E7|DZD>:*AAXWE!7O&,YN[YW&5DDH(MVWY)\,/@?
X#TSJDI7OVFO M&^AKKES;ZQ#8Z7ISUU-%;HGG0I(YA='9B'<*_P"P"OV<"A^VW^SKH/I/?QC M@|+^IY|B;3-
7TY+RPMIFR6 M(\9BSU<;DRI\&_ .2.GF?A|^T)XD\\$_ #750 M@WJ>C6FL^&=8NXKN?3KMW1HIXWC"
<[X7IX# #TE3KQIT7.IR:TW3E7 M>)JRGISQG&5*-'_VYH?:(L MFD4&/3U4-L)1<-(V"=[:0V%(KSROI#1/V.[779O
0^)WCS44\1?%5+V^M+B" M)9([+9_+A7GW_-)\GF)D IM+'DXY'^ (/@C6?AMXXU;P#X@"?;=(OY+6X:(Y M1V1B-
RG^Z1@CV(KU\ES3I8I?5X5O:5\$G)O6S|^49.- LJ<9126R2Z--_*7< M-YOELECJV%5"A)QA&*<
<6X_NH5(1J6_Y>2I3A.3:YRELTXQ^|A @E= _R:?? M_P#8VW7_*(M]^E^*: ^"5W_";?? \
8VW7_HBVKZ4K^:.._P#DJL7_ (V? MZ\$>\$G_)M,J_Z\O_4^70^>TO_"BZ^_7_&+D/_I9;U_/M^R%^R#|^TUK5SJ/
MCSXZ^\$?A?X,TZXCM]3:;+>[88#<2 E+;VB+*UU.5!,M))?)\$OXD3>%_#DUZWV[6AIDM^NGJ MR@-,+;:@TA.Q 0I|(
I*_|SZ.D<5/P|QZP15TI>WEIRASR2IG3NXPUYI6V5I_M_ 9ELXXO<%FU+GC=P""EW_ |?QI_P \$/?"/A?XM:?)
M&'2/B#X%(\67"VVG>)=+L_LQ6X:\$SQJT?FRJR21^I(DC!A&V=OR[MW|A|_@C M=IW[65KI^D?
\$#|M3P)/O&&OZ<+ _..?#V<))J&M7-JT?FORS6XGB, >+\$JIE MY#\$1(4"U|-?%H?V?+ZY_P""7?
P3|>_LS?VT6_!X?::86*VZ6_P"IOIG0 MVT6J-
+NY(;="8"J&%I6'/S!/EW_@AWX1_9R\6_MX>\$?"I0/[1+>&I6\$FN5U+1M%-/FC9LX*V
P=#/(T'2IR7+9.=EKNU*|VM|:Z M^>QVZ?M=?LM_\$C|C#IH3Q%^SE5FM)-7V/SQAKO3Y"IO=PRQK+ #/&6_.UXW4
MX(!4DJ0"#5CID? _94\9?M>?%7_A77AKQ1H?AS3I^R;4/\$GBSQ1J^VNFZ)8H MZ(UQ^*W !>2.-5ZL\BC@98>Y?

%U/@M\;OA! P #\$_\$^I?+OY;^)KOOA9P:
MYHNKVMElF0Z^TD<;CCJ: 3CO;K:Z26Z/%Q5*EA.QG3E%L9/106U]SW^J^1IT_MR \\$/B'^RC M^S8O[6'PG :%A\A
Q4&6T<_NKWVBV^V=H(0)7\$;W_.V:9+F\$.RJSJX(W\MI4 M,5;_9W_."?&H?%3IE'Q;^V\6/B6_@WX<>%=M='%
I9Z%;=J|-I/!\$5A MMVG@7RX MS;/(TH_B'JY4@?2WB3JHVV_8P_X(3:/^R1XLU&23QW\;+VYUC3= MIF3
MJNC0:MXHM;->+*=TX7D<(6|M9KBYGAWHX)6IRCKNRTN;"A03#E.;^(=7(
M*CE4\NX8U4E6C3BISPL9QC4J1IL.#:??-1=TFTG9-^KB*^41Q2LN6I/FY6W M93:NDWOV>YY-
^W^PI^40^">O[0\$ P "?B?J5GJ7FZ?J.AZWIZLL.I64C.B MRA6YC8/(C<[60X+*58X_Q<_9C_._%(7P+|3/'WC?[-
XK?D)]>E>!5TW MIY;:#|V#4KB)W+ C)\?6 L7 M?MW_ +>_C32OVE_%.DZ?9:U9+F_G^/AS4M56SFUJVL?
S#I\)!2*W@MT1 M(.;)614VEMP)]C)N*OYX?\$7AW7?"(B"^\)^*=(N-/U/3+R6TU&PO(C'+;3QN4DB=3RK*P*D'D\$\$
M5_0I_P_Z?^_*+KPO_P!C'K/_*6/7Q7TE91GX=TI1=TI\I\ (J'I\&)K-Y) M_P_C_.)IS5S/Q@_Y)_>_I\7_*_6NFKF?
C!_R3^I_P?^+_T8M?P?J1V_MH M?L3O^W)IL/PP^_ (WOR\7^&?A^EDS:AH7@/4QI\UK-VS\$#I7<%'!+6T: %8% #R
M.6DW"-%K/_/^\#=#X5_&OX_-M@?M% "CP'?=06_#P9K%SH6AZC>WPEANM8
MBO%\$4MNH)4,+43"9X@\$0\$Q^F_P_5KGIKXW76J_L?_%+Q;X&P_M>>1(\$7\$A)+2BU_.23N_P'^<-6-^W#^PI^Q7_
.%E/V>;H:9\0-'07FFQW5M MX\^'OA#Q.MW\I.HH"/IGD:&90Y DC<%MK'!1MK#YP_X-Y?C5>_LR_\\$=I:
M^,W\8OQ" _L'P%X;|=DWAW6=9>1X;:20+6';#M#;_:7YND1\$!+2,P4'(% '6 M?'-WOY_::^ _P"P%IU_ ^SOX@U70I/7?
&4&F>_J2T.5XKFUL'@F9(O-3YH8Y M951&<\$9^6.)2K2-VO?'+X) \$SXS?L:/\ _@BY:QZ1XNUG5WM/B?X4*AHW
M32(6L?MB^ (8D_P!9L\R?_29P6DW-(CN0C#W3_@MU_P_%,+=N_P!@WX>C\DG7_M/#OB3PO^T-
KDOA\O&NH:2M\96FGCIW_/L\IFT3ER5Q*F8_)E^4.H* _W\9?I_M%'C?_@A!_P_%&O@G8?V#_ 'NO3^?
B3K,>EKX70;HS37+QW%K'=;:-M %Q!_ MMQ@?>1N1D\$,B/0\I8?MI:MXA^- _IPA(_V3/VA+3I=)(5^&6IZIIGA75\$W
M27J=XVG:GYMY+\$WR32QF(I2P)BIA67:227_&?I\87CGPW_P23\6_&OIL+QI_M?P?I_\\$NH1):XCUR5Y)?
I)AM;:0P(SDM,\$GDDBB_)9A"OW%4?H?^8/VHV2M<6)E0QR^3,.21!T.UPK_.O#9%?+UEX_M_#?MD?M^V\I-
PN\':9I'I.OI.LPG6I)T6QCM\^-1^+X<2V^E)%& C6FG; MEGF7\K73Q(RGRF- '>?L!_!|XA>)M9\0?M]?
M*>I'=/(WQ2MHDITGP_>4@C\T^*FJ_ %7XK_P#I\27\LCXMVGI<_OU\ _&_7 M?ID_['B30M*%^@^:3(D5G;
(=N;_YDO+=E*WLDIT=K\PG#JAF(0*%7'ZI?L) M_'WQ#^U-^QO_-VB/%VAO:=JOC#P=9:EJ=G;J5B2X>
(>88PQ)\$;."R@DG:R\ MGK0\|C_"C_DG^G?IDG_HQJZ&N>^%')/L_W)\ T8U=#0_4444 %%%_% !11 M10_4444 %%%_%
!1110_5YI^VA_R9W\6/^R::[_Z;YZI+KS3J]M#_DSOXL?IDT MUW_TWSUK0_CQJ5^8GL?Q54445^WF_4444 %%%_%
!1110_4444 ?T;_!_IG!_MR9U\6\I LID7_IO@K\A*_'O_(X/^3.OBQ_V4R+_P!-!%?L)7Y)Q!_R_*WJ
MOR1M^X3@_P\J\ DV\QW_-BG?_
HAZ_*33M8U;2'9I)U2YM6<8\3+2\N\NXX^PNIOX)%DAFA>>1DYYG+/(I')9B>22222>M7=-\7>+&-&T
MNXT/2/\$^HVME= _\ 'W9VU\)'%-QCYT4@-QZBLZBIE3IRCRM)HJ?>M3FYPDTW M?5-WUWU\^H5^AG_!*_I_DV^
_QMNO\ T1;5^>=?H9_P2N_Y-OO _/L;:K_T M1;5^>^*/_)*O_'I3IX^C;_R_X+2_ \HNOC%_V+D/_*66I?B2!/\
R6>6_P#811_L1/I\ZS+_)%U_M;_!+!F?S(4445_JB?A@4444 %%%_% !1110_4444 ?T5?&Z7_*+KPO\ IC'K_M/_I8I?L_
I8I??"5#@X/TKWSXP?D_O?I^+_ _&+7BM?#GIC+>W@M(\$M;6!(XHT"QQQJ_M%55_P_@_ [4^BB@".
I]M+2_M9;&^MHYX)HRT,R\DD4C!5@>""_#1:6EI86L5C8VT<\$\$.82&&% J1J!@*H*_ J2B@_JMK&CZ1XBTBZV/^(-
*MKZPOK9I_M>ILKR!98;B%U*O&Z,"KJRD@J0002#5FB@("MHVC/XUV/>_M)MK'PL+9+>_MQL;*18H;>%%"I&B*
I\Q@_*_I6+XF^#OPB\>*I.\>>_?A9XAV\I\W98.X>3,Z%X\GY2:.Z.B@_KV_X4?D_TI_*DXMM:K=;|IF<|S|_V7?VH?
AU_P1OT\XWS_M_!W\JKPO\60\$ _P_0_!+^%O!L/@6TU%+"\$SLH<:Q?27EM_J20Q[A%;Q&%/B3K%G_V?=\+_!+_!+SXB:
I\T\8:YXRM_Y_.L^)-_M.U,7&FZ7!;W&8H&OK.W0&;:6)F*:G/D_A2<I\Q\9?CA_P1=_8)_;6_9C_:@_MX)JW.O\
B_3O" _S7_P_4I-O)+N21HRL4<4P^V\@2_P\LET\11E80\46I'G)_M,BBDLMCR*\$JLY)?L'X=?!OQQOIFL_%CX\::
M6^ (NM;:=K-_PBOA19?W6@B1"=EU>21B:Z4\$%88X867+/7N_ [#\I7/P*?;?_M\!#OX\?_!+GQ#X\T'PA1/\$?
BVR\1>;SQ1J4>GZ=K,2WNDRRPM=RD1131KI_M\2LN\9\$"[BK_?F\13JX"G5A9MWYE*_FG=?);6\>>H7/T'_X.+?V?
V?OVW\ MVKO_-A^S;X@3Q#H'PY"PI\XMB@>.+5KOSI)##O_9X4W*JN0_S&0KE=K^-_MBO\ P9P?F=?%C_LID7_
*_X*_ GCK^AS_@S@_P*3.OBQ_PIE,B_I_-!%>GV&MIX/AYT8;1Y=_4J+O(_82N#_:_C_Y-N=_JBG?_P#HAZ[RN#_:_C_Y-
N=_JBG?_M_P#HAZ^%RG_D:4\Q_ \$ _XR_LQ_ \$6"&7/(S*"
M3DDUY;165/(LNT'1<7)._H>|*4FHR^))MMI.RV=I%V1U5^-,_KXV_*4XPF\ MPJ^Y3IPC*I3OR3E&,5&3C=_ \$FM9:>)
I^RQ?MAZ_X=_: ?U\IHSP\X2M+_CU)A_M'=Z#OS%<6^Q%=790/G9HQ(6_X?G\YS9G_:_ST3PCI?
CNW^#'\@>|T>|>^(=OQU6_MZU#4UF%AS?_+16RI&O4S28=CD_C_R-U>(T5G+AS)YXKJOC\3X/B5XD@70=,?3?
#VC6:V' _MAO2&<|'+:IT+8X:5V)D=N\,>2_*X^BO4GAZ4\1M)7<4TNRON|=I+7WM+=+W
M^;I8_ \$T<4PD?%1Q?%\$+QOK^Q^BN'Y)EN6UY5WPZ^-EJ\OV+2\%6G3-H5W9I5L>9;VDBNQ+9D#L5OCR2,
M_?W2_P""T\O_RBZ^,7_8NO_ ^EEO7R%?P3\3_8C.,1,5"CB)T)+%6R MT:=SY66.=16J04M\$E>_NJ\;S^ ^|SIC^,7L\,L_7
4?_P""I?AOXK?MC+JN_MA?!BSMET2-"I\BZ73X(KB2\|EK;+)YMW+OE\K)1)2JL=F^H?AYX(_X(I\VO_!3_M'O'KOB?
XZRZ5^S\X8O;>\\-Z9?Z'JM_+XAG\$49>T\BMY)!;.),*IUL?J5^UIXR_X(+>+^ (?I07@G\HCQ\1?BWJ>@_M7Y\,V7B?
3-6-K+J4MNT%LVR33X842_LC1QEEB00HH7_"U^8&@:/+XAUVRT""
M^M+9[ZICMTN=0NE@B+L%#R2.0L:#.69B_H)Z54HKMX8X6APO@IX>GBZU>I
MK.M*_G!15HQBHQ@E%;VM\|K9XW'/'5%.5_.?*:O?>N\>I]"_MK?&#X>:5X?_MV/?L6_LX^(HM1^'GP\D>;4-?
M\!M3Q=XCE0+>:L?IT0P+>V!SM@C!!_>@O\O_M^%O\?^D)WQ8E_8P^<-VL_&?P_X1M_V?@O#VM;:2-#U>|\FMG.BV\I
I\;X+W MB2R6PVB_2%1_P!#8_ (NBO)SGPIRO.M*BFGRZ=%RM2BEY^R7FO/4I/_;5^&_M?M?%?_ \$ M3X\^%='DL-
+5>+>+S4-.M9U'R+_ \A\LR_9_D90&8_D:F\ZU^I?_ _I?HN MO" _&,>L_ |8I?SJU_15_P;I?HNO" _P#V,>L_ ^ECU^8?
2*P=#+_###86B_MK0IUJ48I=(TZB6OHCW.\$*DJN=SG+=QDWVCIFKF?C!_R3^I_WXO_ \$8M=-7,_M_&#
))_>_I\7_HQ:_A4_3SX(_8_P""57I'/I57QRTG\IOX@^%=>TOXA;+!_M%#8>?!_BV\TF^1(IWE_/2J-RIF<_/_@I=V_ /5?
A)^SI\(_@I;:N\!_AR: M2\|0R))XDUS6\3N-2U+5V1/+3\5=W;R33A\$RJ(SE(U)5%5>*|BB@#Y/^G_!_M%CI\A+X#>(IT?
&I/D?IG?X\I_X7OD\Q/^&-A)\KW38+_ _A&I.4V<-M#_Z20" _M#R"IA\MX\XV39C\0=LBO2**_ /I\|C_
(OF_L0ZA^R#IOI">L?_C3\IX9:1E\T_M*[NIVDMYS)) *UTESO\$Z3EY96.JN&_>..I25J;P9_P3P_9N_\$ _PU\9_ \$UIX
MD\;^)!>D;3P9JWC_P_67FLH-4;_IFMH\B0QI^VU.E=K_M10\!O?&?_@D)^QU\;O'7C?
QGKNE^ (=)MOBA)\GQ1\>='>9^RZ?XL>RN\<6\ MW@:I#(C'0\F:W>%G))?:MH?
\F=_%C_LFFN_ ^F^>M;:'>JOS\$|C^*JBBBO\VP"BBB@_HHHH_M**** "BBB@#^AS_ (X/^3.OBQ_V4R+_P!-!%?
L)7X\I_P#!G!_R9U\6/^RF_M1?_I_O@K\A*_) /(^1O6\5^2-H_"<' ^U'_R;=X\I_ .Q3O_ \T0I?DW7ZR?M1
M_P#)MWCO_L4I_P#I\$ /7Y-U^Q^\$/_ "3_C7_D_ \$?TJ/^2ER_ \Z\R_]+84_M445^N\LA1110_4444 %%%_% !7Z&?
\\$KO^3;I_ \I&VZ_P#1%M7YYU^AG_!*_M\ _DV^ _ ^QMNO_1%M7YUXH_ \DJ_ \OJ&OE\ _@M+_RBZ^,7_8N0_
I9;U^)\\$ _P#)9Y;_ -A%_M'_TY\$ _OK,O\ D75O\ \$OR9_ A1117^J^&!1110_4444 %%%_% !1110!_15_P_M;I?
\HNO" _P#V,>L_ ^ECU\I5\ _!NE_RBZ+_ \8QZS_P"ECU\I5_E_XE_ \MG"S7_L\Q_P#I;VW)O\ D4T\A\$?
R1S/Q@_Y)_>_I\7_HQ:45KVXKP?) /IW_M_?B_ |&+7BM?#GIA1110_4444 %%%_% !1110_5I?^*A_DG^G?IDG_HQ\J0KV
M_P""%) /L_W)\ T8U_ 'OT444 %%%_% !1110_4444 %%%_% !1110_4444 %%%_% !1110_4444 %%%_% !1110_4444 %%%_%
%%!1110_4444 %%%_% !1110_44_M44 %%%_% !1110_4444 %%%_% !1110_4444 %%%_% !1110_4444 %%%_% !111
M0_4444 %%%_% 'FG\;) _G?Q8_P'R::I_ _F^>OXJJ_M5:_0_Y,I^+_ _9--=_ M_-I\?Q55\ _P9_ K>J_)F53<****^U("BBB@
HHHH **** "OZ/^#.#_),Z_M^+_ _&4R+_ TWP5_ /'7\#G_IG!_R9U\6/^RF1?^F^"OGN*? _D3S\8_F5#XC\I_MA^X\I/_)-
N\=_JBG?_ /HAZ\RN#_:_C_P'3;O'?_8IW_P#Z(>OSS?^110_MQO_J*1Y\\$_ \R36-_P"O-3_TB1^3=%%%?V0?Y+A1110
4444 %%%_% !1110!_M^AG_2N_P'3;I_ _+&VZ_ \1%M7TI7S7_P2N_Y-OO\ _L;:K_T1;5\5_)W_M&? _R56+_P_ /I/_ D_Y-

```

?7 F7F/ZGR1 P6E Y1=?& L7(? 2RWK^9'OZ; M P#@M+ RBZ^7 8N0\ I9;U A7|>?1? Y(S&?|A# _|TSGXV_Y&-/
?J MPH HHK^E3XP**** "BBB@ HHHH * HJ_X-TO^477A? L8I9 _|+K^=6OZ^O\ M@W2_Y1=>%\
L8I9 P#2QZ_GOZ2 _|O:~ 813\ 2^A|P7 _C:7^! G$^Y MJYGP^)\|W ?B _|&+735S/O@ _Y) > _|7_
*6OX+U\A5HHHH **** "B MBB@ HHHH **** /; A1_R3_3OIR3 P!&-70USWPH P"2?Z= _N2?^C&KH: "B MBB@
HHHH **** "BBB@ HHHH **** "O-/VT/^3_ BQ_V337? 3?/7I=>:~M MH^)\G?Q8_DIKO *_YZUH?QX^J_3V/XJJ*** ;S
**** "BBB@ HHHH * M*** /Z/^#.# DSKXL?|E,B _|-%|7|X| _|&<' "9U\6/^RF1?^F^"OV$K M\DX@_P"1O6I5^2-H_ "
<^U' _FW> _Q3O _/T0|?DW7R?M1 _FW> _P#L M4| _-$/7Y-U^Q^$/ (KQ\ C7 _J) $?
TJ/^2ER_KS+ P!+84445^N\LA1 M110 4444 %%% %!7Z&?^$KO^3;| _|/VZ _|$6U?GG7Z&? _|*| _)-OO _|
ML;~K P!$6U?G7BC _DJ P#~|3| ^C; P G+C UYJ?^VGTI7R| P6E Y1=? M&+ L7(? $LMZ^H:~70^"TO "BZ^,7
&+D/ I9;U^)\$ _|EGEO 811_P#3 MD3^~LR_Y^U; _2 _|G\R%% %%% %?ZHG8%% %%% %!1110 4444 %%% %!1%7 _|I M?
\HNO" _&,>L _|8|?OYD* _JO_X+ M2 _|*+KXQ? \8N0 _^EEO7\R?^UY| _|Y(S&?|A#_P#3=,Y^~O\ D8T _|\ZL
M**** I4^ "BBB@ HHHH **** "OZ^O\ @W2_Y1=>%\ _|L8I9_P#2QZ_G5K^B
MK @W2_Y1=>% _^OCUG TL>OY|^DO _F| _|813 _/2^A|P7_R-I?X^<3| MEKF?C| R3^| WXO $8M=-7, &#
))> _|7 HQ: @L_4S06BBB@ HHHH * M*** "BBB@ HHHH |O^' )/_|W/_|1C5T-<|/ ^2?Z= _N2?^C&KH: "BBB
M@ HHHH **** "BBB@ HHHH **** "O-/VT/^3_ BQ_V337? $WSUZ77FGI: M' _JG?
Q8_DIKO IOGK6A 'CZK\Q/8_BJHHHK|O, HHHH **** "BBB@ HHHH M_H< P"#.# DSKXL?|E,B _|3?|7| "5^/? \P9P?
F=?%C_LID7 *_X* 82 MOR3B#_D<5O5?DC:/PG! M1 _FW> _P#L4| _-$/7Y-U^LG|4? \R:=X| _|% M _|_1#U^3=?L?
A#_P BO$ _XU_Z2?Q^|*C_DI=?H9_P2N_Y-OO _/L; M;K_T1;5^=>*)^*O _|3| ^C; _R_X+2 _\HNOC%_V+D/_ *66|?B?| \A
R6>6_P#811 _|1|/ZS+ _M)%U; _|!+F?S(4445_JB?A@4444 %%% %!1110 4444 ?T5?&Z7 _*+KPO\ M|C'K/_|8|? _|L _|8|?
W _|C _)| _|W^Y _Z:~O$*|O\ A1_R3_3O MIR3 _&-0|T-%%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %
M%% %!1110 4444 %%% %!1110 4444 %%% %!1110 4444 %%% %!1110 44 M44 %%% %!1110 4444 %%% %!1110
4444 %%% %!1110 4444 %%% %!111 M0|YI^VA_R9W\6\ LFFN_P#IOGK^~|O|5?VT/^3_ BQ_V337? 3?/7/55? \A M&?
P*W|JOR9E4W~BBBOM2 HHHH **** "BBB@ K^AS _@S@_P#3.OBQ_P|E,B _|M-%?SQU_OY_P9P?F=?
% C_LID7_IO@KY|BG _|$) _6/YE0^ (82N# _C_P'3 M;O'? 8IW_P#Z(>N\K@_VH _|DVIQW_V*= _|^B'K\RG_D:4\3O/_
M_DUC? \KS4 _|(D?DW1117|D^~2X4444 %%% %!1110 4444 ?H9_P $KO\ MDV^ _P"QMNO_$1:5|*5U _|\KO^3;|
_|/VZ _|$6U?2E?R=QG _E5B _|M&S_3_P)^/3:95_UYC^~O?^I?^477QB _|%R' _TLMZ_F0K^F _|X+2 _\HNO
MC%_V+D/_ *66|?S(5_7GT7_~2.OG_80_3=,Y^~O^1C3_P'Z|**** I4^," MBBB@ HHHH ****
"OZ^O^#=#+ F%UX7 _|&/6? 2QZ_G5K^BK _(-TO^477A? M+&/6? \TL>OY|^DO_R;VG_V$4 _$BH?6%_P#(VE_@?
YQ/N;N9^ _|' "3^ _M|_W_XO_1BUTUM:~>|JOS$|C^~JBBB^V|P~BBB@ HHHH **** "BBB@#^AS _@S
M@_Y_Z^+~' 93(O_3?|7| "5^/? _|G|_P_F=?%C_LID7_IO@K|A^).(\D<5O M5?DC:/PG! M1_P#)MWCO_L4|_P#|$_/7Y-
U^LG|4?)MWCO\ _|% _P#1#U^3 M=?L?A#_R^3 _|(U_Z2?Q^|*C_DI:G_M|*5O?^I?^477QB _|%R' _P|+
M+>OJ&OE| _@M+ _P_HNOC%_P|BY#_Z66|?B?|/ _|9Y;_V$4? \TY$ _OK_O^1=6_M_P $OR9_A1117^ _|)^&!1110 4444
%% %!1110! 15_P&Z7 _*+KPO_P|C_M'K/_ *6/7W-7PS_P;I?HNO" _P#V,>L _^ECU|S5_E_XE_P#)PLU _|"O_I:/
MVW)O^130_P $?R1S/O@ _Y) > _P" _%_Z,6O%:_|J^ _|/ _|W ?B _|1BUXK7PY_MZ84444 %%% %!1110 4444
%>W _|C_DG^G?|DG_HQ|0KV_X4? \)\A_3O\ MOYV/^#R#_D|3X3?| MDTE _|L$|>KDN!HYCCXT^C:33VWT7FF3)V1^F?
_$2G_P12_Z/1 _|<^)/_E= M1_Q$| _|!%+ _*/1_P#,<^)/_E=7|H|??:?ZG99 _/|X_P#R)'_S^KC _|B4
M_P#@BE_T>C_YCGO) P#~*C_B)3_X(I?|H _^8Y2? *ZOY1Z^~4|+/_Y?
M'_Y$=G|7' _$2G_P12_Z/1 _|OSXD_P#E=1_Q$| _|40^CT? _#/_B3_Y75_* M/_11_J=EG\ _|OC _|
(ASL_JX_XB4 _|^~*7_1Z/_F?~$G_RNH_XB4 _|^~*7_ $>C_M_P'8Y2? *ZOY1Z^*/|3LL_GG|?) _|$.=G|7' _$2G_P12_Z/1 _|
<^)/_E= M6GX+ _P"#B+ _@CK\O_&D^ _|! _P"V|!LU?7-3@T_2K3_A7_B&S|F:18XDW/_I
MX5E_L6 _|GB _|; _LIF@ _^G""HJ<(9:"FY<|_%WC _/(\A_MSL_M5HHHK\Y-3XV _| _|L^/GP3^~
EIX1^&/CS^S-_EV07+V_P#9=K-F5I9E_M+;|8F;HBC&<=<~*0_P''A?|8' 17O_*|I _|\CUUG_15#_DY&Q _|_%U _|W%_M?-
=?TWPED&18GAO^U:V%|IRD\X)MN$6V_-M79_G1XH<~;~9?X@YEAL+F>(\TX5
M9^,8UJD8Q79)222\DCVC_AX7^V! T5| _H&G _|R/1_P|+ _&P/^BO?^4#3_M_P#Y^KO~BOHO|6N/^~@*E_X+A_D?|?)
$0^/_P#H;XK _|^*O_R9|1_P|+; _M_Z| _Y0^~L_D>C_AX7^V! T5| _H&G _|R/7B| _|^K7#G_0%2_P#| _|^!I_P_CT?)
#PO|L#_H_MKW_E_T _|Z\7HH_P|6N'^~@*E_X+A_D_ $0^/_/H;XK_PHJ _|"9|1_P|M+; _P'BO? \A_E_T_P"1Z\A
AX7^V! T5|_R@~? _/(\>+T4?ZM<~? 0%2_M_%P_R#_B(?) _/T-5_X45? _)^E?@+^W)^U+XT^~
GA/PCXE^~V'G3M3\0V_MEK?6_P#8EBGF1/_JLNY(0PR^1D$'WK|'Z_)O|EW _|.0^"?|C;8?^CTK|9*_
M$_%+~+~|E^98>.%1IIP;:C%13=^MDC^P_HV9|G>>VXZIF6*J5Y1JDU)RFT
MN1_R9Y\*R|?)^PS8VYQG>C|6DJ_YIR>E_MGW3|+ _B+&_ZL& _|RG _|ZZ/^(\; *_L&_P#_I _|WKK|=Z*_K;_B_A1_P|"
M|_RM7 _|E| _|K3GW _/|_P_EC _|G|$_?18W_5@W_F4_P#|UT?~18W_%8-_M_P"93 _|O77X|T4?~0^~\A_H7?^5J_
_M#_6G/O^?W_DL?_D3|B\B+&_MZL& _|RG _/N>C_B+&_ZL& _|I _|'KK|=Z^/_|^#^% _|$+O_*U?_P"6A_K3
MGW _/|_R6/_R|O^' _|%C?|6#?^93_P#O71_Q^C?|6#?^93 _|^|=QO11_O?P_MH_Z^W_E:O _|^+O_UIS| _|^?
^2Q_~1/V(\XBQO\JP; _RG_P#>N04?V+^~M^C#3 _|G _|;B'V2LV?<~P# _|^"6:B|K;~7_"POM?V7;#)+N^G^SX|_P|S
M&-Z|-L912>2I/4FL;_A;GO#_Z&#_R4A _^(IOQ_M7_Y*|J/^ _|^Z+6N=H_Z3_A;GO#_Z&#_R4A _^(H_X6Y\0_P#H8\A
R4A _^(KF_MZ*_D_X6Y\0 _^A@ _|E(?_B^/_^N?$_\A_Z&# _|^E(?_B^YNB@#|/_^N?$_/_H8_M/_|2'_XBC_A;GO#_
_A@_P#)2'_XBN;HH_Z3_A;GO#_Z&#_R4A _^(H_X6Y\0_M_P#H8\A_R4A _^(KFZ*_|O?AO\1/&_O\ C"UTO5M8V"19"\V>-
_J)F53<****^U( M"BBB@ HHHH **** "OZ/^#.# DSKXL?|E,B_P#3?|7|~=?T.? \G!_R9U_M6\A
LID7_IO@KY|BG_D3S|8_F5#XC|A^X\ _C_Y-N|= _P#8IW _*(>N\K@_M_P|J/_DVIQW_-BG? _|HAZ _|I_Y&E# _|" _
*1Y/$ _)-8W_KS
```

MM2U[5+;1-L9+FO)TAM::%=SRR,0JH[DD@5M1Q>\$Q\$92I5(R4=VFG;KK::
M0Y,5E>9X&I'GB:\$X2GK%2C*+EK;1.*^NFG70KT5?4>&M8\&^(KWPIXA@CBO MM/N6@O(HKF.98Y%.&7?
&S*Q'X.">015"MH3A4@I1=TJ4ULT<=6E5H594ZD7&A46TTU9IK1IIZII[HSIEW_DY#P)V-MA_P"CTKJ9*_)OIEW
)0V"?JC;8? M^CTKJ9*!O!G D;8; 2C^V H_K P#)-9A_U^C_.D(* G5_P"BW_F*+X_H M_P"Q-?^2-S+_L'K?
^FY;EG_(RH_M_P')/YH IOHHHK_*T_.' BC3I\$T72;5IG5-6U6I2WMK2%!EI))'(5% ZDC% M
&G17AG@W_@I/^Q5XYU[POX>T?XT?97\<2M'X)OM=\.EI=CXB<\$#;87EY;Q M6IXQ)4 0R.6++C.1GW.@
HKYZ^./!5W_@G?^S7\4-3^" OQ :HV/>'?%.C> M3 :FC7<5PTMMYL*31AC\$RY;?V?=IIFI:I
(S+8VVHO"+.XG7S8_W4@^(M-BOI'NIO3+BRDGM1%#1R&&YCCE0 M,I#>#BD@@"#6_0!T_P?
P"2@67^Y+ _Z+:O:~6^# \ R4"R_P!R7_T6U>TT M %%%!1110 4444 >:MH?F= %C_LFFN ^F^>OXJJ_M5 :0_Y
[+'_9-- M= \ 3?/755?&?P*WJOR9E4W"BBBOM2_HHHH **** "BBB@_K^AS_@S@_Y_M,Z^+^_93(O\ TWP5_/'7I#G
9P?F=>?%C_ +*9%_Z;X*^>XU_Y\$ _6/YEO M^(_82N#_&H_ ^3;O?^ V*= _P"B'KO*X\ :C_Y-N= _P#8IW_ *(>OSS* M?
^110_QQ_P#2D>3Q/ R36- ZI_U/ \$B1^3=%%?V0?Y+AH1110 4444 %%% M!1110!^AG_!*[_DV^\
^QMNO_1%M7TI7S7_.\$KO^3;I \ [^VZ_P#1%M7T MI7\G<9 \E5B \:/ \ "3_DVF5? \ 7F/ZGR]_P6E_Y1=?&+_L7(?
\$LMZ_F0 MK^F_ @M+ _P_HNOC%_P!BY#_Z66]S(5_7GT7_P#DC,9_V\$/_--TSGXV_P"1_MC3_P?JPHHHK^E3XP****
"BBB@_HHHH_*_HJ_P"#=+_E%UX7_P"OCUG_ -+ _MK^=6OZ^O^#=#+_E%UX7_]&/6?_2OZ_GOZ2 \ R;VG_P!A%/_I
(J^UOI?_(VE_M_@?YO/N:N9^,')/W_?B_ \ 1BUTU:2MH?F= %C_LFFN ^F^>M:\>/JOS\$IC^*JBBBOV\ P"BBB@
HHHH *** M* "BBB@#^AS_ (X/^3.OBQ_V4R+_P!-%?L)7X]_P#!G!_R9U\6/^RF1? \ MIO@KIA*_)./^1Q6I5^2-H_ "
<^U'_R;=X]_ .Q3O_ \ T0I?DW7ZR?M1_P#) MMWCO_L4I_P#I\$/Y-U^O^\$/ _"*3_C7_D_\$?TJ/^2ER_ \ ZR_] +84445^
MN^LA1110 4444 %%%!17Z&?SKO^3;I \ [^VZ_P#1%M7YU^AG_!*[_DV M^\
^QMNO_1%M7YUXH_]DJ_]OJ&OEI_@M+_RBZ^_7_8N0 \ I9;U^)_P#)9Y;_-A%_ TY M\$ _OK,O\
D75O\ \$OR9_ .A1117^J)^&!1110 4444 %%%!1110!_15_P:I^ MHNO" _P#V,>L_ ^ECUJS5_ \ !NE_RBZ+ \\
8QZS_P"ECUJS5_E_XE_ \ G"S7_M_L(J_P#I;VW)O\ D4T\ \$?R1S/Q@_Y)_> \ I7_HQ:5KVKXP? \)/W_?B_ MJ&+7BM?
#GIA1110 4444 %%%!1110 5I?^*A_ DG^G?IDG_HQJ\0KV_P"% M'_)/.W)\ T8U_ '0T444 %%%!1110 5_)_P>0?
 \ GB?";_LFD0 \ Z<)Z_M_H;K^>3_ (/ (^3O/A- _V327_P!.\$I?1<+?CB/H_P_B) _"?D\^- \>?(2B
MIX5T#XG:R^F^&KIQ)8V_#48V_ :UL7N\$6>4\$]_L9=L^U?T*_ML?L?:M7_ / _M (\$*_LP7?I"?
@Q;:IEQ[K1]!8^#/'ELC;#;M>.=0NM6MUREU'-8N&%(W.), M\$C0^>?&VE;#-JJ@K9+>7<5N9_MR"0"\$ \$F!
Z5_0%Q_X*#6G_ 3B_P"JW@?_@B'8>IM7^"QX6T;POHMSX_MAO)M0/4KZ-
I\$N_FF8B6VD>=+9I<*L42J\$?J^AC?ZS/G6M#V/O-1FW%I): ME?EAA:LW_CV?(\$ _"?%K_ 8B_ :EC_8-U.?XI_#7X#>#?
%/Q\$DOE73M?^Z6V_MHVFB6;J"?L=L^0+(KPSHUQ!%I^H*W%K;S3P^9-(D<:"6;JW%N!_D6-0=M?(/
M@3PO^UU^R_JEM^U^X.^/BWPT/!_BJ32XO&5QX7D:RT_68@5DLWEFB: 7"Y(M,+Y8?W:]+#SPV)P\$*?-
S7C'105W6G-:O^/F2IIGZ> \ !RA!6?@=\:OV-/V: M_BYI0/@YIW@_IH:QMHHMKK^O:996IBGM-&FLF,T5PQ
:_P#!03I_OSPQ_P4>_X-OI"^/G[3?A[2?(BKIOQ2@ \ M.Z)?06RQ->ZC:LDN;JW0_-!T^74S=V.DZ)JTR+!^21-
:BV53F"X:.1HS+%MD96*Y(XKQ)@:V) MRY4?A=.OI5ND_M_M0?%RTM?ACX>E^/?##P+I2>/_A3X3=O\ D&:-
QVR2XX:ZN+W\$AR6EE;YB% M7'N_QMT;?LI_#GPI_P_\$M- \ 416WQ-^*OB#2=0_ :3\4O+YC:?--C6'APR9^
M9;S1=7?)W7+A^"V(G,5^C4G_!\$I@KQ= _P4)9_ \ !FP@!NF:7X6T;I^S^1_M:XV1&.00:^=3^SMJ.I8-0E6O)*.C\E9,:\
MY7T\O45FS^?Z02_V+? \ D\7X3? \ 93-!_P#3A!7FIU!JFN9+;S4D\N0KYD:9
M5L'&0>XKTCIBW_D\7X3?IE,T'_TX05IM;^#+T9*W/I5:***_ \$H/SS_X*H?
MG(V/_8IVO_H^XKC/V%OB=X^\$ _J1.F>?)B!)!8S6TUHE_*N5LY9%_64^@ZH_M6I!R3P#79_ \ !5#_).1L?)
L4I7_P!W%8/ _!EOALO2EF?B-ID5_9TWI@_MF^QY?IH;HIGWN-VSS=N?XMN.
<5_2V!JDO#6/M(RE^V+NH[OI];_D_1G^>6<+_M\$OZ0D_IJ2%.?UR-I35X)J2W5U?LDFFW:S3U/HR[^#0_9%?)?
Q"_:HBDGU_P!MJ^B7+1Z+(-0)+BXN\$E<2<%(?4J3YA"N<@XRWY_=S%L_9/0=J^YOV2OB;_M5/_GB?XEZ1^T>I
I; >%=DN;RXO>=C;RHKAYSNA8^'6569@BYIV@J/GY^>?" MOI*UQ0?
@#XH_:TGOJIIA9:+>3B#19D+T;:6VM)NPCX_MIE93L,TZU2FFX2MIL>G*U%-R2:'^VS^T1X;V:-X
^&7B9=\$TS2I&&TM+_M"STZ"9I9_IOD9I(V8LIEFP!NP!QDJE^V1\6-4C^_W@?PG\0M2;66"6.GMX
MC;8F+F]6I:BIMW?VDSX>IQ7Q)3X&OB\74J*O6A&G" M4Y.\$:>'2DI4V^5)SE24;)+JW**ZGW)?
!F^%7A_XY>./CUJ/C32KIPMJGPI_MM8-/\$5I&[7Y+#+I,L6=_F?*P92_5#9;_YKY?^&T0^!PV/QPOH(>)M>66R!
M6S+EK9.4N-3Q_LY,47JY9L'9FN8^""PTL/B#XEGU#Q7>O9>&-IM3J'B?44',_M5LI_\$>LLK8C1>I9LX(KUSIE?
XE>&OBQ^VWH_B?QY96EG91P260A32W(^SZ_M>(HBMI;H#QE5SM/>0IA\QKQGE='(-
B(TG^K%&+_J+;A:47R4^NLJ7-_RZ;2S?#U)RARN\$W'35_M.R3NO+6WJF?F/&?#%A;'4*4O.JM*-356E&I1Y9*
IUIWF7>,DI?>?LN \ MR)^3_L;#_T>E2K)7Y-_LN_IG(>!\A_L;:#_P!^I7R5^/>+W_(TPW^! \\
MI1_5WT5^2:S#_KI'_TA!7ZO_!Q:_RE%\4?IBYHW_I&E?T55_ _K_P_'%O\MRE%\4?_8N:-_P"D:5I1I&C_
)%.5_I!ZG_I=, >,>_ ^100\:_G+ _ \ !#/X_M/_#XX?
 \ %\$?"_@G]HG3+4M,73KVITC1=5"M;:EJ,48:&&1&XD4+YDGEGAC\$ M_0P)4_??A:X'?%GX?_MA_M(>\$O\
@IV%U'IFVZ':AJWA14I>53HVGHUI\$MA_M'IF1MLKJ.W;:/R8-LGF1H0&)C9O@;_@AI^QIX
_:FLO!GO+ \ 2ZAI^E^%M_M"F\2M#I.H:75I+;7%O'%#/'&1)\$=\ZR%HR""Q-M*DAE_23I@:IN?PI_ _%<_MV^_W!"]?
I9WPKTNZMM*:]O=*F2(KLTM;LP*KLY)CNK5I(=EP^&.:3AD9G_50% MG%8ZCO)BL1AY2J4*5"BL0DO?
P9UFXU<_VU^?^*^:RTM%MO:/@Y#^E+!TX32_M4I2ER=IM1UC/RUT^?S_!R3R_ ;RB2N3MW#G';-?0_P#P3F_99\ \$M
_3PWJ_MGQWO)[X=IXUT?1-0:[9=9U&^NDBMM+M^02SY:25@?W5O%*^=QC5N1TI1B7_MII#Q=I(?
%OI2/PU^%VIZI_-!^J3VFI>+I:RQ""C89D5"XDD0^R.S(K^@:YB_M,&OT-_9C\#?@\$@O"C+IG/3?#GI>NNZ?
XAI&:KH%OHGPII_"UUIFN_\$LES;3_M7#3S-9X>6XNE2)I2X58HXD4A(EK16XVXMHX')ZE/!2G.3YXRE1A*K^BU#FM)
M04G3F[IDSY>5-S^RD_"RW_2JXA.K9+1I2:BI:VTO:ZWVWVZZ>+Z;?K:@016.F_:7B<)MP(U2',_8"A?:OMWQ%_M?
A+XD_::^OI/(O/N:~9? _P_ \ L:7=6'AXPK'INAB-I#JNMT^YI,N^9O_ M7#DQ@ECM&/CO_@YZ+?!BR_:K\>+I
^ (EU=>_KIP_:'^ (O#VC+86,>3:W_M'R%_&:5GF!4.2/+&0_ \ (7P0=?MJ_MB^)=%_9"T+XI>((K3:-MX=/O8I3UN
M06EII-KOF+7^O^K*IT?N_#GBAU^RSTI'4S0^VFYQG\$2!_M<^S17A_Q1^)^OCCXS_ \$6_BQ\2M?FU37_!#J4M_JU_?
FFED8LQOT51G_48" M@_"OO?IE;P\A_L]_ \ %/^"AGP_P#V)M\$DNE^_GPTL:'A_2Q*UO^XF>?>_M.MN0G92&66I]N-
LCI<_D^+&NPKD:W12'I^OI^Q2_XL_&O\ :LT+X9+>X^5_M?^+XIZIX?T5_ _#UJ+2^"T==0M+>?SFC419^C6\&V8CS6.
(#_VYC7W5/C/_9=Q_M^EF-*_KU_8Q2LK4:=^KTN?FI7U#_P1:_Y2B_!W_L8YO\TCN^*7J^H? \ @BU_RE%^#O\
MV_ _CMK)M.TI3Y_MI.(VP+"3I?O4_ME&'EA7:P#XC_H>C0OQK&79MJ@:F)IS7X_ \ !7SIEWJD
MIX^_"SIF#QA_P32AT34_BSXDMM.T:3I#^ \ IS\$;RTV&Q0Q7ETD!S_ID)"&T_MFQD#L;(\$V?
HY6/^"L=A^SM_P4)^%G_!-3QA\$?\$.OZYXVT6P: ^ \ V_X2" M*XG\R,21VYC)GA#PNTL@=!&-WRML(H=XI_X(?
 \ \$X/B= \ 1/GI0G14?POE \ M<*>?%.07FL:OK^L^)-0LX\2W9R8;>_ *VN8XTB@ @6./>06;RRQ(SM'BO_19_M_9&+7/I
QV^+OI.GAF/P7?>=>11#:/SYB=+T2!;FQTD_K^2DC7\$I<_MDD^8".U?0W_ \ 7XT>)OA1^P^XF^?#ABWC/XIWUG\A
P7;(^UYI_5Y?LQ52_M.0PMS<'.04'UKWWJIGGX^&?V<_@1X.^_G@Y1_9G@IPU9:/9N\$VF5;>%8_ ;_M_:H_MU?
M/^ (V=?AE8_M>'OA)HD&N?%+X@:H/#WPM)-RM\MWJDBDFYF_Y6TM8PIS_ _\$<6_@NM?'O_!6_M'IF^XF_LB?
!#+QE+?@#K>KZUK=QJ%OJGO:\50!OI0\0&ZNEDU;4)BGSD2_M2%=XR0ELI0GRT-'Z)>_OB \ /B'93^X7^/-
!URVTIQ!<'0=4@N4MFOQ&WDL_M0AP.%..E;U?C;^R*WB@?%I_V:E_9FR/"K?L>>'C3AHW_'IIC_LNI^S_:=G_M&[S?
L.V:N<L.V:_9*#@I_@_ _E_LO\+?! \ Y^I9?IDO_HMJ_MIIH **** "BBB@_HHHH IT_0_YI[^+_9--= \ 3?/755?VJ_MH?
)G?Q_M8_DIKO_*YZ_BIKI_@S^!6I5^3.JFX4445IJO%%!!1110 4444 %?T.? M\<'_)G7Q8_I*9%_Z;X*_GCK^AS_

(X/^3.OBQ_V4R+_P!-%?/<4\B>?K M^\RH?S?L)7!_M1\FW>._P#L4I_-\$/7>5P?I4?)MWCO\I%._P#1#U^>
M93_R-'^.^Z4CR>).^2:QO_7FI_P"D2/R:HHHK^R#_"7"BBB@ HHHH ** M** "BBB@#I#/^"5W)M]_P#[C;=?
^B+:OI2OFO\X)7?FWW_P#V-MU_Z(MJ M^E^_D|C/_D|L7_C9_I_X2?)M]_P"O,?U/E|_@M+_RBZ^,7_8N0_\I9;U
M_A7I-_6E_P"477QB_P"QOYD*_KSZ+_P#R1E,|'"_FZ9S;M?AC&G_@_5A1117?^GQ@4444 %%%!1110
5_15_P:I?^HNO^\V,>L_P#I M8I?S]U_15_P:I?^*+KPO_V,>L^ECU_/?TE_P#DWM/_+?"?_I%0^MX+_Y& MTO\ _SB?
*T4 M44 %%%!1110 4444 %%%! 'M_PH_Y)_IW^Y)_Z:NAKGOA1_R3_3OIR3_T M8U=#0 4444 %%%!1110 4444
%%!1110 5YI^VA_P F=_%C_LFFN_\MIOGKTNO-/VT/^3._BQ_V337?_3?/6M#^/'U7YB>Q_%51117[>8!1110 4444
M %%%!1110!_OY_P9P?F=?%C_LID7_*;X*_82OQ|_#.#_DSKXL?IE,B_M_P#3?I7I"5^2<0?
|CBMZK|D;1^\$X|I|_DVIQW_V*=_B^K\FZ_63I|A_MY-N|= \8IW_/Z(>OR;K|C(?_D5XG_&O_\$D_B/Z5')2Y? \I>9?
^EL* M***_7#^60HHHH **** "BBB@_K|I#/^"5W)M]_|_|C;=?^B+:OSSK|I#/^"5W M)M]_P#[C;=?
^B+:OSKQ|_Y5_XX_|?OOT?^3EQ_P"O-3_VT^E^*70^TO_M_"BZ^,7_&+D/_I9;U|O0?%I?^477QB_I%R' _-
++>OO|@G_DLIM_|'"_M_IR)_69?BZM_@E^3YD****_U1/PP**** "BBB@ HHHH **** /Z^O^#+=+M_E_UX7_|&/6?
_2QZ^YJ^&? _@W2_Y1=>% _L8I9_P#2QZ^YJ_R_|2_^3A9K_M_P|A^7_TMGI:DW_(IH?X(CDF?C!_P
D_O?I^+_T8M>*U|5|8\ DG|I_OO? M^C%KQ6OASTPHHHH **** "BBB@ HHHH *|O^%')/_|_W|/_\$8U>(5I?^*/_M^2?
Z=_N2?^C&H_Z&BBB@ HHHH **** "OYY/^#R#_D\3X3?IDTE_I_|\$|?T-U_M_)_P>0?^GB?";_LFDO_<*)Z^BX6_Y\$?
1_D1/X3?;:YN+.XCN|2=XI8G#_MQ2QL59&IR""_.00>OP^&/BOX*:7|1=%|3>\$/&V|7>J^)/#?CO
MPE8ZS:7EY=/YES*RW,3\$^:_SLA.PMEMH8DGY9HK.>#PE1MRIIWM73;|N@79 MW'OH_.;^+?Q|;2K;XB>
(+8Z9H\$\$_L/AWP|HVDVVFZ5I\$O%'|_/QJT^X|>|O#VAZEKGAFI-YHL?B+3S=6UO=A6\$
M55Y6Y0\D3E98|V5B(2KQ6|Z45M|^G|DMIV_O\B7Q3XD\8^)|_.;^*|=N MM1U?
5;^6|U+4KR25W/+.SL6+^DDDU|5>(/^"W|/7>B3PSJ-O?_MB_14|6ZS/VXO
^L_\$Z#2BOB*|V|QRR2K9/<>9Y0):5|UPL2W#<:I25|'R-14 M5E_L6_P#)XOPF_P"RF:#_M_G""JK?P9>C!;GIJM% %%%?
AYT^YY_P#|5#_DY&O_|%_U_P#1|O7S77TI_P_%M4\ DY&O_P"O3M?_\$?<5\UU_67|G_)*X3_
C_#Q;_Y.7FO_7Z7Z%FIUG6-_M3BC@U'5KFX2+_5|/_SA.W)_X|)+JZCMWM\$N9%BD8-)\$'(5B.A(Z'&CHKZ11
MBE9+0_/95*DIQ9@UC5K;39I&MM4N8|_Z='N:1)V\$4K+G:64'#9."1ODU71WC<_C%64Y!!
MP0:2BA1BKV6XW.)=0U)H\$V0-?WCS&-?1= MY.!|"L^BBE"\$<>6*LO(JK5JUZCG4DY2>
|;N_O9WG|+O_R|@3_L|;#_-I M7ZR5^3?|+O\ R+W _-._@?_I1_?7T5_P#DFLP_MZ_1_|05_K_,'%O_*47Q1_V+FC?
^D|5_157ZQ_|%_P_I1?%'_8I-_Z1 MI7UT/^3A5?^P>I_P"ETS|YXS_Y%"_QKF?(P:~/_Q4_9Z^)&F?%WX+>-|
M|P|XDT>4R:J|M_X#OD@JRD,"KHRD|T,"K D\$%'>H>)"^"CW|3VNZ:XPL="U
M3P|X6G^(08>.|4|'>\$|+3+W758DR)-!/&'5'9F9TC*+(7;<&S7@|?%W|B|VER
MC'XA5\3AX3FDE>44W9/F2NUJE+W DGH|:K74_Z>)Q%*");2|_+M|O|D^' MG|??
|5GPL_9@|1_L=^!_B>|GX|5322:OI/V" |W82|JS1I,R&2-) BAU5@#S MTW/NR^' COQ7|+?'NB?\$(P|)JOV'7/#FKVV|:-?
>1'+|GN|>5989-DBLC|71 M3M92IQ@|CBLBBM*.5Y9A_>RHPC|9N52T4N=M6;GI|S:T;=[HF5>M/EYI-|N
MBUV|_OZ#^TM^U-|= _P|L#XE?|+>_+|=?)%XB.GO67|H_V9:VG|B,L43R|6 M*_/C>W.W)SR34/PN_:'?|SX>>-
OA|XIAT^S'C|2XHM+UW6OLS&_73UD\$DEG
M#^+NQ%R,|RD0%RZH|DI<@|)11*MA@H8.%&:;_7E@HI17*TXI15DDFDTK6T M|UZS|JNHY-R=
|N^NN^IU/P3^~7Q._9U^*>C?&GX-^+)|\$|2!:=?;_U*W"L8V M^E65E8%71D9D9&|5E8@@@FO2_P|H' _@H;^T!^T-|
KGX:_PFA^??"NI>*|KQ M/KFA>%-/>VAU;6+AR|MY<&221W8L21&6>-J#;N"/"Z*SQ&393B|=3QE:A&5
M6%N632;5KM:~3;Z_KOU|A7U#_P1:_Y2B_|W_L8Y MO_2.XKY>KZA_X(M?|I1?@|_V,9OK_R1N9?|@|;_--R-|L_Y&5'
M_"|T?TWT445_E:~N9XC|5_^2@:C_OO_^BUKG:Z+XK_|E_U'?C_/1:USM M&9H?@GP9X8N|B_|
#7A+3-._GNSFZGL;."%YCG/SE!;DYJW-I.E7&HPZO/I_MEN|W;HR6|T^F2)6QN56(RH.!D#K@58HH
JZGH6B;T|M+K.C6MVUE#?"&I^)'K'QK|7A73;C6=+AFATS5I|&-_M|FTCEV^:D4I&^~7VKN"D|MHS
KOFABN|E|GB5T=2KHYZ#_|\$S|^10|SWP_M_P#A%*|A-|=VOPK^&A|PS%?S>=?1^|J%|LEN9.?
GD\$*+O;D|G|YKH:**_MG^#_/R4"R_W)?|T6U>TUXM|^_2@67^Y+_.BVKVF@ HHHH **** "BBB@
M#S3|M#_DSOXL?|DTUW_TWSU_%57|J|OI:)_G?Q8_DIKO_IQK^*|JOO^#/_X%_M;U7Y,RJ:A1117VI_4444 %%%!
!1110_5_OY_P<^'|_G7Q8_P"RF1?^F^"O MYXZ_H<_X,X/^3.OBQ_V4R+_TWP5|I|O3_>B>?K^\RH?S?
L)7!_M1_P#)MWCO_M_L4I_P#|I\$|7>5P?I4? \R;=X|_|%_._1#U^>93_P_C2A_CC_Z4CR>)_P#D_MFL;_-
>:G_I\$C\FZ***_L@_R7"BBB@ HHHH **** "BBB@#I#|A_@E=_R;??_M_P#8VW7_*(M|^E^*~:~"5W_";?? _
8VW7_HBVKZ4K^3N_P#D|L7_(V? MZ? \A_R;3^O^O,?U/E|_@M+_P_HNOC%_P|BY#_Z66|?S(5_3? \^I?^477
MOB_|%R' _-+>OYD*_KSZ+_ "1E_|'"_Z;IG/QM_R:?)_@_5A1117?^GQ_M@4444 %%%!1110_5_15_P:I?
*+KPO_V,>L^ECU_K71%7_|NE_RBZ|+_M_P#8QZS_._ECU_/?TE_^3>T^PBG_P"D5#ZW@O|
Y&TO\#_) |S5S/O@_P"2_M?WO^_%_Z,6NFKF?C!_R3^|_WXO\ T8M?P6?|9XK1110 4444 %%%!1110 M4444 >W_
H_Y)_IW^Y)_P"C&KH:Y|X4? \D_T|_|%/'- _XCT3PK=ZY=VD|D@TFQ91=-D?(A;C/U|_M*_-BO" _^&L/C9_T8_XI_P#
JV_~^H_X:P^-G_1C_CO_,"K;_XJ@#W2O-/V MT\ DSOXL? \9==_P#3?/7+?|-8?&S_*_?|=^!5M_57_&CXV?&SXO?|
MWQ9|O\ AC?QWIW_E'AF_TC^T-UM-|F^TV|P^;L|Q=^W?NV|ESC&1UK2E)
M1JQ:V30_CYHK|6_^(6:XV?|I%|= _P#AIK;_.75'_ \$+~:/^BC^._ \PTUM_M_P#+|JOU/ 67)/^?O_D|O|C'DD?
E|17ZM_P#\$+~:/^BC^._ TUM_|+|C_M_(A9OC9_T4?QW_X:V_~75^~LN2? _?_"67^0_P##&7CNR_MO_M29|+
|9YEM)Y|EQE-^S>N|&#?^~K_P_DJ? \R_?0#^6 MO^A=_P"5J'_RTCHKUS_(8V^-G_2/QW_X3MM_F4? \;?&S_HD?
CO_P)_MVV_~3?^~(B|&P#05_Y4 _D_X@^X'M?|'_|P_K4|Y:~1T5ZY_P_?&S_M_HD?QO|
)VV_P#DRC_AC:XV?|I\$C|=^\$|:?)_E'_\$1>#? \H*_|DJ?_"? M|O#^6O\ H7?^5J'_M/(Z_O\$@E=_R:?? _
_8VW7_HBVKY/_P"&-OC9_P|\$ MC|=^\$|:?)_E?0O|*_BKXV?LS?#>?X? \G>_|_5I;W|7Y-M;:=|<:;-GF
MOG'EYSGOTXKXOCWB_AW.L@>&P5?GGS1=N6:T5|ZRB^)^O>"/A7Q|PAQPLPS
M?|^RH^SG^FI|EJ|65H3D^G:Q|?U|O?%I?^477QB_I%R' _TLMZZW_AK#XV? M|&/^._ \P*MO_BJ|N_3U|XV?M?
++OC'IFS_AE+QWX=_X2S3DM?|:|BVN_
MLNV:~7=Y/G|I_N8QO7KG/&*_+N%L:ALNXFP.+Q\$N6G3K4IR=F|1C.+;LDV|) M|1|OLC^N|=3G6P56G|7;C)+U:9_-
I|7Z)_|\$/3|/A_H>._P_P#PVUM_|M|/_M^(>GXV?|!KOW_P"&VMO_);5_?O_'!CPH_Z&A_Y1K_/RH_*?|5L^_Y|_<
M31_~2/SLHK|S_P#B|T^-G_0:|=^&VMO_EM1_P_O|/Q|_P"@UX|_|#;6W_R_MVH_XCOX4?|I#'_P_HU_|Y4'^JV??^? _?
":/_P_D?G917Z)_|O|/Q|_Z#7CO_M_P-M;?_"VH_P"(>GXV?|!KOW_X:V_~6U'_ \$>/'C_H8_|E&O_/_@_P|5 ML^_Y|_DT?
)(_RBOT3_XAZ?C9_T&O'?_(;V_|EM1_O#T_&S_H>._M_#;6W_RVH_XCOX4?|I#'_ _HU_P#Y4'^JV??^? _R:/_D?
G917Z)_|O|/Q ML_Z#7CO_-M;? \RVH_XAZ?C9_T&O'?_AMK;_Y:4? _>/'C_H8_P#E&O_M_*@_U6S|_GS_
_31_P#DC|I%_<#+=_E%UX7_|&/6?_2QZ^YJ^% _@G3X>^~G_M|_?|+NE_LV? \T>._%G|FZC>77|IM?
8+;P\$SYFEV^3|HFOQMSC_YQG_Z5|I_MPUA\^H_Q_OW_X%6W_Q5?P?
QQF6"SCC+;=_@YU*K6J2B|~7C*3:=FDU==& MDS|2RRC4P^74J516E&*37FD>G?&#_DG|I_OO?
^C%K6K6C*_|HWXV>+/#|VA? M|_5^_|?SBA|WSK9|6#=-X|6N+_.SN^~G_\$:;X|_I|6W_=_KY4|CK**Y
M/_A+OC9_T:;X|_I|6W_QVC_A+OC9_P|&F^._^5M_P#':_LHKD_~N^~G_1_MIOCO_OU:?'_|^\$N^~G_\$:;X|_I|6W_
_H_ZRBN3_X2|XV?|&F^._^5M_M=H_X2|XV? \I|OCO_OU:?)_QV@#K**Y/_A+OC9_T:;X|_I|6W_QVC_A+OC9
M_P|&F^._^5M_P#':_LKV_X4? \)_ \3O\ &#|O|H7_#%7CN?|&F^=;+NRQ;IO..OKO|I" T5X7_P_MUA\|^C'_?_
(%6W_Q5'_#6'Q|_Z,?)= _@5:~?_4>Z45X7_PUA\|^C'_M'_?_(%6W_Q5'_#6'Q|_Z,?)= _@5:~?_4
>Z45X7_PUA\|^C'_?_(%6 MW_Q5'_#6'Q|_Z,?)= _@5:~?_4>Z5_)_P>0?^GB?";_LFDO\ Z<|Z_?_M_(P^~G_

s8_X\ "K; *K\?~R' 3'-G 5J\ 7A/XL\ (7X\^' M/ PB AE\ (L_ A\$+;+?

 M.ZX>;S= _IH6^S\^W;M;IG/:O:R#%X?19E&K6E:*3 MULWT\KDR3:/YX:* 50\ XA9OC9 T4?QW P"&FMO _)=4?

 \0LWQL Z*/X\ \ M#36W P_NJ\^1 UER3 GI _2R P C/DD?E)17ZM \0LWQL Z*/X\ /#36W R MZH_XA9OC9 T4?QW

 .&FMO\ Y=4?ZRY) P _?)92Y\ R2/RDHK16 P#B?F^- MG 11 _? (:V\ EU1 Q"S?&S HH CO P --;? "ZH P195YGIL

 LW:-N\ Y.P<8J*O\$F2RIR2J\ \ F7^0*.KG\ \ #1%>% \ #6^Q ML Z,? \ = ^15M P#%4? \ #6^Q L Z,? \ = ^15M P#%5^5FQ\ S

 \ /5# DYQ\ \ I M\ U\ I W?>? =24W5? \ P\ ^-G13 Q\ (@^7 SIXIT3R=)BL0L?IF6USNV22/OW M :4QGS,8QVZ\ UYK _;?

 &S _*)X\ \ VV ^3* H7AGCGA;+[\ PV&Q\ (Y9P MBUDR3=GZ\ +7W, A#Q%&?&K/>.,?F&I/P\ \ 1JU^*,O:T5=(K:51-?

)GD=%>N M?.,?&S _*)X\ \ VV ^3*/^&-OC9 T2/QW P"\$[:? "97N \ \$1>#?^@K M P DJ? \ R\ 7 P 0#\6O^A= Y6H?

 +3R.BO7/\^&-OC9 T2/QW_X3MM \ F4? \ M.;?&S HD?CO _)\ VV \ DRC (B+P; T%? \ DE3 .0#_B ?BU T+O\ RM0

 M^6GD=%>N?.,?&S _*)X\ \ VV ^3*/^&-OC9 T2/QW P"\$[:? "91 P 1 M%X- Z"O "2I P#(\ Q/O: Z%W _)6H?

 +3R.BO7\ AC:XV? \ 1('? A. MVW_R91 PQM; \ ^B1^ _ G.; Y.H XB+P: -17 DE3 P"0#_B ?BU T+O _M

 "M0 P#EIS [+O\ R\ ^R?V: 1^=Y4@?90^UUMMSC<^H: ^L \ AK#XV? \ 1C CO P"MO\

 MXJOR+Q&S^1\ @\ I\ @\ I\ @\ G/&6GD6= \ :2ZF/ >"N\ N\ IF>Z5 _K P %O\ RE%4? \ 8N:- P"D:5^VW_#6^Q L Z,? \ M= \

 @5;? %5^=7 _!; \ EUV; \ V /VHM4 :3 _.\$\ A=^\$ P"TM.LI7^Q?^\$ M

 MK_R (A6+=YWIH0YW8SC8.90D1: \ P.XKR#@ C&ICLWK>RI.C."?+.70.4&E:

 M\$9/9/6UO_6^)\ L#BLPRY4L/'FES)VNEI9\VC\>* 1/ (AZ?C9 T&O'? AM MK; Y:4? \ 0\ /Q L Z#7CO _-M;? \ RVK^MO\

 B\ A1 T,? *-? Y4? ZK9\ MSY \ FC \ D?G917Z) P#\$/3; \ ^@UX\ \ M;? +:C B\ I^G _\$&O'? \ X;:V

 M P#EM1 Q'CPH P"AC Y1K \ RH\ /5L^ \ Y\ ^31 ^2/SLHK\ \$ P#B\ I^G 0: M= ^&VMO EM1 P 0\ /Q L P"@UX\

 \ /#;6W RVH_XCQX4? \ #_ P HU \ Y4^ \ MJV? \ ^? _; \ P D?G917Z) \ 0\ /Q L Z#7CO P -M;? "VH_P"(>GXV? \ !K

 MQW_X;:V ^6U _\$> \ /X\ H8 \ E&O _/* @P;5L^ \ Y\ \ DT?) (C.ROJ^ \ @B MU RE^ \ ^G O_8QS?

 ^D=Q7N? \ \$/3; \ ^@UX\ P##;6W _M\ J1_8L X\ I \ S\ I D^ \ M\ J+P=^TG _&+X\ \ 1? \ (\ #J+ \ W7\ B\

 "#VUIJ\ JW0R1:?. M*39\ _C=,8YS7A< M4>-GACF/ \ #..PF\ Q _4J4:L8KV597E*\$DE=TTE=O=M+N=6\ I X:SJCC:52=*R4H

 MM^1'9->9^UE%>% \ -8?&S HQ P = P#@5;? !5\ #6^Q L Z,? \ '? \ X%6W M P 57\ \ 1'ZL3?>? \ Y* \ J/ ^ _ P"BUKG:P %?

 Q,^-GB?Q\ !<: \ P_A>.X/M\ 4 M^5MMFVX4+U\ T9Z>E9 \ PEWQL Z-- \ = \]^K; P".T =917) \)= \ ; \ A HTWQ MW_WZMO\

 X\ 1 PEWQL Z-- \ = \]^K; P".T =917) \)= \ ; \ A HTWQW WZMO\ MX\ 1 PEWQL Z-- \ = \]^K; P".T =917) \)= \ ; \ A

 HTWQW WZMO\ X\ 1 PEWQ ML Z-- \ = \]^K; P".T =917) \)= \ ; \ A HTWQW WZMO\ X\ 1 PEWQL Z-- \ = \ M\]^K; P".T

 >I _! _)*!9? \ IDO_HMJ\ IKY6' _\$XV> \$ _\$N P##\ (CNX\ D. M*Q; \)GA^4E%?JW_Q"S?&S HH CO\ \ --;? +JC_B%F^-

 G_11 _\ 2\ X;:V M P#EU7U^ \ LN2\ ?)9?Y+ \ A- P*; \ = \$ _\$ A/*SRZO \ VA_8%M\ 17V;; MQP^5Y?VRXW_N# _&H

 M^3;O? \ V*= P"B'KA ^&L/C9 T8_X\ P# \ JV ^*K\ ^*7QZ^-GO*^&^O?#W M_AC+QW9?

 VWL\ IE\ L\ RVD\ GS8RF_9O7=C.<9&?45; \ E\ 16G0Q\ *I-VC&46_1--

 MGG9\ AJV_R3%8>BKSG3G&*T5VXM)7=DKM\ =#\; *!<_X8V^-G_1('? \ X3MM

 M_P#)E' _#&WQL_P"B1^ _"=MO_DROZ6_XB+P; T%?^25/ D# /' _(@^XM? \ M" \ RM0 ^6GD=%>N?.,?&S HD?CO_P

 \ VV ^3*/^&-OC9 T2/QW _\$[:? \ MR91_Q\$7@W_H* P#) *G_R ? \ \$ _%K_H7?^5J' RT\CHKUS_AC:XV? \ \$C\ = ^ M\$[:?

)E' _#&WQL_Z)X\ P#"=MO _),H_P#(B\ & \ /7 _)4_P#D_X@^XM? M\ "I

 \ K4; \ EY\ 17KG _#&WQL_P"B1^ _"=MO_DRC_AC:XV? \ \$C\ = \ A.VW_M_P F4? \ \$1>#?^@K_P DJ? \ R?

 \ 0#\6O^A= P"5J' RT\CHKUS_ (8V^-G_M \$2/QW_X3MM \ F4?.,?&S HD?CO_P) \ VV ^3*/^ (B\ &_P#05_Y)4 \ D_X

 M@^XM? \ "I_P K4\ Y:26' _! \ DV^ \ ^OMNO_1%M7TI7R\ ^ROX\ ^-G\ LWPW

 MG^W_W#)WCO6 _/U:6\ ^U^3;6VW?&FS9YKYQY>3YT> \ FE;UZYSQBOS' M_P"(>GXV? \ !KOW_X;:V ^6U?

 T:X#^ \)/? \ G#.)PF_P#PVUM_M\ M\ J\ ^ \ (^>' _0Q _\ *-? _5\ JMGW _/G_P FC \)YV45^B? \ \$/3; \ ^@UX_M\ \ #;6W_P MJ\

 B\ I^G 0: \ = ^&VMO EM1 Q'CPH_Z/ _)1K_P#RH\ M5;/O^? \)-' P"2/SLHK\ \$ _^(>GXV? \ !KOW_P"&VMO _);4?

 \ 0\ /Q L Z#7C MO_PVUM _M\ J\ ^ \ (^>' _0Q_P#*-? \ 5\ JMGW _/G _FC_P#)YV5_15_P? \ M\ HNO _\ V,>L_P#18\?

 G1_Q#T _\$S_H-> _\ PVUM_P#+:OT5_P"'=A\ IX? \ M\ L_NZ7^S9_P51X\ 16?V; \ J-Y=? \ VU\ @MK#S\ /F:Y\ VB; &W _\ ISG&

 <#17XYXX M^ \)W _& \ IL_#E+ \ IK55: \$FOU8^ZHS3=YPBVMW+W\ HN&ES\ +LQ=7\$4^6/*U>

 M\ 7K= =F^QIT5S/Q@_Y) > P" _%Z_6O.^&L/C9 T8_X\ P# \ JV ^*K+ \ 8?M& M _&SQ9X?

 FT+ _ABOQW; ^<4/F^=; \ /C:P; IO\ IZU _)\ !\ 5Z*Y\ X2\ IXV? \ 1IOC MO_OU; ? \ QVC _ (2\ IXV? \ I&F^ _P#OU; ? _!V@#K**Y\

 X2\ IXV? \ 1IOC_OU_M; ? \ QVC _ (2\ IXV? \ I&F^ _P#OU; ? _!V@#K**Y\ X2\ IXV? \ 1IOC_OU; ? \ MQVC

 (2\ IXV? \ I&F^ _P#OU; ? _!V@#K**Y\ X2\ IXV? \ 1IOC_OU; ? \ QVC_M (2\ IXV? \ I&F^ _P#OU; ? _!V@#K**Y\ X2\ IXV? \

 1IOC_OU; ? \ QVC _ (2\ MXV? \ I&F^ _P#OU; ? _!V@#Z; ^%) \ /L_W) / _\$8U =#7SUX4 :2^ -GACP_Z% M_P

 5>_Y_LX8>;YULN\ +%NFXZ^M^: \ A_PUA; \ A HQ_QW_X%6W_Q5_NE%>% M_P#6^Q L Z,? \ C' '? @5;? %4?-8?&S _*,?

 \ = ^15M \ 50\ \ 117- "GQOXB M^ \ (A% \)?BCX_Z3\ JSHTRJX%+2X\$4^MZF_ZR0AR#Y4\ JCR22D^8B_9BB-1^U^

 _\ 9H^Q\ MFT\ I\ G7O1% \ /VW/% \)LSVBEOQR ?=? \ !/2R_X* M\ J?M? S0OVT/VC/VWD^#>E^ \ !-7&?"WX9?

 #G1KA+32Y1OM9KR\ I\ U>VNYI&E MC^2>7&4PC*=X9BD?K? \ +_P 1O^"B&B?MZ>*OV9_VNM> \ ; \)X\ TOX;0:UX\ #8

 M>\$ _#; MOX\$^&FNZ_I=O+ \ N62XL\ ;XC5AW4O\$N\ I\ V\ H\ F^ \ ^ \ (?@#3%5MX\$U+QSH\ IOKEZ_MA>ST;?

 4XDNYU_O)"6WL/<U>UO7-% \ -;3<;XCUBUT^QM8S)=7M\ [+>% _"@ZL_M\ ILO%'N37Y? \ I(?

 PW\ * _I _@V0 _E; \ 2^&FP> \ OBUJWQ^OM=D^).KPK+K<5Y_M9M13V\ 1WA^FQ;7;1 IE \$ \ @PQ% =E^T%X \

 ^"D _!OG _@W@_9F _; ^>^>CW? MQO_U?X5>/9M3^

<8! BIQIX% ^IG%J'CSOKL B6] MQ.(8)I7U**V220]5\$!& +T'-?SZ?\$. /VO/V?H/VL @A^P+^W1^R59 !WIH
M'X(: =:X!<:9X:33[C7 -TZLWT?64VJYFE2Z,D=P2ZS2*A&OI&WKW !+ MGQ?! P %-O\ @X0 :T1?M@^\$=.\9:5V/-
%UCPEX(\+ ^*:!+RRT33ZM29RVP MV\ P9(I'BMV,C* S-<39/SF@#]8OV^ 'Q#^&G]#WQ6^,/P\=/H/B/PA.17
M\0Z?JD5C;W<9GLK*6ZC22.=1XG,05@ &VL=K*,<F; (-Q/V OVDO^ ^D7] M &H_M]M3^ (M.U/Q+;? \$?
4= 'BN=,TF*RC%K#<V:9K43V M2.Y)6)38I(B9P#+*0!FO_ V?Q?VI/BI^R3_P:0?&XA_1;7;02/\$6K?&FYT" T
MUNPE,W1Y&6-? ME0%B?E' K\ -/VT/V)/V8/AU_P:?? "W]H?P: *-LO'NI+HFI:SXTL:81:EJK MW\SSPWDZ8>[B]9-
L4I94,\$14 H"/V<_X(J?^HD/V*HM,1:9\.-):O/!*UJ'3HC*KQ%/G20NVT#Y@,8%?ME7 MT? _3@F :SLO\
@XQ_8UC]B6:P4_Q#T^;XG76BZ9X^T>YNI/U5D\4PD69 M-O>6K6IR/L"SEG1.0R\$.N4 ^? W_19W]LWID?)
X+867_!)/IN>Z(_ \$#P] MXNO+&V\&? \$;PUX=?2-0BDOH0IH;FV6:2%U,O^CN%"D'JZ&*)7ZOZ_XAT#PI
MI\$ _B#Q1KEGIMA:INN;Z_N4AAB7_.L]D*HR>I-?SZ?& OB?X3? \2G (+ M_ \$#JJC @/IX@U8?M1^#IQKKP?
X)N]_.PTBVBMB80L?>C:F406LW_L_5(IMMPJ,]0G8 MQQ(%1F*10%)Q@&OR4\$? \$V_ ^"LOP \V:OVYO@;\-
M!TWP1X5^+ [W>O? GP.M?I7C""1]"N+FEZE0]AK;'+=6S'\$;66)6"D%06:O / ^""W[;'I-WC?IKWX M+ _L; M;_
+*5C\&VCO@E#?Z!X8\2:/X973#XMMAI%U:2:5J\)5'BO KBY65 M]XEDB?:8FG*R@'IW^)O'/GP6:1?&C#2M)-
(+\$:GJ\$<'VB4XPD>IAO;D< M#)YK39E52S\$ 9)/:OP' _8;^ (GO, P""J7I<7I?)^*O[.EK6=>N=/F\$^!; M+7M/@K_ (-I
M?#??.OI>W]>GA;X;O\ #SQE&/\$WBW7=4EU6T\0^&HC*;32YVA!DNFS+\$JVP M20S"SCC96#\$T ?
L!X5^)/P\=W5W8^"/VBZS-I]A+^'2M5AN&MF/02"-B4/ ML<5H'7-%@I_9IU>U%QNV^0:A=^?3;G.; GK\9_ %=#? _>
[20+ _Q MI]"UC"1RL"5,<9YV 4 ?OEI/B;PWKU>V.A>(+&]FTVY^SZC#:7:2:-S8!N0 M*24;!!VM@X-5=-^ (7@'6?
\$IW\X)T?QQHIWK-@FZ^TBVU_*2ZMESC,D2L709XR M0*)' @I^R+ \?^#> _()@?M& '+ _@G;XC\;Z1XF^-
&N2)IEW?ZSXE: ^.@ M(Q-&SV\$)*UKQ=JGAW0\$ENO%TLZVMQJ50<7"RQL)&NXIV-GD\U2MW,&1A MI -WXB?A%-
_VV/AM_P_+/@S_ @F; \5+4?A+XJL#J4^EWOAJ\$Y;A]O;I0 M)*=-U:"WN6M]B;3+Z.= (IE M^]&Q0D*PR,J>17X-
_MW_F&_ '/ @\0^&GPH^ (<-Y-H>L^\$+> /5:6RU"6U: MZ@70=1D>W>2%E?RI0GER(")&[HV58BMS_@@SH^E?L^?
V)?[7_]*/P^T.[M]*0_9UE_LNY>%UBNMC\$!_ +(/VH_#>@OV]HM_>H_ J4WCGP3;>G;+P
ME<>,*CU748# /I^F/J\$8N+J(DR1QEMSJ "25! "%B/_ ,_% =5NOC+ _P;&_ L MX_+XG!;-17WE> =1N?\$6HQ++>-
_ \SVOVKO@-I=UHWQ'U_P_ %:5J>M^_QJ<[NH7D\,FZ%<6P:5W)\$ M.&-<+%%B-0%4 '1.6LZUHWAS2YI
<10ZM;6%E:QF2YO+V=8HH4'5F=B MHIR: *]M7_@J3^V-^SQ_P_ %Z/@#^Q%*/CUIFO_ D^,%EHN17UO=:!I\ D M,-
YJ>H6DEO;7<\$2LT(6S4HY+,-YR[8S7E\ P<0_ '%Q\> / ^"T_]'O\ P3, \ M?
WL\GPHUS60VO>* _#OG,MKKTMYKLUF8KA0<2JL-DR*#]W]5)CDYKS? (* / M_LI_ 4_9L_XJ?
V2?" /P% ^&E^ \$M\$U33/#6IRZ#H-JMM86]R^M:M\$YMI9,1 M6RL(5=DB55:1D)""CLP!_0+7\A
C_Q#X#M\!7627MMH.FOJ5U#%:Q2@K_45IS@EC"N&DE<\$-(Q(I]* P#! MN_ \ %0_ VT/V^?V@/VD?A)^U?0-
U^T^%6K;?8^&IC30#EOIIG?=ZG%GD M@;BPM8C@ \#G'6OT\O_ '/@K2_ \$MIX,U/QAI=MK%_&7L=)GU"-
+FX49RT<1;>X M&#R >E?@1_P;_>+O^&=?B%_P4]'>:%9SZC_P@ME'?V=O?7,DTEUIBEU^1%DD
M8EY&;R@("Q)8DDDY-?&I=2/ MORUOQ:9V= HFI61TNZMXH7;_ \$FVCBA,JOB':BBZ95 7(! 13=^(-I^FI:A'
;F7CY(P]#>W(X&3S7P1_P_9-)T&BZ MP/'UIH>HZ=J6@VEI:7EM#?;B: KME;1^!]DDU:"WAM\$NN8P)(61W MA
82VXD)WR9,O_!9OX0?MI?L^? \!LE;-?@7^WMJEK]C]PG\9+3AJ5MK7] MH&YTU(-3-GOF_B9(66'GG;"N2222 ?
ME^QC6/\$QOA 8K^&'QS^>)I6S:OXI M^%YA:[X@O\$C6"\$W-SIL%Q/(%&%C7>[G X4>PKO"/CGP3X_TUM9\I^,-
*UNS M29HGN](U".YC61?O(6C8@,.XSD5^ ? \ P6(: (^)=Q^QI_P3@_ 8!TK6;RP"
M_%'P)XON?'UO;3M&NM0I;Z1;16DC*06A7SII&C.59C"O&8U->J_MX_\$(_P#! M.C_@YI_9KT+ID_P]9>\$?
#WQ; \'^O#WQ \)>&;-+3M7BN]8O].2>:WA"HSP MH('197] *O_-P(!^UX\2>'6,@77[(F%&>4"Z3Y%498GG@
=3VJ/PSXN)^-- M&3Q%6X.\3Z=JVGR,RI?9>OSPL5.& ="5)!!!YXK \ ?!OI+WP)^+W_IX?5_@
MCXZ^'5A<^#] \$>^U+PG#\$(=U)V\,Z?.\=S#A9XGG6L_M\UL/X%)4YV+@_ /-&P'\$?KS?I=-M2+
I'LSMW>=NV8SQG.\5_/M_P_ \$=/V,MOV_ VC/^ ^ ^OI;7P4^,7POLI?#Z-X@15?9?!.JX=)D^)O*B26VB*I+'\$I)C MC8%
(W"JAXXV7SK_ ((?LU??"? _9_X)Z?MK^"OCW15YXIV_ #+0K04? ?A MO5=4G?3M&U*?3-3\SH;8;
(MF+&V\$SD%XPCL"OEFN/Z8_+U33_-TZ#6-%U M&"(M+J)9;:ZM9EDCF1AE65E)# CD\$<&J5GXA\$ZCXHN?!&G^,-
*GUJRA\$MYI M\$.H1M=01GHIQIMZJ<\$@ "OP#_ P""3OI:OOV_9B_X_//CI\;_!XLO;K_@+X
MAWV@>"KPR%WT;4/I\$B\R'.0ABEU2XN%I!<=<=;V/V>OV_?VU/VH?^"4_]*7Q MJ_X)T_L^;-H?Q5\$<-
)&5Q\9=6\;645UXB:66^34X;F1=US_YISY*21SDAH MI_ /WBNZOK+PMXLTS4 MIM+N?L^IPZ??QS-3? \
/4(28V_V6P;_! ?_ (+9_!_P_XU_X.E?V6?U_HL MFE6_C+PEX8?Q0^@W;V-S>.^M;O!
(S7%N4D#M#%"1958/L10K#;I&M_P3G#^ M\$OV2O^#N7XS?LT_LZZ"%X3\W?@V6:3PKI+,ED=)TV_&(AD#;<:
I+>=Q@N M-2*_ /U&OO^?I?P\$O_P#@I?I_!+P'KVGZOXEM?VI:IXIU"*17RM_+6ZV1
MBOJ;F3SF=D)S&B)D9D&WZ?I#_IR#T(K=>C]DW]CSIE^XC?^8_OX_9] ^C_ MI_!>G6_
MCX>U"VL_ "&J^&;XTV&X^S:9)YRVIH8P^&65MV,YD8]2;_H3M+2_MUL+6*QLK=(888UCABC4*I!*@.*_&_4
9_B#QSX*)WMCIOBKQAI>F7.IS^ M3IMOJ&H1PO=RWB#QQ^SG9_%QIXXM_P#A&_#6I^(/\$E;IX"L94U=-,@M
M\$NLO:0%/"(3" 2IHKMN?D_9_P_3O^". P" T3^VW_P_\$(I&_9+;_RL=\$O_VB
MOA]H=W_PA/C7^THIR8?%K/*UC\$IZ0&*3VHBMIBQ.3^I;+HI !^H^2^&9%7 M7I(F7_5
72?/SCCGGD8IR;_H4MRUG'K5HTRIMT2W*EAC_.'/IBOP^X_M7/&?
P+;_R+Z;H7]1W@OPA]GQ%_9< \C0\AYID_ ARW\$UOIM]=R3R:LS'D S]D M/%#:A@H,"Q%IQ>I+O!%J?
#_B#0FO&Q&BV(^S0 M:HW_ B\$TJ?Q;-CF=)D;Y9E9TD*! I @^H^O&TJA#QSI\AUKP3XJTW6+-M9GA;
ITJ^CN(AIPR;HR1N]ZC.13? \$CGP3X3OK'3/%C#2M,N=4G\G3+24-0 MCADNY,DB5VID;D<+D\U^&G]#WV?
_@GU_P_':_Q&_85_9GL/I!^%Q#T=IKI_MP7IQ*?8S? _1.RDL<(^2,QW"S1QI0-D=R4&%. *X#_ (S>C_ C#_P6(A_;
MT\1^>?V<I/XH_ \$#QW!_PCOA05?\$'B"RMU\I6I#2X+5+K+P113HDF80"SV_MBLVY^2_?T+7VKZ3I94:GJEO;E\
H;J;L=<9/4Y?/I^J^Q);^#9?&&EK]H_M;&XLM*;4(Q"/BM::<>)(K1-0GDL?L^K"W_P]*OO8M;);K)DY=X0S98
CQK_@K+I" MAM^OMX)X)G_+2WI/FEW6B>/ \$AJQU^Q+XP_M.;>4-3N+>W\;2V]2S2.25
MB^U31H@PB1.L2I(T50_?TJ>* _&W@SP)81ZKXX7:9HUK+L\$5SJM_':QO*WW_M4#2,6/8=35VU"PU_2&PO89Q%
(8Y3)&(&V_."5_.AP1QI]BOQ3_X.3=6_;\$_9 M" _A^\$ _4WTO_9ITGXO? [P5X,ET/7"/B32Q?:7IEY&O_M&EYZ>Z5*
(M3L'4(YI;-_HJQ,9X#^'_BM2OQE^#_]\$[8?BN]_8_-O\ M^"??
LGAIX=Z1_/6FQ_?7QXRL(W;^&M0@TV6<3);_M-&C,Z"IGQ_EA+=;Q_M\XR/V:H_**** "BBB@_HHHH_/3]O? \
X*=^+O#?_!5CX2? \$F?AQ<- / ^\$B_M>- /#KZIXK^)UWIUI=7F7^TI9:3IR7Z26D=S_ILP,L4JGS(T1"_RMZI?O_P4
M_9X_;\$^ _PTU+X]6GO.^#GCCQ#JMAXFUIQ+X3LK7Q/IMW;H.I7MM#)-IT=O
M92VLEJ&Q+2&I'A1"SK+BO"/^W7_!\$IX#_!9SQ)A_ BS;^#OCK\,=\$ MM;4W]W;/+9WFG71FGM;6]5?G6,R+
<&.> /<4+3 DP% ^/ ^";WI=W_!7K_@CG_M_P_# /AM_P_\$NA_@IG%J?BGP^1=>L\]
(ZAJVH4C:FZN%M+6ZTW4>7EME MF>%) +4YB1AA(6X8_?IQ7XU\&^!_.35_"BW3-&M))EACNM5OXI>-I&^Z@;
M1@^"QI#J;^2?^"OI4OI07I\$ _!IQK^UI^S\2(I#^2^"IS2)(N=(M;ZUU" M&\U.TL7CE2>-B_%N3(K(RG<@SD"?
G]#OC_ -?VX?^#C#H?P_8/V>I?X_MPZA_?I^J^ _GP^UK5I-"QT33HKVTL]VAABO/W9EG.^11YA6Z*YV;0,? \ M;? \
V6_VIOV/^#5^XZ?LS?MUWMEI?M>_ \%;/V^OAC_P;X_!3_@IO\A_XP:28?\$Q^J= MK:>*(Y"/MC_
I^H\F%T^S13&RKAGW*Q*E?=_P!IKXZ?%A/C;_P_M2>_9Q^./!_ _Q+X0^Q\;^%?"GB#XAS:P+MS-
;7FD1W%R(\$>H?Z,D9N) 75_M?W@3B+D&OSY_;U_Y4W_@!_V_.D?^E.IUG? \P5X6;R?&W]IGC9_#ID=9 MB\&^#
I&/53;+IH6V?PFLC0B3&IRRZ(Q7_ J#C_ -I"OAW7;S3_#&E1? \$:6= 'MAUQI.@:55LKC;M<%YIA\P]O+WIMN>
<8SS5BW\>#KOO3/X'M?%FF2;W;6X MN+G1XI^_W441QB1H@=ZJ&/#H_8_9^8KH5H-7?3IFR?5 M%ME%PUL-

IL7\$)DON*!RS!2<L2!DFK_42^!2PV8/P"#F7!CN#IE2KKMPYXK304!6ZBNISSW>NRW>M7EE=W%Y/*
I/<33P,5EDY%J1_ROK'X-R_V3O!NK?!\5!K+!K+P#\M"M'D^%>E_\$;6;3X^/H_."6Z_)J5!%)#14RX26U-
H^UMFY%7R,)%CD_>ZDDMD2!&EE<*J@EF8X_J:6ORZ_X.VM+;_U?_@E_!_LP6NO3Z\$&#?%2#PTDCM7#Z&+>?
_%HC^8V(N)/N..\$+?<(H_2!PE!0?7C^&XN/GC?2;CM)*NGMTC4HKD0R<_(YC8!6X!YXJQXE4^&!/>C3>
(^/B.PTG3!<W%J=XD\$.0)P-M-SN0J_B:GY_X%*?LU?LLM8?M2?\$(4L\$!SP_X!L&^!:)!1!^Z?M!<6.?
A99!+!\$NIFWXB00^4/GD(D#<+!Y4^UOX^_M>+_BQ_P=%Z#^QAJ_P?B!M=^!O@CVUC^?PMNM3MK;3I=2FT&&?4
4^EV?)EFCANG12P+*MLI3!4D@!181_MZ!HDVE1!%K%JUE/&LD%XMP!BD1AE65!X(((P0>_!HZWA0_!AJP@U7Q^XYT?
M3!6ZNEMK_YO=3BBCEf;IL2LS_Y!*.37Y">OV&OVO?V5?_@EC_,%OA^_MUA_V_L0A!J7A;Q?
XM^!/(A)=;_@U0>&H9+/5+DVJH*VX@*6\$D83Y5E\$KK@DD_M_G!_V4/(7XD_X-1?2!5?B;P.#WOMWU!-
(='@DU+38)8K6,MMY<*RI/(9-JYD)0N6!N/8?U45E>&?/GOHUV0@IQAI6K&PG!B^&F:A^A!M9!?
!DFQCL_V.#7X_P#137!O?H#X6?&N!_!JX/!<(>K6NM_%73=^>*/\$ML5XXNY=*M!Y9X/_!WAIOL!_VE?
SS_#7!D5P^T^_P_87Q_9IN+BW/>!^!V!MD/&>D^&HMDU+3Y=-T^6:T6:WYR0)*?&>O?%*?
^TEU^*56!TMXK6%#=#+N2!MDLUA<3F##JO+/0!^J_A/XD?#OO!_VW@7Q!HNM26#A+Z/2=5AN6MF/19!&QV
M^V_*,#XK?!\37!MKX4_P#!R=X%_P^!5!6++40A/XOLAJ=SIE_P^&K(7E
MLLNEWMS!G2YBC1RB2VZ!27Q#IT>I1?:!NPM798!_L,3+!_?000LZOR+M3T7!J_MW_E=%^"O_8!6_P#Z9-5H
=&BBN!!J!>_!"LWQ!^?#KXP!V!_U3P9J_M5KI/CJ3_7P_!M(Q7Q)9=HB)!S=N!7:D\$S4
=)!2OAS^XO3X>S>/!\$77Y%+M1Z&VJPB!90_Y\$.!>1CGITK2OM9T?3^6/4M5MK=F&56>=4!MDU_+5_P4G/@G
MX;_!\$=?@N/@S)!_Q3I/VC6WM4^TE_M_G!>_!D(JY4<\$HIQP^/W!^C?P6?Z>!"XNTO^VI+7!3!^H1_!F@
M_P>HBW;RG^UC^B/Q_X<^Z/XC!6!<+2!ME#7_-J_VD\$.0)P^SN0JC_M)Y/>OYT?
^"H^P^&_!\$GI>W_!SXM_LXZ7=,%XK!4!Z7<+!^!0HSS7VN3B_M!TU&ENY!9H>_YFB;!/B?R!_54>
!_!%8_!MI^U!_P4?";X?_!3P39>&O#!Z&U!_!H4_M?E65E)+X=U_I%MH!EO&SIGVJ_*@=W8_%C7!_4_8GBSXE?
#KP!_!VOCGQ_HF_MBRWS!+*5M5AMFN&SC:@D8;SGC_S6V^!_@U_3^U!_?#WPI^!O!^WPI^!GQ
M.T7!J3XB:E=#Q)!/C^2O^T+?^LMXY!%#?;M=-F.XG9\$&_JF25B%_!K\(_@!_Q#^R_M!V^!#7K!G!CXZ?#7X2Z-
!C36(!M!KWBK2!58+!W6^U^QGO+!F!E3#7:B9@4_M\$O?RO+4)M_(!L?_P7!_!^_4_X-5/V8_!\$NHZ%9SZCI?
A+X<#3;^6V5IK42Z_MBRB-R_R!P%#_!\$MHSG_H_<X)=^!I/7!+PI=^_M^BU34X3_IVFR:C\$MQ=1_M@9+QOEMTB@
!J^*4>_!9!5GP&!/E_VX+?!0=&_M^!/7Y/_#T!G=OV_P^U_MC%2S+!_!93!G#X3_LO?^\$DOV^_VM_@HMSHWQ/U?
PGH=HJ/CU_2F?5)!H5_MC=0+Y!_6\$=NZHMN@PL\$*D851BO?>^!S^P^&GI#O_!77!A?XF_LW:3)3J_TVH>
(!@Z091RW%1<2,7N998!F_!1W)+!4(8/R!M^*!10_P!M_MW6_!BO^NT?_!0WX%?>Q5K2
@A/@5!NA7XU6^L7&GB!9NOWX*SG!3S:E!L_P!D_M^S!^!^!Q7V,=;T47O!_9IU>U^T;MOV?H0N_/MSG-?
A5_P7A!+>&M%_X_6_MV(=?T?P_96M!JVO^\$)-5N!_V5)+QT4,B^P,C!%!;)"@#H!6'_P%B?@O_MV?&_P#P=;?
LX^!+!W2^L+^Q?X6T^3Q^*A7+V%QJ#_?;M%(7GMRD@9X8DA9PP_M?RP%##_(!/WHV/>_!/WBZ;_!MO^GBS3-3DTVY-
QJ!>GW!&AE0AK%I=QH!78N=JOY!41^!9_MYFWS_A_M!K<5!KC%?G7_P2X!&^%OV4_P#@!&^/7L_!FBQ>%?
5QX/NE/MA32F9+!0+73+M,19P-DLDI3^X)75%?#?@O_@!7_!C!_!#=-LM^MT^W!>(&#;6.GVJPPEI_!\$9VVH@!J"S_<
<#>_!ICS?&7X26^OW?A2+QWHR_M!86HN;137U2(7%M>DLD9;(!Z^?/V!_P#@!J%#?V^/B3(O@+K>K66_M!?
\$XP_00!/#>@&!&=A9?;PO-3(M;K5)!S_MQ(!K&ZR(C3Q,KY,220W_<)_!7X*>_(!#A7!C:QOOAEX=OK^XB^(!"L?C:*
M73(9(O\$4+^X!4K=@!J!G%_!X2>)O#D2))X@L561=T_=-H_M_PR!D<^C((^D3O-
X;D!0MX13Q#8M!JRV@NFTP7;&X\$!;_!3^G=LW<;L8SQFO_MP<_X)?V?O@7!^?V!OV>O#P5^#WAGPGIVC^+-7L-
*LO#NB06<5!R0BX>_!M8E4!&TSO*5!_!V;&237Z^_LZ?&3!/@7!\$?V@!C_@H^X?^+WCR7XX^!OAO!&
MO^!H9UU;ZPFU_Z@02ZHED3^LK^H2W21;_!%1(5V@^@_O!6^!7PYT#O+>_!M!_!>Z)9:Q?
D^QTFIU6&_YN">GEQ_P=^!P<+^VC^V9!^V!_V=O\$!3/!1GC_M^2?#^A6S-
!%07!3J5T5)BLK6,D>;/*PVJHIV8J!LP_G8_!^!>"OA_!\$8_M_B3!_8/&C_M!>_!^?Q!AU#O_!TYX>T^_*TL+RYDC
TM=7N2+06+TH!))O(M,BBCCG!H1LB#_2O_7#^CXV_P#!K^!LX_M%_!%BR@!0>_UTCPI;M7:K^!LVH
M!KK32;IA.P+!@S&*!JGYRH+9Q0!^F7Q(-;_!V_!6_X)!Z=^TC^PH/^!C?&S_MQ!^!1>_%
+U_!MGM;"!OH+6ZGMU;ZQ\$9\$ADN%B_X\$9D5#(-NZO1OV_O\$!_M5%O^QE/KC_@H3KWAQ?B!-!\$A!92;-3YOD_NO-
!S9_M^NVOS!_!_9)_9;^&O!_P;2K!2?A!^SMX^T/O^XD^!^PVUSQ!KNE>&;_!"U'
M4IVE\$WLTR(^DGA/VYS(26(N)IG#MG!^!O_!_C1^!B^!_!0_#?P_H^A&^!^!M!/@?PUK7B3X?7:6P;Z^TVV!Z@!IE&V-
Q%\$LD6S(4R&%CDQC!^X#Z_H4=JE_M!D)K5HL\$C%4F_RH1B.H!S@FHO\$7BWPIX0T.3Q/XM!3Z?>FQ*&EU4;V_!"
>MA_CD^*_60Q6_X(R?&3X\$!^7?^"9WP#_!_="WBWX;^!_00OAYXS\$WQ-TJ72H_M2D6AZ!+!>VUT%V!-?
3W&EVD&G4ZD_MGP!^!%!S!J%K::!1110_4444_%%%!!1110_4444_%%%!!1110_4444_%%%!!M1110_4444_%%
%>1_MP_L/_!/_!_!0W!G;6/V9!0?3ZIX=U5DEAGM9A#Z;=Q_M4YJM9<RIDW_@X^E69^5D=E/KE%_!P-
^Q=_P3M_X*>?&Z/AG;_!_!_!M+6_!5^+=!4?&GCS2UTSQ1-?6_L=&CTX+*HT^PTO!)2UMB)Y
M2Q=YIY3)^!GD^QJGL=%_!Y>+_!P;Z_%SX5?L:6226>0>=-,S#=#)!U%&8MQ7_!(!_@B7X_!^!2WB!QA
MX>^!_MH77B3X8;XD;6=A&OX;AM;TS?9VMXUN!HSWU\$C924BBBWR0QOE%W_MQ!_H%10!R?
QW^!7PX_!3^#BCX_%_05U/POXQT.YTG7+\$N5.EO-&4;PY1_MQGG^!KSP9X7L_#37-T%!CO(K2WC@CD-N
MIS<%^Q@MB0@DG_XKT&B@#^)!_@XM)-0^*OI&MA%\$UH^_B;Q/&MU;%1)_M^3/X>&!P(W#.1D\$9^(-?
8WQ_X(!_#IL!OGX7?M;?%_!VL_#WC7PW!P_MDG@;PAX3!
OI#;G=).MPEU!3R7DZ&ORQP&5(56*7R5^!"I93!*_M_!+!+!MA2!_L!7:XY_!S^!H!::EX>@;+07U#Q+J<46G*
!SF^"&Y2!)G^1EG50S>6_MFXG:N/SB\$&_F!G/>3LH!O/<^!K?H3LQ/K0!\$M?M!_!\$2OB3^YO_P4M^%7_!122_VQ-
!)S?!"M);PUX0G^%TNH!<_8KH_X_!;MD;M_7!R21E^2_-!H1R06/U!^U5^RI+_!_M#!FCQ9^RQ!>_!_#GC/138;MO!C-
^4D;Y5X!B^=OV213)^_&3N^O&N=P!;!HH_+W7_P#@WV^+?Q@_8^!%M/_!-3!H;IK!1M6^!OPG!9^6!>70/!(K31A>6
MD-K;R12P6DD&!^!%AD@C>)PQV">"CA^/O.B@#^O?C9_P00_!_!_?_&_?A3_P
M45^_7_!172V!_#2RTN2.OTCX5@;JROIK!(!%K!_#;GS!O,CS2N!RL&C5_MHXX_0?^!@J_!\$5_!OI!/!_P<X^"!!_M-
6/P!^!OPG2UM4FUGPH=5L+Z_MVM!N2!A/DB>-E9))!@%"O\$BR@;D^*F_0&B@#^XOV=A_@@Y!4_@/_P_%9K!_M
(*LZU^WV_C+6!_M7@^2^!>^&2!O=K+8PVT!PBN;74\$2W4_#^"OD_(HPD9^T
MJ9&YO!HC_@WQ^+!E_P#!26^_X^9_!\$U/VX/^!>+O\$!S-/XRTF_!HJE=37
M&#>2^C2!JLB3L!^!\$JL^S(LB\$(\$4&B@#Y\$;_X)42?MO?&Z\$7!#OO!_!MC3Z!XB!27D&JW?
Q.OM/AWQ:K#++&6GQ%((+!+!\$8M8B@V%F.C3!SBV>DW!=(!LVD_MM=O-"SP3!_!%DCV+L7#%_N2B@#XH^!G-
2>UVS_!"FUS_P55_!8!>"K_Q_M!>%"!_Z+I/PY!(3Z38NY\$B3:K=M<75Q+<7;PR&W_W!8XE52TA56^TG^UK!%
M/\$!1OI_/C;X&^\$?B!_X3U?Q/X?GL=)!46!)DDTBZ89ANT4!9HI_K@!EY4<_MCK7HE%_!P?KO_!&XG?
M#_MR?!?H!W!MCXT^!O\$NI?_B&9M_N_!PIET;4!%M_X6C>VN-4DDO)U5+>2/S4@A_3S)92^B_8ZM3_P#!)#QW!
/^"A_CW_@HQ^P/!M7_#/AC6_BMX;GT!Q!X_!^&9!_3)KZ22*4!;!/7_!D4OFP!HQ_!60RS^3HNH!>_!MJ4E4M?
722P^!S_@E3Y4Y#*V!6P_M/T9HH_(!Q#_!&ZO!_!X)!OVC_!+_!_!/3/2)_A!X8U^!Z&3^!A+RE
MT+=_!JYE^S7!X2/S)!^!HPK;"TLBQQHOZ(!L\$LO_B!BW!D!CP1^RMK!WQ_M43QFO@71(=
(TW7OH(TYYK2%0L2O")H1N51MW!N0!D9R3!H10_4444_%%%!!M1110_4444_%%%!!1110_4444_%%%!!
%37H=^N-&N8/#!&I6EGJ!1\$6EU?V37_M_3!F>))F<>P=3!BOS7_8>_X(!^&C!BK_@H!XZ_X*3Z;^WAX=^!1!H2+O7)
MO%/ARY^#_UO:E=4U!+^=;>1=;9HBLR+L+^3"@@&DYK!Z^/S2_!M_X-UM_!M_!_X^&^!_P%+OV1OVNY_@1!1-
N(!+5Y_A^"KJ!&ZE"=JWA3!;_!#)%^ZG_M0ATG7!P!;00!A?%/_P#@A^XT_!O^7PU_!7^\$?H6_PP_#^5K;P_XUT3PH
M_P#9VJ_9YFFA?!(QU(INT;R28+2SAD8QN^7:5_1NB@#Y+?^8+_!T=^LK^+M/_QV_!TOM?^+?BBUT^+3_B-I?

A*#3K#PN;^CNX'L-A<(9%F3S'ED!TUFRF>ZD\$MVT;-BR1R3 3B)U!CDR4 MD (5-1 X*B?^\$;13_P""DWI&/A+JFW7-
L37I+Q5X<^9'Q+JOCG7-&2137; MV6&2&=L;.*6".1563; D1"01QB, @EJ_0.B@#^NOB5_P:M &?XA MB_P#; MAUC_
(*A>*=6?) PJTNQL-9U!QO^A 3IY-2CM)H(OLD4+1068VSR)ME2Y M+>8[2.6W] ^V-_P1(^)W15?_15;X<_1%01;_
(T7P1>_""^TFRSV>?#KX5R MWT4UO:75S5_ML_L@??"710A 9^7 M?LF^:UGEV>+1-
%O=7%BP2>TG1UE@NH2P8+1)%_"(N002F&#2#172^\$S/^ M^?I=?I>BQ?L1ZS_P%6-4UKX^:9K+WVG>"-
1^#0V&H3*TOG/;C49)99K&-" M1_FECMVW-OD^*/\$SLQ_26B@#^1^OB; P \$1_B1^0_""^S/AI_@KJ#^V)HUC>>&3 M%;;?2
X";X72RQO8+936;127G|K*3,T=Q*1*(^H;?+((4I^QE_P \$1_B3^R;_M_%,6/B3_%,0K_1;?T?Q)=_%&WU6U^0>#
(OA;+8QP6IY=VUT%@NCJTI5XWM M(1N;-PR!_E!8%?T&HH X_P#;\$^\$&G_M"?/OO\16\07VDVOC?PAJ6@7.JZ8
MP6YLH(RUDMVF)X\$B"0LON!7Y1^&-P#@U3^1^P3P1_L1^+O\@1_XAU#0 MIGQ;XC\);;>>
+2WTC3+12JR3Q&9|JZ:2)2H074<4;7\$;L-Q_8RB@#^Z_ MVK?
^""Q3_-K_P""4_PN_P""8'B+|N6VL|X>_V6MYXRN/A>EQ+>P_P;=:&ULI_M:"WBU" 6Z)&?F:1YY)-
IEZ5OOI^VUUH^CJO^---8WC03QW^HJHJPS_MQ^ERGFQ^S9^F^16\$F!^*^9_%I_@C^U+^T;_P43^%_P#P4H^_
/_11+2W^;_#K_M21+OI^F?^L2V?#6I>"A\$619;EX2UV;IC^+^J82^RE5IY_M^4<\$>?2LF?^
!OI^UI_P3J_!18:C_P3I_X*?7^@/X2>_K1:C5O!VJ_#RWUB_M^L8U+>6MO+6LUNT\$DDLT6D6G8,7.IRO<|NM>;_1!*
O\ M>#/_^"8?1%/A?IDGPEKD>L7&DR7_YK_B%;3R&U;4+B5D)9V3;./@/@:OJ.O:DL4Z;E2^IM(;-'PX6%\$98XXXHTVJG
MS?>%%_P'^U/_P_\$+1#_&L/V&O@G^SCXX^/D%E120V>1+380AA^51^1^F%(MVIX+>+<+?)=R|XY5M;=I^6=?
WD*,I508SM^&A_@D?XF^+7_!2SP_1%1_MVYOBGX=13^/_OA.WT/X?>\$/GAZ>QTG2FC-PYOI7N;B:6YF^R|N71?
D6(LA_MRY12/N&B@#^?^P+^_WQ9_P>1_%JT^!7Q2L?"/BBV\I<:9J6KZ"-3L)BGAC_M3-
UO=VPEA>2U)HJ:~13M97&W?#HI_P3=X(WZY^R5^US5_P#@HC^TE|=+M#XA?&KXKR7\$5Q?;/X=?
3MD)T^SEECE(WMH)Y9^R8;==|N&6_%.4&27="8=" X_M)/?L\$>&OVFI_VS-"^"EL?%2O.N;KQS^XWUKI2.HY;*
IF^>,Q@1^404V_M)MV@^OHN@#^V/V#O^"(QB_8<;^,^OI?FG?MJ>?^\$FK?&<_W-K^AZX^\$4HK_M;6%U?W_V^_
XG76G=HXHH;C\$2#EO^">?_?Y?%?_OI? W|H+X^M>\$?V|_#1)1)>_#@TZZU/4?
@1+^"VBS^7=PEFX1\$UHB=3%>S#RR5PZQMNP(K_Z<M44?GO\1\$O^""/A;ICO_@GK|5/^":WQN^/UO\
%P%4=5NI^ZN;7P4VB7_MUA:1(%*2*2=X(Y+_@G7_P0|_>_8-T:1_9GA_X^F7_MNJ?L_3ZM-
>P5IO@.&UU::5MTUK^J#S2^A7Z^MAZ-X:N?A7;3:>^O!_MDO8YI_M:RO+FI^SW(U:(LTCW(?^"O\O
ML#_@AOXRTW_@KEK?_!4OIG/|LFY"S^-=%;3O&WAR7P9%J1(I|M!;S-8W,DZ
MLNZV3JTD,OERJ6O(K>6OZ\$HH10@)P!@9.3^9I:*/RWMO^#?GJH?_9B_X
M*!>+OVT_1^"87_10""X1Z91KF>7QCX,USP#K5JGGS>2.L*1.D5UUB,DRO&MP75%"SA7"87_M:~BW|H?PS120%_1
P>=:HOP>^)D/A^Q+_PBB2Z3KMWHJZC:Q21^#H/+GMF_M>,S02*IBD5)(I-DC%)
(W"NOH5Z:E_P2>_8(U;H!OVU;WX*71^*17ANAX\MC\;ZTFHHYA,&U)%O!LC\F\$1*_@B_#A0GRT>,_L)?^!&IQ5\$?
^"@OO&_X_M^G?M??22OB%18^EN,*PB1>>&Y_TC0+0Q0P;8(YIY9'\$%O#_K,_R1AP?,M9RX\GL/^#?C|HC|EW|O_
7+9O_!;_@H#^#(I)^US+_XP1%ZYX!CUJVC_M^;SY5A1YTCDD02LSQ^RHT.2@D*,PKI2:*
/A+_@H_P1B^5_1%&V)_?7I%Y_M_#NO^#&B>+E12^)/&7B+P;_&WJ>O:B(I-D-(1^>VD5LC/=S/Y:(411%'\$L4
M<84^6_MU^&AOQ5_-D^%7I_/PO1?MX;)H^S;X572M^OI+X.RS^6YPMC&_M+F5&UH^>5IUI/+4MYE;=AU2A
3^B@#YC^1^*48/B#JH21^/PF_:(1_MFQUSX5Z=X^&7PX;_#YXOI\$UZ6WN=1G;1_COEDM>-0=1%F96C+D)O.QT-
M^#O_1L?LS^!O\@E/XO_X)E>.O&UUIP^=(IO\$VN>_M.TU;_K/7"8?(GLK_M=GD\F&1!>&1-(V1!
(&8>1%WZ7^ACP5HW@>+3KJX6;SH;>YU!Y99ULTE_IW)A,F17ES=322W9"Z.K2#S59P;1;+P""4WOA;-
MX)W^O)OV(O^GI^DWB^X@:O8ZC^O/B3K7@_MKMJ6YM;B*&QT^"IMH=/@5K;1_M%C#2?
+YC.7EE>9OM2B@#S_C7_P;P#Q1^7_1)+X?2\$GGM3;CT.RTCP)KJ_MWI90?"&5KF_@B>=
1>^R#K.V)E:XDWR;FW@(-B\$;63|N/_@W|^*/IE?1/3K&UA06/PAEEGU?1%8?V?;_T;R%@O1\OQ?Y@4'R5_M^F-%
_YO_P#153_@U3_P#@J=\$?@W%_&W1;B^&X_A1I9@A5O?MK_1\$A_XT?MG?_10_X.?_10_6_M/VV?
#F@ZW1+;0QIGAZV^\$S^1KJ;A>M?2R2N=:5U2;201%YCCVKN=E,C7H_ME10!^*O_4Y0?
1%6/B;_P6G^0Z%_P3(^GXP5?^OX2Z;8^?AWXSM+7^SO_M14M^ZW(E,>12PP=72)%
(LT\$CRB\$F.0^JKN|W|BK|MO_+10^/VKI/^"57_M_5_9Q^?#N3XE_"?7+KP=XI^&\$T"W>@OPVYA^V|K6|N8
J.ZH@Q\$Z3-\$?F_M5A7Z_?%1@H_D_XT?%?CCXU^\$L<C<6^V,GC/PUK%|HFKS6JXVP2WNG303R_MQ#_PCNRC'
K8^&OD^1.WP0U#5=<^WPRMDU;7;-;37/\$&L7<^J;GJ-LD6W_MGO;V26XFB19B(WD*L2!R;/_@W_@W_8A^,71^FK?
M1?^C4_VFH|XK?#2^Q5_ML^@SQ3)8R6MG=:O%1B;NJ_X.6O%OQHM?_MV#_#?PE_9L^+T7A_X@?+\$+XLZ%H/AOPT4?
S/&KRO)G15<^8XTD?RI)_.R0/"_M4C@2X;1"-TW3M^T^#2-(L;6TM85BMK6VB"1POJ_*BJH_50_.17?^I
M|FWX^_M3^_1%9?M\$";1/&^&K>QWD^AK=DLHMKJ//EW\$+?>AF7(OV"?VD?B?^Q-13_P!GWXW?
M)XF^_GQ<1^W^AKQ^X_MO/|DINEV\$UM;M18:1;74^Q14N;AA^S2/1)ND+(D<?RYX6_X-P-B^X_M)&?)?
^"2<1^>6D2Z%XD^P^1(9%1_!^074\$22V16HA_MG8Q_UM\$PEW#"EUV_M\$D_OZG44?7CS_@@IX1^O_21^?2
1\$1_CW\SDNYQ*1^/_%(HE42)(=OEMAAM_1^1_G_O1?MU?1J^%/"WPJ_Q_M_P""C<_O_1^_#R.*+P1X1T?P?
%IA98%VVHO|TR/<74_P81?4^\$6>18U0?_M<5%_Y?_S_@B14?@U_P6^16_16J?1LG1-4OO&BW%KJ_@%H726
30G>;*1^7YUP0Y*_%_%Y@?S'_@WF^_MCO\;C^#126K_13_Q5J_CIX::59V7B"7?2@#3IYM5^SO.5:TCA:*WLP8
MYWC^R17&#^1=17+INV^+P#P1%*^Q1_X+%^&_1@KK:~ME^IU_X5^FVTGP_M_PJEGA:Q2UFM3%+=?
VNC^8|B4^L;J&VGR^#1_0FB@#J/V5/^="QON_9D_M_P"#A^QA\="19.O_1^PWXYTCQ^KOO6/7=I(D/AF&ZD@;1M-
N)OM^QS3F2_M29H(Q\$T=M8%L19_#^<1:O1_VG_+9G)GO_95U7QI?>?Q1X6NM&DUS3
MHP(MGYR%1)1)42+G&Z/CYMDMS=27-RM;K&J)9_MY&W22MM_W.S+>2>2:M4?CCKO_
1_1\$OQG_P3@T71@COU_P_%O\$&I6OA_M^ODWB^P1;#P1;Q;H12_?M?2
V=9OM4IRM=2N)NML9)V1#>^1WO_@H_P_\$M+_BA_P_%?V^OA#^Q9XR;GM|^C^&4T%WJ|BN?X6I=7.M74-
1+;Q%(H=0MXI_M6%8IG4)B5SM0M(2&+?HG10!^?1FGCU>|MIK>5KB4-K2F-'K"/*4DK\ _P19&WLO^"F_P#P17^0
M?MG_+3/PJ_1_9W_&M/A1<_A6UHD&O7^ALWNF:S!!_TT<4|OYRNFUY)AG_M>^Z.5HVW#;R_25%
^YF6G_!|CHC7O\@JOX8_X^P_1\$O_@H+9ZEXS\6ML)1_M)@^&*K97+BTEN)H(4^W_VMKY,S(B\$S2Y)D:5G)-?
IG110!^2^P2_X=O%_PA_M)1_P"#^7_13;QD/A_1<+>=;OPUI_@ZS25YPTSVD1_="!U^YGN=U12_1\F-X
M>N&O&O8H\$;DKS.MR1.QDEPZ^RPJ_L6_0^B@#^COB+P_JJ_M1?7_@G;X6_X
M)M_&C_@IH\$ _@SP#X@MYO|H1P1PN*2FRB1;+W>=|KAXDFN&)B1^R7;8B_MQ^V?MB?^12B/^UQ_P_1LOAI_P
\$P-0_1_T_2_1^J;5;R^9/A@USY;3?M7_0Y+?H+10!^8/I=-1O#12OVY?V^_@%Q)X1;_MIT;01_16@PZ;Z18_"&66;6?
(M(K^11HVUD+!M@B4,H+IW)8%1A!T?_4_M_P""WQH_P""@G107P/_&A_\$?18Q.1^C=%_YZ_M^1!\$7XJ_MR?
1%#OA#_1_E_1_M1+PK??1N71YO#_A@?^B:1^AO)K^4/M1&XF_MB)BLDQ*1452B8&68%RIHJS_@B_M-
14/VG/^"KOPY_X^ECHG1_#O_AL:7;Z/X^PJEN8;BWM)KB9UEN?171B1C_M74X#1+&_@?^*Q4EOT(HH_/GX+?^1\$?
XD?^3_@L9XJ_X^XW/18FCZG=^+_M_MMJ?@1/A=+!"8R6\11W?^SD2JEO\$3^8F5F#^RP&_5G1^7_1\$;XH_LU?1
M%8_1G_15#44VRM^U^1^B+^#J%KK_1(B^44MG#%:W,MO)1@N3AK(Z&UA&1H_MW1^1Y1D_0FB@#1T?
C=1_P01^/G161_PX_8;_Q_1R1>+2AWX^U^SU^V3_M0_#>:WA60V";G1DP79OGA5#&1^1J.0210?P_M0;P^"711"?
#^QY^12LYM!GO?"HUBPN;6^BO+96M_M\$!131D_?^NK%21P_MP^1;*_SS_X^1_1^#?XD_167X1_#3X2>+P1N-?#L?
@^XN10U+6+sx;+J_M-WK.HW(>0>7J%M^0*JD^H048^F-BOM^Q5\(<^>)?1_NL?;XE^5;11>_M#KO0=71>&=/?
3ROVBV>W>XMHD)IV@90^Y09^PP^KZ^/QT1_1&J7Q\$1_M_P#1/1QQ^P_XG_X^?^<(K1PWKWBB+Q#X9TJP\
6EMI>G:DCQ_W-S&TSW5T7AA_M5/+6YBAC9M^R1U#51)?%:_@AZ/CS_P_<=_X)4?&#J16^U*^1+66G)X=^(%
MKX5@MTL9+\$!+9/L2R9DA\$6Z-@QD8ORJOWS10\1^/1^711/Q_P""

[illegible]

<M6T1V7EG,A#)*IPR[D0.A8 I3 _&./VG?@5^V' M'=.^A
^S\0(('%@_5[Ff@TW7+TGACN7MKF6UFVK.B.56:&10VW:P7\K\0?^"+W_!2?XP_L8?!\#^X:>(/AE_P3O\B7\6O#7A
^(\HWX>?*?#1 MU:V-K!%L=1&8HP&1/BBCU+516F,JMIY6618H9(3;W)G=W\$<26LSEB-M%&X^B:*^3-
!P'''GVI^#OVWM&_8W_M_9RN? ?C3QKX.NM:&^>H+XJAU2 MO%"VR\HFD16S6IVJOL?
+EC'''\$GS)OHTW_@NWXZ^=(= \ %CPO\O^"7GQ MA:~)O@H0(#?BSPH1HOVYTBLSLDNI#+++\$Q\PI<-N\YD6-
Y"TC<LX/T M^*KP3XK_!%2?^"<P+^J_LI_&#IM/X=>/&?G)%/H.J^")H(L:61P"B7!+;+= MB'''%E9#A@>A&?
=(@\IS9AT5H))(\A95!;,\$=P#@D'T./>OBSILG_@FW_P3L^' M7_!,OXH>#OBS%/"UQI6E^~7U?
7_&JZ\;MK5UJ;6LL\FL2WI3S7OGG;EAS M=EG;8IM.R@#H6AFAN(4N+>59(Y%#(Z-D.#R''' .HKP^_."FW_!.G3/B9+!%
MH0_>C^\$T/B^~7#HTOAA_'U@+!-1\$WDFS_'FL_!WJWY>-V!Y<9XKP;IAIPG^ MWM!O^"
O@3PAX)\&3^<(OCS8?!"8?^VB.WJ_.LJK=7!;f!')92\Q.9A^*Z(P!^PU%-%F65X76&0(Y M4A^*Y"GL<=Z_!OBO_P5)_X)S_~
OXRK^SWA8\VT_AUX<^9^%KC2M+!>OJ^O\ CC5='MVUJZU+66>36); MTIYKWSS@R^9NRSML
VGR97Q5^V7XV_!H_9\$X-=/!>C9SQX\I2KZI7C_XJS>? MAH%W/*RWNEZ?J+7-T+1LHRZ?
MFZGE5+KP10!^KGP!_9_9+^~?C7_ (5W M(OV@_ " B#69(9YK.STW4U?
^T(H'''3RVC_ =O(XV(5W@+JA8!B.BI_P!HGL7 MIEG\C/PE:~.?VJ/CWX8\Z9?W!M\N/\$>J) UY^* "R0ODIYF
O)"*=H.3@BVG)O_!+7PQ^T%~S\HOX?UK\G^QYX5U;X=9IY8L8XKF/3?L@VX M/D;W)BDC^ZZ## BOKFS_98_9O\
CWA1(VMOB9\=(A8;MK?A.OL_#H5:5 M!>QZ^IC(9VAMHY598GEDF=Y9%:_0+\$C\$K"@
!VGP%_.*^!^I4GPZMOBW^SG\ M7?#_ (U\74C11;SX;U2.Z@>JXW1,4)V2+D;D;#>D9_K5^*Q0^~GP4^>L_~
M%KXL^_=/>@&O#VGR7VMZUJEP(K>SMXQEI'8!CMU)(!) K\^/^"27L/AW MX"?%8?
YU;OJF;1(f!~"8UCPWIMH6F)LTM/% T\7.I1V<_)'Y\N-LB+@({ M PL8&(PJX/_!
<_415_0_85_&O='U^*XB^&GP!^*Z@AFMIF1%_C" A&3 M66F,6!^*RW^0<&P(<_3^P=XN\~?
\$#PCI7CWP9K\$.HZ/K>FP7^DZA;DF.ZMI MHUDBE7A+>(RL/8UI5Y#_,\$^O^3"?@A_V2^PU_Z;f:O7J"BBB@#\
IOC9^W3-M^U1X1^,WB\PGX>^*7V?3!+>3W\H8V_!8EB_E0QW\$B(NYH"S850,DDG')~"2\
'=,\53IYKB5%5)H)5ZJ22DD)+GT2;/^A? M!8'_ \$5I_P H&G_ "/7V'_ P3Z^,GQ(^.P9U/Q9\4/\$?J;A;^)YK2&X^QP
MP;85MI9PNV%64_-(YR1GGKP^~2OT\$ X)1^FIZS_P!CI=), 50_B\BS.2\$&&S#,*!G!H^615J3C=)6?+*
M35UTT/IRO*/CA^W;^Q7^S/XUM?AM^T1^UA//_B&^TY+^RT/O7XOM+^IGM7_MDDC2=(H%9HR\4JA@,\$OL.H-
>KUR.DM_~P'''6C_#6_VB;?1\$?Q9KWAW3!^N M\3EC0O\HG-
=3101MMW*ADO)G8;B&)4X^45_/! =)Y^*W_173_@EFLUPW_!1 M+X+B.W?
9.Y^&)&FXC;...?X.;>_&MC5O^"E7!FD^_/AYX_7HJPCJ&L_%BYB
MA^FGZ^J\HOK7F'"21_91(%A)X\$SE8_HOBS_@W'''00>M9O_!6KX=?"SID^X_!^/A?P#X8OH_#GAC MIH+5)M^T;2-
_S\!#.#<_8K2"!-S^*K2'''*)5)"I&I(W\$ _56BOD;X\$?%1_ M%/C;HNB7\@CH_!8S\6?">O7JO@V;Q5X\GUKO)INJ1>
(-AF\N56;PEDCMK ME>6_/F2 '!')=<^>7OR^!_P4_X)E?%SQAXI^H\YI46K>#K M74-
%Y=072RO)5IVI1QQ1FSFV>6*PLVC\$URRJ2(D.KH@=B-HW\J MY(RP&2 "S17PE&O^"S?Q_:@\&_%2I_92\
^";Q(3^~OA7\12\Z)SX1U M^Q\6FM')8QQ&9YKN29K=9C^*D26UNITY,6YBJ.K^A #A P7.U?XX?L36W
ML;G(G\!WXB_!0M-T\U^X@6MQJHAP;28VD6ZMD>Y?>J-PBQ/*\$M8W^E MI=S) (XBH_!^.*^<=4_X^B?LTZ?A
L>!_P\N^T MJ_T#XE+!MX\$!-6-G&VL M;UJVI.(K72\6D5#=#F7=&09!&OE2_7'''6KG_!Q_P4QUW\FOX?#SX_MQ?L
MZA_#K2OBOJHT?P_XITCQ^K6DC6&_>EZ@WD6IV5Q(#A"%EA9@V)<^S^K M]^~. B7_~%
<1X!_X^!;C_P3LTW\B\XE;SXQB^~4WBO0)+*?3=GB&(7JVD(M MB+EHX(C;SV:XO9+41BW(9"SH&O\!^G_4\7?
M6WWQI^~6I_LB;YX+^~?P M1N\2#Q#\+8\4V4RW7VV\!K"6+48OW)BF1&)<*=B\2^Y00#Z6^*Q4^&WP3
M\ZE\4\BIXZTKPUX=T>W_!IZUK5ZEO;6R#NSN0\DX_4D@_ \$D^"L?IG^IH_X^* M_M;_9T?IH3IG?QS%XE\>(<#<_V-
K<%G/_EUY%S+;2E4G1^P)H9%!*@-MW+ ME2^?A#_@CW^VA^UG^V\^Q?%_#XG?M%_!"&!/??
\$7C)IO\$=OXFBFMK1HE,\$> ME0VC#S1#%>OEK(3AA^N/+DUX_~P2>_X\$5?3IAG_((&?^7XI>&?V&^!^O&\
M\$>!M_UBX^<_B\3-7L=-@TBV;7HJG;UBNG\$VI^&DBM(84\$^9^F;#JF7CC?>CJR^5P0#UNBN#_&D\VO_!+_,F^)?C
MZ>!NO\JEELAZ)\$%^*RWVMZK>3L;Y>GVL;LJO/-(B+N947)=V1%9E\%US_@J M\KOP_~&^D\!96L^%?S^A^~?
#&F^,O#%HITW5!"&IT^Y\DV^"5_!7_9WF/E\$;+F6>/S4.D^8?9H>^/VG=,^"WP+^!^?PE\ M>#
IGQ7\0/'W@JR3PCX3M+R.V\$T-HT\$EW>W-Q)E;T@5XA)+M=ITT21QR.ZJ M0#Z-KFOB\9/A3\?AH7Q8^~?
Q"TCPMX;TB S:CK6MWR6IO_H\!+1DG^"C M)X)KP+IFG_ (*7Z=\5?VQ?&? P3\^/GP9N?
AK60^/A^+Q#;Z6=>BU33_~M>T5V5!>V_XL<3/M9U5XY(HW7)P&VOLZ^/^_4+!7 M%_L_?% XY_LS_LMW
M7CCX067AKQ\$!^+CXHAM;WQ!;V\%Q;7FH;3H0LMY;1.DH#2W%O)-Y+^5'(" MA<^MO@!^??
A^<U^"M^<OP^8)X@(^);9KC0\9CM)H%NHED>,N\$G1)%&I M^&S^*XR."#75ZAJ%AI-A\JNJWT-M;VT+2W-
S<2A(XHU!+S^A5 !))X %?%&_ M_!O^_P_H7V?_P#L3?_>N\$N;^2O^~VGO\3?M&?%/_V5_~"ZZS=62@/XE
M;H_BKXM6-K.T\0:59M+^%IDC(0WV=08W?F)GYBT1XV"@#137_@J1_P3S-S\$ M#^USX-6QGO?LD^B%11VZ/+6VB-
=2(^OLO;Y0!^*Y\BWN\+=JUG26_M*5_&YM.C:Q> MQ.?EFV_&W9Y6SY=F_NWC&*_#_@A9^U-
<_LU_\$HKK_@G%_B_)_P^*P#V M7O%MWJ^@77_\$%ZTC:1X3:6\8VLLKDGRK.*")U)S@32^*B^*#16Z^*^~(V_~
M\%F;CIGSX!^>SOVW?B=^R+XBLO@+XOUC3I6U8+KD;Y965\2+35+C1Q#^!M) M1Y;"Y_P^F3= KDQCC\VM?
VI\U^"O^P6C^~W\I(P_~P!GZ/4?S^"=>\1 MV6GO>f>TG\4S+;M;^?S L_PV^Z39\$^6D9RY^E4/T3K%^<(GO&\
_"/P5J M/Q(^/C/3/#V@;1;^?J>LZO>I;VUMD#<CD^N20\SR2_D@5XYXX_~WO+;>(!+RSF0ADE 4X9=R^<0L>I_LT?
M_ K\H.Z.Z=^?V;B!! MXH^ZO_X^* M3_&I^C#_ ((8_#3Q\!O^"~ =_Q+^+7AKP@?S=H0%/A^ZM;^UTBV.N7\S&W2
MX/GZBZ1S^<(C;48.E5E=4_37P_~P_%/V%*MD=V\!VBM MFM\MC5C8^7+&\$_) /F3?Y11O_7A=?\$ _BQX7^~7_~
2\^/C7Q_!OB! M^X\6>%/_OM^~VVD6=DEU(8998F/F!ECAMWG,BQO(6CC5G_!^A5>"?%?_@J3_M_P
\$Y_@7\95_9I^_!^?PZ\>_..2*?0=5\3012VLC@%N^6V6\\$\$\$+^R^* M\^!^Y\FS#HK02219^R^8V(f@!(/H<>I?
%G\9/_!O_@G9\O^~"9?Q0\ M?%GX*>%KC2M+!>OJ^O^~.5T>W;6KK4TM99Y-8EO2GFO?/#+Yf\+VP#:=E M
U\U00BC\~?A)X U^XK?%Q\HWAWPQI_HJU/Q#K6H16UE.PD@"22:1@B+E M@,DXY^K7AW_#X?^X)0_!>
(@A_X<I3/_CU>8?^!_7\B*!^*~\ P1K^7L_M_P"WYH%YKW\G^&M,U^Q)X1UQBT51#%)99HC\ID#H MWG^_4-
_P'''=^!_O4?C+^SU^Q_!%OV%/_WX9U\XC?&+6O\$6K^&_ACI-C> M6OA?
0\$&I;B^N(+=9(A;MA9DJ1N6J92<\$@^Z1PQ?72SP2!T=0R.IR&Z\$4_MZBFS+^+K#(\$_~M.2*?
0=5\3012VLC@%N^6V6\\$\$\$+^R^* M\^!^BIM6M1?+E/>^><&7S-V6=M@&T!^*^OVR_&W\5^IG_!K\#/\V>^! M?
B/5=^?_%6;P\V=0NYY66\TW3\1_YNA;GE&73X%LW4JH=>^*_/U<^%/H M;f)Q\$;_!
"N_A%^T^X7\0:S)#/_9V>FZFK_VA^X2>6T?IMY^&Q^N\!>4 M+ _1D5/^TS^V+^RS^QGXM2?/f5^Q\!>
f.O\^V^GW^B/5\$@A_E_!9(8R=^! MS_\$\$A%.T)P.;^*?^#B/1;3IDW_@EKX8_;"_9^T^W\ZU^SCX\!ZM\GLT\ ML6;
<5S^IOV0;<^R^MIDO21_==!A@17US9_LL2LW_!^<(D^f6WQ_&^ND>_~6 MUOPG8V?AT>*M^@O8\#TOD;
f0VT;6^O#N\^)(8H>20_QI.2=MNS M_J0LI4D,I PPS\G_~f)+f^P\!/^"L\H:MW^S-HD>@_~!^QX;TVTT+3\$V;
M6GB@;>+G4H\~?DC@W&V1^P\$;X6_#8\$5^O&/Q&=+?P8VO(LFHQ;U=72Y0WEPIJ27^+^fEQ/>fEILB9=GV_?H
MT"&_93D\H117?LP^"H^&^_!7P^<GA_P"(\6V&^&M\TZV\5^X68;S#19 MQ1)>fU9^G^HDW\B^OR">M=S0
4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
!111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 ?
QI_!%00^4E_!1^_9=/%W_!YNZ\+K^<KJ^_@T?^&DOVF/B M)^T3_P / O\^P^"=\$=;OXC_+^_~.4_~?L/VZHEN?
(W^~U4\W9YNS?L7=M MSM7\PO_!;2\9) P#S#G_WXK\1P_>30H0C^KJDOLR\>ABXRN?A?7\G_! MGM_RC0\
<_P#9=-3_/3-HM>%_P#\$%M_UDG_!PY_!^*_2+@CU_P3\$X=/_LS

MZY^SM_PN_P#X3I^VO^5SXC_MC_A&OI*GSK*RMOKI3<;L?8I^>,^9C:N M3Y7\$&=99CLN=*A4O*ZTM)?
FD5&+3/JZD9E12IL_DD^4MC0\$ASPIXNT6X_M\^*!LM3TZI39=V&H6J30S+G.UT<%6&0#@CM7P9H?EW_P
&VGC3PCXC^/J M=^?4\$UC?&Y_!MUW4;<6ETDGFVDUS<^5<+M)S&^UMKC@X.#78?^!;Q-X=T M;IOC|@SU?
7;UE;IH&618|BY5&*9XHIV">F^1%SZN;U?>7A7JGWX">!=MAI4>"/@CX0T;4H8;+?
4=^!-6MO\$&4JVVY(N5)4X(O)>I/&(P)^!_OQH_M_A(2^P_A^!J'E+!%NUCPL;74VQ.7(1Zi&OT^_X)3^,/!">H_P#1
M;+ @HCHEAXEL9KR:Q%Q\$DAMHKI&>18-*NX9RH;RPEC*H^/N.P!P2^*^+OIG# M1GB_U@>
(KIX#>"YM05T=;Z7PO^;^&0 (=YCW94*H;SQ@8Z4_PM^SWA_O ^NP M>?*!7PA^Z/J=KN^S:CI?
AFUMYX=RE&VR1QAERK;IP>0Q^0T ?D18_&^IA?I MBG_@LC^TG&O^"M7PF\$6VF_%K7^-A9_"#XF?
\$3P=;WIA=6OV**WN+!5/" MD"-HE1!"^+23K+XD6NE7_491;16R?;+2(R;&G<.)/LUUM!2-6D_5+XI_X M*_/2I;0_C9)
(/"_C&RL|CS|2S4^!L;4(H)?^>B).CA6X^(&:Z#2!*TOOL_MM|T73;>SLK2;8;6TM85CBAB4!51\$4_*H_P*_ /SA^! /I7?)
P;^+5I M^!^WD)_LGP8;^;Q;0;HC-X9!#6?PJL(M;T2X\$B-!>7(^QL;+!-!)<9VX M@Q\$TC&^_2:N/^!/?
P;^_O:GX!^SWPA^A?4!;^L:CX=VME?JG;I M;TD;M+SSO/-=5J6FZ=K.G7&D:080W=I=PO#=#6MS\$)
(YHV!5D=6!#*02^#P_M0<4 ?G^_&^?B|PHJ7BG|N^T|Q)83PC|MOQM?F6*!1E%KA!1CGR#CRV^_0 M_0|&P>#7G^_!#
IQ;X5;_(-Y?BG|^(I VME!1C>3_!TV0!C=2*7.<+E^1A MGJ&Z\$5^F>G?LT_LY:1%=P;3^/!-
JE_!FVODM_"MF@N(2ZN8I L8WIN1&VG M(RBGJ!1;?LT_LY66FW6C6?P_\$PV=|8S>VD7A2S6*X*\$E"ZB/#
I221D^&3B@_M#^/M17QIX7_X(9?)\$OVW?"_A=;X+9^>+E^!)OB=8;AN^M=AU*=);MD3 M)_<%6C/&4-P^1M#&?
9G_7NMO_!0#|E7X)_LV?LT^/!^4^*?B?&^?P! MJ7@BX;7^=VT&G0+!+=ZT#\$25M;>V=BWW5\O%SN=0?T-
!)?"KX7^_)N|!^M"?#?0_!\$!DWUEI&CP6T5P2NTF1(U ?Y>.0>.*R_A=^SI^SY#|V^U+X+? G MP;X0N-
4=3N/"_ABTTHLSX^!:"\$)SSV:/A?6?GAX_!^U|F.#7+3I2 M/V(6LS;HH7?IH_X2::?R<9SO^D^9MZI/FZ)/#UY_P<3?
MX;99;Y:2W M\$GAX=18(KA69CHHR1S8_//ENZJWTL<\$UIXR_L^_6?Q3_)SA\$?"#ZV
M;X7O|L/X:M3=2:0^3^Y>_S-WS^!LVS1X;_9|^G@SQ!^XL^!^!PALJ MVL;?4|-
^6L%Q\$64JO61(PRY5F!P>0Q^>@#^RO^" ?I07P3\+^_!\$V/B=^SU
MX@^)^C6GGGP|XV^!%UXA^*2WBB_TJVC GD9|FZA^!;P#>J^=(%C+D(&+?+7%_ML=>(?
#Z_!&9&N22;W9A8/@SXXM)BUPN(|A14U14B;GAV9T_4DNN;R*7"Z^ M^"P6ODUN;|^!\$A>9?S\$MO^<>
(UET^V8;K+&=R27.4 ?LI (9^D^D503|E;|F^ M/29-!C_9|!\$+8S7^7\$MD/"EF(GE165)"GEX+*KN_Q&0^8#J;-/SGO?
@S^PQ^>MVO^!\$YOV&V5_VD_B3J7A#Q5XF^#&DZE&OB5X7^1KI^H:/X@T!1M^62WMI MN091%G8^4W4VC
;95C^J?^!^7XD?MS>%C_P#^S|@CHLXQVOQ?M/@K=Z^ M^X7^!D=@(^O4HKZVEN/I.OBI(>Z@CH!9Y%;QWNX>-
CIAZI^S^S9KGA=? M^M2L|!HS14>5TF>Z!)V3@UBETFJ>^!1+N^C>%P5D0?;4+;@55-MSL-
J\$B+IGW|I_P#X(M.;>||AO)^QA_L^!COY!1=1UJRUP_I6@_"^QM!6 M^*QOS1RW&JW#FSW;8;1%;@=BADF2**
B|B&OT-EBCFC&^;71U^NC#(8^J^ M!02;M_X8^_VM@|ZX)(8P1J9^,GEL|3 M0!&_P#1;?Q)X>U^_@O#_P
%\$;_PURTFEN/AQY<45PK;WV?1;F*? !R?+D8 M(^_!&8@^! ?2^6B^!^O!2W_)^X^F?"|HG^KV>G;+*)HW
M3HM4TZ|F\$2H29!;6MT|!<^8057).* ; 3?V:/V<=&NWU#1_V?^P3;3R030
MR3VWA25C=HI8VCE0E8P2KONZ..C*S_Y!Q_X^*^7P8^&NJ2;W!^?A%*X8T"IF
MMS!+>.)H^M^:2O\$65C&7B125+^IP3C^@!A0!^47|?7_!2W|C/HJ_-(J?SUS M-
/CKX6/B^50AAH^F2^!U!>#;M9;E!-9BYM&LPWG_Q>5(V!L;^8#L;N<_M;^_W!^?PG^!/|G_!0WX|!^" #_O-
_9JO0@!X^!7ZY_8T&OZ=X;U&X@M)H; MN2+9(H?S(PC_R!;>=0^X^_!LZ?LF_LL17NNZE^!S1/UN?%)!37^!#;\$/I
MY\$JR@W3>5FXO(B/^W?;H;J;ZWO^X)&>."EQX\$!7>\$=+U70|NV%O=;J5_MA^!;30C&(WA=2C+P/E(OP^!/@?
1M7_X)I?M;^OB7X^_X)*?;X3ZMXIO/@W MK|C< %7X=^#+*P7P|+>6.D%A9-J\$5LA;IQ^X6ZN-D=M^!FW\$;R>*^!
!3_M(*^2LKZ9_P0@U^!F?XG_%00!|Q+^%O@/O#X0?7_#IQ?QV.K0;BOVQ(4CM
M)2LTS3;XP!&K\$REX%U(KJ5OAK*/A^&?"Z>"/@_P#70/"FBQ2-)%^AK1 MH+"U1VON810*J_G_R<>);GPM;
M2;A/O&8WA>X;R-T9*%2Q!4X(QO0!E^!M0!10_7CK_@C7!%=^!>=, MU;|T#P_/8;Y:6-
^DLNG7^WUR3#.BDM\$^_!%8_E2&^!Krk_@N%^SO3/A%^V MS^S=_P%F?
AAX(U+O^!H7P1U=1+^+6E);^!VL%U" ^&?@_M74+=H=4C^VTL|Q9PS1^!CN+O^\$?E-
SA(SP)^!^L^G_L= LC:3!0A!6!*_99 M^!%MXK\$_G#Q/^!^!-0!S= VD0B3=DDYW9YKT>@#W_/_@GS_P7<_83^!OI
M^7PY;W^CN^;XNZ=X8T_PU(+!%+86=M;E_&P!\$_"_AXPU%674/=EX; MM8M2N@WWA)=+&)7!
HF.;U_%P^!^>+K3;|QIX(TC6)!&O1>:/JFFO7#V- MP.DT)D4F^0?WEP?>@#^T?V;/B\$V4?^ @X&_4^?M_ZFVD:?
^TIX9+^*?@_M_P^(M2!K2^68M;LW@ETZ;S!2MS\$+IP;=L2!;;)4;ESUWL;PQE^+/_!P5^T) M^V?+
H+OP+X>^"VE_#|5M;L6#VFJ>)"FMKN;&5\$ _/A/P^X=M/^!_@;POIVBZ181>58Z7I-E;6ULG7;^%&J#D^4 ?E_M_P
&Z7I3_P^SK!^_!GAW4OC)!3=|T|AW_XG3QSHUY?1&T^1M9O!4M)K8 MGS!/*DD8CA^IY^*BJ^6 KY0U7|EWXK?
!\$Y^!<3?1%G|0_P^U)^SO^XCV^_# # MXP;KXE^?PXO!&2_L;1==_Q^"JK;I4O!#(A*2;+B=4.TY8?N5=?LU?LYW
MWQ.C^E!^?!.WC.%P^7BZ7PK9M;..A%T8_!IPU=AJ;G;?J^GSZ3JUC#=6 MMU^T5S;7\$0>.6_@0R;K9#*02^#P0;
/A7|F+X|?1_VA/COX%_X=^_P+^# M7CCQUE|237?|GPXL;|&^;<(7_E_FY".HKIU^ M^!/_!O@YHFH>&?
A%\$O^/A73=6=GU73_#?ANUL8+QB""98X8U60D;02P/! M/K3O^/P%^!GP_P!;7Q^X^" ^/A1-12-
D2_TCPY;VTR|PPRAXT#_=\$1GF@#J+ MNIM+"UEO!^YC@@@C;2:9P1H;DLO/R2;_JX?^!93_00?M8?&2;P
M+^9/VW/_FE^;P!XBCE;0!R_9SX|UFTD62*;541E_LFVF5712%/ MM7Z7ZAHJUA/16JV_U;W4+17-M<1!XY8V!#
(RG(92^00>^#7#?^V;G_++/M_1M7P^_!^L2_C5^F=E_P5>_8.G_9A!^>J?^*#2_A/<>^0^\$?TGQYJFFW
M;5CJ=UYOD&2^!V9#)Q+^9G1\$W6C9V.WC/_!0R+IGG_@!HKWP)^#_!GQ&
M^_!O%OACXV>^!0^0^#M6@U%?"NC6\$YN+J^GN;=F6W6>/_!A^P;TL956\$ M+O^!GW_PA^\$^J?#U_A)J?
PP;W/A26+RI/#\$^B0/HQ|H^PVQ3RRN_YL;<9Y_MZU)_A^!OA#X>7PC)OASH/A?25D+KI?AW2(^*W#^JPCA55R<=
<4><>/_O M^" @G!GPN_X+?L^>/_ (WZ?IGQ5^;3_7AKPK<6EQNO(^TJK^_9@1W,\$ MP2-
Y%=_+U3D9|AN|NTL+66_OIF.""^DHG^I&@&2S\$#))KOGXW?LA^M&/C|^T1X#^+?<?
C/PAX5BM_A|J;&K6.M1Z6DNN:A=0^<;>S-RT8;ULHI9!(HY6T^OV<^/9M)%DBFE5\$9 M?D)MIE5T4G-
Y|\$KD^WA3|4S_ (+%7&@?^%O^"1MY^T3^P#=\$M_#/A#P!8Z5IMHI6UT_3;1((026(2-4\$D
MG@=230!>7_!U6%;^Q^X|HGW|7KW|?7_50_9/_&^!4_!L5Q?M>\$ M/GCC5M&CC&L>(KA98?!VDHBBH+^>(^ =
(15!8?SX2>+&^!U?79;US5=%T&WM;G47SG=+!^BM;/_@=X/U?4|HK|JU5/#_K<3S;+>NDDC+A551D^=J/E3|DS|
MKA_X)X?/X9Z|P3V_XC_M2;_!+X\$UF/C+PW;3;A/H=O/E>OKF81 MK<7DEI^K;07AR;5G;0;R(^? !1_@FU_P
%)?V6O^"2/QA^_K_!%CYO\$W MPU^?#;";X=1_L>^M-34;&^/LQO86;>FZM;"TC;2Q)9B3^NG@?X_"/X M97;H^
OA9X<^372!+J70!#M1!IE!R%8Q(I8_X;^&O;H7BG1HCPIXGT2T MU+3IR(QW=C?VRS0SH>JNC@JPIB;4 ?_O_!&
IX8_P" &7_!WX=P?^!HV7X MG3;QX2T;40#\$O@ZRT?_ (1_29*_L_(TD^UXNA^5<_9/WC^9^W05|2U#I^G
MV&D6\$&E;58PVMK;PK%;6UO\$C\$CBC4_*BJ;15_X%34_%%%"Y)_M(^G\$ M>/?^OTU3_P!^Y;XNONKXD?^!+7
(6#^1-?^?+T^Q_P!N;U=;A|D_X1CS_M/(Z9I-FH2-V-V_X&<9P_E8O_#H;_JX3_RT_P#|KK^F;#X@/(4<%2ISQ-FH
MQ3|IRINDO!_G=G/^5XJ80_17I9?>ZDY)^UH*Z?^GAIQ=HMQX^5Z#9;GIUVFR|L-0M4FAF7.=KHX^L;@^!^!OQ_
ML@+O_@VT!>\$?S_QQ;K7P|XFL;XW|H5NNZC;BTND|VTFN;GRKA=1.8WVM MM<^!P;|!#_@MMXF;Z-
^WQ^P!9ZOKMG;RM^T#+(L=Q|!/?3?(BY| M7_ZFOO+PK^S|!/_ NNP^*^!^P1!G;
J=L&%OJ.E>&K6WGB#*5;)"&^7^DJ< M^D\$CO4GC^X\$ _XAZQ_PD/C_#?A37=0|I8OMVL>";ZFV+G^IY\$+8&3@9P
M;T?7I5_B/P_9^+^!^VDW&MVD=V_P7^6H+9|A1(2\$|1_X+9?^!1^1+^#Q+8S7DWB+P)##;172^BP;5=PSE0#EA^*5
M1|?<9@#^D5|X7?L^!/_K_!17WP&^%S;@KHZWTOA>T;8;@_0!S^NRH50^GC M OTI_A;IGOX!>|!>@^4^"O@?X/T?
4I7=|FU^2_#_K;SP|E^MDCC#+E693@_MAB;AH_)VO^_/!^!_!%/_61_3^#7_!6KX3>"+;3?BUKFF^_A!3/B)X.M

MI^PNK7I!%;W%CHJGA?R!&T2HN2\$W0R@E2T>_8_X*6:%^S!6_P#@EIXJ!%;
MX)@_L>>#Y_AYX^",GASQJJ>#O!%OIUE!2+72KG?J.HMHK9/MEI\$9-C3N'\$G MV:ZV@I&K2?JEM4_@?^%?
CGI=MH?QI^\$A?QC96=QYH9^*?#IMJ\$4\$O_#T1 M)T<^*W Y
S70:7I6EZIEOHFBZ;V=E:0+#+VEK^L<4,2@*J(B@!5 <10 M!^=(7L9O#/@:S^%5A%K>B7_D1 MHRY^V-
C8)9H)H+C.W\$&F(D9XP_Z35Q_P_ PIGOXI??"7M3\4_";X^#_# M^IZTV=8U^PIX9M;*>_.=V9H(8U:7GGYB>:ZK4M-
TI6=.N-(U>PANI2IA>&ZM M;F(21S1L^K(ZL"&4@D\$'@@XH_/_@WS\7>%_2\4_MQWFG>)+>?\$MM^~K\R
MQ7:;HM9'B,<^0<>6P1R'Z'8V#P:X_X(?>+?"K?&\&OO3U_?\$=@;6RG^(OO) M_M;:(QNI%+G.%RCHPSU#
I!*_3/3OV:~?V"8;.^_9O:2+PI9K%< M%"2A=1^AH(D(R#C)QO!^~VHKXT+^_P#;#+_@GE^VIX1L+K7_7^S!6=+~3 M?
\$ZPT=#,H;@\$C:&(^S/^"IUMX'_."@!^OP3_9
ML_9I>:3XI4_\$XS^"M2\5^7^AR_CNV@TZ!9Y;O6@8B2MK;VSL7F^ZOF(N=S MJ#^AOA+X5?"_PIH-WH/@3X;Z!HEC?
DF^LM(T">"VBN"5VDR)&H#_+OR#QQ67^M+OV=IV?/@?>WVI?;X\$^#?"%QJASJ=QX7^,6FGO=G.?WK01J9.>?FS0!&
(ZS MXD)/_@ZITG3!KEH!^+69@^T^O^T^2^/_X_YW^22.VI=GS=:/V!/\$G MAZI_X)OYA_IIMX
M!O5?.D"QER\$#%OEKB_V.O\$/AI?^@S(UR236L+!&?%L6N%Q*O\$WP8TG4O@U^2O" MB-=/U#1_\$&G:I2R6IM-
R#-(L!^RFZFT8#;*L97U3_@CK\2/VYO"GO_/_G! M!8/QCM?B_?;!6IT.+PO\9(I 07>I17UM+81\$T90%O+CW".O<
MYVBMWX>?#/XTJ&RM82QR2L4*JBY)/P. M:/A#_@Y)T^QE9?L:~?OIH70_A1_PG7A_P""_P
>O#GCOXA>#VL4NDU3P_.) M=PW<:PN"LB#I2A;<^JIN=AM0D1?L^_M/ P#!GHSQY-YA^_V??@QX\^(N
MHZU9:CX?TK0?A?8V^K>%8XYHY:C5;AS9IM.-HBF0.Q0R3)%%&Q>1#7Z&R01S M1M#-
&KHZE71AD;^U!>N3^&7I\^!O@I=;C?~!KX)>\$?^4^KR"35IO#^ANU ML^O7!)#3&"-3(1D^MGJ:
/@W_@F/XD\^C_P7A_X*(V=AKEI--+STH191-/Z\$=%JFG7S6Y^EO-\$T^VM)7B+*QC+Q(I^EE4X)QE0>PH_+~+I0K_(*6
M_L9_M7_~U/B_Y^&GOU+^Q#JWPPT?3?>ZZO"-6LM2@FLQ_?A_P")OI-5I^!IO_?B_7/I M&@U_3O#6HW\$%I-
#=R1;)%#^9&\$8_0+;SJ_7_1OUG3IDWIEB^IUW4H_V:/A^
MMSXI(B:X7P;8AI7(E64&Z;RLW&)\$1_WFIYE#=0#76^(_!/@SOCX4N/ GBIP
MGI>JZ'=VPMIK1M2L(YI2:\$8Q&\+J49>~!I&.!0!\#Z_J_P#P32_~V/?\$OP5_M_P \$E/(@M)\I6>WGP;U^QN?
BK\ _IEE8+X=EO+&2^PLFU""V0F>XF?<+~7&R M.VE>3;B-9!/?>^4G_!03IE?3/^"~\$&H LS_ \$XK:%X)^?)
PM\!^("B_X?>) MK^~.QU:~#45^V)"D=I^5FF:~?&-(U8F4O'^NI%?JMA~?A1+~?@SX73P1\^AKH
M^A318I&D0TCPUHT^A:HI8W,(H%5_3@9..<5E;G^S;^SMK7CZ^~VL?_3P7=^
M^;VS>TO\$MSX6M)-0GMWC;PO<~&9&C;E"IB@J<\$8XH_~2_~#;CXC>_O'7_M_1K^"NE>#O&F:G=Z!X?GL-JY(R-
N\$61E_2IPOX6\^~"?#HX2&G>_#2~*T^~0V&F:99I M;VIM&.B1QQ@*BCL*OT>7;U^VS^R+X?^
/_#4^J_M(>#8_AX=.^W1>+5UZ_M%I2;+;N_C96)DD/01*#(\$S^%+~?E%!_P#@G)^T_P#M?L)_M_ML7GPWUG
M0/"I6"ZA?^PS"ZA;M#JD?A^VEGN+.&:(X;=Q>(XCHN<)&>!(0/UGT_~
M8I_9&TGXA^XMZ5^RS\+;Q6)_B>W\#V":AYF<I_M(A\$F!)SNSS7H!_YO M_P#I/G_@NY^PG\1?
V\$OASX=N/'<\$WQ=TIPOI_AJX^",%LYU^~\06T^6PLI_U M^Y9)9HP5F_U4:/NE:/RY-F/^W^7OAI^S!_P<%?LP?
%KJHKQUH7@K0;GX>~* MK&37==U5+73EO02I0"XFV^6^90H."Q=^!E@#^A6B_I_~_~\$JH^,WAWX)
M^<#;QAJ^LNH>~!+PW;Q:E=IOO"2Z6,2N#WW,BAT>;5-BN^L;@=)H3(I,4@_O+@^~!^YH_LN_
M9C^&_OO9_P"#@KJH3H_X7W272@7P!M+^YK;U8L^M-4/2/-7&-T72+~"~+R^K^2)LIH;VMDZI_M8XHP%0.=&O+
MZ(WFGR-K_I^EI;~\$8)Y4DC\$<)??(94502P%?*&J_LN_%;_@G+ P2;_8L_~' M_~D_9WG\1^#_(8??\$OOC^~%_HR7_
/8VBZZ;B.%YI692I>~&1^4D_V7\$ MZH=IRP_~\$!_~9;YTC1O\$EC=W2?M(S7+6IM=(I^28GC\$ MF_?NIXY%STW(1U%?
>OPX_9_~WPB;BD;(E_I^ARUMIE5_MAAE#QH&(ZC/_^47=W:6%K+~?WIS^!!!&TDTTSA4C0#)9B>_!DDU^9WQ2_X
M+~?~\$H/VL/C)-X%~,GL;G@32_A_X\11RMH=Y?LY>~:S:2+)%~*J(R_V3;3*
MKHL;R>)7(%O"GVKI+~I0T^PU:PGTK5;&&ZM;J%HKFVN(@\9I<^ M^3:M(VL9(+?
5C;L(YIK82?I>~>9A+~#O*KN>"3;E=KMX7^S"G_#1W_!47_MXY_M12_OM#^%.D6^PA%\3#IC78\$>K;I^N?
XO/GT^U)>P8=C7U=X\>~&O;N MB6_AGPAX>L=^TVT4K;Z^IMHD\$(\$+)\$&@~"J^23P.D)PIX^%>_I6I?_W@
M_2I%@U#4IC4K^2=~/CMBDN;RXD;DJS((U>62I1F=Y#EG8DL23F@#RIQI_P4\$ _M8^%6WI?^A;IA3Q_~\!TSXJ^--
)_M+PUX5N+2XW7D&Z55_?B,P(I^F"8)&^BN M_EG;IR,^PW=W:6%K+~?WIS^!!!&TDTTSA4C0#)9B>
!DDUXS\;OV0#^QI_~ M@!_%OQGX0^*Q6_P^UK^6H!+277-0NH?-.O9FY;~.V44L@N2B.YFE5?_M+1'\$SWLFH:?
8:M83Z5JMC#=#6MU^T5S;7\$0>_.6_@0R;IR&4@D\$'@@T^FA^4O^ M^RG_2@_~P^,DW@7XR?MN>I-
+^\$W@#O%~*VAWE^SGQYK-I(LD4TJHC+_9_M M_JNBDYO)XE<@6!~?F?~%BKC0A_@K=P2-O/VB?
V#DO_&^7PN^)=GXR^36_MVG2Q+XF.CO)#>FR5U\$DJ^DIXBG8#);N!@R.WWS_P_G_LL_P#1M7P_P#" M-L?_
(U78^&_#AKP;HEOX9\(>^K^2M-M%~VNGZ;);!!""2Q"1H J@DD^J2 M:/S:_X+D>.O"G_I^2A_X)I_T_9_~9~V7V7B36_P!?
QEX>/AN+39UGDMM M\$BE6_O_5G1^3^;VPH6AW^=4^0*1>~;Z_X^H?LG_L+ZIX=8KB_~\(>I/M^&K-:
'&-8\17"RP^#M)1%07\0\ZY^X%M;D?O7PH84=J^K_!GP4^#7PX\1_MZKXP^~GPD\;~J^NR>9KFJZ+H-
O;W.HOG.Z>6)%~8Y).7)Y_5?%~I/P!~;Z MI/XH;?_?P?J^IW17I5J.J>~&6XGFVJ\$7=)~&6;"JJC)X_I4_?~?_~I;IN?
M_@F%~XKET_P#8Z_8^~MIXWET70IW7M=O_~\$USY*>>K76I;E>RJBR7-S=7&I^F M);6625WV[59E/VC_~
K3_@E/^W%~^PUXZM_~\$QZ^~7Q%~!ZGHUW97-AIVJU_M>~>F-DABM;8\$S_~S(4^SJB>I^&WPL\>~IKI M
EU+H>AVIHTR@Y"~L8D4L>~<&LCP=^R_~S1_.&4WQ%~^_P"SOX%T+Q!<~IW& MNZ-
X2LI6^E9^ERTT<2NQ;)R2>5FB\6 M^~^!D2:Q9W\$F^2P:622=+~CDC=!"D!_)_6_2_~*F***"BBB@_HHHH *** M*
"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH M ***"BBB@_HHHH ***"BBB@_HHHH ***
"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***"BBB@_HHHH ***
SILS_@MQ_P4I^%~!8^O6^%O@#1_MKI!H/AKXE;I6B6/_%"Z+~+IFM+~?4)X88\EF5OMC11N9BOQDDG)KS;_~(2I M?
~%:O^CL/_+~\$T_Y!KQW_@HA_P_I/CG_P!EB\3_/_IUN\=K_33(N N!;V2_M86I4RK#.3IP;H4FVW%7;?+JV?BV^S7-
(XF;5>=KOI4N_J?8G_#_&_X^U?I M^8?^6)H/_P_@U^N^!!/KSHCHM+IC_~22%+HICXA?)~+KUA12KS2K2^_I
MFTL_+M\$T_3YECV6L42^\$DIW%2WS8)P_~!_77IU?A&M_~*/_~82IEBU#_TU M;37Y;X!<)<~Y/X?3Q_P%&C4I137-
^E3A^S;NKQBG9I=3W.%L?CL1FRA5JRD MK\1R;7W-GZ35R?QI^~WP9_9R\^3?~\$IXI?
\$~1^6@03QP/JNO@EO\$TTAQ""A M8@R2N>%C7+L>~!-=97YF_P#I>KQ7^T%~RM^T5^S7_P
%+O36P+U^XH_~"OX(Z MMKTGO&);6F^>;33?6D=O#K^QX(+O)YQ65QMB8^"T8F+K_#1^FGV=^~^"A?I M\$?
QA136G@7X= M_~^\$I_O%?7RV=KX7?4A!JKS-&JCI^"N"D4C!C&%(1CG@ MUN^OVN/V=?AI^TGX_9I8?
\$VVLOB\A0+OM1\(>~&&LIAL_0MK_-I+B02+& M8HJJ(I_2_K;?~&VG^S9\#_CI_P3C_X+O>~*/A-
^UW^S#~3="U;QC\^!\$!RM MM>6PM_~\$&DVUQ8W-G<6-S W!U(7-PK;ANA>2!2CMC-=M2/V^/_WA#_@J+~\O
MV"O\$GI+NM_~\^2>~?>~LZEX<^>6HMIWV2^SMK9YITM3^+~+~_T^QONDBP?P-B M1<~&@#ZDHKY^O_P#@JC?>~!O!
@I+HG_!/_XX?LX7^@N^~4:~>ZSX3^>ZEXM@?_M1I=M;~.W=;5A\$^X_I M+A&0^S\$D&R>K_LI_M0^~?VO?
A2_QGUIX\$7^@K0; M^I=?~.S=Z^EXVOV2R.BZE\$JQH8I68^DD^/AY8Y^Q%~E@#V6BO#?^~BGL^EC_M_P
~\$OY5O\$GI5>N^!/_Q/XWTKPS;K_J=EX8N+~!5&=8UEF-U/1^0^O=QB69U_M!W>65I(^?_CG_P^N11_9WA#?
#KIHXXG?L>~!;X(^_IG2+34?BG+K-BOIDS MZA&K1R?V;6^V2VJLQ0W#I#OV%HT=7A;H!Y45\9>_A
@K=XD^\$^I3WPR^\$W MOU_8=^~^_~A!8O%L?A;X>_~%#6I6LKS#_~\$6&YTN-VN;I;@X!OSIDHS^~
MAC^R^GK7Q8_~330_VDH/V~?@)_~^\$I^@)\+~?)+K>GSZVNF:7X?TLS>3#_? MWGE3^/_/N6^&*~&:1@CNRH@WD
ISHKYC_9F_X^7>~_CYXI^~)WL?B+X%>)/# M/QJ^\$;QR^~*/A0^H64ISJ^K;JO;7NF7%_#S_M_~(+O^~
~CU^R9XI_~M_9M_P""_7Q^66/@G6=7A\7;=~<^(-TX;59Z>_TLC33 M/BYNB@= LEHMPRI/G=3)\$'
/T0KRGIH_IN\IDSID;5?#?AHHOXYZ+X9U3Q? MK%M!^AG2+ADKW4;FXE\$;2QV\^O^5;AVF3;L7DLP~)KXF_X^Z_~

!5CXGP? M\$4K\MOIA;PA,^C?%'1+&";Q5J.J1VEWX6MM0ECM6"0J2\EZ'E>\$%&"1.K2I MVV*KX0\ P<
>/?\NM_LL2+!&MX?.1 MK5.NS N!&JE^, \$D"@#12.*^/= # . "K7B;1OVZ/ GI& P"T^O\XU^&=E\6
M\4W^\$WC37M>6 MUB,C%>=BCE0#Z-HKD/V?OBQ%\>O@+X(^.<AVXT=/&GA#3==32;QITMD+RUC MN! Y
&63S-I.RIX%<^8/VJ-0+ &6V_9E^! PT^CCXBS>(&SXA0)N_33 M7T;2S,T\$5>W9CE;/SIDDCACBAE=S#*2JH&S@
IAHKXN^%? 68\^-. AC\ M=+ Q#^S#XUT XD_LXRS#XI?"G3M1TZZO(+=(9IUOK2YEN(+NU>*11@P*RG;
M@1\$M&^V17%^(2.) (6VB5MDA0_1.0*?\$^I) BYJD.G?^SP?H.D:7/B".2#[0TV^8JL%K#;YGGN'^6*;
M=&=D10A7X\ Q)^/B_ (/ P!C+PI;?@'X.U;1 "'CR:WU'2/\$HU'2I6 MMH\$GV^1"-5TK7-*91:Q# 4GDCDT^Q! ;>
H(GC= M5B^T0N(9<390;OUKH Y^XS _SX) LZ^\$U< _?XK;X1TF2Y2V@O=?U2.V6X MN'^Y!%O(LK'A8T!=CP_Y;X1?
MR?LD_7QR_P+2AC=I#02%*VINE\+7O_2GI_P \$COB#?A_!2O_(*V_M0?ML_&=SJE ME\SO\$J_#
IX(=/_>_>'K3SKM+RIAC"QW5PMK"S3#Y3RQIM@51I!_!^!SX M";40\ @FCX_P#C#H%Q+I^CIX-Z5)XI^?<
C+37.H:Z=BYD>WF7YD\R. M6)@#@A@2,J1!JIT5\3_+)?_!601/B1_P \$X/V?VE?_ ANI\UXD&J"#0_
M#W@KPD27&O>((3-#>M&)&6.VM4:UN+B65R\$AB^3;\$?J_7_!2IO^+^V7K/M_I/GXX?
LSWGACXHQ_#1 &G@ZWT3Q_!JND^M/5WB:**ID@MC;SB5&0K_#J#; M30QMW_U;17YW_!%OINO\;'.N\72M
^(VB/@M;6&E;/^T7XAT_ U6U\ M9PRV?A)-TK3;==,BB=1).@:'S'N%V(ES))M7D#TV^ X^H^, %/I.>M?MN_ML?<
L>ZUX^^#&A-?3GQ#>X+/6=;TZREDCNM3TO3)(B+FV7RI6037%O_*L99 M(B&0L >V_M/?MQ_LF?L9VVC3_M-
?'!2"-RNC)C(Q7L?B;_@MY=?;JJP5&_VNOV M"OB9))/?Q.UU=&^?Q6\4W5E);7MI(0((FV@=WTPRGHDS>:H.Z2-
%60Q@_ MWA17B?Q_ ;S\3Q_&60V=V:/@I^0?&OA?0I750%L_IXE32_-T6&ZSD);S M79AG(V+?BQ^U1; LS^)/\$/P)U
MV_T3X0_PPM;K33J/AJIM_XFD>;6YCBGM04;\$T_IR\$?1*, ?+-=LI+TO3;62ZU'4M1ND@MI6"-2SRR2.0J(J@DLQ !)-?<
*_I?_ M 4R^?7I8^Q\VVV_L\$ _/00AWX1^&_BG3OBQJ^U/I4=T_3R6;5<2@IY M&B2;18S.8S)\$T++?=_VB?V=?<
A1^U%X)L_A=V7;+^TO'O\;=KJ&O>^?T#6 MNN1VY_L5I=*?I9;_&@02O&?ED\@X9=2<7^SI_P %?+V OVN/=X\A;
MOVN_GC/Q%91O++HNB;I%);I\>=&J&M_/U;7M>U&_TLI/<?WRRRD(@W,!DDKZ5U@C4L\LD CD*B^H)+,0<
237C7I.G_!2W\@+IKCQW>?##|FK|KOP)XS M\164;RRZ+HFO127+Q(^)T#6NN1VY_L5I=*?I9;_&@02O&?<
ED\@X9'=3^?W_!7 MGIAWX.VOI7OI%WBWID/X5Z%X/^8_ ;#L!?'\$-)AL))/"G;RW6L/<+ JB6" M%\$@7#Y<
%RT8XF((1^B_O=^/PF^?@Y_B\;/B^I/AG1EN8K9;_5I0Q5EN)6 MVO01@RS.WRI\$@+N>%!/%1?WXZ?!\<
;A+R^_O@Q0\A1.7;7LEE>RZ=<M;GLIJ/F6\9P\ \$RY4M%(JN_P) R^*"/GO#U3H+ @YP\&?LI^YGA+_I<
MG^_\\;I%>C.EK>0I&2^4)D^D^C4WBCXBZ^SC_';A\X M;=>+DV^A?M\$ _LI/XJTQ?I5<:WISUZUMJ#<
8S^MG;_9\IT_#T&^#ZC^_!4 M?_@G5\ /C^GP ^-/I/PI;^6>_)MIU?Q_!%+;LX!1;@DL8L""!*)4)#_I"<
M#7NM;OJTC;IJG_@FU_P3N\!\$Y_B9X_M/^P8+7NE6G@?5I9I7>/_8T;W;6+S45MI;B26I;TKYIO6F#3>8&R&(50%<
M6H?^2VJ>+OV_A @B^)?\$GI:6OWFGW?A/X<" UIM11Y+JULDI9K&R\K\I D M;=+6UMD@ +EU6(*6P*_J/QS?O@O\<
#3XD>\$/@_P"/?B5I.E^*?IS=0># M_!NID+=:O);0^?<%"K"/YE/09'.2 >OK\@OV@?AQ4?^V_P"P1^TU^T#; M7-<
AXZ^)>M?2&6?PO)=>9%X4T;VT.W.G;NTE&FB6XGEN)5SONKJ?QB2\$+^O MM !1110 4444 %%%<
'D/B;XH^_MA1ZA86>N;(H+Z6)/LL1VJKD_9^Y/ J MC_PMSXA_!#1_Y*0_ \$5F^_O^1OU7_L)3_P#HOJS:_D_X6Y0_<
H8/_ "4A M_P#B^I\$^\$OB/6?\$_AR>_UR\\^5+YHU?RU7"A\$_.* _I->+UZU\!O^10N?^PD_M_P#Z+CH I;N3^<
(+U>*V@OY5OVBOY;_""EWAKX%ZC4?A7A\$=6UZ M3XC>M M+3?HOK2.WAU8A8%\$H\$XK*XYQ_%!;3%U<
/LIX9_\\% V(C#XFM M/ OPI_ :)W_ (BOKY;_U+OJ0@U5YFC>51IBF"7_!2*1@QC"D(QSP;W?&7I M7^I.OP^_3^?<
L@^_/B;;67Q^(&EWWH^\$/#6=PTFH6UG&TEQO)%C.4>U\$= M@)'5F"/M#;3CYL^!_P =/^")VUE;AM MA;(^<
)MKBON;XL;F!OWJON;A6W#=""D"E";&+XD?M\>!O""_!47X9?L%><
M)/V7=;_X23OCX;UG4O#GO^U%M.^R16=M;/_EJ8Y9;GYFA6-TD6#^!L2+@T M?4E%?(=_P %4;IP_ P4ET3<
OQ_#1G^X\%WWBC0KW6?"CW40%L#Z/KMK M;1N\K:L@I7 "-OA<(R!68D@QF3U?IB/IJ^QS^U\I^7^_>O? BX\%;#?<
W;KX M1N;O7DO^U^R61T74HE6_#';S!4D@9V/+('V(I4L >RT5X;_ ;%%/VW+^_@G<
ME^RMXD;KUSX^)&^E>=&9M3LO#%Q91O;H\$K&LONIXR(MH&2S.H.IRR MH)'S_P#/_@MWJ/L_@;X=?<
M&_ \$HA+QI8?^'QOK6;_O5YA_HL-SI<;M%O^\$EUO3YI;73_+V/69O)AFOISRIGC MDGDW+%%##-(P1W940;R<
>YT5AQ_LS?^!2IP_P#SQ\3OV<_ \$7P^2>=&?C5_M(UCF\4?^A10LHG4+695>VO=,NY)8;>[MI5=,22-<
"4+J)%CW*6+^G_!>/ MQO\ 'KIDSQ3^U;^S;_P32^)^7BRQ\ \$ZSJ/B\3KGQ;ING#2K/3QNEB::9\7-T<
M4#OJDM%N&0)\J9(@X!^B%>4_M_+4J9#M.FW8O)9@_37Q_ P5U_X^L?^\$^#_@BE8_<
MMM_L+>\$)GT;XHZ)8P3>*M1U2.TN_"UMJ\$=JP2%27DO0\KP@HP2)U;7>VQ5? M%_X_ /OCW6_V./@#XY^_/P?<
D\%W^G?MB>#97T>'5HJ8D6"-P^Z'_P %6O\$VC?MT>I/V_-VAOV)_&OPSLOBW;_F_PFI;<
M;JKEG7*;W+8PB>:&YM;661I/D,15E25B^9(U9\$8L^176?VYO^OB\XG?%#X=_ MLN?LIV_Q"/P;NI>P;B?<
QI;Y<C+91WHLM_@_WE6YD\$,T0+SRVL1D8HKL4 M/NELA>6L=P(^RR> M9M)P5/ KC?CI^UIJ^A?<
XRVWL.OP/^&@#_?'PQ^_E_P"(V8? M&NG_!) 9QEF^Q2^%.G:CIUU>06Z0S3K?6ES+<007=J4\$C!@5E.W B);/Y<
MUXB_X+;YI/I%7A;_@H9HW_!.CXC;A(IROM+SOUXLBU\3X;X?CGN5M_I^MY MF2XU/RV=_D<20<
MM\$K;)"@!^BU>4^(/VX?V3?#^I4/AHBS5OCEHO\ PM/Q M1#<3;/X)M6DN+QHX+62ZD:81^RVH\$\$3N#;R;@<
%W%E!R/VC?VZ?A?^!_#7P_ MDV/Z3>^/_\$ _OK6T^B3I?(N6 M@MI1)\$\4BR120)MWQLI=7R<
#15Z^>>?^O!;OO_UOQ\X\^?L>?LSO\59_AE> M'3_%US_<
XP@T;XDU>=>1(K^E6,CPS?;KR_*6\$R!O#^C3^GG&02(G?'W_@M^'Q MU\5/^">EI_P47T>XUV/PI=;DNB)X1-<
@KZ)WA>=>1/1K=7VRWLM'\^!6DFOM3NIN MX6VMU2""7D6-IF">_#<
M7+?"^!N3IDGXZ^_7^%OPO^_&AWOBE;4W2^%KN1I+4Y;<=9XI2Y6.:2(=Y\$0J_M/7FOS^ X')?\$&^ X*5_!%;?<
VH/VV?C.YU2R^"7B5?A\I\$-_N_GMO#UIYUVEY M>POME8JX6UA9IA(^)Y8IVP^H^@ ^" GP\$TWXI?^T?'_P8= N)=<
(??!O2 MI/?P\9;_YAU#0K_3L7,CV\R_ GF01RQ_<\$_ "1E5(/M6BOB?IDO\ X^UZ_M)2/^<^/OI2OC_ _W>O?<
\$CXU00;X>^%>'4B2XU!Q!"9H;UHQ(RQVUJC6 MMQ<2RN0D_0_B;8C\7X" _X*7>(Y?VS\9_X)_#IF>\?<
%&/X=XT^6^B>_) MH\5TGO_IZN\3117LD%L;><2HR%9HE0;2=^NX ^K;*_ _P#X(M MU_MC_M7> M+OV@?<
\$!1^P6M+^#2M'_+!0Z?'ZK;^_X9;/PDFF;5IMNNF11.HDG0_#YCW^I M\$>2YDDVKR\Z;??\<
!5QGX\9SUK\MWJ\GC\CW6O\WP8T)KZ<^<3Q/!9ZSK> MG64LD=UJ>EZ9)\$1B^\$Y/\$6I0V&@V-<
VTDUWJ?Q*X1%AMX%>:0;C@L\$*KU8@5ZM7Y6?^%Z/VEO M@E^U_P2.^\$!5/P7\4+K?<
@WQ#V\T#N^F&4I\$E;S5!W21HJR&_ ^!*(3^!)GI62B>/XQZU^SI^S1^H MB#XUA+Z;ZMXMAO?J;1HFBPW7F?<
9+>;L;IFZN!#*^<*0L_B;Y7A5XC)X-X M;_X+F_ "IQ^Q\6/VJ+?IF?OY)XA^!.NW^B?%_X86MUHU^PU>VF32/<
+^Y"/B(E&_/N6J?B+Q%X?\"&@7OBK09KMGI>EZ;R76HZEJ-TD M%O;P\J6>621R%1%4\$EF()KY7_&_ ^F7Q*_<
^(/@.VT7I@GXAZ%\"_ ' MOPQ@4Z=\6_0NK9)*CNGAB>2P*KB4/(T232+&9S&9(XFA99C\O^T3^SK\? MVHO!-<
G+OB\9?VEX5_MNUU#70#DZ\K77(I0\$<M.CNI_+ _&=/^"EOI_7I7^CN^&^I-7I7?@3QGXBLHWEET7I-<
>BDN7B0X>6* M.D&;>I0IE&02>174?M _MD_LE_LGR;5#^TI^TMX%^SZZLS:*GC+Q3;Z<;X M0I/-<
0G=?;?>9^NVYQO7/45!^?!7GIAWX.VOI7OI%WBWID/X5Z%X/^8_ ;#L!?'\$^-)AL))/"G;RW6L/<+ JB6"%\$@7#Y<
%RT8XF(Q7\ _@GO^QQ^T M9\7)/C5^TM^SYX5^!)6L)HL.DZ5#X^T^UU;STFTC=Y2EK.W;1Q)))(S+M;G<
MX12VR_%4 ?^!_ @HA^P9^T?XZB^&^I/_ P"V5;O&OB.>WDGAT+PMXVLKZ\> M*_9=Q%#(S%5^). "O9^*_V OV6?<
V9;?_@JE\>OV@?VB+X%(V6E6\ JSJFK;W<.MM\$@>6/SI-M=Q!(B11C)S\^4_4_\$7B+P_X M0T"1\5>+<
=LI+TO3;62ZU'4M1ND@MI6"-2SRR2.0J(J@DLQ !)->?LZ^_M!2W\@+IKCQW>?<
##|FK|KOP)XS\164;RRZ+HFO127+Q(A>#_ (OCH.P\$=_X M0TF&PDD(V=O+=;PIPL")8(42!D^&=&6YBMEOA<
5I0Q5EN)6VQ01@RS.WRI\$@+N>%!/%1?WXZ?!_JH^PO<

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~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j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


```
P5Z-9GT? (+*/J-!&7/L.M&M8-%OP0!0ZGXZO%2X.CZ!/:RBP/VJW NEF7A<.D4*0 OR*IAIK X(^
M:23P=_P46_9>M180I#3_12_1PWAIXJ!+!>1%;1=6MCY4C1Q@G%K*4+Q, M,J!NCW%HFZKZ/\A P@^$WA/4=1U?
PK\+ _#NF7>KJZZM=:?HD$,EZK$LPF9$! MD!)).1.234@WX&?!+XE 'RW_P<.,GINE?A$8?C_-J=1#;1+X-2&)H
H>1HNW5$&>K,Q ZDF MOF#_ (+2^+!/"Q X-N AH?A PD5B;>_ L2AT:&24FVXPIE(=AS\VS1V..BJQ MZ U^J/C?
X:_#GXF64.F $CP!HGB"VMI? MI?61*ANTB?&RK*KI3@D9'.*Q+ MGIFGIG*!TRUT2^
^C6RL6&D:RM)?MFT5N9""Y1#A"Q52< 9P,1* /#_@ MX7^7^6-/U#1B34+WQ-80P!MGP1J"S27B13:1FI
M^7&#&=B;W=MHP-SL>1-70?P/^WQ2$0_#*+XF_?"POXC-VROK;^!1=VU MY8Q"-=1J8)4;-0J#/"#4 2"?PF^
^_W !Q!0?VN?A9J$4W@GX=2LIV7@ MGOAKIC(&M;OO)<.:@:OI#YJ )(\-HL+R@($F)A"K!2PKS' _@AYXQ\ (W\A P11
M:%UJ#Q+HV5KX(^)$UUV_9F_9OLK"YTJS_9 M^\$0VMZ$%Y;1>+%-8YPC;DWJ(\-M/(SG!Y% 'XG?
&"XAUK_@RT$;GHT@O(- M*71GU%171YIG$7BP))OVYQM8@'TS7TW_,%1?VG/V>OC;^R9^SU0_A'90# MOB+P^?
VQ\BPZIHJ1S65OY*7,L10SJ2+P2)9%$COLRQN'1B'1U71)M%^"GP M:\^&11&>'?A)X8L'UA"FK:59;#:Q6UZI7:1-
$J19 5...#QQ575OV=OV? MM>L= /T07/@7X.O;2;06FE61WX8M)(1* '(BB5HR(T!)-U<#GI0!^!^%?A MQ+X=TO^X*O_
/!&4'=1X)6^?)B.WA:Y#6;F M.*-0J1J6C.%50 %' P*K^>?V4?V6_B)XAA6_ $#!FOP!KNJYXFMJ3UCP=8
MW50Q%8-9)(F96&R*G@4<5 P-R V@OBK^U7^P"V/C=X!C!^*O%O@ M^VOM8TB'V;#)7.56:-
LF..9%29$).U95&3C) /HM+XF LN?L4?%W18^(O M !37X0>' 3^# P_? ".6K;=H.L:9)*DEHYEBD^SAUE9W91OY
MT#-\FYD_74_*J@< 5@_ $CX5_##XR>%Y?_P_70AQH/BK19I%>;1_$FCP7 MUK(RYVLT4ZLA(R<$CC-
'PAGQ$X)N>-OV3_ IOXE?A$ _O@A-M;^V/P>U MBU\4_%GP-X2L!L=800I.NV_LI+F&WC^V_9XPDDC[VCC-
S$BEG\PI_6N^ (O M#Q_X,R8IHZW9^4?@K;V@D^T+M^T?VHD?E9SJ_?A +MZIN.M2K>?@Q^CX" M? MA4?
A/X: X1>R"BR\_-V%:_8+<*25"6^SRTP22,*, $UF_\S7LWG21H!_9^\$ M?8!<_ :!9?(I9^3YVW;YFSRIN;ONQG"%
'Y0 MQ2_%/R_92_-!X)N?A"OB MOJ#X'Z'=^YO^V!>*X09;+0+_4!$2&*YF=NZ?XGM9K" TGO^-V6L,ERCF)9)6 M9
J%MQV/CIXFH1^@M)2^A< ">7X3>+6!*W@87?AIM:MSAX9@S1H?9Y M;98 G^MD9JKX_9Z^ /PIET>X?_
^Z$ AZVGM! ?1O#K:G3(9RK31VY MCC7R4D*J75.!BH)S@4 ?DA LH?" _@G)^QQ^W#^T!^Q!_P5V^%7PZT/Q=JO
MQQUWQYV_ 'WQ-!%6MS;^ (/#^K3>?"B7L#A3'M)VE@NZ1XU^>)Q5W_@JJ/P MB\+?L;_
'INKIB?IEC3O#/P!^% 'I6NA^/=;T_P_#^#HM*^U_2+<1OGQ%IAB@ MAV1O*DEO*ZDR1;S^7(NW1;?B?^ /@A;I;?"
XT?/PCXO?2I3)I;^*/# = MKJILW)!+1&>-O+;0.5P>17376DZ5?5)H5HEO-936Y@FLY85;XBNTQE"% M2O!4C&_*
/R: P""Y?I>OI%OO=^?L9^/A;^U%X^0:39?M@>!_$VI7ND^ ( MH)ET_28A=M)=76ULVJ*#R)MA11OC;_!2UDT?6-
^0Z1:Z_H&J6H87ULEQ97 MMG.LL_Q^ZADD1U)#JRD$,"00017^%>?V5?V7_ MC;7X)_90!/:?K0UBP
MMJ^V50^;B$>7D:QQ )_$.DD7S1A1KLX8UWM_Y1?L!<^Q_P1Y_X?Y2M_M_CHH&>?0?
AE^TOXDC\7 !GOWJ4@ATN74O.NL;GOWN&^2*I_NRL<;L#(MJI7 M)E4'WO\ X+D?M$Z;=2L6^+?
V(O@0T7C+XT?#1)/"G@CP!H5PDH_#>8ANI^ M9%)^S6<%L$SO$?"IHIG.<_ .M+>--W//:_/R4_Z^"FK?
\1K+@_G3>?%-I>:H/V=9>^;2%K6=)LY)XM M-N?%$C%!"J8C4%_ *Z2\=&IFELO#EB4/DK/T
M#Q;H=WX8!5:9ZGIM_T%IH^H6R307$3#)#)&X^NT!!!!K)^&P@^$SWP3\_-M_P#""?KX7^?^?>D>&_ $@L+;S&ON?
RH$5=QP.G&3B@#^H/^"8WB+PO-MXU^"W_!0?I@#0/BCI>C_!D^?M)_%B#PIX7FO_FHJMYI<<-OJ!B'SI;2)_MI
(8)"%7?N=W_L?_00_%;%_WA3_@CKI/@/H?Q/IG@_7/@)I.I>?&B_P""M? $L6RUWHDEG\;7$A#8E@V,O&=&G0996
_023AIX" T3Q9J/CS10!&D6FN: MO""JVM6NFQ1W=ZB#"-JAY H $%XQ06#XB_9K_9S!7_>U^_7BSX ^"=4
M\7610V7BG4?"MG/5N4QLV7+QF5-N!C#&_* /PT8_LW? $J_ID/ _ (AO@=I M/QST>^T.Z_X: T'O;JFC;I&R-X?
TRZU;+;+1N'ID>2T4CAMNOYRK88&ON?_ M (+P;=X/_N^ 'PE_8M_9!3Z5XK!;$GXL;#J_AYM_OHIS^S-
&M)&EO=>=X MBPCM(86*&.;&X1$W,X%?HEJFE:9KFFW&C:WIL%Y9W<+1751=0K)%-&PPR.K M
AE0!!&*"YCX5_L_?_X%1WD/P1^"7A'P:FHR'34$!^*&173A=.;D-(+>-- MYV)SU_-Y2_$XM_L7?L4?
!%SOCIX: X*N_ "3P>?"OUT_PYXA^$/Q*?^M@^#4= /B:QTR.ON!IYH9!;_@'557R5+D>='GU/IJSQO^P3XI_X)!?M??
$C!M@IX> O"W@#4/AKJ_@_Q^!>%K71;/QCJJVUPDBQ>5!%IMCA>.;)+G+K)-/
M&G.3%OT0^%P8^@WQPT&PM:GA/X:A8:9%.)XM;4Z%;ZA DH& XCG1E#_$
MXSS3M9^#OPC\1^!#PXA^%GAR_T!2IGF+>+Z;RVEIH0HGE0LA2;I^C: M!@$@<&@#RA
X)1ZIHOB3_@F#^SMJF@;M;WMO_P!PM"9K68.HDCTFVCD0D=
M&5U9&7JK^0<$5$5U_187180I/OI"7P'U?IHSH7QY;.%X^?AKI4FA?#KP/H^@6,MP9Y;/1_-BM8G
ME*JID*1^H+%;54;L9PH'84WQO\OAW3+!""2_B/XIT7O!;VWFP6VMZ5#>OOR M8(WJLJL%!(R.<$T?G5\#_ ^"PW_
2H/&N?M!;4!/H&FJD;B>6;8UQ.OVF?9RL;_ "1_?7107QR)_LW_L^M^_?VB_B$K6^C^"O"FIKNJ1/H?
RK;W>9HP02^YV;0_3EB_Y%1Z;^S!^S5H^ MHP:OF!/^@:UN!699K6ZMO"5FDD,BD,KJRO JP(!!"(KI?&O@?
P5?2?"UYX M^!@O@_2?T348QJ^CZUA=U;W*!P6I?561QN_."#R>U^'AA P2E^!_BI MX&?
L+^#71X10X!>;4NO&GQF$=")U16;B34KQ?SR3)<>0/HF1VKIOV1_ ^M"@G!G!>LGB^#IE#XW:2XOE\ZW_
&3XKAM;2X@>QN27"- /+&ADB%="0_$%+"UO=(\Z6EM86=E92 M7DT*EECC-W6VA M>^)-0^ID=?OIE@?
*M+.;D>;/(00J@@_!F8JBLR_$'P_P""PW_!FPA;ZI^ MUQ\OVTO!OB+XM>(1+32M%)>$S/_UK=VLSR6MU;>$K-)(9%
(975EB15@0""010! M\2&+X?7?1*7_1PW\VW/%4)TIP_!>?@O=?#6^UF=5@TSQ!<17IM;SR9V
M1FYBM8HH1GYY8W5220"FE_#_ /X:Q_X.+YOVK/"=Y#<^ /V;?@B?"^I^)(90
MUH_BJ_FNY;%)1CM!8W>Z8*287V^*^X_0GOAX;_!_+PW=^#?"WA33= M_C\N^TK6+ ".YMKa,@f9(15<9
_."#TJ#PS;^AIX^&1?#CP=X$T;2?#T_NU MOH.F:7%191Q-G=&L""$G)RH&#D^M_YR?&_@_LA_P2C_ M^_5WA+?
C^VU MX$TOX2>_ $;W^CWFH;Y>ZO:R+?O"MRG2+;95<G_39XE.;1#1718>% ^M^T!WB;IG<_M=3?
M!;3H_PNF6'PH/CWQ%NL_-U;4A&-LAP4M$)1-%YC* MJIK:8C*"/HO_#) I+/_ $;5\A_P(VQ_ ^5LZI%?
@WKGPI;X0ZU)?#- MYX39<-X7NM!MY_.(W^9@VS(8OODMIWIW/6@#X(X*E_ "+IG_ /H_:0_97U? MHEOQ!X;1?%
IPO\&_0_$K^*O!UY!>W.E^#;11+C4)IX@+!+1F2!(A(P$LI MHD>=^E?HI7_#7X0?"7X.Z*_AOX/_
IPX4T7Z23S)+#PUHD%A_S_ XI BJ3 MIXKHJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@
```

[illegible]

JO=-<6-MIOCP"DF.T0*M\5=FST"D_0U M^I5S>06=K+=3S1PVT2&22:1@J(@&2Q)X YS6V.?%3?D\$3/&/?_?"MX=-I
M*7;-/IT6OV9>?LM_?"XG^);CQ#XJ\Z5KFM7"HDMI=(OD<(H50<L!^%? MB_ \N\3QA^W#X/U#3
UQ;7GC^VOXB#.3#_-?"RIL?@)K\H^O-)2ISAKLI; M\$ _GZ_:(Z-X"-;?Z\X?T^2M&L;Y8\;SMP0D2^4AP,^Y/YU^S6F?
L6?_ M1M2M-0LOAKHEM>6LJ3P3)&VZ.16#P^;J"-;WIO;-DI_XG?IA%?_1;=?O; M3S^I_-&C:35U^B\$C\;?^"MW_
="1:2\ 8N6? HV>O=N(3!-DCBO#?^"MW_="1:2\ 8N6? HV>O8?A MA_P27\)>/?AKX2\37^CW6K6?6M(M-
2D@CM(2L;30I(5I/)+8_"NERI+"4O: MS(-1^!UMI"M&(-25)M.MYHC@IFC5O, ST<^5^2FC^I M_A6?
MZ)HNKV D=_I6H?S\$1I6ZM9AE)HGU JZ-I\$BOK_9+_9IT?_9+T_Q): M3X@OM>76Y8)9&O84C,1B#@
;>N=Y_*ORD\^I\$M+_I*7_IDC6_"E'GK.G)M M6W>X/H?J-XR_X)U?+_OAI.1U_?>^OK;2 ML;IO+B*TM(\$,DI\
I\$C4#)9F/I37X3?MX_%I2?CW^TYK>K^%6;4=(A2#2 MK*XB7/VORQ@N@)5G9MOJ-HXJ^&/%=K M&8;?7-
_MM2CB)R46;)9 HQNQ^%<#^V^_P FK_%;_L7+W T4U=-\I^!MU_-M@GX^7XVW^D:%965T V0)D@19
#Z;@V*YGLA Y-7^H-8N7O_*O\$A9 M5THI7_49^0OI^U\^+XG:V QL73F-G1W6T_M*66\I5Y_W C_=GF7\$4\$-
OX4>65PB+_9IHR_-/N=M?2I\$7L_-E_M5_*K6O#_JZW= MZ%;8:0^I+/9Q+(S,IT4>TAN,8D)"OMS3?
@COX.TW4+6I7XA;XI6\JRA39 MPX)4@X_2OI<9*^IKHI5E%IEL2KGJ?_I36UAL/V+?SEM;OB*"^XTZ_->BJ+F M(-#Z
5\4_P#!?PW\)/\$5\1\15+?PK<1POV\IG_-/"3O_H)N\AKS2/I_X M_PIG_?;G_!4#_DSGO7_U^?_-E4=?F-
^R/^QWK^I6UUXGATGO#8Z!_8*VS2 MM>0O)YHF,H&W;Z>4>OJ^Y%RO_SYY;S;_AWR;ASP)7IGFY^":#D==P^U-
^TI;^*-<X)6_"NZDCN_UH M-)EU !6;.(0ROPL_I2ULV3W(KK?@Y_P2&(^\$=?M=6\=^++CQC^R+*FDVMD
M+.VH6&N6VG_P#"_29^BO+>^5!;"V"\$ M_#?*\$"@YSP_*RKXVE^V4;S>(MA_BYHNGR-I MJ.T0L-8U?3%OK*
(*0T1RK&(EB#NVX(/)^VOTB^#/I//P*L^%Q)5OAHFAW M%U>P?9HKK1)TEL;-H9=8^&GB
M2X^SW^*^?9W!/^W:HTI\IBVW^W>HHHKY< ML****"BBB@ HHHH ****"BBB@ HHHH ****
"BBB@ HHHH ^?A?C?)^P1_9E4;WHS\$6VN7OEZ587^9!ADG;T@Z(L8D93_>5;
M_+3I@GIEFS_-D^+5I\XAFG3PKH<"WNIK!(4EN69L10A^JAB&+;_="J_02"/T M;_X^@^"HOA^R5K4IA\$TIZ)?
VNJROH^6,2L8W;!V592QI I;OCG_@D?8M% M!_%?
Q/X1UFIBL^5VUN+&:=E5^N(&D*PICT9EF?..Y7^4@^Z3!MT^#4G2^+ M_AOT)>YI_P^L?L)_?6?#4FB^-
=&LX&1D6ZLXS%=H2;_A_#O)4;B1I&OO M_*^\$^K_+(/I1EIHND:K<)+I-O#J>B;JK!9O)8IX7) WJ05;_0)8^?OV
M\BOHSNP1%&2S^I_#+_@HM\8-&^_GI3FL7WA^Z2_TC2+6^1HKR\$@QSM\$7; M1T8?>7?
(X#="":!%3E56K4JRC)MQMU^1^C^I0?Q&_X6I_P3?USQD8UAFUKP MU;7<12 A8YC)%YJKGL^#>P%?!"
35T^X9^/(BKXHA^*AR2\$T4O_KXE M>%81/YA0RGFD#=#M+<_<9K1\$?^"HX>_YJH!U)H-1MO^MNJO^X(*22;:
M5D8^H5+I3I@U^?;M^I+>J_M6^M7\;3KEGH4VG6^VIYKR)Y%=>2.1-H^N M#^%=&C#Z067-ROYGKIPF>E_!%'-
<^"N@ \$CP_%(^T<2-9R^68?^PELHWW M+Y6TJ2BN10W^O3^Y)Y^H/#_FJ2_\$>;TZJ9&D&E7^P&7_IRIJ+^+^H&A
M9VTSX7_\$=O#NBZS!>?_-%UXDLXF5_I+TNS^QI)@YVO*7=BIZ\$*\$/HPI?1G ML;VDV6@?L6?+\$+3-
M6#3I/2(X+>UMT^I01K+5%55^Q6%3\$T!>QH4Y.5 MI+5C2/R^_8/O_@A8>+?%#?2I=;_2FL8QIWHP32KYWF?-
M\$8)IV^M?;_DWWI MI>N;I9Z;8VGA6XOKR9+>";_!>1V^JN2F.20;_<^?V&_P!DI2?VL^%7B;2=
M6UZIF&/2;*.Z22RB20R^I-N^NZ^OMGPG_P_BO^"A/Q5HVN1>A_6YY=-08;
MU(GM(OKM&ZNB%)8I<5TXR5;57SU9)HEL)7;_@LO_P B+^/PE>?^BHZR^V M_!OI/EM?LXVUW2;7P^XB_M"
I\$LGB&:U2Y\$08;<<8P8^C_#6M_P68_Y\$7X M^I_82O/_14=2%6A_LBZOXG_&3M1^FDZKIM33-1>UO=#6TPT5LFT-
<"7? MV^ZY38,+N;=QBIP(U,%),AMWO^V4YSIHW3_!EG^T7XEM/A#(USX66_B72 M#8L@;I1-ZPL2691-O"\$9R-
N,C\K^@31Q=#2+\$7Q#7OD1^>1T,FT;OUS7Y(- M\$G_-I+O\$WQ1U)/\$VF&I^^(6F@:AH\$EW-FVV*,2%(L_&9^0X)+
<^*A3&6/Z M#_MJ_&X? A_9U4>(K>?R:N8OI, TG;PWVJ8%59?=%WR?^;N7,6ZE6GAH MIW6EWUO8;
IGY>_M<^_I0_<_6^AG0)O/L8IOA!+:2P&455DVRS>ZF1I7W?W M_OI6A\$/SUI^QA
MLK8ZO.T6GZ7IFNA;K(-RK+8RN%XC^Z%J<#_9%>??L ML_73_V.HPK_PELC;31V=H;-
_R^":1=AE+^5)G^&1<8^+YSO@V/ MVK_C_I_I3^Q6?QO9^<_ \$1NKBSAMIRV_M#I8)Y(JLN\RH^9L7&#IP/->Z
MJ4D_J+^IY;7AR?_3I1^NXY)YPM^X5^AG_I/GXV_P#^I/V?#?TJW<?&?=?^JB;CN.69H5^E2^N=T1C)/=MWI7Q% M_P
%CA DN7@K_L7I_Z4S5X.7^TI8OV,GHKZ="GL?2W\&_D/P>^>?LR>_? M0?#_2-5UF^L6DN;RX1BK>_XR<-Z^?E7F7-
5ZT.P\+_"GX1Z-I5K^8Z7I MUS<6ELQ#^0POP1(B+I!0!^%?5/I!A_R;#V_2\ L&M_Z.DKYE_X+^2B+^M/^PE>2\
HJ.HH5)RQZ4G=)OIOZ^H?_I)_DU>I_I&_I%05^4-UX-U?X@2% MS6=!T^T;_P!6NM003;VL?WY2ADD^J;
I\$(O!W;I7ZO^I)_-7N_ \L8IS_M_P!%05\ _LERK#^WMX39C@^Q+=+^)\$P^ZFO1PG^OB9+I_P1=CWG_@E+^U\$?
M" _B2?X/^ (KO;I>K2_>GOO_X6OG+IHGXU7/H0^O'_.\$SOI2I^J=UIUG;WJJ_\$XA@2*1U_Z*
MO0L!VW8I5U8>G&I66+H26OKH+R/U_-X^9?^#5/A+^S=INBZ^<:-GXME&FR
M7^9#1V@B+3I3V9LHG^I2=#BOCI_@FI^QOH/I0^L:UXM;Q/>=>"F2VBTR.0 MH+VZ(#D2;_?+12I*=@L77G_(T-
P5VA7NJ!X?>)+=#):J+6ISM!_P7 M\$^VN?;="SZNOX61_P_>/BMHT7A/OA;KEICM!;4OI;MO^"%S&^<4@3N
MO3R5^HV?7^F4I2IYO_%GX8?L;Y=M?^!O\$^7@+PCJEJ@CD% MK+I8;C:LRAU8R+ARV&5AOW
@C(XKT?IDP?I;P;X+B\I?^/Q1I^B!=-.C^U7K MV=Y^<74ILOK7\$Y3J2<#H_I7R_ \MR_ \\$/^/\$NUCXH?&_P#X3H)Y.G/
MJO_87IC^_9K15^OS_/_WO)^ILXW=#CGS+_ (W_P#)7O^O_8^C_P#2A^Q= M*3".I&HW:UUTN/I?K-1117@E!1110
4444 %%%!!1110 4444 %%%!!11 M10 4444 %%%!!1110 4444 %%%!!7YZ_ \I6GIF_XD_M!_!J_X5IX6N/\$
MOID?VKIN^B:&/R?^Q^7GS^7_IRL.F?NU^A5%_ 'RM^PG'="7&_L8Z=^/B7 MX=-C M>
(+P\JSZXB7ELB7IH3PDBF12^3%&^I;R6QV-?MS10A3?^%OA_X^_4_ M9=^Z?X-
_VWUUX6.OV>JW>B230I/QO_8KI75V+^A^4>5\$UB^3D9?^G7X7_8 MO_ \$^Y,MEX<^>+?#IG+Y)YTEOI>OO6T;N0
7^I<_%L_#7?>2O;10!^%PD M_9Q_;/TOXK#^+W7H^0T_VUJRFOS<^>O)IG6=#+O7I2=RI_V1@Y^OVHHHH M
_ \$HKW_ ON_%I;HKOKI^PX^#7^N>#14O#J5E^W-O&L9F_DEBVO(I4)(S MJ^C^T+7Z_ \I/CIG>I_&;OV;I%T+6;+
I#XJU^*:35=9B+*QCGDPJODJ2#LB_M2-3@D9#\$=^E**/C?^X^G?I/OO>?V??#_ (?^!;-XBUBV\46H+^P2QQ
ME8%M+M&?;C^;I\$^7/S5^>7A?IB_IL3P/8RV7ASPXM/V@=#0I;6K^;-_QXG\$D M?V=9T.NI?
M)W+L#9&#D=J^GO^"M/I-Q)_#_P^%5?^"O?"UQXE_LC^U?MW MD30Q^3YOV/R^8ZYW>5)TSIVOT*HH
^WPR3_I_IDWP?X4A8:3)HGB^ MREOFN+&5T=HPIY_(F2C%>593P>I2^O^P4<_X)S^,O&^QB^CWX1>&6UN^Q\$&
MEUG3;6^*(VIX;IP)&4%90;J);(AMVO@LO7^6N;_X^*?^I-37?BYXPOB-M?^H;6XUN^C5M8V22^"IN51CSX&8A-
Y4#5Y>/^6>=OM7VK_P3L_X)JZS M&_#MA3OBC^Q^&(6)OI(^Q2^8V_C_I9YW7^*0*2%52P&I<3N_Q^DE%_ 'Q
MO_P5_<^?C2X_L^<^_#_ ("T";Q%K%MXHMIZ6U@ECC^P+^7;_<9&48#2C.N? MEKVO)_I%_I8G>QELO#GAKO;X?
LY9;DMI+U^*VC=R^Y5+@_ M@_9ZX_KH M;_ /O7^G^I_/I9^E_%;P9>Z!XZ&AVVM64U^;CQ;)(LZSH9=Z_3N78&R;^
M(I5^U%%!!1110 4444 %%%!!1110 4444 %%%!!1110 4444 %%%!!11 M10 4444 %%%!!1110!^I_MI?
#7Q+^6_V9/\$AGPCI4FM;YEA^24PU_TXO36^HK^XQ>&_<^9OI0_Q.UV&Z^7I;Z&LN/^U+7I72 M^F"?=NQ-(Q)PI(Y)?
IK^RW^ROX4_97^\$RZ-HDDU#5;XK+JFM7^A9;R100
MOR@D(BY;@)QDDDDDGVBBIQ&.K8B/+1+1=D^K^Y@_!%OV4_BO\;V@K?Q^X+
M^76NZB6UJ;J&X@0^59)BRX=U/_9>W>OJZ^<^&B>7I@I?_*Z3(2%_@D M>E?
Y7O3?IJ^HJ&+^=NVYW&#^W#XT&MBV^L6CPN)HIQ<\$/+(X M^4RI25_4D^&8Y)(V_?=%%<%>O/\$3YZFXS?^
QVP/V+?C5^1OVE?^OB3PYX#O_ M4T34+Y9;6CN;=5E7RD7(#2_CD^I.U?L#116E?%3Q\$80DOA_X^06L?F#_P4
M>_93^*_QH_:"M_\$^@P==;IHZZ);6INH;B!)5DF++AW4^E!^Z^LOV8_VR M_-LX+2TL?&MK;6\;OOP0^)%2-
%&%55%Q@_#IBOVPHKKIYE4ITU3Y4TN_M_#BL^GK_,\$I/A^T%X#^&M;A5X_\$B>^9/^T%N=8U@7D7VHW-
LRX3S7PV MO9?FQTR^U^M_\$HB^IH_I^_BWQ^X^Z^ZFB3;_>7IAJ^K?2V3A6N^>.1#YH
M93@(@@^\$5^UU%*.3U(5)5%*:Z!8_%&^A_8I_<U^)"_8==TO7+NS4C(I0>)(GB M7G(UYV)Y8'%?7^I^O_

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|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

[illegible]

Y3H** O (4^+O_M \$53QM X45Y \XGEVWUPJH)8X5549/' :OC^*. \3PO@H8VM7C-2 MDHV2:W4G?
7-"=%/%*M+E2L>^T445^7G:%%/% !1110 4444 %%%/% !1110 4 M45Y=\5OVGOAA#\I:M-(\<>+?+P J-
W:BZ@AFMYG+Q/F7<"B,/O*PQG/Q%5&,I MNT5=BO,<1HKYX_X>#?L1\ 12I#_P [K_XU1_P&_9I_Z*78?^=U \:K7
MZ06_D?W7-'N?01??" \&-9I_.'BEV' @'^?_ HJ_C AX^SW_ ='+LA MP^NO_C5'U>M_ (N8YI#T5\?V\OV>_ \HI=A_P"
=U \:H_X>#?2I\ \M12I#_P [K_XU1I7K?R\F'_N?01??" #P:I6O_HI=A_XI?W7_OJC AX^S MW_T4NP_\ [K_-.4?
5ZW\C^YAS1IGT/7F/1_P#R275/^NL'_HU:X;_AX^S MW_T4NP_\ [K_-.5B>_OVI/A9\;O
^N:X(7VVOZM;Q17LMM#!,A6%9XD+Y M=%&_TB#KGYJ|^+-6_-H-Q=N>/3S1_Q#)?V-C=?^753_P!(9X71117IP?P\A
M%%/% !1110 4444 %=-I'^\DK7A\ [KK)_Z^>N^KO?@3_P E:\?I=9/_13U MYN9_[C7_
_.\$OR9I#PI_R.L%_UH_ ^EH^V;*** 3^X@HHHH **** "BBB@_H MHHH **** "BBB@_KXF^_W_)60\$/_
%UC_P#1251LU3?';_DK7B'_KK'_P'B MDK\A+ ?I_X'^<3>\4?^1-2_P'OL? \TB9P5%%/%?K1_+H4444 %%%/% !111
M0 5ID?LX?DETO\ ZZZ_ /HUJ^-Z^R/VI?^EP/3J***)3^H0HHHH **** "BBB@_HHHH **** M "OGC_@H-
R9S\2 ^O.#_P!*H:^AZ> /'^"@W_)G/Q+ \ZX/_ \$JAK?#_.' MJOS)E\+P;HHHKI&("BBB@_HHHH **** "BBB@
ML_F_PJWA%GILN?I7Y MLBIYC?I*ILGZ5IP?M*?L?_IOX" "AA?GO_.;.MLW%S:;OTZ"IN+.%9IHXMPWLB,RAF S@%
MAI;_2=_VD/A%)_V<I_1K3XK;M4K^4=,U+3MA_#FJ63O_#7XH?;3O)XJU+XBRZEX MKL=\$N=73P_H!6,Z>
(@X5;H8V)+,H^4!..E68\$-7R%8VCZA>VJK&562;18U+ MG"@DX&3V'_?2?I%_OC(\?"?2/B1#XKU?
^RI=>\3;=IR_9HO/N&#(@)^HMO M4I>82"W0_AJG@SOW<^_.\$>L:_XEM+\$2>&/3K?S(VYVO_)?+;_W"
M/IT?I8I>^*UAI^=3GNUL3O_D!I? \$*?QM3IHK9Z3I_OHA=\$MP^HDEN&A7_MSW_!F23DQCH'?_IU=37UU-
<7\$KS3S.9)))^EG6G))/B(**** /Z,?@/_D_ M^?_&+FG?_I_7=5POP'_Y(=_P#L M7_-)HZHJOS27Q,N.R"BBBI*"BBB@
HHHH **** "BBB@_HHHH **** "BB MB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH 'S_M
(+^?AG,>?^Q1M?_2VIKX7KIH_X+^?AG,>?^Q1M?_TMO: ^%Z^_P #_NT/MOS>X4445W""O8?
V;/\$WPG_^GG^*_CZ->1B6WET_4M#N44V\$B2ARIPL\Y@_M #R<+NPD!'CU%1_//%O;
^I/BE_P4&_0_%SX=7G@_013UWPUX+U2_O9+O7_M+C%SJ#7/F(_E=^D:K(QCW<_%?C#^SMX<\#;:\-
)T37+=F^TM;I_4-H@T:/I_*RLT>\+AJ, MIC7R#15_5*7,IM:IWO<5PHHHKL **** /IO_(OJ_P#)ZWPY_P"XE_Z;;JOW
MOK\+ _P#@FK_R>M\?^XE_P" FVZKI^T^/SC_>(^GZLN.P4445X11YO^TI_P F MY_%3_L5-5_\
2.6OP_KI\ VE/^3<_BI_V^FJ_P#I'+7X&5_4O@_+CB_P#&_MOR/\$S#XHA1117I_!E!2J-S 9OI;2G1I3(HH7A2WNI?
%6@V<<I G&7AF8*B#/#G^@,S\$'??LI_L MD^I_B1)I;OIKHXNUYH6_I(CTSP5;PR3V+8\$UV'5)BXPY(^ZK*?FS7L7P
M+^_GP@^!GPO+W;_%I7O\$.CPS@GPGJ6GLUTS&T=6MEC)*&7^?_5^"VL:=XBDU>YN-
'TZ6=^3A:61UA+0+G;=%\$(M88Q&.&_G^_X B6&Q\$(2K2?M(>_R27NVES)4^3G5FHWY.9JUE>_JM&ZO;
M;^M3YA_:(^%=C%?CIX@'\:=K2ZL;:(BI=A0K#NI<=QT^0?0_M@^ICOX8P^%_AM;?\$/Q?KNF>-OB%\$9I
(M+=+2\$6ULK(&B\$V\&8DID^!7+/MOP6_MKE_B)XV^!_O_.;6>(/\$E_JWA#P7+8?Z+>Z7: ?OI^0*!(Z>6^TAW503A2
MO4DUZ=X_.;!^"7CO1?A#XD?^^(I5T+O?A:(;C38;"69=3I5I@Z*RKSC<
MLO)93QAJ^CS+^YS++L+^\$.T:B@G4<87DYNG)Q2LFK6%I/%*U M3ECS?
XK*_P")Q2MS/EV"BBBNTD*_S_@G;_R9SV_P#N(?_IPN:_%OVL_X M)V^F<_#_P#IB'_IPN:_\$?%S_D14?^OL?_2*AZ6
_BOT_P_CZ/HHHK^2#W@H MHHH **** "BBB@_HHHH **** "ORO_X+&?^H_AB)=#X#HHK;\#_V'_PFF@?)YVW_-
_X/I_M3^S9I\+YB+;MQSNY;I8KI=NRN28QC<IARKI&)4_C@D8R_B/S%-KI6OCIX1 MT7Q!^SC=W^PD^GPU?>
>"K:"EM6TU&34_-B,<&B/I#_-I23S!N5SMAR#@J_M>0^*^%?A?A\$=, 9Z\ ZK\+ _#WC&I^)-
M^<;UKNJ6R3W,33K&%%\$AR4^O*/ND_M#;G'S,37E1QZE&ZCKKHITU^0^YJ45ZE^T1\=-*\$OI00BIP=;3.NAZ;JICA
M8-YCQVSI75<^IF5'_YY)7FOTTV_+.?@O6/\$A>&_#_&O NO_.OM^R M7QIHBDU5IBK^*S ^=N)"=X&XG>N-
E;5L9^C&I73U_KS\@L?CS17Z!_LK?_M^7P;_?I5OHNBZ=X3UI6I&%YKGAS27W6MG<@_HA_*OQ1_MM
!K(K)IQQ<9508VU_I;A8^1_!FOV"?^1^<_IBLW_*<;"OF6OIKI\@G_D M^O/_8K_-P"G&PKTJ?^%I_XH_\I2/GN(?^1-
C/^O53_P!(9)=T445]^?Q_ M%%/% !1110 4444 %=-I'^\DK7A\ [KK)_Z^>N^KO?@3_P E:\?I=9/_13U MYN9_[C7_
_.\$OR9I#PI_R.L%_UH_ ^EH^V;*** 3^X@HHHH **** "BBB@_H MHHH **** "BBB@_KXF^_W_)60\$/_
%UC_P#1251LU3?';_DK7B'_KK'_P'B MDK\A+ ?I_X'^<3>\4?^1-2_P'OL? \TB9P5%%/%?K1_+H4444 %%%/% !111
M0 5ID?LX?DETO\ ZZZ_ /HUJ^-Z^R/VI?^EP/3J***)3^H0HHHH **** "BBB@_HHHH **** M "OGC_@H-
R9S\2 ^O.#_P!*H:^AZ> /'^"@W_)G/Q+ \ZX/_ \$JAK?#_.' MJOS)E\+P;HHHKI&("BBB@_HHHH **** "BBB@
HHHH **** /Z,?@/_D_ M^?_&+FG?_I_7=5POP'_Y(=_P#L7_-)HZHJOS27Q,N.R"BBBI*"BB MB@_HHHH ****
"BBB@_HHHH **** "BBB@_HHHH **** "BBB@_HHHH **** M "BBB@_HHHH **** "BBB@_HHHH 'S_ (+^?AG,>?>
^Q1M?_2VIKX7KIH_X M+^?AG,>?^Q1M?_TMO: ^%Z^_P #_NT/OS>X4445W""BBB@_HHHH **** "B MB@_HHHH
^F_":O_)ZWPY_IB7_IMNJ="OPO_X)J_)ZWPY_IB7_IMNJ="M^OCIX_WB/I^K+CL%%/%>\$4>;_M^?FY_%3_L5-5_I
(Y;_ROWS_4_Y S^*G_M_8J;K_Z1RU^IE?U+XA^XXO_&OR/\$S#XHA1117I_!E!1110 4444 %%%/% !1110 4444 %?
M9_P3M_Y,Y^'_P#W\$A_TX7^BG7I62\$[?^3.?A_P#IO#_T MX7^?B/BY_P B^C_UIC_Z14/2P^5^G^1I^T445_)!IP4444
%%/% !1110 4 M444 %%%/% !7Y(? \!8S_) +CX*_I%P?^E,U?K?7Y(? \!8S_) +CX*_I%P?^ ME,U>ME?^I1^?
Y\$2Z^P'5_0-2AT;7+^N=MM7M\;=)I+^+^3<*K_F\IC^VT MXP<\$^FJ%?%;IDGVIK^I?GA71A?<;\A #KX2V7@WO)J-I?
6-Q+;=^W.TA50HN_XR^R?A?_P4\$7P9X\&Z5XE^&6E>-?\$_@N_X?#FOW-Z
MT\$EDA0(H/RVWE0%&OR)*OOC=7R#17%13H6LU^+ _#^<IHTCHJSNA_A:U\ MXQ\Z+XU2>.\$D:'6+X/HI
I^9F2W!5B;_O@*R\$>6OS\$#%;A7HJC_A7/I>=ML?#3P;XU;0=;U^8-K?>
BS^T2.GNX>088XQOE+MPOWVX:3N^1X^16SH4WHUV? MW;^/4?V?<^F@R:29MJ_M(X;C^&9OW4FV;E1QAL^/M
KF?BE3>^>_CW6%/WB2Z_WJN13&5^3LB7^")>B(N^N^!7?45?LX)_M+I M %?37I/ (>?^L5F_I_-
A7S+7TU^P3_RWCG_+ %9O_3C85T4_P"+3_Q1_M_P#2D?A0_\ (FOG_7JI_P'D,^NZ***^/XA"BBB@_HHHH ****
"N\^!A MR5KPI_UUD_\13UP5=I'^\DK7A\ [KK)_Z^>O-S/_<;_P#@E^3/H>'?^1U@_MO^OM/ TM^VS1117X"?
W\$%%/% !1110 4444 %%%/% !1110 4444 %? \$WQV_Y M^UXA_P^NL?_Z^2OMFOB;XI?AE^0_\76/_%)7VW"7^_3_P
#_.)^/>*/_M (FI?I28_P#I\$S@I*** 6C^70HHHH **** "BBB@_KI(9P_Y)+I?_76?_T: MU?&I?9'I_')=+_NL_P#Z-
:OB>+?IQA_C7Y2/V+PM_P'1S5_ZI2_+@>G M4445^2GI0A1110 4444 %%%/% !1110 4444 %?/_!0;_DSGXE_I><^'
*50_MUJ^U\?I^O^3?B7_UYP^I5^6^_C0I5^9,0A9^#=%%?HQ 4444 %%%/% M !1110 4444 %%%/%
!1110!_1CI_P#DAWPI_P"Q?^7B#1-)A M@LVBLK^498HD+6L;0JM@9))N37SU_PU9\9?^BH>* _;3?_%5ZA%\%(O
M^3NO%G\ UIV^D%7S^7H\CY%E;R^"5J^\$IRDX*!<(MOU;5V?_5ZDU5DDW MN>J_\62?&7_HJ^BO_P
&TW_Q5^_#5GOE_P"BH>* _!M_ P#%5Y517UW^K>?2_MI_5+_P_P_R;3_)F>J_\#5GOE_Z^AXK_!M_- \ %4?^6?
&7_HJ^BO_M,&TW_Q5>55IJ_LP_I@^"O&7P97XB>+AXB\2K?1ZA%%?AB^-R\J;O;G!RS M3\$IF-0;FC!#
UX6<87AK(\L3B%3LWRI^E;MMW=MK;J)M&M^VM5\L92B?/M_P#PU9\9?^BH>* _;3?_%4?^6?&7_**AXK_\&TW_
574>!@S\+?^7O MQU?0^1+KPIX)L64PW&MV?E;E>MO5&@B0#;OW\$C+ _W\X8##_:_P^#VC?_GX
MUZKX/T^YOKO3+6^WE274I\$>8F2)7.2B(9^/RTJ.%X:KXR_C@8^I^/9T4M M_-KBE?WE=+J#IHH_\IZE/_(:L^_O_
\$5#Q7_XIO_ (JC_AJSXR_I%0\5_M_P#@VF_ ^*KT;EG#IEFP^9/_COQ_XJ^BZ/AZ6V2#3O\^4MU_)V\\$:QN7_M(P#@8P
3S7DWQX\^\$ _"CZ;2?IGXKL+"W@C%Q>_I> _;3?_2P*(X74Q_MXDL44+PWB*_ _;3?_%5Y517O?ZMY)_T14O_
7#_(RHA MF9ZK_P_6?&7_HJ^BO_\&TW_P_51_PU9\9?^BH>* _\P;3?_%5Y511_JWDG_M_0%2_P#!*WU^&DG
MC23I1^N^Q(I2,^YK);_*C_@DG_P EQ\6_IBX_I3!7ZKU_ _B!AJO_M_#04(+DLHD)* (O1+3?4^@P;&?^
I4;7_P!+VOA>ONC_@L)_P_G M,>?^Q1M?_2VIKX7KI_ _P"IOI#_!A1117<(**** "BBB@_HHHH **** "BB
MB@#Z;_XJ_)ZWPY_IB7_IMNJ="OPO_P""O\ R>M\?^N)?^FVZKI^T^M/SC_ _B/I^K+CL%%/%>\$4>;_+2G_)N?
Q4_I%35?_2.6OP_KI\ VE\ DW/X MJ^_8J;K_P"D\%%/% !1110 4444 %%%/% !1110 5^2_!8S_DN/@K_L7I_P"E,U?K?

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

OKPT=-.UIYI70Q%=1G4%QZG^TM6?V MB A?8^)O"A6+X5VOPOTS3XI0CD\5+J(U0+Y*ET=(G";S(2JJ.N5:YKYZA1>
M! VK?& Q^/C_?_?_%L B#I^BSLWA;PI+XLL+33-+(B?R?/8RRD*IW2=#S M@80)IW^V=_BA^TS>?
#7X<66@/IGPXN[R#5/&FMHJ%N!&L9S1D2/S/,<@G MDV&BZD_K<+W?V338I(X?L12-Y#A
M7=V&^+8+\\W;176 &#QWJ^PS^&NO^)=\\,ZEXRU6PMRHH6D0M)<7DI^(" MJL0,D%F_%.!.#CAR_ D^NM? 'PK\\-
(A:9IESX@>2)+#PSIUCJ\$SDI\$4 M+A@H8Y\$R^H_BP_\\UZ5\\9M5%\\+O\$-L.M%M2?7CB^Y_XE>G7LJQ0S3%
M/G9G08);!=<I<9YH ^50A;^V\\:;I& ;#\\#_ X^?@7PUHJ^..DU#3&\\2 MRFZTX(DCE;N-Y^Y CPO 4 Y.3A@O"WW_
4: ^+4GAS6OC#17PZT"Z^>E: ^- M%=Y)YUUI>+<\$-RC;O+"Y9!@IPSA\$/BI/K_5?@K'J_B'Q M-
))IKOO&U3Q38W%Q:VA4I88+6*0B_/A5VQCG(_A X;Z_8Z_+TKX5Z1^S7I M.:@#_211_VA%XFU&(-#8F19?
*,VR)3)N1"<(IG>%I&T^WKIQ=XT2>?3IU#^YHAM&5XU9@N,DL1G(.T+N;<M_ M1^_OC^R'I/Q2^'_(LIWQ;?
^9"VDZKJ;VME;&*22.6X,SE=\\0,>=H(M/_C.37B_P"V)\\+ _HGOMXDT#X>#/#AX?SOP&T2TM(H/L0\$-
H82+&C*M5%P3DG:5)SL+GXVZ?\\L5:7%X6^\$O@_PGXMLG-FW@'5-06> MR_LI25"130.(H)C<[?F.
ID8([QW([7I8WC/XR?&2Q9I^/G-GX+UFYT?3I L M4C5?>J^DNH<(<T8,DLIA [P\\IAS&XVIZ^Q^C(OV0_@+13_
[^T7XJ^ (VO M>I.'^'""@R^TE+\\+P#X?U" &XMI^BYIC TEDM_W*L C?, K?;!@Y8GI=H **** M"BBB@ HHHH ****
"BBB@ HHHH *^,I5/_ MO=#\$;2=0N+_, YERR*/O+D!B1N&0,UI&U^_P)?B5IGI OI/0QA^,^E:E MI.E>-
M;:6=%;PZ?+=VUY"997%NSQAF#@2@I><\$-NP-I(\\IH?L_+3W@'H M;1I^I&ZC;\\3)1!J>C:E
;:L) #C"RQ'IT(CW*67*L,Y4@>F:QJUIX?TB^U2 M_EBQLH)+FXEVEMD:*69L \$G !. ". _P"#\$>D \$/XL_%KH?X_?
#CPIJGAC M2I>\\2Z9X2^W6HM;C5+U88MES'&PY^_L')P6E Y(8+Y_P#LT?#7IGSXM^ M M5\\;E8^_7_;
O/#>H^O^INLR:E')/?(WFKYQ4B,D/&AC!;D<."I 'ZB_#/X MF>&_C!X(TSQ?
X1U+\\U_#N!SVEYY\$LF/79&^215<896?^2CXH>-?A A6WP MUA6>+?L?IH_V#I-UJGV/S?^*_P
F9I+\\WI6VIMN_X,YP: (X>V.CV?I"5H MOPIM?5\$HJ7B6T@^_>@BZ74?I?I9:H* K (LIVY\$73S/XH?X;KX>_MCXZ-
M^SY_PD' S^/AHJ8U7^U#<8?I5^S2;?LXG^;S_9SSCS/X=M 'Z3?LY_&+ M A?WP4* \$^'R/I MRW>?A
LIH3IAC;*Z8\\S8FHIF?NCK7I?A=\\4\\&Q_ M#7X,K\\,U\\,K^U'_.MN4"B[?IGF64Y&\\ISID,94_\\V+;_EWTHIHJU>WWI3'
MCZWA<;KI^A>_FUUAX7U'5QKYU" &U\$S_1FFL6"/#L"!O(6W%OXLX_/W/K@/C MC\\=//I_L_P/HOOCXVU%K#2876"-
(8S)I"VGC26Z2I)=%&\$ (RX(C_+X) S@S\$ M\$ I____+O)X@\\,V^D^_)!WBO1+3I?<^'_!<I@LKUK8I2940.X(^=
M_.0WS XQS7+?!_\\X*&^/CAKF@V7AKX6?%1I-UBZ?I#X@F\\,Q?V9\$=Q5GDN M\$N&"HIW!Q@\\5\\W_L6_?/?
P\\A0B7X\\I)WB?Q=^?CEKGARZ\\KPKX/_ M2=C52;6T,ZK')/P@&7P22-SIF<^!OBE_#7I?C?XN:EJ8UD0>
M*/A_XRBV>F6/F9N&FB6-88FY06)W*V P^P5>(_ [HKKP5^SWK>B>'M M3L=\\A5>+\\91HK+POX3T_I=J,L*
[MTWEJE 0:6ZMDI6P M;_:=Z5\\80"&N2%+6 MOAU8:O_?&BVD5HJ.G);38MH9-IC+2I/+RP92%W;L_5L?A_10KIL+2?
MV9I_ '\$3-"T:3A A:6M6Q6R\\3:I8^9%HMFSM&\\Y94:1R"7Q&H(^\\2&^XXI:Z MGH_I>7PCUCIGW4/C"NK7EKX9T^?
I%=V=S:XOXXI\\=MJ8@2#(=RXPO7!)W8!(MF^#//OP\\^=WXBL&MM>\\":SH&GG5I_2O&E@_\\N(I\$
\$W0&JE,014DIL@_#C MIS7P)X@\\!^#14_8;M=6^\$_.N:A5I CPOX\\M2\$WC6\\3IX9K^;RCYKK'+N*** M3UP"\\I>M>R>!?
B;X<;_\\,UCXU>&I6^N A-X5^TIEK6JW>FND%W)\\^=I:8 MZ_O"\$*/&CWL T-U=+9VFGZ7&DM MW#I'_M0?#
IX<^\$M:C_X0 MOX?Z;L127IXJ^7" _C;JGQ#^+GCSQ\\)T M2> M+\\,WFC>&I5;Q#9PQ;+R1\$7-^+8NTDDSY:C.K;?
EYPI^C_P_ BHM P_Z5OAI^<8Z3#<6^F:I80Z4;0WJLRLR1*^4_09E#8/&(\\ZZ:OG3_@GYK?B M36OV3_
_\\I>&U_TTVWM=\\VWT=SINLU@C\\JZ\$ 5EAM\\I\\YEV\\^ABZ "B MBB@ HHHH ****_3^*/Q4+?I?
P1J/BIOEJ.B:I8*#<=2AF.2<*BJH+Q) M"J"37SIH/ !37X5:AJ6D)KFA>- ^@ZQ(M_\\4>*"- KI-X6^Z4G5V^4C!W;
MH4#EB!DU4_X*?_"Q9\\5O@3HD_A/I?I\$OAK7X:O?#\\(9GOI9(Y\$=50YNH8S':3\\U'\\6:4"J1@XV9 M-
'ZZUXAXC_6_X1_P#;V\\?!' A'//_+=T&76_I=^W?;(V&8>5Y^EG=GR? MO;QHIO\$^/QM7PROCOXX#XU?)R/CH-
6F'PV^P2:O*^S9_T+I^Y7I0;G;OS MV^I^\\W5H &^*V^I0GP) X:&O:1_#&/_A+6TKSS/IGNQFZ_\\IS9N,8E*_O\$
MYXS0!^PE%?BO>_\\1U_97^_)1^%\\3M"\\XXA_LI=1^TICHNV;\\I1C9^_\\LGF> M10VO:#<_#>3P-J* V/X'9HI?Q!K
M'AS21=:?HTKOL"7,S2+M. 6 M\\3:5\\V?B+\\1M)U\\2H=8LM9)\$^'Q?V9AE+;%9S(A63"ABI&0&7/7%='^S+^U
M\\X9_\\J(ZMXB\\+3KND6FF:B^ESPZ_103>\\\$ _%*OA
M\\XXI=;\\X>BT_Q;I&G^ (KMI+00%&KZ;2=5F601H8)2Y?M^HLS"9&W0NH;E,Y1E\\YIP17Y7^\$ _V\\A
MA^U/^T5X.G\\O*MSD?>I Z#XN?MM?#GX3Q^SHHUKOUK/BNS74M&T/P,IYOI\\ZILRA<7(C M+*!M\\I)!U_L
I6Q\\+>(OB!:_LXWG\\I7GPO\\&VDZM)XK^ (MI=77A4PZ?)-. M6Z\$ROA&5;?(95)YQG>H^88/7?I\\HA_V?V)=V7.I-
A8\$L\$USWP;_&I/_QC^)%AX&30_ _%_@I@Q\\J MEJU\\,BS1_L2ZG_%9_@{=IRE4=@6VY"G'/%>5?L: ^/?AE%_V4?
%WB;X=W MGB3XS7EAJ+7WB>[TO2Y\$OIV_E6,N\\<4^PF-5(8X+\$_W))%>+_ /Q/IGQ&;
MZ&^*OAEKGB_XJZ/+8WIU^Z\\=6LLI>%/_-CB&VF=5\$)!/EA5R#N906W<_ZG MT444 %%%%_!1110_4444 %%%%
!1110_4444 +?7I4G\\I77B7X9_\$OPS)/A7 MX-A=??/Q#;->Q6UY/Y5G8VXW8EF(*L^7(<TP%SGD\\EX(_#^+/PI^_A
M\\X8_M!^M?T*?QA(8=#11>+^EWLWF&-(GC=Y&R695+;@067Y2I\\W#2_ ;G_9S^
M)W_"^/_O^"LNEZAXTT73FTF^_ZU)Y<&I6LA_1R0%;IX0060<*0V00W>&_ M'_@3/?VGOC\\I\\O'WOTT'0?AYX8\\
W+7VF^\\D)NTN\\FINMR.K.Z22(%WQ(2= MP.\$"A-O\$\\>O+XFO_4X+2YTZ, MW'FM*DN7\\>I?VXO@7\\2O'R^" _#?
Q&TS40\$;R&& M&V\\N:*X_?# M7PXU:&_F=Z7J<\\^H+^"V1IGB3IY&GWF+@;G_8I<;2U?@/^T\\)_&'\\1N@
M_\\7PYXTTKXEZQ?16EWJFL6<<\\%M(T^R=D9V\\'5FSY19'W#I0\\H_\$WIK:X0?
M! PIH6M^*O>FV.FZ\\I\$)+DM1)>M>1\$ B6-(%=F3D?_!MY'_.UWIK^X2^&_A MCH/O\$O\\
QM9\$X*URIC^'6(8I\\HG<.0CA\$+1D>6^\\S NPJ0V#7PMK/I ?Q? M^\$S_ L0>%O1_W^X^B^&T#5I_\\+^+6_\\
WL_C7\$T^ZWO'\\A!FVE2.G9G;S M00^_I?B!:=?L>#>I^C^&^EE42^_HO\$NM:+)K\\5XL1CE21C\\,8UY0 M7RS,06'0
^Y"70P\\+?S;X77GCP5)=>+M'ACN6@_LYSF&UV\\I97CAC=59V+ M*57 P3T...^0K7IMX\\I^"2"PUN_BA\\+
>I B!K/ID:=I_O+NOV):1\$1 MIT=_0^!VB)<\\HA(\\^Y?#\$7VB^\$M2;PIH_YJ5I92'3M.W+%'+*L9J+_.0%4 ML%7J>U?
G1(\\? 74447I0\$?Q_ ^*7P+M?&?B6>[2WL\\6NO%5A^_&I%FPXL_M19GY568\\LESZ\\F8L
=A10VU/B\\^TQ0_AMX2U7X_&=&_3VD-K)\\1+ZYL MIB^:_%Q\$5G_D8,3D*HP^O7-?=7A\\M3;0=-.M?9/I8-
M&;W\\!N^S^2I^F>5N M^;9NSMSSC&^?VI_PIGWXL_\\I6_'OA_30V=\\AAX@C\\27_\\I\\XCV\\Q!;ZA8Q MG;-N3(PG>4
#_5_*,8PXX/L^&-&\\/_N?LS? ?IYM.\\2:IJ=FHKNI7MO*
MYCLK*W0R2Q;9\$VD_\\JEI\\W094G@\\@K/I27Q2\\5_"7X9SZMX"\\#;A0?%=Q<1V M5AI-C"\\HLCDCSIR@RL2
9)XSP,J"6'SY*?VUOB_X^&GC_X>_\\;POX?TW5_M_ AF3Q6VH>#19)+<6L<_.T4B22.OY#\\\$LO(VD,K'W?\\JK5/BYIGP?
OQ\\\$\\\$ M=\\=7_\\JVT7VJ;_.6L+\\M\\Z^=(B_Z_+M#\$C)!*L 17RI^RY^SY48 "OCSP'
M\\1_@ZGAE_'&C7L7B#XD7OB:UU74=0O)\$*INC1V95!=F"CY1MYR220'3P5_P4 M^+\\IO)_/_CIX?>_)^#_Q!UG^R-
,GTVXG;4I/WOLBEN&9BCJ<_PVHI948_ M+H;IOV@OVMOV@O>J>/_\$A+X5Z/8?#P#)&EYJ7C(7%M=:R-
X5Y++#HNSG M_\\SP1ECY=>5>&\\V4?VB?F@_"3X>/?#&@Z_\\OA\\KBZC<>*+?4XIVU:")V M,
<<4GS\$.QW7+HN=P)QMPVS^TYV_ PHKXP_N1I6^#L'CWX.Z#>,^C>&\$\\3
M66G\\VFI_L=W=V&GAR0\\GIVP50,\\#;R^\\^G_&WI\\7FA>"?V4M^&_HITUNVLZ7 M;7.EZ#*3Y\\U>W\$8:&U7
RV6AW@/N^S8XQ6!^P7^TXY_3^>_0^\\(C:3H6 MOZ\\X@ET62STB"6)\$;
<<98.)9#O#LP.#C@<5S/QF_98^)7I2C_\\+QF%EI'M_?A.U^U#PRVEP;U;V_\\2I#KF3R7;_*J=K;05<(9W_\\
3I_9W^_OPA4?S_M^Y^ (FMK_&)JVMW=W\\I V6SSJ<\\NA M/S(79H=ZJP^SG_7=G%_\\USXW\\9;7\\ M\\!\\NN>*-
;G^S;\\HUE-?W(K*B@_*<Q\\1A=I?;GQ2^\\I\\C\\50A0XG&_MZE+)!8ZHMQITTT\\WXUEC*;U\\OG/X5_>
_"_P"VI^SOX"B^\$GA3PAX_\\9:% MIXDM=(A:3:@D)MK=W8J9(7F1RR;C@!&QP.R<@'T7\\%_VV/ 7Q0_9S7XO:W=
MQ>I\\'M9GLI4AU.?<+Z0C,2I%\\EW;E*15W-N V@Y\\U^+G_\\53X_&^_AY^&^ M\\FJ1^\\HRXU
62Z6JW>GN%&TRR.TEL=NQ64@%10R=L#CS;Q%_P3;\\5^\\V. MO#'_@GPIJ&D>)/>C^\\T\\8:A8Z@"--U6XV&-

I4%@N4"!%!?& .V=@:!"1"2?MF?MA/H?I.?@OXC?!KQU8G3I3\5V>FW&K6\,Z?9VBF:6)TG1 MO*8;\$)RJNN.V:O/B\!>
CA)\;OI'f0FD?71_\$'B'_A&WT'5?A\J6O6WG:7(M)9"LT%XV(6)5ADCD\F7IW9'D7C'I@GXPWW\LEYIMMH&C7'C7QA
\$+:Q9>=^MK.[ACTS1\;R9T*9=PK**ZAECA+;M"IL9H^?Z?A^U\?'CAK&L:5X*=\Z?K. MH:3&TJW
R2VOQ6)3AI4Y\$<SD8INFY1D9\\$(S4^?I?P3^+^CUO!A/X@?Z?J_B M/+B.U6*)+@IRPAE=%CF(&3B-
FXI\0\$UAM:M^RSI9/VFOB_J7B3QOX+V\B MPL\INH>%(I1)*U**^DU&6XAE63IR^#18M1#1W7VI-
=N/B\;W3V>+5-8Z<=%8P X 9&"AE)Y3@4 29.C MB M?H7OB@WPZL/&<5SXV74YI\CK8W0E%U^K-
*)DBVf0\$;YGC<\$B:Y\HHXN M?&;P_P"-O#G@KX-?#NUU_411@DO+WQ_XDBG71+<@1-) &5S*V#QNR/E^5LG
M;S\I?P"5?"OXS?M#^)^O%/\AZ+3(??%?BAFW1\|S|>:2ZLS+.^?W;LR+VZ:^ MTY/3BL7_(*:A M">.{??WP?
M MJ@N_@W^(KZQU>UL+VX4N5:S22:53 M&C)RS*A)R\G&Y6 &?!"JXT_M-? 6_U:P'X<V%Z1\2=11-HFKQ>O;F31Y
MDCBW226SP.6W;GC 4NP!.XY6E_9;_6^-?Q*_6\=D!.#&1G@BNA^!R?%+X;_LQ^=(=)TGX^V\@/O'H
ML;6_AKPI8Z-?7WS;H_TB6X;4\$S.Q9H\F"J2*T_P' M_!LU? FZN/M&LG_!7.NW_B'O1A<6UUK(WA7DLL.BI.<
Z?H&6/EUIC@MO MO90%7f07P1L_0BG31/TQM6OIAZ;HSD2_8HY3'\$SB21R7)1B2_@C\IGY M2_;
<^' [37QA^/+M8^\$/@_X_&#)DN?"CWP_XGF'BR286>EV:(6 ?R MBK,24?# C@+A3O&\$V%?MT>H&OI?B;6+^%-
YK7Q@VZ^?"HX7TE))K;_I M_P"?EV&62 ?-G)ZKC>=XROBI)/C=;%CX6?M^!A\H-SXSL_#QT/Q%XD
MU:WA6%&WE1%N>=%=\$TC5OCK\00 M\$;ZI>VD-S;B'2H90V61I9%B>1&9R!N909!PX4Y_/0?
V'=A4V.D+K<%_X1FDDM1\$?+ =RK)(Y5OWOWB5Y&-H5CYM\;VH/C9 M!&DK? MV#?AQ?7A7KNJ6?C?X-
I>'M0UN&6UOXB:AXFMM5O\3O00462..0LJ\$LO"J<M#").3Q\I07P5_:1_:UJ#2;OX0^!/#/B>WU:*6W^,&@:LD-
Q:6<9;8B_MJK MSAN?X3SA<\$'_Z-1MYD:M@KN&=K#!'UIU06_ MK8V;Tf74T<:H\I R_6 M(C)"/K4\!1110 4444
%/%%_11110 4444 %?SP_0_&7_HK?CK_P_*M2\^_T?A_0_&7_HK?CK_*2\^CM?2V-4_G1\;T/45_/_#_PU#9?
^BM^M.O.PI+W_P".T?V_4#4/OE_Z*WXZ_?2\ P#CM\IC5Y/T_?T/45_/_#_PU#9 M?^BM^O_I+W_XI1_PU#9?
^BM^O.PI+W_P".T?V_4_G0> M&0? M\$3Q9KND7/V_S\U+6\FXMY=NGW+KNC=RK89589'!/LZF4SIPE-R6BN'?
L MM117R\ P4_^_C'X&_!;1=>=\$Q_8FK7'B"&OEN/LL-QNA:VN7*!94=1T:!
M(&>O)KFRO+JN:XVE@*#2G4=DW>WSLF_P%.:IQ)?M"?1%_P#*+I_ CT?V\$OVA/^B@?^473_P#Y'H_XA'GO
M_/ZE_P"13_\E8?7Z79_U\$IK**_%A X>)?M"?1%_ \HNG_/R/1_P\2:\$_ M_P"B@?A'E%T_P"1ZA_B\$>>_P#ZE_X%A
^5A\I=G_7S/VLHK4_ ^B7I M0G_10A_RBZ?_P#(I' #Q+IH3_HH'_E%T_ ^1Z/^ (1YI_S^I?@_4_)6'
MU^EV?I?_:RBOQ3_.'B7I0G_10/_*+I_P#CT?V\$OVAA_HH')1=/_MD>C_(A'GO\ S^I?^I3_/E8?
7Z79_U\$IK**_%/_AXE^T)_T4#_ _HNG_\MR/1_P\2:\$_ Z*!_Y1=/_/D>C_B\$>>_\J7_ (%/_P"5A\I=G_7S/VLHK4
M_P#AXE^T)_T4#_RBZ?_ (I' #Q+IH3_**!_P"473_) 'H_P"(1YI_ _J7_@4_P#Y6'U^EV?I?_:RBOQ3_X>)?M"?1%
P#*+I CT?V\$OVA/^B@? M^473_P#Y'H_XA'GO_/ZE_P"13_\E8?7Z79_U\$IK**_%A X>)?M"?1%_ \MHNG_
/R/1_P\2:\$_ P"B@?A'E%T_P"1ZA_B\$>>_P#ZE_X%A ^5A\I=G M_7S/U_ _P\+>_&'BOQ5H^E_9?
\$'BF6"76+YKB65HH4*1# #10BH("H% M'/2NMK4_P#AXE^T)_T4#_RBZ?_ (I' #Q+IH3_**!_P"473_) 'H_P"(M1YI_
J7@4_P#Y6'U^EV?I?_:RBOQ3_X>)?M"?1%_P#*+I_ CT?V\$ MOVA/^B@?^473_P#Y'H_XA'GO_/ZE_P"13_\E8?
7Z79_U\$IK**_%A X>)?M"?1%_ \HNG_/R/1_P\2:\$_ P"B@?A'E%T_P"1ZA_B\$>>_P#ZE_X%A M^5A\I?
I=G_7S/VLHK4_ ^B7I0G_10A_RBZ?_P#(I' #Q+IH3_HH'_E%T_ M^1Z/^ (1YI_S^I?@_4_)6'U^EV?I?_:RBOQ3_
_B7I0G_10/_*+I_P#MCT?V\$OVAA_HH')1=/_D>C_(A'GO\ S^I?^I3_/E8?7Z79_U\$IK**_%/_AXE^T)_T4#_
_HNG_\R/1_P\2:\$_ Z*!_Y1=/_/D>C_B\$>>_\J7_ M (%/_P"5A\I=G_7S/VLHK4_P#AXE^T)_T4#_RBZ?_ (I' #Q+IH3_
**!_M_P"473_) 'H_P"(1YI_ _J7_@4_P#Y6'U^EV?I?_:RBOQ3_X>)?M"?1% M_P#*+I_ CT?V\$OVA/^B@?
^473_P#Y'H_XA'GO_/ZE_P"13_\E8?7Z79_MU\$IK**_%A X>)?M"?1%_ \HNG_/R/1_P\2:\$_ P"B@?A'E%T_P"1ZA
MB\$>>_P#ZE_X%A ^5A\I=G_7S/VLHK4_ ^B7I0G_10A_RBZ?_P#(I' # M0+IH3_HH'_E%T_ ^1Z/^ (1YI_S^I?@_4_)
6'U^EV?I?_:RBOQ3_.'B M7I0G_10/_*+I_P#CT?V\$OVAA_HH')1=/_D>C_(A'GO\ S^I?^I3_M/E8?
7Z79_U\$IK**_%/_AXE^T)_T4#_ _HNG_\R/1_P\2:\$_ Z*!_Y1=/_M/D>C_B\$>>_\J7_ (%/_P"5A\I=G_7S/VLKD_B?
*_ _QF(S^%&_F?VQ MH-Q+%-9&XEA61HW#IN;_2 R@I2<'(C?_A #Q+IH3_HH'_E%T_ _1Z
M/^B7I0G_10/_*+I_P#CT?V\$OVAA_HH')1=/_D>C_(A'GO\ S^I?^I3_M/E8?7Z79_U\$IK**_%/_AXE^T)_T4#_
/R/1_P\2:\$_ P"B@?A'E%T_P"1ZA_MB\$>>_P#ZE_X%A ^5A\I=G_7S/VLHK4_ ^B7I0G_10A_RBZ?_P#(I' #
M0+IH3_HH'_E%T_ ^1Z/^ (1YI_S^I?@_4_)6'U^EV?I?_:RBOQ3_.'B M7I0G_10/_*+I_P#CT?V\$OVAA_HH')1=/_
D>C_(A'GO\ S^I?^I3_M/E8?7Z79_U\$IK**_%/_AXE^T)_T4#_ _HNG_\R/1_P\2:\$_ Z*!_Y1=/_M/D>C_B\$>>_\J7_
 (%/_P"5A\I=G_7S/VLHK4_P#AXE^T)_T4#_RBZ?_ M (I' #Q+IH3_**!_P"473_) 'H_P"(1YI_
J7@4_P#Y6'U^EV?I?_:MRBOQ3_X>)?M"?1%_P#*+I_ CT?V\$OVA/^B@?^473_P#Y'H_XA'GO_/ZE_P"13_\E8?
7Z79_U\$IK**_%A X>)?M"?1%_ \HNG_/R/7Z%_\$\C/XO M_7.P6UK7O&L?VWJUOX@FL8KCI+ #;185MK9PNV)\$4_
(YR1GGKP^=SI@#- M^<\$?BZE.4\$TK1H_R2O"NA<-A(ZAX@T^MS4:O&NGZ1<MS=(H8LT:\$Y8
(Q:/HKL/K6(P"?C^I^A8^9/^:OI'_ M \$3G_P_KFI?"11_P_U?V) DDF9#F'8<@XSDZ M45+Q_
>2LYNWJP"O+OVAOV>?#GI2W@NR,)>fW5+"PM-034DDTF6..4R+)& M3)&XVXE;C&<@<^QJ-
%5A<57P5:.)PTN6<=4UNF*45)6>Q4_ _F?A%_T.?C;_M_P_#KA^1:/^3/PB_Z&/QM_P"UG_ \BU\K5Y\7?CSX-^!O_ "
_P#7ZA_M8?)"0ZDFDZ=Y5M)-YEP_P\U3L\VCW/%?26_ZI<1_HL_P_R\JU^4^;_P#A MTS(O^ACV?^!UG_
(M' #IGX1?I#XV_ \ZS_/D6OM:BC_7;B\A_Z#9_MA_D'U:C_"GO3_PZ9^\$7_0Q^~O\ P.L_D6C_ATS(O^ACV?^!UG_
(M?:MU%^ ^NW\$?_0;AA (/JU^4^?^ \ATS(O\ H8_&W_@=9_ \R+1_PZ9^\$7_0 MQ^~O_ZS_P#D6OM:BC_7;B/_
*#9_A_D'U:C_*?%/_ #IGX1?I#XV_ \ZS_M/D6C_ATS(O^ACV?^!UG_@=9_(M?:U%^ ^NW\$?_0;AA@^K4Y3XI_X=, "+
M_H8_&W_@=9_" +1_P_F2A%_P\#XV_ \#K/_P"1:^UJ*A M7;B/_H-G^~^025J\A4_P#IGX1?I#XV_ \#K/_
_1:/^3/PB_Z&/QM_X'6? \BU\K44? MZI<1_P#0;A_# (/JU^4^?^ ^3/PB_Z&/QM_P"UG_ \BT?A_F?A%_T.?C;_ M
_#K/_Y%KI6HH_UVXC_Z#9_A_D'U:C_*?%/_ Z9^\$7_\$.?C;_P.L_) %H M_P"3/PB_P'ACV?^!UG_P#(M?:U%^ ^NW\$?_
\$&S_# (/JU^4^?^ ^3/PB_MZ&/QM_X'6? \BT?A_F?A%_T.?C;_P_#KA^1:^UJ*/I=N(P#H-G^~^025JA_*?
%/_ #IGX1?I#XV_P#_ZS_ ^1:/^3/PB_Z&/QM_X'6? M_P_BUIK44?ZI M<1_HL_P_P @^K4Y3XI_P"3/PB_P'ACV?^!UG_P#
(M' #IGX1?I#XV_ \M#K/_ _1:^UJ*/I=N(\H-G^~^025J\A4_ _F?A%_T.?C;_P_#KA^1:/
M^3/PB_Z&/QM_P"UG_ \BU\K44?ZI<1_HL_P_R#ZM1_E/BG_ATS(O^ACV?^!UG_ \ (M'_Z9^\$7_\$.?C;_P.L_
)%KI6HH_P!=N(^@V?X?Y\H6H_R_MGQ3_ _F?A%_T.?C;_P.L_ \Y%KZ%_9Y_9Y.?LT^"fWPOX8_MO=40I"
_H_P_A@^K4Y3XI_X=, "+ H8_&W_@=9_?R+1_PZ9^\$7_0Q^~O\ P.L_M_D6O\3XN_GPA#?^\$;_\$.SOU":P_P"\$AU-
)TIRK:2;S+A_NJ=@.T>YXKT* MC_7;B\A_Z#9_A_D'U:C_"GO3_PZ9^\$7_0Q^~O\ P.L_D6C_ATS(O^ACV?^!UG_
(M?:U%^ ^NW\$?_0;AA (/JU^4^?^ \ATS(O\ H8_&W_@=9_ \MR+1_PZ9^\$7_0Q^~O_ZS_P#D6OM:BC_7;B/_
*#9_A_D'U:C_*?%/_ #IGX1? M\#XV_ \ZS_/D6C_ATS(O^ACV?^!UG_@=9_(M?:U%^ ^NW\$?_0;AA@^K4 M?
Y3XI_X=, "+ H8_&W_@=9_" +1_P_F2A%_P\#XV_ \#K/_P"1:^UJ*A M7;B/_H-G^~^025J\A4_P#IGX1?I#XV_ \#K/_
_1:/^3/PB_Z&/QM_X' M6? \BU\K44?ZI<1_P#0;A_# (/JU^4^?^ ^3/PB_Z&/QM_P"UG_ \BT?A_M.F?A%_T.?C;_
_#K/_Y%KI6HH_UVXC_Z#9_A_D'U:C_*?%/_ Z9^\$7_\$.?C;_P.L_) %H M_P"3/PB_P'ACV?^!UG_P#(M?:U%^ ^NW\$?_
\$&S_# (/JU_ M^4^?^ ^3/PB_Z&/QM_X'6? \BT?A_F?A%_T.?C;_P_#KA^1:^UJ*/I=N(P#H-G^~^025JA_*?
%/_ #IGX1?I#XV_P#_ZS_ ^1:/^3/PB_Z&/QM_X'6? M_P_BUIK44?ZI<1_HL_P_P @^K4Y3XI_P"3/PB_P'ACV?^!UG_P#
(M' # MIGX1?I#XV_ \#K/_ _1:^UJ*/I=N(\H-G^~^025J\A4_ _F?A%_T.?C;_M_P_#KA
^1:/^3/PB_Z&/QM_P"UG_ \BU\K44?ZI<1_HL_P_R#ZM1_E/BG_M_ATS(O^ACV?^!UG_ \ (M'_Z9^\$7_\$.?C;_P.L_
)%KI6HH_P!=N(^ M@V?X?Y\H6H_RGO3_ _F?A%_T.?C;_P.L_ \Y%KZ%_9Y_9Y.?LT^"fWPOX8_MO=40I"
fU\H2>35I8Y)1(T<<9,<:#;B)>,9R3SZ>HT5YV/XESC.*U;&XF4X_M;V>UT7&C3@fQ5F%F2;J;

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l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

HF(3D@8S@9S@8;.C MX _1?1 V>?A#X<^VA3SW>GZ-"Z"YN<>9/))TL1C8X&YW
M/(CKX@_9W^.,GOUBUR+5H16==-&N6"6CF"(^18%1-
>^)EQ0IS1)J5>U=M.BTDECABWB@&'JDY\$(IQNOVKI65:&OBCPOK M&C_.,==1LYK0S*NXH)\$*.L=\9SB@#A
O^="NL> M!_:=T>1^>4YAP>%5L;Q9 MG\1+>SUIYAB(3<) 5SNZ>1?3G_13#QI^RYKOPH+;X:P^\$K0X@-J\$3PW?
A&UB MC\NW_;/DA4(RD8 5B6R00_-! AQSH^T504/_!'\ 'ZUO^A P1% M\$6.JPS:_12-P5@7M;*QBM^<>GF%L
=\%SU^H^X(BZQKEW\B1H1U)M-)X?L15M7L%+6=>?:KK5ZWEZ9H%M,J7%XPQN;):V1J#\SD^&0
"2!7PG^V%>V= M&OYE&_9_O\3-662QTOQC.WGB-2_9LF512TW1^,YRE2DB;OP.PN';:OT;^ M-WL_P/?VBO#J;-
X^1_VVN6\>9K:X8M%.AH ^_ MM4A\>/?V1+%/@E8FPV?7BZR L&VA<+'MEBW3*A 9(IZO*0J>F/T_X M+0?>1?7?
IPMXWLD.R^\$M1DCNT5!\$:&3/H)(H5_X'151^_LS_L"-? MIEG41-8\6-
HJWB5D;.:YKLZSW,2,,,D81\$2,\$9:*KN("2*1_UW0M.4:++? M:1JHEJ6EWT#VUU9W*!XYHG!5D93P002*/RK_X)D_MY?
#CX_!#50 OQ(UX M^I=*OI;139GMHEN8)0&>-?+1L.L@8X_,B08Z&OD>U@U#IN3JN)GLK:2&/Q
MAXC.Y1QN:UT1&RQ;4L:Q1B51Z_0WQI_P \$60AAXA\13W_AOQ;KWA33YI-Y MFO9>1Q_DY6-
WPX7IC<7(I37T3^RK^PA\^V2I>Z\N/#_-UJOB2IB\FZU_575_MIAH\@F*_*L<>X X R<#<6P_\$/49WI;GASIC?
POHEYJ>CW7B/6M'OVMOABWB10K"ZTB6UNWL+_3_M;M@1V4JJKX#CAU*Ni#8'4C(JM^U9^QIX'_1\Z3IOBZ34+
TB627313TN M1SG@P*)\$^=65D;8F01G*+@BMW1FOHFSPA^RS\5\^#UNI+5IAKRZO;^17N
M+J=E52IE551J*H"@_1WR2 8/16"PQ^"/B+X>ZGXO\CX.TW41\^VCROJ M\$P.*ZC3_
)Y12QLDF68@*:@EF&.: "WX>-"F71JKIHN'PK.O#L?A?3-9OF: MWL4EEN8M)L5.6DDDD9G?
8@R26^9CA<;E6OW;.:@_93V_M8^&1+V^*O\$OB; M1M%L;@W1LO#JU!#'=2XPK3>9!(6V#=#M('S\$D\$XOD?LL_L/_
Y_9%EURY\ MOJVI ZGK"1/J6NS1331\$O(BC,<485"WS\$8R2%R3M7!ZK\)_AAH?P7^"A_P M3X;MS;+HMJMM
K1NX9V/C M^1IY7U"8-%=1L_SRBEC9).LO 5 W+.,Q266YBTFQ4Y:2221F=1B#);.YF.%QN5:_H9^\$ _PPT+X
M+;#CP_X)_6YMMM'T6U6V@5N7<1EY'/=W5?LL_L/_Y_9%EURY\ MOJVI ZGK"1/J6NS1331\$O(BC,
<485"WS\$8R2%R3M7!T0 0 4444 %%%%!.111 M 0 4444 %%%%!.1110 4444 %>\$ _M;_M?>#_V1_
&LZA\U76KUO+TS0+;94N M+OAC_MX6*?1*Q-AX>N_%UE_8,=M" MX6/+%NF5" R1HU>4 @;4L?>
)\AI V&;C T0* 2JO#_ M_J;1D3P=^UUh&AZ1XPU+7_-MM'NGNX&T.>)&V=DVD.98I 1CT H\% X(V_
MFCWG_8S7O\Z*MZI?A VSOVU/#G1&_AC1+S41NOS>M.Y+1^I^E6TP@#K\$% M.LDDI#;.%7S\$""L26'&
2.S_9I_9M\ _LK_#J3P9X3OM6U#2Y+Z74#-K.T4L_
MF2*BD9CCC7;B.8^7)YK\$ _L_8^1#_M=^&1DTWO=)J%A=Z1+)+1^IZ7(B3P> M8%\$B?K*R-L3((SE%P10!9_9_-;FV?
M;?%O%VA6%UI\$MK=087^FW;1WMYU_M57P"#J5=2&P.I&-17Y: P#11+ @H9KOOLUI6/AMX-
SH@'3IE12^8G9<:O M+&Y5C)C1L(8?+1_%@.W95_5HFOHFSPA^RS\5\^#UNI+5IAKRZO;^17N+J
M=E52IE551J*H"@_1WR3S>(?>C)?% \$NOZGJHUG>1W.H74MW*L.H60 M0/(Y8A0;0G&2<9)H ^,?V#?
BA^S^SKIE\^1=0U7Q\1_06T<>D);:0# S MRR?GFOUDO\N<+W9OU1^>712G@?1\1\$^&)O_Y?>
>V@;3YY;ZU.#)))\$2I M.&5U=4V@(8HHP!CU!H_\$K1F'OE;_+(-18GA15/B'1.T?AC4KJQ
MU6WAHM);.T4MN957^+87#C_.0OR\D&OO#_@I^WA&_B9^S1J?@;P9XBA\7Z MIKTHH9M) EC'%.DS2NSJN&
(C*11WSG(KZ@ _;X)^"C1J34O1;U^RO_M#\5%51M>T.58IYE485959620_#)7<P_Q7A^@K_@BQ*M\$UF*11>+/\$G
MB:SBDWC3U_5G*;/IDG(IH7S4&1W+ #M7Z?UB^#?IFA_#SPOIOASPUI=MHNZ=%Y_K8VB
M;8XER3@#U))))Y)))R36U0 4444 %%%%!.1110 4444 %%%%!.1110 4444 M0%%%%
'D_12_12GA1E0X:77B1Q3,9&R8=/TN%@)10N""5B3/0<99CPH/// MYN?MK_1
10+X;_M5_LAP;+17FA^_#JMG=7/A\^@=^JH'SC1SJOEN+1#&2K\$ M'.T%KCPYXST&R1;+.0SVE1'N
8=4148=F4@CL: /1J MC_@D_X87P4=0^".FZLWBS19&+HTF1UB+1'1G.=1;IANW+A
M(OA16/VBH_@QHVW11Z&TM4@T^Q:W6^OB-KO#!M4K08J;.068%L?_71"/A" MPO=*)Z)9;G/JJU*VL8(F?_
)Z2K&H=0Q8\$ _C7SI^SK_P \$Y_@Y^SKKEIXC MTG2;17/%%N T&1^(+E;F2U?&"8D1\$C5NOS;=P1\$5114 ?\$=_
6%_P"3/W_1 M&"Q_E+7E7_1#1_D0?BG_ _A.R_14E?<_10WI?A?1_::^T&>+Y_0BT@W M<51NTV=8I?;CW;?
F96&F/11F7IDGP/^R=LNZ?X)EU:6WUB>.XN?15N4F M8,B1J2J+@88^M_#?VN/VL_
#_9(^&7_"8ZQIUOK4IQ>)I^GZ9;2"-KFX97?# M.0=B18W);!Z_8)(KDOV)?
VX=&^;T/Q);>9_"FN:\$>+O39+1749BEW^5(MDNO_V?+<\$%1@=@=<@UZ9^T^SQX/_&G/AU_
X\;61P^C-MU1_9" _LD>16TWP4FHW_&K21+?;GJZ374\$S= MY;SHB*%3>^%_WCG)H_ZSXX>_OAOXX\1W1?
?1M(U3PO1<3WTYVKQ@L*BD0 M*K_K>0A0>5C_*_G\6:110W11W _1?P8_ T?6+16.AZ0LTLK>7DYGF>1
MG*Y&Z1N=J*,#A)_4UG3M#GGCGN81%NE@:Y""*QR M%D;*_L_MXY53VKSGLF_1@/X4_LN^+KWQ/X2M14O-
;N+8VBW6L723FWC)R_E! M47:6P_3R<# P"<@'H'1_P#T1/FKX/Z^X%T".5;/_O;W;M>1NG_L1?4C'
M.%5515^_P"WA>1Z?^W=11J8D0P:Y1*^T9.U8H2?T%?T(5\B?%W_@E_1?C M512=1;^<GQ.FLZS.+BY6RU"..\$,.%5?
E4Q\$@84=S0!YC\90^"K_ _O\$WPK M4:_.6&L>*+G4=/FM(1+N1+^03.Z%5\QG;_0\$@DC)XX!_?%?_!>7PWK^K?MD
M>12TJ&RZO.BGRTA>VDCC5ST^:5HL_W<1J^1^1_@CM_+6<22GQ5_M>)C_ %4^JH%_YPL_#_'D(L0>+;
M>Y;2H(5<28GFA512S_C"G""@+W/DO1^OOQ1)MG>+M&D^&*NZE?;#;M.N1; M1-VE1>32P;./#>3E;1)6)&A^8!<
AH1R<5Z+X@_P""OBSQHOCD^)/CO> MZSXG\9K96FKZT AN&%9+&V?>L" PQSC.Q98_GW8PN-ISFMCQ5_P
\$L_AAHWA MC6?A1)-1+>@ZLZE#KGF7>J+Y63Y".AQ0!Y^W5\=OB
M;J'OXU6V^>OZC8:A&M'M_\$GB2UT^F@BU":2Y@8VLX1@LBK1A1K C F'7B MMW1O3X16FJ;.#^SAXFL/B-
XH^"WP^16WCW.K:MX5U"XM+E;XH'R1\$K%F0,>" MC8.?EKN_"O\
P2U^&6I7'BC60BU+1)\4/&6OZI<:E+KBM=;2L(EP?+2"*Z9<* MVX@L3U_Z"K7@7_@GW1'A'2?
@WIEY\3FUBR^&7B.XUK3O,T0D);RLCBU9OM) M"165SY@&..1L&WD SO\ @G\100%GC>^&^L#>*O\$OC_X5:?
L_7A^Q5XK2317 M>+>1\$XV1Y%:0#;'G&;1V#P2H1X)KY5T71)1#_&'PMU7XL?M;^1?Q1XC2UU>X\HEQ>1?1S M\$#
1?#D+PQ+O1>3><<D^F011Y_%X;::180A_K?@SQ19;M"UBW_O9_MU?;XFZA>_5MOA7K^HV&C_>T>W2>)+7
M31R;+14)1+FC:SA&"R*L&'VL""8=>=*Y;_Z_@71_V

'4_AUI/ACP&OQ\$UGQM?R:286:ZU'IP\Q50IB1_MXW0AM_4E0,=,^,4_9^,":,R:,'+QW:>%O#N@:/XN10#-
G8_\$FVU&OU*#3_MH&BD@DM(A'B,LT<3IGR/5N.N9=4/#_%'X^?#?1_91T+Q)X8^(7A37/#/B"?
M1=>UBQL+JUOM/AB6!(KY;AHB\$!C"XF.5W*)P:/M3IF3IJ9OCJWC7PSK?@_MVH
=>?IUS%;ZQH=U>1WB)YH8HTA M6W@6XAT\I09XNUZV/V6JW_4H8^&9I<,"X3;D@XW\$10*V^&./AKX#_+3_M(-?
\\$^@/V1_B%X1=WS8BO/!^O1W-W8WTF+>_QLT300(2V^>%&8/(U%^MT\O#127PUO/GBE;B.TDE2YM;VS<)
<65RF=DT3\$!ADCD8(8CO7SW8_L(M_\$>^15^&-<17?M%;KXOF
(B>7PXYX<@1K.X>_HDLTGG%KC\H8@MM^T M>?&?IJ3X@6O14FN_%?01?U,?13X9^(1A(ZOI-
K=S+9WGFEB9+NX>\$'9(T8".F:~BOV_OBEXC;PQV?A?_M?N-&V_\$O68+2RU33;B2*:ULHV62; MX62;AE
S'D@H7QWKE-!_P""17P>M_A73S5G1\@F1HGBKO-H%1\&S2%?2/#_(-=A;Z5I*Z? M/I A2)@4F>6*9W?&X\$<1@?
X0*_M_VC/0%7BK_(A^_I277M5TKXG>IU_MAW510A0981^1@N8D\TS A1
IOLNLYL+ADUO_1/Q>UO7OVE/AQ\PY^*_M M^+A.A.T%IGQYXNDN+NWTF\ARJORS1*4'G:0NW(/WMDXHLA
P3-TKPIH M_P7/#?@QK)X51">A3H6V^A^3Y1+1^S+B"1'\$Z327(0'SH*L_O\V% M/UUX#1+_
/"\$>1O#OASI3IM_LC3K;3_M/E^7YOE1+'OVY.W.W.G>IH W.* M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M#\?:
^"@GOY^G@OIKSQIHWA_XB>+~TBV^P>11^FZWW=AE8E)ROY)Z=*X7_ASW\&O^AF=??\@?9? M_(E?
54<=A(4HODM4ET(1S\R?^&H?C+_T5OQU_P"%)>_1VC_AJXR_1%:_M?^%)>_1QVOTV_X<1!K_H9O'7_@?9?
")1_P_>_@U_P!#_XZ_1#1+_P"1 M*V M#!=OP"S(S) X:A^_O_16_17_(4EI_1:/^&H?C+_T5OQU_X4EI_P#'
M:3;_ASW\&O^AF=??1IE_(E' _YI^#7_\$,WCK_P/LO_)\$H_M#!=OP"MS/S)_P"&H?C+_P!%:_M?^?
^%)>_P#QVC_AJXR_P#16_17_A27O_QVOTV_X<1_M1K_H9O'7_@?9?(E' _#GOX-?1#_XZ_1^R_1^1/10P7\LSR?^&H?
C+_T5OQU_P"%)>_1VC_AJXR_1%:_M?^%)>_1QVOTV_X<1!K_H9O'7_@?9? M")1_P_>_@U_P!#_XZ_1#
1+_P"1*/10P7\LSR?AJXR_16_17_A2_M7O\1=H X:A^_O\T5OQU_X4EI_1=K1-O^1/P:Z&QU_X'V7_R)1_PYI^#
M7_0S>_O_/LO_D2C^T,%V_+_G_AJXR_1%:_M?^%)>_1A27O_P=H X:A^_O_M_16_17_A27O_1=K1-O^1/P:Z&QU_X'V7_P
B4?1_#GOX-?1_0S>_O_1^MR_1D2C^T,%V_+_G_(A^_O_\$5OQU_X4EI_1:/^&H?C+_1%:_M?^?
M%)>_1:3;_ASW\&O^AF=??1IE\B4?1>_@U_T,WCK_P#1+_Y\$H_M#!=O MP"S(S) X:A^_O_16_17_(4EI_1:/^&H?
C+_T5OQU_X4EI_P#':3;_ASW_M\&O^AF=??1IE_(E' _YI^#7_\$,WCK_P/LO_)\$H_M#!=OP"S(S)_P"&MH?
C+_P!%:_M?^%)>_P#QVC_AJXR_P#16_17_A27O_QVOTV_X<1!K_H9O'7_M_@?9?(E' _#GOX-?1#_XZ_1^R_1^1/10P7\LSR?
LSR?^&H?C+_T5OQU_P"%)>_1VC_AJXR_1%:_M?^%)>_1QVOTV_X<1!K_H9O'7_@?9?")1_P_M>_@U_P!#_XZ_1#
XZ_1#1+_P"1*/10P7\LSR?AJXR_16_17_A27O\1=H MX:A^_O\T5OQU_X4EI_1=K1-O^1/P:Z&QU_X'V7_R)1_PYI^#
P:Z&QU_X'V7_R)1_PYI^#7_0S>_O_M_/LO_D2C^T,%V_+_G_AJXR_1%:_M?^%)>_1A27O_P=H X:A^_O_16_17_A27O_1=
=K1-O^1/P:Z&QU_X'V7_P B4?1_#GOX-?1_0S>_O_1^R_1D2C^T,%V_+_G_(A^_O_\$5OQU_X4EI_1:/^&H?C+_1%:_M?^?
%)>_1:3;_ASW\&O^AF=??1IE\B4?1>_@U_T,WCK_P#1+_Y\$H_M#!=OP"S(S) X M:A^_O_16_17_(4EI_1:/^&H?
C+_T5OQU_X4EI_P#':3;_ASW\&O^AF=??1IE_(E' _YI^#7_\$,WCK_P/LO_)\$H_M#!=OP"S(S)_P"&H?
C+_P!%:_M?^%)>_P#QVC_AJXR_P#16_17_A27O_QVOTV_X<1!K_H9O'7_@?9?(E' _#GOX-?1#_XZ_1^R_1^1/10P7\LSR?
^R_1^1/10P7\LSR?^&H?C+_T5OQU_P"%)>_1VC_M_AJXR_1%:_M?^%)>_1QVOTV_X<1!K_H9O'7_@?9?")1_P
>_@U_P!#_XZ_1#1+_P"1*/10P7\LSR?AJXR_16_17_A27O\1=H X:A^_O\MT5OQU_X4EI_1=K1-O^1/P:Z&QU_X'V7_R)1_PYI^#
P:Z&QU_X'V7_R)1_PYI^#7_0S>_O_/LO_D2 MC^T,%V_+_G_AJXR_1%:_M?^%)>_1A27O_P=H X:A^_O_16_17_A27O_1=K
M1-O^1/P:Z&QU_X'V7_P B4?1_#GOX-?1_0S>_O_1^R_1D2C^T,%V_+_G_(A^_O_\$5OQU_X4EI_1:/^&H?C+_1%:_M?^?
%)>_1:3;_ASW\&MO^AF=??1IE\B4?1>_@U_T,WCK_P#1+_Y\$H_M#!=OP"S(S) X:A^_O_16_M_17_(4EI_1:/^&H?
C+_T5OQU_X4EI_P#':3;_ASW\&O^AF=??1IE_(E' _YI^#7_\$,WCK_P/LO_)\$H_M#!=OP"S(S)_P"&H?
C+_P!%:_M?^%)>_M_P#QVC_AJXR_P#16_17_A27O_QVOTV_X<1!K_H9O'7_@?9?(E' _#GOX-?1#_XZ_1^R_1^1/10P7\LSR?
^R_1^1/10P7\LSR?^&H?C+_T5OQU_P"%)>_1VC_AJXR_1M%:_M?^%)>_1QVOTV_X<1!K_H9O'7_@?9?")1_P
>_@U_P!#_XZ_1#1+_M_P"1*/10P7\LS[HKQ3]LXB>(AALU^,%7A74/U13_L2V:1F;R1_M1Y1&P
DBLIRCL_0>N>M>UUG/OG^&ND?/X:ZQX(UZYOK32=4GSIM.=6G7R
MIDF7:71U'S1J#E3P3TZUXF4UL/A\PP1%J*,XN2M>15).2MUTOIU"HFX-1W M/R) X>)?M"?1%- \HNG_
/R/1_P12_:\$ _P"B@?1_E%T_ P"1Z^UO^3/PB_Z M&/QM_P"!UG_1BT?A.F?A%_T;?C;_#K/_Y%K^D1:1/^@.'_@B/^1X_L,5
M_1^14_V\$OVA\HH'_)1=/_1D>C_(>)?M"?1%- \HNG_P#R/7VM_P_MF?A%_P!#XV_1#K/_P"1:A ATS\O\H8_&W_@=9_1R+1_K7P!_P!_OM;_ATS\O^AC\;?1_@=9_(M' _#IGX1?1#XV_P#ZS_1:1:/^@.'_@B/^1X_L,5
M_@B/^0>PQ7\WXGQ3_P/\$OVA/^B@?^473_1Y'H X>)?M"?1%- \HNG_/R/ M7VM_PZ9^\$7_0Q^O_
ZS_P#D6C_ATS\O^AC\;?1UG_/(M'^M?_'_0#_P_M1'(/88K^A3XI_X>)?M"?10/"BZ?_1(I'12_:\$ _Z*!_Y1=/_P#D
M>OM;_ATS\O^AC\;?1UG_(M' _M9^\$7_?C;P.L_) %H_P1:/^M@.'_((C_D'L,5_1^14_P1M2_:\$ _P"B@?1_E%T_1
1Z/^B710G_\$4#_P_H MNG_"/7VM_PZ9^\$7_0Q^O_1_P#Y%_H X=,"+_H8_&W_('6?_R+1_K7
MP!_T1P_1\$1_R#V&*F_\$^*?^B710G_10A_RBZ?_P#(I' _#Q+1H3_HH'_E%_MT_1^1Z^UO\ATS\O\H8_&W_@=9_1R+1_PZ9^\$7_0Q^O_1_ZS_P#D6C_6_MO@#_ *X?^"(P'0>PQ7\WXGQ3_P12_:\$ _Z*!_Y1=1_D>C_AXE^T) T4#_M
_HNG_1R/7VM_PZ9^\$7_0Q^O_1_P.L_ D6C_ATS\O^AC\;?1UG_1(M'^MM?'_0#_P\$1_R#V&*F_\$^*?)
AXE^T) T4#_RBZ?_/(I' _#Q+1H3_HH'_M_E%T_P#^1Z^UO^3/PB_Z&/QM_X'6?1BT?A.F?A%_T;?C;_P#K\1:/M1:1/^@.'_@B/^0>PQ7\WXGQ3_P12_:\$ _P"B@?1_E%T_ P"1Z\AXE^T) T4#_RBZ?_/(I?W_Z9^\$7_?C;P.L_1
)%H_P13/PB_P'AC\;?1UG_M_P#(M'^M?_'_0#_P_P1'\$?1(/88K^A3XI_X>)?M"?1%- \HNG_/R/1_P1M2_:\$ _P"B@?1_E%T_ P"1Z^UO^3/PB_Z&/QM_P"!UG_1BT?A.F?A%_T;?C;_M_#K/_Y%_H UKX_Z X?^"(Y1H#%2S?B2%/_
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

MC#:W>NV.TB*20%#&HW;3*6CC&YM50I+U;2H^6+30I M5TNICA-
SI5OIZCJUG#9NMO80I(B;Z:80VT>7&92MO+(=V\$1!N9@.:7P\9K35K7Q\$FI>'MM\ZIH-D-10-
U71*UV;9A(8Y8V@GEA=7,J.CS0#(0VV@#T*BO)? /I1NE^M/+_PS&?"WB7PH_BFW-
QH&J;QI;I;ZF;I*YQ5%BGDEB;R@S@3I^D<9K;T_XT_M;J7PIT3QC%:Z@NF;M?V^GP1/&@F62;
I%6J8;JH4.PIPO.WG1/%^T5Y;XD_M_:TIPIT\$4@4JP!1I MT?Q2!21^OASJVL+J=HFI4,22+?:5%:/-@+J 8UF!C;.979)-
TUS&7_U<@M TGR M""\$&\$I&O?&S0I-T'POJ&DVFI>+GQ1"+C1+T6!3@45Y/X@_:#A_
VOA>.Z\^+FU_Q%=7%C9^X\>U^UBXAC,C(MIM<"*45F\$@E,/>%/S@X!_8_&L=&6_O&(^);GPI)9-
9\0V=HUGI3I@&=9_M_@2R^5R^WCE52K#)*G!ZQ17G/CIXSQ^99YY/I_B;6M;L!47NHZ_I4%NU
MG90X+%)R))TEF"J"O%O*0.V>*=XN^_%MX;U\:/IOACO!XONXK*4IW^P(8)/_ML5I^B13,9HVEW&&:"0"63IV?
DY7(IZ)17GGBCXQ+H>N7>E:/X01^_IG3U MC?4FI*.U"6==ZB0W\$.HF&\N+>X*#=OS+FGJ7Q^T:1=
3PKH^L_!"IUO35 MUBUL_#T<!"LMDQ_6>62ZFABB#\$X57<.Q5PJG8V_#T^BO+?@5XKG!7W^Q%NI;B
M^EA@4RVTF%AS;I55LI3=").P+(9.J.EB.YR.WB3X16S2>)H/2?#GB+4I, MT87%KJ/BBQB(6PL)TB+.N7F2:4H2
S012!6!!(*M@_1;HKRKX7_\$B*W%!_M2=5>^O\60\$A^&=+QR)-SQ6<4LKS.S;BS;NN&).>7;>_Y3B
>7MBWC#>8\$XH_ID_MHKRO0?V@M/U74=\$34/"OB;POI&O3I;+KFMVT\$5KJ\$CHSOH\$69IX&=5.T7,4
M1)*J/F8*>O\WC_\$WX=+%;J&HQW=W)9:QIJ9C MF@N)879F) 4/QM._9D9-%_:.TG5OA!9^_I?
#B73=+U62WBT*WKNK6!KO6VG7_M=#IG@CF=UW#) ?B+; 7;: @+1;HKR-OVD-TN9K/Q^X<0>\$19CEL1+I6) M:O-
W5R+6*ZWP7\$!+PK*5#E)&/6\$> MHZN%A7;*CPM,%MR6^F. H4CC#.HSS0!ZK17@4GQS!4;_XN^(GAE_.O:"IFE
MZ&EW;:U+8J8&DBNB)/+O6DVN84L)"O4AO."<&M#X)?J/Q5H/@.OU+PIX
MFTU==TR^R_\$&L10_9I7E2V\$LFW;R,4220&XCBWA21GN>VT5R7Q#UX;!' MX=8ZA?
Z1HUNTLP;"&3SMI\$>5)YH.V-OXF3#C^\$UPFI?M1;1I>H>)P_A^Q5_M-H?A?4&TI7?\$.5O:_8M/=0C%V!N!-
FR1)ABD@_%,((I117+_S\$XAZ9) M*? 6L^+I8BNH)TF#I3GHEQXDC\? M^K/G "47%J=1M-
_.6G"2YI@VQID3&I\$\$.JO13"+*DN77IV>< 'M5%>8R?M! M;I/X3\-.OI&FZSX@OO\$?F+IF@Z?;
(+^5XLB=7\$KI%Y1!5WED5_V%#LH8A^M/^A+X&I\$U#3OA3XJ^WW6OVND7FG:A_9R20+)-"OROIN6*1
MI%EO&4DB*ZD2%-I%>U;:=2WVG6MS/9SZ=-_SLCV=R8S+Q_1S&S(64^!S_M+D<\$CF@"S1110_4444_%%%%
!1110_45C>_!0N\)_Z!P6LGE75M83S128!V_MNL;%3@V! ZUXAX_VA_Q5NOA^X>\:Z14I4I2>(KO1+?
5#H7B73=,&FW4KP_M+(T(TM)HLDE5?S&VY?OC!/HBB0\$K3XP0?#\$PI#K.D:AJUA^J_@237I;3_MC%"L_X#\$AE
T3*6VX!V8R>N#73?#XB6^H6_A3PQMRWDVY&2_M1&"QG(YFDND220+R8I=I6P5(!#*6_/2Z*PU+X_:(N@)X5T?6?
B!>ZWHJZ MQ;V?AZ;!66R8@+I+)=30Q11B<*KN*8JX53L;#I/@5XKG!7W^Q%NL;B^EA@4VR_MVT\$%AS;I55LI3=").P+
(9.J..EB.YR0#U*BODJ3X0:3>>/_ (A6/BS!H\O MX5IFZ5I_4\$?*,< M@'545Y!JGQPTWP#HNMZJH/A
PD/B)%5CP_#;P6=N9H!B7RUBAB5"FZ+>RJ' M*":Z6.?<+H_LDDZ3> M:RLBK&I,6&TJ#@&\$
I/HKRC4_V@80#/#@OQ^XG!4>I/%WA73I\$M5O9%U"WMM99+ MB_I%+Q?
9IB5=R9R8W9),=\$7ICXS/9Z^I=Q/X^31;HLDJ^A994P652_S!2>D45YWI_QFM15\+ZH%IX7\0W&NZ7>+HX5C
MA@;4H+ED1UC8B;I_8Y\$<2^=Y6UA_.LT?M"Z=-9)+>%O\$?LP"-VIY:/5J*\OOC%)9Z#HUS_PUB?B27QIJ
MS3);>X!P)J6Z\$D3;B!RP^B?O3_Y;TVNVIEZS9Z5_Z ME^HLWA=K>.75%OY\$62.W"12/QO_UBWK(8PA+%PJL0
H45XQ9^<(FI>+CY MI6G7FE:YX49?UI=-7IA_5Y820WVRU6*8_9YI8^7S_&5V(8^R^P/VS?B#K
MW@/P#FPURI^Z+ M?8P14W.FY&VD-T/PUUKQ#X?^?7B/P!XB07/BT6NG6NM;:K5I;V\TT.TDT4
MD\$PMXXXF9^@W*ROIE90""4+\$_16HKPS!HS7M0#;?<^<(9?C(OP_00^5HNBBP ML9(I2O "WDR+.CS7)<I5\$=LT+
\$DX8=;XTU;QM\&UU^3?L/AKQ.VF+=7IS_MCI0-/80%Y1\$O*RN^&Q=QV#.XIPNQ@#T:BN3^\$FN7WB?X4^#-8U.?
I3J6H;+9_M7=S_L5/_ED@1W;:H &6)./2NLH_***S_5!3;YX^_C76O#6H_V1KUIH MI/97_D)-Y\$I(?
8X*MC/0@B@#TRBOF6Z_:"3^X^/X!2/_A!XO>" +=+?6((M8P!7FD@17L"R+AK>X0.Z9!Q^R^YD-
>K>)OC+%H_BFIV;+X3!1>=2TI(Y-3_M&@QVPCTI9!N3S)+F>%74:U^TAX>LI^\$;AHNE: MUXO_
_\$.R.J;+;+!5)99(XS!<@GDB+I4DAPJ#;_E8J<_I9;_2B+9?52I MZXMI" T>^TV?3M1TK5\$1;FRN557;F-WC;Y)\$8-&
H0XPOH_ZNB0!^7B;Q_M)XJ^>2?#SPCK47AF6UTR/6-9USI;ES)/_M_&K^%5^~
=E!1=5LX6;ZT2^DTTZO8R(ZJS.MDD(6;.@I5X(=^!)5SJUC>1Q_#CPK>6FC^<HGMP3+/@%YQ(5)5;42V_M;5(7;-
<;N8QC/N/C1XFU;2= TI1/#=Y_9_BKQ+QZ3IEWY"S?920TDI\$SL8%3 MY4\$I&R1#@@U!*_B9_-?
Q5TK1?"OO;XU^;NRNIM6N\; M-(Z5X!UKP_M9I/_C5SJLO!B6NGRR33+=0Q+N;IM9!%0D;A00-5I?
QIXI^7B_4I/BW7I_M?#\$K=^!S6M%30V4_/_LO1;F*>_5\$#R+YT+HZHB-EE9!MRPH!A17B5G!0I_M-^7?;
K%SJ;AHD/P^;6YHI=BR3LLD;F5HD(B\$Q7/W<\$D_@5Z_/B9IC0^" M9I;WF/%SA+;\$S&3:277IWYN/DB8?
+N^8CMR_#K;^A^?M%;EJC>/IGQ=X' MUKPGI/AS46M(KRX-EYGIJW*6Q2WNYI)+EWG^4(FPAD4?D5U&B_"QFU*
IT_M_P3>I9I_7<-C/JPD*^<(S;;JS@*B>:_I;XF4^S(IHR5+/_-AJGB;18I#5-32&V34X)+N.N@CCG;,-N)2XCB+M^2,'D5T?
I47CBZ^<=(OH/%W_""VUUX@TZPOM?_-%^V2UEG"2ONNHY(5^4_MGYG4@4>P45X5X!>^>^?
&6H>_%CTWQ;N=/TR24P_-\$NEL'"_R2\$6%K\$0_M25(<_>%E.TX%>P-'UY17SO_"Q9KWC7Q)/K/Q5ETOQDL\DN!?
#2YL+M&*.UMUD92D<+1+>_H&+GSGC)_\$/BGXEK\/"FLO^&I+72TUC6_6WCN+F"&65XK>*VCD!C\$CM%,Q>17
M^K&I;L8N"N3?ZIXP^"GBCPT!K^BN!>?>\$2&IQZ-<:Q9VL.HZ==2AQ(E#VD_M_4D#_HC*F;ID5MY*
>UT5Y#=-M&1?VUXBL=)^'C/Q^';U!5M2TVUM_M?LILZHCL5\$MRDD^\$<-B!)&I=Q"G8U;XW;Y&D^PMHNK?
\$&ZU33X!6M!7PH MF#?8I>7_AEU-\$BMSM!<_VUL*=K8_/I^BU?^_5T*QTI PK-IN@>(\$6H>M)+RITVSTG3;>
74=Y;I_MQO-YTT:1.GE2@LSI/W9^;E=VIXX^#> PIQ>>I? M%=YI-I9K>ZKJUE!M;Z9^@LWF!KA9)BB@EA);-
C"VWQTU_5/B- MXH-3>"]=T00^TJ^*M_D#Z<^Q72Y;S!HNW9ED!E3\$ODY!SYJ!"OS_!A MT6;PGX?L?#?
BKQSAUCP_K<"Z?#8Q236X!M9))6EGAAC<&1"5R-2^\$S@@" ML-
%>7M^T)H%QX6V;KI.F:UK^HZ_)/H_A^PM46_DE@9EN4<2ND47E,K*[R2_M*%; #S_LFZ!_OC-9?5\$S7?
\$NACPIKOAK6_#OV8;C8;Y!\$COM.KL@1XI9\$D&U_MID9D^8_2&/0J^Z4?&B'1/\$IYH&C>\$_\$?
C74=-.CCEU0!#;^7IZR#(N_C-?^%?C9\0_A\>_O&45I8Z_M9>M;Z;L+1;=TYCD4.C+IH>)\K!L_R\CKO7@?
P%UK6K6C2?@K?WS>+I&M\11W5!JJ^<I-Z=0D.GJ_GHB7,T<4+;=R1*(PG_#S0T?4M%>0CH;1/+&
MJMX=I11^!CXFDF6!HF@0A;+A;^ROD#;:/5Z*YC2_-MB^I>M>-
HPO9";XNK/2I75I;N;*,RKAY4B4,&SO/D.V.8VX.;Y+Q9\&_&M&GQ(UK6+O6;I3/#-
K975U8PYD#++;1R^V6M!INV20G&Y@Y)&M^*#G!/5**I\ M_-;3M0U6_TIQ!X?
UOP'=VNF2:TB^<(EM@MQ8QI%EN\$>WGF50A9-R2%!)O!*4 MS0?CD_-*B1-^C\$YF@9EY5;F.\$GIP>*/
M3J^I_#M#:=XA!67BT>%?5EAIVJO_FAVIWI;_M;Y\9MXDG9D!4\$GS_*MVJH8X4%JT!^_UOJUOKT-
IX7\0Z%>XBT_VCO+CPU>0P3WAD_A=89(OLTTL4BN MT4Q_M#;=9Z?K)U!PMXC+ZSI@LR="U**VDNKD7<_PIG
MM?)>WGE@;S)LO^RC8>7V+AJW+XL6^7@Q5/\$7B_P!KG@;+Y^FZQ;Q/G^<O#^L^+N&QGU2?>M\$9M-
MU9P%1/_&IM<3!^YD>Y7^N_X.W&37">_OCA>>)=)(36?ASQ9X1L-4I
M3;+8;IJ:0VR;G)=QET\$<<I31AHIQ*7\$<1921@B@#Z#HKS+IH+Q=K'^OP3_M:7NEW5QI-
I+J_0JVN6MG!KETFO;=YMTD11P2!"KN9^1_Y=U^HU>4_#_.._JO MB#PW^R79>_>->Q?
\$G4;ZSTVSTZIU80S&WU"YEBMID\ML\$U\$EG0E642#8P9_MV)R_#ZCHKQWPS?>*OAY!6M^)\>
(/%UYXWTSQ^I=U>6MYJ-G;V!Q975L/V!F1C MI-%\$K0R)."H96=#\$)/!&C6J;=:KJ?B35KE=.T?36;+BY8\$Y8_M_P
_4;^LC=DC;&3@&\$I&BO+V;?5?B^Q+1+<>*=8_M_6I76=7TZ743;1V_MG+;C<01GRXU"K!D2C@=N23DGE_"P
9+_0=0?Q^PYXJ;Q;XFNHKE;25A MF73+<11JXFGC9P_6;RK=9'(^3YUW^O=%%>3;I1K/7FO)U^<GLHP7/K
M5B+6.(6CQDCRIE9<"82888&=N#G&X5SOAWQ9J<>I:)=QJ2V\PK5=2F;. M3S7\^F<))E&EP3@N#GH>;

/>Z*LD^50LE^%I/TW10S?Cf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f3= OI;R*S\IO))=-&; IBOIH8?DI(\$IM!&N*!%O'?;J MZB@#RC7_ (?^*9/B)XNOI-BT>YT'Q1H4.FW\$UU>RP75E-"ET\$*1+"ZS(YN%R M2\93:2 ^<4ZZ^%K3Q_!A5N+(P7=KJ&7?IZHTNYM,0_+Q\R93\ VWY03UP M#U_CWXA:1_M+MKO4S<3SWEPMI8Z78P-/WMPP+""&->6;K,3P%569BJJ2, MGP?A3I12:S'INJ_#SQ;X/>:- I+C6(I:~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f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f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fW7M+2IH;:>V:19D2%I5FG"&X4.8D;#?HXM- H8USQ;XVO^)_X26XT.XT/2_*TDR/8Z5#_A\T\BAYY)&2+>)Y M<8"Q%02.6VO"QXT_PAK^HZ/8^&? \$7B^TFTCOI8'A^VAD&F6\FXH\OFRQE MV8(I*"\$22D+G9\RYI_T76:'Q%HCINF7=-HUI ES;7;)RDL3J&1U/H00?QH M\PL/@S?226\$&HW5KIA7P1_PBUSY#N7\TI_SJ"HRF%;!)Z<5SGACX9_%&;Q_M#^U\1- X5LI#A#/(LKZ3>W.TVJ_ZI+;QS>6"'+;D%F+?+I_O/D?IM+;_0 MT+5M;L8H=#UY?#%_J3;/9^,) {(115Q>YVC\3YOG@-(C1K*T(B=L;7_Y<[NI M?&0=-^*6C^_A?7>L:B95-Q;P VMK(D#3^7+!(6&'-2P10Q *E@H=20#S_Q MA\!=?A;A;_3_K>MHB>&O%&HPZI8;I^IW\$T_Y\$+OI!<6+1".2'?;f(G!=6_M*I%^12>_P!G\;QI/B33-

=^?PI^P:H%UH7?@R.SWDBSIY:R"5K6WAE=I M:JWB3)(^?C:HHH \$U:P7A9?&\$?@ 2-<7P5;Z:H>LZ=J-
HJUE>W:SZ!^3* MY"6K6ZK:L2H^G3#C:D IOVGOTV^^(?&GAO1^X7BTRYU?2=>T 6\$M^7O)+2" M9:>82,AECAF9"0,
^6U>CUP?CSXS:#/??\$A10KV^*O=2UJMI-(1" 2+:B> M7RHI9V+ 1HSY4) M+G4F:9U*@.DEA;15P<1@S'C&WO71?
#/PW=>#?A0X4/WLD,MH,DVEA),DM M&TD4*(Q4D E(%TJQ34190='A@>'215S
M)MDE\$DR/(2(93L@25))IWE<13I?CC31^4W^AV"S71J#^Q+S" M6SGS"F'Y@'11L-ZY/+ \$W@/XF?&K4?#^F>)<
1+P;1^D: KEKK"^(*O;J6^ MF^S3K^J16DD^K;&0+Y;MHEPC,,NXIQHHH **** "BBB@ HHHH **** /-?
M'W@+Q&OC&TV;^!KK380\$<=E _9EHVL^ULI3M!(9(T:6,,\D;M(4D"N)9 4 M;(*Y2> ?
&WQ)\6>^'6^(%:HFCA^;S^TK/PI^X?O9M0%S>JG)%//=2P0'9&'9 MEB6(?M8N=H6O7Z*/GWP:WQ#BO/B-%X.M?
#E1#=>+Q&FURIGMFT^5"#(J M10R?;1 %Y9:DS>9AAMR-0 9-3PS-X1O=\$V/>\$?B(VB^&;PO/IGCB,0I^D#
M,)=U%<+;W1A?)+NC\HAPZ _NP;0?I-H-+103Z=9Z#+:PW4;:A/J<\$4*6TDY
M95*OAMYF(PV2F)^IGBMJ@#RGP_);K110^IU:IOAO08=#EOYIW3_#1L;V M#3Q,BB%
OS\$9&YFYH(L#L#T>@0:40&UMOLB.L<21IUEA:(9MP?;_3M% ^CEQ_%EGXN0RV*:=Z+ MXB\^VVDW41Q>S0W-
E<615Rj^Q ZS(YG7)+OE L'SBMGP5\=3\^*/#>17 M;H^F^\$XM!F6)V+-KQL67*%@,(>20>G%=U?;K-
9ZMIMFFF7EW0%>&027D'E M^3;:5W RIG#?;?E&Q6YZX^9/PW\A? "P?MEKVV/I;H>9/L F^9M^N9X\ M1L#.=F>G&
<4>-;:*_ \$OPYN/#YI.K>&IO&=OJOB26WT;5+V2"WU2PU" _A M:))1&TDVV8NL4@&UUP0P8;OP4U+5-
>^_7Q2O14 _1AW4,&D:=(LO1#^V^R+7J?BIPX<^(&DG2O%/A _2_NF%@YLM7LH M1J\$1LAV2*5R/7%
<K=1HWP3+Z#8ZIX\$OB\X\<>)18\$0^'.T O/_#W=IKH/80874=O' M;F:~X)O/1HX8?W1\$1#
(OPI+YMA9/V:_%OO&N _B3Z5X\$173>(K(06.O\ MBA9C/X;:(L#19VAAF4H91)*&\$T3;HCN\$S~WTY?
7+V=C<7"6TMX4;2+P; M2,E(1=Q"ICT&2HD4D4W3+Q10TVFNI+2>PDGB25K6ZV^;"64\$H^UF7<X,"
M1D^1/6@#PSXU?1Q03XXMM/MM&T/PC=WB.E"PM?Q?EYJ_YIFK),>&FMYI>)GE M0D(WEH?)CPS,&^700#/(@'5-
'4>,-2O+VWO1K%E8V4HRLC20PNDCNN,+N9 M@0 3WK0J* _.\$^?@6\ 7P1\<
(^#M0FMIM3TC0;72YY;9F:%18X% C9D+*&*Y M!P2H..U8/A3X2ZOH>F _!ZVN;BR=O!^F-9:@8I(E- \$ AH^Y/IB):A:~?
W>=YZ.V-N!MV1,=3G/;:@QY_@M0; MCX8K\OKCPI _(\$EO'18;21W4XU0Z;K*/L_V(P&(2^2/*\ _101G\YY7%?:?
MC+IG>15?M\$;XR: MCX.%BG\KZ*6+W=1;1<1V<@&-10)>S1LD'=%#P<9'N ME%
'C7LGP4UGX+>&M;L _\$JV^MZE=WX2VNX^Y*;;POVUC^Y8 IUAB4MCC> MID\$YR9 "PAUGO_ PLOI+HH \<
MH^*/P7^1)OC:~ZN;j^#0) " _M>+&KP(Y%R&OGM-KQC;MP%@DR20#DX33=) M^~VJZ+>^O\$17A%+;\$:9-
9 VOIUUKTCQ;M1LVB;1 M1 F71K15 "DUC?0VNL6WVK3;R;"H9(95^YV.DD@#124)5JK;=1Q6^1.M7_P M^11V-
AX51_#76=0:U"6WA/S#*=0Q3K)+;W~VEO;R&*%6,1^O'H'8_O_KXZ" MHH^9?" _1NOZ/>,>_2B1?"W0L;7M(L1-3P?
8P//IEQY-Q)-IJE%K#O;JS M8#^0=A RDF#NO6?I-NM^)/A\XX(\;-16@P:Y?P7VE.);75QK>G:08#!(D>; ME8C+^1L
=H%2*,1F51R6/T910!X%X^V?QK&D^)-,UWX= _#OP+!JFD76CM= M^#(S/>2+.GEO06M;?
R5VEOW>),DCY^_%VK>" C+XPCV^Z1KB^~K23=#UG3M M10M6LKV|>?5(I:97(2U:W5;5B5#8/Z8<;<@'>/>Z*
,#QHWB>/25E)O:3=: ME'(&TUF26&&XCPW#E(Q_9#&&4#"I"%\$C</_IKQ\JLVB;/ZEEFAAVDB"-5B"-
M1EK>6\5WX*0;KI4,<\$TP.U6AGB=MR10;1V1N0XXQ711% 'E/L.OP4_P"%
M(>\$M4TR61O+VYO=7U"^(+7&LWNH1K#+>3RP!M+ML?RY4\PI;O<,S%\$QPM~M(_&#P3KWC9=
C&ZMI^B'69=2L[C4I^ZMIH^62_-#NB2WD6ZY0OLWPI=N_!!
M7W.L1Q%JW1@>'13U/RO/^Q6LMSY6L;OV(6VYP<9QUO0!Y-H^P#NO"-G9:9IM M_#>O^S71A'7?)
A*/"NC:SY^V;^T;*&C?O\ +\R-7VIL M#,,XS@9QTK6H^6A^&WCCP^J&AZ\X270~U)/#>CX>U;2-8O9K*",1^9&BGA
MNHX)F0JTX*"-X=3E"GS)I?P2UR#2XKB\U&QN/\$&H>X?%FJM^O2VC5-B"" M#Y2S;(8HDW-C>RLOV;MHJHH
X31?M_10QJ15^))K9M;U;1+TV")6;SED MMIKUY"PVX^D7>""3D-D# SW=%% 11110 4444 %%%% 11110 4444
%%0% M17S5;14^EC^T-HEO\ \$^:QA+W7A2Y1_1?"C1GD^U&561;3IUG&XHLIVE@ M2-6"X^E*
<CJ.YT1"?)IO:/+1F^#^B?S'3;_1KO:YM+;31!"<2VY (6Q6 MXD3~RE)I<,\<-T S8EED967>1M4^U/5?
<KX+^>QK^+>1X1V/6S0S0Z; MID=J-0A69;-(F)G@# ^5-1T>:N'1",51^44 ?"5QJO\7;#))10^~M>#; M;P9?_#13;F'4?
B1#;EL,VJL,W/F,IU#"FPR&D;19F DV8P^>A\;>?"6D M#;P:2%?Q ^ZUHD#ZHV6G6Q\TB;WA;W;DJM'#&9IF6*2
+LMY&S>2TFQ" MSCLHH ^& B=K @NZ\+^\$?%FO0>&8KW (1*U?3OA X\>16YW(9&1M^OW'FK
M=MN"%HX7G;,,,B(XW=E^T%)9:M\4_%;Q _=\$1!^EOX\CXK^(' @W6M\$@?5 M&TZT^(.D36_AV_ADE5HX8S-
,RQ20!>EO(QE;R6DV(X^BU;0I@W\$^EM;+LCRTTJ;B-S *9-KN 3MX;159D^AO3;?Q)> M; _8U;1M8;..X+L2?\$R-9?
BAXA1U#HWPIO M@RL,@@SC((KSWP;^?#GPIN?V<13+Z5;Z7K.N~UC5(4"W6K1-HMS;2MDH MPUP?<
AC<&0G:1QBOK"B@#Y7^1.GPGCO/#)1_PIG_P#" _P R\$;MIM#^Q^IM. M1S\ _M_L6=VS_EWAK9CY;53V/Z_I?
@72O@EXL1C;);X;L;W7K2IU:~?RK6 MVDF;RO-E/R1^QC90SD#<57.6 /UI10!;WGB12^&D^1J9DDNKCX:S _1+B
M771ET\$H2XTU=*MT25B@#;MM?AYJN+^PL(SH4K7\$1(A;\$>3YAQ&ZUHD#ZHV6G6Q\TB;WA;W;DJM'#&9IF6*2
M#F/Q9H=EXCL+;XSN=OI/GAFU MUJ?4)/>F^_.3TK7C%);DH%1?P6\,=+ MUS5M^OP\KL?
A15(Y%DCN91%;R%1=8Y8BR,R^OL=&X&&% 'S\(^%&1E^TE M;A)TT=/#UIX0O!)_PB11_V.TJ7MJ"TF
A_<^9SB0Q\G:@;D5O\Q"^(^7A^X M9_M2:~>^/,%B^%+X\&WD;_<
QK>HPV<))K%+=@.E:6=,LK2V\$AD98XFFF\$18L/A_H'C/P/HIG9^\$;,"L-4^(6FR;G!732+L>VT^V M\^%?M2+\$1+
(S2_OH@J\$^GI.HH ^_V\4;WPS_9DU^XCWMT=(NK*1-5NM0\$@B M.=/(P!+EBL)8_.96(R0)"5+935VB3PE\4V^<
PA;X=C31+;8+P-/IQN?MC M_P1?V=;,<@<9,>8MNRYPVA2)-YK1-HH ^/OAW~_AYXRO=>MO#FO?#?Q7H
M4^BW,>K^O+P7441V%1-NC>&21^VF>+13&ZH42_7^R\?V_@R^X0_!FUT M27P+1^PR%E+%XODN1
(2\T:6A:6P0;1%#1 B/Q-K- F2QW5E^X?EC&JOV4QM9;AN6B-H1\$R1JWG>2MQM MP&(1L^N?L?S?
PR_P1^Z7:6%CX?34;14+^1^1^1D1O3H^D=IK.1HUO:E! MN0X6-
ORHA(V;O;*S+CPWIMYXBL==FMO,U6QMYK6VG+MB..5HVD 7.W),4?S8 MR-N 0"<@F/QB:3PC3/
'C^1ANIKPOH&HZ=j7V6HS8FZ\$!CO&106V^8&C M9E!VB?<<('77OCM\?B%X61; X8^7Z/XONYM*O
>@W"ZC""H@11%K16^ MRM*;S5BK6E6;1XF=4+ROAF P^Y#P;Z?J L.GQWT+3-4TN\;1.E;PZ;<^ M\$1"33~1'MK-
GDT^HA"YI=@T:E^1YEZY/W%10!AQ^)/ ?AWX2_%:32/IN MBV7AK21^<
Z1<:C9Z9"155W;RV8BGE58P+\$.037&_&340>L6^P M_P!<
>9Q^1H1/PC87EAJGO"TV34X+Z:1=CVVGVWGPKJ18E)9&71H\$%0@_M_9U% 'S1^S5J5JK&H?
#_IU>Y^N=OF^&T+3S7?<3, P!HB1+1RS;O7<2<123S M4/I1 B.V/Q-L1-
>0_ \$&U^\$&G:91/V_00\$=Y)#;QZG>RF:*XM^NIL*(DC6(O# M&R2MYJNKJ8@11.T4 ?.'1^Q7^C^SU?1K?
11/P7H_AV"VL=-, 2FXDC"DR: MBDDH5YK69R5ADV N(G=SO_X M5KXL_P"\$6S_PDW1DW71E1<9^U>2WDXSQG?
MZU\\$: _PJW^T_A1_P1W1+ _P + M)_MJO_MKD_R&OLF&^W2VYN_??ZKS^ CZ^:SO+V_/MK1_HH \,^!PUI-0>
M/_B7XP;2+6X3/XIO((M3N(EDGM8?A#10N1F)&YF52 S.O;:A70" Q^U/ MXC6&NZ/H?
A;Q^X8T731^1+/6/\$%SITL.H2"1);EDLC;A9"1)\$16^CM MX11#);ZC'(MS+&LCW;:SB1F=2Z;G7K1+T4 ?^<
DEY%;Y+17_YA9X-j> MFM>Z>GC>*XNFEA,TCK11^XC8WK13<7\$A;:5Y+E1LE\$8:01/7M4N<^#>HZC
M=V.FF75H.EQ+8S?2MW>W+&W Y4D@1H79UG>(M) M_P J>F>Y^YVUEMO~MVIMF1N1&1G&>F:/C?
PWT^POT7PC\1?XM:U 'R1HOPK^?S\$IX@?#J/Q9H=EXCL+;X<0L~U21+BTDBWEI8;JT9%M=71JUU!& M_9GB62-
G^L)%/N^Q/AIX%PI\^QZ7)?R:M?RW\$1?ZC(FPW-U/*TLKA?Y?
V3R_~;F^7_7G6BZYH" _&ZMXITRIF/@S1_BS;W\NHW^2;(+) M;:VB\1D7(MUWJ1(TE\$0#1MOS51H44
?UC\1#1/2&7QVU#X8:A1K5 _#X/TZ# M1M4L91+;75YMU)HS#*/DD42;JE)7\$+_PUXT^V7B
MN\$>;K>E>O#\$1KKMTIMW62WUAGO99%(81MURF1S8UPL^)+*W:&..V5RT\$4DTRX5?.*E%8X\PC'S M\$5P7B/A

X57_7# P"%G?9 ^%L2;I3 _+^V9 MSI+N?^S _P\ O<>1Y6/ MLG _+;S-WSIZ^Q*./? ^\$5NO&WP#L1%^(>CV6O:O=:%-7T^IM8KF&6!6%6? M,>"C\$3+D8& 0".@KYU^/P _^%WCKP?) L^Z%I&F^!O0HUN&US2=(2%);?4\$ MTM!/#?0QC#R!MIDCE&257>#C%?;2%% 'O=XLL|OPYX;^!&-!BM=^!^!A_\$:V MM-0LS837=AI^DR:5;3NK6T4L9%J+J9='=98U1G+ #8"!J1_9?T+PH^J>{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|OP|<37>AR>+ ID6+0G GPW^_VJ _#|QS_9GC5=.UFYD"WG\H-3U'S;^\$5C(I.INRC8>W*JYC MAU= _|PO|LU7DT^UFOH+U\;|V"- XHKAH9P(TUM?>^!Z2P^Y3+GS4(7Y M@3TWP/U2T^&^PI^G@?Q+^VD^*=7TL06FF/#(6\$!4_G2PDA=J&- _CYBH^7 I M*IFHH _I\5Z7> _L^>"?@PERI^*%GJ6EZ7=^6!^W6QM-0BDFOI(AEDM _+@ M:99S\;C|DPQ+^O"?^%\$ M_P|A_P|G^?7 _/"6?(CY7V\I_Y|O\;Y7R _; M'D; _|;YWA.^OJ'B@#PS MIDSX;^&O"?PIBUW3M(M8I>U6XO?MFK- \$INYHQ>3%(3+C=Y2 !4CSM4 8%;! M1W _(!?!ICOHG_I4M>MT4 > _|P/X2O_LVIWFASZQXLU;9H=AHQJ5W:0;J MQOWNL_I#(J7%M&IFD=9E=53S<*2V&X#P#12M4!\^ .K7P8NN^&;R EUU*_\ M"TUK./\$EYO<^9K#.)MH@;_ 6A1;^6L05%FRH6QJ6B@ HHHH **** "BBB@ HH MHH **** /FIXV;1\;=1^/VDW'Q0M\I/#%IX5GD;_A(MITB.0W<85IE9/W.1 MR\$;48!)P0Q&>;PKHOC3P3)HIC&TWPINOBI>^&8X69;33 _"8//2V/_H\ M_P!H0OR%&<)\A6QJ5O\FIXE1^+? MGW-(2_L2E=&M(_!6T31!^LM)T.V^!5H!HUC;I#;Q1^>/D6-0%5>3P!CFO;=_ M_9Y^!MK>? I\6G _".6.R;W9RIKK31\FUX)IAF4;@Z+X+!#^ _!EUI>BV _@2#X@'2(SKRO _&#H-FJA#>\$W,*B&V\YF186 M9(MAR D#&!O#WP|^ (WPF;T;POHEAH.EI<;I(+73I=(4 M+M;'<|!0-SL>2QY)Y)- >;Z7JT'PK^&7@3XKR0LJEHCZGI>M&/<6_L^YNY"&" M@'<4N8K8!%>3GU^!^X;XB _# 40B%>;+9RZU;V7A2WNX;W4=-2R9KJ^D@E6: M%!<><%CBWHN!#\$Y=01N7)H Y3PYX\4^" V;=8MM*RWQ#OM+U#5BRXR=7NA+ M<\$#/&%FD"+GLBBO#+C5/\@7;VOPWL_A|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|*VBRZHP8W;W#3?N3D0:WX;TIP=)-I%J4#RVW% |Y.OE3@EB@SY3\$ M?*KDIP0;_E** /A+X7Z;8ZW\AQM=;\;#/#?QLCU*)I3B3PQ;2%QF2Y;FC>0 MWIE>TD * |^*SF&0%0H<^>)B70=1^(EUKT#^\$/#OO!M?&-G8H3;9=>;# M;QZE# ;C|5H5X+.6\$.^WR6@J4#*Y=7TP6GA|5(YK;Q/IX80Q%)F!9Y;;_K11QK&6-R))<%E7D?&VCZ;KWC+ MQQ>;.O%W@SPG\03K=I^H5SK/AN;Y1PVA? \T*;2)OMJ.X\$7EX%M%@2*X=6; M?GIHHH |M _;%CFB^ OB)+B87%PMK")@FP.WFOY;VR><=JX/5?@KX+^)'OK M^+|X|X/V6OS0Z;ID=J_0A69;-(F)G@# ^5-IT>;N' 1 ".5!44 >=?LZZ MY? \B7|GWX;ZMJ-S)>;E>^&|/N+BYF8L\LC6R%G9CR2223U)KOKX&S?">"X M\;XB6P?IH#>? I66I#^Q;WYO/_Y;_8\|MG+_MY6S'R8KZJHH ^\$/ _/B30- M2^+OPW0Z)+X0T? Q3K6M2_VIH.^Z7_B.PCDL|MW@UBI^P6?&_IW^A74C/BKP^DUKK"&.)A=MR7W7#\$G\H M.ZR;UE"Q(&<#|9HH ^40I/PW\ _BX_9UU^PSI;GZSKLBV&LZNH/VS58FT; MZG(NY1U?P?_AC8>9NVE1MQ7U;110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !7A?QLL|R?Q|HLWB1O&8^!\$>FG!\\$7- %;FH&7!;Y&GLMVR>6 M5V;=T8(D,@'R&O=*XCQUX>\>;CJ5O=^#O&>EZ!%Y)AGL=;T_ZG_S9)\$L?EW- MO(C\X.YW4@#"@Y) ..O/BI/X5T#X>Z7X#MG^*3>)'N+>PU2^UI(HPL4;2F2X MN!\$Y*J%*A&D! !5FS5+Q_-8+UO"7C? 10%_AZ30Q\$^A6=I23V>@Z_*8KBUGF M9(9K;^6**4?-#(K Q(05(P58, M>^\$0A|I0\$\$XU5+ _7-0;5|NW20 M3W<!_ "W M@ "RUV'PW;6M]=AJ&NM8K.DR.PB@5;67=;/_Y6*I@H2XW8%GQ9>(M/^%A MKQULH.AKIFNV\Y%=>;_?CT.RMH98A^OG3^7,0Y|P%1'R03CR)/C=;IMWS9WYZ#&_I>=VG/I;K^&_#OPPC\^*|& MYA>!=.A07NL;*(U|9743Q0))<9;B)XY?_IUVLLWRAW4|PW _IF>'BA?& M#Q1!(O\$5G%#""#?2;W9S1VMVEW)H(9(9%#.GRROED)5\ E2"54Y4; P"U9X+M M;|X0^./%4>K>)M)US1/#=-<6;VB>)M2TV..6."21';&VGCCD8;_* MO^ O@1<^#Y _#ES>^*9=;Y'G1-'OV97=C=G&1G'44 >%W/Q\$ M/_ #4;+P|HFJ6|YXEU32;25;L_\$GXD7L- I^#N9\$;4EVUVP=V\$ORPO_83YV'R M9Z|2/VE;XV/>&SX,T"/O;XGUR6^ACT^34TBL;I^((H;6!1);P'WB"/%(' (M7|Z(A "Q7A1_"36T3;?XN&^)!7P_XDAT|/1;LZKL;A87MLCEX\I"3PN) M\$=I^K+!*X96R_LOB+X5^(-6C\ ZQ9^_A;_M#6XCBUFXTM);2YBN"IFMYK M1'C)AS'\$5"2JX,*\$R_VX X;XC>* &MOXQ^\$EP?!- L_BZ6_U.U&EQZONL%/V M1CYS7GDIO;M&=WD;D#R^:Z#4/V@+|I1A5XZ2;AX4W>(_!MT;+4M T_41<) M+*\$AE MYS&I<=0^1LN^"2=15>M=IWPYUVXUCPGK/B/Q1#K.K;+!>3RM;Z8 M+2WE\^+RO"%YCM&B#GYWE8G.6Z8S- 2^!O\;^&D_SVR_MOR _&TU6+4 _R9 M^OI+;T@Y8W_O_9=V?E^C^&2+57XZ;IX9UG4M/^(WAJS\^*KQ)!<;7J MS;E\$|G;.@N%DW6\+);GFOG8HD4ACASBBS^-'BG2|KP|>;? D7AGPWX@O8-/ MLKJ'6/MEI;33@^0M|B;4AWOLCS%->103MRPWO'7PO;%V\P-NU;P:A96L.C_8IVIF@|\AKZX\$|)-L?9)B*& \;DC;E2_8GAWX@-X|M/&9 MM_*FUW6|7|=W6F;7ID;JQ?;+AH\$D^>1N(XTCCDD=L\$A8VVJS84I'8 _""Z\W MVN;9\1=#M?^NIZ7HDOB;R;5J#ZE97%CSQ6=HYF@?@S(CY>|&B7_6IM+?M?J MGP;^L_0;Tf0S;;K? _"2OXGTO4H;96^Q7#1>5Y;QL2)8VC.B_.J665MI1L_* MI^#DNI'Q)KWQ+UN'Q7>WV@3Z#)"HNE2V- I;V\$A9YUAM_N)6EFPFYC(Q/E(\$ M5>0P!F7OQS?;#<>+S7/A=#I_A|Q)JMGID\$7B_37VG_-) J>V_P|G"1D MXQ%- _Y52P|W U;XZ;-!=_2ZC=CR9Y?TNAV;YKVRVENC&KY__RVL(17 M;8H(78=JLS;3YE#XP? QQJ@3PCI7Q;7FXI36?B'3+D6>BZ>L6HVEO2";6;5 MISFD56"1;0#%;9D(&TL=HIGUKX#5_-O_(03;? K(3MXJTK4H;93IBN?+\$8 M1XV8B6;H9\$<94LLC_%#A@ _(&*;P'!%>L _#+Q9K'C+PY _&LZ7I>FS&4K#) MHFL#5;&ZBV@K+#+<>7\$S*\$5/\$-SH>CPZ;86UK';X<16KR2MOF;_4;R%Y')E+ J%&T_7|KRW|OZE\!\$T MOPOXI#P;K;J>)=+L8=9TUR)(#)< 9901YB9QNC/#+D'K7)2?#6O&/@_P - MV.I"7PO\0_#<;-H? BG2K;=D4.R\$LA!RIK<1L'0G(96*G)5A7M_O&_ P#" MP+70(?MWV#^RM;L=9W>3YGF_9Y1)Y? WAMW8QNYQZ&N&^+7|_G_\$KXH^"/E MEJGAW6M OK>6 _| (MQ(FL6D,HFCMIAN7|24|DDY*;H@ASO!S'C|LK1 _#> ML>(#:GPK=)X=NH/4DO/%D-KK,CP'\$PM- A|O_*L&4*IL3.5.T\$%2WJOAGX MH0^)_ \$WC'2I>S'V?0G;_!6:(NUN+YWGQ6MUJQM;23SJE%R3_-) "8PNY=ROD|MN M%_|@G^_WC"VM=F>I M8VI?I3Q3;Q'QI7A?QI'H'A+Q#<75U>64VCBYOK.6Y+<&QNA,BQ;G=Y\WL ^ MUW8CC"@ 36/CEKFK>*?#FC?#|PI8^*XM=V _/"1VVJZG|FFVB6^!%"N5MI MG#;_4*@(<_#MVY.'X/_ &EO\$7B'3_#?B+4_ \$6A>#-:U=;!%Y)K8FU""S M6P9K98/+;_N\$*""03|R&5O+&2;Z1X=^%=AX4\4;1J.E2_9=,TKP^OAZUTP(6V M1) (C(WF%LG"H%P02>N;YJU ^ ?V;X8^ _A _NI^R?\$.O?;/L>/_O4C?>5 ML\$SYO^O#|Q=6MY>S;P+;^O);8LM MP+&U\$+K+M=C _S0;G1@;_>H _&K4/\$&IZ/IGPWT"TV76H;/_#K|W>J;F^F M6-

M93DBW9Y%<FD,DNR7:~B/\$3IBO&:FI?I3Q3:~Q%I7A?QI'H'A+Q#<75U>6 M4VCBYOK.6Y+<&QNA,BQ:G=Y/WL,^UW8CC"BWJ7P5U#P J6CZG\-\$%GX1N\ M/T:P^UJFF/J=C<64\ MU>-9X9\)%OEVN)1Q*^X-Q@<XWX?>?R?PO?>*H G M1)\$N=<^2:++>2SA#~)8VH,@(4^8H,9QTW\:@%?L?E_MV5LFW_VOS<^;JHN95V;-OR{?LVTNO^IOO%5UXG3 M09;~)I,8CMH%A^Q&W#~/#B(IM#J_EOC?N^F%J?L\ZJFW_"?WGB7QM;ZIK'MB^RT^SEDLM&K;VOM^E91#&T/C;6WD/QW#;CNP0J#~(Z?M(CX(ZFO9Q;3P MP_*MLWLWH>+8--U*[10S.MC:-\$ P^H8^C<220@L GK4NH?&#XB2?M\$:%H M.EZ3H-OX(O=#EU R7&LRQ7+(K56G\H638D3S658O-VN&W,R\$56)??L>(/ M\$E\081\<6WA\2/*7#-(5*[N.PU/ MX:ZL/"A+Q)HNO6EC)I.GR:1?6U\HK7*7EHAD#MY96;~PRY@&/'F*QRAX-M'(^?BY=6O@WPAIOA?PI=-\XEUY\O>SL=7UN1HX8;>X*S3W-(DD@C#/\$H"Q MR-F6-0NT%EFUG\HB^~\+^"UYK'A\DA7>#G;>XO=L\SQ7D4P\BDM;@Q(9% M;\$J#?&C;XF!500QMA\!0T?0 "S>^O%*Z7XJ\>K~;G<~;H M;B&Z\F R:WN M+;S59XR5B/R2HP:~%NON4I)\!;O5O#OC0;\XE74\%?BQ;6.^U:WL#1;016~/M*AMH8RL4C\;K8;5V+3.2Q&T T\OQ117?CZ/PAXR*V7AO5+W3)=7TZ33-M8;48H(8HY4E+00F.53\$=JAU(8X?BNP\9>#A:=0-U*XU;YMQ(LN_1M8 MN\+GW#~;YUK+~)MY7=@\9'KE/B)X(UB3Q0GCOP-(+K7M^~;KI>GZ0T:@7 M-O3:@^KN;)PH>~;I0\X3^S^;DK;50\$-UKGC#412TWQ1KFGVPU3QCJHY;B MWAOKB")MYKIH\ L.J 70G(#9W#-5M^>:VOC\$3_(F7&KWC^/~\$>M-X6M\ M:7=;VION\FROU4-C=-I(N\#~+1WD&>(P;H\ L @J.C_"P 8>%=~\3FPO\?U M#5;Z\6%LMS67VZYEF(6/S\F9*5#;AD@-M AKGI; 8N^~"X1N\%TIX;^%- "MNI+-K;UUG3\ \$MH\^TDV;4CGG5\ 04.&#IMV1G-\$A0XC7OPK\! \$VPUV2^U MS4O \S<2V1NIGEN=2M+@&>P4.O+Q:0VH8DEG@/KBO*_NH:=~?%'\K2_BQ MXN>3:98>";K4M5O?#=-KRKJM^S"TUQ.-;~>L2AY0IE.O%PH(P*IPU\X\$W'B M?QEX\1;EXB\$D^EVIO^KUM#9;(~=>V?SK1V4R'RO)N2RCY_OD9\UO% \.8M M1^~;7BZXND@709\#DTR2W#+(LL\%UX>+I+AM9N M-4MN\DU&XDT*37)1+J\TPD&W#Y)9C\Q4N3)L> YIU>GUYH?P\H?2#GP\X M\^>~;T6#7P11E@G:"0@1L2%D7YD;CAAR#R^GC^'BB.^& M>%O\ @N^7KO4_"6N"UWQ#~;PV\F-#/~>+1Y#YBX;82Y#EMN,GU_Q%I/ MIO\ A_4\WR/MMK+;~;MW;-Z%=V.C.;LUROA7X7~\ ,^(-"U/^T M\IE^ M'(^_#_E?9\GF\^1O.SN.;\NX/7K0\REC^T)=^)?#_AA?#?A1\0\8;+~?P#1; MZ_6VM\%K&;R+Q\BY5)"(DEVH&2)V8R1_(6^R^*B\IXZ\ OX,T@?#RRNO%GB M^NK;V@0\$6%L88C+YON1;%S"RJPW&%7#;1Y9SD067\>H>~=-TRY\>+~%TW MQ5I>J;S?VF17&F^?R0ZC>/FT\X/VHX? M"?BR_P##=I_PABZOH\4#;0#XC\91Z1MDDB\$OE6H;VG(1E.YUA0\U& \X+~A M6?M,0V\@GPAXIT^PS^T^B^S6\BN^&OBF/0%^8*1^F^9I)\M@KA4^_FN@U MGX5>)=A<~;WXE#>+K+P\ B#R&UBQUC1VU^*22*,1+~;LN(&BE;HC%G(A\$; M?("^#NK>/(@_XG;QI^X\^~K73M9N-&@T/4;K6=\$6_-2*)Y^SUN\$F@6"9FF<MMD21G;^~\^7D YW -(D?Q\<>SH?";@;J\$^OZ^>(6770\$6F3W4\$S.#9 M 1RK=3IL^=^<~^9#^~P^1M?%SIHBR^/BFU\+VDOAA/\$\$MB-2D7Q=XE31+6 M.;I&C3\$OE3.ILR285(R\I.YERN\ USIF;7_.SND?#>W\;9=>%X=%CT;^B M0>&(11DEV K\H MV\Z.13D^K(LR!E0A\A@W8^)/A^K;?B>P\4>~%_6A>(X=M*CT6Z?7~;412_M4N&5LC;~;OPC^)^G?%I P3;^(= M-5(T\H\%~;LZ)-#(T<@25?EDC)7U>&\#4=-T6VMH6 MU0ZUJ*@F\^SI)&+~\$X6>%49V@9)P\EF.2>~\+ _9 X1O_(0? B#\16HS M6>JZG)KACNYHHD21Y\6V^S%90J2 LKS13L^S\;VMO+SN.^XIMV\^?QCC)YWQ%\$?I?^&OQ~)~VUY M'";/~/L^RIOL^VVG%8L;X\S;MSU7.<~;=:~;@1O1^CX4~;IX;TF7P?+> M.;L+;B/%^BZ+17S+&)5CMXS^*TK>6R-E+3YP-0VVGX^GC;Q)J_P?U3X=M:3HM_P~%;2%PDG==;L2OQD T.;~;R9\$6RG\;L5MROEG4H0K>~>NMU+X2^)=~ M8ZMX@~\#>+~\+0^UU;?^V+/6-&;48))8Q\$ L 2X@~;4QJB.6.B\$1A@0;3< M_#G6_\$4?@ZITGO_#9>(O#5T;F_U73\>0W>^VDMY?-ABE@P665F1U^L\ P1\ MM #OC\51\)^#F7WV6PFGU+4(I AFUC4AIVG6\COR.K7-T8Y/*0^7Y:D1N6 MDDC4#YLC&A7?&+7\ PUTOO%J.B^&=&OIF4QW)\0>+HK^2+8#~AQ?>2\2*X4 M.F(Q\^<1X(C^9^M^1\;IHT^1)HX%_DLZP6;5Q\$ MT 5HP(RLY(#2\ C)O)H 9X=^*G\70%PC\1VD<~;JK=G.EK>)=P";~&2&0Q M3\LL99^5?)4@E5.5&;I?;N@ZH6F7L;.(8 MYGTU8OECW.K-B8R(A+~&"&[CP^H\GPA-X=N+I\Q1+KMYI>JZMJMQ<36:Q=- M27\2,ZX5L(\$AQ@~@<~;=X#^\$7BSX9N&Z@~;H\QNU+QUA1M5T.PT+2CH^F7\ISIMY(-?0Z MQ9R0LRB6?3S\$+/+@D*~@QL)F=EEB? RPK\$KV7Q+187^@7P?>J\$;YVGVW.L149U?5 M\$TVRB\8#?/6@SR51VY "G-<1\^P3U_O#4~\2;YXKTS4=~/ZA-J&EI M^X=CAU;/?(GV=[X2E3 \!P*~I.C.%0;I88MTOO8^&UU\0\7P -INKOZ/K.@: MHNK;?>V7VVT:98I8MLIN)(S(NV9B-LB,KJC\N,\$ \STHK*36O \N\;X=T MOQ/K4^B2S~R6OAWO%?;?+);6*W.Y\YD:(B2-IP=Q^(70 M_@~\A-U? ZCKWC%=9UC4\ \$UCXDN9H=+^S0*UO#~^+>&+S7*1D1#19W89.2QYK M2\9?>V\>)&J7.M7%E;^EZ78P&SB59M/N+"YN+F"Z1V+~S"69&"LF 8N M=P;_7U;7_%VH_%OX1P>+O"JAX? G;5=0EMVTG5GU*\$H_.N05E=K>#RYI_\$OQA<>~!~\HK-K;~?D^+~PVNOB^~^YM-U:~1J9T#5U;3YKVR^VVC3+~+~%MGMO)~9 M%VS.1MD1E=48-Q@&?^ SXU6GOHT?69H1D~O^O18W4F@:PFK;? *S0Q\$ (IO M=B^8I25<~\D1@P8;<8)I+KS_~%7PWU?P+?>*14UQ*OB76/\$=_%J\$S+~8?8 MX(&2WB@\$<~;? F2%8P(@0&=FY.68\UZ!0 4444_%^G6NMKS#HJ+~1^"O%L6\X\HNB\XSAES^~R M#V- \$&D_%;Q9I7BO0~)=^#~A-VWB.=~32KS2M<~.I8N%ADG\BZ5K;'RG,<4 MA\C;5^R%=P^4MR2?&CQ\XX^#OB7Q5K^@UO#_(-%UGO=XLM~;~IUC\^V)Q<~# M)\YUW^9H.ZORR >6D^9?P!;^~M\$S_B8_9>F^Y_~KW\H M\O>_M0\A^OC;XPTOOIXOT3PWX\LJZA? ZZUBLT4L)M6%MKO@R^PH\ C;V>XT^ICU?I5=~0?;%CO(M\1(C~;\$.P\$P^\$H=8+~#P(@0LMMM-IC3Y+/W_W7^LW_73^O0\ S&F_MM-(?B18^=5M?#~L^HW\NG6MOIOBR^&U>WD2.613>6^Q+Y*LL\$G*2RD\$J"!D ME="R^+7B/Q9>_2U;P?%8>%O#;EHT^K_P\N20W=W+~L@~M&D^RJ5<R&52 MC@I0^UE>#_VZN@OH\IMN^99G M F+;XXHMS99E8GCT/2_AK_9NA^=..M^SA A)+V\O\AC^V?SXEVCVXW?/MV MYSD9ST^EC>+~I012\$6G^~)H(T;YUNZMOAI;\$&DS7\I/<7&)8G\LV#J2A\A&I MAEFZ\A2>()=22;"6\N7B2W^7=QF+R\$ L;EJFL&PCCEDC67R+=5@F.TJO/&Y#^4G\U\Y MF=VWB? A%\1_~\$1^~#O@FX_LN6;_A(9%UH?E3OY,EMY^I7C;V&&R5VX^~;~^~\~(1>+I9\T35#K-EXDN\ C_K2_AQ=^_I9M1#8^~;TZ^~TURD8N)+R>>".+YHJ1 M_/\$@WL^W\YD\I0)Q\A7^TC;^~/"^*~\$HO^IU.ZM)KZRD(^)UUR\HXF172=A M\!89?WBD+M96 ?#_"D5_OI-NH>)\=W7C3QFVK;EXKM=-B_OHNF3DTR6QD MDE@EM5>65!~;3H1TY.H M/F2E\B=GDX(^0Q\AQ^3I@X\I7~"Q^M?VD=)\V&D;~;X.FT>~DDN-9DBN6 M5)\5^G\L638D3S^58A-M<~N9T~(J@? YBM;C+CO+X(CB^~C%)5U@ZL6U3H(MT@07Q1L 4^S\3YO_~\>Y?E\ODKN?\$_@#5=2^)'AWQ=HVMVFG26-I-IM_9 MWVG=-)=6DL\ C~EFC;~;H(<~&N&~.4%<~?V=+~;D+CP\+XWCE^~BE(ET9N^>@#HOVE? &~BWP+~%_>O>"H~/FUB MSMGE\4+PP+;QA23*~\B82.#MQ&RJIR^KO MPG<&YM?^~\$@E32K-\$O8^6O#9F5F8%=JBVY.I) 7%I+M\ M/CU;RDL_M42\VA+~0^"G@X.#COCM67X;\ZU;>+K^O\XAUROU36(M^?2KC^S M=,>RMY2UP)1(J\;R8_"[2\9.3D?~H X^6_VK=+TOPEX;NS;Z1\2B+7\)^T3 M3_\$FO1;~96\UE*8;L27>Q\JLH^KLC9FWJ=@&~;V7P5^_MC\8~)U9X?L.74M^ MO\8WRZ/J2ZE8LYC217M\H43S8RK@9*(ORNI4%YFU_9UO="L=(N\~5KIWB\$S M1\6UG4;+4KC3O/M7AU& \DN)6KXMQ^K21C="RDL;~H48\$#*~T_P^~7KVEZ4R M>)=@U_5)~(H\G8^RMXQ@~9%~%OD95&"?GD=LL?FQ@ \U7XP77@G1==O& M\7_ (COIO&R^TL;C67;~+Y;B5^D1A#\$1928U&U%#L;G\IN@?&RXL^~\$WM M?FBVOA? 5/"G1.S?_V7J+~E;26.B3.LL4K0PN2/LTRLK1+@J.%@MX1C;NS.3G@ SM^)/CR72\I6\^EIHNB_V;J M%HI/I? \$UZA2/>L5Y"(D+~;~W.MP%/7CFN)E_JU+2_"/A;4_\$ASPIX3U/Q= M;W0K#7_!8MI&+58DD= \V9\;\$#CS8E\N)9R2XZ_5\1?AKX\CT^ZT;7?B) M;ZWH(T^~PME305@OI=9C62\GYDF90<_N8K<%N3OQ2ZYA% \V73? USH^B= M&~6>#L\ V-EJ=O8_~;6YA>*~;~XMA(C_&_E1OA)496C0A\ A@##T#H2+Q~A M?>N;2.^IM7\WJ\6%~^/~\$FB&B(SHCK_-2,2,&V0 L(=X8.OEY%5-#_&K-M.U3X5^~%K6NCW4WAN_@TZ\;1=?

BOM)+3" I<" *!;JMRCRR/\$IC5)#L(4; MNA\3 "/O1XNV/Z#)J7C.RG\7;)K"ZU9WK:&/I+640R0B)K+SH1:9789N/,#
Ml6\$F%"TGA?X1^+O#NG>-+L^/HYO%WB2_AU(ZHFBHML:O"!#"(5M6E8F K" 5 M/T289L2!OGH S!6-;
(D_-#>T1>*M.T#2[W4=232]-IXFBGTF!9T,B2K?O M"LC"K(6+Q!@8F"J^4W:P7^/5A5-8UG0ISH!N:7!#=R-
X7UU=9T^6&5G5 M2ER(HCO5HV#QM&I7);,Rl6W/B&+Q/;CX=T1-/ML+;IC@\$ *V;2REUDCWK-OE+2"1L,GRE?4?
^C^+--+CN!2%OB6P!07DQ41H, MD?3K6!1GE8WFGD+-D9+2D?*,*O.0#_?&WQ87X;R?%?7+?1=1UNY,VFGW+V
MU20I=;U;"01,"D+XSIT?O&VIB.M;/@WXH^(KOO!X0\9>;+PWJEHDNKZ=) MIFL-J,4T\$4L4&;7Q)X@2Q74I
MQ!5U0Z;8V=N\COQ;YDAGD,DC1R!56(C\$3EF7Y=U#5OBKXKDUBP\>-'!%M?> M,#IJ:IJ=KJVM"TL--
B=WC16N8H9W=Y'BEV!(2"L3%S&< W_&OPVUZ!8)XN\ M&>)K7PWX@>Q73+Q-
5TLZE8WENDCR1;X4F@D\$D;22!664#S\$KAE;Y=N?J?PH\6 M0ZM8>)=
VWFKZ*+NPU*)9'DC+6T4T#1M&\LOEE9N%D8.)#A@_ M 3Y8T"1NQ;!.%PJ MLQ"GLM,^!*:?
HUI#)KDUYJH^X_#6J;G;-C-IE7VD^)SJ5MI5_K6B16DJVG@K7(!;MKlW4Q@MX8+AHX!YS3;49)% M0+YB'<5;
(C^+GO+^?A?X0>+=8A\%>=#U:QLSZBBCVMN)#6 S.I MV8CV&-@6_>@@!NTO/A?
XB!>#-7T7Q5XOAU"ZO&@EM;KPYI0TV/3IH)1+#!/ MDLMPQD61(W>_Z\$QCY "0:FH "OQGXTV%^*?
#WC/QW8ZC#JVG/HLVBZ!l@6 MWW_OY!)<3M+;)G'W6C3&?DR00 8/CG!H^\\ ZAIGA05;7P3I7CB:P_M*!L1: MA9_8-
;@@;KQQ^7=26GFS.VQSA;<;6W\$?*6GTGH3_A?#_AH^" _#V/B'Q-K MDU! NGR:HL-E;"S<1W,VVB2;H
H! CCP!>+IWIDZE=-X>EETG4+=97EBS9_!+!)&??;PN2/WDF58%0M!Q!"\$6
MK1^&=8LO&;VOCG0AE1Z/JL6E;"<6UO<&YM!^FC,,Q2,R)W#%\$.005!&*XZ! M76Y/VG?&WB+7/!A?
5;;PKX;MKK2;^?6)9KNR4F_(>)-!+;#)/LV2!D/E5\$^ M:7!H!A AA\;\$'A'Q;XK!3>)O%D/B?5?
\$\$=G&Z6FE_8+T6W\$H"0H996V'S M_#C_!^/B2Y^6@>)-3!+9;GXJFMH/#?A^WU?SKFX;.%IAHK9H8TM
MMD;22/M,Y\$1L;FPAJ>*OVC<^D^8O%G@B&'Q3!D#7+73=\$U9KVUU.V\$Z MPR+!^\$3:MX""*:.+;Y-
I>M^%S;3Z7K4,"OY M=Q#"8=SPL2&CDC>1'3<"5D8*RMAAS6J? #6/&D>MZAXQ!6VNI^)K!3%T>VNM
M+TAI.QL+83K!)Y=L!Q*Y>1DCWLTQXB3;%^8, 4V^-7Q.7QU!X*/PPT-?\$=WI MS:S;2-XMD_L!;1)%C<3S"Q,B3AWC
C2&1"&)T;?3/A?X^A^)^O@;3?45E) MIKW!EAGLIG#M;W\$4KPS1EAPV2-P#QD ' SBHYO /F_%FU;?;L>1HDVC?
8? M)^!OGCFIS?NI>7MVI>^<8H^%G@_ A6?A^'P_M_H? \ \$POHS)\K CYNKY MC9MW-IWS=N<HF&QIU";??"
Q9X:US4%)^.;?10"NJ:C+JEUIEYHHO+NWEF MD\RX%G<>)/%FE^_ #ND>/K?0?"C">2\O M+-M"%Q>P3R(@D\$-
P)T01.8P65XF?YY LBY4J ;T_OPU*Z^+EWX+T?0)=O/I- MEMDOTO/\$"6FJ&.-)/M-K9&(B>W028;H8SNBF558IAN5!-
!O!>+; \$O5 M?GA!2GT01-;&FV%MX?U=KR!DN)\$LU@LHDDLI=&#R7 Q+)(("&DVD!5W5TWQ+
M^".O_ \$K7;) +WQ7IG_ "VVH6>IQ6=QX=CFU.RF@=' L!WSE6\$;T8RS0R2#>X# MC*!9-3^!-WK%UXYLI \$PA\^
^);R+6(H;6PV:CINI1BVAN>*Y:1HV1&M8W6-H M#W5F7Y; +N@_ /Q+8^,M\$!>.- "CX;N-?6?^R;K2-8?4X'DB02-
;S,UO-8 MI3'YC@*0B)_ GSM#>?+^U%XV;PUI/B7_ (57 VA;MK!\V2KXC_TUIQKA!;* M1H6M@BVS2)_K!;*9
K;O*/2Q0=!*%GB6^!9;)XC\=^++^Q)<;L_IDVND;^F M0!)*@C;XF5KB5MW_+G=MW9,.9QVH R9OVC&'Z'XWE!?
Z)9^'-8)*+9R7%OI^K"IL MIF;I8!M';R_ "/!5%OKFK;GHY%X4NM6CTFIU>P7 MPGXXK76;>5+<*7BN)!;QM;R'>I V.I
+R_U>ZMX?S\$M MAI=K'!BC5)!/FL9HH;B.1MRLPDE1@&3_7_X' T=*\$!\$^_ .W3=8LO%OC73=8
MBN!6Q@CTG0#8(FI<=>+ON9FDD'W&C3D_+T()D_-:0Z!+?#_C'7?IVC M^&AXEN;:'28=6!2&&W@6>!YD?
4;@VNVTV)"*@GS))&N!;6> MH;SI<.C:C(K&;UM;U;V 88@/%;JKYD; !E8JK88;E4Y P-2!"^<7X>Z%H'A MKQ+9Z5?
Z7;P6S7&L:0+ZTO(TB\MDFM_-C?;WWALE0@@@9+#!LOP9^%Z?"3P.N M@?;+>I=[NYOI396*V-I')/*TKI;VZEA#\$&
<I4W,>I+;230!XQ?7BOXF^(! M/?C+7;?P7#;> M1TJ;^S!3;52^I3QL=L5RUF(-B0,..&\N\$8%HOR!|=HWQ\$
M_M;QEXXT'^S_ "O^\$96U;I1YVH3YT!E^!M^3;C'4YZ=*\$OUS!FWQE>?#V M^6E_ \$NVTSP"TIH!6WDV!/"?
4I;W#;DM?M7VD1M'H_C_U DV#F;OGKJO&?P> M!2ZGXL!0ZKX5!9VWAJU\36,5EK\$%SHPO9LQJZ+;RB;12!)-
LJ3)B\$(- MN,GQ)^TH^@^!A_JKPZ+I^M^--74;*R!0ZAFFV,""&.27S+MHV.%;L:C9
M\$S,6!V@!B04_!7XRV7Q@TG5WA&G+J>CWGV&^71!274.%G;2*!O=*B>;&5<# M<41@RNI4%:Q?
^%*"7FD^%/AQ#X? \ \$XTSQ5X&TQ=+L=6N-A M%K=PF".*.X MMA*C-&_DQO A)496C0A!A00 !VEZJH>E,GB378-?
U220R//9V LK>;8 V11; MY&51@GYY;+Y!8 /%?!_QO!>+; \$O5?GA!2GT01-;&FV%MX?U=KR!DN)
M\$LU@LHDDLI=&#R7 Q+)(("&DVD!5W5V^@_ /Q+8^,M\$!>.- "CX;N-?6?^R; MK2-8?4X'DB02-;S,UO
8I3'YC@*0B)_ GSM#4M3^!-WK%UXYLI \$PA\^);R M+6(H;6PV:CINI1BVAN>*Y:1HV1&M8W6-
H#W5F7Y;NZ#!+/\$M!XRT3Q'X!H6 M6/B2XT!9_P"R;72-'?3(\$DE01M<3*UQ.991YB J40"5_DSM* @&E/9/B5<_ "M_P-
P;G!#X?"R3^5)>>*O\$*;)IUNNTG,EP8Y6W'&%58VSSD!FN L?VG=2\4 MZ'X(FV(^\$; /Q!JGB74-1THQC756QM)!/S;/D-
U"!)YEN3\$^V14W'='^!RQ"! MO!2OACJ_BCQ7X;5>&!>L=\$!1:'# =VL!UC2VU*R>*X!KS"85G@=91Y*A9%D&_M
S@A@W&3X"^-!%SX/G;7-[XIEUR]TO5=6U;>XFLUB:ZDOFD9EPK80(9#C / M XZT =+!+/B)<^/K/7;?5-
(30_&@:DVDZG8P7?YN!9A%%,K0S%(S)&T5Y.SI-ML!;V!O.XI \ CVW; ML+!_&..G"16_!G_A*?)
A//^)QIE_P"\$IALHO^/7?IF^SYY^<^!/^SCWH R MI7XZ;IX9UG4M/^ (WAJS!*<KQ)!
<:7JS:E\$!G;,@N%DW6+),GFOG8HD4A MCASBKNC_!)>2Z3?WK?P\M-%T7^S9M0M!_XFO4*1HUBO(1
\$A9AQ^YEN MIZV+MY@;Y=JVV7&TY MS.1MYSM%^&OCN/3HK1M=^(EOK>@C3YK"V5-!6"^EWQF-9+R?
SF29E!S^YBMP-M6Y!/" '\$R_M5;EI?A'PMJ?B#PYX=)\ZGXN@-IH5AK_BQ;2.6JQ)(IWL SVV(' M'FQ+Y<2SDEQT
8KUWP_/_UOX_P#_ OBG5K*TTRIUCPW(UO>6VEZW%+!IF; &RU.XL?M-K